<SEC-DOCUMENT>0001213900-25-013463.txt : 20250213
<SEC-HEADER>0001213900-25-013463.hdr.sgml : 20250213
<ACCEPTANCE-DATETIME>20250213160154
ACCESSION NUMBER:		0001213900-25-013463
CONFORMED SUBMISSION TYPE:	F-4/A
PUBLIC DOCUMENT COUNT:		183
FILED AS OF DATE:		20250213
DATE AS OF CHANGE:		20250213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-AUTO DEALERS & GASOLINE STATIONS [5500]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282351
		FILM NUMBER:		25620023

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-4/A
<SEQUENCE>1
<FILENAME>ea0230821-f4a2_scisparc.htm
<DESCRIPTION>AMENDMENT NO. 2 TO FORM F-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Feb 13 15:57:36 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sprcy="http://trpx.com/20240630" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">As filed with the Securities and Exchange
Commission on February 13, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No.&#160;333-282351</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549 </b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-104933">Amendment No. 2</ix:nonNumeric> to</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span style="-sec-ix-hidden: hidden-fact-0">F-4</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REGISTRATION STATEMENT </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Under </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>The Securities Act of 1933 </i></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-73"><b>SciSparc Ltd.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as specified in its
charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; padding-top: 0.2pt; padding-right: 0.2pt; padding-left: 0.2pt; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b>State of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-104934">Israel</ix:nonNumeric></b></span></td> <td style="padding: 0.2pt 0.2pt 1.5pt; vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; padding-top: 0.2pt; padding-right: 0.2pt; padding-left: 0.2pt; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b>2834</b></span></td> <td style="padding: 0.2pt 0.2pt 1.5pt; vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; padding-top: 0.2pt; padding-right: 0.2pt; padding-left: 0.2pt; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Not Applicable</b></span></td></tr> <tr> <td style="text-align: center; vertical-align: top; padding: 0.2pt"><b>(State or Other Jurisdiction of<br/> Incorporation or Organization)</b></td> <td style="vertical-align: bottom; padding: 0.2pt; font-size: 10pt">&#160;</td> <td style="vertical-align: top; padding: 0.2pt; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(Primary Standard Industrial<br/> Classification Code Number)</b></span></td> <td style="vertical-align: bottom; padding: 0.2pt; font-size: 10pt">&#160;</td> <td style="padding: 0.2pt; text-align: center; vertical-align: top"><b>(I.R.S.&#160;Employer <br/> Identification Number)</b></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-104935">20 Raul Wallenberg Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-104936">Tower A</ix:nonNumeric>,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-104937">Tel Aviv</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-104938">6971916</ix:nonNumeric> <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-104939">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: <ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-104940">(+972)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-104941">(3) 717-5777</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address, including zip code, and telephone
number, including area code, of Registrant&#8217;s principal executive offices) </b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-142"><b>Puglisi &amp; Associates</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-104942">850 Library Ave</ix:nonNumeric>., <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-104943">Suite 204</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-104944">Newark</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressStateOrProvince" id="ixv-104945">DE</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-104946">19711</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-104947">(302)</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-104948">738-6680</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Please send copies of all communications to:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="padding: 0.2pt; text-align: center; vertical-align: top; width: 24%"><b>Shachar Hadar, Adv. <br/>
    Matthew Rudolph, Adv.<br/>
    Meitar | Law Offices<br/>
    16 Abba Hillel Silver Rd. <br/>
    Ramat Gan 52506, Israel <br/>
    Tel: (+972) (3) 610-3100</b></td>
    <td style="padding: 0.2pt; text-align: center; vertical-align: bottom; width: 2%; font-size: 10pt">&#160;</td>
    <td style="padding: 0.2pt; text-align: center; vertical-align: top; width: 23%"><b>Oded Har-Even, Esq. <br/>
    Howard Berkenblit, Esq. <br/>
    Sullivan &amp; Worcester LLP<br/>
    1251 Avenue of the Americas <br/>
    New York, NY 10020 <br/>
    Tel: (212) 660-3000</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; vertical-align: top; width: 23%"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b>David
                                            Huberman, Esq.<br/>
                                            Greenberg Traurig, P.A.<br/>
                                            One Azrieli Center<br/>
                                            Round Tower, 30<sup>th</sup>&#160;floor<br/>
                                            132 Menachem Begin Rd<br/>
                                            Tel Aviv 6701101<br/>
                                            Telephone: 312.364.1633</b></p></td>
    <td style="padding: 0.2pt; text-align: center; vertical-align: bottom; width: 2%; font-size: 10pt">&#160;</td>
    <td style="padding: 0.2pt; vertical-align: top; width: 24%; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Gregory
                                            Irgo, Adv.<br/>
                                            Ido Zaborof, Adv.<br/>
                                            Lipa Meir &amp; Co., <br/>
                                            Advocates<br/>
                                            2 Weizmann St.,<br/>
                                            Tel Aviv 6423902, Israel<br/>
                                            Tel: (+972) (3) 607 0603</b></p>
</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Approximate
date of commencement of proposed sale to the public: As soon as practicable after the effectiveness of this registration statement and
the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If this Form is filed
to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If applicable, place
an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Exchange Act&#160;Rule&#160;13e-4(i)&#160;(Cross-Border
Issuer Tender Offer) <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Exchange Act&#160;Rule&#160;14d-1(d)&#160;(Cross-Border
Third-Party Tender Offer) <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Emerging growth company
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-257"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">If an emerging growth
company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)
of the Securities Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file&#160;a further amendment
that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the
Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section&#160;8(a), may determine.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="color: Red"><b>The
information in this proxy statement/prospectus is not complete and may be changed. SciSparc may not sell its securities pursuant to the
proposed transactions until the Registration Statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus
is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where
the offer or sale is not permitted.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="color: Red"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="color: Red"><b>Preliminary
Proxy/Statement - Subject to completion, dated [&#9679;],
2025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg" style="height: 108.75pt; width: 108.75pt"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>PROPOSED MERGER<br/>
YOUR VOTE IS VERY IMPORTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">To the Shareholders of SciSparc
Ltd.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are cordially invited
to attend a special meeting of the shareholders of SciSparc Ltd., or SciSparc, an Israeli limited company, which we refer to as &#8220;we,&#8221;
&#8220;SciSparc,&#8221; or the &#8220;Company,&#8221; which will be held at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
local time, on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, unless postponed or adjourned to a later date. This is an important meeting that affects your investment in SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2024, SciSparc
and AutoMax Motors Ltd., an Israeli limited company, or AutoMax, entered into an Agreement and Plan of Merger as amended on August 14,
2024, or the Merger Agreement, pursuant to which SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of
SciSparc, or Merger Sub, will merge with and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary of SciSparc. Ordinary
Shares, as well as pre-funded warrants exercisable into ordinary shares, of SciSparc will be issued to AutoMax&#8217;s shareholders at
the effective time of such merger, or the Merger. The final exchange ratio, or the Exchange Ratio, has been determined pursuant to a
formula described in more detail in the Merger Agreement and later in this proxy statement/prospectus. Under the Exchange Ratio formula
described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders, and M.R.M Merhavit Holding &amp; Management
Ltd, or the Advisor, in connection with the Merger, are expected to own approximately 49.99% of SciSparc&#8217;s share capital, on a
fully-diluted basis, subject to certain exceptions, and as further defined in the Merger Agreement, and SciSparc&#8217;s shareholders
are expected to own approximately 50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions.
The Merger has been unanimously approved by the boards of directors of both companies and will be presented for approval by the shareholders
of AutoMax. On August 14, 2024, the parties entered into an addendum to the Merger Agreement, or the Merger Agreement Addendum, pursuant
to which the right to terminate the Merger Agreement if the Merger was not consummated by August 30, 2024, was deferred to November 30,
2024. On November 26, 2024, the parties entered into a second addendum to the Merger Agreement, or the Merger Agreement Second Addendum,
pursuant to which the right to terminate the Merger Agreement, if the Merger was not consummated by November 30, 2024, was deferred to
March 31, 2025. The Merger is expected to close in the first quarter of 2025, subject to the approval of SciSparc&#8217;s shareholders,
approval of the AutoMax shareholders, including a separate approval by AutoMax shareholders who are not controlling shareholders of AutoMax
or SciSparc, and court approval (as further detailed under &#8220;Regulatory Approvals&#8221;), as well as other customary conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the effective time of
the Merger, the officers of SciSparc will include Mr. Oz Adler, Chief Executive Officer and Chief Financial Officer and Dr. Adi Zuloff-Shani,
Chief Technology Officer. In addition, each of Mr. Alon Dayan, Mr. Lior Vider and Mr. Itschak Shrem will resign from SciSparc&#8217;s
board of directors upon the effective time of the Merger. In accordance with the Merger Agreement and subject to the approval by the
SciSparc shareholders of Proposal No. 1 at the Special Meeting and immediately upon the resignation of Mr. Dayan and Mr. Vider from SciSparc&#8217;s
board of directors in accordance with the terms of the Merger Agreement, AutoMax&#8217;s designees to SciSparc&#8217;s board of directors
will be assigned to two separate classes, whereby one such designee will be assigned to Class I with a term of office expiring at the
annual general meeting of SciSparc to be held in 2027 and the other such designee will be assigned to Class III with a term of office
expiring at the annual general meeting of SciSparc to be held in 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc&#8217;s ordinary
shares are currently listed on the Nasdaq Capital Market under the symbol &#8220;SPRC.&#8221; Prior to consummation of the Merger, SciSparc
intends to file an additional listing application with Nasdaq, as required by Nasdaq to effect the additional listing of SciSparc&#8217;s
ordinary shares issuable in connection with the Merger. After completion of the Merger, SciSparc will continue to trade on the Nasdaq
Capital Market under SciSparc&#8217;s existing name, SciSparc Ltd., and existing trading symbol, &#8220;SPRC&#8221;. The closing price
of SciSparc&#8217;s ordinary shares on Nasdaq as of February 12, 2025, the latest practicable date before the date of this prospectus,
was $0.53.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is holding a special
meeting of shareholders, or the Special Meeting, for the following purposes, as more fully described in the accompanying proxy statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. To approve the consummation
of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and
the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. To approve the form of
indemnification agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, or the Indemnification
Agreement, effective upon the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement
with all office holders of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed
to the board of directors of SciSparc; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">3. Subject to and contingent
upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, chairman of the board
of directors, or Chairman, and President, contingent upon the approval and the closing of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. Subject to and contingent
upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the
effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">5. To approve a reverse
share split of SciSparc&#8217;s issued and outstanding ordinary shares in the range of a ratio of up to 1:100, to be effected at the
discretion of, at such number of increments, and on such dates, as may be determined by the SciSparc board of directors within 18 months
from the Special Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We know of no other matters
to be submitted at the Special Meeting other than as specified herein. If any other business is properly brought before the Special Meeting,
the persons named as proxies may vote in respect thereof in accordance with their best judgment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">After
                                            careful consideration, SciSparc&#8217;s board of directors has determined that the Merger
                                            is fair to and in the best interests of SciSparc and its shareholders, has approved the Merger
                                            Agreement, the Merger, the issuance of ordinary shares and the pre-funded warrants of SciSparc
                                            to AutoMax&#8217;s shareholders pursuant to the terms of the Merger Agreement, the approval
                                            of form of Indemnification Agreement, the approval of a one-time cash bonus to SciSparc&#8217;s
                                            Chief Executive Officer, Chairman and President, contingent upon the approval and the closing
                                            of the Merger, the appointment of each of Tomer Levy and Yaarah Alfi to serve on the SciSparc
                                            board of directors upon of the effective time of the Merger, the ratification of the class
                                            structure of the SciSparc board of directors, the reverse share split, and the other actions
                                            contemplated by the Merger Agreement, and has determined to recommend that the SciSparc shareholders
                                            vote to approve each of the proposals set forth in this proxy statement/prospectus. Accordingly,
                                            SciSparc&#8217;s board of directors unanimously recommends that the SciSparc shareholders
                                            vote FOR each of the Proposals Nos. 1 through 5 described above.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Your vote is very important,
regardless of the number of shares you own.</b> Whether or not you expect to attend the Special Meeting in person, please complete, date,
sign and promptly return the accompanying proxy card in the enclosed postage paid envelope to ensure that your shares will be represented
and voted at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More information about SciSparc,
AutoMax and the proposed transactions is contained in this proxy statement/prospectus. SciSparc urges you to read this proxy statement/prospectus
carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;<b><span style="text-decoration:underline">RISK FACTORS</span></b>&#8221;
BEGINNING ON PAGE 11.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is excited about
the opportunities the Merger brings to its shareholders, and thanks you for your consideration and continued support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%; text-align: justify">&#160;</td>
    <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chairman of the Board</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>None of the Securities and Exchange Commission,
the Israel Securities Authority or any state securities commission has approved or disapproved the Merger described in this proxy statement/prospectus
or the SciSparc ordinary shares and pre-funded warrants to be issued in connection with the Merger or passed upon the adequacy or accuracy
of this proxy statement/prospectus. Any representation to the contrary is a criminal offense.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying proxy statement
is dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, and is first being mailed to SciSparc shareholders on or
about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>PRELIMINARY PROXY STATEMENT,
SUBJECT TO COMPLETION<br/>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>SCISPARC LTD.<br/>
20 RAUL WALLENBERG ST.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>TOWER A, 2<sup>ND</sup> FLOOR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>TEL AVIV 6971916 ISRAEL</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>NOTICE OF SPECIAL MEETING
OF SHAREHOLDERS<br/>
TO BE HELD ON &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Dear Shareholders of SciSparc
Ltd.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are cordially invited
to attend the Special Meeting of the shareholders of SciSparc Ltd., or SciSparc, to be held at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, local time, on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, for the following purposes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. To approve the consummation
of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and
the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. To approve the form of
Indemnification Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, upon the effective
time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with all office holders of SciSparc
to be in office immediately following the effective time of the Merger or thereafter elected or appointed to the board of directors of
SciSparc; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">3. Subject to and contingent
upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President,
contingent upon the approval and the closing of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. Subject to and contingent
upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the
effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">5. To approve a reverse
share split of SciSparc&#8217;s issued and outstanding ordinary shares in the range of a ratio of up to 1:100, to be effected at the
discretion of, at such number of increments, and on such dates, as may be determined by the SciSparc board of directors within 18 months
from the Special Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We know of no other matters
to be submitted at the Special Meeting other than as specified herein. If any other business is properly brought before the Special Meeting,
the persons named as proxies may vote in respect thereof in accordance with their best judgment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Israeli law, one or
more shareholders holding at least 1% of the voting rights at the Special Meeting of the shareholders may request that the board of directors
include a matter in the agenda of a Special Meeting of the shareholders to be convened in the future, provided that it is appropriate
to discuss such a matter at the Special Meeting. Notwithstanding the foregoing, as a company listed on an exchange outside of Israel,
a matter relating to the appointment or removal of a director may only be requested by one or more shareholders holding at least 5% of
the voting rights at the Special Meeting of the shareholders. SciSparc&#8217;s Amended and Restated Articles of Association contain procedural
guidelines and disclosure items with respect to the submission of shareholder proposals for special meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors of
SciSparc has fixed &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 as the record date for the determination
of shareholders entitled to notice of, and to vote at, the Special Meeting and any adjournment or postponement thereof. Only holders
of record of ordinary shares of SciSparc at the close of business on the record date are entitled to notice of, and to vote at, the Special
Meeting. At the close of business on the record date, SciSparc had ordinary shares outstanding and entitled to vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b style="-keep: true">Your vote is important.
The affirmative vote of a simple majority of shareholders present (in person or by proxy) and voting (not including abstentions) is required
for approval of Proposals Nos. 1, 4, and 5. The approval of each of Proposals Nos. 2, and 3, require the affirmative vote of a simple
majority, plus either (i)&#160;a simple majority of shares voted at the Special Meeting,&#160;<i>excluding</i>&#160;the shares of controlling
shareholders, if any, and of shareholders who have a personal interest in the approval of the resolution (each, an &#8220;Interested
Shareholder&#8221;), or (ii)&#160;the total number of shares of non-controlling shareholders and of shareholders who do not have a personal
interest in the resolution voting against approval of the resolution does not exceed two&#160;percent (2%) of the outstanding voting
power in SciSparc.&#160;We encourage you to read this proxy statement/prospectus carefully. If you have any questions or need assistance
voting your shares, please contact our Chief Executive Officer:</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Oz Adler</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>20 Raul Wallenberg St., Tower A, 2<sup>nd </sup>Floor,
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel Aviv Israel, 6971916</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>+972-3-7175777</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Even if you plan to attend
the Special Meeting in person, SciSparc requests that you sign and return the enclosed proxy card or grant your proxy by telephone or
through the Internet to ensure that your shares will be represented at the Special Meeting if you are unable to attend.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: left; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By Order of the Board of Directors
    of</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chairman of the Board</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv, Israel</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2025</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THE SCISPARC BOARD OF
DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, SCISPARC
AND ITS SHAREHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE SCISPARC BOARD OF DIRECTORS RECOMMENDS THAT SCISPARC SHAREHOLDERS VOTE
&#8220;FOR&#8221; EACH SUCH PROPOSAL.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>REFERENCES TO ADDITIONAL
INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This proxy statement/prospectus
incorporates important business and financial information about SciSparc that is not included in or delivered with this document. You
may obtain this information without charge through the Securities and Exchange Commission, or the SEC, website (www.sec.gov) or upon
your written or oral request by contacting the Chief Financial Officer of SciSparc Ltd., at 20 Raul Wallenberg St., Tower A, 2<sup>nd
</sup>Floor, Tel Aviv Israel, 6971916, or by calling +972-3-7175777.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>To facilitate timely delivery
of these documents, any request should be made no later than &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 to receive
them before the Special Meeting.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For additional details about
where you can find information about SciSparc, please see the section entitled &#8220;<i>Where You Can Find More Information</i>&#8221;
in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ABOUT THIS DOCUMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc Ltd., which we refer
to herein as the &#8220;Company,&#8221; &#8220;SciSparc,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us,&#8221; is providing
these proxy materials in connection with the solicitation by our board of directors of proxies to be voted at a Special Meeting of our
shareholders to be held on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, commencing at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
local time, at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, or at any adjournment or postponement thereof. This
proxy statement/prospectus and the enclosed proxy card will be mailed to each shareholder entitled to notice of, and to vote at, the
Special Meeting of shareholders commencing on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are cautioned not to
rely on any information other than the information contained in or incorporated by reference into this proxy statement/prospectus. No
one has been authorized to provide you with information that is different from that contained in or incorporated by reference into this
proxy statement/prospectus. This proxy statement/prospectus is dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025. You should not assume that the information contained in this proxy statement/prospectus is accurate as of any other date, nor should
you assume that the information incorporated by reference into this proxy statement/prospectus is accurate as of any date other than
the date of such incorporated document. The mailing of this proxy statement/prospectus to our shareholders will not create any implication
to the contrary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>This proxy statement/prospectus
does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction
in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 9.5pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-size: 9.5pt; vertical-align: top">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in; width: 90%; text-align: right"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt"><b>&#160;</b></span></td>
    <td style="font-size: 9.5pt; border-bottom: Black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-decoration: none"><b>Page</b></span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_001"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">QUESTIONS
    AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">ii</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_002"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">SUMMARY</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">1</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_003"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">MARKET
    PRICE AND DIVIDEND INFORMATION</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">10</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_004"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">RISK
    FACTORS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">11</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_005"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">FORWARD-LOOKING
    STATEMENTS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">85</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_006"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">THE
    SPECIAL MEETING OF SCISPARC SHAREHOLDERS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">87</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_007"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">THE
    MERGER</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">90</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_008"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">THE
    MERGER AGREEMENT</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">111</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_009"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">AGREEMENTS
    RELATED TO THE MERGER</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">133</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_010"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">MATTERS
    BEING SUBMITTED TO A VOTE OF SCISPARC SHAREHOLDERS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">134</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_011"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">SCISPARC
    BUSINESS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">139</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_012"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">AUTOMAX
    BUSINESS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">176</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_013"><span style="font-family: Times New Roman, Times, Serif">SCISPARC
    MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">188</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_014"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">AUTOMAX
    MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">199</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_015"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">DIRECTORS
    AND OFFICERS OF SCISPARC FOLLOWING THE MERGER</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">205</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_016"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">RELATED
    PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED COMPANY</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">211</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_017"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">UNAUDITED
    PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">217</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_018"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">NOTES
    TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center">221</td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_019"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">Description
    of SHARE Capital</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center">225</td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_020"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">COMPARISON
    OF SHAREHOLDER RIGHTS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">232</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_021"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">PRINCIPAL
    SHAREHOLDERS OF SCISPARC</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">235</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_022"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">PRINCIPAL
    SHAREHOLDERS OF AUTOMAX</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">237</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_023"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">PRINCIPAL
    SHAREHOLDERS OF Combined company</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">239</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_024"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">LEGAL
    MATTERS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">240</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_025">EXPERTS</a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">240</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_026"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">WHERE
    YOU CAN FIND MORE INFORMATION</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">240</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_027"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">HOUSEHOLDING
    OF PROXY MATERIALS</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">241</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td></tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_027a">SCISPARC
    LTD. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">F-1</span></td></tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase"><a href="#S_001">AUTOMAX
    MOTORS LTD. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">F-81</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_028"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ANNEX
    A AGREEMENT AND PLAN OF MERGER</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">A-1</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_029"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ANNEX
    B FORM OF automax SHAREHOLDER SUPPORT AGREEMENT</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">B-1</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_030"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ANNEX
    C INDEMNIFICATION AGREEMENT</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">C-1</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_031"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ANNEX
    D SCISPARC&#8217;S AMENDED AND RESTATED Articles of association </span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">D-1</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: White">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font-size: 9.5pt; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 9.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_032"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ANNEX
    E tRANSLATION OF VALUATION  REPORT OF E.D.B. Consulting and investments Ltd.</span></a></span></td>
    <td style="font-size: 9.5pt"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font-size: 9.5pt; text-align: center"><span style="font-size: 9.5pt">E-1</span></td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase"></p><div>


</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">QUESTIONS
AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following section provides
answers to frequently asked questions about the Merger and other matters relating to the Special Meeting. This section, however, provides
only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced
sections. SciSparc urges its shareholders to read this document in its entirety prior to making any decision.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What is the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2024, SciSparc
and AutoMax entered into the Merger Agreement, pursuant to which Merger Sub will merge with and into AutoMax, with AutoMax surviving
as a wholly-owned subsidiary of SciSparc. Ordinary Shares of SciSparc will be issued to AutoMax&#8217;s shareholders at the effective
time of such merger, or the Merger. The Exchange Ratio will be determined pursuant to a formula described in more detail in the Merger
Agreement and later in this proxy statement/prospectus. Under the Exchange Ratio formula described in the Merger Agreement, immediately
following the Merger, AutoMax&#8217;s shareholders, and the Advisor in connection with the Merger, are expected to own approximately
49.99% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions, and as further defined in the Merger
Agreement, and SciSparc&#8217;s shareholders are expected to own approximately 50.01% of SciSparc&#8217;s share capital on a fully-diluted
basis, subject to certain exceptions. The Merger has been unanimously approved by the boards of directors of both companies and will
be presented for approval by the shareholders of AutoMax, including a separate approval by AutoMax&#8217;s shareholders who are not controlling
shareholders of AutoMax or SciSparc. On August 14, 2024, the parties entered into the Merger Agreement Addendum, pursuant to which the
rights to terminate the Merger Agreement if the Merger was not consummated by August 30, 2024, was deferred to November 30, 2024. On
November 26, 2024, the parties entered into the Merger Agreement Second Addendum, pursuant to which the right to terminate the Merger
Agreement if the Merger was not consummated by November 30, 2024, was deferred to March 31, 2025. The Merger is expected to close during
the first quarter of 2025, subject to the approval of the shareholders of SciSparc, approval of AutoMax shareholders, and court approval,
as detailed in section entitled &#8220;<i>Regulatory Approvals</i>&#8221; in this proxy statement/prospectus, as well as other customary
conditions. Since the Merger is subject to a number of conditions, neither SciSparc nor AutoMax can anticipate either the timing of the
closing of the Merger or whether it will occur at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, SciSparc anticipates that per each AutoMax ordinary share AutoMax shareholders will receive the number of SciSparc&#8217;s
outstanding shares on fully-diluted basis, subject to certain exceptions, divided by 0.5001, multiplied by 0.4749, divided by (the number
of AutoMax&#8217;s outstanding shares, minus SciSparc&#8217;s holdings in AutoMax), so, that in any event, AutoMax shareholders (other
than SciSparc), together with the Advisor in connection with the Merger, shall own approximately 49.99% of SciSparc&#8217;s share capital,
on a fully-diluted basis, subject to certain exceptions. Under the Exchange Ratio formula described in the Merger Agreement, immediately
following the Merger, AutoMax&#8217;s shareholders, together with its Advisor in connection with the Merger, are expected to own approximately
49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders are expected to own approximately 50.01% of SciSparc&#8217;s
share capital, on a fully-diluted basis, subject to certain exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more complete description
of the Merger, please see the section entitled &#8220;<i>The Merger Agreement</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What will happen to SciSparc if, for any
reason, the Merger does not close?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, for any reason, the Merger
does not close, the SciSparc board of directors may, following the termination of the Merger Agreement, elect to, among other things,
attempt to complete another strategic transaction similar to the Merger, attempt to sell or otherwise dispose of certain assets of SciSparc
or continue to operate the business of SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Why are the two companies proposing to merge?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax believe
that the Merger will result in a combined company that will maximize shareholder value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s board of
directors considered a number of factors that supported its decision to approve the Merger Agreement. In the course of its deliberations,
SciSparc&#8217;s board of directors also considered a variety of risks and other countervailing factors related to entering into the
Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a discussion of SciSparc&#8217;s
reasons for the Merger, please see the section entitled &#8220;<i>The Merger &#8211; Reasons for the Merger.</i>&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What is the anticipated business of the combined
company?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc anticipates to continue
its current business activities as the parent company, while AutoMax&#8217;s current business activities will continue to be carried
out by AutoMax as a wholly-owned subsidiary of SciSparc.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Why am I receiving these materials?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are receiving these proxy
materials because you have been identified as a shareholder of SciSparc as of the record date, and you are entitled to vote at the Special
Meeting to approve the matters described in this proxy statement/prospectus. This proxy statement/prospectus contains important information
about the proposed Merger and the Special Meeting and you should read it carefully and in its entirety. The enclosed voting materials
allow you to authorize a proxy to vote your SciSparc ordinary shares without attending the Special Meeting. As promptly as practicable,
please complete, sign, date and mail your proxy card in the pre-addressed postage-paid envelope provided or call the toll-free telephone
number listed on your proxy card or access the Internet Web site described in the instructions on the enclosed proxy card.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What am I voting on?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">There are five matters
scheduled for a vote at the Special Meeting:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The approval of the consummation
of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and
the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. To approve the form of
Indemnification Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, effective upon
the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with all office holders
of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed to the board of
directors of SciSparc; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <span style="-keep: true">Subject to and contingent
upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President,
contingent upon the approval and closing of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. Subject to and contingent
upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the
effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">5. To approve a reverse
share split of SciSparc&#8217;s issued and outstanding ordinary shares in the range of a ratio of up to 1:100, to be effected at the
discretion of, at such number of increments, and on such dates, as may be determined by the SciSparc board of directors within 18 months
from the Special Meeting, or the Reverse Split.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What is required to consummate the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">To consummate the Merger,
Proposals Nos. 1, 2, 3, and 4 must be approved at the Special Meeting, or at any permitted adjournment thereof, by the requisite holders
of SciSparc ordinary shares on the record date for the Special Meeting. The Merger will not occur if Proposals Nos. 1, 2, 3, and 4 are
not approved by SciSparc&#8217;s shareholders. The approval of Proposal No. 5 is not required for the consummation of the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the requirement
of obtaining such shareholder approvals, each of the other closing conditions set forth in the Merger Agreement must be satisfied or
waived.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more complete description
of the closing conditions under the Merger Agreement, we urge you to read the section entitled &#8220;<i>The Merger Agreement &#8211;
Conditions to the Completion of the Merger</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Are there any federal or state regulatory
requirements that must be complied with or federal or state regulatory approvals or clearances that must be obtained in connection with
the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither SciSparc nor AutoMax
is required to make any filings or obtain any approvals or clearances from any antitrust regulatory authorities in the United States
or other countries to consummate the Merger. In the United States, SciSparc must comply with applicable federal and state securities
laws and Nasdaq rules and regulations in connection with the issuance of the shares in connection with the Merger, including the filing
with the SEC of this proxy statement/prospectus. In addition, in connection with the Merger, AutoMax has obtained a Withholding Tax Ruling
and a 104H Tax Ruling from the tax authorities in Israel; both SciSparc and AutoMax are required to comply with the provisions thereunder.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What will AutoMax shareholders receive in
the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
AutoMax shareholders will be entitled to receive SciSparc ordinary shares and pre-funded warrants exercisable into ordinary shares of
SciSparc in exchange for AutoMax ordinary shares in an amount to be calculated by the application of an Exchange Ratio formula in the
Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, each outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares, in accordance
with the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares that AutoMax shareholders will be entitled to receive to
account for changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc ordinary
shares issued pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger closes and
could vary significantly from the market value of the SciSparc ordinary shares on the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, AutoMax shareholders will receive SciSparc ordinary shares in exchange for AutoMax shares held by them in an amount equal
to the number of AutoMax shares held by each AutoMax shareholder multiplied by the Exchange Ratio. Certain AutoMax shareholders will
receive pre-funded warrants exercisable into SciSparc&#8217;s ordinary shares. No fractional SciSparc ordinary shares will be issued
in connection with the Merger. Instead, each AutoMax shareholder who otherwise would be entitled to receive a fractional SciSparc ordinary
share (after aggregating all fractional SciSparc ordinary shares issuable to such shareholder) will receive such amount rounded to the
nearest whole number of SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (other than SciSparc, which
currently holds shares in AutoMax) and its Advisor are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s
shareholders are expected to own approximately 50.01% of SciSparc&#8217;s share capital on a fully-diluted basis (subject to certain
exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exchange Ratio is the
result of the following calculation (rounded to four decimal places): the number of the SciSparc outstanding shares on a fully-diluted
basis (subject to certain exceptions) divided by 0.5001, multiplied by 0.4749, then divided by the number of the AutoMax outstanding
shares less the number of the AutoMax ordinary shares held by SciSparc; so that, in any event, immediately following the effective time,
holders of AutoMax outstanding shares (and its Advisor, but other than SciSparc), will hold together 49.99% of SciSparc&#8217;s share
capital, on a fully-diluted basis (subject to certain exceptions), immediately following the effective time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For example, if the Merger
were consummated as of February 7, 2025, then based on 10,828,251 SciSparc outstanding shares and 118,310,565 AutoMax outstanding shares,
each AutoMax shareholder would have been entitled to receive 1.097 SciSparc shares, equal to $0.54, based on the closing price of SciSparc
ordinary shares on Nasdaq on February 7, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more complete description
of what AutoMax shareholders will receive in the Merger, please see the sections entitled &#8220;<i>Market Price and Dividend Information</i>&#8221;
and &#8220;<i>The Merger Agreement &#8211;&#8201;Merger Consideration</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What is the AutoMax Shareholder Support Agreement?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the execution
of the Merger Agreement, certain shareholders of AutoMax entered into a shareholder support agreement, or the AutoMax Shareholder Support
Agreement, covering approximately 55.56% of the outstanding shares of AutoMax. The AutoMax Shareholder Support Agreement provides, among
other things, that the shareholders who are party to the AutoMax Shareholder Support Agreement will vote all of the shares of AutoMax
held by them in favor of the adoption of the Merger Agreement, the approval of the Merger and the other transactions contemplated by
the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What is the closing financing?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As part of the Merger
Agreement, SciSparc has agreed to transfer to AutoMax a total of $4.25 million at the closing, less any amount due by AutoMax to SciSparc
under any loan agreement between the parties, or the Closing Financing Amount. As of the date of his prospectus, SciSparc has advanced
to AutoMax the aggregate amount of the Closing Financing Amount, $4.25 million, as a loan, under the Bridge Loan (as defined below) and
its amendments thereto, to enable AutoMax to have sufficient cashflow to further develop its operations. As a result of AutoMax receiving
the entire Closing Financing Amount, SciSparc will have no obligations to transfer additional financing amounts to AutoMax at the closing
of the Merger. On the closing date of the Merger, SciSparc will be due interest at a rate of 7% per annum (or 9% per annum if the Merger
is not consummated), of the Loan Amount (as defined below), from the period starting December 1, 2024 and ending on the effective date
of the Merger. In consideration for the Loan Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s
shares of its wholly-owned subsidiary AutoMax Direct Import Ltd. (formerly known as AutoMax Leasing Ltd.), which it wholly owns, or AutoMax
Direct Import, in favor of SciSparc.</span></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Did SciSparc&#8217;s board of directors
obtain a&#160;third-party fairness opinion in determining whether or not to proceed with the Merger?</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">No. SciSparc&#8217;s board
of directors did not obtain a third-party fairness opinion. However, SciSparc&#8217;s board of directors obtained an independent third-party
valuation report from E.D.B. Consulting and Investments Ltd., or E.D.B. SciSparc&#8217;s board of directors ensured that the third-party
valuation met all necessary regulatory and legal standards, as there was no legal requirement under Israeli law to obtain a fairness
opinion in connection with the approval of the Merger. The board of directors of SciSparc also considered the cost implications, as fairness
opinions can be expensive, and determined that the third-party valuation provided sufficient information at a lower cost. SciSparc&#8217;s
board of directors believed that the valuation, conducted by a reputable independent firm with industry expertise, offered comprehensive
and reliable data adequate for making an informed decision about the Merger. For more information see &#8220;<i>Summary &#8212; Valuation
Report of E.D.B. Consulting and Investments Ltd</i>&#8221;.</span></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What will happen to AutoMax&#8217;s outstanding
options, warrants and Series B bonds in the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
each AutoMax warrant, option and certain convertible rights that had resulted from a prior AutoMax transaction (in each case, whether
or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled immediately prior to the
effective time for no consideration.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms
of AutoMax&#8217;s Series B Bonds and the Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual
installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that was made on
February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made on February
28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, due on February 28, 2025, will
constitute 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will
constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger the Series B Bonds will remain
outstanding and subject to repayment in accordance with the terms of the Trust Deed. The Series B Bonds bear interest at a rate of 5.9%
per annum. As of February 7, 2025, NIS 34,245 thousand (approximately $9,110 thousand) in principal amount of Series B Bonds remains
outstanding and will therefore become a liability of the combined company following the completion of the Merger. The next payment by
AutoMax to Series B bondholders is due on February 28, 2025, in the principal amount of NIS 13,698 thousand (approximately $3,644 thousand)
and NIS 996 thousand (approximately $265 thousand) of interest accrued thereon.</span></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Will holders of the SciSparc ordinary shares
issued in the Merger be able to sell those shares without restriction?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
                                            sale of the SciSparc ordinary shares and pre-funded warrants issued as consideration in the
                                            Merger are being registered under the Securities Act of 1933, as amended, or the Securities
                                            Act, pursuant to the registration statement of which this prospectus forms a part, and will
                                            be able to be sold without restriction following the consummation of the Merger for so long
                                            as such registration statement remains effective, other than shares held by affiliates that
                                            will be subject to resale restrictions as control securities under Rule 144.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who will be the directors of SciSparc following
the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At and immediately after
the effective time of the Merger, the board of directors of SciSparc is expected to be composed of the individuals set forth in the table
below. The directors shall serve until their respective successors are duly elected or appointed and qualified or their earlier death,
resignation or removal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; width: 35%; text-indent: 0pt"><b>Designee</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; padding: 0pt; border-bottom: Black 1.5pt solid; width: 10%"><b>Age</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; padding: 0pt; border-bottom: Black 1.5pt solid; width: 53%"><b>Position(s)</b></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><i>AutoMax Designees </i></span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Yaarah Alfi</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">36</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Financial Officer of AutoMax, director nominee of
    SciSparc</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Tomer Levy</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">29</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">VP Business Development and Headquarters,
    director of AutoMax, director nominee of SciSparc</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt; vertical-align: top"><span style="font-size: 10pt"><i>SciSparc Designees</i></span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Amitay Weiss</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">62</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chairman of SciSparc&#8217;s board of directors</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Amnon Ben Shay</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Moshe Revach</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">48</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Liat Sidi</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who will be the executive officers of SciSparc
immediately following the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately following the
Merger, the executive management team of SciSparc is expected to be composed as set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: left; vertical-align: bottom; width: 25%; text-indent: 0pt"><b>Name</b></td>
    <td style="padding: 0pt 0pt 1.5pt; text-align: center; width: 1%; text-indent: 0pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 27%; text-indent: 0pt"><b>Position
    with SciSparc</b></td>
    <td style="padding: 0pt 0pt 1.5pt; text-align: center; width: 1%; text-indent: 0pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 35%; text-indent: 0pt"><b>Current
    Position</b></td>
    <td style="padding: 0pt 0pt 1.5pt; text-align: center; width: 1%; text-indent: 0pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 10%; text-indent: 0pt"><b>Age</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Oz Adler</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Technology Officer</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Technology Officer</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">55</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>What interests do the current officers and directors of SciSparc
have in the merger?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In considering the recommendation
of SciSparc&#8217;s board of directors to vote in favor of the Merger, shareholders should be aware that, aside from their interests
as shareholders, certain of SciSparc&#8217;s directors and officers have interests in the Merger that differ from, or extend beyond,
those of SciSparc&#8217;s shareholders generally. SciSparc&#8217;s directors were aware of and considered these interests, among other
matters, in evaluating the Merger and in recommending to shareholders that they approve the Merger. Shareholders should take these interests
into account in deciding whether to approve the Merger. These interests include, among other things, the fact that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Each
                                            of Amnon Ben Shay, Moshe Revach and Liat Sidi will continue to be a director of the combined
                                            company after the effective time of the Merger, and, following the closing of the Merger,
                                            will be eligible to be compensated as a non-employee director of the combined company pursuant
                                            to the compensation policy of SciSparc;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subject
                                            to the approval of SciSparc shareholders by the requisite majority, as described further
                                            in this prospectus, SciSparc&#8217;s Chief Executive Officer, Chairman and President will
                                            each be entitled to receive a one-time cash bonus, subject to and upon the closing of the
                                            Merger;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
                                            to the Merger Agreement and form of Indemnification Agreement, SciSparc&#8217;s directors
                                            and executive officers are entitled to continued indemnification, expense advancement and
                                            insurance coverage; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Mr. Amitay Weiss, the Chairman of SciSparc&#8217;s
    board of directors, serves as the chairman of AutoMax&#8217;s board of directors. Pursuant to the terms of the Merger Agreement,
    Mr. Amitay Weiss will continue to be a director of the combined company after the closing of the Merger and will receive compensation
    as a director and be entitled to continued indemnification. In addition, if approved by SciSparc shareholders, Mr. Amitay Weiss will
    be entitled to receive a one-time cash bonus of $150,000 as the Chairman of SciSparc upon the closing of the Merger. These interests
    may present him with actual or potential conflicts of interest. Mr. Amitay Weiss recused himself from the decision of approving the
    Merger and did not participate in the discussion or voting on the matter due to his personal interest.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>What is the one-time bonus to be granted to SciSparc&#8217;s Chief
Executive Officer, Chairman and President?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc is proposing
that in connection with, and subject to, the closing of the Merger, Mr. Oz Adler, SciSparc&#8217;s Chief Executive Officer, shall receive
a cash bonus in the amount of $315,000. In addition, SciSparc is proposing that Mr. Amitay Weiss, SciSparc&#8217;s Chairman of the board
of directors, shall receive a cash bonus in the amount of $150,000, and Mr. Itschak Shrem, SciSparc&#8217;s President, shall receive
a cash bonus in the amount of $50,000, in connection with, and subject to, the closing of the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc&#8217;s
reasons for granting the above mentioned bonuses include providing an appropriate award for advancing SciSparc&#8217;s Restructuring
Plan (as defined below), including the recipients&#8217; individual contributions to the execution of the Merger Agreement and incentivizing
individual excellence and corporate performance. For more information see the section titled &#8220;<i>Proposal No. 3 &#8211; Approval
of a one-time cash bonus to the SciSparc </i></span><i>Chief Executive Officer, Chairman and President</i><span style="background-color: white">.&#8221;
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What are the material Israeli income tax
consequences of the Merger to me?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are urged to consult
with your own tax advisor for a full understanding of the tax consequences of the Merger to you, including the consequences under any
applicable, state, local, foreign or other tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more detailed description
of the material Israeli tax consequences of the Merger, see the section entitled &#8220;<i>The Merger &#8211; Certain Material Israeli
Income Tax Consequences of the Merger.</i>&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">What are the material U.S. federal income
tax consequences of the Merger to me?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">You are urged to consult
with your own tax advisor for a full understanding of the tax consequences of the Merger to you, including the consequences under any
applicable, state, local, foreign or other tax laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For a more detailed description of the material U.S. federal income
tax consequences of the Merger, see the section entitled &#8220;Material U.S. Federal Income Tax Considerations to U.S. Holders.&#8221;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a SciSparc shareholder, how does the
SciSparc board of directors recommend that I vote?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">After
careful consideration, the SciSparc board of directors recommends that SciSparc shareholders vote:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#8220;FOR&#8221;
                                            Proposal No. 1 to approve the consummation of the Merger and the other transactions contemplated
                                            by the Merger Agreement, including the issuance of SciSparc ordinary shares and the pre-funded
                                            warrants at the effective time of the Merger to the shareholders of AutoMax;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#8220;FOR&#8221;
                                            Proposal No. 2 to approve the form of Indemnification Agreement for directors and officers
                                            of SciSparc; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#8220;FOR&#8221;
                                            Proposal No. 3, subject to and contingent upon the approval of Proposal No. 1, to approve
                                            a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President,
                                            contingent upon the approval and closing of the Merger.</span></p></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#8220;FOR&#8221;
                                            Proposal No. 4, subject to and contingent upon the approval of Proposal No. 1, to elect each
                                            of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the effective
                                            time of the Merger and to ratify the class structure of the SciSparc board of directors.</span></td>
</tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#8220;FOR&#8221; Proposal No. 5, to approve a
    reverse share split of SciSparc&#8217;s issued and outstanding ordinary shares in the range of a ratio of up to 1:100, to be effected
    at the discretion of, at such number of increments, and on such dates, as may be determined by the SciSparc board of directors within
    18 months from the Special Meeting.</span></td></tr>
  </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">What
risks should I consider in deciding whether to vote in favor of the matters set forth above?</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully review
the section of this proxy statement/prospectus entitled &#8220;Risk Factors,&#8221; which sets forth certain risks and uncertainties
related to the Merger, risks and uncertainties to which SciSparc&#8217;s business will be subject, risks and uncertainties to which SciSparc,
as an independent company, is subject and risks and uncertainties to which AutoMax, as an independent company, is subject.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When do you expect the Merger to be consummated?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc anticipates that
the Merger will occur as promptly as practicable after the Special Meeting to be held &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025 and following satisfaction or waiver of all closing conditions, but cannot predict the exact timing. For a more complete description
of the closing conditions under the Merger Agreement, please see the section entitled &#8220;<i>The Merger Agreement &#8211;Conditions
to the Completion of the Merger</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What do I need to do now?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc urges you to read
this proxy statement/prospectus carefully, including its annexes, and to consider how the Merger affects you.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a shareholder
of record of SciSparc, you may provide your proxy instructions in one of two different ways. First, you can mail your signed proxy card
in the enclosed return envelope. Second, you may also provide your proxy instructions via telephone or the Internet by following the
instructions on your proxy card or instruction form. Please provide your proxy instructions only once, unless you are revoking a previously
delivered proxy instruction, and as soon as possible so that your shares can be voted at the Special Meeting. The laws of Israel, under
which SciSparc is incorporated, permit electronically transmitted proxies, provided that each such proxy contains or is submitted with
information from which it can determine that the proxy was authorized by the shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The telephone and Internet
voting procedures below are designed to authenticate shareholders&#8217; identities, to allow shareholders to grant a proxy to vote their
shares and to confirm that shareholders&#8217; instructions have been recorded properly. Shareholders granting a proxy to vote via the
Internet should understand there may be costs associated with electronic access, such as usage charges from Internet access providers
and telephone companies, that must be borne by the shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether you hold your shares
directly as the shareholder of record or beneficially in &#8220;street name,&#8221; you may vote your shares by proxy without attending
the Special Meeting. Depending on how you hold your shares, you may vote your shares in one of the following ways:</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">Shareholders
of Record: For Shares Registered in Your Name</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>By
                                            telephone or over the Internet</i>. You may vote your shares by telephone or via the Internet
                                            by following the instructions provided on your proxy card. If you vote by telephone or via
                                            the Internet, you do not need to return a proxy card by mail. If you have Internet access,
                                            we encourage you to record your vote on the Internet. It is convenient, reduces the use of
                                            natural resources and saves significant postage and processing costs. In addition, when you
                                            vote via the Internet or by phone prior to the Special Meeting&#8217;s date, your vote is
                                            recorded immediately and there is no risk that postal delays will cause your vote to arrive
                                            late and therefore not be counted.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>By
                                            Mail</i>. If you received printed proxy materials, you may submit your vote by completing,
                                            signing and dating each proxy card received and returning it in the prepaid envelope. Sign
                                            your name exactly as it appears on the proxy card.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>In
                                            person at the Special Meeting</i>. You may vote your shares in person at the Special Meeting.
                                            Even if you plan to attend the Special Meeting in person, we recommend that you also submit
                                            your proxy card or voting instructions or vote by telephone or via the Internet by the applicable
                                            deadline so that your vote will be counted if you later decide not to attend the Special
                                            Meeting.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">Beneficial
Shareholders: For Shares Registered in the Name of a Broker or Bank</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most beneficial owners whose
ordinary shares are held in &#8220;street name&#8221; receive instructions for granting proxies from their banks, brokers or other agents,
rather than using SciSparc&#8217;s proxy card. If you are a beneficial owner of your shares, you should have received a Voting Instruction
Form from the broker or other nominee holding your shares. You should follow the voting instructions provided by your broker or nominee
in order to instruct your broker or other nominee on how to vote your shares. The availability of telephone and Internet voting will
depend on the voting process of the broker or nominee. Shares held beneficially may be voted in person at the Special Meeting only if
you contact the broker or nominee giving you the right to vote the shares and obtain a legal proxy from such broker or nominee.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">General
Information for All Shares Voted Via the Internet or By Telephone</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Votes submitted by telephone
or via the Internet must be received by 11:59 p.m., Eastern Time on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. Submitting
your proxy by telephone or via the Internet will not affect your right to vote in person should you decide to attend the Special Meeting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who can vote at the Special Meeting?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, on the record date, your
SciSparc ordinary shares are registered directly in your name with the SciSparc transfer agent, you are considered to be the shareholder
of record with respect to those shares, and the proxy materials and proxy card are being sent directly to you by SciSparc. If you are
an SciSparc shareholder of record, you may attend the Special Meeting of SciSparc shareholders and vote your shares in person. Even if
you plan to attend the Special Meeting in person, SciSparc requests that you sign and return the enclosed proxy to ensure that your shares
will be represented at the Special Meeting if you are unable to attend.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, on the record date, your
ordinary shares are held in a brokerage account or by another nominee, you are considered the beneficial owner of ordinary shares held
in &#8220;street name,&#8221; and the proxy materials are being forwarded to you by your broker or other nominee together with a voting
instruction card. As the beneficial owner, you are also invited to attend the Special Meeting of SciSparc shareholders. Because a beneficial
owner is not the shareholder of record, you may not vote these shares in person at the Special Meeting unless you obtain a proxy from
the broker, trustee or nominee that holds your shares, giving you the right to vote the shares at the Special Meeting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">How are votes counted?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Votes will be counted
in the Special Meeting, including votes &#8220;For&#8221; and &#8220;Against,&#8221; abstentions and, if applicable, broker non-votes.
Abstentions will have no effect and will not be counted towards the vote total with respect to Proposals Nos. 1 through 5. Broker non-votes
will not be counted towards the vote total for any proposal.</span></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What are &#8220;broker non-votes&#8221;?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If you hold SciSparc ordinary
shares beneficially in street name and do not provide your broker or other agent with voting instructions, your SciSparc ordinary shares
may constitute &#8220;broker non-votes.&#8221; Broker non-votes occur on a matter when banks, brokers and other nominees are not permitted
to vote on certain non-discretionary matters without instructions from the beneficial owner and instructions are not given. These matters
are referred to as &#8220;non-discretionary&#8221; matters. Proposals Nos. 1 through 5 are non-discretionary matters. As a result, banks,
brokers and other nominees will not have discretion to vote on Proposals Nos. 1 through 5.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Broker non-votes will
not be considered as votes cast by the holders of SciSparc ordinary shares present in person or represented by proxy at the Special Meeting,
and will therefore not have any effect with respect to Proposals Nos. 1 through 5.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">How many votes are needed to approve each
proposal?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 8%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proposal
    Number</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proposal
    Description</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
    Required for Approval</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    approve the consummation of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of
    SciSparc ordinary shares and the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A simple majority
    of shareholders present (in person or by proxy) and voting on the matter (excluding abstentions)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    approve the form of Indemnification Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus,
    effective upon the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with
    all office holders of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed
    to the board of directors of SciSparc.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            simple majority of all votes properly cast in person or by proxy at the Special Meeting (excluding
                                            abstentions), and the fulfillment of one of the following additional voting requirements:</span></p>
                                                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                    <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
                                            &#160;the majority of the Shares that are voted at the Special Meeting in favor of the Proposal,
                                            excluding abstentions, includes a majority of the votes of shareholders who are not controlling
                                            shareholders or do not have a personal interest in the approval of the Proposal (each, an
                                            &#8220;Interested Shareholder&#8221;); or (ii) the total number of Shares of the shareholders
                                            mentioned in clause (i) above that are voted against the Proposal does not exceed two percent
                                            (2%) of the total voting rights in the Company.</span></p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Subject
                                            to and contingent upon the approval of Proposal No. 1, to approve a one-time cash bonus to
                                            SciSparc&#8217;s Chief Executive Officer, Chairman and President, contingent upon the approval
                                            and closing of the Merger.</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            simple majority of all votes properly cast in person or by proxy at the Special Meeting (excluding
                                            abstentions), and the fulfillment of one of the following additional voting requirements:</span></p>
                                                                    <p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p>
                                                                    <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
                                            &#160;the majority of the Shares that are voted at the Special Meeting in favor of the Proposal,
                                            excluding abstentions, includes a majority of the votes of shareholders who are not controlling
                                            shareholders or do not have a personal interest in the approval of the Proposal (each, an
                                            &#8220;Interested Shareholder&#8221;); or (ii) the total number of Shares of the shareholders
                                            mentioned in clause (i) above that are voted against the Proposal does not exceed two percent
                                            (2%) of the total voting rights in the Company.</span></p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to and contingent upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board
    of directors upon the effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A simple majority
    of all votes properly cast in person or by proxy at the Special Meeting.</span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">5.</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To approve a reverse share split of SciSparc&#8217;s issued and
    outstanding ordinary shares in the range of a ratio of up to 1:100, to be effected at the discretion of, at such number of increments,
    and on such dates, as may be determined by the SciSparc board of directors within 18 months from the Special Meeting.</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">A simple majority of all votes properly cast in person or by proxy at the Special Meeting.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">The term &#8220;controlling
                                            shareholder&#8221; means a shareholder having the ability to direct the activities of a company,
                                            other than by virtue of being an office holder. A shareholder is presumed to be a controlling
                                            shareholder if the shareholder holds 50% or more of the voting rights in a company or has
                                            the right to appoint the majority of the directors of the company or its general manager.
                                            To the knowledge of SciSparc, there is no shareholder who is a controlling shareholder. For
                                            the purpose of Proposals Nos. 2 and 3, the term controlling shareholder shall also include
                                            a person who holds 25% or more of the voting rights in the general meeting of the company
                                            if there is no other person who holds more than 50% of the voting rights in the company;
                                            for the purpose of a holding, two or more persons holding voting rights in the company each
                                            of which has a personal interest in the approval of the transaction being brought for approval
                                            of the company will be considered to be joint holders.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ix<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Under the Israeli
                                            Companies Law, 5759-1999, or the Companies Law, a &#8220;personal interest&#8221; of a shareholder
                                            in an action or transaction of a company includes a personal interest of any of the shareholder&#8217;s
                                            relatives (i.e. spouse, brother or sister, parent, grandparent, child as well as child, brother,
                                            sister or parent of such shareholder&#8217;s spouse or the spouse of any of the above) or
                                            an interest of a company with respect to which the shareholder or the shareholder&#8217;s
                                            relative (as defined above) holds 5% or more of such company&#8217;s issued shares or voting
                                            rights, in which any such person has the right to appoint a director or the chief executive
                                            officer or in which any such person serves as director or the chief executive officer, including
                                            the personal interest of a person voting pursuant to a proxy which the proxy grantor has
                                            a personal interest, whether or not the person voting pursuant to such proxy has discretion
                                            with regards to the vote; and excludes an interest arising solely from the ownership of ordinary
                                            shares of a company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Under Israeli law, every
voting shareholder is required to notify the Company whether such shareholder is an Interested Shareholder.&#160;To avoid confusion,
every shareholder voting by means of the enclosed proxy card or voting instruction form, or via telephone or internet voting, will be
deemed to confirm that such shareholder is NOT an Interested Shareholder. If you are an Interested Shareholder (in which case your vote
will only count for or against the ordinary majority, and not for or against the special tally under Proposals Nos. 2 and 3), please
notify Mr. Oz Adler, Chief Financial Officer, at c/o SciSparc Ltd.,&#160;20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel,
telephone: +972-3-717-5777 or by email (oz@scisparc.com). If your shares are held in &#8220;street name&#8221; by your broker, bank or
other nominee and you are an Interested Shareholder, you should notify your broker, bank or other nominee of that status, and they in
turn should notify the Company as described in the preceding sentence.</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When and where will the Special Meeting
of SciSparc shareholders be held?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Special Meeting of SciSparc
shareholders will be held at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, local time, on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025, at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Subject to space availability, all SciSparc shareholders
as of the record date, or their duly appointed proxies, may attend the meeting. Since seating is limited, admission to the meeting will
be on a first-come, first-served basis. Registration and seating will begin at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
local time. Any such change will be announced in a Report of Foreign Private Issuer on Form 6-K furnished to the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What happens if I do not return a proxy
card or otherwise provide proxy instructions, as applicable?</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">Shareholder
of Record: Shares Registered in Your Name</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a shareholder
of record and do not vote by telephone, through the Internet, by completing the enclosed proxy card or in person at the Special Meeting,
your shares will not be voted.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">Beneficial
Owner: Shares Registered in the Name of a Broker or Bank</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Proposals Nos. 1, 2, 3,
4, and 5 are non-discretionary matters. As a result, banks, brokers and other nominees will not have discretion to vote on Proposals
Nos. 1, 2, 3, 4, and 5.</span></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What if I return a proxy card or otherwise
vote but do not make specific choices?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If you return a signed
and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221;
the approval of the consummation of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance
of SciSparc ordinary shares and pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax, as contemplated
by the Merger Agreement (Proposal No. 1); &#8220;For&#8221; the approval of the form of Indemnification Agreement between SciSparc and
its directors (Proposal No.2); &#8220;For&#8221; the approval of a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman
and President (Proposal No. 3); &#8220;For&#8221; the approval of the election of each of Tomer Levy and Yaarah Alfi and ratification
of classes, subject to approval of Proposal No. 1. (Proposal No. 4); and &#8220;For&#8221; the approval of the Reverse Split (Proposal
No. 5).</span></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May I change my vote after I have submitted
a proxy or provided proxy instructions?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s shareholders
of record, may change their vote at any time before their proxy is voted at the Special Meeting in one of three ways. First, a shareholder
of record of SciSparc can send a written notice to the Chief Executive Officer of SciSparc stating that it would like to revoke its proxy.
Second, a shareholder of record of SciSparc can submit new proxy instructions either on a new proxy card or via telephone or the Internet.
Third, a shareholder of record of SciSparc can attend the Special Meeting and vote in person. Attendance alone will not revoke a proxy.
If an SciSparc shareholder of record or a shareholder who owns SciSparc shares in &#8220;street name&#8221; has instructed a broker to
vote its SciSparc ordinary shares, the shareholder must follow directions received from its broker to change those instructions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your most current proxy card
or telephone or Internet proxy is the one that is counted.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->x<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should AutoMax&#8217;s and SciSparc&#8217;s
shareholders send in their share certificates now?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No. To the extent AutoMax&#8217;s
and SciSparc&#8217;s shareholders have certificated shares, such shareholders should keep their existing share certificates at this time.
Similarly, holders of shares that are held in book-entry form should refrain from attempting to surrender their shares currently. Shareholders
should await further instructions in relation to their share certificates, if any.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Am I entitled to dissenters&#8217; rights?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No, SciSparc&#8217;s shareholders
are not entitled to dissenters&#8217; rights in connection with the Merger.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Have AutoMax&#8217;s shareholders agreed
to adopt the Merger Agreement?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[Yes]. On , 2025, AutoMax&#8217;s shareholders adopted the Merger Agreement
and approved the Merger and related transactions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who is paying for this proxy solicitation?</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc will bear the cost
of soliciting proxies. In addition to these proxy materials, SciSparc&#8217;s directors and employees may also solicit proxies in person,
by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting
proxies. SciSparc and AutoMax may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to
beneficial owners.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What is the quorum requirement?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A quorum of shareholders is necessary to hold a valid meeting. The
presence (in person or by proxy) of any two or more shareholders holding, in the aggregate, at least 15% of the voting power of SciSparc&#8217;s
ordinary shares constitutes a quorum for purposes of the Special Meeting. On the record date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
SciSparc ordinary shares outstanding and entitled to vote. Thus, the holders of at least &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares must be present in person or represented
by proxy at the Special Meeting to have a quorum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your shares will be counted
towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if
you vote in person at the Special Meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If half an
hour has elapsed from the time set for the Special Meeting and a quorum is not present, the Special Meeting will be adjourned to the
following day, at the same time and place, or to a different date, as shall be determined by the board of directors in a notice to the
shareholders. If a quorum is not present at the adjourned Special Meeting, as stated above, a minimum of one shareholder, whether present
in person or by proxy, shall be deemed as constituting a quorum.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What happens if a quorum is not present?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If half an hour has elapsed
from the time set for the Special Meeting and a quorum is not present, the Special Meeting will be adjourned to the same day the following
week, at the same time and place.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who can help answer my questions?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a SciSparc shareholder
and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger and related
transactions, including the procedures for voting your shares, you should contact the Chief Executive Officer of SciSparc, at the following
address and phone number: 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup> Floor, Tel Aviv Israel, 6971916, or by calling +972-3-7175777.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<a id="m_002"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SUMMARY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This summary highlights
selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better
understand the Merger, and the proposals being considered at the Special Meeting, you should read this entire proxy statement/prospectus
carefully, including the Merger Agreement attached as Annex A, the form of the AutoMax Shareholder Support Agreement and form of Indemnification
Agreement attached as Annexes B and C and the other annexes to which you are referred herein. You may obtain the information incorporated
by reference into this proxy statement/prospectus without charge by following the instructions in the section entitled &#8220;Where You
Can Find More Information&#8221; beginning on page 240.</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Companies</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20 Raul Wallenberg Street</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Tower A</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Tel Aviv</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6971916 Israel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">+972-3-7175777</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">SciSparc
is a specialty clinical-stage pharmaceutical company. SciSparc&#8217;s focus is creating and enhancing a portfolio of technologies and
assets based on cannabinoid therapies. With this focus, SciSparc is currently engaged in the following development programs based on
&#916;9-tetrahydrocannabinol, or THC, and/or non-psychoactive cannabidiol, or CBD, and/or other cannabinoid receptors, or CBR, agonists:
SCI-110 for the treatment of Tourette syndrome, or TS, for the treatment of obstructive sleep apnea, or OSA, and for the treatment of
Alzheimer&#8217;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of Autism Spectrum Disorder,
or ASD, and Status Epilepticus, or SE. SciSparc also has a majority-owned subsidiary whose business focuses on the sale of hemp seeds
oil-based products and others on Amazon Marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-110
is a proprietary drug candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and
(2) CannAmide&#8482;, a proprietary Palmitoylethanolamide, or PEA, formulation. PEA is an endogenous fatty acid amide that belongs to
the class of nuclear factor agonists, which are molecules that regulate the expression of genes. SciSparc believes that the combination
of THC and PEA may induce a reaction known as the &#8220;sparing effect,&#8221; which has strong potential to treat various diseases
such as TS, OSA and Alzheimer&#8217;s disease&#160;and agitation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">SCI-210
is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. SciSparc believes that the combination of
CBD and PEA may also induce a sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-160
is a novel pharmaceutical preparation containing a cannabinoid receptor type 2, or CB2 receptor, agonist for the treatment of pain. This
innovative CB2 receptor agonist was synthesized by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry at the Hebrew University,
a member of the SciSparc Scientific Advisory Board. SciSparc believes that modulating CB2 receptor activity by selective CB2 receptor
agonists holds unique therapeutic potential for addressing pain conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">SciSparc
believes that modulating CB2 receptor activity by selective CB2 receptor agonists holds unique therapeutic potential for addressing pain
conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><span style="background-color: white">&#160;</span></p>

</div><div>


</div><!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Pursuant
to the positive results obtained in a phase IIa TS study conducted at Yale School of Medicine, SciSparc is developing a regulatory dossier
to be submitted to the U.S. Food and Drug Administration, or FDA, The German Federal Institute for Drugs and Medical Devices, or BfArM,
and the Israeli Ministry of Health, or MoH, for its SCI-110 program for TS.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
was incorporated under the laws of the State of Israel on August 23, 2004. SciSparc&#8217;s ordinary shares are listed on the Nasdaq
Capital Market under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is completed,
the business of AutoMax will become the business of SciSparc as described beginning on page 176 of this proxy statement/prospectus under
the caption &#8220;<i>AutoMax Business</i>.&#8221;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AutoMax Motors Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Harehavim 15,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Jerusalem,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9346213, Israel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">+972-2-622-5987</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax
                                            imports and markets a variety of private vehicle models, from various categories such as
                                            small vehicles, crossovers, executive vehicles, premium vehicles, work vehicles, and buses
                                            manufactured by Temsa. AutoMax&#8217;s operations are conducted in Israel. AutoMax believes
                                            there are several primary factors that contribute to the success of vehicle importers in
                                            Israel, including: (i) innovative vehicle models and the manner in which these are branded
                                            among customers; (ii) trade conditions, especially the exchange rates of the foreign currencies
                                            in which the importer imports in comparison to the currency exchange rates of competitors;
                                            (iii) the existence of good relations with the manufacturer and/or the agent which is also
                                            reflected in import prices; (iv) the technological quality of the imported vehicles; (v)
                                            high marketing ability of the importer, which is also reflected in the adjustment of the
                                            vehicle and the prices to market demands; (vi) the level of provided service and the reputation
                                            of the importer; (vii) good geographical layout of purchasing agencies across the world (especially
                                            true for parallel importers, who purchase non-counterfeit product imported from different
                                            countries to be sold on the open market); and (viii) the geopolitical situation in the countries
                                            from which the vehicles are imported. AutoMax&#8217;s clients range from private customers
                                            to institutional customers, including companies that lease, rent, and operate vehicle fleets,
                                            and car dealerships.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax operates through
various subsidiaries, which include Dalhom AutoMax Ltd., of which it holds 50% of the voting rights, or Dalhom AutoMax; AutoMax Trade-In
Ltd., of which it holds 80% of the voting rights, or AutoMax Trade-In; AutoMax Direct Import Ltd.; and Global AutoMax Ltd., which it
wholly owns, or Global AutoMax.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Global AutoMax holds a number
of subsidiaries: AutoMax HaShfela Ltd., in which it holds 50% of the voting rights; AutoMax Netanya Ltd., a wholly owned subsidiary;
AutoMax Fleet Vehicles Ltd., in which Global AutoMax holds 50% of the voting rights; and AutoMax HaSharon Ltd., in which Global AutoMax
holds 67% of the voting rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Industry Overview</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The vehicle market in Israel
differs from most vehicle markets in the world due to the absence of open land borders for free trade in vehicles and high import duties.
The percentage of vehicle ownership in Israel is relatively low compared to various Western countries, due to, among other factors, the
relatively high price of vehicles, mainly due to high taxation, inferior road infrastructure compared to other Western countries, and
high population density. Furthermore, the vehicle market in Israel includes a relatively large number of vehicle importers, compared
to other sectors in the economy, that import vehicles that are manufactured in different countries around the world. Most vehicle importers
import several brands and products. The development of the automotive market in Israel is characterized by fluctuations resulting from
changes in the macroeconomic environment of the economy, among other factors. The main characteristics of the automotive market that
affect AutoMax&#8217;s activity and the competitors in this market are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 92%; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>High
    dependence on suppliers</i>. The success of vehicle importers depends mainly on the relationship with manufacturers of the vehicles
    imported and the strategy of the manufacturers&#8217; activity in relation to the launch of new products, brand positioning in the
    world, model policy, trade conditions, price policy and marketing support. It should be noted that the dependence on the vehicle
    manufacturers is mainly relevant to the direct importers who have, in practice, exclusive franchise agreements with manufacturers
    whose products they import to Israel. AutoMax believes that it has no significant reliance on the activity of a particular vehicle
    manufacturer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

</div><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; width: 92%"><span style="font-size: 10pt"><i>Changes in consumer preferences</i>. The vehicle preferences
    in Israel are subject to frequent changes, resulting from the preference of certain models by consumers, and due to a variety of
    factors, including but not limited to, engine type (diesel, oil, electric, hybrid or gasoline), the size of the vehicle, its design,
    technological advantages, environmental rating, fuel economy, safety standard, price and marketability on the resale market.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Taxation of vehicles</i>. The importing of most private vehicles
    in Israel is subject to purchase taxes, Value Added Tax and customs imposed at cumulative rates of approximately 30%-130% (or, oftentimes,
    more), of the cost of the vehicles. The aforementioned tax rates are among the highest in the world. Changes in tax rates, including
    reduction in tax rates given to vehicles of a certain type, have a direct impact on the preferences of customers in the area of activity.
    In addition, changes in taxation on vehicles provided to employees as part of their employment conditions may affect their preference
    in relation to receiving vehicles from the workplace versus purchasing.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Fuel and electricity prices</i>. Changes in fuel and electricity
    prices may have an impact on consumer preferences in the long term. Vehicle model preferences vary depending on the type of energy
    used (i.e., diesel, gas, gasoline, or electricity) and each such energy price.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Regulation</i>. The automotive industry in Israel is characterized
    by vast regulation and strict regulatory requirements, including the standardization requirements, which may affect the Company&#8217;s
    expenditure and the results of its operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Infrastructure levels and density of the roads</i>. According to
    research conducted by the Bank of Israel, the roads in Israel are characterized by high levels of density, especially in the areas
    with greater population concentration. This affects the scope of vehicle purchases and is expected to affect it in the future as
    well.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in currency and interest rates as well as the economic environment.</span></td></tr>
  </table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">AutoMax
operates in two highly competitive industries: the vehicle industry in Israel as an importer and seller and in the international vehicle
industry as a purchaser of vehicles. The value chain in the automotive industry includes international vehicle manufacturers, vehicle
importers, vehicle dealers (over 8,000 authorized vehicle dealers), financing entities and end users: households, corporate firms and
public organizations. According to the Automotive Industry Review published by Dun &amp; Bradstreet in February 2024, or the Automotive
Industry Review, there are approximately 20 official import groups representing various manufacturers in Israel, which are responsible
for approximately 97% of the automotive imports to Israel. Alongside these, there are several dozen parallel importers who are collectively
responsible for approximately 3% of the imports. However, during the years 2019 to 2024, a small number of parallel importers were responsible
for approximately 75% of the total parallel import to Israel. Additionally, there are vehicle leasing and rental companies, consisting
of approximately five primary companies, alongside smaller companies.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">According
to the Automotive Industry Review, as of year-end-2023, there were approximately 4.1 million vehicles on the roads in Israel, of which,
approximately 86% are private vehicles. According to the State of Israel Central Bureau of Statistics, despite a relatively low level
of vehicle ownership in Israel, based on the number of vehicles per 1,000 residents, the traffic density remains among the highest in
the world. Based on studies conducted in previous years, as detailed in Automotive Industry Review, the density is 3.5 times higher than
the Organization for Economic Co-operation and Development, or the OECD, average. The main contributors are the concentration of population
in central Israel, an underdeveloped public transportation system and the lack of correlation between the construction of roads and the
increase in population.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>SciSparc Merger Sub Ltd.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc Merger Sub Ltd.
is a wholly-owned subsidiary of SciSparc, and was formed solely for the purposes of carrying out the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Merger (see page 90 and page 110)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is completed,
Merger Sub will merge with and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary of SciSparc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, each AutoMax ordinary share outstanding immediately prior to the effective time (excluding certain AutoMax ordinary shares
that may be cancelled pursuant to the Merger Agreement) will be automatically converted into the right to receive a number of SciSparc
ordinary shares and pre-funded warrants. The Exchange Ratio has been determined pursuant to a formula described in more detail in the
Merger Agreement and later in this proxy statement/prospectus. Under the Exchange Ratio formula described in the Merger Agreement, immediately
following the Merger, AutoMax&#8217;s shareholders, and its Advisor in connection with the Merger, are expected to own approximately
49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders are expected to own approximately 50.01% of SciSparc&#8217;s
share capital, on a fully-diluted basis, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Exchange Ratio is based on the number of
SciSparc&#8217;s outstanding shares on a fully-diluted basis, subject to certain exceptions, divided by 0.5001, multiplied by 0.4749,
divided by (the number of AutoMax&#8217;s outstanding shares minus SciSparc&#8217;s holdings in AutoMax), so, that in any event, AutoMax
shareholders (other than SciSparc) shall own approximately 49.99% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject
to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
</div><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the Merger
will occur as promptly as practicable but in no event later than the second business day after the last of the conditions to the Merger
has been satisfied or waived, other than those conditions that by their nature are to be satisfied at the closing of the Merger, but
subject to the satisfaction or waiver of each such conditions, or at such other time as SciSparc and AutoMax agree. SciSparc and AutoMax
anticipate that the consummation of the Merger will occur in SciSparc&#8217;s first quarter of 2025, the quarter ending March 31, 2025.
However, because the Merger is subject to a number of conditions, neither SciSparc nor AutoMax can predict exactly when the closing of
the Merger will occur or if it will occur at all.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following diagrams illustrate
the corporate structure of SciSparc prior to and following the consummation of the Merger:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation
of the Merger:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_023.jpg" style="width: 493px; height: 132px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the consummation
of the Merger:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_024.jpg" style="width: 521px; height: 329px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reasons for the Merger (see page 96)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax believe
that the combined company will have the following potential advantages:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the range
    of options available to the combined company to access the public equity markets to fund future capital needs or to complete business
    development transactions, which would likely be greater than the options available to AutoMax alone as a publicly traded company
    on the Tel-Aviv Stock Exchange Ltd., or TASE;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected
    reaction and support of the transaction from the market, investment banks, AutoMax shareholders and SciSparc shareholders;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the
    Merger will result in AutoMax shareholders, in exchange for their AutoMax shares, receiving shares in SciSparc, a publicly traded
    company on Nasdaq, which would provide AutoMax shareholders with the opportunity to obtain greater liquidity for their shares than
    on TASE;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Merger
    will make AutoMax more profitable and enable it to continue the process of diversifying the vehicles it imports and sells in Israel;
    and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the average
                                            daily trading volume of SciSparc shares is greater than the average daily trading volume
                                            in AutoMax&#8217;s shares, and therefore the combined entity is expected to have a higher
                                            trading volume.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the boards of directors
of SciSparc and AutoMax also considered other factors for the Merger, as described herein. For example, the SciSparc board of directors
considered, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the strategic
                                            alternatives to the Merger available to SciSparc, including the discussions that SciSparc&#8217;s
                                            management and the SciSparc board of directors previously conducted with other potential
                                            merger partners;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the risks
                                            associated with continuing to operate SciSparc on a stand-alone basis, including liquidity
                                            needs and cash-burn relating to, among other things, funding SciSparc&#8217;s contemplated
                                            clinical trials<span style="background-color: white">;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s
                                            management&#8217;s belief that it would be difficult to obtain sufficient equity or debt
                                            financing on acceptable terms, if at all;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the valuation
                                            report prepared by an independent valuator by E.D.B., as to the valuation of AutoMax pursuant
                                            to the Merger Agreement to SciSparc, as more fully described below in the section entitled
                                            &#8220;&#8212;<i>Valuation Report of E.D.B. Consulting and Investments Ltd</i>&#8221;; and</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#9679;</td><td style="text-align: justify">Mr. Weiss&#8217; dual role as both
                                            the Chairman of SciSparc&#8217;s board of directors, and as the chairman of AutoMax&#8217;s
                                            board of directors, and whether his interests in the Merger may differ from, or extend beyond,
                                            the interests of SciSparc&#8217;s shareholders generally.</td></tr>
     </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Valuation Report of E.D.B. Consulting and
Investments Ltd. (see page 101)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the March 31, 2024 meeting
of the board of directors of SciSparc, representatives of E.D.B. presented a valuation report of AutoMax, based upon and subject to the
assumptions made, procedures followed, matters considered and qualifications and limitations on the scope of the review undertaken by
E.D.B. in connection with the preparation of its valuation report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. provided its valuation
report for the information and assistance of SciSparc&#8217;s board of directors (in its capacity as such) in connection with, and for
purposes of, its consideration of the Merger and its valuation report only addresses the valuation of AutoMax. The valuation report of
E.D.B. did not address any other term or aspect of the Merger Agreement or the Merger. The valuation report does not constitute a recommendation
to the board of directors of SciSparc or any SciSparc shareholder as to how the SciSparc board of directors, such shareholder or any
other person should vote or otherwise act with respect to the Merger or any other matter.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overview of the Merger Agreement (see page
111)</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Merger Consideration and Exchange
Ratio (see page 103)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time, each
outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares and pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares and pre-funded warrants that AutoMax shareholders will
be entitled to receive for changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc
ordinary shares issued pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger
closes and could vary significantly from the market value of the SciSparc ordinary shares on the date of this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, each AutoMax shareholder will receive SciSparc ordinary shares in exchange for its AutoMax shares in an amount equal to the
number of AutoMax shares held by such AutoMax shareholder multiplied by the Exchange Ratio. Certain AutoMax shareholders will receive
pre-funded warrants exercisable into SciSparc&#8217;s ordinary shares. No fractional SciSparc ordinary shares will be issued in connection
with the Merger. Instead, each AutoMax shareholder who otherwise would be entitled to receive a fractional SciSparc ordinary shares (after
aggregating all fractional SciSparc ordinary shares issuable to such AutoMax shareholder) will receive such amount rounded to the nearest
whole number of SciSparc ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
</div><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders, and its Advisor in connection
with the Merger, are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders, immediately
prior to the Merger are expected to own approximately 50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to
certain exceptions. The Exchange Ratio formula is based on the number of SciSparc&#8217;s outstanding shares on a fully-diluted basis,
subject to certain exceptions, divided by 0.5001, multiplied by 0.4749, divided by (the number of AutoMax&#8217;s outstanding shares
minus SciSparc&#8217;s holdings in AutoMax), so, that in any event, AutoMax shareholders (other than SciSparc) shall own approximately
49.99% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Treatment of AutoMax Warrants, Share
Options and Series B Bonds</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
each AutoMax warrant, option, and certain convertible rights that had resulted from a prior AutoMax transaction (in each case, whether
or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled immediately prior to the
effective time for no consideration.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms
of AutoMax&#8217;s Series B Bonds and the Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual
installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that was made on
February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made on February
28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, due on February 28, 2025, will
constitute 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will
constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger the Series B Bonds will remain
outstanding and subject to repayment in accordance with the terms of the Trust Deed. The Series B Bonds bear interest at a rate of 5.9%
per annum. As of February 7, 2025, NIS 34,245 thousand (approximately $9,110 thousand) in principal amount of Series B Bonds remains
outstanding and will therefore become a liability of the combined company following the completion of the Merger. The next payment by
AutoMax to Series B bondholders is due on February 28, 2025, in the principal amount of NIS 13,698 thousand (approximately $3,644 thousand)
and NIS 996 thousand (approximately $265 thousand) of interest accrued thereon.</span></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conditions to the Completion of the
Merger (see page 125)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations to consummate
the Merger and the other transactions contemplated by the Merger Agreement shall be subject to the satisfaction or waiver, on or prior
to the closing of the Merger, of the conditions set forth in the section entitled &#8220;<i>The Merger Agreement &#8211;&#8201;Conditions
to the Completion of the Merger</i>&#8221; below.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No Solicitation by SciSparc and AutoMax
(see page 126)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax
and their representatives are prohibited by the terms of the Merger Agreement from (i) soliciting, initiating or knowingly encouraging,
inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry or
take any action that could reasonably be expected to lead to an acquisition proposal or acquisition inquiry; (ii) furnishing any non-public
information regarding SciSparc or AutoMax, as applicable, or any of its respective subsidiaries to any person in connection with or in
response to an acquisition proposal or acquisition inquiry; (iii) engaging in discussions or negotiations with any person with respect
to any acquisition proposal or acquisition inquiry; (iv) approving, endorsing or recommending any acquisition proposal; (v) executing
or entering into any letter of intent or any contract contemplating or otherwise relating to any acquisition transaction; or (vi) publicly
proposing to do any of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>Share Ownership of SciSparc
Directors and Executive Officers </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement/prospectus, SciSparc&#8217;s directors and executive officers as a group, owned and were entitled to vote  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
shares of SciSparc&#8217;s ordinary shares, or &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
% of the outstanding shares of SciSparc ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The directors and executive
officers have informed us that they intend to vote all of their shares of SciSparc&#8217;s ordinary shares <b><i>&#8220;FOR&#8221;&#160;</i></b>the
approval of the reincorporation merger and&#160;<b><i>&#8220;FOR&#8221;</i></b>&#160;any adjournment of the special general meeting,
if necessary or appropriate, to solicit additional proxies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>Share Ownership of AutoMax
Directors and Executive Officers </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement/prospectus, AutoMax&#8217;s directors and executive officers as a group, owned and were entitled to vote &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
 shares of AutoMax&#8217;s ordinary shares, or &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
% of the outstanding shares of AutoMax ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The directors and executive
officers have informed us that they intend to vote all of their shares of AutoMax&#8217;s ordinary shares <b><i>&#8220;FOR&#8221;&#160;</i></b>the
approval of the reincorporation merger and&#160;<b><i>&#8220;FOR&#8221;</i></b>&#160;any adjournment of the special general meeting,
if necessary or appropriate, to solicit additional proxies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
</div><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Termination (see page 131)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Either SciSparc or AutoMax
can terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated. In the event that
the Merger Agreement is terminated, neither party is required to pay a termination fee to the other party.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AutoMax Shareholder Support Agreement
(see page 133)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the execution
of the Merger Agreement, certain shareholders of AutoMax entered into the AutoMax Shareholder Support Agreement, covering approximately
55.56% of the outstanding shares of AutoMax. The AutoMax Shareholder Support Agreement provides, among other things, that the shareholders
party to the AutoMax Shareholder Support Agreement will vote all of the shares of AutoMax held by them in favor of the adoption of the
Merger Agreement, the approval of the Merger and the other transactions contemplated by the Merger Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Indemnification Agreement (see page 133)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to approval by the
shareholders in this Special Meeting, SciSparc will enter into a form of Indemnification Agreement with each of its office holders.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executive Officers of SciSparc Following
the Merger (see page 125)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately following the
Merger, the executive management team of SciSparc is expected to be composed as set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom; width: 18%"><b>Name</b></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom; width: 30%"><b>Position with SciSparc</b></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom; width: 31%"><b>Current Position</b></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom; width: 18%"><b>Age</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Oz Adler</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Technology Officer</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Technology Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td></tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors of SciSparc Following the Merger
(see page 125)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At and immediately after
the effective time of the Merger, the board of directors of SciSparc and its committees are expected to be composed of the individuals
set forth in the table below. The directors shall serve until their respective successors are duly elected or appointed and qualified
or their earlier death, resignation or removal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 19%"><b>Designee</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: top"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 8%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; width: 71%"><b>Position(s)</b></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>AutoMax Designees</i></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaarah Alfi</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer of AutoMax</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tomer Levy</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP Business Development and Headquarters, director
    of AutoMax</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SciSparc Designees</i></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors of SciSparc</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amnon Ben Shay</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe Revach</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liat Sidi</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interests of the SciSparc and AutoMax Directors
and Executive Officers in the Merger (see page 110)</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In considering the recommendation
of SciSparc&#8217;s board of directors with respect to the issuance of SciSparc ordinary shares in connection with the Merger and the
other matters to be acted upon by SciSparc&#8217;s shareholders at the Special Meeting, SciSparc&#8217;s shareholders should be aware
that certain members of the board of directors and executive officers of SciSparc have interests in the Merger that may be different
from, or in addition to, your interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of Amnon Ben Shay, Moshe
Revach and Liat Sidi will continue to be a director of the combined company after the effective time of the Merger, and, following the
closing of the Merger, will be eligible to be compensated as a non-employee director of the combined company pursuant to the compensation
policy of SciSparc. In addition, pursuant to the Merger Agreement and form of Indemnification Agreement, SciSparc&#8217;s directors and
executive officers are entitled to continued indemnification, expense advancement and insurance coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Mr. Amitay Weiss, the
Chairman of SciSparc&#8217;s board of directors, serves as the chairman of AutoMax&#8217;s board of directors. Pursuant to the terms
of the Merger Agreement, Mr. Amitay Weiss will continue to be a director of the combined company after the closing of the Merger and
will receive compensation as a director and be entitled to continued indemnification. In addition, if approved by SciSparc shareholders,
Mr. Amitay Weiss will be entitled to receive a one-time cash bonus of $150,000 as the Chairman of SciSparc subject to and upon the closing
of the Merger. Each of Mr. Oz Adler and Mr. Itschak Shrem will also be entitled to receive a one-time bonus of $315,000 and $50,000,
as the Chief Executive Officer of SciSparc and President of SciSparc, respectively. These interests may present them with actual or potential
conflicts of interest, as further described in Proposal No. 3 (see page 136), and should be aware that the directors and officers of
SciSparc may have interests in such proposal, which differ from, or extend beyond, your interests.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of February 7, 2025,
all directors and executive officers of SciSparc, together with their affiliates, beneficially owned under 1% of the outstanding SciSparc
ordinary shares.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of February 7, 2025,
all directors and executive officers of AutoMax, together with their affiliates, beneficially owned approximately 52.71% of the outstanding
AutoMax ordinary shares.<b>&#160;</b></span></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Material Israeli Income Tax Consequences
of the Merger (see page 112)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under the Israeli
Tax Ordinance [New Version], 5721-1961, the disposition of shares of an Israeli company, such as AutoMax, is deemed to be a sale of capital
assets subject to capital gains tax by both residents and non-residents of Israel, unless a specific exemption is available or unless
a treaty for the prevention of double taxation between Israel and the seller&#8217;s country of residence provides otherwise. AutoMax
has obtained the Tax Ruling (as defined herein) from the Israel Tax Authority for which AutoMax had applied, therefore, the Israeli income
tax consequences of the Merger are in accordance with the Tax Ruling (as applicable to a particular AutoMax shareholder). For more information,
please see the section entitled &#8220;<i>The Merger &#8212; Certain Material Israeli Income Tax Consequences of the Merger</i>&#8221;
of this proxy statement/prospectus.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk Factors (see page 11)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax
are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility
that the Merger may not be completed, poses a number of risks to each company and its respective shareholders, including the following
risks:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Exchange
                                            Ratio is not adjustable based on the market price of SciSparc ordinary shares, so the Merger
                                            consideration at the closing of the Merger may have a greater or lesser value than at the
                                            time the Merger Agreement was signed;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">If the conditions
                                            to the Merger are not met, the Merger will not occur;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Merger
                                            may be completed even though material adverse changes may result from the announcement of
                                            the Merger, industry-wide changes and other causes;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The market
                                            price of the combined company&#8217;s shares may decline as a result of the Merger;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc
                                            and AutoMax shareholders may not realize a benefit from the Merger commensurate with the
                                            ownership dilution they will experience in connection with the Merger; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">During the
                                            pendency of the Merger, SciSparc and AutoMax will be subject to contractual limitations set
                                            forth in the Merger Agreement that restrict the parties&#8217; ability to enter into business
                                            combination transactions with another party.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These risks and other risks
are discussed in greater detail under the section entitled &#8220;<i>Risk Factors</i>&#8221; in this proxy statement/prospectus. SciSparc
and AutoMax both encourage you to read and consider all of these risks carefully.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory Approvals (see page 112)</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, SciSparc
must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance
of shares of SciSparc and the filing of this proxy statement/prospectus with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition to closing
of the Merger, the Merger Agreement sets forth that AutoMax shall obtain a court approval for the Merger, under sections 350 and 351
of the Companies Law. According to the Companies Law, the required majority at a general meeting of shareholders to approve a merger
as described is a majority of the number of voting participants, excluding abstainers, who hold at least three-quarters (3/4) of the
voting power represented at such meeting, in accordance with Section 350(9) of the Companies Law. As part of the Merger, shares of SciSparc
will be offered to AutoMax&#8217;s shareholders. As such, it is plausible to conclude that SciSparc is making an offer to the public
and is required to file a prospectus with the Israeli Securities Authority. Based on the foregoing, SciSparc and AutoMax have requested
that an Israeli court approve an exemption to the foregoing requirement given that SciSparc is a public company traded on Nasdaq and
therefore subject to the Securities Act, and as such, all relevant information is available to the Israeli public, and SciSparc shall
continue to provide information in accordance with the Securities Act. The Israeli Securities Authority has responded to AutoMax&#8217;s
petition to the court and has indicated that it will not require filing a prospectus is Israel. Pursuant to AutoMax&#8217;s petition
to the court, the court ordered that AutoMax will convene a shareholders meeting for approval of the merger, and in addition will convene
a separate meeting of AutoMax&#8217;s shareholders who are not controlling shareholders or SciSparc to vote on the approval of the Merger.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Stock Market Listing (see page 123)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to consummation of
the Merger, SciSparc intends to file a listing of additional securities application with Nasdaq, as required by Nasdaq to effect the
issuance of ordinary shares in connection with the Merger or upon exercise of AutoMax&#8217;s outstanding options that will be assumed
by SciSparc in connection with the Merger. If such application is accepted, SciSparc anticipates that its securities will be listed on
the Nasdaq Capital Market following the closing of the Merger and will trade under SciSparc&#8217;s existing name, SciSparc Ltd., and
trading symbol, &#8220;SPRC&#8221;.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anticipated Accounting Treatment (see page
124)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-weight: normal">SciSparc
and AutoMax each prepare their respective financial statements in accordance with International Financial Reporting Standards, or IFRS,
as issued by the International Accounting Standards Boards. The Merger will be accounted for using the acquisition method of accounting,
and SciSparc will be treated as the accounting acquirer.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comparison of Shareholder Rights&#160;(see
page 233)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax
are incorporated under the laws of Israel and, accordingly, the rights of the shareholders of each are currently, and will continue to
be, governed by Israeli law. If the Merger is completed, AutoMax shareholders will become SciSparc shareholders, and their rights will
be governed by Israeli law and the Amended and Restated Articles of Association of SciSparc attached to this proxy statement/prospectus
as Annex D, as are currently in effect, and may differ from the rights of AutoMax shareholders under AutoMax&#8217;s current amended
and restated articles of association, as more fully described under the section entitled &#8220;<i>Comparison of Shareholder Rights</i>&#8221;
in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

</div><div>
</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 6pt; border: Black 1.5pt solid; width: 98%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<a id="m_003"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">MARKET
PRICE AND DIVIDEND INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ordinary Shares</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s ordinary
shares are listed on the Nasdaq Capital Market under the symbol &#8220;SPRC.&#8221; AutoMax&#8217;s ordinary shares are listed on the
TASE under the symbol &#8220;AMX&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The closing price of SciSparc&#8217;s
ordinary shares on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, as reported on Nasdaq,
was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per ordinary share. The closing price of ordinary shares on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025, the record date for the Special Meeting, as reported on Nasdaq, was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Assuming approval of Proposals
Nos. 1 through 4 and successful application for the listing of additional securities with Nasdaq, following the consummation of the Merger,
SciSparc&#8217;s ordinary shares will be continue to be listed on Nasdaq and will trade under SciSparc&#8217;s existing name, SciSparc
Ltd., and existing trading symbol &#8220;SPRC&#8221;.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025, the record date for the Special Meeting, SciSparc had&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
holders of record of its ordinary shares. As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, 2025, AutoMax had&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;holders
of record of its ordinary shares. For detailed information regarding the beneficial ownership of certain SciSparc shareholders upon consummation
of the Merger, see the section entitled &#8220;<i>Principal Shareholders of Combined Company</i>&#8221; in this proxy statement/prospectus.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>SciSparc</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc has never declared
or paid any cash dividends on its share capital, and it does not currently anticipate declaring or paying cash dividends on its share
capital in the foreseeable future. SciSparc intends to retain all future earnings, if any, to finance the operation and expansion of
SciSparc&#8217;s business. Any future determination relating to SciSparc&#8217;s dividend policy will be made at the discretion of SciSparc&#8217;s
board of directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions, future
prospects, contractual restrictions and covenants and other factors that SciSparc&#8217;s board of directors may deem relevant.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AutoMax</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax has never declared
or paid any cash dividends on its share capital. In accordance with the trust deed pertaining to AutoMax&#8217;s Series B Bonds, dated
February 23, 2022, or the Trust Deed, until the Series B Bonds are repaid in full, AutoMax will not distribute or pay any cash dividends.
According to the terms of the Series B Bonds and the Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal
annual installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that was
made on February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made
on February 28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, due on February 28,
2025, will constitute 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February
28, 2026, will constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger the Series
B Bonds will remain outstanding and subject to repayment in accordance with the terms of the Trust Deed. The Series B Bonds bear interest
at a rate of 5.9% per annum. As of February 7, 2025, NIS 34,245 thousand (approximately $9,110 thousand) in principal amount of Series
B Bonds remains outstanding and will therefore become a liability of the combined company following the completion of the Merger. The
next payment by AutoMax to Series B bondholders is due on February 28, 2025, in the principal amount of NIS 13,698 thousand (approximately
$3,644 thousand) and NIS 996 thousand (approximately $265 thousand) of interest accrued thereon.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax does not anticipate
paying any cash dividends on shares of AutoMax&#8217;s share capital in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
</div><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="m_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">RISK
FACTORS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The combined company will
be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control.
In addition to the other information contained in this proxy statement/prospectus, you should carefully consider the material risks described
below before deciding how to vote your shares of SciSparc. You should also read and consider the risks associated with the business of
SciSparc because these risks may also affect the combined company. You should also read and consider the other information in this proxy
statement/prospectus. Please see the section entitled &#8220;Where You Can Find More Information&#8221; on page 240 of this proxy statement/prospectus.</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk Factors Summary</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
following is a summary of some of the risks and uncertainties that could materially adversely affect SciSparc&#8217;s business, financial
condition and results of operations. You should read this summary together with the more detailed description of each risk factor contained
</span>below<span style="background-color: white">:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks related to the Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    the Exchange Ratio is fixed, AutoMax shareholders cannot be certain of the precise value of the consideration that they may receive
    in the Merger.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">If the proposed
                                            merger with AutoMax is not consummated, SciSparc&#8217;s share price could decline.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Some SciSparc
                                            and AutoMax officers and directors have interests in the Merger that are different from yours
                                            and that may influence them to support or approve the Merger without regard to your interests.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The market
                                            price of the combined company&#8217;s shares may decline as a result of the Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc
                                            and AutoMax shareholders may not realize a benefit from the Merger commensurate with the
                                            ownership dilution they will experience in connection with the Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc
                                            and AutoMax may become involved in securities litigation or shareholder derivative litigation
                                            in connection with the Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to SciSparc&#8217;s Business</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc
                                            is a specialty clinical-stage pharmaceutical company and has incurred significant losses
                                            since the date of its inception, and anticipate that it will continue to incur significant
                                            losses until SciSparc is able to successfully commercialize its product candidates.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc
                                            has not generated any revenue from the sale of current product candidates and may never be
                                            profitable.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to SciSparc&#8217;s Intellectual Property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">If SciSparc
                                            is unable to obtain and maintain effective patent rights for its product candidates, it may
                                            not be able to compete effectively in its markets.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc
                                            may not be able to identify infringements of its patents and accordingly the enforcement
                                            of its intellectual property rights may be difficult.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to SciSparc&#8217;s Intended
Corporate Restructuring Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Restructuring
                                            Plan may not be completed in accordance with the expected plans or anticipated timeline,
                                            or at all, and may not achieve the expected results.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Risks Related to the Ownership of SciSparc&#8217;s
Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc
                                            will need additional capital in the future.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Risks Related to Israeli Law and SciSparc&#8217;s
Operations in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Provisions
                                            of Israeli law may make it easy for SciSparc&#8217;s shareholders to demand that it convene
                                            a shareholders meeting and/or allow shareholders to convene a shareholder meeting without
                                            the consent of SciSparc&#8217;s management, which may disrupt its management&#8217;s ability
                                            to run its company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s
                                            results may be adversely affected by political, economic and military instability in Israel.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Risks Related to AutoMax&#8217;s Business
and Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">A decline
                                            in available financing may adversely affect AutoMax&#8217;s business.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Failure
                                            to renew AutoMax permits and licenses or their revocation could materially adversely affect
                                            its business, results of operations, financial condition and cash flows.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">AutoMax&#8217;s
                                            ability to import and sell vehicles depends in large part on agreements with suppliers and,
                                            therefore, any disruption or deterioration in its relationship with such suppliers could
                                            impact its business.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Import product
                                            restrictions may impair AutoMax&#8217;s ability to sell vehicles or parts profitably.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">AutoMax
                                            is subject to various legal proceedings, which could adversely affect its business, results
                                            of operations and financial condition.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">AutoMax&#8217;s
                                            business and operations face many risks inherent to international trade, and its location
                                            in Israel including the ongoing interplay of the Israel &#8211; Hamas war, may exacerbate
                                            the import process, which is material to the success of AutoMax&#8217;s business and operations,
                                            including disruptions to the maritime route in the Red Sea, and Turkey&#8217;s trade embargo.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Macroeconomic
                                            factors such as fluctuation in vehicle prices, fuel prices, supply chain disruptions, and
                                            vehicle-related technology advancements could have an adverse effect on AutoMax&#8217;s revenues
                                            and operating results.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">AutoMax&#8217;s
                                            operations are subject to a wide range of governmental regulations and laws. Its failure
                                            to comply with or any changes to these regulations and laws, could adversely affect AutoMax&#8217;s
                                            business, sales, results of operations and financial condition.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Risks Related to the Combined Company</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The combined
                                            company does not anticipate paying any cash dividends on the combined company&#8217;s ordinary
                                            shares in the foreseeable future.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Maintaining
                                            and improving the combined company&#8217;s financial controls and the requirements of being
                                            a public company may strain the combined company&#8217;s resources, divert management&#8217;s
                                            attention and affect its ability to attract and retain qualified board members.</td>
</tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the Merger</b></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because the Exchange Ratio is fixed and
will not be adjusted in the event of a change in either SciSparc&#8217;s share price or AutoMax&#8217;s share price, AutoMax shareholders
cannot be certain of the precise value of the consideration that they may receive in the Merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, each outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares, to be
determined in accordance with the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares that AutoMax shareholders will be entitled to receive to
account for changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc ordinary
shares issued pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger closes and
could vary significantly from the market value of the SciSparc ordinary shares on the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (other than SciSparc, which
currently holds shares in AutoMax) and its Advisor are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s
shareholders are expected to own approximately 50.01% of SciSparc&#8217;s share capital on a fully-diluted basis (subject to certain
exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exchange Ratio is the
result of the following calculation (rounded to four decimal places): the number of the SciSparc outstanding shares on a fully-diluted
basis (subject to certain exceptions) divided by 0.5001, multiplied by 0.4749, then divided by the number of the AutoMax outstanding
shares less the number of the AutoMax ordinary shares held by SciSparc; so that, in any event, immediately following the effective time,
holders of AutoMax outstanding shares (and its Advisor, but other than SciSparc), will hold together 49.99% of SciSparc&#8217;s share
capital, on a fully-diluted basis (subject to certain exceptions), immediately following the effective time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of SciSparc
ordinary shares and, as a result, the value of the consideration that AutoMax shareholders may receive pursuant to the Merger Agreement,
has been fluctuating since the date that the Merger Agreement was executed and publicly announced and may continue to fluctuate through
the date of the completion of the Merger. Accordingly, upon the completion of the Merger and the issuance of the SciSparc ordinary shares
to the AutoMax shareholders, the market price of the SciSparc ordinary shares that will be issued to the AutoMax shareholders as the
Merger consideration could be greater than, less than or the same as the market price of SciSparc ordinary shares on the date the Merger
Agreement was executed, on the date of this prospectus or on the date of the SciSparc and AutoMax shareholder meetings. Share price changes
may result from a variety of factors, including, among others, changes in SciSparc&#8217;s or AutoMax&#8217;s respective businesses operations
or prospects, risks described in the risk factors of each of SciSparc and AutoMax; legislative, regulatory and legal developments; general
market, industry and economic conditions; shareholder litigation relating to the Merger or otherwise relating to SciSparc or to AutoMax;
and market assessments of the likelihood that the Merger will be completed. Because the value of the consideration will depend on the
market price of SciSparc ordinary shares at the time the Merger is completed, AutoMax shareholders will not know or be able to determine
at the time of the AutoMax shareholders meeting the market value of the Merger consideration they may receive upon completion of the
Merger. Similarly, SciSparc shareholders will not know or be able to determine at the time of the Special Meeting of SciSparc&#8217;s
shareholders, the market value of the consideration to be paid to the AutoMax shareholders in the form of issuance of SciSparc ordinary
shares pursuant to the Merger Agreement compared to the market value of AutoMax ordinary shares that are being exchanged. You are urged
to obtain current market quotations for SciSparc ordinary shares and AutoMax ordinary shares in determining <span style="background-color: white">whether
to vote for approval of the Merger-related proposals. In addition, see the section entitled &#8220;Comparative Per Share Market Price
Information</span>&#8221; beginning on page 84.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the proposed merger with AutoMax
is not consummated, SciSparc&#8217;s share price could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The consummation of the
proposed Merger with AutoMax is subject to a number of closing conditions, including the approval by SciSparc&#8217;s shareholders, approval
by Nasdaq of SciSparc&#8217;s listing of additional securities application of its ordinary shares issued in connection with the Merger,
and other customary closing conditions. SciSparc is targeting a closing of the transaction in the first quarter of 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the proposed Merger is
not consummated, SciSparc may be subject to a number of material risks, and its share price could be adversely affected, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc
                                            has incurred and expects to continue to incur significant expenses related to the proposed
                                            Merger with AutoMax, even if the Merger is not consummated.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Merger
                                            Agreement contains covenants restricting SciSparc&#8217;s solicitation of competing acquisition
                                            proposals and the conduct of SciSparc&#8217;s business between the date of signing the Merger
                                            Agreement and the closing of the Merger. As a result, significant business decisions and
                                            transactions before the closing of the Merger require the consent of AutoMax. Accordingly,
                                            SciSparc may be unable to pursue business opportunities that would otherwise be in its best
                                            interest as a standalone company. SciSparc has invested significant time and resources in
                                            the transaction process and if the Merger Agreement is terminated SciSparc will have a limited
                                            ability to continue its current operations without obtaining additional financing.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s
                                            collaborators and other business partners and investors in general may view the failure to
                                            consummate the Merger as a poor reflection on its business or prospects.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Some of
                                            SciSparc&#8217;s collaborators and other business partners may seek to change or terminate
                                            their relationships with SciSparc as a result of the proposed Merger or the failure thereof.</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>


</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s
                                            management team may be distracted from day to day operations as a result of the proposed
                                            Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; background-color: white">On July 16, 2024, SciSparc
    received a written notice, or the Notice, from Nasdaq indicating that it is not in compliance with the minimum bid price requirement
    for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price
    of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), SciSparc was granted a period of 180 calendar days to regain compliance
    with the minimum bid price requirement. On January 14, 2025, SciSparc received an additional written notice from Nasdaq indicating
    that it had been granted, per its request, an additional 180-day compliance period, or until July 14, 2025, to regain compliance
    with the minimum bid price requirement. No assurance can be given that SciSparc will remain eligible to be listed on Nasdaq. Further,
    because of the previous delisting of SciSparc&#8217;s American Depositary Shares, or ADSs, from Nasdaq, if SciSparc falls out of
    compliance with Nasdaq requirements in the future, its ordinary shares may be more likely to be subject to Nasdaq&#8217;s delisting
    process and no assurance can be given that SciSparc will be able to regain compliance. Any delisting could adversely affect SciSparc&#8217;s
    ability to obtain financing for the continuation of its operations and could result in the loss of confidence by investors, customers
    and employees.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="background-color: white">In
                                            addition, if the Merger Agreement is terminated and SciSparc&#8217;s board of directors determines
                                            to seek another business combination, it may not be able to find a third party willing to
                                            provide equivalent or more attractive consideration than the consideration to be provided
                                            by each party in the Merger. In such circumstances, SciSparc&#8217;s board of directors may
                                            elect to, among other things, divest all or a portion of SciSparc&#8217;s business, and,
                                            in such case, the consideration that SciSparc receives may be less attractive than the consideration
                                            to be received by SciSparc pursuant to the Merger Agreement.</span></td>
</tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the conditions to the Merger are
not met, the Merger will not occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if the Merger is approved
by the shareholders of SciSparc and AutoMax, specified conditions must be satisfied or waived to complete the Merger. These conditions
are set forth in the Merger Agreement and described in the section entitled &#8220;<i>The Merger Agreement &#8212; Conditions to the
Completion of the Merger</i>&#8221; in this proxy statement/prospectus. SciSparc and AutoMax cannot assure you that all of the conditions
will be satisfied. If the conditions are not satisfied or waived, the Merger will not occur or will be delayed, and SciSparc and AutoMax
each may lose some or all of the intended benefits of the Merger.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some SciSparc and AutoMax officers
and directors have interests in the Merger that are different from yours and that may influence them to support or approve the Merger
without regard to your interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain officers and directors
of SciSparc and AutoMax participate in arrangements that provide them with interests in the Merger that are different from yours, including,
among others, the continued service as an officer or director of the combined company, the continued receipt of compensation for such
service, and continued indemnification. Each of Amitay Weiss, Amnon Ben Shay, Moshe Revach and Liat Sidi will continue as directors of
the combined company after the effective time of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Amitay Weiss is also the
Chairman of SciSparc&#8217;s board of directors and serves as the chairman of AutoMax. In addition, contingent upon the approval and closing
of the Merger, shareholders are asked to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President.
Furthermore, certain officers, directors and shareholders of AutoMax entered into the AutoMax Shareholder Support Agreement, pursuant
to which they agreed, solely in their capacity as shareholders, to vote their shares in AutoMax covering approximately 55.65% of the outstanding
shares of AutoMax in favor of adoption of the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Mr.&#160;Yaki Baranes,
a business analyst, presented a market overview on the motor vehicle market in Israel and a company overview of AutoMax as a vehicle
importer in Israel, to SciSparc&#8217;s board of directors on February 23, 2023. Mr. Baranes was appointed on May 30, 2023, as VP Strategy
and Business Development of SciSparc. Mr. Baranes previously provided services to AutoMax. In addition, Mr. Baranes and Mr. Amitay Weiss
both serve as members of the board of Charging Robotics Inc. and Mr. Baranes provided market overview services to certain other companies
of which Mr. Amitay Weiss serves as a director.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These interests may present
them with actual or potential conflicts of interest. These interests, among others, may influence the officers and directors of SciSparc
and AutoMax to support or approve the Merger. For more information concerning the interests of SciSparc and AutoMax executive officers
and directors, see the section entitled &#8220;<i>Interests of the SciSparc and AutoMax Directors and Executive Officers in the Merger</i>&#8221;
in this proxy statement/prospectus.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>SciSparc&#8217;s board of directors did
not obtain a fairness opinion&#160;in determining whether or not to proceed with the Merger.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc&#8217;s board
of directors did not obtain a fairness opinion&#160;in connection with its determination to approve the Merger. In analyzing the Merger,
SciSparc&#8217;s board of directors conducted due diligence on AutoMax and researched the industry in which AutoMax operates by obtaining,
for example, an independent third-party valuation report on AutoMax from E.D.B. Accordingly, investors will be relying solely on the
judgment of SciSparc&#8217;s board of directors in determining the value of the Merger and will not have assurance from an independent
source that the terms of the Merger are fair to the Company from a financial point of view. The lack of a&#160;fairness opinion&#160;may
also lead an increased number of SciSparc&#8217;s shareholders to vote against the proposed Merger, which could potentially impact SciSparc&#8217;s
ability to consummate the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger may be completed even
though material adverse changes may result from the announcement of the Merger, industry-wide changes and other causes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, either party
can refuse to complete the Merger if there is a material adverse change affecting the other party following April 10, 2024, the date
of the Merger Agreement. However, some types of changes do not permit either party to refuse to complete the Merger, even if such changes
would have a material adverse effect on SciSparc or AutoMax, to the extent they resulted from the following (unless, in some cases, they
have a disproportionate effect on SciSparc or AutoMax, as the case may be):</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">changes
                                            or conditions generally affecting the industries or markets in which SciSparc and AutoMax
                                            operate, and changes in the industries in which SciSparc and AutoMax operate regardless of
                                            geographic region (including legal and regulatory changes);</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">acts of
                                            war, armed hostilities or terrorism;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">changes
                                            in financial, banking or securities markets;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">any change
                                            in, or any compliance with or action taken for the purpose of complying with, any federal,
                                            state, national, foreign, material local or municipal or other law, statute, constitution,
                                            principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling
                                            or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect
                                            by or under the authority of any governmental body (including under the authority of Nasdaq
                                            or the Financial Industry Regulatory Authority), or changes in any interpretations thereof;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">any change
                                            in U.S. generally accepted accounting principles or interpretations thereof;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the announcement
                                            of the Merger Agreement or the pendency of the Merger;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the taking
                                            of any action required to be taken by the Merger Agreement;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">pandemics,
                                            including any worsening thereof, man-made disasters, natural disasters, acts of God or other
                                            force majeure event; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">changes
                                            in U.S. or non-U.S. general economic or political conditions, or in the financial, credit
                                            or securities markets in general, including any shutdown of any governmental authority.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If adverse changes occur
but SciSparc and AutoMax must still complete the Merger, the combined company&#8217;s share price may suffer.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of the combined
company&#8217;s shares may decline as a result of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of the combined
company&#8217;s shares may decline as a result of the Merger for a number of reasons, including if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the combined
                                            company does not achieve the perceived benefits of the Merger as rapidly or to the extent
                                            anticipated by financial or industry analysts;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the effect
                                            of the Merger on the combined company&#8217;s business and prospects is not consistent with
                                            the expectations of financial or industry analysts; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">investors
                                            react negatively to the effect on the combined company&#8217;s business and prospects from
                                            the Merger.</td>
</tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc and AutoMax shareholders
may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the combined company is
unable to realize the strategic and financial benefits currently anticipated from the Merger, SciSparc shareholders will have experienced
substantial dilution of their ownership interest without receiving any commensurate benefit. Significant management attention and resources
will be required to operate the two companies. Delays in this process could adversely affect the combined company&#8217;s business, financial
results, financial condition and share price following the Merger. Even if the combined company were able to operate the two businesses
operations successfully, there can be no assurance that this operation will result in the realization of the full benefits of synergies,
innovation and operational efficiencies that may be possible from this integration and that these benefits will be achieved within a
reasonable period of time.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the pendency of the Merger,
SciSparc and AutoMax will be subject to contractual limitations set forth in the Merger Agreement that restrict the parties&#8217; ability
to enter into business combination transactions with another party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Covenants in the Merger Agreement
impede the ability of SciSparc or AutoMax to make acquisitions or complete other transactions that are not in the ordinary course of
business pending completion of the Merger. As a result, if the Merger is not completed, the parties may be at a disadvantage to their
competitors. In addition, while the Merger Agreement is in effect and subject to limited exceptions, each party is prohibited from soliciting,
initiating, encouraging or taking actions designed to facilitate any inquiries or the making of any proposal or offer that could lead
to the entering into certain extraordinary transactions with any third party, such as a sale of assets, an acquisition of SciSparc&#8217;s
securities, a tender offer for SciSparc&#8217;s securities, a Merger or other business combination outside the ordinary course of business.
Any such transactions could be favorable to such party&#8217;s shareholders.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain provisions of the Merger
Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the
arrangements contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Merger Agreement
prohibit each of SciSparc and AutoMax from soliciting alternative takeover proposals or cooperating with persons making unsolicited takeover
proposals. Because the lack of a public market for AutoMax shares makes it difficult to evaluate the fairness of the Merger, the shareholders
of AutoMax may receive consideration in the Merger that is less than the fair market value of the AutoMax shares.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain shareholders could attempt
to influence changes within SciSparc that could adversely affect SciSparc&#8217;s operations, financial condition and the value of SciSparc&#8217;s
ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s shareholders
may from time to time seek to acquire a controlling stake in SciSparc, engage in proxy solicitations, advance shareholder proposals or
otherwise attempt to effect changes. Campaigns by shareholders to effect changes at publicly-traded companies are sometimes led by investors
seeking to increase short-term shareholder value through actions such as financial restructuring, increased debt, special dividends,
share repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist shareholders can
be costly and time-consuming and could disrupt SciSparc&#8217;s operations and divert the attention of the SciSparc board of directors
and senior management from the pursuit of the proposed transaction. These actions could adversely affect SciSparc operations, financial
condition, SciSparc&#8217;s ability to consummate the Merger and the value of SciSparc ordinary shares.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc and AutoMax may become involved
in securities litigation or shareholder derivative litigation in connection with the Merger, and this could divert the attention of SciSparc
and AutoMax management and harm the combined company&#8217;s business, and insurance coverage may not be sufficient to cover all related
costs and damages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities litigation or
shareholder derivative litigation frequently follows the announcement of certain significant business transactions, such as the sale
of a business division or announcement of a business combination transaction. SciSparc and AutoMax may become involved in this type of
litigation in connection with the Merger, and the combined company may become involved in this type of litigation in the future. Litigation
often is expensive and diverts management&#8217;s attention and resources, which could adversely affect the business of SciSparc, AutoMax
and the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the events described in
AutoMax&#8217;s General Risk Factors&#8221; or &#8220;Risks Related to the Combined Company&#8221; occur, those events could cause the
potential benefits of the Merger not to be realized.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s
                                            business is expected to constitute a significant portion of the business of the combined
                                            company following the Merger. As a result, the risks described below in the sections entitled
                                            &#8220;AutoMax Business&#8221; beginning on page 176, and &#8220;Risks Related to the Combined
                                            Company&#8221; beginning on page 81 are among the most significant risks to the combined
                                            company if the Merger is completed. To the extent any of the events in the risks described
                                            in the sections referenced in the previous sentence occur, those events could cause the potential
                                            benefits of the Merger not to be realized and the market price of the combined company&#8217;s
                                            shares to decline.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks
                                            Related to SciSparc&#8217;s Business</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Financial Condition and Capital Requirements</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc is a
specialty clinical</i></b>-<b><i>stage pharmaceutical company and has incurred significant losses since the date of its inception, and
anticipate that it will continue to incur significant losses until it is able to successfully commercialize its product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has historically incurred substantial net losses; including net losses of approximately $3.7 million for the six months ended June 30,
2024, $5.9 million for the year ended December 31, 2023, $2.6 million for the year ended December 31, 2022 and $5.8 million for the year
ended December 31, 2021. As of June 30, 2024, SciSparc had an accumulated deficit of approximately $72 million. As of December 31, 2023,
it had an accumulated deficit of approximately $69 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has devoted substantially all of its financial resources to develop its product candidates, and more recently, to a lesser degree, SciSparc
has been searching for strategic transactions. SciSparc financed its operations primarily through the issuance of equity securities.
The amount of its future net losses will depend, in part, on completing the development of its product candidates, the demand for its
product candidates, the rate of its future expenditures and its ability to obtain funding through the issuance of its securities, strategic
collaborations or grants. Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of
risk. SciSparc is in the late stages of preclinical and at the early stages of clinical development for its product candidates, it has
not yet commenced pivotal clinical studies for any product candidate. Although SciSparc has begun early commercialization efforts for
its proprietary Palmitoylethanolamide, or PEA, oral tablets formulation, CannAmide&#8482;, which it expects will be marketed to pharmacies
and other retail outlets across Canada following its entering into a distribution agreement(s), it may be several years, if ever, before
SciSparc completes pivotal clinical studies and has its lead product candidate approved for commercialization. Even if SciSparc obtains
regulatory approval to market a product candidate, its future revenue will depend upon the size of the markets for which its product
candidates may receive approval and its ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors
and adequate market share for its product candidates in those markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
expects to continue to incur significant losses until it is able to commercialize its main pharmaceutical product candidates, which it
may not be successful in achieving. SciSparc anticipates that its expenses will increase substantially if and as it:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">continues the research and development of its product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expands the scope of its current clinical studies for its product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">seeks regulatory and marketing approvals for its product candidates
    that successfully complete clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establishes a sales, marketing and distribution infrastructure to commercialize
    its product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">seeks to identify, assess, acquire, license, and/or develop other product
    candidates and subsequent generations of its current product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">seeks to maintain, protect, and expand its intellectual property portfolio;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">seeks to attract and retain skilled personnel; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">creates additional infrastructure to support its operations as a public
    company and its product candidate development and planned future commercialization efforts.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc has not
generated any revenue from the sale of its current pharmaceutical product candidates and may never be profitable.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has not yet commercialized any of its pharmaceutical product candidates and have not generated any revenue from sales of its pharmaceutical
product candidates since the date of its inception. Although SciSparc has begun early commercialization efforts for its proprietary PEA
oral tablets formulation. CannAmide&#8482;, it does not currently expect the sale of CannAmide to result in material revenues, nor is
CannAmide&#8482; its lead pharmaceutical product candidate. SciSparc does not know whether or when it will become profitable. Its ability
to generate revenue and achieve profitability depends on its ability to successfully complete the development of, and to commercialize,
SciSparc&#8217;s pharmaceutical product candidates and on the demand for its pharmaceutical product candidates. SciSparc&#8217;s ability
to generate revenue and achieve profitability depends on its ability, alone or with strategic collaboration partners, to successfully
complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, one or more of its pharmaceutical
product candidates. SciSparc&#8217;s ability to generate future revenue from pharmaceutical product candidate sales depends heavily on
its success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">completing
                                            research and preclinical and clinical development of its pharmaceutical product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">obtaining
                                            regulatory and marketing approvals for pharmaceutical product candidates for which SciSparc
                                            completes clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">establishing
                                            and maintaining supply and manufacturing relationships with third parties that can provide
                                            adequate (in amount and quality) pharmaceutical products to support market demand for its
                                            pharmaceutical product candidates, if approved;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">launching
                                            and commercializing pharmaceutical product candidates if and when SciSparc obtains regulatory
                                            and marketing approval, either directly or with a collaborator or distributor;</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">obtaining
                                            market acceptance of its pharmaceutical product candidates as viable treatment options;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">addressing
                                            any competing pharmaceutical or biotechnological and market developments;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">identifying,
                                            assessing, acquiring and/or developing new pharmaceutical product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">negotiating
                                            favorable terms in any collaboration, licensing or other arrangements into which SciSparc
                                            may enter;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">maintaining,
                                            protecting and expanding its portfolio of intellectual property rights, including patents,
                                            trade secrets and know-how; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">attracting,
                                            hiring and retaining qualified personnel.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if one or more of the pharmaceutical product candidates that SciSparc develops is approved for commercial sale, SciSparc anticipates
incurring significant costs associated with commercializing any approved pharmaceutical product candidate. Its expenses could increase
beyond expectations if it is required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or
foreign, to perform clinical, nonclinical or other types of studies in addition to those that SciSparc currently anticipates. In cases
where SciSparc is successful in obtaining regulatory approvals to market one or more of its pharmaceutical product candidates, its revenue
will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price
for the pharmaceutical product candidate, the ability to get reimbursement at an acceptable price and whether it owns the commercial
rights for that territory. If the number of its addressable patients is not as significant as SciSparc estimates, the indication approved
by regulatory authorities is narrower than it expects, or the reasonably expected population for treatment is narrowed by competition,
physician choice or treatment guidelines, SciSparc may not generate significant revenue from sales of such pharmaceutical product candidates,
even if approved. Additionally, if it is not able to generate revenue from the sale of any approved pharmaceutical product candidates,
SciSparc may be forced to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc expects
that it will need to raise substantial additional funding before it can expect to become profitable from sales of its pharmaceutical
product candidates. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital
when needed may force SciSparc to delay, limit or terminate its pharmaceutical product candidate development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of June 30, 2024, SciSparc&#8217;s cash was approximately $0.3 million, other accounts receivable was approximately $0.3 million, SciSparc
had working capital of approximately $1.6 million and it also had an accumulated deficit of approximately $72 million. As of December
31, 2023, SciSparc&#8217;s cash was approximately $2.1 million, other accounts receivable was approximately $0.5 million, SciSparc had
working capital of approximately $4.9 million and it also had an accumulated deficit of approximately $69 million. Based upon its currently
expected level of operating expenditures, SciSparc does not expect that its existing cash will be sufficient to fund operations for at
least the next 12 months. SciSparc expects that it will require substantial additional capital to commercialize its pharmaceutical product
candidates. In addition, SciSparc&#8217;s operating plans may change as a result of many factors that may currently be unknown to SciSparc,
and may need to seek additional funds sooner than planned. SciSparc&#8217;s future funding requirements will depend on many factors,
including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the scope, rate of progress, results and cost of pharmaceutical product
    development, clinical studies, preclinical testing, and other related activities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost, timing and outcomes of regulatory approvals;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost and timing of establishing sales, marketing, and distribution
    capabilities; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the terms and timing of any collaborative, licensing, and other arrangements
    that SciSparc may establish.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
additional fundraising efforts may divert SciSparc&#8217;s management from their day-to-day activities, which may adversely affect its
ability to develop and commercialize its pharmaceutical product candidates. In addition, SciSparc cannot guarantee that future financing
will be available in sufficient amounts or on terms acceptable to it, if at all. Moreover, the terms of any financing may adversely affect
the holdings or the rights of holders of its securities and the issuance of additional securities, whether equity or debt, by SciSparc,
or the possibility of such issuance, may cause the market price of its ordinary shares to decline. The incurrence of indebtedness could
result in increased fixed payment obligations, and SciSparc may be required to agree to certain restrictive covenants, such as limitations
on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights and other
operating restrictions that could adversely impact its ability to conduct its business. SciSparc could also be required to seek funds
through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and SciSparc may
be required to relinquish rights to some of its technologies or pharmaceutical product candidates or otherwise agree to terms unfavorable
to it, any of which may have a material adverse effect on its business, operating results and prospects. Even if SciSparc believes that
it has sufficient funds for its current or future operating plans, it may seek additional capital if market conditions are favorable
or if it has specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more
of its research or development programs or the commercialization of any pharmaceutical product candidates or be unable to expand its
operations or otherwise capitalize on its business opportunities, as desired, which could materially affect its business, financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The report of
SciSparc&#8217;s independent registered public accounting firm contains an explanatory paragraph regarding substantial doubt about its
ability to continue as a going concern, which could prevent SciSparc from obtaining new financing on reasonable terms or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
report of SciSparc&#8217;s independent registered public accounting firm on its audited consolidated financial statements for the period
ended&#160;December 31,&#160;2023 contains an explanatory paragraph regarding substantial doubt about its ability to continue as a going
concern.&#160;SciSparc&#8217;s consolidated financial statements do not include any adjustments that might result from the outcome of
the uncertainty regarding its ability to continue as a going concern. This going concern opinion could materially limit its ability to
raise additional funds through the issuance of equity or debt securities or otherwise. Further reports on its consolidated financial
statements may include an explanatory paragraph with respect to its ability to continue as a going concern. Until SciSparc can generate
significant recurring revenues, it expects to satisfy its future cash needs through debt or equity financing. SciSparc cannot be certain
that additional funding will be available to it on acceptable terms, if at all. If funds are not available, SciSparc may be required
to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to its products.
This may raise substantial doubts about its ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to the
Discovery and Development of SciSparc&#8217;s Pharmaceutical Product Candidates</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc is heavily
dependent on the success of its pharmaceutical product candidates, which are in the late stages of pre-clinical development or early
stages of clinical development. SciSparc cannot give any assurance that any of its pharmaceutical product candidates will receive regulatory
approval, which is necessary before they can be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
date, SciSparc has invested substantially all of its efforts and financial resources to design and develop its pharmaceutical product
candidates, including conducting preclinical studies and providing general and administrative support for these operations. SciSparc&#8217;s
future success is dependent on its ability to successfully develop, obtain regulatory approval for, and then successfully commercialize
one or more pharmaceutical product candidates. SciSparc currently generates no revenue from sales of any pharmaceutical product candidate,
and it may never be able to develop or commercialize a marketable pharmaceutical product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Each
of its pharmaceutical product candidates is in the late stages of pre-clinical development or early stages of development and will require
additional clinical development (and in some cases additional preclinical development), management of nonclinical, clinical and manufacturing
activities, regulatory approval, obtaining adequate manufacturing supply, building of a commercial organization and significant marketing
efforts before SciSparc generates any revenue from pharmaceutical product candidate sales. It may be years before a pivotal study is
initiated, if at all. Any clinical trials in the United States will require the approval of an Investigational New Drug, or IND, application
by the FDA, and SciSparc cannot assure that it will obtain such approval in a timely manner, or at all. SciSparc is not permitted to
market or promote any of its pharmaceutical product candidates before it receives regulatory approval from the FDA or comparable foreign
regulatory authorities, and it may never receive such regulatory approval for any of its pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
as a company has never submitted marketing applications to the FDA or comparable foreign regulatory authorities. SciSparc cannot be certain
that any of its pharmaceutical product candidates will be successful in clinical studies or receive regulatory approval or what regulatory
pathway the regulatory authorities shall designate for its pharmaceutical product candidates. Further, its pharmaceutical product candidates
may not receive regulatory approval even if they are successful in clinical studies. If SciSparc does not receive regulatory approvals
for its pharmaceutical product candidates, it may not be able to continue its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
generally plans to seek regulatory approval to commercialize its pharmaceutical product candidates in the United States, the European
Union and in additional foreign countries. To obtain regulatory approvals SciSparc must comply with the numerous and varying regulatory
requirements of such countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales,
pricing and distribution of its product candidates. Even if SciSparc is successful in obtaining approval in one jurisdiction, it cannot
ensure that it will obtain approval in any other jurisdictions. If SciSparc is unable to obtain approval for its pharmaceutical product
candidates in multiple jurisdictions, its revenue and results of operations would be negatively affected.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The regulatory
approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If SciSparc
is ultimately unable to obtain regulatory approval for its pharmaceutical product candidates, its business will be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following
the commencement of clinical studies and depends upon numerous factors. In addition, approval policies, regulations or the type and amount
of clinical data necessary to gain approval may change during the course of a pharmaceutical product candidate&#8217;s clinical development
and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. SciSparc has
not obtained regulatory approval for any pharmaceutical product candidate, and it is possible that none of its existing pharmaceutical
product candidates or any pharmaceutical product candidates it may seek to develop in the future will ever obtain regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Applications
for its pharmaceutical product candidates could fail to receive regulatory approval for many reasons, including but not limited to the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may disagree with the design or implementation
                                            of SciSparc&#8217;s clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc
                                            may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that
                                            a pharmaceutical product candidate&#8217;s safety-benefit ratio for its proposed indication
                                            is acceptable;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may disagree with its interpretation of
                                            data from preclinical studies or clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            data collected from clinical studies of its pharmaceutical product candidates may not be
                                            sufficient to support the submission of a New Drug Application, or NDA, in the United States
                                            or elsewhere;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes,
                                            test procedures and specifications or facilities of third-party manufacturers with which
                                            SciSparc contracts for clinical and commercial supplies; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            approval policies or regulations of the FDA or comparable foreign regulatory authorities
                                            may significantly change in a manner rendering its clinical data insufficient for approval.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in SciSparc failing to obtain
regulatory approval to market any of its pharmaceutical product candidates, which would significantly harm its business, results of operations
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Clinical drug
development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive
of future study results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during
the clinical study process. The results of preclinical studies and early clinical studies of its product candidates may not be predictive
of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies
may still suffer significant setbacks in subsequent advanced clinical studies. There is a high failure rate for drugs proceeding through
clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits
despite having progressed satisfactorily through preclinical studies and initial clinical studies. A number of companies in the pharmaceutical
industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses.
SciSparc does not know whether any Phase I, Phase II, Phase III or other clinical studies it may conduct will demonstrate consistent
or adequate efficacy and safety sufficient to obtain regulatory approval to market its product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may find
it difficult to enroll patients in its clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of
its pharmaceutical product candidates.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Identifying
and qualifying patients to participate in clinical studies of its pharmaceutical product candidates is critical to its success. The timing
of its clinical studies depends in part on the speed at which SciSparc can recruit patients to participate in testing its pharmaceutical
product candidates, and it may experience delays in its clinical studies if SciSparc encounters difficulties in enrollment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Some
of the conditions for which SciSparc plans to evaluate its current pharmaceutical product candidates are for rare diseases. Accordingly,
there is a limited patient pool from which to draw for clinical studies. Further, the eligibility criteria of its clinical studies will
further limit the pool of available study participants as SciSparc will require that patients have specific characteristics that it can
measure or to assure their disease is either severe enough or not too advanced to include them in a study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
the process of finding patients may prove costly. SciSparc also may not be able to identify, recruit and enroll a sufficient number of
patients to complete its clinical studies because of the perceived risks and benefits of the pharmaceutical product candidate under study,
the availability and efficacy of competing therapies and clinical studies, the proximity and availability of clinical study sites for
prospective patients and the patient referral practices of physicians. If patients are unwilling to participate in its studies for any
reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential pharmaceutical product
candidates will be delayed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc experiences delays in the completion or termination of any clinical study of its pharmaceutical product candidates, the commercial
prospects of its pharmaceutical product candidates will be harmed, and its ability to generate pharmaceutical product candidate revenue
from any of these pharmaceutical product candidates could be delayed or prevented. In addition, any delays in completing its clinical
studies will increase SciSparc&#8217;s costs, slow down its product candidate development and approval process and jeopardize its ability
to commence pharmaceutical product candidate sales and generate revenue. Any of these occurrences may harm its business, financial condition
and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
studies may also ultimately lead to the denial of regulatory approval of its pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If the FDA does
not conclude that its pharmaceutical product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway,
or if the requirements for its pharmaceutical product candidates under Section 505(b)(2) are not as SciSparc expect, the approval pathway
would likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated
and in either case may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc
intends to seek FDA approval through the Section 505(b)(2) regulatory pathway for its pharmaceutical product candidate SCI-110 and potentially
for its drug candidate SCI-210. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments,
added Section 505(b)(2) to the Federal Food, Drug, and Cosmetic Act of 1938, as amended, or the FDC Act, or Section 505(b)(2). Section
505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted
by or for the applicant and for which the applicant has not obtained a right of reference.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the FDA does not allow SciSparc to pursue the Section 505(b)(2) regulatory pathway as anticipated, it may need to conduct additional
clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur,
the time and financial resources required to obtain FDA approval, and complications and risks associated with FDA approval, would substantially
increase. SciSparc may need to obtain additional funding, which could result in significant dilution to the ownership interests of its
then existing shareholders to the extent SciSparc issues equity securities or convertible debt. SciSparc cannot assure you that it would
be able to obtain such additional financing on terms acceptable to it, if at all. Moreover, inability to pursue the Section 505(b)(2)
regulatory pathway could result in new competitive pharmaceutical product candidates reaching the market faster than its pharmaceutical
product candidates, which could materially adversely impact its competitive position and prospects. Even if SciSparc is allowed to pursue
the Section 505(b)(2) regulatory pathway, it cannot assure you that its pharmaceutical product candidates will receive the requisite
approvals for commercialization.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, notwithstanding the approval of a number of pharmaceutical product candidates by the FDA under Section 505(b)(2) over the last
few years, some pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). For example,
several companies have previously petitioned the FDA regarding the constitutionality of allowing others to rely upon FDA findings that
are based on their proprietary data. If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may be
required to change its 505(b)(2) policies and practices, which could require that SciSparc generates full data regarding safety and effectiveness
for previously approved active ingredients and delay or even prevent the FDA from approving any NDA that SciSparc submits under Section
505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements
designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These
requirements may give rise to patent litigation and mandatory delays in approval of its potential future NDAs for up to 30 months depending
on the outcome of any litigation. It is not uncommon for a manufacturer of an approved pharmaceutical product to file a citizen petition
with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing pharmaceutical products.
If successful, such petitions can significantly delay, or even prevent, the approval of the new pharmaceutical product. However, even
if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition.
In addition, even if SciSparc is able to utilize the Section 505(b)(2) regulatory pathway for its pharmaceutical product candidates,
there is no guarantee this would ultimately lead to faster pharmaceutical product development or earlier approval. Moreover, even if
these pharmaceutical product candidates are approved under the Section 505(b)(2) pathway, as the case may be, the approval may be subject
to limitations on the indicated uses for which the pharmaceutical products may be marketed or to other conditions of approval or may
contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the pharmaceutical products.
Its pharmaceutical product candidates are at early stages of development and are subject to uncertainty over what SciSparc must do on
its development program in order to secure approval under Section 505(b)(2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may encounter
substantial delays in its clinical studies, or it may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory
authorities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Before
obtaining marketing approval from regulatory authorities for the sale of its pharmaceutical product candidates, SciSparc must conduct
extensive clinical studies to demonstrate the safety and efficacy of the pharmaceutical product candidates in humans. Clinical testing
is expensive, time consuming and uncertain as to outcome. SciSparc cannot guarantee that any clinical studies will be conducted as planned
or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing, and its future clinical
studies may not be successful. Events that may prevent successful or timely completion of clinical development include but are not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability to generate sufficient preclinical, toxicology or other in
    vivo or in vitro data to support the initiation of human clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the occurrence of a pandemic or the spread of a virus that diverts
    the attention of regulatory agencies from reviewing its study design or results or which, as a result of such pandemic or widespread,
    requires SciSparc to materially modify its planned clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in reaching a consensus with regulatory agencies on study design;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in reaching agreement on acceptable terms with prospective contract
    research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary
    significantly among different CROs and clinical study sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in obtaining required Institutional Review Board, or IRB, approval
    at each clinical study site;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">imposition of a clinical hold by regulatory agencies, after review
    of an IND, application, or equivalent application, or an inspection of its clinical study operations or study sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in recruiting suitable patients to participate in its clinical
    studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulty collaborating with patient groups and investigators;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure by SciSparc&#8217;s CROs, other third parties or it to adhere
    to clinical study requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to perform in accordance with the FDA&#8217;s Good Clinical
    Practices, or GCP, requirements, or applicable regulatory guidelines in other countries;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in having patients complete participation in a study or return
    for post-treatment follow-up;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">patients dropping out of a study;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">occurrence of serious adverse events associated with the pharmaceutical
    product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in regulatory requirements and guidance that require amending
    or submitting new clinical protocols;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of clinical studies of its pharmaceutical product candidates
    being greater than SciSparc anticipates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical studies of its pharmaceutical product candidates producing
    negative or inconclusive results, which may result in SciSparc deciding, or regulators requiring it, to conduct additional clinical
    studies or abandon pharmaceutical product candidate development programs; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in manufacturing, testing, releasing, validating or importing/exporting
    sufficient stable quantities of its pharmaceutical product candidates for use in clinical studies or the inability to do any of the
    foregoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
inability to successfully complete preclinical and clinical development could result in additional costs to SciSparc or impair its ability
to generate revenue. SciSparc may also be required to conduct additional safety, efficacy and comparability studies before it will be
allowed to start clinical studies with its repurposed drugs. Clinical study delays could also shorten any periods during which its pharmaceutical
product candidates have patent protection and may allow its competitors to bring pharmaceutical product candidates to market before it
does, which could impair its ability to obtain orphan exclusivity and successfully commercialize its pharmaceutical product candidates
and may harm its business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>In respect of
its pharmaceutical product candidates targeting rare indications, orphan drug exclusivity may afford limited protection, and if another
party obtains orphan drug exclusivity for the drugs and indications SciSparc is targeting, it may be precluded from commercializing its
pharmaceutical product candidates in those indications during that period of exclusivity</i>.</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is seeking to obtain an orphan designation for some of its pharmaceutical product candidates in the United States. Under the Orphan Drug
Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, defined, in part,
as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States
where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Additionally,
designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating
or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient
to justify the necessary investment in developing the drug.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the United States, the first NDA applicant with an orphan drug designation for a particular active moiety to treat a specific disease
or condition that receives FDA approval is entitled to a seven-year exclusive marketing period in the United States for that product
candidate, for that indication. In the European Union, orphan drug designation also entitles a party to financial incentives such as
reduction of fees or fee waivers and 10 years of market exclusivity is granted following drug approval. This period may be reduced to
six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable
not to justify maintenance of market exclusivity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2016, SciSparc submitted a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. In a letter dated
September 29, 2016, the FDA informed SciSparc that its request could not be granted at such time, and is being held in abeyance until
and subject to SciSparc providing additional information pertaining to the overall prevalence of TS in both children and adults, and
further clinical data to support its scientific rationale for its request for orphan drug designation within 12 months. In September
2017, SciSparc responded to such FDA letter within the designated time frame, and provided the FDA with its articulated and reasoned
responses including documentation and clinical data that supports it. On December 26, 2017, SciSparc received the FDA&#8217;s response
to its response. The FDA accepted that there is adequate scientific rationale for the treatment of TS with SCI-110 mainly through the
preliminary results of ongoing clinical trials, suggesting that SCI-110 may provide benefit in treating TS. However, the FDA stated that
it was unable to grant SciSparc&#8217;s request and indicated that SciSparc did not provide adequate prevalence estimates, and any evidence
to support its statement that only moderate to severe TS patients would require pharmacological treatment. SciSparc further responded
in January 2018 by providing additional information. On January 23, 2020, following additional correspondence with the FDA, the FDA still
did not grant us SciSparc&#8217;s request due to the fact that SciSparc has not yet provided adequate prevalence estimates. However,
the FDA did agree with SciSparc&#8217;s position that SciSparc could potentially qualify for orphan drug designation with respect to
the moderate-to-severe TS sub-group population only rather than the entire population. After SciSparc had provided additional prevalence
estimates, the FDA raised a concern in its letter, dated December 7, 2020, about SciSparc&#8217;s ability to limit the use of the pharmaceutical
product to the subset of patients SciSparc is pursuing. Due to the fact that SciSparc disagrees with this concern, it requested a clarification
call. In the clarification call conducted on February 2, 2021, SciSparc agreed with the FDA concern about its ability to limit the use
of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics population
so SciSparc suggested to amend its preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March 2021, SciSparc sent its response to the
FDA. In June 2021, SciSparc received a response from the FDA explaining that they are unable to grant SciSparc&#8217;s request until
new information becomes available to support its request for orphan drug designation. SciSparc will re-visit the application after it
obtains clinical results from its upcoming phase IIb clinical trial in TS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
is no assurance that SciSparc will successfully obtain orphan drug designation for TS, any future rare indications or orphan exclusivity
upon approval of any of its pharmaceutical product candidates that have already obtained designation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if SciSparc does obtain orphan exclusivity for any pharmaceutical product candidate, the exclusive marketing rights may be lost if the
FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
quantity of the drug. Moreover, a drug product candidate with an active moiety that is a different cannabinoid from that in its drug
candidate or, under limited circumstances, the same drug product candidate, may be approved by the FDA for the same indication during
the period of marketing exclusivity. The limited circumstances include a showing that the second drug is clinically superior to the drug
with marketing exclusivity through a demonstration of superior safety or efficacy or that it makes a major contribution to patient care.
In addition, if a competitor obtains approval and marketing exclusivity for a drug product candidate with an active moiety that is the
same as that in a pharmaceutical product candidate SciSparc is pursuing for the same indication, approval of its pharmaceutical product
candidate would be blocked during the period of marketing exclusivity unless SciSparc could demonstrate that its product candidate is
clinically superior to the approved pharmaceutical product candidate. In addition, if a competitor obtains approval and marketing exclusivity
for a drug product candidate with an active moiety that is the same as that in a pharmaceutical product candidate SciSparc is pursuing
for a different orphan indication, this may negatively impact the market opportunity for its pharmaceutical product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
have been legal challenges to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan
Drug Act, and future challenges could lead to changes that affect the protections afforded SciSparc&#8217;s pharmaceutical product candidates
in ways that are difficult to predict. In a recent successful legal challenge, a court invalidated the FDA&#8217;s denial of orphan exclusivity
to a drug on the grounds that the drug was not proven to be clinically superior to a previously approved pharmaceutical product candidate
containing the same ingredient for the same orphan use. In response to the decision, the FDA released a policy statement stating that
the court&#8217;s decision is limited just to the facts of that particular case and that the FDA will continue to require the sponsor
of a designated drug that is the &#8220;same&#8221; as a previously approved drug to demonstrate that its drug is clinically superior
to that drug upon approval in order to be eligible for orphan drug exclusivity, or in some cases, to even be eligible for marketing approval.
In the future, there is the potential for additional legal challenges to the FDA&#8217;s orphan drug regulations and policies, and it
is uncertain how such challenges might affect SciSparc&#8217;s business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>While orphan drug
product candidates are typically sold at a high price relative to other medications, the market may not be receptive to high pricing
of SciSparc&#8217;s product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
develops its product candidates to treat rare diseases, a space where medications are usually sold at high prices compared with other
medications. However, its product candidates are repurposed drugs, which means, among other things, that they contain drug substances
available in pharmacies for the purpose of treating indications that are different from the indications for which SciSparc plans to use.
Accordingly, even if regulatory authorities approve its product candidates, the market may not be receptive to, and it may be difficult
for SciSparc to achieve, a per-patient per-year price high enough to allow us to realize a return on its investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc&#8217;s
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
                                            use of dronabinol has been associated with seizures, paranoia, rapid heart rate and unusual
                                            thoughts and behaviors. Undesirable side effects caused by SciSparc&#8217;s product candidates
                                            could cause us or regulatory authorities to interrupt, delay or halt clinical studies and
                                            could result in a more restrictive marketing label or the delay or denial of regulatory approval
                                            by the FDA or other comparable foreign authorities. Potential side effects of its cannabinoid-based
                                            treatments may include: asthenia, palpitations, tachycardia, vasodilation/facial flush, abdominal
                                            pain, nausea, vomiting, amnesia, anxiety/nervousness, ataxia, confusion, depersonalization,
                                            dizziness, euphoria, hallucinations, paranoid reaction, somnolence and abnormal thinking.
                                            Results of its studies may identify unacceptable severity and prevalence of these or other
                                            side effects. In such an event, its studies could be suspended or terminated, and the FDA
                                            or comparable foreign regulatory authorities could order SciSparc to cease further development
                                            of or deny or withdraw approval of its product candidates for any or all targeted indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Drug-related
side effects could affect patient recruitment, the ability of enrolled patients to complete the study or result in potential product
candidate liability claims.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
if one or more of its product candidates receives marketing approval, and SciSparc or others later identify undesirable side effects
caused by such product candidates, a number of potentially significant negative consequences could result, including but not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may withdraw approvals of such product candidate;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require additional warnings on the label;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc may be required to create a Risk Evaluation and Mitigation
    Strategy, or REMS, plan, which could include a medication guide outlining the risks of such side effects for distribution to patients,
    a communication plan for healthcare providers and/or other Elements To Assure Safe Use, or ETASU;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc could be sued and held liable for harm caused to patients;
    and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">its reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
of these events could prevent SciSparc from achieving or maintaining market acceptance of the particular product candidate, if approved,
and could significantly harm its business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Even if SciSparc
obtains regulatory approval for a product candidate, its product candidates will remain subject to regulatory scrutiny.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
its product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other
post-market information, including both federal and state requirements in the United States. In addition, manufacturers and manufacturers&#8217;
facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures
conform to current Good Manufacturing Practices, or cGMP, regulations and Quality System Regulation, or QSR. As such, SciSparc and its
contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP, QSR and adherence to commitments
made in any NDA. Accordingly, SciSparc and others with whom SciSparc works must continue to expend time, money and effort in all areas
of regulatory compliance, including manufacturing, production and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
regulatory approvals that SciSparc receives for its product candidates may also be subject to limitations on the approved indicated uses
for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. SciSparc will
also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning
advertising and promotion for its product candidates. Promotional communications with respect to prescription drugs are subject to a
variety of legal and regulatory restrictions and must be consistent with the information in the product candidate&#8217;s approved label.
As such, SciSparc may not promote its product candidates for indications or uses for which they do not have FDA approval. The holder
of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product
candidate, product candidate labeling or manufacturing process. SciSparc could also be asked to conduct post-marketing clinical studies
to verify the safety and efficacy of its product candidates in general or in specific patient subsets. If original marketing approval
were obtained via the accelerated approval pathway, SciSparc could be required to conduct a successful post-marketing clinical study
to confirm clinical benefit for its product candidates. An unsuccessful post-marketing study or failure to complete such a study could
result in the withdrawal of marketing approval. Furthermore, any new legislation addressing drug safety issues could result in delays
in product candidate development or commercialization or increased costs to assure compliance. Foreign regulatory authorities impose
similar requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
a regulatory agency discovers previously unknown problems with a product candidate, such as adverse events of unanticipated severity
or frequency, or problems with the facility where the product candidate is manufactured, or disagrees with the promotion, marketing or
labeling of a product candidate, such regulatory agency may impose restrictions on that product candidate or SciSparc, including requiring
withdrawal of the product candidate from the market. If SciSparc fails to comply with applicable regulatory requirements, a regulatory
agency or enforcement authority may, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">issue warning letters;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">impose civil or criminal penalties;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">suspend or withdraw regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">suspend any of its ongoing clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refuse to approve pending applications or supplements to approved applications
    submitted by SciSparc;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">impose restrictions on its operations, including closing its contract
    manufacturers&#8217; facilities; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">seize or detain product candidates, or require a product candidate
    recall.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
government investigation of alleged violations of law could require SciSparc to expend significant time and resources in response and
could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect
its ability to commercialize and generate revenue from SciSparc&#8217;s product candidates. If regulatory sanctions are applied or if
regulatory approval is withdrawn, the value of SciSparc and its operating results will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc is subject
to numerous complex regulations and failure to comply with these regulations, or the cost of compliance with these regulations, may harm
its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
research, testing, development, manufacturing, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising,
marketing, distribution, possession and use of its product candidates, among other things, are subject to regulation by numerous governmental
authorities in the United States and elsewhere. The FDA regulates drugs under the FDC Act and implements regulations. Noncompliance with
any applicable regulatory requirements can result in refusal to approve product candidates for marketing, warning letters, product candidate
recalls or seizure of product candidates, total or partial suspension of production, prohibitions or limitations on the commercial sale
of product candidates or refusal to allow the entering into of federal and state supply contracts, fines, civil penalties and/or criminal
prosecution. Additionally, the FDA and comparable governmental authorities have the authority to withdraw product candidate approvals
that have been previously granted. Moreover, the regulatory requirements relating to its product candidates may change from time to time
and it is impossible to predict what the impact of any such changes may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is developing product candidates that are controlled substances as defined in the Controlled Substances Act of 1970, or CSA, which establishes,
among other things, certain registration, production quotas, security, recordkeeping, reporting, import, export and other requirements
administered by the Drug Enforcement Administration, or the DEA. As a result, any product candidate that is a controlled substance (or
includes a controlled substance) cannot be marketed before such substance is rescheduled by the DEA as a Schedule II, III, IV or V substance.
The active ingredient in SciSparc&#8217;s product candidates is dronabinol, which is a Schedule III controlled substance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
manufacture, shipment, storage, sale and use, among other things, of controlled substances that are pharmaceutical product candidates
are subject to a high degree of regulation. The DEA also conducts periodic inspections of registered establishments that handle controlled
substances. Facilities that conduct research, manufacture, distribute, import or export controlled substances must be registered to perform
these activities and have the security, control and inventory mechanisms required by the DEA to prevent drug loss and diversion. Failure
to maintain compliance, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a
material adverse effect on its business, results of operations, financial condition and prospects. The DEA may seek civil penalties,
refuse to renew necessary registrations, or initiate proceedings to suspend or revoke those registrations. In certain circumstances,
violations could lead to criminal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Individual
states also have controlled substances laws. Though state controlled substances laws often mirror federal law, because the states are
separate jurisdictions, they may separately schedule its product candidates as well. While some states automatically schedule a drug
when the DEA does so, other states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial sale
of any product candidate for which SciSparc obtains federal regulatory approval and adverse scheduling could have a material adverse
effect on the commercial attractiveness of such product candidate. SciSparc or its partners must also obtain separate state registrations,
permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale,
and failure to meet applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from
the DEA or otherwise arising under federal law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Reliance on Third Parties</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc relies
on third parties to conduct its preclinical and clinical studies and perform other tasks for it. If these third parties do not successfully
carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, SciSparc may not be able to obtain
regulatory approval for or commercialize its product candidates and its business could be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for its ongoing preclinical and clinical
programs, including Target Health, Inc., FGK Clinical Research GmbH, or FGK, and others. SciSparc relies on these parties for execution
of its preclinical and clinical studies, and control only certain aspects of their activities. Nevertheless, SciSparc is responsible
for ensuring that each of its studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards
and its reliance on the CROs does not relieve SciSparc of its regulatory responsibilities. SciSparc and its CROs and other vendors are
required to comply with current cGMP, GCP, QSR and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by
the FDA, the Competent Authorities of the Member States of the European Economic Area, and comparable foreign regulatory authorities
for all of its product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections
of study sponsors, principal investigators, study sites and other contractors. If SciSparc or any of its CROs or vendors fail to comply
with applicable regulations, the clinical data generated in its clinical studies may be deemed unreliable and the FDA, EMA or comparable
foreign regulatory authorities may require SciSparc to perform additional clinical studies before approving its marketing applications.
SciSparc cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of
its clinical studies comply with GCP regulations. In addition, its clinical studies must be conducted with product candidates which are
produced under cGMP regulations. SciSparc&#8217;s failure to comply with these regulations may require it to repeat clinical studies,
which would delay the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
any of its relationships with these third-party CROs terminate, SciSparc may not be able to enter into arrangements with alternative
CROs or do so on commercially reasonable terms. In addition, its CROs are not SciSparc employees, and except for remedies available to
SciSparc under its agreements with such CROs, SciSparc cannot control whether or not they devote sufficient time and resources to its
on-going clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to SciSparc&#8217;s clinical protocols, regulatory requirements or for other reasons, its clinical studies
may be extended, delayed or terminated and SciSparc may not be able to obtain regulatory approval for or successfully commercialize its
product candidates. CROs may also generate higher costs than anticipated. As a result, its results of operations and the commercial prospects
for its product candidates would be harmed, SciSparc&#8217;s costs could increase and its ability to generate revenue could be delayed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Switching
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays may occur, which could materially impact SciSparc&#8217;s ability to meet its
desired clinical development timelines. Though SciSparc carefully manages its relationships with its CROs, there can be no assurance
that SciSparc will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material
adverse impact on its business, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc will
rely on third parties to manufacture its API and formulations. Its business could be harmed if those third parties fail to provide SciSparc
with sufficient quantities of its needed supplies, or fail to do so at acceptable quality levels or prices.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
does not have the infrastructure or capability internally to manufacture the API formulations, and SciSparc lacks the resources and the
capability to manufacture any of its product candidates on a clinical or commercial scale. SciSparc plans to rely on third parties for
such supplies. There are a limited number of manufacturers who have the ability to produce its API and there may be a need to identify
alternate manufacturers to prevent a possible disruption of its clinical studies. Any significant delay or discontinuity in the supply
of these components could considerably delay completion of its clinical studies, product candidate testing and potential regulatory approval
of its product candidates, which could harm its business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc and its
collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing its product candidates.
The manufacturing facilities on which SciSparc relies may not continue to meet regulatory requirements and have limited capacity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
entities involved in the preparation of therapeutics for clinical studies or commercial sale, including its existing contract manufacturers
for its product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial
sale or a product candidate used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern
manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control
and assure the quality of investigational product candidates and products approved for sale. Poor control of production processes can
lead to the introduction of contaminants or to inadvertent changes in the properties or stability of its product candidates that may
not be detectable in final product testing. SciSparc, its collaborators or its contract manufacturers must supply all necessary documentation
in support of an NDA, or Marketing Authorization Application, or MAA, on a timely basis and must adhere to GLP and cGMP QSR regulations
enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of its contract manufacturers have
never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals
to do so. The facilities and quality systems of some or all of its collaborators and third-party contractors must pass a pre-approval
inspection for compliance with the applicable regulations as a condition of regulatory approval of SciSparc&#8217;s product candidates
or any of its other potential product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing
facility involved with the preparation of its product candidates or its other potential product candidates or the associated quality
systems for compliance with the regulations applicable to the activities being conducted. SciSparc does not control the manufacturing
process of, and are completely dependent on, its contract manufacturing partners for compliance with the regulatory requirements. If
these facilities do not pass a pre-approval plant inspection, regulatory approval of the product candidates may not be granted or may
be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
regulatory authorities also may, at any time following approval of a product candidate for sale, if ever, audit the manufacturing facilities
of its collaborators and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations
or if a violation of its product candidate specifications or applicable regulations occurs independent of such an inspection or audit,
SciSparc or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for SciSparc or
a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales, or the
temporary or permanent closure of a facility. Any such remedial measures imposed upon SciSparc or third parties with whom SciSparc contracts
could materially harm its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc, its collaborators, or any of its third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable
regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new
drug product, withdrawal of an approval or suspension of production. As a result, its business, financial condition and results of operations
may be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA or MAA
amendment, or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional
studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is
likely to result in a delay in SciSparc&#8217;s desired clinical and commercial timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
factors could cause SciSparc to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions,
required approvals or commercialization of its product candidates. Furthermore, if its suppliers fail to meet contractual requirements
and SciSparc is unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, its clinical
studies may be delayed or SciSparc could lose potential revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc&#8217;s
reliance on third parties requires it to share its trade secrets, which increases the possibility that a competitor will discover them
or that its trade secrets will be misappropriated or disclosed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
SciSparc relies on third parties to develop and manufacture its product candidates, SciSparc must, at times, share trade secrets with
them. SciSparc seeks to protect its proprietary technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with its collaborators, advisors,
employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights
of the third parties to use or disclose SciSparc&#8217;s confidential information, such as trade secrets. Despite the contractual provisions
employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that
such trade secrets become known by its competitors, are inadvertently incorporated into the technology of others, or are disclosed or
used in violation of these agreements. Given that SciSparc&#8217;s proprietary position is based, in part, on its know-how and trade
secrets, a competitor&#8217;s discovery of SciSparc&#8217;s trade secrets or other unauthorized use or disclosure would impair its competitive
position and may have a material adverse effect on its business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to Commercialization
of SciSparc&#8217;s Pharmaceutical Product Candidates</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If the market
opportunities for its pharmaceutical product candidates are smaller than SciSparc believes they are, its revenue may be adversely affected,
and its business may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
projections of both the number of people who have its target diseases, as well as the subset of people with these diseases who have the
potential to benefit from treatment with its pharmaceutical product candidates, are based on SciSparc&#8217;s beliefs and estimates.
These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations
or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases.
The number of patients may turn out to be lower than expected. The effort to identify patients with diseases SciSparc seeks to treat
is in early stages, and SciSparc cannot accurately predict the number of patients for whom treatment might be possible. Additionally,
the potentially addressable patient population for each of its pharmaceutical product candidates may be limited or may not be amenable
to treatment with its pharmaceutical product candidates, and new patients may become increasingly difficult to identify or gain access
to, which would adversely affect its results of operations and its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc faces
intense competition and rapid technological change and the possibility that its competitors may discover, develop or commercialize therapies
that are similar, more advanced or more effective than that of SciSparc, which may adversely affect its financial condition and its ability
to successfully commercialize its product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
biotechnology and pharmaceutical industries are highly competitive. There are many pharmaceutical companies, biotechnology companies,
public and private universities and research organizations actively engaged in the research and development of products that may be similar
to SciSparc&#8217;s product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
first THC-based pharmaceutical, a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company
called Unimed Pharmaceuticals, with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment
for chemotherapy-related nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market,
other pharmaceuticals containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed
by SVC Pharma LP and Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole
cannabis extract administered as an oral spray. Furthermore, to the best of SciSparc&#8217;s knowledge, multiple companies that are working
in the cannabis therapeutic area and are pursuing regulatory approval for their product candidates. For example, GW Pharmaceuticals PLC,
or GW, which markets Sativex, a botanical cannabinoid oral mucosal for the treatment of spasticity due to multiple sclerosis, received
FDA approval in the United States in June 2018 for Epidiolex, a liquid formulation of highly purified cannabidiol extract, as a treatment
for Dravet&#8217;s Syndrome, Lennox Gastaut Syndrome, and various childhood epilepsy syndromes. In addition, GW is developing, among
others, cannabidivarin, or CBDV, based therapy for ASD and therapy for neonatal hypoxic-ischemic encephalopathy and schizophrenia. Zynerba
Pharmaceuticals, Inc., or Zynerba, is developing a transdermal formulation of cannabidiol for Fragile X and certain refractory epilepsies
and ASD. Skye Bioscience, Inc., or Skye, is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma
and other diseases with significant unmet need. Corbus Pharmaceuticals Holdings is seeking FDA approval for their synthetic cannabinoid
for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus and metabolism and solid tumors. RespireRx
Pharmaceutical Inc., or RespireRx, developing dronabinol for OSA treatment. Synendos Therapeutics AG, or Synendos, is a developer of
endocannabinoid modulators for the treatment of central nervous system, or CNS, disorders. It has developed pharmaceutical products to
restore the natural function of the brain and treat neuropsychiatric disorders. Synendos is developing small molecules as selective endocannabinoid
reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders caused by cannabinoid deficiency. Inversago
Pharma (formerly GIcare Pharma) is focused on developing peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment
of metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Its drug INV-101 (Inverse agonist of peripheral CB1) under
phase-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">More
established companies may have a competitive advantage over us due to their greater size, cash flows and institutional experience. Compared
to SciSparc, many of its competitors may have significantly greater financial, technical and human resources. As a result of these factors,
SciSparc&#8217;s competitors may have an advantage in marketing their approved products and may obtain regulatory approval of their product
candidates before SciSparc is able to, which may limit its ability to develop or commercialize its product candidates. SciSparc&#8217;s
competitors may also develop drugs that are safer, more effective, more widely used and less expensive than those of SciSparc, and may
also be more successful than us in manufacturing and marketing their products. These advantages could materially impact SciSparc&#8217;s
ability to develop and commercialize its product candidates successfully.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
product candidates may also compete with medical and recreational marijuana, in markets where the recreational and/or medical use of
marijuana is legal. There is support in the United States for further legalization of marijuana. In markets where recreational and/or
medical marijuana is not legal, its product candidates may compete with marijuana purchased in the illegal drug market. SciSparc cannot
assess the extent to which patients may utilize marijuana obtained illegally for the treatment of the indications for which SciSparc
is developing its product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if SciSparc successfully develops its product candidates, and obtain marketing approval for them, other treatments or therapeutics may
be preferred and SciSparc may not be successful in commercializing its product candidates or in bringing them to market.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Many
of SciSparc&#8217;s competitors have substantially greater financial, technical and other resources, such as larger research and development
staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated in SciSparc&#8217;s competitors. As a result, these companies may obtain
regulatory approval more rapidly than SciSparc is able to and may be more effective in selling and marketing their products as well.
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large,
established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater
availability of capital for investment in these industries. SciSparc&#8217;s competitors may succeed in developing, acquiring or licensing
on an exclusive basis, products that are more effective or less costly than any product candidate that SciSparc may develop, or achieve
earlier patent protection, regulatory approval, product commercialization and market penetration than SciSparc does. Additionally, technologies
developed by its competitors may render its potential product candidates uneconomical or obsolete, and SciSparc may not be successful
in marketing its product candidates against competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc currently
have no marketing and sales organization. If SciSparc is unable to establish sales and marketing capabilities or enter into agreements
with third parties to market and sell its product candidates, SciSparc may be unable to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
its employees may have sold other similar products in the past while employed at other companies, SciSparc as a company have no experience
selling and marketing its product candidates and SciSparc currently has no marketing or sales organization. To successfully commercialize
any products that may result from its development programs, SciSparc will need to develop these capabilities, either on its own or with
others. If its product candidates receive regulatory approval, SciSparc intends to establish a sales and marketing organization with
technical expertise and supporting distribution capabilities to commercialize its product candidates in major markets, which will be
expensive, difficult and time consuming. Any failure or delay in the development of its internal sales, marketing and distribution capabilities
would adversely impact the commercialization of its products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
given its lack of prior experience in marketing and selling pharmaceutical products, its initial estimate of the size of the required
sales force may be materially more or less than the size of the sales force actually required to effectively commercialize its product
candidates. As such, SciSparc may be required to hire substantially more sales representatives to adequately support the commercialization
of its product candidates or SciSparc may incur excess costs as a result of hiring more sales representatives than necessary. With respect
to certain geographical markets, SciSparc may enter into collaborations with other entities to utilize their local marketing and distribution
capabilities, but SciSparc may be unable to enter into such agreements on favorable terms, if at all. If its future collaborators do
not commit sufficient resources to commercialize its future products, if any, and SciSparc is unable to develop the necessary marketing
capabilities on its own, SciSparc will be unable to generate sufficient product revenue to sustain its business. SciSparc may be competing
with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support
of a third party to perform marketing and sales functions, SciSparc may be unable to compete successfully against these more established
companies.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The commercial
success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party
payors and others in the medical community.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of SciSparc&#8217;s product
candidates will depend in part on the medical community, patients and third-party payors accepting its product candidates as medically
useful, cost-effective and safe. Any product that SciSparc brings to the market may not gain market acceptance by physicians, patients,
third-party payors and others in the medical community. The degree of market acceptance of any of its product candidates, if approved
for commercial sale, will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the safety and efficacy of the product as demonstrated in clinical
    studies and potential advantages over competing treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the prevalence and severity of any side effects, including any limitations
    or warnings contained in a product&#8217;s approved labeling;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the clinical indications for which approval is granted;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">relative convenience and ease of administration;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of treatment, particularly in relation to competing treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the willingness of the target patient population to try new therapies
    and of physicians to prescribe these therapies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the strength of marketing and distribution support and timing of market
    introduction of competitive products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">publicity concerning its products or competing products and treatments;
    and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">sufficient third-party insurance coverage and reimbursement.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if a potential product displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance of the
product will not be fully known until after it is launched. Its efforts to educate the medical community and third-party payors on the
benefits of the product candidates may require significant resources and may never be successful. If its product candidates are approved
but fail to achieve an adequate level of acceptance by physicians, patients, third-party payors and others in the medical community,
SciSparc will not be able to generate sufficient revenue to become or remain profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The insurance
coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement
for new or current products could limit its ability to market those products and decrease its ability to generate revenue.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
pricing, coverage and reimbursement of its product candidates, if approved, must be adequate to support SciSparc&#8217;s commercial infrastructure.
SciSparc&#8217;s per-patient prices must be sufficient to recover its development and manufacturing costs and potentially achieve profitability.
Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients
to be able to afford expensive treatments such as those of SciSparc, assuming approval. Sales of its product candidates will depend substantially,
both domestically and abroad, on the extent to which the costs of its product candidates will be paid for by health maintenance, managed
care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government authorities, private health insurers
and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, SciSparc may
not be able to successfully commercialize its product candidates. Even if coverage is provided, the approved reimbursement amount may
not be high enough to allow SciSparc to establish or maintain pricing sufficient to realize a return on its investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services,
or CMS, an agency within the U.S. Department of Health and Human Services, or DHHS, as CMS decides whether and to what extent a new drug
will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to
a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as the SciSparc
ones.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Outside
the United States, international operations are generally subject to extensive governmental price controls and other market regulations,
and SciSparc believes the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue
to put pressure on the pricing and usage of its product candidates. In many countries, the prices of medical products are subject to
varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially
lower than in the United States. Other countries allow companies to fix their own prices for medicinal products, but monitor and control
company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that SciSparc is
able to charge for its product candidates. Accordingly, in markets outside the United States, the reimbursement for its products may
be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover,
increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause
such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover
or provide adequate payment for SciSparc&#8217;s product candidates. SciSparc expects to experience pricing pressures in connection with
the sale of any of its product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs
and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the
entry of new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Healthcare legislative
reform measures may have a material adverse effect on its business and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. The following
are among the provisions established by the Patient Protection and&#160;Affordable Care Act of 2010, or ACA, of greatest importance to
the pharmaceutical and biotechnology industry:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded
    prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare
    programs;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate
    Program to 23.1% and 13% of the Average Manufacturer Price, or AMP, for most branded and generic drugs, respectively, and capped
    the total rebate amount for innovator drugs at 100% of the AMP;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals
    who are enrolled in Medicaid managed care organizations, or MCOs; &#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to
    offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income
    at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (now
    70%) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap
    period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; &#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#9679;</td>
    <td style="text-align: justify">expansion of the entities eligible for discounts under federal 340B; &#160;</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
    clinical effectiveness research, along with funding for such research;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery
    models to lower Medicare and Medicaid spending. This center is currently focused on the following priorities:</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">testing new payment and service delivery models;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">evaluating results and advancing best practices; and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">engaging a broad range of stakeholders to develop additional models for testing.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">implementation of the federal physician payment transparency requirements, or the Sunshine Act. The
    Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, or the SUPPORT Act,
    signed into law on October 24, 2018, expanded Sunshine Act reporting to include data for physician assistants, nurse practitioners,
    clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwifes. The amendment applies to reports
    submitted to CMS on or after January 1, 2022.</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ACA may be modified, amended or repealed at any time and may or may not be replaced with a different law or health care payment system.
The ACA is expected to continue to have a significant impact on the health care industry. With regard to pharmaceutical product candidates,
among other things, the ACA may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the
coverage requirements under the Medicare D program. Since the enactment of the ACA, numerous regulations have been issued providing further
guidance on its requirements. The ACA continues to be implemented through regulation and government activity but is subject to possible
amendment, additional implementing regulations and interpretive guidelines. Several states have decided not to expand their Medicaid
programs and are seeking alternative reimbursement models to provide care to the uninsured. The manner in which these issues are resolved
could materially affect the extent to which and the amount at which pharmaceuticals are reimbursed by government programs such as Medicare,
Medicaid and Tricare.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
2016, CMS issued a final rule regarding the Medicaid Drug Rebate Program that, among other things, revised the manner in which the AMP
is calculated by manufacturers participating in the program and implemented certain amendments to the Medicaid rebate statute created
under the ACA. In addition, on December 21, 2020, CMS issued a final rule that made changes to the Medicaid Drug Rebate Program regulations
in several areas, including some changes to the treatment of value-based purchasing arrangements and price reporting for patient benefit
programs sponsored by pharmaceutical manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Two
bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the
TCJA, included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on
certain individuals who fail to maintain qualifying health coverage for all or part of a year, that is commonly referred to as the &#8220;individual
mandate.&#8217;&#8217; Additionally, on January 22, 2018, then President Trump signed a continuing resolution on appropriations for fiscal
year 2018 that delayed the implementation of certain ACA-mandated fees. Further, the Bipartisan Budget Act of 2018, among other things,
amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut
hole.&#8221; In July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health
plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation
regarding the method CMS uses to determine this risk adjustment. On April 27, 2020, the U.S. Supreme Court reversed a Federal Circuit
decision that previously upheld Congress&#8217; denial of $12 billion in &#8220;risk corridor&#8221; funding. Congress may consider additional
legislation to repeal, or repeal and replace, other elements of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge
on procedural grounds that argued that the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress.
Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden
issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the
ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and
rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include
work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or
the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges
and the healthcare reform measures of the Biden administration will impact the ACA and its business. SciSparc continues to evaluate the
ACA and its possible repeal and replacement, as the extent to which any such changes may impact its business or financial condition remains
uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the Budget
Control Act of 2011 among other things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare
payments to providers of 2% per fiscal year. These reductions, known as Medicare sequestration adjustments, went into effect in 2013.
However, under the Coronavirus Aid, Relief, Economic Securities Act of 2020, and related legislation, Medicare sequestration adjustments
from May 1, 2020 through March 31, 2021 have been suspended, though sequestration has been extended through 2030. Additionally, there
has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For
example, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for drug products. At the federal level, including the former Administration&#8217;s
budget for fiscal year 2020, there were further drug price control measures to permit Medicare Part D plans to negotiate the price of
certain drugs under Medicare Part D, to continue to allow some states to negotiate drug prices under Medicaid through supplemental rebate
negotiations and other mechanisms, and legislation was introduced to eliminate cost sharing for generic drugs for Part D low-income patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, in November 2020, the U.S. DHHS, finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending
for prescription drugs by excluding rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors
or pharmacy benefit managers, or PBMs, acting under contract with Medicare Part D plan sponsors from the existing discount safe harbor
under the federal Anti-Kickback Statute, or the AKS. The regulation reflects the first change to the AKS Statute discount safe harbor
since the Medicare Part D program was established. In addition to the rebate exclusions, two new safe harbors were added. One of these
new safe harbors protects point-of-sale reductions in price from a manufacturer to a plan sponsor under Medicare Part D or a MCO, for
a prescription drug payable, in whole or in part, by a plan sponsor under Medicare Part D or a MCO, provided certain conditions are met.
The other protects certain fixed-fee services arrangements between manufacturers and PBMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Congress
and the executive branch have each indicated that it will continue to seek new legislative or administrative measures to control drug
costs. At the state level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation
from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the European Union, similar political, economic and regulatory developments may affect SciSparc&#8217;s ability to profitably commercialize
any of its product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments
at the European Union or member state level may result in significant additional requirements or obstacles that may increase its operating
costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing
and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments
and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement
of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions
on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national
regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of its product candidates,
restrict or regulate post-approval activities and affect its ability to commercialize any products for which SciSparc obtains marketing
approval. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue
after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade, i.e., arbitrage between
low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls
or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products,
if approved in those countries. In international markets, reimbursement and healthcare payment systems vary significantly by country,
and many countries have instituted price ceilings on specific products and therapies.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
expects that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria
and lower reimbursement, and in additional downward pressure on the price that SciSparc receives for any approved product. Any reduction
in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors.
The implementation of cost containment measures or other healthcare reforms may prevent SciSparc from being able to generate revenue,
attain profitability or commercialize its drugs, once marketing approval is obtained. SciSparc cannot predict what healthcare reform
initiatives may be adopted in the future. However, it is possible that there will be further legislation or regulation that could harm
the business, financial condition and results of operations.</p><div>


</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The COVID-19 pandemic
has resulted in delays to SciSparc&#8217;s product development and may adversely affect any potential future revenues, results of operations
and financial condition.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">COVID-19
and the various precautionary measures taken by many governmental authorities around the world to limit its spread had a severe effect
on global markets and the global economy. The extent to which the coronavirus impacts SciSparc&#8217;s business and operations will depend
on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the
severity of COVID-19 and the nature and extent of governmental actions taken to contain or treat its impact and the availability, costs,
effectiveness and public acceptance of any FDA-approved vaccines, among others. COVID-19 and official actions taken in response to it
caused a major slowdown in overall economic activity in the U.S. and elsewhere, curtailed consumer spending and made it more challenging
to adequately staff and manage SciSparc&#8217;s business and operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
COVID-19 pandemic impacted its various vendors, including CROs, and caused delays in the development of its product candidates. SciSparc
also experienced delays in the preparation toward various clinical trials, including being unable to receive prioritization to conduct
clinical trials, availability of physicians and other staff members involved in its clinical trials. At this time, SciSparc does not
anticipate that the COVID-19 pandemic and official responses would cause a material adverse effect on its results of operations and financial
condition but there can be no assurance that this will be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If SciSparc is
unable to obtain and maintain effective patent rights for its product candidates, SciSparc may not be able to compete effectively in
its markets. If SciSparc is unable to protect the confidentiality of its trade secrets or know-how, such proprietary information may
be used by others to compete against SciSparc.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Historically,
SciSparc has relied on trade secret protection and confidentiality agreements to protect the intellectual property related to its technologies
and product candidates. Since 2015, SciSparc has also sought patent protection for certain of its product candidates. Its success depends
in large part on its ability to obtain and maintain patent and other intellectual property protection in the United States and in other
countries with respect to its proprietary technology and new product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
seeks to protect its proprietary position by filing patent applications in the United States and in other countries, with respect to
its novel technologies and product candidates, which are important to its business. Patent prosecution is expensive and time consuming,
and SciSparc may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely
manner. It is also possible that SciSparc will fail to identify patentable aspects of its research and development output before it is
too late to obtain patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Not
including patents and applications which SciSparc is in the process of being assigned, SciSparc has a portfolio of seven granted patents
with the U.S. Patent and Trademark Office, or USPTO, nine patent families and two trademarks, of which four families include Patent Cooperation
Treaty, or PCT, applications, that have entered the national phase in various national entities. SciSparc cannot offer any assurances
about which, if any, patent applications will issue, the breadth of any such patent or whether any issued patents will be found invalid
and unenforceable or will be threatened by third parties. Any successful opposition to its patents after issuance could deprive SciSparc
of rights necessary for the successful commercialization of any new product candidates that SciSparc may develop and would allow other
third parties to compete with it.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has exclusively licensed: (i) one U.S. patent from Dekel Pharmaceuticals Ltd., or Dekel, and (ii) one U.S. patent family from Yissum
Research Development Company of the Hebrew University of Jerusalem Ltd., or Yissum. SciSparc cannot assure you that it will ever enter
into definitive license agreements with any third party licensor. To the extent the licensed or future licensed patents are found to
be invalid or unenforceable, SciSparc may be limited in its ability to compete and market its product candidates. Moreover, the terms
of its licenses affect its ability to control the value of any of its product candidates. If SciSparc or any of the parties that control
the enforcement of licensed patents elect not to enforce any or all of the licensed patents it could significantly undercut the value
of any of its product candidates, which would materially adversely affect its future revenue, financial condition and results of operations.
Moreover, fluctuating currency rates may create inconsistencies in the royalty payments SciSparc is obligated to make under its licenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Also,
there is no guarantee that the patent registration applications that were submitted by SciSparc with regard to its technologies will
result in patent registration. In the event of failure to complete patent registration, its developments will not be proprietary, which
might allow other entities to manufacture its product candidates and compete with them.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
there is no assurance that all potentially relevant prior art relating to its patent applications has been found. Such prior art, to
the extent it exists, may invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do
successfully issue, and even if such patents cover SciSparc&#8217;s product candidates, third parties may challenge their validity, enforceability,
or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged,
SciSparc&#8217;s patent applications and any future patents may not adequately protect its intellectual property, provide exclusivity
for its new product candidates, or prevent others from designing around its claims. Any of these outcomes could impair its ability to
prevent competition from third parties, which may have an adverse impact on its business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Engagement
in any type of intellectual property collaboration agreement requires diligent management of intellectual property rights. Joint intellectual
property engagements may create additional administrative and financial burdens and may place us at heightened risk of disputes or litigation
regarding ownership, maintenance or enforcement of such joint intellectual property. For example, SciSparc&#8217;s collaboration with
Clearmind Medicine Inc., or Clearmind, has resulted in filings of provisional patent applications related to certain combinations of
its respective proprietary compounds. As a joint-owner of intellectual property, SciSparc is generally or would be unable to use or exploit
the intellectual property without the consent of the other joint owner. If SciSparc cannot obtain sole commercial use rights for such
jointly-owned intellectual property as a result of its collaboration, its future product development and commercialization plans may
be adversely affected. Moreover, if SciSparc cannot obtain and maintain effective patent rights for its product candidates, SciSparc
may not be able to compete effectively, and its business and results of operations may be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may not
be able to identify infringements of its patents and accordingly the enforcement of its intellectual property rights may be difficult.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
drug substance in some of SciSparc&#8217;s product candidates is repurposed, which means that it is available in other pharmaceutical
products for the purpose of treating indications that are different from the indications for its product candidates. It is possible that
if SciSparc receives regulatory approval to market and sell its drug candidates, some patients that receive a prescription could be sold
the same drug substance but not its product candidate. It would be difficult, if not impossible, for SciSparc to identify such instances
that may constitute an infringement of its patents. In addition, because the drug substance of some of its product candidates is repurposed,
such substance may not be eligible for patent protection or data exclusivity. Even if SciSparc identifies infringing parties, there is
no guarantee that a court will agree with its arguments and find that a third party is infringing its patents or that the court will
issue an order for an adequate remedy for that infringement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If SciSparc is unable to maintain effective proprietary rights
for its product candidates, SciSparc may not be able to compete effectively in its markets.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to the protection afforded by any patents currently owned and that may be granted, historically, SciSparc has relied on trade
secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that SciSparc elects not to
patent, processes that are not easily known, knowable or easily ascertainable, and for which patent infringement is difficult to monitor
and enforce and any other elements of its product candidate discovery and development processes that involve proprietary know-how, information
or technology that is not covered by patents. However, trade secrets can be difficult to protect. SciSparc seeks to protect its proprietary
technology and processes, in part, by entering into confidentiality agreements with its employees, consultants, scientific advisors,
and contractors. SciSparc also seeks to preserve the integrity and confidentiality of its data, trade secrets and intellectual property
by maintaining physical security of its premises and physical and electronic security of its information technology systems. Agreements
or security measures may be breached, and SciSparc may not have adequate remedies for any breach. In addition, SciSparc&#8217;s trade
secrets and intellectual property may otherwise become known or be independently discovered by competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
cannot provide any assurances that its trade secrets and other confidential proprietary information will not be disclosed in violation
of its confidentiality agreements or that competitors will not otherwise gain access to its trade secrets or independently develop substantially
equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of its trade secrets and intellectual
property could impair its competitive position and may have a material adverse effect on its business. Additionally, if the steps taken
to maintain its trade secrets and intellectual property are deemed inadequate, SciSparc may have insufficient recourse against third
parties for misappropriating any trade secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Intellectual property
rights of third parties could adversely affect SciSparc&#8217;s ability to commercialize its product candidates, and SciSparc might be
required to litigate or obtain licenses from third parties in order to develop or market its product candidates. Such litigation or licenses
could be costly or not available on commercially reasonable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">It
is inherently difficult to conclusively assess its freedom to operate without infringing on third party rights. SciSparc&#8217;s competitive
position may be adversely affected if existing patents or patents resulting from patent applications issued to third parties or other
third party intellectual property rights are held to cover its product candidates or elements thereof, or its manufacturing or uses relevant
to its development plans. In such cases, SciSparc may not be in a position to develop or commercialize product candidates or its product
candidates unless SciSparc successfully pursue litigation to nullify or invalidate the third party intellectual property right concerned,
or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may
also be pending patent applications that if they result in issued patents, could be alleged to be infringed by its new product candidates.
If such an infringement claim should be brought and be successful, SciSparc may be required to pay substantial damages, be forced to
abandon its new product candidates or seek a license from any patent holders. No assurances can be given that a license will be available
on commercially reasonable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">It
is also possible that SciSparc has failed to identify relevant third-party patents or applications. For example, certain U.S. patent
applications that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United
States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering its new product candidates or platform
technology could have been filed by others without SciSparc&#8217;s knowledge. Additionally, pending patent applications which have been
published can, subject to certain limitations, be later amended in a manner that could cover its platform technologies, its new product
candidates or the use of its new product candidates. Third party intellectual property right holders may also actively bring infringement
claims against SciSparc. SciSparc cannot guarantee that it will be able to successfully settle or otherwise resolve such infringement
claims. If SciSparc is unable to successfully settle future claims on terms acceptable to it, SciSparc may be required to engage in or
continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in pursuing the
development of and/or marketing its new product candidates. If SciSparc fails in any such dispute, in addition to being forced to pay
damages, SciSparc may be temporarily or permanently prohibited from commercializing its new product candidates that are held to be infringing.
SciSparc may, if possible, also be forced to redesign its new product candidates so that SciSparc no longer infringes the third-party
intellectual property rights. Any of these events, even if SciSparc were ultimately to prevail, could require it to divert substantial
financial and management resources that SciSparc would otherwise be able to devote to its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><b><i>Third-party
claims of intellectual property infringement may prevent or delay SciSparc&#8217;s development and commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
commercial success depends in part on its avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S.
and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which SciSparc is
developing new product candidates. As its industries expand and more patents are issued, the risk increases that its product candidates
may be subject to claims of infringement of the patent rights of third parties.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Third
parties may assert that SciSparc is employing their proprietary technology without authorization. There may be third-party patents or
patent applications with claims to materials, designs or methods of manufacture related to the use or manufacture of its product candidates.
There may be currently pending patent applications that may later result in issued patents that its product candidates may infringe.
In addition, third parties may obtain patents in the future and claim that use of SciSparc&#8217;s technologies infringes upon these
patents.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
any third-party patents were held by a court of competent jurisdiction to cover aspects of its formulations, processes for designs, or
methods of use, the holders of any such patents may be able to block its ability to develop and commercialize the applicable product
candidate unless SciSparc obtains a license or until such patent expires or is finally determined to be invalid or unenforceable. In
either case, such a license may not be available on commercially reasonable terms or at all.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Parties
making claims against SciSparc may obtain injunctive or other equitable relief, which could effectively block its ability to further
develop and commercialize one or more of its product candidates. Defense of these claims, regardless of their merit, would involve substantial
litigation expense and would be a substantial diversion of employee resources from SciSparc&#8217;s business. In the event of a successful
claim of infringement against SciSparc in the U.S. or any other relevant jurisdiction, SciSparc may have to pay substantial damages,
including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign its infringing product candidates
or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Patent policy
and rule changes could increase the uncertainties and costs surrounding the prosecution of its patent applications and the enforcement
or defense of any issued patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Changes
in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of any
patents that may issue from its patent applications, or narrow the scope of its patent protection. The laws of foreign countries may
not protect SciSparc&#8217;s rights to the same extent as the laws of the United States. Publications of discoveries in the scientific
literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically
not published until 18 months after filing, or in some cases not at all. SciSparc therefore cannot be certain that SciSparc was the first
to file the invention claimed in its owned and licensed patent or pending applications, or that it or its licensor was the first to file
for patent protection of such inventions. Assuming all other requirements for patentability are met, in the United States prior to 2013,
the first to make the claimed invention without undue delay in filing, is entitled to the patent, while outside the United States, the
first to file a patent application is entitled to the patent. After 2013, the United States moved to a first to file system. Changes
in patent litigation could increase the uncertainties and costs surrounding the prosecution of its patent applications and the enforcement
or defense of any issued patents, all of which could have a material adverse effect on its business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
involved in lawsuits to protect or enforce its intellectual property, which could be expensive, time consuming, and unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Competitors
may infringe SciSparc&#8217;s intellectual property. If SciSparc was to initiate legal proceedings against a third party to enforce a
patent covering one of its new product candidates, the defendant could counterclaim that the patent covering its product candidate is
invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability
are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including
lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected
with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The
validity of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome following legal assertions of
invalidity and unenforceability is unpredictable.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Derivation
proceedings initiated by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with
respect to SciSparc&#8217;s patent or patent applications or those of its licensors. An unfavorable outcome could require SciSparc to
cease using the related technology or to attempt to license rights to it from the prevailing party. Its business could be harmed if the
prevailing party does not offer SciSparc a license on commercially reasonable terms. Its defense of litigation or interference proceedings
may fail and, even if successful, may result in substantial costs and distract its management and other employees. In addition, the uncertainties
associated with litigation could have a material adverse effect on its ability to raise the funds necessary to continue its clinical
trials, continue its research programs, license necessary technology from third parties, or enter into development partnerships that
would help SciSparc bring its new product candidates to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of its confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements
of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of its ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
subject to claims challenging the inventorship of its intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
may be subject to claims that former employees, collaborators or other third parties have an interest in, or right to compensation, with
respect to its current patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For
example, SciSparc may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing
its product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the
right to compensation. If SciSparc fails in defending any such claims, in addition to paying monetary damages, SciSparc may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could
have a material adverse effect on its business. Even if SciSparc is successful in defending against such claims, litigation could result
in substantial costs and be a distraction to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may not
be able to protect its intellectual property rights throughout the world.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Filing,
prosecuting, and defending patents on product candidates, as well as monitoring their infringement in all countries throughout the world
would be prohibitively expensive, and its intellectual property rights in some countries can be less extensive than those in the United
States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and
state laws in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Competitors
may use its technologies in jurisdictions where SciSparc has not obtained patent protection to develop their own products and may also
export otherwise infringing products to territories where SciSparc has patent protection, but enforcement is not as strong as that in
the United States. These products may compete with its product candidates. Future patents or other intellectual property rights may not
be effective or sufficient to prevent them from competing.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, which could make it difficult for SciSparc to stop the marketing of competing products in
violation of its proprietary rights generally. Proceedings to enforce its patent rights in foreign jurisdictions, whether or not successful,
could result in substantial costs and divert its efforts and attention from other aspects of its business, could put its future patents
at risk of being invalidated or interpreted narrowly and its patent applications at risk of not issuing and could provoke third parties
to assert claims against SciSparc. SciSparc may not prevail in any lawsuits that SciSparc initiates, and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, SciSparc&#8217;s efforts to monitor and enforce its intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that SciSparc develops
or licenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc has received
a termination notice for a license agreement for certain intellectual property rights from an entity controlled by its former chairman
and chief executive officer, Dr. Ascher Shmulewitz.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
May 2015, SciSparc entered into a license agreement, which, following an amendment thereto in August 2015, became effective, with Dekel,
an Israeli private company controlled by Dr. Ascher Shmulewitz, SciSparc&#8217;s former chairman and chief executive officer, under which
SciSparc was granted an irrevocable, worldwide, exclusive, royalty-bearing license to certain of Dekel&#8217;s technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
does not have any agreement with Dr. Shmulewitz to notify SciSparc with business opportunities he may wish to pursue, subject only to
his duties under Israeli law, and SciSparc does not have proprietary rights to Dr. Shmulewitz&#8217; inventions that are not included
under the consulting and services agreement SciSparc previously had entered into with him (pertaining solely to the field of immunomodulators
including cannabinoids to treat chronic pain and inflammation).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 17, 2017, SciSparc entered into an amendment to the license agreement, which, if certain conditions precedent were met by June
30, 2018, would provide for an amendment to the compensation terms of such license agreement. SciSparc did not meet the conditions precedent
required under such amendment to the license agreement with Dekel by June 30, 2018, and as a result thereof, the amendment never went
into effect. On July 14, 2019, SciSparc entered into an amendment to the license agreement, which encompasses its and Dekel&#8217;s original
intention to exclude certain consumer packaged goods (including, inter alia, food, beverage, cosmetics, pet products and hemp based products,
which are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the
field of its activity, as described in the license agreement, which intention was not reflected in the license agreement, and therefore,
desired and agreed to amend the license agreement to reflect the foregoing clarification, as well as certain additional less material
matters as discussed in the amendment. The amendment also prescribes a specific development plan under the license agreement requiring
SciSparc to invest in the licensed technology (as defined under the license agreement) formulation development and maintain a total annual
investment cap of $350,000 and for a non-compete and non-solicitation obligation by Dekel and Dr. Shmulewitz, towards its field of activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2020, Dr. Shmulewitz was replaced by Mr. Amitay Weiss, who was later replaced by Mr. Oz Adler in January 2022, each of whom was
appointed as SciSparc&#8217;s Chief Executive Officer. In February 2021, SciSparc received a request from Dr. Shmulewitz to provide him
with information relating to its compliance with the Dekel license agreement. On February 5, 2024, SciSparc received a written notice
from Dekel for the termination of the license agreement, effective immediately, based on its allegation that SciSparc failed to provide
Dekel with certain reports regarding the licensed products under the license agreement. SciSparc rejects all of Dekel&#8217;s allegations
as set forth in the termination notice and intend to defend itself vigorously, should it be necessary. SciSparc is assessing the effects,
if any, on its business as a result of the termination notice received from Dekel. If SciSparc is no longer able to license certain of
Dekel&#8217;s technology under the Dekel license agreement or if any potential dispute results in a determination adverse to SciSparc,
its business may be impeded or materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Pharmaceutical Business Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>From
time to time, SciSparc may sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation
of definitive agreements. There can be no assurance that SciSparc will enter into any such definitive agreements. Similarly, SciSparc
may strategically invest in transactions from time to time, and there can be no assurance that the value of its investment will increase
or that it will not fluctuate.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">From
time to time, SciSparc may sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation
of definitive agreements. SciSparc may never enter into definitive agreements after signing a letter of intent and/or entering into a
term sheet or other similar arrangement for a multitude of reasons, including, but not limited to, regulatory, operational, financial
and other considerations. There may also be forces outside of SciSparc&#8217;s control that have an effect on its ability or decision
as to whether SciSparc enters into such definitive agreements. As a result, there can be no assurance that upon signing a letter of intent
and/or entering into a term sheet or similar arrangement, that SciSparc will enter into definitive documents. This could have a material
adverse effect on SciSparc&#8217;s reputation and could cause SciSparc to incur expenses if any legal claims arise as a result thereof.
For example, in November 2019, SciSparc entered into a memorandum of understanding with Heavenly Rx, Ltd., or Heavenly Rx, pursuant to
which SciSparc and Heavenly Rx agreed to pursue a business combination. In accordance with the memorandum of understanding between the
parties, any transaction between the parties remained subject to entry into definitive agreements, and to shareholder and regulatory
approvals. SciSparc never entered into definitive agreements and does not expect to do so.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Similarly,
SciSparc may strategically invest into various pharmaceutical companies. However, SciSparc can offer no assurance that the value of its
investment will increase or that it will not fluctuate because the value of its investments may be adversely affected by a number of
factors, such as negative changes in a company&#8217;s results of operations, cash flows, financial position and accounting impairment.
For example, on March 31, 2022, SciSparc entered into an agreement with and invested in MitoCare X Bio Ltd., or MitoCareX, a company
focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. In addition, on November
17, 2022, SciSparc invested in Clearmind, a psychedelic pharmaceutical biotech company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and underserved health problems. The potential benefits of the agreement with MitoCareX,
the investment in Clearmind or other potential investments may not be realized to the full extent, in a timely fashion, or at all, which
may have a material adverse effect on SciSparc&#8217;s results of operations, cash flows and financial position. The potential benefits
of agreements with potential ventures may not materialize or may not be realized to the full extent, in a timely fashion, or at all,
which may have a material adverse effect on its results of operations, cash flows and financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc will
need to expand its organization and SciSparc may experience difficulties in recruiting needed additional employees and consultants, which
could disrupt its operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
its development and commercialization plans and strategies develop and because SciSparc is so leanly staffed, SciSparc will need additional
managerial, operational, sales, marketing, financial, legal and other resources. The competition for qualified personnel in the pharmaceutical
field is intense. Due to this intense competition, SciSparc may be unable to attract and retain qualified personnel necessary for the
development of its business or to recruit suitable replacement personnel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial
amount of time to managing these growth activities. SciSparc may not be able to effectively manage the expansion of its operations, which
may result in weaknesses in its infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity
among remaining employees. SciSparc&#8217;s expected growth could require significant capital expenditures and may divert financial resources
from other projects, such as the development of additional pharmaceutical product candidates. If its management is unable to effectively
manage its growth, its expenses may increase more than expected, its ability to generate and/or grow revenue could be reduced and SciSparc
may not be able to implement its business strategy. Its future financial performance and its ability to commercialize pharmaceutical
product candidates and compete effectively will depend, in part, on its ability to effectively manage any future growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>SciSparc may not be successful in its efforts to identify, license
or discover additional pharmaceutical product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
a substantial amount of its effort will focus on the continued clinical testing, potential approval and commercialization of its existing
pharmaceutical product candidates, the success of its business also depends in part upon its ability to identify, license or discover
additional pharmaceutical product candidates. Its research programs or licensing efforts may fail to yield additional pharmaceutical
product candidates for clinical development for a number of reasons, including but not limited to the following:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s research or business development methodology or search
    criteria and process may be unsuccessful in identifying potential pharmaceutical product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc may not be able or willing to assemble sufficient resources
    to acquire or discover additional pharmaceutical product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s pharmaceutical product candidates may not succeed
    in preclinical or clinical testing;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s potential pharmaceutical product candidates may be
    shown to have harmful side effects or may have other characteristics that may make the pharmaceutical products unmarketable or unlikely
    to receive marketing approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competitors may develop alternatives that render SciSparc&#8217;s pharmaceutical
    product candidates obsolete or less attractive;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pharmaceutical product candidates SciSparc develops may be covered
    by third parties&#8217; patents or other exclusive rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the market for a pharmaceutical product candidate may change during
    its program so that such a pharmaceutical product may become unreasonable to continue to develop;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a pharmaceutical product candidate may not be capable of being produced
    in commercial quantities at an acceptable cost, or at all; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a pharmaceutical product candidate may not be accepted as safe and
    effective by patients, the medical community or third-party payors.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
any of these events occur, SciSparc may be forced to abandon its development efforts for a program or programs, or SciSparc may not be
able to identify, license or discover additional pharmaceutical product candidates, which would have a material adverse effect on its
business and could potentially cause SciSparc to cease operations. Research programs to identify new pharmaceutical product candidates
require substantial technical, financial and human resources. SciSparc may focus its efforts and resources on potential programs or pharmaceutical
product candidates that ultimately prove to be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy
and security laws. If SciSparc is unable to comply, or has not fully complied, with such laws, SciSparc could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc obtains FDA approval for any of its pharmaceutical product candidates and begins commercializing those pharmaceutical products
in the United States, its operations may be directly or indirectly through its customers, subject to various federal and state fraud
and abuse laws, including, without limitation, the federal AKS, the federal False Claims Act and physician sunshine laws and regulations.
These laws may impact, among other things, its proposed sales, marketing and education programs. In addition, SciSparc may be subject
to patient privacy regulation by both the federal government and the states in which SciSparc conducts its business. The laws that may
affect its ability to operate include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal AKS, which prohibits, among other things, persons from
    knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for,
    the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid
    programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">federal civil and criminal false claims laws and civil monetary penalty
    laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for
    payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the Health Insurance Portability and Accountability Act of 1996, or
    HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and
    making false statements relating to healthcare matters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">HIPAA, as amended by the Health Information Technology and Clinical
    Health Act, or HITECH and its implementing regulations, which imposes certain requirements relating to the privacy, security and
    transmission of individually identifiable health information;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal physician sunshine requirements under the ACA requires
    manufacturers of drugs, devices and medical supplies to report annually to the U.S. DHHS information related to payments and other
    transfers of value to physicians, other healthcare providers and teaching hospitals and ownership and investment interests held by
    physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">state law equivalents of each of the above federal laws, such as anti-kickback
    and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state
    laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and
    the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare
    providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments
    and other transfers of value to physicians and other healthcare providers or marketing expenditures and state laws governing the
    privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and
    may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of SciSparc&#8217;s
business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation
has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal anti-kickback and
criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to
violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation
of the federal AKS constitutes a false or fraudulent claim for purposes of the False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc&#8217;s operations are found to be in violation of any of the laws described above or any other governmental regulations that
apply to it, SciSparc may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation
in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of its operations,
any of which could adversely affect its ability to operate its business and its results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Widespread public
health pandemics could have a material and adverse effect on its business, financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
public health pandemic or other disease outbreak in countries where SciSparc or its CROs operate could have a material and adverse effect
on its business, financial condition and results of operations. For example, SciSparc reduced its operating expenses at the onset of
the COVID-19 pandemic and its Chief Technologies Officer was on temporary unpaid leave between May 2020 and September 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
operating results and financial condition may also be materially adversely affected by laws, regulations, orders or other governmental
or regulatory actions addressing widespread public health concerns that place restrictions on, or require it to make changes to, its
operations. For example, a significant reduction in its workforce and its compliance with instructions imposed by relevant authorities
may harm its ability to continue operating its business and materially and adversely affect its operations and financial condition. In
addition, the impact of a widespread public health crisis may cause delays to SciSparc&#8217;s future research and development operations,
including but not limited to its pharmaceutical products development, manufacturing, pre-clinical and clinical trials, and may make it
difficult for SciSparc to recruit patients to all of its clinical trials, and keep all of its research and development projects on time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">With
respect to its suppliers, disruptions resulting from the COVID-19 pandemic resulted and in the event of a future widespread public health
crisis may result in cancellations or delays and increased transport times for delivery of materials to its facilities. If such difficulties
arise, SciSparc may need to seek alternate suppliers, which may be more expensive, may not be available or may result in delays in shipments
to SciSparc.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Disruptions
to its business as a result of a widespread public health crisis, as well as any global recession resulting from the impact of such a
crisis, could materially adversely affect its business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The use of any
of its pharmaceutical product candidates and marketed products could result in product liability or similar claims that could be expensive,
damage its reputation and harm its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
business exposes it to an inherent risk of potential pharmaceutical product liability or similar claims. The pharmaceutical and nutraceuticals
industries have historically been litigious, and SciSparc faces financial exposure to pharmaceutical product liability or similar claims
if the use of any of its pharmaceutical products were to cause or contribute to injury or death. There is also the possibility that defects
in the design or manufacture of any of its pharmaceutical products might necessitate a pharmaceutical product recall. Although SciSparc
plans to maintain pharmaceutical product liability insurance, the coverage limits of these policies may not be adequate to cover future
claims. In the future, SciSparc may be unable to maintain pharmaceutical product liability insurance on acceptable terms or at reasonable
costs and such insurance may not provide SciSparc with adequate coverage against potential liabilities. A pharmaceutical product liability
claim, regardless of merit or ultimate outcome, or any pharmaceutical product recall could result in substantial costs to it, damage
to its reputation, customer dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought
against SciSparc in excess of, or outside of, its insurance coverage could have a material adverse effect on its business, financial
condition and results of operations.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If SciSparc fails
to comply with environmental, health and safety laws and regulations, SciSparc could become subject to fines or penalties or incur costs
that could have a material adverse effect on the success of its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
research and development activities and its third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage,
use and disposal of hazardous materials, including the components of its pharmaceutical product candidates and other hazardous compounds.
SciSparc and its manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and
disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored
at SciSparc and its manufacturers&#8217; facilities pending their use and disposal. SciSparc cannot eliminate the risk of contamination,
which could cause an interruption of its commercialization efforts, research and development efforts, business operations and environmental
damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal
of these materials and specified waste pharmaceutical products. Although SciSparc believes that the safety procedures utilized by its
third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws
and regulations, SciSparc cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these
materials. In such an event, SciSparc may be held liable for any resulting damages and such liability could exceed its resources and
state or federal or other applicable authorities may curtail its use of certain materials and/or interrupt its business operations. Furthermore,
environmental laws and regulations are complex, change frequently and have tended to become more stringent. SciSparc cannot predict the
impact of such changes and cannot be certain of its future compliance. SciSparc does not currently carry biological or hazardous waste
insurance coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Intended Corporate Restructuring Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The intended Restructuring
Plan, which may involve transferring SciSparc&#8217;s pharmaceutical activities to a new wholly-owned subsidiary, may not be completed
in accordance with the expected plans or anticipated timeline, or at all, and may not achieve the expected results.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 25, 2023, SciSparc announced that its board of directors resolved to pursue a restructuring plan, or the Restructuring Plan,
which may involve transferring its pharmaceutical activities to a subsidiary, which may be listed on a stock exchange. As part of the
plan, SciSparc announced that it would examine a spin-off of certain of its assets, followed by a listing of the spun-off subsidiary,
or NewCo, on a leading stock exchange, while maintaining its controlling interest in NewCo such that SciSparc will continue to control
its current business activities. SciSparc also intends to explore other potential new opportunities, activities and investments in a
variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 22, 2023, SciSparc announced the signing of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated
terms as announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Restructuring Plan, on June 25, 2023, SciSparc entered into a securities purchase agreement with AutoMax, pursuant to which, at
the closing and upon the terms and conditions set forth in the securities purchase agreement with AutoMax, or the AutoMax SPA, SciSparc
invested NIS 2,500 thousand (approximately $691) in cash, in exchange for ordinary shares of AutoMax based on a price per share of NIS
0.5. Following the closing, SciSparc held approximately 5.6% of the issued and outstanding share capital of AutoMax.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
January 14, 2024, SciSparc entered, as a lender, into a bridge loan agreement with AutoMax, pursuant to which AutoMax received a bridge
loan in the amount of $1.4 million, or the Bridge Loan, further to the previously-announced non-binding letter of intent for SciSparc
to acquire AutoMax. On June 9, 2024, SciSparc entered, as lender, into an amendment to the Bridge Loan, or the Amended Bridge Loan, pursuant
to which AutoMax received an additional loan in the amount of $1.0 million, for an aggregate amount of $2.4 million. On September 5,
2024, SciSparc entered, into a second amendment to the Bridge Loan, or the Second Amendment, pursuant to which SciSparc extended an additional
loan in the amount of $1.85 million to AutoMax under terms similar to the Amended Bridge Loan, bringing the total Bridge Loan amount
to $4.25 million, or the Loan Amount. &#160;During the month of September 2024, SciSparc provided AutoMax with the loan amounts due under
the Second Amendment to the Bridge Loan, and offset any interest due until November 30, 2024 from the principal amount, such that on
the closing date of the Merger, SciSparc will be entitled to be paid the due interest at a rate of 7% per annum (or 9% per annum if the
Merger is not consummated), of the Loan Amount, accruing from the period beginning on December 1, 2024 and ending on the effective date
of the Merger. In consideration for the Loan Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s
shares of its wholly-owned subsidiary AutoMax Direct Import in favor of SciSparc.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc signed the Merger Agreement with AutoMax, as further described in this prospectus. On August 14, 2024, and on
November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement Addendum and the Merger Agreement Second Addendum, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On July 8, 2024, SciSparc
signed a non-binding letter of intent, or the Spin-off LOI, for the spin-off of its advanced clinical stage pharmaceutical portfolio
to a publicly traded company on the Toronto Stock Exchange Venture in Canada, or TSXV. Pursuant to the letter of intent, SciSparc will
sell, assign, convey and transfer to Miza III Ventures Inc., or Miza, certain assets for consideration of common shares and contingent
rights of Miza, based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold a controlling interest
in Miza, the exact percentage of which is contingent on agreeing on definitive terms between the parties. The resulting entity, in which
SciSparc will hold an equity stake, will be active in both the pharmaceutical and supplement sectors. On December 16, 2024, SciSparc
announced that it entered into an amendment to the Spin-off LOI, solely to extend the deadline to enter into definitive agreements by
no later than March 31, 2025, which was extended from July 31, 2024, provided that such date may be further extended by mutual written
agreement of the parties, and to close the proposed transaction by no later than April 30, 2025, which was extended from October 31,
2024.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Completion
of the transactions contemplated by the Merger Agreement, the Spin-off LOI or any other potential restructuring plans or transactions
in addition to the possible listing of NewCo on a stock exchange, may be subject to, among other things, market conditions, tax or other
business analyses, regulatory approvals, receipt of any necessary consents, final approvals from its board of directors and shareholders
and satisfaction of any closing conditions to effectuate such corporate restructuring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unanticipated
developments or changes, including but not limited to, changes in the general or financial market conditions, possible delays in obtaining
various regulatory and tax approvals, changes in the law, and challenges in executing the Acquisition or any other restructuring plan
could delay or prevent the completion of the Restructuring Plan and listing of NewCo, or cause the restructuring and listing of NewCo
to occur on terms or conditions that are different or less favorable than initially expected. These or other developments could cause
SciSparc not to realize some or all of the expected benefits of the Restructuring Plan and listing of NewCo or to realize them on a different
timeline than expected. If the Restructuring Plan and listing of NewCo do not occur, SciSparc could pursue other transactions involving
its pharmaceutical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The Restructuring
Plan and listing of NewCo may not achieve the anticipated benefits and may expose SciSparc to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc
may not realize the anticipated strategic, financial, operational or other benefits of the Restructuring Plan and listing of NewCo. SciSparc
cannot predict with certainty when the benefits expected from these transactions will occur or the extent to which they will be achieved.
There is no assurance that following the Restructuring Plan and listing of NewCo that each separate company will be successful. Whether
or not the Restructuring Plan and listing of NewCo is completed, SciSparc may face material challenges in connection with the intended
transactions, including but not limited to, the diversion of management time on matters relating to the Restructuring Plan and listing
of NewCo, the impact of having to operate under the terms of any transition service agreements, the impact on its ability to retain talent
and potential impacts on its relationships with customers, suppliers, employees and other counterparties. In addition, SciSparc will
incur one-time costs and ongoing costs in connection with, or as a result of, the Restructuring Plan and listing of NewCo, including
costs of operating as independent, publicly-traded companies that the separate businesses will no longer be able to share. Those costs
may exceed its estimates or could negate some of the benefits SciSparc expects to realize. Further, SciSparc has not yet analyzed whether
the Restructuring Plan and listing of NewCo will be tax-free to its shareholders for Israeli tax purposes and there is no assurance that
the Restructuring Plan and listing of NewCo will qualify for this treatment. If the Restructuring Plan and listing of NewCo is ultimately
determined to be taxable, any of NewCo, its shareholders or SciSparc could incur income tax liabilities that could be significant. If
SciSparc does not realize the anticipated benefits of the Restructuring Plan and listing of NewCo it could adversely affect its business,
results of operations, cash flows and financial condition.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Following any
Restructuring Plan and listing of NewCo, the trading price of SciSparc&#8217;s ordinary shares may fluctuate significantly.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
cannot predict whether the market value of its ordinary shares after any Restructuring Plan and listing of NewCo will be, in the aggregate,
less than, equal to or greater than the market value of its ordinary shares prior to such transactions. The trading price of its ordinary
shares may be more volatile around the time of the intended separation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to the
eCommerce&#160;Operations of SciSparc Nutraceuticals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
unable to successfully pursue, integrate, or execute upon the eCommerce operations business of SciSparc Nutraceuticals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2022, SciSparc purchased Wellution&#8482;, a business and brand which sells hemp-based products on the Amazon Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
management has limited prior experience in eCommerce business operations. There can be no assurance that SciSparc will be able to successfully
implement its new business ventures or successfully operate within this industry.&#160;The successful integration of a new business also
depends on SciSparc&#8217;s ability to manage the new business, realize forecasted synergies and full value from the combined business.
Its business, results of operations, financial condition and cash flows could be materially adversely affected if SciSparc is unable
to successfully integrate&#160;Wellution into its existing operations and any inability to do so may also hinder its ability to grow,
divert the attention of management and its key personnel, disrupt its business and impair its financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals rely on Amazon Marketplace and fulfillment by Amazon Marketplace and changes to the Amazon Marketplace,
Amazon Marketplace&#8217;s services and their terms of use may harm its business.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Wellution&#8217;s
products are sold predominantly on Amazon Marketplace and orders are fulfilled entirely by Amazon Marketplace utilizing the fulfilled
by Amazon, or FBA, model. In order to continue to utilize the Amazon Marketplace and FBA, SciSparc must comply with the applicable policies
and terms of use relating to these services. Such policies and terms of use may be altered or amended at Amazon Marketplace&#8217;s sole
discretion, including changes regarding the cost of securing these services, and changes that increase the burden of compliance with
its requirements, may cause SciSparc to significantly alter its business model or incur additional costs in order to comply, which could
negatively impact its results of operations. Non-compliance with applicable terms of use and policies can result in the removal of one
or more products from the marketplace and suspension of fulfillment services either of which could have a material adverse effect on
its business and results of its operations. While SciSparc has experienced a past instance of non-compliance that was resolved, it remains
committed to maintaining compliance. However, there is no guarantee that similar issues will not arise in the future, which could lead
to product removal from the marketplace or suspension of fulfillment services, adversely impacting its business and operational outcomes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals rely on other information technologies and systems to operate its business and to maintain its
competitiveness, and any failure to invest in and adapt to technological developments and industry trends could harm its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
depends on sophisticated information technologies and systems, technology and systems used for Wellution&#8217;s websites and apps, customer
service, logistics and fulfillment, supplier connectivity, communications and administration. As its operations grow in size, scope and
complexity, SciSparc will need to continuously improve and upgrade its systems and infrastructure to offer an increasing number of consumer-enhanced
services, features and functionalities, while maintaining and improving the reliability and integrity of its systems and infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
future success also depends on its ability to use A.I. tools and infrastructure, including logistics and fulfillment platform which leverages,
to meet rapidly evolving eCommerce trends and demands. The emergence of alternative platforms may require SciSparc to continue to invest
in new and costly technology. SciSparc may not be successful, or it may be less successful than its competitors, in adopting technologies
that operate effectively across multiple eCommerce platforms, which would negatively impact its business and financial performance. New
developments in other areas, such as cloud computing providers, could also make it easier for competitors to enter its markets due to
lower up-front technology costs. In addition, SciSparc may not be able to maintain its existing systems or replace its current systems
or introduce new technologies and systems as quickly or cost effectively as SciSparc would like. Failure to invest in and adapt to technological
developments and industry trends may have a material adverse effect on its business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals rely on data provided by third parties, the loss of which could limit the functionality of its
platforms, cause SciSparc to invest in the wrong product or disrupt its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
uses third party software to determine market trends and what markets to enter into. Its ability to successfully use this software depends
on its ability to analyze and utilize data, including search engine results, provided by unaffiliated third parties, primarily, Google
and Amazon. Some of this data is provided to SciSparc pursuant to third-party data sharing policies and terms of use, under data sharing
agreements by third-party providers or by customer consent. The majority of this data is sourced for free or for de minimis amounts.
These sources of data allow SciSparc, along with A.I. tools, to determine trends, performance and consumer sentiment on products and
searches within eCommerce platforms. This functionality allows SciSparc to help determine which products to market, in some cases manufacture
through contract manufacturers, import and sell on eCommerce marketplaces. The connection to multiple eCommerce platforms through application
programming interfaces allow SciSparc to develop the automation of the purchase of marketing and automate the change of pricing of product
listings on those eCommerce platforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the future, any of these third parties could change its data sharing policies, including making them more restrictive, charging fees
or altering its algorithms that determine the placement, display and accessibility of search results and social media updates, any of
which could result in the loss of, or significant impairment to, its ability to collect useful data. These third parties could also interpret
SciSparc, or its service providers&#8217;, data collection policies or practices as being inconsistent with their policies, which could
result in the loss of its ability to collect this data. Privacy concerns may cause end users to resist providing the personal data necessary
to allow SciSparc to determine market trends as well as its ability to effectively retain existing customers. Privacy advocacy groups
and the technology and other industries are considering various new, additional or different self-regulatory standards that may place
additional burdens on SciSparc. Any such changes could impair its ability to use data and could adversely impact select functionality
of its proprietary software, impairing its ability to use this data to anticipate customer demand and market trends, as well as adversely
affecting its business and its ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals depend on its ability to build and maintain strong product listings on eCommerce platforms. SciSparc
may not be able to maintain and enhance its product listings if SciSparc receives a substantial number of customer complaints, negative
publicity or otherwise fail to live up to customers&#8217; expectations, any of which could materially adversely affect its business,
results of operations and growth prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Maintaining
and enhancing its product listings is critical in expanding and growing its business. However, a significant portion of its perceived
performance to the customer depends on third parties outside of its control, including suppliers and logistics providers such as FedEx,
UPS, postal services and other third-party delivery agents and online retailers, mainly Amazon. Because SciSparc&#8217;s agreements with
its online retail partners are generally terminable at will, SciSparc may be unable to maintain these relationships, and its results
of operations could fluctuate significantly from period to period. Because SciSparc relies on third party logistics companies to deliver
its products, SciSparc is subject to shipping delays or disruptions caused by inclement weather, natural disasters, labor activism, health
epidemics or bioterrorism. In addition, because SciSparc relies on national, regional and local transportation companies for the delivery
of some of its other products, SciSparc is also subject to risks of breakage or other damage during delivery by any of these third parties.
If these third parties do not meet its or its customers&#8217; expectations, its brands may suffer irreparable damage. In addition, maintaining
and enhancing its current and future brands may require SciSparc to make substantial investments, and these investments may not yield
sufficient returns. If SciSparc fails to promote and maintain its brands, or if SciSparc incurs excessive expenses in this effort, its
business, operating results and financial condition may be materially adversely affected. SciSparc anticipates that, as its market becomes
increasingly competitive, maintaining and enhancing its brands may become increasingly difficult and expensive. Maintaining and enhancing
its brands will depend largely on its ability to anticipate market trends and customer demand and to provide high quality products to
its customers and a reliable, trustworthy and profitable sales channel to its suppliers, which SciSparc may not be able to do successfully.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
substantial number of customer complaints or negative publicity about its sites, products, delivery times, customer data handling and
security practices or customer support, especially on blogs, social media websites or its sites, could rapidly and severely diminish
consumer views of its products and result in harm to its brands. Customers may also make safety-related claims regarding products sold
through its online retail partners, such as Amazon, which may result in an online retail partner removing the product from its marketplace.
Such removal may materially impact its financial results depending on the product that is removed and length of time that it is removed.
SciSparc also uses and relies on other services from third parties, such as its telecommunications services, and those services may be
subject to outages and interruptions that are not within its control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations&#8217; efforts of SciSparc Nutraceuticals to acquire or retain customers, and its efforts to sell new products or increase
sales of its existing products, may not be successful, which could prevent SciSparc from maintaining or increasing its sales and achieving
profitability.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc does not successfully promote and sustain its new and/or existing product listings and brands through marketing and other tools,
SciSparc may fail to maintain or increase its sales and achieve profitability. Promoting and positioning its brands and product listings
will depend largely on the success of SciSparc&#8217;s marketing efforts, its ability to attract customers cost effectively and its ability
to consistently provide a high-quality product and maintain consumer satisfaction. SciSparc also uses promotions to drive sales, which
may not be effective and may adversely affect its gross margins. SciSparc&#8217;s investments in marketing may not effectively reach
potential customers, potential customers may decide not to buy its products or the spending of customers that purchase from SciSparc
may not yield the intended return on investment, any of which could negatively affect its financial results. The failure of its marketing
activities could also adversely affect its ability to promote its product listings and sell its products, and to develop and maintain
relationships with its customers, retailers and brands, which may have a material adverse effect on SciSparc&#8217;s business, results
of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If the eCommerce
operations of SciSparc Nutraceuticals fail to offer high-quality customer support, SciSparc&#8217;s business and reputation may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">High-quality
education and training of customer support personnel to deliver high-quality customer support are important for the successful retention
of existing customers. Providing this education, training and support requires that its support personnel has specific knowledge and
expertise of SciSparc&#8217;s products and markets, making it more difficult for SciSparc to hire experienced personnel and to scale
up its support operations. The importance of high-quality customer support will increase as SciSparc expands its business and pursue
new customers. If SciSparc does not provide effective and timely ongoing support, its ability to retain existing customers may suffer,
and its reputation with existing or potential customers may be harmed, which would have a material adverse effect on its business, results
of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations&#8217; efforts of SciSparc Nutraceuticals to expand SciSparc&#8217;s business into new brands, products, services, technologies
and geographic regions will subject SciSparc to additional business, legal, financial and competitive risks and may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Wellution&#8217;s
business success depends to some extent on SciSparc&#8217;s ability to expand its consumer offerings by launching new brands, products
and services and by expanding its existing offerings into new geographic regions. SciSparc&#8217;s strategy is to use its skills to determine
which markets to enter and optimize the mix of products and services that SciSparc offers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Launching
new brands, products and services requires significant upfront investments, including investments in marketing, namely digital marketing
and Pay Per Click (PPC), information technology and additional personnel. SciSparc operates in highly competitive industries with relatively
low barriers to entry and must compete successfully in order to grow its business. SciSparc may not be able to generate satisfactory
revenue from these efforts to offset these costs. Any lack of market acceptance of its efforts to launch new brands, products or services
or to expand its existing offerings could have a material adverse effect on its business, prospects, financial condition and results
of operations. Further, as SciSparc continues to expand its fulfillment capability or add new businesses with different requirements,
its logistics networks will become increasingly complex and operating them will become more challenging. There can be no assurance that
SciSparc will be able to operate its networks effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has also entered and may continue to enter new markets and provide product offerings in which SciSparc has limited or no experience,
which may not be successful or appealing to its customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
eCommerce consumer products goods industry is subject to evolving standards and practices, as well as changing consumer needs, requirements
and preferences. SciSparc&#8217;s ability to attract new customers and increase revenue from existing customers depends, in part, on
its ability to enhance and improve its existing tools that enable SciSparc to pinpoint new markets and introduce new products. The success
of any enhancements or new instruments depends on, in part, market-accepted pricing levels and overall market acceptance. SciSparc may
not be successful in these efforts, which could result in significant expenditures that could impact its revenue or distract management&#8217;s
attention from current offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Increased
emphasis on the sale of new products could distract SciSparc from sales of its existing products in existing markets, negatively affecting
its overall sales. SciSparc has invested and expect to continue to invest in new businesses, products, features, services and technologies.
Such endeavors may involve significant risks and uncertainties, including insufficient revenue from such investments to offset any new
liabilities assumed and expenses associated with these new investments, inadequate return of capital on its investments, distraction
of management from current operations and unidentified issues not discovered in its due diligence of such investments that could cause
SciSparc to fail to realize the anticipated benefits of such investments and incur unanticipated liabilities. Because these new strategies
and offerings are inherently risky, no assurance can be given that they will be successful. SciSparc&#8217;s new features or enhancements
could fail to attain sufficient market acceptance for many reasons, including:</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in introducing products in new markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to accurately predict market demand or end consumer preferences;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">introduction of competing products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">poor financial conditions for SciSparc&#8217;s customers or poor general
    macroeconomic conditions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in legal or regulatory requirements, or increased legal or
    regulatory scrutiny, adversely affecting SciSparc&#8217;s products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure of SciSparc&#8217;s brands, and products, digital promotion
    activities or negative publicity about the performance or effectiveness of its existing brands and products; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disruptions or delays in the online retailers and, or in addition to,
    logistics providers distributing its products.</span></td></tr>
  </table><div>


</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
is no assurance that SciSparc will successfully identify new opportunities or develop and bring new products to market on a timely basis,
which could materially and adversely affect its business and operating results and compromise its ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations&#8217; use of social media and email by SciSparc Nutraceuticals may adversely impact SciSparc&#8217;s reputation or subject
us to fines or other penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">SciSparc
uses social media and email as part of its digital marketing efforts. As laws and regulations rapidly evolve to govern the use of these
channels, the failure by SciSparc, its employees or third parties acting at on its behalf to abide by applicable laws and regulations
in the use of these channels could adversely affect its reputation or subject SciSparc to fines or other penalties. In addition, SciSparc&#8217;s
employees or third parties acting on its behalf may knowingly or inadvertently make use of social media in ways that could lead to the
loss or infringement of intellectual property, as well as the public disclosure of proprietary, confidential or sensitive personal information
of its business, employees, customers or others. Any such inappropriate use of social media or email could also cause reputational damage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Customers
value readily available information concerning retailers and their goods and services and often act on such information without further
investigation and with no regard to its accuracy. Its customers may engage with SciSparc online through its social media platforms, including
Facebook and Instagram, by providing feedback and public commentary about all aspects of its business. Information concerning SciSparc
or its retailers and brands, whether accurate or not, may be posted on social media platforms at any time and may have a disproportionately
adverse impact on its brand, reputation or business. The harm may be immediate without affording SciSparc an opportunity for redress
or correction and could have a material adverse effect on its business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>With respect to
the eCommerce operations of SciSparc Nutraceuticals, if SciSparc&#8217;s emails are not delivered and accepted or are routed by email
providers less favorably than other emails, or its sites or mobile applications are not accessible or are treated disadvantageously by
Internet service providers, its business may be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
email providers or Internet service providers, or ISPs, implement new restrictive email or content delivery or accessibility policies,
including with respect to net neutrality, or begin enforcement of existing policies, it may become more difficult to deliver emails to
SciSparc&#8217;s customers or for customers to access its sites, products and services. For example, certain email providers, including
Google, categorize SciSparc&#8217;s emails as &#8220;promotional&#8221;, and these emails are directed to an alternate, and less readily
accessible, section of a customer&#8217;s inbox. If email providers materially limit or halt the delivery of SciSparc&#8217;s emails,
or if SciSparc fails to deliver emails to customers in a manner compatible with email providers&#8217; email handling or authentication
technologies, its ability to contact customers through email could be significantly restricted. In addition, if SciSparc is placed on
&#8220;spam&#8221; lists or lists of entities that have been involved in sending unwanted, unsolicited emails, its operating results
and financial condition could be substantially harmed. Further, if ISPs prioritize or provide superior access to its competitors&#8217;
content, its business and results of operations may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals are subject to risks related to online payment methods.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals accepts payments using a variety of methods, including credit card, debit card, PayPal, Payoneer, credit accounts (including
promotional financing) and gift cards. For certain payment methods, including credit and debit cards, SciSparc Nutraceuticals pays interchange
and other fees, which may increase over time and raise its operating costs and lower profitability. In addition, its credit card and
other payment processors could impose receivable holdback or reserve requirements in the future. SciSparc Nutraceuticals relies on third
parties to provide payment processing services, including the processing of credit cards and debit cards, and it could disrupt its business
if these companies become unwilling or unable to provide these services to SciSparc Nutraceuticals. SciSparc Nutraceuticals are also
subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers, which
could change or be reinterpreted to make it difficult or impossible for SciSparc Nutraceuticals to comply. If SciSparc Nutraceuticals
fails to comply with the rules or requirements of any provider of a payment method SciSparc Nutraceuticals accepts, if the volume of
fraud in its transactions limits or terminates its rights to use payment methods SciSparc Nutraceuticals currently accept, or if a data
breach occurs relating to its payment systems, SciSparc Nutraceuticals may, among other things, be subject to fines or higher transaction
fees and may lose, or face restrictions placed upon, its ability to accept credit card or debit card payments from customers or to facilitate
other types of online payments. If any of these events were to occur, its business, financial condition and operating results could be
materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>With respect to
the eCommerce operations of SciSparc Nutraceuticals, if SciSparc Nutraceuticals is unable to manage its inventory effectively, its operating
results could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
ensure timely delivery of products, SciSparc Nutraceuticals generally enters into purchase orders in advance with manufacturers. As a
result, SciSparc Nutraceuticals is vulnerable to demand and pricing shifts and to suboptimal selection and timing of product purchases.
SciSparc Nutraceuticals relies on its procurement team to order products and SciSparc Nutraceuticals relies on its data analytics to
inform the levels of inventory SciSparc Nutraceuticals purchases, including when to reorder items that are selling well and when to write
off items that are not selling well. In these instances, SciSparc Nutraceuticals may be unable to always predict the appropriate demand
for its products by customers with accuracy, which may result in inventory shortages, inventory write offs and lower gross margins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
its sales and procurement teams do not predict demand well or if its algorithms do not help SciSparc Nutraceuticals reorder the right
products or write off the right products timely, SciSparc Nutraceuticals may not effectively manage its inventory, which could result
in inventory excess or shortages, and its operating results and financial condition could be adversely affected.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals, including the costs and supply chain, are subject to risks associated with sourcing, importing
and warehousing.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals sources the products it offers from third-party vendors and, as a result, SciSparc Nutraceuticals may be subject to price
fluctuations or demand disruptions. Its operating results could be negatively impacted by increases in the prices of its products, and
SciSparc Nutraceuticals has no guarantees that prices will not rise. In addition, as SciSparc Nutraceuticals expands into new categories
and types of products, SciSparc Nutraceuticals expects that it may not have strong purchasing power in these new areas, which could lead
to higher costs than SciSparc Nutraceuticals has historically seen in its current product categories and types. SciSparc Nutraceuticals
may not be able to pass increased costs on to customers, which could adversely affect its operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, SciSparc Nutraceuticals cannot guarantee that products SciSparc Nutraceuticals receives from vendors will be of sufficient
quality or free from damage or defects, or that such merchandise will not be damaged during shipping or storage. While SciSparc Nutraceuticals
takes measures to ensure product quality and avoid damage, including evaluating vendor facilities, operations and product samples, conducting
inventory inspections and inspecting returned products, SciSparc Nutraceuticals cannot control merchandise while it is out of its possession
or prevent all damage while in its distribution centers. SciSparc Nutraceuticals may incur additional expenses and its reputation could
be harmed if or current or potential customers believe that its merchandise is not of high quality or may be damaged.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Risks associated
with the suppliers from whom SciSparc Nutraceuticals products are sourced could materially adversely affect its financial performance,
as well as its reputation and brand.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals depends on its ability to provide its customers with a wide range of products from high quality suppliers in a timely
and efficient manner. Its agreements with most of its suppliers do not provide for the long-term availability of merchandise or the continuation
of particular pricing practices, nor do they usually restrict such suppliers from selling products to other buyers or directly themselves.
There can be no assurance that its current suppliers will continue to seek to sell SciSparc Nutraceuticals products on current terms
or that it will be able to establish new or otherwise extend current supply relationships to ensure product acquisitions in a timely
and efficient manner and on acceptable commercial terms. Its ability to develop and maintain relationships with reputable suppliers and
offer high quality products to its customers is critical to its success. If SciSparc Nutraceuticals is unable to develop and maintain
relationships with suppliers that would allow it to offer a sufficient amount and variety of quality products on acceptable commercial
terms, its ability to satisfy its customers&#8217; needs, and therefore its long-term growth prospects, would be materially adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals is also unable to predict whether any of the countries in which its suppliers&#8217; products are currently manufactured
or may be manufactured in the future will be subject to trade restrictions imposed by the U.S. or foreign governments or the likelihood,
type or effect of any such restrictions. Any event causing a disruption or delay of imports from suppliers with international manufacturing
operations, including the imposition of additional import restrictions, restrictions on the transfer of funds or increased tariffs or
quotas, could increase the cost or reduce the supply of merchandise available to its customers and materially adversely affect its financial
performance as well as its reputation and brand. Its competitors may have greater existing inventory positions and other advantages that
may allow them to price more competitively relative to its products. Furthermore, some or all of its suppliers&#8217; foreign operations
may be adversely affected by political and financial instability, resulting in the disruption of trade from exporting countries, restrictions
on the transfer of funds or other trade disruptions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may not
accurately forecast revenues, profitability and appropriately plan its expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
bases its current and future expense levels on its operating forecasts and estimates of future income and operating results. Income and
operating results are difficult to forecast because they generally depend on the volume and timing of the orders SciSparc receives, which
are uncertain. Additionally, its business is affected by general economic and business conditions around the world. A softening in income,
whether caused by changes in consumer preferences, a weakening in global economies or inflation, may result in decreased net revenue
levels, and SciSparc may be unable to adjust its spending in a timely manner to compensate for any unexpected shortfall in income. This
inability could cause its income (loss) from operations after tax in a given quarter to be lower or higher than expected. SciSparc also
makes certain assumptions when forecasting the amount of expenses it expects related to its share-based payments, which includes the
expected volatility of its share price, and the expected life of equity awards granted. These assumptions are partly based on historical
results. If actual results differ from its estimates, its operating results in a given quarter may be lower than expected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operation&#8217;s operating results of SciSparc Nutraceuticals are subject to seasonal fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
eCommerce business is seasonal in nature and the fourth quarter is a significant period for SciSparc&#8217;s operating results due to
the holiday season. As a result, revenue generally declines and loss from operations generally increases in the first quarter sequentially
from the fourth quarter of the previous year. Any disruption in its ability to process and fulfill customer orders during the fourth
quarter could have a negative effect on its quarterly and annual operating results. For example, if a large number of customers purchase
SciSparc Nutraceuticals&#8217; products in a short period of time due to increased holiday demand, inefficient management of its inventory
may prevent it from efficiently fulfilling orders, which may reduce sales and harm its brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The inability
to acquire, use or maintain SciSparc&#8217;s marks and domain names for its sites could substantially harm its business and operating
results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
currently has registered trademarks for its brands in numerous jurisdictions and have registered the Internet domain names for its websites,
as well as various related domain names. However, SciSparc has not registered its trademarks or domain names in all major international
jurisdictions. Domain names generally are regulated by Internet regulatory bodies. If SciSparc does not have, or cannot obtain on reasonable
terms, the ability to use its marks in a particular country or to use or register any of its domain names, SciSparc could be forced either
to incur significant additional expenses to market its products within that country, including the development of a new brand and the
creation of new promotional materials and packaging, or to elect not to sell products in that country. Either result could materially
adversely affect its business, financial condition and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Furthermore,
the regulations governing domain names and laws protecting marks and similar proprietary rights could change in ways that block or interfere
with its ability to use relevant domains or its current brand names. Furthermore, SciSparc might not be able to prevent third parties
from registering, using or retaining domain names that interfere with its consumer communications or infringe or otherwise decrease the
value of its marks, domain names and other proprietary rights. Regulatory bodies also may establish additional generic or country-code
top-level domains or may allow modifications of the requirements for registering, holding or using domain names. As a result, SciSparc
may not be able to register, use or maintain the domain names that utilize the Wellution name in all of the countries in which SciSparc
currently or intends to conduct business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Any significant
disruption in service on SciSparc&#8217;s websites or apps or in its computer systems, a number of which are currently hosted or provided
by third-party providers, could materially affect its ability to operate, damage its reputation and result in a loss of customers, which
would harm its business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
ability to sell and market its products relies on FBA platform whose functionality relies upon a number of third-party related services,
including those relating to cloud infrastructure, technology services, servers, open-source libraries and vendor application programming
interfaces. Any disruption or loss of any of these third-party services could have a negative effect on its business, results of operations,
financial condition and prospects. SciSparc may experience interruptions in its systems, including server failures that temporarily slow
down or interfere with the performance of its platforms and the ability to sell on eCommerce marketplaces.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Interruptions
in these systems, whether due to system failures, human input errors, computer viruses or physical or electronic break-ins, and denial-of-service
attacks on SciSparc, third-party vendors or communications infrastructure, could affect the availability of its services on its platform
and prevent or inhibit the ability of selling its products. Volume of traffic and activity on eCommerce marketplaces spikes on certain
days, such as during a Black Friday promotion, and any such interruption would be particularly problematic if it were to occur at such
a high-volume time. Problems with the reliability of its systems or third-party marketplaces could prevent SciSparc from earning revenue
and could harm its reputation. Damage to its reputation, any resulting loss of customers, eCommerce confidence and the cost of remedying
these problems could negatively affect its business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
ability to maintain communications, network and computer hardware in the countries in which they are used may in the future be subject
to regulatory review and licensing, and the failure to obtain any required licenses could negatively affect its business. Its systems
and infrastructure are predominately reliant on third parties. Problems faced by its third-party service providers with the telecommunications
network providers with whom they contract or with the systems by which they allocate capacity among their users, including SciSparc,
could adversely affect the experience of its customers. Its third-party service providers could decide to close their facilities without
adequate notice. Any financial difficulties, such as bankruptcy or reorganization, faced by its third-party service providers or any
of the service providers with whom they contract may have negative effects on its business, the nature and extent of which are difficult
to predict. If its third-party service providers are unable to keep up with its needs for capacity, this could have an adverse effect
on its business. Any errors, defects, disruptions or other performance problems with SciSparc&#8217;s services could harm its reputation
and may have a material adverse effect on its business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>Risks
Related to the Ownership of SciSparc&#8217;s Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc will
need additional capital in the future. Raising additional capital by issuing securities may cause dilution to existing shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has incurred losses every year since its inception. If SciSparc continues to use cash at its historical rates of use it will need significant
additional financing, which SciSparc may seek through a combination of private and public equity offerings, debt financings and collaborations
and strategic and licensing arrangements. To the extent that SciSparc raises additional capital through the sale of equity or convertible
debt securities, an existing shareholder&#8217;s ownership interest will be diluted, and the terms of any such offerings may include
liquidation or other preferences that may adversely affect the then existing shareholders rights. Debt financing, if available, would
result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting its ability to
take specific actions such as incurring debt or making capital expenditures. If SciSparc raises additional funds through collaboration,
strategic alliance or licensing arrangements with third parties, SciSparc may have to relinquish valuable rights to its technologies,
future revenue streams or product candidates, or grant licenses on terms that are not favorable to SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc does
not know whether a market for the ordinary shares will be sustained or what the trading price of the ordinary shares will be and as a
result it may be difficult for you to sell your ordinary shares</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
SciSparc&#8217;s ordinary shares are listed on Nasdaq, an active trading market for the ordinary shares may not be sustained. It may
be difficult for you to sell your ordinary shares without depressing the market price for the ordinary shares or at all. Further, an
inactive market may also impair SciSparc&#8217;s ability to raise capital by selling ordinary shares and may impair its ability to enter
into strategic partnerships or acquire companies, products, or services by using its equity securities as consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Sales of a substantial
number of SciSparc&#8217;s ordinary shares in the public market by its existing shareholders could cause its share price to fall.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Sales
of a substantial number of SciSparc&#8217;s ordinary shares in the public market, or the perception that these sales might occur, could
depress the market price of its ordinary shares and could impair its ability to raise capital through the sale of additional equity securities.
SciSparc is unable to predict the effect that sales may have on the prevailing market price of its ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The exercise of
outstanding warrants will cause significant dilution to holders of SciSparc&#8217;s equity securities and could adversely affect the
price of its ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">As
of February 7, 2025, holders of warrants (including pre-funded warrants) may exercise their warrants into up to 377,892 ordinary shares.
In the event that such warrants are exercised in full, the ownership interest of existing holders of SciSparc&#8217;s equity securities
will be diluted and may have a negative effect on the trading price of its ordinary shares.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The market price
of SciSparc&#8217;s securities may be highly volatile, and you may not be able to resell your ordinary shares at or above the price you
paid.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
market price of SciSparc&#8217;s ordinary shares is volatile. The SciSparc ordinary share price is and will continue to be subject to
wide fluctuations in response to a variety of factors, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">adverse results or delays in preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reports of adverse events in its product candidates or clinical trial
    failures of its product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability to obtain additional funding;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any delay in filing a regulatory submission for any of its product
    or product candidates and any adverse development or perceived adverse development with respect to the review of that regulatory
    submission by the FDA or European or Asian authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to successfully develop and commercialize its products or product
    candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to enter into strategic collaborations or failure to successfully
    integrate acquisitions SciSparc has made;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure by SciSparc or strategic collaboration partners to prosecute,
    maintain or enforce its intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in laws or regulations applicable to future products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability to scale up its manufacturing capabilities through third-party
    manufacturers, inability to obtain adequate product supply for its products or the inability to do so at acceptable prices;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">introduction of new products or technologies by its competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to meet or exceed financial projections SciSparc may provide
    to the public;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failures or delays in SciSparc&#8217;s intended Restructuring Plan;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to meet or exceed the financial expectations of the investment
    community;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">announcements of significant acquisitions, strategic partnerships,
    joint ventures or capital commitments by its competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disputes or other developments relating to proprietary rights, including
    patents, litigation matters and its ability to obtain patent protection for its platform technologies, technologies, products or
    product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">additions or departures of key scientific or management personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">significant lawsuits, including patent or shareholder litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in the market valuations of similar companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in general conditions in the economy and the financial markets
    in the countries in which SciSparc operates including those related to recent unrest and actual or potential armed conflict in Israel
    and other parts of the Middle East;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">sales of SciSparc&#8217;s securities by SciSparc or its shareholders
    in the future; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">trading volumes of its securities.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, companies trading in the stock market have experienced extreme price and volume fluctuations that have often been unrelated
or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market
price of SciSparc&#8217;s ordinary shares, regardless of its actual operating performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Outstanding warrants
and pre-funded warrants to acquire SciSparc ordinary shares are speculative in nature. Furthermore, holders of its warrants and pre-funded
warrants will have no rights as shareholders until such holders exercise their warrants and acquire SciSparc ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Until
holders of the warrants and pre-funded warrants acquire SciSparc ordinary shares upon exercise of the warrants and pre-funded warrants,
holders of the warrants and pre-funded warrants will have no rights with respect to its ordinary shares underlying such warrants and
pre-funded warrants. Upon exercise of the warrants and pre-funded warrants, the holders thereof will be entitled to exercise the rights
of a holder of ordinary shares only as to matters for which the record date occurs after the exercise date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
warrants and pre-funded warrants only represent the right to acquire ordinary shares at a fixed price, and in the case of the warrants,
for a limited period of time. Specifically, holders of the warrants and pre-funded warrants that SciSparc issued in private placements
in March 2020, March 2021, June 2022 and October 2023 and in its November 2020 and August 2023 public offerings may exercise their right
to acquire ordinary shares and pay an exercise price per ordinary shares (in the case of the pre-funded warrants, $0.001 to $0.026 per
ordinary share and in the case of other warrants, ranging from $68.38 to $637.00 per ordinary share), subject to adjustment upon certain
events, within five years from their date of issuance, with the exception of the June 2022 warrants, which will expire seven years from
the date of issuance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc cannot
assure you that its ordinary shares will remain listed on Nasdaq or any other securities exchange.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
July 16, 2024, SciSparc received a Notice from Nasdaq indicating that SciSparc is not in compliance with the minimum bid price requirement
for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of
$1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), SciSparc was initially granted a period of 180 calendar days to regain compliance
with the minimum bid price requirement, or until January 12, 2025. On January 14, 2025, SciSparc received an additional written notice
from Nasdaq indicating that it had been granted, per its request, an additional 180-day compliance period, or until July 14, 2025, to
regain compliance with the minimum bid price requirement. The trading price of SciSparc&#8217;s ordinary shares on the Nasdaq Capital
Market as of the close of market on February 7, 2025, was $0.496.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
ADSs, which previously represented its ordinary shares, were listed on Nasdaq from March 2017 through July 2020. On September 21, 2020,
its ADSs were delisted from Nasdaq as a result of not meeting the shareholders equity requirements of Nasdaq. Between December 2020 and
August 2021, its ADSs were quoted on the OTCQB. In August 2021, its ADR program was terminated and its ADSs were converted to ordinary
shares on a one-for-one basis. In September 2021, its ordinary shares began to be quoted for trading on the OTCQB under the ticker &#8220;SPRCF&#8221;.
In December 2021, SciSparc&#8217;s ordinary shares were re-listed on Nasdaq and began trading under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
assurance can be given that SciSparc will remain eligible to be listed on Nasdaq. Further, because of the previous delisting of its ADSs
from Nasdaq, if SciSparc falls out of compliance with Nasdaq requirements in the future, SciSparc&#8217;s ordinary shares may be more
likely to be subject to Nasdaq&#8217;s delisting process and no assurance can be given that SciSparc will be able to regain compliance.
Any delisting could adversely affect its ability to obtain financing for the continuation of its operations and could result in the loss
of confidence by investors, customers and employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Failure to achieve
and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect
on SciSparc&#8217;s business, results of operation or financial condition. In addition, current and potential shareholders could lose
confidence in its financial reporting, which could have a material adverse effect on the price of SciSparc&#8217;s ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Effective
internal controls are necessary for SciSparc to provide reliable financial reports and effectively prevent fraud. SciSparc is required
to document and test its internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which
requires annual management assessments of the effectiveness of its internal control over financial reporting. In addition, if SciSparc
fails to maintain the adequacy of its internal control, as such standards are modified, supplemented or amended from time to time, SciSparc
may not be able to ensure that SciSparc can conclude on an ongoing basis that SciSparc has effective internal control over financial
reporting in accordance with Section 404. Disclosing deficiencies or weaknesses in its internal control, failing to remediate these deficiencies
or weaknesses in a timely fashion or failing to achieve and maintain an effective internal control environment may cause investors to
lose confidence in its reported financial information, which could have a material adverse effect on the price of SciSparc&#8217;s ordinary
shares. If SciSparc cannot provide reliable financial reports or prevent fraud, its operating results could be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;<b><i>SciSparc
has not paid, and does not intend to pay, dividends on its ordinary shares and, therefore, unless its traded securities appreciate in
value, its investors may not benefit from holding its securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has not paid any cash dividends on its ordinary shares since inception. SciSparc does not anticipate paying any cash dividends its ordinary
shares in the foreseeable future. Moreover, the Companies Law, imposes certain restrictions on its ability to declare and pay dividends.
As a result, investors in its ordinary shares will not be able to benefit from owning these securities unless their market price becomes
greater than the price paid by such investors and they are able to sell such securities. SciSparc cannot assure you that you will ever
be able to resell its securities at a price in excess of the price paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unfavorable outcomes in legal proceedings may harm its business
and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Regardless
of whether or not there is merit to the claims underlying any legal proceedings to which SciSparc is subject, and regardless of whether
or not SciSparc is found as a result of such proceedings to have violated any applicable laws, such proceedings can be expensive to defend
or respond to, and could result in substantial costs and diversion of management&#8217;s attention and resources, which could harm its
business, and potentially could cause substantial and irreparable harm to its public reputation. For example, on May 2, 2023, Capital
Point Ltd., or Capital Point, filed a lawsuit in the Tel Aviv-Jaffa District Court against SciSparc as the sole defendant in connection
with the warrant SciSparc issued to Capital Point pursuant to a joint venture transaction entered into on May 15, 2020 by and between
SciSparc, Capital Point and Evero Health Ltd. one of SciSparc&#8217;s subsidiaries. The lawsuit includes allegations of breaches of contract
under the Israeli Contracts Law (General Part), 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches under
the Israeli Torts Ordinance (New Version), 1968. The lawsuit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million),
which accounts for, as of the date of the filing of the lawsuit, liquidated damages according to the provisions set forth in the warrant,
and seeks as well for the court to order a mandatory injunction order for SciSparc to issue a warrant to Capital Point to purchase $340,000
of its ordinary shares, the return of any unlawful profits received by SciSparc and punitive damages. As of February 7, 2025, in connection
with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health
Ltd. As of the date of this prospectus, SciSparc cannot predict the likelihood of its success in the lawsuit. If SciSparc does not prevail
in such lawsuit, its results of operations and reputation could be adversely affected.<b><i>&#160;</i></b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
a &#8220;passive foreign investment company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may
become one in any subsequent taxable year. There generally would be negative tax consequences for U.S. taxpayers that are holders of
SciSparc ordinary shares if SciSparc is or were to become a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">In
general, SciSparc will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1) at least 75%
of its gross income is &#8220;passive income&#8221; or (2) on average at least 50% of its assets by value produce passive income or are
held for the production of passive income. Passive income for this purpose generally includes, among other things, certain dividends,
interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property that gives
rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds, including those
raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets
of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. If SciSparc is
a PFIC in any taxable year during which a U.S. taxpayer holds the ordinary shares, such U.S. taxpayer would be subject to certain adverse
U.S. federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified electing
fund,&#8221; or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer, and
any gain realized on the sale or other disposition of the ordinary shares by the U.S. taxpayer: (1) would be allocated ratably over the
U.S. taxpayer&#8217;s holding period for the ordinary shares; (2) the amount allocated to the current taxable year and any period prior
to the first day of the first taxable year in which SciSparc was a PFIC would be taxed as ordinary income; and (3) the amount allocated
to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer
for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable
to each such other taxable year. In addition, if the U.S. Internal Revenue Service, or the IRS, determines that SciSparc is a PFIC for
a year with respect to which SciSparc has determined that SciSparc is not a PFIC, it may be too late for a U.S. taxpayer to make a timely
QEF or mark-to-market election. U.S. taxpayers that have held the ordinary shares during a period when SciSparc was a PFIC will be subject
to the foregoing rules, even if SciSparc ceases to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a
timely QEF or mark-to-market election. A U.S. taxpayer can make a QEF election by completing the relevant portions of and filing IRS
Form 8621 in accordance with the instructions thereto. U.S. taxpayers that hold the ordinary shares are strongly urged to consult their
tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences to them of
making a QEF or mark-to-market election with respect to the ordinary shares in the event that SciSparc is a PFIC. See &#8220;The Merger
&#8212; Material U.S. Federal Income Tax Considerations to U.S. Holders&#8221; for additional information.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to Israeli
Law and SciSparc&#8217;s Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b style="-keep: true"><i>Conditions
in Israel, including Israel&#8217;s conflicts with Hamas and other parties in the region, as well as political and economic instability,
may adversely affect our operations and limit our ability to market our products, which would lead to a decrease in revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc
is incorporated under Israeli law, and many of our employees, including our Chief Executive Officer and our Chief Financial Officer,
and other senior members of SciSparc&#8217;s management team, operate from its headquarters located in Israel. In addition, all of SciSparc&#8217;s
officers and directors are residents of Israel. Accordingly, SciSparc&#8217;s business and operations are directly affected by economic,
political, geopolitical, and military conditions in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Since
the establishment of the State of Israel in 1948 and in recent years, armed conflicts between Israel and its neighboring countries and
terrorist organizations active in the region have involved missile strikes, hostile infiltrations, terrorism against civilian targets
in various parts of Israel, and recently abduction of soldiers and citizens.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Following
the October 7th attacks by Hamas terrorists in Israel's southern border, Israel declared war against Hamas and since then, Israel has
been involved in military conflicts with Hamas, Hezbollah, a terrorist organization based in Lebanon, and Iran, both directly and through
proxies like the Houthi movement in Yemen and armed groups in Iraq and other terrorist organizations. Additionally, following the fall
of the Assad regime in Syria, Israel has conducted limited military operations targeting the Syrian army, Iranian military assets and
infrastructure linked to Hezbollah and other Iran-supported groups. Although certain ceasefire agreements have been reached with Hamas
and Lebanon (with respect to Hezbollah), and some Iranian proxies have declared a halt to their attacks, there is no assurance that these
agreements will be upheld, military activity and hostilities continue to exist at varying levels of intensity, and the situation remains
volatile, with the potential for escalation into a broader regional conflict involving additional terrorist organizations and possibly
other countries. Also, the fall of the Assad regime in Syria may create geopolitical instability in the region.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">While
SciSparc&#8217;s facilities have not been damaged during the current war, the hostilities with Hamas, Hezbollah, Iran and its proxies
and others have caused and may continue to cause damage to private and public facilities, infrastructure, utilities, and telecommunication
networks, and potentially disrupting its operations and supply chains. For example, SciSparc&#8217;s SCI-210 ASD clinical trial at Soroka
Medical Center was delayed by three months. In addition, Israeli organizations, government agencies and companies have been subject to
extensive cyber attacks. This could lead to increased costs, risks to employee safety, and challenges to business continuity, with potential
financial losses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
continuation of the war has also led to a deterioration of certain indicators of Israel&#8217;s economic standing, for instance, a downgrade
in Israel&#8217;s credit rating by rating agencies (such as by Moody&#8217;s, S&amp;P Global, and Fitch).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">In
connection with the ongoing war, several hundred thousand Israeli military reservists were drafted to perform immediate military service,
and military reservists are expected to perform long reserve duty service in the coming years. None of SciSparc&#8217;s employees have
been called to active military duty. The absence of SciSparc&#8217;s employees due to their military service in the current or future
wars or other armed conflicts may materially and adversely affect SciSparc&#8217;s ability to conduct our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc&#8217;s
commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli
government currently covers the reinstatement value of certain direct damages that are caused by terrorist attacks or acts of war, SciSparc
cannot assure you that such government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses
or damages incurred by SciSparc could have a material adverse effect on its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
global perception of Israel and Israeli companies, influenced by actions by international judicial bodies, may lead to increased sanctions
and other negative measures against Israel, as well as Israeli companies and academic institutions. There is also a growing movement
among countries, activists, and organizations to boycott Israeli goods, services and academic research or restrict business with Israel,
which could affect business operations. If these efforts become widespread, along with any future rulings from international tribunals
against Israel, they could significantly and negatively impact business operations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Prior
to the October 2023 war, the Israeli government pursued changes to Israel&#8217;s judicial system and has recently renewed its efforts
to effect such changes. In response to the foregoing developments, certain individuals, organizations, and institutions, both within
and outside of Israel, voiced concerns that such proposed changes, if adopted, may negatively impact the business environment in Israel.
Such proposed changes may also lead to political instability or civil unrest. If such changes to Israel&#8217;s judicial system are pursued
by the government and approved by the parliament, this may have an adverse effect on SciSparc&#8217;s business, results of operations,
and ability to raise additional funds, if deemed necessary by its management and board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Provisions of
Israeli law may make it easy for SciSparc shareholders to demand that SciSparc convene a shareholders meeting, and/or allow shareholders
to convene a shareholder meeting without the consent of its management, which may disrupt its management&#8217;s ability to run its company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a company listed on an exchange in the U.S., Israeli law may allow any one or more of its shareholders holding, in the aggregate, at
least 10% of its voting rights to demand that SciSparc convene a special shareholders meeting. Also, in the event that SciSparc chooses
not to convene a special shareholders meeting pursuant to such a request, Sections 64-65 of the Companies Law provide, among others,
that such shareholders may independently convene a special shareholders meeting within three months (or under court&#8217;s ruling) and
require SciSparc to cover the costs, within reason, and as a result thereof, its directors might be required to repay SciSparc such costs.
If SciSparc&#8217;s shareholders decide to exercise these rights in a way inconsistent with its management&#8217;s strategic plans, its
management&#8217;s ability to run its company may be disrupted, and this process may entail significant costs to SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc&#8217;s
operations are subject to currency and interest rate fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
incurs expenses in U.S. dollars and NIS, but its financial statements are denominated in U.S. dollars. U.S. dollars is its functional
currency and is the currency that represents the principal economic environment in which SciSparc operates. As a result, SciSparc is
affected by foreign currency exchange fluctuations through both translation risk and transaction risk. As a result, SciSparc is exposed
to the risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation
rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel.
In any such event, the dollar cost of its operations in Israel would increase and its dollar-denominated results of operations would
be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Provisions of
Israeli law and SciSparc&#8217;s Amended and Restated Articles of Association may delay, prevent or otherwise impede a merger with, or
an acquisition of, its company, which could prevent a change of control, even when the terms of such a transaction are favorable to SciSparc
and its shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Provisions
of Israeli law and SciSparc&#8217;s Amended and Restated Articles of Association could have the effect of delaying or preventing a change
in control and may make it more difficult for a third party to acquire SciSparc or its shareholders to elect different individuals to
its board of directors, even if doing so would be considered to be beneficial by some of its shareholders, and may limit the price that
investors may be willing to pay in the future for its ordinary shares. Among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Israeli corporate law regulates mergers and requires that a tender
    offer be effected when more than a specified percentage of shares in a company are purchased;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Israeli corporate law does not provide for shareholder action by written
    consent, thereby requiring all shareholder actions to be taken at a general meeting of shareholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s Amended and Restated Articles of Association divide
    its directors into three classes, each of which is elected once every three years;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s Amended and Restated Articles of Association require
    a vote of the holders of a majority of its outstanding ordinary shares entitled to vote present and voting on the matter at a general
    meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision
    stating that each year the term of office of only one class of directors will and dividing its directors into three classes, requires
    a vote of the holders of 65% of the voting power represented at a general meeting of its shareholders and voting thereon has been
    obtained, provided the majority constitutes more than 33.33% of the total issued and outstanding share capital as of the record date
    of such meeting. The affirmative vote of at least three-quarters (3/4) of the directors, in addition to the approval of its shareholders,
    is also required in order to amend its Amended and Restated Articles of Association;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s Amended and Restated Articles of Association provide
    that director vacancies may be filled by its board of directors;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">subject to certain exceptions, SciSparc&#8217;s Amended and Restated
    Articles of Association restrict SciSparc from engaging in certain business combination transactions, with any shareholder who holds
    15% or more of its voting power. The transactions subject to such restrictions include mergers, consolidations and dispositions of
    its assets with a market value of 10% or more of its assets or outstanding shares. Subject to certain exceptions, such restrictions
    will apply for a period of three years following each time a shareholder became the holder of 15% or more of its voting power; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">subject to certain exceptions, SciSparc&#8217;s Amended and Restated
    Articles of Association restrict certain transactions which may have a significant effect on the company&#8217;s structure, assets
    or business, including significant mergers and acquisitions, a disposition of all or substantially all of the assets of SciSparc,
    a voluntary dissolution and material changes to the principal business of SciSparc.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
Israeli tax considerations may make potential transactions undesirable to SciSparc or to some of its shareholders whose country of residence
does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax
law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including
a holding period of two years from the date of the transaction during which certain sales and dispositions of shares of the participating
companies are restricted. See &#8220;The Merger &#8212; Certain Material Israeli Income Tax Consequences of the Merger&#8221; for additional
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>It may be difficult
to enforce a judgment of a United States court against SciSparc and its officers and directors and the Israeli experts named in this
prospectus in Israel or the United States, to assert United States securities laws claims in Israel or to serve process on its officers
and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
was incorporated in Israel and its corporate headquarters are located in Israel. All of its executive officers and directors and the
Israeli experts named in this prospectus are located in Israel. All of its assets and most of the assets of these persons are located
in Israel. Service of process upon SciSparc or its non-U.S. resident directors and officers and enforcement of judgments obtained in
the United States against SciSparc or its non-U.S. directors and executive officers may be difficult to obtain within the United States.
SciSparc has been informed by its legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original
actions instituted in Israel, or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts
may refuse to hear a claim based on a violation of U.S. securities laws against SciSparc or its non-U.S. officers and directors because
Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it
may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable
U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed
by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments
rendered outside Israel, which may make it difficult to collect on judgments rendered against SciSparc or its non-U.S. officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover,
an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of
judgments of Israeli courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of
the State of Israel, if it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that
was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a
court or tribunal in Israel at the time the foreign action was brought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Competition for skilled technical and other
personnel in Israel is intense, and as a result SciSparc may fail to attract, recruit, retain and develop qualified employees, which
could materially and adversely impact its business, financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
competes in a market marked by rapidly changing technologies and an evolving competitive landscape. In order for SciSparc to successfully
compete and grow, SciSparc must attract, recruit, retain and develop personnel with requisite qualifications to provide expertise across
the entire spectrum of its intellectual capital and business needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
principal research and development as well as significant elements of its general and administrative activities are conducted at its
headquarters in Israel, and SciSparc faces significant competition for suitably skilled employees in Israel. While there has been intense
competition for qualified human resources in the Israeli high-tech industry historically, the industry experienced record growth and
activity in 2021, both at the earlier stages of venture capital and growth equity financings, and at the exit stage of initial public
offerings and mergers and acquisitions. This flurry of growth and activity has caused a sharp increase in job openings in both Israeli
high-tech companies and Israeli research and development centers of foreign companies, and intensification of competition between these
employers to attract qualified employees in Israel. As a result, the high-tech and bio-tech industry in Israel has experienced significant
levels of employee attrition and is currently facing a severe shortage of skilled human capital, including engineering, research and
development, sales and customer support personnel. Many of the companies with which SciSparc competes for qualified personnel have greater
resources than SciSparc does, and SciSparc may not succeed in recruiting additional experienced or professional personnel, retaining
personnel or effectively replacing current personnel who may depart with qualified or effective successors. Failure to retain or attract
qualified personnel could have a material adverse effect on its business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Your rights and
responsibilities as a holder of SciSparc securities will be governed by Israeli law, which differs in some material respects from the
rights and responsibilities of shareholders of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is incorporated under Israeli law. The rights and responsibilities of holders of SciSparc&#8217;s ordinary shares are governed by its
Amended and Restated Articles of Association and the Companies Law. These rights and responsibilities differ in some respects from the
rights and responsibilities of shareholders in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder
of an Israeli company has to act in good faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations
toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things,
in voting at the general meeting of shareholders, on amendments to a company&#8217;s articles of association, increases in a company&#8217;s
authorized share capital, mergers and certain transactions requiring shareholders&#8217; approval under the Companies Law. In addition,
a controlling shareholder of an Israeli company or a shareholder who knows that it possesses the power to determine the outcome of a
shareholder vote or who has the power to appoint or prevent the appointment of a director or officer in the company, or has other powers
toward the company has a duty of fairness toward the company. However, Israeli law does not define the substance of this duty of fairness.
There is little case law available to assist in understanding the implications of these provisions that govern shareholder behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>SciSparc received Israeli government grants
for certain of its past research and development activities and programs, some of which SciSparc sold or is in the process of selling.
The terms of such grants may require SciSparc, in the future, to pay royalties and to satisfy specific conditions if and to the extent
SciSparc receives future royalties or in order to complete the sale of such grant based technologies and programs. SciSparc may be required
to pay penalties in addition to payment of the royalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
research and development efforts with respect to some of its past activities, which was focused on developing an immunotherapeutic monoclonal
antibody for the treatment of Alzheimer&#8217;s disease, which SciSparc sold in March 2015, and its Anti-CD3 technology directed toward
the treatment of inflammatory and autoimmune diseases, which in part was returned and re-assigned to Hadasit Medical Research Services&amp;
Development Ltd., or Hadasit, and in part is still in the process of being sold, were financed in part through royalty-bearing grants
from the Israeli Innovation Authority, or the IIA. As of June 30, 2024, SciSparc had received the aggregate amount of approximately $1.1
million from the IIA for the development of its abovementioned technologies. As of December 31, 2022, its contingent liabilities regarding
IIA grants received by SciSparc were in an aggregate amount of $1.1 million including interest. With respect to such grants, SciSparc
is committed to pay certain royalties up to $1.1 million relating only to technologies in its possession and excluding any royalties
for technologies that SciSparc sold to third parties. SciSparc is required to comply with the requirements of the Israeli Encouragement
of Industrial Research, Development and Technological Innovation Law, 5744-1984, as amended, or the Innovation Law, and related regulations,
or the Research Law, with respect to those past grants. When a company develops know-how, technology or products using IIA grants, the
terms of these grants and the Research Law restrict the transfer or license of such know-how, and the transfer of manufacturing or manufacturing
rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. Therefore, the discretionary
approval of an IIA committee would be required for any transfer or license to third parties inside or outside of Israel of know how or
for the transfer outside of Israel of manufacturing or manufacturing rights related to those aspects of such technologies. SciSparc may
not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer
technology or development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Innovation Law and the regulations thereunder, a recipient of IIA grants is required to return the grants by the payment of royalties
of 3% to 6% on the revenues generated from the sale of products (and related services) developed (in whole or in part) under an IIA program
up to the total amount of the grants received from IIA plus the relevant interest rate, if any. Under IIA regulations, grants received
before June 30, 2017, bear the annual interest rate that applied at the time of the approval of the applicable IIA file which will apply
to all of the funding received under such IIA approval. Grants received from the IIA after June 30, 2017, bear an annual interest rate
based on the 12-month Secured Overnight Financing Rate, or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%.
Grants approved after January 1, 2024, shall bear the higher interest rate of (i) 12 months SOFR, plus 1%, or (ii) a fixed annual interest
rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
transfer or license of IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products,
technology or know-how outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred
or licensed technology or know-how, SciSparc&#8217;s research and development expenses, the amount of IIA support, the time of completion
of the IIA-supported research project and other factors. These restrictions and requirements for payment may impair its ability to sell,
license or otherwise transfer SciSparc&#8217;s technology assets outside of Israel or to outsource or transfer development or manufacturing
activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to its shareholders
in a transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar
transaction) may be reduced by any amounts that SciSparc is required to pay to the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a &#8220;foreign private issuer&#8221; SciSparc is permitted to and follow certain home country corporate governance practices instead
of otherwise applicable SEC requirements, which may result in less protection than is accorded to investors under rules applicable to
domestic U.S. issuers.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
status as a foreign private issuer also exempts it from compliance with certain SEC laws and regulations, including the proxy rules and
the short-swing profits recapture rules. In addition, SciSparc will not be required under the Exchange Act to file current reports and
financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange
Act and SciSparc will generally be exempt from filing quarterly reports with the SEC. Also, although the Companies Law requires SciSparc
to disclose the annual compensation of its five most highly compensated senior officers on an individual basis, this disclosure is not
as extensive as that required of a U.S. domestic issuer. Furthermore, as a foreign private issuer, SciSparc is also not subject to the
requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies will reduce the frequency
and scope of information and protections to which you are entitled as an investor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>International
expansion of its business exposes SciSparc to business, regulatory, political, operational, financial and economic risks associated with
doing business outside of the United States or Israel.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than SciSparc&#8217;s headquarters and other operations which are located in Israel (as further described below), SciSparc currently
has limited international operations, but its business strategy incorporates potentially significant international expansion, particularly
in anticipation of approval of its product candidates. SciSparc plans to maintain sales representatives and conduct physician and patient
association outreach activities, as well as clinical trials, outside of the United States and Israel. Doing business internationally
involves a number of risks, including but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and
    changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory
    requirements and other governmental approvals, permits and licenses;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by SciSparc to
    obtain regulatory approvals for the use of its products in various countries;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially
    relevant third-party patent rights;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties
    in obtaining protection and enforcing its intellectual property;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing
    and managing foreign operations;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated
    with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in its ability to
    penetrate international markets;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as
    longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and
    payment for its products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political
    and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and
    other business restrictions;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an outbreak of a contagious
    disease, such as coronavirus, which may cause SciSparc, third party vendors and manufacturers and/or customers to temporarily suspend
    SciSparc or their respective operations in the affected city or country;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including,
    among others, expenses for travel, translation and insurance; and</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance
    risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the
    U.S. Foreign Corrupt Practices Act of 1977, or FCPA, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could significantly harm SciSparc&#8217;s future international expansion and operations and, consequently, its results
of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with the FCPA could subject SciSparc to penalties and other adverse consequences.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
is subject to the FCPA, which generally prohibits companies, such as SciSparc, whose securities are listed in the United States, from
paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign government official,
political party or candidate for public office for the purpose of influencing any act or decision of such foreign person in order to
assist companies like SciSparc in obtaining or retaining business. The FCPA also obligates companies like SciSparc, whose securities
are listed in the United States, to comply with accounting provisions requiring the companies to maintain books and records that accurately
and fairly reflect all transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system
of internal accounting controls for international operations. The U.S. Department of Justice and the SEC, which have responsibility for
enforcement of the FCPA, both consider employees of government-operated health care systems to be &#8220;foreign officials&#8221; for
FCPA purposes. In addition, the U.S. Department of Justice and the SEC are both engaged in a long-running FCPA compliance review of pharmaceutical
companies. If SciSparc&#8217;s employees or agents are found to have engaged in conduct that violates the FCPA, SciSparc would be held
responsible and could suffer severe penalties and other consequences, including adverse publicity and damage to its reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cybersecurity
issues, security breaches and other disruptions could compromise its information, expose SciSparc to liability and harm its reputation
and business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
business relies upon information technology systems operated by SciSparc and by its third-party service providers. These systems may
fail or experience operational disruption, experience cybersecurity attacks, or be damaged by computer viruses and unauthorized access.
In the ordinary course of its business SciSparc collects and stores sensitive data, including intellectual property, personal information
and its proprietary business information. The secure maintenance and transmission of this information is critical to its operations and
business strategy. SciSparc relies on commercially available systems, software, tools and domestically available monitoring to provide
security for processing, transmitting and storing this sensitive data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hackers
may attempt to penetrate its computer systems, and, if successful, misappropriate personal or confidential business information. In addition,
an associate, contractor or other third-party with whom SciSparc does business may attempt to circumvent its security measures in order
to obtain such information, and may purposefully or inadvertently cause a breach involving such information. While SciSparc continues
to implement additional protective measures to reduce the risk of and detect cyber incidents, cyber-attacks are becoming more sophisticated
and frequent, and the techniques used in such attacks change rapidly. If its third-party vendors fail to protect their information technology
systems and its confidential and proprietary information, SciSparc may be vulnerable to disruptions in service and unauthorized access
to its confidential or proprietary information and SciSparc could incur liability and reputational damage and the further development
and commercialization of its product candidates could be delayed. While SciSparc has not, to its knowledge, experienced any material
IT system failures or cybersecurity attacks to date, SciSparc cannot assure you that its data protection efforts and its investment in
information technology will prevent significant breakdowns, data leakages, breaches in its systems or those of its third-party vendors
and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon its reputation, business,
operations or financial condition. If such an event were to occur and cause interruptions in its operations, it could result in a material
disruption of its development programs, business operations, a breach of sensitive personal information or a loss or corruption of critical
data assets including trade secrets or other proprietary information. For example, the loss of clinical trial data from future clinical
trials could result in delays in its regulatory approval efforts and significantly increase its costs to recover or reproduce the data.
Such IT system failures, cybersecurity attacks or vulnerabilities to SciSparc&#8217;s or its third-party vendors&#8217; information security
programs or defenses could result in legal liability, reputational damage, business interruption, and its competitive position could
be harmed and the further development and commercialization of its products or any future products could be delayed or disrupted. Moreover,
containing and remediating any IT system failure, cybersecurity attack or vulnerability may require significant investment of resources.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
information technology networks and infrastructure may still be vulnerable to damage, disruptions or shutdowns due to attack by hackers
or breaches, employee error or malfeasance, power outages, computer viruses, telecommunication or utility failures, systems failures,
natural disasters or other catastrophic events. Furthermore, significant security breaches or disruptions of its internal information
technology systems or those of its third-party vendors and other contractors and consultants could result in the loss, misappropriation
and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets
or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business
and reputational harm to SciSparc. Any such compromise could disrupt its operations, damage its reputation and subject SciSparc to additional
costs and liabilities, any of which could adversely affect its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>SciSparc
may be subject to securities litigation, which is expensive and could divert management attention.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action
litigation. SciSparc may be the target of this type of litigation in the future. Litigation of this type could result in substantial
costs and diversion of management&#8217;s attention and resources, which could seriously hurt its business. Any adverse determination
in litigation could also subject SciSparc to significant liabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish or cease publishing research or reports about SciSparc, its business or its market, or
if they adversely change their recommendations or publish negative reports regarding its business or its shares, the share price and
trading volume of its securities could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for SciSparc&#8217;s ordinary shares will be influenced by the research and reports that industry or securities analysts
may publish about SciSparc, its business, its market or its competitors. SciSparc does not have any control over these analysts and SciSparc
cannot provide any assurance that analysts will cover SciSparc or provide favorable coverage. If any of the analysts who may cover SciSparc
adversely change their recommendation regarding its securities, or provide more favorable relative recommendations about its competitors,
the price of its securities would likely decline. If any analyst who may cover SciSparc were to cease coverage of its company or fail
to regularly publish reports on SciSparc, SciSparc could lose visibility in the financial markets, which in turn could cause the price
or trading volume of its securities to decline.</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to AutoMax&#8217;s Business and Operations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
decline in available financing may adversely affect AutoMax&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of AutoMax&#8217;s customers finance their vehicle purchase. As the credit markets have historically experienced volatility and disruption,
such downturns could adversely affect the credit market and affect AutoMax clients&#8217; ability to secure the required financing. A
part of AutoMax&#8217;s success is subject to the availability of affordable financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
AutoMax has non-guaranteed credit lines from four banking corporations, which aggregated to approximately NIS 150 million (approximately
$41.46 million) for the year ended December 31, 2023, of which it had utilized approximately NIS 143 million (approximately $39.52 million).
These credit lines bear interest rates that vary between prime +0.5% and prime +2.25%. If the financial market or the banking system
deteriorates, AutoMax&#8217;s ability to obtain additional financing may be affected. Such a decline in available financing could have
an adverse effect on its business, operations, and financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
signed certain indemnification clauses within asset and share purchase agreements, as part of the sale of its digital media operations
between the years 2017 and 2019, and if such indemnification is sought out, AutoMax&#8217;s results of operations and financial conditions
could be adversely impacted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
the years 2017 and 2019, AutoMax sold its digital media and advertising operations to various third parties. As part of such sales, AutoMax
has agreed to identify the buyers in case of a breach of representations provided by AutoMax. While AutoMax estimates that there is a
low probability it will be required to indemnify any such purchasers, any such indemnification could adversely impact its financial condition
and results of operations. <b><i>&#160; </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to renew AutoMax permits and licenses or their revocation could materially adversely affect its business, results of operations, financial
condition and cash flows. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s subsidiary,
Global AutoMax, operates in accordance with and subject to the permits and licenses granted to it for the purpose and within the framework
of its activity as a parallel importer, as further detailed in this prospectus. The main licenses used for the AutoMax operations are
in accordance with the Vehicle Services Licensing Law, Licensing Regulations for Services and Professions in the Automotive Industry
(Vehicle Import and Marketing and Vehicle Trade), 5775-2016, or the Vehicle Services Licensing Law. Since its inception, Global AutoMax
was granted the required permits and licenses, and these were extended, from time to time, new permits were obtained when required. However,
failure to meet certain criteria as detailed in the Vehicle Services Licensing Law may lead to such permits and licenses being suspended
or not eligible for renewal and/or extensions. Furthermore, such permits could be suspended or revoked until the required conditions
are met. There are currently pending legal proceedings against AutoMax that could, among other things, impede on its ability to renew
or obtain new licenses. For additional information, see &#8211;<i>&#8220;Global AutoMax is subject to various legal proceedings. If the
outcomes of these proceedings are adverse to AutoMax, it could have a material adverse effect on its business, results of operations
and financial condition</i>.&#8221; Cancellation, conditioning, limitation or non-renewal of any of the AutoMax licenses, due to the
aforementioned reasons or for any other reason, may have an effect on its activities and business results.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
ability to import and sell vehicles depends in large part on agreements with suppliers and, therefore, any disruption or deterioration
in its relationship with such suppliers could impact its business. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
purchases its vehicles and components from a limited number of suppliers. Disruption or termination of these sources could occur (due
to several factors, including, but not limited to, supplier capacity limitations, bankruptcy, acts of war, terrorism, fire, earthquake).
Good relationships with such suppliers are important for AutoMax&#8217;s business prospects. If AutoMax&#8217;s relationship with its
suppliers were to deteriorate, or if its suppliers fail to supply vehicles, its business, financial condition, commercialization and
results of operations could be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, as a result of difficulties faced by major vehicle manufacturers, there has been an increase in consolidation of activities
and mergers and acquisitions in the automotive industry, as well as collaborations between vehicle manufacturers. The acquisition of
a major supplier by a larger group may lead to cancellation or non-renewal of franchise agreements, and concentration of the import of
brands to Israel under one importer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s
success depends greatly on its ability to retain and/or recruit suppliers who will provide it with a vehicle inventory, in the scope
that will enable AutoMax to remain competitive in the marketing of vehicles to its customers in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exchange
rate fluctuations between the U.S, dollar, Euro and the New Israeli Shekel currencies may negatively affect AutoMax&#8217;s earnings.
</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the international nature of AutoMax&#8217;s business, it is exposed to risks associated with changes in foreign currency
exchange rates. Substantially all its cost of purchases are either in U.S. dollars or Euros while the majority of its revenues and AutoMax&#8217;s
management, marketing, sales and research and development costs are in New Israeli <span style="background-color: white">Shekels</span>.
AutoMax is therefore exposed to foreign currency risk due to fluctuations in exchange rates. This may result in gains or losses with
respect to movements in exchange rates, which may be significant and may also cause fluctuations in reported financial information that
are not necessarily related to its operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increases
in interest rate could materially adversely affect AutoMax&#8217;s business, financial condition, and results of operations. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
recent inflation, geopolitical issues, increase in energy costs, increases in interest rates, unstable global conditions and changes
in currency exchange rates have led to global economic instability. Furthermore, as interest rates are reaching historically high records,
it could impede AutoMax&#8217;s ability to obtain financing or comply with its existing credit lines if the banks. Such changes, and
their impact on the global macro-economic environment, can impact AutoMax&#8217;s business, operating results, and financial condition.
Furthermore, as the majority of the customers require financing to purchase vehicles, such increase in interest rates could make it less
appealing and/or more difficult to purchase vehicles and thus decrease sales, which could adversely affect AutoMax&#8217;s business,
financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Import
product restrictions may impair AutoMax&#8217;s ability to sell vehicles or parts profitably. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the spare or replacement parts AutoMax installs in its vehicles are manufactured outside of Israel. As a result, the AutoMax business
is sensitive to customary risks of importing merchandise, such as import duties, trade regulations and restrictions, transportation costs,
unforeseeable disasters, work stoppages, exchange rates, and general political conditions in other countries. Changes in trade policies
could limit AutoMax&#8217;s ability to import vehicles and/or its ability to purchase vehicles and/or parts at reasonable prices. Such
restrictions could additionally limit AutoMax&#8217;s ability to provide servicing for vehicles and decrease its sales and/or marketability
for customers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any inability to receive the required approvals to import its vehicles or any disputes or disagreements with officials regarding
the import duties, tariffs, or similar matters, could adversely affect AutoMax&#8217;s ability to import vehicles into Israel as well
as impact its profit margins.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
is subject to various legal proceedings. If the outcomes of these proceedings are adverse to AutoMax, it could have a material adverse
effect on its business, results of operations and financial condition. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, AutoMax or its subsidiaries may be party to legal proceedings and claims in the ordinary course of business. While the
outcomes of these matters cannot be predicted with certainty, AutoMax does not believe they will have a material effect on its consolidated
financial position, results of operations, or cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are currently two pending legal proceedings against AutoMax, certain beneficial owners as well as officers of AutoMax and its subsidiaries,
which AutoMax considers material to its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 5, 2021, the Tel
Aviv District Attorney&#8217;s Office filed an indictment against Global AutoMax, Haim Levy Trade-In Ltd., and the following beneficial
owners and officers: Daniel Levy, CEO of AutoMax; Yinon Amit, Chief Business Officer of AutoMax; and Haim Levy, Trade and Procurement
Officer of AutoMax and the son of Daniel Levy, or together the Officers, together with Global AutoMax and Haim Levy Trade-In, the Defendants.
Pursuant to the indictment:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Global
                                            AutoMax was accused of committing forgery offenses according to the Penal Law, fraud under
                                            the Penal Law, smuggling according to the Customs Ordinance [new version] and money laundering
                                            offenses, according to the Money Laundering Prohibition Law.</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haim
                                            Levy Trade In was accused of committing forgery offences under the Penal Law, fraud under
                                            the Penal Law, smuggling under the Customs Ordinance, tax and customs violations under the
                                            Customs Ordinance [new version], Value Added Tax Law and the Purchase Tax Law (Goods and
                                            Services), and money laundering offenses according to the Prohibition of Money Laundering
                                            Law and the Penal Law.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Officers were accused of forgery offences under the Penal Law, fraud under the Penal Law,
                                            smuggling under the Customs Ordinance, and money laundering offenses according to the Prohibition
                                            of Money Laundering Law and the Penal Law.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preliminary hearings were completed, and the evidence trials began in March 2023 for each of the Defendants. AutoMax denies the claims
against Global AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc was informed that
AutoMax believes, based on the position taken by its legal counsel on this matter, that Global AutoMax has strong claims in order to
deal with the allegations in the indictment. Furthermore, based on information received from its legal counsel, in the event of a conviction
against Global AutoMax, the penal sanctions would consist of a monetary fine, and if convicted of money laundering there could be repossessions.
In addition, AutoMax could be exposed to an administrative procedure on behalf of the Israeli Ministry of Transportation and Road Safety,
or the Ministry of Transportation. Subject to Section 8 of the Vehicle Services Licensing Law, the Deputy Director General has the authority
to refuse granting a license or the renewal of a license, if the applicant has been convicted of a criminal offense that, due to its
nature, severity, or circumstance the applicant is not deemed fit to provide vehicle services or to provide services in the automotive
field for which the application was submitted. The Deputy Director General has the same authority in the event an indictment was filed,
even if a final verdict has not yet been reached. Furthermore, under Section 10(a)(7) of the Vehicle Services Licensing Law, the Deputy
Director General can revoke or suspend a license until the licensee complies with the conditions put in place.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional lawsuit was
filed on September 29, 2022, with the District Court in Tel Aviv in the form of a request for approval as a class action, or the Request,
against Global AutoMax, Union Motors Ltd., or Union, Lex Motors Ltd., or Lex, Toyota Motor Corporation, or Toyota, and Denso Corporation,
or Denso.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicant claims that
the defendants, Toyota as a manufacturer of vehicles; Danso as a manufacturer of allegedly defective fuel pumps, installed in Toyota
and Lexus vehicles, and are the subject of the Request. Union and Lex served as direct importers of Toyota and Lexus vehicles in Israel.
Global AutoMax served as a parallel importer of Toyota vehicles in Israel, and Global AutoMax imported the applicant&#8217;s vehicle
to Israel. The applicant claims that each of Lex, Union and Global AutoMax breached their obligations towards the group represented in
the class action, inter alia, producing and/or importing and/or marketing and/or selling vehicles in which a defective fuel pump was
installed, refraining from performing a service recall on all vehicles in which defective pumps were installed, avoided bearing the costs
of damages caused by the defective fuel pumps and the service recall, etc.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This,
according to the applicant, is in breach of the defendants&#8217; obligations according to the Liability for Defective Products Law,
5740-1980, the Sales Law, 5728-1968, the Contracts Law (General Part), 5733-1973, the Licensing of Services and Professions in the Automotive
Industry Law, 5776-2016 and other laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicant estimates the total damages for all members of the claim exceed an aggregate of NIS 2.5 million (approximately $691,000), and
as such that cannot be estimated by him.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, Global
AutoMax submitted a reply to the Request, in which Global AutoMax rejected all of the applicant&#8217;s claims in the Request. In February
2024, the applicant submitted a reply to the respondents&#8217; reply to the Request. A preliminary hearing is scheduled for March 2025.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
AutoMax cannot accurately predict the outcome of this proceeding, it does not believe the claims are substantial and estimate the exposure
with respect to such claim is likely immaterial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
is dependent on its management team and professional personnel, and its business could be harmed if it is unable to attract and retain
personnel necessary for its success. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s
success depends highly on its ability to attract and retain skilled, professional personnel, consultants, and contractors. The departure
of highly skilled professional personnel, in particular, any particular key management personnel, could have an adverse impact on AutoMax&#8217;s
operations and ability to execute its growth plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s
efforts to retain and attract professional personnel may also result in significant additional expenses, which could adversely affect
its profitability. There can be no assurance that professional personnel will continue to be employed or that AutoMax will be able to
attract and retain qualified personnel in the future. Failure to retain or attract qualified personnel could have a material adverse
effect on AutoMax&#8217;s business, financial conditions and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
business is sensitive to changes in the prices of new and used vehicles. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s business
is sensitive to various changes, specifically to changes in the prices of new and used vehicles. A decrease in the prices of new or used
vehicles, due to a reduction in import taxes or a reduced tax for purchasing vehicles could reduce its profit margins. For example, following
an update of the Pollution Regulations and the Procedure for Testing Pollutants in Vehicles in the European Union (WLTP) the Israeli
green taxation formula was updated. Pursuant to such updated taxation formula, the tax benefits in relation to vehicles with a low polluting
level and set tax benefit limits, are gradually decreasing, which causes an increase in the prices of the vehicles that benefited from
the purchase tax. For example, on January 1, 2023, the purchase tax on hybrid vehicles increased from 40% in 2022 to 50%, while the limit
of the tax benefit was reduced from NIS 40,000 (approximately $11,055) in 2021 to NIS 30,000. The purchase tax on electric vehicles was
doubled from 10% in 2022 to 20% in 2023, while the limit of the tax benefit was reduced from NIS 75,000 (approximately $20,730) in 2021
to NIS 60,000 (approximately $16,583) in 2022. On January 1, 2024, the purchase tax on hybrid and plug-in cars increased to 83% and the
tax benefit limit was cancelled, and the purchase tax on electric cars increased to 35% and the tax benefit limit was reduced to NIS
50,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
operates in Israel, and prices AutoMax sets are denominated in New Israeli Shekel, or NIS. Any depreciation of the NIS against foreign
currencies in which AutoMax purchases vehicles from manufactures and the reduction of the price of the vehicles by the manufactures or
the importers for other reasons may adversely affect the value of the vehicles important and marketed by AutoMax. AutoMax has a policy
in place to reduce exchange risk, which includes both financial protections and options to import the same vehicle models from different
suppliers in different currencies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors could lead to a decrease in the value of AutoMax&#8217;s inventory, and a decrease in AutoMax&#8217;s sales, which could adversely
affect AutoMax&#8217;s business, sales, and results of operations.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
business and operations face many risks inherent to international trade, and its location in Israel including the ongoing interplay of
the Israel &#8211; Hamas war, may exacerbate the import process, which is material to the success of AutoMax&#8217;s business and operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
imports, distributes and sells vehicles in Israel, and all the vehicles AutoMax sells are manufactured outside of Israel. While AutoMax
manages its inventory of vehicles and spare parts in a manner that allows AutoMax to provide a rapid response to its customers&#8217;
needs, AutoMax&#8217;s business remains sensitive to customary risks of importing merchandise, such as currency fluctuations, import
duties, trade regulations and restrictions, transportation costs, unforeseeable disasters, work stoppages, exchange rates, and general
political conditions in other countries. Changes in trade policies could limit AutoMax&#8217;s ability to import vehicles and/or its
ability to purchase vehicles and/or parts at reasonable prices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
to the maritime route in the Red Sea may adversely affect AutoMax&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Red Sea is a vital maritime route for international trade traveling to or from Israel. Following Hamas&#8217; attack on Israel and the
Israeli security cabinet&#8217;s declaration of war against Hamas, the Houthi movement, which controls parts of Yemen, launched a number
of attacks on marine vessels traversing the Red Sea, which marine vessels were thought to either be in route towards Israel or to be
partly owned by Israeli businesses or persons. As a result of such disruptions, and in order to mitigate continued economic harm, suppliers
have changed routes from Europe to the Middle East, and, as a result, AutoMax has experienced, and may continue to experience in the
future, delays in vehicle deliveries, extended lead times, and increased cost of freight, increased insurance costs, purchased materials
and manufacturing labor costs. All of these factors have had and may continue to have an effect on AutoMax, which is substantially reliant
on its ability to import and sell vehicles, and such delays and increased costs could have an impact on AutoMax&#8217;s inventory which
may prevent AutoMax from supplying vehicles in a timely fashion to purchasers and/or impede AutoMax&#8217;s ability to replenish its
inventory based on consumer trends. Such delays in supplying vehicles could result in purchasers cancelling orders, which could have
a negative effect on AutoMax&#8217;s results of operation. Furthermore, such increase in costs could impact AutoMax&#8217;s ability to
sell vehicles at competitive prices, which could materially affect its financial results and operations. Additionally, some of the main
maritime companies have announced they will no longer plan routes to Israel, until such time as it is safe, which could impede on AutoMax&#8217;s
ability to import vehicles, and as a result could have a material adverse effect on its business and financial results. The risk of ongoing
supply disruptions may further result in delayed deliveries of AutoMax&#8217;s products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Turkey&#8217;s
trade embargo on Israel may adversely affect AutoMax&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, the Turkish Trade Ministry announced an embargo on trade between Turkey and Israel, which restricts the export of goods from
Turkey to Israel and the import of products from Israel to Turkey, or the Embargo. The Embargo could have a short-term impact on the
supply of vehicles and on the prices of logistics and transportation of vehicles to Israel. As a result of the Embargo, AutoMax may experience
delays in vehicle deliveries, extended lead times, increased cost of freight, and increased insurance costs. All of these factors have
had and may continue to have an effect on AutoMax, which is substantially reliant on its ability to import and sell vehicles, and such
delays and increased costs could have an impact on AutoMax&#8217;s inventory, which may in turn prevent AutoMax from supplying vehicles
in a timely fashion to purchasers or impede AutoMax&#8217;s ability to replenish its inventory based on consumer trends. Such delays
in supplying vehicles could result in purchasers cancelling orders, which could have a negative effect on AutoMax&#8217;s results of
operations. As of the date of this prospectus, the Embargo remains ongoing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Macroeconomic
factors such as fluctuation in vehicle prices, fuel prices, supply chain disruptions, and vehicle-related technology advancements could
have an adverse effect on AutoMax&#8217;s revenues and operating results. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Macroeconomic
factors that affect oil prices and the automobile and commodity markets can have adverse effects on AutoMax&#8217;s revenues, revenue
growth rates (if any), and operating results. Significant increases in the cost of fuel could lead to a reduction in miles driven per
car and a reduction in accident rates. A material reduction in accident rates, whether due to, among other things, a reduction in miles
driven per car, vehicle-related technological advances such as accident avoidance systems and, to the extent widely adopted, the advent
of autonomous vehicles, could have a material impact on revenue growth. Similarly, a reduction in total loss frequency rates, due to
among other things, sharp increases in used car prices that make it less economical for insurance company sellers to declare a vehicle
involved in an accident a total loss, could also have a material impact on revenue growth. In addition, under the AutoMax Percentage
Incentive Program contracts, or PIP, the cost of transporting the vehicle to one of AutoMax&#8217;s facilities is included in the PIP
fee. AutoMax may incur increased fees, which it may not be able to pass on to its vehicle sellers. A material increase in transportation
rates could have a material impact on AutoMax&#8217;s operating results. Volatility in fuel, commodity, and used car prices could have
a material adverse effect on its revenues and revenue growth rates in future periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conditions
in Israel, including the ongoing war between Israel and Hamas, and other conflicts in the region, may adversely affect AutoMax&#8217;s
operations and limit its ability to market its products, which would lead to a decrease in revenues.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax
is incorporated under the laws of the State of Israel, and its employees, including management members, operate from their offices that
are located in Tel Aviv, Israel. In addition, a number of its officers and directors are residents of Israel. Accordingly, AutoMax&#8217;s
business and operations are directly affected by economic, political, geopolitical and military conditions in Israel. Since the establishment
of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist
organizations active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian
targets in various parts of Israel, which have negatively affected business conditions in Israel.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against
these terrorist organizations commenced in parallel to their continued rocket and terror attacks.&#160;Since the commencement of these
events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts
of Yemen, and most recently with Iran. As a result of the war, operations at two of AutoMax&#8217;s branch locations were closed and
have not reopened as of the date of this prospectus.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict, as are such war&#8217;s economic implications
on AutoMax&#8217;s business and operations and on Israel&#8217;s economy in general. These events may be intertwined with wider macroeconomic
indications of a deterioration of Israel&#8217;s economic standing, for instance, a downgrade in Israel&#8217;s credit rating by rating
agencies, which may have a material adverse effect on AutoMax and its ability to effectively conduct its operations.&#160;As many of
AutoMax&#8217;s customers purchase their vehicles through credit financing, an adverse material effect on Israel&#8217;s economy could
impact the ability to obtain such credit financing on favorable terms, which in turn could lead to a decrease in AutoMax sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the Israeli security cabinet&#8217;s declaration of war against Hamas and possible hostilities with other organizations,
several hundred thousand Israeli military reservists were drafted to perform immediate military service. As of the date of this prospectus,
none of AutoMax&#8217;s current employees have been called to active military duty. AutoMax also relies on service providers located
in Israel and has entered into certain agreements with Israeli counterparties. AutoMax&#8217;s employees and consultants in Israel, in
addition to employees of AutoMax&#8217;s service providers located in Israel, may be called for service in the current or future wars
or other armed conflicts with Hamas and others, and such persons may be absent for an extended period of time. As a result, its operations
may be disrupted by such absences, which disruption may materially and adversely affect its business and results of operations. Additionally,
the absence of employees of AutoMax&#8217;s Israeli suppliers and contract manufacturers due to their military service in the current
or future wars or other armed conflicts may disrupt their operations, which in turn may materially and adversely affect its ability to
deliver or provide products and services to customers.&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
the event that AutoMax&#8217;s facilities are damaged as a result of hostile actions, or hostilities otherwise disrupt its ongoing operations,
its ability to deliver or provide products and services in a timely manner to meet AutoMax&#8217;s contractual obligations towards customers
and vendors could be materially and adversely affected. AutoMax&#8217;s commercial insurance does not cover losses that may occur as
a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of certain
direct damages that are caused by terrorist attacks or acts of war, AutoMax cannot assure you that such government coverage will be maintained
or that it will sufficiently cover its potential damages. Any losses or damages incurred by AutoMax could have a material adverse effect
on its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
is a holding company and as a result are dependent on its operating subsidiaries to generate sufficient cash to fund its ongoing operations.
</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuation of AutoMax&#8217;s activities depends on its operating subsidiaries&#8217; ability to generate sufficient cash and raise
additional financial sources in order to develop its activities. The loss of operations or not sufficient operations of its subsidiaries
could have a material adverse effect on its business, sales and results of operations. There is no certainty that AutoMax will succeed
in raising funds in the required amount, or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
business is sensitive to changes in consumer preferences and global trends in the automotive industry. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
may be affected by various global trends and/or events in the environment in which it operates, on which AutoMax has no ability to influence,
which in turn may affect its operating results. The vehicle manufacturing industry has been characterized in recent years by significant
technological progress, especially in the fields of vehicles driven by alternative energy sources and autonomous vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there is a noticeable increase in the cooperative economy trend and a trend of decreasing the environmental damages caused
by the use of vehicles, which are expressed, <i>inter alia</i>, by increase in demand for the use of electric and hybrid vehicles, by
the development of new models of vehicle&#8217; sharing, by short-term vehicle rentals, in a pay-as-you-go model, and by shared travels.
Alongside this, major cities in Europe are promoting processes intended to reduce and even limit completely the entrance of polluting
vehicles into the cities. This trend has recently expanded to Israel, as part of which, restrictions were imposed on the entry of polluting
vehicles into Jerusalem and Haifa, and potentially in other cities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
developments described above may create uncertainty in the long term regarding the motorization level as well as the growth rate of the
vehicle manufacturing industry in which manufacturers whose vehicles AutoMax imports are operating, as well as reducing, in the long
term, the demand for car ownership, which in turn may influence AutoMax&#8217;s activity and affect AutoMax&#8217;s business results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
may experience credit default or losses if AutoMax&#8217;s customers default from the financing it provides.</i></b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
for the date of the report, through certain subsidiaries, AutoMax provides its corporate customers with credit lines in low volumes (by
way of payment in installments). However, as is customary in the automotive industry, it is possible that according to AutoMax&#8217;s
management decision, sales made to its corporate customers will be partially made on credit. In such cases, AutoMax may be exposed to
the risk that these customers will not meet their obligations to repay the full amount of the loan made available to them for the purpose
of purchasing the vehicles. As of the day of this prospectus, these credit lines are in volumes which are immaterial to AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
operations are subject to a wide range of governmental regulations and laws. Its failure to comply with or any changes to these regulations
and laws, could adversely affect AutoMax&#8217;s business, sales, results of operations and financial condition. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
operates in a highly regulated industry, and it is subject to various local laws and regulations. Additionally, the automotive industry
in Israel is characterized by vast regulation and strict regulatory requirements, including the standardization requirements, which may
affect AutoMax&#8217;s expenditures and its operational results. Changes in regulatory arrangements that apply to the automotive industry,
such as changes in government taxation policy, changes in the policy regarding the classification of vehicles as private or commercial
for tax purposes or changes in the policy regarding the value of use of a personal vehicle provided by the employer for the use of the
employee, or changes in the standards of vehicles permitted to be imported into Israel, may, in AutoMax&#8217;s estimation, lead to changes
in demand for various types of vehicles, and affect in the long term the results of its activity. In addition, regulatory changes introduced
following the recommendations of the Committee for the Increase of Competitiveness, as well as changes in the legal provisions that will
completely remove or ease the barriers to entry into the industry, will allow the entry of additional parallel importers, increase competition
and, as a result, may cause a decrease in AutoMax&#8217;s revenues and profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
operates in a highly competitive industry. Failure to develop and execute strategies to remain a preferred importer and seller of vehicles
and to adapt to the increasing use of digital and online tools to market, buy, sell, lease and finance vehicles could adversely affect
its business, sales and results of operations. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
automotive imports industry is highly competitive, including publicly and privately owned car importers, which import the same vehicle
brands in a variety of models. The value chain in the automotive industry includes international vehicle manufactures and importers.
There are approximately 22 official import groups in Israel, representing various manufactures, and responsible for approximately 97%
of the automotive imports to Israel. In addition, there are a few dozen parallel importers, who are collectively responsible for approximately
3% of the imports. AutoMax&#8217;s competition is dynamic and changes annually based on the selection of vehicles its choses to import
and hold in inventory for that year. AutoMax&#8217;s selection of product lineup is done annually and determined by a comprehensive analysis
of various factors, including vehicle availability in the importing country, local market demand, tax advantages, currency exchange rates,
and other relevant factors. Certain of AutoMax&#8217;s competitors have access to more capital than it, which may provide them with an
advantage in forging relationships or providing customers with more competitive prices. Certain car dealers leverage relationships with
vehicle manufacturers to sell used cars as &#8220;certified pre-owned&#8221;, which could provide such competitors with an advantage
over AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
competitors are shifting more focus to online sales, as this is becoming a consumer trend. While AutoMax currently provides online sale
services, there is no guarantee it will be successful in transitioning to online tools, for buying, selling, leasing and financing vehicles
which could adversely affect its business, sales and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s agreement with Al Damani
is conditioned upon receiving the required regulatory approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s
strategic agreements with Al Damani New Motor Vehicles Trading LLC, or Al Damani, is contingent on obtaining necessary regulatory approvals,
which have not yet been fully secured. These approvals are crucial for importing and distributing vehicles in Israel. Delays or failures
in securing these approvals could adversely impact AutoMax&#8217;s revenues, market expansion, and competitive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">On March 13, 2023,
Dalhom AutoMax entered into a direct import agreement with Al Damani, a United Arab Emirates manufacturer, to import, distribute, sale
and market fully electric Al Damani vehicles in Israel. Dalhom AutoMax&#8217;s obligations under such direct importer agreement are conditional
on receiving the required regulatory approvals from the Ministry of Transportation for the import of vehicles manufacturer by Al Damani
to Israel, which have not yet been granted as of the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The failure to secure these
regulatory approvals could delay or prevent the importation and sale of Al Damani vehicles in Israel, which in turn may negatively impact
AutoMax&#8217;s revenue and plans. Additionally, any changes in regulatory requirements or delays in the approval process could increase
AutoMax&#8217;s operational costs and affect its competitive position in the market, which could adversely affect its business, sales
and results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
laws, regulations, or governmental policies in response to climate change, including fuel economy and greenhouse gas emission standards,
or changes to existing standards, could adversely impact AutoMax&#8217;s business, results of operations, financial condition, cash flow,
and prospects. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax
is subject to a variety of local laws and regulations that pertain to the environment. Its business involves the use, handling and disposal
of hazardous materials and wastes, including motor oil, gasoline, solvents, lubricants, paints and substances. AutoMax is subject to
compliance with regulations concerning, among other things, the operation of underground and above-ground gasoline storage tanks, gasoline
dispensing equipment, above-ground oil tanks and automotive paint booths. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Clean Air Law, 5768-2008, or the Clean Air Law, authorizes the Israeli Minister of Environmental Protection, or the Minister to set provisions
regarding the prevention and reduction of air pollution from mobile emission sources, in accordance with values commonly accepted in
the developed countries of the world. The Clean Air Law determines that a person shall not sell, import or market a mobile emission source,
except in accordance with the provisions set by the Minister. This law also states that it is mandatory to include the degree of air
pollution of the vehicle and data regarding the fuel consumption of the vehicle in any new vehicle&#8217; advertisement, as part of the
advertisement itself; and, in addition, said data must be displayed by any entity engaged in the business of selling and marketing new
vehicles within its premises. Similar provisions were established as part of the Clean Air Regulations (disclosure of air pollution data
from a motor vehicle in an advertisement), 5769-2009, as well. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
the best of AutoMax&#8217;s understanding, it complies with the provisions of the Clean Air Law and the regulations established by virtue
thereof and includes the required data in its publications. In addition, the Clean Air Regulations (air pollution from vehicles), 5772-2012
determines what constitutes unreasonable air pollution from a vehicle and regulates the obligation to carry out an air pollution test
for a vehicle before registering it, issuing a license, and renewing it. It should be noted that new vehicles imported to Israel undergo
inspections to verify their suitability for delivery and registration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, there is a noticeable increase in the cooperative economy trend and a trend of decreasing the environmental damages caused
by the use of vehicles, which are expressed, inter alia, by increase in demand for the use of electric and hybrid vehicles, by the development
of new models of vehicle&#8217; sharing, by short-term vehicle rentals, in a pay-as-you-go model, and by shared travels. Alongside this,
major cities in Europe are promoting processes intended to reduce and even limit completely the entrance of polluting vehicles into the
cities. This trend has recently expanded to Israel, as part of which, restrictions were imposed on the entry of polluting vehicles into
Jerusalem and Haifa, and potentially, in other cities. The developments described above may create uncertainty in the long term regarding
the motorization level as well as the growth rate of the vehicle manufacturing industry in which manufacturers whose vehicles AutoMax
imports are operating, as well as reducing, in the long term, the demand for car ownership, and thus influence AutoMax&#8217;s activity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to maintain the security and functionality of AutoMax&#8217;s information systems, or to defend against or otherwise prevent a cybersecurity
attack or data breach, could adversely affect its business, financial position, results of operations and liquidity.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax&#8217;s
activities are linked by information systems, including telecommunications, the internet, network communications, emails and various
computer hardware and software applications. As such, it could suffer damage to the aforementioned communication systems. In the current
environment, there are numerous and evolving risks with regards to cybersecurity and privacy, including criminal hackers, hacktivists,
state-sponsored intrusions, industrial espionage, employee malfeasance and human or technological error.&#160;While AutoMax implements
various measures to minimize and even prevent these risks, including having a detailed action policy, it cannot guarantee no cyber-attack
may be carried out. Computer hackers and others routinely attempt to breach the security of technology products, services and systems,
and to fraudulently induce employees, customers, sub-contractors, agents, distributors or others to disclose information or unwittingly
provide access to systems or data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Although
AutoMax has invested in measures to reduce these risks, it can provide no assurance that its current IT systems are fully protected against
third-party intrusions, viruses, hacker attacks, information or data theft or other similar threats. The cost and operational consequences
of implementing, maintaining and enhancing further data or system protection measures could increase significantly to overcome increasingly
intense, complex, and sophisticated global cyber threats. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Despite
its best efforts, AutoMax is not fully insulated from data breaches and system disruptions and, accordingly, it has experienced and expects
to continue to experience actual or attempted cyberattacks of its IT networks. To the best of AutoMax&#8217;s knowledge, no cybersecurity
incidents were detected. Although no attempted cyberattacks has had a material adverse effect on its operations or financial condition
thus far, AutoMax cannot guarantee that any such incidents will not have a material adverse effect on AutoMax&#8217;s operations or financial
condition in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
such, its tools and servers are vulnerable to computer viruses, break-ins and similar disruptions from unauthorized tampering with the
AutoMax computer systems and tools located at its facility, at cloud services or at customer sites, or could be subject to system failures
or malfunctions for other reasons. Increased information technology security threats and more sophisticated computer crime pose a risk
to the security of AutoMax&#8217;s systems and networks and the confidentiality, availability and integrity of AutoMax&#8217;s data or
customer data. Cybersecurity attacks could also include attacks targeting the security, integrity and/or reliability of the hardware
and software installed in its products. System failures or malfunctioning could disrupt AutoMax&#8217;s operations and its ability to
timely and accurately process and report key components of its financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Environmental,
social and corporate governance, or ESG issues, including those related to climate change and sustainability, may have an adverse effect
on AutoMax&#8217;s business, financial condition and results of operations and damage AutoMax&#8217;s reputation.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Public
companies are facing increasing scrutiny related to ESG practices and disclosures from certain investors, capital providers, shareholder
advocacy groups, other market participants, and other stakeholder groups. For example, certain institutional and individual investors
have requested various ESG-related information and disclosures as they increasingly incorporate ESG criteria in making investment and
voting decisions. With this increased focus, public reporting regarding ESG practices is becoming more broadly expected. Such increased
scrutiny may result in increased costs, enhanced compliance or disclosure obligations, or other adverse impacts on AutoMax&#8217;s business,
financial condition or results of operations. If AutoMax&#8217;s ESG practices and reporting do not meet investor or other stakeholder
expectations, which continue to evolve, AutoMax may be subject to investor or regulator engagement regarding such matters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
March 2024, the SEC published climate disclosure rules, subject to which SciSparc, upon consummation of the Merger, would be required
to disclose certain climate-related information such as governance of climate-related risks and relevant risk management processes, among
other things. While the final rules have yet to be implemented and are subject to ongoing litigation, AutoMax cannot predict the ultimate
scope and impact these rules will have on AutoMax&#8217;s business. If the SEC&#8217;s climate disclosure rules are implemented, they
would likely result in additional legal, accounting and financial compliance and increased general and administrative expenses. Moreover,
this could result in increased management time and attention to ensure AutoMax are compliant with the regulations and expectations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in local or foreign tax laws, changing interpretations of existing tax laws, or adverse determinations by tax authorities could increase
AutoMax&#8217;s tax burden or otherwise adversely affect its results of operations, and financial condition. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
certain degree of judgment is required in evaluating its tax positions and determining its provision for income taxes. In the ordinary
course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. As AutoMax operates
in numerous taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by
tax authorities of these jurisdictions. It is not uncommon for tax authorities in different countries to have conflicting views. In addition,
tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. For example,
the work being carried out by the OECD on base erosion and profit shifting as a response to increasing globalization of trade could result
in changes in tax treaties or the introduction of new legislation that could impose an additional tax on businesses. As a result of changes
to laws or interpretations, AutoMax&#8217;s tax positions could be challenged, and its income tax expenses could increase in the future.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that its effective tax rate for the year ended December 31, 2023 will not change over time as a result <span style="background-color: white">of
changes in corporate income tax rates or other changes in the tax laws of the jurisdictions in which AutoMax operates. Any changes in
tax laws could have an adverse impact on its financial results. </span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
business is subject to a variety of local and international laws regarding privacy and data protection obligations. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
collects, uses, maintains and otherwise processes certain data about clients, suppliers, candidates and employees. AutoMax&#8217;s ability
to collect, use, maintain or otherwise process personal data has been, and could be further, restricted by existing and new laws and
regulations relating to privacy and data collection and protection, including the Israeli Privacy Protection Law, 5741-1981, or the Privacy
Law. AutoMax implements measures for the purpose of adapting the relevant aspects of its activity to the provisions applicable subject
to the Privacy Protection Law and the regulations enacted by virtue thereof, and for this purpose it contracted with a company that manages
its information security and privacy protection aspects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
may not be able to satisfy its debt obligations upon the occurrence of a change in control under its debt instruments or to obtain additional
financing based on existing debt. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax
intends to continue making investments to support its business growth and will likely require additional funds to respond to business
challenges and opportunities, including the need to purchase inventory of vehicles, improve AutoMax&#8217;s operating infrastructure
to support volume growth or acquire complementary businesses and technologies. Accordingly, AutoMax may need to engage in equity or debt
financing to secure additional funds if its existing sources of cash and any funds generated from operations do not provide it with sufficient
capital. If AutoMax raises additional funds through future issuances of equity or convertible debt securities, its existing stockholders
could suffer significant dilution, and any new equity securities AutoMax issues could have rights, preferences, and privileges superior
to those of holders of its other classes of shares. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Any
future debt financing that AutoMax may secure in the future could involve restrictive covenants relating to its capital raising activities
and other financial and operational matters, which may make it more difficult for AutoMax to obtain additional capital and to pursue
business opportunities, including potential acquisitions. AutoMax may not be able to obtain additional financing on terms favorable to
it, if at all. If AutoMax is unable to obtain adequate financing or financing on terms satisfactory to it when it requires it, AutoMax&#8217;s
ability to continue to support its business growth and to respond to business challenges and opportunities could be significantly impaired,
and its business may be adversely affected</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
collection, use, storage, disclosure, transfer and other processing of personal information, could give rise to significant costs, liabilities
and other risks, including as a result of investigations, inquiries, litigation, fines, legislative and regulatory action and negative
press about its privacy and data protection practices, which may harm AutoMax&#8217;s business, financial conditions, results of operations
and prospects.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax&#8217;s
operations are dependent on secure processing, transmission, storing on its computers and networks proprietary and confidential information.
AutoMax uses various third-party storage platforms which could make it more vulnerable to such cyberattacks. Furthermore, AutoMax relies
on digital technologies to process payments, both on its networks and third-party systems. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Privacy
laws are ever changing and continue to create new individual privacy rights, including regulations regarding the manner in which such
personal information should be handled. As part of its ongoing operations, AutoMax gathers certain personal information from customers,
vendors, manufactures and others. AutoMax has invested in implementing security controls and adapting its systems, amongst others, by
engaging Integrity Consulting and Risk Management (I.C.M.) Ltd., which manages information security and privacy protection within the
company. However, any misuse of such information or storing it inappropriately and not adequately protecting it could lead to inquiries,
litigation, fines, legislative and regulatory action against AutoMax. </span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
light of the stated, there is a certain dependence on the information security, backup and retrieval capabilities of those providers.
In this aspect, AutoMax has a system of backups, designed to create a recovery mechanism from a situation where one backup environment
cannot, for whatever reason, support the provision of services. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of Israeli law may make it easy for AutoMax&#8217;s shareholders to demand that AutoMax convenes a shareholders meeting, and/or allow
shareholders to convene a shareholder meeting without the consent of AutoMax&#8217;s management, which may disrupt AutoMax&#8217;s management&#8217;s
ability to run the company.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
law may allow any one or more of AutoMax&#8217;s shareholders holding, in the aggregate, at least 5% of <span style="background-color: white">AutoMax&#8217;s
</span>voting rights to demand that AutoMax convenes a special shareholders meeting. Also, in the event that AutoMax chooses not to convene
a special shareholders meeting pursuant to such a request, Sections 64-65 of the Companies Law provide, among others, that such shareholders
may independently convene a special shareholders meeting within three months (or under court&#8217;s ruling) and require AutoMax to cover
the costs, within reason, and as a result thereof, AutoMax&#8217;s directors might be required to repay such costs. If AutoMax&#8217;s
shareholders decide to exercise these rights in a way inconsistent with AutoMax&#8217;s management&#8217;s strategic plans, AutoMax&#8217;s
management&#8217;s ability to run the company may be disrupted, and this process may entail significant costs to AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may be difficult to enforce a judgment of a United States court against us and AutoMax&#8217;s officers and directors in Israel or the
United States, to assert United States securities laws claims in Israel or to serve process on AutoMax&#8217;s officers and directors
and these experts.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
is incorporated in Israel and the company&#8217;s corporate headquarters are located in Israel. All of AutoMax&#8217;s executive officers
and directors are located in Israel. All of AutoMax&#8217;s assets and most of the assets of these persons are located in Israel. Service
of process upon AutoMax or the non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against
AutoMax or the non-U.S. directors and executive officers may be difficult to obtain within the United States. AutoMax has been informed
by <span style="background-color: white">AutoMax&#8217;s</span> legal counsel in Israel that it may be difficult to assert claims under
U.S. securities laws in original actions instituted in Israel, or obtain a judgment based on the civil liability provisions of U.S. federal
securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against AutoMax or AutoMax&#8217;s
non-U.S. officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli
court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to
be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain
matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described
above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered
against AutoMax or AutoMax&#8217;s non-U.S. officers and directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of
judgments of Israeli courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of
the State of Israel, if it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that
was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a
court or tribunal in Israel at the time the foreign action was brought.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to the Combined Company</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The combined company&#8217;s success
depends on the experience and expertise of its management team and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is a pharmaceutical
company with limited experience outside of the drug development and healthcare industries, while AutoMax is engaged in the business of
importing and distributing vehicles. These are distinct and unrelated businesses requiring different operational expertise, industry
knowledge, and strategic approaches. Following the Merger, SciSparc will become the parent company of AutoMax, and the two companies
will operate as the combined company. AutoMax is anticipated to continue to operate its current business with its own board of directors
and management; however, the management team of the combined company will be the same as SciSparc&#8217;s existing management team, and
the combined company&#8217;s board of directors will have a minority representation from AutoMax&#8217;s management. Mr. Amitay Weiss,
who is the Chairman of both SciSparc and AutoMax, will be the Chairman of the combined company after the Merger and has experience in
both industries, which may help facilitate the oversight of AutoMax&#8217;s operations. While the combined company&#8217;s management
team has experience in the pharmaceutical industry, its experience in the automotive sector is limited and may present challenges in
effectively overseeing AutoMax&#8217;s operations following the Merger. Although AutoMax is expected to retain its current management
team, which possesses automotive experience, the combined company&#8217;s overall unfamiliarity with the automotive industry may impact
its ability to effectively oversee and support AutoMax&#8217;s operations, and achieve the full extent of the expected benefits of the
Merger. This, in turn, could adversely affect the financial performance and successful operations of the combined company.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company does not anticipate paying any cash dividends on the combined company&#8217;s ordinary shares in the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither
                                            SciSparc nor AutoMax have ever declared or paid cash dividends on their respective ordinary
                                            shares. In accordance with the Trust Deed, until the Series B Bonds are repaid in full, AutoMax
                                            will not distribute or pay any cash dividends. According to the terms of the Series B Bonds
                                            and the Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal
                                            annual installments, which will be paid annual as of February 28, 2023 until 2026, inclusive,
                                            such that the first payment that was made on February 28, 2023 constituted 10% of the aggregate
                                            principal amount of the Series B Bonds, the second payment, that was made on February 28,
                                            2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third
                                            payment, due on February 28, 2025, will constitute 30% of the aggregate principal amount
                                            of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will constitute
                                            45% of the aggregate principal amount of the Series B Bonds. Following the closing of the
                                            Merger, the Series B Bonds will remain outstanding and subject to repayment in accordance
                                            with the terms of the Trust Deed.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither SciSparc nor AutoMax
anticipate paying any cash dividends on the combined company&#8217;s ordinary shares in the foreseeable future. It is anticipated that
the combined company will retain all available funds and any future earnings to fund the development and growth of its business. As a
result, capital appreciation, if any, of the combined company&#8217;s ordinary shares will be the combined company&#8217;s shareholders&#8217;
sole source of gain for the foreseeable future.</p><div>
</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining
and improving the combined company&#8217;s financial controls and the requirements of being a public company may strain the combined
company&#8217;s resources, divert management&#8217;s attention and affect its ability to attract and retain qualified board members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, the combined company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and
Nasdaq rules. The requirements of these rules and regulations will increase the combined company&#8217;s legal and financial compliance
costs, make some activities more difficult, time-consuming or costly and place strain on its personnel, systems and resources. The Exchange
Act requires, among other things, that the combined company file annual, quarterly and current reports with respect to its business and
financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and
internal control over financial reporting. Ensuring that the combined company will have adequate internal financial and accounting controls
and procedures in place is a costly and time-consuming effort that needs to be re-evaluated frequently.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
and AutoMax do not expect that the combined company will have an internal audit group, and the combined company may need to hire additional
accounting and financial staff with appropriate public company experience and technical accounting knowledge. Implementing any appropriate
changes to the combined company&#8217;s internal controls may require specific compliance training for the combined company&#8217;s directors,
officers and employees, entail substantial costs, and take a significant period of time to complete. Such changes may not, however, be
effective in maintaining the adequacy of the combined company&#8217;s internal controls, and any failure to maintain that adequacy, or
consequent inability to produce accurate financial statements on a timely basis, could increase the combined company&#8217;s operating
costs and could materially impair its ability to operate its business. Moreover, effective internal controls are necessary for the combined
company to produce reliable financial reports and are important to help prevent fraud.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq rules, the combined company will be required to maintain a majority independent board of directors. The various
rules and regulations applicable to public companies make it more difficult and more expensive for the combined company to maintain directors&#8217;
and officers&#8217; liability insurance, and the combined company may be required to accept reduced coverage or incur substantially higher
costs to maintain coverage. If the combined company is unable to maintain adequate directors&#8217; and officers&#8217; insurance, its
ability to recruit and retain qualified officers and directors will be significantly curtailed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
and AutoMax expect that the rules and regulations applicable to public companies will result in the combined company incurring substantial
legal and financial compliance costs. These costs will decrease the combined company&#8217;s net income or increase its net loss and
may require it to reduce costs in other areas of its business.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities or industry analysts do not publish research or publish unfavorable research about the combined company&#8217;s business,
its share price and trading volume could decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for the combined company&#8217;s securities will depend in part on the research and reports that securities or industry
analysts publish about the combined company. The combined company may never obtain sufficient research coverage by securities and industry
analysts. If no sufficient securities or industry analysts commence coverage of the combined company, the trading price for the combined
company&#8217;s shares could be negatively impacted. If the combined company obtains sufficient securities or industry analyst coverage
and if one or more of the analysts who covers it downgrades the combined company&#8217;s shares or publishes inaccurate or unfavorable
research about the combined company&#8217;s business, its share price would likely decline. If one or more of these analysts ceases coverage
of the combined company or fails to publish reports regularly, demand for the combined company&#8217;s shares could decrease, which could
cause its share price and trading volume to decline.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could
have a material adverse effect on the combined company&#8217;s share price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC require an annual management assessment of the
effectiveness of its internal control over financial reporting. AutoMax maintains disclosure controls and procedures and internal control
over financial reporting pursuant to the Israeli Securities Law in its Annual and Interim Filings, and has complied with applicable Israeli
reporting requirements. To date, AutoMax has never conducted a review of internal controls over financial reporting for the purpose of
providing the reports required by the Sarbanes-Oxley Act. During review and testing, AutoMax may identify deficiencies and be unable
to remediate them on a timely basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the combined company fails to maintain the adequacy of its internal control over financial reporting as such standards are modified,
supplemented or amended from time to time, it may not be able to ensure that it can conclude on an ongoing basis that it has effective
internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and
regulations of the SEC. If the combined company cannot in the future favorably assess the effectiveness of its internal control over
financial reporting, investor confidence in the reliability of its financial reports may be adversely affected, which could have a material
adverse effect on the combined company&#8217;s share price.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of the combined company in the public market by its existing shareholders could cause its share price
to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of the combined company in the public market or the perception that these sales might occur, could
depress the market price of its securities and could impair its ability to raise capital through the sale of additional equity securities.
Neither SciSparc nor AutoMax is able to predict the effect that sales may have on the prevailing market price of the combined company&#8217;s
securities.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company&#8217;s securities could be delisted from Nasdaq if it does not comply with Nasdaq&#8217;s listing standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Nasdaq rules, consummation of the Merger requires the combined company to submit listing of additional securities application and,
at the time of the Merger, meet all of the criteria applicable to a company initially requesting listing. While SciSparc and AutoMax
intend to obtain listing status for the combined company and maintain the same, no guarantees can be made about the combined company&#8217;s
ability to do so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the combined company&#8217;s security is delisted by Nasdaq, its security may be eligible to trade on the OTC Bulletin Board or another
over-the-counter market. Any such alternative would likely result in it being more difficult for the combined company to raise additional
capital through the public or private sale of equity securities and for investors to dispose of or obtain accurate quotations as to the
market value of, the combined company&#8217;s securities. In addition, there can be no assurance that the combined company&#8217;s securities
would be eligible for trading on any such alternative exchange or markets.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales and issuances of the combined company&#8217;s ordinary shares or rights to purchase ordinary shares by it, including pursuant to
its equity incentive plans, could result in additional dilution of the percentage ownership of its shareholders and could cause its share
price to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company will not be generally restricted from issuing additional ordinary shares, including any securities that are convertible
into or exchangeable for, or that represent the right to receive, ordinary shares. The market price of the combined company&#8217;s ordinary
shares could decline as a result of sales of shares or securities that are convertible into or exchangeable for, or that represent the
right to receive, shares of the combined company or the perception that such sales could occur.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
and AutoMax expect that significant additional capital will be needed in the future to continue the combined company&#8217;s planned
operations and costs associated with operating as a public company. To the extent the combined company raises additional capital by issuing
equity or convertible securities, its existing shareholders may experience substantial dilution. The combined company may sell ordinary
shares, convertible securities or other equity securities in one or more transactions at prices and in a manner determined from time
to time by its board of directors. If the combined company sells ordinary shares, convertible securities or other equity securities in
more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to
its existing shareholders, and new investors could gain rights superior to its existing shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the combined company may grant or provide for the grant of rights to purchase shares of its ordinary shares pursuant to the
combined company&#8217;s equity incentive plans. Increases in the number of shares available for future grant or purchase pursuant to
the combined company&#8217;s equity incentive plans may result in additional dilution, which could cause the combined company&#8217;s
share price to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPARATIVE
                                            PER SHARE DATA</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the historical comparative share information for SciSparc and AutoMax on a stand-alone basis and pro forma combined per share information
after giving effect to the business combination.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The pro forma combined
value information reflects the Merger as if it had occurred on June 30, 2024, and is computed by multiplying the historical number of
AutoMax by the Exchange Ratio.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pro forma combined share
information below does not purport to represent what the actual results of operations or the earnings per share would been had the companies
been combined during the periods presented, nor to project the combined company&#8217;s results of operations or earnings per share for
any future date or period. The pro forma combined shareholders&#8217; equity per share information below does not purport to represent
what the value of SciSparc and AutoMax would have been had the companies been combined during the periods presented.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The unaudited pro forma
book value information reflects the Transactions as if they had occurred on June 30, 2024. The weighted average shares outstanding and
net earnings per share information reflect the Transactions as if they had occurred on January&#160;1, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">SciSparc<br/> (Historical)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">AutoMax<br/> (Historical)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro Forma Combined</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">As of and for the six months ended June 30, 2024 for SciSparc and AutoMax</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Book value per share&#160;<sup>(1)</sup></span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2.41</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.09</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2.53</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Weighted average outstanding shares (basic and diluted)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,166,282</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">103,691,969</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,126,251</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Weighted average loss per share (basic and diluted)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">1.70</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">0.00</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.16</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Note:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#8211; Book value per share is calculated using
    the formula: total shareholders&#8217; equity from the balance sheet as of June 30, 2024 divided by shares outstanding as of June
    30, 2024.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>COMPARATIVE PER SHARE
MARKET PRICE INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc ordinary shares
trade on Nasdaq under the symbol &#8220;SPRC&#8221; and AutoMax ordinary shares trade on the TASE under the symbol &#8220;AMX&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The table below sets forth
the closing price per SciSparc ordinary share on Nasdaq and per share of AutoMax ordinary shares on the TASE on April 10, 2024, the date
preceding public announcement of the Merger, and on February 7, 2025, the latest practicable date before the date of this prospectus,
and the equivalent price per share of AutoMax ordinary shares (as determined by multiplying the closing price per share of SciSparc ordinary
shares by the Exchange Ratio) on each such date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The table below shows
that the equivalent value of merger consideration per AutoMax ordinary share has decreased from $1.72 on April 10, 2024, to $0.496 on
February 7, 2025. This decrease is mainly due to the decrease in the share price of SciSparc during the same time frame.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The calculation of the
Merger consideration is based on the number of SciSparc outstanding shares and the number of AutoMax outstanding shares, as of April
10, 2024 and February 7, 2025. The amount of SciSparc outstanding shares is divided by (0.5001 multiplied by 0.4749) and then divided
by the amount of AutoMax outstanding shares as of each applicable date. The resulting number is then multiplied by AutoMax outstanding
shares. The resulting number is thereafter added to the number of AutoMax outstanding shares and divided by the same, to receive the
amount of SciSparc shares owed in return of one AutoMax share. Such amount is then multiplied by the share price of SciSparc on each
applicable date, to receive the value of Merger consideration per AutoMax share.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Date</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">SciSparc <br/> ordinary <br/> shares<br/>
    closing price per<br/> share<br/> (in $ amount)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">AutoMax<br/> ordinary shares<br/>
    closing price per<br/> share <br/> (in $<br/> amount)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Equivalent value of<br/> Merger
    consideration <br/> per<br/> AutoMax ordinary<br/> share<br/> (in $ amount)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="-keep: true">April 10, 2024</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1.680</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.0746</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1.72</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">February 7, 2025</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.496</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.408</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.54</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market prices of SciSparc
ordinary shares and AutoMax ordinary shares have fluctuated since the date of the announcement of the Merger Agreement and will continue
to fluctuate from the date of this prospectus to the date of the SciSparc general meeting and the AutoMax general meeting, and the date
the Merger is completed and thereafter. See &#8220;Risk Factors - Because the Exchange Ratio is fixed and will not be adjusted in the
event of any change in either SciSparc&#8217;s share price or AutoMax&#8217;s share price, AutoMax shareholders cannot be certain of
the precise value of the consideration that they may receive in the Merger&#8221;. We encourage you to obtain current quotes for the
SciSparc ordinary shares and AutoMax ordinary shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_005"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING
STATEMENTS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus and the documents incorporated by reference into this proxy statement/prospectus contain forward-looking statements.
These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could
cause actual results to differ materially from expectations. These forward-looking statements should not be relied upon as predictions
of future events as SciSparc cannot assure you that the events or circumstances reflected in these statements will be achieved or will
occur. You can identify forward-looking statements by the use of forward-looking terminology including &#8220;believes,&#8221; &#8220;expects,&#8221;
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro
forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of
these words and phrases or comparable terminology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, forward-looking
statements include any statements of the plans, strategies and objectives of management for future operations, including the execution
of integration and restructuring plans and the anticipated timing of filings; any statements concerning proposed new products, services
or developments; any statements regarding future economic conditions or performance; any statements regarding the impact of the Israel-Hamas
war on its business or financial condition; statements of belief and any statement of assumptions underlying any of the foregoing. Forward
looking statements may also include any statements of the plans, strategies and objectives of management with respect to the approval
and consummation of the Merger, SciSparc&#8217;s ability to solicit a sufficient number of proxies to approve the Merger and other matters
related to the consummation of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements include, but are not limited to, statements concerning the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">likelihood
                                            of the satisfaction of certain conditions to the completion of the Merger and whether and
                                            when the Merger will be consummated;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            expected benefits of and potential value created by the proposed Merger for the shareholders
                                            of SciSparc and AutoMax;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Exchange Ratio and relative ownership percentages of the SciSparc and AutoMax shareholders
                                            of the combined company;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
                                            ability to control and correctly estimate its operating expenses and its expenses associated
                                            with the Merger;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">any
                                            statements of the plans, strategies and objectives of management for future operations, including
                                            the execution of integration plans and the anticipated timing of filings</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements concerning the ability to protect and enhance the combined company&#8217;s products,
                                            product candidates and intellectual property;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements concerning proposed new products, services or developments;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements concerning the attraction and retention of highly qualified personnel;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements regarding expectations concerning AutoMax&#8217;s relationships and actions with
                                            third parties;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
                                            regulatory, judicial and legislative changes in AutoMax&#8217;s industry;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements regarding future economic conditions or performance;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements regarding the impact of the Israel-Hamas war, including indirect effects such
                                            as the Houthi attacks in the Rea Sea and the Turkish Embargo, on AutoMax&#8217;s business
                                            or financial condition;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
                                            ability to achieve and maintain effective internal control over financial reporting in accordance
                                            with Section 404 of the Sarbanes-Oxley Act; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements
                                            of belief and any statement of assumptions underlying any of the foregoing.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a discussion of the factors that may cause SciSparc, AutoMax or the combined company&#8217;s actual results, performance or achievements
to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, or
for a discussion of risk associated with the ability of SciSparc and AutoMax to complete the Merger and the effect of the Merger on the
business of SciSparc, AutoMax and the combined company, see &#8220;<i>Risk Factors</i>&#8221; beginning on page 11.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in
reports filed with the SEC by SciSparc. See &#8220;<i>Where You Can Find More Information</i>&#8221; beginning on page 240.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
any of these risks or uncertainties materializes or any of these assumptions proves incorrect, the results of SciSparc, AutoMax or the
combined company could differ materially from the forward-looking statements. All forward-looking statements in this proxy statement/prospectus
are current only as of the date on which the statements were made. SciSparc and AutoMax do not undertake any obligation to publicly update
any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence
of unanticipated events.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="m_006"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">THE
SPECIAL MEETING OF SCISPARC SHAREHOLDERS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date, Time and Place</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Special Meeting of SciSparc
shareholders will be held on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, commencing at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
local time, at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Any such change will be announced in a Report
of Foreign Private Issuer on Form 6-K furnished to the SEC. SciSparc is sending this proxy statement/prospectus to its shareholders in
connection with the solicitation of proxies by the SciSparc board of directors for use at the Special Meeting and any adjournments or
postponements of the Special Meeting. This proxy statement/prospectus is first being furnished to shareholders of SciSparc on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Purposes of the Special Meeting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purposes of the Special
Meeting are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. To approve the consummation
of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and
the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. To approve the form of
Indemnification Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, effective upon
the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with all office holders
of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed to the board of
directors of SciSparc; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">3. Subject to and contingent
upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President
contingent upon the approval and closing of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. Subject to and contingent
upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the
effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">5. To approve a reverse
share split of SciSparc&#8217;s issued and outstanding ordinary shares in the range of a ratio of up to 1:100, to be effected at the
discretion of, at such number of increments, and on such dates, as may be determined by the SciSparc board of directors within 18 months
from the Special Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We know of no other matters
to be submitted at the Special Meeting other than as specified herein. If any other business is properly brought before the Special Meeting,
the persons named as proxies may vote in respect thereof in accordance with their best judgment.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recommendation of the SciSparc Board of
Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The SciSparc board of directors
                                            has determined and believes that the consummation of the Merger pursuant to the Merger Agreement
                                            and the issuance of SciSparc ordinary shares and pre-funded warrants at the effective time
                                            of the Merger, as contemplated by the Merger Agreement, is in the best interests of SciSparc
                                            and its shareholders and has approved such items. The SciSparc board of directors recommends
                                            that SciSparc shareholders vote &#8220;<b>FOR</b>&#8221; Proposal No. 1 to approve the consummation
                                            of the Merger, pursuant to the Merger Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The SciSparc board of directors
                                            has determined and believes that it is advisable to, and in the best interests of, SciSparc
                                            and its shareholders to approve and adopt the form of Indemnification Agreement for directors
                                            and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, effective
                                            upon the effective time of the Merger, and to authorize the execution and delivery of such
                                            Indemnification Agreement with office holders of SciSparc to be in office immediately following
                                            the effective time of the Merger; The SciSparc board of office holders recommends that SciSparc
                                            shareholders vote <b>&#8220;FOR&#8221;</b> Proposal No. 2 to approve and adopt SciSparc&#8217;s
                                            Indemnification Agreement effective upon the effective time of the Merger.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 48px"/><td style="width: 24px"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">The SciSparc board of directors has
                                            determined and believes that it is advisable to, and in the best interests of, SciSparc and
                                            its shareholders to approve, subject to and contingent upon the approval of Proposal No.
                                            1, a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President;
                                            The SciSparc board of directors recommends that SciSparc shareholders vote <b>&#8220;FOR&#8221;
                                            </b>Proposal No. 3 to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer,
                                            Chairman and President, contingent upon the approval and closing of the Merger.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The SciSparc board of directors has determined and believes that it is advisable to, and in the best interests of, SciSparc and its shareholders to approve, subject to and contingent upon the approval of Proposal No. 1, the election each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The SciSparc board of directors has determined and believes that
    it is advisable to, and in the best interests of, SciSparc and its shareholders to approve a reverse share split of SciSparc&#8217;s
    issued and outstanding ordinary shares in the range of a ratio of up to 1:100. The SciSparc board of directors recommends that SciSparc
    shareholders vote <b>&#8220;FOR&#8221;</b> Proposal No. 5 to approve the Reverse Split.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Record Date and Voting Power</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only holders of record of
SciSparc ordinary shares at the close of business on the record date,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, 2025, are entitled to notice of, and to vote at, the Special Meeting. At the close of business on the record date, SciSparc ordinary
shares were issued and outstanding. Each SciSparc ordinary share that you own entitles the holder thereof to one vote on each matter
submitted for shareholder approval. See the section entitled &#8220;Principal Shareholders of SciSparc&#8221; in this proxy statement/prospectus
for information regarding persons known to the management of SciSparc to be the beneficial owners of more than 5% of the outstanding
SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Voting and Revocation of Proxies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proxy accompanying this
proxy statement/prospectus is solicited on behalf of the board of directors of SciSparc for use at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a shareholder
of record of SciSparc as of the record date referred to above, you may vote in person at the Special Meeting or vote by proxy using the
enclosed proxy card. Whether or not you plan to attend the Special Meeting, SciSparc urges you to vote by proxy to ensure your vote is
counted. You may still attend the Special Meeting and vote in person if you have already voted by proxy. As a shareholder of record:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">to vote in person, come to
                                            the Special Meeting and SciSparc will give you a ballot when you arrive.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">To vote by internet, go to
                                            &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">to vote using the proxy card,
                                            simply mark, sign and date your proxy card and return it promptly in the postage-paid envelope
                                            provided. If you return your signed proxy card to SciSparc before the Special Meeting, SciSparc
                                            will vote your shares as you direct.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">to vote by telephone, call
                                            the toll-free telephone number&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                                            .</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If your SciSparc ordinary
shares are held by your broker as your nominee, that is, in &#8220;street name,&#8221; the enclosed voting instruction card is sent by
the institution that holds your shares. Please follow the instructions included on that proxy card regarding how to instruct your broker
to vote your SciSparc ordinary shares. If you do not give instructions to your broker, your broker can vote your SciSparc ordinary shares
with respect to &#8220;discretionary&#8221; items but not with respect to &#8220;non-discretionary&#8221; items. Proposals Nos. 1, 2,
3, 4, and 5 are non-discretionary matters. As a result, banks, brokers and other nominees will not have discretion to vote on Proposals
Nos. 1, 2, 3, 4, and 5.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">All properly executed proxies that are not revoked will be voted at
the Special Meeting and at any adjournments or postponements of the Special Meeting in accordance with the instructions contained in the
proxy. If a holder of SciSparc ordinary shares executes and returns a proxy and does not specify otherwise, the shares represented by
that proxy will be voted &#8220;FOR&#8221; Proposal No. 1 to approve the consummation of the Merger and the other transactions contemplated
by the Merger Agreement, including the issuance of SciSparc ordinary shares at the effective time of the Merger to the shareholders of
AutoMax, as contemplated by the Merger Agreement; &#8220;FOR&#8221; Proposal No. 2 to approve the form of Indemnification Agreement for
directors and officers of SciSparc, attached as Annex C; &#8220;FOR&#8221; Proposal No. 3, subject to and contingent upon the approval
of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President; &#8220;FOR&#8221;
Proposal No. 4, subject to and contingent upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on
the SciSparc board of directors upon the effective time of the Merger and to ratify the class structure of the SciSparc board of directors;
and &#8220;FOR&#8221; Proposal No.5 to approve the Reverse Split.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc shareholders of
record may change their vote at any time before their proxy is voted at the Special Meeting in one of three ways. First, a shareholder
of record of SciSparc can send a written notice to the Chief Executive Officer of SciSparc stating that it would like to revoke its proxy.
Second, a shareholder of record of SciSparc can submit new proxy instructions either on a new proxy card or via telephone or the Internet.
Third, a shareholder of record of SciSparc can attend the Special Meeting and vote in person. Attendance alone will not revoke a proxy.
If an owner of SciSparc ordinary shares in &#8220;street name&#8221; has instructed a broker to vote its SciSparc ordinary shares, the
shareholder must follow directions received from its broker to change those instructions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Required Vote</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The presence of two shareholders
who are present in person or by proxy, and who hold or represent at least fifteen percent (15%) of the voting rights in the Company,&#160;is
necessary to constitute a quorum at the Special Meeting. Abstentions and broker non-votes will be counted towards a quorum. If half an
hour has elapsed from the time set for the Special Meeting and a quorum is not present, the Special Meeting will be adjourned to the
following day, at the same time and place, or to a different date, as shall be determined by the board of directors in a notice to the
shareholders. If a quorum is not present at the adjourned Special Meeting, as stated above, a minimum of one shareholder, whether present
in person or by proxy, shall be deemed as constituting a quorum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Approval of Proposals
Nos. 1,4, and 5, requires the affirmative vote of a simple majority of shareholders present (in person or by proxy) and voting (not including
abstentions). The approval of each of Proposals Nos. 2 and 3 requires the affirmative vote of a simple majority of votes properly cast
(not counting &#8220;abstentions&#8221; or &#8220;broker non-votes&#8221; as votes cast) plus either (i) a simple majority of shares
voted at the Special Meeting, excluding the shares of controlling shareholders, if any, and of shareholders who have a personal interest
in the approval of the resolution, or (ii) the total number of shares of non-controlling shareholders and of shareholders who do not
have a personal interest in the resolution voting against approval of the resolution does not exceed two percent of the outstanding voting
power in SciSparc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Votes will be counted by
SciSparc, that will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221; votes, abstentions and broker non-votes. Abstentions
and broker non-votes will have no effect and will not be counted towards the vote total but will be used to determine whether a quorum
is present at the Special Meeting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Solicitation of Proxies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc will bear the cost
of soliciting proxies. In addition to these proxy materials, SciSparc&#8217;s directors and employees may also solicit proxies in person,
by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting
proxies. SciSparc and AutoMax may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to
beneficial owners.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement/prospectus, the SciSparc board of directors does not know of any business to be presented at the Special Meeting other than
as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Special
Meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment
of the persons voting the proxies.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_007"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">THE
MERGER</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This section and the section
entitled &#8220;The Merger Agreement&#8221; in this proxy statement/prospectus describe the material aspects of the Merger, including
the Merger Agreement. Although SciSparc and AutoMax believe that this description covers the material terms of the Merger and the Merger
Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus
for a more complete understanding of the Merger and the Merger Agreement, including the Merger Agreement attached as Annex A, the form
of Voting and AutoMax Shareholder Support Agreement attached as Annex B, and the Indemnification Agreement attached as Annex C and the
other documents to which you are referred herein. See the section entitled &#8220;Where You Can Find More Information&#8221; in this
proxy statement/prospectus.</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax, entered
into the Merger Agreement, pursuant to which Merger Sub will merge with and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary
of SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Merger Consideration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, ordinary shares of SciSparc, as well as pre-funded warrants exercisable into ordinary shares of SciSparc will be issued to
the AutoMax shareholders. The Exchange Ratio has been determined pursuant to a formula described in more detail in the Merger Agreement
and elsewhere in this proxy statement/prospectus. Under the Exchange Ratio, immediately following the Merger, AutoMax&#8217;s shareholders
(and its Advisor in connection with the Merger) are expected to own approximately 49.99% of SciSparc&#8217;s share capital, on a fully-diluted
basis, subject to certain exceptions, and as further defined in the Merger Agreement, and SciSparc&#8217;s shareholders are expected
to own approximately 50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of AutoMax Warrants, Options and
Series B Bonds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a result of the Merger, each AutoMax warrant, option and certain convertible rights that had resulted from a prior AutoMax transaction
(in each case, whether or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled
immediately prior to the effective time for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">According
to the terms of AutoMax&#8217;s Series B Bonds and the Trust Deed, the Series B Bonds will be due for principal repayment in four (4)
unequal annual installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that
was made on February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made
on February 28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, due on February 28,
2025, will constitute 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February
28, 2026, will constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger the Series
B Bonds will remain outstanding and subject to repayment in accordance with the terms of the Trust Deed. The Series B Bonds bear interest
at a rate of 5.9% per annum. As of February 7, 2025, NIS 34,245 thousand (approximately $9,110 thousand) in principal amount of Series
B Bonds remains outstanding and will therefore become a liability of the combined company following the completion of the Merger. The
next payment by AutoMax to Series B bondholders is due on February 28, 2025, in the principal amount of NIS 13,698 thousand (approximately
$3,644 thousand) and NIS 996 thousand (approximately $265 thousand) of interest accrued thereon.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Background of the Merger</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The merging companies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white"><b><i>SciSparc</i></b>.
SciSparc is a specialty clinical-stage pharmaceutical company. SciSparc&#8217;s focus is creating and enhancing a portfolio of technologies
and assets based on cannabinoid therapies. With this focus, SciSparc is currently engaged in developing and testing pharmaceutical compositions
comprised of N-acylethanolamines and cannabinoids such as Palmitoylethanolamide, or PEA, and/or &#916;9-tetrahydrocannabinol, or THC,
and/or non-psychoactive cannabidiol, or CBD, and/or other cannabinoid receptor agonists, from which SciSparc has derived three main proprietary
combinations: SCI-110 for the treatment of Tourette syndrome and Alzheimer&#8217;s disease and agitation; SCI-160 for the treatment of
pain; and SCI-210 for the treatment of Autism Spectrum Disorder, or ASD, and Status Epilepticus, or SE. SciSparc holds a 50.86% controlling
stake in its subsidiary, SciSparc Nutraceuticals Inc., which focuses on the sale of hemp-based products on Amazon Marketplace.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc was incorporated
under the laws of the State of Israel on August 23, 2004. SciSparc&#8217;s ordinary shares are listed on the Nasdaq Capital Market under
the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>AutoMax</i></b>. AutoMax
is a company in the field of importing and marketing a variety of vehicles for personal use (including trade-in), this includes an array
of vehicle sizes such as: small; family sized; crossover, sedans, SUVs, as well as luxury vehicles and buses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initially AutoMax, under
its then corporate name Matomi Media Group Ltd., and its subsidiaries provided a variety of programmatic data-driven platforms, which
focused on two main activities of domain monetization and mobile digital advertising. These services were mainly for U.S. and Europe
based advertising agencies, app developers and domain owners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2018, AutoMax
completed a public offering of series A convertible loans, in the aggregate amount of NIS 103 million (approximately $24.5 million).
Beginning in the second half of 2017 through December 2019, AutoMax sold all its activities related to digital marketing. On January
8, 2020, following a unanimous approval of the bondholders, AutoMax repaid the full debt, approximately NIS 101 million (approximately
$27.9 million).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 9, 2020, AutoMax
entered into a share exchange agreement with Global AutoMax and its Advisor, or the Share Exchange Agreement. Upon the closing, on March
24, 2021, AutoMax issued to the shareholders of Global AutoMax 120,279,312 ordinary shares representing, upon issuance, approximately
52.53% of the issued and outstanding shares of AutoMax, with additional issuances subject to fulfilling certain milestones, as detailed
in the Share Exchange Agreement. In exchange, the Global AutoMax shareholders transferred all their shares to AutoMax. Upon successful
completion of such milestones, the total holdings of the Global AutoMax shareholders in AutoMax would consist of 73% of the issued and
outstanding shares of AutoMax on a fully-diluted basis. Following the closing of the Share Exchange Agreement, Global AutoMax became
a wholly owned subsidiary of AutoMax. In addition, some of the key officers in Global AutoMax, who were appointed as officers in AutoMax,
were issued options to purchase up to 11,851,420 ordinary shares of AutoMax (adjusted to reflect the 5 to 1 reverse share split), subject
to the terms of the company employee share incentive plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On June 19,
2022, AutoMax entered into a joint venture agreement, or the Agreement, with Dalhom Motors Ltd., or Dalhom, pursuant to which, AutoMax
and Dalhom formed a jointly-owned subsidiary, Dalhom AutoMax, a special purpose company established for the purpose of importing and
marketing of Temsa Skoda Sabanc&#305; Ula&#351;&#305;m Ara&#231;lar&#305; A.&#350;,, or Temsa, buses in Israel. In addition,
prior to the closing, Dalhom AutoMax entered into a franchise agreement with Temsa for a period of three years, pursuant to which Dalhom
AutoMax will serve as a direct importer of Temsa buses in Israel. Furthermore, Dalhom AutoMax entered into a service and warranty agreement
for a term of three years, pursuant to which it will provide maintenance and warranty services for Temsa buses, as agreed upon in the
agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0.5in; text-align: justify"><span style="font-weight: normal">On
March 13, 2023, Dalhom AutoMax entered into a direct import agreement with Al Damani New Motor Vehicles Trading LLC, a United Arab Emirates
manufacturer, to import, distribute, sale and market fully electric Al Damani vehicles in Israel. Dalhom AutoMax&#8217;s obligations
under such direct importer agreement are conditional on receiving the required regulatory approvals from the Ministry of Transportation
for the import of vehicles manufacturer by Al Damani to Israel, which have not yet been granted as of the date of this proxy statement/prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><span style="font-weight: normal">Since
the closing of the merger with Global AutoMax, AutoMax has engaged in importing and marketing a variety of private vehicles in Israel
(including trade-in). AutoMax has a parallel importer&#8217;s license for 27 vehicle brands and a variety of models, as defined under
Section 42 of the Services Licensing for Professions in the Automotive Industry Law 5776-2016. As of the date of this prospectus, AutoMax
holds eight sales branches in Acre, Haifa, Afula, Netanya, Ra&#8217;anana, Rishon Lezion, Ashdod, and Jerusalem. It additionally operates
a storage system and a system for preparing vehicles for sale. AutoMax has an international network of suppliers, mainly located in Europe
and North America, that supply the company with vehicles of different brands and models, tailored to order. AutoMax further has an import
system that consists of procurement, transportation and handling the procedure for releasing vehicles from customs, as well as vehicle
storage facilities in Israel.	</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0.5in; text-align: justify">AutoMax is authorized
by the Ministry of Transportation, to perform licensing inspections for the purpose of the initial registration of vehicles imported
by it. Additionally, AutoMax has been authorized by the Ministry of Transportation to import spare parts and to carry out various forms
of installations that involve changing the vehicle structure (such as installing towing hooks).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">AutoMax was formed
under the laws of the state of Israel in February 2006, as a private company, under the name Cubeeffect Ltd. In November 2009, Cubeeffect
Ltd. changed its name to Adsmarket G.M. Ltd, and in July 2011 changed to Matomy Media Group Ltd. On April 18, 2021, the company changed
its name to AutoMax Motors Ltd. AutoMax&#8217;s ordinary shares were initially listed on the London Stock Exchange in July 2014 and in
February 2016 on the TASE. From November 2020 onwards, AutoMax ordinary shares have been traded solely on TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>SciSparc&#8217;s Historical Background of the Merger </i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors and
senior management of SciSparc regularly review SciSparc&#8217;s operations, financial performance and industry conditions as they may
affect SciSparc&#8217;s strategic goals and plans, both near and long term, and consider and evaluate options for enhancing shareholder
value as an independent company (including reviewing options for raising funds) and alternatives for business combination transactions
to enhance shareholder value. As such, on June 9, 2022, following SciSparc&#8217;s board of directors meeting on May 25, 2022, SciSparc
first announced that its board of directors resolved to initiate a&#160;process to review potential strategic transactions with the goal
of maximizing shareholder value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following chronology
sets forth a summary of the material events leading up to the execution of the Merger Agreement. This chronology does not purport to
catalogue every conversation of or among the SciSparc board of directors, its committees, its representatives or other parties.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 14, 2022, as part of its efforts to expand and increase its potential market, SciSparc entered into the Wellution Acquisition
Agreement with M.R.M., and the other parties named therein, to acquire from M.R.M. its rights to purchase, the Wellution&#8482; brand,
or the Brand. In connection therewith, SciSparc incorporated a new wholly owned subsidiary,&#160;SciSparc Nutraceuticals, to hold the
new assets of the Brand. The Brand sells hemp-based products, on Amazon Marketplace. In accordance with the closing of the Wellution
Acquisition Agreement for the Brand which took place on September 30, 2022, SciSparc paid $4.59 million for the Brand and issued to M.R.M.
$15 million worth of warrants to purchase up to an aggregate amount of 82,418 of SciSparc&#8217;s ordinary shares, or the M.R.M. Warrants.
On March 26, 2024, M.R.M. agreed with us to waive all its rights under the M.R.M. Warrants and have the M.R.M. warrants cancelled for
no consideration. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 23, 2023, SciSparc&#8217;s
board of directors held a meeting in which they discussed the possibility of a corporate restructuring plan, or the Restructuring Initiative,
which would include the following steps: (i) the sale of approximately 50% of the shares held by SciSparc in SciSparc Nutraceuticals,
its then wholly owned subsidiary, to Jeffs&#8217; Brands Ltd., or Jeffs&#8217; Brands, as part of a secondary sale; (ii) the transfer
of the pharmaceutical activities and remaining stake in SciSparc Nutraceuticals, to a new wholly-owned subsidiary, which would potentially
merge with a NewCo or a Canadian-traded shell company; and (iii) the usage of the proceeds from the potential secondary sale to Jeffs&#8217;
Brands and the proceeds from future capital raises for an investment in purchasing a controlling interest in a profitable target company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On January 25, 2023, SciSparc
announced that its board of directors resolved to pursue the Restructuring Plan, the second step of the Restructuring Initiative, which
involves transferring its pharmaceutical activities to a NewCo. SciSparc also announced that it intends to explore other potential new
opportunities, activities and investments in a variety of sectors. Other than the Merger and the entry into the Spin-off LOI and the
amendments thereof, SciSparc has thus far not initiated further steps relating to the Restructuring Plan.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On
February 23, 2023, SciSparc entered into a stock purchase agreement, as amended on March 22, 2023, with Jeffs&#8217; Brands Holdings Inc.,
a wholly owned subsidiary of Jeffs&#8217; Brands, and Jeffs&#8217; Brands, pursuant to which Jeffs&#8217; Brands Holdings Inc. acquired
from SciSparc 57 shares of common stock of SciSparc Nutraceuticals Inc., which owns Wellution<sup>TM</sup>, subject to the holdback by
SciSparc of 11 shares, representing approximately 49% of the issued and outstanding shares of common stock of SciSparc Nutraceuticals
Inc., for approximately $3.0 million in cash, of which approximately $2.5 million was paid at the closing. Following the closing of the
Wellution Sale Agreement on March 28, 2023, SciSparc completed the first step of the Restructuring Initiative. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the third step
of the Restructuring Initiative, on February 23, 2023, SciSparc&#8217;s board of directors held a meeting in which Mr.&#160;Yaki Baranes,
a business analyst, presented a market overview on the motor vehicle market in Israel, including market trends on private vehicles and
public transportation segments, and market status of electric vehicles. The market overview data was taken from various market research
reports publicly available. At the meeting, Mr.&#160;Baranes also presented a company overview of AutoMax (and solely AutoMax) as a vehicle
importer in Israel, which was solely based on available public information, and information received from AutoMax. The company overview
included AutoMax&#8217;s strategy in various sectors, including parallel import of personal-use vehicles, buses, and electric vehicles
as published by AutoMax. The market overview also included AutoMax&#8217;s competition in Israel, which includes direct and parallel
vehicle importers. SciSparc&#8217;s board of directors had the opportunity to ask Mr. Baranes questions regarding the data presented
on the automative industry and about AutoMax. The market and company overview presentation was intended to inform SciSparc&#8217;s board
of directors on the presented subjects, and did not include any recommendations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 30, 2023, SciSparc
announced that, as part of its Restructuring Initiative, it had appointed Mr. Baranes to be its VP Strategy and Business Development,
with a view to structuring business strategies and facilitating the identifying of new business opportunities. Mr. Baranes previously
provided services to AutoMax, which included market overviews of companies AutoMax was interested in collaborating with and the preparation
of investor presentations. Other than Mr. Baranes and Mr. Weiss both serving as members of the board of Charging Robotics Inc. and Mr.
Baranes providing a market overview services to certain other companies Mr. Amitay Weiss serves as a director of, there is no other connection
between Mr. Baranes and Mr. Weiss. AutoMax was first introduced to SciSparc by AutoMax&#8217;s Advisor after the board of directors announced
its Restructuring Initiative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 22, 2023, SciSparc&#8217;s
board of directors held a meeting in which it approved an investment in the aggregate amount of NIS 4 million (approximately $1.1 million)
in AutoMax. Mr. Weiss recused himself from the decision and did not participate in the discussion or voting on the matter, due to his
personal interest by virtue of serving as the Chairman of the board of directors of both SciSparc and AutoMax. The board of directors&#8217;
approval of the investment was following the recommendation of the audit committee, according to the Companies Law, due to Mr. Weiss&#8217;
personal interest in the matter. The audit committee convened on June 22, 2023, prior to the meeting of the board of directors. At its
meeting, at which AutoMax&#8217;s Advisor participated by invitation, the audit committee was presented with the terms and conditions
of the investment in AutoMax. The audit committee considered and reviewed the terms and conditions of the investment and believed that
it would be a good investment opportunity for SciSparc and a way to commence relations with AutoMax gradually. Accordingly, the audit
committee resolved that the investment in AutoMax of NIS 4 million is not deemed to be an &#8220;Extraordinary Transaction&#8221; under
the Companies Law and that it is the best interest of the SciSparc to enter into the transaction, thus recommending that the board of
directors approve. SciSparc entered into a joinder to an investment agreement with AutoMax on June 25, 2023, for an amount of NIS 2.5
million (approximately $692,000).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between the months of June
and November 2023, Tomer Levy, VP Business Development and Headquarters of AutoMax, met with Oz Adler, Chief Executive Officer and Chief
Financial Officer of SciSparc to negotiate and discuss a potential transaction structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 30, 2023, Mr. Adler
shared with Mr. Levy an initial draft letter of intent. The draft set forth the structure of the proposed transaction, which included
a reverse triangular merger between a newly incorporated subsidiary of SciSparc and AutoMax, with AutoMax as the surviving company and
a wholly owned subsidiary of SciSparc. As a result of this proposed merger, the outstanding share capital of AutoMax would be converted
into the right to receive SciSparc Ordinary Shares, subject to a 9.99% ownership blocker (in which case, pre-funded warrants would be
issued in lieu), according to an exchange ratio to be determined in the definitive agreements. The ownership percentage of the pre-merger
AutoMax shareholders&#8217; and SciSparc shareholders&#8217; holdings in SciSparc post-merger were not determined in this draft. The
draft further set forth that the board of directors of SciSparc post-merger would consist of the current composition of SciSparc&#8217;s
board of directors in addition to two members designated by AutoMax. In addition to the proposed merger, the draft letter of intent also
discussed the potential spin off of SciSparc&#8217;s pharmaceutical assets to a separate legal entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 27, 2023, SciSparc&#8217;s
board of directors held a discussion with respect to the merger opportunity with AutoMax and was presented with the updated draft letter
of intent, which was received from AutoMax. This draft provided for, in addition to the previous draft, the transfer of a to be determined
amount to AutoMax upon the closing of the proposed merger and for the composition of the board of directors of SciSparc post-merger to
be agreed later in the definitive agreements. Prior to the board&#8217;s discussion and review of the letter of intent and proposed transaction,
they were informed of Mr. Weiss&#8217; personal interest in the matter, due to his service as the chairman of the board of directors
of both SciSparc and AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax continued
to negotiate the terms of the proposed transaction and on October 20, 2023, SciSparc&#8217;s counsel provided AutoMax&#8217;s counsel
with a revised draft letter of intent. The revised letter of intent provided that following the closing of the proposed merger and the
contemplated closing of a concurrent financing round, AutoMax&#8217;s pre-merger shareholders will hold approximately 80% of SciSparc&#8217;s
share capital. The revised letter of intent also included a milestone payment to AutoMax&#8217;s pre-merger shareholders of an additional
7% of SciSparc&#8217;s share capital as of immediately following the proposed merger, in the event that AutoMax secures a direct import
license pursuant to which it sells at least 100 vehicles prior to a certain end date to be determined. This draft of letter of intent
determined the amount of cash for SciSparc to transfer to AutoMax at the closing, to be $3 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties continued to
negotiate the offer terms with regards to the milestone payment, with AutoMax requesting that the milestone payment be in the form of
pre-funded warrants to be issued upon the closing and exercisable in the event of the achievement of the milestone within 36 months from
the closing date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 25, 2023, SciSparc&#8217;s
counsel shared an updated draft of the letter of intent, with the end date for the achievement of the milestone to be 36 months from
the closing date, to be paid in the form of ordinary shares upon such event. The parties continued to share drafts of the letter of intent,
including negotiations regarding certain non-material terms of the proposed merger, including certain tax implications and the treatment
of existing options and warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 31, 2023, the
SciSparc board of directors held a meeting to discuss the latest terms of the letter of intent. All of the then serving members of the
SciSparc board of directors were present at this meeting. The board of directors discussed the interests of SciSparc and its shareholders
in the proposed merger. The board of directors believed that the proposed merger would create the most value for SciSparc&#8217;s shareholders,
enable SciSparc to expand its activity in non-pharmaceutical spaces, and provide cash-flow positive operations to SciSparc in order to,
among other things, fund SciSparc&#8217;s pharmaceutical operations, and that SciSparc&#8217;s current cash position was sufficient to
execute the proposed merger. Therefore, the board of directors approved the execution of the letter of intent. The approval of the board
of directors followed the approval and recommendation of the audit committee, in accordance with the Companies Law, due to the personal
interest of Mr. Weiss. Mr. Weiss did not participate in the discussion or voting on the matter at the meetings of the audit committee
and the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the letter of
intent presented to the board of directors included: (i) a reverse triangular merger between a newly incorporated subsidiary of SciSparc
and AutoMax, with AutoMax as the surviving company and a wholly owned subsidiary of SciSparc; (ii) the conversion of the outstanding
share capital of AutoMax into the right to receive SciSparc Ordinary Shares (subject to a 9.99% ownership blocker) (iii) the equity split
of SciSparc post-merger to be 80% for AutoMax&#8217;s current shareholders and 20% for SciSparc&#8217;s current shareholders; (iv) a
milestone payment to AutoMax&#8217;s pre-merger shareholders of an additional 7% of SciSparc&#8217;s share capital as of immediately
following the proposed merger in the event that AutoMax secures a direct import license pursuant to which it sells at least 100 vehicles
within 36 months from the closing; (v) a cash transfer of $3 million by SciSparc to AutoMax at the closing of the merger; (vi) a contemplated
closing of a concurrent financing with the merger (which terms were not discussed in the letter of intent); (vii) a contemplated transfer
of SciSparc&#8217;s pharmaceutical activities, to a separate legal entity with the possible distribution of the legal entity&#8217;s
shares as a dividend in kind to SciSparc&#8217;s shareholders; and (viii) that the board of directors of the combined company post-merger
would be determined in the definitive agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 10, 2023, SciSparc&#8217;s
legal counsel distributed an initial draft of the Merger Agreement to AutoMax and its counsel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2023, SciSparc
signed the non-binding letter of intent with AutoMax, substantially as presented to the board of directors on October 31, 2023 and issued
a press release on a no-name basis announcing the event.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 7, 2023, following
comments received from AutoMax&#8217;s legal counsel and negotiations between Mr. Oz Adler and Mr. Tomer Levy, SciSparc&#8217;s legal
counsel distributed a revised draft of the Merger Agreement to AutoMax&#8217;s legal counsel. This draft, among other things, deleted
references to a separate capital raise by SciSparc concurrent with the closing of the Merger and deleted references to a transfer of
SciSparc&#8217;s pharmaceutical activities to a separate legal entity. The draft also removed the provisions relating to milestone payments
and changed the formula of the Exchange Ratio to such ratio that would result in AutoMax&#8217;s shareholders (other than SciSparc, who
currently holds shares in AutoMax) and its Advisor to own approximately 49.99% of SciSparc&#8217;s share capital as of immediately following
the Merger. On December 7, 2023, SciSparc issued a press release announcing these updated negotiated terms of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 28, 2023, SciSparc&#8217;s
board and audit committee held discussions in relation to the AutoMax Merger and a potential financing by SciSparc to AutoMax. At the
meeting of the audit committee, which was held prior to the meeting of the board of directors, the committee discussed the approval of
the Bridge Loan with AutoMax. Mr. Weiss, who participated at the meeting by invitation, recused himself from the discussions and voting
on the matter. Mr. Adler explained that the amounts provided by SciSparc under the Bridge Loan would be set-off against the financing
amount the Company is to provide AutoMax pursuant to the terms of the Merger Agreement, upon the closing of the Merger. The audit committee
considered the reasons for assuming the Bridge Loan and believed that the Bridge Loan would provide working capital to AutoMax to continue
its business and increase its share value, hence increasing the value to SciSparc shareholders from the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 16, 2024, SciSparc&#8217;s
audit committee and board of directors convened to discuss the negotiated terms of the Bridge Loan. Due to the personal interest of Mr.
Weiss in the matter, and according to the Companies Law, the audit committee examined the transaction contemplated under the Bridge Loan
and determined to classify the transaction as &#8220;Extraordinary Transaction&#8221; under the Companies Law. Accordingly, the audit
committee determined that it is in the best interest of SciSparc to assume the Bridge Loan, and thereafter approved and recommended to
the board of directors to approve the assumption and performance by SciSparc of the Bridge Loan. SciSparc&#8217;s board of directors
convened subsequently thereafter to discuss the matter and approved the Bridge Loan following the recommendation of the audit committee.
Mr. Weiss recused himself from the discussion and voting on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On January 19, 2024, SciSparc
entered into the Bridge Loan with AutoMax in the aggregate amount of $1.4 million, with an interest rate of 7% per annum (or 9% per annum
if the Acquisition, as defined in the Bridge Loan, is not consummated prior to the repayment date), compounded annually. The Bridge Loan
was amended on June 9, 2024, in which SciSparc made available to AutoMax an additional loan in the amount of $1.0 million under similar
terms. The Second Amendment was entered into on September 5, 2024, in which SciSparc extended an additional loan in the amount of $1.85
million to AutoMax under similar terms as those of the Bridge Loan. The amendments to the Bridge Loan were duly approved on June 9, 2024
and on September 4, 2024, by the audit committee and board of directors of SciSparc, respectively. Mr. Weiss did not participate in the
voting or discussions on the matter. In the month of September 2024, SciSparc provided AutoMax with the loan amounts due under the Second
Amendment to the Bridge Loan, and offset any interest due until November 30, 2024 from the principal amount, such that on the closing
date of the Merger, SciSparc will be due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated), of the
Loan Amount, from the period starting December 1, 2024 and ending on the effective date of the Merger. In consideration for the Loan
Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax
Direct Import in favor of SciSparc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between December 7, 2023
and March 26, 2024, SciSparc&#8217;s legal counsel and AutoMax&#8217;s legal counsel continued to exchange drafts of the Merger Agreement.
In the exchanged drafts, the parties discussed, among other issues, the following: (i) the procedure for the tax withholding ruling;
(ii) whether the issuance of pre-funded warrants would be required (due to the question if any AutoMax shareholder will hold more than
9.99% of SciSparc&#8217;s share capital immediately following the Merger); (iii) the procedure of the distribution of SciSparc ordinary
shares to AutoMax shareholders; (iv) the scope of the representations to be provided by each company; (v) the composition of the board
of directors of the combined company; and (vi) the amount of cash to be transferred by SciSparc to AutoMax at the closing of the Merger
(which would be $4,250,000, less any amount due by the Company due to the Parent Company under the Bridge Loan).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 28, 2024, and March
31, 2024, during SciSparc&#8217;s audit committee and board of directors meetings, AutoMax&#8217;s VP Business Development and Headquarters,
presented AutoMax&#8217;s business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On March 31, 2024, SciSparc&#8217;s board of directors held a meeting
in which the Company&#8217;s legal counsel, a representative of E.D.B., and representatives of the management, were present. At the meeting,
SciSparc&#8217;s counsel presented a detailed summary of the key provisions of the transaction documents and reviewed the fiduciary duties
of directors in connection with the proposed transaction. At this meeting, a representative of E.D.B. discussed their valuation report
of AutoMax, and then delivered to SciSparc&#8217;s board of directors its valuation report. The SciSparc board of directors engaged E.D.B.
to provide the valuation report in order to ascertain the value of AutoMax and in order to evaluate the financial feasibility of the transaction.
The valuation report, and the value ascribed to AutoMax by E.D.B. revealed that the terms of the transaction contemplated under the Merger
Agreement were favorable to SciSparc at the time of the March 31, 2024 meeting, based on the per-share consideration if the Merger was
consummated on such date. If the Merger had been consummated at the time of presentation of the E.D.B valuation report, then SciSparc
would have paid approximately $4.37 million in SciSparc Ordinary Shares, for a company valued $44.8 million, based on the Exchange Ratio,
with 2,468,876 SciSparc shares outstanding, 105,643,744 AutoMax shares outstanding, and SciSparc&#8217;s share price of $1.77, as of March
31, 2024. The valuation report was primarily used as a data point, as part of the legal, financial and business due diligence, to evaluate
whether the Merger was favorable to SciSparc&#8217;s shareholders. After such discussion, the board of directors unanimously determined
that it was advisable and fair to, and in the best interests of SciSparc and SciSparc&#8217;s shareholders, for SciSparc to enter into
the Merger Agreement, and, accordingly, the board of directors approved the Merger Agreement and the transactions contemplated thereby.
The approval of the board of directors followed the approval and recommendation of the audit committee, in accordance with the Companies
Law, due to the personal interest of Mr. Weiss. Mr. Weiss did not participate in the discussion or voting on the matter at the meetings
of the audit committee and the board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>AutoMax&#8217;s historical
background for the Merger	</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the course of 2023,
AutoMax&#8217;s management assessed several potential funding and transactional opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax and SciSparc signed
a confidential disclosure agreement in November 2023, and various representatives of each party&#8217;s management, financial, legal
and scientific teams were given access to the other party&#8217;s data room in the following days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 30, 2023, SciSparc
sent AutoMax a draft of a non-binding letter of intent. AutoMax provided detailed, written comments to the draft on September 13, 2023,
and several weeks of negotiations ensued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 19 and October
23, 2023, the AutoMax&#8217;s board convened, and AutoMax&#8217;s VP Business Development and Headquarters provided an overview of the
letter of intent as sent to SciSparc and as negotiated with SciSparc. The AutoMax board considered the proposed terms, and a consensus
emerged among the board members in favor of the proposed non-binding letter of intent with SciSparc. Consequently, the board resolved
to approve the letter of intent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax
executed the non-binding letter of intent on November 21, 2023. On November 10, 2023, SciSparc provided an initial draft of the Merger
Agreement to AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In parallel to the negotiation
of the merger agreement, each of the parties conducted financial and legal due diligence. Moreover, throughout December 2023 to April
2024, each of SciSparc&#8217;s and AutoMax&#8217;s management and other employees, as well as external advisors, conducted due diligence
on the other party through access to confidential data rooms, phone calls, review of legal, financial and other diligence materials,
diligence inquiries and follow-ups and assessments of the competitive landscape.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2024, AutoMax&#8217;s
board held a meeting in which the company&#8217;s legal counsel, Lipa Meir &amp; Co., Advocated, or Lipa Meir, was present. At the meeting,
Tomer Levy, AutoMax&#8217;s VP Business Development and Headquarters and director, and Lipa Meir presented a detailed summary of the
key provisions of the transaction documents and reviewed the fiduciary duties of directors in connection with the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax conducted
final negotiations on remaining outstanding issues over the course of March and early April, 2024, including the disclosure schedule,
the AutoMax Shareholder Support Agreement and other ancillary agreements to which shareholders are a party, and the various agreements
were substantially finalized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2024, AutoMax&#8217;s
audit committee and board of directors held meetings in which the company&#8217;s legal counsel was present. At the meeting, Tomer Levy,
AutoMax&#8217;s VP Business Development and Headquarters and director, and Lipa Meir, presented a detailed summary of the key provisions
of the transaction documents, and Ziv Haft Certified Public Accountants, an Israeli partnership, is a member of BDO International Limited,
or BDO Consulting, AutoMax&#8217;s financial advisors presented a financial analysis of SciSparc. After a comprehensive discussion, AutoMax&#8217;s
audit committee and board of directors unanimously resolved entering into the Merger Agreement, and authorized and empowered Yaarah Alfi,
AutoMax&#8217;s Chief Financial Officer, and Tomer Levy, VP Business Development and Headquarters and director, to execute and deliver
all transaction documents of behalf of AutoMax. The Merger Agreement was subsequently executed on April 10, 2024.</p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>SciSparc&#8217;s reasons for the Merger</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SciSparc board of directors
considered the following factors, among others, in reaching its conclusion to approve and adopt the Merger Agreement, the Merger, the
issuance of SciSparc ordinary shares in the Merger and the other transactions contemplated thereby and to recommend that the SciSparc
shareholders approve the Merger Agreement, the Merger, the issuance of SciSparc ordinary shares in the Merger and the other transactions
contemplated by the Merger Agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">As part of its reorganization
                                            strategy, the SciSparc board of directors and its advisors and valuator have undertaken a
                                            process of reviewing and analyzing potential Merger transaction candidates to identify the
                                            opportunity that would, in the SciSparc board of directors&#8217; opinion, create the most
                                            value for SciSparc&#8217;s shareholders, enable SciSparc to expand its activity in non-pharma
                                            spaces, and provide cash-flow positive operations to SciSparc in order to, among other things,
                                            fund SciSparc&#8217;s pharma operations. SciSparc believes that expanding its activities
                                            outside of the pharmaceutical world will provide maximum shareholder value. Following the
                                            Merger, SciSparc will continue to search for ways to maximize shareholder value, both within
                                            and outside of the pharmaceutical sector. SciSparc may opt to sell certain pharmaceutical
                                            assets, or participate in a spin-off, which may include its advanced clinical stage pharmaceutical
                                            portfolio and its equity stake in SciSparc Nutraceuticals Inc.</td></tr></table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The SciSparc board of directors
                                            believes that, as a result of arm&#8217;s length negotiations with AutoMax, SciSparc and
                                            its representatives negotiated the most favorable exchange ratio for SciSparc that AutoMax
                                            was willing to agree to, and that the terms of the Merger Agreement include the most favorable
                                            terms to SciSparc in the aggregate to which AutoMax was willing to agree.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The SciSparc board of directors
                                            believes, after a thorough review of strategic alternatives and discussions with SciSparc&#8217;s
                                            senior management, financial advisor and legal counsel, that the Merger is more favorable
                                            to the shareholders of SciSparc than the potential value that might have resulted from other
                                            strategic options that may have been available to SciSparc, including remaining a standalone
                                            public company.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The SciSparc board of directors
                                            believes, based in part on its financial, legal and commercial diligence and analysis of
                                            AutoMax&#8217;s operations, the potential market opportunity for its importation and leasing
                                            services, which was conducted over several weeks by SciSparc&#8217;s management and external
                                            consultants, and reviewed with the SciSparc board of directors, that AutoMax&#8217;s operations
                                            represent a sizeable potential market opportunity, and may thereby create value for the shareholders
                                            of the combined company and an opportunity for SciSparc&#8217;s shareholders to participate
                                            in the potential growth of the combined company. Following the Merger, each entity will continue
                                            its respective operations, with SciSparc as the parent company and AutoMax a wholly owned
                                            subsidiary.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The SciSparc board of directors&#8217;
                                            consideration of the fact that while in the short term its market capitalization had responded
                                            favorably to positive announcements, SciSparc was not able to maintain this positive market
                                            capitalization in the long term.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The SciSparc board of directors
                                            concluded that the Merger would provide the existing SciSparc shareholders a significant
                                            opportunity to participate in the potential growth of the combined company following the
                                            Merger given the potential ability of AutoMax to monetize its operations and contemplated
                                            strategies more quickly.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The SciSparc board of directors
                                            also considered that the combined company will be led by an experienced senior management
                                            team, including Daniel Levy, AutoMax&#8217;s chief executive officer and Tomer Levy, VP Business
                                            Development and Headquarters of AutoMax, both of whom will remain in their respective current
                                            positions.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The
                                            SciSparc board of directors considered the valuation report prepared by an independent valuator
                                            whose valuation report was delivered to the SciSparc board of directors (in its capacity
                                            as such) by a representative of E.D.B. on March 31, 2024, and based on AutoMax&#8217;s management&#8217;s
                                            estimates and assumptions as provided to E.D.B., as more fully described below in the section
                                            entitled &#8220;&#8212;<i>Valuation Report of E.D.B. Consulting and Investments Ltd.</i>&#8221;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SciSparc board of directors
also reviewed the recent financial condition, results of operations and financial condition of SciSparc, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the risks associated with
                                            continuing to operate SciSparc on a stand-alone basis, including liquidity needs and cash-burn
                                            relating to, among other things, funding SciSparc&#8217;s contemplated clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the consequences of current
                                            market conditions, what SciSparc believes is a low valuation of its share price, compared
                                            to its deemed peer group, continuing net operating losses, and the likelihood that the resulting
                                            circumstances for SciSparc, on a stand-alone basis, would not change for the benefit of the
                                            SciSparc shareholders in the foreseeable future;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s management&#8217;s
                                            belief that it would be difficult to obtain sufficient equity or debt financing on acceptable
                                            terms, if at all;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the results of substantial
                                            efforts made over a significant period of time by SciSparc&#8217;s senior management and
                                            financial advisor to solicit strategic alternatives for SciSparc to the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the projected liquidation
                                            value of SciSparc and the risks, costs and timing associated with liquidating compared to
                                            the value SciSparc shareholders will receive in the Merger; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s board of
                                            directors believes that the combined entity will have a more favorable positioning and positive
                                            listing on The Nasdaq Capital Market than SciSparc as a standalone company.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SciSparc board of directors
also reviewed the terms of the Merger and associated transactions, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Exchange
    Ratio, which establishes the ratio of SciSparc ordinary shares and pre-funded warrants to be issued to AutoMax shareholders in the
    Merger, and sets forth, the relative percentage ownership of SciSparc shareholders and AutoMax shareholders immediately following
    the completion of the Merger is similarly fixed;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the limited number and nature
                                            of the conditions to AutoMax&#8217;s obligation to consummate the Merger and the limited
                                            risk of non-satisfaction of such conditions as well as the likelihood that the Merger will
                                            be consummated on a timely basis;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the respective rights of,
                                            and limitations on, SciSparc and AutoMax under the Merger Agreement to consider certain unsolicited
                                            acquisition proposals under certain circumstances should SciSparc or AutoMax receive a superior
                                            offer;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the AutoMax Shareholder Support
                                            Agreement, pursuant to which officers, directors and certain shareholders of AutoMax agreed,
                                            solely in their capacity as shareholders, to vote shares of their AutoMax capital stock covering
                                            approximately 55.65% of the outstanding shares of AutoMax in favor of adoption of the Merger
                                            Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the fact that AutoMax would
                                            file a request for court approval for the Merger under sections 250 and 351 of the Companies
                                            Law; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the belief that the terms
                                            of the Merger Agreement, including the parties&#8217; representations, warranties and covenants,
                                            and the conditions to their respective obligations, are reasonable under the circumstances.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the course of its deliberations,
the SciSparc board of directors also considered a variety of risks and other countervailing factors related to entering into the Merger,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the substantial expenses to
                                            be incurred in connection with the Merger, including the costs associated with any related
                                            litigation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the possible volatility, at
                                            least in the short term, of the trading price of the SciSparc ordinary shares resulting from
                                            the Merger announcement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the risk that the Merger might
                                            not be consummated in a timely manner or at all and the potential adverse effect of the public
                                            announcement of the Merger or on the delay or failure to complete the Merger on the reputation
                                            of SciSparc;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the risk to SciSparc&#8217;s
                                            business, operations and financial results in the event that the Merger is not consummated,
                                            including the diminution of SciSparc&#8217;s cash and its likely inability to raise additional
                                            capital through the public or private sale of equity securities, in addition to the possibility
                                            that SciSparc would become a creditor of AutoMax due to the bridge loan;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the strategic direction of
                                            the continuing company following the completion of the Merger, which will be determined by
                                            a board of directors, which may be materially influenced by members designated by AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the failure to successfully
                                            manage the separate business and operations of each of AutoMax and SciSparc could disrupt
                                            SciSparc&#8217;s current business activities, including the risk of entering markets in which
                                            SciSparc has no prior experience. Even if the Merger is successfully completed, SciSparc
                                            cannot assure that it will be able to run the operations of AutoMax without encountering
                                            difficulty regarding different business strategies, corporate cultures and business sectors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">the
                                            possibility of SciSparc requiring a substantial additional funding following the consummation
                                            of the Merger to fund the continuing company, which may not be available on acceptable terms,
                                            or at all, and the risks associated with failure to obtain necessary capital;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Weiss&#8217;
    dual role as both the Chairman of SciSparc&#8217;s board of directors, and as the chairman of AutoMax&#8217;s board of directors,
    and whether his interests in the Merger may differ from, or extend beyond, the interests of SciSparc&#8217;s shareholders generally.
    The audit committee and the board of directors of SciSparc were aware of this potential conflict of interest and considered it, among
    other matters, in reaching its decision to approve the Merger Agreement and the Merger; and</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">various other risks associated
                                            with the combined company and the Merger, including those described in the section entitled
                                            &#8220;Risk Factors&#8221; in this proxy statement/prospectus.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing information
and factors considered by the SciSparc board of directors are not intended to be exhaustive but are believed to include all of the material
factors considered by SciSparc board of directors. In view of the wide variety of factors considered in connection with its evaluation
of the Merger and the complexity of these matters, the SciSparc board of directors did not find it useful, and did not attempt, to quantify,
rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of SciSparc&#8217;s
board may have given different weight to different factors. SciSparc&#8217;s board conducted an overall analysis of the factors described
above, including thorough discussions with, and questioning of, the SciSparc management team and the legal and financial advisors of
SciSparc, and considered the factors overall to be favorable to, and to support, its determination.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AutoMax&#8217;s reasons for the Merger</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In approving and authorizing
AutoMax&#8217;s entry into the Merger Agreement and consummation of the Merger, AutoMax&#8217;s board of directors considered a number
of factors and alternatives. In reaching its decision, AutoMax&#8217;s board of directors consulted with AutoMax&#8217;s management with
respect to strategic and operational matters and with AutoMax&#8217;s legal counsel with respect to the Merger Agreement and the transactions
contemplated thereby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among the factors considered
by the AutoMax board of directors in its decision to approve the Merger Agreement were the following potential benefits of the Merger:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">AutoMax was evaluating manners
                                            in which it could improve its financial situation and considered multiple avenues including
                                            strengthening its equity through capital raising, examining debt raising, and more;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">as
                                            part of the Merger Agreement, SciSparc will invest in AutoMax a total of $4.25 million, of
                                            which an aggregate amount of $4.25 million was already advanced to AutoMax as a loan. The
                                            agreement as amended on June 9, 2024, and on September 5, 2024, states that the principal
                                            amount of the Bridge Loan will bear interest at a rate of 7% per annum (or 9% per annum if
                                            the Acquisition is not consummated prior to the repayment date), compounded annually. This
                                            loan was made as an advancement of the Closing Financing agreed upon in the Merger Agreement,
                                            to enable AutoMax to have sufficient cashflow to further develop its operations;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the investment will improve
                                            AutoMax&#8217;s financial situation and help it continue the process of changing the variety
                                            of vehicles its imports and sells in Israel, which could improve its profitability;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">consideration for the Merger,
                                            which was determined in the negotiations between the parties, was examined by AutoMax&#8217;s
                                            audit committee and board of directors. In the opinion of the members of the audit committee
                                            and the board of directors, it is fair, reasonable, in accordance with market conditions,
                                            and represents a fair price for AutoMax&#8217;s shareholders for their shares after considering,
                                            among other things, their familiarity with AutoMax&#8217;s business, financial situation,
                                            market situation, the feasibility and chances of completing the merger and the timetables.
                                            SciSparc&#8217;s position, based on a financial analysis of SciSparc&#8217;s financial condition
                                            was conducted by an external consultant and presented to the audit committee and the board
                                            of directors, as well as the findings of a due diligence carried out by Lipa Meir and BDO
                                            Consulting, AutoMax&#8217;s external legal advisors, all of which was considered by AutoMax&#8217;s
                                            audit committee and board of directors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the average daily trading
                                            volume in SciSparc stock is greater than the average daily trading volume of AutoMax&#8217;s
                                            shares; therefore the combined entity would have a higher trading volume;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">considering the financial
                                            situation of AutoMax and SciSparc, as well as their obligations pursuant to the merger agreement,
                                            AutoMax has no reasonable concern that it would not be able to reimburse the Bridge Loan
                                            when it becomes due;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the consideration received
                                            in SciSparc shares, pursuant to the Merger Agreement, will enable AutoMax&#8217;s shareholders
                                            to participate in a potential increase in the value of SciSparc&#8217;s securities as a result
                                            of, among other things, the potential long-term growth opportunities, or a sale or spin-off
                                            of SciSparc&#8217;s existing activities; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the fact that the Merger will
                                            result in AutoMax Shareholders, in exchange for their AutoMax shares, receiving shares in
                                            SciSparc, a U.S. publicly traded company, which would provide AutoMax&#8217;s shareholders
                                            with the opportunity to obtain liquidity for their shares in relation to the liquidity for
                                            their shares when trading on the TASE.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of the AutoMax
board of directors also identified and considered the following material uncertainties and risks:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the risk that the potential
                                            benefits of the Merger might not be realized;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the risk of diverting AutoMax&#8217;s
                                            management&#8217;s attention from other strategic priorities to be implemented post-closing
                                            due to administrative matters related to managing any unexpected SciSparc liabilities that
                                            may arise;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the risk that the Merger may
                                            not be consummated, and that a more limited range of alternative strategic transactions would
                                            be available to AutoMax in that event;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">the
                                            substantial expenses to be incurred in connection with the Merger and the related administrative
                                            challenges associated with combining the companies; and</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Amitay
    Weiss&#8217; dual role as both the chairman of AutoMax&#8217;s board of directors, and as the Chairman of SciSparc&#8217;s board
    of directors, and the required approvals under the Companies Law for the approval of the Merger Agreement. The audit committee and
    the board of directors of AutoMax were aware of this potential conflict of interest and considered it, among other matters, in reaching
    its decision to approve the Merger Agreement and the Merger.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The AutoMax board of directors
weighed the benefits and opportunities that arise from the potential transaction against the negative factors described above and concluded
that the potential benefits significantly outweighed the potential risks of completing the merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After taking into account
these and other factors, the AutoMax board of directors approved entry into the Merger Agreement and authorized consummation of the transactions
contemplated thereby, including the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Valuation Report of E.D.B.
Consulting and Investments Ltd.</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2024, SciSparc
engaged an independent valuator to render a written valuation report, or the valuation report, to the board of directors as to the valuation,
from a financial point of view, of AutoMax. SciSparc selected E.D.B. because E.D.B. is an experienced independent valuator, with prior
knowledge of AutoMax. In exchange for the services provided, SciSparc paid E.D.B. an amount of NIS 46,800 including VAT (approximately
$12,935) as a flat rate fee, which was not contingent on the signing or closing of the Merger Agreement and the Merger, respectively.
E.D.B. has not rendered any other services to SciSparc, prior to March 4, 2024. E.D.B. was not paid by AutoMax for providing its valuation
report nor was it engaged by AutoMax in the past to provide services. E.D.B. was retained by Matomy Media Group Ltd. in the past to provide
valuation services on AutoMax, in connection with the merger between Matomy Media Group Ltd. and Global AutoMax in March 2021. In November
2024, E.D.B. was retained by SciSparc to perform a Purchase Price Allocation analysis on AutoMax in connection with the Merger, for which
SciSparc paid E.D.B. NIS 14,040 including VAT (approximately $3,900).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the presentation
of the valuation report, a representative of E.D.B. attended (via conference call) the meeting of the board of directors held on March
31, 2024, at which the board of directors evaluated the proposed Merger. At this meeting, a representative of E.D.B. reviewed the financial
aspects of AutoMax and rendered the valuation report, as of such date and subject to the procedures followed, assumptions made, matters
considered, and qualifications and limitations on the review undertaken by E.D.B. as set forth in its valuation report, as to the valuation
of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The full text of the English
translation (from the Hebrew) of the valuation report of E.D.B. dated January 4, 2024, which sets forth, among other things, the assumptions
made, matters considered and limits on the valuation undertaken, is attached as Annex E to this joint proxy statement/prospectus and
is incorporated herein by reference. The summary of the valuation report of E.D.B. set forth in this proxy statement is qualified in
its entirety by reference to the full text of such valuation report. SciSparc&#8217;s shareholders are urged to read the valuation report
in its entirety. The valuation report was for the information of, and was directed to, the SciSparc board of directors (in its capacity
as such) in connection with its consideration of the financial terms of the Merger. The valuation report addressed the valuation, from
a financial point of view, of AutoMax. It did not address the underlying business decision of the board of directors to engage in the
Merger or enter into the Merger Agreement. It did not constitute a recommendation to the board of directors in connection with the Merger
or a recommendation to any holder of ordinary shares as to how to vote or act in connection with the Merger or any other matter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following is a summary
of the valuation performed by E.D.B. Some of the summaries of the valuation performed by E.D.B. include information presented in tabular
format. In order to understand the valuation performed by E.D.B. more fully, you should read the tables together with the text of each
summary. The tables alone do not constitute a complete description of E.D.B.&#8217;s valuation, including the methodologies and assumptions
underlying the valuation, and if viewed in isolation could create a misleading or incomplete view of the valuation performed by E.D.B.
The data presented and the corresponding imputed ranges of values for AutoMax should be considered as a whole and in the context of the
full narrative description of the valuation set forth in the following pages, including the assumptions, and Projections (as defined
below) underlying these analyses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Except as otherwise noted,
the information utilized by E.D.B. in its valuation, to the extent that it was based on market data, is based on market data as it existed
on or before January 4, 2024 and is not necessarily indicative of current market conditions. The valuation described below does not purport
to be indicative of actual future results, or to reflect the prices at which any securities may trade in the public markets, which may
vary depending upon various factors, including changes in interest rates, dividend rates, market conditions, economic conditions and
other factors that influence the price of securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the valuation
report, E.D.B. reviewed, analyzed and relied upon information and material bearing upon the financial and operating condition of AutoMax,
including, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">AutoMax&#8217;s public information;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">(i) audited financial statements
                                            of AutoMax for fiscal years ended December 31, 2022 and 2021, and (ii) unaudited financial
                                            statements of AutoMax for the six month period ended June 30, 2023;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">financial
                                            forecasts, budget, and estimates relating to AutoMax prepared by the management of AutoMax,
                                            or the Projections;</span></p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">discussions with the senior
                                            management and advisors of AutoMax with respect to the business and prospects of AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">visitation to AutoMax&#8217;s
                                            main branch in Jerusalem;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">certain publicly available
                                            financial data for companies that E.D.B. deemed relevant in evaluating AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">other public information concerning
                                            AutoMax; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">other information and other
                                            factors as E.D.B. deemed appropriate.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In rendering the valuation
report, E.D.B. relied upon and assumed, without independent verification or investigation, the accuracy and completeness of all of the
financial and other information provided to or discussed with E.D.B. by AutoMax and its employees, representatives and affiliates or
otherwise reviewed by E.D.B. with respect to the Projections, E.D.B. assumed without independent verification or investigation, that
those forecasts and estimates were reasonably prepared on bases reflecting the best available information, estimates and judgments of
AutoMax&#8217;s management as to AutoMax&#8217;s future financial condition and operating results. E.D.B. did not receive any instructions
or limitations by AutoMax&#8217;s management or any affiliate of AutoMax with respect to the preparation of the valuation report. E.D.B.
also assumed that there were no material changes in the assets, liabilities, financial conditions, results of operations, business or
prospects of AutoMax since the date of the last financial statements of AutoMax that were made available to E.D.B. E.D.B. neither made
nor obtained any independent evaluations or appraisals of the assets or liabilities, contingent or otherwise, of AutoMax. For purposes
of its valuation report, E.D.B. valued AutoMax, without further verification, at $44.8 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>AutoMax
Projections</i></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Projections furnished
to E.D.B. were prepared by the management of AutoMax, which were discussed with, and approved for E.D.B.&#8217;s use by AutoMax in connection
with the valuation report. AutoMax and SciSparc do not publicly disclose internal management projections of the type provided to E.D.B.
in connection with E.D.B.&#8217;s valuation report, and such projections were not prepared with a view toward public disclosure. The
Projections were based on numerous variables and assumptions that are inherently uncertain and may be beyond the control of the managements
of AutoMax and SciSparc, including, without limitation, factors related to general economic and competitive conditions and prevailing
interest rates. Accordingly, actual results could vary significantly from those set forth in the Projections.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax does not, as a
matter of course, publicly disclose forecasts or projections as to future performance, earnings or other results due to the inherent
unpredictability of projections and their underlying assumptions and estimates. However, in connection with the discussions regarding
the proposed Merger, AutoMax supplied E.D.B. and SciSparc with certain unaudited business and financial information that was not publicly
available. AutoMax&#8217;s management provided E.D.B. with certain financial forecasts for AutoMax for the calendar years 2022 through
2028. The Projections were provided to E.D.B., for its use and reliance on in its valuation report. The Projections were prepared without
giving effect to the Merger, including the impact of negotiating or executing the Merger, the expenses that may be incurred in connection
with consummating the Merger, the impact on the combined company as a result of the Merger and the effect of any business or strategic
action that would be taken as a result of the Merger Agreement having been executed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Projections were not
prepared with a view toward public disclosure and, accordingly, do not necessarily comply with published guidelines of the SEC, or the
guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of financial forecasts
or GAAP, but, in the view of AutoMax&#8217;s management, were prepared on a reasonable basis, reflected the best available estimates
and judgments at the time of preparation and presented as of the time of preparation, to the best of AutoMax&#8217;s management&#8217;s
knowledge and belief.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Neither SciSparc&#8217;s
independent registered public accounting firm, Ernst &amp; Young Global, nor AutoMax&#8217;s independent registered public accounting
firm, Ben David Shalvi Kop &amp; Co., audited, reviewed, compiled or performed any procedures with respect to the Projections or expressed
any opinion or any form of assurance related thereto. Accordingly, neither Ernst &amp; Young Global nor Ben David Shalvi Kop &amp; Co.,
express any opinion or any form of assurance related thereto. An English translation of the summary of the Projections is included in
this proxy statement/prospectus solely to give SciSparc&#8217;s shareholders access to certain financial forecasts that were made available
to the SciSparc&#8217;s board of directors, and E.D.B., and is not being included in this proxy statement/prospectus to influence any
SciSparc shareholder&#8217;s decision whether to vote for the Merger-related proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Projections, while
presented with numerical specificity, necessarily were based on numerous variables and assumptions that are inherently uncertain and
many of which are beyond the control of AutoMax&#8217;s management. Because the Projections cover multiple years, by their nature, they
also become subject to greater uncertainty with each successive year. Please consider carefully the discussion entitled &#8220;Forward-Looking
Statements&#8221; beginning on page 85. There can be no assurance that the Projections will be realized, and actual results may vary
materially from those shown.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The inclusion of the Projections
in this proxy statement/prospectus should not be regarded as an indication that AutoMax, nor SciSparc, nor any of its respective affiliates,
advisors, officers, directors or representatives considered or considers the Projections to be predictive of actual future events, and
such Projections should not be relied upon as such. Neither AutoMax nor SciSparc, nor any of their respective affiliates, advisors, officers,
directors or representatives has made or makes any representation to any of SciSparc shareholders or any other person regarding the ultimate
performance of AutoMax or SciSparc compared to the information contained in the Projections or can give any assurance that actual results
will not differ materially from the Projections, and none of them undertakes any obligation to update or otherwise revise or reconcile
any of the Projections. Neither SciSparc nor AutoMax intends to make publicly available any update or other revision to the Projections
or any of the other forecasts described herein, except as otherwise required by law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Certain of the forecasted
financial information set forth herein may be considered non-GAAP financial measures. Non-GAAP financial measures should not be considered
in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures as
used by AutoMax may not be comparable to similarly titled amounts used by other companies. No reconciliation of non-GAAP financial measures
in the Projections to GAAP measures was created or used in connection with preparing such forecasts or relied upon by E.D.B. for purposes
of its valuation report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In light of the foregoing
factors and the uncertainties inherent in the Projections and the other forecasts described herein, SciSparc&#8217;s shareholders are
cautioned not to place undue, if any, reliance on such Projections.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. received from AutoMax
the Projections which were prepared by its management in October 2023, in order to perform the valuation report. The statements below
are taken from the Projections and reflect AutoMax&#8217;s management&#8217;s beliefs as of October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Projections were divided
into six chapters. The first chapter of the Projections describes AutoMax&#8217;s business and its subsidiaries. It stated that Global
AutoMax imports thousands of vehicles annually, with an operational turnover of NIS 400-450 million, which it sells through 12 sales
branches nationwide. Global AutoMax owns facilities for vehicle storage and warehouses, as well as a licensing and preparation facility
for vehicle sales. Additionally, Global AutoMax operates a vehicle transportation network, a spare parts warehouse, and holds a license
for spare parts import, along with agreements with a nationwide network of garages. In addition to Global AutoMax, AutoMax also controls
AutoMax Trade-In, which operates a used car sales branch at the Glilot Junction, and holds control over Dalhom AutoMax, which is the
direct importer of Temsa buses to Israel. The Projections state that AutoMax and its subsidiaries are growing each year, and currently
employ about 120 employees. According to the Projections, AutoMax&#8217;s optimal utilization of a central headquarters (finance, logistics,
human resources, information systems, etc.) and commercial and financial strength allow the group to develop activities adjacent to the
core vehicle import business, which in turn are expected to enhance profitability. According to the Projections, AutoMax Direct Import
will operate as an independent company, which will be a subsidiary of Global AutoMax, held jointly with a group of investors. Additionally,
AutoMax is actively working to sign direct import agreements with car manufacturers from China and other countries. AutoMax is in various
stages of negotiations with car manufacturers, and if one or more of these negotiations mature into direct import activities, this activity
is expected to become the main activity of the group and significantly impact its operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The second chapter of the
Projections describes Global AutoMax&#8217;s aim of importing new vehicles to Israel through parallel import. Global AutoMax is engaged
in importing and marketing a variety of private car models in Israel, holds an indirect import license for 27 vehicle products from various
models, and operates through twelve sales branches. The Projections detail which branches are operated by AutoMax, which ones are operated
by joint ventures with third-parties, and which ones are operated by authorized dealers of AutoMax. AutoMax has an international network
of suppliers, mainly in Europe and North America, providing it with vehicles of different products and models according to orders, as
well as an import system that includes procurement, transportation, handling customs clearance procedures, and vehicle storage facilities
in Israel. From January to September 2023, AutoMax delivered approximately 1,550 vehicles. The second chapter then provides that the
nature of AutoMax&#8217;s business is sensitive to external influences and macroeconomic factors. As a result of these influences, AutoMax&#8217;s
financial results for 2023 were affected. At the time of the Projections, AutoMax believed that it (and the market as a whole) will be
able to adjust purchase and sale prices to current market conditions. Therefore, AutoMax estimated that 2023 was not a representative
year for its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The third chapter of the
Projections focuses on Dalhom AutoMax, which is a subsidiary, established with Dalhom Motors Ltd., dedicated to the import of Temsa brand
buses. AutoMax signed an agreement with the manufacturer, under which the Dalhom AutoMax will serve as the direct importer of Temsa buses
in Israel. Temsa offers several models of buses and minibuses intended for tourism and public transportation, powered by electricity,
gas, or diesel, all suitable for marketing in Israel. At the time of the Projections, AutoMax was working on establishing a central bus
garage covering 4,000 square meters in Hod Hasharon. Dalhom AutoMax was considered one of the growth engines of AutoMax and was expected
to generate significant profitability. According to the Projections, in 2023, AutoMax intended to stabilize service systems, a central
garage, and stable sales to tourism and transport companies. Starting in 2024, the company planned to begin competing in public transportation
tenders. The Projections also included certain statistics about the public transportation market in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fourth chapter of the
Projections elaborates on the global automative industry, and includes statistics for before and after the COVID-19 pandemic. The Projections
note that most car manufacturers are organized into global groups with factories in many countries, producing different models and brands.
Further, due to the high costs associated with vehicle development, smaller car manufacturers merge to form large conglomerates, each
holding manufacturing plants in various countries and producing multiple brands while sharing platforms and components. Most car manufacturers
will have at least one luxury brand, mid-range brands, and a popular brand. The variety of models allows manufacturers to offer vehicles
for every budget and tailor their offerings to consumer preferences in different countries. Most car models are designed and styled according
to consumer tastes in various regions. The Projections then describe vehicle manufacturers&#8217; approach to parallel import/export.
According to the Projections, the vast production and employment volumes give car manufacturers significant economic and political power,
which they use to protect their interests in the countries where they operate. According to the Projections, car manufacturers design
different models for each region based on local consumer preferences, weather conditions, regulations, and purchasing power. The Projections
then stipulate reasons for such diversification. The Projections then note that fluctuations in business cycles, regulatory changes,
and changing tastes constantly create supply surpluses in different parts of the world, pressuring manufacturers to export vehicles between
regions. Arbitrage gaps are not a passing opportunistic phenomenon but an integral part of the market. As a result, the Projections state
that about 10% of global vehicle trade is conducted as &#8220;parallel&#8221; trade between brokers/traders rather than directly from
the manufacturer. The Projections review anti-trust and competition regulations in the United States and in Europe. The Projections state
that most car manufacturers impose various legal or less legal barriers on vehicle exports by agents, and explains the hurdles involved
in purchasing vehicles for parallel import. The Projections explain that AutoMax has experienced procurement systems and contractual
agreements with some of the largest official agents of car manufacturers in Europe and Canada, allowing it to order production batches
specifically for export. AutoMax purchases most of the models it imports in three or four different currency zones to reduce exposure
to currency rates or other blocking attempts and to ensure continuity of supply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fifth chapter of the
Projections describes the Israeli automative industry. The Projections provide statistics about car ownership in Israel. The Projections
explain that the institutional market&#8217;s share in purchasing new vehicles is significantly higher than its share in the overall
vehicle fleet. The Projections provide statics about the average vehicle age in Israel and the level of motorization, compared to Europe
and the United States. The Projections describe the decline in the global vehicle supply due to the effects of the COVID-19 pandemic,
which also impacted delivery volumes in Israel, and increased price for new vehicles in Israel, which, in light of the increase in the
consumer price index, the Projections estimated will continue in coming years. The Projections state that AutoMax focuses mainly on the
main market segments (NIS 130,000-350,000). According to the Projections, in the last decade, there has been a clear consumer preference
in Israel (and globally) for SUV-crossover models, and AutoMax focuses on importing these models. In addition, the Projections state
that in recent years, there has been a massive influx of Chinese-made vehicles, which accounted for nearly 20% of car sales in Israel.
The Projections note that among the top ten models in 2023, there are three Chinese models and not a single European one. The Projections
further state that in recent years, there has been a significant increase in the share of electric vehicles, expected to continue at
the expense of gasoline and diesel vehicles. The Projections then describe the car import market in Israel, which it describes as concentrated,
and provides statistics to support such notion. The Projections note that the market distribution among companies and different brands
changes according to public preferences, model development by manufacturers, and currency exchange rates. Currency rates are crucial
to an importer&#8217;s competitive ability, so there is a high correlation between the currencies in which vehicles are manufactured
and the market shares of different brands. In addition to direct importers, dozens of companies operate in Israel for parallel vehicle
import. Additionally, hundreds operate in the minor import sector and personal import agencies providing consulting, logistical services,
and purchasing services for personal import. The Projections provide statistics for each type of import (direct, parallel, minor, personal),
and the market share for such import.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sixth chapter of the
Projections describes parallel import. Parallel import is a process where a consumer product is imported not through the official importer
but via competing importers who meet legal requirements and import the product themselves from the manufacturer&#8217;s agents abroad.
This process occurs in many sectors, such as food, pharmaceuticals, mobile phones, electrical goods, and also in the automotive market.
Countries, including Israel, often impose import restrictions in various fields, including vehicles, to ensure the quality and safety
of products sold to their citizens and to protect local industries. Traditionally, each manufacturer had an exclusive importer with a
license to market the manufacturer&#8217;s products in that country, responsible for complying with local regulations. To foster competition,
some regulators required manufacturers to appoint multiple official representatives in the same country. However, a widespread measure
globally has been allowing parallel import, regulated by legislation and monitored by the same regulator using uniform tools and standards
as those applied to regular importers. The import process, standards, requirements, and customs and taxation rules are identical for
both types of importers. The official importer benefits from an annual allocation of vehicles with a given model distribution, a planned
schedule, and a fixed currency, while the parallel importer can choose the manufacturer, model, import country, and currency at any time
to maximize profits and/or compete and reduce vehicle prices. Official importers in different countries may choose to sell part of their
allocation to parallel importers due to market and currency conditions in their country and to earn financial incentives for meeting
annual sales targets. The main advantage of parallel import is flexibility in choosing the mix of vehicles imported and the ability to
quickly adapt to changing market conditions. The parallel importer is not tied to a specific brand and is not obligated to a fixed model
mix or specific technology, allowing easy adaptation of the product and model offerings to changes in local demand and foreign supply.
In Israel, the Vehicle Services Licensing Law was amended in 2009 to increase competition by allowing parallel imports, enabling vehicles
to be imported from authorized agents rather than directly from manufacturers. Actual parallel imports began in 2012, with regulations
established by the Ministry of Transport. In 2016, the law was consolidated to clearly regulate parallel imports and remove barriers.
It distinguishes between four types of importers: direct, indirect (parallel), minor, and personal import brokers. The law sets conditions
for each type, including agreements, capital, and maintenance infrastructure. Direct importers must handle recalls and warranties for
all vehicles they import, even if imported by parallel importers. Indirect importers can now use secondary agents and import new vehicles
with minimal mileage, and restrictions on the number of products they can import have been lifted. The Minister of Transport can impose
conditions and restrictions on license holders to ensure compliance and competition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The summary of the Projections,
as of the time of writing, notes the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Sales:
                                            AutoMax&#8217;s sales rely solely on the vehicles it imports, mostly sold at its branches
                                            to private buyers. Occasionally, it sells cars to large fleets and local dealers based on
                                            specific needs and demand. AutoMax offers a diverse range of vehicles appealing to a broad
                                            audience. The average vehicle price is estimated at approximately NIS 210,000, slightly above
                                            the market average. AutoMax&#8217;s pricing is 2-5% lower than regular importers for similar
                                            vehicles, with a higher gap for luxury models. AutoMax expects an average gross margin of
                                            about 11% on parallel imports. Starting in late 2024, AutoMax plans to market directly imported
                                            vehicles, which are more profitable, with an estimated margin of 17%. This activity is expected
                                            to grow to 75% of sales, increasing the average gross margin.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financing:
                                            AutoMax has credit lines from banking corporation transferred as a subordinated loan to its
                                            subsidiaries. Global AutoMax has approved credit lines from four Israeli banks, mainly for
                                            working capital and inventory financing. The time gap between purchase and sale dictates
                                            the required inventory and credit. AutoMax expects reduced credit needs, allowing increased
                                            sales cycles without significant credit growth. AutoMax is also obtaining a &#8220;bonded
                                            warehouse&#8221; approval to save on customs financing for display cars, reducing credit
                                            needs. AutoMax Trade-In and Dalhom AutoMax have separate credit lines. AutoMax Direct Import
                                            was negotiating with banks for credit approval. AutoMax has pledged all assets as collateral
                                            for bank credit. Financing costs are mainly due to exchange rate differences and foreign
                                            trade fees, influenced by currency fluctuations.</span></td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Operational,
                                            Sales, and Marketing Expenses: Operational costs, including transport, storage, sales preparation,
                                            and licensing, range from NIS 5,000-10,000 per vehicle. AutoMax has a central headquarters
                                            providing services to all subsidiaries. A significant portion of the budget is allocated
                                            to digital advertising, primarily on Google and Facebook, with an independent telemarketing
                                            center coordinating sales appointments. Marketing costs increased in 2022 and early 2023
                                            due to luxury vehicle sales but are expected to decrease as sales shift back to mainstream
                                            vehicles.</span></td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Service
                                            and Warranty: Since January 2017, official importers must cover manufacturer warranty costs
                                            for their brand&#8217;s vehicles, even if imported parallelly. AutoMax has agreements with
                                            nationwide garages and spare parts importers to provide initial parts inventory for imported
                                            vehicles. AutoMax has diagnostic equipment, technical expertise, and translated materials
                                            for imported models. Warranty costs are borne by the manufacturer, so the company does not
                                            incur significant expenses in this area.</span></td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The summary of the Projections
included a table titled &#8220;Profit and Loss Pro Forma (in thousands NIS)&#8221; and its footnotes, presented (as translated), below:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; border-bottom: Black 1.5pt solid; width: 26.5%; font-weight: bold; text-align: left"><span style="-keep: true">Year</span></td><td style="text-align: center; padding-bottom: 1.5pt; width: 0.5%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; width: 0.5%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="-keep: true">2023f</span></td><td style="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: center"/><td style="text-align: center; padding-bottom: 1.5pt; width: 0.5%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="-keep: true">2024f</span></td><td style="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: center"/><td style="text-align: center; padding-bottom: 1.5pt; width: 0.5%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="-keep: true">2025f</span></td><td style="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: center"/><td style="text-align: center; padding-bottom: 1.5pt; width: 0.5%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="-keep: true">2026f</span></td><td style="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: center"/><td style="text-align: center; padding-bottom: 1.5pt; width: 0.5%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="-keep: true">2027f</span></td><td style="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: center"/><td style="text-align: center; padding-bottom: 1.5pt; width: 0.5%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="-keep: true">2028f****</span></td><td style="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">Revenue</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">453,617</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">420,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">544,340</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">598,774</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">658,652</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">724,517</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">796,969</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">Cost of Sales</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">392,918</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">375,900</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">479,020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">514,946</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">566,441</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">623,085</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">685,393</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Gross Profit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">60,699</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">44,100</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">65,321</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">83,824</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">92,211</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">101,432</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">111,576</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">13</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Sales and Marketing Expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">27,612</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">27,612</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">27,612</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,993</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30,442</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">31,964</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">33,563</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">General &amp; Administrative Expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">16,849</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">18,534</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">18,534</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">19,461</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20,434</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">21,455</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">22,528</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">Employee Share Options*</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9,976</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,451</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Other Expenses and Losses (Profit) capital gains**</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(226</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(4,400</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Financing Expenses (Net)***</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,232</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,496</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Share in Profits (Loss) of the Company in Associated
    Companies in Accordance with The Book Value Method</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(585</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">594</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Profit (Loss) Before Tax on Income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">671</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(4,999</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9,175</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,375</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">34,335</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41,013</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">48,485</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Profit (Loss) Before Tax, adjusted for Employee Share
    Options and Capital Gains</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10,421</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(6,948</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9,175</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,375</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">34,335</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41,013</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">48,485</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">EBITDA (Adjusted)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">24,646</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10,536</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">27,357</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">43,557</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">49,517</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">56,159</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">63,667</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="-keep: true">*</span></td><td style="text-align: justify"><span style="-keep: true">See notes to financial statements. The share option
                                            plan ended in the first quarter of 2023.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="-keep: true">**</span></td><td style="text-align: justify"><span style="-keep: true">In 2023, we recognized capital gains of NIS 4 million
                                            as a result of sale of shares in AutoMax Leasing to a third party.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="-keep: true">***</span></td><td style="text-align: justify"><span style="-keep: true">Deducting profits/losses of exchange rate from hedging
foreign exchange. After June 30, 2023, there were no profits or losses.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="-keep: true">****</span></td><td style="text-align: justify"><span style="-keep: true">f stands for forecast.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Projections were based
on the following working assumptions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023
                                            is a transition year from a world of undersupply caused by the chip crisis during the COVID-19
                                            period (buying high and selling high) to full supply (buying low and selling low). The need
                                            to replace expensive inventory, combined with the sharp and rapid weakening of the NIS due
                                            to legal reforms and accompanying social protests, affected the company&#8217;s results.
                                            AutoMax estimates this impact is not lasting, as vehicle prices will adjust to currencies,
                                            and current purchase prices have also decreased. Therefore, 2022 was chosen as the base year
                                            for planning.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Sales,
                                            administration, and general expenses will grow from 2025 at a rate lower than revenue growth&#8212;5%
                                            per year.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Starting
                                            in the last quarter of 2024, AutoMax will begin marketing a directly imported Chinese electric
                                            car brand, leading to an expected increase in the gross profit margin.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
                                            the last quarter of 2024, AutoMax will start consolidating profits from AutoMax Direct Import,
                                            and the profitability of the Dalhom AutoMax will also increase.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Starting
                                            in 2024, interest rates in the market will begin to decline, leading to a 15% annual reduction
                                            in financing expenses (equivalent to about 1.2% interest), offset by a similar increase in
                                            the financial debt volume.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Except
                                            for vehicle inventory, there will be no significant changes in fixed assets, including intangible
                                            license assets, so depreciation expenses will remain similar to their 2023 level.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Calculation of Enterprise Value of AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In calculating AutoMax&#8217;s
enterprise value, E.D.B. considered various factors, as detailed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. noted that AutoMax&#8217;s
market value reflected in the value of its shares on TASE is not reflective of AutoMax&#8217;s real value, and cited the following reasons:
lack of public float; the TASE not being a developed enough stock market; correlation between market trends and share price; the COVID-19
pandemic, the Israeli legal reform and the Iron Swords War preventing a reasonable value assessment based on share price; Israeli capital
market operating differently than other prominent capital markets around the world; that the stock market may self-correct in the long-term
by forecasting better years; and certain examples of volatility in the share price, which do not represent the real value of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. presented the EBITDA
multiplier and the profit multiplier, both multiplier methodologies, as two metrics commonly used to assess the value of a company. Both
metrics measure the ratio between the share price and the company&#8217;s profit, in different ways. E.D.B. explains that the multiplier
methodology is the simplest methodology for a valuation and it is primarily used to compare the value of companies; however, the profit
generally represents past results already recorded. Thus, the disadvantage of the multiplier methodology is that it is based on figures
from the past, inherently without tools to consider the potential for future profit. This disadvantage makes this method ineffective
for establishing the enterprise value of AutoMax because this methodology does not take into account the effect of AutoMax&#8217;s existing
significant growth engines which may potentially result in AutoMax generating 100% or more sales turnover and annual profit within a
few years. The results using these metrics reflect a starting point to gauge AutoMax&#8217;s enterprise value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EBITDA multiplier is
a financial metric used to assess the enterprise value of a company. It is calculated by dividing the value of the company&#8217;s operations
by its EBITDA (earnings before financing expenses, tax, depreciation and amortization). This metric determines the company&#8217;s operating
profitability prior to expenses not directly related to its operating activities. According to E.D.B., the EBITDA multiplier in the Israeli
parallel vehicle import sector ranges between 2 to 3.5, with an average multiplier of 2.5, meaning that companies in this sector are
traded based on a multiplier of 2-3.5 times their gross operating profit. Factors affecting the multiplier include: the size of the company;
its profitability; forecasted future growth; and commercial risks. In Israel, the multiplier may also vary based on: competition in the
sector; changes in government policy; changes in exchange rates; and the volatility of vehicle prices. To calculate AutoMax&#8217;s value
through the EBITDA multiple methodology, E.D.B. considered the fact that AutoMax has stable operations and is the largest player in its
sector in Israel. E.D.B. chose a multiplier of 3 as being representative for AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The profit multiplier is
a financial ratio used to assess the enterprise value of a company. It is calculated by dividing the market capitalization of the company
by its net annual profit. According to E.D.B, the profit multiplier indicates how much investors are prepared to pay for each NIS of
profit generated by a company. A higher profit multiplier means that investors expect that the company will continue to grow and increase
its profits in the future. A lower profit multiplier can be indicative of the fact that the company is not growing or that it is in a
difficult financial position. E.D.B. notes that the profit multiplier is only a single tool to assess the enterprise value of a company.
There are other factors that should be considered, including: forecasted future growth; commercial risks; competition; management. E.D.B.
notes the following limitations of the profit multiplier: that the profit multiplier does not take into account a company&#8217;s accounting;
that the profit multiplier is impacted by external factors, such as the interest in the economy; and that the profit multiplier is not
always precise. The profit multiplier in the Israeli parallel vehicle importer sector ranges between 5 to 10, with an average of 7.5.
The meaning is that companies in the sector are traded based on a multiplier of 5-10 times their net profit. Factors which affect the
profit multiplier include: the size of the company; its profitability; forecasted future growth; and commercial risks. E.D.B. chose a
multiplier of 8 as representative of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Taking into account the 2022
EBITDA of NIS 24,818 thousand, and an operating profit multiplier of 3, the operating value estimate is NIS 74,454 thousand (approximately
$20,682 thousand at the time of preparation of E.D.B.&#8217;s valuation report). Taking into account an operating profit of NIS 10,431
thousand, and an operating profit multiplier of 8, the operating value estimate is NIS 83,448 thousand (approximately $22,862 thousand
at the time of writing of E.D.B.&#8217;s report). Accordingly, E.D.B. valued AutoMax&#8217;s enterprise value, according to the average
of both commonly used multiplier methodologies and with an emphasis on the fact that these methodologies do not take into account AutoMax&#8217;s
new and significant growth engines, at approximately $21.77 million (based on an exchange rate of NIS 3.65 per $1 as of the date of the
valuation report &#8211; January 4, 2024).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Next, E.D.B. assessed the
enterprise value of AutoMax through the Discounted Cash Flow, or DCF, methodology, which assesses a company&#8217;s future net cashflow
and discounts it to the present. In order to use this methodology, it is necessary to estimate the profit and loss for future years,
until the profitability plateaus at a terminal year which can be assumed to represent the permanent net annual amount. E.D.B. presented
an explanation about the calculation of the total cost of capital used to finance AutoMax&#8217;s activities and the calculation of the
discounted cashflow to assess the enterprise value. The cost of equity is the return required by a company&#8217;s shareholders. It is
established based on factors, including the risk entailed in investing in the company, as well as the possible return on alternate investments.
E.D.B. counts the various ways to assess the cost of equity, including: capital asset pricing model, or CAPM; internal rate of rate model
and average rate of return model. E.D.B. then explains that the cost of debt is the return required by a company&#8217;s lenders, which
is established based on the present interest rate of similar bonds. The cost of debt can be reduced by the tax rate since the company
is able to deduct the interest costs from its taxable revenues. E.D.B. explains that the weighting refers to the relative share of any
kind of capital, the total debt and equity of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. used the following
explanations in order to calculate the capital and interest of the discount rate for the valuation model for AutoMax: the weighted average
cost of capital, or the WACC, is the rate of return required for a company&#8217;s entire capital, including equity and debt. It is used
to discount the company&#8217;s future cashflows in order to establish its present value. CAPM is used to assess the cost of equity of
the investment. It is based on the assumption that shareholders require a higher rate of return on higher risk investments. The rate
of return required for zero risk assets is the return required for risk-free investments. It is used as the basis to assess the cost
of equity of higher risk assets. The risk parameter measures the risk entailed in investing in an asset. It is calculated by comparing
the historical return of the asset against the historical return of the market. The average market return is the average rate of return
of the assets in the market. It is used as a metric of the systemic risk entailed in investing in the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. begins calculating
the WACC of AutoMax by calculating the CAPM. E.D.B. notes that it is difficult to unequivocally establish the interest rate which reflects
the risk premium prevailing in the Israeli share market, appropriate for the vehicle parallel import sector. This is because it is dependent
on multiple factors, as mentioned above. However, according to E.D.B., it can be assessed that this interest rate will be relatively
high due to the high risks entailed in operating in this sector. These factors include: fierce competition; regulatory changes; volatility
in the foreign exchange market; financing risks; size of investment requires a higher interest rate; entrepreneurial experience affects
interest rate accepted; and the issuance of collateral on loans may reduce interest rate. Based on these factors, E.D.B. assessed that
the interest rate which reflects the risk premium in the Israeli vehicle parallel import sector ranges between 10%-12%. In order to more
accurately assess the interest rate for the sector, E.D.B. calculated the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Rate
                                            of return of risk-free capital assets was based on 6%, based on data from the Bank of Israel
                                            as of January 2, 2024, the LIBOR interest rate, and other institutional interest rates.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            risk parameter was set at 1.5, based on: AutoMax&#8217;s sensitivity to changes in the vehicle
                                            market; competition; and volatility in market share. According to E.D.B., risk interest can
                                            come to a 5%-10% premium on top of the basic risk-free interest applicable in the market,
                                            and the model applied a risk parameter of 1.5%.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Average
                                            market return was set at 10%, based on an examined period of time. According to E.D.B., the
                                            average market return is calculated at approximately 10% over the long-run. This is based
                                            on data from the global share markets over the preceding 100 years. The average market return
                                            may be higher or lower than 10% in the short-run, and is impacted by various factors, which
                                            include: economic growth; inflation; and base interest. The valuation model applied a conservative
                                            rate of 10% for the market return for the calculation.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to E.D.B.&#8217;s
calculations of the weight of equity, and the WACC, E.D.B, forecasted a cashflow model after having established the weighted interest
rate for the model at 10.22%. Please refer to E.D.B.&#8217;s full translated report, attached as Annex E to this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. explains the assumptions
underlying the DCF methodology as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023
                                            was a transition year, due to the shortage of supply due to the chip crisis associated with
                                            COVID-19 (buying high and selling high) to full supply (buying low and selling low), the
                                            need to replace expensive stock together with a sharp and quick decline of the NIS due to
                                            the judicial reform and associated civil unrest and the Swords of Iron war in the fourth
                                            quarter. All of these adversely impacted AutoMax&#8217;s results &#8211; AutoMax assesses
                                            that this adverse response has ended because vehicle prices adjust themselves to the currencies,
                                            and AutoMax&#8217;s current purchasing prices have also decreased. 2022 was therefore selected
                                            as the base year for the model.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Sales,
                                            management and general expenses were assumed to increase from 2025 at a lower rate of the
                                            increase in revenues - 5% annually.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
                                            the fourth quarter of 2024, it was assumed that AutoMax will start directly importing a Chinese
                                            brand of electric vehicles and therefore the gross profitability is anticipated to increase.
                                            There will be a greater impact in 2025.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
                                            the fourth quarter of 2024, it was assumed that AutoMax will start consolidating the earnings
                                            of AutoMax Direct Import and the profitability of the bus company will increase. There will
                                            be a greater impact in 2025.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
                                            2024 there it was assumed that there will be a 15% annual decline in financing costs (equivalent
                                            to interest of approximately 1.2%) which will be offset with a similar increase in the scope
                                            of the financial debt.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Apart
                                            from inventory of vehicles, it was assumed that there will be no material changes in fixed
                                            property, including intangible license assets and therefore depreciation costs will remain
                                            similar at NIS 7,888 thousand per year.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues
                                            &#8211; The basis used is the Projections that were prepared in October 2023. The plan referred
                                            to AutoMax&#8217;s new growth engines in the bus import and Chinese electric vehicle direct
                                            import segments in addition to AutoMax&#8217;s parallel vehicle import activities. The business
                                            plan also relied on 2022 as the basis and referred to a 5-year model for 2024-2028. The base
                                            assumption was a significant 20% increase in sales in 2024, with continued annual growth
                                            of 10% until stabilizing in 2028. As noted above, 2023 cannot be referred to as a representative
                                            year for the current commercial activities due to the multitude of events that occurred throughout
                                            the year which impacted activity in the economy. For similar reasons E.D.B. noted that it
                                            chose to be cautious with its working assumptions for 2024 which started in a state of war
                                            and with significant uncertainty for subsequent months. E.D.B. therefore assumed that the
                                            sales target presented in the business plan will be achieved in 2029, and that there will
                                            only be a growth rate of 6% in 2024. It was further assumed that the growth rate in 2025
                                            will increase to 16% and the growth rate will stabilize at 10% from 2026-2029, which will
                                            also serve as a terminal year for calculating the discounted revenues. E.D.B. noted that
                                            the working assumption is that the period of war will only have a short-term impact on the
                                            scope of sales. Past experience shows that vehicle demand in Israel (and around the world)
                                            is inelastic, and that vehicle demand is only adversely impacted in the short-run during
                                            periods of severe crisis but subsequently reverts. E.D.B. details various of reasons for
                                            the rapid recovery from crises in the vehicle market.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Corporate
                                            tax rate of 23%.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Discount
                                            rate for the terminal year &#8211; the discount interest rate of the model, 10.22% less a
                                            permanent 2% annual increase, i.e., 8.22%.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Investment
                                            in working capital &#8211; E.D.B. assumed an average rate of working capital by subtracting
                                            AutoMax&#8217;s current liabilities from its current assets based on its 2022 balance sheet
                                            and set a fixed rate of 9%.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on these assumptions,
E.D.B. concluded that the enterprise value totals approximately NIS 393.6 million (or $107.8 million based on an exchange rate of NIS
3.65 per $1 as of the date of the valuation report &#8211; January 4, 2024). E.D.B. noted that enterprise value should also consider
the value of AutoMax&#8217;s net assets in the 2022 base year, which include: cash value equal to: the value of cash, less cash liabilities,
at NIS 300,848 thousand; the value of investments includes fixed property, working capital, and total other assets including intangible
assets, at NIS 94,379 thousand; changes in working capital considering the value of the difference between the working capital in the
base year (2022) and the terminal year (2029) capitalized based on the established discount interest rate &#8211; NIS 23,741 thousand;
and the total assets at NIS 230,210 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After referring to the net
asset value, E.D.B. came to an enterprise value for AutoMax totaling NIS 163.4 million, or $44.8 million, based on the DCF methodology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
valuation model is presented below (in thousands of NIS, unless specified otherwise):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">Mean</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">Forecast</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">2026</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">2027</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">2028</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">2029</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; font-weight: bold; text-align: left"><span style="-keep: true">Total Sales</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true">&#160;</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; font-weight: bold; text-align: right"><span style="-keep: true">453,617</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; font-weight: bold; text-align: right"><span style="-keep: true">480,834</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; font-weight: bold; text-align: right"><span style="-keep: true">557,767</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; font-weight: bold; text-align: right"><span style="-keep: true">613,544</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; font-weight: bold; text-align: right"><span style="-keep: true">674,899</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; font-weight: bold; text-align: right"><span style="-keep: true">742,388</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; font-weight: bold; text-align: right"><span style="-keep: true">816,627</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Rate of Change (ROC)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">10.30</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">6.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">16.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">10.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">10.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">10.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">10.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Cost Of Sales*</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">558,605</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">392,918</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">423,134</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">479,680</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">527,648</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">580,413</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">638,454</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">702,300</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Gross Profit</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">89,072</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">60,699</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">57,700</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">78,087</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">85,896</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">94,486</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">103,934</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">114,328</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="-keep: true">Rate of Profit</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">13.70</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">13.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">12.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">14.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-decoration: underline; font-weight: bold; text-align: left"><span style="-keep: true">Operating
    Expense (OpEx)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Other</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">7,500</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,567</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Rate</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1.20</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3.40</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">2.10</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1.30</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1.10</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">0.90</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">0.90</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Sales and Advertising</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">31,582</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">27,612</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">27,612</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,993</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30,442</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">31,964</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">33,563</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">36,919</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Rate</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">4.90</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6.10</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5.70</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5.20</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">4.70</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">4.50</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">4.50</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">G&amp;A</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">21,199</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">16,849</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">18,534</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">19,461</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20,434</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">21,455</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">22,528</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">24,781</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Rate</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3.3</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3.70</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3.90</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3.50</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3.30</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3.20</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">3.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="-keep: true">Total</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">60,281</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">60,028</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">56,146</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">55,454</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">57,876</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">60,419</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">63,091</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">68,700</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Rate</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.50</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">13.20</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">11.70</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.90</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.40</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">8.50</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">8.40</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Operating Profit</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">28,791</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">671</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1,554</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">22,633</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">28,020</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">34,067</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">40,843</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">45,628</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="-keep: true">Rate of Profit</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">4.20</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">0.10</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">0.30</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">4.10</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">4.60</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5.50</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5.60</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Tax Rate</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">23.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">25</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">23.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">23.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">23.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">23.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">23.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">23.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Working Capital</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">58,291</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">41,703</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">43,275</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">50,199</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">55,219</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">60,741</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">66,815</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">73,496</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Working Capital Ratio</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">9.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Net Operating Profit</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">22,169</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">503</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1,197</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">17,428</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">21,576</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">26,231</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">31,449</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">35,133</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Depreciation and Amortization</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">7,888</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,500</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,888</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,888</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,888</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,888</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,888</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,888</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Fixed Capital</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">-4,000</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-3,815</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-4,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-4,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-4,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-4,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-4,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-4,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Cashflow for Capitalization</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">26,057</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5,085</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">21,316</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">25,464</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">30,119</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">35,337</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">39,021</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Capitalization rate</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">10.22</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Growth</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">2.00</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Operational Value</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">393,585</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Fiscal</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">-300,848</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Investments</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">94,379</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Change in Capital Ratio</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">-23,741</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Total Assets</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">-230,210</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Enterprise Value (EV) in NIS</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">163,375</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Enterprise Value (EV) in USD</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">44,760</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forecasts, projections
and estimates of AutoMax provided to E.D.B. were based on numerous variables and assumptions that are inherently uncertain, including,
without limitation, factors related to general economic and competitive conditions. Accordingly, actual results could vary significantly
from those set forth in those forecasts, Projections and estimates. E.D.B. assumed, based on discussions with AutoMax&#8217;s management,
that the projections provided a reasonable basis upon which E.D.B. could form its valuation report and E.D.B. expressed no view as to
any such information or the assumptions or bases therefor. E.D.B. relied on all such information without independent verification or
analysis and did not in any respect assume any responsibility or liability for the accuracy or completeness thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. did not express any
opinion as to AutoMax&#8217;s future performance or long-term viability of AutoMax or the price at which the combined company&#8217;s
ordinary shares would trade at any time. E.D.B. did not express any view as to, and its valuation report did not address, any terms or
other aspects or implications of the Merger or any aspect or implication of any other agreement, arrangement or understanding entered
into in connection with the Merger or otherwise. In addition, E.D.B. expressed no view as to, and its valuation report did not address,
SciSparc&#8217;s underlying business decision to proceed with or effect the Merger nor did its valuation report address the relative
merits of the Merger as compared to any alternative business strategies that might have existed for SciSparc or the effect of any other
transaction in which SciSparc might have engaged. E.D.B.&#8217;s valuation report was necessarily based on the information available
to E.D.B. and general economic, financial and stock market conditions and circumstances as they existed and could be evaluated by E.D.B.
on the date of its valuation report. It should be understood that, although subsequent developments may affect E.D.B.&#8217;s valuation
report, E.D.B. does not have any obligation to update, revise or reaffirm its valuation report. The credit, financial and stock markets
had been experiencing unusual volatility and E.D.B. expressed no opinion or view as to any potential effects of such volatility on the
AutoMax, and its opinion does not purport to address potential developments in any such markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. is not a financial,
legal, tax, regulatory or accounting advisor. In addition, E.D.B.&#8217;s valuation report did not constitute a solvency opinion or a
fair value opinion, and E.D.B. did not evaluate the solvency or fair value of AutoMax under any federal or state laws relating to bankruptcy,
insolvency, similar matters or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In performing its valuation
report, E.D.B. made numerous assumptions with respect to the industry performance, general business, economic, market and financial conditions
and other matters, which are beyond the control of AutoMax. Any estimates contained in the valuation report performed by E.D.B. are not
necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by the valuation
report. Additionally, estimates of the value of businesses or securities do not purport to be appraisals or to reflect the prices at
which such business or securities might actually be sold. Accordingly, the valuation report and estimates are inherently subject to substantial
uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the valuation report presented by E.D.B. to the SciSparc board of directors in connection with valuation report. The summary is not
a complete description of the valuation report or the presentation made by E.D.B. to the SciSparc board of directors, but summarizes
the material valuation performed and presented in connection with its valuation report. The preparation of a valuation report is a complex
process. Therefore, the valuation report is not readily susceptible to partial analysis or summary description. In arriving at its valuation
report, E.D.B. did not attribute any particular weight to any analysis or factor that it considered, but rather made qualitative judgments
as to the significance and relevance of each analysis and factor.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The valuation report&#8217;s
summary stated the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">AutoMax is the largest parallel
                                            importer of cars in Israel. The vehicle market in Israel and worldwide is undergoing a reform,
                                            driven by two main forces, the first of which is the shift to usage of electric vehicle,
                                            and the second is the growing use of Chinese-produced vehicles.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">AutoMax&#8217;s management
                                            has adjusted itself to the changing market by signing an agreement with a Chinese company
                                            for the sale of its cars, as a direct importer to Israel. AutoMax plans to continue its operations
                                            as a parallel importer by using its current branches and salespersons, in order to sell Chinese-produced
                                            vehicles. These operations are expected to generate growth for AutoMax.</td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Another path to generating
                                            growth is AutoMax&#8217;s joint venture with Dalhom Motors Ltd. which AutoMax will use to
                                            import Temsa buses into Israel. AutoMax signed an agreement with Temsa in order to serve
                                            as a direct importer of its buses. The Temsa buses appeal to the Israeli markets, for both
                                            tourism and public transportation.</td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            valuation report used two methodologies of valuation to estimate AutoMax&#8217;s value, namely
                                            the multiplier methodology and the DCF methodology, and supported such valuations using AutoMax&#8217;s
                                            business plan. The multiplier methodology is only based on past data and does not refer to
                                            future data, whereby, according to the valuation report, it cannot be used as an appropriate
                                            metric to assess the enterprise value which is anticipated to double or even more the scope
                                            of its operations in the coming years. According to E.D.B., the current valuation of AutoMax
                                            can serve as basis and be used as a comparison for a valuation based on the DCF methodology.</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.D.B.
    found AutoMax&#8217;s business plan to be realistic, given AutoMax&#8217;s trained personnel and operating branches. E.D.B. notes
    that the existing infrastructure of showrooms and trained sales personnel together with efficient management and marketing are a
    good basis for meeting the planned targets of AutoMax. E.D.B. also states that its valuation was conservative in light of the situation
    in Israel, specifically with respect to ongoing military tensions in Israel, and due to such short-term uncertainty, E.D.B. moderated
    AutoMax&#8217;s growth forecast in the model&#8217;s assumptions and chose an interest rate which incorporates risk components appropriate
    for AutoMax&#8217;s operating sector.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The valuation based on the
                                            multiplier methodology assessed the enterprise value at approximately $21.7 million and the
                                            valuation based on the DCF methodology assessed the enterprise value at approximately $44.8
                                            million. AutoMax&#8217;s anticipated growth is expected to double its activities and also
                                            increase its profitability which AutoMax believes strengthens the reliability of the valuation.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">E.D.B.
                                            stated that the valuation of AutoMax is $44.8 million, as of the date of its report &#8211;
                                            January 4, 2024.</p></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The $44.8 million valuation of AutoMax, according to the E.D.B. valuation
report, was primarily used as a data point by SciSparc&#8217;s board of directors during the due diligence process to assess the business
of AutoMax and the transaction. This valuation is not recorded in the financial statements of SciSparc or AutoMax. E.D.B.&#8217;s valuation
report was used in order to ascertain the value of AutoMax and in order to evaluate the financial feasibility of the transaction. The
valuation report, and the value ascribed to AutoMax by E.D.B., revealed that the terms of the transaction contemplated under the Merger
Agreement were favorable to SciSparc at the time of the March 31, 2024 meeting, based on the per-share consideration if the Merger was
consummated on such date. If the Merger had been consummated at the time of presentation of the E.D.B valuation report, then SciSparc
would have paid approximately $4.37 million in SciSparc Ordinary Shares, for a company valued $44.8 million, based on the Exchange Ratio,
with 2,468,876 SciSparc Ordinary Shares outstanding, 105,643,744 AutoMax shares outstanding, and SciSparc&#8217;s share price of $1.77
as of March 31, 2024. The actual merger consideration and Exchange Ratio were determined based on several key factors:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negotiations
                                            between the parties: The terms of the merger consideration were heavily influenced by the
                                            negotiations between the managements of SciSparc and AutoMax, ensuring that both sides reached
                                            a mutually desirable arrangement;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&#8217;
                                            equity in the financial statements for the year ended December 31, 2023: The shareholders&#8217;
                                            equity as reported in the financial statements for both companies during the year ended December
                                            31, 2023 was relatively equal, providing a financial basis for the transaction; and</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control
                                            retention by SciSparc&#8217;s board of directors: SciSparc&#8217;s board of directors was
                                            adamant about SciSparc&#8217;s current shareholders retaining control over the combined company
                                            following any strategic transaction, which influenced the structure and amount of the merger
                                            consideration.</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interests of the SciSparc and AutoMax Directors
and Executive Officers in the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In considering the recommendation
of the SciSparc board of directors with respect to issuing SciSparc ordinary shares and pre-funded warrants in the Merger and the other
matters to be acted upon by the SciSparc shareholders at the Special Meeting, the SciSparc shareholders should be aware that Amitay Weiss,
the Chairman of SciSparc&#8217;s board of directors, serves as the chairman of AutoMax&#8217;s board of directors, and as such might
have interests in the Merger that are different from, or in addition to, the interests of SciSparc&#8217;s shareholders generally, including,
among others, the continued service as an officer or director of the combined company and the continued receipt of compensation for such
service and continued indemnification. In addition, if approved by SciSparc shareholders, Mr. Amitay Weiss will be entitled to receive
a one-time cash bonus of $150,000 as the Chairman of SciSparc&#8217;s board of directors, subject to and upon the closing of the Merger.
Each of Mr. Oz Adler and Mr. Itschak Shrem will also be entitled to receive a one-time bonus of $315,000 and $50,000, as the Chief Executive
Officer of SciSparc and President of SciSparc, respectively. These interests may present them with actual or potential conflicts of interest.
See Proposal No. 3 (page 135) for more information.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of Amnon Ben Shay, Moshe
Revach and Liat Sidi will be a director of the combined company after the effective time of the Merger. Furthermore, following the Merger,
and subject to the approval of the SciSparc shareholders, each of Mr. Tomer Levy, who is currently the VP Business Development and Headquarters
of AutoMax, as well as a member of the board of directors of AutoMax, and Ms. Yaarah Alfi, currently the Chief Financial Officer of AutoMax,
will be elected to serve as a director of SciSparc. Following the closing of the Merger, the directors of the combined company will be
eligible to be compensated as directors, pursuant to the compensation policy of SciSparc. In addition, pursuant to the Merger Agreement
and form of Indemnification Agreement, SciSparc&#8217;s directors and executive officers are entitled to continued indemnification, expense
advancement and insurance coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit committee and the
board of directors of SciSparc were aware of these potential conflicts of interest and considered them, among other matters, in reaching
its decision to approve the Merger Agreement and the Merger, and to recommend, as applicable, that the SciSparc shareholders approve
the Proposals to be presented to the SciSparc shareholders for consideration at the Special Meeting as contemplated by this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_008"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">THE
MERGER AGREEMENT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following is a summary
of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached as Annex A to this proxy statement/prospectus
and is incorporated by reference. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information
regarding its terms. It is not intended to provide any other factual information about SciSparc, AutoMax or Merger Sub. The following
description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to
the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Merger Agreement,
SciSparc Merger Sub Ltd., or Merger Sub, a wholly-owned subsidiary of SciSparc formed in connection with the Merger, will merge with
and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary of SciSparc.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Merger Consideration</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time, each
outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares, in accordance with the
Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares that AutoMax shareholders will be entitled to receive for
changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc ordinary shares issued
pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger closes and could vary significantly
from the market value of the SciSparc ordinary shares on the date of this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, AutoMax shareholders will receive SciSparc ordinary shares in exchange for AutoMax shares held by them in an amount equal
to the number of AutoMax shares held by each AutoMax shareholder multiplied by the Exchange Ratio. Certain AutoMax shareholders will
receive pre-funded warrants exercisable into SciSparc&#8217;s ordinary shares. No fractional SciSparc ordinary shares will be issued
in connection with the Merger. Instead, each AutoMax shareholder who otherwise would be entitled to receive a fractional SciSparc ordinary
share (after aggregating all fractional SciSparc ordinary shares issuable to such shareholder) will receive such amount rounded to the
nearest whole number of SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (and its Advisor in connection
with the Merger) are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders are expected
to own approximately 50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis (subject to certain exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exchange Ratio is the
result of the following calculation (rounded to four decimal places): the number of the SciSparc outstanding shares on a fully-diluted
basis (subject to certain exceptions) divided by 0.5001 multiplied by 0.4749 divided by (the number of the AutoMax outstanding shares
less the number of the AutoMax ordinary shares held by SciSparc); so that, in any event, immediately following the effective time, holders
of AutoMax outstanding shares (other than SciSparc will hold together 49.99% of SciSparc&#8217;s share capital, on a fully-diluted basis
(subject to certain exceptions), immediately following the effective time.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of AutoMax Warrants, Options and
Series B Bonds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
each AutoMax warrant, option and certain convertible rights that had resulted from a prior AutoMax transaction (in each case, whether
or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled immediately prior to the
effective time for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms
of AutoMax&#8217;s Series B Bonds and the Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual
installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that was made on
February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made on February
28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, due on February 28, 2025, will
constitute 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will
constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger the Series B Bonds will remain
outstanding and subject to repayment in accordance with the terms of the Trust Deed. The Series B Bonds bear interest at a rate of 5.9%
per annum. As of February 7, 2025, NIS 34,245 thousand (approximately $9,110 thousand) in principal amount of Series B Bonds remains
outstanding and will therefore become a liability of the combined company following the completion of the Merger. The next payment by
AutoMax to Series B bondholders is due on February 28, 2025, in the principal amount of NIS 13,698 thousand (approximately $3,644 thousand)
and NIS 996 thousand (approximately $265 thousand) of interest accrued thereon.</span></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective Time of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement requires
the parties to consummate the Merger after all of the conditions to the consummation of the Merger contained in the Merger Agreement
are satisfied or waived, including the adoption of the Merger Agreement by the shareholders of AutoMax and the approval of the Resolutions
by the SciSparc shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the Merger
is subject to satisfaction or waiver of certain conditions including, among other things, (i)&#160;the required approvals by the parties&#8217;
shareholders, (ii) Court Approval&#160;(as defined in the Merger Agreement) in accordance with the Companies Law, including in accordance
with Sections 350 and 351 of the Companies Law and exempting, among others, the Company from the requirement to publish a prospectus
in Israel; (iii) this Registration Statement having been declared effective; (iv) the accuracy of the representations and warranties,
subject to certain materiality qualifications, (v)&#160;compliance by the parties with their respective covenants, (vi)&#160;no law or
order preventing the Merger and related transactions, (vii)&#160;the listing of the ordinary shares on Nasdaq, (viii)&#160;certain minimum
requirements of net cash (as defined in the Merger Agreement) held by SciSparc at the time of closing, and (ix) receipt of the 104H Tax
Ruling or Interim 104H Tax Ruling in Israel, which has been received. For more information, please see the section entitled &#8220;<i>The
Merger &#8212; Certain Material Israeli Income Tax Consequences of the Merger.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement also
includes termination provisions for both SciSparc and AutoMax. Neither SciSparc nor AutoMax can predict the exact timing of the consummation
of the Merger.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory Approvals</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc must comply with
applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of SciSparc ordinary
shares and pre-funded warrants and the filing of this proxy statement/prospectus with the SEC. SciSparc does not intend to seek any regulatory
approval to consummate the transactions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition to closing
of the Merger, the Merger Agreement sets forth that AutoMax shall obtain a court approval for the Merger, under sections 350 and 351
of the Companies Law. According to the Companies Law, the required majority at a general meeting of shareholders to approve a merger
as described is a majority of the number of voting participants, excluding abstainers, who hold at least three-quarters (3/4) of the
voting power represented at such meeting, in accordance with Section 350(9) of the Companies Law. As part of the Merger, shares of SciSparc
will be offered to AutoMax&#8217;s shareholders. As such, it is plausible to conclude that SciSparc is making an offer to the public
and is required to file a prospectus with the Israeli Securities Authority. Based on the foregoing, AutoMax has requested that an Israeli
court approve an exemption to the foregoing requirement given that SciSparc is a public company traded on Nasdaq and therefore subject
to the Securities Act, and as such all relevant information is available to the Israeli public, and SciSparc shall continue to provide
information in accordance with the Securities Act. The Israeli Securities Authority has responded to AutoMax&#8217;s petition to the
court and has indicated that it will not require filing a prospectus is Israel. Pursuant to AutoMax&#8217;s petition to the court, the
court ordered that AutoMax will convene a shareholders meeting for approval of the merger, and in addition will convene a separate meeting
of AutoMax&#8217;s shareholders who are not controlling shareholders or SciSparc to vote on the approval of the Merger.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Material Israeli Income Tax Consequences
of the Merger</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli Tax Considerations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary is
a discussion of certain tax considerations in connection with the Merger to holders of AutoMax shares under Israeli tax law, as well
as general tax considerations with respect to the shareholders of SciSparc with respect to capital gain and dividend distributions. This
summary is limited to shareholders for whom disposition of their shares is treated as a capital gain within the meaning of the Israeli
Tax Ordinance [New Version], 5721-1961, or the ITO, and does not discuss all of the aspects of Israeli tax law that may be relevant to
a particular shareholder in light of his or her personal investment circumstances such as shareholders that do not hold their AutoMax
shares as a capital asset or shareholders that are subject to special tax rules. The following summary is for general information purposes
only and is based upon current Israeli tax law. No assurance can be given that new or future legislation, regulations or interpretations
will not significantly change the tax considerations described below, and any such change may apply retroactively. The following summary
should not be construed as legal or professional tax advice and does not cover all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under the ITO,
the disposition of shares of an Israeli company is deemed to be a sale of capital assets which is subject to capital gains tax, by both
residents and non-residents of Israel, unless a specific exemption is available or unless a treaty for the prevention of double taxation
between Israel and the seller&#8217;s country of residence provides otherwise. As AutoMax obtained the Withholding Tax Ruling and the
104H Tax Ruling (as defined below) from the Israel Tax Authority, or the ITA, the Israeli income tax consequences of the Merger shall
be in accordance with the Withholding Tax Ruling and the 104H Tax Ruling (if applicable to a particular AutoMax shareholder).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><i>Israeli
Capital Gains Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a consequence of the Merger,
holders of AutoMax shares will be treated under Israeli tax laws as having sold their AutoMax shares in the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capital gain tax is imposed
on the disposition of capital assets by an Israeli resident, and on the disposition of such assets by a non-Israeli resident if those
assets are, inter alia (i) located in Israel, (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent,
directly or indirectly, rights to assets located in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The capital gains tax rate
applicable to the real capital gain derived from the disposition of AutoMax shares in the Merger is generally 25% for individual shareholders
unless such shareholder claims a deduction for interest and linkage differences expenses in connection with such shares, in which case
the gain will generally be taxed at a rate of 30%. An individual holding, directly or indirectly, alone or together with such person&#8217;s
relative or another person who collaborates with such person on a permanent basis based on a contract, at least 10% of one or more of
the &#8220;means of control&#8221; in a company, or a Significant Shareholder, at the time of sale or at any time during the 12 months
preceding the sale of its securities, is subject to a 30% tax rate. &#8220;Means of control&#8221; generally include, among others, the
right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds
any of the aforesaid rights how to act, regardless of the source of such right. Individual shareholders dealing in securities in Israel
are taxed at the tax rates applicable to business income (a marginal tax rate of up to 47% for an individual in 2024 (excluding surtax
as discussed below)), unless contrary provisions in a relevant tax treaty apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional tax at a rate
of three percent (3%) on the real capital gain may be imposed upon individual shareholders (whether any such individual is an Israeli
resident or non-Israeli resident) whose annual income from all sources that is taxable in Israel exceeds a certain threshold (NIS 721,560
(approximately $199,436) for 2024, linked to the annual change in the Israeli Consumer Price Index), including, but not limited to, income
derived from dividends, interest and capital gains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Real capital gain derived
by companies is generally subject to the ordinary corporate income tax rate (currently 23%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the ITO, non-Israeli
residents (whether individuals or a corporations) generally may be exempt from Israeli capital gains tax on any gains derived from the
sale of their shares pursuant to the Merger (subject to the receipt of a valid certificate from the ITA allowing for an exemption or
a reduced tax rate), provided that, inter alia, (i) the shares were purchased on or after January 1st 2009 (ii) the capital gain is not
derived from a fixed enterprise of such shareholders maintained in Israel; (iii) the shares were not purchased from a related party or
are subject to restrictions due to a tax free restructure under Israeli tax law (iv) the principal value of the shares does not derive,
directly or indirectly, from real property situated in Israel. Notwithstanding the foregoing, non-Israeli corporations will not be entitled
to the foregoing exemption if Israeli residents: (i) have a controlling interest of more than 25% in such non-Israeli corporation or
(ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly
or indirectly.</p><div>


</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">In addition, the
sale of AutoMax shares by a non-Israeli resident may be exempt from Israeli capital gain tax under the provisions of an applicable tax
treaty between Israel and the seller&#8217;s country of residence (subject to the receipt of a valid certificate from the ITA allowing
for an exemption or a reduced tax rate). For example, under the Convention between the Government of the State of Israel and the Government
of the United States of America with Respect to Taxes on Income, as amended, or the U.S. Israel Tax Treaty, Israeli capital gains tax
generally will not apply to the disposition of securities by a resident of the United States (as defined in the U.S.-Israel Tax Treaty),
or a U.S. Treaty Resident, who holds the securities as a capital asset and is entitled to claim the benefits afforded to such person
by the treaty. However, such exemption will not apply if, among other things, (i) the capital gain arising from the disposition is attributed
to a permanent establishment of the shareholder in Israel, under certain terms (ii) the U.S. Treaty Resident holds, directly or indirectly,
securities representing 10% or more of the voting rights during any part of the 12-month period preceding the effective time of the sale,
subject to certain conditions; (iii) the U.S. Treaty Resident, if an individual, was physically present in Israel for a period or periods
aggregating to 183 days or more during the relevant taxable year;(iv) the capital gain arising from the disposition is attributed to
real estate located in Israel; or (v) the capital gain arising from the disposition is attributed to royalties. If the exemption is not
available, such disposition would be subject to Israeli capital gains tax to the extent applicable.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli Tax on Dividends</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax rate on dividend
income received by an Israeli resident shareholder, other than an Israeli corporation, is 25%. In the case of a Significant Shareholder,
determined at the time of distribution or at any time during the preceding 12 month period, the tax rate is 30%. Generally, dividends
received by Israeli corporations from another Israeli corporation are tax exempt provided the income from which such dividend is distributed
was derived or accrued within Israel (although, if such dividends are subsequently distributed to individuals or a non-Israeli company,
the aforesaid will apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax on dividends is 20%
(regardless of the holding percentage) if the distribution is from profits attributable to an &#8216;approved enterprise&#8217;, a &#8216;beneficiary
enterprise&#8217;, a &#8216;preferred enterprise&#8217;, a &#8216;preferred technology enterprise&#8217; or a &#8217;special preferred
technology enterprise&#8217; (as defined under the Law for the Encouragement of Capital Investments, 1959, or the Encouragement Law)
of the distributing company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax on dividends distributed
from profits attributable to &#8216;preferred technology enterprise&#8217; or a &#8217;special preferred technology enterprise&#8217;,
and in certain cases an &#8216;approved enterprise&#8217;, to a non-Israeli resident company that holds solely or together with other
foreign companies 90% or more in the Israeli company, under certain conditions detailed in the Encouragement Law, is at the rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends received by non-Israeli
residents from an Israeli resident company are subject to tax at a rate of 30% or 25% (or less, if a tax treaty is applicable) if the
non-Israeli resident is not a Significant Shareholder at the time of distribution or at any time during the preceding 12 month period,
or if the company is traded on a stock exchange.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli Tax Rulings</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax filed an application
for and obtained a tax ruling, the Withholding Tax Ruling, of which provides, among other things, the obligation to pay capital gains
tax on the exchange of the AutoMax ordinary shares for SciSparc ordinary shares, subject to certain conditions and limitations, will
be deferred in accordance with the provisions of Section 104H of the ITO with respect to the shareholders who are not otherwise exempt
from Israeli tax on the Merger, who are eligible and elect to become a party to the Withholding Tax Ruling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the 104H
Ruling, and subject to certain conditions and limitations, the exchange of shares will not be deemed a sale for the shareholders eligible
and electing to be subject to that ruling, and any tax liability with respect to such exchange will be deferred until the earlier of
(i) two years after the closing of the Merger, with respect to 50% of the shares held by such shareholder, and four years after the closing
of the Merger, with respect to the other 50% of the shares held by such shareholder, and (ii) the date on which such shareholder sells
the shares of SciSparc ordinary shares it receives in the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The main conditions, limitations
and restrictions are expected to be as follows: (i) the ratio between the market value of the transferred shares and the market value
of the merged company immediately after the exchange of shares is equal to the ratio between the market value of the issued shares and
the market value of all rights in the merged company immediately after the exchange of shares; (ii) the issued shares issued to all of
the transferors grant equal rights to all of such transferors; (iii) all of the shares and all of the rights of a transferor (and of
parties associated with it) to purchase shares in the transferred company, were transferred as part of the exchange of shares, unless
the ITA approves otherwise; (iv) an application for a pre-ruling is submitted to the ITA to certify that such share exchange meets the
conditions specified in Section 104H of the ITO (such application should be submitted at least 30 days prior to the share exchange and
is subject to the ITA&#8217;s approval); (v) the issued shares must be deposited with an Israeli trustee, in order to secure the payment
of tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If SciSparc deducts any amount
from the Merger consideration payable to you in respect of Israeli withholding tax obligations, you should consult your tax advisor concerning
the possibility of obtaining a refund from the ITA of any such withheld amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are urged to consult
with your own tax advisor for a full understanding of the Israeli tax consequences of the Merger to you, including the consequences under
any applicable, state, local, foreign or other tax laws or tax treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing discussion
is for general information purposes only and is not intended to be a complete analysis or description of all potential Israeli income
tax consequences of the Merger. In addition, the discussion does not address tax consequences which may vary with, or are contingent
on, your individual circumstances. Moreover, the discussion does not address any non-income tax or any United States federal income tax
consequences, any foreign (other than Israeli), state or local tax consequences of the Merger. Accordingly, you are strongly encouraged
to consult with your own tax advisor as to the tax consequences of the Merger in your particular circumstances, including the applicability
and effect of the alternative minimum tax and any state, local or foreign and other tax laws and of changes in those laws.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>MATERIAL U.S. FEDERAL INCOME
TAX CONSIDERATIONS TO U.S. HOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following discussion
is a summary of the material U.S. federal income tax considerations applicable to you if you are a U.S. Holder (as defined below) of
AutoMax Ordinary Shares, as a consequence of your shares being exchanged for SciSparc Ordinary Shares and SciSparc pre-funded warrants
in the Merger. With respect to the ownership and disposition of SciSparc Ordinary Shares and SciSparc pre-funded warrants, this discussion
is limited to SciSparc Ordinary Shares and SciSparc pre-funded warrants received in the Merger solely as a result of holding AutoMax
Ordinary Shares prior to the Merger. This discussion addresses only those U.S. Holders that hold AutoMax Ordinary Shares as capital assets
within the meaning of Section 1221 of the Code (generally property held for investment).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Sullivan &amp; Worcester
LLP has delivered an opinion that, based upon and subject to the terms of the opinion, and subject to customary assumptions, representations
and covenants, the Merger as structured is a reverse triangular merger that meets the requirements of a &#8220;reorganization&#8221;
as in Section&#160;368(a)(1)(A) of the Code, as augmented by the provisions of Section&#160;368(a)(2)(E), which opinion has been filed
by amendment as Exhibit 8.1 to this proxy statement/prospectus.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">This discussion does not
address all U.S. federal income tax considerations that may be relevant to any particular investor&#8217;s particular circumstances,
including the alternative minimum tax, the Medicare tax on certain investment income and the different consequences that may apply to
investors subject to special rules under U.S. federal income tax law, such as:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">banks, financial institutions or financial services
    entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">broker-dealers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">taxpayers that are subject to the mark-to-market
    tax accounting rules;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">tax-exempt entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">governments or agencies or instrumentalities thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">insurance companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">pension funds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">mutual funds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">regulated investment companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">real estate investment trusts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons that acquired AutoMax Ordinary Shares pursuant
    to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#8220;specified foreign corporations&#8221; (including
    controlled foreign corporations), passive foreign investment companies or corporations that accumulate earnings to avoid U.S. federal
    income tax;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">tax-exempt organizations (including private foundations);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons that hold AutoMax Ordinary Shares as part
    of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion,&#8221; &#8220;synthetic security,&#8221; &#8220;constructive
    ownership transaction,&#8221; &#8220;constructive sale,&#8221; &#8220;wash sale,&#8221; or other integrated or similar transaction
    for U.S. federal income tax purposes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons that have a functional currency other than
    the U.S. dollar;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">U.S. expatriates or former long-term residents
    of the U.S.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">accrual method taxpayers that file applicable financial
    statements as described in Section&#160;451(b) of the Code;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">partnerships (or entities or arrangements classified
    as partnerships or other pass-through entities for U.S. federal income tax purposes, including S corporations) and any beneficial
    owners of such partnerships or other pass-through entities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons who are not U.S. Holders, all of whom may
    be subject to tax rules that differ materially from those summarized below.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If a partnership (including
an entity or arrangement treated as a partnership for U.S. federal income tax purposes) or other pass-through entity holds AutoMax Ordinary
Shares, the tax treatment of a partner or other member in such partnership or other pass-through entity generally will depend upon the
status of the partner or other member, the activities of the partnership or other pass-through entity and certain determinations made
at the partner or member level. If you are a partner or member of a partnership or other pass-through entity holding AutoMax Ordinary
Shares, you are urged to consult your tax advisor regarding the tax consequences to you of the Merger, and/or the ownership and disposition
of SciSparc Ordinary Shares and SciSparc pre-funded warrants by the partnership or other pass-through entity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">This discussion is based
on the Code, the regulations promulgated by the U.S. Treasury Department, or Treasury Regulations, and judicial and administrative interpretations
thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect
the tax considerations described herein. The Company has not sought, and does not intend to seek, any rulings from the Internal Revenue
Service (the &#8220;IRS&#8221;) as to any U.S. federal income tax considerations described herein. Accordingly, there can be no assurance
that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained
by a court.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Consequences of the Merger to U.S.
Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The U.S. federal income
tax consequences of the Merger will depend primarily upon whether such transaction qualifies as a &#8220;reorganization&#8221; within
the meaning of Section&#160;368(a) of the Code. Generally, no gain or loss is recognized by a corporation on a transfer of assets to
another corporation in exchange for stock or securities of such transferee corporation if such exchange is pursuant to a &#8220;plan
of reorganization,&#8221; as defined in section 368(a), and the transferee corporation is a party to the reorganization.&#160;Likewise,
no gain or loss is recognized by the transferee corporation on the receipt of such property in exchange for its stock.&#160; In addition
to meeting the statutory definition, a transaction must also satisfy certain other requirements to qualify as a reorganization, including
the business purpose, continuity of business enterprise, and continuity of interest requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Pursuant to the Merger,
AutoMax will merge with and into SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of SciSparc, and former
shareholders of AutoMax will receive voting common shares (and in some cases pre-funded warrants to acquire SciSparc voting common shares)
of SciSparc. It is the opinion of SciSparc&#8217;s U.S. federal tax counsel that the Merger as structured is a reverse triangular merger
that meets the requirements of a &#8220;reorganization&#8221; as in Section&#160;368(a)(1)(A) of the Code, as augmented by the provisions
of Section&#160;368(a)(2)(E).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If the Company or AutoMax
is not treated as a PFIC, a U.S. Holder that exchanges its AutoMax Ordinary Shares in the Merger for SciSparc Ordinary Shares and SciSparc
pre-funded warrants should not recognize any gain or loss on such exchange, except to the extent of the value of any such pre-funded
warrants. The aggregate adjusted tax basis of the SciSparc Ordinary Shares received in the Merger by a U.S. Holder should be equal to
the adjusted tax basis of the AutoMax shares surrendered in exchange therefor. The holding period of the SciParc Ordinary Shares received
in the Merger will include the holding period of the AutoMax shares surrendered in exchange therefor. The tax basis of any SciSparc pre-funded
warrants received in the Merger will equal their value on the date of the Merger, and their holding period will commence on that date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If the Company or AutoMax
is treated as a PFIC, the tax consequences of the Merger to U.S. Holders should be similar to those described above. Under the Treasury
Regulations, if the Merger otherwise qualifies as an A Reorganization (as augmented by Section 368(a)(2)(E)), the treatment of the Company
or AutoMax as a PFIC would not adversely impact the tax consequences of the Merger to U.S. Holders, except that receipt of SciSparc pre-funded
warrants might be treated as an &#8220;excess distribution&#8221;, as described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The tax matters described
above are very complicated and U.S. Holders are urged to consult their tax advisors regarding the potential tax consequences to them
if the Merger does not qualify as an A Reorganization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>PFIC Considerations in the Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">A foreign (i.e., non-U.S.)
corporation will be classified as a PFIC for U.S. federal income tax purposes if either (i) at least 75% of its gross income in a taxable
year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares
by value, is passive income or (ii) at least 50% of its assets in a taxable year (ordinarily determined based on fair market value and
averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at
least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends,
interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the
disposition of passive assets. Cash may be treated as a passive asset for this purpose. Pursuant to the start-up exception, a corporation
will not be a PFIC for the first taxable year the corporation has gross income (the &#8220;Start-Up Year&#8221;), if (1) no predecessor
of the corporation was a PFIC; (2) the corporation establishes to the satisfaction of the IRS that it will not be a PFIC for either of
the first two taxable years following the Start-Up Year; and (3) the corporation is not in fact a PFIC for either of those years (the
&#8220;Start-Up Exception&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Following the Merger,
the annual PFIC income and asset tests in respect of SciSparc will be applied based on the assets and activities of the combined business.
To determine whether the PFIC asset test has been met, a calendar-year corporation generally divides the average of the values of passive
assets at the end of each quarter by the average value of all assets at the end of each quarter. Based on the projected composition of
SciSparc&#8217;s income and assets, SciSparc does not believe that it will be classified as a PFIC for its taxable year that includes
the date of the Merger and in the foreseeable future. However, because PFIC status is based on income, assets and activities for the
entire taxable year, it is not possible to determine the PFIC status of AutoMax or SciSparc for any taxable year until after the close
of the taxable year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The rules related to PFICs
discussed above are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders
are strongly urged to consult their tax advisors concerning the application of the PFIC rules to their particular circumstances, including
as a result of PFIC Elections that such U.S. Holders may have made (or may wish to make for the taxable year including the Merger).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Tax Consequences of Ownership and Disposition
of SciSparc Ordinary Shares and SciSparc Pre-Funded Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Dividends and Other Distributions on SciSparc
Ordinary Shares (Pre-and Post-Merger)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Subject to the PFIC rules
discussed below under the heading &#8220;&#8212; Passive Foreign Investment Company Rules,&#8221; distributions on SciSparc Ordinary
Shares generally will be taxable as a dividend for U.S. federal income tax purposes to the extent paid from SciSparc&#8217;s current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of SciSparc&#8217;s
current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below
zero) the U.S. Holder&#8217;s adjusted tax basis in its SciSparc Ordinary Shares. Any remaining excess will be treated as gain realized
on the sale or other disposition of the SciSparc Ordinary Shares and will be treated as described below under the heading &#8220;&#8212;
Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of SciSparc Ordinary Shares and SciSparc Pre-Funded Warrants.&#8221;
SciSparc (which, as discussed above, should be a continuation of AutoMax for U.S. federal income tax purposes) may not maintain calculations
of earnings and profits under U.S. federal income tax principles for purposes of determining whether a distribution is a dividend for
U.S. federal income tax purposes. Thus, it is possible that the full amount of any distributions will be reported as dividends for U.S.
federal income tax purposes. The amount of any distribution will include any amounts withheld by SciSparc (or another applicable withholding
agent), which would include amounts expected to be payable in respect of Israeli income taxes, if any. Any amount treated as dividend
income will be treated as foreign-source dividend income. Amounts treated as dividends that SciSparc pays to a U.S. Holder that is a
taxable corporation generally will be taxed at regular rates and will not qualify for the dividends received deduction generally allowed
to domestic corporations in respect of dividends received from other domestic corporations. With respect to non-corporate U.S. Holders,
under tax laws currently in effect and subject to certain exceptions (including, but not limited to, dividends treated as investment
income for purposes of investment interest deduction limitations), dividends generally will be taxed at the lower applicable long-term
capital gains rate only if the SciSparc Ordinary Shares are readily tradable on an established securities market in the United States
(which should include Nasdaq) or SciSparc is eligible for benefits of the Convention between the Government of the United States of America
and the Government of the State of Israel with respect to Taxes on Income (the &#8220;U.S.-Israel Tax Treaty&#8221;), and SciSparc is
not treated as a PFIC with respect to such U.S. Holder at the time the dividend was paid or in the preceding taxable year and provided
certain holding period requirements are met. The amount of any dividend distribution paid in Israeli dollars will be the U.S. dollar
amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the
payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the dividend is
converted into U.S. dollars after the date of receipt.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Tax Consequences of Ownership and Disposition
of SciSparc Ordinary Shares and SciSparc Pre-Funded Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Dividends and Other Distributions on SciSparc
Ordinary Shares (Pre-and Post-Merger)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Subject to the PFIC rules
discussed below under the heading &#8220;&#8212; Passive Foreign Investment Company Rules,&#8221; distributions on SciSparc Ordinary
Shares generally will be taxable as a dividend for U.S. federal income tax purposes to the extent paid from SciSparc&#8217;s current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of SciSparc&#8217;s
current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below
zero) the U.S. Holder&#8217;s adjusted tax basis in its SciSparc Ordinary Shares. Any remaining excess will be treated as gain realized
on the sale or other disposition of the SciSparc Ordinary Shares and will be treated as described below under the heading &#8220;&#8212;
Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of SciSparc Ordinary Shares and SciSparc Pre-Funded Warrants.&#8221;
SciSparc (which, as discussed above, should be a continuation of AutoMax for U.S. federal income tax purposes) may not maintain calculations
of earnings and profits under U.S. federal income tax principles for purposes of determining whether a distribution is a dividend for
U.S. federal income tax purposes. Thus, it is possible that the full amount of any distributions will be reported as dividends for U.S.
federal income tax purposes. The amount of any distribution will include any amounts withheld by SciSparc (or another applicable withholding
agent), which would include amounts expected to be payable in respect of Israeli income taxes, if any. Any amount treated as dividend
income will be treated as foreign-source dividend income. Amounts treated as dividends that SciSparc pays to a U.S. Holder that is a
taxable corporation generally will be taxed at regular rates and will not qualify for the dividends received deduction generally allowed
to domestic corporations in respect of dividends received from other domestic corporations. With respect to non-corporate U.S. Holders,
under tax laws currently in effect and subject to certain exceptions (including, but not limited to, dividends treated as investment
income for purposes of investment interest deduction limitations), dividends generally will be taxed at the lower applicable long-term
capital gains rate only if the SciSparc Ordinary Shares are readily tradable on an established securities market in the United States
(which should include Nasdaq) or SciSparc is eligible for benefits of the Convention between the Government of the United States of America
and the Government of the State of Israel with respect to Taxes on Income (the &#8220;U.S.-Israel Tax Treaty&#8221;), and SciSparc is
not treated as a PFIC with respect to such U.S. Holder at the time the dividend was paid or in the preceding taxable year and provided
certain holding period requirements are met. The amount of any dividend distribution paid in Israeli dollars will be the U.S. dollar
amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the
payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the dividend is
converted into U.S. dollars after the date of receipt.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Subject to applicable
limitations, Israeli income taxes withheld from dividends on the SciSparc Ordinary Shares at a rate not exceeding the rate provided by
the U.S.-Israel Tax Treaty generally will be eligible for credit against the U.S. treaty beneficiary&#8217;s U.S. federal income tax
liability. The rules governing foreign tax credits are complex and U.S. Holders are urged to consult their tax advisers regarding the
creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, a U.S. Holder may deduct
foreign taxes, including any Israeli income tax, in computing their taxable income, subject to generally applicable limitations under
U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in
the taxable year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Gain or Loss on Sale, Taxable Exchange
or Other Taxable Disposition of SciSparc Ordinary Shares and SciSparc Pre-Funded Warrants (Pre- and Post-Merger)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Subject to the PFIC rules
discussed below under the heading &#8220;&#8212; Passive Foreign Investment Company Rules,&#8221; upon any sale, exchange or other taxable
disposition of any SciSparc Ordinary Share or SciSparc pre-funded warrant, a U.S. Holder generally will recognize gain or loss in an
amount equal to the difference between (i) the sum of (x) the amount cash and (y) the fair market value of any other property, received
in such sale, exchange or other taxable disposition and (ii) the U.S. Holder&#8217;s adjusted tax basis in such SciSparc Ordinary Share
or SciSparc Warrant, as applicable (determined as described above or below), in each case as calculated in U.S. dollars. Any such gain
or loss generally will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for
such SciSparc Ordinary Share or SciSparc pre-funded warrant, as applicable, exceeds one year. Long-term capital gain realized by a non-corporate
U.S. Holder generally will be taxable at a reduced rate. The deductibility of capital losses is subject to limitations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">This gain or loss generally
will be treated as U.S. source gain or loss. Accordingly, in the event that any Israeli tax (including withholding tax) is imposed upon
such sale, exchange or other taxable disposition, a U.S. Holder may not be able to utilize foreign tax credits unless such U.S. Holder
has foreign source income or gain in the same category from other sources. In addition, there may be other limitations on utilizing foreign
tax credits even if a U.S. Holder has foreign source income or gain in the same category from other sources. The rules governing foreign
tax credits are complex and U.S. Holders are urged to consult their tax advisers regarding the creditability of foreign taxes in their
particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If SciSparc Ordinary Shares
or SciSparc pre-funded warrants are sold, exchanged, or otherwise disposed of in a taxable transaction for Israeli shekels, the amount
realized generally will be the U.S. dollar value of the Israeli shekels received based on the spot rate in effect on the date of sale,
exchange, or other taxable disposition. If a U.S. Holder is a cash method taxpayer and the SciSparc Ordinary Shares or SciSparc pre-funded
warrants are traded on an established securities market, Israeli shekels received will be translated into U.S. dollars at the spot rate
on the settlement date of the taxable disposition. An accrual method taxpayer may elect the same treatment with respect to the taxable
disposition of SciSparc Ordinary Shares or SciSparc pre-funded warrants traded on an established securities market, provided that the
election is applied consistently from year to year. Such election cannot be changed without the consent of the IRS. Israeli shekels received
on the taxable disposition of a SciSparc Ordinary Share or SciSparc pre-funded warrants generally will have a tax basis equal to its
U.S. dollar value as determined pursuant to the rules above. Any gain or loss recognized by a U.S. Holder on a sale, exchange, or other
taxable disposition of the Israeli shekels will be ordinary income or loss and generally will be U.S.-source gain or loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Exercise, Lapse or Redemption of a SciSparc
Pre-Funded Warrant</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0"><span style="-keep: true">A U.S. Holder generally
will not recognize gain or loss upon the acquisition of a SciSparc Ordinary Share on the exercise of a SciSparc pre-funded warrant for
cash. A U.S. Holder&#8217;s tax basis in a SciSparc Ordinary Share received upon exercise of the SciSparc pre-funded warrant generally
will equal the sum of the U.S. Holder&#8217;s tax basis in such SciSparc pre-funded warrant and the exercise price. It is unclear whether
a U.S. Holder&#8217;s holding period for the SciSparc Ordinary Share received will commence on the date of exercise of the SciSparc pre-funded
warrant or the day following the date of exercise of the SciSparc pre-funded warrant; in either case, the holding period will not include
the period during which the U.S. Holder held the SciSparc Warrant. If a SciSparc pre-funded warrant is allowed to lapse unexercised,
a U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the SciSparc pre-funded warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The tax consequences of
a cashless exercise of a warrant are not clear under current law. Subject to the PFIC rules discussed below, a cashless exercise may
not be taxable, either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S.
federal income tax purposes. In either situation, a U.S. Holder&#8217;s tax basis in SciSparc Ordinary Shares received generally should
equal the U.S. Holder&#8217;s tax basis in the SciSparc pre-funded warrants exercised therefor. If the cashless exercise was not a realization
event, it is unclear whether a U.S. Holder&#8217;s holding period for the SciSparc Ordinary Shares received would be treated as commencing
on the date of exercise of the SciSparc pre-funded warrants or the day following the date of exercise of the SciSparc pre-funded warrants;
in either case, the holding period will not include the period during which the U.S. Holder held the SciSparc pre-funded warrants. If
the cashless exercise were treated as a recapitalization, the holding period of the SciSparc Ordinary Shares received would include the
holding period of the SciSparc pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">It is also possible that
a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder
could be deemed to have surrendered a number of SciSparc pre-funded warrants equal to the number of SciSparc Ordinary Shares having a
value equal to the exercise price for the total number of SciSparc pre-funded warrants to be exercised. In such case, subject to the
PFIC rules discussed below, the U.S. Holder would recognize capital gain or loss with respect to the SciSparc pre-funded warrants deemed
surrendered in an amount equal to the difference between the fair market value of the SciSparc Ordinary Shares that would have been received
in a regular exercise of the SciSparc pre-funded warrants deemed surrendered and the U.S. Holder&#8217;s tax basis in the SciSparc pre-funded
warrants deemed surrendered. In this case, a U.S. Holder&#8217;s aggregate tax basis in the SciSparc Ordinary Shares received would equal
the sum of the U.S. Holder&#8217;s tax basis in the SciSparc pre-funded warrants deemed exercised and the aggregate exercise price of
such SciSparc pre-funded warrants. It is unclear whether a U.S. Holder&#8217;s holding period for the SciSparc Ordinary Shares would
commence on the date of exercise of the SciSparc pre-funded warrants or the day following the date of exercise of the SciSparc pre-funded
warrants; in either case, the holding period will not include the period during which the U.S. Holder held the SciSparc pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Due to the absence of
authority on the U.S. federal income tax treatment of a cashless exercise, including when a U.S. Holder&#8217;s holding period would
commence with respect to SciSparc Ordinary Shares received, there can be no assurance regarding which, if any, of the alternative tax
consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult
their tax advisors regarding the tax consequences of a cashless exercise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Passive Foreign Investment Company Rules</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The treatment of U.S.
Holders of SciSparc Ordinary Shares and SciSparc pre-funded warrants could be materially different from that described above if SciSparc
is treated as a PFIC for U.S. federal income tax purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">It is not entirely clear
how various aspects of the PFIC rules apply to the warrants. Section&#160;1298(a)(4) of the Code provides that, to the extent provided
in Treasury Regulations, any person who has an option to acquire stock in a PFIC shall be considered to own such stock in the PFIC for
purposes of the PFIC rules. No final Treasury regulations are currently in effect under Section&#160;1298(a)(4) of the Code. However,
proposed Treasury Regulations under Section&#160;1298(a)(4) of the Code have been promulgated with a retroactive effective date (the
&#8220;Proposed PFIC Option Regulations&#8221;). Each U.S. Holder is urged to consult its tax advisors regarding the possible application
of the Proposed PFIC Option Regulations to an investment in the SciSparc pre-funded warrants. Solely for discussion purposes, the following
discussion assumes that the Proposed PFIC Option Regulations will apply to the SciSparc pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Although the PFIC status
of SciSparc is determined annually, an initial determination that SciSparc (or, before the Merger, AutoMax) is a PFIC generally will
apply for subsequent years to a U.S. Holder who held shares or warrants in such company while such company was a PFIC, whether or not
such company meets the test for PFIC status in those subsequent years. If AutoMax is determined to be a PFIC (for any taxable year) with
respect to a U.S. Holder who exchanges AutoMax Ordinary in the Merger, and such U.S. Holder did not timely make any of the PFIC Elections
with respect to such shares or warrants, such U.S. Holder generally will be subject to special rules with respect to (i) any gain recognized
by the U.S. Holder on the sale or other disposition of its SciSparc Ordinary Shares and SciSparc pre-funded warrants (which may include
gain realized by reason of transfers of such shares or warrants that would otherwise qualify as nonrecognition transactions for U.S.
federal income tax purposes) and (ii) any &#8220;excess distribution&#8221; made to the U.S. Holder (generally, any distributions to
such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by
such U.S. Holder in respect of the SciSparc Ordinary Shares during the three preceding taxable years of such U.S. Holder or, if shorter,
the portion of such U.S. Holder&#8217;s holding period for such shares that preceded the taxable year of the distribution) (together,
the &#8220;excess distribution rules&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Under these excess distribution
rules:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the U.S. Holder&#8217;s gain or excess distribution
    will be allocated ratably over the U.S. Holder&#8217;s holding period for the SciSparc Ordinary Shares and SciSparc pre-funded warrants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the amount allocated to the U.S. Holder&#8217;s
    taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder&#8217;s
    holding period before the first day of SciSparc&#8217;s first taxable year in which SciSparc is a PFIC, will be taxed as ordinary
    income;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the amount allocated to other taxable years (or
    portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in effect for that
    year and applicable to the U.S. Holder without regard to the U.S. Holder&#8217;s other items of income and loss for such year; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">an additional amount equal to the interest charge
    generally applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable to each such
    other taxable year of the U.S. Holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In general, if SciSparc
is determined to be a PFIC, a U.S. Holder may be able to avoid the excess distribution rules described above with respect to SciSparc
Ordinary Shares (but, under current law, not the SciSparc pre-funded warrants) by making (or having made) a timely and valid QEF election
(if eligible to do so) to include in income its pro rata share of SciSparc&#8217;s net capital gains (as long-term capital gain) and
other earnings and profits (as ordinary income), on a current basis, in each case whether or not distributed, in the taxable year of
the U.S. Holder in which or with which SciSparc&#8217;s taxable year ends. A U.S. Holder generally may make a separate election to defer
the payment of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest
charge.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If a U.S. Holder makes
a QEF election with respect to its SciSparc Ordinary Shares in a year after SciSparc&#8217;s first taxable year as a PFIC in which the
U.S. Holder held (or was deemed to hold) SciSparc Ordinary Shares, then notwithstanding such QEF election, the excess distribution rules
discussed above, adjusted to take into account the current income inclusions resulting from the QEF election, will continue to apply
with respect to such U.S. Holder&#8217;s SciSparc Ordinary Shares, unless the U.S. Holder makes a purging election under the PFIC rules.
Under one type of purging election, the U.S. Holder will be deemed to have sold such SciSparc Ordinary Shares at their fair market value
and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a result of such purging
election, the U.S. Holder will have additional basis (to the extent of any gain recognized on the deemed sale) and, solely for purposes
of the PFIC rules, a new holding period in the SciSparc Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Under current law, a U.S.
Holder may not make a QEF election with respect to its SciSparc pre-funded warrants. As a result, if a U.S. Holder sells or otherwise
disposes of such warrants (other than upon exercise of such pre-funded warrants) and SciSparc were a PFIC at any time during the U.S.
Holder&#8217;s holding period of such warrants, any gain recognized generally will be treated as an excess distribution, taxed as described
above. If a U.S. Holder that exercises such warrants properly makes and maintains a QEF election with respect to the newly acquired SciSparc
Ordinary Shares (or has previously made a QEF election with respect to SciSparc Ordinary Shares), the QEF election will apply to the
newly acquired SciSparc Ordinary Shares. Notwithstanding such QEF election, the excess distribution rules discussed above, adjusted to
take into account the current income inclusions resulting from the QEF election, will continue to apply with respect to such newly acquired
SciSparc Ordinary Shares (which, while not entirely clear, generally will be deemed to have a holding period for purposes of the PFIC
rules that includes the period the U.S. Holder held the SciSparc pre-funded warrants), unless the U.S. Holder makes a purging election
under the PFIC rules. U.S. Holders are urged to consult their tax advisors as to the application of the rules governing purging elections
to their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The QEF election is made
on a shareholder-by-shareholder basis and, once made, can be revoked only with the consent of the IRS. A U.S. Holder generally makes
a QEF election by attaching a completed IRS Form&#160;8621 (Information Return by a Shareholder of a Passive Foreign Investment Company
or Qualified Electing Fund), including the information provided in a PFIC Annual Information Statement, to a timely filed United States
federal income tax return for the tax year to which the election relates. Retroactive QEF elections generally may be made only by filing
a protective statement with such return and if certain other conditions are met or with the consent of the IRS. U.S. Holders should consult
their tax advisors regarding the availability and tax consequences of a retroactive QEF election under their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In order to comply with
the requirements of a QEF election, a U.S. Holder must receive a PFIC Annual Information Statement from SciSparc. In general, if SciSparc
determines that it was a PFIC in any taxable year, SciSparc will use commercially reasonable efforts to provide the statements and information
(including a PFIC Annual Information Statement) necessary to enable U.S. Holders to make and comply with the requirements of QEF elections
or to file a protective statement. However, there is no assurance that SciSparc will timely provide such required information. There
is also no assurance that SciSparc will have timely knowledge of its status as a PFIC in the future or of such information in order for
U.S. Holders to make or maintain a QEF election.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If a U.S. Holder has made
a QEF election with respect to the SciSparc Ordinary Shares, and the excess distribution rules discussed above do not apply to such shares
(because of a timely QEF election for SciSparc&#8217;s first taxable year as a PFIC in which the U.S. Holder holds (or is deemed to hold)
such shares or a purge of the PFIC taint pursuant to a purging election, as described above), any gain recognized on the sale of SciSparc
Ordinary Shares generally will be taxable as capital gain and no additional interest charge will be imposed under the PFIC rules. As
discussed above, if SciSparc is a PFIC for any taxable year, a U.S. Holder of SciSparc Ordinary Shares that has made a QEF election will
be currently taxed on its pro rata share of SciSparc&#8217;s earnings and profits, whether or not distributed for such year. A subsequent
distribution of such earnings and profits that were previously included in income generally should not be taxable when distributed to
such U.S. Holder. The tax basis of a U.S. Holder&#8217;s shares in a QEF will be increased by amounts that are included in income, and
decreased by amounts distributed but not taxed as dividends, under the above rules. In addition, if SciSparc is not a PFIC for any taxable
year, such U.S. Holder will not be subject to the QEF inclusion regime with respect to SciSparc Ordinary Shares for such a taxable year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Alternatively, if a U.S.
Holder, at the close of its taxable year, owns shares in a PFIC that are treated as marketable stock, the U.S. Holder may make a mark-to-market
election with respect to such shares for such taxable year. If the U.S. Holder makes a valid mark-to-market election for the first taxable
year of the U.S. Holder in which the U.S. Holder holds (or is deemed to hold) SciSparc Ordinary Shares and for which SciSparc is determined
to be a PFIC, such U.S. Holder generally will not be subject to the excess distribution rules described above with respect to its SciSparc
Ordinary Shares. Instead, in general, the U.S. Holder will include as ordinary income in each taxable year the excess, if any, of the
fair market value of its SciSparc Ordinary Shares at the end of its taxable year over its adjusted basis in its SciSparc Ordinary Shares.
These amounts of ordinary income would not be eligible for the favorable tax rates applicable to qualified dividend income or long-term
capital gains. The U.S. Holder also will recognize an ordinary loss in respect of the excess, if any, of its adjusted basis in its SciSparc
Ordinary Shares over the fair market value of its SciSparc Ordinary Shares at the end of its taxable year (but only to the extent of
the net amount of previously included income as a result of the mark-to-market election). The U.S. Holder&#8217;s basis in its SciSparc
Ordinary Shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable
disposition of its SciSparc Ordinary Shares will be treated as ordinary income. Under current law, a mark-to-market election may not
be made with respect to warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The mark-to-market election
is available only for stock that is regularly traded on a national securities exchange that is registered with the Securities and Exchange
Commission, including Nasdaq (on which the SciSparc Ordinary Shares are intended to be listed), or on a foreign exchange or market that
the IRS determines has rules sufficient to ensure that the market price represents a legitimate and sound fair market value. If made,
a mark-to-market election would be effective for the taxable year for which the election was made and for all subsequent taxable years
unless the SciSparc Ordinary Shares ceased to qualify as &#8220;marketable stock&#8221; for purposes of the PFIC rules or the IRS consented
to the revocation of the election. U.S. Holders are urged to consult their own tax advisors regarding the availability and tax consequences
of a mark-to-market election with respect to SciSparc Ordinary Shares under their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If SciSparc is a PFIC
and, at any time, has a non-U.S. subsidiary that is classified as a PFIC, U.S. Holders generally would be deemed to own a portion of
the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge described above if SciSparc
receives a distribution from, or dispose of all or part of SciSparc&#8217;s interest in, the lower-tier PFIC or the U.S. Holders otherwise
were deemed to have disposed of an interest in the lower-tier PFIC. In general, if SciSparc determines that it was a PFIC in any taxable
year, SciSparc will use commercially reasonable efforts to cause any lower-tier PFIC to provide to a U.S. Holder the information that
may be required to make or maintain a QEF election with respect to the lower-tier PFIC. There can be no assurance that SciSparc will
have timely knowledge of the status of any such lower-tier PFIC. In addition, SciSparc may not hold a controlling interest in any such
lower-tier PFIC and thus there can be no assurance that SciSparc will be able to cause the lower-tier PFIC to provide such information.
A mark-to-market election generally would not be available with respect to such lower-tier PFIC. U.S. Holders are urged to consult their
tax advisors regarding the tax issues raised by lower-tier PFICs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">A U.S. Holder that owns
(or is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder may have to file an IRS Form&#160;8621 (whether or
not a QEF or mark-to-market election is made) and such other information as may be required by the U.S. Treasury Department. Failure
to do so, if required, will extend the statute of limitations until such required information is furnished to the IRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The rules dealing with
PFICs and PFIC Elections are very complex and are affected by various factors in addition to those described above. Accordingly, U.S.
Holders of SciSparc Ordinary Shares and SciSparc pre-funded warrants should consult their own tax advisors concerning the application
of the PFIC rules to SciSparc Ordinary Shares and SciSparc pre-funded warrants under their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Additional Reporting Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Certain U.S. Holders may
be required to file an IRS Form&#160;926 (Return by a U.S. Transferor of Property to a Foreign Corporation) to report a transfer of property
(including cash) to SciSparc. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this reporting requirement,
and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in the event of a failure to
comply. Furthermore, certain U.S. Holders who are individuals and certain entities will be required to report information with respect
to such U.S. Holder&#8217;s investment in &#8220;specified foreign financial assets&#8221; on IRS Form&#160;8938 (Statement of Specified
Foreign Financial Assets), subject to certain exceptions. Specified foreign financial assets generally include any financial account
maintained with a non-U.S. financial institution and should also include SciSparc Ordinary Shares and SciSparc pre-funded warrants if
they are not held in an account maintained with a U.S. financial institution. Persons who are required to report specified foreign financial
assets and fail to do so may be subject to substantial penalties, and the period of limitations on assessment and collection of U.S.
federal income taxes may be extended in the event of a failure to comply. U.S. Holders are urged to consult their tax advisors regarding
the foreign financial asset and other reporting obligations and their application to an investment in SciSparc Ordinary Shares and SciSparc
pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Treasury Regulations meant
to require the reporting of certain tax shelter transactions could be interpreted to cover transactions generally not regarded as tax
shelters, including certain foreign currency transactions. Under the applicable Treasury Regulations, certain transactions are required
to be reported to the IRS including, in certain circumstances, a sale, exchange, retirement or other taxable disposition of foreign currency,
to the extent that such sale, exchange, retirement or other taxable disposition results in a tax loss in excess of a threshold amount.
You should consult your tax advisor to determine the tax return obligations, if any, with respect to SciSparc Ordinary Shares, SciSparc
pre-funded warrants, and the receipt of Israeli shekels in respect thereof, including any requirement to file IRS Form&#160;8886 (Reportable
Transaction Disclosure Statement).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Information Reporting and Backup Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Dividend payments with
respect to SciSparc Ordinary Shares and proceeds from the sale or exchange of SciSparc Ordinary Shares or SciSparc pre-funded warrants
may be subject to information reporting to the IRS and possible United States backup withholding. Backup withholding will not apply,
however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise
exempt from backup withholding and establishes such exempt status.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Backup withholding is
not an additional tax. Amounts withheld as backup withholding may be credited against a U.S. Holder&#8217;s United States federal income
tax liability, and a U.S. Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely
filing the appropriate claim for refund with the IRS and furnishing any required information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Stock Market Listing</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc ordinary shares
currently are listed on Nasdaq under the symbol &#8220;SPRC.&#8221; SciSparc has agreed to use its reasonable best efforts to maintain
its existing listing on Nasdaq, and to obtain approval for listing on Nasdaq of the securities of SciSparc that AutoMax shareholders
will be entitled to receive pursuant to the Merger. In addition, under the Merger Agreement, each party&#8217;s obligation to complete
the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the Merger, of various conditions, including
that the existing securities of SciSparc must have been continually listed on Nasdaq, and SciSparc must have caused the securities of
SciSparc to be issued in the Merger to be approved for listing on Nasdaq as of the closing of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to consummation of
the Merger, SciSparc intends to file a listing of additional securities application with Nasdaq. If such application is accepted, SciSparc&#8217;s
additional securities will be listed on Nasdaq following the closing of the Merger under its existing trading symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anticipated Accounting Treatment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax prepare
their respective financial statements in accordance with IFRS. The Merger will be accounted for using the acquisition method of accounting,
and SciSparc will be treated as the accounting acquirer. In identifying SciSparc as the acquiring entity for accounting purposes, SciSparc
and AutoMax took into account a number of factors as of the date of this proxy statement/prospectus, including the estimate of the relative
voting rights of all equity instruments in the combined company, the expected composition of senior management of the combined company
and the expected corporate governance structure of the combined company. No single factor was the sole determinant in the overall conclusion
that SciSparc is the acquirer for accounting purposes; rather, all factors were considered in arriving at such conclusion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Risk Allocation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement contains
representations and warranties that SciSparc and Merger Sub, on the one hand, and AutoMax, on the other hand, have made to one another
as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement
and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if such statements made
in the representations and warranties prove to be incorrect. In addition, the assertions made in the representations and warranties are
qualified by the information in confidential disclosure schedules exchanged by the parties in connection with the signing of the Merger
Agreement. While SciSparc and AutoMax do not believe that these disclosure schedules contain information required to be publicly disclosed
under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain
information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Merger Agreement.
Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about SciSparc,
AutoMax or Merger Sub, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between SciSparc
and Merger Sub on the one hand, and AutoMax on the other hand, and are modified by the disclosure schedules.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Structure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Merger Agreement,
Merger Sub will merge with and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary of SciSparc.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Completion and Effectiveness of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger will be completed
as promptly as practicable after all of the conditions to completion of the Merger are satisfied or waived, including the approval of
the shareholders of each of SciSparc and AutoMax. The Merger is anticipated to occur after the Special Meeting. However, SciSparc and
AutoMax cannot predict the exact timing of the completion of the Merger because it is subject to various conditions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Merger Consideration</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time, each
outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares, in accordance with the
Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares that AutoMax shareholders will be entitled to receive for
changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc ordinary shares issued
pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger closes and could vary significantly
from the market value of the SciSparc ordinary shares on the date of this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, AutoMax shareholders will receive SciSparc ordinary shares in exchange for AutoMax shares held by them in an amount equal
to the number of AutoMax shares held by each AutoMax shareholder multiplied by the Exchange Ratio. Certain AutoMax shareholders will
receive pre-funded warrants exercisable into SciSparc&#8217;s ordinary shares. No fractional SciSparc ordinary shares will be issued
in connection with the Merger. Instead, each AutoMax shareholder who otherwise would be entitled to receive a fractional SciSparc ordinary
share (after aggregating all fractional SciSparc ordinary shares issuable to such shareholder) will receive such amount rounded to the
nearest whole number of SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>


</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (and its advisor in connection
with the Merger) are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders are expected
to own approximately 50.01% of SciSparc&#8217;s share capital, on fully-diluted basis (subject to certain exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exchange Ratio is the
result of the following calculation (rounded to four decimal places): the number of the SciSparc outstanding shares on fully-diluted
basis (subject to certain exceptions) divided by 0.5001 multiplied by 0.4749 divided by (the number of the AutoMax Outstanding Shares
less the number of the AutoMax ordinary shares held by SciSparc); so that, in any event, immediately following the effective time, holders
of AutoMax outstanding shares (other than SciSparc) will hold together 49.99% of SciSparc&#8217;s share capital, on a fully-diluted basis
(subject to certain exceptions), immediately following the effective time.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Treatment of AutoMax Warrants, Options and
Series B Bonds</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
each AutoMax warrant, option and certain convertible rights that had resulted from a prior AutoMax transaction (in each case, whether
or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled immediately prior to the
effective time for no consideration.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms
of AutoMax&#8217;s Series B Bonds and the Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual
installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that was made on
February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made on February
28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, due on February 28, 2025, will
constitute 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will
constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger the Series B Bonds will remain
outstanding and subject to repayment in accordance with the terms of the Trust Deed. The Series B Bonds bear interest at a rate of 5.9%
per annum. As of February 7, 2025, NIS 34,245 thousand (approximately $9,110 thousand) in principal amount of Series B Bonds remains
outstanding and will therefore become a liability of the combined company following the completion of the Merger. The next payment by
AutoMax to Series B bondholders is due on February 28, 2025, in the principal amount of NIS 13,698 thousand (approximately $3,644 thousand)
and NIS 996 thousand (approximately $265 thousand) of interest accrued thereon.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors and Officers of SciSparc Following
the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of
the Merger, Mr. Oz Adler will serve as the combined company&#8217;s Chief Executive Officer and Chief Financial Officer. Additionally,
following the closing, the board of directors of the combined company is expected to initially consist of six (6) directors and will
be comprised of two (2) members designated by AutoMax and four (4) members designated by SciSparc. The composition of the combined company&#8217;s
board of directors following the effective time of the Merger is expected to satisfy the requisite independence requirements, as well
as the sophistication and independence requirements for the required committees, pursuant to Nasdaq listing requirements. For more information
regarding the composition of board of directors following the Merger, please see the section entitled &#8220;<i>Directors and Officers
of SciSparc Following the Merger</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conditions to the Completion of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the Merger
is subject to satisfaction or waiver of certain conditions including, among other things, (i)&#160;the required approvals by the parties&#8217;
shareholders, (ii) Court Approval&#160;(as defined in the Merger Agreement) in accordance with the Israeli Companies Law, including in
accordance with Sections 350 and 351 of the Companies Law and exempting, among others, SciSparc from the requirement to publish a prospectus
in Israel; (iii) this Registration Statement having been declared effective; (iv) the accuracy of the representations and warranties,
subject to certain materiality qualifications, (v)&#160;compliance by the parties with their respective covenants, (vi)&#160;no law or
order preventing the Merger and related transactions, (vii)&#160;the listing of the ordinary shares on Nasdaq, (viii)&#160;certain minimum
requirements of net cash (as defined in the Merger Agreement) held by SciSparc at the time of closing, and (ix) receipt of the 104H Tax
Ruling or Interim 104H Tax Ruling in Israel, both of which were received. For more information, please see the section entitled &#8220;<i>The
Merger &#8212; Certain Material Israeli Income Tax Consequences of the Merger</i>&#8221;.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representations and Warranties</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Merger Agreement contains customary representations and warranties of SciSparc, Merger Sub and AutoMax for a transaction of this type
relating to, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">corporate organization and
                                            power, and similar corporate matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">subsidiaries;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">authority to enter into the
                                            Merger Agreement and the related agreements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">votes required for completion
                                            of the Merger and approval of the proposals that will come before the Special Meeting and
                                            that will be the subject of the AutoMax shareholder approval;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">except as otherwise specifically
                                            identified in the Merger Agreement, the fact that the consummation of the Merger would not
                                            contravene or require the consent of any third party;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">capitalization;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">financial statements and with
                                            respect to <span style="background-color: white">SciSparc</span>, documents filed with the
                                            SEC and the accuracy of information contained in those documents;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the absence of material changes
                                            or events;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">liabilities and absence of
                                            undisclosed liabilities;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">title to assets;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">real property and leaseholds;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">intellectual property;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">material contracts to which
                                            the parties or their subsidiaries are a party and any violation, default or breach to such
                                            contracts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">regulatory compliance, permits
                                            and restrictions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">legal proceedings and orders;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">tax matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">labor, employment, and employee
                                            benefit plans;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">environmental matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">insurance;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="background-color: white">any
                                            brokerage or finder&#8217;s fee or other fee or commission in connection with the Merger;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">transactions with affiliates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">anti-bribery;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">with respect to <span style="background-color: white">SciSparc</span>,
                                            the valid issuance in the Merger of the <span style="background-color: white">SciSparc ordinary
                                            shares</span>;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">with respect to <span style="background-color: white">SciSparc</span>,
                                            receipt of an opinion from its financial advisor; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">an assertion that no other
                                            representations and warranties, except as set forth in the Merger Agreement, are being given
                                            to the other party.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The representations and warranties
of AutoMax, <span style="background-color: white">SciSparc</span> and Merger Sub contained in the Merger Agreement or any certificate
or instrument delivered pursuant to the Merger Agreement will terminate at the effective time of the Merger, and only the covenants that
by their terms survive the effective time and certain miscellaneous provisions of the Merger Agreement will survive the effective time.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-Solicitation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both <span style="background-color: white">SciSparc
</span>and AutoMax and their representatives are prohibited by the terms of the Merger Agreement from (i) soliciting, initiating, responding
to or taking any action to or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of
any acquisition proposal or acquisition inquiry or taking any action that could reasonably be expected to lead to an acquisition proposal
or acquisition inquiry; (ii) furnishing any non-public information to any person in connection with or in response to an acquisition
proposal or acquisition inquiry; (iii) engaging in discussions or negotiations with any person with respect to any acquisition proposal
or acquisition inquiry; (iv) approving, endorsing or recommending any acquisition proposal; (v) executing or entering into any letter
of intent or any contract contemplating or otherwise relating to any acquisition transaction; or (vi) publicly proposing to do any of
the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of
the Merger Agreement, each of <span style="background-color: white">SciSparc</span> and AutoMax will immediately cease any existing discussions,
negotiations and communications with any person relating to any acquisition proposal or acquisition inquiry as of the date of the Merger
Agreement and request the destruction or return of any of such party&#8217;s (or its subsidiary&#8217;s) nonpublic information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If <span style="background-color: white">SciSparc
</span>or AutoMax, or any of their respective representatives, receives an acquisition proposal or acquisition inquiry prior to the closing
of the Merger, then such party will (within one business day of such part becoming aware of such acquisition proposal or acquisition
inquiry) advise the other party orally and in writing of such acquisition proposal or acquisition inquiry (including the identity of
the person making such acquisition proposal or acquisition inquiry, and the material terms of the acquisition proposal or acquisition
inquiry).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An acquisition proposal means,
with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made between the parties) contemplating
or otherwise relating to any acquisition transaction with such party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An acquisition inquiry means,
with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest
or request for information made between the parties) with respect to or that is reasonably likely to lead to an acquisition proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An acquisition transaction
means any transaction or series of related transactions involving:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">any merger, consolidation,
                                            amalgamation, share exchange, business combination, issuance of securities, acquisition of
                                            securities, reorganization, recapitalization, tender offer, exchange offer or other similar
                                            transaction: (i) in which a party is a constituent entity; (ii) in which a person or &#8220;group&#8221;
                                            (as defined in the Exchange Act and its rules) of persons directly or indirectly acquires
                                            beneficial or record ownership of securities representing more than 20% of the outstanding
                                            securities of any class of voting securities of a party or any of its subsidiaries; or (iii)
                                            in which a party or any of its subsidiaries issues securities representing more than 20%
                                            of the outstanding securities of any class of voting securities of such party or any of its
                                            subsidiaries; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="background-color: white">any
                                            sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses
                                            or assets that constitute or account for 20% or more of the consolidated book value or the
                                            fair market value of the assets of a party and its subsidiaries, taken as a whole.</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">SciSparc
</span>Special Meeting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger Agreement,
as promptly as reasonably practicable after the filing of the definitive proxy statement, <span style="background-color: white">SciSparc
</span>will take all action necessary under applicable law to call, give notice of and hold a Special Meeting of the holders of <span style="background-color: white">SciSparc
</span>ordinary shares to vote on the Resolutions. <span style="background-color: white">SciSparc</span> will take reasonable measures
to ensure that all proxies solicited in connection with the Special Meeting are solicited in compliance with all applicable law. If,
on or before the date of the Special Meeting, <span style="background-color: white">SciSparc</span> reasonably believes that it (i) will
not receive proxies sufficient to obtain the required approvals or (ii) will not have sufficient SciSparc ordinary shares represented
to constitute a quorum necessary to conduct the business of the Special Meeting, <span style="background-color: white">SciSparc</span>
may postpone or adjourn, or make one or more successive postponements or adjournments of, the Special Meeting by up to 90 calendar days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc
</span>agreed that, subject to certain exceptions in the Merger Agreement: (i) the <span style="background-color: white">SciSparc</span>
board of directors will recommend that the holders of <span style="background-color: white">SciSparc</span> ordinary shares vote to approve
the <span style="background-color: white">Resolutions</span>; (ii) this proxy statement/prospectus would include a statement to the effect
that the <span style="background-color: white">SciSparc</span> board of directors recommends that <span style="background-color: white">SciSparc&#8217;s
</span>shareholders vote to approve the <span style="background-color: white">Resolutions</span>, or the <span style="background-color: white">SciSparc
</span>Board Recommendation; and (iii) the <span style="background-color: white">SciSparc</span> Board Recommendation would not be withheld,
amended, withdrawn or modified (and the <span style="background-color: white">SciSparc</span> board of directors would not publicly propose
to withhold, amend, withdraw or modify its recommendations without AutoMax&#8217;s prior written consent (the actions set forth in the
foregoing clause (iii), collectively, hereinafter referred to as an <span style="background-color: white">SciSparc</span> Board Recommendation
Change).</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Covenants; Conduct of Business Pending the
Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax agreed that it will
conduct its business in the ordinary course in accordance with past practices and in compliance with all applicable laws, regulations
and certain contracts, and to take other agreed-upon actions. AutoMax also agreed that, subject to certain limited exceptions, without
the consent of <span style="background-color: white">SciSparc</span>, it will not, during the period prior to consummation of the Merger:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">declare, accrue, set aside
                                            or pay any dividend or make any other distribution in respect of any shares of its share
                                            capital or make any other actual, constructive or deemed distribution in respect of AutoMax&#8217;s
                                            share capital, or directly or <span style="background-color: white">indirectly</span> acquire,
                                            or repurchase, redeem or otherwise reacquire any shares of its share capital or other securities
                                            (except in connection with the payment of the exercise price and/or withholding taxes incurred
                                            upon the exercise, settlement or vesting of any award granted under AutoMax&#8217;s share
                                            incentive plan in accordance with their current terms);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">sell, issue, grant, pledge
                                            or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (i)&#160;any
                                            share capital or other security of AutoMax (except for outstanding AutoMax ordinary shares
                                            issued upon the valid exercise of AutoMax options); (ii)&#160;any option, warrant or right
                                            to acquire any share capital or any other security, other than option grants to employees
                                            and service providers; or (iii)&#160;any instrument convertible into or exchangeable for
                                            any share capital or other security of AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">except as required to give
                                            effect to anything in contemplation of the closing of the Merger, amend any of its organizational
                                            documents, or effect or be a party to any merger, consolidation, share exchange, business
                                            combination, recapitalization, <span style="background-color: white">reclassification</span>
                                            of shares, stock split, reverse stock split or similar transaction except, for the avoidance
                                            of doubt, certain transactions contemplated by the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">propose to adopt a plan of
                                            complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization
                                            or other reorganization of AutoMax, or elect or appoint any new directors or executive officers
                                            of AutoMax, <span style="background-color: white">except</span> for the transactions contemplated
                                            by the Merger Agreement and actions and resolutions adopted in the course of its implementation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">form any subsidiary or acquire
                                            any equity interest or other interest in any other entity or enter into a joint venture,
                                            strategic alliance or partnership with any other entity;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">acquire or agree to acquire
                                            (by merger, consolidation or acquisition of stock or assets or by any other manner) (i) any
                                            business or other person or (ii) any assets that are material, individually or in the aggregate,
                                            to AutoMax; or (iii)&#160;other than in the ordinary course of business, sell, lease (as
                                            lessor), license or otherwise dispose of or subject to any lien any properties or assets
                                            of AutoMax, which are material to AutoMax, except for purchases of inventory, services or
                                            supplies in the ordinary course of business;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">(i) lend money to any person
                                            (except for the advance of expenses to employees, directors and consultants in the ordinary
                                            course of business), (ii)&#160;incur or guarantee any indebtedness for borrowed money, or
                                            (iii)&#160;guarantee any debt securities of others;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">recognize any labor union,
                                            labor organization, or similar person;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">enter into any material transaction
                                            other than in the ordinary course of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">acquire any material asset
                                            or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant
                                            any encumbrance with respect to such assets or properties, except in the ordinary course
                                            of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">sell, assign, transfer, license,
                                            sublicense or otherwise dispose of any material intellectual property (other than pursuant
                                            to non-exclusive licenses in the ordinary course of business);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">make, change or revoke any
                                            material tax election, fail to pay any income or other material tax as such tax becomes due
                                            and payable (subject to good faith disputes with respect to such taxes), file any amendment
                                            making any material change to any tax return, settle or compromise any income or other material
                                            tax liability, enter into any tax allocation, sharing, indemnification or other similar agreement
                                            or arrangement (other than customary commercial contracts entered into in the ordinary course
                                            of business the principal subject matter of which is not taxes), request or consent to any
                                            extension or waiver of any limitation period with respect to any claim or assessment for
                                            any income or other material taxes (other than pursuant to an extension of time to file any
                                            tax return granted in the ordinary course of business of not more than six months), or adopt
                                            or change any material accounting method in respect of taxes;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">enter into, materially amend
                                            or terminate any material contract, except if such execution, amendment or termination is
                                            in the ordinary course of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">(i) except in the ordinary
                                            course of business, make any expenditures, incur any liabilities, settle or discharge or
                                            satisfy any claims, litigation, obligations (absolute, accrued, asserted or unasserted, contingent
                                            or otherwise) or liabilities, or (ii)&#160;cancel any material indebtedness for borrowed
                                            money (individually or in the aggregate) or waive any claims or rights with a value in excess
                                            of $250,000, or (iii)&#160;give any material discount, accommodation or other concession
                                            (other than in the ordinary course of business consistent with past practice) in order to
                                            accelerate or induce the collection of any receivable;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">enter into, engage in or amend
                                            any transaction or contract with any interested parties (<i>Ba&#8217;alay Inyan</i>), except
                                            as required for the consummation of the closing of the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">other than as required by
                                            law or IFRS, take any action to change accounting policies or procedures;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">cancel or fail to in good
                                            faith seek to renew any material insurance policies;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">apply for or accept (i) any
                                            government grant from the IIA or any other Israeli governmental authority, or (ii) any material
                                            government Grants from any other governmental authority;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">initiate or settle, compromise,
                                            or agree to settle any legal proceeding; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">agree, resolve or commit to
                                            do any of the foregoing.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc
</span>agreed that it will conduct its business in the ordinary course consistent with past practices and in compliance with all applicable
laws, regulations and certain contracts, and to take other agreed-upon actions. <span style="background-color: white">SciSparc</span>
also agreed that, subject to certain limited exceptions, without the consent of AutoMax, it will not, during the period prior to the
consummation of the Merger:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">declare, accrue, set aside
                                            or pay any dividend or make any other distribution in respect of any of its shares or make
                                            any other actual, constructive or deemed distribution in respect of <span style="background-color: white">SciSparc&#8217;s
                                            </span>share capital, except for cash dividends made by any direct or indirect subsidiary
                                            of <span style="background-color: white">SciSparc</span> to <span style="background-color: white">SciSparc
                                            </span>or one of its subsidiaries, or directly or indirectly acquire, repurchase, redeem
                                            or otherwise reacquire any of its shares or other securities (except in connection with the
                                            payment of the exercise price and/or withholding taxes incurred upon the exercise, settlement
                                            or vesting of any award granted under <span style="background-color: white">SciSparc&#8217;s
                                            </span>share incentive plans and in accordance with their current terms);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">sell, issue, grant, pledge
                                            or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (i)&#160;any
                                            shares or other security of <span style="background-color: white">SciSparc</span> (except
                                            for <span style="background-color: white">SciSparc</span> ordinary shares issued upon the
                                            valid exercise of outstanding <span style="background-color: white">SciSparc</span> options,
                                            restricted share units or warrants); (ii)&#160;any option, warrant or right to acquire any
                                            shares or any other security; or (iii)&#160;any instrument convertible into or exchangeable
                                            for any shares or other security of <span style="background-color: white">SciSparc</span>;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">except as required to give
                                            effect to anything in contemplation of the closing of the Merger, amend any of its or its
                                            subsidiaries&#8217; organizational documents, or effect or be a party to any merger, consolidation,
                                            share exchange, business combination, recapitalization, reclassification of shares, stock
                                            split, reverse stock split or similar transaction except, for the avoidance of doubt, the
                                            Contemplated Transactions and as permitted by the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">propose to adopt a plan of
                                            complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization
                                            or other reorganization of <span style="background-color: white">SciSparc</span> or any of
                                            its Subsidiaries, or elect or appoint any new directors or executive officers of <span style="background-color: white">SciSparc</span>,
                                            except for the transactions contemplated by the Merger Agreement and actions and resolutions
                                            adopted in the course of its implementation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">form any subsidiary or acquire
                                            any equity interest or other interest in any other entity or enter into a joint venture,
                                            strategic alliance or partnership with any other entity;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">acquire or agree to acquire
                                            (by merger, consolidation or acquisition of stock or assets or by any other manner) (i)&#160;any
                                            business or other person or (ii)&#160;any assets that are material, individually or in the
                                            aggregate, to <span style="background-color: white">SciSparc</span> and its subsidiaries,
                                            taken as a whole; or (iii)&#160;sell, lease (as lessor), license or otherwise dispose of
                                            or subject to any lien any properties or assets of <span style="background-color: white">SciSparc
                                            </span>or its subsidiaries, which are material to <span style="background-color: white">SciSparc
                                            </span>and its subsidiaries, taken as a whole;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">(i) lend money to any person,
                                            (ii)&#160;incur or guarantee any indebtedness for borrowed money, (iii)&#160;guarantee any
                                            debt securities of others, or (iv)&#160;make any capital expenditure in excess of the budgeted
                                            capital expenditure amounts set forth in <span style="background-color: white">SciSparc&#8217;s
                                            </span>operating budget set forth in the disclosure schedules to the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">other than as required by
                                            applicable law or the terms of any <span style="background-color: white">SciSparc</span>
                                            benefit plan as in effect on the date of the Merger Agreement: (i)&#160;adopt, terminate,
                                            establish or enter into any <span style="background-color: white">SciSparc</span> benefit
                                            plan; (ii)&#160;cause or permit any <span style="background-color: white">SciSparc</span>
                                            benefit plan to be amended in any material respect; (iii)&#160;pay any bonus or make any
                                            profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions,
                                            benefits or other compensation or remuneration payable to any of its directors, officers
                                            or employees; (iv)&#160;increase the severance or change of control benefits offered to any
                                            current or new employees, directors or consultants or (v)&#160;hire, terminate or give notice
                                            of termination to any officer or employee whose annual base salary is or is expected to be
                                            more than $25,000 per year;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">recognize any labor union,
                                            labor organization, or similar person;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">enter into any material transaction;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">acquire any material asset
                                            or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant
                                            any encumbrance with respect to such assets or properties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">sell, assign, transfer, license,
                                            sublicense or otherwise dispose of any material <span style="background-color: white">SciSparc
                                            </span>intellectual property;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">make, change or revoke any
                                            material tax election, fail to pay any income or other material tax as such tax becomes due
                                            and payable (subject to good faith disputes with respect to such taxes), file any amendment
                                            making any material change to any tax return, settle or compromise any income or other material
                                            tax liability, enter into any tax allocation, sharing, indemnification or other similar agreement
                                            or arrangement, request or consent to any extension or waiver of any limitation period with
                                            respect to any claim or assessment for any income or other material taxes (other than pursuant
                                            to an extension of time to file any tax return granted in the ordinary course of business
                                            of not more than six months), or adopt or change any material accounting method in respect
                                            of taxes;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">enter into, materially amend
                                            or terminate any material contract;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">(i) except as otherwise set
                                            forth in <span style="background-color: white">SciSparc&#8217;s</span> operating budget,
                                            make any expenditures, incur any liabilities, settle, discharge or satisfy any claims, litigation
                                            or obligations (absolute, accrued, asserted or unasserted, contingent or otherwise) or liabilities,
                                            in each case, in amounts that exceed the aggregate amount of the budget by $200,000, or (ii)&#160;cancel
                                            any material indebtedness for borrowed money (individually or in the aggregate) or waive
                                            any claims or rights with a value in excess of $200,000, or (iii)&#160;give any material
                                            discount, accommodation or other concession (other than in the ordinary course of business
                                            consistent with past practice) in order to accelerate or induce the collection of any receivable;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">enter into, engage in or amend
                                            any transaction or contract with any interested parties (<i>Ba&#8217;alay Inyan</i>);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">other than as required by
                                            law or IFRS, take any action to change accounting policies or procedures;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">cancel or fail to in good
                                            faith seek to renew any material insurance policies;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">apply for or accept (i)&#160;any
                                            government grant from the IIA or any other Israeli governmental authority, or (ii)&#160;any
                                            material government grants from any other governmental authority;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">initiate, settle, compromise,
                                            or agree to or settle any claims or legal proceeding; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">agree, resolve or commit to
                                            do any of the foregoing.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Termination</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement may
be terminated prior to the effective time of the Merger (whether before or after approval of the <span style="background-color: white">SciSparc
</span>Shareholder Matters by <span style="background-color: white">SciSparc&#8217;s</span> shareholder and whether before or after approval
of the Company Shareholder Matters (as defined therein) by AutoMax&#8217;s shareholders, unless otherwise specified below):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="background-color: white">at
                                            any time prior to the effective time of the Merger, by mutual written consent of SciSparc
                                            and AutoMax;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by either
    SciSparc or AutoMax if the Merger was not consummated by March 31, 2025, which may be extended by mutual consent of SciSparc and
    AutoMax;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>



</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="background-color: white">by
                                            either SciSparc or AutoMax if a court of competent jurisdiction or other governmental body
                                            shall have issued a final and non-appealable order, decree or ruling, or shall have taken
                                            any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting
                                            the Contemplated Transactions, as defined in the Merger Agreement;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="background-color: white">by
                                            either SciSparc or AutoMax if: (i)&#160;the shareholders&#8217; meeting of SciSparc, including
                                            any adjournments and postponements thereof shall have been held and completed and SciSparc&#8217;s
                                            shareholders shall have taken a final vote on the SciSparc Shareholder Matters and (ii)&#160;the
                                            SciSparc Shareholder Matters shall not have been approved at the such shareholders&#8217;
                                            meeting of SciSparc, or at any adjournment or postponement thereof, by the required SciSparc
                                            shareholder vote; provided, that SciSparc may not terminate the Merger Agreement if SciSparc&#8217;s
                                            breach of its obligations thereunder was the principal factor contributing to the failure
                                            to have obtained the approval of its shareholders of the SciSparc Shareholder Matters at
                                            the shareholders&#8217; meeting of SciSparc, including any adjournments and postponements
                                            thereof;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="background-color: white">by
                                            SciSparc (at any time prior to AutoMax&#8217;s required shareholder approval being obtained)
                                            if a Company Triggering Event (as defined in the Merger Agreement) shall have occurred;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="background-color: white">by
                                            AutoMax (at any time prior to AutoMax&#8217;s required shareholder approval being obtained)
                                            if a Parent Triggering Event (as defined in the Merger Agreement) shall have occurred;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="background-color: white">by
                                            AutoMax, upon a breach of any representation, warranty, covenant or agreement set forth in
                                            the Merger Agreement by SciSparc or Merger Sub or if any representation or warranty of SciSparc
                                            or Merger Sub shall have become inaccurate, in either case, such that certain closing conditions
                                            would not be satisfied as of the time of such breach or as of the time such representation
                                            or warranty shall have become inaccurate;&#160;<i>provided</i>&#160;that AutoMax is not then
                                            in material breach of any representation, warranty, covenant or agreement under the Merger
                                            Agreement;&#160;<i>provided</i>,&#160;<i>further</i>, that if such inaccuracy in SciSparc&#8217;s
                                            or Merger Sub&#8217;s representations and warranties or breach by SciSparc or Merger Sub
                                            is curable by the End Date (as defined in the Merger Agreement) by SciSparc or Merger Sub,
                                            then the Merger Agreement shall not terminate as a result of such particular breach or inaccuracy
                                            until the expiration of a 30 calendar day period commencing upon delivery of written notice
                                            from AutoMax to SciSparc or Merger Sub of such breach or inaccuracy and its intention to
                                            terminate (it being understood that the Merger Agreement shall not terminate as a result
                                            of such particular breach or inaccuracy if such breach by SciSparc or Merger Sub is cured
                                            prior to such termination becoming effective);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="background-color: white">by
                                            SciSparc, upon a breach of any representation, warranty, covenant or agreement set forth
                                            in the Merger Agreement by AutoMax or if any representation or warranty of AutoMax shall
                                            have become inaccurate, in either case, such that certain closing conditions would not be
                                            satisfied as of the time of such breach or as of the time such representation or warranty
                                            shall have become inaccurate;&#160;<i>provided</i>&#160;that SciSparc is not then in material
                                            breach of any representation, warranty, covenant or agreement under the Merger Agreement;&#160;<i>provided</i>,&#160;<i>further</i>,
                                            that if such inaccuracy in AutoMax&#8217;s representations and warranties or breach by AutoMax
                                            is curable by the End Date by AutoMax then the Merger Agreement shall not terminate as a
                                            result of such particular breach or inaccuracy until the expiration of a 30 calendar day
                                            period commencing upon delivery of written notice from SciSparc to AutoMax of such breach
                                            or inaccuracy and its intention to terminate (it being understood that the Merger Agreement
                                            shall not terminate as a result of such particular breach or inaccuracy if such breach by
                                            AutoMax is cured prior to such termination becoming effective);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">by AutoMax, if SciSparc&#8217;s
                                            net cash at the anticipated closing date of the Merger is less than $4,250,000 (less any
                                            amount owned by AutoMax to SciSparc under any loan agreement between the parties).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Merger
Agreement is terminated, neither party is required to pay a termination fee to the other party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_009"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AGREEMENTS
RELATED TO THE MERGER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>AutoMax Shareholder Support
Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the execution
of the Merger Agreement, certain shareholders of AutoMax entered into the AutoMax Shareholder Support Agreement, covering approximately
55.56% of the outstanding shares of AutoMax. The AutoMax Shareholder Support Agreement provides, among other things, that the shareholders
party to the AutoMax Shareholder Support Agreement will vote all of the shares of AutoMax held by them in favor of the adoption of the
Merger Agreement, the approval of the Merger and the other transactions contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Indemnification Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
connection with the Merger, and subject to approval of Proposal No. 2 in the Special Meeting, to approve the form of Indemnification
Agreement for directors and officers of SciSparc, SciSparc plans to enter into Indemnification Agreements with each of the directors
and officers, following the effective time of the Merger. The Indemnification Agreements and the Amended and Restated Articles of Association
permit SciSparc to exculpate, indemnify and ensure its directors and officeholders to the fullest extent permitted by the Companies Law.
As such, the Indemnification Agreements will allow SciSparc to indemnify its directors and office holders for any obligation imposed
on them or expense spent by them as a result of their capacity as directors or executive officers of SciSparc. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
entry into the Indemnification Agreements will allow the combined company to attract and retain highly qualified directors and officers.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="background-color: white"><b>Form
of Pre-Funded Warrant</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Merger Agreement contains an ownership limitation, stating that no AutoMax shareholder may beneficially own over 9.99% of SciSparc ordinary
shares. As a result of the Exchange Ratio, certain AutoMax shareholders would be considered to hold over 9.99% of SciSparc&#8217;s share
capital following the merger. In lieu of shares, such AutoMax Shareholders will receive pre-funded warrants to purchase SciSparc&#8217;s
ordinary shares. Each SciSparc pre-funded warrant will be exercisable for $0.001 per each SciSparc ordinary share. The pre-funded warrants
will be registered in the SciSparc books and upon exercise of the pre-funded warrants, the ordinary shares underlying such exercised
pre-funded warrants will be listed for trading on any stock exchange or trading market.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="background-color: white"><b>Bridge
Loan, Amendment to Bridge Loan and the Second Amendment to the Bridge Loan</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
January 14, 2024, SciSparc entered, as lender, into a bridge loan agreement with AutoMax, pursuant to which AutoMax received a Bridge
Loan in the amount of $1.4 million. On June 9, 2024, SciSparc entered, as lender, into the Amended Bridge Loan, pursuant to which AutoMax
received an additional loan in the amount of $1.0 million, for an aggregate amount of $2.4 million. On September 5, 2024, SciSparc entered
into the Second Amendment, pursuant to which SciSparc extended an additional loan in the amount of $1.85 million bringing the total Loan
Amount to $4.25 million. &#160;During the month of September 2024, SciSparc provided AutoMax with the loan amounts due under the Second
Amendment to the Bridge Loan, and offset any interest due until November 30, 2024 from the principal amount, such as that on the closing
date of the Merger, SciSparc will be entitled to be paid the due interest at a rate of 7% per annum (or 9% per annum if the Merger is
not consummated), of the Loan Amount, accruing from the period beginning December 1, 2024 and ending on the effective date of the Merger.
In consideration for the Loan Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of
its wholly-owned subsidiary AutoMax Direct Import in favor of SciSparc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Bridge Loan, the Amended Bridge Loan and the Second Amendment, state that the principal amount of the Bridge Loan, the Amended Bridge
Loan, and the Second Amendment, will bear interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated prior
to the repayment date), compounded annually. The Bridge Loan, the Amended Bridge Loan Amount, and the Second Amendment, together with
any accrued interest, or the Owed Amount, may be repaid in part or in whole at the discretion of the AutoMax prior to the repayment date.
The repayment of the Owed Amount will be due at the earlier date of: (i) the closing of the Merger, in which the Owed Amount shall be
deemed a part of, and set-off against, the Closing Financing Amount SciSparc; or (ii) if the definitive agreement for the Merger is terminated,
in accordance with its terms, within three months from such termination date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><b>Merger
Agreement Addendum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 14, 2024, SciSparc and AutoMax entered into the Merger Agreement Addendum, pursuant to which the right to terminate the Merger
Agreement if the Merger was not consummated by August 30, 2024, was deferred to November 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Second Merger Agreement
Addendum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement Second Addendum, pursuant to which the right to terminate the
Merger Agreement if the Merger was not consummated by November 30, 2024, was deferred to March 31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Consulting Agreement </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc
has entered into a consulting agreement with Pure Capital Ltd., or Pure Capital, on December 1, 2020, as amended on August 15, 2024,
for the provision of business development and strategic consulting services, including ongoing consulting to SciSparc, its management
and its chief executive officer in the following fields: M&amp;A, investment activities, and SciSparc&#8217;s position in the capital
markets, for a monthly fee of $30,000 (plus VAT), per month, and entitlement to bonus payments upon consummation of business opportunities
achieved with the assistance of Pure Capital. In addition, on February 12, 2025, SciSparc&#8217;s board of directors approved,
that in connection with and contingent upon the closing of the Merger, Pure Capital will be entitled to a cash bonus of $1,153,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="m_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">MATTERS
BEING SUBMITTED TO A VOTE OF <span style="background-color: white">SciSparc</span> SHAREHOLDERS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal No. 1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approval of the consummation of the Merger
and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and the pre-funded
warrants at the effective time of the Merger to the shareholders of AutoMax.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Special Meeting, <span style="background-color: white">SciSparc
</span>shareholders will be asked to approve the consummation of the merger of Merger Sub with and into AutoMax, with AutoMax surviving
as a wholly-owned subsidiary of <span style="background-color: white">SciSparc</span>, and ordinary shares (and pre-funded warrants)
of <span style="background-color: white">SciSparc</span> will be issued to the AutoMax shareholders at the effective time of such Merger,
as contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula in the Merger Agreement, at the effective time of the Merger and before accounting for the financing transaction discussed below,
the AutoMax shareholders (and its Advisor in connection with the Merger) are expected to own approximately 49.99% of the aggregate number
of SciSparc&#8217;s share capital, on a fully-diluted basis, and the shareholders of <span style="background-color: white">SciSparc</span>
immediately before the Merger are expected to own approximately 50.01% of the aggregate number of SciSparc&#8217;s share capital, on
a fully-diluted basis. The Merger has been unanimously approved by the boards of directors of both companies and is expected to close
in 2025, subject to approval of <span style="background-color: white">SciSparc&#8217;s</span> shareholders as well as other customary
conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc expects that the
combined company will take advantage of the potential benefits resulting from the combination of <span style="background-color: white">SciSparc&#8217;s
</span>U.S. public company structure with the AutoMax&#8217;s business. After consummation of the Merger, SciSparc anticipates that it
will continue to search for ways to maximize shareholder value, both within and outside of the pharmaceutical segment. SciSparc may opt
to sell, assign, convey and transfer certain pharma assets or participate in a spin-off, pursuant to the Spin-Off LOI entered into on
July 8, 2024 and amended on December 16, 2024, including of its advanced clinical stage pharmaceutical portfolio and its equity stake
in SciSparc Nutraceuticals Inc. to Miza, a publicly traded company on the TSXV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Merger Agreement,
upon the effective time of the Merger, each of Mr. Alon Dayan, Mr. Lior Vider and Mr. Itschak Shrem, will resign from SciSparc&#8217;s
board of directors, and the designees of AutoMax, subject to each designees election at the Special Meeting, will be assigned to two
separate classes, whereby one such designee will be assigned to Class I with a term of office expiring at the annual general meeting
of SciSparc to be held in 2027 and the other such designee will be assigned to Class III with a term of office expiring at the annual
general meeting of SciSparc to be held in 2026<span style="background-color: white">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of, reasons for,
and other aspects of the Merger Agreement, the Merger and the issuance of <span style="background-color: white">SciSparc</span> ordinary
shares and pre-funded warrants in the Merger are described in detail in the other sections in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE SCISPARC BOARD OF DIRECTORS RECOMMENDS
THAT THE SCISPARC<br/>
SHAREHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 1.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal No. 2</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approval of the form of Indemnification Agreement
for directors and officers of SciSparc</b></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal; background-color: white">Our
Amended and Restated Articles of Association permit us to exculpate, indemnify and ensure our directors and officeholders to the fullest
extent permitted by the Companies Law. We have entered into agreements with each of our current directors and office holders undertaking
to indemnify them for any obligation imposed on them or expense spent by them as a result of their capacity as directors or executive
officers of the Company. As part of the Merger, SciSparc shall enter into new Indemnification Agreements with each of our current directors
and office holders, and the designees of AutoMax, each, an Office Holder, and together, the Office Holders.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
light of our interest in continuing to attract and retain highly qualified directors and executive officers and due to an increasing
difficulty in obtaining a fit insurance policy for our directors and executive officers, the increasing cost of obtaining such insurance
and our current market valuation of the Company, our compensation committee and board of directors concluded that it is in our best interest
and that of our shareholders to enter into and execute with each Office Holder an Indemnification Agreement in the form attached as Annex
C to this proxy statement/prospectus.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal; background-color: white">Additionally,
our compensation committee and board of directors believe that approval of the form of Indemnification Agreement is in the best interests
of our shareholders, as it will enable the combined company to attract and retain highly qualified directors and officers. Our board
of directors has further determined that based on the ongoing and planned activity to be performed by the combined company, the events
listed in the Indemnification Agreement are reasonably anticipated, and that the amounts stated in the Indemnification Agreement are
reasonable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
light of the foregoing, our compensation committee and board of directors recommended that the shareholders approve the form of Indemnification
Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, effective upon the close of
the Special Meeting, and authorize the execution and delivery of such Indemnification Agreement with all office holders of SciSparc to
be in office immediately following the close of the Special Meeting or thereafter elected or appointed as an office holder of the Company.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal; background-color: white">Under
the Companies Law, the adoption of the proposed resolution requires the approval of the compensation committee, board of directors and
shareholders, in that order.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE SCISPARC BOARD OF DIRECTORS RECOMMENDS
THAT <span style="background-color: white">SCISPARC</span> SHAREHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 2 TO APPROVE THE FORM OF
INDEMNIFICATION AGREEMENT BETWEEN SCISPARC AND ITS OFFICE HOLDERS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal No. 3</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approval of a one-time cash bonus to SciSparc&#8217;s
Chief Executive Officer, Chairman and President</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">At the Special Meeting,
shareholders will be asked to approve a one-time bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President, which bonus
shall be subject to and contingent upon the approval of Proposal No. 1, and the closing of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Under the Companies Law,
the compensation of directors and officers must comply with the company&#8217;s compensation policy and requires the approval of the
company&#8217;s compensation committee, the board of directors and shareholders, in that order. The compensation committee and the <span style="background-color: white">board
of directors</span> have reviewed, discussed and approved the proposed bonuses as detailed hereunder, in light of our compensation policy,
and determined that Mr. Adler&#8217;s bonus is in line with the terms and conditions of SciSparc&#8217;s compensation policy; however,
Mr. Weiss&#8217;s and Mr. Shrem&#8217;s bonuses are not in line with the terms and conditions of its compensation policy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc&#8217;s compensation
policy states that SciSparc may grant its Chief Executive Officer a special bonus as an award for special achievements (such as in connection
with mergers and acquisitions) or as a retention award, at the compensation committee&#8217;s and the board of directors&#8217; discretion,
subject to any additional approval as may be required by the Companies Law, or the Special Bonus. According to SciSparc&#8217;s compensation
policy, any such Special Bonus will not exceed 200% of the Chief Executive Officer&#8217;s annual base salary. However, SciSparc&#8217;s
compensation policy does not provide for the grant of special bonuses to the Chairman or the President. Therefore, in considering the
bonuses for the Chairman and the President, the compensation committee and the board of directors also considered certain factors as
required by the Companies Law. In addition, the compensation committee and the board of directors considered SciSparc&#8217;s cash position,
the Chairman&#8217;s and President&#8217;s efforts relating to the transactions contemplated under the Merger, and the fact that the
bonuses will only be distributed contingent upon the consummation of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc&#8217;s President,
Mr. Itschak Shrem, and Chairman of the board of directors, Mr. Amitay Weiss, both currently receive a monthly service fee of NIS 52,500
(approximately $14,500), and received a grant of options to purchase 1,196 ordinary shares and a grant of 200,000 restricted share units
under the SciSparc 2023 Share Incentive Plan. In addition, they are entitled to receive an annual bonus of up to 6 monthly fees and up
to 8 monthly fees in the event of over-achievement. Such bonuses are payable upon meeting objectives and targets that are set by our
Chief Executive Officer and compensation committee, and are subject to approval annually by our board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc&#8217;s Chief
Executive Officer and Chief Financial Officer, Mr. Oz Adler, currently receives a monthly fee of NIS 55,000 (approximately $15,230),
customary social benefits, reimbursement of travel and other business expenses, and received a grant of options to purchase 1,196 ordinary
shares and a grant of 200,000 restricted shares units under the SciSparc 2023 Share Incentive Plan. Mr. Adler is also entitled to receive
an annual bonus of up to 6 monthly salaries and up to 8 monthly salaries in the event of over-achievement. Such bonus is based on pre-determined
targets as set by our board of directors, following the recommendation of our compensation committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">It is proposed that in
connection with the closing of the Merger, as a reward for their individual contribution on its execution, Mr. Adler, SciSparc&#8217;s
Chief Executive Officer, will receive a one-time cash bonus of $315,000, <span style="background-color: white">Mr. Weiss, SciSparc&#8217;s
Chairman of the board of directors, </span>will receive a one-time cash bonus of $150,000, <span style="background-color: white">and
Mr. Shrem, SciSparc&#8217;s President will receive a one-time cash bonus in an amount of $50,000.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
and board of directors of SciSparc believe that the proposed bonuses are designed to appropriately incentivize these officers to realize
and maximize the benefits of the Restructuring Plan, including the Merger Agreement, and hold our executive officers accountable for executing
on the Restructuring Plan. As a result, SciSparc believes that the bonus structure aligns the proposed compensation with shareholder interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE SCISPARC BOARD OF DIRECTORS RECOMMENDS
THAT <span style="background-color: white">SCISPARC</span> SHAREHOLDERS<br/>
VOTE &#8220;FOR&#8221; PROPOSAL NO. 3 TO APPROVE A ONE-TIME CASH BONUS TO SCISPARC&#8217;S CHIEF EXECUTIVE OFFICER, CHAIRMAN AND PRESIDENT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal No. 4</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approval of Election of Each of Tomer Levy
and Yaarah Alfi and Ratification of Classes, Subject to Approval of Proposal No. 1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Background</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Election of Tomer Levy and Yaarah Alfi</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to Section 5.3(a)(iv)
of the Merger Agreement, SciSparc is required to seek the approval of its shareholders to elect two designees of AutoMax to its Board,
which election shall enter into effect contingent upon the closing of the Merger and upon the effective time of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax has submitted the
candidacy of Mr. Tomer Levy and Ms. Yaarah Alfi as the AutoMax designees in accordance with Section 5.3(a)(iv) of the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Special Meeting, shareholders
of SciSparc will be asked to elect each of Mr. Tomer Levy and Ms. Yaarah Alfi as directors of the Company, which election shall be subject
to and contingent upon the approval of Proposal No. 1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law, each of Mr. Tomer Levy and Ms. Yaarah Alfi has certified to us that they meet all the requirements of the Companies Law for election
as a director of a public company, and possess the necessary qualifications and has sufficient time to fulfill their duties as a director
of SciSparc, taking into account the special needs of SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Biographical information
concerning Mr. Tomer Levy and Ms. Yaarah Alfi is set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Mr. Tomer Levy</i></b>
has been serving as VP Business Development and Headquarters and director of AutoMax since March 2021. Prior to that, between May 2017
and March 2021, Mr. Levy served as Global AutoMax&#8217;s VP Business Development and Headquarters. Mr. Levy has experience in a wide
variety of managerial roles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Ms.
Yaarah Alfi</i></b>, has been serving as chief financial executive of AutoMax and its subsidiaries since March 2021. Ms. Alfi previously
served as controller for Global AutoMax from January 2018 until March 2021. Between 2015 and 2018, Ms. Alfi was employed as a certified
public accountant at Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global. Additionally, Ms. Alfi has experience in
a wide variety of managerial, financial, tax and accounting roles. Ms. Alfi holds a B.A. in Accounting and Business management from The
College of Management, Israel and is a certified public accountant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Ratification of Classes</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the Merger Agreement
provides that such designees of AutoMax must be assigned to classes within our Board&#8217;s staggered structure such that one such designee
will be elected for a three year term and the other such designee will be elected for a two year term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board currently consists
of seven directors who are divided into three classes with staggered three-year terms as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the Class&#160;I directors consist of Ms. Liat
    Sidi and Mr.&#160;Amnon Ben Shay and their terms will expire at our annual general meeting of shareholders to be held in 2027;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the Class&#160;II directors consist of Mr.&#160;Lior Vider, Mr.&#160;Alon
    Dayan and Mr. Moshe Revach and their terms expire at our annual general meeting of shareholders to be held in 2025; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the Class&#160;III directors consist of Mr.&#160;Amitay Weiss and Mr.&#160;Itschak
    Shrem and their terms will expire at the annual general meeting of shareholders to be held in 2026.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the effective time of
the Merger, each of Mr. Lior Vider, Mr. Alon Dayan and Mr. Itschak Shrem will resign as members of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply with our
Articles of Association, which requires that members of the Board be classified into three classes as nearly equal in number as practicable,
and the terms of the Merger Agreement, shareholders will be asked to reclassify the class structure of our Board in accordance with the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the Class&#160;I directors consist of Ms. Liat
    Sidi and Ms. Yaarah Alfi and their terms will expire at our annual general meeting of shareholders to be held in 2027;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the Class&#160;II directors consist of Mr.&#160;Amnon Ben Shay and
    Mr.&#160;Moshe Revach and their terms expire at our annual general meeting of shareholders to be held in 2025; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the Class&#160;III directors consist of Mr.&#160;Amitay Weiss and Mr.
    Tomer Levy and their terms will expire at the annual general meeting of shareholders to be held in 2026.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of any
doubt, SciSparc&#8217;s shareholders will be asked at the Special Meeting to vote in favor of the election of Mr. Tomer Levy, Ms. Yaarah
Alfi and the ratification of the classes of our Board in one single proposal such that each of the foregoing actions will only enter
into effect if Proposal No. 1 is approved at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>THE SCISPARC BOARD OF DIRECTORS
RECOMMENDS THAT SCISPARC SHAREHOLDERS<br/>
VOTE &#8220;FOR&#8221; PROPOSAL NO. 4 TO APPROVE THE ELECTION OF EACH OF TOMER LEVY AND YAARAH ALFI, AND RATIFICATION OF CLASSES, SUBJECT
TO APPROVAL OF PROPOSAL NO. 1.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Proposal No. 5</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Approval of the Reverse Split of SciSparc&#8217;s
Issued and Outstanding Ordinary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">At the Special Meeting,
shareholders will be asked to approve a framework to allow the SciSparc board of directors, in its discretion, to effect one or more
reverse splits of SciSparc&#8217;s issued and outstanding ordinary shares, within 18 months from the Special Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true"><span style="background-color: white">On
July 16, 2024, SciSparc received a written notice, or the Notice, from Nasdaq indicating that it is not in compliance with the minimum
bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain
a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), SciSparc was granted a period of 180 calendar days to
regain compliance with the minimum bid price requirement. On January 14, 2025, SciSparc received an additional written notice from Nasdaq
indicating that it had been granted, per its request, an additional 180-day compliance period, or until July 14, 2025, to regain compliance
with the minimum bid price requirement. </span>If at any time during this period the closing bid price of SciSparc&#8217;s ordinary shares
is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide SciSparc with a written confirmation of
compliance and the matter will be closed. Accordingly, the primary intent of the Reverse Split is to increase the price of SciSparc&#8217;s
ordinary shares in order to meet the minimum bid price requirement of Nasdaq.&#160;Due to the decrease in the share price of SciSparc&#8217;s
ordinary shares, on February 12, 2025, the board of directors resolved to approve a flexible framework for the implementation of the
Reverse Split at a ratio of up to 1:100.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On January 17, 2025, the
SEC approved an amendment to Nasdaq Listing Rule 5810(c)(3)(A)(iv), according to which, an issuer is not eligible for any compliance
period to cure a deficiency under the minimum bid price requirement if it has effected a reverse share split over the prior one-year
period. Due to this amendment, SciSparc&#8217;s board of directors has resolved to approve a framework which allows for multiple reverse
share splits, in order to remain in compliance with the minimum bid price requirement for an elongated period of time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc believes that
the Reverse Split of its Ordinary Shares is advisable in order to make its ordinary shares more attractive to a broader range of investors
and regain compliance with the Nasdaq minimum bid price requirement for continued listing if the price of the Company&#8217;s Ordinary
Shares does not otherwise increase such that the closing bid price of SciSparc&#8217;s Ordinary Shares is at least $1.00 per share for
a minimum of 10 consecutive business days. SciSparc&#8217;s board of directors believes that the anticipated increased price resulting
from the Reverse Split may generate additional interest and trading in its ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc is therefore
seeking approval of its shareholders to effect the Reverse Split of SciSparc&#8217;s issued and outstanding ordinary shares in the range
of a ratio of up to&#160;1:100, in one or more increments, such that, depending on the ratio, every&#160;two&#160;ordinary shares and
up to every&#160;hundred&#160;ordinary shares shall be consolidated into one ordinary share. If Proposal No. 5 is approved by SciSparc&#8217;s
shareholders, the board of directors will have the discretionary authority, within 18 months from the special meeting to determine whether
to implement such Reverse Split, the number of increments, and the exact ratio and the effective date of each increment, such that the
maximum range of the Reverse Split shall remain 1:100.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b style="-keep: true">THE SCISPARC BOARD
OF DIRECTORS RECOMMENDS THAT <span style="background-color: white">SCISPARC</span> SHAREHOLDERS<br/>
VOTE &#8220;FOR&#8221; PROPOSAL NO. 5 TO APPROVE THE REVERSE SPLIT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="background-color: white">SciSparc
</span>BUSINESS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>History and Development of the Company</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s legal
and commercial name is SciSparc Ltd. SciSparc was incorporated in the State of Israel on August 23, 2004, and is subject to the Companies
Law. SciSparc&#8217;s registered office and principal place of business is located at 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup>
Floor, Tel Aviv 6971916, Israel. SciSparc&#8217;s telephone number in Israel is: +972-73-3447180.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s website
address is http://www.scisparc.com. The information contained on SciSparc&#8217;s website or available through its website is not incorporated
by reference into and should not be considered a part of this prospectus, and the reference to its website in this prospectus is an inactive
textual reference only. The SEC also maintains an Internet website that contains reports, proxy and information statements, and other
information regarding issuers that file electronically with the SEC. SciSparc&#8217;s filings with the SEC will also be available to
the public through the SEC&#8217;s website at www.sec.gov.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is a foreign private
issuer as defined by the rules under the Securities Act and the Exchange Act. SciSparc&#8217;s status as a foreign private issuer also
exempts us from compliance with certain laws and regulations of the SEC, including the proxy rules and the short-swing profits recapture
rules. In addition, it will not be required to file annual, quarterly and current reports and financial statements with the SEC as frequently
or as promptly as U.S. domestic companies registered under the Exchange Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s capital
expenditures for 2023, 2022 and 2021 amounted to $0, $9,200 and $35,000, respectively. These expenditures were primarily for purchases
of fixed assets. SciSparc&#8217;s purchases of fixed assets primarily include, computers, and equipment used for the development of its
products, and it financed these expenditures primarily from cash on hand<span style="background-color: white">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Overview &#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is a specialty clinical-stage pharmaceutical company. Its focus is creating and enhancing a portfolio of technologies and assets based
on cannabinoid therapies. With this focus, SciSparc is currently engaged in the following development programs based on THC, and/or CBD
and/or other CBR agonists: SCI-110 for the treatment of TS and for the treatment of Alzheimer&#8217;s disease and agitation; SCI-160
for the treatment of pain; and SCI-210 for the treatment of ASD. SciSparc also holds a 50.86% controlling stake in its subsidiary SciSparc
Nutraceuticals Inc., or SciSparc Nutraceuticals, whose business focuses on the sale of hemp seeds oil-based products and others on Amazon
Marketplace.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-110
is a proprietary drug candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and
(2) CannAmide&#8482;, a proprietary PEA, formulation. PEA is an endogenous fatty acid amide that belongs to the class of nuclear factor
agonists, which are molecules that regulate the expression of genes. SciSparc believes that the combination of THC and PEA may induce
a reaction known as the &#8220;sparing effect,&#8221; which has strong potential to treat various diseases of the central nervous system
such as TS and Alzheimer&#8217;s disease and agitation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-210
is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. SciSparc believes that the combination of
CBD and PEA may also induce a sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-160
is a novel pharmaceutical preparation containing a cannabinoid receptor type 2, or CB2 receptor, agonist for the treatment of pain. This
innovative CB2 receptor agonist was synthesized by the late Raphael Mechoulam, who was a professor of medicinal chemistry at the Hebrew
University.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
believes that modulating CB2 receptor activity by selective CB2 receptor agonists holds unique therapeutic potential for addressing pain
conditions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the positive results obtained in a phase IIa TS study conducted at Yale School of Medicine, SciSparc developed a regulatory dossier
that was submitted to the German Federal Institute for Drugs and Medical Devices, or BfArM, and the Israeli Ministry of Health, or MoH,
for its SCI-110 program for TS. SciSparc plans to submit this regulatory dossier to the FDA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2021, SciSparc announced an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical
trial to evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using its
proprietary cannabinoid-based technology. In December 2021, The Israeli Medical Center for Alzheimer&#8217;s recruited the first patient
to participate in the phase IIa clinical trial. In June 2023, SciSparc announced positive topline results from its Phase IIa clinical
trial of SCI-110 in patients with Alzheimer&#8217;s disease and agitation at the Israeli Medical Center for Alzheimer&#8217;s, suggesting
that SCI-110 is safe and tolerable while significantly improving agitation symptoms over time in the elderly population with Alzheimer&#8217;s
disease. This Phase IIa clinical trial was an open label study, which included 18 patients diagnosed with Alzheimer&#8217;s disease and
agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110.&#160;Results showed
that the clinical trial met its primary endpoints of the number of drop-out subjects due to poor tolerability and the number of clinical
trial treatment-related adverse events, with no SCI-110 related safety issues observed and no dropouts from the clinical trial due to
clinical trial medication. Specifically, SCI-110 did not cause delirium, oversedation, hypotension or falls. In addition, analysis of
the clinical trial results showed that the clinical trial also met its secondary end point of change from baseline to end of treatment
in agitation measured by the Cohen Mansfield Agitation Inventory where out of the fifteen patients treated with SCI-110 at least two
consecutive times during the trial, thirteen of them at doses ranging between 7.5mg-12.5mg/day showed amelioration in agitation with
no need to use rescue medication to control agitation. Although not significant, in the exploratory endpoints, eleven patients reduced
food intake and showed feeding difficulties, as measured by the Edinburgh Feeding Evaluation in Dementia scale. There was not an effect
observed resulting from the treatment on cognition and sleep quality, as measured by the Mini Mental State Examination and by the Sleep
Order Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 8, 2022, SciSparc announced that it has received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct
its clinical trial for SCI-210 in patients suffering ASD. On January 9, 2023, SciSparc signed an agreement with Soroka Medical Center
to conduct the clinical trial with pediatric patients suffering from ASD. SciSparc&#8217;s regulatory request to carry out this clinical
trial was granted by the Israeli Medical Cannabis Agency, or IMCA, on July 10, 2023. This randomized, double-blind placebo-controlled
clinical trial to evaluate the potential efficacy, safety and tolerability of SCI-210 in treating patients with ASD was initiated in
July 2023.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
its proprietary SCI-160, in August 2021, SciSparc announced positive top-line results for a controlled pre-clinical trial on neuropathic
and post-operative pain. The study &#8220;An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and
post-surgical pain in the rat hind paw incision model,&#8221; was designed to help assess the potential of SCI-160. Key findings from
the pre-clinical trial are that SCI-160 significantly alleviates pain up to six hours after injection as compared with vehicle-treated
animals. Daily SCI-160 injections significantly alleviate subject pain from mechanical stimuli as compared with vehicle-treated animals,
for up to seven days after surgery. Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical
pain up to four days post surgery as compared with vehicle treated animals, and SCI-160 analgesic effects are prolonged in the presence
of PEA. Collectively, the results indicated that treatment with SCI-160 significantly alleviates both chronic and acute pain. Based on
the positive results, SciSparc decided to continue the development of SCI-160 towards a first in-human clinical study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>SciSparc&#8217;s
Pharmaceutical Drug Development Programs</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SCI-110
- TS, Alzheimer&#8217;s disease and agitation</span>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
believes that its pharmaceutical product candidate, SCI-110, offers a safe and potentially effective solution for a variety of medical
concerns. Despite being in its early phases of clinical testing, the application of SCI-110 has extended into several treatments, including
TS and Alzheimer&#8217;s disease and agitation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>TS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">TS
is a neuropsychiatric disorder, characterized by physical (motor) tics and vocal (phonic) tics. Motor tics generally precede the development
of phonic tics in TS, and the onset of simple tics usually predates that of complex tics. TS ranges from mild symptoms to loud noises
and forceful movements that can result in self-injury (e.g. punching oneself in the face, repeating other people&#8217;s words or involuntary
swearing). Many with TS experience additional neurobehavioral problems and comorbidities including inattention, hyperactivity and impulsivity,
anger control problems, sleep difficulties, and obsessive-compulsive symptoms. Pharmacotherapy is used when symptoms are more severe
and interfere with the ability to function. Furthermore, according to the CDC, in most cases, the prevalence of tics decreases during
adolescence and early adulthood, and sometimes disappears entirely; therefore, there are a limited number of adults with TS and it is
usually manifested mainly through moderate to severe symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Market
Size</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ongoing research advancements, increased awareness and advocacy efforts, government initiatives, innovation in therapeutic approaches,
patient and caregiver involvement, and regulatory approvals drive the TS treatment market. This dynamic landscape reflects a commitment
to understanding TS, developing effective treatments, and creating a supportive environment for affected individuals, contributing to
the market&#8217;s growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
global TS treatment market size was approximately $2.1 billion in 2022 and is expected to reach $3.4 billion by 2034.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the CDC, the prevalence of moderate to severe TS is reported to be 44%, indicating a significant portion of individuals experiencing
notable symptoms of the condition. Interestingly, adolescents between the ages of 12 and 17 show a more than twofold likelihood of being
diagnosed with TS compared to children aged 6 to 11. It highlights the impact of TS on various age groups. It emphasizes the substantial
demand for effective treatments within the TS treatment market to address the diverse needs of individuals with the condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the CDC, 83% of children diagnosed with TS also have at least one additional mental, behavioral, or developmental disorder that serves
as a driver for the TS treatment market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pharmacological
intervention is considered the first line of therapy for TS, but is reserved for more severe symptoms that interfere with the individual&#8217;s
ability to function. Today, a full class of drugs that interact with dopamine and non-dopamine systems in the brain are used in the treatment
of TS symptoms. Although as of the date of this prospectus, the FDA has approved only two pharmacological treatments (for adult TS- haloperidol
and pimozide &#8211; these treatments have a &#8220;black box warning&#8221;. Many drugs approved or off-label to treat TS are limited
to the treatment of a narrow range of TS symptoms (mainly tics), and are associated with severe side effects, both of which limit their
utility. Furthermore, several of these drugs have a black box warning on their label due to their potentially lethal effect. A black
box warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable evidence
of an association of a serious hazard with the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
medications commonly used to treat symptoms of TS can be divided into the following groups:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Antipsychotic medications: belong to a class of drugs primarily used
    to manage psychosis (including haloperidol, pimozide and fluphenazine), all of which are associated with severe side effects (including
    weight gain, sedation, akathisia (a state of agitation, distress, and restlessness), nausea and tardive dyskinesia (involuntary movements
    of the face and jaw), among others).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Alpha2 Adrenergic Agonists: belong to a class of drugs primarily used
    to manage hypertension and migraine headaches prevention (including clonidine and guanfacine), which have limited utility despite
    common application to children with Attention Deficit Hyperactivity Disorder, or ADHD. Similar to antipsychotic medications, these
    also are associated with several side effects, and some of them, such as clonidine, might even be lethal.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Benzodiazepines, an anticonvulsant or antiepileptic drug: belong to
    a class of drugs primarily used to manage seizures, panic disorder and movement disorders. Of these, Clonazepam is used off-label
    for the reduction of tics in TS patients, which also has associated negative side effects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
the currently used medications are managing only a small number of disease symptoms with limited efficacy and questionable safety, there
is a clear unmet medical need for the management of TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-110 Solution for TS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
SCI-110 platform is a drug candidate for the treatment of TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 4, 2018, SciSparc announced topline results of its Phase IIa investigator-initiated study at Yale University of SCI-110 for the
treatment of TS. The study was a single-arm, open-label trial, in which each subject both received one daily treatment of SCI-110 via
oral administration and was followed-up for a period of 12 weeks. 16 subjects participated in the study and received SCI-110 at the Yale
University Child Study Center at Yale University. The primary endpoint of the study was to assess the performance of SCI-110 in the treatment
of adult patients suffering from symptoms of TS, as measured by the Yale Global Tic Severity Scale Total Tic Score, or YGTSS-TTS, the
customary index for assessing symptom severity. Treatment was given in a dose titration regimen with a maximum dose of SCI-110 consisting
of 10mg dronabinol and 800mg CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
topline results of the study showed that each of these 16 subjects with medication-refractory TS sustained a significant reduction of
tic symptoms (paired t-test: YGTSS-TTS mean difference (mean +/- SD) =7.9+/-8.4, t= 3.7, df=15, p=0.002) from baseline (YGTSS-TTS: 38.4
+/- 8.3) to endpoint YGTSS-TTS: 30.5 +/- 10.9). This resulted in an average tic reduction of 21% across the entire sample of 16 TS subjects.
Six of the 16 medication-refractory TS subjects experienced a response to treatment as defined by a reduction in YGTSS-TTS of greater
than 25%. Improvement over time with treatment was also observed when generalized linear models were used to analyze repeated measures
data on the YGTSS-TTS. In the study, SCI-110 demonstrated no significant effects on comorbid ADHD, anxiety, depression or obsessive-compulsive
disorder, or OCD, symptoms. The medication was generally well-tolerated by the subjects with only two subjects stopping treatment early
(one due to sedation and another due to lack of improvement in tic symptoms). 12 of the 16 subjects elected to proceed with a 24-week
extension phase of the trial, which was also completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
the Phase IIa study, SciSparc announced in June 2023 BfArM approval for a Phase IIb clinical trial for SCI-110 in subjects suffering
from TS, with a view to such clinical trial being carried out in Germany at the Hannover Medical School. In August 2022, SciSparc received
MoH approval to conduct the clinical trial in Israel at Sourasky Medical Center. SciSparc also received Ethics Committee approvals in
2022 from Hannover Medical School and Sourasky Medical Center and Internal Review Board approval in 2023 at the Child Study Center at
Yale School of Medicine.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2023, SciSparc initiated the Phase IIb clinical trial at Sourasky Medical Center. The 86 patients in the clinical trial are
randomized to either oral SCI-110 or placebo at a 1:1 ratio. The overall estimated clinical trial duration is 18-24 months. SciSparc
may also be required to conduct further preclinical studies in parallel to its clinical plans as part of registration process with the
FDA and EMA. Following these clinical trials, if successful, SciSparc intends to conduct a Phase III, multinational, multicenter, randomized,
double-blind, parallel-group, placebo controlled clinical trial to evaluate the safety, tolerability and efficacy of up to twice daily
oral SCI-110 in treating TS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2016, SciSparc submitted a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. The request is still
pending and SciSparc is in communication with FDA. SciSparc&#8217;s last communication was in December 2020 when it received a letter
from FDA raising a concern that it will be hard to limit the use of the pharmaceutical product to the subset of patients SciSparc is
pursuing. There is no assurance that SciSparc will successfully obtain orphan drug designation for TS. However, in light of the fact
that SciSparc disagrees with this concern expressed by the FDA, it requested a clarification call. In the clarification call conducted
on February 2, 2021, SciSparc agreed with the FDA concern about SciSparc&#8217;s ability to limit the use of the pharmaceutical product
to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics population so SciSparc suggested
to amend its preliminary request and asked to include only adults in the treated population. An amendment letter was discussed and the
FDA described what it would want to see in such an amendment. In March SciSparc sent its response to the FDA. In June 2021, SciSparc
received a response from the FDA, explaining that they are unable to grant its request until new information becomes available to support
its request for orphan drug designation. SciSparc will re-visit the application after it obtains clinical results from its phase IIb
clinical trial in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the FDA does not allow SciSparc to pursue the Section 505(b)(2) regulatory pathway as anticipated, it may need to conduct additional
clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur,
the time and financial resources required to obtain FDA approval, and complications and risks associated with FDA approval, would substantially
increase. In a pre-IND meeting SciSparc had with FDA in February 2018, the FDA did not oppose its plans to submit an NDA via the 505(b)(2)
pathway relying, in part, on clinical and nonclinical information from literature related to dronabinol and the FDA&#8217;s previous
finding of safety and efficacy for the reference listed drug (Marinol).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Alzheimer&#8217;s
disease and Agitation</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Alzheimer&#8217;s
disease is the most common type of dementia, accounting for over two-thirds of cases of dementia. Alzheimer&#8217;s disease is a neurodegenerative
disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention,
reasoning and judgment. Symptoms of Alzheimer&#8217;s disease depend on the stage of the disease. Neuropsychiatric symptoms like apathy,
social withdrawal, disinhibition, agitation, psychosis, insomnia, poor appetite and wandering are also common in the mid to late stages.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="text-decoration:underline">Market
Size</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">It
is estimated that the global Alzheimer&#8217;s therapeutics market is projected to reach $13.57 billion by 2027 from $7.42 billion in
2019 with a compounded annual growth rate of 9.2% through 2027, which is primarily attributed to the increasing pipeline drug development
and increasing investments for drug development biomarkers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
current pharmacological treatment of agitation in Alzheimer&#8217;s disease has an unsatisfactory benefit/risk ratio and often involves
using off-label drugs. Antipsychotic drugs, which are the most frequently used drugs for this purpose, are only marginally better than
placebo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-110 Solution for Alzheimer&#8217;s disease and Agitation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
drug product, SCI-110, is a unique proprietary combination of dronabinol (synthetic delta-9-tetrahydrocannabinol (&#916;&#8313;-THC),
and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2021, SciSparc signed an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical trial
to evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using its proprietary
cannabinoid-based technology. The study&#8217;s primary objective is the safety of SCI-110 and the secondary objective is the ability
of the compound to ameliorate agitation and other behavioral disturbances in patients with Alzheimer&#8217;s disease.</p><div>


</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Phase IIa clinical trial was an open label clinical trial, which included 18 patients diagnosed with AD and agitation, to evaluate the
safety, tolerability and efficacy trends of twice daily oral administration of SCI-110. Results showed that the clinical trial met its
primary endpoints of the number of drop-out subjects due to poor tolerability and the number of clinical trial treatment-related adverse
events, with no SCI-110 related safety issues observed and no dropouts from the clinical trial due to clinical trial medication. Specifically,
SCI-110 did not cause delirium, oversedation, hypotension or falls. In addition, analysis of the clinical trial results showed that the
clinical trial also met its secondary endpoint of change from baseline to end of treatment in agitation measured by the Cohen Mansfield
Agitation Inventory, or CMAI, where out of 15 patients treated with SCI-110 at least two consecutive times during the clinical trial,
thirteen of them at doses ranging between 7.5mf-12.5mg/day showed amelioration in agitation with no need to use rescue medication to
control agitation. CMAI is a standard measure for measuring agitation in people with dementia. The clinical trial showed that these subjects
had amelioration in agitation (paired t-test: CMAI mean difference (mean +/- SD) =10.6+/-14.88, t= 2.76, df=14, p=0.015) from baseline
(CMAI: 45.87 +/- 15.17) to endpoint (CMAI: 35.27 +/- 11.09). This resulted in an average reduction of 23% across the entire sample.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the exploratory endpoints, a decrease in eating and feeding difficulties was shown in 11 patients out of the 15 patients treated at least
two consecutive times during the trial as measured by the Edinburgh Feeding Evaluation in Dementia Scale, although the increase was not
significant. No effect from the treatment was observed on cognitive measurements and sleep quality, as measured by the Mini Mental State
Exam and by the and the Sleep Disorder Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SCI-210
- ASD and SE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
believes that its pharmaceutical product candidate, SCI-210, offers a safe and potentially effective solution for a variety of medical
concerns. Despite being in its early phases of pre-clinical and clinical testing, the application of SCI-210 has extended into several
treatments, including ASD and SE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>ASD</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">ASD
is a neurodevelopmental disorder. The specific etiologies and neural bases of autism remain largely unknown; it has been proposed that
alterations in multiple genes in combination with environmental factors constitute the cause for the development of the autism phenotype.
ASD is characterized by early dysfunction in communication and social interactions, presenting with repetitive, restrictive, stereotyped
patterns of behavior and loss of interest in diverse activities. Additionally, ASD is frequently accompanied by impairments in adaptive
functioning, sensory processing disorder, aggression, or self-injury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Market
Size</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the World Health Organization, or WHO, fact sheet on epilepsy in 2024, around 50 million people have epilepsy, making it one of the
most common neurological diseases globally. The risk of premature death in people with epilepsy is up to three times higher than for
the general population.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Globally,
an estimated 5 million people are diagnosed with epilepsy each year. In high-income countries, there are estimated to be 49 per 100 000
people diagnosed with epilepsy each year. In low- and middle-income countries, this figure can be as high as 139 per 100,000.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
global epilepsy market size would grow from $7.8 billion in 2022 to $10.7 billion by 2030.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
recent years, there has been a notable increase in the approval of drugs to treat epilepsy, marking a significant step forward in addressing
the challenges posed by severe seizures. Growing awareness of the need for effective therapeutic options and the dedicated efforts of
researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
cure exists for ASD. The goal of treatment is to maximize patients&#8217; ability to function by reducing ASD symptoms and supporting
development and learning. Treatment options may include: (i) behavior and communication therapies - successful programs typically include
a team of specialists and a variety of activities to improve social skills, communication and behavior; and (ii) medications - to date,
no medication can improve the core signs of ASD, specific medications can help control comorbidity symptoms. The main symptoms to be
treated in patients with ASD are: epilepsy, aggression, hyperactivity, irritability, attention deficit, sleep problems, obsessions and
anxiety. Antipsychotic drugs are sometimes used to treat severe behavioral problems and antidepressants may be prescribed for anxiety.
Among the main drugs used in the treatment of ASD are typical antipsychotics such as Haloperidol, Thioridazine, Chlorpromazine and the
atypical risperidone, Olanzapine and Clozapine, whose use is more common. These are used with the objective to treat the child&#8217;s
behavioral problems by blocking the D2 dopaminergic channels, causing a diminished reaction to stimuli known as &#8220;neuroleptic syndrome,&#8221;
observed as calm and quiet behavior in the child. In turn, some atypical antipsychotics also exhibit an antagonism of type 2A receptors
for serotonin, aside from their effect on the D2 channels. It is important to individualize the patient when these drugs are administered,
since there are no pre-established criteria for dosing and such drugs could present extrapyramidal adverse effects such as tremors, sialorrhea,
sedation, impaired liver function, etc. Serotonin reuptake inhibitors such as Fluoxetine, Paroxetine and Sertraline are given to children
with autism because they have been found to increase 25% of serotonin levels in platelets and serum. This treatment is based on suppressing
symptoms such as anxiety, depression, OCDs, and self-injurious behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unfortunately,
about 40% of children with ASD and disruptive behavior do not respond well to standard behavioral and medical treatment. Consequently,
an exceptionally high percentage of parents are seeking help through unproven methods, including the use of compounds made of the cannabis
plant.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-210 Solution for ASD</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
drug product SCI-210 is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 8, 2022, SciSparc announced that it received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct its
clinical trial for SCI-210 in patients suffering ASD. On January 9, 2023, SciSparc signed an agreement with Soroka Medical Center to
conduct the clinical trial on pediatric patients suffering from ASD. Its regulatory request to carry out this clinical trial was granted
by the IMCA on July 10, 2023. This randomized, double-blind placebo-controlled clinical trial to evaluate the potential efficacy, safety
and tolerability of SCI-210 in treating patients with ASD was initiated in July 2023. SciSparc initiated patient enrollment for the clinical
trial in January 2024. In February 2024, SciSparc announced that it had successfully completed the manufacturing of the SCI-210 treatment
for the clinical trial. In March 2024, the first patient was enrolled in this clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>SE</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SE
is a common life-threatening medical emergency characterized by an acute, prolonged epileptic seizure. SE can represent either the exacerbation
of a pre-existing seizure or the initial manifestation of epilepsy. In order to avoid neurological sequelae, a timely treatment should
be started. When the continuous seizure does not respond to conventional drug treatment, SE can pose serious life-threatening risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
2018, GW&#8217;s Epidiolex, a plant-based, pharmaceutical grade CBD extract was approved by the FDA for the treatment of seizures associated
with two rare and severe forms of epilepsy. SciSparc&#8217;s study for SCI-210 previously met its endpoint (efficacy) when comparing
its effect to the effect of CBD alone in an in-vitro hepatocytes model of fat accumulation; the effect of CBD was enhanced by the addition
of PEA, lowering the required effective concentration of CBD. In this study, SciSparc hopes to meet the study endpoint (efficacy) when
comparing treatment using its pharmaceutical product candidate compared to the effect of CBD alone on SE and its neurological cognitive
sequelae.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Market
Size</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the World Health Organization, or WHO, report on epilepsy in 2019, around 50 million people have epilepsy. In addition, it has been
estimated that the global epilepsy market size would grow from $10.6 billion in 2021 to $14.9 billion towards the end of 2031. North
America accounted for approximately 50% of the global epilepsy therapeutics market in 2021. The U.S. is the largest epilepsy drug market
in North America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
2017, the Americas held a 41% market share ($1.49 billion) and are projected to hold such position, estimated to be $1.6 billion in 2023.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
first-line treatment for early SE mainly comprises the administration of benzodiazepines, the most frequently used of which include Diazepam,
Lorazepam, and Midazolam. Seizures continue and progress to established SE in about 40% of patients with Convulsive Status Epilepticus
(CSE) despite benzodiazepine administration as the first-line treatment. The second-line treatment for established SE consists of a loading
dose of antiepileptic drugs. Frequently used antiepileptic drugs include Phenytoin or Fosphenytoin, Valproate, Levetiracetam, Phenobarbital,
and Lacosamide. There is no clear evidence for the relative superiority of any of these drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-210 Solution for SE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
drug product SCI-210 is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 7, 2022, SciSparc announced positive results from its pre-clinical study of SCI-210 on SE, conducted at The Sheba Fund for Health
Services and Research at Chaim Sheba Medical Center, which reaffirms the potential of its proprietary combination products to have a
positive effect while minimizing adverse side effects. SciSparc&#8217;sSCI-210 platform combines PEA with CBD. The non-clinical trial
objective was to study the potential therapeutic effects of SCI-210 on SE and on neuro-biochemical markers for neurological cognitive
sequelae. A pilocarpine SE-induced mice (C57BL/6 male) model to study SCI-210&#8217;s effects on seizure severity and mortality was used.
After calibration, four groups of animals were studied: an effective-high dose CBD group, a sub-effective dose CBD group, a SCI-210 group
(a combination of sub-effective CBD dose and PEA) and a non-treated control group. The results indicated differences in mortality rate
as well as seizure rates over time. In the low-CBD group, a higher mortality rate (although not significant) was found and therefore
it is reasonable to believe that no significant impact on neuronal protection was achieved. In the high-CBD group, higher, although not
significant, levels of neuronal protection were found together with a decreased mortality rate when compared to control. The level of
neuronal protection in the SCI-210 treatment was significantly higher compared to the control group and no mortality was found in this
group. It was concluded that SCI-210 treatment may potentially be more effective than a CBD monotherapy. Moreover, since the concentrations
used in the combo treatment are significantly lower than those recommended for CBD monotherapy, this treatment also has the potential
to be safer.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-160 Pain Solution</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pain
is the most common reason for physician consultation in most developed countries. It is a major symptom in many medical conditions and
can interfere with a person&#8217;s quality of life and general functioning. Opioid medications can provide short, intermediate or long-acting
analgesia depending upon the specific properties of the medication and whether it is formulated as an extended release drug. Opioids
are efficacious analgesics in chronic malignant pain and modestly effective in nonmalignant pain management. However, there are associated
adverse effects, especially during the commencement or change in dose. Prolonged opioid use may cause drug tolerance, chemical dependency,
diversion and addiction. The potency and availability of these substances, despite their high risk of addiction and overdose, have made
them popular both as formal medical treatments and as recreational drugs. Due to their sedative effects on the medulla oblongata, opioids
in high doses present the potential for respiratory depression, and may cause respiratory failure and death. In a 2013 review study published
in Fundamental &amp; Clinical Pharmacology, various studies were cited demonstrating that cannabinoids exhibit comparable effectiveness
to opioids in models of acute pain and even greater effectiveness in models of chronic pain. Cannabis produces several compounds with
various known activities known together as cannabinoids, such as THC and CBD. In general, cannabinoids bind and act through the two characterized
CRP: CB1 and CB2. However, activation of the CB1 receptor (as for example in the case of THC) leads to unwanted psychoactive &#8220;high&#8221;
and other adverse events, whereas activation of CB2 does not lead to any psychoactivity. In addition and unrelated to the above sentence,
the affinity of the cannabis derived cannabinoids to these receptors is limited and partial. Newly synthetic cannabinoid HU-433, a specific
CB2 agonist with high CB2 receptor affinity, was specifically synthesized by Prof. Raphael Mechoulam from Hebrew University of Jerusalem
and is SciSparc&#8217;s proprietary new chemical entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2018, SciSparc executed a license agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem,
for SCI-160, a synthetic cannabinoid synthesized by Prof. Mechoulam. SciSparc completed two preliminary preclinical studies evaluating
analgesic and opioid-sparing effects of this compound in a rat model of acute and chronic pain. In the preclinical studies, SCI-160 was
well tolerated and did not cause any significant adverse clinical effects. In addition, efficacy studies demonstrated the analgesic superiority
of SCI-160 over control and were comparable to high-dose morphine analgesic effects and in some instances exerted greater potency. These
preclinical studies in SCI-160 were able to meet their endpoints - efficacy and safety - for both acute and chronic pain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Market
Size</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
global&#160;pain management drugs market size&#160;was estimated at&#160;$78.14 billion in 2022&#160;and is projected to hit around&#160;$115
billion by 2032, growing at a&#160;CAGR of 3.94% during the forecast period 2023 to 2032. On the basis of geography, North America dominated
the market and captured more than 45% revenue share in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the U.S. National Center for Health Statistics, over 310 million major procedures are performed annually, of which approximately 40
to 50 million are in the U.S. and 20 million in Europe. Moreover, there is a rise in the rate of surgeries worldwide which is the primary
reason for the growing consumption of pain management drugs. Subsequently, the increased cancer therapies associated with pain incidence
and a rising geriatric population having various therapies drive the market. Consumer preference for pain management therapies is influenced
by their high availability, ease of access, heightened awareness, cost-effectiveness, and rapid relief.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Furthermore,
rising road accidents due to the increasing number of vehicles and traffic violations lead to related trauma injuries, which create demand
for pain management post surgeries. According to the WHO, 1.3 million people die yearly from road traffic crashes. Between 20 and 50
million people suffer from non-fatal injuries, with many incurring a disability due to their injury.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Currently
available treatments are antidepressant and anticonvulsant analgesics, opioids and nonsteroidal anti-inflammatory drugs. These are inadequate
to control all pain or are associated with limiting side effects (e.g., most problematic being sedation with the antidepressant and anticonvulsant
group, constipation with the opioids and gastrointestinal and cardiovascular effects with the Non-steroidal anti-inflammatory drugs,
or NSAIDs).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;sSCI-160
Solution for pain</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-160
is a newly synthetic cannabinoid, a specific CB2 agonist with high CB2 receptor affinity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
SciSparc&#8217;s proprietary SCI-160, in August 2021, it announced positive top-line results for a controlled pre-clinical trial on neuropathic
and post-operative pain. The study &#8220;An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and
post-surgical pain in the rat hind paw incision model,&#8221; was designed to help assess the potential of SCI-160. Key findings from
the pre-clinical trial are that SCI-160 significantly alleviates pain up to six hours after injection as compared with vehicle-treated
animals. Daily SCI-160 injections significantly alleviate subject pain from mechanical stimuli as compared with vehicle-treated animals,
for up to seven days after surgery. Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical
pain up to four days post surgery as compared with vehicle treated animals and SCI-160 analgesic effects are prolonged in the presence
of PEA. Collectively, the results indicated that treatment with SCI-160 significantly alleviates both chronic and acute pain. Based on
the positive results, SciSparc is continuing the development of SCI-160 towards a first in-human clinical study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Other Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>SciSparc&#8217;s
CannAmide&#8482; Anti-Inflammatory and Chronic Pain Solution</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">CannAmide&#8482;
is a cannabimimetic compound that regulates endocannabinoid levels by enhancing receptor sensitivity and inhibiting their metabolism,
and is particularly attractive therapeutically as it appears to have a very high safety profile with low or no abuse liability. Although
numerous clinical trials have shown the favorable effect of PEA as an analgesic agent it has low solubility.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2019, SciSparc announced the issuance of a product license for its proprietary PEA oral tablet CannAmide&#8482; by Health Canada&#8217;s
Natural and NNHPD, for the recommended use as an anti-inflammatory and to help relieve chronic pain. This license was issued by the NNHPD
under the authority of the NHPR. Dosage form of the described natural health product is tablets composed of 400mg PEA with a recommended
dose of one tablet three times a day. Chronic pain is estimated to affect 38% of people worldwide, and according to an analysis by the
World Health Organization, half of the most prevalent conditions responsible for living with disability is characterized by the presence
of different kinds of pain. With the NNHPD license, SciSparc is able to offer safe and beneficial non-opiate pain management products.
CannAmide&#8482;&#8217;s active compound PEA is a cannabimimetic compound that regulates endocannabinoid levels by enhancing receptor
sensitivity and inhibiting their metabolism, and is particularly attractive therapeutically as it appears to have a very high safety
profile with low or to no possibility for abuse. On February 10, 2021, SciSparc announced that it had entered into an agreement with
Procaps, a leader in contract development and manufacturing services in softgel advanced technologies for the global pharmaceutical and
nutraceutical industries, to develop and commercially manufacture both of SciSparc&#8217;s drug candidates, SCI-110 and its proprietary
PEA oral tablets CannAmide&#8482;, in softgel capsule form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Cannabinoids
have great therapeutic potential and have been used for years for medicinal purposes. For example, cannabis and cannabinoids are being
used to improve the quality of life of patients with numerous and diverse indications (oncological patients, chronic pain conditions,
etc.). SciSparc believes that the novel approaches and unique mechanism of action of SciSparc&#8217;s proprietary technology platforms,
including its drug delivery systems and unique combination and specific dosages, may be expanded to treat additional diseases and unmet
medical needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the future, SciSparc may consider expanding its pipeline to include these additional indications.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Collaboration
with Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 7, 2022, SciSparc entered into a cooperation agreement, or the Cooperation Agreement, with Clearmind. The Cooperation Agreement
includes, among others, examination of the benefit of integrating the core technologies of each company to explore the development of
psychedelic-centric drug candidates and targeting mental health-related diseases. Pursuant to the terms of the Cooperation Agreement,
SciSparc conducted a joint pre-clinical study with Clearmind. Under the Cooperation Agreement, SciSparc aims to pursue, develop and commercialize
psychedelic-centric drug candidates. Its collaboration with Clearmind has resulted as of the date of this prospectus, in the filing of
nine patent applications. All patent applications refer to the combination of SciSparc&#8217;s CannAmide&#8482; with Clearmind&#8217;s
5-Methoxy-2-aminoindane, or MEAI, an innovative proprietary psychedelic treatment for addictions and others.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
May 2022, SciSparc announced that its collaboration with Clearmind resulted in the filing of a provisional patent application related
to a psychedelic combination therapy treating numerous binge behaviors. The patent application referred to the combination of SciSparc&#8217;s
CannAmide&#8482; with Clearmind&#8217;s MEAI. The patent application followed successful pre-clinical studies that showed a significant
dose dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the
CannAmide&#8482; treatment at the lower sub-effective MEAI dose. Additionally, in May 2022, SciSparc announced positive safety profile
results from its joint pre-clinical trial with Clearmind. The clinical trial tested the proprietary combination of SciSparc&#8217;s CannAmide&#8482;
with Clearmind&#8217;s psychedelic molecule, MEAI, for alcohol consumption. A histopathology assessment was conducted on several organs
(heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland) from all experiment groups (n=3-5 per group) to determine
the safety of the proprietary combination of MEAI and CannAmide&#8482; versus control (mice) that were not exposed to alcohol). The severity
of changes was scored by a 5-point scale by a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). The results
indicated a high safety profile of the combination treatment with no treatment-related changes observed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2022, SciSparc announced that its collaboration with Clearmind resulted in the filing of a provisional patent application related
to treating cocaine addiction. The patent application refers to the proprietary combination of SciSparc&#8217;s CannAmide&#8482; with
Clearmind&#8217;s MEAI, for treating cocaine addiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2022, SciSparc announced additional positive pre-clinical results of its psychedelic-based pharma collaboration for treatment
for cocaine addiction using MEAI. These pre-clinical study results added to SciSparc&#8217;s announcements regarding its collaboration
with Clearmind for their combination treatment based on SciSparc&#8217;s CannAmide&#8482; compound and Clearmind&#8217;s MEAI for various
addictions, including pre-clinical studies results, the filing of two provisional patent applications related to compositions comprised
of MEAI and n-acylethanolamines and uses thereof and treating cocaine addiction. The pre-clinical trial was led by Professor Gal Yadid
and his team from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel) and was designed
to evaluate the possible reward-like effects of MEAI with connection to cocaine and its ability to abolish cocaine-induced conditioned
place preference. In the pre-clinical trial, the self-administration paradigm was utilized, which is the gold-standard model for examining
drug addiction and is based on operant conditioning. Rats were catheterized and trained to self-administer cocaine. The results identified
a statistically significant sub-group within the study, in a non-biased manner and high integrity, which dramatically responded to the
treatment, significantly decreasing the craving for cocaine as compared to non-treated control group. This sub-group, representing 60%
of animals, showed a very high response within the group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2022, SciSparc announced that Clearmind filed a provisional patent application related to metabolic syndromes including obesity,
regarding SciSparc&#8217;s collaboration with Clearmind. The patent application is the third of the collaboration, each referring to
the proprietary combination of SciSparc&#8217;s PEA and Clearmind&#8217;s MEAI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2023, SciSparc announced that announced that Clearmind filed three provisional patent applications were filed by Clearmind with
the USPTO as a part of its ongoing collaboration. The patent applications refer to novel proprietary combinations of lysergic acid diethylamide,
psilocybin, and N,N-dimethyltryptamine and its PEA. Additionally, in February 2023, SciSparc announced that as part of its ongoing collaboration
with Clearmind, Clearmind filed three provisional patent applications with the USPTO, for unique combinations of future psychedelic-based
compounds. The patent applications refer to novel proprietary combinations of 3,4 Methylenedioxymethamphetamine, Ibogaine and Ketamine
each with SciSparc&#8217;s PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2023, SciSparc announced that together with Clearmind, it would conduct a study evaluating its combination treatment for obesity
and metabolic syndrome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2023, Clearmind filed a patent application for the treatment of dyskinesia, a combination of the pyschadelic molecule 3-Methylmethcathinone
and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
November 2023, successful results were announced from a pre-clinical trial on rodents, testing the efficacy of the combination treatment
of PEA and MEAI on obesity, performed by Joseph Tam from the Hebrew University of Jerusalem. The results indicated that there was an
increase in the metabolic process and fat burn, a reduction in appetite and meal sizes, and reductions in ambulation with affecting voluntary
activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>



</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2024, SciSparc announced that a new article was published by Saja Baraghithy et al. on the promising results from a recent study
on MEAI using Clearmind&#8217;s innovative psychoactive molecule, 5-Methoxy-2-aminoindane, or MEAI, for combating obesity. The study
was conducted by a team of experts lead by Prof. Joseph Tam from the Hebrew University of Jerusalem. The study demonstrated that the
treatment significantly induced weight loss and beneficial changes in body composition in diet-induced obesity (or DIO) mice, without
altering food intake, by decreasing fat mass while preserving lean mass. There was a significant improvement in glucose metabolism, increased
energy expenditure and fat utilization, while maintaining a similar food consumption and increased activity-specific energy expenditure
(without overstimulation), providing support for its potential to impact energy balance. Furthermore, there was a decrease in fatty liver,
as evidenced by lower liver triglyceride and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing fat accumulation.
These results further show that the treatment was well tolerated and led to increased oxygen consumption and carbon dioxide emission,
coupled with elevated energy expenditure and fat oxidation which in turn indicates increases in the metabolic process and fat burn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
another study, evaluating the acute effect of numerous doses of MEAI on metabolic and behavioral parameters in mice, in combination with
Palmitoylethanolamide, or PEA, the administered drug exhibited a remarkable degree of tolerance, leaving the animals&#8217; viability
unaffected across all experimental groups. The most favorable outcomes of the combination treatment were notably pronounced at the MEAI
20 mg/kg dose and PEA 25 mg/kg, observed as increased energy expenditure, enhanced fat oxidation, and decreased meal sizes. These findings
underscore the potential of MEAI and PEA in modulating various aspects of metabolism, locomotor activity, and feeding behavior, warranting
further investigation of their roles in the regulation of energy homeostasis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">In
January 2025, SciSparc announced the publication of a European patent application submitted by Clearmind under the European Patent Office
for innovative combination therapy of MEAI and N-Acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco
consumption, shopping and sexual conduct. Under this collaboration, SciSparc and Clearmind are researching innovative combination therapies
that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">In
February 2025, SciSparc announced he publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine
(MDMA) with N-Acylethanolamines. The patent refers to SciSparc&#8217;s innovative combination therapy of N-Acylethanolamines and Clearmind&#8217;s
MEAI, (5-methoxy-2-aminoindane) addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual
conduct. Under this collaboration, the two companies are researching innovative combination therapies that integrate psychedelic molecules
with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">To date,13 patents related to this collaboration have been filed
with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Collaboration
with Polyrizon&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 31, 2022, SciSparc entered into a collaboration agreement with Polyrizon Ltd., or Polyrizon, a biotech company focused on the development
of innovative medical device hydrogels delivered in the form of nasal sprays, or the Polyrizon Collaboration Agreement. As part of this
collaboration, SciSparc will work together to develop a unique technology for the treatment of pain, based on its SCI-160 platform and
Polyrizon&#8217;s Trap and Target<sup>TM</sup>&#160;intranasal drug delivery technology to target the central nervous system. SciSparc
agreed to pay development fees to Polyrizon up to a total of $2,550,000 upon the completion of certain milestones, as well as royalties
in the low single digits upon sales of products under the agreement and additional royalties for sales under any sublicense by us. On
August 13, 2024, SciSparc entered into a termination agreement with Polyrizon to terminate the Polyrizon Collaboration Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
August 13, 2024, SciSparc entered into an exclusive patent license agreement, or the License Agreement, for the out-licensing of its
SCI-160 program with Polyrizon. Pursuant to the License Agreement, SciSparc granted Polyrizon a royalty-bearing, exclusive, sub-licensable
right and license to the SCI-160 platform, or the License. Pursuant to the License Agreement, SciSparc received 320,000 ordinary shares
of Polyrizon, pre-funded warrants to purchase 364,931 ordinary shares of Polyrizon, and common warrants to purchase 2,054,793 ordinary
shares of Polyrizon, at an exercise price of $4.38 per share. On December 30, 2024, pursuant to a share transfer agreement, SciSparc
sold all of the Polyrizon ordinary shares and pre-funded warrants held by it, as well as an aggregate of 1,541,096 Polyrizon common warrants
to third parties, for aggregate consideration of $770,548. In addition, in consideration for the License, SciSparc will receive royalties
from sales related to the SCI-160 platform and income generated from it.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Acquisition
of Wellution&#8482;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 14, 2022, SciSparc entered into the Wellution Acquisition Agreement with the Advisor. and the other parties named therein,
to acquire from the Advisor its rights to purchase, the Wellution&#8482; brand. In connection therewith, SciSparc incorporated a new
wholly owned subsidiary,&#160;SciSparc Nutraceuticals, to hold the new assets of the Brand. The Brand sells hemp-based products, including
hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among
other beauty and hair treatment products that are all manufactured in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
accordance with the closing of the Wellution Acquisition Agreement for the Brand which took place on September 30, 2022, SciSparc paid
$4.59 million for the Brand and issued to the Advisor $15 million worth of warrants to purchase up to an aggregate amount of 82,418 SciSparc
ordinary shares, or the Advisor Warrants. The Advisor Warrants had an exercise price of $182 per share and an exercise period of five
years from the closing, until September 30, 2027.The Advisor Warrants were exercisable during the exercise period upon the earlier of
(i) an achievement of $100 million of gross sales by the Brand in the aggregate or (ii) if the price of the SciSparc ordinary shares
closes at $10.00 or above.&#160;On March 26, 2024, the Advisor agreed with SciSparc to waive all its rights under the Advisor Warrants
and have the Advisor warrants cancelled for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 23, 2023, SciSparc entered into the Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to
which, at the closing on March 28, 2023, Jeffs&#8217; Holdings acquired from us 57 of common stock of SciSparc Nutraceuticals, equal
to approximately a 49% interest in SciSparc&#8217;s wholly owned subsidiary, SciSparc Nutraceuticals, which owns the Wellution<sup>TM</sup>&#160;Brand,
for a cash consideration of $2.5 million. In addition to the cash consideration upon closing, SciSparc received from Jeffs&#8217; Brands
an additional amount accounting for certain purchase price adjustments related to inventory and working capital, which adjustments increased
the purchase price by approximately $489,330.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
the closing of the Wellution Sale Agreement on March 28, 2023, including an equity conversion of the financing amounts SciSparc previously
provided to SciSparc Nutraceuticals for working capital, it holds approximately 51% of the outstanding capital stock of SciSparc Nutraceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the Wellution Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into a consulting
agreement, or the Wellution Management Agreement for the provision of services by Jeffs&#8217; Brands for the management of the Brand
for a monthly fee of $20,000. Jeffs&#8217; Brands also received a one-time signing bonus at the closing in the amount of $51,000. The
Wellution Management Agreement is in effect for an undefined period of time and may be terminated by either party with 30 days&#8217;
advance notice.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, pursuant to the Wellution Sale Agreement, at the closing, SciSparc undertook a share exchange with Jeffs&#8217; Brands, in
which SciSparc acquired 35,345 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 of SciSparc&#8217;s ordinary
shares, in each case having an aggregate value of $288,238, or the Share Exchange. The number of shares exchanged was calculated based
on the average closing price of the shares on the Nasdaq for the 30 consecutive trading days ending on the third trading day immediately
prior to the closing date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><i>Restructuring Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 25, 2023, SciSparc announced that its board of directors resolved to pursue a Restructuring Plan which may involve transferring
its pharmaceutical activities to NewCo. As part of or independent to the Restructuring Plan, SciSparc intends to examine the possibility
of listing NewCo on a leading stock exchange, while maintaining its controlling interest in NewCo such that it will continue to control
its current business activities. SciSparc also intends to explore other potential new opportunities, activities and investments in a
variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
restructuring and possible listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other
business analyses, regulatory approvals, receipt of any necessary consents, final approvals from SciSparc&#8217;s board of directors
and satisfaction of any closing conditions to effectuate such corporate restructuring and listing of NewCo. There can be no assurance
regarding the ultimate timing of the intended restructuring and listing of NewCo or that they will be completed at all. Other than the
signing of the LOI with the Target Company on November 22, 2023, as of the date of this prospectus, SciSparc has not initiated the Restructuring
Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On July 8, 2024, SciSparc
signed the Spin-off LOI for the spin-off of advanced clinical stage pharmaceutical portfolio to a publicly traded company on the TSXV.
Pursuant to the letter of intent, SciSparc will sell, assign, convey and transfer to Miza, certain assets for consideration of common
shares and contingent rights of Miza, based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold
a controlling interest in Miza, the exact percentage of which is contingent on agreeing on definitive terms between the parties. The
resulting entity, in which SciSparc will hold a stake will be active in both the pharmaceutical and supplement sectors. On December 16,
2024, SciSparc announced that it entered into an amendment to the Spin-off LOI, solely to extend the deadline to enter into definitive
agreements by no later than March 31, 2025, which was extended from July 31, 2024, provided that such date may be further extended by
mutual written agreement of the parties, and to close the proposed transaction by no later than April 30, 2025, which was extended from
October 31, 2024.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Strategic
Transaction Opportunity Engagement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2023, SciSparc engaged Rosario Capital Ltd. to identify potential opportunities for a strategic transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Non-Binding
Letter of Intent with AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 22, 2023, SciSparc announced the signing of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated
terms as announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Restructuring Plan, on June 25, 2023, SciSparc entered into a securities purchase agreement with AutoMax, pursuant to which, at
the closing and upon the terms and conditions set forth in the securities purchase agreement with AutoMax, or the AutoMax SPA, SciSparc
invested NIS 2,500,000 (approximately $690,000) in cash, in exchange for ordinary shares of AutoMax based on a price per share of NIS
0.5. Following the closing, SciSparc held approximately 5.6% of the issued and outstanding share capital of AutoMax.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc signed the Merger Agreement with AutoMax, as further described in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Bridge
Loan with AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
                                            January 14, 2024, SciSparc entered, as lender, into a bridge loan agreement with AutoMax,
                                            pursuant to which AutoMax received a bridge loan in the amount of $1.4 million, or the Bridge
                                            Loan, further to the previously-announced non-binding letter of intent for SciSparc to acquire
                                            AutoMax. On June 9, 2024, SciSparc entered, as lender, into the Amended Bridge Loan, pursuant
                                            to which AutoMax received an additional loan in the amount of $1.0 million, for an aggregate
                                            amount of $2.4 million. On September 5, 2024, SciSparc entered into the Second Amendment,
                                            pursuant to which SciSparc extended an additional loan in the amount of $1.85 million to
                                            AutoMax under terms similar to the Amended Bridge Loan, bringing the total bridge loan amount
                                            to $4.25 million. &#160;In consideration for the Loan Amount, AutoMax established a first
                                            ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary
                                            AutoMax Direct Import in favor of SciSparc. This subjects SciSparc to additional risk in
                                            the event of a default or partial default on payment of the bridge loan. Moreover, there
                                            can be no assurance regarding the ultimate timing of the Acquisition or any other restructuring
                                            plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
terms of the Second Amendment, which remained identical to those in the Bridge Loan and the Amended Bridge Loan, state that the principal
amount will bear interest at a rate of 7% per annum (or 9% per annum if the Acquisition is not consummated prior to the repayment date),
compounded annually. The Bridge Loan, the Amended Bridge Loan Amount, and the Second Amendment, together with any accrued interest, or
the Owed Amount, may be repaid in part or in whole at the discretion of the AutoMax prior to the repayment date. The repayment of the
Owed Amount will be due at the earlier date of: (i) the closing of the Merger, in which the Owed Amount shall be deemed a part of, and
set-off against, the financing amount SciSparc will provide AutoMax with upon closing, or $4,250,000; or (ii) if the definitive agreement
for the Merger is terminated, in accordance with its terms, within three months from such termination date. In the month of September
2024, SciSparc provided AutoMax with the loan amounts due under the Second Amendment to the Bridge Loan, and offset any interest due
until November 30, 2024 from the principal amount, such that on the closing date of the Merger, SciSparc will be due interest at a rate
of 7% per annum (or 9% per annum if the Merger is not consummated) of the Loan Amount, from the period starting December 1, 2024 and
ending on the effective date of the Merger. In consideration for the Loan Amount, AutoMax established a first ranking fixed charge security
interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Direct Import in favor of SciSparc.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
intellectual property portfolio comprises seven granted U.S. patents, pending patent applications in nine families, all of which are
in the national phase of examination. Of this portfolio, SciSparc has exclusively licensed one granted U.S. patent from Dekel and one
patent family from Yissum. SciSparc&#8217;s intellectual property portfolio also includes two trademarks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Internally Developed
Patent Applications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
March 2013, SciSparc filed a provisional application with the USPTO for the technology of proprietary sequences of anti-CD3 antibody
and the utilization of the latter in various autoimmune diseases, as well as in hepato-pathologies. The provisional application has been
converted to a PCT and then entered a National Status in December 2014 in the U.S., with the European Patent Office, or EPO, and in China,
Canada and Japan. In the U.S. it received a grant status in June 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
April 2015, SciSparc filed a provisional application with the USPTO for combinations of cannabinoids, n-acylethanolamines, and inhibitors
of n-acylethanolamine degradation, which, in April 2016 was converted into an international PCT application that subsequently entered
national phase in the following state entities: U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to
utilizing the potentiating effect of n-acylethanolamines on cannabinoids for any cannabinoid amenable indication, including but not limited
to analgesia and TS. The 20-year term of any patent issuing from this application would expire in April 2036. In August and September
2021, the patent was granted in Australia and Japan, respectively, and a further patent was granted in Australia in November of 2023.
A patent was granted in Israel in August of 2022, and three patents have been issued in the U.S., two in December 2021 and one in February
2022. In December 2022, SciSparc was granted a patent from the EPO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
May 2015, SciSparc filed a provisional application with the USPTO for combinations of opioids, n-acylethanolamines, and inhibitors of
n-acylethanolamines degradation, which, in May 2016 was converted into an international PCT application that subsequently entered national
phase in the following state entities: U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to potentiating
effect of N-acylethanolamines on opioids for opioid amenable indications. The 20-year term of any patent issuing from this application
would expire in May 2036. In July 2021, the first patent was granted in Australia and a second was granted in November 2023. A patent
was issued in Japan in March 2023, and the EPO granted a patent in November 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2016, SciSparc filed a provisional application with the USPTO for the use of cannabinoids for potentiating the efficacy of antibiotics,
which in July 2017 was converted into an international PCT application that subsequently entered national phase in the following state
entities: U.S., EPO, Canada and China. The 20-year term of any patent issuing from this application would expire in July 2037. In November
2022, the USPTO issued this patent called &#8220;Compositions and Methods of Potentiating Antimicrobials&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
January 2018, SciSparc filed a provisional application with the USPTO directed to methods of treating OSA, which in January 2019 was
converted into an international PCT application that subsequently entered national phase in the following state entities: U.S., EPO,
Canada and Australia. The 20-year term of any patent issuing from this application would expire in January 2039.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
April 2019, SciSparc filed a provisional application with the USPTO directed to compositions and methods for potentiating derivatives
of 4-aminophenols, which in April 2020 was converted into an international PCT application. The PCT application subsequently entered
the national phase in Australia, Canada, China, EPO, Israel, India, Japan, Mexico, Russia, and the U.S. The 20-year term of any patent
issuing from this application would expire in April 2040.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2020, SciSparc filed a provisional application with the USPTO directed to methods for maintaining microvascular integrity, which
in August 2021 was converted into an international PCT application. The PCT application subsequently entered the national phase in Australia,
Canada, China, EPO, Israel, India, Japan, and the U.S. The 20-year term of any patent issuing from this application would expire in August
2041.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2022, SciSparc received an Israeli patent for its core technology that treats central nervous systems disorders. The invention
relates to &#8220;Pharmaceutical compositions comprised of cannabinoids and N-acylethanolamines, and methods for their use in preventing
and treating a variety of cannabinoid-treatable conditions.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
November 2022, the USPTO granted us a new patent - U.S. Patent No. 11,491,172, title: COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS.
This patent further strengthens SciSparc&#8217;s intellectual property portfolio and protection of its core technologies, and in one
of the most important markets in the world. This is SciSparc&#8217;s seventh granted patent in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>In-Licensed Patents
and Patent Applications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
May 2015, SciSparc entered into an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted
U.S. patent related to compositions and methods for treating inflammatory disorders. The agreement became effective in August 2015 immediately
after SciSparc and Dekel entered into an amendment to the license agreement. Pursuant to the license agreement, in May 2016 SciSparc
issued Dekel 200,000 of SciSparc&#8217;s ordinary shares at a price per share of NIS 0.5 on account of future royalty payments. Also,
pursuant to the license agreement, SciSparc is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization.
The milestone payments include: (i) $25,000 upon the successful completion of preclinical trials (which milestone was met in November
2016, resulting in this payment becoming due, and which was paid in March 2017); (ii) $75,000 upon the successful completion of a Phase
I/IIa trial (which was paid in April 2018); and (iii) $75,000 upon the earlier of generating net revenues of at least $200,000 from the
commercialization of the technology or the approval of the FDA / the EMA of a drug based on the licensed assets. In each case, and subject
to its discretion, the respective milestone payments are payable in cash or equity based on a price per Ordinary Share of NIS 0.5. The
royalty payments are 8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of
any patents maturing from this application would likely be 2029.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
July 14, 2019, SciSparc entered into an amendment to the license agreement, to encompass its and Dekel&#8217;s original intention to
exclude certain consumer packaged goods (including, inter alia, food, beverage, cosmetics, pet products and hemp based products, which
are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field
of SciSparc&#8217;s activity, as described in the license agreement, which intention was not reflected in the license agreement, and
therefore, desired and agreed to amend the license agreement to reflect the foregoing clarification, as well as certain additional less
material matters as discussed in the amendment. The amendment also prescribes a specific development plan under the license agreement
requiring us to invest in the licensed technology (as defined under the license agreement) formulation development and maintenance of
a total annual investment cap of $350,000 and for a non-compete and non-solicitation obligation by Dekel and Dr. Shmulewitz, SciSparc&#8217;s
former chairman and chief executive officer, towards its field of activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 5, 2024, SciSparc received written notice from Dekel for the termination of the license agreement, effective immediately, based
on SciSparc allegedly breaching its material contractual obligations by allegedly failing to provide Dekel with certain reports regarding
the licensed products under the license agreement. SciSparc disagrees and rejects Dekel&#8217;s allegations as set forth in the notice
and it is assessing the effects, if any, on its business. For further information, see &#8220;<i>Risk Factors - Risks Related to SciSparc&#8217;s
Intellectual Property &#8211; SciSparc received a termination notice for a license agreement for certain intellectual property rights
from an entity controlled by SciSparc&#8217;s former chairman and chief executive officer, Dr. Ascher Shmulewitz.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
July 29, 2018, SciSparc entered into an exclusive, worldwide, sublicensable, royalty-bearing license agreement with Yissum for a license
to make commercial use of the licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute
or sell products, or the Yissum License Agreement. According to the Yissum License Agreement, SciSparc was required to pay Yissum an
initial payment of $133,000, and shall pay Yissum royalties at the rates of 3% of net sales, subject to the royalty reductions as described
in the Yissum License Agreement. All right, title and interest in and to the Yissum License Agreement shall vest solely in Yissum, and
SciSparc shall hold and make use of the rights granted. All rights in the development results shall be solely owned by SciSparc, except
to the extent that an employee of the Yissum, including the researcher, is considered an inventor of a patentable invention arising from
the development results, in which case such invention and all patent applications and/or patents claiming such invention shall be owned
jointly by SciSparc and Yissum, as appropriate, and Yissum&#8217;s share in such joint patents shall be automatically included in the
Yissum License Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Other Intellectual
Property Protection</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to patent and trademark protection, SciSparc intends to use other means to protect its proprietary rights, including pursuing
marketing or data exclusivity periods, orphan drug status, and similar rights that are available under regulatory provisions in certain
countries, including but not limited to the United States, Europe, Canada, Japan, and China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
also relies on trade secrets, know-how, and continuing innovation to develop and maintain its competitive position. SciSparc cannot be
certain that patents will be granted with respect to any of its pending patent applications or with respect to any patent applications
filed by it in the future, nor can it be sure that any of its existing patents or any patents granted to it in the future will be commercially
useful in protecting its technology.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
also seeks regulatory approval for its products for indications with high unmet medical need, great market potential, and where it has
a proprietary position through patents covering various aspects of its products, including but not limited to: composition, dosage, formulation,
use, and manufacturing process. Its success depends, in part, on an intellectual property portfolio that supports future revenue streams
and erects barriers to its competitors. SciSparc is maintaining and building its patent portfolio through filing new patent applications,
prosecuting existing applications, and licensing and acquiring new patents and patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Despite
these measures, any of SciSparc&#8217;s intellectual property and proprietary rights could be challenged, invalidated, circumvented,
infringed or misappropriated. Intellectual property and proprietary rights may not be sufficient to permit it to take advantage of current
market trends or otherwise to provide competitive one. For more information, see &#8220;<i>Risk Factors-Risks Related to SciSparc&#8217;s
Intellectual Property.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
following table summarizes SciSparc&#8217;s portfolio of patents:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 20%; font-weight: bold; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Country</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 7%; font-weight: bold; text-align: center"><span style="-keep: true">Status</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center"><span style="-keep: true">Filing Date</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%; font-weight: bold; text-align: center"><span style="-keep: true">Title</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center"><span style="-keep: true">Estimated<br/> Expiration&#160;Date</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center"><span style="-keep: true">Product<br/> Covered</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Australia</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">19-Apr-2016</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">April 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">THX-110<br/> THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Australia</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">19-Jul-2021</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">April 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">THX-110<br/> THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Australia</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Pending</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">17-Oct-2023</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">April 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">THX-110<br/> THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Canada</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">19-Apr-2016</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">April 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">THX-110<br/> THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">United States of America</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">19-Apr-2016</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">May 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">THX-110<br/> <br/></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">United States of America</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Abandoned</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">01-Oct-2019</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">April 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">United States of America</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">10-Oct-2019</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">April 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">United States of America</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">30-Aug-2019</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">April 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">United States of America</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">Published</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">27-Aug-2021</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">April 2036</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">THX-110<br/> <br/></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 7%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 35%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Aug-2021</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Nov-2021</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Mar-2022</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    (People&#8217;s Republic)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08-Jun-2023</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    <br/>
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    <br/>
    </span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    <br/>
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Mar-2021</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Jun-2023</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 7%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 35%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Jun-2021</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Oct-2023</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Aug-2023</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    (People&#8217;s Republic)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Apr-2023</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIODS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Apr-2021</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Nov-2023</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Nov-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jan-2025</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 20239</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-210</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18-Mar-2022</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 7%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 35%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russia</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Mar-2022</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES
    TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES
    TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES
    TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES
    TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES
    TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES
    TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2018</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES
    TO CLUSTERS OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-Jun-2020</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Sep-2022</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; text-align: center; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Oct-2024</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Oct-2024</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Jul-2017</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Compositions comprising
    CB receptor agonists, uses thereof and methods for their preparation</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising
    cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising
    cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising
    cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Jul-09</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* COMPOSITIONS AND METHODS
    FOR TREATING INFLAMMATORY DISORDERS</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2029</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7-Jun-2023</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING
    MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc
has also been granted a trademark for CannAmide&#8482; in the United States with registration pending.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validation states are
    not listed separately.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;<span style="font-size: 5pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Sales and Transfer
of Intellectual Property Assets</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Transaction with
Former Subsidiary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2016, SciSparc entered into a share transfer agreement with its former subsidiary, Orimmune Bio Ltd., or Orimmune, and Karma Link
Ltd., or Karma Link. According to the agreement, SciSparc agreed to sell its interests in Orimmune to Karma Link, and also use its best
efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 13, 2018, an additional amendment to the transfer agreement was signed between SciSparc, Karma Link and Orimmune, under which
it was agreed that Orimmune (and Karma Link) will be assigned certain rights in IP related to the licensed technology owned by SciSparc,
subject to certain conditions precedent. In 2021, SciSparc received the approval of the IIA to complete the assignment and it is now
seeking to complete the transaction. As of the date of this prospectus, the conditions precedents have not yet been completed and the
assignment of the intellectual property rights related to the licensed technology owned by SciSparc have not yet been transferred.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>MitoCare X</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 10, 2022, SciSparc entered into a founders and investment agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant
to the MitoCareX Agreement, SciSparc invested an initial amount of $700,000 in MitoCareX and agreed to invest over the next two years
an additional $1,000,000, subject to the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement,
for up to a 50.01% ownership in MitoCareX. MitoCareX is focused on the discovery and development of potential drugs for cancers and other
life-threatening conditions. The MitoCareX Agreement also contains customary representations, warranties, covenants and indemnification
provisions and on March 31, 2022, the closing conditions were met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 17, 2023, SciSparc announced that MitoCareX has achieved its first milestone pursuant to the MitoCareX Agreement. The first
milestone refers to the establishment of MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future
expansion into machine learning system. The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability.
As a result of MitoCareX meeting this milestone, SciSparc invested an additional $400,000 in MitoCareX and increased its share ownership
holdings in MitoCareX from 31.48% to 41.92%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 8, 2023, SciSparc announced that MitoCareX successfully developed its core algorithm for allowing the generation of reliable 3D comparative
models of human SLC25A mitochondrial carrier proteins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 27, 2023, SciSparc announced that MitoCareX achieved positive results with the development of its laboratory capabilities by
establishing a variety of small-molecule screening platforms. With this development, MitoCareX achieved its second milestone pursuant
to the MitoCareX Agreement&#160;and as a result, on March 11, 2024 SciSparc invested an additional $600,000&#160;and increased its share
ownership holdings in MitoCareX from 41.92% to 52.73%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 26, 2024, SciSparc signed a non-binding letter of intent, or LOI, relating to the sale of its entire ownership interest in
MitoCareX, of which it owns 52.73% of the issued and outstanding share capital, to a publicly-traded company in the United States, or
the Purchaser. Pursuant to the terms of the letter of intent, initially, in exchange for transferring and selling to the Purchaser a
number of ordinary shares of MitoCareX that constitute 27% of SciSparc&#8217;s ownership in MitoCareX, SciSparc will receive cash consideration
of $700,000. Subsequent to this first phase, SciSparc will transfer to the Purchaser the remaining 73% of its ownership stake in MitoCareX
in exchange for a certain number of shares based on the valuation of the Purchaser equal to $8,000,000 and a valuation of MitoCareX equal
to $5,000,000 (the latter of which includes the $700,000 in cash consideration for SciSparc&#8217;s shares described above). The letter
of intent also includes provisions for additional milestones that, upon achievement, may increase the consideration paid by the Purchaser
to SciSparc from $5 million to $7 million. The details of the full terms of this transaction are subject to negotiation and execution
of definitive agreements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
SciSparc started early commercialization of its proprietary PEA oral tablets CannAmide&#8482;, it intends to build a global commercial
infrastructure to effectively support the commercialization of its main pharmaceutical product candidates, if and when SciSparc believes
regulatory approval of a pharmaceutical product candidate in a particular geographic market appears imminent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
develop the appropriate commercial infrastructure, SciSparc will likely have to invest significant amounts of financial and management
resources, some of which SciSparc expects to commit prior to completing the regulatory process for its pharmaceutical product candidates.
Where appropriate, SciSparc may elect in the future to utilize strategic partners, distributors, or contract sales forces to assist in
the commercialization of its pharmaceutical products. In certain instances, SciSparc may consider building its own commercial infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2023, SciSparc entered into a license and distribution agreement with SciSparc Nutraceuticals pursuant to which it granted SciSparc
Nutraceuticals an exclusive license to sell and market its PEA oral tablets, CannAmide&#8482; on Amazon Marketplace in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary products. While SciSparc believes that its scientific knowledge, technology and development experience provide it with
competitive advantages, SciSparc faces potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical
and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates
that SciSparc successfully develop and commercialize will compete with existing therapies and new therapies that may become available
in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
first THC-based pharmaceutical, a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company
called Unimed Pharmaceuticals, with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment
for chemotherapy-related nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market,
other pharmaceuticals containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed
by SVC Pharma LP and Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole
cannabis extract administered as an oral spray. Furthermore, to the best of SciSparc&#8217;s knowledge, there are multiple companies
that are working in the cannabis therapeutic area and are pursuing regulatory approval for their product candidates. For example, GW,
which markets Sativex, a botanical cannabinoid oral mucosal for the treatment of spasticity due to multiple sclerosis, received FDA approval
in the United States in June 2018 for Epidiolex, a liquid formulation of highly purified cannabidiol extract, as a treatment for Dravet&#8217;s
Syndrome, Lennox Gastaut Syndrome, and various childhood epilepsy syndromes. In addition, GW is developing, among others, CBDV based
therapy for ASD and therapy for neonatal hypoxic-ischemic encephalopathy and schizophrenia. Zynerba is developing a transdermal formulation
of cannabidiol for Fragile X and certain refractory epilepsies and ASD. Skye is focused on developing proprietary, synthetic cannabinoid-derived
molecules to treat glaucoma and other diseases with significant unmet need. Corbus Pharmaceuticals Holdings is seeking FDA approval for
their synthetic cannabinoid for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus and metabolism
and solid tumors. RespireRx is developing dronabinol for OSA treatment. Synendos is a developer of endocannabinoid modulators for the
treatment of CNS disorders. It has developed pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric
disorders. Synendos is developing small molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous
cannabinoids to treat CNS disorders caused by cannabinoid deficiency. Inversago Pharma (formerly GIcare Pharma) is focused on developing
peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance,
and liver fibrosis. Its drug INV-101 (Inverse agonist of peripheral CB1) under phase-1.</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
competitors, either alone or through their strategic partners, might have substantially greater name recognition and financial, technical,
manufacturing, marketing and human resources than it does and significantly greater experience and infrastructure in researching and
developing pharmaceutical products, obtaining FDA and other regulatory approvals of those products and commercializing those products
around the world. They may also have intellectual property portfolios that provide them with significant competitive advantages or create
substantial barriers in SciSparc&#8217;s target markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
currently contracts with third parties for the manufacturing and testing of its product candidates for preclinical trials and clinical
trials and also intend to do so in the future. SciSparc does not own or operate manufacturing facilities for the production of clinical
quantities of its product candidates. The use of contracted manufacturing and reliance on collaboration partners is relatively cost-efficient
and may eliminate the need to directly invest in manufacturing facilities and additional staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
date, SciSparc&#8217;s third-party manufacturers have met its manufacturing requirements. SciSparc expects third-party manufacturers
to be capable of providing sufficient quantities of its product candidates to meet anticipated full scale commercial demands. To meet
its projected needs for commercial manufacturing, third parties with whom SciSparc currently works might need to increase their scale
of production, or SciSparc will need to secure alternate suppliers. SciSparc believes that there are alternate sources of supply that
can satisfy its clinical and commercial requirements, although it cannot be certain that identifying and establishing relationships with
such sources, if necessary, would not result in significant delay or material additional costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>FDA Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the United States, pharmaceutical product candidates are subject to extensive regulation by the FDA. The FDC Act, and other federal and
state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping,
approval, labeling, promotion, marketing, distribution, post-approval monitoring, reporting, sampling, and import and export of pharmaceutical
drug product candidates. Failure to comply with applicable U.S. rules and regulations may subject a company to a variety of administrative
or judicial sanctions, such as FDA refusal to approve pending NDAs, warning letters, product candidate recalls, product candidate seizures,
total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pharmaceutical
drug product candidate development in the United States typically involves pre-clinical laboratory and animal testing, the submission
to the FDA of an IND Application, which must become effective before clinical testing may commence, and adequate, well-controlled clinical
trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA
pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type,
complexity and novelty of the product candidate or disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Nonclinical
tests include laboratory evaluation of an API or drug substance and drug product&#8217;s candidate chemistry, formulation and toxicity,
as well as animal trials to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the
nonclinical toxicology studies must comply with federal regulations and requirements, including GLP. The results of nonclinical testing
are submitted to the FDA as part of an IND along with other information, including information about product candidate chemistry, manufacturing
and controls, and a proposed clinical trial protocol. Long term nonclinical tests, such as animal tests of reproductive toxicity and
carcinogenicity, may continue after the IND is submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
30-day waiting period after the submission of an original IND is required prior to the commencement of clinical testing in humans. If
the FDA has not imposed a clinical hold on the IND or otherwise commented or questioned the IND within this 30-day period, the clinical
trial proposed in the IND may begin. In practice, a submitting party should contact the division after this 30 day period to ensure that
the FDA has reviewed the IND to the extent that they can assure there will be no hold placed on the IND if the FDA has not responded
to SciSparc within this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Clinical
trials involve the administration of the investigational product to healthy volunteers or patients under the supervision of a qualified
investigator. Clinical trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with GCP, an international
standard meant to protect the rights and health of patients to ensure the quality of the trial and to define the roles of clinical trial
sponsors, administrators and monitors. Clinical protocols and details of the objectives of the trial, the parameters to be used in monitoring
safety, and the effectiveness criteria to be evaluated. Each protocol and any amendment involving testing of U.S. study subjects within
the United States and subsequent protocol amendments must be submitted to the FDA as part of the IND.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA may order the temporary hold of a clinical trial at any time or impose other sanctions if the FDA believes that the clinical trial
either is not being conducted in accordance with FDA requirements, regulations or presents a potentially unacceptable risk to the clinical
trial subjects. The trial protocol and informed consent information for subjects in clinical trials must also be submitted to an IRB
for approval. An IRB may impose other conditions for the protocol and may also require the clinical trial at the site to be halted, either
temporarily or permanently, for failure to comply with the IRB&#8217;s requirements.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>505(b)(2) Regulatory
Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Section
505(b)(2) of the FDC Act, or 505(b)(2), provides a regulatory pathway to FDA approval for new or improved formulations or new uses of
previously approved drug products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the information required
for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference,
or use from the person by or for whom the investigations were conducted. The applicant may rely upon the FDA&#8217;s prior findings of
safety and efficacy for an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also
require 505(b)(2) applicants to perform additional studies or measurements to support any changes from the reference listed drug. The
FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved,
as well as for any new indication sought by the 505(b)(2) applicant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Orange Book Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Section
505 of the FDC Act describes three types of marketing applications that may be submitted to the FDA to request marketing authorization
for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section
505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the information
required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained
a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims
cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published
in Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book. These products may be cited by potential
competitors in support of approval of a 505(b)(2) NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
applicant who submits a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information
on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on
which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product
for which the application is submitted. This last certification is known as a Paragraph IV certification. Generally, 505(b)(2) NDA cannot
be approved until all listed patents have expired, except where 505(b)(2) NDA applicant challenges a listed patent through a Paragraph
IV certification. If the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented
method of use, the 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have
expired.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
some of SciSparc&#8217;s product candidates are based on repurposed drugs, there are at present no patents or other exclusivities listed
in the Orange Book pertaining to a product containing the active ingredient dronabinol.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Three-year
exclusivity is available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed
product, such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability
or bioequivalence trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year
exclusivity period protects against FDA approval of 505(b)(2) NDAs for the condition of the new drug&#8217;s approval. As a general matter,
three-year exclusivity does not prohibit the FDA from approving 505(b)(2) NDAs for generic versions of the original, unmodified drug
product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting
a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled
clinical trials necessary to demonstrate safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>NDA Submission
and Review by the FDA</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Assuming
successful completion of the required clinical and nonclinical testing, among other items, the results of product development, including
chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling,
as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be paid at the
time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions
are available in some circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees,
including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced
or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing
application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
cost of preparing and submitting an NDA is substantial, mainly due to the non-clinical and clinical trial costs. Under federal law, the
submission of most NDAs is additionally subject to a substantial application user fee; the fee in the fiscal year 2023 was $3,242,026.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA has 60 or 74 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the
FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard
review drug product candidates are reviewed within 10 to 12 months, while most applications for priority review drugs are reviewed within
six months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment or provide a treatment
where no adequate therapy exists. The review process for both standard and priority review may be extended by FDA for three additional
months to consider certain late-submitted information, or information intended to clarify information already provided in the submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA may also refer applications for novel drug product candidates, or drug product candidates that present difficult questions of safety
or efficacy, to an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation
and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee,
but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to
assure compliance with GCP. Additionally, the FDA may inspect the facility or the facilities at which the drug substance and drug product
are manufactured. The FDA will not approve the drug product candidate unless compliance with or current cGMP, or cGMP, is satisfactory
and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete
response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction
in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or
six months depending on the type of requested information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition
of NDA approval, the FDA may require a REMS plan to help ensure that the benefits of the drug outweigh the potential risks. REMS can
include medication guides, communication plans for health care professionals, and ETASU. An ETASU can include, but are not limited to,
special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and
the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover,
product candidate approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy.
Once granted, product candidate approvals may be withdrawn if compliance with regulatory standards is not maintained related to the manufacture,
safety or effectiveness or problems are identified following initial marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Disclosure of
Clinical Trial Information</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Sponsors
of clinical trials of certain FDA-regulated product candidates, including prescription drugs, are required to register and disclose certain
clinical trial information on a public website (clinicaltrials.gov) which is maintained by the U.S. National Institutes of Health. Information
related to the product candidate, patient population, phase of investigation, study sites and investigator, and other aspects of the
clinical trial is made public as part of the registration. Sponsors are also obligated to disclose the results of these trials after
completion. Disclosure of the results of these trials can be delayed until the product candidate drug product or new indication being
studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the design and progress
of its development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Fast Track Designation
and Accelerated Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA has programs to facilitate the development, and thus expedite the review, of drugs that are intended for the treatment of a serious
or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet
medical needs for the condition. These therapies for serious conditions are approved and available to patients as soon as it can be concluded
that the therapies&#8217; benefits outweigh their risk. Under the Fast Track Program, the sponsor of a new drug candidate may request
that FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND
for the drug candidate. FDA must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the
sponsor&#8217;s request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the FDA&#8217;s accelerated approval regulations, FDA may approve a drug for a serious or life-threatening illness that provides meaningful
therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical
benefit. Accelerated approval may also be based on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality,
that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, considering the severity,
rarity or prevalence of the condition and the availability or lack of alternative treatments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for
a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly
than clinical endpoints. A drug product that is approved on this basis is subject to rigorous post-marketing compliance requirements,
including the completion of confirmatory or post-approval clinical trial(s) or registries to confirm the effect on the clinical endpoint.
Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw
the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations
are subject to prior review by FDA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with FDA, FDA may
initiate review of sections of a Fast Track drug&#8217;s NDA before the application is complete. This rolling review is available if
the applicant provides, and FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable
user fees. However, FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted.
Additionally, the Fast Track designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data
emerging in the clinical trial process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Patent Term Extension</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">After
NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is
calculated as half of the drug&#8217;s testing phase, the time between IND submission and NDA submission, and all of the review phase-the
time between NDA submission and approval up to a maximum of five years. The time can be shortened if FDA determines that the applicant
did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension
increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval
patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for
which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been
submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Advertising and
Promotion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Once
an NDA is approved, a drug product will be subject to certain post-approval requirements. Products manufactured or distributed by us
pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling
and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional
of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences.
For instance, FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer
advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Drugs
may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of
the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities,
require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new
indication typically requires clinical data similar to that in the original application. The FDA uses the same procedures and actions
in reviewing NDA supplements as it does in reviewing NDAs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><b><i>Adverse
Event Reporting and GMP Compliance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Adverse
event reporting and submission of periodic reports are required following FDA approval of an NDA. The FDA also may require post-marketing
testing, known as Phase 4 testing, REMS and surveillance to monitor the effects of an approved product candidate, or the FDA may place
conditions on an approval that could restrict the distribution or use of the drug product. In addition, quality-control, drug manufacture,
packaging, and labeling procedures must continue to conform with cGMPs after approval. Drug manufacturers and certain of their subcontractors
are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to
periodic unannounced inspections by the FDA, during which the FDA inspects manufacturing facilities to assess compliance with cGMPs.
Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain
compliance with cGMPs. Regulatory authorities may withdraw product candidate approvals or request product candidate recalls if a company
fails to comply with regulatory standards, if it encounters problems following initial marketing or if previously unrecognized problems
are subsequently discovered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Pediatric Exclusivity
and Pediatric Use</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Best Pharmaceuticals for Children Act, or BPCA, provides NDA holders a six-month extension of any exclusivity-patent or non-patent-for
a drug if certain conditions are met. Conditions for exclusivity include a determination by the FDA that information relating to the
use of a new drug in the pediatric population may produce health benefits in that population; a written request by the FDA for pediatric
studies; and agreement by the applicant to perform the requested studies and the submission to the FDA; and the acceptance by the FDA,
of the reports of the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness
of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric
subpopulation for which the drug is safe and effective, unless the sponsor has received a deferral or waiver from the FDA. Unless otherwise
required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted with the exception
of certain oncological indications. The required pediatric assessment must assess the safety and effectiveness of the product candidate
for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation
for which the product candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all
of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval
for use in adults before pediatric studies are complete or that additional safety or effectiveness data need to be collected before the
pediatric studies begin. Under PREA, the FDA must send a non-compliance letter requesting a response with 45 days to any sponsor that
fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Orphan Drugs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition-generally a disease
or condition with a prevalence of fewer than 200,000 individuals in the United States. Orphan drug designation must be requested and
granted before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan
use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory
review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular
disease with an FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that drug
product candidate for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market
the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product candidate
with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or
condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits
for certain research and a waiver of the NDA application user fee. In addition to the potential seven years of market exclusivity after
approval, orphan drug designation status qualifies sponsors for tax credits for qualified clinical trials and exemption from user fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Special Protocol
Assessment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
company may reach an agreement with the FDA under the Special Protocol Assessment, or SPA, process as to the required design and size
of clinical trials intended to form the primary basis of an efficacy claim. According to its performance goals, the FDA is supposed to
evaluate the protocol within 45 days of the request to assess whether the proposed trial is adequate, and that evaluation may result
in discussions and a request for additional information. An SPA request must be made, and all open issues must be resolved before the
clinical trial begins. If a written agreement is reached, it will be documented and made part of the administrative record. Under the
FDC Act and FDA guidance implementing the statutory requirement, an SPA is generally binding upon the FDA except in limited circumstances,
such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the study begins, public
health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and FDA agree to the change in writing,
or if the study sponsor fails to follow the protocol that was agreed upon with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Controlled Substances&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
CSA and its implementing regulations establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes
registration, security, recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the
oversight of the DEA. The DEA is the federal agency responsible for regulating controlled substances, and requires those individuals
or entities that manufacture, import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements
in order to prevent the diversion of controlled substances to illicit channels of commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
DEA categorizes controlled substances into one of five schedules-Schedule I, II, III, IV or V-with varying qualifications for listing
in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment
in the United States and lack accepted safety for use under medical supervision. Schedule I substances may be used only in federally
approved research programs and may not be marketed or sold for dispensing to patients in the United States. Pharmaceutical product candidates
having a currently accepted medical use that are otherwise approved for marketing may be listed as Schedule II, III, IV or V substances,
with Schedule II substances presenting the highest potential for abuse and physical or psychological dependence, and Schedule V substances
presenting the lowest relative potential for abuse and dependence. The regulatory requirements are more restrictive for Schedule II substances
than Schedule III substances. For example, all Schedule II drug prescriptions must be signed by a physician, physically presented to
a pharmacist in most situations and cannot be refilled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
NDA approval of a drug containing a Schedule I controlled substance, that substance must be rescheduled as a Schedule II, III, IV or
V substance before it can be marketed. In 2015, the Improving Regulatory Transparency for New Medical Therapies Act, removed uncertainty
associated with timing of the DEA rescheduling process after NDA approval. Specifically, it requires DEA to issue an &#8220;interim final
rule,&#8221; pursuant to which a manufacturer may market its product candidate within 90 days of FDA approval. The new law also preserves
the period of orphan marketing exclusivity for the full seven years such that this period only begins after DEA scheduling. This contrasts
with the previous situation whereby the orphan &#8220;clock&#8221; began to tick upon FDA approval, even though the product candidate
could not be marketed until DEA scheduling was complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Facilities
that manufacture, distribute, import or export any controlled substance must register annually with the DEA. The DEA registration is
specific to the particular location, activity(ies) and controlled substance schedule(s). For example, separate registrations are required
for importation and manufacturing activities, and each registration authorizes which schedules of controlled substances the registrant
may handle. However, certain coincident activities are permitted without obtaining a separate DEA registration, such as distribution
of controlled substances by the manufacturer that produces them.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
DEA inspects all manufacturing facilities to review security, recordkeeping, reporting and handling prior to issuing a controlled substance
registration. The specific security requirements vary by the type of business activity and the schedule and quantity of controlled substances
handled. The most stringent requirements apply to manufacturers of Schedule I and Schedule II substances. Required security measures
commonly include background checks on all employees and physical control of controlled substances through storage in approved vaults,
safes and cages, and through use of alarm systems and surveillance cameras. An application for a manufacturing registration as a bulk
manufacturer (not a dosage form manufacturer or a repacker/relabeler) for a Schedule I or II substance must be published in the Federal
Register, and the application is open for 30 days to permit interested persons to submit comments, objections or requests for a hearing.
A copy of the notice of the Federal Register publication is forwarded by DEA to all those registered, or applicants for registration,
as bulk manufacturers of that substance. Once registered, manufacturing facilities must maintain records documenting the manufacture,
receipt and distribution of all controlled substances. Manufacturers must submit periodic reports to the DEA of the distribution of Schedule
I and II controlled substances, Schedule III narcotic substances, and other designated substances. Registrants must also report any controlled
substance thefts or significant losses, and must obtain authorization to destroy or dispose of controlled substances. As with applications
for registration as a bulk manufacturer, an application for an importer registration for a Schedule I or II substance must also be published
in the Federal Register, which remains open for 30 days for comments. Imports of Schedule I and II controlled substances for commercial
purposes are generally restricted to substances not already available from domestic supplier or where there is not adequate competition
among domestic suppliers. In addition to an importer or exporter registration, importers and exporters must obtain a permit for every
import or export of a Schedule I and II substance or Schedule III, IV and V narcotic, and submit import or export declarations for Schedule
III, IV and V non-narcotics. In some cases, Schedule III non-narcotic substances may be subject to the import/export permit requirement,
if it is necessary to ensure that the United States complies with its obligations under international drug control treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
drugs manufactured in the United States, the DEA establishes annually an aggregate quota for the amount of substances within Schedules
I and II that may be manufactured or produced in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate
medical, scientific, research and industrial needs. This limited aggregate amount of cannabis that the DEA allows to be produced in the
United States each year is allocated among individual companies, which, in turn, must annually apply to the DEA for individual manufacturing
and procurement quotas. The quotas apply equally to the manufacturing of the API/drug substance and production of dosage forms. The DEA
may adjust aggregate production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during
the year, although the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Individual
states may also maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution,
and dispensing requirements. State Authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure
to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can
result in enforcement action that could have a material adverse effect on its business, operations and financial condition. The DEA may
seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances,
violations could lead to criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Europe/Rest of
World Government Regulation</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to regulations in the United States, SciSparc will be subject to a variety of foreign regulations governing clinical trials
and commercial sales and distribution of its products to the extent it chooses to develop or sell any products outside of the United
States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval.
The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to
country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Whether
or not SciSparc obtains FDA approval for a product candidate, it must obtain the requisite approvals from regulatory authorities in non-U.S.
countries prior to the commencement of clinical trials or marketing of the product candidate in those countries. Certain countries outside
of the United States have a process that requires the submission of a Clinical Trial Application, or CTA, much like an IND prior to the
commencement of human clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and
to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance
with a country&#8217;s requirements, clinical trial development may proceed in that country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
requirements and process governing the conduct of clinical trials, product candidate licensing, pricing and reimbursement vary from country
to country, even though there is already some degree of legal harmonization in the European Union member states resulting from the national
implementation of underlying European Union legislation. In all cases, the clinical trials are conducted in accordance with GCP and other
applicable regulatory requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
obtain regulatory approval of an investigational drug under the European Union. regulatory systems, SciSparc must submit a MAA. This
application is similar to the NDA in the United States, with the exception of, among other things, country-specific document requirements.
Drugs can be authorized in the European Union by using (i) the centralized authorization procedure, (ii) the Mutual Recognition Procedure,
or MRP, (iii) the decentralized procedure or (iv) national authorization procedures. The initial Sativex approvals were a consequence
of an application under the De-Centralized Procedure, or DCP, to the European Union member state of Spain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
European Commission implemented the centralized procedure for the approval of human drugs to facilitate marketing authorizations that
are valid throughout the European Economic Area, or EEA. This procedure results in a single marketing authorization granted by the European
Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway (forming together the EEA). The centralized
procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain
a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases,
autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated &#8220;orphan drugs&#8221; (drugs used for rare
human diseases) and (iv) advanced-therapy medicines, such as gene- therapy, somatic cell-therapy or tissue-engineered medicines. The
centralized procedure may at the request of the applicant also be used for human drugs which do not fall within the above mentioned categories
if the human drug (a) contains a new active substance which, on the date of entry into force of this Regulation, was not authorized in
the Community; or (b) the applicant shows that the medicinal product candidate constitutes a significant therapeutic, scientific or technical
innovation or that the granting of authorization in the centralized procedure is in the interests of patients or animal health at the
European Community level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the centralized procedure in the European Union, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days (excluding
clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee
for Medicinal Products for Human Use, or CHMP, with adoption of the actual marketing authorization by the European Commission thereafter.
Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product candidate is expected to be of a major
public health interest from the point of view of therapeutic innovation, defined by three cumulative criteria: (1) the seriousness of
the disease to be treated; (2) the absence of an appropriate alternative therapeutic approach, and (3) anticipation of exceptional high
therapeutic benefit. In this circumstance, EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and
the opinion issued thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Should
any Member State refuse to recognize the marketing authorization by the reference member state in a decentralized procedure, on the grounds
of potential serious risk to public health, the issue will be referred to the Committee for the Mutual Recognition and Decentralized
Procedures human. Within a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus.
If this fails, the procedure is submitted to the CHMP for arbitration. The opinion of the CHMP is then forwarded to the Commission, for
the start of the decision making process. As in the centralized procedure, this process entails consulting various European Commission
Directorates General and the Standing Committee on Human Medicinal Product candidates or Veterinary Medicinal Product candidates, as
appropriate. Since the initial approvals of Sativex in the United Kingdom and Spain, there have been three &#8220;waves&#8221; of additional
approvals under three separate MRPs. Each of these procedures have been completed without any referral, and therefore without any delay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 182; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
other countries outside of the European Union, the requirements governing the conduct of clinical trials, product candidate licensing,
pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP
and the other applicable regulatory requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension
of clinical trials, suspension or withdrawal of regulatory approvals, product candidate recalls, seizure of product candidates, operating
restrictions and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, most countries are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic
control of narcotic substances, including cannabis extracts. Countries may interpret and implement their treaty obligations in a way
that creates a legal obstacle to SciSparc obtaining marketing approval for Sativex and its other product candidates in those countries.
These countries may not be willing or able to amend or otherwise modify their laws and regulations to permit Sativex or its other product
candidates to be marketed, or achieving such amendments to the laws and regulations may take a prolonged period of time. In that case,
SciSparc would be unable to market its product candidates in those countries in the near future or perhaps at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Expanded Access
to Investigational Drugs in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">An
investigational drug may be eligible for clinical use outside the context of a manufacturer&#8217;s clinical trial of the drug. &#8220;Expanded
access&#8221; refers to the use of an investigational drug where the primary purpose is to diagnose, monitor, or treat a patient&#8217;s
disease or condition rather than to collect information about the safety or effectiveness of a drug. Expanded access INDs are typically
sponsored by individual physicians to treat patients who fall into one of three FDA-recognized categories of expanded access: expanded
access for individual patients, including for emergency use; expanded access for intermediate-size patient populations; and expanded
access for large patient populations under a treatment IND or treatment protocol. For all types of expanded access, the FDA must determine
prior to authorizing expanded access that: (1) the patient or patients to be treated have a serious or life threatening disease or condition
and there is no comparable or satisfactory alternative therapy; (2) the potential patient benefit justifies the potential risks of use
and that the potential risks are not unreasonable in the context of the disease or condition to be treated; and (3) granting the expanded
access will not interfere with the initiation, conduct, or completion of clinical studies in support of the drug&#8217;s approval. In
addition, the sponsor of an expanded access IND must submit IND safety reports and, in the cases of protocols continuing for one year
or longer, annual reports to the FDA. Expanded access programs are not intended to yield information relevant to evaluating a drug&#8217;s
effectiveness for regulatory purposes. If a patient enrolled in one of SciSparc&#8217;s clinical trials is not eligible or able to continue
enrollment, SciSparc may be required to continue to provide its product candidate to such patient through expanded access.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Pricing and Reimbursement
in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Sales
of pharmaceutical product candidates in the United States will depend, in part, on the extent to which the costs of the product candidates
will be covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations.
These third-party payors are increasingly challenging the prices charged for medical product candidates and services. Additionally, the
containment of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in
this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing
cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic product
candidates. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with
existing controls and measures, could further limit its net revenue and results. If these third-party payors do not consider SciSparc&#8217;s
product candidates to be cost-effective compared to other available therapies, they may not cover SciSparc&#8217;s product candidates
after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow SciSparc to sell its
product candidates on a profitable basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and
pricing of prescription drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare
Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage
of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage
as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug
plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies
which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic
category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part
D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs
of prescription drugs may increase demand for product candidates for which SciSparc receives marketing approval. However, any negotiated
prices for SciSparc&#8217;s product candidates covered by a Part D prescription drug plan will likely be lower than the prices it might
otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare
coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result
in a similar reduction in payments from non-governmental payers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ACA was enacted in March 2010. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the law.
The ACA may be modified, amended or repealed at any time and may or may not be replaced with a different law or health care payment system.
The ACA is expected to continue to have a significant impact on the health care industry. With regard to pharmaceutical product candidates,
among other things, the ACA may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the
coverage requirements under the Medicare Part D program. Since the enactment of the ACA, numerous regulations have been issued providing
further guidance on its requirements. The ACA continues to be implemented through regulation and government activity but is subject to
possible amendment, additional implementing regulations and interpretive guidelines. Several states have decided not to expand their
Medicaid programs and are seeking alternative reimbursement models to provide care to the uninsured. The manner in which these issues
are resolved could materially affect the extent to which and the amount at which pharmaceuticals are reimbursed by government programs
such as Medicare, Medicaid and Tricare. SciSparc is unable to predict the full impact of any potential modification, amendment, or repeal
of the ACA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement
for its products, once approved, and related treatments will be available from third-party payors, such as government health administration
authorities, private health insurers and managed care organizations. Third-party payors determine which medications they will cover and
separately establish reimbursement levels. Even if SciSparc obtains coverage for a given product by a third-party payor, the third-party
payor&#8217;s reimbursement rates may not be adequate to make the product affordable to patients or profitable to SciSparc, or the third-party
payors may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their
conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with
their prescription drugs. Patients are unlikely to use SciSparc&#8217;s products unless coverage is provided, and reimbursement is adequate
to cover all or a significant portion of the cost of its products. Therefore, coverage and adequate reimbursement is critical to new
product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established
or lower cost therapeutic alternatives are already available or subsequently become available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Government
authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by
limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug
companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and
preferred drug lists to leverage greater discounts in competitive classes and are challenging the prices charged for medical products.
Further, no uniform policy for determining coverage and reimbursement for drug products exists among third-party payors in the United
States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage
determination process is often a time-consuming and costly process that will require SciSparc to provide scientific and clinical support
for the use of its products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently
or obtained in the first instance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
cannot be sure that coverage and reimbursement will be available for any product that SciSparc commercializes and, if reimbursement is
available, that the level of reimbursement will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any
product candidate for which SciSparc obtains marketing approval. If coverage and reimbursement are not available, or if reimbursement
is available only to limited levels, SciSparc may not successfully commercialize any product candidate for which it obtains marketing
approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a condition of receiving Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate
and report to CMS their AMP, which is used to determine rebate payments shared between the states and the federal government and, for
some multiple source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part B, to also calculate and report
their average sales price, which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final
rule regarding the Medicaid Drug Rebate Program, effective April 1, 2016, that, among other things, revised the manner in which the AMP
is calculated by manufacturers participating in the program and implemented certain amendments to the Medicaid rebate statute created
under the ACA. Drugs that are approved under an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate
and report the manufacturer&#8217;s best price for the drug and inflation penalties which can substantially increase rebate payments.
On December 21, 2020, CMS issued a final rule that made changes to the Medicaid Drug Rebate Program regulations in several areas, including
some changes to the treatment of value-based purchasing arrangements and price reporting for patient benefit programs sponsored by pharmaceutical
manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
NDA drugs, the Veterans Health Care Act of 1992 requires manufacturers to calculate and report to the Department of Veterans Affairs
a different price called the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more
than a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers
to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting
false pricing information to the government creates potential federal False Claims Act liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state
levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer
patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. SciSparc
expects that the pharmaceutical industry will continue to experience pricing pressures due to the trend toward managed healthcare, particularly
towards specialty pharmacy, the increasing influence of managed care organizations, and additional legislative proposals. For example,
CMS issued an interim final rule on November 27, 2020 designed to test whether a Most-Favored-Nation model will help control growth in
spending for Medicare Part B drugs without adversely affecting quality of care. This followed an Executive Order issued in September
2020 that directed the Secretary of DHHS to implement new payment models under the Medicare Part B and Part D programs to curb &#8220;unfair&#8221;
and high drug prices in the United States. Implementation of this interim final rule was blocked by a temporary restraining order and
preliminary injunctions through various court actions and CMS published a final rule on December 27, 2021 that rescinded the interim
final rule. Nonetheless, SciSparc expects that there will continue to be a number of U.S. federal and state proposals to implement governmental
pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs. It is unknown what form any such
changes or any law would take, and how or whether it may affect the biopharmaceutical industry as a whole or SciSparc&#8217;s business
in the future. SciSparc expects that changes or additions to the ACA, the Medicare and Medicaid programs, such as changes allowing the
federal government to directly negotiate drug prices, and changes stemming from other healthcare reform measures, especially with regard
to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the health care industry
in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">At
the state level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. On the federal level, the Trump Administration issued a final rule in 2020 for the safe importation
of drugs from Canada and other countries. Per this rule, the FDA authorized its first section 804 importation program, or SIP, a program
allowing the State of Florida to import certain prescription products from Canada. Section 804 (21 U.S.C. &#167; 384) of the Federal
Food, Drug, and Cosmetic Act provides a pathway for U.S. states and Indian tribes to allow importation of certain prescription drugs
from Canada. Programs under this pathway must significantly reduce the cost of these drugs to the American consumer without imposing
additional risk to public health and safety. As the first program of its kind, SciSparc has yet to see how this Program will be implemented
and what specific products will be imported. There is much opposition from the biopharmaceutical industry regarding this Program, but
if Florida can execute it as planned, it may signal a trend in the U.S. The practical implications of SIPs, and their implications for
the biopharmaceutical industry as a whole or SciSparc&#8217;s business in particular remain to be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2021, the Biden administration issued an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple
provisions aimed at increasing competition for prescription drugs. The DHHS has released a Comprehensive Plan for Addressing High Drug
Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these
principles. While no legislation or administrative actions have been finalized to implement these principles, Congress is considering
legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations
on drug price increases and allowing Medicare to negotiate pricing for certain covered drug products. The impact of these legislative,
executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on
SciSparc and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms
may prevent us from being able to generate revenue, attain profitability, or commercialize any of the product candidates for which SciSparc
receives approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
passage of the Inflation Reduction Act, or the IRA, of 2022 further affects Medicare reimbursement. The IRA has three key elements reforming
Medicare drug-pricing policy. The implementation of certain elements of the IRA are still forthcoming, as outlined below, so the specific
implications for biopharmaceutical pricing and reimbursement are yet to be determined. Likewise, SciSparc is unable to predict potential
modification, amendment, or repeal of the IRA, though some predict that challenges may be made as different provisions are enacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
the first key element, the IRA created a program for Medicare drug-price negotiation, enabling the Secretary of DHHS to negotiate the
prices of certain costly, single-source drugs or biologics within the Medicare program. Certain drugs and biologics are excluded from
this negotiation process, such as drugs that are less than 9 years, and biologics less than 13 years, from their FDA-approval or licensure
date, and drugs with an orphan designation as their only FDA-approved indication. The first set of these negotiated prices will not take
effect until 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; background-color: white">Second,
the IRA requires drug manufacturers to pay rebates to the federal government for price increases above the rate of inflation for single-source
drugs or biologics covered under Medicare Part B and most drugs under Medicare Part D, which already occurs under the Medicaid program.
This inflation-rebate provision for Medicare Part B took effect at the start of 2023, and such provision for Medicare Part D took effect
in 2022 as the starting point for measuring drug-price increases, with rebate payments required as of the beginning of 2023. DHHS will
start to send rebate invoices to drug manufacturers in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; background-color: white">Third,
the IRA restructures the Medicare Part D benefit to limit patients&#8217; out-of-pocket costs and rebalance the bearing of risk for Part
D plans and manufacturers. As of 2024, Medicare Part D plan buyers will no longer have to pay out-of-pocket costs for covered drugs once
they reach the catastrophic coverage level (when the policyholder&#8217;s out-of-pocket spending reaches $7,400). Other aspects of this
provision will take effect in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
bipartisan&#160;<i>Drug-Price Transparency for Consumers Act</i>&#160;was introduced to Senate on April 20, 2023, and the House of Representatives
on October 13, 2023 (S.1250 and H.R.5958, respectively). The Act is currently in committee. This Act would require that direct-to-consumer
advertisements for drugs and biologics include a disclosure of pricing information. The Act would apply to drugs and biologicals reimbursable
under Medicare or Medicaid and for which direct-to-consumer advertisements are required to include information relating to side effects,
contraindications, and effectiveness in accordance with section 202.1(e)(1) of title 21, Code of Federal Regulations. If passed, this
Act would amend the Social Security Act to allow the Secretary of DHHS to require such advertisements to disclose the wholesale acquisition
cost, or WAC, for a 30-day supply or typical course of treatment and clearly and conspicuously present such price information. If enacted,
the Act contemplates that implementing regulations would include the visual and audio components required to communicate the WAC appropriately
for the medium of the advertisement, the reasonable amount of time to update the advertisement to reflect any changes to WAC, and the
way the manufacturer may include a statement explaining that certain consumers may pay a different amount depending on their insurance
coverage. The Act would also subject advertisers to a penalty of up to $100,000 per violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
full implications of changes such as those discussed above, and their practical impact on biopharmaceutical pricing and reimbursement,
as well as advertising requirements and related costs, on the biopharmaceutical industry as a whole and SciSparc&#8217;s business in
particular cannot yet be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the marketability
of any products for which SciSparc receives regulatory approval for commercial sale may suffer if the government and other third-party
payers fail to provide adequate coverage and reimbursement. SciSparc expects that an increasing emphasis on cost containment measures
in the U.S. will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may
change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which SciSparc receives
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pricing and Reimbursement in Foreign Countries</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in some foreign
countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing
vary widely from country to country. For example, a member state of the European Union may approve a specific price for the medicinal
product candidate. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
product candidates will allow favorable reimbursement and pricing arrangements for any of SciSparc&#8217;s product candidates. Historically,
product candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly
lower.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As another example, in Canada,
for patented drugs, the Patented Medicines Prices Review Board (PMPRB) uses the median international publicly available ex-factory list
price (using prices in 11 pre-determined countries) as the maximum price the company is allowed to charge. The PMPRB is a quasi-judicial
body with a regulatory mandate to prevent pharmaceutical patentees from charging consumers excessive prices during the market exclusivity
period. This agency then monitors the prices charged by patentees for patented drugs on an ongoing basis. Under the Canadian Patent Act,
patentees are required to file price and sales information about their patented drug products at introduction and twice a year thereafter
for each strength of each dosage form of each patented drug product sold in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Health Care Laws and Compliance Requirements</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, SciSparc&#8217;s
activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the
CMS, other divisions of the DHHS (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney
offices within the Department of Justice, and state and local governments.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal AKS prohibits,
among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly
or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for, or
purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable, in
whole or in part, by Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include
anything of value, including unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional
practices. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution,
but the exceptions and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular applicable statutory
exception or regulatory safe harbor does not make the conduct per se illegal under the federal AKS. Instead, the legality of the arrangement
will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, the ACA amended
the intent requirement of the federal AKS so that a person or entity no longer needs to have actual knowledge of the federal AKS, or
specific intent to violate it, to have violated the statute. The ACA also provided that a violation of the federal AKS is grounds for
the government or whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false
or fraudulent claim for purposes of the civil False Claims Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November
2020, DHHS finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending for prescription drugs by excluding
rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors or PBMs acting under contract with
Medicare Part D plan sponsors from the existing discount safe harbor under the federal AKS. The regulation reflects the first change
to the AKS discount safe harbor since the Medicare Part D program was established. In addition to the rebate exclusions, two new safe
harbors were added. One of these new safe harbors protects point-of-sale reductions in price from a manufacturer to a plan sponsor under
Medicare Part D or a MCO for a prescription drug payable, in whole or in part, by a plan sponsor under Medicare Part D or a MCO, provided
certain conditions are met. The other protects certain fixed-fee services arrangements between manufacturers and PBMs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal civil and criminal
false claims laws, including the federal False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to, or for approval by, the federal government, including the Medicare and Medicaid
programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
to avoid, decrease or conceal an obligation to pay money to the federal government.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The civil monetary penalties
statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented
a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or
is false or fraudulent.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA created additional
federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, including public and private payors, or obtain, by means of false or fraudulent pretenses, representations or promises,
any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the
payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing
a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device
a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items
or services relating to healthcare matters. The ACA amended the federal health care fraud criminal statute implemented under HIPAA so
that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have violated
the statute.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the federal
Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and its implementing regulations,
require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid
or the Children&#8217;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments
or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated
on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians
and their immediate family members. The SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include
data for physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified
nurse midwifes. The amendment applies to reports submitted to CMS on or after January 1, 2022.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, SciSparc may
be subject to data privacy and security regulation by both the federal government and the states in which it conducts its business. HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations,
impose requirements relating to the privacy, security and transmission of individually identifiable health information on HIPAA covered
entities and their business associates, including mandatory contractual terms and the implementation of certain safeguards of such information.
Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, independent contractors
or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of
a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties
directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions
in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.
In addition, state laws govern the privacy and security of health information in some circumstances, many of which differ from each other
in significant ways, may not have the same effect and may not be preempted by HIPAA, thus complicating compliance efforts.&#160; Most
recently, fourteen states including California have adopted laws that regulate the privacy and security of consumer personal information,
and apply in instances where HIPAA and clinical trial laws do not. In addition, other states such as Washington, have adopted laws that
regulate the privacy and security of consumer health data which, again, apply in instances where HIPAA and clinical trial laws do not.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many states have also adopted
laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor,
including commercial insurers. SciSparc may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state
laws that require drug manufacturers to report information related to marketing expenditures or payments and other transfers of value
to physicians and other healthcare providers.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Enforcement actions can be
brought by federal or state governments or, in some cases, as &#8220;qui tam&#8221; actions brought by individual whistleblowers in the
name of the government. Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal,
civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts, individual imprisonment,
additional reporting requirements and oversight if SciSparc becomes subject to a corporate integrity agreement or similar agreement to
resolve allegations of non-compliance with these laws, exclusion from government programs, refusal to allow it to enter into supply contracts,
including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of its
operations, any of which could adversely affect its business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to distribute product
candidates commercially, SciSparc must comply with state laws that require the registration of manufacturers and wholesale distributors
of pharmaceutical product candidates in a state, including, in certain states, manufacturers and distributors who ship product candidates
into the state, even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements
on manufacturers and distributors to establish the pedigree of product candidate in the chain of distribution, including some states
that require manufacturers and others to adopt new technology capable of tracking and tracing product candidate as it moves through the
distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs,
file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities
or register their sales representatives. Other legislation has been enacted in certain states prohibiting pharmacies and other health
care entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting
certain other sales and marketing practices. All of SciSparc&#8217;s activities are potentially subject to federal and state consumer
protection and unfair competition laws.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Foreign Corrupt Practices Act</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FCPA regulates part of
SciSparc&#8217;s business activities. The FCPA has two main provisions applicable to us: (a) the antibribery provisions, which prohibit
individuals and businesses from bribing foreign government officials in order to obtain or retain business; and (b) the accounting provisions,
which impose certain record keeping and internal control requirements on issuers, and prohibit individuals and companies from knowingly
falsifying an issuer&#8217;s books and records or circumventing or failing to implement an issuer&#8217;s system of internal controls.
Violations of the FCPA can lead to civil and criminal penalties, sanctions, and remedies, including fines, disgorgement, and/or imprisonment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The antibribery provisions
of the FCPA prohibits the paying, offering, promising, or authorizing payment or offering money or of anything of value, directly or
indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of such foreign
official, political party, or candidate in his or her official capacity or to secure any improper advantage in obtaining or retaining
business. Under the statute, a company is liable when its directors, officers, employees, or agents, acting within the scope of their
employment, commit FCPA violations intended, at least in part, to benefit SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accounting provisions
of the FCPA consist of two primary components. First, under the &#8220;books and records&#8221; provision, issuers must make and keep
books, records, and accounts that, in reasonable detail, accurately and fairly reflect an issuer&#8217;s transactions and dispositions
of an issuer&#8217;s assets. Second, under the &#8220;internal controls&#8221; provision, issuers must devise and maintain a system of
internal accounting controls sufficient to assure management&#8217;s control, authority, and responsibility over the company&#8217;s
assets. The accounting provisions do not apply only to bribery-related violations. Rather, the accounting provisions require that all
public companies account for all of their assets and liabilities accurately and in reasonable detail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc, its affiliates,
and its and their operations around the world are subject to the FCPA because SciSparc is an &#8216;issuer&#8217; as defined in the statute.
The U.S. Department of Justice aggressively enforces the FCPA and has, at times, focused its enforcement attention to the pharmaceutical
sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Grants from the IIA</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s research
and development efforts mainly with respect to its past activities (with respect to immunotherapy programs such as the Anti-CD3)&#160;
were financed in part through royalty-bearing grants from the IIA. As of December 31, 2023, SciSparc had received the aggregate amount
of approximately $1.1 million from the IIA for the development of its abovementioned technologies. With respect to such grants, SciSparc
is committed to pay royalties of up to an aggregate amount of approximately $1.1 million relating only to technologies in its possession
and excluding any royalties for technologies that SciSparc sold to third parties. SciSparc is further required to comply with the requirements
of the Research Law, with respect to those past grants. In addition, any change of control and any change of ownership of SciSparc&#8217;s
ordinary shares that would make a non-Israel citizen or resident an &#8220;interested party&#8221; as defined in the Research Law requires
prior written notice to the IIA. Non-Israeli citizens and residents are required to execute an undertaking in favor of the IIA, in the
form prescribed by the IIA. When a company develops know-how, technology or products using IIA grants, the terms of these grants and
the Research Law restrict the transfer or licensing of such know-how inside or outside of Israel, and the transfer or licensing outside
of Israel of manufacturing or manufacturing rights of such products, technologies or know-how, without the prior approval of the IIA.
None of its current projects in the field of cannabinoid therapeutics are supported by the IIA, yet if eligible, SciSparc might apply
for such support in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Current
Regulatory Status of SciSparc&#8217;s Pharmaceutical Products<i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>United
States</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
active ingredient in SciSparc&#8217;s pharmaceutical product candidate SCI-110 is a Schedule I controlled substance. Other drug candidates
in its portfolio are either not controlled or as yet to be scheduled.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
drug candidate SCI-110 is being developed, among others, for the treatment of TS. TS may be considered a serious condition with a potentially
disabling nature. Thus, it may be eligible for a fast-tracked submission. However, a request for eligibility may be filed by SciSparc
later in the development of this molecule. In June 2016, SciSparc submitted a request for orphan drug designation to the FDA for SCI-110
for the treatment of TS. In a letter dated September 29, 2016, the FDA informed SciSparc that its request could not be granted at such
time and is being held in abeyance until and subject to it providing additional information pertaining to the overall prevalence of TS
in both children and adults, and further clinical data to support its scientific rationale for its request for orphan drug designation
within 12 months. In September 2017, SciSparc responded to such FDA letter within the designated time frame and provided the FDA with
its articulated and reasoned responses including documentation and clinical data that supports it. On December 26, 2017, SciSparc received
the FDA&#8217;s response to SciSparc&#8217;s response. The FDA accepted that there is adequate scientific rationale for the treatment
of TS with SCI-110 mainly through the preliminary results of ongoing clinical trials, suggesting that SCI-110 may provide benefit in
treating TS. However, the FDA stated that it was unable to grant SciSparc&#8217;s request and indicated that it did not provide adequate
prevalence estimates, and any evidence to support its statement that only moderate to severe TS patients would require pharmacological
treatment. SciSparc further responded in January 2018 by providing the requested information. On January 23, 2020, following additional
correspondence with the FDA, the FDA still did not grant SciSparc&#8217;s request due to fact that it has not yet provided adequate prevalence
estimates. However, the FDA did agree with SciSparc&#8217; s position that it could potentially qualify for orphan drug designation with
respect to the moderate-to-severe TS sub-group population only rather than the entire population. After SciSparc had provided additional
prevalence estimates, the FDA raised a concern in its letter, dated December 7, 2020, about its ability to limit the use of the pharmaceutical
product to the subset of patients SciSparc is pursuing. Due to the fact that SciSparc disagrees with this concern, it requested a clarification
call. In the clarification call conducted on February 2, 2021, SciSparc agreed with the FDA concern about its ability to limit the use
of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics population
so SciSparc suggested to amend its preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March 2021, SciSparc sent its response to the
FDA. In June 2021, SciSparc received a response from the FDA explaining that they are unable to grant the request until new information
becomes available to support the request for orphan drug designation. SciSparc will re-visit the application after it obtains clinical
results from its phase IIb clinical study in TS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Canada&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>NNHPD
Approval</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to a non-traditional class III Product License Application, CannAmide&#8482;, or TheraPEA, received Health Canada approval (NPN 80093504)
from the NNHPD on July 23, 2019. In the approval letter, the NNHPD confirmed that the application was in compliance with section 7 of
the NHPR. The dosage of 1 x 400 mg tablet 3 times daily was approved for the following use: &#8220;Studies show that PEA may be used
as an anti-inflammatory to help relieve chronic pain&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Any
labels used in the marketing of TheraPEA must reflect the information outlined on the product license and must comply with the labelling
requirements as per Part 5 of the NHPR. In addition, natural health products, such as TheraPEA, must be manufactured, packaged, labelled,
imported, distributed and stored in accordance with GMP as required by NHPR or in accordance with equivalent requirements if the natural
health product is imported. Furthermore, in accordance with Section 44 of the NHPR, each product for sale in Canada must comply with
the finished product specifications submitted to Health Canada.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the NHPR, companies are required to provide the NNHPD with the Canadian site information prior to commencing the importation and/or
sale of the natural health products in Canada.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Changes
made in respect of a licensed product require the submission of an amendment, notification or a new product license application as per
sections 11, 12 and 13 of the NHPR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Organizational
Structure</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
Nutraceuticals Inc. is SciSparc&#8217;s majority-owned subsidiary (approximately 51%), a company focused on e-commerce operations of
Wellution&#8482;, a top- seller account of Amazon Marketplace, which sells hemp-based products. Brain Bright Ltd. is an inactive wholly-owned
subsidiary. SciSparc also own 100% of the issued and outstanding share capital of Evero Health Ltd., a company focused on the development
and commercialization of SCI-110 sleep technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
November 17, 2022, SciSparc invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market,
in exchange for 230,769 ordinary shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind. As of February
7, 2025, following a reverse stock split of Clearmind&#8217;s outstanding shares, SciSparc holds 7,692 ordinary shares of Clearmind,
representing less than 0.1% of the outstanding share capital of Clearmind.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
also holds 52.73% of MitoCareX, an Israeli private company<i>.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
holds a minority interest in AutoMax of approximately 4.82% and a minority interest of approximately 1.14% of Jeffs&#8217; Brands.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Property,
Plants and Equipment </b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
offices are located at 20 Raul Wallenberg Street,&#8239;Tower A, 2nd Floor, Tel Aviv 6971916, Israel, where it currently occupies approximately
120 square meters, under a joint lease with a third-party for a total of 240 square meters. The lease ends on June 30, 2025. SciSparc&#8217;s
current monthly rent payment is NIS 10,200 (approximately $3,300).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">SciSparc
considers that its current office space is sufficient to meet its anticipated needs for the foreseeable future and is suitable for the
conduct of its business. However, it is currently assessing its future needs and has not renewed its lease as of the date hereof.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Legal
Proceedings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">In
connection with a joint venture transaction, entered on May 15, 2020, by and between SciSparc, Capital Point and Evero Health Ltd., one
of SciSparc&#8217;s subsidiaries, it issued a warrant to Capital Point to purchase $340,000 of SciSparc ordinary shares, or the Warrant
Shares, with an exercise price per ordinary share equal to the closing price of SciSparc&#8217;s ordinary shares on the trading day on
which the notice of exercise is actually received by SciSparc. Such warrant was exercisable for 12 months starting from May 15, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
November 4, 2021, SciSparc received from Capital Point a notice of exercise with respect to the Warrant Shares, which was rejected by
SciSparc. On May 2, 2023, Capital Point filed a lawsuit in the Tel Aviv-Jaffa District Court against SciSparc as the sole defendant in
connection with the Warrant Shares. The lawsuit includes allegations of breaches of contract under the Israeli Contracts Law (General
Part), 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches under the Israeli Torts Ordinance (New Version),
1968. The lawsuit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of
the filing of the lawsuit, liquidated damages according to the provisions set forth in the warrant, and seeks as well for the court to
order a mandatory injunction order for SciSparc to issue a warrant to Capital Point to purchase $340,000 of SciSparc ordinary shares
to Capital Point, the return of any unlawful profits received by us and punitive damages.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">As
of February 7, 2025, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant
and were forfeited by Evero Health Ltd. As of the date of this <span style="background-color: white">prospectus</span>, SciSparc cannot
predict the likelihood of its success in the lawsuit.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_012"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif">AUTOMAX
BUSINESS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>This
section sets forth certain information about AutoMax&#8217;s business and certain of AutoMax&#8217;s financial and operating information
appearing elsewhere in this proxy statement/prospectus. It may not contain all the information about AutoMax that may be important to
you, and we urge you to read the entire proxy statement/prospectus carefully, including the sections entitled&#160;</i>&#8220;<i>Risk
Factors,</i>&#8221; &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of AutoMax,</i>&#8221;&#160;<i>and
AutoMax&#8217;s financial statements included elsewhere in this proxy statement/prospectus. Unless otherwise noted, all references in
this subsection to &#8220;we&#8221; or the &#8220;Company&#8221; are to AutoMax.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Business
Overview</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Overview</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
imports and markets a variety of private vehicle models, from various categories such as small vehicles, crossovers, executive vehicles,
premium vehicles, work vehicles, and buses manufactured by Temsa. AutoMax&#8217;s operations are conducted in Israel. AutoMax believes
there are several primary factors that contribute to the success of vehicle importers in Israel, including: (i) innovative vehicle models
and the manner in which these are branded among customers; (ii) trade conditions, especially the exchange rates of the foreign currencies
in which the importer imports in comparison to the currency exchange rates of competitors; (iii) the existence of good relations with
the manufacturer and/or the agent which is also reflected in import prices; (iv) the technological quality of the imported vehicles;
(v) high marketing ability of the importer, which is also reflected in the adjustment of the vehicle and the prices to market demands;
(vi) the level of provided service and the reputation of the importer; (vii) good geographical layout of purchasing agencies across the
world (especially true for parallel importers); and (viii) the geopolitical situation in the countries from which the vehicles are imported.
AutoMax&#8217;s clients range from private customers to institutional customers, including companies that lease, rent, and operate vehicle
fleets, and car dealerships.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
operates through various subsidiaries which include Dalhom AutoMax, AutoMax Trade-In, AutoMax Direct Import, and Global AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Global
AutoMax holds a number of subsidiaries: AutoMax HaShfela Ltd., AutoMax Netanya Ltd., AutoMax Fleet Vehicles Ltd., and AutoMax HaSharon
Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Material
Agreements Relating to AutoMax&#8217;s Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Founders&#8217;
Agreement to establish a joint company in connection with AutoMax&#8217;s branches in Petah Tikva and Ra&#8217;anana</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
April 25, 2021, Global AutoMax entered into a founders&#8217; agreement, or the HaSharon Founders&#8217; Agreement, with A.V.A. Motors
Ltd., which acts as an authorized reseller of vehicles imported by AutoMax and operated a branch in Petah Tikva, or A.V.A. Reseller.
Pursuant to the HaSharon Founders&#8217; Agreement, the parties founded a joint company, AutoMax HaSharon Ltd., or AutoMax Hasharon,
which until October 2022, engaged in operating marketing and sales centers for vehicles imported by AutoMax in the cities of Petah Tikva
and Ra&#8217;anana. For further details on HaSharon Founders&#8217; Agreement, please see page 214.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Exclusive
Distribution Agreement for Chargers and Charging Stations for Electric Vehicles in Israel </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
November 23, 2021, AutoMax entered into an exclusive distribution agreement with Dongfeng Liuzhou Motor Co., Ltd., a company incorporated
under the laws of China, or the Manufacturer, allowing AutoMax to distribute, sell and market chargers and charging stations for electric
vehicles produced by the Manufacturer in Israel, or the Distribution Agreement. Pursuant to the Distribution Agreement, AutoMax offers
such chargers and charging stations to customers who purchased electric and plug-in vehicles marketed by it, and also markets the products
to customers and other resellers, by itself or through a dedicated company established for this purpose. For further details on the Distribution
Agreement, please see page 215.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Direct
Import Agreement with Automobile Plant GAZ Ltd. </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
November 26, 2021, Global AutoMax entered into an agreement with Automobile Plant GAZ Ltd., a company incorporated under the laws of
Russia, or GAZ, for the purpose of distribution, sales, and marketing of the GAZ&#8217;s commercial vehicles and trucks in Israel, or
the GAZ Agreement. For further details on the GAZ Agreement, please see page 215.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Trade-In
Activity in Israel </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March 13, 2022, Global AutoMax entered into a founders&#8217; agreement, as amended, with Av Yo Holdings Ltd., or the Partner, to establish
a joint entity, AutoMax Trade-In Ltd., or AutoMax Trade-In, which engages in the purchase and sale of used vehicles (trade-in), or the
Trade-In Agreement. Pursuant to the Trade-In Agreement, Global AutoMax grants AutoMax Trade-In exclusivity in the purchase of trade-in
vehicles, as purchased by Global AutoMax from its customers, according to pricing determined at Global AutoMax&#8217;s discretion, subject
to fulfilment of certain quotas as agreed in the Trade-In Agreement. For further details on the Trade-In Agreement, please see page 216.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Founders&#8217;
agreement in relation with the branches in Ashkelon and Ashdod </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On July 19, 2022, Global
AutoMax entered into a founders&#8217; agreement, or the AutoMax HaShfela Founders&#8217; Agreement, with an authorized reseller, A.S
Mobility Ltd., that operates AutoMax&#8217;s branch in Ashkelon pursuant to which Global AutoMax and the authorized reseller founded
a joint company, AutoMax HaShfela Ltd., or AutoMax Hashfela, which operates as a vehicle distribution and sales center in Ashdod and
Ashkelon. Pursuant to the AutoMax HaShfela Founders&#8217; Agreement, Global AutoMax owns half of AutoMax HaShfela and the authorized
reseller holds the other half. The board of directors of AutoMax HaShfela consists of four directors, two of which were appointed by
the authorized reseller and two which were appointed by Global AutoMax. For further details on this agreement, please see page 216.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Founders&#8217;
agreement in relation with the branches in Netanya </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
July 28, 2022, Global AutoMax entered into a distribution agreement with an authorized reseller. On November 8, 2022, Global AutoMax
and the authorized reseller signed a founders&#8217; agreement, or the Netanya Founders&#8217; Agreement and cancelled the distribution
agreement, pursuant to which Global AutoMax and the authorized reseller formed a joint company, AutoMax Netanya Ltd., or AutoMax Netanya.
In the third quarter of 2023, the authorized reseller transferred all its holdings in AutoMax Netanya to Global AutoMax, and the Netanya
Founders&#8217; Agreement was canceled, and Global AutoMax is operating the Netanya Branch. For further details on this activity, please
see page 216.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Import
and Marketing of Buses in Israel </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
June 19, 2022, AutoMax entered into a founders&#8217; agreement with Dalhom, which owns a franchise for importing buses of the Temsa
brand, manufactured in Turkey, pursuant to which the companies formed Dalhom AutoMax Ltd., a limited liability company formed under the
laws of the State of Israel, or Dalhom AutoMax, and the Dalhom AutoMax Founders&#8217; Agreement, respectively. The purpose of Dalhom
AutoMax is to serve as a direct importer of Temsa buses in Israel and market these. The Dalhom AutoMax Founders&#8217; Agreement closed
on November 20, 2022, following which each of AutoMax and Dalhom held 50% of Dalhom AutoMax. For further details on the Dalhom AutoMax
Founders&#8217; Agreement, please see page 217.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Agreement
for Direct Import of Electric Vehicles to Israel </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March 13, 2023, Dalhom AutoMax entered into an agreement with Al Damani, a UAE vehicle manufacturer, subject to which Dalhom AutoMax
would distribute, sell, and promote the Al Damani electric vehicles in Israel. This agreement remains subject to Dalhom AutoMax obtaining
all the regulatory approvals as required by the Ministry of Transportation to import vehicles into Israel, a condition that has not yet
been met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Import
and Marketing of Vehicles Manufactured by JAC in Israel</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, AutoMax
Direct Import finalized entering into agreements with Anhui Jianghuai Automobile Group Corp., Ltd., or JAC. On December 27, 2024, AutoMax
Direct Import received its first shipment of vehicles manufactured by JAC, following regulatory approvals for direct importation. AutoMax
management believes the agreement with JAC will generate growth for AutoMax. For further details on the JAC Agreements, please see page
217.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Marketing Channels and Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Direct Distribution and Marketing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement/prospectus, AutoMax and its subsidiaries directly operate five branches,&#160;located in Jerusalem, Haifa, Afula, Netanya,
and Rishon LeZion. The branches located in Ra&#8217;anana and Ashdod are operated by joint companies of AutoMax and third parties, and
the remaining branch in Acre is operated through authorized reseller, as detailed below. The Jerusalem branch also serves as the location
for AutoMax&#8217;s headquarters and includes facilities for licensing and vehicle preparation for sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax maintains an official
website and is active on social media platforms such as Facebook, Instagram, LinkedIn, and TikTok. AutoMax also utilizes paid promotion
and advertising platforms such as Taboola and Outbrain, to share updates on new products and promotions. AutoMax&#8217;s marketing efforts
extend to traditional media as well, including billboards, newspapers and flyers. AutoMax regularly assesses the need to expand its marketing
initiatives and their potential impact to enhance business operations. AutoMax&#8217;s trade-in services (through AutoMax Trade-In),
which also function as a marketing tool for selling new vehicles, are primarily conducted by AutoMax Trade-In at the existing branches,
since the closure of the Glilot branch during the second quarter of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Authorized Resellers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date this proxy
statement/prospectus, AutoMax&#8217;s branch in Acre is operated through authorized Resellers under AutoMax&#8217;s brand. The agreements
with authorized resellers are typically for 3-5 years period, with some agreements automatically renewing unless terminated as specified.
The agreements with authorized resellers typically include sales targets that, if unmet, allow AutoMax or its subsidiaries to terminate
the contract. In addition, most agreements allow either party to terminate the contract&#160;for any reason,&#160;with 90 days&#8217;
prior notice. Authorized resellers are responsible for purchasing demonstration vehicles, maintaining a minimum vehicle inventory, and
running showrooms at their own expense, per AutoMax&#8217;s standards. They also conduct advertising activities and must keep information
confidential during and after the agreement period. Vehicles are sold at prices set by AutoMax, with authorized resellers earning commissions
based on the vehicle model and agreement terms. Marketing efforts are handled by authorized resellers using AutoMax&#8217;s brand, subject
to approval, to attract customers to their branches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table sets
forth AutoMax&#8217;s revenue share in companies held by AutoMax and third parties (not including wholly-owned subsidiaries of AutoMax),
in accordance with its holding percentages of such companies, and pursuant to its founders&#8217; agreements:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; border-bottom: black 1.5pt solid"><b style="-keep: true">Company Name</b></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1.5pt solid"><b style="-keep: true">AutoMax Revenue Share (directly and indirectly)</b></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1.5pt solid"><b style="-keep: true">Third Party Name</b></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1.5pt solid"><b style="-keep: true">Third Party Revenue Share</b></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1.5pt solid"><b style="-keep: true">Agreement Name</b></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b style="-keep: true">Consolidated<br/>
    Company (company<br/>
    controlled by<br/>
    AutoMax (as</b></p>
    <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b style="-keep: true"><br/>
    defined in IFRS 10),<br/>
    whose financial<br/>
    statements are<br/>
    consolidated as part<br/>
    of AutoMax&#8217;s<br/>
    financial statements)</b></p></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: center; vertical-align: top; width: 19%"><span style="-keep: true">AutoMax HaSharon Ltd.</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 11%"><span style="-keep: true">67%</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 18%"><span style="-keep: true">A.V.A. Motors Ltd.</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 11%"><span style="-keep: true">33%</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 25%"><span style="-keep: true">HaSharon Founders&#8217; Agreement</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top; width: 11%"><span style="-keep: true">Yes</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">AutoMax HaShfela Ltd.</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">50%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">A.S Mobility Ltd.</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">50%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">AutoMax HaShfela Founders&#8217; Agreement</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">No</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Dalhom AutoMax Ltd.</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">50%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Dalhom Motors Ltd.</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">50%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Dalhom AutoMax Founders&#8217; Agreement</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">No</span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Dalhom AutoMax Service Centers Ltd. (subsidiary (100%) of Dalhom AutoMax)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">50%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Dalhom Motors Ltd.</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">50%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Dalhom AutoMax Founders&#8217; Agreement</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">No</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">AutoMax Trade-In Ltd.</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">80%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Av Yo Holdings Ltd.</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">20%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Trade-In Agreement</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="-keep: true">Yes</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Industry
                                            Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
vehicle market in Israel differs from most vehicle markets in the world due to its geographical isolation (the absence of open land borders
for free trade in vehicles) and the existence of high import duties. The percentage of vehicle ownership in Israel is relatively low
compared to various Western countries, due to, among other things, the relatively high price of vehicles, mainly due to high taxation,
inferior road infrastructure compared to other Western countries, and high population density.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
the vehicle market in Israel includes a relatively large number of vehicle importers (compared to other sectors in the economy), who
import vehicles that are manufactured in different countries around the world. Most vehicle importers import several brands and products.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
development of the automotive market in Israel is characterized by fluctuations resulting from changes in the macroeconomic environment
of the economy, among other factors. The main characteristics of the automotive market that affect the group&#8217;s activity and the
competitors in this market are:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>High
                                            dependence on suppliers</i>. The success of vehicle importers depends mainly on the relationship
                                            with manufacturers of the vehicles imported and the strategy of the manufacturers&#8217;
                                            activity in relation to the launch of new products, brand positioning in the world, model
                                            policy, trade conditions, price policy and marketing support. It should be noted that the
                                            dependence on the vehicle manufacturers is mainly relevant to the direct importers who have,
                                            in practice, exclusive franchise agreements with manufacturers whose products they import
                                            to Israel. AutoMax believes that it has no significant reliance on the activity of a particular
                                            vehicle manufacturer.</span></td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
                                            in consumer preferences</i>. The vehicle preferences in Israel are subject to frequent changes,
                                            resulting from the preference of certain models by consumers, and due to a variety of factors,
                                            including but not limited to, engine type (diesel, oil, electric, hybrid or gasoline), the
                                            size of the vehicle, its design, technological advantages, environmental rating, fuel economy,
                                            safety standard, price and marketability on the resale market.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Taxation
                                            of vehicles</i>. The importing of most private vehicles in Israel is subject to purchase
                                            taxes, Value Added Tax and customs imposed at cumulative rates of approximately 30%-130%
                                            (or, oftentimes, more), of the cost of the vehicles. The aforementioned tax rates are among
                                            the highest in the world. Changes in tax rates, or benefits given to vehicles of a certain
                                            type, have a direct impact on the preferences of customers in the area of activity. In addition,
                                            changes in taxation on vehicles provided to employees as part of their employment conditions
                                            may affect their preference in relation to receiving vehicles from the workplace versus purchasing.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fuel
                                            and electricity prices</i>. Changes in fuel and electricity prices may have an impact on
                                            consumer preferences in the long term. Vehicle model preferences vary depending on the type
                                            of energy used (i.e., diesel, gas, gasoline, or electricity) and each such energy price.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulation</i>.
                                            The automotive industry in Israel is characterized by vast regulation and strict regulatory
                                            requirements, including the standardization requirements, which may affect the Company&#8217;s
                                            expenditure and the results of its operations.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Infrastructure
                                            levels and density of the roads</i>. According to research conducted by the Bank of Israel,
                                            the roads in Israel are characterized by high levels of density, especially in the areas
                                            with greater population concentration. This affects the scope of vehicle purchases and is
                                            expected to affect it in the future as well.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in currency and interest rates as well as the economic environment.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Based
on data provided for AutoMax, within the private vehicle market in Israel, taking into account only importers that imported 20 vehicles
or more as of June 2024, there are approximately 41 different vehicle importers, of which approximately 19 are direct importers and 22
parallel importers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
vehicle market in Israel is characterized by vast regulations, one of which is the Committee for Increasing Competitiveness in the Economy
under the Ministry of Finance of the State of Israel. In order to increase the competitiveness in the field of the automotive industry
and decrease the price of vehicles and spare parts, while increasing the existing variety in the Israeli market, one of the laws that
was adopted for this purpose was the Vehicle Services Licensing Law, which purpose was to regulate the licensing of automotive services
in the industry. The law came into effect by supervisory orders by virtue of the Supervision of Commodities and Services Law, 5717-1957,
or the Vehicle Services Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law defined three types of importers: (i) Direct importers &#8211; an importer operating according to an agreement with
the vehicle manufacturer; (ii) parallel importer &#8211; an importer operating according to an agreement with an authorized agent of
the vehicle manufacturer; and (iii) small importer &#8211; an importer who imports up to 20 vehicles per year, operating according to
an agreement with an individual in a foreign country. The Vehicle Services Law further mandates that when granting an import license,
the director of the Vehicle and Maintenance Services Department at the Ministry of Transportation, may consider, <i>inter alia</i>, aspects
related to promoting competition in the automotive industry, after consulting with the competition commissioner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><i>Competition</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
operates in two highly competitive industries, the vehicle industry in Israel as an importer and seller and in the international vehicle
industry as a purchaser of vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The value chain in the automotive
industry includes international vehicle manufacturers, vehicle importers, vehicle dealers (over 8,000 authorized vehicle dealers), financing
entities and end users: households, corporate firms and public organizations. According to the Automotive Industry Review published online
by Dun &amp; Bradstreet in February 2024, or the Automotive Industry Review, there are approximately 20 official import groups representing
various manufacturers in Israel, which are responsible for approximately 97% of the automotive imports to Israel. Alongside these, there
are several dozen parallel importers who are collectively responsible for approximately 3% of the imports. However, during the years
2019 to 2024, a small number of parallel importers were responsible for approximately 75% of the total parallel import to Israel. Additionally,
there are vehicle leasing and rental companies, consisting of approximately five primary companies, alongside smaller companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the Automotive Industry Review, as of year-end-2023, there were approximately 4.1 million vehicles on the roads in Israel, of which,
approximately 86% are private vehicles. According to the State of Israel Central Bureau of Statistics, despite a relatively low level
of vehicle ownership in Israel, based on the number of vehicles per 1,000 residents, the traffic density remains among the highest in
the world. Based on studies conducted in previous years, as detailed in Automotive Industry Review, the density is 3.5 times higher than
the Organization for Economic Co-operation and Development, or the OECD, average. The main contributors are the concentration of population
in central Israel, an underdeveloped public transportation system and the lack of correlation between the construction of roads and the
increase in population.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Operating
and growth Strategy </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the Automotive Industry Review, the total number of motorized vehicles in Israel consists of approximately: 3.5 million private vehicles
(representing approximately 86%), 310,000 trucks (representing approximately 8%), 169,000 motorcycles (representing approximately 4%),
and 64,000 buses and taxis in aggregate (representing approximately 2%). The Automotive Industry Review &#8211; 2023, published in Dun
&amp; Bradstreet detailed that in the first part of the year 2023, the volume of automobile deliveries resembled that of the peak year
in 2021; however, commencing from June 2023 there was a slowdown in the volume of deliveries. This deceleration was a result of events
that impacted the economy in 2023, adversely affecting the purchasing power of households, high interest rates prevailing in the economy
in 2023, peaking at 4.75% in the latter half of the year, diminished both purchasing power and financing capabilities, the proposed judicial
reforms in Israel creating significant uncertainty in the economy and threatening Israel&#8217;s credit rating, also affecting the shekel-dollar
exchange rate and increasing the cost of imported goods, including automobiles; and the outbreak of Israel&#8217;s current war against
Hamas that became known as the &#8216;Iron Swords&#8217; war in Israel (for more information, see &#8220;<i>Risk Factors &#8211; Risks
Related to AutoMax&#8217;s Operations in Israel &#8211; Conditions in Israel, including the ongoing war between Israel and Hamas, and
other conflicts in the region, may adversely affect AutoMax&#8217;s operations and limit its ability to market its products, which would
lead to a decrease in revenues</i>&#8221;), which resulted in reduced demand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to an article titled Taxation of Vehicles in Israel for the Year 2023 published on the Israel Transportation Managers website on February
18, 2024, in the year 2023, there was an aggregate of 270,023 passenger vehicles imported to Israel, compared to 268,131 in the year
2022, representing an increase of 0.7%. Based on AutoMax&#8217;s financial results, the import of vehicles in the first three quarters
of 2023 showed an increase compared to the first three quarters of 2022 and declined in the last quarter due to the outbreak of the &#8216;Iron
Swords&#8217; war, which resulted in reduced demand, delays, and increased transportation costs, coupled with security threats associated
with transportation in the Red Sea.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
the &#8216;Iron Swords&#8217; war that began in the fourth quarter of 2023 created market uncertainties and weakened consumer sentiment.
At the onset of the war, numerous employees were put on unpaid leave, many businesses in the commercial sector reduced their workforce
or at least halted recruitments, reducing the inclination to acquire new cars. Due to the reduction in manpower, the number of employed
individuals in the commercial sector holding leased vehicles on behalf of the employer, who constitute major clients of leasing services,
has slowed down, and according to Automotive Industry Review, this is expected to further dampen the demand for leasing services in the
year 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
currently operates eight branches, five of which are operated directly by Global AutoMax, two are operated through joint companies of
Global AutoMax and third parties, and one that is located in Acre, Israel, is operated by authorized representatives. AutoMax agreements
with its authorized representatives are typically for a term between three and five years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">AutoMax&#8217;s
main strategies to help enable its growth include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building
                                            and preserving an inventory of products and models in accordance with customer preferences,
                                            and technological advancements and market developments. AutoMax frequently monitors trend
                                            changes and consumer preferences, in order to expand the range of products and services it
                                            offers.</span></td>
</tr></table><div>

</div><p style="margin: 0; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrating
                                            activity sectors in the vehicle industry synergistic to its activity and the deployment of
                                            supply sources on sales centers, while examining their contribution to its profitability.</span></td>
</tr></table><div>

</div><p style="margin: 0; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
                                            a leasing license and entering the leasing market.</span></td>
</tr></table><div>

</div><p style="margin: 0; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forming
                                            partnerships and/or collaborations with representatives and manufacturers of internationally
                                            leading brands in the automotive industry as well as investment fields.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Financing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">AutoMax
group companies have non-guaranteed credit lines from four banking corporations, which are classified in its financial statements as
short-term loans, as detailed below:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Borrowing
    Company</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Credit
    Line Amount (NIS in thousands)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Utilized
    Amount as of<br/>
    December 31, 2023 (NIS in thousands)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lender</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Interest
                                            Rate (annual)</b></span></p></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; font-style: italic; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: normal; font-style: normal; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Collateral
    provided in favor of the lender and other essential conditions</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commitments
    to<br/>
    comply with<br/>
    financial covenants</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Bank
    consent<br/>
    for the Merger</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Global
    AutoMax</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 6%; text-align: right"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">30,000</span></p>
                                                                   <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">32,500</span></p>
                                                                   <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">42,500</span></p>
                                                                   <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">30,000</span></p></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 0.5in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 7%; text-align: right"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">30,000</span></p>
                                                                   <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">32,500</span></p>
                                                                   <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">38,636</span></p>
                                                                   <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">30,000</span></p></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 0.5in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Bank
                                            A</span></p>
                                                                   <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Bank
                                            B<br/>
                                            Bank C<br/>
                                            Bank D<br/>
                                            &#160;</span></p></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prime
    + 1.15%-2.15%<br/>
    Prime +1.25%-2.25%<br/>
    Prime +0.5%-1.5%<br/>
    Prime +0.75%-1.75%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 0.5in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    detailed below.</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 31%; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
                                            The total tangible equity of Global AutoMax will not be less than NIS 35 million (examined
                                            semi-annually, based on Global AutoMax&#8217;s financial statements); (2) Global AutoMax
                                            total tangible equity divided by Global AutoMax total tangible balance sheet will not be
                                            less than 20% from in Bank A and will not be less than 25% in Banks B, C and D (examined
                                            semi-annually, based on Global AutoMax&#8217;s financial statements) (the &#8220;<b>Equity
                                            to Balance Sheet Ratio</b>&#8221;) (3) Global AutoMax vehicle inventory in accordance with
                                            its financial statements divided by its net credit, will not be less than 115% at any time
                                            (examined monthly) (the &#8220;<b>LTC Ratio</b>&#8221;).</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of June 30, 2024, Global AutoMax met all its financial covenants: the tangible equity of
                                            Global AutoMax was between NIS 66,899 thousand and NIS 68,643 thousand (according to the
                                            differences in the definition of tangible equity for each of the banks); the Equity to Balance
                                            Sheet Ratio was between 25.55% and 26.04% (according to the differences in the definition
                                            of the term tangible equity for each of the banks) and the LTC Ratio was 128.29%.</span></p></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Not
    yet provided as of date of this prospectus. Not yet provided as of the date of this prospectus. Not yet provided as of the date of
    this prospectus Not yet provided as of the date of this prospectus</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"/>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"/>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">AutoMax
    Trade-In</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,641&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Bank
    C</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Prime
    + 0.5% -1.5%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"/>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    detailed below.</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-style: normal; vertical-align: top; font-weight: normal; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">(1)
    The total tangible equity of AutoMax Trade-In will not be less than a total of 25% of the total tangible balance sheet of AutoMax
    Trade-In (examined on a semi-annual basis, according to the annual and semi-annual financial statements of AutoMax Trade-In) (the
    &#8220;<b>Equity to Balance Sheet Ratio</b>&#8221;); and (2) The ratio between (a) the value of AutoMax Trade-In&#8217;s vehicle
    inventory, and (b) its net financial debt, will not be less than 130% (examined every month as well as upon demand of the bank).
    As of June 30, 2024, AutoMax Trade-In did not meet all its financial covenants detailed above: the Equity to Balance Sheet Ratio
    was 19.19 %, and the ratio detailed in section (2) was 134.91%. However, Automax Trade-In received a waiver from Bank C, according
    to which Bank C will not pursue its rights in connection with the non-compliance with the Equity to Balance Sheet Ratio as of June
    30, 2024.</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Not
    yet provided as of the date of this prospectus.</span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-style: normal; vertical-align: top; font-weight: normal; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; width: 8%"><span style="font-family: Times New Roman, Times, Serif">Dalhom
    AutoMax</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 6%"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 7%"><span style="font-family: Times New Roman, Times, Serif">7,500&#160;<br/>
    7,500</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 5%"><span style="font-family: Times New Roman, Times, Serif">Bank
    C<br/>
    Bank D</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif">Prime
    + 0.5% -1.5%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif">As
    detailed below.</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-style: normal; vertical-align: top; font-weight: normal; text-align: justify; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">The
    ratio between (a) the value of Dalhom AutoMax vehicle inventory plus the advance payments made to Dalhom AutoMax supplier, and (b)
    Dalhom AutoMax net financial debt, shall not be less than 1.2 (the &#8220;</span><span style="font-family: Times New Roman, Times, Serif; font-style: normal"><b>Inventory-to-Debt
    Ratio</b><span style="font-weight: normal">&#8221;). The Inventory-to-Debt Ratio is examined every month as well as at the request
    of the Banks. As of June 30, 2024, the Inventory-To-Debt Ratio is 1.24.</span></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 20%"><span style="font-family: Times New Roman, Times, Serif">Not
    yet provided as of the date of this prospectus. Not yet provided as of the date of this prospectus.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">AutoMax
    Direct Import</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,000</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(extended&#160;in
    November 2024)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Bank
    D</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Prime
    +1%-2%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    detailed below.</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">(1)
    The total tangible equity of Automax Direct Import will not be less than an amount equal to 30% of the tangible balance sheet of
    Automax Direct Import (examined each quarter based on Automax Direct reports starting June 2025); (2) the ratio between AutoMax Direct
    Import vehicle inventory and AutoMax Direct Import net credit shall not be less than 130%; and (3) meeting revenue and profit targets
    according to an annual business plan (for this purpose, deviation of up to 10% will not be considered a violation of this covenant).</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;Provided.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>


</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Collateral
provided in favor of the lender and other essential conditions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to secure the repayment of the on-call credit lines provided by the Banks A-D, or the Banks, Global AutoMax provided the Banks
with the liens, collaterals and pledges, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            first-degree floating lien on all assets, funds, property and rights including the proceeds
                                            of Global AutoMax;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            first-degree permanent lien and pledge on the unassigned share capital of Global AutoMax
                                            and its goodwill;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            permanent lien and pledge of the bills of lading, certificates of ownership of goods, documentary
                                            letters of credit, or other documents indicating ownership of goods or goods which will be
                                            delivered from time to time to the Banks;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            permanent lien and pledge of all the securities, documents, bills of others which Global
                                            AutoMax has delivered or will deliver from time to time to the Banks; and</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            commitment not to encumber shares of subsidiary Global AutoMax owns, without the prior written
                                            approval of the Banks.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, AutoMax guaranteed the full obligations of Global AutoMax to the Banks, without limitation on the amount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
terms of the credit lines from Banks A-D include other customary provisions, including subordination of owner loans extended to Global
AutoMax and delivery of financial statements and other financial reports to the Banks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
secure the full repayment of the on-call credit line provided by Bank C, AutoMax Trade-in provided Bank C with a first-degree floating
lien on its plant, business, and all the assets and rights it has now and/or will have in the future. In addition, AutoMax guaranteed
AutoMax Trade-in&#8217;s obligations to Bank C, with a limitation of up to NIS 15 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the terms of AutoMax Trade-In&#8217;s credit line from Bank C include a cross-default provision in connection with the credit
extended by Bank C to Global AutoMax, and other customary provisions, including subordination of owner loans extended to AutoMax Trade-In,
and delivery of reports to Bank C.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
secure the full repayment of the on-call credit lines provided by Banks C and D, Dalhom AutoMax provided Banks C and D with first degree
floating lien on all its assets, including the rights and proceeds arising from the assets. In addition, the terms of Dalhom AutoMax&#8217;s
credit lines include a cross-default provision in connection with the credit extended by the Banks to Global AutoMax, a prohibition on
a direct change of control in Dalhom AutoMax, and other customary provisions, including subordination of owner loans extended to Dalhom
AutoMax, and delivery of reports to the Banks. Dalhom AutoMax has further undertaken that its tangible equity will increase every year
at a rate of no less than 50% of the annual net profit. AutoMax guaranteed Dalhom AutoMax&#8217;s obligations towards Banks C and D.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
secure the full repayment of the on-call credit line provided by Banks D, AutoMax Direct Import provided Bank D with first degree floating
lien on all its assets, including the rights and proceeds arising from the assets. AutoMax guaranteed AutoMax Direct Import&#8217;s obligations
towards Bank D. In addition, the terms of AutoMax Direct Import&#8217;s credit lines include other customary provisions, including subordination
of owner loans extended to AutoMax Direct Import and delivery of reports to Bank D.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>AutoMax&#8217;s
Competitive Advantages</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Unlike
direct importers who are guaranteed a certain vehicle inventory, pursuant to agreements with manufacturers, AutoMax is required to purchase
its vehicle inventory from authorized dealers and various suppliers in various international markets, under more competitive conditions.
AutoMax is able to operate in a larger number of markets with different characteristics, with a variety of products, while aiming to
increase its geographical purchase sources.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">While direct importers
are bound to agreements with manufacturers, and therefore subject to such manufacturers&#8217; framework with a predetermined model cascade,
which limits the vehicle models they can import. Parallel importers, such as AutoMax, have greater flexibility with regards to the brands
and models selected for import. The number of significant parallel importers remains relatively low in Israel (during the years 2019
to 2024, a small number of parallel importers were responsible for approximately 75% of the total parallel import to Israel), reducing
AutoMax&#8217;s competition in this category. The high profit margins characterized by vehicles sold by direct importers allow AutoMax
to sell its imported vehicles at competitive prices, thus gaining consumer preference. Furthermore, its ability to find convenient procurement
sources in terms of price and transportation, distribution, and sales network provides AutoMax with a competitive advantage over other
parallel importers. In accordance with a report generated on December 30, 2024, for the period covering January 1, 2019 to December 30,
2024 from the website &#8220;CarZone&#8221;, at https://www.carzone.co.il/, a service providing statistics regarding the vehicle market
in Israel, AutoMax is currently the leading and largest company in the indirect sectors in terms of vehicle imports, importing approximately
40% of the total vehicles imported to Israel by parallel import during the years 2019 to 2024.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Employees
and Human Capital </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the number of employees employed by AutoMax as of December 31, 2021, 2022, and 2023, by departments. None of
AutoMax&#8217;s employees are represented by a labor&#160;union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="5" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of employees<br/> (including part-time positions)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Department</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2021</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2022</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2023</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management, headquarters and
    finances</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">14</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-delivery inspections</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">14</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Sales</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">93</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">43</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">65</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">126</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">71</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Environmental
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
recent years, as part of the global trend, there has also been a trend in Israel aimed at reducing the environmental damage caused by
the use of vehicles. As part of this trend, the global automotive industry is investing in increasing alternative sources of propulsion,
starting with hybrid vehicles and ending with vehicles powered by gas or electricity. Similarly, governments around the world have joined
the environmental effort, by way of activating regulatory tools to encourage the development, production and purchase of vehicles with
less environmental damage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to an article published on the website Walla vehicles, titled Summary 2023: 1,000 New Cars Every Day. What Was the Most Sold Vehicle,
published on January 1, 2024, in the course of 2023, approximately 276,500 new vehicles were supplied in Israel, representing an increase
in 2% compared to 2022. Based on an article published on the Israel Transportation Managers&#8217; website, approximately 40% of these
vehicles were environmentally friendly, which are therefore eligible for a reduced tax rate. This figure indicates the continuation of
the trend of the public preference to switch regular petrol vehicles to electric vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Over
the last two years, the electric vehicle market began to develop in Israel. As of the date of this prospectus, the electric vehicle category
is mainly dominated by Chinese brands. From the data of the automobile industry for the year 2023, it is evident that electric technology
was widely implemented in the market during this year, as 48,000 electric cars were delivered, accounting for approximately 18% of all
deliveries, compared to 2022 in which approximately 27,600 electric cars were delivered. According to the Automotive Industry Review,
there is currently a high adoption rate of electric vehicles, represented by a growth of approximately 74%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Seasonality</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
is usually a seasonality in vehicle sales in Israel that is manifested in a decrease in vehicle sales towards the end of the calendar
year (in the fourth quarter of the year) and an increase in sales at the beginning of the calendar year (in the first quarter of the
year). This trend stems, to the best of AutoMax&#8217;s knowledge, from the consumers&#8217; preference to postpone the purchase of the
vehicle until the beginning of the next calendar year, so that the registration, as will appear on the vehicle license, will be of a
more advanced calendar year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">However,
in the years 2020 through 2023, the Israeli government decided to reduce the purchase tax discounts for hybrid vehicles starting from
the beginning of the first quarter of the following year. Therefore, buyers of this type of vehicle chose to purchase the vehicles at
a lower price in the fourth quarter of that year. At the same time, importers preferred to release from ports and bonded warehouses a
large number of vehicles for inventory at a lower cost.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Governmental
Regulations </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
operates in a highly regulated environment and is subject to many governmental regulations and laws that can impact its competitive position
and earnings. These regulations are designed to increase competition in the local market and protect consumers. AutoMax is subject to
consumer protection laws, laws regulating the import of spare parts, laws regulating services and recall obligations and regulations
by the Committee for Increasing Competitiveness in the Economy under the Ministry of Finance of the State of Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
governments across the globe, including in Israel, have started adopting new regulations aimed at environmental matters in an attempt
to slow climate change. Over the years AutoMax has seen certain tax repercussions on vehicles pursuant to these regulations, for example
the Green Tax as adopted in Israel in 2009, pursuant to which the taxation on a vehicle is set by the level of pollution for such vehicle.
This Green Tax was adopted to encourage consumers to lean towards ecofriendly vehicles. Additionally, AutoMax is subject to governmental
regulations in the countries from which it imports its vehicles. The European union has adopted the Worldwide Harmonized Light Vehicle
Test Procedure, or WLTP, which is used to measure fuel consumption and CO<sub>2</sub>&#160;emissions. All vehicles imported to Israel
are subject to the WLTP test to determine the Green Tax for such model.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
                                            order to increase the competitiveness in the field of the automotive industry and decrease
                                            the price of vehicles and spare parts, while increasing the existing variety in the Israeli
                                            market, the Vehicle Services Licensing Law was enacted to regulate the licensing of automotive
                                            services in the industry. The law came into effect by supervisory orders by virtue of the
                                            Supervision of Commodities and Services Law, 5717-1957, or the Vehicle Services Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law defined three types of importers: (i) direct importer &#8211; an importer operating according to an agreement with
the vehicle manufacturer; (ii) parallel importer &#8211; an importer operating according to an agreement with an authorized agent of
the vehicle manufacturer; and (iii) small importer &#8211; an importer who imports up to 20 vehicles per year, operating according to
an agreement with an individual in a foreign country. The Vehicle Services Law further mandates that when granting an import license,
the director of the Vehicle and Maintenance Services Department at the Ministry of Transportation may consider, inter alia, aspects related
to promoting competition in the automotive industry, after consulting with the competition commissioner.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, AutoMax is subject to various advertising, sales, employment, financing and privacy laws, all of which could affect its ability
to obtain the required licenses and permits to operate its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following is a description of the Material regulatory provisions applicable to AutoMax&#8217;s activities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Certain
Material Israeli Regulatory Provisions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;The
following summary is a discussion of material Israeli regulatory provisions applicable to AutoMax&#8217;s current activities but does
not discuss all of the aspects of Israeli or other law that may be relevant to AutoMax&#8217;s activities. The following summary is for
general information purposes only and is based upon current Israeli law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Competition
in the Automotive Industry</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the conclusions of the Committee for Increase in Economical Competition, published in 2012, the Israeli government decided to take a
series of measures in the automotive industry with the aim of increasing competition in the industry and supporting the decline in the
prices of vehicles and spare parts, while increasing the existing diversity of vehicle models in the Israeli market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of these measures, during 2016, the Vehicle Services Law was passed into law. The purpose of the Vehicle Services Law is to regulate
the licensing of vehicle services and professions in the automotive industry, most of which were regulated before the law came into force,
by supervision orders by virtue of the Supervision of Commodities and Services Law, 5718-1957. One of the goals of the Vehicle Services
Law is to establish new provisions that would promote competition in the industry and consumer rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law defines three types of importers, or Commercial Importers: direct importer &#8211; an importer acting under an agreement
with the vehicle manufacturer, or a Direct Importer; parallel importer &#8211; an importer acting under an agreement with an authorized
agent of the vehicle manufacturer, or a Parallel Importer; and small importer &#8211; an importer who imports up to 20 vehicles per year,
operating under an agreement with a person in a foreign country, or a Small Importer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">When
granting an import license, the Director of the Vehicle and Maintenance Services Division at the Ministry of Transport may consider,
inter alia, considerations of promoting competition in the automotive industry, after consulting with the Competition Commissioner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, in order to remove competitive barriers on Parallel Importers and Small Importers, the Direct Importer is obligated to provide
a manufacturer&#8217;s warranty as given in the country of origin, spare parts and treatment of serial safety malfunctions for every
vehicle manufactured by a manufacturer imported by it, even if the model of vehicle was not actually imported by the Direct Importer,
but by a Parallel Importer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law is intended to reduce regulation on the import and trade of spare part for vehicles. Such reduction in regulation
shall only apply to spare parts of vehicles certified by an Israeli, European or American standard. Accordingly, the existing complex
and cost-heavy import and trade procedures for spare parts were eliminated. In addition, the Vehicle Services Law regulated the trade
in vehicle safety equipment, while imposing various obligations on the license holder to trade in vehicle safety equipment, such as safety
requirements, providing liability for their products, handling defective products, and correctly marking traffic products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law imposes statutory obligations on Commercial Importers, including providing the buyer with safety information about
the vehicle, publicizing the level of safety equipment of the vehicle, providing information to the garage about the care and maintenance
of vehicles (except for Small Importers), securing the buyer&#8217;s financial liability by limiting the amount paid by each buyer in
advance as down payment for the purchased vehicle, unless the buyer had registered it in his or her name. If a buyer did not register
the vehicle in his or her name, the Commercial Importers must inform him or her before the purchase, of his or her entitlement to receive
a bank guarantee for the cost of the down payment for the vehicle.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Vehicle Services Law opened the market to private imports for personal or family use, which allows such importers to import
vehicles for business needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Safety
Disclosures</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Licensing Regulations for Services and Professions in the Automotive Industry (Car Importation and Marketing, Mediation In Personal Importation
and Fees), 5777-2016, were installed by virtue of the Vehicle Services Law. These regulations stipulated, among other things, provisions
regarding the regulation of serial safety malfunctions in imported vehicles (recalls), publication of safety information regarding a
vehicle in advertising and at the sale centers, provision of instructions for use of the vehicle to the buyer and reporting of damage
caused to the vehicle prior to delivery.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Parallel
Importer License</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
main legal provisions governing the procedure required to obtain a Parallel Importer and Direct Importer license are included in the
Vehicle Services Law, Licensing Regulations for Services and Professions in the Automotive Industry (Car Import and Marketing and Car
Trade), 5776-2016, and Procedure No. 1/16, and Procedure 2/16, of the Vehicle and Maintenance Services Division published by the Ministry
of Transportation, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 201; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->184<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These
provisions establish, <i>inter alia</i>, threshold requirements for obtaining a license for the parallel import of vehicles, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">entering
                                            into an agreement with an authorized agent (either a primary agent (a primary agent is an
                                            entity that has an agreement with the vehicle manufacturer according to which it is authorized
                                            to sell a vehicle made by the vehicle manufacturer) or secondary agent (a secondary agent
                                            is an entity or person connected by an agreement with a primary agent regarding the vehicle
                                            imported by a Direct Importer, according to which that entity or person is authorized to
                                            act on behalf of the primary agent and sell a vehicle manufactured by the car manufacturer
                                            with which the main agent has entered into an agreement to sell a vehicle);</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            letter of commitment both from the vehicle manufacturer in a foreign country and a letter
                                            of commitment from the applicant;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">minimum
                                            equity (as specified in regulation 6 of the Import Regulations, and which varies according
                                            to the number of vehicles imported by the Commercial Importer in the year preceding the year
                                            for which the license application was submitted); and</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Commercial Importer&#8217;s direct reporting obligation to the administration, and infrastructure
                                            for providing maintenance services for the vehicle.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Parallel Importer&#8217;s engagement with the authorized agent, the authorized agent is required to notify the Parallel Importer,
immediately, of any serial safety malfunction discovered in the vehicle sold to the Parallel Importer (recall). In addition, the authorized
agent must have sold more than 1,500 new vehicles in the year preceding the year of submitting the application for the Parallel Importer
license.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Parallel Importer has various obligations towards its customers, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">vehicles
                                            sold by such Parallel Importer must be new vehicles (or a vehicle registered in a foreign
                                            country that have not traveled more than 150 km);</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Parallel Importer must provide maintenance services, supply spare parts to the vehicle for
                                            no less than seven years from the date of delivery of the vehicle to the consumer;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Parallel Importer has the obligation to immediately notify consumers about any serial safety
                                            fault discovered in the vehicle sold to them, as well as providing information to the consumer
                                            regarding the issue;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">timely
                                            reporting the date of termination of contractual engagement with the manufacturer;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">advertising
                                            of service garages;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">providing
                                            relevant information to customers; and</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">remaining
                                            in compliance with the Parallel Importer&#8217;s obligations according to the relevant sections
                                            of the Vehicle Services Law.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the foregoing, AutoMax distribution agreements with authorized agents generally include the following provisions: (a)
the agent undertakes to sell to AutoMax, from time to time, new vehicles manufactured by a particular manufacturer (brand), in quantities
and according to prices, payment terms and supply terms as agreed between the parties, for the purpose of marketing and selling these
vehicles by AutoMax, and AutoMax is not obligated to purchase pre-determined quantities of vehicles; (b) the agreements include the agent&#8217;s
declarations and undertakings as required by the Vehicle Services Law, as a condition for granting a parallel import license, including
declarations regarding the date of manufacture of the supplied vehicles and their mileage at the time of delivery; (c) the agreement
include the agent&#8217;s undertaking to provide AutoMax with the professional booklets, manuals and instruction manuals in English;
and (d) the agreements include the Agent&#8217;s undertaking to update AutoMax as soon as possible regarding the recall of vehicles by
the manufacturer and to provide the AutoMax&#8217;s customers with any material information required in connection with such recall,
including technical instructions for correcting the malfunction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Usually,
agreements are signed for a period of 6 years, where, <i>inter alia</i>, each party may bring the agreement to an end by giving the other
party written notice 90 days in advance. The agent undertakes to continue to sell to AutoMax, even after termination or expiration of
the Agreement for any reason, the spare parts for the vehicles purchased by the AutoMax, for at least seven years from the date of supply
to the customers of vehicles sold by AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">It
is clarified that according to the provisions of the law described above, a Parallel Importer may import and market vehicles of a certain
model for which the Parallel Importer was granted a license from the Ministry of Transportation, even not throughout the authorized agent
with whom the Parallel Importer received the license for that particular model.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Clean
Air Law, 5768-2008</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Section
38 of the Clean Air Law, 5768-2008, or Clean Air Law, requires any person who sells or markets new vehicles, to disclose in the publications
conducted and published by them in the media, the level of air pollution and fuel consumption data of the new vehicles marketed by them,
in accordance with the provisions of the Clean Air Regulations (Disclosure of Air Pollution Data from Motor Vehicles in Advertisements),
5769-2009.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 202; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->185<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
2009, the &#8220;green taxation&#8221; reform in Israel, or the Green Tax, came into effect. The Green Tax is a benefit in the purchase
tax rate imposed on vehicles depending on the level of pollution of the vehicle, while setting tax incentives for the purchase of vehicles
that pollute less. According to the green index, all new vehicles are ranked according to their level of pollution, so that a vehicle
that pollutes less will receive more tax benefits. In order to implement this principle, the purchase tax on the purchase of private
vehicles was raised from 72% to 83%, and tax reductions were given at increasing rates, up to a maximum discount of about NIS 15,000,
for the least polluting vehicles. As part of the Green Tax reform, it was determined that the calculation formula for the &#8220;green
score&#8221; will be updated from time to time, in order to maintain the efficiency of the incentives and keep up with the pace of technological
changes in the world, which reduce the level of emissions from vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Green Tax reform has led to an increase in the market segment of small vehicles with small volume engines that enjoy the full tax benefit.
However, changes in fuel prices may reduce this effect. The effect of the Green Tax reform on society depends on the mix of products
proposed by vehicle manufacturers. According to a report by the Automobile Importers Association, while Green Tax regulation encourages
the entry of new, non-polluting vehicles, there is no incentive to remove old vehicles already in circulation in the Israeli market,
which boasts a high life expectancy of a vehicle and stands at 15.5 years. According to Hezi Shave and Nadav Caspi, &#8220;Multi-Year
Plan for Removing Polluting and Unsafe Vehicles 2021&#8221;, the percentage of vehicles which are 9 years old or older is 31%. Prominent
elements that delay the process of dredging vehicles in Israel are, among others, car insurance that is not affected by the age of the
vehicle, lack of monetary compensation for scrapping an old vehicle, and more.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the update of the Pollution Regulations and the Vehicle Pollution Testing Procedure in the European Union (WLTP), the Green Tax formula
was updated in Israel to reflect the change in the measurement method, or the New Green Tax Formula. The New Green Tax Formula gradually
reduces the tax benefits for vehicles with a low level of pollution and sets tax benefit ceilings, causing an increase in the prices
of vehicles that enjoyed purchase tax benefits as part of the Green Tax (such as electric and hybrid vehicles). The New Green Tax Formula
went into effect on April 1, 2019, and as of the date of this prospectus, it is updated once on January 1 of each year, with the tax
benefit on hybrid and plug-in vehicles expected to be completely eliminated in 2025. On January 1, 2023, the purchase tax on hybrid and
plug-in cars increased from 40% in 2022 to 55% in 2023, and the tax benefit ceiling was reduced from NIS 40,000 in 2022 to NIS 30,000
in 2023. The purchase tax on electric cars doubled from 10% in 2022 to 20% in 2023, and the tax benefit ceiling was reduced from NIS
75,000 in 2021 to NIS 60,000 in 2022. On January 1, 2024, the sales tax on hybrid and plug-in cars increased to 83% and the tax benefit
ceiling was cancelled, the purchase tax on electric cars increased to 35% and the tax benefit ceiling for such vehicles was reduced to
NIS 50,000. This update to the formula on tax rate to be paid on some of the vehicles imported by AutoMax, as well as on the vehicles
of AutoMax&#8217;s competitors, caused a moderate increase in the prices of some of the vehicles marketed in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
January 1, 2024, the Israeli Minister of Finance signed an order stating that the sales tax rates imposed on electric vehicles and plug-in
vehicles, which were in effect in 2023, will continue to apply until January 31, 2024 for vehicles on-route to Israel, provided that
at the time of departure the vehicle was supposed to arrive at a port in Israel by December 31, 2023 and the delay in its arrival was
caused by the security risk involved in the transfer of goods in the Red Sea during the Iron Sword War, and provided that an import declaration
has been filed for the vehicles by January 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, despite the provisions of the law stating that the date of import is the time of docking of the ship carrying the goods, as
determined in section 144 of the Customs Ordinance, it was decided by the Minister of Finance, in accordance with the Customs Tariff
and Exemptions and Purchase Tax on Goods Order (Temporary Order No. 7), 5779-2019 (Amendment), 5774-2024, to approve, in an exceptional
manner, payment of tax according to the tax rate that applied as of December 31, 2023 and not on the date of arrival of the goods. This
relief was approved in light of the security situation due to the Iron Swords War, and in light of inquiries received from representatives
of the community regarding the expected delay of vehicle ships on their way to Israel, due to the change in their route caused by the
security situation, citing expected arrival after December 31, 2023, which would have resulted in payment of tax in accordance with the
aforementioned temporary order. The relief is subject to the Civil Administration&#8217;s conviction that the delay was caused by a threat
in the Red Sea related to the Iron Swords War.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Taxation
</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Changes
in the provisions relating to employee taxation and taxation of the use of an employer&#8217;s vehicle (imputation of the value of a
vehicle) may affect business entities in decisions regarding the granting of benefits to employees by way of providing a vehicle for
their use and on employees&#8217; considerations in obtaining a company vehicle as a substitute for wages. These changes may also affect
AutoMax, as employees tend to forgo receiving a car from the workplace and prefer to purchase a car privately.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Customs Tariff and Exemptions and Purchase Tax on Goods Order (Temporary Order No. 5), 5773-2013, or the Order, stipulated that the tax
on private vehicles whose consumer price exceeds NIS 300,000 will increase. According to the order, the vehicles for which the Order
applies to, in addition to the purchase tax rate applicable to the vehicle, will be tax at an additional tax rate calculated as a multiple
of 20% in the difference between the price of the vehicle to the consumer and NIS 300,000, divided by the price of the vehicle to the
consumer. On June 20, 2018, the order was updated to apply to hybrid (including plug-in) and electric vehicles. Because AutoMax imports
a variety of cars (electric, hybrid, plug-in, gas), AutoMax has the ability to change the types of vehicles imported based on the tax
policies applicable to each type of vehicle.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 203; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->186<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with Amendment No. 3 to the Traffic Regulations, 5728-1961, the year of manufacture of the vehicle will be determined according
to the year it went on the road, and such a vehicle will be considered new if twelve months have not yet passed from the date of manufacture,
with exceptions. This means that a vehicle that resides in the Commercial Importer&#8217;s warehouses beyond the aforementioned period
will be considered a &#8220;second-hand&#8221; vehicle, and as a result, the importer will be required to pay the purchase tax imposed
on the vehicle and sell it as a &#8220;second-hand&#8221; vehicle. Accordingly, if a year has passed since the date of manufacture of
the vehicle and the vehicle has not yet been sold, AutoMax is required to carry out a licensing procedure for the vehicle and register
it in its name, and the sale of the vehicle will be considered as a second-hand car sale. In order to avoid selling second-hand vehicles,
AutoMax updates its marketing personnel shortly before the 12-month period has passed and provides high incentives to salespeople for
selling these vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
July 2013, the Ministry of Transportation published a procedure for implementing Regulation 270D of the Traffic Regulations, which deals
with the provision of tax incentives for vehicles equipped with safety systems. The purpose of the procedure is to encourage the import
and purchase of equipped and safe vehicles. In addition, from time to time the Israel Tax Authority revisions the number of points given
to the various safety systems and lowers scores for systems that have already been sufficiently implemented by the public. In accordance
with the aforementioned procedure, motor vehicles imported to Israel of type 1N and 1M (as defined in the Transportation Regulations),
weighing more than 3.5 tons, are entitled to a reduction in purchase tax according to the level of safety equipment of the vehicle, which
will be determined according to the range of safety systems installed in the vehicle and according to the scoring system set out in the
procedure. As part of the aforementioned reform, it was determined, <i>inter alia</i>, that each vehicle model will have a &#8220;level
of safety equipment&#8221;, to be specified on the vehicle license, and Commercial Importers will be required to report to the Ministry
of Transportation about the existing safety systems in the vehicle model. The more safety systems the vehicle is equipped with, the higher
the level the safety equipment will be considered. As of the date of this prospectus, the tax benefit by virtue of the safety incentive
depending on the various levels of safety equipment ranges from approximately NIS 238 to approximately 2,500 NIS, i.e. NIS 238 per credit
point. AutoMax estimates that the effect of this incentive on the prices of vehicles marketed by it is immaterial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
November 5, 2020, the Israel Tax Authority published a directive to customs agents according to which, from February 1, 2021, it is mandatory
to attach a certificate of conformity, or COC, document to the vehicle file, and for each model (determined by the Ministry of Transportation)
it is mandatory to attach at least one COC document. The directive emphasized that if at the time of creation of the vehicle file, no
COC document will be attached to one of the vehicle files of the same model (in the current file or in one of the previous vehicle files),
it will not be possible to register the vehicle. COC documents form an &#8220;identity card&#8221; of any new vehicle, which is manufactured
in Europe. The COC document includes vehicle data, including tire size, exact weights, safety accessories, technical specifications and
air pollution data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of January 1, 2017, and according to the Services and Professions in the Vehicle Industry Regulations (Vehicle Import and Marketing,
Personal Import Intermediation and Fees), 5777-2016, a Commercial Importer must publish in its show rooms or any other place where it
sells or markets vehicles, information regarding the level of safety equipment of new vehicles sold by it.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of January 1, 2018, the Traffic Regulations (Amendment No. 2), 5778-2017, came into force, according to which private and commercial
vehicles registered for the first time by a Commercial Importer will be required to install a collision warning system and lane departure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Consumer
Protection Regulations (Cancellation of a Transaction), 5771-2010</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the Consumer Protection Regulations (Cancellation of a Transaction), 5771-2010, approved by in August 2011, a consumer may cancel
an order for a new vehicle purchased from a Commercial Importer within 14 days, provided that the vehicle has not yet been delivered
to the buyer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>The
Privacy Protection Law, 5741-1981</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Certain
aspects of AutoMax activities are governed by the Privacy Protection Law, 5741-1981, or the Privacy Protection Law, and the regulations
promulgated thereunder. AutoMax acts to adapt the relevant aspects of its activity to the provisions applicable under the Privacy Protection
Law and the regulations promulgated thereunder, and for this purpose has entered into an agreement with a company that manages the field
of information security and privacy protection in AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>General
</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the above, AutoMax is subject to orders, regulations and procedures governing various restrictions and charges applicable
to vehicle importers or marketers in Israel; Traffic Ordinance [New Version]; Free Import Order, 5774-2014; Ministry of Transportation
procedures that are updated from time to time, as well as the various regulatory requirements defined and updated from time to time by
the Standardization Department of the Vehicle Division of the Ministry of Transportation, which deal mainly with vehicle safety, passenger
and pedestrian safety, and air pollution. As of the date of this prospectus, to the best of AutoMax&#8217;s knowledge, AutoMax complies
with and complies with all instructions, requirements and arrangements relevant to its operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Intellectual
Property and Proprietary Rights </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax&#8217;s
business name and brand image are critical elements to its business strategy. In Israel, it holds a registered tradename &#8220;AUTOMAX&#8221;
in English, and &#8220;Global AutoMax&#8221; in Hebrew, which is set to expire on November 25, 2029. AutoMax&#8217;s business is also
affected by innovation and technology which have become increasingly important. AutoMax relies on its tradename, domain names and certain
copyrights to protect its branding and differentiate it from other brands in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 204; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->187<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="m_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif">SCISPARC
MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>You
should read the following discussion and analysis of SciSparc&#8217;s financial condition and results of operations together with SciSparc&#8217;s
financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. In addition to historical information
this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. SciSparc&#8217;s
actual results may differ materially from those results described in or implied by the forward-looking statements discussed below. Factors
that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the
section entitled &#8220;Risk Factors &#8212; Risks Related to SciSparc&#8221; appearing elsewhere in this proxy statement/prospectus.
SciSparc&#8217;s discussion and analysis for the year ended December 31, 2022 compared to the year ended December 31, 2021 can be found
in its Annual Report for the fiscal year ended December 31, 2022, filed with the SEC on May 1, 2023.</i></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Overview</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">SciSparc
is a specialty clinical-stage pharmaceutical company. SciSparc&#8217;s focus is creating and enhancing a portfolio of technologies and
assets based on cannabinoid therapies. With this focus, SciSparc is currently engaged in the following pharmaceutical compositions comprising
N-acylethanolamines and cannabinoids, such as Palmitoylethanolamide and/or &#916;9-tetrahydrocannabinol and/or non-psychoactive cannabidiol
and/or other cannabinoid receptor agonists: SCI-110 for the treatment of Tourette syndrome and Alzheimer&#8217;s disease and agitation;
SCI-160 for the treatment of pain; and SCI-210 for the treatment of Autism Spectrum Disorder and Status Epilepticus. SciSparc also currently
holds a 50.86% controlling interest in its subsidiary, SciSparc Nutraceuticals Inc., whose business focuses on the sale of hemp-based
products on Amazon Marketplace.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recent
Developments</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
January 21, 2024, SciSparc entered into a Standby Equity Purchase Agreement, or SEPA, as amended on February 26, 2024, with YA II PN,
LTD, or YA, which provided for the sale of up to $20 million of SciSparc&#8217;s Ordinary Shares, or the Advance Shares. As of June 30,
2024, of the $20 million eligible to be sold pursuant to the SEPA, or the Commitment Amount, SciSparc has sold 925,159 ordinary shares.
The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of 97% of the market price, which is
defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing
on the trading day immediately following the delivery of an advance notice to YA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
April 10, 2024, SciSparc entered into the Merger Agreement, as amended, with AutoMax and Merger Sub. Upon the terms and subject to the
satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by SciSparc&#8217;s shareholders
and AutoMax&#8217;s shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned
subsidiary of SciSparc. AutoMax&#8217;s share capital will be converted into the right to receive ordinary shares of SciSparc, equal
to the exchange ratio set forth in the Merger Agreement. The Merger Agreement contemplates that at the closing, SciSparc shall deliver
to AutoMax an amount of $4.25 million (less any amount due by AutoMax to SciSparc under any loan agreement between the parties) through
a wire transfer of the immediate available funds to an account for AutoMax&#8217;s ongoing capital requirements and operational expenses.
At the effective time of the Merger, or the Effective Time, as further defined in the Merger Agreement,&#160;each outstanding share of
AutoMax&#8217;s share capital will be converted into the right to receive ordinary shares of SciSparc, equal to the exchange ratio set
forth in the Merger Agreement, or the Exchange Ratio. Under the Exchange Ratio, following the Effective Time, the former AutoMax shareholders
immediately before the Merger (other than the Company) are expected to hold together approximately 49.99% (minus the Finder Fee, as defined
in the Merger Agreement) of the aggregate number of the outstanding ordinary shares of SciSparc on fully diluted basis (subject to certain
exceptions). The shareholders of SciSparc, together with the holders of SciSparc&#8217;s convertible securities, immediately before the
Merger are expected to hold together approximately 52.51% of the aggregate number of the outstanding ordinary shares of SciSparc&#8217;s
on fully diluted basis (subject to certain exceptions).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
July 8, 2024, SciSparc announced that it signed a non-binding letter of intent, or the LOI, to spin off its advanced clinical stage pharmaceutical
portfolio and its equity stake in SciSparc Nutraceuticals. The LOI references a proposed asset and share purchase agreement, the definitive
agreement of which is to be negotiated between SciSparc and Miza.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 13, 2024, SciSparc entered into the License Agreement of the Assets with the Licensee. According to the License Agreement, SciSparc
granted the Licensee a royalty-bearing, exclusive, sub-licensable right and license to the Assets, or the License. In consideration for
the License, SciSparc received and will receive certain shares of the Licensee, reflecting an issue price of $3 million, and royalties
from sales related to and income generated from the Assets. Further, the Licensee will pay SciSparc pre-determined fees upon the completion
of certain development milestones relating to the Assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
September 5, 2024, SciSparc entered into the Second Amendment to the Bridge Loan Agreement with AutoMax. Pursuant to the Second Amendment,
SciSparc extended the Loan Amount to AutoMax. In the month of September 2024, SciSparc provided AutoMax with the loan amounts due under
the Second Amendment to the Bridge Loan, and offset any interest due until November 30, 2024 from the principal amount, such as that
on the closing date of the Merger, SciSparc will be due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated)
of the Loan Amount, from the period starting December 1, 2024 and ending on the effective date of the Merger. In consideration for the
Loan Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary
AutoMax Direct Import in favor of SciSparc. The Bridge Loan Agreement states that the principal amount of the bridge loan would bear
interest at a rate of 7% per annum (or 9% per annum if the closing of the Merger Agreement does not occur prior to the repayment date)
compounded annually. The Bridge Loan amount, together with any accrued interest, may be repaid in part or in whole prior to the repayment
date, contingent on whether the closing of the Merger Agreement occurs. The repayment date shall be at the earlier date of: (a) the Closing
(as defined below), in which the Owed Amount shall be deemed a part of, and set-off against, the financing amount SciSparc will provide
AutoMax with upon consummation of the Merger, which is expected to be $4.25 million; or (b) if the definitive agreement for the AutoMax
Acquisition is terminated in accordance with its terms, within three months from such termination date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 205; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->188<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
September 26, 2024, SciSparc signed an LOI to sell its entire ownership interest in MitoCareX to the Purchaser. SciSparc currently owns
52.73% of the issued and outstanding share capital of MitoCareX. Pursuant to the terms of the LOI, initially, in exchange for transferring
and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute 27% of SciSparc&#8217;s ownership in MitoCareX,
SciSparc will receive in cash consideration of $700,000. Subsequent to this first phase, SciSparc will transfer to the Purchaser the
remaining 73% of its ownership stake in MitoCareX in exchange for a certain number of shares based on the valuation of the Purchaser
equal to $8,000,000 and a valuation of MitoCareX equal to $5,000,000 (the latter of which includes the $700,000 in cash consideration
for the shares described above). The LOI also includes provisions for additional milestones that, upon achievement, could increase the
consideration paid by the Purchaser to SciSparc from $5 million to $7 million. The details of the full terms of this transaction are
subject to negotiation and execution of definitive agreements.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Operating
Results</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">To
date, SciSparc has not generated revenue from its drug development segment from the sale of any pharmaceutical product candidates, and
it does not expect to generate significant revenue in this business within the next year at least. As of June 30, 2024, SciSparc had
an accumulated deficit of approximately $72 million. As of December 31, 2023, SciSparc had an accumulated deficit of approximately $69
million. SciSparc&#8217;s operating activities are described below under &#8220;Operating Expenses.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Revenues</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">During
the six months ended June 30, 2024, SciSparc generated revenues in the amount of $840 thousand. In the year ended December 31, 2023,
SciSparc generated revenues in the amount of $2,879 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Cost
of goods sold</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
cost of goods sold comprises mainly purchases of Wellution&#8482; brand products, Amazon Marketplace transaction fees, and storage and
transportation costs associated with SciSparc&#8217;s warehouse. The cost of goods sold in the six months ended June 30, 2024, amounted
to $366 thousand. In the year ended December 31, 2023, the cost of goods sold amounted to $683 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Operating
Expenses</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
current operating expenses consist of two components &#8211; research and development expenses, and general and administrative expenses,
including sales and marketing expenses through SciSparc&#8217;s subsidiary SciSparc Nutraceuticals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Expenses, net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
research and development expenses consist primarily of salaries and related personnel expenses, regulatory and other expenses and clinical
studies expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
following table discloses the breakdown of research and development expenses:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"/><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Six
    month period ended<br/>
    June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">(in thousands of
    USD)</span></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Wages and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">224</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Clinical studies</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">145</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and preclinical studies</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Chemistry and formulations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory and other
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">366</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">841</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">781</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 206; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->189<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Wages and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">392</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">436</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">264</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Regulatory, professional and other expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">719</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and preclinical studies</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">101</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">703</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Clinical studies</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Chemistry and formulations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">141</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">281</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,641</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,803</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
expects that its research and development expenses will materially increase as it plans to continue clinical trials and develop new products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of salaries, professional service fees for accounting, legal, bookkeeping, investor relations,
Amazon Marketplace transaction fees, advertising and promotion on Amazon Marketplace, regulatory and other general and administrative
expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
following table discloses the breakdown of general and administrative expenses:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Six
    month period ended<br/>
    June 30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">(in thousands of USD)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Wages and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">311</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">217</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional and directors&#8217; fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,670</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,366</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investor relations and business expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">310</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office maintenance, rent and other expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">68</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Regulatory expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Wellution operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">101</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">107</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amazon Marketplace fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">297</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">686</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Business development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,632</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,921</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">USD in thousands</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Wages and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">415</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">437</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">68</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">633</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amazon Marketplace fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,042</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">424</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Storage</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">145</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional and directors&#8217; fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,594</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,499</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Business development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Regulatory expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">202</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">162</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office maintenance, rent and other expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">110</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">224</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Investor relations and
    business expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,486</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,031</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,972</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 207; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->190<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Comparison
of the year ended December 31, 2023 to the year ended December 31, 2022, and of the six months ended June 30, 2024 to the six months
ended June 30, 2023</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Results
of Operations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><i>(in
                                   thousands of USD)</i></span></p></td><td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,879</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,347</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cost of goods sold</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">683</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">322</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,196</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,025</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,641</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,803</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sales and marketing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,297</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">537</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup>&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Impairment of intangible asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,042</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,031</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,972</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup>&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,815</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,287</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Company&#8217;s share of losses of company
    accounted for at equity, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">210</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">109</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial expense (income), net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,818</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,883</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,592</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable to holders of ordinary
    shares</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,592</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified
                                            for the year ended December 31, 2022 related to certain activities carried out by Wellution
                                            in the year ended December 31, 2023. This reclassification correlates with common practice
                                            in the industry to better reflect profit and loss across the periods presented. For further
                                            information regarding Wellution, see &#8220;Business Overview -- Other Programs -- Acquisition
                                            of Wellution&#8482;&#8221;.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b style="-keep: true"><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc&#8217;s
revenues for the six months ended June 30, 2024, amounted to $840 thousand, representing a decrease of $1,132 thousand, or 57%, compared
to $1,972 thousand for the six months ended June 30, 2023. The decrease is primarily due to operational difficulties which caused the
Welllution<sup>TM</sup>&#160;brand to be temporarily put offline from the Amazon Marketplace.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc&#8217;s
revenues for the year ended December 31, 2023, amounted to $2,879 thousand, representing an increase of $1,532 thousand, or 114%, compared
to $1,347 thousand for the year ended December 31, 2022. The increase is primarily due to the Company operating the Welllution<sup>TM</sup>&#160;brand
for a full year in 2023, compared to less than four months in 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b style="-keep: true"><i>Cost of goods sold</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc&#8217;s
cost of goods sold for the six months ended June 30, 2024, amounted to $366 thousand, representing a decrease of $142 thousand, or 28%,
compared to $508 thousand for the six months ended June 30, 2023. The decrease is primarily due to the decrease in revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc&#8217;s
cost of goods sold for the year ended December 31, 2023, amounted to $683 thousand, representing an increase of $361 thousand, or 112%,
compared to $322 thousand for the year ended December 31, 2022. The increase is primarily due to the Company operating the Welllution<sup>TM</sup>&#160;brand
for a full year in 2023, compared to less than four months in 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b style="-keep: true"><i>Gross profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc&#8217;s
cost of goods sold for the six months ended June 30, 2024, amounted to $474 thousand, representing a decrease of $990 thousand, or 68%,
compared to $1,464 thousand for the six months ended June 30, 2023. The decrease is primarily due to the decrease in revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc&#8217;s
cost of goods sold for the year ended December 31, 2023, amounted to $2,196 thousand, representing an increase of $1,171 thousand, or
114%, compared to $1,025 thousand for the year ended December 31, 2022. The increase is primarily due to the company operating the Welllution<sup>TM</sup>&#160;brand
for a full year in 2023, compared to less than four months in 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 208; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->191<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
research and development expenses for the six months ended June 30, 2024, amounted to $841 thousand, representing an increase of $60
thousand, or 8%, compared to $781 thousand for the six months ended June 30, 2023. The increase is primarily due to the increase in research
and pre-clinical studies, that are derived from the purchase of raw materials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
research and development expenses for the year ended December 31, 2023, amounted to $1,641, representing a decrease of $1,162, or 41%,
compared to $2,803 for the year ended December 31, 2022. The decrease resulted primarily from a decrease in research and preclinical
studies expenses, chemistry and formulations expenses and share-based compensation expenses, which amounted for $101 thousand, $141 thousand,
and $34 thousand, respectively, in the year ended December 31, 2023 (compared to $703 thousand, $281 thousand, and $264 thousand, respectively,
in the year ended December 31, 2022).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
general and administrative expenses totaled $2,632 thousand for the six months ended June 30, 2024, a decrease of $289 thousand, or 10%,
compared to $2,921 thousand for the six months ended June 30, 2023. The decrease was primarily attributable to a decrease of $253 thousand
in investor relations and business expenses, and a decrease of $389 thousand in Amazon Marketplace fees related to Wellution, offset
in part by an increase of $304 thousand in professional and director fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
general and administrative expenses totaled $5,031 thousand for the year ended December 31, 2023, representing a decrease of $941 thousand,
or 16%, compared to $5,972 thousand for the year ended December 31, 2022. The decrease resulted primarily from a decrease in investor
relation and business expenses and share-based compensation expenses, which amounted to $369 thousand and $68 thousand, respectively,
in the year ended December 31, 2023 (compared to $1,486 thousand and $633 thousand, respectively, in the year ended December 31, 2022).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Sales
and marketing expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
sales and marketing expenses in the six months ended June 30, 2024, amounted to $528 thousand, compared to $729 thousand during the six
months ended June 30, 2023. SciSparc&#8217;s sales and marketing expenses totaled $1,297 thousand for the year ended December 31, 2023,
representing an increase of $724 thousand, or 135% compared to $537 thousand for the year ended December 31, 2022. The sales and marketing
expenses comprise mainly of advertising and promotional rebates on Amazon Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Impairment
of intangible asset</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
impairment of intangible assets totaled $1,042 thousand for the year ended December 31, 2023, representing an increase of $1,042 thousand
compared to $nil for the year ended December 31, 2022. The increase resulted primarily from an impairment of an intangible asset related
to the decline of the Wellution brand and its goodwill in the amount of $1,042 thousand for the year ended December 31, 2023 (compared
to $0 in the year ended December 31, 2022).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 209; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->192<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Loss</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
operating loss for the six months ended June 30, 2024, was $3,527 thousand, compared to an operating loss of $2,967 thousand for the
six months ended June 30, 2023, an increase of $560 thousand, or 19%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
operating loss for the year ended December 31, 2023, was $6,815 thousand, representing a decrease of $1,472, or 18%, as compared to an
operating loss of $8,287 thousand for the year ended December 31, 2022. The decrease resulted primarily from the decrease in research
and development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financial
Expense and Income</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Finance
expenses and income consist of revaluation of debt instruments presented at fair value, related issuance expenses of debt instruments
and bank fees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
recognized finance income, net for the six months ended June 30, 2024, of $51 thousand, representing a decrease of $96 thousand compared
to finance income of $147 thousand for the six months ended June 30, 2023. Finance income is mainly due to changes in the fair value
of the warrants issued in June 2022, and interest from bank deposits and loans to a related party. Finance expenses are mainly due to
changes in the fair value of the Company&#8217;s financial assets.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
recognized financial income in the amount of $2,219 thousand for the year ended December 31, 2023, as compared to financial income of
$7,832 thousand for the year ended December 31, 2022. The decrease of financial income for the year ended December 31, 2023 resulted
mainly due to the decrease in the fair value of SciSparc&#8217;s warrant liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
recognized financial expenses for the year ended December 31, 2023, of $1,055 thousand, as compared to financial expense of $2,014 thousand
for the year ended December 31, 2022. The decrease of financial expenses for the year ended December 31, 2023 resulted mainly due to
the decrease in the fair value of SciSparc&#8217;s financial assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Total
Comprehensive Loss</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
total comprehensive loss for the six months ended June 30, 2024, was $3.7 million, representing an increase of $0.75 million, or 25%,
compared to $2.93 million for the six months ended June 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
total comprehensive loss for the year ended December 31, 2023, was $5,883 thousand, representing an increase of $3,291 thousand, or 127%,
as compared to $2,592 thousand for the year ended December 31, 2022. The increase resulted primarily from the decrease in financial income
in the year ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Since
its inception in 2004, and through December 31, 2023, SciSparc has funded its operations principally with $64.5 million from the issuance
of ordinary shares and ADSs, warrants and pre-funded warrants. As of December 31, 2023, SciSparc had $2.1 million in cash, $22 thousand
in trade receivables, $540 thousand in other accounts receivable, $742 thousand in inventory, and an additional amount of $3 million
in short-term bank deposits. In the event that additional financing is required from outside sources, it may not be able to raise such
financing on terms acceptable to us or at all. If SciSparc is unable to raise additional capital when desired, its business, operating
results, and financial condition would be adversely affected, and there is substantial doubt about its ability to continue as a going
concern.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of June 30, 2023, SciSparc had $2.624 million in cash, including short-term restricted deposits and short-term deposits.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
tables below presents SciSparc&#8217;s cash flows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>in thousands of USD)</i></span></td><td>&#160;</td>
    <td colspan="6" style="text-align: right"/><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,226</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,233</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,071</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,811</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 210; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->193<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"/><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>USD in thousands</i></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating activities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,887</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,917</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,109</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,084</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,498</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,700</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase in cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,498</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,301</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash used in operating activities was $2,226 thousand for the six months ended June 30, 2024, compared with net cash used in operating
activities of $3,233 thousand for the six months ended June 30, 2023. The decrease is primarily due to decreases in adjustments to the
profit or loss item of finance expenses relating to the change in fair value of warrants of $253 thousand, offset in part by losses from
remeasurement of investment in financial assets of $256 thousand, and in adjustments to the working capital in the amount of $1,002 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities was $5,887 thousand during 2023 in comparison to $7,917 thousand during 2022. The decrease resulted
primarily from the decrease in operating expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Investing
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash provided by investing activities was $92 thousand for the six months ended June 30, 2024, compared with $1,071 thousand cash used
in investing activities for the six months ended June 30, 2023. Net cash provided by investing activities is due to a decrease in short-term
deposits in the amount of $692 thousand, offset in part by SciSparc&#8217;s investment in MitoCareX in the amount of $600 thousand. Net
cash used in investing activities for the six months ended June 30, 2023 was due to SciSparc&#8217;s investment in MitoCareX and the
investment in financial assets of $687 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Net
cash used in investing activities was $1,109 thousand during 2023 in comparison to $7,084 thousand during 2022. Net cash used in investing
activities during 2023 resulted mainly from the investment in short-term bank deposits in the amount of $3,000 thousand, investment in
financial asset in the amount of $687 thousand, and an investment in a company accounted for at equity in the amount of $400 thousand,
offset by cash generated from the sale of a minority interest in the Wellution brand in the amount of $2985 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Net
cash used in investing activities during 2022 resulted mainly from the purchase of the Wellution brand in the amount of $4,861 thousand,
the purchase of financial assets in the amount of $1,500 thousand, and an investment in a company accounted for at equity in the amount
of $700 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financing
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash provided by financing activities of $0.3 million in the six months ended June 30, 2024, primarily consisted of $2.7 million of net
proceeds from the issuance of share capital, offset in part by loans granted in the amount of $2.4 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Net
cash provided by financing activities of $5,498 thousand in the year ended December 31, 2023, primarily consisted of $5,547 thousand
of net proceeds from the issuance of share capital, pre-funded warrants and warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Net
cash provided by financing activities of $11,700 thousand in the year ended December 31, 2022, primarily consisted of $9,005 thousand
of net proceeds from the issuance of share capital, pre-funded warrants and warrants and $2,770 thousand from warrant exercises.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>June
2022 Securities Purchase Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 27, 2022, SciSparc announced that it had entered into&#160;a securities purchase agreement, which closed on June 1, 2022, with a
single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10,000, before deducting fees to the
placement agent and other offering expenses payable by SciSparc, or the 2022 Private Placement. In connection with the 2022 Private Placement,
SciSparc issued 3,546,100 units and pre-funded units at a purchase price of $2.82 per unit (or $0.001 less per pre-funded unit). Each
unit and pre-funded unit consisted of one Ordinary Share (or Ordinary Share equivalent) and two non-tradable warrants each exercisable
for one Ordinary Share for $2.57 (for a total of 7,092,200 shares underlying the warrants). The warrants have a term of five years from
the issuance date. No actual units were issued in the 2022 Private Placement. Aegis Capital Corp. was the exclusive placement agent in
connection with the 2022 Private Placement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>June
2022 Letter Agreement&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
June 30, 2022, SciSparc and the institutional investor entered into a letter agreement and agreed, among other things, to amend: (i)
the warrants to: (a) extend the termination date for exercising the warrants from June 1, 2027 to June 1, 2029; and (b) amend the exercise
price from $2.57 per share to $2.63 per share; and (ii) the securities purchase agreement to reflect a new purchase price of $2.88 per
unit (or $0.001 less per pre-funded unit), resulting in additional gross proceeds to SciSparc of $212,766. On August 19, 2022, 3,211,100
of the pre-funded warrants were fully exercised at a nominal exercise price of $0.001 per share, which resulted in an issuance of 3,211,100
ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 211; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->194<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Wellution
Acquisition Agreement</i></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 14, 2022, SciSparc entered into the Wellution Acquisition Agreement, pursuant to which it acquired the Wellution&#8482; brand,
or the Brand. SciSparc established SciSparc Nutraceuticals, a wholly owned subsidiary, to hold the new assets, which is also a party
to the Wellution Acquisition Agreement. On September 30, 2022, SciSparc closed the acquisition of the Brand and paid $4.59 million for
the Brand. In addition, at the closing SciSparc issued the Advisor Warrant to the Advisor, to purchase up to 82,418 of SciSparc&#8217;s
ordinary shares On March 26, 2024, the Advisor agreed with SciSparc to waive all its rights under the Advisor Warrants and have the Advisor
warrants cancelled for no consideration.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Wellution
Sales Agreement</i>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
February 23, 2023, SciSparc entered into the Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to
which, at the closing, which occurred on March 28, 2023, Jeffs&#8217; Holdings acquired from SciSparc 57 shares of common stock of SciSparc
Nutraceuticals, which equals approximately a 49% interest in SciSparc&#8217;s wholly owned subsidiary, SciSparc Nutraceuticals, which
owns the Wellution<sup>TM</sup>&#160;brand, for a consideration of $2.5 million in cash, and additional deferred cash payments of approximately
$489 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">In
connection with the closing, SciSparc and Jeffs&#8217; Brands undertook a mutual share exchange in the amount of approximately $288 of
ordinary shares from each of SciSparc and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the
average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately
prior to the closing. Accordingly, SciSparc acquired 35,345 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858
ordinary shares from SciSparc having an aggregate value of $288,238.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Following
the closing of the transaction, which included an equity conversion of the financing amounts of approximately $700 previously provided
by the Company to SciSparc Nutraceuticals for working capital, into shares of common stock at the price per share of the Wellution Sale
Agreement, SciSparc holds approximately 51% of SciSparc Nutraceuticals.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">In
connection with the Wellution Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into the Wellution
Management Agreement for management services of the Wellution<sup>TM</sup>&#160;brand by Jeffs&#8217; Brands, for a monthly fee of $20,
Jeffs&#8217; Brands also received a one-time signing bonus in the amount of $51.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>At-The-Market
Issuance Sales Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
May 16, 2023, SciSparc entered into an At-the-Market Issuance Sales Agreement with Aegis Capital Corp., or the ATM Agreement, pursuant
to which it may offer and sell up to $1,729,964 of SciSparc&#8217;s ordinary shares. Between May 16, 2023 and August, 9, 2023, SciSparc
sold approximately $4,779 of ordinary shares. On August 9, 2023, the ATM Agreement was terminated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>AutoMax
SPA</i>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
June 25, 2023, SciSparc entered into a securities purchase agreement with AutoMax, pursuant to which, at the closing and upon the terms
and conditions set forth in the securities purchase agreement with AutoMax, or the AutoMax SPA, it invested NIS 2,500 thousand (approximately
$691) in cash, in exchange for ordinary shares of AutoMax based on a price per share of NIS 0.5. Following the closing, SciSparc held
approximately 5.6% of the issued and outstanding share capital of AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
January 14, 2024, SciSparc entered, as lender, into the Bridge Loan, further to the previously-announced non-binding letter of intent
for it to acquire AutoMax. On June 9, 2024, SciSparc entered, as lender, into the Amended Bridge Loan, pursuant to which AutoMax received
an additional bridge loan in the amount of $1.0 million, for an aggregate amount of $2.4 million. On September 5, 2024, SciSparc entered,
into the Second Amendment, pursuant to which SciSparc extended an additional loan in the amount of $1.85 million to AutoMax under terms
similar to the Amended Bridge Loan, bringing the total bridge loan amount to $4.25 million. &#160;In consideration for the Loan Amount,
AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Direct
Import in favor of SciSparc. This subjects SciSparc to additional risk in the event of a default or partial default on payment of the
Bridge Loan. Moreover, there can be no assurance regarding the ultimate timing of the Acquisition or any other restructuring plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Underwritten
Public Offering</i><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
August 14, 2023, SciSparc closed an underwritten public offering, or the Public Offering, of 212,500 ordinary shares, at a purchase price
of $5.20 per ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded
warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between SciSparc and Aegis,
or the Underwriter, on August 10, 2023. Pursuant to the terms of the Underwriting Agreement, SciSparc also granted the Underwriter a
45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments, if any, at the Public Offering
share price less underwriting discounts and commissions.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 212; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->195<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $0.026 per share. Following the Public Offering
and as of December 30, 2024, SciSparc issued 25,000 ordinary shares in respect of the exercise of 25,000 pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>October
2023 Private Placement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
October 12, 2023, SciSparc closed a private placement transaction, or the 2023 Private Placement, pursuant to a securities purchase agreement
and a registration rights agreement with an institutional investor for aggregate gross proceeds of approximately $5 million (representing
a 30% original issue discount to the aggregate purchase price of $7,180,000), before deducting fees to Aegis, the placement agent and
other expenses payable by SciSparc in connection with the transaction. SciSparc sold units to the investors at a purchase price of $3.72
per unit, consisting of 1,930,108 pre-funded Ordinary Share purchase warrants to purchase up to 1,930,108 ordinary shares, and an additional
accompanying pre-funded warrant to purchase up to 1,930,108 ordinary shares.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $0.001 per share. Following the transaction
and as of December 30, 2024, SciSparc has issued 3,860,216 ordinary shares in respect of the exercise of 3,860,216 pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>January
2024 Standby Equity Purchase Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 21, 2024, SciSparc entered into a SEPA with YA. Pursuant to the SEPA, SciSparc will be able to sell up to $20.0 million of SciSparc&#8217;s
ordinary shares, at SciSparc&#8217;s sole option, any time during the three-year period following the execution date of the SEPA. Of
the $20.0 million eligible to be sold pursuant to the SEPA, to date SciSparc has sold 980,452 ordinary shares, which includes 55,293
of SciSparc&#8217;s ordinary shares, which it issued in satisfaction of the payment of the commitment fee amount of $200,000 to YA pursuant
to the SEPA. Pursuant to the terms of the SEPA, any ordinary shares sold to YA will be priced at 97% of the market price, which is defined
as the lowest daily volume weighted average price of the ordinary shares during the three consecutive trading days commencing on the
trading day immediately following SciSparc&#8217;s delivery of an advance notice to YA. Any sale of ordinary shares pursuant to the SEPA
is subject to certain limitations, including that YA is not permitted to purchase any shares that would result in it owning more than
9.99% of SciSparc&#8217;s ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Bridge Loan Agreement </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 5, 2024, SciSparc entered into the Second Amendment to the Bridge Loan Agreement, dated January 14, 2024, and as amended on
June 9, 2024 with AutoMax. Pursuant to the Second Amendment, the Company extended the Loan Amount to AutoMax. In consideration for the
Loan amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary
AutoMax Direct Import in favor of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Share
Buyback Program</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
July 6, 2022, SciSparc announced that its board of directors authorized a $1 million buyback program for SciSparc ordinary shares. However,
as of the date of this prospectus it has not proceeded with the buyback program and do not currently intend to do so. If it wishes to
effectuate the buyback program in the future, Israeli law requires it to file a motion seeking a court approval in Israel for the buyback
program and the effectiveness of the buyback plan, if formally approved, will be contingent upon such approval. However, as a company
listed on an exchange outside of Israel, court approval is not required, provided SciSparc notifies its creditors of the proposed buyback
and allow such creditors an opportunity to initiate a court proceeding to review the buyback. If within 30 days such creditors do not
file an objection, then SciSparc may proceed without obtaining court approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Other Financing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 21, 2024, SciSparc entered into the SEPA with YA, which provided for the sale of up to $20 million of Advance Shares. As of June
30, 2024, of the 20 million eligible to be sold pursuant to the SEPA, the Company has sold 925,159 ordinary shares. The Advance Shares
to be purchased or purchased by YA pursuant to the SEPA are for a share price of 97% of the market price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
April 10, 2024, SciSparc entered into a Merger Agreement, as amended, with AutoMax and the Merger Sub. Upon the terms and subject to
the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into AutoMax, with AutoMax surviving
the Merger as a wholly-owned subsidiary of the Company. AutoMax&#8217;s share capital will be converted into the right to receive ordinary
shares of SciSparc, equal to the exchange ratio set forth in the Merger Agreement. The Merger Agreement contemplates that at the closing,
SciSparc shall deliver to AutoMax the Closing Financing Amount. In light of the Bridge Loan and amendments thereto, no Closing Financing
Amount will be transferred, and SciSparc will be due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated)
of the Loan Amount, from the period starting December 1, 2024 and ending on the effective date of the Merger. In consideration for the
Loan Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary
AutoMax Direct Import in favor of SciSparc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On July 8, 2024, SciSparc
announced that it signed the Spin-off LOI to spin its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc
Nutraceuticals. The Spin-off LOI references a proposed asset and share purchase agreement, the definitive agreement of which is to be
negotiated between SciSparc and Miza. On December 16, 2024, SciSparc announced that it entered into an amendment to the Spin-off LOI,
solely to extend the deadline to enter into definitive agreements by no later than March 31, 2025, which was extended from July 31, 2024,
provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by
no later than April 30, 2025, which was extended from October 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 13, 2024, SciSparc entered into the License Agreement for the out-licensing the Assets with the Licensee. According to the License
Agreement, SciSparc granted the Licensee a License. In consideration for the License, SciSparc received and will receive certain shares
of the Licensee, reflecting an issue price of $3 million, and royalties from sales related to and income generated from the Assets. Further,
the Licensee will pay SciSparc pre-determined fees upon the completion of certain development milestones relating to the Assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 213; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->196<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 5, 2024, SciSparc entered into a Second Amendment to the Bridge Loan Agreement. Pursuant to the Second Amendment, SciSparc
extended an additional loan in the amount of $1.85 million to AutoMax under terms similar to the Bridge Loan Agreement, bringing the
total Loan Amount to $4.25 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 26, 2024, SciSparc signed an LOI to sell its entire ownership interest in MitoCareX to the Purchaser. Pursuant to the terms
of the LOI, initially, in exchange for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX, in tranches,
for cash consideration, in addition to milestone achievements which could increase the consideration. The details of the full terms of
this transaction are subject to negotiation and execution of definitive agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Current
Outlook</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">SciSparc
has financed its operations to date primarily through proceeds from sales of SciSparc&#8217;s ordinary shares and, prior to August 13,
2021, ADSs, as well as exercises of warrants and options to purchase ordinary shares or ADSs, as the case may be. SciSparc has incurred
losses and generated negative cash flows from operations since August 2004. Since August 2004, SciSparc has not generated any revenue
from the sale of its pharmaceutical product candidates and does not expect to generate revenues from sale of its pharmaceutical product
candidates in the next few years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of June 30, 2024, SciSparc&#8217;s cash, including short-term bank deposits, was $2,624 thousand.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
believes that its existing cash resources will not be sufficient to finance its operating activities in the foreseeable future, and SciSparc
expects that it will require substantial additional capital to complete the development of, and to commercialize its product candidates.
If SciSparc does seek to raise additional capital, there can be no guarantee or assurance that SciSparc will be successful in raising
such additional capital or that the term of such capital raise will be on terms favorable to it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of December 31, 2023, SciSparc&#8217;s cash, including short-term bank deposits, was $5,076 thousand, compared to $3,634, as of December
31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2022, SciSparc purchased Wellution&#8482;, a business and brand which sells hemp-based products on Amazon Marketplace.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
January 25, 2023, SciSparc announced that its board of directors resolved to pursue a Restructuring Plan which may involve transferring
its pharmaceutical activities to NewCo. As part or independent of the Restructuring Plan, it intends to examine the possibility of listing
NewCo on a leading stock exchange, while maintaining its controlling interest in NewCo such that it will continue to control its current
business activities. SciSparc also intends to explore other potential new opportunities, activities and investments in a variety of sectors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Any
Restructuring Plan and possible listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or
other business analyses, regulatory approvals, receipt of any necessary consents, final approvals from its board of directors and shareholders
and satisfaction of any closing conditions to effectuate such corporate Restructuring Plan and listing of NewCo. There can be no assurance
regarding the ultimate timing of the Restructuring Plan and listing of NewCo or that they will be completed at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, SciSparc&#8217;s operating plans may change as a result of many factors that may currently be unknown to it, and SciSparc may
need to seek additional financing sooner than planned. SciSparc&#8217;s efforts to commercialize its proprietary PEA oral tablets CannAmide&#8482;
may not lead to any revenue or revenue at the level at which we it is expecting. SciSparc&#8217;s future capital requirements will depend
on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the progress
                                            and costs of SciSparc&#8217;s research and development activities;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the costs
                                            of manufacturing SciSparc&#8217;s product candidates;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the costs
                                            of filing, prosecuting, enforcing and defending patent claims and other intellectual property
                                            rights;</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#160;</td><td style="text-align: justify">&#160;</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the potential
                                            costs of contracting with third parties to provide marketing and distribution services for
                                            us or for building such capacities internally; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the magnitude
                                            of SciSparc&#8217;s general and administrative expenses.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Going
Concern</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">As
of June 30, 2024, SciSparc&#8217;s cash and cash equivalents totaled $2.6 million, which includes deposits and refers to the available
funding balance for the purpose of assessing the projected cash flow, rather than the accounting definition of cash and cash equivalents.
In the period ended June 30, 2024, SciSparc had an operating loss of $3.5 million and negative cash flows from operating activities of
$2.2 million. As of December 31, 2023, SciSparc&#8217;s cash and cash equivalents totaled $2.1 million. In the period ended December
31, 2023, SciSparc had an operating loss of $5.9 million and negative cash flows from operating activities of $5.9 million. Its current
cash and cash equivalents position is not sufficient to fund its planned operations for at least a year beyond the date of the filing
date of the financial statements. The ability to continue as a going concern is dependent upon SciSparc obtaining the necessary financing
to meet its obligations and repay its liabilities arising from normal business operations when they become due. While SciSparc has successfully
raised funds in the past, there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient
funds on commercially reasonable terms, would have serious consequences on its financial condition and results of operations. In addition,
SciSparc has started recognizing revenues from sales. However, its pharmaceutical operations are dependent on its ability to raise additional
funds from existing and/or new investors. This dependency will continue until SciSparc is able to completely finance its operations by
generating revenue from its products. These above-mentioned factors raise substantial doubt about its ability to continue as a going
concern.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 214; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->197<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Intangible
Assets</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Separately
acquired intangible assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired
in a business combination are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible
assets, excluding capitalized development costs, are recognized in profit or loss when incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets with a finite useful life are amortized over their useful life and reviewed for impairment whenever there is an indication that
the asset may be impaired. The amortization period and the amortization method for an intangible asset are reviewed at least at each
year end.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Contingent
Liabilities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
evaluations of provisions and contingent liabilities are based on best professional judgment, taking into consideration the stage of
the proceedings, as well as cumulative legal experience in the various topics. Whereas the results of the lawsuits shall be determined
by the courts, these results may differ from these evaluations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Quantitative
and Qualitative Disclosure About Market Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">SciSparc
is exposed to market risks in the ordinary course of its business. Market risk represents the risk of loss that may impact its financial
position due to adverse changes in financial market prices and rates. Its current investment policy is to invest available cash in bank
deposits with banks that have a credit rating of at least A-minus. However, a substantial majority of SciSparc&#8217;s cash is held in
current bank accounts that do not bear interest. In the future, SciSparc intends to hold most of its cash in deposits that bear interest.
Given the current low rates of interest SciSparc receives, once it begins to hold most of its cash in deposits that bear interest, it
does not expect to be adversely affected if such rates are reduced. SciSparc&#8217;s market risk exposure is primarily a result of NIS/U.S.
dollar exchange rates, which is discussed in detail in the following paragraph.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Foreign
Currency Exchange Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s results
of operations and cash flow are subject to fluctuations due to changes mainly in NIS/U.S. dollar currency exchange rates. As of June
30, 2024, the vast majority of its liquid assets are held in U.S. dollars, and the majority of its expenses are denominated in U.S. dollars.
Changes of both 5% and 10% in the U.S. Dollar/NIS exchange rate would decrease/increase SciSparc&#8217;s loss for 2023 by less than 1%,
respectively. However, these historical figures may not be indicative of future exposure, as SciSparc expects that the percentage of
its NIS denominated expenses will materially decrease in the near future, therefore reducing its exposure to exchange rate fluctuations.
Beginning October 1, 2018, SciSparc&#8217;s functional currency is the U.S. dollar.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">SciSparc
does not hedge its foreign currency exchange risk. In the future, SciSparc may enter into formal currency hedging transactions to decrease
the risk of financial exposure from fluctuations in the exchange rates of its principal operating currencies. These measures, however,
may not adequately protect SciSparc from the material adverse effects of such fluctuations.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Share-Based
Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
employees and other service providers are entitled to benefits by way of share-based compensation settled with company options to shares.
The cost of transactions with employees settled with capital instruments is measured based on the fair value of the capital instruments
on the granting date. The fair value is determined using an accepted options pricing model. The model is based on share price, grant
date and on assumptions regarding expected volatility, expected lifespan, expected dividend, and a no risk interest rate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
cost of the transactions settled with capital instruments is recognized in profit or loss together with a corresponding increase in the
equity over the period in which the performance and/or service takes place, and ending on the date on which the relevant employees are
entitled to the benefits, or the Vesting Period. The aggregate expense recognized for transactions settled with capital instruments at
the end of each reporting date and until the Vesting Period reflects the degree to which the Vesting Period has expired and SciSparc&#8217;s
best estimate regarding the number of options that have ultimately vested. The expense or income in profit or loss reflects the change
of the aggregate expense recognized as of the end of the reported period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
selected the Black-Scholes option-pricing model as a fair value method for its options awards. The option-pricing model requires a number
of assumptions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Expected
dividend yield</i>&#160;- The expected dividend yield assumption is based on SciSparc&#8217;s historical experience and expectation of
no future dividend payouts. SciSparc has historically not paid cash dividends and have no foreseeable plans to pay cash dividends in
the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Volatility&#160;</i>-
The expected volatility is based on fluctuations in the price of SciSparc&#8217;s ordinary share prices on the Nasdaq.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Risk
free interest rate&#160;</i>- The risk free interest rate is based on the U.S. Treasury yield curve, in accordance with the option&#8217;s
contractual term.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Contractual
term&#160;</i>- An option&#8217;s contractual term must at least include the Vesting Period and the employees&#8217; historical exercise
and post-vesting employment termination behavior for similar grants. If the amount of past exercise data is limited, that data may not
represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Share
price&#160;</i>- The share price is determined according to the last known or above closing price of SciSparc&#8217;s ordinary shares
at the grant date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 215; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->198<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_014"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif">AUTOMAX&#8217;S
MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>You
should read the following discussion and analysis of AutoMax&#8217;s financial condition and results of operations together with AutoMax&#8217;s
financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. In addition to historical information
this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. AutoMax&#8217;s actual
results may differ materially from those results described in or implied by the forward-looking statements discussed below. Factors that
could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section
entitled &#8220;Risk Factors &#8212; Risks Related to AutoMax&#8221; appearing elsewhere in this proxy statement/prospectus.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Overview</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">AutoMax
is an authorized parallel importer of vehicles and spare parts in Israel and is engaged in importing and marketing a variety of vehicles
in Israel (including trade-in), and buses manufactured by Temsa. AutoMax has a parallel importer&#8217;s license for 30 vehicle brands
and a variety of models, holding twelve branches in Acres, Haifa, Afula, Netanya, Ra&#8217;anana, Rishon Lezion, Ashdod, and Jerusalem.
AutoMax operates as a holding company through its&#8217; subsidiaries, mainly Global AutoMax Ltd., a wholly owned subsidiary, Dalhom
AutoMax Ltd., in which it holds an 50% controlling interest; AutoMax Trade-In Ltd., in which it holds an 80% controlling interest; and
</span>AutoMax Direct Import, <span style="background-color: white">a wholly owned subsidiary. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
main factors to the financial condition and results of operations for the year ended December 31, 2023 were the: (i) issuance of additional
ordinary shares to AutoMax controlling shareholders upon fulfillment of the milestones according to the merger with Global AutoMax; (ii)
reverse stock split at a ratio of 5:1, following which every five (5) ordinary shares of AutoMax became one (1) ordinary share; (iii)
new credit lines in a total of NIS 15,000,000 (approximately $4.1 million) issued to Dalhom AutoMax in September 2023; (iv) private placement
in June 2023 in a total NIS 4,000,000 (approximately $1.1 million); (v) executed memorandum of understanding and negotiations for a merger
with SciSparc; (vi) private placement in December 2023 in a total NIS 10,000,000 (approximately $2.7 million); and (vii) receipt of a
state guaranteed loan in a total NIS 15,000,000 (approximately $4.1 million).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Recent Developments</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 26, 2024, AutoMax signed the Merger Agreement Second Addendum with SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
November 2024, AutoMax Direct Import finalized entering into agreements with JAC, and received a credit line from a bank. For more information,
see &#8220;AutoMax Business &#8211; Financing&#8221;.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Components
of AutoMax&#8217;s Results of Operations</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">AutoMax
revenues stem from the import of vehicles mainly from North America and Europe and sales in Israel in New Israeli Shekels (NIS). Therefore,
the generated revenues are dependent mainly on the exchange rate between NIS, the U.S. Dollar (USD), the Euro, and other European currencies.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; background-color: white">The
revenues for the </span><span style="font-family: Times New Roman, Times, Serif">year <span style="background-color: white">ended December
31, 2023, were NIS 418,932</span> thousand <span style="background-color: white">(approximately $115,791</span> thousand<span style="background-color: white">),
a decrease of 8%, compared to NIS 453,617 </span>thousand <span style="background-color: white">(approximately $125,377</span> thousand<span style="background-color: white">)
for the </span>year <span style="background-color: white">ended December 31, 2022. The decrease in revenues was due to a change in consumer
preference and a decrease in private consumption due to a recession in Israel and inflation rates. Furthermore, there was a significant
decrease in the revenues in October 2023, due to the Israel &#8211; Hamas war. For further details, see Note 1E to AutoMax financial
statements for the year ended December 31, 2023, included elsewhere in this prospectus.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The revenues for the period
ended June 30, 2024, were NIS 208,886 thousand (approximately $57,703 thousand), an increase of 6.8%, compared to NIS 195,583 thousand
(approximately $54,028 thousand) for the period ended June 30, 2023. The increase in revenues was due to a change in the variety of vehicles
imported and marketed by AutoMax to more in-demand vehicles (smaller and cheaper vehicles), which resulted in AutoMax selling more vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Expenses &#160;</i></b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Cost
of Sales</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of sales for the
period ended December 31, 2023 was NIS 381,089 (approximately $105,331), a decrease of 3%, compared to NIS 392,918 (approximately $108,600)
for the period ended December 31, 2022. The decrease in cost of sales relative to revenue was due to the exchange rate between the NIS
and Euro which decreased by 7.8% over the course of 2023 and a decrease of 13.5% in the exchange rate between the NIS and the Polish
Zloty. The depreciation of the NIS along with the increase in the inventory purchase costs lead to a decrease in gross profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of sales for the
six-month period ended June 30, 2024, was NIS 184,947 (approximately $51,090), an increase of 5.1%, compared to NIS 175,946 (approximately
$48,604) for the period ended June 30, 2023. The increase in the cost of sales was due to a change in the variety of vehicles imported
and marketed by AutoMax, to smaller and cheaper vehicles, and relative to the increase in revenues in the period.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 216; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->199<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Gross
Profit</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
gross profit for the year ended December 31, 2023, was NIS 37,843 thousand (approximately $10,460 thousand), a <span style="background-color: white">decrease
</span>of 38%, compared to NIS 60,699 thousand (approximately $16,768 thousand) for the year ended December 31, 2022. The decrease in
gross profit is mainly due to the depreciation of the exchange rates of the NIS compared to the currencies in which <span style="background-color: white">AutoMax
</span>purchase its vehicle inventory. The devaluation of the exchange rate of the NIS compared to the currencies in which <span style="background-color: white">AutoMax
</span>purchase its vehicle inventory has a negative effect on <span style="background-color: white">AutoMax </span>profitability. <span style="background-color: white">AutoMax
</span>act to reduce the effect of currencies on its profitability, among others, by purchasing in different currencies according to
the volatility of currency rates. For further details, see Note 1D to AutoMax financial statements for the year ended December 31, 2023.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The gross profit for the
six-month period ended June 30, 2024, was NIS 23,939 thousand (approximately $6,612 thousand), an increase of 22%, compared to NIS 19,637
thousand (approximately $5,425 thousand) for the period ended June 30, 2023. The increase in gross profit is due to a change in the variety
of vehicles imported and marketed by AutoMax to more in-demand vehicles (smaller and cheaper vehicles) which are more profitable.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Selling
and Marketing Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
selling and marketing expenses for the year ended December 31, 2023, were NIS 27,194 thousand (approximately $7,516 thousand), an increase
of 2%, compared to NIS 27,612 thousand (approximately $7,631 thousand) for the year ended December 31, 2022. The increase was due to
increase of media marketing and the establishment of a sales representative training center.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling and marketing
expenses for the six-month period ended June 30, 2024, were NIS 10,169 thousand (approximately $2,809 thousand), a decrease of 36%, compared
to NIS 16,105 thousand (approximately $4,449 thousand) for the period ended June 30, 2023. The decrease was due to actions taken by AutoMax
to reduce its ongoing expenses in light of the Iron Swords War and a change in the nature of marketing of its vehicles.</p><div>
</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">General
and Administrative Expenses</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of salaries, related benefits, computer systems, travel and share-based compensation expenses for personnel
in executive and administrative functions. General and administrative expenses also include professional fees for legal, consulting,
accounting and audit services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general and administrative
expenses for the year ended December 31, 2023, were NIS 16,965 thousand (approximately $4,686 thousand), an increase of 1%, compared
to NIS 16,849 thousand (approximately $4,654 thousand)for the year ended December&#160;31, 2022. The increase was primarily due to updating
AutoMax computer systems. The decrease of 26% in the fourth quarter of 2023 compared to the fourth quarter of 2022, was due to actions
taken by AutoMax to reduce its ongoing expenses due to the Iron Swords War.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general and administrative
expenses for the six-month period ended June 30, 2024, were NIS 9,939 thousand (approximately $2,745 thousand), an increase of 8%, compared
to NIS 9,180 thousand (approximately $2,536 thousand) for the period ended June 30, 2023. The increase was due to adjustments AutoMax
had to make in its branch operations in light of the Iron Swords War, as well as adjustment of AutoMax import and logistics systems to
the uncertainty regarding the duration and scope of the Iron Swords War and the delays and price increases in the supply and logistics
chains.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Granting
options to employees</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
                                            expenses for granting options to employees for the year ended December 31, 2023, were NIS
                                            2,549 thousand (approximately $704 thousand), a <span style="background-color: white">decrease
                                            </span>of 74%, compared to NIS 9,976 thousand (approximately $2,755 thousand) for the year
                                            ended December 31, 2022. The decrease was due to options granted an AutoMax officer in the
                                            scope the merger agreement with Global AutoMax completed in March 2021, for which the recording
                                            of expenses ended in the first quarter of 2023 (except for options to an AutoMax&#8217;s
                                            consultant).</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The expenses for granting
options to employees for the six-month period ended June 30, 2024, were NIS 83 thousand (approximately $23 thousand), a decrease of 97%,
compared to NIS 2,451 thousand (approximately $677 thousand) for the period ended June 30, 2023. The decrease was due to options granted
to an AutoMax officer in the scope the merger agreement with Global AutoMax completed in March 2021, for which the recording of expenses
ended in the first quarter of 2023 (except for options to an AutoMax consultant).</p><div>
</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Other
income&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The other income for the
year ended December 31, 2023, was NIS 1,557 thousand (approximately $430 thousand), an <span style="background-color: white">increase
</span>of 689%, compared to NIS 226 thousand (approximately $62 thousand) for the year ended December 31, 2022. The increase was due
to revenues for compensations under the <span style="background-color: white">Israel &#8211; Hamas War</span> fund for the month of October
2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The other income for the
six-month period ended June 30, 2024, was NIS 5,219 thousand (approximately $1,442 thousand), compared to other expenses of NIS 201 thousand
(approximately $55 thousand) for the period ended June 30, 2023. The increase was due to revenues for compensation under Iron Swords
War fund for the months of October and November 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Operational
profit (loss)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operational loss for
the year ended December 31, 2023, was NIS 7,308 thousand (approximately $2,019 thousand), a <span style="background-color: white">decrease
</span>of 213%, compared to profit of NIS 6,488 thousand (approximately $1,792 thousand) for the year ended December 31, 2022. The decrease
was mainly due to decrease in revenues, as set forth above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operational profit for
the six-month period ended June 30, 2024, was NIS 8,967 thousand (approximately $2,477 thousand), compared to loss of NIS 8,300 thousand
(approximately $2,293 thousand) for the period ended June 30, 2023. The increase was mainly due to an increase in gross profitability
and other income, as set forth above.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 217; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->200<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
expenses, net</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Financial
expenses, net consist primarily of income or expenses related to revaluation of foreign currencies and interest income on AutoMax&#8217;s
bank deposits.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparison of the Years Ended
December&#160;31, 2023, and 2022 and the six-month periods ended June 30, 2023, and 2024</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
AutoMax&#8217;s results of operations for the years ended December&#160;31, 2023, and 2022 and for the six-month periods ended June 30,
2023, and 2024:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Results
of Operations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">NIS in thousands</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">418,932</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">453,617</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cost of goods sold</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(381,089</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(392,918</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,843</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,699</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sales and marketing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,612</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Impairment of intangible asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,965</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,849</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granting options to employees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,549</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,976</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,557</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">226</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating profit or loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,308</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,488</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">AutoMax&#8217;s share of losses of company
    accounted for at equity, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial (expense) income, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,109</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,232</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Profit or loss before tax</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,017</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">671</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Tax</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(358</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,931</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,375</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,260</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss attributable to holders of ordinary
    shares</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,384</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,104</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">NIS in thousands</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">208,886</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">195,583</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(184,947</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(175,946</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,169</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,105</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,939</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,180</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granting options to employees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(83</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,451</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(201</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,300</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">AutoMax&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,061</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(297</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial (expense) income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,068</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(994</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Profit or loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,838</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,997</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,048</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,387</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,384</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to holders of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(208</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,925</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Liquidity
and Capital Resources</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
has generated its revenue and funded its activities through independent financing, such as issuing bonds, financing from banks and financing
entities, credit lines provided by the suppliers to AutoMax. As of December 31, 2023, AutoMax had a total of approximately NIS 3,811
thousand (approximately $1,053 thousand) outstanding government guaranteed loans. As of December 31, 2023, the interest rate on such
loans was prime plus 1.5%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2024, AutoMax
had a total of approximately NIS 18,042 thousand (approximately $4,984 thousand) outstanding government guaranteed loans. As of June
30, 2024, the interest rate on such loans was prime plus 1.5%</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2024, Global
AutoMax received a government guaranteed loan from a bank in the amount of NIS 16 million (approximately $4.42 million), bearing an annual
interest rate of prime plus 1.5%. The loan was granted for a period of 60 months, to be repaid in 57 equal monthly installments of principal
amount with interest, with a three months grace period. As is customary in government guaranteed loans, Global AutoMax deposited in the
bank an interest-accumulating deposit, in the aggregate amount of 5% of the loan principal, which will be encumbered by a first-class
permanent lien in favor of the bank.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>


</div><!-- Field: Page; Sequence: 218; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->201<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash in excess of immediate
requirements is invested primarily with a view to liquidity and capital preservation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash Flows</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables summarize
AutoMax&#8217;s cash flows for each of the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">NIS in thousands</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash from (used in) operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,142</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(98,042</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(353</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,453</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,891</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(682</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(604</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">NIS in thousands</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash from (used in) operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(8,150</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,852</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,917</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,628</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,926</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(141</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Activities</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash from operating activities
for the year ended December&#160;31, 2023, was NIS 3,142 thousand (approximately $868), and included AutoMax&#8217;s net loss of NIS
17,375 thousand (approximately $4,786 thousand), and adjustments of non-cash amounts. Most of the non-cash amounts are due to share-based
payments (NIS 2,549 thousand), depreciation of import licenses and fixed assets (NIS 4,642 thousand) and non-cash financing expenses
(NIS 2,939 thousand) as well as changes in the property and liability items on the balance sheet of NIS 3,800 thousand. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net
                                            cash used in operating activities for the year ended December&#160;31, 2022, was NIS 98,042
                                            thousand (approximately $27,098), and included AutoMax&#8217;s net loss of NIS 1,260 (approximately
                                            $348), and adjustments of non-cash amounts. Most of the non-cash amounts are due to share-based
                                            payments (NIS 9,976 thousand (approximately $2,757 thousand)), depreciation of import licenses
                                            and fixed assets (NIS 3,663 thousand (approximately $1,012 thousand)) as well as an increase
                                            in vehicle inventory of NIS 97,082 thousand (approximately 26,833 thousand).&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the six-month period ended June 30, 2024, was NIS 8,150 thousand (approximately $2,251), and included AutoMax&#8217;s
net loss of NIS 210 thousand (approximately $58 thousand), and adjustments of non-cash amounts. Most of the non-cash amounts are due
to depreciation of fixed assets (NIS 2,338 thousand (approximately $646 thousand)).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash from operating activities
for the six-month period ended June 30, 2023, was NIS 2,852 thousand (approximately $788), and included AutoMax&#8217;s net loss of NIS
10,384 thousand (approximately $2,869 thousand), and adjustments of non-cash amounts. Most of the non-cash amounts are due to depreciation
of fixed assets (NIS 2,161 thousand (approximately $597 thousand)), and share-based payments (NIS 2,452 thousand (approximately $677
thousand)).</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing Activities</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, net cash used in investing activities was NIS 353 thousand (approximately $98 thousand), which reflected purchases of fixed
assets. &#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, net cash used in investing activities was NIS 18,453 thousand (approximately $5,098 thousand), which mainly reflected investments
in subsidiaries.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six-month period
ended June 30, 2024, net cash used in investing activities was NIS 4,917 thousand (approximately $1,358 thousand), which reflected mainly
purchases of fixed and intangible assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six-month period
ended June 30, 2023, net cash provided by investing activities was NIS 1,628 thousand (approximately $449 thousand), which reflected
repayment of owner loans, partially offset by purchases of fixed and intangible assets. <i>&#160;</i></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financing Activities</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, net cash used in financing activities was NIS 3,471 thousand (approximately $959 thousand), consisting of a payment of NIS
4,567 thousand (approximately $1,261 thousand) to the Series B bondholders, repayment of long-term loans from banks of NIS 1,969 thousand
(approximately $545 thousand), and repayment of obligations for lease agreements of NIS 5,272 thousand (approximately $1,456 thousand),
partially offset by NIS 8,879 thousand (approximately $2,453 thousand) of proceeds from the private placements conducted in June and
December 2023 for ordinary shares of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 219; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->202<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 25, 2023, AutoMax
entered into a private placement agreement with certain investors, for an aggregate amount of NIS 4.0 million (approximately $1.1 million),
in exchange for the sale and issuance of 8,000,000 ordinary shares, at a purchase price of NIS 0.5 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 19, 2023, AutoMax
entered into a private placement agreement with an investor for an aggregate amount of NIS 10.0 million (approximately $2.8 million),
in exchange for the sale and issuance of 14,284,714 ordinary shares, at a price per shares of NIS 0.7 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
                                            the year ended December&#160;31, 2022, net cash provided by financing activities was NIS
                                            115,891 thousand (approximately $32,014 thousand), consisting of net proceeds from the issuance
                                            of AutoMax&#8217;s Series B debentures in the amount of NIS 45 million (approximately $12.4
                                            million), as well as receiving on-call loans in an aggregate amount of NIS 78 million (approximately
                                            $21.5 million) from several banks in Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six-month period
ended June 30, 2024, net cash provided by financing activities was NIS 12,926 thousand (approximately $3,571 thousand), consisting of
receipt of a government guaranteed loan from a bank in the amount of NIS 16 million (approximately $4.42 million), and receipt of a bridge
loan from SciSparc in the amount of NIS 9,003 thousand (approximately $2,487 thousand), partially offset by payment of NIS 6,849 thousand
million (approximately $1,892 thousand) to the Series B bondholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six-month period
ended June 30, 2023, net cash provided by financing activities was NIS 3,580 thousand (approximately $989 thousand), consisting of receipt
of proceeds from the private placement conducted in June 2023 for ordinary shares of AutoMax of NIS 3,880 thousand (approximately $1,072
thousand), and receipt of short-term loans from banks of NIS 7,213 thousand (approximately $1,992 thousand), partially offset by payment
of NIS 4,567 thousand (approximately $1,262 thousand) to the Series B bondholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms
of the Series B Bonds and the Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual installments,
which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that was made on February 28,
2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made on February 28, 2024,
constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, due on February 28, 2025, will constitute
30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will constitute
45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger the Series B Bonds will remain outstanding
and subject to repayment in accordance with the terms of the Trust Deed. The Series B Bonds bear interest at a rate of 5.9% per annum.
As of February 7, 2025, NIS 34,245 thousand (approximately $9,110 thousand) in principal amount of Series B Bonds remains outstanding
and will therefore become a liability of the combined company following the completion of the Merger. The next payment by AutoMax to
Series B bondholders is due on February 28, 2025, in the principal amount of NIS 13,698 thousand (approximately $3,644 thousand) and
NIS 996 thousand (approximately $265 thousand) of interest accrued thereon.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Credit Lines</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax group companies have
non-guaranteed credit lines from four banking corporations, which are classified in its financial statements as short-term loans. For
more information, see &#8220;AutoMax Business &#8211; Business &#8211; Financing&#8221; (page 179).</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funding Requirements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax believes that its
existing cash and cash equivalents, will enable it to fund its operating expenses and capital expenditure requirements for at least the
next 12 months. It has based these estimates on assumptions that may prove to be wrong, and it could utilize AutoMax&#8217;s available
capital resources sooner than it expects.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Critical Accounting Policies and Significant
Judgments and Estimates</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s financial
statements are prepared in accordance with the IFRS. The preparation of AutoMax&#8217;s financial statements and related disclosures
requires it to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and
the disclosure of contingent assets and liabilities in AutoMax&#8217;s financial statements. AutoMax bases its estimates on historical
experience, known trends and events and various other factors that it believes are reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other
sources. AutoMax evaluates its estimates and assumptions on an ongoing basis. AutoMax&#8217;s actual results may differ from these estimates
under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While AutoMax&#8217;s significant
accounting policies are described in more detail in Note&#160;2 to AutoMax&#8217;s financial statements, AutoMax believes that the following
accounting policy is the most critical to the judgments and estimates used in the preparation of its financial statements.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-Based Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">AutoMax&#8217;s
employees and other service providers are entitled to benefits by way of share-based compensation settled with company options to shares.
The cost of transactions with employees settled with capital instruments is measured based on the fair value of the capital instruments
on the granting date. The fair value is determined using an accepted options pricing model. The model is based on share price, grant
date and on assumptions regarding expected volatility, expected lifespan, expected dividend, and a no risk interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
cost of the transactions settled with capital instruments is recognized in profit or loss together with a corresponding increase in the
equity over the period in which the performance and/or service takes place, and ending on the date on which the relevant employees are
entitled to the benefits, or the Vesting Period. The aggregate expense recognized for transactions settled with capital instruments at
the end of each reporting date and until the Vesting Period reflects the degree to which the Vesting Period has expired and the best
estimate regarding the number of options that have ultimately vested. The expense or income in profit or loss reflects the change of
the aggregate expense recognized as of the end of the reported period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 220; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->203<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">AutoMax
                                            selected the Black-Scholes option-pricing model as a fair value method for its options awards.
                                            The option-pricing model requires a number of assumptions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Expected
dividend yield&#160;- </i>The expected dividend yield assumption is based on the historical experience and expectation of no future dividend
payouts. AutoMax has historically not paid cash dividends and have no foreseeable plans to pay cash dividends in the future.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Volatility&#160;</i>-
The expected volatility is based on fluctuations in the price of AutoMax&#8217;s ordinary share prices on the TASE.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Risk
free interest rate&#160;</i>- The risk free interest rate is based on the U.S. Treasury yield curve, in accordance with the option&#8217;s
contractual term.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Contractual
term&#160;</i>- An option&#8217;s contractual term must at least include the Vesting Period and the employees&#8217; historical exercise
and post-vesting employment termination behavior for similar grants. If the amount of past exercise data is limited, that data may not
represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Share
price&#160;</i>- The share price is determined according to the last known or above closing price of SciSparc&#8217;s ordinary shares
at the grant date.</p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantitative and Qualitative Disclosures
about Market Risks</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Rate Risk</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
AutoMax had cash and cash equivalents, restricted cash and long-term bank deposits of NIS 1,961 thousand (approximately $542 thousand),
which consisted of cash, restricted cash and long-term bank deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022,
AutoMax had cash and cash equivalents, restricted cash and long-term bank deposits of NIS 2,769 thousand (approximately $765 thousand),
which consisted of cash, restricted cash and long-term bank deposits.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2024, AutoMax
had cash and cash equivalents, restricted cash and long-term bank deposits of NIS 2,637 thousand (approximately $728 thousand), which
consisted of cash, restricted cash and long-term bank deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, AutoMax
had cash and cash equivalents, restricted cash and long-term bank deposits of NIS 5,075 thousand (approximately $1,402 thousand), which
consisted of cash, restricted cash and long-term bank deposits.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign Currency Exchange Risk</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax is exposed to foreign
exchange rate risk. AutoMax is located in Israel, where the majority of its general and administrative expenses costs are incurred in
New Israeli Shekels. During each of the years ended December&#160;31, 2023, and 2022, AutoMax recognized foreign currency transaction
income NIS 6,971 thousand (approximately $1,926 thousand) and NIS 3,511 thousand (approximately $970 thousand), respectively. AutoMax&#8217;s
functional currency is NIS. These foreign currency transaction gains and losses were recorded in financial expenses, net in its statements
of comprehensive loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six-month periods
ended June 30, 2024, and 2023, AutoMax recognized foreign currency transaction income of NIS 2,821 thousand (approximately $779 thousand)
and NIS 5,967 thousand (approximately $1,648 thousand), respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As
                                            AutoMax continues to grow its business, its results of operations and cash flows will be
                                            subject to fluctuations due to changes in foreign currency exchange rates, which could adversely
                                            impact AutoMax&#8217;s results of operations. AutoMax enters into hedging contracts from
                                            time to time, to mitigate AutoMax&#8217;s exposure to foreign currency exchange risk, subject
                                            to its need and according to market conditions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Off-Balance Sheet Arrangements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax did not have, during
the periods presented, and it does not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of
the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 221; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->204<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_015"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">DIRECTORS
AND OFFICERS OF SCISPARC FOLLOWING THE MERGER</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Resignations of Current Executive Officers
and Directors of SciSparc</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger Agreement,
two (2) of the directors of SciSparc who will not continue as member of the board following the Merger will resign effective immediately
prior to the completion of the Merger.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors of the Combined Company Following
the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SciSparc board of directors
is currently composed of seven directors. The following information sets forth the names, ages, director classes, and proposed titles
of each of the proposed directors of the combined company upon consummation of the Merger, their present principal occupation and their
recent business experience. During the last five years, neither SciSparc nor the proposed directors of the combined company have been
(i) convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or (ii) a party to any judicial or administrative
proceeding (except for matters that were dismissed without sanction or settlement) that resulted in a judgment, decree or final order
enjoining such person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding
of any violation of federal or state securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 20%"><b>Designee</b>&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 15%; text-align: center"><b>Age</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 61%"><b>Position(s)</b></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">AutoMax Designees</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>Yaarah Alfi*</td>
    <td>&#160;</td>
    <td style="text-align: center">36</td>
    <td>&#160;</td>
    <td>Chief Financial Officer of AutoMax</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Tomer Levy*</td>
    <td>&#160;</td>
    <td style="text-align: center">29</td>
    <td>&#160;</td>
    <td>VP Business Development and Headquarters, director of AutoMax</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>SciSparc Designees</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Amitay Weiss</td>
    <td>&#160;</td>
    <td style="text-align: center">62</td>
    <td>&#160;</td>
    <td>Chairman of SciSparc&#8217;s board of directors</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>Amnon Ben Shay</td>
    <td>&#160;</td>
    <td style="text-align: center">61</td>
    <td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Moshe Revach</td>
    <td>&#160;</td>
    <td style="text-align: center">48</td>
    <td>&#160;</td>
    <td>Director</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>Liat Sidi</td>
    <td>&#160;</td>
    <td style="text-align: center">49</td>
    <td>&#160;</td>
    <td>Director</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Subject to the approval
                                            of the shareholders of SciSparc at the Special Meeting.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Mr.
Amitay Weiss</i></b><i>&#160;</i>has served on SciSparc&#8217;s board of directors since August 2020 and as its </span>Chairman <span style="background-color: white">since
January 2022. Mr. Weiss served as SciSparc&#8217;s Chief Executive Officer from August 2020 to January 2022. Mr. Weiss also currently
serves as chairman of the board of directors of AutoMax, as a director of Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR) and as an external
director of Cofix Group Ltd. (TASE: CFCS). Mr. Weiss also chairs and serves as director on the board of directors of several public and
private companies, including Clearmind Medicine Inc. (Nasdaq: CMND), Maris Tech Ltd. (Nasdaq: MTEK) and Save Foods, Inc. (Nasdaq: SVFD).
In 2016, Mr. Weiss founded Amitay Weiss Management Ltd. and now serves as its chief executive officer. From 2001 until 2015, Mr. Weiss
served as vice president of business marketing &amp; development and in various other positions at Bank Poalei Agudat Israel Ltd. from
the First International Bank of Israel group. Mr. Weiss holds a B.A. in economics from New England College, an M.B.A. in business administration
from Ono Academic College in Israel, an Israeli branch of University of Manchester and an LL.B. from the Ono Academic College.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt; background-color: white"><b><i>Mr.
Amnon Ben Shay</i></b></span><span style="background-color: white">&#160;<span style="font-size: 10pt">has served as a member of SciSparc&#8217;s
board of directors since January 2021 and served as an external director under the Companies Law between January 2021 and January 2022.
Mr. Ben Shay has been chief financial officer of Aerodrome Group Ltd since October 2022. Mr. Ben Shay previously served on the board
of directors of Azorim Investments and Building Development Company Ltd. (TASE: AZRM), Value Capital One Ltd. (TASE: VALU) and B.G.I.
Investments (1961) Ltd. (TASE: BGI). Mr. Ben Shay was chief financial officer of Hadar Hasharon Marketing and Distributions Ltd. from
February 2019 to October 2022. From February 2017 to January 2019, Mr. Ben Shay served as the chief financial officer of Fridenson Air
&amp; Ocean Ltd. From January 2014 to January 2017, Mr. Ben Shay served as the chief financial officer of Abetrans Logistics Ltd. Prior
to that, Mr. Ben Shay served as the chief financial officer of Isline Export and Import Services Ltd. from 2010 to 2013. Prior to the
year 2009, Mr. Ben Shay served as the chief financial officer of several Israeli real estate investment groups. Mr. Ben Shay holds a
B.A. in economics and business and an M.B.A in business, both from The Hebrew University of Jerusalem, Israel, and an accounting certificate
from The College of Management Academic Studies, Israel.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt; background-color: white">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 222; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->205<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Mr.&#160;Moshe
Revach</i></b>&#160;has served as a member of SciSparc&#8217;s board of directors since September 2022. Mr. Revach also previously served
as a director since August&#160;2020 until his resignation on March&#160;13, 2022. Mr.&#160;Revach has served as vice-counselor of the
Ramat Gan municipality and has been on its financial committee since March 2024. Mr.&#160;Revach serves as a director of L.L.N IT solutions,
a wholly owned&#160;subsidiary of the Jewish Agency for Israel, RPG Economic Society, ParaZero Technologies Ltd. (Nasdaq: PRZO), Plantify
Foods Inc (CVE: PTFY), and Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR). Mr.&#160;Revach previously served as a director of Biomedico Hadarim,
and Jewish Experience Company on behalf of the Jewish Agency and also served as deputy mayor of Ramat Gan, Israel from 2013 to 2023,
while also heading the sports and government relations departments in the Ramat Gan municipality. Mr.&#160;Revach holds an LL.B from
the Ono Academic College, Israel, and a B.A. in management and economics from the University of Derby.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Ms.
Liat Sidi</i></b>&#160;has served as a member of SciSparc&#8217;s board of directors since August 2020. Ms. Sidi serves as the manager
of the accounting department for Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) and has served as director for Save Foods
Inc. (Nasdaq: SVFD) since November 2023. Ms. Sidi previous served as director for Plantify Foods Inc (CVW: PTFY) from September 2023
to January 2024. Ms. Sidi previously served as an accountant for Panaxia Labs Israel Ltd. (TASE: PNAK) from 2015 to 2020 and as an accountant
for Soho Real Estate Ltd. from 2015 to 2016. Ms. Sidi also served as an accountant for Feldman-Felco Ltd. from 2006 to 2010 and as an
accountant for Eli Abraham accounting firm from 2000 to 2006. Ms. Sidi completed tax, finance and accounting studies in Ramat Gan College
of Accounting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Mr. Tomer Levy</i></b>
has been serving as VP Business Development and Headquarters and director of AutoMax since March 2021. Prior to that, between May 2017
and March 2021, Mr. Levy served as Global AutoMax&#8217;s VP Business Development and Headquarters. Mr. Levy has experience in a wide
variety of managerial roles.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Ms.
Yaarah Alfi</i></b> has been serving as chief financial executive of AutoMax and its subsidiaries since March 2021. Ms. Alfi previously
served as controller for Global AutoMax from January 2018 until March 2021. Between 2015 and 2018, Ms. Alfi was employed as a certified
public accountant at Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global. Additionally, Ms. Alfi has experience in
a wide variety of managerial, financial, tax and accounting roles. Ms. Alfi holds a B.A. in Accounting and Business management from The
College of Management, Israel and is a certified public accountant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Composition
of </b></span><b>the <span style="background-color: white">Board of Directors</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant
                                            to the Merger Agreement, each of the directors and officers of <span style="background-color: white">SciSparc
                                            </span>who will not continue as directors or officers of <span style="background-color: white">SciSparc
                                            </span>or the combined company following the consummation of the Merger shall resign immediately
                                            prior to the effective time of the Merger. In connection with the Merger, the size of <span style="background-color: white">SciSparc&#8217;s
                                            </span>board of directors will be consist of six (6) directors. Pursuant to the terms of
                                            the Merger Agreement, two (2) of such directors will be designated by AutoMax and four (4)
                                            of such directors will be designated by <span style="background-color: white">SciSparc</span>.
                                            Effective as of the effective time of the Merger, it is anticipated that Amnon Ben Shay,
                                            Moshe Revach, Liat Sidi and Amitay Weiss will remain on <span style="background-color: white">SciSparc&#8217;s
                                            </span>board of directors. Subject to the approval of the SciSparc shareholders of Proposal
                                            4 at the Special Meeting and the election thereof, Tomer Levy and Yaarah Alfi will serve
                                            on <span style="background-color: white">SciSparc&#8217;s</span> board of directors as AutoMax&#8217;s
                                            designees. It is anticipated that these directors will be appointed to the three staggered
                                            director classes of the combined company&#8217;s board of directors as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Class I will consist of
Ms. Liat Sidi and Ms. Yaarah Alfi, each with a term expiring at the 2027 annual meeting of shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Class II will consist of
Mr. Amnon Ben Shay and Mr. Moshe Revach, each with a term expiring at the 2025 annual meeting of shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Class III will consist
of Mr. Amitay Weiss and Mr. Tomer Levy, with a term expiring at the 2026 annual meeting of shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The division of <span style="background-color: white">SciSparc&#8217;s
</span>board of directors into three classes with staggered three-year terms may delay or prevent a change of management or a change
of control of <span style="background-color: white">SciSparc</span>, or, following the completion of the Merger, the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The <span style="background-color: white">SciSparc
</span>board of directors has determined that all current members of the board of directors are independent, as determined in accordance
with the rules of The Nasdaq Stock Market.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The <span style="background-color: white">SciSparc
</span>board of directors has also determined that each current member of the compensation committee is independent as defined under
Nasdaq listing standards and the Companies Law, and that each current member of the audit committee is independent as defined under Nasdaq
listing standards and applicable SEC rules and Israeli laws. In making this determination, <span style="background-color: white">SciSparc&#8217;s
</span>board of directors found that none of these directors had a material or other disqualifying relationship with <span style="background-color: white">SciSparc</span>.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 223; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->206<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based
                                            upon information requested from and provided by each proposed director concerning their background,
                                            employment and affiliations, including family relationships, <span style="background-color: white">SciSparc&#8217;s
                                            </span>board of directors has determined that neither of the proposed AutoMax directors is
                                            independent as defined under Nasdaq listing standards. <span style="background-color: white">SciSparc&#8217;s
                                            </span>board of directors also determined that Amnon Ben Shay, Moshe Revach and Liat Sidi,
                                            who will comprise the compensation committee, all satisfy the independence standards for
                                            such committees established by the SEC and Nasdaq listing standards, as applicable. With
                                            respect to the audit committee, <span style="background-color: white">SciSparc&#8217;s</span>
                                            board of directors has determined that Amnon Ben Shay, Moshe Revach and Liat Sidi satisfy
                                            the independence standards for such committee established by Rule&#160;10A-3&#160;under the
                                            Exchange Act, the SEC and Nasdaq listing standards, as applicable. The board of directors
                                            considered the relationships between such directors and certain of the investors of the combined
                                            company and determined that such relationships did not affect such directors&#8217; independence
                                            under the standards of Nasdaq, or, where applicable, under SEC rules.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board Committees</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The <span style="background-color: white">SciSparc
</span>board of directors has established two standing committees to assist it in fulfilling its responsibilities to <span style="background-color: white">SciSparc
</span>and its shareholders: the audit committee and the compensation committee. Each committee acts pursuant to a written charter. Each
committee reviews its charter on an annual basis. In addition to the three standing committees, the <span style="background-color: white">SciSparc
</span>board of directors may approve from time to time the creation of other committees to assist the board in carrying out its duties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately following the
consummation of the Merger, the committees of the board of directors of the combined company will operate pursuant to and apply <span style="background-color: white">SciSparc&#8217;s
</span>written charters and corporate governance policies currently in place. Thereafter, the board of directors of the combined company
intends to review the written charters and corporate governance policies of <span style="background-color: white">SciSparc</span> and,
in the discretion of the board of directors of the combined company, adopt or amend such charters and policies, as may be necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audit Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functions of the audit
committee under the Companies Law include identifying and addressing flaws in the business management of <span style="background-color: white">SciSparc</span>,
reviewing and approving related party transactions, establishing whistleblower procedures, overseeing <span style="background-color: white">SciSparc&#8217;s
</span>internal audit system and the performance of its internal auditor, and assessing the scope of the work and recommending the fees
of <span style="background-color: white">SciSparc&#8217;s</span> independent accounting firm. In addition, the audit committee is required
to determine whether certain related party actions and transactions are &#8220;material&#8221; or &#8220;extraordinary&#8221; for the
purpose of the requisite approval procedures under the Companies Law and to establish procedures for considering proposed transactions
with a controlling shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with U.S. law
and Nasdaq requirements, <span style="background-color: white">SciSparc&#8217;s</span> audit committee is also responsible for the appointment,
compensation and oversight of the work of its independent auditors and for assisting the board of directors in monitoring financial statements,
the effectiveness of internal controls and compliance with legal and regulatory requirements. The audit committee of the combined company
is expected to retain these duties and responsibilities following completion of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc&#8217;s
</span>audit committee currently consists of Amnon Ben Shay, Alon Dayan and Lior Vider. The SciSparc board of directors has determined
that Amnon Ben Shay is an &#8220;audit committee financial expert&#8221; as defined in the SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following
                                            the consummation of the Merger, the members of the audit committee are expected to be Amnon
                                            Ben Shay, Moshe Revach and Liat Sidi. Amnon Ben Shay is expected to be the chairman of the
                                            audit committee and is a financial expert under the rules of the SEC. The SciSparc board
                                            of directors has concluded that the composition of the audit committee meets the requirements
                                            for independence under the rules and regulations of Nasdaq and SEC. SciSparc and AutoMax
                                            believe that, after completion of the Merger, the functioning of the audit committee will
                                            comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functions of the compensation
committee under the Companies Law include recommending to the board of directors, for ultimate shareholder approval by a special majority,
a policy governing the compensation of directors and officers based on specified criteria, reviewing modifications to and implementing
such compensation policy from time to time, and approving the actual compensation terms of directors and officers prior to approval by
the board of directors. The compensation committee of the combined company is expected to retain these duties and responsibilities following
completion of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s compensation
committee currently consists of Amnon Ben Shay, Alon Dayan and Lior Vider.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following
                                            the consummation of the Merger, the members of the compensation committee are expected to
                                            be Amnon Ben Shay, Moshe Revach and Liat Sidi. Amnon Ben Shay is expected to be the chairman
                                            of the compensation committee. The SciSparc board of directors has determined that each member
                                            of the compensation committee is independent within the meaning of the independent director
                                            guidelines of Nasdaq. SciSparc and AutoMax believe that, after the completion of the Merger,
                                            the composition of the compensation committee will meet the requirements for independence
                                            under, and the functioning of such compensation committee will comply with, any applicable
                                            requirements of the rules and regulations of Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 224; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->207<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executive Officers of the Combined Company
Following the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to and effective
upon the closing of the Merger, the current executive officers of AutoMax will be the executive officers of <span style="background-color: white">SciSparc</span>.
The following information sets forth the names, ages, and proposed titles of each of the executive officers of the combined company upon
consummation of the Merger, their present principal occupation and their recent business experience. During the last five years, neither
SciSparc nor the proposed executive officers of the combined company have been (i) convicted in a criminal proceeding (excluding traffic
violations and similar misdemeanors) or (ii) a party to any judicial or administrative proceeding (except for matters that were dismissed
without sanction or settlement) that resulted in a judgment, decree or final order enjoining such person from future violations of, or
prohibiting activities subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 25%"><b>Name</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 10%"><b>Age</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 61%"><b>Position(s)</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Oz Adler</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">38</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Technology Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Oz Adler</i>, CPA,
was appointed to serve as SciSparc&#8217;s Chief Executive Officer in January 2022 and has served as SciSparc&#8217;s Chief Financial
Officer since April 2018 and previously held served as its VP Finance from March 2018 until April 2018 and as SciSparc&#8217;s Controller
from September 2017 to March 2018. Mr. Adler has experience in a wide variety of managerial, financial, tax and accounting roles. Mr.
Adler currently serves on the board of directors of numerous private, such as Polyrizon Ltd., and public companies, including Jeffs&#8217;
Brands Ltd. (Nasdaq: JFBR), Rail Vision Ltd. (Nasdaq: RVSN) and Clearmind (Nasdaq: CMND), (FSE: CWY), and previously served as the chief
financial officer of Medigus Ltd. (Nasdaq: MDGS) from December 2020 to April 2021. From 2012 until 2017, Mr. Adler was employed as a
certified public accountant at Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global. Mr. Adler holds a B.A. in Accounting
and Business management from The College of Management, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Adi Zuloff-Shani</i>,
PhD, has served as SciSparc&#8217;s Chief Technologies Officer since February 2016. Dr. Zuloff-Shani has more than 20 years of experience
as a research and development executive. Prior to joining us, and from 2012 to 2016, Dr. Zuloff-Shani served as a vice president development
at Macrocure Ltd. (Nasdaq: MCUR) where besides leading all research and development activities, she interacted and was involved with
the activities of all departments including clinical, operations, quality assurance, quality control, finance, and regulatory affairs.
Dr. Zuloff-Shani currently serves as the Chief Executive Officer of Clearmind (Nasdaq: CMND), (FSE: CWY). She has served as the Chairman
of Orsus Therapeutics, Inc. since November 2022, as a member of the scientific advisory board of Save Foods Inc. (Nasdaq: SAFD) since
October 2021 and as a director of MitoCareX since May 2022. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan
University, Israel.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DIRECTOR AND OFFICER COMPENSATION</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AutoMax Director Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax currently compensates
its chairman of the board with monthly fee of NIS 25,000 (approximately $6,767), plus VAT for 50% position. In addition, the chairman
is entitled to annual bonus subject to fulfillment of predetermined targets. AutoMax currently compensates certain of its non-executive,
non-employee directors with annual and participation fees at the rate of the maximum amount as specified in the second and third supplements
to the Companies Regulations (Rules Concerning the Compensation and Expenses of an External Director) Regulations, 5760-2000, or the
Compensation Regulations, and its external directors with annual and participation fees at the rate of the maximum amount as specified
in the fourth supplement to the Companies Regulations, which totaled together to NIS 278,962 (approximately $75,518) in the year 2024.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 225; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->208<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AutoMax Executive Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The aggregate amounts
of salaries, consulting and director fees, pension, retirement and other similar benefits, and share-based compensation, that were payable
to AutoMax&#8217;s executive officers and directors and/or to their respective affiliates in respect of employment, consulting and directorship
agreements and arrangements (which includes other amounts described in this &#8220;<i>Director and Officer Compensation</i>&#8221; section
of this proxy statement/prospectus) during the year ended December 31, 2024 is set forth in the below table. The table does not include
any amounts that AutoMax paid to reimburse any of such persons for costs incurred in providing it with services during that period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 44%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    thousands)</b></span></td>
    <td style="width: 2%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary,
    Fees and<br/>
    Related&#160;Benefits</b></span></td>
    <td style="width: 2%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pension,<br/>
    Retirement and<br/>
    Other Similar<br/>
    Benefits</b></span></td>
    <td style="width: 2%; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and senior management as a group, consisting of 12 persons</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIS 4,986,388 (approximately
    $1,349,861)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIS 796,685 (approximately
    $215,670)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Following the Merger,
SciSparc will compensate its directors and senior management team in accordance with the recommendation of its compensation committee
and, generally, subject to the approval of the SciSparc board of directors and shareholders. That compensation will generally need to
be consistent with the terms of the compensation policy, which will require periodic approval, in accordance with the requirements of
the Companies Law (as described below under &#8220;Related Party Transactions of Directors and Executive Officers of the Combined Company&#8212;Director
and Officer Compensation&#8221;). Therefore, the future compensation practices of SciSparc following the Merger may differ from the historical
practices of AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In accordance with the
Companies Law, beginning with SciSparc&#8217;s first annual general meeting of shareholders that takes place following the Merger, the
combined company will be required to disclose the compensation paid to its five most highly compensated officers on an individual basis
for the previous fiscal year, or as otherwise required under SEC rules. Consequently, SciSparc will be required to include that information
in all annual reports on Form 20-F or Form 10-K that SciSparc files with the SEC, just as it has done until the current time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Employment Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax has entered into
a service agreement with Haim Levy &#8211; Trade In Ltd. for CEO services rendered by Daniel Levy, on March 24, 2021, or the CEO Agreement.
According to the CEO agreement, Daniel Levy, through Haim Levy Trade In Ltd. receives a monthly payment of NIS 50,000 (approximately
$13,535), and additional payments for expenses. The CEO Agreement contains a customary provision regarding confidentiality of information.
The CEO Agreement is in effect for three years following its signing, and terminable by either party upon 90 days&#8217; prior written
notice. On March 24, 2024, the shareholders of AutoMax voted in favor of extending the CEO Agreement for an additional period of three
years. The total amount paid under this agreement for the year ended December 31, 2024, - is NIS 702,304 (approximately $190,120).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax has entered into
a service agreement with A. Ynon (2015) Ltd. for Chief Business Officer services rendered by Ynon Amit, on March 24, 2021, or the Chief
Business Officer Agreement. According to the Chief Business Officer Agreement, Ynon Amit, through A. Ynon (2015) Ltd., receives a monthly
payment of NIS 50,000 (approximately $13,535), and additional payments for expenses. The Chief Business Officer Agreement contains a
customary provision regarding confidentiality of information. The Chief Business Officer Agreement is in effect for three years following
its signing, and terminable by either party upon 90 days&#8217; prior written notice. On March 24, 2024, the shareholders of AutoMax
voted in favor of extending the Chief Business Officer Agreement for additional period of three years. The total amount paid under this
agreement for the year ended December 31, 2024, is NIS 695,867 (approximately $188,377).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax has entered into
an employment agreement with Haim Levy, Trade and Procurement Officer, or the Trade and Procurement Officer Agreement. According to the
Trade and Procurement Officer Agreement, Haim Levy receives a monthly salary of NIS 45,000 (approximately $12,182) (in terms of employer
cost) including customary social benefits, and additional payments for expenses. The Trade and Procurement Officer Agreement contains
a customary provision regarding confidentiality of information. The Chief Business Officer Agreement is in effect for three years following
its signing, and terminable by either party upon 90 days&#8217; prior written notice. The total amount paid under this agreement for
the year ended December 31, 2024, - is NIS 768,297 (approximately $207,985).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax has entered into
an employment agreement with Gal Levy, Regulation and Branch Manager Officer, or the Regulation and Branch Manager Officer Agreement.
According to the Regulation and Branch Manager Officer Agreement, Gal Levy receives a monthly salary of NIS 45,000 (approximately $12,182)
(in terms of employer cost) including customary social benefits, and additional payments for expenses. The Regulation and Branch Manager
Officer Agreement contains a customary provision regarding confidentiality of information. The Regulation and Branch Manager Officer
is in effect for three years following its signing, and terminable by either party upon 90 days&#8217; prior written notice. The total
amount paid under this agreement for the year ended December 31, 2024, (including share based compensation) is NIS 774,808 (approximately
$209,747).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax has entered into
an employment agreement with Tomer Levy, Vice President Business Development Officer, or the Vice President Business Development Officer
Agreement. According to the Vice President Business Development Officer Agreement, Tomer Levy receives a monthly salary of NIS 45,000
(approximately $12,182) (in terms of employer cost) including customary social benefits, and additional payments for expenses. The Vice
President Business Development Officer Agreement contains a customary provision regarding confidentiality of information. The Vice President
Business Development Officer is in effect for three years following its signing, and terminable by either party upon 90 days&#8217; prior
written notice. The total amount paid under this agreement for the year ended December 31, 2024, (including share based compensation)
is NIS 775,738 (approximately $210,000).</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 226; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->209<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In relation to Amitay
Weiss&#8217; service as chairman of the board of directors of AutoMax, he is entitled to a monthly retainer of NIS 25,000 (approximately
$6,767) and VAT, and payment for expenses. In addition, Mr. Weiss is entitled to certain cash bonuses, contingent on pre-determined milestones
of AutoMax. The total amount paid to Amitay Weiss for the year ended December 31, 2024 is NIS 300,000 (approximately $81,212).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Directors in AutoMax are
entitled to payment as applicable under the Companies Law and its regulations. In sum, during the year ended December 31, 2024, AutoMax
paid its directors (in total) approximately NIS 279,000 (approximately $75,527). It is clarified that the board members Emanuel Paz Puzailov
and Eyal Baruch do not receive cash compensation for their service as directors of AutoMax. Mr. Puzailov and Mr. Baruch previously received
equity compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Share Incentive Plans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax maintains one
incentive plan &#8212; 2021 Share Incentive Plan, or the AutoMax Plan &#8212;which will be cancelled upon the effectiveness of the Merger.
At that time, outstanding options under the AutoMax Plan will be terminated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>SciSparc Executive Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table presents
in the aggregate all compensation SciSparc paid to all of its directors and senior management as a group for the year ended December
31, 2024. The table does not include any amounts SciSparc paid to reimburse any of such persons for costs incurred in providing us with
services during this period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">All amounts reported in
the table below reflect our cost, in thousands of U.S. dollars.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-keep: true">USD in thousands</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Salary/Fee</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Pension,<br/>
    Retirement<br/> and Other<br/> Similar<br/> Benefits<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Share-<br/>
    Based<br/> Compensation<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">All directors and senior management as a group,
    consisting of nine persons as of December 31, 2024</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">675</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">90</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">157</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Represents the directors
and senior management&#8217;s payment of mandatory social benefits made by SciSparc on behalf of such officer. Such benefits may include,
to the extent applicable to the executive, payments, contributions and/or allocations for savings funds, education funds (referred to
in Hebrew as &#8220;<i>Keren Hishtalmut</i>&#8221;), pension, severance, risk insurances (e.g., life or work disability insurance) and
payments for social security.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Computed based on fair value
for Ordinary Shares options granted and estimated using the Black-Scholes option pricing model.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">In
accordance with the Companies Law, the table below reflects the compensation granted to SciSparc&#8217;s five most highly compensated
officers or directors during or with respect to the year ended December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b style="-keep: true">Annual Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-keep: true">Executive Officer</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Salary/Fee</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Pension,<br/> Retirement<br/> and
    Other<br/> Similar<br/> Benefits</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Share-<br/>
    Based<br/> Compensation<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="-keep: true">USD in thousands</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Oz Adler<br/> <i>Chief
    Executive Officer and Chief Financial Officer</i></span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">374</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">48</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">31</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">453</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Dr. Adi Zuloff-Shani<i><br/> Chief
    Technologies Officer</i></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">283</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">42</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">17</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">342</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Itschak Shrem<br/> <i>President</i></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">269</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">31</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">300</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Amitay Weiss<br/> <i>Chairman</i></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">269</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">31</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">300</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Lior Vider<i><br/> Director</i></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">28</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">9</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">37</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Share-based
                                            compensation includes the cost of SciSparc&#8217;s non-cash share-based compensation in 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 227; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->210<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_016"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">RELATED
PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS<br/>
OF THE COMBINED COMPANY</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Described below are any transactions
occurring since January 1, 2021, and any currently proposed transactions to which either <span style="background-color: white">SciSparc
</span>or AutoMax was a party and in which:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The amounts involved exceeded
                                            or will exceed the lesser of&#8201;(i) $120,000 and (ii) one percent of the average of <span style="background-color: white">SciSparc&#8217;s
                                            </span>or AutoMax&#8217;s total assets at year end for the last two completed fiscal years;
                                            and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">A director, executive officer,
                                            holder of more than 5% of the outstanding share capital of <span style="background-color: white">SciSparc
                                            </span>or AutoMax, or any member of such person&#8217;s immediate family had or will have
                                            a direct or indirect material interest.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">SciSparc
</span>Transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Employment Agreements</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has entered into written employment agreements with Oz Adler, its Chief Executive Officer and Chief Financial Officer, and Dr. Adi Zuloff-Shani,
its Chief Technologies Officer. Each of these agreements contains customary provisions regarding noncompetition, confidentiality of information
and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. These
agreements are terminable by either party upon 30 days&#8217; prior written notice. In addition, SciSparc has entered into agreements
with each executive officer and director pursuant to which it has agreed to indemnify each of them up to a certain amount and to the
extent that these liabilities are not covered by directors and officers insurance. Members of SciSparc&#8217;s senior management are
eligible for bonuses each year. The bonuses are payable upon meeting objectives and targets that are set by SciSparc&#8217;s Chief Executive
Officer and approved annually by SciSparc&#8217;s board of directors that also set the bonus targets for SciSparc&#8217;s Chief Executive
Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Options</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
SciSparc&#8217;s inception, it has granted options to purchase SciSparc&#8217;s ordinary shares to its employees, officers, service providers
and certain of its directors. Such option agreements may contain acceleration provisions upon certain merger, acquisition, or change
of control transactions. SciSparc&#8217;s option plans are described above under &#8220;Director and Officer Compensation&#8221;. If
the relationship between SciSparc and an executive officer or a director is terminated, except for cause (as defined in the various option
plan agreements), options that are vested will generally remain exercisable for 90 days after such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Commercial Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 7, 2022, SciSparc entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, SciSparc&#8217;s
Chief Technologies Officer, Mr. Weiss, SciSparc&#8217;s chairman of the board of directors, and Mr. Adler, SciSparc&#8217;s Chief Executive
Officer and Chief Financial Officer serve as officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 17, 2022, SciSparc invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market,
in exchange for 230,769 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind.&#160;<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Polyrizon&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 31, 2022, SciSparc entered into the Polyrizon Collaboration Agreement with Polyrizon. Mr. Adler, SciSparc&#8217;s Chief Executive
Officer and Chief Financial Officer, serves as a director in Polyrizon.</p><div>


</div><!-- Field: Page; Sequence: 228; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->211<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 13, 2024, SciSparc entered into a termination agreement with Polyrizon to terminate the Polyrizon Collaboration Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, on August 13,
2024, SciSparc entered into the License Agreement, for the out-licensing of its SCI-160 program with Polyrizon. Pursuant to the License
Agreement, SciSparc granted Polyrizon the License.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Jeffs&#8217;
Brands</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 15, 2022, SciSparc entered into a letter of intent with Jeffs&#8217; Brands, to establish the Jeffs&#8217; Joint Venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 23, 2023, SciSparc entered into the Secondary Purchase Agreement with Jeffs&#8217; Brands and Jeffs&#8217; Holdings.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Mr.
Oz Adler, SciSparc&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands,
Mr. Amitay Weiss, SciSparc&#8217;s Chairman of the board of directors and Mr. Moshe Revach, a member of SciSparc&#8217;s board of directors,
are both directors in&#160;Jeffs&#8217;&#160;Brands.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i>AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the third step
of the Restructuring Initiative, on February 23, 2023, SciSparc&#8217;s board of directors held a meeting in which Mr. Baranes, a business
analyst presented a market overview conducted on the motor vehicles market in Israel, including market trends private vehicle ownership
and public transportation, and electronic vehicle market acceptance. Mr. Baranes then presented the market overview conducted in relation
to AutoMax, which was based on available public information, and information received from AutoMax. The market overview included AutoMax&#8217;s
strategy in various sectors, including parallel import of personal-use vehicles, buses, and electronic vehicles. The market overview
also included AutoMax&#8217;s competition, and its growth potential. On May 29, 2023, SciSparc appointed Mr. Baranes to be its VP Strategy
and Business Development. Mr. Baranes previously provided services to AutoMax, which included market overview of companies AutoMax was
interested in collaborating with, and preparation of investor presentations. Both Mr. Baranes and Mr. Amitay Weiss serve as members of
the board of Charging Robotics Inc. Mr. Baranes provided a market overview services to other companies which Mr. Weiss serves as a director
of. AutoMax was first introduced to SciSparc by AutoMax&#8217;s Advisor after the board of directors announced its restructuring initiative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between the months of June
and November 2023, the management of AutoMax met with the management of SciSparc to negotiate and discuss a potential transaction structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 22, 2023, SciSparc&#8217;s
board of directors held a meeting in which it approved an investment in the aggregate amount of NIS 4 million (approximately $1.1 million)
in AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 25, 2023, SciSparc entered into the AutoMax SPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 22, 2023, SciSparc announced the signing of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated
terms as announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 14, 2024, SciSparc entered into the Bridge Loan with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc signed the Merger Agreement with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 9, 2024, SciSparc entered into the Amended Bridge Loan with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 14, 2024, SciSparc signed the Merger Agreement Addendum with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 5, 2024, SciSparc entered into the Second Amendment with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 26, 2024, SciSparc signed the Merger Agreement Second Addendum with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Mr.
Amitay Weiss, SciSparc&#8217;s Chairman of the board of directors is the chairman of the board of directors of AutoMax.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related Party Transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
a related party transaction in which an &#8220;office holder&#8221; has a personal interest may be approved only if it is for the benefit
of the company. An office holder is defined in the Companies Law as a director, a general manager, chief business manager, deputy general
manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of such person&#8217;s
title, and any other manager directly subordinate to the general manager. A transaction that is not an extraordinary transaction in which
an office holder has a personal interest requires the approval of the board of directors, unless the articles of association of the company
provide otherwise. If the transaction is an extraordinary transaction, it must be approved by the audit committee and the board of directors,
and, under certain circumstances, by the shareholders of the company. An &#8220;extraordinary transaction&#8221; is a transaction other
than in the ordinary course of business, other than on market terms or that is likely to have a material impact on the company&#8217;s
profitability, assets or liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 229; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->212<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, extraordinary transactions in which a controlling shareholder has a personal interest require the approval of the audit committee,
or the compensation committee if the transaction is in connection with employment or service with the company, the board of directors
and the shareholders of the company. The shareholder approval must be by a simple majority of all votes cast, provided that (i)&#160;such
majority includes a simple majority of the votes cast by non-controlling shareholders having no personal interest in the matter or (ii)
the total number of votes of shareholders mentioned in clause (i)&#160;above who voted against such transaction does not exceed 2% of
the total voting rights in the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In most cases, the Companies
Law prohibits any director who has a personal interest in a transaction from being present for the discussion or voting pertaining to
such transaction in the audit committee or board of directors. Nevertheless, a director who has a personal interest may be present at
the meeting and vote on the matter if a majority of the directors or members of the audit committee have a personal interest in the approval
of such transaction; in this case, however, the transaction also requires shareholder approval.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director and Officer Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
<span style="background-color: white">SciSparc</span> is required to approve, at least once every three&#160;years, a compensation policy
with respect to office holders. Following the recommendation of <span style="background-color: white">SciSparc&#8217;s</span> compensation
committee, the compensation policy must be approved by the board of directors and shareholders. The shareholder approval must be by a
simple majority of all votes cast, provided that (i)&#160;such majority includes a simple majority of the votes cast by non-controlling
shareholders having no personal interest in the matter or (ii) the total number of votes of shareholders mentioned in clause (i)&#160;above
who voted against such transaction does not exceed 2% of the total voting rights in the company. In general, the terms of compensation
of directors, the chief executive officer and any employee or service provider who is considered a controlling shareholder must be approved
separately by the compensation committee, the board of directors and the shareholders. The compensation terms of other officers who report
directly to the chief executive officer requires the approval of the compensation committee and the board of directors.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AutoMax Transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>Material Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>The Merger Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2024, AutoMax
signed the Merger Agreement with SciSparc, as amended on August 14, 2024, and on November 26, 2024, pursuant to the Merger Agreement
Addendum and the Merger Agreement Second Addendum, as further detailed in this this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Founders&#8217; Agreement to establish a joint
company in connection with the Company&#8217;s branches in Petah Tikva and Ra&#8217;anana</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 25, 2021, Global
AutoMax entered into the HaSharon Founders&#8217; Agreement with A.V.A. Reseller. Pursuant to the HaSharon Founders&#8217; Agreement,
the parties founded a joint company, AutoMax HaSharon, which until October 2022, engaged in operating marketing and sales centers for
vehicles imported by AutoMax in the cities of Petah Tikva and Ra&#8217;anana. According to the HaSharon Founders&#8217; Agreement, Global
AutoMax was to hold a third of AutoMax Hasharon&#8217;s share capital, while A.V.A. held the remaining 2/3. The HaSharon Founders&#8217;
Agreement also stipulated that certain decisions would require a 100% majority of the directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HaSharon Founders&#8217;
Agreement included customary provisions that limit the possibility of transferring shares in AutoMax HaSharon, including the right of
first refusal (except in the circumstances stipulated in the Founders&#8217; Agreement), the right to join the sale of shares (Tag Along)
and forced sale (Bring Along).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 230; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->213<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 23, 2022, an agreement
was signed between Global AutoMax, A.V.A. and AutoMax HaSharon. Pursuant to the agreement, Global AutoMax purchased from A.V.A shares
that constitute a third of the issued share capital of AutoMax HaSharon, in addition to providing AutoMax HaSharon with an owner&#8217;s
loan in accordance with the agreement established between the parties. Following the provision of the aforementioned owner&#8217;s loan,
AutoMax HaSharon paid off an owner&#8217;s loan in the same amount provided to it by A.V.A. Simultaneously with the signing of the aforementioned
agreement, an amendment to the HaSharon Founders&#8217; Agreement was signed according to which Global AutoMax shall be entitled to appoint
two directors to AutoMax HaSharon board of directors, and A.V.A. will be entitled to appoint one director. With the completion of the
aforementioned agreement, Global AutoMax owns two thirds of the issued share capital of AutoMax HaSharon, and the A.V.A. owns the remaining
third, and two directors are appointed by Global AutoMax, and one director is appointed by A.V.A., to serve on the board of directors
of AutoMax HaSharon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2022, in accordance
with the agreement between Global AutoMax and the Reseller, Global AutoMax commenced operating the branch in Petah Tikva directly, while
AutoMax HaSharon continues to operate the branch in Ra&#8217;anana. As of the date of this prospectus, due to the ongoing Israel &#8211;
Hamas war, AutoMax closed the Petah Tikva branch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Exclusive Distribution Agreement
for Chargers and Charging Stations for Electric Vehicles in Israel </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 23, 2021, AutoMax
entered into the Distribution Agreement. Pursuant to the Distribution Agreement, AutoMax offers such chargers and charging stations to
customers who purchased electric and plug-in vehicles marketed by it, and also market the products to customers and other resellers,
by itself or through a dedicated company established for this purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Distribution
Agreement, AutoMax will exclusively distribute, market and sell the chargers and charging stations in Israel, subject to AutoMax meeting
monthly quotas for orders placed with the Manufacturer, as stipulated in the Distribution Agreement. Subject to the successful completion
of such quotas, the Distribution Agreement shall be valid for a period of 12 months from its execution, and will be automatically extended
for an additional 12 month period, unless one of the parties provides the other with a notice of termination. As of the date hereof,
AutoMax and the Manufacturer continue transacting business in accordance with the agreement as signed on November 23, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Direct Import Agreement
with Automobile Plant GAZ Ltd. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 26, 2021, Global
AutoMax entered into the GAZ Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0">Pursuant to the GAZ Agreement,
Gaz sells heavy category vehicles to the designated subsidiary, based on orders placed by Global AutoMax from time to time, without Global
AutoMax committing to a minimal number of orders. In addition, GAZ provides the subsidiary with warranty services for the vehicles purchased.
Furthermore, GAZ will provide Global AutoMax with spare parts, in accordance with the GAZ Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It should be clarified that
the import of vehicles and their distribution in Israel require approvals granted by the Ministry of Transportation and other regulatory
institutions, which have not yet been granted as for the date of this report. In addition, the large-scale import and distribution of
vehicles in Israel are subject to obtaining relevant European certifications by GAZ. Due to the Russia &#8211; Ukraine war, there has
been significant delays on GAZ&#8217;s side to obtain the required certificates from the European Union, and to the best of the Company&#8217;s
knowledge as of the date of the report, there has been no progress. The GAZ Agreement shall remain in effect until December 31, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 231; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->214<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Trade-In Activity in Israel
</i></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2022, Global
AutoMax signed the Trade-In Agreement with the Partner. Pursuant to the Trade-In Agreement, Global AutoMax grants AutoMax Trade-In exclusivity
in the purchase of trade-in vehicles, as purchased by Global AutoMax from its customers, according to pricing determined at Global AutoMax&#8217;s
discretion, subject to fulfilment of certain quotas as agreed in the Trade-In Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Trade-In
Agreement, Global AutoMax owns approximately 80% of the issued and paid-up capital of AutoMax Trade-In, while the remaining 20% is held
by the Partner. The Partner was given options, with a vesting schedule subject to the completion of milestones, as established in the
Trade-In Agreement, which, assuming their full exercise, may increase the holdings of the Partner in AutoMax Trade-In up to 48% of its
issued and paid-up capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the signing of the
Trade-In Agreement, Global AutoMax entered into the Lease Agreement. The lease period according to the Lease Agreement is from February
1, 2022 to August 6, 2023, and AutoMax Trade-In was given an option to extend it for another identical period (subject to the extension
of the lease period of the main tenant). The Lease Agreement can be terminated with six months notice, upon request from the competent
authorities. On July 24, 2023, AutoMax Trade-In exercised its option right and extended the lease for an additional 24 months, set to
expire in August 2025.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
AutoMax has terminated the sublease agreement in respect to the lease in &#8220;Pi Glilot&#8221; complex, and its trade-in activity is
being conducted within AutoMax&#8217;s existing branches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Founders&#8217; agreement
in relation with the branches in Ashkelon and Ashdod </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 19, 2022, Global
AutoMax entered into a founders&#8217; agreement with an authorized reseller, A.S Mobility Ltd., that operates AutoMax&#8217;s branch
in Ashkelon pursuant to which Global AutoMax and the authorized reseller founded AutoMax Hashfela, which operates as a vehicle distribution
and sales center in Ashdod and Ashkelon. Pursuant to the foregoing agreement, Global AutoMax owns half of the AutoMax HaShfela and the
authorized reseller holds the other half. The board of directors of AutoMax HaShfela consists of four directors, two of which were appointed
by the authorized reseller and two which were appointed by Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties also entered
into a distribution agreement, pursuant to which, AutoMax HaShfela became the authorized reseller of vehicles imported by Global AutoMax
in the cities of Ashkelon and Ashdod, replacing the previously existing agreement between the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the founders&#8217;
agreement, Global AutoMax entered into a lease agreement for a property of approximately 500 square meters in Ashdod, Israel, which was
assigned to AutoMax HaShfela and serves as a branch of Global AutoMax in Ashdod. The lease period is from September 15, 2022 for a period
of three years, with an option to extend the lease agreement for three additional periods of two years, each, in total up to September
19, 2031. The lease agreement in the name of Global AutoMax in Ashkelon was also assigned to AutoMax HaShfela.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, due
to the Israel-Hamas war, AutoMax closed the Ashkelon branch, while the Ashdod branch remains operational.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Founders&#8217; agreement
in relation with the branches in Netanya </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 28, 2022, Global
AutoMax entered into a distribution agreement with an authorized reseller. On November 8, 2022 Global AutoMax and the authorized reseller
signed the Netanya Founders Agreement and cancelled the distribution agreement, pursuant to which Global AutoMax and the authorized reseller
formed AutoMax Netanya. In the third quarter of 2023, the authorized reseller transferred all its holdings in AutoMax Netanya to Global
AutoMax, and the Netanya Founders&#8217; Agreement was canceled, and Global AutoMax is operating the Netanya Branch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 232; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->215<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Netanya Founders&#8217;
Agreement, Global AutoMax entered into a lease agreement for a property of approximately 750 square meters in Netanya, Israel, which
was assigned to AutoMax Netanya and serves as a branch of Global AutoMax in Netanya. The lease period is from September 1, 2022 for a
period of three years, with an option to extend the lease agreement for two additional periods of three years, each, in total up to August
30, 2031. To guarantee the lease, Global AutoMax provided a guarantee in the amount of up to 5 months rent, plus VAT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Import and Marketing of
Buses in Israel </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 19, 2022, AutoMax
entered into the Dalhom AutoMax Ltd Founders&#8217; Agreement with Dalhom. The purpose of Dalhom AutoMax is to serve as a direct importer
of Temsa buses in Israel and market these. The Dalhom AutoMax Founders&#8217; Agreement closed on November 20, 2022, following which
each of AutoMax and Dalhom held 50% of Dalhom AutoMax. Pursuant to the Dalhom AutoMax Founders&#8217; Agreement, upon the closing, AutoMax
was required to lend AutoMax Dalhom an aggregate amount of NIS 10 million (approximately $2.7 million), to enable AutoMax Dalhom to fulfill
its obligations toward Dalhom, as prescribed in the Dalhom AutoMax Founders&#8217; Agreement, or the AutoMax Dalhom Loan. Under the foregoing
agreement, the AutoMax Dalhom Loan was provided at the same interest rate (back-to-back), as the loan received by AutoMax from its financing
sources, so long as it does not exceed the rate stipulated in the Dalhom AutoMax Founders&#8217; Agreement. The AutoMax Dalhom Loan is
to be repaid subject to the terms and rates defined in the agreement, and among others, will bear interest of up to 5.9% per annum, and
shall be fully repaid within six years from the closing, or exchanged into shares of Dalhom AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Dalhom AutoMax Founders&#8217;
Agreement includes provisions commonly accepted in franchise agreements, including sales goals agreed between the parties, failure to
comply with the terms set forth in the Dalhom AutoMax Founders&#8217; Agreement will grant Temsa the right to terminate the agreement,
should Dalhom AutoMax fail to be in compliance by the end of the cure period. Furthermore, Dalhom AutoMax will not import or market in
Israel products that compete with those of Temsa, during the time of the agreement, without obtaining a written approval. In addition,
Dalhom AutoMax entered into a service and warranty agreement with Temsa, for a period of 3 years, under which Dalhom AutoMax would provide
maintenance and warranty services for buses manufacture by Temsa in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Turkish Trade Ministry
has announced a trade embargo between Turkey and Israel. This trade stoppage could have a short-term impact on the supply of vehicles
and on the prices of logistics and transportation of vehicles to Israel, in particular for Dalhom&#8217;s operations. However, AutoMax
does not anticipate a significant impact on the group&#8217;s business as it holds (in Israel) a stock of Temsa buses and has taken steps
to find alternative ways to continue the regular supply of Temsa vehicles and buses to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Agreement for Direct Import
of Electric Vehicles to Israel </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2023, Dalhom
AutoMax entered into an agreement with Al Damani, a UAE vehicle manufacturer, subject to which Dalhom AutoMax would distribute, sell,
and promote the Al Damani electric vehicles in Israel. This agreement remains subject to Dalhom AutoMax obtaining all the regulatory
approvals as required by the Ministry of Transportation to import vehicles into Israel, a condition that has not yet been met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Import and Marketing of Vehicles Manufactured by JAC in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, AutoMax
Direct Import finalized entering into agreements with JAC, a manufacturer of private and commercial vehicles, for the direct import,
distribution and service of vehicles and spare parts manufactured by JAC in Israel, or the JAC Agreements. On December 27, 2024, AutoMax
Direct Import received its first shipment of vehicles manufactured by JAC, following regulatory approvals for direct importation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the JAC Agreements,
AutoMax Direct Import serves as a direct importer of JAC brand in Israel, and the JAC will provide AutoMax Direct Import with vehicles
and spare parts for the vehicles for marketing and sale in Israel, in accordance with annual business plans as agreed between the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement includes, among
others, customary provisions regarding warranty for the vehicles by JAC, the supply of spare parts, the duty to notify about malfunctions
(recall) and compliance with other requirements required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax Direct Import will
adapt its existing showrooms for the purpose of selling JAC vehicles in the standards agreed in the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The JAC Agreements are
for a period of three years, subject to AutoMax Direct Import&#8217;s compliance with sales and service network expansion goals determined
in the agreements, and will enter into force only when the appropriate European regulatory approvals are received for JAC vehicles. In
addition, JAC is entitled to terminate the agreement upon the occurrence of certain events provided in the JAC Agreements, as is customary
in such agreements, such as: (a) if AutoMax Direct Import substantially violates its obligations under the JAC Agreements or encounters
special circumstances that give justifiable reasons for early termination (including AutoMax Direct Import&#8217;s failure to meet its
sales goals, service network expansion goals or market share goals); (b) in the event of change of control in AutoMax Direct Import;
and (c) in the event of bankruptcy, moratorium, receivership, liquidation, or any other similar circumstances.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Market Maker Agreement </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 19, 2023, AutoMax
entered into a market maker agreement with I.B.I Investment House Ltd., or IBI, pursuant to which IBI will serve as a market maker for
AutoMax&#8217;s ordinary shares, effective October 22, 2023, subject to the Securities Laws. The agreement will be effective for a period
of 12 months, following which it will be automatically renewed for an additional 12 months, unless terminated by one of the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 233; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->216<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><div><a id="m_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
previously disclosed, on April 10, 2024, SciSparc Ltd., or the Parent Company or SciSparc entered into an Agreement and Plan of Merger
with AutoMax Motors Ltd., an Israeli company traded on the TASE and the leading parallel importer and distributor of vehicles in Israel,
or AutoMax, and SciSparc Merger Sub Ltd., an Israeli limited company and wholly owned subsidiary of SciSparc, or the Merger Agreement.
On August 14, 2024 and on November 26, 2024, the parties entered into addendums to the Merger Agreement, or the Merger Agreement Addendums.
Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement and the Merger Agreement Addendums,
SciSparc Merger Sub Ltd. will be merged with and into AutoMax, with AutoMax surviving the merger as a wholly-owned subsidiary of the
Parent Company, or the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
unaudited pro forma condensed combined statement of financial position is based on the individual historical balance sheet of the Parent
Company and AutoMax, prepared in accordance with IFRS as of June 30, 2024,&#160;and has been prepared to reflect the effect of the acquisition
as if it had occurred on June 30, 2024. The unaudited pro forma condensed combined statement of comprehensive loss for the year ended
December 31, 2023 and for the six month period ended June 30, 2024, gives effect to the acquisition as if it had been completed January
1, 2023, the beginning of the Parent Company&#8217;s fiscal year. The historical condensed combined financial information has been adjusted
to give effect to pro forma events that are: 1) directly attributable to the acquisition; 2) factually supportable; and 3) with respect
to the statement of comprehensive loss, expected to have a continuing impact on the combined results. The unaudited pro forma financial
statements were prepared in accordance with Article 11 of U.S. Securities and Exchange Commission Regulation S-X. In the opinion of management,
all adjustments necessary to present fairly the unaudited pro forma condensed combined financial information have been made, as further
described in the accompanying notes.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
unaudited pro forma condensed combined financial information is derived from and should be read in conjunction with the Parent Company&#8217;s
historical unaudited financial statements for the six month period ended June 30, 2024 and the historical audited financial statements
of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
amounts in the historical financial statements of AutoMax are presented in NIS and in the Unaudited Pro Forma Condensed Combined Statement
of Financial Position, the amounts are presented in USD, translated using a rate of NIS 3.759 to USD 1.00, the last exchange rate published
by the Bank of Israel on June 30, 2024, the last day of the reporting period, as determined according to accepted accounting practices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
amounts in the historical financial statements of AutoMax are presented in NIS and in the Unaudited Pro Forma Condensed Combined Statement
of Comprehensive Loss, the amounts are presented in USD, translated using a rate of NIS 3.694 to USD 1.00, the average exchange rate
during the reporting period as published by the Bank of Israel, as determined according to accepted accounting practices</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Estimated
consideration of approximately $5.63 million is based on the Parent Company&#8217;s 30 day average closing share price of $0.573 between
December 24, 2024, and February 7, 2025. The value of purchase price consideration will change based on fluctuations in the share price
of the Parent Company&#8217;s ordinary shares and the number of ordinary shares of the Parent Company&#8217;s outstanding share capital
on the closing date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
allocation of the purchase price as reflected in the unaudited pro forma condensed combined financial information was based on a preliminary
valuation of the assets acquired and liabilities assumed, and the accounting is subject to revision as more detailed analyses are completed
and additional information about the fair value of assets acquired and liabilities assumed becomes available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">The unaudited pro forma combined
condensed financial statements are presented for informational purposes only and are not necessarily indicative of the results of operations
that would have resulted had the transaction described above been consummated at the dates indicated, nor are they necessarily indicative
of the results of operations which may be realized in the future. Furthermore, the unaudited pro forma combined condensed financial statements
do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings
or expenses that may be associated with the integration of the two companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 234; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->217<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of June 30, 2024<br/>
(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">SciSparc <br/> Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">AutoMax<br/> Motors Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Transaction <br/> Accounting <br/>
    Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro Forma</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Current Assets:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="-keep: true">Cash&#8239;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">252</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">375</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(390</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 5%; text-align: center"><span style="-keep: true">4(b)</span></td><td style="width: 1%; text-align: left"/>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">237</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Restricted deposit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">64</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">64</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Short-term deposit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,308</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,308</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Trade receivables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">19</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,269</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,288</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Receivables and debit balances</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">17,901</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">17,901</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Receivable current taxes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">360</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">360</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other accounts receivable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">298</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">298</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Inventory</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">415</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">44,531</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">44,946</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Indemnity asset</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">266</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">266</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Current Assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">3,356</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">67,703</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(390</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">70,669</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Non-current assets:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Long term bank deposits</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">326</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">326</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Intangible asset, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,006</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,556</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,562</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,448</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,448</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(e)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Investments in company accounted for at equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,196</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,196</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Right-of-use assets, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,739</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,739</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Investment in companies handled according to the book value method</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,136</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,136</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Long term investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,872</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,872</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Long term prepaid expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">83</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">83</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Investments in financial assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">403</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">46</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(283</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(f)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">166</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">73</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,035</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,108</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Deferred taxes</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">601</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">601</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Non-current Assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">7,126</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">16,394</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(2,731</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">20,789</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total Assets</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">10,482</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">84,097</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,121</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">91,458</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="-keep: true">Liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Current liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Short term loan and current portion of long-term loans</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">38,404</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">38,404</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,443</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,443</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(e)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Trade payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,164</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,439</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,603</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Other accounts payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">253</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,055</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,308</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Warrants</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">345</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,823</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,168</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Lease liability</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">38</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,491</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,529</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,800</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">61,656</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(2,443</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">61,013</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Non-current liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Lease liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">26</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,665</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,691</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Long term loans</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,515</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,515</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Loans from related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">269</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">269</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Tax liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">189</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">189</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Warrants liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,380</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,380</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Employees</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">26</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">13,054</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">13,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total Liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">1,826</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">74,710</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,443</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">74,092</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Shareholders&#8217; Equity:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Share capital and premium</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">67,258</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">22,254</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">2,078</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(a)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">91,590</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Reserve from share-based payment transactions</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,298</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,346</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(5,346</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(a)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,298</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Warrants</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,190</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">491</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(491</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(a)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,190</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Foreign currency translation reserve</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">497</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(83</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">-</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">414</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Transactions with non-controlling interests</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">810</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">-</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">810</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Accumulated deficit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(72,133</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(18,204</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">3,081</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(88,993</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,920</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9,804</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(678</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">16,046</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,736</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(417</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,319</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Shareholders&#8217; Equity:</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">8,656</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">9,387</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(678</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">17,365</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total Liabilities and Shareholders&#8217; Equity</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">10,482</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">84,097</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,121</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">91,458</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 235; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->218<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
OF&#160;<span style="background-color: white">COMPREHENSIVE LOSS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the six month period ended June 30, 2024<br/>
(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">SciSparc<br/> Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">AutoMax<br/> Motors Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Transaction<br/> Accounting<br/>
    Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro Forma</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Revenues</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">840</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">56,547</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 5%; text-align: center"><span style="-keep: true">&#160;</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">57,387</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Cost of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(366</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(50,067</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(50,433</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Gross profit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">474</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,480</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,954</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Research and development expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">841</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">841</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Sales and marketing</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">528</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,753</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,281</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">General and administrative expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,632</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,691</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">390</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(d)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,713</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Granting options to employees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">22</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">22</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Other incomes</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(1,413</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(1,413</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Operating loss (profit)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">3,527</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(2,427</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">390</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,490</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">SciSparc&#8217;s share of losses of company accounted for at
    equity, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">208</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">287</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">495</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Other income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,759</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(c)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,759</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Finance income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(323</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(605</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(923</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Finance expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">272</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,247</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">283</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">4(f)</span></td><td style="padding-bottom: 1.5pt; text-align: left"/>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,802</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Loss (profit) before income taxes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,684</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(498</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,081</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">105</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Taxes on income</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">554</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">549</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total comprehensive loss (profit)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">3,679</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">56</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,081</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">655</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Equity holders of SciSparc</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,442</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(56</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,081</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">305</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">237</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">113</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">350</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">3,679</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">57</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,081</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">655</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Weighted average outstanding shares (basic and diluted)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">2,166,282</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">103,691,969</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">4,126,251</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Basic and diluted loss (profit) per ordinary
    share attributable to equity holders of SciSparc</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1.70</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">0.00</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center"><span style="-keep: true">5</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">0.16</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 236; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->219<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>For the year ended December
31, 2023<br/>
(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">SciSparc <br/>
Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">AutoMax Motors Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Transaction Accounting Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Pro Forma</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 46%"><span style="-keep: true">Revenues</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2,879</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">113,539</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 5%; text-align: center"><span style="-keep: true">&#160;</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">116,418</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Cost of goods sold</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(683</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(103,283</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(103,966</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Gross profit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,196</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10,256</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,452</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Research and development expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,641</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,641</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Sales and marketing</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,297</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,370</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8,667</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Impairment of intangible asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,042</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,042</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">General and administrative expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,031</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,598</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,819</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(g)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11,448</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Granting options to employees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">691</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">691</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Other incomes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(422</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(422</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Operating loss</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,815</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,981</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,819</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10,615</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">SciSparc&#8217;s share of losses of company accounted
    for at equity, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">210</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">163</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">373</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Other income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(4,160</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(h)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(4,160</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Finance income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,219</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,093</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(4,312</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Finance expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,055</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,562</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">529</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(i)</span></td><td style="text-align: left"/>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,146</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Loss before income taxes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,861</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,612</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,812</span></td><td style="text-align: left"><span style="-keep: true">)&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8,661</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Taxes on income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">22</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">97</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">119</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Total comprehensive loss</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,883</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,709</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,812</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8,780</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Equity holders of SciSparc</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,122</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,440</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,812</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,750</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Non-controlling interests</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">761</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">269</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">-</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,030</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,883</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,709</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,812</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8,780</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Weighted average outstanding shares (basic and diluted)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">407,681</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">77,377,503</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">776,535</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Basic loss per ordinary share attributable to equity
    holders of SciSparc:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14.43</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.06</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11.31</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Diluted loss per ordinary share attributable to equity
    holders of SciSparc</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14.43</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.06</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11.31</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 237; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->220<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notes to Unaudited Pro Forma Condensed Combined
Consolidated Financial Statements</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Note 1 - Basis of presentation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
unaudited pro forma condensed combined statement of comprehensive loss for the year ended December 31, 2023 and for the six month period
ended June 30, 2024, was derived from the unaudited consolidated financial statements filed herein, and from the unaudited historical
financial information of AutoMax for the same period, and has been prepared as if the Merger had occurred on January 1, 2023. The unaudited
pro forma condensed combined financial information herein has been prepared to illustrate the effects of the Merger in accordance with
IFRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Parent Company has accounted for the Merger under the acquisition method of accounting in accordance with the authoritative guidance
on business combinations under the provisions of IFRS 3 (&#8220;Business Combinations&#8221;). The purchase price allocation is considered
preliminary, and additional adjustments may be recorded during the measurement period in accordance with IFRS 3. The purchase price allocation
will be finalized as the Parent Company receives additional information relevant to the acquisition, including the final valuation and
reconciliation of the assets purchased, including tangible and intangible assets, liabilities assumed. Differences between these preliminary
estimates and the final purchase accounting may occur, and these differences could be material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc has been determined
to be the accounting acquirer based on evaluation of the following facts and circumstances:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s
                                            existing shareholders will have the greater voting interest in the combined entity;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s
                                            directors will represent the majority of the board of directors of the combined company following
                                            the consummation of the Merger; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">SciSparc&#8217;s
                                            senior management will be the senior management of the combined company following the consummation
                                            of the Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The unaudited pro&#160;forma
condensed combined statement of financial position as of June 30, 2024, assumes that the Merger occurred on June 30, 2024. The unaudited
pro&#160;forma condensed combined statements of comprehensive loss for the six month period ended June 30, 2024, presents pro&#160;forma
effect to the Merger as if it had been completed on January&#160;1, 2023.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited pro&#160;forma
condensed combined statement of financial position as of June 30, 2024, has been prepared using, and should be read in conjunction with,
the following:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
    unaudited consolidated statement of financial position as of June 30, 2024, and the related notes, filed herein; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s unaudited
    interim consolidated financial information as of June 30, 2024, and the related notes, filed herein.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audited pro&#160;forma
condensed combined statement of comprehensive loss for the six month period ended June 30, 2024, have been prepared using, and should
be read in conjunction with, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
    unaudited consolidated statement of comprehensive loss for the six month period ended June 30, 2024, and the related notes, filed
    herein; and</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s
    unaudited consolidated statement of comprehensive loss for the six month period ended June 30, 2024, and the related notes, filed
    herein.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 238; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->221<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information has been prepared
based on these preliminary estimates, and the final amounts recorded may differ materially from the information presented. The unaudited
pro&#160;forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax
savings, or cost savings that may be associated with the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has made significant
estimates and assumptions in its determination of the pro&#160;forma adjustments. The pro&#160;forma adjustments reflecting the consummation
of the Merger are based on certain currently available information and certain assumptions and methodologies that SciSparc believes are
reasonable under the circumstances. The unaudited condensed pro&#160;forma adjustments, which are described in the accompanying notes,
may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will
differ from the pro&#160;forma adjustments and it is possible the difference may be material. SciSparc believes that these assumptions
and methodologies provide a reasonable basis for presenting all of the significant effects of the Merger based on information available
to management at the time and that the pro&#160;forma adjustments give appropriate effect to those assumptions and are properly applied
in the unaudited pro&#160;forma condensed combined financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
unaudited pro forma condensed combined financial information is presented solely for informational purposes and is not necessarily indicative
of the combined results of operations or financial position that might have been achieved for the periods presented, nor is it necessarily
indicative of the future results of the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
unaudited pro&#160;forma condensed combined financial information does not necessarily reflect what the combined company&#8217;s financial
condition or results of operations would have been had the transactions occurred on the dates indicated. The unaudited pro&#160;forma
condensed combined financial information also may not be useful in predicting the future financial condition and results of operations
of the combined company. The actual financial position and results of operations may differ significantly from the pro&#160;forma amounts
reflected herein due to a variety of factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note 2 - Adjustments to Unaudited Pro Forma
Condensed Combined Financial Information</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited pro&#160;forma
condensed combined financial information has been prepared in accordance with Article&#160;11 of Regulation&#160;S-X as amended by Release
No. 33-10786 &#8220;Amendments to Financial Disclosures about Acquired and Disposed Businesses.&#8221; Release No. 33-10786 replaces
the existing pro&#160;forma adjustment criteria with simplified requirements to depict the accounting for the transaction, or Transaction
Accounting Adjustments, and present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably
expected to occur, or Management&#8217;s Adjustments. SciSparc has elected not to present Management&#8217;s Adjustments and will only
be presenting Transaction Accounting Adjustments in the unaudited pro&#160;forma condensed combined financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited pro forma combined
provision for income taxes does not necessarily reflect the amounts that would have resulted had the combined company following consummation
of the Merger filed consolidated income tax returns during the periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">All pro forma pre-tax
adjustments have been considered and no tax adjustment was recorded for the income tax expense impact of the transaction adjustments,
either due to the ability to deduct such adjustments for tax purposes or the presence of significant net operating losses with a valuation
allowance, which effectively offset such expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The income tax expense
impact of the transaction adjustments will be determined by applying the expected tax treatment of the individual elements of the transaction
adjustments in the jurisdictions where they are anticipated to be incurred, using the estimated statutory tax rate applicable in those
jurisdictions. These tax adjustments may change based on the final determination of the tax treatment of the individual items and the
statutory tax rates in the relevant jurisdictions, as well as any legislative changes occurring prior to the completion of the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note 3 - Estimated purchase price consideration</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc entered into the Merger Agreement, as amended, by and among SciSparc, SciSparc Merger Sub Ltd. and AutoMax,
pursuant to which AutoMax agreed to convert its share capital in exchange for the right to receive a number of validly issued, fully
paid and nonassessable Parent Company ordinary shares and pre-funded warrants, equal to the Exchange Ratio (as defined in the Merger
Agreement), per each such AutoMax ordinary share and up to 47.49% of SciSparc ordinary shares immediately after to the effective time
(as defined in the Merger Agreement).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Estimated
consideration of approximately $5.63 million is based on the Parent Company&#8217;s 30 day average closing share price of $0.573 between
December 24, 2024, and February 7, 2025. The value of the purchase price consideration will change based on fluctuations in the share
price of SciSparc&#8217;s ordinary shares and the number of ordinary shares of SciSparc outstanding on the closing date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 239; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->222<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following is a summary of the components of the estimated consideration (in thousands except per-share information and the exchange ratio)
if the acquisition of AutoMax had occurred on June 30, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Estimated Parent Company&#8217;s ordinary shares outstanding*</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">10,841,449</span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Exchange ratio</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">0.4749</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Parent Company&#8217;s ordinary share issued<sup>(1)</sup></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">9,818,195</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">Parent Company&#8217;s share price**</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">0.573</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total estimated consideration to be paid</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,628</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="-keep: true">Represents SciSparc&#8217;s outstanding shares as of February 7, 2025, including
    pre-funded warrants</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="-keep: true">Represents the SciSparc&#8217;s 30-day average closing share price between December 24, 2024,
    and February 7, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded warrants to
    be issued in connection with the Merger are considered ordinary shares since SciSparc cannot currently calculate the amount of pre-funded
    warrants to be issued in lieu of ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated consideration
of the purchase price will depend on the market price of SciSparc&#8217;s ordinary shares when the acquisition is consummated. SciSparc
believes that a 72% fluctuation in the market price of its ordinary shares is reasonably possible based on historical volatility, and
the potential effect on estimated consideration would be:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Parent<br/> Company&#8217;s<br/>
    share price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Estimated<br/> consideration</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">As presented</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.573</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">5,628</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">72% increase</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">0.986</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">9,680</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">72% decrease</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">0.161</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">1,576</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note 4 - Pro Forma Adjustments</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following describes the pro forma adjustments related to the Merger, that have been made in the accompanying unaudited pro forma condensed
combined statements of comprehensive loss for the six months period ended June 30, 2024, giving effect to the Merger as if it had been
consummated at the beginning of the period presented, and in the accompanying unaudited pro forma condensed combined financial position
as of June 30, 2024, giving effect of the Merger as if it had occurred on June 30, 2024, all of which are based on preliminary estimates
that could change significantly as additional information is obtained:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (a) the balance sheet impact of the difference between the estimated consideration to be paid ($5,628 thousand) as described in note
    3 - Estimated purchase price consideration, as if the acquisition of AutoMax was consummated on June 30, 2024, and the total equity,
    net, of AutoMax ($9,387 thousand), offset by (ii) the cancellation of reserve from share-based payment transactions in AutoMax against
    increase in share capital and premium in the amount of $5,346, and by (iii) the cancellation of warrants in Automax against increase
    in share capital and premium in the amount of $491 thousand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents additional
    Merger transaction costs in the amount of $390 thousand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the income
    statement impact of the difference between the estimated consideration to be paid ($5,628 thousand) as described in note 3 - Estimated
    purchase price consideration, as if the acquisition of AutoMax was consummated on June 30, 2024, and the total equity, net, of AutoMax
    ($9,387 thousand).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 240; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->223<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the estimated
    transaction costs of approximately $390 thousand incurred by SciSparc in consummating the purchase of AutoMax. The expenses were
    recognized as general and administrative expenses as this is the amount attributed to legal advisors SciSparc consulted with for
    the consummation of the purchase.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the cancellation
    of a short-term loan granted by SciSparc to AutoMax that as of June 30, 2024, amounted to $2,443 thousand. &#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the cancellation
    of investment of SciSparc in the shares of AutoMax, as of June 30, 2024, amounted to $283 thousand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify"><span style="-keep: true">Represents (i) a bonus payable to a consultant upon closing of the Merger in the amount of $1,153
    thousand, (ii) bonuses payable to directors and officers upon closing of the Merger in the amount of $515 thousand, and (iii) the
    estimated transaction costs of approximately $151 thousand incurred by SciSparc in consummating the purchase of AutoMax. The expenses
    were recognized as general and administrative expenses as this is the amount attributed to legal advisors SciSparc consulted with
    for the consummation of the purchase.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the income
    statement impact of the difference between the estimated consideration to be paid ($5,628 thousand) as described in note 3 - Estimated
    purchase price consideration, as if the acquisition of AutoMax was consummated on December 31, 2023, and the total equity, net, of
    AutoMax ($9,788 thousand).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the cancellation
    of investment of SciSparc in the shares of AutoMax, as of December 31, 2023, amounted to $529 thousand.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note 5 - Basic and diluted profit per share</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
loss per share calculated using the historical weighted average shares outstanding after taking into account the issuance of additional
SciSparc ordinary shares in connection with the Merger, assuming such shares were outstanding since January 1, 2024. As the transactions
are being reflected as if they had occurred at the beginning of the periods presented, the calculation of weighted average shares outstanding
for basic and diluted net loss per share assumes that the shares issuable relating to the transactions have been outstanding for the
entire periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the six month period ended June 30, 2024<br/>
(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">SciSparc&#160;Ltd.</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">AutoMax<br/> Motors Ltd.</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Transaction<br/> Accounting<br/>
    Adjustments</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Pro Forma</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Pro forma net profit (in thousands)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">3,679</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">57</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(3,081</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">655</span></td><td style="width: 1%; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Weighted average outstanding shares (basic and diluted)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,166,282</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">103,691,969</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,126,251</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Basic and diluted loss per ordinary share attributable to equity
    holders of SciSparc</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1.70</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.00</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.16</span></td><td style="text-align: left"/></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the year ended December 31, 2023<br/>
(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">SciSparc&#160;Ltd.</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">AutoMax Motors Ltd.</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Transaction Accounting Adjustments</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Pro Forma</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"><span style="-keep: true">Pro forma net loss (in thousands)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">5,883</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4,709</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(1,812</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">8,780</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Weighted average outstanding shares (basic and diluted)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">407,681</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">77,377,503</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">776,535</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">Basic and diluted loss per ordinary share attributable
    to equity holders of SciSparc</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14.43</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.06</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11.31</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 241; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->224<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_019"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Description
of SHARE Capital</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following description
of SciSparc&#8217;s share capital and provisions of its current Amended and Restated Articles of Association are summaries and do not
purport to be complete. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Registration number and purposes of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s registration
number with the Israeli Registrar of Companies is 51-358165-2. SciSparc&#8217;s purpose as set forth in its Amended and Restated Articles
of Association is to engage in any lawful activity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Type and class of securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s authorized
share capital consists of 75,000,000 ordinary shares, of no par value, or the ordinary shares. All of its outstanding ordinary shares
have been validly issued, are fully paid and non-assessable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preemptive rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s ordinary
shares are not redeemable and are not subject to any preemptive right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer of shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s fully paid
ordinary shares are issued in registered form and may be freely transferred under its Amended and Restated Articles of Association, unless
the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are
listed for trade. The ownership or voting of its ordinary shares by non-residents of Israel is not restricted in any way by its Amended
and Restated Articles of Association or the laws of the State of Israel, except for ownership by nationals of certain countries that
are, or have been, in a state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liability to further capital calls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s board of
directors may make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to
shares held by such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon
him or her.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Election of directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under SciSparc&#8217;s Amended
and Restated Articles of Association, its board of directors must consist of at least three (3) and not more than eight (8) directors,
including, if applicable, two external directors appointed as required under the Companies Law. Other than SciSparc&#8217;s external
directors (if any), its directors are divided into three classes with staggered three-year terms. Each class of directors consists, as
nearly as possible, of one third of the total number of directors constituting the entire board of directors. At each annual general
meeting of the SciSparc shareholders, the election or re-election of directors following the expiration of the term of office of the
directors of that class of directors is for a term of office that expires on the third annual general meeting following such election
or re-election, such that from 2020 and after, at each annual general meeting the term of office only one class of directors will expire.
Each director, holds office until the annual general meeting of the SciSparc shareholders for the year in which his or her term expires
and until his or her successor is duly appointed, unless the tenure of such director expires earlier pursuant to the Companies Law upon
the occurrence of certain events or unless removed from office by a vote of the holders of at least 65% of the total voting power of
the SciSparc shareholders at a general meeting of its shareholders in accordance with SciSparc&#8217;s Amended and Restated Articles
of Association.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further<span style="background-color: white">,&#160;SciSparc
</span>shareholders&#160;<span style="background-color: white">approved an approval mechanism similar to a mechanism that exists in the
Delaware Generate Corporate Law, which requires an affirmative vote of the board of directors (by 75% of the members) in addition to
the approval of its shareholders in order to amend such provisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 242; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->225<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&#8217;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving Directors is lower than their minimal one, the board of directors shall not
be permitted to act, other than for the purpose of convening a general meeting of the Company&#8217;s shareholders for the purpose of
appointing additional Directors. For further information on the election and removal of directors see &#8220;<span style="background-color: white">Directors,
Senior Management and Employees</span>&#8212;Board Practices&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contested election</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Amended and Restated
Articles of Association, in the event of a contested election, the board of directors in its discretion, will set the method of calculation
of the votes and the manner in which the resolutions will be presented to the SciSparc shareholders at the general meeting. In the event
that the board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a plurality
of the voting power represented at the general meeting in person or by proxy and voting on the election of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividend and liquidation rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc may declare a dividend
to be paid to the holders of SciSparc ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend
distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s
Articles provide otherwise. The Amended and Restated Articles of Association do not require shareholder approval of a dividend distribution
and provide that dividend distributions may be determined by the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to its then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or SciSparc may distribute dividends that do not meet such criteria only with
court approval; as a company listed on an exchange outside of Israel, however, court approval is not required if the proposed distribution
is in the form of an equity repurchase, provided that it notifies its creditors of the proposed equity repurchase and allow such creditors
an opportunity to initiate a court proceeding to review the repurchase. If within 30 days such creditors do not file an objection, then
it may proceed with the repurchase without obtaining court approval. In each case, SciSparc is only permitted to distribute a dividend
if its board of directors and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will
prevent it from satisfying its existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of SciSparc&#8217;s
liquidation, after satisfaction of liabilities to creditors, its assets will be distributed to the holders of SciSparc ordinary shares
in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential
dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exchange controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on SciSparc&#8217;s ordinary shares, proceeds from the sale of the shares or
interest or other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that are, or have
been, in a state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 243; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->226<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shareholder meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
SciSparc is required to hold an annual general meeting of its shareholders once every calendar year that must be held no later than 15
months after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are
referred to in the Amended and Restated Articles of Association as special general meetings. SciSparc&#8217;s board of directors may
call special general meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition,
the Companies Law provides that the board of directors is required to convene a special meeting upon the written request of (i) any two
of its directors or one-quarter of the members of the board of directors or (ii) as a company listed on an exchange in the U.S., one
or more shareholders holding, in the aggregate, either (a) 10% or more of its outstanding issued shares and 1% or more of SciSparc&#8217;s
outstanding voting power or (b) 10% or more of its outstanding voting power.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include
a matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at
the general meeting. Notwithstanding the foregoing, as a company listed on an exchange outside of Israel, a matter relating to the appointment
or removal of a director may only be requested by one or more shareholders holding at least 5% of the voting rights at the general meeting
of the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the board of directors, which may be between four and 60 days prior to the date
of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general
meeting of the shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">amendments to SciSparc&#8217;s Amended and Restated Articles of Association;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">appointment or termination of its auditors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">appointment of external directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">approval of certain related party transactions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increases or reductions of its authorized share capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">mergers; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the exercise of its board of directors&#8217; powers by a general meeting,
    if its board of directors is unable to exercise its powers and the exercise of any of its powers is required for its proper management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under SciSparc&#8217;s Amended
and Restated Articles of Association, it is not required to give notice to its registered shareholders pursuant to the Companies Law,
unless otherwise required by law. The Companies Law requires that a notice of any annual general meeting or extraordinary general meeting
be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal
of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise
required under applicable law, notice must be provided at least 35 days prior to the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Voting rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Voting rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All SciSparc&#8217;s ordinary shares have identical
voting and other rights in all respects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Quorum requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to SciSparc&#8217;s
Amended and Restated Articles of Association, holders of SciSparc&#8217;s ordinary shares have one vote for each ordinary share held
on all matters submitted to a vote before the shareholders at a general meeting. The quorum required for its general meetings of shareholders
consists of at least two shareholders, present in person or by proxy, holding at least fifteen percent (15%) of the voting rights of
the Company. A meeting adjourned for lack of a quorum will be adjourned for one day at the same time and place, or to such other day,
time or place if such is stated in the notice of the meeting. At the reconvened meeting, if a quorum is not present within half an hour,
any number of shareholders present in person or by proxy will constitute a lawful quorum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 244; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->227<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Vote requirements</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Amended
and Restated Articles of Association provide that all resolutions of its shareholders require a simple majority vote, unless otherwise
required by the Companies Law or by its Amended and Restated Articles of Association. Under the Companies Law, each of (i) the approval
of an extraordinary transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling
shareholder of the company or such controlling shareholder&#8217;s relative (even if not extraordinary) requires the approval described
under &#8220;Approval of Related Party Transactions under Israeli Law&#8212;Disclosure of Personal Interests of a Controlling Shareholder&#8221;
of this prospectus. Certain transactions with respect to remuneration of the SciSparc office holders and directors require further approvals
described under &#8220;Approval of Related Party Transactions under Israeli Law&#8212; Disclosure of Personal Interests of an Office
Holder&#8221; of this prospectus. Another exception to the simple majority vote requirement is a resolution for the voluntary winding
up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires
the approval of the majority of the shareholders voting their shares, other than abstainees, holding at least 75% of the voting rights
represented at the meeting, in person, by proxy or by voting deed and voting on the resolution.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Articles amendment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to amend the Articles,
in addition and prior to the approval of a general meeting of shareholders, the approval of the board of directors with the affirmative
vote of at least three-quarters (3/4) of the directors then in office and entitled to vote thereon is required in order to approve any
amendment to the Articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Access to corporate records</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
shareholders are provided access to minutes of SciSparc&#8217;s general meetings, its shareholder register and principal shareholder
register, its Amended and Restated Articles of Association, its financial statements and any document that SciSparc is required by law
to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be
provided with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions
of the Companies Law. SciSparc may deny this request if it believes it has not been made in good faith or if such denial is necessary
to protect its interest or protect a trade secret or patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Modification of class rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
the Amended and Restated Articles of Association, the rights attached to any class of shares, such as voting, liquidation and dividend
rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class
meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in SciSparc&#8217;s Amended and Restated
Articles of Association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Acquisitions under Israeli law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Full tender offer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share
capital is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of
the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result
hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the
shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the
shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable
class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that
the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted
if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the
applicable class of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 245; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->228<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the
Israeli court as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a tender offer is not
accepted in accordance with the requirements set forth above, the acquirer may not acquire shares of the company that will increase its
holdings to more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who
accepted the tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Special tender offer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already
another holder of at least 25% of the voting rights in the company. Alternatively, such an acquisition may be approved pursuant to a
private placement approved by the company&#8217;s shareholders with the purpose of approving the acquisition of 25% or more, or 45% or
more of the company&#8217;s voting rights. Similarly, the Companies Law provides that an acquisition of shares in a public company must
be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of
the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the
company, subject to certain exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or shall
abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. In addition, the
board of directors must disclose any personal interest each member of the board of directors has in the offer or stems therefrom.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender
offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired
by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding
the purchaser and its controlling shareholder, holders of 25% or more of the voting rights in the company or any person having a personal
interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such
person&#8217;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common
control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of
the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless
the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law permits
merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Companies
Law are met, by a majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of each class of
its shares voted on the proposed merger at a shareholders meeting. The board of directors of a merging company is required pursuant to
the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger,
the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial
status of the merging companies. If the board of directors has determined that such a concern exists, it may not approve a proposed merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 246; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->229<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at
the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting
in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors
of the other party, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority
approval that governs all extraordinary transactions with controlling shareholders (as described under &#8220;Approval of Related Party
Transactions under Israeli law&#8212;Disclosure of Personal Interests of a Controlling Shareholder&#8221; of this prospectus).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction would
have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes
of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting
rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value to&#160;the parties to
the merger and the consideration offered to the shareholders of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further
give instructions to secure the rights of creditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each
party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the
shareholders of each party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Special Majority Board Approvals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the SciSparc Amended
and Restated Articles of Association, at least three-quarters (3/4) of its serving directors are required to vote in favor of certain
transactions which may have a significant effect on its structure, assets or business, including mergers acquisitions, consolidations
and issuance of equity securities or debt securities convertible into equity in each case that would reasonably be expected to result
in change of beneficial ownership of above than fifteen percent (15%) in SciSparc, material changes to SciSparc&#8217;s principal business
and any resolution to transfer SciSparc&#8217;s headquarters outside of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Approval of business combinations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Amended
and Restated Articles of Association restrict certain business transactions with any shareholder and/or its affiliates and/or investors
for a period of three years following (i) with respect to any shareholder of the Company holding fifteen percent (15%) or more of the
voting power of the ordinary shares as of September 15, 2022, the effective date of the Amended and Restated Articles of Association,
and (ii) with respect to all SciSparc shareholders, each time as such shareholder and/or any of its affiliates and/or investors become(s)
(other than due to a buyback, redemption or cancellation of shares by SciSparc) the holder(s) (beneficially or of record) of fifteen
percent (15%) or more of the issued and outstanding voting power of the ordinary shares. The restricted business transactions include
mergers, consolidations and dispositions of assets with an aggregate market value equal to 10% or more of SciSparc&#8217;s assets or
outstanding shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 247; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->230<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Borrowing powers</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and SciSparc&#8217;s Amended and Restated Articles of Association, its board of directors may exercise all powers and take all actions
that are not required under law or under its Amended and Restated Articles of Association to be exercised or taken by a certain organ
of SciSparc, including the power to borrow money for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Amended
and Restated Articles of Association enable it to increase or reduce its share capital. Any such changes are subject to the provisions
of the Companies Law and must be approved by a resolution duly adopted by SciSparc&#8217;s shareholders at a general meeting. In addition,
transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient
retained earnings or profits, require the approval of both its board of directors and an Israeli court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forum for adjudication of disputes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Amended
and Restated Articles of Association, the federal district courts of the United States of America, shall be the exclusive forum for the
resolution of any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted
against any defendant to such complaint. The competent courts in Tel Aviv, Israel shall be the exclusive forum for (i) any derivative
action or proceeding brought on behalf of SciSparc, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director,
officer or other employee of SciSparc to SciSparc or SciSparc&#8217;s shareholders, or (iii) any action asserting a claim arising pursuant
to any provision of the Companies Law or the Securities Law 5728-1968. SciSparc retains the ability to consent to an alternative forum
in circumstances where SciSparc determines that its interests and those of its shareholders are best served by permitting a particular
dispute to proceed in a forum other than the federal district courts or State of Israel, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer agent and registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
transfer agent and registrar is Vstock Transfer LLC, or Vstock. Vstock&#8217;s address is 18 Lafayette Place, Woodmere, New York 11598
and its telephone number is (212) 828-8436.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 248; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->231<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><div><a id="m_020"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">COMPARISON
OF SHAREHOLDER RIGHTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax are
incorporated under the laws of Israel and, accordingly, the rights of the shareholders of each are currently, and will continue to be,
governed by Israeli law. If the Merger is completed, AutoMax shareholders will become SciSparc shareholders, and their rights will be
governed by Israeli law and the Amended and Restated Articles of Association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The table below summarizes
the material differences between the current rights of AutoMax shareholders under AutoMax&#8217;s current articles of association and
the rights of SciSparc&#8217;s shareholders, post-Merger, under SciSparc&#8217;s Amended and Restated Articles of Association, as in
effect immediately following the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Although SciSparc and AutoMax
believe that the summary tables cover the material differences between the rights of their respective shareholders prior to the Merger
and the rights of SciSparc shareholders following the Merger, these summary tables may not contain all of the information that is important
to you. These summaries are not intended to be a complete discussion of the respective rights of SciSparc shareholders and AutoMax shareholders
and are qualified in their entirety by reference to Israeli law and the various documents of SciSparc and AutoMax that are referred to
in the summaries. You should carefully read this entire this proxy statement/prospectus and the other documents referred to in this proxy
statement/prospectus for a more complete understanding of the differences between being an SciSparc shareholder and a AutoMax shareholder
before the Merger and being an SciSparc shareholder after the Merger. SciSparc has filed copies of its current Amended and Restated Articles
of Association with the SEC and will send copies of the documents referred to in this proxy statement/prospectus to you upon your request.
AutoMax will also send copies of its documents referred to in this proxy statement/prospectus to you upon your request. See the section
entitled&#160;<i>&#8220;Where You Can Find More Information&#8221;</i>&#160;in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding: 3pt 2pt; border: Black 1pt solid; text-align: justify; white-space: nowrap; width: 30%"><b>Provision</b></td>
    <td style="padding: 3pt 2pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 35%; text-align: center"><b>AutoMax
    (Pre-Merger)</b></td>
    <td style="padding: 3pt 2pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 35%; text-align: center"><b>SciSparc
    (Post-Merger)</b></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Authorized
    Share Capital</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">The authorized share
    capital of AutoMax consists of 400,000,000 ordinary shares, par value of NIS 0.05 per share.</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">The authorized share
    capital of SciSparc consists of 75,000,000 ordinary shares, no par value.</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Number
    of Directors</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Under the AutoMax
    articles of association, the number of directors shall be no less than three (3) and not more than ten (10), including external directors,
    as may be amended from time to time by resolution of general meeting. &#160;</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Under the SciSparc
    Amended and Restated Articles of Association, the number of directors is not less than three (3) nor more than eight (8), including
    the external directors (if any were elected) as may be amended from time to time by resolution of the board of directors.</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Shareholder
    Nominations and Proposals &#160;</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Under the Companies
    Law, any shareholder(s) holding at least 1% of the voting rights of the company may request that the board of directors (i)&#160;include
    a matter on the agenda of a general meeting, provided that the board of directors determines that the matter is appropriate to be
    considered at a general meeting or (ii)&#160;include on the agenda of a general meeting a nomination of a person to be proposed for
    election as a director. &#160;</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Any shareholder(s)
    holding at least the required percentage under the Companies Law of the voting rights of the company may request, subject to the
    Companies Law and the conditions set forth in the Amended and Restated Articles of Association, that the board of directors (i)&#160;include
    a matter on the agenda of a general meeting, provided that the board of directors determines that the matter is appropriate to be
    considered at a general meeting or (ii)&#160;include on the agenda of a general meeting a nomination of a person to be proposed for
    election as a director.</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Classified
    Board of Directors</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">No equivalent provision.</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">The Amended and
    Restated Articles of Association provide that the directors (excluding the external directors if any were elected), are classified,
    with respect to the term for which they each severally hold office, into three classes, such that following the expiration of the
    term of office of the directors of that class of directors will be for a term of office that expires on the third annual general
    meeting following such election or re-election. Notwithstanding anything to the contrary, each director shall serve until his or
    her successor is elected and qualified or until such earlier time as such director&#8217;s office is vacated. &#160;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 249; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->232<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-size: 7pt; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border: Black 1pt solid; width: 30%">Removal of Directors and Vacancies</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 35%"><p style="text-align: justify; margin-top: 0; margin-bottom: 0">Directors
                                            are appointed and removed by a resolution adopted at a general meeting or special meeting.
                                            In addition, the general meeting will have the right, from time to time: A. To dismiss any
                                            board member, provided that the director can reasonably present their position before the
                                            general assembly; and B. appoint additional director or a replacement for a director whose
                                            position was vacated for any reason.</p>
                                                                                <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            board of directors may appoint a director to fill a vacancy or as an addition to the board
                                            of directors. Such appointment will be valid until the next annual meeting or until the director
                                            ceases to serve in their position in accordance with the provisions of the articles of association
                                            or any applicable law, whichever occurs first. &#160;</p>
                                                                                <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="text-align: justify; margin-top: 0; margin-bottom: 0">Directors,
                                            at the exception of external directors, may appoint themselves a replacement (an &#8220;alternate
                                            director&#8221;). Any such appointment will be effective from the date stated in the appointment
                                            notice but not before the notice is sent to the company.</p></td>
    <td style="padding: 3pt 2pt; text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 35%"><p style="text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            board of directors (and, if so determined by the board of directors the general meeting)
                                            may at any time and from time to time appoint any person as a director to fill a vacancy
                                            (whether such vacancy is due to a director no longer serving or due to the number of directors
                                            serving being less than the maximum number of directors set forth in the articles).</p>
                                                                                <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            SciSparc shareholders may, by vote of at least 65% of the total voting power of the SciSparc
                                            shareholders, remove any director (other than external director, if any were elected) from
                                            office.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Special
    Meeting of the Shareholders</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Pursuant to the
    Companies Law and the AutoMax articles of association, the board of directors may whenever it deems fit convene an extraordinary
    general meeting, and, as provided in the Companies Law, it shall be obliged to do so upon the written request of (i) any two or more
    of its directors, (ii) one-quarter or more of the serving shareholders of its board of directors or (iii) one or more shareholders
    holding, in the aggregate, either 5% or more of AutoMax&#8217;s outstanding voting power. &#160;</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">The SciSparc board
    of directors may, at its discretion, convene a special general meeting at such time and place, within or outside of the State of
    Israel, as may be determined by the board of directors. &#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Quorum
    for General Meeting</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Two or more shareholders
    present in person or by proxy, holding shares conferring in the aggregate at least one-third (1/3) of the voting power of the AutoMax,
    unless otherwise mandated by any applicable law. &#160;</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Such number of shareholders
    present in person or by proxy and holding shares conferring in the aggregate at least thirty-three and one-third percent (33&#8531;%)
    of the voting power of SciSparc, provided, however, that if (i) such general meeting was initiated by and convened pursuant to a
    resolution adopted by the SciSparc board of directors and (ii) at the time of such general meeting is qualified to use the forms
    of a &#8220;foreign private issuer&#8221; under US securities laws, then the requisite quorum shall be shareholders present in person
    or by proxy and holding shares conferring in the aggregate at least fifteen percent (15%) of the voting power of SciSparc.</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Voting
    Shares</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Each shareholder
    present in person, by proxy, or through a written ballot is entitled to one vote for each share held by the shareholder of record,
    on every resolution.</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Each shareholder
    is entitled to one vote for each share held by the shareholder of record, on every resolution.</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-left: Black 1pt solid">Shareholder Action
    by Written Consent &#160;</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid">Under the Companies Law, shareholders are not permitted
    to take action via written consent in lieu of a meeting. &#160;</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid">Under the Companies Law, shareholders are not permitted
    to take action via written consent in lieu of a meeting. &#160;</td></tr>

<tr style="vertical-align: top">
    <td style="padding: 3pt 2pt; text-align: justify; border: Black 1pt solid">Notice of Shareholder Meeting</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">According
    to AutoMax articles of association, a shareholders meeting requires prior notice provided in accordance with the Companies Laws.</td>
    <td style="padding: 3pt 2pt; text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">SciSparc
    is not required to give notice of a general meeting, subject to any mandatory provision of the Companies Law.</td></tr>
</table><div>

</div><p style="font-size: 7pt; margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 250; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->233<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-size: 7pt; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border: Black 1pt solid; width: 30%">Conversion Rights and Protective
    Provisions</td>
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 35%">No
    equivalent provision in the AutoMax articles of association.</td>
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 35%">Without
    derogating from any other approvals required by the applicable law, the following actions shall require the affirmative consent of
    at least three-quarters (3/4) of the directors then in office and entitled to vote thereon: (i) Any resolution to enter a merger,
    consolidation, acquisition, amalgamation, business combination, issue equity securities or debt securities convertible into equity
    or other similar transaction. (ii) Any resolution to sell directly or indirectly, assign, convey, transfer, lease or otherwise dispose,
    in one or series of related transactions, of all or substantially all of the assets of SciSparc and its subsidiaries, taken as a
    whole, to any person. (iii) Any resolution to affect any material change to the principal business of SciSparc, or otherwise materially
    change the SciSparc strategy and/or policies with respect to its main lines of business. (iv) Any resolution to transfer the headquarters
    of SciSparc outside of Israel.</td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Forum
    Selection</td>
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">No
    equivalent provision.</td>
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">The
    Amended and Restated Articles of Association provide that unless SciSparc consents in writing to the selection of an alternative
    forum, (a)&#160;the federal district courts of the United States of America will be the exclusive forum for the resolution of any
    complaint asserting a cause of action arising under the Securities Act; and (b), the competent courts in Tel Aviv, Israel shall be
    the exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of SciSparc, (ii)&#160;any action asserting
    a claim of breach of a fiduciary duty owed by any director, officer or other employee of SciSparc to SciSparc or its shareholders,
    or (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law. &#160;</td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Indemnification</td>
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            articles of association provide that AutoMax may, subject and pursuant to the provisions
                                            of the Companies Law or any other additionally applicable law, indemnify retroactively and
                                            in advance, a director or officer of the company for certain liabilities and expenses incurred
                                            by him or her arising from or as a result of any act (or omission) carried out by him or
                                            her as a director or officer of the company and which is indemnifiable pursuant to applicable
                                            law, to the extent permitted by law. The Companies Law provides that undertakings to indemnify
                                            a director or officer for such liabilities (but not for such legal expenses) be limited to
                                            specified foreseeable events and to reasonable maximum amounts as approved by the board of
                                            directors.</p>
                                                                                <p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">Under
                                            the Companies Law, indemnification of directors and officers must be approved by the compensation
                                            committee and the board of directors (and, with respect to directors and the chief executive
                                            officer, by the shareholders).</p></td>
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            Amended and Restated Articles of Association provide that SciSparc may, subject and pursuant
                                            to the provisions of the Companies Law or any other additionally applicable law, indemnify,
                                            retroactively and in advance, a director or officer of the company for certain liabilities
                                            and expenses incurred by him or her arising from or as a result of any act (or omission)
                                            carried out by him or her as a director or officer of SciSparc and which is indemnifiable
                                            pursuant to applicable law, to the fullest extent permitted by law. The Companies Law provides
                                            that undertakings to indemnify a director or officer for such liabilities (but not for such
                                            legal expenses) be limited to specified foreseeable events and to reasonable maximum amounts.</p>
                                                                                <p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">Under
                                            the Companies Law, indemnification of directors and officers must be approved by the compensation
                                            committee and the board of directors (and, with respect to directors and the chief executive
                                            officer, by the shareholders).</p></td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Dividends
    Declaration and Payment of Dividends</td>
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid">The
    board of directors may, from time to time, declare, and cause, AutoMax to pay dividends as permitted by the Companies Law. The board
    of directors shall determine the time for payment of such dividends and the record date for determining the shareholders entitled
    thereto, and subject to any preferential rights held by shareholders of a particular class, if applicable, and the provisions of
    these regulations concerning a reserved fund, dividends will be distributed and paid to the shareholders recorded in the shareholders&#8217;
    register on the designated &#8220;X&#8221; day set for determining the distribution of dividends. Dividend shall not be paid on shares
    that were not paid in full.&#160;&#160;</td>
    <td style="font-size: 9pt; padding: 3pt 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            board of directors may, from time to time, declare, and cause SciSparc to pay dividends as
                                            permitted by the Companies Law. The board of directors shall determine the time for payment
                                            of such dividends and the record date for determining the shareholders entitled thereto.</p>
                                                                                <p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="font-size: 9pt; text-align: justify; margin-top: 0; margin-bottom: 0">Any
                                            dividend paid by SciSparc shall be allocated among the shareholders entitled thereto on a
                                            pari passu basis in proportion to their respective holdings of the issued and outstanding
                                            shares in respect of which such dividends are being paid. &#160;</p></td></tr>
  </table><div>

</div><p style="font-size: 7pt; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 251; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->234<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_021"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PRINCIPAL
SHAREHOLDERS OF SciSparc</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table and
related notes present information on the beneficial ownership of SciSparc ordinary shares as of February 7, 2025 by:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each shareholder known by
                                            SciSparc to beneficially own more than 5% of the outstanding shares of SciSparc;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify">each
                                            director and named executive officer of SciSparc; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">all of SciSparc&#8217;s directors
                                            and named executive officers as a group.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Beneficial ownership is
determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. SciSparc ordinary
shares that may be acquired by an individual or group within 60&#160;days of February 7, 2025, pursuant to the exercise of options, warrants
or restricted share units, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group,
but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The percentage of ownership
is based on 10,828,251 SciSparc ordinary shares outstanding as of February 7, 2025, adjusted as required by the rules promulgated by
the SEC to determine beneficial ownership. SciSparc does not know of any arrangements, including any pledge by any person of securities
of SciSparc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Except as indicated in the
footnotes to this table, SciSparc believes that the shareholders named in this table have sole voting and investment power with respect
to all SciSparc ordinary shares shown as beneficially owned by them, subject to community property laws where applicable. Unless otherwise
noted, the address of each director and current and former executive officer of SciSparc is 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup>&#160;Floor,
Tel Aviv 6971916, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b style="-keep: true">Holders
                                            of more than 5% of SciSparc&#8217;s ordinary shares</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Number
    of<br/> Ordinary<br/> Shares<br/> Beneficially<br/> Owned<sup>(1)</sup></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Percent
    of<br/> Class<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-decoration: underline; text-align: left"><span style="text-decoration:underline">Officers and Directors who are not 5% holders:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Itschak Shrem</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">38,636</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><sup style="-keep: true">(3)</sup></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">*%</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Amitay Weiss</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">38,321</span></td><td style="padding-bottom: 2.5pt; text-align: left"><sup style="-keep: true">(4)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Oz Adler</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">38,356</span></td><td style="padding-bottom: 2.5pt; text-align: left"><sup style="-keep: true">(5)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Dr. Adi Zuloff-Shani</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">25,840</span></td><td style="padding-bottom: 2.5pt; text-align: left"><sup style="-keep: true">(6)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Amnon Ben Shay</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11,391</span></td><td style="padding-bottom: 2.5pt; text-align: left"><sup style="-keep: true">(7)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Alon Dayan</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11,391</span></td><td style="padding-bottom: 2.5pt; text-align: left"><sup style="-keep: true">(7)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Liat Sidi</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11,391</span></td><td style="padding-bottom: 2.5pt; text-align: left"><sup style="-keep: true">(7)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Lior Vider</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11,391</span></td><td style="padding-bottom: 2.5pt; text-align: left"><sup style="-keep: true">(7)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Moshe Revach</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11,391</span></td><td style="padding-bottom: 2.5pt; text-align: left"><sup style="-keep: true">(7)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"/><td style="text-align: left"><span style="-keep: true">*</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">All directors and executive officers as a group (9 persons)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">198,108</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">%</span></td>
    </tr>
  </table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">*</td>
    <td style="font-size: 10pt; text-align: justify">Less than 1%.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as indicated by
    footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment
    power with respect to all shares shown as beneficially owned by them.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="-keep: true">The percentages shown are based on 10,828,251 ordinary shares issued and outstanding as of February
    7, 2025, plus ordinary shares relating to options and warrants currently exercisable or exercisable within 60 days of February 7,
    2025, which are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding
    for computing the percentage of any other person.</span></td></tr>
  </table><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 252; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->235<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="-keep: true">Includes (i) 340 ordinary shares, (ii) 37,500 vested RSUs, and (iii) options to purchase 996 ordinary
    shares at an exercise price of $169 per share. In addition, Mr. Shrem holds options to purchase 200 ordinary shares that are not
    exercisable within 60 days. Mr. Shrem&#8217;s options have an expiration date of January 3, 2028, and a weighted average exercise
    price of $169.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="-keep: true">Includes (i) 25 ordinary shares, (ii) 37,500 vested RSUs, and (iii) options to purchase 996 ordinary
    shares at an exercise price of $169 per share. In addition, Mr. Weiss holds options to purchase 200 ordinary shares that are not
    exercisable within 60 days. Mr. Weiss&#8217; options have an expiration date of January 3, 2028, and a weighted average exercise
    price of $169.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="-keep: true">Includes (i) 37,500 vested RSUs, (ii) options to purchase 996 ordinary shares at an exercise price
    of $169 per share, and (iii) options to purchase 60 ordinary shares at an exercise price of $5,460 per share. In addition, Mr. Adler
    holds options to purchase 200 ordinary shares that are not exercisable within 60 days. Mr. Adler&#8217;s options have an expiration
    date of January 3, 2028 to October 10, 2029, and a weighted average exercise price of $422.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="-keep: true">Includes (i) 25,000 vested RSUs, (ii) options to purchase 6 ordinary shares at an exercise price
    of NIS 77,241 (approximately $20,876) per share, (iii) options to purchase 38 ordinary shares at an exercise price of $5,640 per
    share, and (iv) options to purchase 996 ordinary shares at an exercise price of $169 per share. In addition, Dr. Zuloff-Shani holds
    options to purchase 200 ordinary shares that are not exercisable within 60 days. Dr. Zuloff-Shani&#8217;s options have an expiration
    date of February 16, 2026 to October 10, 2029, and a weighted average exercise price of $207.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="-keep: true">Includes (i) 11,250 vested RSUs, and (ii) options to purchase 176 ordinary shares at an exercise
    price of $169 per share. Each of Amnon Ben Shay, Alon Dayan, Moshe Revach, Liat Sidi and Lior Vider holds options to purchase 35
    ordinary shares that are not exercisable within 60 days. The options have an expiration date of January 3, 2028, and a weighted average
    exercise price of $169.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Changes in Percentage
Ownership by Major Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
SciSparc&#8217;s knowledge, other than as disclosed in the table above and in its other filings with the SEC incorporated by reference,
there has been no significant change in the percentage ownership held by any major shareholder during the past three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
major shareholders listed above had or have voting rights with respect to their ordinary shares that are different from the voting rights
of other holders of SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Record Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">As
of February 7, 2025, there were 28 holders of record of SciSparc ordinary shares, 9 of which have a registered address in the United
States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
numbers are not representative of the number of beneficial holders of its shares nor is it representative of where such beneficial holders
reside, since many of these shares were held of record by brokers or other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Change in Control
Arrangements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and
there are no arrangements known to SciSparc which would result in a change in control at a subsequent date.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 253; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->236<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_022"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PRINCIPAL
SHAREHOLDERS OF AutoMax</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
following table and related notes present information on the beneficial ownership of AutoMax ordinary shares as of February 7, 2025
by:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify">each
                                            shareholder known by AutoMax to beneficially own more than 5% of the outstanding shares of
                                            AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify">each
                                            director and named executive officer of AutoMax; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify">all
                                            of AutoMax&#8217;s directors and named executive officers as a group.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
AutoMax&#8217;s ordinary shares that may be acquired by an individual or group within 60&#160;days of February 7, 2025, pursuant to the
exercise of options, warrants or restricted share units, are deemed to be outstanding for the purpose of computing the percentage ownership
of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other
person shown in the table.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
percentage of ownership is based on 118,310,565 AutoMax ordinary shares outstanding as of February 7, 2025, adjusted as required by the
rules promulgated by the SEC to determine beneficial ownership. AutoMax does not know of any arrangements, including any pledge by any
person of securities of AutoMax.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Except
as indicated in the footnotes to this table, AutoMax believes that the shareholders named in this table have sole voting and investment
power with respect to all AutoMax ordinary shares shown as beneficially owned by them, subject to community property laws where applicable.
Unless otherwise noted, the address of each director and current and former executive officer of AutoMax is 15 Harechavim St., Jerusalem,
Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><b>NAME OF BENEFICIAL OWNER </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Beneficial
    Ownership</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage
    of Ordinary Shares Beneficially Owned (1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0pt"><b>5% and Greater Shareholders</b></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 76%">Kool Car Rental Kft (2)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">14,285,714</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">12.07</td><td style="text-align: left; width: 1%">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Belporto Investments Ltd. (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,209,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.09</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eliyahu Baruch Ltd. (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,209,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.09</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Executive Officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Daniel Levy, Chief Executive Officer (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,196,941</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.69</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Haim Levy, Procurement and Trade Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,580,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.34</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gal Levy, Regulation and Branch Manager</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,580,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.34</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ynon Amit, Chief Business Officer (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,196,941</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.69</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amitai Weiss, Chairman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eyal Baruch, Director (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,777,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.50</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tomer Levy, Vice President Business Development, Director (8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,580,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.34</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Emanuel Paz Puzailov (9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,226,941</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.72</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">All current executive officers and directors as a group (8 persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">62,374,481</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">52.71</td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">*</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Less than 1%.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The percentages shown are based on 118,310,565
    ordinary shares issued and outstanding as of February 7, 2025, plus ordinary shares relating to options and warrants currently exercisable
    or exercisable within 60 days of February 7, 2025, which are deemed outstanding for computing the percentage of the person holding
    such securities but are not deemed outstanding for computing the percentage of any other person.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 254; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->237<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents 14,285,714 ordinary shares held by Kool Car Rental Kft, a company incorporated in the State of Hungary, controlled by Nikas Kostantinos. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents 7,209,614 ordinary shares held by Belporto Investments Ltd., a company incorporated in the State of Israel. Belporto Investments Ltd. is controlled by Ms. Esther Zochovitsky. The address for this entity is 8 Hamenofim St., Herzliya, Israel. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents 7,209,614 ordinary shares held by Eliyahu Baruch Ltd., a company incorporated in the State of Israel. Eliyahu Baruch Ltd., is controlled by Mr. Eyal Baruch, Ms. Michal Baruch Kind, Mr. Oded Baruch, and Ms. Sima Baruch Hakim. The address for this entity is 8 Hamenofim St., Herzliya, Israel. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 14,419,228 ordinary shares, held by Haim Levy &#8211; Trade
    In Ltd., a company incorporated in the State of Israel, plus 1,777,713 plus ordinary shares relating to options and warrants currently
    exercisable or exercisable within 60 days of February 7, 2025, held by Mr. Levy. Haim Levy &#8211; Trade In Ltd. is controlled by
    Daniel Levy. The address for this entity is 15 Harechavim St., Jerusalem, Israel.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(6) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 14,419,228 ordinary shares, held by A. Ynon (2015) Ltd.,
    a company incorporated in the State of Israel, plus 1,777,713 plus ordinary shares relating to options and warrants currently exercisable
    or exercisable within 60 days of February 7, 2025, held by Mr. Amit. A. Ynon (2015) Ltd. is controlled by Ynon Amit. The address
    for this entity is Moshe 15 Lerrer Ness Ziona, Israel.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 1,777,713 ordinary shares relating to options and warrants
    currently exercisable or exercisable within 60 days of February 7, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(8) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 1,580,189 ordinary shares relating to options and warrants
    currently exercisable or exercisable within 60 days of February 7, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents 14,449,228 ordinary shares held by Puzaylov Investments
    Ltd., a company incorporated in the State of Israel, plus 1,777,713 plus ordinary shares relating to options and warrants currently
    exercisable or exercisable within 60 days of February 7, 2025. Puzaylov Investments Ltd. is controlled by Emanuel Paz Puzailov. The
    address for these entities is 138 Yehuda St., Modi&#8217;in-Maccabim-Re&#8217;ut, Israel.</span></td></tr>
  </table><div>
</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 255; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->238<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_023"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PRINCIPAL
SHAREHOLDERS OF Combined company</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
following table and the related notes present information on the beneficial ownership of the combined company&#8217;s ordinary shares
immediately after the consummation of the Merger, applying an estimated exchange ratio, which may be adjusted based on the amount of
SciSparc net cash and changes in the capitalization of SciSparc or AutoMax prior to the closing of the Merger, and based on beneficial
ownership as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 by:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify">each
                                            shareholder expected by AutoMax and SciSparc to become the beneficial owner of more than
                                            5% of the outstanding ordinary shares of the combined company;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify">each
                                            director and named executive officer of the combined company; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify">all
                                            of the combined company&#8217;s directors and executive officers as a group.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
Shares of the combined company ordinary shares that may be acquired by an individual or group within 60 days of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025, pursuant to the exercise of options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership
of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other
person shown in the table.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
percentage ownership is based on ordinary shares of the combined company outstanding as of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025, adjusted as required by the rules promulgated by the SEC to determine beneficial ownership. Neither AutoMax nor SciSparc know of
any arrangements, including any pledge by any person of securities of the combined company.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Immediately
after the consummation of the Merger, based on the Exchange Ratio, AutoMax shareholders will own approximately 49.99% of the SciSparc
ordinary shares with SciSparc shareholders holding approximately 50.01% of the SciSparc ordinary shares on a fully-diluted basis (subject
to certain exceptions). The following table and the related notes assume that, at the effective time of the Merger, each share of AutoMax
ordinary shares will convert into the right to receive an estimated [&#9679;] ordinary shares of SciSparc and to account for the occurrence
of certain events discussed elsewhere in this proxy statement/prospectus. See &#8220;<i>The Merger Agreement &#8212; Merger Consideration</i>&#8221;
for more information regarding the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Except
as indicated in footnotes to this table, AutoMax and SciSparc believe that the shareholders named in this table have sole voting and
investment power with respect to all shares of ordinary shares of the combined company shown as beneficially owned by them, based on
information provided to AutoMax and SciSparc by such shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NAME OF
    BENEFICIAL OWNER</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
    Beneficial<br/>
    Ownership</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage<br/>
    of&#160;Ordinary<br/>
    Shares<br/>
    Beneficially<br/>
    Owned(1)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5% and Greater Shareholders</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haim Levy &#8211; Trade In Ltd.
    (2)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. Ynon (2015) Ltd. (3)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Puzaylov Investments Ltd. (4)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kool Car Rental Kft (5)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors and Executive Officers</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amnon Ben Shay</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liat Sidi</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe Revach</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tomer Levy</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaarah Alfi</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All current executive officers and directors as
    a group (persons)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 256; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->239<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_024"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">LEGAL
MATTERS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
validity of the securities registered hereby and certain other matters of the laws of Israel will be passed upon for </span>SciSparc
<span style="background-color: white">by </span>Meitar | Law Offices, Ramat Gan, Israel<span style="background-color: white">, and certain
matters of U.S. law will be passed upon for SciSparc by </span>Sullivan &amp; Worcester LLP, New York, New York<span style="background-color: white">.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_025"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">EXPERTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
consolidated financial statements of SciSparc Ltd. at December 31, 2023 and 2022, and for each of the three years in the period ended
December 31, 2023, included in the Proxy Statement of SciSparc Ltd, which is referred to and made a part of this Prospectus and Registration
Statement have been audited by Kost Forer Gabbay &amp; Kasierer, a member of EY Global, independent registered public accounting firm,
as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about
the Company&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing
elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
consolidated financial statements of AutoMax Motors Ltd. as of December 31, 2023 and 2022 and the Years ended December 31, 2023 and 2022,
included in this prospectus have been audited by Ben David Shalvi Kop &amp; Co, independent registered public accounting firm, as set
forth in their report thereon, included herein. Such consolidated financial statements are included herein in reliance upon such report
given on the authority of such firm as experts in accounting and auditing.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><sup>&#160;</sup></b></span></p><div>

</div><div><a id="m_026"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">WHERE
YOU CAN FIND MORE INFORMATION</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has filed a registration statement on Form F-4 to register the issuance of securities described elsewhere in this proxy statement/prospectus.
This proxy statement/prospectus is a part of that registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
AutoMax&#8217;s ordinary shares are traded on the&#160;TASE, AutoMax files periodic and immediate reports with, and furnish information
to, the&#160;TASE&#160;and the ISA, or the ISA, as required under Chapter Six of the Israel Securities Law, 1968 and the regulations
enacted pursuant thereof, as applicable to a public company in Israel. Copies of AutoMax&#8217;s filings with the ISA can be retrieved
electronically through the MAGNA distribution site of the ISA (www.magna.isa.gov.il) and the&#160;TASE&#160;website (www.maya.tase.co.il).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
files reports, proxy statements and other information with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as required
by the&#160;Exchange Act, as applicable to foreign private issuers. You may access information on SciSparc at the SEC website containing
reports, proxy statements and other information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a foreign private issuer, SciSparc is exempt under the&#160;Exchange Act&#160;from, among other things, the rules prescribing the furnishing
and content of proxy statements, and its executive officers, directors and principal shareholders are exempt from the reporting and short-swing
profit recovery provisions contained in Section 16 of the Exchange Act. In addition, SciSparc will not be required under the&#160;Exchange
Act&#160;to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities
are registered under the&#160;Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Information
and statements contained in this proxy statement/prospectus or any annex to this proxy statement/prospectus are qualified in all respects
by reference to the copy of the relevant contract or other annex filed as an exhibit to this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
information contained in this proxy statement/prospectus relating to SciSparc has been supplied by SciSparc, and all such information
relating to AutoMax has been supplied by AutoMax. Information provided by one another does not constitute any representation, estimate
or projection of the other.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
you would like additional copies of this proxy statement/prospectus or if you have questions about the business combination, you should
contact via phone or in writing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SciSparc Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;20 Raul Wallenberg Street,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tower A</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel Aviv 6971916 Israel Attn: Secretary</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AutoMax Motors Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">C/O Mishmeret Trust Company Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">48 Derech Menachem Begin,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel Aviv 6618001, Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Adv. Daniel Bar-On</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><br/>
<br/></p><div>


</div><!-- Field: Page; Sequence: 257; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->240<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_027"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">HOUSEHOLDING
OF PROXY MATERIALS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for shareholder meeting
materials with respect to two or more shareholders sharing the same address by delivering a single set of shareholder meeting materials
addressed to those shareholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience
for shareholders and cost savings for companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
number of brokers with account holders who are SciSparc shareholders will be &#8220;householding&#8221; SciSparc&#8217;s proxy materials.
A single set of meeting materials will be delivered to multiple shareholders sharing an address unless contrary instructions have been
received from the affected shareholders. Once you have received notice from your broker that they will be &#8220;householding&#8221;
communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent.
If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of shareholder
meeting materials, please notify your broker or SciSparc. Direct your written request to SciSparc Ltd., 20 Raul Wallenberg St., Tower
A, 2<sup>nd</sup>&#160;Floor, Tel Aviv 6971916, Israel. Shareholders who currently receive multiple copies of the proxy statement at
their address and would like to request &#8220;householding&#8221; of their communications should contact their broker. In addition,
SciSparc will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the proxy statement
to such shareholders at a shared address to which a single copy of the documents was delivered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 258; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->241<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_027a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SCISPARC LTD. (FORMERLY
THERAPIX BIOSCIENCES LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AS OF DECEMBER 31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>U.S. DOLLARS IN THOUSANDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 89%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_001">Report
    of Independent Registered Public Accounting Firm (PCAOB ID&#160;1281)</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2 - F-3</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_002">Consolidated
    Statements of Financial Position</a></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4 - F-5</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_003">Consolidated
    Statements of Comprehensive Loss</a></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6</b></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_004">Consolidated
    Statements of Changes in Equity</a></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-7
    </b></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_005">Consolidated
    Statements of Cash Flows</a></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-8
    - F-10</b></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_006">Notes
    to Consolidated Financial Statements</a></b></span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-11
    - F-55</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 259; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 33%"><img alt="" src="fin_027.jpg"/></td>
    <td style="vertical-align: bottom; width: 34%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Kost Forer Gabbay
                                            &amp; Kasierer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">144 Menachem Begin Road,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel-Aviv 6492102, Israel</p></td>
    <td style="vertical-align: bottom; width: 33%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: +972-3-6232525</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: +972-3-5622555</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ey.com</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>To the Shareholders and the Board of Directors
of</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD. (formerly known as THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of financial position of SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) and its subsidiaries (the
&#8220;Company&#8221;) as of December 31, 2023, and 2022, and the related consolidated statements of comprehensive loss, changes in equity
and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as
the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material
respects, the consolidated financial position of the Company at December 31, 2023, and 2022, and the consolidated results of its operations
and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting
Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company&#8217;s Ability to Continue as
a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial
statements, the Company has suffered recurring losses from operations, negative cash flows from operating activities and has stated that
substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events
and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 260; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The critical audit matter
communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to
be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical
audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Matter</i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed
    in Note 1 to the consolidated financial statements, the Company has incurred losses since inception, and expects to continue to incur
    losses for the foreseeable future. At December 31, 2023, the Company&#8217;s cash and cash equivalents position is not sufficient
    to fund the Company&#8217;s planned operations for at least a year beyond the date of the issuance of the consolidated financial
    statements. Those factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We determined the Company&#8217;s
    ability to continue as a going concern is a critical audit matter due to the estimation and execution uncertainty regarding the Company&#8217;s
    future cash flows and the risk of bias in management&#8217;s judgments and assumptions in estimating these cash flows to conclude
    the Company would have sufficient liquidity to sustain itself for at least a year beyond the date of the issuance of the consolidated
    financial statements. This in turn led to a high degree of auditor subjectivity and judgment to evaluate the audit evidence supporting
    the liquidity conclusions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
    We Addressed the Matter in Our Audit</i></span></td>
    <td>&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Addressing the matter involved performing
        procedures and evaluating audit evidence in connection with our overall opinion on the consolidated financial statements.&#160;Our
        audit procedures included, among others, testing the reasonableness of the forecasted revenue, operating expenses, and uses and
        sources of cash used in management&#8217;s assessment of whether the Company has sufficient liquidity to fund operations for
        at least one year from the consolidated financial statement issuance date. This testing included inquiries with management, consideration
        of positive and negative evidence impacting management&#8217;s forecasts, the Company&#8217;s financing arrangements in place
        as of the report date, market and industry factors, we evaluated management&#8217;s analysis of their impact on the forecasted
        cash flows.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We assessed the adequacy of the Company&#8217;s
    going concern disclosures included in Note 1 to the consolidated financial statements.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    KOST FORER GABBAY &amp; KASIERER</span></td>
    <td style="width: 20%">&#160;</td>
    <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel Aviv, Israel</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KOST FORER GABBAY &amp; KASIERER</span></td>
    <td>&#160;</td>
    <td>April 1, 2024</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">A Member of Ernst &amp; Young
Global</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2009.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 261; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY
THERAPIX BIOSCIENCES LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; width: 65%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-104949">2,076</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-104950">3,574</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Restricted deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-104951">65</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-104952">60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Short-term deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-104953">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Trade receivables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-104954">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-104955">77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other accounts receivable</td><td>&#160;</td>
    <td style="text-align: center">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-104956">540</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-104957">131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-104958">742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-104959">668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-104960">6,445</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-104961">4,510</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Intangible asset, net</td><td>&#160;</td>
    <td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-104962">3,189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-104963">4,717</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Investments in company accounted for at equity</td><td>&#160;</td>
    <td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-104964">781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-104965">591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8, 24e</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-104966">659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-104967">730</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-104968">108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-104969">57</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-104970">4,737</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-104971">6,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-104972">11,182</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-104973">10,605</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 262; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-104974">802</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-104975">1,199</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other accounts payable</td><td>&#160;</td>
    <td style="text-align: center">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-104976">185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-104977">193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: center">18h</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-104978">532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-104979">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-104980">52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-104981">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-104982">1,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-104983">4,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-104984">24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</td><td>&#160;</td>
    <td style="text-align: center">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share capital and premium</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-104985">64,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-104986">58,592</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reserve from share-based payment transactions</td><td>&#160;</td>
    <td style="text-align: center">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-104987">5,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-104988">5,180</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: center">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-104989">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-104990">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation reserve</td><td>&#160;</td>
    <td style="text-align: center">2d</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-104991">497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-104992">497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transactions with non-controlling interests</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-104993">810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-104994">559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-104995">68,691</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-104996">63,569</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-104997">7,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-104998">6,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-104999">1,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105000">9,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105001">6,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities and equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-105002">11,182</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-105003">10,605</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 263; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY
THERAPIX BIOSCIENCES LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Note</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">USD in thousands (except per share
    data)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-105004">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-105005">1,347</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-105006">683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-105007">322</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-105008">2,196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-105009">1,025</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">21</td><td style="text-align: left">a</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-105010">1,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-105011">2,803</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-105012">1,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-105013">1,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">537</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">(**)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105015">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">21</td><td style="padding-bottom: 1.5pt; text-align: left">b</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105016">5,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">5,972</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">(**)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105018">3,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105019">6,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105020">8,287</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105021">5,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: center">21</td><td style="text-align: left">c</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-105022">210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-105023">109</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: center">21</td><td style="text-align: left">d</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105024">2,219</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105025">7,832</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">21</td><td style="padding-bottom: 1.5pt; text-align: left">e</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105026">1,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105027">2,014</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105028">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-105029">5,861</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-105030">2,578</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-105031">5,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-105032">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-105033">14</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105034">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105035">2,592</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105036">5,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Attributable to:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity holders of the Company</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-105037">5,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-105038">2,592</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-105039">5,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-105040">761</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105041">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105042">2,592</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105043">5,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Basic loss per ordinary share attributable to equity holders of the Company:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-105044">14.43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares">14.82</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">(*)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares">73.58</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">(*)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Diluted loss per ordinary share attributable to equity holders of the Company:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-105047">14.43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" id="ix_2_fact" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares">14.82</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">(*)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares">73.58</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">(*)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Loss per share retroactively adjusted in these consolidated statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see note 18a).</ix:footnote></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(**)</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Reclassified to correlate with common practice in industry and better reflect profit and loss.</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 264; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY
THERAPIX BIOSCIENCES LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Attributable
    to equity holders of the Company</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Share<br/>
    capital<br/>
    and<br/>
    premium</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Reserve<br/>
    from&#160;share-<br/>
    based<br/>
    payment<br/>
    transactions</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Transactions<br/>
    with non-<br/> controlling<br/>
    interests</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign<br/>
    currency<br/>
    translation<br/>
    reserve</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-<br/>
    controlling<br/>
    interests</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total<br/>
    equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">USD
    in thousands</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 23.5%; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at January 1, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105052">49,040</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105053">4,315</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105054">2,207</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105055">559</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105056">497</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-105057">55,188</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105058">1,430</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105059">1,430</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105060">5,789</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105061">5,789</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105062">5,789</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise
    of warrants</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-105063">6,110</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" sign="-" unitRef="usd" id="ixv-105064">1,352</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-105065">4,758</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-105066">4,758</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issue
    of share capital, net of issue expenses</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105067">3,364</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105068">4,335</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105069">7,699</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105070">7,699</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Expiration
    of share options</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-105071">27</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" sign="-" unitRef="usd" id="ixv-105072">27</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cost
    of share-based payment</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105073">43</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105074">43</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105075">43</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December&#160;31, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105076">58,541</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105077">4,331</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105078">5,190</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105079">559</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105080">497</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-105081">60,977</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105082">8,141</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105083">8,141</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105084">2,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105085">2,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105086">2,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise
    of warrants</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-105087">3</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-105088">3</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-105089">3</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cost
    of share-based payment</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105090">48</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105091">849</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105092">897</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105093">897</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December&#160;31, 2022</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105094">58,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105095">5,180</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105096">5,190</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105097">559</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105098">497</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-105099">63,569</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105100">6,449</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105101">6,449</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105102">5,122</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105103">5,122</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105104">761</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105105">5,883</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale
    of minority interest in subsidiary</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105106">251</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105107">251</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105108">2,734</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105109">2,985</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issue
    of share capital in respect of investment in affiliate</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-105110">288</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-105111">288</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-105112">288</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issue
    of share capital, net of issue expenses&#160;(3)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105113">5,552</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105114">5,552</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105115">5,552</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cost
    of share-based payment</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105116">94</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105117">102</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105118">196</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105119">196</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December&#160;31, 2023</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105120">64,526</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105121">5,282</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105122">5,190</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105123">810</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105124">497</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-105125">68,691</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105126">7,614</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105127">1,973</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105128">9,587</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 265; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY
THERAPIX BIOSCIENCES LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; padding-left: 9pt">Loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105129">5,883</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105130">2,592</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105131">5,789</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile loss to net cash used&#160;in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Adjustments to the profit or loss items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-105132">538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-105133">187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-105134">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-105135">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Cost of share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105136">196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105137">897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105138">43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Finance expenses (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-105139">2,205</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-105140">6,585</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-105141">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Group&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-105142">210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-105143">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-105144">1,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-105145">770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-105146">829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105147">4,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-105148">85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Working capital adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Decrease (increase) in other accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-105149">409</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-105150">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-105151">170</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Increase (decrease) in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-105152">397</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-105153">353</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Increase (decrease) in other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" sign="-" unitRef="usd" id="ixv-105154">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-105155">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-105156">120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Decrease (increase) in trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-105157">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" sign="-" unitRef="usd" id="ixv-105158">77</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Increase in inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-105159">74</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-105160">668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-105161">833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-105162">703</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" unitRef="usd" id="ixv-105163">643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Net cash used in operating activities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105164">5,887</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105165">7,917</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105166">5,061</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 266; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Cash flows from investing activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in restricted bank deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-105167">5</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-105168">15</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-105169">35</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in short-term bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-105170">3,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-105171">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-105172">35</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in a company accounted for at equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-105173">400</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-105174">700</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Change in fair value of investments in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-105175">689</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Sale of minority interest in subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-105176">2,985</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Purchase of financial assets at fair value through profit or
    loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-105177">1,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Purchase of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-105178">4,861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by (used in) investing
    activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105179">1,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105180">7,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105181">70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Proceeds from issue of share capital (net of issuance expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-105182">5,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-105183">9,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-105184">7,699</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 27pt">Exercise of warrants (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-105185">2,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-105186">2,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Payment of issuance expenses related to previous period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" scale="3" unitRef="usd" id="ixv-105187">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Interest paid on lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-105188">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-105189">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Repayment of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-105190">47</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-105191">70</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-105192">19</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Repayment of short-term credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ReceiptofShortTermCreditFromOthers" scale="3" sign="-" unitRef="usd" id="ixv-105193">188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-105194">5,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-105195">11,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-105196">10,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-105197">1,498</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-105198">3,301</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" unitRef="usd" id="ixv-105199">4,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cash at the beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105200">3,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105201">6,875</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105202">1,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Cash at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105203">2,076</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105204">3,574</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105205">6,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 267; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <span style="text-decoration:underline">Significant non-cash transactions</span>:</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Right-of-use asset recognized with corresponding lease liability</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-105206">102</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-105207">78</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Registration of warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RegistrationOfWarrants" scale="3" unitRef="usd" id="ixv-105208">2,480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Investment in financial asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentInFinancialAsset" scale="3" unitRef="usd" id="ixv-105209">288</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Unpaid issue expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:UnpaidIssueExpenses" scale="3" unitRef="usd" id="ixv-105210">290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 268; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY
THERAPIX BIOSCIENCES LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="ixv-40958"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly
    known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a pharmaceutical
    company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries
    at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy
    field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of
    approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on
    &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s
    disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel
    Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">The Company&#8217;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated
under the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
board of directors (&#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1, which
became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these interim consolidated financial statements for all periods presented.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
of the Company for the year ended December&#160;31, 2023, were approved on March 31, 2024, and signed on April 1, 2024 (the &#8220;Approval
Date&#8221;).</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 269; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2023, the Group had an accumulated deficit of approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-105211">68,691</ix:nonFraction> as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company&#8217;s
cash and cash equivalents totaled $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105212">2,076</ix:nonFraction>. In the period ended December 31, 2023, the Company had an operating loss of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105213">5,883</ix:nonFraction> and negative
cash flows from operating activities of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105214">5,887</ix:nonFraction>. The Company&#8217;s current cash and cash equivalents position is not sufficient to fund
the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its
liabilities arising from normal business operations when they become due. While the Company has successfully raised funds in the past,
there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially
reasonable terms, would have serious consequences on our financial condition and results of operations. In addition, the Group has started
recognizing revenues from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing
and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue
from its products. These above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly
    known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly
    Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies that are controlled
    by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts are consolidated
    with those of the Company (if active).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity over which the
    Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221; and is
    not a Subsidiary.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Parties</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in IAS 24, &#8220;<i>Related
    Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Accounting
    Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial
    Reporting Standards issued by the IASB.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 270; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-41159"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies
have been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c6_cont_1" escape="true" name="sprcy:BasisOfPresentationOfFinancialStatements" id="ixv-41171"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c6_cont_2" id="sprcy_BasisOfPresentationOfFinancialStatements-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c6_cont_3" id="sprcy_BasisOfPresentationOfFinancialStatements-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c6_cont_4" id="sprcy_BasisOfPresentationOfFinancialStatements-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_BasisOfPresentationOfFinancialStatements-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c6_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory" id="ixv-41192"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is <ix:nonNumeric contextRef="c6" format="ixt-sec:durwordsen" name="sprcy:OperatingTerm" id="ixv-105215">one year</ix:nonNumeric>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c6_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" id="ixv-41204"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c6_cont_2" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c6_cont_3" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 271; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_1"><ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-41260"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c6_cont_1" escape="true" name="sprcy:DescriptionOfAcquisitionOfASingleAssetCompany" id="ixv-41272"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit-c6_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit" id="ixv-41284"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" id="ixv-41296"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_5" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_6" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 272; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_2"><ix:nonNumeric contextRef="c6" continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" id="ixv-41373"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_2" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_3" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_4" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_5" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_6" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 273; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_3"><ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="ixv-41439"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" id="ixv-41451"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-105216">6</ix:nonFraction>-<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-105217">50</ix:nonFraction></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-105218">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c101" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-105219">33</ix:nonFraction>-<ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-105220">50</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-105221">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-105222">20</ix:nonFraction>-<ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-105223">33</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-105224">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c107" name="ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" id="ixv-105225">see below</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="ixv-41504"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="ixv-41519"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 274; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_4"><ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-41569"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business
    model for managing financial assets; and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow
    terms of the financial asset.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured
    at amortized cost when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_10" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_9"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured
    at fair value through profit or loss when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_11" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_12" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_11"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and
    other financial assets held for trading:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_13" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_14" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_15" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 275; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_5"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_16" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_15"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial
    assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_17" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized
only when:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_18" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_17"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights
    to the cash flows from the financial asset have expired;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_19" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_18"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred
    substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has
    neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset;
    or</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_20" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_19"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained
    its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows
    in full without material delay to a third party.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_21" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_20"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_22" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_21"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured
    at amortized cost:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_23" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_24" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_25" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_24"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured
    at fair value through profit or loss:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_26" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_27" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_28" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_27"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial
    liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_29" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_30" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_29"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_31" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 276; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_32" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_31"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_33" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_34" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_33"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c6_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="ixv-41878"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" id="ixv-41893"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="ixv-41905"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 277; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_8" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_7"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_5" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_6" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c6_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted)
    in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted
    prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based
    on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" id="ixv-42014"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_5" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_6" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_7" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_8" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_9" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_10" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c6_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 278; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_9" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_8"><ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-42104"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and
other service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_5" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_6" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_7" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="ixv-42135"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 279; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_10" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_9"><ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="ixv-42191"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_5" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_6" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="ixv-42230"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-42253"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_4" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 280; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_11" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_10"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_5" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_6" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_7" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_8" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_9" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_10" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_9"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination
    options:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_11" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_12" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_13" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_12"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_14" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c6_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 281; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c6_cont_11"><ix:nonNumeric contextRef="c6" continuedAt="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c6_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" id="ixv-42410"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies&#8221;:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c6_cont_2" id="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In February 2021, the IASB issued
an amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; (&#8220;the Amendment&#8221;), which replaces the requirement
to disclose &#8217;significant&#8217; accounting policies with a requirement to disclose &#8216;material&#8217; accounting policies.
One of the main reasons for the Amendment is the absence of a definition of the term &#8217;significant&#8217; in IFRS whereas the term
&#8216;material&#8217; is defined in several standards and particularly in IAS 1.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c6_cont_3" id="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is applicable for annual
periods beginning on January 1, 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The application of the above Amendment
had an effect on the disclosures of the Company&#8217;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#8217;s consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c6_cont_1" escape="true" name="sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" id="ixv-42428"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c6_cont_2" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a
new definition of &#8220;accounting estimates&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c6_cont_3" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForMeasuringInventories-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="ixv-42446"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForMeasuringInventories-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c6_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="ixv-42459"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">y.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c6_cont_2" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">The
Company sells products directly to customers mainly through its online Amazon stores.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c6_cont_3" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="background-color: white">&#160;</span></p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c6_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" id="ixv-42481"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">z.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c6_cont_2" id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 282; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock-c6_cont_1" escape="true" name="sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" id="ixv-42525"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING
    JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount rate for a lease
    liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental
borrowing rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar
security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there
are no financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk,
the lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the fair value
    of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on
its management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are
based, among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best
professional judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the
outcome of the claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 283; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and/or
    termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or
not exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying
asset to the Company&#8217;s operation and whether it is a specialized asset, the company&#8217;s past experience with similar leases,
etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial
    instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When the fair values of financial
assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value
is determined using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken
from observable markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models
are tested for validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="ixv-42669"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock" id="ixv-42679"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105226">1,866</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105227">3,443</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105228">210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105229">131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105230">2,076</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105231">3,574</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 284; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="ixv-42761"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfInvertoryTextBlock" id="ixv-42771"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-105232">73</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-105233">198</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-105234">669</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-105235">470</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-105236">742</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-105237">668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="ixv-42829"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclourseOfAccountsReceivablesTableTextBlock" id="ixv-42839"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ValueAddedTaxReceivables" scale="3" unitRef="usd" id="ixv-105238">62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ValueAddedTaxReceivables" scale="3" unitRef="usd" id="ixv-105239">45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-105240">203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-105241">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-105242">275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-105243">40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-105244">540</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-105245">131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfSignificantInvestmentsInAssociatesExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory" id="ixv-42907"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES
    </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of Orimmune Bio Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 22, 2016, the Company entered
into a share transfer agreement (the &#8220;Transfer Agreement&#8221;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#8220;Orimmune&#8221;)
and Karma Link Ltd. (the &#8220;Buyer&#8221;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On December 13, 2018, an additional
amendment to the Transfer Agreement was signed between the parties, under which it was agreed that Orimmune will be assigned certain
rights in intellectual property (&#8220;IP&#8221;) related to the licensed technology owned by the Company subject to certain conditions
precedent which were still not met as of December 31, 2023. As of the Approval Date, the conditions precedent have not yet been completed
and the assignment of the IP related to the licensed technology owned by us has not yet been transferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coeruleus - Joint Venture
    Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On May 15, 2020, the Company entered
into a series of transactions (together, the &#8220;Joint Venture Transaction&#8221;), including a definitive share transfer agreement
with Capital Point Ltd. (&#8220;Capital Point&#8221;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital
Point sold to Evero <ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesSold" scale="0" unitRef="shares" id="ixv-105246">5,952,469</ix:nonFraction> ordinary shares, NIS <ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesParValue" scale="0" unitRef="ilsPershares" id="ixv-105247">0.01</ix:nonFraction> par value each, of Coeruleus Ltd. (the &#8220;Purchased Coeruleus Shares&#8221;
and &#8220;Coeruleus,&#8221; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately <ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-105248">46</ix:nonFraction>%), engaged in,
among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce
the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic
encephalopathy. The Purchased Coeruleus Shares represented approximately <ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-105249">35</ix:nonFraction>% of the issued and outstanding share capital of Coeruleus.
In consideration thereof, Evero issued and sold to Capital Point <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesSold" scale="0" unitRef="shares" id="ixv-105250">176,470</ix:nonFraction> ordinary shares, NIS <ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesParValue" scale="0" unitRef="ilsPershares" id="ixv-105251">1.00</ix:nonFraction> par value each, constituting <ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-105252">15</ix:nonFraction>% of
the issued and outstanding share capital of Evero, which was valued at $<ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FairMarketValue" scale="3" unitRef="usd" id="ixv-105253">351</ix:nonFraction>, based on apportionment of the fair market value of the Company
as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately <ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-105254">11</ix:nonFraction>% of Coeruleus&#8217; issued
and outstanding share capital. The transaction costs of $<ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" scale="3" unitRef="usd" id="ixv-105255">51</ix:nonFraction> were also capitalized as part of the investment in associate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#8220;Capital Point Warrant&#8221;) to purchase
$<ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfOrdinaryShares" scale="3" unitRef="usd" id="ixv-105256">340</ix:nonFraction> of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is
equal to the closing price of the Company&#8217;s ordinary shares on the trading day on which the notice of exercise was actually received
by the Company and shall be paid by transferring to the Company a duly executed share transfer deed for <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="sprcy:DulyExecutedShareTransferDeedForOrdinaryShares" scale="0" unitRef="shares" id="ixv-105257">9,577</ix:nonFraction> ordinary shares of Evero.
The Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 285; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coeruleus - Joint Venture Transaction (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSignificantInvestmentsInAssociatesExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $<ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentFromShareholders" scale="3" unitRef="usd" id="ixv-105258">30</ix:nonFraction>. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than <ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="sprcy:IssuedAndOutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-105259">1</ix:nonFraction>% of the issued and outstanding shares of
Coeruleus. As of December 31, 2023, the fair value of the Company&#8217;s investment in Coeruleus is $<span style="-sec-ix-hidden: hidden-fact-148">nil</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitocareX - Joint Venture
    Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $<ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-105260">700</ix:nonFraction>, and agreed to invest over the next two years, an additional $<ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-105261">1,000</ix:nonFraction>, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a <ix:nonFraction contextRef="c125" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-105262">50.01</ix:nonFraction>% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $<ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-105263">700</ix:nonFraction> to MitoCareX. As of December 31, 2022, the Company owns
<ix:nonFraction contextRef="c127" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-105264">31.48</ix:nonFraction>% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $<ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-105265">400</ix:nonFraction> in MitoCareX and increase its share ownership in MitoCareX Bio from <ix:nonFraction contextRef="c129" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-105266">31.48</ix:nonFraction>% to <ix:nonFraction contextRef="c130" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-105267">41.92</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $<ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-105268">600</ix:nonFraction> in MitoCareX and increase its share ownership in MitoCareX Bio from <ix:nonFraction contextRef="c132" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-105269">41.92</ix:nonFraction>% to <ix:nonFraction contextRef="c133" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-105270">52.73</ix:nonFraction>%. Notwithstanding the above, the
Company and MitoCare X agreed for the additional $<ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInstallment" scale="3" unitRef="usd" id="ixv-105271">600</ix:nonFraction> installment to be deferred to March 25, 2024. As of the date of this report the
$<ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentPaid" scale="3" unitRef="usd" id="ixv-105272">600</ix:nonFraction> installment has been paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $<ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-105273">210</ix:nonFraction> (for the year ended December 31, 2022
- $<ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-105274">109</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="ixv-43008"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsDate" scale="3" unitRef="usd" id="ixv-105275">700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-105276">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105277">591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAchievementOfFirstMilestone" scale="3" unitRef="usd" id="ixv-105278">400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-105279">210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105280">781</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 286; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" id="ixv-43094"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN FINANCIAL
    ASSETS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2022, the Company invested $<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAmount" scale="3" unitRef="usd" id="ixv-105281">1,500</ix:nonFraction> in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedButNotFullyPaid" scale="0" unitRef="shares" id="ixv-105282">230,769</ix:nonFraction> common shares of Clearmind, resulting in the Company holding <ix:nonFraction contextRef="c136" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-105283">9.33</ix:nonFraction>% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; &#160; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company&#8217;s shares in Clearmind was reduced from <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-105284">230,769</ix:nonFraction> common shares to <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-105285">7,692</ix:nonFraction>. As of December 31, 2023, the listed share price of Clearmind on Nasdaq was $<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:SharePricePerShare" scale="0" unitRef="usdPershares" id="ixv-105286">2.81</ix:nonFraction>, and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2023, of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLoss" scale="3" unitRef="usd" id="ixv-105287">727</ix:nonFraction> on its investment (for the year ended December 31, 2022 - $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLoss" scale="3" unitRef="usd" id="ixv-105288">771</ix:nonFraction>). &#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 25, 2023, the Company entered into an investment agreement (the &#8220;Agreement&#8221;) with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;), an Israeli company traded on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) and the leading parallel importer and distributor of vehicles in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS <ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="ils" id="ixv-105289">2,500</ix:nonFraction>,000 in cash, in exchange for ordinary shares, NIS <ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-105290">0.05</ix:nonFraction> par value, of AutoMax based on a price per share of NIS <ix:nonFraction contextRef="c142" decimals="1" format="ixt:num-dot-decimal" name="sprcy:PricePerShare" scale="0" unitRef="ilsPershares" id="ixv-105291">0.5</ix:nonFraction>. As of December 31, 2023, the listed share price of AutoMax on the TASE was NIS <ix:nonFraction contextRef="c142" decimals="3" format="ixt:num-dot-decimal" name="sprcy:SharePricePerShare" scale="0" unitRef="ilsPershares" id="ixv-105292">0.384</ix:nonFraction>, and the Company has recorded a loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLoss" scale="3" unitRef="usd" id="ixv-105293">158</ix:nonFraction> on its investment.</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory" id="ixv-43122"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 1, 2020, the Company
entered into a one-year lease agreement with a third party for an area of approximately <ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-105294">100</ix:nonFraction> square meters for the Company&#8217;s offices
in the district of Tel Aviv, Israel. The yearly lease fee was set at approximately $<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LeaseFee" scale="3" unitRef="usd" id="ixv-105295">44</ix:nonFraction>, linked to the NIS. The lease expired on <ix:nonNumeric contextRef="c144" format="ixt:date-monthname-day-year-en" name="sprcy:ExpireTerm" id="ixv-105296">August
31, 2021</ix:nonNumeric>. The Company did not exercise its option to extend the lease until August 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 1, 2021, the Company entered
into a two-year joint lease agreement with a third party and for a total area of approximately <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-105297">240</ix:nonFraction> square meters, whereby the Company
occupies approximately <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-105298">120</ix:nonFraction> square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel. The Company and the third
party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately $<ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LeaseFee" scale="3" unitRef="usd" id="ixv-105299">40</ix:nonFraction>, linked to the NIS.
On July 7, 2023, the lease was extended until June 30, 2025.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 287; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="ixv-43162"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY AND EQUIPMENT,
    NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="ixv-43172"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Assets owned and used by the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/>
    equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105300">11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105301">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105302">78</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105303">122</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">New lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105304">103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105305">103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105306">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105307">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105308">181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105309">225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105310">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105311">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105312">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105313">65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105314">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105315">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105316">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105317">52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105318">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105319">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105320">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105321">117</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-105322">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-105323">28</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-105324">75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-105325">108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105326">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105327">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105328">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105329">114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105330">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105331">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105332">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105333">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105334">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105335">78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-105336">122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105337">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105338">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105339">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105340">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105341">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105342">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105343">39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105344">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105345">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105346">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105347">59</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-105348">65</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-105349">8</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-105350">30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-105351">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-105352">57</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2023, 2022 and 2021 amounted to $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-105353">52</ix:nonFraction>, $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-105354">43</ix:nonFraction> and $<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-105355">32</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfIntangibleAssetsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="ixv-43797"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;),
American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the
Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-105356">4,540</ix:nonFraction> and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" scale="3" unitRef="usd" id="ixv-105357">1,120</ix:nonFraction> during the 12-month period following the closing of the Acquisition.
The Company paid an additional $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseCosts" scale="3" unitRef="usd" id="ixv-105358">321</ix:nonFraction> as purchase costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, the Company issued to
M.R.M $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsToPurchase" scale="3" unitRef="usd" id="ixv-105359">15,000</ix:nonFraction> worth of warrants to purchase ordinary shares of the Company at an exercise price of $<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-105360">7.00</ix:nonFraction> per share (with a cashless exercise
mechanism) and with an exercise period of <ix:nonNumeric contextRef="c6" format="ixt-sec:durwordsen" name="sprcy:ExercisePeriod" id="ixv-105361">five years</ix:nonNumeric> from the closing of the Acquisition (the &#8220;September 2022 Warrants&#8221;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $<ix:nonFraction contextRef="c164" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" unitRef="usd" id="ixv-105362">100</ix:nonFraction> million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $<ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="sprcy:pricePerShare" scale="0" unitRef="usdPershares" id="ixv-105363">10.00</ix:nonFraction> or above.&#160;</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 288; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfIntangibleAssetsExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AmountTotal" scale="3" unitRef="usd" id="ixv-105364">4,861</ix:nonFraction> as an intangible asset, to be amortized over a period of <ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" id="ixv-105365">10</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-105366">1,042</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of <ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="sprcy:RevenueTerm" id="ixv-105367">8.7</ix:nonNumeric>
years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined
based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#8217;s expectations
that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter of <ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="sprcy:GrowthRatePercentage" scale="-2" unitRef="pure" id="ixv-105368">13.8</ix:nonFraction>%
and a declining growth rate for the long term, reaching <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:LongTermPercentage" scale="-2" unitRef="pure" id="ixv-105369">2</ix:nonFraction>% at the terminal year. Theoretical royalties arising from the brand were capitalized
at a discount rate of <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" unitRef="pure" id="ixv-105370">20.6</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock" id="ixv-43858"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseofAssets" scale="3" unitRef="usd" id="ixv-105371">4,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost" scale="3" unitRef="usd" id="ixv-105372">144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105373">4,717</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-105374">1,042</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost" scale="3" unitRef="usd" id="ixv-105375">486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105376">3,189</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2023, the Company recognized depreciation expenses in respect to intangible asset in the amount of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105377">486</ix:nonFraction> (for the year ended December
31, 2022 - $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105378">144</ix:nonFraction>).&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-43922"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADE PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfTradePayables" id="ixv-43932"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AccruedExpenses" scale="3" unitRef="usd" id="ixv-105379">538</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AccruedExpenses" scale="3" unitRef="usd" id="ixv-105380">901</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-105381">264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-105382">298</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-105383">802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-105384">1,199</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 289; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfOtherAccountsPayableTextBlock" id="ixv-44014"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" id="ixv-44024"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-105385">48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-105386">102</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-105387">104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-105388">77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-105389">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-105390">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-105391">185</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-105392">193</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-44092"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of financial
    assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c6_cont_1" escape="true" name="sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities" id="ixv-44110"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105393">2,141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105394">3,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-105395">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-105396">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-105397">45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-105398">203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-105399">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-105400">659</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-105401">591</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-105402">6,065</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-105403">4,316</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-105404">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-105405">102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-105406">532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-105407">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-105408">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-105409">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-105410">656</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-105411">2,866</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 290; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top"> <td style="text-align: justify; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of financial assets and financial liabilities: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c6_cont_1"><ix:continuation continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c6_cont_2" id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison
between the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2023, and 2022, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair
                                            Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105412">2,141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105413">2,141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-105414">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-105415">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-105416">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-105417">62</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-105418">203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-105419">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-105420">659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-105421">659</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-105422">6,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-105423">6,065</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-105424">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-105425">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-105426">532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-105427">532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-105428">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-105429">76</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-105430">656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-105431">656</ix:nonFraction></td><td style="text-align: left"/></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105432">3,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105433">3,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-105434">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-105435">45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-105436">46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-105437">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-105438">591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-105439">591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-105440">4,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-105441">4,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-105442">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-105443">102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-105444">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-105445">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-105446">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-105447">27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-105448">2,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-105449">2,866</ix:nonFraction></td><td style="text-align: left"/></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 291; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c6_cont_3" id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c6_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dekel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#8220;Dekel&#8221;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#8220;Private Placement&#8221;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#8220;Notes&#8221;), with an aggregate original principal amount of approximately
$<ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="3" unitRef="usd" id="ixv-105450">350</ix:nonFraction>, at an aggregate purchase price of $<ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" scale="3" unitRef="usd" id="ixv-105451">315</ix:nonFraction> to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to <ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-105452">12,088</ix:nonFraction> ordinary shares of the Company (the &#8220;Private Placement Warrant&#8221;) and <ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-105453">1,538</ix:nonFraction> ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $<ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="3" unitRef="usd" id="ixv-105454">220</ix:nonFraction> at a purchase price of $<ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasePrice" scale="3" unitRef="usd" id="ixv-105455">5,148</ix:nonFraction>. The Notes are
unsecured, have a maturity date of <ix:nonNumeric contextRef="c165" format="ixt:date-monthname-day-year-en" name="sprcy:MaturityDate" id="ixv-105456">March 23, 2021</ix:nonNumeric>, bear interest at a rate of <ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-105457">12</ix:nonFraction>% per annum, and may be converted, at the election of
the holder, into ordinary shares at an initial conversion price of $<ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InitialConversionPrice" scale="0" unitRef="usdPershares" id="ixv-105458">0.35</ix:nonFraction> per ordinary share (the &#8220;Fixed Conversion Price&#8221;),
subject to adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower
of the Fixed Conversion Price or <ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ConversionPrice" scale="-2" unitRef="pure" id="ixv-105459">70</ix:nonFraction>% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which
the ordinary shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion
is received by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing
date and on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $<ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinaryShareExercisePrice" scale="0" unitRef="usdPershares" id="ixv-105460">0.35</ix:nonFraction>
per ordinary share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 292; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dekel (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c6_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" id="ixv-44944"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-105461">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-105462">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-105463">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-105464">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-105465">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-105466">122.01</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-105467">3.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-105468">4.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-105469">0.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-105470">4.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-105471">19.66</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-105472">11.18</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-105473">637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-105474">637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-105475">637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-105476">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-105477">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-105478">0.36</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2023, the Company expects
to settle all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Refer to Note 14a for more information.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 293; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="ixv-45122"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment
term which establish the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. <ix:nonNumeric contextRef="c6" continuedAt="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c6_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" id="ixv-105479">These contributions and contributions for compensation represent defined contribution plans.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
    in respect of defined contribution plans</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-105480">105</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-105481">115</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-105482">98</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-45196"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to
    the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Israeli statutory corporate tax
rate and real capital gains tax rate were <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-105483"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-105484"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-105485">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2023, 2022, and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward tax losses
    and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company&#8217;s
net carryforward tax losses are estimated to grow to approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:OperatingLossCarryforwardsTaxAmount" scale="3" unitRef="usd" id="ixv-105486">62,000</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 294; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-45264"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES,
    COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with
    Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments
include: <ix:nonNumeric contextRef="c6" name="sprcy:DekelLicenseAgreementDescription" id="ixv-105487">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 14, 2019, an amendment to
the Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention
to exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which
are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field
of activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect
the foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment also prescribes for
a specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined
under the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AnnualInvestment" scale="3" unitRef="usd" id="ixv-105488">350</ix:nonFraction>. The Amendment
also included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive
Chairman of the Board and former interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $<ix:nonFraction contextRef="c178" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalMilestoneAmount" scale="3" unitRef="usd" id="ixv-105489">75</ix:nonFraction>, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 295; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c6_cont_2" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with
    Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement with Hannover
    Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $<ix:nonFraction contextRef="c179" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentAmount" scale="3" unitRef="usd" id="ixv-105490">122</ix:nonFraction> out of a total estimated amount
of approximately $<ix:nonFraction contextRef="c179" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-105491">776</ix:nonFraction>. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of
the first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under
a new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $<ix:nonFraction contextRef="c180" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-105492">1,385</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $<ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-105493">370</ix:nonFraction>.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 296; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c6_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit challenges a certain warrant issued by the Company to Capital Point (the &#8220;Capital Point Warrant&#8221;) to purchase $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalOrdinaryShares" scale="3" unitRef="usd" id="ixv-105494">340,000</ix:nonFraction> of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit claims damages in the amount of NIS <ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="3" unitRef="ils" id="ixv-105495">10,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c2" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="6" unitRef="usd" id="ixv-105496">2.75</ix:nonFraction> million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of December 31, 2023, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-45421"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-45437"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-105497">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-105498">706,683</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-105499">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-105500">261,494</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 297; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c6_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#8217;s share capital
to <ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105501">75,000,000</ix:nonFraction> ordinary shares with <span style="-sec-ix-hidden: hidden-fact-208">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 18, 2023, <ix:nonNumeric contextRef="c184" name="sprcy:DescriptionOfReverseShareSplit" id="ixv-105502">the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital
up to a ratio of 30:1</ix:nonNumeric> (the &#8220;Third Reverse Split&#8221;). Following the implementation of the Third Reverse Split, the Company&#8217;s
authorized share capital was adjusted under the Company&#8217;s Articles, which as of the date hereof consists of <ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105503">75,000,000</ix:nonFraction> ordinary
shares, <span style="-sec-ix-hidden: hidden-fact-209">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfIssuedAndOutstandingShareCapital" id="ixv-45556"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number
                                            of<br/> ordinary</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-105504">261,494</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; in respect of investment in
    affiliate (Note 18f)</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" scale="0" unitRef="shares" id="ixv-105505">13,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share issued to a consultant (Note 19(a)(5))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:ShareIssuedToAConsultant" scale="0" unitRef="shares" id="ixv-105506">7,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of shelf prospectus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus" scale="0" unitRef="shares" id="ixv-105507">296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of August 2023 financing round (Note 18i)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-105508">237,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of rounding errors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors" scale="0" unitRef="shares" id="ixv-105509">2,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of October 2023 financing round
    (Note 18j)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" scale="0" unitRef="shares" id="ixv-105510">182,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-105511">706,683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 298; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c6_cont_3" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c6_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at the shareholders
meeting, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital management in the
    Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuance of
    ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 2, 2022, the Company issued
a consultant <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105512">923</ix:nonFraction> ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 1, 2022, the Company issued
a consultant <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105513">1,423</ix:nonFraction> ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 22, 2023, the Company issued
<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105514">13,858</ix:nonFraction> ordinary shares in respect of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement entered
into by and among Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also note 25a)</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 299; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c6_cont_4" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c6_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $<ix:nonFraction contextRef="c189" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceeds" scale="3" unitRef="usd" id="ixv-105515">8,150</ix:nonFraction>, providing for the issuance of an
aggregate of <ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-105516">44,332</ix:nonFraction> units, as follows: (a) <ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-105517">35,243</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-105518">183.82</ix:nonFraction> per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series B
Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase
half the number of units, and (b) <ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-105519">9,089</ix:nonFraction> pre-funded units at a price of $<ix:nonFraction contextRef="c191" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-105520">183.79</ix:nonFraction> per unit, consisting of (i) one pre-funded warrant to
purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The 2021 Series A Warrants have an
exercise price of&#160;$<ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-105521">183.82</ix:nonFraction>&#160;per ordinary share and the 2021 Series B Warrants have an exercise price of&#160;$<ix:nonFraction contextRef="c193" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-105522">275.60</ix:nonFraction>&#160;per
ordinary share). Both were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c194" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-105523">five years</ix:nonNumeric> from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2021, the Company issued <ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-105524">4,929</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-105525">385</ix:nonFraction> 2021 Series A Warrants and the exercise of <ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-105526">4,544</ix:nonFraction> of
pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2022, the Company issued <ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-105527">3,846</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-105528">3,846</ix:nonFraction> pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $<ix:nonFraction contextRef="c199" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceeds" scale="3" unitRef="usd" id="ixv-105529">10,210</ix:nonFraction>(the &#8220;June 2022 Financing Round&#8221;), providing for the issuance
of an aggregate of <ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-105530">136,388</ix:nonFraction> units and pre-funded units, as follows: (a) <ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-105531">12,885</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-105532">74.88</ix:nonFraction> per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) <ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-105533">123,504</ix:nonFraction> pre-funded units at a price of $<ix:nonFraction contextRef="c202" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-105534">73.29</ix:nonFraction> per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$<ix:nonFraction contextRef="c203" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WarrantsExercisePrice" scale="0" unitRef="pure" id="ixv-105535">68.38</ix:nonFraction>&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c200" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-105536">seven years</ix:nonNumeric> from
the date of issuance.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 300; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c6_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" id="ixv-45861"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-105537">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-105538">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-105539">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-105540">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-105541">3.872</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-105542">3.97</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-105543">4.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-105544">19.656</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-105545">68.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-105546">68.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-105547">192</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-105548">2,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2022, the Company issued <ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-105549">123,504</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-105550">123,504</ix:nonFraction> pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 14, 2023, the Company closed
an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of <ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105551">212,500</ix:nonFraction> ordinary shares, at a purchase price of $<ix:nonFraction contextRef="c206" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-105552">5.20</ix:nonFraction> per
ordinary share and pre-funded warrants to purchase up to <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105553">37,500</ix:nonFraction> ordinary shares at a purchase price of $<ix:nonFraction contextRef="c207" decimals="3" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-105554">5.174</ix:nonFraction> per pre-funded warrant,
for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c206" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateGrossProceeds" scale="3" unitRef="usd" id="ixv-105555">1,300</ix:nonFraction>, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#8220;Aegis&#8221;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional <ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105556">37,500</ix:nonFraction> ordinary shares solely to
cover over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2023 Financing
    Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $<ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-105557">5,026</ix:nonFraction>, before
deducting fees to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the private placement,
the Company issued an aggregate of <ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-105558">1,930,108</ix:nonFraction> units, each unit consisting of two pre-funded warrants, or Pre-Funded Warrants. The Pre-Funded
Warrants have an exercise price of $<ix:nonFraction contextRef="c211" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-105559">0.001</ix:nonFraction>, are immediately exercisable upon issuance and have a term of five years from the date of issuance.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 301; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-45986"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT
    TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based
    payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" id="ixv-46004"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentsExpenses" scale="3" unitRef="usd" id="ixv-105560">34</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentsExpenses" scale="3" unitRef="usd" id="ixv-105561">264</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentsExpenses" scale="3" unitRef="usd" id="ixv-105562">27</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-105563">68</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-105564">633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-105565">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-105566">102</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-105567">897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-105568">43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2005 and 2015 ESOP
    and 2023 Plan of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#8220;2023 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="background-color: white">The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. </span>Under the 2023 Plan, the Company may grant its employees and other
service providers equity based incentive awards (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board approved
to reserve for <span style="background-color: white">issuance under the 2023 Plan <span style="-sec-ix-hidden: hidden-fact-210">1,000,0000</span> Ordinary Shares. As </span>of the date of
this report, no shares were issued.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 302; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c6_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board approved and granted <ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesGranted" scale="0" unitRef="shares" id="ixv-105569">45</ix:nonFraction> ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $<ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-105570">10,920.00</ix:nonFraction> per share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c6_cont_1" escape="true" name="sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" id="ixv-46154"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-105571">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-105572">76</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-105573">2.61</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-105574">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
was set at $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOption" scale="3" unitRef="usdPershares" id="ixv-105575">5,824</ix:nonFraction> per Share Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 10, 2019 (the &#8220;2019 Grant Date&#8221;), the Board approved the grant of 3 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2019 General Meeting&#8221;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 1 Share Options was not granted. Out of the 2 Share Options that were granted, 1 Share Options didn&#8217;t require the general meeting&#8217;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $<ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-105576">5,460.00</ix:nonFraction> per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">According to IFRS 2, &#8220;<i>Share-based
Payment</i>&#8221;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#8217;s approval was calculated based on parameters as of December 31,
2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c6_cont_2" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c6_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-105577">2,031.12</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-105578">4,004</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-105579">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c215" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-105580">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-105581">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c215" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-105582">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c219" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-105583">1.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c215" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-105584">1.67</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c219" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-105585">9.78</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c215" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-105586">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the 2019 General Meeting (valuated as of December 31, 2019) was
set at $<ix:nonFraction contextRef="c215" decimals="1" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOption" scale="0" unitRef="usdPershares" id="ixv-105587">2,966.6</ix:nonFraction> and $<ix:nonFraction contextRef="c216" decimals="1" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOption" scale="0" unitRef="usdPershares" id="ixv-105588">1,328.6</ix:nonFraction>, per Share Option, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 303; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements: (Cont.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c6_cont_3" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c6_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of <ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsGranted" scale="0" unitRef="shares" id="ixv-105589">6,851</ix:nonFraction> Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-105590">169</ix:nonFraction> per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c6_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;10,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-105591">129.74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c221" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-105592">174.98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-105593">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c221" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-105594">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-105595">133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c221" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-105596">134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-105597">2.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c221" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-105598">1.46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c220" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-105599">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c221" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-105600">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
granted on January 3, 2022, was set at $<ix:nonFraction contextRef="c217" decimals="2" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOptionsGranted" scale="0" unitRef="usdPershares" id="ixv-105601">158.34</ix:nonFraction> per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $<ix:nonFraction contextRef="c218" decimals="2" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOptionsGranted" scale="0" unitRef="usdPershares" id="ixv-105602">114.66</ix:nonFraction> per Share Option. The Share Options&#8217; vesting period was set to commence retroactively from April 21, 2021, and
end at April 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company issued to consultants <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-105603">7,942</ix:nonFraction> ordinary shares in respect of services rendered. The ordinary shares were granted at a discount rate of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesGrantedDiscountRate" scale="-2" unitRef="pure" id="ixv-105604">25</ix:nonFraction>% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:FairValueOfOrdinarySharesGranted" scale="0" unitRef="usd" id="ixv-105605">94</ix:nonFraction>. </span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 304; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c6_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c6" continuedAt="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock-c6_cont_1" escape="true" name="sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" id="ixv-46453"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/>
    price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the
    year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-105606">7,060</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-105607">166.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" scale="0" sign="-" unitRef="shares" id="ixv-105608">47</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-105609">144.55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-105610">7,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-105611">166.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-105612">5,869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-105613">165.58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-105614">209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-105615">76.70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-105616">6,851</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-105617">169</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of
    the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-105618">7,060</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-105619">166.14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of
    the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-105620">4,141</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-105621">163.80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Share Options were granted
    during 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was <ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption" id="ixv-105622">4.03</ix:nonNumeric> years and <ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption" id="ixv-105623">5.03</ix:nonNumeric> years as of December 31, 2023, and 2022, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices of Share Options outstanding at the end of the year was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-105624">169</ix:nonFraction> - $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-105625">21,944</ix:nonFraction> (inclusive) as of December 31, 2023, and 2022, respectively.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 305; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="ixv-46658"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES AND COST OF
    REVENUES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company sells products directly
to customers mainly through its online Amazon stores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s standard
contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return, the Company recognizes
revenue based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a
significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable
if it expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its
estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December
31, 2023, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables.
A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the
customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In certain contracts, the Company
evaluates the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining
the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis
based upon its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible
for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other
factors. Based on its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore,
sales are recorded on a gross basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" id="ixv-46674"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022(*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Amazon fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Purchased goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd" id="ixv-105626">672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd">301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Storage</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd" id="ixv-105628">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd" id="ixv-105630">683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" id="ix_11_fact" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd">322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US">Reclassified to correlate with common practice in industry and better reflect profit and loss.</ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 306; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationExplanatory" id="ixv-46831"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:-
    </b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION
    TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss" id="ixv-46841"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year ended December&#160;31,</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Research
    and development expenses:</span></i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and related expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105633">392</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105634">436</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105635">357</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105636">34</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105637">264</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c239" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105638">27</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory,
    professional and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105639">719</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105640">750</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c242" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105641">934</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and preclinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c243" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105642">101</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c244" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105643">703</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105644">165</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105645">254</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105646">369</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c248" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105647">172</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemistry
    and formulations</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c249" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105648">141</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c250" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105649">281</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c251" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105650">335</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105651">1,641</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105652">2,803</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-105653">1,990</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">General
    and administrative expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and related expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105654">415</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105655">437</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105656">256</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105657">68</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105658">633</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c239" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105659">16</ix:nonFraction></span></td>
    <td>&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amazon
    fees</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c252" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105660">1,042</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c253" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105661">424</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c255" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105662">145</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105663">90</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    and directors&#8217; fees</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105664">2,594</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105665">2,499</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105666">2,417</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    development expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c260" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105667">86</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c261" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105668">161</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c262" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105669">5</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105670">202</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c264" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105671">162</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c265" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105672">165</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    maintenance, rent and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c266" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105673">110</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)<ix:nonFraction contextRef="c267" decimals="-3" format="ixt:num-dot-decimal" id="ix_12_fact" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd">80</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c268" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105675">135</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
    relations and business expenses</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c269" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105676">369</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c270" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105677">1,486</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c271" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105678">784</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105679">5,031</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105680">5,972</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105681">3,778</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Other
    expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company&#8217;s
    share of losses of company accounted for at equity, net</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-105682">210</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-105683">109</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Finance
    income:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change
    in fair value of financial liabilities designated at fair value through profit or loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c272" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105684">2,205</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c273" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105685">7,832</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    rate differences, net</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c275" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105686">14</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105687">2,219</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105688">7,832</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance
    expenses:</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    expenses related to warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c279" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105689">1,204</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c280" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105690">6</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    rate differences, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c276" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105691">4</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c277" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105692">3</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses
    from remeasurement of investment in financial assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c281" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105693">1,046</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c282" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105694">770</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    expense in respect of leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c284" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105695">9</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c285" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105696">15</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c286" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105697">4</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    expenses from interest and commissions</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c288" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105698">21</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c289" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105699">8</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105700">1,055</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105701">2,014</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105702">21</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice
                                            in industry and better reflect profit and loss.</td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 307; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="ixv-47700"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 22:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS PER SHARE/ADS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c6" continuedAt="_EarningsPerShareExplanatory-c6_cont_1" escape="true" name="ifrs-full:EarningsPerShareExplanatory" id="ixv-47716"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_EarningsPerShareExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares
    (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares
    (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>In</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>thousands</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares" id="ixv-105703">408</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-105704">5,883</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares" id="ixv-105705">176</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-105706">2,592</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares" id="ixv-105707">79</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-105708">5,789</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares" id="ixv-105709">408</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-105710">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares" id="ixv-105711">176</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-105712">2,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares" id="ixv-105713">79</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-105714">5,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Loss per share retroactively adjusted in these
                                            consolidated statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see
                                            note 18a).</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The computation of diluted
    loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive
    effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Options to employees,
    officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable warrants
    to investors.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 308; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="ixv-48016"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The review of the CODM is carried
out according to the results of the segment&#8217;s activity. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="ixv-48032"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
    Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
    Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-105715">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-105716">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-105717">2,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-105718">2,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c290" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105719">5,359</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105720">414</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105721">5,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-105722">210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-105723">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-105724">1,164</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TaxExpense" scale="3" unitRef="usd" id="ixv-105725">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105726">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c293" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-105727">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-105728">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c293" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-105729">1,347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-105730">1,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment
    loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c292" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105731">8,405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c293" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-105732">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105733">8,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Company&#8217;s share of losses of company accounted for at equity,
    net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-105734">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-105735">5,818</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TaxExpense" scale="3" unitRef="usd" id="ixv-105736">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105737">2,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 309; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS (CONT.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfOperatingSegmentsExplanatory-c6_cont_1"><ix:continuation id="_DisclosureOfEntitysReportableSegmentsExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">External</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment
    loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c294" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105738">5,768</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-105739">5,768</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" unitRef="usd" id="ixv-105740">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105741">5,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-105742">7,069</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-105743">4,113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-105744">11,182</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-105745">1,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-105746">154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-105747">1,595</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-105748">9,664</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-105749">941</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-105750">10,605</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-105751">4,021</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-105752">135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-105753">4,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 310; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="ixv-48691"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS AND BALANCES
    WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c6" continuedAt="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory-c6_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" id="ixv-48707"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-105754">121</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-105755">108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-105756">95</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c304" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-105757">70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c305" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-105758">55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c6" continuedAt="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory-c6_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" id="ixv-48812"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-105759">40</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-105760">208</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-105761">2,985</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c6_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-48871"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c6_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-105762">1,204</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-105763">1,940</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-105764">962</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-105765">220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-105766">84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-105767">779</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-105768">43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands. Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands (see also note 25a).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#8220;Cooperation Agreement&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-105769">40</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-105770">208</ix:nonFraction>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, we invested $<ix:nonFraction contextRef="c300" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="6" unitRef="usd" id="ixv-105771">1.5</ix:nonFraction> million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for <ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExchangeOfCommonShares" scale="0" unitRef="shares" id="ixv-105772">7,692</ix:nonFraction> common shares of Clearmind, representing <ix:nonFraction contextRef="c301" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-105773">9.33</ix:nonFraction>% of the outstanding share capital of Clearmind (see also note 8).</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Amitai Weiss, our chairman
    of the board of directors, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 311; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" id="ixv-49022"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px; text-align: left"><b>NOTE 25:- </b></td><td style="text-align: justify"><b>SIGNIFICANT EVENTS DURING THE
                                            REPORTING PERIOD</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a <ix:nonFraction contextRef="c306" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestPercentgae" scale="-2" unitRef="pure" id="ixv-105774">49</ix:nonFraction>% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution<sup>TM</sup>, for $<ix:nonFraction contextRef="c307" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-105775">2,500</ix:nonFraction> in cash, and additional deferred cash payments of approximately $<ix:nonFraction contextRef="c306" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DeferredCashPayments" scale="3" unitRef="usd" id="ixv-105776">489,330</ix:nonFraction> accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#8217; Brands, the Company holds approximately <ix:nonFraction contextRef="c308" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-105777">51</ix:nonFraction>% of the share capital of SciSparc US.</span></td></tr> </table>

<p style="text-indent: 1.25in; margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the agreement, at the
closing of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217;
Brands provides management services to SciSparc US for the Wellution<sup>TM </sup>brand for a monthly fee of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FeeExpenses" scale="3" unitRef="usd" id="ixv-105778">20</ix:nonFraction> and Jeffs&#8217; Brands
received a one-time signing bonus in the amount of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BonusAmountReceived" scale="3" unitRef="usd" id="ixv-105779">51</ix:nonFraction>. The consulting agreement is for an undefined period of time and may be terminated
by either party with 30 days advance notice. On November 2023 the monthly fee reduced to $<ix:nonFraction contextRef="c309" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FeeExpenses" scale="3" unitRef="usd" id="ixv-105780">10</ix:nonFraction> thousand. For the year ended December 31,
2023, the Company has recorded management services expenses in the amount of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-105781">220</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, in connection with the
closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MutualShareExchangeAmount" scale="3" unitRef="usd" id="ixv-105782">288,238</ix:nonFraction> of ordinary
shares from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average
closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior
to the closing. Accordingly, the Company acquired <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesAcquired" scale="0" unitRef="shares" id="ixv-105783">35,345</ix:nonFraction> ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired <ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesAcquired" scale="0" unitRef="shares" id="ixv-105784">13,858</ix:nonFraction>
ordinary shares of the Company having an aggregate value of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateValue" scale="3" unitRef="usd" id="ixv-105785">288,238</ix:nonFraction>, which was adjusted from $<ix:nonFraction contextRef="c310" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustedAmountOfAggregateValue" scale="3" unitRef="usd" id="ixv-105786">300,000</ix:nonFraction> according to the <ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-105787">4.99</ix:nonFraction>% ownership
limit included in the definitive agreements. As of December 31, 2023, the listed share price of Jeff&#8217;s Brands on the NASDAQ was
$ <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ListedSharePrice" scale="0" unitRef="usdPershares" id="ixv-105788">3.05</ix:nonFraction>, and the Company has recorded a loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLossOnInvestment" scale="3" unitRef="usd" id="ixv-105789">180</ix:nonFraction> on its investment.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 312; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c6" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-49072"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS AFTER THE REPORTING
    DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD (&#8220;YA&#8221;),
which provided for the sale of up to $<ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" unitRef="usd" id="ixv-105790">20,000</ix:nonFraction> of the Company&#8217;s Ordinary Shares (the &#8220;Advance Shares&#8221;). Of the $<ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-105791">20,000</ix:nonFraction>
eligible to be sold pursuant to the SEPA, or the Commitment Amount, Company has sold <ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-105792">925,159</ix:nonFraction> ordinary shares as of the issuance date
of these financial statements. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of <ix:nonFraction contextRef="c311" decimals="2" format="ixt:num-dot-decimal" name="sprcy:SharePricePercentage" scale="-2" unitRef="pure" id="ixv-105793">97</ix:nonFraction>%
of the market price, which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive
trading days commencing on the trading day immediately following the delivery of an advance notice to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PrepaidAdvance" scale="3" unitRef="usd" id="ixv-105794">5,000</ix:nonFraction>, each a Pre-Paid Advance. Each Pre-Paid Advance will
be evidenced by a promissory note, each, a Promissory Note. Each Promissory Note will fully mature 24-months following its issuance and
shall accrue interest on the outstanding principal balance thereon at a rate of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AccruedInterestPercentage" scale="-2" unitRef="pure" id="ixv-105795">5</ix:nonFraction>% per annum, increasing to <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:CommitmentPercentage" scale="-2" unitRef="pure" id="ixv-105796">18</ix:nonFraction>% per annum upon an Event
of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note, the Company shall pay to
YA a monthly installment payment of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InstallmentPaymentPercentage" scale="-2" unitRef="pure" id="ixv-105797">10</ix:nonFraction>% of the original principal amount of the Promissory Note and accrued interest, payable in cash
or by submitting an advance notice, where YA will offset the amount due to be paid to us under such notice against an equal amount of
the monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash, the installment amount shall also
include a payment premium in the amount of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PaymentPremiumPercentage" scale="-2" unitRef="pure" id="ixv-105798">5</ix:nonFraction>% of the principal amount of the installment payment. The Promissory Note contains the Company&#8217;s
customary representations and warranties and Events of Default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of <ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-105799">55,293</ix:nonFraction> of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-105800">200</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred to register under the Securities Act the offer
and sale of the Ordinary Shares pursuant to the SEPA by YA.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - - - - - - - - - - - - - - - - - - - - -
- -</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 313; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INTERIM CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF JUNE 30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">Consolidated Statements of Financial Position</a></b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-57 - F-58</b></span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_002">Consolidated Statements of Profit or Loss and Other Comprehensive Loss</a> </b></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-59</b></span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_003">Consolidated Statements of Changes in Equity (Deficit)</a></b></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>F-60 <span style="font-size: 10pt">- F-62</span></b></span></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_004">Consolidated Statements of Cash Flows</a></b></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>F-63 <span style="font-size: 10pt">- F-65</span></b></span></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_005">Notes to Interim Consolidated Financial Statements</a> </b></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-66 - F-80</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 314; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><div><a id="a_001"></a></div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: justify; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">&#8239;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105801">252</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105802">2,081</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105803">2,076</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Restricted deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105804">64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105805">44</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-105806">65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Short-term deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-105807">2,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-105808">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Trade receivables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-105809">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-105810">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-105811">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Other accounts receivable</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-105812">298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-105813">815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-105814">540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-105815">415</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-105816">660</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-105817">742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-105818">3,356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-105819">3,643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-105820">6,445</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Intangible asset, net</td><td>&#160;</td>
    <td style="text-align: center">4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105821">3,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105822">4,474</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105823">3,189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Related parties</td><td>&#160;</td>
    <td style="text-align: center">5,6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd" id="ixv-105824">2,448</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Investment in company account for at equity</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-105825">1,196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-105826">893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-105827">781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: center">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-105828">403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-105829">849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-105830">659</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105831">73</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105832">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-105833">108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-105834">7,126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-105835">6,249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-105836">4,737</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-105837">10,482</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-105838">9,892</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-105839">11,182</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 315; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-105840">1,164</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-105841">1,247</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-105842">802</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other accounts payable</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-105843">253</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-105844">153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-105845">185</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Warrants</td><td>&#160;</td>
    <td style="text-align: center">8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-105846">345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-105847">1,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-105848">532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-105849">38</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-105850">52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-105851">1,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-105852">3,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-105853">1,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">NON-LIABILITIES</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-105854">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-105855">24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</td><td>&#160;</td>
    <td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share capital and premium</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-105856">67,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-105857">58,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-105858">64,526</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Reserve from share-based payment transactions</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-105859">5,298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-105860">5,248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-105861">5,282</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-105862">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-105863">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-105864">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign currency translation reserve</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-105865">497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-105866">497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-105867">497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Transactions with non-controlling interests</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-105868">810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-105869">712</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-105870">810</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-105871">72,133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-105872">66,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-105873">68,691</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-105874">6,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-105875">4,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-105876">7,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105877">1,736</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105878">2,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105879">1,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105880">8,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105881">6,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105882">9,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total liabilities and equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-105883">10,482</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-105884">9,892</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-105885">11,182</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 316; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><div><a id="a_002"></a></div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Six months ended <br/> June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Year Ended<br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Audited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Note</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">USD in thousands, except per
    share amounts</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Revenues</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="-keep: true">&#8239;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-105886">840</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-105887">1,972</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-105888">2,879</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Cost of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-105889">366</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-105890">508</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-105891">683</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Gross profit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-105892">474</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-105893">1,464</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-105894">2,196</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Research and development expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">10a</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-105895">841</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-105896">781</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-105897">1,641</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Sales and marketing</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-105898">528</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-105899">729</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-105900">1,297</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Impairment of intangible asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-105901">1,042</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">General and administrative expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">11b</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105902">2,632</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105903">2,921</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-105904">5,031</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Operating loss</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105905">3,527</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105906">2,967</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-105907">6,815</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Company&#8217;s share of losses of companies accounted for
    at equity, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-105908">208</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-105909">99</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-105910">210</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Finance income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105911">323</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105912">1,024</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-105913">2,219</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Finance expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105914">272</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105915">877</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-105916">1,055</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Loss before income taxes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-105917">3,684</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-105918">2,919</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-105919">5,861</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Taxes on income</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-105920">5</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-105921">13</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-105922">22</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total comprehensive loss</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105923">3,679</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105924">2,932</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105925">5,883</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Attributable to:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Equity holders of the Company</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-105926">3,442</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-105927">2,880</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-105928">5,122</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-105929">237</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-105930">52</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-105931">761</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105932">3,679</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105933">2,932</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105934">5,883</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Weighted average outstanding shares (basic and diluted)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares" id="ixv-105935"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares" id="ixv-105936">2,166,282</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares" id="ixv-105937"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares" id="ixv-105938">270,354</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares" id="ixv-105939"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares" id="ixv-105940">407,681</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Basic and diluted loss per share attributable to equity holders of
the Company:</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-105941"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-105942">1.70</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" id="ix_7_fact" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares">10.85</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">(*)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-105945"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-105946">14.43</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">Loss per share retroactively adjusted in these consolidated statements of comprehensive loss to reflect &#8220;Reverse Share Split&#8221;. See Note 9.</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 317; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><div><a id="a_003"></a></div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>For the six months ended June 30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Attributable to equity holders of
    the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> capital<br/> and<br/>
    premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reserve<br/> from<br/> share-based<br/>
    payment<br/> transactions</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transactions<br/> with non-<br/>
    controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign<br/> currency<br/> translation<br/>
    reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-<br/> controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23.5%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2024</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105948">64,526</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105949">5,282</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105950">5,190</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105951">810</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105952">497</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-105953">68,691</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105954">7,614</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105955">1,973</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105956">9,587</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105957">3,442</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105958">3,442</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105959">237</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105960">3,679</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Issuance of shares, net of issuance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105961">2,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105962">2,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-105963">2,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105964">10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105965">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105966">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105967">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105968">67,258</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105969">5,298</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105970">5,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105971">810</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105972">497</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-105973">72,133</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105974">6,920</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105975">1,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105976">8,656</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 318; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>For the six months ended June 30, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Attributable to equity holders of
    the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> capital<br/> and<br/>
    premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reserve<br/> from<br/> share-based<br/>
    payment<br/> transactions</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transactions<br/> with non-<br/>
    controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign<br/> currency<br/> translation<br/>
    reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-<br/> controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23.5%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105977">58,592</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105978">5,180</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105979">5,190</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105980">559</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105981">497</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-105982">63,569</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105983">6,449</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-105984">6,449</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105985">2,880</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105986">2,880</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105987">52</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-105988">2,932</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital in respect of investment in affiliate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-105989">288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-105990">288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-105991">288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105992">153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105993">153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105994">2,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-105995">2,887</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Issuance of shares, net of issuance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" sign="-" unitRef="usd" id="ixv-105996">45</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" sign="-" unitRef="usd" id="ixv-105997">45</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" sign="-" unitRef="usd" id="ixv-105998">45</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-105999">63</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106000">68</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106001">131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106002">131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106003">58,898</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106004">5,248</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106005">5,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106006">712</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106007">497</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-106008">66,449</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106009">4,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106010">2,682</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106011">6,778</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.4pt">The accompanying notes are
an integral part of the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 319; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>For the year ended December 31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Attributable to equity holders of
    the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> capital<br/> and<br/>
    premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reserve<br/> from<br/> share-based<br/>
    payment<br/> transactions</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transactions<br/> with non-<br/>
    controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign<br/> currency<br/> translation<br/>
    reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-<br/> controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23.5%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106012">58,592</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106013">5,180</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106014">5,190</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106015">559</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106016">497</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-106017">63,569</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106018">6,449</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">-</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106019">6,449</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106020">5,122</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106021">5,122</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106022">761</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106023">5,883</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sales of minority interest in subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-106024">251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-106025">251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-106026">2,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-106027">2,985</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital in respect of investment in affiliate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-106028">288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-106029">288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-106030">288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital, net of issuance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-106031">5,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-106032">5,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-106033">5,552</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106034">94</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106035">102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106036">196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106037">196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106038">64,526</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106039">5,282</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106040">5,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106041">810</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106042">497</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-106043">68,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106044">7,614</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106045">1,973</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-106046">9,587</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 320; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><div><a id="a_004"></a></div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106047">3,679</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106048">2,932</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106049">5,883</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net loss to net cash used&#160;in
    operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Adjustments to the profit or loss items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-106050">219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-106051">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-106052">538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-106053">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Cost of share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106054">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106055">131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-106056">196</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Finance expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-106057">206</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-106058">1,023</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-106059">2,205</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Group&#8217;s share of losses of company accounted for at
    equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-106060">185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-106061">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-106062">210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Losses from remeasurement of investment
    in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-106063">256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-106064">855</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-106065">1,048</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-106066">480</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-106067">328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-106068">829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Working capital adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Decrease (increase) in other accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-106069">242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-106070">684</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-106071">409</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Increase (decrease) in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-106072">362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-106073">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-106074">397</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Increase (decrease) in other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-106075">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" sign="-" unitRef="usd" id="ixv-106076">40</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" sign="-" unitRef="usd" id="ixv-106077">8</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Decrease (increase) in trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-106078">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-106079">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-106080">55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Decrease (increase) in inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" unitRef="usd" id="ixv-106081">327</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" unitRef="usd" id="ixv-106082">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-106083">74</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" unitRef="usd" id="ixv-106084">1,002</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-106085">629</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-106086">833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Net cash used in operating activities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-106087">2,197</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-106088">3,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-106089">5,887</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 321; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Six months ended
June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">Year Ended  December&#160;31,</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2023</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Audited</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">USD in thousands</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Cash flows from investing activities:</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Investment (withdrawal) in restricted bank deposits</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106090">1</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106091">16</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-106092">5</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Investment (withdrawal) in short-term bank deposits</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" unitRef="usd" id="ixv-106093">692</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-106094">3,000</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Purchase of property and equipment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-106095">1</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="-keep: true">-</span></div></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Investment in a company accounted for at equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-106096">600</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-106097">400</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-106098">400</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Investments in financial assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-106099">689</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Loans to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-106100">2,400</ix:nonFraction>)</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="-keep: true">-</span></div></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Purchase of financial assets at fair
    value through profit or loss</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-106101">687</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"><span style="-keep: true">-</span></div></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Net cash provided by investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-106102">2,308</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-106103">1,071</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-106104">4,094</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Cash flows from financing activities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Proceeds from issuance of share capital and warrants (net
    of issuance expenses)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-106105">2,722</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" unitRef="usd" id="ixv-106106">50</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-106107">5,552</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Repayment of lease liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-106108">41</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-106109">26</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-106110">47</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Interest paid on lease liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-106111">7</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Proceeds from issuance of shares to minority interests in
    a subsidiary</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" scale="3" unitRef="usd" id="ixv-106112">2,887</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" id="ix_8_fact" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" scale="3" unitRef="usd">2,985</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><span style="-keep: true">(*)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Net cash provided by financing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><p style="margin: 0pt 0"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-106114">2,681</ix:nonFraction></span></p></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-106115">2,811</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-106116">8,483</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Increase (decrease) in cash and cash equivalents</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-106117">1,824</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-106118">1,493</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-106119">1,498</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Cash and cash equivalents at the beginning
    of the period</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106120">2,076</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106121">3,574</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106122">3,574</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Cash and cash equivalents at the end
    of the period</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106123">252</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106124">2,081</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106125">2,076</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">Reclassified</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 322; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">(a) <span style="text-decoration:underline">Significant non-cash transactions:</span></span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Mutual share exchange of
    ordinary shares (see note 10)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MutualShareExchangeOfOrdinaryShares" scale="3" unitRef="usd" id="ixv-106127">288</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MutualShareExchangeOfOrdinaryShares" scale="3" unitRef="usd" id="ixv-106128">288</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Right-of-use asset recognized with corresponding
    lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-106129">102</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 323; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><div><a id="a_005"></a></div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="ixv-53746"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 1:-
GENERAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221;
    or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a specialty clinical-stage pharmaceutical company, was incorporated in
    Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged
    in developing several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy field. In August 2015,
    the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on
    cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#916;9-tetrahydrocannabinol
    (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s disease and agitation,
    autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s ordinary shares are
        listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, the Company had three
    private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
    an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated
    under the laws of the State of Delaware: SciSparc Nutraceuticals Inc. (&#8220;SciSparc Nutraceuticals&#8221;) (together with Evero
    and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2023, the Company&#8217;s
    board of directors (the &#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be
    26:1, which became effective on September 28, 2023. Consequently, all share numbers, share prices, and exercise prices have been
    retroactively adjusted in these interim consolidated financial statements for all periods presented.&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">These interim consolidated financial statements should be read in conjunction
    with the Company&#8217;s annual financial statements for the year ended December 31, 2023, and accompanying notes, that were approved
    on March 31, 2024, and signed on April 1, 2024 (the &#8220;2023 Annual Consolidated Financial Statements&#8221;).</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 324; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 1:-
GENERAL (cont.)</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.5in"><span style="font-size: 10pt">c.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred a net loss of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106130">3,679</ix:nonFraction> and had negative cash flows from operating activities of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-106131">2,197</ix:nonFraction> for the six-month period ended June 30, 2024. As of June 30, 2024, the Company had an accumulated deficit of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-106132">72,133</ix:nonFraction> as a result of recurring operating losses. As of June 30, 2024, the Company&#8217;s cash and cash equivalents position is not sufficient to fund the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the consolidated financial statements. The Company&#8217;s pharmaceuticals operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue from its pharmaceutical products. These above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand and issuing equity and/or debt securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interim consolidated financial statements for the period ended June 30, 2024, do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The interim consolidated financial statements of the Company for the
    six-month period ended on June&#160;30, 2024, were approved for issuance on October 22, 2024 (the &#8220;Approval Date&#8221;). In
    connection with the preparation of the interim consolidated financial statements and in accordance with authoritative guidance for
    subsequent events, the Company evaluated subsequent events after the consolidated statements of financial position date of June 30,
    2024, through November 4, 2024, the date on which the unaudited interim consolidated financial statements were available to be issued.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-53831"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 2:-
SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b>Unaudited Interim Financial Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s unaudited condensed
consolidated financial statements have been prepared in accordance with International Accounting Standard (&#8220;IAS&#8221;) 34, &#8220;Interim
Financial Reporting&#8221;. The significant accounting policies adopted in the preparation of the interim consolidated financial statements
are consistent with those followed in the preparation of the 2023 Annual Consolidated Financial Statements. Accordingly, these condensed
consolidated financial statements should be read in conjunction with the 2023 Annual Consolidated Financial Statements. The results for
any interim period are not necessarily indicative of results for any future period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The unaudited condensed consolidated
financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#8217;s
management, the accompanying unaudited condensed consolidated financial statements contain all adjustments that are necessary to present
fairly the Company&#8217;s financial position and results of operations for the interim periods presented. The results for the six-month
period ended June 30, 2024, are not necessarily indicative of the results for the year ending December&#160;31, 2024, or for any future
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of June 30, 2024, there have been
no material changes in the Company&#8217;s significant accounting policies from those that were disclosed in the 2023 Annual Consolidated
Financial Statements.<b>&#160;</b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 325; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory" id="ixv-53869"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 3:-
INVESTMENT IN ASSOCIATE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $<ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="3" unitRef="usd" id="ixv-106133">700</ix:nonFraction>, and agreed to invest over the next two years, an additional $<ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" unitRef="usd" id="ixv-106134">1,000</ix:nonFraction>, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a <ix:nonFraction contextRef="c125" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-106135">50.01</ix:nonFraction>% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $<ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="3" unitRef="usd" id="ixv-106136">700</ix:nonFraction> to MitoCareX. As of December 31, 2022, the Company owned
<ix:nonFraction contextRef="c127" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-106137">31.48</ix:nonFraction>% of the outstanding shares of MitoCareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $<ix:nonFraction contextRef="c314" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" unitRef="usd" id="ixv-106138">400</ix:nonFraction> in MitoCareX and increased its share ownership in MitoCareX from <ix:nonFraction contextRef="c129" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-106139">31.48</ix:nonFraction>% to <ix:nonFraction contextRef="c130" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-106140">41.92</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $<ix:nonFraction contextRef="c315" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" unitRef="usd" id="ixv-106141">600</ix:nonFraction> in MitoCareX and increased its share ownership in MitoCareX from <ix:nonFraction contextRef="c132" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-106142">41.92</ix:nonFraction>% to <ix:nonFraction contextRef="c133" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-106143">52.73</ix:nonFraction>%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="usd" id="ixv-106144">600</ix:nonFraction> installment to be deferred to March 25, 2024, and the $<ix:nonFraction contextRef="c316" decimals="0" format="ixt:num-dot-decimal" name="sprcy:InstallmentPaid" scale="0" unitRef="usd" id="ixv-106145">600</ix:nonFraction> installment was paid March 11,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the six months ended June 30,
2024, and 2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $<ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" scale="0" unitRef="usd" id="ixv-106146">185</ix:nonFraction> and $<ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" scale="0" unitRef="usd" id="ixv-106147">98</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="ixv-53881"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106148">591</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentFollowingAchievementMilestone" scale="3" unitRef="usd" id="ixv-106149">400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" scale="3" unitRef="usd" id="ixv-106150">210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106151">781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of second milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentFollowingAchievementMilestone" scale="3" unitRef="usd" id="ixv-106152">600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" scale="3" unitRef="usd" id="ixv-106153">185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106154">1,196</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 326; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="ixv-53969"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4:- INTANGIBLE ASSET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition (&#8220;Wellution Acquisition&#8221;) of Wellution<sup>TM</sup>, an Amazon Marketplace account
and American food supplement and cosmetics brand and trademark (the &#8220;Brand&#8221;). In connection with the Wellution Acquisition,
the Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
cash payment of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-106155">4,540</ix:nonFraction> and an additional $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="sprcy:PurchaseCostsValue" scale="0" unitRef="usd" id="ixv-106156">321</ix:nonFraction> in purchase costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, the Company issued to
M.R.M $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsToPurchase" scale="3" unitRef="usd" id="ixv-106157">15,000</ix:nonFraction> worth of warrants to purchase ordinary shares of the Company at an exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-106158">7.00</ix:nonFraction> per share (with a cashless exercise
mechanism) and with an exercise period of <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="sprcy:ExercisePeriod" id="ixv-106159">five years</ix:nonNumeric> from the closing of the Wellution Acquisition (the &#8220;September 2022 Warrants&#8221;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $<ix:nonFraction contextRef="c164" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" unitRef="usd" id="ixv-106160">100</ix:nonFraction> million of gross sales by the Brand
in the aggregate or (ii) if the price of the Company&#8217;s ordinary shares closes at $<ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="sprcy:pricePerShare" scale="0" unitRef="usdPershares" id="ixv-106161">10.00</ix:nonFraction> per share or above.&#160;On March 26, 2024,
M.R.M. agreed with the Company to waive all its rights under the M.R.M. Warrants and have the M.R.M. warrants cancelled for no consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under International Financial Reporting Standard (&#8220;IFRS&#8221;) 3, Business Combinations, for the transaction and
determined that the fair value of the gross assets acquired was concentrated in a single identifiable asset, a brand. Accordingly, the
Company treated the transaction as an asset acquisition. On the closing date of the Wellution Acquisition, the Company fully recognized
the Wellution Acquisition amount total of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AmountTotal" scale="3" unitRef="usd" id="ixv-106162">4,861</ix:nonFraction> as an intangible asset, to be amortized over a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" id="ixv-106163">10</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-106164">1,042</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that the owner of the asset would have been required to pay
if instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of
<ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="sprcy:RevenueTerm" id="ixv-106165">8.7</ix:nonNumeric> years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined
based on the current period revenues, assuming a short-term growth rate that is consistent with management&#8217;s expectations that
revenues of the Brand will resume their past extent, as of the date of purchase of the Brand, a growth rate thereafter of <ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="sprcy:GrowthRatePercentage" scale="-2" unitRef="pure" id="ixv-106166">13.8</ix:nonFraction>% and a
declining growth rate for the long term, reaching <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:LongTermPercentage" scale="-2" unitRef="pure" id="ixv-106167">2</ix:nonFraction>% at the terminal year. Theoretical royalties arising from the Brand were capitalized
at a discount rate of <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" unitRef="pure" id="ixv-106168">20.6</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock" id="ixv-53986"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-106169">4,717</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-106170">1,042</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-106171">486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-106172">3,189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-106173">183</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-106174">3,006</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the six months ended June 30,
2024, and 2023, the Company recorded depreciation expenses with respect to intangible asset in the amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="usd" id="ixv-106175">183</ix:nonFraction> and $ <ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="usd" id="ixv-106176">243</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 327; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" id="ixv-54070"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5:- INVESTMENT IN FINANCIAL ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i><span style="text-decoration:underline">Share Purchase Agreement</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On June 25, 2023, the Company entered
into a share purchase agreement (the &#8220;Share Purchase Agreement&#8221;) with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;), an Israeli
company traded on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) and the leading parallel importer and distributor of vehicles in Israel,
pursuant to which, at the closing and upon the terms and conditions set forth in the Share Purchase Agreement, the Company invested NIS
<ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="ils" id="ixv-106177">2,500</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-106178">689</ix:nonFraction>) in cash, in exchange for ordinary shares, NIS <ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-106179">0.05</ix:nonFraction> par value, of AutoMax (the &#8220;AutoMax Shares&#8221;)
based on a price per share of NIS <ix:nonFraction contextRef="c319" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-106180">0.5</ix:nonFraction>. As of June 30, 2024, the listed share price of AutoMax on the TASE was NIS <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-106181">0.213</ix:nonFraction>, and the Company
has recorded a loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c320" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106182">246</ix:nonFraction> on its investment. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i><span style="text-decoration:underline">Bridge Loan Agreement </span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On January 16, 2024, the Company entered,
as a lender, into an agreement (the &#8220;Bridge Loan Agreement&#8221;) with AutoMax, pursuant to which AutoMax received from the Company
a bridge loan (the &#8220;Bridge Loan&#8221;) in the amount of $<ix:nonFraction contextRef="c321" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LoansReceived" scale="3" unitRef="usd" id="ixv-106183">1,400</ix:nonFraction>, further to the previously announced non-binding letter of intent
for the Company to acquire AutoMax (the &#8220;AutoMax Acquisition&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Bridge Loan Agreement states that
the principal amount of the Bridge Loan will bear interest at a rate of <ix:nonFraction contextRef="c322" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-106184">7</ix:nonFraction>% per annum (or <ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-106185">9</ix:nonFraction>% per annum if the AutoMax Acquisition is not
consummated prior to the repayment date), compounded annually. The Bridge Loan amount, together with any accrued interest (the &#8220;Owed
Amount&#8221;), may be repaid in part or in whole at the discretion of AutoMax prior to the repayment date. The repayment of the Owed
Amount will be due at the earlier date of: (a) the consummation of the Merger (as defined below), in which the Owed Amount shall be deemed
a part of, and set-off against, the financing amount the Company will provide AutoMax with upon Closing, which is expected to be $<ix:nonFraction contextRef="c324" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-106186">4,250</ix:nonFraction>;
or (b) if the definitive agreement for the AutoMax Acquisition is terminated in accordance with its terms, within three months from such
termination date; or (c) July 15, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On June 9, 2024, the Company entered
into an amendment (the &#8220;Amendment&#8221;) to the Bridge Loan Agreement with AutoMax. Pursuant to the Amendment, the Company extended
an additional loan in the amount of $<ix:nonFraction contextRef="c325" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalLoan" scale="3" unitRef="usd" id="ixv-106187">1,000</ix:nonFraction> to AutoMax under terms similar to the Bridge Loan Agreement, bringing the total Bridge Loan
amount to $<ix:nonFraction contextRef="c326" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" scale="3" unitRef="usd" id="ixv-106188">2,400</ix:nonFraction>. In addition, the repayment date was amended such as that the Owed Amount will be due at the earlier date of: (a) the
consummation of the Merger, in which the Owed Amount shall be deemed a part of, and set-off against, the financing amount the Company
will provide AutoMax with upon Closing, which is expected to be $<ix:nonFraction contextRef="c325" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentClosingAmount" scale="3" unitRef="usd" id="ixv-106189">4,250</ix:nonFraction>; or (b) if the definitive agreement for the AutoMax Acquisition
is terminated in accordance with its terms, within three months from such termination date. As of June 30, 2024, the loan amount and
accrued interest stand at $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="3" unitRef="usd" id="ixv-106190">2,448</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 5, 2024, the Company
entered into a second amendment (the &#8220;Second Amendment&#8221;) to the Bridge Loan Agreement with AutoMax. Pursuant to the Second
Amendment, the Company extended an additional loan in the amount of $<ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalLoan" scale="3" unitRef="usd" id="ixv-106191">1,850</ix:nonFraction> to AutoMax under terms similar to the Bridge Loan Agreement,
bringing the total Bridge Loan amount to $<ix:nonFraction contextRef="c328" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" scale="3" unitRef="usd" id="ixv-106192">4,250</ix:nonFraction>. In consideration for the loan amount, AutoMax established a first ranking fixed charge
security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Leasing Ltd. in favor of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i><span style="text-decoration:underline">Merger Agreement </span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On April 10, 2024, the Company entered
into an Agreement and Plan of Merger, as amended (the &#8220;Merger Agreement&#8221;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli
limited company and wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction
of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#8217;s shareholders and AutoMax&#8217;s
shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the
Company (the &#8220;Merger&#8221;) (see also note 6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">At the
effective time of the Merger (the &#8220;Effective Time&#8221;, as further defined in the Merger Agreement): (a)&#160;each outstanding
share of AutoMax&#8217;s share capital will be converted into the right to receive ordinary shares of the Company, equal to the exchange
ratio set forth in the Merger Agreement (the &#8220;Exchange Ratio&#8221;). Under the Exchange Ratio, following the Effective Time, the
former AutoMax shareholders immediately before the Merger (other than the Company) are expected to hold together approximately <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="sprcy:FinderFeePercentage" scale="-2" unitRef="pure" id="ixv-106193">47.49</ix:nonFraction>%
(minus the Finder Fee, as defined in the Merger Agreement) of the aggregate number of the outstanding ordinary shares of the Company
on fully diluted basis (subject to certain exceptions). The shareholders of the Company, together with the holders of the Company&#8217;s
convertible securities, immediately before the Merger are expected to hold together approximately <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="sprcy:NumberOfSharesOutstandingPercentage" scale="-2" unitRef="pure" id="ixv-106194">52.51</ix:nonFraction>% of the aggregate number of the
outstanding ordinary shares of the Company on fully diluted basis (subject to certain exceptions); (b) subject to the consummation of
the Merger (as defined in the Merger Agreement, the &#8220;Closing&#8221;), and immediately after the Effective Time, AutoMax shall have
the right to (i) designate two members to the Company&#8217;s board of directors (the &#8220;Company&#8217;s Board&#8221;) if the Company&#8217;s
Board is comprised of five or six directors; or (ii) designate three members if the Company&#8217;s Board is comprised of seven directors.
At least one such designee shall be an independent director, as defined under the Nasdaq Stock Market listing rules.</span></p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 328; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="ixv-54125"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:- TRANSACTIONS AND BALANCES WITH RELATED
PARTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Balances with related parties:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" id="ixv-54137"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-106195">15</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-106196">121</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" id="ix_13_fact" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd">2,554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">(*)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-106198">108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c331" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-106199">167</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-106200">95</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US">See note 5.</ix:footnote></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory-c0_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" id="ixv-54241"><span style="font-size: 10pt">Transactions with related parties (not including amounts described in Note 6c):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c332" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106202">26</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106203">40</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" id="ix_14_fact" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" scale="3" unitRef="usd">2,985</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">(*)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_6_footnote" xml:lang="en-US">Sale of approximately <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-106206">49</ix:nonFraction>% of the outstanding shares of Scisparc Nutraceuticals Inc. to Jeffs&#8217; Brands Holdings Inc.</ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-54316"><span style="font-size: 10pt">Benefits to key management personnel (including directors):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-106207">438</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-106208">585</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-106209">1,204</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management fees</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-106210">60</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-106211">80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-106212">220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-106213">11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-106214">54</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-106215">84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands Ltd. (&#8220;Jeffs&#8217; Brands&#8221;) and Jeffs&#8217; Brands Holdings Inc. (&#8220;Jeffs&#8217; Holdings&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, in which Jeffs&#8217; Holdings acquired from the Company common stock of SciSparc Nutraceuticals equal to approximately a 49% for a cash consideration of $<ix:nonFraction contextRef="c329" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashConsideration" scale="3" unitRef="usd" id="ixv-106216">2,500</ix:nonFraction>. In consideration, the Company received from Jeffs&#8217; Brands an additional amount accounting for certain purchase price adjustments related to inventory and working capital. Mr. Oz Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
</table></ix:nonNumeric><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 329; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:- TRANSACTIONS AND BALANCES WITH RELATED
PARTIES (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><ix:continuation id="_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-size: 10pt">e.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, the Company entered into a cooperation agreement with Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) in which the Company and Clearmind test and integrate their core technologies with a view to developing novel psychedelic drug candidates (the &#8220;Cooperation Agreement&#8221;). Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Amitai Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors of Clearmind.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six-month period ended June 30, 2024, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CooperationAgreementAmount" scale="3" unitRef="usd" id="ixv-106217">26</ix:nonFraction>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Mr. Weiss, our chairman of the board of directors, is the chairman of the board of directors of&#160;AutoMax (see Note 5).</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-54476"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7:- FINANCIAL INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Classification of financial assets
and financial liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities" id="ixv-54482"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221;:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106218">316</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106219">2,081</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106220">2,141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-106221">2,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-106222">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Loans to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LoansAndAdvances" scale="3" unitRef="usd" id="ixv-106223">2,448</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeReceivables" scale="3" unitRef="usd" id="ixv-106224">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeReceivables" scale="3" unitRef="usd" id="ixv-106225">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeReceivables" scale="3" unitRef="usd" id="ixv-106226">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-106227">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-106228">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-106229">62</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-106230">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-106231">715</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-106232">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-106233">403</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-106234">849</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" sign="-" unitRef="usd" id="ixv-106235">659</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd" id="ixv-106236">5,665</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd" id="ixv-106237">3,788</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd" id="ixv-106238">6,087</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-106239">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-106240">345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-106241">1,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-106242">532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-106243">64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-106244">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total financial and lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-106245">409</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-106246">1,714</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-106247">656</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 330; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:WarrantsTextBlock" id="ixv-54881"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 8:-
WARRANTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $<ix:nonFraction contextRef="c199" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssuanceOfPrivateOffering" scale="3" unitRef="usd" id="ixv-106248">10,210</ix:nonFraction> (the &#8220;June 2022 Private Placement&#8221;), providing for the
issuance of an aggregate of <ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceAggregateOfPrefundedUnits" scale="0" unitRef="shares" id="ixv-106249">136,388</ix:nonFraction> units and pre-funded units, as follows: (a) <ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="sprcy:PreFundedUnitShares" scale="0" unitRef="shares" id="ixv-106250">12,884</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c199" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PreFundedUnitPerShare" scale="0" unitRef="usdPershares" id="ixv-106251">74.88</ix:nonFraction> per unit, each consisting
of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) <ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="sprcy:PreFundedUnitShares" scale="0" unitRef="shares" id="ixv-106252">123,504</ix:nonFraction> pre-funded units at a price of $<ix:nonFraction contextRef="c335" decimals="3" format="ixt:num-dot-decimal" name="sprcy:PreFundedUnitPerShare" scale="0" unitRef="usdPershares" id="ixv-106253">73.294</ix:nonFraction> per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The June 2022 Warrants have an exercise
price of $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-106254">68.38</ix:nonFraction> per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the date of
issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" id="ixv-54899"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-106255">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-106256">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-106257">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-106258">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-106259">3.872</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-106260">4.324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-106261">4.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-106262">0.80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-106263">68.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-106264">68.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-106265">192</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-106266">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The June 2022 Warrants are classified
as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the six months ended June 30,
2024, and 2023, the Company recorded finance income from the change in fair value of the June 2022 Warrants in the amount of $<ix:nonFraction contextRef="c336" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-106267">188</ix:nonFraction> and
$<ix:nonFraction contextRef="c337" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-106268">1,023</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 331; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-55001"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 9:-
EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Reverse Share Split</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On August 18, 2023, <ix:nonNumeric contextRef="c184" name="sprcy:DescriptionOfReverseShareSplit" id="ixv-106269">the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital
up to a ratio of <ix:nonNumeric contextRef="c185" name="sprcy:CapitalRatio" id="ixv-106270">30:1</ix:nonNumeric></ix:nonNumeric>. Following the implementation of the Reverse Split, the Company&#8217;s authorized share capital was not adjusted
under the Company&#8217;s Articles, which as of the date of these financial statements consisted of <ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-106271">75,000,000</ix:nonFraction> ordinary shares, <span style="-sec-ix-hidden: hidden-fact-270">no</span> par
value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.75in; font-size: 10pt">&#160;</td> <td style="width: 0.5in; font-size: 10pt"><span style="font-size: 10pt">a.</span></td> <td style="font-size: 10pt; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-55020"><span style="font-size: 10pt">Composition of share capital as of June 30, 2024, June 30, 2023, and December 31, 2023:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 27%; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Ordinary
    shares, no par value </span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-106272">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-106273">3,586,104</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-106274">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-106275">706,683</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-106276">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-106277">282,782</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfIssuedAndOutstandingShareCapital" id="ixv-55104"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> ordinary<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-106278">706,683</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of Standby Equity Purchase Agreement (Note 6j)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors" scale="0" unitRef="shares" id="ixv-106279">980,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued to consultants (Note 6e)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:ShareIssuedToAConsultant" scale="0" unitRef="shares" id="ixv-106280">5,869</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Issuance of share in respect of exercise of pre-funded October 2023 Warrants (Note 6i)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" scale="0" unitRef="shares" id="ixv-106281">1,893,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-106282">3,586,104</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 332; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 9:-
EQUITY (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at shareholders meetings,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Capital management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Additional issuance of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 26, 2024, the Company
issued a consultant <ix:nonFraction contextRef="c338" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-106283">3,465</ix:nonFraction> ordinary shares in respect of services rendered in the amount of $<ix:nonFraction contextRef="c338" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="0" unitRef="usd" id="ixv-106284">10</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 9, 2024, the Company issued
<ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-106285">2,404</ix:nonFraction> ordinary shares to two consultants in respect of services rendered in the amount of $<ix:nonFraction contextRef="c339" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-106286">7</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $<ix:nonFraction contextRef="c189" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceeds" scale="3" unitRef="usd" id="ixv-106287">8,150</ix:nonFraction>, providing for the issuance of an
aggregate of <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-106288">44,331</ix:nonFraction> units, as follows: (a) <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-106289">35,242</ix:nonFraction> units at a price of $<span style="-sec-ix-hidden: hidden-fact-269">183,82</span> per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series B
Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the &#8220;March 2021 Warrants)
to purchase half the number of units, and (b) <ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-106290">9,089</ix:nonFraction> pre-funded units at a price of $<ix:nonFraction contextRef="c191" decimals="3" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-106291">183.794</ix:nonFraction> per unit, consisting of (i) one pre-funded
warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Series A Warrants have an exercise
price of&#160;$<ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-106292">183.82</ix:nonFraction>&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$<ix:nonFraction contextRef="c193" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-106293">275.60</ix:nonFraction>&#160;per ordinary share).
Both were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c194" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-106294">five years</ix:nonNumeric> from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The March 2021 Warrants are classified
as issued warrants in the Company&#8217;s equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the six-month period ended
June 30, 2024, and the year ended December 31, 2023, there were no exercises of the 2021 Series A Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">June 2022 Financing Round (see also note 8)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 1, 2022, the Company completed
the June 2022 Private Placement with an investor for gross proceeds of $<ix:nonFraction contextRef="c199" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceeds" scale="3" unitRef="usd" id="ixv-106295">10,210</ix:nonFraction>, providing for the issuance of an aggregate of <ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-106296">136,388</ix:nonFraction>
units and pre-funded units, as follows: (a) <ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-106297">12,884</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-106298">74.88</ix:nonFraction> per unit, each consisting of (i) one ordinary share of
the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;), and (b) <ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-106299">123,504</ix:nonFraction> pre-funded
units at a price of $<ix:nonFraction contextRef="c202" decimals="3" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-106300">73.294</ix:nonFraction> per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) two June
2022 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$<ix:nonFraction contextRef="c340" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WarrantsExercisePrice" scale="0" unitRef="pure" id="ixv-106301">68.38</ix:nonFraction>&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c341" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-106302">seven years</ix:nonNumeric> from
the date of issuance.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants are classified
as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the six-month period ended
June 30, 2024, and the year ended December 31, 2023, there were no exercises of the June 2022 Warrants.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 333; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:- EQUITY (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">August 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 14, 2023, the Company closed
an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of <ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-106303">212,500</ix:nonFraction> ordinary shares, at a purchase price of $<ix:nonFraction contextRef="c206" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-106304">5.20</ix:nonFraction> per
ordinary share, and pre-funded warrants to purchase up to <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-106305">37,500</ix:nonFraction> ordinary shares at a purchase price of $<ix:nonFraction contextRef="c207" decimals="3" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-106306">5.174</ix:nonFraction> per pre-funded warrant,
for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c206" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateGrossProceeds" scale="3" unitRef="usd" id="ixv-106307">1,300</ix:nonFraction>, pursuant to an underwriting agreement between the Company and Aegis Capital Corp,
the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement, the Company
also granted the underwriter a 45-day option to purchase up to an additional <ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-106308">37,500</ix:nonFraction> ordinary shares solely to cover over-allotments.
This 45-day option was not exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">i.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">October 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $<ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-106309">5,026</ix:nonFraction>, before
deducting fees related to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the private placement,
the Company issued an aggregate of <ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-106310">1,930,108</ix:nonFraction> units, each unit consisting of two pre-funded warrants (the &#8220;October 2023 Warrants&#8221;).
The October 2023 Warrants have an exercise price of $<ix:nonFraction contextRef="c211" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-106311">0.001</ix:nonFraction>, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the six-month period ended
June 30, 2024, <ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-106312">1,893,100</ix:nonFraction> ordinary shares were issued in respect to the exercise of <ix:nonFraction contextRef="c343" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-106313">1,893,100</ix:nonFraction> October 2023 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the period between July 1,
2024, and through to the date of this report, <ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-106314">1,784,211</ix:nonFraction> ordinary shares were issued in respect to the exercise of <ix:nonFraction contextRef="c345" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-106315">1,784,211</ix:nonFraction> October 2023
Warrants. As of the date of these financial statements, there are no outstanding October 2023 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">j.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">January 2024 Standby Equity Purchase Agreement</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD. (&#8220;YA&#8221;),
which provided for the sale of up to $<ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SaleOrIssueOfTreasuryShares" scale="3" unitRef="usd" id="ixv-106316">20,000</ix:nonFraction> of the Company&#8217;s Ordinary Shares (the &#8220;Advance Shares&#8221;). As of June 30,
2024, of the $<ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CommitmentAmount" scale="3" unitRef="usd" id="ixv-106317">20,000</ix:nonFraction> eligible to be sold pursuant to the SEPA (the &#8220;Commitment Amount&#8221;), the Company has sold <ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SaleOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-106318">925,159</ix:nonFraction> ordinary
shares. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price equal to <ix:nonFraction contextRef="c312" decimals="2" format="ixt:num-dot-decimal" name="sprcy:SharePriceRate" scale="-2" unitRef="pure" id="ixv-106319">97</ix:nonFraction>% of the market price,
which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing
on the trading day immediately following the delivery of an advance notice to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CommitmentAmount" scale="3" unitRef="usd" id="ixv-106320">5,000</ix:nonFraction> (each a &#8220;Pre-Paid Advance&#8221;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#8220;Promissory Note&#8221;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of <ix:nonFraction contextRef="c346" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestRate" scale="-2" unitRef="pure" id="ixv-106321">5</ix:nonFraction>% per annum, increasing to
<ix:nonFraction contextRef="c347" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestRate" scale="-2" unitRef="pure" id="ixv-106322">18</ix:nonFraction>% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InstallmentPayment" scale="-2" unitRef="pure" id="ixv-106323">10</ix:nonFraction>% of the original principal amount of the Promissory Note and accrued
interest, payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such
notice against an equal amount of the monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash,
the installment amount shall also include a payment premium in the amount of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PaymentForPremiumPercentage" scale="-2" unitRef="pure" id="ixv-106324">5</ix:nonFraction>% of the principal amount of the installment payment. The
Promissory Note contains the Company&#8217;s customary representations and warranties and events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateIssuedAmount" scale="0" unitRef="shares" id="ixv-106325">55,293</ix:nonFraction> of its Ordinary Shares in satisfaction of payment of the commitment fee of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-106326">200</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA. See also note 11b.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 334; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationExplanatory" id="ixv-55362"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 10:-
ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss" id="ixv-55367"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify">a. Research and development expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c348" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106327">224</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c349" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106328">202</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106329">392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106330">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c351" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106331">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106332">34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c352" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106333">117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c353" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106334">145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106335">254</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c354" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106336">386</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c355" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106337">366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106338">719</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c356" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106339">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c357" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106340">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c243" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106341">101</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c358" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106342">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c249" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106343">141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106344">841</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106345">781</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-106346">1,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: justify">b. General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c348" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106347">311</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c349" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106348">217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106349">415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106350">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c351" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106351">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106352">68</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c360" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106353">1,670</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c361" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106354">1,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106355">2,594</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c362" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106356">53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c363" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106357">38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c260" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106358">86</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c364" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106359">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c365" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106360">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106361">110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Investor relations and business expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c366" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106362">57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106363">310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c269" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106364">369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Wellution operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c368" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106365">101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c369" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106366">107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c370" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106367">145</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amazon fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c371" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106368">297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c372" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106369">686</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c252" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106370">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Regulatory expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c373" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106371">67</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c374" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106372">104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106373">202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106374">2,632</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106375">2,921</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-106376">5,031</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 335; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b style="-keep: true">SCISPARC
                                            LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="ixv-55762"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>NOTE&#160;11:-</b></span> <span style="font-size: 10pt"><b>OPERATING SEGMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company applies the principles of IFRS
8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment reporting
is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating Decision
Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles of IFRS
8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The review of the CODM is carried out according
to the results of the segment&#8217;s activity. His review does not include certain expenses that are not related specifically to the
activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="ixv-55780"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Group&#8217;s CODM is the CEO of the Company.</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Six months ended June 30, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Drug Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Online <br/>
Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">External</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c376" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-106377">840</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-106378">840</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-keep: true">Total</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c376" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-106379">840</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-106380">840</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Segment loss (gain)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c375" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106381">3,040</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c376" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106382">487</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106383">3,527</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-106384">208</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Loss on impairment of intangible asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Finance expense (income), net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-106385">51</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Tax expense (income)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TaxExpense" scale="3" sign="-" unitRef="usd" id="ixv-106386">5</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106387">3,679</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Six months ended June 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Drug Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Online <br/>
Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">External</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c378" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-106388">1,972</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-106389">1,972</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-keep: true">Total</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c378" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-106390">1,972</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-106391">1,972</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Segment loss (gain)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c377" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106392">2,772</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c378" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106393">195</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106394">2,967</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-106395">99</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Loss on impairment of intangible asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Finance expense (income), net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-106396">147</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TaxExpense" scale="3" unitRef="usd" id="ixv-106397">13</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106398">2,932</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 336; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b style="-keep: true">SCISPARC
                                            LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">NOTE&#160;11:- <span style="font-size: 10pt">OPERATING
SEGMENTS  (cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><ix:continuation id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1"><ix:continuation id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Year ended December&#160;31, 2023</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Drug Development</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Online <br/>
Sales</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="text-decoration:underline">Revenues</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">External</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278"><span style="-keep: true">-</span></div></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-106399">2,879</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-106400">2,879</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-keep: true">Total</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279"><span style="-keep: true">-</span></div></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-106401">2,879</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-106402">2,879</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Segment loss (gain)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c290" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106403">5,359</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106404">414</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-106405">5,773</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-106406">210</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Loss on impairment of intangible asset</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-106407">1,042</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Finance expense (income), net</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-106408">1,164</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Tax expense</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TaxExpense" scale="3" unitRef="usd" id="ixv-106409">22</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">&#160;Loss</span></td>
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-106410">5,883</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of June 30, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Drug <br/>
Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Online<br/>
 Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c379" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106411">6,834</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c380" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106412">3,648</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106413">10,482</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c379" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106414">1,742</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c380" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106415">84</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106416">1,826</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of June 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Drug<br/>
 Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Online<br/>
 Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c381" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106417">4,290</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c382" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106418">5,602</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106419">9,892</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c381" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106420">2,741</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c382" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106421">373</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106422">3,114</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Drug<br/> Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Online<br/> Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106423">7,069</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106424">4,113</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-106425">11,182</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106426">1,441</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106427">154</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-106428">1,595</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 337; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;SCISPARC LTD.</b></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-57152"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b style="-keep: true">NOTE 12:-
EVENTS AFTER THE REPORTING PERIOD </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a.</p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2024, the Company announced that it signed a non-binding letter of intent (the &#8220;LOI&#8221;) to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. (collectively, the &#8220;Target Assets&#8221;). The LOI references a proposed asset and share purchase agreement (the &#8220;Asset and Share Purchase Agreement&#8221;), the definitive agreement of which is to be negotiated between the Company and Miza III Ventures Inc. (&#8220;Miza&#8221;) (TSXV: MIZA.P), a publicly traded company on the Toronto Stock Exchange Venture in Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Asset and Share Purchase Agreement is based on the approximate total USD <ix:nonFraction contextRef="c383" decimals="-5" format="ixt:num-dot-decimal" name="sprcy:AssetAndSharePurchaseAgreementValue" scale="6" unitRef="usd" id="ixv-106429">3.3</ix:nonFraction> million (CAD <ix:nonFraction contextRef="c383" decimals="-5" format="ixt:num-dot-decimal" name="sprcy:AssetAndSharePurchaseAgreementValue" scale="6" unitRef="cad" id="ixv-106430">4.5</ix:nonFraction> million) enterprise value of Miza, when including its $<ix:nonFraction contextRef="c384" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" scale="3" unitRef="usd" id="ixv-106431">1,000</ix:nonFraction> cash position, and an approximate $<ix:nonFraction contextRef="c385" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-106432">11,600</ix:nonFraction> (CAD <ix:nonFraction contextRef="c385" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="6" unitRef="cad" id="ixv-106433">15.8</ix:nonFraction> million) value of SciSparc&#8217;s assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LOI, SciSparc will sell, assign, convey and transfer to Miza the Target Assets in consideration for <ix:nonFraction contextRef="c386" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-106434">63,300,000</ix:nonFraction> common shares of Miza and up to <ix:nonFraction contextRef="c384" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-106435">48,000,000</ix:nonFraction> Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately <ix:nonFraction contextRef="c387" decimals="2" format="ixt:num-dot-decimal" name="sprcy:EntityStakeholdersRange" scale="-2" unitRef="pure" id="ixv-106436">75</ix:nonFraction>% to a maximum of <ix:nonFraction contextRef="c388" decimals="4" format="ixt:num-dot-decimal" name="sprcy:EntityStakeholdersRange" scale="-2" unitRef="pure" id="ixv-106437">84.53</ix:nonFraction>%, will be active in both the pharmaceutical and supplement sectors.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b.</p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From July 16, 2024, through September 17, 2024, the Company has sold <ix:nonFraction contextRef="c389" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-106438">4,817,626</ix:nonFraction> ordinary shares in respect of the SEPA for proceeds of $<ix:nonFraction contextRef="c390" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" unitRef="usd" id="ixv-106439">3,576</ix:nonFraction>.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">c.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 13, 2024, the Company entered into an exclusive patent license agreement (the &#8220;License Agreement&#8221;) for the out-licensing of its SCI-160 program (the &#8220;Assets&#8221;) with Polyrizon Ltd. (the &#8220;Licensee&#8221;). According to the License Agreement, SciSparc granted the Licensee a royalty-bearing, exclusive, sub-licensable right and license to the Assets (the &#8220;License&#8221;). In consideration for the License, the Company received and will receive certain shares of the Licensee, reflecting an issue price of $<ix:nonFraction contextRef="c391" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromRoyalties" scale="3" unitRef="usd" id="ixv-106440">3,000</ix:nonFraction>, and royalties from sales related to and income generated from the Assets. Further, the Licensee will pay SciSparc pre-determined fees upon the completion of certain development milestones relating to the Assets.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2024, the Company signed a non-binding letter of intent (&#8220;LOI&#8221;) to sell its entire ownership interest in MitoCareX to a publicly-traded company in the United States (&#8220;the Purchaser&#8221;). SciSparc currently owns <ix:nonFraction contextRef="c392" decimals="4" format="ixt:num-dot-decimal" name="sprcy:IssuedAndOutstandingSharePercentage" scale="-2" unitRef="pure" id="ixv-106441">52.73</ix:nonFraction>% of the issued and outstanding share capital of MitoCareX. Pursuant to the terms of the LOI, initially, in exchange for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute <ix:nonFraction contextRef="c393" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-106442">27</ix:nonFraction>% of the Company&#8217;s ownership in MitoCareX, SciSparc will receive in cash consideration of $<ix:nonFraction contextRef="c393" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106443">700</ix:nonFraction>. Subsequent to this first phase, SciSparc will transfer to the Purchaser the remaining <ix:nonFraction contextRef="c394" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-106444">73</ix:nonFraction>% of its ownership stake in MitoCareX in exchange for a certain number of shares based on the valuation of the Purchaser equal to $<ix:nonFraction contextRef="c392" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalOrdinaryShares" scale="3" unitRef="usd" id="ixv-106445">8,000</ix:nonFraction> and a valuation of MitoCareX equal to $<ix:nonFraction contextRef="c395" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalOrdinaryShares" scale="3" unitRef="usd" id="ixv-106446">5,000</ix:nonFraction> (the latter of which includes the $<ix:nonFraction contextRef="c394" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-106447">700</ix:nonFraction> in cash consideration for SciSparc&#8217;s shares described above). The LOI also includes provisions for additional milestones that, upon achievement, could increase the consideration paid by the Purchaser to SciSparc from $<ix:nonFraction contextRef="c396" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ConsiderationPaidReceived" scale="3" unitRef="usd" id="ixv-106448">5,000</ix:nonFraction> to $<ix:nonFraction contextRef="c397" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ConsiderationPaidReceived" scale="3" unitRef="usd" id="ixv-106449">7,000</ix:nonFraction>. The details of the full terms of this transaction are subject to negotiation and execution of definitive agreements.</p></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 338; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><img alt="" src="fin_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="S_001"></a></div><p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax
Motors Ltd.</span></b></p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Consolidated Financial
Statements as for</span></b></p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">December 31, 2023</span></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="fin_005.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 339; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Consolidated Financial
Statements as for</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">December 31, 2023</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Table of Contents:</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 89%"><a href="#Fin_001">Auditor&#8217;s report to the shareholders</a></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 10%">F-83 - F-84</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#Fin_002">Consolidated statements of financial position</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-85 - F-86</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#Fin_003">Consolidated statements of profit and loss</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-87</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#Fin_004">Consolidated statements of comprehensive income</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-88</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#Fin_005">Consolidated statements of changes in shareholders&#8217; equity</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-89</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#Fin_006">Consolidated statements of cash flows</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-90 - F-92</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#Fin_007">Notes to the consolidated financial statements</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-93 - F-183</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 340; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="fin_002.jpg"/>&#160;</p><div>

</div><div><a id="Fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Auditors&#8217;
Report</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">To the shareholders
of</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have audited the accompanying balance sheets
of Automax Motors Ltd. (hereafter: &#8220;the Company&#8221;) as of December 31, 2023 and 2022, and the related statements of profit
and loss, statements of changes in equity and statements of cash flow for the years then ended. These financial statements are the responsibility
of the Company&#8217;s board of directors and management. Our responsibility is to express an opinion on these financial statements based
on our audits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We conducted our audits in accordance with the
standards of the AICPA. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the board
of directors and management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In our opinion, the financial statements referred
to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022 and the results
of its operations, the changes in equity and cash flow for those years then ended, in conformity with International Financial Reporting
Standards (IFRS) and the provisions of the Securities Regulations (Annual Financial Statements), 2010.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without
                                            qualifying our above opinion, we refer to note 21(a) to the financial statements regarding
                                            the indictment that was filed against the company Global AutoMax Ltd. along with its officers,
                                            for suspicions of committing offenses as detailed in the note, and also to what is stated
                                            in note 1(d) regarding the company&#8217;s financial situation, the company&#8217;s losses
                                            and regarding the steps the company is taking in order to meet its obligations. The company
                                            estimates that its financial strength, together with its financial sources and taking the
                                            actions detailed in the note, will allow it to continue to finance its activities and meet
                                            its obligations in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Key matters in the audit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Key matters in the audit are matters that were
communicated, or were required to be communicated, to the company&#8217;s board of directors and which, according to our professional
judgment, were most significant in the audit of the consolidated financial statements for the current period. These matters include,
among other things, any matter which: (1) relates, or may relate, to material sections or disclosures in the financial statements and
(2) our judgment regarding it was particularly challenging, subjective or complex. These matters are answered as part of our audit and
formation of our opinion on the consolidated financial statements as a whole. The communication of these matters below does not change
our opinion on the consolidated financial statements as a whole and we do not use it to give a separate opinion on these matters or on
the sections or disclosures to which they refer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="fin_003.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 341; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="fin_002.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Vehicle inventory</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As described in note 8 to the consolidated financial
statements, as of December 31, 2023, the balance of the vehicle inventory amounts to approximately 183,647 thousand NIS and constitutes
approximately 60% of the total assets in the company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Also, as described in note 2(9), the company&#8217;s
management measures the inventory according to the lower of cost or net realizable value. The inventory cost includes the expenses for
purchasing the inventory and bringing it to its current location and condition. Net realizable value is the estimate of the sale price
in the normal course of business minus the estimate of costs for completion and costs necessary to carry out the sale. Vehicle inventory
cost is determined based on a specific cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Due to the materiality of the vehicle inventory
balance in the consolidated financial statements and due to the fact that the audit of the inventory is an essential part of the audit
work, we determined, according to our professional judgment, that the examination of the existence and evaluation of the inventory as
of December 31, 2023 is a key matter in the audit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>The audit procedures carried out in response to the key matter in
the audit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The audit procedures we performed, related to this
key matter, included, among others, the following procedures: understanding the internal control environment regarding the vehicle inventory
registration process; Attending the company&#8217;s inventory counts and sampling inventory details for the purpose of checking their
existence; receiving direct counting approvals from external websites; checking vehicle inventory costs and their book value; Assessing
the adequacy of the disclosure in the consolidated financial statements; Checking that inventory items are shown according to the lower
of cost or net realizable value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Examining the decline in value of the company&#8217;s assets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As a continuation of Notes 2(12) and 2(15), the
company identified signs of asset impairment and performed an asset impairment assessment, in accordance with the requirements of International
Accounting Standard IAS 36, through a comparison between the book value of the cash-generating unit and its recoverable amount. We identified
the examination of the decline in value of the company&#8217;s assets, as of December 31, 2023, as a key matter in the audit. Determining
the recoverable amount for the aforementioned cash-generating units involved a great deal of subjective judgment, since changes in the
assumptions can have a material effect on the result of the examination of the decline in value of the cash-generating units.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>The audit procedures carried out in response to the key matter in
the audit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The audit procedures we performed, related to this
key matter, included, among others, the following procedures: understanding of processes and the control environment, regarding the examination
of impairment by the company; Examining the adequacy of the identification of the cash generating units; Examining the methodology used
in determining the refundable amount; assessment of the skills, experience and independence of the valuer on behalf of the company&#8217;s
management; Assessing the plausibility of the significant assumptions underlying the works to examine impairment; Performing a sensitivity
analysis regarding the management&#8217;s significant assumptions used in the valuation; due diligence of the book value and value in
use of the cash-generating units; Examination of the adequacy of the disclosures in the financial statements related to the examination
of the decrease in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 40%; font-weight: bold">Sincerely,</td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><img alt="" src="fin_004.jpg"/></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Ben David Shalvi, Kop &amp; Co.</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Certified Public Accountants, (Isr.)</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Jerusalem,</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: right">Jerusalem, March 31, 2024</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="fin_003.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 342; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><div><a id="Fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of financial position</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for 31 December</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="text-decoration:underline">Current Assets</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">5</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,552</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,234</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade receivables</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,552</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,819</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable and debit balances</td><td>&#160;</td>
    <td style="text-align: center">7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Receivable current taxes</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vehicles inventory</td><td>&#160;</td>
    <td style="text-align: center">8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,863</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Indemnity assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249,575</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">246,366</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in companies treated according to the book value method</td><td>&#160;</td>
    <td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,779</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets, net</td><td>&#160;</td>
    <td style="text-align: center">10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,485</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,797</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: center">11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,430</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: center">12</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,670</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial assets stated at fair value recognized through profit and loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term prepaid expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term deposits in banking corporations</td><td>&#160;</td>
    <td style="text-align: center">13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">24</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,741</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,716</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">305,316</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">303,082</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes
constitute an integral part of the financial statements. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 343; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of financial position</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As for 31 December</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Current Liabilities</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Short term credit from banking corporations and financing bodies</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">14</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">141,430</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">141,392</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current maturities of liabilities with respect to lease agreements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Suppliers and service providers</td><td>&#160;</td>
    <td style="text-align: center">15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and credit balances</td><td>&#160;</td>
    <td style="text-align: center">16</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,145</td><td style="text-align: left">(*)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payable current taxes</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,451</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Liabilities with respect to bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">19</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,849</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,566</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216,043</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">203,706</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="text-decoration:underline">Non-current liabilities</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term credit from banking corporations</td><td>&#160;</td>
    <td style="text-align: center">17</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,807</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term redeemable checks</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,143</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term liabilities with respect to lease</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,855</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loans from non-controlling shareholders</td><td>&#160;</td>
    <td style="text-align: center">18</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">957</td><td style="text-align: left">(*)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities with respect to bonds</td><td>&#160;</td>
    <td style="text-align: center">19</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,543</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investments in companies treated according to the book value method</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Liabilities with respect to employee benefits, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">20</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,859</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="text-decoration:underline">Total Equity</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Total equity attributed to Company shareholders</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share capital</td><td>&#160;</td>
    <td style="text-align: center">22</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,389</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Share premium</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,382</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Options</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,457</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital reserves</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(312</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(430</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Retained loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68,635</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52,252</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total equity attributable to Company&#8217; shareholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,562</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-controlling interest rights</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,148</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(156</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,414</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities and equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">305,316</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">303,082</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 22%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31/03/2024</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/S/
    Daniel Levy</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/S/
    Amitay Weiss</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/S/
    Yaarah Alfi</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of approval</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Levy</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaarah Alfi</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of financial</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>The accompanying notes
constitute an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 344; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><div><a id="Fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors
Ltd. <br/>
Consolidated statements of profit and loss<br/>
</span>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 63%; text-indent: -0.125in; padding-left: 0.125in">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">25</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">418,932</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">453,617</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">26</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(381,089</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(392,918</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Gross profit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,843</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,699</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: center">27</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,194</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,612</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Administrative and general expenses</td><td>&#160;</td>
    <td style="text-align: center">28</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,965</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,849</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Granting options to employees</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,549</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,976</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance related expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Other incomes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,557</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Operational profit (loss)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,488</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Financing expenses</td><td>&#160;</td>
    <td style="text-align: center">29</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,831</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,935</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Financing incomes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">29</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,703</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Financing expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,232</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Company&#8217;s share in losses
    of &#160;companies handled according to &#160;the book value method</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(585</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Profit (loss) before taxes on &#160;income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,017</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">671</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">(Taxes on income) tax benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">24</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,931</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total profit (loss) for the year</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,260</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Annual profit (loss) allocation:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Company&#8217; shareholders</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,384</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,104</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Non-controlling shareholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(991</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(156</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Profit (loss) per share attributable
    to Company&#8217; shareholders</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Profit (loss) per share in ILS</td><td>&#160;</td>
    <td style="text-align: center">30</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.02</td><td style="text-align: left">)</td>
    </tr>
  </table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>The accompanying notes
constitute an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 345; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><div><a id="Fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of comprehensive
income</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="6" style="text-align: center"><b>For the year ended</b></td>
    <td style="text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31,</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-weight: bold; text-align: left">Loss for the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(17,375</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(1,260</td><td style="width: 1%; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other comprehensive income (loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Items not reclassified to profit or loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Recalculation of net liability with respect to employment termination</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total annual other comprehensive income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total annual comprehensive income (loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(17,257</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,162</td><td style="padding-bottom: 2.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Annual comprehensive income (loss) allocation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Company&#8217; shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,266</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,006</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling shareholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(991</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(156</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(17,257</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,162</td><td style="padding-bottom: 2.5pt; text-align: left">)</td>
    </tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>The accompanying notes
constitute an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 346; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><div><a id="Fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of changes in shareholders&#8217;
equity</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Options</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital reserves</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share- based payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Retained loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total equity attributed to Company
    shareholders</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Minority Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;<b>Total</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%">Balance&#160;as&#160;for&#160;January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">2,389</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">67,382</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">1,457</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(430</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">17,465</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(52,252</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">36,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(156</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">35,855</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Issuance of shares and allocation of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of shares via private offer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,765</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of shares according to milestones</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,681</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,549</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,383</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,383</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance as for December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,184</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">78,466</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,845</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(312</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(68,635</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">36,562</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,148</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">35,414</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>


<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital reserves</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share- based payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Retained loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total equity attributed to Company
    shareholders</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Minority Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Balance as for January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(413</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,148</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,155</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,977</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Allocation of rights to shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(115</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(115</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(115</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,104</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,104</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(156</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance as for December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,389</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">67,382</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,457</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(430</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">17,465</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(52,252</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">36,011</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(156</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">35,855</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>The accompanying notes
constitute an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 347; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: 001 --><div>
</div><div><a id="Fin_006"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Automax
Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Consolidated Statements
of Cash Flows</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the year ended</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.25in; padding-left: 0.25in; font-weight: bold"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td style="white-space: nowrap">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; width: 74%; text-align: left">Loss of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(17,375</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(1,260</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Adjustments required for the presentation
    of net cash flows from operating&#160;activities (Appendix A)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,517</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,782</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">(*)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash generated by (used for)
    operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,042</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; font-weight: bold; text-align: left"><span style="text-decoration:underline">Cash flows from investing activities:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Consolidation commencement (Appendix B)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Withdrawal from (investment in) affiliated companies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,534</td><td style="white-space: nowrap; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Acquisition of leasehold assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(90</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Consideration with respect to realization of property, plant
    and equipment items, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Investment in indemnity assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Investment in financial asset measured at fair value, recognized
    through profit and loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(172</td><td style="white-space: nowrap; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Investment in intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,416</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(923</td><td style="white-space: nowrap; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,951</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,810</td><td style="white-space: nowrap; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Withdrawal of (investment in) short-time
    deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash generated by (used for)
    investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(353</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,453</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; font-weight: bold; text-align: left"><span style="text-decoration:underline">Cash flows from financing activities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in">Issuance of equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Receipt (repayment) of short-term credit from banking corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(391</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,874</td><td style="white-space: nowrap; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Repayment of liability with respect to lease agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,272</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,785</td><td style="white-space: nowrap; text-align: left">)(*)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Repayment of long-term loans from banking corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,969</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,446</td><td style="white-space: nowrap; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Provision of loans to related parties in consolidated companies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(151</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(767</td><td style="white-space: nowrap; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">(Repayment) issuance of bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,567</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,015</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash generated by (used for)
    financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,891</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">Decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(682</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(604</td><td style="white-space: nowrap; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents as for
    the beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,234</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,838</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Cash and cash equivalents as for year
    end</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,552</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,234</td><td style="white-space: nowrap; padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    </tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: center"><b>The accompanying notes constitute
an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 348; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.<br/>
Consolidated Statements of Cash Flows<br/>
</span>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Appendix A - Adjustments required for the presentation of net
cash flows from operating activities</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: bottom"><td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the year ended</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="text-decoration:underline">Incomes and expenses non-involving cash flows</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 74%; text-align: left">Depreciation and amortization</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">10,392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">8,182</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred tax expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">293</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">421</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other incomes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(226</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,976</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">The group&#8217;s share in the results of companies treated
    according to the book value method, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">585</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">IFRS 16 implementation effects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left"><sup>(*)</sup></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Financing expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,662</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Trade registration expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="text-decoration:underline">Changes in assets and liabilities
    items</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase in vehicles inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,551</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97,082</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Decrease (increase) in accounts receivable and debit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,806</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,238</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase in trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,733</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,253</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase (decrease) in suppliers and service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,949</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,403</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase (decrease) in accounts payable and credit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,743</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,368</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase in long-term prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(191</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase in employee&#8217; benefits and employee related
    provisions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Increase (decrease) in current
    payable taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,355</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,848</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118,382</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><b>20,517</b></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>(96,782</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>)</b></td>
    </tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes
constitute an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 349; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.
<br/>
Consolidated Statements of Cash Flows<br/>
</span>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Appendix
B - Consolidation Commencement</span></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Working capital not including cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">167</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">613</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment and intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">938</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Balances with respect to lease, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(167</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loan from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,780</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">764</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">465</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes
constitute an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 350; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="Fin_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax
Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Company
                                            description:</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">The company has been incorporated in
2006, and until December 2019, offered and provided, together with its subsidiaries, a variety of proprietary programmatic data-driven
platforms that focused on two main activities of domain monetization and mobile digital advertising for advertisers, advertising agencies,
application developers and domain owners, mainly in the U.S.and European countries. Its shares were traded on the London Stock Exchange
(&#8220;LSE&#8221;) and at the Tel Aviv Stock Exchange Ltd. (&#8220;TASE&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">On June 23, 2020, the trading in the
Company&#8217;s shares on the LSE and TASE exchanges was suspended. On November 25, 2020, trading resumed on TASE as part of the list
for limited trading (retention list) and on January 12, 2021, the Company&#8217;s shares returned to trading as part of general trading
on the main list on TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in">On November 23, 2020, the Company&#8217;s shares were delisted
from trading on the LSE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">During the period between the middle
of 2017 and up to December 2019, the Company sold all of its activities in the field of digital advertising.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As
                                            of the date of the completion of the merger transaction (as defined in Note 1(c) hereunder),
                                            the Company is engaged, through Global Auto Max Ltd, a fully controlled subsidiary in the
                                            import to Israel and marketing of a variety of private and commercial vehicles models. In
                                            addition, the Company is engaged in direct import and marketing in Israel of buses manufactured
                                            by Temsa (through Dalhom Automax (as defined below), as well as in the purchase and sale
                                            of used vehicles (trade-in) (through Automax Trade-in (as defined below). Regarding the merger
                                            with Global AutoMax Ltd. see Note 1(c) hereunder.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">On April 22, 2021, the company changed
its name from Matomy Media Group Ltd. to Automax Motors Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in">Following are details of companies held by the Company as
for the balance sheet date:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .5in"/><td style="width: .25in">&#9679;</td><td style="text-align: justify">Global Auto Max Ltd. - holding
                                            100% of the issued and paid-up capital, a private company incorporated and registered in
                                            Israel (hereinafter: &#8220;Global Auto Max&#8221;) in 2014.</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Automax
                                            Trade In Ltd. (hereinafter: &#8220;Automax Trade In&#8221;) - holding 80% of the issued and
                                            paid-up capital, a private company incorporated and registered in Israel in 2022.</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Dalhom
                                            Automax Ltd. (hereinafter: &#8220;Dalhom&#8221;) - holding 50% of the issued and paid-up
                                            capital, a private company incorporated and registered in Israel in 2022.</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Automax
                                            Leasing Ltd. (hereinafter: &#8220;the leasing company&#8221;) - holding 100% of the issued
                                            and paid-up capital, a private company incorporated and registered in Israel in 2022.</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 351; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in"><b>B.</b></td><td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Description
                                            of Global AutoMax Ltd.:</span></b></p></td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Global AutoMax Ltd. was incorporated
in Israel in 2014 as a private company in accordance with the provisions of the Companies Law, 2019-1999 (hereinafter: the Companies
Law&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The head offices of Global AutoMax
are situated in Jerusalem. As of the day of its incorporation, Global AutoMax has been engaged in importing into Israel and marketing
a variety of various vehicles intended for private use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Global AutoMax is a licensed indirect
importer, as defined in Paragraph 42 of the Services and Professions Licensing in the Automotive Industry Law, 5766-2016 (hereunder:
&#8220;Automotive Services Licensing Law&#8221;). Said license covers 27 vehicle products in a variety of models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the date of the financial statements,
Global AutoMax conducts its operations through 12 car sale centers located in Jerusalem, Rishon Le-Zion, Petah Tikva, Afula, Be&#8217;er
Sheva, Haifa, Ashkelon, Ra&#8217;anana, Akko, Netanya, Ashdod and Glilot, in addition to operating a series of storage facilities and
PDI (pre-delivery inspection) service agencies for vehicles up for sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 352; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">Since the outbreak of the Iron Swords
War, the Company&#8217;s branches in Ashkelon and Petah Tikva have been closed, and the Company is examining the continuance of their
operation. The Company assesses that the impact of not operating these branches is immaterial to the group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Following are details of companies held by Global AutoMax
as for the balance sheet date:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .5in"/><td style="width: .25in">&#9679;</td><td style="text-align: justify">EDV Car Importers Ltd. - holding
                                            100% of the issued and paid-up capital, a private company incorporated and registered in
                                            Israel in 2019. In August 2023, the company changed its name to Automax Fleets Ltd. (hereinafter:
                                            &#8220;Automax Fleets&#8221;).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .5in"/><td style="width: .25in">&#9679;</td><td style="text-align: justify">Automax HaSharon Ltd. (hereinafter:
                                            &#8220;Automax HaSharon&#8221;) - holding of 67% of the issued and paid-up capital. A private
                                            company incorporated and registered in Israel in 2021.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .5in"/><td style="width: .25in">&#9679;</td><td style="text-align: justify">Automax Netanya Ltd. - holding
                                            100% of the issued and paid-up capital, a private company registered and incorporated in
                                            Israel in 2022.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .5in"/><td style="width: .25in">&#9679;</td><td style="text-align: justify">Automax HaShfela Ltd. &#8211;
                                            holding 50% of issued and paid up capital, a private company incorporated and registered
                                            in Israel in 2022.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .5in"/><td style="width: .25in">&#9679;</td><td style="text-align: justify">Automax Leasing and Vehicle
                                            Fleets Ltd. (hereinafter: &#8220;Automax Leasing and Vehicle Fleets&#8221;) - holding 100%
                                            of the issued and paid-up capital, a private company incorporated and registered in Israel
                                            in 2023.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in"><b>C.</b></td><td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Merger
                                            with Global AutoMax Ltd.:</span></b></p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On November 9, 2020, the Company,
Global AutoMax, and its (former) shareholders (controlling shareholders of the Company as for the date of the financial statements) and
M.R.M. Merhavit Holdings and Management Ltd. (hereunder: &#8220;Transaction Initiator&#8221;) entered into a merger agreement by means
of exchanging stock between the Company and the former shareholders of Global AutoMax (hereunder: the &#8220;Merger Agreement&#8221;
or the &#8220;Merger Transaction&#8221; or the &#8220;Transaction&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On March 24, 2021, the Merger Transaction
has been finalized after the preconditions detailed within the Merger Agreement were met. As part of the transaction, the Company allocated
ordinary shares to the shareholders of Global AutoMax (above and hereunder: (&#8220;Date of completion of the merger transaction&#8221;),
which constituted immediately after their allocation 52.53% of the Company&#8217;s issued and paid-up share capital, as well as rights
to the allocation of additional shares upon the fulfillment of milestones established in the Merger Agreement, which, if fully fulfilled,
will increase the holdings of the former shareholders of Global AutoMax to 73% of the Company&#8217;s fully diluted issued and paid-up
share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In exchange, all shareholders of Global
AutoMax at that time transferred their shares in Global AutoMax to the Company, so that after the completion of the transaction the Company
owns 100% of Global AutoMax shares, fully diluted, as well as every right of any kind and type in Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 353; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, a number of Global AutoMax
officers who serve as Company officers after the completion of the transaction were assigned with options to purchase 59,257,103 ordinary
shares of the Company, according to an employee, officers and service providers&#8217; option allocation plan upon the time of completion
of the merger by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the time of completion of the Merger
Transaction, the directors of the Company who were in term at that time ceased to hold office (with the exception of the external directors
and Mr. Amitay Weiss), as well as the other officers of the Company, and replaced by directors and various officers proposed by the former
shareholders of Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, it was determined that
according to the Merger Agreement, the amount of cash in the Company&#8217;s &#8220;petty cash&#8221; account as on the date of the Merger
Transaction completion should be approx. 22 million ILS. Despite the aforementioned, according to the reconciliation, as carried out
subject to the provisions of the Merger Agreement, the &#8220;petty cash&#8221; balance at the date of the reconciliation amounted to
just 21.5 million ILS. The entire amount of the difference (approx. 500 thousand ILS) is subject to the indemnification provision stipulated
in the Merger Agreement, according to which the amount of the difference will be paid by way of allocating the indemnity shares against
capital raising to be carried out by the Company. In accordance with the provisions of the merger agreement, to the extent that it is
not possible for any reason to make the indemnification in shares in the manner stated above, the controlling owners will be given indemnification
in cash.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 354; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">The Agreement also includes provisions
regarding mutual compensation, instructions regarding the settlement of previous Company&#8217; undertakings, preliminary terms and additional
stipulations with respect to the completion of the Merger Transaction according to its terms as well as provisions regarding future issuance
of securities subject to Company&#8217; prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">On March 28, 2023, in light of the
Company&#8217;s compliance with milestones #2 and 3 stipulated in the merger agreement, the Company allocated to the controlling owners
168,105,258 additional ordinary shares of the Company, which constituted approx. 41% of the issued and paid-up capital of the Company
after the allocation. As for the signature date of the financial statements, the controlling shareholders hold, jointly, about 55.65%
of the Company&#8217;s issued and paid-up share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>D.</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Effect
                                            of changes in the business environment on the Group&#8217;s activities and the Group&#8217;s
                                            business situation:</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">The Company imports its inventory of
vehicles from various suppliers situated in Europe and North America. Its revenues derive from the sale of vehicles in Israel in ILS.
Therefore, the Company is exposed to depreciation in the exchange rate of the shekel against the foreign currencies of the countries
from which the vehicles are imported. From the beginning of 2023, there has been a depreciation in the exchange rate of the shekel against
various currencies, and more specifically the various currencies to which the Company is exposed. According to the Bank of Israel, this
trend, which began to moderate as of November 2023 and as for the date of the publication of the report, is mainly due to the legislative
changes regarding the judicial system in Israel, as detailed below. The erosion trend in the exchange rate of the shekel against foreign
currencies that the Company is exposed to, has a negative effect on the Company&#8217;s profitability, especially in the short term,
if it is not possible for the Company to adjust the selling prices of the vehicles it sells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">In light of the erosion trend in the
exchange rate of the shekel against foreign currencies that the Company is exposed to from the beginning of 2023, the Company has made
a change in the mix of vehicles it imports and in the purchase currencies (in accordance with the changes in the market). In addition,
the Company implements a currency risk&#8217; management policy which is designed to reduce said exposures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">From the second quarter of 2022 and
until the second quarter of 2023, <i>inter alia</i> due to the appearance of a number of economic and geopolitical events that affected
price levels worldwide, there was a sharp increase in inflation (during the 12-months period between March 2022 and March 2023, the consumer
price index in Israel rose by 5%). In the second quarter of 2023, there was a certain moderation in the rate of increase in the consumer
price index, which continued in the third quarter of 2023, and moved to a decrease in the fourth quarter of 2023 (mainly in light of
the effect of the Iron Swords War). The increase in the consumer price index in Israel in 2023 amounted to 3%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 355; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In response to the increase in prices
and subsequently to the interest rate increases by the central banks in Europe and the USA, starting in April 2022, the Bank of Israel
decided to raise the Bank of Israel&#8217; interest rate, and it increased several times from a rate close to zero (which prevailed for
about 7 years) to a rate of 4.75% per year, in the second quarter of 2023. In January 2024, the Bank of Israel decided to lower the annual
rate by 0.25% to a level of 4.5%, which also prevails at the time of the publication of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">According to the Bank of Israel Research
Department&#8217;s forecast published in January 2024, the inflation rate during 2024 is expected to be 2.4%, and the average Bank of
Israel&#8217; interest rate is expected to be 3.75%/4.00% in the fourth quarter of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The credit lines provided by banking
corporations to the companies within the Group bear interest at the rate of the prime interest rate (which is the Bank of Israel&#8217;
interest plus 1.5%. At the time of the publication of the financial statements, the prime interest rate is 6%), plus a certain rate,
as agreed during deliberations with the banking corporations upon actual takeout of the credit. Said rate is affected, <i>inter alia</i>,
by the market interest rate, by the extent of credit and by the familiarity of the bank with the Company. Therefore, the increase in
the Israeli interest rate has led to a rise in the Group&#8217;s financing costs (which are expected to continue increasing with the
continued rise in interest), which might affect the financial results of the Group and its profitability. However, the Company does not
expect that a higher interest rate environment will be a practical obstacle in taking credit from banks or other financing bodies. In
addition, the Company does not anticipate that the continued increase in the market interest rate may harm the covenants established
with the banking corporations, since most of the benchmarks that Group&#8217; companies undertook with respect to the banking corporations
are virtually unaffected by changes in interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 356; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><!-- Field: Split-Segment; Name: 002 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">However, the high interest rate
environment and the effects of the Iron Swards War are expected to slow down the growth rate of the market in general, and of the Company
in particular, as well as harm private consumption. According to the Central Bureau of Statistics, the Israeli growth rate in 2023 was
2%, which is a 0.1% decrease in GDP per capita in comparison to 2022. In a forecast published in January 2024 by the Research Department
of the Bank of Israel, the Israeli growth rate in 2024 is expected to be 2% as well, and the rate of growth in private consumption is
expected to increase from a negative rate of 0.7% in 2023, to 3% in 2024, and 6% in 2025. The increase in inflation and interest have
a negative effect on the Company&#8217;s sales rate and, as a result, on its profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As described above, the rise in
interest rates has a direct and indirect negative effect on the economy and the Company. Therefore, at the time when the monetary policy
of raising interest rates moderates, it is expected to have a positive effect on the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">During the first quarter of 2023,
the new government began promoting a plan to make fundamental changes to the judicial system in Israel, parts of which were approved
by the Knesset in first reading of the bill. The proposed changes have aroused widespread controversy and criticism, which according
to various publications by international credit rating companies (such as Moody&#8217;s), economic entities, senior economists in the
market, heads of academic institutions and experts in the fields of law, economy, society and the humanities in Israel, may impact the
robustness of the market and economy in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In April 2023, the international
rating agency Moody&#8217;s lowered Israel&#8217;s rating forecast from &#8220;positive&#8221; to &#8220;stable&#8221;, and in May 2023,
the International Monetary Fund lowered the growth rate forecast for the Israeli economy for 2023, while these bodies note that the crisis
surrounding the changes in the judicial system constitute a cause of instability, and the lack of a broadly-agreed solution may cause
an increase in the risk of Israel&#8217;s economy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In July 2023, after the legislative
proceedings were suspended for a certain period for negotiations between the coalition and the opposition, the Knesset approved in the
second and third readings the Basic Law: The Judiciary (Amendment No. 3) (Reduction of the Reason for Reasonableness), without agreement
with the opposition, in a manner that provoked public criticism and widespread protest. Following the aforementioned amendment, the credit
rating agencies Moody&#8217;s and-S&amp;P published outstanding reports in which they warned against the consequences of promoting changes
in the judicial system without broad agreement on the Israeli economy. It should be clarified that petitions were submitted to the Supreme
Court on its session as the High Court of Justice against the amendment to the Basic Law: the Judiciary, which were discussed in September
2023, for the first time before a full panel of 15 judges. On January 1, 2024, the Supreme Court, in its session as the High Court of
Justice, rejected by a majority of votes the amendment to the Basic Law: the Judiciary (Reduction of the Reason for Reasonableness).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 357; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">At the beginning of August 2023,
the Bank of Israel published a report regarding the financial stability for the first half of 2023, according to which the legislative
changes regarding the judicial system in Israel caused a considerable increase in the economic uncertainty in the economy and the accelerated
development of the negative sentiment in the markets. According to the aforementioned report, the uncertainty surrounding the legislative
changes raised the risk premium of the economy and was accompanied by a devaluation of the exchange rates which contributed to an increase
in inflation, a decrease in stock prices and increased volatility in the foreign exchange market and the financial markets. As of the
date of the publication of this report, no further changes have yet been promoted in the judicial system in Israel, and it seems that
in light of the outbreak of the Iron Swords War, there is no prospect of further changes being promoted in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Such changes may have a negative
impact on the economic environment in which the Company operates, on the cost of funding sources, on the credit rating of the Israeli
economy, and more. However, since these are changes most of which have not yet been enacted or entered into force, the extent of their
impact on the Israeli economy and the automotive industry in general and the Company in particular, are unknown and cannot be assessed
at this stage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Starting at the beginning of 2023,
the supply of vehicles in the intermediate category began to return to its normal level from before the corona crisis and the chip crisis
in the automotive industry, and even the discount rates for the purchase of vehicles in the world began to rise during the second quarter
of 2023. Therefore, the Company is gradually working to reduce the cost of vehicle inventory per vehicle it owns by increasing the supply
of vehicles of the intermediate category and lower, that are marketed by the Company, with the aim of adjusting the Company&#8217;s vehicle
inventory to the increased demand for vehicles of the intermediate category and lower, as a result of the economic and financial situation
in the State of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 358; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin: 0pt 0pt 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company is looking at expanding
and diversifying the sources of supply of vehicles imported by it, including brands manufactured in China that have gained demand in
the Israeli car market. In the Company&#8217;s estimation, the realization of this move will have a positive effect on its revenues.</p><div>

</div><p style="margin: 0pt 0pt 0pt 0.25in; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="margin: 0pt 0pt 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">In the second half of 2023, global
economic trends, including the increase in inflation and interest rates in the countries where the Company purchases its vehicle inventory,
led to opportunities to purchase vehicle inventory in larger volumes and at better prices compared to previous periods. This trend increased
during the period that elapsed between the date of this report and until the signature date of the financial statements.</p><div>

</div><p style="margin: 0pt 0pt 0pt 0.25in; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="margin: 0pt 0pt 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">The changes in the business environment
(including the outbreak of the Iron Swords War as detailed in Note 1E hereunder) caused a decrease in the Company&#8217;s revenues during
the reported period to a total of approx. ILS 418.9 million compared to approx. ILS 453.6 million in the corresponding period last year,
to an erosion of the Company&#8217;s gross profit during the reporting period to a total of approx. ILS 37.8 million compared to a total
of approx. ILS 60.7 million in the corresponding period last year, as well as losses (before tax) in the amount of approx. ILS 17 million
during the reporting period compared to a profit (before tax) of 0.6 million ILS in the corresponding period. The adjusted loss (before
tax) for 2023, deducted by options granted to employees, non-cash-flow rate differences with respect to the Optimatic transaction (as
detailed in Note 16(b) hereunder) as well as the &#8220;Iron Swords&#8221; grants for the months of November and December 2023 (which
were not recognized during the reporting period), constitutes approx. ILS 8.6 million, compared to a profit of about ILS 11.8 million
(before tax) in the corresponding period last year.</p><div>

</div><p style="margin: 0pt 0pt 0pt 0.25in; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="margin: 0pt 0pt 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company builds its cash flow
for the following periods on the basis of a consolidated cash flow, which takes into account the individual cash flows of the companies
held by it, so that all of the Company&#8217;s liabilities with respect to bondholders (series B) and the held companies towards banking
corporations and various third parties will be used.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin: 0pt 0pt 0pt 0.25in; font: 10pt Times New Roman, Times, Serif">To this end, the Group takes the following steps:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Changing the
                                            mix of imported and sold vehicles in the Company&#8217;s branches according to the current
                                            demand of its customers. The changes in the business environment as mentioned above, caused
                                            a demand for vehicles in the intermediate and small vehicle categories. The Company&#8217;s
                                            management anticipates that as a result the inventory turnover rate will increase, which
                                            will lead to a positive cash flow from current operations, a trend that began in the second
                                            quarter of 2023, continued in the third quarter of 2023, and is expected to continue in the
                                            following quarters as well. After the date of the financial statements and until the date
                                            of approval of the financial statements, the Company sold mainly vehicles from the intermediate
                                            category, which corresponds with the Company&#8217;s plans to change its vehicle mix to vehicles
                                            in the intermediate and small category. As of the date of approval of the financial statements,
                                            the rate of orders for new vehicles in December 2023 is higher than the rate of orders in
                                            the corresponding period last year.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 359; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">The Group has
                                            flexibility regarding the financing of advances to suppliers and discount policies to customers
                                            according to the market situation, interest rates and exchange rates and the needs of the
                                            Company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">The financing
                                            that the Company provides to the companies within the Group is subject to the Company&#8217;s
                                            amortization schedule towards the bondholders (series B).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">Strengthening
                                            the Company&#8217;s equity capital through capital raising (including the Merger Transaction
                                            (insofar completed) with the receiving company, as detailed in Note 21(S) below).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">It should be clarified that the
Company&#8217;s assumption in relation to the repayment of loans provided by it to invested companies that have been provided credit
lines from banking corporations, is based on the fact that at the said repayment date, the invested companies will comply with the financial
covenants and other terms stipulated by said banking corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company raised funds from the
public via bonds (series B), as detailed in Note 19 below. As part of the shelf prospectus and the deed of trust, the Company undertook
to comply with a number of financial covenants, detailed in note 21c hereunder. The Company&#8217;s policy and operations are aimed at
meeting the principal and interest payments to bondholders (series B) as well as the financial covenants at any point in time. The Company
has various instruments for implementing this policy, as detailed hereunder:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 360; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Selecting the
                                            mix of imported vehicles, the import currencies, the amount of advances to suppliers and
                                            the selling prices in Israel. This implementation began during the second quarter of 2023,
                                            continued during the third and fourth quarters of 2023, and is expected to continue in the
                                            following quarters as well.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Inventory management
                                            policy - the Group can increase or decrease the amount of vehicles as well as inventory value
                                            according to its operational plans and to the seasonality in the automotive industry. During
                                            the second quarter of 2023, the Company reduced its inventory of vehicles, based on seasonal
                                            planning that took into account the school holidays and the Tishrei holidays. During the
                                            third and fourth quarters of 2023, the Group prepared for the demands of the fourth quarter
                                            (which is traditionally characterized as the quarter with the highest sales in the automotive
                                            industry) by increasing the inventory of vehicles from the intermediate category and lower,
                                            while taking into account increased demand at the end of 2023 following the expected tax
                                            increase on plug-in and electric vehicles.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of the publication of this report, the Company is unable to assess the full future effects, to the extent that they may be
of all of the factors mentioned above on the automotive industry in Israel in general and on the Company&#8217;s activities in particular.
However, the Company estimates that its financial strength, together with its financial sources and taking the actions detailed above,
will allow it to continue to finance its activities and meet its obligations in the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. <span style="text-decoration:underline">Effects of the Iron Swords War:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On October 7, 2023, the terrorist
organization Hamas launched a murderous attack on the State of Israel, which included firing rockets and the infiltration of thousands
of terrorists into its territory. The attack claimed many victims, including Israeli and foreign citizens who were abducted to the territory
of the Gaza Strip. Following the attack, the Israeli government declared an &#8220;Iron Swords&#8221; war, mobilized approximately 300,000
reservists and launched an attack on the Gaza Strip (hereinafter: &#8220;<b>the war</b>&#8221;). At the same time, a conflict is taking
place in the northern territory of the country against the terrorist organization Hezbollah, and attacks have also been carried out from
other arenas aimed at the State of Israel. The immediate impact of the outbreak of the war on Israel&#8217;s economy was evident, and
was reflected, <i>inter alia</i>, in the devaluation of the shekel against foreign currencies, declines in stock exchange rates, the
closing of many businesses due to the directives of the Home Front Command and the extensive mobilization of reserves, a trend that was
moderated until the publication of the report, with the release of reserve forces, appreciation of the shekel against foreign currencies,
increases in exchange rates and a return to a certain routine in the shadow of the war.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 361; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">With
                                            the outbreak of the war, most of the Company&#8217;s branches were closed and there was no
                                            customers&#8217; traffic. As of November 2023, the Company&#8217;s branches began to open
                                            in a partial format, in accordance with customer traffic and in accordance with the directives
                                            of the Home Front Command. As for the signature date of the financial statements, the Company&#8217;s
                                            branches in Ashkelon (operated by a joint venture with Global AutoMax and a third party)
                                            and in Petach Tikva (operated directly by Global AutoMax) are closed due to the lack of a
                                            protected space, and the lack of personnel. The Company is examining the continued operation
                                            of these branches. The Company assesses that the impact of not operating these branches is
                                            immaterial to the group. At the time of publication of the report, all other branches of
                                            the Company are operating as normal in accordance with the directives of the Home Front Command
                                            and a vibrant movement of customers is noticeable in them.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">With the outbreak of the war, the Company
worked to reduce its current expenses, as much as possible under the circumstances, including reducing advertising and marketing expenses,
reducing other current expenses and reducing personnel related expenses. In addition, the Company also worked to reduce its fixed expenses,
as much as possible under the circumstances, including partial or no payment of rent in some of its branches.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">During the months of October and November
2023, the Group reduced about 10% of the workforce within the Group and about 30% of the Group&#8217;s employees were placed on layoff,
while by the date of the publication of this report all Group&#8217; employees who were placed on layoff returned to work. In addition,
there are a small number of employees who were recruited into the reserves, and some of them returned to full-time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">During the fourth quarter of 2023,
there was a significant decrease in the Group&#8217;s sales turnover compared to the corresponding period last year, attributed to the
months of October and November 2023, in which most of the Company&#8217;s branches were closed and were not open to the public, while
in December there was a significant increase in the amount of orders for vehicles compared to the corresponding period last year. The
upward trend in vehicle orders from customers that began in December 2023 continued at the beginning of 2024 (not reviewed or audited),
compared to the corresponding period last year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">With the outbreak of the war, the Houthis,
an Islamic political and military organization in Yemen, declared war on Israel, and began to launch missiles at targets in Israel to
support the terrorist organizations in the Gaza Strip and Hezbollah, to launch drones at Israel, and to attack vessels that supposedly
have a connection to Israel. As a result of the vessel attacks, several shipping companies have announced the suspension of sailing through
the Red Sea. The situation developed into an international crisis that has led to the establishment of an international coalition to
guarantee freedom of navigation and to the announcement by the United States and its allies that Operation Prosperity Guardian has been
launched against the Houthis in order to stop their attacks against vessels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 362; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company imports its vehicle
inventory mainly from Europe and North America, and therefore it is not expected to be directly affected by the disruptions resulting
from the Houthi organization&#8217;s attacks on vessels in the Red Sea region which have caused changes in sailing routes. At the same
time, the changes and disruptions in the sailing routes as mentioned above have caused significant delays in delivery dates and an increase
in logistics and transportation prices within Europe and from Europe to Israel. The delays in delivery dates and the increase in logistics
and transportation prices within Europe and from Europe to Israel have had a negative impact on the Company&#8217;s financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">It should be noted that with the
outbreak of the war and with its continuation, a number of government decisions were made which may have a positive effect on the Group&#8217;s
activities. This includes providing compensation for the decrease in transaction volumes of businesses, and some of the Group&#8217;s
companies are included in the standards established for this matter (a request for such compensation has been submitted), compensation
for the full damage caused to businesses in frontier settlements (which is relevant to the Company&#8217;s branches in Ashkelon, Ashdod
and Be&#8217;er Sheva) (a request for such compensation has been submitted), receiving a state-guaranteed loan, and granting a three-month
grace period for the first registration of vehicles that must be registered for traffic for the first time from 11 October 2023 until
31 December 2023, which will allow them to be sold as new for an additional period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company frequently reviews its
eligibility and takes action in order to receive the benefits in respect of the aforementioned government decisions. In addition, in
January the Company received a state-guaranteed loan from a banking corporation in the amount of NIS 16 million (for additional details,
see Note 32(1) above). Additionally, for the month of October 2023 the Group companies are entitled to receive compensation from the
state in the amount of approximately NIS 2.07 million (which was recognized in the financial statements), and for the months of November-December
2023 the Group companies are entitled to receive additional compensation in the amount of approximately NIS 5.9 million, which was not
recognized during the report period in light of its approval by the government after the report period (and which will be recognized
in the financial statements for the first quarter of 2024).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In light of the outbreak of the
war and its effects on the Company&#8217;s financial results which can be assessed at the time of this report&#8217;s publication, the
Company took action to raise capital by way of a private offering in the amount of NIS 10 million which was completed on 31 December
2023 and strengthened the Company&#8217;s equity and liquidity. For additional details, see Note 21b(20) below. In addition, the Company
continues to negotiate a merger with a company that was incorporated in Israel and whose securities are traded on NASDAQ (&#8220;The
Receiving Company&#8221;), and on 16 January 2024 signed an agreement to receive a bridging loan in the amount of USD 1.4 million from
the Receiving Company. For additional details, see Note 32(2) below. This transaction, as soon as it is completed, is expected to strengthen
the Company&#8217;s liquidity and equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In January 2024, the Bank of Israel
published a report on financial stability for the second half of 2024, according to which the murderous terrorist attack that occurred
on 7 October and the &#8220;Iron Swords&#8221; war that began as a result are the materialization of an extreme scenario for geopolitical
turbulence. The materialization of the risk did not result in damage to the financial stability of the economy. This occurred, among
other things, against the background of the high standards of the stabilising regulation implemented until the outbreak of the war and
thanks to the preventive measures taken by the Bank of Israel when everything started and the government&#8217;s assistance plans. According
to the Bank of Israel, the effect of the war is reflected all the main risk exposure channels. However, in light of the policy measures
that moderated the turmoil transmission, the level of risk increased only in the macroeconomic channel, as reflected in the increase
in the country&#8217;s risk premium. According to the Bank of Israel, as the duration of the war, its scope and its negative consequences
on the economy intensify, additional challenges are expected for the financial system.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 363; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On 9 February 2024, the international
rating agency Moody&#8217;s announced the lowering of Israel&#8217;s credit rating to A2 (from a level of A1), and lowered the rating
forecast from &#8220;stable&#8221; to &#8220;negative&#8221;. In the report, the rating agency estimated that the lateral consequences
of the current conflict with Hamas, both when it still continues and after it ends, substantially increase the political risks in Israel,
weaken its legislative and executive authorities, and significantly affect the budgetary stability of Israel in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of the publication of this report, in light of the war being a dynamic occurrence characterized by significant uncertainty,
the Company is unable to assess the full future effects, if any, of the war and/or the expansion of its scope on the automotive industry
in Israel in general and on the Company&#8217;s activities in particular. The Company estimates that its financial stability, along with
its financial sources and taking the actions detailed above (including those covered in Note 1d above), will allow it to continue to
finance its activities and meet its obligations in the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>f. <span style="text-decoration:underline">Separate financial information:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The
                                            Company did not attach separate financial information to these financial statements due to
                                            the negligent value of such additional information. The Company fully owns Global AutoMax,
                                            and as of the date of the report on the financial position, most of the Group&#8217;s business
                                            activity is carried out in Global AutoMax, which is fully reflected in the Group&#8217;s
                                            consolidated report. As of the date of the report on the financial position, the Company
                                            has no business activity and therefore the publication of separate financial statements will
                                            not constitute additional material information for the reasonable investor.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g.
Definitions:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><p style="margin: 0"></p><div>




</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company</span></td>
    <td style="text-align: center; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automax Motors Ltd.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its affiliates</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated companies</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies controlled by the Company (as</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">defined&#160;&#160;in&#160;&#160;IFRS&#160;&#160;10),&#160;&#160;whose&#160;&#160;reports&#160;&#160;are</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated as part of the Company&#8217;s reports.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related parties</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in IAS 24</span></td></tr>
  <tr style="text-align: left; vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stakeholders and holders</span> <span style="font-size: 10pt">of
    controlling </span> interest</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as defined in the Securities Regulations (Annual Financial
    Statements), 5770-2010.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 364; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Unless stated otherwise, the principal
accounting policies as detailed below have been consistently implemented by the Company during the preparation of the financial reports
for all presented periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>a.</b></td><td style="text-align: justify"><b>Statement
                                            regarding implementation of International Financial Reporting Standards (IFRS):</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The consolidated financial statements
of the Group have been prepared in accordance with the International Financial Reporting Standards (hereunder: &#8220;IFRS&#8221;) and
their interpretations as published by the International Accounting Standards Board (IASB).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>b.</b></td><td style="text-align: justify"><b>Application
                                            of securities regulations:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The financial statements have been
prepared in accordance with Securities Regulations (Annual Financial Statements), 5770-2010 (hereunder: &#8220;Financial Statement Regulations&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>c.</b></td><td style="text-align: justify"><b>Operational
                                            turnover period:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The operational turnover period of the Company is 12 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 365; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><!-- Field: Split-Segment; Name: 003 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>d.</b></td><td style="text-align: justify"><b>Format
                                            of the analysis of expenses recognized in profit or loss:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company elected to present profit
or loss and other comprehensive income items using the &#8220;nature of business activity&#8221; method. The Group estimates that due
to the organizational structure of the Group, the classification of expenses in such manner provides more reliable and relevant information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>e.</b></td><td style="text-align: justify"><b>Basis
                                            for preparation of financial statements:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The financial statements of the Company
have been prepared on a cost basis, excluding financial instruments measured at fair value through profit or loss. The Company elected
to present its statement of comprehensive income based on the nature of business activity method.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>f.</b></td><td style="text-align: justify"><b>Consolidated
                                            Financial Statements</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><b>(1)</b></td><td><b>General:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The consolidated financial statements
of the Group include the financial reports of the Company and of entities controlled by the Company, whether directly or indirectly.
An investor company controls an investee company when it is exposed or when it has rights to any variable returns deriving from its holding
of the investee, and when it has the ability to use its power to affect those returns. In determining whether control exists, the Company
considers potential voting rights that could be exercised or converted to shares in the held company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Potential voting rights shall be considered
de-facto rights in the event that the Group has practical ability to realize such rights. When de-facto potential voting rights exist,
such as: convertible instruments, options and forwards of the investee held by the Company or other investing parties, whose realization
shall increase the number of voting rights in the investee - the Group considers whether the existence of said potential voting rights,
together with other existing voting rights, amount to control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The results of the operations of any
subsidiaries acquired or sold during the reported periods are included in the Company&#8217;s consolidated statements of profit and loss,
as of the date that control was attained or the date it ceased to exists, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial statements of subsidiaries
that were not prepared in accordance with the accounting policies of the Group have been adjusted, prior to consolidation, in compliance
with the accounting policy implemented by the Group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For consolidation purposes, all inter-company
transactions, balances, incomes and expenses are fully cancelled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in;"/><td style="width: 0.25in"><b>(2)</b></td><td><b>Business combinations:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Group implements the Acquisition method for all business
combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The acquisition date is the date when
the purchaser attains control of the purchased. Control exists when the Group is exposed, or has rights to variable returns from its
involvement in the purchased, and has the ability to influence these returns through its influence in the purchased. When examining control,
actual rights held by the Group and by others are taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Group recognizes goodwill as of
the acquisition date according to the fair value of the consideration transferred, including amounts recognized with respect to any rights
that do not confer control over the purchased, as well as the fair value as of the acquisition date of an equity interest in the purchased
that was previously held by the Group, with deduction of the net amount attributed in the purchase of identifiable assets acquired and
liabilities assumed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On the purchase date, the purchaser
recognizes a contingent liability it assumed as part of a business combination insofar as a liability arising from past events exists
in the present, and its fair value could be reliably measured.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If the Group makes a bargain purchase
(one that includes negative goodwill), it recognizes the resulting profit in the statement of profit and loss at the date of acquisition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 366; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Furthermore, goodwill that is not updated
due to utilization of losses carried forward for tax purposes that existed at the time of the business combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The consideration transferred includes
the fair value of assets transferred to the previous owners of the purchased, liabilities incurred by the buyer vis-&#224;-vis the
previous owners of the purchased and capital rights issued by the Group. In a business combination achieved in stages, the difference
between the fair value at the time of the acquisition of capital rights in the purchased that were previously held by the Group and their
book value at that time, is recognized in the statement of profit and loss under other income or expenses. In addition, the transferred
consideration includes the acquisition-date fair value of the contingent consideration. Subsequently to the acquisition date, the Group
recognizes changes in the fair value of contingent consideration classified as a financial liability in the profit and loss statement,
while contingent consideration classified as an equity instrument is not measured once again.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in;"/><td style="width: 0.25in"><b>(3)</b></td><td><b>Subsidiaries:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subsidiaries are entities controlled
by the Company. The financial statements of subsidiaries are included in the consolidated financial statements from the day control is
obtained until the day control is lost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accounting policy of subsidiaries
has been changed, if necessary, in order to adjust it to the accounting policy adopted by the Group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in;"/><td style="width: 0.25in"><b>(4)</b></td><td><b>Non-controlling interest:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The share of non-controlling interest
in the net assets (excluding goodwill) of combined subsidiaries is presented separately within the Group&#8217;s equity. Non-controlling
interests include the balance of said interests on the date of business combination and the share of non-controlling interest in any
changes in the combined company&#8217;s equity as of the date of business combination. Any losses of combined companies attributable
to non-controlling interests, that exceed the non-controlling interest in the equity of the combined company, shall be assigned to non-controlling
interests which do not confer control while disregarding their undertakings and the ability of said shareholders to make additional investments
in the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For transactions with non-controlling
shareholders with respect to acquiring additional shares in the combined company, following establishment of control, the excessive costs
of acquisition, which exceed the book value of said non-controlling interests as of the date of acquisition, shall be recognized as part
of equity attributable to the parent company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The results of any transactions with
non-controlling shareholders involving the sale of the Group&#8217;s investment in a combined company, while maintaining control, shall
be recognized as part of equity attributable to the parent company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in;"/><td style="width: 0.25in"><b>(5)</b></td><td><b>Investment in consolidated companies and joint
                                            ventures:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Consolidated companies are entities
in which the Group has a significant influence over the financial and operational policies, yet no control or joint control has been
achieved. There is an assumption which can be refuted according to which holdings of 20% to 50% confer essential influence. In examining
the existence of essential influence, potential voting rights that can be exercised or converted immediately into shares of the held
company are taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Joint ventures are joint arrangements
in which the Group has rights to the net assets of the arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 367; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Investment in consolidated companies
and joint ventures are handled according to the equity method and are initially recognized at cost. The investment cost includes transaction
costs. Transaction costs directly related to the expected acquisition of a consolidated company or a joint venture are recognized as
an asset. The deferred expenses item with respect of an expected acquisition of a consolidated company or a joint transaction is recognized
as an asset in the deferred expenses item of the statement of financial position. These costs are added to the investment cost at the
time of acquisition. When a company first obtains essential influence or joint control in an investment treated as a financial asset
measured at fair value through other comprehensive income until the date of obtaining the essential influence or joint control, other
comprehensive income accumulated in respect of the investment will be credited to the retained earnings balance at that time. The consolidated
financial statements include the Group&#8217;s share of the income and expenses in the profit or loss and of other comprehensive income
of held companies that are handled according to the equity method, after adjustments required to adapt the accounting policy to that
of the Group, from the day on which the essential influence or joint control exists and until the day on which the essential influence
or joint control ceases to exist.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in;"/><td style="width: 0.25in"><b>(6)</b></td><td><b>Transactions eliminated during consolidation:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mutual balances within the Group and
unrealized income and expenses, arising from inter-company transactions, were eliminated as part of the preparation of the consolidated
financial statements. Unrealized profits arising from transactions with consolidated companies and joint transactions were eliminated
against the investment, according to the Group&#8217;s rights in these investments. Unrealized losses were eliminated similarly to the
way in which unrealized gains were eliminated, as long as there were no indications of impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>g.</b></td><td style="text-align: justify"><b>Functional
                                            currency, presentation currency and foreign currency</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><b>(1)</b></td><td><b>Functional currency and presentation currency:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The financial statements of each of
the companies within the Group are prepared in the currency of the primary economic environment in which they operate (hereunder: &#8220;functional
currency&#8221;). For the purpose of consolidation of the financial statements, the results and the financial position of each of the
companies within the Group are converted into NIS, which constitutes the functional currency of the Company. The consolidated financial
statements of the Group are presented in NIS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><b>(2)</b></td><td><b>Conversion of transactions that are not in the
                                            functional currency:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the preparation of the financial
statements of each of the companies within the Group, any transactions carried out in currencies which do not constitute the functional
currency of said company (hereunder: &#8220;foreign currency&#8221;) are documented in accordance with the official exchange rates at
the time they occur. At the end of each reporting period, monetary items denominated in foreign currency are translated in accordance
with the official exchange rates at the time they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><b>(3)</b></td><td><b>Recording exchange rate differences:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Exchange rate differences are recognized
in profit and loss during the period in which they occurred, except in the event that such exchange differences arise from receivable
or payable monetary items originating in foreign operations whose settlement is not planned or expected to happen, which therefore constitute
a part of net investment in foreign operations, in which case they are recognized under other comprehensive income as part of the adjustments
deriving from translation of financial statements of foreign operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 368; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.25in"><b>h.</b></td><td><b>Cash and cash equivalents</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cash and cash equivalents are considered
highly liquid investments. This includes short-term deposits in banking corporations that are non-restricted by liens, with original
maturities that do not exceed three months as of the date of investment, or that exceed three months and yet can be withdrawn immediately
without fines, and constitute a part of the Group&#8217;s cash flow management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.25in"><b>i.</b></td><td><b>Inventory</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Inventory is measured at the lower
of cost and net realizable value. Inventory cost comprises all costs of purchase and any other costs incurred in bringing the inventory
to its present location and condition. Net realizable value constitutes the estimated selling price that would be established in a regular
transaction, deducted of any completion costs and costs required in order to finalize the sale. The Company reviews the state and the
age of its inventory on a periodical basis, and recognizes corresponding slow inventory allowances. For details regarding considerations
taken into account during the review of net realizable value of the new vehicle inventory, see Note 3b1 below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Inventory cost is determined as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Vehicle inventory &#8211;based on specific cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Accessories &#8211; based on average cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0pt"/><td style="width: 0.25in"><b>j.</b></td><td><b>Income Recognition</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"><b>Accounting policies implemented since
1 January 2018 with respect to income recognition are as follows:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income deriving from contracts with
customers are recognized in profit or loss upon the transition of control over the asset or the service to the customer. The price of
the transaction equals the expected consideration amount as per the contract terms, deducted of any amounts collected in favor of third
parties (e.g. taxes).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Following are the specific income
recognition criteria to be fulfilled prior to income recognition:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Income from sales of new vehicles</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income from sales of new vehicles
and spare parts is recognized upon transfer of control over the new vehicle or the spare parts to the customer. Usually, control is transferred
when the vehicle is delivered to the customer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Income from sales of used vehicles</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income from sales of used vehicles
is recognized upon transfer of control over sold used vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Credit transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company elected to use the relief
provided by the standard, based on which it would not be required to separate the credit component in transactions with credit terms
of less than 12 months and would recognize income in accordance with the consideration amounts as set within the contract, even in the
event the customer pays before or after the date the product or service are delivered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5pt"/><td style="width: 14.5pt"><b>k.</b></td><td><b>Income Tax</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The taxes on income that are included
in the statement of profit and loss include current taxes, taxes with respect to prior years and deferred taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Tax expenses comprising current or
deferred tax expenses are recognized in profit or loss, except in the event said taxes derive from items recognized in other comprehensive
income or in equity. In such case, the tax amount is recognized in the corresponding item within equity as well.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Current taxes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The current tax liability is determined
while using tax rates that have been enacted or substantively enacted by the reporting date, as well as any adjustments required with
respect to tax liabilities from prior years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 369; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax
                                            Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Deferred taxes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Deferred taxes are calculated on temporary
differences between the amounts as presented in the financial statements and amounts adjusted for tax purposes. Deferred tax balances
are calculated using the expected tax rates that would apply upon the realization of the asset or the removal of the liability, based
on tax laws that have been enacted or substantively enacted by the reporting date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On every reporting date, deferred
tax assets are reviewed according to their expected usage. Losses carried forward and deductible temporary differences for which deferred
tax assets have not been recognized are reviewed at each reporting date and an appropriate deferred tax asset is recognized for them
if it is expected that they will be utilized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In calculating deferred tax amounts
the Company does not take into consideration any taxes that would apply in the event of the realization of investments in held entities,
as long as the sale of the held entities is not expected in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>l.</b></td><td style="text-align: justify"><b>Leases</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Initial implementation of IFRS 16
&#8211; Leases (hereunder: the &#8220;Standard&#8221;) &#8211; the Company elected to implement the provisions of the Standard using
the modified retrospective manner (without restatement of comparative figures). The Company adopted the following accounting policy as
of 1 January 2018 with respect to leases:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company treats the contract as
a lease when, in accordance with the terms of the contract, the right to control an identified asset is transferred for a period of time
in exchange for consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b><span style="text-decoration:underline">(1)</span></b></td><td style="text-align: justify"><b><span style="text-decoration:underline">The
                                            Group as a lessee</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For transactions in which the Company
serves as a lessee, it recognizes the leased property as a right of use asset as of the beginning of the lease term against a lease liability,
excluding lease transactions with lease terms of less than 12 months and lease transactions where the underlying asset is of low value,
in which case the Company recognizes lease related expenses in profit or loss using the straight line method over the lease term. As
part of the measurement of the liability for a lease, the Company chose to apply the relief provided in the Standard and did not make
a separation between lease components and non-lease components such as: management services, maintenance services and more that were
included in the same transaction on the date the liability for the lease commenced. This includes all lease payments not yet paid, capitalized
with the interest rate included in the lease when it can be easily determined, or with the Company&#8217;s additional interest rate.
After this date, the Company measures the lease liability using the effective interest method. The right-of-use asset on the formation
date is recognized at the amount of the lease liability plus lease payments paid on or before that date plus any transaction costs incurred.
The right-of-use asset is measured by the cost model and depreciated over its useful life or over the lease term, whichever is shorter.
Below are data regarding the number of years of depreciation of the relevant right-of-use assets according to groups of right-of-use
assets:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: center"><b>Number</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>years</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Mainly</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Land and office buildings</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">1-6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">4</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vehicles</td><td>&#160;</td>
    <td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">5</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">When indicators of impairment exist,
the Company reviews whether there is a need to recognize any right-of-use asset impairment subject to the provisions of IAS 36.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>(2)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">CPI-linked
                                            lease payments</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At the time the lease is created, the
Company uses the index rate existing at that time for the purpose of calculating future lease payments. For transactions in which the
Company constitutes the lessee, any changes in future lease payments originating in index variations are capitalized (without amending
the capitalization rate used for lease liability calculations) to the balance of the right-of-use asset and are credited as an adjustment
to the balance of the lease obligation. Only when there is a change in the cash flows resulting from a change in the index (that is,
at the time when the coordination of the lease payments takes effect).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>(3)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Options
                                            for extending and canceling a lease period</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The lease period that cannot be canceled
includes both periods covered by an option to extend the lease when it is reasonably certain that the option to extend will be exercised,
and periods covered by an option to cancel the lease when it is reasonably certain that the option to cancel will not be exercised. In
the event that there is a change in the expectation for exercising an extension option or for not exercising a cancellation option, the
Company recalculates the remaining liability for the lease in accordance with the updated lease period, according to the updated discount
rate on the day of the change in expectation, with the total change credited to the balance of the right-of-use asset until it is reset,
and beyond that to profit or loss.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 370; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>(4)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Lease
                                            revisions</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">When the Company amends the terms of
a lease, and said amendment does not reduce the scope of the lease and is not handled as a separate lease transaction, the Company re-measures
the balance of its lease liability in accordance with the new lease terms, using the discount rate applicable on the modification date,
and credits the change in the liability balance for the lease to the balance of the right to use asset. When an amendment is made to
the terms of the lease that results in a reduction in the scope of the lease, the Company recognizes the profit or loss resulting from
the partial or full write-off of the balance of the right-of-use asset and the liability for the lease. Subsequently, the Company re-calculates
the balance of the lease liability in accordance with the new lease terms, using the discount rate applicable on the modification date,
and credits the change in the liability balance for the lease to the balance of the right to use asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>m.</b></td><td style="text-align: justify"><b>Fixed Assets</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>(1)</b></td><td style="text-align: justify"><b>Fixed
                                            asset items are measured at cost with deduction of accrued depreciation and accrued impairment
                                            losses</b></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The cost of fixed assets includes expenses
directly attributable to the purchase of the asset. The cost of self-constructed assets includes the cost of materials and direct labor,
as well as any additional cost that can be directly attributed to bringing the asset to the location and condition necessary for it to
be able to operate in the manner intended by the management, an estimate of the costs of dismantling and removing the items and restoring
the site where the item is located, as well as credit costs that have been used. The cost of purchased software, which is an integral
part of the operation of the related equipment, is recognized as part of the cost of this equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The spare parts, auxiliary equipment
and backup equipment are classified as fixed assets when they meet the definition of fixed assets according to IAS-16, and otherwise
they are classified as inventory. A fixed asset item purchased in exchange for another non-monetary item as part of a commercial transaction
is recognized at fair value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">When significant fixed asset parts have different life spans,
they are treated as separate items (significant components) of the fixed asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Changes in the obligation to dismantle
and remove items and restore the site where they are located, except for changes resulting from the passage of time, are added to or
subtracted from the cost of the property in the period in which they occur. The amount deducted from the cost of the asset shall not
exceed its book value. The balance, if any, is immediately recognized in profit and loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Profit or loss arising from deducting
a fixed asset item is determined by comparing the net proceeds from deducting the asset to its book value, and recognized net in the
other income or other expenses items, as the case may be, in the profit and loss statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>(2)</b></td><td style="text-align: justify"><b>Depreciation</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation is a systematic allocation
of the depreciable amount of an asset over its useful life. A depreciable amount is the cost of the asset, or another amount that replaces
the cost deducted of its residual value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">An asset is depreciated when it is available for use, that
is, when it has reached the location and condition necessary for it to be able to operate in the manner intended by management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation is recognized in the profit
and loss statement using the straight-line method over the estimated useful life of each component of the fixed asset items, since this
method reflects the predicted consumption pattern of the future economic benefits inherent in the asset in the best way. Assets leased
under financing leases are depreciated over the shorter of the lease term and the useful life of the assets, unless it is reasonably
expected that the Group will receive ownership of the asset at the end of the lease term. Owned lands are not depreciated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The estimated useful life for the current period and the
comparison period is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5-10</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout the leasing&#160;&#160;period
    including extension option</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15-33</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mainly 33%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-33</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mainly 25%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicles</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15-20</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mainly 15%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 371; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Leasehold improvements are depreciated
using the straight-line method over the lease period (including the Group&#8217;s lease term extension option which it is planning to
exercise) or over the useful life of the improvement, whichever is shorter. The Company reviews the useful life period, the depreciation
method and the residual value of each asset at least annually. Any adjustments are implemented as a change in an accounting estimate,
in a prospective manner. Depreciation of assets is terminated as soon as possible between the date on which the asset is classified as
held for sale and the date on which the asset is written off.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The estimates regarding the depreciation
method, the useful life and the residual value are re-examined at least at the end of each reporting year and adjusted when necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>n.</b></td><td style="text-align: justify"><b>Intangible assets</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Intangible assets that are acquired
separately are measured upon initial recognition at cost plus direct acquisition costs. Intangible assets purchased as part of business
combinations are included based on fair value on the date of acquisition. Costs related to internally developed intangible assets, excluding
capitalized development costs, are recognized in the profit or loss as incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The intangible assets of the Group
have a defined useful life. The assets are amortized over their economic useful life, while the need for impairment is reviewed whenever
impairment indicators exist. The amortization period and method are reviewed at least annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Goodwill</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Goodwill arising from an acquisition
of a business is measured by the excess of the acquisition cost, plus the fair value of the rights that do not confer control, including
the net fair value of the identified assets, liabilities and contingent liabilities of the consolidated company recognized at the time
of acquisition. The method of measuring goodwill, in accordance with the alternatives listed above, is determined individually in each
business combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Goodwill is recognized for the first
time as an asset at cost, and is measured in subsequent periods at cost deducted of accumulated impairment losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For the purpose of examining impairment,
goodwill is allocated to each of the Group&#8217;s cash-generating units that are expected to benefit from the synergy of the business
combination. Cash-generating units to which goodwill has been allocated are reviewed annually or more frequently insofar as indicators
attesting to a possible decrease in value of said unit exist. When the recoverable amount of a cash-generating unit is less than the
book value of that unit, the impairment loss is allocated first to reduce the book value of any goodwill attributed to the cash-generating
unit. After that, the remaining impairment loss, if any, is allocated to other assets of the cash-generating unit, in proportion to their
book value. An impairment loss of goodwill is not eliminated in subsequent periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Upon disposal of a consolidated company,
the amount of the related goodwill is included in determining the profit or loss from the disposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Website</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company operates an official website
and official Facebook and Instagram pages, where it publishes product updates and promotions. In addition, the Company also operates
a LinkedIn page.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 372; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Licenses</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The capitalized costs for the license
are the costs of purchasing the license and costs that can be directly attributed and which are needed to obtain the license and include,
among others, legal costs and consultants, travel costs abroad and salary costs that can be directly attributed to the license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The capitalization of the costs for
the license begins in the development phase and stops when the license is achieved, that is, when the property is in the necessary condition
in order to be able to operate in the way management intended. Initial costs incurred during the research phase, meaning amounts used
for obtaining knowledge and for searching for dealers and sub-agents, cannot be capitalized and shall therefore be recognized as incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The useful life of a license shall
not exceed the term of its contractual rights, yet the useful life might be shorter, according to the period the Company expects to use
the license. In the event the contractual rights are provided for a renewable limited period, the useful life of the license shall include
the renewal period only insofar as evidence exists supporting the Company&#8217;s intent of such renewal without incurring material costs.
In the opinion of the Company, the requirements for including the renewal period as part of the useful life of the license have not been
fulfilled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Depreciation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Depreciation is a systematic allocation
of the depreciable amount of an intangible asset over its useful life. A depreciable amount is the cost of the asset, deducted of its
residual value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The depreciation is recognized in
profit and loss using the straight-line method, over the estimated useful life of the intangible assets as of the date when the assets
are available for use, since these methods reflect the predicted consumption pattern of the future economic benefits inherent in each
asset in the best way. Goodwill and intangible assets with an indefinite lifespan are not systematically depreciated, but are tested
at least once a year for impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 373; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>





</div><!-- Field: Split-Segment; Name: 004 --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Intangible assets that are formed
in the Group are not systematically depreciated as long as they are not available for use, that is, they are not in the location and
condition required for them to be able to operate in the way management intended. Therefore, these intangible assets, such as development
costs, are tested for impairment at least once a year, until the time they become available for use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The estimated useful life for the
current period and the comparative periods is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 88%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Website</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td>
    </tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licenses</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout</span> license
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">validity period</span></td>
    </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The estimates regarding the useful
life and the residual value are re-examined at least at the end of each reporting year and adjusted when necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Group reviews the estimated
useful life of an intangible asset that is not amortized at least annually in order to determine whether the events and circumstances
continue to support the determination that the intangible asset has an indefinite life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>o.</b></td><td style="text-align: justify"><b>Impairment
                                            of non-financial assets</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company reviews the need for impairment
of non-financial assets whenever indicators resulting from events or changes in circumstances show that the carrying amounts as stated
in the financial reports may not be recoverable. In the event the carrying value of non-financial assets exceeds their recoverable amount,
said value is reduced to the value of the recoverable amount. The recoverable amount of an asset is determined as the higher of fair
value deducted by cost of disposal, and its value of use. In assessing the value of use, the expected cash flows are capitalized according
to a pre-tax discount rate that reflects the specific risks for each asset. For assets which do not generate individual cash flows, the
recoverable amount is determined for the cash-generating unit to which they can be attributed. Any impairment losses are recognized in
profit and loss. An impairment loss of an asset, with the exception of goodwill, is canceled only when there have been changes in the
estimates used to determine the asset&#8217;s recoverable amount from the date the impairment loss was last recognized. Such impairment
reversal is limited to the lower of previously recognized impairment (deducted of depreciation or amortization) and the recoverable amount
of the asset. As for assets measured at cost, said impairment reversal shall be recognized in profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>p.</b></td><td style="text-align: justify"><b>Financial
                                            instruments</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On 1 January 2018 the Company implemented
the provisions of IFRS 9 &#8211; Financial Instruments (hereunder: the &#8220;Standard&#8221;) for the first time. The Company elected
to implement the provisions of the Standard using the modified retrospective manner, without restatement of comparative figures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The accounting policy implemented
with respect to financial instruments as of 1 January 2018, is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>(1)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Financial
                                            assets</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial assets are initially measured
at fair value, plus any transaction related costs directly attributable to the acquisition of the financial asset, excluding financial
assets measured at fair value through profit or loss, for which transaction related costs are recognized in profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company classifies and measures
debt instruments in its financial statements based on the following criteria:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Company&#8217;s
                                            business model for managing financial assets, and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the contractual
                                            cash flow characteristics of the financial asset.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 374; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">a.</td><td><span style="text-decoration:underline">The Company measures debt instruments at amortized cost
                                            when:</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company&#8217;s business model is
holding the financial assets in order to collect contractual cash flows, and the contractual terms of the financial assets provide entitlement
at specified times to cash flows that are only principal and interest payments for the principal amount that has not yet been repaid.
After initial recognition, debt instruments in this Group are measured according to their terms at amortized cost using the effective
interest method and deducting an allowance for impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">At the time of first recognition, a company
can designate, without the possibility of changing this designation, a debt instrument as measured at fair value through profit or loss,
if this designation eliminates or significantly reduces inconsistencies in measurement or recognition, for example in the case where
the related financial liability is also measured at fair value through profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">b.</td><td><span style="text-decoration:underline">The Company measures debt instruments at fair value through
                                            other comprehensive income when:</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company&#8217;s business model is
holding the financial assets in order to collect contractual cash flows, and the contractual terms of the financial assets provide entitlement
at specified times to cash flows that are only principal and interest payments for the principal amount that has not yet been repaid.
Following initial recognition, all instruments within this Group are measured at fair value. Any gains or losses arising from fair value
adjustments, except interest and exchange rate differences, are recognized through other comprehensive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">c.</td><td><span style="text-decoration:underline">The Company measures debt instruments at fair value through
                                            profit or loss when:</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A financial asset that is a debt instrument
does not meet the criteria for measuring it at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses as a result of fair value adjustments are credited to profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">d.</td><td><span style="text-decoration:underline">Equity instruments and other financial assets held for
                                            trading</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Investments in capital instruments that
do not meet the aforementioned criteria and are therefore measured at fair value through profit or loss. Other financial instruments
held for trading, such as derivatives, including embedded derivatives separated from their host contracts, are measured at fair value
through profit or loss, unless designated to serve as effective hedging instruments. With respect to certain equity instruments not held
for trading, upon initial recognition the Company may irrevocably elect to present as part of other comprehensive income any subsequent
fair value changes which otherwise would have been measured at fair value through profit or loss. These changes will not be attributed
to profit or loss in the future, not even when the investment is withdrawn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Dividend incomes deriving from investments
in equity instruments are recognized on the effective date for dividend eligibility, in the statement of profit and loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>(2)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Impairment
                                            of financial assets</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Group examines, on each reporting
date, the provision for loss for financial debt instruments that are not measured at fair value through profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>(3)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Financial
                                            liabilities</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="text-decoration:underline">Financial liabilities measured at amortized cost</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Upon initial recognition, the Company measures financial
liabilities at fair value, deducted of any transaction related costs directly attributable to issuance of the financial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 375; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Following the initial recognition,
the Company measures all of its financial liabilities at amortized cost, while using the effective interest rate method, excluding:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Financial liabilities at fair value
through profit or loss, such as derivatives;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">a.</td><td style="text-align: justify">Financial liabilities that arise
                                            when the transfer of a financial asset does not qualify for amortization or when the continuing
                                            involvement approach applies;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">b.</td><td style="text-align: justify">Financial guarantee contracts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">c.</td><td style="text-align: justify">Obligations to provide a loan at
                                            an interest rate lower than the market interest rate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">d.</td><td style="text-align: justify">Contingent consideration recognized
                                            by a purchaser in a business combination to which International Financial Reporting Standard
                                            3 applies.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>(4)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Warrants
                                            for the purchase of shares of the Company and/or a consolidated company</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Receipts for the issuance of warrants
to purchase the shares of the Company and/or a consolidated company, which give the holder the right to purchase a fixed number of ordinary
shares in exchange for a fixed amount of cash, are presented within the capital in the section &#8220;Share-based payment&#8221;. In
this context, for an exercise amount that changes according to the exercise date, the exercise price can be determined for any possible
exercise date on the issuance date, and therefore it is considered a fixed amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 376; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>(5)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Derivative
                                            financial instruments for hedging (protection) purposes</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">At times, the Company enters into engagements
involving derivative financial instruments, such as foreign currency forwards, in order to mitigate risks arising from foreign currency
exchange rates&#8217; fluctuation.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Group does not implement accounting
hedging. Profits or losses deriving from changes in fair value of derivatives that are not held for hedging purposes, are immediately
recognized in profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>(6)</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Offsetting
                                            financial instruments</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial assets and financial liabilities
are offset against each other. The net amount is presented as part of the statement of financial position, in the event the Company has
a legally enforceable right to offset any amounts recognized, and insofar as the Company intends to clear the asset or the liability
on a net basis, or realize the asset while clearing the liability, in parallel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>q.</b></td><td style="text-align: justify"><b>Fair
                                            value measurement</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Fair value is the price that would
have been received for the sale of an asset or the price that would have been paid to transfer a liability in a normal transaction between
market participants at the time of measurement. Fair value measurement is based on the assumption that the transaction is made in the
active market of the asset or the liability, or in absence of active markets, the most advantageous market. The fair value of the asset
or the liability is measured by using the following assumptions: that it would be used by market participants for quoting the price of
the asset or liability, and that market participants act with the purpose of achieving their economic interests. Fair value measurement
for a non-financial asset takes into account the ability of a market participant to generate economic benefits by using the asset in
its best use or by selling it to another market participant who will use the asset in its best use. The Group uses valuation techniques
that are appropriate to the circumstances and for which there is sufficient obtainable data to measure fair value, while maximizing the
use of relevant data. All assets and liabilities measured or presented at fair value are categorized into different fair value levels
based on the lowest data level that is significant for the fair value measurement as a whole:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Level 1: Quoted prices (not adjusted) in active markets
for identical assets and liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Level 2: Data other than quoted prices
included in level 1 which can be directly or indirectly observed. Level 3: Data not based on observable market data (valuation techniques
without the use of observable market data).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>r.</b></td><td style="text-align: justify"><b>Provisions</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A provision is recognized when the
Group has a current legal or implied obligation, as a result of an event that occurred in the past, that can be reliably measured, and
when it is expected that a negative flow of economic benefits will be required to settle the obligation. Provisions are determined by
capitalizing future cash flows using the pre-tax interest rate which reflects current market assessments with respect to the time-value
of the cash and the specific risks of the liability without taking the Company&#8217;s credit risk into consideration. The book value
of the provision is adjusted in each period in order to reflect the passage of time. The amount of the adjustment is recognized as financing
expenses. The Group recognizes indemnification assets if and only if it is virtually certain that the indemnification amount would be
received insofar as the liability is settled. The recognized amount with respect to the indemnification shall not exceed the value of
the provision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>Legal Claims</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A provision for claims is recognized
when the Group has a legal obligation at present or an implied obligation as a result of a past event, when it&#8217;s more likely than
not that the Group will require its financial resources to settle the obligation and when it can be reliably estimated. When the effect
of the time value is material, the provision is measured according to its present value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 377; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>s.</b></td><td style="text-align: justify"><b>Share-based
                                            payments:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Share-based payments to employees
and others who provide similar services that are settled in the Company&#8217;s capital instruments are measured at their fair value
at the time of granting. The Company measures at the time of granting the fair value of the capital instruments granted by using the
Black-Scholes model. When the capital instruments granted do not mature until those employees complete a specified period of service
during which the employees may also be required to meet certain performance conditions, the Company recognizes the share-based payment
arrangements in the financial statements over the vesting period against capital growth, under the section &#8220;Capital fund for share-based
payment&#8221;. At the end of each reporting period, the Company estimates the number of capital instruments expected to mature. A change
in estimate compared to previous periods is recognized in profit or loss over the remainder of the vesting period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>t.</b></td><td style="text-align: justify"><b>Profit
                                            (loss) per share</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Profit per share is calculated by
dividing net profit attributable to Company shareholders by the weighted number of actual ordinary shares that exist for the period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Potential ordinary shares are included
in the calculation of diluted profit per share in the event their effect dilutes the profit per share that arises from ongoing operations.
Potential ordinary shares converted during the period shall be included as part of the diluted profit per share, only until the date
they are converted. As of said date, potential ordinary shares shall be included in the basic profit per share. The Company&#8217;s share
in profits of subsidiaries is calculated based on the Company&#8217;s portion in the profit-per-share of the subsidiaries, multiplied
by the number of shares held by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>u.</b></td><td style="text-align: justify"><b>Accounting
                                            aspects of Global AutoMax Ltd. merger transaction</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">As
                                            part of the transaction described in note 1 (b) above, the Company issued shares for the
                                            purpose of purchasing all of Global AutoMax&#8217;s shares. The Company constitutes the legal
                                            buyer of the transferred operation. However, since as of the date the transaction was finalized
                                            Global AutoMax&#8217; shareholders became the Company&#8217;s controlling shareholders with
                                            the power to determine its financial and operational policies, the Company constitutes the
                                            accounting acquiree in the transaction. Therefore, the transaction is treated in the financial
                                            statements as a reverse purchase in which the net assets of the Company are considered as
                                            assets purchased by Global AutoMax (the accounting purchaser). In addition, since at the
                                            time of the transaction the Company was without any business activity, then it is not a &#8220;business&#8221;
                                            as defined by International Financial Reporting Standard IFRS 3 and therefore the transaction
                                            was treated as a share issue. The financial statements prepared after the completion of the
                                            transaction as stated above were described as a continuation of the financial statements
                                            of Global AutoMax and the comparative information presented in these reports will be for
                                            Global AutoMax only, excluding the activity previously reported as part of the Company&#8217;s
                                            financial statements.</p>
<p style="margin-top: 0; margin-bottom: 0"></p>

</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Below
                                            are the principles that were applied in the context of the accounting treatment of the purchase
                                            of the Company by Global AutoMax, which was handled in the way of a &#8220;reverse purchase&#8221;.</p>
<p style="margin-top: 0; margin-bottom: 0"></p>

</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The assets
                                            and liabilities of the accounting purchaser and accounting acquiree were recognized in the
                                            consolidated financial statements according to their book value immediately before the transaction.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Surpluses
                                            and the other capital items of the consolidated entity after the merger transaction are those
                                            of the accounting purchaser Global AutoMax, which is the legal subsidiary (shortly before
                                            the business combination). The structure of the legal capital, i.e. the type and number of
                                            remaining shares of the Company (the legal parent company).</p>

</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The accounting
                                            acquiree was a shelf corporation as of the date of the transaction. As a result of the transaction,
                                            no original differences or goodwill were created. The difference between the consideration
                                            for the value of the capital instruments of the Company (the accounting acquiree) on the
                                            day of completion of the transaction and the balance sheet value of the net assets of the
                                            accounting acquiree on the day of completion of the transaction is credited as one-time expenses
                                            for the registration for trading.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Comparative
                                            information presented in the consolidated financial statements for the periods preceding
                                            the date of the transaction is that of the accounting purchaser.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 378; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>v.</b></td><td style="text-align: justify"><b>Implementation
                                            of new financial reporting standards and amendments to existing accounting standards for
                                            the first time</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify"><span style="text-decoration:underline">Amendment
                                            to IAS 1, Disclosure of Accounting Policies</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In February 2021, the IASB published
an amendment to International Accounting Standard 1:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Presentation of Financial Statements
(hereunder: &#8220;the amendment&#8221;). In accordance with the amendment, companies will be required to provide disclosure of their
material accounting policies instead of the current requirement to provide disclosure of their significant accounting policies. One of
the main reasons for this amendment stems from the fact that the term &#8220;significant&#8221; does not have a definition in the IFRS
while the term &#8220;material&#8221; has a definition in various standards and in particular in IAS 1.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The standard will be applied for annual
periods beginning on 1 January 2023.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The above amendment had an impact on
the Company&#8217;s accounting policy disclosures, but had no impact on the measurement, recognition or presentation of any items in
the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify"><span style="text-decoration:underline">Amendment
                                            to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In February 2021, the IASB published
an amendment to International Accounting Standard 8: Accounting Policies, Changes in Accounting Estimates and Errors (hereunder: &#8220;the
amendment&#8221;). The purpose of the amendment is to introduce a new definition of the term &#8220;accounting estimates&#8221;.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Accounting estimates are defined as
&#8220;financial amounts in the financial statements that are subject to measurement uncertainty.&#8221; The amendment clarifies what
changes in accounting estimates are and how they differ from changes in accounting policy and error corrections.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The amendment was applied prospectively
for annual periods beginning on 1 January 2023 and applies to changes in accounting policies and accounting estimates that occur at the
beginning of that period or afterwards.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The above amendment did not have a
material impact on the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.</td><td><span style="font-size: 10pt"><span style="text-decoration:underline">Amendment to IAS 12 Taxes
                                            on Income</span></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In May 2021, the IASB published an
amendment to International Accounting Standard 12, Taxes on Income (hereunder: &#8220;IAS 12&#8221; or &#8220;the standard&#8221;) which
reduces the applicability of the &#8216;first recognition exception&#8217; in deferred taxes stated in Articles 15 and 24 of IAS 12 (hereinafter:
&#8220;the amendment&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As part of the guidelines for the recognition
of deferred tax assets and liabilities, IAS 12 excludes the recognition of deferred tax assets and liabilities for certain temporary
differences arising from the initial recognition of assets and liabilities in certain transactions. This exception is called the &#8216;first
recognition exception&#8217;. The amendment narrows the applicability of the &#8216;first recognition exception&#8217; and clarifies
that it does not apply to the recognition of deferred tax assets and liabilities arising from a transaction that is not a business combination
and for which equal temporary differences arise in debit and credit even if they meet the other conditions of the exception.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The standard will be applied for annual
periods beginning on 1 January 2023 or later. Early application is possible. Regarding lease transactions - the amendment will be applied
starting from the beginning of the earliest reporting period shown in the financial statements in which the amendment was first applied,
attributing the cumulative effect of the application for the first time to the opening balance of the surpluses (or another component
of capital, as applicable) for that date.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The above amendment did not have a
material impact on the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 379; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 3 - The main considerations, estimates and assumptions
in preparing the financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In preparing the financial statements in accordance
with the IFRS, the Company&#8217;s management is required to use discretion in assessments, estimates and assumptions that affect the
implementation of the accounting policy and the amounts of assets and liabilities, income and expenses. It is hereby clarified that the
actual results may differ from said estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the formulation of accounting estimates
used in the preparation of the Group&#8217;s financial statements, the Company&#8217;s management was required to make assumptions regarding
circumstances and events involving significant uncertainty. In its discretion in formulating the estimates, the Company&#8217;s management
bases the estimates on past experience, various facts, external factors and reasonable assumptions according to the circumstances appropriate
to each estimate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimates and assumptions based on which
changes in recognized accounting estimates are regularly reviewed are recognized in the period in which the estimates were revised and
in any affected future period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding assumptions made by the
Group regarding the future and other main factors of uncertainty in connection with estimates where there is a significant risk that
their result will be a substantial adjustment to the book values of assets and liabilities during the next financial year is included
in the following notes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>a.</b></td><td style="text-align: justify"><b>The
                                            considerations</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>Discount rate of a liability for a lease</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company cannot easily determine
the interest rate inherent in leases, and therefore for the purpose of calculating the liabilities for a lease, it uses the additional
interest rate of the Company. The additional interest rate determined by the Company constitutes the interest rate that the Company had
to pay on a loan for a period similar to the lease period and with similar security, in order to obtain an asset of similar value to
the right-of-use asset resulting from the lease, and all in a similar economic environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.5pt"/><td style="width: 18.5pt"><b>b.</b></td><td><b>Estimates and assumptions</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In preparing the financial statements,
management is required to use estimates, evaluations and assumptions that affect the implementation of the accounting policies and the
amounts reported for assets, liabilities, income and expenses. Actual results may differ from management&#8217;s estimates. The changes
in the accounting estimates are credited in the period in which the change in the estimate is made. Below are the main assumptions made
in the financial statements in connection with the uncertainty for the reporting date and critical estimates calculated by the Group,
where a material change in the estimates and assumptions may change the value of assets and liabilities in the financial statements in
the following reporting periods:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Determining
                                            the net disposal value of the new vehicle inventory</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company regularly examines the
realizable value of its inventory, and in particular the inventory of new vehicles. As part of the considerations used to determine the
realization value of the new vehicle inventory, the Company estimates the expected sales prices of the inventory and the total additional
costs that it is expected to incur in order to complete the sale, including agent commission payments and costs for preparing the vehicle
for sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Legal
                                            Claims</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In assessing the chances of the results
of the lawsuits filed against the Company and its held companies, the companies relied on the opinions of their legal advisors. These
evaluations of the legal advisors are based on their best professional judgment, taking into account the stage of the proceedings as
well as the legal experience gained in the various issues. Since the results of the legal claims will be determined by the courts, these
results may differ from the estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 380; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 3 - The main considerations, estimates and assumptions
in preparing the financial statements (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><b>3.</b></td><td><b><span style="text-decoration:underline">Pension benefits and other benefits after employment
                                            is terminated</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The liability for post-employment
benefit plans is determined using actuarial valuation techniques. Calculating the liability involves determining assumptions regarding
discount rates, expected rates of return on assets, the wage increase rate and employee turnover rates, among other assumptions. The
balance of the obligation may be significantly affected by changes in these estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><b>4.</b></td><td><b><span style="text-decoration:underline">Lease transactions that include extension and
                                            cancellation options</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">For the purpose of assessing whether
it is reasonably certain that the Company will exercise an option to extend a lease period or to cancel a lease period, the Company takes
into account all the relevant facts and circumstances that create an economic incentive for the Company to exercise or not exercise the
option, such as: significant amounts invested for improvements to the leased property, the importance of the underlying asset and the
uniqueness inherent in it for the purpose of the Company&#8217;s activity, the Company&#8217;s past experience in similar lease transactions
and more.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">After the start date, the Company
re-evaluates whether it is reasonably certain that it will or will not exercise an option when a significant event or a significant change
in circumstances occurs that has the potential to influence the Company&#8217;s decisions regarding the exercise of the option, such
as: significant improvements made to the leased property that were not foreseen at the start date, entering into a lease of a sub-asset
of the base asset for a period that exceeds the end of the previously determined lease period and more.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 4 - New standards and interpretations that have not yet
been adopted</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Standard/interpretation/<br/>
    correction</b></td>
    <td style="text-align: justify"><b>&#160;</b></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center"><b>Financing expenses</b></td>
    <td style="text-align: justify"><b>&#160;</b></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center"><b>Beginning and<br/>
    transition instructions</b></td>
    <td style="text-align: justify"><b>&#160;</b></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center"><b>Expected effects</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to
    IAS 1, Presentation of Financial Statements: Classification of Current or Non- Current Liability</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amendment
    replaces certain classification&#160;&#160;requirements of liabilities&#160;&#160;as&#160;&#160;current&#160;&#160;or&#160;&#160;non-
    current. For example, according to the amendment, a liability will be classified as non-current when the entity has the right to
    postpone payment for a period of at least 12 months after the reporting period, when it has &#8220;substance&#8221; and when it exists
    at the end of the reporting period,&#160;&#160;and&#160;&#160;this&#160;&#160;replaces&#160;&#160;the requirement for a right that
    is &#8220;unconditional&#8221;. According to the amendment, a right exists as of the reporting date only if an entity meets the conditions
    for deferring payment&#160;&#160;as&#160;&#160;of&#160;&#160;this&#160;&#160;date.&#160;&#160;In addition, the amendment clarifies
    that the right to convert a liability will affect the classification of the instrument as a whole as current or non-current, unless
    the conversion component is equity.</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amendment
    will be implemented in reporting periods beginning on 1 January 2024, with the possibility of early implementation. The amendment
    will be applied retroactively, including the amendment of comparison numbers.</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The implementation
    of the standard is not expected to have a material impact on the Company&#8217;s reports. </span></td></tr>

<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to
    IFRS16, Leases: Liability for Lease on Sale and Leaseback</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amendment
    clarifies the accounting treatment of variable payments for a seller-lessee in a sale and leaseback transaction. According to the
    amendment, a seller-lessee will include variable lease&#160;&#160;payment estimates when measuring the lease liability for the first
    time, and additionally after recognition for the first time the&#160;&#160;lessee-lessor&#160;&#160;applies&#160;&#160;the requirements
    to the subsequent measurement of the lease liability, so that no profit and loss is recognized relating to the right of use remaining
    in the hands of the seller-lessee.</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amendment
    will be implemented in reporting periods beginning on 1 January 2024, with the option of early implementation. The amendment will
    be applied retroactively, for sale and leaseback transactions that occurred after the adoption of IFRS 16, including the amendment
    of comparison numbers.</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group is
    examining the consequences of the amendment on the financial statements without the intention of early implementation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 381; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Split-Segment; Name: 005 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
                                            5 - Cash and cash equivalents</span></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
    for 31 December</b> &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
    </b>&#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash in banking corporations in Israeli currency</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,958</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash in banking corporations in foreign currency</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Short-term deposits in foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><b>Total cash and cash equivalents</b></td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,552</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><b>2,234</b></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
6 &#8211; Customers</span></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
    for 31 December</b> &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">A. The composition:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Open debts</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,709</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,649</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Checks for collection and credit cards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,965</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,941</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Less - provision for doubtful debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><b>Total net customers</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>26,552</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>17,819</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Customer
debts do not bear interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>b.</b></td><td style="text-align: justify"><b>Below is the movement in the provision
                                            for doubtful debts:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Thousands<br/>
    of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance as for 1 January 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(122</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recognition of written off bad debts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Cancellation for secured debts that have been collected</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as for 31 December 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Recognition of written off bad debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Balance as for 31 December 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(122</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 382; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 6 - Customers (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>c.</b></td><td style="text-align: justify"><b>Information
                                            regarding the Company&#8217;s exposure to credit risk regarding customer balances:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Customers
                                            whose due date has passed</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">and the delay
                                            in their collection is</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Customers<br/>
    whose<br/>
    repayment<br/>
    date has not<br/>
    yet arrived<br/>
    (without<br/>
    arrears in<br/>
    collection)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Up to 60<br/>
    days</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">60-90<br/>
    days</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than<br/>
    90 days</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As for 31 December 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Customer balance before provision</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,143</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,123</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,704</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,709</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Doubtful debts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Balance of provision for doubtful debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,143</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,123</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,617</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,587</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Customers
                                            whose due date has passed</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">and the delay
                                            in their collection is</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Customers<br/>
    whose<br/>
    repayment<br/>
    date&#160;has not<br/>
    yet&#160;arrived<br/>
    (without<br/>
    arrears in<br/>
    collection)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Up to 60<br/>
    days</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">60-90<br/>
    days</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More<br/>
    than 90<br/>
    days</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As for 31 December 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Customer balance before provision</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">268</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,015</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,649</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Doubtful debts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Balance of provision for doubtful debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,366</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,527</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 383; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
7 - Receivables and debit balances</span></b></span></p><div>



</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As for 31 December</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advanced payments to suppliers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,287</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">39,494</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses in advance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Receivables and other debit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Value Added Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,556</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>The assessing officer - a company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Asset for future transactions (forward)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>34,801</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>48,331</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
8 - Vehicles inventory</span></b></span></p><div>



</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As for 31 December</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">a. The composition:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">New cars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170,009</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">157,957</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Used cars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,137</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Accessories</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,769</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>183,647</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>176,863</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">b.</td><td style="text-align: justify">As stated in Note 2 (i) above, the Group measures
                                            its inventory according to the lower of the cost base and the net realizable value. The Group
                                            regularly examines the realizable value of the inventory, taking into account a number of
                                            factors and characteristics, and in particular the age and condition of the inventory. Regarding
                                            the considerations taken into account regarding the examination of realizable value in respect
                                            of the new car inventory, see also Note 3b1.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify; text-indent: -14.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify; text-indent: -14.1pt"></p><div>

</div><!-- Field: Page; Sequence: 384; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify; text-indent: -14.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify; text-indent: -14.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 9 - Investments in companies treated according to the balance
sheet value method</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further to what was covered in Notes 1 (c) and
2 (u) regarding the merger and reverse acquisition: as stated, Metomy is the legal purchaser of Global AutoMax and both own subsidiaries
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>a.</b></td><td style="text-align: justify"><b>Additional information regarding
                                            subsidiaries whose reports are consolidated in the Company&#8217;s reports:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Country of<br/>
    incorporation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">The<br/>
    Company&#8217;s<br/>
    rights in<br/>
    capital and<br/>
    voting<br/>
    rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amounts<br/>
    advanced&#160;by&#160;the<br/>
    Company&#160;to&#160;the<br/>
    consolidated<br/>
    company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">The&#160;scope&#160;of<br/>
    investment<br/>
    in the<br/>
    capital&#160;of&#160;the<br/>
    consolidated<br/>
    company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">As for 31 December 2023</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 41%; text-align: left">Automax Hasharon(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">270</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,899</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,169</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Automax Trade In Ltd. (2)</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,128</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automax Leasing Ltd. (3)</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Automax Netanya Ltd. (4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,157</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,899</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,056</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="text-decoration:underline">As for 31 December 2022</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Automax Hasharon (1)</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Automax Trade In Ltd. (2)</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,036</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Automax Leasing Ltd. (3)</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Automax car fleets (5)</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Metomy Germany GmbH (6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right"/><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,262</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,845</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,107</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 385; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 9 - Investments in Companies handle according to the Balance
Sheet Value method (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Automax Hasharon
                                            Ltd.:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 25, 2021, Global AutoMax entered
into a Founder&#8217;s Agreement with a third party that acts as an authorized distributor of vehicles imported by the Company, and operates
the Company&#8217;s branch in Petah Tikva (hereunder: &#8220;<b>the marketer</b>&#8221; and &#8220;<b>the Founders&#8217; Agreement</b>&#8221;,
as applicable).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the Founder&#8217;s Agreement,
the parties will work to establish a joint company (which was established under the name of Automax Hasharon), which will, among other
things, operate marketing and sales centers for vehicles in the cities of Petah Tikva, Ra&#8217;anana, and other locations to be decided
by the parties (below: &#8220;<b>The joint company</b>&#8221;). According to the Founder&#8217;s Agreement, the subsidiary company will
own 1/3 of the joint company&#8217;s share capital, while the marketer will own the remaining 2/3. The parties undertook to provide the
joint company with an initial amount as an owner&#8217;s loan for the purpose of financing its activities, divided between them according
to the relative share of each party in the joint company&#8217;s share capital. Distribution of profits in the joint company will be
made subject to any law, according to the relative share of each party in the joint company&#8217;s share capital. The joint company&#8217;s
Board of Directors will appoint 3 members, where two will be appointed by the marketer and one by the subsidiary. The Founder&#8217;s
Agreement also stipulates that certain decisions will require a 100% majority of the directors, including a change in the joint company&#8217;s
incorporation documents, including a change in the rights attached to the joint company&#8217;s shares, providing loans and/or guarantees
and/or other financing for the joint company&#8217;s activities that deviate from its normal course of business or Providing loans to
stakeholders in the joint company, as well as approving transactions in which an office holder, director, shareholder and/or stakeholders
in the company have a personal interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Founders&#8217; Agreement includes
customary provisions that limit the possibility of share transferring in the joint company, including the right of first refusal (except
in the circumstances stipulated in the Founders&#8217; Agreement), the right to join the sale of shares (Tag Along) and forced sale (Bring
Along). The joint company operates the company&#8217;s branches in Petah Tikva and Ra&#8217;anana.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On May 3, 2021, a vehicle marketing
agreement was signed between the subsidiary and the joint company. The agreement is valid for a period of 5 years from the its signature
date. In return for the marketing and distribution services, the marketer will receive a commission at certain determined rates from
the price of each vehicle sold by the joint company (before VAT and minus license fees amount).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 23, 2022, an agreement was
signed between Global AutoMax, and the marketer Automax Hasharon (joint company of the subsidiary and the marketer) entered into a Founders
Agreement according to which Global AutoMax purchased from the third party shares held by it which constitute 1/3 of the issued share
capital of Automax Hasharon, as well as granted Automax Hasharon with an owner&#8217;s loan in accordance with the agreement established
between the parties. After granting the aforementioned owner&#8217;s loan, Automax Hasharon paid off the owner&#8217;s loan in the same
amount granted by the third party. Simultaneously with the signing of the aforementioned agreement, an amendment to the Founder&#8217;s
Agreement was signed according to which Global AutoMax will be entitled to appoint two directors to the Hasharon Automax board of directors,
and the third party will be entitled to appoint one director. With the completion of the aforementioned agreement, Global AutoMax owns
2/3 of the issued share capital of Automax Hasharon, and the third party owns 1/3, and two directors on behalf of Global AutoMax, and
one director on behalf of the third party, serve on the board of Automax Hasharon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In October 2022, in accordance with
the agreement between Global AutoMax and the Marketer, Global AutoMax commenced operating the Petah Tikva branch directly, while the
joint company continues to operate the Ra&#8217;anana branch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">No consideration was transferred for
the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 386; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 9 - Investments in Companies handle according to the Balance
Sheet Value method (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">b.</td><td style="text-align: justify"><span style="text-decoration:underline">The attached cash flows that resulted to
                                            the group as a result of the purchase transaction:</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Thousands<br/>
    of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; width: 88%; text-align: left">With the deduction of cash and cash equivalents that were purchased</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">465</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">465</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">c.</td><td style="text-align: justify"><span style="text-decoration:underline">Attribution of excess cost:</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Thousands<br/>
    of NIS</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; width: 88%; text-align: left">Balance of acquired assets and liabilities, net</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(764</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Excess cost for attribution</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">764</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="text-decoration:underline">Attributed</span>:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Goodwill</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">764</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">See Note 21b(c) below.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">The company was established on June 1, 2022
                                            for the purpose of examining the possibility of engaging in leasing activities.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">See Note 21b(g) below.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Automax car
                                            fleets Established in February 2019. As of September 24, 2020 Automax Fleets was inactive.
                                            On July 30, 2023, an agreement was signed between Automax Fleets, Global AutoMax and I.V.
                                            Drive Ltd. (hereinafter: &#8220;I.V. Drive&#8221;), as part of which 50% of Automax Fleets&#8217;
                                            share capital was transferred to I.V. Drive, and Automax fleets began the activity of brokering
                                            leasing transactions, as detailed in Note 21b (17) below.</p></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">6.</td><td style="text-align: justify">Matomy Germany GmbH was dissolved during the
                                            last quarter of 2023.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 387; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 9 - Investments in Companies handle according to the Balance
Sheet Value method (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Details regarding affiliated companies held by the company:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Company<br/>
    rights in<br/>
    capital and</b></td><td><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>As for December 31</b></td><td style="font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><b>Investment in affiliated</b></td><td><b>&#160;</b></td>
    <td style="text-align: center"><b>Number of</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: center"><b>Nominated</b></td><td><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><b>voting rights</b></td><td style="font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2023</b></td><td style="font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2022</b></td><td style="font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><b>companies</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>shares</b></td><td style="font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Type</b></td><td style="font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>value</b></td><td style="font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>%</b></td><td style="font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Thousands of NIS</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></p> Dalhom Automax Ltd. (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">Ordinary
                                            </span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">0.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,256</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,635</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: center">0.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">Management</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">0.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Automax Shefela Ltd. (2)</td><td>&#160;</td>
    <td style="text-align: center">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ordinary </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Automax car fleets (3).</td><td>&#160;</td>
    <td style="text-align: center">171,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ordinary </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">0.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: center">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">Management</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Automax Netanya Ltd. (4)</td><td>&#160;</td>
    <td style="text-align: center">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ordinary </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(133</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Hiteczone Motors Ltd. (5)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">2,880</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">Ordinary
                                            </span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">30</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: right"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center"/><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,489</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,646</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 388; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 9 - Investments in Companies handle according to the Balance
Sheet Value method (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dalhom
                                            Automax Ltd.:</b></span></td>
</tr></table><div>



</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">(*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Debits and Credits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,697</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,662</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,577</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Equity losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(246</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><b>17,635</b></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
                                            lower than 1 thousand ILS. In addition, see Note 21b(e) below.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Automax
                                            Shefela Ltd.:</b></span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">(*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Debits and Credits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,249</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">244</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(548</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(114</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Loan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">447</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,148</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><b>130</b></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Amount lower than
                                            1 thousand ILS. In addition, see Note 21b(h) below.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 389; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 9 - Investments in Companies handle according to the Balance
Sheet Value method (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Automax
                                            car fleets Ltd:</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Share capital</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debits and Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Equity losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(34</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">85</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, see Note 21b(p) below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Automax
                                            Netanya Ltd.:</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">(*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Debits and Credits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(26</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Equity losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><b>(133</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>)</b></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Amount lower than 1 thousand ILS. See Note
                                            21b(g) below.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hiteczone
                                            Motors Ltd.:</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">(*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Debits and Credits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">39</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Equity losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><b>14</b></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>(*)</b></td><td style="text-align: justify"><b>Amount lower than 1 thousand ILS.</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2021, Global AutoMax signed an agreement
with Hi Biz Ltd., the operator of the Hiteczone consumer club, to establish a joint company to engage in automotive activity including
marketing and sales of vehicles, and become, among other things a web based platform for Hiteczone consumer club and joint the national
marketing and sales network of the new company (hereinafter: Hi Biz, the Agreement&#8221; and the &#8220;Joint Venture&#8221; as the
case may be).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 18, 2023, Global AutoMax transferred
all of its rights in the joint venture to High Biz. The transfer of the shares was done without any consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 390; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for Lease Agreements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of January 1, 2018, the company applies standard IFRS 16 as detailed
in Note 2 p. This note refers to leases where the Group is the lessee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assets
                                            composition due to Lease Agreements</b></span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
    for December 31</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Thousands
    of NIS</b> &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><b>Cost:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Opening balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,044</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,461</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Entry into consolidation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,202</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,897</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,351</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Changes during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,030</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Closing Balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">36,409</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Accrued depreciation and amortization:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Opening balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,309</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Entry into consolidation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">766</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,516</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Changes during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,073</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Closing Balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,924</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,247</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right">20,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right">16,797</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Composition
                                            of liabilities for the Lease Agreements:</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
    for December 31</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Thousands
    of NIS</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Opening balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,032</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,508</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Entry into consolidation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,701</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,807</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,351</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(509</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,002</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Payments and changes due to leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,226</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,530</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><b>Total</b></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">22,104</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,032</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current maturities of lease related liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Long-term lease related liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right">22,104</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right">18,032</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 391; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>




</div><!-- Field: Split-Segment; Name: 006 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for Lease Agreements (Continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amounts
                                            recognized in profit and loss:</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the year ending on</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>2022</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Thousands of NIS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Depreciation expenses with respect to right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,887</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing expenses with respect to liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">951</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in"><b>d.</b></td><td><b>The Lease Agreements include ten properties according
                                            to the following breakdown:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .25in"/><td style="width: .25in">1.</td><td style="text-align: justify"><span style="text-decoration:underline">Lease agreement for a land plot
                                            with a structure where Global AutoMax Jerusalem branch is built</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global AutoMax has a Lease Agreement
with a third party for the lease of an asset in Jerusalem. The Lease Agreement is valid until March 31, 2025, <b>after exercising its
extension option</b>. Also, Global AutoMax is granted with additional options to extend it until March 31, 2027. Global AutoMax is entitled
to notify the lessor every year at the appointed time of shortening and/or termination of the Lease Agreement with a written notice of
6 months in advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">The current monthly lease fees amount
to 110 thousands ILS, plus VAT and linkage differences. On April 1, 2020, and every two years thereafter, lease fees shall increase by
3%, in comparison to the monthly fees paid on the previous month.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In order to guarantee Global AutoMax
undertakings subject to the Lease Agreement, the lessor was provided with various collaterals, as detailed: (a) personal guarantees by
Daniel Levi, Yinon Amit, Emanuel Paz Puzailov and Eyal Baruch (hereunder: the &#8220;Guarantors&#8221;); (b) a promissory note by Global
AutoMax at the amount of 500 thousands ILS, personally guaranteed by the Guarantors; and (c) a deposit of 1-month lease fees provided
by Global AutoMax and held by the lessor as collateral for Global AutoMax undertakings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with the approval of
the General Assembly of the company&#8217;s shareholders, the subsidiary intends to replace the personal guarantees given by the guarantors
as mentioned above, with other acceptable guarantees to be given by Global AutoMax in the amount of up to 5 months lease fees. As for
the reporting date, said guarantees have not yet been replaced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">This property houses the subsidiary&#8217;s
building in Jerusalem, which includes an exhibition center, a parking lot for vehicles imported by the subsidiary, the company&#8217;s
management offices, as well as a facility and system for preparing vehicles for sale (PDI).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The inherent interest rate of this lease is estimated at
4.3%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .25in"/><td style="width: .25in">2.</td><td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration:underline">Lease
                                            agreement for a land plot with a structure where Global AutoMax Rishon Lezion branch is built</span></p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global AutoMax has a Lease Agreement
with a third party according to which it leases a 2,000 square meters plot of land on which a 566 square meters building is built in
Rishon Lezion. The Lease Agreement is until May 2031. Global AutoMax may shorten the lease term by a written notice that would be provided
to the lessor 6 months in advance. Also, the lessor may shorten the lease period with a written notice of five months in advance, if
it wishes to build on the property, provided that it presents the subsidiary with a signed and valid building permit from the Rishon
LeZion Planning and Construction Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The monthly lease fees vary between
82 to 100 thousands ILS, plus VAT and linkage differences from May 2015 (predefined annual increases).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 392; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for Lease Agreements (Continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In order to guarantee its undertakings
subject to the Lease Agreement, the Company provided the lessor with various collaterals, including a bank guarantee on behalf of the
Company, promissory notes by the Company, and Company guarantee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global AutoMax branch is located in
this property including a presentation center comprised of a showroom for sale of vehicles imported by Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The inherent interest rate of this
lease is estimated at 3.7%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Lease agreement for a land
    plot with a storage lot of Global AutoMax in Jerusalem</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The subsidiary has a Lease Agreement
with a third party according to which it leases a plot of land with an area of 1,776 square meters in Jerusalem. The Lease Agreement
is until July 2024 (after the subsidiary exercised options granted to it to extend the lease period). The subsidiary may shorten the
lease period provided that it notifies the lessor of this with a written notice 60 days in advance. The lessor has the right to cancel
the agreement with a written notice of 6 months in advance, in cases of development and/or planning and/or sale of the leased property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The current rent is ILS 42 thousand, plus VAT and linkage
differences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On March 24, 2024, the general meeting
of the company&#8217;s shareholders approved the extension of the Lease Agreement for a period of up to 5 additional years, with monthly
lease not exceeding NIS 44,100, plus VAT and linkage differences.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Approximately 47% of the leased property
rights are held by an affiliated party of one of the Company&#8217;s Directors, who is also a controlling shareholder of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In order to guarantee its undertakings
subject to the Lease Agreement, the Company provided the lessor with a sum for a total of 3-months lease fees (120 thousands ILS) plus
VAT, as payment for the last three months of the lease term, and an additional CPI-linked promissory note by the subsidiary for the amount
of 100 thousands ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This property contains the logistic
warehouse of the Company, where it stores its imported vehicles after they are released by the Customs Authorities and prior to their
transportation to the Company&#8217;s PDI center.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The inherent interest rate of this lease is estimated at
3.7%.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 393; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for Lease Agreements (Continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Lease agreement for a land
    plot with a structure where Global AutoMax Haifa branch is built </span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global
                                            AutoMax has a Lease Agreement with a third party according to which it leases a plot of land
                                            with an area of 510 square meters on which a building with an area of approximatively 363
                                            square meters is built in Haifa. The Lease Agreement is until May 2026, after it was extended
                                            for an additional period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The
                                            monthly lease fees total 42.5 thousand ILS, plus VAT and linkage differences, lease fees
                                            for the additional period total 44 thousand ILS.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Against
                                            possession hand over, a deposit equal to three months&#8217; rent plus VAT was paid to the
                                            lessor. Global AutoMax branch is located in this property including a presentation center
                                            comprised of a showroom for sale of vehicles imported by Global AutoMax.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The inherent interest rate of this
lease is estimated at 2%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Lease agreement for a land
    plot with a structure where Global AutoMax Ra&#8217;anana branch is built</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Automax Hasharon has a Lease Agreement
with a third party according to which it leases a 1,550 square meter lot on which a building of approximately 1,550 square meters is
built in Ra&#8217;anana. The Lease Agreement is for the period from May 1, 2021 to April 30, 2026, when Automax Hasharon is granted options
to extend it until April 30, 2031. Automax Hasharon is entitled to notify the lessor every year at the appointed time of the shortening
and/or termination of the Lease Agreement with a written notice of 3 months in advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The monthly lease fees total 55,000 ILS, plus VAT and linkage
differences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global AutoMax branch is located in
this property including a presentation center comprised of a showroom for sale of vehicles imported by Global AutoMax.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The inherent interest rate of this lease is estimated at
9%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Lease
    agreement for a land plot with a structure where Global AutoMax Petach Tikva branch is built</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Automax Hasharon has a Lease Agreement
with a third party according to which it leases a 4,095 square meter lot on which a building of approximately 4,095 square meters is
built in Petach Tikva. The Lease Agreement is until December 2024, when she is granted options to extend it until December 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The monthly lease fees total 27,500 ILS, plus VAT and linkage
differences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global AutoMax branch is located in
this property including a presentation center comprised of a showroom for sale of vehicles imported by Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The inherent interest rate of this lease is estimated at
17%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 394; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for Lease Agreements (Continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .25in"/><td style="width: .25in">7.</td><td><span style="text-decoration:underline">Lease agreement for a land plot with a structure where Global
                                            AutoMax Glilot branch is built</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Automax Trade in does not have a Lease
Agreement with a third party according to which it leases a 1,100 square meter lot on which a building of approximately 1,100 square
meters is built in Glilot. The Lease Agreement is for a period until August 2025 (after exercising an option for its extension). The
monthly lease fees total 37,500 ILS, plus VAT and linkage differences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Global AutoMax branch is located in this property including
a presentation center for sale of new and used vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The inherent interest rate of this lease is estimated at
1.7% and during the option period at 7.2%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .25in"/><td style="width: .25in">8.</td><td><span style="text-decoration:underline">Lease agreement for a plot with a structure where Global
                                            AutoMax Afula branch is built</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global AutoMax has a Lease Agreement
with a third party according to which it rents a plot of land with an area of 545 square meters on which a building with an area of approximatively
545 square meters is built in Afula. The Lease Agreement is for the period from December 1, 2021 to December 1, 2024, when Global AutoMax
is granted options to extend it until December 1, 2030. Global AutoMax is entitled to notify the lessor every year at the appointed time
of shortening and/or termination of the Lease Agreement with a written notice of 3 months in advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5pt">The monthly lease
fees were set at the amount of 27,250 ILS, plus VAT and linkage differences. Global AutoMax branch is located in this property including
a presentation center comprised of a showroom for sale of vehicles imported by Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The inherent interest rate of this lease is estimated at
2.9%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .25in"/><td style="width: .25in">9.</td><td><span style="text-decoration:underline">Lease Agreement in connection with the office in Ashdod</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">The subsidiary had a Lease Agreement
with a third party according to which it rents an 80 square meter office in Ashdod. The Lease Agreement was for the period from April
3, 2023 until it ended on April 2, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in">The monthly lease fees totaled 3,900 ILS, plus VAT and linkage
differences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This property houses the sales office
for institutional customers and the subsidiary&#8217;s vehicle fleets, and once the lease period ended, its activity was transferred
to other Company branches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The inherent interest rate of this lease is estimated at
2%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: .25in"/><td style="width: .25in">10.</td><td><span style="text-decoration:underline">Vehicles under operational lease</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">During 2023, Global AutoMax signed operational
Lease Agreements for 19 vehicles for a 3-year period. The aforementioned vehicles are presented on the basis of cost plus one-time setup
costs transaction minus accrued depreciation. The vehicles are amortized based on individual calculations for each vehicle over the lease
period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in">The inherent interest rate of this lease is estimated between
4.53% and 6.9%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 395; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 11 - Fixed Assets, net</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center">As for December 31</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Vehicles</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Office <br/> equipment<br/> and <br/>
    furniture</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">electronic<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Cost</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -0.125in; padding-left: 0.125in">Balance as for January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,365</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,834</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,893</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">7,235</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">12,587</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Additions during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">924</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Subtractions during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,680</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(220</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(138</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,084</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance as for December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,159</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,059</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,939</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">435</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="text-decoration:underline">Accumulated depreciation</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Balance as for January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">817</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,838</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,157</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Additions during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">771</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Subtractions during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(229</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(249</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance as for December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,604</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(974</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(70</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,583</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><b>Fixed assets, net, as for December
    31, 2023</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>1,495</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>555</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>1,085</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>4,339</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>365</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>7,871</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 396; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 11 - Fixed Assets, net (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center">As for December 31</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Office</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">equipment</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">and</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Leasehold</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">electronic</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Vehicles</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">furniture</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Cost</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balance as <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    January 1, 2022</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">351</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,414</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,484</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">4,904</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">61</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">8,214</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Entry into consolidation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">648</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Additions during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,728</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,811</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Subtractions during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(428</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(494</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance as for December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,365</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,834</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,587</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="text-decoration:underline">Accumulated depreciation</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Balance as for January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">958</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">673</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,857</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Entry into consolidation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Additions during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Subtractions during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance as for December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(208</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,269</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(817</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,838</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,157</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><b>Fixed assets, net, as for December
    31, 2022</b></td><td style="font-weight: bold; padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><b>1,157</b></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>565</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>1,076</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>4,397</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>235</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>7,430</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 397; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
12 - Intangible assets, net</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for December 31 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Import</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Website</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="text-decoration:underline">Cost</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance as for January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,020</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">764</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,045</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,829</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Additions during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">772</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,415</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance as for December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,664</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">764</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,817</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,245</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="text-decoration:underline">Cumulative reduction</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as for January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Additions during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,765</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance as for December
    31, 2023</b> &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,879</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,247</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,126</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Reduced cost, net, as for December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9,785</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">764</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">570</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,119</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for December 31 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Import</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Website</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Cost</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance as for January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,098</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,045</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,143</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Additions during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">922</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">764</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,686</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance as for December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,020</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">764</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="text-decoration:underline">Cumulative reduction</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as for January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,744</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Additions during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,415</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,415</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance as for December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,159</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Reduced cost, net, as for December 31, 2022 &#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9,906</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">764</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,670</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 13 - Long-term deposits in banking corporations</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-term deposits in banking corporations, as
for December 31, 2023 total 409 thousands ILS. As for December 31, 2022, long-term deposits totaled 535 thousands ILS. The deposits constitute
a part of the terms of state-guaranteed loans, as well as an additional deposit deposited by Automax Hasharon with respect to a guarantee
provided in relation with the Lease Agreement of the R&#8217;aanana branch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 398; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 14 &#8211; Short-term credit from banking corporations
and financing bodies</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Interest rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Bank - overdraft</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current maturities of long-term loans (see Note 17)</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,928</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term loans</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">6.25-9</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139,418</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139,464</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>141,430</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>141,392</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group has unsecured credit lines, that totaled
as for December 31, 2023 in approx. 148.1 million ILS as for December 31, 2022 approx. 148.1 million ILS. Out of these credit lines the
Group utilized approx. 143 million ILS as for December 31, 2023 (approx. 145 million ILS as for December 31, 2022). The Group does not
pay for its unutilized credit lines, which are, as stated, unsecured. For details regarding financial benchmarks, see Note 21 C below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 399; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
15 - Suppliers and services providers</span></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Open debts</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,117</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">24,525</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Checks for cashing and credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">cards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,052</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,169</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">27,975</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
16 - Accounts payable and credit balances</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
                                            composition:</b></span></td>
</tr></table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Advanced payments from Trade receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22,407</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,190</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Contingent liability in respect of former shareholders
    of a subsidiary (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Value Added Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,898</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expenses payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,999</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Employees and related institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,824</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Obligation to Global AutoMax (c) previous shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">495</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Obligation for future transactions (Forward)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Provision for sick leave and vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Obligation to the control holders of the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Obligation for bonds (d)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">45,820</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">24,145</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Contingent
                                            liability in respect of the subsidiary&#8217;s former shareholders and an indemnifying asset
                                            for it</span> -</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">On November 13, 2015, Metomy USA (the
company&#8217;s wholly-owned subsidiary, incorporated in accordance with the laws of Delaware, USA), acquired the entire holdings (100%)
in Optimatic Media Inc. (&#8220;Optimatic&#8221;) by means of a reverse triangular merger (&#8220;The Transaction&#8221;). In accordance
with the transaction documents, since Optimatic had a large number of shareholders, including inactive companies, and after the company
took all reasonable measures to locate those shareholders, the company transferred the full transaction proceeds to a trustee, who was
responsible for locating the shareholders and making the payment to the located shareholders. In accordance with the provisions of the
Trust agreement signed with the Trustee, after one year from the date of completion of the transaction, the Trustee transferred to Matomy
USA the balance of the proceeds of those shareholders who had not yet been located until that date, in the amount of 2,971 thousand US
dollars (the &#8220;Obligation amount&#8221;). On October 29, 2019, Matomy USA was dissolved in accordance with Delaware law, when as
part of the liquidation the company undertook to bear the claims filed against Matomi USA. To the best of the Company&#8217;s knowledge,
according to the law applicable in Delaware, lawsuits can be filed against Matomi USA for a period of up to 3 years from the dissolution
date as stated, and the Company&#8217;s obligation to bear claims filed against Matomi USA is valid for a period of up to 10 years from
the date of dissolution. As part of the merger transaction between the Company and the shareholders of the former Global AutoMax Ltd.
and as a condition precedent to its completion, an agreement was signed with M.R.M Merhavit Holdings and Management Ltd. (the initiator
of the transaction) and L.I.A. Pure Capital Ltd. (hereafter collectively: &#8220;the Indemnifiers&#8217;), according to which in return
for a payment of 1 million ILS, plus VAT, to be paid to the Indemnifiers by the company, the Indemnifiers will Indemnify the company
for any amount paid to any of Optimatic&#8217;s undocumented shareholders as specified above, up to the obligation amount. This obligation
was settled in an agreement signed on March 18, 2021 between the company and the Indemnifiers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 400; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 16 - Accounts payable and credit balances (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">It should be noted that the aforementioned
summary was approved by the Company&#8217;s Board of Directors at meetings held prior to the approval of the merger transaction by the
Company&#8217;s shareholders, and was brought to the Company&#8217;s shareholders for approval as part of the merger transaction, which
was approved by them on February 28, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">C.</td><td style="text-align: justify">In an immediate
                                            report published by the company on March 24, 2021 in connection with the merger transaction
                                            completion, it was clarified that according to the merger agreement the cash amount in the
                                            company&#8217;s treasury should be approximately 22 million NIS. On the accounting deadline
                                            according to the aforementioned report, the cash amount in the company&#8217;s treasury amounted
                                            to of about 21.6 million NIS. In accordance with the aforementioned report, the indemnification
                                            provision set forth in item 1.1.10.5 of the meeting summons report dated February 22, 2021,
                                            whose agenda was the approval of the merger transaction (&#8220;the meeting summons report&#8221;)
                                            applies to the entire amount of the difference (about NIS 495 thousand) (&#8220;the difference
                                            amount&#8221;) &#8220;), according to which the amount difference will be paid by way of
                                            allocating the indemnification shares (as defined in the merger agreement) against the capital
                                            raising to be carried out by the company (and everything as specified in item 1.1.10.5 of
                                            the report convening the meeting), without the absorption of 150,000 NIS stipulated in item
                                            1.1.10.2 of the report convening the meeting applying. It should be clarified that as of
                                            the date of publication of these reports, to the best of the company&#8217;s knowledge, the
                                            former shareholders of the subsidiary postponed the execution date of the aforementioned
                                            mechanism in accordance with the right granted to them to postpone it until after the date
                                            of the third milestone, but no later than 72 months from the date of completion of the transaction.
                                            It should be noted that if the company fails to raise capital, the obligation will be repaid
                                            in cash. As of December 31, 2023, the amount of the difference was recorded as capital fund
                                            in the Company&#8217;s books.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">d.</td><td style="text-align: justify">As part of the
                                            issuance of the bonds (series B) as detailed in note 19 below, the Company undertook to grant
                                            the distributors 733.592 non -marketable warrants exercisable for up to 733.592 ordinary
                                            shares of the company with a par value of 0.05 ILS each (after capital consolidation at a
                                            rate of 1.5 as stipulated in Note 22 below) (hereinafter: the &#8220;Warrants&#8221;). The
                                            fair value (according to the B&amp;S formula) of each warrant is ILS 0.1058 as of the day
                                            the bonds were issued (series B), and a total of about 388 thousand ILS. On July 26,2023
                                            the company has allocated the warrants.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 401; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><!-- Field: Split-Segment; Name: 007 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
17 &#8211; Long-term credit from banking corporations</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">In ILS, non-linked (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">With deduction of current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,004</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,928</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,807</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,675</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Loans are provided
                                            in ILS and bear a Prime+1.5% interest rate during 2023 and 2022. The loans are not CPI linked.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For details regarding financial benchmarks, see Note 21 C below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
18 - Non-granting control Loans from Right Holders</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">A. O. A. Motors Ltd. - a shareholding company</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">985</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">957</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
19 - Liability for bonds</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal"><b>A.</b></span></td><td style="text-align: justify"><span style="font-style: normal"><b>Composition
                                            as for <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
                                            31, 2023</span></b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Balance</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">with</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">deduction</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Nominal</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">effective</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">of current</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">maturities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Unlinked bonds (series A)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41,094</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41,447</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34,598</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><b>B.</b></td><td><b>Additional information regarding bond issuance (series B)</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On March 1, 2022, the company issued
to the public a total of ILS 45,660 thousand nominal bonds (series B) of the company, worth 1 ILS each, in accordance with the shelf
offer report published by the company on February 27, 2022, by virtue of the shelf prospectus of the company bearing the date November
30, 2021 (hereinafter: &#8220;The Shelf Offer Report&#8221;). The total gross consideration received by the Company for the bonds (series
B) allocated according to the shelf offer report, totaled 45,660 thousand ILS. The Company bore the issuance costs totaled approx. 1,034
thousand ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="text-decoration:underline">Terms of the bonds (series B)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The bonds (series B) bear a fixed,
non-linked annual interest rate of 5.9%, which will be paid twice a year, on February 28 and August 31 of each of the years 2023 to 2025
(inclusive) and on February 28, 2026, all for a period of The interest that ended on the last day before the payment date (hereinafter:
the &#8220;Interest period&#8221;). The interest rate to be paid for a certain interest period (except for the first interest period,
as detailed below), will be calculated as the annual interest rate divided by two. The first interest payment date will be made on February
28, 2023 for the period that begins on the first trading day after the auction day according to the first shelf offer report, and ends
on February 27, 2023 (hereinafter: &#8220;the first interest period&#8221;), and the last payment will be made on February 28, 2026,
together with The final repayment of the bond fund and against handing over the bond certificates to the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 402; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 19 - Liability for bonds (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The bonds (series B) will be settled
for repayment of principal in 4 unequal annual payments, to be paid on February 28 of each of the years 2023 to 2026 (inclusive), in
such a way that the first payment (on February 28, 2023) will be 10% of the principal nominal value of The bonds, the second payment
(on February 28, 2024) will be 15% of the total nominal value of the bonds, the third payment (on February 28, 2025) will be 30% of the
total nominal value of the bonds, the fourth and final payment (on February 28, 2026) will constitute 45% of the total nominal value
of the bonds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="text-decoration:underline">Securing the bonds</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order to guarantee the complete
fulfillment of all the Company&#8217;s obligations according to the terms of the bonds (series B) and to guarantee the full and accurate
repayment of all the principal and interest payments the Company must pay to the bonds (series B) holders, the Company undertook to create
and/or register the guarantees listed below for the trustee&#8217;s benefit:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">As a condition for providing owner
                                            loans to the controlled companies, the Company undertook to pledge, with a floating lien,
                                            the full rights of the Company by virtue of the owner loans provide from time to time to
                                            the controlled companies, and this is to ensure the full and exact fulfillment of all the
                                            Company&#8217;s obligations according to the bonds (series B) and the deed of trust.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">The Company has committed that
                                            as long as the bonds (series B) have not been paid in full, in a final settlement, the company
                                            will not create general current liens on all of its assets and all of its rights, existing
                                            or future, for the benefit of any third party, to secure any debt or any obligation, unless:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.25in">(A)</td><td style="text-align: justify">Prior approval will be obtained
                                            from the bonds holders (series B), to create the lien in favor of a third party.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 403; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 19 - Liability for bonds (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 72.5pt"/><td style="width: 18.5pt">(B)</td><td style="text-align: justify">The Company created for the benefit
                                            of the bonds (series B) holders to guarantee the unpaid balance of debt towards the holders,
                                            at the same time as the creation of the current lien in favor of the third party, a current
                                            lien of the same level PER PESO according to the ratio of the Company&#8217;s debts to the
                                            third party and to the holders of the bonds as it may change from For the time, this lien
                                            will be in effect as long as the bonds (series B) have not been paid in full or until the
                                            cancellation of the lien given in favor of the aforementioned third party, whichever comes
                                            first.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In addition, the Company undertook
as long as the bonds (series B) were not paid in full, it will not create and will not undertake to create, for the benefit of any person
and/or entity, liens of any kind and type on the shares of Global AutoMax Ltd. it owns.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">The Company undertook that as long
                                            as the bonds (series B) were not paid in full, it would not make a distribution (as defined
                                            in the Companies Law, 5759-1999 (hereinafter: &#8220;The Companies Law&#8221;)), including
                                            that it would not declare, pay or distribute dividends (as defined in the Companies Law).
                                            Notwithstanding the above, subject to every law, the Company will be entitled to make a distribution
                                            by way of a dividend in kind of shares held by it in the affiliated companies and are listed
                                            for trading on the stock exchange, provided that the equity of the company, after making
                                            the distribution, will not be less than ILS 60 million.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For details regarding financial benchmarks, see Note 21 C below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 20 &#8211; Employee benefits</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Post-employment
                                            benefits</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Israeli Labor Law and Severance
Pay Law require the Company to pay severance payments to its employees upon termination or retirement. Therefore, the Company handles
the corresponding liability as a post-employment benefit. Calculation of the company&#8217;s liability for employee benefits is done
in accordance with valid employment contracts and is based on employees&#8217; salaries and employment period, entitling them to receive
severance pay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Defined
                                            deposit plans</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">A portion of the Group&#8217;s severance
payments to its employees in Israel is subject to the provisions of Paragraph 14 of the Severance Pay Law, 5723-1963. According to this
paragraph, current contributions to pension funds and/or insurance policies with insurance companies exempt the Group from recognizing
any further liabilities toward those employees for whom said amounts were deposited. Said contributions, as well as deposits in respect
of remunerations, constitute defined deposit plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Defined
                                            benefit plans</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The portion of severance pay not
covered by contributions to defined deposit plans, as detailed above, are handled by the Group as defined benefit plans, where the Group
recognizes an employee&#8217; benefits liability for which the Group is contributing amounts in corresponding insurance policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 404; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 20 &#8211; Employee benefits (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="text-align: left; width: 0.25in"><b>D.</b></td><td style="text-align: justify"><b>The composition
                                            of employee benefits liability presented in the financial status report:</b></td>
</tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As for December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Benefits after employment termination by departments:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">PDI department</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Management</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">140</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">215</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b><span style="text-decoration:underline">Claims
                                            and legal decisions in the field</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As part of its regular business
activity, the Group may be exposed to legal proceedings and claims from time to time. Regardless of the outcome of said actions, legal
proceedings might have negative impacts over the Company as a result of various costs arising from settlements and the need to receive
legal defense and settlement, reassignment of management resources and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in">&#9679;</td><td>During 2015, an investigation was initiated against a subsidiary, Haim Levy Trade In
                                            Ltd. (hereunder:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#8220;<b>Haim Levy Trade In</b>&#8221;),
one of the Company&#8217;s controlling shareholders, and against Company&#8217; position holders &#8211; Daniel Levy, CEO; Yinon Amit,
Chief Business Officer and Director; Haim Levy, Trade Manager and the son of Daniel Levy; and, Gal Levy, VP of Regulations and Branch
network and the son of Daniel Levy, suspecting them of fraud, forgery and money laundering. In addition, said position holders (excluding
Daniel and Gal Levy) were interrogated in relation with tax related offenses and regulatory breaches with respect to Company activities
as a parallel importer of vehicles subject to the provisions of the Product and Services Supervision Order (Vehicle Import and Provision
of Automotive Services), 5769-1978 (hereunder: the &#8220;Order&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">At the end of the investigation,
Global AutoMax, Haim Levy Trade In and the aforementioned position holders (with the exception of Mr. Gal Levy) (hereinafter: &#8220;<b>Position
holders</b>&#8221;) received hearing letters, according to which the attorney&#8217;s office is considering prosecuting them for committing
the aforementioned offenses. On August 5, 2021, the parties involved received a notice from the Tel Aviv District Attorney&#8217;s Office
(Taxation and Economy), according to which, after a hearing procedure that was held for Global AutoMax, the office holder (excluding
Gal Levy) and Haim Levy Trade In, it was decided to reject their claims and file an indictment against them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 405; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On August 25, 2021, a notice of
indictment was received against Global AutoMax, Haim Levy Trade In and position holders. The offenses attributed to the accused in the
indictment:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">A.</td><td style="text-align: justify">Global AutoMax is accused of committing
                                            forgery offenses under the Penal Law, 5737-1977 (hereinafter: the &#8220;Penal Law&#8221;),
                                            fraud under the Penal Law, smuggling under the Customs Ordinance [new version] (hereinafter:
                                            the &#8220;Customs Ordinance&#8221;) and money laundering offenses, according to The Money
                                            Laundering Prohibition Law 5760-2000 (hereinafter: &#8220;Money Laundering Prohibition Law&#8221;)
                                            and the Penal Law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">B.</td><td style="text-align: justify">Haim Levy Trade In is accused
                                            of conducting forgery acts subject to the Penal Law, fraud subject to the Penal Law, contraband
                                            subject to the Customs Ordinance, tax and customs offenses (subject to the Customs Ordinance
                                            [New Version], the Value Added Tax Law, 5736-1975 and Acquisitions Tax Law (Goods and Services),
                                            5712-1952) and money laundering offenses subject to the Anti-Money Laundering Law and the
                                            Penal Law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">C.</td><td style="text-align: justify">The position holders are accused
                                            of forgery according to the Penal Law, fraud according to the Penal Law, smuggling according
                                            to the Customs Ordinance and money laundering offenses according to the Law on the Prohibition
                                            of Money Laundering and the Penal Law.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">D.</td><td style="text-align: justify">In regard to events related to
                                            Albar&#8217;s Group activity, Haim Levy Trade In is accused of conducting acts of forgery
                                            subject to the Penal Law, fraud subject to the Penal Law, contraband subject to the Customs
                                            Ordinance, tax and customs offenses (subject to the Customs Ordinance [New Version], the
                                            Value Added Tax Law, 5736-1975 and Acquisitions Tax Law (Goods and Services), 5712-1952)
                                            and money laundering subject to the Anti-Money Laundering Law and the Penal Law; In addition,
                                            Yinon Amit is accused in the aforementioned case with impeachment of the investigation, conspiracy
                                            to commit crime and misdemeanor, and obstruction of justice according to the Penal Code.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">As of the financial statements signing
date, the preliminary hearings regarding the indictment were completed, and in March 2023, hearings on the substantial evidence began.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 406; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global AutoMax rejects the charges
against the subject of the indictment, among other things in light of the fact that as of 2016 the Order was replaced by the Vehicle
Services Licensing Law, which allows the importer to purchase vehicles from any source. Since then, and despite Global AutoMax being
under investigation and later even being summoned to a hearing - which was well known to the Ministry of Transportation as the regulator
entrusted with licensing and supervision of the field where Global AutoMax operates - the Ministry of Transportation renewed and extended
Global AutoMax&#8217;s import licenses in accordance with the Vehicle Services Licensing Law, and even issued additional import licenses
and permits to Global AutoMax. It should be emphasized that the vehicles subject to the indictment were not released from Customs at
all, and no import documents, registrations or invoices were submitted to Customs. In addition, Global AutoMax did not continue to operate
according to the import license, the subject of the indictment, which expired in 2015. In fact, this is a single incident, originating
from the beginning of Global AutoMax&#8217;s activity; Global AutoMax has learned lessons regarding the manner of conduct and control
with its suppliers, and it operates under internal procedures with regard to the company&#8217;s contracts with suppliers from which
it purchases vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global AutoMax believes, relying
on the position of its legal advisors, that it holds good arguments to handle, the charges, the subject of the indictment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">According to legal advice received
by Global AutoMax, in the event of a conviction, as part of a sentence, the punitive sanction as far as Global AutoMax is concerned may
be a financial fine, while for the aforementioned party, in the case of a conviction for money laundering offenses, confiscation may
be also possible as part of the sentence. In addition, besides the aforementioned, there is exposure to an administrative procedure by
the Ministry of Transportation, as detailed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">According to Section 8 of the Vehicle
Services Licensing Law, an employee of the Ministry of Transportation serving as the Deputy Director General for Traffic (in this item
&#8220;<b>the Director</b>&#8221;) has the authority to refuse granting or renewing a license &#8220;if the license applicant has been
convicted of a criminal offense which, due to its nature, seriousness, or circumstances, he is not fit to engage in providing vehicle
service or in a profession in the automotive industry for which he requested the license, or if an indictment was filed against him for
a criminal offense as mentioned and a final judgment has not yet been given in his case.&#8221; Also, according to Section 10(a)(7) of
the Vehicle Services Licensing Law, the Director may revoke a license, suspend it until ordered conditions are fulfilled, limit it or
refuse to renew it, after giving the license holder an opportunity to assert his claims, if the license holder &#8220;has been convicted
of a criminal or a disciplinary offense, which due to its nature, seriousness or circumstances, he is not fit to engage in providing
car service or in a profession, or an indictment was filed against him for a criminal offense as mentioned and a final judgment was not
yet given in his case.&#8221; In the opinion of the Company&#8217;s Management and Global AutoMax, based on its legal advisors&#8217;
opinions, the filing of an indictment against Global AutoMax, or the fact that it may be convicted in relation to the offences in the
indictment, is insufficient to cause the of the director refusal to grant it import licenses, renew its indirect importer license, revoke,
restrict, or refuse to renew any licenses granted to Global AutoMax, due to the following reasons, cumulatively, or to any of them:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">A.</td><td style="text-align: justify">The offenses,
                                            the subject of the indictment due to their nature, severity and circumstances, as described
                                            above, do not lead the Director to the conclusion that Global AutoMax is not appropriate
                                            to engage in the importation and sale of vehicles.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">B.</td><td style="text-align: justify">The Ministry of Transportation
                                            is aware of the criminal investigation and the filing of the indictment against Global AutoMax,
                                            and this did not prevent it from granting the company an indirect importer&#8217;s license,
                                            extending it on an ongoing basis to additional vehicle products (when most indirect importer
                                            licenses for vehicle products were received or renewed after receiving the summons for the
                                            hearing) and granting the Company import permits for various types of vehicles since its
                                            operation began. The management of the company concludes from this that the Ministry of Transportation
                                            does not see the investigation opened and the indictment filed against Global AutoMax and
                                            their possible results, as possibly leading to the conclusion that Global AutoMax is not
                                            suitable to engage in the import of vehicles.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 407; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">C.</td><td style="text-align: justify">According to
                                            the &#8217;s management, the policy of the Ministry of Transportation is to increase competition
                                            in the industry including the promotion of the company and its business. Thus, the goal of
                                            realizing the purpose of the Vehicle Services Licensing Law is to open up the vehicle import
                                            market in Israel to competition and to lower entry barriers for commercial imports in the
                                            vehicle industry. The Company is a leading party in competition in the industry and it has
                                            brought about a real revolution in it, therefore, per the understanding of the company&#8217;s
                                            management, a refusal to grant Global AutoMax licenses or renew its licenses is against the
                                            competition that the Ministry of Transportation aims to promote.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">D.</td><td style="text-align: justify">To the best
                                            of Global AutoMax&#8217;s knowledge, since the enactment of the Vehicle Services Licensing
                                            Law, the Director has not exercised his authority not to grant or renew a license, and in
                                            the opinion of the company&#8217;s management, the use of such authority will be done sparingly
                                            and very carefully.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, Global AutoMax believes, relying
on the position of its legal advisors, that if such administrative proceedings were taken against it, it would be possible to establish
a substantial argument against it, including a delay in execution (and this is based, among other things, on similar administrative proceedings
underway today, for example the proceedings of the Commissioner of the Capital market, Insurance and Savings vis-&#224;-vis credit
service providers).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">It should also be noted that the
company and Global AutoMax have a broad and solid managerial and professional framework, a good management system and excellent trade
relations, which the company and Global AutoMax expect to be able to successfully deal with all the challenges that will arise, to the
extent that they arise, following the filing of the indictment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In light of the above, Global AutoMax
assesses, relying on the position of its legal advisors, that the filing of the indictment does not cause cancellation or non -renewal
or refusal to grant licenses to Global AutoMax by the Director, or to harm the functioning of the company and Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">On September 29, 2022, a lawsuit
                                            was filed with the District Court in Tel Aviv and an application for its approval as a class
                                            action against Global AutoMax Ltd. (hereinafter: Global AutoMax), Union Motors Ltd. (hereinafter:
                                            &#8220;Union&#8221;), Lex Motors Ltd. (hereinafter: &#8220;Lex&#8221;), Toyota Motor Corporation
                                            (hereinafter: &#8220;Toyota&#8221;), and Denso Corporation (hereinafter: &#8220;Denso&#8221;)
                                            (hereinafter: the &#8220;Request&#8221;).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The subject of the application,
is applicants claim that the defendants (Toyota as a manufacturer of vehicles; Danso as a manufacturer of allegedly defective fuel pumps
which are installed in vehicles made by Toyota and Lexus and are the subject of the request; Union and Lex as direct importers of vehicles
made by Toyota and Lexus to Israel; and Global AutoMax as an indirect importer of vehicles made by Toyota to Israel, as well as the company
that imported the applicant&#8217;s vehicle to Israel) breached their obligations towards the members of the group by, inter alia, producing
and/or importing and/or marketing and/or selling vehicles in which a defective fuel pump is installed, refrained from performing a service
call for all vehicles in which defective pumps are installed, avoidance from bearing the costs caused by the damaged fuel pumps and the
service call, and more.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 408; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">This, according to the applicants,
in breach of the defendants&#8217; obligations according to the Liability for Defective Products Law, 5740-1980, the Sales Law, 5728-1968,
the Contracts Law (General Part), 5733-1973, the Licensing of Services and Professions in the Automotive Industry Law, 5776-2016 and
other laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">the group Which the applicants wish
to represent as part of the class action (if approved) is all owners (at any time) or holders of vehicles made by Toyota or Lexus, where
a fuel pump made by Denso was installed and of the type for which the service call was made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">The respondents estimate the total
damage allegedly caused to all the members of the alleged group, in the amount of over 2.5 million NIS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On November 14, 2023, Global AutoMax
submitted a response to the approval application, in which it rejected all the claims raised in the approval application. In particular,
Global AutoMax rejected the claims specifically directed at it, and this in view of its being an indirect importer, for which most of
the alleged obligations on which the request for approval purports to be based - do not apply to it at all, and in view of the fact that
with regard to the service calls, the object of the request for approval, it fully complied with all obligations (that are limited in
any case) applies to it in this context. On February 25, 2024, the applicants submitted a response on their behalf, in response to the
respondents&#8217; answers to the approval request. In their response, the applicants repeated their main claims. Pre-trial hearing is
set for September 25, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">At this proceedings preliminary
stage, the company&#8217;s legal advisors are unable to assess the chances of an approval request being accepted, But according to the
information and data provided to them by Global AutoMax, the company&#8217;s legal advisors estimate that the exposure applicable to
the company regarding this procedure is not material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><b>B.</b></td><td><b><span style="text-decoration:underline">Engagements</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><img alt="" src="fin_006.jpg"/></td><td style="text-align: justify">On
                                            January 6, 2022, the Company contracted with an attorney for the purpose of joint legal representation
                                            of Global AutoMax Ltd., and the position holders who are accused together in the indictment
                                            filed against them and others in August 2021, as detailed in Item 21A above.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><img alt="" src="fin_007.jpg"/></td><td style="text-align: justify">On
                                            December 29, 2021 and March 16, 2022, the Company&#8217;s Board of Directors approved the
                                            allocation of 9,284,280 non-marketable warrants exercisable for up to 9,284,280 ordinary
                                            company shares, by virtue of the option plan for office holders, employees, consultants and
                                            service providers of the company and controlled companies, to a company consultant where
                                            no employer-employee relationship exists.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 409; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><img alt="" src="fin_008.jpg"/></td><td style="text-align: justify">On
                                            March 16, 2022, the company signed an agreement with third parties (hereinafter: the &#8220;partners&#8221;),
                                            under which the parties will work to establish and register a joint company, engaging in
                                            purchase and sale of used vehicles (trade-in) (hereinafter in this sub-item: &#8220;the Agreement&#8221;
                                            and the &#8220;Joint company&#8221;, as the case may be).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company will
grant the joint company exclusivity in the purchase of trade-in vehicles (to be purchased from the company&#8217;s customers), according
to pricing to be determined at the company&#8217;s discretion, subject to meeting the goals set forth in the agreement.</p><div>

</div><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&#160;</p><div>

</div><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">According to an
agreement, at the time of the joint company&#8217;s establishment, the Company will own 80% of its issued and paid-up capital, while
the partners will jointly own the remaining 20%. The partners were given options (exercisable subject to meeting the joint company&#8217;s
objectives as stipulated in the agreement (hereinafter: &#8220;the Option subject to meeting objectives&#8221;), as well as the Company
meeting the milestones set forth in the merger agreement between the Company and the subsidiary), which, assuming their full exercise,
may increase the partners holdings in the joint company up to 48% of its issued and repaid capital.</p><div>

</div><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&#160;</p><div>

</div><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">According to the
option subjected to meeting the objectives, if in a certain period after the signing of the agreement the net profit of the joint company
will be higher than a set threshold, and also the joint company will purchase a minimum amount of vehicles from the subsidiary as stipulated
in the agreement, the partners will be entitled to purchase ordinary shares of the joint company at a rate of 20% from the issued and
repaid capital, according to a company value of ILS 30 million pre-money.</p><div>

</div><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Close to the establishment
of the joint company, the Company will provide financing to the joint company, in the form of an owner&#8217;s loan in the amount of
ILS 3 million, for its current activities (hereinafter: &#8220;the Owner&#8217;s loan&#8221;). The owner&#8217;s loan will bear interest
according to Item 3(j) of the Income Tax Ordinance [new version] (hereinafter: &#8220;the Ordinance&#8221;), to be repaid in 30 equal
monthly payments starting on January 1, 2025. Should the joint company require additional financing for the needs of its current activities
in addition to the owner&#8217;s loan, the parties will provide the joint company with such financing, in the form of owner loans, according
to each relative share in the Company&#8217;s issued share capital (hereinafter: &#8220;Additional owner loans&#8221;). The additional
owner loans, if any issued, will bear interest according to item 3(j) of the ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify">Prior to the signing
of the agreement, the Company entered into a sublease Agreement in connection with offices with an area of approximately 100 square meters
as well as land with an area of approximately 1,000 square meters in the &#8220;Pi Gillot&#8221; complex, which will be assigned to the
joint venture company from the date of its establishment and will be used for its activities (hereinafter: &#8220;Agreement Lease&#8221;).
The lease period according to the Lease Agreement is from February 1, 2022 to August 6, 2023, and the company was given an option to
extend for another identical period (subject to the extension of the lease period of the main tenant). The agreement can be terminated
with a 6-months notice, upon request from the competent authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 410; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><img alt="" src="fin_009.jpg"/></td><td style="text-align: justify">On
                                            March 16, 2022, a Lease Agreement addendum was signed for the property used as the Company&#8217;s
                                            logistics warehouse in Jerusalem, according to which the lease period was extended until
                                            July 20, 2023, with a Company option to extend said lease period by additional 12 months.
                                            The monthly lease fees total 42,000 ILS, plus VAT and linkage differences, and during the
                                            optional period, insofar exercised, totals 44,100 ILS, plus VAT and linkage differences.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                 <tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">About 47% of the rights in the property are held by a party
                                            related to a Company&#8217;s Director, who is also one of a controlling owners of the Company.</td></tr>
                                                                                 </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><img alt="" src="fin_010.jpg"/></td><td style="text-align: justify">On
                                            April 27, 2022, following the company&#8217;s signing on April 27, 2022 of a non-binding
                                            memorandum of understanding with Dalhom Motors Ltd. (hereinafter: &#8220;Dalhom&#8221;),
                                            a franchise holder for importing Temsa brand buses (hereinafter: &#8220;the Franchise&#8221;),
                                            to establish a joint venture, on June 19, 2022, a detailed agreement was signed between the
                                            company, Dalhom and Dalhom Automax Ltd., a dedicated company established to operate the said
                                            joint venture (hereinafter: &#8220;the <b>Agreement</b>&#8221; and &#8220;<b>the Joint company</b>&#8221;,
                                            and the transaction subject to the agreement &#8220;<b>the Transaction</b>&#8221;), that
                                            will engage, among other things, with import to and marketing in Israel of Temsa brand buses.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Below are the main points of the agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Each
    party&#8217;s holdings, appointment of directors, and management of the joint company</span></b>: at the agreement completion, each
    party will hold 50% of the joint company&#8217;s ordinary shares, and the Company will be entitled to appoint more than half of the
    board of directors members. When the Company&#8217;s loans (as defined below) are repaid to the Company in full, the directors appointment
    rights of the Company and Dalhom in the joint company&#8217;s Board of Directors will become equal. The joint company&#8217;s Articles
    of association stipulates that decisions on certain matters in connection with the management of the joint company will require Dalhom&#8217;s
    approval.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Company
    loans</span></b>: As of the completion date, the Company will provide the joint venture with owner loans in the total amount of 10 million
    NIS (above and below: &#8220;<b>Company loans</b>&#8221;) set at times to allow the joint venture to meet its obligations to Dalhom
    as detailed in Item 4 below. The Company&#8217;s loans will be offered at the same interest rate (back-to-back), as loans the company
    will raise the said amount from its financing sources, however, in any case loans will not exceed the rate stipulated in the agreement.
    The Company&#8217;s loans, plus interest, will be repaid to the Company or converted to the joint company&#8217;s serf capital, all
    in the manner and at the times stipulated in the agreement.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 411; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 &#8211; Contingent liabilities, engagements, liens and
guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">3.</td><td style="text-align: justify"><b><span style="text-decoration:underline">The initial repayment to
                                            the Company</span></b>: The Company will be entitled to receive first from the joint company&#8217;s
                                            profits or from its other sources, a total equal to the actually advanced Company&#8217;s
                                            loans, plus interest accrued on the Company&#8217;s loans.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Payments
    to Dalhom</span></b>: Subject to the completion of the agreement, the joint company will transfer to Dalhom an aggregate amount equal
    to the total of the Company&#8217;s loans, according to the details and under the following conditions and dates:</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">A.</td><td style="text-align: justify">The inventory: at the completion
                                            date, Dalhom will sell to the joint company, all of the Temsa spare parts inventory that
                                            it will have at that time, according to the amount of the cost of the inventory in Dalhom&#8217;s
                                            books (hereinafter: &#8221; <b>Inventory</b>&#8221; and &#8220;<b>Amount of Inventory Value</b>&#8221;).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">B.</td><td style="text-align: justify">Contingent advance: at the time
                                            of completion, the joint company will pay Dalhom an additional amount, as a conditional advance
                                            for the transfer of the franchise to the joint company (hereinafter: &#8220;<b>the Conditional
                                            advance for the franchise</b>&#8221;). The agreement sets a mechanism according to which
                                            the conditional advance in respect of the concession will gradually become a payment for
                                            the franchise to Dalhom, depending on the number of years the franchise will be in effect
                                            from the date of completion.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">C.</td><td style="text-align: justify">Dalhom loan: As of the date of
                                            completion, the joint company will transfer to Dalhom an interest-bearing loan (hereinafter:
                                            <b>&#8220;Dalhom loan&#8221;</b>), as a loan at the expense of Dalhom&#8217;s share of future
                                            profits of the joint company which will be repaid in the manner and at the times stipulated
                                            in the agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">5.</td><td style="text-align: justify"><b><span style="text-decoration:underline">Collaterals</span></b>: To guarantee
                                            repayment of the company&#8217;s loans, at the time of completion the joint company will
                                            pledge to the Company its rights towards Dalhom for the repayment of the Dalhom loan, and
                                            Dalhom will pledge to the company its shares in the joint company as a first-class lien.
                                            The liens will be removed upon full repayment of the Dalhom loan and the company&#8217;s
                                            loans in accordance with the provisions of the agreement.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">6.</td><td style="text-align: justify"><b><span style="text-decoration:underline">Liability and maintenance</span></b>:
                                            Dalhom will cease to be a party to bus maintenance agreements it entered into until the date
                                            of the agreement and will bear its obligations according to these, and the joint company
                                            and/or the Company will not have any liability or obligation in connection with these maintenance
                                            services. The parties reached agreements regarding the manner and conditions of supplying
                                            spare parts to Dalhom by the joint company, for the purpose of providing the said services.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">7.</td><td style="text-align: justify"><b><span style="text-decoration:underline">Financing the joint company&#8217;s
                                            activity:</span></b> In addition to the Company&#8217;s loans as mentioned above, after the
                                            agreement completion, the Company will provide the joint company with a credit line, or arrange
                                            a credit line to be provided by financing entities, to the extent stipulated in the agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">8.</td><td style="text-align: justify"><b><span style="text-decoration:underline">Preconditions</span></b>: It
                                            was agreed between the parties that the completion of the agreement will be subject to the
                                            existence of a number of preconditions, including: (a) receiving Temsa&#8217;s consent to
                                            transfer the franchise to the joint company, and signing a franchise agreement between Temsa
                                            and the joint company, with substantially similar wording to the existing franchise agreement
                                            wording and to the satisfaction of the agreement parties, for a period of at least 3 years;
                                            and (b) receiving the approval of the Commissioner of Competition (received at the time of
                                            publication of the financial statements).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59pt; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On November 20, 2022, after all of
the conditions for agreement completion had been met, the transaction will be completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 412; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><!-- Field: Split-Segment; Name: 008 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify">Prior to completing
the Transaction, Dalhom Automax signed a franchise agreement with Temsa for a period of three years, under which the joint company would
serve as a direct importer of buses manufactured by Temsa in Israel (hereinafter: &#8220;<b>The Franchise Agreement</b>&#8221;). The
Franchise agreement includes the provisions accepted in agreements of this kind, including sales objectives agreed between the parties,
failure to comply with which will give Temsa the right to cancel the franchise agreement, at the end of an agreed recovery period. Also,
the joint company has committed that without Temsa&#8217;s prior written approval, it will not import and market in Israel during the
period of the agreement products competing with those of Temsa.</p><div>

</div><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify">The franchise agreement
includes additional conditions as is customary in the industry.</p><div>

</div><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify">In addition, the
joint company signed a service and warranty agreement with Temsa for a period of three years, under which the joint company would provide
maintenance and warranty services for buses manufactured by Temsa in Israel, according to commercial terms established between the parties
(hereinafter: &#8220;<b>The Service and Warranty Agreement</b>&#8221;).</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_011.jpg"/></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 24, 2022, the Company entered an agreement with a third party, under which it shall
                                            serve as an authorized distributor of the Company (hereunder: the &#8220;Distribution Agreement&#8221;
                                            and the &#8220;Distributor&#8221;, as applicable).</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify">Simultaneously with signing the Distribution
Agreement, the distributor entered an agreement to rent a display center located in the city of Acre, where the distributor intends to
operate a Company&#8217;s branch, in accordance with the provisions of the Distribution Agreement (hereunder: the &#8220;Lease Agreement&#8221;).
The Company committed to the lessor in the Lease Agreement that insofar the distributor shall terminate the Lease Agreement (or fail
to comply with the provisions of the Lease Agreement), then it will step in its place and sign a lease agreement with the lessor under
identical terms. The Lease Agreement is for a period of 3 years starting August 1, 2022, and the Distributor is given an option to extend
it for a period of additional 3 years. The Distribution Agreement is for a period of 5 years, and includes the occurrence of certain
events, after which each party will be entitled to cancel the Distribution Agreement immediately. In addition, each party will be entitled
to cancel the Distribution Agreement for any reason by giving 3 months&#8217; written notice to the other party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify">The Distribution Agreement stipulates
that the Distributor will purchase demonstration vehicles from the Company for the purpose of demonstration drives, and that the Company
will loan inventory of vehicles to the distributor for displaying them in the showroom, subject to the preparation of an insurance policy
by the distributor and other established commercial matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify">According to the Distribution Agreement,
the vehicles sold by the Distributor to end customers will be priced in accordance with the price list set forth by the Company, where
each vehicle sale by the Distributor will earn the Distributor a commission at a certain rate determined in the Distribution Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_012.jpg"/></td><td style="text-align: justify">On
                                            July 28, 2022, Global AutoMax entered an agreement with a third party, under which it shall
                                            serve as an authorized distributor of Global AutoMax in the city of Netanya (hereunder within
                                            this paragraph: the &#8220;<b>Distribution Agreement</b>&#8221; and the &#8220;<b>Distributor</b>&#8221;,
                                            as applicable).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, on August 7, 2022, the
Company entered an agreement to lease a property in the city of Netanya with a total area of approx. 750 sq. m. (which was assigned to
the joint company as detailed below), where the Distributor was supposed to operate a branch of the Company, in accordance with the provisions
of the Distribution Agreement (hereunder within this subitem: &#8220;<b>The Lease Agreement</b>&#8221;) The Netanya branch includes offices,
a display center and a yard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 413; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The
                                            Lease Agreement is for a period of 3 years starting September 1, 2022, and the Company is
                                            granted two options to extend it for additional 3 years periods each (and in total until
                                            August 30, 2031). To guarantee the Company&#8217;s obligations according to the Lease Agreement,
                                            among other things, a guarantee was given from the Company limited in to up to 5 months&#8217;
                                            rent amount, plus VAT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On November 8, 2022, a Founders&#8217;
Agreement was signed between the Company and the Distributor, in relation with founding a joint company, Automax Netanya Ltd., which
will operate the branch in Netanya, and additional branches as may be decided between the parties (hereunder within this subitem: the
&#8220;<b>Founders&#8217; Agreement</b>&#8221; and &#8220;<b>the Joint Company</b>&#8221;, as applicable).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the Founders&#8217; Agreement,
the Company holds half of the joint company&#8217;s issued share capital, while the distributor holds the remaining half. The parties
undertook providing the joint company with an initial amount as an owner&#8217;s loan for financing its activities, divided between them
according to the relative share of each party in the joint company&#8217;s share capital (hereunder within this paragraph: &#8220;<b>Owner&#8217;s
Loan</b>&#8221;). Distribution of profits in the joint company will be made subject to any law, according to the relative share of each
party in the joint company&#8217;s share capital. The Company shall be entitled to appoint one director to the Board of Directors of
the joint company, while the Distributor shall be entitled to appoint one director on his behalf to the Board of Directors after providing
his share in the Owner&#8217;s Loan (through repayment of a loan provided to it by the Company as detailed below).</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The
                                            Founder&#8217;s Agreement includes customary provisions limiting the possibility of transferring
                                            shares in the joint company, including the right of first refusal (except in the circumstances
                                            stipulated in the Founders&#8217; Agreement), the right to join the sale of shares (Tag Along)
                                            and forced sale (Bring Along).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At the same time of signing of the
Founders&#8217; Agreement, a loan agreement was signed between the parties, according to which the Company shall finance the distributor&#8217;s
share of the owner&#8217;s loan, and until the repayment of the such loan provided by the Company to the distributor as stated, the distributor&#8217;s
holdings in the joint company will be mortgaged in favor of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, at the same time of signing
the Founders&#8217; Agreement, the Distribution Agreement was terminated, and a similar Distribution Agreement has been signed between
the Distributor, the joint company and Global AutoMax, and the Lease Agreement was assigned to the joint company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the second quarter of 2023,
The retailer transferred his holdings in Automax Netanya (50%) to Global AutoMax Company Without consideration, in the manner that after
such transfer Global AutoMax holds 100% b The share capital of Automax Netanya company And Automax Netanya activity was transferred to
Global AutoMax. As of the date of the report Automax Netanya it is an empty company with no activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 21.75pt"/><td style="width: 17.25pt"><img alt="" src="fin_013.jpg" style="height: 13px; width: 15px"/></td><td style="text-align: justify">On
                                            August 5, 2022, Global AutoMax entered a Founders&#8217; Agreement with a third party that
                                            acts as an authorized distributor of vehicles imported by the Company, and operates the Company&#8217;s
                                            branch in Ashkelon (hereunder: &#8220;<b>the Distributor</b>&#8221; and &#8220;<b>the Founders&#8217;
                                            Agreement</b>&#8221;, as applicable).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the Founder&#8217;s Agreement,
the parties founded a joint company, Automax HaShfela Ltd., which, inter alia, operates vehicle&#8217; distribution and sales centers
in the cities of Ashdod, Ashkelon and other locations to be decided by the parties (hereunder: the &#8220;<b>Joint Company</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the Founder&#8217;s Agreement,
Global AutoMax holds half of the joint company&#8217;s issued share capital, while the distributor holds the remaining half. The parties
undertook to provide the joint company with an initial amount as an owner&#8217;s loan for the purpose of financing its activities, divided
between them according to the relative share of each party in the joint company&#8217;s share capital. Distribution of profits in the
joint company will be made subject to any law, according to the relative share of each party in the joint company&#8217;s share capital.
The joint company&#8217;s Board of Directors will appoint four members, of whom two will be appointed by the distributor and two by the
subsidiary company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 414; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements, encumbrances
and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Founder&#8217;s Agreement includes
customary provisions limiting the possibility of transferring shares in the joint company, including the right of first refusal (except
in the circumstances stipulated in the Founders&#8217; Agreement), the right to join the sale of shares (Tag Along) and forced sale (Bring
Along).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Prior to the signing of the Founder&#8217;s
Agreement, Global AutoMax entered an agreement for the lease of a showroom with an area of approx. 500 sq. m. in Ashdod which has been
assigned to the joint company and is used as a branch of Global AutoMax in the city (hereunder: the &#8220;Lease Agreement&#8221;). The
lease period is from September 15, 2022 and for three years thereafter, while the joint company is granted an option to extend the Lease
Agreement for three additional periods of two years each and in total until September 19, 2031. The Lease Agreements in connection with
the properties in Ashdod and Ashkelon were assigned to the joint company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the last quarter of 2022, the
parties signed a vehicle Distribution Agreement between the joint company and Global AutoMax, according to which the joint company shall
be the authorized distributor of the vehicles imported by the Company in the cities of Ashkelon and Ashdod, which shall replace the existing
agreement between the Company and the Distributor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 21.4pt"/><td style="width: 17.6pt"><img alt="" src="fin_014.jpg" style="height: 13px; width: 15px"/></td><td style="text-align: justify">On
                                            February 28, 2023, the company paid the first payment of principal and interest to the bonds
                                            (series B) holders in a total amount of approximately ILS 7.2 million.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 21.75pt"/><td style="width: 14.25pt"><img alt="" src="fin_015.jpg"/></td><td style="text-align: justify">On
                                            March 13, 2023, Dalhom entered a conditional agreement for the distribution, sale, and marketing
                                            in Israel of private electric vehicles manufactured by Al Damani, a manufacturer from the
                                            United Arab Emirates (hereinafter: &#8220;the Distribution Agreement&#8221;, &#8220;the Vehicles&#8221;
                                            and &#8220;the Manufacturer&#8221;, respectively).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with the Distribution
Agreement, the vehicles will be sold to Dalhom according to the orders it will place from time to time, while the appointment of Dalhom
as a distributor of the vehicles in Israel is subject to its meeting order goals within a certain period from the date of signing the
Distribution Agreement. Prices and additional commercial terms to be agreed upon between the parties until the date when Dalhom&#8217;s
obligations under the Distribution Agreement come into effect. The manufacturer will provide Dalhom with warranty services for the vehicles,
for the period stipulated in the Distribution Agreement, and will also provide it with spare parts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Distribution Agreement is valid
for several years, and subject to Dalhom meeting order goals, its validity will be automatically extended for several additional years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The law applicable to the Distribution
Agreement is the law of the Dubai International Financial Center (hereinafter: &#8220;DIFC&#8221;), and the place of jurisdiction in
relation to any dispute between the parties regarding the Distribution Agreement will be in Dubai, in accordance with DIFC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">It should be emphasized that all Dalhom
obligations according to the Distribution Agreement are conditional on receiving all the required regulatory approvals from the Ministry
of Transportation for the import of vehicles to Israel, which have not yet been granted as of the date of the financial reports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 415; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><!-- Field: Split-Segment; Name: 009 --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The information presented above in
connection with the import and distribution of vehicles in Israel is considered forward-looking information as defined in the Securities
Law, 5728-1968, which at this stage there is no certainty of its realization, <i>inter alia</i>, due to factors that are not under the
control of the Company or are not under its full control. The realization of the aforementioned information depends, <i>inter alia</i>,
on the certificates of the Ministry of Transportation and other institutions, which, as mentioned, have not yet been granted at this
stage and there are no certainty that they shall be obtained in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_016.jpg"/></td><td style="text-align: justify">A
                                            lease agreement that is used as a service center for buses that are manufactured by Temsa
                                            In February 2023, Dalhom Automax signed a lease agreement with third parties (hereinafter:
                                            &#8220;the Lease Agreement&#8221; and the Lessors&#8221;, as applicable, according to which
                                            Dalhom Automax will rent from the Lessors an asset at Hod HaSharon that its area is approx.
                                            4,000 square meters for the purpose of establishing and operating a vehicles&#8217; repair
                                            shop, which will be used as a service center for buses that are manufactured by Temsa.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify">The initial lease period according to
the agreement is 5 years starting from March 15, 2023, and ending on March 14, 2028 (&#8220;the First Lease Period&#8221;). Dalhom Automax
will have the option to extend the initial lease period for an additional period of 5 years, subject to its compliance with the provisions
stipulated in the Lease Agreement (&#8220;the Additional Lease Period&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify">During the first year of the lease period,
Dalhom Automax will pay a monthly rental fee of 120 thousand ILS, plus VAT. Starting from the beginning of the second year of the First
Leasing Period (i.e., starting from the 13th month of the rental period), Dalhom Automax will pay a monthly rental fee of 130 thousands
ILS plus VAT. The rental fees during the Additional Leasing Period will increase by 5% compared to the last rent that was paid until
the beginning of the Additional Lease Period. The rental fee shall be linked to the consumer price index.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify">In order to guarantee Dalhom Automax&#8217;s
undertakings according to the Lease Agreement, the Lessors were provided with the following securities: (a) a Compay guarantee, jointly
and severally with Dalhom Motors and for an unlimited amount, for all the undertakings of Dalhom Automax according to the Lease Agreement;
(b) an autonomous bank guarantee in an amount that is equal to the rental fees for a 4-months period plus VAT, when the sum guarantee
is linked to the consumer price index. Instead of providing a bank guarantee, Dalhom Automax may provide to the Lessors an amount of
561,600 ILS which shall be used as a deposit that will be held by the Lessors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">Dalhom Automax has undertaken to indemnify
the Lessors and/or anyone on their behalf for any amount they will be required to pay in connection with a lawsuit of a certain third
party, insofar it is filed, for the failure of Dalhom Automax and that said third party to jointly rent the asset. The service center
was opened to customers during January 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_017.jpg"/></td><td style="text-align: justify">Given
                                            that the Company met milestones no. 2 and 3 that were set in the merger agreement between
                                            the Company, Global AutoMax and its shareholders at the time (the current shareholders in
                                            the Company), and between M.R.M Merchavit Holdings and Management Ltd. (the initiator of
                                            the transaction), on March 28th 2023 it allocated to the controlling shareholders in the
                                            Company an additional 168,105,258 ordinary shares of the Company, which constitute about
                                            41% of the Company&#8217;s issued and paid-up share capital after the allocation. After this
                                            said allocation, the controlling shareholders of the Company held together about 70.9% of
                                            the issued and paid-up share capital of the Company, and as of the day the financial statements
                                            are signed they hold together about 55.65% of the Company&#8217;s issued and paid-up share
                                            capital.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><img alt="" src="fin_018.jpg"/></td><td style="text-align: justify">Following
                                            the approval of the general assembly of the Company&#8217;s shareholders, which took place
                                            on May 8th 2023, on May 21st 2023 the Company&#8217;s registered share capital and its issued
                                            and paid-up share capital were consolidated at a ratio of 1:5, in such a way that every five
                                            (5) ordinary shares in the Company&#8217;s registered share capital and in its issued and
                                            paid-up share capital, that the denominated value of each one of them is 0.01 ILS, were consolidated
                                            into one (1) share that its denominated value is 0.05 ILS and the articles of association
                                            were accordingly amended.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 416; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_019.jpg"/></td><td style="text-align: justify">Following
                                            the approval of the Company&#8217;s board of directors, on June 28, 2023 8,000,000 ordinary
                                            shares of the Company that the denominated value of each one is 0.05 ILS were allocated to
                                            3 investors in exchange for a total investment of NIS 4,000,000 at a price of 50 Agorort
                                            per share by way of a private offer.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_020.jpg"/></td><td style="text-align: justify">On
                                            July 26, 2023, the Company allocated 733,592 (non-tradable) warrants, which can be exercised
                                            up to 733,592 ordinary shares of the Company, to Leumi Partners Ltd., as part of the consideration
                                            for the distribution services they provided to the Company in connection with the Company&#8217;s
                                            bond offering (series B). The warrants can be exercised in full on the date of their allocation
                                            and for a period of 48 months thereafter, at an exercise price of NIS 3 per share.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_021.jpg"/></td><td style="text-align: justify">On
                                            July 30, 2023, an agreement was signed between E.V Drive and Global AutoMax and Automax Vehicle
                                            Fleets (which until the signing of the aforementioned agreement was a non-active company,
                                            that was fully owned (100%) by Global AutoMax). According to this agreement, shares which
                                            represent 50% of the issued and paid-up capital of Automax Vehicle Fleets were transferred
                                            to E.V. Drive, without consideration, and it was decided that Automax Vehicle Fleets will
                                            engage in the field of leasing or in the brokerage of leasing transactions (hereinafter in
                                            this sub-article: &#8220;<b>the Agreement</b>&#8221;). The Agreement settles the management
                                            of Automax Vehicle Fleets and states, among other things, that Global AutoMax will provide
                                            to Automax Vehicle Fleets an initial amount as an owner&#8217;s loan for the purpose of financing
                                            its activities, which will be repaid from the profits of Automax Vehicle Fleets in 24 payments
                                            starting at the end of 36 months from the signing of the agreement. The distribution of profits
                                            in the joint company will be done subject to any law, according to the proportional share
                                            of each party in the joint company&#8217;s share capital. The board of directors of the joint
                                            company will appoint two members, when each party will appoint one director. The founders&#8217;
                                            agreement also stipulates that certain decisions will require a majority of 100% of the directors,
                                            including a change in the joint company&#8217;s incorporation documents, and inter alia,
                                            a change in the rights that are attached to the joint company&#8217;s shares, the provision
                                            of loans and/or guarantees and/or other financing for the joint company&#8217;s activities
                                            that deviate from its regular course of business or the provision of loans to stakeholders
                                            in the joint company, as well as the approval of transactions in which an office holder,
                                            director, shareholder and/or stakeholders in the company have a personal interest.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Founders&#8217; Agreement includes
acceptable provisions that limit the possibility of transferring shares in the joint company, including the right of first refusal (except
in the circumstances stipulated in the Founders&#8217; Agreement), the right to join the sale of shares (Tag Along) and a forced sale
(Bring Along).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><img alt="" src="fin_022.jpg"/></td><td style="text-align: justify"><span style="font-size: 10pt">Following
                                            the approval of the Company&#8217;s board of directors from August 15, 23 and 24, 2023, on
                                            September 18th 2023 new credit limits were provided to Dalhom Automax from two banking corporations
                                            (which also provided credit limits to Global AutoMax Ltd.) at a sum of NIS 7.5 million each
                                            (hereinafter: the &#8220;C<b>redit Limits</b>&#8221;). The credit, which was provided out
                                            of the Credit Limits carries an annual interest that ranges between prime + 1.5%-0.5%. The
                                            Company guarantees the undertakings of Dalhom Automax towards each of the banking corporations
                                            in connection with the Credit Limits. The Credit Limits include a commitment of Dalhom Automax
                                            to comply with financial standards, as detailed in note 21c below.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_023.jpg"/></td><td style="text-align: justify">On
                                            October 19, 2023, the Company entered into a market making agreement (the &#8220;<b>Agreement</b>&#8221;)
                                            with Israel Brokerage and Investments -IBI Ltd. (&#8220;t<b>he Market Maker</b>&#8221;),
                                            according to which the Market Maker will act as a market maker in the Company&#8217;s ordinary
                                            shares (the &#8220;Securities&#8221;) which are traded on the Tel Aviv Stock Exchange Ltd.
                                            (&#8220;<b>the Stock Exchange</b>&#8221;) from October 22, 2023. Such market making will
                                            be done according to the rules set forth in Chapter IX of Part III of the Stock Exchange&#8217;s
                                            bylaws, and the instructions pursuant thereto, in exchange for an amount, which was set forth
                                            in the agreement, that is not significant for the Company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The agreement is for a period of one
year starting from the day it came into effect, and it will be automatically extended, as long as it is not canceled in accordance with
its instructions, for additional periods of 12 months each.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 417; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_024.jpg"/></td><td style="text-align: justify">Following
                                            the Company&#8217;s announcement on November 9, 2023, regarding negotiations to sign a memorandum
                                            of understanding with a public company that is incorporated in Israel and its securities
                                            are traded on the NASDAQ Stock Exchange (the &#8220;Absorbing <b>Company</b>&#8221;), for
                                            a merger with the acquiring company (hereinafter: the &#8220;<b>Memorandum of Understanding</b>&#8221;
                                            and <b>the Transaction</b> &#8220;or the &#8220;M<b>erger</b>&#8221;, as the case may be),
                                            subject to the signing of a detailed agreement based on the principles that were set forth
                                            in the Memorandum of Understanding (hereinafter: the &#8220;D<b>etailed Agreement</b>&#8221;),
                                            the parties signed the Memorandum of Understanding on November 21st 2023, and on December
                                            26, 2023, the Company notified that part of the commercial terms between the parties, shall
                                            be updated in the following manner.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Here below are the main points of the Memorandum of Understanding,
as they were updated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">The Company will merge with the
                                            Absorbing Company through a reverse triangular merger - in such a way that the target company,
                                            which is a subsidiary that is fully owned by the Absorbing Company and was established for
                                            the purpose of the merger, will be merged with and into the Company and will be liquidated
                                            afterwards, so that the Company will become in exchange for an allocation of shares of the
                                            Absorbing Company to the Company&#8217;s shareholders, which will constitute 49.99% of the
                                            fully diluted issued and paid-up share capital of the Absorbing Company, a subsidiary of
                                            the Absorbing Company.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">At the time the Transaction is
                                            completed, the Absorbing Company will invest in the Company as equity a total of sum of cash
                                            that will not be less than 4.250 million US dollars.</td></tr></table><div>

</div><p style="font-size: 10pt; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">At the time the Transaction is
                                            completed, the Absorbing Company will have assets and activities, in addition to the Company&#8217;s
                                            field of activity.</td></tr></table><div>

</div><p style="font-size: 10pt; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">4.</td><td style="text-align: justify">According to legal advice the Company
                                            received, the shares of the Absorbing Company that will be allocated to the Company&#8217;s
                                            shareholders will not be blocked.</td></tr></table><div>

</div><p style="font-size: 10pt; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">5.</td><td style="text-align: justify">Completion of the Merger is subject
                                            to the fulfillment of contingent terms, which are acceptable in transactions of this type,
                                            including the completion of a due diligence by both parties up to their satisfaction, the
                                            receipt of all required approvals from third parties (including a ruling from the Israeli
                                            Tax Authority), compliance with the NASDAQ rules that guarantee that the shares of the Absorbing
                                            Company will continue to be registered for trade, the obtainment of approvals for the merger
                                            according to section 350 of the Companies Law, 5799-1999, as well as an exemption for Absorbing
                                            Company from publishing a prospectus in Israel.</td></tr></table><div>

</div><p style="font-size: 10pt; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">6.</td><td style="text-align: justify">The composition of the board of
                                            directors and the manner the Absorbing Company and the Company will be managed after the
                                            completion of the merger will be decided within the Detailed Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">7.</td><td style="text-align: justify">The Memorandum of Understanding
                                            is non-binding agreement, except for the provisions regarding confidentiality, No Shop, and
                                            the applicable law and place of jurisdiction, which bind the parties.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 418; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">It should be noted that if the Transaction
is completed according to the above principles, then the Company&#8217;s shares are expected to be deleted from the trade in the Stock
Exchange subject to the receipt of all the approvals that are required by law, while the bonds (series B) of the Company will continue
to be traded in the Stock Exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Absorbing Company provided to
the Company after the date of the report about the financial situation a bridging loan in the amount of 1.4 million dollars, as detailed
in note 32(2) below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><b>It should be noted that there
is no certainty that the Detailed Agreement will be signed or that it will be signed under the conditions, which are listed above, or
that the conditions pending for the completion of the transaction will be met, therefore it is also not possible to estimate if and when
the Transaction will be completed (if at all). The company will continue and report in every case that significant changes will apply
and as required by law.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><img alt="" src="fin_025.jpg"/></td><td style="text-align: justify">In
                                            accordance with the announcement of the Securities Authority on October 16, 2023, regarding
                                            an extension that is granted to the publication of the quarterly reports for the third quarter
                                            of 2023 due to the &#8220;Israel-Hamas&#8221; War, on November 28, 2023, the Company&#8217;s
                                            board of directors approved the postponement of the publication date of the quarterly report
                                            for the third quarter of 2023 to December 31, 2023.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><img alt="" src="fin_026.jpg"/></td><td style="text-align: justify">Following
                                            the approval of the Company&#8217;s board of directors, on December 31, 2023 14,285,714 ordinary
                                            shares of the Company that the denominated value of each one is 0.05 ILS were allocated by
                                            way of a private offer at a price of 70 Agorot per share in exchange for an offset of a current
                                            credit of suppliers in the sum of 10,000,000 NIS because of an inventory of about 90 vehicles
                                            that the Company purchased and they were given to it.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5pt"/><td style="width: 0.25in"><b>C.</b></td><td><b><span style="text-decoration:underline">Liens and financial standards</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="text-decoration:underline">Banking Corporations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td><b><span style="text-decoration:underline">Global AutoMax Ltd.</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company has On-Call credit limits
from 4 banking corporations, which are unsecured and as of December 31st 2023 they amount to 150 million NIS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On January 12, 2023, Global AutoMax&#8217;s
credit limit from banking corporation B was increased from 30 million ILS to 40 million ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company guarantees Global AutoMax&#8217;s
undertakings towards the banking corporations in connection with the credit limits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order guarantee the full repayment
of the amounts that will be provided to Global AutoMax according to the credit limits from the banking corporations, Global AutoMax mortgaged
in favor of the banking corporations certain assets and rights that were agreed upon, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">A floating lien
                                            in the first degree on the entire plant, the equipment, the assets, the funds, the property
                                            and rights of Global AutoMax, including their fruits;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">A permanent lien
                                            in the first degree and pledge on Global AutoMax&#8217;s unallocated share capital and its
                                            reputation;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">A permanent lien
                                            and pledge on the bills of lading, certificates of ownership of goods, documentary letters
                                            of credit, or other documents that indicate an ownership of goods or chattel which will be
                                            delivered from time to time to the banking corporation;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">A permanent lien
                                            and pledge on all the securities, documents, and bills of others that Automax has delivered
                                            or will deliver from time to time to the banking corporation.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 419; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Also, as part of Global AutoMax&#8217;s
undertakings to the banking corporations, it must meet financial standards. Here below is a specification of the maximum and cumulative
financial standards that Global AutoMax undertook towards the banking corporations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The tangible equity in the
                                            Company&#8217;s financial statements shall be no less than 35 million ILS. This standard
                                            will be examined according to Global AutoMax&#8217;s consolidated financial statements for
                                            June 30th and December 31st of every year.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The tangible equity will constitute
                                            no less than 25% of Golbal Automax&#8217;s tangible balance sheet. This standard will be
                                            examined according to Global AutoMax&#8217;s consolidated financial statements for June 30th
                                            and December 31st of every year.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The ratio between the inventory
                                            and net credit (LTC) will always be no less than 115%. This standard shall be examined once
                                            a month.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">The aforesaid financial standards will
be examined in relation to the consolidated financial statements of Global AutoMax Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">In the letters of commitments that Global
AutoMax gave the banking corporations, it undertook, amongst other things, that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">No dividend will be distributed
                                            if the equity in the financial statements of Global AutoMax is less than 35 million ILS and
                                            its ratio in relation to the total balance sheet is less than 25%.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Loans and promissory notes
                                            that were issued in favor of Global AutoMax&#8217;s shareholders will be inferior to the
                                            credit of Global AutoMax, which was received from the banks.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Here below are the results of financial
stipulations as of December 31, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Bank A</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Bank B</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Bank C</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Bank D</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Tangible equity</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">62,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64,080</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64,080</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64,080</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tangible Equity compared to the Balance Sheet</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.63</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.24</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LTC ratio to net credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131.77</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131.77</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131.77</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131.77</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As was specified above, on December
31, 2023, Global AutoMax met all the financial stipulations, which are specified above</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On December 31, 2022, Global AutoMax
met all the financial stipulations, which are listed above, except for the stipulation of the ratio between the net financial debt and
the EBITDA towards banking corporation A (as is specified here below, this stipulation was canceled) However, Global AutoMax received
a disclaimer from the aforementioned banking corporation that it will not act with respect the failure to meet the aforesaid standard
on December 31, 2022 according to the rights that were granted to it in the financing agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On March 27, 2023, Global AutoMax
signed an update to the letter of commitment with Banking Corporation A regarding the adjustment of the standards of Banking Corporation
A to the other banking corporations (except with respect to the definition of the term tangible equity and tangible balance sheet). The
financial stipulation of the ratio between the net financial debt and EBITDA has been canceled in this update.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 420; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td><b><span style="text-decoration:underline">Automax &#8220;Trade In&#8221; Ltd.</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On January 25, 2023, Automax Trade
In Ltd. was given a credit limit of 15 million NIS from a banking corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company guarantees Automax Trade
In&#8217;s undertakings towards the banking corporation in connection with the credit limit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The credit limit includes Automax
Trade In&#8217;s undertakings to meet financial standards in accordance with a letter of commitment that was signed between Automax Trade
In and the banking corporation, which specifies as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The amount of Automax Trade
                                            In&#8217;s tangible equity shall be no less than 25% of Automax Trade In&#8217;s tangible
                                            balance sheet.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in">An examination of compliance with
this standard will be conducted on the basis of Automax Trade In&#8217;s semi-annual and annual reports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">As of December 31, 2023, the said
ratio is 28.66%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 37pt"/><td style="width: 18pt">&#9679;</td><td style="text-align: justify">The ratio between (a) the value
                                            of Automax Trade-in&#8217;s vehicles, and (b) the net financial debt, will not be less than
                                            130% (hereinafter: <b>&#8220;the LTV Ratio&#8221;</b>). The value of the vehicles according
                                            to Yad 2&#8217;s price list or according to another price list that will be approved by the
                                            banking corporation as was known at the time of the relevant calculation.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">An examination of compliance with
this standard will be conducted on a monthly basis as well as according to the banking corporation&#8217;s demand. As of the date of
the financial statements, the ratio of this standard was 140.90%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, the letter of commitment
includes a provision of a cross-commitment regarding the credit that was provided by the banking corporation to Global AutoMax Ltd.,
and a subordination and lowering of the owner&#8217;s loans that were given to Automax Trade In.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As was specified above, on December
31, 2023, Global AutoMax met all the financial stipulations, which are specified above</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td><b><span style="text-decoration:underline">Dalhom Automax Ltd.</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">On September 28th 2023 new credit
limits at a sum of 7.5 million NIS each were provided to Dalhom Automax by two banking corporations. The Company guarantees the undertakings
of Dalhom Automax towards each of the banking corporations in connection with the credit limits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The credit limit includes Dalhom
Automax&#8217;s undertakings to meet a financial standard in accordance with the letters of commitment that were signed between Dalhom
Automax and the banking corporations, which specifies as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The ratio between (a) the
                                            value of the inventory of vehicles of Dalhom Automax together with the remainder of the advance
                                            payment to the supplier, and (b) the net financial debt, shall be no less than 1.2.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">An examination of compliance with
this standard will be conducted on a monthly basis as well as according to the banking corporation&#8217;s demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">As of the date of the financial
statements, the ratio of this standard was 1.35.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 421; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In the letters of commitment that
Dalhom Automax gave the banking corporations, it undertook, amongst other things, that its tangible equity will increase every year at
a rate that will be no less than 50% of the annual net profit:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In
                                            addition, the letters of commitment include a cross default provision regarding the credit
                                            that is provided by the banking corporations to Global AutoMax, a prohibition on directly
                                            changing the control at Dalhom Automax and other acceptable instructions, including an inferiority
                                            and subordination of the owners&#8217; loans that were given to Dalhom Automax, the provision
                                            of statements and reports to the banking corporations and etc.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order to guarantee the full repayment
of the amounts that will be provided to it according to the credit limits, Dalhom Automax mortgaged in favor of the banking corporations
all its assets, including the rights and fruits that derive from the assets, in a floating lien (a general current lien)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">It should be noted that at the Company&#8217;s
request, part of the credit limits for Dalhom Automax were diverted from an existing credit limit of another company in the Group, so
that after the credit limits were provided to Dalhom Automax, the total amount of credit for the Group (including Dalhom Automax) actually
increased by 7.5 million NIS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Bonds</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On March 1, 2022, the Company issued
bonds to the public (series B) (see Note 4 here below). The Company undertook within the issuance of these bonds to meet (until the date
of the final and full repayment of the bonds (series B)) certain financial standards as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">The ratio between the Company&#8217;s
                                            equity and its total balance sheet, according to the Company&#8217;s consolidated financial
                                            statements, will be no less than 11%. In order to calculate the ratio of the equity, the
                                            liabilities because of lease agreements and the current liabilities because of lease agreements
                                            will be neutralized from the total balance sheet. As of December 31, 2023, the ratio is 16.29%.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#8220;Equity&#8221; means the equity
(including minority rights) that is presented in the Company&#8217;s consolidated financial statements, in accordance with the regulation
and accounting standardization, which exist at the time of the issuance, and without taking into account regulatory changes. When calculating
the equity, the Company&#8217;s undertaking to the former shareholders of Optimatic Media, Inc. will be taken into account as part of
the equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Regulatory changes mean changes in
the relevant legislation and/or accounting standardization, including changes in the direct or indirect tax regime, which applies to
the fleet of vehicles of the Company and of its subsidiaries and/or to their activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">The Company&#8217;s equity shall
                                            be no less than 25 million NIS according to the Company&#8217;s consolidated financial statements
                                            (&#8220;a Minimal Equity&#8221;). As of December 31, 2023, the Equity as defined above was
                                            46,191 thousand NIS.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 422; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">The sum of the Company&#8217;s
                                            assets according to its consolidated financial statements, which are not encumbered with
                                            a specific lien, will not be less than the principal of the bonds that has not been repaid
                                            yet, together with the interest that has accrued thereon up to that date and has not yet
                                            been paid. As of December 31, 2023, the sum of the Company&#8217;s assets (which is calculated
                                            in the manner that is specified below) is 270,893 thousand ILS, and the sum of the principal
                                            of the bonds that has not yet been repaid together with the interest that accumulated until
                                            that date, is 41.700 thousand ILS.</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the deed of trust, the
assets due to the lease agreements, intangible assets and deferred taxes will be neutralized for the purpose of calculating the total
sum of the assets in the manner that is specified in the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">4.</td><td style="text-align: justify">The quotient that is obtained
                                            from dividing (a) the value of the vehicles that are owned by the Company by (b) the net
                                            credit, will be no less than 110% (&#8220;the Minimum Value of a Vehicle&#8221;). As of December
                                            31, 2023, the ratio is 112%.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify">The aforementioned standards are reviewed
once a quarter, according to the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify">If for two or more consecutive reporting
periods, the equity ratio (as defined above) shall be lower than 11% and/or the Equity (as defined above) will fall below 20 million
NIS, and/or the minimal sum of the assets shall be lower than the principal of bonds that has not yet been repaid plus the interest that
it accrued up to that date and has not yet been paid and/or the Minimal Value of a Vehicle shall be less than 110%, this will be grounds
for immediate repayment of the bonds (series B). What is said above will not apply if the Company will notify within the financial statements
for the second consecutive reporting period, from which it derives that it has not met the undertakings regarding the Equity and/or the
Minimum Equity and/or the Minimum Sum of Assets and/or of the Minimum Value of a Vehicle, which it will do until the date these financial
statements are signed, that it has amended the violation after the date of the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify">As was mentioned above, the Company
met as of the date of the financial statements all the financial stipulations, which are listed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 423; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements, liens and guarantees
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><b>d.</b></td><td><b><span style="text-decoration:underline">Guarantees</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The
                                            Company guarantees the undertakings of Global AutoMax, Automax Trade In and Dalhom Automax
                                            with respect to loans they received from banking corporations, including the state-guaranteed
                                            loans and Global AutoMax&#8217;s undertakings according to the rent agreements regarding
                                            the branch in Rishon Le-Zion and branch in Netanya.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The additional shareholder at Dalhom
Automax undertook to indemnify the Company due to the guarantee the latter gave with respect to Dalhom Automax undertakings to banking
corporations for the credit limits they submitted to it at a sum of half (50%) of the expenses the Company expended in connection with
the exercise of any of the guarantees by any of the banking corporations, and it also undertook to pay to the Company every month a sum
of 25,000 NIS plus VAT, as long as the shareholder is not a guarantor towards the banking corporations in accordance with their requirements.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In
                                            addition, some of the Company&#8217;s controlling shareholders guarantee, either directly
                                            or through companies controlled by them, the undertakings of the subsidiary according to
                                            the rent agreement regarding the Global AutoMax branch in Jerusalem. For additional details,
                                            see Note 10D1 here below.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">A consolidated company provided
to the customs authorities a bank guarantee at the amount of approx. 1,315 thousands ILS and a bank guarantee to a third party at the
amount of approx. 50 thousands ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
22 &#8211; Share capital and premium on the shares</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#1488;.
Registered, issued and paid up share capital:</b></span></p><div>



</div><p style="font-size: 10pt; margin: 0">&#160;</p><div>


</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of 31 December 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Registered</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and Paid up</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Ordinary shares, 0.05 ILS par value each</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">400,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">103,691,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="margin: 0; font-size: 10pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issued
                                            and</b></span></td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; width: 76%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registered</b></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid
                                            <span style="font-size: 10pt"><b>up</b></span></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Ordinary shares, 0.01 ILS par value each</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">248,684,895</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="margin: 0; font-size: 10pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.4in; text-align: left">(*)</td><td style="text-align: justify">including dormant
                                            shares that their dominated value is 1,951,775.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.4in; text-align: left">(*)</td><td style="text-align: justify">including dormant
                                            shares that their dominated value is 9,758,875.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.4in; text-align: left">(***)</td><td style="text-align: justify">A capital consolidation
                                            was carried out in a ratio of 1 to 5, see below section V.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 424; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 22 &#8211; Share capital and premium on the shares (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Rights that are attached to shares:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The ordinary shares entitle their
holders with the right to participate in the Company&#8217;s general assemblies and vote in them. All the ordinary shares entitle their
holders with a right to receive dividends and distributions of the surpluses of the Company&#8217;s property in the event of a liquidation
or to any other form of capital return, based on their par value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Management shares give their owners
all the rights that are granted to ordinary shares, and in addition they grant the right to appoint a director to the Company&#8217;s
Board of Directors, as detailed in the Company&#8217;s articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Capital note conversion:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">According to the provisions of the
merger agreement, the capital note that has been issued to the former shareholders of the subsidiary, based on their proportional share
in its equity, at a total amount of approx. 15.6 million ILS, has been converted into premium on the issued share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
and rights to shares:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 28, 2021, the merger agreement was approved by the general meeting of the Company&#8217;s shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2021, the merger transaction was completed, in which securities were allocated as follows (before the capital consolidation
had been carried out at a ratio of 1:5): The developer received in exchange for the transaction 7,900,947 ordinary shares of the Company
without any financial consideration on its part.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,257,103
warrants of the Company were allocated to candidates for service as officers of the Company and 3,394,549 warrants of the Company were
allocated to a candidate for service as an active chairman of the board of directors of the Company</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">168,105,258 rights to the Company&#8217;s
shares were allocated to former shareholders of Global AutoMax and 6,738,368 warrants of the Company were allocated to the candidate
for service as an active chairman of the board of directors of the Company, subject to the Company&#8217;s compliance with the milestones
that were stipulated in the merger agreement. These rights were converted on March 29, 2023 into ordinary shares after the Company met
the 2nd and 3rd milestones, which were set in the merger agreement.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29pt; text-align: justify; text-indent: -14.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 425; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 22 &#8211; Share capital and premium on the shares (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Here
                                            below is a specification of the allocations:</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rights to shares that were converted
    into ordinary shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rights to shares (the indemnification)
    (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 33%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Haim Levy &#8211; Trade
    In Ltd.</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: right">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">42,026,314</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,460,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">A. Yinon 2015 Ltd</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,026,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,460,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Pozilov Investments Ltd.</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,026,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,460,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Eliyahu Baruch Ltd.</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,013,158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,730,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Belporto Investments Ltd.</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,013,157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,730,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Daniel Levy</td><td>&#160;</td>
    <td style="text-align: left">CEO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,888,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Yinon Amit</td><td>&#160;</td>
    <td style="text-align: left">Chief Business Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,888,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Emanuel Paz Puzailov</td><td>&#160;</td>
    <td style="text-align: left">Shareholder and Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,888,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Eyal Baruch</td><td>&#160;</td>
    <td style="text-align: left">Shareholder and Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,888,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Haim Levy &#8211; Trade In Ltd.</td><td>&#160;</td>
    <td style="text-align: left">Vice President of Trade and Procurement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,900,948</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Gal Levy</td><td>&#160;</td>
    <td style="text-align: left">Vice President of Standardization and Manager of Chain of Branches</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,900,948</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Tomer Levy</td><td>&#160;</td>
    <td style="text-align: left">Vice President of Business Development and Headquarters and Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,900,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Doron Shorer</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Former chairman of the board of directors (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,132,917</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">168,105,258</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">69,390,020</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,840,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in">(1)</td><td>This includes the indemnification shares because of undertaking to the controlling shareholders,
                                         see note 16c.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in">(2)</td><td style="text-align: justify">On December 29, 2021, Doron Shorer ceased to serve as chairman
                                         of the board and as a result 2,545,912 options from series B1, 2,799,014 options from series
                                         B2 and 3,939,354 options from series B3 expired. On March 16, 2022, the Company&#8217;s board
                                         of directors approved an allocation of 9,284,280 non-tradable warrants (series B) to Mr. Shorer,
                                         instead of the warrants that expired.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The allocation
of options and rights to shares is in accordance with the terms and in compliance with the milestones that are stipulated in the merger
agreement. Also, it was agreed in the merger agreement on employment agreements for the designated officers, as was approved in the merger
transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 426; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 22 &#8211; Share capital and premium on the shares (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Here below is a table that
                                            includes the number of stock options and the changes that were made in the employee option
                                            plans: Following the capital consolidation that is detailed in note 22F here below, the amount
                                            of shares that will result from the exercise of the options will be one fifth of the amount
                                            of options that is shown here below:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">For the year ended December&#160;31</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">The number of warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Warrants and rights to shares for the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">69,390,020</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants to shares that were awarded during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants that expired during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Warrants to shares for the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">69,390,020</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Here
                                            below is data that was used while deciding the fair value of the option:</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="text-decoration:underline">Series A</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Stock price (in ILS)</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">0.589</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: center">1.6</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: center">0%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vesting term</td><td>&#160;</td>
    <td style="text-align: center">4 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest</td><td>&#160;</td>
    <td style="text-align: center">0.3%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Standard deviation</td><td>&#160;</td>
    <td style="text-align: center">43%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Series A</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock price (in ILS)</td><td>&#160;</td>
    <td style="text-align: center">0.589</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: center">2.91</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: center">0%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vesting term</td><td>&#160;</td>
    <td style="text-align: center">2.25-5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest</td><td>&#160;</td>
    <td style="text-align: center">0.4%-0.13 &#160;%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Series B for allocation that was given in March 2022
    (*)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock price (in ILS)</td><td>&#160;</td>
    <td style="text-align: center">0.427</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: center">2.7065</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: center">0%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting term</td><td>&#160;</td>
    <td style="text-align: center">2-4 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest</td><td>&#160;</td>
    <td style="text-align: center">1.4%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            stated above following the expiration of the options to Mr. Shorer and re-granting in March
                                            2023.</span></td>
</tr></table><div>

</div><p style="font-size: 10pt; margin: 0">&#160;</p><div>

</div><p style="margin: 0; font-size: 10pt"></p><div>

</div><!-- Field: Page; Sequence: 427; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0; font-size: 10pt">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 22 &#8211; Share capital and premium on the shares (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Given
                                            that the Company met milestones no. 2 and 3 that were set in the merger agreement between
                                            the Company, Global AutoMax and its shareholders at the time (the current shareholders in
                                            the Company), and between M.R.M Merchavit Holdings and Management Ltd. (the initiator of
                                            the transaction), on March 28th 2023 it allocated to the controlling shareholders in the
                                            Company an additional 168,105,258 ordinary shares of the Company, which constituted 41% of
                                            the Company&#8217;s issued and paid-up share capital after the allocation. The controlling
                                            shareholders hold together as of the day the financial statements are signed about 55.65%
                                            of the Company&#8217;s issued and paid-up share capital.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Following the approval of the general
assembly of the Company&#8217;s shareholders, which took place on May 8th 2023, on May 21st 2023 the Company&#8217;s registered share
capital and its issued and paid-up share capital were consolidated at a ratio of 1:5, in such a way that every five (5) ordinary shares
in the Company&#8217;s registered share capital and in its issued and paid-up share capital, that the denominated value of each one of
them is 0.01 ILS, were consolidated into one (1) share that its denominated value is 0.05 ILS and the articles of association were accordingly
amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Following the approval of the Company&#8217;s
board of directors, on June 28, 2023 8,000,000 ordinary shares of the Company that the denominated value of each one is 0.05 ILS were
allocated to 3 investors in exchange for a total investment of NIS 4,000,000 at a price of 50 Agorort per share by way of a private offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On July 26, 2023, the Company allocated
733,592 (non-tradable) warrants, which can be exercised up to 733,592 ordinary shares of the Company, to Leumi Partners Ltd., as part
of the consideration for the distribution services they provided to the Company in connection with the Company&#8217;s bond offering
(series B). The warrants can be exercised in full on the date of their allocation and for a period of 48 months thereafter, at an exercise
price of NIS 3 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-size: 10pt">Following
the approval of the Company&#8217;s board of directors,	on December 31, 2023 14,285,714 ordinary
</span>shares of the Company were allocated by way of a private offer at a price of 70 Agorot per share in exchange for an offset of
a current credit of suppliers in the sum of 10,000,000 NIS because of an inventory of about 90 vehicles that the Company purchased and
they were given to it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">During 2023 expenses with respect
to the awarding of options in the amount of 2,549 thousand ILS were recorded in the income statement, and in 2022 expenses with respect
to the awarding of options in the amount of 9,976 thousand ILS were recorded in the income statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 23 - Financial instruments</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial risk factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s activities expose it to various
financial risks, such as a market risk (foreign exchange risk, consumer price index risk, interest rate risk), credit risk and liquidity
risk. The Group uses derivative financial instruments in order to reduce certain exposures to risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="text-decoration:underline">1.</span></td><td style="text-align: justify"><span style="text-decoration:underline">Foreign
                                            currency risk</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Group imports vehicles from
suppliers abroad, and is exposed to an exchange rate risk, which arises from exposure to various currencies, mainly the Euro and Polish
zloty. An exchange rate risk arises from future commercial transactions, recognized assets and recognized liabilities that are in a currency,
which isn&#8217;t the Group&#8217;s measurement currency, including transactions in foreign currency derivative instruments. The Group&#8217;s
exposure to the foreign currency also derives from the fact that you cannot completely link the sales price of the vehicles to changes
in the exchange rates of the foreign currency. In addition, a change in the prices of new vehicles, which are affected by changes in
foreign currency exchange rates, may also affect the value of the Group&#8217;s vehicle inventory.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 428; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 23 - Financial instruments (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Here below is a segmentation of
the balances that are shown in the financial statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of 31 December 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-linked NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Canadian dollar</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US dollar</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">European Euro</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pound sterling</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Polish zloty</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Total assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash&#160;and&#160;cash&#160;equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,480</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,552</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,552</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,552</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Long-term deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,809</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Overdraft</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Credit from banking corporations and financing institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(143,229</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(143,229</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Suppliers and service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,205</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,941</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,215</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,809</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,169</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,698</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,097</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,795</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Liabilities with respect to bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,447</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,447</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(200,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,941</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,312</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,809</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(224,648</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(157,850</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,936</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(17,264</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3,792</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(181,839</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 429; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: 010 --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 23 - Financial instruments (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-linked<br/>
    NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Canadian<br/>
    dollar</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US dollar</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">European<br/>
    Euro</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pound<br/>
    sterling</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Polish <br/>
    zloty</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Total assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">164</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,234</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,819</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,806</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,629</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Long-term deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">535</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">535</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,941</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,217</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Credit from banking corporations and financing institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(145,067</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(145,067</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Suppliers and service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,079</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,253</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(526</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(293</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,118</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,457</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,455</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,912</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Liabilities with respect to bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(206,712</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,253</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,981</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,967</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(293</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(241,206</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(184,771</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(15,717</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(10,953</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3,054</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(213,989</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 430; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 23 - Financial instruments (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table here below reasonably demonstrates
the sensitivity test to a possible change to the various exchange rates when all other variables are unchanged. The impact on the Company&#8217;s
pre-tax profit is due to the changes in the fair value of financial assets and liabilities, including foreign currency derivatives. The
Company&#8217;s exposure to foreign currency risk, based on nominal values, is as follows: (in thousands of ILS)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of 31 December 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Decrease</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Profit (loss)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Profit (loss)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="text-decoration:underline">Change in the exchange rate of:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Canadian dollar by 5%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(147</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(147</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">147</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">147</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">US Dollar by 5%</td><td>&#160;</td>
    <td style="text-align: center">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(554</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(554</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Euro by 5%</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Polish zloty by 5%</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(109</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Pound sterling by 5%</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86</td><td style="text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Decrease</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Profit (loss)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Profit (loss)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="text-decoration:underline">Change in the exchange rate of:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Canadian dollar by 5%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(812</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(812</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">812</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">812</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">US Dollar by 5%</td><td>&#160;</td>
    <td style="text-align: center">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(523</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(523</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">523</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Euro by 5%</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(549</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(549</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Polish zloty by 5%</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(515</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(515</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Pound sterling by 5%</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79</td><td style="text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in">(1)</td><td>The sensitivity mainly stems from supplier balances that are
                                            denominated a foreign currency.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">The sensitivity
                                            mainly stems from accounts payable balances that are denominated in a foreign currency.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in">(3)</td><td>The sensitivity mainly stems from receivable balances that are
                                            denominated in a foreign currency.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31pt; text-indent: -30.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Here below is data regarding the significant exchange rates:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year that ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">on December 31st</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Spot rate at the <br/> time of the
    report</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Canadian dollar exchange rate</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">5.20</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">5.95</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">2.739</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">2.596</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">US dollar exchange rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11.62</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.519</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Euro exchange rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.012</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Polish Zloty exchange rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12.39</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.913</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.799</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Pound Sterling exchange rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8.29</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.81</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.620</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.237</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 431; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 201pt">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 209pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 23 - Financial instruments (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify"><span style="text-decoration:underline">Credit risk</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Credit risk is the risk that the counter
party will not meet its obligations as a customer or its obligations that arise from a financial instrument, which will result in a loss
for the Group. The Group&#8217;s incomes derive mainly from customers in Israel. In addition, the Group regularly monitors customer debts
and the terms of the credit it grants, and the financial statements include allocations for doubtful debts that adequately reflect, in
the opinion of the Company&#8217;s management, the inherent loss in debts that their collection is in doubt. The Group is exposed to
credit risk because of its operational activity (mainly because of customer balances) and its financial activity, including loans that
the Group has provided, transactions in a foreign currency and other financial instruments.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Here below is information regarding
the maximum exposure to credit risks (book value):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">on December 31st</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,552</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,234</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,552</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,819</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable and debit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,629</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141,430</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141,392</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,169</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,118</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable and credit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,795</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,912</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term loans and debts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,807</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,675</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Liabilities with respect to bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,447</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(181,839</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(213,989</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify"><span style="text-decoration:underline">Liquidity risk</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Company&#8217;s goal regarding
the liquidity risk is to maintain the extent of cash balances and other liquid assets in a way that will allow for the preservation of
a level of liquidity, which is sufficient for meeting all of its financial obligations - both under regular conditions and in extreme
scenarios, and without the occurrence of unwanted losses.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The table below shows the repayment
dates of the Group&#8217;s financial liabilities according to the contractual terms in uncapitalized amounts (including interest payments):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: bottom"><td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Book<br/>
    value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Projected<br/>
    cash <br/>
    flow</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">First<br/>
    year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Second <br/>
    year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Third to<br/>
    fifth year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="text-decoration:underline">December 31, 2023</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">Suppliers and service providers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts payable and credit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Credit and loans from banking and
    other corporations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">199,707</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">204,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">165,908</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,872</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,360</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">239,671</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">244,104</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">205,872</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,872</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">21,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 432; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 201pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 209pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 23 - Financial instruments (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: bottom"><td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Book<br/>
    value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Projected<br/>
    cash flow</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">First <br/>
    year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Second <br/>
    year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Third to<br/>
    fifth year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="text-decoration:underline">December 31, 2022</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">Suppliers and service providers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30,118</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30,118</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27,975</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,143</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts payable and credit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Credit and loans from banking and
    other corporations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">192,174</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">192,945</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">236,938</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">237,709</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">192,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,380</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">31,397</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify"><span style="text-decoration:underline">Interest rate risk</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The Group is exposed to a risk due
to changes in the market interest rate that arises from loans, which carry a variable interest. Loans that carry fixed interest rates
expose the Group to an interest rate risk because of a fair value. The Company only accepts credit limits and prime-linked loans.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="text-decoration:underline">Interest rate sensitivity analysis</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The sensitivity analysis is determined
based on the exposure to interest rates of derivative and non-derivative financial instruments during the period of the report. The sensitivity
analysis regarding liabilities that carry a variable interest was prepared under the assumption that the sum of the liabilities at the
end of the period of the report remained the same throughout the entire year of the report.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">A 1% change in the interest rates
at the end of the period of the report would increase (decrease) the capital and the profit and loss in the amounts shown below (after
taxes). This analysis was done under the assumption that the other variables, and especially the foreign exchange rates, remained constant.
The analysis regarding 2022 is done according to the same basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Effect of a 1% change<br/>
    in the interest rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">on December 31st</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,990</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,911</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 24 - Income Tax</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Tax rates applicable to the Group</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The applicable corporate tax rate
in Israel for 2022 &#8211; 2023 is 23%.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">An assembly of people is liable for
tax on real capital gain at the corporate tax rate, which is applicable in the year of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 433; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 24 - Income Tax (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Income tax assessments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">The companies within
the Group have not yet been assessed by the Income Tax Authorities from the day they were incorporated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Carried forward losses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The companies of the Group have business
losses for tax purposes, which are carried forward to the following years, and as of December 31, 2023, these losses amount to approx.
7.3 million ILS, and as of December 31, 2022 they amounted to&#8211; approx. 6.3 million ILS. As a result of these losses, deferred taxes
in the amounts of approx. 3 million ILS for 2023 and 3.3 million ILS for 2022 were acknowledged in the financial statements. The losses
of the subsidiary that is tax liable in New York, USA, are acknowledged from the date it was decided during 2020 to dissolve that subsidiary
as losses for tax purposes in Israel. Therefore, starting from the date of that aforesaid decision the Group acknowledged a tax asset
with respect to these losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">According to an agreed tax ruling
from December 10, 2020, which was given with respect to the merger transaction (hereinafter: the &#8220;<b>Ruling</b>&#8221;), every
kind of loss of the Company for tax purposes, including losses that would be decided as a result of any tax assessments prior to the
finalization of the merger, and including any losses incurred by the Company during or as a result of the dissolution of subsidiaries,
shall be deleted and would no longer be available in any way for a direct or indirect carrying forward and/or offset and/or deduction
and/or capitalization. In addition, according to the Ruling, the Company and/or a party close to it (as this term is defined in section
88 of the Ordinance) will not be left in any way with a balance of advance payments on the expense of its excess expenses, which can
be transferred and utilized in the following tax years, nor will the Company and/or the party close to it be left with any kind of credit
balance due to foreign taxes and/or with any kind of tax balance, which was deducted and not yet used and is associated to it, and which
can be transferred and credited and/or deducted in any way starting from the date of completion of the merger transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 434; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 24 - Income Tax (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Deferred taxes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Deferred taxes &#8211; composition and movements:</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Employee</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Carried</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">and</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intangible</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">forward</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">others&#8217;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">benefits</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">differences</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%">Balance as for January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">109</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,494</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,890</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,662</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Changes that were imputed to the income statement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,171</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(358</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Changes that were imputed to the
    comprehensive income statement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt">Balance as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">201</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,544</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Changes that were imputed to the income statement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(123</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,704</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(363</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Changes that were imputed to the
    comprehensive income statement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt">Balance as for December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">354</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,698</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">113</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">840</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,005</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 435; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 24 - Income Tax (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt"><b>Theoretical tax</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">on December 31st</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Thousands
    of NIS</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 74%; text-align: left">Profit (loss) before taxes on income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(17,017</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">671</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">The Company&#8217;s share in profits (losses) of companies
    that are handled according to the method of the balance sheet value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(577</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">585</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Profit (loss) when the Company&#8217;s share in the losses
    of companies that are handled according to the method of the balance sheet value is neutralized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,440</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,256</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Statutory tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax expenses (incomes) according
    to the statutory tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,781</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">289</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Increase (decrease) of income tax amounts
    due to:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-deductible expenses and exempted incomes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">213</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Temporary differences and losses for tax purposes in respect
    of which no deferred taxes were imputed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,027</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,136</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Carried forward losses that because of them deferred taxes
    were created for the first time</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Differences in the basis of the
    measurement and other differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">374</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Tax expenses
    (incomes) in the income statement</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right">358</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right">1,931</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><span style="text-decoration:underline">Note
25 &#8211; Incomes</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year that ended <br/>
    December 31st</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Incomes from selling new vehicles</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">346,922</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">434,786</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from selling used vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,094</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from accessories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,052</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Other Incomes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,685</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>418,932</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>453,617</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td>
    </tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 436; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 26 - Cost of sales</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 445.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year that ended<br/> December
    31st</td>
    <td colspan="4" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Inventory at the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">176,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">79,168</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">362,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">449,860</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchase commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,857</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vehicle transportation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,757</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortizations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,611</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fuel, spare parts, repairs and vehicle fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,084</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,345</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Salaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,112</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Miscellaneous</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Less the inventory at the end of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(183,647</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(176,863</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>381,089</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>392,918</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td>
    </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 27 - Sales and marketing expenses</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year that ended<br/> December
    31st</td>
    <td colspan="4" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Salaries of sales agents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">12,090</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">10,483</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advertisement and sale promotion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,184</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortizations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,563</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit cards commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Miscellaneous</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>27,194</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>27,612</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td>
    </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 28 - General and administrative expenses</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year that ended <br/>
    December 31st</td>
    <td colspan="4" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Salaries and salary related payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">3,979</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">4,483</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,518</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,375</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortizations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,009</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Miscellaneous</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,935</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,387</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Taxes and fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Consultation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,430</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Traveling abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,266</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Bad debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>16,965</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>16,849</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td>
    </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 437; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Note
                                            29 &#8211; Financing expenses, net</span></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year that ended<br/> December
    31st</td>
    <td colspan="4" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Financing expenses</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Interest for banking corporations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">11,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">4,347</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bond interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,483</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fees for banking corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,132</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest for commitment to lease &#160;agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">951</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Miscellaneous</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Miscellaneous</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,831</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,935</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="text-decoration:underline">Financing revenue</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,511</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes of Interest from related &#160;companies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes of interest from related &#160;companies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Incomes from deposit interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,703</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Net financing expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><b>(9,109</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 2.5pt; font-weight: bold"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><b>(5,232</b></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><b>)</b></td>
    </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 30 - Loss per share:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss
                                            per share:</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The basic loss per share is calculated
by dividing the loss that is attributed to the holders of the Company&#8217;s ordinary shares by the weighted average of the number of
issued ordinary shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year that ended<br/> on December
    31</td>
    <td colspan="4" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Loss that is attributed to the Company&#8217;s shareholders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(16,384</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(1,104</td><td style="width: 1%; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">The weighted average of the number of issued ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,377,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,785,204</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Basic loss per share (ILS)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.21</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.02</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    </tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The number of shares that was used
for calculating the loss per share in the periods that preceded the date of the reverse purchase, has been retroactively adjusted according
to the exchange rate that was decided in the merger agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Diluted loss per share</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The diluted loss per share is calculated
by adjusting the weighted average of the number of ordinary shares by including all potential ordinary shares with dilutive impacts.
The diluted loss per share as for the reported years is equal to the basic loss per share because the impact is anti-dilutive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 438; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 140pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 31 - Concentration of balances and transactions with related
parties</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>a.</b></td><td style="text-align: justify"><b>The
                                            composition:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">on December 31st</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 76%; text-align: left">Accounts receivable and debit balances</td><td style="padding-bottom: 2.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">433</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">161</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,144</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,806</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Commitment to controlling shareholders (the previous shareholders of Global AutoMax)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transactions with related and interested parties &#8211; general</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Some of the Company&#8217;s employees
and its service providers are parties who are related to the Company. Some of them might be parties who are related to the Company&#8217;s
shareholders, according to their identification on any date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s key people as
of December 31, 2023 are the Company&#8217;s CEO, Chief Business Officer, CFO, VP of Trade, Chief of Technology, the Company&#8217;s
Manager of Regulation and Chain of Branches, and the Manager of HQ and Business Development. There had been no personnel changes amongst
the Company&#8217;s managerial key people during the period of the report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 439; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 31 - Concentration of balances and transactions with related
parties (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Here below are the total expenses that were
paid or received by the Company to/from related parties during the period of the report:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><b>The nature of the</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thousands of NIS</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 53%; text-align: left">Company shareholders</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 20%; text-align: left">Management fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,200</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Granting options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,688</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Interest on loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Key people in the Company who are related
    parties:</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">VP of Trade</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Salary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">616</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,264</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Vice President of Technology, Standardization and the
    Manager of the Chain of Branches</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Salary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">615</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,264</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">VP of HQ and Business Development</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Salary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">616</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,264</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Payments to suppliers who are related
    parties:</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">872</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Automax Hasharon (a consolidated company
    that was included last year)</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Automax HaShefala (an included company)</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Automax Netanya (a consolidated company
    that was included last year)</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Dalhom Automax (an included company)</td><td>&#160;</td>
    <td style="text-align: left; vertical-align: top">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(678</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(192</td><td style="text-align: left">)</td>
    </tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 440; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Automax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Notes to the consolidated
financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(in thousands ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 209pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 31 - Concentration of balances and transactions with related
parties (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Owner&#8217;s loans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Prior to the completion of the merger
transaction, three stakeholders in the subsidiary provided in April 2019 loans to the Company in the total sum of 1.5 million ILS, which
carried an interest rate of 6% per annum, and their repayment date was December 31, 2019. During 2020, an amendment to the agreement
was signed with the above three stakeholders according to which the repayment dates of the loans were extended until December 31, 2020,
and also that from January 1, 2020 the loans will carry an interest rate of 9.5% per annum. On December 24, 2020, another amendment to
the agreement was signed according to which the repayment dates of the loans were extended until February 28, 2021. At the beginning
of 2021, the aforementioned loans were repaid in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Note 32 - Significant events after the Period of the Reports</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">On January 11,
                                            2024, Global AutoMax received from a banking corporation a state-guaranteed loan in the sum
                                            of 16 million NIS. The loan carries an annual interest of prime + 1.5%, and it is not linked
                                            to any linkage base. The loan was granted for a period of 60 months, and it will be repaid
                                            in 57 equal monthly payments of principal and interest, while the first 3 months of the loan
                                            will constitute a grace period in which the principal and loan will not be repaid. As is
                                            customary in state-guaranteed loans, Global AutoMax deposited at the banking corporation
                                            an interest-accruing deposit against the loan that its sum is 5% of the principal of the
                                            loan, and this deposit will be encumbered with a permanent lien in the first degree in favor
                                            of the banking corporation.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Following what
                                            was said in note 21.S above, on January 17, 2024, the Company received a bridging loan in
                                            the amount of 1.4 million dollars as an advance payment in the expected investment within
                                            the merger transaction with the Absorbing Company. The loan will be repaid at the earliest
                                            date out of the following:</td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">if the merger
                                            agreement is canceled (in case that is has been signed) in accordance with its terms - then
                                            within 3 months from the date of its cancellation; (b) on the date of completion of the merger
                                            agreement, by way of converting the loan and the interest that was accrued thereon into equity
                                            on the expense of the amount that the Absorbing Company will undertake to invest in the Company
                                            on the date the merger is completed (as of this date this sum is 4,250,000 US dollars); or
                                            (c) on July 15, 2024 (Hereinafter: &#8220;<b>The Repayment Date</b>&#8221;).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The loan carries an annual interest
of 7% (if the merger transaction will not be completed before the Repayment Date then 2% will be added to the annual interest), and it
is not linked to any linkage base. On the Repayment Date the loan (principal and interest) will be repaid in one payment (or it converted
into equity)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">3.B.</td><td style="text-align: justify">On February
                                            28, 2024, the Company paid the second payment of principal and interest for the bonds (series
                                            B) that its total sum was approximately 8 million NIS. After this payment, the Company repaid
                                            25% of the principal of the bonds (series B).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">Following the
                                            approval of the Company&#8217;s audit and balance committee and compensation committee and
                                            the Company&#8217;s board of directors, on March 24th 2024 the general assembly of the Company&#8217;s
                                            shareholders approved: (a) the extension of the service agreement between the Company and
                                            Haim Levy - Trade Inn Ltd., a company that is owned by Mr. Daniel Levy, regarding the provision
                                            of CEO services for an additional three-years; (b) the extension of the service agreement
                                            between the Company and A. Yinon (2015) Ltd., a company that is owned by Mr. Yinon Amit,
                                            regarding the provision of the services of a chief business manager for an additional three-years;
                                            (c) the extension of the indemnification and exemption letters to the officers and directors
                                            who are amongst the controlling shareholders, their relatives, or who are serving on behalf
                                            of the controlling shareholders, or which the controlling shareholders have a personal interest
                                            in their provision; (d) the Company&#8217;s updated compensation policy; and (e) the extension
                                            of a lease agreement with third parties regarding a lot that is used as a logistics warehouse
                                            in Jerusalem.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 441; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="fin_028.jpg" style="height: 139px; width: 310px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of Interim Consolidated</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Financial Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">June 30, 2024</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">(Unaudited)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 442; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->184<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">June 30, 2024</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Table of Contents</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 88%; text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 12%; text-align: center; direction: ltr; unicode-bidi: embed"><b>Page</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><a href="#k_007"><span style="font-size: 10pt">Auditor&#8217;s
    review report for shareholders</span></a></td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">F-186</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><a href="#k_001"><span style="font-size: 10pt">Summary of statements
    on the consolidated interim financial condition</span></a></td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">F-187 - F-188</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><a href="#k_002"><span style="font-size: 10pt">Summary of consolidated
    interim profit and loss reports</span></a></td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">F-189</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><a href="#k_003"><span style="font-size: 10pt">Summary of consolidated
    comprehensive interim profit reports</span></a></td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">F-190</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><a href="#k_004"><span style="font-size: 10pt">Summary of statements
    on the changes in consolidated interim equity</span></a></td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">F-191 - F-193</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><a href="#k_005"><span style="font-size: 10pt">Summary of consolidated
    interim statements of cash flow</span></a></td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">F-194 - F-196</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><a href="#k_006"><span style="font-size: 10pt">Notes for the consolidated
    interim financial statements</span></a></td>
    <td style="text-align: center; direction: ltr; unicode-bidi: embed">F-197 - F-216</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 443; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->185<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><div><a id="k_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>Auditor&#8217;s
review report for shareholders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 444; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->186<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><div><a id="k_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of statements on the consolidated
interim financial condition</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="text-decoration:underline">Current assets</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,411</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,590</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,552</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,256</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,552</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Receivables and debit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,291</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,801</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Receivable current taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,051</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,023</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vehicle inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,647</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Indemnity asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">254,496</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">233,221</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">249,575</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term deposits in banking corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,485</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed Assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,871</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment in companies handled according to the book value method</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,789</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,284</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,489</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,794</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial asset stated at fair value through profit and loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,005</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Long-term prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">191</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">61,624</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">57,786</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">55,741</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">316,120</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">291,007</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">305,316</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 445; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->187<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of statements on the consolidated
interim financial condition</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="text-decoration:underline">Current liabilities</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Short-term credit from banking corporations and financing bodies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">144,362</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">148,567</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">141,430</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current maturities of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,775</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Suppliers and service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,169</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and credit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,820</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liability for bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,849</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,849</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loan given as an advance on the merger transaction</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">231,764</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">202,814</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">216,043</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term credit from banking corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,213</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,807</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term redeemable checks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term liabilities with respect to lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,776</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,141</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,329</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loans from non-controlling shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">985</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Liability for bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,598</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment in companies handled according to the book value method</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Liabilities for employee benefits, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">709</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">49,069</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">56,393</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">53,859</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Total equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Total equity attributed to AutoMax shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share premium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,467</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,181</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,467</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,845</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital reserve funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(312</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(431</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(312</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,917</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Retained loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68,428</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,177</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68,636</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total equity attributable to AutoMax shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,562</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling rights</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,566</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(617</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,148</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">35,287</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31,800</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">35,414</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities and equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">316,120</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">291,007</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">305,316</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 25%; text-align: center; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">Date of approval<br/>
    Financial statements</span></td>
    <td style="width: 1%; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="width: 24%; text-align: center; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">Daniel Levy<br/>
    CEO</span></td>
    <td style="width: 1%; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="width: 24%; text-align: center; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">Amitay Weiss<br/>
    Chairman of the Board</span></td>
    <td style="width: 1%; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="width: 24%; text-align: center; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">Ya&#8217;ara Alfie<br/>
    CFO</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 446; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->188<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="k_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of consolidated interim profit and
loss reports</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended <br/>
    June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended <br/>
    June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended,<br/>
    December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">208,886</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">195,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">101,481</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98,655</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">418,932</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(175,946</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,524</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(381,089</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,843</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,169</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,105</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,765</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,763</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,194</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,939</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,180</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,823</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,935</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,965</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granting options to employees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(83</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(54</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,549</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,219</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(201</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(193</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,557</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operational profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,967</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,096</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,814</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,308</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,302</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,453</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,050</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,291</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,831</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financing incomes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,234</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,622</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,068</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(994</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,466</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(669</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,109</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">The Company&#8217;s share in profits (losses)
    of companies handled according to the balance sheet value method</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,061</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">297</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">424</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">355</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Profit (loss) before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,838</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,997</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(946</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,128</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,017</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">(Taxes on income) tax benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,048</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,387</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(462</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Profit (loss) for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,384</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,408</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,388</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,375</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allocation of profit (loss) for the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">To AutoMax shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,925</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,104</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,108</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,384</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">To non-controlling shareholders of AutoMax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(418</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(459</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(304</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(280</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(991</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(210</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(10,384</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,408</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3,388</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(17,375</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Profit (loss) per share attributable to AutoMax&#8217;s
    shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Profit (loss) per share in NIS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.15</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.011</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 447; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->189<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="k_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of consolidated comprehensive interim
profit reports</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months ended<br/> June 30,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Three months ended <br/>
    June 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended<br/>
    December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(210</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(10,384</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(1,408</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(3,388</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(17,375</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other comprehensive income (loss)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Items not reclassified to profit or loss:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Recalculation of net liabilities due to
    termination of employment relationship</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">118</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other comprehensive
    income (loss) for the period.</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">118</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss for the period.</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(210</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(10,384</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,408</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(3,388</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(17,257</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; text-indent: -9pt; padding-left: 9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Total income allocation (loss) for the period:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">For AutoMax shareholders</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">208</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(9,925</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,104</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,108</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(16,265</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">For non-controlling shareholders in AutoMax</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(418</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(459</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(304</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(280</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(992</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(210</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(10,384</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(1,408</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(3,388</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(17,257</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 448; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->190<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="k_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of statements on the changes in
consolidated interim equity</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital<br/> reserve<br/> funds</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share-<br/> based<br/> payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Retained<br/> loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total equity<br/> attributed to<br/>
    AutoMax<br/> shareholders</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minority<br/> rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23.5%; text-align: left; text-indent: -9pt; padding-left: 9pt">Balance as of January 1, 2024</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">5,184</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">78,467</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,845</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(312</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">20,014</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(68,636</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">36,562</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(1,148</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">35,414</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Profit (loss) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(418</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance as of June 30, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,184</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">78,467</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,845</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(312</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,097</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(68,428</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">36,853</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,566</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">35,287</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital<br/> reserve<br/> funds</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share-<br/> based<br/> payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Retained<br/> loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total equity<br/> attributed to<br/>
    AutoMax<br/> shareholders</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minority<br/> rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; width: 23.5%">Balance as of January 1, 2023</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,389</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">67,382</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,457</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(431</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">17,466</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(52,252</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">36,011</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(156</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">35,855</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares via private offer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,480</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,880</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares according to milestones</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,681</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,451</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,925</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,925</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(461</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,386</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance as of June 30, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,470</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">69,181</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,457</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(431</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,917</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(62,177</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">32,417</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(617</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">31,800</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 449; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->191<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of statements on the changes in
consolidated interim equity</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital<br/> reserve<br/> funds</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share-<br/> based<br/> payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Retained<br/> loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total equity<br/> attributed to<br/>
    AutoMax<br/> shareholders</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minority<br/> rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; width: 23.5%">Balance as for April 1, 2024</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">5,184</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">78,467</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,845</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(312</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">20,057</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(67,324</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">37,917</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(1,262</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">36,655</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,104</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,104</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(304</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,408</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance as of June 30, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,184</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">78,467</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,845</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(312</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,097</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(68,428</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">36,853</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,566</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">35,287</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital<br/> reserve<br/> funds</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share-<br/> based<br/> payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Retained<br/> loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total equity<br/> attributed to<br/>
    AutoMax<br/> shareholders</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minority<br/> rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; width: 23.5%">Balance as for April 1, 2023</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">4,070</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">65,701</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,457</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(431</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">19,862</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(59,069</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">31,590</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(335</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">31,255</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares via private offer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,480</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,880</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(282</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,390</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance as of June 30, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,470</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">69,181</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,457</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(431</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,917</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(62,177</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">32,417</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(617</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">31,800</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 450; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->192<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of statements on the changes in
consolidated interim equity</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares<br/> premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital<br/> reserve<br/> funds</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share-<br/> based<br/> payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Retained<br/> loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total equity<br/> attributed to<br/>
    AutoMax<br/> shareholders</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minority<br/> rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; width: 23.5%">Balance as of January 1, 2023</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,389</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">67,382</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,457</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(430</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">17,465</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(52,252</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">36,011</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(156</td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">35,855</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares and allocation of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares via private offer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,880</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares according to milestones</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,681</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,549</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other total income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,384</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,384</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,376</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance as of December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,184</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">78,467</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,845</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(312</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,014</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(68,636</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">36,562</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,148</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">35,414</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 451; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->193<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="k_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of consolidated interim cash flow
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="text-decoration:underline">Cash flow from current operations</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(210</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(10,384</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,408</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,388</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(17,375</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Adjustments required to present net cash
    flows from operating activities (Appendix A)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,940</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,460</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,516</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash generated by (used for) operating
    activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,150</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,852</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,052</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,604</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from
    investment activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Purchase of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(626</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,827</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(510</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,141</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,951</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Payment for credit balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,104</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(321</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Withdrawal (investment) in affiliated companies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(237</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Withdrawal (deposit) of a short-term deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(800</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Investment in intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,820</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(398</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,416</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Compensation for realization of fixed assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,703</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Acquisition of leased assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash generated by (used for) investment
    activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,917</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,628</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,069</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(353</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from
    financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Receiving a loan that was given as an advance on the merger transaction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,880</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Receipt (repayment) of short-term credit from banking corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,213</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,238</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,319</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(391</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Repayment of liabilities for lease agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,195</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,518</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,785</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,301</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,272</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Receipt (repayment) of long-term loans from banking corporations,
    net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,806</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,059</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,706</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(561</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,969</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Providing loans to related parties in subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(151</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">(Repayment) bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,567</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,567</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash generated by (used for) financing
    activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,926</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(977</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,650</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,470</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,356</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(994</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(682</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents at the beginning
    of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,552</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,234</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,943</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,234</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents at the end of
    the period</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,411</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,590</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,411</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,590</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,552</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 452; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->194<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of consolidated interim cash flow
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Adjustments required to present cash flows
from operating activities (Appendix A)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="text-decoration:underline">Incomes and expenses that do not involve cash flows</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation and amortizations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,481</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,840</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,877</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,586</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,392</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(154</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">293</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,549</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">The group&#8217;s share in the results of companies handled according
    to the book value method, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(309</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(425</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(367</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">599</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net financing expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(613</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,559</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,542</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,939</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,467</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,521</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,785</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,662</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,668</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in assets
    and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease in vehicles inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,347</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,843</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,302</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease (increase) in accounts receivable and debit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,616</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,352</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,806</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease (increase) in customers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,438</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,582</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,551</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,733</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in suppliers and service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,240</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,142</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,409</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,949</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in accounts payable and credit balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(187</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,686</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,743</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase in long-term prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(120</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(191</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease in employee benefits and employee related provisions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in current payable
    taxes to receive (to pay)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,383</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">513</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,395</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,355</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,407</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,989</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(325</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,330</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,848</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(7,940</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,532</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,460</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9,992</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,516</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 453; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->195<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Summary of consolidated interim cash flow
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Non-cash transactions (Appendix B)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Increase in right-of-use assets
    against lease liabilities</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,647</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">5,338</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,339</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,402</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">9,325</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Payment for credit balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,690</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 454; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->196<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="k_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Company description:</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">AutoMax Motors Ltd. (&#8220;AutoMax&#8221;
or the &#8220;Company&#8221;) was incorporated in 2006 and until December 2019, it offered and supplied, together with its subsidiaries,
a variety of proprietary programmatic data-driven platforms that focused on two main activities of domain monetization and mobile digital
advertising for advertisers, advertising agencies, application developers, and domain owners, mainly in the United States of America
(&#8220;U.S.&#8221;) and in European countries. Its shares were traded on the London Stock Exchange (&#8220;LSE&#8221;) and on the Tel
Aviv Stock Exchange Ltd. (&#8220;TASE&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On June 23, 2020, trading in the
Company&#8217;s shares was suspended on the LSE and on TASE. On November 25, 2020, trading resumed on TASE as part of the list for limited
trading (the retention list) and from January 12, 2021 onwards, the Company&#8217;s shares were again traded on the main list of TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On November 23, 2020, the Company&#8217;s
shares were delisted from trading on the LSE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">During the period between the middle
of 2017 and December 2019, the Company sold all of its activities in the field of digital advertising.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of the date of the completion
of the merger transaction with Global AutoMax (as detailed in Note 1(c) hereunder), the Company is engaged, through Global AutoMax Ltd.,
a fully controlled subsidiary, in the import to Israel and marketing of a variety of private and commercial vehicles models. In addition,
the Company is engaged in direct importing and marketing in Israel of buses manufactured by Temsa&#160;Skoda Sabanc&#305; Ula&#351;&#305;m
Ara&#231;lar&#305; A.&#350; (&#8220;Temsa&#8221;) (via Dalhom AutoMax (as defined below), as well as in the purchase and sale of
used vehicles (trade-in) (through AutoMax Trade-in (as defined below). Regarding the merger with Global AutoMax Ltd. see Note 1(c) hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On April 22, 2021, the Company changed
its name from Matomy Media Group Ltd. to AutoMax Motors Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The following are details of companies
held by the Company as of the reporting date:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Global
                                            AutoMax Ltd. (&#8220;Global AutoMax&#8221;) - holding 100% of the issued and paid-up capital,
                                            a private company incorporated and registered in Israel in 2014.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">AutoMax
                                            Trade In-Ltd. (&#8220;AutoMax Trade In&#8221;) - holding 80% of the issued and paid-up capital,
                                            a private company incorporated and registered in Israel in 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Dalhom
                                            AutoMax Ltd. (&#8220;Dalhom AutoMax&#8221;) - holding 50% of the issued and paid-up capital,
                                            a private company incorporated and registered in Israel in 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">AutoMax
                                            Leasing Ltd. - holding 100% of the issued and paid-up capital, a private company incorporated
                                            and registered in Israel in 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Description of Global AutoMax
    Ltd.:</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global AutoMax Ltd. was incorporated
in Israel in 2014 as a private company in accordance with the provisions of the Companies Law, 1999 (&#8220;the Companies Law&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The head office of Global AutoMax
is situated in Jerusalem. As of the day of its incorporation, Global AutoMax has been engaged in importing into Israel and marketing
a variety of private vehicle models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global AutoMax has an indirect importer
license, as defined in Paragraph 42 of the Services and Professions Licensing in the Automotive Industry Law, 5766-2016 (hereunder: &#8220;Automotive
Services Licensing Law&#8221;) for 29 different vehicles in a variety of models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 455; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->197<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">At the time of signing the financial
statements, Global AutoMax operates through eight car sale centers located in Jerusalem, Rishon Le-Zion, Afula, Haifa, Ra&#8217;anana,
Akko, Netanya, and Ashdod, and operates a storage system and a vehicle preparation system for sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">During the financial statements
period, Global AutoMax closed its branches in Ashkelon and Petah Tikva (which were closed since the current war between Israel and Gaza
started), in Beer Sheva (due to the end of an agreement with an authorized distributor who operated this branch), and also after the
financial statements period, the branch in Glilot, which served as a trade-in activity center and for the sale of new vehicles. It should
be clarified that starting from the closure of the branch in Glilot, the trade-in activity is not being carried out within the framework
of the existing branches of Global AutoMax. Global AutoMax assesses that the impact of closing these branches has no significant impact
on the Group (as defined in Note 1(g)).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Following are details of companies
held by Global AutoMax as of the reporting date:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">EDV
                                            Car Importers Ltd. - holding 100% of the issued and paid-up capital, a private company incorporated
                                            and registered in Israel in 2019. In August 2023, this company changed its name to AutoMax
                                            Fleets Ltd.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">AutoMax
                                            HaSharon Ltd. (&#8220;AutoMax HaSharon&#8221;) - holding of 67% of the issued and paid-up
                                            capital, a private company incorporated and registered in Israel in 2021.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">AutoMax
                                            Netanya Ltd. - holding 100% of the issued and paid-up capital, a private company registered
                                            and incorporated in Israel in 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">AutoMax
                                            HaShfela Ltd. - holding 50% of the issued and paid-up capital, a private company incorporated
                                            and registered in Israel in 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">AutoMax
                                            Leasing and Car Rental Ltd. - holding 100% of the issued and paid-up capital, a private company
                                            incorporated and registered in Israel in 2023.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Merger with Global AutoMax
    Ltd.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On March 24, 2021, a merger transaction
was completed in which the Company allocated shares to the controlling shareholders of the Company (former shareholders of Global AutoMax),
in exchange for the transfer to the Company of 100% of the share capital of Global AutoMax - ordinary shares which immediately after
their allocation constituted 52.53% of the Company&#8217;s issued and paid-up share capital, as well as rights to the allocation of additional
shares upon the fulfillment of milestones set in the merger agreement. On March 28, 2023, in light of the Company&#8217;s fulfilment
of the second and third milestones stipulated in the merger agreement, the Company allocated additional ordinary shares of the Company
to the controlling owners, which together constituted approximately 41% of the issued and paid-up capital of the Company after the allocation.
As of the date of signing the financial statements, the controlling shareholders of the Company collectively hold approximately 55.65%
of the issued and paid-up share capital of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">For more information about the merger
transaction with Global AutoMax, refer to Note 1C in the Company&#8217;s consolidated financial statements for December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Effect of changes in business
    environment on Group&#8217;s activities and business condition:</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company imports its inventory
of vehicles from various suppliers, from Europe and North America. Its revenues derive from the sale of vehicles in Israel, as denominated
in the New Israeli Shekel (&#8220;NIS&#8221;). Therefore, the Company is exposed to depreciation in the exchange rate of NIS against
foreign currencies, from which vehicles are imported. In light of the decline trend in the exchange rate of NIS against foreign currencies
that the Company has been exposed to since the beginning of 2023, the Company has modified the combination of vehicles it imports and
the purchase currencies (in accordance with the changes in the market). In addition, the Company implements a currency risk management
policy which is designed to reduce these exposures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 456; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->198<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In June 2024, the consumer price
index rose by 0.1%, according to forecasts, leading to an annual inflation rate (between June 2023 and June 2024) of 2.9%. In January
2024, the Bank of Israel decided to lower the annual interest rate by 0.25% to a level of 4.5%, which also applies at the time of the
statements&#8217; publication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The credit lines provided by banking
corporations to the companies within the Group (as defined in Note 1(g)) bear interest at the rate of the prime interest rate (which
is the Bank of Israel&#8217;s interest plus 1.5%. At the time of the publication of the financial statements, the prime interest rate
is 6%), plus a specific rate, as agreed during deliberations with the banking corporations upon actual takeout of the credit. This rate
is influenced, among other things, by the market interest rate, the credit volume, and the bank&#8217;s familiarity with the Company.
Therefore, the increase in the Israeli interest rate has led to a rise in the Group&#8217;s financing costs, which may affect the financial
results of the Group and its profitability. However, the Company does not expect that a higher interest rate environment will pose a
practical obstacle in obtaining credit from banks or other financing entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">However, the high interest rate
environment and the effects of the current multi-front war that Israel is involved in, especially if the war continues or expands, are
expected to slow down the growth rate of the market in general and the Company in particular, as well as cause a decline in private consumption.
In a forecast published in July 2024 by the Research Department of the Bank of Israel, the Israeli growth rate in 2024 is expected to
be 1.5% (a decrease of 0.5% compared to the forecast published in April), and the rate of growth in private consumption is expected to
increase from a negative rate of 0.7% in 2023, to 2% in 2024, and 5% in 2025 (a decrease of 2.5% and 0.5%, respectively, compared to
the forecast published in April). High inflation and interest rates may negatively affect the Company&#8217;s sales pace and consequently
its profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">During the first quarter of 2023,
the government began promoting a plan to make fundamental changes to the legal system in Israel, culminating in the Knesset&#8217;s approval
of the Fundamental Law: The Judiciary (Amendment No. 3) (reducing the grounds of reasonableness), without agreement with the opposition,
in a manner that provoked public criticism and widespread protests, and its annulment on January 1, 2024 by the Supreme Court. The proposed
changes aroused widespread controversies and criticisms, which may, according to various publications by international credit rating
companies (such as Moody&#8217;s), financial bodies, senior economists in the market, heads of academia and experts in the fields of
law, economics and society in Israel, influence the stability of the economy and the market in Israel. These changes, along with other
factors detailed below, have led to a downgrade of Israel&#8217;s credit rating by international rating agencies, as well as a downgrade
of rating forecasts by these agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of the date of the publication
of these financial statements, no further changes have yet been promoted in the judicial system in Israel, and it seems that in light
of the outbreak of the war that Israel is currently involved in, there is no prospect of further changes being promoted in the foreseeable
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 457; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->199<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Such changes may have a negative
impact on the economic environment in which the Company operates, on the cost of financing sources, on the credit rating of the Israeli
market, and more. However, since these are changes, most of which have not yet been enacted or entered into force, the extent of their
impact on the Israeli economy and the automotive industry in general and the Company in particular, are unknown and cannot be assessed
at this stage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of the second quarter of 2023,
the Company is working to reduce the cost of vehicle inventory per vehicle it owns by increasing the supply of vehicles of the intermediate
and lower category, that are marketed by the Company, with the aim of adjusting the Company&#8217;s vehicle inventory to the increased
demand for vehicles of the intermediate and lower category, as a result of the economic and financial situation in the State of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company is exploring the expansion
and diversification of the sources of supply of imported vehicles, including brands manufactured in China that have gained increased
demand in the Israeli car market. According to the Company&#8217;s assessment, the implementation of this move will have a positive impact
on its revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company bases its cash flows
for the upcoming periods on the consolidated cash flows, taking into account the individual cash flows of the companies it holds, in
order to prudently attend to all of the Company&#8217;s obligations towards bondholders (series B) and the held companies towards various
banking corporations and third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">To this end, the Group has taken
and continues to take the following steps:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Modifying
                                            the combination of imported and sold vehicles in the Company&#8217;s branches according to
                                            the current demand of its customers. The changes in the business environment as mentioned
                                            above, caused a demand for vehicles in the intermediate and small vehicle categories. During
                                            the reporting period, the Company mainly sold vehicles from the intermediate category, which
                                            corresponds with the Company&#8217;s plans to change its vehicle mix to vehicles in the intermediate
                                            and small category and contributed to an increase in sales compared to the same period last
                                            year.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -10.9pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Group is flexible regarding the financing of advances to suppliers and discount policies
                                            to customers according to the market situation, interest rates and exchange rates and the
                                            needs of the Company.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            financing that the Company provides to the companies within the Group is subject to the Company&#8217;s
                                            amortization schedule it has agreed to with the bondholders (series B).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Strengthening
                                            the Company&#8217;s equity capital through capital raising (including the merger transaction
                                            (insofar as it is completed) with SciSparc Ltd. (&#8220;SciSparc&#8221;), as detailed in
                                            Note 5(2) below).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">It should be clarified that the
Company&#8217;s assumption regarding the repayment of loans provided to held companies, which have been granted credit facilities by
banking corporations, is based on the fact that on the repayment date as mentioned, the held companies will comply with the financial
covenants and other terms that they have undertaken towards those banking corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 458; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->200<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company raised funds from the
public via bonds (series B), as detailed in Note 4 below. As part of the shelf prospectus and the deed of trust, the Company undertook
to comply with a number of financial covenants, detailed in note 3(c) hereunder. The Company&#8217;s policy and operations are aimed
at meeting the principal and interest payments to bondholders (series B) as well as the financial covenants at any point in time. The
Company has various tools for implementing this policy, as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Selecting
                                            the mix of imported vehicles, the import currencies, the amount of advances to suppliers
                                            and the selling prices in Israel, as detailed above.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Inventory
                                            management policy - the Group can increase or decrease the quantity of vehicles and inventory
                                            value according to its operational plans and seasonality in the automotive industry.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of the date of the publication
of this report, the Company is unable to assess the full future effects, to the extent that they may be, of all of the factors mentioned
above on the automotive industry in Israel in general and on the Company&#8217;s activities in particular. However, the Company estimates
that its financial stability, along with its financial sources and the actions detailed above, will enable it to continue and finance
its activities and meet its obligations in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Effects of Israel&#8217;s Multi-Front
    War:</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On October 7, 2023, Hamas launched
an attack on the State of Israel. Following the attack, the Israeli government declared war, named the Iron Swords war, and mobilized
approximately 300,000 reserve soldiers and launched an attack on the Gaza Strip (&#8220;the war&#8221;). Subsequent to this, the conflicts
between Hezbollah in Lebanon and Israel and Iran and Israel have intensified. The immediate impact of the outbreak of the war on Israel&#8217;s
economy is evident, and was reflected, inter alia, in the depreciation of the shekel against foreign currencies, declines in stock market
prices, the closing of many businesses due to the directives of the Home Front Command and the extensive mobilization of reserve soldiers,
a trend that was moderated in the first quarter of 2024, with the release of reserve forces, the appreciation of the shekel against foreign
currencies, increases in exchange rates and a return to a certain routine in the shadow of the war.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">However, as part of the macro-economic
forecast published by the Bank of Israel in July 2024, as detailed in the above explanation, the Bank of Israel has updated its forecast
regarding growth in output and private consumption, and it now expects that the direct economic impact of the conflict, on all fronts,
will continue until the beginning of 2025 and that against the backdrop of the ongoing conflict, the recovery of economic activity during
2025 is expected to be gradual. This assumption reflects a prolonged and intense waging of battles, compared to the assumption that was
at the basis of the previous forecast from April 2024. In addition, the forecast is characterized by a high level of uncertainty and
an increased likelihood of more severe security scenarios, such as further prolongation of the war and/or its intensification in various
arenas.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 459; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->201<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">With the outbreak of the war, the
Company worked to reduce its ongoing expenses, as much as possible under the circumstances, including reducing advertising and marketing
expenses, reducing other ongoing expenses, and reducing personnel expenses. In addition, the Company also worked to reduce its fixed
expenses, as much as possible under the circumstances, including partial or no payment of rent in some of its branches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">With the outbreak of the war, the
Houthis, an Islamic political and military organization in Yemen, declared war on Israel, and began to launch missiles at targets in
Israel as a supportive action for Hamas and Hezbollah, to launch drones at Israel, and to attack ships that they claim have a connection
to Israel. As a result of these attacks on ships, several shipping companies have announced the suspension of sailing through the Red
Sea. The situation developed into an international crisis that led to the formation of an international coalition to ensure freedom of
navigation and the declaration by the United States and its allies of the launch of Operation Prosperity Guardian against the Houthis
in order to stop attacks against vessels. In July 2024, following a missile attack in Tel Aviv, Israel retaliated against Yemen.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company imports its vehicle
inventory mainly from Europe and North America, and therefore it is not expected to be directly affected by the disruptions resulting
from the Houthi organization&#8217;s attacks on vessels in the Red Sea region which have caused changes in shipping routes. However,
the changes and disruptions in the shipping routes as mentioned above have caused significant delays in delivery dates and an increase
in logistics and transportation prices within Europe and from Europe to Israel. The delays in delivery dates and the increase in logistics
and transportation prices within Europe and from Europe to Israel have had a negative impact on the Company&#8217;s financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">It should be noted that with the
outbreak of the war and its continuation, a number of government decisions have been made that may have a positive impact on the Group&#8217;s
activities. This includes providing compensation for the decrease in transaction volumes of businesses, some of which are included in
the standards established for this matter (a request for compensation has been submitted), compensation for the full damage caused to
businesses in frontier settlements (which is relevant to the Company&#8217;s branches in Ashkelon, Ashdod, and Beer Sheva) (a request
for compensation has been submitted) and receiving a state-guaranteed loan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 460; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->202<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company regularly examines its
eligibility and works to receive the benefits in accordance with government decisions as stated. In addition, in January 2024, the Company
received a state-guaranteed loan from a banking corporation in the amount of NIS 16,000 (for additional details, see Note 32(1) in the
Company&#8217;s consolidated financial statements as of December 31, 2023). In addition, for the months of November and December 2023,
the Group companies are entitled to receive compensation from the state in the amount of approximately NIS 5,400 (as recognized in the
financial reports).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In light of the outbreak of the
war, the Company took action to raise capital by way of a private offering in the amount of NIS 10,000 which was completed on December
31, 2023 and strengthened the Company&#8217;s equity and liquidity. Furthermore, on April 10, 2024, the Company entered into a binding
merger agreement, or the &#8220;Merger Agreement&#8221;, with SciSparc, a company incorporated in Israel and whose securities are traded
on Nasdaq Capital Market. For further details, see Note 5(2) below. This transaction, as soon as it is completed, is expected to strengthen
the Company&#8217;s liquidity and equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On February 9, 2024, the international
rating agency Moody&#8217;s announced the downgrade of Israel&#8217;s credit rating to A2 (from a level of A1), and also lowered the
rating outlook from &#8220;stable&#8221; to &#8220;negative&#8221;. In the report, the rating agency estimated that the broad implications
of the war significantly increase the political risks in the State of Israel, weaken the legislative and executive authorities, and significantly
impact Israel&#8217;s budgetary stability in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In April 2024, S&amp;P Global Ratings
also announced the downgrade of Israel&#8217;s rating from AA- to A+, and maintained the rating outlook as &#8220;negative&#8221;, mainly
due to the escalation of tensions between Israel and Iran, as detailed below, and the geopolitical risks that Israel has been dealing
with since the outbreak of the war.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In April 2024, Iran directly attacked
Israel, launching hundreds of ballistic missiles, cruise missiles, and drones, an attack that was thwarted by air defense systems, in
cooperation with other countries, including the United States. The escalation with Iran, as also noted by the rating agency S&amp;P,
may have a significant impact on Israel, the Middle East, and other involved countries. Since the publication of the report, it is impossible
to dismiss the threat of escalation on the Iranian front and any other unforeseen developments in the war, especially escalation leading
to a full-scale war on the northern front, particularly in light of Iran&#8217;s threats and Hezbollah&#8217;s organization that they
will attack Israel in response to Israel&#8217;s alleged actions. As mentioned, escalation can have a significant impact on Israel as
well as on other involved countries in the Middle East region and globally, and may cause a substantial negative effect on the economic
situation in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 461; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->203<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">During the reporting period, Turkish
trade officials announced the suspension of trade between Turkey and Israel. Dalhom AutoMax imports and markets buses manufactured by
Temsa in Turkey in Israel. Furthermore, Global AutoMax imports and markets the vehicles it purchases in Turkey. The cessation of trade,
as mentioned, has a negative impact on the supply of vehicles and on the prices of logistics and transportation of vehicles to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company does not have the ability
to assess or estimate the duration of the period in which the trade suspension with Turkey will remain in effect, and therefore the impact
of the above on the long-term results of the Group&#8217;s operations. However, the Company does not expect a significant impact on the
Group&#8217;s business since it has (in Israel) a stock of Temsa buses and has worked to find ways of operation and alternatives for
the continued regular supply of Temsa vehicles and buses to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On May 20, 2024, the Prosecutor
of the International Criminal Court in The Hague announced his request filed with the Court to issue arrest warrants for war crimes and
crimes against humanity allegedly committed by Israeli Prime Minister Benjamin Netanyahu, Defense Minister Yoav Galant, and Hamas leaders.
Furthermore, on May 24, 2024, following South Africa&#8217;s appeal to the International Court of Justice (&#8220;ICJ&#8221;) in the
Hague, alleging that Israel is apparently violating its obligations under the resolution regarding the prevention and punishment of the
crime of genocide within the framework of the war, the court decided to issue orders for a ceasefire in Rafah and to submit a status
report within a month. On July 19, 2024, at the request of the United Nations, an advisory opinion was given by the ICJ, according to
which the ongoing occupation of Israel in the Palestinian territories (including the Gaza Strip and East Jerusalem), as well as the establishment
of settlements and exploitation of natural resources, apparently violate international law. As mentioned, these developments may undermine
Israel&#8217;s international standing and lead to the imposition of sanctions on Israel, which could have a negative impact on its economy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of the date of the publication
of these financial statements, in light of the war being a dynamic occurrence characterized by significant uncertainty, the Company is
unable to assess the full future effects, if any, of the war and/or the expansion of its scope on the automotive industry in Israel in
general and on the Company&#8217;s activities in particular. However, the Company estimates that its financial stability, along with
its financial sources and the actions detailed above (including those detailed in Note 1d of the Company&#8217;s consolidated financial
statements as of December 31, 2023), will enable it to continue financing its operations and meet its obligations in the foreseeable
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Separate financial information:</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company did not include separate
financial information in these financial statements due to the insignificance of the additional information. The Company fully owns Global
AutoMax, and as of the date of the report on the financial condition, most of the Group&#8217;s business activity is carried out through
Global AutoMax, which is fully reflected in the Group&#8217;s consolidated report. As of the date of the statement of financial position,
the Company has no business activity and therefore the publication of separate financial statements will not constitute additional material
information for the reasonable investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>G.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Definitions:</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 35%; padding-left: 9pt; text-align: left; direction: ltr; unicode-bidi: embed; text-indent: -9pt"><span style="font-size: 10pt">The
    Company</span></td>
    <td style="width: 3%; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">-</span></td>
    <td style="width: 62%; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">AutoMax Motors Ltd.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: left; direction: ltr; unicode-bidi: embed; text-indent: -9pt"><span style="font-size: 10pt">The
    Group</span></td>
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">The Company and its affiliates.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: left; direction: ltr; unicode-bidi: embed; text-indent: -9pt"><span style="font-size: 10pt">Consolidated
    companies/ subsidiary companies</span></td>
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">Companies over which the Company
    has control (as defined in IFRS 10), and whose reports are consolidated with the Company&#8217;s reports.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: left; direction: ltr; unicode-bidi: embed; text-indent: -9pt"><span style="font-size: 10pt">Related
    parties</span></td>
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">As defined in IAS 24.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: left; direction: ltr; unicode-bidi: embed; text-indent: -9pt"><span style="font-size: 10pt">Interested
    parties and controlling parties</span></td>
    <td style="text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">As defined in the Securities Regulations
    (Annual Financial Statements), 5771-2010.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 462; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->204<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Drafting format of consolidated
    financial statements</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The interim financial statements
are prepared in accordance with International Accounting Standard 34 - &#8220;Interim Financial Reporting&#8221;, as well as in accordance
with the disclosure requirements of Chapter D of the Securities Regulations (Periodic and Immediate Reports), 1970. The accounting policy
applied in the preparation of the consolidated interim financial statements, except as described below, is consistent with that applied
in the preparation of the consolidated annual financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Disclosure of new IFRS standards
    prior to their implementation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As part of the Company&#8217;s annual
financial reports for 2023, information was provided regarding new International Financial Reporting Standards (&#8220;IFRS&#8221;) and
amendments to the existing IFRS that are not yet mandatory and which the Company has not chosen to adopt early.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of the date of approval of these
financial reports, there are no new regulations or amendments to existing regulations that have not been included in the Company&#8217;s
annual financial reports for the year 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: left"><b><span style="text-decoration:underline">International Financial Reporting
Standard 18 &#8220;Revenue Recognition&#8221; (&#8220;IFRS 18&#8221;)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On April 9, 2024, IFRS 18 was published,
replacing International Accounting Standard (&#8220;IAS&#8221;) 1 &#8220;Presentation of Financial Statements&#8221;. The purpose of
the standard is to improve the manner of information presentation by entities to users in their financial reports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The standard focuses on the following
areas:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Profit
                                            or Loss Statement Structure - Presentation of defined interim summaries and categorization
                                            into profit or loss statement categories.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Requirements
                                            regarding the improvement of cooperation and the dissemination of information in financial
                                            reports and explanations.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Presentation
                                            of information regarding performance measures defined by management that are not based on
                                            Generally Accepted Accounting Principles (non-GAAP) in the explanations to the financial
                                            reports.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In addition, amendments to other
IFRS standards, including IAS 7 &#8220;Statement of Cash Flows,&#8221; will come into effect with the implementation of IFRS 18, aimed
at improving comparability between entities. The changes mainly include the use of a sub-summary of operating profit as a single starting
point in the implementation of the indirect method for reporting cash flows from current operations as well as the cancellation of the
alternatives for choosing an accounting policy regarding the presentation of interest and dividends. In light of this, except for certain
cases, interest and dividends received will be included within the framework of cash flows from investment activities, while interest
and dividends paid will be included within the framework of financing activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The standard will come into effect
for annual reporting periods beginning on January 1, 2027 or later. The standard is applied retroactively, with specific transition instructions.
Early adoption is possible. The Company is examining the impact of IFRS 18, including the impact of amendments to other IFRS standards
as a result of its application, on the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 463; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->205<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Implementation for the first
    time of new standards, amendments to standards, and interpretations.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: left"><b><span style="text-decoration:underline">Amendment to IAS 1, Presentation
of Financial Statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In January 2020, the IASB published
an amendment to IAS 1 regarding the requirements for the presentation of current or non-current liabilities (&#8220;the original amendment&#8221;).
In October 2022, the IASB published an amendment to the aforementioned amendment (&#8220;the follow-up amendment&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The amendment determined that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Only
                                            financial covenants that an entity must meet at the end of the reporting period or earlier,
                                            affect the classification of that obligation as current or non-current.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">For
                                            commitments that the compliance with financial covenants is tested within the following 12
                                            months from the reporting date, disclosure should be provided in a manner that allows users
                                            of the financial statements to assess the risks associated with that commitment. According
                                            to the follow-up amendment, disclosure should be made regarding the value in the books of
                                            the obligation, information on financial covenant units, as well as facts and circumstances
                                            at the end of the reporting period that may lead to the conclusion that the entity has difficulty
                                            in complying with the financial covenant units.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The original amendment determined
that the right of conversion of an obligation will affect the classification of the entire obligation as either a current or non-current
obligation, except in cases where the conversion component is monetary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The original amendment and the amendment
will be applied for settlement starting from annual periods beginning on January 1, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The above amendment did not have
a material impact on the Company&#8217;s interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 464; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->206<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 3 - Contingent liabilities and financial
covenants</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -21.3pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Significant claims and legal
    decisions in the field</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">From time to time, the Group may
be exposed to legal proceedings and claims as part of its regular business activity. Regardless of the outcome of these proceedings,
legal disputes may have a negative impact on the Company due to the costs involved in defense and settlements, diversion of management
resources, and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">For details regarding the indictment
filed against Global AutoMax, Haim Levy Trade In Ltd., and against the officers of the Company, Mr. Daniel Levy, CEO, and the controlling
owners of the Company, Yanon Amit, Chief Business Officer, and Chaim Levy, Trade and Procurement VP and son of Daniel Levy, on the suspicion
of committing various offenses in connection with the activity of Global AutoMax and to see the position of the Company and of Global
AutoMax regarding the indictment, see Note 21a to the Company&#8217;s consolidated financial statements as of December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Contingent liability to former
    shareholders of a subsidiary and an indemnifying asset for it</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">For details regarding a contingent
liability in the amount of $2,971, for former shareholders of a subsidiary company and compensation assets in the amount of NIS 1,000,
see Note 16B to the Company&#8217;s consolidated financial statements for December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Liens and financial covenants</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Banking corporations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Global
                                            AutoMax Ltd.</span></b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global AutoMax has on-call credit
limits from four banking corporations, totaling NIS 135,000, of which a NIS 125,000 is utilized as of the reporting date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company guarantees Global AutoMax&#8217;s
obligations towards the banking corporations in connection with the credit limits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order to guarantee the full repayment
of the amounts that will be provided to Global AutoMax according to the credit limits from the banking corporations, Global AutoMax mortgaged
in favor of the banking corporations certain assets and rights that were agreed upon, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">A
                                            first degree floating lien on the entire plant, all the equipment, assets, funds, property
                                            and rights including the proceeds of Global AutoMax,</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">A
                                            first-degree fixed lien and pledge on the share capital of Global AutoMax that has not yet
                                            been allocated and its goodwill.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 465; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->207<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 3 - Contingent liabilities and financial
covenants (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Fixed
                                            lien and pledge over bills of lading, ownership certificates for goods, documentary letters
                                            of credit, or other documents attesting ownership of goods or assets that will be delivered
                                            from time to time to the banking corporation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Permanent
                                            lien and pledge of all securities, documents, bills of others that AutoMax has delivered
                                            or will deliver from time to time to the banking corporation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Also, as part of Global AutoMax&#8217;s
obligations to the banking corporations, Global AutoMax must meet financial covenants. Below are specifications of the maximum and cumulative
financial covenants that Global AutoMax undertook towards the banking corporations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            tangible equity in the Company&#8217;s financial statements shall be no less than NIS 35,000.
                                            This standard will be examined according to Global AutoMax&#8217;s consolidated financial
                                            statements for June 30 and December 31 of every year.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            tangible equity will constitute no less than 25% of Global AutoMax&#8217;s tangible balance
                                            sheet. This standard will be examined according to Global AutoMax&#8217;s consolidated financial
                                            statements for June 30 and December 31 of every year.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The inventory to credit ratio
(&#8220;LTC&#8221;) will not be less than 115% at any given time. This standard shall be examined once a month.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The aforementioned financial covenants
will be examined in relation to the consolidated financial statements of Global AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In the letters of commitments that
Global AutoMax gave the banking corporations, Global AutoMax undertook, amongst other things, that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">No
                                            dividend will be distributed if the equity in the financial statements of Global AutoMax
                                            was less than NIS 35,000 and its ratio in relation to the total balance sheet is not less
                                            than 25%.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Loans
                                            and securities issued for Global AutoMax shareholders will be subordinate to the credit of
                                            Global AutoMax received from the banks.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Here below are the results of financial
stipulations as of June 30, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">The ratio</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bank A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bank B</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bank C</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bank D</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Tangible equity</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">66,899</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">68,643</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">68,643</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">68,643</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tangible Equity compared to tangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.55</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.04</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.04</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LTC ratio to net credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128.29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128.29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128.29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128.29</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of June 30, 2024 and December
31, 2023, Global AutoMax met all the financial stipulations specified above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 466; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->208<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 3 - Contingent liabilities and financial
covenants (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b><span style="text-decoration:underline">AutoMax Trade In</span></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -28.4pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">AutoMax Trade In Ltd. has a credit
limit of NIS 15,000 from a banking corporation, of which NIS 14,200 has been utilized as of the reporting date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company guarantees AutoMax Trade
In&#8217;s obligations towards the banking corporation in connection with the credit limit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The credit limit includes AutoMax
Trade In&#8217;s obligations to meet financial covenants in accordance with the letter of commitment signed between AutoMax Trade In
and the banking corporation, as detailed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            amount of AutoMax Trade In&#8217;s tangible equity shall be no less than 25% of AutoMax Trade
                                            In&#8217;s tangible balance sheet (hereinafter referred to as &#8220;equity-to-assets ratio&#8221;).
                                            As of June 30, 2024, the ratio of this standard was 19.19%.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: left">Compliance with this standard will be assessed
based on semi-annual and annual reports from AutoMax Trade In.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            ratio between (a) the value of AutoMax Trade-in&#8217;s vehicles, and (b) the net financial
                                            debt, will not be less than 130% (&#8220;the LTV Ratio&#8221;). The value of the vehicles
                                            will be calculated according to the second hand price list or another price list to be approved
                                            by the banking corporation as was known at the time of the relevant calculation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.8pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Compliance with this standard will be
examined on a monthly basis and also at the request of the banking corporation. As of the date of the financial statements, the LTV Ratio
was 134.91%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In addition, the letter of commitment
includes a provision of a cross-commitment regarding the credit that was provided by the banking corporation to Global AutoMax, as well
as subordination and discounting of the owner&#8217;s loans that were given to AutoMax Trade In.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As detailed above, as of June 30,
2024, AutoMax Trade does not meet the financial covenant of the LTV Ratio, and does not meet the financial covenant of the equity to
assets ratio. However, AutoMax Trade-In Ltd. received a waiver letter from the aforementioned banking corporation, according to which
it will not act according to the rights granted to it according to the financing agreement in connection with the failure to comply with
the aforementioned measure as of June 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 467; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->209<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 3 - Contingent liabilities and financial
covenants (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Dalhom AutoMax</span></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify; text-indent: 0.1pt">Dalhom AutoMax has
credit limits from two banking corporations in the amount of NIS 7.5 million each, of which a total of NIS 15,000 has been utilized as
of the reporting date. The Company guarantees the undertakings of Dalhom AutoMax towards each of the banking corporations in connection
with the credit limits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The credit limit includes Dalhom
AutoMax&#8217;s undertakings to meet a financial covenant in accordance with the letters of commitment that were signed between Dalhom
AutoMax and the banking corporations, as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            ratio between (a) the value of the inventory of vehicles of Dalhom AutoMax together with
                                            the remainder of the advance payment to the supplier, and (b) the net financial debt, shall
                                            be no less than 1.2.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.2pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Compliance with this standard will be
examined on a monthly basis and also at the request of the banking corporation. As of the date of the financial statements, the actual
ratio stood at 1.24.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In the letters of commitment that
Dalhom AutoMax gave the banking corporations, Dalhom AutoMax undertook, amongst other things, that its tangible equity will increase
every year at a rate that will be no less than 50% of the annual net profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In addition, the letters of commitment
include a cross-default provision regarding the credit that is provided by the banking corporations to Global AutoMax, a prohibition
on directly changing the control at Dalhom AutoMax and other acceptable instructions, including a subjection and subordination of the
owner&#8217;s loans that were given to Dalhom AutoMax, the provision of statements and reports to the banking corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order to guarantee the full repayment
of the amounts that will be provided to Dalhom AutoMax according to the credit limits, Dalhom AutoMax mortgaged in favor of the banking
corporations all its assets, including the rights and proceeds that derive from the assets, in a floating lien (a general current lien).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Bonds</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On March 1, 2022, the Company issued
bonds to the public (series B) (see Note 4 below), within the framework of which the Company committed to meeting financial standards
(until the date of final and full repayment of the bonds (series B)) as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.9pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            ratio between the Company&#8217;s equity and its total balance sheet, according to the Company&#8217;s
                                            consolidated financial statements, will be no less than 11%. In order to calculate the equity
                                            ratio, the liabilities due to lease agreements and the current liabilities due to lease agreements
                                            will be neutralized from the total balance sheet. As of June 30, 2024, the ratio is 15.18%.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 468; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->210<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Note 3 - Contingent liabilities and financial
covenants (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#8220;Equity&#8221; means the equity
(including minority rights) that is presented in the Company&#8217;s consolidated financial statements, in accordance with the regulation
and accounting standardization, which exist at the time of the issuance, and without taking into account regulatory changes. In calculating
the equity, the Company&#8217;s liability to the former shareholders of Optimatic Media, Inc. will be taken into account as part of the
equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Regulatory changes mean changes in
the relevant legislation and/or accounting standardization, including changes in the direct or indirect tax regime, which apply to the
fleet of vehicles of the Company and of its subsidiaries and/or to their activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Company&#8217;s equity shall not be less than NIS 25,000 according to the Company&#8217;s
                                            consolidated financial statements (minimal equity). As of June 30, 2024, the equity as defined
                                            above was NIS 48,003.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            total assets of the Company, according to its consolidated financial statements, which are
                                            not encumbered with a specific lien, will not be less than the principal of the bonds that
                                            has not been repaid yet, together with the interest that has accrued thereon up to that date
                                            and has not yet been paid. As of June 30, 2024, the total assets of the Company (which is
                                            calculated as detailed below) is NIS 285,354 and the bond fund that has not yet been repaid
                                            as of that date, is NIS 34,918.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">According to the deed of trust for
the purpose of calculating the Company&#8217;s total assets, assets related to lease agreements, intangible assets, and deferred taxes
will be neutralized, as detailed in the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            quotient obtained from dividing (a) the value of vehicles owned by the Company by (b) net
                                            credit, shall be no less than 110% (&#8220;the minimum vehicle value&#8221;). As of June
                                            30, 2024, the ratio was 112%.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">If for two or more consecutive reporting
periods, the equity ratio (as defined above) is less than 11% and/or the minimum equity (as defined above) falls below NIS 20,000, and/or
the minimum amount of assets is less than the outstanding bond fund including the accrued interest up to that date and not yet paid,
and/or the minimum vehicle value is less than 110%, this will be grounds for immediate repayment of the bonds (series B). Except if by
the time of signing the financial statements for the second reporting period in a row, it will be revealed that the Company has not complied
with the obligations of the equity capital and/or the minimum equity capital, and/or the minimum amount of assets and/or the minimum
value of vehicles, the Company will notify in the said statements that it has corrected the violation after the date of the financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of the date of the financial
statements, the Company met all the financial conditions listed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 469; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->211<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Note 3 - Contingent liabilities and financial
covenants (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>d.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Guarantees</span></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The Company guarantees the obligations
of Global AutoMax, AutoMax Trade In, and Dalhom AutoMax with respect to loans they received from banking corporations, including state-guaranteed
loans, and also Global AutoMax&#8217;s obligations under the rental agreements for the Rishon Le-Zion and Netanya branches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The additional shareholder at Dalhom
AutoMax undertook to indemnify the Company due to the guarantee the latter gave with respect to Dalhom AutoMax undertakings to banking
corporations for the credit limits they submitted to it at a sum of half (50%) of the expenses the Company expended in connection with
the exercise of any of the guarantees by any of the banking corporations, and it also undertook to pay to the Company every month a sum
of NIS 25,000 plus VAT, as long as the shareholder is not a guarantor towards the banking corporations in accordance with their requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In addition, some of the Company&#8217;s
controlling shareholders guarantee, either directly or through companies controlled by them, the undertakings of the subsidiary according
to the rent agreement regarding the Global AutoMax branch in Jerusalem. For additional details, see Note 10D1 in the consolidated financial
statements of the Company for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 4 - Bonds</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">A.</span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt">Composition as for June 30, 2024
    (in NIS):</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital<br/> amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nominal<br/> interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Effective<br/> interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance&#160;with<br/> deduction of<br/>
    current<br/> maturities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Unlinked bonds (series A)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">45,660</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34,594</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,222</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -18pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-size: 10pt"><b>Additional information regarding
    bond issuance (series B)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On March 1, 2022, the Company issued
a total of NIS 45,660 face value bonds (series B) of the Company, worth NIS 1 each, in accordance with the shelf offer report published
by the Company on February 27, 2022, based on the Company&#8217;s shelf prospectus dated November 30, 2021 (&#8220;the Shelf Offer Report&#8221;).
The total gross consideration received by the Company for the bonds (series B) allocated according to the Shelf Offer Report, amounted
to a total of NIS 45,660. The Company incurred issuance costs of approximately NIS 1,034.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 470; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->212<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 4 - Bonds (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Terms of the bonds (series B)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The bonds (series B) bear a fixed,
non-linked annual interest rate of 5.9% and will be paid twice a year, on February 28 and August 31 of each of the years 2023 to 2025
(inclusive) and on February 28, 2026, all for the interest period that ended on the last day before the payment date (the &#8220;interest
period&#8221;). The interest rate that will be paid for a certain interest period (except for the first interest period, as detailed
below), will be calculated as the annual interest rate divided by two. The first interest payment date was on February 28, 2023 for the
period that began on the first trading day after the auction day according to the first Shelf Offer Report, and ended on February 27,
2023 (&#8220;the first interest period&#8221;), and the last payment will be made on February 28, 2026, together with the final repayment
of the bond fund and against handing over the bond certificates to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The bonds (series B) will be settled
for repayment of principal in 4 unequal annual payments, to be paid on February 28 of each of the years 2023 to 2026 (inclusive), in
such a way that the first payment (on February 28, 2023) will be 10% of the principal of the total face value of the bonds, the second
payment (on February 28, 2024) will be 15% of the total face value of the bonds, the third payment (on February 28, 2025) will be 30%
of the total face value of the bonds, and the fourth and final payment (on February 28, 2026) will constitute 45% of the total face value
of the bonds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Securing the bonds</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order to guarantee the full implementation
of all the Company&#8217;s obligations according to the terms of the bonds (series B) and to guarantee the full and accurate repayment
of all the principal and interest payments that the Company must pay to the holders of the bonds (series B), the Company undertook to
create and/or register for the benefit of the trustee the guarantees listed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">As
                                            a condition for providing owner&#8217;s loans to the controlled companies, the Company undertook
                                            to pledge, with a floating lien, the full rights of the Company by virtue of the owner&#8217;s
                                            loans that it will provide from time to time to the controlled companies, and this is to
                                            ensure the full and exact fulfillment of all the Company&#8217;s obligations according to
                                            the bonds (series B) and the deed of trust.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Company has committed that as long as the bonds (series B) have not been paid in full, in
                                            a definitive manner, the Company will not create general current liens on all of its assets
                                            and all of its rights, existing or future, for the benefit of any third party, to guarantee
                                            any debt or obligation, unless:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(A)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Prior
                                            approval will be obtained from the bond holders (series B), to create the lien in favor of
                                            a third party.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(B)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Company established - for the benefit of the holders of the bonds (series B) to secure the
                                            undisputed balance of debt towards the holders, at the same time as the creation of the ongoing
                                            lien in favor of the third party - an ongoing lien of the same level per NIS according to
                                            the ratio of the Company&#8217;s debts to the third party and to the holders of the bonds
                                            as will change from time to time, and this lien will be in effect as long as the bonds (series
                                            B) have not been fully paid or until the cancellation of the lien given in favor of the aforementioned
                                            third party, whichever comes first.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">In addition, the Company undertook that
as long as the bonds (series B) are not fully paid, it will not create or be obligated to establish, for the benefit of any person and/or
entity, any liens of any kind and type on the shares of Global AutoMax Ltd., which it owns.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Company undertakes that as long as the bonds (series B) are not fully repaid, it will not
                                            carry out a distribution (as defined in the Companies Law, and including that it will not
                                            declare, pay or distribute dividends (as defined in the Companies Law). Notwithstanding the
                                            above, subject to law, the Company will be entitled to make a distribution by way of a dividends
                                            in kind of shares that are held by it in the controlled companies and are listed for trading
                                            on the stock exchange, provided that the equity of the Company, after making the distribution,
                                            will not be less than NIS 60,000.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 471; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->213<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 5 - Significant events during the reporting
period</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt">On
                                            January 11, 2024, Global AutoMax received a state-guaranteed loan in the amount of NIS 16,000
                                            from a banking corporation. The loan carries an annual interest of prime + 1.5%, and it is
                                            not linked to any linkage base. The loan was granted for a period of 60 months, and it will
                                            be repaid in 57 equal monthly payments of principal and interest, while the first 3 months
                                            of the loan will constitute a grace period in which no payments of principal and interest
                                            will be made. Against the loan acceptance, and as customary in state-guaranteed loans, Global
                                            AutoMax deposited an interest-accruing deposit at the banking corporation, in the amount
                                            of 5% of the loan principal, which will be encumbered with a first-degree permanent lien
                                            in favor of the banking corporation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Following
                                            what was stated in note 21.S in the financial reports as of December 31, 2023, on January
                                            17, 2024, SciSparc provided the Company with a bridging loan in the amount of $1.4 million
                                            as an advance payment for the expected investment within the merger transaction, under the
                                            loan agreement signed between the parties (hereinafter referred to as &#8220;the loan&#8221;
                                            and &#8220;the loan agreement&#8221; respectively).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">The loan carries an annual interest
rate of 7% (if the merger transaction will not be completed, then 2% will be added to the annual interest), and it is not linked to any
linkage base.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">On June 10, 2024, an addendum was signed
between the Company and SciSparc to amend the loan agreement, as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">a.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            loan fund has been increased by an additional $1 million, so it has been allocated to the
                                            Company by SciSparc as a total loan fund of $2.4 million, which serves as an advance on the
                                            expected investment in the Company under the Merger Agreement (once completed).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            loan will be repaid at the earliest date out of the following: (a) if the Merger Agreement
                                            is canceled in accordance with its terms - then within 3 months from the date of its cancellation;
                                            (b) on the date of completion of the Merger Agreement, by way of converting the loan and
                                            the interest that was accrued thereon into equity at the expense of the amount that SciSparc
                                            undertook to invest in the Company on the date the merger is completed ($4,250,000).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Apart from what was detailed above,
there have been no changes to the loan agreement and both parties continue to be obligated to it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">As discussed in note 21.19 in the Company&#8217;s
consolidated financial reports for the year ended December 31, 2023, on April 10, 2024, after approval by the audit committee and board
of directors, the Company entered into a binding Merger Agreement with SciSparc and the transaction, or Transaction, carried out under
the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 472; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->214<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 5 - Significant events during the reporting
period (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In accordance with the Merger Agreement,
subject to the fulfillment of the conditions set forth therein, a reverse triangular merger will be carried out within the framework
of the Israeli Companies Law, 5759-1999 (the &#8220;Law&#8221;), in accordance with the provisions of sections 350 and 351 of the Law,
whereby a wholly-owned subsidiary of SciSparc (established in Israel for the purposes of the merger), or the Target Company, will merge
into and with the Company, so that the Company will become a wholly-owned subsidiary of SciSparc and the Target Company will cease to
exist.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Upon completion of the Transaction,
the current shareholders of the Company (excluding SciSparc) will hold, as a group, about 47.49% of the issued and paid-up capital of
SciSparc in full dilution at the time of completion of the merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">After the completion of the merger
(subject to the conditions set forth below), the Company will become a private company that is a bond company and its shares will be
delisted from trading on TASE, but its bonds (series B) will continue to be traded on TASE until their full repayment. All assets, rights,
business activities, authorities, licenses, obligations, and liabilities of the Company will continue to be transferred to it, and it
will continue to engage in the field of importing vehicles and marketing them in Israel (or in other areas as may be decided from time
to time). The Company will continue to hold its subsidiaries (including Global AutoMax Ltd.) and affiliated companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">After the merger is completed, all
business activities, assets, rights, authorities, licenses, obligations, and liabilities of SciSparc will continue to be operated by
it (including its existing activity in the pharmaceutical field), and its ordinary shares will continue to be traded on the Nasdaq Capital
Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Upon completion of the merger, SciSparc
will hold no less than $4,250,000 (minus sums that the Company owes to SciSparc in accordance with the loan agreements between the parties),
of net cash (this would be minus all obligations of SciSparc at the time of completion and minus all fees and payments in connection
with the Transaction as stipulated in the Merger Agreement). During the merger, SciSparc will invest a total of $4,250,000 in cash into
the Company (net of amounts owed by the Company to SciSparc under the loan agreements between the parties), which will be used by the
Company for its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The obligations of the parties to
complete the Transaction will be subject to the fulfillment or waiver in writing by the relevant party of the conditions detailed in
the agreement, which include, among others, the following main conditions: (a) obtaining court approval for the Transaction, including,
among others, an exemption from the requirement for SciSparc to publish a prospectus in Israel (a petition for a court order for the
convening of a meeting of shareholders of the Company to approve the Transaction, in accordance with the provisions of the Merger Agreement,
was submitted by the Company on May 30, 2024, and on August 8, 2024, a decision was issued by the court ordering the convening of a meeting
of shareholders for the purpose of approving the Transaction); (b) approval of the Transaction at the general meeting of the Company&#8217;s
shareholders, by a majority of at least 75% of the participants in the meeting (and if necessary, in accordance with the court&#8217;s
decision, at the meetings of creditors and bondholders (series B) of the Company, by the aforementioned majority); (c) approval of the
Transaction at the general meeting of the shareholders of SciSparc, by a simple majority, as well as approval of the appointment of the
candidates on behalf of the Company as directors of SciSparc; and (d) that the U.S. Securities and Exchange Commission will have declared
effective the registration statement on Form F-4 that SciSparc will have submitted for the purpose of registering for trading the shares
that will be allocated to AutoMax shareholders, so that no restriction will apply to their trading.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 473; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->215<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">For the purpose of the consolidated financial
statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of NIS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 5 - Significant events during the reporting
period (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-size: 10pt">On
                                            February 28, 2024, the Company made the second payment of principal and interest for the
                                            bonds (series B), in a total amount of approximately NIS 8,000. After giving effect to the
                                            mentioned payment, the Company has repaid 25% of the principal of the bonds (series B).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Following
                                            the approval by the Company&#8217;s audit and balance committee and compensation committee
                                            and the Company&#8217;s board of directors, on March 24, 2024 the general assembly of the
                                            Company&#8217;s shareholders approved: (a) the extension of the service agreement between
                                            the Company and Haim Levy - Trade In Ltd., a company that is owned by Mr. Daniel Levy, regarding
                                            the provision of CEO services for an additional three years; (b) the extension of the service
                                            agreement between the Company and A. Yinon (2015) Ltd., a company that is owned by Mr. Yinon
                                            Amit, regarding the provision of the services of a CFO for an additional three years; (c)
                                            the extension of the indemnification and exemption letters to the officers and directors
                                            who are amongst the controlling shareholders, their relatives, or those serving on behalf
                                            of the controlling shareholders, or which the controlling shareholders have a personal interest
                                            in their provision; (d) the Company&#8217;s updated compensation policy; and (e) the extension
                                            of a lease agreement with third parties regarding a lot that is used as a logistics warehouse
                                            in Jerusalem.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-size: 10pt">During
                                            the reporting period, the Company invested a total of approximately NIS 10,800 in obtaining
                                            licenses for the direct import of vehicles.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 6 - Significant events after the balance
sheet date</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">On August 14, 2024, the Company, SciSparc,
and the Target Company signed an amendment to the Merger Agreement, according to which the final date for completing the Transaction
was postponed from August 30, 2024, to November 30, 2024. Apart from as detailed above, there have been no changes to the provisions
of the Merger Agreement and they continue to bind the parties to the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 474; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->216<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="m_028"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ANNEX
A</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><p style="text-align: right"><i>Execution
                                            Copy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>AGREEMENT AND PLAN OF MERGER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">among</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt"><b>SCISPARC
LTD.</b>,</span><br/>
an Israeli limited company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt"><b>SCISPARC
MERGER SUB LTD.</b>,</span><br/>
an Israeli limited company; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt"><b>AUTOMAX
MOTORS LTD.</b>,</span><br/>
an Israeli limited company</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Dated as of April 10, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: 0in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 475 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 28.35pt">TABLE OF CONTENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>



</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>1.</td>
    <td colspan="2"><b>DESCRIPTION OF TRANSACTION</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0pt">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%">1.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; width: 80%"><b>The Merger</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 6%">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Effects of the Merger</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>1.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Closing; Effective Time</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Articles of Association; Directors and Officers</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>1.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Conversion of Shares</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Calculation of Parent Net Cash</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>1.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Closing of the Company&#8217;s Transfer Books</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Payment of Aggregate Merger Consideration</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>1.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Further Action</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Withholding; Tax Rulings</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>2.</td>
    <td colspan="2"><b>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Due Organization; Subsidiaries</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">11</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Organizational Documents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Authority; Binding Nature of Agreement</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Vote Required</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Non-Contravention; Consents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Capitalization</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">13</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>TASE Filings, Financial Statements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">15</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Absence of Changes</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Absence of Undisclosed Liabilities</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Title to Assets</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.11</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Real Property; Leasehold</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.12</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Intellectual Property</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.13</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Agreements, Contracts and Commitments</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.14</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Compliance; Permits</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.15</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Legal Proceedings; Orders</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.16</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Tax Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.17</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Employee and Labor Matters; Benefit Plan</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">24</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.18</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Environmental Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">27</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.19</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Insurance</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">28</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.20</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Financial Advisors</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">28</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.21</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Transactions with Affiliates</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">28</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.22</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Anti-Bribery</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.23</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Disclaimer of Other Representations or Warranties</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>3.</td>
    <td colspan="2"><b>REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Due Organization; Subsidiaries</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Organizational Documents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Authority; Binding Nature of Agreement</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Vote Required</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Non-Contravention; Consents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Capitalization</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>SEC Filings; Financial Statements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Absence of Changes</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Absence of Undisclosed Liabilities</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">36</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 476; Options: NewSection --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%">3.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; width: 80%"><b>Real Property; Leasehold</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 6%">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.11</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Intellectual Property</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.12</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Agreements, Contracts and Commitments</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.13</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Compliance; Permits</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.14</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Legal Proceedings; Orders</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">39</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.15</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Tax Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">39</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.16</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Transactions with Affiliates</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.17</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Insurance</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.18</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Financial Advisors</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.19</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Anti-Bribery</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.20</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Valid Issuance</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.21</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Opinion of Financial Advisor</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.22</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Disclaimer of Other Representations or Warranties</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>4.</td>
    <td colspan="2"><b>CERTAIN COVENANTS OF THE PARTIES</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>4.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Operation of Parent&#8217;s Business</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>4.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Operation of the Company&#8217;s Business</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">50</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>4.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Access and Investigation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>4.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Parent Non-Solicitation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>4.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Non-Solicitation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>4.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Notification of Certain Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>4.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Post-Closing Financing</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>5.</td>
    <td colspan="2"><b>ADDITIONAL AGREEMENTS OF THE PARTIES</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Court Approval, Registration Statement and Transaction Report</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Meetings</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Parent Shareholders&#8217; Meeting; Merger Sub Approval</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Regulatory Approvals</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Certificate of Merger</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Options</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Warrants</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>TASE De-Listing of Company Ordinary Shares</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Additional Agreements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Disclosure</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.11</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Listing</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.12</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Tax Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.13</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Directors and Officers</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.14</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Termination of Certain Agreements and Rights</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.15</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Cooperation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.16</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Allocation Certificates; Ownership Certificate</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.17</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Financial Statements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.18</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Shareholder Litigation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.19</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Certain Adjustments</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>6.</td>
    <td colspan="2"><b>CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>6.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Restraints</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>6.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Shareholder Approval</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>6.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Court Approval</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>6.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Tax Rulings</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>6.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Certificate of Merger</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>6.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Legal Prohibition</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>6.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Bonds Trustee</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">65</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 477 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>7.</td>
    <td colspan="2"><b>ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%">7.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; width: 80%"><b>Accuracy of Representations</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 6%">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>7.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Performance of Covenants</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>7.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Documents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>7.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Company Material Adverse Effect</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>7.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Termination of Investor Agreements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>8.</td>
    <td colspan="2"><b>ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>8.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Accuracy of Representations</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>8.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Performance of Covenants</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>8.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Documents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>8.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Parent Material Adverse Effect</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>8.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Parent Net Cash</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>8.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Listing</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>8.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Directors and Officers</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>9.</td>
    <td colspan="2"><b>TERMINATION</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2"/>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>9.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Termination</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>9.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Notice of Termination; Effect of Termination</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>9.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Expenses</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>10.</td>
    <td colspan="2"><b>MISCELLANEOUS PROVISIONS</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Non-Survival of Representations and Warranties</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Amendment</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Waiver</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Entire Agreement; Counterparts; Exchanges by Electronic Transmission</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Applicable Law; Jurisdiction</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Attorneys&#8217; Fee</b>.</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Assignability</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Notices</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Cooperation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Severability</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.11</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Other Remedies; Specific Performance</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.12</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Third Party Beneficiaries</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">75</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.13</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Construction</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">75</td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 478 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>Exhibits:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 10%; text-align: justify">Exhibit A</td>
    <td style="vertical-align: bottom; width: 90%; text-align: justify">Definitions</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">Exhibit B</td>
    <td style="vertical-align: bottom; text-align: justify">Company Shareholder Support Agreements</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">Exhibit C</td>
    <td style="vertical-align: bottom; text-align: justify">Form of Restated Company Articles</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">Exhibit D</td>
    <td style="vertical-align: bottom; text-align: justify">Form of Pre-Funded Warrant (to be agreed prior to the Closing)</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">Exhibit E</td>
    <td style="vertical-align: bottom; text-align: justify">Company Allocation Schedule (to be agreed prior to the Closing)</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">Exhibit F</td>
    <td style="vertical-align: bottom; text-align: justify">Form of Indemnification Agreement</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 479 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>AGREEMENT AND PLAN OF MERGER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THIS AGREEMENT AND PLAN
OF MERGER</b> (together with its exhibits and schedules, this &#8220;<b><i>Agreement</i></b>&#8221;) is made and entered into as of April
10, 2024, by and among SciSparc Ltd., an Israeli limited company (&#8220;<b><i>Parent</i></b>&#8221;), SciSparc Merger Sub Ltd., an Israeli
limited company and wholly-owned subsidiary of Parent (&#8220;<b><i>Merger Sub</i></b>&#8221;), and AutoMax Motors Ltd., an Israeli limited
company (the &#8220;<b><i>Company</i></b>&#8221;). Certain capitalized terms used in this Agreement are defined in <b><span style="text-decoration:underline">Exhibit A</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>RECITALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A. &#160;Parent and the Company
intend to effect a merger of Merger Sub with and into the Company (the &#8220;<b><i>Merger</i></b>&#8221;) in accordance with this Agreement
and by way of a court approved arrangement between the Company and its shareholders and, if applicable, its Bondholders and creditors,
in accordance with the provisions of Sections 350 and 351 of the Companies Law. Upon consummation of the Merger, Merger Sub will cease
to exist, and the Company will become a wholly-owned subsidiary of Parent, on the terms and subject to the conditions set forth in this
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B. &#160;The Parent Board
has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its shareholders,
(ii) approved and declared advisable this Agreement and the Contemplated Transactions, including the authorization and issuance of ordinary
shares, with no par value, of Parent (&#8220;<b><i>Parent Ordinary Shares</i></b>&#8221;), listed and traded on Nasdaq, to the shareholders
of the Company pursuant to the terms of this Agreement and (iii) determined to recommend, upon the terms and subject to the conditions
set forth in this Agreement, that the shareholders of Parent vote to approve the Parent Shareholder Matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C. &#160;The Merger Sub Board
has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Merger Sub and its sole shareholder,
(ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms
and subject to the conditions set forth in this Agreement, that the sole shareholder of Merger Sub votes to adopt this Agreement and
thereby approve the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D. &#160;The Company Board
has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its shareholders,
(ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms
and subject to the conditions set forth in this Agreement, that the shareholders and, if applicable, the creditors of the Company, vote
to approve the Company Approval Matters and if required, pursuant to the Companies Law or the Applicable Court, that the Bondholders
of the Company vote to approve the Company Approval Matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E. &#160;Concurrently with
the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement,
(a) the shareholders of the Company listed in Section A-1 of the Company Disclosure Schedule (the &#8220;<b><i>Company Signatories</i></b>&#8221;)
(solely in their capacity as shareholders of the Company) are executing support agreements in favor of Parent in substantially the form
attached hereto as <b><span style="text-decoration:underline">Exhibit B</span></b> pursuant to which such Company Signatories are agreeing to take specified actions in furtherance
of the Merger, including actions relating to the approval of the Merger and adoption of this Agreement by the Company&#8217;s shareholders
(the &#8220;<b><i>Company Shareholder Support Agreements</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 480; Options: NewSection --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>AGREEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties, intending to
be legally bound, agree as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">1.
<b><span style="text-decoration:underline">DESCRIPTION OF TRANSACTION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1 &#160;<b><span style="text-decoration:underline">The Merger</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the terms and subject
to the conditions set forth in this Agreement, at the Effective Time, Merger Sub shall be merged with and into the Company, and the separate
existence of Merger Sub shall cease. The Company will continue as the surviving company in the Merger (the &#8220;<b><i>Surviving Company</i></b>&#8221;)
and shall (a) become a private debenture company (<i>Chevrat Igrot Hov</i>) within the meaning of the Companies Law and a wholly-owned,
direct subsidiary of Parent, (b) continue to be governed by the Laws of the State of Israel, (c) maintain a registered office in the
State of Israel, and (d) succeed to and assume all of the rights, properties and obligation of Merger Sub in accordance with the Companies
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2 &#160;<b><span style="text-decoration:underline">Effects of
the Merger</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger shall have the
effects set forth in this Agreement. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time (as
defined below), by virtue of, and simultaneously with, the Merger and without any further action on the part of Parent, Merger Sub, the
Company or any Company Shareholder, (a) Merger Sub shall be merged with and into the Company, the separate corporate existence of Merger
Sub shall cease and the Company shall continue as the Surviving Company; (b) all the properties, rights, privileges, powers and franchises
of the Company and Merger Sub shall vest in the Surviving Company; (c) all debts, liabilities and duties of the Company and Merger Sub
shall become the debts, liabilities and duties of the Surviving Company; and (d) all the rights, privileges, immunities, powers and franchises
of the Company (as the Surviving Company) shall continue unaffected by the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3 &#160;<b><span style="text-decoration:underline">Closing;
Effective Time</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless this Agreement is
earlier terminated pursuant to the provisions of <span style="text-decoration:underline">Section &#8206;9.1&#8206;</span>, and subject to the satisfaction or, to the extent permitted
by Law, waiver by such party entitled to waive such condition of the conditions set forth in <span style="text-decoration:underline">Sections &#8206;6</span>&#8206;, <span style="text-decoration:underline">&#8206;7</span>
and <span style="text-decoration:underline">&#8206;&#8206;8</span>, the consummation of the Merger (the &#8220;<b><i>Closing</i></b>&#8221;) shall take place remotely as promptly
as practicable (but in no event later than the second Business Day following the satisfaction or waiver by such party entitled to waive
such condition of the last to be satisfied or waived of the conditions set forth in in <span style="text-decoration:underline">Sections &#8206;6&#8206;</span>,<span style="text-decoration:underline">&#8206;7</span> &#8206;and
<span style="text-decoration:underline">&#8206;&#8206;8</span>, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction
or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing.
The date on which the Closing actually takes place is referred to as the &#8220;<b><i>Closing Date</i></b>.&#8221; As soon as practicable
after the determination of the Closing Date in accordance with this <span style="text-decoration:underline">Section &#8206;&#8206;1.3</span>, each of the Company and Merger Sub
shall (and Parent shall cause Merger Sub to), in coordination with each other, deliver to the Registrar of Companies of the State of
Israel (the &#8220;<b><i>Companies Registrar</i></b>&#8221;), a notice of the proposed date of the Closing, in which notice the parties
shall request that the Companies Registrar issue a certificate evidencing the Merger (the &#8220;<b><i>Certificate of Merger</i></b>&#8221;)
on the date that the Parties shall provide further notice to the Companies Registrar that the Closing has occurred, and the Parties shall
deliver such further notice to the Companies Registrar on the Closing Date. The Merger shall become effective upon the issuance by the
Companies Registrar of the Certificate of Merger (the time at which the Merger becomes effective is referred to herein as the &#8220;<b><i>Effective
Time</i></b>&#8221;). For the avoidance of doubt, and notwithstanding any provision of this Agreement to the contrary, it is the intention
of the Parties that the Merger being declared effective and that the issuance by the Companies Registrar of the Certificate of Merger
shall both occur on the Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 481 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4 &#160;<b><span style="text-decoration:underline">Articles
of Association; Directors and Officers</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">At the Effective
Time:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;the articles of association
of the Surviving Company shall be amended and restated, as reflected in the form of amended and restated articles of association attached
hereto as <b><span style="text-decoration:underline">Exhibit C</span></b> (the &#8220;<b><i>Restated Company Articles</i></b>&#8221;), until thereafter amended as provided by
the Companies Law and such articles of association;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;unless otherwise
agreed upon by the Parent and the Company, the articles of association of Parent shall be amended in order to change the name of Parent
to such name as to be reasonably agreed upon by the Parties, and as may be approved by the Company and the Israeli Companies Registrar
(the &#8220;<b><i>Restated Parent Articles</i></b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;the directors and
officers of Parent, each to hold office in accordance with the amended and restated articles of association of Parent, shall be as designated
by the Parent and the Company prior to Closing after giving effect to the provisions of <span style="text-decoration:underline">Section <b>&#8206;</b>5.13</span>, or such other
persons as shall be mutually agreed upon by Parent and the Company, until the earlier of their resignation or removal or until their
respective successors are duly elected or appointed and qualified, as the case may be; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;the directors and
officers of the Surviving Company, each to hold office in accordance with the articles of association of the Surviving Company, shall
be the directors and officers of the Company as in office immediately prior to the Effective Time, until the earlier of their resignation
or removal or until their respective successors are duly elected or appointed and qualified, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5 &#160;<b><span style="text-decoration:underline">Conversion
of Shares</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) At the Effective Time,
by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any shareholder of the Company
or shareholder of Parent, the following shall occur:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 113.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 113.4pt">(i) &#160;any Company Ordinary
Shares held in the treasury of the Company or held or owned by the Company or Merger Sub immediately prior to the Effective Time shall
be canceled and retired without any conversion and shall cease to exist, and no consideration shall be delivered in exchange therefor;
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 113.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 113.4pt">(ii) &#160;subject to <span style="text-decoration:underline">Section
<b><i>&#8206;</i></b>1.5(d)</span> each Company Ordinary Share outstanding immediately prior to the Effective Time (excluding shares to be
canceled pursuant to <span style="text-decoration:underline">Section <b><i>&#8206;&#8206;</i></b>1.5(a)(i)</span> and excluding Company Ordinary Shares held by the Parent immediately
prior to the Effective Time) shall be automatically converted solely into the right to receive a number of validly issued, fully paid
and nonassessable Parent Ordinary Shares, equal to the Exchange Ratio, per each such Company Ordinary Share (the &#8220;<b><i>Merger
Consideration</i></b>&#8221;) in accordance with <span style="text-decoration:underline">Section <b><i>&#8206;&#8206;</i></b>1.8(a)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 482 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;Notwithstanding any
other provision of this Agreement, under no circumstances shall the Parent issue Parent Ordinary Shares to any Company Shareholder pursuant
to the terms of this Agreement, to the extent that after giving effect to such issuance, the Company Shareholder, together with any affiliate
thereof, would beneficially own (as determined in accordance with Section 13(d) of the Exchange Act and the rules promulgated thereunder)
in excess of 9.99% of the number of Parent Ordinary Shares outstanding immediately after giving effect to such issuance (the &#8220;<b><i>Ownership
Limitation</i></b>&#8221;). If the Parent cannot issue Parent Ordinary Shares due to be issued pursuant to this Agreement, the Parent
shall (i) issue all such Parent Ordinary Shares that may be issued without causing a Company Shareholder to exceed the Ownership Limitation,
and (ii) issue to the Company Shareholder, pre-funded warrants to purchase Parent Ordinary Shares, in substantially the form attached
hereto as <b><span style="text-decoration:underline">Exhibit D</span></b> (the &#8220;<b><i>Parent Pre-Funded Warrant</i></b>&#8221;), in lieu of Parent Ordinary Shares not
so provided to such holder. Each Parent Pre-Funded Warrant shall be exercised for $0.001 per each Parent Ordinary Share. The Pre-Funded
Warrants will be registered in the Parent&#8217;s books and will not be listed for trading on any stock exchange or trading market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;If any Company Ordinary
Shares outstanding immediately prior to the Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture
under any applicable restricted share purchase agreement or other similar agreement with the Company, then the Parent Ordinary Shares
issued in exchange for such Company Ordinary Shares will to the same extent be unvested and subject to the same repurchase option or
risk of forfeiture, and the certificates representing such Parent Ordinary Shares shall accordingly be marked with appropriate legends.
The Company shall take all actions that may be necessary to ensure that, from and after the Effective Time, Parent is entitled to exercise
any such repurchase option or other right set forth in any such restricted share purchase agreement or other agreement in accordance
with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;No fractional Parent
Ordinary Shares shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued.
Any holder of Company Ordinary Shares who would otherwise be entitled to receive a fraction of a Parent Ordinary Share shall not receive
such fraction, and shall instead receive such amount rounded to the nearest whole number of Parent Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;All Company Options
outstanding immediately prior to the Effective Time under the Company Share Plans shall be treated in accordance with <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.6(a)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) &#160;All Company Warrants
outstanding if any, immediately prior to the Effective Time shall be treated in accordance with <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.7(a)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) &#160;Each ordinary share,
with no par value, of Merger Sub issued and outstanding immediately prior to the Effective Time shall automatically and without further
action be converted into and exchanged for one validly issued, fully paid and nonassessable ordinary share, NIS 0.05 par value per share,
of the Surviving Company. Each share certificate of Merger Sub evidencing ownership of any such shares shall, as of the Effective Time,
evidence ownership of such ordinary shares of the Surviving Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 483 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) &#160;If, between the time
of calculating the Exchange Ratio and the Effective Time, the outstanding Company Ordinary Shares or Parent Ordinary Shares shall have
been changed into, or exchanged for, a different number of shares or a different class, by reason of any share dividend, subdivision,
reclassification, recapitalization, split, combination or exchange of shares or other like change, the Exchange Ratio shall be equitably
adjusted to reflect such change to the extent necessary to provide the holders of Company Ordinary Shares, Parent Ordinary Shares, Company
Options with the same economic effect as contemplated by this Agreement prior to such share dividend, subdivision, reclassification,
recapitalization, split, combination or exchange of shares or other like change; <i>provided, however</i>, that nothing herein will be
construed to permit the Company or Parent to take any action with respect to Company Ordinary Shares or Parent Ordinary Shares, respectively,
that is prohibited or not expressly permitted by the terms of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.6 &#160;<b><span style="text-decoration:underline">Calculation
of Parent Net Cash</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;For the purposes
of this Agreement, the &#8220;<b><i>Anticipated Closing Date</i></b>&#8221; shall be the date, as agreed upon by Parent and the Company,
to be the anticipated date for Closing. At least fifteen (15) calendar days prior to the Anticipated Closing Date, Parent shall deliver
to the Company a schedule (the &#8220;<b><i>Net Cash Schedule</i></b>&#8221;) setting forth, in reasonable detail, Parent&#8217;s good
faith, estimated calculation of the Parent Net Cash (the &#8220;<b><i>Net Cash Calculation</i></b>&#8221;) as of the Anticipated Closing
Date, prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer, the principal accounting
officer). <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(a)</span> of the Parent Disclosure Schedule is an illustrative Net Cash Schedule containing an
illustrative Net Cash Calculation. Parent shall make available the work papers and back-up materials used or useful in preparing the
Net Cash Schedule, as reasonably requested by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;Within five (5) calendar
days after delivery of the Net Cash Schedule (the &#8220;<b><i>Response Date</i></b>&#8221;), the Company will have the right to dispute
any part of the Net Cash Schedule by delivering a written notice to that effect to Parent (a &#8220;<b><i>Dispute Notice</i></b>&#8221;).
Any Dispute Notice shall identify in reasonable detail any information available and known to the Company at such time related to the
nature of any proposed revisions to the Net Cash Calculation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;If on or prior to
the Response Date, the Company: (i) notifies Parent in writing that it has no objections to the Net Cash Calculation or (ii) fails to
deliver a Dispute Notice as provided in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(b)</span>, then the Net Cash Calculation as set forth in the Net
Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent Parent Net Cash at the
Anticipated Closing Date for purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;If the Company delivers
a Dispute Notice on or prior to the Response Date, then Representatives of both Parties shall promptly meet and attempt in good faith
to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon Parent Net Cash amount
shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash, at the Anticipated
Closing Date for purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 484 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;(x) If Representatives
of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash at the Anticipated Closing Date pursuant
to <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(d)</span> within three (3) calendar days after delivery of the Dispute Notice (or such other period as
Parent and the Company may mutually agree upon), then the Chief Executive Officer of Parent and the Chief Executive Officer of the Company
shall promptly meet and agree on the amount of Parent Net Cash. (y) If the Chief Executive Officer of Parent and the Chief Executive
Officer of the Company are unable to negotiate an agreed-upon determination of Parent Net Cash at the Anticipated Closing Date within
three (3) calendar days after delivery of the Dispute Notice (or such other period as Parent and the Company may mutually agree upon),
then Parent and the Company shall jointly approach (or either party may approach) one of the &#8220;big four&#8221; accounting firms
(other than EY) (the &#8220;<b><i>Accounting Firm</i></b>&#8221;) to resolve any remaining disagreements as to the Net Cash Calculation
within seven (7) calendar days; <i>provided</i> that the Accounting Firm shall be authorized and empowered by the parties solely as a
neutral expert and not as an arbitrator to resolve accounting issues, and shall not be authorized to resolve any disputes related to
the interpretation of this Agreement or any other legal disputes between the parties. Parent shall promptly deliver to the Accounting
Firm the work papers and back-up materials used in preparing the Net Cash Schedule, and Parent and the Company shall use commercially
reasonable efforts to cause the Accounting Firm to make its determination within seven (7) calendar days of approaching the Accounting
Firm. The Company and Parent shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved
disputes and to discuss the issues with the Accounting Firm; <i>provided, however</i>, that no such presentation or discussion shall
occur without the presence of a Representative of each of the Company and Parent. The determination of the Accounting Firm shall be limited
to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash made by the Accounting Firm
shall be deemed to have been determined for purposes of this Agreement and to represent Parent Net Cash at the Anticipated Closing Date
for purposes of this Agreement, and the Parties shall delay the Closing until the resolution of the matters described in this <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>1.6(e). </span>The fees and expenses of the Accounting Firm shall be allocated between Parent and Company in the same proportion
that the disputed amount of Parent Net Cash that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm)
bears to the total disputed amount of Parent Net Cash (and, for the avoidance of doubt, the fees and expenses to be paid by Parent shall
reduce Parent Net Cash). If this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(e)</span> applies as to the determination of Parent Net Cash, at the Anticipated
Closing Date described in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(a)</span> upon resolution of the matter in accordance with this <span style="text-decoration:underline">Section <b>&#8206;</b>1.6(e)
</span>(the &#8220;<b><i>Resolution Number</i></b>&#8221;), the Parties shall not be required to determine Parent Net Cash again, even though
the Closing Date may occur later than the Anticipated Closing Date, except that either Party may request a re-determination of Parent
Net Cash if the Closing Date occurs later than (10) ten Business Days after the Anticipated Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.7 &#160;<b><span style="text-decoration:underline">Closing of
the Company&#8217;s Transfer Books</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Effective Time: (a)
all Company Ordinary Shares outstanding immediately prior to the Effective Time shall be treated in accordance with <span style="text-decoration:underline">Section &#8206;&#8206;1.5(a)</span>,
and all holders of Company Ordinary Shares that were outstanding immediately prior to the Effective Time shall cease to have any rights
as shareholders of the Company; and (b) the share transfer books of the Company shall be closed with respect to all Company Ordinary
Shares outstanding immediately prior to the Effective Time. No further transfer of any such Company Ordinary Shares shall be made on
such share transfer books after the Effective Time. If, after the Effective Time, a valid certificate previously representing any Company
Ordinary Shares outstanding immediately prior to the Effective Time (a &#8220;<b><i>Company Share Certificate</i></b>&#8221;) is presented
to the Parent, such Company Share Certificate shall be canceled and shall be exchanged as provided in&#160;<span style="text-decoration:underline">Sections&#160;&#8206; &#8206;1.5</span>&#160;and&#160;<span style="text-decoration:underline">&#8206;Section
&#8206;1.8(b)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 485 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.8 &#160;<b><span style="text-decoration:underline">Payment of
Aggregate Merger Consideration</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;<i>Payment Procedures
with Respect to Company Ordinary Shares.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Effective Time
(but in no event later than five (5) Business Days prior to the anticipated Effective Time), the Parent shall select a bank or trust
company in Israel that is a TASE member and reasonably acceptable to the Company, to act as the paying agent for the Merger (the &#8220;<b><i>Paying
Agent</i></b>&#8221;) and, in connection therewith, shall enter into an agreement with the Paying Agent in form reasonably satisfactory
to the Company and Parent (the &#8220;<b><i>Paying Agent Agreement</i></b>&#8221;). No later than the Effective Time, the Parent shall
deliver to the Transfer Agent an irrevocable letter instructions, instructing the Transfer Agent to deposit, via The Depository Trust
Company Deposit or Withdrawal at Custodian system (&#8220;<b><i>DWAC</i></b>&#8221;), with the account of the Paying Agent, in trust
for the benefit of the Persons who were holders of Company Ordinary Shares (excluding Company Certified Shares), that were converted
into the right to receive the Merger Consideration, such number of whole Parent Ordinary Shares and, if applicable, Parent Pre-Funded
Warrants, representing the Merger Consideration to which the holders thereof are entitled to receive pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(a)</span>.
Immediately following the execution of this Agreement and prior to the Effective Time, the Parties will jointly discuss with the TASE
all procedures relating to the transfer of the Company Ordinary Shares to the Parent as of the Effective Time and the delivery of the
relevant portion of the Merger Consideration to the holders of Company Ordinary Shares, including the delivery of any information required
by the Paying Agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;<i>Payment Procedures
with Respect to Company Certified Shares</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Effective Time, the
Company will deliver to Parent a true, complete and accurate listing of all record holders of Company Certified Shares at the Effective
Time, including the number and class of Company Certified Shares held by such record holder, and the number of Parent Ordinary Shares
such holder is entitled to receive pursuant to <span style="text-decoration:underline">Section &#8206;1.5</span>, in the form attached hereto as <b><span style="text-decoration:underline">Exhibit E</span></b> (the &#8220;<b><i>Company
Allocation Schedule</i></b>&#8221;). Promptly after Parent&#8217;s receipt of the Company Allocation Schedule (and in no event later
than five (5) Business Days after the date of such receipt), the Parties shall cause to be mailed to the record holders of Company Certified
Shares that were converted into the right to receive the Merger Consideration: (A) a letter of transmittal in such form as the Company
and Parent may reasonably agree (a &#8220;<b><i>Letter of Transmittal</i></b>&#8221;), which shall specify that delivery shall be effected,
and risk of loss and title to such Company Ordinary Shares shall pass, only upon delivery of the Company Share Certificates (or affidavits
of loss in lieu thereof as provided below) to the Parent; and (B) instructions for use in effecting the surrender of the Company Share
Certificates into the right to receive the Merger Consideration payable in respect thereof pursuant to the Company Allocation Schedule.
Upon, surrender of Company Share Certificates (or affidavit of loss in lieu thereof as provided below) for cancellation to the Parent,
the Parent shall deliver to the Transfer Agent an irrevocable letter instructions, instructing the Transfer Agent to deposit, via DWAC,
with the account of the record holders of Company Certified Shares, that were converted into the right to receive the Merger Consideration,
such number of whole Parent Ordinary Shares representing the Merger Consideration to which the holders thereof are entitled to receive
pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(a)</span>. Until surrendered as contemplated by this <span style="text-decoration:underline">Section&#8206;1.8(b)</span>&#8206;, each Company Share
Certificate shall be deemed, from and after the Effective Time, to represent only the right to receive book-entry Parent Ordinary Shares
representing the Merger Consideration. If any Company Share Certificate shall have been lost, stolen or destroyed, Parent may, in its
discretion and as a condition precedent to the delivery of any Parent Ordinary Shares, require the owner of such lost, stolen or destroyed
Company Share Certificate to provide an applicable affidavit with respect to such Company Share Certificate and post a bond (in reasonable
amount), as indemnity against any claim suffered by Parent with respect to such lost, stolen or destroyed Company Share Certificate as
Parent may reasonably request. In the event of a transfer of ownership of a Company Share Certificate that is not registered in the transfer
records of the Company, payment of the Merger Consideration may be made to a Person other than the Person in whose name such Company
Share Certificate so surrendered is registered if such Company Share Certificate shall be properly endorsed or otherwise be in proper
form for transfer and the Person requesting such payment shall pay any transfer or other Taxes required by reason of the transfer or
establish to the reasonable satisfaction of Parent that such Taxes have been paid or are not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 486 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;The Merger Consideration
and any dividends or other distributions shall be deemed to have been in full satisfaction of all rights pertaining to Company Ordinary
Shares. Notwithstanding the above, any Merger Consideration payable in respect of Company Ordinary Shares subject to the Withholding
Tax Ruling or the 104H Ruling shall be transferred by the Paying Agent on the Closing Date to the Withholding Agent or the 104H Trustee,
respectively, to the extent required by the Withholding Tax Ruling or the 104H Ruling for the benefit of the beneficial owners thereof,
and shall be held and released (or otherwise treated) by said trustee to the beneficial holders of such Company Ordinary Shares in accordance
with the requirements of the Withholding Tax Ruling, the 104H Ruling and the Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;No party to this
Agreement shall be liable to any holder of Company Ordinary Shares or to any other Person with respect to any Parent Ordinary Shares
(or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable
abandoned property Law, escheat Law or similar Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.9 &#160;<b><span style="text-decoration:underline">Further Action</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at any time after the
Effective Time, any further action is determined by the Surviving Company to be necessary or desirable to carry out the purposes of this
Agreement or to vest the Surviving Company with full right, title and possession of and to all rights and property of the Company, then
the officers and directors of the Surviving Company shall be fully authorized, and shall use their and its commercially reasonable efforts
(in the name of the Company, in the name of Merger Sub, in the name of the Surviving Company and otherwise) to take such action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.10 &#160;<b><span style="text-decoration:underline">Withholding;
Tax Rulings</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;Notwithstanding anything
to the contrary hereunder, Parent, the Surviving Company, the 102 Trustee, the Transfer Agent, the Withholding Agent, the 104H Trustee,
the Paying Agent, the Hevra Le&#8217;Rishumim, and the TASE members and any of their respective agents (each, a &#8220;<b><i>Payor</i></b>&#8221;)
shall be entitled to deduct and withhold from any payment or consideration made pursuant to this Agreement (including the Merger Consideration)
such amounts as may be required to be deducted and withheld with respect to the making of such payment under the Code, the Ordinance,
or under any provision of applicable U.S. federal, state, local, Israeli, or other Tax Law, including the Withholding Tax Ruling and
the 104H Ruling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;The parties herby
acknowledge that they and the Withholding Agent shall act in accordance with Income Tax Circular 19/2018 (Transaction for Sale of Rights
in a Corporation that includes consideration that will be transferred to the Seller at Future Dates) (the &#8220;<b><i>Circular</i></b>&#8221;)
and the Withholding Agent shall provide the Company, prior to the Closing Date, with an undertaking as required under Section 6.2.4.3(c)
of the Circular.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 487 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;Notwithstanding the
provisions of <span style="text-decoration:underline">Section<b>&#8206;</b>1.10(a)</span> above, with respect to withholding of Israeli Tax, subject to the provisions of the Withholding
Tax Ruling or the 104H Ruling, as applicable, no tax shall be deducted or withheld from any payment pursuant to this Agreement, except
as set forth in the Withholding Tax Ruling and the 104H Ruling, if obtained. The Merger Consideration payable or otherwise deliverable
hereunder to any holder of Company Ordinary Shares (each, a &#8220;<b><i>Payee</i></b>&#8221;) shall (notwithstanding <span style="text-decoration:underline">Section <b>&#8206;</b>1.10(a)
</span>above) be paid or delivered to, and retained by, the respective Payor for the benefit of such Payee until the earlier of: (x) (A)
with respect to a Payee which holds 5% or more of the Company share capital on the date which is ten (10) days prior to the Closing Date,
unless a different date for such calculations is specified by the ITA, in which case such date shall be as specified by the ITA (a &#8220;<b><i>5%
Payee</i></b>&#8221;), and the 104H Ruling has been obtained, the date on which the 104H Ruling has been obtained or (B) if such Payee
is a Less Than 5% Payee and the Withholding Tax Ruling has been obtained, the date on which the Withholding Tax Ruling has been obtained,
or (C) with respect to a Payee that is not included in the application for the Withholding Tax Ruling nor the 104H ruling, the date on
which such Payee delivers to the Withholding Agent a Valid Tax Certificate, and (y) the date that is 180 days following the Closing Date,
as may be further extended (with respect to all or some of the Payees) by mutual agreement of the Company, Parent and the Withholding
Agent (the &#8220;<b><i>Withholding Drop Date</i></b>&#8221;), during which time (unless a request is submitted by the Payee to Payor
to release its portion of the consideration prior to the Withholding Drop Date) no Payor shall withhold any Israeli Tax from such Merger
Consideration pursuant to this Agreement to such holder<b>&#8206;</b>, except as provided below, and if during which time such recipient
provides the Payor with a Valid Tax Certificate issued by the ITA regarding the withholding (or exemption from withholding) of Israeli
Tax from the consideration payable in respect thereof in accordance with this Agreement, or other treatment with respect to Israeli Tax,
at least three (3) Business Days prior to the Withholding Drop Date, then the deduction and withholding of any amounts under the Ordinance
or any other provision of Israeli Law or requirement, if any, from the Merger Consideration payable to such holder of record of Company
Ordinary Shares shall be made in accordance with the provisions of such Valid Tax Certificate, subject to any deduction and withholding
as may be required to be deducted and withheld under any applicable Law. If any holder of record of Company Ordinary Shares (A) does
not provide the Payor with a Valid Tax Certificate no later than three (3) Business Days prior to the Withholding Drop Date, or (B) submits
a written request to the Payor to release his or her portion of the Merger Consideration prior to the Withholding Drop Date and fails
to submit a Valid Tax Certificate at or before such time, then the amount to be withheld from the payment to such holder shall be calculated
based on the applicable withholding rate on the actual payment date in accordance with applicable Law as determined by the Parent or
its Israeli advisors at their reasonable discretion, and such amount will be calculated in NIS based on the USD-NIS exchange rate known
on the date the payment is actually made to such Payee and shall be delivered to the ITA by the Payor, and the Payor shall deliver to
such holder the balance of the portion of the Merger Consideration due to such holder that is not so withheld (if any).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;To the extent that
amounts are so withheld pursuant to this <span style="text-decoration:underline">Section <b>&#8206; &#8206;</b>1.10</span>, they shall be paid over to the appropriate Governmental
Body prior to the last day on which such payment is required to be paid to such Governmental Body, and such withheld amounts shall be
treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 488 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;For the avoidance
of doubt, to the extent that the Payor is obliged to withhold Israeli Taxes at the rate prescribed under the Ordinance and/or the Withholding
Tax Ruling and/or 104H Ruling (the &#8220;<b><i>Withheld Amounts</i></b>&#8221;), each Person in respect of which such withholding is
required to be made shall provide the Payor a cash payment equal to the Withheld Amounts within seven (7) Business Days from receipt
of a request from the Payor to make such payment, and in any event prior to the release of the Merger Consideration deliverable to such
Person. In the event that such Person fails to provide the Payor with the Withheld Amounts within such timeframe, the Payor will be authorized
to sell on the open market, subject to any lock-up or transfer restrictions applicable at such time to the consideration or a portion
thereof, any number of Parent Ordinary Shares required to cover any amount required to be deducted or withheld under this <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>1.10</span> and such amounts shall be treated for all purposes of this Agreement as having been delivered and paid to such
Payee. Notwithstanding anything else to the contrary in this Agreement, and unless instructed otherwise by the ITA in writing, for Israeli
withholding Tax purposes, the value of the consideration shall be determined based on the closing price of a Parent Ordinary Share on
the Closing Date. Any currency conversion commissions will be borne by the applicable payment recipient and deducted from payments to
be made to such payment recipient.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) &#160;Notwithstanding anything
to the contrary herein, any payments made to holders of any Company Options, if any, will be subject to deduction or withholding of Israeli
Tax under the Ordinance on the sixteenth (16<sup>th</sup>) day of the calendar month following the month during which the Closing Date
occurs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) &#160;Without derogating
from the foregoing, as soon as reasonably practicable, but in no event more than five (5) Business Days after the date hereof, the Company,
in full coordination with Parent and its Israeli counsel, will cause its Israeli counsel, advisors or accountants to prepare and file
with the ITA an application for a Withholding Tax Ruling and 104H Ruling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) &#160;Without limiting
the generality of this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.10</span>, each of the Company and Parent shall cause their respective Israeli counsel,
advisors and accountants to coordinate all material activities and to cooperate with each other with respect to the preparation and filing
of such applications for rulings and in the preparation of any written or oral submissions that may be necessary, proper or advisable
to obtain the Withholding Tax Ruling and 104H Ruling. In any event, the final text of the Withholding Tax Ruling and the 104H Ruling
shall be subject to the prior written confirmation of Parent, which consent shall not be unreasonably withheld, conditioned or delayed.
The Company shall keep Parent informed, on a prompt basis (and, in any event, within two Business Days) of its receipt of any notice
or information in connection with any of the above rulings or approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) &#160;Each party hereto
is relying solely on the advice of its own Tax advisors with respect to the Tax consequences of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">2.
<b><span style="text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>References in this Section
2 to the &#8220;Company&#8221; shall mean the Company and each of its Subsidiaries unless the nature of the context provides otherwise<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 489 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <span style="text-decoration:underline">Section &#8206;&#8206;10.13(h)</span>,
except: (i) as set forth in the disclosure schedule delivered by the Company to Parent (the &#8220;<b><i>Company Disclosure Schedule</i></b>&#8221;)
or (ii) as disclosed in the Company TASE Documents filed with the ISA or the TASE prior to the date hereof and publicly available (but:
(x) without giving effect to any amendment thereof filed with, or furnished to the ISA or the TASE on or after the date hereof and (y)
excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking
statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking
in nature), the Company represents and warrants to Parent and Merger Sub as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 &#160;<b><span style="text-decoration:underline">Due Organization;
Subsidiaries</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;The Company is a
public company, listed and traded on TASE, duly organized and validly existing under the Laws of the State of Israel, is not a &#8220;breaching
company&#8221; under the Companies Law, and has all necessary corporate power and authority: (i) to conduct its business in the manner
in which its business is currently being conducted; (ii) to own or lease and use its property and assets in the manner in which its property
and assets are currently owned or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except
where the failure to have such power or authority would not reasonably be expected to prevent or materially delay the ability of the
Company to consummate the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;The Company is duly
licensed and qualified to do business and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all
jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure
to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;The Company has no
Subsidiaries except for the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;</b>2.1(c)</span> of the Company Disclosure Schedule; and neither
the Company nor any of the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.1(c)</span> of the Company Disclosure Schedule owns any
share capital of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other
Entity other than the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.1(c)</span> of the Company Disclosure Schedule. Each of the Company&#8217;s
Subsidiaries is a corporation or other legal entity duly organized, validly existing and, if applicable, in good standing under the Laws
of the jurisdiction of its organization and has all necessary corporate or other power and authority to conduct its business in the manner
in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property
and assets are currently owned or leased and used, except where the failure to have such power or authority would not be reasonably expected
to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;Except as set forth
in Section <b>&#8206;</b>2.1(d) of the Company Disclosure Schedule, the Company is not and since March 24, 2021 has not been, directly
or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not
agreed or is obligated to make or is bound by any Contract under which it may become obligated to make, any future investment in or capital
contribution to any other Entity. The Company is not and has never been a general partner of or has otherwise been liable for any of
the debts or other obligations of, any general partnership, limited partnership or other Entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;The Company is not
subject to any delisting proceedings by TASE, nor does the Company foresee any reason for delisting proceedings to commence following
the Effective Date contemplated hereby, nor is the Company subject to any enforcement action by the ISA, or equivalent enforcement entities,
nor does the Company foresee any reason for the commencement of enforcement actions against the Company, or its Affiliates, following
the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 490 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2 &#160;<b><span style="text-decoration:underline">Organizational
Documents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has made available
to Parent accurate and complete copies of the Organizational Documents of the Company in effect as of the date of this Agreement. The
Company is not in material breach or violation of its Organizational Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3 &#160;<b><span style="text-decoration:underline">Authority;
Binding Nature of Agreement</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has all necessary
corporate power and authority to enter into and to perform its obligations under this Agreement and, subject to receipt of the Required
Company Approval, and the filing and recordation of appropriate merger documents as required by the Companies Law, to consummate the
Contemplated Transactions. The Company Board (at meetings duly called and held) has: (i) determined that the Contemplated Transactions
are fair to, advisable and in the best interests of the Company and its shareholders; (ii) authorized, approved and declared advisable
this Agreement and the Contemplated Transactions in accordance with the requirements of the Companies Law; and (iii) determined to recommend,
upon the terms and subject to the conditions set forth in this Agreement, that the shareholders of the Company vote to approve this Agreement
and the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization,
execution and delivery by Parent and Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms, subject to the Enforceability Exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4 &#160;<b><span style="text-decoration:underline">Vote Required</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Section 350 Vote (the
&#8220;<b><i>Required Company Approval</i></b>&#8221;) is the only vote of the holders of any class or series of Company share capital,
creditors or holders of any notes or bonds, necessary to adopt and approve this Agreement and to approve the Contemplated Transactions.
Unless otherwise required by the Applicable Court and assuming the fulfilment of Section &#8206;6.7 below, no approval or vote of the Bondholders
is necessary to adopt and approve this Agreement and to consummate the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5 &#160;<b><span style="text-decoration:underline">Non-Contravention;
Consents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to obtaining the
Required Company Approval, the filings with the TASE, the ISA and the Companies Registrar of all notices or filings required under the
Companies Law or the Israeli Securities Law, including with respect to the consummation of the Merger and the issuance of the Certificate
of Merger by the Companies Registrar or any filings with the Applicable Court, neither: (i) the execution, delivery or performance of
this Agreement by the Company, nor (ii) the consummation of the Contemplated Transactions, will directly or indirectly (with or without
notice or lapse of time):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;contravene, conflict
with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 491 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;contravene, conflict
with or result in a violation of, or give any Governmental Body the right to challenge the Contemplated Transactions or to exercise any
remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which the Company, or any of the assets
owned or used by the Company, is subject, except as would not reasonably be expected to be material to the Company or its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;contravene, conflict
with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend,
cancel, terminate or modify, any Governmental Authorization that is held by the Company, except as would not reasonably be expected to
be material to the Company or its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;subject to obtaining
the requisite approvals and consents in respect of the Contracts set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.5(d)</span> of the Company Disclosure
Schedule, contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company
Material Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Company Material Contract;
(ii) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract; (iii) accelerate
the maturity or performance of any Company Material Contract; or (iv) cancel, terminate or modify any term of any Company Material Contract,
except in the case of any non-material breach, default, penalty or modification; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;result in the imposition
or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for: (i) the filings
with the Companies Registrar and all such other notices or filings with respect to the consummation of the Merger and the issuance of
the Certificate of Merger by the Companies Registrar, (ii) or any filings with the Applicable Court and (iii) such consents, waivers,
approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable securities Laws, the Company
is not and will not be required to make any filing with or give any notice to, or to obtain any Consent from, any Governmental Body in
connection with (x) the execution, delivery or performance of this Agreement, or (y) the consummation of the Contemplated Transactions,
which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially delay the
ability of the Company to consummate the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6 &#160;<b><span style="text-decoration:underline">Capitalization</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;The authorized share
capital of the Company is 400,000,00 Company Ordinary Shares, of which 105,643,744 Company Ordinary Shares have been issued and are outstanding
as of the close of business on the Business Day immediately preceding the date of this Agreement. Except as set forth in Section 2.6(a)
of the Company Disclosure Schedule, the Company does not hold any of its share capital in its treasury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;All of the outstanding
Company Ordinary Shares have been duly authorized and validly issued, and are fully paid and nonassessable. None of the outstanding Company
Ordinary Shares is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and
none of the outstanding Company Ordinary Shares is subject to any right of first refusal in favor of Company. Except as contemplated
herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging
or otherwise disposing of (or granting any option or similar right with respect to), any Company Ordinary Shares. Company is not under
any obligation, nor is it bound by any Company Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise
acquire any outstanding Company Ordinary Shares or other securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 492 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;Except for the Company
Share Plans, the Company does not have any share option plan or any other plan, program, agreement or arrangement providing for any equity-based
compensation for any Person. As of the date of this Agreement, Company has reserved 14,611,596 Company Ordinary Shares for issuance under
the Company Share Plans, of which 70,123,612 options are issued and are currently outstanding, with a weighted average exercise price
of NIS 1.77 (collectively, the &#8220;<b><i>Company Options</i></b>&#8221;), and 0 shares remain available for future issuance pursuant
to the Company Share Plans. <span style="text-decoration:underline">Section &#8206;(c)</span> of the Company Disclosure Schedule sets forth the following information with respect
to each Company Option outstanding as of the date of this Agreement: (i) the name of the optionee; (ii) the number of Company Ordinary
Shares subject to such Company Option at the time of grant; (iii) the number of Company Ordinary Shares subject to such Company Option
as of the date of this Agreement; (iv) the exercise price of such Company Option; (v) the date on which such Company Option was granted;
(vi) the applicable vesting schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration
provisions; (vii) the date on which such Company Option expires; and (viii) (A) the Tax route under which such Company Option was granted
and is currently intended to qualify (pursuant to Section 102 or Section 3(i) of the Ordinance), and (B) for Company 102 Options, the
date of the applicable corporate approval and the date of deposit of the respective award agreement with the 102 Trustee. The Company
has made available to Parent an accurate and complete copy of the Company Share Plans and all share option agreements evidencing outstanding
options granted thereunder. Except as set forth in <span style="text-decoration:underline">Section &#8206;&#8206;1.1(c)</span> of the Company Disclosure Schedule, no vesting of
Company Options will accelerate in connection with the closing of the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;All Company Options
granted under Section 102 of the Ordinance were granted under an employee option plan deemed approved, or not rejected within 30 days
from filing, by the ITA under the capital gains route of Section 102 of the Ordinance and comply in all respects with the requirements
of Section 102 of the Ordinance and qualify for treatment under the capital gain route thereunder, and were duly and timely deposited
in accordance with the provisions of Section 102 of the Ordinance with the 102 Trustee and no action has been threatened against the
Company (nor is the Company aware of a reasonable basis for an action against the Company) with respect to the failure of the Company
to comply with such requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;No unexercised Company
Options shall be outstanding immediately prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) &#160;<span style="text-decoration:underline">Section &#8206;1.1(f)
</span>of the Company Disclosure Schedule lists, as of the date of this Agreement: (i) each holder of issued and outstanding Company Warrants,
(ii) the number and type of shares subject to each Company Warrant, (iii) the exercise price of each Company Warrant and (iv) the termination
date of each Company Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) &#160;Except for the Company
Warrants, the Company Share Plans, including the Company Options, and as otherwise set forth on <span style="text-decoration:underline">Section &#8206;&#8206;1.1(g)</span> of the
Company Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable)
to acquire shares or other securities of Company or any of its Subsidiaries; (ii) outstanding security, instrument or obligation that
is or may become convertible into or exchangeable for any shares or other securities of Company or any of its Subsidiaries; or (iii)
condition or circumstance that is reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to
the effect that such Person is entitled to acquire or receive any shares or other securities of Company or any of its Subsidiaries. There
are no outstanding or authorized share appreciation, phantom shares, profit participation or other similar rights with respect to Company
or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 493 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) &#160;All outstanding Company
Ordinary Shares, Company Options, Company Warrants and other securities of Company have been issued and granted in material compliance
with: (i) all applicable securities Laws and other applicable Law, and (ii) all requirements set forth in applicable Contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) &#160;Except as set forth
in Section 2.6(h) of the Company Disclosure Schedule, all of the issued and outstanding Company Ordinary Shares are registered and held
through the Hevra Le&#8217;Rishumim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7 &#160;<b><span style="text-decoration:underline">TASE Filings,
Financial Statements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;The Company has delivered
or made available to the Parent accurate and complete copies of all prospectuses, proxy statements and other statements, reports, schedules,
forms and other documents filed by the Company with the ISA or the TASE since March 24, 2021 (the &#8220;<b><i>Company TASE Documents</i></b>&#8221;),
other than such documents that can be obtained on the ISA&#8217;s or the TASE&#8217;s websites. All material statements, reports, schedules,
forms and other documents required to have been filed by the Company or its officers with the ISA or the TASE have been filed on a timely
basis. As of the time it was filed with the ISA or the TASE (or, if amended or superseded by a filing prior to the date of this Agreement,
then on the date of such filing), each of the Company TASE Documents complied in all material respects with the applicable requirements
of the Israeli Securities Law and, as of the time they were filed, none of the Company TASE Documents contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. The Company has made available to the Parent true and complete
copies of all, but transmittal, correspondences, between the ISA and the Company and all material correspondences between the TASE and
the Company, since March 24, 2021, including all ISA or TASE comment letters and responses to such comment letters by or on behalf of
the Company other than such documents that can be obtained on the ISA&#8217;s or the TASE&#8217;s website. Except as set forth in <span style="text-decoration:underline">Section
<b>&#8206;</b>2.7(a)</span> of the Company Disclosure Schedule, as of the date of this Agreement, there are no outstanding or unresolved comments
in comment letters received from the ISA or the TASE with respect to the Company TASE Documents. To the Knowledge of the Company, none
of the Company TASE Documents is the subject of ongoing ISA or TASE review and there are no inquiries or investigations by the ISA or
TASE or internal investigations pending or threatened, including with regard to any accounting practices of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;The financial statements
(including any related notes) contained or incorporated by reference in the Company TASE Documents: (i) complied as to form in all material
respects with the published rules and regulations of the Israeli Securities Law; (ii) were prepared in accordance with IFRS (except as
may be indicated in the notes to such financial statements, and except that the unaudited financial statements may not contain footnotes
and are subject to normal and recurring year-end adjustments) applied on a consistent basis unless otherwise noted therein throughout
the periods indicated; and (iii) fairly present, in all material respects, the financial position of the Company as of the respective
dates thereof and the results of operations and cash flows of the Company for the periods covered thereby. Other than as expressly disclosed
in the Company TASE Documents filed prior to the date hereof, there has been no material change in Company&#8217;s accounting methods
or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 494 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><!-- Field: Split-Segment; Name: 001 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(c)&#160;The Company is in compliance
in all material respects with the applicable current listing and governance rules and regulations of the TASE. Except as set forth in
<span style="text-decoration:underline">Section &#8206;<b>&#8206;</b>2.7(c)</span> of the Company Disclosure Schedule and the Company TASE Documents, from March 24, 2021 through
the date hereof, Company has not received any correspondence from TASE or the staff thereof relating to the delisting or maintenance
of listing of the Company Ordinary Shares on the TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;The Company maintains
disclosure controls and procedures. Such disclosure controls and procedures are designed to provide reasonable assurance that all material
information concerning the Company (including its Subsidiaries) required to be disclosed by the Company in the Company TASE Documents
is made known on a timely basis to the individuals responsible for the preparation of the Company TASE Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;The Company maintains
a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&#160;transactions are executed in accordance
with management&#8217;s general or specific authorizations; and (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;During the twelve
(12) month period prior to the date hereof, to the Company&#8217;s Knowledge, the Company&#8217;s principal executive officer and its
principal financial officer have disclosed to the Company&#8217;s auditors and the audit committee of the Company Board (i)&#160;those
significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting that are reasonably
likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information of the Company
and its Subsidiaries on a consolidated basis that are known to them and (ii)&#160;any fraud known by such individuals, whether or not
material, that involves management or other employees who have a significant role in the Company&#8217;s and in the Company Subsidiaries&#8217;
internal controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">2.8&#160;<b><span style="text-decoration:underline">Absence of Changes</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on <span style="text-decoration:underline">Section
&#8206;2.8</span> of the Company Disclosure Schedule, between the date of the Company Balance Sheet, together with the statements of income,
shareholders&#8217; equity and cash flows of the Company for the period reflected in the Company Balance Sheet (collectively, the &#8220;<b><i>Company
Financials</i></b>&#8221;) and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business
(except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there
has not been any (a) Company Material Adverse Effect or (b) action, event or occurrence that would have required the consent of Parent
pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;4.2(b)</span> had such action, event or occurrence taken place after the execution and delivery of this
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 495 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.9&#160;<b><span style="text-decoration:underline">Absence of
Undisclosed Liabilities</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, the
Company has no liability, indebtedness, obligation or expense of any kind and is not subject to any claim, whether accrued, absolute,
contingent, matured or unmatured (whether or not required to be reflected in the financial statements in accordance with IFRS) or any
involvement in any special purpose vehicles (each a &#8220;<b><i>Liability</i></b>&#8221;), individually or in the aggregate, of a type
required to be recorded or reflected on a balance sheet or disclosed in the footnotes thereto under IFRS except for: (a) Liabilities
disclosed, reflected or reserved against in the Company Balance Sheet; (b) Liabilities that have been incurred by the Company since the
date of the Company Balance Sheet in the Ordinary Course of Business; (c) Liabilities for performance of obligations of the Company under
any Contract to which it is party; (d) Liabilities incurred in connection with the Contemplated Transactions; (e) Liabilities which would
not, individually or in the aggregate, reasonably be expected to be material to the Company; and (f) Liabilities described in <span style="text-decoration:underline">Section
&#8206;&#8206;2.9</span> of the Company Disclosure Schedule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.10&#160;<b><span style="text-decoration:underline">Title to
Assets</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company owns, and has
good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible
assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets
reflected on the Company Balance Sheet and (b) all other tangible assets reflected in the books and records of the Company as being owned
by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances,
other than Permitted Encumbrances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.11&#160;<b><span style="text-decoration:underline">Real Property;
Leasehold</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in Section
&#8206;2.11 of the Company Disclosure Schedule, the Company does not own and since March 24, 2021 has not owned any real property. The
Company has made available to Parent: (i) an accurate and complete list of all real properties with respect to which the Company directly
or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company
and (ii) copies of all leases under which any such real property is possessed (the &#8220;<b><i>Company Real Estate Leases</i></b>&#8221;),
each of which is in full force and effect, with no existing material default thereunder. The Company&#8217;s use and operation of each
such leased property conforms to all applicable Laws in all material respects, and the Company has exclusive possession of each such
leased property and has not granted any occupancy rights to tenants or licensees with respect to such leased property. In addition, each
such leased property is free and clear of all Encumbrances other than Permitted Encumbrances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.12&#160;<b><span style="text-decoration:underline">Intellectual
Property</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except for the trademarks
set forth on <span style="text-decoration:underline">Section <b>&#8206;</b>2.12(a)</span> of the Company Disclosure Schedule, the Company does not own, license or otherwise have
any right, title or interest in any material Intellectual Property Rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;To the Knowledge of
the Company the operation of the businesses of the Company as currently conducted does not infringe any valid and enforceable Registered
IP or misappropriate or otherwise violate any Intellectual Property Right owned by any other Person. As of the date of this Agreement,
no Legal Proceeding is pending (or, to the Knowledge of the Company, is threatened in writing) against the Company alleging that the
operation of the businesses of the Company infringes or constitutes the misappropriation or other violation of any Intellectual Property
Rights of another Person. Since March 24, 2021, the Company has not received any written notice or other written communication alleging
that the operation of the business of the Company infringes or constitutes the misappropriation or other violation of any Intellectual
Property Right of another Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 496 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;To the Knowledge of
the Company, the Company and the operation of the Company&#8217;s business are in substantial compliance with all Laws pertaining to
data privacy and data security of any personally identifiable information and sensitive business information (collectively, &#8220;<b><i>Sensitive
Data</i></b>&#8221;) except to the extent that such noncompliance has not and would not reasonably be expected to have a Company Material
Adverse Effect. To the Knowledge of the Company, since March 24, 2021, there have been: (i) no material losses or thefts of data or security
breaches relating to Sensitive Data used in the business of the Company, (ii) no violations of any security policy of the Company regarding
any such Sensitive Data, (iii) no unauthorized access or unauthorized use of any Sensitive Data used in the business of the Company or
(iv) no unintended or improper disclosure of any personally identifiable information in the possession, custody or control of the Company,
or a contractor or agent acting on behalf of the Company, in each case of (i) through (iv), except as would not reasonably be expected
to, individually or in the aggregate, have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.13&#160;<b><span style="text-decoration:underline">Agreements,
Contracts and Commitments</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.13(a)
</span>of the Company Disclosure Schedule lists the following Company Contracts in effect as of the date of this Agreement other than any
Company Benefit Plans (each, a &#8220;<b><i>Company Material Contract</i></b>&#8221; and collectively, the &#8220;<b><i>Company Material
Contracts</i></b>&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;each Company Contract
relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;each Company Contract
containing: (A) any covenant limiting the freedom of the Company or the Surviving Company to engage in any line of business or compete
with any Person, (B) any most-favored pricing arrangement, (C) any exclusivity provision, or (D) any non-solicitation provision;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;each Company Contract
relating to capital expenditures and requiring payments after the date of this Agreement in excess of $200,000 pursuant to its express
terms and not cancelable without penalty;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;each Company Contract
relating to the disposition or acquisition of material assets or any ownership interest in any entity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#160;each Company Contract
relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating
to the borrowing of money or extension of credit or creating any material Encumbrances with respect to any assets of the Company or any
loans or debt obligations with officers or directors of the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 497 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#160;each Company Contract
requiring payment by or to the Company after the date of this Agreement in excess of $200,000 pursuant to its express terms relating
to: (A) any distribution agreement (identifying any that contain exclusivity provisions); (B) any dealer, distributor, joint marketing,
alliance, joint venture, cooperation or other agreement currently in force under which the Company has continuing obligations to market
any product, technology or service; or (C) any Contract to license any third party to manufacture or produce any product, service or
technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case,
except for Company Contracts entered into in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#160;each Company Contract
with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the
Company in connection with the Contemplated Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#160;each Company
Real Estate Lease;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#160;each Company Contract
with any Governmental Body;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#160;each Company Contract
containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#160;any other Company
Contract that is not terminable at will (with no penalty or payment) by the Company, and (A) which involves payment or receipt by the
Company after the date of this Agreement under any such agreement, contract or commitment of more than $200,000 in the aggregate, or
obligations after the date of this Agreement in excess of $200,000 in the aggregate, or (B) that is material to the business or operations
of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The Company has delivered
or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. Except
as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.13(b)</span> of the Company Disclosure Schedule, there are no Company Material Contracts that
are not in written form. The Company has not, nor to the Company&#8217;s Knowledge, as of the date of this Agreement has any other party
to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under,
any of the terms or conditions of any Company Material Contract in such manner as would permit any other party to cancel or terminate
any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to be material
to the Company or its business. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding,
enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant
to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material
Contract or any other material term or provision of any Company Material Contract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.14&#160;<b><span style="text-decoration:underline">Compliance;
Permits</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;The Company is in
compliance in all material respects with all applicable U.S., Israeli and other Laws, including the rules and regulations of the Israeli
Ministry of Transport and Road Safety, except for any noncompliance, either individually or in the aggregate, which would not be material
to the Company. No investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to the Knowledge
of the Company, threatened against the Company. There is no agreement, judgment, injunction, order or decree binding upon the Company
which: (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the
Company, any acquisition of material property by the Company or the conduct of business by the Company as currently conducted, (ii) is
reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under
this Agreement, or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with
the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 498 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The Company holds
all required Governmental Authorizations necessary for the operation of the business of the Company as currently conducted (the &#8220;<b><i>Company
Permits</i></b>&#8221;). <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.14(b)</span> of the Company Disclosure Schedule identifies each Company Permit. The
Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the Company,
threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit. All of the Governmental Authorizations are
valid and in full force and effect, except where the invalidity of such Governmental Authorizations or the failure of such Governmental
Authorizations to be in full force and effect would not have a Company Material Adverse Effect; and the Company has not received any
notice of proceedings relating to the revocation or modification of any such Governmental Authorizations which, singly or in the aggregate,
would reasonably be expected to result in a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.15&#160;<b><span style="text-decoration:underline">Legal Proceedings;
Orders</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;As of the date of
this Agreement, there is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence
any Legal Proceeding: (i) that involves (A) the Company, (B) any Company Associate (in his or her capacity as such) or (C) any of the
material assets owned or used by the Company; or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal
or otherwise interfering with, the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except as set forth
in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.15(b)</span> of the Company Disclosure Schedule, since March 24, 2021, no Legal Proceeding has been pending
against the Company that had or would reasonably be expected to have resulted in material liability to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There is no order,
writ, injunction, judgment or decree to which the Company, or any of the material assets owned or used by the Company, is subject. To
the Knowledge of the Company, no officer of the Company is subject to any order, writ, injunction, judgment or decree that prohibits
such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of the Company or
to any material assets owned or used by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.16&#160;<b><span style="text-decoration:underline">Tax Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;Each Tax Return
required to be filed with any Governmental Body by the Company has been filed when due (taking into account extensions in the ordinary
course of business) in accordance with applicable Law, each of which is true, accurate and complete;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;the Company has
timely paid, collected or withheld, to the appropriate Governmental Body all Taxes due and payable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 499 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;the Company has
complied with all applicable Law relating to the payment and withholding of any Tax and has, within the time and in the manner prescribed
by Law, withheld and paid over to the proper Governmental Body all amounts required to be so withheld and paid over;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;the Company has
established adequate accruals or reserves, in accordance with IFRS, for all Taxes for taxable periods beginning on or after the date
of the most recent Company Financials;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#160;Except as set forth
in Section <b><i>&#8206;</i></b>2.16<b><i>&#8206;</i></b>(a)<b><i>&#8206;</i></b>(v) of the Company Disclosure Schedule, there is no Legal
Proceeding against or with respect to the Company in respect of any Tax or any Tax Return and there is no investigation against or with
respect to the Company, pending or threatened or otherwise in respect of any Tax or any Tax Return. All deficiencies asserted or assessments
made against the Company as a result of any examinations by any Governmental Body have been fully paid;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#160;the Company has
not consented or requested to extend the time, or is the recipient of any extension of time, in which any Tax may be assessed or collected
by any Governmental Authority and the Company has not waived any statute of limitations;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#160;no Governmental
Authority in a jurisdiction where no Tax Return has been filed or no Tax has been paid has made or threatened to make a claim for the
payment of any Tax or the filing of any Tax Return;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#160;the Company is
a Tax resident only in its jurisdiction of formation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>2.16(a)(ix)</span> of the Company Disclosure Schedule, no power of attorney granted by or with
respect to the Company for Taxes is currently in force, no ruling with respect to Taxes has been requested by or on behalf of the Company;
and no closing agreement pursuant to Section 7121 of the Code (or any predecessor provision) or any similar provision of any state, local
or non-U.S. Law has been entered into or requested by or with respect to the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#160;the Company has
provided or made available to Parent prior to the date hereof true, correct and complete copies of all material Tax Returns, examination
reports, and statements of deficiencies filed, assessed against, or agreed to by the Company with respect to Taxes and all material written
correspondence with any Governmental Authority regarding Taxes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>2.16(a)(xi)</span> of the Company Disclosure Schedule, the Company is neither a controlled foreign
corporation (as defined in Section 957 of the Code or any similar provision of any state, local or non-U.S. Law) nor a passive foreign
investment company (as defined in Section 1297 of the Code). The Company does not own any interest in any controlled foreign corporation
(as defined in Section 957 of the Code or any similar provision of any state, local or non-U.S. Law), or passive foreign investment company
(as defined in Section 1297 of the Code) or other entity the income of which is or could be required to be included in the income of
the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 500 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii)&#160;the Company is
not and has never been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the
applicable period specified in Section 897(c)(1)(A)(ii) of the Code;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii)&#160;the Company will
not be required to include any item of income in, or exclude any item of deduction from, taxable income for (A) any Tax period (or portion
thereof), as a result of any deferred foreign income within the meaning of Section 965 of the Code, including, but not limited to, as
the result of an election under Section 965(h) of the Code, or (B) any Tax period (or portion thereof) ending after the Closing Date,
as a result of any (1) deferred intercompany gain or any excess loss account described in Treasury Regulations under Section 1502 of
the Code (or any corresponding provision of state, local or non-U.S. Tax Law); (2) installment sale or other open transaction disposition
made on or prior to the Closing Date; (3) prepaid amount, refund or credit received on or prior to the Closing Date; (4) change in accounting
method for a taxable period ending on or prior to the Closing Date; (5) use of an improper method of accounting for a taxable period
ending on or prior to the Closing Date; or (6) &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any corresponding
or similar provision of state, local or non-U.S. Tax Law) executed on or prior to the Closing Date;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv)&#160;all material records
which the Company is required to keep for Tax purposes or which would be needed to substantiate any claim made or position taken in relation
to Taxes by the Company have been duly kept and are available for inspection at the premises of the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv)&#160;the Company is
in compliance in all respects with all terms and conditions of any Tax exemption, Tax holiday or other Tax reduction agreement or order
of a Governmental Body;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi)&#160;all of the Company&#8217;s
property that is subject to property Tax has been properly listed and described on the property Tax rolls of the appropriate Tax jurisdiction
and no portion of any the Company&#8217;s property constitutes omitted property for property Tax purposes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii)&#160;there are no
Liens for Taxes on any of the assets of the Company other than for any Taxes not yet due and payable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section </span><b><i>&#8206;</i></b>2.16<b><i>&#8206;</i></b>(a)<b><i>&#8206;</i></b>(xviii) of the Company Disclosure Schedule,
the Company does not and has never participated or engaged in any transaction listed in Section 131(g) of the Ordinance and the Israeli
Income Tax Regulations (Reportable Tax Planning), 5767-2006, promulgated thereunder; the Company does not and has never taken a tax position
that is subject to reporting under Section 131E of the Ordinance; the Company has never obtained a legal or tax opinion that is subject
to reporting under Section 131D of the Ordinance; and the Company does not and has never performed and was not part of any action or
transaction that is classified as a &#8220;reportable opinion&#8221; under Section 67C of the Israeli VAT Law or a &#8220;reportable
position&#8221; under Section 67D of the Israeli VAT Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xix)&#160;the Company is
duly registered for the purposes of Israeli value added tax and has complied in all respects with all requirements concerning VAT. The
Company (i) has not made any exempt transactions (as defined in the Israeli Value Added Tax Law, 5736-1975) and there are no circumstances
by reason of which there might not be an entitlement to full credit of all VAT chargeable or paid on inputs, supplies, and other transactions
and imports made by it, (ii) has collected and remitted in a timely manner to the ITA all output VAT which it is required to collect
and remit under any applicable Law and (iii) has not received a refund for input VAT for which it is not entitled under any applicable
Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 501 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xx)&#160;each of the Company
Share Plans that is intended to qualify as a capital gains route plan under Section 102 of the Ordinance has received a favorable determination
or approval letter from, or is otherwise approved by or deemed approved by passage of time without objection by, the ITA. All Company
102 Options have been granted and issued, as applicable, in compliance with the applicable requirements of Section 102 and the written
requirements and guidance of the ITA, including the filing of the necessary documents with the ITA, the appointment of an authorized
trustee, the grant of Company 102 Options only following the lapse of the required 30 day period from the filing of each of the Company
Share Plans that is intended to qualify as a capital gains route plan under Section 102 of the Ordinance with the ITA, the receipt of
the required written consents from the option holders and the due deposit of such securities with the 102 Trustee pursuant to the terms
of Section 102 of the Ordinance and the guidance published by the ITA on July 24, 2012, and clarification dated November 6, 2012;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxi)&#160;the Company is
not and has never been a real property corporation (<i>Igud Mekarke&#8217;in</i>) within the meaning of this term under Section 1 of
the Israeli Land Taxation Law (Appreciation and Acquisition), 5723-1963;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxii)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section </span><b><i>&#8206;</i></b>2.16<b><i>&#8206;</i></b>(a)<b><i>&#8206;</i></b>(xxii) of the Company Disclosure Schedule,
neither the Company nor any holder of Company securities is subject to any restrictions or limitations pursuant to Part E2 of the Ordinance
or pursuant to any Tax ruling made with reference to the provisions of Part E2;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxiii)&#160;no independent
contractor was, or to the Knowledge of the Company will be, entitled to be considered to be an employee of the Company by any applicable
Tax authority; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxiv)&#160;the Company did
not apply for any tax benefits under the Law for the Encouragement of Capital Investments, 5719-1959.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except as provided
in <span style="text-decoration:underline">Section </span><b>&#8206;</b>2.16<b>&#8206;</b>(b), the Company is in compliance in all respects with all applicable transfer pricing
laws and regulations, and the prices for any property or services provided by or to it are arm&#8217;s length prices for purposes of
the applicable laws, including Section 85A to the Ordinance and the Income Tax Regulations (Determination of Market Terms) 2006 and including
to the extent required, the execution and maintenance of contemporaneous documentation substantiating the transfer pricing practices
and methodology of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;The Company does not
have any (A) place of management, (B) branch, (C) office (or any other place of business), (D) operations or employees, (E) agent with
binding authority, or (F) other activities, in each case that gives rise to a permanent establishment or taxable presence which has subjected
it to any Tax obligation or to a requirement to file any Tax return in any country other than the country where the Company was organized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section <b>&#8206;</b>2.16<b>&#8206;</b>(d)</span> of the Company Disclosure Schedule, the Company is not, nor at any time has
it been, engaged in the conduct of a trade or business within the United States within the meaning of Section 864(b) or Section 882(a)
of the Code, or considered to be so engaged under Section 882(d) or Section 897 of the Code or, if applicable, considered to have a U.S.
permanent establishment as defined under any applicable or relevant bilateral income tax treaty or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 502 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;(i) The Company is
not nor has it ever been, a party to any Tax Sharing Agreement pursuant to which it will have any obligation to make any payments for
Taxes after the Closing Date, (ii) the Company is not and has never been a member of a group filing a consolidated, combined or unitary
Tax Return, and (iii) the Company has no liability for the payment of any Tax imposed on any Person (other than the Company) as a transferee
or successor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;The Company has never
taken a position that could give rise to substantial understatement of income tax within the meaning of Section 6662 of the Code (or
any corresponding provision of state, local or non-U.S. Tax Law) or has ever been a beneficiary or otherwise participated in any &#8220;reportable
transaction&#8221; as defined in Code Section 6707A(c)(1)) and Treasury Regulation Section 1.6011-4(b)(1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;With the exception
of Israeli VAT, the Company is not, nor is it required to be, registered as a taxable person for purpose of value added Taxes or any
similar indirect Tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this <span style="text-decoration:underline">Section
&#8206;&#8206;2.16</span>, each reference to the Company shall be deemed to include any Person that was liquidated into, merged with, or is
otherwise a predecessor to, the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.17&#160;<b><span style="text-decoration:underline">Employee
and Labor Matters; Benefit Plans</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(a)
</span>of the Company Disclosure Schedule is a list of all material Company Benefit Plans, including, without limitation, each Company Benefit
Plan that provides for change in control, stay or retention, deferred compensation, incentive compensation, pension and severance benefits.
&#8220;<b><i>Company Benefit Plan</i></b>&#8221; means each pension, profit sharing, bonus, incentive, equity or equity-based, phantom
equity, employment (other than at-will employment offer letters or employment agreement on the Company&#8217;s standard form as may be
amended from time to time and other than individual Company Options or other compensatory equity award agreements made pursuant to the
Company&#8217;s standard forms, in which case only representative standard forms of such agreements shall be scheduled) and fringe benefit
plan, program, agreement (including collective bargaining agreement and extension order), policy or arrangement (whether written or unwritten,
but excluding statutory benefits or benefits mentioned in the Company&#8217;s standard form of employment agreement) for the benefit
of any current or former employee, director, officer or independent contractor of the Company or any of its Subsidiaries or under which
the Company or any of its Subsidiaries has any actual or contingent liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;As applicable with
respect to each material Company Benefit Plan, the Company has made available to Parent true and complete copies of each material Company
Benefit Plan, including all amendments thereto, and in the case of an unwritten material Company Benefit Plan, a written description
thereof, and all material correspondence to or from any Governmental Body with respect to each Company Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Each Company Benefit
Plan has been established, maintained, operated and administered in compliance in all material respects with its terms and all applicable
Laws. Each Company Benefit Plan required to be funded is fully funded, and with respect to Company Share Plans that are not required
by applicable Law to be so fully funded, adequate reserves therefor have been established on the Company Financials (except for severance
pay that is fully funded, and full Section 14 Arrangements apply to all of the Company&#8217;s employees). No material liability or obligation
of the Company or any of its Affiliates exists with respect to any Company Benefit Plan that has not been disclosed in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(c)
</span>of the Company Disclosure Schedule. The Company does not have, and except as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(c)</span>
of the Company Disclosure Schedule has never had, any employees in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 503 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;To the Knowledge of
the Company, there are no pending audits or investigations by any Governmental Body involving any Company Benefit Plan, and no pending
or, to the Knowledge of the Company, threatened claims (except for individual claims for benefits payable in the normal operation of
the Company Benefit Plans), suits or proceedings involving any Company Benefit Plan in any case except as would not be reasonably expected
to result in material liability to the Company. The Company does not have any Company Benefit Plan that is maintained in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Neither the execution
of, nor the performance of the Contemplated Transactions will either alone or in connection with any other event(s): (i) result in any
material payment becoming due to any current or former employee, director, officer, or independent contractor of the Company, (ii) increase
any material amount of compensation or benefits otherwise payable under any Company Benefit Plan, (iii) result in the acceleration of
the time of payment, funding or vesting of any benefits under any Company Benefit Plan, (iv) require any material contribution or payment
to fund any obligation under any Company Benefit Plan or (v) limit the right to merge, amend or terminate any Company Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(f)
</span>of the Company Disclosure Schedule sets forth the policy of the Company with respect to accrued vacation, accrued sick time and earned
time off and the amount of such liabilities, including regarding bonuses to employees and independent contractors for the last two years,
as of the date of this Agreement (in the case of accrued vacation, per employee for those who have more than 44 accrued days). The Company
does not have and has not had a policy regarding the payment of bonuses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;The Company is not
a party to, is not bound by, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a
labor union, labor organization, or similar Person representing any of its employees, and to the Knowledge of the Company, there is no
labor union, labor organization, or similar Person representing or purporting to represent or seeking to represent any employees of the
Company. There is not and has not been in the past three years, nor is there or has there been in the past three years any threat of,
any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or,
to the Knowledge of the Company, any union organizing activity, against the Company. No event has occurred, and no condition or circumstance
exists, that might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown,
work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of the
Company, any union organizing activity. The Company has paid all required payments, if any, that the Company has been requested to pay
to any employers&#8217; association or organization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 504 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(h)
</span>of the Company Disclosure Schedule contains a list of all employees of the Company and its Subsidiaries along with the position,
the monthly rate of salary of each such employee, whether such employee is full time or part time, is exempt or non-exempt from the Hours
of Work and Rest Law, is on leave and if so, the type of leave and expected date of return, visa status (as applicable), date of hire,
any incentive payment paid or payable in calendar year 2023 (and whether such incentive is cash or, if not, what other property is due),
short-term or temporary basis, vacation entitlement and accrued vacation or paid time-off balance, car entitlement, sick leave entitlement
and accrual (if any), and recuperation pay entitlement and accrual, pension entitlements and provident funds (including manager&#8217;s
insurance, pension fund, education fund and health fund), their respective contribution rates for each component (<i>e.g.,</i> severance
component, pension savings and disability insurance) and the salary basis for such contributions, severance entitlements (including whether
such employee, to the extent employed in the State of Israel, is subject to a Section 14 arrangement under the Severance Pay Law, 5723-1963
(the &#8220;<b><i>Israeli Severance Pay Law</i></b>&#8221; and &#8220;<b><i>Section 14 Arrangement</i></b>&#8221;), and, to the extent
such employee is subject to such a Section 14 Arrangement, an indication of whether such arrangement (or other applicable pension arrangement)
has been applied to such person from the commencement date of their employment and on the basis of their entire salary including other
compensation (e.g., commission), main work location, notice period entitlement, and any other material compensation payable to such employee.
Neither the Company nor its Subsidiaries is delinquent in payments to any employees for wages, salaries, commissions or bonuses for services
performed as of the date hereof or amounts required by applicable Law to be reimbursed to such employees. The consummation of the Contemplated
Transactions will not give rise to any liability of the Company or any of its Subsidiaries for payments related to severance, termination,
bonus, accrued vacation or personal time, accrued days of sick pay or any similar payment. No current employee of the Company or any
of its Affiliates is or was, during the period of such employment or other service, based in or resident of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(i)
</span>of the Company Disclosure Schedule contains a list of each individual who currently renders services to Company as an independent
contractor or consultant (collectively, the &#8220;<b><i>Company Contractors</i></b>&#8221;) and the Company has made available to Parent
true and complete copies of each Company Contractors agreement and the last 3 months invoices. The Company has accurately classified
each such Company Contractor or former Company Contractor as an independent contractor under all applicable Laws (including for purposes
of Taxes and Tax reporting and under the Company Benefit Plans). Except as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(i)</span> of the
Company Disclosure Schedule, each Company Contractor can be terminated on notice of thirty days or less to the Company Contractor. According
to the Company Contractors&#8217; agreements with the Company, no Company Contractor is entitled to any rights under the applicable labor
laws. All current and former Company Contractors have received all their rights to which they are and were entitled according to any
applicable Law or Contract with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#160;The Company is not
delinquent in payments to any employees for wages, salaries, commissions or bonuses for services performed as of the date hereof or amounts
required by applicable Law to be reimbursed to such employees. The employment seniority for each employee for any employment purposes
began as of the date of hire and prior to such date no employment relations existed between any employee and the Company for any matter
or purpose. The Company has withheld, paid and reported all amounts required by the Ordinance, the National Insurance Law [Consolidated
Version], 5755-1995, and the National Health Insurance Law, 5754-1994 regarding its current and former employees and Company Contractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 505 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#160;The Company is, and
since March 24, 2021 has been, in material compliance with all applicable Laws and agreements (including collective bargaining agreements
and extension orders) respecting labor (including consultants), employment, employment practices, and terms and conditions of employment,
including proper classification of independent contractors as not being employees. There are no actions, suits, claims, charges, lawsuits,
investigations, audits or administrative matters pending or, to the Knowledge of the Company, threatened or reasonably anticipated against
the Company relating to any employee, applicant for employment, consultant, employment agreement or Company Benefit Plan (other than
routine claims for benefits).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#160;There is not and has
not been in the past three years, nor is there or has there been in the past three years any threat of, any material claim, charge, grievance
or Legal Proceeding against the Company brought by or on behalf of any current or former applicant, employee, independent contractor,
subcontractor, leased employee, volunteer, or temporary employee of the Company, alleging violation of any applicable employment Law,
agreement or any other claim arising out of such Person&#8217;s employment, application for employment or termination of employment,
consulting or other relationship with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#160;At all times since
March 24, 2021, the Company has not engaged any employees whose employment would require special licenses or permits by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#160;The Company&#8217;s
obligations to provide statutory severance pay to its Israeli employees pursuant to the Israeli Severance Pay Law are fully funded in
accordance with Section 14 Arrangements and it is and was implemented properly, from the commencement date of each employee&#8217;s employment
and on the basis of 8.33% of the employee&#8217;s entire salary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#160;The Company has not
been and is not subject to, and none of its employees or consultants benefits from, any collective agreement, extension order (<i>tzavei
harchave</i>) or any general contract or arrangement with respect to employment or termination of employment, except those extension
orders that apply to all Israeli companies generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&#160;Each officer of the
Company is a party to a confidentiality agreement with the Company; copies of such agreements have previously been delivered, or made
available, to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&#160;No group of employees
has notified the Company of its intent, or, to the Knowledge of the Company, has any plans, to terminate employment with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)&#160;The Company does not
have unsatisfied obligations of any nature to any of its former employees or consultants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.18&#160;<b><span style="text-decoration:underline">Environmental
Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is, and since
March 24, 2021 has been, in compliance with all applicable Environmental Laws, which compliance includes the possession by the Company
of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions
thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected
to be material to the Company or its business. The Company has not received since March 24, 2021 (or prior to that time, which to the
Knowledge of the Company is pending and unresolved), any written notice or other communication (in writing or otherwise), whether from
a Governmental Body or other Person, that alleges that the Company is not in compliance with or has liability pursuant to any Environmental
Law and, to the Knowledge of the Company, there are no circumstances that would reasonably be expected to prevent or interfere with the
Company&#8217;s compliance in any material respects with any Environmental Law, except where such failure to comply would not reasonably
be expected to be material to the Company or its business. No current or (during the time a prior property was leased or controlled by
the Company) prior property leased or controlled by the Company has had a release of or exposure to Hazardous Materials in material violation
of or as would reasonably be expected to result in any material liability of the Company pursuant to Environmental Law. No consent, approval
or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in connection
with the execution and delivery of this Agreement or the consummation of the Contemplated Transactions. Prior to the date hereof, the
Company has provided or otherwise made available to Parent true and correct copies of all material environmental reports, assessments,
studies and audits in the possession or control of the Company with respect to any property leased or controlled by the Company or any
business operated by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 506 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.19&#160;<b><span style="text-decoration:underline">Insurance</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has delivered
or made available to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs
and arrangements relating to the business, assets, liabilities and operations of the Company. Each such insurance policy is in full force
and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications
from insurance carriers, since March 24, 2021, the Company has not received any notice or other communication regarding any actual or
possible: (i) cancellation or invalidation of any insurance policy; or (ii) refusal or denial of any coverage, reservation of rights
or rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance
carrier(s) of each Legal Proceeding that is currently pending against the Company for which the Company has insurance coverage, and no
such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding or informed the Company
of its intent to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.20&#160;<b><span style="text-decoration:underline">No Financial
Advisors</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on <span style="text-decoration:underline">Section
&#8206;2.20</span> of the Company Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s
fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon
arrangements made by or on behalf of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.21&#160;<b><span style="text-decoration:underline">Transactions
with Affiliates</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.21(a)
</span>of the Company Disclosure Schedule describes any material transactions or relationships, since March 24, 2021, between, on one hand,
the Company and, on the other hand, any: (i) executive officer or director of the Company or, to the Knowledge of the Company, any of
such executive officer&#8217;s or director&#8217;s immediate family members, (ii) owner of more than 5% of the voting power of the outstanding
Company Ordinary Shares or (iii) to the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item 404 of
Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of sub-limb
(i), (ii) or (iii) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 507 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>2.21(b)
</span>of the Company Disclosure Schedule lists each shareholders&#8217; agreement, voting agreement, co-sale agreement or other similar
Contract between the Company and any holders of Company Ordinary Shares, including any such Contract granting any Person investor rights,
rights of first refusal, rights of first offer, director designation rights or similar rights (collectively, the &#8220;<b><i>Investor
Agreements</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.22&#160;<b><span style="text-decoration:underline">Anti-Bribery</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither of the Company nor
any of its directors, officers, employees or, to the Company&#8217;s Knowledge, agents or any other Person acting on their behalf has
directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions,
or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of the Foreign Corrupt Practices
Act of 1977, the UK Bribery Act of 2010, Sections 291 and 291A of the Israeli Penal Law, 5737-1977 or any other anti-bribery or anti-corruption
Law (collectively, the &#8220;<b><i>Anti-Bribery Laws</i></b>&#8221;). The Company is not and since March 24, 2021 has not been the subject
of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.23&#160;<b><span style="text-decoration:underline">Disclaimer
of Other Representations or Warranties</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in this
<span style="text-decoration:underline">Section &#8206;2</span> or in any certificate delivered by the Company to Parent and/or Merger Sub pursuant to this Agreement, the Company
makes no representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets, liabilities or
operations, and any such other representations or warranties are hereby expressly disclaimed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">3.
<b><span style="text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <span style="text-decoration:underline">Section &#8206;&#8206;10.13(h)</span>,
except: (i) as set forth in the disclosure schedule delivered by Parent to the Company (the &#8220;<b><i>Parent Disclosure Schedule</i></b>&#8221;)
or (ii) as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s
Electronic Data Gathering Analysis and Retrieval system (but: (x) without giving effect to any amendment thereof filed with, or furnished
to the SEC on or after the date hereof and (y) excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any
disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are
forward-looking statements or cautionary, predictive or forward-looking in nature), Parent and Merger Sub represent and warrant to the
Company as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&#160;<b><span style="text-decoration:underline">Due Organization;
Subsidiaries</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Parent is a public
company duly organized and validly existing under the Laws of the State of Israel and Merger Sub is a company duly organized and validly
existing under the laws of the State of Israel, and neither Parent nor Merger Sub is a &#8220;breaching company&#8221; under the Companies
Law, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently
being conducted; (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned
or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except where the failure to have such
power or authority would not reasonably be expected to prevent or materially delay the ability of Parent and Merger Sub to consummate
the Contemplated Transactions to which it is a party. Since the date of its incorporation, Merger Sub has not engaged in any activities
other than activities incident to its formation or in connection with or as contemplated by this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 508 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Parent is duly licensed
and qualified to do business and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions
where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified
individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;The Parent has no
Subsidiaries, except for the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.1(c)</span> of the Parent Disclosure Schedule; and neither
the Parent nor any of the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.1(c)</span> of the Company Disclosure Schedule owns any share
capital of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity
other than the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.1(c)</span> of the Parent Disclosure Schedule. Each of the Parent&#8217;s
Subsidiaries is a corporation or other legal entity duly organized, validly existing and, if applicable, in good standing under the Laws
of the jurisdiction of its organization and has all necessary corporate or other power and authority to conduct its business in the manner
in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property
and assets are currently owned or leased and used, except where the failure to have such power or authority would not be reasonably expected
to have a Parent Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;The Parent is not
and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar
business entity. The Parent has not agreed and is not obligated to make, or is bound by any Contract under which it may become obligated
to make, any future investment in or capital contribution to any other Entity. The Parent has not any time, been a general partner of,
or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#160;<b><span style="text-decoration:underline">Organizational
Documents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent has made available
to the Company accurate and complete copies of Parent&#8217;s and Merger Sub&#8217;s Organizational Documents in effect as of the date
of this Agreement. Neither Parent nor Merger Sub is in material breach or violation of its respective Organizational Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&#160;<b><span style="text-decoration:underline">Authority;
Binding Nature of Agreement</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of Parent and Merger
Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and, subject, with
respect to Parent, to receipt of the Required Parent Shareholder Vote and, with respect to Merger Sub, the adoption of this Agreement
by Parent in its capacity as sole shareholder of Merger Sub, to perform its obligations hereunder and to consummate the Contemplated
Transactions to which it is a party. The Parent Board (at meetings duly called and held) has: (i) determined that the Contemplated Transactions
to which it is a party are fair to, advisable and in the best interests of Parent and its shareholders; (ii) authorized, approved and
declared advisable this Agreement and the Contemplated Transactions to which it is a party, including the issuance of Parent Ordinary
Shares to the shareholders of the Company pursuant to the terms of this Agreement and the treatment of the Company Options and Company
Warrants pursuant to this Agreement; and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this
Agreement, that the shareholders of Parent vote to approve this Agreement and the Contemplated Transactions, including the issuance of
Parent Ordinary Shares to the shareholders of the Company pursuant to the terms of this Agreement. The Merger Sub Board (by unanimous
written consent) has: (x) determined that the Contemplated Transactions to which it is a party are fair to, advisable and in the best
interests of Merger Sub and its sole shareholder; (y) deemed advisable and approved this Agreement and the Contemplated Transactions
to which it is a party; and (z) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that
the sole shareholder of Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions to which it is a party.
This Agreement has been duly executed and delivered by Parent and Merger Sub and, assuming the due authorization, execution and delivery
by the Company, constitutes the legal, valid and binding obligation of Parent and Merger Sub, enforceable against each of Parent and
Merger Sub in accordance with its terms, subject to the Enforceability Exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 509 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4&#160;<b><span style="text-decoration:underline">Vote Required</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast by the holders of the outstanding Parent Ordinary Shares is the only vote of the holders of any class or series
of Parent&#8217;s outstanding share capital necessary to approve the proposals in <span style="text-decoration:underline">Section &#8206;5.3(a)&#8206;</span> (the &#8220;<b><i>Required
Parent Shareholder Vote</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5&#160;<b><span style="text-decoration:underline">Non-Contravention;
Consents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to obtaining the
Required Parent Shareholder Vote and the filings with the Companies Registrar or all other notices or filings required under the Companies
Law with respect to the consummation of the Merger and the issuance of the Certificate of Merger by the Companies Registrar or any filings
with the Applicable Court, neither: (i) the execution, delivery or performance of this Agreement by Parent or Merger Sub, nor (ii) the
consummation of the Contemplated Transactions to which it is a party, will directly or indirectly (with or without notice or lapse of
time):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;contravene, conflict
with or result in a violation of any of the provisions of the Organizational Documents of Parent or Merger Sub;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;contravene, conflict
with or result in a violation of, or give any Governmental Body the right to challenge the Contemplated Transactions to which it is a
party or to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which Parent
or Merger Sub, or any of the assets owned or used by Parent or Merger Sub, is subject, except as would not reasonably be expected to
be material to Parent or its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;contravene, conflict
with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend,
cancel, terminate or modify, any Governmental Authorization that is held by Parent, except as would not reasonably be expected to be
material to Parent or its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;subject to obtaining
the requisite approvals and consents in respect of the Contracts set forth in <span style="text-decoration:underline">Section <b>&#8206;</b></span><b>&#8206;</b>3.5<b>&#8206;</b>(d)
of the Parent Disclosure Schedule, contravene, conflict with or result in a violation or breach of, or result in a default under, any
provision of any Parent Material Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Parent
Material Contract; (ii) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Parent Material Contract;
(iii) accelerate the maturity or performance of any Parent Material Contract; or (iv) cancel, terminate or modify any term of any Parent
Material Contract, except in the case of any non-material breach, default, penalty or modification; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 510 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;result in the imposition
or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or Merger Sub (except for Permitted Encumbrances).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for: (i) the filing
with the Companies Registrar and all such other notices or filings with respect to the consummation of the Merger and the issuance of
the Certificate of Merger by the Companies Registrar, (ii) the filing of the Nasdaq Notification and receiving the requisite approval
from Nasdaq, (iii) or any filings with the Applicable Court and (iv) such consents, waivers, approvals, orders, authorizations, registrations,
declarations and filings as may be required under applicable federal and state securities Laws, neither the Parent nor Merger Sub is
or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Governmental Body in connection
with (y) the execution, delivery or performance of this Agreement, or (z) the consummation of the Contemplated Transactions to which
it is a party, which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially
delay the ability of Parent and Merger Sub to consummate the Contemplated Transactions. No takeover statute or regulation is applicable
to this Agreement, the Merger or any of the other Contemplated Transactions to which it is a party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6&#160;<b><span style="text-decoration:underline">Capitalization</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;The authorized Parent
Share Capital is 75,000,000 Parent Ordinary Shares, of which 2,703,674 Parent Ordinary Shares have been issued and are outstanding as
of the close of business on the Business Day immediately preceding the date of this Agreement. Parent does not hold any of its share
capital in its treasury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;All of the outstanding
Parent Ordinary Shares have been duly authorized and validly issued and are fully paid and nonassessable. None of the outstanding Parent
Ordinary Shares is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and
none of the outstanding Parent Ordinary Shares is subject to any right of first refusal in favor of Parent. Except as contemplated herein,
there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or
otherwise disposing of (or granting any option or similar right with respect to), any Parent Ordinary Shares. Parent is not under any
obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any
outstanding Parent Ordinary Shares or other securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Except for the Parent
Share Plans, Parent does not have any share option plan or any other plan, program, agreement or arrangement providing for any equity-based
compensation for any Person. As of the date of this Agreement, Parent has reserved 1,020,800 Parent Ordinary Shares for issuance under
the Parent Share Plans, of which 7,013 Parent Options are issued and are currently outstanding, with a weighted average exercise price
of $166.28, no Parent Ordinary Shares are issuable upon the vesting or settlement of outstanding Parent RSUs, and 1,013,787 Parent Ordinary
Shares remain available for future issuance pursuant to the Parent Share Plans. <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.6(c)</span> of the Parent
Disclosure Schedule sets forth the following information with respect to each Parent Equity Award outstanding as of the date of this
Agreement: (i) the name of the grantee; (ii) the number of Parent Ordinary Shares subject to such Parent Equity Award at the time of
grant; (iii) the number of Parent Ordinary Shares subject to such Parent Equity Award as of the date of this Agreement; (iv) the exercise
price (if applicable) of such Parent Equity Award; (v) the date on which such Parent Equity Award was granted; (vi) the applicable vesting
schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration provisions; (vii)
the date on which such Parent Equity Award expires; and (viii) (A) the Tax route under which such Parent Equity Award was granted and
is currently intended to qualify (pursuant to Section 102 or Section 3(i) of the Ordinance), and (B) for Parent 102 Equity Awards, the
date of the applicable corporate approval and the date of deposit of the respective award agreement with the 102 Trustee. The Parent
has made available to the Company an accurate and complete copy of the Parent Plans and all share award agreements evidencing outstanding
awards granted thereunder. Except as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.6(c)</span> of the Parent Disclosure Schedule, no vesting
of Parent Equity Awards will accelerate in connection with the closing of the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 511 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;All Parent Equity
Awards granted under Section 102 of the Ordinance were granted under an employee option plan deemed approved, or not rejected within
30 days from filing, by the ITA under the capital gains route of Section 102 of the Ordinance and comply in all respects with the requirements
of Section 102 of the Ordinance and qualify for treatment under the capital gain route thereunder, and were duly and timely deposited
in accordance with the provisions of Section 102 of the Ordinance with the 102 Trustee and no action has been threatened against Parent
(nor is Parent aware of a reasonable basis for an action against Parent) with respect to the failure of Parent to comply with such requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>3.6(e)
</span>of the Parent Disclosure Schedule lists, as of the date of this Agreement: (i) each holder of issued and outstanding Parent Warrants,
(ii) the number and type of shares subject to each Parent Warrant, (iii) the exercise price of each Parent Warrant and (iv) the termination
date of each Parent Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;Except for the Parent
Warrants, the Parent Share Plans, including the Parent Equity Awards, and as otherwise set forth on <span style="text-decoration:underline">Section <b>&#8206;</b>3.6(f)<b>&#8206;
</b></span>of the Parent Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not
currently exercisable) to acquire shares or other securities of Parent; (ii) outstanding security, instrument or obligation that is or
may become convertible into or exchangeable for any shares or other securities of Parent; or (iii) condition or circumstance that is
reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled
to acquire or receive any shares or other securities of Parent. There are no outstanding or authorized share appreciation, phantom shares,
profit participation or other similar rights with respect to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;All outstanding Parent
Ordinary Shares, Parent Equity Awards, Parent Warrants and other securities of Parent have been issued and granted in material compliance
with: (i) all applicable securities Laws and other applicable Law, and (ii) all requirements set forth in applicable Contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;The Parent Pre-Funded
Warrants legally bind the Parent and are enforceable against the Parent in accordance with their terms. The Parent Pre-Funded Warrants
and the transactions contemplated thereby were duly approved by all required corporate approvals of the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 512 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7&#160;<b><span style="text-decoration:underline">SEC Filings;
Financial Statements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Parent has delivered
or made available to the Company accurate and complete copies of all registration statements, proxy statements, Certifications (as defined
below) and other statements, reports, schedules, forms and other documents filed by Parent with the SEC since January 1, 2021 (the &#8220;<b><i>Parent
SEC Documents</i></b>&#8221;), other than such documents that can be obtained on the SEC&#8217;s website at <span style="text-decoration:underline">www.sec.gov</span>. All material
statements, reports, schedules, forms and other documents required to have been filed by Parent or its officers with the SEC have been
filed on a timely basis. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this
Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements
of the Securities Act or the Exchange Act (as the case may be) and, as of the time they were filed, none of the Parent SEC Documents
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements
required by: (i) Rule 13a-14 under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section 906 of the Sarbanes-Oxley Act) relating to
the Parent SEC Documents (collectively, the &#8220;<b><i>Certifications</i></b>&#8221;) are accurate and complete and comply as to form
and content with all applicable Laws. As used in this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.7</span>, the term &#8220;file&#8221; and variations
thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made
available to the SEC. Parent has made available to the Company true and complete copies of all correspondences, other than transmittal
correspondences, between the SEC, on the one hand, and Parent, on the other, since January 1, 2021, including all SEC comment letters
and responses to such comment letters by or on behalf of Parent other than such documents that can be obtained on the SEC&#8217;s website
at <i><span style="text-decoration:underline">www.sec.gov</span></i>. As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received
from the SEC or Nasdaq with respect to the Parent SEC Documents. To the Knowledge of Parent, none of the Parent SEC Documents is the
subject of ongoing SEC review and there are no inquiries or investigations by the SEC or internal investigations pending or threatened,
including with regard to any accounting practices of Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The financial statements
(including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material
respects with the published rules and regulations of the SEC applicable thereto; (ii) were prepared in accordance with IFRS(except as
may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except as permitted by
Form 6-K of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring
year-end adjustments) applied on a consistent basis unless otherwise noted therein throughout the periods indicated; and (iii) fairly
present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations
and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to
the date hereof, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed
in Parent&#8217;s financial statements in accordance with IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Parent&#8217;s auditor
has at all times since its retention by Parent been: (i) to the Knowledge of Parent, a registered public accounting firm (as defined
in Section 2(a)(12) of the Sarbanes-Oxley Act); (ii) to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within
the meaning of Regulation S-X under the Exchange Act; and (iii) to the Knowledge of Parent, in compliance with subsections (g) through
(l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight
Board thereunder with respect to services provided to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 513 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Parent is in compliance
in all material respects with the applicable current listing and governance rules and regulations of Nasdaq. Except as set forth in <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>3.7(d)</span> of the Parent Disclosure Schedule and the Parent SEC Documents, from January 1, 2021 through the date hereof,
Parent has not received any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the
Parent Ordinary Shares on the Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Since January 1, 2021,
there have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with,
reviewed by or initiated at the direction of the chief executive officer or chief financial officer of Parent, the Parent Board or any
committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by
the Sarbanes-Oxley Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;Parent maintains a
system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with IFRS and to provide reasonable assurance: (i) that transactions are recorded as necessary to permit preparation
of financial statements in accordance with IFRS, (ii) that receipts and expenditures are made only in accordance with authorizations
of management and the Parent Board and (iii) regarding prevention or timely detection of the unauthorized acquisition, use or disposition
of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness
of Parent&#8217;s internal control over financial reporting as of September 30, 2023, and, to the extent required by applicable Law,
presented in any applicable Parent SEC Document that is a report on Form 20-F or Form 6-K (or any amendment thereto) its conclusions
about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment
based on such evaluation. Parent has disclosed, based on its most recent evaluation of internal control over financial reporting, to
Parent&#8217;s auditors and audit committee (and made available to the Company a summary of the significant aspects of such disclosure):
(A) all significant deficiencies, if any, in the design or operation of internal control over financial reporting that are reasonably
likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B) any known fraud
that involves management or other employees who have a significant role in Parent&#8217;s internal control over financial reporting.
Parent has not identified, based on its most recent evaluation of internal control over financial reporting, any material weaknesses
in the design or operation of Parent&#8217;s internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;Parent maintains &#8220;disclosure
controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are reasonably designed to ensure
that information required to be disclosed by Parent in the periodic reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the required time periods, and that all such information is accumulated and communicated to
Parent&#8217;s management as appropriate to allow timely decisions regarding required disclosure and to make the Certifications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 514 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.8&#160;<b><span style="text-decoration:underline">Absence of
Changes</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on <span style="text-decoration:underline">Section
&#8206;&#8206;3.8</span> of the Parent Disclosure Schedule, between the date of the Parent Balance Sheet and the date of this Agreement, Parent
has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the
discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material Adverse Effect or (b) action,
event or occurrence that would have required the consent of the Company pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;4.1(b)</span> had such action,
event or occurrence taken place after the execution and delivery of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9&#160;<b><span style="text-decoration:underline">Absence of
Undisclosed Liabilities</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, neither
the Parent nor Merger Sub has any Liability, individually or in the aggregate, whether or not of a type required to be recorded or reflected
on a balance sheet or disclosed in the footnotes thereto under IFRS except for: (a) Liabilities disclosed, reflected or reserved against
in the Parent Balance Sheet; (b) Liabilities that have been incurred by Parent since the date of the Parent Balance Sheet in the Ordinary
Course of Business; (c) Liabilities for performance of obligations of Parent under Parent Contracts; (d) Liabilities incurred in connection
with the Contemplated Transactions; (e) Liabilities which would not, individually or in the aggregate, reasonably be expected to be material
to Parent; and (f) Liabilities described in <span style="text-decoration:underline">Section &#8206;&#8206;3.9</span> of the Parent Disclosure Schedule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10&#160;<b><span style="text-decoration:underline">Real Property;
Leasehold</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in Section
&#8206;3.10 of the Parent Disclosure Schedule, the Parent does not own and since January 1, 2021 has not owned any real property. The Parent
has made available to Company: (i) an accurate and complete list of all real properties with respect to which the Parent directly or
indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Parent and
(ii) copies of all leases under which any such real property is possessed (the &#8221; <b><i>Parent Real Estate Leases</i></b>&#8221;),
each of which is in full force and effect, with no existing material default thereunder. The Parent&#8217;s use and operation of each
such leased property conforms to all applicable Laws in all material respects, and the Parent has exclusive possession of each such leased
property and has not granted any occupancy rights to tenants or licensees with respect to such leased property. In addition, each such
leased property is free and clear of all Encumbrances other than Permitted Encumbrances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.11&#160;<b><span style="text-decoration:underline">Intellectual
Property</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except as set forth
on <span style="text-decoration:underline">Section <b>&#8206;</b>2.12(a)</span> of the Parent Disclosure Schedule, the Parent does not own, license or otherwise have any right,
title or interest in any material Intellectual Property Rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;To the Knowledge of
the Parent the operation of the businesses of the Company as currently conducted does not infringe any valid and enforceable Registered
IP or misappropriate or otherwise violate any Intellectual Property Right owned by any other Person. As of the date of this Agreement,
no Legal Proceeding is pending (or, to the Knowledge of the Parent, is threatened in writing) against the Parent alleging that the operation
of the businesses of the Parent infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights
of another Person. The Parent has not received any written notice or other written communication alleging that the operation of the business
of the Parent infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 515 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;To the Knowledge of
the Parent, the Parent and the operation of the Parent&#8217;s business are in substantial compliance with all Laws pertaining to data
privacy and data security of any personally identifiable information and sensitive business information (collectively, &#8220;<b><i>Sensitive
Data</i></b>&#8221;) except to the extent that such noncompliance has not and would not reasonably be expected to have a Company Material
Adverse Effect. To the Knowledge of the Parent, since January 1, 2021, there have been: (i) no material losses or thefts of data or security
breaches relating to Sensitive Data used in the business of the Parent, (ii) no violations of any security policy of the Parent regarding
any such Sensitive Data, (iii) no unauthorized access or unauthorized use of any Sensitive Data used in the business of the Parent or
(iv) no unintended or improper disclosure of any personally identifiable information in the possession, custody or control of the Parent,
or a contractor or agent acting on behalf of the Parent, in each case of (i) through (iv), except as would not reasonably be expected
to, individually or in the aggregate, have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.12&#160;<b><span style="text-decoration:underline">Agreements,
Contracts and Commitments</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.12
</span>of the Parent Disclosure Schedule lists the following Parent Contracts in effect as of the date of this Agreement (each, a &#8220;<b><i>Parent
Material Contract</i></b>&#8221; and collectively, the &#8220;<b><i>Parent Material Contracts</i></b>&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;each Parent Contract
relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;each Parent Contract
containing: (A) any covenant limiting the freedom of the Parent to engage in any line of business or compete with any Person, (B) any
most-favored pricing arrangement, (C) any exclusivity provision, or (D) any non-solicitation provision;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;each Parent Contract
relating to capital expenditures and requiring payments after the date of this Agreement in excess of $200,000 pursuant to its express
terms and not cancelable without penalty;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;each Parent Contract
relating to the disposition or acquisition of material assets or any ownership interest in any entity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#160;each Parent Contract
relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating
to the borrowing of money or extension of credit or creating any material Encumbrances with respect to any assets of the Parent or any
loans or debt obligations with officers or directors of the Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#160;each Parent Contract
requiring payment by or to the Parent after the date of this Agreement in excess of $200,000 pursuant to its express terms relating to:
(A) any distribution agreement (identifying any that contain exclusivity provisions); (B) any dealer, distributor, joint marketing, alliance,
joint venture, cooperation or other agreement currently in force under which the Parent has continuing obligations to market any product,
technology or service; or (C) any Contract to license any third party to manufacture or produce any product, service or technology of
the Parent or any Contract to sell, distribute or commercialize any products or service of the Parent, in each case, except for Parent
Contracts entered into in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 516 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#160;each Parent Contract
with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the
Parent in connection with the Contemplated Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#160;each Parent Real
Estate Lease;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#160;each Parent Contract
with any Governmental Body;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#160;each Parent Contract
containing any royalty, dividend or similar arrangement based on the revenues or profits of the Parent; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#160;any other Parent
Contract that is not terminable at will (with no penalty or payment) by the Parent, and (A) which involves payment or receipt by the
Parent after the date of this Agreement under any such agreement, contract or commitment of more than $200,000 in the aggregate, or obligations
after the date of this Agreement in excess of $200,000 in the aggregate, or (B) that is material to the business or operations of the
Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The Parent has delivered
or made available to Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are
no Parent Material Contracts that are not in written form. The Parent has not, nor to the Parent&#8217;s Knowledge, as of the date of
this Agreement has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached,
violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such manner as would permit any other
party to cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably
be expected to be material to the Parent or its business. As to the Parent, as of the date of this Agreement, each Parent Material Contract
is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or
has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to the Parent under
any Parent Material Contract or any other material term or provision of any Parent Material Contract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.13&#160;<b><span style="text-decoration:underline">Compliance;
Permits</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Parent is in compliance
in all material respects with all U.S., Israeli and other applicable Laws, including the FDA regulations adopted thereunder, and any
other similar Law administered or promulgated by the FDA or other Drug Regulatory Agency, except for any noncompliance, either individually
or in the aggregate, which would not be material to Parent. No investigation, claim, suit, proceeding, audit or other action by any Governmental
Body is pending or, to the Knowledge of Parent, threatened against Parent. There is no agreement, judgment, injunction, order or decree
binding upon Parent which: (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business
practice of Parent, any acquisition of material property by Parent or the conduct of business by Parent as currently conducted, (ii)
is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this
Agreement, or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the
Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 517 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Parent holds all required
Governmental Authorizations which are material to the operation of the business of Parent as currently conducted (the &#8220;<b><i>Parent
Permits</i></b>&#8221;). <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.13(b)</span> of the Parent Disclosure Schedule identifies each Parent Permit. Parent
is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened,
which seeks to revoke, limit, suspend, or materially modify any Parent Permit. All of the Governmental Authorizations are valid and in
full force and effect, except where the invalidity of such Governmental Authorizations or the failure of such Governmental Authorizations
to be in full force and effect would not have a Parent Material Adverse Effect; and Parent has not received any notice of proceedings
relating to the revocation or modification of any such Governmental Authorizations which, singly or in the aggregate, would reasonably
be expected to result in a Parent Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.14&#160;<b><span style="text-decoration:underline">Legal Proceedings;
Orders</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;As of the date of
this Agreement, there is no material pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to
commence any Legal Proceeding: (i) that involves (A) Parent, (B) any Parent Associate (in his or her capacity as such) or (C) any of
the material assets owned or used by Parent; or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal
or otherwise interfering with, the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except as set forth
in <span style="text-decoration:underline">Section <b>&#8206;</b>3.14(b)</span><b>&#8206;</b> of the Parent Disclosure Schedule, since January 1, 2021, no Legal Proceeding has been
pending against Parent that resulted in material liability to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There is no order,
writ, injunction, judgment or decree to which Parent, or any of the material assets owned or used by Parent is subject. To the Knowledge
of Parent, no officer of Parent is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee
from engaging in or continuing any conduct, activity or practice relating to the business of Parent or to any material assets owned or
used by Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.15&#160;<b><span style="text-decoration:underline">Tax Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;Each Tax Return
required to be filed with any Governmental Body by Parent has been filed when due (taking into account extensions in the ordinary course
of business) in accordance with applicable Law, each of which is true, accurate and complete;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;Parent has timely
paid to the appropriate Governmental Body all Taxes due and payable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;Parent has complied
with all applicable Law relating to the payment and withholding of any Tax and has, within the time and in the manner prescribed by Law,
withheld and paid over to the proper Governmental Body all amounts required to be so withheld and paid over;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 518 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;Parent has established
adequate accruals or reserves, in accordance with IFRS, for all Taxes for taxable periods beginning on or after the date of the most
recent Parent financial statements;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#160;there is no Legal
Proceeding against or with respect to Parent in respect of any Tax or any Tax Return and there is no investigation against or with respect
to Parent, pending or threatened or otherwise in respect of any Tax or any Tax Return. All deficiencies asserted or assessments made
against Parent as a result of any examinations by any Governmental Body have been fully paid;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#160;Parent has not
consented or requested to extend the time, or is the recipient of any extension of time, in which any Tax may be assessed or collected
by any Governmental Authority and Parent has not waived any statute of limitations;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#160;no Governmental
Authority in a jurisdiction where no Tax Return has been filed or no Tax has been paid has made or threatened to make a claim for the
payment of any Tax or the filing of any Tax Return;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>3.15(a)(viii)</span> of the Parent Disclosure Schedule, no power of attorney granted by or with
respect to Parent for Taxes is currently in force, no ruling with respect to Taxes has been requested by or on behalf of Parent; and
no closing agreement pursuant to Section 7121 of the Code (or any predecessor provision) or any similar provision of any state, local
or non-U.S. Law has been entered into or requested by or with respect to Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#160;Parent has provided
or made available to the Company prior to the date hereof true, correct and complete copies of all material Tax Returns, examination
reports, and statements of deficiencies filed, assessed against, or agreed to by Parent with respect to Taxes and all material written
correspondence with any Governmental Authority regarding Taxes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#160;[Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#160;Parent is not and
has not been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable
period specified in Section 897(c)(1)(A)(ii) of the Code;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii)&#160;Parent will not
be required to include any item of income in, or exclude any item of deduction from, taxable income for (A) any Tax period (or portion
thereof), as a result of any deferred foreign income within the meaning of Section 965 of the Code, including, but not limited to, as
the result of an election under Section 965(h) of the Code, or (B) any Tax period (or portion thereof) ending after the Closing Date,
as a result of any (1) deferred intercompany gain or any excess loss account described in Treasury Regulations under Section 1502 of
the Code (or any corresponding provision of state, local or non-U.S. Tax Law); (2) installment sale or other open transaction disposition
made on or prior to the Closing Date; (3) prepaid amount, refund or credit received on or prior to the Closing Date; (4) change in accounting
method for a taxable period ending on or prior to the Closing Date; (5) use of an improper method of accounting for a taxable period
ending on or prior to the Closing Date; or (6) &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any corresponding
or similar provision of state, local or non-U.S. Tax Law) executed on or prior to the Closing Date;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 519 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii)&#160;all material
records which Parent is required to keep for Tax purposes or which would be needed to substantiate any claim made or position taken in
relation to Taxes by Parent, have been duly kept and are available for inspection at the premises of Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv)&#160;Parent is in compliance
in all material respects with all terms and conditions of any Tax exemption, Tax holiday or other Tax reduction agreement or order of
a Governmental Body;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv)&#160;all of Parent&#8217;s
property that is subject to property Tax has been properly listed and described on the property Tax rolls of the appropriate Tax jurisdiction
and no portion of any Parent&#8217;s property constitutes omitted property for property Tax purposes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi)&#160;there are no Liens
for Taxes on any of the assets of Parent other than for any Taxes not yet due and payable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii)&#160;Parent has not
ever (A) participated or engaged in any transaction listed in Section 131(g) of the Ordinance and the Israeli Income Tax Regulations
(Reportable Tax Planning), 5767-2006, promulgated thereunder; (B) taken a tax position that is subject to reporting under Section 131E
of the Ordinance; (C) obtained a legal or tax opinion that is subject to reporting under Section 131D of the Ordinance; or (D) performed
or been part of any action or transaction that is classified as a &#8220;reportable opinion&#8221; under Section 67C of the Israeli VAT
Law or a &#8220;reportable position&#8221; under Section 67D of the Israeli VAT Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii)&#160;Parent is duly
registered for the purposes of Israeli value added tax and has complied in all respects with all requirements concerning VAT. Parent
(i) has not made any exempt transactions (as defined in the Israeli Value Added Tax Law, 5736-1975) and there are no circumstances by
reason of which there might not be an entitlement to full credit of all VAT chargeable or paid on inputs, supplies, and other transactions
and imports made by it, (ii) has collected and remitted in a timely manner to the ITA all output VAT which it is required to collect
and remit under any applicable Law and (iii) has not received a refund for input VAT for which it is not entitled under any applicable
Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xix)&#160;each of the Parent
Share Plans that is intended to qualify as a capital gains route plan under Section 102 of the Ordinance has received a favorable determination
or approval letter from or is otherwise approved by or deemed approved by passage of time without objection by, the ITA. All Parent 102
Equity Awards and Parent 102 Shares have been granted and issued, as applicable, in compliance with the applicable requirements of Section
102 of the Ordinance and the written requirements and guidance of the ITA, including the filing of the necessary documents with the ITA,
the appointment of an authorized trustee, and the due deposit of such securities with the 102 Trustee pursuant to the terms of Section
102 of the Ordinance and the guidance published by the ITA on July 24, 2012, and clarification dated November 6, 2012;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xx)&#160;409A. The Parent
believes in good faith that any &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section 409A(d)(1)
of the Code and the guidance thereunder) under which the Parent makes, is obligated to make or promises to make, payments (each, a &#8220;409A
Plan&#8221;) complies in all material respects, in both form and operation, with the requirements of Section 409A of the Code and the
guidance thereunder. To the knowledge of the Company, no payment to be made under any 409A Plan is, or will be, subject to the penalties
of Section 409A(a)(1) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 520 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxi)&#160;Parent is not
and has never been a real property corporation (Igud Mekarke&#8217;in) within the meaning of this term under Section 1 of the Israeli
Land Taxation Law (Appreciation and Acquisition), 5723-1963;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxii)&#160;neither Parent
nor any holder of Parent securities is subject to any restrictions or limitations pursuant to Part E2 of the Ordinance or pursuant to
any Tax ruling made with reference to the provisions of Part E2;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxiii)&#160;no independent
contractor was, or to the Knowledge of Parent will be, entitled to be considered to be an employee of Parent by any applicable Tax authority;
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Parent has not (nor
has it ever had) any (A) place of management, (B) branch, (C) office (or any other place of business), (D) operations or employees, (E)
agent with binding authority, or (F) other activities, in each case that gives rise to a permanent establishment or taxable presence
which has subjected it to any Tax obligation or to a requirement to file any Tax return in any country other than the country where Parent
was organized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Parent is not, nor
at any time has been, engaged in the conduct of a trade or business within the United States within the meaning of Section 864(b) or
Section 882(a) of the Code, or considered to be so engaged under Section 882(d) or Section 897 of the Code or, if applicable, considered
to have a U.S. permanent establishment as defined under any applicable or relevant bilateral income tax treaty or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;(i) Parent is not,
nor has been, a party to any Tax Sharing Agreement (other than an agreement exclusively between or among Parent and its Subsidiaries)
pursuant to which it will have any obligation to make any payments for Taxes after the Closing Date, (ii) Parent has never been a member
of a group filing a consolidated, combined or unitary Tax Return (other than a group the common parent of which is or was Parent or any
of its Subsidiaries), and (iii) Parent has no liability for the payment of any Tax imposed on any Person (other than Parent) as a transferee
or successor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Parent has never taken
a position that could give rise to substantial understatement of income tax within the meaning of Section 6662 of the Code (or any corresponding
provision of state, local or non-U.S. Tax Law) or has ever been a beneficiary or otherwise participated in any &#8220;reportable transaction&#8221;
as defined in Code Section 6707A(c)(1)) and Treasury Regulation Section 1.6011-4(b)(1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;With the exception
of Israeli VAT, Parent is not, nor is required to be, registered as a taxable person for purpose of value added Taxes or any similar
indirect Tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For purposes of this <span style="text-decoration:underline">Section
<b>&#8206;</b>3.15</span>, each reference to Parent shall be deemed to include any Person that was liquidated into, merged with, or is otherwise
a predecessor to, Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 521 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.16&#160;<b><span style="text-decoration:underline">Transactions
with Affiliates</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except as set forth
in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent&#8217;s last proxy statement filed in
2023 with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>3.16(b)
</span>of the Parent Disclosure Schedule describes any material transactions or relationships, since January 1, 2021, between, on one hand,
the Parent on the other hand, any: (i) executive officer or director of the Parent or, to the Knowledge of the Parent or any of such
executive officer&#8217;s or director&#8217;s immediate family members, (ii) owner of more than 5% of the voting power of the outstanding
Parent Share Capital or (iii) to the Knowledge of the Parent, any &#8220;related person&#8221; (within the meaning of Item 404 of Regulation
S-K under the Securities Act) of any such officer, director or owner (other than the Parent) in the case of each of sub-limb (i), (ii)
or (iii) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There is no Investor
Agreement between the Parent and any holders of Parent Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.17&#160;<b><span style="text-decoration:underline">Employee
and Labor Matters; Benefit Plans</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>3.17(a)
</span>of the Parent Disclosure Schedule is a list of all material Parent Benefit Plans, including, without limitation, each Parent Benefit
Plan that provides for change in control, stay or retention, deferred compensation, incentive compensation, pension and severance benefits.
&#8220;<b><i>Parent Benefit Plan</i></b>&#8221; means each pension, profit sharing, bonus, incentive, equity or equity-based, phantom
equity, employment (other than at-will employment offer letters or employment agreement on the Parent&#8217;s standard form as may be
amended from time to time and other than individual Parent Options or other compensatory equity award agreements made pursuant to the
Parent&#8217;s standard forms, in which case only representative standard forms of such agreements shall be scheduled) and fringe benefit
plan, program, agreement (including collective bargaining agreement and extension order), policy or arrangement (whether written or unwritten,
but excluding statutory benefits or benefits mentioned in the Parent&#8217;s standard form of employment agreement) for the benefit of
any current or former employee, director, officer or independent contractor of the Parent or any of its Subsidiaries or under which the
Parent or any of its Subsidiaries has any actual or contingent liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;As applicable with
respect to each material Parent Benefit Plan, the Parent has made available to Company true and complete copies of each material Parent
Benefit Plan, including all amendments thereto, and in the case of an unwritten material Parent Benefit Plan, a written description thereof,
and all material correspondence to or from any Governmental Body with respect to each Parent Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Each Parent Benefit
Plan has been established, maintained, operated and administered in compliance in all material respects with its terms and all applicable
Laws. Each Parent Benefit Plan required to be funded is fully funded, and with respect to Parent Share Plans that are not required by
applicable Law to be so fully funded, adequate reserves therefor have been established on the Parent Financials (except for severance
pay that is fully funded, and full Section 14 Arrangements apply to all of the Parent&#8217;s employees). No material liability or obligation
of the Company or any of its Affiliates exists with respect to any Parent Benefit Plan that has not been disclosed in <span style="text-decoration:underline">Section <b>&#8206;</b>3.17<b>&#8206;</b>(c)
</span>of the Parent Disclosure Schedule. The Parent does not have, and has never had, any employees in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 522 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;To the Knowledge of
the Parent, there are no pending audits or investigations by any Governmental Body involving any Parent Benefit Plan, and no pending
or, to the Knowledge of the Parent, threatened claims (except for individual claims for benefits payable in the normal operation of the
Parent Benefit Plans), suits or proceedings involving any Parent Benefit Plan in any case except as would not be reasonably expected
to result in material liability to the Parent. The Parent does not have any Company Benefit Plan that is maintained in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Neither the execution
of, nor the performance of the Contemplated Transactions will either alone or in connection with any other event(s): (i) result in any
material payment becoming due to any current or former employee, director, officer, or independent contractor of the Parent, (ii) increase
any material amount of compensation or benefits otherwise payable under any Parent Benefit Plan, (iii) result in the acceleration of
the time of payment, funding or vesting of any benefits under any Parent Benefit Plan, (iv) require any material contribution or payment
to fund any obligation under any Parent Benefit Plan or (v) limit the right to merge, amend or terminate any Parent Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;&#8206;&#8206;</b>3.17(f)
</span>of the Parent Disclosure Schedule sets forth the policy of the Parent with respect to accrued vacation, accrued sick time and earned
time off and the amount of such liabilities, including regarding bonuses to employees and independent contractors for the last two years,
as of the date of this Agreement (in the case of accrued vacation, per employee for those who have more than 44 accrued days). The Parent
does not have and has not had a policy regarding the payment of bonuses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;The Parent is not
a party to, is not bound by, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a
labor union, labor organization, or similar Person representing any of its employees, and to the Knowledge of the Parent, there is no
labor union, labor organization, or similar Person representing or purporting to represent or seeking to represent any employees of the
Parent. There is not and has not been in the past three years, nor is there or has there been in the past three years any threat of,
any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or,
to the Knowledge of the Parent, any union organizing activity, against the Parent. No event has occurred, and no condition or circumstance
exists, that might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown,
work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of the
Parent, any union organizing activity. The Parent has paid all required payments, if any, that the Parent has been requested to pay to
any employers&#8217; association or organization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>3.17<b>&#8206;</b>(h)
</span>of the Parent Disclosure Schedule contains a list of all employees of the Parent and its Subsidiaries along with the position, the
monthly rate of salary of each such employee, whether such employee is full time or part time, is exempt or non-exempt from the Hours
of Work and Rest Law, is on leave and if so, the type of leave and expected date of return, visa status (as applicable), date of hire,
any incentive payment paid or payable in calendar year 2023 (and whether such incentive is cash or, if not, what other property is due),
short-term or temporary basis, vacation entitlement and accrued vacation or paid time-off balance, car entitlement, sick leave entitlement
and accrual (if any), and recuperation pay entitlement and accrual, pension entitlements and provident funds (including manager&#8217;s
insurance, pension fund, education fund and health fund), their respective contribution rates for each component (<i>e.g.,</i> severance
component, pension savings and disability insurance) and the salary basis for such contributions, severance entitlements (including whether
such employee, to the extent employed in the State of Israel, is subject to a Section 14 arrangement under the Severance Pay Law, 5723-1963
(the &#8220;<b><i>Israeli Severance Pay Law</i></b>&#8221; and &#8220;<b><i>Section 14 Arrangement</i></b>&#8221;), and, to the extent
such employee is subject to such a Section 14 Arrangement, an indication of whether such arrangement (or other applicable pension arrangement)
has been applied to such person from the commencement date of their employment and on the basis of their entire salary including other
compensation (e.g., commission), main work location, notice period entitlement, and any other material compensation payable to such employee.
Neither the Parent nor its Subsidiaries is delinquent in payments to any employees for wages, salaries, commissions or bonuses for services
performed as of the date hereof or amounts required by applicable Law to be reimbursed to such employees. The consummation of the Contemplated
Transactions will not give rise to any liability of the Parent or any of its Subsidiaries for payments related to severance, termination,
bonus, accrued vacation or personal time, accrued days of sick pay or any similar payment. No current employee of the Parent or any of
its Affiliates is or was, during the period of such employment or other service, based in or resident of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 523 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;<span style="text-decoration:underline">Section </span><b>&#8206;</b>3.17<b>&#8206;</b>(i)
of the Parent Disclosure Schedule contains a list of each individual who currently renders services to Parent as an independent contractor
or consultant (collectively, the &#8220;<b><i>Parent Contractors</i></b>&#8221;) and the Parent has made available to Company true and
complete copies of each Parent Contractors agreement and the last 3 months invoices. The Parent has accurately classified each such Parent
Contractor or former Parent Contractor as an independent contractor under all applicable Laws (including for purposes of Taxes and Tax
reporting and under the Company Benefit Plans). Except as set forth in <span style="text-decoration:underline">Section <b>&#8206;</b></span><b>&#8206;</b>3.17<b>&#8206;</b>(i) of
the Parent Disclosure Schedule, each Parent Contractor can be terminated on notice of thirty days or less to the Parent Contractor. According
to the Parent Contractors&#8217; agreements with the Parent, no Parent Contractor is entitled to any rights under the applicable labor
laws. All current and former Parent Contractors have received all their rights to which they are and were entitled according to any applicable
Law or Contract with the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#160;The Parent is not
delinquent in payments to any employees for wages, salaries, commissions or bonuses for services performed as of the date hereof or amounts
required by applicable Law to be reimbursed to such employees. The employment seniority for each employee for any employment purposes
began as of the date of hire and prior to such date no employment relations existed between any employee and the Parent for any matter
or purpose. The Parent has withheld, paid and reported all amounts required by the Ordinance, the National Insurance Law [Consolidated
Version], 5755-1995, and the National Health Insurance Law, 5754-1994 regarding its current and former employees and Parent Contractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#160;The Parent is, and
since January 1, 2021 has been, in material compliance with all applicable Laws and agreements (including collective bargaining agreements
and extension orders) respecting labor (including consultants), employment, employment practices, and terms and conditions of employment,
including proper classification of independent contractors as not being employees. There are no actions, suits, claims, charges, lawsuits,
investigations, audits or administrative matters pending or, to the Knowledge of the Parent, threatened or reasonably anticipated against
the Parent relating to any employee, applicant for employment, consultant, employment agreement or Parent Benefit Plan (other than routine
claims for benefits).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#160;There is not and has
not been in the past three years, nor is there or has there been in the past three years any threat of, any material claim, charge, grievance
or Legal Proceeding against the Parent brought by or on behalf of any current or former applicant, employee, independent contractor,
subcontractor, leased employee, volunteer, or temporary employee of the Parent, alleging violation of any applicable employment Law,
agreement or any other claim arising out of such Person&#8217;s employment, application for employment or termination of employment,
consulting or other relationship with the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 524 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: 002 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m) At all times, the Parent
has not engaged any employees whose employment would require special licenses or permits by the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n) The Parent&#8217;s obligations
to provide statutory severance pay to its Israeli employees pursuant to the Israeli Severance Pay Law are fully funded in accordance
with Section 14 Arrangements and it is and was implemented properly, from the commencement date of each employee&#8217;s employment and
on the basis of 8.33% of the employee&#8217;s entire salary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o) The Parent has not been
and is not subject to, and none of its employees or consultants benefits from, any collective agreement, extension order (<i>tzavei harchave</i>)
or any general contract or arrangement with respect to employment or termination of employment, except those extension orders that apply
to all Israeli companies generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p) Each employee of the Parent
is a party to a confidentiality, non-competition and protection of intellectual property agreement with the Parent; copies of such agreements
have previously been delivered, or made available, to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q) No group of employees has
notified the Parent of its intent, or, to the Knowledge of the Parent, has any plans, to terminate employment with the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r) The Parent does not have
unsatisfied obligations of any nature to any of its former employees or consultants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.18 <b><span style="text-decoration:underline">Environmental
Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is, and since
January 1, 2021 has been, in compliance with all applicable Environmental Laws, which compliance includes the possession by the Parent
of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions
thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected
to be material to the Parent or its business. The Parent has not received since January 1, 2021 (or prior to that time, which to the
Knowledge of the Parent is pending and unresolved), any written notice or other communication (in writing or otherwise), whether from
a Governmental Body or other Person, that alleges that the Parent is not in compliance with or has liability pursuant to any Environmental
Law and, to the Knowledge of the Parent, there are no circumstances that would reasonably be expected to prevent or interfere with the
Parent&#8217;s compliance in any material respects with any Environmental Law, except where such failure to comply would not reasonably
be expected to be material to the Parent or its business. No current or (during the time a prior property was leased or controlled by
the Parent) prior property leased or controlled by the Parent has had a release of or exposure to Hazardous Materials in material violation
of or as would reasonably be expected to result in any material liability of the Parent pursuant to Environmental Law. No consent, approval
or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in connection
with the execution and delivery of this Agreement or the consummation of the Contemplated Transactions. Prior to the date hereof, the
Parent has provided or otherwise made available to Company true and correct copies of all material environmental reports, assessments,
studies and audits in the possession or control of the Parent with respect to any property leased or controlled by the Parent or any
business operated by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 525 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.19 <b><span style="text-decoration:underline">Insurance</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent has delivered or made
available to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and
arrangements relating to the business, assets, liabilities and operations of Parent. Each of such insurance policy is in full force and
effect and Parent is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications
from insurance carriers, since January 1, 2021, Parent has not received any notice or other communication regarding any actual or possible:
(i) cancellation or invalidation of any insurance policy; or (ii) refusal or denial of any coverage, reservation of rights or rejection
of any material claim under any insurance policy. Parent has provided timely written notice to the appropriate insurance carrier(s) of
each Legal Proceeding that is currently pending against Parent for which Parent has insurance coverage, and no such carrier has issued
a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent of its intent to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.20 <b><span style="text-decoration:underline">No Financial Advisors</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on <span style="text-decoration:underline">Section
&#8206;&#8206;3.20</span> of the Parent Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s
fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions to which it
is a party based upon arrangements made by or on behalf of Parent or Merger Sub.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.21 <b><span style="text-decoration:underline">Anti-Bribery</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither Parent nor any of
its directors, officers, employees or, to Parent&#8217;s Knowledge, agents or any other Person acting on their behalf has directly or
indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other
payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of Anti-Bribery Laws. Parent is not nor has
ever been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.22 <b><span style="text-decoration:underline">Valid Issuance</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parent Ordinary Shares
to be issued in the Merger (including the Parent Ordinary Shares issuable upon exercise of the Parent Pre-Funded Warrants) will, when
issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.23 <b><span style="text-decoration:underline">Valuation Report
of Financial Advisor</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parent Board has received
the valuation report prepared by E.D.B. Consulting and Investments Ltd., and has determined based on the value of the Company estimated
therein, that, as of the date of this Agreement and subject to the assumptions, qualifications, limitations and other matters set forth
therein, the Exchange Ratio is fair, from a financial point of view to the holders of Parent Ordinary Shares. It is agreed and understood
that such valuation report is for the benefit of the Parent Board and may not be relied upon by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 526 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.24 <b><span style="text-decoration:underline">Disclaimer of
Other Representations or Warranties</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in this
<span style="text-decoration:underline">Section &#8206;3</span> or in any certificate delivered by Parent or Merger Sub to the Company pursuant to this Agreement, neither Parent
nor Merger Sub makes any representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets,
liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">4.
<b><span style="text-decoration:underline">CERTAIN COVENANTS OF THE PARTIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1 <b><span style="text-decoration:underline">Operation of Parent&#8217;s
Business</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Except as set forth in
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>4.1(a)</span> of the Parent Disclosure Schedule, as expressly permitted by this Agreement (including the consummation
of a Closing Financing), as required by applicable Law or unless the Company shall otherwise consent in writing (which consent shall
not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until
the earlier to occur of the termination of this Agreement pursuant to <span style="text-decoration:underline">Section <b>&#8206;</b>9</span> and the Effective Time (the &#8220;<b><i>Pre-Closing
Period</i></b>&#8221;): (i) Parent shall conduct its business and operations in the Ordinary Course of Business subject to and without
derogating from any of the Parent&#8217;s covenants set forth in <span style="text-decoration:underline">Section &#8206;<b>&#8206;</b>4.1(b)</span>; (ii) Parent shall conduct its
business and operations in compliance in all material respects with all applicable Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Except: (i) as expressly
permitted by this Agreement, (ii) as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>4.1(b)</span> of the Parent Disclosure Schedule, (iii) for
entering into and consummating the Closing Financing, (iv) as required by applicable Law, or (v) with the prior written consent of the
Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent
shall not do any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) declare, accrue, set
aside or pay any dividend or make any other distribution in respect of any of its shares or make any other actual, constructive or deemed
distribution in respect of the Parent Share Capital, or directly or indirectly acquire, repurchase, redeem or otherwise reacquire any
of its shares or other securities (except in connection with the payment of the exercise price and/or withholding Taxes incurred upon
the exercise, settlement or vesting of any award granted under the Parent Share Plans and in accordance with their current terms);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) sell, issue, grant,
pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any shares or other security of Parent
(except for Parent Ordinary Shares issued upon the valid exercise of outstanding Parent Equity Awards or Parent Warrants); (B) any option,
warrant or right to acquire any shares or any other security; or (C) any instrument convertible into or exchangeable for any shares or
other security of Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) except as required
to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any
merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, share split, reverse share
split, or similar transaction except, for the avoidance of doubt, the Contemplated Transactions and as permitted by this Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 527 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv) propose to adopt a plan
of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the
Parent, or elect or appoint any new directors or executive officers of the Parent, except for the transactions contemplated by this Agreement
and actions and resolutions adopted in the course of its implementation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v) form any Subsidiary or
acquire any equity interest or other interest in any other Entity or enter into a joint venture, strategic alliance or partnership with
any other Entity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi) acquire or agree to
acquire (by merger, consolidation or acquisition of s or assets or by any other manner) (1) any business or other Person, or (2) any
assets that are material, individually or in the aggregate, to the Parent, or (3) sell, lease (as lessor), license or otherwise dispose
of or subject to any Lien any properties or assets of the Parent, which are material to the Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii) (A) lend money to any
Person, (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, or (D) make any capital
expenditure in excess of the budgeted capital expenditure amounts set forth in Parent operating budget set forth in Section <b><i>&#8206;</i></b>4.1(b)(vii)of
the Parent Disclosure Schedule (the &#8220;<b><i>Parent Budget</i></b>&#8221;); other than as required by applicable Law or the terms
of any Parent Benefit Plan as in effect on the date of this Agreement: (i) adopt, terminate, establish or enter into any Parent Benefit
Plan; (ii) cause or permit any Parent Benefit Plan to be amended in any material respect; (iii) pay any bonus or make any profit-sharing
or similar payment to, or increase the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable
to any of its directors, officers or employees except for the payment of annual bonuses according to the targets predetermined for the
year end 2023 (including any discretionary component); (iv) increase the severance or change of control benefits offered to any current
or new employees, directors or consultants or (v) hire, terminate or give notice of termination to any (x) officer or (y) employee whose
annual base salary is or is expected to be more than $25,000 per year;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii) recognize any labor
union, labor organization, or similar Person;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix) enter into any material
transaction;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x) acquire any material
asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such
assets or properties;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi) sell, assign, transfer,
license, sublicense or otherwise dispose of any material Parent IP;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii) make, change or revoke
any material Tax election, fail to pay any income or other material Tax as such Tax becomes due and payable (subject to good faith disputes
with respect to such Taxes), file any amendment making any material change to any Tax Return, settle or compromise any income or other
material Tax liability, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement, request or
consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material
Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than
six months), or adopt or change any material accounting method in respect of Taxes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 528 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii) (A) except as otherwise
set forth in the Parent Budget, make any expenditures, incur any Liabilities, settle, discharge or satisfy any claims, litigation or
obligations (absolute, accrued, asserted or unasserted, contingent or otherwise) or Liabilities, in each case, in amounts that exceed
the aggregate amount of the Parent Budget by $200,000, except for any amounts related to claims, litigations, obligations, or Liabilities
that are outstanding as of the date of this Agreement, or (B) cancel any material indebtedness for borrowed money (individually or in
the aggregate) or waive any claims or rights with a value in excess of $200,000, or (C) give any material discount, accommodation or
other concession (other than in the ordinary course of business consistent with past practice) in order to accelerate or induce the collection
of any receivable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv) enter into, engage
in or amend any transaction or Contract with any interested parties (Ba&#8217;alay Inyan);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv) other than as required
by Law or IFRS, take any action to change accounting policies or procedures;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi) cancel or fail to in
good faith seek to renew any material insurance policies;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii) apply for or accept
(x) any Government Grant from the IIA or any other Israeli Governmental Authority, or (y) any material Government Grants from any other
Governmental Authority; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii) agree, resolve or
commit to do any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing contained in this
Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the Effective
Time. Prior to the Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral
control and supervision over its business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2 <b><span style="text-decoration:underline">Operation of the
Company&#8217;s Business</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Except as set forth in
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>4.2(a)</span> of the Company Disclosure Schedule, as expressly permitted by this Agreement (including a Closing
Financing), as required by applicable Law or unless Parent shall otherwise consent in writing (which consent shall not be unreasonably
withheld, delayed or conditioned), during the Pre-Closing Period, the Company shall conduct its business and operations: (i) in the Ordinary
Course of Business subject to and without derogating from any of the Company&#8217;s covenants set forth in <span style="text-decoration:underline">Section<b>&#8206;</b> 4.2(b)
</span>&#8206;; and (ii) in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute
Company Material Contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 529 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Except: (i) as expressly
permitted by this Agreement, (ii) as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>4.2(b)</span> of the Company Disclosure Schedule, (iii) as
required by applicable Law or (iv) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed
or conditioned), at all times during the Pre-Closing Period, the Company shall not do any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) declare, accrue, set
aside or pay any dividend or make any other distribution in respect of any shares of its share capital or make any other actual, constructive
or deemed distribution in respect of Company Ordinary Shares, or directly or indirectly acquire, or repurchase, redeem or otherwise reacquire
any shares of its share capital or other securities (except in connection with the payment of the exercise price and/or withholding Taxes
incurred upon the exercise, settlement or vesting of any award granted under the Company Share Plans in accordance with their current
terms);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) sell, issue, grant,
pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any share capital or other security
of the Company (except for outstanding Company Ordinary Shares issued upon the valid exercise of Company Options); (B) any option, warrant
or right to acquire any share capital or any other security, other than award grants to employees and service providers; or (C) any instrument
convertible into or exchangeable for any share capital or other security of the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) except as required
to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any
merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, share split, reverse share
split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv) propose to adopt a plan
of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the
Company, or elect or appoint any new directors or executive officers of the Company, except for the transactions contemplated by this
Agreement and actions and resolutions adopted in the course of its implementation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v) form any Subsidiary or
acquire any equity interest or other interest in any other Entity or enter into a joint venture, strategic alliance or partnership with
any other Entity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi) acquire or agree to
acquire (by merger, consolidation or acquisition of shares or assets or by any other manner) (1) any business or other Person or (2)
any assets that are material, individually or in the aggregate, to the Company; or (3) other than in the Ordinary Course of Business,
sell, lease (as lessor), license or otherwise dispose of or subject to any Lien any properties or assets of the Company, which are material
to the Company, except for purchases of inventory, services or supplies in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii) (A) lend money to any
Person (except for the advance of expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incur or
guarantee any indebtedness for borrowed money, or (C) guarantee any debt securities of others;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii) recognize any labor
union, labor organization, or similar Person;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 530 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix) enter into any material
transaction other than in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x) acquire any material
asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such
assets or properties, except in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi) make, change or revoke
any material Tax election, fail to pay any income or other material Tax as such Tax becomes due and payable (subject to good faith disputes
with respect to such Taxes), file any amendment making any material change to any Tax Return, settle or compromise any income or other
material Tax liability, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than
customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request
or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material
Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than
six months), or adopt or change any material accounting method in respect of Taxes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii) enter into, materially
amend or terminate any Company Material Contract, except if such execution, amendment or termination is in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii) (A) except in the
Ordinary Course of Business, make any expenditures, incur any Liabilities, settle or discharge or satisfy any claims, litigation, obligations
(absolute, accrued, asserted or unasserted, contingent or otherwise) or Liabilities, or (B) cancel any material indebtedness for borrowed
money (individually or in the aggregate) or waive any claims or rights with a value in excess of $200,000, or (C) give any material discount,
accommodation or other concession (other than in the Ordinary Course of Business consistent with past practice) in order to accelerate
or induce the collection of any receivable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv) enter into, engage
in or amend any transaction or Contract with any interested parties (Ba&#8217;alay Inyan), except as required for the consummation of
the Closing ;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv) other than as required
by Law or IFRS, take any action to change accounting policies or procedures;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi) cancel or fail to in
good faith seek to renew any material insurance policies;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii) apply for or accept
(x) any Government Grant from the IIA or any other Israeli Governmental Authority, or (y) any material Government Grants from any other
Governmental Authority;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii) initiate or settle,
compromise, or agree to settle any Legal Proceeding; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xix) agree, resolve or commit
to do any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 531 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing contained in this
Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the Effective
Time. Prior to the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral
control and supervision over its business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3 <b><span style="text-decoration:underline">Access and Investigation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the
Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing
Period, upon not less than three (3) Business Days&#8217; notice, Parent, on the one hand, and the Company, on the other hand, shall
and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (a) provide the other Party and such other
Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property
and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and
its Subsidiaries; (b) provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records,
Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such
additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably
request; (c) permit the other Party&#8217;s officers and other employees to hold discussions, upon reasonable notice and during normal
business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial
statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary or appropriate and;
(d) make available to the other Party copies of unaudited financial statements, material operating and financial reports prepared for
senior management or the board of directors of such Party, and any material notice, report or other document filed with or sent to or
received from any Governmental Body in connection with the Contemplated Transactions. Any investigation conducted by either Parent or
the Company pursuant to this <span style="text-decoration:underline">Section &#8206;4.3</span> shall be conducted in such manner as not to interfere unreasonably with the conduct
of the business of the other Party. Each Party shall provide the other Party with unaudited cash balances promptly after such cash balances
are available to such Party, and with a statement of accounts payable of such Party as of the end of each calendar month, promptly after
such Party prepares such a statement, all to the extent prepared by and available to such Party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
any Party may restrict the foregoing access to the extent that any Law applicable to such Party requires such Party to restrict or prohibit
access to any such properties or information or as may be necessary to preserve the attorney-client privilege under any circumstances
in which such privilege may be jeopardized by such disclosure or access.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4 <b><span style="text-decoration:underline">Parent Non-Solicitation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Parent agrees that during
the Pre-Closing Period it shall not, nor shall it authorize any of its Representatives to, directly or indirectly: (i)&#160;solicit,
initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal
or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry;
(ii)&#160;furnish any non-public information regarding Parent to any Person in connection with or in response to an Acquisition Proposal
or Acquisition Inquiry; (iii)&#160;engage in discussions (other than to inform any Person of the existence of the provisions in this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.4</span>)
or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv)&#160;approve, endorse or recommend
any Acquisition Proposal (subject to&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>5.3</span>); (v)&#160;execute or enter into any letter of intent
or any Contract contemplating or otherwise relating to any Acquisition Transaction; or (vi)&#160;publicly propose to do any of the foregoing.
Without limiting the generality of the foregoing, Parent acknowledges and agrees that, in the event any Representative of Parent (whether
or not such Representative is purporting to act on behalf of Parent) takes any action that, if taken by Parent, would constitute a breach
of this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.4</span>, the taking of such action by such Representative shall be deemed to constitute
a breach of this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.4</span> by Parent for purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 532 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) If Parent or any Representative
of Parent receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then Parent shall promptly
(and in no event later than one Business Day after Parent becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the
Company orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting
such Acquisition Proposal or Acquisition Inquiry, and the material terms thereof). Parent shall keep the Company reasonably informed
with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or
proposed material modification thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Parent shall immediately
cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition
Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement and request the destruction or
return of any nonpublic information of Parent provided to such Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Section &#8206;4.4
shall be deemed to restrict Parent and its Representatives from communications, negotiations and entering into agreements to the extent
reasonably necessary for purposes of pursuing and completing for transactions that are specifically authorized by this Agreement, including
transactions related to the Closing Financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5 <b><span style="text-decoration:underline">Company Non-Solicitation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company agrees that,
during the Pre-Closing Period, the Company shall not, nor shall it authorize any of its Representatives to, directly or indirectly: (i)&#160;solicit,
initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal
or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry;
(ii)&#160;furnish any non-public information regarding the Company to any Person in connection with or in response to an Acquisition
Proposal or Acquisition Inquiry; (iii)&#160;engage in discussions (other than to inform any Person of the existence of the provisions
in this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.5</span>) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition
Inquiry; (iv)&#160;approve, endorse or recommend any Acquisition Proposal; (v)&#160;execute or enter into any letter of intent or any
Contract contemplating or otherwise relating to any Acquisition Transaction; or (vi)&#160;publicly propose to do any of the foregoing.
Without limiting the generality of the foregoing, the Company acknowledges and agrees that, in the event any Representative of the Company
(whether or not such Representative is purporting to act on behalf of the Company) takes any action that, if taken by the Company, would
constitute a breach of this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.5</span>, the taking of such action by such Representative shall be
deemed to constitute a breach of this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.5</span>&#160;by the Company for purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 533 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) If the Company or any Representative
of the Company receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then the Company shall
promptly (and in no event later than one Business Day after the Company becomes aware of such Acquisition Proposal or Acquisition Inquiry)
advise Parent orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making
or submitting such Acquisition Proposal or Acquisition Inquiry, and the material terms thereof). The Company shall keep Parent reasonably
informed with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification
or proposed material modification thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Company shall immediately
cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition
Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement and request the destruction or
return of any nonpublic information of the Company provided to such Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Section &#8206;4.5
shall be deemed to restrict Company and its Representatives from communications, negotiations and entering into agreements to the extent
reasonably necessary for purposes of pursuing and completing for transactions that are specifically authorized by this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6 <b><span style="text-decoration:underline">Notification of
Certain Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) During the Pre-Closing
Period, the Company shall promptly notify Parent (and, if in writing, furnish copies of) if any of the following occurs: (i) any notice
or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with
any of the Contemplated Transactions; (ii) any Legal Proceeding against or involving or otherwise affecting the Company is commenced,
or, to the Knowledge of the Company, threatened against the Company or, to the Knowledge of the Company, any director or officer of the
Company; (iii) the Company becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv) the
failure of the Company to comply with any covenant or obligation of the Company; in the case of sub-limbs (iii) and (iv) that could reasonably
be expected to make the timely satisfaction of any of the conditions set forth in <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>6 or <b>&#8206;</b></span>7
<b><span style="text-decoration:underline">&#8206;</span></b>, as applicable, impossible or materially less likely. No notification given to Parent pursuant to this <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>4.6(a)</span> shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations
of the Company contained in this Agreement or the Company Disclosure Schedule for purposes of <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>6 or <b>&#8206;</b></span>7,
as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) During the Pre-Closing
Period, Parent shall promptly notify the Company (and, if in writing, furnish copies of) if any of the following occurs: (i) any notice
or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with
any of the Contemplated Transactions; (ii) any Legal Proceeding against or involving or otherwise affecting Parent is commenced, or,
to the Knowledge of Parent, threatened against Parent or, to the Knowledge of Parent, any director or officer of Parent; (iii) Parent
becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv) the failure of Parent to comply
with any covenant or obligation of Parent or Merger Sub; in the case of sub-limbs (iii) and (iv) that could reasonably be expected to
make the timely satisfaction of any of the conditions set forth in <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>6</span> or <b>&#8206;</b><span style="text-decoration:underline">8</span>, as applicable,
impossible or materially less likely. No notification given to the Company pursuant to this <span style="text-decoration:underline">Section <b>&#8206;</b>4.6(b)</span> shall change,
limit or otherwise affect any of the representations, warranties, covenants or obligations of Parent contained in this Agreement or the
Parent Disclosure Schedule for purposes of <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>6</span> and <b>&#8206;</b><span style="text-decoration:underline">8</span>, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 534 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7 <b><span style="text-decoration:underline">Post-Closing Financing</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Closing, the Parent
shall deliver to the Company an amount of $4,250,000 (less any amount due by the Company to the Parent under any loan agreement between
the parties), by wire transfer of immediately available funds to an account, the details of which shall be provided by the Company, for
the Company&#8217;s ongoing capital requirements and operational expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">5.
<b><span style="text-decoration:underline">ADDITIONAL AGREEMENTS OF THE PARTIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1 <b><span style="text-decoration:underline">Court Approval,
Registration Statement and Transaction Report</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) As promptly as practicable
after the execution and delivery of this Agreement and in accordance with Sections 350 and 351 of the Companies Law, the Company shall
submit to the district court of Tel Aviv-Jaffa (the &#8220;<b><i>Applicable Court</i></b>&#8221;) a first motion to convene, in the manner
set forth in the Companies Law and the regulations promulgated pursuant to Sections 350 and 351 of the Companies Law and as shall otherwise
be ordered by the Applicable Court (the &#8220;<b><i>First Motion Approval</i></b>&#8221;), a shareholders meeting (the &#8220;<b><i>Company
Shareholders&#8217; Meeting</i></b>&#8221;) and, if required by the Applicable Court, a Bondholder or creditors meeting (collectively,
the &#8220;<b><i>Company Meetings</i></b>&#8221;) for the approval of the terms and conditions of an arrangement between the Company
and its shareholders, Bondholders and/or creditors, including the Merger, by a majority representing at least 75% of the votes cast at
the Company Meetings (the &#8220;<b><i>Section 350 Vote</i></b>&#8221;), together with a request to exempt from the need to publish a
prospectus by reason of Section 15A(a)(3) of the Israeli Securities Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) As promptly as practicable
after the execution of this Agreement, the Parties shall prepare and the Parent shall cause to be filed with the SEC, the Registration
Statement. Parent hereby covenants and agrees that the Registration Statement, including any pro forma financial statements included
therein (and the letter to shareholders, notice of meeting and form of proxy included therewith), will not, at the time that the Registration
Statement or any amendments or supplements thereto is filed with the SEC or declared effective by the SEC, contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made
therein not misleading. The Company hereby covenants and agrees that the information provided by the Company to Parent for inclusion
in the Registration Statement (including the Company Financials) will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make such information not misleading. Notwithstanding
the foregoing, Parent makes no covenant, representation or warranty with respect to statements made in the Registration Statement, if
any, based on information provided by the Company or any of their Representatives specifically for inclusion therein. The Company and
its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments
and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration
Statement, prior to the filing thereof with the SEC. Parent shall use commercially reasonable efforts to cause the Registration Statement
to comply with the applicable rules and regulations promulgated by the SEC and to respond promptly to any comments of the SEC or its
staff. Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s shareholders in accordance
with the applicable rules and regulations promulgated by the SEC. Each Party shall promptly furnish to the other Party all information
concerning such Party and such Party&#8217;s Affiliates and such Party&#8217;s shareholders that may be required or reasonably requested
in connection with any action contemplated by this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.1</span>. If Parent, Merger Sub or the Company become aware
of any event or information that, pursuant to the Exchange Act, should be disclosed in an amendment or supplement to the Registration
Statement, then such Party shall promptly inform the other Parties thereof and shall cooperate with such other Parties in filing such
amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to Parent&#8217;s shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 535 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) As promptly as practicable
after the execution of this Agreement, the Parties shall prepare, and as soon as practicable after the First Motion Approval, the Company
shall cause to be filed with the ISA such notice of the Company Meetings to call, give notice of and hold the Company Meetings, which
shall include a transaction report as well as a proxy card (<i>Ktav Hatzbaa</i>) (such notice, transaction report and proxy card, collectively,
shall be referred to herein as the &#8220;<b><i>Transaction Report</i></b>&#8221;), in order to obtain the Required Company Approval,
in each case for purposes of adopting and approving this Agreement and the Contemplated Transactions, including the Section 350 Vote
and the approval of the Restated Company Articles, (collectively, the &#8220;<b><i>Company Approval Matters</i></b>&#8221;). The Company
covenants and agrees that the Transaction Report, including any pro forma financial statements included therein (and the letter to shareholders,
notice of meeting and form of proxy included therewith), will not, at the time that the Transaction Report or any amendments or supplements
thereto is filed with the ISA contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
The Parent covenants and agrees that the information provided by the Parent to the Company for inclusion in the Transaction Report will
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in
order to make such information not misleading. Notwithstanding the foregoing, Company makes no covenant, representation or warranty with
respect to statements made in the Proxy Transaction Report (and the letter to shareholders, notice of meeting and form of proxy included
therewith), if any, based on information provided by the Parent or any of their Representatives specifically for inclusion therein. The
Parent and its legal counsel shall be given reasonable opportunity to review and comment on the Transaction Report, including all amendments
and supplements thereto, prior to the filing thereof with the ISA, and on the response to any comments of the ISA or the TASE on the
Transaction Report, prior to the filing thereof with the ISA. Company shall use commercially reasonable efforts to cause the Transaction
Report to comply with the applicable rules and regulations promulgated by the ISA and the TASE and to respond promptly to any comments
of the ISA, the TASE or its staff. Company covenants and agrees that the Transaction Report will comply in all respects with the requirements
of Israeli law. Each Party shall promptly furnish to the other Party all information concerning such Party and such Party&#8217;s Affiliates
and such Party&#8217;s shareholders that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration:underline">Section
&#8206;<b>&#8206;</b>5.1</span>. If Parent, Merger Sub or the Company become aware of any event or information that, should be disclosed in
an amendment or supplement to the Transaction Report, then such Party shall promptly inform the other Parties thereof and shall cooperate
with such other Parties in filing such amendment or supplement with the ISA and, if appropriate, in mailing such amendment or supplement
to the Company&#8217;s shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) The Parties shall reasonably
cooperate with each other and provide, and require their respective Representatives to provide, the other Party and its Representatives,
with all true, correct and complete information regarding such Party or its Subsidiaries that is required by Law to be included in the
Registration Statement and/or the Transaction Report or reasonably requested by the other Party to be included in the Registration Statement
and or/the Transaction Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 536 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <b><span style="text-decoration:underline">Company Meetings</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company agrees that:(i)
the Company Board shall recommend that the Company&#8217;s shareholders and if applicable, the Company&#8217;s Bondholders and/or creditors
vote to approve the Company Approval Matters and shall use reasonable best efforts to solicit such approval (the recommendation of the
Company Board that the Company&#8217;s shareholders, creditors or Bondholders (as applicable) vote to adopt and approve this Agreement
being referred to as the &#8220;<b><i>Company Board Recommendation</i></b>&#8221;); and (ii) the Company Board Recommendation shall not
be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in
a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation
in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition
Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (ii), collectively, a &#8220;<b><i>Company Board
Adverse Recommendation Change</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) As part of the notice of
the Company Meetings, the Company will deliver to each of its shareholders, and if applicable, creditors and Bondholders, a notice of
the meetings, the order of the court to convene the meetings, the application for the approval of the proposed Merger submitted to the
court and a proxy card for the vote (the &#8220;<b><i>Proxy Materials</i></b>&#8221;). The Proxy Materials will include a description
of the rights of a shareholder to object to the Merger, information on the hearing scheduled before the Applicable Court and the Company
Board Recommendation. Following the approval of the Merger by the shareholders and if applicable, creditors and Bondholders, as set forth
above, the Company will submit to the Applicable Court a second motion for the approval of the arrangement and the Merger and the order
of all actions to be taken in accordance with the Merger, including the exemption from the need to publish a prospectus by reason of
Section 15A(a)(3) of the Israeli Securities Law (these approvals when obtained shall be collectively referred to as the &#8220;<b><i>Court
Approval</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Company&#8217;s obligation
to solicit the Required Company Approval in accordance with <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.2(a)</span> and <span style="text-decoration:underline">Section <b>&#8206;</b>5.2(b)<b>&#8206;
</b></span>shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any other Acquisition
Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <b><span style="text-decoration:underline">Parent Shareholders&#8217;
Meeting; Merger Sub Approval</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Promptly as practicable
following the date the Registration Statement is declared effective by the SEC under the Securities Act, or later, in case the Parent
Board determines, after consultation with its outside counsel that it is likely that there are required changes/amendments to the Registration
Statement, Parent shall take all action necessary under applicable Law to call, give notice of and hold the Parent Shareholders&#8217;
Meeting for the purpose of seeking approval of (i) this Agreement and the Contemplated Transactions; (ii) to the extent applicable, the
adoption of the Restated Parent Articles (which shall include the change of the Parent&#8217;s company name); (iii) adoption of the form
of Indemnification Agreement, (iv) if not so appointed by the Parent Board, election to the post-Closing Parent Board of the candidates
designated by the Company to serve thereon in accordance with Section <b>&#8206;</b>5.13 below (provided that (i) if, in accordance with
Section <b>&#8206;</b>5.13 below, the Company designates two candidates to the post-Closing Parent Board, than one of them shall be appointed
or elected for three year term and another for two year term, and (ii) if, in accordance with Section <b>&#8206;</b>5.13 below, the Company
designates three candidates to the post-Closing Parent Board, than each to be classified to a different class of the Parent Board) and
(v) compensation to the directors and officers of the Parent (as of the Pre-Closing Period), all effective upon the Merger (the matters
contemplated by this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.3(a)</span> are referred to as the &#8220;<b><i>Parent Shareholder Matters</i></b>&#8221;
and such meeting, the &#8220;<b><i>Parent Shareholders&#8217; Meeting</i></b>).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 537 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Parent shall take reasonable
measures to ensure that all proxies solicited in connection with the Parent Shareholders&#8217; Meeting are solicited in compliance with
all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Shareholders&#8217; Meeting,
or a date preceding the date on which the Parent Shareholders&#8217; Meeting is scheduled, Parent reasonably believes that: (i) it will
not receive proxies sufficient to obtain the Required Parent Shareholder Vote, whether or not a quorum would be present, or (ii) it will
not have sufficient Parent Ordinary Shares to constitute a quorum necessary to conduct the business of the Parent Shareholders&#8217;
Meeting, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Shareholders&#8217;
Meeting as long as the date of the Parent Shareholders&#8217; Meeting is not postponed or adjourned more than an aggregate of 90 calendar
days in connection with any postponements or adjournments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Parent agrees that: (i)
the Parent Board shall recommend that Parent&#8217;s shareholders vote to approve the Parent Shareholder Matters, (ii) the Registration
Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s shareholders vote to approve the
Parent Shareholder Matters (the recommendation of the Parent Board with respect to the Parent Shareholder Matters being referred to as
the &#8220;<b><i>Parent Board Recommendation</i></b>&#8221;); and (iii) the Parent Board Recommendation shall not be withheld, amended,
withdrawn or modified (and the Parent Board shall not publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation)
without the Company&#8217;s prior written consent (the actions set forth in the foregoing clause (iii), collectively, a &#8220;<b><i>Parent
Board Adverse Recommendation Change</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) Nothing contained in this
Agreement shall prohibit Parent or Parent Board from making any disclosure to the Parent shareholders if the Parent Board determines
in good faith, after consultation with its outside legal counsel, that such disclosure is required for the Parent Board to comply with
its fiduciary duties to the Parent shareholders under applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) Without derogating from
the above, nothing contained in this Agreement shall prohibit Parent or the Parent Board from: (i) complying with Rule 14d-9 promulgated
under the Exchange Act, or (ii) issuing a &#8220;stop, look and listen&#8221; communication or similar communication of the type contemplated
by Section 14d-9(f) under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) Promptly after the execution
of this Agreement, and in any event within 2 Business Days, Parent, as the sole shareholder of Merger Sub, shall deliver to the Company
a unanimous written consent in lieu of a meeting that adopted and approved this Agreement and the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) Parent as the sole shareholder
of Merger Sub shall not take any action to rescind the unanimous written consent in lieu of a meeting that adopted and approved this
Agreement and the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 538 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4 <b><span style="text-decoration:underline">Regulatory Approvals</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Each Party shall use reasonable
best efforts to file or otherwise submit, as soon as practicable after the execution of this Agreement, all applications, notices, reports,
filings and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental
Body with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental
Body.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) No Party hereto shall take
any action that could reasonably be expected to adversely affect or materially delay the approval of any Governmental Body, or the expiration
or termination of any waiting period under any antitrust, competition or trade regulation Laws that are designed or intended to prohibit,
restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening competition through merger
or acquisition, including by agreeing to merge with or acquire any other person or acquire a substantial portion of the assets of or
equity in any other person. The parties hereto further covenant and agree, with respect to a threatened or pending preliminary or permanent
injunction or other order, decree or ruling or statute, rule, regulation or executive order that would adversely affect the ability of
the parties to consummate the Contemplated Transactions, to use reasonable best efforts to prevent or lift the entry, enactment or promulgation
thereof, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <b><span style="text-decoration:underline">Certificate of
Merger</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required under the Companies
Law, the Company and Merger Sub shall (and the Parent shall cause Merger Sub to) file any required filings with the Companies Registrar.
On the Closing Date and subject to the terms and conditions hereof, the Parties shall cause the Merger to be consummated by obtaining
a certificate of merger (the &#8220;<b><i>Merger Certificate</i></b>&#8221;) issued by the Companies Registrar. The Merger shall become
effective at such time as the Merger Certificate is issued and delivered by the Companies Registrar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6 <b><span style="text-decoration:underline">Company Options</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Each Company Option that
is outstanding and unexercised immediately prior to the Effective Time under the Company Share Plans, whether or not vested (taking into
account any acceleration of vesting as a result of the consummation of the Merger), shall be cancelled immediately prior to the Effective
Time for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Prior to the Effective
Time, the Company shall take all actions that may be necessary (under the Company Share Plans and otherwise) to effectuate the provisions
of this <span style="text-decoration:underline">Section <b>&#8206;</b>5.6</span> and to ensure that, from and after the Effective Time, holders of Company Options have no rights
with respect thereto other than those specifically provided in this <span style="text-decoration:underline">Section <b>&#8206;</b>5.6</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7 <b><span style="text-decoration:underline">Company Warrants</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Each Company Warrant that
is outstanding and unexercised immediately prior to the Effective Time, shall be cancelled immediately prior to the Effective Time for
no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Prior to the Effective
Time, the Company shall take all actions that may be necessary to effectuate the provisions of this <span style="text-decoration:underline">Section <b>&#8206;</b>5.7</span> and
to ensure that, from and after the Effective Time, holders of Company Warrants have no rights with respect thereto other than those specifically
provided in this <span style="text-decoration:underline">Section 5.7.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 539 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Company shall use its
reasonable best efforts to maintain the effectiveness of the Registration Statement under the Securities Act, including if necessary
the filing with and seeking effectiveness from the SEC of a replacement registration statement on an appropriate form, as long as the
Pre-Funded Warrants are outstanding following the Closing, for the purpose of registering the issuance of Parent Ordinary Shares upon
the exercise of any Parent Pre-Funded Warrants issued, pursuant to the terms of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8 <b><span style="text-decoration:underline">TASE De-Listing
of Company Ordinary Shares</span></b><span style="text-decoration:underline">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Effective Time,
the Company shall cooperate with Parent and use commercially reasonable best efforts to take, or cause to be taken, all actions, and
do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable Law and rules and policies
of the TASE to enable the de-listing of the Company Ordinary Shares from the TASE under the Israeli Securities Law effective as of the
Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9 <b><span style="text-decoration:underline">Additional Agreements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties shall (a) use
commercially reasonable efforts to cause to be taken all actions necessary to consummate the Contemplated Transactions and (b) reasonably
cooperate with the other Parties and provide the other Parties with such assistance as may be reasonably requested for the purpose of
facilitating the performance by each Party of its respective obligations under this Agreement and to enable the Surviving Company to
continue to meet its obligations under this Agreement following the Closing. Without limiting the generality of the foregoing, each Party
to this Agreement: (i) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given
by such Party in connection with the Contemplated Transactions; (ii) shall use reasonable best efforts to obtain each Consent (if any)
reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated
Transactions or for such Contract (with respect to Contracts set forth in <span style="text-decoration:underline">Section &#8206;2.5(d)</span> of the Company Disclosure Schedule)
to remain in full force and effect; (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other
legal bar to, the Contemplated Transactions; and (iv) shall use commercially reasonable efforts to satisfy the conditions precedent to
the consummation of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10 <b><span style="text-decoration:underline">Disclosure</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The initial press release
relating to this Agreement shall be a joint press release issued by the Company and Parent and thereafter Parent and the Company shall
consult with each other before issuing any further press release(s) or otherwise making any public statement or making any announcement
to Parent Associates or Company Associates (to the extent not previously issued or made in accordance with this Agreement) with respect
to the Contemplated Transactions and shall not issue any such press release, public statement or announcement to Parent Associates or
Company Associates without the other Party&#8217;s written consent (which shall not be unreasonably withheld, conditioned or delayed).
Notwithstanding the foregoing: (a) each Party may, without such consultation or consent, make any public statement in response to questions
from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and make disclosures
in Parent SEC Documents and/or Company TASE Documents, so long as such statements are consistent with previous press releases, public
disclosures or public statements made jointly by the parties (or individually, if approved by the other Party); (b) a Party may, without
the prior consent of the other Party hereto but subject to giving advance notice to the other Party, issue any such press release or
make any such public announcement or statement as may be required by any Law; and (c) a Party need not consult with the other Party in
connection with such portion of any press release, public statement or filing to be issued or made pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;5.3(e)
</span>or with respect to any Acquisition Proposal or Board Adverse Recommendation Change, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 540 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11 <b><span style="text-decoration:underline">Listing</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent shall use its commercially
reasonable efforts, to the extent required by the rules and regulations of Nasdaq (including pursuant to any applicable discretion afforded
to Nasdaq under such rules and regulations), to prepare and submit to Nasdaq a notification form for the listing of the Parent Ordinary
Shares to be issued in connection with the Contemplated Transactions (including the Parent Ordinary Shares issuable upon the exercise
of the Parent Pre-Funded Warrants) (the &#8220;<b><i>Nasdaq Notification</i></b>&#8221;). The Parties will use commercially reasonable
efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Company will cooperate with Parent as reasonably
requested by Parent with respect to the Nasdaq Notification, and promptly furnish to Parent all information concerning the Company and
its shareholders that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration:underline">Section &#8206;&#8206;5.11</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12 <b><span style="text-decoration:underline">Tax Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties will cooperate
in preparing and filing all Tax Returns of the Company that are required to be filed for any taxable periods ending on or before the
Closing Date. All such Tax Returns will be prepared by treating items on such Tax Returns in a manner consistent with the past practices
of the Company with respect to such items, except as required by applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13 <b><span style="text-decoration:underline">Directors and
Officers</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties shall take all
necessary action so that immediately after the Effective Time, (a)&#160;the post-Closing Parent Board shall be comprised of at least
five and not more than seven directors; whereby (b) the Company shall have the right to designate two members to the post-Closing Parent
Board, if the post-Closing Parent Board is comprised of five or six directors, or three members, if the post-Closing Parent Board is
comprised of seven directors; provided that at least one shall be an independent director (as defined under the Nasdaq listing rules)
and if so required (based on the advice of counsel) in order to meet such condition, such director shall be acceptable by the Company
but appointed by the Parent Board; (c) one designated member shall be mutually agreed between the Company and the Parent (initially being
Mr. Amitai Weiss); (d) the Parent shall designate the remaining directors (the &#8220;<b><i>Company Designees</i></b> and the &#8220;<b><i>Parent
Designee</i></b>s&#8221;, respectively) and (e) the Persons designed by the Parent Board shall be appointed to the positions of officers
of Parent, as set forth therein, to serve in such positions effective as of the Effective Time until successors are duly appointed and
qualified in accordance with applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14 <b><span style="text-decoration:underline">Termination of
Certain Agreements and Rights</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall cause any
Investor Agreements (excluding the Company Shareholder Support Agreements) to be terminated immediately prior to the Effective Time,
without any liability being imposed on the part of Company, Parent or the Surviving Company, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 541 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15 <b><span style="text-decoration:underline">Cooperation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Party shall cooperate
reasonably with the other Party and shall provide the other Party with such assistance as may be reasonably requested for the purpose
of facilitating the performance by each Party of its respective obligations under this Agreement and to enable the combined entity to
continue to meet its obligations following the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16 <b><span style="text-decoration:underline">Allocation Certificates;
Ownership Certificate</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company will prepare
and deliver to Parent at least ten Business Days prior to the Closing Date a certificate signed by the chief financial officer of the
Company in a form reasonably acceptable to Parent setting forth (as of immediately prior to the Effective Time): (i) each record holder
of Company Ordinary Shares, Company Options or Company Warrants, (ii) such record holder&#8217;s name and address, (iii) the number of
Company Ordinary Shares held and/or underlying the Company Options or Company Warrants as of the Effective Time for such holder (the
&#8220;<b><i>Company Outstanding Shares Certificate</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Parent will prepare and
deliver to the Company at least ten Business Days prior to the Closing Date a certificate signed by the chief financial officer of Parent
in a form reasonably acceptable to the Company, setting forth, as of immediately prior to the Effective Time: (i) each record holder
of Parent Ordinary Shares, Parent Equity Awards or Parent Warrants, (ii) such record holder&#8217;s name and address, (iii) the number
of Parent Ordinary Shares held and/or underlying the Parent Equity Awards or Parent Warrants as of the Effective Time for such holder
(the &#8220;<b><i>Parent Outstanding Shares Certificate</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Parent will deliver to
the Company at least ten Business Days prior to the Closing Date either (i) an ownership certificate, issued by a TASE member, confirming
Parent&#8217;s ownership of the Company Ordinary Shares on the date of issuance thereof, together with a confirmation of the chief financial
officer of Parent that no changes in Parent&#8217;s ownership of the Company Ordinary Shares were made since such ownership certificate
was issued, or (ii) a certificate signed by the chief financial officer of Parent confirming that on the date of issuance thereof Parent
does not own any Company Ordinary Shares, all in a form reasonably acceptable to the Company (a certificate provided under this Section
<b>&#8206;</b>5.16<b>&#8206;</b>(c) &#8211; the &#8220;<b><i>Parent Ownership Certificate</i></b>&#8221;). Following the issuance of the
Parent Ownership Certificate and up to the Closing Date, the Parent shall not dispose of or acquire Company Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17 <b><span style="text-decoration:underline">Company Financial
Statements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) As promptly as reasonably
practicable following the date of this Agreement: (i) the Company will furnish to Parent audited financial statements for the fiscal
years ended 2022 and 2021, and to the extent necessary to be included in the Registration Statement, for the fiscal year ended 2023,
translated into English for inclusion in the Registration Statement (the &#8220;<b><i>Company Audited Financial Statements</i></b>&#8221;);
(ii) the Company will furnish to Parent unaudited interim financial statements, translated into English for each interim period completed
prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing
if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;<b><i>Company
Interim Financial Statements</i></b>&#8221;); and (iii) the Company will furnish to Parent any such additional information or documents
reasonably required by Parent, after consulting with its independent auditors, for compliance with Regulation S-X. The Company hereby
covenants that each of the Company Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion
in the Registration Statement and prepared as applied on a consistent basis during the periods involved (except in each case as described
in the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations,
changes in shareholders&#8217; equity, and cash flows of the Company as of the dates of and for the periods referred to in the Company
Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 542 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Following the Closing,
the financial statements shall be audited in accordance with the auditing standards of the U.S. Public Company Accounting Oversight Board
(&#8220;<b><i>PCAOB</i></b>&#8221;) by a PCAOB qualified auditor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18 <b><span style="text-decoration:underline">Shareholder Litigation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Closing, Parent
shall conduct and control the settlement and defense of any shareholder litigation against Parent or any of its directors relating to
this Agreement or the Contemplated Transactions; <i>provided</i> that (i) Parent shall keep the Company reasonably apprised of any material
developments in connection with any such shareholder litigation, (ii) Parent shall consult with the Company in connection with the defense
and settlement of any such shareholder litigation and (iii) any settlement or other resolution of any such shareholder litigation shall
be subject to the approval of the Company, which approval shall not be unreasonably withheld, delayed or conditioned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19 <b><span style="text-decoration:underline">Certain Adjustments</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent and the Company shall
discuss and agree the terms of any reverse split of the Parent Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">6.
<b><span style="text-decoration:underline">CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of each Party
to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction
or, to the extent permitted by applicable Law, the written waiver by each of the Parties, at or prior to the Closing, of each of the
following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1 <b><span style="text-decoration:underline">No Restraints</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No temporary restraining
order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions shall have been
issued by any court of competent jurisdiction or other Governmental Body of competent jurisdiction and remain in effect and there shall
not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2 <b><span style="text-decoration:underline">Shareholder Approval</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Parent shall have obtained
the Required Parent Shareholder Vote and (b) the Company shall have obtained the Required Company Approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3 <b><span style="text-decoration:underline">Court Approval</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Court Approval shall
have been obtained in accordance with the Companies Law, including after obtaining the Required Company Approval, in accordance with
Sections 350 and 351 of the Companies Law and exempting among others, the Parent from the requirement to publish a prospectus in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 543 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4 <b><span style="text-decoration:underline">Tax Rulings</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall have received
the Withholding Tax Ruling and the 104H Ruling, in the forms reasonably acceptable on the Parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5 <b><span style="text-decoration:underline">Certificate of
Merger</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and Merger Sub
shall have received the Merger Certificate from the Companies Registrar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6 <b><span style="text-decoration:underline">No Legal Prohibition</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Governmental Authority
of competent jurisdiction shall have (i) enacted, issued or promulgated any Law that is in effect and has the effect of making the Merger
illegal or which has the effect of prohibiting or otherwise preventing the consummation of the Merger, or (ii) issued or granted any
order that has the effect of making the Merger illegal or which has the effect of prohibiting or otherwise preventing the consummation
of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7 <b><span style="text-decoration:underline">Bonds&#8217; Trustee</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not less than seven (7) Business
Days prior to the Closing, the Company and the Parent shall provide the Bonds&#8217; Trustee, to the extent not reported by the Company
on an immediate report filed with the TASE, with (a) a written confirmation that no reasonable concern exists that due to the Merger
the Company and the Parent as the absorbing company, will be unable to perform all and any obligations to the Bond holders under the
terms of the Series B Bonds and the Bonds Trust Deed, and (b) a written confirmation that as a result of the Merger, no pledges that
are inconsistent with the Company&#8217;s obligations under the Bonds Trust Deed regarding the creation of certain pledges, will be assigned
to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.8 <b><span style="text-decoration:underline">Registration Statement</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registration Statement
will have been declared effective and continue to be effective under the Securities Act. No stop order suspending the effectiveness of
the Registration Statement will be in effect, and no proceedings for purposes of suspending the effectiveness of the Registration Statement
will have been initiated or be threatened by the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"></p><div>

</div><!-- Field: Page; Sequence: 544 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">7.
<b><span style="text-decoration:underline">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of Parent
and Merger Sub to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction
or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1 <b><span style="text-decoration:underline">Accuracy of Representations</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Fundamental Representations
shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the
same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made
as of a particular date, in which case such representations and warranties shall be true and correct as of such date) other than, with
respect to the representations and warranties set forth in <span style="text-decoration:underline">Section &#8206;&#8206;2.6</span>, for inaccuracies that are <i>de minimis </i>in
nature and amount as of such date. The representations and warranties of the Company contained in this Agreement (other than the Company
Fundamental Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as
of the Closing Date with the same force and effect as if made on the Closing Date except: (i) in each case, or in the aggregate, where
the failure to be true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect
to any references therein to any Company Material Adverse Effect or other materiality qualifications), and (ii) for those representations
and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to
the qualifications as set forth in the preceding clause (i), as of such particular date) (it being understood that, for purposes of determining
the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Schedule made or purported
to have been made after the date of this Agreement shall be disregarded).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2 <b><span style="text-decoration:underline">Performance of
Covenants</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall have performed
or complied in all material respects with all agreements and covenants required to be performed or complied with by it under this Agreement
at or prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3 <b><span style="text-decoration:underline">Documents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent shall have received
the following documents, each of which shall be in full force and effect:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) a certificate executed
by the chief executive officer or chief financial officer of the Company certifying: (i) that the conditions set forth in <span style="text-decoration:underline">Sections
<b>&#8206;&#8206;</b>7.1</span>, <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">7.2</span>, <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">7.4</span> and <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">7.5</span> have been duly
satisfied and (ii) that the information set forth in the Company Allocation Schedule and the Company Outstanding Shares Certificate delivered
by the Company in accordance with <span style="text-decoration:underline">Section <b>&#8206;</b>1.8(b)</span> and <span style="text-decoration:underline">Section <b>&#8206;</b>5.16(a)</span> is true and accurate in all
respects as of the Closing Date; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) the Company Allocation
Schedule and the Company Outstanding Shares Certificate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 545 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4 <b><span style="text-decoration:underline">No Company Material
Adverse Effect</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the date of this Agreement,
there shall not have occurred any Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5 <b><span style="text-decoration:underline">Termination of
Investor Agreements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investor Agreements shall
have been terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">8.
<b><span style="text-decoration:underline">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of the Company
to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the
written waiver by the Company, at or prior to the Closing, of each of the following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1 <b><span style="text-decoration:underline">Accuracy of Representations</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parent Fundamental Representations
shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the
same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made
as of a particular date, in which case such representations and warranties shall be true and correct as of such date) other than, with
respect to the representations and warranties set forth in <span style="text-decoration:underline">Section &#8206;&#8206;3.6</span>, which shall be true and correct as of the Closing
Date except for inaccuracies that are <i>de minimis</i> in nature and amount as of such date. The representations and warranties of Parent
and Merger Sub contained in this Agreement (other than the Parent Fundamental Representations) shall have been true and correct as of
the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the
Closing Date except (a) in each case, or in the aggregate, where the failure to be true and correct would not reasonably be expected
to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other
materiality qualifications), and (b) for those representations and warranties which address matters only as of a particular date (which
representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such
particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update
of or modification to the Parent Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2 <b><span style="text-decoration:underline">Performance of
Covenants</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent and Merger Sub shall
have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with
by each of them under this Agreement at or prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 546 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3 <b><span style="text-decoration:underline">Documents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall have received
the following documents, each of which shall be in full force and effect:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) a certificate executed
by the chief financial officer of Parent certifying that the conditions set forth in <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>8.1</span>, <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">8.2
</span>and <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">8.4</span> have been duly satisfied; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) the Parent Outstanding
Shares Certificate; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) the Parent Ownership Certificate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4 <b><span style="text-decoration:underline">No Parent Material
Adverse Effect</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the date of this Agreement,
there shall not have occurred any Parent Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5 <b><span style="text-decoration:underline">Parent Net Cash</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent and the Company have
agreed in writing upon the calculation of the Parent Net Cash, or the Accounting Firm has delivered its determination with respect to
the calculation of the Parent Net Cash, in each case pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;1.6</span>, and the Parent Net Cash shall be no less
than $4,250,000 (less any amount owned by the Company to the Parent under any loan agreement between the parties) and the sum of $4,250,000
(less any amount owned by the Company to the Parent under any loan agreement between the parties), in accordance with Section &#8206;4.7
shall have been transferred and cleared to the Company&#8217;s designated bank account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6 <b><span style="text-decoration:underline">Listing</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parent Ordinary Shares
shall remain listed on Nasdaq and shall not be subject to a delisting notice from Nasdaq that will not be cured by the Contemplated Transactions.
The Nasdaq Notification shall have been accepted and approved (subject to official notice of issuance).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7 <b><span style="text-decoration:underline">Directors and Officers</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) The Parent shall have
appointed, effective as of the Effective Time in accordance with <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>5.13</span>, to the Parent Board all Persons
designated by the Company to the Parent Board and all such Persons shall receive an executed Indemnification Agreement with Parent in
the form of <b><span style="text-decoration:underline">Exhibit F</span></b>, and (ii) Parent shall have appointed the Persons designated by the Company to the positions of officers
of Parent, as set forth therein, to serve in such positions effective as of the Effective Time in accordance with <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>5.13</span>;
all until successors are duly appointed and qualified in accordance with applicable Law and Restated Parent Articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">9.
<b><span style="text-decoration:underline">TERMINATION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1 <b><span style="text-decoration:underline">Termination</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be terminated
prior to the Effective Time (whether before or after approval of the Company Approval Matters and whether before or after approval of
the Parent Shareholder Matters by Parent&#8217;s shareholders, unless otherwise specified below):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) at any time prior to the
Effective Time, by mutual written consent of Parent and the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 547 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) by either Parent or the
Company if the Contemplated Transactions shall not have been consummated by August 30, 2024, which can be extended by mutual consent
of the Parent and the Company by additional periods (subject in either case to possible extension by agreement between the Parties, the
&#8220;<b><i>End Date</i></b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) by either Parent or the
Company if a court of competent jurisdiction or other Governmental Body shall have issued a final and non-appealable order, decree or
ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated
Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) by either Parent or the
Company if: (i) the Parent Shareholders&#8217; Meeting (including any adjournments and postponements thereof) and/or the Company Meetings
shall have been held and completed and the Parent&#8217;s and/or the Company&#8217;s shareholders and/or the Company&#8217;s Bondholders
or creditors (if applicable), shall have taken a final vote on the Parent Shareholder Matters or the Company Approval Matters, as applicable
and (ii) the Parent Shareholder Matters or the Company Approval Matters, as applicable, shall not have been approved at the Parent Shareholders&#8217;
Meeting or the Company Meetings, as applicable (or at any adjournment or postponement thereof), by the Required Parent Shareholder Vote
or the Required Company Approval, as applicable; provided, that Parent or the Company may not terminate this Agreement pursuant to this
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(d)</span> if its breach of its obligations under this Agreement was the principal factor contributing to
the failure to have obtained the approval of the Parent Shareholder Matters at the Parent Shareholders&#8217; Meeting or of the Company
Approval Matters at the Company Meetings, as applicable (including any adjournments and postponements thereof), <i>provided, however</i>,
that Parent shall not be deemed in breach of its obligations under this Agreement in the event that a request for additional information
has been made by any Governmental Body, or in the event that the SEC has not declared effective under the Securities Act the Registration
Statement or otherwise delayed such declaration and as a result Parent did not have sufficient time to solicit votes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) by the Company (at any
time prior to the approval of the Parent Shareholder Matters by the Required Parent Shareholder Vote) if a Parent Triggering Event shall
have occurred;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) by Parent (at any time
prior to the Required Company Approval being obtained) if a Company Triggering Event shall have occurred;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) by the Company, upon a
breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Sub or if any representation
or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>8.1</span>or
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>8.2</span> would not be satisfied as of the time of such breach or as of the time such representation or warranty
shall have become inaccurate; <i>provided</i> that the Company is not then in material breach of any representation, warranty, covenant
or agreement under this Agreement; <i>provided</i>, <i>further</i>, that if such inaccuracy in Parent&#8217;s or Merger Sub&#8217;s representations
and warranties or breach by Parent or Merger Sub is curable by the End Date by Parent or Merger Sub, then this Agreement shall not terminate
pursuant to this <span style="text-decoration:underline">Section <b>&#8206;</b>9.1(g)<b>&#8206;</b></span> as a result of such particular breach or inaccuracy until the expiration
of a 30 calendar day period commencing upon delivery of written notice from the Company to Parent or Merger Sub of such breach or inaccuracy
and its intention to terminate pursuant to this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(g)</span> (it being understood that this Agreement shall
not terminate pursuant to this <span style="text-decoration:underline">Section <b>&#8206;</b>9.1(g)</span> as a result of such particular breach or inaccuracy if such breach by
Parent or Merger Sub is cured prior to such termination becoming effective);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 548 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) by Parent, upon a breach
of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty
of the Company shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration:underline">Section <b>&#8206;</b>7.1</span><b>&#8206;
</b>or <span style="text-decoration:underline">Section <b>&#8206;</b>7.2<b>&#8206;</b></span> would not be satisfied as of the time of such breach or as of the time such representation
or warranty shall have become inaccurate; <i>provided</i> that Parent is not then in material breach of any representation, warranty,
covenant or agreement under this Agreement; <i>provided</i>, <i>further</i>, that if such inaccuracy in the Company&#8217;s representations
and warranties or breach by the Company is curable by the End Date by the Company then this Agreement shall not terminate pursuant to
this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(h)</span> as a result of such particular breach or inaccuracy until the expiration of a 30 calendar
day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate
pursuant to this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(h)</span> (it being understood that this Agreement shall not terminate pursuant to this
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(h)</span> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior
to such termination becoming effective); or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) by Company, if the Parent
Net Cash is less than $4,250,000 (less any amount owned by the Company to the Parent under any loan agreement between the parties), by
the End Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j) by Parent, if the Company
Audited Financial Statements have not been provided by the Company to Parent within 45 calendar days immediately following the date hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2 <b><span style="text-decoration:underline">Notice of Termination;
Effect of Termination</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any proper and valid termination
of this Agreement pursuant to <span style="text-decoration:underline">Section &#8206;9.1</span> shall be effective immediately upon the delivery of written notice of the terminating
party to the other party or parties hereto, as applicable. In the event of the termination of this Agreement as provided in <span style="text-decoration:underline">Section
&#8206;9.1</span>, this Agreement shall be of no further force or effect; <i>provided</i>, <i>however</i>, that (a) this <span style="text-decoration:underline">Section &#8206;&#8206;9.1</span>,
<span style="text-decoration:underline">Section &#8206;&#8206;5.10</span>, <span style="text-decoration:underline">Section &#8206;9.3&#8206;</span>, <span style="text-decoration:underline">Section &#8206;10</span> and the definitions of the defined terms in such
Sections shall survive the termination of this Agreement and shall remain in full force and effect, and (b) the termination of this Agreement
and the provisions of <span style="text-decoration:underline">Section &#8206;9.3</span> shall not relieve any Party of any liability for fraud or for any willful and material
breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement. For purposes of this Agreement,
&#8220;willful breach&#8221; shall mean any act or failure to act by any person with the actual knowledge that the taking of such act
or the failure to take such act would cause a breach of this Agreement. In addition to the foregoing, no termination of this Agreement
shall affect the obligations of the Parties set forth in the Confidentiality Agreement, all of which obligations shall survive termination
of this Agreement in accordance with their terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 549 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3 <b><span style="text-decoration:underline">Expenses</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Except as set forth in
this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.3(a)</span>, all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions
shall be paid by the Party incurring such expenses, whether or not the Merger is consummated (including any attorney&#8217;s, accountant&#8217;s,
financial advisor&#8217;s or finder&#8217;s fees); <i>provided that</i> (i) Parent shall pay all fees and expenses incurred in relation
to the drafting, printing and filing with the SEC of the Registration Statement and any amendments and supplements thereto and paid to
a financial printer or the SEC, and (ii) drafting, printing and filing with the ISA of the Transaction Report and any amendments and
supplements thereto. It is understood and agreed that all fees and expenses incurred or to be incurred by the Company in connection with
the Contemplated Transactions and preparing, negotiating and entering into this Agreement and the performance of its obligations under
this Agreement shall be paid by the Company and that it is understood and agreed that all fees and expenses incurred or to be incurred
by Parent in connection with the Contemplated Transactions and preparing, negotiating and entering into this Agreement and the performance
of its obligations under this Agreement shall be paid by Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Each of the Parties acknowledges
that: (i) the agreements contained in this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.3</span> are an integral part of the Contemplated Transactions,
(ii) without these agreements, the Parties would not enter into this Agreement and (iii) any amount payable pursuant to this <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>9.3</span> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Company in
the circumstances in which such amount is payable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">10.
<b><span style="text-decoration:underline">MISCELLANEOUS PROVISIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1 <b><span style="text-decoration:underline">Non-Survival of
Representations and Warranties</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The representations and warranties
of the Company, Parent and Merger Sub contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement
shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time and this <span style="text-decoration:underline">Section &#8206;10
</span>shall survive the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2 <b><span style="text-decoration:underline">Amendment</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be amended
with the approval of the respective boards of directors of the Company, Merger Sub and Parent at any time (whether before or after obtaining
the Required Company Approval or before or after obtaining the Required Parent Shareholder Vote); <i>provided</i>, <i>however</i>, that
after any such approval of this Agreement by a Party&#8217;s shareholders, no amendment shall be made which by Law requires further approval
of such shareholders without the further approval of such shareholders. This Agreement may not be amended except by an instrument in
writing signed on behalf of each of the Company, Merger Sub and Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3 <b><span style="text-decoration:underline">Waiver</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) No failure on the part
of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising
any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and
no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of
any other power, right, privilege or remedy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) No Party shall be deemed
to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver
of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf
of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 550 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.4 <b><span style="text-decoration:underline">Entire Agreement;
Counterparts; Exchanges by Electronic Transmission</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement, the Company
Disclosure Schedule, the Parent Disclosure Schedule and the other agreements referred to in this Agreement constitute the entire agreement
and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the
subject matter hereof and thereof; <i>provided</i>, <i>however</i>, that the Confidentiality Agreement shall not be superseded and shall
remain in full force and effect in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall
be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts
or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions
of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.5 <b><span style="text-decoration:underline">Applicable Law;
Jurisdiction</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) This Agreement shall
be governed by, and construed in accordance with, the Laws of the State of Israel, regardless of the Laws that might otherwise govern
under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to
this Agreement or any of the Contemplated Transactions, each of the Parties irrevocably and unconditionally consents and submits to the
exclusive jurisdiction and venue of the courts located in Tel Aviv, Israel; and (b) agrees that all claims in respect of such action
or proceeding shall be heard and determined exclusively in accordance with clause (a) of this <span style="text-decoration:underline">Section &#8206;&#8206;10.5</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.6 <b><span style="text-decoration:underline">Attorneys&#8217;
Fees</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In any action at law or suit
in equity to enforce this Agreement or the rights of any of the Parties, the prevailing Party in such action or suit (as determined by
a court of competent jurisdiction) shall be entitled to recover its reasonable out-of-pocket attorneys&#8217; fees and all other reasonable
costs and expenses incurred in such action or suit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.7 <b><span style="text-decoration:underline">Assignability</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement shall be binding
upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns;
<i>provided</i>, <i>however</i>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned
or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement
or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 551 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.8 <b><span style="text-decoration:underline">Notices</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices and other communications
hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a) one Business Day after being
sent for next Business Day delivery, fees prepaid, via a reputable overnight courier service, (b) upon delivery in the case of delivery
by hand, or (c) on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery)
prior to 5:00 p.m. Israel time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">if to Parent or Merger Sub:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">SciSparc Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">20 Raul Wallenberg
Street, Tower A</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel Aviv, Israel,
6971916</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Oz Adler</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: oz@scisparc.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">with a copy to (which shall
not constitute notice):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Meitar | Law Offices</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">16 Abba Hillel
Rd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Ramat Gan 5250608,
Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel: (+972) (3)
610-3100</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Dr.
Shachar Hadar</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: shacharh@meitar.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">And</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Sullivan &amp;
Worcester LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">1633 Broadway</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">New York, NY 10019</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel: (212) 660-3000</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Oded
Har-Even, Esq., Howard E. Berkenblit, Esq</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: ohareven@sullivanlaw.com,
hberkenblit@sullivanlaw.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">if to the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">AutoMax Motors
Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">15 HaRechavim St.,
Jerusalem</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Tomer
Levy</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: tomer@automax.co.il</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">with a copy to
(which shall not constitute notice):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Lipa Meir &amp;
Co. Law Office</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">2 Weizmann ST.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel -Aviv 6423902,
Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel: +973 (3) 6070600</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Gregory
Irgo, Adv.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: gregory@lipameir.co.il</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">And</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Greenberg Traurig,
P.A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">One Azrieli Center</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Round Tower, 30th
floor</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">132 Menachem Begin
Rd, Tel Aviv 6701101, Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: David
A. Huberman</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: David.Huberman@gtlaw.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 552 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.9 <b><span style="text-decoration:underline">Cooperation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Party agrees to cooperate
fully with the other Parties and to execute and deliver such further documents, certificates, agreements and instruments and to take
such other actions as may be reasonably requested by the other Parties to evidence or reflect the Contemplated Transactions and to carry
out the intent and purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.10 <b><span style="text-decoration:underline">Severability</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any term or provision of
this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability
of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision
of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit
such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid
and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement
shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence,
the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will
achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.11 <b><span style="text-decoration:underline">Other Remedies;
Specific Performance</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy
conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of
any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy,
would occur in the event that any Party does not perform the provisions of this Agreement (including failing to take such actions as
are required of it hereunder to consummate this Agreement) in accordance with its specified terms or otherwise breaches such provisions.
Accordingly, the Parties acknowledge and agree that the Parties shall be entitled to an injunction, specific performance and other equitable
relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy
to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific
performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance
is not an appropriate remedy for any reason at law or in equity. Any Party seeking an injunction or injunctions to prevent breaches of
this Agreement shall not be required to provide any bond or other security in connection with any such order or injunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 553 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.12 <b><span style="text-decoration:underline">No Third Party
Beneficiaries</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Agreement,
express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by
reason of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.13 <b><span style="text-decoration:underline">Construction</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) References to &#8220;cash,&#8221;
&#8220;dollars&#8221; or &#8220;$&#8221; are to U.S. dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) For purposes of this Agreement,
whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine
and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine
and feminine genders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Parties have participated
jointly in the negotiating and drafting of this Agreement and agree that any rule of construction to the effect that ambiguities are
to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement, and no presumption
or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) As used in this Agreement,
the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but
rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; The word &#8220;or&#8221; shall not be exclusive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) Except as otherwise indicated,
all references in this Agreement to &#8220;Sections,&#8221; &#8220;Exhibits&#8221; and &#8220;Schedules&#8221; are intended to refer
to Sections of this Agreement and Exhibits and Schedules to this Agreement, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) Any reference to legislation
or to any provision of any legislation shall include any modification, amendment, re-enactment thereof, any legislative provision substituted
therefor and all rules, regulations, and statutory instruments issued or related to such legislations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) The bold-faced headings
and table of contents contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement
and shall not be referred to in connection with the construction or interpretation of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) The Parties agree that
each of the Company Disclosure Schedule and the Parent Disclosure Schedule shall be arranged in sections and subsections corresponding
to the numbered and lettered sections and subsections contained in this Agreement. The disclosures in any section or subsection of the
Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other sections and subsections in this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) Each of &#8220;delivered&#8221;
or &#8220;made available&#8221; means, with respect to any documentation, that prior to 11:59 p.m. (Israel time) on the date that is
two calendar days prior to the date of this Agreement: (i) a copy of such material has been posted to and made available by a Party to
the other Party and its Representatives in the electronic data room maintained by such disclosing Party or (ii) such material is disclosed
in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC&#8217;s Electronic Data
Gathering Analysis and Retrieval system and/or disclosed in the Company TASE Documents filed with the ISA prior to the date hereof and
publicly made available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j) Whenever the last day for
the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Friday, Saturday, or any date on which banks in
Tel Aviv, Israel are authorized or obligated by Law to be closed, the Party having such privilege or duty may exercise such privilege
or discharge such duty on the next succeeding day which is a regular Business Day.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(<i>Remainder of page intentionally
left blank</i>)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 554 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>IN WITNESS WHEREOF, </b>the
Parties have caused this Agreement to be executed as of the date first above written.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt"><b>SCISPARC LTD.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1.5pt solid; width: 35%; text-align: justify; font-size: 10pt">/s/ Oz Adler</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Name:&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Oz Adler</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Title:</td>
    <td style="text-align: justify; font-size: 10pt">Chief Executive Officer</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>SCISPARC MERGER SUB LTD.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; font-size: 10pt">/s/ Oz Adler</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Name:</td>
    <td style="text-align: justify; font-size: 10pt">Oz Adler</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Title:</td>
    <td style="text-align: justify; font-size: 10pt">Director</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>AUTOMAX MOTORS LTD.</b> &#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; font-size: 10pt">/s/ Tomer Levy</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Name:</td>
    <td style="text-align: justify; font-size: 10pt">Tomer Levy</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Title:</td>
    <td style="text-align: justify; font-size: 10pt">Director</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; font-size: 10pt">/s/ Yaarah Alfi</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Name:</td>
    <td style="text-align: justify; font-size: 10pt">Yaarah Alfi</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Title:</td>
    <td style="text-align: justify; font-size: 10pt">Chief Financial Officer</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[SIGNATURE PAGE TO MERGER
AGREEMENT]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 555 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">addendum no. 1<br/>
<i>to<br/>
</i><span style="text-decoration:underline">AGREEMENT AND PLAN OF MERGER</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">This addendum, dated August
14, 2024 (the &#8220;<b>Effective Date</b>&#8221;) constitutes addendum no. 1 (the &#8220;<b>Addendum</b>&#8221;) to that certain Agreement
and Plan Of Merger dated April 10, 2024 (hereinafter together, the &#8220;<b>Agreement</b>&#8221;), by and between, SciSparc Ltd., an
Israeli limited company (the &#8220;<b><i>Parent</i></b>&#8221;), SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned
subsidiary of Parent (&#8220;<b><i>Merger Sub</i></b>&#8221;), and AutoMax Motors Ltd., an Israeli limited company (the &#8220;<b><i>Company</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 63.8pt"><b>WHEREAS</b></td><td style="text-align: justify">the Parties wish to modify
                                            and amend certain provisions set forth in the Agreement, all as further stipulated herein.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOW THEREFORE,</b> the parties hereto agree
to amend the Agreement as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">1.</td><td style="text-align: justify; padding-right: 35.4pt"><span style="text-decoration:underline">Amendment
                                            of End Date</span>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 0.25in; text-align: justify; text-indent: 0in">Notwithstanding
Section 9.1(b) of the Agreement, the End Date shall be extended from August 30, 2024, to November 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 21.3pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">2.</td><td style="text-align: justify; padding-right: 35.4pt"><span style="text-decoration:underline">General</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 28.35pt">2.1.</td><td style="text-align: justify; padding-right: 4.25pt">Any
                                            and all provisions, terms and/or conditions contained in the Agreement shall continue in
                                            full force and effect, unless and to the extent otherwise expressly provided herein which
                                            provisions will supersede any such provisions of the Agreement. In the event of a conflict
                                            or inconsistency between the terms of the Agreement, previous addendums/amendments (if any),
                                            and the terms of this Addendum, the terms of the latter shall govern and prevail.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 28.35pt">2.2.</td><td style="text-align: justify; padding-right: 4.25pt">This
                                            Addendum shall be deemed for all intents and purposes an integral part of the Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 28.35pt">2.3.</td><td style="text-align: justify; padding-right: 4.25pt">Terms
                                            used but not defined herein shall have the meanings assigned to such terms in the Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>[Signature page to follow]</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 556; Options: NewSection; Value: 77 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IN WITNESS WHEREOF,</b> the undersigned have
caused this Addendum to be executed as of the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>SCISPARC
    LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="width: 35%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>SCISPARC MERGER
    SUB LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>AUTOMAX MOTORS
    LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">/s/ Tomer Levy</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:
    </span></td>
    <td style="text-align: justify">Tomer Levy</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yaarah Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:
    </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaarah Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 557; Value: 77 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Exhibit
A</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Certain
Definitions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
purposes of this Agreement (including this Exhibit A):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>104H
Ruling</i></b>&#8221; means a ruling </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant to Section
104H of the Ordinance, (i) exempting from or deferring any applicable Israeli Tax with respect to any consideration payable to 5% Payee,
pursuant to this Agreement, until the date set forth in Section 104H of the Ordinance or (ii) instructing the Payor and its agents on
how such withholding is to be executed from the payment of such consideration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>104H
Trustee</i></b>&#8221; means </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the trustee appointed for
the purpose of 104H Ruling.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>102
Trustee</i></b>&#8221; means the trustee appointed by the Company from time to time in accordance with the provisions of the Ordinance,
and approved by the Israel Tax Authority, with respect to the Company 102 Options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Acquisition
Inquiry</i></b>&#8221; means, with respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry,
indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to
the other Party) that would reasonably be expected to lead to an Acquisition Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Acquisition
Proposal</i></b>&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal
made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its
Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Acquisition
Transaction</i></b>&#8221; means any transaction or series of related transactions involving:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(i)
</b>any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities,
reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Party is a constituent entity;
(ii) in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly
or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class
of voting securities of a Party or any of its Subsidiaries; or (iii) in which a Party or any of its Subsidiaries issues securities representing
more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; <i>provided</i>,
that in the case of Company, the Closing Financing shall not be an &#8220;Acquisition Transaction&#8221;; or</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(ii)
</b>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute
or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken
as a whole.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 558; Options: NewSection; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Affiliate</i></b>&#8221;
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such Person. The term &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under
common control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Applicable
Court</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;5.1(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Bondholders</i></b>&#8221;
means holders of the Company&#8217;s Series B Bonds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Bonds&#8217;
Trustee</i></b>&#8221; means Mishmeret Trust Company Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Bonds
Trust Deed</i></b>&#8221; means the trust deed dated February 23, 2022, by and between the Company and the Bonds&#8217; Trustee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Business
Day</i></b>&#8221; means any day other than a Friday, Saturday or other day on which banks in Tel Aviv, Israel are authorized or obligated
by Law to be closed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Cash
and Cash Equivalents</i></b>&#8221; means all (a) cash (not including restricted cash) and cash equivalents (not including restricted
cash); (b) deposits; (c) marketable securities and (d) short term receivables, in each case determined in accordance with IFRS, consistently
applied.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Closing</i></b>&#8221;
shall have the meaning ascribed thereto in Section &#8206;1.3.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Closing
Date</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;1.3.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Closing
Financing</i></b>&#8221; means any offering, issuance and sale by Parent, by means of a public offering, a registered direct offering,
a private placement offering or such other offering that the officers of Parent shall determine to be advisable, of securities of the
Parent to investors, which may be consummated prior to or concurrently with the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Code</i></b>&#8221;
means the Internal Revenue Code of 1986, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Companies
Law</i></b>&#8221; means the Israeli Companies Law, 5759-1999, and all rules and regulations thereunder, all as amended from time to
time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
102 Options</i></b>&#8221; means Company Options that are granted and subject to Section 102(b)(2) and Section 102(b)(3) of the Ordinance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Approval Matters</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;5.1(c).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Affiliate</i></b>&#8221; means any Person that is (or at any relevant time was) under common control with the Company within the meaning
of Sections 414(b), (c), (m) and (o) of the Code, and the regulations issued thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 559; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Associate</i></b>&#8221; means any current or former employee, independent contractor, officer or director of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Board</i></b>&#8221; means the board of directors of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Ordinary Shares</i></b>&#8221; means the ordinary shares, par value NIS 0.05 per share, of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Certified Shares</i></b>&#8221; means Company Ordinary Shares represented by Company Share Certificates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Contract</i></b>&#8221; means any Contract: (a) to which the Company is a Party; (b) by which the Company or any asset of the Company
is or may become bound or under which the Company has, or may become subject to, any obligation; or (c) under which the Company has or
may acquire any right or interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Fundamental Representations</i></b>&#8221; means the representations and warranties of the Company set forth in <span style="text-decoration:underline">Sections &#8206;&#8206;2.1
</span>(Due Organization; Subsidiaries), <span style="text-decoration:underline">&#8206;&#8206;2.3</span> (Authority; Binding Nature of Agreement), <span style="text-decoration:underline">&#8206;&#8206;2.4</span> (Vote Required),
&#8206;2.6 (Capitalization) and <span style="text-decoration:underline">&#8206;&#8206;2.20</span> (No Financial Advisors).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Material Adverse Effect</i></b>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to
the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material
adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of the Company; <i>provided</i>,
<i>however</i>, that Effects arising or resulting from the following shall not be taken into account in determining whether there has
been a Company Material Adverse Effect: (a) changes or conditions generally affecting the industries or markets in which the Company
operates, and changes in the industries in which the Company operates regardless of geographic region (including legal and regulatory
changes), (b) acts of war, armed hostilities or terrorism, including the current ongoing war declared by Israel against Hamas, (c) changes
in financial, banking or securities markets, (d) any change in, or any compliance with or action taken for the purpose of complying with,
any Law or IFRS (or interpretations of any Law or IFRS), (e) resulting from the announcement of this Agreement or the pendency of the
Contemplated Transactions, (f) resulting from the taking of any action required to be taken by this Agreement or (g) changes in U.S.
or non-U.S. general economic or political conditions, or in the financial, credit or securities markets in general, including any shutdown
of any Governmental Authority; except in each case with respect to clauses (a) through (c), to the extent disproportionately affecting
the Company, relative to other companies in the industries in which the Company operates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Meetings</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;5.1(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Options</i></b>&#8221; means options or other rights granted by the Company to purchase Company Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 560; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Shareholder</i></b>&#8221; means a holder of Company Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Share Plans</i></b>&#8221; means Company&#8217;s 2021 Equity Incentive Plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Triggering Event</i></b>&#8221; shall be deemed to have occurred if: (a) the Company shall have made a Company Board Adverse Recommendation
Change; (b) the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal
(or shall have not publicly recommended against any Acquisition Proposal that is a tender offer or exchange offer within five Business
Days after the commencement thereof); or (c) the Company shall have entered into any letter of intent or any Contract contemplating or
otherwise relating to any Acquisition Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
TASE Documents</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;2.7(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Balance Sheet</i></b>&#8221; means the audited balance sheet of the Company for the period ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Warrant</i></b>&#8221; means the warrants to purchase Company Ordinary Shares listed in <span style="text-decoration:underline">Section &#8206;&#8206;1.1(f)</span> of the Company
Disclosure Schedule.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Confidentiality
Agreement</i></b>&#8221; means the non-disclosure agreement, dated as of November 28, 2023, between the Company and Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Consent</i></b>&#8221;
means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Contemplated
Transactions</i></b>&#8221; means the Merger and the other transactions and actions contemplated by this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Contract</i></b>&#8221;
means, with respect to any Person, any agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license,
sublicense or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or
any of its assets are bound or affected under applicable Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Effect</i></b>&#8221;
means any effect, change, event, circumstance, or development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Effective
Time</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;1.3.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Encumbrance</i></b>&#8221;
means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, license, option, easement, reservation, servitude,
adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction
or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security
or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any
restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 561; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;<i>Enforceability
Exceptions</i>&#8221;</b> means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors; and
(b) rules of law governing specific performance, injunctive relief and other equitable remedies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Entity</i></b>&#8221;
means any corporation (including any non-profit corporation), partnership (including any general partnership, limited partnership or
limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company
or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Environmental
Law</i></b>&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment
(including ambient air, surface water, ground water, land surface or subsurface strata), including any Law or regulation relating to
emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Exchange
Act</i></b>&#8221; means the Securities Exchange Act of 1934.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Exchange
Ratio</i></b>&#8221; means, subject to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(h)</span>, the result of the following calculation (rounded to four decimal
places): the number of the Parent Outstanding Shares divided by 0.5001 multiplied by 0.4749 divided by (the number of the Company Outstanding
Shares less the number of the Company Ordinary Shares set forth in the Parent Ownership Certificate); so that, in any event, immediately
following the Effective Time, holders of Company Outstanding Shares (other than the Parent) and Parent Pre-Funded Warrants issued hereunder
will hold together 49.99%, <i>minus</i> the Finder Fee, of the Parent Outstanding Shares, immediately following the Effective Time, all
which shall be calculated in accordance with the example of the calculation set forth in <span style="text-decoration:underline">Section &#8206;&#8206;1.6(a)</span> of the Parent
Disclosure Schedule.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Outstanding Shares</i></b>&#8221; means subject to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(h)</span>, the total number of Company Ordinary Shares outstanding
immediately prior to the Effective Time expressed on a fully-diluted basis, but assuming, without limitation or duplication, Company
Warrants, and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior
to the Effective Time, whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or
associated with the consummation of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Outstanding Shares</i></b>&#8221; means, subject to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(h)</span>, the total number of Parent Ordinary Shares outstanding
immediately prior to the Effective Time expressed on a fully-diluted basis, including any shares or warrants issued in relation with
the Closing Financing(s) (solely to the extent consummated) and assuming, without limitation or duplication, the issuance of Parent Ordinary
Shares in respect of all Parent Equity Awards, Parent Warrants (but excluding Parent Warrants with an exercise price per Parent Ordinary
Share ranging between $68.38 to $637), and other outstanding options, warrants or rights to receive such shares, in each case, outstanding
as of immediately prior to the Effective Time, whether conditional or unconditional and including any outstanding options, warrants or
rights triggered by or associated with the consummation of the Merger.</span></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>"<b>Parent
Ownership Certificate</b></i>" shall have the meaning ascribed thereto in Section 5.16(c).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 562; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<b>Finder
Fee</b>&#8221;</i> means such amount: (i) of Parent Ordinary Shares equal to 2.5% of the Parent Outstanding Shares immediately following
the Effective Time, to be issued at the Effective Time to Merhavit M.R.M Holding and Management Ltd. by the Parent, on account of the
Company and (ii) VAT applicable thereto to be paid by the Company, all against appropriate tax invoice to be issued by Merhavit M.R.M
Holding and Management Ltd. to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<b>First
Motion Approval</b>&#8221;</i> shall have the meaning ascribed thereto in Section &#8206;5.1(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>GAAP</i></b>&#8221;
means generally accepted accounting principles and practices in effect from time to time within the United States applied consistently
throughout the period involved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Governmental
Authorization</i></b>&#8221; means any: (a) permit, license, certificate, franchise, permission, variance, exception, order, clearance,
registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental
Body or pursuant to any Law; or (b) right under any Contract with any Governmental Body.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Governmental
Body</i></b>&#8221; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of
any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation,
center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority); or
(d) self-regulatory organization (including Nasdaq).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Governmental
Grant</i></b>&#8221; means any grant, incentive, subsidy, award, participation, cost sharing arrangement, reimbursement arrangement,
including any application therefor, whether pending, approved, provided or made available by or on behalf of or under the authority of
the IIA, the Israeli Investment Center, the State of Israel, the BIRD Foundation, the European Union, the Fund for Encouragement of Marketing
Activities of the Israeli Government or any other Governmental Body.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Hazardous
Materials</i></b>&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable
or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject
to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and
petroleum products or by-products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Hevra
Le&#8217;Rishumim</i></b>&#8221; means Mizrahi Tefahot nominee company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>IFRS</i></b>&#8221;
means the international financial reporting standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>IIA</i></b>&#8221;
means the Israel Innovation Authority, formerly known as the Office of the Chief Scientist of the Ministry of Economy of the State of
Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Indemnification
Agreement</i></b>&#8221; means the agreement between the Parent and the members of Parent&#8217;s Board, in the form attached hereto
as <b><span style="text-decoration:underline">Exhibit G</span></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 563; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Innovation
Law</i></b>&#8221; means the Israeli Encouragement of Research, Development and Technological Innovation in the Industry Law, 5744-1984
(formerly known as the Israeli Encouragement of Research and Development in Industry Law, 5744-1984), and all rules and regulations thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Intellectual
Property Rights</i></b>&#8221; means and includes all past, present, and future rights of the following types, which may exist or be
created under the laws of any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation
rights, copyrights, moral rights, software, databases, and mask works; (b) trademarks, service marks, trade dress, logos, trade names
and other source identifiers, domain names and URLs and similar rights and any goodwill associated therewith; (c) rights associated with
trade secrets, know how, inventions, invention disclosures, methods, processes, protocols, specifications, techniques and other forms
of technology; (d) patents and industrial property rights; and (e) other similar proprietary rights in intellectual property of every
kind and nature; (f) rights of privacy and publicity; and (g) all registrations, renewals, extensions, statutory invention registrations,
non-provisionals, continuations, continuations-in-part, provisionals, divisions, or reissues of, and applications for, any of the rights
referred to in clauses &#8220;(a)&#8221; through &#8220;(f)&#8221; above (whether or not in tangible form and including all tangible
embodiments of any of the foregoing, such as samples, studies and summaries), along with all rights to prosecute and perfect the same
through administrative prosecution, registration, recordation or other administrative proceeding, and all causes of action and rights
to sue or seek other remedies arising from or relating to the foregoing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>IRS</i></b>&#8221;
means the United States Internal Revenue Service.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>ISA</i></b>&#8221;
means the Israel Securities Authority.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Israeli
Securities Law</i></b>&#8221; means the Israeli Securities Law, 5728-1968, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>ITA</i></b>&#8221;
means the Israel Tax Authority.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Knowledge</i></b>&#8221;
means, with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably
be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment or officer/director responsibilities.
Any Person that is an Entity shall have Knowledge if any officer or director of such Person as of the date such knowledge is imputed
has Knowledge of such fact or other matter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Law</i></b>&#8221;
means any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law,
resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented
or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of Nasdaq or the Financial
Industry Regulatory Authority).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Legal
Proceeding</i></b>&#8221; means any action, suit, claim, litigation, arbitration, proceeding (including any civil, criminal, administrative,
investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard
by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Merger
Sub Board</i></b>&#8221; means the board of directors of Merger Sub.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 564; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Nasdaq</i></b>&#8221;
means the Nasdaq Stock Market, including the Nasdaq Capital Market or such other Nasdaq market on which Parent Ordinary Shares are then
listed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Ordinance</i></b>&#8221;
means the Israeli Income Tax Ordinance [New Version], 1961, and all rules and regulations promulgated thereunder, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Ordinary
Course of Business</i></b>&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of
its normal operations and consistent with its past practices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Organizational
Documents</i></b>&#8221; means, with respect to any Person (other than an individual), (a) the articles of association or certificate
of incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company,
operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization
of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such
Person, in each case, as amended or supplemented.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Associate</i></b>&#8221; means any current or former employee, independent contractor, officer or director of Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Balance Sheet</i></b>&#8221; means the audited balance sheet of Parent as of December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Board</i></b>&#8221; means the board of directors of Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Closing Price</i></b>&#8221; means the volume weighted average closing trading price of a Parent Ordinary Shares on Nasdaq for the five
consecutive trading days ending five trading days immediately prior to the date upon which the Merger becomes effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Contract</i></b>&#8221; means any Contract: (a) to which Parent is a party; (b) by which Parent or any Parent IP or any other asset of
Parent is or may become bound or under which Parent has, or may become subject to, any obligation; or (c) under which Parent has or may
acquire any right or interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Equity Awards</i></b>&#8221; means the Parent RSUs and the Parent Options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
102 Equity Awards</i></b>&#8221; means Parent Equity Awards that are granted and subject to Section 102(b)(2) and Section 102(b)(3) of
the Ordinance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Fundamental Representations</i></b>&#8221; means the representations and warranties of Parent and Merger Sub set forth in <span style="text-decoration:underline">Sections
&#8206;&#8206;3.1</span> (Due Organization; Subsidiaries), <span style="text-decoration:underline">&#8206;&#8206;3.3</span> (Authority; Binding Nature of Agreement), <span style="text-decoration:underline">&#8206;&#8206;3.4</span>
(Vote Required), &#8206;<span style="text-decoration:underline">3.6</span> (Capitalization) and <span style="text-decoration:underline">&#8206;&#8206;3.20</span> (No Financial Advisors).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
IP</i></b>&#8221; means all Intellectual Property Rights that are owned or purported to be owned by Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 565; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Material Adverse Effect</i></b>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to
the date of determination of the occurrence of a Parent Material Adverse Effect, has or would reasonably be expected to have a material
adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Parent, regardless
of whether or not such change constitutes a breach of the representations and warranties made by the Parent or Merger Sub in this Agreement;
<i>provided</i>, <i>however</i>, that Effects arising or resulting from the following shall not be taken into account in determining
whether there has been a Parent Material Adverse Effect: (a) changes or conditions generally affecting the industries or markets in which
Parent operates, and changes in the industries in which Parent operates regardless of geographic region (including legal and regulatory
changes), (b) acts of war, armed hostilities or terrorism, including the current ongoing war declared by Israel against Hamas, (c) changes
in financial, banking or securities markets, (d) any change in, or any compliance with or action taken for the purpose of complying with,
any Law or IFRS (or interpretations of any Law or IFRS), (e) resulting from the announcement of this Agreement or the pendency of the
Contemplated Transactions, (f) resulting from the taking of any action required to be taken by this Agreement, or (g) pandemics, including
any worsening thereof, man-made disasters, natural disasters, acts of God or other force majeure event, or (h) changes in U.S. or non-U.S.
general economic or political conditions, or in the financial, credit or securities markets in general, including any shutdown of any
Governmental Authority; except in each case with respect to clauses (a) through (c) and (h), to the extent disproportionately affecting
Parent, relative to other similarly situated companies in the industries in which Parent operates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Net Cash</i></b>&#8221; means, without duplication and including after taking into account the proceeds of the Closing Financing, a dollar
amount which may be greater than or lower than zero, equal to (a) the sum of Parent&#8217;s Cash and Cash Equivalents, in each case as
of the Anticipated Closing Date, <i><span style="text-decoration:underline">minus</span></i> (b) the sum of Parent&#8217;s short and long term liability or obligations accrued
at Closing (as reasonably and in good faith estimated by the Company) and <i><span style="text-decoration:underline">minus </span></i>(c) all fees and expenses incurred in connection
with this Agreement and the Contemplated Transactions (including but not limited to any investment bankers, financial advisors, attorneys,
accountants or other advisors, agents or representatives retained by Parent or any of its Subsidiaries) outstanding and not paid as of
the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Options</i></b>&#8221; means options or other rights granted by Parent to purchase Parent Ordinary Shares pursuant to the Parent Share
Plans or otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Pre-Funded Warrant</i></b>&#8221; shall have the meaning ascribed thereto in Section <b><i>&#8206;</i></b>1.5(b).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<b>Parent
RSUs</b></i>&#8221; means any restricted share unit award granted pursuant to the Parent Share Plans or otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Share Capital</i></b>&#8221; means the Parent Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Share Plans</i></b>&#8221; means Parent&#8217;s (a) 2023 Share Incentive Plan, (b) Israeli Share Option Plan (2015), and (c) Israeli
Share Option Plan (2005).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Triggering Event</i></b>&#8221; shall be deemed to have occurred if: (a) Parent shall have failed to include in the Proxy Statement,
the Parent Board Recommendation or shall have made a Parent Board Adverse Recommendation Change; (b) the Parent Board or any committee
thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal (or shall have not publicly recommended against
any Acquisition Proposal that is a tender offer or exchange offer within five Business Days after the commencement thereof); or (c) Parent
shall have entered into any letter of intent or Contract or similar document contemplating or otherwise relating to any Acquisition Proposal
(other than a confidentiality agreement permitted pursuant to <span style="text-decoration:underline">Section &#8206;4.4</span>).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 566; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Warrants</i></b>&#8221; means all the warrants to purchase Parent Ordinary Shares outstanding immediately prior to the Effective Time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Party</i></b>&#8221;
or &#8220;<b><i>Parties</i></b>&#8221; means the Company, Merger Sub and Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Permitted
Encumbrance</i></b>&#8221; means: (a) any liens for current Taxes not yet due and payable or for Taxes that are being contested in good
faith and for which adequate reserves have been made on the Company Unaudited Interim Balance Sheet or the Parent Balance Sheet, as applicable;
(b) minor liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract
from the value of the assets or properties subject thereto or materially impair the operations of the Company or Parent, as applicable;
(c) statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements; (d) deposits or pledges
made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by
Law; (e) non-exclusive licenses of Intellectual Property Rights granted by the Company or Parent, as applicable, in the Ordinary Course
of Business and that do not (in any case or in the aggregate) materially detract from the value of the Intellectual Property Rights subject
thereto; (f) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or
supplies and (g) any restrictions imposed pursuant to the rules and regulations of the Securities Act, the Nasdaq, or applicable law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Person</i></b>&#8221;
means any individual, Entity or Governmental Body.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Proxy
Statement</i></b>&#8221; means the proxy statements to be sent to Parent&#8217;s shareholders in connection with the Parent Shareholders&#8217;
Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Registered
IP</i></b>&#8221; means all Intellectual Property Rights that are registered or issued under the authority of any Governmental Body,
including all patents, registered copyrights, registered mask works, and registered trademarks, service marks and trade dress, registered
domain names, and all applications for any of the foregoing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Registration
Statement</i></b>&#8221; means the Registration Statement on Form F-4 for the registration of the Parent Ordinary Shares, including the
Parent Ordinary Shares issuable upon exercise of Parent Pre-Funded Warrants, to be issued in connection with the Contemplated Transactions,
including the Proxy Statement contained therein and any and all amendments and supplements to such registration statement, in each case
including a prospectus contained therein, all exhibits thereto and any document incorporated by reference therein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Representatives</i></b>&#8221;
means directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 567; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Required
Company Approval</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;2.4.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Required
Parent Shareholder Vote</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;3.4.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Sarbanes-Oxley
Act</i></b>&#8221; means the Sarbanes-Oxley Act of 2002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>SEC</i></b>&#8221;
means the United States Securities and Exchange Commission.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Securities
Act</i></b>&#8221; means the Securities Act of 1933, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
entity shall be deemed to be a &#8220;<b><i>Subsidiary</i></b>&#8221; of a Person if such Person directly or indirectly owns or purports
to own, beneficially or of record, (a) an amount of voting securities or other interests in such entity that is sufficient to enable
such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body, or (b) at
least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Series
B Bonds</i></b>&#8221; means the Series B bonds of the Company, par value NIS 1.00 each.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Surviving
Company</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;1.1.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>TASE</i></b>&#8221;
means the Tel Aviv Stock Exchange Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Tax</i></b>&#8221;
or &#8220;<b><i>Taxes</i></b>&#8221; means: (a) any federal, state, local, foreign or other tax, including any income, capital gain,
gross receipts, share capital, profits, transfer, estimated, registration, stamp, premium, escheat, unclaimed property, customs duty,
ad valorem, occupancy, occupation, alternative, add-on, windfall profits, value added, severance, property, business, production, sales,
use, license, excise, franchise, employment, payroll, social security, disability, unemployment, workers&#8217; compensation, national
health insurance, withholding or other taxes, duties, fees, assessments or governmental charges, surtaxes or deficiencies thereof of
any kind whatsoever, however denominated, and including any fine, penalty, addition to tax or interest imposed by a Governmental Body
with respect thereto (b) any liability for the payment of any amounts of the type described in clause (a) as a result of being a member
of an affiliated, consolidated, combined, unitary or similar group (including any arrangement for group or consortium relief or similar
arrangement) for any period, and (c) any liability for the payment of any amounts of the type described in clauses (a) or (b) as a result
of any express or implied obligation to indemnify any other Person or as a result of any obligation under any agreement or arrangement
with any other Person with respect to such amounts and including any liability for taxes of a predecessor or transferor or otherwise
by operation of Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 568; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Tax
Return</i></b>&#8221; means any return (including any information return), report, statement, declaration, estimate, schedule, notice,
notification, form, election, certificate or other document, and any amendment or supplement to any of the foregoing, filed with or submitted
to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection
or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating
to any Tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Transfer
Agent</i></b>&#8221; means Computershare Inc. the current transfer agent of the Purchaser, with a mailing address of 480 Washington Blvd,
Jersey City, NJ 07310, email Brian.Cossin@computershare.com, and any successor transfer agent of the Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Treasury
Regulations</i></b>&#8221; means the United States Treasury regulations promulgated under the Code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Valid
Tax Certificate</i></b>&#8221; means a valid certificate, ruling or any other written instructions regarding Tax withholding, issued
by the ITA in form and substance reasonably satisfactory to Parent, that is applicable to the payments to be made to any holder of securities
of the Company pursuant to this Agreement stating that no withholding, or reduced withholding, of Tax is required under Israeli law with
respect to such payment or providing other instructions regarding such payment or withholding. For purposes hereof, the Withholding Tax
Ruling and the 104H Ruling will be considered a Valid Tax Certificate, provided they include such instructions, and further provided
that if the applicable ruling requires the affirmative consent of the relevant holder, such holder consented in writing to join any such
applicable ruling.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>VAT</i></b>&#8221;
means Value Added Tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Withholding
Agent</i></b>&#8221; means a bank or trust company in Israel appointed, if necessary, by the Parent reasonably acceptable to the Company
to act as Parent&#8217;s withholding agent for Israeli tax withholding purposes and taking such other actions with respect to, Israeli
Tax, as stipulated in <span style="text-decoration:underline">Section </span>1.10.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Withholding
Tax Ruling</i></b>&#8221; means a ruling (i) </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exempting
from or deferring Israeli Tax on any consideration payable to each Payee which holds less than 5% in the Company share capital on a date
which is ten (10) days prior to the Closing Date (a &#8220;<b><i>Less Than 5% Payee</i></b>&#8221;), pursuant to this Agreement, to such
time as determined in the Withholding Tax Ruling, or (ii) instructing the Payor and its agents on how such withholding is to be executed
from the payment of such consideration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><!-- Field: Page; Sequence: 569; Value: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><div><a id="m_029"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ANNEX
B</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: normal"><i>Execution
Copy</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SHAREHOLDER SUPPORT AGREEMENT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Shareholder Support
Agreement, dated as of April 10, 2024 (this &#8220;<b>Agreement</b>&#8221;), is entered into by and among SciSparc Ltd., an Israeli limited
company (the &#8220;<b>Parent</b>&#8221;) and each of the shareholders of AutoMax Motors Ltd. (the &#8220;<b>Company</b>&#8221;) listed
on <span style="text-decoration:underline">Schedule I</span> hereto (the &#8220;<b>Shareholders</b>&#8221;).</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">W I T N E S S E T H:</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, Parent, SciSparc
Merger Sub Ltd., a company organized under the laws of the State of Israel and a wholly-owned subsidiary of Parent (&#8220;<b>Merger
Sub</b>&#8221;), and the Company are concurrently with this Agreement entering into that certain Agreement and Plan of Merger a copy
of which was provided to the Shareholders (the &#8220;<b>Merger Agreement</b>&#8221;), pursuant to which, among other things, at the
Effective Time, Merger Sub will merge with and into the Company, with the Company continuing as the Surviving Company and a wholly owned
subsidiary of Parent on the terms and conditions set forth in the Merger Agreement (the &#8220;<b>Merger</b>&#8221;) on the terms and
subject to the conditions set forth in the Merger Agreement and by way of a court approved arrangement between the Company and its shareholders
and, if applicable, its creditors and bondholders, in accordance with the provisions of Sections 350 and 351 of the Companies Law 5759-1999
of the State of Israel (together with the rules and regulations promulgated thereunder, the &#8220;<b>Companies Law</b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, each Shareholder,
as of the date hereof, holds or Beneficially Owns its Existing Shares; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, as a condition
and material inducement to the Parent&#8217;s willingness to enter into the Merger Agreement and to consummate the transactions contemplated
thereby, including the Merger, the Shareholders have agreed to enter into this Agreement, pursuant to which the Shareholders are agreeing,
among other things, to vote all of their Covered Shares in accordance with the terms of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the mutual representations, warranties, covenants and agreements contained herein, and intending to be legally bound
hereby, the parties hereto hereby agree as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE I<span style="font-size: 10pt"><br/>
<br/>
GENERAL</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Defined
Terms</span>. Each of the following capitalized terms, as used in this Agreement, shall have the meaning set forth below next to such term.
Each capitalized term used but not otherwise defined in this Agreement shall have the meaning ascribed thereto in the Merger Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Beneficial
Ownership</span>&#8221; the ownership of Company Shares, including Company Shares of which a Shareholder directly or indirectly, through
any contract, arrangement, understanding, relationship, or otherwise has or shares the power to vote or direct the voting of, or the
power to dispose or to direct the disposition of, such Company Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Company
Shares</span>&#8221; means ordinary shares, par value NIS 0.05 per share, of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Covered
Shares</span>&#8221; means each Shareholder&#8217;s Existing Shares, together with any Company Shares or other voting share capital of Company
issuable upon the conversion, exercise or exchange of securities that are, as of the relevant date, convertible into or exercisable or
exchangeable for Company Shares or other voting share capital of Company, and any other Company Shares or other voting share capital
of Company, in each case that such Shareholder has or acquires Beneficial Ownership of on or after the date hereof and prior to the termination
of this Agreement (including by means of purchase, dividend or distribution, or upon the exercise of any stock options, warrants or other
rights).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 570; Options: NewSection --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Existing
Shares</span>&#8221; means the Company Shares Beneficially Owned by such Shareholder as of the date hereof. Each Shareholder represents
and warrants that all of the Existing Shares owned by such Shareholder are as set forth in <span style="text-decoration:underline">Exhibit B</span> hereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Expiration
Date</span>&#8221; means any date upon which the Merger Agreement is validly terminated (for any reason) in accordance with its terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Permitted
Transfer</span>&#8221; means a Transfer of Covered Shares by any Shareholder to a Permitted Transferee, <i>provided</i> that (i) the transferee
remains a Permitted Transferee of such Shareholder at all times following such Transfer until the termination of this Agreement in accordance
with Section 5.1 hereof; <i>provided further</i>, that prior to the effectiveness of such Transfer (A) written notice of such Transfer
is delivered to Parent in accordance with <b>&#8206;</b><span style="text-decoration:underline">Section 5.4</span>, and (B) such transferee executes and delivers to the Parent
a joinder to this Agreement in the form attached hereto as <span style="text-decoration:underline">Exhibit A</span>, pursuant to which such transferee agrees to assume all of
such Shareholder&#8217;s obligations hereunder in respect of the securities subject to such Transfer and to be bound by the terms of
this Agreement, with respect to the securities subject to such Transfer, to the same extent as such Shareholder is bound hereunder and
to make each of the representations and warranties in respect of the securities Transferred as such Shareholder shall have made hereunder
(the &#8220;<span style="text-decoration:underline">Joinder Agreement</span>&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Permitted
Transferee</span>&#8221; means transfers of a Shareholder&#8217;s Covered Shares as <i>bona fide </i>charitable contributions, gifts or
donations, (ii) transfers or dispositions of a Shareholder&#8217;s Covered Shares to an immediate family member of such Shareholder or
to any trust for the direct or indirect benefit of the Shareholder or the immediate family of such Shareholder, (iii) transfers or dispositions
of a Shareholder&#8217;s Covered Shares by will, other testamentary document or intestate succession to the legal representative, heir,
beneficiary or a member of the immediate family of such Shareholder, (iv) if a Shareholder is a partnership, limited liability company,
corporation or other entity, transfers of such Shareholder&#8217;s Covered Shares to the shareholders, partners (general or limited),
members, managers, other equity holders or affiliates of such Shareholder, as applicable, or to the estates of any such shareholders,
partners, members, managers, other equity holders or affiliates, or to another corporation, partnership, limited liability company or
other entity that controls, is controlled by or is under common control with such Shareholder or with any of such Shareholder&#8217;s
partners, members, managers or other equity holders or affiliates (v) transfers that occur by operation of law pursuant to a qualified
domestic relations order or in connection with a divorce settlement, (vi) transfers or dispositions not involving a change in beneficial
ownership, and (vii) if a Shareholder is a trust, transfers or dispositions to any beneficiary of such Shareholder or the estate of any
such beneficiary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Transfer</span>&#8221;
means, directly or indirectly, to sell, transfer, assign, pledge, encumber, hypothecate, convey any legal or beneficial interest in,
or otherwise dispose of (by merger (including by conversion into securities or other consideration), by tendering into any tender or
exchange offer, by testamentary disposition, by operation of Law or otherwise), either voluntarily or involuntarily, or to enter into
any Contract or other arrangement or understanding with respect to the voting of or sale, transfer, assignment, pledge, encumbrance,
hypothecation, conveyance of any direct or indirect legal or beneficial interest in, or other disposition of (by merger, by tendering
into any tender or exchange offer, by testamentary disposition, by operation of Law or otherwise) the Covered Shares.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 571 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE II<span style="font-size: 10pt"><br/>
<br/>
VOTING</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Agreement
to Vote</span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt">Each
Shareholder hereby irrevocably and unconditionally agrees that during the period beginning on the date hereof and ending upon the termination
of this Agreement in accordance with its terms, at any meeting of the Company&#8217;s Shareholders, however called, including any adjournment
or postponement thereof, such Shareholder shall, in each case, to the fullest extent that such matters are submitted for the vote of
the Company Shareholders and that the Covered Shares are entitled to vote thereon or consent thereto:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;<span style="font-size: 10pt">appear
at each such meeting or otherwise cause all of its Covered Shares to be counted as present for purposes of calculating a quorum; and
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;<span style="font-size: 10pt">vote
(or cause to be voted), in person or by a proxy covering all of its Covered Shares (A) in favor of (1) the approval of the Merger and
the other transactions contemplated by the Merger Agreement; (2) any action in connection with the Merger and the Contemplated Transactions;
or (3) any proposal to adjourn or postpone to a later date any meeting of the Company&#8217;s Shareholders at which any of the foregoing
matters of this <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.1(a)(ii)</span> are submitted for consideration and vote of the Company Shareholders if
there are not sufficient votes for approval of any such matters on the date on which the meeting is held, and (B) against (1)&#160;any
Acquisition Proposal or Acquisition Inquiry; (2)&#160;any other action, proposal, transaction or agreement involving Company that is
intended or would reasonably be expected to have the effect of frustrating the purposes of the Merger or preventing, impeding, interfering
with, delaying, postponing or impairing the ability of the Company, Parent or Merger Sub to consummate the Merger or any other transaction
contemplated by the Merger Agreement; or (3)&#160;any action or Contract that would be expected to result in any condition to the consummation
of the Merger set forth in Sections 6, 7 or 8 of the Merger Agreement not being fulfilled on or prior to the End Date. No Shareholder
shall enter into any Contract with any Person prior to the termination of this Agreement to vote in any manner inconsistent herewith.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt">Any
vote required to be cast or consent required to be executed pursuant to this <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.1</span> shall be cast (or
consent shall be given if legally valid) by such Shareholder in accordance with such procedures relating thereto so as to ensure that
it is duly counted, including for purposes of determining whether a quorum is present.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt">Except
as explicitly set forth in this <span style="text-decoration:underline">Section 2.1</span>, nothing in this Agreement shall limit the right of each Shareholder to vote in favor
of, against or abstain with respect to any other matters presented to the Company Shareholders. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="font-size: 10pt">The
obligations of each Shareholder specified in this <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.1</span> shall not be affected by the commencement, public
proposal, public disclosure or communication to Company of any Acquisition Proposal, Acquisition Inquiry or by any Company Board Adverse
Recommendation Change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 572 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.2 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Grant
of Irrevocable Proxy; Appointment of Proxy.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt">From
and after the date hereof until the Expiration Date, each Shareholder hereby irrevocably and unconditionally grants to, and appoints,
the Parent as such Shareholder&#8217;s proxy and attorney-in-fact (with full power of substitution) in accordance with the Companies
Law, for and in the name, place and stead of such Shareholder, to attend any and all meetings of the Company&#8217;s Shareholders and
to vote or cause to be voted (including by proxy) the Covered Shares in accordance with this Agreement; <span style="text-decoration:underline">provided</span> that each Shareholder&#8217;s
grant of the proxy contemplated by this <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.2</span> shall be effective if, and only if, such Shareholder has
failed to act in accordance with such Shareholder&#8217;s obligations as to voting pursuant to <span style="text-decoration:underline">Section 2.1</span> of this Agreement by
delivering to Company at least 5 business days prior to the meeting at which any of the matters described in <b>&#8206;</b><span style="text-decoration:underline">Section 2.1
</span>are to be considered, a duly executed irrevocable proxy card directing that the Covered Shares of such Shareholder be voted in accordance
with this Agreement. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;<span style="font-size: 10pt">Each
Shareholder hereby represents that any proxies heretofore given in respect of the Covered Shares, if any, are revocable, and hereby revokes
all such proxies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;<span style="font-size: 10pt">Each
Shareholder hereby affirms that the irrevocable proxy set forth in <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.2</span>, if it becomes effective, is
given in connection with the execution of the Merger Agreement, and that such irrevocable proxy is given to secure the performance of
the duties of such Shareholder under this Agreement. The parties hereby further affirm that the irrevocable proxy, if it becomes effective,
is coupled with an interest and is intended to be irrevocable until the Expiration Date, at which time it will terminate automatically,
at which time any underlying appointment shall automatically be revoked and rescinded and of no force and effect, in each case without
further action by any party. The proxy granted by the Shareholders herein shall survive the dissolution, bankruptcy, death or incapacity
of any Shareholder. If for any reason any proxy granted herein is not irrevocable after it becomes effective, then the Shareholder granting
such proxy agrees, until the Expiration Date, to vote, or to cause the holder of record on any applicable record date to vote, the Covered
Shares in accordance with this Agreement. The parties agree that the foregoing is a voting agreement.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE III<span style="font-size: 10pt"><br/>
<br/>
REPRESENTATIONS AND WARRANTIES </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Representations
and Warranties of Each Shareholder</span>. Each Shareholder hereby represents and warrants to Parent and the Company, as of the date hereof,
and at all times during the term of this Agreement, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Authorization</span>.
Such Shareholder has the power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate
the transactions contemplated hereby. The execution and delivery by such Shareholder of this Agreement, the performance by it of its
obligations hereunder and the consummation by it of the transactions contemplated hereby have been duly and validly authorized by all
necessary action on the part of such Shareholder and no other actions or proceedings on the part of such Shareholder are necessary to
authorize the execution and delivery by it of this Agreement, the performance by it of its obligations hereunder or the consummation
by it of the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by such Shareholder and,
assuming this Agreement constitutes a valid and binding obligation of Parent, constitutes a legal, valid and binding obligation of such
Shareholder, enforceable against it in accordance with its terms (except to the extent that enforceability may be limited by the Enforceability
Exceptions).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 573 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Ownership</span>.
Such Shareholder&#8217;s Existing Shares are, and all Covered Shares of such Shareholder from the date hereof through and on the Closing
Date will be, Beneficially Owned and owned of record by such Shareholder or by a Permitted Transferee. Except as set forth in Schedule<b>&#8206;&#8206;&#8206;
</b>3.1(b), such Shareholder has good and valid title to such Shareholder&#8217;s Existing Shares, free and clear of any Encumbrances
(except for transfer restrictions arising under securities Laws). Except as set forth in Schedule<b>&#8206;&#8206;&#8206;</b> 3.1(b1), other
than the Existing Shares, as of the date hereof such Shareholder does not Beneficially Own or own of record: (i)&#160;any securities
of Company convertible into or exchangeable or exercisable for shares of the share capital or other voting securities or equity interests
of Company; (ii)&#160;any warrants, calls, options or other rights to acquire from Company any share capital, voting securities, equity
interests or securities convertible into or exchangeable or exercisable for share capital or voting securities of Company, or any stock
appreciation rights; (iii)&#160;&#8220;phantom&#8221; stock rights, performance units or other rights to receive Company Shares (or cash
or other economic benefit in respect thereof) on a deferred basis; or (iv) other rights that are linked to the value of Company Shares.
As of the date hereof, such Shareholder&#8217;s Existing Shares constitute all of the Company Shares that are Beneficially Owned or owned
of record by such Shareholder. Such Shareholder has and will have at all times through the Effective Time sole voting power (including
the right to control such vote as contemplated herein), sole power of disposition, sole power to issue instructions with respect to the
matters set forth in <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">ARTICLE II</span> and sole power to agree to all of the matters set forth in this Agreement,
in each case with respect to all of such Shareholder&#8217;s Existing Shares and with respect to all of the Covered Shares owned by such
Shareholder at all times through the Effective Time. Each Shareholder hereby represents that all proxies, powers of attorney, instructions
or other requests given by such Shareholder prior to the execution of this Agreement in respect of the voting of such Shareholder&#8217;s
Covered Shares, if any, are revocable by such Shareholder at any time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">No
Violation</span>. The execution, delivery and performance of this Agreement by such Shareholder does not and will not, and the consummation
of the transactions contemplated hereby and the compliance with the provisions hereof do not and will not (in each case, whether with
or without notice or lapse of time, or both):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;<span style="font-size: 10pt">violate,
conflict with or result in the breach of any provision of the Organizational Documents of such Shareholder (to the extent such Shareholder
is not a natural Person);</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;<span style="font-size: 10pt">violate,
conflict with or result in the breach of any of the terms or conditions of, result in any (or the right to make any) modification of
or the cancellation or loss of a benefit under, require any notice, consent or action under, or otherwise give any Person the right to
terminate, accelerate obligations under or receive payment or additional rights under, or constitute a default under, any Contract to
which such Shareholder is a party or by which it is bound; </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;<span style="font-size: 10pt">require
any consent of, approval, authorization or permit of, filing with or license from or registration, declaration or notification to any
Governmental Body (except for filings, if any, under the Israeli Securities Law, 5728-1968 or the Companies Law); or </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;<span style="font-size: 10pt">violate
or conflict with any Law applicable to such Shareholder or by which any of such Shareholder&#8217;s assets or properties is bound.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except under the Organizational Documents of
Company and as set forth by such Shareholder&#8217;s name in <span style="text-decoration:underline">Exhibit B</span>, such Shareholder&#8217;s Existing Shares are not, with
respect to the voting or Transfer thereof, subject to any other Contract (other than a Contract for Transfer of Existing Shares to a
Permitted Transferee), including any voting agreement, shareholders agreement, irrevocable proxy or voting trust.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Absence
of Litigation</span>. There is no Legal Proceeding pending or, to the knowledge of such Shareholder, threatened by, against, involving or
affecting such Shareholder or the Covered Shares, that would reasonably be expected to impair the ability of such Shareholder to perform
its obligations hereunder or to consummate the transactions contemplated hereby on a timely basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Reliance
by the Parent</span>. Such Shareholder understands and acknowledges that the Parent is entering into the Merger Agreement in reliance upon
the execution and delivery of this Agreement by such Shareholder and the representations, warranties, covenants and agreements of such
Shareholder contained herein and that the same are a material inducement thereto. Such Shareholder understands and acknowledges that
the Merger Agreement governs the terms of the Merger and the other transactions contemplated by the Merger Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 574 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="font-size: 10pt; background-color: white">&#160;</span><span style="font-size: 10pt"><span style="text-decoration:underline">Independent
Advice</span><span style="background-color: white">. </span>Such Shareholder has carefully reviewed the Merger Agreement, the other documentation
relating to the Merger and other transactions contemplated in the Merger Agreement referred to therein and this Agreement and has had
an opportunity to discuss the Merger Agreement, such other documentation and this Agreement with an attorney of his, her or its own choosing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.2 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Representations
and Warranties of the Parent</span>. The Parent hereby represents and warrants to the Shareholders, as of the date hereof, and at all times
during the term of this Agreement, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Authorization</span>.
The Parent has the power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate
the transactions contemplated hereby. The execution and delivery by the Parent of this Agreement, the performance by the Parent of its
obligations hereunder and the consummation by the Parent of the transactions contemplated hereby have been duly and validly authorized
by all necessary action on the part of the Parent and no other actions or proceedings on the part of the Parent are necessary to authorize
the execution and delivery by the Parent of this Agreement, the performance by the Parent of its obligations hereunder or the consummation
by the Parent of the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by the Parent
and, assuming this Agreement constitutes a valid and binding obligation of the other parties hereto, constitutes a legal, valid and binding
obligation of the Parent, enforceable against the Parent in accordance with its terms (except to the extent that enforceability may be
limited by the Enforceability Exceptions).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">No
Violation</span>. The execution, delivery and performance of this Agreement by the Parent does not and will not, and the consummation of
the transactions contemplated hereby and the compliance with the provisions hereof do not and will not (in each case, whether with or
without notice or lapse of time, or both):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;<span style="font-size: 10pt">violate,
conflict with or result in the breach of any provision of the Organizational Documents of the Parent;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;<span style="font-size: 10pt">violate,
conflict with or result in the breach of any of the terms or conditions of, result in any (or the right to make any) modification of
or the cancellation or loss of a benefit under, require any notice, consent or action under, or otherwise give any Person the right to
terminate, accelerate obligations under or receive payment or additional rights under, or constitute a default under, any Contract to
which the Parent is a party or by which the Parent is bound; </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;<span style="font-size: 10pt">require
any consent of, approval, authorization or permit of, filing with or license from or registration, declaration or notification to any
Governmental Entity (except for filings, if any, under the Exchange Act, the Israeli Securities Law, 5728-1968 or the Companies Law);
or </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;<span style="font-size: 10pt">violate
or conflict with any Law applicable to the Parent or by which any of the Parent&#8217;s assets or properties is bound.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Absence
of Litigation</span>. There is no Legal Proceeding pending or, to the knowledge of the Parent, threatened by, against, involving or affecting
the Parent that would reasonably be expected to impair the ability of the Parent to perform its obligations hereunder or to consummate
the transactions contemplated hereby on a timely basis.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 575 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE IV<span style="font-size: 10pt"><br/>
<br/>
OTHER COVENANTS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">No
Solicitation</span>. Each Shareholder shall not (a)&#160;engage or participate in, or knowingly facilitate, any discussions or negotiations
regarding any Acquisition Proposal of the Company, (b)&#160;furnish to any Person other than the Company or Parent any non-public information
that could reasonably be expected to be used for the purposes of formulating any Acquisition Proposal of the Company, or (c)&#160;enter
into any letter of intent, agreement in principle or other similar type of agreement relating to any Acquisition Proposal of Company.
If prior to the Expiration Date, any Shareholder receives an Acquisition Proposal, then such Shareholder will promptly notify the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.2 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Prohibition
on Transfers; Other Actions</span>. During the term of this Agreement, each Shareholder hereby agrees not to (a) Transfer any of the Covered
Shares, Beneficial Ownership thereof or any other interest therein (including by tendering into a tender or exchange offer), unless such
Transfer is a Permitted Transfer; (b) grant any proxy, consent or power of attorney with respect to any of the Covered Shares or deposit
any of the Covered Shares into a voting trust or enter into a voting agreement, voting trust or arrangement with respect to any such
Covered Shares; (c) take any other action that would or would reasonably be expected to make any representation or warranty contained
in this Agreement untrue or incorrect or that would or would reasonably be expected to restrict or otherwise adversely affect the performance
of or have the effect of preventing or disabling such Shareholder from performing any of its obligations under this Agreement; or (d)
commit or agree (whether or not in writing) to take any of the actions prohibited by the foregoing clause (a), (b) or (c). Any Transfer
or other action in violation of this provision shall be void <i>ab initio. </i>It is hereby clarified that if any involuntary Transfer
of any of the Covered Shares shall occur (such as in the case of appointment of a receiver to Shareholder&#8217;s assets as part of bankruptcy
proceedings), the transferee (which term, as used herein, shall include the initial transferee and any and all subsequent transferees
of the initial transferee) shall take and hold such Covered Shares subject to all of the restrictions, liabilities and rights under this
Agreement, which shall continue in full force and effect until the valid termination of this Agreement. During the term of the Agreement,
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent (if relevant) with respect to any sale,
pledge, or transfer, except upon the conditions specified in this Agreement. A transferring Shareholder will cause any proposed transferee
of the Covered Shares pursuant to a Permitted Transfer to agree to take and hold such securities subject to the provisions and upon the
conditions specified in this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.3 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Share
Dividends, etc</span>. In the event of a share split, share dividend or distribution (including any dividend or distribution of securities
convertible into Company Shares), or any change in the Company Shares by reason of any split-up, reverse share split, recapitalization,
reorganization, combination, reclassificat<span style="text-decoration:underline">i</span>on, reincorporation, exchange of shares or the like, the terms &#8220;Existing Shares&#8221;
and &#8220;Covered Shares&#8221; shall be deemed to refer to and include such shares as well as all such share dividends and distributions
and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.4 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Public
Announcements</span>. Except as required by applicable Law (in which case the Shareholders shall use reasonable best efforts to allow the
Parent reasonable time to comment on such announcement and shall consider in good faith any comments provided by the Parent), no public
announcements by the Shareholders regarding this Agreement, the transactions contemplated hereby, the Merger Agreement or the transactions
contemplated thereby are permitted. Each Shareholder (a) to the extent such consent or authorization of such Shareholder is required,
consents to and authorizes the publication and disclosure by Parent, the Company and their respective affiliates of such Shareholder&#8217;s
identity and holding of the Covered Shares and the nature of its commitments and obligations under this Agreement in any announcement
or disclosure required (in the opinion of the Parent&#8217;s counsel) by the SEC, the Israel Securities Authority or any other Governmental
Body or the rules or regulations of any applicable securities exchange (including Nasdaq and TASE); (b) agrees as promptly as practicable
to give to Parent and the Company any information that it may reasonably require for the preparation of any such announcement or disclosure
documents; and (c) agrees to promptly notify Parent and the Company of any required corrections with respect to any written information
supplied by it specifically for use in any such disclosure document, if any, to the extent that any shall be or have become false or
misleading, in any material respect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 576 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.5 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Further
Assurances</span>. Each Shareholder agrees, from time to time, at the request of the Parent and without further consideration, to execute
and deliver such additional documents and take all such further action as may be reasonably required to consummate and make effective,
in the most expeditious manner practicable, the transactions contemplated by this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.6 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Acquisition
of Covered Shares</span>. Each Shareholder agrees that any additional Covered Shares acquired by such Shareholder after the date of this
Agreement and prior to the Expiration Date (including through the exercise of any Company options or otherwise) shall automatically be
subject to the terms of this Agreement as though owned by such Shareholder on the date hereof. Each Shareholder hereby agrees to notify
the Company in writing as promptly as practicable (and in any event within one Business Day of receipt following such acquisition by
such Shareholder) of the number of any additional Covered Shares or other securities of Company of which the Shareholder acquires Beneficial
Ownership on or after the date hereof.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE V<span style="font-size: 10pt"><br/>
<br/>
MISCELLANEOUS </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Termination</span>.
This Agreement shall remain in effect until the earliest to occur of (a) the Expiration Date and (b) the Effective Time; <i>provided,
however,</i> that the provisions of this <b><i><span style="text-decoration:underline">&#8206;</span></i></b><span style="text-decoration:underline">ARTICLE V</span> shall survive any termination of this Agreement.
Neither the provisions of this <b><i>&#8206;</i></b><span style="text-decoration:underline">Section 5.1</span> nor the termination of this Agreement shall relieve any party hereto
from any liability of such party to any other party arising out of or in connection with a breach of this Agreement incurred prior to
such termination or expiration. For the avoidance of doubt, in the event this Agreement is terminated prior to the Effective Time, any
consent or other document executed pursuant hereto shall be deemed null and void and shall have no further effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.2 </b><span style="font-size: 10pt"><span style="text-decoration:underline">No
Ownership Interest</span>. Nothing contained in this Agreement shall be deemed to vest in the Parent or any other Person any direct or indirect
ownership or incidence of ownership of or with respect to any Covered Shares. All rights, ownership and economic benefits of and relating
to the Covered Shares shall remain vested in and belong to each respective Shareholder, and neither the Parent nor any other Person shall
have any authority to direct such Shareholder in the voting or disposition of any of the Covered Shares, except as otherwise expressly
provided herein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.3 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Expenses</span>.
All costs and expenses incurred in connection with this Agreement and the transactions contemplated by this Agreement shall be paid by
the party incurring such costs and expenses, whether or not the Merger is consummated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 577 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.4 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Notices</span>.
All notices, consents and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly
given upon receipt) by hand delivery, by prepaid overnight courier (providing written proof of delivery) or by confirmed electronic mail,
addressed as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to the Parent, to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">SciSparc Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">20 Raul Wallenberg
Street, Tower A </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Tel Aviv, Israel,
6971916</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Attention: Oz Adler</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Email: </span>oz@scisparc.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">with a copy to (which shall not constitute notice):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Meitar | Law Offices</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">16 Abba Hillel Rd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Ramat Gan 5250608,
Israel</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Tel: (+972) (3) 610-3100</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Attention: Dr. Shachar
Hadar</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Email: shacharh@meitar.com</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">And</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Sullivan &amp; Worcester
LLP</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">1633 Broadway</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">New York, NY 10019</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Tel: (212) 660-3000</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Attention: Oded Har-Even,
Esq., Howard E. Berkenblit, Esq</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Email: ohareven@sullivanlaw.com,
hberkenblit@sullivanlaw.com </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to the Shareholders, to the address set forth in the signature
page hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any notice received at the
addressee&#8217;s location on any Business Day after 5:00 p.m., addressee&#8217;s local time, or on any day that is not a Business Day
will be deemed to have been received at 9:00 a.m., addressee&#8217;s local time, on the next Business Day. From time to time, any party
hereto may provide notice to the other parties of a change in its address through a notice given in accordance with this &#8206;<span style="text-decoration:underline">Section
5.4</span>, except that notice of any change to the address or any of the other details specified in or pursuant to this &#8206;<span style="text-decoration:underline">Section
5.4</span> will not be deemed to have been received until, and will be deemed to have been received upon, the later of the date that is
(a) specified in such notice; or (b) five Business Days after such notice would otherwise be deemed to have been received pursuant to
this &#8206;<span style="text-decoration:underline">Section 5.4</span>. The inability to deliver because of changed address of which no notice is given will be deemed to be receipt
of the notice as of the date of such inability to deliver.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.5 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Interpretation.
</span>The words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; &#8220;hereunder&#8221; and &#8220;herewith&#8221; and
words of similar import shall refer to this Agreement as a whole and not to any particular provision of this Agreement. References to
articles, sections, paragraphs, exhibits, annexes and schedules are to the articles, sections and paragraphs of, and exhibits, annexes
and schedules to, this Agreement, unless otherwise specified, and the headings in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221;
or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the phrase &#8220;without limitation.&#8221;
Words describing the singular number shall be deemed to include the plural and vice versa, words denoting any gender shall be deemed
to include all genders, words denoting natural persons shall be deemed to include business entities and vice versa and references to
a Person are also to its permitted successors and assigns. The term &#8220;or&#8221; is not exclusive. The word &#8220;extent&#8221;
in the phrase &#8220;to the extent&#8221; shall mean the degree to which a subject or other thing extends, and such phrase shall not
mean simply &#8220;if.&#8221; Any Law or agreement defined or referred to herein or in any agreement or instrument that is referred to
herein shall mean such Law or agreement as from time to time amended, modified or supplemented, including (in the case of statutes) by
succession of comparable successor Laws (provided that for purposes of any representations and warranties contained in this Agreement
that are made as of a specific date or dates, references to any statute or agreement shall be deemed to refer to such statute or agreement,
as amended, and to any rules or regulations promulgated thereunder, in each case, as of such date).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 578 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.6 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Counterparts</span>.
This Agreement and any amendments hereto may be executed in one or more identical counterparts, all of which will be considered one and
the same agreement and will become effective when one or more counterparts have been signed by each party hereto and delivered to the
other parties, it being understood that all parties need not sign the same counterpart. Any such counterpart, to the extent delivered
electronically will be treated in all manners and respects as an original executed counterpart and will be considered to have the same
binding legal effect as if it were the original signed version thereof delivered in person. No party hereto may raise the use of electronic
delivery to deliver a signature, or the fact that any signature or agreement or instrument was transmitted or communicated through the
use of electronic delivery, as a defense to the formation of a contract, and each party forever waives any such defense, except to the
extent such defense relates to lack of authenticity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.7 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Entire
Agreement</span>. This Agreement and the documents and instruments and other agreements among the parties as contemplated by or referred
to herein or therein constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof and thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Section 5.8 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Governing
Law; Consent to Jurisdiction</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt">This
Agreement and any dispute, controversy or claim arising out of, relating to or in connection with this Agreement, the negotiation, execution,
existence, validity, enforceability or performance of this Agreement, or for the breach or alleged breach hereof (whether in contract,
in tort or otherwise) shall be governed by and construed and enforced solely in accordance with the Laws of the State of Israel, without
giving effect to any choice of Law or conflict of Law provision or rule (whether of the State of Israel or otherwise) that would cause
the application of the Laws of any jurisdiction other than the State of Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt">Each
of the parties (i) irrevocably consents to the service of statement of claim and any other process in any action or proceeding relating
to the transactions contemplated by this Agreement, for and on behalf of itself or any of its properties or assets, in accordance with
<b>&#8206;</b><span style="text-decoration:underline">Section 5.4</span> or in such other manner as may be permitted by Applicable Law, and nothing in this <b>&#8206;</b><span style="text-decoration:underline">Section
5.8</span> shall affect the right of any party to serve legal process in any other manner permitted by Applicable Law, (ii) irrevocably
and unconditionally submits, for itself and its property, to the exclusive jurisdiction of any court located in Tel Aviv-Jaffa, Israel,
in any action or proceeding arising out of or relating to this Agreement or the agreements delivered in connection herewith or the transactions
contemplated hereby or thereby or for recognition or enforcement of any judgment relating thereto, and (iii)&#160;irrevocably and unconditionally
(A) agrees not to commence any such action or proceeding except in any competent court located in Tel Aviv-Jaffa, Israel, (B)&#160;agrees
that any claim in respect of any such action or proceeding may be heard and determined in any competent court located in Tel Aviv-Jaffa,
Israel, (C)&#160;waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have
to the laying of venue of any such action or proceeding in such courts, and (D) waives, to the fullest extent permitted by Law, and agrees
not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient
forum. Each of the parties agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 579 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt">Each
party hereto irrevocably consents to the service of process in any Legal Proceeding with respect to this Agreement and the transactions
contemplated by this Agreement or for recognition and enforcement of any judgment in respect hereof brought by any other party hereto
made by mailing copies thereof by registered mail, postage prepaid, return receipt requested, to its address as specified in or pursuant
to <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 5.4</span> and such service of process shall be sufficient to confer personal jurisdiction over such party
in such Legal Proceeding and shall otherwise constitute effective and binding service in every respect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.9 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Specific
Performance</span>. The Shareholders hereby acknowledge and agree that the Parent will suffer irreparable damage in the event that any of
the obligations of the Shareholders in this Agreement are not performed in accordance with its specific terms or if the Agreement is
otherwise breached by the Shareholders and that money damages, even if available, would not be an adequate remedy therefor. Accordingly,
each Shareholder agrees that the Parent shall be entitled to specific performance, an injunction, restraining order and/or such other
equitable relief, in addition to any other rights and remedies existing in its favor at law or in equity, as a court of competent jurisdiction
may deem necessary or appropriate to enforce its rights and such Shareholder&#8217;s obligations hereunder (without posting of bond or
other security). The Shareholders agree not to raise any objection or legal or equitable defense to the availability of any equitable
remedy that the Parent may have in respect of this Agreement. These injunctive remedies are cumulative and in addition to any other rights
and remedies the Parent may have at law or in equity. In the event the Parent seeks an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions of this Agreement, the Parent shall not be required to provide
any bond or other security in connection with any such order or injunction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.10 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Amendment;
Waiver</span>. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except
by an instrument in writing signed by each of the parties. Any party hereto may, to the extent permitted by Law, waive compliance with
any of the agreements or conditions for the benefit of such party contained herein if such waiver is set forth in an instrument in writing
signed on behalf of such party. Any delay in exercising any right under this Agreement shall not constitute a waiver of such right.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.11 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Severability</span>.
In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court of competent jurisdiction
to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such
provision to other Persons or circumstances will be interpreted so as reasonably to effect the intent of the parties. The parties further
agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to
the extent possible, the economic, business and other purposes of such void or unenforceable provision.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.12 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Assignment;
Successors; No Third Party Beneficiaries</span>. Neither this Agreement nor any of the rights, interests or obligations hereunder shall
be assigned by any of the parties hereto (whether by operation of Law or otherwise) without the prior written consent of the other parties
hereto. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by and against
the parties and their respective permitted successors and assigns. Any attempted assignment in violation of this <b><i>&#8206;</i></b><span style="text-decoration:underline">Section
5.12</span> shall be null and void <i>ab initio</i>. Nothing in this Agreement, express or implied, is intended to or shall confer upon
any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy
of any nature under or by reason of this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.13 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Shareholder
Capacity</span>. The parties acknowledge that this Agreement is entered into by each Shareholder solely in his or its capacity as the record
or Beneficial Owner of such Shareholder&#8217;s Company Shares and nothing in this Agreement restricts or limits any action taken by
such Shareholder in his capacity as a director or officer of Company. The taking of any action (or failure to act) by any Shareholder
in his capacity as an officer or director of Company will not be deemed to constitute a breach of this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<i>The remainder of this page is intentionally
left blank</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 580 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.3in; text-indent: -0.3in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.3in; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt"><b>THE PARENT:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt"><b>SCISPARC LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/s/ Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Oz Adler </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title:</span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">CFO </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>[Signature Page to Shareholder Support Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 581 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>SHAREHOLDERS:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">Haim Levy Trade-In Ltd.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in">/S/ Daniel Levy</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name: </span></td>
    <td style="text-indent: 0in; width: 31%">Daniel Levy</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title: </span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[SHAREHOLDERS]<br/>
[&#160;&#160;&#160;]<br/>
[&#160;&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [&#160;&#160;&#160; ]<br/>
Email: [&#160;&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with copies (which shall not constitute notice) to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#160;&#160;&#160;]<br/>
[&#160;&#160;&#160;]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [&#160;&#160;&#160;]<br/>
Email: [&#160;&#160;&#160;]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Shareholder
Support Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 582 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>SHAREHOLDERS:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt">A. Yinon (2015) Ltd. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/S/ Yinon Amit</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name: </span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Yinon Amit</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title: </span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[SHAREHOLDERS]<br/>
[ &#160;&#160;&#160;]<br/>
[ &#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [ &#160;&#160;]<br/>
Email: [ &#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with copies (which shall not constitute notice) to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#160;&#160; ]<br/>
[&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [ &#160;&#160;]<br/>
Email: [&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Shareholder
Support Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 583 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>SHAREHOLDERS:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt">Puzailov Investments Ltd.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/S/ Emanuel Paz Puzailov</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name: </span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Emanuel Paz Puzailov</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title: </span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director </span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 40%"><b>Emanuel Paz Puzailov</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">/S/ Emanuel Paz Puzailov</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[SHAREHOLDERS]<br/>
[&#160;&#160; ]<br/>
[&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [&#160;&#160; ]<br/>
Email: [ &#160;&#160;]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with copies (which shall not constitute notice) to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[ &#160;&#160;]<br/>
[&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [ &#160;&#160;]<br/>
Email: [ &#160;&#160;]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Shareholder
Support Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 584 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>SHAREHOLDERS:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt"><b>Eliyahu Baruch Ltd.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/S/ Eyal Baruch</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name:</span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Eyal Baruch</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title:</span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><b>Belporto Investments Ltd.</b></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/S/ Eyal Baruch</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Eyal Baruch</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title:</span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 20%">&#160;</td>
    <td style="width: 80%"><span style="font-size: 10pt">[SHAREHOLDERS]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">[&#160;&#160;&#160;] </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">[&#160;&#160;&#160;]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Attention: [&#160;&#160;&#160;]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Email: [&#160;&#160;&#160;]</span>&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>with copies (which shall not constitute notice) to:</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 20%">&#160;</td>
    <td style="width: 80%"><span style="font-size: 10pt">[&#160;&#160;&#160;] </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">[&#160;&#160;&#160;]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Attention: [&#160;&#160;&#160;]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Email: [&#160;&#160;&#160;]</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Shareholder
Support Agreement]</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 585 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">SCHEDULE I</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Haim Levy Trade-In Ltd.,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Yinon (2015) Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eliyahu Baruch Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Belporto Investments Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Puzailov Investments Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emanuel Paz Puzailov</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 586 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-decoration:underline">EXHIBIT A</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt">FORM
OF JOINDER AGREEMENT</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned is executing
and delivering this Joinder Agreement pursuant to that certain Shareholder Support Agreement, dated as of April 10, 2024 (as amended,
restated, supplemented or otherwise modified in accordance with the terms thereof, the &#8220;<b>Shareholder Support Agreement</b>&#8221;)
by and between SciSparc Ltd., an Israeli limited company, and each of the shareholders of AutoMax Motors Ltd., an Israeli limited company
(the &#8220;<b>Company</b>&#8221;), listed on Schedule I thereto (the &#8220;<b>Shareholders</b>&#8221;). Each capitalized term used
but not defined in this Joinder Agreement shall have the respective meaning ascribed to such term in the Shareholder Support Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By executing and delivering
this Joinder Agreement to the Shareholder Support Agreement, the undersigned hereby (i) adopts and approves the Shareholder Support Agreement,
(ii) assumes and agrees to comply with all of the Shareholder&#8217;s obligations under the Shareholder Support Agreement in respect
of the securities subject to the applicable Transfer and (iii) agrees, effective commencing on the date hereof and as a condition to
the Transfer, to become a party to, and to be bound by and comply with the provisions of, the Shareholder Support Agreement applicable
to the Shareholders, in the same manner as if the undersigned were an original signatory to the Shareholder Support Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby (i)
represents and warrants that, pursuant to this Joinder Agreement and the Shareholder Support Agreement, it is a Permitted Transferee
under the Shareholder Support Agreement and (ii) makes all of the representations and warranties set forth in Article 3 of the Shareholder
Support Agreement, <i>mutatis mutandis</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned acknowledges
and agrees that the provisions of &#8206;<span style="text-decoration:underline">ARTICLE V</span> of the Shareholder Support Agreement are incorporated herein by reference, <i>mutatis
mutandis</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<i>Remainder of page intentionally left blank</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 587 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, the undersigned have executed and
delivered this Joinder Agreement as of the _____ day of _______, _______.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.3in; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
    <td style="width: 40%; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PERMITTED TRANSFEREE</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Notice Information</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>


</div><!-- Field: Page; Sequence: 588 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="m_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ANNEX
C</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="text-decoration:underline">FORM OF indemnification
agreement</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS INDEMNIFICATION AGREEMENT (the &#8220;<b>Agreement</b>&#8221;),
dated as of __________, 2024, is entered into by and between SciSparc Ltd., an Israeli company whose address is 20 Raul Wallenberg St.,
Tower A, 2nd Floor, Tel Aviv 6971916, Israel (the &#8220;<b>Company</b>&#8221;), and the undersigned Director or Officer of the Company
whose name appears on the signature page hereto officer (the &#8220;<b>Indemnitee</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in">WHEREAS,</td><td style="text-align: justify"><span style="font-weight: normal">Indemnitee
                                            is an Office Holder (&#8220;<i>Nosse Misra</i>&#8221;), as such term is defined in the Companies
                                            Law, 5759&#8211;1999, as amended (the &#8220;</span>Office Holder<span style="font-weight: normal">&#8221;
                                            and the &#8220;</span>Companies Law<span style="font-weight: normal">&#8221;, respectively),
                                            of the Company; </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 70.9pt">WHEREAS,</td><td style="text-align: justify"><span style="font-weight: normal">both
                                            the Company and Indemnitee recognize the increased risk of litigation and other claims being
                                            asserted against Office Holders of companies and that highly competent persons have become
                                            more reluctant to serve corporations as directors and officers or in other capacities unless
                                            they are provided with adequate protection through insurance or adequate indemnification
                                            against inordinate risks of claims and actions against them arising out of their service
                                            to, and activities on behalf of, companies; </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 70.85pt">WHEREAS<span style="font-weight: normal">,</span></td><td style="text-align: justify"><span style="font-weight: normal">the
                                            Articles of Association of the Company authorize the Company to indemnify and advance expenses
                                            to its Office Holders and provide for insurance and exculpation to its Office Holders, in
                                            each case, to the fullest extent permitted by applicable law; </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 70.85pt">WHEREAS,</td><td style="text-align: justify"><span style="font-weight: normal">the
                                            Company has determined that (i) the increased difficulty in attracting and retaining competent
                                            persons is detrimental to the best interests of the Company&#8217;s shareholders and that
                                            the Company should act to assure such persons that there will be increased certainty of such
                                            protection in the future, and (ii) it is reasonable, prudent and necessary for the Company
                                            contractually to obligate itself to indemnify, and to advance expenses on behalf of, such
                                            persons to the fullest extent permitted by applicable law, so that they will serve or continue
                                            to serve the Company free from undue concern that they will not be so indemnified; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 70.85pt">WHEREAS,</td><td style="text-align: justify"><span style="font-weight: normal">in
                                            recognition of Indemnitee&#8217;s need for substantial protection against personal liability
                                            in order to assure Indemnitee&#8217;s continued service to the Company in an effective manner
                                            and, in part, in order to provide Indemnitee with specific contractual assurance that the
                                            indemnification, insurance and exculpation afforded by the Articles of Association will be
                                            available to Indemnitee, the Company wishes to undertake in this Agreement for the indemnification
                                            of and the advancing of expenses to Indemnitee to the fullest extent permitted by applicable
                                            law and as set forth in this Agreement and provide for insurance and exculpation of Indemnitee
                                            as set forth in this Agreement.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOW, THEREFORE</b>, the parties hereto agree
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">1.</td><td style="text-align: justify"><b>INDEMNIFICATION AND INSURANCE.</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.1.</td><td style="text-align: justify">The Company hereby undertakes
                                            to indemnify Indemnitee to the fullest extent permitted by applicable law for any liability
                                            and expense specified in Sections &#8206;1.1.1 through &#8206;1.1.4 below, imposed on Indemnitee
                                            due to or in connection with an act performed by such Indemnitee, either prior to or after
                                            the date hereof, in Indemnitee&#8217;s capacity as an Office Holder, including, without limitation,
                                            as a director, officer, employee, agent or fiduciary of the Company, any subsidiary thereof
                                            or any other corporation, collaboration, partnership, joint venture, trust or other enterprise,
                                            in which Indemnitee serves at any time at the request of the Company (the &#8220;<b>Corporate
                                            Capacity</b>&#8221;). The term &#8220;act performed in Indemnitee&#8217;s capacity as an
                                            Office Holder&#8221; shall include, without limitation, any act, omission or failure to act
                                            and any other circumstances relating to or arising from Indemnitee&#8217;s service in a Corporate
                                            Capacity. Notwithstanding the foregoing, in the event that the Office Holder is the beneficiary
                                            of an indemnification undertaking provided by a subsidiary of the Company or any other entity,
                                            with respect to his or her Corporate Capacity with such subsidiary or entity, then the indemnification
                                            obligations of the Company hereunder with respect to such Corporate Capacity shall only apply
                                            to the extent that the indemnification by such subsidiary or other entity does not actually
                                            fully cover the indemnifiable liabilities and expenses relating thereto. The following shall
                                            be hereinafter referred to as &#8220;<b>Indemnifiable Events</b>&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 589; Options: NewSection --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 63.8pt"/><td style="width: 42.5pt">1.1.1.</td><td style="text-align: justify">Financial liability imposed
                                            on Indemnitee in favor of any person pursuant to a judgment, including a judgment rendered
                                            in the context of a settlement or an arbitrator&#8217;s award approved by a court. For purposes
                                            of Section &#8206;1 of this Agreement, the term &#8220;<b>person</b>&#8221; shall include,
                                            without limitation, a natural person, firm, partnership, joint venture, trust, company, corporation,
                                            limited liability entity, unincorporated organization, estate, government, municipality,
                                            or any political, governmental, regulatory or similar agency or body;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 63.8pt"/><td style="width: 42.5pt">1.1.2.</td><td style="text-align: justify">Reasonable Expenses (as defined
                                            below) expended by Indemnitee as a result of an investigation or any proceeding instituted
                                            against the Indemnitee by an authority that is authorized to conduct such investigation or
                                            proceeding, and that was concluded without filing an indictment against the Indemnitee and
                                            without imposing on the Indemnitee a financial liability in lieu of a criminal proceeding,
                                            or that was concluded without filing an indictment against the Indemnitee but imposing a
                                            financial liability in lieu of a criminal proceeding in an offence that does not require
                                            proof of <i>mens rea</i>, or in connection with a financial sanction. In this section &#8220;conclusion
                                            of a proceeding without filing an indictment in a matter in which a criminal investigation
                                            has been instigated&#8221; and &#8220;financial liability in lieu of a criminal proceeding&#8221;
                                            shall have the meaning assigned to such terms under the Companies Law, and the term &#8220;financial
                                            sanction&#8221; shall mean such term as referred to in Section 260(a)(1a) of the Companies
                                            Law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 63.8pt"/><td style="width: 42.5pt">1.1.3.</td><td style="text-align: justify">Reasonable Expenses expended
                                            by or imposed on Indemnitee by a court, in a proceeding instituted against Indemnitee by
                                            the Company or on its behalf or by another person, or in a criminal charge from which Indemnitee
                                            was acquitted or in which Indemnitee convicted of an offence that does not require proof
                                            of <i>mens rea</i>; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 63.8pt"/><td style="width: 42.5pt">1.1.4.</td><td style="text-align: justify">Any other event, occurrence,
                                            matter or circumstances under any law with respect to which the Company may, or will be able
                                            to, indemnify an Office Holder (including, without limitation, in accordance with Section
                                            56h(b)(1) of the Israeli Securities Law 5728-1968 (the &#8220;<b>Israeli Securities Law</b>&#8221;),
                                            if applicable, and Section 50P(b)(2) of the Israeli Economic Competition Law, 5758-1988 (the
                                            &#8220;<b>Economic Competition Law</b>&#8221;)).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify">For the purpose of this Agreement,
&#8220;<b>Expenses</b>&#8221; shall include, without limitation, legal fees and all other costs, expenses and obligations paid or incurred
by Indemnitee in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing
to defend, be a witness in or participate in any claim, action, suit, proceeding, alternative dispute resolution mechanism, hearing,
inquiry or investigation relating to any matter for which indemnification hereunder may be provided. Expenses shall be considered paid
or incurred by Indemnitee at such time as Indemnitee is required to pay or incur such cost or expenses, including upon receipt of an
invoice or payment demand. The Company shall pay the Expenses in accordance with the provisions of Section&#8206;1.3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 590 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify">&#160;</p><div>


</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 28.4pt">&#160;</td>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything herein to the contrary, the Company&#8217;s undertaking to indemnify the Indemnitee under Section &#8206;1.1.1 shall only
    be with respect to events described in <b><span style="text-decoration:underline">Exhibit A</span></b> hereto. The Board of Directors of the Company (the &#8220;<b>Board</b>&#8221;)
    has determined that the categories of events listed in Exhibit A are foreseeable in light of the operations of the Company. The maximum
    amount of indemnification payable by the Company to the Indemnitee under Section &#8206;1.1.1 and other indemnitees under similar indemnification
    agreements with the Company (the &#8220;<b>Indemnifiable Persons</b>&#8221;) shall be as set forth in <span style="text-decoration:underline">Exhibit A</span> hereto (the
    &#8220;<b>Limit Amount</b>&#8221;) for each five year period commencing as of [DATE OF APPROVAL], and for every subsequent five year
    period thereafter, and shall apply to all Indemnifiable Persons, in the aggregate. If the Limit Amount is insufficient to cover all
    the indemnity amounts payable with respect to all Indemnifiable Persons during the relevant five year period, then such amount shall
    be allocated to such Indemnifiable Persons pro rata according to the percentage of their culpability, as finally determined by a
    court in the relevant claim, or, absent such determination or in the event such persons are parties to different claims, based on
    an equal pro rata allocation among such Indemnifiable Persons. The Limit Amount payable by the Company as described in <span style="text-decoration:underline">Exhibit
    A</span> is deemed by the Company to be reasonable in light of the circumstances. The indemnification provided under Section &#8206;1.1.1
    herein shall not be subject to the limitations imposed by this Section &#8206;1.2 and Exhibit&#160;A if and to the extent such limits
    do not or are no longer required by the Companies Law.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.3.</td><td style="text-align: justify">If so requested by Indemnitee
                                            in writing, and subject to the Company&#8217;s repayment and reimbursements rights set forth
                                            in Sections &#8206;3 and &#8206;5 below, the Company shall pay amounts to cover Indemnitee&#8217;s
                                            Expenses with respect to which Indemnitee is entitled to be indemnified under Section &#8206;1.1
                                            above, as and when incurred. The payments of such amounts shall be made by the Company directly
                                            to the Indemnitee&#8217;s legal and other advisors, as soon as practicable, but in any event
                                            no later than fifteen (15) days after written demand by such Indemnitee therefor to the Company,
                                            and any such payment shall be deemed to constitute indemnification hereunder. As part of
                                            the aforementioned undertaking, the Company will make available to Indemnitee any security
                                            or guarantee that Indemnitee may be required to post in accordance with an interim decision
                                            given by a court, governmental or administrative body, or an arbitrator, including for the
                                            purpose of substituting liens imposed on Indemnitee&#8217;s assets.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.4.</td><td style="text-align: justify">The Company&#8217;s obligation
                                            to indemnify Indemnitee and advance Expenses in accordance with this Agreement shall be for
                                            such period (the &#8220;<b>Indemnification Period</b>&#8221;) as Indemnitee shall be subject
                                            to any actual, possible or threatened claim, action, suit, demand or proceeding or any inquiry
                                            or investigation, whether civil, criminal or investigative, arising out of the Indemnitee&#8217;s
                                            service in the Corporate Capacity as described in Section &#8206;1.1 above, whether or not
                                            Indemnitee is still serving in such position.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.5.</td><td style="text-align: justify">The Company undertakes that,
                                            subject to the mandatory limitations under applicable law, as long as it may be obligated
                                            to provide indemnification and advance Expenses under this Agreement, the Company will purchase
                                            and maintain in effect directors and officers liability insurance, which will include coverage
                                            for the benefit of the Indemnitee, providing coverage in amounts as reasonably determined
                                            by the Board; provided that, the Company shall have no obligation to obtain or maintain directors
                                            and officers insurance policy if the Company determines in good faith that such insurance
                                            is not reasonably available, the premium costs for such insurance are disproportionate to
                                            the amount of coverage provided, or the coverage provided by such insurance is so limited
                                            by exclusions that it provides an insufficient benefit. The Company hereby undertakes to
                                            notify the Indemnitee 30 days prior to the expiration or termination of the directors and
                                            officers liability insurance.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.6.</td><td style="text-align: justify">The Company undertakes to give
                                            prompt written notice of the commencement of any claim hereunder to the insurers in accordance
                                            with the procedures set forth in each of the policies. The Company shall thereafter diligently
                                            take all actions reasonably necessary under the circumstances to cause such insurers to pay,
                                            on behalf of Indemnitee, all amounts payable as a result of such action, suit, proceeding,
                                            inquiry or investigation in accordance with the terms of such policies. The above shall not
                                            derogate from Company&#8217;s authority to freely negotiate or reach any compromise with
                                            the insurer which is reasonable at the Company&#8217;s sole discretion provided that the
                                            Company shall act in good faith and in a diligent manner.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 591 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">2.</td><td style="text-align: justify"><b>SPECIFIC LIMITATIONS ON INDEMNIFICATION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Notwithstanding anything to the contrary
in this Agreement, the Company shall not indemnify or advance Expenses to Indemnitee with respect to (i) any act, event or circumstance
with respect to which it is prohibited to do so under applicable law, or (ii) a counter claim made by the Company or in its name in connection
with a claim against the Company filed by the Indemnitee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">3.</td><td style="text-align: justify"><b>REPAYMENT OF EXPENSES</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">3.1.</td><td style="text-align: justify">In the event that the Company
                                            provides or is required to provide indemnification with respect to Expenses hereunder and
                                            at any time thereafter the Company determines, based on advice from its legal counsel, that
                                            the Indemnitee was not entitled to such payments, the amounts so indemnified by the Company
                                            will be promptly repaid by Indemnitee, unless the Indemnitee disputes the Company&#8217;s
                                            determination, in which case the Indemnitee&#8217;s obligation to repay to the Company shall
                                            be postponed until such dispute is resolved.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">3.2.</td><td style="text-align: justify">Indemnitee&#8217;s obligation
                                            to repay to the Company for any Expenses or other sums paid hereunder shall be deemed as
                                            a loan given to Indemnitee by the Company subject to the minimum interest rate prescribed
                                            by Section 3(9) of the Income Tax Ordinance [New Version], 1961, or any other legislation
                                            replacing it, which is not considered a taxable benefit.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">4.</td><td style="text-align: justify"><b>SUBROGATION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">4.1.</td><td style="text-align: justify">In the event of payment under
                                            this Agreement, the Company shall be subrogated to the extent of such payment to all of the
                                            rights of recovery of Indemnitee, who shall execute all documents required and shall do everything
                                            that may be necessary to secure such rights, including the execution of such documents necessary
                                            to enable the Company effectively to bring suit to enforce such rights.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">5.</td><td style="text-align: justify"><b>REIMBURSEMENT</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company shall not be liable under
this Agreement to make any payment in connection with any Indemnifiable Event to the extent Indemnitee has otherwise actually received
payment under any insurance policy or otherwise (without any obligation of Indemnitee to repay any such amount) of the amounts otherwise
indemnifiable hereunder. Any amounts paid to Indemnitee under such insurance policy or otherwise after the Company has indemnified Indemnitee
for such liability or Expense shall be repaid to the Company promptly upon receipt by Indemnitee, in accordance with the terms set forth
in Section &#8206;3.2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">6.</td><td style="text-align: justify"><b>EFFECTIVENESS</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement shall be valid, binding
and enforceable in accordance with its terms and shall be in full force and effect immediately upon its approval by the Company&#8217;s
general meeting of shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">7.</td><td style="text-align: justify"><b>NOTIFICATION AND DEFENSE OF CLAIM</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Indemnitee shall notify the Company
of the commencement of any action, suit or proceeding, and of the receipt of any notice or threat that any such legal proceeding has
been or shall or may be initiated against Indemnitee (including any proceedings by or against the Company and any subsidiary thereof),
promptly upon Indemnitee first becoming so aware; but the omission so to notify the Company will not relieve the Company from any liability
which it may have to Indemnitee under this Agreement unless and to the extent that such failure to provide notice prejudices the Company&#8217;s
ability to defend such action. Notice to the Company shall be directed to the Chief Executive Officer or Chief Financial Officer of the
Company at the address shown in the preamble to this Agreement (or such other address as the Company shall designate in writing to Indemnitee).
With respect to any such action, suit or proceeding as to which Indemnitee notifies the Company of the commencement thereof and without
derogating from Sections &#8206;1.1 and &#8206;2:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.1.</td><td style="text-align: justify">The Company will be entitled
                                            to participate therein at its own expense.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 592 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.2.</td><td style="text-align: justify">Except as otherwise provided
                                            below, the Company, alone or jointly with any other indemnifying party similarly notified,
                                            will be entitled to assume the defense thereof, with counsel selected by the Company. Indemnitee
                                            shall have the right to employ his or her own counsel in such action, suit or proceeding,
                                            but the fees and expenses of such counsel incurred after notice from the Company of its assumption
                                            of the defense thereof shall be at the expense of Indemnitee, unless: (i)&#160;the employment
                                            of counsel by Indemnitee has been authorized in writing by the Company; (ii) the Company,
                                            in good faith, reasonably concluded that there may be a conflict of interest between the
                                            Company and Indemnitee in the conduct of the defense of such action; or (iii)&#160;the Company
                                            has not in fact employed counsel to assume the defense of such action within reasonable time,
                                            in which cases the reasonable fees and expenses of Indemnitee&#8217;s counsel shall be at
                                            the expense of the Company. The Company shall not be entitled to assume the defense of any
                                            action, suit or proceeding brought by or on behalf of the Company or as to which Indemnitee
                                            and the Company shall have reached the conclusion specified in (ii) above.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.3.</td><td style="text-align: justify">The Company shall not be liable
                                            to indemnify Indemnitee under this Agreement for any amounts or expenses paid in connection
                                            with a settlement of any action, claim or otherwise, effected without the Company&#8217;s
                                            prior written consent.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.4.</td><td style="text-align: justify">The Company shall have the right
                                            to conduct the defense as it sees fit in its sole discretion (provided that the Company shall
                                            conduct the defense in good faith and in a diligent manner), including the right to settle
                                            or compromise any claim or to consent to the entry of any judgment against Indemnitee without
                                            the consent of the Indemnitee, provided that, the amount of such settlement, compromise or
                                            judgment does not exceed the Limit Amount (if applicable) and is fully indemnifiable pursuant
                                            to this Agreement (subject to Section &#8206;1.2 of this Agreement) and/or applicable law,
                                            and any such settlement, compromise or judgment does not impose any penalty or limitation
                                            on Indemnitee without the Indemnitee&#8217;s prior written consent. The Indemnitee&#8217;s
                                            consent shall not be required if the settlement includes a complete release of Indemnitee,
                                            does not contain any admission of wrong-doing by Indemnitee, and includes monetary sanctions
                                            only as provided above. In the case of criminal proceedings, the Company and/or its legal
                                            counsel will not have the right to plead guilty or agree to a plea-bargain in the Indemnitee&#8217;s
                                            name without the Indemnitee&#8217;s prior written consent. Neither the Company nor Indemnitee
                                            will unreasonably withhold or delay their consent to any proposed settlement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.5.</td><td style="text-align: justify">Indemnitee shall fully cooperate
                                            with the Company and shall give the Company all information and access to documents, files
                                            and to his or her advisors and representatives as shall be within Indemnitee&#8217;s power,
                                            in every reasonable way as may be required by the Company with respect to any claim which
                                            is the subject matter of this Agreement and in the defense of other claims asserted against
                                            the Company (other than claims asserted by Indemnitee), provided that the Company shall cover
                                            all expenses, costs and fees incidental thereto such that the Indemnitee will not be required
                                            to pay or bear such expenses, costs and fees.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 593 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">8.</td><td style="text-align: justify"><b>EXCULPATION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Subject to the provisions of the
Companies Law, the Company hereby releases, in advance, the Office Holder from liability to the Company for any damage that arises from
the breach of the Office Holder&#8217;s duty of care to the Company (within the meaning of such terms under Sections 252 and 253 of the
Companies Law), other than breach of the duty of care towards the Company in a distribution (as such term is defined in the Companies
Law).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">9.</td><td style="text-align: justify"><b>NON-EXCLUSIVITY</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The rights of the Indemnitee hereunder
shall not be deemed exclusive of any other rights Indemnitee may have under the Articles of Association, applicable law or otherwise<b><i>,
</i></b>and to the extent that during the Indemnification Period the indemnification rights of the then serving directors and officers
are more favorable to such directors or officers than the indemnification rights provided under this Agreement to Indemnitee, Indemnitee
shall be entitled to the full benefits of such more favorable indemnification rights to the extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">10.</td><td style="text-align: justify"><b>PARTIAL INDEMNIFICATION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">If Indemnitee is entitled under any
provision of this Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually
or reasonably incurred by Indemnitee in connection with any proceedings, but not, however, for the total amount thereof, the Company
shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled
under any provision of this Agreement. Subject to the provisions of Section &#8206;5 above, any amount received by Indemnitee (under any
insurance policy or otherwise) shall not reduce the Limit Amount hereunder and shall not derogate from the Company&#8217;s obligation
to indemnify the Indemnitee in accordance with the provisions of this Agreement up to the Limit Amount, as set forth in Section &#8206;1.2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">11.</td><td style="text-align: justify"><b>BINDING EFFECT</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement shall be binding upon
and inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns. In the event
of a merger or consolidation of the Company or a transfer or disposition of all or substantially all of the business or assets of the
Company, the Indemnitee shall be entitled to the same indemnification and insurance provisions as the most favorable indemnification
and insurance provisions afforded to the then-serving Office Holders of the Company. In the event that in connection with such transaction
the Company purchases a directors and officers&#8217; &#8220;tail&#8221; or &#8220;run-off&#8221; policy for the benefit of its then
serving Office Holders, then such policy shall cover Indemnitee and such coverage shall be deemed to be in satisfaction of the insurance
requirements under this Agreement. This Agreement shall continue in effect during the Indemnification Period regardless of whether Indemnitee
continues to serve in a Corporate Capacity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Any amendment to the Companies Law,
the Israeli Securities Law, the Economic Competition Law or other applicable law adversely affecting the right of the Indemnitee to be
indemnified, insured or released pursuant hereto shall be prospective in effect, and shall not affect the Company&#8217;s obligation
or ability to indemnify or insure the Indemnitee for any act or omission occurring prior to such amendment, unless otherwise provided
by applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">12.</td><td style="text-align: justify"><b>SEVERABILITY</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The provisions of this Agreement
shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of
the other provisions hereof. If any provision of this Agreement, or the application thereof or any circumstance, is invalid or unenforceable,
(a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the
intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision
or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the
validity or enforceability of such provision, or the application thereof, in any other jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 594 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">13.</td><td style="text-align: justify"><b>NOTICE</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">All notices and other communications
pursuant to this Agreement shall be in writing and shall be deemed provided if delivered personally, telecopied, sent by electronic facsimile,
email, reputable overnight courier or mailed by registered or certified mail (return receipt requested), postage prepaid, to the parties
at the addresses shown in the preamble to this Agreement, or to such other address as the party to whom notice is to be given may have
furnished to the other party hereto in writing in accordance herewith. Any such notice or communication shall be deemed to have been
delivered and received (i) in the case of personal delivery, on the date of such delivery, (ii) in the case of telecopier or an electronic
facsimile or email, one business day after the date of transmission if confirmation of receipt is received, (iii) in the case of a reputable
overnight courier, three business days after deposit with such reputable overnight courier service, and (iv) in the case of mailing,
on the seventh business day following that on which the mail containing such communication is posted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">14.</td><td style="text-align: justify"><b>GOVERNING LAW; JURISDICTION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement shall be governed
by and construed and enforced in accordance with the laws of the State of Israel, without giving effect to the conflicts of law provisions
of those laws. The Company and Indemnitee each hereby irrevocably consent to the exclusive jurisdiction and venue of the courts of Tel
Aviv, Israel for all purposes in connection with any action or proceeding which arises out of or relates to this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">15.</td><td style="text-align: justify"><b>ENTIRE AGREEMENT</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement represents the entire
agreement between the parties and supersedes any other agreements, contracts or understandings between the parties, whether written or
oral, with respect to the subject matter of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">16.</td><td style="text-align: justify"><b>NO MODIFICATION AND NO WAIVER</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">No supplement, modification or amendment,
termination or cancellation of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of
any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar)
nor shall such waiver constitute a continuing waiver. Any waiver shall be in writing. The Company hereby undertakes not to amend its
Articles of Association in a manner which will adversely affect the provisions of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">17.</td><td style="text-align: justify"><b>ASSIGNMENTS; NO THIRD PARTY RIGHTS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Neither party hereto may assign any
of its rights or obligations hereunder except with the express prior written consent of the other party. Nothing herein shall be deemed
to create or imply an obligation for the benefit of a third party. Without limitation of the foregoing, nothing herein shall be deemed
to create any right of any insurer that provides directors and officers&#8217; liability insurance, to claim, on behalf of Indemnitee,
any rights hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">18.</td><td style="text-align: justify"><b>INTERPRETATION; DEFINITIONS</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in">Unless the context
shall otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun shall include the corresponding
masculine, feminine and neuter forms; the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed
to be followed by the phrase &#8220;without limitation&#8221;; the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;
and words of similar import refer to this Agreement in its entirety and not to any part hereof; all references herein to Sections or
clauses shall be deemed references to Sections or clauses of this Agreement; any references to any agreement or other instrument or law,
statute or regulation are to it as amended, supplemented or restated, from time to time (and, in the case of any law, to any successor
provisions or re-enactment or modification thereof being in force at the time); any reference to &#8220;law&#8221; shall include any
supranational, national, federal, state, local, or foreign statute or law and all rules and regulations promulgated thereunder; any reference
to a &#8220;day&#8221; or a number of &#8220;days&#8221; (without any explicit reference otherwise, such as to business days) shall be
interpreted as a reference to a calendar day or number of calendar days; reference to month or year means according to the Gregorian
calendar; reference to a &#8220;company&#8221;, &#8220;corporate body&#8221; or &#8220;entity&#8221; shall include a, partnership, firm,
company, corporation, limited liability company, association, joint venture, trust, unincorporated organization, estate, or a government
municipality or any political, governmental, regulatory or similar agency or body, and reference to a &#8220;person&#8221; shall mean
any of the foregoing or a natural person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">19.</td><td style="text-align: justify"><b>COUNTERPARTS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement may be executed in
any number of counterparts, each of which shall be deemed an original and enforceable against the parties actually executing such counterpart,
and all of which together shall constitute one and the same instrument; it being understood that parties need not sign the same counterpart.
The exchange of an executed Agreement (in counterparts or otherwise) by facsimile or by electronic delivery in pdf format shall be sufficient
to bind the parties to the terms and conditions of this Agreement, as an original.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>[SIGNATURE PAGE TO FOLLOW]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 595 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 28.35pt; text-align: justify"><b>IN WITNESS
WHEREOF</b>, the parties, each acting under due and proper authority, have executed this Indemnification Agreement as of the date first
mentioned above, in one or more counterparts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-size: 10pt"><b>SciSparc Ltd.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 13%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 27%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 60%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Name and title:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: left"><span style="font-size: 10pt"><b>Indemnitee:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 13%; text-align: left"><span style="font-size: 10pt">Name:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 27%; text-align: left">&#160;</td>
    <td style="width: 60%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-size: 10pt">Signature:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-size: 10pt">Address:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 596 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-transform: uppercase"><b><span style="text-decoration:underline">EXHIBIT
A*</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="width: 95%; text-align: center"><span style="font-size: 10pt"><b>CATEGORY OF INDEMNIFIABLE EVENT</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">1. </span></td>
    <td style="text-indent: 0in; padding-left: -0.125in; text-align: justify"><span style="font-size: 10pt">Matters, events, occurrences
    or circumstances in connection or associated with employment relationships with employees or consultants or any employee union or
    similar or comparable organization. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">2. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Matters, events, occurrences or circumstances in connection or associated
    with business relations of any kind between the Company and its employees, independent contractors, customers, suppliers, partners,
    distributors, agents, resellers, representatives, licensors, licensees, service providers and other business associates.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">3. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Negotiations, execution, delivery and performance of agreements of
    any kind or nature and any decisions or deliberations relating to actions or omissions relating to the foregoing; any acts, omissions
    or circumstances that do or may constitute or are alleged to constitute anti-competitive acts, acts of commercial wrongdoing, or
    failure to meet any standard of conduct which is or may be applicable to such acts, omissions or circumstances.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">4. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Approval of and recommendation or information provided to shareholders
    with respect to any and all corporate actions, including the approval of the acts of the Company&#8217;s management, their guidance
    and their supervision, matters relating to the approval of transactions with Office Holders (including, without limitation, all compensation
    related matters) or shareholders, including controlling persons and claims and allegations of failure to exercise business judgment,
    reasonable level of proficiency, expertise, care or any other applicable standard, with respect to the foregoing or otherwise with
    respect to the Company&#8217;s business, strategy, operations and prospective outlook, and any discussions, deliberations, reviews
    or other preparatory or preliminary phases relating to any of the foregoing.&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">5. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Violation, infringement, misappropriation, dilution and other misuse
    of copyrights, patents, designs, trade secrets, confidential information, proprietary information and any intellectual property rights,
    acts in connection with the registration, assertion or protection of rights to intellectual property and the defense of claims related
    to intellectual property, breach of confidentiality obligations, acts in regard of invasion of privacy or any violation of privacy
    or privacy related right or regulation, including with respect to databases or handling, collection or use of private information,
    acts in connection with slander and defamation, and claims in connection with publishing or providing any information, including
    any filings with any governmental authorities, whether or not required under any applicable laws.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">6. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Violations of or failure to comply with securities laws, and any regulations
    or other rules promulgated thereunder, of any jurisdiction, including without limitation, claims under the U.S. Securities Act of
    1933 or the U.S. Exchange Act of 1934 or under the Israeli Securities Law, fraudulent disclosure claims, failure to comply with any
    securities authority or any stock exchange disclosure or other rules and any other claims relating to relationships with investors,
    debt holders, shareholders, optionholders, holders of any other equity or debt instrument of the Company, and otherwise with the
    investment community (including without limitation any such claims relating to a merger, acquisition, change in control transaction,
    issuance of securities, restructuring, spin out, spin off, divestiture, recapitalization or any other transaction relating to the
    corporate structure or organization of the Company); claims relating to or arising out of financing arrangements, any breach of financial
    covenants or other obligations towards investors, lenders or debt holders, class actions, violations of laws requiring the Company
    to obtain regulatory and governmental licenses, permits and authorizations in any jurisdiction, including in connection with disclosure,
    offering or other transaction related documents; actions taken in connection with the issuance, purchase, holding or disposition
    of any type of securities of Company, including, without limitation, the grant of options, warrants or other rights to purchase any
    of the same or any offering of the Company&#8217;s securities (whether on behalf of the Company or on behalf of any holders of securities
    of the Company) to private investors, underwriters, resellers or to the public, and listing of such securities, or the offer by the
    Company to purchase securities from the public or from private investors or other holders, and any undertakings, representations,
    warranties and other obligations related to any of the foregoing or to the Company&#8217;s status as a public company or as an issuer
    of securities.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 597 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 5%"><span style="font-size: 10pt">7. </span></td>
    <td style="text-align: justify; width: 95%"><span style="font-size: 10pt">Liabilities arising in connection with any products or
    services developed, distributed, rendered, sold, provided, licensed or marketed by the Company or any Affiliate thereof, and any
    actions or omissions in connection with the distribution, provision, sale, marketing, license or use of such products or services,
    including without limitation in connection with professional liability and product liability claims or regulatory or reputational
    matters.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">8. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The offering of securities by the Company (whether on behalf of itself
    or on behalf of any holder of securities and any other person) to the public and/or to offerees or the offer by the Company to purchase
    securities from the public and/or from private investors or other holders pursuant to a prospectus, offering documents, agreements,
    notices, reports, tenders and/or other processes.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">9. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Events, facts or circumstances in connection with change in ownership
    or in the structure of the Company, its reorganization, dissolution, winding up, any other arrangements concerning creditors rights,
    merger, change in control, issuances of securities, restructuring, spin out, spin off, divestiture, recapitalization or any other
    transaction relating to the corporate structure or organization of the Company, and the approval of failure to approve of any corporate
    actions and any matters relating to corporate governance, capital structure, articles of association or other charter or governance
    documents, appointment or dismissal of office holders or compensation thereof and appointment or dismissal of auditors, internal
    auditor or any other person performing any services for the Company.&#160;&#160;&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">10. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any claim or demand made in connection with any transaction not in
    the ordinary course of business of the Company, as well as the sale, lease, purchase or acquisition of, or the receipt or grant of
    any rights with respect to, any assets or business.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">11. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any claim or demand made by any third party suffering any personal
    injury and/or bodily injury or damage to business or personal property or any other type of damage through any act or omission attributed
    to the Company, or its employees, agents or other persons acting or allegedly acting on its behalf, including, without limitation,
    failure to make proper safety arrangements for the Company or its employees and liabilities arising from any accidental or continuous
    damage or harm to the Company&#8217;s employees, its contractors, its guests and visitors as a result of an accidental or continuous
    event, or employment conditions, permanent or temporary, in the Company&#8217;s offices.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">12. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any claim or demand made directly or indirectly in connection with
    complete or partial failure, by the Company or its directors, officers and employees, to pay, report, keep applicable records or
    otherwise, of any local or foreign federal, state, county, municipal or city taxes or other taxes or compulsory payments of any nature
    whatsoever, including, without limitation, income, sales, use, transfer, excise, value added, registration, severance, stamp, occupation,
    customs, duties, real property, personal property, capital stock, social security, unemployment, disability, payroll or employee
    withholding or other withholding, including any interest, penalty or addition thereto, whether disputed or not.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 598 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 5%"><span style="font-size: 10pt">13. </span></td>
    <td style="text-align: justify; width: 95%"><span style="font-size: 10pt">Any administrative, regulatory, judicial or civil actions
    orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices of noncompliance
    or violation by any governmental entity or other person alleging potential responsibility or liability (including potential responsibility
    or liability for costs of enforcement investigation, cleanup, governmental response, removal or remediation, for natural resources
    damages, property damage, personal injuries or penalties or for contribution,&#160;&#160;indemnification, cost recovery, compensation
    or injunctive relief) arising out of, based on or related to (a) the presence of, release, spill, emission, leaning, dumping, pouring,
    deposit, disposal, discharge, leaching or migration into the environment (each a &#8220;<b>Release</b>&#8221;) or threatened Release
    of, or exposure to, any hazardous, toxic, explosive or radioactive substances, wastes or other pollutants, including petroleum or
    petroleum distillates, asbestos or asbestos-containing material, polychlorinated biphenyls (&#8220;<b>PCBs</b>&#8221;) or PCB-containing
    materials or equipment, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant
    to any environmental law, at any location, whether or not owned, operated, leased or managed by the Company or any of its subsidiaries,
    or (b) circumstances forming the basis of any violation of any environmental law or environmental permit, license, registration or
    other authorization required under applicable environmental law.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">14. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any administrative, regulatory or judicial actions, orders, decrees,
    suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices of noncompliance or violation by
    any governmental or regulatory entity or authority or any other person alleging the failure to comply with any statute, law, ordinance,
    rule, regulation, order or decree of any governmental entity applicable to the Company or any of its businesses, assets or operations,
    or the terms and conditions of any operating certificate or licensing agreement, and without derogating from the generality of the
    above, including the Israel Innovation Authority or the Investment Center at the Ministry of Industry and Trade, the Antitrust Authority
    and/or the Securities Authority in Israel and/or the U.S.A. and/or in any other country and/or location, the Ministry of Health and/or
    any competent food and drug administrations in Israel, the U.S.A.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">15. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Participation and/or non-participation at Company Board meetings, expression
    of opinion or view and/or voting and/or abstention from voting at Company Board meetings, including, in each case, any committee
    thereof, as well as expression of opinion publicly in connection with the service as an Office Holder.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">16. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Review and approval of the Company&#8217;s financial statements and
    any specific items or matters within, including any action, consent or approval related to or arising from the foregoing, including,
    without limitations, engagement of or execution of certificates for the benefit of third parties related to the financial statements.&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">17. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Violation of laws, rules or regulations requiring the Company to obtain
    regulatory and governmental licenses, permits and authorizations (including without limitation relating to export, import, encryption,
    antitrust or competition authorities) or laws related to any governmental grants in any jurisdiction. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">18. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Resolutions and/or actions relating to investments in the Company and/or
    its subsidiaries and/or affiliated companies and/or investment in corporate or other entities and/or investments in other traded
    or non-traded securities and/or any other form of investment.&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">19. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Liabilities arising out of advertising, including misrepresentations
    regarding the Company&#8217;s products or services and unlawful distribution of emails.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">20. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Management of the Company&#8217;s bank accounts, including money management,
    foreign currency deposits, securities, loans and credit facilities, credit cards, bank guarantees, letters of credit, consultation
    agreements concerning investments including with portfolio managers, hedging transactions, options, futures, and the like.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">21. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">All actions, consents and approvals, including any prior discussions,
    reviews and deliberations, relating to a distribution of dividends, in cash or otherwise, or to any other &#8220;distribution&#8221;
    as such term is defined under the Companies Law.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 599 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 5%"><span style="font-size: 10pt">22. </span></td>
    <td style="text-align: justify; width: 95%"><span style="font-size: 10pt">Any administrative, regulatory, judicial, civil or criminal,
    actions orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices of noncompliance,
    violation or breaches alleging potential responsibility, liability, loss or damage (including potential responsibility or liability
    for costs of enforcement, investigation, cleanup, governmental response, removal or remediation, property damage or penalties, or
    for contribution,&#160;&#160;indemnification, cost recovery, compensation or injunctive relief), whether alleged or claimed by customers,
    consumers, regulators, shareholders or others, arising out of, based on or related to: (a) cyber security, cyber attacks, data loss
    or breaches, unauthorized access to information, data, or databases (including but not limited to any personally identifiable information
    or private health information) and use or disclosure of information contained therein, not preventing or detecting the breach or
    failing to otherwise disclose or respond to the breach; (b) circumstances forming the basis of any violation of any law, permit,
    license, registration or other authorization required under applicable law governing data security, data protection, network security,
    information systems, privacy or any cyber environment (including, users, networks, devices, software, processes, information systems,
    databases, information in storage or transit, applications, services, and systems that can be connected directly or indirectly to
    networks); (c) failure to implement a reporting system or control, or failure to monitor or oversee the operation of such a system;
    (d) data destruction, extortion, theft, hacking, and denial of service attacks; losses or liabilities to others caused by errors
    and omissions, failure to safeguard data or defamation; or (e) security-audit, post-incident public relations and investigative expenses,
    criminal reward funds, data breach/privacy crisis management (including, management of an incident, investigation, remediation, data
    subject notification, call management, credit checking for data subjects, legal costs, court attendance and regulatory fines), extortion
    liability (including, losses due to a threat of extortion, professional fees related to dealing with the extortion), or network security
    liability (including, losses as a result of denial of access, costs related to data on third-parties and costs related to the theft
    of data on third-party systems).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">23.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any claim or demand instituted in connection with the acts of the Company
    and/or its subsidiaries and/or affiliates, as shall exist from time to time, concerning the Company&#8217;s field of activities and
    operations, as shall be conducted from time to time, and including in connection with the research, development, manufacture, commercialization,
    marketing and/or sale of pharmaceuticals and/or medical instruments and/or any act directly and/or indirectly associated with the
    execution of the aforesaid acts, including and without derogating from the generality of the above, in connection with clinical and
    preclinical trials, as well as in connection with actions associated with the promotion, marketing and/or support of products, solutions
    and technologies in the Company&#8217;s field of activity.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">The Limit Amount
        for all Indemnifiable Persons during each relevant period referred to in Section 1.2 of the Indemnification Agreement for all
        events described in this <span style="text-decoration:underline">Exhibit A</span> (in Sections 1-23 (inclusive) above), shall be the greater of:</p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 24.5pt; background-color: white">(a)&#160;twenty-five
    percent (25%)&#160;of the Company&#8217;s total shareholders&#8217; equity according to the Company&#8217;s most recent financial
    statements as of the time of the actual payment of indemnification;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 24.5pt; background-color: white">(b)&#160;US$
    7.5 million;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 24.5pt; background-color: white">(c)
    ten percent (10%) of the Company&#8217;s Total Market Cap (which shall mean the average closing price of the Company&#8217;s ordinary
    shares over the 30 trading days prior to the actual payment of indemnification multiplied by the total number of issued and outstanding
    shares of the Company as of the date of actual payment); and</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 24.5pt; background-color: white">(d)&#160;in
    connection with or arising out of a public offering of the Company&#8217;s securities, the aggregate amount of proceeds from the
    sale by the Company and/or any shareholder of Company&#8217;s securities in such offering.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Any reference in
                                            this <span style="text-decoration:underline">Exhibit A</span> to the Company shall include the Company and any entity in which the
                                            Indemnitee serves in a Corporate Capacity.</td>
</tr></table><div>
</div><p style="margin: 0">&#160;</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>


</div><!-- Field: Page; Sequence: 600 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><div><a id="m_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ANNEX
D</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE COMPANIES LAW, 1999</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A LIMITED LIABILITY COMPANY</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AMENDED AND RESTATED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ARTICLES OF ASSOCIATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As Adopted on September 15, 2022</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Preliminary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Definitions;
    Interpretation</span></b>. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In these
    Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless
    the subject or context requires otherwise.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 180px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Affiliate&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with respect to any specified
    person, shall mean, any other person who or which, directly or indirectly, controls, is controlled by, or is under common control
    with such specified person.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Articles&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean these Amended
    and Restated Articles of Association, as amended from time to time.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Board of Directors&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Board of
    Directors of the Company.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Chairperson&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Chairperson
    of the Board of Directors, or the Chairperson of the General Meeting, as the context implies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#8220;Companies
    Law&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Israeli
    Companies Law, 5759-1999 and the regulations promulgated thereunder.&#160;The Companies Law shall include reference to the Companies
    Ordinance (New Version), 5743-1983, of the State of Israel, to the extent in effect according to the provisions thereof.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Company&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean SciSparc Ltd.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Director(s)&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the member(s)
    of the Board of Directors holding office at a given time.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Economic Competition
    Law&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Israeli
    Economic Competition Law, 5758-1988 and the regulations promulgated thereunder.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Effective Time&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the effective
    time of these Articles.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;External Director(s)&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning
    provided for such term in the Companies Law.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;General Meeting&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean an Annual General
    Meeting or Special General Meeting of the Shareholders (each as defined in Article 23 of these Articles), as the case may be.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NIS&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean New Israeli
    Shekels.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Office&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the registered
    office of the Company at any given time.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 180px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Office
    Holder&#8221; or &#8220;Officer&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning
    provided for such term in the Companies Law.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Ordinary Resolution&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a resolution adopted
    at the (Annual or Special) General Meeting by a majority of those voting and without counting the abstaining votes.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Securities Law&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Israeli
    Securities Law, 5728-1968, and the regulations promulgated thereunder. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Shareholder(s)&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the shareholder(s)
    of the Company, at any given time.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Stock Exchange&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Nasdaq Stock
    Market or on any other stock exchange on which the Company&#8217;s ordinary shares are then listed for trading.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 601; Options: NewSection --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless the context shall
    otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun shall include the corresponding
    masculine, feminine and neuter forms; the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be
    deemed to be followed by the phrase &#8220;without limitation&#8221;; the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;
    and words of similar import refer to these Articles in their entirety and not to any part hereof; all references herein to Articles
    or clauses shall be deemed references to Articles or clauses of these Articles; any references to any agreement or other instrument
    or law, statute or regulation are to it as amended, supplemented or restated, from time to time (and, in the case of any law, to
    any successor provisions or re-enactment or modification thereof being in force at the time); any reference to &#8220;law&#8221;
    shall include any law (&#8217;<i>din</i>&#8217;) as defined in the Interpretation Law, 5741-1981 and any applicable supranational,
    national, federal, state, local, or foreign statute or law and shall be deemed also to refer to all rules and regulations promulgated
    thereunder; any reference to a &#8220;day&#8221; or a number of &#8220;days&#8221; (without any explicit reference otherwise, such
    as to business days) shall be interpreted as a reference to a calendar day or number of calendar days; any reference to a business
    day shall mean each calendar day other than any calendar day on which commercial banks in New York, New York or Tel-Aviv, Israel
    are authorized or required by applicable law to close; reference to a month or year means according to the Gregorian calendar; any
    reference to a &#8220;person&#8221; shall mean any individual, partnership, corporation, limited liability company, association,
    estate, any political, governmental, regulatory or similar agency or body, or other legal entity; and reference to &#8220;written&#8221;
    or &#8220;in writing&#8221; shall include written, printed, photocopied, typed, any electronic communication (including email, facsimile,
    signed electronically (in Adobe PDF, DocuSign or any other format)) or produced by any visible substitute for writing, or partly
    one and partly another, and signed shall be construed accordingly.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The captions in these Articles
    are for convenience only and shall not be deemed a part hereof or affect the construction or interpretation of any provision hereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The specific provisions
    of these Articles shall supersede the provisions of the Companies Law to the extent permitted thereunder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Limited
Liability</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a limited
    liability company and each Shareholder&#8217;s liability for the Company&#8217;s debt is therefore limited (in addition to any liabilities
    under any contract) to the payment of the full amount (par value (if any) and premium) such Shareholder was required to pay the Company
    for such Shareholder&#8217;s Shares (as defined below) and which amount has not yet been paid by such Shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Company&#8217;s
Objectives</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Objectives</span></b>.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company&#8217;s objectives are
to carry on any business, and do any act, which is not prohibited by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Donations</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company may donate a reasonable
amount of money (in cash or in kind, including the Company&#8217;s securities) to worthy purposes such as the Board of Directors may
determine in its discretion, even if such donations are not made on the basis or within the scope of business considerations of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Share
Capital</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Authorized
    Share Capital</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The authorized share capital
    of the Company shall consist of 75,000,000 Ordinary Shares without par value (the &#8220;<b>Shares</b>&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Shares shall rank <i>pari
    passu</i> in all respects. The Shares may be redeemable to the extent set forth in Article 18.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 602 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Increase
    of Authorized Share Capital</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time
    to time, by a Shareholders&#8217; resolution, whether or not all of the Shares then authorized have been issued, and whether or not
    all of the Shares theretofore issued have been called up for payment, increase its authorized share capital by increasing the number
    of Shares it is authorized to issue by such amount, and such additional Shares shall confer such rights and preferences, and shall
    be subject to such restrictions, as such resolution shall provide.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent otherwise
    provided in such resolution, any new Shares included in the authorized share capital increase as aforesaid shall be subject to all
    of the provisions of these Articles that are applicable to Shares that are included in the existing share capital.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Special
    or Class Rights; Modification of Rights</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time
    to time, by a Shareholders&#8217; resolution, provide for shares with such preferred or deferred rights or other special rights and/or
    such restrictions, whether in regard to dividends, voting, repayment of share capital or otherwise, as may be stipulated in such
    resolution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If at any time the share
    capital of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by
    these Articles, may be modified or cancelled by the Company by a resolution of the General Meeting of the holders of all shares as
    one class, without any required separate resolution of any class of shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of these
    Articles relating to General Meetings shall apply, <i>mutatis mutandis</i>, to any separate General Meeting of the holders of the
    shares of a particular class, it being clarified that the requisite quorum at any such separate General Meeting shall be Shareholders
    present in person or by proxy and holding not less than thirty-three and one-third percent (33&#8531;%) of the issued shares of
    such class, <i>provided</i>, <i>however</i>, that if (i) such separate General Meeting of the holders of the particular class was
    initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii) at the time of such meeting the Company
    is qualified to use the forms of a &#8220;foreign private issuer&#8221; under US securities laws, then the requisite quorum at any
    such separate General Meeting shall be Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present
    in person or by proxy and holding not less than fifteen percent (15%) of the issued shares of such class.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise provided
    by these Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized
    share capital of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital,
    shall not be deemed, for purposes of this Article 7, to modify or derogate or cancel the rights attached to previously issued shares
    of such class or of any other class.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Consolidation,
    Division, Cancellation and Reduction of Share Capital</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time
    to time, by or pursuant to an authorization of a Shareholders&#8217; resolution, and subject to applicable law:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">consolidate
                                            all or any part of its issued or unissued authorized share capital;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">divide
                                            or sub-divide its Shares (issued or unissued) or any of them and the resolution whereby any
                                            Share is divided may determine that, as among the holders of the Shares resulting from such
                                            subdivision, one or more of the Shares may, in contrast to others, have any such preferred
                                            or deferred rights or rights of redemption or other special rights, or be subject to any
                                            such restrictions, as the Company may attach to unissued or new shares;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="padding-bottom: 0; width: 1in; text-align: right"/><td style="padding-bottom: 0; width: 0.25in">(iii)</td><td style="padding-bottom: 0; text-align: justify">cancel
                                            any authorized Shares which, at the date of the adoption of such resolution, have not been
                                            issued to any person nor has the Company made any commitment, including a conditional commitment,
                                            to issue such Shares, and reduce the amount of its share capital by the amount of the Shares
                                            so canceled; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="padding-bottom: 0; width: 1in; text-align: right"/><td style="padding-bottom: 0; width: 0.25in">(iv)</td><td style="padding-bottom: 0; text-align: justify">reduce
                                            its share capital in any manner.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 0; width: 47px">&#160;</td>
    <td style="padding-bottom: 0; width: 32px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="padding-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to any consolidation of issued Shares and with respect to any other action which may result in fractional Shares, the Board
    of Directors may settle any difficulty which may arise with regard thereto, as it deems fit, and, in connection with any such consolidation
    or other action which could result in fractional shares, may, without limiting its aforesaid power:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="padding-bottom: 0; width: 1in; text-align: right"/><td style="padding-bottom: 0; width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">determine,
                                            as to the holder of Shares so consolidated, which issued Shares shall be consolidated;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">issue,
                                            in contemplation of or subsequent to such consolidation or other action, Shares sufficient
                                            to preclude or remove fractional share holdings;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iii)</td><td style="text-align: justify">redeem such
                                            Shares or fractional shares sufficient to preclude or remove fractional Share holdings;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 603 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iv)</td><td style="text-align: justify">round up, round
                                            down or round to the nearest whole number, any fractional Shares resulting from the consolidation
                                            or from any other action which may result in fractional Shares; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(v)</td><td style="text-align: justify">cause the transfer
                                            of fractional Shares by certain Shareholders of the Company to other Shareholders thereof
                                            so as to most expediently preclude or remove any fractional Share holdings, and cause the
                                            transferees of such fractional Shares to pay the transferors thereof the fair value thereof,
                                            and the Board of Directors is hereby authorized to act in connection with such transfer,
                                            as agent for the transferors and transferees of any such fractional Shares, with full power
                                            of substitution, for the purposes of implementing the provisions of this sub-Article&#160;8(b)(v).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Issuance
    of Share Certificates, Replacement of Lost Certificates</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent that the
    Board of Directors determines that all Shares shall be certificated or, if the Board of Directors does not so determine, to the extent
    that any Shareholder requests a share certificate or the Company&#8217;s transfer agent so requires, share certificates shall be
    issued under the corporate seal of the Company or its written, typed or stamped name and shall bear the signature of one Director,
    the Company&#8217;s Chief Executive Officer, or any person or persons authorized therefor by the Board of Directors. Signatures may
    be affixed in any mechanical or electronic form, as the Board of Directors may prescribe.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the provisions
    of Article 9(a), each Shareholder shall be entitled to one numbered certificate for all of the Shares of any class registered in
    his or her name. Each certificate shall specify the serial numbers of the Shares represented thereby and may also specify the amount
    paid up thereon. The Company (as determined by an officer of the Company to be designated by the Chief Executive Officer) shall not
    refuse a request by a Shareholder to obtain several certificates in place of one certificate, unless such request is, in the opinion
    of such officer, unreasonable. Where a Shareholder has sold or transferred a portion of such Shareholder&#8217;s Shares, such Shareholder
    shall be entitled to receive a certificate in respect of such Shareholder&#8217;s remaining Shares, <i>provided</i> that the previous
    certificate is delivered to the Company before the issuance of a new certificate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A share certificate registered
    in the names of two or more persons shall be delivered to the person first named in the Register of Shareholders in respect of such
    co-ownership.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A share certificate which
    has been defaced, lost or destroyed, may be replaced, and the Company shall issue a new certificate to replace such defaced, lost
    or destroyed certificate upon payment of such fee, and upon the furnishing of such evidence of ownership and such indemnity, as the
    Board of Directors in its discretion deems fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Registered
    Holder</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Except as otherwise provided in these
Articles or the Companies Law, the Company shall be entitled to treat the registered holder of each Share as the absolute owner thereof,
and accordingly, shall not, except as ordered by a court of competent jurisdiction, or as required by the Companies Law, be obligated
to recognize any equitable or other claim to, or interest in, such Share on the part of any other person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Issuance
    and Repurchase of Shares</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unissued Shares from
    time to time shall be under the control of the Board of Directors (and, to the extent permitted by applicable law, any Committee
    thereof), which shall have the power to issue or otherwise dispose of Shares and of securities convertible or exercisable into or
    other rights to acquire from the Company to such persons, on such terms and conditions (including, inter alia, price, with or without
    premium, discount or commission, and terms relating to calls set forth in Article 13(f) hereof), and at such times, as the Board
    of Directors (or the Committee, as the case may be) deems fit, and the power to give to any person the option to acquire from the
    Company any Shares or securities convertible or exercisable into or other rights to acquire from the Company on such terms and conditions
    (including, inter alia, price, with or without premium, discount or commission), during such time as the Board of Directors (or the
    Committee, as the case may be) deems fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may at any
    time and from time to time, subject to applicable law, repurchase or finance the purchase of any Shares or other securities issued
    by the Company, in such manner and under such terms as the Board of Directors shall determine, whether from any one or more Shareholders.
    Such purchase shall not be deemed as payment of dividends and as such, no Shareholder will have the right to require the Company
    to purchase his or her Shares or offer to purchase shares from any other Shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 604 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Payment
    in Installment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If pursuant to the terms of issuance
of any Share, all or any portion of the price thereof shall be payable in installments, every such installment shall be paid to the Company
on the due date thereof by the then registered holder(s) of the Share or the person(s) then entitled thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Calls
    on Shares</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors
    may, from time to time, as it, in its discretion, deems fit, make calls for payment upon Shareholders in respect of any sum (including
    premium) which has not been paid up in respect of Shares held by such Shareholders and which is not, pursuant to the terms of issuance
    of such Shares or otherwise, payable at a fixed time, and each Shareholder shall pay the amount of every call so made upon him or
    her (and of each installment thereof if the same is payable in installments), to the person(s) and at the time(s) and place(s) designated
    by the Board of Directors, as any such times may be thereafter extended and/or such person(s) or place(s) changed. Unless otherwise
    stipulated in the resolution of the Board of Directors (and in the notice hereafter referred to), each payment in response to a call
    shall be deemed to constitute a pro rata payment on account of all the Shares in respect of which such call was made.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of any call for
    payment by a Shareholder shall be given in writing to such Shareholder not less than fourteen (14) days prior to the time of payment
    fixed in such notice, and shall specify the time and place of payment, and the person to whom such payment is to be made. Prior to
    the time for any such payment fixed in a notice of a call given to a Shareholder, the Board of Directors may in its absolute discretion,
    by notice in writing to such Shareholder, revoke such call in whole or in part, extend the time fixed for payment thereof, or designate
    a different place of payment or person to whom payment is to be made. In the event of a call payable in installments, only one notice
    thereof need be given.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If pursuant to the terms
    of issuance of a share or otherwise, an amount is made payable at a fixed time, such amount shall be payable at such time as if it
    were payable by virtue of a call made by the Board of Directors and for which notice was given in accordance with paragraphs (a)
    and (b) of this Article 13, and the provision of these Articles with regard to calls (and the non-payment thereof) shall be applicable
    to such amount or such installment (and the non-payment thereof).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint holders of a Share
    shall be jointly and severally liable to pay all calls for payment in respect of such Share and all interest payable thereon.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any amount called for payment
    which is not paid when due shall bear interest from the date fixed for payment until actual payment thereof, at such rate (not exceeding
    the then prevailing debitory rate charged by leading commercial banks in Israel), and payable at such time(s) as the Board of Directors
    may prescribe.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the issuance of Shares,
    the Board of Directors may provide for differences among the holders of such Shares as to the amounts and times for payment of calls
    for payment in respect of such Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Prepayment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">With the approval of the Board of Directors,
any Shareholder may pay to the Company any amount not yet payable in respect of his or her Shares, and the Board of Directors may approve
the payment by the Company of interest on any such amount until the same would be payable if it had not been paid in advance, at such
rate and time(s) as may be approved by the Board of Directors. The Board of Directors may at any time cause the Company to repay all
or any part of the money so advanced, without premium or penalty. Nothing in this Article 14 shall derogate from the right of the Board
of Directors to make any call for payment before or after receipt by the Company of any such advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Forfeiture
    and Surrender</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any Shareholder fails
    to pay an amount payable by virtue of a call, installment or interest thereon as provided for in accordance herewith, on or before
    the day fixed for payment of the same, the Board of Directors may at any time after the day fixed for such payment, so long as such
    amount (or any portion thereof) or interest thereon (or any portion thereof) remains unpaid, forfeit all or any of the Shares in
    respect of which such payment was called for. All expenses incurred by the Company in attempting to collect any such amount or interest
    thereon, including, without limitation, attorneys&#8217; fees and costs of legal proceedings, shall be added to, and shall, for all
    purposes (including the accrual of interest thereon) constitute a part of, the amount payable to the Company in respect of such call.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 605 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the adoption of a
    resolution as to the forfeiture of a Shareholder&#8217;s Share, the Board of Directors shall cause notice thereof to be given to
    such Shareholder, which notice shall state that, in the event of the failure to pay the entire amount so payable by a date specified
    in the notice (which date shall be not less than fourteen (14) days after the date such notice is given and which may be extended
    by the Board of Directors), such Shares shall be ipso facto forfeited, <i>provided</i>, <i>however</i>, that, prior to such date,
    the Board of Directors may cancel such resolution of forfeiture, but no such cancellation shall stop the Board of Directors from
    adopting a further resolution of forfeiture in respect of the non-payment of the same amount.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without derogating from
    Articles 51 and 55 hereof, whenever Shares are forfeited as herein provided, all dividends, if any, theretofore declared in respect
    thereof and not actually paid shall be deemed to have been forfeited at the same time.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, by resolution
    of the Board of Directors, may accept the voluntary surrender of any Share.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Share forfeited or
    surrendered as provided herein, shall become the property of the Company as a dormant Share, and the same, subject to the provisions
    of these Articles, may be sold, re-issued or otherwise disposed of as the Board of Directors deems fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any person whose Shares
    have been forfeited or surrendered shall cease to be a Shareholder in respect of the forfeited or surrendered Shares, but shall,
    notwithstanding, be liable to pay, and shall forthwith pay, to the Company, all calls, interest and expenses owing upon or in respect
    of such Shares at the time of forfeiture or surrender, together with interest thereon from the time of forfeiture or surrender until
    actual payment, at the rate prescribed in Article 13(e) above, and the Board of Directors, in its discretion, may, but shall not
    be obligated to, enforce or collect the payment of such amounts, or any part thereof, as it shall deem fit. In the event of such
    forfeiture or surrender, the Company, by resolution of the Board of Directors, may accelerate the date(s) of payment of any or all
    amounts then owing to the Company by the person in question (but not yet due) in respect of all Shares owned by such Shareholder,
    solely or jointly with another.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors
    may at any time, before any Share so forfeited or surrendered shall have been sold, re-issued or otherwise disposed of, nullify the
    forfeiture or surrender on such conditions as it deems fit, but no such nullification shall stop the Board of Directors from re-exercising
    its powers of forfeiture pursuant to this Article 15.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Lien</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent the
    same may be waived or subordinated in writing, the Company shall have a first and paramount lien upon all the Shares registered in
    the name of each Shareholder (without regard to any equitable or other claim or interest in such Shares on the part of any other
    person), and upon the proceeds of the sale thereof, for his or her debts, liabilities and engagements to the Company arising from
    any amount payable by such Shareholder in respect of any unpaid or partly paid Share, whether or not such debt, liability or engagement
    has matured. Such lien shall extend to all dividends from time to time declared or paid in respect of such Share. Unless otherwise
    provided, the registration by the Company of a transfer of Shares shall be deemed to be a waiver on the part of the Company of the
    lien (if any) existing on such Shares immediately prior to such transfer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 606 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors
    may cause the Company to sell a Share subject to such a lien when the debt, liability or engagement giving rise to such lien has
    matured, in such manner as the Board of Directors deems fit, but no such sale shall be made unless such debt, liability or engagement
    has not been satisfied within fourteen (14) days after written notice of the intention to sell shall have been served on such Shareholder,
    his or her executors or administrators.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net proceeds of any
    such sale, after payment of the costs and expenses thereof or ancillary thereto, shall be applied in or toward satisfaction of the
    debts, liabilities or engagements of such Shareholder in respect of such Share (whether or not the same have matured), and the remaining
    proceeds (if any) shall be paid to the Shareholder, his or her executors, administrators or assigns.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Sale
    After Forfeiture or Surrender or For Enforcement of Lien</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon any sale of a share after forfeiture
or surrender or for enforcing a lien, the Board of Directors may appoint any person to execute an instrument of transfer of the Share
so sold and cause the purchaser&#8217;s name to be entered in the Register of Shareholders in respect of such Share. The purchaser shall
be registered as the Shareholder and shall not be bound to see to the regularity of the sale proceedings, or to the application of the
proceeds of such sale, and after his or her name has been entered in the Register of Shareholders in respect of such Share, the validity
of the sale shall not be impeached by any person, and the remedy of any person aggrieved by the sale shall be in damages only and against
the Company exclusively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Redeemable
    Shares</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may, subject to applicable
law, issue redeemable shares or other securities and redeem the same upon terms and conditions to be set forth in a written agreement
between the Company and the holder of such shares or in their terms of issuance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Transfer
of Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Registration
    of Transfer</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.05pt">No transfer of
Shares shall be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to
the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer) has been submitted to the Company
(or its transfer agent), together with any share certificate(s) and such other evidence of title as the Board of Directors or an officer
of the Company to be designated by the Chief Executive Officer may require. Notwithstanding anything to the contrary herein, Shares registered
in the name of The Depository Trust Company or its nominee shall be transferrable in accordance with the policies and procedures of The
Depository Trust Company. Until the transferee has been registered in the Register of Shareholders in respect of the Shares so transferred,
the Company may continue to regard the transferor as the owner thereof. The Board of Directors, may, from time to time, prescribe a fee
for the registration of a transfer, and may approve other methods of recognizing the transfer of Shares in order to facilitate the trading
of the Company&#8217;s shares on the Stock Exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.05pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Suspension
    of Registration</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Board of Directors may, in its
discretion to the extent it deems necessary, close the Register of Shareholders of registration of transfers of Shares for a period determined
by the Board of Directors, and no registrations of transfers of Shares shall be made by the Company during any such period during which
the Register of Shareholders is so closed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Transmission
of Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Decedents&#8217;
    Shares</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Upon the death of a Shareholder,
the Company shall recognize the custodian or administrator of the estate or executor of the will, and in the absence of such, the lawful
heirs of the Shareholder, as the only holders of the right for the Shares of the deceased Shareholder, after receipt of evidence to the
entitlement thereto, as determined by the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Receivers
    and Liquidators</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may recognize
    any receiver, liquidator or similar official appointed to wind-up, dissolve or otherwise liquidate a corporate Shareholder, and a
    trustee, manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or
    similar proceeding with respect to a Shareholder or its properties, as being entitled to the Shares registered in the name of such
    Shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 607 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such receiver, liquidator
    or similar official appointed to wind-up, dissolve or otherwise liquidate a corporate Shareholder and such trustee, manager, receiver,
    liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or similar proceedings with respect
    to a Shareholder or its properties, upon producing such evidence as the Board of Directors (or an officer of the Company to be designated
    by the Chief Executive Officer) may deem sufficient as to his or her authority to act in such capacity or under this Article, shall
    with the consent of the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer (which the
    Board of Directors or such officer may grant or refuse in its absolute discretion), be registered as a Shareholder in respect of
    such Shares, or may, subject to the regulations as to transfer herein contained, transfer such Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center"><span style="font-variant: small-caps"><b>General
Meetings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">General
    Meetings</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An annual General Meeting
    (&#8220;<b>Annual General Meeting</b>&#8221;) shall be held at such time and at such place, either within or outside of the State
    of Israel, as may be determined by the Board of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All General Meetings other
    than Annual General Meetings shall be called &#8220;<b>Special General Meetings</b>&#8221;. The Board of Directors may, at its discretion,
    convene a Special General Meeting at such time and place, within or outside of the State of Israel, as may be determined by the Board
    of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If so determined by the
    Board of Directors, an Annual General Meeting or a Special General Meeting may be held through the use of any means of communication
    approved by the Board of Directors, provided all of the participating Shareholders can hear each other simultaneously. A resolution
    approved by use of means of communications as aforesaid, shall be deemed to be a resolution lawfully adopted at such general meeting
    and a Shareholder shall be deemed present in person at such general meeting if attending such meeting through the means of communication
    used at such meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Record
    Date for General Meeting</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">Notwithstanding any provision of these
Articles to the contrary, and to allow the Company to determine the Shareholders entitled to notice of or to vote at any General Meeting
or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or grant of any rights, or entitled
to exercise any rights in respect of or to take or be the subject of any other action, the Board of Directors may fix a record date for
the General Meeting, which shall not be more than the maximum period and not less than the minimum period permitted by law. A determination
of Shareholders of record entitled to notice of or to vote at a General Meeting shall apply to any adjournment of the meeting; <span style="text-decoration:underline">provided</span>,
<span style="text-decoration:underline">however</span>, that the Board of Directors may fix a new record date for the adjourned meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Shareholder
    Proposal Request</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Shareholder
    or Shareholders of the Company holding at least the required percentage under the Companies Law of the voting rights of the Company
    which entitles such Shareholder(s) to require the Company to include a matter on the agenda of a General Meeting (the &#8220;<b>Proposing
    Shareholder(s)</b>&#8221;) may request, subject to the Companies Law, that the Board of Directors include a matter on the agenda
    of a General Meeting to be held in the future, provided that the Board of Directors determines that the matter is appropriate to
    be considered at a General Meeting (a &#8220;<b>Proposal Request</b>&#8221;). In order for the Board of Directors to consider a Proposal
    Request and whether to include the matter stated therein in the agenda of a General Meeting, notice of the Proposal Request must
    be timely delivered in accordance with applicable law, and the Proposal Request must comply with the requirements of these Articles
    (including this Article 25) and any applicable law and stock exchange rules and regulations. The Proposal Request must be in writing,
    signed by all of the Proposing Shareholder(s) making such request, delivered, either in person or by registered mail, postage prepaid,
    and received by the Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company). To be considered timely,
    a Proposal Request must be received within the time periods prescribed by applicable law. The announcement of an adjournment or postponement
    of a General Meeting shall not commence a new time period (or extend any time period) for the delivery of a Proposal Request as described
    above. In addition to any information required to be included in accordance with applicable law, a Proposal Request must include
    the following: (i) the name, address, telephone number, fax number and email address of the Proposing Shareholder (or each Proposing
    Shareholder, as the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity; (ii) the number
    of Shares held by the Proposing Shareholder(s), directly or indirectly (and, if any of such Shares are held indirectly, an explanation
    of how they are held and by whom), which shall be in such number no less than as is required to qualify as a Proposing Shareholder,
    accompanied by evidence satisfactory to the Company of the record holding of such Shares by the Proposing Shareholder(s) as of the
    date of the Proposal Request; (iii) the matter requested to be included on the agenda of a General Meeting, all information related
    to such matter, the reason that such matter is proposed to be brought before the General Meeting, the complete text of the resolution
    that the Proposing Shareholder proposes to be voted upon at the General Meeting, and a representation that the Proposing Shareholder(s)
    intend to appear in person or by proxy at the meeting; (iv) a description of all arrangements or understandings between the Proposing
    Shareholders and any other person(s) (naming such person or persons) in connection with the matter that is requested to be included
    on the agenda and a declaration signed by all Proposing Shareholder(s) of whether any of them has a personal interest in the matter
    and, if so, a description in reasonable detail of such personal interest; (v) a description of all Derivative Transactions (as defined
    below) by each Proposing Shareholder(s) during the previous twelve (12) month period, including the date of the transactions and
    the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions; and (vi)
    a declaration that all of the information that is required under the Companies Law and any other applicable law and stock exchange
    rules and regulations to be provided to the Company in connection with such matter, if any, has been provided to the Company. The
    Board of Directors, may, in its discretion, to the extent it deems necessary, request that the Proposing Shareholder(s) provide additional
    information necessary so as to include a matter in the agenda of a General Meeting, as the Board of Directors may reasonably require.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 608 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A &#8220;<b>Derivative Transaction</b>&#8221;
means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proposing Shareholder
or any of its Affiliates or associates, whether of record or beneficial: (1) the value of which is derived in whole or in part from the
value of any class or series of shares or other securities of the Company, (2) which otherwise provides any direct or indirect opportunity
to gain or share in any gain derived from a change in the value of securities of the Company, (3) the effect or intent of which is to
mitigate loss, manage risk or benefit of security value or price changes, or (4) which provides the right to vote or increase or decrease
the voting power of, such Proposing Shareholder, or any of its Affiliates or associates, with respect to any Shares or other securities
of the Company, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position,
note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting
agreement, performance-related fee or arrangement to borrow or lend Shares (whether or not subject to payment, settlement, exercise or
conversion in any such class or series), and any proportionate interest of such Proposing Shareholder in the securities of the Company
held by any general or limited partnership, or any limited liability company, of which such Proposing Shareholder is, directly or indirectly,
a general partner or managing member.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information
    required pursuant to this Article shall be updated as of (i) the record date of the General Meeting, (ii) five business days before
    the General Meeting, and (iii) as of the General Meeting, and any adjournment or postponement thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions
    of Articles 25(a) and 25(b) shall apply, <i>mutatis mutandis,</i> to any matter to be included on the agenda of a Special General
    Meeting which is convened pursuant to a request of a Shareholder duly delivered to the Company in accordance with the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Notice
    of General Meetings; Omission to Give Notice</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
    is not required to give notice of a General Meeting, subject to any mandatory provision of the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accidental
    omission to give notice of a General Meeting to any Shareholder, or the non-receipt of notice sent to such Shareholder, shall not
    invalidate the proceedings at such meeting or any resolution adopted thereat.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Shareholder
    present, in person or by proxy, at any time during a General Meeting shall be entitled to seek the cancellation or invalidation of
    any proceedings or resolutions adopted at such General Meeting on account of any defect in the notice of such meeting relating to
    the time or the place thereof, or any item acted upon at such meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition
    to any places at which the Company may make available for review by Shareholders the full text of the proposed resolutions to be
    adopted at a General Meeting, as required by the Companies Law, the Company may add additional places for Shareholders to review
    such proposed resolutions, including an internet site.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 609 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Proceedings
at General Meetings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Quorum</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No business
    shall be transacted at a General Meeting, or at any adjournment thereof, unless the quorum required under these Articles for such
    General Meeting or such adjourned meeting, as the case may be, is present when the meeting proceeds to business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the
    absence of contrary provisions in these Articles, the requisite quorum for any General Meeting shall be Shareholders (not in default
    in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding shares conferring in the aggregate
    at least thirty-three and one-third percent (33&#8531;%) of the voting power of the Company, provided, however, that if (i) such
    General Meeting was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii) at the time of
    such General Meeting the Company is qualified to use the forms of a &#8220;foreign private issuer&#8221; under US securities laws,
    then the requisite quorum shall be Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in
    person or by proxy and holding Shares conferring in the aggregate at least fifteen percent (15%) of the voting power of the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If within
    half an hour from the time appointed for the meeting a quorum is not present, then without any further notice the meeting shall be
    adjourned either (i) to the same day in the next week, at the same time and place, (ii) to such day and at such time and place as
    indicated in the notice of such meeting, or (iii) to such day and at such time and place as the Chairperson of the General Meeting
    shall determine (which may be earlier or later than the date pursuant to clause (i) above). No business shall be transacted at any
    adjourned meeting except business which might lawfully have been transacted at the meeting as originally called. At such adjourned
    meeting, if the original meeting was convened by a Shareholder pursuant to a request under Section 63 of the Companies Law, such
    Shareholder in addition to at least one or more Shareholder, present in person or by proxy, and holding the higher of ten percent
    (10%) of the voting power of the Company or the number of Shares required for making such request, shall constitute a quorum, but
    in any other case any Shareholder (not in default as aforesaid) present in person or by proxy, shall constitute a quorum.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Chairperson
    of General Meeting</span></b>. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Chairperson of the Board of Directors
shall preside as Chairperson of every General Meeting of the Company. If at any meeting the Chairperson is not present within fifteen
(15) minutes after the time fixed for holding the meeting or is unwilling or unable to act as Chairperson, any of the following may preside
as Chairperson of the meeting (and in the following order): a Director designated by the Board of Directors, the Chief Executive Officer,
the Chief Financial Officer, the General Counsel, the Secretary or any person designated by any of the foregoing. If at any such meeting
none of the foregoing persons is present or all are unwilling or unable to act as Chairperson, the Shareholders present (in person or
by proxy) shall choose a Shareholder or its proxy present at the meeting to be Chairperson. The office of Chairperson shall not, by itself,
entitle the holder thereof to vote at any General Meeting nor shall it entitle such holder to a second or casting vote (without derogating,
however, from the rights of such Chairperson to vote as a Shareholder or proxy of a Shareholder if, in fact, the Chairperson is also
a Shareholder or such proxy).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Adoption
    of Resolutions at General Meetings</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as required by the Companies Law or these Articles, including, without limitation, Article 39 below, a resolution of the Shareholders
    shall be adopted if approved by the holders of a simple majority of the voting power represented at the General Meeting in person
    or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting.
    Without limiting the generality of the foregoing, a resolution with respect to a matter or action for which the Companies Law prescribes
    a higher majority or pursuant to which a provision requiring a higher majority would have been deemed to have been incorporated into
    these Articles, but for which the Companies Law allows these Articles to provide otherwise (including, Sections 327 and 24 of the
    Companies Law), shall be adopted by a simple majority of the voting power represented at the General Meeting in person or by proxy
    and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
    question submitted to a General Meeting shall be decided by a show of hands, but the Chairperson of the General Meeting may determine
    that a resolution shall be decided by a written ballot. A written ballot may be implemented before the proposed resolution is voted
    upon or immediately after the declaration by the Chairperson of the results of the vote by a show of hands. If a vote by written
    ballot is taken after such declaration, the results of the vote by a show of hands shall be of no effect, and the proposed resolution
    shall be decided by such written ballot.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A defect
    in convening or conducting a General Meeting, including a defect resulting from the non-fulfillment of any provision or condition
    set forth in the Companies Law or these Articles, including with regard to the manner of convening or conducting the General Meeting,
    shall not disqualify any resolution passed at the General Meeting and shall not affect the discussions or decisions which took place
    thereat.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A declaration
    by the Chairperson of the General Meeting that a resolution has been carried unanimously, or carried by a particular majority, or
    rejected, and an entry to that effect in the minute book of the Company, shall be prima facie evidence of the fact without proof
    of the number or proportion of the votes recorded in favor of or against such resolution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 610 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Power
    to Adjourn</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A General Meeting, the consideration
of any matter on its agenda, or the resolution on any matter on its agenda, may be postponed or adjourned, from time to time and from
place to place: (i) by the Chairperson of a General Meeting at which a quorum is present (and he shall do so if directed by the General
Meeting, with the consent of the holders of a majority of the voting power represented in person or by proxy and voting on the question
of adjournment), but no business shall be transacted at any such adjourned meeting except business which might lawfully have been transacted
at the meeting as originally called, or a matter on its agenda with respect to which no resolution was adopted at the meeting originally
called; or (ii) by the Board of Directors (whether prior to or at a General Meeting).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Voting
    Power</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the provisions of Article
32(a) and to any provision hereof conferring special rights as to voting, or restricting the right to vote, every Shareholder shall have
one vote for each Share held by the Shareholder of record, on every resolution, without regard to whether the vote thereon is conducted
by a show of hands, by written ballot, or by any other means.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Voting
    Rights.</span></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Shareholder
    shall be entitled to vote at any General Meeting (or be counted as a part of the quorum thereat), unless all calls then payable by
    him or her in respect of his or her Shares in the Company have been paid.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A company
    or other corporate body being a Shareholder of the Company may duly authorize any person to be its representative at any meeting
    of the Company or to execute or deliver a proxy on its behalf. Any person so authorized shall be entitled to exercise on behalf of
    such Shareholder all the power, which the Shareholder could have exercised if it were an individual. Upon the request of the Chairperson
    of the General Meeting, written evidence of such authorization (in form acceptable to the Chairperson) shall be delivered to him
    or her.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Shareholder
    entitled to vote may vote either in person or by proxy (who need not be a Shareholder of the Company), or, if the Shareholder is
    a company or other corporate body, by representative authorized pursuant to Article (b) above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If two
    or more persons are registered as joint holders of any Share, the vote of the senior who tenders a vote, in person or by proxy, shall
    be accepted to the exclusion of the vote(s) of the other joint holder(s). For the purpose of this Article 32(d), seniority shall
    be determined by the order of registration of the joint holders in the Register of Shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a Shareholder
    is a minor, under protection, bankrupt or legally incompetent, or in the case of a corporation, is in receivership or liquidation,
    it may, subject to all other provisions of these Articles and any documents or records required to be provided under these Articles,
    vote through his, her or its trustees, receiver, liquidator, natural guardian or another legal guardian, as the case may be, and
    the persons listed above may vote in person or by proxy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 611 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Proxies</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Instrument
    of Appointment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px">&#160;</td>
    <td style="width: 32px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An instrument
    appointing a proxy shall be in writing and shall be substantially in the following form:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 13%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;I</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 31%; text-align: justify">&#160;</td>
    <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 39%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Name of Shareholder)</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address of Shareholder)</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="4" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Being a shareholder
    of SciSparc Ltd. hereby appoints</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Name of Proxy)</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address of Proxy)</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="4" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as my proxy
    to vote for me and on my behalf at the General Meeting of the Company to be held on the ___ day of _______, _______ and at any adjournment(s)
    thereof.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td colspan="4" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="4" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed this
    ____ day of ___________, ______.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td colspan="4" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td colspan="4" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of
    Appointor)&#8221;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">or in any usual or common form or in
such other form as may be approved by the Board of Directors. Such proxy shall be duly signed by the appointor of such person&#8217;s
duly authorized attorney, or, if such appointor is company or other corporate body, in the manner in which it signs documents which binds
it together with a certificate of an attorney with regard to the authority of the signatories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the Companies Law, the original instrument appointing a proxy or a copy thereof certified by an attorney (and the power of attorney
    or other authority, if any, under which such instrument has been signed) shall be delivered to the Company (at its Office, at its
    principal place of business, or at the offices of its registrar or transfer agent, or at such place as notice of the meeting may
    specify) not less than forty eight (48) hours (or such shorter period as the notice shall specify) before the time fixed for such
    meeting. Notwithstanding the above, the Chairperson shall have the right to waive the time requirement provided above with respect
    to all instruments of proxies and to accept instruments of proxy until the beginning of a General Meeting. A document appointing
    a proxy shall be valid for every adjourned meeting of the General Meeting to which the document relates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 612 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Effect
    of Death of Appointer of Transfer of Share and or Revocation of Appointment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A vote
    cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the prior death or bankruptcy of the appointing
    Shareholder (or of his or her attorney-in-fact, if any, who signed such instrument), or the transfer of the Share in respect of which
    the vote is cast, unless written notice of such matters shall have been received by the Company or by the Chairperson of such meeting
    prior to such vote being cast.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the Companies Law, an instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the Chairperson,
    subsequent to receipt by the Company of such instrument, of written notice signed by the person signing such instrument or by the
    Shareholder appointing such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed)
    or of an instrument appointing a different proxy (and such other documents, if any, required under Article 33(b) for such new appointment),
    provided such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time
    for delivery of the instrument revoked thereby as referred to in Article 33(b) hereof, or (ii) if the appointing Shareholder is present
    in person at the meeting for which such instrument of proxy was delivered, upon receipt by the Chairperson of such meeting of written
    notice from such Shareholder of the revocation of such appointment, or if and when such Shareholder votes at such meeting. A vote
    cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the revocation or purported cancellation
    of the appointment, or the presence in person or vote of the appointing Shareholder at a meeting for which it was rendered, unless
    such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article 34(b) at or prior to
    the time such vote was cast.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Board
of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Powers
    of the Board of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may exercise all such powers and do all such acts and things as the Board of Directors is authorized by law or as the
    Company is authorized to exercise and do and are not hereby or by law required to be exercised or done by the General Meeting. The
    authority conferred on the Board of Directors by this Article 35 shall be subject to the provisions of the Companies Law, these Articles
    and any regulation or resolution consistent with these Articles adopted from time to time at a General Meeting, provided, however,
    that no such regulation or resolution shall invalidate any prior act done by or pursuant to a decision of the Board of Directors
    which would have been valid if such regulation or resolution had not been adopted.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
    limiting the generality of the foregoing, the Board of Directors may, from time to time, set aside any amount(s) out of the profits
    of the Company as a reserve or reserves for any purpose(s) which the Board of Directors, in its absolute discretion, shall deem fit,
    including without limitation, capitalization and distribution of bonus Shares, and may invest any sum so set aside in any manner
    and from time to time deal with and vary such investments and dispose of all or any part thereof, and employ any such reserve or
    any part thereof in the business of the Company without being bound to keep the same separate from other assets of the Company, and
    may subdivide or re-designate any reserve or cancel the same or apply the funds therein for another purpose, all as the Board of
    Directors may from time to time think fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 613 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Exercise
    of Powers of the Board of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A meeting
    of the Board of Directors at which a quorum is present in accordance with Article 45 shall be competent to exercise all the authorities,
    powers and discretion vested in or exercisable by the Board of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A resolution
    proposed at any meeting of the Board of Directors shall be deemed adopted if approved by a majority of the Directors present, entitled
    to vote and voting thereon when such resolution is put to a vote.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may adopt resolutions, without convening a meeting of the Board of Directors, in writing or in any other manner permitted
    by the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary herein, including under Articles 36(a) and 36(b), and without derogating from any other approvals required
    pursuant to these Articles or applicable law, the following actions shall require the affirmative consent of at least three-quarters
    (3/4) of the Directors then in office and entitled to vote thereon:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="text-align: justify">Any resolution
                                            to enter into a merger, consolidation, acquisition, amalgamation, business combination, issue
                                            equity securities or debt securities convertible into equity or other similar transaction
                                            (collectively, a &#8220;<b>Transaction</b>&#8221;), in each case that would reasonably be
                                            expected to result (A) in any person (together with its Affiliates) becoming, as a result
                                            of such Transaction, a beneficial owner (as determined in&#160;accordance with&#160;Rule&#160;13d-3
                                            under the Securities Exchange Act of 1934, as amended) of fifteen percent (15%) or more of
                                            the Ordinary Shares issued and outstanding immediately following the consummation of such
                                            Transaction or (B) in the increase in the beneficial ownership of Ordinary Shares of any
                                            person (together with its Affiliates) who immediately prior to the consummation of such Transaction
                                            holds fifteen percent (15%) or more of the then issued and outstanding Ordinary Shares;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="text-align: justify">Any resolution
                                            to directly or indirectly sell, assign, convey, transfer, lease or otherwise dispose, in
                                            one or series of related transactions, of all or substantially all of the assets of the Company
                                            and its subsidiaries, taken as a whole, to any person;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iii)</td><td style="text-align: justify">Any resolution
                                            to effect any material change to the principal business of the Company, enter into new lines
                                            of business that are materially different from the Company&#8217;s then current line of business,
                                            or exit the then current line of business of the Company, or otherwise materially change
                                            the Company&#8217;s strategy and/or policies with respect to its main lines of business;
                                            or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iv)</td><td style="text-align: justify">Any resolution
                                            to transfer the headquarters of the Company outside of Israel.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 614 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Delegation
    of Powers</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees (in these Articles
    referred to as a &#8220;<b>Committee of the Board of Directors</b>&#8221;, or &#8220;<b>Committee</b>&#8221;), each consisting of
    one or more persons (who may or may not be Directors), and it may from time to time revoke such delegation or alter the composition
    of any such Committee. Any Committee so formed shall, in the exercise of the powers so delegated, conform to any regulations imposed
    on it by the Board of Directors, subject to applicable law. No regulation imposed by the Board of Directors on any Committee and
    no resolution of the Board of Directors shall invalidate any prior act done or pursuant to a resolution by the Committee which would
    have been valid if such regulation or resolution of the Board of Directors had not been adopted. The meetings and proceedings of
    any such Committee of the Board of Directors shall, mutatis mutandis, be governed by the provisions herein contained for regulating
    the meetings of the Board of Directors, to the extent not superseded by any regulations adopted by the Board of Directors. Unless
    otherwise expressly prohibited by the Board of Directors, in delegating powers to a Committee of the Board of Directors, such Committee
    shall be empowered to further delegate such powers.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may from time to time appoint a Secretary to the Company, as well as Officers, agents, employees and independent contractors,
    as the Board of Directors deems fit, and may terminate the service of any such person. The Board of Directors may, subject to the
    provisions of the Companies Law, determine the powers and duties, as well as the salaries and compensation, of all such persons.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may from time to time, by power of attorney or otherwise, appoint any person, company, firm or body of persons to be
    the attorney or attorneys of the Company at law or in fact for such purposes(s) and with such powers, authorities and discretions,
    and for such period and subject to such conditions, as it deems fit, and any such power of attorney or other appointment may contain
    such provisions for the protection and convenience of persons dealing with any such attorney as the Board of Directors deems fit,
    and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions vested in him or her.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Number
    of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors shall consist of such number of Directors (not less than three (3) nor more than eight (8), including the External Directors,
    if any were elected) as may be fixed from time to time by resolution of the Board of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Election
    and Removal of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Directors
    of the Company shall be appointed or re-appointed by Ordinary Resolution at the Annual General Meeting (other than External Directors,
    if any) following the expiration of the term of office of the Directors of that class of Directors will be for a term of office that
    expires on the third annual general meeting following such election or re-election, such that from the Annual General Meeting of
    2021 and thereafter, each year the term of office of only one class of Directors will expire, unless their office is vacated pursuant
    to any law or as stipulated in these Articles.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">This Section 39 (a) shall not be amended
unless an affirmative vote of 65% of the voting power represented at a general meeting of shareholders and voting thereon has been obtained,
provided that such majority constitutes more than 33.33% of the Company&#8217;s total issued and outstanding share capital at the record
date for such general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 615 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
    with the provisions of Section 39 (a) above, the Directors (excluding the External Directors if any were elected), shall be classified,
    with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable,
    hereby designated as Class I, Class II and Class III (each, a &#8220;<b>Class</b>&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
    with the provisions of Section 39 (a) above, at each Annual General Meeting, each Nominee or Alternate Nominee (each as defined below)
    elected at such Annual General Meeting to serve as a Director in a Class whose term shall have expired at such Annual General Meeting
    shall be elected to hold office until the third Annual General Meeting next succeeding his or her election and until his or her respective
    successor shall have been elected and qualified. Notwithstanding anything to the contrary, each Director shall serve until his or
    her successor is elected and qualified or until such earlier time as such Director&#8217;s office is vacated.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the
    number of Directors (excluding External Directors, if any were elected) that comprises the Board of Directors is hereafter changed
    by the Board of Directors, any newly created directorships or decrease in directorships shall be so apportioned by the Board of Directors
    among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of
    Directors constituting the Board of Directors shall shorten the term of any incumbent Director.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to every General Meeting of the Company at which Directors are to be elected, and subject to clauses(a), (b) and (h) of this Article,
    the Board of Directors (or a Committee thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or
    such Committee), a number of persons to be proposed to the Shareholders for election as Directors at such General Meeting (the &#8220;<b>Nominees</b>&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Proposing
    Shareholder requesting to include on the agenda of a General Meeting a nomination of a person to be proposed to the Shareholders
    for election as Director (such person, an &#8220;<b>Alternate Nominee</b>&#8221;), may so request provided that it complies with
    this Article 39(f), Article 25 and applicable law. Unless otherwise determined by the Board of Directors, a Proposal Request relating
    to an Alternate Nominee is deemed to be a matter that is appropriate to be considered only at an Annual General Meeting. In addition
    to any information required to be included in accordance with applicable law, such a Proposal Request shall include information required
    pursuant to Article 25, and shall also set forth: (i) the name, address, telephone number, fax number and email address of the Alternate
    Nominee and all citizenships and residencies of the Alternate Nominee; (ii) a description of all arrangements, relations or understandings
    during the past three (3) years, and any other material relationships, between the Proposing Shareholder(s) or any of its Affiliates
    and each Alternate Nominee; (iii) a declaration signed by the Alternate Nominee that he or she consents to be named in the Company&#8217;s
    notices and proxy materials and on the Company&#8217;s proxy card relating to the General Meeting, if provided or published, and
    that he or she, if elected, consents to serve on the Board of Directors and to be named in the Company&#8217;s disclosures and filings;
    (iv)&#160;a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable law and stock
    exchange rules and regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information that
    is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment
    has been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable
    disclosure requirements under Form 20-F (or Form 10-K, if applicable) or any other applicable form prescribed by the U.S. Securities
    and Exchange Commission (the&#160;&#8220;<b>SEC</b>&#8221;)); (v) a declaration made by the Alternate Nominee of whether he or she
    meets the criteria for an independent director and, if applicable, External Director of the Company under the Companies Law and/or
    under any applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi) any other information
    required at the time of submission of the Proposal Request by applicable law, regulations or stock exchange rules. In addition, the
    Proposing Shareholder(s) and each Alternate Nominee shall promptly provide any other information reasonably requested by the Company,
    including a duly completed director and officer questionnaire, in such form as may be provided by the Company, with respect to each
    Alternate Nominee. The Board of Directors may refuse to acknowledge the nomination of any person not made in compliance with the
    foregoing. The Company shall be entitled to publish any information provided by a Proposing Shareholder or Alternate Nominee pursuant
    to this Article 39(f) and Article 25, and the Proposing Shareholder and Alternate Nominee shall be responsible for the accuracy and
    completeness thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 616 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nominees
    or Alternate Nominees shall be elected by a resolution adopted at the General Meeting at which they are subject to election. Notwithstanding
    Articles 25(a) and 25(c), in the event of a Contested Election, the method of calculation of the votes and the manner in which the
    resolutions will be presented to the General Meeting shall be determined by the Board of Directors in its discretion. In the event
    that the Board of Directors does not or is unable to make a determination on such matter, then the method described in clause (ii)
    below shall apply. The Board of Directors may consider, among other things, the following methods: (i) election of competing slates
    of Director nominees (determined in a manner approved by the Board of Directors) by a majority of the voting power represented at
    the General Meeting in person or by proxy and voting on such competing slates, (ii) election of individual Directors by a plurality
    of the voting power represented at the General Meeting in person or by proxy and voting on the election of Directors (which shall
    mean that the nominees receiving the largest number of &#8220;for&#8221; votes will be elected in such Contested Election), (iii)
    election of each nominee by a majority of the voting power represented at the General Meeting in person or by proxy and voting on
    the election of Directors, provided that if the number of such nominees exceeds the number of Directors to be elected, then as among
    such nominees the election shall be by plurality of the voting power as described above, and (iv) such other method of voting as
    the Board of Directors deems appropriate, including use of a &#8220;universal proxy card&#8221; listing all Nominees and Alternate
    Nominees by the Company. For the purposes of these Articles, election of Directors at a General Meeting shall be considered a &#8220;Contested
    Election&#8221; if the aggregate number of Nominees and Alternate Nominees at such meeting exceeds the total number of Directors
    to be elected at such meeting, with the determination thereof being made by the Secretary (or, in the absence thereof, by the Chief
    Executive Officer of the Company) as of the close of the applicable notice of nomination period under Article 25 or under applicable
    law, based on whether one or more notice(s) of nomination were timely filed in accordance with Article 25, this Article 39 and applicable
    law; <span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>, that the determination that an election is a Contested Election shall not be determinative
    as to the validity of any such notice of nomination; and provided, further, that, if, prior to the time the Company mails its initial
    proxy statement in connection with such election of Directors, one or more notices of nomination of an Alternate Nominee are withdrawn
    such that the number of candidates for election as Director no longer exceeds the number of Directors to be elected, the election
    shall not be considered a Contested Election. Shareholders shall not be entitled to cumulative voting in the election of Directors,
    except to the extent specifically set forth in this clause (g).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary in these Articles, the election, qualification, removal or dismissal of External Directors, if so elected,
    shall be only in accordance with the applicable provisions set forth in the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Commencement
    of Directorship</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Without derogating from Article 39,
the term of office of a Director shall commence as of the date of his or her appointment or election, or on a later date if so specified
in his or her appointment or election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Continuing
    Directors in the Event of Vacancies</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors (and, if so
determined by the Board of Directors, the General Meeting) may at any time and from time to time appoint any person as a Director to
fill a vacancy (whether such vacancy is due to a Director no longer serving or due to the number of Directors serving being less than
the maximum number stated in Article 38 hereof). In the event of one or more such vacancies in the Board of Directors, the continuing
Directors may continue to act in every matter, provided, however, that if the number of Directors serving is less than the minimum number
provided for pursuant to Article 38 hereof, they may only act in an emergency or to fill the office of a Director which has become vacant
up to a number equal to the minimum number provided for pursuant to Article 38 hereof, or in order to call a General Meeting of the Company
for the purpose of electing Directors to fill any or all vacancies. The office of a Director that was appointed by the Board of Directors
to fill any vacancy shall only be for the remaining period of time during which the Director whose service has ended was filled would
have held office, or in case of a vacancy due to the number of Directors serving being less than the maximum number stated in Article
38 hereof the Board of Directors shall determine at the time of appointment the class pursuant to Article 39 to which the additional
Director shall be assigned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Vacation
    of Office</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The office of a Director shall be
vacated and he shall be dismissed or removed:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ipso facto,
    upon his or her death;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if he
    or she is prevented by applicable law from serving as a Director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the
    Board of Directors determines that due to his or her mental or physical state he or she is unable to serve as a director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 617 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if his
    or her directorship expires pursuant to these Articles and/or applicable law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by a resolution
    adopted at an Annual General Meeting by a majority of at least 65% of the total voting power of the Shares (with such removal becoming
    effective on the date fixed in such resolution);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by his
    or her written resignation, such resignation becoming effective on the date fixed therein, or upon the delivery thereof to the Company,
    whichever is later; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with respect
    to an External Director, if so elected, and notwithstanding anything to the contrary herein, only pursuant to applicable law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Conflict
    of Interests; Approval of Related Party Transactions</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the provisions of applicable law and these Articles, no Director shall be disqualified by virtue of his or her office from holding
    any office or place of profit in the Company or in any company in which the Company shall be a Shareholder or otherwise interested,
    or from contracting with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract or arrangement
    entered into by or on behalf of the Company in which any Director shall be in any way interested, be avoided, nor, other than as
    required under the Companies Law, shall any Director be liable to account to the Company for any profit arising from any such office
    or place of profit or realized by any such contract or arrangement by reason only of such Director&#8217;s holding that office or
    of the fiduciary relations thereby established, but the nature of his or her interest, as well as any material fact or document,
    must be disclosed by him or her at the meeting of the Board of Directors at which the contract or arrangement is first considered,
    if his or her interest then exists, or, in any other case, at no later than the first meeting of the Board of Directors after the
    acquisition of his or her interest.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the Companies Law&#160;and these Articles, a transaction between the Company and an Office Holder, and a transaction between the
    Company and another entity in which an Office Holder of the Company has a personal interest, in each case, which is not an Extraordinary
    Transaction (as defined by the Companies Law), shall require only approval by the Board of Directors or a Committee of the Board
    of Directors. Such authorization, as well as the actual approval, may be for a particular transaction or more generally for specific
    type of transactions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary in these Articles, the Company shall not engage in any Business Combination (as defined below) with any
    Shareholder and/or any of its Affiliates and/or investors for a period of three years following (i) with respect to any Shareholder
    holding as of the Effective Time fifteen percent (15%) or more of the voting power of the Shares, the Effective Time and (ii) with
    respect to all Shareholders, each time as such Shareholder and/or any of its Affiliates and/or investors become(s) (other than due
    to a buyback, redemption or cancellation of shares by the Company) the holder(s) (beneficially or of record) of fifteen percent (15%)
    or more of the issued and outstanding voting power of the Shares (the &#8220;<b>Threshold</b>&#8221; and such shareholder, an &#8220;<b>Interested
    Shareholder</b>&#8221;), except if the Board of Directors approves either the Business Combination or the transaction which resulted
    in such Shareholder and/or any of its Affiliates and/or investors becoming an Interested Shareholder prior to consummation of a Business
    Combination. As used in this Article 43 only, &#8220;<b>Business Combination</b>&#8221; means (i) a merger or consolidation of the
    Company in which the holders of a majority of the Ordinary Shares issued and outstanding immediately prior to the consummation of
    such transaction hold immediately following the consummation of such transaction less than 50% of the issued and outstanding share
    capital of the surviving, acquiring or resulting company (or if the surviving, acquiring or resulting company is a wholly owned subsidiary
    of another company immediately following the consummation of such transaction, the parent company of such surviving, acquiring or
    resulting company) or (ii) a disposition of assets of the Company with an aggregate market value equal to 10% or more of the Company&#8217;s
    assets or of its outstanding shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 618 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Proceedings
of the Board of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Meetings</span></b>.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may meet and adjourn its meetings and otherwise regulate such meetings and proceedings as the Board of Directors thinks
    fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A meeting
    of the Board of Directors shall be convened by the Secretary upon instruction of the Chairperson or upon a request of at least two
    (2) Directors which is submitted to the Chairperson or in any event that such meeting is required by the provisions of the Companies
    Law. In the event that the Chairperson does not instruct the Secretary to convene a meeting upon a request of at least two (2) Directors
    within seven (7) days of such request, then such two (2) Directors may convene a meeting of the Board of Directors. Any meeting of
    the Board of Directors shall be convened upon not less than two (2) days&#8217; notice, unless such notice is waived in writing by
    all of the Directors as to a particular meeting or by their attendance at such meeting or unless the matters to be discussed at such
    meeting are of such urgency and importance that notice is reasonably determined by the Chairperson as ought to be waived or shortened
    under the circumstances.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
    of any such meeting shall be given orally, by telephone, in writing or by mail, facsimile, email or such other means of delivery
    of notices as the Company may apply, from time to time.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary herein, failure to deliver notice to a Director of any such meeting in the manner required hereby may be
    waived by such Director, and a meeting shall be deemed to have been duly convened notwithstanding such defective notice if such failure
    or defect is waived prior to action being taken at such meeting, by all Directors entitled to participate at such meeting to whom
    notice was not duly given as aforesaid. Without derogating from the foregoing, no Director present at any time during a meeting of
    the Board of Directors shall be entitled to seek the cancellation or invalidation of any proceedings or resolutions adopted at such
    meeting on account of any defect in the notice of such meeting relating to the date, time or the place thereof or the convening of
    the meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Quorum</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Until otherwise unanimously decided
by the Board of Directors, a quorum at a meeting of the Board of Directors shall be constituted by the presence in person or by any means
of communication of a majority of the Directors then in office who are lawfully entitled to participate and vote in the meeting. No business
shall be transacted at a meeting of the Board of Directors unless the requisite quorum is present (in person or by any means of communication
on the condition that all participating Directors can hear each other simultaneously) when the meeting proceeds to business. If within
thirty (30) minutes from the time appointed for a meeting of the Board of Directors a quorum is not present, the meeting shall stand
adjourned at the same place and time forty-eight (48) hours thereafter unless the Chairperson has determined that there is such urgency
and importance that a shorter period is required under the circumstances. If an adjourned meeting is convened in accordance with the
foregoing and a quorum is not present within thirty (30) minutes of the announced time, the requisite quorum at such adjourned meeting
shall be, any two (2) Directors, if the number of Directors then serving is up to five (5), and any three (3) Directors, if the number
of Directors then serving is more than five (5), in each case who are lawfully entitled to participate in the meeting and who are present
at such adjourned meeting. At an adjourned meeting of the Board of Directors the only matters to be considered shall be those matters
which might have been lawfully considered at the meeting of the Board of Directors originally called if a requisite quorum had been present,
and the only resolutions to be adopted are such types of resolutions which could have been adopted at the meeting of the Board of Directors
originally called.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 619 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Chairperson
    of the Board of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors shall, from
time to time, elect one of its members to be the Chairperson of the Board of Directors, remove such Chairperson from office and appoint
in his or her place. The Chairperson of the Board of Directors shall preside at every meeting of the Board of Directors, but if there
is no such Chairperson, or if at any meeting he is not present within fifteen (15) minutes of the time fixed for the meeting or if he
is unwilling to take the chair, the Directors present shall choose one of the Directors present at the meeting to be the Chairperson
of such meeting. The office of Chairperson of the Board of Directors shall not, by itself, entitle the holder to a second or casting
vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Validity
    of Acts Despite Defects</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">All acts done or transacted at any
meeting of the Board of Directors, or of a Committee of the Board of Directors, or by any person(s) acting as Director(s), shall, notwithstanding
that it may afterwards be discovered that there was some defect in the appointment of the participants in such meeting or any of them
or any person(s) acting as aforesaid, or that they or any of them were disqualified, be as valid as if there were no such defect or disqualification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Chief
Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Chief
    Executive Officer</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Board of Directors shall from time
to time appoint one or more persons, whether or not Directors, as Chief Executive Officer of the Company who shall have the powers and
authorities set forth in the Companies Law, and may confer upon such person(s), and from time to time modify or revoke, such titles and
such duties and authorities of the Board of Directors as the Board of Directors may deem fit, subject to such limitations and restrictions
as the Board of Directors may from time to time prescribe. Such appointment(s) may be either for a fixed term or without any limitation
of time, and the Board of Directors may from time to time (subject to any additional approvals required under, and the provisions of,
the Companies Law and of any contract between any such person and the Company) fix their salaries and compensation, remove or dismiss
them from office and appoint another or others in his, her or their place or places.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Minutes</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">49.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Minutes</span></b><span style="text-decoration:underline">.
    </span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any minutes of the General Meeting
or the Board of Directors or any Committee thereof, if purporting to be signed by the Chairperson of the General Meeting, the Board of
Directors or a Committee thereof, as the case may be, or by the Chairperson of the next succeeding General Meeting, meeting of the Board
of Directors or meeting of a Committee, as the case may be, shall constitute prima facie evidence of the matters recorded therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Dividends</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Declaration
    of Dividends</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors may, from
time to time, declare, and cause the Company to pay dividends as permitted by the Companies Law. The Board of Directors shall determine
the time for payment of such dividends and the record date for determining the shareholders entitled thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Amount
    Payable by Way of Dividends</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the provisions of these
Articles and subject to the rights or conditions attached at that time to any Share in the capital of the Company granting preferential,
special or deferred rights or not granting any rights with respect to dividends, any dividend paid by the Company shall be allocated
among the Shareholders (not in default in payment of any sum referred to in Article 13 hereof) entitled thereto on a <i>pari passu</i>
basis in proportion to their respective holdings of the issued and outstanding Shares in respect of which such dividends are being paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 620 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Interest</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">No dividend shall carry interest
as against the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Payment
    in Specie</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">If so declared by the Board of Directors,
a dividend declared in accordance with Article 50 may be paid, in whole or in part, by the distribution of specific assets of the Company
or by distribution of paid up Shares, debentures or other securities of the Company or of any other companies, or in any combination
thereof, in each case, the fair value of which shall be determined by the Board of Directors in good faith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Implementation
    of Powers</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors may settle,
as it deems fit, any difficulty arising with regard to the distribution of dividends, bonus shares or otherwise, and in particular, to
issue certificates for fractions of shares and sell such fractions of shares in order to pay their consideration to those entitled thereto,
or to set the value for the distribution of certain assets and to determine that cash payments shall be paid to the Shareholders on the
basis of such value, or that fractions whose value is less than NIS 0.01 shall not be taken into account. The Board of Directors may
instruct to pay cash or convey these certain assets to a trustee in favor of those people who are entitled to a dividend, as the Board
of Directors shall deem appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Deductions
    from Dividends</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">The Board of Directors may deduct
from any dividend or other moneys payable to any Shareholder in respect of a Share any and all sums of money then payable by him or her
to the Company on account of calls or otherwise in respect of Shares of the Company and/or on account of any other matter of transaction
whatsoever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">56.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Retention
    of Dividends</span></b><span style="text-decoration:underline">. </span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may retain any dividend or other moneys payable or property distributable in respect of a Share on which the Company
    has a lien, and may apply the same in or toward satisfaction of the debts, liabilities, or engagements in respect of which the lien
    exists.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may retain any dividend or other moneys payable or property distributable in respect of a Share in respect of which
    any person is, under Articles 21 or 22, entitled to become a Shareholder, or which any person is, under said Articles, entitled to
    transfer, until such person shall become a Shareholder in respect of such Share or shall transfer the same.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Unclaimed
    Dividends</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">All unclaimed dividends or other
moneys payable in respect of a Share may be invested or otherwise made use of by the Board of Directors for the benefit of the Company
until claimed. The payment of any unclaimed dividend or such other moneys into a separate account shall not constitute the Company a
trustee in respect thereof, and any dividend unclaimed after a period of one (1) year (or such other period determined by the Board of
Directors) from the date of declaration of such dividend, and any such other moneys unclaimed after a like period from the date the same
were payable, shall be forfeited and shall revert to the Company, <i><span style="text-decoration:underline">provided</span></i>, <i><span style="text-decoration:underline">however</span></i>, that the Board of Directors
may, at its discretion, cause the Company to pay any such dividend or such other moneys, or any part thereof, to a person who would have
been entitled thereto had the same not reverted to the Company. The principal (and only the principal) of any unclaimed dividend of such
other moneys shall be if claimed, paid to a person entitled thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 621 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Mechanics
    of Payment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Any dividend or other moneys payable
in cash in respect of a Share, less the tax required to be withheld pursuant to applicable law, may, as determined by the Board of Directors
in its sole discretion, be paid by check or warrant sent through the post to, or left at, the registered address of the person entitled
thereto or by transfer to a bank account specified by such person (or, if two (2) or more persons are registered as joint holders of
such Share or are entitled jointly thereto in consequence of the death or bankruptcy of the holder or otherwise, to any one of such persons
or his or her bank account or the person who the Company may then recognize as the owner thereof or entitled thereto under Article 21
or 22 hereof, as applicable, or such person&#8217;s bank account), or to such person and at such other address as the person entitled
thereto may by writing direct, or in any other manner the Board of Directors deems appropriate. Every such check or warrant or other
method of payment shall be made payable to the order of the person to whom it is sent, or to such person as the person entitled thereto
as aforesaid may direct, and payment of the check or warrant by the banker upon whom it is drawn shall be a good discharge to the Company.
Every such check shall be sent at the risk of the person entitled to the money represented thereby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Accounts</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Books
    of Account</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Company&#8217;s books of account
shall be kept at the Office of the Company, or at such other place or places as the Board of Directors may think fit, and they shall
always be open to inspection by all Directors. No shareholder, not being a Director, shall have any right to inspect any account or book
or other similar document of the Company, except as explicitly conferred by law or authorized by the Board of Directors. The Company
shall make copies of its annual financial statements available for inspection by the Shareholders at the principal offices of the Company.
The Company shall not be required to send copies of its annual financial statements to the Shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Auditors</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The appointment, authorities, rights
and duties of the auditor(s) of the Company, shall be regulated by applicable law, provided, however, that in exercising its authority
to fix the remuneration of the auditor(s), the Shareholders in General Meeting may act (and in the absence of any action in connection
therewith shall be deemed to have so acted) to authorize the Board of Directors (with right of delegation to a Committee thereof or to
management) to fix such remuneration subject to such criteria or standards, and if no such criteria or standards are so provided, such
remuneration shall be fixed in an amount commensurate with the volume and nature of the services rendered by such auditor(s). The General
Meeting may, if so recommended by the Board of Directors, appoint the auditors for a period that may extend until the third Annual General
Meeting after the Annual General Meeting in which the auditors were appointed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Fiscal
    Year</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The fiscal year of the Company shall
be the 12 months period ending on December 31 of each calendar year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Supplementary
Registers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Supplementary
    Registers</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to and in accordance with
the provisions of Sections 138 and 139 of the Companies Law, the Company may cause supplementary registers to be kept in any place outside
Israel as the Board of Directors may think fit, and, subject to all applicable requirements of law, the Board of Directors may from time
to time adopt such rules and procedures as it may think fit in connection with the keeping of such branch registers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 622 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Exemption,
Indemnity and Insurance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">63.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Insurance</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to the provisions of the
Companies Law with regard to such matters, the Company may enter into a contract for the insurance of the liability, in whole or in part,
of any of its Office Holders imposed on such Office Holder due to an act performed by or an omission of the Office Holder in the Office
Holder&#8217;s capacity as an Office Holder of the Company arising from any matter permitted by law, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach
    of duty of care to the Company or to any other person;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach
    of his or her duty of loyalty to the Company, provided that the Office Holder acted in good faith and had reasonable grounds to assume
    that act that resulted in such breach would not prejudice the interests of the Company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial
    liability imposed on such Office Holder in favor of any other person; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other
    event, occurrence, matters or circumstances under any law with respect to which the Company may, or will be able to, insure an Office
    Holder, and to the extent such law requires the inclusion of a provision permitting such insurance in these Articles, then such provision
    is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section 56h(b)(1)
    of the Securities Law, if and to the extent applicable, and Section 50P of the Economic Competition Law).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Indemnity</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the provisions of the Companies Law, the Company may retroactively indemnify an Office Holder of the Company to the maximum extent
    permitted under applicable law, including with respect to the following liabilities and expenses, provided that such liabilities
    or expenses were imposed on such Office Holder or incurred by such Office Holder due to an act performed by or an omission of the
    Office Holder in such Office Holder&#8217;s capacity as an Office Holder of the Company:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">a
                                            financial liability imposed on an Office Holder in favor of another person by any court judgment,
                                            including a judgment given as a result of a settlement or an arbitrator&#8217;s award which
                                            has been confirmed by a court;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">reasonable
                                            litigation expenses, including legal fees, expended by the Office Holder (A) as a result
                                            of an investigation or proceeding instituted against him or her by an authority authorized
                                            to conduct such investigation or proceeding, provided that (1) no indictment (as defined
                                            in the Companies Law) was filed against such Office Holder as a result of such investigation
                                            or proceeding; and (2) no financial liability in lieu of a criminal proceeding (as defined
                                            in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding
                                            or if such financial liability was imposed, it was imposed with respect to an offense that
                                            does not require proof of criminal intent or (B) in connection with a financial sanction;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iii)</td><td style="padding-bottom: 0; text-align: justify">reasonable
                                            litigation costs, including legal fees, expended by an Office Holder or which were imposed
                                            on an Office Holder by a court in proceedings filed against the Office Holder by the Company
                                            or in its name or by any other person or in a criminal charge in respect of which the Office
                                            Holder was acquitted or in a criminal charge in respect of which the Office Holder was convicted
                                            for an offence which did not require proof of criminal intent; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iv)</td><td style="padding-bottom: 0; text-align: justify">any
                                            other event, occurrence, matter or circumstance under any law with respect to which the Company
                                            may, or will be able to, indemnify an Office Holder, and to the extent such law requires
                                            the inclusion of a provision permitting such indemnity in these Articles, then such provision
                                            is deemed to be included and incorporated herein by reference (including, without limitation,
                                            in accordance with Section 56h(b)(1) of the Israeli Securities Law, if and to the extent
                                            applicable, and Section 50P(b)(2) of the RTP Law).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 623 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the provisions of the Companies Law, the Company may undertake to indemnify an Office Holder, in advance, with respect to those
    liabilities and expenses described in the following Articles:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="text-align: justify">Sub-Article 64(a)(i)(a)(ii)
                                            to 64(a)(iv); and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="text-align: justify">Sub-Article
                                            64(a)(i), provided that:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.25in; text-align: right"/><td style="width: 0.25in">(1)</td><td style="padding-bottom: 0; text-align: justify">the
                                            undertaking to indemnify is limited to such events which the Directors shall deem to be foreseeable
                                            in light of the operations of the Company at the time that the undertaking to indemnify is
                                            made and for such amounts or criterion which the Directors may, at the time of the giving
                                            of such undertaking to indemnify, deem to be reasonable under the circumstances; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.25in; text-align: right"/><td style="width: 0.25in">(2)</td><td style="padding-bottom: 0; text-align: justify">the
                                            undertaking to indemnify shall set forth such events which the Directors shall deem to be
                                            foreseeable in light of the operations of the Company at the time that the undertaking to
                                            indemnify is made, and the amounts and/or criterion which the Directors may, at the time
                                            of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Exemption</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to the provisions of the
Companies Law, the Company may, to the maximum extent permitted by law, exempt and release, in advance, any Office Holder from any liability
for damages arising out of a breach of a duty of care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">General</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any amendment
    to the Companies Law or any other applicable law adversely affecting the right of any Office Holder to be indemnified, insured or
    exempt pursuant to Articles 63 to 65 and any amendments to Articles 63 to 65 shall be prospective in effect, and shall not affect
    the Company&#8217;s obligation or ability to indemnify, insure or exempt an Office Holder for any act or omission occurring prior
    to such amendment, unless otherwise provided by applicable law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions
    of Articles 63 to 65 (i) shall apply to the maximum extent permitted by law (including, the Companies Law, the Securities Law and
    the Economic Competition Law); and (ii) are not intended, and shall not be interpreted so as to restrict the Company, in any manner,
    in respect of the procurement of insurance and/or in respect of indemnification (whether in advance or retroactively) and/or exemption,
    in favor of any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor
    of the Company who is not an Office Holder; and/or any Office Holder to the extent that such insurance and/or indemnification is
    not specifically prohibited under law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Winding
Up</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Winding
    Up</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">If the Company is wound up, then,
subject to applicable law and to the rights of the holders of Shares with special rights upon winding up, the assets of the Company available
for distribution among the Shareholders shall be distributed to them in proportion to the number of issued and outstanding Shares held
by each Shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Notices</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Notices</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any written
    notice or other document may be served by the Company upon any Shareholder either personally, by facsimile, email or other electronic
    transmission, or by sending it by prepaid mail (airmail if sent internationally) addressed to such Shareholder at his or her address
    as described in the Register of Shareholders or such other address as the Shareholder may have designated in writing for the receipt
    of notices and other documents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 624 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any written
    notice or other document may be served by any Shareholder upon the Company by tendering the same in person to the Secretary or the
    Chief Executive Officer of the Company at the principal office of the Company, by facsimile transmission, email or other electronic
    submission, or by sending it by prepaid registered mail (airmail if posted outside Israel) to the Company at its Office.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any such
    notice or other document shall be deemed to have been served:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">in
                                            the case of mailing, forty-eight (48) hours after it has been posted, or when actually received
                                            by the addressee if sooner than forty-eight hours after it has been posted, or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">in
                                            the case of overnight air courier, on the next business day following the day sent, with
                                            receipt confirmed by the courier, or when actually received by the addressee if sooner than
                                            three business days after it has been sent;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iii)</td><td style="padding-bottom: 0; text-align: justify">in
                                            the case of personal delivery, when actually tendered in person, to such addressee;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iv)</td><td style="padding-bottom: 0; text-align: justify">in
                                            the case of facsimile, email or other electronic transmission, on the first business day
                                            (during normal business hours in place of addressee) on which the sender receives automatic
                                            electronic confirmation by the addressee&#8217;s facsimile machine that such notice was received
                                            by the addressee or delivery confirmation from the addressee&#8217;s email or other communication
                                            server.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a notice
    is, in fact, received by the addressee, it shall be deemed to have been duly served, when received, notwithstanding that it was defectively
    addressed or failed, in some other respect, to comply with the provisions of this Article 68.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All notices
    to be given to the Shareholders shall, with respect to any Share to which persons are jointly entitled, be given to whichever of
    such persons is named first in the Register of Shareholders, and any notice so given shall be sufficient notice to the holders of
    such Share.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Shareholder
    whose address is not described in the Register of Shareholders, and who shall not have designated in writing an address for the receipt
    of notices, shall not be entitled to receive any notice from the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary contained herein, notice by the Company of a General Meeting, containing the information required by applicable
    law and these Articles to be set forth therein, which is published, within the time otherwise required for giving notice of such
    meeting, in either or several of the following manners (as applicable) shall be deemed to be notice of such meeting duly given, for
    the purposes of these Articles, to any Shareholder whose address as registered in the Register of Shareholders (or as designated
    in writing for the receipt of notices and other documents) is located either inside or outside the State of Israel:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">if
                                            the Company&#8217;s Shares are then listed for trading on a national securities exchange
                                            in the United States or quoted in an over-the-counter market in the United States, publication
                                            of notice of a General Meeting pursuant to a report or a schedule filed with, or furnished
                                            to, the SEC pursuant to the Securities Exchange Act of 1934, as amended; and/or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">on
                                            the Company&#8217;s internet site.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The mailing
    or publication date and the record date and/or date of the meeting (as applicable) shall be counted among the days comprising any
    notice period under the Companies Law and the regulations thereunder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Amendment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Amendment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">Any amendment of these Articles shall
require, in addition and prior to the approval of the General Meeting of Shareholders in accordance with these Articles, also the approval
of the Board of Directors with the affirmative vote of at least three-quarters (3/4) of the Directors then in office and entitled to
vote thereon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 625 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Forum
for Adjudication of Disputes</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Forum
    for Adjudication of Disputes</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America,
    shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the U.S. Securities
    Act of 1933, as amended, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt,
    this provision is intended to benefit and may be enforced by the Company, its officers and directors, the underwriters to any offering
    giving rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that
    person or entity and who has prepared or certified any part of the documents underlying the offering. The foregoing provisions of
    this Article 70 shall not apply to causes of action arising under the U.S. Securities Exchange Act of 1934, as amended.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the Company consents in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall be the exclusive
    forum for (i)&#160;any derivative action or proceeding brought on behalf of the Company, (ii)&#160;any action asserting a claim of
    breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#8217;s shareholders,
    or (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any person
    or entity purchasing or otherwise acquiring&#160;or holding&#160;any interest in&#160;shares of the Company shall be deemed to have
    notice of and consented to the provisions of this Article 70.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;*</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 626 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><div><a id="m_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ANNEX
E</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>OPINION OF E.D.B. CONSULTING
AND INVESTMENTS LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">&#8220;Automax Motors Ltd&#8221;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Company Valuation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_002.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drafted on January 4, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This valuation of &#8220;Automax Motors Ltd&#8221;
(hereinafter - Automax or the Group) was commissioned by Mr. Oz Adler, CEO of &#8220;SCISPARC Ltd&#8221;. This valuation is a commercial
document solely intended to convey information to the organs of SCISPARC, to Automax, its advisors and anyone the Company&#8217;s management
determines it should be presented to. This document includes data, assessments, forecasts and plans of Automax regarding its operations
which constitute forward looking information, as such term is defined in the Israel Securities Law, 1968 (hereinafter: the &#8220;Securities
Law&#8221;), the manifestation of which is uncertain and not exclusively within Automax&#8217;s control. Forward looking information
is based on assessments made by Automax&#8217;s management, which, <i>inter alia</i>, are based on the information known by the management
at the time this document was prepared. Only partial information and details are included in this document, they are presented in a condensed
format solely for convenience purposes, and they should be read jointly with the details, descriptions, clarifications, assumptions,
qualifications, assessments and overview of the risk factors included in the Company&#8217;s periodic and annual reports published on
the Israel Securities Authority distribution website (&#8220;MAYA&#8221;). There is no certainty that the data and/or assessments and/or
forecasts and/or plans will be achieved, in whole or in part, and they may manifest differently than as presented in the document, <i>inter
alia</i>, due to them being dependent on external factors not within Automax&#8217;s control, including: Changes in the competitive and
commercial environment and the manifestation of any of the risk factors applicable to Automax. Additionally, the document may include
data taken from external sources not independently verified by Automax, and Automax should therefore not be held responsible for their
accuracy. The document may also include information not presented in the Company&#8217;s financial statements and immediate reports and/or
information which may be presented or applied differently. It should be clarified that the document is no substitute to the Company&#8217;s
public reports, and in any event of any inconsistency between the data presented in this document and the public reports, the data in
the aforementioned public reports should prevail. The forecasts and assessments in this document are based on the information held by
the Company at the time the document was being prepared, and the Company is not subject to any obligation to update and/or change said
forecasts and/or assessments, in order to reflect events and/or developments which may occur after the document has been drafted. All
calculated assessments applied in this valuation were done on the basis of my professional assessments which are based on more than 35
years of experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 627; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Preface</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to perform this valuation I received
the Company&#8217;s audited balance sheets for the 2020-2022 annual periods, an unaudited balance sheet as of June 30, 2023, and a budget
and business plan prepared by the Company&#8217;s management for the 2024-2028 5-year period, quantitative data about the Company&#8217;s
sales, progress about the bus marketing project and the direct import of the electric vehicle from China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I also met with the Company&#8217;s managers,
including the VP and Director of Business Development as well as with current and former officers and advisors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I visited the Company&#8217;s head branch in
Jerusalem and I examined public materials regarding competitors and about the vehicle import market in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on my study of the materials in recent
weeks I am presenting the valuation document containing six chapters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter A</b> - Which will include an exhaustive
overview of the Company and its activities in the parallel import segment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter B</b> - Which will include an overview
of both the Israeli and global sector in which it operates and competes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter C</b> - Which will include an overview
of the Company&#8217;s planned activities for the sale of TEMSA buses in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter D</b> - Which will include an overview
of the Company&#8217;s planned activities for the sale of HYCAN electric vehicles in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter E</b> - Which will propose a valuation
of the Company&#8217;s enterprise value based on multiplier methodologies and the net DCF methodology which, unlike the multiplier methodology,
is forward looking.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter F</b> - In which I will summarize
my work and in which I will argue an enterprise value of USD 44.8 million, based on the independent valuation I presented in the previous
chapter, which is a cautious and conservative assessment of the Company&#8217;s activities which I rely upon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">65-66 Bareket Street, Mevasseret
Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160; Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 628; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter A - The &#8220;Group&#8221; - A
general and historic overview of the Group and of the parallel import industry</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax Motors Ltd (hereinafter: &#8220;Automax&#8221;
or the &#8220;Group&#8221;) is a public company which has been listed on the Tel Aviv Stock Exchange since 2021 and which owns multiple
companies, primarily &#8220;Global Automax Ltd&#8221; - an indirect (parallel) importer of vehicles to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2021, &#8220;Global Automax Ltd&#8221;
(&#8220;Global Automax&#8221;) merged via a share swap transaction into the public shell company &#8220;Matomy Media Group&#8221; which
changed its name to &#8220;Automax Motors&#8221; and which holds Global Automax&#8217;s entire issued share capital as of the merger
date (see the description in the Group&#8217;s financial statements and in the prospectus).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Global Automax&#8221; is the largest indirect
parallel importer in Israel, and imports thousands of vehicles, with annual sales turnover of ILS 400-450 million, which it sells via
12 showrooms throughout Israel. It owns facilities to store vehicles, a PDI (pre-delivery inspection) licensing site and facility. The
Company also operates a vehicle transport network, a replacement part storage facility, and it is licensed to import replacement parts
and has agreements with a national service center network.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to Global Automax, the Group also
owns a controlling stake in &#8220;Automax Trade-In&#8221; which operates a used vehicle sales branch at Glilot Junction, and it also
owns a controlling stake in &#8220;Dalhom Automax&#8221; which is the direct importer of TEMSA-Skoda buses to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has equity totaling tens of millions
of shekels, and it is consistently growing on an annual basis. The Group has approximately 120 employees. The optimal utilization of
central headquarters (finance, logistics, HR, IT, etc.) and its strong commercial and financial position, allow the Group to launch new
activities at the core of vehicle importing which in turn are expected to bolster profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax Leasing (under formation) is one of these
operating segments and it will operate as an independent company, jointly owned by &#8220;Global Automax&#8221; (30%) and a group of
investors. The company has also entered into an agreement with a Chinese vehicle manufacturer - HYCAN - for direct import activities.
This operating segment is expected to become the Group&#8217;s primary operating segment and materially impact its activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_003.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 629; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below are the Group&#8217;s operating
results (on a consolidated basis) for the 2022 annual period in ILS 000&#8217;s:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: normal 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-style: normal; vertical-align: bottom; font-weight: normal">
    <td style="font-style: normal; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify"><b>&#160;</b></td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td>
    <td colspan="2" style="font-style: normal; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>For the<br/>
    period&#160;ended<br/> December 31, <br/> 2022</b></td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; width: 88%; font-weight: normal; text-align: justify">Revenues</td><td style="font-style: normal; width: 1%; font-weight: normal">&#160;</td>
    <td style="font-style: normal; width: 1%; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; width: 9%; font-weight: normal; text-align: right">453,617</td><td style="font-style: normal; width: 1%; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Cost of sales</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(392,918</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify"><b>Gross profit</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">60,699</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Sales and
    marketing expenses</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(27,612</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Issuance related
    expenses</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">-</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Administrative
    and general expenses</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(16,849</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Granting options
    to employees</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(9,976</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Other incomes</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">226</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Operating
    profit (loss)</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">6,488</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Net financing
    expenses</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(5,232</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: left"><b>Profit (loss)
    when the Company&#8217;s share in the losses of companies that are handled according to the method of the balance sheet value is
    neutralized</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">1,256</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Company&#8217;s
    share in losses of&#160;&#160;companies handled according to&#160;&#160;the book value method</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(585</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify"><b>Profit
    (loss) before taxes on&#160;&#160;income</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">671</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">(Taxes on
    income) tax benefit</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(1,931</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify"><b>Total profit
    (loss) for the year</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(1,260</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: left">Adjusted profit
    (loss) before tax deducted by options granted to employees, non-cash-flow rate differences with respect to the Optimatic transaction
    and expenses related to the merger transaction</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">10,421</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: left"><b>EBITDA, adjusted
    for options granted to employees, issuance related expenses relating to the merger transaction</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">24,352</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#8220;Global Automax&#8221;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Global Automax Ltd&#8221; (hereinafter:
&#8220;Automax&#8221; or the &#8220;Company&#8221;) was established in 2015 with the stated objective of importing new vehicles to Israel
via indirect (parallel) imports. The Company is engaged in importing and marketing a range of private vehicle models to and in Israel.
The Company holds an indirect importer license, as defined under Section 42 of the Vehicle Industry Services and Professions Licensing
Law, 2016 (hereinafter: the &#8220;Vehicle Services Licensing Law&#8221;), with respect to a wide range of models produced by 27 vehicle
manufacturers. The Company operates 12 showrooms - Jerusalem, Rishon Letzion, Petah Tikva, Raanana, Beer Sheva, Haifa, Afula, Akko, Netanya,
Glilot, Ashkelon and Ashdod, and it is licensed to import an unrestricted number of new vehicles to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 630; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_004.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s branches in Jerusalem, Haifa,
Afula, Petah Tikva and Rishon Letzion are directly operated by the Group; the Company&#8217;s branches in Netanya, Raanana, Ashdod, Ashkelon
and Glilot are operated by companies jointly owned by a subsidiary and third-parties, and the two remaining branches, in Akko and Beer
Sheva, are operated by the Company&#8217;s authorized retailers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a map of the Company&#8217;s
branches in Israel:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_005.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an international network of suppliers,
primarily in Europe and in North America, which supply it with various brand and model vehicles, subject to orders, and an import structure
which includes procurement, shipping, vehicle customs release handling, and vehicle storage facilities in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indirect (parallel) importing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indirect (parallel) importing is a process under
which a particular consumer product is imported not through the direct importer (the official importer), but rather through indirect
competing importers, which comply with statutory requirements and which personally import the product from a manufacturer&#8217;s overseas
direct agents. This process exists in many industries including the food, pharmaceutical, cellular, and electric product markets, and
now also in the vehicle market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Countries around the world, including Israel,
often apply import restrictions to various sectors, including the vehicle market, in order to ensure the quality and safety of the products
sold to their citizens and/or to protect local industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 631; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It was previously common practice for each manufacturer
to have a sole importer licensed to market that manufacturer&#8217;s products in their country, and which would be responsible <i>vis-a-vis
</i>the government authorities to comply with regulatory rules. This arrangement, convenient for all parties (apart from consumers),
resulted in uncompetitive and over-priced markets. In order to generate competition, some of the regulators required manufacturers to
appoint multiple official representatives in their country; however, the most significant measure which has succeeded and become commonplace
around the world is to allow for parallel importing regulated by law and overseen by the same regulator with identical tools and metrics
used with respect to the direct importer. The importing process, the standards and requirements and the customs and tax rules are identical
to both kinds of importers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The direct importer benefits from an annual allocation
of vehicles broken down into various models, with a set schedule, and in a set currency; while the parallel importer is able to choose
the manufacturer, model, country of origin and currency at any time and to maximize its profits and/or compete and lower vehicle prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Direct importers in different countries choose
to sell some of their allocated vehicles to parallel importers depending on market and currency conditions in their home countries and
in order to become eligible for financial incentives for meeting annual sales targets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The big advantage of parallel importing is flexibility
with choosing the mix of vehicles the parallel importer can import and the ability to quickly respond to changing market conditions.
The parallel importer is not limited to a specific brand and is not committed to a fixed mix of models or a particular technology and
it is able to easily adjust the supply of products and models imported by it in response to changes in local demand and international
supply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Vehicle and Transportation Services Licensing
Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2009 the Israeli government adopted a formal
resolution to increase competition in the Israeli vehicle market by opening the vehicle sector up to parallel imports, the law was subsequently
amended to allow vehicles purchased from a manufacturer&#8217;s authorized agent (a &#8220;dealer&#8221;) to be imported to Israel, and
not just vehicles directly purchased from the manufacturer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The parallel import of vehicles to Israel only
actually started in 2012 (by Ayalon Motors importing Ford vehicles), which led to operating and control procedures being established
by the Ministry of Transport.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until 2016 the parallel import of vehicles to
Israel was subject to the &#8220;Products and Services Control Order - Vehicle Import&#8221;. The order defined the conditions the parallel
importer is required to meet in order to receive a license, but it did not explicitly specify how the vehicles are to be purchased abroad.
This ambiguity created an opening for various interpretations between the relevant regulators (the Ministry of Transport and the Tax
Authority) and it created an opening for various arguments against the parallel importers operating at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2016 the &#8220;Vehicle and Transportation
Services Licensing Law&#8221; which consolidated all the orders, regulations and procedures in the sector into a single law, which clearly
and more conveniently clarifies various issues including the parallel import of vehicles to Israel was approved by the Knesset (Israeli
parliament) at its third reading. The law removes various barriers in the field.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The law includes the following primary matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">1.</td><td style="text-align: justify">The law makes a distinction between
                                            four kinds of importers:</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Direct importer - being the &#8220;original&#8221;
                                            importer which is party to an agreement with the vehicle manufacturer. i.e., the direct importer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 632; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Indirect importer - an importer
                                            which is party to an agreement with one of the vehicle manufacturer&#8217;s international
                                            authorized agents. i.e., a parallel importer.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Small importer - an importer which
                                            is party to an agreement with the vehicle manufacturer or authorized agent or with an international
                                            party established by the Minister of Transport, and restricted to importing up to 20 vehicles
                                            annually.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Personal import agent - someone
                                            who provides brokerage and consulting services for importing a vehicle but is not personally
                                            an importer.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The law establishes the conditions for all importers,
the requirements for agreements with manufacturers/agents, the scope of equity, the existence of maintenance service infrastructure,
etc., for each importer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">2.</td><td style="text-align: justify">The law subjects the direct importers
                                            to an obligation to issue service bulletins (recalls) and to be liable for all the vehicles
                                            manufactured by the make imported by them (even if imported by a parallel importer) from
                                            January 1, 2017.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">3.</td><td style="text-align: justify">The parallel importer, who until then
                                            could have imported a vehicle via an authorized agent, is now able to import via a secondary
                                            agent (a retailer).</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">4.</td><td style="text-align: justify">The indirect importer is permitted
                                            to import new vehicles (up to 150km) even if the vehicle is already registered abroad.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">5.</td><td style="text-align: justify">The restriction on the number of products
                                            an indirect importer is able to import was cancelled. Products not formally imported to Israel
                                            were also permitted to be indirectly imported.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">6.</td><td style="text-align: justify">As a first, the new law gives the Minister
                                            of Transport the ability to establish conditions and restrictions applicable to the licensee
                                            - i.e., licensed vehicle importers - including to not issue or renew an import license if
                                            the licensee fails to meet established conditions, including adversely impacting competition.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are currently dozens of companies in Israel
engaged in parallel importing vehicles, the largest being Automax which imports approximately 2,500 vehicles annually (on average) and
Ayalon Motors which imports approximately 1,300 vehicles annually (on average).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are also hundreds of companies which operate
in the small import segment (up to 20 vehicles per company annually) and personal import agencies which provide advisement, logistics
and purchasing services for personal import. Approximately 2,000 vehicles are personally imported to Israel annually, almost entirely
in the luxury segment. This kind of import has significant disadvantages relative to direct or parallel import - difficulties with implementing
the vehicle warranty, various restrictions on selling the vehicle, and others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market segment for parallel (and small) import
is relatively negligible and totals approximately 3.5% of the market compared with approximately 10% on average in Europe. (There is
a big difference between Eastern European countries such as Poland with 30% and Italy with only 2%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 633; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a breakdown of the parallel
import market in 2023 (based on the quantity of vehicles, excluding small imports, by importer):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Based on a five-year calculation, the market
segment of each of the first three importers is identical.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax is the leading company in the parallel
vehicle import segment and it is intending to also maintain its status in the future unrelated to it expanding to other fields.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vehicle manufacturers&#8217; response to parallel
import (and export)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The scale of manufacturing and employment give
the vehicle manufacturers significant financial and political clout which they use to entrench and protect their interests in the countries
they operate in.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, vehicle manufacturers designate various
models to each region based on general preferences in that region, weather restrictions, the applicable standards and purchasing power,
and they try to prevent models from &#8220;leaking&#8221; between regions due to engineering and &#8220;anti-competitive&#8221; reasons
- in order to maintain their ability to implement price discrimination between regions/continents based on exchange rates, tax rates
and the competitive standing of the manufacturer in that region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, volatility with business cycles, regulatory
changes and changing preferences constantly create excess supply in some parts of the world and pressure the manufacturers to export
vehicles between regions. Arbitrage differentials are not a passing opportunistic phenomenon but an inherent part of the market (similar
to a certain extent to the &#8220;zero km&#8221; phenomenon in Israel). As a result, approximately 10% of global vehicle trade is performed
as &#8220;parallel&#8221; trade between brokers/merchants and not directly <i>vis-a-vis</i> the manufacturer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">US antitrust law prohibits vehicle manufacturers
from preventing vehicle exports from the US by dealers, and prohibits the manufacturer from owning the dealerships which retail its products
(these dealerships form alliances and act as a counterforce against the manufacturer&#8217;s power).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unlike the US, in Europe there is no legal prohibition
against manufacturers owning retail agencies (dealerships) and therefore some of the largest distributors are wholly or partially owned
by the manufacturers. However, European antitrust laws prohibit manufacturers from preventing exports between European countries, and
even impose significant financial sanctions for associated breaches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In practice, most vehicle manufacturers subject
agents exporting vehicles to more or less legal barriers, including prohibiting agents from selling to companies suspected of engaging
in parallel export, agreements preventing shipping companies from transporting vehicles the subject of parallel import or which require
them to report such to the manufacturer, and the like.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 634; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therefore, most parallel importers try to operate
&#8220;under the radar&#8221;, and typically need to purchase the vehicles from the agent in the territory permitted to it via local
companies, to pay taxes and VAT in the country of origin and to personally export them. This activity requires an extensive logistical
basis and significant interim financing capabilities (for the taxes and VAT).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the manufacturer identifies that a company
is purchasing and exporting the vehicles it includes them on a &#8220;black list&#8221; of companies which cannot be sold to, and the
parallel importer needs to engage new retail companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One of the other common barriers in the field,
primarily in Europe, is the manufacturer refusing to issue original manufacturing certificates - these certificates are required where
Israeli customs authorities request the European customs house to validate the original certificate which gives the vehicle preferential
customs treatment, and without which the parallel importer is required to pay additional customs tax (7% of the total value including
taxes) even if the vehicle is manufactured in a country with a preferential status. The Israeli Customs Tariff Order was recently amended
(in September 2023) to exempt a parallel importer from presenting the original certificate of models imported by direct importers and
which requires customs to rely on the original certificate furnished by the direct importer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As aforementioned, Automax has established and
experienced purchasing networks and contractual agreements with some of the largest vehicle manufacturer agents in Europe and Canada,
which allow it to purchase from production batches especially manufactured for export with almost no restriction. The Company purchases
most of the models it imports in three or four different currency regions, in order to mitigate the exposure to exchange rates or other
blockage attempts, and to enable it to have consistent supply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company&#8217;s sales:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See details about the new vehicles sold by the
Group as of December 31, 2022 and December 31, 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the period ended<br/>
    December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For a Period ended on<br/>
    December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Sales Rate for <br/>
    Institutional <br/>
    Customers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Sales Rate for<br/>
    Institutional <br/>
    Customers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 23%; text-align: right">2,048</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">35.84</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">2,462</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">26.69</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 635; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See sales of vehicles imported by the Group,
split by make:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Product</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the period ended<br/>
    December 31,<br/>
    2022</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For a Period ended on<br/>
    December 31,<br/>
    2021</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quantity</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Sales Rate</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quantity</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Sales Rate</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Toyota</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">497</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">24.27</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">669</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27.17</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Honda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">471</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jeep</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.41</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hyundai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.96</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BMW</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ford</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.74</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.57</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Volkswagen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.81</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.27</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mercedes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.44</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.16</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Skoda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.42</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.52</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Seat</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.03</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.67</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mazda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.83</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.08</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Volvo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.78</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.66</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mini</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.78</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.63</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Land Rover</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.39</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fiat</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.81</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.63</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over January-September 2023, Automax delivered
approximately 1,550 vehicles based on the following breakdown (according to licensing data):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_007.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 636; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact of macro-economic factors on the Company
in 2023: </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operating segment is inherently sensitive
to external and macro-economic factors: The Company&#8217;s financial results in 2023 were adversely impacted as a result of these factors
and, in my view, it (and the entire market) knew how to adjust the price level for sales and purchasing and to adapt to the current market
conditions, therefore, I assess that 2023 was not a representative year for its operating activities. Presented below is an overview
of the relevant trends and their impact on the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trend</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Local
    Influence (Seller-Side)</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Global
    Influence (Buyer-Side)</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
    of the Automotive Industry from the &#8220;Global Chip Shortage&#8221; of 2020-2023<br/>
    (= increase in vehicle inventory).</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
    market competition creates pricing pressure.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    pressure and buying opportunities; Return of the supply of low-priced cars that last year were almost unattainable.</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rising
    in local and global interest rate.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in household disposable income causes decrease in demand of cars, especially amongst luxury vehicle market segment.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in bargaining power of the Company vis-a-vis its suppliers.</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Civil
    protests due to the Israeli legal reform proposal.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in Consumer confidence index (CCI) moderates demand; NIS depreciation vis-&#224;-vis main foreign currencies used for purchasing
    stock, causing an increase in the cost of sales.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Massive
    market penetration of Chinese brands to the Israeli market.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion
    in new brands&#8217; market segment at the expense of the market segment that is relevant to Company&#8217;s brands.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chinese
    manufacturers that did not consider investing in Israeli&#160;&#160;market penetration, increasingly start to show interest. </span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Swords
    of Iron&#8221; War<br/>
    (October 7, 2023 War)</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in Consumer confidence index (CCI) moderates demand; Increase in maritime transportation costs and supply delays due to the &#8220;The
    Houthi Crisis in the Red Sea&#8221;, causing an increase in the cost of sales.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: none"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter B &#8211; The Israeli vehicle market</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are approximately 3.4 million private vehicles
on Israel&#8217;s roads. These include approximately 3.1 million vehicles which are privately owned by individuals and approximately
300,000 vehicles owned by corporations and institutional entities (primarily leasing companies). Approximately 260,000-290,000 new vehicles
are sold annually (and another approximately 500,000 used cars are sold), and approximately 200,000 cars are written off (wear and tear,
scrap metal, accidents and thefts). The institutional market&#8217;s share of new vehicle purchases is significantly greater than its
general share of the vehicle market and is estimated at approximately 40% of total purchases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 637; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average vehicle age in Israel is approximately
6.9 years - slightly below the European average. The vehicle penetration level in Israel (the number of vehicles per 1,000 people) is
relatively low for the Western World and is consistently growing - approximately 380 vehicles per thousand people vs. approximately 600-650
vehicles per thousand people in Western Europe and approximately 700-900 in the US.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a graph of vehicle deliveries
in Israel over time (in 000&#8217;s):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_008.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over 2020-2022 there was a decline in the global
vehicle supply associated with the COVID-19 crisis which also impacted the volume of deliveries in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is an overview of monthly vehicle
deliveries in the first nine months of the year compared with the previous year:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_009.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 638; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average price of a new vehicle in Israel
has consistently risen over time and it is currently ILS 193,000:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_010.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This increase is consistent with rises in the
CPI. In recent years, as a corollary of the COVID-19 crisis and the associated short-supply, there was also an increase in used vehicle
prices - this phenomenon (for used vehicles) is expected to reverse in coming years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Index of new and used vehicle prices, years
2008-2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_011.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Source: Israeli Central Bureau
of Statistics, Ministry of Transportation&#8217;s data, processed by the Israeli Tax Authority</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 639; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a breakdown of new vehicle
sales in 2023 by price (importer&#8217;s pricelist):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_012.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax mainly focuses on the primary market
segments (ILS 130,000-350,000).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Over
                                            the last decade Israeli consumers (and consumers generally around the world) started to have
                                            a clear preference for Crossover SUV models and therefore Automax is focused on importing
                                            these models - presented below is the scope of sales in recent years according to vehicle
                                            structure:</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_013.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 640; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">In
                                            recent years Chinese vehicles have started to penetrate the market <i>en masse </i>and they
                                            are almost at 20% of Israeli vehicle sales (!). The top ten models in 2023 include 3 Chinese
                                            models, and not a single European model. Presented below is a graph of vehicle sales in Israel
                                            in recent years based on country of manufacture:</td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_014.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another trend apparent in recent years which
is anticipated to continue is a significant increase in the market share of electric vehicles on account of the market share of gasoline
and diesel motor vehicles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline"><img alt="" src="image_015.jpg"/></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Israeli vehicle importers - Direct import</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Israeli vehicle market is a concentrated
market - the 12 largest vehicle import groups, which import approximately 55 different brands of private vehicles and buses, trucks and
motorcycles have almost 100% of the vehicle market share in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 641; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The five leading vehicle brands generally comprise
approximately 50% of vehicle deliveries, while the five leading importers are responsible for approximately 70% of the total vehicle
deliveries in Israel. Presented below is a breakdown of the market in 2023 by importer:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_016.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a breakdown of the market
by vehicle brand: As aforementioned, the share of western brands has been declining over time in favor of Korean, Japanese and Chinese
brands:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_017.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The breakdown of the market between companies
and the different brands changes according to public preferences, the development of models by the manufacturers and exchange rates.
Exchange rates play a critical role in the importer&#8217;s competitiveness, there is accordingly a high correlation between the exchange
rate of the currencies relevant to the production of the vehicles and the market segments of the various brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As aforementioned, the scope of vehicles imported
from China to Israel has consistently been increasing which also directly correlates with the increase in the number of electric vehicles
being imported to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 642; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is data about the scope and range
of electric vehicles imported from China to Israel over January-September 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Group</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Manufacturer</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Model</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deliveries<br/>
    until September<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Import<br/>
    Price in<br/>
    NIS&#160;<br/>
    (Entry&#160;Model)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Volume<br/>
    of Money in<br/>
    NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Importer</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 14%; text-align: center; padding-left: 5.4pt">Leapmotor</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center; padding-left: 5.4pt">Leapmotor</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center; padding-left: 5.4pt">T03</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">424</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99,990</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">42,395,760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center; padding-left: 5.4pt">Metro</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Small Ant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">GWM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Ora</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Funky Cat</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">792</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,216,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Colmobil</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Dolphine</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,197,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">JAC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">JAC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">S4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,720,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Automotive Equipment (AEV)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,937,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">DFSK</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SERES</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">E3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,884,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Talcar Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">FX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,973,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geometry C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">987,881,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Union Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Tiggo 7 Pro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,343,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">EVeasy</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Eveasy</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Limo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">351</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,156,490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">ZS SUV</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,917,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Atto 3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,148,630,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,104,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Tiggo 8 Pro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,682</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">994,293,180</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Maxus</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">e Deliver 3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,376,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">China Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Dongfeng</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Forthing</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Friday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,439,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">UMI</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Aiways</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Aiways</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">U5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,118,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Blilious Group</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">HS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490,384,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Maxus</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">V80</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">China Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">WM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">WM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">W5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">795,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Automotive Equipment (AEV)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">ETP-3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Marvel R</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,946,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SKYWELL</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SKYWELL</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">ET 5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">570</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,643,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Caduri</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Aiways</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Aiways</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">U6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,314,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Blilious Group</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Seal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">689,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">XPENG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">XPENG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">P7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Lynk &amp; Co.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">231,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,997,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Mayer</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Maxus</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">EUNIQ 6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,997,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">China Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">DFSK</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SERES</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,926,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Talcar Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Maxus</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">EUNIQ 5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,046,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">China Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">GWM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">WEY</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Coffee 02</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,919,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Samelet</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Polestar</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Polestar2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,672,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Mayer</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">GWM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">WEY</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Coffee 01</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,843,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Samelet</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Tang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,297,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">XPENG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">XPENG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">G9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Han</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,188,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">eT5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Delek</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">LEVC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">TX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Automotive Equipment (AEV)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Dongfeng</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Voyah</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Free</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,586,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Metro</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Honggi</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Honggi</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">E-HS9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,592,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Samelet</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">eS8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Delek</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">eT7</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">499,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Delek</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font-weight: bold; text-align: center; padding-left: 5.4pt">Total</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,661</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,752,495,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-weight: bold; text-align: center; padding-left: 5.4pt">Mean</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 643; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we examine the sales data of all vehicles
in Israel over January-September 2023 we can easily see the revolution in the market with the 10 leading models. There are three Chinese
manufactured models and not a single European model. It can cautiously be said that the &#8220;Western&#8221; brands are slowly disappearing
from the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The data are presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Manufacturer</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Model</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jan-Sep<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jan-Sep<br/>
    2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jan-Sept<br/>
    2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%; text-align: left">BYD Auto</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%">Atto 3</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,913</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kia</td><td>&#160;</td>
    <td>Niro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,662</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,885</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Hyundai</td><td>&#160;</td>
    <td>Elantra</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,673</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Toyota</td><td>&#160;</td>
    <td style="text-align: left">Yaris Cross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Geely</td><td>&#160;</td>
    <td style="text-align: left">Geometry C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kia</td><td>&#160;</td>
    <td>Picanto</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,360</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Chery</td><td>&#160;</td>
    <td style="text-align: left">Tiggo 8 Pro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Hyundai</td><td>&#160;</td>
    <td>Tucson</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,835</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Mazda</td><td>&#160;</td>
    <td style="text-align: left">2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Mitsubishi</td><td>&#160;</td>
    <td>Outlander</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,740</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter C - &#8220;Dalhom Automax&#8221;
(direct import of &#8220;TEMSA-Skoda&#8221; brand buses)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2022, the Company, jointly with Dalhom
Motors Ltd. (hereinafter: &#8220;Dalhom&#8221;), established a SPV to import TEMSA brand buses. The Company signed an agreement with
the manufacturer under which the common company will serve as the direct importer of TEMSA brand buses to Israel. TEMSA has multiple
electric, gasoline or diesel engine model buses and minibuses designed to serve tourism and public transportation, all of which are suitable
to be marketed in Israel.<br/>
The Company is currently completing the establishment of a central bus service center with a total area of 4,000 sqm in Hod Hasharon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company is one of the Group&#8217;s growth
engines, and is anticipated to generate significant profits under the plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 644; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div style="padding: 1pt 4pt; border: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TEMSA
                                            Skoda</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Temsa Skoda is a leader in production of buses
and minibuses worldwide:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* A manufacturing plan of 500,000 sqm in Turkey</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Leading in electric buses</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Production capabilities of 10,000 vehicles,
including Motor Coach, Midibus, Light Trucks</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Selling in 66 countries worldwide</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is an overview of the specifications
of the central service center and garage:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><img alt="" src="image_018.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Area of 4,000 sqm.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Bus service center of 2,000
                                            sqm.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Offices - Located at the
                                            entrance and split over 2 floors: First floor: Service center, office reception and waiting
                                            area. Second floor: Offices + employee rest area.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Work stations (Diagnostics
                                            + mechanics + electric + HVAC)</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">6 work stations (including
                                            one station with a &#8220;safety line&#8221; for working on the top part of the bus roof)
                                            + another work station (with a pit jack) - 7 stations in total.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Metal work area:</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">5 work stations + one area
                                            for preparing the bus before paint + painting area.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Between the general work
                                            stations and the metal work area there is a dividing wall separating the areas.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Parking areas:</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Officially - 8 parking spaces,
                                            16 parking spaces in reality.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 645; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The company is currently
                                            negotiating leasing another 1,000 sqm on the site next to the new service center, which is
                                            meant to add another 30 parking spaces.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is planning to apply for tenders
issued by public transportation companies starting in 2024.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_019.jpg" style="width: 650px; height: 368px"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Israeli commuter transportation market:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Approximately
                                            2,500 buses are sold annually in Israel, half of which are sold for public transportation
                                            purposes (to large companies which win operating tenders) and half of which are sold to tour
                                            and commuter companies (small and medium companies and authorized dealers).</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">933
                                            commuter companies are registered in Israel, 532 of which are actively operating (hold a
                                            valid license to operate a commuter service).</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Approximately
                                            400 commuter companies operate full-size buses (more than 44 seats).</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            commuter sector operates approximately 11,000 buses (more than 19 seats), and approximately
                                            16,000 minibuses (up to 19 seats).</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Average
                                            fleet size of a commuter company: 5-80 buses.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            average age in the sector is 6 years, and the maximum age is 12 years.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            annual mileage of a bus is 50,000-80,000km. The average daily mileage in the industry is
                                            approximately 220km.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            daily cost of operating a bus is approximately ILS 1,300.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            commuter sector is extremely competitive and diverse, and is subject to geopolitical changes
                                            and business cycles.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 646; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Division of bus fleets by year of production,
type, as of year-end 2019</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-left: 0pt; font-weight: bold; text-align: left">Vehicle Type
    /<br/>
    Year of<br/>
    Manufacture</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2014</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2013</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2012</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2011</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2010</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2009</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Until 2008</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; width: 15.5%">Public
    Bus for Special Transportation</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">8,598</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">530</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">914</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">960</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">847</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">823</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">777</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">605</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">370</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">481</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">458</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">401</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">1,432</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Public Bus for
    Tour</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,592</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">70</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">110</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">112</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">110</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">41</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">141</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">100</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">73</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">133</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">156</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">86</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">460</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Public Minibus</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5,330</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">158</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">274</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">512</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">707</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">510</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">390</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">456</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">457</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">485</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">445</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">310</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">626</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Public Minibus
    for Tour</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">38</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">8</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">12</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Public Minibus
    for Special Transportation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3,214</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">239</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">715</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">614</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">454</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">260</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">248</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">212</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">140</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">138</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">88</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">42</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">64</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Private Bus</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">709</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">15</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">42</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">41</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">48</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">47</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">64</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">24</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">38</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">51</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">52</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">48</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">239</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Private Minibus</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">6,852</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">34</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">93</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">108</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">128</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">125</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">165</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">261</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">365</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">429</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">536</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">490</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,118</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Touring Car</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">215</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">41</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">51</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">26,548</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,064</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,173</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,388</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,353</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,846</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,794</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,679</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,461</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,722</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,742</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,380</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,946</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sales of buses and public transport brands</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Make</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">H1 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Volvo</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">220</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">366</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">372</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">285</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Golden Dragon</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">522</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">HIGER</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">438</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">197</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Mercedes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">191</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">396</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">284</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">151</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">OTOKAR</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">BYD Auto</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Isuzu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">TEMSA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">79</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Zhongtong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Irizar</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold">OTHER</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">289</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">453</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">316</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,276</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,534</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,279</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 647; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>
</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">According to the
Company&#8217;s business plan, presented below is a proforma profit and loss statement for the garage activities and an operating budget
for the bus sales activities:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Profit &amp; Loss Forcast (in NIS)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Hod Hasharon Garage</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">Section / Period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Incomes from mechanical work</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">7,393,350</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">8,502,353</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">8,927,470</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from spare parts (mechanics)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3,696,675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4,251,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4,463,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from works outsourcing mechanical works</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,232,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,417,059</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,487,912</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">PDI for new buses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">124,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total income from mechanical work</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">12,447,050</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14,170,588</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14,879,117</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from metal works (&#8216;body work&#8217;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9,556,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10,990,210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">11,539,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from metal works spare parts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9,556,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10,990,210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">11,539,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from outsourcing metal working</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,123,712</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,442,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,564,382</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total Income from metal working</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">21,237,120</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">24,422,688</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">25,643,822</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income from mobile vehicles</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,112,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,428,800</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,550,240</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">35,796,170</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">41,022,076</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">43,073,179</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cost of Sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Mechanics</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">11,575,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,178,646</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,837,579</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Metal works</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,804,128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15,874,747</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">16,668,485</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total Cost of Sales</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">25,379,885</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">29,053,394</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">30,506,063</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">70.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">70.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">70.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10,416,286</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">11,968,682</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">12,567,116</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Sales General &amp; Administrative (G&amp;A) Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and Payroll Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3,948,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4,046,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4,147,868</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Rent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,440,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,596,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,599,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rates (Tax)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">288,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">295,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">302,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advertising &amp; Marketing</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">72,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">72,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">72,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Car Maintenance and Travel Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">312,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">312,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">312,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional Services (Fees)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Maintenance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office Supplies (Electricity, Water, Gas)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">54,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">59,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">59,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Phone &amp; Communication Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office Supplies &amp; IT Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Towing/Transportation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">189,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mobile Units Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">189,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Food &amp; Drink (Refreshments)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unexpected Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">103,920</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total Sales and G&amp;A Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,933,048</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,801,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,944,048</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">20.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">19.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,929,166</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,166,982</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,634,069</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Financing Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">320,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Earning Before Tax (EBT)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,329,166</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3,566,982</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,314,069</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income Tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,181,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,077,181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,181,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Income/Loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,793,457</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,489,801</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,132,232</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 648; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Dalhom Automax - Budget in NIS</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Incomes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Incomes from Sale of Buses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">105,954</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from Sale of Commercial Vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from Sale of Used Vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3,219</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from Sale of Spare Parts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">110,303</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of Sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Direct Cost of Buses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">95,546</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Direct Cost of Commercial Vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">389</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Direct Cost of&#160;&#160;Used Vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,744</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Spare Parts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">204</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Llicensing, Tests &amp; PDI</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,076</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Transportation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">139</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Direct Cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">100,109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10,194</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9.24</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating Cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Salaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,568</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketing, Advertising &amp; Sales Promotion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lot/Warehouse Rent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Translation &amp; Editing</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mobile Unit Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Towing Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Garage Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Insurances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Car Maintenance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Hospitality</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unexpected Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total General &amp; Administrative (G&amp;A) Expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,172</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Operating Cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>G&amp;A</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bookkeeping, Accountancy &amp; Audit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Legal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">96</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Rates (Tax)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unexpected Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total General &amp; Administrative (G&amp;A) Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">420</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5,602</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing cost (FC)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">1,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,162</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.77</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 649; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As stated above, Automax owns 50% of &#8220;Dalhom
Automax&#8221; and the company still does not have a multi-year business plan for selling the buses. The 2024 budget has a forecasted
net profit of approximately ILS 4 million and a similar anticipated profit under the three-year business plan for the service center
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no doubt that Automax entering the bus
import and maintenance sector is likely to be profitable and will be one of the central factors of growth for the Company, if not the
central factor for growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter D - &#8220;HYCAN Automax&#8221;
(direct import of &#8220;HYCAN&#8221; brand electric vehicles (from China))</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax has entered into a commercial agreement
with the Chinese electric vehicle manufacturer HYCAN.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HYCAN is a leading and innovative vehicle manufacturer
which specializes in manufacturing electric and high-tech vehicles for the global market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company was established in 2018 under the
name &#8220;GAC-NIO&#8221; - a reference to the joint venture by its investors - GAC - the state-owned vehicle manufacturer, and NIO
- the US electric vehicle manufacturer. HYCAN benefits from the expertise and resources of its parent companies, GAC and NIO, both of
which are well established in the Chinese and global electric vehicle market. The brand was officially launched in 2020 and focuses on
manufacturing exceptional electric vehicles. HYCAN also established a global R&amp;D center in Silicon Valley, California. The center
focuses on developing advanced technologies for electric vehicles, including autonomous driving and smart mobility solutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By establishing a R&amp;D center in Silicon Valley,
HYCAN will be able to take advantage of the rich skill-set and innovative culture in the area and to collaborate with leading tech companies
and research institutes. This allows HYCAN to be at the forefront of electric vehicle technologies and to develop advanced technologies
which improve the driving experience and which reduce the environmental impact of its vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021 HYCAN announced that they are planning
to expand their business globally and to sell their electric vehicles in selected markets in Europe, the Middle East and in South-East
Asia. The brand is therefore expected to expand its global reach in coming years with a wide range of new EV model vehicles. The company
plans to gradually enter these markets and is focusing on specific regions and countries with high demand for electric vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It should be noted that HYCAN will have to deal
with difficult competition from other companies established in the global electric vehicle market. However, the company&#8217;s focus
on technology, sustainability and premium designs can be a differentiating factor which attracts customers in new markets. All in all,
HYCAN&#8217;s plans for international sales demonstrate their aspirations to become a global player in the electric vehicle market. As
the demand for electric vehicles continues to grow around the world, companies such as HYCAN will have significant opportunities to expand
their business activity and to offer innovative solutions to customers in different regions and markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 650; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 50%">&#160;<img alt="" src="image_020.jpg"/></td>
  <td style="text-align: center; width: 50%"><img alt="" src="image_021.jpg"/></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of HYCAN&#8217;s efforts to become independent
and enter global markets, in 2022 the Chinese investment company Pearl River invested in HYCAN and it currently controls the company
with a 65.5% ownership stake. The GAC group owns 25% and NIO owns the remaining minority stake comprising just 4.5%. Pearl River Investments
is a Chinese investment company which focuses on the vehicle industry. The Company also invests in various industrial sectors, including
electric vehicles, autonomous driving and smart mobility solutions. Pearl River aspires to identify and invest in innovative companies
in the vehicle industry which are able to generate value for their customers and stakeholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HYCAN is committed to creating innovative, reliable,
sustainable and high performance electric vehicles which offer a unique driving experience. The vehicles are designed with advanced technology,
premium design and features which aspire to provide exceptional performance, safety and reliability. The product basket includes a range
of electric vehicles, including Sedans, SUVs, MPVs and Crossovers, all with advanced electric engine systems, innovative battery technology
and smart communication systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The HYCAN vehicle activities will be performed
by a subsidiary of Global Automax/Automax Motors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company will operate in addition to and not
instead of Automax&#8217;s parallel import activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company will operate through Automax&#8217;s
existing infrastructure (showrooms, sales channels, PDI system, head-office and the like), and no independent infrastructure will be
set up for it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales will be performed at all Automax showrooms,
one of which will be converted into a flagship showroom for the brand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One central service center will be established
for the brand, in addition to the network of external service centers currently with an arrangement with Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The brand will have a significant launch campaign
over 2024-2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The transition to electric
                                            vehicle gives the Chinese vehicle industry a relative advantage over its global competitors
                                            and allows it to more easily meet the relevant standards requirements.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Israel is considered to be
                                            a &#8220;gateway&#8221; to Europe for many Chinese manufacturers and is the subject of significant
                                            interest for the Chinese vehicle industry.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Approximately 41,103 of the
                                            vehicles sold over January-September this year were manufactured in China (16.6%) compared
                                            with only 12,736 vehicles in the same period the previous year.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Automax&#8217;s business plan, the
Company will commence selling HYCAN model vehicles already in Q4 2024 and its sales target is approximately 400 vehicles, while the sales
target forecasts annual vehicle sales totaling approximately 2,400 vehicles within 4 years.</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 651; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is the basis of the plan:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: normal">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid">Representive
    Year</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: normal; font-style: normal; text-align: left">Sales
    (Quantity of Vehicles)</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">400</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">800</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">1,600</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">2,400</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Vehicle&#8217;s
    CIF Average Cost (in Thousand NIS)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">After-Tax &amp;
    Tariff Cost (Average Tax for an Electric Vehicle 40%, Tariff 7%)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">127.33</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">127.33</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">127.33</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">127.33</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Average Selling Price (ASP)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">151.58</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">151.58</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">155.28</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">155.28</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Gross</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">16</td><td style="font-weight: normal; font-style: normal; text-align: left">%</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">16</td><td style="font-weight: normal; font-style: normal; text-align: left">%</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">18</td><td style="font-weight: normal; font-style: normal; text-align: left">%</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">18</td><td style="font-weight: normal; font-style: normal; text-align: left">%</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="17" style="font-weight: normal; font-style: normal; text-align: center"><b>Pro Forma Balance Sheet (in Thousand NIS)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: normal; font-style: normal; text-align: left">Vehicles
    Inventory</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">8,500</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">17,000</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">34,000</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">51,000</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Spare Parts Inventory</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">255</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">510</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,020</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,530</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Fixed Assets
    (Garage, Showroom)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">500</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">4,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Demo Cars</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">255</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">425</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">850</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">850</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Total Assets</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">95,510</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">20,935</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">38,870</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">57,380</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="17" style="font-weight: normal; font-style: normal; text-align: center"><b>Statements of Income Pro Forma (in Thousand
    NIS)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: normal; font-style: normal; text-align: left">Income
    from Sales of Vehicles</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">60,633</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">121,267</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">248,449</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">372,673</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Cost of Sales</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">50,932</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">101,864</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">203,728</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">305,592</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Net Revenue from
    Sales of Spare Parts and Garage Services</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,819</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">4,244</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">9,938</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">18,634</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Gross profit</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">11,520</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">23,647</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">54,659</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85,715</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: center">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Marketing &amp;
    Advertising</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">6,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Designated HQ</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,200</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,440</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,728</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">2,074</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Rent &amp; Rent
    Bills (Garage and Showroom)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Travel and Living
    Expenses Abroad</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Depreciation
    and Amortization</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">144.29</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">562.14</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">695.71</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">911.43</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Financing</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">665.7</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,465.45</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">2,720.90</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">4,016.60</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Total Expenses</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">7,610</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">12,068</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">10,745</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">12,602</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: center">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Pre-tax Profit</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,910</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">11,579</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">43,914</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">73,113</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 652; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is apparent that the Company&#8217;s target
is to achieve annual sales totaling approximately 2,400 HYCAN vehicles a year within 4 years by primarily using the Company&#8217;s existing
platform (showrooms, sales personnel, etc.), which is meant to achieve a pretax annual profit of approximately ILS 73 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Granted, the Israeli vehicle import market is
becoming more and more competitive primarily in the electric vehicle segments, and each month we are seeing new models and companies
(the vast majority of which are Chinese) enter the Israeli market, primarily through the large vehicle importers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, despite the significant competition
and considering the fact that Automax is already operating in the market, it appears that the sales target the Company has set for itself
is realistic (in reality it involves approximately 0.8% of the total annual vehicle imports to Israel) and it is certainly achievable
through proper marketing work.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter E - Calculation of the Enterprise
Value</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, I will refer to the simple valuation method
relevant to public companies listed on the TASE and the simple argument that the Company&#8217;s market value reflected in the value
of its shares on TASE is the Company&#8217;s real value and I will explain why I did not find it correct to refer to this valuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reasons are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">There
                                            is little &#8220;public float&#8221;, 5-7 shareholders of the Company&#8217;s controlling
                                            group own the majority of shares (approximately 80%). The trading volume in the market is
                                            extremely low.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">The
                                            Israeli stock exchange on which the Company&#8217;s remaining shares are traded is not developed.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">In
                                            the last two years there has generally been correlation between market trends and the direction
                                            of the share.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">In
                                            recent years there have been multiple events which prevent reasonable value assessments (COVID-19,
                                            the legal reform and the war).</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">The
                                            Israeli capital market operates differently than any other prominent capital market around
                                            the world.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">The
                                            stock market is self-correcting in the long-run and good years are therefore being forecasted.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Just
                                            as on January 21, 2021, the Company&#8217;s value on the Tel Aviv Stock Exchange came to
                                            approximately ILS 278 million (based on a share price of ILS 310), reflecting a value of
                                            approximately USD 84.7 million (based on an exchange rate of 3.28), and in January 2022 the
                                            Company&#8217;s value on the Tel Aviv Stock Exchange came to approximately ILS 197 million
                                            (based on a share price of ILS 220), reflecting a value of approximately USD 63.5 million
                                            (based on an average exchange rate of 3.1) - being high values which do not reflect the Company&#8217;s
                                            real value; so too, the Company&#8217;s low value on January 1, 2024 on the Tel Aviv Stock
                                            Exchange coming to approximately ILS 36 million (based on a share price of ILS 40), reflecting
                                            a value of approximately USD 9.9 million (based on an exchange rate of 3.65), is also not
                                            representative of its real value.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 653; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I will now present the calculations of the valuations
based on two alternative methodologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The representative profit multiplier methodology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier and the profit multiplier
are two metrics commonly used to assess the value of a company. Both metrics measure the ratio between the share price and the company&#8217;s
profit, but do so in different ways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier measures the ratio between
the share price and the company&#8217;s gross operating profit. The gross operating profit is the company&#8217;s profit before financing
expenses, taxes and depreciation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier measures the ratio between
the share price to the company&#8217;s net profit. The net profit is the company&#8217;s profit after financing expenses, taxes and depreciation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Theoretically, this multiplier methodology is
the simplest methodology for a valuation and it is primarily used to compare the value of companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profit data, whether it is EBITDA, operating
profit or net cashflow, are consistently announced and the relevant profit multiplier can be calculated for each company by dividing
the company&#8217;s market cap by the relevant profit line-item. This can also be done by taking a reported profit figure and by multiplying
it by the relevant multiplier and to assess the enterprise value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit generally represents past results
already recorded. Thus, the disadvantage of the multiplier methodology is that it is based on figures from the past, inherently without
tools to consider the potential for future profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This disadvantage makes this method ineffective
for establishing the enterprise value. This is because this methodology does not take into account the effect of the Company&#8217;s
existing significant growth engines, and which are meant to result in the Company doubling or more its sales turnover and annual profit
within a few years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding, I have decided to present the
results of this metric to reflect a kind of starting point to gauge the Company&#8217;s enterprise value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I chose to take the average of the two common
multiplier methodologies, the EBITDA and profit multipliers, which I assess are appropriate for the Company&#8217;s characteristics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As I already noted above, the 2023 annual period
cannot be used as a representative year due to the multitude of macro events which impacted the commercial results of many companies
in the economy including Automax. The 2022 annual period was therefore chosen as the representative year for the assessments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>EBITDA multiplier</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier is a financial metric used
to assess the enterprise value of a company. It is calculated by dividing the value of the company&#8217;s operations by its gross operating
profit (EBITDA).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Formula: EBITDA multiplier = enterprise value
/ EBITDA</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EBITDA is the earnings before financing expenses,
tax, depreciation and amortization. This metric determines the company&#8217;s operating profitability prior to expenses not directly
related to its operating activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier is a popular metric for
valuing companies since it allows for a comparison to be made between companies with different capital structures. Financing expenses,
taxes, depreciation and amortization can significantly change between companies, and therefore the use of net income to value a company
can result in an imprecise comparison.</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 654; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier in the Israeli parallel
vehicle import sector ranges between 2 to 3.5. The meaning is that companies in the sector are traded based on a multiplier of 2-3.5
times their gross operating profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average multiplier in the parallel vehicle
import sector is approximately 2.5. However, there are companies which are traded at higher or lower multipliers, based on different
factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The size of the company, its profitability, forecasted
future growth, commercial risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below are some examples of EBITDA multipliers
of companies in the Israeli parallel vehicle import sector:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Union Motors is traded at a multiplier of 2.8</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eldan is traded at a multiplier of 2.3</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Semel is traded at a multiplier of 3.2</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below are various factors which may
impact the EBITDA multiplier in the Israeli parallel vehicle import sector:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition in the sector, changes in government
policy, changes in exchange rates, volatility with vehicle prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To calculate Automax&#8217;s value through the
EBITDA multiplier methodology and considering the fact that the Company has stable operations and is the largest player in its sector
in Israel I have chosen a multiplier of 3 as being representative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The profit multiplier</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier is a financial ratio used
to assess the enterprise value of a company. It is calculated by dividing the market cap of the company by its net annual profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Formula: Profit multiplier = Market cap / Net
profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier provides us with an indication
of how much investors are prepared to pay for each shekel of profit generated by the company. A higher profit multiplier means that investors
expect that the company will continue to grow and increase its profits in the future. A lower profit multiplier can be indicative of
the fact that the company is not growing or that it is in a difficult financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, it is important to emphasize that the
profit multiplier is only a single tool to assess the enterprise value of a company. There are other factors that should be considered,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forecasted future growth, commercial risks, competition,
management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Limitations of the profit multiplier:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier does not take into account
the company&#8217;s accounting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier is impacted by external
factors, such as the interest in the economy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier is not always precise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier in the Israeli parallel
vehicle import sector ranges between 5 to 10. The meaning is that companies in the sector are traded based on a multiplier of 5-10 times
their net profit.</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 655; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average multiplier in the sector is approximately
7.5. However, there are companies which are traded at higher or lower multipliers, based on different factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The size of the company, its profitability, forecasted
future growth, commercial risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below are some examples of profit multipliers
of companies in the Israeli parallel vehicle import sector:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Union Motors is traded at a multiplier of 8.2</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eldan is traded at a multiplier of 6.8</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Semel is traded at a multiplier of 9.1</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I have chosen a multiplier of 8 as being representative
for Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the assumptions presented above, presented
below is an assessment of the enterprise value based on the EBITDA methodology and the representative profit multiplier methodology:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold">EBITDA 2022</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">24,818</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Profit Multiplier</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Value Estimate in Thousands of NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">74,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Value Estimate in Thousands of Dollars</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">20,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10,431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Profit Multiplier</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Value Estimate in Thousands of NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">83,448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Value Estimate in Thousands of Dollars</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">22,862</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Average Operating Value Estimate in Thousands of Dollars</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">21,772</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">i.e., Automax&#8217;s enterprise value, according
to the average of both commonly used multiplier methodologies and with an emphasis on the fact that this methodology does not take into
account the Company&#8217;s new and significant growth engines, is approximately USD 21.77 million (based on an exchange rate of ILS
3.65 per USD 1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As stated above, the objective of this valuation
was solely to establish a starting point and comparison tool prior to performing a more comprehensive valuation which takes into account
the Company&#8217;s business plan which includes significant growth engines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below I shall present a valuation based on the
future cashflow forecast</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Assessing enterprise value through a DCF methodology
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under this methodology we assess the company&#8217;s
future net cashflow and discount it to the present.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is therefore necessary to estimate the profit
and loss for future years, typically for just a few years, until the profitability plateaus at a terminal year which we assume represents
the permanent net annual amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is an explanation about the calculation
of the total cost of capital used to finance the company&#8217;s activities (WACC) and the calculation of the discounted cashflow to
assess the enterprise value:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The WACC (weighted average cost of capital) of
a company is the total cost of the capital used to finance the company&#8217;s activities.</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">WACC is assessed by calculating the relative
weights of the company&#8217;s debt and equity, and calculating the cost of each kind of capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 656; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Cost of equity</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of equity is the return required by
the company&#8217;s shareholders. It is established based on factors, including the risk entailed in investing in the company, as well
as the possible return on alternate investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are various ways to assess the cost of
equity, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Capital
                                            asset pricing model (CAPM)</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Internal
                                            rate of rate model (IRR)</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Average
                                            rate of rate model (ARR)</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of debt</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of debt is the return required by the
company&#8217;s lenders. It is established based on the present interest rate of similar bonds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of debt can be reduced by the tax rate,
since the company is able to deduct the interest costs from its taxable revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Weighting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighting refers to the relative share of
any kind of capital, the total debt and equity of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, if the company has equity totaling
ILS 100 million and debt totaling ILS 50 million, its weighting would be 0.67 and 0.33, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Calculating the WACC to determine the present
value of the company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WACC, or the weighted average cost of capital,
is the rate of return required for a company&#8217;s entire capital, including equity and debt. It is used to discount the company&#8217;s
future cashflows in order to establish its present value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following formula is used to calculate the
WACC:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WACC = (E / (E + D)) * RE + (D / (E + D)) * RD
* (1 - T)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>E
                                            </b>is the company&#8217;s equity</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>D
                                            </b>is the company&#8217;s debt</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>RE
                                            </b>is the cost of the equity</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>RD
                                            </b>is the cost of the debt</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>T
                                            </b>is the tax rate</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 657; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Capital asset pricing model (CAPM) </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Is used to assess the cost of equity of the investment.
It is based on the assumption that shareholders require a higher rate of return on higher risk investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is the formula for calculating
a company&#8217;s cost of equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RE = Rf + &#946; * (Rm - Rf)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>RE
                                            </b>is the cost of the equity</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Rf
                                            </b>is the rate of return required for risk-free assets, such as government bonds</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>&#946;
                                            </b>is the risk parameter of the asset</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Rm
                                            </b>is the average rate of return in the market</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Rate of return required for risk-free assets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rate of return required for zero risk assets
is the return required for risk-free investments. It is used as the basis to assess the cost of equity of higher risk assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk parameter</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk parameter measures the risk entailed
in investing in an asset. It is calculated by comparing the historical return of the asset against the historical return of the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Average market return</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average market return is the average rate
of return of the assets in the market. It is used as a metric of the systemic risk entailed in investing in the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Example</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let&#8217;s assume that the rate of return required
for risk-free assets is 5%, the parameter of risk of a particular asset is 1.2, and the average market return is 10%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the formula, the cost of equity of the
asset is 11.2%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RE = 5% + 1.2 * (10% - 5%) = 11.2%</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I calculated the capital and interest for the
discount rate for the valuation model for Automax based on these explanations. Presented below is the calculation methodology:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Calculating the WACC for the Company </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculating the cost of equity (CAPM)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is difficult to unequivocally establish the
interest rate which reflects the risk premium prevailing in the Israeli share market, appropriate for the vehicle parallel import sector.
This is because it is dependent on multiple factors, as mentioned earlier.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, it can be assessed that this interest
rate will be relatively high due to the high risks entailed in operating in this sector. These factors include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fierce competition: The Israeli vehicle import
market is extremely competitive, and parallel importers are forced to compete with official importers and local manufacturers.</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 658; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory changes: The Israeli vehicle market
is subject to strict regulation, and regulatory changes are liable to significantly impact the activities of parallel importers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Volatility in the foreign exchange market: The
USD exchange rate impacts the cost of purchasing vehicles abroad, and exchange rate volatility is liable to cause losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financing risks: Parallel importers require significant
equity and bank financing for their activities, a fact which increases the financial risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Size of investment: Large investments generally
require a higher interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Entrepreneurial experience: Entrepreneurs with
proven experience in the sector are likely to accept a lower interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collateral: Issuing collateral for a loan may
reduce the risk for the lender and may make it possible to receive a lower interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on these factors, it can be assessed that
the interest rate which reflects the risk premium in the Israeli vehicle parallel import sector ranges between 10%-12%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to perform a more accurate assessment,
I performed the following calculation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 35%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Rate
    of return of risk-free capital assets</span></td>
    <td style="width: 19%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">6.00%</span></td>
    <td style="width: 4%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="width: 42%; border: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">See
    Appendix 1 - Data from the Bank of Israel and others</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Risk
    parameter</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">1.5</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">See
    Appendix 2</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Average
    market return</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">10.00%</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">See
    Appendix 3</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Calculation of the weight of the equity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="width: 27%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">ILS
    millions</span></td>
    <td style="width: 24%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">%
    of total</span></td>
    <td style="width: 25%; border: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Equity</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Share
    capital</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">2,389</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Share
    premium</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">67,382</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Options</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">1,457</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Share-based
    payments</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">17,466</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Total</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">88,694</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">30%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Debt</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Bonds</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">42,543</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Lease
    liabilities</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">13,855</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Long-term
    credit</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">3,675</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Short-term
    credit</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">141,392</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Current
    maturities</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">4,177</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Total</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">205,642</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">70%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Total
    general</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">294,336</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Calculation of the weighted average cost of
capital (WACC): </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 56%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="width: 44%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">12.00%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Cost
    of equity</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">7.90%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Cost
    of debt&#160;</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">23.00%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Tax
    rate</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">70%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Weight
    of equity&#160;</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">30%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Weight
    of debt</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">WACC</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>10.22%</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Weighted
    cost of capital </b></span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I am able to present the forecasted cashflow
model after having established the weighted interest rate for the model at 10.22%.</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 659; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation model is presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mean</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Forecast</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2029</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2028</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2027</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 12%; font-weight: bold; text-align: left">Total Sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">816,627</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">742,388</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">674,899</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">613,544</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">557,767</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">480,834</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">453,617</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Rate of Change (ROC)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">16.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">6.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cost Of Sales*</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">558,605</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">702,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">638,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">580,413</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">527,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">479,680</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">423,134</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">392,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">89,072</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">114,328</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">103,934</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">94,486</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">85,896</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">78,087</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">57,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,699</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Rate of Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">13.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">12.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">13.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-weight: bold; text-align: left">Operating
    Expense (OpEx)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Other</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">7,500</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15,567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">0.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">0.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Sales and Advertising</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">31,582</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">36,919</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">33,563</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">31,964</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">30,442</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">28,993</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">27,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">27,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">G&amp;A</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">21,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,781</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">22,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">21,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">20,434</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">19,461</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,534</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">16,849</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,281</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">68,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">63,091</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,419</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">57,876</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">55,454</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">56,146</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,028</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">8.4</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">8.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.4</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">11.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">13.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Operating Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">28,791</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">45,628</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">40,843</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">34,067</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">28,020</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">22,633</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,554</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">671</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Rate of Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.6</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.6</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Tax Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Working Capital</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">58,291</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">73,496</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">66,815</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,741</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">55,219</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">50,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">43,275</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">41,703</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Working Capital Ratio</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net Operating Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">22,169</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">35,133</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">31,449</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">26,231</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">21,576</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">17,428</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,197</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">503</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Depreciation and Amortization</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Fixed Capital</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-3,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cashflow for Capitalization</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">26,057</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">39,021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">35,337</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">30,119</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">25,464</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">21,316</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5,085</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Capitalization rate Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.22</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Growth</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Operational Value</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">393,585</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Fiscal</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">-300,848</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Investments</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">94,379</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Change in Capital Ratio</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">-23,741</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">-230,210</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Enterprise Value (EV) in NIS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">163,375</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Enterprise Value (EV) in USD</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">44,760</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">See
                                            Appendix 4</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 660; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various short explanations for the assumptions
underlying the cashflow model are presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in">1.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify">2023 was a transition year from there being a shortage of supply due to the chip crisis associated
    with COVID-19 (buying high and selling high) to full supply (buying low and selling low), the need to replace expensive stock together
    with a sharp and quick decline of the Shekel due to the judicial reform and associated civil unrest and the Swords of Iron war in
    Q4 adversely impacted the Company&#8217;s results - the Company assesses that this adverse response has ended because vehicle prices
    adjust themselves to the currencies, and the Company&#8217;s current purchasing prices have also decreased - 2022 was therefore selected
    as the base year for the model.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>2.</td>
    <td style="text-align: justify">Sales, management and general expenses will increase from 2025 at a lower rate of the increase in
    revenues - 5% annually.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>3.</td>
    <td style="text-align: justify">From Q4 2024 the Company will start directly importing a Chinese brand of electric vehicles and therefore
    the gross profitability is anticipated to increase. There will be a greater impact in 2025.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>4.</td>
    <td style="text-align: justify">From Q4 2024 the Company will start consolidating the earnings of &#8220;Automax Leasing&#8221; and
    the profitability of the bus company will increase. There will be a greater impact in 2025.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>5.</td>
    <td style="text-align: justify">From 2024 there will be a 15% annual decline in financing costs (equivalent to interest of approximately
    1.2%) which will be offset with a similar increase in the scope of the financial debt.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>6.</td>
    <td style="text-align: justify">Apart from inventory of vehicles, there will be no material changes in fixed property, including
    intangible license asset and therefore depreciation costs will remain similar at ILS 7,888 thousands per year).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>7.</td>
    <td style="text-align: justify">Revenues - The point of departure is the Company&#8217;s business plan prepared in September 2023.
    The plan referred to the Company&#8217;s new growth engines in the bus import and Chinese electric vehicle direct import segments
    in addition to the Company&#8217;s parallel vehicle import activities. The business plan also relied on 2022 as the basis and referred
    to a 5-year model for 2024-2028. The base assumption was a significant 20% increase in sales in 2024, with continued annual growth
    of 10% until stabilizing in 2028. As noted above, 2023 cannot be referred to as a representative year for the current commercial
    activities due to the multitude of events that occurred throughout the year which impacted activity in the economy. For similar reasons
    I chose to be extra cautious with my working assumptions also for 2024 which started in a state of war and with significant uncertainty
    for subsequent months. I therefore assumed that the sales target presented in the business plan will be achieved in 2029, and that
    there will only be a growth rate of 6% in 2024, the growth rate in 2025 will increase to 16% and the growth rate will stabilize at
    10% from 2026-2029, which will also serve as a terminal year for calculating the discounted revenues.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 661; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">stabilizing in 2028. As noted above,
2023 cannot be referred to as a representative year for the current commercial activities due to the multitude of events that occurred
throughout the year which impacted activity in the economy. For similar reasons I chose to be extra cautious with my working assumptions
also for 2024 which started in a state of war and with significant uncertainty for subsequent months. I therefore assumed that the sales
target presented in the business plan will be achieved in 2029, and that there will only be a growth rate of 6% in 2024, the growth rate
in 2025 will increase to 16% and the growth rate will stabilize at 10% from 2026-2029, which will also serve as a terminal year for calculating
the discounted revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As aforementioned, the working assumption
is that the period of war we anticipate for the coming months will only have a short-term impact on the scope of sales. Past experience
shows that vehicle demand in Israel (and around the world) is inelastic, and that vehicle demand is only adversely impacted in the short-run
during periods of severe crisis but subsequently reverts. The main reasons for this include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- Vehicle demand has &#8220;cumulative&#8221;
features - a person who typically replaces their vehicle once every 4 years and who experiences an external crisis at the planned replacement
time, will slightly postpone the replacement but will not skip it - unlike, for example, the consumption of tourism or recreational services
- where someone who &#8220;misses&#8221; a meal at a restaurant will not return twice the next day.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- Vehicles are also a sensitive purchase
and people tend to &#8220;treat&#8221; themselves after tense periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- 90% of the demand is intended to
address an increased population (new drivers in the market) and vehicle write-offs (thefts, accidents, old vehicle operating faults or
vehicles not worth repairing) - this component of demand is relatively inelastic.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Presented below is a diagram which
presents the annual scope of sales of vehicles in Israel over 1997-2023 while highlighting crisis periods. We can clearly see that vehicle
demand is inelastic and self-correcting after crisis periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><b>Rapid recovery from crises</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">The exchanges of private vehicles in
Israel over time</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_022.jpg" style="width: 650px; height: 259px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in">8.</td>
    <td>Corporate tax rate - 23%.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>9.</td>
    <td style="text-align: justify">Discount rate for the terminal year - the discount interest rate of the model, 10.22% less a permanent
    2% annual increase, i.e., 8.22%.</td></tr>
  </table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 662; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#160;</td><td style="width: 0.25in; text-align: left">10.</td><td style="text-align: justify">Investment
                                            in working capital - I assumed an average rate of working capital by subtracting the Company&#8217;s
                                            current liabilities from its current assets based on its 2022 balance sheet and set a fixed
                                            rate of 9%.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Based on these assumptions I came to
an enterprise value totaling approximately ILS 393.6 million or USD 107.8 million based on an exchange rate of ILS 3.65 per USD 1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Enterprise
                                            value should also consider the value of the Company&#8217;s net assets in the 2022 base year.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Cash
                                            value is equal to the value of cash, less cash liabilities - ILS 300,848 thousands.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">The
                                            value of investments includes fixed property, working capital, and total other assets including
                                            intangible assets - ILS 94,379 thousands.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Change
                                            in working capital considers the value of the difference between the working capital in the
                                            base year (2022) and the terminal year (2029) capitalized based on the established discount
                                            interest rate - ILS 23,741.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Total
                                            assets - ILS 230,210 thousands.</td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>After referring to the net asset value I came
to an enterprise value for the Company totaling ILS 163.4 million, or USD 44.8 million.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Considering that the valuation is based on working
assumptions which take into account future forecasts, I found it correct to examine the sensitivity of the result of the valuation to
changes with two of the model&#8217;s primary variables, the discount interest rate and the growth in the Company&#8217;s sales after
stabilizing from 2026 through 2029 - the terminal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A sensitivity table is presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sensitivity of company valuation in thousands
of $ to discount rate and profit growth rate from 2026</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 12%; font-weight: bold; text-align: left">Growth Rate</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">9.0%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">9.5%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">10.0%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">10.22%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">10.5%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">11.0%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">11.5%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">8.5%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">52,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">44,198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">37,178</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34,303</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">30,998</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25,519</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">20,629</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">9.0%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">56,471</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">48,070</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41,356</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">37,744</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34,294</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">28,575</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">23,471</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">9.5%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">60,758</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">52,002</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">45,539</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">37,632</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">31,670</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">26,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">10.0%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">65,098</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">55,980</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">49,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">44,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41,014</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34,804</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29,265</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">10.5%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">69,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">60,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">53,898</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">48,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">44,439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">37,988</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">32,218</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">11.0%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">73,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">64,058</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">58,078</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">51,958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">47,908</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41,195</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">35,208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">11.5%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">78,472</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">68,226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">62,258</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">55,627</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">51,421</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">44,451</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">38,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 663; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: none"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B
                                            Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter F - Summary and conclusions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax is the largest parallel importer of vehicles
in Israel. The vehicle market in Israel, just like in most of the world, is currently in the midst of a revolution led by two trends:
first - a transition to electric vehicles; second - an increasing number of Chinese manufactured vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax&#8217;s management has adjusted itself
to the market trends and entered into an agreement with the Chinese company HYCAN to sell its vehicles in Israel as a direct importer.
Automax plans on continuing to operate as the leading company in Israel in the parallel import sector and to also use the existing platform
of showrooms and sales personnel to sell HYCAN vehicles. This activity is anticipated to commence at the end of 2024 and will become
the Company&#8217;s primary growth engine in the coming years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another growth engine is the joint establishment
of a company with Dalhom Motors Ltd. to import TEMSA brand buses. The Company signed an agreement with the manufacturer under which the
joint company will serve as the direct importer of TEMSA brand buses to Israel. TEMSA has multiple electric, gasoline and diesel engine
model buses and minibuses designed to serve tourism and public transportation, all of which are suitable to be marketed in Israel. The
Company is currently completing the establishment of a central bus service center with a total area of 4,000 sqm in Hod Hasharon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this document I presented calculations to
value Automax under two methodologies. The multiplier methodology and the DCF (discounted cashflow) methodology. I also explained why
the enterprise value apparent from the Company&#8217;s share price on the Tel Aviv Stock Exchange should not be relied upon as the representative
value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As emphasized, the multiplier methodology is
only based on past data and does not refer to future data, whereby it cannot be used as an appropriate metric to assess the enterprise
value which is anticipated to double or even more the scope of its operations in the coming years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, a current valuation of the Company can
certainly serve as a point of departure and be used as a comparison for a valuation based on the DCF methodology - as it refers to forecasted
future activities and indeed appears to be so. The valuation based on the multiplier methodology assessed the enterprise value at approximately
USD 21.7 million and the valuation based on the DCF methodology assessed the enterprise value at approximately USD 44.8 million. The
Company&#8217;s anticipated growth is meant to double its activities and also increase its profitability which certainly strengthens
the reliability of the valuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fact should also be emphasized that the working
assumptions applied to the Company&#8217;s business plan were examined in-depth by me and were found to be completely realistic. The
existing infrastructure of showrooms and trained sales personnel together with efficient management and marketing are a good basis for
meeting the planned targets. Furthermore, I was exceptionally conservative considering the prevailing situation in Israel and the short-term
uncertainty and I moderated the Company&#8217;s growth forecast in the model&#8217;s assumptions and chose an interest rate which incorporates
risk components appropriate for the Company&#8217;s operating sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Based on that stated above, I determine
that the current value of Automax is approximately USD 44.8 million. </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Appendix 1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sources for establishing the risk-free interest
rate for the period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk-free interest rate calculated for the
model is 6%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This rate was taken from the Bank of Israel banking
interest rate data records, returns on shares, government bonds and more.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current Bank of Israel data 2/1/2024 (Original
- Bank of Israel)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LIBOR interest rate</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telbond - corporate interest rate spreads</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stated Bank of Israel interest</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Bank of Israel overnight interest rate (for
banks)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 664; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Appendix 2</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk interest for the sector</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk interest for the sector depends on various
market factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will be sensitive to changes in the
vehicle market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market competition: Companies compete for the
same target market; the Company is therefore expected to be adversely impacted by the operations of other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The volatility in the share market, the value
of the Company&#8217;s shares is liable to be extremely volatile. This is attributable to these companies being dependent on the vehicle
market and due to volatility in the general share market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk interest can come to a 5%-10% premium on
top of the basic risk-free interest applicable in the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The model applied a risk parameter of 1.5%, i.e.,
risk interest of 6%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Appendix 3</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Average market return</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average market return changes based on the
examined period of time. The average market return is calculated at approximately 10% over the long-run. This is based on data from the
global share markets over the preceding 100 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average market return may be higher or lower
than 10% in the short-run. For example, in the 10 years prior to 2016, the average market return of the US S&amp;P 500 index was approximately
14%. However, in the 5 years prior to 2016, the average market return of this index was approximately 9%. In recent years (2011-2023)
this index had a significantly higher average return.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">S&amp;P index return - (28% total average) 2011-2023</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average market return is impacted by various
factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Economic growth: Strong economic growth causes
an increase in market returns, since it leads to an increase in corporate earnings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation: High inflation causes a decline in
market returns as it is responsible for a decline in the value of money.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Base interest: An increase in the base interest
rate causes a decline in market returns as it is responsible for an increase in loan costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation model applied a conservative rate
of 10% for the market return for the calculation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Appendix 4</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comments regarding the data for the valuation
taken from the Company&#8217;s financial statements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grant of employee options - see the note in the
financial statements. The options plan ended in Q1 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other capital expenses and losses (profits) -
In 2023 there was a capital gain of ILS 4 million due to the sale of shares in Automax Leasing to a third-party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net financing costs - Less exchange rate gains/losses
from currency hedging transactions. No profits or losses were seen from hedging activities after Q1 2023.</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 665; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>INFORMATION NOT REQUIRED
IN PROXY STATEMENT/PROSPECTUS</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Item
20. Indemnification of Directors and Officers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, 5759-1999, or the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty.
An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to
the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles
of association. SciSparc&#8217;s Amended and Restated Articles of Association include such a provision. An Israeli company may not exculpate
a director from liability arising out of a prohibited dividend or distribution to shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed as an office
holder, either in advance of an event or following an event, provided a provision authorizing such indemnification is contained in its
articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-size: 10pt">a
                                            financial liability imposed on him or her in favor of another person pursuant to a judgment,
                                            including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking
                                            to indemnify an office holder with respect to such liability is provided in advance, then
                                            such an undertaking must be limited to events which, in the opinion of the board of directors,
                                            can be foreseen based on the company&#8217;s activities when the undertaking to indemnify
                                            is given, and to an amount or according to criteria determined by the board of directors
                                            as reasonable under the circumstances, and such undertaking shall detail the abovementioned
                                            events and amount or criteria;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reasonable
                                            litigation expenses, including legal fees, incurred by the office holder (1)&#160;as a result
                                            of an investigation or proceeding instituted against him or her by an authority authorized
                                            to conduct such investigation or proceeding, provided that (i)&#160;no indictment was filed
                                            against such office holder as a result of such investigation or proceeding; and (ii)&#160;no
                                            financial liability, such as a criminal penalty, was imposed upon him or her as a substitute
                                            for the criminal proceeding as a result of such investigation or proceeding or, if such financial
                                            liability was imposed, it was imposed with respect to an offense that does not require proof
                                            of criminal intent; and (2)&#160;in connection with a monetary sanction;</span></td>
</tr></table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reasonable litigation expenses, including legal fees, incurred by the
    office holder or imposed by a court (i) in proceedings instituted against him or her by the company, on its behalf or by a third-party,
    or (ii) in connection with criminal proceedings in which the office holder was acquitted, or (iii) as a result of a conviction for
    an offense that does not require proof of criminal intent; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expenses, including reasonable litigation expenses and legal fees,
    incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation
    payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of
    the Israeli Securities Law, 1968, or the Israeli Securities Law.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Israeli company may insure
an office holder against the following liabilities incurred for acts performed as an office holder if and to the extent provided in the
company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a breach of the duty of loyalty to the company, to the extent that
    the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a breach of the duty of care to the company or to a third-party, including
    a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 666; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a financial liability imposed on the office holder in favor of a third-party;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a financial liability imposed on the office holder in favor of a third-party
    harmed by a breach in an administrative proceeding; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expenses, including reasonable litigation expenses and legal fees,
    incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions
    of the Israeli Securities Law.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Israeli company may not
indemnify or insure an office holder against any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a breach of the duty of loyalty, except to the extent that the office
    holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a breach of the duty of care committed intentionally or recklessly,
    excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an act or omission committed with intent to derive illegal personal
    benefit; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a fine or forfeit levied against the office holder.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
exculpation, indemnification and insurance of office holders must be approved by the compensation committee, the board of directors and,
with respect to directors and the chief executive officer, by the shareholders. However, under regulations promulgated under the Companies
Law, the insurance of office holders shall not require shareholder approval and may be approved by only the compensation committee, if
the engagement terms are determined in accordance with the company&#8217;s compensation policy, and that policy was approved by the shareholders
by the same special majority required to approve a compensation policy, provided that the insurance policy is on market terms and the
insurance policy is not likely to materially impact the company&#8217;s profitability, assets or obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Amended
and Restated Articles of Association allow SciSparc to exculpate, indemnify and insure its office holders for any liability imposed on
them as a consequence of an act (including any omission) which was performed by virtue of being an office holder. SciSparc&#8217;s office
holders are currently covered by a directors and officers liability insurance policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc has entered into
agreements with each of its directors and executive officers exculpating them in advance, to the fullest extent permitted by law, from
liability to SciSparc for damages caused to us as a result of a breach of duty of care, and undertaking to indemnify them to the fullest
extent permitted by law. This indemnification is limited to events determined as foreseeable by the board of directors based on its activities,
and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The maximum indemnification
amount set forth in such agreements is limited to an amount equal to 25% of SciSparc&#8217;s total shareholders&#8217; equity as reflected
in SciSparc&#8217;s most recent consolidated financial statements prior to the date on which the indemnity payment is made. The maximum
amount set forth in such agreements is in addition to any amount paid (if paid) under insurance and/or by a&#160;third-party&#160;pursuant
to an indemnification arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the opinion of the Securities
and Exchange Commission, or the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities
Act, however, is against public policy and therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc has purchased and
currently intends to maintain insurance on behalf of each and every person who is or was a director or officer of the company against
any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 667; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 21. Exhibits And Financial Statements
Schedules</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Exhibits</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed as part of this Registration Statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 90%; vertical-align: bottom"><span style="font-size: 10pt"><b>Description
    of Document</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">2.1***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="#m_028"><span style="font-size: 10pt">Agreement and Plan of Merger, dated as of April 10,
    2024, by and among SciSparc Ltd., SciSparc Merger Sub Ltd., and AutoMax Ltd. (included as Annex A to the proxy statement/prospectus
    forming a part of this Registration Statement)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">2.2*</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="#m_029"><span style="font-size: 10pt">Form of AutoMax Shareholder Support Agreement,
    dated April 10, 2024, by and between SciSparc Ltd. and each of the parties named in each agreement thereof (included as Annex B to
    the proxy statement/prospectus forming a part of this Registration Statement)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>2.3*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex2-3_scisparc.htm">Addendum
    to the Agreement and Plan of Merger, dated August 14, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger
    Sub Ltd.</a></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">2.4*</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024113993/ea022624601ex2-4_scisparc.htm"><span style="font-size: 10pt">Second Addendum to the Agreement and Plan of Merger, dated November 26, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd.</span></a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.1*</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999ex3-1_scisparc.htm"><span style="font-size: 10pt">SciSparc
    Ltd. Amended and Restated Articles of Association (Incorporated by reference to Exhibit 3.1 to the Registration Statement on Form
    F-3 (File No. 333-269839), filed with the Commission on February 17, 2023) </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex4-1_scisparc.htm">SciSparc
    Ltd. Form of Pre-Funded Warrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">5.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex5-1_scisparc.htm">Opinion
    of Meitar | Law Offices</a></span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">8.1</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify"><a href="ea023082101ex8-1_scisparc.htm"><span style="font-size: 10pt">Opinion of Sullivan &amp; Worcester LLP as to certain
    U.S. Federal Tax Matters</span></a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.1*</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex10-7_scisparcltd.htm"><span style="font-size: 10pt">SciSparc
    2023 Share Incentive Plan (Incorporated by reference to Exhibit 10.7 to the Registration Statement on Form F-1 (File No. 333-277394),
    filed with the Commission on February 27, 2024) </span></a></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-2_scisparc.htm">Loan
    Agreement, dated January 14, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-3_scisparc.htm">Amendment
    to Loan Agreement, dated June 9, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-4_scisparc.htm">Second
    Amendment to Loan Agreement, dated September 5, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd.</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.5*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-5_scisparc.htm">Form
    of Indemnification Agreement of SciSparc Ltd.</a></span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="width: 8%"><span style="font-size: 10pt">10.6&#8224;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 91%"><a href="ea023082101ex10-6_scisparc.htm"><span style="font-size: 10pt">Distribution Agreement by and between AutoMax Leasing Ltd. and Anhui Jianghuai Automobile Group Corp., Ltd., dated September 15, 2024</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.7&#8224;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="ea023082101ex10-7_scisparc.htm"><span style="font-size: 10pt">Founders&#8217; Agreement by and between AutoMax Motors Ltd. and Dalhom Motors Ltd., dated June 16, 2022. (translated from Hebrew)</span></a></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="width: 9%"><span style="-keep: true"><span style="font-size: 10pt">21.1</span>*</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex21-1_scisparcltd.htm"><span style="font-size: 10pt">List
    of Subsidiaries (Incorporated by reference to Exhibit 21.1 to the Registration Statement on Form F-1 (File No. 333-277394), filed
    with the Commission on February 27, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023082101ex23-1_scisparc.htm"><span style="font-size: 10pt">Consent of Kost, Forer, Gabbay
    &amp; Kasierer, a member of Ernst &amp; Young Global, independent registered accounting firm for SciSparc Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">23.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><a href="ea023082101ex23-2_scisparc.htm">Consent of Ben David Shalvi Kop &amp; Co., independent registered accounting firm for AutoMax Motors Ltd.</a></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.3*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex5-1_scisparc.htm">Consent
    of Meitar | Law Offices (contained in Exhibit 5.1).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">24.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea0213908-f4_scisparc.htm#POA_001">Power
    of Attorney (included on signature page herein)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Form of Proxy Card for Special Meeting of Shareholders of SciSparc
    Ltd.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">99.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex99-2_scisparc.htm">Consent
    of E.D.B. Consulting and Investments Ltd, relating to valuation report for SciSparc Ltd.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.3*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex99-3_scisparc.htm">Consent
    of Yaarah Alfi as director nominee</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">99.4*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex99-4_scisparc.htm">Consent
    of Tomer Levy as director nominee</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">107*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex-fee_scisparc.htm">Filing
    Fee Table</a></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Previously filed.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">**</td><td style="text-align: justify">To be filed by amendment.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 64.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain schedules and exhibits
    have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to
    the SEC upon request.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain identified information
    contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) is the type that the Company
    treats as private or confidential. &#8220;[***]&#8221; indicates where the information has been omitted from this exhibit.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 64.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The financial statements filed
with this Registration Statement on Form&#160;F-4&#160;are set forth on the Financial Statement Index and is incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 668; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Item 22. Undertakings.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The undersigned registrant
hereby undertakes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b)&#160;if,
    in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth
    in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act, each such&#160;post-effective&#160;amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial&#160;<i>bona fide</i>&#160;offering thereof.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form&#160;20-F&#160;at
    the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by
    Section&#160;10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective
    amendment, financial statements required pursuant to this paragraph (1)(d) and other information necessary to ensure that all other
    information in the prospectus is at least as current as the date of those financial statements.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">That, for
the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities,
the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160; &#160;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Any preliminary prospectus or prospectus of the
    undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The portion of any other free writing prospectus
    relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf
    of the undersigned registrant; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Any other communication that is an offer in the
    offering made by the undersigned registrant to the purchaser.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 669; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white">The undersigned
registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a
prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning
of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration
form with respect to re-offerings by persons who may be deemed underwriters, in addition to the information called for by the other items
of the applicable form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white">The registrant
undertakes that every prospectus: (a)&#160;that is filed pursuant to the immediately preceding paragraph, or (b)&#160;that purports to
meet the requirements of Section&#160;10(a)(3) of the Act and is used in connection with an offering of securities subject to Rule 415,
will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that,
for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">Insofar as
indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by
such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion
of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication
of such issue.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white">The undersigned
registrant hereby undertakes (i)&#160;to respond to requests for information that is incorporated by reference into the prospectus pursuant
to Items 4, 10(b), 11, or 13 of this Form, within one business day of receipt of such request, and to send the incorporated documents
by first class mail or other equally prompt means; and (ii)&#160;to arrange or provide for a facility in the U.S. for the purpose of
responding to such requests. The undertaking in subparagraph (i)&#160;above includes information contained in documents filed subsequent
to the effective date of the registration statement through the date of responding to the request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white">The undersigned
registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company
being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 670; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><div><a id="POA_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURES</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Pursuant
                                            to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused
                                            this registration statement to be signed on its behalf by the undersigned, thereunto duly
                                            authorized, in the City of Tel Aviv, State of Israel, on the 13<sup>th</sup> day of February,
                                            2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160; </p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr><td style="vertical-align: top"><b>&#160;</b></td>
    <td colspan="3" style="vertical-align: bottom"><b>SCISPARC LTD. &#160;</b></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3" style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom">/S/ Oz Adler</td></tr>
  <tr>
    <td style="vertical-align: top; width: 60%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%"><span style="font-size: 10pt">Name:&#8239;</span></td>
    <td style="vertical-align: bottom; width: 31%"><span style="font-size: 10pt">Oz Adler</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Title:</span>&#8239;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by each of the following persons in the capacities
and on the dates indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oz Adler&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Chief Financial Officer</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    13, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive
    Officer, <br/>
    Principal Financial Officer and Principal Accounting Officer)</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board
    of Directors</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    13, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    13, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amnon Ben Shay</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    13, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Dayan</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    13, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe Revach</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    13, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itschak Shrem</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    13, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liat Sidi</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    13, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Vider</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 40%">*By Attorney-in-Fact</td>
    <td style="width: 60%">&#160;</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="border-bottom: Black 1.5pt solid; text-align: justify">/s/ Oz Adler</td>
    <td>&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify">Oz Adler</td>
    <td>&#160;</td></tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 671; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE
UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Pursuant to the Securities
Act of 1933, as amended, the undersigned, Puglisi &amp; Associates duly authorized representative in the United States of SciSparc Ltd.,
has signed this registration statement on February 13, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 40%"><span style="font-size: 10pt; text-transform: uppercase"><b>PUGLISI &amp; ASSOCIATES</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Donald J. Puglisi&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Donald J. Puglisi</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Managing Director</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-7</p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">F-4/A</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="ifrs-full:NoncurrentLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="ifrs-full:NoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-4" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="ifrs-full:NoncurrentReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="ifrs-full:NoncurrentReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-7" name="ifrs-full:CurrentLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-8" name="ifrs-full:NoncurrentLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-9" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-10" name="ifrs-full:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-11" name="ifrs-full:SalesAndMarketingExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-12" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-13" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-14" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-15" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-16" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-17" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-18" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-19" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-20" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-21" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-22" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-23" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-24" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-25" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-26" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-27" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-28" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-29" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-30" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-31" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-32" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-33" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-34" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-35" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-36" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-37" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-38" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-39" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-40" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-41" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-42" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-43" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-44" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-45" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-46" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-47" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-48" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-49" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-50" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-51" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-52" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-53" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-54" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-55" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-56" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c43" id="hidden-fact-57" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-58" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-59" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-60" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-61" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-62" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c43" id="hidden-fact-63" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-64" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-65" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-66" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-67" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c43" id="hidden-fact-68" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-69" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-70" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-71" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-72" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-73" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-74" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-75" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-76" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-77" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-78" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-79" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-80" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-81" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-82" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-83" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-84" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-85" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-86" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-87" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-88" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-89" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-90" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-91" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-92" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-93" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-94" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-95" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-96" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-97" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-98" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-99" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-100" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-101" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-102" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-103" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-104" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-105" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-106" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-107" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-108" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-109" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-110" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-111" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-112" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-113" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-114" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-115" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-116" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-117" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-118" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-119" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-120" name="sprcy:ReceiptofShortTermCreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-121" name="sprcy:ReceiptofShortTermCreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-122" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-123" name="sprcy:RegistrationOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-124" name="sprcy:RegistrationOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-125" name="sprcy:InvestmentInFinancialAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-126" name="sprcy:InvestmentInFinancialAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-127" name="sprcy:UnpaidIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-128" name="sprcy:UnpaidIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-129" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-130" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-131" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-132" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-133" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-134" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-135" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-136" name="sprcy:CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-137" name="sprcy:CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-138" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-139" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-140" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-141" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-142" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-143" name="sprcy:MutualShareExchangeOfOrdinaryShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-144" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-145" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c108" id="hidden-fact-146" name="sprcy:LeaseholdImprovements" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-147" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-148" name="sprcy:FairValueOfInvestment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-149" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-150" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-151" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c152" id="hidden-fact-152" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c154" id="hidden-fact-153" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-154" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-155" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c154" id="hidden-fact-156" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c154" id="hidden-fact-157" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c157" id="hidden-fact-158" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-159" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-160" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-161" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c157" id="hidden-fact-162" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-163" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-164" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-165" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-166" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-167" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-168" name="ifrs-full:RestrictedCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-169" name="ifrs-full:RestrictedCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-170" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-171" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-172" name="sprcy:GovernmentAuthorities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-173" name="sprcy:GovernmentAuthorities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-174" name="ifrs-full:OtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-175" name="ifrs-full:OtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-176" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-177" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-178" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-179" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-180" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-181" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-182" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-183" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-184" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-185" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-186" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-187" name="ifrs-full:RestrictedCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-188" name="ifrs-full:RestrictedCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c173" id="hidden-fact-189" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-190" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-191" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c176" id="hidden-fact-192" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-193" name="sprcy:GovernmentAuthorities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-194" name="sprcy:GovernmentAuthorities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-195" name="ifrs-full:OtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-196" name="ifrs-full:OtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-197" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-198" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-199" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-200" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-201" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-202" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-203" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-204" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-205" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-206" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-207" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c183" id="hidden-fact-208" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c185" id="hidden-fact-209" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" decimals="0" id="hidden-fact-210" name="ifrs-full:NumberOfSharesIssued" unitRef="shares">10000000</ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-211" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c223" id="hidden-fact-212" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c224" id="hidden-fact-213" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c227" id="hidden-fact-214" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c228" id="hidden-fact-215" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c229" id="hidden-fact-216" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c230" id="hidden-fact-217" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c233" id="hidden-fact-218" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-219" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c254" id="hidden-fact-220" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-221" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c274" id="hidden-fact-222" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c276" id="hidden-fact-223" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c277" id="hidden-fact-224" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-225" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c278" id="hidden-fact-226" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c275" id="hidden-fact-227" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c283" id="hidden-fact-228" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c287" id="hidden-fact-229" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-230" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-231" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-232" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c290" id="hidden-fact-233" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c290" id="hidden-fact-234" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c292" id="hidden-fact-235" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c292" id="hidden-fact-236" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c294" id="hidden-fact-237" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c295" id="hidden-fact-238" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-239" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c294" id="hidden-fact-240" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c295" id="hidden-fact-241" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-242" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c295" id="hidden-fact-243" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c302" id="hidden-fact-244" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c304" id="hidden-fact-245" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c305" id="hidden-fact-246" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c302" id="hidden-fact-247" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c304" id="hidden-fact-248" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c305" id="hidden-fact-249" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c303" id="hidden-fact-250" name="ifrs-full:CurrentLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-251" name="sprcy:ResearchAndDevelopmentExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-252" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-253" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-254" name="sprcy:KeyManagementPersonnelCompensationManagementFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-255" name="sprcy:KeyManagementPersonnelCompensationManagementFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c302" id="hidden-fact-256" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c302" id="hidden-fact-257" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c330" id="hidden-fact-258" name="ifrs-full:CurrentLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c303" id="hidden-fact-259" name="ifrs-full:CurrentLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c333" id="hidden-fact-260" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c332" id="hidden-fact-261" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c333" id="hidden-fact-262" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-263" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-264" name="ifrs-full:LoansAndAdvances" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-265" name="ifrs-full:LoansAndAdvances" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-266" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-267" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-268" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c194" decimals="0" id="hidden-fact-269" name="sprcy:AggregateUnitsPerShare" unitRef="usdPershares">18382</ix:nonFraction>
<ix:nonFraction contextRef="c185" id="hidden-fact-270" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c359" id="hidden-fact-271" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c375" id="hidden-fact-272" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c375" id="hidden-fact-273" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-274" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c377" id="hidden-fact-275" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c377" id="hidden-fact-276" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-277" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c290" id="hidden-fact-278" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c290" id="hidden-fact-279" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-106732">0001611746</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-106733">true</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="sprcy-20240630.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact ix_12_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact ix_7_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_8_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-212 ix_9_fact hidden-fact-216 ix_10_fact ix_11_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_13_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_14_fact" toRefs="ix_6_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CoeruleusMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:CapitalPointWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-11-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-29</xbrli:startDate>
    <xbrli:endDate>2020-11-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-25</xbrli:startDate>
    <xbrli:endDate>2023-06-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-30</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-19</xbrli:startDate>
    <xbrli:endDate>2020-03-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-19</xbrli:startDate>
    <xbrli:endDate>2020-03-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-11-13</xbrli:startDate>
    <xbrli:endDate>2019-11-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-04-11</xbrli:startDate>
    <xbrli:endDate>2017-04-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-02</xbrli:startDate>
    <xbrli:endDate>2021-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-27</xbrli:startDate>
    <xbrli:endDate>2022-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-15</xbrli:startDate>
    <xbrli:endDate>2022-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-18</xbrli:startDate>
    <xbrli:endDate>2023-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-02</xbrli:startDate>
    <xbrli:endDate>2022-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-01</xbrli:startDate>
    <xbrli:endDate>2022-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-22</xbrli:startDate>
    <xbrli:endDate>2022-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-04</xbrli:startDate>
    <xbrli:endDate>2021-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHwcigou02yOi3RAgyAKCzKinttrVCX0GS4sD3ObxpwqEzqm9j1cZ4KQuocaRc2hMVSIDbMizaoWZ/nmzHQlBpYQrBXVpspuwa7a1yTY7nXsjphYT7GC7hOyPdg0YxoXQO1gmR5R+ZgPKpBP3bZFMnCOJCkQPyeJVMA/Es6MP8YMw==] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-04</xbrli:startDate>
    <xbrli:endDate>2021-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesBWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-04</xbrli:startDate>
    <xbrli:endDate>2021-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:OverAllotmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sprcy:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-03-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-10-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-10</xbrli:startDate>
    <xbrli:endDate>2019-10-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-15</xbrli:startDate>
    <xbrli:endDate>2020-01-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-31</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-10</xbrli:startDate>
    <xbrli:endDate>2022-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-03</xbrli:startDate>
    <xbrli:endDate>2022-01-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ClearmindMedicineIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ClearmindMedicineIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:NewCoIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-31</xbrli:startDate>
    <xbrli:endDate>2024-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-01</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-21</xbrli:startDate>
    <xbrli:endDate>2024-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-11</xbrli:startDate>
    <xbrli:endDate>2024-03-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMotorsLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sprcy:InvestmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:BridgeLoansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:BridgeLoansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxAcquisitionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-09</xbrli:startDate>
    <xbrli:endDate>2024-06-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:BridgeLoansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-09</xbrli:startDate>
    <xbrli:endDate>2024-06-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-05</xbrli:startDate>
    <xbrli:endDate>2024-09-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:BridgeLoansMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-05</xbrli:startDate>
    <xbrli:endDate>2024-09-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-23</xbrli:startDate>
    <xbrli:endDate>2023-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:TransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:TransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:TransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-26</xbrli:startDate>
    <xbrli:endDate>2024-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-09</xbrli:startDate>
    <xbrli:endDate>2024-04-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c355">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c356">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c357">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c358">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c359">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c360">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c361">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c362">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c363">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c364">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c365">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c366">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c367">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c368">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c369">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c370">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c371">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c372">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c373">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c374">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c375">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c376">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c377">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c378">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c379">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c380">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c381">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c382">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c383">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MizaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-08</xbrli:startDate>
    <xbrli:endDate>2024-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c384">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MizaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c385">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c386">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c387">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c388">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c389">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c390">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-16</xbrli:startDate>
    <xbrli:endDate>2024-09-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c391">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-13</xbrli:startDate>
    <xbrli:endDate>2024-08-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c392">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c393">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c394">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c395">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c396">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c397">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>ea023082101ex8-1_scisparc.htm
<DESCRIPTION>OPINION OF SULLIVAN & WORCESTER LLP AS TO CERTAIN U.S. FEDERAL TAX MATTERS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 8.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding: 1pt; width: 40%"><IMG SRC="ex8-1_001.jpg" ALT=""></TD><TD STYLE="padding: 1pt; vertical-align: middle; width: 30%; text-align: right"><IMG SRC="ex8-1_002.jpg" ALT=""></TD><TD STYLE="padding: 1pt; vertical-align: middle; text-align: right; width: 30%"><IMG SRC="ex8-1_003.jpg" ALT=""></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">February 12, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Merger Sub Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">20 Raul Wallenberg Street, Tower A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel Aviv 6971916 Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AutoMax Motors Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15 HaRechavim St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jerusalem, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You have requested our opinion regarding certain federal income tax
consequences of the proposed merger (&ldquo;the Merger&rdquo;) of&nbsp;SciSparc Merger Sub Ltd.&nbsp;into AutoMax Motors Ltd. pursuant
to which AutoMax Motors Ltd. will become a wholly owned subsidiary of SciSparc Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Facts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Ltd. (&ldquo;SciSparc&rdquo;) is a corporation existing under
the laws of the State of Israel. SciSparc Merger Sub Ltd. (&ldquo;Merger Sub&rdquo;) is also a corporation existing under the laws of
the State of Israel, and is wholly owned by SciSparc. Merger Sub is a transitory corporation that will engage in no substantial business
activity other than to effect the Merger. AutoMax Motors Ltd. (&ldquo;AutoMax&rdquo;) is also a corporation existing under the laws of
the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No party to the Merger is an investment company as defined in IRC &sect;&sect;&nbsp;368(a)(2)(F)(iii)
and 368(a)(2)(F)(iv). No intercorporate debt exists between any of SciSparc, Merger Sub and AutoMax that was issued, acquired, or will
be settled at a discount in connection with the Merger. No party to the Merger is under the jurisdiction of a court in a Title 11 or similar
case within the meaning of IRC &sect;&nbsp;368(a)(3)(A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The terms of the Merger are contained in the Agreement and Plan of
Merger, dated as of April 10, 2024 (the &ldquo;Plan of Merger&rdquo; ), among SciSparc, Merger Sub and AutoMax. Pursuant to the Plan of
Merger, Merger Sub will merge with and into AutoMax, with AutoMax surviving, and AutoMax will become a wholly owned subsidiary of SciSparc
(the &ldquo;Transaction&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex8-1_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Merger Sub Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AutoMax Motors Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Opinion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our opinion, the Merger, as structured, is a reverse triangular
merger that meets the requirements of a &ldquo;reorganization&rdquo; as defined in IRC &sect;&nbsp;368(a)(1)(A), as augmented by the provisions
of IRC &sect;&nbsp;368(a)(2)(E). Assuming that the Transaction is consummated in accordance with the terms, conditions, and other provisions
of the Plan of Merger and that all of the factual information, descriptions, representations, and assumptions set forth in the Plan of
Merger, in your Registration Statement on Form F-4 filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on September
26, 2024, including any amendments thereto, in the proxy statement/prospectus contained therein, and in the Officers Certificate of SciSparc
dated February 12, 2025 are accurate and complete in all relevant respects, and will be accurate and complete in all relevant respects
at the time the Merger becomes effective, it is our opinion that for federal income tax purposes the following will occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Merger will constitute a &ldquo;reorganization&rdquo; within the meaning of IRC &sect;&nbsp;368(a), and SciSparc, Merger Sub and
AutoMax will each be a party to the reorganization within the meaning of IRC &sect;&nbsp;368(b).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Neither SciSparc nor Merger Sub will recognize any gain or loss as a result of the Merger.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>AutoMax will not recognize any gain or loss as a result of the Merger.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Holders of ordinary shares, par value NIS 0.05 per share of AutoMax (&ldquo;AutoMax Ordinary Shares&rdquo;) exchanged in the Merger
for&nbsp;ordinary shares, no par value of SciSparc (&ldquo;SciSparc Ordinary Shares&rdquo;) will not recognize any gain or loss as a result
of the Merger, and Holders of AutoMax Ordinary Shares exchanged in the Merger for&nbsp;SciSparc Ordinary Shares and pre-funded warrants
to acquire SciSparc Ordinary Share will recognize gain, if any, to the extent of the value of the pre-funded warrants to acquire SciSparc
Ordinary Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The adjusted basis of the assets of AutoMax after the Merger will be the same as the adjusted basis of the assets held by AutoMax
and (if any) by Merger Sub immediately before the Merger.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">With regard to shareholders who held their AutoMax Ordinary Shares as capital assets, the period for which they have held such AutoMax
Ordinary Shares will be included in their holding period for SciSparc Ordinary Shares received in the exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify">The tax basis of SciSparc Ordinary Shares received by a shareholder of AutoMax will equal the tax basis of such shareholder&rsquo;s holdings
of AutoMax Ordinary Shares exchanged in the Merger.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify">The tax basis of any pre-funded warrants to acquire SciSparc Ordinary Shares received by a shareholder of AutoMax will equal the fair
market value of such pre-funded warrants to acquire SciSparc Ordinary Shares on the date of the closing of the Merger, and the holder&rsquo;s
holding period for such warrants will commence on that date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Merger Sub Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AutoMax Motors Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our opinion is limited to the foregoing federal income tax consequences
of the Merger, which are the only matters as to which you have requested our opinion, and you must judge whether the matters addressed
herein are sufficient for your purposes. We do not address any other federal income tax consequences of the Merger or other matters of
federal law and have not considered matters (including state or local tax consequences) arising under the laws of any jurisdiction other
than matters of federal tax law arising under the laws of the United States. This opinion is not intended or written by our firm to be
used, and it cannot be used by any taxpayer, for the purpose of avoiding penalties that may be imposed on the taxpayer. Our opinion is
based on the understanding that the relevant facts are, and will be on the Effective Date of the Merger, as set forth in the Plan of Merger.
Our opinion is also based on the Code, Treasury Regulations, case law, and IRS rulings as they now exist. These authorities are all subject
to change and such changes may be made with retroactive effect. We can give no assurance that after any such change our opinion would
not be different. We undertake no responsibility to update or supplement our opinion. We hereby consent to the filing of this opinion
letter with the SEC as Exhibit 8.1 to the Registration Statement and the reference to this opinion letter made in the proxy statement
/ prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>/s/ Sullivan &amp; Worcester LLP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sullivan &amp; Worcester LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>3
<FILENAME>ea023082101ex10-6_scisparc.htm
<DESCRIPTION>DISTRIBUTION AGREEMENT BY AND BETWEEN AUTOMAX LEASING LTD. AND ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD., DATED SEPTEMBER 15, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Certain identified information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii)
is the type that the Company treats as private or confidential. &ldquo;[***]&rdquo; indicates where the information has been omitted from
this exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DISTRIBUTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>By and Between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>And</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>AUTOMAX LEASING</U>
<U>COMPANY</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>AUTOMAX LEASING</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ref. NO. _____________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Sep 15th, 2024</U>, Hefei CHINA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONTENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%">1. Definitions</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">2</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>2. General provisions</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">2.1 Distribution Products</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">2.2 Distribution territory</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> 3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">2.3 Distribution authority</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">2.4 Products price</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">2.5 Market objectives</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2.6 Payment</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>2.7 Production and Delivery</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>3. Rights and duties </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">3.1 Rights of Party A </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">3.2 Duties of Party A </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">3.3 Rights of Party B </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">3.4 Duties of Party B </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>4. Commencement and expiration </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">4.1 Validity of Agreement </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">4.2 Early termination </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">4.3 Consequence of Agreement Termination </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>5. Force Majeure</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>6. Settlement of disputes</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>7. Assignment of Agreement</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>8. Priority and Severability</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>9. Other terms</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>10. Address and contact information</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>11. Execution</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Appendix</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This distribution agreement (hereinafter referred
to as the &ldquo;Agreement&rdquo;) is confirmed by and between the following parties in Hefei City, Anhui Province, China:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD. (hereinafter
manufacturer, called Party A), a corporation existing under the laws of People&rsquo;s Republic of China having its principal office established
at 176 Dong Liu Road, Hefei, China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>AUTO MAX LEASING LTD</U>. (Hereinafter distributor,
called Party B), a corporation existing under the laws of Israel, having its principal office established at <U>15 Harechavim St., Jerusalem,
Israel</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>AUTO MAX LEASING LTD. 15 Harechavim St., Jerusalem,
Israel</U> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#12290;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the business license of Party B is as
Appendix 1, Signed by Party B&rsquo;s legal representative or legally authorized person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of the mutual promises and covenants
set forth in this agreement, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case of any inconsistency between the followings
contents and the Agreement signed in Sep 2<SUP>nd </SUP>by both parties, the clauses of the AGREEMENT signed in Sep 2<SUP>nd</SUP> clauses
should prevail over the clauses of the DISTRIBUTING AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. Definitions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed or expressly provided
in the context of this Agreement, all the terms set out in this Agreement shall have the meaning as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.1 </B>&ldquo;Confidential
Information&rdquo; shall mean any information which relates but not limited to the administrative, financial, products, technical or
operational arrangements of a Party or any subsidiary or associated companies of any Party and any information of a secret or
proprietary nature or which is otherwise expressly stated by that Party to be confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Affiliate(s)&rdquo; refers to any entity
related to any party, and these entities are directly or indirectly controlled by that party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.2 </B>&ldquo;Intellectual Property Right&rdquo;
(hereinafter called IPR) shall mean, in relation to Party A and the &ldquo;Products&rdquo;, the patents, trademarks, trade names, logos
and registered designs details of which are mentioned in the Agreement, and all other patents, trademarks, trade names, logos, designs,
symbols, emblems, copyrights, information, and other identifying materials and all other proprietary rights whatsoever owned by or available
to Party A or adopted or designated now or at any time hereafter by Party A for use by Party A in connection with the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.3</B> &ldquo;Overall market&rdquo; shall
mean the sales volume of the total territory vehicle market (excluding that of the used vehicle market);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.4</B> &ldquo;Segment market&rdquo; shall
mean the total sales volume of the segment which the &ldquo;Products&rdquo; defined in this agreement belong to (excluding that of the
used vehicle market).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.5</B> <FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;</FONT>Force
Majeure<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT> shall mean any event which: (i) is beyond the control of
the affected Party; (ii) is unforeseen or, if foreseen, is unavoidable; (iii) arises after the Effective Date of this Agreement; and (iv)
prevents total or partial performance of this Agreement by the affected Party. Such events shall include, but not be limited to, floods,
fires, droughts, typhoons, earthquakes or other natural disasters, pandemic, transportation disasters, strikes, civil unrest or disturbance,
acts of terrorism, riots and war (whether or not declared), provided that Force Majeure does not apply to a Party<FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;</FONT>s
willful act, neglect or failure to take reasonable precautions against the relevant Force Majeure event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.6</B> &ldquo;Batch order&rdquo; shall mean
an order of more than 50 units of vehicles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.7</B> &ldquo;Required documentation&rdquo;
shall mean the following two documents which Party B shall provide to Party A according to the requirements of Party A before the signing
of this Agreement, namely Party B&rsquo;s copy of business license and Business Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.8 &ldquo;PRC&rdquo;</B> or <B>&ldquo;China&rdquo;
</B>originally means the People&rsquo;s Republic of China, for the purpose of this Agreement, the term &ldquo;China&rdquo; referred to in
Article 6 of this Agreement, it refers to mainland China in particular in this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.9</B> &ldquo;New Agreement&rdquo; shall
mean newly signed distribution agreement or supplemental agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">References to dates shall be construed as references
to dates in the Gregorian calendar and references to &ldquo;month&rdquo;, &ldquo;monthly&rdquo;, &ldquo;year&rdquo;, or &ldquo;yearly&rdquo; shall be construed as references
to the corresponding time period under the Gregorian calendar unless the context requires otherwise. References to &ldquo;weeks&rdquo; or &ldquo;weekly&rdquo;
shall be references to a period of seven (7) calendar days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Territory&rdquo; has the meaning given
in Clause 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. General provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.1 Distribution Products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Party A agrees Party B to import and sell the specified
vehicle models of the JAC brand. Hereinafter referred to as <FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;</FONT>Products<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">Please refer to Appendix
2 for specific Products</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.2 Distribution territory</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Territory&rdquo; shall mean <FONT STYLE="font-family: Times New Roman, Times, Serif">_Israel__.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.3 Distribution authority</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A appoints Party B as a non-exclusive distributor
for the whole area of the Territory of the above-mentioned Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.4 Products price <FONT STYLE="font-family: Times New Roman, Times, Serif">&#20135;&#21697;&#20215;&#26684;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.4.1 Party A will fix the Products price according
to the configuration on the order required by Party B. [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.4.2 [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.5 Market objectives</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.5.1 Sales target</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.5.1.1 </B>On a basis of the non-exclusive
distributor, Party B should fulfill the following order target after the signature of the Agreement, provided that Party A could supply
Party B with products that meet the European standard:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.5.1.2</B> After signing this agreement, Party
B should make a minimum order of [******] units within [******].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.5.2 Market share target</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.5.3 Sales network expansion target</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B shall make its best efforts to maintain
and develop the distribution of Party A&rsquo;s Product, establish wholesale and retail network, distribute and meet the demand for Products,
to meet the demand volume from customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales network expansion target:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.5.4 Service network expansion target</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To provide quality service, technical service
network should be established along with the sales network. Party B shall actively support the market development and after-sales service
of related personnel from Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service network expansion target:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.5.5 Sales and service network expansion
and feedback&nbsp;requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B shall build facilities in the territory
according to the sales and service network requirements. There shall be proper JAC logo, showroom for JAC products, and operation teams
in every sales and service network. In order to promote brand image of Party A and Party B and to increase sales volume, party B shall
build [***] facility according to the standard of Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please refer to Appendix 3 for details of sales target, brand image stores
planning and development of sales outlets. Please refer to <FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;</FONT>JAC
international image facility construction standard<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT>&nbsp;Party
B shall, as required by Party A, timely feedback the details of the sales and service outlets of the direct operation and the second
network on a quarterly basis. For detailed standards, please refer to JAC Dealer Network Archives Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.6 Payment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.6.1 Settlement currency </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All products shall be settled in ____USD_____
Money shall be remitted to the bank account designated by Party A. Details will be as per the sales contract agreed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.6.2 Method of Payment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.6.2.1</B> All payment shall be transferred
by [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]. Production and delivery arrangement shall
be governed by sales contract signed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.6.2.2</B> Other method of payment shall be
discussed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.6.2.3</B> Both parties agree that the ownership
of the designated products that have been delivered shall remain with Party A until Party A receives full payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.7 Production and Delivery <FONT STYLE="font-family: Times New Roman, Times, Serif">&#29983;&#20135;&#21644;&#21457;&#36135;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A is responsible for organizing and providing
supply chain plan design and procurement services before and during production to meet order needs. <FONT STYLE="font-size: 10pt">Production
and delivery condition shall be referred to the Sales Contract signed by both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.7.1</B> Payment Scheme A: [***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment Scheme B: [***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.7.2 </B>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. Rights and duties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.1 Rights of Party A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.1.1</B> Party A has the right to enquire
into the operations of Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.1.2</B> Party A has the right to survey and
inspect the operation of Party B, including its sales and service network in the Territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.1.3</B> Party A shall have the right to inspect
and evaluate the actual implementation of sales and service rules/requirement which are issued by Party A and confirmed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.1.4</B> Party A has the right to survey,
inspect and evaluate the implementation of other duties or obligations of Party B mentioned in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.1.5</B> Party A reserves the right to choose
another distributor in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.2 Duties of Party A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.2.1 Products supply</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.2.1.1</B> Party A shall provide Party B at
the prescribed time with Products and related spare parts as mentioned in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.2.2 Information support</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A shall provide information/answers to questions
reasonably raised by Party B, and shall deal with and make feedback to the information, report and claim needed by Party B to enable Party
B to distribute the Products more efficiently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.2.3 Training and technical support</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A will work out study plan and training
material, organize and perform training programs under the request of the Party B for Party B&rsquo;s employees, and evaluate the knowledge
and skills level of the trainees. The form of training will be discussed by both parties and the related expenses associated with the
training shall be discussed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.2.4 Brand Promotion Support </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A shall have the obligation to provide Party
B with the promotion material and basic material for products and brand promotion, and the material list shall be discussed and determined
by both parties, related expenses incurred shall be borne by Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.3 Rights of Party B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.3.1 Right of Distribution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.3.2 Right to use trademark</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B has and only has the right to use Party
A&rsquo;s trademark to promote, identify, distribute Party A&rsquo;s products and provide after-sales service for Party A&rsquo;s products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4 Duties of Party B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.1 To build an operation team </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>a</B> : [***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>b</B>: At the time of signing this agreement,
Party B shall provide the complete organizational structure chart of its team and the profile of the general manager, brand manager, sales
manager, service manager, spare parts manager and other core management team members, as well as the corresponding personnel recruitment
plan, so as to ensure that it has an independent, professional and complete team to distribute Party A&rsquo;s products; if cannot be provided
before signing, all charts, profile and recruitment plans shall be provided within one month after signing this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>c</B>: In case of any change in the members of Party B&rsquo;s core management team and its staff, Party B shall notify Party A in written
form in advance within 1 week;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B&rsquo;s organizational structure chart and profile of core management team members shall be revert to Party A in accordance with Appendix
5 &ldquo;JAC international distributor organizational structure chart and profile of core management team&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.2 Sales and service network development
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B shall develop sales and service network
according to the quantity, the date, and the standard specified in clause 2.5.3, 2.5.4, and 2.5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.4.3</B></FONT>
The Party B agrees that in the territory specifically reserved by the Party A for itself or allocated by the Party A to other exclusive
distributors or buyers, the Party B will not engage in proactive product promotion activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.4 Forbid to sell competing products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.4.</B> [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.4.2 </B>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.5 Annual business plan <FONT STYLE="font-family: Times New Roman, Times, Serif">&#24180;&#24230;&#21830;&#19994;&#35745;&#21010;&#20070;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In every December, both parties shall set up annual
business plan of the next year, according to the market situation and requirements of annual target in this Agreement, and make corresponding
&ldquo;Annual Business Plan&rdquo;; Please refer to Appendix 4 for business plan of the first year. Party B shall work and meet the requirements
on time according to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.6 After sales service <FONT STYLE="font-family: Times New Roman, Times, Serif">&#21806;&#21518;&#26381;&#21153;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.6.1 Service <FONT STYLE="font-family: Times New Roman, Times, Serif">&#20135;&#21697;&#26381;&#21153;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B shall provide after-sales service of Products
in the Territory by the standard that is no lower than the requirement of the local regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.6.2 Spare parts <FONT STYLE="font-family: Times New Roman, Times, Serif">&#38646;&#37197;&#20214;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To guarantee the efficiency and quality of after sales service, Party
B shall purchase the first batch of genuine parts from Party A prior to the launch of the products and replenish the inventory in a timely
manner during subsequent sales, and Party B shall not use spare parts which are not provided by Party A to perform service to the Products
from Party A. Any product problem/liability aroused from the use of spare parts from any party rather than Party A, Party B shall bear
the full responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.6.3 Related Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The service work by Party B shall be performed
in Territory in accordance with the &ldquo;After-sales Service Agreement&rdquo; and the &ldquo;Spare Parts Distribution Agreement&rdquo;
after being signed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.7 Brand promotion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.7.1</B> Party B shall actively carry out
the advertising and promotional activities for the Products, and the brand promotion philosophy should be in conformity with Party A&rsquo;s
promotion philosophy of JAC brand and JAC products. Party B should promote and operate according to the VI Guidance Manual provided by
Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.7.2</B> In case of large scale advertising
and promotional activities, Party B should inform Party A of the plan and support needed at least 3 month in advance, to facilitate Party
A&rsquo;s corresponding support work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.4.8 Inform</B></FONT><B>ation
feedback and compliance guarantee <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#20449;&#24687;&#21453;&#39304;&#21450;&#21512;&#35268;&#24615;&#20445;&#35777;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.8.1</B> Party B should provide explanation
and feedback in one week to reasonable questions raised by Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.8.2</B> Party B shall develop information
platform, regularly pay visits to customers and specially assign person to maintain customer relationship, make records and keep on file;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.8.3 </B>[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.8.4</B> [***]<FONT STYLE="font-family: Times New Roman, Times, Serif">&#12290;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="border-right: white 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.8.5 </B>The
Party B shall collect and transmit relevant information with the consent of the information subject and comply with the relevant information
protection regulations in the region. If there are any exceptions, the Party B shall notify the Party A in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-right: white 0.5pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.8.6 Compliance with Territory laws </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) In order to enable Party A to develop, design
and manufacture the Products in conformity with all applicable provisions of any Laws in the Territory, Party B shall make its best efforts
to provide Party A, at Party A&rsquo;s request, with information and/or data concerning such laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) Party B shall be prudent and diligent to keep
Party A timely informed of the following information: (1) laws and regulations applicable to the Territory and the Products (such as import
regulations and management, labeling, technical specifications, safety requirements, filing and registration, etc.), and (2) as long as
it is relevant to Party A and may affect Party A.If any applicable legal requirements or policies require any change or modification to
the products, the distribution relationship and matters affecting the cooperation between the Parties in the Territory, Party B shall
promptly inform Party A of such change or modification in writing, to make sure that the relevant acts and decisions of Party A not violate
the mandatory legal requirements in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c) On the basis of current production standard
of Party A&rsquo;s Products of Agreement , Party B, with professional evaluation and confirmation and on its own risk, intends to guarantee
Agreement Products accord with laws, statutes and regulations of relevant institutions or departments of country, government of the Sales
Territory in admission, authentication, technology, environment, security and other stipulations in the Sales Territory; guarantees the
sales activities of Agreement Products accord with laws, statutes and regulations in the Sales Territory. Otherwise, Party B&rsquo;s behaviors
constitute a material breach of agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.8.7 </B>[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9 IPR protection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9.1 </B>&ldquo;Intellectual Property Right&rdquo;
(IPR) shall be protected in the distribution territory, and the title for IPR belongs to Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9.2</B> Without Party A&rsquo;s written
permission, Party B shall not register within the Territory, or behavior unreasonably to a fact which may impose an impediment for Party
A to register the trademarks, trade names, company names and other similar unique logo of Party A for brand identification. Meanwhile
Party B shall have the obligation to supervise any legal entity or natural persons within the Territory market on similar activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9.3</B> During the legal authorization
of the right to use trademark of Party A&rsquo;s Products, Party B put on a record of the sub dealership to Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9.4 </B>Party B should use the trademarks,
trade names and other unique logo of Party A according to the &ldquo;JAC International VI Guidance Manual&rdquo;. In case of improper
use by sub dealers, Party B has the obligation to make the sub dealers to make corrections immediately and remove negative effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9.5 </B>Party B has the responsibility
to protect the trademark of Party A&rsquo;s products from infringement by any third party in the territory. Before signing this agreement, if
Party A&rsquo;s trademark has been registered by other third parties in the territory without Party A&rsquo;s consent, Party B has the obligation
to assist Party A in safeguarding Party A&rsquo;s trademark rights and interests through legal channels and measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case of infringement of Party A&rsquo;s trademarks,
trade names or logos by any third party, Party B shall notice Party A immediately and assist Party A to remove negative effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9.6</B> Without Party A&rsquo;s written
permission, Party B can only use Party A&rsquo;s trademark on the Products, and Party B shall not use any other logo which is not agreed
by Party A on the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9.7 </B>Unless prior agreed in writing
by Party A, Party B shall not make any use of the trade name of Party A or the Party A<FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;</FONT>s
Marks in respect of domain names or other designations that are used or appear on the internet and/or on other forms of electronic and/or
digital media and communications. Otherwise, Party B<FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;</FONT>s behaviors
constitute a material breach of agreement. If Party B intends to adopt such a domain name, it shall first notify Party A, if agreed by
Party A, Party B may then register the domain name in such name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.9.8 </B>Party B acknowledges that its promotion
of the Products identified by any trademark or trade name of Party A shall not create or vest in Party B any right, title, or interest
in such trademark or trade name. Party B shall not adopt, use, or register as a trademark, trade name, business name, or corporate name
or part thereof, whether during or after the term of This Agreement, any word or symbol or combination thereof which is identical or similar
to any of Party A<FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;</FONT>s Marks or trade names without Party A&rsquo;s written
consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.10 Configuration adjustment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.10.1</B> [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.10.2</B> [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.4.11 </B></FONT><B>New
product introduction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.12 Operation situation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.13 Support to accredited personnel from
Party A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B will assist the accredited personnel from
Party A to perform related work in the market, and will give positive assistance to the visa application, transportation and accommodation
of the accredited personnel. Party B shall not for any reason restrict on the freedom of action and work of the Party A&rsquo;s personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.14 Price adjustment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.15 Assistance </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case an accident happens to the employee of
either Party at the other Party&rsquo;s location, the other Party shall take reasonable efforts for timely and necessary salvation and
assistance, for instance, rescuing the employee, assisting to arrange the necessary medical treatment, prepaying the medical expenses
in advance when necessary, assisting to handle the aftermath matters related to the accident. Under such circumstance, the Party providing
assistance shall receive necessary indemnification from the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.16 Registering notification </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before&nbsp;any&nbsp;documents&nbsp;issued&nbsp;by&nbsp;Party&nbsp;A
or joint documents from both parties or this agreement are to be submitted to the authority in the territory&nbsp;for&nbsp;registration
in any form,&nbsp;Party B must notify Party A in written form three month in advance of the preparation of local&nbsp;registration&nbsp;,&nbsp;extension
of registration&nbsp;or its&nbsp;cancellation, and it can be conducted only after being approved by Party A in written form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.4.17 Representations and Warranties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B represents and warrants to Party A that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) it is duly organised, validly existing and
in good standing under the laws of its jurisdiction of incorporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) it is duly qualified to do business and is
in good standing in its jurisdiction in which such qualification is required, except where the failure to be so qualified, in the aggregate,
would not reasonably be expected to adversely affect its ability to perform its obligations under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii) it has the full right, power and authority
to enter into this Agreement, to grant the rights and licenses granted under this Agreement and to perform its obligations under this
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv) when executed, this Agreement will constitute
its legal, valid and binding obligation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(v) Party B shall conduct its business
activities in favor of Party A and Agreement Vehicles at any time and shall not engage in any wrongdoings including but not limited
to deceptive, misleading, illegal and unethical business practices<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65307;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. Commencement and expiration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.1 Validity of Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement shall come into effect from the
date of signature (seal) by both parties, and shall remain valid until terminated in accordance with Article 4.2., and will be valid till
___Aug 31<SUP>st</SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">&#65292;</FONT>2027_. Both parties agree to meet at least
three months in advance before the end of the expiration of the Agreement to discuss the possibility of entering into a new agreement
after the expiration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case of inconsistency between the signing dates
of both parties, both parties agree that the late of signing in the future shall be the effective date of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.2 Early termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">4.2.1. During the
term of this Agreement, if Party B substantially violates its obligations under this agreement or encounters special circumstances that
give justifiable reasons for early termination of the Agreement, Party A should </FONT>give written notice of any violation and gives
Party B a realistic option to correct the violation. Party A <FONT STYLE="font-size: 10pt">may terminate this Agreement and such termination
shall take effect immediately if the party B couldn&rsquo;t finish the corrections request by Party A within six months, provided that
Party A shall notify Party B in writing through <B>email</B> that retains evidence of delivery and delivery date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2.2. During the term of this Agreement, any
failure by Party B to carry out all or part of its obligations under the Agreement resulting in such detriment to Party A as to substantially
deprive such Party A of what it is entitled to expect under the Agreement, shall be considered a substantial breach for the purpose of
Article 4.2.1. above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2.3. Both parties hereby agree that any violation
of Article 2.5.1, and/or 2.5.2, and/or 2.5.3, and/or 3.4.8.6 by Party B during the term of this Agreement shall be deemed a substantial
breach of this Agreement. Moreover, for any other obligations under this Agreement, if Party A requests Party B to fulfill such obligations
under this Agreement, but Party B repeatedly violates the obligations under this Agreement, such violation may be deemed as a substantial
violation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2.4. During the term of this agreement, if Party
A becomes aware that the control, ownership, and/or management rights of Party B&rsquo;s company have changed by more than 50% at the time of
signing this agreement, Party A may also terminate this agreement, and such termination shall take effect immediately, provided that Party
A shall notify Party B in writing by email with evidence of delivery and delivery date retained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2.5. Furthermore, the parties agree that the
following situations shall be considered as exceptional circumstances which justify the earlier termination by the other party: bankruptcy,
moratorium, receivership, liquidation, or any other circumstances which are likely to affect substantially one party&rsquo;s ability to carry
out its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.3 Consequence of Agreement Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4.3.1 </B>After the Agreement is terminated, Party B will be no
longer the distributor of Party A&rsquo;s authorized products in the Territory, and will no longer have the right to import, sell, distribute
and promote the product of Party A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.3.2 </B>After the Agreement is terminated,
Party B shall immediately stop using all the materials in relation to Party A&rsquo;s IPR under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.3.3 Handling of Inventory</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B will be responsible for handling the inventory
of Products within a reasonable period after the Agreement termination, during this period of stock handling, Party B could continue to
use the trademark, trade name and logo of Party A, however this right is only restricted to the sales of stock Products, and Party B shall
cease the use immediately after completing the sales;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.3.4 After-sales Service for Sold Vehicles</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After the Agreement is terminated, Party B shall still be obliged to
provide after-sales service for Party A<FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;</FONT>s products previously sold
by Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.4</B> After the Agreement is terminated;
in avoiding interrupting Party A&rsquo;s future distribution in the Territory, Party B shall have the obligation to revoke any recordation
files in relation to the interests of Party A with relevant local government departments within 30days unconditionally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.5 </B>After the Agreement is terminated,
both parties shall clear all the transactions between their accounts within 30 days since the date of termination. Meanwhile, each Party
will be responsible for its own costs and expenses on operation incurred during the validity of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. Force Majeure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any Party is unable to perform or temporarily
unable to perform its obligation or part of obligation under this Agreement due to force majeure, the Party should be excused from the
legal responsibility; But the Party shall notify the other Party of the occurrence of the Force Majeure within one week in written. If
the Force Majeure Event lasts over 90 days, both parties shall negotiate on the impact of the event of Force Majeure and remedial measures
friendly; if no agreement can be reached through negotiation, either party shall have the right to notify the other party in advance in
writing to terminate this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6. Settlement of disputes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any dispute, conflict or claim, including effectiveness,
invalidity, breach and termination of this Agreement, which arises from or in connection with this Agreement, shall be settled by both
Parties amicably through consultation. If both Parties fail to settle the above-mentioned dispute within 30 days, the dispute should be
settled by Singapore International Arbitration Center. in accordance with its rules of procedure effective on the occasion. The language
for arbitration is English. The decision of arbitrator shall be final and binding on both parties. All the expenses incurred from the
arbitration, including court filing fee and reasonable attorney fee, shall be borne by the losing party. During the arbitration procedure,
except the issues of dispute, both parties shall continuously execute the obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement and its legal force shall be governed,
construed and performed in accordance with the laws of the People&rsquo;s Republic of China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. Assignment of Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither party shall have the right to assign the
rights and obligations under this Agreement to any third party, without prior consultation by both parties to get a written agreement.
The party in breach shall take all responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8. Priority and Severability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8.1</B> If any term or provision of the Agreement
is determined to be illegal, unenforceable, or invalid in whole or in part for any reason, such provisions or part thereof shall not affect
the legality, enforceability, or validity of the remainder of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8.2</B> After the Agreement is signed, it shall
prevail over all commitment on business cooperation previously reached, whether in oral or written form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9. Other terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>9.1 </B>Both parties confirmed that in the process
of cooperation, the two parties each conduct and execute its investment and bear related expenses of the project based on its own independent
business judgment of its own behavior, both parties enjoy the benefits brought by this business practices and bear the risks by themselves.
Nothing in this Agreement is intended to or shall operate to create a partnership, joint venture or employment of any kind between the
parties, or to authorize either party to act as agent for the other, and neither party shall have authority to act in the name or on behalf
of the other in any way or to hold itself out in its advertising or otherwise in any manner which would indicate or imply any such relationship
with the other, except as expressly provided otherwise in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.2</B> When Party B purchase Products from
Party A, all details such as model, price and delivery date shall be regulated by sales contracts which need to be otherwise signed by
both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.3</B> Unmentioned matters shall be addressed
in supplementary agreement to this Agreement by both parties through consultation, and in term of any discrepancies between the supplementary
agreement and this Agreement, the supplementary agreement shall prevail; No modification of this Agreement shall be valid unless it is
in writing and signed by the parties to this Agreement; No modification of this Agreement shall be valid if made by email.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.4</B></FONT>
No failure of either party to exercise any power given to it under this Agreement or to insist upon strict compliance by the other party
with any obligation and no custom or practice of the parties at variance with the terms of this Agreement shall constitute any waiver
of any of such Party&rsquo;s rights under this Agreement. Waiver by either party of any particular default by the other Party shall not
affect or impair such party&rsquo;s rights in respect of any subsequent default of any kind by the other party nor shall any delay or
omission of either party to exercise any rights arising from any default of the other party affect or impair such party&rsquo;s rights
in respect of the said default or any other default of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.5 Confidentiality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.5.1</B> Both parties shall guarantee not
to disclose to any other person or business entity any information in relation to any content in this Agreement or information in relation
to the cooperation between both parties; Unless otherwise mandatorily required by laws or regulations, both parties shall protect the
confidentiality and exclusivity of the Confidential Information, and unless with the prior written consent of the other party, both parties
shall not, within the cooperation term or a term thereafter (as provided in Article 9.5.2 ), by any means directly or indirectly disclose,
duplicate or distribute such Confidential Information in respect of the other party to any other individual, company or entity, and neither
party shall use the aforementioned confidential information for the benefit of their own or any other individual, company or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.5.2 </B>The confidentiality obligation shall
be valid for a period of ten (10) years upon termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.6 Compliance Undertaking</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please refer to Appendix6: Letter of Compliance
Commitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.7</B> This Agreement shall be executed in
three (3) original copies, with two (2) being held by Part A and one (1) being held by Part B with the same legal force. The appendixes
hereto are made an integral and inseparable part of the this Agreement, and Party A reserves the right to adjust part of the appendixes
in content if necessary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.8</B> The Agreement is written in Chinese
and English, and the both versions have the equal legal effect.In case of any discrepancies between the two languages, the English version
should prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.9 </B>In order to avoid ambiguity, about
the following provisions shall remain effective after termination or expiration of This Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) <FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;</FONT>Use
of Trademarks and Intellectual Property<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) <FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;</FONT>Confidentiality<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii) <FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;</FONT>Governing
Law and Dispute Resolution<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv) <FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;</FONT>Address
and contact information<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.10 It is hereby agreed between the parties to
this agreement that, neither party shall arbitrarily use the off set right to offset assets belonging to the other party. If both parties
are willing to exercise, a written document should be signed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10. Address and contact information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within the validity of This Agreement, emails
between authorized employees of the Parties are deemed as written documents; such notices, sent by emails and received with the other
Party<FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;</FONT>s reply, have the same validity as post.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#26412;&#21327;&#35758;&#26377;&#25928;&#26399;&#20869;&#65292;&#21452;&#26041;&#20154;&#21592;&#20043;&#38388;&#24448;&#26469;&#30340;&#30005;&#23376;&#37038;&#20214;&#35270;&#20026;&#20070;&#38754;&#25991;&#20214;&#65292;&#36890;&#36807;&#30005;&#23376;&#37038;&#20214;&#21457;&#20986;&#24182;&#24471;&#21040;&#23545;&#26041;&#22238;&#22797;&#30830;&#35748;&#30340;&#36890;&#30693;&#19982;&#37038;&#23492;&#24418;&#24335;&#30340;&#36890;&#30693;&#20855;&#26377;&#21516;&#31561;&#25928;&#21147;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%">Party A&#65306;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%">Party B&#65306;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD.</TD>
    <TD>&nbsp;</TD>
    <TD>Company&#65306; <U>AUTOMAX LEASING LTD.</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>No. 176, Dongliu Road, Hefei, China</TD>
    <TD>&nbsp;</TD>
    <TD>Address&#65306;<U>15th Harechavim st., Jerusalem, Israel</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Postcode&#65306;230022</TD>
    <TD>&nbsp;</TD>
    <TD>Postcode&#65306; <U>9346213</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Tel&#65306;[***]</TD>
    <TD>&nbsp;</TD>
    <TD>Tel&#65306;_______ [***]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>E-mail:&#65306;[***]</TD>
    <TD>&nbsp;</TD>
    <TD>E-mail&#65306;__________ [***]</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>11. Execution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-style: normal; font-weight: normal">ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD.</FONT></TD>
    <TD><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold"><FONT STYLE="font-style: normal; font-weight: normal"><U>AUTO MAX LEASING
    LTD.</U></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><B>Company</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: normal; font-weight: normal; width: 45%"><FONT STYLE="font-style: normal; font-weight: normal">Representative</FONT>&#65306;____
    [***]</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="font-style: normal; font-weight: normal; width: 5%"><FONT STYLE="font-style: normal; font-weight: normal">Representative&#65306;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; width: 40%">/s/ TOMER LEVY</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: normal; font-weight: normal"><FONT STYLE="font-style: normal; font-weight: normal">Title</FONT>&#65306;__[***]</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal"><FONT STYLE="font-style: normal; font-weight: normal">Title</FONT>&#65306;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">General manager</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Date &#65306; <U>September 15<SUP>th</SUP> 2024</U></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Date &#65306; <U>September 15<SUP>th</SUP> 2024</U></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex10-6_001.jpg" ALT="" STYLE="width: 156px; height: 32px"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>APPENDIX </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APPENDIX 1<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>The
Business License of Party B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APPENDIX 2<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>Products
List</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APPENDIX 3<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>JAC
International Distributor Business Plan JAC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APPENDIX4<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>JAC
international distributor organizational structure chart and profile of core management team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APPENDIX 5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>Letter
of Compliance Commitment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 90%; layout-grid-mode: char; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JAC INTERNATIONAL</FONT></TD><TD STYLE="width: 10%; layout-grid-mode: char; font-size: 10pt; text-align: center">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="text-align: center; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.jac.com.cn</FONT></TD><TD STYLE="text-align: right; layout-grid-mode: char; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> / 14</TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>4
<FILENAME>ea023082101ex10-7_scisparc.htm
<DESCRIPTION>FOUNDERS' AGREEMENT BY AND BETWEEN AUTOMAX MOTORS LTD. AND DALHOM MOTORS LTD., DATED JUNE 16, 2022. (TRANSLATED FROM HEBREW)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 10.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Certain identified information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii)
is the type that the Company treats as private or confidential. &ldquo;[***]&rdquo; indicates where the information has been omitted from
this exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>TRANSLATED FROM
HEBREW <FONT STYLE="font-size: 10pt">FOR CONVENIENCE PURPOSES ONLY</FONT></B></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Founders&rsquo;
Agreement</FONT></P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>That was made
and signed in Tel Aviv on June 16, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Between:</B></FONT></TD>
    <TD STYLE="width: 80%; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Automax Motors Ltd., public company 513795427</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Of 15 Harechavim Street, Jerusalem</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">(Hereinafter: <B>&lsquo;Automax&rsquo;</B>)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; direction: ltr; unicode-bidi: embed"></TD>
    <TD STYLE="text-align: right; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B><U>Of the first part</U>;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>And:</B></FONT></TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Dalhom Motors Ltd., private company 514256783</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Of 1 Hahistadrut Boulevard, Haifa</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">(hereinafter: <B>&lsquo;Dalhom&rsquo;</B>)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; direction: ltr; unicode-bidi: embed"></TD>
    <TD STYLE="text-align: right; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B><U>Of the second part</U>;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>And:</B></FONT></TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Dalhom Automotive Ltd., private company 516610623</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Of 15 Harechavim Street, Jerusalem</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">(Hereinafter: <B>&lsquo;the company&rsquo;</B>)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; direction: ltr; unicode-bidi: embed"></TD>
    <TD STYLE="text-align: right; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B><U>Of the third part</U>;</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">(Automax and Dalhom jointly hereinafter: <B>&lsquo;the founders&rsquo;</B> or <B>&lsquo;the shareholders&rsquo;;</B> Automax, Dalhom and the company jointly hereafter: <B>&lsquo;the parties&rsquo;</B>)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Whereas</B></FONT></TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Automax is an indirect importer of various car brands into Israel;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>and whereas</B></FONT></TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Dalhom is, <I>inter alia</I>, the owner of a concession to import and market in Israel buses manufactured by Temsa (hereinafter: <B>&lsquo;the concession&rsquo;</B> and <B>&lsquo;Temsa,&rsquo; </B>respectively);</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>and whereas</B></FONT></TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">the parties are interested in setting up a joint venture that will operate through the company and will do business, <I>inter alia</I>, in the import and marketing in Israel of buses of the Temsa brand and other passenger vehicles;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>and whereas</B></FONT></TD>
    <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">the parties are interested in arranging the ownership, control, management and method of operation of the company as stated in this agreement;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Wherefore, the parties have declared, stipulated
and agreed as follows</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify; padding-right: 0.3in"><B><U>Preamble</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">The preamble to the agreement, its annexes and the declarations of the parties constitute an integral
part hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">The division of this agreement into sections and subsections and determining the titles that appear in
it were done for reasons of convenience only, and no use should be made of them for interpreting it.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B><U>The founding of the company, its capital and the holdings of the shareholders</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">Before the date of this agreement, Automax founded the company, and as of the date of this agreement,
it is the holder of 100 ordinary shares with a par value of NIS 0.1 each, which constitute the entire issued share capital of the company.
The Articles of the company that are in force on the date of this agreement are attached to this agreement as <B><U>Annex 2.1</U></B>
(hereinafter: <B>&lsquo;the current Articles&rsquo;</B>). From the date of its founding until the date of this agreement, the company
has not carried out any business operations nor has it taken upon itself any undertaking.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">On the completion date (as defined below), the company will adopt a special resolution, according to which
the Articles attached to this agreement as <B><U>Annex 2.2</U></B> (hereinafter: <B>&lsquo;the new Articles&rsquo;</B>) will be adopted
instead of the current Articles. If an express or implied conflict will be found between the provisions of this agreement and/or any amendment
and/or addition hereto and the provisions of the new Articles, as they will be in force from time to time, the provisions of this agreement,
which will prevail over any provision of the new Articles, will bind the shareholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify">According to the new Articles, the share capital of the company will be comprised of two classes of shares,
as follows: (a) ordinary shares, with a par value of NIS 0.1 each, which grant the holder thereof rights to dividends and a right to participate
in any other distribution that will be made by the company, including at the time of its liquidation (hereinafter: <B>&lsquo;ordinary
shares&rsquo;</B>) but do not grant voting rights or a right to be invited to the general meetings of the company and/or participate in
them; and (b) management shares, with a par value of NIS 0.1 each, which grant a right to appoint one director for each management share
and to participate and vote at a general meeting of the shareholders of the company (hereinafter: <B>&lsquo;management shares&rsquo;</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify">On the completion date, the company will issue to Dalhom 100 ordinary shares so that after the issuance,
each of the shareholders will hold an identical number of ordinary shares of the company. Moreover, on the completion date, the company
will issue two management shares to Automax and one management share to Dalhom.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.5</TD><TD STYLE="text-align: justify">On the date on which Automax&rsquo;s loans (as defined below) will be returned to Automax in full, or
on the date when a bank guarantee will be given to Automax for the balance of Dalhom&rsquo;s loan, as stated in section 3.2.2 below (whichever
is the earlier), the company will issue to Dalhom an additional management share, so that the number of management shares that will be
held by Automax and Dalhom will be identical, and Dalhom will be entitled to all the rights by virtue of this share, including the right
to appoint an additional director on its behalf to the Board of Directors of the company. Alternatively, with the consent of the parties,
the management shares will be canceled and all the rights attached to them will be attached to the ordinary shares. Nothing stated in
this section will derogate from Automax&rsquo;s right to a full reimbursement of Automax&rsquo;s loans or to receive the initial reimbursement
to Automax, as these terms are defined below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.6</TD><TD STYLE="text-align: justify">The registered office of the company will be at 15 Harechavim Street, Jerusalem, or anywhere else that
will be agreed upon by the founders with mutual consent between them.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.7</TD><TD STYLE="text-align: justify">The parties will pay the expenses of registering and founding the company in equal shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B><U>The transaction</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify"><B><U>Automax&rsquo;s loans</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.1.1</TD><TD STYLE="text-align: justify">Starting from the completion date, Automax will advance to the company shareholders&rsquo; loans in a
total sum of NIS 10 million (hereinbefore and hereinafter: <B>&lsquo;Automax&rsquo;s loans&rsquo;</B>), on dates that will allow the company
to comply with its undertakings to Dalhom under section 3.3 below, according to a loan agreement in the form attached as <B><U>Annex 3.1.1</U></B>
of this agreement. Automax&rsquo;s loans will bear identical interest (back to back) to the interest at which Automax will raise the aforesaid
amount from its sources of finance, but in any case, the interest will not exceed 5.9% per annum (hereinafter: <B>&lsquo;the interest&rsquo;</B>).
The interest will be calculated from the date of actually advancing each part of Automax&rsquo;s loans until the repayment of that part
or until it becomes permanent capital of the company (according to the FIFO method &ndash; first in, first out). Automax&rsquo;s loans
will be advanced to the company to pay the amount of the value of the inventory, the conditional prepayment for the concession and Dalhom&rsquo;s
loan (as these terms are defined below), on the dates and terms stated in section 3.3 below. Notwithstanding the aforesaid and subject
to the provisions of section 3.3.2.4, Automax&rsquo;s loans for the amount of the conditional prepayment as stated in section 3.3.2 below
will not bear interest.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.1.2</TD><TD STYLE="text-align: justify">Automax&rsquo;s loans, plus the interest, will be returned no later than six years after the completion
date or will be converted into permanent capital of the company as stated in this agreement. Any amount that the company will transfer
to Automax by way of management fees or anything similar, without transferring an identical amount to Dalhom, or without offsetting Dalhom&rsquo;s
loan by an identical amount, will be regarded as an amount that was paid to Dalhom on account of the repayment of Automax&rsquo;s loan
and an identical amount out of Automax&rsquo;s loan will become permanent capital of the company. Notwithstanding the aforesaid, any payment
that the company will make to Automax, Dalhom, any of the officers in them or anyone acting on their behalf, for specific services regarding
which Automax and Dalhom agreed in advance, will not be subject to the aforesaid arrangement, and this payment will not be regarded as
being made on account of the repayment of Automax&rsquo;s loans or as an increase of Dalhom&rsquo;s loan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.1.3</TD><TD STYLE="text-align: justify">It is agreed that the rights in the permanent capital of the company at the time of its liquidation will
belong to Dalhom and Automax, according to the amount of their share in the ordinary share capital of the company on the date of the liquidation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify"><B><U>Initial repayment to Automax</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.2.1</TD><TD STYLE="text-align: justify">It is agreed by the parties that Automax will be entitled to receive first from the company&rsquo;s profits
or its other resources, before any payment in cash to the other shareholders of the company that the founders did not expressly agree
upon, a sum equal to Automax&rsquo;s loans that were actually advanced, plus the interest that will accrue on Automax&rsquo;s loans, which
will be paid to it by way of a distribution of profits or a repayment of Automax&rsquo;s loans as stated in this section below or in any
other way that will be agreed between Automax and the company (hereinbefore and hereinafter: <B>&lsquo;the initial repayment to Automax&rsquo;</B>).
Accordingly, as long as the initial repayment to Automax has not been paid to Automax in full, every dividend that Dalhom will receive
from the company (which in any case will not be paid to Dalhom in cash) will be returned immediately to the company as a repayment of
Dalhom&rsquo;s loan, and this sum will be used to pay the initial repayment to Automax. The payments for the initial repayment to Automax
will be made in the following manner: (a) the payments will be made on a quarterly basis, within seven days of the date of submission
to the company of the company&rsquo;s reviewed financial statements in each calendar quarter or the audited annual financial statements,
as applicable (hereinafter: <B>&lsquo;the financial statements&rsquo;</B>); (b) insofar as the company will be entitled under the law
to distribute a dividend according to the financial statements, and there will be no other impediment to such a distribution because an
undertaking of the company to any third party, all of the profits that are distributable will first be distributed in the manner determined
in this section above; (c) if on the aforesaid date, the company will not be entitled to distribute a dividend according to law and it
will not be prevented from doing so as stated in subsection (b) above, the company will repay Automax&rsquo;s loan in an amount equal
to the difference between the amount of the net profit of the company in the relevant financial statements and the amount of the dividend
that was actually distributed on the basis of the aforesaid statements. Moreover, as long as Automax did not receive from the company
the full initial repayment to Automax, the company will not pay Dalhom, and Dalhom will not receive from the company, any amount in cash,
except for payments as stated in section 3.3 below and payments for specific services as stated in section 3.1.2 above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.2.2</TD><TD STYLE="text-align: justify">At any time, as long as Automax has not received the full repayment of Automax&rsquo;s loans, Dalhom will
be entitled to advance to the company and/or Automax, as joint and several beneficiaries, an autonomous bank guarantee in an amount equal
to the balance of Dalhom&rsquo;s loan plus the interest that has accrued on it up to the date of the delivery of the guarantee as aforesaid
(hereinafter: <B>&lsquo;the bank guarantee&rsquo;</B>), which shall be in force until the repayment date of Dalhom&rsquo;s actual loan.
The bank guarantee will be delivered to Automax and will also be used as collateral for securing the initial repayment to Automax. Upon
the delivery of the aforesaid guarantee to Automax, (a) an additional management share will be issued to Dalhom and the provisions of
section 2.4 above will apply and (b) Dalhom&rsquo;s loan will stop bearing interest.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify"><B><U>Payments to Dalhom</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Subject to the completion of the transaction,
the company will transfer to Dalhom a cumulative sum of NIS 10 million according to the following details and on the following terms and
dates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.3.1</TD><TD STYLE="text-align: justify"><U>The inventory</U>: On the completion date, Dalhom will sell to the company, and the company will buy
from Dalhom, all of the inventory of Temsa spare parts that will be in its possession on that date, according to an inventory check that
will be made jointly by the representatives of Dalhom and Automax, at the cost price of the inventory in Dalhom&rsquo;s books, including
the cost of taxes (without VAT) and the cost of shipping to the place of storing the inventory (hereinafter: <B>&lsquo;the inventory</B>&rsquo;
and <B>&lsquo;the amount of the value of the inventory&rsquo;</B>). The company will pay Dalhom the amount of the value of the inventory
plus VAT in cash. In return for the payment, Dalhom will issue to the company a tax invoice according to law. On the date of the sale
of the inventory, the company will convert an amount identical to the amount of the value of the inventory, before VAT, into permanent
capital out of Automax&rsquo;s loans.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.3.2</TD><TD STYLE="text-align: justify"><U>Conditional prepayment</U>:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.2.1</TD><TD STYLE="text-align: justify">On the completion date, the company will pay Dalhom in cash a sum equal to the difference between NIS
5 million and the amount of the value of the inventory without VAT, as a conditional prepayment for the transfer of the concession to
the company (hereinafter: <B>&lsquo;the conditional prepayment for the concession&rsquo;</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.2.2</TD><TD STYLE="text-align: justify">Insofar as the concession will be valid after three years have passed from the completion date, a sum
of NIS 2 million out of the conditional prepayment for the concession will be converted into a payment for Dalhom&rsquo;s concession.
On this date, a sum of NIS 2 million out of the balance of Automax&rsquo;s loan, plus interest that will accrue on it, will become a permanent
capital note.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.2.3</TD><TD STYLE="text-align: justify">Insofar as the concession will be valid after six years have passed from the completion date, a sum that
is equal to an additional three million shekels, less the amount of the value of the inventory, out of the conditional prepayment for
the concession, will be converted into a payment for the concession to Dalhom. On this date, an amount of Automax&rsquo;s loans that is
equal to the aforesaid amount, plus the interest that has accrued on it, will become a permanent capital note.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.2.4</TD><TD STYLE="text-align: justify">Subject to the aforesaid, if the concession will be granted to the company for a period shorter than six
years (cumulatively) from the completion date, the balance of the conditional prepayment for the concession will become a loan of the
company to Dalhom, will bear annual interest at a rate of 5.9% from the completion date until the repayment date, and Dalhom will repay
it to the company within six years of the completion date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.2.5</TD><TD STYLE="text-align: justify">It should be emphasized that insofar as the conditions stated in sections 3.3.2.2 and 3.3.2.3 above will
be fulfilled, the conditional prepayment for the concession will become a payment to Dalhom, which will not be liable to repay this prepayment
to the company. Insofar as these payments will be liable for VAT, Dalhom will issue a tax invoice according to law to the company for
the amount of these payments plus VAT according to law, and the amount of the VAT will be paid to Dalhom by the company in cash.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.3.3</TD><TD STYLE="text-align: justify"><U>Dalhom&rsquo;s loan</U>:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.3.1</TD><TD STYLE="text-align: justify">On the completion date, the company will transfer to Dalhom a loan of a sum of NIS [***] (hereinafter:
<B>&lsquo;Dalhom&rsquo;s loan&rsquo;</B>), in [***] equal monthly payments of NIS [***] each, as a loan on account of Dalhom&rsquo;s share
of the future profits of the company, in post-dated checks, for the relevant dates where the date of payment of the first postdated check
is the 30<SUP>th</SUP> day after the completion date, according to a loan agreement in the form attached as <B><U>Annex 3.3.3.1</U></B>
of this agreement. Dalhom&rsquo;s loan will be repaid to the company no later than six years after the completion date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.3.2</TD><TD STYLE="text-align: justify">Dalhom&rsquo;s loan will bear annual interest at a rate of 5.9%, from a year after the completion date
until the actual repayment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.3.4</TD><TD STYLE="text-align: justify">It is expressly agreed and declared that all the payments to Dalhom under this section 3.3 (except the
payment of VAT) will be paid as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.4.1</TD><TD STYLE="text-align: justify">[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.6in">3.3.4.2</TD><TD STYLE="text-align: justify">[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.3.5</TD><TD STYLE="text-align: justify">The payments of VAT as stated in sections 3.3.1 and 3.3.2 will be paid by the company in every case by
check to Dalhom only.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.4</TD><TD STYLE="text-align: justify"><B><U>Collateral</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">As collateral for the
repayment of Automax&rsquo;s loan, on the completion date the company will assign by way of a charge to Automax its rights vis-&agrave;-vis
Dalhom for the repayment of Dalhom&rsquo;s loans, and Dalhom will charge in favor of Automax its shares in the company (both the ordinary
shares and the management share) with a first-ranking charge, and for this purpose, Dalhom will sign a pledge and charge deed and a notice
to the Companies Registrar regarding its registration that is attached to this agreement as <B><U>Annex 3.4</U></B> of this agreement,
and the company will sign a document of assignment by way of a charge and a notice to the Companies Registrar that are attached as <B><U>Annex
3.4A</U></B>. The charges will be removed when Dalhom&rsquo;s loan and Automax&rsquo;s loan are repaid in full according to the provisions
of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.5</TD><TD STYLE="text-align: justify"><B><U>Warranty and maintenance</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Before the date of this
agreement, Dalhom sold in Israel 110 buses manufactured by Temsa, according to the list of chassis numbers attached as <B><U>Annex 3.5A</U></B>
of this agreement, and out of these, it undertook to provide maintenance and warranty services for 72 buses, according to a list of chassis
numbers attached as <B>Annex 3.5B</B> of this agreement. The provisions below will apply to the aforesaid buses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.5.1</TD><TD STYLE="text-align: justify">Insofar as during the manufacturer&rsquo;s warranty period a fault will be discovered in a bus for which
Dalhom undertook to provide maintenance and warranty services as stated above, Dalhom will be responsible for repairing it, and the company
will sue Temsa at its expense for the costs of the repair and will transfer to Dalhom the whole amount that will be received in practice
from Temsa. It is agreed that an amount that will be offset by Temsa from the amount payable to the company for a debt or any other reason
will be regarded for the purpose of this section as an amount that will be received in practice by the company from Temsa;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.5.2</TD><TD STYLE="text-align: justify">Regarding the buses for which Dalhom undertook to provide warranty and maintenance services, at Dalhom&rsquo;s
written order, the company will supply Dalhom from the inventory of spare parts in its possession, or, insofar as necessary, it will buy
spare parts for the aforesaid buses for Dalhom from Temsa. The company will supply the spare parts to Dalhom at the price of the cost
of buying them from the manufacturer plus import taxes and VAT according to law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.5.3</TD><TD STYLE="text-align: justify">For the avoidance of doubt, Dalhom will remain a party to the bus maintenance agreements that it made
before the date of this agreement and will carry out its undertakings thereunder, and the company and/or Automax will not have any liability
or undertaking in connection with these maintenance services.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.6</TD><TD STYLE="text-align: justify"><B><U>Equity for the purpose of receiving an import license</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Automax will be responsible for ensuring
that the company complies with the equity requirements in order to receive a main import license from the Ministry of Transport to import
Temsa&rsquo;s buses. Insofar as it will be necessary for this purpose that Automax&rsquo;s loans or a part of them will be converted into
a permanent capital note, this condition will take precedence over the condition of the repayment of Automax&rsquo;s loans provided in
section 3.1 above, insofar as there will be a conflict between them. It is clarified that the conversion of Automax&rsquo;s loan into
a permanent capital note as stated above will not prejudice Automax&rsquo;s right to receive from the company the complete initial repayment
to Automax, before any payment or distribution in cash to the other shareholders out of the company&rsquo;s profits or its other resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.7</TD><TD STYLE="text-align: justify"><B><U>Financing of the company&rsquo;s operations</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.7.1</TD><TD STYLE="text-align: justify">Without derogating from Automax&rsquo;s undertakings to advance Automax&rsquo;s loans, within 60 days
of the completion date, Automax will advance to the company a credit line or will ensure that a credit line will be advanced by financial
institutions, in a sum of at least NIS [***]. The company will use the credit from the credit line according to its needs, but it is agreed
that the credit line will not serve as a replacement for Automax&rsquo;s loans for the purpose of paying the amount of the value of the
inventory, the conditional prepayment for the concession and Dalhom&rsquo;s loan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.7.2</TD><TD STYLE="text-align: justify">Automax will be entitled, but not obligated, to advance an additional amount to the company or to guarantee
it will be advanced to the company, in addition to the amount of NIS [***] stated in section 3.7.1 above, subject to the condition that
any additional credit as aforesaid will be advanced to the company with Dalhom&rsquo;s consent. It is agreed that, in any case, Dalhom
will not be required to advance finance to the company and will not be required to guarantee the company&rsquo;s undertakings unless it
chose to do so.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B><U>Current management of the company; the company&rsquo;s assets in liquidation</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">The current operations of the company will be managed by the operations manager who will be chosen consensually
by Automax and Dalhom.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">Should the company be liquidated, insofar as a material asset of the company, such as the concession,
will come into the possession of any of the shareholders, directly or indirectly, the other party will have a right to share the rights
in the aforesaid asset on the same conditions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><B><U>Declarations and undertakings of the shareholders</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">Each of the parties hereby declares and undertakes that its making of this agreement and the performance
of its undertakings hereunder were approved according to the provisions of every law and its documents of incorporation, do not require
any additional approval, consent or permit of any person or entity and are not contrary to or conflict with the following: (a) its documents
of incorporation; (b) any agreement, undertaking or restriction, whether in writing or oral, to which it is a party; and (c) the provisions
of any law. This agreement constitutes a valid and lawful undertaking of each of the parties that can be enforced against it according
to its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">The persons who are signing this agreement and the documents ancillary to it on behalf of each of the
parties are the persons who are competent to sign this agreement and the ancillary agreement on its behalf and to bind that party by its
signature.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">The shareholders undertake to act honestly and faithfully in the company towards one another, to act separately
and jointly, to the best of their ability, for the best interests of the company and its success, and to devote their time, skills and
connections to the promotion of the company&rsquo;s business as needed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">The shareholders undertake to give one another correct and complete accounts, reports and information
on every matter relating to the company, including regarding commercial operations of any of the shareholders that conflict or may conflict
with the company&rsquo;s operations before entering into this agreement, which relates to the essence of this agreement, which is a subject
of cooperation between the shareholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><B><U>Dalhom&rsquo;s declarations</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Without derogating
from its declarations in section 5 above, Dalhom declares and undertakes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">The concession was acquired by Dalhom from the company Dalhom Car Glasswork and Services Ltd. (hereinafter:
<B>&lsquo;the seller&rsquo;</B>). Dalhom entered into an agreement with the seller for the purchase of its operations in a sale agreement
of October 28, 2020. The operations that were acquired included, <I>inter alia</I>, the concession that is the subject of the agreements,
and the sale agreement (with the seller&rsquo;s trustees) was approved by the court on October 10, 2020, within the framework of the seller&rsquo;s
insolvency proceedings. The full consideration for the concession was paid to the trustees. In practice, the concession was not assigned
as stated in the sale agreement, but on December 7, 2020, a new concession agreement (Authorized Dealer Agreement) was signed between
Dalhom and Temsa Skoda Sabanc&inodot; Ula&scedil;&inodot;m Ara&ccedil;lar&inodot; A.&Scedil; (hereinafter: <B>&lsquo;the current concession
agreement&rsquo;</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.2</TD><TD STYLE="text-align: justify">Dalhom is the owner of the concession by virtue of the current concession agreement, has not granted or
undertaken to grant rights in the concession to any third party and has not received payment on account of the concession as aforesaid,
and it will not do so until the completion date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.3</TD><TD STYLE="text-align: justify">[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.4</TD><TD STYLE="text-align: justify">To the best of Dalhom&rsquo;s knowledge, there are no legal proceedings pending to which Dalhom is a party
in connection with the concession. Dalhom has not received a communication from any third party whatsoever that claims that it has rights
in the concession. As of the date of this agreement, Dalhom is an active company, has not adopted a liquidation, winding-up or striking-off
resolution and is not a party to liquidation or receivership proceedings, a stay of proceedings, etc.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.5</TD><TD STYLE="text-align: justify">The representations made in this agreement do not include any information that, to the best of Dalhom&rsquo;s
knowledge, is incorrect and/or incomplete and/or imprecise. Dalhom knows that Automax is entering into this agreement, <I>inter alia</I>,
in reliance on Dalhom&rsquo;s representations that are set out in this agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.6</TD><TD STYLE="text-align: justify">Dalhom will act to ensure that the representations that were made in this agreement will be correct and
complete also on the completion date, as if they were made with respect to the completion date. If after the date of signing this agreement
there will be any change in Dalhom&rsquo;s representations that are set out in this agreement, then Dalhom will deliver to Automax, as
soon as possible after it becomes aware of the change, a written declaration regarding the change that has occurred as aforesaid (hereinafter:
<B>&lsquo;the representation update notice&rsquo;</B>). If a representation update notice will be delivered as aforesaid, or Dalhom should
have given a representation update notice as aforesaid, the parties will discuss in good faith the repercussions of the change on the
terms of the transaction, and if they do not reach agreement within ten (10) business days, Automax will be entitled to terminate this
agreement in a written notice to Dalhom, and neither party will be entitled to any right or remedy in connection with such a termination
of the agreement; if the agreement was not canceled by Automax as aforesaid, the representations included in this agreement will be regarded
as amended by what is stated in the representation update notice, without Automax being entitled to any right or remedy in connection
therewith.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><B><U>Books of account and other documents; bank account</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">The company will open a bank account, and from the date it is established onward, all the company&rsquo;s
receipts of every kind and type whatsoever will be deposited in the bank account as aforesaid and all the company&rsquo;s payments will
be made with checks that will be drawn on the aforesaid bank account. For the avoidance of doubt, it is hereby clarified that receipts
will not be deposited to the order of the company in the bank accounts of the shareholders, and that checks will not be drawn in favor
of the company and for its operations from accounts that are not its accounts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify">The company will keep its books and its set of accounts according to law, and starting on the completion
date, it will prepare quarterly and annual accounts according to International Financial Reporting Standards (IFRS), as required for the
purpose of complying with the provisions of the Securities Regulations regarding the preparation of financial statements in public companies.
Without derogating from the aforesaid, the company will deliver to Automax (a) audited annual financial statements, no later than sixty
days from the end of each calendar year; (b) reviewed quarterly financial statements no later than 30 days from the end of each calendar
quarter that has passed; any other information that is required so that Automax can comply with its obligations as a reporting corporation,
in such a manner and on such dates as will facilitate compliance as aforesaid.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><B><U>Confidentiality and intellectual property</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The provisions of
the confidentiality agreement of February 16, 2022, between Dalhom and Automax will continue to apply to the parties in connection with
any information that will be delivered by one party to the other in connection with this agreement and/or the company and its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><B><U>No circumvention</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify">Automax hereby irrevocably undertakes not to circumvent Dalhom (and from the completion date, not to circumvent
the company, directly or indirectly, in connection with the concession, not to enter into an agreement with Temsa, not to hold negotiations
with it and not to make any transaction of any kind whatsoever, directly or indirectly, with it and/or with anyone acting on its behalf,
without the cooperation and prior written consent of Dalhom and according to the provisions of this agreement. This undertaking will be
valid for [***] from the date on which the joint operations of any of the shareholders within the framework of the company ended, or from
the date on which this agreement was canceled, whichever is the later.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.2</TD><TD STYLE="text-align: justify">On the completion date, Dalhom will undertake, and it will ensure that its officers will give an identical
undertaking to Automax, not to circumvent the company and Automax in connection with the concession, directly or indirectly, not to enter
into an agreement with Temsa, not to hold negotiations with it and not to make any transaction of any kind, directly or indirectly, with
it and/or with someone acting on its behalf, except with the participation and prior written consent of Automax and the company and according
to the provisions of this agreement. This undertaking will be valid for ten years from the date on which the joint activity of the shareholders
within the framework of the company ended.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify"><B><U>Information and data</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Each shareholder in
the company will be entitled to receive from the company, within 7 (seven) days of the date of the demand, any information and data that
it will ask to receive, which belongs to the company and/or someone related to the company, including a document that is in the possession
of any of the company&rsquo;s service providers, including accountants, attorneys, consultants and any party that has some contact with
the company, including working papers of the accountants and any of the parties that are connected with the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><B><U>Conditions precedent for the performance of the agreement; cancellation of the agreement</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify">The completion of the transaction that is the subject of this agreement and its performance by the parties
is conditional, <I>inter alia</I>, on the fulfillment of the following cumulative conditions before or on the date of the completion:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">11.1.1</TD><TD STYLE="text-align: justify">Receipt of Temsa&rsquo;s consent to the transfer of the concession to the company, and the signing of
a concession agreement between Temsa and the company, with a materially identical working to the wording of the current concession agreement
and to the satisfaction of the parties to this agreement, for a period of at least three years;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">11.1.2</TD><TD STYLE="text-align: justify">Receipt of the approval of the Commissioner of Competition. If the parties do not agree otherwise, conditional
approval will not be regarded as approval for the purposes of this section;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">11.1.3</TD><TD STYLE="text-align: justify">There will be no legal impediment of any kind to the performance of the transaction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">11.1.4</TD><TD STYLE="text-align: justify">All the representations and declarations of Dalhom that are stated in sections 5 and 6 of this agreement
will be correct, complete and precise on the completion date, as if they were given on the completion date, except for changes that were
approved by the parties as stated in section 6.6 of this agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">11.1.5</TD><TD STYLE="text-align: justify">[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.2</TD><TD STYLE="text-align: justify">Each of the shareholders will be entitled to waive the fulfillment of a condition precedent that is in
its favor.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3</TD><TD STYLE="text-align: justify">If one of the conditions precedent stated above (in whole or in part) is not fulfilled within 60 days
of the date of signing this agreement, and the aforesaid date is not postponed or no waiver was given in writing by a shareholder in whose
favor that condition was determined, this agreement will be terminated upon receipt of a written notice of a shareholder regarding the
cancellation hereof and without any of the parties to the agreement having any complaint, demand or claim whatsoever in connection with
the cancellation of the agreement as aforesaid, including the negotiations that preceded it, operations that were done hereunder and/or
in connection herewith.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.4</TD><TD STYLE="text-align: justify">Notwithstanding what is stated above, a shareholder who by an act or omission brought about the non-fulfillment
of the condition precedent will not be entitled to cancel the agreement because of the non-fulfillment of the aforesaid condition.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.5</TD><TD STYLE="text-align: justify">[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify"><B><U>Completion of the transaction</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1</TD><TD STYLE="text-align: justify">The completion of the transactions that are the subject of this agreement will take place on the second
business day after the date of the fulfillment of all the conditions precedent stipulated in section 11.1 above or the waiver of their
fulfillment according to the provisions of this agreement (hereinbefore and hereinafter: <B>&lsquo;the completion date&rsquo;</B>), or
on any other date that will be agreed between the parties, at the offices of Lipa Meir &amp; Co., Advocates, at 2 Weizmann Street, Tel
Aviv.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2</TD><TD STYLE="text-align: justify">On the completion date, all the following operations will be performed:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.2.1</TD><TD STYLE="text-align: justify">Dalhom will deliver to Automax a confirmation of the correctness of its representations as of the completion
date, in the form attached as <B><U>Annex 12.2.1</U></B> of this agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.2.2</TD><TD STYLE="text-align: justify">Automax will advance to the company Automax&rsquo;s loans, <I>inter alia</I> by delivering postdated checks
in the amounts and with the dates stated in section 3.3.3.1;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.2.3</TD><TD STYLE="text-align: justify">The company will pay Dalhom, in cash, the amount of the value of the inventory and the conditional prepayment
for the concession and will deliver to Dalhom the postdated checks for Dalhom&rsquo;s loan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.2.4</TD><TD STYLE="text-align: justify">Dalhom will deliver to the company duly signed undertakings as stated in section 9.2 above;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.2.5</TD><TD STYLE="text-align: justify">Dalhom will deliver to the company a pledge and charge deed duly signed in the form attached as Annex
3.4 of this agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.2.6</TD><TD STYLE="text-align: justify">The company and Automax will sign a loan agreement in the form attached as <U>Annex 3.1.1</U> of this
agreement, and the company and Dalhom will sign a loan agreement in the form attached as <U>Annex 3.3.3.1</U> of this agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">12.2.7</TD><TD STYLE="text-align: justify">The parties will sign every document that is required to give effect to the planned operations according
to this agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.3</TD><TD STYLE="text-align: justify">All the operations that will be performed on the completion date will be regarded as performed simultaneously.
No single operation will be regarded as completed and no single document will be regarded as delivered until all the operations on that
occasion will be completed and all the documents will be delivered.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><B><U>Miscellaneous</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify">This agreement cancels and replaces any term sheet, including the term sheet between Dalhom and Automax
of April 27, 2022, memorandum, offer, discussion summary, letter of intent or understanding and any other document that was exchanged
between any of the parties to this agreement and any other (whether in writing or in orally) on the matters and subjects determined in
this agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.2</TD><TD STYLE="text-align: justify">Dalhom knows that Automax is a public company whose securities are traded on the Tel Aviv Stock Exchange
Ltd. and that the information that will be delivered to Dalhom and/or anyone acting on its behalf in connection with this agreement and
the transactions hereunder may constitute insider information, as this term is defined in the Securities Law, 5728-1968. Dalhom undertakes
to refrain from making use of insider information, including delivering the information or giving an opinion about any of Automax&rsquo;s
securities and/or carrying out transactions with Automax&rsquo;s securities, and it will make use of the information that it will receive
solely for the performance of the provisions of this agreement and sign its officers on a similar undertaking.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.3</TD><TD STYLE="text-align: justify">Except according to the provisions of this agreement, none of the parties to this agreement is entitled
to assign rights or obligations under this agreement without obtaining the prior written consent of all the other parties to this agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.4</TD><TD STYLE="text-align: justify">Any change in this agreement or a waiver of the performance of any of its terms requires a written document
with the signature of the parties. No conduct of any of the parties to this agreement will be regarded as a waiver of any of its rights
under this agreement and/or under the law, or as a waiver or consent on its part to any breach or the non-performance of a term of this
agreement by the other party or as granting a postponement or extension, or as a change, cancellation or addition of any term, unless
they were made expressly and in writing. Any waiver, discount, failure to act on time, giving of an extension, silence in a case of a
breach or noncompliance with any of the terms of this agreement, or a failure of any of the parties to exercise one or more of its rights,
and so on, will not be regarded as a waiver of any right and will not prevent a claim against that party.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.5</TD><TD STYLE="text-align: justify">In a case of a conflict between the provisions of this agreement and the provisions of any of its annexes,
the provisions of this agreement will prevail.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.6</TD><TD STYLE="text-align: justify">Income tax and/or capital gains tax and/or any other tax that will be payable, if at all, by the parties
to this agreement will be the liability of and will be paid by the party who is liable to pay it according to law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.7</TD><TD STYLE="text-align: justify">Each party will pay its expenses in connection with the transaction, including legal costs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.8</TD><TD STYLE="text-align: justify">Should any of the sections of this agreement or its implementation according to this agreement become
or be declared by a competent court to be illegal, void or unenforceable, the remainder of the agreement will remain fully valid, and
the parties agreed to replace a void or unenforceable clause as aforesaid with a valid and enforceable clause that will reflect, insofar
as possible, the original intention of the parties in the void or unenforceable section.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.9</TD><TD STYLE="text-align: justify">The provisions of this agreement will be governed by Israeli law, and the sole venue of jurisdiction for
any differences of opinion between the parties or between any of the parties and the company in connection with this agreement, including
its validity, performance, interpretation, application and any matter relating to the relationship between the parties in connection with
this agreement will be the competent courts in Tel Aviv.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.10</TD><TD STYLE="text-align: justify">A notice that will be sent by one party to another party or other parties by registered mail to the addresses
mentioned in the preamble to this agreement will serve as sufficient notice for the purpose of the provisions of this agreement and will
be deemed to have been delivered (a) within 72 (seventy-two) hours from the time of posting as aforesaid; (b) when delivered by hand,
on the first business day after it is delivered; (c) after it is sent by email or facsimile, on the first business day after receipt of
express confirmation that a notice that was sent as aforesaid was received by its addressee.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.11</TD><TD STYLE="text-align: justify">Without derogating from its undertakings under this agreement, each of the parties undertakes to sign
every document and to perform every action that needs to be signed by it or performed by it to give effect to the provisions of this agreement
and their performance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>In witness whereof, the parties have signed
below:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/ Amitay Weiss</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/ Moad Balom</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/ Tomer Levy</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: center"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Automax Motors Ltd.</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dalhom Motors Ltd.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/
  Tomer Levy</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dalhom Automotive Ltd.</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Attorney&rsquo;s certification</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I the undersigned, Yehuda Chilibo, Adv., hereby
confirm that Mr. Moad Balom, holder of ID card no. [***], signed this agreement on June 16, 2022 on behalf of the company <B>Dalhom Motors
Ltd.</B>, and that he is an authorized signatory of the company and that his signature binds the aforesaid company for all intents and
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: June 16, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature and stamp: /s/ Yehuda Chilibon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">16</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ea023082101ex23-1_scisparc.htm
<DESCRIPTION>CONSENT OF KOST, FORER, GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR SCISPARC LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the reference to our firm under
the caption &ldquo;Experts&rdquo; and to the use of our report dated April 1, 2024, in the Registration Statement (Form F-4) and related
Prospectus of SciSparc Ltd. with respect to the consolidated financial statements of SciSparc Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: left; direction: rtl; unicode-bidi: embed">/s/ <FONT STYLE="font-size: 10pt">Kost
    Forer Gabbay &amp; Kasierer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">February 13, 2025</FONT></TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Kost Forer Gabbay &amp; Kasierer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Member firm of EY Global</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>ea023082101ex23-2_scisparc.htm
<DESCRIPTION>CONSENT OF BEN DAVID SHALVI KOP & CO., INDEPENDENT REGISTERED ACCOUNTING FIRM FOR AUTOMAX MOTORS LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; direction: rtl; unicode-bidi: embed; font-size: 10pt"><IMG SRC="ex23-2_001.jpg" ALT=""></TD>
    <TD STYLE="width: 50%; text-align: right; direction: rtl; unicode-bidi: embed; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the use in this Registration
Statement on Form&nbsp;F-4&nbsp;of SciSparc of our report dated March 31, 2024 relating to the financial statements of AutoMax Motors
Ltd., which appears in this Registration Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in
such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jerusalem, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%"></TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Date: February 13, 2025</TD>
  <TD><B>By:</B></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Ben David Shalvi Kop &amp; Co.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD></TD>
  <TD>&nbsp;</TD>
  <TD>Ben David Shalvi Kop &amp; Co.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex23-2_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M/:I--<QA+)KYA,\<;16[?95,P65U9E(*@[AGX/\ ^"TG_!SG\+/^"<OQ$O\
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MW?QC\%=1^)VN1[7N-<^(&N33"23^+%K T5MM)SPT;''!8]:_-7]COXE^!O\
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MYU4OL?=$X*# S].GGBOP9_X.F?\ @E3XW^%7C6S_ ."RW[%,=]H^N:-=0/\
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M=8U3PSKUU;VUKXG\3317%]I"S2>7#J$6H1$KJ-D7RLI=I'0!BK!HVB;]A/\
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MR.%F8[0&G_= # Q1111111111111111111111111111111111101G@U\B_\
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444444444444444444444445__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L B4# 2(  A$! Q$!_\0
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MV,L.L^/I$N/#VFW*RO/'_P (UX&M1'X<T&VMY7VVDBVAO5C5#-<R2;F;YO\
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MZG[?_P#"[M8_Z)CK)^GB[P)_\OJ4?&W63_S3'6!]?%W@3GZ?\3ZOQ%7QUXH
M .L7G'?S#G^=*OCGQ2I9_P"V+W&0<"0Y[\#.<9[]>]"X5RB[34[+9^VK7?\
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MI[_^!'[8?\+MUG!(^%^M'&.GBWP*>X';7CTSFG#XV:T>1\+]:QG!/_"6>!\
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M,_$Q/.K7I?\ B_?$<>W7VI+@W*'HE4O_ -?:WY>TU-GQ%FJM>I1U_P"G%/\
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M7/"/B/5M!U2+RR+K3;VYM7E6(%4@N#!*GVFVPS!K6<O;R E7B9>*_3/X!?\
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M=I'?9@8Y'>N(OO\ @NE^S!;([^&O@[\6]?,>Y&>_G\+:"@89QD&^U%U#'[I
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M#N';'/H3[$=[_ED<+P.Q(XQGD#K[@"IX;9UVD $!MN#@_>R>]7Q;DH%;@,<
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M$CV/S?X_S_PI^2RDQC.[ 8=6/)QC@$C[M:QJ:*R>RZBLNR^Y?Y&8;5=O"DG
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MOG'!&3SZ].*B>!R<&,9'1LG/./;M6[Y6<\].N!D'_=X_+/\ 0T;!@K@ @?Q
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M%7(.1ZYY[?4_YS4ZVV02R $8SU.<]^V,^GK^-:JV^W@$'(/)'^>?3Z&IXX6
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MLDG>U^:3C9]E;=;ZLYY8:I&VVJNKW_0Y&2%N HV@]5/&2.AYYS^%5_)<A@P
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M],U+7UL_",+)>-J!#6 6[M;5IE2-%9@$/]X<6IM&@6';$H4*!"J1[1V "*H
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M,;F%YK6_U6.TM)8IXK.> &1H"JI)*F.7=T4<_P E%CKYDF:1B[;Y <KA%9@
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M%5^(7\::/X9L/BW!IFJQ^&-/LM2LKS1Y9(X(%T234=0M8([*'S[DR?:D,;K
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M2LWW/]/V+_5K^/\ Z$:*(O\ 5K^/_H1HKU#P#A/B1_R+5]_UPE_] :OX&/\
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M^&KCP^^L:+8QZMX=BM?'KW;O';:LGB#1H=4U*TAN;&.X;5-/D6TEAC^S[O\
M:)^-7PD_;Y^#GP=\+^%_"WPLL/%'PVF\2RQ_%3Q)J/Q/\066F_\ $_M;#2M;
M^(446J/X2U+3-#^UV.G:/X7D$'VZRBOKPNM\]BM+XF']F?3?VIIK+QW:>$7O
MC\ KSQEK]W\+!'H=IX;\6ZS\1!I$*^%M&\0WO]L1VFI^&G\RYM-'L[B1Y3J&
MIK9P64C/%]1C:N'Q,:-.IAJ6,BZ2Q/M'[/W7!N<$JRC!Q491UC*=I7C9'%A<
M/.C*KB)UY8"-*<\+%5JE>%[OV<^:E6G4;M2DG&JE97DN969XX/"_Q^@N;NY\
M1?!Z_P#&OAS3-%N?*^&/@S03XW\,Z5XLL=3TVST:_P!/\*MXSTO4_%VC:9H<
MLT\*6FORI=6EQ%>V6^-%B7 ^(/[*'B+X8>!_!'Q4U'QZVF:WXJ\3K9^-M+U;
MP2W@N7PQ;>)O-NK#3+6#Q#K$EE:ZQI,VG3:;+I6N7]N+,+O@N)9TM6D^P;K]
MJSX(? ^^U>XO/B/KOB!X&0:;X5O-;C\0B<Q:1:V5KJS:?X2@LY(]5%L)+6>6
M^U&*WG5?*U&UNI(5>O)OBQ\<_C=^VMX4T;PEX?\ V;+KQ-X"T?Q-I7BR;7/&
MUD-!\-^(SIVGZI8:7!K,LM]:6%QI%K%>M+"C:L7BN+2WE0[]ZOX^*QV5Z4ZF
M&CB*KC))^UC4J*$H\L::HPG.4HI*R=X)R2DVK$4L8XUI4L+CWBL1&JG[#!X3
M$8YJ7NM^UKT80HT*<M6U4JQ]V\(Q5TWX!\+/V2_B%\3M8T[QI8_$!-.N;W6[
M"6SN]+AL]9UDZ=$0+C4X(-/F<7MK.\#V$T^E3L]O'*+R"*99$ U==^ *_L[?
MM.>(O!TM]::Y%;-X:DL=>\D6^JV&G:[H-IXE3PK<16NHRVQBTJXU)HY)9--C
MOFN8B]Q=*[2V]>Y>"=,_:>N_$-W\);/Q1'\%_"?A3PW!=6_B?X4V6G2>%9KZ
M*RM+.V\(Z9-):6=\MU:VNI2P37SZE.BR6MR\(F$JL?E-O^$BTO\ :?UGP1KV
MKGQ7K/AW1]#O/$GBW5EMKSQ1K7B+6[&WO)A+K+-_:VH>']-M=EEHT=[#'#:1
MQF)#)(':O6RO$8E0H8.>$G3PU+#1KX;$5,1"M.;J59RIPQ'LU[M5)+FIRUBN
M:+2=D3C8JO4KUY*O2<G%3I2C&FI.'(ZBA0C*4X1E)J2JSERJ2Y9<VLCR_P 8
MZUX%B^)OCJ;6?@IX$\;7+>('CEU'7KWQ9%<7)BM8(//D&C>(=,A1SL#R;(]N
M<@*!@58OO$_P^:UCFC_9:^#UA#<6<EJ+V"W^(&UF!@S/;O/XT:W%_&D3;IBC
M[1/*3"V01V&GZ*VI_$S5[&X\#>*M;6Z\86FF3SV5FMNES>ZDR""+3WO1''?9
MB_TB26(/"L 9U\S9+L^FKGX$> [/X@)\/-8NGT&?QC:7OBCPK)KVM&UT6WTZ
M"X@TRZTK6KB[OY['1)XM2CN+E=3@M],L@)HH99W53$?Z$K\6^$>3X')<-'A:
MCG.*EA\$L\KX?Z^_JL:>$HRQ5>$/K]+VU;ZQ*47AZ<8)WD_=Y;/\5P?"WB_F
MM?-L1/B>IDF!4\2LAI8FK@+8JK5KSCA,+7DL+5J86E*BDU7JQJ.+Y4XNY^<F
MHZ+X"U?4;O4HO =GHL=S%%'%IFCZIJ\&G6;Q($,]O'<WEW.)IL>9.9+F5&<E
MD5 =M6(/"?AN[T^ZTNT\-V FO$LHH;R6+4[W5+=[:Z>X(MKEM0CC+:@'^QW8
M:%UDM%2*)$<%S^L@_P""='Q*M[J_U?7%\&^$OAM;VD.H:;XLTW7-%\5ZQJEG
M%^_N]8@L[35!9P:!:>5)!?W-U-'),,O:PR0"69>*D_9*TO6O%&J^&=!\3>'O
M$-UX!BL-3UJW-[)'XBTYM5G2TTS6%\-Z2T?]M65M?2VEXPTW5K@1Z!<F\MY7
MN&:).:OXB^$+>*A@?#BIBE1P\JN&K8BIB<'2JUFXJE"M!YABL11C)2?,U3FU
MRNRY'=7A_#3QA_V.68^(V%P;Q&*5*O0P\Z.,K48)3E4G1G_9N%H5G%P5DZE.
M-IZM25G^=.M?#W2X]6DU"7PAI_AEI8X(_P"QM.TG4=.TB#[/;Q6\C6]@VJLT
M;7!B-W.WFA9+R>:55"E5J_JG@+PY-+;>*[CPU!86GB.274[*UTJTU:TT.-/,
M6-X-/M&UDI#9J8V$2HQ1O,=L_-7Z[1?LV>,;KP)K&F_&ZQTSP)XVNO$5YX%\
M.ZU;7=EKN@6\MYIM[+9>.=(L[>YDO+WP0$M'::]W/%I&H*EMJDMHKM'$?"?]
MB_4M=_8^^"GB7Q=X>TNX\<>'/#%SI?B*30K^*[U;3X-*N+ZWO9O$T-K=S">-
M+%+>_6X2!XX9I8$F>%@@;KP_B#X7NIP=BX\$X'"TZ^8XG!\8X>2QF,E@<))R
MH8"M@*CJJ-2'MKX^LXT9M86E4I.49U87XL5X=>+D(\<8)<<U<5B,)E6&Q_ ]
M7#U\%@X9MC8J.*QU+,:4*7N3ITW' 4+U4GBJE.JH3A"HE^45K'X2LA>V2^!/
M!36FK:>MC>33^%FEO[8&X2Y>?3+N35#)9WD[ 1W-S"P:2 &-L@L3JQ>%?!MK
M86T=EX8LY/(6:6(W.C3W"AY]\N)))=5DDD)9]J_,P2-%B7$:!:^@O%W@70?"
M6K:BJ:+K'B.ST68QWVJ^&UAUO2=/1[<W,$MU+:;ID\Z,,H1;=BK %"Z'<;%F
M=)BM[&2>RTV'3-:CEGT:[&I&/S=/A#J99S<:>J&YEEQ'':)LGB;*2Q[72<_H
M^(XH\ G6I+#9+D2C)SE?ZEF+CRQ:TDY6<$U*R4HWMRO=Z?DU/AGZ1ZPU6KB<
MPSNE*DXQFO[3RQU9NJVVH07\174(RDIZ<LG;<^/_ !%H?A'6;H7]QX*T-M02
MSM+%C8Z+/I,!AL+9;2%C;:;JT5N]Q,BB2\NS&9[V9GEN'<G R])LM-T>#Q%!
MIG@;P<]OXET9M"U.'6/"\6L/#;EXY$NM%N=4O;FYT;4E:-$74M,EM+I%#(K;
M&=3[5XI\:?"K0=3FTUKR_E6-HO-DATB6YMEEEB%RR)?6\DD#/%"&DDB!$@"-
MB,C87Y.\^*?P(LQ'+/XHNK3[19B]3=H&KY>VD/[IXP;4[F8_(%ZJS(7VAE-?
M88;&^ .)I1MD_#$?@;<JCIO:]^6I5A*SZIJZ>CN[GQ&(J?2+P-6M&W$E1N4X
MJ5.KBYJ*TNY.C1G1;;:M*,H0DHWA)Q:MXW;^!_"=NTIN? OAW!4%F>&[?RPH
M'$;2ZH^T,,@A<!A]X[@#72>$? GA#Q'XFTCPM#X+T"+3+"V\1^(HIX;>\M+^
M"^2RLXQ*VHV%Y%>7<!9(R-/N)WM%Q*\*PR2R.777Q0^$FL69OM#\275[;M/'
M;.6T+5(UAN)8PZVL@^RG;/G V!FW,55-SLJMT_PC\9^&;KQO<-I.J733VNDW
MT<\8L-4TYO*N#;(Z;KN"W\X*VT>4&7<_485J\3CVOX/2X+S^EP]E7"U/-YX-
MK U<-B%+&TZLJE&#]A'VCM-PY[VYG:R2O=GTG &*\9*G&F1_ZT3XL662Q*CC
M:.(CBXY;.ERS?-B*DVJ<$I1BTZB2FUR)7>OL>M_!7P#XS;7KRY7Q/;::?#OA
M^RU?11JFFZ;I;6^@6\NFI=:/%I^FVMW::EJDES]IU:Z:XN'NGC@9QM1@W&:5
M\(?AO:>,+7Q!>>#O$\MO80Z?<6FJR^.;FRU:UO=$6TM]!.CP:1#I<%O;6%O:
M1W5S>W27&HW&H9F$^UR1[7IGB:ULVOR(89EU!XX+J*[(>.6U69)%MI+<R&-8
M@Z"5W4+*6PK/M45I6<FDW,(58+62%2V+96B>!7E#EE\\DW:J%(PN\E Q8# R
M/XU]A3C9<DI1225W-[WU3?-OK_F?V'5JU.;FY[NHE.222M)VOHGILOFMCA9M
M:^,*>/9]>'[3/[1$^A>(KJ^C'@;7_%-]K'A:SM+FRBMC:LIU%;R^MU2UDFEF
MNF#.UW</<>;SNH6W[//[/^GZ9+:W?@1Y;YXA=_:KGQ-JUM#=.\ID-[$)KY(_
M+E=FE1$9E(<JAV[0/;KGQ)!9:AX(LK?2(%@TBXU>ZB,5U-%+=2SZ?-#*LLN)
M&6(&8R!!E< (2@.:?>^.+..&YM;KP_:3,[%8IKFZOK^6)0H1(VFE8N4"DGRU
M(11A%   %QP]"W-'#M2V]UMO3R?*O2[TW6H_:SY>1U&U>^RD[^2N_OMV/F+X
MD?"6^_L[P_IO@/QW\9/AGHNB0WL\.A?#?XI^)M*TEI-44223SV-O>7%HMP9%
M>1=@@#O+)),'9PPZSPY\+OA#\1;F[\:W/@GQMIWBRSN-+TN_U;Q_XKN-<\8Z
MYJLVFBS>XGU"SU2Z@DCU ;&TV,22RP6LT=M<)%(NT^JO\0;U8K>&PL;>"(,V
MP++K$4;;$!VNB748 X8!4*@@@ A>#PT'[36F_#74?%FE:OX!\%^*+C4-5T_Q
M'I]_KUYXK@OM*O8=,@L(IM+DTW48522-K=9(YI!)*DC,$(C QSXO#M47.C1;
MG&46E=I^\VGM&^B3=U?UM:_1A*M-5_WM:4:;3YO<5ER)6LN97NWV3374VM=^
M"&@_#KPA\5-/M_\ A)O#DEUHMY<^$%T!/$>C^(=(\1:AI:Z->O8ZCI=R+W[9
M/:6SP""7_1!*PG>!]ISYC^RQX*T*&V\6>"OC%8_$OXDZ?=O'K&E3_%G5?'FN
MW5N'T^VTN;2]*M)FO;.&WNHFD=R+;[8V[S1/$FVV/T=;_P#!5?QIHD^K2:5X
M'^'$(U#2+2*<//XINGGFMA<$3W$MY=R27=UY=R5FN)7=V 0EB^6.M=_\%A_B
M7%-;W,7@;X4A[?1KB$,MEK6UC=+ &$OEZG 9F'V1"CLY"EB"#T'GQABU%+ZL
MKWN_>E>[:T_AWT^\]2K6P-2I&I]<DO9J24%2CU6S:GOIU3W..^'OPR^"NO\
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MAVLS$ K&S=Y&F58=\M>/^'?V)_$GCR*S\;V_Q#%KIFIR:NU[HOB?PQK?AKQ
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M/ITP^T[HT$*744+VLBDSQDSF;8H# 2?(U8/CCPS/IP\<^)_%>AZ7JOBNUNO
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M)G[0@N]2'A3P=K>MZ39RSS3:K>3:3"UV6=Y));>T34 XMU);RQ/NEE'S>6G
MK#\+?LW_ +56AS'5;3X87ATU'TU]7O;VXTN);:QCNH[IYU']K+(JQP^8S AF
M(!!4$;:^GJ\:<'\RC2SW)XUN;D=L=AW%U)14%"'-4C%R]H^5*"E>2:2[_C\J
M&-4ZJE2JRI\WQ<DE%J+WYDK+1:M[:WM9G]>-_P##*W\7V?B?5;/XD^"_ NJQ
M?"[PYH5C/XFMUN@LDVBH([BV25)K?=#,?WJO$7CQ$P*[P#^+>C^%O!MQ\;/$
M]A+?_P#"86MC?ZG;^)=8TV71]/GEDEN)K>RU3PV^HF*SAO8[R&:YT]K^(VCK
M LDI_>JR_='Q0U_2]3M/'L=S),VWX6:=;R2PWDT"*B64:?)&KJD3K]YI0-Q
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M"?7&\0Z:IPI<M)7C"4*,^25:<M.6;;;2UU<>Q_>%%_JU_'_T(T41?ZM?Q_\
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M6IJ=:J[*C=U_"GBN9O%^BV?@CP8_B74-"6_\+_![PVLEP]B^L1[-.UCQ]JT
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M[(\9^ ?V>O&EA-%&MZGB#X)^%D-ZQD8%9SH3Z3%.60#<I@ VCD$X%?1W@_\
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M/-.T33KFP*>(;S3;C3K0WEQ?+'8JL]XD$#0W;^=!%.DD@+$HCA]M?VX?!?\
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MP[%\2_#?PST^?6-*MM26UMO$[:?=-=77V58C<BS>\D,=M"%WJ%5"KDUWDO\
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M-"MQJ/EZ#IULP:36O$6N:7HVD1V\I)+3ZCKMU96T,8W 9,F%P!@<$_-/CO\
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MEA<'E>+I*2KXV=&;IX?!QE6J<S5U)NG&<V^6[?NQY7<]G^'?@[PM>^'KR_\
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M5:E1I*5/!X2$FZ6&HN5VDW;VE:HTI5ZSBG4DDHJ%*%.FBBBBO3/GPHHHH "
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MNGC_ .+;10(8P)/%^F.90VWYIV_X1<-*XVC#$]SQ7]#OD0_\\T_[Y%'D0_\
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M/\/?AU*T4%M$D$,?G2^#GGD"QHH9I97DD.YY'=V9C^P/D0_\\T_[Y%'D0_\
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5MMO=MN[;?5MMON%%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "5 5H# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#RK82O6H2?LZ^-<7.A7IUH*3C>,XS<9-/FE^A_\ PZG_ &!_^B#?^91^,_\
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M#9V7CH3BZ$P\8VMMJ,<'B<3"^O1+_;<=]Y@O+H/D7$V_[.\&_LH^ _$?P?\
MB#KFJ6GQ"\-_$#P7\ M0^-EO?>(OB+\'=$74KBR73]3314_9]B77/C"G@_4=
M"OTN?#_Q/O->TS3]=62QU&3PYHUIJ=C!/B:K\ O@M9? *V^)WA=?B)\6;^R\
M$>"?$?C+Q-X!^)GPT32_A_XMUOQ#8VGB3P1\1?@[>^#[KXG^!M%TW3UUC2-"
M^*<VKZ]X=UWQ'%I%U#HXTS4O(BM9WPY*M4I0P,9U?KV#RNI*.4X+DE6C36(R
M[GQ#C'#O#P5*/U!U<2I4ZU*-/!8>%>G"G&'E.>*E"I+%N-/ZIBLP@I9EBN=4
MI3='&\E!.5;VTG4E]<]G0<9TZCGBJTJ-24Y?(OACXF?$?P3I'B/P_P"#?B!X
MW\):#XQLSI_B[1/#'BO7M!TCQ58-;75FUCXCTW2K^TLM<LVL[Z]M3;:G#=0F
MVO+J IY5Q,K]-8_'_P"/&F:=HVCZ;\;/BYI^D>'-*N]#\/:78_$CQE::=H.B
M7]O':7VCZ-8P:S';:7I5[:Q16UWI]C%!:7-O''#-"\:*H^\_C'\)?A7K_P 6
M/VR/$'Q.U?XQ>)+_ .#?@KX.>.=#UC3O$7PXT[4]?T_6[3X5^%3X5\1V=C\+
M=*T3[28/%%G867B[1;+2H]$M=/&J7W@_Q?>^=9WO%:=^R;\+]=^+UGH/AP_%
M77O"^N_LLZ/^T9X0^&&G:QX8N/B_XNUO5-'L[MOA9H'B>'P?)HNIZI;N^IZY
M_:UC\.+F_G\/Z1>06GA6YOXQ,_/#B'A[$4/K.,RV*E/"TLPKU*N4X2O1G4EE
M>78NT<3B*?/5K0P&9X6'ML3'#JG05:G6Q.'HT*D5M+),ZHU?887'-QCB*F"H
MPAF.(HU(PCC\;A[NA1GRTZ<L9@<1+V5"59SK.G.E0K5:T&_DN']H[]H6WUF?
MQ';_ !X^,T'B&ZT.U\,W.NP_%#QO%K-QX;L9Y[JR\/3ZHFN+?2Z'9W-U<W%K
MI,D[6%O/<3S0VZ232,WZ6_\ !$!F;]K'XALQ+,W[/7BQF9B2S,?B3\)B22>2
M2>23R3R:^&?VK/A=\+_A'K7PZ\-^!-%^)'ASQ+J_PXT/QC\2/"_Q-\:^&_%'
MB+P-XE\1-.T?@+5-,T#X<> )_#^L:'9VD>H7J:TLFJWUEKFEO=Z%X:G@EMKO
M[E_X(??\G7_$'_LWGQ9_ZLGX35Y/&U3+\3X:<48_+\'3PE'%Y%5Y;8/"X.K.
ME0QV%HTN>.%BXRI)TZTL-:O6I.C4C5H-4L1&57T>%(8W#\></X/&XJ>)JX;-
MZ?-?%8C$TX5*N$Q%6IRO$2YHU&ITHU_W5*I[6#IUDZE&4:?]3U?//[77_)J'
M[3W_ &;S\:?_ %6WB6OH:OGG]KK_ )-0_:>_[-Y^-/\ ZK;Q+7\79)_R.LE_
M['.3_P#JVRH_J7-?^15FG_8KS/\ ]5N8'\5'@?XY_&WX8Z5<:'\-OC%\4_A[
MHEW?R:I=Z/X'^(/BWPGI5UJ<T%O:RZC<:?H.KV%I-?RVMG:6TEY)"UP\%K;P
MM(8X(E7#C^)GQ(B\:)\28OB!XWC^(L=R;U/'T?BO7D\:)>-;-9M=IXI6_&N+
M<FT9K4SB_$IMF: OY1*GZO\ V)M'UOPQKGBS]H71SX%76OA#'HEE\/K7XC?$
M#X??#?P[J_Q(\874]K;1+KGQ*\1^&?#]Y<:!X+L/&7B(:=%=W%[]LL]*E2W4
M,LJ^E?$[]FGX>3?M.?M,^'+IM9'A1O@S\0?VE/@WJ_@KQ-X:;0IM.N?"H^(W
MAVWGN(M%\4Z;XJ\*9O+OP[YOAO6=*6;[ ;S3]<G@"K+_ '=7SK)<)G&9X.KE
MV%4HX!5L7C:6$PE2OC*CKY?1QF"KP6"I5,1&AA\TRW$577QN*C5IU:T'AO\
M9)<_\AT<KS7$99@,53QN(<98QTL-A:F)Q,*.%@J.,J87%49_6ZD*#K5LOQ]&
MFJ6%P[ISITIJO_M,>7XX@_:1_:)M;N"_MOCW\:;>^MM0U35[:]@^*7CF*[M]
M5UR,Q:UJ<%S'KJS1:AK$3&/5+V-UN=0C)2[EF4D533]H'X\QPZ%;1_&WXNI;
M^%M8NO$7AFW3XD^,EA\.^(+[^TOMNNZ%$NM"/2-8O/[9UC[5J>GK;WMQ_:NI
M>;._VZZ\W[G_ &;_ (*_ D>/?V*/$VL^$_%GBZT^-?A[XO2>+_"OBCQ'X2U+
MPW%XM^'D^L:/;:C9V4WPYE2\\,7T>G7.HCPUJJ75_9ZA<Z>&\27L&DSKK/S_
M *?\//@!8_"R[^/GB?P[\7[CP3XC^*,_PO\  GPWT#XH^!8_%>ES^'O"NA^(
M_%GB+QA\1[WX0W6F7T<AUVRA\.:!IOPNT::X1[EM0UJWCL[>XU:(9ID$L55P
MT,A4G3=&C3G#)LI;Q&+K8[.LK^ITJ?)":J1GE693]I4G3PTL*ZDE5@JLJ->Y
M9?G,:$*TLX:4E5JU(RS3,4J.&IX3*\?]:J3YI0=.4<QP,>2G&I7CB%"+IR=.
M-2CXAHGQV^-_AKQ#XB\7>'/C)\5= \5^+WCE\6^)]$^(?B[2O$/BB2)F>*3Q
M%K5CK$&I:V\;NSQOJ=S<LC,S*06).;I?Q=^*^B67B_3=%^)_Q#TC3OB"UPWC
MW3]+\:^)-/LO&[7<=S#=-XOM;34H8/$K7,5[>17!UF.],T=W<I(66>4/^GWP
M1NM#_9%^(W[3>@/JVO>-?@/JWP=^#WB;7?#6NK#;7>N?#+XP^*OA2EU!XG\.
MVEQ/I,?CC0? ?Q&US1TOH4BD^V&XNM+>QL-5$0WKKPO9?LK_  +_ &T?@9X*
M\4VVJ>,I?AKIOC/QMXY\-7MNYN_!GBGXS>!?"'PQ\*6^I6;/-%:ZK\*]=UCQ
M7XBLX;A8[J/XFQZ1?"?^R1CSZW$F7+$SH4,@PF(6*EP]]0KRP^'I0Q>#Q%7+
MX5:N,4LKG/"SX?GB\(Z6%G+$7G4PL<%+#2C4G0[:>18UT(UJV<XFB\.LZ^N4
ME7KU)X;%4:>,E3IX5K,(QQ$,YCAL2IXB*HVC#$/%JO&4(U?S(?\ :0_:'DO9
MM3D^/7QH?4KG05\*W&H/\4?'#7L_AA)99T\.37;:Z9Y=!6>>>9='>1M/66:6
M06X>1R?%Z_0OP;^RCX#\1_!_X@ZYJEI\0O#?Q \%_ +4/C9;WWB+XB_!W1%U
M*XLET_4TT5/V?8EUSXPIX/U'0K]+GP_\3[S7M,T_75DL=1D\.:-::G8P3C_
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M(4Y-[2%7^V>)75IQKPA4>/PCJ1CBG5EB8J;P$I6Q$J]9UKRDZKK5'-OGE?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 6$# 2(  A$! Q$!_\0
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M=-10!S/_  A7@W_H4O#/_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=-10!S/\
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M3V'BWP6VKJ=5L-(UW0?%.DW4FAZK-<ZGHM[]IM+FXE0P2. ?65%%% !1110
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M2Q@N+N8Y8$K##(RKN=@$5F&#X*_Y$WPE_P!BSH/_ *:K2NFH YG_ (2W2O\
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M]/$W_A%>,O\ Y0UTU% ',_\ "6Z5_P ^GB;_ ,(KQE_\H:/^$MTK_GT\3?\
MA%>,O_E#7344 4K"_@U* W%O'>QQB1H]M_INHZ5/N4*21:ZI:V=R8R&&V41&
M)R&".Q5@+M%% 'YGT444 ?H5X*_Y$WPE_P!BSH/_ *:K2NFKF?!7_(F^$O\
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M ")OA+_L6=!_]-5I734 <S_PA7@W_H4O#/\ X(=*_P#D2C_A"O!O_0I>&?\
MP0Z5_P#(E=-10!S/_"%>#?\ H4O#/_@ATK_Y$H_X0KP;_P!"EX9_\$.E?_(E
M=-10!S/_  A7@W_H4O#/_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=-10!S/\
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M-$\):;I,FDZ;K?AW09[>WGT'QQXEO'U%[SQ+8210R6$5LUM%=N]W'+'##/\
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MJ%I:WUI-_P +.\ZUO+>*ZMI?+^#GQ"EC\R"='B?9*B2)N4[9$5UPR@C^P?\
MX0KP;_T*7AG_ ,$.E?\ R)7\@/\ P2G_ .3^/@-_W5'_ -4Q\1*_LDK^0?'_
M /Y+'+?^R<PG_JQS0_I;P;_Y)C'?]CS$_P#J#EYS/_"%>#?^A2\,_P#@ATK_
M .1*/^$*\&_]"EX9_P#!#I7_ ,B5TU%?AI^M',_\(5X-_P"A2\,_^"'2O_D2
MC_A"O!O_ $*7AG_P0Z5_\B5TU% ',_\ "%>#?^A2\,_^"'2O_D2C_A"O!O\
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MW_LG,)_ZL<T/Z6\&_P#DF,=_V/,3_P"H.7G345S/V3QE_P!![PS_ .$EJO\
M\VM'V3QE_P!![PS_ .$EJO\ \VM?AI^M'345S/V3QE_T'O#/_A):K_\ -K1]
MD\9?]![PS_X26J__ #:T =-17,_9/&7_ $'O#/\ X26J_P#S:T?9/&7_ $'O
M#/\ X26J_P#S:T =-17,_9/&7_0>\,_^$EJO_P VM'V3QE_T'O#/_A):K_\
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M_P UM=-10!S/]O:K_P!"5XF_\"_!O_S6T?V]JO\ T)7B;_P+\&__ #6UTU%
M',_V]JO_ $)7B;_P+\&__-;1_;VJ_P#0E>)O_ OP;_\ -;7344 <S_;VJ_\
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M_P#U&QA_4OA+_P D;0_[&F;?^G\,<S_;VJ_]"5XF_P# OP;_ /-;1_;VJ_\
M0E>)O_ OP;_\UM=-17Y ?I9S/]O:K_T)7B;_ ,"_!O\ \UM']O:K_P!"5XF_
M\"_!O_S6UTU% ',_V]JO_0E>)O\ P+\&_P#S6U_/U_P75O[J^_X9:^TZ+J>C
M^5_PN[9_:,NC2_:-_P#PJ+=Y/]D:MJFWR=B^9]H\C/FIY7FXE\O^BNOYY_\
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M_P#5,?$2O[)*_C;_ ."4_P#R?Q\!O^ZH_P#JF/B)7]DE?R#X_P#_ "6.6_\
M9.83_P!6.:']+>#?_),8[_L>8G_U!R\****_#3]:"BBB@ HHHH **** "BBB
M@ HHHH **** /S/HHHH _0KP5_R)OA+_ +%G0?\ TU6E;UW9VE_;RVE]:V][
M:3 +-:W<$5Q;S*K!U66&97CD =58!U(#*&'(!K!\%?\ (F^$O^Q9T'_TU6E=
M-0!S/_"%>#?^A2\,_P#@ATK_ .1*/^$*\&_]"EX9_P#!#I7_ ,B5TU% ',_\
M(5X-_P"A2\,_^"'2O_D2C_A"O!O_ $*7AG_P0Z5_\B5TU?R@?\%+?VB_V@_
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MX9_\$.E?_(E'_"%>#?\ H4O#/_@ATK_Y$KIJ*_(#]+.9_P"$*\&_]"EX9_\
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M6T>XA(8,6B6^M;VT)8 H?.M9EVLQ50^UE +%%<S_ &#JO_0Z^)O_  $\&_\
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M<9!C.)L@JY5@:F&I8B>,P.(4\5.I"CR8:K6G43E2I5I\S52/(N1IM.[6C?\
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M$?P)_9+M/A5\7-0^(*6-KX9\+>$O#/BCX<_!OX?Z=\5_C%\6+#P_X3\3>(-
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3OS/HH _3"BOS/HH **T** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "M *<# 2(  A$! Q$!_\0
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M:WF"-)$S"*>*0/#))&R.I#;MRKU]?DKX"^+?C#X>1W-MH=^PL;MS+-8S+!-
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MG_@J:FMD^#[S]H-=),-B]N/$.N>"9;RVOF@C-[#=301V]M/;07>]$F6W5'@
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M;W3S)'?8LCE4WL6V*68MM4':NXD[0,DG)K\J_P!H;]@'QO\ &']HF3XRVOQ
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MOCIXD^-O_"=S+)XIC6;4?"6O^'[?6M-BU2.WLX8+JVOC=1W!L(9+&"==,:%
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.::UUZ]?D9_UM_P $_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $' ?<# 2(  A$! Q$!_\0
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M10!6ELH[C3I;*=Y)(Y49'9F^9@>O/;KVJC;Z L,\<\NH7MS-#$T4$DQCS$&
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M ,5^//O7I5E?6NHVJ7-I,LL3=&4_H?0UX#6GHNNWNA7@GM7^4_ZR)ONN/?\
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MEQQO>W*0+(XC0OT)/]/?H*M2.L4;2.P5%!9F/0 =Z\0\4Z^_B#6'G!(MH\I
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M*%JK@]&8OQ&UK[%I2:;"V)KO[^.T8Z_F>/P->45M^+=3.K>)+N<-F)&\J/\
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MX;KSST]NE>[[7R_K3_,\SV7F:U%9IOKDA$CC1I,.6/;Y3CN1_.I%N;ES*1Y
M6/!(8^JYZYQUJE5B]B?9R1>HJK:W#ON69D#AMH4#:>F<=3^AIEU%'),N !("
MK-(3]P#^6?2J<]+H7+K9EVBLL2.;@S-Y;?O_ "@I'*]LCG\>E0[9($:)H\!E
M7S!N'S<XS_P(D?D:S]MY%^R\S=AE>":.:,X>-@RGT(.17OMK<+=6<-PGW)8U
M=?H1FOGJWE\Z+<5VD,5(SG!!Q7M_@Z?[1X3T]SU5"G_?+%?Z5RXY)QC)'1A'
M:3BS<HHHKRCT HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"*V_X]8?]P?RHHMO^/6'_<'\J* "?_5C_?3_ -"%2U%/_JQ_OI_Z$*EH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCXGL?[ M%[&Z!
M_P#'6KMZP_%-OIEQIT1U2"::!)00L38.[!Z\CCK51J1IOGELAIV=V>'T5Z(+
M?PA'@IHL[D'^.9O_ (JG+<^'XS\GANW(!XWR9_F*T>:X9=2_:Q/.:*]*&J:7
M'@Q>'-.4@Y!,:D_^@T]?$<D9_=:=I\8!R-L/3]:R><4%M<7MD>9JK.P506)Z
M #-68]-OY<>797+YZ;8F.?TKT;_A+-1 PBVZ#_9C_P#KU"?$VKDD_:\>PC7_
M  K-YU2Z19/MEV.'C\/:S*1LTF^.>_V=@/SQ5F/P?X@DQMTN<9_O87^9KJV\
M0:JW6]?\ !_(57.JZ@3DW]S_ -_6_P :S>=KI$7M_(M^&+#Q/IJ?8;_2S<:7
M(>8WF3,?NOS?I^/%=!XST6[UO1X;:R"&1)Q(=[8X"L/ZBN7M9+Z_O(K874[-
M(V.9"<>IZ^E97CS5EGU>+3K5R+?3E\L$-U?^(Y]L ?4&BGF#F_:J-K?F;4,/
M];FX;=V0'X?Z]%,S)I<>XG!=98_F_7-0/X%UJ/DZ-DAL_+L//KP?UK)34KZ+
M_5WMRF#GY96']:L1^(-9B(*:M?#!SC[0V/RS76LTEUBCI?#_ &J#W\*ZDG[M
MM"N<*QX%JQ&?4<8_&HWT.]BWE]*N$W\,6MR-WL>.:M)XP\01_=U6<\Y^;#?S
M%68_'GB2,C_B8[AZ-"AS_P".UHLU7\AD\@J])G/BUBB< 0JA0G"A<8/?CUI&
MMH'?>T,;/_>* FNJ3XC:^N-S6TG^]%_@13Q\1=2; GT_395SDYA;/_H56LTI
M]8F+R'$K:2^\Y3R8O-\WRT\S^]M&?SI&MXG$@9<^9][D\_X5U8\:V;'=-X7T
MIV)R2(P,_H:</%VAR8$WA*U SDF.0#]-M:?VG1>Z,GDF+7_#G*1QI$@1!A1[
MYKV#X?L3X3A![2.!^=<2-:\'.<R>';A"3D[+AC_[,*]$\*O82^'X9=,MY+>T
MD9RD<C9(^8@]SW%16QE*M#E@1' 5\.^>JM#:HHHKC- HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"*V_X]8?\ <'\J*+;_ (]8?]P?RHH
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M,?(L4!D_VI"/Z _^/&N,KUU'DBH+I^9];EF']E1YGO(****#TPHHHH ****
M"BBB@ KW?PM;?9/"^FQ$8/D*Y'NWS'^=>):99-J.IVMFF<SRJF1V!/)_ 5]!
MJJHBHHPJC 'H*ZL.MV>)FT](P^8M%%%=1X04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!%;?\ 'K#_ +@_E11;?\>L/^X/Y44 $_\ JQ_O
MI_Z$*EJ*?_5C_?3_ -"%2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H0J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0RD?PCV]3^'T]@1%CC6-%"HH 55&  .PK:C3^TSS\QQB2=&&_7_(=11176>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH BMO\ CUA_W!_*BBV_X]8?]P?RHH 696>/"XR&!Y..A!I-
MT_\ SSC_ ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#S
MSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *
M** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X
M_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** #=/\ \\X_^_A_
MPHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_
M //./_OX?\*-T_\ SSC_ ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_
M  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\
MSSC_ ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[
M^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** #
M=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#O
MX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** #=/\ \\X_^_A_PHW3
M_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //.
M/_OX?\*-T_\ SSC_ ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HH
MH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_
M ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"
MC=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** #=/\
M\\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\
M"BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** '0H8X8T.,JH!Q1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &S 8H# 2(  A$! Q$!_\0
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MCXW?])Q/^"E?_A:3?_-90!_4[17\L7_$-Q\;O^DXG_!2O_PM)O\ YK*^_?\
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M&W_!=S]L_2O@%\/?B'X>^'7P-L?'5WX@_P""E/ASQEHWB_X3_%V:+6?^&/\
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M@)_P44\9_MR>%/'/PD^).KZ7^S]_;_[*\FAOIGQ.N?"O@KX=> /!GC'Q_?\
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M!5$?^@30!\J:S_R?!\.?^S5/C3_ZMWX!U]5U\J:S_P GP?#G_LU3XT_^K=^
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MC\'AY-=W3I4:[CZ.I+U/]>M)(Y5#Q.DB'(#(RNI(Z@,I(X[\T^O\B/0_CO\
M'7PQ(DOAKXW?&+P_)&XDC;1_B=XVT_8ZG(91;ZVBA@><XSFON7X0?\%EO^"F
M7P5FL/\ A&_VL?'_ (HTW3B@CT'XI)I7Q-TF:%.#;3GQ78WVJB%U)5C;ZI;S
M+D-',CJK#/$>%^80BWALSP=:2O:%6CB*%^RYTZT4WMK&W4UP7TBLAJS4<?P_
MFN$@VDZN'Q.#QBC=V;=.4<+4:BM?=DY.UDKV/]/>BOXPOV9_^#J/Q1:7>EZ'
M^UU^SOI>IZ:?)M[_ .(7P-U&YLM1@RRK)?W7P_\ %5W=V]YA2SR0Z9XHLS@
M0V['Y6_IT_9-_;__ &2?VV]#?5OV=/C'X<\9:E:6L5WK7@FZDDT'X@^'4E#<
M:WX-U=;76K>.,J4DO;:WN],WX5+YR1GXW-.&LZR=.6.P-2-%.WUFBUB,-O97
MK4E)4[Z6]K&ENM;Z'ZOPYQ_PEQ4XT\GSC#U,5)7^H8E/!8_:[4<-B'&5:VMW
MAZF(V;M97/LFBBBO"/L@HHHH **** /Y$?\ @KK_ ,K'?_!!;_KW^('_ *>-
M;K^NZOY$?^"NO_*QW_P06_Z]_B!_Z>-;K^NZ@#Y4UG_D^#X<_P#9JGQI_P#5
MN_ .OJNOE36?^3X/AS_V:I\:?_5N_ .OJN@ HHHH **** "@D $DX Y)/0#U
M-%?SE_\ !PM_P4FU']E'X':=^S/\(=<GTOXZ_M$:-J*ZIKNF730:C\/?A&DK
M:;KVL6TT++-::YXNN#/X<T*8,DD%I'KM_$5FMK9QZ&5Y;B,WQ^&R_"J]7$3Y
M>9IN%*G'WJM:I;50I4U*<NK?+!>]-'B<1Y_@.&,EQ^=YC/EPV!HN?)%I5,17
MG[F'PM&^CJXBLX4X:-13J5)+DI2O^;'_  7*_P""V^L^+M:\:?L6?L?>+)M*
M\&Z1<W7AKXW_ !J\,ZBT5_XKU"!FM]8^'?@+5[&4-:^';2026'BKQ%93"?6+
MA)]'TV:/34O)K_\ DH550!5  &< >YR2>Y)))).22222232JH4 #/?DDDDDY
M+,QR69B2S,Q+,Q+,2232U_2639-@LCP5/!X."5DI5ZTDO:XFMRI2JU9)7;;N
MH03Y*<+0@DDW+^ >+>+,VXQS>OFN:5I/FE*&#PD92^K8#"\S=/#X>#=DDK.I
M4<?:5ZO-5JR<G%0*^L?V2?C+X*^#WBGQ9)\3+N[OOAIXLTG1=/\ '?PX3X8^
M%_B5IWQ;T31-:CUM?!6I/XGU/35\%&:ZABFL/&6DM/JFCW86\MHC+;QY^3J*
M]#$4(8FA5P]2_LZT'"5K<R3L^:+:DE.+C&4)<K<)QA.-IPA*/AX'&5<OQ=#&
MT%%U<//VD%/F<'+EE&TE"<)2C:;O'F2DG*,DX3G&7Z+>&/VI?A/\./A%X+\
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M[GXT?$*PO]/\/ZI9VUY<O'(/A_H<>N>/[A8D58;G1])4[3<QAOVE_P""=_\
MP4J\=>.?V3OV?M8U[Q9)>NWP&^#FHZSK&INU[/9VFH^'[?PLOB?4FEA:6]TF
MT\:Z'J_A;QE<_9Y7TJ[FT?5V6:VN;NOPKQDH8OPRXCJ\*Y3FF7<3YKE.1X;.
M>))1P6(P.%RN6/Q%.G@\'1<\;B*]6I2PM7#8S'U<2J,<-2Q^!O3C"5>=/],X
M;^C_ ,/9MCLERBMFN?8G-N(\=BLLR#"8.E@J=?.<UPF68S-XY-EN&Y:D\5G.
M9X+*\W6199"LL5G>/RNKDV7JMG&,RG!9E_(]K7_!/3]K_P -3/;^)?A/!X<N
M(R1)#X@\??#O194()!WKJ7BFV*X(.2>*PT_8=_:4DR(_"G@QR."$^,OP>8@^
MA"^."0?8@5_?KK/[7GAJZ%QI_P 8='\)Z%:P2VMM<^)/%_A'3O&7PSBEOU!T
M^/Q=,(Y-<^'\>JJ\<VE:[>7>I^!M5BD2YTSQ*6;[+'YO\2/@Q^S'XOL_[3^(
M'[)GP^N],U"V%W;^//A=X \)?$_P_=6<Q><ZF+'0+;P[XZ@LYMZE[K3+?7HH
M[95BCO,;I#_.:\;<QGF2R3FX6R[/)5(4J.2\15,PX?Q^,JU4W1IY=4Q^+IY9
MFTZ\5S8:.69KB:V)C[V'PF(5U']-PWT2>&,7D^7\0X'%<7Y]P_FCQ,<!G7#&
M/X8S7!XNM@:LL/F."I0Q5#)ZT,URK%0J8/.,BQ4LLXCR7&TJN!SGAW*\73=*
MI_"O_P ,*_M-_P#0F^$O_#P?"+_YMJ/^&%OVF_\ H3?"7_AX/A#_ /-M7];^
MH?\ !.G]B[XL_:Y/A!X;^#_B>^C,ADT/P5\2/$GPY\7V4I("P77@WQ3.L]M/
M ?,WVKR6VXA(B3DN/E3XD_\ !*SX?>%VFDO/!O[0/@2",DO>"TM?&FD6Z*)-
MTAN](\.>*X77*AXUFOK- C*'E9LM75C_ !1\1\NG.GB."<+*4/BCAJ.8XN:\
MW0HXV&+L^EL'-OIS:7\JI]'?P3P>(>#SSC_BKA/&12<L+QGED^$I0OLY8K.>
M%GE/)U]K_;,*'*U-8AP:F?SE_P##"W[3?_0F^$O_  \'PA_^;:O[!_\ @V7^
M%WQ.^#WP6_:C\'_$C2]/THW/Q8\'^(="@TWQ;X4\5VSQ7W@Z2RU*1I?"NM:S
M#8S--IUJ&BO&MY9E"R1HZ*S#\>-0_8(\&WD\UKX/^-MI=7L6X'3-8\*>'[W4
M4D#*HMY;+1/&4.O^8H93*Q\,1%&)B$+2*4K^BO\ X(9_LXZ]^S_\)_CRVO:G
MI>JOXP^)^CM97.FZ-XCT+%OX>\,0VKK/8^)M'TB]#F;4&*RP)<VD@&([AF1U
M'RV(\7<WXFJ_ZLYGE&#RR>)3Q#A4P>?X#')8*U?FI4<WR_!0J13:51TYUN6$
MKI]3[S)/H[<%<'85^(/"'%];BK#8%QP/UK+.(>!>),F;S1RPG)B<3PGQ%G57
M#U)*,G0CB</@G*K3Y7!-.*_<RBBBLCV@HHHH *_S;OV?/^5R/XT?]E]_:!_]
M4[K%?Z2-?YMW[/G_ "N1_&C_ ++[^T#_ .J=UB@#_2,@_P!1#_URC_\ 0%J6
MHH/]1#_URC_] 6I: "BBFNZQHSNP5$5G=CT55!9F/L "30!_GK_\'(_[15Y\
M7_\ @H'/\*+345N/"7[-_@/0O!]E9PN3!'XP\6V\/BWQA=2J&*&]2.[T329#
M@.D>F+&Q[#\//AA\4?%WPA\3S>*O!TFCO=7_ (?U[PCKNC^)=#T_Q/X6\4^$
M?%%D=/\ $7A;Q1X=U6.6PUG0M7M-J7=G.JG?%#-%)%-$CCTG]L'XCWOQ>_:R
M_:6^)NH7<E]<>-/CE\2]7CNI'WM)8CQ3J-GIBJW3RXM-M+6&(#A8XU4=*^<Z
M_J+)\OI8/)<!E\H0E3A@:-.K"44XSE4I1J5^:+5GSU:M1N^KLGHTG'_.CBK/
M,3FG%V=YW3K5(5JN<8JMAJL9/GI4J&(G1PBA+6RIT,/145K&S:LXR:?TYXF_
M:\^-'BS2OB'INJ3>!+>[^*.D/X5\7>)]&^'?A?1O&$_@!DT2"/X9:9XBL+.*
M[TCX=VMGX<T/3[+PS8K'#::=IT-E#.L#2I)1U3]K#XW:SX&\1_#B]U_1?^$2
M\1Z9:Z"=/MO"VC6DGASPS;Z;X>TFX\*^#+F"!'\+>&M7LO"GAU=;TK30L6IS
MZ8EW,PN;B[EN/G&BNSZC@]OJU%WE";O#FO.GRJG*\I2=X<JY7?2\WJZM:5;S
M)9[G,Y.<LRQ;E*G4HN7M>5NE5]I[2#Y80NI^TES-W>D$I)4:"H%%%%=1Y(44
M44 %%%% !1110 4444 %?W;?\&N_[1-YX^_9/^*O[/6MZG]JO_@#\1DO_"]K
M-*SW-OX%^)-M/K,%M$'8D65CXFL?$"Q*H"Q&]5!\I11_"37](7_!K_\ $F3P
MK^WM\0_AX\Y2S^*OP!U]5MRS>7-JG@7Q'H>O6SJ@.TSQZ==:KM<@E(?.4$"0
MY^1XYP4<9PUCVXISPBIXVF[:Q="I'GL^G-2JU$^ZT/U'P;S:>5\?Y-%3<:.9
MNOE5>-VHSCBZ-1T5)+1N.(H491NK)ZW5S^^ZBBBOYU/[O/Y$?^"NO_*QW_P0
M6_Z]_B!_Z>-;K^NZOY$?^"NO_*QW_P $%O\ KW^('_IXUNOZ[J /E36?^3X/
MAS_V:I\:?_5N_ .OJNOE36?^3X/AS_V:I\:?_5N_ .OJN@ HHHH **** /%/
MVCO 4WQ.^!7Q3\#VD-K/J.M^#M771TO+"RU.$:Y80'4]%D^Q:A;W=I-+'JEG
M:/!YUO((Y@DBA716'\:&K^,/&VKJUEX@\2^(;LVKR6LVG7.IWD5G;3V[M#/;
MIID,D-C (9DDC,<5LBJ05  XK^YJOY-/^"C/[/=Q\"/VC/$%[IMB8/ OQ3EN
M_'/A.:-"+6WO+RXSXHT)2,HDNG:M*UU##G=]@U"V? &<?W?]"#BK**&>\4\%
M9CA\O_M+-*&'S_A_&5\)@YXR57+*4L+G&78;%UL-4Q,.; U<+F<,/1Q%-3>$
MQ514Y2A-GS7$.'?+1Q<%9PO1JRBK2Y)/FI\TDE)Q4^:-G)Q3E\*;N_@@(BDE
M552>I"@$_7 YIU>N^#_AEI7BSP3?^*SXTMM,U'3/B!X \&ZAH5QI,ZV^G:5X
MZO[RPC\4WNO37$-B(; V,\QTZ*-I/)C:6YN8$*Y]J@_9/35_%7BCPEH/BK5X
MM1T^"V;P</$FF^&K,>,8Y[76+I?$MM-I7B;4K2?P/=R:0VG6.JZ)/JVHQW]R
MJZEI]G'#*:_T"S#C/AW+*V)HYACZF&GA'B(XJ57!8Y4Z*PL\NA7G*JZ*C.E3
M6:X*JZM%5Z:PTZN+<H8;#U*TOFXX>K)0DHW51*4-5>2=2K23\KU*-2*3:;?+
MI^\I\_QQ1SQA6=B0JH@+22.Q"I'&HY:1V(1% )9R% )(%=EX_P#!U[X#\6:K
MX9O(=55;"4?8KO6-+;1[G5;%AMBU:"Q:68QV-[(DS63>:[/ J&41S>9$GB/Q
M>^-6A_LR_!;XK_M)>(EMIK;X/>%FU;PMIMV<0>)/BOK<QT7X4^&2I5O.6Z\5
MS0ZYJ,2AF30O#VK3LOEQL:?$7%N3\-<(YMQKCJ\99+E.28C/)U82BGB:%/#>
MVPU"BW*2^L8ZO4PF"H0YI26)Q<827/2JQ@4\/4J8B&&2_>2J*G;>SNN9ORC'
MFDWM:+LVFF_YUO\ @N?^T@GC'XW^$_V5/"^H+-X3_9GL+M?')M9O,M-8^/7C
M"&SO/'LCNC&.Y7P1IL&B> +)\DV]SH^NA<&ZD!_5+_@D1\>)]+_8U_9Y\9.C
MZU#\*/''QA^ WC[1"ZG^W/ &NW]AXZBT.15)*L^A^+M1;1GGP\&J:3:W$ 58
M Q_CU\2^(];\8^(]?\6^)M1N=8\1^*-:U3Q#K^K7DAEN]4UK6KZ?4=4U"ZD/
M,EQ>7MS/<3.?O22,>]?T$_\ !$KQL=5^$G[67PCGD0R>'-8^%'QLT.#<QEV"
M\U;X=^+I(T,A78+76_#+RF.+<1$&EE$<:BO\8LAXHQ?%?BEB,^XC<<56XUS'
M.J.<4YN4J,Z?$%#%4HX.*DVXX;#0IX#!86/_ "[HX3#<O+.*:\/QRP^9X+PL
MSC.>',9BLKS_ (&Q7#O'7#N:8&I*CCLLS?@W/LKSC"YCA*M.TJ>)PW+6Q$9I
MV?)4C-3I5*L)_P!B6C^)K71+JT\(ZGXE/_"/2:9#>?"[XGI;K?16?A'Q- +[
M2[#Q%821SP^(_AIK]M.(=>\/WD%Y_P ([J0OY;*!EAN[&7+TN7XL_!;7[V+X
M!>(=-^''B>.X2_UC]GOQA>'5OV??B,;H"XCU/X9WMY=$?#C5=<B87.EQZ5J=
MGX=U+ST.EZGIK,+(?+/[/GBW_A-/ FI?#&_D$OB?X<6^I>*? ;.V;C5_ EQ,
MUYXR\*0D_-/-X8O)&\5Z1;#YETVZUZ*)2L*JOT?X<\2Z-K>D6G@7QY<_9]'M
MQ(G@[QD8GNKOP-<W+F0V%_&@:;4O E_,Q:_TU=\^B32/JND!?]*M+G\Y\1>
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M^(_AK4O"?BK2G*W&FZE"46XAW%8[_2[M0;;5=+N0N^UU"QDFMYD(.Y7W(O\
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MT5/$]U+XE^&DUPX5+#XBVEIY=[X?CD; BM_'^C6PT]8\JC^(=/T>0_/,Q/\
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M +-4^-/_ *MWX!U]5U^7'[<J>*I/B#JR>"4U]_%3?L>?%3^QT\+"^.OF8?M
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M2PTJ+1+/6/$%E-<WEOI,-Q/=Q6$;QW$2BW2YN;B95VD[Y7.><5K?"?\ 9J^
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MZ1=7.HVFB7UYH6C0:_K#>']$?7-6@1K?31JFLK]@M/.SNF93)Y<;!Z\0UO\
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M'3R]Y+F^)RVC'&YG6JY)6QN8TZN#GA,N]C&AFT:.68>JE3A-RFZL7S4,2_\
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M/A-_\T='E?\ !,__ *+S^RQ_X>#X3?\ S1U^:G_$*A_P3'_Z$#3?_ #Q7_\
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M_P#-'7YJ?\0J'_!,?_H0--_\ /%?_P \2C_B%0_X)C_]"!IO_@!XK_\ GB4
M?I7Y7_!,_P#Z+S^RQ_X>#X3?_-'1Y7_!,_\ Z+S^RQ_X>#X3?_-'7YJ?\0J'
M_!,?_H0--_\  #Q7_P#/$H_XA4/^"8__ $(&F_\ @!XK_P#GB4 ?I7Y7_!,_
M_HO/[+'_ (>#X3?_ #1T>5_P3/\ ^B\_LL?^'@^$W_S1U^:G_$*A_P $Q_\
MH0--_P# #Q7_ //$H_XA4/\ @F/_ -"!IO\ X >*_P#YXE 'Z5^5_P $S_\
MHO/[+'_AX/A-_P#-'1Y7_!,__HO/[+'_ (>#X3?_ #1U^:G_ !"H?\$Q_P#H
M0--_\ /%?_SQ*J2?\&IW_!-<NQA\#^'4BXV+-H/C6:4<#.^6/XLVZ-ELD;84
MP, [B"Q /TV\K_@F?_T7G]EC_P /!\)O_FCH\K_@F?\ ]%Y_98_\/!\)O_FC
MK\QO^(4W_@FY_P!"3X9_\)WQQ_\ /@H_XA3?^";G_0D^&?\ PG?''_SX* /T
MY\K_ ()G_P#1>?V6/_#P?";_ .:.CRO^"9__ $7G]EC_ ,/!\)O_ )HZ_,;_
M (A3?^";G_0D^&?_  G?''_SX*/^(4W_ ()N?]"3X9_\)WQQ_P#/@H _3GRO
M^"9__1>?V6/_  \'PF_^:.CRO^"9_P#T7G]EC_P\'PF_^:.OS&_XA3?^";G_
M $)/AG_PG?''_P ^"C_B%-_X)N?]"3X9_P#"=\<?_/@H _3GRO\ @F?_ -%Y
M_98_\/!\)O\ YHZ/*_X)G_\ 1>?V6/\ P\'PF_\ FCK\QO\ B%-_X)N?]"3X
M9_\ "=\<?_/@J]I?_!JG_P $R[?4]/GU?X=Z!JFDPWMM+J>F6VF>.=*N=0L$
ME5KNRM]37XKWC:=-<PAXH[Y;2Z-L["86\I380#]*_*_X)G_]%Y_98_\ #P?"
M;_YHZ/*_X)G_ /1>?V6/_#P?";_YHZ^-/^(7C_@BY_T:S>?^'0^(W_S14?\
M$+Q_P1<_Z-9O/_#H?$;_ .:*@#[+\K_@F?\ ]%Y_98_\/!\)O_FCH\K_ ()G
M_P#1>?V6/_#P?";_ .:.OC3_ (A>/^"+G_1K-Y_X=#XC?_-%1_Q"\?\ !%S_
M *-9O/\ PZ'Q&_\ FBH ^R_*_P""9_\ T7G]EC_P\'PF_P#FCH\K_@F?_P!%
MY_98_P##P?";_P":.OC3_B%X_P""+G_1K-Y_X=#XC?\ S14?\0O'_!%S_HUF
M\_\ #H?$;_YHJ /LORO^"9__ $7G]EC_ ,/!\)O_ )HZ/*_X)G_]%Y_98_\
M#P?";_YHZ^-/^(7C_@BY_P!&LWG_ (=#XC?_ #14?\0O'_!%S_HUF\_\.A\1
MO_FBH ^R_*_X)G_]%Y_98_\ #P?";_YHZ/*_X)G_ /1>?V6/_#P?";_YHZ^-
M/^(7C_@BY_T:S>?^'0^(W_S14?\ $+Q_P1<_Z-9O/_#H?$;_ .:*@#[+\K_@
MF?\ ]%Y_98_\/!\)O_FCH\K_ ()G_P#1>?V6/_#P?";_ .:.OC3_ (A>/^"+
MG_1K-Y_X=#XC?_-%1_Q"\?\ !%S_ *-9O/\ PZ'Q&_\ FBH ^R_*_P""9_\
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MDE9[34=.NK:^LKA8[FTN(;B*.1?S=\+?\$M?V<_@3I<&O?LE:!8_"+XV>#/
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M+:P^7\6/#<X,S@LHD,%U((4P"3-,8X5Z-("10!^E]%?FQ_P^,_X)7?\ 1_\
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M:QJ*:9:;-/T^35=;U75-9U&+3+6SM[W5]1OM3N8I;ZZGG?U^@ HHHH ****
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MSL]%^8\<^,?AUX=N5'B;B/"TLR4%..29?&>:YU)-7AS9?@95)X6,U;DGCZV
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MY4%NMUX>O)BOS,CV%GYC])4R2?W _9F_X*+?LP_M1O:Z-X/\9CPMX]GC0O\
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M):PW'Q>UG3K@K<"&Y EL? T,\+[HA<P[;SQ"%(D\A[?3VV>9<!OP>
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MV;R6FH6,T4T,F2Z)_1MUZUY]\<O@;X5_:E\!6'@?Q'J&G^&OBAX3MYH?@O\
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M/C@ZU>OBI5L2HXI5(Q<*5"G1PM)>U]E=?O>6.D>Y_HBT445_"1_405_G+?\
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M[NROK2=$N+6[M+B.2"YMYHUEAE1XW0,I%0NH5V4,KA690RY*M@D9&0IP<<9
M/J!7\JJI!S4$[RE3]JK1DXN',H<RFHNGK*2M'VG.XOG4'"\U_.#PU94)8B4%
M&E#$K"3<JE&-2.(=&>(Y'AW66*Y52IS<JRPKP\9KV,\1'$2CAY-HHHJS ***
M* "NJ\">.O$'PO\ '/@OXE^$[N:P\3_#WQ7X?\:Z#=P2-%+#JGAK5+;5K4K(
MA#*)'M?)<#[T<CH058@\K2$ @@\@C!'J#4SC&<)0DE*,XRA*+5U*,HRC)-:W
M3C)IJVJ;1I1JSH5:5:G*4*E&I3JTYQ;C*,Z<X5(2C):J490BTULTGT/]=3X
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MY..*_1-_^"'7_!2V-&ED^"'AI8E8J9C\7/ASY&X=0)QKAA;'?:Y [D5ES_\
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MCAZM5LH4>.O GQ9R%4W*R2Q&)P69YUA()-VG*%:<59M-Q5S]0?\ @WD_9_\
MC'^S9^R;\4/AY\9=%T[0]8D^-^LZ_I%IIGB#3?$-NVF:EX?T.-Y3<Z9)+#!(
MUU:2AK=V$@"K(5 >OWWK\X_^"8.O0^+OV>=1\6V7CO6/B%IVM>/_ !#'8:[K
M=CK.FWJ1:;'96<MBUGK<DUS&MM.LGS132V[LY,<A(;'Z.5^)YW6QE?-LPJYA
MA9X''2Q,_K>#J1Y*F'KQC3A4I3BI2Y9IQ3DN9V<MS][RO),AX<R[!Y)POQED
MWB'PYE^'A1R7C?A[#9CA,CXFRZ:=?#YIE>&S;_A2I8.JL14HTXXQ*LY82M)I
M1E32****\L[S^5?_ (+!_P#*=_\ X-[?^Q^^/O\ Z0>$J_JHK^5?_@L'_P I
MW_\ @WM_['[X^_\ I!X2K^JB@#Y4UG_D^#X<_P#9JGQI_P#5N_ .OJNOE36?
M^3X/AS_V:I\:?_5N_ .OJN@ HHHH ^*_^"@7P]E^(/[,/CE;. SZGX0-AXVL
M%2/?*?["G+WZ1X!8;M-FNV;;R1&!7X _L^^.(/ GQ,TO6K[7F\/Z!?:)XHTK
M7KS#&&YL=1\,ZM#9V-T(H9YC!<ZG)9)B%5S(8_,<1!J_K%U+3K/5].O]*U"%
M;BPU.RNM/O;=P"D]I>0/;W$3 @@K)%(Z'@\&OY+OCM\*]1^"GQ<\;_#;4(I%
MCT'6)Y-%N'1E6_\ #FHLUYH5]$6 WI)8RI$Q'"S0RH<,I XL5%J49K9IP?W2
M2^^,GZVMW/\ 2WZ#_$V7<3<%^(?@YF]9)R=;/\NI/V,ZL\JSJCALLSMX6GB(
M5:4JV7YG@\KS"*E2J*F\53KN"]FIQ]\TGXP^'/#?P7\+V.D:]X=N=?\ #_A[
MP=;Z;H][<:^?$4_BS3O%>JWNKZ/KVC)#'X;TWP78Z7JUU=V7BW29T\42S&V5
MKN5XO)CH?&'QO\*/'G@&2*QUI8O$/A58K32K*QO]7QXB\16ITC2_[;?3]1M9
MYM9T>\T"&[@M_$.LZP-8T^/3K6 VS/>S9^.**YYS<TT^MG?5M.*233?737IM
M=/E3?]L8?PMR3"9K0SK#YAFU',:&?8W/HXBC4PM*52>/Q#KXG UU&E.%;"3C
M4Q%+FE3C72Q->M3="K)1B4JJ[ND<4<DTLLD<,,,*-+-/-*ZQPPPQ("\LTTC+
M'%&@+R2,J*"2!36945F8A54%F8G   R23V '6O=]/NO"_P"SKX$U#XW_ !.M
MS+K=G;6I\&^%6*Q:A%J>KV[S:!8QI*I,7B_Q);!KV#=&Q\&>$EN?$UZJ:C>:
M+"<YU*%"AB<7BZ]/"X+!4*F+QN+K-JEAL-22<ZD[:RDVXTZ-*%ZM>O5HT*49
M5*J2KQ0\2\N\,\CP.*EE^+XDXKXGSC"<)>'? >45*,>(./N-\UC5>5<.91&M
MS4\-1A"EB,VXCS[%PCE'"?"V5YYQ+G6(H8++J5+,.<^*OQ,M_P!BOX:&72YK
M6;]J?XJ:+>V'ATJ\5R?@WX,O0UIJGB% I9$\3W:>=I]C= DIJ'G):L;?3;B:
M?\3I))99)9IYIKB>>66>XN+B1YKBXN)W:6>XN)I"9)IYY7>6:5R7DD=G8EF)
MKL?B'\0?%/Q4\:^(/'_C2^^W^(?$=X;FY*;EM+"UC41:?H^F0L6^S:5I-HL=
ME86ZG"11^8^Z:65VXROY.XTXJK<5YM/%*-2AEF%Y\/E."FU>CAN>[KUU%N$L
M;C)1C7Q<U=1;I86G+V.%CS_J7A+X?YEP7DN*S+B[,<)G_B5Q=4PV;<>Y_@:=
M:&6+'4Z,XY?PIPM2Q5\3@>!N"\+B*F2\,X2KR8G'..;<59RJW$'%./J8+W;]
MF7XR3? +XZ_#SXH%I#HVDZO_ &3XQM8S_P A#P/XC0:1XHM'7(#^583_ -HP
M D!;FQA<<@$?U7SI DI^R7$=Y92I#=:?>PL'AO=.O(8[O3KV%U^5XKNRF@G1
MQP0_M7\;+*KJR, RLI5E/1E8$,I]B"0?8U_29_P3[^,3?%S]FKP_INIW9NO%
M_P &KR/X9^(3(VZYN?#Z0/?> =7ER2SK+HXN=%>9A_K](5"<L!7\O^/?#']K
M\)T.(,/3YL;PMB'4K.,;SJ9'F=6C0QJ;2NX8#,?[/S!=(4\3BY:1YV?@OTNN
M"?;8/A[Q"P=&]3 U(<+Y_*$=7@L;5K8KA[&56EJL+F2S#*G.7PTLSPL')+D1
M]JT44H!.X@,0@RY"DA 3@%R 0@)( +$ G@9-?QBDWHDV]=$FW9)MNR3=DDVW
M:R2;;23:_A@:0#C(!QTR.GN/0\=15BYN)+^S?3=36VUK2Y%*2:7KUG::YIKJ
MPP5-GJL-W"H(./W:H?0BF)%-(5$<,TA<.4$<,DA<1C,A0(K%Q&.9"N0@^_BF
M$, K%6"N"48J0K@':2A( 8!@02I(!!!.:]#+<QS?),71S3)\PS7)L?0DI8?,
MLJQN8Y5C*4HN+3HX[+\3E^(@TY0?N8IKWH7BU.*GG4A1JI0JPI54G=1J1ISY
M9:V<5+FE&2L[2CR25G:2<7R^ >,/V5?V=?'!FFU#X;0>%M1FW,VK_#K4[KPM
M.)6Y\TZ3*-2T&4YY,8L($;&/E!)KZB_X)Z?L@^%O@9XK^)7Q(T#Q3K?B6WU_
M2]-\(Z7!XAT>RL-1T:"VNCJNI1_;M/NIK34EN)?L0,L=O:,GD[7BRW'.*DDC
M)'$C2RR.D<42 L\DLC!(XU R2SNRJH R20*_3GX8^$QX+\%:)H;@"\2W^UZD
MP ^?4;P^?=9QU\MV$"G^[$M?Z5?0]\:?I \?Y_G7#O$OB%GO$WAYDN0RJ9M1
MXDIX/.<6\?C*]&AD6 PF?XO!PSJA)U,-C,=7IRS'&.I@\&H5$J=3G?YIXLY_
M7ROA2IE%+'XQ//JU/"/!SQ=6O1>"PTZ>*Q4U3Q,L34IPYJ6$HITJ].+E-P<9
M1O [ZBBBO[^/Y6"O\Y;_ (/=O^3G/V#O^R)?$_\ ]6#HE?Z--?YRW_![M_R<
MY^P=_P!D2^)__JP=$H _T,OAG_R3?X??]B1X4_\ 3#85V]<1\,_^2;_#[_L2
M/"G_ *8;"NWH **** "OY??^"MO@"?PI^U''XMCM/+T[XD>!]&U6"9>$N-4\
M/F31-20MC F"1V4C@Y.R1&X'7^H*ORF_X*V?!2?X@_ /3OB7H]J9];^#VL-J
M]Z(XM\TOA'65BT_7<%?G*V,HL=0*C($<,[D#&:_HOZ*_%]'A#QFX=>,JQHX#
MB6CC>$\54J2Y:<*F<PI/*YS?-&*BLXP> I<TM(O&1=XWN>7G%!U\!5Y5>5)Q
MK175JFWSI?\ ;DI/_MT_&'PQ\6/@SX#\!>#-#N=+G\?:CHGBO_A-5LO#.DWG
M@J6'Q!_PC,^F6>M^-KWQ-)K^D^+-=\,ZG/'+X=33+&VTD06QDNXG\T)7ID_[
M6/@>W^+GC3Q?;_V_K?@W6)-"FTNR\2Z397_BM]>UW2=$TCQ_XC&N0I:?V?9V
M\6CQ7PTE8I+C6-4M[>:WGM8E K\ZNO2BO]3,5X9\-8ZOC,3CY9MC*^.IYC1Q
M,Z^93Y7#,\?A,PQ#H4(4(TL'5CB,'15.MA)4JG(ZOM8U7.$<-\;'%U8QC&*I
MQ4?9V:@N9NE[1Q;EO*[J3<HR3B[VM9R<O2OBUJ'@;5/&ES??#Z$1:+/I]@]_
M-%;:G8V6H>(G$LFM:EIMCK5Y?ZO9V5Y-)')Y.H7<UPUU]IFRD<J(/-:**^WP
M6%C@<'A<%"KB*\,)0IX>%;%U77Q-6-).,9UZS474J--)RLDHPIPBN6G PJ3=
M2<IM13FW)J*M%-[V5WN]7J]6WU"D9@JLS'"J"Q/H ,D_@!2UN^%M%_X23Q-X
M>\/[@B:UK.GZ=/(WW(;2XN4%]<2'^&.VLA<7$C' 5(V8D $C7$5Z.%H5\5B:
MD:6&PM"OBL15DU&-+#X:C6Q->I)MI*-.AAZTVVTDH:NQ,4Y244KN344N[DTD
MOFVC^:#_ (+\_%![_P"-7P#^ %K.?LGP:^"]CXH\0VJ.=B>._C/J$OC74A<1
M@[1=VGAE?"EJ2072,>7N(&!^!-?7G[?/QK_X:(_;,_:1^+\,QFTOQ7\5O%"^
M&SOWI'X2T&\/AOPE%#AF584\.:1I@1$.P#.WJ<_(=?X'\8\0UN+>+>)N*,0Y
M.KQ!G^;YO:3;<*6.Q^)K8:EKK:C@E@:$5TC12Z'Z50I*C1I45M2IPAZN,4F_
MG+F?S/TY_89_X*7_ !#_ &4X8?A;\0=+N_C/^S'JFIF\U7X7ZCJAM->\"7UT
MRK>>,?@OXFN4N7\%^)U3]]>:2T<WA+Q48_LNOZ6994U.T_I8\%^*/AW\7OAY
M9?&;X%^-[3XH?"+4+B"RGU^VMUT[Q/X#URY3S(_!OQ:\)":XO/ _BI 2MM+.
M\_AOQ$B_;/#>LW\#B-/X;J^B?V9OVJ/C7^R/\1(?B3\%?%3:)J,UN=,\2^'=
M2MTUCP3X]\.2MF\\*^//"EVQTSQ+X?O5++):7D8GM)&%YIEU8:A%#=Q>]P5X
MAYKPC5CAY<^89).=ZV6U*EI4'-WG7RZK-R6&K:N4Z+OA,0U^\ITJDEB%^%^,
M7@'POXJX:IF%-4LAXSHT>7!\0X>@G3QOLX-4<'Q!AJ2A+,<(K1ITL7%K-,!!
MWP^(Q-"#P+_L7KWSP%^SGXY^(WA.Q\4:!J7AN*[UZ7Q7'X.\)W\^IQZ]XQC\
M"_83XOGTVY@TZ?0M,CT5=0@<KKVJ:=+?*L[6:2",%_A#]E7]JWX*?MQZ(9?A
M%#'X!^.6FZ<^H>-?V8]6U-KS5)TM8FEU/Q)\"-9O62Y^(?A6())=77@V4-X]
M\+6HPT&OZ;$NIG[U^%_[06M?"KX?>./"/AT>*FU;QAI^OZ-',_C*YM_ ^C6W
MB&Q32M5U"3P&EAMO?%,5HDMO;ZA)JMO#"\BO<V4L]K&1_3^%X@H\19-',N%<
M50Q5256A&5.M"*J8>3DO;8?&T)U(SPM2$7S3DU/FI4YRPLZSJ4JE/_-G-.!,
M5X?\6U>'O$[+,?EM&&%QM2EB,'5F\/CX0@_JN/R?&TL/4HYGAZTX.E1A!T72
MQ=>C#,Z6$6&Q.&Q#/B5^SEXU^%FA7GB?Q%JWAV?0(&M+*QU"T76K=M<U^74[
MW2]2\.:38ZGI=E>R7F@R:?<W>IZA/##H[Z>;6[L[ZX6^M5D^?)9!%%)*W2-'
M<_1%+'ISVZ=:^Q[#]K_7K7X?W7PZO_#5SKNCP>%?^$?T*36O%-WJ<_V^^T&_
MT7Q!JOBR2_LKJ?Q+;:C/?)K.G:6D^G)HM_I6D);SO!:E7\W_ &5/@?J7[0W[
M0'PI^#VGPS7%KX@\26$_B6X52WV'P?H<B:GXEOYV (2,:=;26X8X#37,2#+,
M >W#8S'8/!YCBL]]C2HX"-;$+%4G3A3JX*A1JU9U'1C*4J511I>]&4W>I6I4
MJ=^64I^/F&4Y-F^;9!EO!+QF)Q6>3P>7O+<2J]6OALXQN*PN%IT(XJI3IQQ.
M'E5Q3]G4ITDXT,'B,16:52G"E_7Y_P $X/AE/\)_V+_@7X;O;9[35=2\*IXO
MU>&0;9%O_%US-KI\P$ AQ;7ELK @%2NT]*^X:IZ=86FE:?8Z780I;6&FV=M8
M65O&,)!:6<"6]M"@[)%#&B*.P45<K^(,TQU3,\RS#,:NE3'XW%8R:WY7B<15
MK*-^T(SA!>4$?[.\-Y+0X<X>R'A_#-.AD>399E-*25N>.7X'"X5U+='5J4:U
M9^=9WUN%%%%<)[1_*O\ \%@_^4[_ /P;V_\ 8_?'W_T@\)5_517\J_\ P6#_
M .4[_P#P;V_]C]\??_2#PE7]5% 'RIK/_)\'PY_[-4^-/_JW?@'7U77RIK/_
M "?!\.?^S5/C3_ZMWX!U]5T %%%% !7YB?\ !23]FR?XD^![7XP>$-.>Z\:?
M#JRFCUNSM8MUSKO@DNUS=A40;Y[S09B^H6Z_,[V;WT2_=C6OT[IKHDJ/'(BR
M1R*R21NH='1P5='5@5964E65@0P)!!!J9P4XN+Z]>SZ->G^9]SX;\?9UX8\:
MY%QKD,D\9DV+4ZV%G.<,/F>6UTJ&9Y5BW#7ZMF&"E5H2E:3HUEA<53BZN%AS
M?QD*P90RG*L 01W!_P _4=Z6OTM_;P_8QO/A)K6I?%SX:Z9)/\+M<O&NO$&C
M6,+R/X"U:[DW2S)$@9O^$8U"=B\,H&W2KF0VTVVW>"0_$7P_\'6FH11>+O$F
MGW6I^&HM6AT30/#-D9$U3XF^,)BAL_">D-'B1-*A>2&;Q3J\?R65DZV4+B]N
MT,7%1PE?$8B&%HTW.M4ERPBM$UJW-R>D81BG*4Y-1C&,G)JQ_M%C_I(>$>3^
M"V9^/>><487*> ,CRJ>.SJMB90J9IE^9PA3IKA3^S:,WB<7Q5B\SK8?*,IRC
M"4ZE?.,7C,!5R]5<%BI8K"]%\-_"%AI5I!\0_%[:;:6L%E?>(?#%IKX!T2TT
M?0F9M8^*/C*$\GP5X8="FCZ:X67QGXF%GI5JLEJLQE_+;]I3X]ZA\=_&_P!M
MM9=2A\!^&Y=0MO!6GZI*6U*]^WSB;6/&OB/;A)O%?B^Y1;[47QLTVR6QT2S\
MNRL(T/NG[97Q_NM=OM4^#WA[6+3488+ZRD^+GB31?+CTCQ!XAT/]UH_PX\,"
MW/D1?#?X:*JV-I:6V+75_$4-SJ,GG16EHQ^ J_GWQ6XVHYC7?">18A5<ERW$
M*69XZC+W,\S:@Y1DX23]_*\MG[2E@HW<,3B57Q\E)+"N/F_1;\.N-^-\\J_2
MP\=\EKY#Q[Q?DV(RSP7\+<Q_>?\ $ _!W.)4<70PF-HR3I+Q;\2\+#+,]\3<
MXA3ABLLR^>2< 8&KA<MRO-L-BBBNNTGP#XXUWP]?^+M'\):]J'A/2M6TG0-3
M\3P6$H\/V&N:]=+9:-I-UJTOEV4=_J-TZ0P6YF+@LKS>5&0]>C7O[,7[0FG7
M%A:WGPC\51S:I8ZGJ6FB(:5=PWMCH\\-KJ<UO=V>I7%H[6MW<V]H;<3_ &J:
M[F2UMX99R8Q^0PP6,J1YZ>#Q=2'+"7/##8B<>6I[3V<E*-%IPJ>RJ\DTW"?L
MZG)*7))+^T,3Q#P_@JKH8W/LCP==5*])T<5G&5X:JJN%IT*N)I.G6Q].<:N&
MI8G#5<11E&%:A2Q%"K6HTZ=:E.IX77WI_P $Y/C(GPL_:-TKPUJ]Z+7P?\:;
M)?AOKC2MMMK37KB?[;X%UB3)"(UIXCCBT]Y201;:K.N=IQ7Q%J^@:YX?.F+K
MNDWVD/K.E6VN:7%J$#6TU[HUY)-%::E%"Y$JVMT]O,+=Y4C:58S(BF,JS94<
MMQ!)%<6=Q):7EM-#=6=W"Q2:TO+65+BTNH77#)+;7,44\; @J\:D$5PXO"8?
M&8?%Y?F%!UL'C<-B<#CL-)<LJN$QN'J8;$TO>7N3EA\0Y4Y.-X58X:K9.$6<
M'%?#V6\<<)Y[PUBZM*> X@RK&9>L52=/$0P]>:G]3Q]&5.=2$ZN6YI@\'C(.
M$V_:X"M2YE*51+^R!XY(G>*52DL3O%*AX*21L4D0CL5=2I'J*ZS0]5C@\.>+
MM'O+[[/:ZA;Z3);VP2-I9[J+58&N);?Y \LT-HKNL+RK%\N< L37SI\ /BY!
M\>?@G\.?BRC1_P!I^(M%&F>,;>/'^@^/O#6S2?%4#J"?+%Y=Q1:Q #C=;ZBC
M#(.:]=K_ #TQM#,O#_BO.\KDH5L3EW]N9%5]I[:G0Q^79KE^)P$<1*-&=*I.
MAC<KS#!X^G2]HJ<Y3C3J-QI2<?\ ''.<GQ6#Q>/R3-J+PN8Y1FE3!8^@E&4L
M-F639C*G7C3<XM.,<3@VZ-51O/#8BA6AI65_<Y/%?AJV7PG#H5^@L+,:KILU
MO?6L^E76F:4MW9:BEW/=VLTTT]_>W%M(7C4[;\S&W81P "N/\=7?A[4QI^IZ
M-=8DE"PQZ8DR.EC8>3YY62U6%/[.N([^6:.2)IIVNBS7.X+M%>>5Z!\.OAYJ
MWQ$UM=/LP]KI=LR2:SJQ0F*SMR1F*(D;9;ZX4%+>$'Y>9I,1H<_7PXKXN\2Z
M]/@C+.&<LS+,.(\5E.%RG+LKPN)ISP.+P&$R_ TJF71=>=/ X.&%R]XC&+%5
MYY;@:2JXN<J=#!8>#^2GEN5Y!!YSB<PQ&'H9?3Q-7$XC$U*<E6I5JE:K.-=J
M$95JLJE;DI>S@L16DU3BI3K3:](_9]^'C^(]?7Q;J4!_L3P].&LA(OR7^LH
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MC/X>N/LNM0:)J$=S<:?)YTUNKS0$),;:2>VN(8KR-'M)I8)HXIW>-PO\B_\
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MIC%S=6VB?$OX&:E-;VYE98A/-';-'$9&5 [*6(7)K\\/^']GP+^S&Y_X4?\
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M/'$8^A6>'Q,88V,HTYT<O<,3A(>UH^VE6A2QF-K+#574IT\+6ISUOAOXNO\
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M>M^ -<T[5_$_B?7?&_PLTG5/B/X(^'?@IM;\=:#XQL]0^$\'A6^L;JZU6-=
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M>!;UO--2_8U^)OQ;^)?[1MU<V?@'P!X9U?X_>-O&WA_QIJ/A753\4O$$FH?
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M=<NK&ZECL(;%I;E+>2%1/JT4T4)2*T<Y MM)>0QWDBDW+W#Q*ZI$-TGY%?\
M#W_P&;6WLS_P2_\ ^"KK6MK.;J"%OV(M898[AOOS#=XL+,[X D9BWF !7W
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M]9I%<VW[ W_!9'4+O2%TB#PE&W[$26Y\.0Z/X@N-?L7W2>)!#K+P2W,EK/\
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MJ]S-/9I8RW=E&P<3%Q_:I0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I :D# 2(  A$! Q$!_\0
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M_P""^#_XFC_A7?@7_H4]"_\ !?!_\376[V]?T'^%&]O7]!_A0!R7_"N_ O\
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M (T;SZ#]?\: +/F>WZ__ %J/,]OU_P#K56WGT'Z_XT;SZ#]?\: +/F>WZ_\
MUJ/,]OU_^M5;>?0?K_C1O/H/U_QH L^9[?K_ /6H\SV_7_ZU5MY]!^O^-&\^
M@_7_ !H L^9[?K_]:CS/;]?_ *U5MY]!^O\ C1O/H/U_QH L^9[?K_\ 6H\S
MV_7_ .M5;>?0?K_C1O/H/U_QH L^9[?K_P#6H\SV_7_ZU5MY]!^O^-&\^@_7
M_&@"SYGM^O\ ]:CS/;]?_K56WGT'Z_XT;SZ#]?\ &@"SYGM^O_UJ/,]OU_\
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M*H^;_M?I_P#6H\W_ &OT_P#K4 7MZ^OZ'_"C>OK^A_PJCYO^U^G_ -:CS?\
M:_3_ .M0!>WKZ_H?\*-Z^OZ'_"J/F_[7Z?\ UJ/-_P!K]/\ ZU %[>OK^A_P
MHWKZ_H?\*H^;_M?I_P#6H\W_ &OT_P#K4 7MZ^OZ'_"C>OK^A_PJCYO^U^G_
M -:CS?\ :_3_ .M0!>WKZ_H?\*-Z^OZ'_"J/F_[7Z?\ UJ/-_P!K]/\ ZU %
M[>OK^A_PHWKZ_H?\*H^;_M?I_P#6H\W_ &OT_P#K4 7MZ^OZ'_"C>OK^A_PJ
MCYO^U^G_ -:CS?\ :_3_ .M0!>WKZ_H?\*-Z^OZ'_"J/F_[7Z?\ UJ/-_P!K
M]/\ ZU %[>OK^A_PHWKZ_H?\*H^;_M?I_P#6H\W_ &OT_P#K4 7MZ^OZ'_"C
M>OK^A_PJCYO^U^G_ -:CS?\ :_3_ .M0!>WKZ_H?\*-Z^OZ'_"J/F_[7Z?\
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M14?\-"_M!_\ 1??CA_X=SX@__-%1_P 2H9S_ -%MD_\ X9,V_P#FT/\ B->
M_P"B>QW_ (<,%_\ ,Y_H&^7+_P \I?\ OU)_\3365D&71T&<99'49ZXR0!G
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M'G'W_(5_#+_PW=^VM_T=7\<?_"VO/_C='_#=W[:W_1U?QQ_\+:\_^-U^M_\
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MC<PP.6T/K.8XS#8'#\\*7M\76A0I>TJ<W)3YZGN\\^27+'=\LK;,^X?./O\
MD*/./O\ D*_+W_A[[^P9_P!%/\7_ /AI?'__ ,J:/^'OO[!G_13_ !?_ .&E
M\?\ _P J:^D_XAGXB_\ 1"\6?^&+'?Y'D?ZW<*_]%'DG_ARPW^9^H7G'W_(4
M><??\A7Y>_\ #WW]@S_HI_B__P -+X__ /E31_P]]_8,_P"BG^+_ /PTOC__
M .5-'_$,_$7_ *(7BS_PQ8[_ "#_ %NX5_Z*/)/_  Y8;_,_4+SC[_D*/./O
M^0K\O?\ A[[^P7_T4_Q?_P"&E\?_ /RIK[_\!>/O#7Q-\#^$?B-X-O)M0\)>
M.?#VF>*?#5_=6-WIMS>:+J]NMU87$^GWJ17EE++"ZL]M<QI/"25D4,"*\C..
M$^*.'J-'$9]P[G634,35E0P];,\NQ&"I5Z\*?MI4:4ZRY9U(TOWLH1U4/>V.
M_ 9WD^:3J4LMS3+\PJ4H*I5IX/%4L1.G3E+D4YQIZQ@Y^XI/1RTW/0_./O\
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MUBVU"T6WENM5M/,R/GNR_;"UOPM\.?%/@3X4_!SX.?!K6/B%8^"].^)7Q)\
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MI=HXE+E54%B2 !@ \X^_Y"N?L+R6YT_3KJ>3S;BZT[3[JXE8?-+/<V<$\TA
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M+)<-]7K83#X[%_D5*GP7&%!U9QE?!5OK$(U\7.K2Q*]K.3A44**Q%64W2PF
MA&G2C&G!9A5]K3KU<-0\2_9J_9=U/X_^'?B/X_O_ !#K_A?X<_"__A&K'7;_
M ,'?#+Q/\8_'>L^)/&#W8\/^'/"7PX\)2VFI:O<&VL+W4M8U"YU'3]-T73;<
MW%U<,9$2N\_9]_9&^'W[0OQ-USX-Z#^T0_AWXD7&K^/+'X=^'_$'P6\8VJ:]
MIG@71YM9GUOX@7MQJMG'\+TU*&"YACTJ>/Q-J6G7%C?1:G';R?85O?3_  M^
MTU^SO^SI=_%CX(_#BV^,WB?X(>+X_@3X@G^('P@^*ES\/?'U_P#%OX76,=WX
MNU?P[XAUW2I)F^%_B_5+R^TK^QK[3K2\_L^R2ZM([>.[CC@UK']OCX+:S?\
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MC]*UWS+@;1+_ (3>(-O^QEE9^_\ @I_N?$>EO]LRO37_ *!,9W-#[0??]?\
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M;V]?T'^%&]O7]!_A5;S#_>'Z4>8?[P_2O[4YE_3C_F?S[R^<OO99WMZ_H/\
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MXN*_"2_['&6]$^F.[GYF;QZ']/\ &C>/0_I_C5?>/0_I_C1O'H?T_P :_O\
MO_5G_D?S);S7_@*+&\>A_3_&C>/0_I_C5?>/0_I_C1O'H?T_QHO_ %9_Y!;S
M7_@*)V<8/!Z'T]/K7]H/[&TV/V2?V:1S_P D5\!=A_T!8*_BV9Q@\'H?3T^M
M?V:?L<S8_9+_ &:QCI\%_ ?;_J#0>]?RW]*E_P#&,<)?]E)CNG_4AD?LG@PK
M9QGG_8IPW1+_ )F2['U/YQ]_R%?C1_P6#7PE=6'[)L'C^^UW3/ LOQ8\6Q^,
MM1\,65KJ/B6R\,-HOAL:W<>'["\GMK2\UE-/\\Z=!=7$,#W7E^:X0$']@//]
MOT_^O7XF_P#!:R0MX$_9V(X(\<_$'MZ^&M ]S7\\^"$>?Q3X1@JE2DYXG,X*
MK2DHU:3GP_GD%4I2E"I&-6FY^TI2E3J*-2%.3IS47"?ZEXB2Y.#,\FXQDH4L
M'+DFFX3Y<SRZ7)-*4'*$^7EG%3BY0E)*46U*/RA\9?C/^Q%\5/B3\ ],G\9_
M&VW_ &4OA$LWAZR^ ^A?!S3?"\WA;P=%ITVIWEQ:^)G^)^M7?C/QC\1?%]M8
M0>/?$MW:Z)J(TF\N;S3'BFLHK>6]XC^/G[&GQ$_:M\-_&+XP>,?BQ\1/A'X.
M\)?V?X$^%=E\"-*\(>%/ C^$KNR@^%OPVM_"T'Q6U636_AOI%E+J.M^(YDUO
M2-1\0:U916=\IL]9N6M/R<WMZ_H/\*-[>OZ#_"O[UI\"972HT*-/-N)(+#95
MF644*D,RPT:]*AF]>>(S+%T\1'*%6IYMC:DYK%YO3J1S'%TY2IXG$U(MG\T3
MXGQ4YU*D\'E<G5QF$QU2,L'4E2G4P-*-+"4)TGCW3G@</&,70P,HO"T9)2HT
M8-(^_OC;+\'OC2/CY^TAXH_:+\<^.?&&J>+?AEHO@>VUOP#X:\">(/$NL:[<
MW[>.K(?#2V\7^+K[2?AW\+?A]IFF1^%M3L-=L=.N]4N+#P[.XN?.D.E^TC\1
M/V4/BOX7_96\&>$OBE\9!8?!7P'9_!OQ?K.M? _1].N9O"!UO7?$5YX\T72X
MOB?>)?ZY;W6H6NG6_@R6]M+:YA\V];Q) T8MG_.[)SNXW8QNP,XSG&<9QGG'
M3-+O;U_0?X5WT.%Z%&>5S6;YQRY'4Q']CT:4LLPU# X?$9/0R1894*&4*E5A
M2PE&=2G+DHI8FJZGLN2"I3YZF>3J1QB^I8.^8QI?7JDXXNM4Q%2ECZF8.JZE
M3'N<)5*TXPFN:HW2@H\_-)SC^KOQ9_:=^ OB3]IC0OC9\)_C_P#M*_"4R?!G
M0/AEJ/C#PM\(/"T/BGPO?>"O#'AOPMIDL6C:A\0IX/%GA[QG9:=J=QKEA!J&
M@WN@W<>E)!=:K;&Y8?N5^R-\?O!/[0_PWU7QIX$TG6(;'1/$EKX&UOQAXET3
MP_X;\6_%CQ1X:\&^$XM9^*'BOP_X9,FCZ/K7B22XB1[&"ZO)(;6RMEFN2V(X
M_P"-C>WK^@_PK^EO_@CM*5_9;\5@C/\ Q>SQ5V_ZE?P7[BOP+Q]X.R?*/#G"
MXS#5,?6Q&48W(<GP53%U\-.4<#5Q69<T*]3#9;@J^,<8ODHQQ>(Q&'P[O7P^
M$H8N=7%5?TSPRX@QN/XKK8>I'#TZ6.P^9X_$0HTJL8O$0HX2TJ4:F+Q%.@G)
M<U1T*5*K55J=6O4H1IT8?KEYQ]_R%?!__!3:7/[#7QW!)_X\?!78?]%%\)>G
M-?;/G^WZ?_7KX2_X*939_8=^.HQUL?!?;_JHGA/W/\J_E#@#_DN^"_\ LK.'
M?_5O@S]KXG_Y)OB#_L29K_Z@US^2'>/0_I_C1O'H?T_QJKYH]O\ OH?X4>:/
M;_OH?X5_J;S>7_I/_P B?QI9^7WK_,M;QZ']/\:-X]#^G^-5?-'M_P!]#_"C
MS1[?]]#_  HYO+_TG_Y$+/R^]?YEK>/0_I_C7[/_ /!$F7'QR^.>,_\ )&]'
MXX_Z'W2_PK\5O-'M_P!]#_"OV:_X(GS ?'#XXD8_Y(YH_O\ \SYI?T'>OS#Q
MHE?PLXU7_4II=O\ H;9-V2/L/#]/_7/A[;_?9]5_T!8_S/Z4O./O^0K*UZ8_
M\(_XAY/_ "+VO=0O_0(O*;Y_M^G_ ->LO79_^)!X@X_YE_7>W_4)O/>O\UZ7
M\6C_ -?J/_I^@?UK/X)_X*G_ *;J'\)L!'DQ<C[B]QZ5+D>H_,5GP2?N8N/X
M%[^WTJ7S/;]?_K5_KXVKOU?YL_AA)66BV71=O0MY'J/S%&1ZC\Q53S/;]?\
MZU'F>WZ__6I77]?\.%EV7W+_ "+>1ZC\Q7V-_P $]G"_MN?LU$'I\1&Z8/\
MS+'B*OB[S/;]?_K5]B?\$^9,?ML_LUG'3XAMW_ZEGQ%]*^8XV:_U+XPM_P!$
MIQ)_ZHLU\SV.'DO[?R+1?\CK*>B_Z&."\C^Q_P X^_Y"CSC[_D*R//\ ;]/_
M *]'G^WZ?_7K_*<_M$_CP_;_ ),_ML_M-G&?^+H7GM_S!-$]*^0O,]OU_P#K
M5]8_M^2_\9K?M,G@9^)]YU_[ FB#U_Q_I7R)YONOY_\ UZ_U7X-D_P#4[A'?
M_DEN&^K_ .A#E'D?Q=GZ_P"%[/-O^1UFW5?]#+'>9:\SV_7_ .M1YGM^O_UJ
MJ^;[K^?_ ->CS?=?S_\ KU])SOS^]_Y'DV?E]Z_S+7F>WZ__ %J0R=./XT[_
M .VOM5;S?=?S_P#KTADSCE?O)TZ_?'N:.=^?WOS\@L_+[U_F?WPZ9,?[*TCK
M_P @C2NP_P"@?;5=\X^_Y"N;TR?_ (E6D<?\PC2NW_4/MO>KOG^WZ?\ UZ_R
M'J?Q*G_7RI_Z<JG]RQ^&/^&/_I$#5>;]W)U_U<G8?W&KQJO3GFRCC'_+.3M_
ML'WKS38?4?K_ (5!1V=G+BUMQEN(D'Z?6K'F^[?G_P#7K(@?$,0QTC4=?;Z5
M+YGM^O\ ]:@#7@E_?P\M_K8^_P#MK[U_$]^T:X'[0_Q[!R3_ ,+H^)__ *FF
MM>M?VGP2?OX>/^6L??\ VU]J_BB_:.D'_#1'Q[^8C_B]'Q/Z9_Z'363V_G7]
M3_18=L]XQ_[$>4_^KG$GXUXRJ^6Y#_V,<=UM_P P%+R9Y1O'H?T_QHWCT/Z?
MXU1\P?WC^M'F#^\?UK^T.==W^/\ F?@')_5__M2]O'H?T_QHWCT/Z?XU1\P?
MWC^M'F#^\?UHYUW?X_YAR?U?_P"U/0_AHX_X6;\,L9'_ !<KX?\ /T\8:+Z&
MO[EKZ7_3;SEO^/JX[_\ 39_>OX6_AG(/^%F_#+YC_P E)^'_ *_]#AHU?W)7
MTG^FWG'_ "]7'?\ Z;/[5_&_TJ7?,>"-;_\ ";G_ '_Z&.5]S]Y\&5;"\0_]
MA66=;_\ ,+C/)%CS?=OS_P#KU_+U_P %='+?MD7A!/'PC^&0Y//^KU_T/3TK
M^G/S/;]?_K5_+[_P5RD_XS&O./\ FDOPT[_],]>]J^/^C6[>)4O^R8S[_P!*
MR@][Q:5^$DO^IQEOY8[O8_-;)]3^9HR?4_F:I>9[?K_]:CS/;]?_ *U?WUS>
M:^__ ()_,_(_/[E_\D7<GU/YFC)]3^9JEYGM^O\ ]:CS/;]?_K4<WFOO_P""
M'(_/[E_\D7&)P>3T/<^E?V7?L=28_9,_9L&6X^"_@/O_ -0:#WK^,1I.#QV/
M?V^E?V5?L=2?\8F_LV\?\T8\"=_^H-![5_+_ -*5WX8X3UO_ ,9)CO\ U0R\
MV?L7@TK9OG>__(IP_;_H9+LV?4/F^[?G_P#7K\4?^"T\F? O[._4_P#%<_$'
M&?\ L6=!^M?LYYGM^O\ ]:OQ4_X+2R8\#?L[]O\ BN/B#SU_YEK0>V*_GWP-
M=O%;@W_L,Q__ *H\Y/T[Q%UX*S[_ *\87_U8X _!+S/;]?\ ZU'F>WZ__6JG
MYO\ M?I_]:CS?]K]/_K5_I1='\EV?=_A_D7/,]OU_P#K4>9[?K_]:J?F_P"U
M^G_UJ/-_VOT_^M1=!9]W^'^1<\SV_7_ZU?TI_P#!'N3'[+OBOJ/^+U>*NA_Z
MECP7]*_F@\W_ &OT_P#K5_2=_P $?),_LO>+.,_\7K\5<YQ_S+'@OV_STK\&
M^DB_^-88E?\ 50\.?^I.8'Z5X3+_ (S"EJW_ ,)>:]O^?6%[(_6CS?=OS_\
MKU\*?\%,)?\ C![XZ\M_QX^"^O3_ )*)X3Z\U]L^9[?K_P#6KX5_X*7R?\8/
M_'3C_EQ\&=_^JA^%*_B;@'_DNN#/^RKX>_\ 5M@S^@^)O^2;X@_[$F:_^H-<
M_DKWKZ_H?\*-Z^OZ'_"J>]O7]!_A1O;U_0?X5_J+S2[O^OD?QU\OR+F]?7]#
M_A1O7U_0_P"%4][>OZ#_  HWMZ_H/\*.:7=_U\@^7Y%S>OK^A_PK]F/^"*4@
M'QO^-^">?@]I&<9SQX[TOZ5^+>]O7]!_A7[*_P#!%20_\+O^-X//_%GM(]O^
M9ZTS_"OS+QFDWX7<:7?_ #*J7_JUR8^OX!_Y++A_3_F-GV_Z L>?TC^;[M^?
M_P!>LO79?^)!X@Y;_D7]=[_]0F\]Z=YGM^O_ -:LO79/^)!X@X_YE_7>_P#U
M";SVK_-ZE_%I?]?J/_IZ@?UA/X)_X*G_ *;J'\+<,W[F+I]Q>Q[C-2^</;\C
M6;!)^YBX_@7O[?2I?,]OU_\ K5_KG*:YGZOMW?F?PZH:+;9?9\O4N^</;\C1
MYP]OR-4O,]OU_P#K4>9[?K_]:ESK^K?YCY/3_P !_P""7?.'M^1K[#_X)]R@
M_ML?LV_]E#;H"#_R+/B'UKXO\SV_7_ZU?8/_  3]D_XS5_9OX_YJ"V.?^I:\
M0>U?,\:S3X,XO_[)7B3M_P!"/-3U^'XVS_(]O^1SE73_ *F.#\S^Q'S?=OS_
M /KT>;[M^?\ ]>LWS/;]?_K4>9[?K_\ 6K_*\_LP_C[_ &^W4_MJ_M,9/_-3
MKSKG_H#:+7R+O7U_0_X5]6?M]2'_ (;4_:7^8#_BYMYQQQ_Q)=%KY&\P_P!X
M?I7^IW!TI?ZH<):O_DE^'/\ U193Y'\:9\E_;N=Z+_D<9KT7_0QQI=WKZ_H?
M\*-Z^OZ'_"J7F'^\/TH\P_WA^E?2<TN[_KY'DV79?<O\B[O7U_0_X4A=?EY_
MC3L?[Z^U4_,/]X?I2&0_+\P^_'Z?WUHYGW?]?(++LON7^1_>CIDO_$JTCEO^
M01I7?_J'VWO5WS?=OS_^O6!IDG_$JTCC_F$:5W_ZA]M[5=\SV_7_ .M7^2%3
M^)4_Z^5/_3E4_M^/PQ_PQ_\ 2(&@\ORMRWW6_4$>M<771M)P>.Q[^WTKG*@H
MU89"(D&X<*!VJ3S#_>'Z511P$4<]/\]Z=O'H?T_QH T8)#Y\/S#_ %L?I_?6
MOXH/VC9?^,A_CURO_)9_B=_ZF>L^]?VIP.//AX/^MC]/[Z^]?Q/?M&R?\9#_
M ![X_P":S_$_O_U.FL_6OZC^BX[9[QA_V),I_P#5QB?-'XWXQ_\ (NR+_L88
MW_U I'E'F^Z_G_\ 7H\WW7\__KU1\SV_7_ZU'F>WZ_\ UJ_LRZ_JW^9^!E[S
M?=?S_P#KT>;[K^?_ ->J/F>WZ_\ UJ/,]OU_^M1=?U;_ # ]#^&<O_%S?AER
MO_)2? '?_J;]&]Z_N4OI#]MO/F'_ !]7'I_SV>OX7?AG)_Q<WX9<?\U)^'_?
M_J<-%^GX5_<M?./MMYP?^/JX]/\ GL_O7\>?2E=\QX)_[%V?_P#JQRSS9^[^
M#7^Z\0_]A66_^HN+'>8?[P_2OY>O^"N<I_X;&O.<_P#%I/AIT./^6>O>E?T\
M[QZ']/\ &OY>?^"ND@'[8]Y@X_XM)\,^W/W-?^O^<U\?]&[_ ).1+_LF<]_]
M*R@]WQ8_Y)-?]C?+?RQQ^:OFGW_[Z/\ A1YI]_\ OH_X52\W_:_3_P"M1YO^
MU^G_ -:O[TO_ %9_Y'\U6\W_ %\B[YI]_P#OH_X4>:??_OH_X52\W_:_3_ZU
M'F_[7Z?_ %J+_P!6?^06\W_7R+C2G!Z]#_$?3Z5_9=^QU(?^&3/V;?F'_)%_
M GI_T!H*_C$:7@_-V/;V^E?V7?L=2#_ADS]FSK_R1?P'Z?\ 0&@]Z_F+Z4+_
M .,9X4_[*/&_^J*9^P>#G_(WSK_L58?_ -643Z<\P_WA^E?BG_P6FDQX%_9W
M)(/_ !7/Q ]#_P RUH/IS7[0;QZ']/\ &OQ1_P""U$F/ O[.^,#/CGX@YS_V
M+6@].:_ ?!!V\5.#WVQF/V_[$F<GZ;XB:\&9ZO\ IQA?_5C@#\$?.'M^1H\X
M>WY&J'F^Z_G_ /7H\WW7\_\ Z]?Z0^T7][^OF?RAR+R^Y_\ R1?\X>WY&CSA
M[?D:H>;[K^?_ ->CS?=?S_\ KT>T7][^OF'(O+[G_P#)%_SA[?D:_I1_X(]R
M?\8O>+,$#_B]?BH]O^A7\%^O/M7\S_F^Z_G_ /7K^E/_ ((\R _LN^+">3_P
MNSQ7TQCCPQX+'K7X1](Z?-X98E:_\E!P[O\ ]A.8>9^D>%,;<84=O^17FO?_
M )\X7S9^LGF'^\/TKX5_X*7R8_8?^.GS _Z#X+]/^BA^%/3GZ^U?;V\>A_3_
M !KX5_X*7N#^Q!\= ,Y^Q>"^O_90_"GUK^+. O\ DN>#/^RJX>_]6V#/Z XE
M_P"2<S__ +$N:?\ J%7/Y*=X]#^G^-&\>A_3_&JF]O7]!_A1O;U_0?X5_J#S
M>?XO_P"1/XZ+>\>A_3_&C>/0_I_C53>WK^@_PHWMZ_H/\*.;S_%__(@6]X]#
M^G^-?LK_ ,$5)!_PO#XWX./^+/:1UQ_T/>F?X?SK\7][>OZ#_"OV5_X(J/\
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MD2LO7?\ D >(/^Q?UW_TTWE6F=4^\0/\C_'O6-KMS#_8'B#YQ_R+^N]Q_P!
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MQ_PQ_P#2(%FJ]%%046%3*@[0<@>E+Y9_NC]*T(808HSCJBG^'N,U+Y _N_\
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MS_PKXO\ ^"AOQ(BUW]CCXSZ4#S=V?A%1_P!L_'GAF;T_Z9U_&O G_);\'?\
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MF1G'O7\T?2<=^&N%ME;B+&;:?\R.1^N>$'_(VSG_ +%=#_U8Q/1OL9]OS/\
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MDG*$8":3>/D]>/EZG'-?YUTOXU'_ *_4?_3U$_JF?P3_ .O=3_TW4/XJ8O\
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M$+,R>%/#K[0=VD6C9QURAKHOL!_NC\C_ (T <C%8A98FPPQ+&<G( PZ\DE0
M!UR>*_@U_:>^ _QUU#]I7]H?4M/^"'QDO],U#XY?%>^T[4K+X6^.KO3]0L;O
MQUKD]I>V-[;Z#+;7EG=V\D<]M=6\LD%Q"Z312/&ZL?[^/L!_NC\C_C4XBNP
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MU(^H/AX4W_A0/Q[_ .B%_&C_ ,-3X^_^9^O]'7R[S_GO/_W^E_\ BZ/+O/\
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M/<WT]W/(]M%;6[& @'GWB[]NGXTZ!XU\;?%&"T^'4'[,?PW_ &W?#7[$VO\
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M$_3_  SH?BWQ;$&F\4>/+SPEJ>H:Q=)!;SP#1H5TN@#A? W_  4'\1>-M?\
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M ?IA]LLO^?VS_P# F+_XJC[99?\ /[9_^!,7_P 57YGT4 ?IA]LLO^?VS_\
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7\V]C_P!UO^^3_A0GWU_WE_F*Z:@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $_ BH# 2(  A$! Q$!_\0
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M\/\ [1OC[X\:I::9^S?I?@FVL--^'G@CQYXS\5?%%-=O-/TO4OB+IDVK^&/
M.G:-X8O-/O+G7(--MYM1\1:M)J'V#2H'L;:&TO;F]!A]J^ ?Q;N_B_X-U+4]
M;\/IX5\8^#_&'B7X=^//#T%[_:5AI_B[PC>BRU)](U QPR7NBZC$]KJFDSSP
M0W'V*]BBN(_/BD9@#K_^$]?_ *$CQ_\ ^""#_P"6-'_">O\ ]"1X_P#_  00
M?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?\)Z__0D>/_\ P00?_+&N_HH
MX#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\ \$$'_P L:[^B@#@/^$]?_H2/
M'_\ X((/_EC1_P )Z_\ T)'C_P#\$$'_ ,L:[^B@#@/^$]?_ *$CQ_\ ^""#
M_P"6-'_">O\ ]"1X_P#_  00?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?
M\)Z__0D>/_\ P00?_+&N_HH X#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\
M\$$'_P L:[^B@#@/^$]?_H2/'_\ X((/_EC1_P )Z_\ T)'C_P#\$$'_ ,L:
M[^B@#@/^$]?_ *$CQ_\ ^""#_P"6-'_">O\ ]"1X_P#_  00?_+&N_HH X#_
M (3U_P#H2/'_ /X((/\ Y8T?\)Z__0D>/_\ P00?_+&N_HH X#_A/7_Z$CQ_
M_P"""#_Y8T?\)Z__ $)'C_\ \$$'_P L:[^B@#@/^$]?_H2/'_\ X((/_EC1
M_P )Z_\ T)'C_P#\$$'_ ,L:[^B@#@/^$]?_ *$CQ_\ ^""#_P"6-'_">O\
M]"1X_P#_  00?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?\)Z__0D>/_\
MP00?_+&N_HH X#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\ \$$'_P L:[^B
M@#@/^$]?_H2/'_\ X((/_EC1_P )Z_\ T)'C_P#\$$'_ ,L:[^B@#@/^$]?_
M *$CQ_\ ^""#_P"6-'_">O\ ]"1X_P#_  00?_+&N_HH X#_ (3U_P#H2/'_
M /X((/\ Y8T?\)Z__0D>/_\ P00?_+&N_HH X#_A/7_Z$CQ__P"""#_Y8T?\
M)Z__ $)'C_\ \$$'_P L:[^B@#@/^$]?_H2/'_\ X((/_EC1_P )Z_\ T)'C
M_P#\$$'_ ,L:[^B@#@/^$]?_ *$CQ_\ ^""#_P"6-'_">O\ ]"1X_P#_  00
M?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?\)Z__0D>/_\ P00?_+&N_HH
MX#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\ \$$'_P L:[^B@#@/^$]?_H2/
M'_\ X((/_EC1_P )Z_\ T)'C_P#\$$'_ ,L:[^B@#@/^$]?_ *$CQ_\ ^""#
M_P"6-'_">O\ ]"1X_P#_  00?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?
M\)Z__0D>/_\ P00?_+&N_HH X#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\
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M9B H!)( K\^_AG^UYXJ\9?&SXHQ:SHV@:5^SSHWP7U3XL_#/7X(M0D\9^)M
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M/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\
MH)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@
MU7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z
M*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$
M:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB
M_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_
M .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:
MMO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(
MO_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y
M)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=
M_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^
M@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"
M@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:
M/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\
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MU?9>'G_)=\'_ /90Y9_Z?F?(\??\D1Q9_P!B#,O_ $S _F*N/^/>?_KC+_Z
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M.IZ=8^+?"-XMGJ$VCW[Q037>B:I#+:ZKI,MS!%<K97L4-RIGAD=@#W"BBB@
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M?_KC+_Z U?L)_P %#O\ DG7[&7_9(8O_ %'/!M:_M)O^3"Q_['>$7_E_DO\
MD>A^S6_Y2"I?]B7,/_59G1\Z_L*P_:/VL/A%!YT]OYE]KP,MM(89U \/:B2$
MD )4-C#8'*DCO7]-_P#PC0_Z#WB7_P &I_\ C-?S+?L&?\G;_!__ *_M?_\
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M)UMK#3M/^(6AWE]>W#AF6"UM;>XDGN)F56*QQ([D*2!@&O0O^$:'_0>\2_\
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M27O>SA&.R05\2_\ !1?_ ),U^-?_ &!]%_\ 4HT2OMJOB7_@HO\ \F:_&O\
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MBM##8?$8FHI.GAJ%?$5%!)S<,/1K5YJ*;BG)PHS44VDY.*;2;:]&HK^6R/\
MX*<?MEM'&S?$3PV2R(2?^%=>$ADE02<?8>,GM7] W[-?Q1U'QO\ LZ?!SXB_
M$GQ!I"^)?&?@W2]4UC4KC^SM M+_ %6Y262<VUHK6]I 2B;_ +/;*%15+!0
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M/%TH4<!AL+)5XXW#45)U*+YI1]G4FN1^[=J6Z1]F4445_.9_004444 %%%%
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MK^&/H?\ _)O>(?\ LL<1I_W1<J_KY']O_32_Y.1PW_V1.%U_[KN<'2U\ ?\
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MU(2((BD( RH Q8[8TYSFO2_:5?\ */,/^ROR/_T]$U_9I?\ *1T?^R/XA_\
M4:9YA^R-_P G1? 3_LI&E?\ I%J5?U@5_)U^R;&TW[3GP)B2:6V:3XBZ6JSP
M%!-"39ZB=\9D5T#@ @;E888\9P1_5"= O"2?^$EUT9/3?8<>W_'C7\#_ $./
M^2,XQ_[*S"_^L]AC^[_IL?\ );\$_P#9'XO_ -:7%'245S7]@7G_ $,VN_\
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M:?\ )/\ 'O\ V/\ (_\ U1XL_P!#?IN_\E#X>?\ 9/Y__P"K[!'25X)^U/\
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MC>A;Q'IH#ID%=R$[EW C(&01D5_7FV@WA)(\2ZX,]@]A@?3_ $&O\V?H9_\
M(K\0?^QIP[_ZK,S/](OIO?\ (U\./^Q5Q-K_ -U7*3I*\?\ VA/^2"_&K_LE
M/Q!_]135:[O^P+S_ *&;7?\ ONP_^0:\E^/NBW</P+^,TK>(=:F"?"OQ^QBE
M:R,<@'A;524<+9JQ1P"K!64[2<$&O[GR?_D;Y3_V-LK_ /5GEQ_ V;?\BK-?
M^Q7F7_JNQY_'E#_JHO\ KFG_ *"*_7G]HX;O^">'[$?+#YM.^Z[(?^1/\0=T
M*DCV/%?D-%_JH_\ KFG_ *"*_6_]H>V>+_@GQ^Q5.UY=3+,UAMMI3$;>#/A'
M7F'DA8ED78%*+ND?*NV[+8(_3/VA7_*.G$'_ &%4_P#TK+#XG]GG_P I)<+_
M /7FK_Z8S<_.CP\@'B/PX=TO'B'0NLTI_P"8M9]B^*_LTK^,[P_D^(?#P!()
M\0:& 1U4G5;0!A[KG(SD9 R#TK^PTZ#>$DCQ+KH![![# _\ )&O\Q?H9+_9?
M$3_L*X8[_P#0+G7J?Z;_ $X&WBO#6_\ T"<5_P#J7D1TE?,7[:/_ ":A\?\
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M"7AFU\67L;0WGBBWT'2H/$5W"R)&T5SK<5HNI3QM'%&C)+<NI2-%(*HH'&>
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M),P_]5N='SW^P9_R=O\ !_\ Z_M?_P#4<U*OZCJ_EQ_8,_Y.W^#_ /U_:_\
M^HYJ5?U'5_#'T/\ _DWW$/\ V6%?_P!4N5']O_32_P"3D<-_]D3A?_5YG 5\
M ?\ !3G_ ),]^(/_ &%?!_\ ZDEA7W_7P!_P4Y_Y,]^(/_85\'_^I)85_;W
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M &1_$/\ ZCS/*OV1O^3HO@)_V4C2O_2+4J_K K^3_P#9&_Y.B^ G_92-*_\
M2+4J_K K^!_H<?\ )&\8_P#9687_ -9[#']W_38_Y+?@G_LC\7_ZTN*"OD#]
MOK_DSSX\?]BA#_Z?M'KZ_KY _;Z_Y,\^/'_8H0_^G[1Z_N'A#_DK.%_^RBR/
M_P!6N /X/XL_Y);B7_LG\Z_]5>-/Y-J_2#]I3_DV#]@;_LE/BG_TI\.U^;]?
MI!^TI_R;!^P-_P!DI\4_^E/AVOI?VD'_ "CAC?\ LJ,B_P#4J@<7[-O_ )25
MRW_LE^(O_4#$GA'[-W_)POP/_P"RI^"__3U:U_6_7\D'[-W_ "<+\#_^RI^"
M_P#T]6M?UOU_GA]#;_DF../^RCRK_P!4-0_T&^FW_P E7P%_V3&;_P#K0TPK
MY?\ VU/^34?CS_V3O6O_ $&*OJ"OE_\ ;4_Y-1^//_9.]:_]!BK^Y.&/^2EX
M=_['^2_^K7+C^#.)/^2<X@_[$><?^JO'G\AT_P#QY3_]>DW_ *(>OV%_;H_Y
M-X_8=_[)S=_^HQX'K\>I_P#CRG_Z])O_ $0]?L+^W1_R;Q^P[_V3F[_]1CP/
M7U'[1[_E'W%?]CC"_P#J;DAYG[-__E(G+?\ L4X[_P!5V=GPI\#?^2W?!G_L
MJ_P\_P#4LTFOZ]Z_D(^!O_);O@S_ -E7^'G_ *EFDU_7O7^=OT-/^2?X]_['
MV1_^J/%G^AWTW?\ DH?#S_LG\_\ _5]@@KP3]J?_ )-J^/7_ &23Q]_ZC6HU
M[W7@G[4__)M7QZ_[))X^_P#4:U&O[DR#_D?9'_V.\G_]6V6'\%9Y_P B3.O^
MQ/FW_JKS(_CM7_4#_KD/_0*_7G]K3_DRG]A;_L78O_4-LJ_(9?\ 4#_KD/\
MT"OUY_:T_P"3*?V%O^Q=B_\ 4-LJ^Z_:*_\ */&;?]C'#?\ J3E)\U^SI_Y2
M.R'_ + <5_ZA9R?G]\-O^2D?#G_L?_!?_J2:97]BM?QU?#;_ )*1\.?^Q_\
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M\:_^P/HO_J4:)7VU7Q+_ ,%%_P#DS7XU_P#8'T7_ -2C1*_M[@G_ )++A/\
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M/^4<,;_V5&1?^I5 XOV;?_*2N6_]DOQ%_P"H&)/"/V;O^3A?@?\ ]E3\%_\
MIZM:_K?K^2#]F[_DX7X'_P#94_!?_IZM:_K?K_/#Z&W_ "3'''_91Y5_ZH:A
M_H-]-O\ Y*O@+_LF,W_]:&F%?+_[:G_)J/QY_P"R=ZU_Z#%7U!7R_P#MJ?\
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MS_R4O#O_ &/\D_\ 5MEI_GIQ)_R3N?\ _8CSC_U5Y@?R)KT'T'\J_6OXP?\
M*,W]E'_L;F_EXRK\E%Z#Z#^5?K7\8/\ E&;^RC_V-S?R\95^F_M /^4;^*?^
MOD/_ $G"'P_[/_\ Y25X.]9_ECCXE^!W_);?@W_V53P#_P"I/IM?U\5_(/\
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M=4@_98^.TD^OW5U$OP\UDM ]E8QJX A)4M'&K@, 5.#G!)'.*^O*^7_VU/\
MDU'X\_\ 9.]:_P#08J_N3AC_ )*7AW_L?Y+_ .K;+C^#.)/^2=X@_P"Q'G'_
M *J\P/Y#I_\ CSGR,_Z)-QZ_N&XK]>OVX(+B+]GW]B1YKV2YCE^'=V8HGAAC
M6W'_  C?@IL*T:AG^5DC^<GY8E8?,S9_(6?_ (\I_P#KTF_]$/7["_MT?\F\
M?L._]DYN_P#U&/ ]?4?M'O\ E'W%?]C?"_\ J;DAYO[-_P#Y2(RW_L58Y_\
MF.SO_,^$?@BK/\:_@ZB2&%W^*GP_5)557:)V\5:4JRJC@HS1L0X5@58@!N":
M_K7.D:R22/$]X 22 -/T[ !/09ASQTK^2OX&_P#);O@S_P!E7^'G_J6:37]>
M]?YV_0T_Y)_CW_L?Y'_ZH\6?Z&?3=_Y*'P\?_5/Y_P#^K[!'-_V1K/\ T,]Y
M_P""_3O_ (S7A7[3^F:K%^SC\=I)?$-U<1K\)O'I>%K&P19%'AO4"4+)$KJ'
M *EE(8!B5Y KZ9KP3]J?_DVKX]?]DD\??^HUJ-?W)D'_ "/LC_['>3_^K;+#
M^"\\_P"1)G7_ &)\V_\ 57F1_':O^I7_ *Y#_P! K];OVK;>XC_8Q_8=EDO9
M)XI/#D7E6[10HD!/A&U?*NBB1\(5B&\G*J&/S$U^2*_Z@?\ 7(?^@5^O/[6G
M_)E/["W_ &+L7_J&V5?=?M%/^4>,V_[&.'_'$Y3_ )'S7[.G_E([(?\ L!Q7
M_J%G1^?GPY#-\1OAXJN8V;Q[X-59% +1L?$>FA7 8%24)# ,"I(P>":_KT.D
M:R22/$]X,GH-/T[ ]N8LU_(;\-O^2D?#G_L?_!?_ *DFF5_8K7^;/T,_^17X
M@_\ 8TX=_P#59F9_I%]-[_D:^''_ &*N)O\ U:Y2<W_9&L_]#/>?^"_3O_C-
M>2?'[2]6C^!?QF>3Q'=3QK\+/'S/$UC8*LBCPMJA:,LD090Z@H64A@&)'(%>
M_P!>/_M"?\D%^-7_ &2GX@_^HIJM?W/D_P#R-\I_[&V5_P#JSRX_@?-O^15F
MO_8KS+_U78\_C3B_U4?_ %S3_P!!%?K?^T/!<)_P3Y_8JFDOI)H9&L/*M6AA
M1(,^$=?(VRH!*^Q047>3D,6;D+C\D(?]5%_US3_T$5^O7[1O_*/#]B/_ 'M.
M_P#4/\05^F_M"O\ E'3B#_L*A_Z5EA\1^ST_Y21X7_Z\U?\ TQFY^<'A_GQ#
MX>&<$^(-# /<$ZK: $>X/(!X.,'BO[#CI&LDD_\ "3W@]AI^G<?^0:_CQ\/?
M\C%X=_[&'0O_ $[6=?V8U_F)]#+_ '7Q#_["N&/_ %%SH_TW^F__ +UX:_\
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M5Z%0!P'CW[_@C_L?] _]$:C7?UP'CW[_ ((_['_0/_1&HUW] !1110 4444
M%%%% !1110 4444 %?G-_P %4/\ DT/Q%_V._P /?_4DMJ_1FOSF_P""J'_)
MH?B+_L=_A[_ZDEM7V7AY_P EWP?_ -E#EG_I^9\CQ]_R1'%G_8@S+_TS _F*
MN/\ CWG_ .N,O_H#5^PG_!0[_DG7[&7_ &2&+_U'/!M?CW<?\>\__7&7_P!
M:OV$_P""AW_).OV,O^R0Q?\ J.>#:T_:3?\ )A8_]CO"?^IV3'H?LUO^4@J7
M_8DS#_U6YT?/?[!G_)V_P?\ ^O[7_P#U'-2K^HZOY<?V#/\ D[?X/_\ 7]K_
M /ZCFI5_4=7\,?0__P"3?<0_]EA7_P#5+E1_;_TTO^3D<-_]D3A?_5YG 5\
M?\%.?^3/?B#_ -A7P?\ ^I)85]_U\ ?\%.?^3/?B#_V%?!__ *DEA7]O<!?\
MEOPC_P!E%E/_ *EQ/X4XY_Y(SBK_ +)_-?\ U$D?RWW7_'K=?]>UQ_Z)>OV.
M_;P_Y-R_86_[)Y=?^H9\/:_'&Z_X];K_ *]KC_T2]?L=^WA_R;E^PM_V3RZ_
M]0SX>UZ_[1W_ )1^Q7_8UP__ *FY"3^S@_Y2)RW_ +%F-_\ 5=GY\M_L3?\
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M $&*O[DX8_Y*7AW_ +'^2_\ JURX_@SB3_DG.(/^Q'G'_JKQY_(=/_QY3_\
M7I-_Z(>OV%_;H_Y-X_8=_P"R<W?_ *C'@>OQZG_X\I_^O2;_ -$/7["_MT?\
MF\?L._\ 9.;O_P!1CP/7U'[1[_E'W%?]CC"_^IN2'F?LW_\ E(G+?^Q3CO\
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M1_3>_P"1KX<?]BKB;_U:Y4%>/_M"?\D%^-7_ &2GX@_^HIJM>P5X_P#M"?\
M)!?C5_V2GX@_^HIJM?W/D_\ R-\H_P"QME?_ *L\N/X%S;_D59K_ -BO,O\
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MZW3S/,,7+V=%XO%\]+V.)I6J>TC>?-'D]WF?1U\ ?\%.?^3/?B#_ -A7P?\
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M:O0?0?RK]:_C!_RC-_91_P"QN;^7C*OLP?\ !(W]G4 #_A*/B9P,?\AK3/\
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MQ%/DC:ISQYI7CRV?]N_25\6^$?%;&\(8CA-YNZ>28+.</CO[6RQY;+VF/QN
MKX?V$7C<9[:/L\/4]I*]/DERQM+FNNBHK.T^WU* 2_VAJ,>H%BOE&.Q2R\H#
M.X';//YF[@\[=N.,YK1K^D#^8CSWP/\ \A7XA?\ 8Z3_ /IGTBO0J\]\#_\
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MLK074(FC:,RVTZ_-#/'NWPRK\T<BJXY K^=;]C*]^,L'Q'^,?Q#^)GC;]O\
M\1?"G]GC]I+]M>V;XP>)OVE_!/B_X+Z_\/\ ]GOXA>,]#\.?##6?@W#+>>-=
M4N5\*6,FG7.M^(_#GA22]U_PY#JEAXFU&6_ACD /Z,**_F6_:,_;[^.O[5'[
M.EAXITO]FC]HG]G&U\+?M+_\$\?BK\#_ !(_C?Q3\-=%_:/\'?$S]IKP)H2?
M#3Q)>Z[X4\ WH6?2-7TV;QSHMG%XQ^%M]::UIMYIWC;Q+#ILEG=_M]^RM^T5
MXB^/6G_%O1?'WP[L/AC\4/@5\6]<^#_Q$\.:!XR_X6'X-N=7TW1]#\2Z7X@\
M%^-9?#G@[4-9T#7/#OB32;U8M;\(^&==TJ^:\TS4M(B>VCGN0#ZKHHHH **_
M&K_@HE\1?C5^RW^T5^SG^UCX$^)_Q&N/@3X"T+QC??MB_ 9]275/AQJWP A\
M5?"WP%K7QAT+PV=.DO=(\:_!&?XH'XEZK?Z9J=NNN^%_#VH:??VTR0QD9>L?
M'+XM>,/^"D]_KFA^/_%U]^SS\.?V'OCK\4OA7\'?#OCSP_X&^'7QC^('PJ^)
M?@3PAJ?CSQIXIU+&D7>AZY>^,M<\'^&K_P 1:G;>#="LO#-AX]$UQ::G]IA
M/VIHK\,-#_X*_?$+Q5IT'A_P7^S3\//B'\4)OVSOA_\ L:RWG@7]I@:C\ [+
M7_B5\+;SXDZ#XY_X6QJWP<T3Q9KV@:9-I^I>'-<B\'?";Q';32:;/KGA?6?$
MFDWNC2:GZQX__:=^.O[0/PC_ &I='\-_!N'P?\%_"O@C]J3X.>+_ (_> ?VA
MY](^)_P_^,OP8^'NN0>)=4\+^#S\/]!U27P1)\0K'4?!W@KQOH_BZ'QT]Q96
MOB?6?AWX;TJ[+V@!^N]%?DK_ ,$M_P!I[XF?$;X<?";X%?&#X:GPAXE\,_L5
M?LK_ !J\*^,)/B@WQ,USX@^#?B)H.M^&9=3\?[M T]/"_CE=9\%R:K=Z?9^)
MO']MJ-AK]O=7'B*#5+:_L$_6J@ HK\N?^"KWQ\UGX4?L^CX?> /CU/\ LV_&
M+XQ)XDB^&WQ8MO"NK^+I?#MS\.=+A\97T+Z?I7A_Q']EMO%FHQ>'?AU<ZK=V
M#1Z;%XW-Y;+/>PV\#\K;?\%+O%OB;X&_\$[?B-\'/@3:_&#Q!^WJ+/PW:S:E
M\2].^%W@_P"&'CJV^&>N>,?$-IXOGO\ PYXH\726FEZ]X5\2>']1L]&\'W^K
M:2VDWB7%D^J)::1>@'ZX45^.OP9_X*;_ !E^/'Q5^%?PI\%?L>P:5J6O_!WX
MF?%7XL:KXP^/>A:9:>#]3^!W[0?B;]F[XN?#?X>6FE^!M9O/B%XDT_QWX6OK
MCP9K?B=?A=X1\3Z1-;7&IZSX883K#X=^RU\98?C9^TS_ ,$L/B[X*T;X@_!S
MP)\9?V(_VXM8OOV?KSXL:_XY\%>&]2\,_%GX#&TO;^.9X-+\1^,K6^\0Z_;S
M^++B"ZE33IK72=)EBTZS62[ /W[HHHH **^-OV_O#GBSQ1^RA\4M,\!_%GXC
M_ _QJ\&@+X6^)_PKUQ-"\6^%-;O?$FDZ18ZE'+-9W]KJ6FVTNI"XU/0[VUEL
M]8M86LI]BR>8OY,_'3]M/]H;QY_P3OU+P/IOC[5/A'^V-\)/&EI\)_VN/%O@
M&ZLM/\3>!]0^#?QD^'G@/QQK_A&2ZAEDT2/]H/3?$OACQ'\//$$&DZC8P>$_
M'LCV_ES10WEN ?T7T5^4_CK]NGQ;\#/VH/@]^QA9?#WP/XZN/B(=2^%_PN\1
M^(_VDY]6^,NM^+O!WP&U_P"*5AXK^,/@W2OA;XDB\&^#/$\GA&Y\-7?C'7_&
M\WC[5-9OCXHL?AOJ>C/<31>K?LB_MD>/_P!J/_A"WN/@_P"$O S6_A'Q])^T
M#HT?Q3UCQ#XG^!?Q:\'_ !+UKX;6'PGGTBZ^%WAJ'Q/=ZM>^%?%VH7>MSW_A
MDZ9;: 9(='U2RU;2+^\ /T"HHHH **^9/VTO[9B_9%_:7U'PYXN\7> O$7A_
MX'?$[Q7X?\8> ];D\.>+/#^N^$O"&K>)M'O](UB.&X-K+'J.E6RW"O!-#=6;
MW%I/%)#/(I_++X5_\%!/BK\"/@$GA;Q!\.]0^-NM_"']C_\ 8T_:2U/XE?$;
MX[ZM<>./BCI?[3?B"30?'#>)6/PDOCX?\3^"_$7]KWGAW1K:;7-'UKP]%I>E
M?VIX::W*Q '[T45^0GA__@I]XZOOC/XD\'>*OV5[KP/\(_"'[9?Q!_8QUKXE
MW_QF\,ZYXLN?%?A'X#Z_\>](\=Z-\-O#WAN_MIO"6K>'?#LMGK%KJGCC2M<T
M.76M%DL;+Q!<1Z[8:/Z9^PS^W]XY_;(\6>(X-5_9.^+?P5^%NH?#W0?BI\%_
MB]XUL]<L?#WQ.\*ZWK$]@=(FL?%'A'P=<V/B^QTBZ\*^*77PA-\0?!%UHWB:
M-;;QN;ZP:UN@#]+Z*** "BO@#_@J9J7C#P[_ ,$_?VI_&GP^^(7Q"^%WCKX?
M?"?Q+X]\(>-/ACXA?PSXJTOQ#X5LWU32Q%?K:7T=SIL]U#'%JNE7%K-;:I9&
M6SF"I+N7YLT3]OGQU\([OQ5\%)_A)<_$ _ /XT_\$\/@-JWQ \7_ !SU76O&
M?CKP=^VTWAWP]:_%+59KCX5>==?$#P1KVO6<VM>#+J[_ +/\3V9NKNV\<Z5<
MK#8S '[)45^ ?[*_[4GQ!_9N3QGI/B^QNOB%\$O&O_!5O]L_X%>-OCO\6OC3
MXGN/$7P38^*M6U#X4V$FE7G@KQ7_ ,)#X5\1ZMIO_"OM#5O$W@W2/"VM:MX9
MTE(3:7\;I^T/P*\;^./B1\*/!OCOXB>"M%^'OBCQ5ISZU-X2\/\ BVZ\<:;I
MNE7MW<2^'95\27OA;P;/>7.I: =-U2]@.@6J:==WDVG1SWR6JWUP >MT444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD5Z%0!P'CW[_ ((_['_0/_1&HUW]<!X]^_X(_P"Q_P! _P#1&HUW] !1110
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MWXO_ #T+_P"7%'_"::U_T3OQ?^>A?_+BOR!_XAP_^",O_1G<_P#XD=^UE_\
M/VH_XAP_^",O_1G<_P#XD=^UE_\ /VH _7[_ (336O\ HG?B_P#/0O\ Y<4?
M\)IK7_1._%_YZ%_\N*_('_B'#_X(R_\ 1G<__B1W[67_ ,_:C_B'#_X(R_\
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M]J /U^_X336O^B=^+_ST+_Y<4?\ "::U_P!$[\7_ )Z%_P#+BOR!_P"(</\
MX(R_]&=S_P#B1W[67_S]J/\ B'#_ .",O_1G<_\ XD=^UE_\_:@#]?O^$TUK
M_HG?B_\ /0O_ )<4?\)IK7_1._%_YZ%_\N*_('_B'#_X(R_]&=S_ /B1W[67
M_P _:C_B'#_X(R_]&=S_ /B1W[67_P _:@#]?O\ A--:_P"B=^+_ ,]"_P#E
MQ1_PFFM?]$[\7_GH7_RXK\@?^(</_@C+_P!&=S_^)'?M9?\ S]J/^(</_@C+
M_P!&=S_^)'?M9?\ S]J /U^_X336O^B=^+_ST+_Y<4?\)IK7_1._%_YZ%_\
M+BOR!_XAP_\ @C+_ -&=S_\ B1W[67_S]J/^(</_ ((R_P#1G<__ (D=^UE_
M\_:@#]?O^$TUK_HG?B_\]"_^7%'_  FFM?\ 1._%_P">A?\ RXK\@?\ B'#_
M .",O_1G<_\ XD=^UE_\_:C_ (AP_P#@C+_T9W/_ .)'?M9?_/VH _7[_A--
M:_Z)WXO_ #T+_P"7%'_"::U_T3OQ?^>A?_+BOR!_XAP_^",O_1G<_P#XD=^U
ME_\ /VH_XAP_^",O_1G<_P#XD=^UE_\ /VH _7[_ (336O\ HG?B_P#/0O\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #O BH# 2(  A$! Q$!_\0
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M?75T4N9?R0_\G_\ DQ\K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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MQ7=^'=&\66^BW[75K!#-<R^'?$.C:HLEC+=6P@OXD:83K+%& >@T4A( ))
M!)).  .223P !R2>E>3> ?C[\"OBMX;\2^,?A=\:?A-\2?"/@RYOK+QAXI\
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ME[S4&HRM_1+17XD?"K]K+]H*W_X*):5^SWXC^,4OC_P-K^F?%@>+_"/C_P"
M)_9_L_#'B'PA/#_PC&D_ #Q=KOV?4/C:GEFX&O75O?:S;MI5NVLPW""18X/H
MK_@I%\:?VB?@=\(_"OQ*^#/BC0? ]A9_%+X8>%_%=GJ_A'3_ !7KWB.R\:>.
M=%T"6QTJ[OM1.DZ':)8W-V+J[;3KW49)IK<6DEJJ22-+RZM'$8?#N='FQ,(5
M*<G*2A:IS\J=X<RE>#6D6G>,N91>C6,INE6K<M3EH3E"<;1<KPY;M6ERVM)/
M5IJS5FUK^EM%?DO_ ,%+_C'^U'\"O#?A?XC_  ,^,&A>&-<U#Q=X%\!_#/\
M9XG^&7A_QIKGQ\\=^(O$*P:OH=QK5YJ4NN:?I]MH+&Z67PM96C:/!;7NHZO?
M>2T'E]7^T7\;/VFOAO\ M*_L,Z)9^(_"_ASX9_'/XD+X#\=_#RT\*V6JZ]=7
M]IX#U+Q'K33^-M0O[@6EE!J<<-KI<.B6%G.T%K/->WLS2QQ*H8"I4A1G&I1M
M6CB)13G)23PU-U*D6G#5N*:C*#E3YTX2G&49).6+A&52+A5O3E13:BFFJ\N2
M$D^;1)N[4E&?+:2BXM-_HE=?\CII'_8 UC_TLTRNKKBOM$UQXRTHS6<UF5T'
M5PJS/ Y<&\TS)7R9),;<<[B,Y&,X-=K7)/3D_P"O:\_M3[&\/M_XW^43D]3_
M .1N\+?]>/B+_P!%Z=765R>I_P#(W>%O^O'Q%_Z+TZNLHGM3_P '_M\PCO/_
M !_^VQ/ /"/[+OP-\!>+KSQSX-\&7'AWQ'J/B76?&.HSZ;XO\<1:9J/BCQ"T
MCZWKFH>'6\2OX<OM0U)Y6:YFN])FW,(V4*88BDV@_LP_ +PSJ_B36]&^%WAN
MWO/%EAXBTK6;>X2]U+13I?B^=[GQ7IFE>'-3O+SP]X=T_P 37$CRZ_9>'M+T
MNVUAW8ZA%<9-;/AWX^_"'Q;\5/&?P5\->.-*UKXE?#S0[+Q%XU\.V"W<W_"/
M:;?WCV$!OM4%N-(^V)=1F*[TZ&_EO[!BOVZVM]ZYXOP]^UY^SYXFU+4M/L/'
M]O;0Z?H?B3Q/:Z]K.E:UH7A7Q'X<\&OY?BO7/!_BG5M/L]!\6Z9X>.'U.ZT"
M_OXX8"+I3):D3UO_ +;+FO\ 66^2FY:U;NG*TJ;>S<792AO=*\?=5S/_ &96
M_@)<TU'^';G6D[;I-:J6VNCUT,/7?V.?A!-\._$/PS\%Z0/ N@>-M4\''QW=
MVEQJVOZ]XB\*>$-5LM1@\&Q:]XAUB^U;2=(EALAIMC!:7AL=$L[N_.F:=%+=
MRNWHUO\ LZ_!2T^(K_%>V^'VCP^.GU)M<.JI-J8L5\0OIJ:/)XFC\.?;CX8B
M\52Z7&MC+XHCT9/$$MON234FWN6E^%WQ]^&/QAOM9TGP7K&H-K>@V6EZMJ.@
M>(?#OB#PEKRZ%K@F.B^(K;2/$NFZ7?7WA_56MKF*RUBSAGL9)[>:W>9)T,=9
M+?M,_!E/B)%\,6\4S#Q%-XG/@:*^_L/73X1D\>"T-\? J^-AIQ\*'QB+<'_B
MG?[6&I?:%:Q\C[<IM@-XQN<&\1S1C*51>_S<LTN9SL[RBXP25W)<L6HJRD"6
M&2C)*E9M1@_=MS1;LHZ633D]DG=ZO6):T3]FOX%>'?&&L>.](^&OA^V\2:Z/
M$'V^>47M[I2OXL4)XJGTWPU?7ESX:T2Z\3QAH_$5WHND:?=:Y%-<Q:I-=1W5
MRLNE\+_@)\(O@S+J<_PT\$V'AFXU:ULM/N[F.\U;5+I-)TUIGTW0M/N=;U#4
MI](\.Z<\\SZ?X=TF2RT.R>1FM=/B8YKF-/\ VJO@5J/C&X\$Q>-XK?48IO$U
MK::QJ.E:SIO@W6;[P5;S7?B_3O#_ (WOK"W\*ZYJ'AJVM;V?5[33-6N9K:'3
M]1DVLEA=M#L?"_\ :(^%'Q@U;4-!\$Z]?3ZS8Z-9>)H],UOP[X@\,7FK^$]2
MN)+73O%WA^#Q%INFOK_A:^N(VAM]<TD7=@TC0J\R&> 2*:QG++G^L<G+!SYW
M4Y>1?!S7=G%=+IVZI#B\/S1Y?8\W-+EY5#FYG\5K*]WUMOTN>W4445S&P444
M4 %%%% !1110 4444 %%%% !7Y0_\%&M;M?V@/LO[ 7ASX9:Q^T#'\2_".H>
M-_VG/A=X!^+7@/X7>-].^ $+S:-H,#:WXSUS1(;&#QU\1Y-%MIX;6Y:]U'PM
MX=\4V!MC9ZDUU#^KU><VOP>^$EE\2M1^,UE\+?AS:?&#5]&C\.:M\5K7P1X9
MM_B5J?AZ);1(M"U'QU%IB>*+W1HTL+!(]+N=4EL46RM%6 "VA" 'X(?L^_$/
M]J/]K7_@F%\>?V3O#GQN\<_ W_@IQ^P??ZU\%?%=WX-\8^"+KX@:[XM^$MLN
MM_!C4_$FH0V/BCP_JGAG]HCX7-X9L/$?B*PL7LAXLU'Q->Z//%=:!&HS_'G[
M:GQ$UW]E+P]^W;\(?BO\0?!'P>^//BW]E?\ 9H(^.OCNY\&>!O@?I,U[/X:^
M/?Q<\1^*HOAKXQOOAWXE/Q-:/X$:_P#%"]\-:SI?AWQ-H^M>-+?2K>UNK#4H
MOWH\%?L_? ;X;>,/$OQ"^'7P2^$7@'Q_XT^T'QCXX\%?#;P;X5\8>+#>7HU&
M[/B7Q-H6BV&M:[]JU "_N/[4O;KS[T"ZEW3_ +RNQU#P%X%U;PCJ'P_U7P7X
M3U/P%J]A?:5JO@G4/#FCWOA'4],U-Y9=2T[4/#=S9R:->V&H27$\E]9W-E+;
MW;S2O/'(TCE@#^=L?$[]J?P_H7[(/PH\=?M]>$[RS^,W_!0OXC_!#2OB5\"O
MB3X<^(NK7?P+\5_LX_$7QIX9^&.M?&'QY\+O!UG\2?BC\.O&NGZ;%I?C[PYX
M,MV::\\,Z7K<.H^(K.^M)<ZX_:=^-'P[_;+^#-OH7[6'Q"^)'PLT7_@H/IO[
M!OQ5N_BWXC^&_@WPUK-I:_LZ>(-4U/P9IWP<T?1GU77_ !KX>\;^&M/\5^(/
MVB]2U;X=Q^)->\3IH/A;P7K'AQHW@_>N^_9;_9EU/2OAYH6I?LZ? G4-$^$<
MPN?A1HU]\(OA_=Z5\,;@7<%^)_AYI\_AZ2T\%S"^MK:]$OAN'37%W;P7&[SH
MHW7=NO@)\"[WQ+J7C2\^"_PFN_&.L>)/#OC+5_%ES\.?!]QXFU3QAX0MY+/P
MGXKU'79=&?5+[Q+X7M)I;7P[KMU=2ZIHEO+)!IMU;1.RD _G9^%/QB_:5^.O
M[<OA'0X_VL_B%?:Q\)?VIOVLX?VA_AMX ^-?P@\.?L]^.?@_\.'\>:%^SY\+
M/AKX#"S_ !;/Q%TWQCHO@[1/B+H]SI6GW^I3Z?\ $;4_%.JZGX=NO#4TWL/_
M  3)_:$_:D_:(^,'PE^-'B?]JGX(>+/ GQ6^''Q*@^.?[,FE_%K7OB'\1_!'
MQ3T"_LWTQ](^$D_P3\!7/[,DWPIU*#4?A_\ $/PQKWC7Q;IOB"75-(N/MM_K
MKZ?JNI?5'PI_X)8Z=X7^(>D^+/BUXB_9_P#C'-X6^)</Q7\/?%Z7]DCP'X*_
M;!UGQ78>,9?'&DW'Q#_:1T7Q-<OXAGMM8E$>IZOX>\!^#]9\0:?$;'4+Q;>[
MO4G_ $T\+_"/X4>!_%/C'QSX+^&/P]\(>-OB)=0WWQ \8>%_!?AOP_XI\<WM
MN"+>\\8^(-)TVTU;Q-=0 D0W&M7=]-$"0CKDT ?C;^VSXW^)=W^V=\:?@Y#^
MW!\1/V6O .F?\$V[S]H_PB?"FI_#31AX?^*'@CXL^)M%G\802>+O"FMZAKWA
M^STFPTW_ (3;PVS7%EJNGW4=I*UD)K9SP?['7QB_:1_:O_:5\(:+\8?VH?'?
MPEUW0OV ?^">_P"U=XY^ _P__P"%>>'+.#XJ?$6S^):_%_2O$&@^(/#FN^*[
M#P)XG.DZ-+K'AZ:YL[W2);JP:#5=/>.T1OO3QE^P8_Q._;XA_:[^*^J_ OXG
M_#72?@AH_P &O"GP3\=_L[6?BKQ!X2GT/Q9?_$&Q^(6A?$_Q#X^U73[#Q?\
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M_P# I?YF/]@U/_H.W'_@#IW_ ,CT?8-3_P"@[<?^ .G?_(];%%',_+_P&/\
MD'*O/_P*7^9C_8-3_P"@[<?^ .G?_(]'V#4_^@[<?^ .G?\ R/6Q11S/R_\
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MT4RL#D\'J>M?)G_!1/X=CXB?LG?$JWCM_M%_X4M['QOIRJGF2"7P[=+->"(
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MD:-I-CIUA:Q#$<%M;06J1QHHY.!N=BSNS.S,3P%X(\/?#;P9X9\!^%+)-/\
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MX&V__P <K1V)_=7_ +Y'^%&Q/[J_]\C_  H]WM+[X_Y!KY?<_P#,SO[:T?\
MZ"NG?^!MO_\ '*/[:T?_ *"NG?\ @;;_ /QRM'8G]U?^^1_A1L3^ZO\ WR/\
M*/=[2^^/^0:^7W/_ #,[^VM'_P"@KIW_ (&V_P#\<H_MK1_^@KIW_@;;_P#Q
MRM'8G]U?^^1_A1L3^ZO_ 'R/\*/=[2^^/^0:^7W/_,SO[:T?_H*Z=_X&V_\
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M^1L45Y[XY\=-X"\%^*_&VLZ4(-+\*>'M6U^]DDU&T"F'2[*:[,?5?FF,0B0
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MYEY_^ R_R-BBL?[;JO\ T!&_\&-I1]MU7_H"-_X,;2CE?>/_ (''_,.9>?\
MX#+_ "-BBL?[;JO_ $!&_P#!C:4?;=5_Z C?^#&THY7WC_X''_,.9>?_ (#+
M_(V**Q_MNJ_] 1O_  8VE'VW5?\ H"-_X,;2CE?>/_@<?\PYEY_^ R_R-BBL
M?[;JO_0$;_P8VE'VW5?^@(W_ (,;2CE?>/\ X''_ ##F7G_X#+_(V**Q_MNJ
M_P#0$;_P8VE'VW5?^@(W_@QM*.5]X_\ @<?\PYEY_P#@,O\ (V**Q_MNJ_\
M0$;_ ,&-I1]MU7_H"-_X,;2CE?>/_@<?\PYEY_\ @,O\C8HK'^VZK_T!&_\
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MT:-.G1HT80I4J5*$:=*E3IQ4(4Z=.$8PA"$(QC&$8QC&*22204445F6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
MI=?\CII'_8 UC_TLTRNKKE+K_D=-(_[ &L?^EFF5U=7/:G_U[7_I4R([S_QO
M_P!)B<GJ?_(W>%O^O'Q%_P"B].KK*Y/4_P#D;O"W_7CXB_\ 1>G5UE$]J?\
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MUC#23SR)&J\DCY2_;J_8^L_VC?!L?BGP=%%I?QI\#V[7?A/5HG^R/KUK;/\
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MS_X[1_8MO_S]:I_X,[S_ ..UL44<TN_Y?Y!RQ[?G_F8_]BV__/UJG_@SO/\
MX[1_8MO_ ,_6J?\ @SO/_CM;%%'-+O\ E_D'+'M^?^9C_P!BV_\ S]:I_P"#
M.\_^.T?V+;_\_6J?^#.\_P#CM;%%'-+O^7^0<L>WY_YF/_8MO_S]:I_X,[S_
M ..T?V+;_P#/UJG_ (,[S_X[6Q11S2[_ )?Y!RQ[?G_F8_\ 8MO_ ,_6J?\
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M*<X0C>SE-J*6C:UE))O3;<^D?[=TK_GZ/_@/=?\ QFC^W=*_Y^C_ . ]U_\
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M5VN514')RNK62;OI:XV[1<G**25VWI%+>[;DDE;6[=K=3IO[=TK_ )^C_P"
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MEN9/VOK\0/C+:_ ']I3XS?#2?PC\0?B?^S%XW\:?%[X0^(/%7A?XN? 7XA>
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M+WX=.*2=%J2IN+G34O:6<8KG7O).4>:47RN,5).5VDI/W9:'PH^'?[!7PO\
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M5^?/[5<_PT^%_P"T!^SE^T+KGQ4OO!_Q!T/3_'OPSTWX:Z1\/]9^*OB+XT^
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M?AGX\\3?LQ?LE_MK_ Z3P_'\1_B(/"_@GXL?!SQ=XAU?PUXTUGQ!JWB_QMX
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M;>S76M1TJ_GN5<?0G[%?B_6]6^.W[1WA'3_B)#^T5\+_  AHOPQ;PM^TA?\
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MX^U<H2I>U;A3UTJ2HQ=J=+E<%.]3])Z_ _\ :Q_:D^*L?BC]J3PQ)^T1X_\
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M?%KP=96'B72/ 7PVD^!GQ@\;>'+[7-&L9-%^,7Q_\.VBP^"/@EKGC/5$DLO
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M_P"1N\+?]>/B+_T7IU=97-/:G_@_]OF;1WG_ (__ &V(4445!84444 %%%%
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M:YFE).C*4)I6<>9.Z:<6KJRC#M.,K2@TI62ISJ34=+V?M(QE%ZWM:UM5IJ_
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MTDJRQI,)%'1^+(?"]QX7\1P^-XM%F\&R:'JB^*HO$B6;^'W\._8IO[9&MIJ
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MBF66S?RPR^OV\5O!;P0VJ116L,,45M% JK!';QHJ0I"J818DC"K&J *$ "\
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M'M[/1Q:YG9P<Y1Z:)U%&;MM[R36VR3?)ZG_R-WA;_KQ\1?\ HO3JZRN3U/\
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M/K&GIJD,,[6MS?W,<4!3Z3_9D_9_3]GGP1XDT.]\8:AX_P#&/Q#^)'C+XO\
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M ),ZJBN5_LGQ1_T-J_\ @@L?_C]']D^*/^AM7_P06/\ \?HY8_\ /R'W3_\
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M?\D__)/_ ),ZJBN5_LGQ1_T-J_\ @@L?_C]']D^*/^AM7_P06/\ \?HY8_\
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M=/\ ^0#F?\D__)/_ ),ZJBN5_LGQ1_T-J_\ @@L?_C]']D^*/^AM7_P06/\
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M7_P06/\ \?HY8_\ /R'W3_\ D YG_)/_ ,D_^3.JHKE?[)\4?]#:O_@@L?\
MX_1_9/BC_H;5_P#!!8__ !^CEC_S\A]T_P#Y .9_R3_\D_\ DSJJ*Y7^R?%'
M_0VK_P"""Q_^/T?V3XH_Z&U?_!!8_P#Q^CEC_P _(?=/_P"0#F?\D_\ R3_Y
M,ZJBN5_LGQ1_T-J_^""Q_P#C]']D^*/^AM7_ ,$%C_\ 'Z.6/_/R'W3_ /D
MYG_)/_R3_P"3.JHKE?[)\4?]#:O_ ((+'_X_1_9/BC_H;5_\$%C_ /'Z.6/_
M #\A]T__ ) .9_R3_P#)/_DSJJ*Y7^R?%'_0VK_X(+'_ ./T?V3XH_Z&U?\
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:7M>\GU2?5=!QO[S::O)M)VO:T5T;71]3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %K BH# 2(  A$! Q$!_\0
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MIXY_\+/P)_\ +*ODI4SP.!G_ #]?_KBK21@=OP]?K_A]>.: /J[_ (;RU?\
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MP^_^6-/'[5/Q&)P/V9/&/_AP/A]_\L:S53/; _S^9]ZG1,\ 8'KC.?\ '^E
M%X?M2_$@G'_#,GC#G_JH7P\_^65/'[4'Q+/(_9D\7_\ APOAY_\ +*H4C"]@
M3^?K^?XU85,]?P'^- !_PT_\3#T_9C\8'_NH7P\_^65.'[3OQ-;./V8_&''K
M\0OA[_\ +&IE3ID?0?Y_E5E(R>HX]/3ZXZ4 4A^TS\4#G;^S%XN..N?B)\/1
M_P"Y'FGC]I7XID _\,Q>+>?7XB_#P'_TX5J*F. .<?Y^@_\ K585.G<^OI_G
MUZ_RH QA^TE\5#S_ ,,P^+/_  XWP\_^6%.'[1_Q6(S_ ,,P^+!]?B-\//\
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M\//_ )85UI.>3_\ J_\ K5"7)R!T]>__ -:@#EC^T;\6!_S;!XL_\.-\//\
MY84G_#1WQ8_Z-?\ %O\ X<;X=_\ RQKIZC9^H'Y_X4 <Y_PT=\5^_P"S#XL'
MU^(_P\_^6%'_  T=\5O^C8O%?_AQ_AY_\L*WZC9^H'Y_X4 89_:0^*HZ_LQ>
M*_\ PX_P\_\ EA3?^&DOBK_T;#XL_P##C?#O_P"6-;). 2:B9BWL/2@#)/[2
MGQ3_ .C8O%G_ (<;X>?_ "P_EQ1_PTI\4_\ HV+Q9_X<;X>?_+"M0G )]*B9
MR>!P/U_S_G- &<?VE_BB/^;8O%A^GQ&^'G_RPI/^&E_BE_T;%XM_\.-\//\
MY8U?J-G[#\_7_"@#5^'_ .TCJ_BKXEZ-\,O%?PB\1_#[4_$7A_7?$&C:C?\
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MP.P!%6%A;'3 [8(S_7_&@"!4YXY/^>?;ZYJPJ?B?Y?Y]34Z0,>@XZ]1D^_/
M_P \<U:2 C QD_48_IV% %>.+N?\\]L_SQQS5I4[#@=S_GJ>:F6%N.,GTR,?
MS_GQ[5.(6[CGT!'Y?_JH B5/0<>I_P \U.D?I^)]?8?X582W8@9&/Q&/I_\
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MQC^=  S]AQ[^O^'\ZC+ ?X?Y_G2$MV'YD?X_XU&58\D?J/\ &@!"Q/7\J:6
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MH*B@#Y^_X9<^!_\ T)4'_@PU/_Y,H_X9=^!__0E0?^##5/\ Y,KZ!HH ^?\
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M_P"$ Z>&)1_W&=9_^3J]SHH \,_X9P^$'_0LR_\ @YUG_P"3J/\ AG#X0_\
M0LR_^#G6?_DZO<Z* /#?^&<?A#_T+4W_ (.M:_\ D^C_ (9Q^$7_ $+4W_@Z
MUK_Y/KW*B@#P[_AG+X1_]"W/_P"#O6O_ )/I?^&=/A)_T+EQ_P"#O6__ )/K
MW"B@#P[_ (9R^$?_ $+<_P#X.]:_^3Z/^&<OA'_T+<__ (.]:_\ D^O<:* /
M#?\ AG+X1'KX:F/_ '&M:_\ D^C_ (9Q^$7_ $+4W_@ZUK_Y/KW*B@#PW_AG
M'X1?]"U-_P"#K6O_ )/H_P"&<?A#_P!"U-_X.M:_^3Z]RHH \,_X9P^$'_0L
MR_\ @YUG_P"3J/\ AG#X0?\ 0LR_^#G6?_DZO<Z* /#/^&</A!_T+,O_ (.=
M9_\ DZC_ (9P^$'_ $+,O_@YUG_Y.KW.B@#PS_AG#X0?]"S+_P"#G6?_ ).H
M_P"&;_A!_P!"S+_X.=9_^3J]SHH \+_X9N^#_P#T+$G_ (.-9_\ DZC_ (9N
M^#__ $+$G_@XUG_Y.KW2B@#PO_AF[X/_ /0L2?\ @XUG_P"3J3_AFWX/'KX7
M<_\ <8UC_P"3J]UHH \*_P"&;?@]_P!"L_\ X.-8_P#DZ@_LV?!T]?"SGZZO
MK'_R=7NM% 'A/_#-?P<_Z%5O_!OK'_R=1_PS7\'/^A5;_P &^L?_ "=7NU%
M'A/_  S7\'/^A5;_ ,&^L?\ R=0/V;/@X#G_ (14GG.#J^L8/UQ? ^W6O=J*
M /SP^%K%/!=I;[YI%M-4\0V4#3S//(EK::Y?6]M$992TCB&&-(U+L6VJ,DXK
MO_K7GGPQ.WPDN>/^)]XJ^O'B+4>W^1FN]9B?IZ4 <;X>(/[6'P<P>GPV^*G_
M *,\.U^A%?GIX<_Y.P^#O_9-OBI_Z,\.U^A= 'RS^VS_ ,FL?&7_ +%NT_\
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M[JNMZ!X>ABN?$7B#P_X>MYYO(M[GQ#KNDZ#;3W& ?(MY]7O+*&>< @F&)WE
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M*)\)O_"0UG_Y+H ^E:*^:O\ A'OVK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\
MHHGPF_\ "0UG_P"2Z /I6BOFK_A'OVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)
MO_"0UG_Y+H ^E:*^:O\ A'OVK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGP
MF_\ "0UG_P"2Z /I6BOFK_A'OVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0
MUG_Y+H ^E:*^:O\ A'OVK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGPF_\
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M6BOFK_A'OVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0UG_Y+H ^E:*^:O\
MA'OVK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGPF_\ "0UG_P"2Z /I6BOF
MK_A'OVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0UG_Y+H ^E:*^:O\ A'OV
MK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGPF_\ "0UG_P"2Z /I6BOFK_A'
MOVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0UG_Y+H ^E:*^:O\ A'OVK/\
MHHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGPF_\ "0UG_P"2Z /I6BOFK_A'OVK/
M^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0UG_Y+H ^E:*^:O\ A'OVK/\ HHGP
MF_\ "0UG_P"2Z/\ A'OVK/\ HHGPF_\ "0UG_P"2Z /I6BOFDZ!^U4H+-\1?
MA*J@$DGPCK(  ZDDW> !W)H'A_\ :K(!'Q$^$I! ((\(:R00>001=X((Z&@#
MZ6HKYJ_X1[]JS_HHGPF_\)#6?_DNC_A'OVK/^BB?";_PD-9_^2Z /I6BOFK_
M (1[]JS_ **)\)O_  D-9_\ DNC_ (1[]JS_ **)\)O_  D-9_\ DN@#Z5HK
MYJ_X1[]JS_HHGPF_\)#6?_DNC_A'OVK/^BB?";_PD-9_^2Z /I6BOF6?1OVI
M;6*2XN?B5\(;>")&DEFG\*:M%%&B@LSR227BHB*H+,S,  "20!7Q5XT_; ^.
M>G>([WPE\,=8\&?&'6M-/EZA/X3\"^()='M+E6VO:_;TDECG*GAIHF\G<"%9
MNM>'GG$N1<-T:5?.\RH8%8BI[+"TI*M7Q>+JI.3IX3 X2AB\;BI1BKS]AA:D
M:::=2=--7RJUZ5!)U9J%W:*U<I/M&$5*<GZ1=NK1^M]? G[5?QVUC4;V7]FW
MX+VUUKWQ3\8PKINMWFG,WV?PAH]X!]L>\N8\K#=2V;/YY=D6UM)'+$S2(J^-
MZ+\9/^"AOC#4U\+1?"_0?"]SJ=FK)K]_HL]K::1#,0K7\T]W.UL-BM^ZBVM.
M)"O[O(%>J?"+]E[X[?"/4O$WB?2?B-\/=6\7^-YXK[Q)K_B+PWJNI:H9VW2S
MVEO>+,C"T:X=I& "[V5<@JJ ?#9CGF8<=J/#_"M#.LKRG%.I2XDXJQ^4XS*'
MA,O=)JOEF1T<UIX3%U\XQ\9_598N.$^K99AZU7$*M4Q+HPARSJSQ=J.'56G3
ME=5\1.G*GRPMK3I*HHR=6=^7F4>6G%N5W*R7U5\"?A#HOP2^&V@>!M)CB>XM
M+9+C7=26-5FU?7+A%?4+^9P-[[YLI"'9O+A1%7 S7L-?-7_"/?M6?]%$^$W_
M (2&L_\ R72CP]^U7D9^(?PFQD9_XI#6>G?_ )>Q_,?6OTG+\!A,JP.#RW 4
M(8;!8##4<)A</35H4J%"G&G3@N[M'FG)WE.I.I4FY3J3D^V$(TX1A!*,8148
MI;))62_K=W;U;/G#X;,?^$6V],:_XJ_'/B'4?\XKNB0.M><_"O[5%X+M$OY8
M9]075?$2WTULC16\UXNNWXN98(F^:*"27>T4;99$(5N17H!.3D]Z["CF?"9W
M?M8_!\C_ *)K\4Q_Y$\.U^BM?G1X1_Y.P^#_ /V3;XI_^C/#M?HO0!\N?MJ_
M\FN?&'_L7K+_ -2#1Z^)+1,6MKM'_+K;<_\ ;"/C/]*^W/VT_P#DUWXP_P#8
MOV/_ *D&CU\76B?Z+:]A]DML ?\ 7".@!R)Z<GN?\_\ Z_RJPB>G)[GT_P _
MF:D6/UX'8"K*19XZ>W]2>?I0 R+?&X>)W21>5=&*,I]592"I]P<UH)<WN_S3
M>7?F%0ID^TS;RH((7?OWE0>0,[<\XS3$B .!SW]A[]_\]N*L+'^)_3_/U_*@
M!PFN2LBFXGV3$-,#-*1,1C#2@MB4C P7W$8&#Q4\4MPC;DN)T.SRRZS2*QC'
M'EE@P/EXXV?<'3;2+'SZGT[?Y_SBK"19Z_\ UOZ&@")$R>!^.,D_XFM_X#)L
M_:KC'K^S_P"*"?7_ )*%X([_ .<5GI&.W Z9_+C'%:_P,4+^U9#CO^S_ .*?
MQ_XN#X'H _1FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **CFFB
MMXI9YY$BA@C>::61@J1Q1J7DD=C@*B(I9F)P "3Q7QM'^WO^S>VL7.D3>)]5
MM!;7DMB=5NM!O(]&EFAF,$C0WREU>(2*</L&4&_ &,^+F_$>09 \+'.\YRW*
M7C93AA%F&+I87ZQ*DH.HJ7M7:2I\\.>3<(1<XJ51.23RJ5J-'E]K5A3YVU'G
MDH\S5KVOVNK[+7<^S:*Y_2_%?AC6[6RO-)\0:-J%MJ-I%?6,MKJ-I+]IM)U#
MQ7$2++O,;*>I4%2"K ,"!Y3\7_VCOA7\%+."7Q?KRS:I?!QIGA[1D_M36[^0
M*=H2SMV9H8F<+&9IMJ@ME5?!%=&.SG*<MP-7,\?F> PF7481G4QM?%T(8:,9
MJ+A:JJLU-U%.'LX4U5J57."ITYN4;U.K3A!U)SA&"5W)R2C9[:W=[W5K7;OH
MF>PZSKNB^';";5-?U;3M&TZW1GFO=3O(+*VC51EBTUQ)&G [ DG@ $FOF77O
MVV/V<] \2:+X;?Q[::K)K#JCZOH<9U/0=(,C^7$=7U.%Q';"1P0?)2X,(!><
M1("1\R?"GX(ZQ^UQJNN?&CX_S^*H?"5[K<\?P^^'#7MYI>GP:-:N4CN;JU.R
M1877;&-B127<GFR/(%5 ?LR#]EO]G^UT'5_#=K\+?"]OIFN016^I!+-FNY5@
MR87BOY9)+NVEB8EUDMIHFWDEMV3GX+#YYQ_Q1A8YGPSEW#V19/7E*MEN)XFG
MF>+S3-,+2J5?8UY97@*6%I95ALRC17L98K$5\=0PN(IXOV'M%&A+CC5QF(CS
MT(4:-)N].5?VDJE2*;M+V<%%4XS2TYFYJ,E*U]#U+POX\\%^-A?'PAXIT+Q*
M-,DCAU#^Q=3M=0^QR2J7B2X%M)(8C(H)3=@, <$X-=+<7-M:1M-=7$%M"@+/
M+<2QPQJJC+,SR,JJ%'))( ')XK\\_%/['_C+X7^*4\??LE>(['P1?2:4-,UC
MP9K<MQ=:)JZQ\),LUR9U$C<2,+L.(YU\R!TW% S2/V(?$WCNW&L?M _&GQWX
MGUO4F>YU+P]H.L36/AZQ>9B[6=JQ9P\2 E#Y=O'%_P \U*@&M:7%'':E/+*W
MA].OG-&=5SQV'SO"83A*KA>:/U;$X;-<;"KF-2I4YW"O@)97'%T)T:E1RE1G
M28UB,7_#>#;JJ]YQJQCAG&_NN-2:<VW>SA[/F33>S1]0R_M-_ "#7?\ A&Y?
MBSX,35P[1- =6B,*3*_EM"]\ ;%9@_'EM<!O:N_MOB3\/;S6!X?M/&WA6YUL
MVJ7RZ9#KNFR7C6D@#).L*7!9HV5@P*Y.TAL8YKQJV_8Y_9QMO#0\+_\ "L=$
MGM/+V-J%Q]HEUN23:5-RVK>:+H3G);*,L>[D1X %><2_\$]/V;I-,_L]=&\2
MPS?:Y+K^UHO$MZNJ[) 0MG]H*%/L<6?W<7DAACF0UN\5XJT>5RR7@3'J=JLH
M4,\S[+Y4(KXL%SXK+,7#$5I<RY,=&-'#KV=3VF%M.E:N;'K_ )=82=];*K6A
M;^[>5.2D^TU:.CO'5'V]#-#<1K+!+'/$_*RPR+)&PZ95T+*>?0FI*_+_ . '
MCM/V6/B3X_\ V>OBMKSZ=X.A>Y\5_#?Q-KL\@M)='93)+:+<295?,A3=Y2#B
M\CDC #28-O\ X6/^T#^U]JGB#2_@Y?P?"[X*6.I/I$_C^:*9?$7B"*/*W#Z4
M01)&94)81VI1(4:$3SEV85RX;Q-P%;+\+'^R\?7XMKXO,,LJ\%Y<Z6+S;#9G
ME=25/'1Q%6I+#4,+E=)/#XB.<XU8?!U,+B\/4IJO4G[$E8Z#A']W.6(<IP>&
MA:52-2F[33;Y5&FM&JLN6+C*+5V['Z7QW-O*[1Q7$,DB??CCEC=T_P!Y%8LO
MX@5-7YLZ[^PYXF\#6-AXO^!_Q7\9)\4M(N8+R>?Q1K<TFD>)G0CSX;V(%DMU
M<;CLD\^&1"T;CD&JZ?M!?M+_   UZ5?VC/!8\9^#M6LTO;?Q'\/=/6:+P_<+
M@3VLYA7;)%&/FF6=590-\4FTX.DN/L;E%3DXRX3S;A[#N5)O.<#.'$?#^'HU
MXS]G+,,QRZC3KX*K3JP]AB8SRRM1I2E"M]8^K255#QDJ32Q.'J44[?O(-5Z,
M4T[<\X).+35I+D:5T^;EU/TNHKSSX9_%/P/\7/#5KXI\"ZY:ZQIUPJB:*-U6
M]T^? +VFH6A;SK6>,G:5==K$$QLP!->*_&_]KCX=?"&6X\-V#S>./B/)&(]-
M\%^'$>_NC>3#%O'J<UJLHLT+,I>,!Y]N5V(QR/K,=Q/P_EV40S[&9Q@*645J
M<*F&QT<13JTL8JD7*E#!*BZU3&UJR7+1P^%I5Z]2;Y%2C)24.B=>C"FJTJL%
M3:3C/F34K[*%FW)OI&*;;TMV^K:*_-/2OVQ_C?X&CN++XU?L^^)O[3U2-+WP
MG-X1LKB6VN$O5W6FG:B"+H0RPDK'+,&20'<)8PW3LO#'[?\ \/(V_LGXL^%O
M%WPN\40726][8:CI%U>Z= DO,5U)?HD1A@*,F_?&Y!W$$C%?,X?Q4X(JRI4L
M5FU7)Z]3F4Z.?99FN32PU1-<E#%U<=E]/"X?$5H-5L/2GBVZ]!^UIRY8S4,%
MF&%;2E4=)O=5H5*7*^D9.<%%2:U2YM5JG:]OOJBOB[QW^W1\&?#OV*Q\#W5]
M\6_$&I1S-:Z/X&MY;\Q&-3L^VSF(>0&DV@J(W<(6<XP ?#_"W[87Q;\ ^.K>
M[_:8\'/X*^'/CW3IM3\)36NF2O-X:$#LL%MJ,L>^69KB, 3Q7!%PCLDZJ%8H
M:QWBAP7@<91PG]K1QM-UZ5#'9EEM&KC\ER;ZPK8>IG&<8:-3+<%2KU94Z$']
M;KRC4J0=:%&GS5(N6/PL9*/M.9<RC.<$YTJ7-\+J5%[D4W9)\TM6KV5VOU!H
MK\Z?$'[:WBGX@3?\(Y^S1\*_$GC#6+JY\J'Q1X@TR>Q\-06T>6DNEW&-9,JI
M ,UPL:H^\JS "JMG^W#XX\&WFBVWQQ^!OB/P/I"WKZ+XF\6P+/-IEIJ:I^[G
MLH&1O.MI!B5U,^=K8A9L8&<O%7@F-5K^T<9+ J4*?]N4\FSFIP^ZLIQA.FLZ
MAESP2]A&=.KB*TG'"TJ4XS>+G:48K^T,+?XY.&B]JJ51T;MZKVJARZ)IR?PI
M._,S](*XS5_B-X T"1X=;\;>%=*FC1G>&_U[3+:5%3[Q:*6Y5QCN"N?:OS^\
M>_M)^/?VD+B+X5?LQ:'XAT^PUJ1[7Q-\4]6T^YTRQTK2"%%RVFRN!Y321F13
M,KM<2#;% L;.6/IWA/\ X)]?L_Z1I5G%XGTC5/&FN^7%)JFM:MK&H)]LO^'N
M9XK:WFB2&*64MB-C(VP_,Q8DU"XSS?B#%5Z/ 649?G678-*&*XCSC,,;E>25
M<5)ZX/*'A\NQ&+S>=&'O8K%4*=+ T92A1AB,14<N0^M5*TFL)3A5A'25>K.=
M.DY?RT^6#E4:WE))06B3D]M?XA_MW_ 7P+?6&GZ?K%YX^GGF_P")F_@F&/5+
M;1+%& GOKV[>2&"019R(;=Y&8*V]X_EW?27@OXH> /B%X<B\5^$?%6CZQH;P
M^?+=PWD*&R"QB22/4(9726QEA7/G1W*1E,$\J-U8OA/X%_"#P-:W=GX6^'?A
M;2H=0LI-.U II=O<37UC*-LUK=7%VL\TT$P_UL+N8Y.-RG Q\Y>*/V ?@OK>
MLWFK:!?>,/ =OJLA;5]$\*:W+9:->QN<O"MFP86\3]T5GC'144<4^?Q4P%26
M,J4>$.(J6)3C+),%6Q^02RN45:C5PN<9A#'_ -ITZC;>,IXS"82K!I/ R<;T
MV7S"'O..&K*7_+J#G1]GV:JSY_:)_:4HQ:^SV/)OC1^T#XE_:/>\^!O[.&C^
M)[F&^UR+1_%_Q-B@EL] L=,AFQ>QV=_;NTD5J[+NFO)7MII88REM!()-Q;X"
M^-?[1?[/VBI\)_B#\$/&?Q-O]"FGLO"GB_P_/-=VFLZ5'(?LT5Q>+97ID6&(
M-Y$\KK=+"8K>>$-'NK] /AG\,O!_PC\):?X+\$:8NFZ-8!F^9O-N[RYDYFO+
M^Z*A[JZF/+ROV 50J@"N_KAPW O$V(Q:XES#C;,,OXLQ.'CA<0LHP>!K\/X+
M+7S5'DV%RG,54HXJ.'KS^L0S?$.&/K8N$J[C&A-8=1'"5W+V\\5.&(DE&7LH
MP=&-/?V4:<TU)1E[RJ2M-RN]$['YN7/[7G[0MU>Q^)M(_9B\41?#K1YXK+Q)
M;W\=Z?%,]U,-KOI2)!$#%;O@973[F,Y FEC+C;[#\/\ ]MKX.>+K/Q /$]S?
M?##Q!X8CGGU;PSXV1;'4C! I=GL, ?;I#C;]E2-+O>0! RY8?85>(_$C]G+X
M,?%G48=8\=>!M*U?5X!&@U1?.L[^:*)@R0W-Q:20M<Q#& L_F$+\H(7 KMED
M/B%E=\5E7&F'XAK5)2EB,LXJRC"8/ 2E.G.FJF!QN04Z>,RY46J%6&$E2QF'
MK2A752K!XA2HW['&4_>IXI5F[WAB*<8P;::O"5%*4$M&HVE%VE=WEI2^#W[2
MWPC^.$=VO@GQ$HU*QED6?0M91-+UKR4;"7D-E+,_VFTE&&66WDE* @3I$WRU
M[<VI:<D@A?4+))B0!$UU LA)Z 1F0,2>W%?*GQ+_ &+?@Q\0;C3-3TW3[WX=
MZ_I,-O:VVM^!)QHMP]G;1>3%!<PPA89F2(!5N $N#R9)9,UYRO\ P3L^$,L;
M7.I>+?B=J6O\F'Q!-XJF6[@?_EFZQ^4X8Q\@;I.0<9%51S'Q0P</JF)X9X9S
MVO2U><8/B.>1X3&4[*5EE>+RS,<7A,6FW3</K%7!S<8U(U8*<H0%/'Q]V5"A
M5:_Y>PK.E&2_Z]RA.49;JW,XO1W5VE]G6'Q!\"ZIK=]X;T[QAX;O=?TPA;_1
M[;6;"74;5B =LMJDYE5AD;@%)3HP!K@?CM\=/"OP)\#7GB[6RNIWS21V.@^'
M;2YB34-;U6XW"WM81^\>*!=IDN;KRI%AC& K2/&C?/G_  [Q^!2Z+9VD%UXR
MM/$=K++</XSM?$$\.N7EQ*Q8R71"F!E0_P"K5%1EYS(<\;/@?]A3X3^%_$VG
M>+/$.K^+_B+JNC7$%UI">,=8DOK&RGMI%EAD-H=RW!CE42(DSF(,/FC89SE6
MS#Q4Q.&JX.GPUPUEN,QD7&AG,.)98["Y1"LTG5Q&65LII8G,,9@J4I.-+#U8
MX+%8F$'ST\.Y)ISS"47%4*$)26E55W.-._65-TU*<HKI%J$I);*YY'HWP-^-
M_P"U-J5UXZ^/?B37OAEX(OK2W'A3X:^$]3-O.=.N$$OFZKDR)&9X65I6NUDO
M9G?#16\2+&/NOX8?"3P#\'O#L'AKP%H%KH]DBI]JN0HEU+4YU4 W6I7[CS[N
M=R,DNPC3I&B#BO20      , #@ #H .P%%>[P_P5DV0UY9ERULUX@KQFL=Q'
MFU1XS-\5.M)3K*%6;=' 8:4ERT\'EN'P6'I484J*52,+RUHX6E1;GK4K2OSU
MZCYJDFW=ZO2$>BC!1222U2"BBBOKCI"BBB@#\T_AP0/##9X_XJ#Q5_ZD.HUV
M[.3P.!^IK@_AV?\ BF6]!K_BHX_[F+4<_P J[0N>W'\_\* ,'P:0?VL/A#@@
MX^&WQ3S[?O/#O6OT;K\W_!/_ "=C\(_^R;_%'_T/P[7Z04 ?+O[:?_)KOQ@_
M[%^Q_P#4AT>OCFRC_P!$M.Y^R6O)Z?ZB/]?UYK['_;2&?V7OC /7P_8C_P N
M'1Z^1[) +2S &3]DM>W_ $PC[=!]: %2$]6Q^O'7MQFK2Q\#L/U/O4BISZG_
M #_GFK"I[9/\O\^M $2Q^G'N>I_^M^E6%C)'RC_$_D.:F2+N?P]/Z?G5I4].
MG<G_ #S^% $*1 =>3[=_Z_A5E8_7\ /_ *WI[5*J>@X[G_/\A^E3HAQQ^)_S
M_P#7H C6/UQCT'^16A\$5V_M66_&,_L_>*N.>WQ"\#^OUIJ18Y.<_J>GY?3K
M5GX,+M_:MM>,#_AG[Q7C_P .%X&_&@#]#:*** "BBB@ HHHH **** "BBB@
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MLZ=.*<I1BG*<4W**3O))IM)7;22W;:27JVTOQ/"_^&C$_P"B'_M%?^&KOO\
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M\ JJ      , 8IW_  T8G_1#_P!HK_PU=]_\GU]'45]Z=9\X_P##1B?]$/\
MVBO_  U=]_\ )]'_  T8G_1#_P!HK_PU=]_\GU]'44 ?./\ PT8G_1#_ -HK
M_P -7??_ "?1_P -&)_T0_\ :*_\-7??_)]?1U% 'SC_ ,-&)_T0_P#:*_\
M#5WW_P GT?\ #1B?]$/_ &BO_#5WW_R?7T=10!\X_P##1B?]$/\ VBO_  U=
M]_\ )]'_  T8G_1#_P!HK_PU=]_\GU]'44 ?./\ PT8G_1#_ -HK_P -7??_
M "?1_P -&)_T0_\ :*_\-7??_)]?1U% 'SC_ ,-&)_T0_P#:*_\ #5WW_P G
MT?\ #1B?]$/_ &BO_#5WW_R?7T=10!\X_P##1B?]$/\ VBO_  U=]_\ )]'_
M  T8G_1#_P!HK_PU=]_\GU]'44 ?./\ PT8G_1#_ -HK_P -7??_ "?1_P -
M&)_T0_\ :*_\-7??_)]?1U% 'SC_ ,-&)_T0_P#:*_\ #5WW_P GT?\ #1B?
M]$/_ &BO_#5WW_R?7T=10!\X_P##1B?]$/\ VBO_  U=]_\ )]'_  T8G_1#
M_P!HK_PU=]_\GU]'44 ?./\ PT8G_1#_ -HK_P -7??_ "?1_P -&)_T0_\
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M44 ?./\ PT8G_1#_ -HK_P -7??_ "?1_P -&)_T0_\ :*_\-7??_)]?1U%
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M-"C37-.I4G+11BK;*4I-QC&,YRC&4SG&$93G)1C%-RE)V22W;9ZE17P#IO\
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MI8M[PB^N88R(Y+6%X+:WP\]T1(Q4ZTN 4N>MB^+^"L/@J,)UZN)H9[3S"O\
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M5#&,7FP_+^BGG1?\]8_^^U_QI&G@17=IHE2-6=W:1 J(@+,[L2 JJH)9B0
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MUC_[[7_&@"2BH_.B_P">L?\ WVO^-'G1?\]8_P#OM?\ &@"2BH_.B_YZQ_\
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MRE\)OBI^T(GA+4M.U+2(=5^#7C#Q7)?6.L:G>R_\)$OCGPC9K?M;ZU>:E;"
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M\U]?1]% 'SA_PR5\ O\ H3-3_P##@?$C_P":^C_ADKX!?]"9J?\ X<#XD?\
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MA_PR5\ O^A,U/_PX'Q(_^:^C_ADKX!?]"9J?_AP/B1_\U]?1]% 'SA_PR5\
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MK*Q^N<^@_P#U?RH C5.PX'<G_/6IT3T_$_Y_E_C4BQ],]?0>GIT_E5I(L]>
M,?3Z?_J_/F@"%$[#KCDG_/\ *N(\&J5_:ST3/?\ 9Z\9?7_DHG@/J.W^%>C)
M'S\OZ]!^0Z_XUP'A10O[6FA<YS^SSXSS^'Q$\!B@#[0IKHDJ/'(JO'(K(Z.
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M%EMH/A#0-+\.:3$WPRU3>MAI%G%96QEV>*T0S/'"KS,JJ'D+/C+&NI_X1?\
M:E_Z*O\ "O\ \-EJ_P#\UM>_E>"CEV PF#BES4:%.-6:WJ5VN>O5E+><JE>I
M6FY2;;<K]3\JXVXEK\7<59[Q!6E4]GF.9XJK@J$FU#!Y;"?U;+,'1I<WLZ%'
M"Y9A<OP].C2A"%.-/E4=#Z0HKYO_ .$7_:E_Z*O\*_\ PV6K_P#S6T?\(O\
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M3O.DAT_Q-80Q>,I/-T75&BD%O(<21,%2=4:2,-Y>0YC1>7Y;A,5B*<<?RXG
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MXRO;#87#QK0Q$<#@*:C)4HU81C!U<37<Z^(E!)RY:4&[02/J.-N(,AH9%D7
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M *E6@UT5BG^A6.!_RXV?)_Z]8>_]!7._MC_\FU?%/_L&Z)_ZE6@UT]HP%E9
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M](LK6_\ B!HGB_5_!NH1:#K_ (;\+>/- \;Z7'<GPO>B:W-P_P!#_P##Q?\
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M7?#.[TNZU'X?7TR^&-=U%O$5AK%C8?6M !1110 4444 %%%% !1110 4444
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M]SWK]K* /F7]L?\ Y-J^*?\ V#=$_P#4JT&M.T)-G9?]>-G^'^BQ5F?MD?\
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M? #QC;2.^HV:+'<?\+"\#,;>1FF 6?;&[>2V)-J.VW"D@ ^[Z*PO^$H\-?\
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MF^$_@O\ %SPGXF\(Z+#H>O1W6J_\)7XJ9/#4K:4\<5KJ-P&D742_F:>'4@D
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MZ'J\=W,OF6^H:+;V^G7,($L$"*6K%\6_LU^+/&FJ>/O%.F_M4_M'_#^WU1/
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M ELBV@&&)=BWW/O%Y)&ZY+2.V<NQ-9[6R;K96F JJ,V\/"H"J ?)P$4D*.<
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MO_&>@?"6]N(M'N-3UK45FT'3M2CN?[#OH(7U.Q:6(HY/AY^U!^V=^T1KN@_
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M8Q:KJNJ6NCQ7,\6E0VB2," <Q\*/B-^U!\5?'_[7WPH\9Z]X'^#_ (G\!R>
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MO0=$U+P))X=M/#?AVU@L]*\#:0=6\#:CKND^#HK6W6%](LM8B$A:29Y3,V\
M#/%WQ3^-X_:;\8_"'6]*\%:/\)+W]G/XB^-_ T-E>/J_BG7O$?AWQ)X1T2WU
MSQ%>HD<6C:8T>OW5M!HD FG=5-[-*#Y2'YON_P!HK]H[X+ZMXJL?$'Q*\!_M
M!KX/^!/B+Q[\0_#/A;P1'X9T;X$^*;>UTZ/X<Z!<^*[*XN'UV#Q%/>/%>:7J
M_DZ]%9Z=)J9@CMKB(G[^\;_"72/$OBV\^)4-WJUMXUC^$WB_X3Z7]FO((-/B
MT?Q;?Z/JMW>"*6WD==8M[_0[%[*\,PMX%\WS+:0LI3YL^#G["OA#X1^%M3\$
MGXM_&;QOX#\4>']=TGQE\/?&FJ>"[KP]XCO/%5J8];UC6M0T3P9HWB74]<CE
MEF:RU6YUR2>!O+(9A#$$ .7\.^.OVN-.\87WP9U_XK_#/Q/XU\?_  2TOXR>
M!_B%?^!X?#NC?#;;J=K;>+M%U'1K.ZDB\1:;IFGWBS^'+Z\D@EN[B%QJ)2+)
MK-^&_P 2OVE?'_A/XN6.E?'SX<7/A;P%XWT;3],_:VUCX>V.C:-J?ANTL+NZ
M^(T&D>$3=KX;U>[\)7L%I8VOB!;T:)<F\F5IGEM) .ROOV"_A[?^#?'?A/4_
MBW\>=4U#QSX8T/P$WCG4O&FF7OC+PM\.M OUO[3P!X6O9?#[:?:>'KMU6WUA
MKW3;_5-9M56'4=0G"@BEK_[#&@^)_A;;?!WQ!\?_ (_ZEX,T_7_#6NZ59_VA
M\.;*/3(O"N6TSP_#IVG_  ]M=$N?#3S^5=WFDW^F7<=U<V\+2L5#*X!UW[#_
M ,0?'_Q"^!\NM^/;NSU]+7Q[XXT?P5X_L=&;PW!\3O VG:U<1:'X[3P^Q*Z6
MFLCSC"L!-K=0Q1WEH3;S1D_6TDN<] #Q^'L/\]<\5XI\#/AKJOPD\!0^$M9\
M=^,?']U%J-_=PZIXUN=!N=0L+.:4BUTJR/AS1="TZ'3;>)5>"W6R,D32,GF;
M J)ZV\A8GG _+_\ 4/\ )H ^J_V%F#?M:^&P.WPP\?9_&[T'_/-?O37X'_L(
M.&_:U\. 9)_X5AX].?K=:#^/Z5^^% 'S'^V5_P FS?%;_L$Z1_ZE&AUA61_T
M*R)/_+E9\G_KWBK=_;*_Y-F^*W_8)TC_ -2C0ZYVU)^QV0[?8K/CM_Q[14 6
M2Y/3@?K_ /6_SS3*0L!U_+O4+,3UP /RH >S]A^?^'^-1,V.3U_G3"_I^?\
MA_\ 7J.@!2Q/7\NU-) ZTTN!TY_E_G]*C)).30 K,3[#_/6FTQG Z8)_2HRQ
M/7\NU "LQ/3@?S^M-IK.!P.3_GK43,3UX'Z4 .9L\#IZ^O\ ]:HR0!_(>M,+
M^GY_X?\ UQ49/<G\30 I8GK^7:FDX&:87]!^)_P__53"23DT *6)_P /\]Z:
M2!UIC/CIR?TJ)F[D_P"?04 .9B?8>E1LV/<_R^M,+D]./Y__ %O\\TPG')-
M"DDG)IC,![GT_P ?2F%SR!T]>_\ ]:F?6@!223DTTL!]?2F%_3]:B+ =3D_F
M?\_6@!Y8GZ=A43-C@8^OIU_7_.*:SD\=!^OXU&2!U- "TQGQP.3_ "II<G([
M?KBF$@=: %))ZTQF ]SZ?X^E,+GD#IZ]_P#ZU1,P&><G\^??^O>@!Y.>2?\
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MO^?J?>HFE)X&/?KST]ZK/(!DYR?\_G_(4 2,^>3T_G_B:JR2X'\^?Y^OT_\
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M:5Y_T1GX_P#_ (;&[_\ EC36^*-\>!\&?C\!_P!DQO,_C_Q,*_1^B@#\W?\
MA9U]_P!$9^/W_AL;S_Y84QOB=J!Z?!GX_8_[)E=\_P#E0_2OTEHH _-?_A9E
M_P#]$8^/W_ALKO\ ^6%(?B9J)Z?!GX_#W_X5E=__ "P_6OTIHH _-+_A9.H_
M]$8^/O\ X;*[_P#EA4;?$C4V_P":,?'T#T_X5G=__+"OTQHH _,S_A8VI_\
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M ?QK.>O_ !1+Y_6^JNWPY^-+$Y^ ?QK//_0E,/\ V_\ _P!5?TBT4 ?S:/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #5 <@# 2(  A$! Q$!_\0
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M_P HJ/MOB?\ Z &E_P#A13?_ "BKHJ* .=^V^)_^@!I?_A13?_**C[;XG_Z
M&E_^%%-_\HJZ*B@#G?MOB?\ Z &E_P#A13?_ "BH^V^)_P#H :7_ .%%-_\
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M;6/B;4?#EFFJ?#&:WN[3PA'I,NOR3WJ?$$V]FUJFN::88[AE>[\Z00!C!)@
M];^V^)_^@!I?_A13?_**C[;XG_Z &E_^%%-_\HJ\GN_C??6'BS3/ ]Y\)?B!
M!XHUNPDU/1M/&I_#26*_LK5;][^7[?%X_>TM6LDL2TD5Y+ \_P!HA%H+AA.(
M?/?BS^TC\0O!EIXG\-^"?V=_''BWXNQ?!_XC_%'P'X1U+Q-\.=,T#Q1<> X]
M*M8= U'7M*\8Z]J6ERZQKOB#0M-A>Q\/ZQ=K#=W%U!97+VIMY #Z:^V^)_\
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M?MOB?_H :7_X44W_ ,HJ/MOB?_H :7_X44W_ ,HJZ*B@#G?MOB?_ * &E_\
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MU5MKZ2^1H)9IH%+N]C9!&+PMM5?,) 8L$ 4N55B_Y'"]_P"Q<T[_ -.6I44
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M!\0ZMK.I?'?P%X]M/A[\2&\-^&_"^L:9JMV_A*ZBFCO-6AUN.TCM[.29;RZ
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M9] _[!?B+_T=H5=%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?!SP68QP>/P7Y0_%SX,_P#"1:[XA;X=^#O'\>O:#\.==^,/Q:^&H\3:I/\
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M0.IYZ8'. >,9P"F#NH!)]<DXZ9Z@=0O.#P3C&< IM.[/U;Z[?U_7X'R_;?\
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MY'FB'_1KV+.^&]MYXS@ %KWP1!/C"XYS_P 22\'0CK-;?7)/ XZC..E?K?\
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M#%<4Y>U_A6$XNC&*\E"R['ITO&3Q/HI*/&.9S2Z5J66U_O=7*VW]YZVGQ2(
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M^"[VVU"+P;I]S;VR:;]NF9+VQ_M@^(H],?3KM'&DVL\+"7]3+W1=8TUWCO\
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MS6IN*Y7&<<MA.,;5ZZ]Z/UAQ=\/AY+FNXUZL52C"%;V7X2_ [0=,/@W3=/\
M"FD^&]#^&_@3X):#X/8^ -.@L=9\*_#;4/%1\*V>L7C:K-/+XA\*K<7-YX8T
MM//MOAO?ZU<^)=.U/7+SQC?V&D_:-4]/TZPTFS@T[2[*TTZPM4,=M96-O%:V
MENA9G*0V\")%$I=F<JB*"S,Q&235ROZ"C&,(QA&*C&$8QC&*2C&,8J,8Q2LE
M&,8QBDDDDDDK(_G24I3E*<Y.4YRE.4I-N4I2E*4I2;NW*4I2E)MMMR;;NV%%
M%%,04444 %%%% !1110 4444 %%%% '-1?\ (X7O_8N:=_Z<M2HHB_Y'"]_[
M%S3O_3EJ5% #[W_D9] _[!?B+_T=H5=%7.WO_(SZ!_V"_$7_ *.T*NBH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^8M6^!^LFTT^]N+SP3XL?1O#OA71I_!
MDOP^T_0O!_BF/0=)%EJG]HZ/_:FL:7'<3WL%I=>"9KG3M2?X?Z;_ &QX=TPW
MUKX@O+R'\;?VP?\ @GIXHT0W_P 6O@/X>US5(;_0O".I^,OA6GAW2_"6CVWB
MG4;*ZG\3^(/ YN-<OK7P[;:A+%+?^(?!E[J46B>$M5CM[+1-0U >(O\ B5?T
M7US5_P"#O#&I:@FL7FA:7<:Q#>Z7J=OJ5Q9Q374&IZ';ZE;:-?K(V&^T:9!K
M&J16C[@T4=]=(I F:@#^)GQ1X>\2>$M9U#PQXO\ #>O^$?$NDW5[9:AH/B;2
MKS2-2@N+"2.&]\F*YC6'4K6WEECC;4M)GO\ 3G,L1@NY5F0MQTX)=L<Y3&=@
M() 8]CDX[ \I]\_,"#_5A\>?V&OA=\;==^&5M\3_  U/XLTS1M,U'P_;^,/#
MQOO#_B[PC++:WIM='L)]&G22S\ S-J>I:CHL%UJ4NF?#S5-#TO3K+1?$(\77
M-]H'XF_%W_@F1^T+\-[>RE^&D^I?&Y]0O]6N+/P;K&FZ5X2^)X\$6FG07FG:
M['*\^F>&?$>M17=Q;:3XJT2*'1QX8OM3T-9-3U=]1GGMP#\[KC/<@X8]B/\
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M:@#[1TG_ (*%?';3AY&M:C!XCM1Y68M4M+&]+*HRX9[RUD)+;ODP^5!)4$9
M[6+_ (*%Z)>;?^$K^%6AW>#^_FLK&WM9"3G)!M @C"DL?E4DD#@L0:_-FX&"
M>#PH]?0<\@+R2/5VX9<#=6!=D_O#G@8'WR>!GT&%P<9W9QQC)H _5X?MM_L\
MWJ :AX#U?3)AM+M9WDJH,98MY?E,B@C!"DEF.2F6XH'[6G[-=T"?/UK3^"<2
MNDA/1@ KF-A\P.>A!((&5.?Q\O,Y?G&,=]ISCCD#@GGE@=W50,M7,7(SOR,\
M?W2Q/0C@X& 3U7(4<\D8H _:-OVG_P!GQ^$\0WL1; 3S4BSS@\A9AM /)!Z,
M0Z[FW8S9OVI?@/%YFWQ)(Q3GDQ8R"202)2,YR3R3D$\OG/XF7*C+9&3D=B3]
M>1D8/<#'H"*Y2^ _>?*,D8/3J&Z91<D]R@P0/F)W;@0#]O;[]KKX(6BY'B#S
M"<Y3=$NWN"I#."2>>>=W3+GCB=2_;C^#EFA:*]>0J3A6D0;B.R%58ENCA0!R
M P.^OQ0NU7<"% '7@)S@\<XVGZ#!'&PEBHKG+SJ_ Q]<\YXX89'.>,EC][UH
M _7_ %G_ (*&>!;4R"Q@N)=@/*0.X.UT*X;8RY.3DL1DG=P1BO"/$O\ P4<N
M<.-(T_5),,2I5(858;F9C\X! Q@#Y1\X+ G)K\T[S/S<C@<?,Q[CT&%QGOD#
MMDD5REYD@YYY8]-XZGG@!A@YR_7NO- /9^C_ "/H?Q[^VS\1==OK_P#L]KJQ
M26XD:,O<1Y3>?,;,:(/F+\XR, G;R,5\T>(_CC\3?$ID2^\37T4,H.Z.!C'D
M%B<&3.\XR>A&3D\'KP&I9-U/W_>'."3V_P!H9.?[O4?>]<X9SGCT'4G'KG[O
M7\3Q7\;8_AS(<%GF=3PV4X"E-YUFM3F6&I-J<\RQM24HN4&HWG4G*T4DN9V2
M1_;F!XHXAQV0Y%3Q6<YC5A'),HIJ'UJM&+A3RO 4H*2A4BYM0IPC>3DW:[;;
M;+EUJ&H7[E[V]N[MR"2UQ+++_%_MN0!WZ=>:I@-S[],+QQCW]#]?PH /49SM
M)ZG'WCG^'T]^E !R3WQP 3C.1_L_U^GI70HQBDHI12V44HKY)))?<<4I2DYR
ME*4I/>4FY-MWW<FWKYL.<GJ<+GA>./QH.X=??@*<]">>>E:6A:)K?BG6;3P[
MX7T36?$_B'46,6G>'_#>F7^NZW?2#DK9Z3I=M=W]P4'S2&*!A$@,DA1 6'[
M_LL?\$.OVV_VA[S2=3\7>#K;X(>$+C6H]/O+7XCW\^A?$K4(;74/[.UV/1_
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B_L&GV5CYF/,^QVD%MYFW.W?Y,:;]N3C=G&3CJ:*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #4 BH# 2(  A$! Q$!_\0
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M;_\ "FOO_F<KLJ* .-^W>//^A=\-_P#A37W_ ,SE'V[QY_T+OAO_ ,*:^_\
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M?;O'G_0N^&__  IK[_YG*[*H;BYM[6)IKJ>&VA4@-+<2I#$I8X4-)(RH"Q(
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MN\>?]"[X;_\ "FOO_F<KJ+6^L;X.;*\M;P1[0YM;B&X"%@2H<Q.X7< 2N<9
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MXO\ @S5/%/@/Q'J^DK#':>*]*GT.ZBU&QU:;8]U=1-$FV]DO98KUK?5+FSC
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .-\3?\ (:\"?]C)=?\
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M_4:UVNRH XSQ?_Q\>#/^QST__P!->LUV=<9XO_X^/!G_ &.>G_\ IKUFNSH
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M4&HRG/GKQ<&J;@ESS@=N7T,)BL;A\/C\PAE6#JS<:^83P>,S".%@H3DJCP6
ME'&8B\XPI\E"2FG44V^2$S8^(WQ.\!?"/PU)XP^)'B;3_"7AJ*]L].?5M2%P
MUO\ ;K]V2SM52T@N9WEG9'"*D3<*S-A5)')?"[]HKX*?&G4M5TCX7?$+1?&.
MIZ'90:CJMEIL>H13V=C<SFV@NI%OK*T#1/.IBW1%]KX#!=RY^'_VE_V(/BEX
MR^&;Z-X)^.'Q?^*>N#Q#HMXOA;XM>.M$;PFUI;/<?:M1'V;PS92C5;)9%:P)
MN GSS!D<E<>0?LK?L _'7P1XI\5WWC[QWXF^$5C?>'[.ST_5O@WXZTH:SJ]X
MFI>?+I^LFZT&_3^RX( +F (D3F[()<J"I_#LRX_\7L/X@93D>$\*JE3A;%8?
M#3QV.>/PV*JTZM3#YE4K*/$>%Q%/AO!*%7#X2*I8S U:E-5'3JRE4Q6%E3_>
M\L\.O!G$^'.<9_C/%VE3XMPF(Q-/ 9?'+L5A*-6E3Q.5TZ+EPQB\/4XHQSG1
MQ.-DZN!Q]&G4=*-2C&-+"8N-7]J*\]MOBM\/+RST._MO%%A-9^)?&^K?#?0[
MA8[S9J/C?0[S7[#5O#L&ZV!%Y97GA?7X)7E$=JSZ9<&.X=3$TGE?P_\ V>=<
M\"^*]-\3W?[17[0/CFWT];M9?"_C?Q7H>J^&M2^TVTENIO[.V\,V-Q(UJSBY
MMFANX62>-&)9-R-X5HO[+7C/1AX!\16TE^_B[0?VF/BI\3]2TS4?B/XEN_ \
M/A7Q3JGQ>N_#]S;^%?MDF@PW<L?BKPPU[;:9I<.H61N-5E@G:Z$K2_M&4XS,
ML;AIU<TR6ID6(C6E3AA*F:99FTJE)1A*.(6)RJ$,/!2E*</8S7M8NFY2;C.%
MOPW.<%E>!Q,*.4YY3S_#RHQJ3QE+*<UR>-.LYSC+#O#9O.IB)N$8PG[:$O8R
M510BE.$[_=.K>+O"NA16,^M>)-"TF'4]:M_#FG2ZAJMC:17WB"[9UM=%M9)Y
MT6?5)VCD6*QC+7+E&"QDJ<9OB_X@^%? UMI]UXAU'R(]2\3^%_"$"VT,E[-%
MK?C'5+?2-!BNX;59)+.VNKRYB\R]N5CMK>#?<S2)!&[C\PO#_P"RI\8[R+4=
M>\>?#+P;JYM_B)^SE\0A\.DN?A_::-J&N> )?&5E\4;KPKIVEV-MX<TT:A;>
M(-+DT+5/%%_/XH\3Z1I<$'BS58-3ABBC].3]FSQQJ_ANY\%^*/AGX;U'66^/
M/AGQSXS^*MUXETV27XL^";/XW#Q[':WMG$K>(4ET+P<;72)=%UMK:RMIM*71
MO#[7FC7"2)ZAY)]W7'Q!\*6WC/1_ 4VI!?$6O^&-2\7Z5&(I#876B:5JVB:+
M=2IJ8!L?M+ZAX@TR*UL_.^TW:2R2V\<D<$K+UZW-NT[VJSPM<Q1I+);K*AGC
MBD)"2/"&\Q(W*L$=E"L00"2#7Y7^,?V4/B(TTME8_"WPIXPT"UT?]JSP?X"L
M)?&-EI$/PT@^+GQ)T+Q'\+/$NDV5W;^1'8>%=-L[V[DM--D36?"16"/PO:7-
MTL5O')XP_9J_:;\2^/\ 6;ZQOM!T2Z@\#?$7P19?$O3=1T71IO%=CKOPFT7P
M]X5U/Q)=:;8R?$;4_$$_C*POKCQ$NIWT7A_PV);+5/"%C=74<LR@'Z-Q?$3P
ME/XV?X?0ZF)?$<?A)/&SQQQ2/IX\/OKDWAP3_P!JJIL#<C5H);=K(3_:D"^8
MT80@UV]?EY=_LV?$O4/B=\._B5X9^$?ASX=^"O!'A[PQINO_  '/B[0'T'X@
M7MCXVBU&[U#5)_#T1T^WU3PBAA\;>"Y)KVYTS6];T>*#Q7917=_%)I?ZAT %
M%</\0O!MWX[\/-H-EXT\8> IFO;6[_M[P/J%IINN!+8N6LA=7MAJ,2VEUN N
M46!9'"(%E0;@WS'XW_9P^)UEX2U^Y\!_M$?'W6_&46GR_P#".Z7KGCW1+#1[
MK4F9$B74KJ/PPLL=I&K/-*(GCDD$?E))&SAP ?6^@^)O#_BB'4+CP[K%AK,&
ME:QJ.@:C-I]PES'9ZUI,P@U+39VC)"75G*0DT9.5W*P)5E)W:_)S]GG]DG]H
MWPGKFLZ9XU\>^+/AYX/U>&YUB>]^&7Q"L!?7?BII;=?M&I65YHM^ETM[:F<2
MW*""998HFEDD!"C[4\-?L_ZWX>\0:/KL_P"T+\>O$,.E7T5Y+H6O^*=$O-$U
M9(L[K'5+6/PW!)/9S9Q*D4\,AP"DJ$9H ])\)_%GX?\ CC5=<T?PKK_]KW'A
MZ6_@U&\ATO68=">72=0FTG5DTKQ)=:=!X>UTZ3JEO/IVJ_V'J>H#3KZ&6VO#
M#-&Z+L^,?'/AKP)X0UOQUXBU%8/#F@:-J&O7UW:HU]+)IVF6,^HW3V%M:B2?
M4)A9V\TT5O9I+-,$/E(QK\[_ !E^S?\ &O5'^*&B_"C3=3^$7P[\3VUUJWB#
MX;WWQ T/Q3X,\;^,6^).A^++^]^&&F7%CJ,?PYL?&FAV_C"W\9V>LV^E>&_$
M.J>*;*'4?!L4<6K:P_*>-?V2/B7J'@&[\.:=X$_X3C3/$?PS^+_AOP[X/\>^
M,/!&C1_!KQ[X]\61^(]/\4:=!X.T>U\*Z5HR62OIMMI_@6VU*^\/"&'2[26Y
MTG5=2N+0 _5FRU2PU"*&6UNH9//L[74%B+JMPEI>1B6VFFMV(FA65&&TR(O(
M*]00+4,\%PK/!-%.J221.T,B2*LL3%)8V9"P62-P4D0D,C JP!!%?EQX^_9S
M_:&\6_$/QIJ]GHGAO2+"Z^'_ ,:? VGZOH>K^'="C\4:-XQ^$UCX<\!0ZUJ%
MI9GQWJFN6GBNWDGUXZ_J,/AGP[/#97W@^RD0/<)]7_ /X.ZG\)?%?Q/\C2M,
MT+P5XETSX3SZ!I6DWIEMO^$DT'P;+H?CC4Y;#I:WFHWEMI1NK]BT^MO;B_NG
MDN?-ED /IVBBO'?$7PGU+7]:O]7A^+7Q4T&*]E61-'T+7=-M-)L0L:1^596\
MFCS21QL5,C>9-(Y=V)<\ ?,<4YOQ'D^"P^(X:X.K\:XRKBE1KY=A^)N'.%I8
M7#>QJ3>-EC>)J-;!XB*JQA0^JT(K$MU56YE2IS3]++,+E^+K5*>8YM#)Z,:7
M/#$5,NS#,U5J<\8^Q5'+I0JTWRN4_:S?L[1Y+<\D>GOK6D1WUUIDFI6,>H66
MGIJUW9R7,4=Q;Z9))-$NH2Q.RLEEYD$T;7)'DH\;*[J< SZ?J%CJUC:ZEIEW
M!?:??01W-G>6TBRV]S;RKNCFAE4E9(Y%(9'4E6!!!(-?(_BO]F/Q%XGU>4S_
M !7\;7.FVOAJ^M-/O]=U:#4]4N-6U&4B2PN$M=-TY8?#216\#ZA:&>YDU*68
M!!;"!FD[71?@=XD72-,34_C+\6M.U!+&VCO+'2?%.FR:7:W$<2I+#I[/X=@?
M[&C*1;*T2,D6Q&&5)/XGE'BAX]8OB/.,NS'Z-V.PN283Z_\ V3F4?%#@'#U,
MQ^KYEE^&@JM?&TJN74_9X?$8ETY8>E;.HTWF>7K!8'!8O"XC[#%<-\#TLOPE
M?#^(5&IC*OL/K6'?#>>SC0Y\/7J2Y8491Q$N:I"GS*I+_9')8>O[:M6I5:?T
M?7@GQ@_:1^&OP6UOPGX0\0'Q5XG^(?CNSUW5?!_PP^&WA'7?B#\1-?T'PLVF
MIXI\36WA;PW:7E[:^%_#DFLZ/;ZQXCU,V.CVU_J^DZ4MY)JNJ:?97/KOAG1)
M?#NAV&C3ZWK/B.6R697UKQ#<Q7>L7OG7,UP&O;B""VBD:%91;Q%((]L$,2D,
MREF^,/C!^S_\6K']KKP#^V7\$4\">,/$6C?L_P#C3]FSQW\*?B1XCUKP-IVM
M^#_$?CWPO\2_#_BWP?X_T/PEX]F\/>)/#OB;P[/9:UHVH>#]0TOQ9X?U=2VH
M:5J?AW2GN?Z'R^OBL3@,%B<=@)97C<1A,/6QF63QF%S">78JK1A/$8&6/P,8
M8+&RPE64Z#Q>#A'"XATW6H1C2G!+X*O"E3KUJ="NL31IU:D*6)5*K06(I1FX
MPK*A7;K455BE-4JS=6FI<E1N28OBW_@I#^R5X9^$.I_&'3?B(?'=EIWPG^*7
MQFA^'W@G3WO?B_J?@_X*:W;^&/BK#:_#76IM"\167B3P)XEFF\/^)_#6O0:-
MJVB:OI>O6FIV]JV@:R;'Z^L_'O@N]T*R\21^*O#T>BW][;Z7!J,VN:4EG_;-
MS.MI'H;78O&M/[9%ZWV!M,2=[L7RM:B-IAMK\'/'G_!)WXY2>&/B9K?AMOV<
MO&WQD_:&^#W_  4&\.?%G6?$UQXH\%Z%X#^)?[;?COP3XTL+KX3ZO:^ ?'?B
MF[\$> -,\/ZMX(E_MAM$UW5[74]4\3>1!<^*-6T.SN>./^"6WQI\=O\ $'1;
MKP[\)/"WP9\3?%/Q=X@M/@+\.?C1XI\ Z!J'A/XE?LT_!OX(^(-6G\3:1\ Y
MSX:\;^&?$WPGU3Q'8RZ/X=N[[7=+^(^OZE8^,_!_C33EU'5^PR/WS@UG2+J_
MN=*M=5TVYU2R3S+S38+ZUFO[2,L$$ES9QRM<0(794WRQHNY@N<D"M*OSG_8/
M_8SE_9A\2?M/^+_%?@'X2:9XR^,'Q[\6^-/#7COP/J>J>)O%^J?"_6M#\$VE
MEH7C+7_$?A#P[KEC?3^)O"^J^,-2T&#5?$NDMK7B&ZU235[[6)]0O[O]&* "
MBBB@ HHHH **** "BBB@ HHHH **** .-\3?\AKP)_V,EU_ZC6NUV5<;XF_Y
M#7@3_L9+K_U&M=KLJ .,\7_\?'@S_L<]/_\ 37K-=G7&>+_^/CP9_P!CGI__
M *:]9KLZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN)@^)7P\
MN;[QKIMOXX\*3ZA\-XK6?X@V<6OZ9)<>"8KVRGU&T?Q5&MR6T$7&GVUQ>Q?V
MD+8M:PR3@>6I:@#MJ*\:?]H?X&1^&H/&$OQ7\"Q>&;G5YM BUF7Q!8169UFW
MMEOKC3G:257BN;:PDCO[E)D3[/82Q7TQ2UECF;I;CXK_  SM/%FE>!+GQYX4
MA\8:Y9Q7^D>'7UNP&J:C:3VT][;36EOYV91=65K<WMHBGS+JTMYKJW22"-Y
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M-8NA?\>EU_V&-;_].UY6U0 4444 %%%% !1110 4444 %%%% !1110 4444
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M &,EU_ZC6NUV5 '&>+_^/CP9_P!CGI__ *:]9KLZXSQ?_P ?'@S_ +'/3_\
MTUZS79T 8=G_ ,A[7/\ KUT;_P!!U"MRL.S_ .0]KG_7KHW_ *#J%;E !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+H7_'I=?]AC6_\
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MN$N&$^:60955E_-B<)'&2TZN6.K8YM^;;?F?/>D?LF_LR:"Z2:7\!OA5;S(
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M0O\ CTNO^PQK?_IVO*VJQM#4K:W61C.KZV1[C^UKSG]*V:[#C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *P_$O_(#U'_KBO\ Z-CK<K#\2_\
M(#U'_KBO_HV.@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K&U/_ (_O#_\ V%9__3+JU;-8VI_\?WA__L*S_P#IEU:@#9KXZ@_;5^&_
MV[Q2NH>'_%FGZ'X?TOXAZE9:VJZ!J4NL2?#'Q3IO@KQ'I4WAS3=<N?$OA76+
M_P 3ZOI^F^$K'QCI>A-XG,_G63HBD'[%K\V(?^"?GGZGXWO[_P ?Z59:EXLT
MSQG!JOCCP]X0EL?B#\1]8U[Q/IOBOP=K?QLU&[UZ\T?QU+\,M2T?3T\,V]II
M6C%H(FA@N=*M));.4 ]IE_:XL8]>USX?K\)OB%<?&#PI97OB'Q7\*K2\\#7.
MMZ+X(LM*TK6%\:+KD?BO_A%-3TG48M:L-,TBTT_6YM6O_$(O]'%C&^FWD\4%
M]^VS\++/3%\:KIGB>X^#]I/X6T[Q)\7TM]+B\+>%M;\9>'].\2:#I6JZ;/J<
M?BB3-IK6A6.JZA8:)=V&CZSK5CIEY,LJ7[67+/\ LK?$U/B?XG^/]A\3?!=A
M\:_'WA*Y^&GC"=? 6KW'@&'X>"PTB'1;7PWH4_C,ZY:>(M"UC29?$2:GJ?B'
M4;'4KC6M1TRZTV.Q@L&M^9U']@:RO? &N_ -/'VW]GSQA?\ A#7_ !5H4N@E
M_B'<:[X0\-^'M%2+3/%J:FFCVNCZWJGA+P_XEU..X\,W5_#=QZEIMC=0V%_%
M]B /J'X6_'/3_B3KVH^%KWP=XK\ ^);;PIX<^(.EZ/XL&AO<:[X!\6SZA::'
MXDLY-!UC6(+:3[;I=Y8ZOHFHR6FL:+=B".\M=ES#(WN=?./PB^"_BKPAXMNO
M'_Q$\9:1XP\6P_#CPI\)-%F\.^'+GPOI5OX/\)W^IZLNHZC97FM:[-=>)_$&
MJZH]WJLUO<VNE6<5I:VFF6$2>?++]'4 <;XF_P"0UX$_[&2Z_P#4:UVNRKC?
M$W_(:\"?]C)=?^HUKM=E0!QGB_\ X^/!G_8YZ?\ ^FO6:[.N,\7_ /'QX,_[
M'/3_ /TUZS79T 8=G_R'M<_Z]=&_]!U"MRL.S_Y#VN?]>NC?^@ZA6Y0 4444
M %%%% !1110 5!<VUM>02VMY;P75K.ACGMKF*.>":-N&CEAE5HY$8=4=64]Q
M4]%)I23C)*49)J49)2C)---2C)----IIIIIM---IM-Q:E%N,HM2C*+<91DFF
MI1E%QE%II-.,DTTFFFDUS:>#?"$3QR1>%?#<<D3I)%(FAZ8CQR(P9'C=;4,C
MHP#(RD,K $$$"NDHHK.E0H4%)4:%&BI-.2HT:-%2:NDY*C2I*32;2<E)I-I-
M7=]*M>O7<77KUZ[BFHNO7K5G%-W:BZU:LXIM)M1<4VDVFTFBBBBM3(**** *
M5WING7XVWUA97HZ8N[6"Y&..,31N.P_(>E<?J7PJ^&&L*5U;X<^!-2#?>%]X
M2T"ZSTSDSZ>Y.<#//.!Z5WM%<N(P.!Q::Q6!P6*3T:Q6#P>)3]5B,)B$_FF=
M>'S#'X-J6$Q^.PDHZQ>$QV-PK3[IX;&89KY-'SYJG[)_[-&L@C4/@9\,9 PP
M?(\):38G'UL;>V(Z=B,5QMQ^PO\ LL2KMM/A38Z)@85O#NO>*M!*^Z?V7KEJ
M$([%0,=N:^M:*^?Q' G!&*;EB.#>%*TGO.7#F21GW_B4LKP]1?*I$^CPWB!Q
MYA(J&&XVXOHP6JIPXGSYT^W\.KFV)I/336G(^)=*_8C^#XMIFT3Q#\9_"ABU
M'5;>,^'?C+X[M?+2WU&XABV"ZU6]4%4C3YF5F9AN=G8DG4'[(M]IZ[?#7[3?
M[3NAX&$^T?$2T\0JO3&1KFA7?F $#(D+ XP<Y.?JS0O^/2Z_[#&M_P#IVO*V
MJX_^(<\#QUH<.8/!/H\MQ6<Y6X_X5EG$6!C'_MVFK=+';_Q$WCV7\?B;&XY7
MNUFF$R/-E)_WWFO#682G_P!O5'^I\<)^SO\ 'K31C0_VS/B7E0?+_P"$H\"?
M#[Q-SQM\T_V?I9DQ@;ON[OFY&[A&^&?[9^F+MTO]IKX?:_MSM/BGX)6EFTF!
M\OFG0/$<!7<0-_EXQN?:.%Q]D44?Z@9%!6PN,XLP%MOJ7'/&%)1](8C.LSIZ
M=+PE\^I_Q$7/YN^*P/!V87=W]>X!X*JN7^*>&R+*ZNO6U2/?1[?'"6/[>FE*
M"NN_LQ^+64=+O2?B)X9:4@#EOLEQJBQ%B.0K2!=YQNV %O\ PFW[<FF?\?OP
M.^"7B8J/F_X1OXKZQHWFD=?+_P"$A\.OLWX.WS/N[UW'Y6K[)HH_U+JTU;"<
M;>(&&MLI\0X3,HKUCFW#&+<O^WZLK]0_UXHU&WB^!/#G%7=Y.'#>,RR3\E+)
M^*L&H_\ ;E*-NEM#XW?XZ?M.Z4A.N?L<ZU>,JY8^$?B[X$UD' ^;RTO$TQG/
MRML5BA.4SC<=J)^U7XVL1N\2?LC_ +1^EJN#*VCZ#X9\5A,<OL.D^(_WNW#[
M0G+X7:,.M?9-%'^K7$])_P"S>(V>M)64<PX=X+S%>LY1RW*:D_/WH7\MT_\
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M&'0AT+( RD,N00:^7Q\+/VQX/DM_VI_!]Q&?F9]0^!FC/,K\ JAM_$$*>7@
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M<1A8QXO_ (3+]L+_ *(K\)__  Z-_P#_ "@H_P"$R_;"_P"B*_"?_P .C?\
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M(\017R<<?4=_*R7GT?(?\)]^UK_T;]X$_P##N6G_ ,IZ/^$^_:U_Z-^\"?\
MAW+3_P"4]=?_ ,*-O?\ HLGQ@_\ "FM?_E91_P *-O?^BR?&#_PIK7_Y64O]
M=_%K_HPV+_\ %P^&'_SJ'_8W"W_1;TO_ !$^)/\ YJ.0_P"$^_:U_P"C?O G
M_AW+3_Y3T?\ "??M:_\ 1OW@3_P[EI_\IZZ__A1M[_T63XP?^%-:_P#RLH_X
M4;>_]%D^,'_A36O_ ,K*/]=_%K_HPV+_ /%P^&'_ ,Z@_L;A;_HMZ7_B)\2?
M_-1P.E?$;]J*"WGC3]F[P]=$:CJC2SP?&'0H(6G?4;EIUBCN=,,VR*4M$KMC
MS F\ !@*TO\ A9?[4O\ T;-H?_AYO#?_ ,JZV])^#>N26\_D?&OXLVT4>I:K
M"L2:OI3C]SJ-S&9&>727=Y)BIEE=F^:1W( &!6G_ ,*7\0_]%S^+G_@UT;_Y
M34?Z]^*BT?@%G3:T;CXL^$DHM]7&3A!N-_A;A!M6;C%W2G^Q>&O^BXPGSX7X
MI3^:YFD^Z3:3O9M:G(_\++_:E_Z-FT/_ ,/-X;_^5='_  LO]J7_ *-FT/\
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MG4Q&#5/V&*E/$QJR?(?\+H_: _Z-.\1?^'1\#?X4?\+H_: _Z-.\1?\ AT?
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M46_6+X7;7H[M&!_PT'\5?^C3_B[_ .#;P3_\NJ/^&@_BK_T:?\7?_!MX)_\
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M_-37<!?VF8A_K/@U=ENS+XOMMF/38LF_=GOC&.^>%\S]IG_GU^"__@3XQ_\
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MY(W;$OMW^MCQC+XSG'7/T-=I6-XACDFT:_CB1Y)'B4*B*7=CYL9PJJ"2< G
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M_P"'T7_!)3_I([^QO_X?SX>__+NC_A]%_P $E/\ I([^QO\ ^'\^'O\ \NZ
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MZ9H&FZG;PV>KW6KW6H<?_P /HO\ @DI_TD=_8W_\/Y\/?_EW1_P^B_X)*?\
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M /\ $4 ?JS17Y3?\/K?^"8/_ $?W^P]_XE-\/_\ XBC_ (?6_P#!,'_H_O\
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MOTD      !@ <  = !V K\IO^'UO_!,'_H_O]A[_ ,2F^'__ ,11_P /K?\
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M8_\ !!I7_P B444 '_"$^#/^A1\,?^"#2O\ Y$H_X0GP9_T*/AC_ ,$&E?\
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(D&MNBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I BH# 2(  A$! Q$!_\0
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M?7VHW+_>7IGJ.GK]* .0W^/_ /GW\'_^!FM?_(-&_P ?_P#/OX/_ / S6O\
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M )!HW^/_ /GW\'_^!FM?_(-=?N7^\.N.HZ^GU]J3<O\ >7\QVZ]Z .1W^/\
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M::7N95%<7");K&I>]BFAB>XM4BN9V2]O+2%XS+?:=>*2FMV4A%SX4;]_:DH
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M);"SNH?,AL7O0GF'1[BX(ETKQ<I%REV1IEVI0$&=DF:8NAG>1[EY]P6&"_\
M[1M;=(&F:(Q^1'XMM(PZ0V>?[)\0:>&N) TI7$_F( '0H(_(EN5DMX':(6$\
M^VXN8K5P6?2KAP8]<T%_]*TN<M>62A0IH JNB/=7,>PN6^R0%'5(KMKNQEEE
M1"JAH8_$-@@$D=H/^);XDMPG(9R0MN$5O,VH GF:BLJP9"%FE2]U%+5E'VB&
M3*IXB\.$B;0)238,1MS%$ACN)(Y%38MKIEBT;OOM/*;[0VGV372*)GT,RLK^
M'?$BXOK:[/DZ@QBCV5:E#R$!?/:0W4C(6"QW?]I68"/) I!AB\5V2J5@5_\
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M4CW-E%*TRK;S2Q6]V55A9W,L5M=^3/*D; #O'W_(HZS_ -<[7_TOM:["N/\
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MHX0W.F3-&#XL\*[O/TV8[X@OREC_ %CP<_XW!_"%2_6E@L[P3U[?4^*4D_\
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M/X;<B*ZD7+**-[?:=92L=0\06%E+]KB9EU35M"L+\W<$"1#SYY9(XXO%-M"
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M . H^'S^PAX(U-HSXC_:!_;/\7-F\F/]J_M$>,-.NKB.1HS?3I#I%MHGDZM
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MZ)#<,RLJ_8]2:9$ DEA#JD>G>)U21DN]+;]UX@TT/=1H3,=H!6>&65)%-R[
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MXCB\R[^?<09G BC:9/)PD,UQN02/9+;2D_:IY()\&Y\+R.Q&J:: ;WP]/O\
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M;HPO;@3VJV=S+(+87U\I-S-H4SJ#X7U>(F_L-0_<WFV$.*L^6_S@B[,KR(C
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M(@) ("EW*YWV\OF^8L126]DL[\SJ"MM%++'"L=KXA6(YTO7@0FMV 6RG<R.
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M]6\-?&$_M9^#+[5-7NM \#^(-+UK2X? -M'X;NYY-!\&>7,9;'P<?#]M8_\
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M =8[77XX\2V/B7 AUJP4:;(&=U<RK)&<;)49MUQ)$UK;[6:4@)?3VVFGG[5
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M^'?C?Q=8>3'+$B65QK,NF6&FWUE=7";])U:34([[1Y&2VB+V\9!]7\*_L_\
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MSQ# 9)/+N&*B/T#PV8SI%N8FMVC,MX4>UB:"W<&\G)>*%P&A#MEFB8#RW+H
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M1>6^FQ:?\/--\=WEO>^(K2/5+:VCU?Q$D:VR:;H#ZU<32:+HTD]ENO9I!>(
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MANK3=_:'AN8IO6.-0D<$44TH83W%V[![.-UGFMP5EBR]A9S7#VK%[RV=(Y-
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M'<RR1 !>W'Q$_:^NT62+]F_X?7!>XNWCEM_CKI[2?VK8X6WEBD'ALP)KT:*
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M1,CRW+>=J$%K(B7<4BW%TEAJ$=O);0W;E1XB\.D>6)#YMHX=%S:'[0/P,W"
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M!N!F5[_*,KEYW-Q*DBV[V^H27MJ@BO9TM\_9K37K5/EU/36QI_B"#,ML"2:
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M;!&A@\4VH,P.D#_0/%,!EF8Y.!WWAPHVDP-'Y)1I;ME-O&886#7<[%HX2 8
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MCN&'F^$OA[;N'*2+<^)/$$MP=2C01VCS7<=A&(_$?DA4M-5!VZI9E+43W 8
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M$6NY+)I%9JX77?V=?C3XWOY;GXD_&"?Q9H#;0_@Z.^USPMX&?3!-YNGBXM/
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M:ZU"-+'Q';J=:G5V75M*,:P:UF2:"T7/'H(\._%FW5,?%+3S'Y%TIW?#733
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MC7,$?R2>&?$L)"Q78AM;V1S$\9$)@'#3$R7$EP#$@2Z:Z@7;<W,XB1X[;Q;
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M%M>LBQR@@ ["W$>QH ACED1E5C 82PBN9=.MW#EO#[ D>(]#DQ)H0WW-M&6
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MPR%P+3.\3B[+F=$99)5M=1-RD<?DQW-Q&$&E^*4BF)TZXC;[/X@TP1K/(7G
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M'BV:*PO)2VEF74O$&M647]F,@5]-U3[-,FF;H[6X5&5U65O@3\6-4N$?Q/\
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MZ07_ .$C\X:L#IAA%\/(KVD2Q%(Y!+&4EV&)PZE)!(,QF-@</O'*;2=PY7-
M'/'PGHY;>1J&XSM<[AJVI@^>X DDXNP!YP'[]0-EQ_RW60T@\):,%"!=0VB*
M6 *=6U-AY$S^9+!AKL@P,_SB _NHV ,:)@8Z))H9"HCEB<LK,H216+*K;&9=
MI.55_E8C@-\I.>*:+BW,(N1/";=E#K.)4,+(V-KB4-L*MD88-@Y&#S0!S[>$
M=&?.X:DQ*1(6.LZMN(A_U+;Q>!_.B'RI<;O/5/D$FSY:>?"ND%]Y_M#?Y[7(
M8:MJ:D7#KLDF&VZ&'E7Y9L<3CB8/6\EQ!(P2.:)W*&0(DB,QC#F,R!58DH)
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M[9Q_KX\>7,?FD1FYJ,>$-$52H2_VF)[=E.KZH5:!W\PPNIO")(U<!HE<,(,
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MC@$8U'D0Y/\ ;&JDEK;_ %$I)O"3/%_#<Y^T8 #2L   ^$]')W$:AGSGN/\
MD+:F )I!ME< 78 $PXG0#RY^LR2$DUTM% ',CPEHP4)MOR@BDMPK:MJC#R)7
M\QX"&NSF$R'>L1S'$W,2H<4-X1T9B2PU%B5B4L=9U;<?(XA??]LW>=&/E6XS
MYX3Y/,V?+735Y[\1OBU\,?A#IFG:S\4/'OA7P%IFL:I%HFD7?BG6K'1TU75Y
MH9KE=.TU;N:.2^NTM+>YOIX;5)7MK"UN[^X$5G:W$\8!O'PII!;<1J&[SGN,
MC5M3!$\J[)9!BZ&&F7Y9P,+./]<'))J-/!^B1JJ(E^J+%) $_M?5"OD2\O R
MM=D/!GE(6#11$GR4C!(K3T+7M#\4:-I?B/PUK.E>(?#VMV-MJ>BZ[H>H6FK:
M-J^FWD2SV>HZ7J=A-<66H6%W"Z36MY:3S6]Q"Z2PR.C*QN7=[9V$(N+ZZMK.
M!KBTM%FNIX[>)KJ_NX;"PME>5D5KB]OKFWLK.!29;F[N(+:!'FEC1@#"?PCH
MSA@PU$[TB1S_ &QJNYA  L#%Q>;_ #85&R*<,)HT^19 O%/7PKI*L&7^T583
M&X4KJ^IC9.R>6\L8%WB-I4^6;RPJS DRARS$]'7"_$WXF>!/@UX!\5?%'XG>
M([/PAX \$:5-KGBOQ/J,=W+8Z)I%N\:3W]VEC;W=W]GA,B&5H;>4QH3(P"*S
M* :8\(:(%10E_M1)(T7^UM3*B*4EGBVF[VF'<2Z0L#'$Y+Q(C<TX^$]'961O
M[1962%&W:QJK,PMO^/<LYO"[20=(9BQFC'"R 5T:.LB*Z'*NJNIP1E6 (."
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M:K)*$^4.S;>,5T5% !1110!Q_C[_ )%'6?\ KG:_^E]K785Q_C[_ )%'6?\
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M?@1^U+XS^,WQJT2W\7^(M&TW58WD^$7C2;X0Z)K&EZ=I-IXBTJUN?!;V6D^
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MEG>64MS>:GHOB;PEH<.F7*3^5'83P>(M2LKB>6:+_2%EMDDA5!L=@^ ?//\
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M)'B#_P #/#7_ ,O*/^$BUK_H2/$'_@9X:_\ EY7744 <C_PD6M?]"1X@_P#
MSPU_\O*/^$BUK_H2/$'_ (&>&O\ Y>5UU% '(_\ "1:U_P!"1X@_\#/#7_R\
MH_X2+6O^A(\0?^!GAK_Y>5UU% '(_P#"1:U_T)'B#_P,\-?_ "\H_P"$BUK_
M *$CQ!_X&>&O_EY7744 <C_PD6M?]"1X@_\  SPU_P#+RC_A(M:_Z$CQ!_X&
M>&O_ )>5UU% '(_\)%K7_0D>(/\ P,\-?_+RC_A(M:_Z$CQ!_P"!GAK_ .7E
M==10!R/_  D6M?\ 0D>(/_ SPU_\O*/^$BUK_H2/$'_@9X:_^7E==10!R/\
MPD6M?]"1X@_\#/#7_P O*/\ A(M:_P"A(\0?^!GAK_Y>5UU% '(_\)%K7_0D
M>(/_  ,\-?\ R\H_X2+6O^A(\0?^!GAK_P"7E==10!R/_"1:U_T)'B#_ ,#/
M#7_R\H_X2+6O^A(\0?\ @9X:_P#EY7744 <C_P )%K7_ $)'B#_P,\-?_+RC
M_A(M:_Z$CQ!_X&>&O_EY7744 <C_ ,)%K7_0D>(/_ SPU_\ +RC_ (2+6O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "" BH# 2(  A$! Q$!_\0
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M1%IJ>'QI\=YJ%Q:VVH6Q74TTZRTC4HFOI(KJVNHU]*^"?Q$\5^.)O$&I^*_
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M]K7A37K1Q):ZUX;U2]T35(77!!6]TZ:WF91@9CD9XV'#(PR*_9/]E#_@LO\
M%[X8WVF>&OVA8)_BCX+#Q6S^--,M[>T\?Z-!G8;G4+*'[/I?BV"),&4)'IFL
M,H9EN+V4B)_Q5HI<5\#<*\;826$XDR;"8]\DH4,<H1H9I@FTTIX+,Z,(XR@X
M-J2INK7PTFK5,)4BY)^MDO$>=</5U7RG'U\,N92J8=R=3!XBS5XXC"5).A44
MDK.:A3K).\*\6E;_ $(?@K\>/AK\>_!FD^.?AMXITGQ1X>U>+?;:AIMP'59D
M53/97ELX2ZT[4K1F$=YIM]#;WEK)\LT*Y4M[/7\"G[*G[6/Q1_9'^(5OXS\
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MIQC4P.*JRJ5:-/1.6 Q564ZM"<8W<:-2=7"3LH2IT;JI'_1O1UD4.C!E89#
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MMI$+@O9ZC A*VNJ01ESI&NP)]MTR<KS-:-/:R_VS?LM?M,_#W]J;X4Z!\3?
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MTMX5%U::I?WH@CCDU";6+Y;J6X5(4FU!G20-]MNS!&US)(TH*;[5 ME)+;.
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M''5F8LS'J69F)9F8Y+,Q+,Q))))-?TO^SV\->+O$'%XSZ47BK*55U?[3X?\
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M:I=D]F2T"0:9 1U >"\(/61L5QNI:OJFL.)-4U"[ORIRB3RDP1'MY-JFRU@
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MPF6Y3%RY:M#"8&4I2IU6Z:ABL7BY8G,\74I<V.QM1QAA\.4445]T?+A1110
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M4G&3@X'M48N-*"=2=5VO[2I;GDI-R3E:%-)I22MR1:22:YE(****P-0HHHH
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M.6UT*RA31O">G3?ZS3_#EE)(UJ9P.!J&J3RSZSJSCEM1OIDR8X8@OGE%%?\
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MWMX(HX8XH8TBCCCB18XXXTC"I''&BJD<:*J1HJHBJJ@#3HHK^:OZ_K^OUO\
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- CD# 2(  A$! Q$!_\0
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MPG%\</%/Q3_;,U/QOK?B:SUV]MO%'PE^$OA_Q9I.OWWB7QM'8W%Q%I6A>-/
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M[=4FO(M0N8I&,;[12^'O[)7[,'PGU[Q[XH^&GP ^$?@;Q!\4(+ZT^(.K>&?
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MRMC,\=Q=WD,?DR2&/'YRW/[-KZ/^S=\)O$_BC4XM#\6:OXDUSQ:OPVNM*O\
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MT7PO\2M-DA>UGT[QG&=9A9/$?AK1-/MM5.H>'(+FU:YD'VB9+V*%H![_ #?
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M3X/\-0ZIJBQ''R#^W/%=_!.H/S26:,>BX]ZH **** .<\8QZK-X1\4PZ%/\
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M^!O$%UH%SHD\:2NJ:G?RVK7$+J[VMNK>5-(74D\2O[33:7JWBCQ3=6/BO6]
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M\:^%_%UH\0F\WP]KFG:L8XV.,SQ6=Q+-;,&^5X[B.*1'!1U5@17\;=7]&O\
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M3/C)IET>Z^TS:_<74OA<WHS(NL8#PM"&%PFF, <0,N1QMW\"_B)-HW@FWO\
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M)/$^I>/O$47BCXG^%_&7C;XVZ%^T%IGC;PIXCT?3/$GPZ^)'A[P1:?#NTN_
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M?#+5_"FD1>)M0TG5M'U_P[-K\GB/P=XJGE_X1O7=#L=7TA-.ETU!=K)]O%]
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MC:6^I:GJ-W)))'IFD:9I\$:Q0VUE#'& ?6: "OQ&_P""L_\ P4T_X9=\/R_
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M<DI1EAN&KI.\-4C]YM6UWP]X8M?-UW6M"\.6<87YM5U+3M(@08PN%NIK=0"
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M_P"/&]_Z]+G_ -$O7YE4 ?H;\.O^1%\)_P#8"T__ -$)79UQGPZ_Y$7PG_V
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M:5.5::J8G$U%%^RPF#H8W&5FK4<)4>JNU4N+VWMA^]D&_&1&OS.?^ YX'NQ
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M]CI%O%::9IGC'X7V,.EV=G';1*!&;[P,=$,<DA9[AM(N2[;D!?\ ".O]!/\
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M33[-6?XGBIIJZ::>S337WH****0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH *0@,"IZ,"#]",&EHHVU734#]?\ X!^)QXL^$G@W4'D$EW86#>'[\[B6
M^U:%(;$%\\AI+5+6;&2 ) H/RU[#7PU^Q;XF,EEXT\&RN/\ 19[+Q+8J3@^7
M=#^SM01/51+#9RD#[K2.Q^]Q]RU_@;](;@__ %&\:?$/(:='V.#EQ#B<[RN"
M5H?V5Q,EQ#@U3227LZ4LSQ^&BHZ1^J\FG+9?H66UOK&!PU1N\E35.?\ CI?N
MW?S:C%_,****_&3N"BBB@ HHHH **** "BBB@ HHHH **BFGA@4O-(D:CNS
M?EGK7G_B+XD:%H4,C&YB>1 >KKC(&> #DX]R!T'TTI4:M:2A2ISJ2;LE&+?Y
M*WXEPISJ-1A&4F^R;/0I)(XE+R.L:#DLY"@?B:\K\:?%/1/#-O+MN8GE56^?
M<N%(!Z G!QCG_./CSXJ_M2V>G1W$<5\HVAML<<@R>H  !X[8 'N3SQ^=?Q ^
M.OB+Q;)/#:SRV]K(S#S"Q\QE).<#/&1QEL\=N]?>9%P)C\PE"KBH^QH-IOFN
MDUH]6U>6G2*U[GT67\/5\0XSKKDIZ.STOUZZOT1]9_&?]J=C)<VEA=M<7#%E
M6.)^G498@X YZGWK\]_$WBO5_%5])>ZG<.^]BR0[V,<8/H">3COCV  KG9))
M)G:25WDD<DL[L69B>I)))-,K]GRG(\!E%*,,-2C[11M*JXKF??ET]U>FO=]#
M[?"8'#X."C2@D[:RLK_+M^?F%%%-=@BLQR0H)PH+,<=E49+,>BJ 2Q( !)%>
MR=A^O?\ P1 _9M;]H3]O?X?ZWJFG->^!_P!GZRN?C7XK>2));)M4T.1;#X?:
M7<B6.2-GU#QC=V5]%%A9##HMW/&ZO N[_0I\)6K3WJR$;B6+$X&=Q/).>>3D
M]\\FOQD_X(U_L2_\,??LD^'KOQ7HPT_XV?'5=.^)?Q2-Q"HU'1;.[M6;P+X#
MF?:)(U\,>'KI;G4;4ML3Q#J^KY4M&&/[H>!M+*[)64C(SG'/0=OH1C'XU^P\
M-9=++LKI1J1Y<1B7]:K*UG#VD8JE2E?6].BHJ2>TYS71GVV585X7"04E:I5?
MM:BZKF2Y(OSC"UUTE)KH>L6B;($'3@<?A]!USD^]6::B[5 [XY^M.KWST@HH
MHH **** "BBB@"I?_P#'C>_]>ES_ .B7K\RJ_36__P"/&]_Z]+G_ -$O7YE4
M ?H;\.O^1%\)_P#8"T__ -$)79UQGPZ_Y$7PG_V M/\ _1"5V= !1110!\;Z
M-^P5^S9H/C?X@_$73]"^(1\7_%30/$OA;Q]J=]\</C5JB>(]!\56&J:9?:;=
MV&I>/[K3XX=-L=:U*#PJ;:UAD\&BY9O"CZ,ZHRS_  O_ &$_V=/@WX7\2>"?
MAYI'Q%T3P=XI\#WOPYU#PK<?'#XTZWX>LO".H2B6\T[PUHVN^/=2T_PC<3YE
MB.K>%[?2-76WN;J".^2*YG5_L&BO%I\-\/TIPJTLERRG4IO%2A4AA(1G%XZ4
MI8UJ2J*7^URG*>)3<E7G)SJ1E.TU[M3B?B.M3G2JY[FM2E46#C4I5,94G3FL
MOC&& 4H2IN+^I0A&&%:494(14*4HT[TW\Z:I^R;^S]K'COX8?$:Z^'EI#XF^
M#FB:'X<^'PTS6?$6D>'M(T7PH]S-X/L+SPAI>KV?A/7X_!ES>7EYX/?Q!HVJ
M2^&+V[N+S19+*YD,M?1=%%>CA\%@\(Z\L)A<-AI8FI&KB'AZ%*BZ]6%*G0A4
MJ^SA#GG"A1I48-I<M.G"$5&,5?S,3CL;C(T(XS%XG%1PM.5'#+$UZM=4*4ZU
M3$3IT?:SFZ<)UZU6M-)OFJU)SDY2D[%9FIV:75NZLN<@YZ>G/8YZ _49K3I"
M P(/0C%=)RGS%XGTAK.X=@I"Y."!@9SG/3/X^Y'6OY6/^"V__!/R6SO-6_;;
M^$.DR2V=_+:K^T/X;LDGGFM=0?[/IVF?%/3+*"!Q%I\\4<-CX[.]([6X6RU]
M@L<^IR)_87XHT);V%V"DG!.0.<X('/H>V,D$9KYP\1>'[2[M-4T36=.M=4T?
M5[&^TC5]+U"W2YT_5-+U&VDL]0TZ^MI08[FSO;2:6VN8'&V6&1E(YS7S7%O"
M^ XOR3%9/CDH.HO:X+%J*E4P..IQFL/BJ:T;47)TZ]+F2KX:I6HMING*'U/!
MO%F8\&9]A,[R]N:IOV..P;FXTLPR^I.#Q.$J[J+DHJKAZO*Y8?%4J-:-U[6-
M3_,PZ^]4Y.WX_P"?TK]??^"G_P#P3-U[]C?Q1<?%'X7VFI>(/V8_%VKE-/O6
M#7>H?"+7=3G=K?P1XIG4%Y- GD8P^#?$TZJEU$$T34I%U6"*6_\ R#D&!CT;
M'\Z_A;.\AS/AK-L1E&;8=T,7AY/57E1Q%&7-['%8:K91K8:O&//3J1U7O4ZD
M:=:E5IQ_OW(>(<JXHRK#9SD^)CB,'BEMI&OAJR456PF+I<SE0Q6'E)PJTY:/
MW*M.52C5I59UWZ#Z_P"-<QJZXN$;^]$I_$%A^@QS[CM74/\ =/X?S%<YK0^:
MW?U1E/7^$CG\CVK^B/HB8[ZGXVY/1<N59GP_Q7E]NDI?V50Q]..^KY\N;5[Z
MINW5?SM]+W _6_!'.:RC>66<0<*YA?\ EBLUQ& J2\ERYBDWV:[V="SU:_TR
M59+2XDCP0VT,=I(/IGCIVQZ\U[OX'_:&\3^%Y8T:\E,*%0\,S&:VD4=05<X4
M8..0?3..1\[OU'T_S_.JS_>/X?RK_6^ACL5A'>C5E%+7D;;@[-?9;T^5C_(F
MO@\/B5:K3C)_S))2^]+7YW/TTT;XM?";XD0):>,=(@TV^F4)_:=D%50Y &]U
M7! R>>#@"K&I?LZ:?KL3WWP^\3:=J\+ O'9F>-9P, A-I;.[^?X&OS#BNKBU
MDWV\TD1!#?*Q )Z\CH?RKO/#WQ5\5^&[A);+4;J%HV5@\$\D;9&",@-M/3'/
MY&O:H<24IVAC:.NBYXKFCZ_S+\3QJV05(7GA*S2>O))M?+=I_<?1GB7X6^-O
M"LCIJFB7D:(3^^6%VB8#N' *D>^:X!XY(F*R(R,."K*5/Y&O8?!/[:'B"T2+
M3_$T-EX@LB DD&J0+([)T.'8<G&1GOGZFO:[?XC?LU_$91_;>B2>&+^=1YES
M9%3 LC'!; RH4')P!GC&?3U:6(P.)5Z&(BF_LR:T\K-IKMU/.J4L;AVU6P\F
ME]J*>OW)K\#XPHK[.NOV=? _B=#<_#_X@:7=EP3%9WDZ0S$DY"G+=><'CV&>
M*\I\1_LZ?$SP^7?^QWU&V7)$]@?M",!W'E[LYP>PQ6KI2WCRS7]UI_@0J\-I
M<T'VE%K\5<\'HK;U#PWKVENR7^DWULRD@^;;R* 1UY*]O7I6*RLIPRE3Z,"#
M^1J'&4=XM>J?]?B:J49;23]&F)1114C"BBB@ HHHH **** "BBB@ HHHH ]W
M_9K\3-X9^,'AC?,8K/7VNO#-Z.=KKJL)%GO R3LU&&S9< D-CC!;/ZTD8)!Z
MC@U^%%E>W&FWEGJ5H[1W>G7=M?VTB,4=+BSF2XA96'*D21KR.17[@Z!K5MXC
MT'1?$-FP:VUO2K#5(B,<"]MHYV0A20#'([QLH)VLI4\BO\LOV@7!_P!4XHX%
MX[H4;4L\R;'<,9C5C"R>89!B/[1RUU9I6<ZF3YMBJ5/F;DX8-Q3Y867UG#E:
M]+$8=O6G.-6"_NU%RSMY*<$_^WC6HHHK_/0^D"BBB@ HHHH **ADN((@3)+&
MF.N6''X=:P[WQ3H]BI,MRF0#QN4?GDY'Y5483F[1A*3[*+?Z#492=HQ;?DF_
MR1T5(2%&20 .I) 'YFO%M<^,FAZ8K[9X1MXR6&<C.>IQSSCCC&3[_/GC+]IW
M3K**7%_&@0-_RU48 ST (';GT[\&O5PF1YEC))4L-4LVK-Q?6W2QVT<NQ==K
MDI2L^K3_ ,C[5OM=TO3T9KBZB!4'*A@3QUR<X SWYKRCQ+\9]#TB*3RIX@4#
M?,74G@<')X'J#CIUQ7Y<^./VKIKEYHM/GFN6.X QL=F3ZMT'N<D@CIZ_+_B3
MXN^+?$+R;[V2VB<ME8W;>0?5L\'Z5]WE?AQBJW+/&S]E%V;4M';_  K5_.Q]
M!A.&*D[2Q$N5:73WMZ+4_1_XD_M5V=DL\<>H N=P"1R9;^+@*#N.<^G;M7PQ
MXW_:%\2^(GFBL99((9"P\QV.2#GE5!ZXQR??CM7SS-/-<N99Y9)I&))>1BS$
MGKR345?I.6<*Y3EL8\E"-6I&WOSBK7\HK3[[GU&%RK"86*4::E)?:DEOY+_.
MY<O=0O=1F:>]N9;B5B26D<MU[ $X ]A5.BBOI$E%)1226B2222\DDDON/222
M5DK+L@HHHI@%?O[_ ,$._P#@FPW[2GQ)MOVI?C+H#2_ /X0>(X7\&:)J=O<Q
M6WQ8^*FC307MFB*T:0ZAX+\"W2P7^OD/);:KKPL-#99(8-45/C#_ ()J?\$V
M/B/_ ,%!/B>]N'U/P5\ ?!-]:M\5_BHEIDH&V7">!O!+3K]FU/QUK-L?E_UM
MIX;L';6-54XL[2\_T#?A%\)O!'PB\ >"_A+\+O#=KX5^'_@#0;'PUX4\/66]
MHK#2[%-J-+.Y,UY?WDQFOM3U"X9[G4-1N;J]N&:6=C7V/"^0RQ=6&88NG_L=
M&7-0A-?[S6A+27*UK0I27-)OW:M2,8+FC"HW[F4Y<ZTXXFM']Q!WIQDOXLT]
M'9[TX-7;>DY)15TI,]4T+3IK^[#%=Q9]S' P23G@*N .O& !R ,8KZ-T2P6S
MMD&W!VCT'/IQSU!_R:Y/PGX?%K$DSIAB%(R.<XXZG/MUZ<GMCT=1M  [5^GG
MU@M%%% !1110 4444 %%%% %2_\ ^/&]_P"O2Y_]$O7YE5^FM_\ \>-[_P!>
MES_Z)>OS*H _0WX=?\B+X3_[ 6G_ /HA*[.N,^'7_(B^$_\ L!:?_P"B$KLZ
M "BBB@ HHHH **** "BBB@!DD:R*58 Y&.1_7K_]>O,_%7AA+E'EB0;L%N!T
MX/;'')Y[XQSWKT^HY(DE4JP!R".??_/O]* /B/QQX(\/>+_#WB'P/XX\.Z7X
MJ\(>*=+O-#\2^&]<LX[[2-:TF^C,-W8WUK*"LD4BD,CKLGMYECN;:6*XACE3
M^+__ (*2?\$H_B!^R-J.O_%KX0V6K?$']E^>Y:^DOXRVH^+O@V+R=B-&\;VL
M2FYU'PE:.Z6VD>/(8Y(D@,%MXG%E>@7EW_>GXG\*1W2M+$F'PQR%[]A^?7'8
M\&O"]8T4)'=6-_9P7=E=P3V=[9WEM%=65[9W$;PW-I>6DZRP7-K<0L\-Q;7$
M<D,\3/'(CJQ#?'\8\$Y/QI@%ALP@Z.,P\9O+\SHQB\5@JDU=QULJ^%J2477P
ME27).W/3E1KJ-5_:\$\=YUP-F+Q>6S5?!8B5-9CE5><EA,=3@[*6EWA\73BY
M*ABZ4>>%_9U8U\/*5*/^8L2&3*D$$!@0001U!!&001R".#6%K*YA@;^[(ZG_
M ($,_P!/QS7]1W_!07_@AW=7]_XB^,W[#]E80M=FXU?Q)^S5/-#IUH;@AIKR
MY^#6K7+K:63W<A,J> =:EM]/CD+Q^'M4M4:'2Q_,)XLTC5M O=4\/>(=(U;P
M]XC\/ZD^G:YX=U_3;O1]=T34(2R2V6K:3?Q07MA<H1_J[B)1(A$D3/&RNWY'
MX/\ #6>^'_CSX<QS7#M87%<15,MPV94%*>!QE/,\KSK +V=5K]W5DZM+GPM?
MV=>FV_<J14:DOVSQ>XHX?\1/ 3Q'J91B8O$X7AVGF>*RS$.$,PP-7+<UR7'O
MVM&_[RE'V=94\7A_:8>HDFITI2E2CP\G;\?Z56?J/I_4U9<< ^^/S_\ U57D
M[?C_ $K_ %JGM]_Y/_(_R.*S]?P_QJL_WC^'\A5E^H^G]35=^H^G]37)/XO5
M(VC\*]/\RN_4?3^II8[V[MGS!<2QX(("N<#@=CQ2/U'T_J:KOU_#_&I3:=TV
MGW3:?WIHJR>C2:NM&DUOV::.QTOXA>)='E1[:_G4J00T<LD3C'HR,!G@=OSX
MKWKPI^UY\1_#R)"NNWS0I@&*Z8W,>!QC+ECM[GCW^GR;)V_'^E4_K773S'&T
M%>GB)V5M)/F7W,F>6X+$7]I0A?O%<KU]#],=(_;<&I((?%/A[0-:1L+(\MM$
MDK#C/49SG!."!DBNLB^,'[._B]<:SX3;1IY<!IK%P$4MD%@HXXY P!_6OR:H
MBN[J YBN)8R.FUV'3VSC'/3H:[:?$^,IZ5*<*JT_NOK\NAY]7AO"2NZ52I3?
M;==>VO0_65_"?[/FNJ6TCQI-ILC\JET %4]@6X''0\=JS+CX%Z)=C=H'CS1K
MT$91))HU8Y^Z#R#DY'8=_K7Y=P^)-9MS\EY(=IXW<^W;';OUYK:M?B+XBLF&
MVYDXP04FD0]<Y #=<\<FNN/%>'>E;#2BW;5)/?7I8YI<,XA?PL0I=DVU?KUT
M/T!OO@7XPMLFV>POT[-!<(2WX G_ #STKE;OX8^,[,D2:/,X&>8R'''/;C\C
MUKY7L/CQXLL5VKJ6IQA3_!=NPXSGAF_+IV_#J;3]IKQ9#@/K%^1D'$A:0=>_
M)'XX'OZUTQXCRR6[E#U37YJQA+(,SALE)>2B[_<SU^X\+^(+8D3:3>KCJ1"S
M ?B :RWL+Z,D/:7"D=087X_\=Z^W6N5@_:DUPC;/?1R<8/G0H??!+*2<_7W/
M;.D/VEWE $R:9(3UW0(,^N?;_.,FMHYYE<ML0EY-Q_S_ *_+%Y1F4=Z+T_NR
M_1/^M31,,J_>BD'U1A_,4W:PZJP_ _X5GM^T'I\PS+8Z6_K\@7/Y9XS_ )%,
M/QMT.?[^F:?]5(&2>#[=/K[FM%F^7/;$Q^^'_P D9O+<>MZ#];32_&)I8/H?
MR-&#Z'\C6%)\7_#[9QI]FN?<=<]@.O7%4I/BUH9SBSME],8STXX[?RH>;9>O
M^8B/WQV_\"W!9=CW_P P[_\ )O\ Y$ZK!]#^1HP?0_D:XF3XL:1SMAMEZ_Q*
M<?4@^OM^&*RY_BYIX!V"V7&>XZ'_ #CZ_KG+.LMBKO$0_P# H+_VYEQRK,);
M8>7_ (#-_P#MIZ5M)[?GQ_.OU0_94\2-K_PCT_3I26NO">I7V@ON8DFT9QJ&
MGD$]%$-XT(&YN83T!51^)<_QALQD>= OT8=>?]KCZ_3/'7ZF_9F_:4M?#NE^
M-K)]01(I[_2;U$W*!YHMKJW=ER2064(",D' /4 U_*/TQ\OR[B[P5Q\<*X5\
MTR'B+AW.LMLTYQ=3%U\GS",5'F;C5R_,VI+1/V,&_A1[V0Y1F4,?"]&<85:=
M6G+W)VTBIQO==)0_'S/V=8A1EF5?8L!Z?AW]:KO=VT?WYXEZ]7'89/0^E?FS
MJG[6=H-P6]D<Y_@+$<DGC 'X=L<G(Z>>ZG^U=,V\1?:7SZ*_/'<D@<G@?X"O
M\FJ/!6<5;7I<E^ZM^;1]_#(,;+>#2]+?G;\C]5KCQ#I-L,R7<6!UPP/]?TKF
M[SXB:#:AO](1B,X^;T'7C''TY]17Y#:Q^T[KUQN^S13]/XW"\9/OGT^F#SWK
MRW5OCMXSO2VR<1 [L9D=R/7C@?E_*O:POAWC:EO;580[WFEY[139W4N&:TOC
MDEZR2_*_];'[+ZI\:=$LPVV>%=N?XESQ]2:\B\1?M*:5:!\7T0"[NCKVSSUX
M]NWL:_'W4OB1XOOBPEU:958L"(R1Q]23ZGG_ .O7$7FJ:C>.QNKZZG)Z^9-(
M0<@=MP'Z5]-@_#C!PLZ]=2=[6C%RUM?>5EMY'IT.&L/%IU)\VMK)>5^OH?IO
MXH_:VL(#(L>I*QR0 DF>YY 4CD<8_KBOG7Q1^U7J5]O33Q<2$Y 8DHO/N3G'
MT_7BOCF3G<3USU_$5!7U.$X1R;"6:P_M&K:SLD_517ZGL4<HP-&UJ2DU_-M]
MR_(]2USXO>,M:9]U^UO&Q/$;,SX.?XF.,\\\8XKSJ[U&_OF+WEW<7#'))EE=
MASU^4G;S]*I45]!1PV'PZ4:-&E22T7)"*?WVO^)Z$*=.FK0A&*\HI?C:_P"(
M4445N6%%%% !114L$%Q=7%M9VEO<WE[>3Q6EE965O-=WM[=SN(X+2SL[9);F
M[NIY"$@MK>*2:9R$C1F(% $5?J3_ ,$XO^"6'QF_;Z\2P>(7^V?#7]G+1-3\
MCQA\7M0LF9]:DLYD%]X5^&=A.(T\2^)) 6M[G4P_]@>'"6EU*YFNTCTV;]!?
M^";_ /P0:\=_$C4_#GQE_;=TB_\ A]\+H7MM8T3X$O<26/Q$^(2!5N+/_A.W
MM6\WP)X2N0\,UQI(G7Q=J\ >SGAT*"5YI/["_!7@CP_X3\/:!X)\#>'-'\)^
M$/"^FVNB^&O"_AW3K?2M"T+2;1?+M=/TO3;1([>TM8ER=J)F1R\TS22R22-]
MID7"M3%.&*S.$Z.&TE3PKO"MB-FG4VE1HOL^6M46B5*#<G[V7Y/*JU6Q<90I
M;QI.\9U.J<^L(>6DY=H1=WP?P(^!?PW_ &??ACX.^"WP=\+VWA/X?^"K 6.C
MZ5;#S9[B:5A+J&LZQ>LHFU77M9NV>^U?5;LM<7EU(22D*0Q1_7?A/PL$"SSI
MW!Y4<C/Y^XQ^0'23PQX06$)-.O)VG!'H!CU]>V,],9KU:"!($"(  !T X_K_
M #Q7Z5"$*<(TZ<8PA",80A!*,81BE&,8Q2248I)))627W_4QBHI1BE&,4HQB
ME9))6226B22LD+#$L*!%   QP,<>G^?Z5+115#"BBB@ HHHH **** "BBB@"
MI?\ _'C>_P#7I<_^B7K\RJ_36_\ ^/&]_P"O2Y_]$O7YE4 ?H;\.O^1%\)_]
M@+3_ /T0E=G7&?#K_D1?"?\ V M/_P#1"5V= !1110 4444 %%%% !1110 4
M444 -=%<%6&0>/\ /;\Q7&Z[X7MK^-B(QN(."/7'7@#_ #["NTHZT ?+NM>&
M+O3W8A&9 3R![^XZ=#U]:_-#]N+_ ()J_LY_MT:/)<?$#2;KP+\7+*S2U\.?
M''P/;65MXVL(X HMM.\2VUPBZ9X^\.QJOEIH_B199K&-V;1M2TN7YC^W][IE
MO>(5= <]>G/.>_U]?TKRK7_ A;?+;+U)..<@8Z$9[9SGZGTJH2=.MA\1"RK8
M3$T,9AJO+&4Z&*PM6-;#8BDY1ER5J%6*G3J12E%WL[2G&:DN>EB*$G+V6+PV
M(P>)IJ4XQKX3%4I4<3AJJA*/M*->E)PJTY7A.-KQO&$H?YQ?[9G_  2Z_:T_
M8G35/$OCCPK!\2?@S8W$OD_'#X7PWFK>&;&Q,PCM)_'GAYXV\1?#VYE22-9I
M-4M[OP^MP7CM]?G5"P_.,2Q3Q1S0R1S0R*'CEB=9(W5@"K(Z$JRD="I(K_4Z
MU/0YX%GM;NTCN+6YAEMKFWN88[BUNK:93'-;75O.KP7%O/&QCFMYHWAFC9DD
M1D8J?PR_;-_X(5?LP?M'W]]XY^#%X?V5OBK=R7=YJ,W@C0+75/A3XOOYHLQ/
MXD^&QN=/M=#N6N55KG6/!%UHTTJ27#W6F:A<NLJ_MG#OBRTH87B2AS;169X.
MGKM:^*PD7OUE4PS[N5 _&>(/"Q/GQ/#M>V\GEV+J:=7;#8N2T72-/$K:R59G
M\1LG;\?Z57D[?C_2OOW]JW_@F1^VG^Q[+JNI?$KX37_C3X::63*OQH^#\5]X
MX\ -8E]J7>NVMI;+XJ\%N,I]HA\2Z):VML74+J-PO[P_GW%<V]W$D]K/%<PO
MNVRP2+)&V#@X9"1D'@@\@\$ \5^K8+-,NS6C'$Y=C,/C*+2]ZA4C)Q;UY:E.
MZJ4IV>L*E.$EKIU/RO&Y9F&557A\QP>(PE57]VM3E&,DFUS4ZEG3J1[2IU)K
MTV$D[?C_ $JO)V_'_/ZU8D[?C_2J\G;\?Z5V'$5Y.WX_TJHW4_4_SJX_0?7_
M #_*JC?>-)_I^L3KI[OS7]?F53P2/2J]66ZGZG^=5VZGZG^=<D_\OP;1MT?J
MOU*[=3]3_.H7ZCZ?U-3-]X_7^?-0OU'T_P _SKFGNO3]6=$-X^GZ%1_XOQ_K
M5>K+=3]3_.JU93V?]=4='3Y_H0O]X_A_(5#)V_'^E3/]X^]0R=OQ_I7)/=?/
M\S2'7Y?DBE)_%]?ZU6=W&,.PZ]&(]/>K,G1OK_6JDG;\?Z5']?F;QV7^)_D1
M/))Q^\?O_&WM[_I5>223C]X_?^)O;WJ63M^/]*KR=OQ_I6$]WY+]/4Z()6>B
MW[+L0M++DCS),>F]O3ZU3F=N<LW;&6/M[_7]:L/]X_A_(54FZGZC^5<LMF_+
M]%_F=<4K+1;+\BK)T_'_ !KW/X++^Y\1MC_EMIRY^D=PV,?CG.._6O#'Z#Z_
MT->[_!8?Z'XB;GF]L%SVP+:5L?7)SZU^3^,TN7PZSS^]6RB/_@6;8=_^V_\
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M@>.)4\+AL/.>&POL,%]:>,SG!X_&RQ-/$X*KF,_[0IX:EBN;$5*$YX&&'5+
MT\NJXW"8JC#$8C"T\/\ .O#Y\XTJ5.4J5'V=#VOM\=1Q%=U8U:$\3+ZS&E"M
M>I*G*6'C34,/##3KT:T%4J4HTO.M*_;<376\-IHWP$^+%^_CNQ\=2_#]DNO
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ME45.%4+VXKWCT3FM+\-65@JD1*&'?'S>G?I_]>ND1$0 *H '3  _S_7O3Z*
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M:KQHQIXR5YUZ5OJLXUJE:G5]C1CAJ4JBC7AB*E+%J%66(PL8K"3E*-IT^?\
MH(HK\!-2_P""I?[3GBGP5KWQ2^&7PX^"&B^$/ O[%?P;_:_\8Z!\0!X]U+Q)
MJ"^,=?\ $ND^*_ ?A34]!U;2M--O=V_ARXN_"OBW4]/,=FC6;WNBZQ%J+/IO
MTQ_P4Y\3_%WQ'\%/V7=#^!WQ0\;_  3\8?'3]I'X4>"[7Q/X)\07.@ZQ;P^+
M_"'C#4[#2+_4+%HVN=(EUFVTE=5LWS:WD,!$L3J M1_J=F=''Y=@<?6P6"_M
M#$5\-*LZ[Q<<%/#87%8RL\72PL%4CRX;"5:RC2G6<X*ZDG[CI<6Y=6P.88W
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M>-[_ ->ES_Z)>OS*K]-;_P#X\;W_ *]+G_T2]?F50!^AOPZ_Y$7PG_V M/\
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M.)G2KN5:I7HP>'@ZS@Z7[,6G[+W[/.GQ>18?!_P-8P_\+J7]HSRK/18+5/\
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MBBB@ HHHH **** "BBB@ HHHH **** *E_\ \>-[_P!>ES_Z)>OS*K]-;_\
MX\;W_KTN?_1+U^95 'Z&_#K_ )$7PG_V M/_ /1"5V=<9\.O^1%\)_\ 8"T_
M_P!$)79T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\S_&S]C?
M]F#]H[Q%HWBWXX_!CP?\2O$?AW3$T?0M7\1PWTUWI.G1WESJ$<%BUM>VR6[1
MWEY=3I<(@N5-Q*JS!&*UZYXB^%_P_P#%H\!CQ+X4TG6O^%8>)=+\8_#_ .W1
M/+_PBGBC1=+O]%TK7=)_>#R=0L=*U74;"WG?S"MO>W"$'S&-=Y176\?CI4\/
M2EC<7*E@XU(X2D\37=/"QK1G&K'#0=5QH1JQJ5(U(T8TU4C.<9J2G)2Y5@<%
M&>(JQP>$C5Q<J<L546&H*IB94I0E2EB)JES5Y4I4X2INM*HZ<H0<'%QBUXAX
MJ_9L^ WC?PC\0? ?B[X5>#_$/A+XJ^)W\:_$31M3TU;B+Q9XN9].:/Q'JMRS
MB]DUBT&D:5%I]]%<Q3Z;;:=96NGO;6UM%$GJ?AGPSX?\&>'=#\)>$]&T[P[X
M8\-:58Z'H&A:1:Q6.EZ1I&F6\=I8:=86D"I%;VMK;11PPQ(H"HHZG).Y16=3
M%8JK35&KB<15HQJ.M&E4KUJE*-5TJ=!U53G4E!5'1HTJ+J*"FZ5*G3YN2G"$
M;AAL-2J.K2P]"G5=-4G5IT:4*CI*I4K*DZD*<9NFJU6K54'-P]K4J5.7GG.4
MBBBBL#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&@#ZKHKY4_X:.OO^A5M/_!K-_P#(-'_#1U]_T*MI_P"#6;_Y!H ^JZ*^5/\
MAHZ^_P"A5M/_  :S?_(-'_#1U]_T*MI_X-9O_D&@#ZKHKY4_X:.OO^A5M/\
MP:S?_(-'_#1U]_T*MI_X-9O_ )!H ^JZ*^5/^&CK[_H5;3_P:S?_ "#1_P -
M'7W_ $*MI_X-9O\ Y!H ^JZ*^5/^&CK[_H5;3_P:S?\ R#1_PT=??]"K:?\
M@UF_^0: /JNBOE3_ (:.OO\ H5;3_P &LW_R#1_PT=??]"K:?^#6;_Y!H ^J
MZ*^5/^&CK[_H5;3_ ,&LW_R#1_PT=??]"K:?^#6;_P"0: /JNBOE3_AHZ^_Z
M%6T_\&LW_P @T?\ #1U]_P!"K:?^#6;_ .0: /JNBOE3_AHZ^_Z%6T_\&LW_
M ,@T?\-'7W_0JVG_ (-9O_D&@#ZKHKY4_P"&CK[_ *%6T_\ !K-_\@T?\-'7
MW_0JVG_@UF_^0: /JNBOE3_AHZ^_Z%6T_P#!K-_\@T?\-'7W_0JVG_@UF_\
MD&@#ZKHKY4_X:.OO^A5M/_!K-_\ (-'_  T=??\ 0JVG_@UF_P#D&@#ZKHKY
M4_X:.OO^A5M/_!K-_P#(-'_#1U]_T*MI_P"#6;_Y!H ^JZ*^5/\ AHZ^_P"A
M5M/_  :S?_(-'_#1U]_T*MI_X-9O_D&@#ZKHKY4_X:.OO^A5M/\ P:S?_(-'
M_#1U]_T*MI_X-9O_ )!H ^JZ*^5/^&CK[_H5;3_P:S?_ "#1_P -'7W_ $*M
MI_X-9O\ Y!H ^JZ*^5/^&CK[_H5;3_P:S?\ R#1_PT=??]"K:?\ @UF_^0:
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MMI_X-9O_ )!H ^JZ*^5/^&CK[_H5;3_P:S?_ "#1_P -'7W_ $*MI_X-9O\
MY!H ^JZ*^5/^&CK[_H5;3_P:S?\ R#1_PT=??]"K:?\ @UF_^0: /JNBOE3_
M (:.OO\ H5;3_P &LW_R#1_PT=??]"K:?^#6;_Y!H ^H+_\ X\;W_KTN?_1+
MU^95?2,O[1%]<12P'PM:*)XWA+?VI,=HD4H3C[$,XW9QD9Z9'6O!/[-3_GJW
(_?(_QH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Q /\# 2(  A$! Q$!_\0
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M=%\/V$84A2I"J  ?Z[GQ;_X+D_\ !);X*>($\)>,OV[/@3J/BJ35K/0AX?\
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MRC9<T;.\7>][Z']%,?\ P6+_ &8VE19/"OQ@CB)P\H\,:%(47GYO*'BA6?Z
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M4E[]:M%2J5))2J58IS<ZD%4Y.OU'_P""2W_!1;Q+_P $[/VG-(\77]]J%W\
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M'X!>(_V;_@WXUGNM0\"?$[Q)\,M?OIKF\G\/_&6TE\8>&+N_N97N)OL_Q/\
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M+.G5A6G0J91:E3JP<(U,0ZOV)1J_O5XCT-/AA\2?A%X0T_X-?%K3?B9^W?\
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MY^%-O:Q:Q;:;>OIU_<V/D:U;RR6]M?QRV;W C2)KF*6*)Y&AD"8[?%;2Y?\
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MM"]".'I-PYL-/FFY>YH[/F/V5HHHKX4_: HHHH **** "BBB@ HHHH ****
M"OPV_P""L.A2P?$3X2>)_*Q;ZEX,UW03,!P9]&UN/45B8]V\K6W=!SP'/&.?
MW)K\Y_\ @I3\)M=^(_P@\+:UX5T;4->\0>"O&=O.NG:9;M<W4FC:_9S:9JDV
MU2 D-I<)IEW<32,L,%M#-+*R(A8>MD=>.'S/#3G*,(2]I2E*4E&,54I22<I2
M<8Q2E&-W*226K:6J_#OI'\.XOB?P;XNP.7X;$8W'X2&5YSA,)A:%7$XK$U<I
MS;!UYT</AL/1Q&(KUIX;$XKV=&A0K5JLH\E*G4FU"7XE_!+4/$FF^.C/X5\.
M^'?%>IW/A?Q=H]QH7BG7;?PYI%]HNOZ%=:'K:/JEQKGAPQ71TW4+A;1+;5H+
MQI7W6RNZ?+],Z+J_@OX<_$^V\*Z!I/@C3/!NE6'@?XS^-[9_&.H>)+#X4_$G
MP?X?U>+7=/\  GB"RUB-O'%_#'JL6F:+X>O;W7K6?7]1M[::ZN(--NYS\4>)
M;?X:?#_S8OBW\:OAIX.O("?/\*:#J1^+'CH2)OS _ASX>_VSIFG7&Y0FW7O$
M>CB/S8I7_<F1X_#=>_:X^!7A@-;_  Z^$7BWXFWT)Q;^(/B_XAB\&^&A(N0E
MQ;_#[X>SW.KS1?<=;?4_'R?\M89H9(Y%9'Q)XF\!9&ZD,?Q+@JU>%&I1E@<J
MY\WQ;E[[A&<,#6GAH^QK3=:$*^(IRC7^*JJ4JM*I^,_1Z_9__3>\5<'E4^$/
M #B+),GEFV'S;"<9>*E; ^&W#^&PE65"IC(9?'BK)J?$];#YQ3P^ I9I/+\H
MQU+%X+!89X+!87,J>%S;#?I)\==&\%^-- T[QIX4MKIM<O[/X8Z5\/\ 1M'\
M56'B8ZOH-_HFJ/K_ (0T[X?Z5:OK'A;_ (5K>PV6FW5W<*9-<U>\O;RZ\^\U
M17'S;J_P\U#P?:QZC\4O$7@GX,Z;(@E27XJ>*;#PWK$\)"L)+#P5!_:7CW4B
M4<21QV?A>4RA9$C9I8W0?GQXJ_;0_:&\1VMWI6B^,+/X5>';Q&BG\.?!?0=-
M^&=E/ 5">1?:OH4:^+]87RP(W;6O$VH/,BIYS2,BL/ENXFFN[N6]O)KB^U&]
MF'G7EW+->ZC>W$\@ \VYG::[N[B>5@ '>26:5@!N=@#^,9O](^GAXU</PQP_
M5K1YYNCC,_Q7*H1;ER\N!P$IU)MN3G)U\;%SJ2<G&+G44O\ 53P]_8,QXCS/
M"<2_2$\:,)E]>KAL(\UX0\$\B<:6*Q=*$'B:E?C+C2C3A2=106'C_8_"*AA\
M+0H4J56HL/1JQ_3_ %_]HG]E[P9YD>GW7Q+^.FK1_=C\.Z?;?"7P(\@ RC^(
MO%,&N^--0M]WF)YMEX.T=G40SQ38DDBCXOPK^T_^TG\6_%UK\/OV6OA)X3\%
M>(]2!-E;_#CP@/&GC^VLPP274]5^)/Q%E\0W/AW3[8%I;W7(/^$6TRQ1I]TT
M$!6).R_9N_X)E?$/XB0:7XU^/=YJ?P7^'=Y';W^G^&S912?&'QGI\P$D4FF>
M&[]3;^"-(NX\;/$/C..*Y>%_/TKP[J8"N/V[^&/PT^'OPD\)S^!?A+X5T#X:
M>";:TDU7Q-=F["7&H6>EP^=?>*?B=XYU(C4=;2QA5[JYNM3N(M(L2?*TC2K,
MO#;/_-/B-])CB6CC*>0XC.\VS;B;,L11P.6\ \#TXX3,L1C<;4A1P>#Q\\OI
MXG$9<\16KT:<,-B:^+SJNJB]CDU'F5>']393]'/]GY]%J+PWA/X&\'>*/'^5
M)JIQMXDXFOXD8')L;AWRRQ.*SCB!8W)<7CZ%>',\LX-X:]G3Q$5AZ^>X6=Z!
M\6?!S_@GWITFK1_$K]LCXA3_ +1GQ(L+637+SPYXH\8ZQJWP9^'MI81&XO\
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M(Y-2U&5)+'6/BOJMC+F#6M=MR?.L?"=E,IE\+^%)&PH*:SK2S:K+'%8_4/\
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M7J]%.-"A!WA0HP?>-&E%_?&DG^(IXO%U5RU,5BJD=N6IB<1.-NSC.O*+^:8
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MTN36+S0K.Y&@07WBSP[+_:JZ?$UU<V]Q=?V7$;*V#\;IG[-GC*'XH7VH>*]
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M/J4L5@L13IT8U)TX5J'U>="5"6&DE&C"E.47AU3<%&5%TH./+R.$&K+\5/\
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M:/9ZIIFI6&J^)=5MV@M].O+TQZK%JEB;[0KGR/L"'P3X2B\*:7X'E\/:5?\
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MK/,,PS#&+!8.==T:+K3P&31P<<QK481PF-SNMB<?1=1N<PHHHKZ(_/0HHHH
M**** "BBB@ HHHH **** *E_=?8K&]O-GF?9+2YNO+W;?,\B%Y=F[!V[MFW=
M@XSG!Z5_+Z?^#D&X!8?\,DGY7=?^2O1<['9<_P#(B]\9]LXK^H#4[>2\TW4+
M2(J);JQN[>,N2$$D\$D2%B 2%#,-Q ) R0#TK^,H_P#!OW^V^6<_\)3\ _F>
M1A_Q67BKHSLP_P"9(ZX(S[YY->#G=3-J;PW]EQJRNJOMO9TJ=2UG3]G?VFWV
M[6WUOLCZWA>CP]56-_MV="#B\/\ 5?;UZ]&Z:K>VY?8_%9JG?FVTMNS]T/\
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M@[7KOQ[\'_"GQ%TS6= UCXE>,/B9I%QH^D:UJ5N?"WB7PWJ7CC7].M]7@O\
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C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Q 54# 2(  A$! Q$!_\0
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MR.+^P'^Z?T_^)H^P'^Z?T_\ B:[3["/?]:/L(]_UH^N_WW]\O_D@_LU?RO\
M#_(XO[ ?[I_3_P")H^P'^Z?T_P#B:[3["/?]:/L(]_UH^N_WW]\O_D@_LU?R
MO\/\CB_L!_NG]/\ XFC[ ?[I_3_XFNT^PCW_ %H^PCW_ %H^N_WW]\O_ )(/
M[-7\K_#_ ".+^P'^Z?T_^)H^P'^Z?T_^)KM/L(]_UH^PCW_6CZ[_ 'W]\O\
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M_P#DCCOL _NC]?\ XFC[ /[H_7_XFNQ^PM_=_P#'Q1]A;^[_ ./BCZVN[_\
M O\ @A_9;\ON?_R1QWV ?W1^O_Q-'V ?W1^O_P 378_86_N_^/BC["W]W_Q\
M4?6UW?\ X%_P0_LM^7W/_P"2..^P#^Z/U_\ B:/L _NC]?\ XFNQ^PM_=_\
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MUWS?_DW^8?V7+R^^7^1QOV$^GZM_\31]A/I^K?\ Q-=E]@_V(_\ /X4?8/\
M8C_S^%'UWS?_ )-_F']ER\OOE_D<;]A/I^K?_$T?83Z?JW_Q-=E]@_V(_P#/
MX4?8/]B/_/X4?7?-_P#DW^8?V7+R^^7^1QOV$^GZM_\ $T?83Z?JW_Q-=E]@
M_P!B/_/X4?8/]B/_ #^%'UWS?_DW^8?V7+R^^7^1QOV$^GZM_P#$T?83Z?JW
M_P 379?8/]B/_/X4?8/]B/\ S^%'UWS?_DW^8?V7+R^^7^1QOV$^GZM_\31]
MA/I^K?\ Q-=E]@_V(_\ /X4?8/\ 8C_S^%'UWS?_ )-_F']ER\OOE_D<;]A/
MI^K?_$T?83Z?JW_Q-=E]@_V(_P#/X4?8/]B/_/X4?7?-_P#DW^8?V7+R^^7^
M1QOV$^GZM_\ $T?83Z?JW_Q-=E]@_P!B/_/X4?8/]B/_ #^%'UWS?_DW^8?V
M7+R^^7^1QOV$^GZM_P#$T?83Z?JW_P 379?8/]B/_/X4?8/]B/\ S^%'UWS?
M_DW^8?V7+R^^7^1QOV$^GZM_\31]A/I^K?\ Q-=E]@_V(_\ /X4?8/\ 8C_S
M^%'UWS?_ )-_F']ER\OOE_D<;]A/I^K?_$T?83Z?JW_Q-=E]@_V(_P#/X4?8
M/]B/_/X4?7?-_P#DW^8?V7+R^^7^1QOV$^GZM_\ $T?83Z?JW_Q-=E]@_P!B
M/_/X4?8/]B/_ #^%'UWS?_DW^8?V7+R^^7^1QOV$^GZM_P#$T?83Z?JW_P 3
M79?8/]B/_/X4?8/]B/\ S^%'UWS?_DW^8?V7+R^^7^1QOV$^GZM_\31]A/I^
MK?\ Q-=E]@_V(_\ /X4?8/\ 8C_S^%'UWS?_ )-_F']ER\OOE_D<;]A/I^K?
M_$T?83Z?JW_Q-=E]@_V(_P#/X4?8/]B/_/X4?7?-_P#DW^8?V7+R^^7^1QOV
M$^GZM_\ $T?83Z?JW_Q-=E]@_P!B/_/X4?8/]B/_ #^%'UWS?_DW^8?V7+R^
M^7^1QOV$^GZM_P#$T?83Z?JW_P 379?8/]B/_/X4?8/]B/\ S^%'UWS?_DW^
M8?V7+R^^7^1QOV$^GZM_\31]A/I^K?\ Q-=E]@_V(_\ /X4?8/\ 8C_S^%'U
MWS?_ )-_F']ER\OOE_D<;]A/I^K?_$T?83Z?JW_Q-=E]@_V(_P#/X4?8/]B/
M_/X4?7?-_P#DW^8?V7+R^^7^1QOV$^GZM_\ $T?83Z?JW_Q-=E]@_P!B/_/X
M4?8/]B/_ #^%'UWS?_DW^8?V7+R^^7^1QOV$^GZM_P#$T5V7V#_8C_S^%%'U
MWS?_ )-_F']ER\OOE_D=K_9Y_P">9_(_X4?V>?\ GF?R/^%=K_9[>GZ#_"C^
MSV]/T'^%?*_75W7]?,^\_LR?\O\ Z3_F<5_9Y_YYG\C_ (4?V>?^>9_(_P"%
M=K_9[>GZ#_"C^SV]/T'^%'UU=U_7S#^S)_R_^D_YG%?V>?\ GF?R/^%']GG_
M )YG\C_A7:_V>WI^@_PH_L]O3]!_A1]=7=?U\P_LR?\ +_Z3_F<5_9Y_YYG\
MC_A1_9Y_YYG\C_A7:_V>WI^@_P */[/;T_0?X4?75W7]?,/[,G_+_P"D_P"9
MQ7]GG_GF?R/^%']GG_GF?R/^%=K_ &>WI^@_PH_L]O3]!_A1]=7=?U\P_LR?
M\O\ Z3_F<5_9Y_YYG\C_ (4?V>?^>9_(_P"%=K_9[>GZ#_"C^SV]/T'^%'UU
M=U_7S#^S)_R_^D_YG%?V>?\ GF?R/^%']GG_ )YG\C_A7:_V>WI^@_PH_L]O
M3]!_A1]=7=?U\P_LR?\ +_Z3_F<5_9Y_YYG\C_A1_9Y_YYG\C_A7:_V>WI^@
M_P */[/;T_0?X4?75W7]?,/[,G_+_P"D_P"9Q7]GG_GF?R/^%']GG_GF?R/^
M%=K_ &>WI^@_PH_L]O3]!_A1]=7=?U\P_LR?\O\ Z3_F<5_9Y_YYG\C_ (4?
MV>?^>9_(_P"%=K_9[>GZ#_"C^SV]/T'^%'UU=U_7S#^S)_R_^D_YG%?V>?\
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MFO\ X*PO_P U$_\ $!>)?^AED/\ X.Q__P Q'C/]G?[*_G_]:C^SO]E?S_\
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M"US3HM0GU^\BOM1TK6X-2MHU@EL94DC99/,/@Q_P5U\)1R6/AO\ ;$^%^J?
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M'_PTE\%\R+(P_P",:O%V<)LSC'[1I'&[^(CMC/-+_B)?#?\ T$8S_P (*_\
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MG@'0?$'B**]FT+2=4UV.:"UO-5BTU);]K**7 G^R123JI+)&Y&T_R+_LN_\
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M>\2>)/"]GX>&DW'A'7KB^N0^@RSM<C4+17EO;>UB@:2.1F^C?^"//_!6-/\
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MX674?[77PY)X[\,:;XCDT1=5-K8G4ETQ[]K1;XV5F;H1"8VL!<QK_%]\5/\
M@U4_;+\:^//CIJF@?M.?LXP>$_BM\6O$_P 1(;+5_"GC.;6;!=2\3>(]<T4)
M=I8W#Z9>PV'B*>QU%;2>2*=6D56=-C'^RO\ 8_\ @A?_ +._[*W[.WP"\1:I
MIOB37O@I\&?AS\+=9U_2K>YM-+UG5/!'A32] OM3TVVNW>Z@L+VYLI;BUBN&
M,Z0R*)</FOZQ^D%2^B]#@S@-^!4(4^+:>9JAQ?.GG?B!FT\PR3_B&/AKBO[2
MS/#<8Y-EF5Y-F[\4<5XFY9++>&\1F&#CE&69/BH5Y87%4)/PLJ>=?6,5_:;O
M0<+X>]/"TU"I]=QD>2$L/4G.I3^I1P4^>LH2]I.I&UXL^BK8C[(.1TE[C^_)
M0K V.<CFU)ZCO&:@@M+;[-_J4_Y;>O\ STD]^U-6SMOL /DI_P >OO\ \\OK
MWK^3CW3^='_@X16/^R?V29-J^8-4^,Z"3 WA&T[X:$H&ZA6902.A*CN*_G'\
M-,O_  E'A0;AG_A*O"HZCMX@T_/?M7]&W_!P;#$FB_LDE$5?^)K\9NG_ &#?
MAL>Y/=C^=?SCZ 8K;Q+X2DN7AMD?Q9X22-[AXX%D>3Q%IJ(D9E9!(\CLJ(B;
MF=R%4%B!0!_HY230BXA!EC!"3YRZ\?ZKKSQ1'/#YL_[Z+[R?\M$_YYK[UP'Q
M1^*7PL^"OA>X^(7QA\?>"/A?X$TV>TLM1\8^/_$6C^$_#-E>ZO>6VGZ5:7>M
MZY=66G07&HWTT5I90RW"/<W,B0PAY753\S+_ ,%)?^"=JR2AOVWOV2P69<*?
MCU\+U(P@!SGQ(.<CL3Z'!&* /M,S0BU4>=%P8_\ EHG:5?>I7GA\Z']]%]V7
M_EHG^Q[U\1_\/(_^"=Q@53^V_P#LD;LIR/CU\+]O$@/ _P"$CSR/]GKSTYHD
M_P""E7_!.=9(W?\ ;D_9&C4"0?O/C]\+(PQ(7 !;Q*%)&"<9SZ \T ?;L<\/
MF3?OHOOI_P M$_YY)[U )X?LD/[Z+_EV_P"6B?\ /2/WKXG7_@I?_P $X@\A
M/[=/[('S,I'_ !D'\* >$1<9_P"$G&3D<8)P,=.E1#_@I9_P3D\B-/\ ANG]
MD#<ODY/_  T'\*<'8Z$X'_"39.0"!E>2?FQR: /N)IH3<PXEB/[N7I(OJGO3
MHYHO-G_>Q_>C_C7_ )YK[U\+2?\ !3G_ ()M)<)N_;P_8\1HUD5T;]H7X4*X
M)V<$?\)/QC'(8@\\ \T)_P %/?\ @FP'E8_MY?L>88J1_P 9#_"?L@4YSXH
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M2F/+N#T/K#[T 3;E^V#YE_X]CW'_ #U7WIR,IN9_F!'DV_<?W[CWJL;2V^V
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M37<#3M%<;)Y+=I8RT9<!'J)0E"RE%QOJK];:=V--/9W/@?\ XB6/^"N>,?\
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MXUC%=^)=52RTN!8X799;OQ EK;(D<BQD++<-/.9I$$F<@4 ?T(ZQ_P '%/\
MP6@\//(-9^(OPMTY1AFFG_9M\/-:D$$*1=Q:_):@E4+;?-#A1N=1UKG1_P '
M+'_!7CDCXR_!@Y.?^3>?#)].G_%0' ]AQ7X^+^VXNH>)=,\&:1\/-.\:7VI6
M=G<37GA3Q+<ZMH5K)<V$NH7UK*]SHD$[R:-;12#5C]GV1-'+L9T7)R];^*7@
M7QE!X&FLOAKX=O\ 5_'GAC7_ !1=0>#_ !9-;:MX*/A_Q7>^&-3T[Q:!HB:7
M+JW[B/Q HL5U6*?1M1L]LGV\M;1@'[+C_@Y6_P""O &!\9/@SC)//[//AHGD
MDGD^(,]3Z\4\_P#!S1_P5TTJPU"X;XH_ K4S#932Q17W[/6C!$:WADD !L_%
M5L["3:$DWF3Y>5 8'/XN-\-M8BU>PM]:U3P=X)\/WOB31]!U#Q7XKUF\C\/^
M$K?6;VSMFU[Q->V>DSS0Z)HMK>KJVL7=K;3/%IT$[0PR7"" _K)\4/\ @@Y^
MTS\./V6[[]KGQA^T7^QAI'[-=]X%TCQEI7QA?XD>*I/"&L^'?&UO9Q>#-0TN
M\A\'233Q^*[G6-)L]&#0(9;G4;:.80[G* 6>]G;:]GO:]MGK;6RN[:VMJ?LM
M_P '4O[0_P 6/"W[(7_!,[XC>$_$47A?Q=\3F\87OB;4]*TVT<H^O_"SX;^)
M-0BTF&_CO(;&)M3P8@4GD2W40A\Y>OXU/V+OBIJGBS]N']G*^^,OB/Q/\0])
MG^)NF1KIWB"\N_$-J-<NX+J'P]>VN@SWEOI5M+IOB"33=1CNK>WB.F_9/MT<
M,LEO'&W]@W_!SQX2\.^)/V'/^"4O_"7:EK]KH.@^'O$.LW<OA+3++4-7NH['
MX$?#K-G;/J=[::=8Q7K?>U*[,J6JA56VGDD5#_+K^QUX%\+:+XB^#_B3P[9Z
M:M[K7Q3\*26FJ^(?"LNH^,Y=(A^(>C&.&37TU@:?I]PNERVZ3-I5E:VCDAQ;
MS2"5:.S[.X'^@U_P<SP3ZG_P2,^->GV"&6^N/B)\"(;=&M]5D#2O\5O#6-L>
MDQG5)2%5V"::K79( C')-?YI0^%_C"V6>3^P--N7=Y;B0R^%?CI=7$LA7+*G
MF(OS-L CCRJEVP2H)(_TS/\ @Y2O]=TK_@D]\7=5\,:8=9\0Z;\2_@/>:/I6
M&(O[Z+XJ^&Q%;OMDA(5]QSB6,D@ -D@'_-UU7]J/]H30(UNO$'PA33;*2V2\
M2\>.Y^SF"4.T;M-)K$<2;ECD8H[+*JH6:-5YH \F/@GQC)(N_P %ZE9Q .7-
MI\+?BS>S.QQY:XO]5BBC1?F+%"68E0, $F&[\)^(].A,\O@CQ-J"'AU'P&\8
MZOY('(D\G4M6E6+<?E,D \Q@=K?*.+<O_!1/Q.28H_#.GQRAMH<VLLJ AL'@
M>(45@>@82 #[V2*Z2']M[XA3W*6(TKPQ]NDD$2V@C220RGE8U:/Q4T;NP(VA
M';)(49;B@#RS4S;Z;8O>>(/"OB_PY:12QJ-03]G"2SMRSJX$-S<:U?K I;:6
MB5#O<HW7''-R^(O"EOIUGXAM[W46T.YO[O3+;6[OX4^$M+L3K>FQVUS?Z0DM
MU/+!)J-A;7MA=W5JD[30V]]9S21)'/$S_6FB^._CC^T7JN@?"K1/AOK/B'Q!
MXBU16L-%\%^';_5?$5W-;6&IW+Q6>DVVI:E<7?D:?#?7LBQ1%C%:.X9$60-^
MD7_!-7_@WA_;(_X*-?LY>&-/\<Q>)?V5OA]X=_:2\<>+=5\6_&3P-XAL-0\0
M>#O%7@#P1HUWK/P[\#:B-&U+7M=&M^$#83'4I-$T81^3+/JV;=+:X /PIB^)
M'@.19EO-3$\DY55NH?"7P^T^>')^9Q(+>[#DDJ2\B,553A3N-1R^,O!"2NL&
MN17$2D!)FN/A[;F08!)\B3PA(R88E>6).W<, X']\<G_  9G?\$Y?"FB:==>
M._VL/VC[.\"6UK?Z]<ZU\*/"6CZAJP1B9+*QU#PE>1V F"R-!IQU.^=(PP,T
MY4O65_Q""?\ !*#*HG[9?QW4R1XVCXE_!,F522Q=0?!I.&P"=N0=I(."10!_
M"1HOQ$\(6LQAE\026]M,<M]G\1^"M/CCD P)9%L/!9>9BH$2J5R P8'Y0*^N
M_A#_ &A:_M$?LJ:1<V>L6:VK_$O7)(=;61-1'_"0:/JL5C+*)-.THR07=MI4
MDMG/'I\$<EL(]@= '?\ :[_@LM_P;T?\$[?^"=O[ GQ,_:=^"O[2GQ?^(?Q*
M\.^*?AQX9\*>%=?\:_"_7-#U&^\6^*]/TC4'U"Q\.>&M.U9UM-'DU+4(WM;R
M/R9+9'E22$,!^!7_  34@USXH_&OQ%XZ\=Z]XE\5WGPS\'V"^';C6=<U'4!I
MU]J]S-HUD"+J>4RPVNCG68+*U9OL\'GNZQD@8 /]9[_@F7_RCR_9#[?\63\#
M=?\ KDE?=MS_ ,N_7_CZBZ#/][]/>O@O_@F?'(__  3S_9#9+AHQ_P *2\#C
M:J(1_JP0?F!/ (7KSM!/).?NNX@G_<8NW_X^8LYCBZ?-_LT 6I?]=:_]=)/_
M $1+0_\ Q\V__7.X_G#566"?S;;_ $M^9),'RH^/W$OM0\-Q]H@'VM\^7/SY
M47','M0!8/\ Q^C_ *]6_P#1JTY/^/J?_KC;?^AW-5?*N!=@?:B?]&/)AC/_
M "V!]NW'>E2*Y^U3_P"E?\L;?K!'_?N>.H_SZ4 6(<>?>=<^9%GT_P!1'C%?
M(W[=VH6VD_L5_M7ZM>F066D_!?XD:I>&&/S91::=X:NKVY,465\V4002&./<
MOF/M3<N<CZQBCN?.NO\ 20!YD7_+!?\ GA'G^*OA?_@IG/=:?_P3D_;UOXYU
M,MA^RK^T#?0[K>-U6:S^&6OW43/&Y=)4#0@-%(I2125=64X(!_/I>_\ !4S]
MD.W6YOKS6?B1I]A&9)[B_O?A[*MK:6VXL]Q<F#6KB=88D.Z0Q032*H.V-R,'
MZ/\ A[^T1X?^+/A+3O'OPP^&'[0WCWP3JYNQI/BKPS\$_%>H:+J0L;F2TNFL
M[L>6)4AN8987;8!O1AVK^#G]FW_@IQX.^'-CXVT3X_\ [('P4_:03Q%X<M=!
MT&]U*\\2_#GQ#X.U[5-/O+:VURSE\*WT>FWP,FH6]U<VU_I3P[M-A6W2%6G8
M_P!ZW["WCWXI^'O^":7[&&B?"/XC6?@[5])\7>*]9\:PW\UYID^N^'++QIJH
ML--:_'@KQ?:-H-_>SE/$=G9Q6>IM;2QM8W,4D; ^SE=#$9KCJ&!IU</AY5O:
M/V^(C5]A25.E5JWJ.E&I-*3IQI1:@U[2K3NU'F:\S-,=2RK U\=4HU\3&C[-
M*AA_9>VJNI6I4K4U5J4J;<%4E5DG-/V=&IRJ4N6+]+\,>)[#Q9%J?V*SUS2]
M2T+4?[(\0^'/$VB7_ASQ1X=U0Z?8:JEAKFA:G%%>V,TNF:II]_ Y62VN+:[B
MDMYY1O"=(58<E6 ]2"/YBOY\O^"L'PM^+/Q:_P""DO[1WQ8^#E[X=N/#5\_P
MPM-'UR?Q;;>#==;4=,^#OP_AN/*%]K.DZQ9V&YU6&[%B)$=&$$=P@+K\AV_Q
M/_X*'? _0;OQ-+\3_B+8^'-$M#=ZIJUK\9?!GQFTS3["W'^DWO\ 8/BR_P#%
M-S::38(K3W4Z:4C6]NCR/#M5A7)]9<6X5:<HS@Y1FK6<91;C).,K2BTTTXO5
M--/7;M45.,9PE&4914HR34HRC)*491DKJ2::::NFFFKK4_K'HK^870?^"J?[
M9FD6202Z[\,?%:NL<D6J>)_A>U_J,L90,KFY\*>+?"6E2),K+(&BTM P(*$+
MU*KZU2[3_P# ;_J/D?E_7R/Z>J*YOQ5XT\&>!-/.K>./&'A3P7I0.&U/Q9XC
MT?PYIZD?PM>:O>6=N&]%,F3T )KX[\=?\%)/V.? K36X^*O_  G6IP[O^)3\
M,_#^K^+IK@*2,V>L"#3O"-T&8$ Q>)2#U!((K9RC'XI17JTOU_0BS/NBBOQ3
M\;_\%D=#C\ZW^%GP#\0ZJQ+"TUKXD>*-/\/6F1]TWOA?P_%J>K(IY)^SZZQ'
M S7QQX[_ ."I7[7?BX20Z1XC\ ?"NRN RFS\"^$TU'5H V0CV'B?Q5<7NJ0R
M+D%2UA,NX D'&#E+$4ELW+_"F_Q=D4H2]/4_H%_:(_X1>;]@/]MG3/%]Y'::
M1?\ QK^'.H741W_;-3TGPIX*^&_BOQ+I.EK'^\_M+6/#^DWV@Z>Z8QJ>LZ?
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MO&\VDW^DZ1XEN/M-Y>7'BGQWX5:PM(O)M;+3[&R34+R;QCKCVD?FRW]C9YO
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M  [:175M(3!J&FZ3.UU#<Q*\MC!J&J1W$!2[MKRQ_P _&X^&6I>'? &F:/\
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M"07%S;22HJ(H8A$VY']BZ/Y0@_LZR$*PI;K&%VQB"*Y^V1PJJRC$<=V3<H@
MQ-\P./E$&AY?XTU+6)K6\T?6?%'AGPS9:B+:R-AI33ZOXFU2-D*ZKIMG;M S
M0+J]M))%I]U);1W=BXCN&CE&]!_3A^QS_P %8OV0_P!A#X'ZA\._V;OV4O\
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M.X@>CP?\$J?VV90_F>&_@Y8.I&V*?XFV5T[I&05D1[#3I(U16.U$D(=6!90
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M)K>+6$E$80S(88A+?RA(XR6D4?9=;%I<A0D-MKGB;49F5?\ 26_X(NM%9?\
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M7-.>./Y<^Q]>F"/P'!&#\0!SC'( SV' [_BIZ#H5 ],>G&<9X'\\<\\[3ZT
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ME(&-V,\\GG!Z@>V2V3@#@#!)IO'3D<$G&0>3GGDD;CUR/08%.)SZC&<X&><
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MC'0 X [>G''893N3QD 7_/;H?; '/0=1GJ%)I,@]-W7G'8D''H<D9ZG_ +Z
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C %W/\A110 H^['_U\'^;T_\ C'_74_\ H*T44 )1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (S ^(# 2(  A$! Q$!_\0
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M@ %)BG<T8H ,48HQ2XH 2BG8HQ0 VBG8HQ0 VBG8HQ0 VBG8H H ;BE"YIW
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MOJ%_K]GX6TB8V\DPWSSJ>0O)P/3@$^_%1W/PZ:SM&GTS6K]=01<JSR\.?0X
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M<\"Z=K-\+U7FL[[O/;OM9OK_ (]:@TOX>Z=9:@E]>W-UJ-RF"C7+[@I]0/\
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M[1I=:MJ5S:(<K;22_+]/_P!6*Q3ES2LNIZ5:%!TJ+JR:]WM>ZN]C&\%6,_\
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M%/\ DDEW_P!<;C^;54T:UDO/@O=01 L^)& '?:^[^E=MIWABUTWPV^AQRRM
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M'_UZ7(U&S5SL>+IRK.<9N+LDFO)*]T<K-;:GX"\1:3;VFK275G>2",V\G89
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M-R]V&FN[U^MS.VYO?'I_.DXS<>5HTC7P].M+$PDVW>RMU?=^1SNO<?%O0_\
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M8Y.T^'>A7MK%<P:C?/%*H96$PP0?PJ+PQIOANS\67$.F7%Y/J%O&RN9&RF.
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M*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M)BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
M "8HQ2T4 )BC%+10 F*,4M% "44M)0 4&BB@!*2EI*  TVG&F]Z $--IQI*
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M)O7U/;=PI%8.%>9I1M92JG=GL,MM^HIM]XOT>UT:XU*&[AN8X&5&6.09W,>
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M-(&G)?\ ]I6OV1WV+-Y@VEO[H]_:B3Q!I$=G#=OJ5J+>;/E2>:,/CJ!ZGVH
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M0TJZM%@FV_NG=HY)-JE>67JK @]*DO?'$5G)J3G2;Z6STRX\B\ND\O9'PIR
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M3:3INHK!,(K^[%I&IQE6+LN3STRM '145Q\?CJ&2TN;PZ5?K:1SM:Q2_N_\
M2)Q+Y?EHN[/)[G Z\\4^;QO;65M>MJ%A<VMW:^23;L\;;Q*^Q&5PVW;NX))&
M,<T =;163I.J3:DDWVC3KFQDB(&)BK*X(R&1U)5A_*L&/Q=<6NI^(DU&SF^S
MV-Y#;6BQ;"\K.D>U -W+,S[AG  (SC!H [2BL/2]>-]J$^G75A<6%_#&LWDS
M,K;XV) 964D'D$'TJMJ/BI;/4;FSM=,N[YK.-9+MH6C41!AD ;F&YL#.![>M
M '2T5RDWC6*2Y,.F:7>:D/L45]O@,:J89-V#\[#GY>GO3O\ A,(KAK8:3IMY
MJ3SV27Q2'8GEPO\ =W;V'S'!PH]#0!U-%<J_B\2R,FG:1J-\T5O'<7*(JQM"
MKC*J5=E)? SM']15[3/$MCJ]Z(+/>Z-8PWR2XP&CD9PH]<_(: -RBN1M?&\>
MH3Z7!8:3?7,E_9QWH"F-1#"S;26+,.GH,DYXJ5?%Q%]917.CW]K:WMP;:WN9
M]BEGYQF/=O4':<$CTSC- '4T5R!\;Q'[/.NE7SZ;=7J65O? Q['=I/+W;=VX
M)G/)'./<9>_C6V6:206%TVFQ7/V5]0W1[ ^[83MW;BH;Y2V/TYH ZRBN:\7Z
MO?:-I]E-86[3/-?VT#@%?NO*JD?,1RV=N>V:Q8_&=YI]QXAEO]/O;FQT^_VO
M<1^6%MHC%$<8W M@LQ.,\&@#OZ*Y;4/%T5C>7T<.G7=Y%IX'VV>%HP(OEW8
M9@7(4AB%'?UXK2U+7;32M EUB4M+:I&) T>,N&QMQG YR.3@4 :]%<P?%B6^
MF75YJ.F7MKY)C")A)!<&0[46)E8JQ+<8SQGGCFF?\)G;6L-Z=4LKFRN+2))C
M Q24RJ[;%V%&()+87'')'8YH ZJBN'U[Q=JMEH\[Q:%>VE['+;8$QC9#')*$
M)#!BN[^';U!8'IS5ZZ\7&W:\\K2+ZYAT]1]NEA,9$#;0Y4 MEV52"=N?Q/%
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MK3N3:1Q><65<E@1Q@>IR./>L:Y\9'3+&ZN=4T/4[3R$CD"E4?S%=P@ 96(W
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M&QF82+M/)^=OE..W-=M10!R7AOPI/H<]A))<QR"UTF/3SM4@EE<MN^E8ECX
MOK>XTR2=]+,]E>)<27PA9KJ\ )^^[?=Z].1G'2O2** /)0MXW]D^';"Y#VUI
MK$4GV5[.1;B.*.?S#YC9VA5 X8?>^7UK77X>^3>2Q16F@O:R79N?MD^GK)=H
MK/O9,L"K=2H8]!V.*]#HH P_$NE7&LZ7'#9311W,-U!=1&4$H6BD5\-CG!VX
MK,N/"ES=:!XHT]KF%9M9F>56"G;'NBC3!]>4)_&NOHH X'5? 37.K:C<VMIH
M<XU%Q(TVHV0FEMGVA24R"&'R@A3@ Y]:Z>^TZ>;P^^G6,T4$@A6.-G@5X\#'
M!3&W:0,$#L>*UZ* /.5^'3SV>I12C3;%;DP/#96L3/:K)$Y?>Z-@'=]TJ !M
M'>K$?@-YK74%D@T72Y9DB$"Z78JH1XY!('=L!FRRK\O P/7FN^HH XW4M"\0
MZUIM['?:A912N(?L\$$;&%7CE63>Q/S$MM P.@]:9+X=UU%U6&SO;".'6/WE
MP71V:WE:-8Y#'_>!V@@-C!]:[6B@#G]!\/#0]0OI(Y UO-%;11)_$JQ1[.:H
M>)/#-UJ^N6]\JZ?>6T<!B^R:@C/%&^[/FJHX9NV#Z#D5U])SGVH X[PYX0N-
M%DT9I;N&4:=;W<+;(]F_SI5=2!_#@+C%1P^%-1TZ>"_TZYMFO8;B]8K,K".2
M*XE\S:2.0RD+S['UKMJ* ,+PSI-WI%C=)?7$=Q<7%W+<N\2%5^=LX /I6$OA
M+68K:STF&]LAI-GJ,=XA,;><R+,)?*/\/'3=WP.!7=44 >>'X>&.]G2*TT%[
M::\:X^UW&GK+=QJS[V0;@5;J0&/0=CBH]6^'][J4NJAI-+DDN[DSPW]S"TES
M$NX,(ESPJC&W*GIVS7H]% &/H^E/IU[K$SRJXO[W[2H4?='E1I@_]\?K7/ZC
MX%DO-4URZ2\5$O82;2,K_P >\Y\LL_XM#$WX&NXHH Y&V\(/"NB)]J!^P65S
M;SMMYEDF";G'_ E8_C1X<\,W^EW6E37MQ;2&PTHZ=B%6&\;D*MS[)S[FNNHH
M QO#FE/HFC1V,DJRNLTTA=1@?/*[C_T+%8NA^%+[3YM'-S=6[QZ6]TL?EJP,
MD<N-N<]&!SG\*[.B@#@K_P  M=,9V^P7<\>HSWD<%];^9 Z2@ HP[$8!##N.
ME;OAC16T.SN$>&PAEGF,ABT^U6&*,8 "C !;I]YN>>PQ7044 <8GA.^_M"0M
M=6_V4:RNJ185M_*L'1NW4C!^M5-?\#W>LZKJD[-IL\5[$$AEO86EDLODVD1+
M]WDY;/!!/>N^HH XYO"-R]KJ,1NHPUYH46E@A3A759 7^G[P?E2:AX-EOY;E
MQ>I$SV%I;PL$SLE@E:17([KDKQ]:[*B@#%TNVUL7DUSJMW;;718XK6U4[%P2
M2Y9OF+'(&.@ [UF3:#K=K?:F-(U&UM[;4YA/)))&6EMY"BHQ0?=;(4$;NA]:
MZVB@#B+OPIJSV>JZ-;7UJNDZI/)++))&QGB$IS*JX^5LDM@G&-W0XJW<>%)9
M='\56,=S&O\ ;);RB5.(@8$B&?7[F:ZRB@#RSQ))<Z6?$NF:==B-]1BW?9I;
M*1Y)96A6/,#*<,&VJIS]U@3TJ_<^ I7N6O(K+0KN:YMH8I?[2M!,8)(T";D.
M#D8 ^4XY7KS7HE)TH X+6?!%W?VT5I&-(G@CM4MX9;BT$<EHZ@@O$8P,9X.W
M@ C@U+J/@W4+HZK!%J$30:C8V]N\DZL91)%G#<<$$$Y]Z[@TM '&WOAO5Q_;
M-EI]]9II^KR-)*TR,9;<NH5]@'#9QD9Q@GO5A/";0VOB&V@G01ZG;)!""#^Z
M"P"(;O7IFNI(YHH PM0T$:AX1;0Y)RC&W2(3*OW64#:V/]X XK+O]!\0ZW93
MP:EJ-E&A\D)#;QL4+),DA=BW.2%P%' SWKL324 <UJ^@7E[JU[?6EY#"]QIR
M6B"6$2KE9&<[E/!4AMI^M8D'@2Y6VU! VGZ>MW+:.MI8J_D*89A(7P?XF V\
M #@=:[_M24 </=^#KZ[\0Q7\DFG*T=XMPNH10F.\\L-N\D[<*PQ\NYOX>V:[
M4TXFFF@!II*4TE #6IIIS4TT -HHHH NBEI!2T +1WHH[T +1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "&B@T4 !I*4TE "4TTZFF@ II
MIU-- #324II* &M333FIIH ;1110!=%+2"EH 6CO11WH 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@#"U_Q'8>&K(37C$LQQ'&OWG/M7&K\6HA*"^C3" _\
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MIIIU-- !333J:: &FDI324 -:FFG-330 VBBB@"Z*6D%+0 M'>BCO0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !165;Z[IEU>"VBO(VF+,BJ01N9<[
M@,]2,'IZ&KTL\44D*22!7F8I&#_$VTM@?@I/X4 3T55%Y ;EK<2@S*=I4=CC
M=_*I)IH[>%Y9I%CC0;F9C@ >I- $U%%% !1110 45#YL7G>3YB^;MW[,\[>F
M<>E34 %%1NZQHSNP55&6). !0CK(BNC!E89!!X(H DHHHH **@GN(K<(99 @
M=Q&N>['H*GH ***JRWEO#.L#R@2L 0G?!(4?J10!:HI,C=CO2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 E%4#JMJNK+II<_:6B\T#'&W)'7UX;C_9-6(KJ"<LL,T<A3&X(P.,],
MTKA8GI:II?VSE 9D1W)"HS ,<$CI^!IQOK9?,+7,(\LX?,@^4^A]*+CL6L48
MJN+NW+2*)XBT0S( X^3Z^E-%[:LL3"YA*RG$9$@PY]!ZTQ6+5%0K<0R2O$DJ
M-(GWT# E?J*B%];@@/*D;%S&JNP!8@D<?E2N!;S1FLV]U:RTZ417,P61HVE"
M#J5!4$_FP_R*G^VVOE++]IA\MVVJ_F##'T!HN@LRW129!.,]*6F 4444 %%%
M% !1110 4444 %%%% !14;NJ(S,0%49)/0"HK.[@OK6.ZM95E@E&Y'4\$4 6
M*6J1U"T%G)>F9/LT88M)G@;20?RP:1M1M%#%IT&P.S#OA" QQ[$C\Q0.Q>HH
MHH$)144$T<\>^-UD7)&Y3D9!P?U%-EGBA:,2NJ&1BJ!CC<0"V!^ )_"@"Q14
M,$\5S;QSPL'BE4.C#HP(R#4U !14#31I)&CR*K2G:@)Y8X)P/P!-$LT4*!Y7
M5%+*@+''S,0H'U)('XT 3T444 %%%% !1110 4444 %%%% !1110 AHH-%
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M5B>PL61"2B_9UVJ3UX_ ?E3YHW%RRMN5-9O[BUN=-EMY@+=FE>5 FXRJL3,
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MMW'4444Q!1110 4444 %%%% !1110 AHH-%  :2E-)0 E--.IIH *::=330
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M6/"NGW&F:7)#<1"W$EP\D-J'WBW0]$S^!/''--;B>QT-%%%62%%%% !1110
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MZ5(7EDFMQ<R+:RRDEGA!^4Y/)[X/<8JU)\UB7%<MSH*6D%+6A 4444 %%%%
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M5L<G\ZV*AJSL4G=7%HHHH&%%%% !1110 4444 %%%% "55%[:->M9K<Q&Z1
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M& /F8*(]JG(.X\&NCTHL/$&M*H(A)@=@>TI3YOQVB.FG<3C8WJ***HD****
M"BBB@ HHHH **** $) JI;WD%U),D+,QA<QN2C ;NX!(P?PK(U[1[C4IG:.*
MWE#VS11F9B#;R$\2+P>?I@_**AN])>S\,:U#%!&TMP9I L:X+[LXS@=:EME)
M(ZC(JI]NM\73>9Q:DK,<'Y2%#?C\K \5SBZ+?P323VEM:1"0RJMJLI5(PR(N
M00O]Y,D =_6JZ^%[Q3(/)M%D8J?M0<[R!;+%L^[T+#UQCWI<S[!9=SKH+B.X
M7?'N*\8)4KGC/&>O6G&>);A8"P$K(7"]RH(!/ZBN5/AVZ68N]O9W0(<+',Y
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M(.HWXO+$L8+XR*TWS=0V5VL#QP1V%6]*T:'21.ZRSW%S<OYD]Q.07D;&!G
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M@ IIIU-- #324II* &M333FIIH ;1110!=%+2"EH 6CO11WH 6BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 (:*#10 &DI324 )333J::
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIIH ::2E-)0 UJ::<U-- #:*** +HI:04M "T=Z*.] "T444 %%%% !1110
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M1:X;4Z%XEDT81;O,"1;O,STK TSP1X[L]4M;B[^($]S;QR!I(#;_ .L7N.M
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M::: $HHHH NTM(** %I:2ES0 4444 +1244 +1244 +1244 +1244 +1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
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MUSP^JR*59DB.0#Z?)7JE% '-^!?"B>#?"UOI"SF>16:267&-SL<G'M72TE%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
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M-JG'/OFAP:U8*29HT4VBI*'44VB@!U%-HH =13:* '44VB@!U%-HH =13:*
M'44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U%-HH =1FFT?C0
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M_P"1YL/I)_Z :]RKU<)\#/SWB7_>U_A7ZCLT9IM%=9\T.S2')4@-@GOZ4E%
M$4<,R.&>\>0#^$HH_E4DJO(F$F:)O[P4'^=.!I: (T218BIN'9S_ !E1G\NE
M,>*=ONWCI](U-3=\4$XH 0!@>921MQC Z^M1Q121R%GNI)>,!2J@#\JEHS0
M@##&9"<'G@<TD:LBD-(TASG) 'X<4*V[=_LMBEH =FC--HH =FC--HH =FC-
M-HH =FC--HH =FC--HH =FC--HH =FC--HH =FC--HH =FC--HH =FC--HH
M=FC--HH =FC--HH =FC--HH =FC--HH =FC--HH =FDS24$XH 6C--S10 ZD
MS2$TF: %S29I,YHH ":3-)F@T (32$T4A- "&D)I33: $S1244P+(-+FF TN
M:0#A13<TM #LT9IN:,T .S1FFY]J,^U #LT9IN?:C/M0 [-&:;GVHS[4 .S1
MFFY]J,^U #LT9IN?:C/M0 [-&:;GVHS[4 .S1FFY]J,^U #LT9IN?:C/M0 [
M-&:;GVHS[4 .S1FFY]J,^U #LT9IN?:C/M0 [-&:;GVHS[4 .S1FFY]J,^U
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M_P#%4?\ ""^)_P#H$R?]_$_^*KW#-&ZCZI#N/_6;%?RQ_'_,\/\ ^$%\3_\
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MY4>1%_SS7\J** #R(O\ GFOY4>1%_P \U_*BB@ \B+_GFOY4>1%_SS7\J**
M$\B+_GFOY4OD1?\ /-?RHHH #!%_SS7\J/L\/_/-?RHHH /L\/\ SS7\J/L\
M/_/-?RHHH 3[-#_SR7\J/LT/_/)?RHHH /LT/_/)?RH^S0_\\E_*BB@ ^S0_
*\\E_*BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "D 40# 2(  A$! Q$!_\0
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M3@IJ?RZ=Y?O4W*2(,<=*4+4_E4OE5%QV(0G-." 5-Y5.\NE<=B+ IP4>E2!
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M*WS?9/,Z_P#7-CU_W3SZ$]*X$W91T:-R&0Y#*<%3Z@UW?AWQFLQ%MJ3HLC'
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M4N7W+TX')K'DUO6;>!3]K/G-T!C7C]*Z95$CE5-L[L1#%)Y0 )KSF?Q+K,6
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MECD\FG1RO$VY#M8=Q34VA.)[U:B2YLFD%M+#($+%)0 1@>H.*P)CFT)]9/\
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)<#':BBBD,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 +\# 2(  A$! Q$!_\0
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M  DM];6Q\F\BD^1B>)%P#@_G^%-/34+'HIEL-O.HPC'M3%FT\LL:ZG"68[5
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M(FV^ _%@_O31#_R,AI-$5C8(!<2I\[<*V!5<1N?!GB%D+.BR1[SN_P"FB?\
MUJZ>ADF?2'G.YVY &<8' IZ ;@2,@'L>#4:)P.001VJPD;2-B-<^N* $PNT
M#!_K2J C/D!@>,>E$F5<J-P[#<.127+QV:R3W4J00 YWR'D_04K@2CRS!)DX
ME!&WWITJQQ1M<WLR01@<LQQQ]*QO$&N/H5M&T4$:-/&3#-(<Y('0CMVKG8!_
M;^G1W=]/++)*,G)QM/H!Z5G.I&&Y<8.6QUEUKB1V[?V<J@E?EF?G\:K>*;@V
MWAVRF##[1-C<V,[_ )<GFL./3KLP-Y,ZR@<!6&UO\#6GXL<IX;TIY(SY<;#S
M3C)0;>N.]*,XS6C&XN+U,ZT@M9K#=,NX@;V8G&W_  J"\UTFW:/38VN!$!OD
M4\ ?U_"H;&ZBGT/Q 8)FN8S&-@SR?EZ8[5REL+G3'>XN+Q;*"5<>0HR[C'I5
M6L(]+\(R1SSWEQ%<F571/E/5#D\8KCO&^F;_ !/J5Y<WL=O%E6C55W2$A1S6
MO\-;ZWN9]2@M+3R((D0@G[SDD\FN2\?6UQ)X^U*2+<N"@W9X^X.*KH(Y@7_V
MO D8)=)PLG02#WK3\,WK/XHTI&)#?:XP5].:Z'3O!NFZE;6S7B2EY%!<H^SG
MV]*Z/3_AYI%KJMI?0P7*R6\BNCO.<$@^F.:<6UH%RG\7)C!#HTBMM822X_):
M\^_M5M@G!.TC# $<5[CXC\,:7XCCM5U2.5Q SF/RY2F,XSG'7I6+'\-O"D1=
M1:W6&&"#<L<TI),$['G,/BF[-NEO;X61>#)U8CM6GX>UN&WDU:<,\ET+<-*L
MK^8I&>^?Y5W<'PS\))CR[2<$]_M+9-4K;POX7TR6Y2VTB8>9F.0FZ8[@#64I
M1I_$RHQE+8XI?%/B&Z5UM_#.FM#N(SM R/7&:GT&]U.6[N/.T'3K9! ^#"B@
MNV.%.#T/>N[M?AMX1N[9)_[,F7?DE?M4G!_.GO\ #[PMINYK:QD21T*L?M#G
MY3U[UHFFKHEIIZG-:)J]TNF0K+I]K;2$DM%",*ASV JX;^:X\0S0FT@V1VF?
M-QEF8Y^3/9>GYU<CTO3=/ACM;.R;RD^5%+DX_$UT4'A+1(YY+MK1C=S(%FD\
MUOFP,8QFN:E2:J.3-YS3@HH\HMI-7<E?^$?TR)U/*(JX'ZUB^*-2U ^#M6LK
MC0[2SRT9<P0@X7S$.XD=.<#/OCO7L@^&_A$ E=,(.?\ GXD_QKD?B9X=T+0?
MAWKL>EV'E2-Y+/)Y[GGSH^Q)S]#]>U=+DD8I'=<*VU>0><@5.J^4GFS2B!?[
MS'!/TK'F\0V\3J+2,[68+Y[ '&3V%5?'=C?7$MC_ &=")!M8R[I-O.1CK^-$
MIJ*N)1;=AVH^-8('N(-*MVEFB.V264< ^P[UY]J]W=:Y/YMS<S-(IXY.U?PZ
M5IR:'J;1,\EL&P/FVR XKJ_"\=O9:*MO,4$BROD'DG)]^U9*2GU+:<>A4^),
M;MIFD-D!%#;F)P!\J]:YSPWKUFL*Z8OFM*FY]^PA2.IP:]4OE1W@#*K 8X(S
M088@Q/EI_P!\BJJ4U/1BC-QV.4T[5[0\&4!6.0^<C\Q6EXJ5)_#=JD@W1R28
M(]05J]):P//Q&BX'.%%:AV?9H0%!"MP,>U8K#V32>YHZMVFT>5Z!&L6AZQ;V
MT20E8V52HQGK@FN3:QDV/<W!9E ^:1L_SKZ&=HU4_*H_X"*J&2)D(VKTZ;16
M\8M*S9DVF]$<=\.[>&-9Y8=I66",A@,;N3S67XRL5F\4WDC1[C\N#S_=%>@1
MW$5ON>3Y5. ,+5C^TK*2;"ODMT)2B4HK1L$F];'G.GOJ5K;0-:7,4*HN LEL
M'Q^)K:L]4UF:^M8Y[Z%E:50X6V W#/3KQ782%=@(*D9Z@538H;L8QP1T%4*Y
M0\4W6HVL%L=/N8X&+/NWQ!\XQ^5<A#XBU^68(;V++<9-N!BO4.&BY4'YO2F;
M5S_JU_[Y%#N"9YX=2\2#_F,Q+Z8M5XJ['=@H&E+R2'[[A1RW<UU\K*QP(UVC
M_9'-0&(/]Q #GL*PK4O:))LUA4Y6<Q>ZWJ-FMO'9W8AB*DX:,-SGWJD^NZK(
MK%]2#,1T\A:[5[BVCQ!E#LZY7J:%F@;[OE_]\BG&+BK7$Y)N]CAM,NM5N]4A
MB^WA!G<9#$OR@=ZZU?MJYW>(';/_ $RC%:/VBS@'ER,@?J1L_P#K5-"8)TWQ
M*C)G&=E:0DMKW9+OO8P;F2[M[5Y3XBF+#[J^3'R?P%<%\2[WS/AYJ23-)-)(
M\15PO /F*>?P!KUYPB1,1&@.,?=%>??%V(#X7ZJ0 ,-">%_Z;+6=6'-9_P!;
MHJ$^6YP]K*C74&)&7$BG!;@<BO4?$6K65O<PPS7"12;3@.<9^E9-UXQ6UL;:
MZDM8529U4*;<$@D@=C[UJ>(]<CTDJ\L2&,*6+-"'(JI4U*+C<F,FG<R6OHS;
MS[95.Y/EP<YKD-?O)O(AV[_]<O*YK;D^)%A^X/V20"0@*WV4 <G'K5[4_&W]
MCW9M7AC9MF_<EN",?B:YOJBO=,W5=VM8K?$J\N8;'2FADDC+L 63/3 S7"V6
MH7Q\0O:BXNI5\MB"TC$UZKXO\<V7ABWTZ2XAWI=@[<0A\$ 'UXZUG>'_ (B6
MWB'58[&TM1')(C.'DME P/<'-=+@^:]S)25K6/*[OQ%/;),$%W-< LN&8JJG
M^M=I\2=4O;;X=>&)X+F6WFE9"[(VTG,6<5HWWQ6TZRO+BVDLVWPNR,1:KC(Z
M]ZU_%OB73;/PIIE[?:>EW;WV,1O"&QE,YP3Q6B,V>:>&=4U"X\"^);B>]N9+
MB';Y3M(24X[5Q/\ ;NL$<ZG=_P#?TUZ'"++4?#?B"XT"U^Q6BQ#SX#QN;'!'
M)KS403; 2$(Q_>% CTSX27UW>7>L"YN9I@L,1&]BVWYC7I:3HLH_>+Z?>KSW
MX% KK&M9V_\ 'O'T.?XC7>:IX\\.Z3JT^G7:HMU$1N0@#=D9ZFN>I04WS-FT
M*CBK&%X@\RX\46-IY]S%'-!("T$A4AL<'(KG+5]3L]0T5/[0NI=^HQQR,Y.7
M7=SFO1_^$\T[:'2PDEC X>)D8?I3;?X@:5<WD%LEC<>9-*L8&P?*2<9/M13I
M.#W'.:DMCF?C5J>H:;9:,^GWDUJS33!S$^W< %K@O".O:Q>ZK,E]J]W)&L!8
M N6^;(KV_P :VV@WEC;6>NVZR0RR'8Q!^0CJ01R*X#3_ (>V>FZC<ZAIFIBY
MTXJ452<NN>1R.H_6NAF2MU/,IO$GB$3.!JUT &( \T^M=5\/M8U74-5O8+S4
M+B>/[/\ *ID/RMNQFN)G$8NYE\SI(PSCCK7<_"*P^U>(-2W-L6.SW[B,#[PJ
M6:-16S.1G\1Z\+J91JUQQ(P'S^YKJ/ >K:Q>:GJ27-_<2)'ID\BAFZ.!P?K3
MS\+-:>\>1;_2MIE9Q^_)ZG/I77>"?A]J>E:A?RW%Y82+-9S1*L<A)#L, GCI
M3"T;;FAX2U$2^$-*EOKZ-KIX=TC2RC<22>N:?H][<77Q"UFW6\9[*#3%DCB5
M\H'*MR,=^*PG^'VJB"&)Y-%#Q*%+B^/./;;Q6WX \$ZCH6KZM>7M_ILQO+9H
MT6VE+%3@]>.@KGIT.6?/?<J=2\>4\:'B_P 2.N7UJ[)S_?K?^VSZU\)O%-QJ
MUT]W/;36YMFFDR4)E0';[X+#Z$U8;X4:U$2AOM++ ]IC_A4^N>#[OPS\+]<^
MVWVGR-)) Z)!/EB/,08QW/.<>@)[5TF!M:XR+X6M%9 6::(HW<$,,_F*W_B"
M56QRQP#$P'Z5R^O)Y7A'34!SB=!D_P"\*ZOXC6HFTJW=6VD1N3[]*8'F%VO_
M !+]*/\ M)_Z$*L_$B.X.L;85E9?(!*HI.>?:HC%$FEV;7#LQ^5HL'A3N'7V
M[_A76KXMOQ?WBV5A=ZAI1?\ T>X@49''S*,_>7.<$5RXFLZ5/G2O\TOS%<O>
M/=%U/5].T)-+L1=.L4D<I+*!$&C49YK+\%>"=6T#6;;4+Z2S BB=&CCEWG)Z
M=.*PM8^*%Z'>WM-.:!EX)N@<K_P&N8G\8ZO>+MGNYG8GA4;8@_ 5C3GBZCYN
M517F[O\ #3\0;=CM]8^',M]JMY=G6+"!9YGD"N>1DYP:Z'Q)IEIK?AC2=(&K
MV,#V 7=*\JD/A=O SQ7DT6II;?NY;<3SS<F1VSL!Z<?K4R^*8D58QIL?RC;G
M:O/Z5TJE5ZU%_P" _P#!(N^QZ+HNAV6D:#J^FOKVG2-?KM602@!.,<C/-<V?
MAU 8RH\3Z7G&!\W_ ->LZPO#KK75NL*6D<-K),[K&I<[>PXXSGK6#Y$/E,49
MU50< D9XINE56TU]W_!"_<]9^'>@P^#K^_N+C6;"Z6YB6-1#( 5PV><FL?QK
MX&O?$OBN[U73KNP-O.$"I)< ,,* :\X27:O0]>XQ5F0C;N3*DXQSUXH]G6M\
M:^[_ (([F_-\/_%&G'S8;)Y%6+&ZUE#<_@:[?2[::U\/:#/+%)%?M>0I.TJ_
MO,>9@@YZ<5YEIU]?HDSP7]S"T2[E"2'G]:]25_%FE:=97MMJ]OK$%R8T$5S'
ML?<V,#</?C-2W6CT3_#^OO*3)?C3?WFGVNDO:3>7NED!^4'. /6N4^&.H7>J
M^(;F*\E\V,6K-M"A1G(YXK4\226VLB/3_%(U/1KM&)A^V$R09/!VN.<?G4?A
M726\':S)J-[ODTV2W,275L/.CYQ@DKR/Q%$:T7))Z/L_ZU^0SRF?!OKGC.)7
M Q_O&O2O@P@.N:NY(.ZRVE3Z;A7!W# 7MRP!VEB5)'7YCS7H7P="?VOJ2C'F
M?9"3ZXR*V:$F<)=3W27ER?[0GC_>OA5D;^\<<9KM?AI-<MJ.K>9?W,C#2IR%
M=F.#M'/)ZUR%Y;A;^X+L"?,.,_[QKLOALF-5UECQ_P 2N?'_ 'R*A+4;D<-)
M?S%6W7]P.,?>8Y->C?"*>61=4+SRR,+1@-[$X//(S7E<V$+$<\D<UZG\'<O;
MZD.F+9OZULD9K<\VDO-0".?MUWN$F"1,WK]:ZBW'VCX->*YYV::5)+?:\A+E
M3YT0ZGIP37,IN$5R,[AN;G'7FNKLE'_"C?%WJ);;/'_3>.I+.BUVQOKOPS80
MP6<\DB2J64)R "*ZKQO!<W6F6MO:V\DTLB.H"C@'CJ>U:8Q]F4<C\*DU:Y6"
M&!FY&2,  YK.M55*G*;Z#1YOIWAEGMH!J\1Q","V X8_[1[CV'XUTBP%4"A0
M !P , >PJU'>0H?F\R1.I4A1G\0*?)J%LZ?);,I]=]? 9A6GB)\[FI?>K>23
M#0Q]2T.RU:/;>VJR$#"OT=?H:XJ^^&CQRF73IQ(O_/*7@CZ'I7I7VZV[PM_W
MU3DO;+YBT+]<?>K/"X_%8;2$M.SU7]>@61X?=^'=1MK\R7%M,G/ \L]/J*9_
M8C@@Q*^3V=2,?G7NXOK#IY<@_P"!BC[5IIZK+^E>]#B"25I4U][_ ,A6/%M$
M8:3/J N@<W%F]NA7HK,1R?;BJEGIR"4AYH7&>%#=37N#OISG"H6'^T@-,-MI
M;_>MX#]85H?$L(NSI/[_ /@!R7ZGA6L)Y=YP  P)XHALY;F**5#&5VCJ^"*]
MQETS17CR;:V)R.# *8^@:!+G=I]H?^V0%7_K-17Q4W^ ^0\8L;*9;AP#%^]C
M*XW]^U>P:2&;PCHD,DD7G1W,1==XR )/\*8_@[PZYXLH%/L"/ZTS_A!]!8Y$
M*#Z.P_K5KB7!O>,ON7^8<K+'QBMFU"TT>*W97S/(/E8'&0/2O/= LM<T76H8
MH[^XT^"1'+,!E7(4E04;Y2"0!^-=XO@32(G26-G21#N4B8\&M'9<1!;:207-
MHXV21G!('KSZ5%3B##2:BH\T>M_Z:?WH.5G#R75AJ=NCZWIZ:;<2#_C\M(_,
M@<_[<9Y7ZBM;PO:)X2OKC41$ES8W4'EK/9R;X^N<C/(Z=#6L/"\FQDCU>X15
M/!$<9./RJKIW@N\TC46O++6[I1(V9H7A4QR#N-HZ?454LXPD=:-2_DT_P=FU
M\[_(:C+J>8:M*\%]*3$2K,6R5_VB:ZWX:W"27^K%5X.FS<XQ_#7=2^&=+N9O
M/GT>W=SU8*5W?7&,U?BTC1(RQMK..PD,9A=H8\$J>H-72SK#U%>S3[,7)8^=
M+\QLQ\M=N"2W%>E_!B0%=53TM3_6K^H?#;P]=O(+#71$P.TJ6#$'W4\U<\%^
M$[KPG>:D\MS!=6\]L4CD@Z[N>"*].GCZ/PR?+Z_Y[?B2HL\CBV@RQ@?+YA&/
MQKKH@O\ PI3QD%& DUJ/_(T=<2TQMFG2<B*X#G,;C# Y[BNML+D2_!+QB=ZE
MGGM0<?\ 76,_TKM3N.Q[*S%H@0*HZ\2]O'MYVY)K-:SC"[074?\ 75O\:;>R
MS%%#2EAC Q7EYEB$L+.RWT^\T=-I792$C[MHQ]34@5O^>@_[YJ!7")(S' !Y
M)[<5YWKGC*^OIY;?2I#;VL?#SCAF]\]A7R6$P-7%3Y:?3=F9Z;Y3_P#/5?\
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ML2:=\O\ M4 2@C_(I<@#'>HLXY&<_6CZ YH FR1B@'D9_G40/4$4X$8)S]*
M)?K^E9GB%A_8-T!WV_\ H:U=XSU(K/\ $!']A7(!_NGZ_,M)@,[=*7BF9H!%
M,!_%+BF\=J7KUH >!]*./;\*82>G2@&@!V12YIF1G%&?PH D!/TI?>H\BDS^
M- $V[TI0V>N*C!]J.<<#% $V_P!J7<,=!4.X@XXI0_6@";C&>*4%:AW9%.W
M]* ).A/(%.)&<^OI4(<9'^%+P>@H EW8YQDBE!)ZU%RH[@_2DW'Z4 3@YYR.
M33MRD9('6H,YYZ9I<G!YR/6@";>N>3UK.UZ0?V%=*-O(4?\ CZU;S[5GZXY.
MBW((QG;_ .A+28'/_P!NW7]R'\C_ (T?V[=?W(?R/^-%%2 ?V]=?\\X?^^3_
M (TO]OW?_/.'_OD_XT44 ']OW7_/.'\C_C1_;]U_SSA_(_XT44 ']OW7_/.'
M\C_C1_;]U_SSA_[Y/^-%% !_;]U_SSA_[Y/^-']OW?\ <A_(_P"-%% !_P )
M!=_\\X?^^3_C2_\ "07?_/.'_OD_XT44 '_"0W?_ #S@_P"^3_C1_P )#=_\
M\X/^^3_C110 O_"17G_/.#_OD_XT?\)'>8QY<&/3:?\ &BB@ _X2*\_YYP?]
M\G_&E'B2\!SY<'_?)_QHHH 7_A);W_GG!_WR?\:3_A)+S_GG!_WR?\:** %_
MX26\_P">4'_?+?XTO_"3WO:*W'_ 3_C110 G_"2W@_Y9V_\ WR?\:BN==N+N
8TEMY88"L@^]M.5.X'(YZ\8^A-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %A W<# 2(  A$! Q$!_\0
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M&_[Y- $E%1^:OHW_ 'R:/-7T;_ODT 244U2&&1G\:=0 4444 %%%% !1110
M445'YJ^C?]\F@!]%8/B3Q)'X>T]+@Q-(SOM5>F?6KFE:Q;:O81W=LQ*L.0!D
MJ?0U3IR4.>VA/,N;EZFG14?FKZ-_WR:/-7T;_ODU)1)14?FKZ-_WR:/-7T;_
M +Y- $E%1^:OHW_?)H\P?W7_ .^30!)14?F#^Z__ 'R:/,']U_\ ODT 244T
M'<.A_$4Z@ HHHH *:Z!T*MT88.*=10!172[-?*/E9,9)4DD]?7U_&FC2;15V
M!&"9+;=QY)K0HHN!0&E68*GR0=HQSSGW/J?<U8MK:*VCVQ# )R23DG\:GHH
M**** *<=F&DDDN LK,?E!Y"KV&#4OV2W_P"?>+_O@5/10!!]DM_^?>+_ +X%
M'V2W_P"?>+_O@5/10!6>RMG4@0HI/\2J 1^-.MUE2$+,P9@< @]1V_&IZ* "
MBBB@ HHHH **** *\\$LS "8I'_$JKR?QJ'^R;?^]/\ ]_F_QJ]10!1_LFW_
M +T__?YO\:/[)M_[T_\ W^;_ !J]10!1_LFW_O3_ /?YO\:/[)M_[T__ '^;
M_&KU% %'^R;?^]/_ -_F_P :/[)M_P"]/_W^;_&KU% %'^R;?^]/_P!_F_QH
M6P\DYMYY(SWW$N#^=7J* &C..2"?84ZBB@ HHHH **** "BBB@ JK=027+1K
MOQ!SO 8@GTP15JB@"C_9-O\ WI_^_P W^--.F(@W0O*)1RI:5B,^]:%% #4W
M;%WXW8YQTS3J** "BBB@ HHHH *KW7GF,)!PS'!?CY1ZU8HH H_V3;_WI_\
MO\W^-']DV_\ >G_[_-_C5ZB@"C_9=N.0\X/8^<W^-2VIG\@"<8D!(ZCD9X/Y
M59HH **** "BBB@ HHJ">XBM+>6XGD2*&)"\CN<*J@9))[ "@">BL.T\4:1>
MP7LR73PK8*'NUNX9+=X5(W!F6158*0#@XP<'T-/MO$>E7.GW-\+GR(+;_CX-
MU&]NT0QG+K(%91@@@D<CI0!LT5C#Q)I"^&U\0O?1II+1"87,@*+L/3@@'))
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M87!:0]&_ASWP,&X\!^)-5_M$ZC)ISS75I;*SW%W)=K+-!*TJ[D,2*L;EL%5
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MCIP>Z/-CX;\2Z<=UIJMPX'178D4'7O%^EC?>117,2<D!,''UKT>F201S(5=
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MMV >PH **** "BBB@ HHJ*=E2"1GSM"DG'7% $M%<G',^VQ>"3SVWOMC9F#
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MWS0N_G<![8H =1110 4444 %%%% !1110 4444 %%,;?GY0N/>E7?SN ]L4
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MT 245'B7_8_,T8E_V/S- $E%1XE_V/S-&)?]C\S0!)14>)?]C\S1B7_8_,T
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M>[EL=1FM4GD5%>1%P5+! JY^;' '2NFH **** "BBB@ HHHH **** "BBB@
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M&?O$=LGHJ** "BBB@ HHHH **** "BBB@ HHHH *CE_U3_[IJ2HY?]4_^Z:
M*^E_\@NV_P"N8JY5/2_^07;?]<Q5R@ HHHH *HZ5_P >TG_7>3_T(U>JCI7_
M ![2?]=Y/_0C0!>HHHH **** "BBJLT[QWEM" -LN[<3UX% %JBBB@ HHHH
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M %V_]E-7JHWW_'U8?]=O_930!>HHHH *HZ5_QYM_UUD_]"-7JHZ5_P >;?\
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M_KFO\JGH **** "BBB@ JC??\?5A_P!=O_935ZJ-]_Q]6'_7;_V4T 7J***
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M -7;_P#7Q'_.KU4=3_U=O_U\1_SJ]0 4444 %4;7_D)7_P!4_P#0:O51M?\
MD)7_ -4_]!H O4444 %%%% !1110 4444 4=7_Y!=Q_N_P!15T=!5+5_^07<
M?[O]15T=!0 M%%% !5&P_P"/B^_Z[_\ LHJ]5&P_X^+[_KO_ .RB@"]1110
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MY7^V_P"='E?[;_G0!)14?E?[;_G1Y7^V_P"= $E4KG_D*V/TD_D*L^5_MO\
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M>Q_Z!<?._P#JF[^U $EI_P ><'_7-?Y5/56TC_T.#YW_ -6O?VJ;RO\ ;?\
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M?[;_ )T 245'Y7^V_P"='E?[;_G0!)14?E?[;_G1Y7^V_P"= $E%1^5_MO\
MG1Y7^V_YT 245'Y7^V_YT>5_MO\ G0!)14?E?[;_ )T>5_MO^= $E%1^5_MO
M^='E?[;_ )T 245'Y7^V_P"='E?[;_G0!)14?E?[;_G1Y7^V_P"= $E%1^5_
MMO\ G1Y7^V_YT 245'Y7^V_YT>5_MO\ G0!5U/\ U=O_ -?$?\ZO5G:G'^[M
M_G?_ (^(^_O5[R_]M_SH ?14?E?[;_G1Y7^V_P"= $E4;7_D)7_U3_T&K7E?
M[;_G5*UC_P")E?\ SOU3O_LT :-%1^5_MO\ G1Y7^V_YT 245'Y7^V_YT>5_
MMO\ G0!)14?E?[;_ )T>5_MO^= $E%1^5_MO^='E?[;_ )T 5=7_ .07<?[O
M]15T=!6?JT>-+N/G?[OK[BKHBX'SO^= $E%1^5_MO^='E?[;_G0!)5&P_P"/
MB^_Z[_\ LHJZHVC&2?K5*P_X^+[_ *[_ /LHH O4444 %%%% !1110 4444
M%1R_ZI_]TU)4<O\ JG_W30!7TO\ Y!=M_P!<Q5RJ>E_\@NV_ZYBKE !1110
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M -7;_P#7Q'_.KU4=3_U=O_U\1_SJ]0 4444 %4;7_D)7_P!4_P#0:O51M?\
MD)7_ -4_]!H O4444 %%%% !1110 4444 4=7_Y!=Q_N_P!15T=!5+5_^07<
M?[O]15T=!0 M%%% !5&P_P"/B^_Z[_\ LHJ]5&P_X^+[_KO_ .RB@"]1110
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M_P#7Q'_.KU !1110 51M?^0E?_5/_0:O51M?^0E?_5/_ $&@"]1110 4444
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M@"Y1110!1D_Y#<'_ %P?^8J]5&3_ )#<'_7!_P"8J]0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1U/_ %=O_P!?
M$?\ .KU4=3_U=O\ ]?$?\ZO4 %%%% !5&U_Y"5_]4_\ 0:O51M?^0E?_ %3_
M -!H O4444 %%%% !1110 4444 4=7_Y!=Q_N_U%71T%4M7_ .07<?[O]15T
M=!0 M%%% !5&P_X^+[_KO_[**O51L/\ CXOO^N__ +** +U%%% !36.U2V"<
M#.!WIU-92R$!BI(P".U &6=93?; HJ+,6!,C[2,'& .Y]J=%JX>UFF>%D*,
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M??WJ[YJ?WU_.J>IJ/+M^!_Q\1]O>KVU?0?E0 WS8_P"^OYT>;'_?7\Z7:O\
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MH 6BBB@ JC8?\?%]_P!=_P#V45>JC8?\?%]_UW_]E% %ZBBB@ HHHH ****
M"BBB@ IDO^J?_=-/J.7_ %3_ .Z: //YO!]Y<>7?V5[-$\B \-TJ$0>,M,^Y
M?/<@=!(,UWNE_P#(,MO^N8JV0#UK=8F=K/7U1DZ4;W6AYVGC+Q'8G_3]+64#
MKY7%78/B/8-_Q^6=S:^N1N_I79/:PR?>C4_A5&XT#3KC[]NI_"G[6F_BA]V@
MN2:VD8W_  L3PW_S^R?]^6_PJM9^/?#\$3J]XXS*[#]TW0G(K8_X1'2\_P#'
MO'_WP*IZ?X6TV2!RT"$B5Q]P= :?-0_E?WK_ "'RU.Z^X9_PL7PW_P _K_\
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M )BKU49/^0W!_P!<'_F*O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4=3_U=O\ ]?$?\ZO51U/_ %=O_P!?$?\
M.KU !1110 51M?\ D)7_ -4_]!J]5&U_Y"5_]4_]!H O4444 %%%% !1110
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M_P >-Q_UR;^56*KWO_'C<?\ 7)OY4 +:?\><'_7-?Y5/4%I_QYP?]<U_E4]
M!1110 4444 %4;[_ (^K#_KM_P"RFKU4+_\ X^+%NPFY/I\IH OT444 %4=*
M_P"/-O\ KK)_Z$:O51TK_CS;_KK)_P"A&@"]1110 4444 %%%% #)?\ 5/\
M[IJMI7_(*M?^N8JS+_JG_P!TU6TK_D%6O_7,4 7**** *,G_ "&X/^N#_P Q
M5ZJ#\ZW#[0-G\Q5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"CJ?^KM_P#KXC_G5ZJ6HJ6MU<#/E2+(1Z@<U:C=
M98U=3E6&10 ^BBB@ JC:_P#(2O\ ZI_Z#5TD 9/:J5E^\GNK@?<E8!?P&* +
MU%%% !1110 4444 %%%% %'5_P#D%W'^[_45='052U?_ )!=Q_N_U%71]T?2
M@!:*** "J-A_Q\7W_7?_ -E%7JHV'_'Q??\ 7?\ ]E% %ZBBB@ ICY\ML$ X
M.">@I]-90RE6 ((P0>] './JEUMA82J65FRJ\B7!Z5)!J,_]GSNTP=RP"L1]
MW) ('T'-;"65K'LV01KL.4PH^7Z4GV*V!'[A, D@;>,GJ:JZ%9G.R:Q>Q)<.
MLF\VTHC0%?\ 6@_Q'\NWK6WID\D@N$>7S1&X"N>X(!_K5H6T"E"(8P47:N%'
M ]!3XHHX4"1(J*.@48%)L+#F8CHI;Z4W>_\ SR;\Q4E8MQXBMK?4[BQDBF#0
M0><SE/E(R!@>O6E89>N+:*ZQYUNS8Z?-C^1J'^S+3_GT;_OX?\:H?\)3;@(K
M1$2;G61=W"A "QSWX-6[;5FN-2^R?9P%,7FB0/D '& >."<]*=F%R3^S+3_G
MT;_OX?\ &C^S+3_GT;_OX?\ &M+-8'_"36[2WD202B2VE6$"1=N]F!/Y<=:5
MKA<O+IUJC!EM2".F7)_K5W<W_/(_F*PAXJLV:-@C>68A(Y[KDD 8[\U;TK6H
M=5DN8XU*M P#<YZ]/Q]J=F*YH[W_ .>3?F*-[_\ /)OS%-N)UMK>29@Q5%+$
M*,D_2L5?%5LT%M*(9 LP=R'&"BKC)(]>>E%FQW-S>_\ SR;\Q1O?_GDWYBL(
M^++01RR>6VP()(SW<%MOX<UKV-ZE];F11@JQ1U]&'4468KDV]_\ GDWYBC>_
M_/)OS%5]0O&L;;S5BW@'YLM@*/4FLM/%EDX\Q4D\@H[!R.<J,D8HLQW-6>W6
M=@YC9)!]V12,BHOLES_S^W?Y)_A6<WBJW5"#"_FJHDD3/W4/0_J.*Z!7#J&4
MY!&118+E#[)<_P#/[=_DG^%'V2Y_Y_;O\D_PINH:LNGW-NDL1\J5Q'YF?XCT
M '>L]?%=LT:D0OYDBF2)#_$@ZGVZ'BBS"YI?9+G_ )_;O\D_PH^R7/\ S^W?
MY)_A4$'B"VN=4M[".*7?/;F<.5PN..,^O-;&:5@N9WV2Y_Y_;O\ )/\ "C[)
M<_\ /[=_DG^%5+KQ#':WAM9H665CMA&?OGW] :C7Q3:L(R(WP4WR'^X-VW\3
MFG9A<O\ V2Y_Y_;O\D_PH%DS'_2))YU'(5R ,_A1::FMSJ-S9/$8Y855\$YR
MIS@^W2KTC%(V8*6(' '4T@&AF P(B .PQ1O?_GDWYBL,>*(<^683YRR.DBAL
MA=@RQS]*EM_$D%V["WB=U,1DB/\ ?P<$>W-.S%=&QO?_ )Y-^8HWO_SR;\Q5
M;3=034;03HI7L1U&?8]Z6_NFL[8RK'O(/.3@ >I/84K#)][_ //)OS%&]_\
MGDWYBL2/Q792LK*K^20P+D=&49(Q]*'\56D.F2WDR,I0*1'U)##*_I3LQ71N
M;W_YY-^8HWO_ ,\F_,4J-OC5Q_$ :HZGJ7]FQK*T1:+^-LXVC^I]J0RYO?\
MYY-^8J"XM_M&Q@)(Y$SM=",C/7K62/%EGY;R['\ORQ)$<<N,[>G;FI%\20/=
MP6JA!,SE)!))M"$=AZFG9BNB[]DN?^?V[_)/\*3[%*Q_>7-Q(O=#MP:TLUD7
MVN1Z=>+%<1,L;([(^>6VC)XI6'<T5+*H40D # &12[W_ .>3?F*PF\56Z1\P
MOYJH)'3/W4/0_J.*MV>O6U]J,UK"RGRSM)W<Y R>/3WIV8KHT][_ //)OS%)
MYC_\\F_,5+7/R>)8H9GMY(&%R 66//4#KD]CCM0E<9M[W_YY-^8HWO\ \\F_
M,5CQ^)+>>=8X8V;<$ 8G'SN,JM6],U%M0%P&@\OR9/+R&W*WN#W%%F*Y=WO_
M ,\F_,4R5//C:.2%BI]Q3IY&BA9TC,CCHH[FL-/%EH\:2>6VW8TDI[( VT_7
MFBS8[FC]DN?^?V[_ "3_  H^R7/_ #^W?Y)_A6=)XKM4MY93&V%V%,G 8.<
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M-$DBYVNH89]#69<^(K&SGN(9EG$D"JQ B/S G V^M*P[D_V2Y_Y_;O\ )/\
M"C[)<_\ /[=_DG^%0GQ!9"0(1,,PF<'RS@J,9Y]>>E.L=>LM1GCA@9R\D(F
M9<84DCG\J=F%R9;&X(R=0N1[$+_A5N&%((A'&,**DHI %%%% !1110 4444
M%%%% !6;<:4D^HM>^:ZR&V-O@ $8+9SSWK2HH YL>$[86L=O]IF*!V>0X&9-
MW4$_X5JV>F16-Q<S1L29RF0?X0JA0!^ J_Q1Q3NQ6"L>?0HYI-0D%Q)&UZ4+
MD ?+M7'%;%%*XSG6\)V;)!$TLI@BCV>7P-W.<D]<U<TK1(M+EGD29Y#-M^\
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MNT2)C*_3-6**5QG.0>$H(+.VMUNYSY.[+D#<X88(-2P>&XK-R]K=30XC,<0
M!\K)R2,_UK>HIW8K(HZ=8)I\+1K(TA=R[LW<GV' J'6](&M62VK74T$>\,_E
M8RX'\)]JU**5^HS!/ABV:<2-+(5PQ:/  +%=N[ZXJ"3P=IT]FT-RTLTIC$:S
M$X90.!@#CBNEHIW8K(CBB6&%(USM10HS[5F:MHHU6ZLYGNYHDMFWB),;7;L3
MGTK7HI7&<\WA2V83*9Y=KIL08'[OYMV1^-2GP[&51#<R%1+YT@V+F1_4G&1^
M%;E%.[%9" 8&!VK"E\-QW&JW%]->3.9HC$(SC:BG/3\ZWJ*2=AG.-X2MVC.;
MF;S601O+QED'1?T%6K70+>TU-KQ';EBZI@84D8//4\5LT4[L5D-(RI .,CK7
M.0>$HH;=T-_<23/(TAG<*6R1@]O3BNDHH3L,Q(/#5M;W4<R32;4$?[OC!9!@
M-]:T--L(]-L([2-F=4S\S=3DD_UJYFC-%V%BAJEB=2TZ6T%Q+;^:-I>/&['>
MLW_A%+8QPQ&XE,:0^2ZX'[Q<YY_&NAXHXHNQ6.<;PI;M'(GVF;DIY9P/W80Y
M 'K^-;%C9I8VB6Z,S*N3ENIR<U;XHXHNPL9&KZ*-7>U+W<T4<$GF&-,8<]L_
M2JS^%K:0S;IY=CQLBK@80L<DC\:Z#BCBB["QS\GA:WE$8DN)6VRB5^!^\88Y
M/Y"M\# P*6BD,PYO#R7.L/J,UW,Y:(Q+$0-J ^GOS21^&X(]/DM3<2L9 JF0
M@;MJ\ 5NT4[L5D8\.@P0ZD;P2R-\XD6,XVJVW;G\JU^U+12N,YN'PG%$DQ:_
MN))I)3+YSA=RMTXX].*O1:'!#+ILBR/FP1U0<?/N !S^5:U%.[%9%'2M.CTN
MR^S1NSKYCOENOS,6_K3M1M&O[":U6>2#S5VF2/&X ]<5<HI7&<ZGA.W2"VA^
MT3%88S$W3]XI()S^53:AX?2\2\"7D]N;I51C'C( /0?7I6Y13NQ615L;-;"R
MBM48LD2[5) SBJNM:4-8L?LC74UNA8%C%C+ <X^E:E%*XS$C\.P)>I<>=(54
M1_NL *2GW33CH>()HXKR6,32^9)A5.X8QMY'2MGBCBG=BL06UNEK;16\>=D:
MA5R><"LW4="74=3M;R6ZF5;<';" -A)[GWQQ6S11<9A0^&[>&&\B\Z4K<0>0
M,@?NTP1Q^?>@^&-/:YL[G:XN+4H1)N.7VKM /;\JW:*+L5D)BN??PO%-=W]Q
M/>32M>)L.X#]V.VVN@HH3L,QQH$/V98FGD9A,)GD(&788Z_D*E@TA8M1:]>=
MY9/F" JJA0QR1P.?QK4S1FB["Q%,ADB>,.4+*0&7J/>N>B\'P16(M_MMPS_-
MF9@NYMWWL\=ZZ;-)0FT!DRZ#;3W'FNSX^RBVV<8P&W9^N14VE:6FEVSQ+*TI
M>0R,S #)/L.*T<T9HNPL9NLZ7_:^G/9FYEMT<C<T6,D>E5%\-VZW,4OG2%41
M%,> %;8<J3^-;O%'%%V*QCMH,+K,K32%9IA*ZX&#CM]*U^E+12N,Q]4T0:G?
M6ER]W,BVQ++"H&UF[$Y]*9;>'8+9KC;-(RRPF%5(&(U.>GYUM\4<4[L5C 'A
M> /9,)Y?]%6,8P/GV# SZ?A6_110W<9@2^&8KC4+V[GNYY&NHS%L;&(U_P!F
MI!X>@^QFW::1F:19'D(&6(&!^@K;HHNQ61DVVB0P:K)J#2O)*Q8J"  F>H&*
MU3R",X]Z6BD,YQ/"<:I=;[ZXDEN)A,96"[E8'(QQT]J<GA:%-0@NC=SLL(;;
M"0-N6.6/U)KH:*=V*R,G2=%BTHDK-)*VP1AGQPH)(''U-6[^V:]L)K9)Y+=I
M5*B6/&Y?<9JW11<9SB>$K>.VAA6YF C 4G RZ@[L'\:GL_#R6EQ?3-=RS->9
MW>8!\H[ >PK<HHNQ615LK-;&RBM49F6,8!;J><U3UO1AK,$4+74T$:.'98\?
M/CH#GM6M10,P9/#433RS)=31LY#+M ^1@NW<./2JP\'Q+:65J-1N?)M9#)MP
MO[QN,%N.<8KIZ*.9BLAJC"@9S@5A7/AI;J6ZEDO[@O.X*MA?W8'\(XZ5OT4D
M[#,.'03#</,E_/\ -'Y:J54A!WQQWZU)IFA0:7*)4E>1Q (26 Y ).?UK8XH
MXIW8K!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
.%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "\ L # 2(  A$! Q$!_\0
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MY_\ UJ-S_P#/1_S_ /K5C_Q+QX5_] L__"K$_P#S01_Q$GBK_G]_7W'[V?\
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M ,]'_/\ ^M1_Q+QX5_\ 0+/_ ,*L3_\ - ?\1)XJ_P"?W]?<?O9_P_J^,_\
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M_$U=_B?OOO?;=Y_::ZRZ_B%%%%6 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/Y]/^"^?_)+?@5_V47Q+_P"H[:5_,$/NC_>?^8K^GW_@OG_R2WX%?]E%\2_^
MH[:5_,$/NC_>?^8K_1'Z.W_)M,C_ .R@S#_U,QA_*_BI_P CN/\ U]?_ *4P
MK]8?"GPW\'>&_P!F/X8?$KX:? +P5^T1J6NW>JQ?%C^W(=0UWQ/X7:"ZU>&.
M'0K/0-5T^:P"6%M9WOFW]E?1ABY) =0/R>K]"_@-HO@SP?<>!?'7A#]KG0OA
MUI5U,NI>,?!WBC5?$>C:Z+ZP>:&[MM)\,:#IFI>&M<MKRSMW@7^V;F 2BX+R
M*' -?0^)U&M.GA\11Q53#RPN;8VHJ4/KW+BI2H8:-.C4_LY/$\JG&,HRBXQC
M4<74;@Y(^:R2.'EB<6J\X07LJ/*Y\M_CGS<O,G&ZCO?5K;6QYAX&_9^T[XSW
M7Q8^)-MK>G_!7X-^ A<SZIK?B^UGU.'19;PWDNF:7#IEE)9ZA?WRQV-RAT^T
M26[#QB,QAV4'UGX1?LSZ7/XB\6P>%_%/PG^,/AY/@YK7C:V\1Z_H6N):6=E:
M/K$"WL&A1ZW8:OH6NFYL7ALSK!,;8M9/LCQR+YGL&N_'3]G_ /:$L_VE_AE'
MXLT#X5:3XM\36'B_P'XMUW3%T7P?J%_X.FUZ0VWB+1]#M+NWMX]6?5K4AK32
M[UY$24.!M0-Q?[/.N_ [X!>(/B_87/QC\/\ B67Q/\$-4L-1\1VD5Y!X0N/%
MEQ-J,%AX;\(R+80WEWI\\/\ 9LG_ !,--T\QWUS<D1 (LS_G4L_XJQ\Z^&Q=
M7'X=0HTG2P_L*SIQHRAA9.K+$0BI5*RJ2K4N18B/\.SPT7>H_H?998E%QK4'
M[S][FU;3DDDN6R32B]8[O25K(U/AK\,O"UC^R5HOQ6\ ? OP3\?/&=[XHN]/
M^(&F:Y;ZAK^O^%M-M[B_2P;1-"\/ZK8:I9+J%G"UPUY?6U[;!HHC\N]5;Y[\
M _L[6/[2OC?XT:QX&N]-^$'A'P8-.UV?1/%DJ*=!T>ZGEBN!;2236(5K/['=
M3?V.X?5-0 2RLD:ZGBW=%\ _#W@[2)/!?C?X>?MB:-\(-3O+N2Z\;>%_%FI>
M)-(U2WU3295B:VTS0=$TS4_#_B33/FNXX%\03PB2(P&2%3(ZI]??#/QI\'?C
M5XW_ &PM=L;T>$O OB?P5X+TX^*;?3;:UB.M-K.M6X\47>BV?_$OLK)9Y+>Y
MNX[2)A#;P/-% TI*'@S',,[RW'XZ.#S'$UY.MSNJJ>8RJ47.M",:3HXAPPM;
MV5-S]A+!RC>G%*K"<U>IK*E@\0J:J.G!6:LW!)JS;?-%.:N[74UOM9;? 'C[
M]E^WT+X?Z9\3OAW\3]"^*W@*X\2GP;JVJV.A:KX,U;PUXI,UTB6^LZ5XFF2_
M;2IX;.YNK:]2U@MIK8V\Z7,D3JS]'#^R%H^JZ+X_E\*_'7P=XN\=?"[PY=Z_
MX[^'^E>']8C$.F:=;7=S=3^&O%LEW)X=UZZLDL[HWW]E3:@)Q]E,,<?F+YGK
M;^*/@S\ _@Y:_!YOB/X:^,B?$+XK:?XK\5ZMX1FOKS2/#WAO25O]+?SK[5++
M3-2FU>[WVL\EHUNUM:PR7-O;7'DPQH_V)JGQX^">AV_QYL+#XS_ *Q^&7BOP
M+X\\-?"#PCX.\":3:>-8(+_3+NVTR+QCXOB\'V.NQ7J":T7_ $?6]32\E%Q]
MHE<*I>L3Q;QY1A@J>%6:8J%:I.5/$_5G35:C"M1CRUXO#IQFX3K-+V.!<X4H
MRC54HN-9++<EBY>TQ.&@W&[CS2?*VFKQTVNDMYV<G>+6WYW']C73-&^!_@7X
MV^.OC;X;\(:3\2M&U2Z\*>&_^$9USQ#XB.HZ;JFK646D7<FCS2I->:A-I,GE
MWD5I%:V\%S%!,OG0RL6M^QOI6EZ3X%B\=_'+PCX!\<_%#0;35_#/@+4]#U62
M\MX[ZUM;C2)=9\2I=+H7A:/58;M)3)KS6BP;6,A3RWK9_:"^*O@CQ+^S5^RK
MX:\.^(K#6?%'@"WU*3Q%X9T]I;?4+2X_X2_Q/=V\<Q\N"*)+FQNK2Z\^*<S&
M.?##.5KO/C>/@/\ M#W'@#XKZW\=_"_P\70_AOX4\*^._ ^IC4)?&EA%X9T6
MRT^8>#;2WT^\TS7KVY,,GDR:[J=@VX1YE0RR$>E0SCBVI##SQV-S"A3KXC%1
MK2CA'4E2]G7JPP=&-"%*M.<<1[L)SDHN:A"4:^'C4E5>57 Y+[*K[+$X:514
M[QBIM.3LG+5PBKK6ROO=6D]#Q_\ 9J^&OA7Q)X7_ &EW\6^'=)UFZ\#>"+*X
M\-7LQ?43;ZPFJWEO>W6FZG83C3YT>TCB=+J/S;=3DLQV,*Z?]@CX0_"?XL?$
M#Q#;_$S5-+3^SM OWL/!FJ>&]>UZ.X3R8Y!K:ZWHK+ID[VO#?8X9#<1&8Q2)
MYD3BH/V./$OPVTZV^/G@WQ'\1/#GP[/C_P %C2?#FI>+9]2BTRZ2TN;V=+QX
M;*QU :>9X@JRPV5OY9.<AB[5UO[-%E\+/V=/C9X>UGQ!\??A?XF\,:YH^M:'
M9ZWX,U3Q/>:5I-[J W74WB"/4]!TR6&*.YCE6,VMO=[4P%4+@5]-G.<8IXOB
MVA1S?$JMB\'1G@O90Q,W6C2PB=2&'E+"5:$7*<9QE3=15>>4G3BYN+?#0HX2
M/))SH\M[.[6_,]TK2?36R5NMMO&/!G[,?AOX@ZUXYET/XQ:#+\*/A[I5CKVO
M?$G4?#NLZ-##J!FU)],L;?PWJ4MMKEW,DU@0$M8Y'NFE2*!3(,5[A\;OA[X7
M\"_L.^!M0\,>/-'^(6B^)_C'.-'\2:;X9U?1+FZL[?PYK:WMGJ6FZEG5-.$6
MHVMP]N]XL"SB*!X]ZS1EZGPEE^%FB>#_ (]_LX^(?C=\/DM?&4.DW_@[XFZ?
M!>W'A.XO= NM6O9M+U#4;G1(=72219;1(2NG3!6G)5E.28?BC<_ _P -?LX>
M ?@/X:^,FD>,O$&G?%BQUCQK?Z2^HW6D:?IU]HU[;3:CX4DO+2">_LK:&_A^
MW+?VUB(K];M(HY$BBDD^9J9OGM3-LJP\JF85Z6&65UGRX6JZ=2A#+Z=6=6K5
M]E3E"HJDY4?9<T7S15-X92]Z/I5L)@W@75C*BVU--J2NI*?+RQWNK+>S5M5*
MU[_G LBN?+@G1D!P)+JUG@E(YY!D,:Y_X#CM3L$#!# AA\S,K!QD89=H&%[=
M^0>:]<^-_A'X:^!/'LN@_";XDCXJ^&U=@NIO8QVIP&P#N$:L/EYR3V^HKR!<
M[I005Q* $+%M@^7Y1DD@?D/2OZ(P6,AC<%3K1<KSRVO/EG"=.I%3P\9)3A.,
M90FE)*4))2C*\9).+1^>UI*.*G3332C4U6JT6Z:T:[-:6)EZCZC^=?UN_P#!
M#C_DT?Q%_P!E@\6?^F7PM7\D2]1]1_.OZW?^"''_ ":/XB_[+!XL_P#3+X6K
M^>OI0?\ ) \-_P#8QC_Z3C3](\)O^1U+UE^;/VEA^X/J:EJ*'[@^IJ6OX+>[
M]7^9_4CW?J_S"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#^?3_@OG_P DM^!7_91?$O\ ZCMI7\P0^Z/]Y_YBOZ??^"^?_)+?
M@5_V47Q+_P"H[:5_,$/NC_>?^8K_ $1^CM_R;3(_^R@S#_U,QA_*_BI_R.X_
M]?7_ .E,*?NDAG!8R/=X'V"YM&^UK N!N#&('8V"X8%@5/!Z4RE4E?NDKU^Z
M<=>O3U[U^V58X:6(QGUFC[9+&5N16OROEI7>SW5ON/SJK4J4ZLG3W:2?HKV_
M$EEEF$Z3>9-.T2^;(3<+(\ERHW+&MHJB0F1MP<;B<[0?=8FN(T:$7)6(M]IC
M"W"^<TSX1HC;8\R+8OSAB2$(WD8!J#ON_BSG/?/KGKGWI,#=NP-W][^+TZ]>
ME2J65W7^Q+=?9\UY$+$XC31[HL2RS-\MG.X<_P"J#'SY?.'%QB9-@#-)DDA.
MO/7->H_#SXQ^+/A=H?CC0O"D4"67Q)TFW\.ZPUXWVR=;"-[CSY8XHS RQQQW
MDKH"&"L"<]J\G'RD%>""2"."">21CN3R?7O0.""." 0".H!X('H".H[UEB\M
MRK%554> C)*49.].Z3C)2B[-/5-)IZ--)IK==7]H8CI==]_Z_P"!H-MT,#K;
MVR644!,UP)9T%@]U<+OC:.,S.<[XVDD &XEES@BG6[Q1Q%D-Y+:@V ;3(=S
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M ":/XB_[+!XL_P#3+X6K^2)>H^H_G7];O_!#C_DT?Q%_V6#Q9_Z9?"U?S?\
M2@_Y('AO_L8Q_P#2<:?IOA-_R.I>LOS9^TL/W!]34M10_<'U-2U_!;W?J_S/
MZD>[]7^84444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?SV_\%];B%/A?\!8FFB26;XE^)((E=PH9_\ A';0L"<<%5.[')Q^=?S&
M!"HD60$,LSK$T?[R*559ED;S/EPR,%7: <Y)R,5_7E_P5S_9>^-_[2_@OX5Z
M1\$_#%OXIU3PMXNU_6]3MKS4M,TR.&VO-#BLX]DFI7=FA;?&=I61CD\\8%?A
M-;_\$F?V[0L<<?P>@62(222D^,_"'EM)>/\ :7"9UHDB-F9>"0._:O[;\!_$
M#@GA_@B67\0<2TL#B,-BL3BL)A)JFG1JSK5).:;H2E-SE.;<9RG%-I))*Q_.
M'B+P[F^8YTIX;"U*D.=R4HQ;5N9M.Z\FC\Y=IZ88?A_/)&*-OLW_ 'S_ /7K
M](W_ ."37[>*CYOA!9^I_P"*S\']3W^76CGZTG_#IG]O \_\*@L^>?\ D=/"
M'_R[K]HH>+WA3/"PG4XQP]'%U*U6>(J25.]5RC"WNO"RA&SC?W(QW/A%PCQ$
ML153P59I1A:]/^]+JXM'YN[?][_OG_Z]&W_>_P"^?_KU^D7_  Z9_;P_Z)!9
M_P#A:>#_ /Y=T?\ #IG]O#_HD%G_ .%IX/\ _EW5_P#$6_"G_HNL+_X#1_\
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M %Z"N>S=C]WT.?7_ #[=_P!(O^'3/[>'_1(+/_PM/!__ ,NZ/^'37[> P/\
MA4%IUSQXS\'GD9Q_S&NG;'/7-.KXR>&4*;5+C#!8YRM3EAY>PI*5.I[M1^TA
MA:4X\L==*BO?J3_J;Q ^:V!K*7)*WN/MVM8_-](RS*J\%C@%_E7/^T<G _"O
MZV?^"(!-O^R3XD61'&SXP>+A]TY.S1/"S,<'^'!&&[\U^(,G_!)K]NIT*3?!
MJSGC8$/"_C+PD%D']TE-=5\$C^%EQC@U_0W_ ,$L/@!\5_V<_P!GS6/!/Q=\
M,V_AKQ5<?$OQ!KT6G6E_:ZC;C3=4TSP_9PL)[*[O8C\UC.&'GD@+T .3^ _2
M!XZX8XKX:P. R+,L)B?J>+I584:%>-5TH\F(4I-WYFE*I&]W*U]%8^U\,<GS
M7*<YE4S'!5O9OF2<H2BKWTU5O-]NY^H]LV^%7QC=D@'T/0_B*GJ"W9'B!0$#
M+ @JR_,K%6P&P<9!QV(P1Q4]?QK"[A&\N=\JO+^9VU>EEKOHD?TDVI-M*R;;
M2[)ZI?(****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 457WR^J_E_]:C?+ZK^7_P!:JY?.
M/WHKE\X_>BQ14*N^?FP1[#G^E/WCT/Z?XU#;3MRREYQ7,O2Z>Y$G&+LY13WW
M0^BF;QZ']/\ &C>/0_I_C2YG_P ^ZG_@#_S%SP_FC]Z'T4S>/0_I_C1O'H?T
M_P :.9_\^ZG_ ( _\PYX?S1^]#Z*I2W+)*%7;M$1<JX*Y.[:H$F=H)/&W!/?
MI7SI\9_VI/AO\!=6\-:/X^NM9?5O&5MJ-UH&A^&?#NJ>)M5EMM#:T36;AK;2
M8KF>2.V;4+/@0+GS, ^E4(U\376'HX3%SJ/X5&A)QFK7;C)2::2W>EK.ZTU5
M2K3I052<DHO9IW_K[SZ8HKX/_P"'A_P('72?C)QV_P"%,>/OQ_YA/'TSGTIW
M_#P_X##@Z1\9/_#,^/A^ATG->E+)LVC\678Q7_Z<3?ZF$<;AI*ZJ?>K?J?=U
M%?"/_#Q#X"_] CXR_A\&?'Q/Y?V32_\ #P_X"_\ 0'^,_P#X9;Q__P#*FI_L
MG-/^A?C/_!$Q_6Z'_/Q?>?=M%?"7_#P_X"_] ?XS_P#AEO'_ /\ *FC_ (>'
M_ 7_ * _QG_\,MX__P#E33_LC-/^A?C/_!$P^MT/^?D?O1]VT5\)?\/#_@+_
M - ?XS_^&6\?_P#RIJ _\%#_ (& G_B4_&(C_LC'CX?STK^E5')LUE>V7XM6
M[T9K[B98VA&VLIWO\$>:UN]FK7Z;W/O2BO@T?\%#O@6?^83\8OP^#'CX_P#N
M)%2#_@H9\"OXM*^,?;_FC'CW^FDU$LIS2&LLOQB25V_J\[)*[;;OHDDV^R39
M4<71EMS_ #C;]3[NHKX4_P"'A?P'_P"@5\8?_#,?$#_Y4T?\/"_@/_T"OC#_
M .&8^('_ ,J:P^J8G_GS/_P%E^WI^?W?\$^ZZ*^%/^'AGP'R,Z5\8L>WP8\?
M^A_ZA-._X>%_ 7_H%?&/_P ,QX__ /E36U/*\QK1<J6"Q%2*?*Y0I2DDTDVK
MKK9IV\R7B:2T<K/S/NFBOA0_\%#O@&"1_97QDX_ZHQX^_P#E333_ ,%#_@(.
MFD_&0_\ =&?'P_\ <35O)LU2N\OQ>G_3B8OK=#^?\-#[MHKX1_X>(? 7_H$?
M&3_PS/CW_P"5-+_P\/\ @+_T!_C/_P"&6\?_ /RIJ?[)S3_H7XS_ ,$3#ZWA
M_P#GXC[MHKX2_P"'A_P%_P"@/\9__#+>/_\ Y4T?\/#_ ("_] ?XS_\ AEO'
M_P#\J:?]D9I_T+\9_P"")A];H?\ /R/WH^[:*^$O^'A_P%_Z _QG_P##+>/_
M /Y4T'_@H=\"=DTHT3XS&.(1G/\ PICQ^"QD+#:J_P!D'D%>>3UIQR?-9-)9
M=C&WLO83']:H:VFG97W6Q]VT5^:>O?\ !5/]F'PUKT'AW5A\78]5O-!/BBVT
M^'X)_$&>[&A+J3:.UR\4>EM)QJ2-"3L  [=Q27_@K5^RC_%;?''_ ,,-\2?_
M )2UM+A_.XKF>5XVUKW]A.QG''X:4G!3U7HEKYW/TM.[S9,E=I(X[X[Y]_T_
M2B3"+NC^GKQW/<?3Z'-?F;)_P5B_9.D^]!\<QR3Q\!OB4.O_ '!>?RJ)?^"L
M'[)L(RD'QR/;YO@+\2B.?^X**Q629U3DE1R;$.$GS3:I3IW;UDW'D?,Y-MMW
M77N8SS;+77C[7&9<E2O!J>)I\\91]UIQ<?=DFFFKZ.Z/TRC=IA^\P>3VQG X
MZ8[^G^-2[,= N.W+=/SK\R6_X*S_ +)[+M-O\<0/;X"?$H=\_P#0&Q4P_P""
MLO[)^!^Y^.73_H@GQ)_KHM5/(<UF[/*<8H+6*5">C=D]+::)%3S?*'5E..,R
MVSBE_O5-/1O>T7IKH?IAL/HOYM_C1L/HOYM_C7YHC_@K)^R@<_N/CF?^Z"_$
M@?ST2E_X>Q_LH?\ /O\ '/\ 'X#?$C'XXT2L_P#5[,5I_96-_P#!$_\ (7]K
MY6]L7@'VMB8.[[+W=6WHO-GZ6[#Z+^;?XT;#Z+^;?XU^9_\ P]C_ &4_^?;X
MY?\ AAOB/_\ *6G+_P %9/V4?XK7XY?^&'^)']-%H_U>S'_H58S_ ,$R_P C
M19AAG]F"]6D?I8RD*3A1@=LY_7BOD3]O$Y_8K_:CSSGX#_$S/7_H5]0';V_Q
M]Z\-E_X*R_LH+&Q%K\<L@?\ 1!OB2>XSP-%R>.U?./[5G_!2G]G'XH_LS?'K
MP!X6TOXV76L^*_A3XR\/6$4OP/\ B):EKO6-"O+.W0>;HPY:1P *UPN19HJT
M'')\3[-23G.5.49:--Q2<=8N*^+FW;5N\8C'X:-&4?90J5)*\4DI12::UET=
M];6VUOT/U"_9=V_\,]?!W/4_#_PWSGI_Q+XL9KWD9.%].<'^N.>]?CE\#?\
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MQ^.7_AA/B3_\I*:X=S)[93C?_!$_\@_MC*O^@W+EZXJ"_P#;3],-A]%_-O\
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M  \/^ O_ $!_C/\ ^&6\?_\ RII_V1FG_0OQG_@B8?6Z'_/R/WH^[:*^$O\
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MF4$B++8. <@8.1Z<5:^UVYY#0X/(_> <'_@)KI;Q:_YC,S3ZWB_NM[-/OO\
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M;ZWB>731/E]M;KVT.R_X6/\ $/\ Z'SQG_X5&N?_ "=1_P +'^(?_0^>,_\
MPJ-<_P#DZN/\J4KN\I\X<A, .3&-TB!2>60<L >,CFH8Y/->:*)'DEAC226-
M5RZ*Y4 $9 R=ZY&:UQ7"O"D<QHPIY+D3@^6\5E67<KNUO%8.S^:%+/LVI[XS
M&OO?$XC]:OW_ ".V_P"%C_$/_H?/&?\ X5&N?_)U'_"Q_B'_ -#YXS_\*C7/
M_DZN.E1[<S"=&A,$8E?S!MS&P8AUZY7"D]N,>M+&AEB2YA(EM9&5$NHSF!I&
M8+Y8<X.]<[G&W 4$Y)&*A<)<*PJSYLGR.SJ3T>5Y=9+FEI;ZGHELDE9+1;(7
M]NYN]5C,=9Z_[SB-M_\ G]INCL/^%C_$/_H?/&?_ (5&N?\ R=1_PL?XA_\
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M"-:O!2>59=)ODK5(M7>";]UQY4NB21XLLUS6#<?K6+=F]?K%=]7_ -/#M/\
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M?[$VG**2;6K2L[I(_&Z&>YH\+33Q6-E)I7D\37;=NO,ZM]?,[/\ X6/\0_\
MH?/&?_A4:Y_\G4?\+'^(?_0^>,__  J-<_\ DZN/*-D%2)(F?RXKA#N@F88
M$3\%MV1MRHSGZTUQ+&D;R0RQB:;RH@RX9\!B95 )_<KA@S]BIX.,UY\.&N$G
M7:>49$U?;^R\NMHWT^IV_KU#^V\V_P"@K&^?^TU]O_!VC\]_O.R_X6/\0_\
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M /J,:G7^>D?OR?\ ;;/4_P ?MS^5?Z%_QT&?@[\4/;X=^-S_ .6QJ=?YZ/\
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M[-M-VU2=D_F#X=_'S]HKXI1^&+;2/@I\/_C5XT^'UC!:^'O$6J?#&\\<^/\
MPQX?L[J6XTY[/4K;4%N;1;?4))WME6W58IV)&6R#\Q^.+WXH_%#XJ:T?%<?B
MCQ1\2];UJYLM5T5K2]O_ !-'=1SS*WA]=""R:A&-/9#:V]FP9[."V$!5BA-?
ML-XWO/@W\/\ Q;\1/"Z>-])^!NH?%CP]\-O'V@^,DM/$7E:9J-MXET:?7/#E
MM'X?L=1NE$]MH]W=H@M7M9'U 0F1@6A6MXY\#ZO>2^,OB?\ !3PO!K_Q?\=Z
M)8:5X>U"XN=(T.]T?PMH-DFDZM\3(KC6[O2M+L]7\7W*:9KVCVFILFI3V6J7
M#OIR2Q3)%\WD_%& R/.\3BEEU'#QQ6&55^WI58\M>O*E.3K56YX>-&G.?+4C
MAO92]I"<W&3J0F_1QN68C,,+3P4:DKTZT*MU*WNTXSCHKIW?/>\KJUE?1H_%
M.T\#^,;V'Q%(GAS4YHO!TT2^*1%#++!X?LI9"EN^HE8MEM!/(EQ'#),8UNI(
MY84PR-CF@T=N#+"SP/M8D0L$MIHC($CB\C!VLT;*V[>>A&WD8_0W]D#0/$>@
M_&SXB? GXD:;J=G?>)_!GQ%TGQ1#>&UG?4=4@\*ZG+H;Z@ZO,6CT_5)_M5A+
M9L ;AI-[N@4#X(US1_[&U_6-"F.];3Q!JFFQE2#L73+B[M0K8'&3;#@]?<\5
M^RY-Q1A,QSQ16%BH1^KRI5(4VX5(5(7DKI-<].I"7-RVAR3I:N7,SY/.,OKX
M"BE*;D[-.[;:<=.[\M];I^1GLY3"1F00Q!1#932>98*X^](]MM4.[8&6#KT[
MU6\BU59TCL[2..X<2R*(1Q,-OS(01L!V@8^8]>>:>K%E5F&"0"1[GKZ4ZONI
MPP<ISE_:F70YIRER2RVG*4.:4GRRD\NDW*%^5OFDVXM\SO=^-&&*<8M5FDXQ
M:7/LG%:;]M!@C0)'"N[[/&)G$+-N47$S*QE48 "[@Q*8[CYLCE$@@\ORWC"(
MMQ]JA2W_ '*0SX3#QKAMO**<#N.HXQ)1_G\ZPQ%# O"SF\1A,:X8C"N/L,)#
M#NDW.I=RY<)A^;GLK7Y[<KVOKHZM>A1K*=1SYU%+WKVMS>;[G0^$,?\ "6^&
M"5WR-XCT9I)FYED+:K:G,KXRY4':N<84 >]?Z)FD?\>.G_\ 7M!_Z+6O\[3P
MA_R-OA?KSXAT7Z#_ (F=K^>??\*_T2M+.+#3N,_Z- 3^"CKZ9&*_C/Z6E2-7
MBKAY05E'**BMMM5HO]#]\\').I0Q$O*_X2;-RBBBOY(/V\JWG%N^/;^=?Y]7
M[1W'[0_QS()X^,/Q%P>O7Q?K?7G_ !].]?Z"M[_Q[R?A_,5_GU?M&X/[0_QS
M![?&'XC#\O%^MC)/8=#WQ7]4_16I2KYOX@4HNSGP_D"WM_S.L?YK9:NU[+5V
M6I^'^-TY0R3#R2;2JZI7?6'17_+YGUA^P?JNK:+X3_:?UC0I[^VUC0OAE:ZQ
M:75B9$DM?L<7B*X2Z9T!,WV5H#-#$IC*.I(?YLC[Q^"-KH'Q^L[K]K'PC:PQ
M^)KGX:ZGX,^,6D+"MU?P:_H>CO8Z;XGQ'Y4MHE[HFCV8G2>*1FN+XR_:"#L/
MX7>$/B3XW\ V^O6'A'Q'_8NF^+]+;1O%*^2':ZTTI.DEKS;REE:.ZG7*G_EI
MD,.:Z7X9_'CXK_"*W\2#X=^,=2\/0^.-/GT_Q)I=C%826.M6*!;-8)4U&VGB
MM#/;VT,IEA-K,6&SS '*M_07$'AMFF9XW%XO#XG"4ZD)Y<Z4\7*M["5">%H?
M6J=;V3G.4)*$90<*511K4Z7,M96_+,MSW#T,JRZG4A=>[S*RNFJ;Y7JG:SWN
MKM-GUAJ4,NH_\$\/",NF+=7$[_$[Q!->K#)]HN+;3;V733I4$WEIOA%TD=PJ
M,X 4HV%;D5]F'7O'7PM^-/[$?A_1=5USP;=7OP2M-.UK2+*66RF-E/XS\77Z
MVK6059)K:83)<%,#=)*T@.#7Y&?"O]HGXN_!G2M7T'X=>,Y=#TW6KC3M6O/#
MM_H7A_7H;.6R:YDC\E-?TC5+.)R9W#JCC&Q>P&)_%7[0WQC\<^(_!/BSQ?XZ
MU'5-<^'L6/"NL7=KI5OJ.C-'J%WJ2BW&D64$$D0ENYEC@U2.:U <((PFQ1Q5
MN ,YK2KT)5.')8:5;C.O2E*>.J.3XGRW+\#A(3HRRMPA##U,#*=.:J3UG+W*
M=KS]!<18.-FH6=U=**5DK-:JUWUM;1];L_3WX+_%GXE^)?VT?VE=2\8>*]0\
M83^!O _QOM/!^E>+;MM8BT>QLO%NB0V-JVF2M');:)Y$%ONM2RJPBML3#RQN
M\0^$OCSXX_$V3XH_'WQ[\>-<\&:5X"&E^''^)D^BW_C7Q3X4^WZM-96VE> K
M6UU72[K2K*^:^2QU.>&:XC>PN)(W15C8M\D:C^U3\?M:\3ZKXUOO'=W;^+=5
MT#7?#NH>(H_#?@RROK[PGK]U976J6-W!I6APVUQ+=2V-@\-U);M<[8G;[0ID
M<OS7PW^.GQ.^$-YJMU\.=>3PW-KMJD.J6KZ?I>O6.HQ+)+)%=W^F>([/5=$^
MTK-+)(K06RM&R(QQM4CSJ?A'G;P^8U*=?AFG7EA,)1HI?7)QHPH86E2Q-.ES
MY5R4H59PG><:$H2;4JU*I&"I'3#B?+HJ,944[-N7N+F=VVFU:[:5OM>2DMS]
MJ-?\.^%/'OQL_8R\6>,M?7XDZWKGA;Q9>-XLU_0)?!=_XXO=(.HQ^'&G\-ZK
M=:G>:G<PVEM;*UREX_VAX3.B1K(J)\>>!?BW\<_C]\=-,^''[0=SJ'B7X=7O
MQ3\)67C33_$EM<W&F?#J[EUX10:#I-Q<L;?PT=8;SK-;:=9'U#[&D2(3;D5\
M4^,?VC_C5X[USPEXI\1_$#4!KO@"X:'PO=)IFB6!L[R\:2[9X(-,TN"WM+=U
M:956*&* HX4 AAF_\1?VG_CE\4+-++QMXNBNK+2;T7UQ:Z;HFA^'Y;NY=D:.
M^U'4-$TK2]0OKS26A^T6$\MU-+#-))(S$MSX>5^&G$-%5%A\;E-:MR5,/1K8
M>=98K!J4L4WB,&YX'#PC->WA3DJ-3#Q4:=).,Z:]DYJ\2Y?4@XQPZC[T9/W$
ME.R2:DVK6=KJ[D]7UU/U7\;_ +0WPO\ "GQ0^(G@_P")7[2_CO6?AO-9ZCX4
MU+]GS4_@[XAL/"^FV^GZ3G0H+6YN?$,UEIKP3VVF:R-4?3I(KR$&6.&(722+
M\A>-;73;[]@OPC=^#XOM&G3_ !M\5Q:+<_8RL.IV=UJ\S:78PRJ=ADNX$S:6
MX+F958Q@[#7@<W[7W[1%UI4VEWOCBUO;>?24M);?5O GP[OM7;3D1;.*TEU1
MO"\]Y-OMDC>.\N[Q[XHR1M<<!*Y/X;_M'_&CX266IZ7X!\<R:'I6KZC8ZMJ6
MFWOASPQKVE)?D7,EI-;Z?KFB:I;Z7+I@GN(V;38+624R@KYPC!3T<F\,>->'
MZL\="M0K/V\*T:,L7&C2K2490G5JRPV'2C6E"5W*="O.3?+*HU%,YY9[@)-<
MU*T>5IOD3:N[V2E)W5]K.*7:[/UOT_7?'/PV_:5_9!\.:7?:CX O]8^!-AI?
MBO2;>6319]2T:VU?Q?J%GH.HV3A9#%'=R27T<$H(=[G>JY<$^:_LY?$3XA_$
M7]MGXTS?$;7O$GB6Z\-Z'\5M&\/0Z^EQ/#IGA^V\40V]CINGVD^6EM(K.VM$
M01.B%88V4 8%?F?X@_:%^,OB?Q=X:\?:WX[U/6?%G@2VMK?PAK/V;1U;1H5O
MI[G[/:J+*)[R$RW5P^S4([K F:+ B5%7I;_]K#]H6]\<W/CW_A,WM_'']ER:
M -4AT+PM92:E:ZRD-U=6=Q%I^CPVK/+]F5WFEB6YW1Y,P+/NU?AUF\XXS$5J
M_#JQ.)RO.JF(FOKL:CJ5LWPM;DD_J$IMI5IQ]ZK*2Y9)73;&^(<)9)4O=3]U
M<JLM$GIRV5[*]E;UL?:D?C'QG\"OV&O OC3X'ZAJW@S7?''Q:\8_\)SXUT"6
M2TUV..SM_"DVB:5>7,"K)I]FMY=7H N&9,7$H"@AJO?#F^^-VEZ%XG^/?CWX
MH:C^SU<^*/'?A?2F\0^!?ASK&M_$GQIJG_"*V3VEMKK:?KEA>W7AS4[*U74;
MB-X#'<W@@OA+M*H?S_\ AG^T5\9/A!::WH7@+Q==:/I>J7AU;4]%U_2_#/B7
M2;W6H6\^Y>R@U?3M8M;0W6V&-?+%N'VJ%Y7(Z+P[^UO\?O"=UJ=[IOCV&TD\
M4WS:GK/VC1='UE;?Q +8VUI-INGZWI&H6%J8=,1(5^QVT=O#@I&%48HS/PXS
ME/-:5+$9+6^M9AB9SGA:E6=:M2;HU7A\1'$X/D5"DOX$JD<91C+G?U:"LU:X
MCP:<6Z33CLE&R32MS*RCKWMRO;WNA^OFGZ;;6?\ P4.\ :O!.]SJ_B/]GW3/
M$OB;7?[+D\.76MZOJNG6MSJFIZEIEQ+=3V4VI3%IOLMQ/++$=Z-)(06'QY\
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M^N;J=@Q,LC>8V6"J =TA.",D@\<&O1/V=,G]H#X(,22S?&+X:$Y&.3XST8$
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M-/;EHP&4MR[$;L.6!D:-60''G7#QEFN&.""$(=-G4LV[<,8/WU^SWI=UX]^
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M:Z^/V;;7X3ZMI_AB?QQK/QJ'C6_^P>(IK GP<_A>"X(@N6T+^T9;(7S1L'=
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MNZIHZ3ZA>7EPB12SRS%P6=DC09()X].*YT_\$_/V+LX?]G'X92D #?+H2,Q
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M23QJ[!R2P_MV_P"'?G[%G_1MWPO_ /!"O_QZC_AWY^Q9_P!&W?"__P $*_\
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MM8G"_P#"S]+CR> '>QU JI)X!8*2,X''6O[L+9E8@J00%QP0>U?(/A+]BO\
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M9^OY'_"C(]_R/^%?W._\._/V+/\ HV[X7_\ @A7_ ./4?\._/V+/^C;OA?\
M^"%?_CU*/TH,AA2C2APYG<5&;G=5LLN[IKE?[^UM;Z).Y<_#B<XI/'Q5G>Z4
MNUK?!8_ABR/?\C_A1D>_Y'_"O[G?^'?G[%G_ $;=\+__  0K_P#'J/\ AWY^
MQ9_T;=\+_P#P0K_\>K3_ (FDR&UGPUG+\W6RV_\ Z?"/AO)6_P!N@VNKB_\
MY _ABR/?\C_A1D>_Y'_"O[G?^'?G[%G_ $;=\+__  0K_P#'J/\ AWY^Q9_T
M;=\+_P#P0K_\>J?^)HLB_P"B<SK_ ,'9;_\ +P_XAQ+_ *#H?=+_ .0/X8LC
MOG\C_A1D>_Y'_"O[G?\ AWY^Q9_T;=\+_P#P0K_\=H_X=^?L6?\ 1MWPO_\
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M_&_C_EO$O"F<<.87(\?AH9G&I*>(Q$\)*=)RL_<C2KM-)Q6DE=I[GM\/<!O
69I0QKQO/*-134$O=?*[V?[M27WG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $= NL# 2(  A$! Q$!_\0
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M$^.+*YU#P^=:L8]/O'M[:_O-);[1#%<7:H3>V,Z<328P/>O\O9"0RCLQV,"
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MYBG4R0D(Q R<=,XSS1=+5[+5Z-Z+5Z+5[;+5B:;32W::735JVY_!S_P<(_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLM+:+3MY?+;Y'[:]][^??S^>_P PHHHI@%%%% !1110 4444 %%%% !1110
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M(#GZK&/\:Y7F<:?OO+:$EMRNG)K31Z*=U=^9V?V9B;<O]JXF^_-[17M+5?\
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M0_A5_P"'H\"?_+:OT=/Q;^%V3_Q<KP#^/BS2,_C_ *;1_P +;^%W_12O /\
MX5FD?_)M5^]>O]F4%?6WU>MI?6V_2]OD7S8#_HJ:W_A?A_\ Y$_.(_&?_@KC
M@_\ &(7PJ/\ W6CP)_\ +:J[?&S_ (*XJ,G]D/X4^F/^%T>!,Y[<#53_ /J]
MZ_24?%OX79_Y*5X!/L/%FD9/M_Q^]ZZ/0O&7A3Q3%=R^'/$6@Z]'8.$O9-(U
M*WU)+9VW;5F:TDFV%@K84D$[6(! -8XFO/#X:K4>54&HV?,J%5272RE)V2;\
MFVT5&G1Q+6&PG$F(J5JKNI0Q=&I.*CHU'EA)ZW3:Y7L?ER/C9_P5R(X_8_\
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M<?\ HT/X5?\ AZ/ G_RVH/QG_P""N/\ T:%\*OQ^-'@0?^Y6OT=_X6W\+O\
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MT"".."SAAUX0=>G/T[=^X.*KR&.(L\TBHB+N=I&50HP>6"D@=.N!P*BKF/\
MM$.7+,,H2I27+"C/D<GR<KY?:-\V]GS6U?N]NRIE\IQN\VQ-.,%[THUH1UCN
MY2=-I=;K\CX$_P"%N?\ !0@?\VI>#_\ P]/@4_RFI1\7/^"A!_YM3\&_^'J\
M"_R$W'XU]AS_ !<^%EK))#+\0_ Z31,4ECE\4:,LD;@X9'0WH*,IZJ0"#D$
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M ,+A^%?_ $4CP)_X56B?_)U'_"X?A7_T4CP)_P"%5HG_ ,G5P?5\R_Z Y_\
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M,ZZ&)PF+7/AL5"JH](5(24O51<K_ "L6:***V.D**** "BBB@ HHHH ****
M"BBB@ HHHH **** /Y_/^#C%43]AW2+II%@D7XV>!K0SNNQ'TZXT+Q>]Y9M,
M2!LGEBA9A@C,8!!(K^')Y252#S+>WB0M?0QVDZFVE%T!"8IBHVEX1#YJ@@X9
M@< FO[E/^#C!5;]A?1MRAO\ B^W@!>>1M.@^,R1M/!R0.W;WK^&O89$"*$W%
M9&CRI \Z52BX*C"$MM"M)B",_-)M3<:_I+PCP&$Q>28R=>A2J>Q=24G.$9-K
M>T6X/HNKW;[G\:>/>9YEAN*,LIX+%5:--2A&I!5)Q3::O91FE;6VMB,MC!\R
M+^\!YZ]^V-OM_@:7>/[\ ^LP/_LO_P"JNM;X?^-1I3>*+GP7XQB\*:;9+?:E
MKMKX=U*72X+59([,W$^H?8I+26%[V:&)IK25HE:0*SCMRYBF2!E-M$]R'9S#
MYT2RQ+;_ #72-F7:\<:LI:1,KCD,:_2\+A,AJX=IT,)2Y*LK^UITU=V>B4:<
MM;*^MKH_,\RS#B&&(IUJ>(Q56G4H0BHTZE3FC).,G*5ZD8\MM-&W?R(MX_YZ
M0?\ ?X?_ !-&\?\ /2#_ +_#_P")KJ=1\(:QIFG6>L3IILNFZM,T>G36E_9W
M."ML99%N$AN9)8=A27YI5C0L%4$D@5C:1I=_KVH1:7H&EZIK6K7#06T6CZ?I
M=_?WTS,I!N+*WLK>2:X61L$,BRJ=Z8'(S4L#D$?L8%Z7NJ<?UI+]#CCFG$<O
M^7F,7K5G_P#+OZ^\SB5QP\6>,_Z0,_EMQ^6?ZT;QQAXN@_Y;KU'_  $=>_7Z
MUT.N^%]=\*W,%IXLT/6O#4MU</$EOK.AZKI5]-"J!H;BQBU"UAWQ23;H99G1
MHI%22. F=2 NO>%];\,)IL^K65G$=71;K3[.'4-/U"Z>Q.U8YKJVTVZN+BV>
MX#QS+#.D,R!MKHI!49?V?P__ "X/_P  C_\ *SAE6SO#32=;,Y2;NG&M-I7?
M7FKIVU.=W _\M(?IY_3\E_J<=L4;E_YZ0_\ ?\__ !-;.I:#JFG[8Y],O[*6
M1S';7&IZ;>0V%^^1F&PF$$8>?E-BF0C=)&&&#S%)I%^NH/I":;J?]I*]NC:?
M+93'49&E@CN=UG!'""Z&-MP)1_D#$=,U+P&0)I*GA'==(0LM;=8'5/&\1J$9
MRQ6/M;W8^WJW2_\ !]NRT,O<O_/2'_O^?_B:-R_\](?^_P#_ #R.GYUI+I-_
M//J4$5C?K/I[SK=V[Z;=I)8QVY*LUPC0!PPPWF!00"O %%MINH:G!>7=IIUQ
M):Z<!=WEW965T;2TMIB+.%=1DGC86X>[&(BS1EY71!D$ [QRSA]+G<<'+E7,
MZ<8+GG;7EBG3Y>:6RNTK[NQ%/,>(TI5XXC,(J@G5<I5JO*E!<UW:O+2RUT>A
MFE@,8DBZ?\]U.#SZ@U_3E_P;1WA/Q2_:AL$*FVM? WPYU&)8KQ;B0:A?Z_XF
MM[UUC55^SL\%O "O+<#)/%?S'8'EJ0!NWA6.!G 8@Y&,#TZ#G.*_J"_X-G(X
MV^*/[5<>Q=B>"/AHZ@* 0[^(/$JN=PPQR%'!8@8X KXCQ,P& PG#M7$X;#4Z
M:J0BH\M.G&<;SAHW&'6]G9O1L_0/#+,\[QG&V7Y?B\?.K[?]_K5K.FH*,IM-
M2E=RM'2RM>UW:Y_7Y;%5*JORYC+L)/\ 7,VX#+YP< <<^WK5]9%^[D ]<C'\
M@/3O56*-%?A1PO<DG!8DC)R<?R[5:\N-7^Z!D=<G^9/H,5_*%>I546W[/GE5
MG9N[BH\VB?NW;[^[:^Q_=%/V33BE/FIQ5*3;WE37*Y+5Z/IULM;'\P__  <K
MXA^ O[._VE[H23?%W6K=)+!&A:17\(:JT,$KJ6/E).RS8.1N!.,G-?QV2,=P
M$K*EQ$BP7"R3\F2 ;&DX7.Z4Y9L@$GGDDU_8C_P<HH#\"/V>5D,BO%\:==2!
MI SB\=_ VID/B($JD0;'RA<>5N/))/\ 'A L<[QP3SQB**Y+W-[:1R ;XRP>
MSD:Y#;VG8ELH"1Y1 9<@'^H?"O+,OQF059XBC0JU_;24;PBVTIP_FCHN5O1/
M1=.A_$WC)F6;X3B>-*CB\32PSBVTJE2-GR.R7)-:<RWZ_<1AB"#'+&) 04*3
MDN'!^4J-O+!L;??%+.D$@\PARX_X^M1U"X.R-NZKO08.>V_/!^E.C!"1A51Y
M6FN&F$P*M;QI&#"H5 I.^0?+PS$G STJ]I,*RW-C'$L,<1UJREFAUM@=+B )
M,LVHK:LM[=64CY*V]A(UXF^,2( DH'Z)5R?*Z>^7TY6[4J7ZH_+J6:9M5VS7
M$1]<1B+?.U3^NI121(BDBH1;QXBN3/"8;5H;P^7#=1SME'\W9)C YV=3GC<T
M?PYK7B)]0&C:;J&MI8PG4KVYM;EE6QM(]EMO55@F#H"45@&0;&;/I7[6_%*P
MT+QU\'/#ECXTUJU\&>$O[2^'.CPV^F:K\'K_ ,":UI$VIO#J6IZ!I>A1W_Q?
MTF6.T97F3Q?/ 84^S;X4=;C/$2?#KX>V/C&TTW5_@O\ !'X?>#8]+:P\.^*-
M!^(^J:EKGC/R+9[ZUF\56-M\0-5M],M+AXA?2H=.TF8M''  #((7\6=?!4YU
M*<,HC*%.4H1DJ.'DFHMK?EUU33NM[KI<^CP^$S:M1I599[;VD%/EEB,7S*]W
M9I-J_P _F?C:D\D,\\C&W$226T#1V=NL3QS#S!:)=7"NVYKD"0Y=%+%&(![1
M*AC&QY;4L"=Q2Y7;DDG P,<9P??.>:_=CXK:=8^-?A7X9A\52:58>&]-\3?#
MBQM?"UAJ/PKNO"OBR"RMM1BC3PE;>&/-^*=B&0!9I?&5\@;SX"[F19FKK/$/
M[-?P+B=UU/X&?!+PKK_A[Q;?+HGAF+XAWJR?$'PQ_P (EIMZCZR][X]G_LFY
MCO9K^2UC>?1V>Z@B5XWA<(_-5Q^$I1B_[$<N:7+[E##.SUW;47;1+U=K'2LO
MS5W]GG\(R2NW+$8RS796;UO;<_ !"N[_ %D'(_Y^1]?3VJ7C_GI!_P"!(_PK
M]I/CO\-/V3_A_-I'AW3_ (;_  VL9_&?B7X;&_U"U\4ZCK^J^"[+6O"=YJ.N
M:=IM[HGB?4- %I#JS06VH2:H+N>WGBCC26("7/Q;^V+X3M/">MV&E:3\&/AA
M\,=&M-2U:'0=<\!^+I?%$_C2VCM;1GFUWS/%_B:WTZ*TC9;FQ\N'2VDGGN$E
M$RHD:=N$>'Q:3CE5*G?5>THT-5IK[D7IT^7H>5BJN<85M2SFI4M_S[K8IJ__
M &]-'Q46&3^\CZ_\_"_X4;A_STC_ ._Z_P#Q-,C$C*J>6C1W&[_2FV"6 J2&
MV#A67((!*-D<@\YH"J%^0M(H9D$DD: N4X+?*JCG.>@'IWKVJF5Y73:4LL3;
M2?NTZ-KNU]TNK?3:QXM/-\TJ<S6:8A<K:=ZU?HWVJ^0\,0<JR,PY55N55F(Y
M"JVT[23P&P<'G%?US?\ !LY*@\!_M5(TMPPM_%WPWEDAO+PW\EB+K1O%DMS%
M"Q2/8D\H5R H#; 2#BOY%CC!X4<'HJ@_GBOZZ?\ @V8Y\%_M7N0"S>+?A3&Q
MP.47P]XO !XYP .>I[DU^<>*.7X3#\.NI0PE.CS3IWO"$9.]2VCA'M=.[^3/
MU'P=S',L5QM@J53'UJM",:GM83JU9-M<KCRJ4Y+9/5V/ZD8$E2T5"[N4(42L
M=SR#.=S>AYQ@DD #GL'W!Q"8BX4R* &==ZC!&<ID;L=@2!G'OE\*+''($& T
MI8C)/.%&>2<<#H,#VHNDW1.RQ^9(JD(,@'YB <%B%&!DY/''X5_,N'G&=*TH
MQ4(RDFK*UDMW=-:7UTV/[8G3I1QE:4O:24J,K1A9/6$MDY63[:[ZW73^$/\
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M [^Y@U;O"/7M^[,X9KQ%&,XQK8]N:2]^K-I6OJOWTN_X 6_Z:PG'0>>IZ?\
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MXT?:+#P3YG%Z+I:_YG]"%Q\5_P!G[XE^/M%\7>+_ !U^SQXFM?%WA'X:Z?\
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M#3M \;O)87VL'4U\:W%CH,MV+JRBO-/-WYMYJ#([S%F8DEOZIO\ @CND5O\
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MSM'W_BZPO*_X>AA_K/6G[BH1O/W%HMY>ZOQ:V/TY_:6\3?"V^\*^ IM/\0_
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M8^#XY%1"GB301&J,&"6_]MV/V:/ )VF.'8A!P<@\"O\ 5$T3_D$:7_UPM_\
MT5'7XEXV0]GB\+!_9HR7_D])_J?T5]'6?M,/FT_YI0?X-?H;8^\W_ ?Y50U%
M&%O.ZM@LFQ2>@)4C\^_M5\?>;_@/\JH7\@:*6(]$ D; YP%)X.?I^7X5^.49
M<OU7SG17WJ^W75+[S^AJOM?J69>Q5YJG5:7S/\X?]G'XIZ/\)?CM\<?%]]J=
MC;HDOQ L[6#4I!;C4!<7&MP7NDR/B0I%K%K+)IIPLF_[04:,@D'Z6^&7[4'P
M=\:?!WQ#X=\5:#\.OAYH6A_%?POXE\)?#6]U""_M;_[9HWB6YUS5YM5N=+M9
MV<:K>(\(-C)_8Z73:=;2- =Y_)CXCE)_B/X]G$3P-_PF/BEEX?8[1ZY?E257
M!)X! ]0#STKD(R'W70CCF9]L3PWL4L30PE3]I,2%HMS3S*LT1PQ,8^7>.:_L
M;#936QN!P$J>C=*GJM&[)6NTKV6MEJE=VM=W_P ^\?GN.P6>YBJE%.U>INGO
M?UZZ,_8N\^*7PV\7?$'3M1OO&'[-2ZP/@UH</@J_\1Z=H3>#]#U;3;GQ+<ZI
MI'CK1)=&GTTZC+:RV45C]HBO9&N)1@QD!CTGQ9^)GP]\0Z5H^A_L]_M"_"CX
M':UH>K>']0^):Z'K:?#+PUXPN1H\3:BN@Q^&K7R=;T\SS"6."XM;6(^3Y)C5
M4W5^*26\4L0LTD,9N;BW+;V2.WNQ92"="&?!62<MY7EF3YL !?7Z!_9P^%FG
M?%SQHUKK^H7FE>$O#>CZIKGB*ZMYK>/4X;."9].C:R66&4RQB]N+6 [;>?;&
MS'("[AR8C((81RG6Q$[WDY+FM9W;:MVO=?(Z</Q)6Q\U3CAXWV;2Z[7^\_1O
MX.:]\!U\;>)]>\:^/?@-XUTS5/B>;_QO??$C2]$T>ZO/"USJ4LB:SX>OFL-;
MGN].EMS=2I 6LX;I/+$A48*U(/B_^S,GQ:\,Z=;Z)\!=9\.Z/X6U^+PHVHZ1
MH6E>$+'5)-6U^:,^/=<AT>[DU6UDLYA]B?4+"[*"2QB1%6*,KYUXR_9)^ ?A
MKPO\.O&UE8^)M1\!FS\,7'C7Q'X:^(G@SQGXJN=7UQ0[>%]/\#^&K&]\3>&=
M0O&@N(=,?7M,GC:7>JQS&"9:^>/CQ\._@A\-OB+X(M-!M_'UUX7U/P[#J'BO
MP1J'B/0&\5:!JUUJ=[:P>'K?6(]&@T[[5?Z2NGZC)"UE++;?VBZS*IC8+Q4U
M@&W'V\KPL]6KJ]UW_I?AZ->GCJ2IU%07[UR^SK9)/3_P(_0K1?C?\#O#2>/=
M%U3QU\)M"O\ QVGAN3P!IGP\U"VUSPI\+_$5GI5_#J7Q$L[E['1%\):?9WEV
M#IT&E6(CU:UOQ=3R6LEI'')Y)^Q!\5_"'@'PM\1M$U+XE^"=(\13?$+PUJ6C
M3:Q\8-<^$]EK]GI_B'3;Z_NK?5]!TG5+CQ"MO:Q2W4NDW=O';7Z?Z'/,D-Q(
MXY'5?V?_ -FF#Q+\-O#.C_#GXZK_ ,))X?M]>\466L_%3X=0:9X.OM9ATZ\\
M&V=SXDD\*VVD6EMJ&EW6HSW,%W<B2-[1(W:)T93TVN_L#?#:\U;7O#/A/Q?J
M%[J&D:[X;::Z\1Z]HED\$6I:K:V]]H%YITMO87FCZT+/<-.U34!#I^HW-S:P
MVEO.\4B/;IX&496KSBW=6DTW[MTFES-)26S3NTU)I/1;T9XY)?[/'17T7E?L
M=C!XX_9=U#Q7KNO-XN^#FO>*M7\=ZYJ&G7.O:#H-WX=T_52VK)<7_B6ZN+>X
M.J:(9WD2/5;RTDEF,UL[6JF4A?&E\7?"^/\ :A^%.H6OB?X4Z,8O 'A_2?''
MB'X?SV>E_"=/%FHM<V^I7L,NG:?8VT.GK($D>Z&F*X@ 8P?*JUX[KW[+1T.7
MXZ6&K?VK9:YX!\&:CXX\/-%XAT+6-/N_#FD^(='\.S:7>MID#@74\^J073CS
MH9&,+D)C./B:-@L<B1I=QQ+;S"SABD6"UED5/]'BF69#)Y2,1MD\Q$8,=K<$
MCMRW*</6HM?6))N+L[IV=M'9Z.S:=GH[6;5SQ<SS;$T:MUAXJUM+?U^'7S/U
M#\"ZOX;^%OA#]HWP-<?%O]F/Q5IWC#7;/Q%8S6E[IWB?4=7TI/$FAOJ.G:1J
MM_H,-W#J"6UM=OY,!&$B<%PI->S?%#7/A?XW_9T\7?"?PC\5OV5M TWQKXC^
M%OB+P)H.D7.D>#_$>GV^GZ9XB&I+X^;2/#YEURZB?4K%;T:G-=>5-YZEW,KD
M_BL8I6$D9<VA$L;#3XRJ6Y588Y3Y5RX,8+3@LX,K;LLH&33S,99F\V21!>!$
MNE5=OV,$'[2B7!7RD^UN5>(DG(B)7(S752R6IA\12^K57*FYQG-[WFG%/9V6
MB5K;7V=D<.)SF&(P\_K--0J*#C#3[%F__2F^I[C^SW&D/[3'P)ACGM[I8/C9
M\,85N;28W%K,8?'6BQF6WF9$,D+LI:-BBY0CY0.*_P!0[3_]3'_NO_Z$M?Y<
M_P"S6KI^T;\ %=-C+\9_A:"N]),#_A.=%Q^\C^1OEQDCUK_47L#B-%/4!_\
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MC;R5!#!>H!4;0V.F57Y0<9 X&!0?F 4\J,  \@ 9P #P,9./3)Q3MI_NR?\
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M[$$8VE"=S;N.0,ER4NE^T7R_:[A)[GR6DC^W&.-%0:CDL+K:T:;<A,1HD?\
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M]0UR*=8=+MH(]/M#>I;00I' D21-EU"$[S\R+<7"^;Y@EG5Y(9$AN89I;?\
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MTI.,6N:$HZ\ZOO%;+717M?L?J=" 8\XZKD<<#@]/08P:JWC!(') PT<H&?\
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MX+-_L"V]M)<S_&C3XX[8+(71[%5\PD>1")!J66DN9 (8X@/WCLJ@Y:N;MO\
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M"Y'[17QKP?FP=.\#^@X_Y @/^>M?K7_P\G_8Z_Z++X6_\&-E_P#)5'_#R?\
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M_H1?!_\ X2VB_P#R#7\'P_X+O_\ !20O'&OQ7\*EI1)Y2CX6^ \N(2RR$?\
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M_>3_ ,*O^'/_ $(7@S_PEM%_^5]'_"K_ (<_]"%X,_\ "6T7_P"5]?PA1_\
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M7A?Q5LJV';[_ %J-_P OT-%XW\"N*7]GUVUHXJBVUUUBJ;:_KN?U9_'WX?\
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M^SZE6-3ZL[0G&7P[V=[:+57W6VSZ'YO2JXZA:E#%*TFH_%_-IKKV\]-SYO\
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MI#>_#";2?$6G:7?>%;F&:6TM-1UO-[,VB2WO]I:=+I=G,VHWT>H-#%)1L_\
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M>A^.XX=I  )&1HV< !FC? ="W4HP #+G! P12$ LSD N^-[8&Y\  ;CC+8
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M=RRQ6$1L[>\E6\U"11<>=&DQ6*(QLLY"*SH')7QP(@4*%4*LAF50  )22QD
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M\"_K_P 3D?UI?Z\<,3^+-<-W=X5]_P#P0S2EP/Q1+^)DN90_[EZOX<L&?C^
M$,10!3!)YL)48,4IY:6,]4D)Y+J0Q/.:;M4(T>!Y;/YC)_ SY!WE?NEL@')&
M<@5^KWB'_@BY^WCX2DTN'Q1X.^&OAZ76]2M=)TB+6?C3\--,EU&_NPYBMK2.
M]\0P-/,Q0A8X@[OG@<8KHX/^"%7_  4@FB$A^$_A!69LQJGQ7\ 3+) 5!2=9
M8]:*%7)("@D_*3G!%:RXRX3IQ4EF^$M)73Y*SO:UTG]7Z-Z];[&?_$/N*TY2
MAD^93][_ )]3MJ[K>S6GDM#\@O,? 7>VT# &XX /8#/3VZ4VOV%_X<2?\%(O
M^B3>%/\ PZ7@+_Y=4S_AQ1_P4@_Z)-X5_P##H>!/_ES1#CGA6I?_ (6L)%1M
M;G]K3WOLYT8\UK=+VZ[E_P"H_%\-)Y!F6OP_N)2]=E)KIO8_'VD;H?H?Y5^P
M?_#BC_@I!_T2;PK_ .'0\"?_ "YI#_P0G_X*0$$#X3>%,D'&?BCX$ S[DZQQ
M5KC7A5--YY@;)INTYMV33=DJ;;=ELDV]DFVA/@KBMII9#F-VFE>A)*[TU;BD
MEKJVTDM6TDVOQ\B_UR_[MU_Z(:O].[]B_P#Y-+_9J_[(3\*/_4%T&OXE1_P0
ME_X*1+*=GPF\)2-%&991_P +4\!($AFS$[J[:R!(T2[I?*3+R!=JC<17]R?[
M,G@[7/A_^SY\%? OB6"&U\0>#?A;X$\*ZU!!<PW<,.JZ!X7TO2[^..YMWDAE
M1;JTE56C=E88(8@@G\7\6<\RG/*>%658VEC'35935.-2#CSQARW]K3I7O9[7
MVUL?T%X*<.9WDM?$5,TR^M@X3A%1E4E2DFU)75J=2H]/-(]T(S&1G&6Z_A_7
MI5 \+(/\]36CMRA!X^8'GCIC\OK51X& ;#!@>X![YXXSZ@U^.T+ITT].5:ZK
M?[_0_HRI93C)Z07UB\K-I<])1CLF]6FMC_-:_P""D_S?M[?M=QMS'_POSQ^_
MEGE-\>NW)C?:<C<F24/5<\&OB,JI9G(!=AM9B,LPQC#'J1CCG/''2OZ*OVU/
M^",_[?'QC_:T_:'^*O@+X:^%]2\%_$#XK^,/%7AC4+KXD^"M-N;S1=6U6:ZL
M;B;3[[5H;RSDEA<,UO<Q1RQGY74$5\O'_@A#_P %(U^]\)_"/X?%7P$Q_$#6
MB17]6\/<6\*8;),OHXC.,+3Q-'#T8U*4HUG*,E1IQ<7:A)-IIK1O;L?PMQ#X
M>\3U,USW$PRG%RAB,^QF,H.$J3]KAZE3&\E6,8UG*TE5INSBI^]K%).WX[CY
M=N,C8I1,$C:AQE5]%.T<#C@4#@H1P8F+1D<&-F&&9,?=8C@E<$CK7[#?\.(_
M^"D/_1)_"?\ X=+P)_\ +FC_ (<1_P#!2'_HD_A/_P .EX$_^7->Q_KOPE_T
M.<)_X+K_ /S,>#_J%Q7_ -"?,/\ P%?YGX]9.[?D[L[MV?FW'.6W=<\GG.>3
MZT*2IRI*DMO)'!+==QQU;W/-?L+_ ,.(_P#@I#_T2?PG_P"'2\"?_+FC_AQ'
M_P %(?\ HD_A/_PZ7@3_ .7-9OCGA9-VS;"M='R5O_E"_(A\#<5P;MDF/;[\
MFKV>_-8_'=E5V9W =G*L[,-Q9D(*EB<DE2JE2>A4$=!3CRSL>6>0S.W=Y223
M*QZM(222YRV3UK]AO^'$?_!2'_HD_A/_ ,.EX$_^7-'_  XC_P""D/\ T2?P
MG_X=+P)_\N:<>.N%D[O-\*NFD*_W:4'_ )!_J;QC>T<BS!K_  1M^,K:>A^/
M!56SD Y8.<@'+ @ACZL"!@GG@4;5Q,N!MN"C3KCB9HP5C:0='* D*6R5!XQ7
M[#_\.(_^"D/_ $2?PG_X=+P)_P#+FC_AQ'_P4A_Z)/X3_P##I>!/_ES5_P"N
M_"$OCSC"^GLZ[_+#_P!6&^!>+JGQ9+CX_P#;B_21^/9=V*DLQ*L64DDE68 ,
MP/4,P4 D<G R:854[25!VJRKD [59_,91Z!I"7(Z%B6//-?L/_PXC_X*0_\
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M2-MZ*QZE4;YE4Y"MR!FI'=Y&+2.SL552SL68J@"HI)))"J J@\ # XK]A_\
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M=_\ 17_VE/\ P\#?_*.C_A@3X?\ ;XO_ +2F.W_%X)/Z:'5<M#_G[5^<5_\
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M0_%YQ^/&A<?3OG/:N>%#EJ1_VF<J2>J:5[6>RYN]M['9'$3J2C[#!TEB9/\
M=RJJT.>S;<WRMVY>;OK8^W/[1L_^?VP_\"XO_BJ/[1L_^?VP_P# N+_XJOB+
M_A@3P!_T5_\ :4_\/!+_ /*.C_A@3P!_T5_]I3_P\$O_ ,HZZ^2A_P _:G_@
M*_\ DC;_ (7/^@?+/O?_ ,K/M\:C8][VP/\ V]Q?_%TO]I6'_/Y8_P#@7%_\
M77Q$O[ OP] ._P",'[28]/\ B[\A_7^PQ3O^&!OAU_T6+]I,>_\ PMZ3C_RA
MU+C1_P"?E7_P'_[<I4\[>OU7+=?[R_6F?;?]I6'_ #^6/_@7%_\ %TTZC99X
MO; #_K[B_P#BS7Q1_P ,#?#K_HLW[2O_ (=V3_Y1T?\ # WPZY_XO#^TJWO_
M ,+>D'8?]0*E:A_S\K?^"W_\D#AG<=5ALM[?%_E3/M;^T;/_ )_;#_P+B_\
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M>WM=SR7T6TO,JYX)SQ7X8Q?\',W[/TJKC]G3XT1/(JN([B^\%JT:D D2$Z\
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MTVOK2A9OW7B97CO[NL[Z7ZW=TKW.N7BWXHN<FLII6;=E:&BOZ^5O1G]5[?\
M!S#^SXEO%.?V=/C06=BDUL-3\!^=;L7(1W?_ (2'R60J,D([.&8# .14C_\
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MM]9Z==:I(;C^TKRV78+2V+$J6^9L>N/RT3_@YA_9\5F6X_9[^,;@A987@O\
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MJEO=_P#04C^R3_B)9_9TS_R;[\:OK]N\#D?DNN[C] -W8#-?IQ_P3Y_X*.>
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ME0ISDHTDHR22;V<H2E:UNK[/J?V0C_@Y8_9Y!^?]GSXSX]K[P/U[#G7<>_\
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M#EA<O@*< '..G(_.E4ED218@4DD:)&%RY#2*0&13MY8$@$=LBK?A)D;WJO\
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MH/K_ $-15*_0?7^AJ*HJ_##_ !?YA2_B5/2/Y'\RW_!RW_R0;]G7_LKNO?\
MJ$:M7\P_[&VL:9I7QRT"*\NGTW4-7T6^TCP]K0<1C1==NY+!K+4HI67;;W4
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M=-.\;Z5^T!X-U#QM?^)M>^*/C[P+JO@W6+G2[W2;75CI^N:E/JEY=QW4LO\
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M_+?&##U,)@,+&KNIU-_*C)G[+X$8FGB\TK3II)66W^-'ZCK]T?055O?]0_\
MN2?^@&K$?W%^E5[W_4/_ +DG_H!K\"HZXC#OO&+^]0/ZHQW_ "+L;_UZK?\
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M^$=2M(+EX[2&=A')=21P98(K,X&[) /\L(_X)R?MY(L('[)/QT8HD$N#\/\
M708;@)\X5C9DGRV)53@%1D8YK_2D^S+/)<&1BP\T;%PI"8"$E<@X+8()&, G
M'/-/AM;=6D B7!(?C.<OEFSDGN<#&,#UK[SA_CO'</X3V>%HPG&,FVJDI.+<
MVDWR6<//6+L]59ZGY%Q5X2Y?Q/C_ &^)Q$HN>[6LU9<R]Z_-J]&U):;WZ_YJ
M_P#P[E_;QRK?\,B_'+<@*J?^$ US*J<Y /V+@')X]Z7_ (=S?MY?]&C?'/\
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M -H-?1YR5;8^NO24U_[D/\U'_AW+^WE_T:-\<_\ P@=<_P#D.D'_  3D_;Q
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M@7T'@'7 /R^Q4W_AW-^WE_T:-\<__"!US_Y#K_2N^SV__/(?G_\ 6H^SV_\
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7=V7J***^;/M@HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T +<# 2(  A$! Q$!_\0
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JL;O9]IL[>;8,+YD8;:/;-2V]M!:PB&WA2*,=$10 /P%%% $M%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>fin_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "' S@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0D $DX !)).
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MDX[DSFJ;2FI.]DG2C*O'5I*\J=TE=ZMZ)7;T3+U%%%24%%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDF/+?)*C8V64E6 VG)#
M@J0.0000>0:/5V75]EU?R5W\@UZ*[Z+N^B^;LOF/HKA/$7BKP]X9M1J'B'Q!
M9Z!8R.5CNM7UJ+3HIMHR?)\Z2/J., ,3U SBI_#/C3POXH$B>&_$NB^(&MBG
MVM=(UBWU.2V#LOEM.L4TKQJV>=VTXY (SC?ZIC7A9X^."Q4\!&<8QQL:%:6&
MG%V4YJLJ#I15.<E!QE64FWHE\+\U9MEZQZRJMF&4T<T<>;^S'G.6U,SU3E%/
M+H8A8Q<U-.HFZ"2CWLV=I112,< GT!/'7@5@>DW9-O9*[]%J_P $+15:20!-
MY+*.@ )!/N>0">_?C]>3\1>-_"OA&&WF\4^(])\.17+[+636M6M-.6<J TC!
M[J:,,$5@SA0Q1?F=5&T55*,Z^(A@\/3JXG&3BY0PN&HU<17DDKMQIT:=2<K=
M%&$G)VC&+;2.7%8W!X'"U,=C\5AL!@:;2EB\9B*.&H+F?+'FJ5ZE*$$VTKSF
MDE>3LHR:[6BO'O\ A>7P?_Z*MX _\+'1?_C]-?XY_!X*Q/Q7\  !22?^$RT0
M8 !.<F? QUR>!WKT?[$SW_HG^(UYRX<SZ*7FY2RE**6[DVE%)MM)-KPUQGP@
MVE_K;PEJTM.*>'I/5I:1CFSE)]HQ3E)VC%-M)^QT5YKH'Q0\!>)[N.P\-^-O
M#6OW>SSI+;2M;L-3G>$$+YT0L[L@1QD@RN(W!'RE02-W?O(QCE +!@CE2"<Y
M"G!!XP.AZ^A%<&(P^,PG/'%X/$86I%<T:6)A*A4G#I.,:M.FU%ZV<HK9_+V,
M%F>69I1JXC*\PP>94:+E&I5P.)HXF"G%-N#E1J58\VFW-=75T6Z1N58>H/\
M*LX^;\TGFN%\L _,?E8+@G!./]K/?//0UXC\0OVB/@Y\,]3T[0_'7Q,\->%-
M5\17T>EZ59:MJD<%P]W<*D$4")'*IMGGED4P3WC10[W&')0%7A<-BL=B:^$P
MF%Q.(G0P]*O.6'HU*UHUI2@]*4)N+I)<\I2:A;EM)-I/+-,[R/):%#$YQF^
MRS#XFRIU<;B*>'A*5E*<;U:E.\J<'*4TKM*$M%:Y[C/&54,IC18D+%FV_(N,
MLPXZ8SG'4#&:^2_VPOV.O@C^VW\)=7^$/QR\,VVM:3>QBZT+74"VOB+P=K[Q
M>39^(/".LPE+[3[N&98I9[>&XC@U%$6VOHY8)=@^H;"[M+^.TOK6^-S:WME%
M/:/'-YT,\#(-MRC!W5E<?.'4L"""&QUU3!&RY7: -ICP " #_#T"EFSG! R<
MDXK.A6Q6&Q#^KU:F Q."Q%*<*V'3I8B56C4A4@JCE"TJ<Y45"O"2ESP=6G).
M,IQEO-83,\'2IUZ<*V"Q,?:8>I"<)1JX64.:AC(SB[.C5C.G.FK\UI0E=W3/
MXNOV=_C]^TK_ ,$$?VE+3]EC]KC4/$/Q"_89^(.H)_PK?XIVMC>7UEX?><SR
M)XB\.02.]OH<]G"P_P"%@^#+06FGVNG6MQK6GP2WQ4O_ &1^%?%6@>-=#T;Q
M-X2US3O$7AW6K2QU#2]:TFYAO-,U*QNX$NH;^SN8)&BG@N(I$50K,8)MP90R
M/CYJ_;-_8[^$7[;OP/\ $GP1^,>E076G:G9LV@>*K2U@F\2^!O%XMRNF^*/#
M4TT3-%>V4TL<L]NDL<.J6JR:?>A[>5C'_.7_ ,$R/VJ?C!_P3#_:EN_^"5W[
M;>KW ^&^HZM-;_LV?%#55G7P_H]SJ5XT^C:%IVJWKF)?A_X]AE23PS&CPIX8
M\5B;0KF"TAFD4?=8Z.&XTR[$YK34<+Q'A)PGCL)A$J,,=2B_?Q-"$%93A[-1
MK0:]Z$];R5*;\7#UL1E.*>"Q2OE"7)A*S6TVTH0;EK9R<;:[ZK2Z/Z^**HI,
M)E4HSD%T57+@)*NP3I+"\1Q(KH1[-AD88!#6EW=\]1USZ'^N*^#]Y2<91<9+
MHVG?OMV\]?)69],FG!3333^_\R2BBBF!7<+C( Q@D8 X)!SC'0\\X]:_S&?^
M"F<:)_P5Q_:85$157]J?344*H4*E[=^"KJ\50  %N[HFYN5'$\Y\Z4/)\U?Z
M=C!0K$@8 )Z#TYK_ #!_^"J>JPZ%_P %7/VL]?E@FN+;0OVC[;6)K:U2-[BX
MCTRV\'7LD5O'*\<+SRI"4B662.-I&"O(BDL/USP4I+^W\Y7)*I?)LR<*::O*
M;PN,C""YFH^]-Q2O)+WM7'5KX?C>/-A<%)RY(PQ>&N[.Z2Q.'DY*W6*3:\TC
M_33\-[WT+16<@XTRQ&XDGCR(^,G)Z@8 Z$#OBMN55DC=24P496! (*D8;<",
M$$=03@]".E?S[^!O^#A+]D^X\+Z3'JGP-_;0TW4;/0-/N;G2K;]G;Q+XB98X
MDM=.,<6HZ3J4WVR3[26O9&C@N)9;,^8D4DC*#\P?M)_\'._PA\*Z#J^B_ 3]
MGKXQ:YX^N;2[AT:_^+&CVOP]T/399;>2-=1N]%AO=9\4W/\ 9DS1W,EE+I-M
M/(D+Q!3(X6OC9\!\39GF&,PE+(:SJXRM*G!WP<$G7G.G3YIO'NS4L1#WHJT.
M6_O<NOM1SC+L-@XU'B,17]G!R22E>3A%RM[RVER<NKW;OI<_'[_@Y'M/!EO_
M ,%*;D>&$TY-4N/@CX'O?'"VA@E\OQ3+/XGC\ZZ,8W6VI7>@_P#".QS^:1/<
M6\D,3YB\M!RG_!N=\W_!4?X<J2=O_"K_ (MY&>./#=X1[<8KYM^'7[-?Q]_X
M*.:C^U#^U[\2_C%\,;34?"WA+Q]\7OB/!K7B[0)/BAXUOO _A[4-;A\)^$/A
M#ITEWXHT+PII*Z/9PZ?XGUB'2].L=(@++''"HBKZ2_X-Q"'_ ."H?PX!)++\
M*?C#&A)R9!;^&[,/*Q/+.P>7<QR3YLF3\[9_I;-J<LO\-^(N&(8A8['\/<-Y
M;0SBC&-2G++\1",$XU*M9N.+496YI8:4HM1NGJ?F<:L\5Q5A<6X\U/%U*=6%
M*"2G27M:<KS?PRY6KWBELS_199%((PC*00V<'(.<AL\;3G!'?\Z@GC8Q2IY>
M]3&Z[ =N04((# ?+N!QD [?3CFY@>@_(4U]H1\CY0K$CCD8.?0<CUK^//9TY
MW56E2FYIPF[.\HR3C)<UU+6,I+1IZW33LU^SR@Y:<]1IM7BVK2[Q>EK27NZZ
M6D[W5S^,7_@Y_P#V5]!M];^#O[4GA3PW::=J>LZ5JWPZ^)?B&SLU#:VEA?V.
MN>%)M:N84!>^L=VHVEA<W4C.MO:Q6L6U(<5YK_P;3_MR/X+\>^._V*_B'XKM
MT\"^.K/4_B7\'O[9O7M[/1/&]I<0/XP\*6:WEPMI:6GB71Y++6K*TM$3[;XA
MM-3N4BDO;NX>3^FG_@JI\)?!?Q?_ & /VH]!\7Z/::JFD?"/QGXR\/S7!V7.
MC^+/#.C:CJ?A[5K9@I(DLKZ,;5W 31M/ <B8E?\ -4_9QU2]L_CG\)KVQD9Y
M%\7Z;;1LJW$;"WE:338V$MJT5W&(WGF9&M98YXFEE:W=)7R?ZE\/,%@_$SP]
MI\)XFK+#8S(5+)\%.#5>E.OC<RP\,)B:T:TG7E'#4,1+#U(JI&M*S5*:@T?S
M]QYC,[X"Q?$O&3Q<,[I48U\WRW(<P52C@LNR[+,ES#%8S NKA(JI)XBO@75C
M.$9T80E+VU*K./++_6KCE$L6+>,-&8-\6XH8W$B_N_+<$@QMDGDGKA@,&OS0
M_P""G/[.OBOXZ_ K0/\ A7WA+_A*O'/@OQKI6JV&FZ?-#:W;:+?V\VD:]:VM
MR2OF0PI>1ZH+,R" W5O%.Z[K=77\F_V9_P#@J#\:?@>NC^&?B"U]\9_ANHCM
MA+K%Y'%XWT2VA*QFUTO7S(VG7MI:V^\6NG:RK7\FQ(3.-S$?T*_ S]I;X0_M
M$^%I?$_PL\3V6HM9?9H]<\/W*?V?XC\,W]YAH],\0:%<D7.DW%QM"V[F)X=1
MV[K24H4E'R7%'A=XD^ ?$^#XKJY6J]#+JL:65<193*I6RGV<XUJ+PN95J<JD
MLNQ%>->5+V&)4HQE*$?:2<3X;A7QC\&_I:\ YSX?0SVMPWFW$.2QR_->$,?/
M"4<ZP=2I[.?]KY53Q,7#'4L/C%3J9;CL+-U(48T_;83#-MQ_D%\"^&]4\,?'
MWP)X;UK3KO1];\.?&+PII^J:=>K']LL9M.\7Z+ILRI+#E97BN)C(B%BK2HA/
M)K^S[QEXW\'_  Y\,ZIXP\;ZOIGAO0M#@EN;[5]4NX[*VCMH(89;ET8$.UP$
M#BW55,AD&V)6;BOY$OCYK">%OVR?B=XED(CM?#7QQ.O3"VB#R+;Z;XFTK5KD
M0PH/WLCM;&81 $RSA6(+X->G?M0?MFZW^U'\3M"3QC/J/AC]G_2/%&CO;^#=
M'N;^&XD\/V>IZ3>ZAXC\202-$X\9VEM;7UYI0,/F0*8XX'0'G^K/&7PZSSQ9
MQOA?G6)JO"\/91P'6S//,VI_O:TZN%RW+LRQ.6X#">]7J8^O2Q%3#X>M5I3P
MM*JXXBNG1C*G4_@3Z.WC9PS]'?*_'3)U4J9WQ!F/'G"O"' V49_+V=+%XS+Z
MF=98\TSW-,/&& P^"PN(J8;%UZW/&;P]"LX3YDIP_0N%OBC_ ,%3OB7:W=]:
MZS\._P!BOX>^)GDAM+U+S2-9^+&L:5>A(Q<1[XY5998GCN("LMKX9L960NWB
MTV.I6?[6>$?"7AKP3X=T;PAX7TO3M#T#P[96&BZ5HVG0Q06FF:;9E1%:1QHD
M2J)642.50&:8O(Q9V)/-?"R+X?/\/_"C?"Z/1#X(&AV*^&+;1&MDT2WL8XH$
MABMK.T"V=@T(.R>"!45)MX95<N*]$2T:6?<\4:(\EG*RE 6$\$L;.C\;B" V
MQFW8.WD<D?PSQGQ+4SFO_8. RZMPYP?D%6I2R?))54Z[J1E&-;'X[E4*N(SK
M&5*;J8_&XAN="<IX/+O8X*$83_U0\+?#O"\*PK\9YGFDN*N/_$&.75>/>+92
M=6G[+ZHL7EN6\-T93JK+>%,LJ.G@\!3H-8;,8QAF&,53%5E*GI; N$B,<:CG
M:#C\?SY[ &IRK?NL,!AESR#NYY'XXP3^O J011#D1Q@^H1?\*?M7CY5XZ<#C
MZ>GX5\(E&+O!6;W<M6]+:MMM_-G[-R\LW4C.I.<M).M+F5M;V4=G9NW2]A:*
M**"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN&9()W099
M89&4>K*C$#\2!4M(P!5@1D$$$'H1CH::M=75U=73V:NKKYJZ^9,XN<)PC)PE
M*$XQFMX2E"48S7G"4HR7G%'\\7_!:ZYNV\0?!33C+-=6#:-K=Y<:6\DDEA+>
MQ:E#!#<R6>XP27%KY;&&=HS+%DA&&>?"O^"-]_J%M^U'KNFVLMQ:6&J?#K6+
MV_L8)9(+.]N;:[T)([J[M498;FXMXY)UAFF226(22!'7>P/M_P#P6JD>+Q=\
M%VB=XV/ASQ#EHV*$_P#$QMVY*D'[S,W^\Q/4FO$/^".[,_[5=RSLSL?A9XCR
M6)8G%WH>,DY)Q@8SZ"O]$LCPF!E]#-XJIEN7RKX?AKB+#RQ"H+ZQ+%SX@]IA
M\3&HX:1H4%[%J<G5YK.$E!'^,O%.8U?^*DF6X?"RQ&$HOCGAO*Z]2EC,6Z^)
MA'A/VN(]K!U_JGL<15BG.G&BGRW^TVS^I.FN2%8CJ%)'U .*=37&58=,J1D=
M>AK_ #JDG*,HI\KE&45+^5RC**EIKHY)Z:Z::G^SFE]=NM]K=;^5KW\KE9GC
M?=&P!V+N; X)&#@CI@C@CK^%?S@_\%HX]1/Q(^$+:A'>MH$WA36_[-9UO9=*
MM]:CU2 W N4B$MDMTNGL#!/)&7C&XH0F#7]'DB1>2X9!)O1E;=C]X&&-K-M+
M;2/O#& ,G!Q7@WQL\1_ #PWI^CW/QVN/AQ;Z6;Y?[&E^(-OH]S&EU,5$AL(-
M3@E/FI&% N40O#E7?C#-^B^#_&4N O$+*N):.0SXGJX##U\+7R6A",LPQ,\1
M1]E"MA:LZ&(I4ZE)S]O";I3J0G&$Z:]I""?X/](KPYCXH^%.=<*5^+\+P7#%
M8O#8BCQ#BZE:EEN&A3K<RHXNG2Q.$JSI58.5.:=:%*47/G:I.HU_$<4MQ\J?
M8'!XR%D9^>,C-AR>X_AS@'@THAA4AB44 @EDB*NN#G<C+8JP8=5*L"#@@@\U
M_7L/C#_P3GCP/^$B_9R&?6P\)G/7UTW'/.?Y4K_&+_@G8R.L?B']F\R%6$8;
M3O"+*7((4%?[-&06P",C(XK^Y?\ B:G-6TO^(,^(33T:J9KC*E)INS52G+AY
M1J4W>U2G)J-2FZD)-1FVO\PH_01RB#4Y?2;\*8*#4Y3C]7I2@H-2<XU(\4R=
M.4%%SC4C&3IN"J*,G!1?\TG[&-MJ-S^U5\!G\(Q7D&HKX_T;S;FWCFMGA\-P
MM#<Z]9WDT5LCFWO+9)6-O+*()7(=E)):O[0DD=+8*6W31P1J^?[^TYSTY#?*
M<]P0*^1/A;\2/V/==\41Z;\)M?\ @C<^,W4110^$!H,&N3QVH O61;6W2[FD
M2V9DE:)6=XAL9TC7*?7[!-C,IC8NNXN!DR<$@Y')/.5W9P?3//\ ('C]Q[+Q
M)XDP>95.#\3P92P.!="K@<0J%&KBM:DIXK]QA<)&%*"E*;C.G*;5-W=TC_0+
MZ)/A+AO";A//LMPGB9D_B?+,,TIUX9GD.:5,SP6!IQ=->PG[;%8J?M)1NYN%
M2,5=M+5I,FDW0W4>]8WD00*S8VI-)$VUF&1E5<98$CCC(SQ_$5\?E\42?&CX
MPO\ $=KR?QQ#X\\7V.MG4_,NB\%KJZQ1V\*W9E:32?*:"73K0;K>/1C+;PQB
MUDD1O[<YH0Z3Q!4Y3=YDH!43@95B2><'*DYSM)&1W_G8_P""O7[.'_".^,O#
MW[1/AVT2+1?%MRGACQP;>*5EM/%HTMH- UF>-%\B&#4--CN-#ENACS+V>P\Q
MRS**^S^BEQ5D^2^(&*R+-L#E^*?%&3_V=@*&.5&JZV)I3O2PD<1*#IT<1F6%
M=;ZLY:QJ^R4[RLW^8_M ^ L_XH\),FXGX?Q&:./ O$^,Q_$5'*JM?#U9Y#C:
M%6A]=C34X.I0P.,>'IUW)2AR5:DX^Y!V^UO^"5O[2:?%OX/-\-/$=\UYXW^$
M=P/#27-U<R7-]JG@R:(S^&=7DEF=Y[EX;>*ZT.^G9I#)>Z.;B1@U\A?]7MJ-
M%S@H55.<$$ XP1Z'GU'8]Z_BY_9'_:!O?V<?CIX1^(5JDBZ%<Z@F@^-[2"1X
M89/!^I7=I'=/)#$R1SQV/E"_M(IE>&*ZM8)E021J1_93X:U;3=?TG2=8T>[3
M4-(U*PM;RSNXIC/#<VUPB2V-Q$^YUE6XAE,CS#F3"DXR,>3]);PV_P"(?\>U
ML?E]/V.0\3J>/RSDIS]EA\95E.>(RN4VO9NOA*K<YNDU2<95%3C'I];]"'QG
MEXI>%6'R7B'&PJ<6<&QADM?#2J0GB9Y'AH4Z668B48R=2_)!4JDY)WE3C)NT
MT;TH7@Y"[%)!QDK\N2RJ!DGJ>.3SUSBOR _X+ ?\$WM$_;W_ &=[@^%+&RTK
M]H;X2VMYXC^#?BNW46][)?0;-6U+P-<WZ1I=MI7B06B6VD*9O(T;7I[/5;:.
MWG@,M?L3M4\E03ZX%0S0QM%(#&GW& )4<<9!SC(P0"".00".17X'E^.Q.5X[
M"X_"N+G0;E7I>\HXE<MI4]-E5CST9.2?[NKHN:,6O[,Q6%I8Z@\+72=/3V;5
M^:%17]G-OJH3]G-I/7D=M6?A5_P0\_;_ -7_ &JO@9?_  0^,LTFD_M0_LO7
MD'PZ^)/A_54>PU;5] T@W.D:-XY%K=,MQ?/<3V<OA35G</,FHZ;'J<[E]6!E
M_=I6W9XQBOY._P#@IEX&UK_@E_\ \%!/@K_P5)^$NER6_P (?BKX@M/AA^U/
MH&C6\T5M,?$,T%YX@U>:RM%2T4^(]*TVVU^SO;N.067B3P;=3AEN]<+R_P!3
M/A?Q%HWBS1-#\4^'-7M];\/>)M-TS6-#U6QG>>TU"PO[075O=QM&YB-O<61C
MD3'R&>0EE#XQ[G%6&P[KX;.\OARY7F]-U</9>[#&RL\5EW,ER^VPLW.4FK0G
M%N4$E+W?.RFI5;QN!K-^TP%14U5=^7$15O?II^\HV7V[O34ZVBBBOF3V1&Y5
M@>F#_*O\QC_@I^J_\/;OVH%P-K_M1Z0CK@;61CX(5D8=&5@2"I!!!((Q7^G
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M,]-\8Z/!<?8;JXL)96DM+IG0-;WEI<XFB9E#B S1KP=T98*37(?'+X]?L_?
M]-)3XV^*_#&A2ZE-)-H=AK%E+J=U<VZ2A[BX@T^WMKJ=VC&Z0-% Y)Z"60F.
MOI/"G.N(O#KQ0R_%X;@K,\^SW"X?%T,5PC/*\7+/7.="<*GM,&J-:MAJE&G%
MR55TYSHS4:U-WA&1^>>/O#/"WC+X+9EEO_$1,AX8R?,<5EV*PG&$\VHKAQ4:
MF+KP]C]?HXFA2QL:E+#XB'LJ56,:[E[)VC*;/XO)C.#DPVIP>@^RY_\ 1Y)(
MZ=\\=^*C5GD98Y+>U"2,$<NEJ5",=K%@3*"H!.08I 1G*/\ =/\ 68O[?O[
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M6$'BH1E91E_,=11117YZ?M(4444 %%%% !1110 4444 %%%% !1110 4444
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M"9-[)9^8$*AMQ0A@N=IR*_ND-K:D &V@(5%C4&&,A8T!54 *\(H)"J/E )
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ML: .YHKAO^%G_#;_ **#X(_\*SP__P#+&C_A9_PV_P"B@^"/_"L\/_\ RQH
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MX(_\*SP__P#+&C_A9_PV_P"B@^"/_"L\/_\ RQH [FBN&_X6?\-O^B@^"/\
MPK/#_P#\L:/^%G_#;_HH/@C_ ,*SP_\ _+&@#N:*X;_A9_PV_P"B@^"/_"L\
M/_\ RQH_X6?\-O\ HH/@C_PK/#__ ,L: .YHKAO^%G_#;_HH/@C_ ,*SP_\
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ML: .YHKAO^%G_#;_ **#X(_\*SP__P#+&C_A9_PV_P"B@^"/_"L\/_\ RQH
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MX(_\*SP__P#+&C_A9_PV_P"B@^"/_"L\/_\ RQH [FBN&_X6?\-O^B@^"/\
MPK/#_P#\L:/^%G_#;_HH/@C_ ,*SP_\ _+&@#N:*X;_A9_PV_P"B@^"/_"L\
M/_\ RQH_X6?\-O\ HH/@C_PK/#__ ,L: .YHKAO^%G_#;_HH/@C_ ,*SP_\
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ML: .YHKAO^%G_#;_ **#X(_\*SP__P#+&C_A9_PV_P"B@^"/_"L\/_\ RQH
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MX(_\*SP__P#+&C_A9_PV_P"B@^"/_"L\/_\ RQH [FBN&_X6?\-O^B@^"/\
MPK/#_P#\L:/^%G_#;_HH/@C_ ,*SP_\ _+&@#N:*X;_A9_PV_P"B@^"/_"L\
M/_\ RQH_X6?\-O\ HH/@C_PK/#__ ,L: .YHKAO^%G_#;_HH/@C_ ,*SP_\
M_+&C_A9_PV_Z*#X(_P#"L\/_ /RQH [FBN&_X6?\-O\ HH/@C_PK/#__ ,L:
M/^%G_#;_ **#X(_\*SP__P#+&@#N:*X;_A9_PV_Z*#X(_P#"L\/_ /RQIK_$
M[X<;'V_$'P0&VMM)\6^'P V#@Y-](!@X.3'(!UV-]T@'=!5&,*!@ #  P!T
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M^$MH?_R#1_PK?X=_]"%X+_\ "6T/_P"0:** #_A6_P ._P#H0O!?_A+:'_\
M(-'_  K?X=_]"%X+_P#"6T/_ .0:** #_A6_P[_Z$+P7_P"$MH?_ ,@T?\*W
M^'?_ $(7@O\ \);0_P#Y!HHH /\ A6_P[_Z$+P7_ .$MH?\ \@T?\*W^'?\
MT(7@O_PEM#_^0:** #_A6_P[_P"A"\%_^$MH?_R#1_PK?X=_]"%X+_\ "6T/
M_P"0:** #_A6_P ._P#H0O!?_A+:'_\ (-'_  K?X=_]"%X+_P#"6T/_ .0:
M** #_A6_P[_Z$+P7_P"$MH?_ ,@T?\*W^'?_ $(7@O\ \);0_P#Y!HHH /\
MA6_P[_Z$+P7_ .$MH?\ \@T?\*W^'?\ T(7@O_PEM#_^0:** #_A6_P[_P"A
M"\%_^$MH?_R#1_PK?X=_]"%X+_\ "6T/_P"0:** #_A6_P ._P#H0O!?_A+:
M'_\ (-'_  K?X=_]"%X+_P#"6T/_ .0:** #_A6_P[_Z$+P7_P"$MH?_ ,@T
M?\*W^'?_ $(7@O\ \);0_P#Y!HHH /\ A6_P[_Z$+P7_ .$MH?\ \@T?\*W^
M'?\ T(7@O_PEM#_^0:** #_A6_P[_P"A"\%_^$MH?_R#1_PK?X=_]"%X+_\
M"6T/_P"0:** #_A6_P ._P#H0O!?_A+:'_\ (-'_  K?X=_]"%X+_P#"6T/_
M .0:** #_A6_P[_Z$+P7_P"$MH?_ ,@T?\*W^'?_ $(7@O\ \);0_P#Y!HHH
M /\ A6_P[_Z$+P7_ .$MH?\ \@T?\*W^'?\ T(7@O_PEM#_^0:** #_A6_P[
M_P"A"\%_^$MH?_R#1_PK?X=_]"%X+_\ "6T/_P"0:** #_A6_P ._P#H0O!?
M_A+:'_\ (-'_  K?X=_]"%X+_P#"6T/_ .0:** #_A6_P[_Z$+P7_P"$MH?_
M ,@T?\*W^'?_ $(7@O\ \);0_P#Y!HHH /\ A6_P[_Z$+P7_ .$MH?\ \@T?
M\*W^'?\ T(7@O_PEM#_^0:** #_A6_P[_P"A"\%_^$MH?_R#1_PK?X=_]"%X
M+_\ "6T/_P"0:** #_A6_P ._P#H0O!?_A+:'_\ (-'_  K?X=_]"%X+_P#"
M6T/_ .0:** #_A6_P[_Z$+P7_P"$MH?_ ,@T?\*W^'?_ $(7@O\ \);0_P#Y
M!HHH /\ A6_P[_Z$+P7_ .$MH?\ \@T?\*W^'?\ T(7@O_PEM#_^0:** #_A
M6_P[_P"A"\%_^$MH?_R#1_PK?X=_]"%X+_\ "6T/_P"0:** #_A6_P ._P#H
M0O!?_A+:'_\ (-'_  K?X=_]"%X+_P#"6T/_ .0:** #_A6_P[_Z$+P7_P"$
MMH?_ ,@T?\*W^'?_ $(7@O\ \);0_P#Y!HHH /\ A6_P[_Z$+P7_ .$MH?\
M\@T?\*W^'?\ T(7@O_PEM#_^0:** #_A6_P[_P"A"\%_^$MH?_R#1_PK?X=_
M]"%X+_\ "6T/_P"0:** #_A6_P ._P#H0O!?_A+:'_\ (-'_  K?X=_]"%X+
M_P#"6T/_ .0:** #_A6_P[_Z$+P7_P"$MH?_ ,@T?\*W^'?_ $(7@O\ \);0
M_P#Y!HHH /\ A6_P[_Z$+P7_ .$MH?\ \@T?\*W^'?\ T(7@O_PEM#_^0:**
M #_A6_P[_P"A"\%_^$MH?_R#1_PK?X=_]"%X+_\ "6T/_P"0:** #_A6_P .
M_P#H0O!?_A+:'_\ (-'_  K?X=_]"%X+_P#"6T/_ .0:** #_A6_P[_Z$+P7
M_P"$MH?_ ,@T?\*W^'?_ $(7@O\ \);0_P#Y!HHH /\ A6_P[_Z$+P7_ .$M
MH?\ \@T?\*W^'?\ T(7@O_PEM#_^0:** #_A6_P[_P"A"\%_^$MH?_R#1_PK
M?X=_]"%X+_\ "6T/_P"0:** #_A6_P ._P#H0O!?_A+:'_\ (-'_  K?X=_]
M"%X+_P#"6T/_ .0:** #_A6_P[_Z$+P7_P"$MH?_ ,@T?\*W^'?_ $(7@O\
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<6>F65M86J,3DLMO:Q11*Q/)(0$GG-%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>fin_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "' L8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***,T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT"[:UB@_M,D6S*]LS0@E&4G&[GYN#CM2]T>I+-XFL[<@2P72D())1Y7^I4G
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M8SE<>M B+[;:_P#/Q'_WT*/MMK_S\1_]]5-A<9P*0%#R"I% $7VVU_Y^(_\
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M;:_\_$?_ 'T*D.U1DX'UI T97<"NWUSQ0 S[;:_\_$?_ 'T*/MMK_P _$?\
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MM26_C^.[@5K;3)Y)7D543S% 8%2P.>G0'BM"'P5HT+*5BF)5E8;IF.-N<#Z
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MJ\UN[L!Y4:VDTAD=QC=& ,!?4\\GM6M%I$,=\+QI)Y95!V"64LJ9ZX':HY=
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M&TLK-(1IZ,B[CG?N4+R:U:3MT&KA1112&%%%% !1110 4444 %%%% !1110
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&***
M#%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>fin_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O *X# 2(  A$! Q$!_\0
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M)]<TYN-M'<44RS1116984444 %%%% !4-Q:PW=N;>=/,B;&5)/.""/U%344
M(!M  S@<<G-+110 4444 %%%% !1110 4444 %87BIU31P<XD6:)XAURP=>/
B?.2/\X.[2$ D$@$@Y'M51=G<35P7E0<$<=#U%+114C/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>fin_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &C M8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*1#@<]S0!6BM"<&0X'H*M)$B#Y5 I^** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM=2[%V#[
MS#\JL,< D]*S))#)(6]>E #**** "BBB@ HHHH **** "BBB@ J>&V:3D\+_
M #I;:#S#N;[H[>M7@* $1%1=JC %.HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O=OM
MBP/XCBJ%6+M]TN.RU7H **** "BBB@ HHHH **** "I(HC*V!T[FF*I=@J\D
MUIQ((T"CM0 JJ$&%& *=110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37.U2Q[#-.JO=
MOMBQ_>.* *+'<Q8]32444 %%%% !1110 4444 %%%.1=SJOJ: +5I%@>81R>
ME6Z10  !VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J-XV75?05>K,N#NG8^^
M* (Z*** "BBB@ HHHH **** "K5FF7+GMP*JUHVZ;(ESU/)H FHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *R6.6)]36HYPC'T%95 !1110 4444 %%%% !1
M110 J#<ZKZG%:U9ML,SK[<UI4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444QY @Y_ 4 /HIJYQSUHH =1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% $<Q_<O\ 2LRM*?\ U+_[M9M !1110 4444 %%%% !1110!8L
MQ^^)]!5^J-G_ *QOI5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M*9)(L:Y)H ;+*L:\]>PJ.%&8F1^2>E1+NN)<GH*NJ,#%2M2Y+E5NHM%%%40%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 13_ZI_P#=K-K5<91A[&LJ
M@ HHHH **** "BBB@ HHHH L69_?$>U7ZSK8XG7WXK1H **** "BBB@ HHHH
M **** "BBB@ HHHH ***CED$:Y/Y4!N)-,(QUR3T%4G=I&R>3V%(S%V+'J:G
MMHLG>>@Z5.YNDH*_4F@C\M/<]:FI!2U1BW?4****!!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !621@D>AK6K,N!MG?ZYH CHHHH **** "BBB@ H
MHHH <C;75O0UJUD5I6[[X5/?I0!+1110 4444 %%%% !1110 4444 %%%12R
MB-<]Z!I7T$EF6,<\GL*IN[.VXFD)+')ZTE0W<Z(P41\:&1\#\:OJH4 #M3+=
M-D?3D\U+5(QG*["BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVJ83=ZU),VR)F]!5HY)N\C-/+'ZTE%%,@**** "BBB@ HHHH **** "BBB@
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MF_9Y?[OZU?Q12LBU4D41;2'K@5,EJBGYCDU8HQ19"<Y,10 ,"EHHID!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>fin_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ,  \# 2(  A$! Q$!_\0
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?BERQG%8%.4D[OEE4J?O,3%J4:V(4\52]E/%8J,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>fin_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ,  X# 2(  A$! Q$!_\0
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A:5;:UK;+Y[3M<27FZ5F;)()QC&23@ <\GFG'9W!]#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>fin_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  -  \# 2(  A$! Q$!_\0
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,G.<G/'TQ0NH/H?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>fin_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  .  \# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>fin_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  .  X# 2(  A$! Q$!_\0
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D4;4W=Y]J9K.7RF!\M8]N<'(PH/UIQMU_K;_@A_7Y_P# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>fin_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  -  \# 2(  A$! Q$!_\0
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HT4=TGELZC) SSBK<5MY4\DOG2L'51Y;-E5QZ#MG/-"V_KM_F#W/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>fin_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  .  X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V'Q/JNI:3
M'8RZ=#93F:Y6%H;F0QF3<#@(P! ;CN,'IQUK<0ED4LNUB,E2<X]JR/%6A?\
M"1^'KC3DF\B<E9()_P#GE*C!D;\"!6E%%<+<,\ESOB,:J(]@&&&<MGWR..V*
%%L#/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>fin_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 !,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U+QEXKU/P
M[>:/9:1H?]KW>HRR(L)NE@&$3<<,W&>_/H:D\+>+KK6]1O=)U?1)=&U>T1)7
MMGG696C8D!E=>#R,'TJWK.CW&H>)/#U[&J>3I\TTTK,>?FB*  >N6S^!J&XT
M:_'C6?6[3R0#I7V5?-8[6D\PL,@<X _GQWH7GY_\ 'Y>7_!.DHI!G:-V,XYQ
-10 M%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>fin_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  / !$# 2(  A$! Q$!_\0
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0J'-UZ0_F?\**JQ/-Y'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>fin_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1  \# 2(  A$! Q$!_\0
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HU8#^]CC/IGU-2VTDTL >>#R)"2#'O#8&>#D>HY_&CH'4FHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>fin_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  / !0# 2(  A$! Q$!_\0
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+M0;U7YHCFMHS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>fin_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  / !4# 2(  A$! Q$!_\0
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CJP90RG((R#14223&YEC:W*Q(%V2;P=^<YX[8X_.BD*Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>fin_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  2 !(# 2(  A$! Q$!_\0
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,ZBG444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>fin_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  3 !,# 2(  A$! Q$!_\0
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M )H) \9) ;!'0D'K[@T46%=$DL,4Z!)HTD4,&"NH(R#D'GN",T^BB@84444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>fin_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  2 !0# 2(  A$! Q$!_\0
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35;>J,^:V^YL4445F6%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>fin_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 !@# 2(  A$! Q$!_\0
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;B1R78A3S@L2 .PHINU]"4;=%%%(84444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>fin_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 !(# 2(  A$! Q$!_\0
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84%DW [3CD9[XHIV%<EHHHI#"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>fin_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 !4# 2(  A$! Q$!_\0
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4AM7T'&#:O^J-:BBB@D**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>fin_024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  2 !4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V6_\ %N@Z
M99:C=WFI11P:;(L=VP!;RG(!"X )).X<#-49?B%X;32+'5TO7FTR[E\H7D4+
MM'"?^FIQ^[&<#YL=?K6%J=Q=>$?B%>W\'AW5=5L=9MX6/]GVXE\NYC)7+$D!
M 5*\D]JUM)\*N_AK4[2\B2R;6;J2YNK:/YQ&DF T8/3)4<D=R2*%JK_UOJOU
M!Z.W];'7*RNH92"I&00>"**KP2HDCVD<$J) JA6V80@C@*>^,<T4_05^Y9HH
)HI#"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>fin_025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  / !$# 2(  A$! Q$!_\0
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GLU35WTM]<OGB686HD$"0H<!5W?,3@L<GN?041ZW!]+'4T444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>fin_026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 !@# 2(  A$! Q$!_\0
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'4%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>fin_027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 $<# 2(  A$! Q$!_\0
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M>VUPTMNLK3*LQ=0K9ZY!;/!]@*M7M_=7RRM"DAB^81N$(.,+_7-3KXEOC</
M;#)C+@L,X)3.['Z8^M/M];U"\DBAA^S.SDYF4$IC;NP/?M0!4:[OI;]RY<F-
M64P>60J#>H'/?(YJ7[?K,<#R2,2'#,,0\P@/C\?EI-/UJ[>QC$R.9(Y5 WL0
MT@^;YO<<8I[:]?+"(YUMT:8(1(0=B*P.0WOQ^M #QJUV_A]+I79I6G:,3*G
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+,444 2T444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>fin_028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "M 8$# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBDZ?\
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M*/J:<EQ%(/DD!_&BZ*<9=B>BF9XX;\Z&. .OX4$7'T54ENXHY &F5?8FD%[
M3_KU/8#=1=%\DM-"Y141D 3<QP!WS5?[?;$D"X4?C1H)1E+9%VBJL5S%.2(Y
M@WT-2Y., GBFM=@:L[,EHJ)@VX')Q]:7=R1GC'6D2KLDHJBU];JVW[0O'7YJ
M6&]BG)1)06[8-3S(ODG:[1=HIB$\<FGU1*V"BBB@!,\XJEJ.H6VFVC7-RZK&
MOJ>M33S"!&D=L(@Y->!_$;QA+KFI&PM9-EG 3E@?O&@#4\4_%J^N)I+71U$,
M(X,AZFO/+K5-1O,M<W<LFXY/S8Q510SLJQJ=[GY0.I-=SH/PMUK5XDGN%%JC
M>O6@#AM[+G][(/?>:NV6L:G8,)K:\F0KT.XFO4S\%D\OY-116[Y!KD_$/PTU
MC0P9XXUN(!_$G6@#H?"?Q:NEFCM-:19%;@2C@CZBO7K2\@O+=)[>021OT(KY
M,(*L0Z;7Z$>E>B_#;QF^EWZ:5?2%K>4X1B>E 'NX.3@BO#?B[J5];>)K>*"Y
MDB7R03M/N:]O#!@&4Y&,@^U<UXA\%:7XDNDN;S.Y5V\4 ?.QUG4@Q_XF,WYT
MG]LZE_T$9OSKW8?"?0,#F7]*7_A4^@>LOZ4 >$?VSJ6/^0C-^=21Z[JL;AEU
M"8'''/6O<6^$V@!>LOZ5ROB;X3&VMGN](DW[,DHW7% '.:'\3=>TF1?/E^TP
MYP58=O6O:O#WB>T\1V FMR!( -R9YKYEDC:&5UD4AD.&4UU'P^UY]#\2VR;L
MPS':P)XYH ^D""$P.*^7]=U?4QXAOP+^90L[J%!]S7U!D-'G.0>>*XF]^&.A
M7EU+=3;@\C%B1[T >##6-3(.-0F..HS1_:^IY_Y"$WYUO^-K?1=-U4V.D\F,
M8D;UK"T72;G7-3CL;1<ECR3VH 9_;&I][^?'UI\>NZO&VY=1F&/>O9M)^$NE
M6]NOVUS)/CYAVJOKWPBL+BV:3393'*@RJGN: .#T7XE^(-)=?.F%U#G[K\'%
M>S>%?&-EXGM=T0$5RH^:,G^5?..H6,^FZC/:7B%9XCM^N*N^&M;GT'6X;N)R
M$+ .,]J /J89[UYC\4KNY@\GR9VCS_=->B:?>1ZAI\-S$<B10:\U^*W_ "Q^
MM95M(GJ95&,L4E(\\;4]0*@"\EP!ZU[5\/)I9O#$<DLC.V<$M7AG8U[?\.,C
MPJGUKBP\FY'TO$-"G"A'V9QWQ+O+NWU>*."X>,'K@UQ@U/4!(,7DI&?6NL^)
M^?[:ASZ5Q!^\/<TJTVJFAWY=AZ<L$I-)NQ[W;:Q%IGAVWN;R0D^6.O>O//$'
MQ'O[V5H]/ @B!P'[D5V&H:(VM^#K:*,XD1 1[\5Y[I'@?5-0O6BDC,21MAB>
M];5.?E31\]@*6$C.=2L]GL8\NLZG<$N]_*3Z@U-:^)=7M)4DCNW)7^%CUKOK
MGX66YLRT4S"=1G'8UYK?V4NG7KVTJXD4XKGFJL/>9[V$E@,8W3BM3UWPAXW&
MLC[->82< 9/K7<]<%3GBOFO3KN2QOH;B,X*, ?<5]$Z;<_:]-@N%QAXP?TKL
MHU7-'S.=9>L)57+LSQKQO?WD/BF:..ZD5 .@-8FG:E?MJ5LINY"/,&1GWK1\
M>'_BJY_I6+IO_(4MO^NB_P ZXYSE[0^KPV&IO QD[7L>_7=M+>Z"\,<I65HO
ME;WQ7A5_/JVGW;P3W,RNC$$D\'Z5]!V8_P!"B9AT7-<5X]\)C4[9KZV3]ZHR
M0!UKLK1DX71\EEF*C2Q#A4MRMGGWASQ/>Z5JD;RSN\)/S FO=+"]CO[:.XA8
M%'&3[5\ULK*QCD4JZMS[5WOP^\5M9W36%VY$;_<)K'#U'%\LCV<YRV,H>VHG
ML9)QBJM\2NGSD,0=AP14T<JLH93D,,BJ^H'&F3?[A_E7>]FSXRG?G43YZN]3
MOQ?W0%W+C>0!FN@\ W]Y)XGB62ZD=,=":Y:[_P"0A<_]=#_.ND^'<9D\4(1T
M"G^=>7";<['Z'BL/2C@&[:V/=U[4^F+VI]>FMC\Z84444Q'&?$35SI/AA]K8
MDERO6OG-W+\OSD[C]:]@^-%Q@6<&XA2F[^=>10Q^9/#$>=S"@#U3X6^#([I3
MJ]_'N5?]6&'>O8T Q\HVJ!@5E>&K5+;P]9QH-H\L$XK5S@=\"@0H VD=137C
M5XF5QE6&"*@N;Z*T12Y +'@=ZFBD,B!@,9]:+W*M?4\3^*?A!-)D75[2(>2[
M8=5' KS,2-"0T9.8_F!'45]->.+-+SP?J$;C)";AGMS7S'C P,_>(.?2@1].
M>"M5&K>&+6;.XA K9/M5[5-=T[1FC%]<)$&Z;FZUP_P=G,FAO%NR$)_G65\;
MD5OL (QQGC\: .Y/Q!\.K]Z_B_[Z%;NEZI;:M;?:+619(CT(.:^3&0!2"!ZU
M]%?"Y=OA2/T)XXH [?&:B:-6#*1PW%2TS!+$]J /FSXC:<NE^+YXE&%D&[@5
MS5L[0WD$B]0ZG]:[OXO2*WBZ-0/F\OD_E7 *,2*0>0RC]: /JW1)6GT>VD/5
MD&:I>+=431]!N;DMABN!4_AI2GAZSW'GRQG\JX/XQZ@8]-M[521OZT >,3SM
M<W#SN26D8DD]:]3^#.E+)-<Z@ZYP,+GUKR;!*8'8X%?1'PPL19>%$<KAI&SD
M4 =L$'7&#04!.3S3A[TM 'B/QBT=(=1BOD&#(/F('4UY:0,,<#MQ7N?QD5?[
M#MFQSO/->&@4#1]!_#"^-WX312Q+1G R>@K#^*W2'ZU-\&Y"VD7"=@:A^*W2
M'ZUC7^$]7)_]\1YEV->X?#C_ )%5/K7A_8U[A\-^?"L?UKCPGQ,^GXC7[E'#
M_$__ )#4/TKB1]]?K7<?%!3_ &U![@UPXQO7W(K.K_$.[*U?!+T/HKP\@;1+
M;//R#^5:@B51P!^59?AOG1+;_<'\JUZ].&L3\[Q#:JR]1NQ0.E>(_$B!(O$8
M90%W#G'>O;STKQ3XGD?V[&?:L<3\!Z^0?[VCB/X1[5]">$CGPU:?]<A_*OGH
M_*IKZ#\(?\BQ:?\ 7(?RKGPFQ[G$OP1/(O'G_(US_2L73O\ D*6O_71?YUM>
M/>/%4_TK$TTYU2U_ZZ+_ #K&?\4]3#+_ &"/H?1]ES90Y_NU(XP&##*L,5'8
M\64/^[4&JZC%IMG)/*X 49&:]7:-S\UE"<ZC4.YY9\0O"XLKHZC;+MB?EU''
M-<$CO&R.I^93E:Z'Q/XNN]<O63>1:KT7'6N<!.T'')Z5Y5:=W='Z5EU.L\-&
M&(/9? OBE-1MA9W#C[2@QS72Z]<^1HMQ*&Z(1BO --U"73;Z*XC;#*<M@\FN
MU\1>.UU/1%MH1AV'SBNJ%>+IGSV+R:I'%1=-7U."D8O-(QZLY)-=W\+;%I=3
MN+P#Y$&P5PD<;22(B98L<8KW7P-HRZ1H$>4Q+(=S5CAX\T[GI9YB%0PRAU9U
M2=!3Z8G'%/KTSX **** /)/C/9F2VM+@#A1MKQV)_+GBE'\+ FOI#QWHK:UX
M:FC49EC^9?6OF^6-H9I(95(VY!H!-.-V?3_A6_CU#P[:2HP(5 #5G4]4M].M
M)+BXD"JHX4]Z\A^&7BZ;3XWL[M"UH%+!^PJ;4M4O/&NNBTM03:H^#CTK.I/E
MT._"X256\]HKJ=?X>:X\2:G)JMSE;1"1$GJ.QKN$4KQ[<?2J>E:=%INGPVD8
M 6-0O JS<W4%E"TUQ(L:J.<GK51V.2K).5H['/>.]0CL/!UZTC -(FT?G7S2
M"1N)]#7??$;QI_PD5R;&SXM(C\W^U7"Q0/<SQPPJS-*VU15&9[?\';0P>'VE
M*XWDFLKXV?>L/]W^IKT+PEI/]C^';6U(P^P%OQKSSXV_>T__ '?ZF@#R)Q][
MZ5]&_#+_ )%&&OG-^C?2OHWX9_\ (HP4 =CG%1R2! S$\*-U*2>W/TKD?'GB
M>'0=&D4./M,BX4 \B@#Q?X@ZDNJ>,+J5#E5^5:P]/MC>:I:6R]7E -122/<3
MO/+]]VW'Z5V?PPT%M7\3PW+QGR+;+L2.O:@#WO3(/L^G6\1_@3%>,?&2[W:Y
M';@\(HX_"O<0NT  \"OG3XFW7VGQC<#.0I _*@#D8U+SQQ@?>85]0>%;<6WA
MJRBQSL!KYGTJ)I]8M(QSF05]4Z<@BTZV3 !$8% %H=:4TW..XS2;AR0W3KGM
M0!YE\9;A!H]O!_$237AX^Z"/2O1/BUKJ:AKZ6$+;EARK$'O7G0W9VJ.<X'O0
M![C\'(630YI#_$U5_BMTA^M=/\.]-.G>$X59=LDGS5S/Q6Z0_6L:_P )ZV3_
M .]H\Q[&O<?AM_R*T?UKP\]#7M_PWR/"\9[9KBPC]YGU'$?^[IG%_%$$:U;^
MF#_*N#;C:V>AS7J'Q8L&\NVO47.UL-7F# 8((ZCBIK)JI<Z\EFIX-6/H;PI,
M)= MF']P5MEAUKA/ASJJW>D"U=P'C]Z[<LO'(KTJ3YHGP..INGB)1EW%+9X%
M>)?$F1)?$*J#R!7L\\JV]O+*[ !5)KY]\37ZZCKLTX.0#@5CBFE"Q['#M-RQ
M'/V,D_-\OK7T+X50Q^&K-3_SR'\J\#T^W:\OH84&2[@?K7T5IT'V73K>#'^K
MC /Y5AA%HST>):B]V'4\1\><^*I_I6'I@_XFEM_UT7^=;OCS_D:YOI6'IW_(
M5MO^NB_SKGG_ !3VL-_N$?0^C;,G[%%CTYKR[XG:XTTZZ="V OWL&O3[60)8
M1L>@7FOG[Q'=&\UZX<DG#D9_&NZO)QIGR63855L8W):(HV=L;VZBMT&#(P%>
MM7?@"TD\.+'"@%TB!MU>>^#+?[3XFMQC(49Q7O@&(]IX&.:SPU-3CJ>AGV-J
MTZZC3=DCYJNK>2RN7AGC(D5L4P+\Z *,MP#7J7Q!\)&: ZE:+\Z?>4#K7E2
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M7,ZIX T*33IA% \;X)5E<]: >NYU$,T,\:RQLLBD\%>E0WNH6E@L;74BHLG
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M##L:H:=H]MIK7#0+@SR&1OJ:T:* &@=,CD4I&:6B@!FWT)'N*-G/.6]S3Z*
M&%/8_A0JD YW'ZFGT4 1[<# 4CZ&EVDCDG\:?10 S:>G3W%&TCN33Z* "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>ex8-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G /D# 2(  A$! Q$!_\0
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M")!^[M8TQM'JQ.3GV_R-VL91Y78^>3NKA1114C"BBB@ HHHH **** "BBB@
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M^2_R6@#T4WEL#@W$/_?8IT<\,IQ'+&Y'.%8&OBS4R?[5O/\ KN__ *$:]-^
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M(-1L8+?3C%;7,D2%H6)PK$#/S=>*]8\!^-+;QMH(O8T$-U$?+N8,YV-CJ/\
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MXQR=H'YGUH PZ^H/B%_R12[_ .O2V_\ 0XZ^7Z^H/B%_R12[_P"O2V_]#CH
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M% 'D/_#/VA_]!C4?R3_"NW\$^";/P/I]S9V=U/<)/+YK--C(. ,# ]JZ>B@
MHHHH **** "BBB@ HHHH **** "BBB@ KQ/1]5O;/Q[:3ZEJ-U=Q7VHO#;WE
MCJ0D@D!.%B> _= XY&,5[961!X6T&VU8ZI!I%G'?DEC.L0#9/4Y]?>@#RW3]
M>N6\(1PMJLQOSXI6'89SYFSS!\N,YVXSQTKJ/"&K-(?&$-SJ!:9-6N4@CDFR
MRJ%& H)SCZ5U:^%]"36#JZZ19C4"V[[0(AOW>N?7WJ-?"'AU=3;4ET:S%ZSF
M0S^6-Q8]3GU.30!Y_I>MS3? *>?^TW?4TLYG+^?F9<2$ YSD<8K-UC6=7T>_
M?3H;RZ>3Q)I5HMBQD8^5.2L;E?[IP2V1WQ7IMOX(\,6@F%OH5C&)XS%*%B W
MH2"5/MD#\JT)=$TN:>RFEL+=Y;$8M79 3#P!\OIT'Y4 >/ZUXNN-,^)UHT6H
M7?\ 9FESP:=+$=YCD4J1)([?=W L!SSQ5+Q9K_B#1]3\67"7=T^EW5T;!-DK
M9M9@J.C+S\H(+#BO:9/#NCRZ=<:?)IMLUI<RF::$H"LDA()8CN<@'-$WA[1[
MBUNK6;3;:2"ZD$L\;(")'&,,?4\#\J ,'XA:T^C^ Y6BFFBN[P):V\L3!2LC
MC@EC]T<')KF/A5XAN?[4OO#MX;B2Z1FDD1YS*EMM"K@.Q)?<<MP<"O3K_3+'
M5+%K*^M(;BU8 &*50RG'3BJ.G>%= TF>*?3](L[::)2J211 , >O/6@#S7QW
M>ZW8^+]1T+3KJZ$GB""W:S(D;$+(Q$FW^[D+SCUK(7Q5K.J>$=1UV.^NK:)F
ML=+>4.1Y. #/(/0EF S[U[=/I=C<ZA;7\]I#)=VH803,N6CW#!P>V:AAT'2;
M?39M.BTZV2RG+-+ (QL<GJ2.] 'C^LZA=Z/I?C?2M+UB]N;"RBM);>X:Y,CP
MN[+N429SSSQ3;/6-?TFR\9R6DU_;?8+*("SOKO[3+'(Y'[U3T"[<G\J];B\*
MZ!!I,NE1:19I83,&D@$0VN0002._05:&C::+Z6]%C!]IFA\B238,O'_=/J.*
M /*6,6E:%J;Z;XPN[N:?P\UU):23-*PDQ_KEDSA.>-O6JVEF_7P#J%Y'J<^F
MZA/9PK%<WNMB9)-Q!8A?^61.,#/3=BO5+3PEX>L+:ZM[31K*&&[79.B1 "1?
M0^WM4=KX+\,V23I;Z'8QI<1^5*HA&'7(.#[9 /X4 >;:$6U'0/$^DW-SK=C>
MZ=$MWY8U/SE0B-B-DHYP3R5)/;WK-OUO;/P/X/GAU+5;B;5;I7N%;46C+Y3[
MHD/W!]>!7LNG^'=&TJRGLK#3+:WMIP1-''& ) 1@[O7BH[KPOH5]IUMI]UI5
MK-9VW^HA>,%8^W [4 >7:\MY;V_A&SM?[6D-U-=F>S@U?S)7(4$+YP.#C&<?
M45V7PJN[V^\$QW5Y>/<B2XE,'FR&22*,-@(['JPP?S%=!:>&-#L?LOV72K6'
M[([R0;(P/+9AAB/0D 5;T_2['2HI(K"UBMHY)#*ZQ+@%SU/UH MT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>ex8-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, -,# 2(  A$! Q$!_\0
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M7_/X_P#UJX2X\>^#[;Q1!X*E\1:)%XNN+'[=;>&FOXEU5]-'_+<:9YH?8 "
M_EYVX*_(,&J=*O7UP]W9.3M%R:BOBDTD[**U;:LD<V(Q&&P]GB6ET5^_;=;]
M%<[VBBBI.D**** "BBB@ HHHH YN:2*WMKJ2:7RT@M7:5G;]W;!D8;HF\I5(
M)VC@X.X8)QN'\^%UI-SX<L?'7B1M)^&_QG\&2^*MVL>)KW5]1T_Q7"7U<%H]
M'9/$GAS6VF\2-P?+FFA+K\KS1L"_]#4&!&J8(C54Q;Y)F@W?*QE_>-D=>W.1
M\J9&?F+6?V2?V>M2UNY\2:AX LFUR[N'N[BVM]6U>RTZ_D PA.@0ZQ%X?<@Y
M8YL/FQTP>?T;@+C#*^$Y9O#-*56I3SR.'@XT^1R<:55U'%?[1A*D)<J@E4C6
ME"-[SA7C=R_!/&;PSS7Q"ADD\IJ4Z<\ACQ.[U)**<J]&$8).>%XFC+WD_==!
MSE:R2OR'R-8?&77]1^.?P"TS1-3U+PC\._$/P375I?!DU_"^FVD>A>$/'DJ1
M/E/F2(Z%H/E!MP1HUD.6R:^?/%OCCQ9X]_8^MM:\::_>^(-9@^/VFV=K>:G<
M+J#66E)X1#@;@!E5>XE<(> \KL!EVS^KGC3]GSX/?$F[\/ZKXP\#Z=J%[H%B
M-*T>W@O+_3K>UTF=1''I!&BS6\9T$2["L+1L@#;2A"J#SI_9?^!W_"!#X=#P
M;*?";^(AXPAT<^(M>5YO$KZ5)HH*:F=6^UF;R(741>:(FD&-GF%<_2Y9X@\$
MX/\ L?'KAZ49T:O"LI58PH2G4A1GQDJT57;C4D\;1XLPT95)R3J+!IUYM4Z;
MA\#G?A!XGYM/C#!U.,Z$<FXBAQG%RE6XKDH_ZV\*<%8=1EPHINGRTJW"_%RA
M"-5J+QD%2BI59J7Q?<F>']J?XFR0[3/9_L]ZL^6(QE/A+H3CCINSRO'WL  G
M&/.O!'Q+\>?#_P"%?P?^+EKKM]%X/TWXO7^A?$/0-/A%CI=WIOF:/K4,L6CL
MIQ)'X?CU\C:=\88$8\P5^HDGP)^&\_BO6/&C>'RWBC7?#Z>#M;OSJFIE+WP\
M^EMHDD.!<*I*Z./LY< N 2QD\[]\8+']GKX46_PUOOA3;>%#%X#U35+C6+S1
MGUC6"TFH(8#'(-6^U+K2MOTV/+&X+[055B"<"\0.&5@,LP&-R*=2,8<'PJPD
MJ,I26$I\8PXH=.,Y-IUO];E/!SY7>=*-2;H2A!KLQ/@SQQ/,,UQN SZGD$IR
MX[=.4'-OFXKXSX,XPX3<I1A:U^#W#B_5>T5248MJ33^+=7^+WB>Q^##_ !%U
M[XD>+_"UW\6_B%XEO?AK8:!X?TC7M>3P7-YB:5I6BP:W:^1H;2Q+"$E5XI 7
MT./Y(Y&5^7\ _&+XMV^I_M+^!O$GB?Q+]J\"?";Q/XK\-'Q7=:%J/B3PWK&A
M6VBQ)G6_#W$K*FNEHRVXJL>58[ 1^@/C'X&_"OQIX/TCX?>)/#5K?^%_"\.G
M1>'-,6XO[1].BTB.*"S,.K0S"Z!3:I!+_.%8,6W?N\+2/V9/@9X<O/$\NB>#
MXM+7Q5X/U+PGXEAM-8UHK>^'=7:&":U._5Y6C$C:<JI,C>;M+!2HW@>5A.-N
M!Y91FF#QN42J5J\GRNGA^&53HQAC>%JE!<[A0J1C'A"A6A5O*<9XBNIQBJ%=
MSJ^GBO"[Q.><9/B\'Q5&.2Y'[)SIQXNXMYZLI<'\8T^*I58*\)RGQCQ52JT'
M9\M"A2Y>6="G"G^<W@OXS_&K3)_V8O$FH?%#7?$=M\3/%NJZ)J^@ZFB1Z>NE
M:7XQT/P[+Y3QA9-:9H]:VL\;JY7'(*BON[]LKQYH7P^^"GB)=2L]1O?^$V-[
MX"TR'2KI;-WUCQ'HNJLNZ<G*>4FC2*4&2=X(*JK;NEC_ &9/@M;6W@#3XO"]
MRL'PSU74M8\'K_PD6N,ND:IJFK1>);E[C&K!M2D;6=.AG"7DDRH0%$> ^[U7
MQ9X.\(^/=!O] \5Z79Z]HVN*99M,U0$V[2HQ#$!60Y'S#(8#;]X$@&N3->*.
M%LPS_A7.<#DOLH9#7Q$ZZI8>E1EB*+XJGB:-)2H**YZ&'A&A*K47-)4I1<^1
MJ3]+AKP[\1<LX.\0N&LPXLC/-.(N%\/0X4KUZTN*5A:ZX-_U7XEE-5U!U(U,
M2U.,%*SE-3M*[3_$;P%XC\1_ /XGZ))XC\(PZIX\T70])TCP-H'A^VTC3].\
M<67BZ;6MFM:OK&C*Z:V$FU-7*A%CWJTH1V\+O(?V$^/?@R?XC? _QSX;:PMY
M]8U#PO+J-C:L1>K!X@T:,:WH:PJ(PCI%KNFV^%W$MY9&0V<<#'^Q9^S1%;RV
M:> U:.XG-V]P/%'B<:@9#R&.JGQ";S</19U7'5>]?4.FZ=8:3IMCI>FQHEA8
MVMI:6L (<I:Q(D2 8GP2J*<   [>V:?&/&>6<0YMDV<Y72J4LZR-1=6<XJ"]
MI3FJM*4(*O6=%<[DY4Y.3<IS;J.')3@_"_PLS[A3*.+>&^)*M.OD>?.;IPIU
MJ=1Q56FZ53FC'A:BFW!+5J2M&*4>9.3_ )YAXO\ &_C3PYX8\<6/.G_LPZ1X
M#M,'D GQGK_]AZRHQP#C0SCD_P#$A)[@5]5:!\3/%_@[X"?&#]HS0;)8/$_Q
M@^++6NCZC>VB:E_8_AV&75C#(T>WD6S#6_#:NN DSQ,,,JD?H!HG[,/P@\/^
M'/&OA/2?"L-IX?\ B"VG#Q7:#4M4+:BFC1[=)1V:8N&B?8Q\IHERB^8)  !V
M.F?![P-I'P^M_A<FC6<O@2WL/L2:!<JU[ P.I2:RPD20OYBBY?S!OSPL>"0H
M!^IS[Q2X=S>G]1CD-7E_UMC-TY*FHU.#95_]:ZN$G'FDG5EQ=4J56N3V;IKD
M]HN9P7PG"?@-Q[D[6-QG%ZEG4N$N+H2FG[D>+YT9<(\'XE.RO"CP;&-.6TE.
M3LG92?Y^?#?XL?%7PK\;/A?X!U/XA7GQ!T/XJ_##2_&&KRZG&F[0M2U;0M?U
MR,:.0N2@31W4)GY5;"@9(/E7P\^,W[0R_!?XA?&*Y\?-K>D>$;C_ (0S3=&U
M6&/4M2?Q#KPT"(ZK-\N&B\,IKC1>5)E98UD4*RHX'Z0_#W]G/X/_  SO-0U3
MP+X4M=+UB\MTL;C5[FXU'4]0AL8Q&[6]B=:N)SHOGA^%LQ%RH1OE<A=OP9\
MOAKX"\):]X$\/>'+=/"OB6ZFGUO3-5N=2\0QW\TQQY<B:U<W,FQ!'&?F=OF
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M_AXW@Z:.37G\2>"Y?#C)*WB/Q]\0)GC\[R@#]SN$'?K^)-'"#OU_$FOYWO\
M@I'\%?CY=?\ !,[2_%/QY^/OCG5_$OP?_9Z_9RL_B1\-O"<FG>&_"WQ$_:)C
M\:> ]"\=_$CQ[XRT5F\2^/-)^T22CP9X1CCA\&0^+5B\:7G_  E;QV$7A7ZT
M_;*L;+XV?MG_ +"G[)'Q MY-4^ /CW1?VF_CG\1/!>H93PS\6_$'P0TGX<Z#
MX%\#^-;:/R9]:\.6^N?%?7/B+-X:ND'A3Q5/X7\./=0SQVJQ. ?K5'*LT8DC
MY##(SQ_GZUY-%\*_AK<_%_\ X7E%X>LY_BO#\.1\(SXS6]U7[4? C:VGC4>%
M?[-^TKX?: Z^T>NA_LYO%E*MYRQ 8_GP^.O@3XF?"+XH_MO_ +&G[)FB?$=?
M@0? ?["G[4NK? [X0:EJVE^)_"WPQ\=?M!_$'P'^V+\'OV>PD;OX8;XL?#3X
M42>*(O"?A>2W0&[\51>";=;OQA%##Z#\-?&WP-^'G_!0']AO3/V(/@1X^^"'
MPG^.FD?'SX8?'VQN_A#\1?@)X-\>GP%\,)?BIX'N%^&'C_P[X0\0:Y\1/A?X
MA\$G_A+_ (H?\(@C)!\0%\$7/CGQ;)XTFM+8 _HLHHHH **** "BBB@ HHHH
M **** "OREL/^">GQ+\*)\:/"OP__;F^.?PX^&'QW^+/Q@^+/B[P3X2^''P$
M.J:=J'QSU_6M:\=:5X,\<^)/AEXJ\3^'6-UKK"R\11F:7PN4BFME+&1;?]6J
M* /S*O/^"<WA'P7JGP]UC]EWXS_$_P#9*UGP-\"/ 7[,U[=?#JV^'WC*P\;?
M!WX>R2R>!-'\1:5\6?"_B^&3QYX6;5=9B\)_$XNGB^W&O^)HKE[R"^1*UK/]
M@.P^''@OX0^#OV:_VA?CC^SD_P '_"WB;P7ITVCZUX1^)6F_$G3_ !KX@B\<
M>-M<^*_@WXN>&_%WAGQW\0_%'BJ+7/$=Q\2DA\,^,EN?$?B1VNA#*8T_1^B@
M#\M]._X)E>"_!?A[X-CX2_&+XJ_#CXN?!KXI_&;XTV'QLL=*^&/B+6O&'CW]
MH]]='QP_X37P/KWP^/PO/AKQH-<\V'PWX2\)>#8O!<>A>&T\&FS:W=9:OB7_
M ()F>"?$<WQ%^'O_  N[XO:1^R]\7OBGJ7Q>^*O[)VD-X,A^''BSQIXD\1R^
M./'>BIXT?PW+\4_#WPZ^*GB&#_A)O&_PT\,^+X+2ZFUOQ2_F6\/BN0P_JE10
M!\80?L@^$;.Y_;7G@\4>*7_X;7;3T\96B_V)_P 4-L^"6A_ C=X.'D*6 \/Z
M%'XC;^VUG(NW$2JR)(!N?"KX0?$GX4>(/A=X6T?XEVU_^S_\-_V<_#/PHM/
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H]QXEN;?0(;2.2*V01G[KHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>ex8-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W 'H# 2(  A$! Q$!_\0
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M7VH VJ*K:??VVJ6$-[9R^9;S#*-@CV((/((.00:Q9/&NDQN[%;LV4<ODO?B
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M,FJR%H+9H!<,9A@HFW=\WI@5DV_C/3I%WW4%Y80M;O=12W<0198E +,N"2,
M@X(!P>E6]7TZ75].U#16A6&RN;-H5N%DR0S KC9CH!SG-8EUHOB'7]&FTC5/
ML5E;&R>W9X',IFE( 5QE1L48)QR3G':@#4L?%=K=W<5M+97]E)<1--;?:H@H
MG51D[<$X(!!VM@X[53M_'NG7$5E,MAJ8AOE_T20VXQ.^,[%P<[NO7 .#S@4Q
M-*US5M5TRZU:"SM4TQ)"H@F,AGE9"F>5&U0"3CD\CTIMCX;U"WTGP?;/Y/F:
M2ZFYP_'$+I\O'/+#TH WM'UF#689VBBG@EMYC!/!.H5XW !P<$CH0<@D<UHU
MC:+IEQ8:KKMS-L\N]O%FAVG)VB)$Y]#E36S0 4444 %%%% !1110 4444 %%
1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>ex8-1_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  + 2@# 2(  A$! Q$!_\0
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K #.<_M&[:XB6>X>W<QQM&@BSYI/7C^E%=)BBIE5B_LEPH2C>\V_Z]3__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>ex10-6_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-6_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ )P# 2(  A$! Q$!_\0
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5S.\K@ N[$LQP. ,GH.E;5%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>ex23-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 *H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#UO6)O%4-R
M[:1:Z9-;A,@7#N')]..*\PU'XS^)-+OYK*\T.RBN(6VR(6?@_G7N1Z5\V?&.
M%8OB%,5'+V\;'Z\C^E=.'49RM)'-7<HQNF=GI'Q(\<:[#Y^F^%H)X<[?,!8+
MGZYK0G\6?$B",NW@^W8#GY'9C^0-7?@T,_#^(_\ 3Q)_2O0MO-1.45)I(J$9
M.*;9X7=_&KQ%93M;W>@VL$J]4EWJ1^!J'_A>VM?] FQ_[Z?_ !KUCQ9X4T_Q
M7I4EK=Q+YP&89@/FC;L0:^6K^RET[4;FRGXEMY6C?Z@XKJH1I5%MJ<U:52F]
MST^+XXZ]-(L<.BV<DC'"JA<DGV&:W[7QY\0;I0\?@S*'D%DD7/YUYG\-O^2A
MZ/\ ]=3_ .@FOJ3%95U"F[)%T7*HKMGD=U\3_%FE R:KX/DBA7JX#@#\2"*L
MZ;\;M$NG5+^RN+(DX+ [U'Y8KU$KN&#R.XKS;QU\*[#6K:6^TB&.VU)06\M!
MA)O8CL?>LHNG+22L:RC4BKQ=SI[GQEI*Z4M]9W4=TDG$8B;))]#Z5A6][XE\
M1,9;5DMK?/# 8!_'O7@-G=W>B7[?(R21OMDB88R0>0:^HO"FL6&N>';6]TW
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F[T44AB4Q^4<>U%%-$LIZ+;PVVC6\,,82-4(51VYK2[444V"/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>ex23-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! FH# 2(  A$! Q$!_\0
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M 'MSRN>?6NB0%4 8[B!R?6AV&K]1]%%%(84444 %%%% !1110 4444 %%%%
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MU$_AV0VT42:G<@P,'MG*HQB(W =1\WRMMY["D;PYON#(U_.4>1)I(]JX>50
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M 'S1YW_3*3_OFI:,T 1>=_TRD_[YH\[_ *92?]\U+FB@"+SO^F4G_?-'G?\
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M>"4(P<8.TCKUI;CPWYEBMO%>O$RV!L-_EAOE.,MCUP/UI\GAU'NUN%N75T$
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M"-8T!.?E48'\JLU)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS4NHZ]:Z;,\$J3/*JQL$B3);>Q10.>N15.7PW(^F36G]HL'N9Q+<S>2O[S&
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MC/;1S174TEQ$\ZI;Q;R$7&YCR.!D5%_PF>EF4*JW#I]HBMC,L645I55D).>
M=RC/K5S7M)M]0TR?_0XIKJ.WE6V+*-R,4(PI[9XK*3PJUUHFD6[2BR> VTUV
MB1*QF>(+@,W;!7&10N6VHWS7T+VG^+M/U+48[.%;I?-,@@FDAVQ3[#AMC=\?
MA709KE]+\))INHV\YOYIK:T,IL[9D4"'S#ELL.6ZX&>E=12=AJY0O]5LM+C1
MKR<1JQVKP3G'4X Z#N>@I%U:RDU 6 F/GE=RJ48!AC/RMC!X(Z&J6OZ9>7LD
M4MGY)=8I8&69B!MD !88!Y&.G>JL6A7O]HVQ:3R[6VMS '6X8NXV!00N,(<C
M.1S19 V[FM>ZU8:?<Q6]W<K%-+@(K \Y.!SC'6HF\0:;%]J\RZ"&U($V]&7;
MDX&,CD9XR,TU]*D+6$(N))+6WE,LOG.7>0@?(,^@)S^ K,.E:I=?V@VHVEE/
M)-M\K;<NH"JV57A<KCKD9R:+(+LW/[6L5AMI6N45+IPD!;(\QCT SWJK_P )
M+H^9U%\FZW&95VMD#.T<8R>>.*QYO"^J7$-@3JH$UM(C%'3S  )-Y 9N2<8&
M3UQ5[4=#NKY;V8O&9Y)HFA4NR@1QD$*6'(R=QR/6BR"[+[ZY81M;>9*R?:<>
M47B=0<G !)'RG/8XI]YK&G:?-'#=W<4,C\JKGMTR?0>YK$CTO6XQI]O*UM<V
MD+>;*LEP^[=ORHR02P08QG&2!FIM5T?4+BZOFLS;F*_MEMI3,2&BQN^90!SP
MW3CD46079I2:]ID-^+*2[C2X+!0C C)/09QC]:=9ZWINH3O!:7D4TJ@DJIYP
M#@D>H^E94=E<ZA>7%K+(WV*VOD8J^<LB1H55?;?R?I1I6A7=IJ=O+((XK6T6
M984$[2L?,*^H&T#;TYZT607=S<O+ZWL+9I[B3RXQ@9P3DDX  ')/L*JC7M.9
MK4"YR+K_ %+[&VL<XP3C .>,'!JK<>'TMM*@M=(C2-K>Z%U'')(VUFW%B">2
M,Y-45T'4A%I\ :)1#.;B259W #&0NRA,88<X!/UH20-LWM0U6RTJ)9;Z=848
MD!B">G/85%_;NG&<0&X&]HO.4E6"LF-V0V,'CGBH;K1I6TZ:S@O+AA<R 2O<
M2ERL>?F"^F1D?C5:;3]1GUEWFMK22P6)H[=#,RE05P25V\D].O H5@=R[_PD
M>D_8X[O[:GD2/Y:-M;YFQG &,]*E_MFP%W+:&Z3SXD\R1,'Y5QG).,#CFN?_
M .$<U#^S##Y4'F"7=;I]MEQ:C9MRKXW'UQTJR=#OCJ8F_=%##LN',[YNSY>W
M#)C:O/.1SQ19"NS2/B/2?LD=T;U/(E?RT?:WS-C. ,9Z5/J>I1:98->R([Q*
MRAM@R0&8#/T&<USI\.W_ /9A@\J#S!+NMT^VRXM1LVY5\;CZXZ5T<4=U$D$3
M,DH6'$DC$AF< <X]#SFBR'=E9/$FD2P-/'?Q-&N[<>>-N-W&,\;A^=:,,\5Q
M"DL,BO'(H9&4Y# ]"*YI=$U2S>PN+8VL]U&DXN/-=D#/*P8L" >A'3TK1L=
M@@M=*%P/-N=-CVQ2*2H!*X8XSS^-%D";)UUNP>2ZB2</):@F945F*8ZC@<GV
M%1CQ%I?EV[_;%Q<,4B!5@2P.",8R,9'6L\Z7JEOJ5]=Z<EM 9%<QJT[LDTC$
M8=UQA<8/3KFJTN@:E+I]M&L4$-ZC.3=+=R;D+$$OP!N)(^Z>.!19"NS?75K(
MW<UIYVV>%2[JZE<*.I!(P0,]J4ZQIXL([XW<(M)6"I-N^5B3@ ?C5&SM=3_M
MV:[O8K=H=IC@=)3N1,@XVXQDXR3GL!6;=^%+^XT:WM(=1CA>'?A3$'0EI-V>
M>00./Q-%D.[.FCO[:6\EM(YXWN(@&DB!^90>A-44\2Z/)--"M_%YD*%Y%.1M
M4'!)R.F:FBL94UV2_9U*-:I#C&"6#$D_3FL_7-#N-2EO&BDC43V/V9=V>&W[
MLGVQ2T!W+HU_3'O?L0NT%SN*["".1R0,C!-,;Q+HZO&K:C;@OMV_-_>&5)]
M?>J%I9W>IWFZZD8VMK?3N$;.6(^6/'^R 6/UQ45UX=N4M[RUL!;BWNH8;8&0
MG,:("">GS'GBG9"NSK :6FA< #/08IU(L**** "BBB@ HHHH **** "BBB@
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&BBDP/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>66
<FILENAME>sprcy-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Feb 13 15:57:33 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://trpx.com/20240630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:sprcy="http://trpx.com/20240630" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20240630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20240630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20240630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20240630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedBalanceSheet" id="sprcy_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedIncomeStatement" id="sprcy_r_ConsolidatedIncomeStatement">
        <link:definition>002 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedIncomeStatementAlt0" id="sprcy_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>002 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareholdersEquityType2or3" id="sprcy_r_ShareholdersEquityType2or3">
        <link:definition>003 - Statement - Consolidated Statements of Changes in Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedCashFlow" id="sprcy_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/General" id="sprcy_r_General">
        <link:definition>005 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPolicies" id="sprcy_r_SignificantAccountingPolicies">
        <link:definition>006 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" id="sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
        <link:definition>007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Cash" id="sprcy_r_Cash">
        <link:definition>008 - Disclosure - Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Inventory" id="sprcy_r_Inventory">
        <link:definition>009 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsReceivable" id="sprcy_r_OtherAccountsReceivable">
        <link:definition>010 - Disclosure - Other Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociates" id="sprcy_r_InvestmentinAssociates">
        <link:definition>011 - Disclosure - Investment in Associates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinFinancialAssets" id="sprcy_r_InvestmentinFinancialAssets">
        <link:definition>012 - Disclosure - Investment in Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Leases" id="sprcy_r_Leases">
        <link:definition>013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNet" id="sprcy_r_PropertyandEquipmentNet">
        <link:definition>014 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAsset" id="sprcy_r_IntangibleAsset">
        <link:definition>015 - Disclosure - Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TradePayables" id="sprcy_r_TradePayables">
        <link:definition>016 - Disclosure - Trade Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsPayable" id="sprcy_r_OtherAccountsPayable">
        <link:definition>017 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstruments" id="sprcy_r_FinancialInstruments">
        <link:definition>018 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EmployeeBenefitLiabilities" id="sprcy_r_EmployeeBenefitLiabilities">
        <link:definition>019 - Disclosure - Employee Benefit Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TaxesonIncome" id="sprcy_r_TaxesonIncome">
        <link:definition>020 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens">
        <link:definition>021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Equity" id="sprcy_r_Equity">
        <link:definition>022 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactions" id="sprcy_r_ShareBasedPaymentTransactions">
        <link:definition>023 - Disclosure - Share-Based Payment Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/RevenuesandCostofRevenues" id="sprcy_r_RevenuesandCostofRevenues">
        <link:definition>024 - Disclosure - Revenues and Cost of Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLoss">
        <link:definition>025 - Disclosure - Additional Information to the Items of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LossPerShareAds" id="sprcy_r_LossPerShareAds">
        <link:definition>026 - Disclosure - Loss Per Share/Ads</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegments" id="sprcy_r_OperatingSegments">
        <link:definition>027 - Disclosure - Operating Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties" id="sprcy_r_TransactionsandBalanceswithRelatedParties">
        <link:definition>028 - Disclosure - Transactions and Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod" id="sprcy_r_SignificantEventsduringtheReportingPeriod">
        <link:definition>029 - Disclosure - Significant Events during the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EventsAftertheReportingPeriod" id="sprcy_r_EventsAftertheReportingPeriod">
        <link:definition>030 - Disclosure - Events After the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Warrants" id="sprcy_r_Warrants">
        <link:definition>031 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AccountingPoliciesByPolicy" id="sprcy_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables" id="sprcy_r_SignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/CashTables" id="sprcy_r_CashTables">
        <link:definition>996002 - Disclosure - Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InventoryTables" id="sprcy_r_InventoryTables">
        <link:definition>996003 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsReceivableTables" id="sprcy_r_OtherAccountsReceivableTables">
        <link:definition>996004 - Disclosure - Other Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesTables" id="sprcy_r_InvestmentinAssociatesTables">
        <link:definition>996005 - Disclosure - Investment in Associates (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNetTables" id="sprcy_r_PropertyandEquipmentNetTables">
        <link:definition>996006 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAssetTables" id="sprcy_r_IntangibleAssetTables">
        <link:definition>996007 - Disclosure - Intangible Asset (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TradePayablesTables" id="sprcy_r_TradePayablesTables">
        <link:definition>996008 - Disclosure - Trade Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsPayableTables" id="sprcy_r_OtherAccountsPayableTables">
        <link:definition>996009 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstrumentsTables" id="sprcy_r_FinancialInstrumentsTables">
        <link:definition>996010 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables" id="sprcy_r_EmployeeBenefitLiabilitiesTables">
        <link:definition>996011 - Disclosure - Employee Benefit Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EquityTables" id="sprcy_r_EquityTables">
        <link:definition>996012 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables" id="sprcy_r_ShareBasedPaymentTransactionsTables">
        <link:definition>996013 - Disclosure - Share-Based Payment Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables" id="sprcy_r_RevenuesandCostofRevenuesTables">
        <link:definition>996014 - Disclosure - Revenues and Cost of Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables">
        <link:definition>996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LossPerShareAdsTables" id="sprcy_r_LossPerShareAdsTables">
        <link:definition>996016 - Disclosure - Loss Per Share/Ads (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegmentsTables" id="sprcy_r_OperatingSegmentsTables">
        <link:definition>996017 - Disclosure - Operating Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesTables">
        <link:definition>996018 - Disclosure - Transactions and Balances with Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/WarrantsTables" id="sprcy_r_WarrantsTables">
        <link:definition>996019 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/GeneralDetails" id="sprcy_r_GeneralDetails">
        <link:definition>996020 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails" id="sprcy_r_SignificantAccountingPoliciesDetails">
        <link:definition>996021 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" id="sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable">
        <link:definition>996022 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofCashTable" id="sprcy_r_ScheduleofCashTable">
        <link:definition>996023 - Disclosure - Cash - Schedule of Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofInventoryTable" id="sprcy_r_ScheduleofInventoryTable">
        <link:definition>996024 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" id="sprcy_r_ScheduleofOtherAccountsReceivableTable">
        <link:definition>996025 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesDetails" id="sprcy_r_InvestmentinAssociatesDetails">
        <link:definition>996026 - Disclosure - Investment in Associates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable" id="sprcy_r_ScheduleofFairValueoftheInvestmentTable">
        <link:definition>996027 - Disclosure - Investment in Associates - Schedule of Fair Value of the Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails" id="sprcy_r_InvestmentinFinancialAssetsDetails">
        <link:definition>996028 - Disclosure - Investment in Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LeasesDetails" id="sprcy_r_LeasesDetails">
        <link:definition>996029 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails" id="sprcy_r_PropertyandEquipmentNetDetails">
        <link:definition>996030 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable" id="sprcy_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996031 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAssetDetails" id="sprcy_r_IntangibleAssetDetails">
        <link:definition>996032 - Disclosure - Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" id="sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable">
        <link:definition>996033 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTradePayablesTable" id="sprcy_r_ScheduleofTradePayablesTable">
        <link:definition>996034 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" id="sprcy_r_ScheduleofOtherAccountsPayableTable">
        <link:definition>996035 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstrumentsDetails" id="sprcy_r_FinancialInstrumentsDetails">
        <link:definition>996036 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" id="sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
        <link:definition>996037 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" id="sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable">
        <link:definition>996038 - Disclosure - Financial Instruments - Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable" id="sprcy_r_ScheduleofDefinedContributionPlansTable">
        <link:definition>996039 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TaxesonIncomeDetails" id="sprcy_r_TaxesonIncomeDetails">
        <link:definition>996040 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
        <link:definition>996041 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EquityDetails" id="sprcy_r_EquityDetails">
        <link:definition>996042 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofShareCapitalTable" id="sprcy_r_ScheduleofShareCapitalTable">
        <link:definition>996043 - Disclosure - Equity - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" id="sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable">
        <link:definition>996044 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" id="sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
        <link:definition>996045 - Disclosure - Equity - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails" id="sprcy_r_ShareBasedPaymentTransactionsDetails">
        <link:definition>996046 - Disclosure - Share-Based Payment Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" id="sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable">
        <link:definition>996047 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" id="sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable">
        <link:definition>996048 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" id="sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
        <link:definition>996049 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" id="sprcy_r_ScheduleofCostofSalesandGrossProfitTable">
        <link:definition>996050 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" id="sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
        <link:definition>996051 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" id="sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
        <link:definition>996052 - Disclosure - Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable" id="sprcy_r_ScheduleofOperatingSegmentsTable">
        <link:definition>996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHwcigou02yOi3RAgyAKCzKinttrVCX0GS4sD3ObxpwqEzqm9j1cZ4KQuocaRc2hMVSIDbMizaoWZ/nmzHQlBpYQrBXVpspuwa7a1yTY7nXsjphYT7GC7hOyPdg0YxoXQO1gmR5R+ZgPKpBP3bZFMnC2Ebp6iJyWLF8z43Po3rwKA==] CSR-->
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>996054 - Disclosure - Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" id="sprcy_r_ScheduleofBalanceswithRelatedPartiesTable">
        <link:definition>996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" id="sprcy_r_ScheduleofTransactionswithRelatedPartiesTable">
        <link:definition>996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" id="sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable">
        <link:definition>996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" id="sprcy_r_SignificantEventsduringtheReportingPeriodDetails">
        <link:definition>996058 - Disclosure - Significant Events during the Reporting Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EventsAftertheReportingPeriodDetails" id="sprcy_r_EventsAftertheReportingPeriodDetails">
        <link:definition>996059 - Disclosure - Events After the Reporting Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0" id="sprcy_r_ScheduleofFairValueoftheInvestmentTable0">
        <link:definition>996060 - Disclosure - Investment in Associate - Schedule of Fair Value of the Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0" id="sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable0">
        <link:definition>996061 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0" id="sprcy_r_ScheduleofBalanceswithRelatedPartiesTable0">
        <link:definition>996062 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0" id="sprcy_r_ScheduleofTransactionswithRelatedPartiesTable0">
        <link:definition>996063 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0" id="sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable0">
        <link:definition>996064 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" id="sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable0">
        <link:definition>996065 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/WarrantsDetails" id="sprcy_r_WarrantsDetails">
        <link:definition>996066 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable" id="sprcy_r_ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable">
        <link:definition>996067 - Disclosure - Warrants - Schedule of Fair Value was Calculated using the Black&#8211;Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofShareCapitalTable0" id="sprcy_r_ScheduleofShareCapitalTable0">
        <link:definition>996068 - Disclosure - Equity - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0" id="sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable0">
        <link:definition>996069 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0" id="sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0">
        <link:definition>996070 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable0" id="sprcy_r_ScheduleofOperatingSegmentsTable0">
        <link:definition>996071 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="ConsolidatedStatementsOfChangesInEquityDeficitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract"/>
  <xs:element name="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
  <xs:element name="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract"/>
  <xs:element name="ScheduleOfCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCashAbstract"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfInventoryAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsReceivableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheIntangibleAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
  <xs:element name="ScheduleOfTradePayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfTradePayablesAbstract"/>
  <xs:element name="DisclosureOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
  <xs:element name="ScheduleOfDefinedContributionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
  <xs:element name="ScheduleOfShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfShareCapitalAbstract"/>
  <xs:element name="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfExpensesDueToShareBasedCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
  <xs:element name="ScheduleOfFairValueForShareOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
  <xs:element name="ScheduleOfCostOfSalesAndGrossProfitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
  <xs:element name="DisclosureOfAdditionalInformationTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
  <xs:element name="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
  <xs:element name="ScheduleOfOperatingSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOperatingSegmentsAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfTransactionsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
  <xs:element name="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
  <xs:element name="WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsAbstract"/>
  <xs:element name="ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
  <xs:element name="AttributableToAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AttributableToAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract2"/>
  <xs:element name="AdjustmentsToTheProfitOrLossItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract22"/>
  <xs:element name="AdjustmentsToTheProfitOrLossItemsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract37"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract0"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract43"/>
  <xs:element name="NumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesAbstract"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract44"/>
  <xs:element name="a2022Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_a2022Abstract"/>
  <xs:element name="CostOfGoodsSoldAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostOfGoodsSoldAbstract"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract45"/>
  <xs:element name="AResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract47"/>
  <xs:element name="BGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract49"/>
  <xs:element name="COtherExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_COtherExpensesAbstract"/>
  <xs:element name="DFinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DFinanceIncomeAbstract"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract50"/>
  <xs:element name="EFinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EFinanceExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract51"/>
  <xs:element name="ContinuingOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ContinuingOperationsAbstract"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract52"/>
  <xs:element name="FinancialAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialAssetsAbstract"/>
  <xs:element name="FinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialLiabilitiesAbstract"/>
  <xs:element name="NumberOfSharesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesAbstract0"/>
  <xs:element name="AResearchAndDevelopmentExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AResearchAndDevelopmentExpensesAbstract0"/>
  <xs:element name="BGeneralAndAdministrativeExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BGeneralAndAdministrativeExpensesAbstract0"/>
  <xs:element name="ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExerciseOfWarrants"/>
  <xs:element name="IssueOfShareCapitalNetOfIssueExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
  <xs:element name="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
  <xs:element name="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
  <xs:element name="CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities"/>
  <xs:element name="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
  <xs:element name="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
  <xs:element name="ReceiptofShortTermCreditFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReceiptofShortTermCreditFromOthers"/>
  <xs:element name="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
  <xs:element name="RegistrationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegistrationOfWarrants"/>
  <xs:element name="InvestmentInFinancialAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentInFinancialAsset"/>
  <xs:element name="UnpaidIssueExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnpaidIssueExpenses"/>
  <xs:element name="MutualShareExchangeOfOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MutualShareExchangeOfOrdinaryShares"/>
  <xs:element name="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfOtherAccountsPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
  <xs:element name="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
  <xs:element name="WarrantsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsTextBlock"/>
  <xs:element name="BasisOfPresentationOfFinancialStatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BasisOfPresentationOfFinancialStatements"/>
  <xs:element name="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
  <xs:element name="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
  <xs:element name="DescriptionOfAcquisitionOfASingleAssetCompany" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
  <xs:element name="DescriptionOfAccountingPolicyForRestrictedDeposit" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
  <xs:element name="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock"/>
  <xs:element name="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
  <xs:element name="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
  <xs:element name="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
  <xs:element name="DisclosueOfCashAndCashEquivalentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
  <xs:element name="DisclosureOfInvertoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInvertoryTextBlock"/>
  <xs:element name="DisclourseOfAccountsReceivablesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
  <xs:element name="DisclosureOfFairValueOfTheIntangibleAssetTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock"/>
  <xs:element name="DisclosureOfTradePayables" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfTradePayables"/>
  <xs:element name="DisclosureOfFinancialAssetsAndFinancialLiabilities" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
  <xs:element name="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
  <xs:element name="DisclosureOfIssuedAndOutstandingShareCapital" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
  <xs:element name="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
  <xs:element name="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
  <xs:element name="DisclosureOfInformationToTheItemsOfProfitOrLoss" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
  <xs:element name="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
  <xs:element name="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
  <xs:element name="DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock"/>
  <xs:element name="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable"/>
  <xs:element name="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems"/>
  <xs:element name="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
  <xs:element name="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
  <xs:element name="LeaseholdImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseholdImprovements"/>
  <xs:element name="CashScheduleofCashDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_CashScheduleofCashDetailsTable"/>
  <xs:element name="CashScheduleofCashDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashScheduleofCashDetailsLineItems"/>
  <xs:element name="InvestmentsDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentsDate"/>
  <xs:element name="EquityLossesFromInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityLossesFromInvestment"/>
  <xs:element name="InvestmentAchievementOfFirstMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAchievementOfFirstMilestone"/>
  <xs:element name="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
  <xs:element name="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems"/>
  <xs:element name="PropertyPlantAndEquipmentAccumulatedDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
  <xs:element name="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
  <xs:element name="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems"/>
  <xs:element name="PurchaseofAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseofAssets"/>
  <xs:element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccruedExpenses"/>
  <xs:element name="FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GovernmentAuthorities"/>
  <xs:element name="InvestmentsInFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentsInFinancialAssets"/>
  <xs:element name="CreditFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CreditFromOthers"/>
  <xs:element name="WarrantsLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsLiability"/>
  <xs:element name="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable"/>
  <xs:element name="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems"/>
  <xs:element name="DividendYield" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DividendYield"/>
  <xs:element name="ExpectedVolatility" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpectedVolatility"/>
  <xs:element name="RiskFreeInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RiskFreeInterestRate"/>
  <xs:element name="UnderlyingAdsPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnderlyingAdsPrice"/>
  <xs:element name="ExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePricePerShare"/>
  <xs:element name="WarrantsFairValueinDollarsPerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsFairValueinDollarsPerShares"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
  <xs:element name="ShareIssuedToAConsultant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareIssuedToAConsultant"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfShelfProspectus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfRoundingErrors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
  <xs:element name="ResearchAndDevelopmentsExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentsExpenses"/>
  <xs:element name="GeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GeneralAndAdministrativeExpenses"/>
  <xs:element name="ExpensesDueToSharebasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpensesDueToSharebasedCompensation"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
  <xs:element name="UnderlyingOrdinarySharePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnderlyingOrdinarySharePrices"/>
  <xs:element name="NumberOfOutstandingShareOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfOutstandingShareOption"/>
  <xs:element name="NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
  <xs:element name="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
  <xs:element name="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
  <xs:element name="CostOfGoodsSold" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostOfGoodsSold"/>
  <xs:element name="IncomeStatementsLocationsDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IncomeStatementsLocationsDomainDomain"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
  <xs:element name="ResearchAndDevelopmentExpenses1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentExpenses1"/>
  <xs:element name="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
  <xs:element name="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable"/>
  <xs:element name="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems"/>
  <xs:element name="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
  <xs:element name="ExternalRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExternalRevenues"/>
  <xs:element name="TaxExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxExpense"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
  <xs:element name="ResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentExpenses"/>
  <xs:element name="KeyManagementPersonnelCompensationManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_KeyManagementPersonnelCompensationManagementFees"/>
  <xs:element name="InvestmentFollowingAchievementMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentFollowingAchievementMilestone"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems"/>
  <xs:element name="SignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="OperatingTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingTerm"/>
  <xs:element name="InvestmentinAssociatesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesDetailsTable"/>
  <xs:element name="InvestmentinAssociatesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesDetailsLineItems"/>
  <xs:element name="OrdinarySharesSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesSold"/>
  <xs:element name="OrdinarySharesParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesParValue"/>
  <xs:element name="PercentageOfSharesIssuedAndOutstandingShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
  <xs:element name="FairMarketValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairMarketValue"/>
  <xs:element name="PurchaseOfOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseOfOrdinaryShares"/>
  <xs:element name="DulyExecutedShareTransferDeedForOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares"/>
  <xs:element name="InvestmentFromShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentFromShareholders"/>
  <xs:element name="IssuedAndOutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuedAndOutstandingSharesPercentage"/>
  <xs:element name="FairValueOfInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfInvestment"/>
  <xs:element name="InitialInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialInvestment"/>
  <xs:element name="AdditionalInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInvestment"/>
  <xs:element name="OwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OwnershipPercentage"/>
  <xs:element name="OutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingSharesPercentage"/>
  <xs:element name="AdditionalInstallment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInstallment"/>
  <xs:element name="InstallmentPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPaid"/>
  <xs:element name="InvestmentinFinancialAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinFinancialAssetsDetailsTable"/>
  <xs:element name="InvestmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAmount"/>
  <xs:element name="ShareCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareCapitalPercentage"/>
  <xs:element name="SharePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePricePerShare"/>
  <xs:element name="ComprehensiveLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ComprehensiveLoss"/>
  <xs:element name="PricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PricePerShare"/>
  <xs:element name="AdditionalLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalLoan"/>
  <xs:element name="RepaymentClosingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RepaymentClosingAmount"/>
  <xs:element name="FinderFeePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinderFeePercentage"/>
  <xs:element name="NumberOfSharesOutstandingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesOutstandingPercentage"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeasesDetailsLineItems"/>
  <xs:element name="SquareMeters" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SquareMeters"/>
  <xs:element name="LeaseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseFee"/>
  <xs:element name="ExpireTerm" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpireTerm"/>
  <xs:element name="PropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetDetailsTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyandEquipmentNetDetailsLineItems"/>
  <xs:element name="PurchaseCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseCosts"/>
  <xs:element name="WarrantsToPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsToPurchase"/>
  <xs:element name="ExercisePrice1" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePrice1"/>
  <xs:element name="ExercisePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePeriod"/>
  <xs:element name="pricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_pricePerShare"/>
  <xs:element name="AmountTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AmountTotal"/>
  <xs:element name="RevenueTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RevenueTerm"/>
  <xs:element name="GrowthRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GrowthRatePercentage"/>
  <xs:element name="LongTermPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LongTermPercentage"/>
  <xs:element name="PurchaseCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseCostsValue"/>
  <xs:element name="FinancialInstrumentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsDetailsTable"/>
  <xs:element name="PurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePrice"/>
  <xs:element name="MaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MaturityDate"/>
  <xs:element name="InitialConversionPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialConversionPrice"/>
  <xs:element name="ConversionPrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConversionPrice"/>
  <xs:element name="OrdinaryShareExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinaryShareExercisePrice"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsTaxAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingLossCarryforwardsTaxAmount"/>
  <xs:element name="DekelLicenseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DekelLicenseAgreementDescription"/>
  <xs:element name="AnnualInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AnnualInvestment"/>
  <xs:element name="AdditionalMilestoneAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalMilestoneAmount"/>
  <xs:element name="InstallmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentAmount"/>
  <xs:element name="EstimatedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EstimatedAmount"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityDetailsLineItems"/>
  <xs:element name="DescriptionOfReverseShareSplit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfReverseShareSplit"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GrossProceeds"/>
  <xs:element name="IssuanceOfAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfAggregateShares"/>
  <xs:element name="AggregateUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateUnits"/>
  <xs:element name="AggregateUnitsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateUnitsPerShare"/>
  <xs:element name="DateOfIssuance" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DateOfIssuance"/>
  <xs:element name="WarrantsAndExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsAndExercise"/>
  <xs:element name="WarrantsExercisePrice" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsExercisePrice"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePricePerShare"/>
  <xs:element name="AggregateGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateGrossProceeds"/>
  <xs:element name="CapitalRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalRatio"/>
  <xs:element name="CommitmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CommitmentAmount"/>
  <xs:element name="SaleOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SaleOfOrdinaryShares"/>
  <xs:element name="SharePriceRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePriceRate"/>
  <xs:element name="InterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestRate"/>
  <xs:element name="InstallmentPayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPayment"/>
  <xs:element name="PaymentForPremiumPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentForPremiumPercentage"/>
  <xs:element name="AggregateIssuedAmount" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateIssuedAmount"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
  <xs:element name="OrdinarySharesGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesGranted"/>
  <xs:element name="FairValueOfShareOption" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfShareOption"/>
  <xs:element name="ShareOptionsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareOptionsGranted"/>
  <xs:element name="FairValueOfShareOptionsGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfShareOptionsGranted"/>
  <xs:element name="OrdinarySharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesIssued"/>
  <xs:element name="OrdinarySharesGrantedDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesGrantedDiscountRate"/>
  <xs:element name="FairValueOfOrdinarySharesGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfOrdinarySharesGranted"/>
  <xs:element name="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
  <xs:element name="ExchangeOfCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeOfCommonShares"/>
  <xs:element name="OutstandingShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingShareCapital"/>
  <xs:element name="PercentageOfOutstandingShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfOutstandingShareCapital"/>
  <xs:element name="CashConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashConsideration"/>
  <xs:element name="CooperationAgreementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CooperationAgreementAmount"/>
  <xs:element name="SignificantEventsduringtheReportingPeriodDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
  <xs:element name="SignificantEventsduringtheReportingPeriodDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
  <xs:element name="InterestPercentgae" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestPercentgae"/>
  <xs:element name="DeferredCashPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DeferredCashPayments"/>
  <xs:element name="FeeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FeeExpenses"/>
  <xs:element name="BonusAmountReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BonusAmountReceived"/>
  <xs:element name="MutualShareExchangeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MutualShareExchangeAmount"/>
  <xs:element name="OrdinarySharesAcquired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesAcquired"/>
  <xs:element name="AggregateValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateValue"/>
  <xs:element name="AdjustedAmountOfAggregateValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustedAmountOfAggregateValue"/>
  <xs:element name="ListedSharePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ListedSharePrice"/>
  <xs:element name="ComprehensiveLossOnInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ComprehensiveLossOnInvestment"/>
  <xs:element name="EventsAftertheReportingPeriodDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EventsAftertheReportingPeriodDetailsTable"/>
  <xs:element name="EventsAftertheReportingPeriodDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EventsAftertheReportingPeriodDetailsLineItems"/>
  <xs:element name="SharePricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePricePercentage"/>
  <xs:element name="PrepaidAdvance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrepaidAdvance"/>
  <xs:element name="AccruedInterestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccruedInterestPercentage"/>
  <xs:element name="CommitmentPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CommitmentPercentage"/>
  <xs:element name="InstallmentPaymentPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPaymentPercentage"/>
  <xs:element name="PaymentPremiumPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentPremiumPercentage"/>
  <xs:element name="AssetAndSharePurchaseAgreementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AssetAndSharePurchaseAgreementValue"/>
  <xs:element name="EntityStakeholdersRange" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EntityStakeholdersRange"/>
  <xs:element name="IssuedAndOutstandingSharePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuedAndOutstandingSharePercentage"/>
  <xs:element name="WarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_WarrantsDetailsTable"/>
  <xs:element name="WarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsDetailsLineItems"/>
  <xs:element name="ProceedsFromIssuanceOfPrivateOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProceedsFromIssuanceOfPrivateOffering"/>
  <xs:element name="IssuanceAggregateOfPrefundedUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceAggregateOfPrefundedUnits"/>
  <xs:element name="PreFundedUnitShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PreFundedUnitShares"/>
  <xs:element name="PreFundedUnitPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PreFundedUnitPerShare"/>
  <xs:element name="IncomeStatementsLocationsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="sprcy_IncomeStatementsLocationsAxis"/>
  <xs:element name="AmazonFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AmazonFeesMember"/>
  <xs:element name="AutoMaxAcquisitionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AutoMaxAcquisitionMember"/>
  <xs:element name="AutoMaxMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AutoMaxMember"/>
  <xs:element name="AutoMaxMotorsLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AutoMaxMotorsLtdMember"/>
  <xs:element name="BridgeLoansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BridgeLoansMember"/>
  <xs:element name="BusinessDevelopmentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BusinessDevelopmentExpensesMember"/>
  <xs:element name="CapitalPointMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalPointMember"/>
  <xs:element name="CapitalPointWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalPointWarrantMember"/>
  <xs:element name="ChemistryAndFormulationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ChemistryAndFormulationsMember"/>
  <xs:element name="ClearmindMedicineIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClearmindMedicineIncMember"/>
  <xs:element name="ClinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClinicalStudiesMember"/>
  <xs:element name="CoeruleusMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CoeruleusMember"/>
  <xs:element name="DrugDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DrugDevelopmentMember"/>
  <xs:element name="EveroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EveroMember"/>
  <xs:element name="ExchangeRateDifferencesNetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeRateDifferencesNetMember"/>
  <xs:element name="FinanceExpenseInRespectOfLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpenseInRespectOfLeasesMember"/>
  <xs:element name="FinanceExpensesFromInterestAndCommissionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
  <xs:element name="FreightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FreightMember"/>
  <xs:element name="InvestmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentMember"/>
  <xs:element name="InvestorRelationsAndBusinessExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestorRelationsAndBusinessExpensesMember"/>
  <xs:element name="IssuanceExpensesRelatedToWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
  <xs:element name="JeffsBrandsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_JeffsBrandsMember"/>
  <xs:element name="June2022WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_June2022WarrantsMember"/>
  <xs:element name="LeaseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseMember"/>
  <xs:element name="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
  <xs:element name="March2021FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_March2021FinancingRoundMember"/>
  <xs:element name="MitoCareXBioLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXBioLtdMember"/>
  <xs:element name="MitoCareXMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXMember"/>
  <xs:element name="MizaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MizaMember"/>
  <xs:element name="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
  <xs:element name="NewCoIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NewCoIncMember"/>
  <xs:element name="OfficeEquipmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeEquipmentsMember"/>
  <xs:element name="OfficeMaintenanceRentAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
  <xs:element name="OnlineSalesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OnlineSalesMember"/>
  <xs:element name="OverAllotmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OverAllotmentMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrefundedWarrantsMember"/>
  <xs:element name="PrivatePlacementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrivatePlacementsMember"/>
  <xs:element name="ProfessionalAndDirectorsFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProfessionalAndDirectorsFeesMember"/>
  <xs:element name="PurchasedGoodsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasedGoodsMember"/>
  <xs:element name="RegulatoryExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryExpensesMember"/>
  <xs:element name="RegulatoryProfessionalAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
  <xs:element name="ResearchAndPreclinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndPreclinicalStudiesMember"/>
  <xs:element name="SEPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SEPAMember"/>
  <xs:element name="ScenarioForecastsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScenarioForecastsMember"/>
  <xs:element name="SciSparcMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SciSparcMember"/>
  <xs:element name="SeriesAWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SeriesAWarrantsMember"/>
  <xs:element name="SeriesBWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SeriesBWarrantsMember"/>
  <xs:element name="ShareBasedPaymentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentMember"/>
  <xs:element name="StorageMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StorageMember"/>
  <xs:element name="SubsequentEventsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SubsequentEventsMember"/>
  <xs:element name="TransactionsWithRelatedPartiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsWithRelatedPartiesMember"/>
  <xs:element name="TwoThousandTwentyThreePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TwoThousandTwentyThreePlanMember"/>
  <xs:element name="WagesAndRelatedExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WagesAndRelatedExpensesMember"/>
  <xs:element name="WellutionOperatingExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WellutionOperatingExpensesMember"/>
  <xs:element name="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
  <xs:element name="InventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InventoryAbstract"/>
  <xs:element name="SegmentReportingRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SegmentReportingRevenueAbstract"/>
  <xs:element name="SignificantNonCashTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantNonCashTransactionsAbstract"/>
  <xs:element name="WorkingCapitalAdjustmentssAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WorkingCapitalAdjustmentssAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>67
<FILENAME>sprcy-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Feb 13 15:57:33 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedIncomeStatementAlt0" roleURI="http://trpx.com/role/ConsolidatedIncomeStatementAlt0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"/>
  <calculationLink xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentReceivables" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentWarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_SharePremium" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_WarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_OtherEquityInterest" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_RetainedEarnings" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_NoncontrollingInterests" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SalesAndMarketingExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ConsolidatedIncomeStatementAlt0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHwcigou02yOi3RAgyAKCzKinttrVCX0GS4sD3ObxpwqEzqm9j1cZ4KQuocaRc2hMVSIDbMizaoWZ/nmzHQlBpYQrBXVpspuwa7a1yTY7nXsjphYT7GC7hOyPdg0YxoXQO1gmR5R+ZgPKpBP3bZFMnCsk6Ztze7AzHrzymcTRVGHQ==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" xlink:href="sprcy-20240630.xsd#sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20240630.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_FinishedGoods" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20240630.xsd#sprcy_AccruedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="sprcy_AccruedExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_Accruals" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_OtherPayables" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20240630.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentsExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentsExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_ResearchAndDevelopmentsExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAndAdministrativeExpenses" xlink:href="sprcy-20240630.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_GeneralAndAdministrativeExpenses" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansAndAdvances" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansAndAdvances"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_LoansAndAdvances" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_TradeReceivables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20240630.xsd#sprcy_GovernmentAuthorities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="sprcy_GovernmentAuthorities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_OtherReceivables" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssets" xlink:to="sprcy_InvestmentsInFinancialAssets" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_CreditFromOthers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="sprcy_CreditFromOthers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="sprcy_WarrantsLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_LeaseLiabilities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>68
<FILENAME>sprcy-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Feb 13 15:57:33 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_General" roleURI="http://trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Cash" roleURI="http://trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Inventory" roleURI="http://trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinAssociates" roleURI="http://trpx.com/role/InvestmentinAssociates"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Leases" roleURI="http://trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_IntangibleAsset" roleURI="http://trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TradePayables" roleURI="http://trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_FinancialInstruments" roleURI="http://trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TaxesonIncome" roleURI="http://trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Equity" roleURI="http://trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_LossPerShareAds" roleURI="http://trpx.com/role/LossPerShareAds"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OperatingSegments" roleURI="http://trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EventsAftertheReportingPeriod" roleURI="http://trpx.com/role/EventsAftertheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Warrants" roleURI="http://trpx.com/role/Warrants"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_CashTables" roleURI="http://trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InventoryTables" roleURI="http://trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinAssociatesTables" roleURI="http://trpx.com/role/InvestmentinAssociatesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TradePayablesTables" roleURI="http://trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EquityTables" roleURI="http://trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_LossPerShareAdsTables" roleURI="http://trpx.com/role/LossPerShareAdsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_WarrantsTables" roleURI="http://trpx.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofCostofSalesandGrossProfitTable" roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable0" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable0" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable0" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable0" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable0" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofShareCapitalTable0" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable0" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOperatingSegmentsTable0" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_GeneralDetails" roleURI="http://trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinAssociatesDetails" roleURI="http://trpx.com/role/InvestmentinAssociatesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_LeasesDetails" roleURI="http://trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_FinancialInstrumentsDetails" roleURI="http://trpx.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EquityDetails" roleURI="http://trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EventsAftertheReportingPeriodDetails" roleURI="http://trpx.com/role/EventsAftertheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_WarrantsDetails" roleURI="http://trpx.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#DocumentAndEntityInformation" roleURI="http://trpx.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Inventories" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_SharePremium" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_WarrantLiability" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_RetainedEarnings" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_WarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_OtherEquityInterestMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ParentMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfWarrants" xlink:href="sprcy-20240630.xsd#sprcy_ExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_ExerciseOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20240630.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreviouslyStatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20240630.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20240630.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegistrationOfWarrants" xlink:href="sprcy-20240630.xsd#sprcy_RegistrationOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_RegistrationOfWarrants" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentInFinancialAsset" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentInFinancialAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_InvestmentInFinancialAsset" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnpaidIssueExpenses" xlink:href="sprcy-20240630.xsd#sprcy_UnpaidIssueExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_UnpaidIssueExpenses" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" xlink:href="sprcy-20240630.xsd#sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_MutualShareExchangeOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_MutualShareExchangeOfOrdinaryShares" order="39" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Cash" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InventoryAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OtherAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinAssociates" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinFinancialAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/IntangibleAsset" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TradePayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OtherAccountsPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EmployeeBenefitLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/RevenuesandCostofRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/LossPerShareAds" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OperatingSegments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriod" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EventsAftertheReportingPeriod" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Warrants" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsAbstract" xlink:to="sprcy_WarrantsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20240630.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/CashTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAbstract" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInvertoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfInvertoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InventoryAbstract" xlink:to="sprcy_DisclosureOfInvertoryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OtherAccountsReceivableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinAssociatesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/IntangibleAssetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TradePayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayables" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfTradePayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="sprcy_DisclosureOfTradePayables" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OtherAccountsPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EmployeeBenefitLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/RevenuesandCostofRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/LossPerShareAdsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OperatingSegmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/WarrantsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsAbstract" xlink:to="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:to="ifrs-full_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20240630.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovements" xlink:href="sprcy-20240630.xsd#sprcy_LeaseholdImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="sprcy_LeaseholdImprovements" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_CashScheduleofCashDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_CashScheduleofCashDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashScheduleofCashDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_CashScheduleofCashDetailsLineItems" xlink:to="sprcy_CashScheduleofCashDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_CashScheduleofCashDetailsTable" xlink:to="srt_CurrencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_ILS" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CashScheduleofCashDetailsLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfInventoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_FinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_Inventories" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsDate" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_InvestmentsDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestment" xlink:href="sprcy-20240630.xsd#sprcy_EquityLossesFromInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_EquityLossesFromInvestment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20240630.xsd#sprcy_OfficeEquipmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="sprcy_OfficeEquipmentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:href="sprcy-20240630.xsd#sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseofAssets" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseofAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="sprcy_PurchaseofAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20240630.xsd#sprcy_AccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="sprcy_AccruedExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_Accruals" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BusinessCombinationsDomain" xlink:to="ifrs-full_CarryingAmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20240630.xsd#sprcy_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="sprcy_GovernmentAuthorities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_OtherReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="sprcy_InvestmentsInFinancialAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_CreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="sprcy_CreditFromOthers" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="sprcy_WarrantsLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DividendYield" xlink:href="sprcy-20240630.xsd#sprcy_DividendYield"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="sprcy_DividendYield" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpectedVolatility" xlink:href="sprcy-20240630.xsd#sprcy_ExpectedVolatility"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="sprcy_ExpectedVolatility" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RiskFreeInterestRate" xlink:href="sprcy-20240630.xsd#sprcy_RiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="sprcy_RiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingAdsPrice" xlink:href="sprcy-20240630.xsd#sprcy_UnderlyingAdsPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="sprcy_UnderlyingAdsPrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="sprcy_ExercisePricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofDefinedContributionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultant" xlink:href="sprcy-20240630.xsd#sprcy_ShareIssuedToAConsultant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ShareIssuedToAConsultant" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentsExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentsExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ResearchAndDevelopmentsExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAndAdministrativeExpenses" xlink:href="sprcy-20240630.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_GeneralAndAdministrativeExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20240630.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ExpensesDueToSharebasedCompensation" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20240630.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingOrdinarySharePrices" xlink:href="sprcy-20240630.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_UnderlyingOrdinarySharePrices" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOutstandingShareOption" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_NumberOfOutstandingShareOption" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_AmazonFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_AmazonFeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasedGoodsMember" xlink:href="sprcy-20240630.xsd#sprcy_PurchasedGoodsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_PurchasedGoodsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageMember" xlink:href="sprcy-20240630.xsd#sprcy_StorageMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_StorageMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FreightMember" xlink:href="sprcy-20240630.xsd#sprcy_FreightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_FreightMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostOfGoodsSold" xlink:href="sprcy-20240630.xsd#sprcy_CostOfGoodsSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="sprcy_CostOfGoodsSold" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="sprcy_IncomeStatementsLocationsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_0" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WagesAndRelatedExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ShareBasedPaymentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ClinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ClinicalStudiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20240630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ChemistryAndFormulationsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_AmazonFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_AmazonFeesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageMember" xlink:href="sprcy-20240630.xsd#sprcy_StorageMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_StorageMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_BusinessDevelopmentExpensesMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryExpensesMember"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHwcigou02yOi3RAgyAKCzKinttrVCX0GS4sD3ObxpwqEzqm9j1cZ4KQuocaRc2hMVSIDbMizaoWZ/nmzHQlBpYQrBXVpspuwa7a1yTY7nXsjphYT7GC7hOyPdg0YxoXQO1gmR5R+ZgPKpBP3bZFMnCrFZBe/fcy29IzwFHEuOz9Q==] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryExpensesMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20240630.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeRateDifferencesNetMember" xlink:href="sprcy-20240630.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ExchangeRateDifferencesNetMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20240630.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20240630.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20240630.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_ResearchAndDevelopmentExpenses1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20240630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_FinanceIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_FinanceCosts" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:to="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreviouslyStatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:to="ifrs-full_WeightedAverageShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20240630.xsd#sprcy_DrugDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_DrugDevelopmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20240630.xsd#sprcy_OnlineSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_OnlineSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20240630.xsd#sprcy_ExternalRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_ExternalRevenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20240630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxExpense" xlink:href="sprcy-20240630.xsd#sprcy_TaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_TaxExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_ResearchAndDevelopmentExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20240630.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentFollowingAchievementMilestone" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentFollowingAchievementMilestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_InvestmentFollowingAchievementMilestone" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsWithRelatedPartiesMember" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsWithRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_TransactionsWithRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20240630.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansAndAdvances" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansAndAdvances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LoansAndAdvances" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_TradeReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20240630.xsd#sprcy_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_GovernmentAuthorities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_OtherReceivables" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_InvestmentsInFinancialAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_CreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_CreditFromOthers" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_WarrantsLiability" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultant" xlink:href="sprcy-20240630.xsd#sprcy_ShareIssuedToAConsultant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ShareIssuedToAConsultant" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="sprcy_IncomeStatementsLocationsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_0" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WagesAndRelatedExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ShareBasedPaymentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ClinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ClinicalStudiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20240630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ChemistryAndFormulationsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_BusinessDevelopmentExpensesMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WellutionOperatingExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_WellutionOperatingExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WellutionOperatingExpensesMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_AmazonFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_AmazonFeesMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryExpensesMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20240630.xsd#sprcy_DrugDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_DrugDevelopmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20240630.xsd#sprcy_OnlineSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_OnlineSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20240630.xsd#sprcy_ExternalRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_ExternalRevenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20240630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxExpense" xlink:href="sprcy-20240630.xsd#sprcy_TaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_TaxExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:to="sprcy_SignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20240630.xsd#sprcy_OperatingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:to="sprcy_OperatingTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinAssociatesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinAssociatesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinAssociatesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InvestmentinAssociatesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EveroMember" xlink:href="sprcy-20240630.xsd#sprcy_EveroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_EveroMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointMember" xlink:href="sprcy-20240630.xsd#sprcy_CapitalPointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_CapitalPointMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CoeruleusMember" xlink:href="sprcy-20240630.xsd#sprcy_CoeruleusMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_CoeruleusMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20240630.xsd#sprcy_MitoCareXBioLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXBioLtdMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20240630.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointWarrantMember" xlink:href="sprcy-20240630.xsd#sprcy_CapitalPointWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_CapitalPointWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesSold" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_OrdinarySharesSold" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesParValue" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_OrdinarySharesParValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairMarketValue" xlink:href="sprcy-20240630.xsd#sprcy_FairMarketValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_FairMarketValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_PurchaseOfOrdinaryShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_DulyExecutedShareTransferDeedForOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentFromShareholders" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentFromShareholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InvestmentFromShareholders" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20240630.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfInvestment" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_FairValueOfInvestment" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20240630.xsd#sprcy_InitialInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InitialInvestment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInvestment" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_AdditionalInvestment" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20240630.xsd#sprcy_OwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_OwnershipPercentage" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20240630.xsd#sprcy_OutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_OutstandingSharesPercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInstallment" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInstallment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_AdditionalInstallment" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaid" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InstallmentPaid" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestment" xlink:href="sprcy-20240630.xsd#sprcy_EquityLossesFromInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_EquityLossesFromInvestment" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_InvestmentIncome" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_OtherIncome" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinFinancialAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxMotorsLtdMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxMotorsLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_AutoMaxMotorsLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BridgeLoansMember" xlink:href="sprcy-20240630.xsd#sprcy_BridgeLoansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_BridgeLoansMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxAcquisitionMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxAcquisitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_AutoMaxAcquisitionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_AutoMaxMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="currency_ILS" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentMember" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="sprcy_InvestmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScenarioForecastsMember" xlink:href="sprcy-20240630.xsd#sprcy_ScenarioForecastsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="sprcy_ScenarioForecastsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_InvestmentAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20240630.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_SharePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_SharePricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLoss" xlink:href="sprcy-20240630.xsd#sprcy_ComprehensiveLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_ComprehensiveLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_Cash" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_PricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_PricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_LoansReceived" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_FinanceIncome" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalLoan" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_AdditionalLoan" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaymentClosingAmount" xlink:href="sprcy-20240630.xsd#sprcy_RepaymentClosingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_RepaymentClosingAmount" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_InterestExpense" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinderFeePercentage" xlink:href="sprcy-20240630.xsd#sprcy_FinderFeePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_FinderFeePercentage" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesOutstandingPercentage" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfSharesOutstandingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_NumberOfSharesOutstandingPercentage" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20240630.xsd#sprcy_LeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_LeaseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SquareMeters" xlink:href="sprcy-20240630.xsd#sprcy_SquareMeters"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_SquareMeters" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseFee" xlink:href="sprcy-20240630.xsd#sprcy_LeaseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeaseFee" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpireTerm" xlink:href="sprcy-20240630.xsd#sprcy_ExpireTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_ExpireTerm" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_DepreciationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/IntangibleAssetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCosts" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_PurchaseCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsToPurchase" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsToPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_WarrantsToPurchase" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePrice1" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_ExercisePrice1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePeriod" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_ExercisePeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_pricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_pricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_pricePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmountTotal" xlink:href="sprcy-20240630.xsd#sprcy_AmountTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_AmountTotal" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenueTerm" xlink:href="sprcy-20240630.xsd#sprcy_RevenueTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_RevenueTerm" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrowthRatePercentage" xlink:href="sprcy-20240630.xsd#sprcy_GrowthRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_GrowthRatePercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LongTermPercentage" xlink:href="sprcy-20240630.xsd#sprcy_LongTermPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_LongTermPercentage" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCostsValue" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseCostsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_PurchaseCostsValue" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrivatePlacementsMember" xlink:href="sprcy-20240630.xsd#sprcy_PrivatePlacementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="sprcy_PrivatePlacementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePrice" xlink:href="sprcy-20240630.xsd#sprcy_PurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_PurchasePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MaturityDate" xlink:href="sprcy-20240630.xsd#sprcy_MaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_MaturityDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialConversionPrice" xlink:href="sprcy-20240630.xsd#sprcy_InitialConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_InitialConversionPrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConversionPrice" xlink:href="sprcy-20240630.xsd#sprcy_ConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_ConversionPrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareExercisePrice" xlink:href="sprcy-20240630.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_OrdinaryShareExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20240630.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20240630.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_DekelLicenseAgreementDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20240630.xsd#sprcy_AnnualInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_AnnualInvestment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalMilestoneAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_AdditionalMilestoneAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_InstallmentAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EstimatedAmount" xlink:href="sprcy-20240630.xsd#sprcy_EstimatedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_EstimatedAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_CapitalCommitments" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreationDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_CreationDateAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20240630.xsd#sprcy_JeffsBrandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_JeffsBrandsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreviouslyStatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="sprcy_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OverAllotmentMember" xlink:href="sprcy-20240630.xsd#sprcy_OverAllotmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="sprcy_OverAllotmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesAWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_SeriesAWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_SeriesAWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesBWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_SeriesBWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_SeriesBWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_June2022WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_June2022WarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_March2021FinancingRoundMember" xlink:href="sprcy-20240630.xsd#sprcy_March2021FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="sprcy_March2021FinancingRoundMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfReverseShareSplit" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_DescriptionOfReverseShareSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrossProceeds" xlink:href="sprcy-20240630.xsd#sprcy_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_GrossProceeds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_IssuanceOfAggregateShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnits" xlink:href="sprcy-20240630.xsd#sprcy_AggregateUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_AggregateUnits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnitsPerShare" xlink:href="sprcy-20240630.xsd#sprcy_AggregateUnitsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_AggregateUnitsPerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DateOfIssuance" xlink:href="sprcy-20240630.xsd#sprcy_DateOfIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_DateOfIssuance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAndExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_WarrantsAndExercise" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExercisePrice" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_WarrantsExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_PurchasePricePerShare" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20240630.xsd#sprcy_AggregateGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_AggregateGrossProceeds" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalRatio" xlink:href="sprcy-20240630.xsd#sprcy_CapitalRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_CapitalRatio" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_ServicesExpense" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_CommitmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_CommitmentAmount" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_SaleOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_SaleOfOrdinaryShares" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePriceRate" xlink:href="sprcy-20240630.xsd#sprcy_SharePriceRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_SharePriceRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestRate" xlink:href="sprcy-20240630.xsd#sprcy_InterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_InterestRate" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPayment" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_InstallmentPayment" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentForPremiumPercentage" xlink:href="sprcy-20240630.xsd#sprcy_PaymentForPremiumPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_PaymentForPremiumPercentage" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateIssuedAmount" xlink:href="sprcy-20240630.xsd#sprcy_AggregateIssuedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_AggregateIssuedAmount" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20240630.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="sprcy_TwoThousandTwentyThreePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGranted" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinarySharesGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOption" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueOfShareOption" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareOptionsGranted" xlink:href="sprcy-20240630.xsd#sprcy_ShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareOptionsGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOptionsGranted" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueOfShareOptionsGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesIssued" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinarySharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfOrdinarySharesGranted" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfOrdinarySharesGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueOfOrdinarySharesGranted" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20240630.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClearmindMedicineIncMember" xlink:href="sprcy-20240630.xsd#sprcy_ClearmindMedicineIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_ClearmindMedicineIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_ResearchAndDevelopmentExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeOfCommonShares" xlink:href="sprcy-20240630.xsd#sprcy_ExchangeOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_ExchangeOfCommonShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_OutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_OutstandingShareCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_PercentageOfOutstandingShareCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashConsideration" xlink:href="sprcy-20240630.xsd#sprcy_CashConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_CashConsideration" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CooperationAgreementAmount" xlink:href="sprcy-20240630.xsd#sprcy_CooperationAgreementAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_CooperationAgreementAmount" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NewCoIncMember" xlink:href="sprcy-20240630.xsd#sprcy_NewCoIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_NewCoIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20240630.xsd#sprcy_JeffsBrandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_JeffsBrandsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentgae" xlink:href="sprcy-20240630.xsd#sprcy_InterestPercentgae"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_InterestPercentgae" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Cash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayments" xlink:href="sprcy-20240630.xsd#sprcy_DeferredCashPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_DeferredCashPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20240630.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FeeExpenses" xlink:href="sprcy-20240630.xsd#sprcy_FeeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_FeeExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20240630.xsd#sprcy_BonusAmountReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_BonusAmountReceived" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ServicesExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeAmount" xlink:href="sprcy-20240630.xsd#sprcy_MutualShareExchangeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_MutualShareExchangeAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesAcquired" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_OrdinarySharesAcquired" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValue" xlink:href="sprcy-20240630.xsd#sprcy_AggregateValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_AggregateValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustedAmountOfAggregateValue" xlink:href="sprcy-20240630.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_AdjustedAmountOfAggregateValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20240630.xsd#sprcy_OwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_OwnershipPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ListedSharePrice" xlink:href="sprcy-20240630.xsd#sprcy_ListedSharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_ListedSharePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLossOnInvestment" xlink:href="sprcy-20240630.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_ComprehensiveLossOnInvestment" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EventsAftertheReportingPeriodDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_EventsAftertheReportingPeriodDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingPeriodDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_EventsAftertheReportingPeriodDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_EventsAftertheReportingPeriodDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_RangeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SEPAMember" xlink:href="sprcy-20240630.xsd#sprcy_SEPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_SEPAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MizaMember" xlink:href="sprcy-20240630.xsd#sprcy_MizaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MizaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SciSparcMember" xlink:href="sprcy-20240630.xsd#sprcy_SciSparcMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_SciSparcMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20240630.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentEventsMember" xlink:href="sprcy-20240630.xsd#sprcy_SubsequentEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="sprcy_SubsequentEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScenarioForecastsMember" xlink:href="sprcy-20240630.xsd#sprcy_ScenarioForecastsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="sprcy_ScenarioForecastsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePercentage" xlink:href="sprcy-20240630.xsd#sprcy_SharePricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_SharePricePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrepaidAdvance" xlink:href="sprcy-20240630.xsd#sprcy_PrepaidAdvance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_PrepaidAdvance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedInterestPercentage" xlink:href="sprcy-20240630.xsd#sprcy_AccruedInterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_AccruedInterestPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentPercentage" xlink:href="sprcy-20240630.xsd#sprcy_CommitmentPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_CommitmentPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaymentPercentage" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPaymentPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_InstallmentPaymentPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentPremiumPercentage" xlink:href="sprcy-20240630.xsd#sprcy_PaymentPremiumPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_PaymentPremiumPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AssetAndSharePurchaseAgreementValue" xlink:href="sprcy-20240630.xsd#sprcy_AssetAndSharePurchaseAgreementValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_AssetAndSharePurchaseAgreementValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Assets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EntityStakeholdersRange" xlink:href="sprcy-20240630.xsd#sprcy_EntityStakeholdersRange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_EntityStakeholdersRange" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_RevenueFromRoyalties" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20240630.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_IssuedAndOutstandingSharePercentage" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/WarrantsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_WarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_WarrantsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssuanceOfPrivateOffering" xlink:href="sprcy-20240630.xsd#sprcy_ProceedsFromIssuanceOfPrivateOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_ProceedsFromIssuanceOfPrivateOffering" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceAggregateOfPrefundedUnits" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceAggregateOfPrefundedUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_IssuanceAggregateOfPrefundedUnits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreFundedUnitShares" xlink:href="sprcy-20240630.xsd#sprcy_PreFundedUnitShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_PreFundedUnitShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreFundedUnitPerShare" xlink:href="sprcy-20240630.xsd#sprcy_PreFundedUnitPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_PreFundedUnitPerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>69
<FILENAME>sprcy-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Feb 13 15:57:33 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Profit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_lbl3" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_ProfitLoss_lbl4" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl4"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xml:lang="en-US">Total adjustments to the profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl" xml:lang="en-US">Increase (decrease) in working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash for immediate withdrawal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract_lbl" xml:lang="en-US">Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAbstract_lbl" xml:lang="en-US">Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_CashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCashAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCashAbstract_lbl" xml:lang="en-US">Schedule of Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCashAbstract" xlink:to="sprcy_ScheduleOfCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_InventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InventoryAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InventoryAbstract" xlink:to="sprcy_InventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfInventoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="sprcy_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Total Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsReceivableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl0" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl" xml:lang="en-US">Investment in Associates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Investment in Financial Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl" xml:lang="en-US">Cost, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl0" xml:lang="en-US">Cost, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:href="sprcy-20240630.xsd#sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl" xml:lang="en-US">Accumulated depreciation, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl0" xml:lang="en-US">Accumulated depreciation, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract_lbl" xml:lang="en-US">Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Intangible asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfTradePayablesAbstract_lbl" xml:lang="en-US">Schedule of Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="sprcy_ScheduleOfTradePayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:to="sprcy_DisclosureOfOtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US">Business combinations [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_lbl" xml:lang="en-US">Employee Benefit Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract_lbl" xml:lang="en-US">Contingent Liabilities, Commitments, Claims and Liens [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl2" xml:lang="en-US">Issuance of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl3" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl3"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl" xml:lang="en-US">Share-Based Payment Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20240630.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="sprcy_ExpensesDueToSharebasedCompensation_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_ExpensesDueToSharebasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOutstandingShareOption" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl" xml:lang="en-US">Number of Share Options , Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl0" xml:lang="en-US">Number of Share Options, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US">Revenues and Cost of Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl" xml:lang="en-US">Income Statements Locations [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share/Ads [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsAxis_lbl" xml:lang="en-US">Segments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel[Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract_lbl" xml:lang="en-US">Significant Events during the Reporting Period [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Events After the Reporting Period [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Total financial and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">Total financial and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsAbstract_lbl" xml:lang="en-US">Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAbstract" xlink:to="sprcy_WarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Short-term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xml:lang="en-US">Investment in company account for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentWarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">NON-LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterest_lbl" xml:lang="en-US">Transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AttributableToAbstract" xlink:href="sprcy-20240630.xsd#sprcy_AttributableToAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AttributableToAbstract_lbl" xml:lang="en-US">Attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AttributableToAbstract" xlink:to="sprcy_AttributableToAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average outstanding shares (basic) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Basic loss per share, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Weighted average outstanding shares (diluted) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl0" xml:lang="en-US">Diluted loss per share, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfWarrants" xlink:href="sprcy-20240630.xsd#sprcy_ExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20240630.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl" xml:lang="en-US">Issuance of shares, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Expiration of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Issuance of share capital in respect of investment in affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract0" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract1" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments to reconcile loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract2" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl" xml:lang="en-US">Adjustments to the profit or loss items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract3" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract3" xlink:to="sprcy_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Loss on impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Loss on impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl1" xml:lang="en-US">Impairment to its intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xml:lang="en-US">Group&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract4" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract4" xlink:to="sprcy_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract5" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract5" xlink:to="sprcy_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WorkingCapitalAdjustmentssAbstract" xlink:href="sprcy-20240630.xsd#sprcy_WorkingCapitalAdjustmentssAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WorkingCapitalAdjustmentssAbstract_lbl" xml:lang="en-US">Working capital adjustments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WorkingCapitalAdjustmentssAbstract" xlink:to="sprcy_WorkingCapitalAdjustmentssAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract6" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract6" xlink:to="sprcy_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US">Decrease (increase) in other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Increase (decrease) in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract7" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract7" xlink:to="sprcy_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract8" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract8" xlink:to="sprcy_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract9" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract9" xlink:to="sprcy_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Investment (withdrawal) in restricted bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US">Investment (withdrawal) in short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Purchase of financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract10" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract10" xlink:to="sprcy_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract11" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract11" xlink:to="sprcy_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract12" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract12" xlink:to="sprcy_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20240630.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl" xml:lang="en-US">Payment of issuance expenses related to previous period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers_lbl" xml:lang="en-US">Repayment of short-term credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceiptofShortTermCreditFromOthers" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract13" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract13" xlink:to="sprcy_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract14" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract14" xlink:to="sprcy_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract15" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract15" xlink:to="sprcy_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl" xml:lang="en-US">(a) Significant non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract16" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract16" xlink:to="sprcy_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20240630.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract17" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract17" xlink:to="sprcy_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegistrationOfWarrants" xlink:href="sprcy-20240630.xsd#sprcy_RegistrationOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegistrationOfWarrants_lbl" xml:lang="en-US">Registration of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract18" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract18" xlink:to="sprcy_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentInFinancialAsset" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentInFinancialAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentInFinancialAsset_lbl" xml:lang="en-US">Investment in financial asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentInFinancialAsset" xlink:to="sprcy_InvestmentInFinancialAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract19" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract19" xlink:to="sprcy_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnpaidIssueExpenses" xlink:href="sprcy-20240630.xsd#sprcy_UnpaidIssueExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnpaidIssueExpenses_lbl" xml:lang="en-US">Unpaid issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract20" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract20" xlink:to="sprcy_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract21" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract21" xlink:to="sprcy_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract22" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract22" xlink:to="sprcy_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0" xlink:href="sprcy-20240630.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0_lbl" xml:lang="en-US">Adjustments to the profit or loss items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract23" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract23" xlink:to="sprcy_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract24" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract24" xlink:to="sprcy_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract25" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract25" xlink:to="sprcy_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract26" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract26" xlink:to="sprcy_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract27" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract27" xlink:to="sprcy_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract28" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract28" xlink:to="sprcy_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract29" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract29" xlink:to="sprcy_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract30" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract30" xlink:to="sprcy_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract31" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract31" xlink:to="sprcy_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract32" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract32" xlink:to="sprcy_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl" xml:lang="en-US">Proceeds from issuance of shares to minority interests in a subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract33" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract33" xlink:to="sprcy_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract34" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract34" xlink:to="sprcy_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract35" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract35" xlink:to="sprcy_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract36" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract36" xlink:to="sprcy_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_MutualShareExchangeOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MutualShareExchangeOfOrdinaryShares_lbl" xml:lang="en-US">Mutual share exchange of ordinary shares (see note 10)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeOfOrdinaryShares" xlink:to="sprcy_MutualShareExchangeOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Company&#8217;s share of losses of companies accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl1" xml:lang="en-US">Financing amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Equity holders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US">Finance expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Investment in a company accounted for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl" xml:lang="en-US">Proceeds from issuance of share capital and warrants (net of issuance expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Interest paid on lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" xlink:href="sprcy-20240630.xsd#sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Loans to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" xlink:to="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WarrantsMember_lbl0" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterestMember_lbl" xml:lang="en-US">Transactions with non- controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParentMember_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non- controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreviouslyStatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US">Previously Stated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_PreviouslyStatedMember_lbl0" xml:lang="en-US">Previously stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_PreviouslyStatedMember_lbl1" xml:lang="en-US">Previously Stated [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20240630.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl" xml:lang="en-US">Straight-line basis over the useful life of the assets, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovements" xlink:href="sprcy-20240630.xsd#sprcy_LeaseholdImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseholdImprovements_lbl" xml:lang="en-US">Leasehold improvements (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInvertoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfInvertoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInvertoryTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvertoryTextBlock" xlink:to="sprcy_DisclosureOfInvertoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl" xml:lang="en-US">Goods in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ValueAddedTaxReceivables_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ValueAddedTaxReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl" xml:lang="en-US">INVESTMENT IN ASSOCIATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsDate" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentsDate_lbl" xml:lang="en-US">Investment date March 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract37" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract37" xlink:to="sprcy_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl" xml:lang="en-US">Investment following achievement of first milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl" xml:lang="en-US">INVESTMENT IN FINANCIAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostAbstract" xlink:href="sprcy-20240630.xsd#sprcy_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">New lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract" xlink:href="sprcy-20240630.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl" xml:lang="en-US">Depreciated cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract0" xlink:href="sprcy-20240630.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US">INTANGIBLE ASSET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:to="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseofAssets" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseofAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseofAssets_lbl" xml:lang="en-US">Purchase date September 30, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseofAssets" xlink:to="sprcy_PurchaseofAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">TRADE PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayables" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfTradePayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfTradePayables_lbl" xml:lang="en-US">Schedule of Trade Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20240630.xsd#sprcy_AccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedExpenses" xlink:to="sprcy_AccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US">Open debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accrued vacation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20240630.xsd#sprcy_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract38" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract38" xlink:to="sprcy_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xml:lang="en-US">Total financial assets at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract39" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract39" xlink:to="sprcy_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract40" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract40" xlink:to="sprcy_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_CreditFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CreditFromOthers_lbl" xml:lang="en-US">Credit from others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsLiability_lbl" xml:lang="en-US">Warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract41" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract41" xlink:to="sprcy_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract42" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract42" xlink:to="sprcy_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract43" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract43" xlink:to="sprcy_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DividendYield" xlink:href="sprcy-20240630.xsd#sprcy_DividendYield"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DividendYield_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpectedVolatility" xlink:href="sprcy-20240630.xsd#sprcy_ExpectedVolatility"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExpectedVolatility_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RiskFreeInterestRate" xlink:href="sprcy-20240630.xsd#sprcy_RiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingAdsPrice" xlink:href="sprcy-20240630.xsd#sprcy_UnderlyingAdsPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnderlyingAdsPrice_lbl" xml:lang="en-US">Underlying Share Price ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingAdsPrice" xlink:to="sprcy_UnderlyingAdsPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePricePerShare_lbl" xml:lang="en-US">Exercise price ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePricePerShare" xlink:to="sprcy_ExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares_lbl" xml:lang="en-US">Warrants fair value ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsFairValueinDollarsPerShares" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">EMPLOYEE BENEFIT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Expenses in respect of defined contribution plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesAbstract_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of investment in affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultant" xlink:href="sprcy-20240630.xsd#sprcy_ShareIssuedToAConsultant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareIssuedToAConsultant_lbl" xml:lang="en-US">Share issued to a consultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ShareIssuedToAConsultant_lbl0" xml:lang="en-US">Shares issued to consultants (Note 6e)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of shelf prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of August 2023 financing round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of rounding errors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of Standby Equity Purchase Agreement (Note 6j)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of October 2023 financing round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl0" xml:lang="en-US">Issuance of share in respect of exercise of pre-funded October 2023 Warrants (Note 6i)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Underlying share price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Underlying share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US">Warrants fair value ($) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0" xml:lang="en-US">Warrants fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE-BASED PAYMENT TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentsExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentsExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentsExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentsExpenses" xlink:to="sprcy_ResearchAndDevelopmentsExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAndAdministrativeExpenses" xlink:href="sprcy-20240630.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralAndAdministrativeExpenses" xlink:to="sprcy_GeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20240630.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl" xml:lang="en-US">Expected life of share options (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingOrdinarySharePrices" xlink:href="sprcy-20240630.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl" xml:lang="en-US">Underlying ordinary share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Exercise Prices of Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US">2023:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options cancelled during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options cancelled during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract44" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract44" xlink:to="sprcy_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_a2022Abstract" xlink:href="sprcy-20240630.xsd#sprcy_a2022Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_a2022Abstract_lbl" xml:lang="en-US">2022:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_a2022Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">REVENUES AND COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of Cost of Sales and Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostOfGoodsSoldAbstract" xlink:href="sprcy-20240630.xsd#sprcy_CostOfGoodsSoldAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostOfGoodsSoldAbstract_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSoldAbstract" xlink:to="sprcy_CostOfGoodsSoldAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostOfGoodsSold" xlink:href="sprcy-20240630.xsd#sprcy_CostOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSold" xlink:to="sprcy_CostOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract45" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract45" xlink:to="sprcy_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl" xml:lang="en-US">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">a. Research and development expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract46" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract46" xlink:to="sprcy_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract47" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract47" xlink:to="sprcy_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">b. General and administrative expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract48" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract48" xlink:to="sprcy_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract49" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract49" xlink:to="sprcy_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_COtherExpensesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_COtherExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_COtherExpensesAbstract_lbl" xml:lang="en-US">c. Other expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_COtherExpensesAbstract" xlink:to="sprcy_COtherExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20240630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DFinanceIncomeAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DFinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DFinanceIncomeAbstract_lbl" xml:lang="en-US">d. Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DFinanceIncomeAbstract" xlink:to="sprcy_DFinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract50" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract50" xlink:to="sprcy_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EFinanceExpensesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_EFinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EFinanceExpensesAbstract_lbl" xml:lang="en-US">e. Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EFinanceExpensesAbstract" xlink:to="sprcy_EFinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract51" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract51" xlink:to="sprcy_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE/ADS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContinuingOperationsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ContinuingOperationsAbstract_lbl" xml:lang="en-US">Continuing operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl" xml:lang="en-US">Basic loss per share, Loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract52" xlink:href="sprcy-20240630.xsd#sprcy_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract52" xlink:to="sprcy_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl" xml:lang="en-US">Effect of potential dilutive ordinary shares, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl" xml:lang="en-US">Diluted loss per share, Loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US">OPERATING SEGMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US">Schedule of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SegmentReportingRevenueAbstract" xlink:href="sprcy-20240630.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20240630.xsd#sprcy_ExternalRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExternalRevenues_lbl" xml:lang="en-US">External</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl" xml:lang="en-US">Segment loss (gain)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRevenueExpense_lbl" xml:lang="en-US">Finance expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxExpense" xlink:href="sprcy-20240630.xsd#sprcy_TaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TaxExpense_lbl" xml:lang="en-US">Tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_TaxExpense_lbl0" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Segment Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US">Segment Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl" xml:lang="en-US">Schedule of Balances with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses" xlink:to="sprcy_ResearchAndDevelopmentExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Recognized expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses" xlink:to="sprcy_ResearchAndDevelopmentExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20240630.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl" xml:lang="en-US">Management fees (see also note 25a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl0" xml:lang="en-US">Management fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl" xml:lang="en-US">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">EVENTS AFTER THE REPORTING PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentFollowingAchievementMilestone" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentFollowingAchievementMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentFollowingAchievementMilestone_lbl" xml:lang="en-US">Investment following achievement milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFollowingAchievementMilestone" xlink:to="sprcy_InvestmentFollowingAchievementMilestone_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialAssetsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_FinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialAssetsAbstract" xlink:to="sprcy_FinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansAndAdvances" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansAndAdvances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LoansAndAdvances_lbl" xml:lang="en-US">Loans to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansAndAdvances" xlink:to="ifrs-full_LoansAndAdvances_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialLiabilitiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_FinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialLiabilitiesAbstract" xlink:to="sprcy_FinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsTextBlock_lbl" xml:lang="en-US">WARRANTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsTextBlock" xlink:to="sprcy_WarrantsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value was Calculated using the Black&#8211;Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" xlink:to="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract0" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfSharesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesAbstract0_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract0" xlink:to="sprcy_NumberOfSharesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract0" xlink:href="sprcy-20240630.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract0_lbl" xml:lang="en-US">a. Research and development expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract0" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract0" xlink:href="sprcy-20240630.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract0_lbl" xml:lang="en-US">b. General and administrative expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract0" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestment" xlink:href="sprcy-20240630.xsd#sprcy_EquityLossesFromInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_EquityLossesFromInvestment_lbl" xml:lang="en-US">Equity losses from investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityLossesFromInvestment_lbl0" xml:lang="en-US">Equity losses from the investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl" xml:lang="en-US">Depreciation of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_InvestmentsInFinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsInFinancialAssets" xlink:to="sprcy_InvestmentsInFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments_lbl" xml:lang="en-US">Equity losses from investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:to="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_ILS_lbl" xml:lang="en-US">NIS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="currency_ILS_lbl0" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20240630.xsd#sprcy_OfficeEquipmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeEquipmentsMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US">Carrying amount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_AmazonFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AmazonFeesMember_lbl" xml:lang="en-US">Amazon fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_AmazonFeesMember_lbl0" xml:lang="en-US">Amazon Fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasedGoodsMember" xlink:href="sprcy-20240630.xsd#sprcy_PurchasedGoodsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasedGoodsMember_lbl" xml:lang="en-US">Purchased goods [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasedGoodsMember" xlink:to="sprcy_PurchasedGoodsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageMember" xlink:href="sprcy-20240630.xsd#sprcy_StorageMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StorageMember_lbl" xml:lang="en-US">Storage [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StorageMember" xlink:to="sprcy_StorageMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FreightMember" xlink:href="sprcy-20240630.xsd#sprcy_FreightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FreightMember_lbl" xml:lang="en-US">Freight [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FreightMember" xlink:to="sprcy_FreightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl" xml:lang="en-US">Wages and related expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedPaymentMember_lbl" xml:lang="en-US">Share-based payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl" xml:lang="en-US">Regulatory, professional and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl" xml:lang="en-US">Research and preclinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ClinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClinicalStudiesMember_lbl" xml:lang="en-US">Clinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20240630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl" xml:lang="en-US">Chemistry and formulations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl" xml:lang="en-US">Professional and directors&#8217; fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl" xml:lang="en-US">Business development expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryExpensesMember_lbl" xml:lang="en-US">Regulatory expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl" xml:lang="en-US">Office maintenance, rent and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl" xml:lang="en-US">Investor relations and business expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20240630.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl" xml:lang="en-US">Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeRateDifferencesNetMember" xlink:href="sprcy-20240630.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeRateDifferencesNetMember_lbl" xml:lang="en-US">Exchange rate differences, net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeRateDifferencesNetMember" xlink:to="sprcy_ExchangeRateDifferencesNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl" xml:lang="en-US">Issuance expenses related to warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20240630.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20240630.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl" xml:lang="en-US">Finance expense in respect of leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20240630.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl" xml:lang="en-US">Finance expenses from interest and commissions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20240630.xsd#sprcy_DrugDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DrugDevelopmentMember_lbl" xml:lang="en-US">Drug Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20240630.xsd#sprcy_OnlineSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OnlineSalesMember_lbl" xml:lang="en-US">Online Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US">Key management personnel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl" xml:lang="en-US">Other related parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsWithRelatedPartiesMember" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsWithRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TransactionsWithRelatedPartiesMember_lbl" xml:lang="en-US">Transactions with related parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsWithRelatedPartiesMember" xlink:to="sprcy_TransactionsWithRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WellutionOperatingExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_WellutionOperatingExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WellutionOperatingExpensesMember_lbl" xml:lang="en-US">Wellution operating expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WellutionOperatingExpensesMember" xlink:to="sprcy_WellutionOperatingExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US">Geographical areas [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xml:lang="en-US">Classes of financial assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US">Classes of assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreationDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreationDateAxis_lbl" xml:lang="en-US">Creation date [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_CreationDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20240630.xsd#sprcy_OperatingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingTerm_lbl" xml:lang="en-US">Operating term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesSold" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesSold_lbl" xml:lang="en-US">Ordinary shares sold (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesSold" xlink:to="sprcy_OrdinarySharesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesParValue" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesParValue_lbl" xml:lang="en-US">Ordinary shares par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesParValue" xlink:to="sprcy_OrdinarySharesParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Percentage of issued and outstanding share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairMarketValue" xlink:href="sprcy-20240630.xsd#sprcy_FairMarketValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairMarketValue_lbl" xml:lang="en-US">Fair market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl" xml:lang="en-US">Purchase of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_DulyExecutedShareTransferDeedForOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl" xml:lang="en-US">Duly executed share transfer deed for ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:to="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentFromShareholders" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentFromShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentFromShareholders_lbl" xml:lang="en-US">Investment from shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFromShareholders" xlink:to="sprcy_InvestmentFromShareholders_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20240630.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl" xml:lang="en-US">Issued and outstanding shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfInvestment" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfInvestment_lbl" xml:lang="en-US">Fair value of Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfInvestment" xlink:to="sprcy_FairValueOfInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20240630.xsd#sprcy_InitialInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialInvestment_lbl" xml:lang="en-US">Initial investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInvestment" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInvestment_lbl" xml:lang="en-US">Additional investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20240630.xsd#sprcy_OwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipPercentage" xlink:to="sprcy_OwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20240630.xsd#sprcy_OutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingSharesPercentage_lbl" xml:lang="en-US">Outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInstallment" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInstallment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInstallment_lbl" xml:lang="en-US">Additional installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaid" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPaid_lbl" xml:lang="en-US">Installment paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentIncome_lbl" xml:lang="en-US">Initial investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Additional investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments_lbl" xml:lang="en-US">Equity losses from the investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" xlink:to="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAmount_lbl" xml:lang="en-US">Investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl" xml:lang="en-US">Received shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20240630.xsd#sprcy_ShareCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareCapitalPercentage_lbl" xml:lang="en-US">Share capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_SharePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePricePerShare_lbl" xml:lang="en-US">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLoss" xlink:href="sprcy-20240630.xsd#sprcy_ComprehensiveLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ComprehensiveLoss_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Par value, per share (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_PricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PricePerShare_lbl" xml:lang="en-US">Price Per Share (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LoansReceived_lbl" xml:lang="en-US">Loan received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Interest rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalLoan" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalLoan_lbl" xml:lang="en-US">Additional loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalLoan" xlink:to="sprcy_AdditionalLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:to="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaymentClosingAmount" xlink:href="sprcy-20240630.xsd#sprcy_RepaymentClosingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RepaymentClosingAmount_lbl" xml:lang="en-US">Repayment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaymentClosingAmount" xlink:to="sprcy_RepaymentClosingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinderFeePercentage" xlink:href="sprcy-20240630.xsd#sprcy_FinderFeePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinderFeePercentage_lbl" xml:lang="en-US">Finder fee percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinderFeePercentage" xlink:to="sprcy_FinderFeePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesOutstandingPercentage" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfSharesOutstandingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesOutstandingPercentage_lbl" xml:lang="en-US">Outstanding, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesOutstandingPercentage" xlink:to="sprcy_NumberOfSharesOutstandingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SquareMeters" xlink:href="sprcy-20240630.xsd#sprcy_SquareMeters"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SquareMeters_lbl" xml:lang="en-US">Square meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SquareMeters" xlink:to="sprcy_SquareMeters_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseFee" xlink:href="sprcy-20240630.xsd#sprcy_LeaseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseFee_lbl" xml:lang="en-US">Lease fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseFee" xlink:to="sprcy_LeaseFee_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpireTerm" xlink:href="sprcy-20240630.xsd#sprcy_ExpireTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExpireTerm_lbl" xml:lang="en-US">Lease expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpireTerm" xlink:to="sprcy_ExpireTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl" xml:lang="en-US">Exceeds amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCosts" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseCosts_lbl" xml:lang="en-US">Purchase costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCosts" xlink:to="sprcy_PurchaseCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsToPurchase" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsToPurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsToPurchase_lbl" xml:lang="en-US">Warrants to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsToPurchase" xlink:to="sprcy_WarrantsToPurchase_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePrice1" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePrice1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice1" xlink:to="sprcy_ExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePeriod" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePeriod_lbl" xml:lang="en-US">Exercise period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePeriod" xlink:to="sprcy_ExercisePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Gross sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_pricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_pricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_pricePerShare_lbl" xml:lang="en-US">Ordinary shares price closes (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_pricePerShare" xlink:to="sprcy_pricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmountTotal" xlink:href="sprcy-20240630.xsd#sprcy_AmountTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AmountTotal_lbl" xml:lang="en-US">Amount total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmountTotal" xlink:to="sprcy_AmountTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl" xml:lang="en-US">Amortized over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenueTerm" xlink:href="sprcy-20240630.xsd#sprcy_RevenueTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RevenueTerm_lbl" xml:lang="en-US">Revenue term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenueTerm" xlink:to="sprcy_RevenueTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrowthRatePercentage" xlink:href="sprcy-20240630.xsd#sprcy_GrowthRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GrowthRatePercentage_lbl" xml:lang="en-US">Growth rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrowthRatePercentage" xlink:to="sprcy_GrowthRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LongTermPercentage" xlink:href="sprcy-20240630.xsd#sprcy_LongTermPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LongTermPercentage_lbl" xml:lang="en-US">Long term, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" xml:lang="en-US">Discount rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCostsValue" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseCostsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseCostsValue_lbl" xml:lang="en-US">Purchase costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US">Cash paid for principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US">Issued of warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePrice" xlink:href="sprcy-20240630.xsd#sprcy_PurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePrice_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePrice" xlink:to="sprcy_PurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MaturityDate" xlink:href="sprcy-20240630.xsd#sprcy_MaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MaturityDate" xlink:to="sprcy_MaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialConversionPrice" xlink:href="sprcy-20240630.xsd#sprcy_InitialConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialConversionPrice_lbl" xml:lang="en-US">Initial conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConversionPrice" xlink:href="sprcy-20240630.xsd#sprcy_ConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ConversionPrice_lbl" xml:lang="en-US">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConversionPrice" xlink:to="sprcy_ConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareExercisePrice" xlink:href="sprcy-20240630.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinaryShareExercisePrice_lbl" xml:lang="en-US">Ordinary share exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareExercisePrice" xlink:to="sprcy_OrdinaryShareExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20240630.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl" xml:lang="en-US">Carryforward tax losses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20240630.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl" xml:lang="en-US">Milestone payments, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20240630.xsd#sprcy_AnnualInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AnnualInvestment_lbl" xml:lang="en-US">Annual investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalMilestoneAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalMilestoneAmount_lbl" xml:lang="en-US">Additional milestone amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentAmount_lbl" xml:lang="en-US">Installment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EstimatedAmount" xlink:href="sprcy-20240630.xsd#sprcy_EstimatedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EstimatedAmount_lbl" xml:lang="en-US">Estimated amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EstimatedAmount" xlink:to="sprcy_EstimatedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl" xml:lang="en-US">Capital purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl0" xml:lang="en-US">Number of shares valuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalCommitments_lbl" xml:lang="en-US">Capital warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfReverseShareSplit" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfReverseShareSplit_lbl" xml:lang="en-US">Description of reverse share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfReverseShareSplit" xlink:to="sprcy_DescriptionOfReverseShareSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrossProceeds" xlink:href="sprcy-20240630.xsd#sprcy_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfAggregateShares_lbl" xml:lang="en-US">Issuance of aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnits" xlink:href="sprcy-20240630.xsd#sprcy_AggregateUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateUnits_lbl" xml:lang="en-US">Number of units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnitsPerShare" xlink:href="sprcy-20240630.xsd#sprcy_AggregateUnitsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateUnitsPerShare_lbl" xml:lang="en-US">Units Per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DateOfIssuance" xlink:href="sprcy-20240630.xsd#sprcy_DateOfIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DateOfIssuance_lbl" xml:lang="en-US">Expire term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DateOfIssuance" xlink:to="sprcy_DateOfIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAndExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsAndExercise_lbl" xml:lang="en-US">Warrants and exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExercisePrice" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsExercisePrice_lbl" xml:lang="en-US">Warrants exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20240630.xsd#sprcy_AggregateGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Gross cash proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalRatio" xlink:href="sprcy-20240630.xsd#sprcy_CapitalRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalRatio_lbl" xml:lang="en-US">Capital ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ServicesExpense_lbl" xml:lang="en-US">Services rendered amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ServicesExpense_lbl0" xml:lang="en-US">Management services expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US">Purchase sale (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_CommitmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CommitmentAmount_lbl" xml:lang="en-US">Commitment amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_SaleOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SaleOfOrdinaryShares_lbl" xml:lang="en-US">Sale of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePriceRate" xlink:href="sprcy-20240630.xsd#sprcy_SharePriceRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePriceRate_lbl" xml:lang="en-US">Share price rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestRate" xlink:href="sprcy-20240630.xsd#sprcy_InterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestRate_lbl" xml:lang="en-US">Interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPayment" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPayment_lbl" xml:lang="en-US">Installment payment, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentForPremiumPercentage" xlink:href="sprcy-20240630.xsd#sprcy_PaymentForPremiumPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentForPremiumPercentage_lbl" xml:lang="en-US">Payment for premium percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateIssuedAmount" xlink:href="sprcy-20240630.xsd#sprcy_AggregateIssuedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateIssuedAmount_lbl" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Commitment fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl0" xml:lang="en-US">Payment commitment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGranted" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesGranted_lbl" xml:lang="en-US">Ordinary shares granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGranted" xlink:to="sprcy_OrdinarySharesGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOption" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfShareOption_lbl" xml:lang="en-US">Fair value of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOption" xlink:to="sprcy_FairValueOfShareOption_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareOptionsGranted" xlink:href="sprcy-20240630.xsd#sprcy_ShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareOptionsGranted_lbl" xml:lang="en-US">Share options granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsGranted" xlink:to="sprcy_ShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOptionsGranted" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl" xml:lang="en-US">Fair value of share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesIssued" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesIssued" xlink:to="sprcy_OrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl" xml:lang="en-US">Ordinary shares granted discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfOrdinarySharesGranted" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfOrdinarySharesGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfOrdinarySharesGranted_lbl" xml:lang="en-US">Fair value of ordinary shares granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfOrdinarySharesGranted" xlink:to="sprcy_FairValueOfOrdinarySharesGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20240630.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US">Invested amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeOfCommonShares" xlink:href="sprcy-20240630.xsd#sprcy_ExchangeOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeOfCommonShares_lbl" xml:lang="en-US">Exchange of common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_OutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingShareCapital_lbl" xml:lang="en-US">Outstanding share capital, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfOutstandingShareCapital_lbl" xml:lang="en-US">Outstanding share capital, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfOutstandingShareCapital" xlink:to="sprcy_PercentageOfOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashConsideration" xlink:href="sprcy-20240630.xsd#sprcy_CashConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CashConsideration_lbl" xml:lang="en-US">Cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CooperationAgreementAmount" xlink:href="sprcy-20240630.xsd#sprcy_CooperationAgreementAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CooperationAgreementAmount_lbl" xml:lang="en-US">Cooperation agreement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentgae" xlink:href="sprcy-20240630.xsd#sprcy_InterestPercentgae"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestPercentgae_lbl" xml:lang="en-US">Interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayments" xlink:href="sprcy-20240630.xsd#sprcy_DeferredCashPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DeferredCashPayments_lbl" xml:lang="en-US">Deferred cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FeeExpenses" xlink:href="sprcy-20240630.xsd#sprcy_FeeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FeeExpenses_lbl" xml:lang="en-US">Fee expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20240630.xsd#sprcy_BonusAmountReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BonusAmountReceived_lbl" xml:lang="en-US">Bonus amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeAmount" xlink:href="sprcy-20240630.xsd#sprcy_MutualShareExchangeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MutualShareExchangeAmount_lbl" xml:lang="en-US">Mutual share exchange amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesAcquired" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesAcquired_lbl" xml:lang="en-US">Acquired ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValue" xlink:href="sprcy-20240630.xsd#sprcy_AggregateValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateValue_lbl" xml:lang="en-US">Aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustedAmountOfAggregateValue" xlink:href="sprcy-20240630.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl" xml:lang="en-US">Adjusted amount of aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ListedSharePrice" xlink:href="sprcy-20240630.xsd#sprcy_ListedSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ListedSharePrice_lbl" xml:lang="en-US">Listed share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLossOnInvestment" xlink:href="sprcy-20240630.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl" xml:lang="en-US">Loss on investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US">Proceeds from ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US">Commitment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePercentage" xlink:href="sprcy-20240630.xsd#sprcy_SharePricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePricePercentage_lbl" xml:lang="en-US">Shareprice, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePercentage" xlink:to="sprcy_SharePricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrepaidAdvance" xlink:href="sprcy-20240630.xsd#sprcy_PrepaidAdvance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrepaidAdvance_lbl" xml:lang="en-US">Prepaid advance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrepaidAdvance" xlink:to="sprcy_PrepaidAdvance_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedInterestPercentage" xlink:href="sprcy-20240630.xsd#sprcy_AccruedInterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccruedInterestPercentage_lbl" xml:lang="en-US">Accrued interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedInterestPercentage" xlink:to="sprcy_AccruedInterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentPercentage" xlink:href="sprcy-20240630.xsd#sprcy_CommitmentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CommitmentPercentage_lbl" xml:lang="en-US">Increasing per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentPercentage" xlink:to="sprcy_CommitmentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaymentPercentage" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPaymentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPaymentPercentage_lbl" xml:lang="en-US">Installment payment percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaymentPercentage" xlink:to="sprcy_InstallmentPaymentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentPremiumPercentage" xlink:href="sprcy-20240630.xsd#sprcy_PaymentPremiumPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentPremiumPercentage_lbl" xml:lang="en-US">Payment premium percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentPremiumPercentage" xlink:to="sprcy_PaymentPremiumPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AssetAndSharePurchaseAgreementValue" xlink:href="sprcy-20240630.xsd#sprcy_AssetAndSharePurchaseAgreementValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AssetAndSharePurchaseAgreementValue_lbl" xml:lang="en-US">Enterprise value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AssetAndSharePurchaseAgreementValue" xlink:to="sprcy_AssetAndSharePurchaseAgreementValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl" xml:lang="en-US">Cash position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EntityStakeholdersRange" xlink:href="sprcy-20240630.xsd#sprcy_EntityStakeholdersRange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EntityStakeholdersRange_lbl" xml:lang="en-US">Stakeholder&apos;s entity range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EntityStakeholdersRange" xlink:to="sprcy_EntityStakeholdersRange_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromRoyalties_lbl" xml:lang="en-US">Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromRoyalties" xlink:to="ifrs-full_RevenueFromRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20240630.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl" xml:lang="en-US">Issued and outstanding shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl" xml:lang="en-US">Cash consideration received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHwcigou02yOi3RAgyAKCzKinttrVCX0GS4sD3ObxpwqEzqm9j1cZ4KQuocaRc2hMVSIDbMizaoWZ/nmzHQlBpYQrBXVpspuwa7a1yTY7nXsjphYT7GC7hOyPdg0YxoXQO1gmR5R+ZgPKpBP3bZFMnC0nX6D5JqGTC/TNLcq0G/Gg==] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xml:lang="en-US">Consideration paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssuanceOfPrivateOffering" xlink:href="sprcy-20240630.xsd#sprcy_ProceedsFromIssuanceOfPrivateOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ProceedsFromIssuanceOfPrivateOffering_lbl" xml:lang="en-US">Gross proceeds of private offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssuanceOfPrivateOffering" xlink:to="sprcy_ProceedsFromIssuanceOfPrivateOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceAggregateOfPrefundedUnits" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceAggregateOfPrefundedUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceAggregateOfPrefundedUnits_lbl" xml:lang="en-US">Issuance aggregate of pre-funded units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceAggregateOfPrefundedUnits" xlink:to="sprcy_IssuanceAggregateOfPrefundedUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreFundedUnitShares" xlink:href="sprcy-20240630.xsd#sprcy_PreFundedUnitShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PreFundedUnitShares_lbl" xml:lang="en-US">Pre-funded unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitShares" xlink:to="sprcy_PreFundedUnitShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreFundedUnitPerShare" xlink:href="sprcy-20240630.xsd#sprcy_PreFundedUnitPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PreFundedUnitPerShare_lbl" xml:lang="en-US">Pre-funded unit per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitPerShare" xlink:to="sprcy_PreFundedUnitPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20240630.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl" xml:lang="en-US">Basis of presentation of the financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl" xml:lang="en-US">The operating cycle</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl" xml:lang="en-US">Consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Functional currency and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl" xml:lang="en-US">Acquisition of a single asset company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl" xml:lang="en-US">Restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl" xml:lang="en-US">Investment in joint arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl" xml:lang="en-US">Investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xml:lang="en-US">Finance income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl" xml:lang="en-US">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl" xml:lang="en-US">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EveroMember" xlink:href="sprcy-20240630.xsd#sprcy_EveroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EveroMember_lbl" xml:lang="en-US">Evero [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EveroMember" xlink:to="sprcy_EveroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointMember" xlink:href="sprcy-20240630.xsd#sprcy_CapitalPointMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalPointMember_lbl" xml:lang="en-US">Capital Point [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointMember" xlink:to="sprcy_CapitalPointMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CoeruleusMember" xlink:href="sprcy-20240630.xsd#sprcy_CoeruleusMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CoeruleusMember_lbl" xml:lang="en-US">Coeruleus [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CoeruleusMember" xlink:to="sprcy_CoeruleusMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointWarrantMember" xlink:href="sprcy-20240630.xsd#sprcy_CapitalPointWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalPointWarrantMember_lbl" xml:lang="en-US">Capital Point Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointWarrantMember" xlink:to="sprcy_CapitalPointWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20240630.xsd#sprcy_MitoCareXBioLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXBioLtdMember_lbl" xml:lang="en-US">MitoCare X Bio Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20240630.xsd#sprcy_MitoCareXMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXMember_lbl" xml:lang="en-US">MitoCareX [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxMotorsLtdMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxMotorsLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AutoMaxMotorsLtdMember_lbl" xml:lang="en-US">AutoMax Motors Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxMotorsLtdMember" xlink:to="sprcy_AutoMaxMotorsLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentMember" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentMember_lbl" xml:lang="en-US">Investment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentMember" xlink:to="sprcy_InvestmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BridgeLoansMember" xlink:href="sprcy-20240630.xsd#sprcy_BridgeLoansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BridgeLoansMember_lbl" xml:lang="en-US">Bridge Loans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BridgeLoansMember" xlink:to="sprcy_BridgeLoansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxAcquisitionMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxAcquisitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AutoMaxAcquisitionMember_lbl" xml:lang="en-US">AutoMax Acquisition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxAcquisitionMember" xlink:to="sprcy_AutoMaxAcquisitionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AutoMaxMember_lbl" xml:lang="en-US">AutoMax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxMember" xlink:to="sprcy_AutoMaxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScenarioForecastsMember" xlink:href="sprcy-20240630.xsd#sprcy_ScenarioForecastsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScenarioForecastsMember_lbl" xml:lang="en-US">Scenario Forecasts [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScenarioForecastsMember" xlink:to="sprcy_ScenarioForecastsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20240630.xsd#sprcy_LeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseMember_lbl" xml:lang="en-US">2021 Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrivatePlacementsMember" xlink:href="sprcy-20240630.xsd#sprcy_PrivatePlacementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrivatePlacementsMember_lbl" xml:lang="en-US">Private Placements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrivatePlacementsMember" xlink:to="sprcy_PrivatePlacementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_PrivatePlacementsMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrivatePlacementsMember" xlink:to="sprcy_PrivatePlacementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20240630.xsd#sprcy_JeffsBrandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_JeffsBrandsMember_lbl" xml:lang="en-US">Jeffs&#8217; Brands [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Pre-funded warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesAWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_SeriesAWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesAWarrantsMember" xlink:to="sprcy_SeriesAWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_SeriesAWarrantsMember_lbl0" xml:lang="en-US">Series A Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesAWarrantsMember" xlink:to="sprcy_SeriesAWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesBWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_SeriesBWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesBWarrantsMember" xlink:to="sprcy_SeriesBWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_March2021FinancingRoundMember" xlink:href="sprcy-20240630.xsd#sprcy_March2021FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_March2021FinancingRoundMember_lbl" xml:lang="en-US">March 2021 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_March2021FinancingRoundMember" xlink:to="sprcy_March2021FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_June2022WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_June2022WarrantsMember_lbl" xml:lang="en-US">June 2022 Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OverAllotmentMember" xlink:href="sprcy-20240630.xsd#sprcy_OverAllotmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OverAllotmentMember_lbl" xml:lang="en-US">Over Allotment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OverAllotmentMember" xlink:to="sprcy_OverAllotmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20240630.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TwoThousandTwentyThreePlanMember_lbl" xml:lang="en-US">2023 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TwoThousandTwentyThreePlanMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClearmindMedicineIncMember" xlink:href="sprcy-20240630.xsd#sprcy_ClearmindMedicineIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClearmindMedicineIncMember_lbl" xml:lang="en-US">Clearmind Medicine Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClearmindMedicineIncMember" xlink:to="sprcy_ClearmindMedicineIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NewCoIncMember" xlink:href="sprcy-20240630.xsd#sprcy_NewCoIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NewCoIncMember_lbl" xml:lang="en-US">NewCo Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NewCoIncMember" xlink:to="sprcy_NewCoIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SEPAMember" xlink:href="sprcy-20240630.xsd#sprcy_SEPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SEPAMember_lbl" xml:lang="en-US">SEPA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SEPAMember" xlink:to="sprcy_SEPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MizaMember" xlink:href="sprcy-20240630.xsd#sprcy_MizaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MizaMember_lbl" xml:lang="en-US">Miza [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MizaMember" xlink:to="sprcy_MizaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentEventsMember" xlink:href="sprcy-20240630.xsd#sprcy_SubsequentEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SubsequentEventsMember_lbl" xml:lang="en-US">Subsequent Events [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SubsequentEventsMember" xlink:to="sprcy_SubsequentEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SciSparcMember" xlink:href="sprcy-20240630.xsd#sprcy_SciSparcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SciSparcMember_lbl" xml:lang="en-US">SciSparc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SciSparcMember" xlink:to="sprcy_SciSparcMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Common shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityDomain_lbl" xml:lang="en-US">Components of equity [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ComponentsOfEquityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US">Currently stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl" xml:lang="en-US">Classes of property, plant and equipment [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeDomain_lbl" xml:lang="en-US">Range [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_RangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:to="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashScheduleofCashDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashScheduleofCashDetailsTable_lbl" xml:lang="en-US">Cash - Schedule of Cash (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashScheduleofCashDetailsTable" xlink:to="sprcy_CashScheduleofCashDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashScheduleofCashDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_CashScheduleofCashDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashScheduleofCashDetailsLineItems_lbl" xml:lang="en-US">Cash - Schedule of Cash (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashScheduleofCashDetailsLineItems" xlink:to="sprcy_CashScheduleofCashDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems_lbl" xml:lang="en-US">Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable_lbl" xml:lang="en-US">Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsDomain_lbl" xml:lang="en-US">Business combinations [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsDomain" xlink:to="ifrs-full_BusinessCombinationsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl" xml:lang="en-US">Levels of fair value hierarchy [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:to="sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" xlink:to="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems_lbl" xml:lang="en-US">Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl" xml:lang="en-US">Categories of related parties [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable_lbl" xml:lang="en-US">Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems_lbl" xml:lang="en-US">Schedule of Cost of Sales and Gross Profit [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_lbl" xml:lang="en-US">IncomeStatementsLocationsDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable_lbl" xml:lang="en-US">Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" xlink:to="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems_lbl" xml:lang="en-US">Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:to="sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsDomain_lbl" xml:lang="en-US">Segments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsDomain" xlink:to="ifrs-full_SegmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable_lbl" xml:lang="en-US">Operating Segments - Schedule of Operating Segments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xml:lang="en-US">Schedule of Operating Segments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Schedule of Balances with Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems_lbl0" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems_lbl0" xml:lang="en-US">Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesDetailsTable" xlink:to="sprcy_SignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:to="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinAssociatesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesDetailsTable_lbl" xml:lang="en-US">Investment in Associates (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesDetailsTable" xlink:to="sprcy_InvestmentinAssociatesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinAssociatesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesDetailsLineItems_lbl" xml:lang="en-US">Investment in Associates [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InvestmentinAssociatesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_lbl" xml:lang="en-US">Classes of financial assets [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasDomain_lbl" xml:lang="en-US">Geographical areas [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_GeographicalAreasDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl" xml:lang="en-US">Non-adjusting events after reporting period [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl" xml:lang="en-US">Investment in Financial Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US">Investment in Financial Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsTable" xlink:to="sprcy_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsTable" xlink:to="sprcy_PropertyandEquipmentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems_lbl" xml:lang="en-US">Disclosure of property, plant and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsDomain_lbl" xml:lang="en-US">Classes of assets [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsDomain" xlink:to="ifrs-full_ClassesOfAssetsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsTable_lbl" xml:lang="en-US">Financial Instruments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsTable" xlink:to="sprcy_FinancialInstrumentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US">Financial Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsTable" xlink:to="sprcy_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Disclosure of income tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_lbl" xml:lang="en-US">Default financial statements date [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsTable" xlink:to="sprcy_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_EquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl" xml:lang="en-US">Types of share-based payment arrangements [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl" xml:lang="en-US">Significant Events during the Reporting Period (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems_lbl" xml:lang="en-US">Significant Events During the Reporting Period [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_lbl" xml:lang="en-US">Classes of share capital [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingPeriodDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_EventsAftertheReportingPeriodDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EventsAftertheReportingPeriodDetailsTable_lbl" xml:lang="en-US">Events After the Reporting Period (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsTable" xlink:to="sprcy_EventsAftertheReportingPeriodDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_EventsAftertheReportingPeriodDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EventsAftertheReportingPeriodDetailsLineItems_lbl" xml:lang="en-US">Events After the Reporting Date [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EventsAftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_EventsAftertheReportingPeriodDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl" xml:lang="en-US">Types of antidilutive instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsDetailsTable_lbl" xml:lang="en-US">Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDetailsTable" xlink:to="sprcy_WarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsDetailsLineItems_lbl" xml:lang="en-US">Warrants (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_WarrantsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AccruedInterestPercentage_lbl0" xml:lang="en-US">Accrued interest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedInterestPercentage" xlink:to="sprcy_AccruedInterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalInstallment_lbl0" xml:lang="en-US">The amount of additional installment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalInvestment_lbl0" xml:lang="en-US">The amount of additional investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalLoan_lbl0" xml:lang="en-US">Represent the amount of additional loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalLoan" xlink:to="sprcy_AdditionalLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl0" xml:lang="en-US">The adjusted amount of aggregate value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl0" xml:lang="en-US">Adjustments for losses from remeasurement of investment in financial assets&#xd;
  to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateGrossProceeds_lbl0" xml:lang="en-US">Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateIssuedAmount_lbl0" xml:lang="en-US">Aggregate issued amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateUnits_lbl0" xml:lang="en-US">Number of shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateUnitsPerShare_lbl0" xml:lang="en-US">Per share of aggregate units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateValue_lbl0" xml:lang="en-US">The amount of ordinary shares of aggregate value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AnnualInvestment_lbl0" xml:lang="en-US">Amount of annual investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AssetAndSharePurchaseAgreementValue_lbl0" xml:lang="en-US">Asset and share purchase agreement value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AssetAndSharePurchaseAgreementValue" xlink:to="sprcy_AssetAndSharePurchaseAgreementValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes inrBasis of presentation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BonusAmountReceived_lbl0" xml:lang="en-US">Bonus amount received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CapitalRatio_lbl0" xml:lang="en-US">Capital ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">The amount of cash advances and loans made to other parties (other than advances and loans made by a financial institution), classified as investing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" xlink:to="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CashConsideration_lbl0" xml:lang="en-US">Represent the amount of cash consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CommitmentAmount_lbl0" xml:lang="en-US">Commitment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CommitmentPercentage_lbl0" xml:lang="en-US">Commitment percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentPercentage" xlink:to="sprcy_CommitmentPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ComprehensiveLoss_lbl0" xml:lang="en-US">Comprehensive loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl0" xml:lang="en-US">Amount of comprehensive loss on investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CooperationAgreementAmount_lbl0" xml:lang="en-US">Represent the amount of cooperation agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CostOfGoodsSold_lbl0" xml:lang="en-US">The amount of cost of goods sold.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSold" xlink:to="sprcy_CostOfGoodsSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CreditFromOthers_lbl0" xml:lang="en-US">The amount of credit of others.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DeferredCashPayments_lbl0" xml:lang="en-US">Deferred cash payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl0" xml:lang="en-US">Dekel license agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl0" xml:lang="en-US">Description of Accounting Policy Amendment to IAS 1, &#8220;Disclosure of Accounting Policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Description of accounting policy cost of sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in Consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for investments in associates. The description of the entity&apos;s material accounting policy information for investments accounted for using the equity method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in operating cycle Explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for acquisition of a single asset company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for changes to accounting estimates and errors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">The entire disclosue of cash and cash equivalents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about balance with relate parties explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about defined contribution plans explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about transactions with relate parties explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl0" xml:lang="en-US">Disclosure of expenses due to share-based compensation explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl0" xml:lang="en-US">Disclosure of fair value for share options granted explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl0" xml:lang="en-US">Disclosure of fair value of the intangible asset text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:to="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock_lbl0" xml:lang="en-US">Represent the tabular disclosure of fair value was calculated using the black&#8211;scholes option pricing model.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" xlink:to="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl0" xml:lang="en-US">The tabular disclosure of financial assets and financial liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl0" xml:lang="en-US">Tabular disclosure of disclosure of information to the items of profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInvertoryTextBlock_lbl0" xml:lang="en-US">Disclosure of inventory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvertoryTextBlock" xlink:to="sprcy_DisclosureOfInvertoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0" xml:lang="en-US">Disclosure of detailed inforamtion about issued and outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The tabular disclosure of share options and weighted average exercise prices of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfTradePayables_lbl0" xml:lang="en-US">The disclosure of trade payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl0" xml:lang="en-US">The entire disclosure for useful life of the assets at annual rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0" xml:lang="en-US">The disclosure of accounts receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DividendYield_lbl0" xml:lang="en-US">The percentage of an expected dividend used to calculate the fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl0" xml:lang="en-US">Number of duly executed share transfer deed for ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:to="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EntityStakeholdersRange_lbl0" xml:lang="en-US">Entity stakeholders range.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EntityStakeholdersRange" xlink:to="sprcy_EntityStakeholdersRange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EquityLossesFromInvestment_lbl1" xml:lang="en-US">Amount of equity losses from investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExchangeOfCommonShares_lbl0" xml:lang="en-US">Number of shares exchanged.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExerciseOfWarrants_lbl0" xml:lang="en-US">Amount of exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExpectedVolatility_lbl0" xml:lang="en-US">The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExternalRevenues_lbl0" xml:lang="en-US">Amount of external revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairMarketValue_lbl0" xml:lang="en-US">Fair market value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfInvestment_lbl0" xml:lang="en-US">The amount of fair value of Investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfInvestment" xlink:to="sprcy_FairValueOfInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfOrdinarySharesGranted_lbl0" xml:lang="en-US">The amount of fair value of ordinary shares granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfOrdinarySharesGranted" xlink:to="sprcy_FairValueOfOrdinarySharesGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfShareOption_lbl0" xml:lang="en-US">Fair value Of share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOption" xlink:to="sprcy_FairValueOfShareOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl0" xml:lang="en-US">Fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FeeExpenses_lbl0" xml:lang="en-US">Fee expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FinderFeePercentage_lbl0" xml:lang="en-US">Represent the percentage of finder fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinderFeePercentage" xlink:to="sprcy_FinderFeePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_GovernmentAuthorities_lbl0" xml:lang="en-US">Government authorities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_GrossProceeds_lbl0" xml:lang="en-US">Gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InitialConversionPrice_lbl0" xml:lang="en-US">Initial conversion price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InitialInvestment_lbl0" xml:lang="en-US">Initial investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentAmount_lbl0" xml:lang="en-US">Amount of installment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPaid_lbl0" xml:lang="en-US">The amount of installment paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPayment_lbl0" xml:lang="en-US">Installment payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPaymentPercentage_lbl0" xml:lang="en-US">Installment payment percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaymentPercentage" xlink:to="sprcy_InstallmentPaymentPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InterestPercentgae_lbl0" xml:lang="en-US">Interest percentgae.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InterestRate_lbl0" xml:lang="en-US">Interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl0" xml:lang="en-US">The amount of investment following achievement of first milestone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAmount_lbl0" xml:lang="en-US">Investment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentFollowingAchievementMilestone_lbl0" xml:lang="en-US">Represent the amount of investment achievement of milestone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFollowingAchievementMilestone" xlink:to="sprcy_InvestmentFollowingAchievementMilestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentFromShareholders_lbl0" xml:lang="en-US">The amount of investment from shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFromShareholders" xlink:to="sprcy_InvestmentFromShareholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentInFinancialAsset_lbl0" xml:lang="en-US">The amount of investment in financial asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentInFinancialAsset" xlink:to="sprcy_InvestmentInFinancialAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentsDate_lbl0" xml:lang="en-US">The amount of investment date,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceAggregateOfPrefundedUnits_lbl0" xml:lang="en-US">Represent the issuance of aggregate of prefunded units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceAggregateOfPrefundedUnits" xlink:to="sprcy_IssuanceAggregateOfPrefundedUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfAggregateShares_lbl0" xml:lang="en-US">The issuance of aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of investment in affiliate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl1" xml:lang="en-US">Number of share capital issued in respect of October 2023 financing round.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl1" xml:lang="en-US">Number of share capital issued in respect of rounding errors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of shelf prospectus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0" xml:lang="en-US">Issue of share capital, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl0" xml:lang="en-US">Issued and outstanding shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl0" xml:lang="en-US">Issued and outstanding shares, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl1" xml:lang="en-US">The amount of compensation to key management personnel in the form of management fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LeaseholdImprovements_lbl0" xml:lang="en-US">Leasehold improvements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ListedSharePrice_lbl0" xml:lang="en-US">Amount of listed shares price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LongTermPercentage_lbl0" xml:lang="en-US">The percentage of long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MutualShareExchangeAmount_lbl0" xml:lang="en-US">Mutual share exchange amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MutualShareExchangeOfOrdinaryShares_lbl0" xml:lang="en-US">The amount of mutual share exchange of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeOfOrdinaryShares" xlink:to="sprcy_MutualShareExchangeOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl1" xml:lang="en-US">The number of share option outstanding in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercisable at the end of the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options granted during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options cancelled during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfSharesOutstandingPercentage_lbl0" xml:lang="en-US">Represent the percentage of number of shares outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesOutstandingPercentage" xlink:to="sprcy_NumberOfSharesOutstandingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0" xml:lang="en-US">The amount of net operating loss carryforward tax as of the reporting date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesAcquired_lbl0" xml:lang="en-US">Ordinary shares acquired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesGranted_lbl0" xml:lang="en-US">Number of ordinary shares granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGranted" xlink:to="sprcy_OrdinarySharesGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl0" xml:lang="en-US">Ordinary shares granted discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesParValue_lbl0" xml:lang="en-US">Ordinary shares par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesParValue" xlink:to="sprcy_OrdinarySharesParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesSold_lbl0" xml:lang="en-US">Number of ordinary shares sold.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesSold" xlink:to="sprcy_OrdinarySharesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingShareCapital_lbl0" xml:lang="en-US">Percentage of outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingSharesPercentage_lbl0" xml:lang="en-US">Outstanding shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PaymentForPremiumPercentage_lbl0" xml:lang="en-US">Payment for premium percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PaymentPremiumPercentage_lbl0" xml:lang="en-US">Payment premium percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentPremiumPercentage" xlink:to="sprcy_PaymentPremiumPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfOutstandingShareCapital_lbl0" xml:lang="en-US">Represent the percentage of outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfOutstandingShareCapital" xlink:to="sprcy_PercentageOfOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl0" xml:lang="en-US">The percentage of shares issued and outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">The useful lives or depreciation rates used for property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PreFundedUnitPerShare_lbl0" xml:lang="en-US">Represent the price of pre-funded unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitPerShare" xlink:to="sprcy_PreFundedUnitPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PreFundedUnitShares_lbl0" xml:lang="en-US">Represent the number pre-funded unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitShares" xlink:to="sprcy_PreFundedUnitShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PrepaidAdvance_lbl0" xml:lang="en-US">The amount of prepaid advance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrepaidAdvance" xlink:to="sprcy_PrepaidAdvance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PricePerShare_lbl0" xml:lang="en-US">price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ProceedsFromIssuanceOfPrivateOffering_lbl0" xml:lang="en-US">Represent the amount of proceeds from issuance of private offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssuanceOfPrivateOffering" xlink:to="sprcy_ProceedsFromIssuanceOfPrivateOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl0" xml:lang="en-US">The amount of proceeds from issue of share capital and warrants net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl1" xml:lang="en-US">Represents the amount of accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseCostsValue_lbl0" xml:lang="en-US">Represent the amount of purchase costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Purchase of financial assets at fair value through profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl0" xml:lang="en-US">Purchase of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchasePricePerShare_lbl0" xml:lang="en-US">The purchase price is the price an investor pays for an investment, and the price becomes the investor&apos;s cost basis for calculating gain or loss when selling the investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RegistrationOfWarrants_lbl0" xml:lang="en-US">Registration of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RepaymentClosingAmount_lbl0" xml:lang="en-US">Represent the value of repayment closing amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaymentClosingAmount" xlink:to="sprcy_RepaymentClosingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl0" xml:lang="en-US">The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ResearchAndDevelopmentsExpenses_lbl0" xml:lang="en-US">The amount of research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentsExpenses" xlink:to="sprcy_ResearchAndDevelopmentsExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RevenueTerm_lbl0" xml:lang="en-US">Revenue term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenueTerm" xlink:to="sprcy_RevenueTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RiskFreeInterestRate_lbl0" xml:lang="en-US">The risk-free interest rate for the option contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SaleOfOrdinaryShares_lbl0" xml:lang="en-US">Represent the number of ordinary shares sold.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareCapitalPercentage_lbl0" xml:lang="en-US">Share capital percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareIssuedToAConsultant_lbl1" xml:lang="en-US">The shares were issued to a consultant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareOptionsGranted_lbl0" xml:lang="en-US">Number of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsGranted" xlink:to="sprcy_ShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePricePerShare_lbl0" xml:lang="en-US">Share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePricePercentage_lbl0" xml:lang="en-US">Share price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePercentage" xlink:to="sprcy_SharePricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePriceRate_lbl0" xml:lang="en-US">Share price rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl0" xml:lang="en-US">The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_TaxExpense_lbl1" xml:lang="en-US">Tax expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl0" xml:lang="en-US">Underlying ordinary share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_UnpaidIssueExpenses_lbl0" xml:lang="en-US">Unpaid issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantsExercisePrice_lbl0" xml:lang="en-US">Warrants exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantsTextBlock_lbl0" xml:lang="en-US">Represent the entire disclosure of warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsTextBlock" xlink:to="sprcy_WarrantsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl0" xml:lang="en-US">The weighted average remaining contractual lifes of outstanding share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl1" xml:lang="en-US">Basis Of Presentation Of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansAndAdvances_lbl0" xml:lang="en-US">Loans and advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansAndAdvances" xlink:to="ifrs-full_LoansAndAdvances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfAggregateShares_lbl1" xml:lang="en-US">Issuance Of Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Purchase of investments other than investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for investment in associates and joint ventures [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RepaymentClosingAmount_lbl1" xml:lang="en-US">Repayment Closing Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaymentClosingAmount" xlink:to="sprcy_RepaymentClosingAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl1" xml:lang="en-US">Issued And Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Investment In Affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl0" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumption Expected Term1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentMember_lbl0" xml:lang="en-US">Investment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentMember" xlink:to="sprcy_InvestmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract51" xlink:to="sprcy_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract52" xlink:to="sprcy_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract50" xlink:to="sprcy_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegistrationOfWarrants_lbl1" xml:lang="en-US">Registration Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesAcquired_lbl1" xml:lang="en-US">Ordinary Shares Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl1" xml:lang="en-US">Revenue from sale of goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostOfGoodsSold_lbl1" xml:lang="en-US">Cost Of Goods Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSold" xlink:to="sprcy_CostOfGoodsSold_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl1" xml:lang="en-US">Underlying Ordinary Share Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalLoan_lbl1" xml:lang="en-US">Additional Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalLoan" xlink:to="sprcy_AdditionalLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RiskFreeInterestRate_lbl1" xml:lang="en-US">Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses" xlink:to="sprcy_ResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl0" xml:lang="en-US">Income Statements Locations Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsToPurchase_lbl0" xml:lang="en-US">Warrants To Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsToPurchase" xlink:to="sprcy_WarrantsToPurchase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExerciseOfWarrants_lbl1" xml:lang="en-US">Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl0" xml:lang="en-US">Segment Reporting Revenue Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract0_lbl0" xml:lang="en-US">AResearch And Development Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract0" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ContinuingOperationsAbstract_lbl0" xml:lang="en-US">Continuing Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl1" xml:lang="en-US">Adjustments For Losses From Remeasurement Of Investment In Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpectedVolatility_lbl1" xml:lang="en-US">Expected Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WorkingCapitalAdjustmentssAbstract_lbl0" xml:lang="en-US">Working Capital Adjustmentss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WorkingCapitalAdjustmentssAbstract" xlink:to="sprcy_WorkingCapitalAdjustmentssAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract28" xlink:to="sprcy_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromRoyalties_lbl0" xml:lang="en-US">Royalty income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromRoyalties" xlink:to="ifrs-full_RevenueFromRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract29" xlink:to="sprcy_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl0" xml:lang="en-US">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SEPAMember_lbl0" xml:lang="en-US">SEPAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SEPAMember" xlink:to="sprcy_SEPAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SciSparcMember_lbl0" xml:lang="en-US">Sci Sparc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SciSparcMember" xlink:to="sprcy_SciSparcMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers_lbl0" xml:lang="en-US">Receiptof Short Term Credit From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceiptofShortTermCreditFromOthers" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_a2022Abstract_lbl0" xml:lang="en-US">a2022 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_a2022Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract30" xlink:to="sprcy_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl1" xml:lang="en-US">Investment Achievement Of First Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl2" xml:lang="en-US">Issuance Of Share Capital In Respect Of October2023 Financing Round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract33" xlink:to="sprcy_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract34" xlink:to="sprcy_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl0" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract31" xlink:to="sprcy_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract32" xlink:to="sprcy_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract37" xlink:to="sprcy_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract38" xlink:to="sprcy_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract35" xlink:to="sprcy_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseCostsValue_lbl1" xml:lang="en-US">Purchase Costs Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract36" xlink:to="sprcy_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract39" xlink:to="sprcy_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl1" xml:lang="en-US">Research And Development Expenses1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl1" xml:lang="en-US">Proceeds From Issue Of Share Capital And Warrantsnet Of Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl0" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AnnualInvestment_lbl1" xml:lang="en-US">Annual Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl0" xml:lang="en-US">Research And Preclinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl2" xml:lang="en-US">Key Management Personnel Compensation Management Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashConsideration_lbl1" xml:lang="en-US">Cash Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 1 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract40" xlink:to="sprcy_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract41" xlink:to="sprcy_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract44" xlink:to="sprcy_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Useful Life Of Assets At Annual Rates Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract45" xlink:to="sprcy_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract42" xlink:to="sprcy_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract43" xlink:to="sprcy_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentsInFinancialAssets_lbl0" xml:lang="en-US">Investments In Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsInFinancialAssets" xlink:to="sprcy_InvestmentsInFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract48" xlink:to="sprcy_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract49" xlink:to="sprcy_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract46" xlink:to="sprcy_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract47" xlink:to="sprcy_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ListedSharePrice_lbl1" xml:lang="en-US">Listed Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl0" xml:lang="en-US">Chemistry And Formulations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_March2021FinancingRoundMember_lbl0" xml:lang="en-US">March2021 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_March2021FinancingRoundMember" xlink:to="sprcy_March2021FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MutualShareExchangeAmount_lbl1" xml:lang="en-US">Mutual Share Exchange Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl1" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OverAllotmentMember_lbl0" xml:lang="en-US">Over Allotment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OverAllotmentMember" xlink:to="sprcy_OverAllotmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestPercentgae_lbl1" xml:lang="en-US">Interest Percentgae</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl0" xml:lang="en-US">Other non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1" xml:lang="en-US">Disclosure Of Issued And Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansReceived_lbl0" xml:lang="en-US">Loans received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EveroMember_lbl0" xml:lang="en-US">Evero Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EveroMember" xlink:to="sprcy_EveroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract11" xlink:to="sprcy_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract12" xlink:to="sprcy_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract10" xlink:to="sprcy_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0" xml:lang="en-US">Reserve of exchange differences on translation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract15" xlink:to="sprcy_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EntityStakeholdersRange_lbl1" xml:lang="en-US">Entity Stakeholders Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EntityStakeholdersRange" xlink:to="sprcy_EntityStakeholdersRange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract16" xlink:to="sprcy_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract13" xlink:to="sprcy_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract14" xlink:to="sprcy_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract19" xlink:to="sprcy_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract17" xlink:to="sprcy_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract18" xlink:to="sprcy_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExternalRevenues_lbl1" xml:lang="en-US">External Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AutoMaxMember_lbl0" xml:lang="en-US">Auto Max Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxMember" xlink:to="sprcy_AutoMaxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1" xml:lang="en-US">Description Of Accounting Policy For Consolidatedfinancialstatements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl1" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy Cost Of Sales Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NewCoIncMember_lbl0" xml:lang="en-US">New Co Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NewCoIncMember" xlink:to="sprcy_NewCoIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0" xml:lang="en-US">Adjustments for finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl1" xml:lang="en-US">Adjusted Amount Of Aggregate Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPaid_lbl1" xml:lang="en-US">Installment Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SquareMeters_lbl0" xml:lang="en-US">Square Meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SquareMeters" xlink:to="sprcy_SquareMeters_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Investment Accounted For Using The Equity Methodtext Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInvertoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Invertory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvertoryTextBlock" xlink:to="sprcy_DisclosureOfInvertoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentPremiumPercentage_lbl1" xml:lang="en-US">Payment Premium Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentPremiumPercentage" xlink:to="sprcy_PaymentPremiumPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl1" xml:lang="en-US">Current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract22" xlink:to="sprcy_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares_lbl0" xml:lang="en-US">Warrants Fair Valuein Dollars Per Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsFairValueinDollarsPerShares" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl0" xml:lang="en-US">Increase (decrease) in number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract23" xlink:to="sprcy_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract20" xlink:to="sprcy_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl0" xml:lang="en-US">Finance Expense In Respect Of Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract21" xlink:to="sprcy_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract26" xlink:to="sprcy_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract27" xlink:to="sprcy_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract24" xlink:to="sprcy_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract25" xlink:to="sprcy_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl0" xml:lang="en-US">Cash and cash equivalents if different from statement of financial position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl1" xml:lang="en-US">Percentage Of Shares Issued And Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Current restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePricePerShare_lbl0" xml:lang="en-US">Exercise Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePricePerShare" xlink:to="sprcy_ExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl1" xml:lang="en-US">Israel, New Shekels</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInvestment_lbl1" xml:lang="en-US">Additional Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Shelf Prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl0" xml:lang="en-US">Non-controlling interests [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Current trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OnlineSalesMember_lbl0" xml:lang="en-US">Online Sales Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareIssuedToAConsultant_lbl2" xml:lang="en-US">Share Issued To AConsultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasedGoodsMember_lbl0" xml:lang="en-US">Purchased Goods Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasedGoodsMember" xlink:to="sprcy_PurchasedGoodsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Other cash receipts from sales of interests in joint ventures, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating diluted earnings (loss) per instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Financial Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialLiabilitiesAbstract" xlink:to="sprcy_FinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl0" xml:lang="en-US">Proceeds from issue of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Option Exercisable In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl0" xml:lang="en-US">Wages And Related Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl1" xml:lang="en-US">Financial assets measured at fair value through other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1" xml:lang="en-US">Issue Of Share Capital Net Of Issue Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl1" xml:lang="en-US">Comprehensive Loss On Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl1" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Categories of financial liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl0" xml:lang="en-US">Number of shares issued but not fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeOfCommonShares_lbl1" xml:lang="en-US">Exchange Of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract3" xlink:to="sprcy_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract5" xlink:to="sprcy_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConversionPrice_lbl0" xml:lang="en-US">Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConversionPrice" xlink:to="sprcy_ConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfOrdinarySharesGranted_lbl1" xml:lang="en-US">Fair Value Of Ordinary Shares Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfOrdinarySharesGranted" xlink:to="sprcy_FairValueOfOrdinarySharesGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract4" xlink:to="sprcy_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl1" xml:lang="en-US">Impairment loss recognised in other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl1" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract7" xlink:to="sprcy_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract6" xlink:to="sprcy_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract9" xlink:to="sprcy_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract8" xlink:to="sprcy_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateGrossProceeds_lbl1" xml:lang="en-US">Aggregate Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Schedule Of Operating Segments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:to="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0" xml:lang="en-US">Disclosure Of Significant Events During The Reporting Period Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterestMember_lbl0" xml:lang="en-US">Other equity interest [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentForPremiumPercentage_lbl1" xml:lang="en-US">Payment For Premium Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl0" xml:lang="en-US">Earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Interest paid, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WellutionOperatingExpensesMember_lbl0" xml:lang="en-US">Wellution Operating Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WellutionOperatingExpensesMember" xlink:to="sprcy_WellutionOperatingExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsAndExercise_lbl0" xml:lang="en-US">Warrants And Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceAggregateOfPrefundedUnits_lbl1" xml:lang="en-US">Issuance Aggregate Of Prefunded Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceAggregateOfPrefundedUnits" xlink:to="sprcy_IssuanceAggregateOfPrefundedUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl0" xml:lang="en-US">Other cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MizaMember_lbl0" xml:lang="en-US">Miza Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MizaMember" xlink:to="sprcy_MizaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPayment_lbl1" xml:lang="en-US">Installment Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseMember_lbl0" xml:lang="en-US">Lease Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PreFundedUnitPerShare_lbl1" xml:lang="en-US">Pre Funded Unit Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitPerShare" xlink:to="sprcy_PreFundedUnitPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl1" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentsDate_lbl1" xml:lang="en-US">Investments Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_pricePerShare_lbl0" xml:lang="en-US">price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_pricePerShare" xlink:to="sprcy_pricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DateOfIssuance_lbl0" xml:lang="en-US">Date Of Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DateOfIssuance" xlink:to="sprcy_DateOfIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy Amendment To IAS1 Disclosure Of Accounting Policies Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl0" xml:lang="en-US">Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl1" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScenarioForecastsMember_lbl0" xml:lang="en-US">Scenario Forecasts Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScenarioForecastsMember" xlink:to="sprcy_ScenarioForecastsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLiabilities_lbl0" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Weighted average share price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl0" xml:lang="en-US">Financial assets at amortised cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl0" xml:lang="en-US">Amount by which unit&apos;s recoverable amount exceeds its carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentWarrantLiability_lbl0" xml:lang="en-US">Current warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialConversionPrice_lbl1" xml:lang="en-US">Initial Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PreFundedUnitShares_lbl1" xml:lang="en-US">Pre Funded Unit Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitShares" xlink:to="sprcy_PreFundedUnitShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl0" xml:lang="en-US">Prices specified in forward agreements to purchase financial assets for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesOutstandingPercentage_lbl1" xml:lang="en-US">Number Of Shares Outstanding Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesOutstandingPercentage" xlink:to="sprcy_NumberOfSharesOutstandingPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl2" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl4" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0" xml:lang="en-US">Payment Of Issuance Expenses Related To Previous Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SubsequentEventsMember_lbl0" xml:lang="en-US">Subsequent Events Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SubsequentEventsMember" xlink:to="sprcy_SubsequentEventsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnderlyingAdsPrice_lbl0" xml:lang="en-US">Underlying Ads Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingAdsPrice" xlink:to="sprcy_UnderlyingAdsPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl0" xml:lang="en-US">Carrying amount [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccruedExpenses_lbl0" xml:lang="en-US">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedExpenses" xlink:to="sprcy_AccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments_lbl0" xml:lang="en-US">Profit (loss) on disposal of investments and changes in value of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:to="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl2" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl0" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating basic earnings (loss) per instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AttributableToAbstract_lbl0" xml:lang="en-US">Attributable To Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AttributableToAbstract" xlink:to="sprcy_AttributableToAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInstallment_lbl1" xml:lang="en-US">Additional Installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesGranted_lbl1" xml:lang="en-US">Ordinary Shares Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGranted" xlink:to="sprcy_OrdinarySharesGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl0" xml:lang="en-US">Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareCapitalPercentage_lbl1" xml:lang="en-US">Share Capital Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1" xml:lang="en-US">Disclosue Of Cash And Cash Equivalents Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrepaidAdvance_lbl1" xml:lang="en-US">Prepaid Advance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrepaidAdvance" xlink:to="sprcy_PrepaidAdvance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentInFinancialAsset_lbl1" xml:lang="en-US">Investment In Financial Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentInFinancialAsset" xlink:to="sprcy_InvestmentInFinancialAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesAbstract0_lbl0" xml:lang="en-US">Number Of Shares Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract0" xlink:to="sprcy_NumberOfSharesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinaryShareExercisePrice_lbl0" xml:lang="en-US">Ordinary Share Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareExercisePrice" xlink:to="sprcy_OrdinaryShareExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1" xml:lang="en-US">Description Of Acquisition Of ASingle Asset Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl0" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialInvestment_lbl1" xml:lang="en-US">Initial Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl1" xml:lang="en-US">Dekel License Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock_lbl1" xml:lang="en-US">Disclosure Of Fair Value Was Calculated Using The Black Scholes Option Pricing Model Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" xlink:to="sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments_lbl0" xml:lang="en-US">Reserve of gains and losses from investments in equity instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" xlink:to="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1" xml:lang="en-US">Description Of Accounting Policy Foroperatingcycle Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SeriesAWarrantsMember_lbl1" xml:lang="en-US">Series AWarrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesAWarrantsMember" xlink:to="sprcy_SeriesAWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Defined Contribution Plans Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl0" xml:lang="en-US">Consideration paid (received)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CooperationAgreementAmount_lbl1" xml:lang="en-US">Cooperation Agreement Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Options Cancelled In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Share Options And Weighted Average Exercise Prices Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl0" xml:lang="en-US">BGeneral And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfInvestment_lbl1" xml:lang="en-US">Fair Value Of Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfInvestment" xlink:to="sprcy_FairValueOfInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Percentage Of Useful Lives Or Depreciation Rates Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SeriesBWarrantsMember_lbl0" xml:lang="en-US">Series BWarrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesBWarrantsMember" xlink:to="sprcy_SeriesBWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingShareCapital_lbl1" xml:lang="en-US">Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OwnershipPercentage_lbl0" xml:lang="en-US">Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipPercentage" xlink:to="sprcy_OwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePrice1_lbl0" xml:lang="en-US">Exercise Price1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice1" xlink:to="sprcy_ExercisePrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXMember_lbl0" xml:lang="en-US">Mito Care XMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostOfGoodsSoldAbstract_lbl0" xml:lang="en-US">Cost Of Goods Sold Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSoldAbstract" xlink:to="sprcy_CostOfGoodsSoldAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl1" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GrowthRatePercentage_lbl0" xml:lang="en-US">Growth Rate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrowthRatePercentage" xlink:to="sprcy_GrowthRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl0" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsLiability_lbl0" xml:lang="en-US">Warrants Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinderFeePercentage_lbl1" xml:lang="en-US">Finder Fee Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinderFeePercentage" xlink:to="sprcy_FinderFeePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentFollowingAchievementMilestone_lbl1" xml:lang="en-US">Investment Following Achievement Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFollowingAchievementMilestone" xlink:to="sprcy_InvestmentFollowingAchievementMilestone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl0" xml:lang="en-US">Losses From Remeasurement Of Investment In Financial Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ServicesExpense_lbl1" xml:lang="en-US">Services expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl1" xml:lang="en-US">Fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfOutstandingShareCapital_lbl1" xml:lang="en-US">Percentage Of Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfOutstandingShareCapital" xlink:to="sprcy_PercentageOfOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeRateDifferencesNetMember_lbl0" xml:lang="en-US">Exchange Rate Differences Net Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeRateDifferencesNetMember" xlink:to="sprcy_ExchangeRateDifferencesNetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl" xml:lang="en-US">Schedule Of Additional Information To The Items Of Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateUnits_lbl1" xml:lang="en-US">Aggregate Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0_lbl0" xml:lang="en-US">Adjustments To The Profit Or Loss Items Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl0" xml:lang="en-US">Disclosure Of Other Accounts Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Revenues And Cost Of Revenues Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Fair Value For Share Options Granted Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CommitmentPercentage_lbl1" xml:lang="en-US">Commitment Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentPercentage" xlink:to="sprcy_CommitmentPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPaymentPercentage_lbl1" xml:lang="en-US">Installment Payment Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaymentPercentage" xlink:to="sprcy_InstallmentPaymentPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FreightMember_lbl0" xml:lang="en-US">Freight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FreightMember" xlink:to="sprcy_FreightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of general information about financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnpaidIssueExpenses_lbl1" xml:lang="en-US">Unpaid Issue Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Lifes Of Outstanding Share Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsTextBlock_lbl1" xml:lang="en-US">Warrants Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsTextBlock" xlink:to="sprcy_WarrantsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalMilestoneAmount_lbl0" xml:lang="en-US">Additional Milestone Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0" xml:lang="en-US">AResearch And Development Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MaturityDate_lbl0" xml:lang="en-US">Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MaturityDate" xlink:to="sprcy_MaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalPointMember_lbl0" xml:lang="en-US">Capital Point Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointMember" xlink:to="sprcy_CapitalPointMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Was Calculated Using The Black Scholes Option Pricing Model Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl1" xml:lang="en-US">Disclosure Of Fair Value Of The Intangible Asset Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:to="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Financial Assets And Financial Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivables_lbl0" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClinicalStudiesMember_lbl0" xml:lang="en-US">Clinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl1" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Purchase of interests in investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DFinanceIncomeAbstract_lbl0" xml:lang="en-US">DFinance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DFinanceIncomeAbstract" xlink:to="sprcy_DFinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl0" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0" xml:lang="en-US">Office Maintenance Rent And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseholdImprovements_lbl1" xml:lang="en-US">Leasehold Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1" xml:lang="en-US">Operating Loss Carryforwards Tax Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxExpense_lbl2" xml:lang="en-US">Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePricePercentage_lbl1" xml:lang="en-US">Share Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePercentage" xlink:to="sprcy_SharePricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Range Of Dividend Used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GrossProceeds_lbl1" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl1" xml:lang="en-US">Purchase Of Financial Assets At Fair Value Through Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0" xml:lang="en-US">Disclosure of additional information [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfOrdinaryShares_lbl1" xml:lang="en-US">Sale Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CommitmentAmount_lbl1" xml:lang="en-US">Commitment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AssetAndSharePurchaseAgreementValue_lbl1" xml:lang="en-US">Asset And Share Purchase Agreement Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AssetAndSharePurchaseAgreementValue" xlink:to="sprcy_AssetAndSharePurchaseAgreementValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl2" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl0" xml:lang="en-US">Applicable tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities_lbl1" xml:lang="en-US">Cash Advances And Loans Made To Related Parties Classified As Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" xlink:to="sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesSold_lbl1" xml:lang="en-US">Ordinary Shares Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesSold" xlink:to="sprcy_OrdinarySharesSold_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossProfit_lbl0" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingTerm_lbl0" xml:lang="en-US">Operating Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseofAssets_lbl0" xml:lang="en-US">Purchaseof Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseofAssets" xlink:to="sprcy_PurchaseofAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentIncome_lbl0" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfShareOption_lbl1" xml:lang="en-US">Fair Value Of Share Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOption" xlink:to="sprcy_FairValueOfShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateIssuedAmount_lbl1" xml:lang="en-US">Aggregate Issued Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl0" xml:lang="en-US">Sale or issue of treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrivatePlacementsMember_lbl1" xml:lang="en-US">Private Placements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrivatePlacementsMember" xlink:to="sprcy_PrivatePlacementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl1" xml:lang="en-US">Fair Value Of Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl0" xml:lang="en-US">Description Of Accounting Policy For Restricted Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl0" xml:lang="en-US">Net Change In Fair Value Of Financial Liabilities Designated At Fair Value Through Profit Or Loss Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Warrants Fair Value Using Blackscholes Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesParValue_lbl1" xml:lang="en-US">Ordinary Shares Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesParValue" xlink:to="sprcy_OrdinarySharesParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CoeruleusMember_lbl0" xml:lang="en-US">Coeruleus Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CoeruleusMember" xlink:to="sprcy_CoeruleusMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXBioLtdMember_lbl0" xml:lang="en-US">Mito Care XBio Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_COtherExpensesAbstract_lbl0" xml:lang="en-US">COther Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_COtherExpensesAbstract" xlink:to="sprcy_COtherExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl0" xml:lang="en-US">Property, plant and equipment, gross carrying amount of fully depreciated assets still in use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseFee_lbl0" xml:lang="en-US">Lease Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseFee" xlink:to="sprcy_LeaseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl0" xml:lang="en-US">Significant Non Cash Transactions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalCommitments_lbl0" xml:lang="en-US">Capital commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl0" xml:lang="en-US">Current trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract0_lbl0" xml:lang="en-US">BGeneral And Administrative Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract0" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl1" xml:lang="en-US">Issued capital, ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentMember_lbl0" xml:lang="en-US">Share Based Payment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0" xml:lang="en-US">Short-term employee benefits accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl0" xml:lang="en-US">Business Development Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl1" xml:lang="en-US">Ordinary Shares Granted Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract_lbl" xml:lang="en-US">Schedule Of Warrants Fair Value Using Black Scholes Opm Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParentMember_lbl0" xml:lang="en-US">Parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Balance With Relate Parties Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProceedsFromIssuanceOfPrivateOffering_lbl1" xml:lang="en-US">Proceeds From Issuance Of Private Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssuanceOfPrivateOffering" xlink:to="sprcy_ProceedsFromIssuanceOfPrivateOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl1" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DeferredCashPayments_lbl1" xml:lang="en-US">Deferred Cash Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl1" xml:lang="en-US">Other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0" xml:lang="en-US">Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GovernmentAuthorities_lbl1" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfTradePayables_lbl1" xml:lang="en-US">Disclosure Of Trade Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl1" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl2" xml:lang="en-US">Number Of Outstanding Share Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseCosts_lbl0" xml:lang="en-US">Purchase Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCosts" xlink:to="sprcy_PurchaseCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl1" xml:lang="en-US">Disclosure Of Financial Assets And Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePeriod_lbl0" xml:lang="en-US">Exercise Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePeriod" xlink:to="sprcy_ExercisePeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpense_lbl0" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EstimatedAmount_lbl0" xml:lang="en-US">Estimated Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EstimatedAmount" xlink:to="sprcy_EstimatedAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Balances With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, general and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl0" xml:lang="en-US">Actuarial assumption of discount rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl0" xml:lang="en-US">Other related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareOptionsGranted_lbl1" xml:lang="en-US">Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsGranted" xlink:to="sprcy_ShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl0" xml:lang="en-US">Issuance Expenses Related To Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAmount_lbl1" xml:lang="en-US">Investment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl0" xml:lang="en-US">Current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0" xml:lang="en-US">Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GeneralAndAdministrativeExpenses_lbl0" xml:lang="en-US">General And Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralAndAdministrativeExpenses" xlink:to="sprcy_GeneralAndAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Other property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl1" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl2" xml:lang="en-US">Issuance Of Share Capital In Respect Of Rounding Errors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl1" xml:lang="en-US">Description Of Amendment To IAS8 Accounting Policies Changes To Accounting Estimates And Errors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_lbl0" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1" xml:lang="en-US">Disclourse Of Accounts Receivables Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccruedInterestPercentage_lbl1" xml:lang="en-US">Accrued Interest Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedInterestPercentage" xlink:to="sprcy_AccruedInterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0" xml:lang="en-US">Reserve of share-based payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl2" xml:lang="en-US">Property Plant And Equipment Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsExercisePrice_lbl1" xml:lang="en-US">Warrants Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl0" xml:lang="en-US">United States of America, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl0" xml:lang="en-US">Finance Expenses From Interest And Commissions Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfReverseShareSplit_lbl0" xml:lang="en-US">Description Of Reverse Share Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfReverseShareSplit" xlink:to="sprcy_DescriptionOfReverseShareSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl0" xml:lang="en-US">Current inventories in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AutoMaxAcquisitionMember_lbl0" xml:lang="en-US">Auto Max Acquisition Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxAcquisitionMember" xlink:to="sprcy_AutoMaxAcquisitionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl1" xml:lang="en-US">Disclosure Of Information To The Items Of Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PricePerShare_lbl1" xml:lang="en-US">Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TwoThousandTwentyThreePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Three Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TwoThousandTwentyThreePlanMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl1" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_lbl0" xml:lang="en-US">Cash repayments of advances and loans from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:to="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePrice_lbl0" xml:lang="en-US">Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePrice" xlink:to="sprcy_PurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePriceRate_lbl1" xml:lang="en-US">Share Price Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl0" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:to="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl0" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl0" xml:lang="en-US">Cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Changes In Equity Deficit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract" xlink:to="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0" xml:lang="en-US">Reserve of exchange differences on translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairMarketValue_lbl1" xml:lang="en-US">Fair Market Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract_lbl" xml:lang="en-US">Schedule Of Cost Of Sales And Gross Profit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:to="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenueTerm_lbl1" xml:lang="en-US">Revenue Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenueTerm" xlink:to="sprcy_RevenueTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentsExpenses_lbl1" xml:lang="en-US">Research And Developments Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentsExpenses" xlink:to="sprcy_ResearchAndDevelopmentsExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BonusAmountReceived_lbl1" xml:lang="en-US">Bonus Amount Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl1" xml:lang="en-US">Issued And Outstanding Share Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ComprehensiveLoss_lbl1" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for taxes other than income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl0" xml:lang="en-US">Commitments made by entity, related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialAssetsAbstract_lbl0" xml:lang="en-US">Financial Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialAssetsAbstract" xlink:to="sprcy_FinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRevenueExpense_lbl0" xml:lang="en-US">Interest income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl2" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_June2022WarrantsMember_lbl0" xml:lang="en-US">June2022 Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl2" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StorageMember_lbl0" xml:lang="en-US">Storage Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StorageMember" xlink:to="sprcy_StorageMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl0" xml:lang="en-US">Number of shares authorised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CreditFromOthers_lbl1" xml:lang="en-US">Credit From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryExpensesMember_lbl0" xml:lang="en-US">Regulatory Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl3" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl1" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0" xml:lang="en-US">Proceeds from contributions of non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl1" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule Of Share Capital Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="sprcy_ScheduleOfShareCapitalAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl2" xml:lang="en-US">Intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePricePerShare_lbl1" xml:lang="en-US">Share Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MutualShareExchangeOfOrdinaryShares_lbl1" xml:lang="en-US">Mutual Share Exchange Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeOfOrdinaryShares" xlink:to="sprcy_MutualShareExchangeOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl0" xml:lang="en-US">Proportion of ownership interest in associate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingSharesPercentage_lbl1" xml:lang="en-US">Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrefundedWarrantsMember_lbl1" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Non-current receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl1" xml:lang="en-US">Purchase Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Option Granted In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl0" xml:lang="en-US">Current finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl0" xml:lang="en-US">Proceeds from issuing shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AmountTotal_lbl0" xml:lang="en-US">Amount Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmountTotal" xlink:to="sprcy_AmountTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl0" xml:lang="en-US">Adjustments To The Profit Or Loss Items Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreviouslyStatedMember_lbl2" xml:lang="en-US">Previously stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalRatio_lbl1" xml:lang="en-US">Capital Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DrugDevelopmentMember_lbl0" xml:lang="en-US">Drug Development Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl0" xml:lang="en-US">Professional And Directors Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsWithRelatedPartiesMember_lbl0" xml:lang="en-US">Transactions With Related Parties Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsWithRelatedPartiesMember" xlink:to="sprcy_TransactionsWithRelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AutoMaxMotorsLtdMember_lbl0" xml:lang="en-US">Auto Max Motors Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxMotorsLtdMember" xlink:to="sprcy_AutoMaxMotorsLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClearmindMedicineIncMember_lbl0" xml:lang="en-US">Clearmind Medicine Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClearmindMedicineIncMember" xlink:to="sprcy_ClearmindMedicineIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Intangible Asset Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation and amortisation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeEquipmentsMember_lbl0" xml:lang="en-US">Office Equipments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Transactions With Relate Parties Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateUnitsPerShare_lbl1" xml:lang="en-US">Aggregate Units Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AmazonFeesMember_lbl1" xml:lang="en-US">Amazon Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DividendYield_lbl1" xml:lang="en-US">Dividend Yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateValue_lbl1" xml:lang="en-US">Aggregate Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Exercise Prices Of Share Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpireTerm_lbl0" xml:lang="en-US">Expire Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpireTerm" xlink:to="sprcy_ExpireTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0" xml:lang="en-US">Key management personnel of entity or parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl0" xml:lang="en-US">Intangible asset fair value used as deemed cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1" xml:lang="en-US">Rightofuse Asset Recognized With Corresponding Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LongTermPercentage_lbl1" xml:lang="en-US">Long Term Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestRate_lbl1" xml:lang="en-US">Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl5" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesAbstract_lbl0" xml:lang="en-US">Number Of Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ValueAddedTaxReceivables_lbl0" xml:lang="en-US">Value added tax receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ValueAddedTaxReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl0" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterest_lbl0" xml:lang="en-US">Other equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesIssued_lbl0" xml:lang="en-US">Ordinary Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesIssued" xlink:to="sprcy_OrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityLossesFromInvestment_lbl2" xml:lang="en-US">Equity Losses From Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of accrued expenses and other liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl0" xml:lang="en-US">Dilutive effect of all instruments on weighted average number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl1" xml:lang="en-US">Significant Accounting Judgments Estimates And Assumptions Used In Preparation Of Financial Statements Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalPointWarrantMember_lbl0" xml:lang="en-US">Capital Point Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointWarrantMember" xlink:to="sprcy_CapitalPointWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Reversal of impairment loss recognised in other comprehensive income, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl0" xml:lang="en-US">Regulatory Professional And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl1" xml:lang="en-US">Property, plant and equipment, revalued assets, at cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl1" xml:lang="en-US">Duly Executed Share Transfer Deed For Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:to="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpensesDueToSharebasedCompensation_lbl0" xml:lang="en-US">Expenses Due To Sharebased Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_ExpensesDueToSharebasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Exercise price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EFinanceExpensesAbstract_lbl0" xml:lang="en-US">EFinance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EFinanceExpensesAbstract" xlink:to="sprcy_EFinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) other than changes in working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl0" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0" xml:lang="en-US">Communication and network equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentFromShareholders_lbl1" xml:lang="en-US">Investment From Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFromShareholders" xlink:to="sprcy_InvestmentFromShareholders_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl0" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Number Of Shares And Loss Used In The Computation Of Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0" xml:lang="en-US">Investor Relations And Business Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FeeExpenses_lbl1" xml:lang="en-US">Fee Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsInAssociates_lbl0" xml:lang="en-US">Investments in associates reported in separate financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Expenses Due To Share Based Compensation Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_JeffsBrandsMember_lbl0" xml:lang="en-US">Jeffs Brands Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 2 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl0" xml:lang="en-US">Disclosure of associates [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0" xml:lang="en-US">Categories of financial assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentAmount_lbl1" xml:lang="en-US">Installment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1" xml:lang="en-US">Companys Share Of Losses Of Company Accounted For At Equity Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0" xml:lang="en-US">Number of shares issued and fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BridgeLoansMember_lbl0" xml:lang="en-US">Bridge Loans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BridgeLoansMember" xlink:to="sprcy_BridgeLoansMember_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>70
<FILENAME>sprcy-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Feb 13 15:57:33 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_General" roleURI="http://trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Cash" roleURI="http://trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Inventory" roleURI="http://trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinAssociates" roleURI="http://trpx.com/role/InvestmentinAssociates"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Leases" roleURI="http://trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_IntangibleAsset" roleURI="http://trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TradePayables" roleURI="http://trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_FinancialInstruments" roleURI="http://trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TaxesonIncome" roleURI="http://trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Equity" roleURI="http://trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_LossPerShareAds" roleURI="http://trpx.com/role/LossPerShareAds"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OperatingSegments" roleURI="http://trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EventsAftertheReportingPeriod" roleURI="http://trpx.com/role/EventsAftertheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_Warrants" roleURI="http://trpx.com/role/Warrants"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_CashTables" roleURI="http://trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InventoryTables" roleURI="http://trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinAssociatesTables" roleURI="http://trpx.com/role/InvestmentinAssociatesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TradePayablesTables" roleURI="http://trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EquityTables" roleURI="http://trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_LossPerShareAdsTables" roleURI="http://trpx.com/role/LossPerShareAdsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_WarrantsTables" roleURI="http://trpx.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofCostofSalesandGrossProfitTable" roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable0" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable0" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable0" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable0" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable0" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofShareCapitalTable0" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable0" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ScheduleofOperatingSegmentsTable0" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_GeneralDetails" roleURI="http://trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinAssociatesDetails" roleURI="http://trpx.com/role/InvestmentinAssociatesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_LeasesDetails" roleURI="http://trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_FinancialInstrumentsDetails" roleURI="http://trpx.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EquityDetails" roleURI="http://trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_EventsAftertheReportingPeriodDetails" roleURI="http://trpx.com/role/EventsAftertheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#sprcy_r_WarrantsDetails" roleURI="http://trpx.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20240630.xsd#DocumentAndEntityInformation" roleURI="http://trpx.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_WarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLoss_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfChangesInEquityDeficitAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfChangesInEquityDeficitAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_WarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherEquityInterestMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ParentMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="8.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrants" xlink:href="sprcy-20240630.xsd#sprcy_ExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ExerciseOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20240630.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IssueOfShareCapitalNetOfIssueExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreviouslyStatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToTheProfitOrLossItemsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalAdjustmentssAbstract" xlink:href="sprcy-20240630.xsd#sprcy_WorkingCapitalAdjustmentssAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="WorkingCapitalAdjustmentssAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentssAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentssAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentssAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentssAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentssAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentssAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" xlink:href="sprcy-20240630.xsd#sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20240630.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ReceiptofShortTermCreditFromOthers" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SignificantNonCashTransactionsAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MutualShareExchangeOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_MutualShareExchangeOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="MutualShareExchangeOfOrdinaryShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20240630.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegistrationOfWarrants" xlink:href="sprcy-20240630.xsd#sprcy_RegistrationOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="RegistrationOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentInFinancialAsset" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentInFinancialAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="InvestmentInFinancialAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidIssueExpenses" xlink:href="sprcy-20240630.xsd#sprcy_UnpaidIssueExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="UnpaidIssueExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract" xlink:to="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Cash" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="InventoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OtherAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinAssociates" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinFinancialAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/IntangibleAsset" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TradePayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OtherAccountsPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherAccountsPayableAbstract" xlink:to="DisclosureOfOtherAccountsPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EmployeeBenefitLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/RevenuesandCostofRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/LossPerShareAds" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OperatingSegments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriod" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EventsAftertheReportingPeriod" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Warrants" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="WarrantsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="WarrantsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20240630.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="BasisOfPresentationOfFinancialStatements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAcquisitionOfASingleAssetCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForRestrictedDeposit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/CashTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAbstract" xlink:to="DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="InventoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInvertoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfInvertoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="DisclosureOfInvertoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OtherAccountsReceivableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="DisclourseOfAccountsReceivablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinAssociatesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/IntangibleAssetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="DisclosureOfFairValueOfTheIntangibleAssetTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TradePayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradePayables" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfTradePayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="DisclosureOfTradePayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OtherAccountsPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="DisclosureOfFinancialAssetsAndFinancialLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EmployeeBenefitLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="DisclosureOfIssuedAndOutstandingShareCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/RevenuesandCostofRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="DisclosureOfInformationToTheItemsOfProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/LossPerShareAdsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OperatingSegmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/WarrantsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="WarrantsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:to="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable" xlink:to="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20240630.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovements" xlink:href="sprcy-20240630.xsd#sprcy_LeaseholdImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems" xlink:to="LeaseholdImprovements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfCashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashScheduleofCashDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CashScheduleofCashDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_CashScheduleofCashDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAbstract" xlink:to="CashScheduleofCashDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashScheduleofCashDetailsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_USD" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_ILS" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashScheduleofCashDetailsTable" xlink:to="CashScheduleofCashDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashScheduleofCashDetailsLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_FinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_Inventories" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsDate" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="InvestmentsDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesFromInvestment" xlink:href="sprcy-20240630.xsd#sprcy_EquityLossesFromInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="EquityLossesFromInvestment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="InvestmentAchievementOfFirstMilestone" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeEquipmentsMember" xlink:href="sprcy-20240630.xsd#sprcy_OfficeEquipmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="OfficeEquipmentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="sprcy-20240630.xsd#sprcy_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="sprcy-20240630.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:href="sprcy-20240630.xsd#sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="PropertyPlantAndEquipmentAccumulatedDepreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentAccumulatedDepreciation_0" xlink:href="sprcy-20240630.xsd#sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="PropertyPlantAndEquipmentAccumulatedDepreciation_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseofAssets" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseofAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="PurchaseofAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedExpenses" xlink:href="sprcy-20240630.xsd#sprcy_AccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="AccruedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_Accruals" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="sprcy-20240630.xsd#sprcy_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="GovernmentAuthorities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="InvestmentsInFinancialAssets" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_CreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="CreditFromOthers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="WarrantsLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable" xlink:to="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DividendYield" xlink:href="sprcy-20240630.xsd#sprcy_DividendYield"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="DividendYield" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedVolatility" xlink:href="sprcy-20240630.xsd#sprcy_ExpectedVolatility"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="ExpectedVolatility" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RiskFreeInterestRate" xlink:href="sprcy-20240630.xsd#sprcy_RiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="RiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderlyingAdsPrice" xlink:href="sprcy-20240630.xsd#sprcy_UnderlyingAdsPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="UnderlyingAdsPrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="ExercisePricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems" xlink:to="WarrantsFairValueinDollarsPerShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofDefinedContributionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfSharesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="NumberOfSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedToAConsultant" xlink:href="sprcy-20240630.xsd#sprcy_ShareIssuedToAConsultant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ShareIssuedToAConsultant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfShelfProspectus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfRoundingErrors" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentsExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentsExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="ResearchAndDevelopmentsExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpenses" xlink:href="sprcy-20240630.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="GeneralAndAdministrativeExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20240630.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="ExpensesDueToSharebasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20240630.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderlyingOrdinarySharePrices" xlink:href="sprcy-20240630.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="UnderlyingOrdinarySharePrices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingShareOption" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfOutstandingShareOption" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingShareOption_0" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfOutstandingShareOption_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:to="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AmazonFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_AmazonFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AmazonFeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasedGoodsMember" xlink:href="sprcy-20240630.xsd#sprcy_PurchasedGoodsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="PurchasedGoodsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StorageMember" xlink:href="sprcy-20240630.xsd#sprcy_StorageMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="StorageMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FreightMember" xlink:href="sprcy-20240630.xsd#sprcy_FreightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="FreightMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostOfGoodsSold" xlink:href="sprcy-20240630.xsd#sprcy_CostOfGoodsSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="CostOfGoodsSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsAxis" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="IncomeStatementsLocationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPHwcigou02yOi3RAgyAKCzKinttrVCX0GS4sD3ObxpwqEzqm9j1cZ4KQuocaRc2hMVSIDbMizaoWZ/nmzHQlBpYQrBXVpspuwa7a1yTY7nXsjphYT7GC7hOyPdg0YxoXQO1gmR5R+ZgPKpBP3bZFMnCmNZhLiaBQrkKrpdWH5cWfA==] CSR-->
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IncomeStatementsLocationsDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WagesAndRelatedExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WagesAndRelatedExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentMember" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ShareBasedPaymentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryProfessionalAndOtherExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ResearchAndPreclinicalStudiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ClinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ClinicalStudiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChemistryAndFormulationsMember" xlink:href="sprcy-20240630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ChemistryAndFormulationsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmazonFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_AmazonFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="AmazonFeesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StorageMember" xlink:href="sprcy-20240630.xsd#sprcy_StorageMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="StorageMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ProfessionalAndDirectorsFeesMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessDevelopmentExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="BusinessDevelopmentExpensesMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryExpensesMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="OfficeMaintenanceRentAndOtherExpensesMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InvestorRelationsAndBusinessExpensesMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20240630.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateDifferencesNetMember" xlink:href="sprcy-20240630.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ExchangeRateDifferencesNetMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IssuanceExpensesRelatedToWarrantsMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20240630.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20240630.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="FinanceExpenseInRespectOfLeasesMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20240630.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="FinanceExpensesFromInterestAndCommissionsMember" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="AResearchAndDevelopmentExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchAndDevelopmentExpenses1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="BGeneralAndAdministrativeExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BGeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="COtherExpensesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_COtherExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="COtherExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20240630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COtherExpensesAbstract" xlink:to="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DFinanceIncomeAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DFinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="DFinanceIncomeAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DFinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="EFinanceExpensesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_EFinanceExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="EFinanceExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EFinanceExpensesAbstract" xlink:to="ifrs-full_FinanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreviouslyStatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable" xlink:to="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ContinuingOperationsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems" xlink:to="ContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugDevelopmentMember" xlink:href="sprcy-20240630.xsd#sprcy_DrugDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="DrugDevelopmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlineSalesMember" xlink:href="sprcy-20240630.xsd#sprcy_OnlineSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OnlineSalesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingRevenueAbstract" xlink:href="sprcy-20240630.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="SegmentReportingRevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExternalRevenues" xlink:href="sprcy-20240630.xsd#sprcy_ExternalRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="ExternalRevenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20240630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxExpense" xlink:href="sprcy-20240630.xsd#sprcy_TaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="TaxExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20240630.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="KeyManagementPersonnelCompensationManagementFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentFollowingAchievementMilestone" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentFollowingAchievementMilestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="InvestmentFollowingAchievementMilestone" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TransactionsWithRelatedPartiesMember" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsWithRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="TransactionsWithRelatedPartiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20240630.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="KeyManagementPersonnelCompensationManagementFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_FinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="FinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansAndAdvances" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansAndAdvances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_LoansAndAdvances" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="sprcy-20240630.xsd#sprcy_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="GovernmentAuthorities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsInFinancialAssets" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="InvestmentsInFinancialAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilitiesAbstract" xlink:href="sprcy-20240630.xsd#sprcy_FinancialLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="FinancialLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditFromOthers" xlink:href="sprcy-20240630.xsd#sprcy_CreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="CreditFromOthers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="WarrantsLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract0" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfSharesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="NumberOfSharesAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfRoundingErrors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedToAConsultant" xlink:href="sprcy-20240630.xsd#sprcy_ShareIssuedToAConsultant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ShareIssuedToAConsultant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsAxis" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="IncomeStatementsLocationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20240630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IncomeStatementsLocationsDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WagesAndRelatedExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WagesAndRelatedExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentMember" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ShareBasedPaymentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ClinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ClinicalStudiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryProfessionalAndOtherExpensesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ResearchAndPreclinicalStudiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChemistryAndFormulationsMember" xlink:href="sprcy-20240630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ChemistryAndFormulationsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ProfessionalAndDirectorsFeesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessDevelopmentExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="BusinessDevelopmentExpensesMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="OfficeMaintenanceRentAndOtherExpensesMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InvestorRelationsAndBusinessExpensesMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellutionOperatingExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_WellutionOperatingExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WellutionOperatingExpensesMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmazonFeesMember" xlink:href="sprcy-20240630.xsd#sprcy_AmazonFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="AmazonFeesMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryExpensesMember" xlink:href="sprcy-20240630.xsd#sprcy_RegulatoryExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryExpensesMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugDevelopmentMember" xlink:href="sprcy-20240630.xsd#sprcy_DrugDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="DrugDevelopmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlineSalesMember" xlink:href="sprcy-20240630.xsd#sprcy_OnlineSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OnlineSalesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingRevenueAbstract" xlink:href="sprcy-20240630.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="SegmentReportingRevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExternalRevenues" xlink:href="sprcy-20240630.xsd#sprcy_ExternalRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="ExternalRevenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20240630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxExpense" xlink:href="sprcy-20240630.xsd#sprcy_TaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="TaxExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="SignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OperatingTerm" xlink:href="sprcy-20240630.xsd#sprcy_OperatingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:to="OperatingTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinAssociatesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinAssociatesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinAssociatesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="InvestmentinAssociatesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalPointWarrantMember" xlink:href="sprcy-20240630.xsd#sprcy_CapitalPointWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="CapitalPointWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EveroMember" xlink:href="sprcy-20240630.xsd#sprcy_EveroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="EveroMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalPointMember" xlink:href="sprcy-20240630.xsd#sprcy_CapitalPointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="CapitalPointMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CoeruleusMember" xlink:href="sprcy-20240630.xsd#sprcy_CoeruleusMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="CoeruleusMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXBioLtdMember" xlink:href="sprcy-20240630.xsd#sprcy_MitoCareXBioLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXBioLtdMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20240630.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsTable" xlink:to="InvestmentinAssociatesDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesSold" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="OrdinarySharesSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesParValue" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="OrdinarySharesParValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="PercentageOfSharesIssuedAndOutstandingShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairMarketValue" xlink:href="sprcy-20240630.xsd#sprcy_FairMarketValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="FairMarketValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="PurchaseOfOrdinaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DulyExecutedShareTransferDeedForOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_DulyExecutedShareTransferDeedForOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="DulyExecutedShareTransferDeedForOrdinaryShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentFromShareholders" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentFromShareholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="InvestmentFromShareholders" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20240630.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="IssuedAndOutstandingSharesPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfInvestment" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="FairValueOfInvestment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialInvestment" xlink:href="sprcy-20240630.xsd#sprcy_InitialInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="InitialInvestment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInvestment" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="AdditionalInvestment" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipPercentage" xlink:href="sprcy-20240630.xsd#sprcy_OwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="OwnershipPercentage" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingSharesPercentage" xlink:href="sprcy-20240630.xsd#sprcy_OutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="OutstandingSharesPercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInstallment" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalInstallment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="AdditionalInstallment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPaid" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="InstallmentPaid" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesFromInvestment" xlink:href="sprcy-20240630.xsd#sprcy_EquityLossesFromInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="EquityLossesFromInvestment" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_InvestmentIncome" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_OtherIncome" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinFinancialAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="InvestmentinFinancialAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InvestmentMember" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="InvestmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ScenarioForecastsMember" xlink:href="sprcy-20240630.xsd#sprcy_ScenarioForecastsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ScenarioForecastsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="currency_ILS" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AutoMaxMotorsLtdMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxMotorsLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AutoMaxMotorsLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BridgeLoansMember" xlink:href="sprcy-20240630.xsd#sprcy_BridgeLoansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="BridgeLoansMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AutoMaxAcquisitionMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxAcquisitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AutoMaxAcquisitionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AutoMaxMember" xlink:href="sprcy-20240630.xsd#sprcy_AutoMaxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AutoMaxMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InvestmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_InvestmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="InvestmentAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20240630.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ShareCapitalPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_SharePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="SharePricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLoss" xlink:href="sprcy-20240630.xsd#sprcy_ComprehensiveLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ComprehensiveLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_Cash" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_PricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="PricePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_LoansReceived" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_FinanceIncome" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalLoan" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="AdditionalLoan" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentClosingAmount" xlink:href="sprcy-20240630.xsd#sprcy_RepaymentClosingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="RepaymentClosingAmount" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_InterestExpense" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinderFeePercentage" xlink:href="sprcy-20240630.xsd#sprcy_FinderFeePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="FinderFeePercentage" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesOutstandingPercentage" xlink:href="sprcy-20240630.xsd#sprcy_NumberOfSharesOutstandingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="NumberOfSharesOutstandingPercentage" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LeaseMember" xlink:href="sprcy-20240630.xsd#sprcy_LeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="LeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SquareMeters" xlink:href="sprcy-20240630.xsd#sprcy_SquareMeters"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="SquareMeters" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseFee" xlink:href="sprcy-20240630.xsd#sprcy_LeaseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="LeaseFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpireTerm" xlink:href="sprcy-20240630.xsd#sprcy_ExpireTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="ExpireTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="PropertyandEquipmentNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="PropertyandEquipmentNetDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_DepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/IntangibleAssetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseCosts" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="PurchaseCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchase" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsToPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="WarrantsToPurchase" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice1" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ExercisePrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePeriod" xlink:href="sprcy-20240630.xsd#sprcy_ExercisePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ExercisePeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="pricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_pricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="pricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountTotal" xlink:href="sprcy-20240630.xsd#sprcy_AmountTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="AmountTotal" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueTerm" xlink:href="sprcy-20240630.xsd#sprcy_RevenueTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="RevenueTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrowthRatePercentage" xlink:href="sprcy-20240630.xsd#sprcy_GrowthRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="GrowthRatePercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermPercentage" xlink:href="sprcy-20240630.xsd#sprcy_LongTermPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="LongTermPercentage" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseCostsValue" xlink:href="sprcy-20240630.xsd#sprcy_PurchaseCostsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="PurchaseCostsValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="FinancialInstrumentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementsMember" xlink:href="sprcy-20240630.xsd#sprcy_PrivatePlacementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="PrivatePlacementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePrice" xlink:href="sprcy-20240630.xsd#sprcy_PurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="PurchasePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityDate" xlink:href="sprcy-20240630.xsd#sprcy_MaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="MaturityDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialConversionPrice" xlink:href="sprcy-20240630.xsd#sprcy_InitialConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="InitialConversionPrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPrice" xlink:href="sprcy-20240630.xsd#sprcy_ConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ConversionPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareExercisePrice" xlink:href="sprcy-20240630.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="OrdinaryShareExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20240630.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="OperatingLossCarryforwardsTaxAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20240630.xsd#sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="DekelLicenseAgreementDescription" xlink:href="sprcy-20240630.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="DekelLicenseAgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualInvestment" xlink:href="sprcy-20240630.xsd#sprcy_AnnualInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="AnnualInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalMilestoneAmount" xlink:href="sprcy-20240630.xsd#sprcy_AdditionalMilestoneAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="AdditionalMilestoneAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="InstallmentAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedAmount" xlink:href="sprcy-20240630.xsd#sprcy_EstimatedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="EstimatedAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_CapitalCommitments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_SeriesAWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="SeriesAWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_SeriesBWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="SeriesBWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2022WarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_June2022WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="June2022WarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember" xlink:href="sprcy-20240630.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JeffsBrandsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreviouslyStatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="sprcy-20240630.xsd#sprcy_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverAllotmentMember" xlink:href="sprcy-20240630.xsd#sprcy_OverAllotmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="OverAllotmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreationDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_CreationDateAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="March2021FinancingRoundMember" xlink:href="sprcy-20240630.xsd#sprcy_March2021FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="March2021FinancingRoundMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfReverseShareSplit" xlink:href="sprcy-20240630.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DescriptionOfReverseShareSplit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="sprcy-20240630.xsd#sprcy_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="GrossProceeds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfAggregateShares" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceOfAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="IssuanceOfAggregateShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUnits" xlink:href="sprcy-20240630.xsd#sprcy_AggregateUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateUnits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUnitsPerShare" xlink:href="sprcy-20240630.xsd#sprcy_AggregateUnitsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateUnitsPerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DateOfIssuance" xlink:href="sprcy-20240630.xsd#sprcy_DateOfIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DateOfIssuance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsAndExercise" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAndExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantsAndExercise" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisePrice" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantsExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="sprcy-20240630.xsd#sprcy_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PurchasePricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceeds" xlink:href="sprcy-20240630.xsd#sprcy_AggregateGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateGrossProceeds" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalRatio" xlink:href="sprcy-20240630.xsd#sprcy_CapitalRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CapitalRatio" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ServicesExpense" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentAmount" xlink:href="sprcy-20240630.xsd#sprcy_CommitmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CommitmentAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfOrdinaryShares" xlink:href="sprcy-20240630.xsd#sprcy_SaleOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="SaleOfOrdinaryShares" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePriceRate" xlink:href="sprcy-20240630.xsd#sprcy_SharePriceRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="SharePriceRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate" xlink:href="sprcy-20240630.xsd#sprcy_InterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="InterestRate" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPayment" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="InstallmentPayment" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentForPremiumPercentage" xlink:href="sprcy-20240630.xsd#sprcy_PaymentForPremiumPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PaymentForPremiumPercentage" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIssuedAmount" xlink:href="sprcy-20240630.xsd#sprcy_AggregateIssuedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateIssuedAmount" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20240630.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="TwoThousandTwentyThreePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ShareBasedPaymentTransactionsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesGranted" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinarySharesGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfShareOption" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueOfShareOption" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsGranted" xlink:href="sprcy-20240630.xsd#sprcy_ShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfShareOptionsGranted" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueOfShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesIssued" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinarySharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinarySharesGrantedDiscountRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfOrdinarySharesGranted" xlink:href="sprcy-20240630.xsd#sprcy_FairValueOfOrdinarySharesGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueOfOrdinarySharesGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20240630.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClearmindMedicineIncMember" xlink:href="sprcy-20240630.xsd#sprcy_ClearmindMedicineIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ClearmindMedicineIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses" xlink:href="sprcy-20240630.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeOfCommonShares" xlink:href="sprcy-20240630.xsd#sprcy_ExchangeOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ExchangeOfCommonShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_OutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="OutstandingShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOutstandingShareCapital" xlink:href="sprcy-20240630.xsd#sprcy_PercentageOfOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="PercentageOfOutstandingShareCapital" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashConsideration" xlink:href="sprcy-20240630.xsd#sprcy_CashConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="CashConsideration" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CooperationAgreementAmount" xlink:href="sprcy-20240630.xsd#sprcy_CooperationAgreementAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="CooperationAgreementAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="SignificantEventsduringtheReportingPeriodDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NewCoIncMember" xlink:href="sprcy-20240630.xsd#sprcy_NewCoIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="NewCoIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember" xlink:href="sprcy-20240630.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JeffsBrandsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="SignificantEventsduringtheReportingPeriodDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InterestPercentgae" xlink:href="sprcy-20240630.xsd#sprcy_InterestPercentgae"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="InterestPercentgae" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredCashPayments" xlink:href="sprcy-20240630.xsd#sprcy_DeferredCashPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="DeferredCashPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20240630.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ShareCapitalPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FeeExpenses" xlink:href="sprcy-20240630.xsd#sprcy_FeeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="FeeExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusAmountReceived" xlink:href="sprcy-20240630.xsd#sprcy_BonusAmountReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="BonusAmountReceived" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ServicesExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MutualShareExchangeAmount" xlink:href="sprcy-20240630.xsd#sprcy_MutualShareExchangeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="MutualShareExchangeAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesAcquired" xlink:href="sprcy-20240630.xsd#sprcy_OrdinarySharesAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="OrdinarySharesAcquired" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateValue" xlink:href="sprcy-20240630.xsd#sprcy_AggregateValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="AggregateValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustedAmountOfAggregateValue" xlink:href="sprcy-20240630.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="AdjustedAmountOfAggregateValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipPercentage" xlink:href="sprcy-20240630.xsd#sprcy_OwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="OwnershipPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ListedSharePrice" xlink:href="sprcy-20240630.xsd#sprcy_ListedSharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ListedSharePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossOnInvestment" xlink:href="sprcy-20240630.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ComprehensiveLossOnInvestment" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EventsAftertheReportingPeriodDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="EventsAftertheReportingPeriodDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_EventsAftertheReportingPeriodDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EventsAftertheReportingPeriodDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_EventsAftertheReportingPeriodDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="EventsAftertheReportingPeriodDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsMember" xlink:href="sprcy-20240630.xsd#sprcy_SubsequentEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentEventsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScenarioForecastsMember" xlink:href="sprcy-20240630.xsd#sprcy_ScenarioForecastsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ScenarioForecastsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SEPAMember" xlink:href="sprcy-20240630.xsd#sprcy_SEPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SEPAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MizaMember" xlink:href="sprcy-20240630.xsd#sprcy_MizaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MizaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SciSparcMember" xlink:href="sprcy-20240630.xsd#sprcy_SciSparcMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SciSparcMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20240630.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsTable" xlink:to="EventsAftertheReportingPeriodDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SharePricePercentage" xlink:href="sprcy-20240630.xsd#sprcy_SharePricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="SharePricePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidAdvance" xlink:href="sprcy-20240630.xsd#sprcy_PrepaidAdvance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="PrepaidAdvance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterestPercentage" xlink:href="sprcy-20240630.xsd#sprcy_AccruedInterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="AccruedInterestPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentPercentage" xlink:href="sprcy-20240630.xsd#sprcy_CommitmentPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="CommitmentPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPaymentPercentage" xlink:href="sprcy-20240630.xsd#sprcy_InstallmentPaymentPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="InstallmentPaymentPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentPremiumPercentage" xlink:href="sprcy-20240630.xsd#sprcy_PaymentPremiumPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="PaymentPremiumPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AssetAndSharePurchaseAgreementValue" xlink:href="sprcy-20240630.xsd#sprcy_AssetAndSharePurchaseAgreementValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="AssetAndSharePurchaseAgreementValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Assets" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityStakeholdersRange" xlink:href="sprcy-20240630.xsd#sprcy_EntityStakeholdersRange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="EntityStakeholdersRange" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_RevenueFromRoyalties" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20240630.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="IssuedAndOutstandingSharePercentage" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/WarrantsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="WarrantsAbstract" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsTable" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsLineItems" xlink:href="sprcy-20240630.xsd#sprcy_WarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="WarrantsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="WarrantsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfPrivateOffering" xlink:href="sprcy-20240630.xsd#sprcy_ProceedsFromIssuanceOfPrivateOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="ProceedsFromIssuanceOfPrivateOffering" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceAggregateOfPrefundedUnits" xlink:href="sprcy-20240630.xsd#sprcy_IssuanceAggregateOfPrefundedUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="IssuanceAggregateOfPrefundedUnits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedUnitShares" xlink:href="sprcy-20240630.xsd#sprcy_PreFundedUnitShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="PreFundedUnitShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedUnitPerShare" xlink:href="sprcy-20240630.xsd#sprcy_PreFundedUnitPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="PreFundedUnitPerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="sprcy-20240630.xsd#sprcy_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>176
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!F$OM%8LT)Z' U,S (4[UFMK4;#;HU0O>N9,K;^G3$*2?NV0Q?8.?I28>V\
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M^X,A/XJZ+K;MRR>6K%G9 /CGFZ*HWRZ:WR Y_9C/W?\ 4$L#!!0    ( !V
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M]N#R-8V68?@IY*8N0U1W2.S46+QBY**6P/N*7I"CATUSB)F"QI["B>,\2C\
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MYU^_+"XOR9,8>@P*7E[*5[^*+SUT8!V2Y,F.X^+E^>5E<?&U^0D];(SA(^9
M>&C2CL5+9%B^."^./,*NO2 ##G6Z^V*T>PI;V$YWSLX]Q2&>Y48_&124Y=H>
M",\J).)-)04"0,3H1? *1]D._&5;/3=JSN"Q44 BQ7BR"\GQB:>RR$A+F-)(
MGHJK\'Q$GL2P)=])@Z"R]RQV<&/@I(+XHK#)N6VJ0(5J)4Z-7 "*HDY@^R$;
MH*KFAS570'P/(%ZWIYA61HHI0'PWB* 0$LH.Y FB_8H^D]SCZ*?2'Q&R" %6
MX(1QY?I@'H:A)AN*L=H8X/H#G88>('?10;LJ;N/M4HCVN?%C)I/@%%MDWR;U
MGM2N>I+PF($E7?](:-:<T"2*MY$F61;O4$94CIV8U"1UG(&(1M_6-G0-,;/W
M12*#UN7!]66-^#05J-NZ9;85><@$IQC';8S2,<BF /S@;4DUAP*)]VT0O\H
MAIB$"%--T\"[KLMD%S.$4/S(3L6UK0R3^$T3TJO4WXSDLR_Q_D0F & YH,X
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MZV-SH4@9/=R!1OVN<;X9U8UQS)6RN_'2J#\! #><*F-;IX<4D3!FN^7.8\>
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MCW))1IW+* .DW' ]V&UL2F='<V/Y[XE?"4OZ(0;3TY@,6A&BFK%_"?8 Y R
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M\*_?6=O_6/;EF]=PC%O[EO08&43?G[TZ2[Y%IOS^[/K5U?7%V0L8&1]_\_H
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MB9;6TB,G%$./5J>VVC1.N VP$X_$>"<EZ H)I]C>1DRTO3"7.H(W(333Z>.
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M?8?(9L0:0XO*MO5&:!P2N\WQ50)I O!\*X0^&N:"]IV+_P!02P,$%     @
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MV@^5(>>UO+0]*,(4$N)#.2N\7H#3G$G[86*(-!$JTI))4(X,/_*3.-"$YD;
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MT_]EB(X$CZWG1<@=9U0:WU"&3K"?@K5(T]".KSOE]'W38\A8Y1B=NY3,WG!
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MW;4#[E[<R#G*HZT[BO(@T/IR;D?;TK:L;_3O[G5=?.3RF!:*]O^!0KV[4>B
MK&M-W=&BM/?[7FBJ%K:94'E&:1S(?A!"OW;,!&W!7_P#4$L#!!0    ( !V
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M;"]W;W)K<VAE971S+W-H965T,3@N>&ULE53;;MLP#'W/5Q#:L*>MOK;-LL2
MDV;H@+4)>MDP#'M0;"8VJHLG*4WS]Y/DQ,N -,!>;)'B.3HD10TW4CWI"M'
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MVST5>3LA?\/;=^:&JE4M-#!<6FAX=GE.0+6SVQI&-GY>%M+8Z?/+RCYWJ%R
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M'([_,A&0 ')T$CT&6Q49+)9!)_-OJ!U;7U!.($>&'3#"3V0&\CWJ]=MR 1D
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M.D"X^:<1X:*P*_YUP<P6A<WXXQ)[;NUH )[/+=2O+FB!^O<I9_\!4$L#!!0
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M2(,@HDEA,T  >S4W5-327%JB?1ER$P!907C3_W709);5#D"B,FX5$2#]X:D
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MN@3:R!_$PHA"[4DJ)B47(V2V#?06M&C4V0]!N$$::T=K-3)GQTDX&X-8HAZ
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MT]:E03"=]OF;!?%->E^:%<!-N&"&IN8,(4LVHUPT'%[?2VW1/E4Q%@'<1#"
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MX[TI^,^%DL ,#<#W,V-\_4 ;-#_N.OL/4$L#!!0    ( !V 35J*SL=4(A(
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M]AWS[V9@=/_]#/R)S83)L6>"^3<24R-1W]_/1.,CG/3_L)-IQ+"&S>^QB1]
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M&;UX/HCRUSUX4X<C]<IX2$.X+?"+B"QOP/O<&-\]<(#^-];B7U!+ P04
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M.$E_9M9^1'=?L'RG.[6C2 .E-:B#-2M\1'-@(]5ZDQ_6QH81Z?OO<'CG(:(
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MWU(>$;2VH<T=N-%HO/.Y"5$?\K( -'?<"A5^P!+3;C<Q&-MCVWE"* *RL-S
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MP/'KAB;@^%RAJ?D#+5 >IY_]#U!+ P04    "  =@$U:TJP#M1(%  #!"P
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M*HJ6J)QRXBK%CF>\E4R\<;+[L+4/(-$D,08!!H=DYM?O=_8!-"'9,[4OB44
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MF])VBVQ]XC].V5/]\=EWSWN8#C]ZOI&A?^"A5V>&OEIE/S=UO^^R'^O"%O$
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M([,K-Z-/!%.=C=U%8AT(!<02.5G@8W1A9]>+Z0EZSW X-WN$%R*8]8T#L"M
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M;;PM)O#]GW68!*AF$JCFPECH3N_SG948"DT+L*+_9'JP;"7;[#X?\V 0>-V
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M,".WI"@9JDPTA)IWN!XYC:@Z\)!_+ ^<#-]SHBH>E!;:FF:-O(4&H.X,DD6
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MD_]T07<N24KP3V&Q!IQ4\.B6'<]O7.%V+OV2^]/12EFPCFG&[=32ET[]1-0
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M"Y;>V'5+MN?J<G7%:(P7TTM=J"'EZNQ,[]C9X=SWOE/ >^=<T9M!-4<"9W#
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MVS ,O?=7$%HQ;$ 6?R8ILL1 TZY8#QV*9MT.PPZ*S<1"]>%)2MW]^TERXF5
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M[9L579:HG0/92Z7L8\=-,%R_JQ]02P,$%     @ '8!-6K?I7[SF @  AP@
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M$&00:\- \>\!SB#+#!&&\;/F=)HC#7!WO66_L-I1RY(J.!/9-Y;H=.P,')+
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M;S?AL[:Q_X6WS\.]T.NB,B!Q1=#PXOJ2@6Y'KC6LJGV;)\K2T/AM3J\4:A=
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MH-%P1&[4G5^[P*K&>V2I+#G.3RMZXE"[!-I?*64/@3N@?S3S/U!+ P04
M"  =@$U:.]89B*8&  "^$P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6S=6%M3XS84?O>OT&1I!V9"XEN<A-L,"TM+A^TR7'8?.GU0[!.BP;:\DIQ
M?WW/D4UBP,E"IWWI!.*+SEW?^:3H8"'5O9X!&/:0I;D^[,R,*?;Z?1W/(..Z
M)PO(<60J5<8-/JJ[OBX4\,0J96G?=]VHGW&1=XX.[+M+=70@2Y.*'"X5TV66
M<?7X$5*Y..QXG:<75^)N9NA%_^B@X'=P#>:VN%3XU%]:240&N18R9PJFAYUC
M;^]D0/)6X*N A6[<,\ID(N4]/9PGAQV7 H(48D,6.%[F< )I2H8PC.^US<[2
M)2DV[Y^LG]G<,9<)UW BTV\B,;/#SJC#$ICR,C57<O$KU/G8 &.9:OO-%I7L
M(.JPN-1&9K4R1I")O+KRA[H.#861NT;!KQ7\MRH$M4)@$ZTBLVF=<L./#I1<
M,$72:(UN;&VL-F8C<IK%:Z-P5*">.3H3.<]CP5-VGFNC2IP@H]GV#9^DH'<.
M^@9]D&0_KNU]K.SY:^Q%[+/,S4RS3WD"28O^R69]S]]@H(_)+3/TGS+\Z&^T
M^%N9]UC@=IGO^F%;0)O53R%&=<^J!QO""98%#ZR]X%T%_^-X@@^(Z3_;2EY9
M#-LM4I_OZ8+'<-C!1M:@YM Y^OF#%[G[;>G^2\:>)1\NDP\W63^Z1A)*RA28
MG+)5(8ZU!JP!SY/&RPO!)R(51H!N*\E&/^U9W,R 39?V^<KI\J63KIPRD3.#
M&K',M4Q%P@TD3!N\5#.&&:R,%5*+BI44:J1H6TP%RD\>V9V29?%"7#1FOBB5
M+GENF)'L_.SJFHV[SL\?1K[O[K-6K#@(:+" 1FA"-@%%\'0(W1:C]LNYS7F9
M"(KYN+HZOTL#[/;ZM$I,EAI3U\[9BX+L.2=<SVQ98KJ![Z68\]2&2F$%XWVV
MA0XC_/:[[LBS5R_TG.N95&;7@,J01FU!-(X$[HCMLJ#KNJYS(7FN*4\%J2UG
MP95Y1*$P)*%=YT;Q!' T!O1)!,2\,0LQ(]_Y1<Y!Y50 QDL,7U63- R9Y[HL
M\ITO.%GJF>YXR(;> ,L1..?Y'+2I"H[IOT)!Z 9L%(Y9-!@[JRP'W2@:4+;=
MX6B$UPCS'38JUD +EDT!UIE-E<R8I%B:]=JM_\.1\XTKQ2F.)^U'%H0#YG6'
M7L@&@>]< *Y*C=$H1-5AY-Q(@SX;H>,4I<]DJ2 KGZ$[QN_*+L8^B%@;&VSN
MU_]+R[SL%-LD_B;P(VL8)6+*8(GF&ND6$5$05HAGSQ%OD8Y07H/7R&?AH 6K
M"%(61C_$*>*3#<;>:RS4,X/.,HQ)_(5AQU(;@BQ"..QBP[X#N-B.GNNW014!
MBD48!L-7,!U&S!^^$:05'*F<HRAB!#)3E6%"NTJ+"([Q9\@/0LO<F8!9 -3@
MPJ >17Y'F99474(C%XHA2Y5V82&I$U+.'PD5WG!?KP$2MR!K@L.29]<:)81T
MV6(FXAE%Y-B%)"= U#!?V6Q@/)>&IJ$1T;8M*FIPR[M8BH7]?C%3 L-!2'#,
MEVK!>%$H^2!PHTI-0KV )AUK4N\04)^7X8Q&O]+H,["_3JZ"_P7,(65>??7K
M:_!6_#_Q68/YV_M@R?WK^X%D6OF;>H(&WT+@U!BKL(C&W]PB6W63--3IN:TO
MB,!_R.;4(A1V&Y=CD^R^A\V?&H6\V?O6>6?_^;Q;OFMDOI[_=JO/NOG&E8[&
M6SDPK(KS!AI$"FP$\RY"W*K(L#F+EAQ;9QM)L"&XAA(M'59 ;25&OQY\.SE6
MM/@TZ_9IP]Y[L-Q[#]Z\]UZFL8(/N]4$JX\IC^\M;7K[J"%I8KY<?F[;@F]T
M]]Y?)?_ &*T;BSJ1FNB;O+O@VHEY&I?57K.TZ1%OKTGQB>L-O[=;&=Q<\#BV
M349:N!;Q# P! Y>-1.@X119/ZB5K*A4#CMH%*"$3&P*Y[:(AIUY#ZI=$YQ@;
M2=(A#)I E&Z+'>M%:-K9Q,!H\U2M0]L"QZQMA4V&6,8T:)0MA)E5"Y%,,09+
M"JB>%>0"%_;U?/"9*S2'"YUS*N8B ?3R*"!%7S_M,)<^SJ>' BP+S"76KT(R
MC0Y]^O-\O^=ZSI70][M3!4#E J(.IB@R$@QZHY"%/5P$W%XPPM\C":C4,M?U
MC!;X2V09E-S:02'<77OC'F+>\WK>"'V#B@6V1;&4B;#%ZO]5#S87V:TZ\%[P
M<I];-4N_<422@;JS)T>:V?FM3DN6;Y>'4\?V3*:_$J].MK!Z=[B+P-:=HJK;
M&R)V575:5#T86=@#EXDT1F;V=@;XRT:1 (Y/)?X4JQ_(P?+([NAO4$L#!!0
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M_^6/FWO8"3AY+B#;!&1!=W]04'G!/<]GUJR9)6^DT22D&J)1G-#T*+?>XJ[
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ML"V==0DWFA(Z0"@^RR*?TLPG?YC@;G)(/XM&J$48O, @M :XW0*^#Z+0]RE
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MZD]?_8UIY^X ,VD-CD/N<H8#JU!6 ._+MC7+&^M@=00^_0]02P,$%     @
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ML+_(^HY03[0H[3%[)30>VNTPPVL52". W]<"@VPFQD%[49O_#5!+ P04
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M@6RV4@^XZ72'-O@1RX^[!ZYZ;J]2D I301@%'*]GSIT_624:WP#^)O@@CMI
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MH;0#S/V%$/KYQ"9HNX+3OP!02P,$%     @ '8!-6IK>;C=; P  %14  !D
M  !X;"]W;W)K<VAE971S+W-H965T-38N>&ULM9A=CYLX%(;_BL56JU;J#M\D
MF4TB;8>/3M6N1LVV>U'MA2><#*B 4]N9M/^^-C!LF%#$5*<W"3;G?0[V>;$3
M+X^,?Q89@"1?RZ(2*R.3<G]IFF*;04G%!=M#I>[L&"^I5$U^9XH]!YK6HK(P
M'<L*S)+FE;%>UGTW?+UD!UGD%=QP(@YE2?FW5U"PX\JPC8>.]_E=)G6'N5[N
MZ1UL0'[8WW#5,CM*FI=0B9Q5A,-N9?QE7R8+'5\'?,SA*$ZNB1[)+6.?=>,Z
M71F6?B H8"LU@:JO>[B"HM @]1A?6J;1I=3"T^L'>ER/78WEE@JX8L6_>2JS
ME3$W2 H[>BCD>W9\#>UX?,W;LD+4G^38Q/H+@VP/0K*R%:LG*/.J^:9?VWDX
M$=C>#P1.*W"F"MQ6X$X5>*W FRKP6X$_51"T@F"J8-8*9G6QFMFM2Q-22==+
MSHZ$ZVA%TQ=U?6NUJDA>:2=N)%=W<Z63ZRLJ,O('V2B'IX<""-N1NNMY")+F
MA7BA;G[8A.3YLQ?D&<DK\D_&#H)6J5B:4N77%'/;YGK5Y')^D.O-H;H@KO62
M.);C#<BOQN4A;)7<KN7N@#R<GGU('DW/[@S(X^ER>T">3)=;?;FI*MZ5W>G*
M[M0\]Z?+_NFMDI!K":7X;ZC4#=\;YNOU\U+LZ196AEH@!?![,-:__V8'UI]#
MA<>$A9BP"!,68\(2)%C//FYG'W>,WMA';8,D+TM(<RI!+5LR2SD]TF+(+0W.
MKW%Z<[Q?.[YZB^Y/33 08\V"?E X%#2W^T'1>9#KS[Q^4'P>%,QG?C\H.0^R
M%][_S]2;/*^;/&]T\O1R^ND=E+? !]^L4?53WRQ,6(@)BS!A,28L08+US.%W
MYO!_\<+L8]H'$Q9BPB),6(P)2Y!@/?L$G7T"W(5Y%/=4MS2PX'2UG >/5W#,
MC-%Y1M?SW$<K/6;&! G6J^ZLJ^YLM+I_7V]&=XY1]5.+B0D+,6$1)BS&A"5(
ML)XYYITYYK]XYYACV@<3%F+"(DQ8C E+D& ]^RPZ^RQP=XY1W%/=LCC_66];
MCS8.S(31>4+;??0W(L9,F"#!FMJ:)P<^^L#P'>5W>25( 3N%MRYF:F"\.81K
M&I+MZS.@6R8E*^O+#&@*7 >H^SO&Y$-#'RMU)Z'K[U!+ P04    "  =@$U:
M:G6\MJD"   Q"0  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RM5EU/
MVS 4_2M6AB8F;>2C20JLC01MV9@T"5'8'J8]N,EM8^'8F>VT\.]G.R&T-%1%
MZDMB._><XWNN8WNPXN)!Y@ */1:4R:&3*U6>NZY,<RBP/.$E,/UESD6!E>Z*
MA2M+ 3BSH(*Z@>?%;H$)<Y*!';L1R8!7BA(&-P+)JBBP>+H$RE=#QW>>!V[)
M(E=FP$T&)5[ %-1]>2-TSVU9,E( DX0S)& ^="[\\TEDXFW +P(KN=9&)I,9
MYP^F<YT-'<],""BDRC!@_5K"""@U1'H:_QI.IY4TP/7V,_N5S5WG,L,21IS^
M)IG*A\ZI@S*8XXJJ6[[Z#DT^=H(II](^T:J.C<\<E%92\:(!ZQD4A-5O_-CX
ML ;PPS< 00,(]@7T&D!O7T#8 ,)] 5$#L*F[=>[6N#%6.!D(OD+"1&LVT[#N
M6[3VBS"S3J9*Z*]$XU1RS9; %!=/Z N:ZD685100GZ.7\>,Q*$RH_*0C[J=C
M='ST"1TAPM!=SBN)628'KM(S,7QNVJA>UJK!&ZH_*G:">MYG%'A!V $?[8:/
M(=5PW\)['?#Q_NI=\,G^ZL$FW-7NMR4(VA($EJ_W!E^W[7\N9E()_1_][;*W
M9@R[&<W><BY+G,+0T9N'!+$$)_GXP8^]KUUF'Y)L?$BRR8'(-LK2:\O2V\6>
M?.,\DV:=ZRKH;5%UE6$GPWO+4)-%ELQL[\NDKU?G<MW<0^I-MO7\L]-6<,.S
ML/4LW.G9%6%$[T496ACSNAS;B7^O8S59O)9!')^]LNR0@I-MP;#O=5L6M99%
M.RV[XPK3E_^^R[-HJU"A'VVF.=J.Z8?!*RNV8^+8VXR9=,6\7A3NVG%C+A,_
ML5@0)A&%N49Y)WT-%_4!77<4+^T)-.-*GV>VF>L[#0@3H+_/.5?/'7.HM;>D
MY#]02P,$%     @ '8!-6OGU'^/> @  4PH  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3@N>&ULK59M;YLP$/XK%JNF3MK*.VF[!*D-V9LT+6K6[<.T#PY<
M@E7 S#9)]^]G V$DD(A*^1+\<L]S=\]=;(^WE#WQ&$"@YS3)^$2+A<AO=9V'
M,:287]$<,KFSHBS%0D[96N<Y QR5H#31+</P]!233//'Y=J<^6-:B(1D,&>(
M%VF*V=][2.AVHIG:;N&!K&.A%G1_G.,U+$ \YG,F9WK#$I$4,DYHAABL)MJ=
M>3OSE'UI\(/ EK?&2&6RI/1)33Y'$\U0 4$"H5 ,6'XV,(4D440RC#\UI]:X
M5,#V>,?^H<Q=YK+$'*8T^4DB$4^T:PU%L,)%(A[H]A/4^;B*+Z0)+W_1MK8U
M-!067-"T!LL(4I)57_Q<Z] "F,X1@%4#K*$ NP;80P%.#7"& MP:4*:N5[F7
MP@588'_,Z!8Q92W9U*!4OT1+O4BF^F0AF-PE$B?\;R(&AN["D!:9X.@!0B ;
MO$P O4,+V911(8=TA8[;708@,$GX&XEX7 3H\N(-ND D0]]C6G"<17RL"QFI
M\J>'=53W5536D:B^%-D5LHVWR#(LIP<^/0T/()1PLX3;/?!@N/<^^&RX=VL?
MKLOJ-"6RFA)9)9]]A&]8&7[=+;E@\G_WNT_NRH/3[T&=1;<\QR%,-'G8<& ;
MT/S7KTS/>-\G_CG)@G.2S<Y$ME<FNRF3?8K=_T@WP#)YA J$"Q%31@2!WMX_
MR?/28E1D;DFF+H6-[\FFV[0E/J>_6=>?XS;^]H1S&N&<D\)5/<V:5N[5S.FX
MO1GMISFM3+R6B678!U)T:4:FNV\SZ_(X7G^&;I.A>S+#.8,<DPC!L[S>>7^"
M)QE>VA1N5XK109K!.1W.N@X=HU\SK]',&] 5>'?2_6^//O&\3EFMF^N#]NC:
MN*T8*TVZ-M>=]NC:F+9YD*O>NI#5<^LK9FN2<93 2J*,JY&$L^H)4TT$S<L[
M>DF%O/'+82Q??<"4@=Q?42IV$W7M-^](_Q]02P,$%     @ '8!-6E^:??]7
M#P  '_P  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULM=WO;Z-& L;Q
M?P6EIZJ53AN#C1UOLY%VPV^8=M5MKY6J>\'&)$%KFQ1PTI7ZQQ^VB?'89 R]
M;]ZT218^0^(\8\9^ I=/6?ZEN$^24OMK,5\6[\[NR_+A[?EY<7.?+.+B3?:0
M+*M_N<WR15Q6G^9WY\5#GL2SS4Z+^;DQ&(S/%W&Z/+NZW'SM8WYUF:W*>;I,
M/N9:L5HLXOSKAV2>/;T[T\^>O_!S>G=?KK]P?G7Y$-\EGY+RUX>/>?79^4Z9
MI8MD6:394LN3VW=G[_6W8CQ:[[#9XC]I\E3L?:RMOY7/6?9E_8D_>W<V6!]1
M,D]NRC415_][3*Z3^7PM5<?Q9XV>[<9<[[C_\;/N;+[YZIOY'!?)=3;_+9V5
M]^_.+LZT67(;K^;ES]F3E]3?D+GV;K)YL?FO]K3==F*>:3>KHLP6]<[5$2S2
MY?;_\5_U#V)O!\-X80>CWL'HNL.PWF'8=8=1O<.HZPYFO8/9=8=QO<.XZPZ3
M>H?)X0X7+^QP4>]P<;##4']AAVF]P_1PA.E+#]S@^9$;=/TN]-V#W?G1UI\?
M;KWSXZT_/^#ZYA$_W_XN;GZ1K;B,KR[S[$G+U]M7WOJ#31HV^U>_O^ER'=Q/
M95[]:UKM5U[YR\>D**LDEEJZU-X717:3QF52:-]921FG\^+[R_.R&F>]]?E-
M;09;TWC!U U-9,OROM#LY2R9R<!Y=8"[HS2>C_*#H11%G+_1=/W?FC$P1MJO
MGRSMNW^U'=BUFODQ>WRC&>:&&2H82\TXR>?J:"8G&;O#-S7<?E.&@G&Z_&P&
M)QFWR\]FNF$&"L8[=31?-=V4%:VXC_.D:,'\'MBWWUP,Q\8/VGG-O:P&:M5*
M;G8_]^'I8PR[:ZH??Z1F@M6R8@8G?\-%=^:%7TTI@,/=-#'<N,.^T\0?4;6E
MYI?)HOAOR^%^V+*C=G9]5O*V>(AODG=GU6E'D>2/R=G5M]_HX\$/;>DF,8O$
M;!)S2,PE,8_$?!(+2"PDL8C$!(1)<\!H-P>,5/K53T_+)"_NTP?M(<EOJJF@
M.K%OB[Q2Z1MY$K-(S"8QA\1<$O.VV'2#K5>!CU>#-Z/QY?GC?I3)$0,2"TDL
M(C$!85*4S5V43664/^X"K&6W6EH4JV2FQ<N95BWMB[+Z(%W>;<^(M)OX(2WC
M>5O0E6/T#3J)621FDYA#8BZ)>69+T(?F0=#)$0,2"TDL(C$!85+0Q[N@CY5!
M=^(TUQ9Q_B4IM<=XOFI]PE82?7-,8A:)V23FD)A+8MX6,_=R/#3UP6!PD&1R
MS(#$0A*+2$Q F)3DR2[)$V62?\GC91%O7^V^R8JR[:6*#TJB;Y))S"(QF\0<
M$G-)S)L<);DMR.20 8F%)!:1F( P*<@7NR!?*(.\]U+:;9XMMJ?9]]E\5BVN
MVS*MU/IFFL0L$K-)S"$Q]^+X"75P%$./'-(GL8#$0A*+2$Q F)3IZ2[34W6F
M%2OHXL3+94JY;[Y)S"(QF\0<$G.G+0O?@7X0;W)$G\0"$@M)+"(Q 6%2O/5!
M\R[YX/0Z>K. 7K]@UCR%MP5:3?5--*I9J&:CFH-J+JIYJ.:C6O!/-*TM_.AA
M1:@F*$W._UY+1C]QTIZ6:3S7TN;D/5YDJQ<F *75>P(@-0O5;%1S:FW_3'LR
M.#[5=M%1/53S42U M1#5(E03E";GVVCR;2#O;:N9WM$F-0O5;%1S4,U%-0_5
M?%0+:FW][+>_.AE-I_*<&*+#1J@F*$W.=E-=TY6MF*OWLUFZ?ME\\_1=K<WG
M\Q?/W-&V6JWM/YV-6Y[.+'14&]4<5'-1S4,U']4"5 M1+4(U06ERN)M.FJ[L
MR50GYKM$:P]Q.FN-]:@MB'(*K]LW:DDK60*R4<U!-1?5/%3S42U M1#5(E03
ME":GM:F=Z>K>F?WG*BV_:O.L*))B^_97>9_LK:I;XXOVS%#-0C4;U1Q4<U'-
M0S4?U8):VW\F,/3C9X*P93M],#W:+D*/3E":G."F3Z:K"V7]7@A#FV6H9J&:
MC6I.K8U/OA"&%L=0S4>U -5"5(M035":G.^F9::K:V8?LK*LGI6S6RV/EW>)
M]L<B67Q.\M:_[5)3O>.-]LU0S48U!]5<5/-0S4>U -5"5(M035":/ DT#35]
M6Y;!_]I31\MJJ&:AFHUJ#JJYJ.:AFH]J :J%J!:AFJ T>49H^FVZNN#6^?TQ
MM,U6:P?O?HSTJ7'XHAQ:54,U!]5<5/-0S4>U -5"5(M035":?&F5IMMFJ+MM
M7;.M9OIFN]9.9QL=UD8U!]5<5/-0S4>U -5"5(M035":G.VFMV:H>VN_9 _=
MUO)JIW>XT<X:JMFHYJ":BVH>JOFH%J!:B&H1J@E*DV> IMEF&*^SEC?0JANJ
M6:AFHYJ#:BZJ>:CFHUJ :B&J1:@F*$V>$9H^G*'NPW4^WT?;<+5V<+YO&I/A
MX?D^6H=#-0?57%3S4,U'M0#50E2+4$U0FISMI@YG* L\W;--MHJN:ZU#MLEA
M;51S4,U%-0_5?%0+4"U$M0C5!*7)V6[*<\:)\MQCDF?:'T*QB$>;<JAFH9J-
M:@ZJN:CFH9J/:@&JA:@6H9J@-#GZ3>O.&+_2(AYMX*&:A6HVJCFHYJ*:AVH^
MJ@6H%J):A&J"TN09H>GI&>J>WD_Y+%W&^=?=Q?"S^4S[KIH</FT^_U[[^^4K
MVG]0V[UG!;2XAVHVJCFHYJ*:5VO[G6%S:AJC\<%?BOI=-PS0XPM1+4(U06ER
MEINZG:&^(MQAEA_BYVO-K /]8_)4A3KYDLPW5Y+:;K3.]^$-,5J3CA;R4,U"
M-1O5'%1S4<U#-;_6=%UZ[>;P^E<!.FB(:A&J"4J3)X.F:6>HFW;,I=G5@_3.
M/7I9.52S4<U!-1?5/*/M0G7ZX17:T3$#5 M1+4(U06GR[96:$MY07<*S5O.O
M6O)7<K,JJ[QO\UVN+_E\6SWESY+J:[=9KF4'9PI=3_C5@_>=#E#-0C4;U1Q4
M<U'-0S4?U8):VU]C3,W)Y. /:-$Q(U03E"9/!TUO;ZCN[4G7K%']<;S:Z9UL
MM+>':C:J.:CFHIJ':CZJ!</C:_0=74LE1(>,4$U0FASLIHXW5%]H[GI[SJY]
MS-)EJ7PS3PWU3C;:OT,U&]4<5'-1S4,U']4"5 M1+4(U06GR%+!W*]77NI<J
M>S-5]FZJ[.U4V?NILC=49>^HRMY2E;VG*GM35?:NJNQM55^CM3=L6GM#97/H
M_WLS3VWWGA5(S4(U&]4<5'-1S:NU_?6S/AF/)H?W?NJX78 >78AJ$:H)2I.3
MW'3TANJ.WBN^E:<>N7?.T7(?JMFHYJ":BVH>JOFUMK[<<C,=',X$:&4/U2)4
M$Y0FSP1-96^HOE#>=9;DJWFR*M2+?+2?AVH6JMFHYJ":BVH>JOFH%J!:B&H1
MJ@E*D^/?]/.&DU=:Y*/=/%2S4,U&-0?57%3S4,U'M0#50E2+4$U0FCPC-"V_
MH;KEQQ1[U(/TGA[00A^JV:CFH)J+:EZM'11[],.U/GKE/%0+42U"-4%I<NR;
M/M]0W><3:9E=KT/]N_8AS;2HG*D7!&AQ#]4L5+-1S4$U%]4\5/-1+4"U$-4B
M5!.4)LT#HZ;@-QJ\SH)@A';W4,U"-1O5'%1S4<U#-1_5 E0+42U"-4%I\HS0
M=/Q&4,=/[?2> =".'ZK9J.:,CKMJF_NX'-U' QW60S4?U0)4"U$M0C5!:7*X
MFY[?B+FAK)KIG6VTY8=J-JHYH]8;HYJ#PS]<<]%A/53S42U M1#5(E03E"9G
MNRGPC7K<4%;YQ(T6]E#-0C4;U9S1\9US7WCB1KMXJ.:C6H!J(:I%J"8H30YW
MT\4;*1M"JM?KM+^U/K?'4@_4._VD9J&:C6H.JKFHYJ&:CVH!JH6H%J&:H#1Y
MBFA*?B/SE5[*0RM\J&:AFHUJ#JJYJ.:AFH]J :J%J!:AFJ T>49HRGXC==FO
M\VH?K?NAFE5K!ROJH3ZZD$^Z;718!]5<5/-0S4>U -5"5(M035":G.VFR3<Z
M<:6]KME&BWNH9M5:AVRCG3Q4<U'-0S4?U0)4"U$M0C5!:7*VFT[>2-W)4R_V
M.]\\2SU*[^BCI3Q4LU'-0347U3Q4\U$M0+40U2)4$Y0FSP]->6\T?:65/EKC
M0S4+U6Q4<U#-134/U7Q4"U M1+4(U02E23."V=3X3.9FN6JF[P2 :I;9\=:[
M-CJL@VHNJGFHYJ-:@&HAJD6H)BA-SG93R#/5A;S.V4;[>*AFU5J';*-5.U1S
M4<U#-1_5 E0+42U"-4%I<K:;/IZI[N,]K_1_5_[UC1KIG6RTC8=J-JHYJ.:B
MFH=J/JH%J!:B6H1J@M+D^#>5/?.5KKEGHA4^5+-0S48U!]5<5/-0S4>U -5"
M5(M035":/",T/3]361*J9H2T3*4&KQ8OLE5[D5=M]9X%2,U"-;O6]JNWDY;F
MK8..ZJ*:AVH^J@6H%J):A&J"TN1\-R4]4WTEOLXE?;73.]OF47[&+?FQ6K8;
MM6QGHT?GH)J+:AZJ^:@6H%J(:A&J"4J34]L4Z<P31;K#:^&T7@I3C?2.+%JC
M0S4;U1Q4<U'-0S4?U0)4"\V.1<L('590FISLID9GJFMT]I^KM/RJS;.BJ);=
MMWFVT,K[Y-1S,]JI0S4+U6Q4<U#-134/U7Q4"\SC>^,:^O%965AO)_^!XO1H
MNP@].D%I<H*;LIRI+LOU6S&CE3A4LU#-KK73*V:T[(9J'JKYJ!:@6HAJ$:H)
M2I/SW93=3/65ZKJOF-%R6ZV=7C$?;]>^8D8+::CFHIJ':CZJ!:@6HEJ$:H+2
MI-2.FT+:F"FDJ9F^H44U"]5L5'-0S44U#]5\5 M0+1RW5A9;ULSHL(+2Y&PW
MA;2QNI#VC];,:K-WT-%V&JK9J.:@FHMJ'JKYJ!:@6HAJT;CE"H 7ICQEB):-
MILVT(D>WZ9N-^]SG];<XS^,3]WM5@[USBW;/4,U&-0?57%3S4,U'M0#50E2+
M4$U0FCP5--VS\2MUS\9H]PS5+%2S4<U!-1?5/%3S42U M1#5(E03E";/"$WW
M;*SLOEQ]7.4W]W&QN1%,)M\QLG4>('LYUZAFH9J-:@ZJN:CFH9J/:D&M[9\0
M#T<M[X*AHT:H)BAMF_#SXCY)2BLNXZO+19+?)=?)?%YH-^MWO]9/_'M?U?+D
MMIH!]+?OC;/SHZ][^EM?;_EZH+\--U\_;_BKRX?X+A%Q?I<N"VV>W%9##=Y,
MJH<E3^_N=Y^4V<.[LVH)\WES:<K-A_=)/$OR]0;5O]]F6?G\R7J IRS_LOEV
MKOX'4$L#!!0    ( !V 35H_YS0O"P,  !<)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;*U6VV[;, S]%<$KA@U8ZTNN[1(#N:Q8'PH4[6[ L ?%
MIF-ALI1)<M+^_2@Y]=S4,5I@+[8DDT?G4!3IR4ZJWSH',.2^X$)/O=R8S87O
MZR2'@NHSN0&!7S*I"FIPJM:^WBB@J7,JN!\%P= O*!->/'%K-RJ>R-)P)N!&
M$5T6!54/<^!R-_5"[W'AEJUS8Q?\>+*A:[@#\W5SHW#FUR@I*T!H)@51D$V]
M67BQ&%M[9_"-P4XWQL0J64GYVTZNTJD76$+ (3$6@>)K"PO@W (AC3][3*_>
MTCHVQX_HETX[:EE1#0O)O[/4Y%-O[)$4,EIR<RMWGV&O9V#Q$LFU>Y+=WC;P
M2%)J(XN],S(HF*C>]'X?AX9#.#SB$.T=HD.'_A&'WMZAYX16S)RL)34TGBBY
M(\I:(YH=N-@X;U3#A#W%.Z/P*T,_$U^)+6B#QV(($V2FM4P8-:#)*;G#C$E+
M#D1FY)(R1;Y17KJ9R8$T'-\MP5#&]7MT^GJW).].WI,3"_<EEZ6F(M43WR!7
MNZ.?['G-*U[1$5YA1*ZE,+DFGT0*Z5, 'T762J-'I?.H$W$)R1GIA1](%$2]
M%D*+E[M''71Z=>![#J]W!._%T?TY6VFC,-U_M46QVJ3?OHDM 1=Z0Q.8>GC'
M-:@M>/';-^$P^-@6@?\$]B0>_3H>_2[T>$XY%0D0:L@*UDP()M9M@BN4@4.Q
M)6H;#\[#B;]MZNC<J5T'Z9 PJ"4,.B4T#BW%.T2NJ4KR(SE3B>G$>^WI56##
M1F1&05!'YHFB8:UHV*GHTY^2F0?"I=98$C(E"[S6S8)QS8Q<4 4_VM0-GQ$Z
MC<+@X*Q:C,+@O)WVJ*8]>FDN@4B/)-+H>;C&AXDTZDRV)]S&-;?Q2Y,DDQR;
M*-+#9I8SV();Q0J0,:4-5GN.EE) &_OQ,V;]X#"TG41>>YW]1H\I0*U=Z]4D
MD:4P51&N5^ON/G--[6!]CEV_:M+_8*I?!KPO>/$UX9 A9' V0GFJ:L/5Q,B-
MZV0K:; ONF&.?RZ@K %^SZ0TCQ.[0?TO%/\%4$L#!!0    ( !V 35JF[U+;
MB!   )(: 0 9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;+7=:V^C5A['
M\;>"LM5J*E43@Z^9SD3*#/<[I-U]4.T#:C.)5=ND0#*MU!>_V"'!8.?$C+Z9
M!ZWC<#X'F_#S\8$_?/R6Y7\4MVE:2G^M5YOBT]EM6=Y].#\OYK?I.BG>9W?I
MIOK-URQ?)V7U8WYS7MSE:;+8-5JOSI7!8'*^3I:;L\N/N^?"_/)C=E^NEILT
MS*7B?KU.\K\_IZOLVZ<S^>SIB7AY<UMNGSB__'B7W*37:?GK79A7/YT_*XOE
M.MT4RVPCY>G73V=7\H=XK&P;[);XSS+]5NP]EK8OY?<L^V/[@[7X=#;8KE&Z
M2N?EEDBJ_SVD7]+5:BM5Z_%GC9X]][EMN/_X2==W+[YZ,;\G1?HE6_UWN2AO
M/YW-SJ1%^C6Y7Y5Q]LU,ZQ<TWGKS;%7L_BM]JY<=G$GS^Z+,UG7C:@W6R\WC
M_Y._ZC=BKX&BO-! J1LHIS88U@V&G0;RZ(4&H[K!Z-0>QG6#<:?!</A"@TG=
M8-+MX>*%!M.ZP?34!K.ZP>S4!A=U@XM.@]&+&V[PM.4&I_8A/V_LD[>V_+2Y
MY8/M/7ZIR=,&E[M;_.5>GC:Y?+#-7^SE::/+)V]U^6FSRP?;_<5>GC:\W-WR
M+_[URD^;7MYM^_/'77&W'ZM)F5Q^S+-O4KY=OO*V#W9AL&M?[;[+S3:WKLN\
M^NVR:E=>6IN'M"BK("JEY4;2EYMD,U\F*^FJ*-*RD-ZI:9DL5\6/TK__-1M.
ME)^E<ZFX3?*TV"[^ZV99%C])/QQ[\FGYZIE?;K/[(MDL=HON__SQO*Q>PG9%
MSN?UZIJ/JZN\L+H3R<LVY6TA:9M%NCC2WA:WEQ4!<%Z]=\]OH/+T!GY6A.)U
M>O=>&HQ_DI2!,I)^O5:E=S_\>&3%OH@9^WY3,1>O,NHK3%(Q0_F1.=)<.V$M
ME,<7,Q2LA?X=S,%?T!'7$+M^]O!>DJ<[5WEV7]3,$]9R.&B_Y2]KUNG:\'7-
M%FMJ.G_>CHVVMZ.]"#NGPR>\A>[IFBSX>_'Z;(D3_D[\$_8">?+JSA2(F:O[
MFXJ9U1OA!]$*A7UV",N]EM[5K_*DW2(Z(8+D<;U-A>L9BR4OR2OI,84&@G <
M/G^Z#'?>\/L^77YSJ^4EJTS7Q?^.K.SG1WQT'-^.Z#\4=\D\_716#=F+-'](
MSR[__2]Y,OCY6/Z2F$IB&HGI)&:0F$EB%HG9).:0F$MB'HGY)!:06$AB$8G%
M$-:*XM%S%(]$^GX4)^OL?E,>"UPAT3=P24PE,8W$=!(S'K'Q#MM..3U<RN-!
M]4G\L!^D9(\6B=DDYI"82V(>B?DD%I!82&(1B<40U@K2\7.0CH5!&J?S=/F0
M+IZ^B;VK1K;7NX<_2O^\//+^+%3[9BN)J22FD9A.8L8C-MG+5F4XF$XN.NE*
M]FF1F$UB#HFY).:1F$]B 8F%)!:16 QAK72=/*?K1)BNNR25YLG=LDQ6TEV:
MSZL1:W*3'DM4H=0W44E,?<0N]J)F\'XLMX-&(WO42<QXQ+:'@/;6?W Q5"[V
M_W5RDUP#B\1L$G-(S"4QC\1\$@M(+"2QB,1B"&OEYO0Y-Z?"W/R2K=?9IN^8
M5&CV35 24TE,(S&=Q P2,Z<' ]SA>#:1!Z-V4EN'RRDS93I3VHO9AXM-!Y/)
M;-A>S#FB3>311:=3EWRE'HGY)!:06$AB$8G%$-:*NMESU,U.&"+>Y<MY6H7;
MNVJ,^)APQX[P?192?1..Q%02TTA,?\3D86OX-YQU]FB#[-,D,8O$[$=LMI]O
M[V>=L;Q#]NB2F$=B/HD%)!:26$1B,82UHO+B.2HO7AL55NKM]C33AU1:9<71
M4:#0Z)N1)*:2F'9QY-C*K+T?ZV2'!HF9)&:1F'WXODZ5:2<?CRPS[62H2ZZ4
M1V(^B04D%I)81&(QA+5B3QX\Y]YV<DH4?$EQ>RSJQ,WZ9AVJJ:BFU=K^+C>9
M=>;L]'HA61$M9: K9AY9L=%XU#G&;:%]VK4V$?;IH'VZJ.:AFH]J :J%J!:A
M6DQI[53;.U=?%J9:F.320[*Z3W^2GK_U[N;Z_/2;='V;_I&NBN8W/[[^[5C<
M7^\X)#45U314TU'-0#43U2Q4LU'-0347U;Q:ZTRB*')G]M1'>PV^1Y..AG"]
M^G+[$."XO?81U5],O0WM8%6:8%7$P;J;3 RKK+Q^/5-/.&'_L[B_WL%*:BJJ
M::BFUYH\:A\Z[PY(R3Y-5+-0S48U!]5<5/-0S4>U -5"5(M0+::T=@XWY4*R
M\!3X$^<KQ4CO<$4+@U!-0S4=U0Q4,VNM??"Z.XUHU4OMSQTH%Y/.4O81:SR=
M=H];'UEJILPZEGNDQ_%TTIDV]M#WPD>U -5"5(M0+::T=G@U!3;;48D@O*Q-
MF59N*>5)F;YRZJ*8ZAUAI*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B
M6H1J<:VUSX"6FS/,VA';E-[(XMJ;NH)\<R.H8103O:,5K;1!-0W5=%0S4,V4
M#VMWALJP.S@<'Q[@WUT%I3TX/%Q*4>2+[N#P<*GI;*AT!X??\2*/37]YZ+OE
MHUJ :B&J1:@64UH[W)K*%UE<^G*U6"RWUW)+5M4WWV1S--O0DI=::^\PW6IC
M%>U30S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K68TMK)VM3&R.+BF#B]
M2_Y^Y=(78J)WM!Y618R4\4&THE4NJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J
M(:I%J!936CM:FUH<65R,<S6?Y_?I0EK6DY]'HQ4MPD$U%=4T5--1S4 UL]9:
M7Z-'HUGW*SE:B8-J#JJYJ.:AFH]J :J%J!:A6DQI[6AM:G=D<?&.OMPLTESZ
MFKYZ, DMX$$U%=4T5--1S4 UL]8ZU^ 834<7W8A%:WE0S4$U%]4\5/-1+4"U
M$-4B5(LIK7WI]J9,2!&7"07W95$FF\5R<_/3*R$KEOJ&+*JIJ*:AFHYJ!JJ9
MM=8)V;'2O523A79KHYJ#:BZJ>:CFHUJ :B&J1:@64UH[9)NJ)45<M?1+=B=E
M7Z4\V=RDTF_K=/U[FA^]W+O8Z1VQ:#42JFFHIJ.:@6HFJEFH9J.:@VHNJGFH
MYJ-:@&HAJD6H%E-:.X>5)H<?3]Y_HYMQ*&A)$ZJIJ*:AFHYJ!JJ9J&:AFHUJ
M#JJYJ.:AFH]J :J%J!:A6DQI[71N2I^45TN?ON,"GF*T=RBCI5"HIJ&:CFJ&
M<EA*=/32\FBO%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%E-:.VZ98JWHHBMO/65EF
MZQ/G)814[Y E-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+*:T=
MQ4U1ES)^TWD)M-X+U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M
MIK1V.C=5:8JX*NT[YR700C544U%-0S4=U8Q::]W"8W*A=&<ET$(U5+-1S4$U
M%]4\5/-1+4"U$-4B5(LIK1VV3:&:(BY4N[HO,R_Y2_*R,LL+R2T7TF^>8&("
MK5E#-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+*:V=QDUMFS)[
MTXD)M.P-U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU MIK1V.C?E
M<8JX/*[_S1!.N7"WN-/>H8W6TJ&:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H
M%M::^"+V$=IG3&FM,!XVA71#<2'=YWRYN$DE-TLVA7#*0NSTS5=44U%-0S4=
MU0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K68TMHYW-3:#>6WG+(8HA5XJ*:B
MFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:6UTUEITEE\F['M\%C*
MTWFZ?$@71_,7K;%#-175-%334<U -1/5+%2S4<U!-1?5/%3S:ZUUY>Q1]\K9
M =IGB&H1JL64UL[5IG9N**Z=ZW/G'3'5.V+1BCE4TU!-1S4#U<Q::]]M9# =
MM/YUK^F#KH*-:@ZJN:CFH9J/:@&JA:@6H5I,:>W$;<KGJH>OCF1?OIBZN'7O
MD!T=?-HJ!Y^V*MJGAFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQI;53
MM:F$&XIO;_9T^N_5_,_[9;&[&9#X8!I:^H9J*JIIJ*:CFH%J)JI9J&:CFH-J
M+JIYJ.:C6H!J(:I%J!936CN.F]*WX>1-#Z:A-7"HIJ*:AFHZJAFH9J*:A6HV
MJCFHYJ*:AVH^J@6H%J):A&HQI;73N:F5&XIKY7I-^J*%<JBFHIJ&:CJJ&:AF
MUEIGTK=[>PRT3QO5'%1S4<U#-1_5 E0+42U"M9C2VA';%, -7[FY6ST?(9R#
M0*O<4$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DIK1W!3Y3:\
M>-,Y"+2<#=545--034<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+::T5CJ/
MFK*WD;CLK<[CS8W@7 @QT3>"44U%-0W5=%0S4,VLM?TS4D;*N'-&BH7V::.:
M@VHNJGFHYJ-:@&HAJD6H%E-:.UJ;2K:1^*YQ5I$GZ4HX]2 6>B<K6JV&:AJJ
MZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ9363F"E2> WO5_<"*UE0S45
MU314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BRFMG<Y-S=OHE?O%)<5M
M<TVSHP&,5KJAFHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6EAKLK(WTZ6,
MN[57$=II3&GM9&UJVZJ'HF2]GJ>;)%]FDI[EZ3PI2O$5S<1:[Y@E-175-%33
M4<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+*:V=QDU-W.A-[PXW0DOD4$U%
M-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DIKIW-3(C<2WQWN:K'8
ME2E7@;S*DLW1!)X<'"N79]UCY5_$_?1.5K2\#=5T5#-0S40U"]5L5'-0S44U
M#]5\5 M0+42U"-5B2FLG:U/>-A*7MPEF(:1_I).OMR[NI??X%ZU\0S4-U714
M,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)*:Z=T4R$W>M-;Q(W0XCE44U%-
M0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K68TMKIW!3/C<2WB'OE*I5U
M:_%9_%_$??1.5;3H#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B2FNE
MZK@I>AN+B][VQKRBF0>QTG=LBVHJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:
M@&HAJD6H%E-:.X6;^KCQF][I;8S6SJ&:BFH:JNFH9J":B6H6JMFHYJ":BVH>
MJOFH%J!:B&H1JL64UDYGI4EG\9W>OF3KRKU--\7R(95667'T9O-BI'<(HR5R
MJ*:AFHYJ!JJ9X\-;@RFC2>?*$&B7-JHYJ.:BFH=J/JH%J!:B6H1J,:4]9NMY
M<9NFI9J4R>7'=9K?I%_2U:J0YMM9VVTG>\]*>?JURE[YPY5R=G[PO"9_T.4C
MSYOR!^O8\[;\P=T]?]YT>_GQ+KE)O22_66X*:95^K59A\'Y:[<WY\N;V^8<R
MN_MT5GW"_)Z59;;>/;Q-DT6:;Q>H?O\UR\JG'[8=?,OR/W8O\_+_4$L#!!0
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M+MRBHWAF[ZP%5_H&M,U$OU% F  ]O^)<[3OF&JQ>/=$?4$L#!!0    ( !V
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MR&#C=H.;MVX,)Y3=5Q>I<_':(N6'"[7-M\UE[7?5%>7.]Y?NV=7ARK6$.=P
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MN?RRI"S#0D[92N<% QQ7H(SHEF%X>H;37 O\:FW& I^6@J0YS!CB999AMGT
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MV'RTCQ+5]PYW=77[CMDJS3DBL)0HX^96PEE]':HG@A;5>;^@0MX>JF$B;Y#
ME('\OJ14[";J"M'>28/_4$L#!!0    ( !V 35H$/]M&50,  !8+   9
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MI3'*+W,:7%&["_1^K91]VKA9JAN%DZ]02P,$%     @ '8!-6J[->X%,"0
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MV@!S?R6$?AK8!;H6./T/4$L#!!0    ( !V 35KV2,R>E0(  .0&   9
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M@C0!^'XIA-YN3()N0$=_ %!+ P04    "  =@$U:8+1_-;P%   Z&0  &0
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M5/-0S4>U -5"5(M0+4:U!-525,M0+4>U@M+Z<=65$LC'M!+<E*O[$Y,*[29
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M+4.U'-4*2NOGE]+EET(<&531;@E4TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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MEJ%:CFH%I?43K*N-&$Z0=Y?06@A4TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M8//SS\ME\_S%=H*OR_H_CZM]_7]02P,$%     @ '8!-6MQMY(:! @  T@<
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MI$,&THMFP&C5HH%SQB>+GHZ(IHD3A-[)'1Z;>5%RYF5SG5]?;N>B>NYSR3;
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M)B3,@H39D+ %),R!A+F0, \2YJLGO8ZBUCU.PSU:[1ZMUSW6=\J",*-HR\*
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ME@O]2S9MK&60N!:2%2T8%119V3SI4YN''8#M'P X+<#I [P# +<%N*\%>"W
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M:9U?H"#>W'+-0+)*]_T%DWB+Z-<4/PR JP!<7S(FMP.U0?>I$?X%4$L#!!0
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MW*@S%' -4.]7C,GCC1Z@.97-_@-02P,$%     @ '8!-6KU8[-F6 P  30X
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M%9 ,F%H@YQ>4BOU ;=#^8V'Z'U!+ P04    "  =@$U:HE69D_0,  !OAP
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MLZQ\_E+MX"G+_ZZK9O)_4$L#!!0    ( !V 35K+:C,B5@0  + 8   9
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M(%<%Y/TEI>+EI*J@W0A;_ -02P,$%     @ '8!-6N&O1[Z9 P  HA   !D
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MI)\,[Z=5<]"NR>ZVF^;-7%KI<]/TM-AV=5_N'>F\T7?9N[S1\!VJ>:CFHUJ
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M4 ^K.Z%G;JV2D!R8))PA >G8F?@7LZ'!6\ C@8ULC)&)9,'YDYG<)&/',X:
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M;[V);?;N&[R\,F^QT"=7(@JIIGJG0[VS**^A<J+XRG;R!5?Z7K##3-_<( Q
MOT\Y5]N)V:#^+Q#] U!+ P04    "  =@$U:250?$5<#  "I#0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Y-"YX;6RM5UV/TSH0_2M60 @DV'PV798VTK9I
M!5<@K=@+/" >W&3:6"1VL9TM_/MK.]G0;=W<+/2EM9TY9\9G[+$]V3'^710
M$OVL2BJF3B'E]LIU159 A<4%VP)57]:,5UBJ+M^X8LL!YP94E6[@>;%;84*=
M9&+&;G@R8;4L"84;CD1=59C_FD')=E/'=^X'/I)-(?6 FTRV> .W(#]M;[CJ
MN1U+3BJ@@C"*.*RGSK5_M1QK>V/PF<!.[+61GLF*L>^Z\RZ?.IX."$K(I&;
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MU;78- OUE@*N#=3W-6/ROJ,==*^SY#]02P,$%     @ '8!-6A2<41B9 P
M%Q$  !D   !X;"]W;W)K<VAE971S+W-H965T.34N>&ULS5A;;]LV%/XKA%8,
M+;!&-\MV,MM 8VMHNUZ"N-T>@CW0TK$EE"(UDHK;?U^24A3+952G%;"]V"+%
M[^,YW^'E',WVC'\2&8!$GPM"Q=S)I"PO7%<D&118G+$2J'JS9;S 4C7YSA4E
M!YP:4$'<P//&;H%SZBQFIN^*+V:LDB2G<,61J(H"\R^70-A^[OC.7<=UOLND
M[G 7LQ+O8 WR8WG%5<MM6=*\ "IR1A&'[=QYX5_$?J@!9L1?.>S%P3/2KFP8
M^Z0;K]*YXVF+@$ B-056?[>P!$(TD[+CWX;4:>?4P,/G._8_C//*F0T6L&3D
M[SR5V=R9.BB%+:Z(O&;[E] X%&F^A!%A?M&^&>LY**F$9$4#5A84.:W_\>=&
MB . /WH $#2 X!@0/@ (&T!XZ@RC!C Z%1 U ..Z6_MNA%MAB1<SSO:(Z]&*
M33\8]0U:Z953O5#6DJNWN<+)Q0>.J< F: )AFJ)+3#!-0"@[9(:N@6 )*;K"
M7.:J\SE:JZ6:5@00VWYG[-,52)P3\4RA/JY7Z.F39^@)RBGZD+%*J+G$S)7*
M!6V(FS3F7M;F!@^8^[JB9RCT?D.!%XPL\%4_? 6)@OL&'EK@\>GPH MWE>ZM
M^$$K?F#X1@_PO9<9<+7=:MW*1K>;MU!L@/]C4Z>73Q\J%Z+$"<P==6H(X+?@
M+'[]Q1][O]NT&I(L'HBLHV/8ZA@:]O"_7,0W;]2LZ)6$0EA#$PX9FB')XH'(
M.J$9M:$9]2[Q9<4Y4(FP$""M&[[&1P:OK[7;A1_-W-M#-2Q# K\[)NXUP^XD
MZO$O:OV+>OU[Q^CSY+L^UASC P>"*!IU/5CV3W3CVU;=ZEMFWYL>2=-+_'AI
MQJTTXY-"3W*\R4FNMY--FUZ2DZRKE1B()QY_HVATOQX[0DQ:(2:]0OP)7]25
M357>56@]2N""40JD]Z3OI7SL<3(D63P064?*:2OE]/]_TD^'#,V09/% 9)W0
MG+>A.?_)D[X7_UC=?H#,NMU_GJ>CEN_=)][> #='/\EC1?L1-JMJ Q!U93NH
M5_PA;I6&I9,SC"='>85ET/E1[A%;QDP\^WW@Z[R_VW.?P?J]69B^WM< B#()
M*#JS*>4>%'D%\)VIK@5*6$5EG2JWO74%?^E?+$VA>]3_P@]4:1]8WX1W1;][
M/T7]R> MYKM<';H$MFHZ[VRB%.%U%5XW)"M-F;EA4A6MYC$#G +7 ]3[+5.^
M-0T]0?LM9/$54$L#!!0    ( !V 35K7\&N>9@,  '4*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#DV+GAM;,56WV_;-A#^5PBU*UI@BV19ME/7%A#_&)IB
M&8*XW1Z"/-#2V2)*D2I)V<E_OZ,D:[;#:'T(L!>+/-[W\;XC?;S)7JKO.@,P
MY#'G0D^]S)AB[/LZR2"G^D(6('!E(U5.#4[5UM>% II6H)S[81 ,_9PRX<63
MRG:KXHDL#6<";A7199Y3]30#+O=3K^<=#'=LFQEK\.-)0;>P O.MN%4X\UN6
ME.4@-)."*-A,O:O>>#FR_I7#7PSV^FA,K)*UE-_MY#J=>H$-"#@DQC)0_.Q@
M#IQ;(@SC1\/IM5M:X/'XP/Y[I1VUK*F&N>1_L]1D4^_2(REL:,G-G=Q_AD;/
MP/(EDNOJE^P;W\ C2:F-S!LP1I S47_I8Y.'(P#RN %A PC/ =$+@'X#Z)\#
MAB\ H@80G0/Z+P &#:"2[M?:J\0MJ*'Q1,D]4=8;V>R@RGZ%QGPQ8>_)RBA<
M98@S\5=%A:;5H6E"14IFE%.1@,8X3$;N@%,#*;FERC T_D96>%/3D@.1&W("
M=OJ_7X"AC.L/B'SNK1KOHO&^OX%\#>H!G;^M%N3]VP_D+6&"?,UDJ3$X/?$-
M:K:1^TFC;U;K"U_0-R0W4IA,DZ5((77@%]WX7MA!X&.RVXR'AXS/PD[&+Z6X
M(/W@5Q(&8>0(:/[S\+Y+3S=\ 0G">R[XB9I^>W_Z%5___[X_]W_@SN3:0*X?
M7->@#C-RAVFK[5@7-(&IA^54@]J!%[][TQL&GUQ'\)IDBU<B.SF>J#V>J(L]
MOD-&JI*L.IH4=O@N%%CE#8%'?&DT./]1->6@HK3OS"X.AQ-_=YR@SEW=FH@K
M-\^WBH)VJQ/%@U;QH%/QBM9W"VNE5,P\8?TP@$$86TATN=8L9?@@NG1W$O^\
MJ/DK\2P&S\_AX^7@]"26W=FX[SUTW**A=V88M4D>_1?M(<^T*)1\9/AD W\B
MT<=?K-%DN%8:;?#:,;$E.J,HU:ZL$H;B54+^+(W"))2&)91K<BVP+AE)OL!F
MH]^]N0Q[HT]DIFS1)Y\EMRRUDTN.?_3^Y:"V5>.A22)+86J5K;7M;:ZJ)_W,
M/NN-YSV'?8&]D-,>CI<NGJOA>#ETV4=-3^7_&V;=D-U0M658!3EL,.3@8H3G
MJNHFIYX8652O^%H:[ FJ889](2CK@.L;*<UA8C=H.\WX'U!+ P04    "  =
M@$U:G,+:GT<#  !B"P  &0   'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6RM
M5EUOVC 4_2M65DV=M#;?*640J1#0/E0)E79[F/9@D@N)FMC,-M#^^]E)R" )
M$=/Z0F+GG'.OS[TR=["C[)G'  *]9"GA0RT68MW7=1[&D&%^3== Y)<E91D6
M<LE6.E\SP%%.RE+=,@Q/SW!"-'^0[\V8/Z ;D28$9@SQ399A]CJ"E.Z&FJGM
M-QZ252S4ANX/UG@%<Q!/ZQF3*[U2B9(,"$\H00R60^W.[$\]A<\!WQ/8\8-W
MI$ZRH/19+;Y$0\U0"4$*H5 *6#ZV,(8T54(RC=^EIE:%5,3#][WZ-#^[/,L"
M<QC3]$<2B7BH]304P1)O4O% =Y^A/(^K]$*:\OP7[4JLH:%PPP7-2K+,($M(
M\<0OI0\'!*G33K!*@E4G."<(=DFPZP3O!,$I"<ZY$=R2X)Y+\$I"7DR],"MW
M.L "^P-&=X@IM%13+WFY<K8T."&JL>:"R:^)Y G_D6'"<5YECC")T BGF(3
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MYDHW7!L6^M(%80!Z?<.Y>AJ8KMM=X^D_4$L#!!0    ( !V 35IA\?69,P,
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M5DD01)$= <RN( @P!%8CCF *0 .&!$'Y'-QZ'GFKYY37_)TQ_ M02P,$%
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MK8KBPA[[5EY7,M_])XK=?]'X^!]02P,$%     @ '8!-6O$(LOGR @  &ST
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M^>QP_?[/Y=?%]B[^A+J_S1@?_P)02P,$%     @ '8!-6F51Z6]F @  ZSH
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M-3]9_N-Z\Q-02P$"% ,4    "  =@$U:!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !V 35H$Z-FL
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( !V 35J97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ '8!-6OA]I<QA!   F1(
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M965T-2YX;6Q02P$"% ,4    "  =@$U:-7#(Z] ,   \*P  &
M    @(&[-P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M'8!-6LI S'#]*0  78T  !@              ("!P40  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !V 35JZUN\B# H   @9   8
M          " @?1N  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    "  =@$U:+W_8F$<"   6!0  &               @($V>0  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ '8!-6N+?WHY" @  \P0
M !D              ("!LWL  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    "  =@$U:14VA.&L"  !2!0  &0              @($L?@
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !V 35JC;,-7
MB@L  ) F   9              " @<Z   !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ '8!-6F,BZ]<=#   5B4  !D
M ("!CXP  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  =
M@$U:LX4K>V4#   $"   &0              @('CF   >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !V 35IA"XT/80,  /P'   9
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M970Q.2YX;6Q02P$"% ,4    "  =@$U:NN#QKW<$  "3"@  &0
M    @(%<NP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M !V 35HS7NRI#P,  (,&   9              " @0K   !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ '8!-6I'L!UG-#@  Z"4  !D
M             ("!4,,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    "  =@$U:BL['5"(2  !K1   &0              @(%4T@  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !V 35K.XNN+#PD
M *,:   9              " @:WD  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ '8!-6N'F*ICW!0  ;PT  !D              ("!
M\^T  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  =@$U:
ML\BEH4<&  !Y#P  &0              @($A]   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( !V 35H+V34@SP,  #0(   9
M      " @9_Z  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ '8!-6D"WFEEH!0  )!,  !D              ("!I?X  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  =@$U:0SO.X:D'  !:%P
M&0              @(%$! $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( !V 35K2K .U$@4  ,$+   9              " @20, 0!X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ '8!-6GA=0%WQ
M"P  GQX  !D              ("!;1$! 'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    "  =@$U:*<?(+XX%   8#   &0
M@(&5'0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !V
M35J70KN5PRH  !N8   9              " @5HC 0!X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ '8!-6OC[K7JZ @  _ 4  !D
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M=#,X+GAM;%!+ 0(4 Q0    ( !V 35K) ;Y[%P,  (H'   9
M  " @?Q; 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M'8!-6K?I7[SF @  AP@  !D              ("!2E\! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    "  =@$U:I'\YP40"   #!0  &0
M            @(%G8@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( !V 35HQ4-Z56 (  $ %   9              " @>)D 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ '8!-6CO6&8BF!@
MOA,  !D              ("!<6<! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    "  =@$U:]BA>_7<"  "=!0  &0              @(%.
M;@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !V 35J?
MT%6S9@4  .H/   9              " @?QP 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ '8!-6M?#^/EM!0  Q0X  !D
M     ("!F78! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !V 35K8NNC@=@0  +0-   9              "
M@=6- 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ '8!-
M6KQ+>-1% P  [P8  !D              ("!@I(! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    "  =@$U:C\B].(4#  #*#0  &0
M        @('^E0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( !V 35I^D'*'$P(  +@$   9              " @;J9 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ '8!-6G")_:1P!   (1P
M !D              ("!!)P! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    "  =@$U:FMYN-UL#   5%0  &0              @(&KH $
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( !V 35IJ=;RV
MJ0(  #$)   9              " @3VD 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ '8!-6OGU'^/> @  4PH  !D
M ("!':<! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  =
M@$U:7YI]_U</   ?_   &0              @($RJ@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !V 35H_YS0O"P,  !<)   9
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M970V-"YX;6Q02P$"% ,4    "  =@$U:X7A9;.H%  !%+P  &0
M    @($<V@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (
M !V 35J<VS>ID@,  &4/   9              " @3W@ 0!X;"]W;W)K<VAE
M971S+W-H965T-C8N>&UL4$L! A0#%     @ '8!-6F#6ZA>I @  /PD  !D
M             ("!!N0! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"
M% ,4    "  =@$U:8,OZ.-D"  "?"@  &0              @('FY@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( !V 35H$/]M&50,
M !8+   9              " @?;I 0!X;"]W;W)K<VAE971S+W-H965T-CDN
M>&UL4$L! A0#%     @ '8!-6J[->X%,"0  UEL  !D              ("!
M@NT! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    "  =@$U:
M+"ODUVT#   ."P  &0              @($%]P$ >&PO=V]R:W-H965T<R]S
M:&5E=#<Q+GAM;%!+ 0(4 Q0    ( !V 35KV2,R>E0(  .0&   9
M      " @:GZ 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%
M  @ '8!-6DK1Y#:> @  K <  !D              ("!=?T! 'AL+W=O<FMS
M:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    "  =@$U:8+1_-;P%   Z&0
M&0              @(%*  ( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+
M 0(4 Q0    ( !V 35IW?Q._%A@  %.[ 0 9              " @3T& @!X
M;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ '8!-6MQMY(:!
M @  T@<  !D              ("!BAX" 'AL+W=O<FMS:&5E=',O<VAE970W
M-BYX;6Q02P$"% ,4    "  =@$U:X9>AJG,#  #@"P  &0
M@(%"(0( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( !V
M35KZQ44QFP,  )\+   9              " @>PD @!X;"]W;W)K<VAE971S
M+W-H965T-S@N>&UL4$L! A0#%     @ '8!-6F$ $@L1!@  2#0  !D
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M=#@S+GAM;%!+ 0(4 Q0    ( !V 35JB59F3] P  &^'   9
M  " @8<^ @!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @
M'8!-6LMJ,R)6!   L!@  !D              ("!LDL" 'AL+W=O<FMS:&5E
M=',O<VAE970X-2YX;6Q02P$"% ,4    "  =@$U:6L%S-7@&   Q*   &0
M            @($_4 ( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4
M Q0    ( !V 35K>4,3 800  !0;   9              " @>Y6 @!X;"]W
M;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ '8!-6N&O1[Z9 P
MHA   !D              ("!AEL" 'AL+W=O<FMS:&5E=',O<VAE970X."YX
M;6Q02P$"% ,4    "  =@$U:RD^5^L8"   W"   &0              @(%6
M7P( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( !V 35IP
MNFDJ6 ,  '8+   9              " @5-B @!X;"]W;W)K<VAE971S+W-H
M965T.3 N>&UL4$L! A0#%     @ '8!-6IOW$1L,!P  2D4  !D
M     ("!XF4" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !V 35K7\&N>9@,  '4*   9              "
M@4.' @!X;"]W;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ '8!-
M6IS"VI]' P  8@L  !D              ("!X(H" 'AL+W=O<FMS:&5E=',O
M<VAE970Y-RYX;6Q02P$"% ,4    "  =@$U:?$I:'FP$   R%   &0
M        @(%>C@( >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0
M   ( !V 35JK-7,S%P4  .TI   9              " @0&3 @!X;"]W;W)K
M<VAE971S+W-H965T.3DN>&UL4$L! A0#%     @ '8!-6C')-_:@ P  >PL
M !H              ("!3Y@" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL
M4$L! A0#%     @ '8!-6MQMY(:! @  T@<  !H              ("!)YP"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%     @ '8!-6F'Q
M]9DS P  % D  !H              ("!X)X" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#(N>&UL4$L! A0#%     @ '8!-6B68W\CJ"   CUD  !H
M     ("!2Z(" 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%
M  @ '8!-6A[=F11X!@  .B@  !H              ("!;:L" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#0N>&UL4$L! A0#%     @ '8!-6@*:*A>  P  VQ@
M  T              ( !';(" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  =
M@$U:EXJ[',     3 @  "P              @ '(M0( 7W)E;',O+G)E;'-0
M2P$"% ,4    "  =@$U:7=$J#^X&  #)0P  #P              @ &QM@(
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ '8!-6O$(LOGR @  &ST  !H
M             ( !S+T" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ '8!-6F51Z6]F @  ZSH  !,              ( !]L " %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     '  < #,'@  C<,"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>184
<FILENAME>0001213900-25-013463-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-013463-xbrl.zip
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M>G.]-?>VV.+;:CH7&?#F3J<!#[Q1F,8  @%T)6=VR'P>"F<!2*X7P7M#J;:
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M?SQ0#Q54/]^S=(RIOSPNCWJ:XX@?Y&;/=Q'F6N:6!P@W%V[J912F@8N<*(R
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MOH2P(!L!S5)-@"\2 <O%8X!,J.7@+Q:T -P ?P/:!GX"4%CO@R5] 9<-7C$
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MF?Z;^0HL)DQCP&W<?'B%/.EC$NE5R2W:Y[[>%S"_5XIM):Y^2$&KV/@L"6(
MW-S^K8@?8J"]3P=T:$+(Z&;BEE;46_PM0V;%4U52YY:PMM9_(\C:ETL$U/:F
M!.HLC"DKY77\Q@ '?T1W/\N*T[$=IG@GUV+O;R$O)GSK?3*I$NH,8X:!'V.8
M6QB9AJ4*, HX*X-6\;H%EZA[W7S(A).#D[JD\C0DN#!ZSZ++WNN-]:W&QB:6
MN&R_N6^$6ZV7'P/%TX'9W+D'&!983S825SE=W->-Q*ULL(:1/2P(,5),5?$(
MA!9V-L2W/^;O0R\1]WVV69?MIS_:C;U%8:B4AG=#R!]G[+.>5'8@LP+)<$9-
MX*O@+F@#$4X]:1 LYN1G7(=[O@JWHGCU2E\,*M#R@55R[IF<V.ASAA6_9$[\
M("3:'GD)G[#OPHOCIR?2G8W'YK]J7D-5U6[9QGA"^EKH2 ,P%3Z+ $M_EH#S
M[K0>]U /U'$ML6 \#N,A->#G_>'3']#6N^=\0 ]-3D<>3UC7<Y= /=U:6(=Y
MP(-Z2\;^+]+%,N_'$V:R3]7\*V=6\YD7[]P[K$.08_OP,BS#TOQ2AI 2P4?S
MNO*X[;HC;]W[I<3\$GG%2@QBMJM&P6R%.?0GE&A8^ P-@%J[H,C1Y:IF9QNU
M[C0,CM1ZK6P>1_]/X%=S7./AFL=(D>!-]87-1M\4;]GB*)V%P-TZ!&H'FR.C
MIU9O[15:9Z*UWLV[+WN%$?@:Q2N$SD1H:[T.H;9W>GE5PM._6=OU152EC=W"
M)? 0/L72<$+R,=7X&U?[6'0?=_4SOWM2X_1^/%FKGS[ST,M!U 0^YK'_3GVP
M<]:Z0QY4&KE+P@HN1'\8 &8N)\^ ;STEL'=D3MO;2VCOW^+-ID.)RK6.F2L3
M.%6'U\RXIU+,JD02A]HIZ![H5973RX^(A?MS4>JN]FC@5,01)M-RW:!KGBIA
M,-2IIU2Q4Y0V_W/=J^*A;@+-KSG-"<->GSRF;OBJ98.7E4;$#L]W\\VZ@U5!
M5S//7!VLOAGYU'*JTG$]K%XE""B-&/"%#?5Z8A(&;L.1Z>:UW3[UYBY%@!.C
M_$E%>;4UO)4FHUVK00UJPK%59AQ;L*K&8#*SUAGQA *&U.%<5>_FG%$RS2K(
M#E(5A.6@U-52D]S >%V"T:TXK03G?!4@<V3W-35%@%H3]#W7[DN0A)4+7.3?
MH\9:B=Q.K19H<"UX7]9R_=(.GSGR2ZN]0@77SRS-H](GZI3S@N2NWWZJ^F8#
MOBJ[?!!%>SN[>TH3FAI;KQ)+ S[R_,G[Z8AZ]:G#^\.%\L<QH)Z+DC68'9(A
MFC%^?^D:EB/'4YV#SW/1>;O":2% =#64;&(_._<1 &L4T_RKBMH:MTJG%W @
M7E9G@,")(-:M<#D#C*UA0[YP(D3M_LV>=-W$0J"H&@NS-/4^"'VO/[%Y[8><
M,D4JR@S]9"Y:FI<T5Y2_+)3?E04@M[EB=B.0?+-D+>I*TZ1'_"\<53BA$J-L
M2H'J\[40$%:_W%);-*,@U+A &LSD+2"C.L,,85<W\UP("BKVKYV^$09BC9@0
M-C7# DL$TBJYH:+_<:&#M.0&MZCV6M'TBJ;I',[N(#=*7:RI]#R,**9X"-K;
M2$YR(KE2T8&QK)LO5A^'?>/*P6,:V6&1F-8E7.JE8X'44 V"A.Z*J/>P(&^)
M4YJK*UL74^D/O.,7IZ\Y2.<6V>3JK5OOQC?3>FWHO=6[>'2(;@L@8>5DQZD>
M&4-V]:\O_*:N-&]Z5A+Z ZU\0&EK3<N1(RC*]G]#%LC$JJD7MC,TKRCV'BG_
MNLG."A6WN38*I>[2!$01]@65]@I%O+I9A&EZH,6DK:D2)*0IFW5X4!IO54O]
MQ4G, VTLY^:A%'P?E1N7Y[* 7*=^LJWM]<;Z^KH^M:J#KY/W=:8\ 3+BV,@'
M/H<3'7JJ7QA8\*F<W3X.$X23TW$-0-5/8KM%0K.\1=A*B@D@\+)8^(.LL:=I
M%!9JW.G$$[HCV1'JEGW4U1;;0"3&S>=Z,;P]5N565V%B=0&5WA9J+H&]7U%_
M@T.@;JH&W%LX3Q^)T=ZC2U7>$'.1Y!V21':)W0#DE:M6:)VY%=I?V==:+TOL
MU">XPF/9@5=VW2KU-&P4>M(TIO@$B)!T['H1<T,6/2H&XG";;RBBR7JH_.MF
M:QNY2(&956Y*^AW+8J<"LHP5F?)/IR!R;"#9#" 5JY/80P .DQBDU$_6'49B
M5 &!N9,+8D.O<Z>3F[<KS"] ">4HZ+6,<9=4CTCP&)L\8"\+XCG:(<9[Z%]&
MU0!0C;(3CT88K[)JI:EZ3)*4&$<>]1F_1E6$!O"2]HV/E"[".3:82$%X88C$
M.?,K^XBK?F2N%47QQMBS,U;OL>J/98L*KY=FS;J'UDR4.K5'^?4QR <O^AN!
ML=Z)4\-\GSH&R&A"- ZIFQ3(*^J3"=],:9ZI6I?1OTO#ALZ(?&$1[(^[J><$
ML;;RIR!95NL8:FN&%=C%/%Y=OD>=;* ?SW5SFGKHT8,-I[K=()"-5>>+ZLX7
MWJ_?^N+9),9C'[I(:.47?@ETKULP _?!;F\)OZ%^?>J<BH8:4/U(O/B4^!]A
M2HA, 2?:"L2VK X90Q/LD8F]]Q,<O:"FRI(@HCF1LF61:;RG\(O/3L<[O+8H
MB7(_,(,_'!"#V,&ZAT,1J9]3@_EA'X=5(A'!]M 64G%86-;GUZLYQM;@/U<D
MW/.I4W5N\%\EV4P_MT9) (ORO+^+[)BU^-7SPX\+RSF'DDHO8-7]VE6;5F_K
M7[B%;NUHAFI&]ZW9;;*!P$YVON)VSFRJ(V[WB+./:K:T].,5?DF6^$ :YKT@
MO."D7DH89S!55F2JBY/H; 9[G'OY%_7R A\U_2W)KJ$GOTJ?;-/PT?D0_>S;
MH%$#^RKW=(,-PVOFAD+.1C>/5&0,FO0TZ1,ZI/S!!] :Y9_-4GRSYKH^I*IQ
M"U!N'5-M4V^U/IP,,,]\?]9&WBB?=C8J4; Z6P(/[/V#,9?%D+56Q6<6P=<,
M5KE*"3 I 7= <2FH^6 I!8JQ?SD]U[Z@1>+I.8=7JYC$.J7-[IRS;1=K!3RI
MCH(6E!ILQDPI ';PKJJ3L^R%KKLY+Y8V:$:\)#-3%[7SKV: \^+)/RL^LN(C
MSYF/;!3YR,PL);)^JLL9%DU^-GFTM\H+6I'>BO1N37I5'G:T+.9/;YAFX-X;
M>6Z6,EUEVLXE$J))@K%SB/-:0L,B[\52".M"9W?-#EZL)&#J;@D=,P/5*WZR
MXB<O0I1OW0>OH [AE)"_J##/NJS2VE9#73D;!UN5*QBF6?D&4*/&+Y: 75;Y
MR;P(<8H5')7*;N%QS'0"17G43$4RZ"VUD_N=:/$R>,;MTZ,5%YZ>UGR[A&G-
M9I8S9;K$1?*DO6VK 8P3!!$.?]:3JE@\]KVDLHQ8CU-"-=^:NE:TX57*&1CB
ME[)XF.@MQ+^F8UR]];Z%"6@R.5/2MK+SE=F.":^1GKW6P$]IQD^0CGJR%;47
M].4(9C79#Y.$\ D7A_=0+11F^/:$/<Y8N2FF,1P,\W@R9[KUCHT M<,X2^7M
MC@6U=CD6 EGI'&FUSY@1K&"^)Y@QCNM$7OS3%*H?&F]W745Z9:<"55=O-1BD
MM,+_7(;HV1+D/F#L5B%8!15\'/%^Y8EKQPZM$39ERN_-A)E)86^M\6C%Z-LY
MG![[PF56K^:J<K(:'$:L3D.W?)!G+<</J\]HRELDR+6:KPMKU#V.C\DERMTM
M=+_VPLRQ!=[5P(X5-,\\&YRNZDT:F ^ME4<:C#[KI:81_%SO7,YYR/><HR8"
M[.PR@2LI.X46W,X]RT<OW!>?B69$,J9,R](7-8'/0AM=]K#?3R.\9T"MHW$B
M)S&/(PQA4%Z$52Q5D-8*[33J3V[YOOYL.#C%595UZC8(6'T5#]00<^#AUQRL
M%V+EF*FO/14XB=E3T^E[:8(3QZD$*!*NIRZ-N*'&(MX(-0YFY2*H^;2B*L&K
M_'YK1F4Y3@/OX:C^+93EE3F!5;[7OEG,42QNOV:$KI7995>=U[#C%\$PL+M/
M")I!(*2$@'\$X?6*,Y@B/[@W,3%4JAODKC-+B!LEP(Y#>A@:# )Q(_1(\#!3
MQC SQ/85D&%"B[[XQ-+# >$>S4-N!TR1X6 NAC2DC'9!#\L:2RQL$3)U3AZ6
M%TAG"W$E[) 52*?+=:CZ6U';"#[!4>E>%"?R9< 9X86>+]]$HU=<]<(^%EXI
MFU,$R/K@*[ >TPA9&$VT$4T<MXM-L@QDW(_#F>!=>1S0X8OQD*"4_/,0"PX"
M@6._"ZW$<[\%IF>]MD^V9F2_GL)K378FF>\L4,( A%T("E@#6+F/VI\^$-!Q
MPY]4.X2"X\H+T]B?.*[P4>(8+%DODS<?6Y:%  4*T#".J<E.',IT&HED:<TC
MYD%PHDGB:ON\: G31$),-Z1H(67Y-J3$<?)Z)^J!F!*G:G_@/,9HGB?2UQB%
M ;IW8*.4F "?)PI^#^^P0I'*QZ)&(63T*PP#$="H7\0R:9OJ]VC4.W8Y$1GT
M$BZ/9&[F)3!MQ]1+KU&E39-A&'E_9RX$BP!>/&>XH&)X32)XL31].*I0&3#9
M%VZ*=XE*T>0(2J%H&)U1@&#4-?I8#69G8YC*-)=4$;H$^#S27*%;7"@+[H@&
M\."T$4V-^AP[N808_L"+1O*L*]>S"8_:\O6$"!2CDS<2KBTUT,LUUM,E?T4@
MB(T ?S"<0]FI6<(P?AT)[;3JA]ARCL=QV/>XOL(6B6!#.Q%3YQOL# ;*78P5
M/GT !J4DW6^SEGQ6$T\4.[2<.3%IH4G4(CY&<-@(0R^$7Z\N?$6B\$(5=9NK
MBKJ:BKI52=USIX3ORF&)B@@R!UMM<*1371KH!1;"+*4Q EX3B(&'ZH2/6HHV
M-H$#@W+! K@WQN6F=3=BJK:.TIMH>0V,,@1#&EVE%)QP*M65 W)0J2X:J/97
M;:%1OYZEME*:E%8"46V=W?_32P"[_0?T3%\+.0LA0)7'7]1M_N#@S>4X5^&U
MXE9L@8O&QSG=H_?D&.G*PSD7EUZ<D.H+Y_0#CTT.:UGE@:^2/I8NZ>.C]^GS
M9+&T!ML@Q6YJ.:L4?6M-O/6UG#+W>Z6:9DK[(I 4#>"\XFS,M;(EW&3*H4#P
M5<"T&$(L^"73)N]98IQIRAG ;5L<%D5_@H&$U/R"TKQ@RUIR/\!&434PGBH2
M<[1]VJM*:-$+89<7M%;!)+D2@4?>6&!<:5_6)X%B;X8KS_N_@,-F.7:#B6'5
MOC)[8H[-S]#FHC1>L)3 Z$\04OR63+18N8S!]BATRKG&> ;L82$X;,LG0RP*
M?!#6=-3CR M-%GY!1F==#ZG,,4.@MUAFL;'9[ EYF<$%J ]"BG!)ZX>0XH-U
MZH,D5PW;.!Y"!@ :H%&T:"Z23]U<]+JHL](-)6,OQ>94M\TJ6HFKE;A::G%U
M#%Q6"B7%:56;*N0Z7I 8!Z6NG[7T;NG#LVBO-]%A+SBSQ;@SL3YJL.0B3\&_
MD@?1$@D&,(IZD\R0,0.=T32.Q)A[KNU5AK<N! ;M!8T:&=B3]A&LP,=CP:-8
MRP=+5*[XPHHO/ N^<+@8)<@VE341A1E:+-#CU)\W%X*D ZH7MC9%MC/&[FDH
MXLF!4)E(8!9OH,I7J!*GH R&EB3O6IPWY,-%RH6>CP1%M6IS*3ZELKQ5UXB%
MH'$%=WT,B>2"0K2RSCM2JHO&'>HXD<QGD]I-)1X7[,->3K5<O%%TF>R?H=>D
M"-YGXS=S;*?(%%<('@)Z0F1.[N<H_(F^N(A]YL'/51(A@7 <4O1#8Q:[O6!D
MYQHG*SFE6N5(Y1-5>BVUTU*W_\S1<*Y#I IPVI.E>G DF!-$9Q1G;5WX)>4\
M.Q&7J:)#N"1I7-D5LL+:EN'[XO;P.I3<GBI"159QIA>Q/R0_.LSVXGS!(E&3
M(]TSMTH"'(085A7D7,5?6@M)_JX6DGX$>D45SS.^!.!I](IL';4"9@"0Z$:N
MHW];?#8/D_+]ZBA=#C0,:_(K4%UYS_.]A$:]5(<Y-;S4Y%IF/FHMS@Z QJ;G
M2PGTIB97NDPY?[@*",K@^RRI)W,$O(%#"1,8#E<Y9*45V:5WI4Y#INHC:[%C
MIG8Y?MBCM%8.ZL@E+";O%1TXA1_+VUD^7KGDK/QW.9'-.;23% "A;1"SZFK\
M03?@CPIWRN<)N] 7<\7%"01$EIT!8FM*3I6FI(/>AM/!+UJM]]M[;-P<-1NL
MPU&*!@0>$O?"*:(,4T2!SB5(&)>RE+V9BASI6ZA0R90TR:GR-)OQ!L50R0TJ
M5;&IZNR+R*X,*<N'$%7-.E]\HN7AH*&EEO)99XY7I[Y;"Z6?&1W3Q'R]P')T
M4/)*KO**LKL&6IUI&-W$GC!)V=J%P+&5;4@O!1#&JL15SK[4&DS612;G6=*^
M;FU@X9H]0>G:F'1HP)=-^>P)%[8*Y<!5JNHWE86UK2S#>C.R=L87 EEO\3:U
MN>HL;JZ:]7!^&(VU-#8KNL<LOU<^F=)D,PD<XR-*.8*.-@@CH89JU*8*:EN1
MNBP&7$WVD^"_^-2BJ40XS?K@2@NC>(X:=BHC+3S(Z;S5M(8J8H514%P15W.F
M9VC4$IZA--!KL*>])'%%95.U]"2\E&DF<D:+4JKM7%MEY+3CRIUD6R:_C!=<
M>:H*ZQ;$V62?A0P(V7:4(U%&P:2D/MLE8POXF%:U#=N:K=];B;]&*<_4<2=3
M]1M8T@Q,6=@Z/U$MPA3GS;VY;8%J5]NOKS]\53FK5Z16*J?7B]<8Z@OII?I=
M<!+J#/W"];&+,R1^=?UZ&-E,17W:OL04[R3C-[TXD5,U8CF(5DZH,EUR%5/!
M*;'T]J;3MGY!()*+(PA5'7HV32L?G@6"0+85:[L>^1)&BHMZB*ZU!X2',;7F
M&T9A>CEDH/U_+@#C++ .M1D.)FI0#??GG;_R[(EOL73;K56Z;5VZ[0O(MWWV
ME]WT?%?LKLB^%-M;R9Y:V:.SN?!42F:KK@,IIAQ;FJS,#Y#I8[F2K*)Z2J:K
M9/\5#FN5L51G.#NH!*(&GGA)FM0>MV[;79(<J@X:-475%D+F:!7"!N2]M95I
MJ8C3WJCL"N6RUO10CU8=#'"=K 4+@JU[3^C\ZGPPPSC_BT:$' AE/:J7!YU3
M!'HTHWJY([T) Q$I!P WRD )((T8]=/F%+FKUJS9$9D-'"5XZB<-A4!G"@*-
MS":]P6I48^%QBA+P4&/3?A7Z+=UT"JL8'<G8K#S6ZCB/3:3;:N);Z[+24S\S
M8PM(VO9;F%J":GNGX1@-,9_*1_<!532E2"Z@&3Z?2W'O=M4(,29/DNA4".4:
MT!VJJ/V<UGI?O."[R)6;R"0I:B."]:DQ>0" 3WFC="29434^C15A_#7JSF)B
M0-ZB*EM02WD$#SBPNP_HYN,8=%[]M]LUJY,Z<;E?73'A:[;-\8&I35K&@OXD
MDI'%W&?XUGRJV[O?BNBM;E^W2*5.KA%>SXQDI.V>4.,V.?BGOON=AM=8#[CE
M[%!^NT\(9S?[FWT*55;<74]F:_M>MUD\B(.L5\SJ-)[B-- W1GL[!P/<0TV&
M OVJ$6OQ3$Q7P1GII^5!H]%E[_7&^E9C8_-=8V-[^TV9[ZA=JPV7N=!#\H=6
ML^JL'_5"58J<"IP\$ 8N0MGO\EZG=MQB$@=!L< TCON<L/'TE^#QSKO-8@\+
M%T#S^2N,O$364  N<KC1QLGKG'6B+9(W.C2L"I>SII#LM;C1!VPI<&_NAY=\
MET.+[\Y ]('8QUWQV9U(=,$U%GC=K\J,-YZ>#I>/&=]E]$F^%180*)A<TF71
MQM9C;%_RQ:GMRV1Q4\9<RZW0*_BM:6EF6A:I%H)Z<#LY-V5C*,IHI03.^BU2
MYR3"#+9>I-U5^EADL@XFX,IG[%K+?('P5&DA^VM%0O9PI'8W@JH@X&!"*A4C
M8)10J6C?;,'T7._T70H8;BV;%BRDR\DQW=)2^G!T9R3IEJN48G7)#9D(6VPX
MB27NLL2O0>H//-^G6XR9+%7-.G1],_>U3(VD3DY]Q>VY@0L!5/>_!8XV\W(\
M]LKW=ZE>>V\6 E[N6:HTV<VBBR)UT43'QJ9UHBLUS=;6[V+%HI7:E-:B42\N
M :G",@5][GH8FI '*NH17+Y%+WA>>8YT<$JZFQ5]T:!9S,&,3:VJ/=O#1@30
M&8@CI)0%CX<",8=J%3@ J^A(16/>?$#X7GO>&UI1)BYD/?O5.2IX[&TM!,E(
M'H>LA^C[E(P%ETTV0R_=$IDODL< 37]%',(Q4X>(ZQ#QB$Z#A2!YO?';&S/F
MF3:K^0@Z%\P<A'W9 [LTB&BED#_$&K^JEK[YBV@TQN<_KU=^6K2P*UO*+]8M
MYJZSTVKGH2T$QIUGITW=P6(JU/RST]2->'[7;J5(S[P%OZ B/?>PIY6FO=*T
M5YIVX7\K37NE:;] 37OKN6K:]P:@K5;?Q_C0.XT$U8&R:6-!'V?4YU/<A"6(
M4-Z'4EHQ*]%9<>,[!2+OD^W.&"FZ/0<=+#A*=<Y.&?DHG66!+SZR5%[G>Q];
M>IN1I3*F=M]C2Q<=67JG<YQQ5B5F\H",I#AT];[24A\\VW3IFA,NW)KP=>O-
M7&T%+VA(3#32QLT]6&BF D1PS%3.55R#Q:8#SKI]$XY4(WJ1GZ+60 -E)*'K
M,94+ 1-F+;C@TEYY49(2WY!U[MQ$P]7<%-;.P>C);)]T9)I=\/LP7+$ MEB
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M/P8!-.)]D5*S2M/@JQRO'H3]E )H_4AUI9"1FB'V*")O)HIND&)R+D B^L,
M +KT9&F:@S5)F)?.8^F*[X,HYO\_>V_>'+=RY(O^CT^!\-@WI BHS4TZDN5Q
M!+6-.=<Z1R')XS?OQ8L;Z$8U&R,TT,9"JOWI;VZU8>EN4-Q$MB.L(Y%8"E59
M6;G\\I?3-$>**CR:XQ7EDO_!X*!47F@3Y_1J#8:#]Y[#Z$WML1.25A<J*U9+
M07.?E_'2OC3X7_\&4OSZU;-:@7&\6"?@VNMA9.0.?_WK6[*M_EAPQ'Y5K6>+
M(N;".;DV2>7BMV_>F8O9O' _"C'Y*PQ>R[6?X=KS(D^KNOI3\.7MV;/#PP,3
MPJMQ4G4KN:]%4Z+Q%U;K'(:XY$#ZUR]1_^7%5&P%K"C*$-L8KW(5TTV_?3F-
MM!'5N3,XS?ZU4""LI8-*J)"6BD.(YX+W "<;A_MB8+BK&,65D)IPV='05X'!
MEU9+,D=K#$R^2RORU"*$VI]^X:D$=8Y\3.'[59K![*4D O#[+^]=F '""I@B
M6O-R/</4?X+)'K!^4[3E+ZG>8=I4:8[1%)(F3#6*+15G5,BS4$O8TDHE55"D
MV3,6%)";!.;302;0?:?+^%_PGX]Q^4W5.LYIN^3=#^5P[[252#JK(?16RE35
MN$!)V9SCADE2S E9Q8 9=51#14X]$L,GAT]Y6[+!+J@'6GAOORT+\-B:3!D6
M<OY=A2%I#'RC$GIR]#0$(SD_78*/!$)_\O+H==0:UZ<X6Z9U ?.&A.M%%N.U
M)(2?WI_2%EPVF<!JX"?"Q:?RI#A7>0&R.P=W9!W&,T33X+WLYDU!+>7GA%BA
MT5'')9# O)EE"#.:Q\2NJ56$_EST3?27"<ZX5.<X "6X:8SL5U(QBL3T+B '
M7IJJ"WTC8VJ6,%^QKA6%B>7FJ? AZ.W JC8S[B(C/+K8+B /A9%4ESG!PU'9
M<DUQI+T+R]T."JD@- -E0I%IJ&!E$%[ G3A)HFC T4:4-MR"Z@VT%6.(AO02
M2[>GG&[3\CWZA0),/\W>V]%28*W]8SM4GX5AWQ;;52+Q3(('>1(I_1U$+'W)
M,U(:74GV0BU[</KPX?-^K]%WU.@O1%[R NRMMA4)*@G6B9=40F!L(O;91V&]
M7BGD%R$KZ<C\W)A+PU8'XH+2*DAS&$5,]H_[ '/_)4K%.D=D9OHOAAE\CF'(
M"H-B,XR$Q<LH_+28O)M$6!T_!X7*W5L_JB0%ZQ8^Z2U8"DC.9C ]?U73$J;\
M[WF*%?#(1!> .:)T3RN*O&FAA[^@+"(/R&ER@7;/.GR#((?!C;$$"R1C,]O_
M)&[/L\9O$&Z+UE<'^@014NLF3__9*#&Q:8&<K4'M,3C?1.BSF)'ZG(BK]JKU
MVIRPZUK=\ =7-_!6][95W99%WFU..XQ9;DIHQTSAR]?A;RN:A3_AYWWAR.K=
MIP^9=NONLHBG)6CG63>#>/B0$H@WE4'\H8J'GTJM?1+&^T!@0JL"#D!45<Q"
M5DG21#.'PE$+KOC960Q&/CR[2=9TR#2Z2>1_HS/^!0[B(G,.7>7'?B2PPW:$
MN$!XCB8%:#=5!MR.R:(]96A_GWS!#F4%$Q.^0XOV-$%PGR9:);OCPSMDQX;+
M_T,AET_X0274X.M,8ZQ)E^+='!2@(<+OWZD+9/6B9[R9GY8?HT#GFS0'_$=^
M%[70^*N*LWI!5W\L_LKA'.)_D&B0!*SHYU^_: 5][X3DW@W('+.71+9A,W-"
MPH[KD<67%A*/*3E**=(B47"G.4=T]]$QEI8=G/0$0#M\6^"99VDER&)F0*R2
M^)_!VWB%Z1X)%#E#J-;+*8BX.-%?/GU^*Y[SK69OV@";VWWOF<<[1JP91/RI
MDHCB(B9@9^G'-#P1B9/#]C4V*.BRLG?SG(>_O-@%/D:+Q0&:F P$O5I_3O^B
MA_-&7H]ITXFLX,/-,NJO_E@0$/OQY!K_BKB$^")=AH?/H]M^^7^JLL$8]?+6
MW_SJ^.3%T>%Q=)>YOJ-G+XZ.GCU_]?(.DWVW6J_&>VQ<[S/"#&FX$9XT%17!
M8/".C(V5L+-?J$4ZPW[31:*P$I5 3#H4AA00YT69VF#8N-Y 2^I<S6^ 9\]
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M=\T1Z9JEL?/-9O6HBQ$<6E@K 2?<X&1,W!T%?Y2D1/Y(.NL:G*!^(]?%9>T
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MEJ>S6<&-+^I"S(=*Q7#:.>!%(<U^0_3E<P/_,T]J>3:=F#_E6V0TR+G-@_&
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MG<G\(5#/-IMR;$>Q,:TQR*M @'5S%$S76C=B<(;JFN@,=<OWQE7M(>0.BPE
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M@C78H)]Y>&#8[.+S<S1-:^5\9[S$M'G_+$;:P"Q0H_/K(_-^4NI!S_M/(G\
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MUR<GSOSA-7C?JU<OAB?]Z,5SYQ:'81>EIFR8+Z]41?[X@DNRE,9!L&Y!()Y
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M9'051-$M,+A*,0AVPDJ].D.A<X07.[1,\46<9O2.PCOE*()%1P >@%DV"3_
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M;2^=1S$H&XGPX>;&?S:YF.#UVOFT[9^@]YPDR;V?A5C@E%)7OY;VYGRU__2
M,_V=Q,R6UH/B+[G.EWOJ3,(/<'IR3'K%^6W)WO7.;>#,+9[+=F('Q(!L;)A;
MC3@8,V-_IU91KG=L4%&!C\[24%%+UNCTET-[ 8ZT:KYV^Z!1^A!37G8&:9X*
MXVD:I3?I>.A3I3TR!F7T0"ZZ3CI]?3_XP?'%S^:RKFBC$B!,/R :=!4#BW2
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MPH"EB#,3@I A$>%ZI*QGADZ=SEM<7Y%:,'4+CP2;K$'LL2PQ+9!*!I=H<%U
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M.-K4LA7S\^247+=-72W3<N)?P\R%=24W@ZHS(:*DW[VA5>%]LJ^55Y-FCJ=
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M^S><]:H3-JS@CX9G=I%$5!8Y^,K[03F3^7E)9X Z_8X+O#"^*5*<E\IF'"Z
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M'ARWN5Q"A"WJL2<#A;;7TZ7SWLW-P5/QZ@M(A!"[.()= UY([ =9R'('_.T
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M *F#M@SIN8PIMI_0ZSTM_J^X^!20A[6L)<4",#ESVDWP>*%I[P#FK$040^-
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MI5*04#D0Z@4'3\BY]0+Z67 B3?YRD\HH3)0"?!.QQI(:X0&#V38K$G*DN@]
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M!AH1N9#XQ3Y?40:1BO^*@%:$0Y_47+!MEVXJ]]W+^,#0#^LL@N&Q)LB_%VN
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MAT=M#GC1U<QXD.N6"TABI6R!"QO^S"%^QZE+IKN2(OXPHJ*+*D5$U>P[_F3
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MNTW_^ELUJVJM6@#8#UF.6M[\$*?530+K4:M6/>>LN"" U;$C1IH[B^GBJ1Y
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M OR*]0D9&V00, 7JGTT'?0^Z+KXS'FXD_,-AEI:1?D-W588N=7:XZ?]'Y;V
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M%E$.+:YPBBWT.H=[BROTRN&2AMI=#^X*2WG3^6PS "5K;M"L(]J5*C'ZZ'=
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M#0\[T20N0[P%'EBTJ4.#B*]$41+G S*?Y?K 34;7>F;O<UCM[).S]GC5UW4
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MGWW)B,\)K/*BY_^*-\[%%TQ M]D^EH*' 'ZEVWR^*7_ND/$F#0M Z@\E</R
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M2EK/ZUF, I_'(IS3E+XY-]G-R.\/Q8KZGQ$0'<L\^<J>TH-;.D+G1XO2.M?
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M%9Q)1P^073W%?B82IQ&@M6;YAGYD$7GVY,O7KWYX\0U^?OHE(.3\FCTM;M<
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M1LC:[(N81\<3IP?KLEYC0*-#R!E[M!;)@43&EUZRJE$@39_W3\KPI/,9V6B
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M6?Q\"SYMNPSP\VT2>R]-5#03^ZR!D#ZKIL4K[J#%<^^L<=2#WP]CX;^XHM+
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MB&DH%$_MB5?3E?\DCE-:0^WZ@#N5]@L$G]&/Z\=RT8U%MW-^7,_R25[TX+#
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MM>R0%O&1OWO=X%]"R'3:%9O0Q-R3$__KZU_S9!,$!UNK07KDH!K6S(+:O$&
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MF)[DX.:CM^(&@>BV42__W\M_+?P#+ #ARGXJ%T4#?VL&G3H+3G41G,IJCOU
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M.V?T<H@(*A0Q*)(G)2!P-Z$,J*&A,M6&9TQ. ]%4\XG@?\G\5/R88Z8M#^G
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MU2G3==W_"T=C8]JPZ70F(.BJ7-9%Q_28VZ):S:^#BF0RMD+K%SA6;S(.92E
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MT2T*;W\?_O*N+G?X/:69_[/H5\7_L,09E1KF+A=DU4S/+F6E:&Q!0>#2#<?
MS4/29TX:10@,!FD-0XPV83;+I\ YXATDW!PU1]?%LM2-*8P(#-=M4,^WRMIA
M9_+$]9DY/!NE TNZ;C+6O<MCH+3WMM9(*'.XEF>":9:1:1J5WYQ4(B3 5WJX
M4*; NYD3Y;E?N^ ^[FRD 6<VV_LNJ, 1'@4>C#1A<G@%:"@O'V&\#R<<2SM8
MM0.Q("?9#]#^"\2'A\T0UY>4;2_<(.4K-$J'.CPW&1YX'6B?<F-XW+V3K>WG
MS'W2?E1@5^U%4K(K'XJ,$1&?$C;.7^*X.VX%JO/;(ZKS(*KS\1'5>=Q<'VM.
MFG5PIB"O"$RN75[/P#?1M!>C=SQ8HSUF_&8.J<A^?9;R@[N#PK?]X.,<04.:
MGI%)F#7!01$5%M78S74#@N4D>VWY? AA$"\=Q(FT]>.0KSH].;4%AQN=J8MZ
M+4,4Y5YR-W%+S1D<O'9 ;.0N[>]2_9 \-/2."Z0.!W8 R3VF)P 7N4C:?8F^
MFO @#,ELA<Y\*$4;7B<N_3IY1+4LRH@H8&7[$$YSAI4.^^7NRDS,WC.+G-UK
M/QLX*WY<P9NA=:@7!W;5$3$%'>3@((IA[Y:4UQ 0> ?:D/SR"AHT4&FDH\8[
M$HNB1QE^HF]V>1Y)N>,Y$#$:*Y ?]*NG#AR\T[#<HHUBCBL K#/[>*?+"J6U
MID2Y'SFLZ=H)*#7S%$ .QXFHB1\G*3H6J?8_"^$ P6.V'9,9$&SYZ"3=^CF]
M;MRT6FOC]"L2!98A(>RWPO_SGPP*,^P0<XA1BH6%^-#-A_UI%UUBL"E>GV<D
MYZ;:3M7+L2,.6<MDZ&%HFJNUO;'R.]-H636BC7?%>35Y4OZ!EUN$:=AF*Z:P
M@+?#DJ=C9\VQMP5GU2DP 8%H(8Q6OQC$Y?=NGC"8QQ>D4=5TNMG<=,TDO=U)
MB'?*98<&@-DLX8&NSI!B2BC'_:1Q#I5'BW'[YS3K^4U=OO?:S%(8(IZ6:KXV
MQ1M$.GS#)G&79_R4L871S;R/Z%ZK\CH'=E,.*BO).U1$3)G_-*M;R:%9QZV2
MLBL=I'Q'Y @I$5/@^WNEJOM1(KE/Y9[7:]LN3Z]>4*&%]ZQV>*?:<H:5W%.&
MM?0[@]1^]'< FZK:1/@[LUU?CKM6 FL"GE(=$<@#C4VZ@NK\(C+$_B.@7OX[
M1QMZZ^>$Q*V^0C^:M^5P=31GUJ(8+WA6E-\DOMM&:C6ZQ,CVLKO._%VS:]F%
MM:P+]O#:9'_M0$2.A*_P5$3=ISB<X.0L$C4EEDN=#(7\F::UU[EJ(T+%O&13
MK\[4O$LDZ"AY]KRA#@5#:17?Z*4H=WVMX' 0#Q_RP?BA]->?39@#%YG74S(\
MBI5UXFB:H,_W1&S07C2G4!V?[VJ93BB:*4J4A["7J-B"V7+O9;:RJ=FZ8/)>
M;I954X6GMC^]WDQPB<.VC\_D4'L'5'B\"]D'SX+L,:]_]D$ZB*@):=_5N\V^
M<O43<LN_[IB>Y!K6F;@"KVN:[P?%\.T^V7_D+)&S0='AW,G!8E8*IN/@65@6
MLV>/G@5<X'Z%SO_ER:-'3V0A:2N5I'^"=C@/Z4J8EEE]QZ/_UL])%HB[W@*)
M0"'NOYR/J_0Z/[R*JIF-(KE-RQ\I"O;*ZP48:ECUTB::L2CPM:NY48E-I:ZO
M5S'>NX<[N,DLIREFJ9P-;^(A^A-S"V'L+P6^[F\!:ORNVF0_5C57OK7ACR/#
MH(X<@U*E@YH'O'CWIX4B39DR?;/K ]C$2 U;H!H]K_QZ(.&<:1KVX#3W]:<=
M,UE$ 6H]S"23M-@=6#TGV?=<8I>!<#&C9VYGJYW'LB1K',?LFBS5)_-.#B>.
M'(6QFW)52<?C9C__?;0ZMZ(6_MVQ%GZP%O[D6 L_;JZ/5D-9SP/=0SQB2I%I
MF?-&IRUZLIB$&UT>12?]<IMV11GWW*'UF"O2W.[G-X&?LL@U:[D6_QLH#2?B
MJ65#Y[827((^T \*@CW47(/F>I'3(;L?/DB-ZNI)7!\,]L?]YX/ND9MWCPY'
MZ2RB,5'=U1!X)YX3=V9?VV5R,W/.11*(%:Q)&"SVZG/%E>LK<N']VNM!#=8D
M.LTF087[!$'%[0[Z[E, ^Z:H2]('*1+H1C,"DQ\EPP]R82B5!%=@) /I_<E4
M-]VRV?.BFDUYN!OE-^Z28;^/A]5'63H:NY2=D.:%2F /5AH89:9N;9%B%+P,
M:*@ZM:IR(<ZAB>V;Y(D%9#.+C('&^?_/WILVMVUE:Z.?7_P*5-[DE%T%L259
M\A#W294\)'&?.'99[LX]]\LMD 1%Q"#  *!DY=??->X! TG(DBW9/!_Z."()
M[&'MM=?PK&<EIL"KGA,E'%?MPMN)/]=V!$<'JG;#T*-@73$=(8<U9PF.5RJ\
M&HE2;&!PG>=(W4C/3;,I!,/$Y'VVYK=.^3IIIYWNO75SZ>+>Z$K2F&S!%&[U
MJE8[3- U3-=H*#LH)''IXF]L-8NJ8[7Z=DKVUL_IK<2L\&KTX51<<*#M$%D/
M"!^5EFWTPI1 7R] :%0@?*7F*DN.:&F-7Q2X))K>.R-JR4-5N*J3X!EH,#:P
M&K&C_U/!)4EG(1R*#$E9KKK8NL@M(*)S31,Z@EVOJGZ %I-4.1X4TIQ%F" \
M6\4EK#*2M@O5.5$Q;$Y3N2BF*2QLL3M3MWY./5YV4_42Z,VH7+!I^?Q%KD5A
M4'GPM;-4&?I+H?' M[QY_SQ\MLHR[%<5/F/D8JE,NA2KWH-_[1$L'+O?T>T^
M"D]RZ1$59^0/4C[)2WQ:>%-:2[EO [NX#JC(9HZ#>.^R>,0T8QZ9<PS;J@W4
M,GQ"S86J4\J-S=)*0M!N\PE-#O^U*FK%<RF^/1#S!@NE\'<;B-@<^\9OS5!3
M!P$YRSFUTV#L87\Q0<=#@PN]>LW^TJ)*5I:T8L<^)5K(6NB&[LROVS>7GRDT
M$[#!39FD"J_:2;_+TLO@ /MLN_DM5R5L?Y6TOD5NL=NXVDE($39+3A5\ ;,I
MYXEV9&,#T!YXY[*>IMG*M0#(<8(+#H7O(@=_>YXNC1?DNN'6#VJXX@%[%CM7
M_ [-J<N3L-1EV&DER8FQDJZ-&C;8>!$H]!02MC+5D%M78DG=6:7/!3&<H$66
M"-20:)X5>")4"\:B-B-V[N/:,KQRK)+\>4:!)\@!UAP H\6&^+V6=ZZ)OD&!
M]MHX8IR"-( 3L"@WS3$<.,>@/<<-P9&>. A'[6F\/"4*@WPS8*"[<1HWXMK=
M,CCGW*D)II4-6)QH*;@ED^#11J\[ GAW( 31X6/5;DW4,JY WB*%+IA2,CX;
M?CDCP14H3L7$LIT"2P9EU34=O/98R01RP7'*PAPF>]BB-7%CZAIJZRK=D*->
M@FM@I56294VM$/6,@FQ5"N*US5SBY[ H0[ $\TJ[KL6BG1270DD3V(/2-OQR
M4FB!I- T6MY5U=278\+9M*R0JTTGX'G,8YZ8,Z'(L>7%RW'J"FG-V2_"K9 B
M2%)-4K]I(YG4[\N:+P:>9HP7M7^Z-I[1-GERX0R'=1_Q78G=5:VHGK143I+.
M1^TLF5L_)ZPB=)VX[M-\AL$:]DO]%CWRP:S+'+<W+I%@-XSS!CBL/S#;;:2C
M^\G07L-NUTJ$./1TB#%F?6ZGHN-TO8*U&KY[)%+VO<97\-.[;/ZOSR(XJ.2O
MUB_XY]@<J/%M.EI#D%L'^_L[Z%8O=.O!#KIU/9)XEX_Y+3O95W[?%VW$!;KR
M^9O7;T_>G;Q_]9^7@\A_W[Y\%Y[^>O+N9?CBY/W)KEWZS<WI/;' &N;HF+V"
MN@J0GHP#_/,4[6EBIJ$[O^3X-=_WW/Z:DW]HL'3EXAC"30EE&!,Z$(SG$YQ^
M2$^PA@78Z.V'!]Q/YRP]%_8TAS#24 OR(V*A$_QRBN@6T#5[LKKW(4E #]3E
M*N$=;Z]ZP+D4=SO+9(:=BBLW:0R./T,)YK&$E4KNTOVO58X$[9&0RW.DG.1%
M'< %V)KI,KO4 @-'K(P1;)JY2[&!(?M\AT/ZRFS)VZ4$.@XB1_I=D1@GH"@L
MC(2*1TJE?)=(YH6FSN))O8J588%<*K?KCW1+5;9M>^@UFY;D)&3B<S!G0T!_
M-@.<*K5C(D11E;:60GAJSHX^3.Q/[4W4ZR7U#K)C@+ <@4,8/I425AX!1Y?Z
M%M.GYE;?K%/A;;/6@5EKS81VZ]\+"]'M7M=P^W7=*=9UBG65$ZU<XEQLP;@H
M/H0;U.M[+T1(2A;^?+E>S;*L7208Q<!*,"E%UQ"&WY\A0/*0#FGN&-*P$<4Y
M=L#@G3F0@=T&I?9%7]XGJ&Q@39(L6V+,)3_[[^_VOS.N(WO1$S#'XF4%]X3^
MZVEXD4[K.;GN/PS)R,@383,F\"Z<QL>GWZ'S^,^ZU+=2,!AN89T7>PC?B8M9
M3[N20YW.@G<8&I=;/?W)>11=A2RWW%OX:2C+85UB#!X,>X$9,"P;_O6_OSO\
M;LT;N\(*6\0Q>@>DFO>?X_(?/X7W?C7FS?V>5>B<LM@)[E!WR^P.2.ZTW2K?
MZ"J_A=OK9S)@GHM1\'F7]Q]U>44U->C-)V3QN0P=5?HQ7, CYMC=&!.KWHW;
MZ^(V5N?:MMK=5\I6#!;3&_W^;NC7,O1MI1W.-)QAI"S.IV@F%"6,[VQ\[W#_
M*#I\\#@Z/#Z^WSX18CL\//JA8:OL/<&CJB<X2V;PMR<M1=7R6Y]9>]:8D3*I
M:K7\Z=X!JN+5\J<>C:&FS ]75(C-Q_C*#V>Q[L'?KQ_5D\;C-N[^X>CH8--$
MAXUP[67S=2W>_FC_R3>S>-L,[0KB=_S@QE?P4]33'W/PAGN<B6%ZR!OE'TVG
MU_5VQ0&^AU'FB1#"$@ZE:2-^DAA<V]X/V_#HX.'#Z/#QX18/N]*H[N":'.P_
MB!X^.8B>/.S3)M_BJAQ%!X<@*<=]U],75 J;;99KUP]$FVNC7K=(-_1=JL..
MP.C1_IV7_6M9"; I[OY*7)\6V!\=/+Q9!? /BFEJG/,6Q5JO$351<CAA?S.,
M@A?R]Z).?KQ[ >CMA^7%HZ\2988E[O54#X_@ 1UXDK5>*;N=O:>O\?VMZ\;\
MA.WCPX.#IV&7 TS9[CB;K)@9"!$)9S2&FMOL+N #G#5BW=>D AGXC9B&.*-"
MQ&I.%=,4I_)#45-JK,S8ZHZ,C_D%C<*DC+8XPG<YI^[A,S]3%LK$6UMVS@4[
M/SX0RH*;@M<G[_[GY?OP[;M7SU^&KW[_^<V[U_"5-[_SX&]0GVU$@=V"1*L)
MLS9 V(&IG!:J UCP1(*WEXMQD85XI@[WGYZ^??><_GGPU$<C-4#=7B7V^Y/3
ME[U//'G]_\@#1U]F:0Z;B-!;<6);67"^9!C @&"RD,!DC%,'0]Q2H2]=#AQ_
M7YP-)IR84;2@UOIVTMU#^/<)O 0AQ@I*PL\0K1%@/_9$BFNIA@G9V%:@;AVN
M6D-904UJ\O#G9%QBHCM\1(\[YL>AMJ^PH@<SY4Q?07@0QO^:-_(S4X11%-05
M=U5%@;+)H>J'VP1?;5=EXUSOQ95;,=0!L&HOM7EH:\VU!+(3=W4?YY_$6*V#
M)3LXH2^;X3]LVP/KK-6[<4[FQ07H-@7T.$)AL#T+QN AIPO<_ Q2HGWMEA'B
M250N>:DI^QX<Q</.LU&$W^^/CIX\A ^#IJPCT"2UST);!QE2L,!KE2@*TWXJ
MM"E./8@K<@ZX")E5N+QM5L(_=T)U'4*E5JBM]P]>=PD.;.*8!*-H5B)9[= .
MJJK2LM\VPM?Z<B16*,E:H+)&C^B2L 3[1Z]8 :\; DJBM7WOP:+L[Q^H]DOY
MKR#*CXZ>W-?AYOJ+0!2<?5/_\&7TI/@<>B)2?])/'D&#^ -9#>(HA9?Y8^EX
M0^#6K/<\!@X309[!3>,^;MLNNT2US I9#B-;6DYBT;'<>I%><$EQF=2KDL0(
M4=OZ2OJ2U&_*,[IGODX-R)42-%:V.4BK_3J%V-5^/*S6 ;TCOO?M!G]U0$X^
M!5[R G;Z6X+3&*EGV)*YI_D_^=#1OVF<+</-^9K@GN!L?B]G;P=\NC%X6</F
MWFZ'0F>+^)^[?;K^?7K9MH]YL?F:X%WRK@K^V.Q5TV:^36?L<^&!UAX$ST'X
M=A 5!Z.'C_L22#M0RK8IN$='?5FGW1INF]#M@WC<2F#/FA<W?;VO(:EZ].2&
MLJIW=3WV'^_6PUF/X[X;\\XGW6]-"J))]U>YX86@&2Y?EP"BPLA9ML)Z54S>
M5BE3P+JQ^V1-CB \.2L3:7F73YF93>G7D,#+/-JF=WN2 B:6ZKS7^(Y"ST@<
MVE+41U_0:34^C\P7*.?A#%<*L[.$ %+\)8DVC6!7$DUWO4NK#^'/,=&,A7OA
ML\2R /D) GSB+/TH3W,I)>,I[J'AIPN2<UD]:H+#C\!NF'X[A*ZV,*'MD-#U
M<>2'@4P?$>ZS,\:P2TG$P@7S.F,*",F-37B)ZV%=AT%C\9="EL0Q*8EN\U)J
M-C#\(PF3?%*L"&MV6:P<WG$JE81)(Y%Q8GC'@[[TYCI)_:*UMW<[27][2T4'
M<C<=[+B;>KF;CG;<3;?CA&_(E='_Q&$ZA>7Z__;WC_$0Q#]U3W@@+_@V6!>B
MKT1,UH_A:HGDN3%&V6^6#.GG-^_^.'GW8N^W-V_^Y]7OOP2G[T_>OWS]\O?W
MI[=" 7ZNG;^3<\+D-W;'_0CW< VV%%IZ_W",-F-G%9,5M>Y%ML4"Z3IBX;XI
MDQE86-QZCTP\MOKZ'HC&(YH.(*,7<3G=RXKB@[8ND>; P7MJ=M7_#6*C-@E>
M-4*88#BV3+_C)$N3F9+1GA?9.249$_#U*W!TJ@_\$1J^9#]9MFNW*WV#ZH6:
M.LQFU*G"<,&2[>N^G[*?Z^=0S8FY1$PX[%>(V,HE\DE5VAP+'X4-QH2.A2Q,
MRMT:"TN,0.KN(-:9@5GPMY%K."UA]S"5BJZ$,&$8PQ690>VPE'LYGLQ3> (U
MZ\"_!4RT'?XOO *[2IB&QVNF*&G2%3? :'Z1\3U%5IQ=.@3K8I_3WIV#Y"K*
M3?[.BVS^',B?P8IM?A,'W?P;KWGKKTGRH?4B[K'3^C,W)&C^L2P"8AIIC1;.
M,(J)_06LIGR&U,V3=(F?.A]2(CPY8QHR-MTKY VB%J6(%9N71+%J*(W/8Y!!
M;<X9K/FZ\)M1BQ:[\K>#SF2GHM?,Z00.GW.H>-N)K]K]Z\PE'9N!TB(EZ7S#
M*C;NI(:=R-=I8>1( )T6HS,=-;_H#BB5MK;$R^V-B)Q1[N!1U7AAG&FCG&+\
M)W=^I>_!*H!]2$$&AQC8DE6Y#1B8ACV9$)%O((WAS\2MQ4=3?P<,2A 4BQF!
M]1:S9VZ*V"QI_37CKO9/FS/ AKT)D0KAA89]?)B&&_X#&]3CK)+R',,S08$4
MY^=)5BSIIZU'E7"D2QJ_JG)X>+$@BOF<^8DK(=HB14(>0>\S<"K8O'%B@C6O
MJC).LKU?XT5<!;!1>"\2I[K2!Q9NVV#SSJ>-#>,;DY;+>SE%->"*62QYI 0B
M9C0F]6J8:2E 0CV-27907(*.2\'PH5^KW!")/VS]TN%.C)?(CHT->XGVOZ];
M7-2.S3@]S=!/G*0U]?C$OE(IOLU"E=#2(;.AD-<E'J4@#IG.*[P8M&X5:'ME
M&6+_J':*^=;/B4R\8(W](Q(>P3%D=8RF6@9ZAR4@ZE$VM<M;^N.-K1G_+R[*
M-JNWMS\Z_+PRL192=D7<V%:.=#>X;&/!5SN-R1+WCXX$YTTLYI.'CYYLD^*Y
M@4YBU)$OG1?%=! 5LBB\"M1?-6,^/OR;AK.=J]&H2PKMMQM^4FQ^GI"J14+
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MY4N?J:73YSC=VX]F8%[IX2ZOU)M7>O+UYY6^\!&A_[$-VAY=8X.V#2C5@1/
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M%E6:TDAE5]]4'[Y%H^F&]*\IG1UM==KOO"_R"_A?99Q]ZUY(EU**0KIADFD
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M)I7[@?$,^H;(&U8FBIK%%Y8IHQ9K^%55QDE&2[PZ0Y/Z\ ':=OM''4JNQ>4
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M//(' >KQZ/'A4PY#18%$!I[A?Y$#YK!IT/MP=&ZQB@-0EP8]/8  Z<?14U!
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MX^CQHX>-K%KE@I0CT.+'T<.C!]&CHR/?9&M\S^6D:=B6X!:SN?O]P>C1HTB
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M[*+JT;!T,;<M3*K#[. \36]_X8?8E*?F[Q<VV6RQ,S9B[YD:3LQGXP3":YV
MWU! (*7-,?QX_6+%_XMRLXV [>V/#M=*>4VXB FXVTNLRLG/_ON[_>^N.L2U
M(7(3N$=^4<*![R\_/OT.W(AI/?_O[P[V]W\ O5&7^G)L:86)99T@//L[4)OU
M5+] /]0S](^?NC[1N3]Y^.@)3+Z>NM_J5%PG?E/I,BG*,[@-_^:02SC@_[0S
M?.3);W>;7N%E52N 4XP(J"E*QCH1**R./V!"<- H"%U>T7W&CI[FC,FF^)MZ
MTYN<LHBO!TU#;P1A7F3M:^-JT@=#AN$U?3?\,J9/Q)K5T38SQ1)<)#1J&J2X
M@X:Q+8%N>!4"W6'2<6TDNUW$2(.&LHZ0UX5&.[O$[!85;R4OC-XUEN5HF("
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MCGTB2D&?&6/,J4V>PB* O9#,9J!]#=4K<3,-M/.LA#8L4/2_I4\V*&@"V,W
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M1:3.4$R_D&:@27$V)HS)Q:2VA>'5RAWG1-R&=QC<&I919Q2^1.JHM(5*<S;
M.$M3"Z(8>*WFQ!E744=.4R EVD2IY,J5M#+V=LBDR=*:^C'#H#D"/#2?:\JP
M,&)W%I>TX/C'Q-\92V:%=0/ELB 9PA^N%)QHO\L:;*=\[K;RN0;:G*%ER(Y5
MZ*%-,:F;ED)Q[<2[K4%KF F:=[>8WU>(6SA''\XA-4;JMA?<JUJB0):TVZM7
ME!K$82/1B%'DU^^THN[.12'UE'F"V@H#H&+"?Q8>F-MY++L@\M>*@^]$I>^
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M5F]>I>WB2W?[,J:3A E,L(FF<8K=N+G@>Q@1>I&M%D0N;NE+B0$+% >XU@@
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M4PV-&C>91B"W=/@_ ]P/:I&TJW@WM%^;/<ABB5,4 =/W'1U*NL<]"8";E",
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MJ)>U<1I4H&; H' $@!2L;+R.HHAJL>0:.T[;M643T4L;T,#J/R>_L;1TU:\
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MN(N!9%U0*'ZMV3-B6T--5A2K>H=A-%69\#M;C=]Z8<EV7]/;PK"F5GKH=%F
M=IRRMZ1]"ET2HA7JR^IZA4]SW#)^)P^IV#J8K4BW7A+J;%J'9OPAW&M!UPA+
M^2-Y^:DACA1>FI=Y@D4\ ^\Q,@FZ]5?MI=C^#=N=(+U,*1\$GO$2FQ:MXS]5
MACTP\,NOYFF&I;,N6+]"BB:<E*&[*F ^NOGZ1DB[X]O<>$D*[S$8&Y&3(C.7
MQ2>=Z<LTS68S*LF,L>]10BU);)DY]?[@DF#GTG5[!C1]I$X8JT*=]DX@(.'
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M*<KE7%O' V9D@+WZ8E8XYD*][YR02!CVA3'O&\?=!OXMN?T&_Z"-<2.-+;P
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M0<Z_L%6A/0 VNDMDVA4$)E$E%%#12Z(\3B'. ^$C' =[#^9>8V-#..A!=54
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M9R:UE$B365(9!N J2;OQ!C#ZZ:+(J!LUG^R R=L%-7Z_'84+@X*> !,F=#\
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M:NMALB2Q+7/[?%JQUO%.<AERT'CF+)_ .NDWRY(QC@N-E-+!-(GHKUE] )U
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M)97M#>)Q,3;$%,W.O60?CR2]4DCY04QC]-]@&^=(?(@L[GK;Q!^I0&L9,NT
M_?UCAHQ1>M/IHR%?%/$E/VNR&#,_R%1;92E*@R6[FBTR9FV!AIH?\9YR,9+
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M..,N]]>4 _?48>"DGTNGCB+2HD$6''5J3?RNM4@9Y^F;*=5Z(=&$O>]@9XH
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MWIZ)279IRFLAMO>0I'_!F9#7U>0 #7KWKQ%XRC6W_A#C8S'[%.A)TZ$H$:A
M+%6,T4AW7FEJIW?)M4KS.0X#;>8*W*7+9.R.M%3%=3+F)I!, Y5GV&W O<S!
MHD=H[^IEB*E+<B!5*>.K1$V;&78)8MD,T!2PI^6OX9O_BF?S9R?PZFOMY=!
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M(^0<N+HX_[___.YUPPF"$9RF!0W#(C"1OM5M!Z4X[DVA]UT*,A$O89SP[]>
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MZ?V?:2]/OU5!?@NT,S<^C &C#P638U#)D6G^*]UQ.B 8JZD]],E$PV%.3&R
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ML$8SVMB2,T"DN*(S4J?2\CG X13(G5!ZE@E*]16;*A7F1IA$;BN^WLZY_'K
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M#;L N_?>K]!1@C1.N/I/><3J'[!>HF3H)_[P677P&GRPAZ_JJJC71&IYG]>
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MGL\T58U?9;ES:<;P*0+ECDT]*33*;VE6B(N1TXXFV&IK@CBBHVWKT6*Z<>6
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M/TY-ZKPXT *,:@4XT22O*QARGZ%IYES(B*"F&D/0NF[GD4"9SX+&)>!)Y [
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M(3,\+HD9#O::!2_DB3&1+ND*CO#P!,U(QUF0S_"XE]KZ;5?ZL![L>(W'",&
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M"/O6S8-<WB!-V#E3$URD+IK0ETM# ;L.)F7*5-]"'X,!H$NROG6=Y62=Q^8
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MEHI+&:'#D@[*)ZYEWY/2,_ZRL!."( %G,BRD_0I^1C9H'!5Z^XD1I RA52G
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M<TN\;;<^F&-B/"3RNE?Z$5?A+-;2\T$C<2X67MT@[:UGQDN%9,5V<A"76T,
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MEVCI@==W59\-1\4.*+?6()+4$GHF5BET8FRA4%-G&BSPW%,0#Y;9"ON]V7+
M(GX/G\&'9@[3/F$OUJ.GA3(AB\UX HR@$#OH[>(?1I 4,1,Y6>*[_!WQ +W/
MQ#%I=&+*^!NJ*+"D:Z:P_-YO*T2?X)BI[ERFZM1NQ9;'@OX<RM*I=LV^# &@
M5$D<) F'M\?P7[7JDEGE7)V4'V12(+5ZE 8:5$K-Z-3(5OQ$S]-41@] [/)=
M(T^J-MJQ1]R$-\'TR)6Y'V2UQW/3U0%=0$!28?=Z-:(%3>BM7P7(LC$1:24/
M^3&'V?[R.Q9QN+N-6B9\J"PWZ5HG;*8)2B..,:"V;*5&5GYB^]'7V\K$P2U2
MMPO'Y!5^'NH5$YT;,O<RXTR';;(<CS?R<KZ,!159YGZ00G@8Z8.'F=3XXN*+
M1[/'CYX^]E20>-_%*<OQ=X-U591615SFUL66I23DB(<_3AW4J(R"D:2CW-[>
MEPR4#R'ZK E4(8FP=U8R0D&%O^]Z:GH$V^Y0TK%R'&>5AT\ O$"AY5(C;M,X
M,M[+>JMAD&6],M4LXN07&="]PC*V8*4%M8GQDZBI&,66.V69^,&M!@P,U:$>
MZ8"0CN)Y1L'@$L@2#4;''X..^=_<;5!$*WTV&FOJX[/Z%#!MT%V+N./+*=[$
MZM'\D;V18)@#D]?8G<,058K'MT,P=H"/A3BC;%L05>J2+I4[D/LR%CGB&C5Q
MGX*-S?HJPFU[RS[9=+R?6(C0;G8=I'FO2C;NY2\Q+W89A'CA0CQ^+TR(EJ"L
M#;8R1ZWI?@&@(CN_"S';-E H09$K05T?EWETR!Q2,!BVH$OR7(Z"[.Y'8D;&
M)HL1I*>.*31J=@]/]X.C$H805Q9GAB6"ON997%#W8\]Q)%%OC6U[QG%D[1X&
M0.<AZI^/P^E\><+I',?I?'/"Z?RKWA*.ZM>.%)_?M>V;R<]*#7"RR?X.-MG
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MJ:V9BN9 CVQ4D?>C4?BG731_9>X<WC&#I[OK#0G%PZP)@O3[%VM@W&JW$L8
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M8+\N@DN4210<4V4;\"'#8Q?O8V<UWG/99Z2+1?$_43'7 SR[ZXVBNC"P+"D
M=8C6\4%4VU,3C+/>:4>]N=6F8YY71JX0M;LJ&QV_4T)P4_-]!@THG]>;<(C3
M]409?)'^W,@&Z>I3K*>9X2G/O,+K$B&=[*5?FW93-\GYT:V,Q9(+5UQ/OK#+
MPWA>\D-JV$5Z?!ZFT'G( O'5+7+W!<*<+]0U4Y!'BBLP(BN3@N^\WEU%VDH
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M2FST4%OS5*"IZ[\R&[,\_%:$^HK3'ZBX I?5/Q4L^Z]SU-*>8ZPXCV*.= F
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M((C8]E@>OV=E)?SN!$=#*T4=CYES!I2QO<)VR-*@^B$ %V+J!7%H>PX3%P'
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M*0F$5B$[321M&GQ'L4!>\YJ VT3(GGD.J2"81%8GH:@=<UN<C+-,<Z]&B#Z
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MPYJ3X=Q&F<**R!0F3XV#%:N.#LG./93!>%GJAUNA1?(Z8G&MQ#&A.@^HJ<#
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M,JO GQ6Z;GIH^^%K#DO,\X([I31?H2E=GSYUER^25KOR1 ).8'S*--AM[5+
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M;J8'+DHO,ATV"3QXJ=+4F+'4I!.[.3'%>.STCK5M/85_G,J93=EQSC?0;5Y
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MSWT;Z20"/B2LC#5I&_5XL,9-M$;>0.(S8>V:)T1#6P;<"%PB21[3'@_*LHN
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M9\S'YM8:1WR]@0%64D$/$ZS82S+B"HZ-1H$-YT>@!=E$-H1'R"="%B;_OM%
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M^XI ?>&B)%I&B=9XV6!=,&90&M,\'WOH8"NFY0MC#>38WAYETIB0=H@$$JI
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MHR.L:7 ;[0I:D,ERB00W!)O0O4>:O.U(R*/IO<!\W&08Q'D-+P$W>L3>&K)
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M1J!*MG_ .YCBN.,2[-44O(3RIV]%3N@2!PV?II+ ^.\?#G[XVBFLO1HLDO<
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MM\.#@U.?2(*#,Q11C;_$FATVMJ6C..!*LVJE&$^CG!.86E0C3(.@2G;YQGY
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MA<4[E= H+A4RR1 G.*SHT>#)/M)UH>;.JD"E$KDF41ZK-%YJQW"$]R0FD$!
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MHT*33LM<9AZXWJV= #8WQ2G!8Z:ZN9R\."XLBA/TU^=%BAE"MH75A'..)@#
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M?6]IR 2:8]1=;J=D+ TOP8$R_J:TK7%J)K4=FO@L<IBK9!P]K[FW3$*V96>
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M/Y3BDO3<9VD,IF\<MU6 VTTT;'M7-.,B^MWC*P)\4LG^>;G$Q(65ZP6)"-R
M4P:"I*W\W76B4:O,-^,B!H>YB&8+=@/9OGW/V[WG5H8WXR*ZG1:]8[/;7OA^
MRCF :X'QJN"R?>1M/?^QW<1A^&VSQ79%3G#K:;L[4C-M97<S;F)4VZZGN:]Z
M=]G]^&7]ORF'FU%IU%9SE_;^M-7<PQT!F]MZ_N=& ?TZU\+1E?/7J"ZE3+^V
MAK\MNU9:E3/J;PN"WM;PM\1T!S%->TT'A/AQ:_C;"K@=V$C;\F87E:AQM03/
MFW :UD2E;7ES3+=U["UO<A/3OQ^A3.B/B[>V60'TQ$4O53XHIH8F^S+;@VD+
MA=I:DQUR6+IU&>EMH5#S+Z_?%@IM7'!;*+1['*T-:#;C(OIMVX&-:V\S%NXS
M4=?I#.JLK?:)/W'^<"V@3W.?>$%F/T T)V$$RGU+(IN?ZX$*1MN;*$XT;>M[
M-JZ]K=Q]E&#E<-IV!VK*70RFS[8_T"-G#+95 -M-=* DU?8B2GK5Z##E&$<C
MSMLROGN$,=O'W8B;Z(X.<Q/-EMMM ?ZCT=>!L![:FRCQW"/TH#6AZJ<:?8?6
M<1<"CYJNK05YLEJ0VC:U;3G0#T("76=0:SJV%4%M1=!S+^(8.IU^TXLX6F(Z
M&F*:CIM>7O8D%4&'+O[99T_&TF3_Z_34?N\)?_&+_<6]!"J[$/].!5C!<,F=
M\6O[OUT_A7]W[=-3^4UZ4OQE^!^U5E[!:1*NX<,]) [Y&T4R(_S=%NGRA=T'
M8;1R_:T.H2H_WUQ6IV)5'6(XQB&H[;^VO]VN8>/GD3OSYJ_M3^Y*\!%]"O$L
MNM..^;6?U??HG/"4]0G5G1CU@CN=B648P<AK.GQSN:.*Y>+)FF=DW'M&5K63
MF^O%G61WVO!VH&IGLU\/\F@>L/(WX6KM1EX<!E:XI!: M\*-N(V9K0JYL(C+
MQN(<[$Y[QV=Z#CNF>+#8^\[]T6+Y<=40#3\Z4,-EG[+*G^I7'VO3#_8YM+C]
M*N+43V*DC,\,'!8&3]'4MBUG_=&K$H^PG)5(E.Y4H%9P$[GKFK-K8"'<\Z:F
MAE5-MC6NQW1;=2;G4;_WW,3T;Z/PM4I[1[&\K8![B-[A8?<\6N4=_ZEHL.?E
M=!)U7<=? ?J<2F,WO)[F>+IW*9M]4*[.M0C2MB3VT1(_)^.ZB%M;%-OXZ^LZ
M_4%M66R5K&UK96G!;\(X01EX&88@#$'A6;3))QLG&DT.4Z'9WD0I0V(WY;JY
MK_Q)4WS_'H5Q;*^C<.FU5?%WJ03=:9NZWXR[Z#J=7BUFR7$]]Z?HQA,+-YI?
M<45>6["S.[&-!FWCCF;<!=AEG3J-Z\@>_I/*^0O7%XRAM2*L#"^X;"GMCE??
M-O9HRET,ZS&N]OSF_Q:GZU]?=4]@>OC'T8G^#ZNUZT4D[,&J]X+$#2X]#$^[
M<2Q:A?].);.%R6G(79RV,G]WVUX$(I) '.YBY05>G&#>S;5H-?^'IYRW'."I
M[Z(^8[O5 C8N_[-NU.F'<?OF[_#H.Y-:.-SVS3_M78"0G!Q*\S]FR4^)V,&M
M!-V*[1@A<-$"P/<O*,MESA^A1;CS.2P5@;67862[B2W^G7K)K6,'K8UPES^J
MA0%HR$UT.[7Y&L?%*?:O#[SW$/K# ]- V@'V*R\ AB!.VB=_]T2ONDYW] 20
M$R?M/6R^AR%H:G5(Y?M^\R=/H!BT F.O]+/U1*WT/O!EM *\L.!/(FE-^6U<
M1I,V/:\A=X&HQFV"WOV?.ICE2>3-4JXN34+[*O07(B);/HP6H-%';,R3K=]R
MAKLX0[<V7;3E#"UG**&N/--R]%VWL1%;I%#"7EV8OH'CPMB5;:J!OY8K1CI>
M\-//%94DG;,> =D\&I'(@LO8^TOP2?TD(T%WO0N]^L>;^*N8^VX<>TM/++:I
M:]3_0;_N75@;NKLB")<Y7(WK!;8[3[QK+_%@E7,WBF!:.TP3>W9K_P,(*D4,
MAYW60:U,-\."G-G?KKP8%J.V.G=Q&GL>1KS &,@LN4(']@I^O8YPC7-QGV5X
MP0+N*+K%'<]$D@C$PESZ8I[(C'@*G;/TG5.B/'YK#9>#U3%K$+-8UK@XL]_#
M\2[3"/%S=US'$A%_:'^1N'11CE]F1^O8L1 V>O%[G=<:<O\SO)MK#VCF]-3^
M3)"]7Z+P,G)7,?[F?/[OU(N]G6\&U @]+\PXF/1>T\3=UV<Y@4/\,<\<CY<W
M[G/),S7VZ9]" --,HE3\Q$ HJE)389\T8EE%@)G'7U0%<WP("%EN Q=S[V+M
M1G,5\K(B><J:]6U&#W)L=R5C8, ,7DP&'5T4C@C9\JWCZW3MA9A'PHTIH/:B
MZW3[/>.S,-MP_-+A^%H$;!J'ZV+N@O[0=DLB1BBRR3SD.!X<*="]O4C)!@@5
MD([KVPL/L;U3GY@UG-<<6*2;8M-+F,K"M\V/FW(9OGTT4QEF$:Z*F"#<QVH=
M1CS+.L6TP:4/?,=>1N&*%EUNN7>VQ_>U3YK9.W,X+,%O$K(%<J=JYUJ"#T!.
MY2A^6*3X;G=0)OG^8%PF^4T*"!.\GJN*X'$(&=Q6Q \KQ-_>3> 6!;=!3OL^
M+P.T #X+M7"<P1<DYF'3RS"-U//DC_9:2G\\>5-5:MP*Q/WQAWGIO.\G&ONC
MT;:B<5!@$[W)2\<R']N+86>R![&8Y#Z JC6SQO;Y-IP0=Q!9HTE_6X'5'W6+
MXJI7),1^KT(_:X75PRRUQLN@?/5[*WV:+WT&X\&6TF<Z[>1?_:@D?;K.8#1H
MY<_AGVY32'$GDZD[K5>$2B93=YR705;>9)+DV.D-]R*%YL]1"C77+?A3Q9@;
MH><G+?1\/?1\MX6>/R+:WRN .,&86,@<WQHP)N]T,>/>P<0?65 UZMX.N+<*
M9^8=D#7W=>MWMQ79HXZ5TQXG16D]GG3OISK>*:VS#Z#J:! ]+/=T[GL!!LWA
MF-.%AV<(DC>QL;X'.+YWC44\RE6_3N&;<D.1>P,7#KS:<_UC4D3;)_+@)[*#
M5DM01W<&O$8]>A*#;M&@(G2>'117/7!$S2'$PG@01,5NP8XRMKS&# %^"Y9\
M"WKK\%2OQ,JCV+Y\GJM4-;G4YX-_H6RYTYF+<3+<"OR%P_'94!Q+T\>$NWO1
M[9B,Y$77Y"OT5%_T\W9JO!:82B'\6V>;) C[59[7=$QGUXO>Q)R=INN-:N>S
M[IZO=W)X9U&C'OJ^=!@)R4 D<IZ'9#@J+<90@1NWMA*GO+P;!P->6>+Z A^2
M,^KO&JI'-2//)'N3:=[YU.V4>>6T=T\-0D]UXYHJ1#%#N+BF8<9$D"=XE?U_
MR[U_F<,4!NL;&T2&5LX*L)="Q&9.F9'6%"Z7L4AP$7 >E$Y6\MEW!KGQT4<+
MB^)4!Y)X'O!_7#U.<Y918H,(L;GLK4EZS$ZODP!9=G*1]>_P$N<D-S[445'1
M'U8G[SRZ=J/>HZ7>8_5SO*?:PJ%;X]&2VC":/$!K*&HIU*"X.$&__P ]Z-CT
MDF?2JHW (JT<6*2!&'4$ZLESYKS 6:RXC.:9\0?YK'9RC Q[)B/(VQX]@VDL
MTDA%#V!\:Y.B4F3T]L9%:PY/L)L[<GAKHR=GW!L4=+'^\&6!Q??OE:I6L2-+
M[P@GB#Q8P\KU N#XL!1W024/,:\2Q4&X"F7Z9B1FE-L>5NE29T]&BDW1^/?%
MVC) 3*L2$+-E;L>YMY):Z6U$/LTQG,Y@-_6NI%*6HKWFB'FK+_#\^P1V:S5(
MF#JW45I+?J_*!K.RS 3*Z)9==;599G,:.!E<<$ 8'K_Q?%_)$Y87%1O<ZL@R
M59&R@SNM\K>_#>P6>YZVL>?ZV'.OC3W_6&_G81O00)O6[X3.<03:Q%%Y<L,<
MD.G6SEETD[[H.\/>N,;(@3LO#$T.4V<Z*ML%UF8/K5-2!X:C0B)B=_KRZ13Z
M5K5\=-6RA@HW:XQ$@X0MNW5AX6#,<=8NYAZX<8%BB\O [Q!>ZEY<E>645B,O
MH2KZW.IN!]B !G:T9#21M/D/A.UXQ-MZLGLY()?AJQ-6SLW/J)SP\(/8XZ3E
M2%R#LLZ^?OAQ(68)?"I.HA1?GP%*@#"^2S ,;?R\<'0@SHOC%"?*7&\5P]"K
MGKG!GRJZ]O0D<PQZB16)>7@9>']A6@C?G[PRPE'=6C\A+:$^,ZT0L3)"+*9-
MG5^ +,"K$ 9W!9C?Y\?Q8N7 E!EJ\RLWN,S<S!F-6=*A<.-&D8NTB*0F*'I+
M4Z"T<219@]TF@*!)M!"=+<0ZC-'MP(@;;A!S!%N1+<:);[/%9:\D$OGU6;7K
M4PZ/(CCV4J/ALFNH#28?S=[J'R)>IZ+@DO^JY_2ZTUU=?@4%K#1-N+1>C)U)
M5?+(#OH7+*\T\E;^-:6X6?G76M3;RD^B%*>1[]?V/7?F^1X\N^=)/#_NP]@Q
M0U2Z?(>FY5+[&A2B.+^S3C>+O5D/?0X[+3NS9/+BX1X/HD) M"KT4V_@&\9K
M+)3=D;@",L#\H-;)M@\G&T7&.'RM3_H>[K:SL0W7ZU.^W\9P6>=L/,P^BC 1
MPU*NY-FTKSZRK2+;S--NI=4V'K8[27 +7QN!/V\-$>'TID60B-X8R+ @YUX0
M6.F#:G2W]; 5U<!M$O*.3C(IJCX^D?2[]^_46X!V3+Z2-^[:0Y+]*N(PC>:8
M)G=\6WH.:H("QSP*M: 5!E7"P$,W*+J"\!]K\G02ED!GP-ZCY KFN[RJ8OQ*
MD-A7P+>7*3%)'$GC)%*Y!'#5M>L#WR4<V1>CP=DP4RX4*U9^4LO 5Y?8ZK2*
M\[<7F&2M?%VJ/%-.JGY_9I^3@W7S6K'LY*RKUP"[G;OQ%19Z&6E$R/XC=X$"
M9"Z\:RSR@ 6\&!I(E?C-D!!A94>WV/@P?'9L9NW(C/,@":-;6>(1V(@0+1,2
M#7^)UKUP$?%5&"6GB8@*GKLS^P,+* 0[2615:C:<%&<@>PG<%YAGI$I5PS2)
M/=B89)T.7!G0XZT=A DB4JIRELC%;,HXG5]9V6!P7+@4!.A%8E&?36.;.]G!
M/</",J,.9T^#_)#&*N>2C]^ U@$[BW&1#I&0RL-WLDBQQ:)<%LAD\GH>!CR@
M?1.F_H+V@)F?L< BG>52S!.Q4+0L(O*QQNDL3H!B\/N+,)W!RF>(M$PN47;#
MD/,U1/TEQ<PNV[4O0UP%_&XNHJ#UTAQJ;^<Q,HE"%D#Q>8]Z@_(#!U;DIX3Y
M;+PJ](Q''M)(WBMN?$2_N=95_<1[P^Q[XC+ $80?WJB 6UQV&^$5VTOX3/Q+
M,_?RG.]IQSX(,F<1QO#==2Q^L=6_"CT-MM]1=?>#;5K.;&XGH[L*J$O(-R"0
M>\N2"3'O4G82N!'8J0.G\1>Y[^OY8-=XI__QTZAX,K79G!5C5V5IHEZ7=]?\
M;1;]_*OFFH^RCZV[^C3AB'N/?\3H?GN<@SR2W?:/B&SN?V);GL<KT&M!F0"]
MX62WN8]CD8]\28_8#>9OWJ_DFV/#BNR]/R[>GK +(C;;Q&S+=,OME7XN?GW/
M'<RDU!N/7M:TY,&^9*3A4(L!STR@S9K&E-HY25GZLIJLBI^JZN)33;?R*]/"
M5V1KJE<]I]<;U2ZF:IH2=1YJZ7VXI!*;VV;I>^Y@6</M-AW.MB=2<0QW?[!J
MP 8MYNGZ#99?Z#H*KSWT2LUN[5?RN9Y(N('J][JG@\,V;XVXP5==IS/NWKV8
M]BDU<#%->4J9$_+)'E"_VVG(Q?6<27>+!U1U;WMJK-CZ0W;SAVPJ"NUVVJ+0
M^J+0?EL4>E3O[P@]?WMJVUMAI%=Z3![O+NXP=+?R&FS%/>Z[7A69I57VNT[-
MR6WO6#I$E_(?A7!V=#?ME7#8_=@@8FEO:_-MU?48/Y:GG9N8_OV+C<D*WEQZ
M!Y^(9U>Y=>^?M>7]^L?%6]OTGU;Y30]Q\H_K.'U@H_K/E=[52GHV/)7[H(AM
M7)#[86N;/:7WGO,59@J/[SK,1]UF7?OX]NIVO+JQ,^T>\NH>T3/XR">_3P)Z
M*JIY3%+9>J)];*B]C,9<QM-YCQ^X]@^5\9F6K#:)@Z[3[4SW3U9%\=W>0TDL
M=R:#I[Z'5A8?"WVTLKB]C*.2Q>\K0[TM66V8:.@,II/VB3?B+KI=9]SI'-T3
MWR)UIJ6>9RT@VLMHT&4<C;3&;"VSARIF;K5D=9?E_"3BNK6<[[B'OM/O= ]E
M.3]E9MX19N'M'S7^W+ NC@"_HLFP5B $K#OK4Q@IB*I#=F_YJ7&!"$8BJ*V'
ML8SY)-:0T13O?HT_JUJ'JS\2]*F[P&-C3&"&@;2PA::7("X"02G!*:TR?#T#
M4I7;#V*7+X:/9$!5@B3*X>1I[(MB<U'5W],V^GOBE# VXCU8D5C!.E/\/]6=
M!UW=]%,.^$BVZN'Q1R;Z(.-7E#=IWX31G[AV!>10V;RFD\%@M#!AQ[.W'9XT
MA?1+;>L(%Q(50GJY7HS@(=CA#H/(51^N \>W[H#NRM;U%&CX3R1>FP#%OK>N
M<"K6UDK@/4A@LVBFJNJ,GVP5K-YN(O@%5749Z.B*5V3=K@L3;RM[*^M_*D<$
MP2S%<;ZY;P;>8FE0E[)L&AF'4"5%2Q@C><GYT4O"-W >_U,U="?#B:(-Y5GI
M XZ'KD]N>NL%2O C:PO1/S(X>2NNCV=OV]$8O7V*VV\OKCN308VX+E6EZSE-
M+=P<OP@3G0' Y2BS#O6LXJ7U0<$T.S[E!K(*)%[U4B?C@JKK!H75N'PFP:T"
M>A/,,]W$1F2UY+9BV(&Y*$OR%N I=%S<A#U1B&R);&Y+'27ME1>$$0\J^S;(
MT8NM(RN0]J>3H?EXGR.=U[UAZ]&V5U6^=]1'MAUK,%YV_3-=IQ$8J'%M.].*
MA^!,1@;6KU4<I22$JFS(8>Z)/\8CM:A7M2FEGXMV_3QM!IT3T-H,>[89J@KM
M)7)\W\14W,9BR"QWV50+/D*"*H.KQY\#6 <L82[$(BYCPN(G" I6N9FJ/5[8
MQ.@2762B4C2>:4#(5JL]GKWM1J&4!9/#W+T;O;Z.1(?.T.CG93&5VCM1:05"
M,<DN#5?\/.^LI4=%CYP)M M!]NH)<@J&SG"_!$D_O.@YX[&Q:!I8=:D2WT4T
M]YZ)BS6O*SV#[:#TM4B!OQ!S4.>)$+\H9?O\,A(4!#K$?I^-SO0YL#ZZMW9O
MK-ZKAIYV@P ^/\?6)8C&[B4$1DTENZ22)"'OR[7C[':T*>2JVW%PIOF5/?=#
M--="V<]1\P=ROKI6#/S&%_:5</WD:N[BRP[GTL"#?26IQ%AG*PD,(3*&+F&6
M2S<1H"EA5%)S#_0\K.&G[\![$@1.?]'MH&/%L1DXQ0:>D<[)9,0>I3K(Z;MS
MCBNZE_2_P"\8$A\T-!&9,1G0U&X)&<1PK%+G%^191+-?(N\:E_9%#4H8]\ $
M S%G?'?<>?W''<N G:=>F'V0X2.G"RPX#;QRVP#Y2UAV=@W ?>>RG=K9I&>O
M82OX,?L5K!0TX$ZG:_L"3P[^4!CJY,Q^Y\ZO+/I\Q51Y?A["G7Y6G0XNB$_C
M'(5?H>EZ[?JPNQ-VXMZ$=A &I]B;@$Y3LVX!4ROVC'^A_F\5D^"O86_#L?V*
M*,+F[C^PHK'3F?:<'IR6;+R 2X_\6PI.&YU&3SA.IV>^<J\%CH/>.C+HKUG$
MR?AS3B8MX,;.[$\A2LH4IN4KN&%8?M6_=!-%G(M++]8-8-Z$T?J,G)K4"N'[
MW$^I>U&1+KW VIZ.&@KS?M22Z=D*VM]% H2?R=;#;;15[A^Z-Q#MIO\B+]L7
M,DQ1*5M-(0^LT&>BT"*=/9;X$WHO5R%V4B$IF5P!<X4%X+?@@XM?[%?>B95K
MZYR$\$OW!)A;(N0BD-,"2R=>A@R5>+ID_45FS>J[H4&,<3+CY^EK6MVKV0DO
M07)25O,M%H<T!@L-E'ML57"GP%$_^Y4<R?-.V#FT2<NA?C!BZ0-+A@,+X$JJ
M1? $A[>V%L&.=%U3YYM<@YV"PF-$3WFJ+I@]H]&9_3FPS]-+(#R[.U5DT'=Z
M70R:=533[2I#BH38,L5.1^KX%JQ<!"%>EZ]_;>R0MZ-/4.E^VO^.>PAR)IVQ
MEGR?I-8BV]=V=@-S[+9@CO5@CH,6S+%]7H^W'1U^M,[G8"G%W >LRM'19)="
MD]<&.M&%6"?LI.P.2HI13O/)1X0KK\1!.8_2C#0 EG9H+L]EB[K<$/_G?T\&
MD]YKCBT[EG06_!914E6VA!@+*;SX"KZN?_DI!1-Y+E*JF(+S<6&N$&5S>!/
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MD%P26!R6D*I.FA%[517>#GZK."VU] KITP0[$20^<[6 U"GX4QP"&T4>!H,
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M6#MBK]"LDW>H-J[W3./G![;^CHT]F&W+-6&G"SIO&D?5B!7A'X'80G;7PHA
MW?=> GJMK0KD#O3P,Y&@54H5+FBHR5IM7B#KNHMT7IG-;Y [OX*4=?,,TL4L
M0_CTX>+G/\XNSF M/D*CF7#@1C_%F!IBIW',5B,C2V4E^JK)'UKJEY&[OMJ?
M5/MAI,S[,!+ +"V&:H*'_DY=3=-%23.C_IE\,)/Y44FS<K&I+'B*<=@B+-K2
M3ZGFC%L*R I1R<VQZI2:'NE79<M7-5=WF']>-2TW6#F-DQQSY2CEOU-O8;J\
M)&>UC<D46#(E&N6_K[O+<TPL"%?HMA*E$<ZL-W)+\,59"")C^)(&[79>JD=/
MGW]+G_\9MIO?F0P:+@0#U/VLD>I*5T!"%(UZC)TC(K0O6*H&=O>E8\D&V<!Y
M_5M#!K$6?>5A'([B?4OODKQGJOX(_0S2$7%-TEV6#2F&2+9"!FEI0HC($#_&
M-*2=@4>'6S1/3!\EQ?RP-C#B *K:<P:?!/>O!!@Y2C $P?Q;E2=K-DW%PN8Y
MFN1V9OV&(H>BW0JOFI(.NI.*Y(9E&LP5!(BB/B_.KHZO^H"0 /NH,WR&3.OA
MVK#6,JX$PIV2ALJRI8HO@6RIU[OP>1EP\MS]+!L%)R#7=08KR9!R\DU8IOJ<
M*;Z:_,E"SG%8^8CR;%-#F$7 5[QU%NY'!SBOQ1,Z-BZ]\7 P5ZKWG>(2[@);
MH5 <?AV%";)XO54-R*;>ME;>N>XXU@ ZN3=:(IE#A)F;ZPL\>F<F-:8Z_0V]
M6!;V[0$A0#??');1NC/OQR>5Y+2PC5%X*X19+R1K%5190\0J%.;;)#Y[&68B
M$$N/NVG<N(S00;3"'L^Y02O89(F^1M:X;/UHPEO*CFC6-UDC16Y(DZ?2%[-U
MYL>3E=%@G"91*K%#XBPHJ3VPQ.&S\*3JF%7^NB4_3-T4N,M[(I/-C.]3*I1N
M)9#&LM\!F/F(>I3!=Z)_@[NE+X3/H] _<0"]-J-MF\/S<DHAW4A . TK.5Z&
MU,!J' QP':+K%_.:G.R7&,Y"&C%^!<0+EQG(OD\N)MZ1=-+F/XJ;-@IZ='O#
M"(5^-U<B_W:V>2P;8^1)>"F(*<C0ZCR,T$P).2M;FSJLNEBRAY$*KZH8IZ=P
ME^3O2)5"SY+,-%0,!UL?44[N7.(>YAM^<9ZM.58D?'&-X.<&&XM@&0:KPH\I
M=N78,GO\OP5G.GZA]<G@[.4EOJY$5Y.8!Z/!TK<^6!D-QAY%<#$8F$77:AAI
MGD(;Y+3)\I)4'Y58(C4B[CCN)MMZX?-7A":\IH01$SM#,WH*0>%W5@R5:R*^
M&-#NBB]K?ZE"@P&U$9VN*I2MSH@ L"@AN$P[N3VP3JN Z3<>=M:M69X>7S4>
M'L*^\9T]S\?\G!F5MM%BX;-(HKX4F*AY>C&_"@EDF^CO-"<V.477$+Y&=@1G
M$DM7U@V0M$RVKQQ'=]%6S0PLKAY1TO67YWGN!4ODF6[QG=1S+*7GV+>8CXI[
MYMV?:KZ54X?X8P89Y%2SDJ?)<,,907;N&8$CN[*2"%NS23><GFGMWF)S\P(V
M>S:BSX;ZVO6D3U9]DY5S8L=!F ,)9N E+$%&/*7\=[S ,LHEGNW%_P"T_=]:
MQ<\V>VKER#FS G+T6^5?TNW8[FAGH(*S4OOZY,8+]]\M'1WQ%C&69BU1E<P9
M?091$8\DL[#\L1QA:=?ZMXAL[5O)1^=I="VXOP_U+B0U7W<V9+&L=5*%K$ =
MFL&8;HGKB+?X)KM,"R_3I*KSH'#U=O'J[57**:R<B2&+A*LL'17OTR:?'#,O
MFKFOBB5A1I/3:SD(?XM[MY'[A@7V3(!T]230ANJ<1JX83$E9%OJO80FCG@.-
M.1??A@]?2["O-N=XX&^E[]W223644**J$D'>^]Q4VL42.<.T#>FA8>Y".,-S
MP<HT/XU)M0@RIJ^7H);?/J CWB)YVRT2ND6.;,CC@NO1+7:(]9$V&4H3L\>Q
M5E)#RFXK^6-+AH;I!; '](F.'4%&BF?^H,C@WV::=JH"%EL5*P[;8L7Z8L5)
M6ZSXA*FI]#\@;A:PZ?_7Z0XP(NK^6KWL&:;JW?<],BP^4-TO=KK&%!$02%6T
M]1!H\#^^??YX_C^2"5U8'\\_G?_]W<=WG[ZI7]EO/UR\^>/BXL/G3_;YI[?P
MW_/?_WGQX<+^_-Y^_^'3^:<W'\Y_M]]\_O3VPS?UF:_O+O[X_1M]Y/.7=U_/
M\0\73RLTFBCJJL38OG?RSS"UXBO*CHH((SF7/RF3+!5V N.Q>^3[E?ULL_R>
M7? 6"C&+PEA6%4*'5BI5\W%0VM!/"(3O$MRH\&-QPX5?:/M0AFGX_38;XF=$
M:$2U+,WC/5#*;*:8>@'%/O OW)2T[A!0/W8]AB-!O^8I=J[D'A!ZT8R6(=M8
M4,:W8V.G#.I=KMLJ& [.L]+!2GV]HH##R/*2V2&A4>FQ$/$\\F8<,N)".=_#
M>.NMZF-5M^@LM78F@!#.[/<&++C%O5[G;LJA!;(2L%25@A^4@,++8S0.:24X
M-GR"8M2$QLUJ.#4(X$6C/PR(V5-SRMO&/^42?:G>1E" )PLAX5'U.J_1=-9+
MI>/KO:;<U-C^FC6L-XZWUWU]7_K9Y>D_B,<_VEO?+6S1C#5_OL:HH[@YO#WQ
M#.)%^TG,.I+)S<NK;XS&K,'BPF$W!?X34;03RPA\'U-"5A3AI#CLM;CRYK[D
MX/&:K#\WXL8X'^+(%0R#B+4_P26HL,2_>  %/VJ D9J==-3(5C;2JPPC +2^
MA8 -GG#\?9;&E&>LD+>9PW\3J]C5LH2"&&YY&UG6,QB=&.%%UTJ_HQ; O;VX
M#4IN@12KHP1&1CM-;@3*MYGL*8X;/9]3BN-_NM[2=>SS9>K#_WT2B1O<PC^^
MNG)J$*8!_NR!#A+8OXN_"(7N/+Y:A#(+YK]$E"+ TNK,4KMA/0)/'G>E%J'R
MEE2#8"_1;B<L$/(6'FX@=E1:_-_]< ;B7@WZ>[(XPV*B&Q@/_HI=WA?9%V\=
M^ZWK7X4K*_]YG3;A);00HIQAYV5EAZ?7>K)O=(>@@VP895(["AR+)?F)&O M
M 4?8'^AB'7L[>J_=[)G=!'9U</S9;?D&IO<@467M4\("T-PV*K&"3538  :8
MGP8-M&]0/X%/_0(<X01X2YR2]QZ#Y!E@6+$)=:;UY C*;'7$,';P2I>>[Z^,
M/FD@XA!=+,#75O1CK41TJ53X_&MZ#<OS3BS$"<,,96X3%8/^2?YCEPK[0IQB
M^ OL++,W^!7@MQ")#%C*J^%)N:>V-CX0Z,Y=H5<6/MDM?I(6 :M D#194.AC
M-25W+B-(15EQ9G>'3J?3P?_:KZA7U'>54/-BD"$N\H&S&LG<0"\$ALPU4^SC
MY-<GZ,Z[IO[EF#"%YXH\G2 IZ3J-E> R!K6KZ!JK@*%A9/$=P>9A,2NQ"I%/
MI]1"%:@3CCQQ.2M+8CF&B6<0F2LOSJ*+4WY&'-6K6#"N4=-AU:*[G=I5]\[&
MQJIQ,3 '3&+V[;)(O\X !A>V'Q*@1GZ2[2ZH <[U)^=;]8YN2A#_*M )!%>H
MP7<,J(L?YY1V"A%\#JQ/X;4D^9$J@U-O/8:196;41^: YYC[1X_E0B"KM\\7
MF-\!+S+WQ!K:Y+;)-_'!O(G<+>0T'F[S1[HZ>3PU6H>K;D;FJ/_7^1M'RF"J
MGUYDQ>8H&]B/XE)!^)G]'ICE*B2'@'8).58LA/(XJ+7\II"W2.'LOK;?*[A7
MZ68X;%G;C^0RP!H84 <"KJ(M^M*^9IK79ZUY;;M! C*;-V2?N]U-HY;^58+G
M-D%6/P>OSOVVL*E!O/2#:)3C&!3;K "1O0<Y%X@TJ>DCG^"/5_8YZ)C>W"5>
M^R[%AD;L)T&H9,-#PCV/Y4^>?7$E_A1^;+\"G>]$MD/%H*-#:9(9YJ!>61Y,
M62XCK"C2!%,AN1&"2N&=8L&X_>J/B[<G_&M<K&-46O'BW<"LY+2.^-[K2?>(
M-K&!>-$8S^"YI4VM-GO?(R.;?#MG0"T,/YGN9.5U)\ZTWY-KPBA'&B.];3=^
MR3($TV@\[19'VVZP$\=R,X0 >-&3EPX[TB(V<VF]P[XSZH[5(3YTO;VATQ^/
M[[E>JW"C][X8Y5+I<3&"B9*@J>?&U9 :KNJ:ZP6$ )<">[/6U!%#9Y>[N5&4
M(<V?7N=0ETC[Y(ABP5D<+'W.=I-X'._3"+D0:J$*D/^&O)YHA'A+X+!8B5B
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MI[!P[K<_:2PU**/L\ M\$\8)&M07J+\_>:96R_4U[ (;4)*'6I6MGXQHD<M
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M9.9[[LSS,>4,1/TJQ@1PSA_U7<PPC*^$T*G$?6?2Z>@ISNP&4*RQA*=])R0
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M%E&4-NIG&IK)-'/,)PUPN@UB,\WVLC"E=#2.V)!_#= )2[YYK6]&Q7=<W-A
MD&9S8=*4,7JE(G :F:$B:#W1=BU)FVUN%\PL<.ZT#DNILRJX7JNFL%"43V*4
M<J\AC9ASV;LH?,#+U!451P[^EN8KRP*0,(A3I6/@AP^JKGFQJ&=:%)H)/(A>
MVMJ\DBEJRP@"5:-%=1]N_YY%\:(M4KS1F%/O5)"C\/!:HC3X$&+JSC1D_3NJ
M'B/G+%66+=;1A],".L'X?QU,TO<2#Q-7\OM"X0@QNU0Z%D&'2TA'PGFQG82(
M^X")I)Z,CVY$7J/"5.QJ#'38>#_>Y6"P]T5,W[G!Z3O'400X-15NFI;8]_H8
MB8:(,Y3'8PNM-/L/DE Q<,#ZJC:L'_(-P3-T6R",0$]C;BZ'>G;FD:M!'=LY
M]=D G=8B.AI-?"9+;NXFON!@(N_LYO2D,K)H@52LNDG%*D_%:FU_*M:+&!GJ
M@9!E^]&>C/DUY#H"*T)2.1_!?US;Z_.#_E^MW@8.[WY^U:U^/;\^/;F]O+ZQ
MCB^^VI=G9^<GI]<W_ ?[YN3\YNKX^L0^N_SV[?+/\XM?[=O?3NWOI]>_GEYO
M?]GH-8-R(\7UA%,CL4]_LMX$;>E+B-=R'0DU^Z\>-R&P@DX+X%6+0ZY_"U>3
M"'H=)C+Z*3JL',O&GHZ5/(3V3F-7^A7Z15#D*G!(6C@*-Z'7@\0:,9FMAYG9
MH1OU<XU$Q!M% Q? J,VP]A,0Z(U&K.]1S\%Q!%%^L<_2]B/;3_89.H:3G\A.
M+2>BRD?UT+%2P+QU0L?^/9)<B0XY^!0U6UZL*65 7>C^@P(K*,A-ORA*DA0)
M:QTU;"R$Y;^*]*7 Q8USJ<?_E0M0'P]1D(QS,,G/"(4;Z#[2G7CJS_T\SJ>Z
M\TS&? /@#9^,1N[TO<#J7R^2.JG63"?L]29C>D+DYW@1MGF$SCVR^T>:Q*F<
MC2I78@ 7%=V-X!3SL&I&03H0E2<+G 0S.+N,!=:.MPM'NO=D>ST7*C5'U)>*
M6O/!3G:XR>E/R#Z,7&#Y]KT72G48.T")M*"1%_<Y6W/YKN)=2._8\?@K7&QZ
M]PBL!=[_+[X4^OH@_2/CF[5R+V6<!JE@.D%+G'J%,4QFC?F[8E$H \D.L4L^
M2AOK?J"(!MCK+CU#AKX\HZP^A8F./<BK@^0F/#2JLA8+_A7R7?%-8.,TCIDX
M%)TP12ZM=OQP@-4_?.=#K^OEQXND7A#''K ^^J1A@^#0A%9HDXB^Y[L/5$7D
MPDZPF10D8'-HJ5?AL) GEJB802*V@-.FN;KE^V)@]5_?U=XMOJT'KY\,X:NU
M]\KJZ'$^X8YCKFS+G]2?XK$+">YPC)^?WCTQK9UKY]-CV)^R;-26&K7W7(_M
M?OZ*XI6Q7SYT9PT2ET^]7WS<>-';Z^WWQ8HMW]'Q'6YFI=LHLM'$VITZ >8*
MHH&<AG?B7;4=FD9NS49*44):=-?=X:::TV@>.HUV>S=%7-$Y9IUMEN'RC"5H
MUKIT7TABB+.SUQ<^[I^4?Z<V\P_7C=RA?>P/O/_O12=M=IY\_//)T&,#V9.*
M,QZA\&L9XR\\W0QDWH8C_J9O[/[Q9>=L'#U]SC^NTDY<7[E"XH=C:L#/A=MO
MS.W_>\(E&$ZQ47K&TD"01_#ZB/BS4B.61:PST'D\\A+WT?Z3<;G]HL-U&O/0
MK>M!+7!A+NFT=KID#!Z/ BZOOW"U]F;H/K[LL/6G#RL-EM7A[GL8<TWRFMUS
MW?E%QVD=KNTX>:1\XV:N?>/UO9<=8 YF4GR #Z@&+3>0LG*=:PY?:[%BEM.^
MGD)?H2%N32LK7-'Z\+G@X_T&9J]/2V,2'25(56^Z28.56,X \>A[UU]T/D4B
M,^%EVU7=A2,RUF_&#"7I=\; 6-@GTD$JR9+(:P3;NOE*A.XK-R"M3._P\KH(
MA-GW:-_*"C@!/1V<4&<)+2FH9&L.L<3M:@@_'$_NH-*E46O41),N#-^*QKA*
MU,VW7US2^IL;4!/@6J.Q;_/=T[;E]O@;IK9'JN"4[Y?L8GV+_!*5+>_Z<9BZ
M@2Q\&[94[6GR.G5D9F"1ZEL.E4CKFMC?V&"@JIV^1"Y4GGY+^OOVSH4;]]U_
M?[3_=O;E>E>"SX5*(<[/N<UOZ<N<A /OI_TK-IFEQZ'4\:-]<G9RLSM]$-BT
M<("HDZ3+!3-.(N>SC"==R$&$WGER\H%J;BM:N*,WY,1G+A34]#G? .])P.SS
MH*<=[^3[Q===!TH^O-B^9;UA[OC?;T__3L>_ ??/61A"5_+L&C=_G'W=W;?.
M XZW>L?1CCL 0H+Y[!J)\W<%+@5/Z5VP>! ^:+  *NTAV3!%-B&1S;Y]!G33
MJ-7JJFM]O:V]TTI)431MXBIJ7\P(47XS2E8 "/V/.^)RI)_3W;T@U^1O+"Q1
M:*1B?X%<U:O0]9EG']]-^OPC2OVC V&&!^#P##OF8TD)A4,XYO!9OA7Q #8F
MUBD$1 !0Z9?]XWW8!K2]#T=>3[0D!FYU&MSYL,F3T/?9'4:I[>_[\@%U1MU'
M%@86/GX9A/9QS^TSOJ)\7L^,= .5Q-CEMX$\GK\''B3/B#3)[_ QM&&)Z%8$
M]K=O_.7I*(ZB=Q1TXS9R*B<JX'5[L?<?1N^<55.GR8ZLQ2#/1,">B[$+<,S8
MR3M= B$+3:-'>79OE4HCC;?74]Z79ZLI'TS;99ZHMMW?W >[RY('Q@\\M5Y&
M>%APHR1<J(\P/$1<)4T;#36_!(O"?@0IBHJ/BYU?\OV(H:E"*JF%.7>Y!R[A
M/VH26K%O:TH0_2>,O!'G"&J6.N[\R\3SD5WK+@09--+ER?$_K[]S;HV)&/:)
MZ/)TR9FZ_J4_CK_]3BS[R_ZO^^? F-/7[=2/.O7=S/>__'J^FSO6@QO/ M5O
M;M^-^+^@L_+S?E?,E,*YD.;?G1"W3!EB.D"@5C\"89\%*[)U_3L'684 IB!F
M]IB2#_5V*MWM603\'USQQUYD$;^_[#%@7+ Y?+'VGE;NO0?/?>\QIU1()K"_
MA7?08;LGH'$%\5(+308W>>[BYS'TJ>=J%;2D0KB?C_#'&^I=ID$>#H':%?]O
M4[Q>6"P63@KDPO39P)4*B90:$8-D; HR>(KN2,S%.2H3HLZ:%G5PGE2.D91!
M":<+.(=?LF1(1X38WV^<>#B#SDJKO[%H D,I1XXFX_JB-Z'L/ IC4[$[:L(L
MM9R4CB3RI,:B!-M-PC4L$ %J0IX0</--G:B@5)%RL4Q0STP/:YCTL/+TL/;V
MIX=MYN3E!4UUVC$Z-2WIU"2-B_XROYI4;K3?0,/445;=H'>1\3BE<5A9HU8W
M_47'9C"NR58:8GM-E9UED_#N#>F+]::3OI0^$F_.'@SDRQXPSY@K*S*'R+IV
M1]P.^I7#<S0)/,QA !Y,O9^$^A7F!Z1PHY6;A@EC8M^X&RPUF=Y$:A]F;?AO
M^]_V+^SS6^ +I'4XE@N93S@L[R%@HG%6/.ER2] #L2Z\!7]C#UX\Y"8<)LA#
MQH"4$==7O]JG0AS9-V'/8]!.]LJ-W']R-1$-Y8#3R)W'\OZ"J^M_7G(5[<J'
ME@N#1PLM9C"8[9V3/[BV=75[]@\Q,'!.Y\,T)*:USBF@?/%"R-#JA:2L>2/'
MHE?BB4_3WE]2S10=6_Q!,7!0: +]I2_LL_&$(WCD/M(K%0%(F:BTCR9I'] T
MX ';D^-*0V@^+ZN/0'<A4:\-+\6!!53] 3V]A0HKDJR+Z:V =DG+(#,UM<V+
MK-2<CJ!L\%$J_[%56M8DQQY*&:7C*XNZCW,/H'J57.^J,MEXW]("+LMFKIJ[
MD1,*UT?A-1ICH9)00'8D)SIJ:F)*A,@KH&:7L](AU0=QB@!OT6\A6G+9BXQ4
M0\;6V?7-_^XJIJA=)GEW8>74U685>-K$62[X/9%RHJF=1C*'LL4E9[(SG.E/
MP9G$X%Y="#6MK&>V5?"R+"=2RK4K0'7%8?K3<[G]WHTSKC)A@EY='/]]5[&+
MMF 7RFN=6=!""(7#D(M%+D%.R=;(6#MB@7I'VVF.>4WO\8QK.QSW>_R_G&OJ
MZ]4Z8CUM0U;NZ5-N^QQW(W?HCG22&7C12"TCC+":OBV1+PN9AN"@)LG(5'65
M6"8F8P-X4<KV!-,"0DWG\U2"ZRSD>*K"?J6"9Z>Y(Y+Y6$IYP:[@X.2([7G3
M/O"#@LR/O+93SYCEX!607J[O+CDA4'JGWR=S'?:IT?2O?MB%84VYJL!Y-[N?
MKBFZ=TL= ;,?'[P^L\ ISDC("3X)6EP$36E?M]QOTRAN09FH)6])PK2+"#/O
MJ='C)XKX7#&Y32G$F'$Z19' H^"%&I/7@BM8T H<B*1*EO:(Y6E.M$-A@.CK
M?Q$DC@R;ZLKKAT[Z6G!"BHZ$0N0+/PVW>63\*V7"G"G^':8.@%3FVW&[77YS
MR-GW=S?V6 2YUKK6<!H%_.OTC7_P5>[$&?C;^U3!"CUMM?U,70J++H5=>"F<
M% L.\/8\2Z<[HZV>B_MH(]?(1:PB5TH7E:XJJ]!5I;1P1'<&?/84^#)B8U53
M2M/DUK6%71:X:2=86X"(!Y&JQU&ZGT$3G&^E+U+W_)HFB0G0OG*PZ75Z$,A"
MID4+S0N+GC)%&*ERCX-A1$D9_'4^3$FS8:&="626UE5IX9YHS7L2%1U/SH<N
M*T6!%*2TUDNO\%ID,YEJL+1@#)L8Y 92GV-A3,"H_D)U%]8*8VQP7"\./16,
M? 84"VQ'T<9"-I_#L(?WT][I[.KE1_F*/3FQ?#'"+Z1ZK=0/*TNFM]873CT8
M\?28$?0XPWBGM;MH3MI<+UH,+0+"BXT>.%4DI,UDF4%6T)X$Q1V_D^ 4H@$*
M7#O(ALJ=A3:AY[$ZMG)0(( SN2V9<??SIE:MAFRY@5F<G2CAI3(,\ZF'5U@3
MMF :8ZLD43%M+NV+BY[@@/:!HQE;^"5-QR4XHK*Y&-T^%^0"BD6>(TYV^;Y6
MBVRI+S/D<:!Q$6'2K,OIJ\;Q%4+G=C4V*AE"T5F<N'><SKD2O- V<F6.955^
MLWQH;BQDR:N.]:A>X&CO!V/CCW8233AEG0!\[7/"8BHQ+%#TLXP#/M%H7B@W
M8JX9]D3$ 5IXA^AJ<;OI@#\:0(?WD;A><M2@N+^5\/]4 $$"#05XX(I'5A00
M,OC'62X_#S;:3V/C;:/AR7N2PQ!87H0A3:A*_*3RPGD*,1US3>:NON?O]&)A
M#3Q382G7G;$)&@DN*7D0=4J*T1_W,!&)5&:<!<U\&*.*=?'W-.1!3>_372!8
M^4Q_L<34\"CT%S^). "44CM3!E-Q1PNG4'ZNZ\87=SBK3!;&7"2("2I=5?;$
M[<$^&T/7R:#'JN0M6=H6%KR8"[H,RB_AT,V,UJ 1\+YLRIH(IZC2"8M4/^QV
M*]&3B*9G:L7,G"!+6?+4!XTO!*<1H=";).S]$"FCKQHRV#8$8X SCV548K)H
MUC3_="AUFH?CQ3JB]>9VF)!M"33Z7BPBDUPZPT!!9>=ELK4=\?'LK;B3OI?,
MOP=!2E;Q'KC9Y'L]+&.\.3W1>O')%%5L> '.IY'[@YB\-GD&P>$L7PYB)0P!
M@NN>TF>1L?N@=3O,-THHJ ;^0RP]Z7OQOV%>R^ 1XP8R)V;HC4F4/L\)LZZ<
MD%?S^R^8P-HT":SE":P=D\ Z6W5:D]#X G/[%O+[8/LIO1<63&S%(=H4/A3-
MKF#J)GIT&>47YII"X;0T%@5")_8B+8M\,4^J-BP.F?5@X/D>,32];G'@CCS_
M,</LXF=SY47VMY@2)=MJY=N"I:UHE1VTV#;F$'_3(GC_=0%4J(#DO.X9'PM2
M@/*)+49'*@"'7?UA8%^Y3N.@L@N?QH-'_)ZG61J:^L!OR8*]RK&_N'A-C'4O
M78Z6(=TET>V71BN4X(QJDI7*LF__R2EJH4V()O?*RY_5I9Y[:02:%]K)G)=F
M?I*0.%LXA%:.WQS.\BB[YMJB2(:O'>\UZ4=5B;A8X$KV6S_N)<[S:.&VT!A;
M:!?H5^L+1PO+,E259):+]6$7?Q8E&,0:"(!"*5=!=\ %-T,1:<R*RU$%[B&[
M/=G(V\5P7VZ7,F]>1_5BDE'5EZ8$ L,I$#GD"*(Y,2E&'/&0LBM,B_MEOY/2
M9TX43]TZ'] S'+1+=1/H# _R"I#X:4*%DF/0<#/&@(F'LW0&$Y^K:3ZV5:79
M'V-@*UV8%>[1]Y^W1Y6)J+GF/Q:Z!*1WH5C"[]NG;H:MXZ2-L9:1X=H/$?P)
M2L QW94>L=)'(,F1/<CF$_@=&WNORE!"U^4@0<>!*Q($IP*S>4@2WU\:_L S
M3E%\)DI/O'0T"(&'&UK254W>@T*TIEX^CMV>&T7H6H!VJ'#Z_@2P^N9C5^=I
M!E0V)& ]T<Y7A_G,OC2%Z5JHU=)8&98E8>'<6C3M)N^=RET$(>_#:!SB*ZG^
M"JL0QJ$/8[7U#LR<7L:^VR/EA!/;()&'GO^(%F0U0+$;/Q3=.OS:,_;UW#@/
M+.U8HI"L[\7\VNBXG/\H7&7KAV.*0W&CMB_42_T$<K.HW<$-[C)N-_98'+O1
M*T^E>FM3%H]1J"CEXJTS.&R8+D;TQ1E?O"86R]JPD*^&6P:PI/!-T]3$/M</
M<"K[ #SMLERS6Y# _NPPK45L0[T39:+RCD.".S4.3\?/<6@IS0>^R!>.$Y]U
M.5=G$34M[\,(=*[XXZ P!E]Z&9_U M'2AG29^#%.V$@I,IS!HU,NH,'U'A:V
MZ@^  4+E9K& )]HJ/2X:)*X>PNB'&#,$"&.!JJ<=,&I:_[)LN(P7*EO4EM&#
MG+(H#C@;/4A52S3/$)A5I)H(&S.+-($O I2&0(Q!P@X;M4\R2(*_UC\!^Q5_
MX60>N3B4C'-7^><!I49;7)J"?TZ"#W<7<PBDJ9$I(902/NXK3*E)?V9 KE*T
MN %2Z1@![2"6R%V1%33H T@58*-WZ<%D"G']OG^S#W$[2W.?"-H20[A>1N@%
MI(O>3&7I^$P2D4S+I"$L&7,$RQ"P#!R*@O4[JBZX=I_HCL<B23L2JKF\P(6I
M-/8H#. ANH2RQBN=<NI8F>QH9+?P:LE7!,5)S6HT]KT4QCZ[$X-OQ="R,'K,
M )G\47E0E>IX5"S5$_FK7,%R21) S!,-#/&NG"V9:MK/'R6S)IUI>9'32MR[
METF[/%WH0ULPM8\:H.5\O\<^__6K^^@&PO/++\(?P#V)V&8,ALFYEJT"US)E
M6TO)D-]@=G9PE$AA,3W.K\C=]V;JM]*918LX5V=7&I&^D,LZFO+X1"S#0;C9
MA.A=:!_S1!FF\H%SK*LK7"O95K,+;:/(FX4EF7DBU+0.E3PE2+#H1BQ:U).]
M/1#4!1T^K4,0 Y8\'67YO4-&;9SJ3T(X++03$'>9$$W^U-.C,Z74QTZT (RT
M/W:@XJV+1:N8[S$H(<)Z>W1D/)'K*6TED4]<!!QPWBP<$O$?T^(W+7M)!Z]2
M6>< CZ27UQ>3V^U-.-%U/^-4F.54T-7D!7P+6;,V+%&,'>0G$S_!0?"Z*97:
M=5UN5]JQJ$P;N?_B.G3R"&W"T#OW*)R+>LJWPFPVQT&O-.ZZ,35\Q86QL+['
MUP7+U+%3#\4H[%-S282(<.1ZP&C@:H-DE3'I]*5B6U-.?B?G[Z .1<F$6JFE
MS\OBT[*MJRI=#4)6,7A)[I1DBY8YL5^L_5O5U/XK<,&FNEV57*Z7*N!5@?,V
MZKHEMRFG\BZHSBR06+.@RON<>29E@=K%S#HM=9Q N+RMY+/,0043!A],HM24
M//U;<J,+[>-NPF\4]&O65+5B#;90*YU9A?0,4IU2\4L A)%(4/>GM/TI#7[Q
MS!M'Z:HYM7I:&.9VI*G,#HZZ3'7F!1/GC'Z]2!K]:XQMGBMUOV52]\M3]P],
MZO[SW:U+)>ZI$4BE@\*MLX))[,MG-]509],F)=A;5P8O+*Q<0.GDA[$FC3.)
M-J*<;&I,D#[V2374P.!(X3>?V<<&;=V%)XX7S!>'/>BMK8IW66AI 9B>2DB:
M>[ZX_<+YXE;Y?/$%CJ0&C=O/'C1NK6;0>/ZE<PP:MY8_:-Q^QJ!Q:^F#Q@%]
M9M"XOJU5#AHGT?J26>-M&JD-&L)KCO:NBYGGE9\PON11N+,';%W^QS[N^R#D
M15N2%XR:G?VFYN&\[WABH;*YCCB9KGC\M_[FY0WHG;W-K]!-IN_9_YSX7/#L
MW0RY:;]Z*+?;2X6RFC?Q.!.4KSX'-CM<[S7-8VKGG5XK[[-CGUP=.]8#U5BE
MG=6PR]Q"DTN]S/"Y1D$W_Y*EU(6PY%)B+ '7RGQJDTS*H6JJ/^1FD+8N)!']
M<276$34 LJ6RZK&<6ZUP.ZIYLS75[Y\&KZ6K4EMP!&-I7_"7M4"&.8:X?.JR
M%B,99LY"#28C%L&@ S$!U2%MB&_Q*O0?(^\_(4UX$QHWM3PNG)*J#V*QR@>Q
M./:URR'[!W5+RG[A^H^;"YKKD(Y<S0]9W3G#F;!_RODOA<,3R._*J<4JG+<&
M8USO)OGM??_ZZXV8G_"5:_!R<@,.')#D "VWQ>S4>B.=G2K&VQ$"IEIN6S-Z
M1B^SY;9&8J5]L*VG^F 7CVS3)K2]+D.J#FLLEHF<15I7PZ_.?+PL,P(IR\[T
M*8X=;C?RM^EOPO5'G&; ]('V[V1$H@VL> M-M0*C%1D158RFLPN4-:D-3I V
MT438V -%[&(:B#.]%7V@3&Y<L/8ZBU/Z=[?';3^PK7)7[^3WZUU1*=K%9[FE
M(R8;B7;*Q4=(C3#.N##*P/4*%PU=^"I<12^X#WW8']B0EHCU2LL-S"^^?G8R
MDN1H/9_#H@=\ERJ)* ,>V\A BG4<3V"Z+TL_$JFA:@*)D\\$Y68U3*W>MZ9@
M.,6U!1<K$Y]\X_/PR'W[AB^2I45:5@2E^#J74<QY(50BN6,V@1&;8C;U](B<
MAI,?&T3I]!Z6+P!CZ]][,9Q429MT#$]^X/6Q&L-C:5-,ZVH\3&;FQW<O"4_<
MB/VOFK$@!YQ/WPS!_*Z&^U^1^PTGD''6]4CWH\2!T42H@DC@7]QH[]SGX$A'
M4,W/\3:^7/CK^?7IR>WEM7U\\=6^/#L[/SF]MD\NOU^=7MP<WYY?7KR]$B?R
M>:JF>GJ64B6=+Y7H1BK!IB=-"+BQV!(EP7KZI^ 2F+<WXAL?0I$H)<1<G-_8
MC;8#\YYV,+WF)R8F\2_\I>,<= XXEQO[G&W]<7R+SL-V[;T:+U]05J."\!"C
M#]!?W"=/)54EA\%$=^/)8FU98,4%FAY.YY!CD,H_\\!Z]P<X>Q &>TKB.A;^
M2EIBMF\UE+70KE"]=2/1Z1K49:A(D@U:L9Y3P''D<O!,1K8[ C4/N&>:327"
M\3$,W.L++[4709'E6&1/Q99("TL3R*ZUP.W.-<9S3S+=BS)7 E>%<8B!:(K-
M,7PJ9Y'+2[2K+^K8[8-.;0_F>:%#-,$!+-J*F>_*"G>6GV^^ GC)@E9H^0\M
M5A64[%E @C87'M=/DI"S(R2M.RK/X@\A*1\<.D>=QA0M'[2==OUP5R))3))N
MM.9NK;L6SCM7 +EM LCE >1#$T!^?N1TE2(^U:Q7*^,K+KJQ*.WNCILJP"6)
M+6+M:^SZ.-K,H>P\7TVC2,=A8HL. !U*6V@"$*5C7JE_AHP<=EG !EXB6#HF
M&>]1 K">J^1H(<"Q^X@Y2>"#R8WD*PB&ZAO#WSZH,3H8E\4F7S@&1;3,HW&0
MLOL7&,^JM5[IB:&ODN7*P3*B7VH409LJ^F"'9(%(P(X%# 10899%+_*Z4C)S
MA4345H%/00(5UI2F7I8PP05"-58QC0*A&:L>>/#"GX]I(>,'_CL>:Q+OVOTT
M[(PR!C+.^JF;JUG'H=4M2.>+62*"[K+HG%O;#W:2=M.B2%\_9#%VEA+GM#"+
M3!R2"LG$'1N[GDA@]D;=210S#'G*+#4*O,JRWY@L<%"H$$#45I&:YHBFYS"H
MK\?B]$S\5>#Q"/N5;DB_P?%1\<Y6Z_V45.Y.!PS%\?9\-N!G.E)]S"6<]HY0
M+DU%;*A=Y<>G # 5W?FE^WG'H_1:2!*(P?.\JT^>FQD=+5(%9G'*W/C+\J6;
MC;F@-5]8[ 6PN0$.+D8UG3%*S/RE&WV@?5]3VP ZU1?!GE\?>/7#:@#O2H@U
M'6"Z?$L_OT0F?T."+OWX%4 Z1U"80%H4%_[ODY/3T[.S:1ZP[EM]+&H L[4W
M,0L\3!5*9\F#JP_.,'9DC8;(JZDWI&PI#"._A$I72W=@,+:<H\..TSP\S)F,
MN)._U)UFZ\@Y[-1W-_!H!T<=IW/8+CQ8H]YV.@>U7=KG2_Y],6 JDQ!0:<.A
M*,G623,85:T!.<6H,]X3-SIA[B@[#".M[%7%C"I9#MV*A84.$.IT[#O.@",:
M0AS/.<JOJ"VS-%?DZ".N"+M)]L5X5O4Z.V!4?Y3.O)0%,O@V55PX53M"98O2
MHR2&(6*5A5!S(<XB]NZ4 RI3EV%-UX?NN+HM0DH^U9(*>T2H!O85IG7>ZEV$
M0FTRKW#^S9N6C>9;XY-\W"JS=(25LRMZY('C0Q:08W)F%F00\T.C ").$H^#
M MJDP4C>8  CM[$P%.)C'K3E!0%I9582!LS*S8JY;UM%9Z]G]EC0>4AZ=[6)
M)EW&7XO.9/S&5'Q\X$5Q(AV[XE*5S2$3G1?<'WQQ[*M8B'FD'JNX4V1771@T
M5*&9H1\6M4.7IBQP'4S='D'NQM"[&V:<__HD9>Q^"MF^W(Y5'5"M@4KMIO05
MOEK,Z0^M<TH1%GZ#!VC+KC:7;YT,7OD8O8D)<+@LW\V=2A:$([2T/'OP>$,0
M7  [8F-N_>/&S_A7[$9M[PPVA+_4:WM_IP726^9!=$ Q'KXW!TF'4JVH%!&&
MM5"RC%YP +78E3#9JW7AP/ HW,POWN?3=/*#&FT<4S;,:XWZJK?VR='LS83@
M:R?L/!FUQ+0\T'?1\<0%MRM=3;9R]A&9_^9Z(YJXB^RJ_@F$([]8YR*?#>[V
MR>EEZJF*P-T647/\K\ $?3& D=\QD2/80@=<70;#\'F%X7WK&#FJUL$!_NZF
MPZTSJR9#;@[=Z?O,[@_J4SS,,5%1U['[*&.=H**W:P615^LO]:;3;K9%XIT,
ML$(5"3U-/CPFXH#D*\R< Q-D7 _*23@3X#)W! E.Z.*+::S*G1N)[L_!@)IB
M4F8--F!3'(N*AK)+8R&RJ'P2;>:@Z(.RHK3Z(FB4S<F%_RR*9VEB%?CF8'(+
MC2*A2A8LGCJJV7WW477*IYX/HLNN%82@*^S;ESD\ML3@]=Q,:$EJ]Z&H4AFX
M]Y3> I'-M/%D]F38UR[(P!O50-*P^+<L/*3PS4( 4L8U45K)_B#0*BFSYE/.
M8,?> ZBBR59K.,U::RI\63^J.?5&;?=UN?C;XT#'^_8_H/7 3J-6;^]J7 >S
MQ51ZI\HH+&)$N ",B)W)AC")=FK!E#/9TYRI> _'*;/2WBQ95<&!G (^9<W#
MI^QG\:DG=JVQ+NM%K&N^M\W'S:RE<C/[>=S,>I*;/7589'"EW,V>D[M9BW(W
MP=LZ1VWGL',P342'AT[SX."5>5LE-=3E,;@@,\NL1,URA/X"!'Y%^</X+4%)
MBEG-_-8LGF7-^:2CJ50%2A3&RA\E;VH59Z_5&T[]L+%K[WA:@RF1"!99$ #=
MU5.0%:N)0ZQBR$;0Y^-M<YY.L3CKA=K9!K"XQ50E:Q%5J7/H-(ZFV4FC=N <
M';8-.WDM=O*K*^VC-&\/"0IJE;BPHV*7:(JKS/7MF;;:@BLX:JLO93)6(9.Q
M5\)D9A[2FJ5/+8'9S 5AZS5,Q&F.8RW).-M)$8B:F3V=2+6KF-)!RSFL3<42
M.5,Z<@Y:&ZCC5&);S^-#M^&(XY$XT1]@VUVI:BDE+;]J)4YY?K3 ,]8L.VV!
M=73>E&Y_7NYD+:0"K88[P6&M10^[7!Z5A;<U<POKY%36RW2C)7$J2W&JMG/0
MS',J2 Q 4[^(4[TZK]*R' [TW.H2ECHSB[YCLNC+L^B/3!;]V]7ZSP,UV18K
M\D=>XCY:?S(O5OQ,>4O+*LWRW0^$!'?L(78RS52&*9E&?9>IW+6T+,T296G(
MAO\XOA7-"82[,BN0,M5I4+2/A\AO0):/]=QX2 5J(@L?0N#H X6\![:G%::-
M(!2;A &-K9+9"R4,7<%0O'X>7B[UR6:MV/%Z6'<:]<;FJ9/5VV.:7@/M&X2B
MR66GI9.()*_,Q.N9,[=H\JPJ6T-:C"<C9]X" 4=Y?9&&LNE<J,\!G>W:6;J@
M"KBC0I*!"K@&MT#L<W0)]:#<!.L6U3@-NKJR^?,I!_^$^5PN_,>^FOS']?SP
M'I.(3A\Y@7]Q(QQP'6)E@E!0Z0IE\C@$L7N1SC.*6 -UU9 O0AC"!^(]6O,1
M\:Z^!1D7R6/F=>8^+)3D<(-*XGD &@6@[\IW@U=.<J@D#)]KKXZX6"&[AHL*
MRU-P'OMBT%.]\8E:,11A0AFB<KDK[3$M9Q'R'B$%S =FI?J03LU52Q.T]JWC
M1-QZ#X8TA)-$38,.QY1XF/*VS-M5<U*R?Q)6[5*@]=\HF:Q55NZXUKLU:Z=Z
ML+ZRESW;LI8*NT1OV%C6CVO5E'YNKHC"AM3#X!LBE7G^<H=9"ILEY?6L@CU;
M+]B;VM/+BO4FE!%H31?K0:%B=8KU-IRA^[Y"(*5M(AXP7$4XI[3NB U\K&^=
M$-8<*NT4M7* 7)P-VH?BP2C>;,0LJ<QR1F5E407FFMK0HJ?I@<%H5.H!- M0
MO]]\S> Y4]R2OG5JS;2"4_E 8 _/K.OC<(-/__JN\>X%YURT*HZ*'C^<P2BQ
MPE,7'G%! !?4#&T?6!>MBL3/J'X=O,_TJUX6F99$QI/QYQTL89N,/^<+)-\Z
MKK!=/O(5!B[9A\@=+P^!J-?O:56JX) G[&3T0L10X]4P]))"UO(NTKF2VTXK
M5W,+%:X%Q:T%A>U/R>8%:E=Q<]GZU0#&O$N%RZ6BJ[P_I@0?4D2]7TXQ=@&
M9BW\E]F[.LHM%P%]S%JO<]!^ZIR+;7 F,]@NV!W5#.B>";IZ^V#EL%MCC?'"
MK016I%G/$1^<2\=^JN=]H>/!FL9B;;_!+8XG,3DE1G>RQ?<E)?2IRV/F8M=,
M^@_0I%>"PRH4'*I*4DN'YW_M4Y/97)H$_TL?TP&4B1\&_(]#UQ\HLUY4*^[;
M-_";]N2C=!8XLD<@YG8G>KQ!_4'V-E2)&!2NBKSN1 V1@89,KN^'<I(K.!)B
M%\:PQC##KL^?8?U)3WCIX0-[AYNO+*(B1O"N_,:Z$2<N5V^<]'<6,?X7+QXF
MKC^:)%J?I%VM.57,.*E09][(BW_PPXD>OOPM;/]NW[%];X"38A["Z ?4@;HX
M5?4Q_29&^*Q,JHD N)C2\KB?X6UXQ;/W>VG7NW3(DKGC2[KCC27><="L)^"A
M42./H1FT?0_I'E@/? G)1)!BA.IYK)S>=YSP9$=KQE\UP@KC22P#=F@][-WT
MAJ&OGH+<GIX8G(Q-C#>6)-?F='K6YL\#JZC]0J[:O<0A%T\7F$M<<Z9:4!-?
M7G!NI07GD69W"+<K,#38FFQT)UCVK$CO>IL>5)-PRO=4'+\XI@KZ;&AE-5&,
MRK+^+7"<3C4SV2"WD?&<5A.L&9=ID;LT;2(WRV5J4+)T9_9"OE#CK5[1_;B%
MO+%J>I>GY0V1$?PLFU._( ZW-"PMY-PJI+"5?M]L_:UO?2WAG':^A>JSPSGE
M\T51./SBT5Q)W,>"$SR],N&Q71[TYL&3 2H3?2A9KW5H0/=<LJL;T#V7ZMK-
MM<6\GB,&9HXM7I7H+!"7+R*9E\O=I6W) ,0 Q "D,CKL:O36PDFU7 4E'X?2
M88N&T1:HJFLCB#+9MA M- [+!-KFW(RE *+5,'# K)ZRI)XW!H?FJ@C"J'=5
MD54&( 8@!B!;K]Z=)W%OZ/ZP;X81&RG?I.HTM/DJ7.=HXZE_*8#8,V"8Z=Y[
M:W"HE>7V&PUN2\21 8@!B '(UFMP>A\N+;A,'<R,_E8!VC?ZF]'?C/Y6(0QL
MAC R #$ ,0#9>OWM&Y3G_N'U6:3"JK)_Y^9K;V5Y:)M#^$9Y6QX8C"I/NMN*
MHL@K[0>QP%Y,7?A,AK_4W@]4@(1%X4C7\_Y?IFY8M&F0%<5QHD]"5Q7$01CL
M83/D.'UG?IU<]6^RXH+Q H#-V4QUKGD*!V:>0ND\A7K-S%,H8))3A*;MY1?7
M]OI\T_]7JW?X*3ZXGXM?"^5HS[X-2>0&,4R/^6A/QF,6\1O+BNOIKD^_'=^>
M?K6NCJ]O_V'?7A]?W!R?W)Y?7MS8EV?VU_/KTY/;R^L;^_CBJWWZOZ<GO]^>
M_W'*_W1V?G)Z?4,UC_R+M[^=VB>7W[^<7YQ^A1^NCB_^\78:)Q=OX2N+>Y'7
MA78=V+(!&F%#)UQ$CMO#SAQ6V(/FMSC8!MIHVW]S@PDT\*C+,;HXH8@_)4;>
M^S@^:!P"V]47@H8,U#I;S.S)2(S26G_)WRW!K;D5(MMB/V!O.1K]@XW_ WK!
MQ^4#E?[=GQ*DQ>#=(YE;CN.9JD9&-UBRWO$<5:-$JX #?BBHGDC/?M0Y./HT
ME_( #9QEDU\ON _]>TX\[&>/L?Z""@-V ?%]\3!J"CZ+8YQL BI"K?YIQ]N%
M^5PTW0/H9L?CGX34B+ G6DUA>VMHI,3Y+_]U,5J5NLA".Y^B;Z71B+DF_!0<
M/&ZB6IJH[MB^RW6AY"%$-<=GT%MEX,4<BS1-Z]-"^^ 02?7TU2CIYC:M]#8=
MJ^8X3MJQ3/8_<Q8B!AJ%C;W7N/X#DPL"N_U>7A!]>@%-/>NY8R@67_S*O.RJ
MX+P&D$$T0277REU=)&\T8GT/^M4/W)''!=70[2N.,>37?;&+(L ,*W!:I9^A
M;U4$=; >#DN,D_T%+].+M*H\)<RI8RSUG<\3Z[>:IK VG6A&[Z-7G-/PQ*Y.
MTZF;:HJCFASSZDKEC.U7>6^*'/-S3M6,VZ)AIS0 PI8U\PY.MZ""^(6*Y4F'
M+BIA<JQTR:+:I7W[U,7>EL"/88Y%NC4UV+-@K&>LS?4,P@"](XD8UC9[SB<V
MZ^2J"(>U[,K)%3;X-H[:^BU\@/:3U V.P6,])MM+"J&1?9^^)VC%V>7:C#?R
ML/D?SL'1FG#Z[@/.^HB9I9T3Q,Y3,T&;\TPOSHRL4XU$IP@B?;6%V&> @"DQ
MBQB58M@>3Z)XX@9):@-Y":Z,BV$G/*#44< IEQ8D8(WX]FE0GYR4)Z;;X2!4
M;'!G,6I6*D>)Q0!  CG0"4 'YJ'TPGL\ @=/MF.WZJFGNG_NV]_%'+(B]UI!
MAV^8V,8OGP?@!Y54#/*C@X &2A-:Y,>PI;'[2'/< #LCQJ@?>/=?-#>)=I;P
M2\ZP?Z"++^&O3O0>KVI+N1MGZ3<.)['=8V-)Z%O'97[1"@63$^FM?ASB:Q.Y
M?[4K..B\.]FOBNRHID2[' NQ_^H#D395>H%CQIJB1OAT3.Q,L!O9>5-V787Y
MBI.HQ__$IHDYE*U:8VK5"DR*$[X88@WGD;S#41,&:3H2$TV=)=/*SWT2/9A%
M%U>-EX,$$'++=GO<HN,&>%Y*(,N0*X]PJAJ7G[U_3_C?Z; PMXD+SSL&$T*Q
M.W/H9UQ1^P6'%1UE80P?,IN^\HVY7<Y A#02W9AEY)MF@ AVHW=2$WV9N5 9
MX*0B.=4U'GIC+N.2!\:T&5GD02L0(O"&5(IXL3;\S4$7QYCFKO9<SEGM'9CO
MR 8X)E5,Z+IW(YC=*(YGX?2[%-Z[3DH)DLER[@L4@B;1'0LX GR<_ @#]6"'
M40\:1@M.+V9MV^Z ;XQ,+KE#&@E9#0933;;'Z64$X.1ZX+0B7TU&DX-E1;=X
MXG.=@Q-AO[J[K+(TN0RL[YPK#>T#]/ W-&4XHPA3#^AP+'FT(F*RBA06'%!?
ML5?THW+1%QL[4VS9*K=\M*G2T\_-,1K;47-NA>VVD%I98LBA'&0TR$:HU;H=
M$*^/(VX3-5YP^8MNO?HT18+QB0+K+_7]-@P']T6$7Y$?_,*5@("A["?:]##.
MX(&)RQ6@+C<P 6&,^HB3Y+QPX[[[;_M$.#3YC?C!$L="(4C:!4K 1K/F''2.
M@,!'_$FA*G%"T\@_DH,O8/FC_69S/@>J6F%?X&<CF.\&;/$J]!\C[S^@I55[
MKQ6_E]^YMBY:Z<\4$@K>7%SX/E>GBP6&^MK^LMDRV2<LIF%DJ3X=:.]<-.GF
MT"3=E"?=U+<YZ:8(EDL-+%;^XA]/[OBC=KU)8S3*[KZK&X.IV9F[[>C'E&;M
M?/S"J%%E&3W'PH$-1KL#JDR**FL6J@#LWSBK#&*6@ME1"09<3]GS\<]B;B,H
M4#<GYWO\P.";N8O<T103O]*<WMKZEK:^VHQT3&E4D3Y1471OAK+S-S88R,"'
M]26BYNQ5W>^KWZ!Y#9'V;*W'M7V6))2( (D DNGIR+ )&0Y<#V["N-P*B6FP
M4N9;?POY O8??(E)5-6;4'&TG;%NA"F+#1)8S5E<\(9Q8[$/W[Z2GO&<GEJ
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MU!NRH0G:*CBIB*+&4AN3"J0[ ?\.SF7E,& P/@VF#.."J2T"-KM84KQ%E1&
MZB6DIO2G"L6=5#RZ662MB.ER^'UM,DY>\/('6#A(;0@5J='@K^1[FJO 4:\J
M39XT@5)5/BS@B48HXSXH%<P^IVY9J2Q6!8JCL O^WBL?;OFOQ_^TOR7]?2-G
MLW*V,V\ ! "XJK;>+TN^F-MAEZO1+ 28VM.TA,A P+%^=?^#S!ZZ^;CWCS9(
MWKLP>DREOGB.,QO^#F3$G-/'7M]S(VX:J(YT688^9402ETSX<7!!_E]J6A).
MDCS21 *-L/Q=FS,Q;Y3)Q:)WY29HPL$R;#'=)G$G;C! U^_'M,.83/559U6:
MT+YU1N%H&$--:R,[EV5:N</A^O&8)DU&2>R4<<=5TM^FW>!SD+$86>)"LN>[
M?#%/Q* P=IAV$%3X$6+*BU*]1:1="_M#Q:A$AE8Z@E DFGWGQ,2?Q##*;:;%
M8T9)O0.=@U\#RQ,.1]!V9&P2DZ$A7>\1!H2"(2Y?XJ8TE;%O*=DL1[#P+1^T
MJ[VX![$/<5[1N2P]73C0@ICJI#B@-%5YPJ[,2X^X$G\/%_YT$G&CW*7AA1RV
M/:&SP=T\_N>^_34UM*\AT=V5!K;]^X^(+\;(Q :(0 )X;.%1T0,(B_$W])D/
MT_CX'OF":;P2+HC:DG!"B<S;="M,*$[P9[73WP.E/8F==2%+4V@NN30%ZT<0
M/O@,VHNX!6X%)J"NG8"0%80T0H K,10HS5Q*H?>) 80P?HE;5AS&%)!679/$
M')J.46.*TC!F!LGJ)DA6'B1KF2#9%EP([S.7+7VVQ_G],4R8IIQVP;JMW.ZL
MK8LF?L=QCG453LPI>%J28@JF; (2.G*Y)A44)1]-/S3EZ4:!G';*54](UP='
MB"5DDQI(3(D5_'N:SPM]$*E_K$2M!>-?.;N<;.1J''D]^+'/R!X'+2')K:(D
M&M2<18S4 TVX#R;^P/-EPU.9GR.\*>E4=W&@:?"0D'I+NF49R5CE)(,1LVS;
MT</:^UP@#OVBKM??FXR+PG'R-3)+*Y>9Q9?SJ&VJ)=111>.WZ2\8!+WS[ED@
MIR4[TKD#C531_]8;LO[$SVB TP'($=\")\I D+'N1B52L8IN$NJX3J8!"->W
M.0GZ<APSN@JQ2(<+FYA..13S1R2\Y%FTM"3U,@X[OM_6X7LQV<DJ!^X;-Y&N
M(@_,B; @]EZ(NQQ)3[D_OK',?!DB.Q\_%)Y--Y_@F'L$N]P SY.3 2PQD)'\
MOIA$WI&]3O5\$+7=E+I=2>"8M(Q^4<A"(,<H66(>@ ,\IW)_.SF*Q\=BX=I-
M\J<1GZ$JS[_'&<(NG3E_*F[.@!6:CCL7)KWW4WIYR:_JT#AXL&? ,%$6#+6>
M!\>=.TF&D!>)21Z86<,92:,E05(@D>A.42-Q 0_*H</6^,)=K)UMVG'<:(E=
MPN!) (W%?H[!#/948C]_>_L5AYU4XC8]'7Q6*@H8BQHQ"'<2P=_5<CCUZL\4
M0YYJ?'/E\3OI^6$B&]T0A_Z9SB=0*H>K%$6PM.$&II,A@!A33JHL;?;3(WD@
M$_:--5I8'9'FLFDC-E)%4R]W.(Z'/Y@OO$'\ES[G(L;9+OE8_:A$I6?9:72#
M,@2HG#K!)O_#^BHD#&F$-_;W4.0Y0YS#H41HD5L23UT PIREXTVO3BK,&I.A
MKH(=J#(%/1=_P.E%>O[41K Y@YP!HWOKK'P5@B JH"-!4KC/::L&+'9*=WDB
M2VSH0LB<&)F>DP,;E:>SBDX'.IH>,82%2!S.;+F8+H[5OG&"?^2@BC(5Q0]0
M_RYGU3 ]I<Q2'<BF]R2ST8J>FS:WWK@Z>*M%@#'Q0EP[2UR[C-M8HZ*I.^%,
MX[;+>I 86H8GW0NO5])D\2-MZK2@IH"?XH!ZW^VEN:]J1HX2:-.Y;GKR[-NF
M@HQ1D..T5CGOR+'HO"XC\AO $1^)S@T96[A=J]GQOR<0=A@QK*Y2C,U1.2!J
M4I7%S4?AY0F+F90^ND?D"_)WYO:L7E%@J4A#)&W)+*>D9G(UR"[@I[1%*P^5
MU9TW/5+]+0L5>EI3MVEA4B8YZQ+K,AQ:"!< >S:0D:LV9Y'H;-;UDV0T27A]
M %>P# QTC\!\PKL_"\)O_(84)[M 9JDEK@T1[-[L3%(%<Z)/W:DC)+H@7'+Q
MQ#*K%HC$:.(OU<0O6.(&C^YK:M^5L5R5'^%P/OV[6!&8I7RCKT(EU(C7+* Z
MZYT').8D\C4_"V810DJ$[XLOSZVS++(9&'VHJ?%B0QA_AT>H<@B$F1BMDXX?
M*])]5+DE^"A]'\UVY>_4')SRW'S'6?2DU1EYT!17P!"$F"C6R N#.)>]+]?\
M\JK)[B_H0]MLF(AP>42X;2+"U0QT9O3PDHL](][T0GW\H%V@CXM=Y!1RK. L
M4A?EIA?1QQ4OG4<AU_5Q2_?)OT@?YSIWB3:NKUNHCY,WW&K6E#(>VG<3%].W
M6/K&Z<K4=%YI^G79^U+-,*1WM&7((")!YD]B^X_C6Z,1XC[.TRRW[ZIU1SBP
MOL X8%-)5%"6G3I=RZN(7'^83G8&U^E3'5[H";K%HI0&*#BWD!>G)9W:* KI
M 8)9N_8M&\4N37/6TQ,#-<0X@1$1]*;<\N5[%%98IG"@)L$P4*73Q-[@INO^
M2GBW>!/V1VE3&#_[\H(2JSDW)V* Z.?BV^3[2#$#G%9O,^HS+00J7H#%]<4#
M4.NUT@FHC?T#-0$5"VU9@/._<XNK;!'?PGABEQ.:JOMZ "\O?9$26[B*V^/*
MMU9<,S<,1)IK[O4PYVW?3ENW*J>V[I@J>0Y5WY31)FFU>MJ%'4"V YU2N>ZR
M!__=Q8,@XX8EU*1SK<F/2M$9> &7:]@?-)Q$.,8BYB@*P=\80^0YWX<3TS?@
ME0552',"BNB^Z+1>;-%D<9C-[?7SJ1QB:B<G'XHXY,;$9$KM^T!&P$;!K8\B
M%2N/W"B%7"J=]H_>@\R$::#8>2WH6ZK4";(\'N6&1- 18N H4K5HMR1[3@0<
M5$,WN)/<2/1XF;YN;YN7/\W\IEL#Q7I#("B*P%E#;@^:]1 A#%!/\W0-*=:;
M_E <ZBZ$/'B1(U;@3N<,U?7\"0PW"+%3G-[P@<@0L@KX54Z&BY(_D2)FXPE!
M@7=*M@A2(?8<35NB,"#W&MBG39<&.]GQK7I87R$"3,!L94M6. ^IAOMVII8C
MMR9N$.Z\+#>(I-SR DL(L[2HE9J08*Z'A)&0G'@Z\#%&TB['8A?9*$/+KQ)5
M+VG&OFL_1- Q-DC[G&<J!:S<EG.6@^S-BS6'LL8EY_01N\L7,3:ELDRS?LC/
MD@<08D+P90L<G9A)DW]AIJB&M(%16DP(&"+\*Q7!< 3[=A+]@#:-F RD2E.L
M8696LTLI(C;7@OBK0G6#X6'VB$@0 .6BQA,))?P<X1AL?9B6Q-$G^O?S:Q4E
M>W#K<A./XLD8KKT6Y;-$ U"*T"%F^5_]\ XB=#U1BI,MH-%CA)PRI0WJ!<1I
M>ER"1D@>1&$JBJ_<YO&^_9L<#B U*B6374@$\\:H-&6J4+(G@1;JXS1!0%:K
MDH"G"/B.HL%=6"H)>S_LG"(+I\,<(/<'U+PD;(S2FHM@< %R $)=+0P!@?H7
M*'57I;*8\7F'1TV!2DMGRICH/0I,QCK$?1QG+/U,<2S8&M.M)Q0 C<$XE7G?
ME,*N)$PP%1HX]OD#?$,>##SX_?A49;B,,F7YFJ8Z0V+HG07 D8Y3Y4".C$(A
M[]7KTKX3TX5N@JNE.Y7!-FT7N?=KDE5T,= *^M+*0-U4>[HZ$#IDD8:@[5'C
M<I@=(]N*@9H ["-3)#ABKUKQN>);/LNYDUY7K;\  OUOQR<IJE=Z@ZL7U#O/
M.#?T+M[9I@!@MOH8D<+K"R"E^ZMT?KJ]')8.COG16CAPV'/A?8]",^A3 ZBH
M!RWGTPJ7=."1YMMQK&Q@3GB(16N)C"33ZI[UET_C5SD-X-.TY3V&'E5A9>,@
MW],\"PUEX9-%#XU,XZ$WEL4Q6K.:J9WHGJ.4(VBUP@")#!2H>4:U(FJOD$Z1
MKPG(XB_-FLYB2H\HY/R&@"E8! (-?9U 9)P4_I@IN"]^!=)]1F/5B7&JO'^@
MC#N]7[3^_H*R??"3\/NB-,FQ[P9ZU56%$M0J0S&WPVQR$_DS'')36=)-5=CY
MF 8(HW-7FI93>)37.6NY9/HO($.# <B<9*%T8\#O>1?,[I'K#[AAA>:&M<.)
MB>L(NY(Y2G\"(E[V D 5@?BLKB_X[L.;QW/9K?1]R^V[?#%JBR22.KGU^1"%
MX2B]F5KD 51$^!+<?%T+1!PG'#\NM,7,5CHJ$GOSB,A,$MO[P=CX([?.)XRN
M8I9?0^L(*^\)RH1."UIY93"LS.O\E2&'HZXL!)P[AM$/3@1\@]C@EMR1:3FL
ME4=FK+7/DBGT8'M#FW":M_XP9-K80:[@@'ZCFD@4BG9@#4IU@,/K= ;N-BMM
MS(%*2YQI_%KBJ$PC06&O-XDBS,S02G39/0)<!37$47/R$YT3<<H. 2+8I4P'
M"7T0?[1WW%V8YU@B<R==N"R)A[W&[KW0Q^!!/A0T40&:'&F 0S_H04B*<V@+
M2IM 5\RVA$?K!BKX!$EZ&(>"4E#9(9)3$4S42ON/@<M%.J5G4U3JBL;N<5@>
MJKFQG2<)*_7?4M-<_'3WD[W3W97@1ZP@FC!R0:/2<'29GLV5V=\G5"YV>M-K
M=-W@1S09)[U'QQZ%$="=!W$506P1**>.[7M<<-#@/]2"H:TAR9?8&WG@+,K
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M2>W,21%:H@D7+.4&6HLD46'699Q ]2%*V1N;>D(\: N+QR$X:910 )Z4JKP
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MPK=_T)1Y3*G1))J6MLC-)/N]VI2?UR;=^AZ" YAE*+MHT[+9TZ#_0Y"NVO?
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MV^B@>6-@_V#>%)6*:Z";BH':?LU@P-AAU;'#UAB?V18*JNW7UUG@+N7]!Q2
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MSX5?63.'ZD.N_7ZI!MG2#EQ11-?K':=5+QL1MCQTK[P':27TPP+E83O28@Q
M#$"JKF\OYR#;CZDJ*?Z+'.4DC!/(1[L+PWX,_LK^YM_(G4[I8/F75'MO(B2@
MEJ9AH#%;_S9,ND)(0I(]ZBR_>ZY1EC=:P!J &( 8/KP=F-I49?G7"(H_J/9C
M\^]BPZD?+4/,;@MOJM<X01F &&:]>9BJ-YQ6>T7C-XS>;"Z: 8@!B&'%KXZI
M3=6;KUG,W*@WI$)J=L_\< QIS#;[.69!/)5\LH%HKSN=UC*F'&T+PZJ^K]7
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MMT9/%N85A/#5C4A$ #M-$ZB^YB9(LSA!F\@Q+PDBV@RD/5SS29[%G_T?9O[
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M(GPHLF4V1%U'U(JF'-6B'B@'>SLGH@_;1SE8!+@E/T[S[I^RF0[RSE%ICY=
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MG:ZN94&UEE?-HJT ".66=T;:AU)V8O%!/AQR)X&(Q3DAX#5B4MUW%:;\@XV
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MB>H\=(8&#J[XKKS+U9OH-;Y5Q7L<G=)'YAH#2=(=5"U6Y'ZQ>EQ(;[,+/NM
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M8^8!&B@)]R& ZY@S9Z*_L#G$ 54_":@^Q&0<VJAUO<P6E3BAZ@MH&-P3F;-
M*'5B@)V)6"^1^<AR7FSAX3\%UH^H_8!K_TV$[LEM<.LI_+RI6Z!ZT\/4L;8-
M034-$![<?TR&QXEWDSC'O P$U1(*1L0H ]R*'O.7[27)G8-)#XF)) KOV@<C
M&-D<6JW]''-@[B0#QJE(SN(YC,^96&C5A& M"N:D[5;$)R>R:<IS@<E.FZTZ
M4Y4OZ4B'C!8L;JU<B2OGCY_N'W:.WK2/#XXLJ#]FPQ+P6M8C$=IFE$H<432P
M3<$B'QFY:8.DEP]32MY'MS4&&/5K=>YAJNJ/#+Z?ZN46FY9R%;C*+D9*T:7.
MQ\$)O')GN"EU#O+'D1S.921!I!&N$F2Z*B4=-=[?A"^M\=5R'%073S]93?&;
M\E5C=[%,Y@;(B-LC"X6W+OJX,*\KZK_IQ6&<_(RACTRL@;28,+=*'Y]LPA9C
M4L8_TRSN?7?U27SZ=$IWGS]OR?\WKJA^GTL&4[=]!)=VX(]%!J3YE;O%_!''
M?9 J\#=<\K_CY+O;;N\?'SFJIB<3H1C=8-&%K!F"%VUUVIUM]PCN_M'>[L'C
M:T0SN:2.-BZI9I=4>^.2FLGIN1*.04WD)S-S^L-W@SYLVW_O=&BN_KOZ2781
M[VOVF4ZD+SE5YE% S3^[^0B]_6#;UM'LJW>G%Y^_GER>7UU\<2X^NE>_G5R>
M_7;QZ</9I7MY_NMOWZX>BREWEFA&S&%$O$?K4^LXR'-/\BS^[/] G05T(HU1
M;I?]A/Y=:E0+KM[QE36B !%,3E-=/AVIJ^1\R),$)H2_(BA$V60+%",.'G6%
MYW"B+>M-5IZKKA;YK!,&)=H4%C2J=91P(DAG)^R#AK"83 \,=(=#^9NF6>A\
MPKD:U[QPLOM&Q5WHG^J*,+YS*9$+>XASR:3.;^@'E)9)^GA79'="YF]+JK&(
MK/:XF63E5Z8V5O[8M\[&MSQG"IC9O'R*X3.*T^S-9YE4F$]L.3RC8YM !!SI
MN@J&0[ 4X0?AV IL&\)_Z<1T$H+E!29T+1]S)+J[22]F6ALS_2'+N)5L;2K5
M%5@:,@B.LZ,-6>HC:/7LX#-R%)>H$E49F[9ZP,10T\K,58T;LDM?]F%5,>X(
MA:,,0Y"U"@0U!$Z>28M['.?DZ]!O#:2[%U^(9JT"8$ WKF:KJH;1LM*M/9BV
M-%NZ%-IDDILSP3Z;<-R#0.,&!%P@#0;]&)EN(N2IX+SJ./ M+"/.4]V&H#@7
M>W@=]*%W<C:;(YV[>C]:8([D"F:O!T\C;"%.P^]S401/3A=(_!B;K@X_F8()
M/3W9#5-/SAJ;%ZQ>X]2^AO-=*.2OSX.8C8[OZQ*>*OEV!>.LU!X-^YGKSL:Q
MFJ5^-NGS4]XVR.2-DOS)/':CTVA[\2@0NK6<8LD3N:13BG#HW-NKLU.C/*38
M4\>\G39D^I;7GQQ?%*Y]@+\D*N.]Y:B],HBXI7%Q58L?%QBE[%S+';,<!:4H
MF3 6Z%/MT!_DO$+Z/85C^@@<T_V,!WEN&(,L\<$:>_[U](DM7-(LP./.:@3F
M$8TP'A1=_^/5SJOY)W47]+,;?'3G=:.S1)O<\&'HCU*P--7?]%?IR,<8$Z[N
MQ]M7:#'^DB5J.I18VO-#M6 V;%Y)NS+KJ^?D2GYV=V'B'6/K:R-?F?@-^T>S
MI:D(-/KO$G^D5[B[\YJLNZ_*W\H&7M:?>19LH%5F(K\D*=#\=<E;8;Y7T]M_
M76_(8=ZF%.DXSZVOB9 ZU_;368%BA'()1F\T:X _DBED [.?A69J2>.!:Y3?
MAV)0_?6K=[*1T%^B3[.C>D)@0#*B/],!+7[2;&WX>FJRWP#.Q,(45PS=;MF]
MM[/C[?#_RJF 'OKL958>//GE_ KXU,X^NO7YB=::KU>+9'O!A_O-ZXUBL^36
M"BFUEM0>O$5?R)=,,X-U?U 1]T<\-%/38;.Y!AN572P&1,ND#.BP))R7@9/F
MW.BMW6W2DPA=24.?@:[O;K5WMNU@*D*P)1&90O+%'D\G+?<(XKHES")&>P?_
MOUNH+X#)55(WE"A?@[TN,.3Y.S'5G8 $H:O;_$CE[-+G@LKQMX[LG:=Y<$2Y
M? +N5L!1]#LJ? RISF3[?D>2U6*LK/):+T< 617L-+TOL0*G83/LJRSU2]>)
M!DU:)$Z$VMV6*A0P];W2E;;=@)M:K%9V"WW[E ^D)M=H*]A69@"GK]-]1Z<(
M6G,*Y/,:,R<XSZ!TK<OXG W#E,/HTO&223PZ3(P:)>CLDDT&26S)2FWNLEO3
M^)02#XK3GV'&\$FDZ4/")S% !_L]=,4RF$PT#[ISG-4 SZHUK0$_.ZF0"\VC
M0C*J:)L!J[A( D-7-8A>G'0Q'WUYI61!FD0U/5 6W\O6 \7>;'.7OFQH>BDT
M_>0EP2EB9) SD6;W7IW:.JAZ7[BH%%1I]'GIQ*?'-AFL>T>3F)IB+"^'(7KK
MYFFHUB9MIDZ9\3@DJ(^.E<YR31N^$"\<>41UF;P$.DP1@HBJP[A_&N6Y>5S)
MRXH8O5ZWQZ2Y%YWNXL<H, VQ%!^C$>.!?&,%+HD_T%TNXV*#;5;)V8-;>A']
MB(;$#9;=5FZ"!,\APG(O><-I$NJ6FPG3(O0EIO3N-^J?+=!_,MP][2&&'<]4
MD[I,X2F!E2>K =64I15!V6H@'+(@=-$Q*%F&;+:#'7X8<UD>'S%LX\.GP@G\
M*4_13\( A8Q=<*C&,RA0O"?PSEN_A[17$*[,C^!/=/DU^2&U=W&&R)3U[)SU
M9<>;9)[F9)[.<T_F>9,&?\',#LT\)M+;4W91/US 3_"4HBOZ4@Q5*<2'0N'#
M/WVL#P[$(B3UDOV]-N'53J-PV:I7[=4[O71:YZS_H;246'Z2_2:XFS45-ZK8
MIDG7U%!WTD<SUS3*'18J Y  U!4YM-]>U4T!+*7E?B.@W&% 0+GCN:;!FCEW
M:*C3W+5T [JR83M41VJ..*NR;->$/N>:A5H[*AE#>/U;.I?W+0VZJ+;*TH8(
M:ATA*77W&U85]/>$CC_7-/0R$#9("E-^*^%_X.(IFC?72V?Y[Z$WP3#1M9O:
MMSE)H:$T51.".5^X 0.*)--113UN.T#-#Q6Y*)6-7CK7- HN/O>*:MYX"D1J
M2CL%)ASTI<I&ODW8(Z6#6IS"/*!>.M=D>EB&*/'/DEMA,CTTP39TL#.%ATKW
M;O"-S[<W?"&LMG(A^M_(JD!+PHU[O1S3<H($P^]K3)QK/+4/Q2#"K/])MJV;
M/%'>:#4P4;A3\(-A*B3BK,U0M^ JR=P(5?LSWV6V;95.^^VV52Y;=YL,JDL1
MV4V:U*J0U/QRKLE$<89V$L*%,AJ>SM*1WP3H5S.5]P7HRA>@3BV 4V]Q4X(!
M3*^FL6K-#VH4G^VY)D%TS"6*;"5'=;$<+3T,GG3!=5>5)7--8JO03E=)(R G
M#>:C!\((8QQA3IA"BD,X-7ZL(3@VUU346SG;S(ZGH7OU1S#,A_4AT+)#60F*
M[8W&L^1[5)_X26V6NZ9GAXY''!BPX"S&Q(0Z$*9"B';6_XH)VFP5%4I@71NH
MJB)5O%KW)-W&.54O]&<9MON4/>H2F).F]EGI@_*(K-U^1"=V"6]F0OC)%+E,
M2*]H4-^!04:D&@89M1] Y3!CV,@(::R(!4^3J(25N&3&@N*6G*HP6VIDHO,Y
M"'B8,TBI'Z)!Y+Y+@@R3."PX9E5[GMW%"B=,Y;I08JI1GJB\/(XT!F@9+4TQ
MX7(!3P-BA:X!QX)-]:I"LC=.0P8F=<\?#7?F*>CH8F."<@5'$V[;&H1BO]F@
MK,96*U,10;#R4:2]1##1:1K2[IA*=$_VO-'ZP8BK:&4/>_0D&)1.NIFR#)PF
M896"RY21612;&A?\TV1@_R>G0G^<&3I"?I5[*WG98]*,N:75NZ*\4T%D]8WK
MCCE+V],Q?HF=""2$F>8,D%^\6T;LXG7G$--6^Z?=[5*8OR!\Y<UCPTVB;.NN
M+-C8LN]G!E^B:$:OP6TD9T>IU^3,FTL7[#[[BWN;C=]PN)%P)O6&:V3*W5W@
M9ON[[;>OMQ6#J#L#@P.B1$6ASPHR$>;VQ!8J?E>J(\-&@?J0^HK+E#MPXR1J
M',:2+1196A6EB%%*V& GYD302#53 DO"A AAX#QENQ7+$E*U$[XRU=&L!8)P
M57MPPN[4S4DX;>7W*QN^&6M3K48OE.V2!AD6%Q&"AI:GI8JM$AWP3!9 "PT@
MLI-/^^FG7_R3>W_@S$@Y?$RU\,PO8MO6WWS/8JH$-D.P/$"*2KWJ N'$5$FG
MBFZ0?E'/(;L&18K0(^EV4:7B9P-8RRP5@=K@4.W\S,=, ZG=JH6MN'FU:T'J
MTW-*$7-*>9AAI7](RCB5T$)+%G>U.:-L*%30AM K*"&&9 84VD2$?<F9(K>!
MH6P%C01W(0Q$SAQX5=G:C[\J)CYGM4%PS ++9"*136&+TT:7X*2U0.?4[D^U
MI.O[K*HT5%4L+=W6MCU<%P0J$$BZ"$ZYE%TJN*QJFM)3/Z!(GW]-WJF52,M)
MMJAHQ\DTF+36['E2]\AC>7C>U/[.)F^J.6]J=Y,W]63SIJSE'>/R9A(AY1\M
M,J_JE/K8$*>XY,1]60"3<5R2YJ*+@.OU\P?-;_E1PB\QI[#7Y%+K6H+)XJE>
M@JSYLO\($.^$ \;PHQC;T6%.,(8*J5\'>5 5QK#5HEPJY^5D!S:_54*Q0E%F
M0[F 6CP8!(0=<"NT<B4]BU/[215SI<D\#R*5[HN$:5L89%W@(D0,^XO>C9-*
MTR+BQKHOG*=K*G2?#<_N#07_ )Y_[0_E5W5=?SSV+CRH2Y1R&_ 1I,$P"/W$
M[@[28D])=3TI<#FY0]S9)(C4OZ@7%I":=! COI;$7O1HUX4>D9QRW%I$\);@
M)K,G/A6)A*9(9"]9&S3;HXN! #(8^>VB=SWC)BL6JHSJ*E("52&X4_A-T \(
M-\63,/<8EN8$?E#^L'%G; 6M6S).4-T)GU&/6.TI]+DR&.3ESE9%5UEA.]0[
M0CX<]2;;IX70EIFX'JN^-B,@(DP\K50>X$J'/AD4$>^EF@ NY[9N-1I-$T>T
M^VDI7Y<!V*WIKU5O&J]>UBS)2_11.^2O5,W"$ACR_<MT&L7+,N3& R).<U<O
M%TMWI%^_  E L#5 Z6A-6P4CJ2DU&91PE%5@)1]Z[I:_;=KPWA-E7*=290T
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M'B_177"X8;(;)KMALALF.Q>3#8''?O#'?O3TCVW#8#<,=HT9QX;!OD0&^RE
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MBC!+^K 0W+H&8:F,&U./N%W"6*(9&M"P,*\@/G#_<MF36"*'<=\E"1ZFT&"
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M+&?=#0KF!D)M#5 PQ0]$5V%U3ET.)'Q]:0@2"MB#J&4F>&<T1N9<DZC'TZQ
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MSWI-A8]0_UM3_^%^,%>+,\URS\0GFHH)EVOXU<QVSF8KP_B E+XT-?SC*J@
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M&%?-)QTK&%7'8?(2OD=O!-3[!A?,.S:UGDS=8=JUR2^;-S;^_-JGZB42U2'
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M^J34U./Z:^I:=OJ$J%.5$5^?+<?U,D3.7+79V:/J, W>^;J )4B\P KHL)/
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M-9F:Z[:;DV&_->B>J*:3$B@E\!@)[!0G@1VLI>N.9/I:"J 40%\ TQ5]'22
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M]LA ><'CEW0XX?T/8_:/E _3,,03$5Z+?WEXV;B=X,Q+D@+ZCTH:=_;/=GN
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MX*@'R^0O8?8"-/>+M3(T'@ET4 FM'(IHB3L]/<$"2Q^<]12[R7WW@%LRDLR
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M5>'!_H7PI&!-,P,<?JZXP-SK@0O?X(D)T@E\^5,+2Q0$3]$ZQ63JZ?JFQ+U
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M_;I'7-34(Q*\AFA!KKWX!.]'#LYR3[3-AU?V^P=Y+[D9ZH[$=V$,[Y'#;W
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ML+$I?+6E/%F61M"Q^"*-S1@-9W#5'SRG!"X!3E[P-HO(L9:-_HDW?16321Z
M<2@9%J8*95AI*)SE*A[@<I[5F'D7&-V!6PF/@B/\PBB(GDU)T<9C(Q9Z)(N(
MTAG*65D6.CA7A/'&@ZU^V5#RU.<N82C"4%^BCEJC+\U?QH$%HB"%*LS!]LU!
M<YXAY+S_P7>/S'UA!+./PV 7L,HY5[I>L>1[GN2$KQN6^;3V;:JD 6.KNBN;
M8+IF_%(#%M7TG^ G,QO>W +=Q]UZ?Z[$L(> DT<K[!D*!T>T1"YCP8QMA-MG
MB,;N&0F#SVM^@BV).YZ DP2[K>G@M2!R1I72[IG%^0)$LVLSP#.[-#5",_/
MS'*)^1W\ZHAZ'P]KH=Z+CO\]E:6TH]!X_R(L/-6V,8A=?.$G_7<T.&\/,.^9
ML@XL1QGR _\Y2FD1-N5_-HZ;>^ZA'S1B@X98KLAY151GG L8Q5!=H8AEN3B
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M1]<P/BLJ&H,!%,18-GO6V0LO?$0^<16F3N>$:7W&3,U/67B-0)O=:7#&-#\
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MGV6+1Z9IA-#M_UYQ1+.S%DS9FJ-+X46$6H>S4F-E4A $GO4JL%K$99@ *8(
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MQ+S[^"8Z!3I9%X'A !\I42<B45X-W5P5W9<S9GOU,<[J$0L_L40!LUJ&$4+
MXDB4+ZJMB90'M>-X4K<II^&@<A(YM6Q<$BW#9#KE8$++4TPJK'-5PL5*NL[P
MK,B6\KARUW?-UVT9D4]^Y.E?^TTHBV[6U70% TY*95&4LO"DCY:ANTX&,N])
M)/P+&$JCL0_!,ZU'V!OG?7CN4GU=L_E\(::"0"N$LVNM$.664O0&Z"@#OV'!
M0]VY;FOP -M]+;SGJ1RASKJ&#^>HU4.HJQ]4Z%4#>L.K--=9\4&$<H0BZR+
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M59*J568S0J0*!Y'IY8ZWH-!$5A=>B^_PREKH$:Y!H&XJ+?Q1=712^91 5W'
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ME<.+Y71_.NG1*O^[LC#+3TD;N,^M3%7#MS#MO3?31.7I:QYF<T@WZ!H*XC2
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MO:/#[52P(S=FE%-BJ?1QZ\&Z%CND!EFO*4*NHB)ZG6[HY'O7^!M)X''WXI2
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M9G"W5IK!*=;H?PYE!E]%K^P3\H;N@?>S)P5G.DA'==,O.A"YC1M82;QF&MC
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MU@0>2Q+\EYA8E$V!.<,I*QF.7T 1L@$17'XY[H/90GVD/_K+-WCS F'77^'
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MD!?# UN)B%:1(J(#EDQ:NX*8B$CMQ:O8HY$_0S?Y1JO;NAW4-JOK@@"L[RH
M*VIF"1@M>2?C%WE#X;Q!/5OAVDB</WF=A(7P".XDKB,TG_.6KMM7#&\H71'N
M( V!+"E=%7DN.S$3B]:*Z^2D0L@Q$E'DJFEPI+S6Z^M,D$]&9*?,B-PF([)7
M9D0>^3$HTR#?1 ^#O+P7]Z(9_+VI65[?TC'?D9(IECDTVJ5#(\6A4:L>@T?C
M_MO=_<VWQS_4_NVU>O/_O@_N\1!5:"*W-X_[=W7L":/CFGF:83)]8'%E#!2E
M_M#VO8V9MY,C\^X?DF)I/6F,7UX8%A/A;TQ]:4%>6@44S!=YX7_.:N'RUY?
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M2N[8!W?LJVX@/^YHGEUV2KE]$.[84_5!?KQ!]=#%B8[2^CL5LZ*<S$E,9E\
M1-LC'M:WHU("AVIS-6VW8'P!I5[U-MS$!6=I9J)K9M.C6U#2<P[<</3EG'7L
ML%5TTFX.A#UZ[,-Z-Q/>WI$1MG'T9>7U'L8%DDT1B[NQUJN .^5!W/O.:((-
M;5]WO E&V0VP:02\Y7+,IOU!-36J9Y?K>>W-!1(S7]6],A$BVV'8S48OZ##4
MRL.PPV%HEXB@F0[#CCB-Q1R%^MGEY@ZKO><F[&1,'ZU[H9Q,.9DB75)[5O!7
M)#K77[=D/X'^'(U&">"WDY)30GCO$0JAV*/0+ '\-G=,'GTCD$8KDV.RW-93
MZBG2:&?K*5):)*]/U2TG<Q*3V:]%4N+W'>>NEY,YB<D<408+G]9.:2R92;6'
M7)9]UH0U.J#E'"W 6&83>7G'ID--/?\DEKVR0?>8V2#_O)6]TA*!OZLG2<RM
M<E7V2<MF%4'47V]FRAL"\-LQ.25'3*5FK80SV^6R+1O*%)*!DB?'UTN.WWCW
MC@9PM D'KK$^H;C<OMPR7O+<O.;99?,(&U.67N1R,N5DCMP\*/-:CL@4;96P
MW[M8#<W2:CC-AA[-=LGXA>2L['43.YDZB92[>,0M3)K=3"U,2E/B]>FHY61.
M8C+%FA*YP_<E;(H2Z6=_"?:Y8?V PKA%X50) Y4S?%\[>U^CDO:Y',P]I?OG
M=C!;V!!S?2) R1U[ 7?<4]5 ?MR!:-R;6V0E=^3 '<>.R-M"1-[-@=IW1>_[
MU=. PI=RW%M_RAQC=*DH?Y]%F0=,RBKLQZ,Q9:YZRU[4;_94LRK\@XKZ #\:
M?U2GFO-DP'#X:#4<;Y;'Z_A_+SHMPXJO[4_?]8SQ/)Y8H[*?,V:Y\';89M6;
M,'7.-,=5&.C,>A+#FJO"JF;I^)>:JM%&PI.>K?ZMH*YA-WS&&;FED=HCK+)F
MMOF%2#>;;7I E.B]>L*[(7]M/V%T_*>1UV'NC,$_GIDYOT#.7CPXJ#LBNW.E
M,">F7\[SX1&+#QR;5()C\=^&A<510,E_7QONR+1=WV%WXX'E:=:3 2*!UTT!
MU4#B:9[MS,]'[7_C#_]=.U,9$'&&IK'CLQ2R9WMA2/)FH]/K@/PF6:2.F&D*
M,?<_9W"E;TS"%T/W)OAH]1>PNOG=XLZT$;P0Z?KSX]D:B]VS9TE37+RU4X<7
MI&_&WV$0*W;ECK6I8<X_K)LPKS$Q_L/X^N!-P\O;N\<;M5;[ /;%$+@,7WVY
MUM^QGZD,;A_[M[\-/GVY4?L/#S>/BS-:O$R*$/8%WRUW%OQPYHE;H\KOBPI=
M+%?V%"@Q5S3+@DMCA)<&?(H' /A-M<?T3RW$4\&/_@4L[E,"J.O/+A^_ C7A
MSXJJ(>NI+GP+P_2GVG]LZV)D3]6OFO.#>7!R,# \&N'EI+[#]_[W?W7K]>K'
M3PZ(4OI[[>/[BM*G8P\,,+9MX!-_-C,9*BLN2=R1[4X9\+NK#O%G])GG:#H#
MFOR(O3:" B-??J$.2$1;C$OK%\.;T HCSQ)=%$$7U;!&MC.S'7)#::H%._(R
ML4%%4NT7BRYC4WO1' ;S'+J&;FC.''9I9#S,-&>DWOHPM1'SZ7RZ,/CHHH*W
M,KR!$QK?IY%HN5 ?X=\Z&QL@UT%"J]J3PVC=BE0"%K8!/R+2J2^:J\*#S($)
M&1:\G];UE3D3[=GPU*\7WRZ^JO^ ,7%/\0=?08@]T<O5+W 6WPF*T8,!K0IC
MSX)/0]^+\GCL&(!=8< V*T/-A0<T=P(?S(E,0._5=_UNJ9-7,%;&RQV;XU9:
MS:293CMK6&JMKDYA9A/4'DW3?L%-CQYJ8BQ2#F%Q\",5;RM\@V8B_S$'V2BV
M>/:7#]_!#S1UZIN> 0=2 8(T5(\VAGB3=$YU.(?C88PF(7,B.]4Z'UWUYM/@
M\;H/JNT(1G?W2DUNR7R:_PNG\AU(Z7YC(QON213P_,L;/HV!MV#^9-P$+$*J
MU%**)E3==R3!:_5SV@@5C"\#1%GZ=HB3')% %\IC@B5CNY2_4B^B@ )V$FO0
M,Q:=(Q!OHYZLQ &IIL[$Z\A][[Y:>3((]R8N3 S7]>F@*5P"[VO;_@4<#(:]
M^VC+#<RX=PBCVJI4JREL_&([P+C FR_BY20OY(:"5FI8B+3M3N#N<R4/RX5K
M'C(L^\F<D0%/S^ Z9^LE:(P ]0W6?R,&NL=Q:L':J_&UWS.'SS9.!$3DZURD
MD0!.+5^?^H[N4XV$HLE<-UB:,F5 $,MPI^])^O+GHDOG)Q_6OL:HB2P6G?8?
M0(S %N@NLY:LE5Z\L)3:V>4850?R%BS:=NK8 5ULM>2)Z4^ARDCN!<EE@7Y
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M,"ZGWJV-9&I4H[_Z5?Z,*"B]!<AXDH3+2#ITF/;C?,C@U,#[9[0[40*T4PB
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M-IXAV!%,K$+G-?QS/P&.+S 2,OT62^REX>C\H@IU/&!E/"C$R;;#R X6XL=
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M<MTJDW@/A^*:_6!F@NNC@#?[9_:\('5J%_6682T9[LY2OVK.:*+6>@0X4:W
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M ZDW1W-:???+^\4UY0!?G[[=.V#8;QT6D\O] U>;->S2KIU=)J,N2^E4:&>
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M:@=_((IB?8MF@,6UXI%2()Z<0*P?4B!>A1?NVQ"(?=!@1IH[(?4"E6>P</'
MZ0R./Y;!"R L)0Z!10=T@AE_6!_U8JM#S?I!)W_@.AHS9?&]PZ*07(%:"V*#
M$BC+XWERQ[-QR./Y)6;!O8D#&KW'I[9EH >!3B+=IXCUIK@3&ZR+)T)R(#.
M3%,XN4^^J3EP-%U0 /!\:VARHN&A87R+/XHEZ9IGN.,YH5Y$;N(+M4\('3*%
M6\7L;<Q>7\ BI#PB5Z':=L]#(Q=D"L)/>%&3/GK%@Y@P$<R";F[;8BHB610I
M"XK9MI'F.)1GP)&RB)@ILE:1LI:7CQ#U2+%)]ALF)T9(QPC,'VZ)X41"%*^+
MG-\8(B, BR%2AUIKDC((Y\%!>S@H,"L!#I8!'#1*@(-M  Y:)<#!D1^#$N#@
M30 <;%X@&R+^1:N2;Z8STYXS]HE9;&S$*H\C%;&M6OV48,"+PU9H);$5"K8
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MV_9J[Z5!Y.2!BK/<Q98:,%H-?%*K+D,^&:[N(AWTRLS3S/N#:0[-D5D(")X
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MAQ><J2FQB'1HRE>6$[U9:4"G+ W8IC2@5Y8&'/DQ*$L#RM* (XE;%1/4/$1
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M5%0522/W*I)BVYV\YM2[@W:$_X8:M LF@8<--GC[75)DCR#W;O]9</^TJ>#
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MB!5)V4'B0^UQE:Z^/0FN.HU!M]EK1RRIKAFN]ANL<AX&:]'A&EY5%\#(U8^
M.@ 3A0@3?3HE-@&N<&+'8HZ[GN:0*$K7?I!$%*DX%R6+LIF<I51MZ66_.&P7
MZ;\?877;?N@JY4*W]E[#D7MU-?$?3R&'="S1VARM@W3U8TEL@RYU*:5TP7BY
M5//@5(DE7=59$F+IQ?%I.;%DG ?J'&,>*#LR('5-! 0#_($R'Q[;KZ9M5L>
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M9RG&:]:<V*SV8;C.7Q<&T>P9&,W(%&./)W436$*'IUX"H0\GNO#_%H8UG;9
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M=I_>^8+36KW 6V(P]K 8O.VF\=9C:JF(PLBZK!"(TDM3B.LT/2]QKP"UG&9
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MTO---LH5XPBN#J O)+XZIUWK\&XDP+%--,<+%.=SCQ7=)[B"BN&]?7=@!4[
M1=3A.J,1X*FV,,#,U%9"V(L<;] /&#^?E\5S4L<O"4"?;5T]HCS<_/*Z$<Q(
M:@YRP+7.0.UI8;5ZRQJLW&CF9O4RK[PQ <R[H;4$JV91&RPK+.=<<<=FA=XZ
ME](J4$;,2VYK(BRHK^L5BYZ!.0 BP5D\ ;&X?EII30.A<H4OHU5!&=^:3K$R
M.9!?QFI!SR9!X0-_73BT7,3VZA*9)M.>-<2*5\D7//]9L-PCB#G-D]A>[?2F
MW6W-$4;GPLUZ@HP8H#NHF824L2R+I;2U]7"/AK"_]LQ+>:"$]$@&U,I,!W+?
M2JCG0T@^];"W)B"B7KCL\4AD%^F$, LS/#=I"F^)2 S#QMD8%#BH?_MMU9ZM
ML4IV6G*KV>!IT#W&^$\6J!%6@B,K$V?#L&&61KF%(*$.T%F08G7J=S!;;SVQ
M>]@Z;Y?G_F U6:<I][=[W/'<: !L6--A;I__&UR_!_3B3/V2X&E0<--RA^67
MSG(K)ER!YIJ0H3FA!W6PV#A.Y5-/I$&$_"J?JD'EODI ,8M"],FV_F8N%1TG
MC4;?> D_QO>./M,-K(4+5+&%6?MTS 7[AA="VG3,]CBZCP'6HB8PM1!>R.JM
M?B!\^\3"H1-_0/-M01LJX)W IIA/MCU]1X\ WJ%-UQL*P[&[NLU9\#9AKF;H
M7>@U"\BB'J2H/#,G_KJ9EA#C_YW!_XHZ6+%@B)D);O-,<)),<.<$,L$'L;._
M2:(08M](YQ:1J0V\>[TUN:"7WMP^7MW??"TK.5PM8 P?A-&U\/NWVRNA+;*T
MTRE<^]OM\-OE#2#^%"Y[<WMY]7]+>?.^E^:8]@];TYG=A("^^"[;4H"5T \?
M K!A$3QM+Q1< N'=#E1D61. 6B\TZ1\+F$4",$.0A+TJRN7#UBO\X^+BZNKZ
M.C^XA./O%TUXL=%Q_H?VERA*N'7!I'1$.R\>UHIC5_-=[RR'1E1^^5D;;&(_
M)UB''_^ZU>F"!P)_]))081@BOK.=**="GA$I,?K0GAS)4]Y+GG>V-=5=C&MA
M*36-&(QHV^-:F37])=*ML(]P=ZU%*8*@^YR2CYZ2VWLI^8*VP=&(G%=%]OZ2
M3/6Q[GXX)'$+(%R/3E51V'Y \-(HEG$GI'?0 S0=B7QSQ]TAFBX$O$=&Z\I^
M6L=1.->&]=VI$&FWHY!VAY/VJ9-VIS' ;"S-<-,Z%7TFK-'ZRF1>47V5C0]5
MI=8T-I2%$K4_/?A(IP4K/'Z?)'ZOGD#\OG+$';[;+%((G_Y'HVERS^MGNG?]
M7(<C39GW:@6C\&>KV#M&I5<Q^;O1P\WCS>BVZ$:R N*7>T*6J3N:&![W;^W<
M3++NWRY':6'OQ/_HSZ:BB-6#XU&-R?;RT#VO S"AG*%+0,*I=TOR>M)O_95A
MY_U]81),AT2"1LA3<[ZQW(A[H/!K^G,#V,O:4D;WC;IQ]LCI4LZ>+EEVKN(T
MF>5MV_RVG/^JHQ>^F=IB F[\Y'3(<ICEA8N@S'2@S!I\&"K("=F2F .!;\PL
MJ!+:P]:/;NP1C4\U4?DIQ._:_:#:/3=C! T?'JZP>HHCJ*((XAQ4<01=?+N_
MO[I]%!@G?>28*AY38=EU^_GIO2PJ.%.Q*7<Z'W:.B^DHX25BFT.<^J@]?:6*
M6XVP&9S5_M,D&6V)P+_@]/U7S6"YA'6=[$>)WD59Q-C?42"&?63M_I8Q%>O9
MTL:SV9:FGW8\<_,D?C1S7T^1DGK/!S85P1]7*W!&;"G"L1N=[46I.P$6!HIP
M@[5B,.Z4!V.<1]P4>]LCTH\/RDD&2&8$Y3:%<E?-#LII1.H?+"T>02O&D)WW
MQ'%M?8S9V F98^%BCAHTY-O["+%@F<>69Z\ DHITE,9 50[2S2%(E '%E%(M
M4RAV&@.EGE!,*;4RA:(*M+C=;1\/BOG:@NEDV,.+9;LMW.EQZC*,0@(!<<G@
MX%P8FN/H4YU,ADXRXNFB#FR+VU-6JL*%@1*)ED/&+?U'ZT6? -5\%-B?+>S4
M;X% ;GGIZ(H</#_QD0,9X#3QT%E/Q8F17.R?1UN;X&8,W$Z$50K.J8H.3^50
M>-ROP!&1/'#.^O9LP3IP6B;F3C*H22*8-]LS2>H M4S,FX10H\N:CMB<86TY
MWM)0)R";3E4T48 L3>*XY(*ADGYUS9?\9%,ZL+4;@YZ4UFNHHW!*!S:<B:G4
MQ4K:D:..+*EN_&7%F]?+HN8E2JH_U2L/EP)$)=!X3\I?8/IXT2.3+09:(G#[
M/H*) *?CPE$ZZ1P?1QC&40^+%HZCS%1!?!QU&X.N<M@X382C*MJL_6V!7$GK
M]/ '"S1>:G^8JMLG(53)+9-*6":>73UT'!(U]"C1T&.[<S@+RS5?UG&M6'CJ
M(Y[4" $MCJ>L(VEQ\"2+8$<VE9!=QMQ*X5;*$1VF,KDF2GZWH]M6<;6J'/W5
M.DP5I>(JBN=J)MN&IJ$>:0HF25Q!H>0,_%RC9CX<F#JE@>#'%\W\U;(F.)X]
MHGZ56*K\L+U:Q=AYVJ!6-B"4@9":2O<42[^R F$;J5#JI4W*5T:)K@I6Z4Y(
M^*V-JPN2RJE.4ZVOI+JUV&:'M035Y8+@1M' SLS(84M9P2(O1:ENEC1BD5>G
M<D5>$0^N)CQXM>V*5^*PW3ET>0K;<^+5-; %GR[MUG'?DG)QN[X\O(*.<V."
MJ+?&N'0S*L,"H4M-J7^:-D8:P &C]4+V0-4!;.ES6<G!AGFM"-U&-;,E C!!
M$;5:;$S]H.2V17VE$K4V5^;%<D!CK !C#ZQWL9X\ED'%55KH]4%"*?6LI<V@
M\"HE]-H8W [9<EYYJRIM*=:=;<WAC&^T#QJ-JCF*M;50#D^!5B(%ZF/JSM!,
M=VA.KGQD1:1P"50QS[$5*-73(DP&/X4CK$!%DA9A;=QP?3@64GAZ-/ND%,^)
MGMAA:F39\"*NJEHP*QL]EFFN@.'2E&1>QU6@[9(051TL$9(C>*$<59E9+0E1
MI6*JM-ON<G.%FRM'=Y@*F"MR]N:*G(FYLOV45*\,%8<*",.)M7@R2*0I7[&>
MD;^=$DN.=M'I:RJ]^,T[<CJ=5U/4I+-+8J&FUQCTF[T^QTP19D@LS.#8#ZDI
MY<4TOOA?VZN5\RH;__T%;<YY?"&T)((61P" !)-N3--L^+$IZ(#69ULS:+63
M8$W/7/BX[JU2&P=7J:URE\YRE=IY8;<H&&@Q]Y9U^-ZR)'O+NGQO6279(-8R
MLQ/?5X:J<HD6G:\F.Z45-'PU69K[\M5(?#59M99UG=9M.?_QU61\-1E?35;C
MU63YYVL"/+/GXZ5^.P'8OMP,/]]\ :_HZD$8WEX*5__S[>;Q3PY&3GU%@,T?
M4A"@PH*V:M4=B-GNP<)P>.Q!YG/M;6V*^<9+TFZ^"E/5%5L7E"YE2*$X-">T
M%^'. ^:C17_\L)C/#9W8$9,CBDA[]")L@:G_CJ9TR< L@2XAT&7E<#E,_8&>
M+L^7)=!!?/;$##>^Y5QU%%.R;LQC]T1LCBHQ?:U-41+2&S_FDT]$<L&U:IU3
M[ _, '8*R+>:PBY#>94,=M@TWZO!(JPH0ND/S;8U,WF/<J^^$LA#O@>!+[KV
MI!NZ^Q:1"-3&H!UA]F$5&2B3D9X)P8;E<<VN=(H3F=(!KM<8=-IEKJO99Q#Q
MBFM^F+(JKID5GK;O_0O1'"(8/E-&"G7S3K&"535%DB\X(T\E4W"@=$YMN'5&
M5\218MV=(\5.#F*YVP;)"+PC@FU0P64AW&*HN)*NU&'RM1AX]WCU1&8V-D%L
M:4E#^[T(*XBY?LLZ:! ?63(=/QPA7L"1E;DQ$AM9./"FV>D>GN_(39$**%Q^
MF(K&YI=[/@*E,YSZ3N8PA62M4]G#/%A69<-X-0 F83A!:0SX=*7$\;(>CY<5
M.>0H(8UW@,9S<BJJ8#UPD_7$#E.-4C=*>ZS-0!@^/M[??/[V./S\Y4IX''G=
M!\)OHR^75_>T>?OQMROA8O3U;GC[9^+*\'X%<<$/4Y6L<#2"?7C!,2EC;:Z[
MN+/!G ASF\STQ:S2\C-'"Y("Y([!(*(^51L#M0MXJ>[JI_R"FPG U6T,.KUF
MKU]/<*6SW1* "VQJ56EV(G@EM=&2]\0A]BL1IK8U$QP$2>L)+%E<2/=&=UVY
MMF8Z[):)JS/+)Y5T@L@#TFA*:8;"YXZ!)ZJ=W\<5?7)-^2R=6$H-/%6DP*OP
M.K_\A%1ZX$D4>!%&VI5N,AV456F+Q,LGAG1B*%G)KBHC!4C]PXGF*K)/.MF3
M$&+M.D,LG<!)"#$E&XA5R#"ZMFP"7Q)8?&_\Q@PA0Z, MYE8/E5!M-1*5S_&
M+YKY3"[UZ90@F(@S,A]7@(I(/9W&0.D?[G&M(K=E9!ME!$BUOH#,R$[*")#=
M+ !9N3!38+C"TJ<3ONONBP"7;"$Z;,LP<&PO'<I+G-.UM6A?YA7=YGSCP2(B
MZ?0:@YY43],A@W6AB4 &WG%72NNAU%%L)0995\R"RBI=XN$+J^%XO)@M##H6
M?$*F^ECG*T 39,'?YVH/NIINDLF59IL E+70A .'@$?N)6;< 2HWI2S72GXX
M<H2EM3O3(4QN#%2UJ62Y4>O8$9;6ODV'L#8@K-=4^QG61'^H3F"0EYF<V&%X
M#7XI3A&S5(>N:^M/"[IJX-$:?3>)[8RF=YH=>25Q5\&%C'WY%+VDS&"(0;.F
MV$^;BZZCVY09#%7<X:JF'@-3MRD3MX>B/=RQJDP)_0I-?H0@8N:WRV8<M7D)
M?8'2/1W&>HV!W%03K)\[:8RE+^%/CC'<&-CL=S,,7' S]T1\F$H=IBX6#*7.
M1PL+I DU D_&8HFV:+5$8X49Y='D9@_3%TVU<R2V20&XR<+IC(@;"9WS;O=(
M1I45@)LLG-F(N)%Q=S38'=S>X/9&G0]3MKTAQ[<WC%5S+VW.BF9_'%ZZ'L7^
MV'Y*JE=6<L][)J%I<Q*[![N'XX+$II+7UO>C0U0F\>\DB%)0^?7Z'$\%QMB3
MX D7$TA-*2^&\G7'SS3RG_F&;?]5^6X]7RX6?WPA=!G+;*Z9;QB,-RT7-8P-
M/S9I9/[9!NTSUVQ7L*9G+GR<ANOU&6*;6JRT-&JJFYHYUN&CC@L_H"U"YX7=
MXI>G)=SRV'N^ZZU;+_J/5DNXUHDQ^2C<:<_ - ^@IK$*^*/0EM1/PC\U8P%_
MEX16R_LFY63VY<!D%?;VEFO-X<,RTJ3W$Y]25?S9(5>B$;AYF)H/OD4,>8F(
M8N<7W.D6A%]KJLUTX^WC(0C2SSKZOPD#>&-PW0K"QX?,)^'Q;0Z?&=K Y^-/
MPBT( @:]6PO!U.D%O_6S_S4*P9_Q; P-2Q#N NF33;2_6T\$I! \?TZQ$P2
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M;3'17=#(G'^S@^JP#)A6@H5S1F=Q*+RU7%(RR4IBH9+@X5+03<%]L1:.9D[
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M-R>!P:R2C8DQV,>"F9Y:]X8]/JFB=#KG@QDX0$YG4D5.D;!'M'L%RPQ/MO!
MV+&XK7GF@%B &BC)*YV]@$?KY@)@[Y4C66;<*B1LR"K2J>53>\MU#>*2T![*
MP9:N(H?Y<AE4 <<D0_K!;J*28_3<:>$F*;?1.4".SFE1,G%9+%<S:+VU35Y
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M>!>GUU'N<!?GPK3;L>]PWJ3:(=-B[_E">:-Z.!!+&DU5UU1EK&I%]5M49K>
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M_!+*@ZVFO-+:XCI>L"L@2(/]G8, ?$9!Z[(G^L)A4$+*IECFJPDR"OX?+:#
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M!F-%@9 /BNTI7W 27&C88$!'YEKAV4P%G07(LO%YM,'@L/(N\I^J):ZB#!
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MB>N;( ,*!G/HS2M]0A&WX2%G5 TZ+1RX4((*59'A(K!9386?P7;.U,^BX7#
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M)%P>R;QEV[ !'WMIVR]8U9#6><1EXFE1':S#J/0Z(3JP@)KJ"@P'#X+FX41
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M=&,'=B3I1JU6'O2CS=*/@Z38%-W/EJ)70WEYC>/&R,J)%43;'L[=$(DMK=N
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MAZ!)*(:A/C@HUIE9/)G@?S'_" 'E3"]:+,W),S!*MC#5"8??(5G3/%.W5AK
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MO3>W#X_WOY'6N[^9?_M'KE,G/'$]2S-7U(A^]R64*]Z'OJ[&%QGM,I+N,IJ
MYQ*4Z&L]U*?N)X%^K3ZZZC4RH*MH+.!@]56XLP#<2SZX.U()?6IH^I%3R[+A
M/\+/%4#BPK!4H<2!&C5QJ\+9^(UAM':Q\KCJW35TI5E+1:=QVC?7]P^L7RE)
MU>EOZL!327SW$YC50&I0AZ2.=U*;MW:X&"4-L:LMXA?Q1*]3E(5E60>3KD8R
MU]5B'YBBBQJVW%1U?:S3%C<W?[+H-UU93E7[!"K8,SOR,,L#'X2F\PM+]!+D
ME'+JM3W<EI4@T@G04':<+X,7A^;[GO1[=\>=\/'AOR\8)G=@5#P4G]<K]O=%
M@=I<H3;;0<=NJ"XLC1PSKM#[0JE7_#]+]471A'<CR(<R:**ZM7!W4RWL5A\V
MNE^:_2\!AW(6F\E+J]ATC6+=7HI#?8K_N?*P&S/0TBL/FO7WTGQX&Z#;1P9T
M'Q,*:[U$4VA/%-3I.FJG!G6CAJ"NMS($]9Z['V]CW[Y6*%-.[F]KJP0+>7VR
MPJI?<E#;M4>6Z78_^":AZ>\MNQN]U9'>FC&FA1X+FK%[(3<W]D+.(R&DXS-[
M((0&"--*+21I/!DT#U>EN(WQ?#<4G7IF^H=RO>T9W[FJ,-TC%R+@@H ;3E_
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MJMJMLFLW*XL2N[#@" UTD0 FS^!2*1ZL$GHL.:'R+[!> B>D'#+= #8_12H
MZ&.BNAGZCB'ZIS1N.2ENBN5L0"8:X[]A&UXC"POVR<6\)ID:#^M'%O7T6LGK
M%SQ>?*-/3.R=\8V+_]X@,,?<',U&,O-:%#9@ 9#/HQ%5WM#%VI$VSD\/G:&^
MDM8-, IHF5L;)2$QZ(94_3!#4.0B9FJ(;V&ZQ^ R#Z!P4/X9J[<JZZ:V0W*E
MKX9B3M$T,S1*5'Z6.<1(8IJ\E;**+'@+1'+\&$SNSD7=(=@QGP"Q,#Z;"4./
M&?Z=-"3+JPIP9 ^45 6DV>5%QDA^W.:6!M."'EA-P'%0'M+OQ77KA?XL_%?;
M>\@H57_[F/7NW.ZC&T7[CHKD)3KEN!54\U+KC%%O#:B'C5H4=/ 6&9;JB(@@
MPQ=<VW%X,>'P\O_9%/XO)T.4-47M:_/"!?FJS'(<MJZ[-J,+TVM56VN=,#9F
MMTND"<F(\-H5<8-WE($<G6F;?:9N9W^9NADFZ9["L=?NX,<Y>H C'38M>WO:
MFK/!_-RW/63&#UUS(:<4MX<S"X, 99^H!S"\BM"/ X0"\07B/\R9]X[XY!(G
M3V)E#Q 7KAC7*(DWLOO(]59!R[Q6K0M_;; %O?NQ5.P;W4\;VKV&E:EL-^<<
MOQ5MS'$OZ09ZBF2.P89>JK[2F)2-(*/>E*XGY ZE3G'?N4LM5,#]>'-[G= !
MZ;@;A9M1\E4KB:NQL=756& Y?UCV=0^)C^8FSM-L]SJ5>DC+G ++F6"Y<>R[
MW"KN\HEA>:>[W 8TUSJ53F\]M:S <28X;A_[)G>*FWQB6-[I)G?+@T:O4>GV
MHHL#TN(X+,G='\7(+/+8;<6-_AXNQKC=8*,HXX:6"%N#R]$=%63$,:D5-@Z$
M'&.-I8F(TE&V.*6!!R)T%P%K;H5&3J=7E'"N8.;;2F<]&7OSQS1! <XJY2VJ
M 9CG\_&[>]8P<*P<K_<3><ROV\]S0DFWG_2OB+].QS$E,=GK?2H/OLIJ'\5F
M_U! ?)AOLF7U6K0TC]UG,M7?DR9V]792W0]7W7F0@L/H!X_?*N3&UR8\F-,B
M^_*A*)5E//C, S+W\1L36=?LSFFX.WPR.64ELK-;P^:L\^^CELK6=B'^8!/S
M8%;+C7XO@#":W2/,@6]=F:9AQN_EW.V7!_U>K=)JYVA.;'$1G+4%GZ,NCZ)[
M*R;7+C6;J@HE3?-3I6DZG.#AC\;PTCU9;.+MU<J#=J77B9YB5I#NGDEW@\*W
MSLB#C-OI X[_]C5/'TUL@Q)U:XVF5T4KZ5U=ZW/XOJ;$[E-*2, B7.6P,_V)
M)$?\.T<SV'O]9J4>PS=V\+&RQ74,A;MT'_IMAR1YEGN9!KBCR_&HT;^$%D>O
MD23P=WK# ?=7IINX0+U1%*CO4J#>*@K4#T_<10WZ:=2@YZ<RFYVA3*OF;.CA
M6K'V6@E_H%)G7T7[C?)Z$5#:-@"950:=6'PL9D1KDG6([!Z9( Z.L7%\CQA4
M0PI5#F)D^P\,_=.@XG?3 4*PREW6QEN5$CV L)G*_NNPHOP1#8W25"#M::!B
MW*FY1R[K_AQ'U.A8R4TEW:H)MJ%A6BO]Q?8T>ZRX5UNNP33ST+/TFP,$04DB
M5W@0RQ_B?CV&]#B8K$&F9(S_+<K%15L^'-UG"MD1WFE!MN6#Y[B.8H>-<8H0
MMRQ'U-&WLGD%]BB@6X[M*>REJ;OE[(%F%R5GBJR8)6K@S]V&Z< 8:<X6M\0T
M.>=RJZ*S@VCH@!_ ]49SEG$1$#'QOZ;LSZ##LO #4+;DQ\1MD?/BL"^XF2;^
MJZ3Q%ZXA%W$ )79]I*:!I\,U]LL@>-8,8@C01'D!"/8/YUUI<O$AN,1(9]=\
M;%)(O=%Q"N9]-[\DXS"*+PP3-:&UE\,.)SW*1V]UVI'-35;<]<@+U0E\;&(S
M3=.;L!B_LV4J>#S(]7&8AFYM'.^Z<MH6CK1>.^HI=S^-(N/APE0UU@\A81E*
M+$5@:8<)U/NGVG9YT*BTPH8.KU(M3K-\#09+,R?D7<:U1U/RUJ:F/4Q,/CHA
M%W(Y1(S.LI;+/Q1S\HSWM\[<2!VC4-T'$<4" *)G5#W(PR8&-D>SJ8$<<+H7
MT9-LQJGK,TVYQ"')V%9.F0 + @5'YH&J.KS?7CKZCJMIHR;^9!J@N"]D[^$8
M$^Y[NW  $:?]%==RVAS'O/O=\J!7J;?7!5D%-_VB4G*K8U+X53E%+RE/3R9_
MDJW;MI^JOT-+MM7@\]!9+N%@^5ZO/&BU*LUF?9W%TS!Y:FXNII=:%^Q,^;RW
MP[A'P''R"4Z ,YO:E49K/9M*G("ZL#/?U//8O>.PB6*]UZQ@M8+L'^>.I ^?
M1A^4BBL.H4K)G16KT"6%VSMT<BT"4^MQ7/M_EG!?=#>;5AS%>0)>@R]&N[A1
M^T(L:_6%-("W4?_RF:ZAN^#7DK/@IC=\77T#OJ!"2<Y."V]OKFWXTH)WR'?[
MV*KS_>>2_[3/BB;@M'):.5MW'$ER]0.37+]6'O0KM=YZ$I0_HR:<^!*<) E[
M"Y[DCIO$!Q*.7^G7B=ZKW7Z(PA=%^M[)2Z\A)!UR.]S;8.@;"$GX8U:^=>GS
MW9H3Z&=:NU-P35X$9Y )7"6'JL3NHDBKD;-9/[ A(K:04C!Q("2X$(JQ/>!\
MW0P<E@PXS;P!IPF&5[==[:SK'IN \[E:^FH 5W[E*T-(*$SA:B<(0FK?R7\N
M5'AR:\]=%.8^4*"PO)@NS5=8V>+Z2GD2,!]1F(3KK!RG!>HZ]@1]XXIIK2;(
M>#,^G%:WSF[?]0T/D8LAHVFD_^MU9:[)JF-<>)W?+;R"XV7.:;P,2B35F(HA
M,Z65GIL.IT""DV-HUOK]542@0-P8W7!YA]MY.5RY*=SQ1S7[G[(V^[WA02M6
M/SNS.#!,S<+H+3"FWN</X@<@B(A+TMCD!@B.7;J3+H$[39F(D"=9" !UQ^+?
MS>#O']3@[^/<NEJE$>*ZCK;X67R+OU&K'<_B[W?@D,U.I1DR::HD;19,#ULQ
M9!+Z 5(<<5>C#*=G-2J]7HCMDMP46]E_/)4P2U,,"R=#I^WZ##&N@ (1TQ%1
M\CLB/-,+??:N;D'OBS#:_%Z#];%KCL\AIND.OSTTE:!+!T1_.RRFX3-A=Z&8
MQC&-]R80[*#;K#:VV^Y;2,9WXY,:\$A%2 RE #&\6VUTPUS)5 9ZL[4SPW$V
M$+!#0ZEG;31[$\<AA4_<W61GBC28D.-G:'@V6_5,#,\FW,D!!B;T+99G*=3R
M/#!)Y8."B\FH[\5T74>N-W8ST 5I'Q,&XT'_T"LGK&YJ%M5-NU0WM8OJIOQ=
MCJ+ZZ6-4/VT')18WL4,4-\5FP,>[49$CC=+61^VUFBFL]=@I^G*?,T^M%@,V
MJ8G%07.X<J=V^J:-A@T!9$CHJ.+KHH3AU51M&U3QQ7*L@37FIG:M)(DTV9UX
M8"0?<)-,HGV>G?PEN#9K&&>M-RKM6%,GA3O(<8C$]@MU=C7LG:9:9-#OZA9J
ME0?M:B/D>" "2\$C5E8]OZYGT.\($F-;(\[<S2.RV^5!LQL+U[NBNKNK"S 3
M5'<0U?7N!@?@.EXK)0QE>'&+]? ,3?O]"=NU,>LK$:$G"M:X'M#D49MF#1W_
ME68(5BN(0?3GD"?3S^JH*,SM5#?F]BOG 7\&W80A?U(MYM3S71KFHD+.(O<U
M5"?FA(K7>&.%O$I3EP_+>6M5;);G[@I_#.^9NY9[^!Z#13$4DWP2V25L=4<*
M:[7/I\H;,R@+)>3N8K#*JT&*0&H.JVF:L*G8-QF,$Z1=:N3V@MY,^#^0EIIA
M4VU>M?3X#$@.@LR9V^RX5:;O+^;_7E1(-6L5,M ([</KD XTZLTP)5+1=0#+
M1*8#H$HI8TI>D< B)",@K") ?"TDT$2QGCTQ))FDLV9BJ92N:LB11=>F,4<N
MY33:CBN<^M@OL=;HA @GX=TJ@4!>3HC;SSB51VDD->2Q/?@I3]S)B*4*95='
MYZ*@"22W\D8,8_RVCZ8"N2//&T*US@76W93T-<JK^&/?3D)=LH2-^@[9#-DT
M-&O"TJ#>])NU2KT6D@T@DS,HKDL.K6!P%R.S80J]WZX+;?WH&'8H'_F&[I ;
MDVZC[F1]ASSW?>;;-F%#@UJU5ENO@JE0Z$J=S_E4%?QF>XA3P(14.@2$E_6Z
M)=;X7B]HXM!71(1\AV21K"YA8UL+SC6=D\)RDM'XJF E2_=W8(TX<7/7]!CG
MC@[UJ7-=XA^VN?6PH;S@(]"PI%S'6OS'4L,Y "5_U-8TED_/#IZ=>VZC@6'R
MA6':D22^0_5<5B2.-?N5;J]5 ?9\0!)O'X7$VUL/ZR?QDDOB;.@:Z1YJ.1QR
M)JP$T&8M&[X@N]*)T"LB0.\?AY*G"U18F)$&X;\S3SB7,T20<43/4?AX-J<+
MGWI8-PW*A@#50=71DQ5G#H54<Q^N[H:^_%2+ 2\AI=@(;4)#]L2_ANSFAMW=
M5BA"[K[J7]Z+2J_/ZN199H?#R]P.4\"'J)*5/&X1N7]!?3AY9PM8:V02OQ_-
M'M'1MG0<:_&LU'JG/&B$C]Y;J6%V\[P<_QV3\Q+\!L5P^D+ZL/C*M20D_W1T
M/BDXY?OW 2$A)V#G<Y6<?4.*]<<$27<S2#C0K(I\$S [YNAAG 8\S52B"-06
M (JW#2;VX=&BG[R!>,4+D\ CB=@D8EEQO\:7F[WRH-]H5^KMD-IG1T4HB5^*
M1-$@+4B(>67L<%N\/^ :PX4+A22*40I6R!P.86F*(OFH:!1J[SM&X&C79&?>
M@V!WP73>V)I46\<)+^M=8SXYM XL\4]NBS,X# 14Q"D'10)=$Y0SR33CE5LV
MJ!HJZ)DOAK:<8[X?YN[@,]ALX\EG<>,O5N_DU--=037EG'P#?++$(GYFFPII
M(U/E#9OG@8%+CLZ2(0(:OJ\#UJ\H 7%>.X6K #MY<TI@)+)UP\9M 6+^-7RW
MEL$&]Q.2:S!:,U=$.T#$)OIB%HHZ=4!E^?AKD#U44*U&F(KV2''D2.W /+)!
MPV!"6>09.:04A_G=P;'O\-B2'7@RX0J?<[XN.=R"$L6!47#JN3H1O &=RL8<
M; X#"(XJ\M96<;_&N25KBP2^%6N@_'P#S-O82Q+4,?)16"6/RK$,).#@ ?ZC
MB2XW2^YVB63RUOC5?+B:<*,6P*"<G&BR".!)"BZ;<1R/S=;.R0-.>E(2QM6H
M T)#^-:">ES"<DB4%,DC!F!$]#1K=0^Z>6HHL&WWPET'=^KJA8N.8]_X3%EJ
MH",J'ON5$=T5<@$J^LJ!/>AX\GJ[)OBF,L.(ZUHQX.J/@QYH04$+Y4TP2'B<
MJ$Y[H] (?$=< +Z?RUW&'[:1#,;N8G=BK=B0;H:V]W/EFV&"?H3!'>\*>$W>
M0F K.M30C2*]GE!?<<,9@!"*"('X!RY@+<? JD1T?%7B@-9.1C< E6ZW,9M9
M(&A]7>:F2T=K(RZ\$EL2W5RMY>2Y)$68\J0@4KR./,&#A"%.D>Q;L4,59Q%B
MKK*;8+-HCLUU1**-\N8<6=#-^LL=)H1I  !A;3E%G[-#,2!CYBI0^UI_O?C"
M(U&6DECVVC#OQ,)WW,2<=5!/8A-4*YSO2"AO(J.0ZT)*9VF5OO"@B,=0A$Q
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MVU9 #8--H(-3J)*PWE+#5Z#(H7',[NN#]T#NU]5J[9 ?,Q/GG\*?,Q )\##
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M;E"7D&^7%=F\88M(S+WEO-%'[OK&N2SF=U]IUZZN8=L.2(JTYLC]OGA1[N-
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MALDW1/]JB.4:47T)X+(U$_>C?7:*?-P"N]B_JDR6M<^!.-WN 4F[=MA8?+_
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M>6IL<8UGRTT?.KUBY[D5Z_V"T1X57\+UC7-9I+2IS)=P BO0<VXN-RJ"4UZ
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M$+D^"$:4(  #@\U3+P ?QH.?IAWF+P[=L?WE3RX^\_\Y/[<_>,*??&__X3Z
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M]IW;05/T>=^YNJH :CK$65V'W7B);H_<":KP!R].)'V4VNRC!\:\^5[M.UF
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MP/@S+R%\*568\2#&/H>GYW@L'ST0_GFF-E>534O$.9&7C>%X_%L@N^\LE.T
M1K(23>HE_2ZE$/_F_MN%F4;>HD"?3./(]3]).QJ #/IDEH!LKJXC>\)BOWF(
M&!(R):BZBS0,F!F#;M?I=KL6'M;HD1:%KFV]-4%N1]+!VAT,<X-V0.ST]VH
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M43D_*G7$#V*AOYRE>J4C*>[2)Y.M+RO4X?'+F&MF%\@90.]31>U8C2O?1PP
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M-[RA/@')O%-JO^L(N6W/](1G[./NG8ESOH%D4<0T"-  *+7FU[]YJ2H4+KR
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MP0.F2VRI/*4L=\DYE>0F@KXA2UM%=&?]B.5*#-)Q$]?.M.6S@^5\Q!@Y1C?
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ME06Q(!BQ=B9,T%1"/'WJPYZA;Y"9!&4IR\_)6)6F7%A#4(&?9#>7BBJ$4,7
M(\DZG'VH--,="RQZ;/>';A;&R<239,30<3(L/G8##*(ED?LL]%]'4>A.) N9
MCU50VXU346;P6,[*M*JX^#J5GBXT; /+7 GJMZ@KRLVTS&*FF-IB, -26@;]
M5724QS,/OC+A$C9;E[!E"[SUX]-Z-5W#AG  LM;6UZZ]N&:QFJYA0WN:DVG9
MAF[V9*G+CY$EV86MS1-R,/Q&[J!L1D[4(1:>#MZG^*<O0?CBB\D33Y]  O0(
MBDC#3Q/A^K!963C+T:V+8=S8R1")I^>//D4EZ;C%N3W=*)/K.FQ6Z]3;,8=T
M<?4&(J%8S/U-=?H4TD9LC:P-58V$$5/ D7F'&BOF 0ASHD ;Z4*T$OINS?=N
M-+"F:%\LJ=/,4T%N&F42GE53Z^)02,OI=IC<2C,2@7BA+8P1'%0V)ABG!/*3
M$852B19O6WR4KYL@!]G(G\#7HK5/ 3QLE[E0" ICCCKP20>&Z8R6!+?@AZO6
M'+S[\,N*P$AFG"TIB' !)R/5)?+Q*J9&66\&!5%Z, .@RDTD1YBS1B:4SN3S
M) (+/C7U?/_B3D@%RR5;Z7ZAULN^:MOSN?+]E+GGJM>M(U2OGU9Y3]:54%MY
M&HWU@$MGBZKII!3FD/:')G"*MC'XSV3+EI35J\)J$:L1Q*JT>L^5U90 75%:
MG>:T@Q* #&=?7>ZC1"17@F1!*D$5)Z<G0.)M-,35L4=+SEUA]@<,&8V6"''N
M+L/ILIB-BP+.;*2WWR8 V6T"D#L%(/L7&( T*D=,F2Q\+[G]))[P "E1M%J]
M_4<NRS=T$\ULHIEG9NHUP<SR)ZO_WQ%C#$IR3@W*#$J4S78"6E ^AMF8$^U5
M?V4%&Q&%<C(?5!$\@XG(2IF(I ^HL5#S'<,YGU6$Q)%V6PFBF#Q8-S:#59:!
M(69#*(]3+;.+'-E-2R'I>,(C0:QR!<$<P&S*;(73[KB-W#%6.7>,Y/HCT*"&
ML-64/6;[MY758NR+/09,FI5$*O?WZPE!=F&.26?3V2N-R+?%ROG-Y -4IG(B
M&HD\PN7H? -E/!$[B^QP9 V%!-G1!94RU,@QZ*P5#6-O[WF&&4RPWT:N%VIA
M=<ZLB*FJPL]7_;'ZMRZBN*]F=RP;;&;IKKYUK7RBI"2(*6TS-MUT#4^A1,8V
MLVH:N(_")C"K3FW(%*L7C9=S<'H"9.I4!C9^56859*15E>$2NE61\A6&.'/C
MDGC6H8).[3X&!RJ%G Y1U(EKGH_1X.^.6=2Y"]=N6*W8<[?6(["7D2L_]:^/
M6BEZ'!+2+9&GYL$O*:>S5HA*E]:9]70Y5G9YH W:=E "F:.-Z=&7].2.W2AZ
M-3/AKN0_U=YE.@Q6X3'1:,L4MU$I4)8O50_7^/W2>7'B-Y8%B,7B \>B4@5^
M"*4?L#I 8SBRM5N%;W,MU(J2A@Q3KRYMDISA,^]IQH2F6-QE\7MT\F?TJG-#
M"C@NJWM@2GI,2YE(QM?$.C%B_MF1Y6JRZ@2K"NPI^DS<K<+$$*A\ML75'7#U
M)N[77 LRR;AL<,<BQP+V2[ C+_["R=F4X^'.QE(;O<$0N"-+WF1E@S *O8S!
M<2/N$JEF):DY1\LJ1W1%#+G<$JR38G28;*)0Z52L$<YGH%956*C5-AIQ<Y\#
MF=0V:N-BW06>D^XJV10)H]_,.-.)P4H-*4239"]=G:?2R?@2T:6%"+R0Q6J9
M%XS@X!V?SA_[WR'C2*H^(M016$2!E3D2@: [!+WPAEZ@#@J7<:['0?JZ&S/)
MF<G_A5&F<O>=81SF9V29>5/D%V:$!&^V?!LLAPN2C#'HB3 P8I0O#5_9X/RL
M2?O/U8I85.R')R^!2D:$1PVX9%#^PBDF?@OLMOTW%VSYZ-7NM-KW&=R2P;EC
M2:"=;%:+!_;C+W]\LA]L4C;M[VTM;*I>D0*T;U"=4?C]/3T:/]UI??\)[(0)
M^('T8_O[=]G*5HJ19BF(A$\W%UY*>E1V<4SX&_5L R/ #3(%\ITG!3X@1X.3
ML'.-8F6'AYD!QZGWA#U@+Q!W4<Q\F,M.EQA,?$%0AM PU(QC(E$3V9WDG']P
MMG8J\SC=)[=-I>VF7I5+=LQNUR=CO/HE[X8P-0XAB?U7;9Y8F>YLDC<"U9[1
MSTU7H#( >6VS29.)0K>#R(S$H,M)_V256$T&Y43"P=*<2>20[I8V]LKA%CEW
MCF!8G93H3-U<F@PNEL0SLIOX1(R2C!+U O+JRL !*8D2+25I5%RY,7:ZCCSW
M[)5K+:C*AM65ZW__U\-@^/#]5IK5V!3*0:ND.#7M"5@SPJ=31YGMS!'6N6O8
M:TW[Y[/;([D"@$K[0\=-,&9 #1$C#QX[CE=< 7>GV!];H21[#4IR)Y3DX )1
MD@W8L0$[-F#'RP<[GI7%L)MQ\,T/[IVR K9>0M.54+Z#7? =7#-)CQY7)<L!
M$P_O"QU"SM(9;V_CD^G\2,ZD]F(+J=Y5U+"00S2Q#@C-PYB86:YI9JY2U&+Z
M=TS4K++&8E7A:2.A8\(!.(P+R,P:YE=(&/CN-'VGT;J405KP,7=U"9# D"9<
MX:]IS20'3?7GC!:JB*? I!P6OE+N*1(+UYO<6<QM5L(F[!1W(NE8+S;PPFDT
M(5<JZT52(H7=:X1NQ73*T5I+3\=@ET_[.[O,</="1),'+T,ZV2Y^3.DX*6=,
MX?+,BKB*Q<S"9.=$8"=[I,/746[: $3:AU2@1#-(24:6.*56^3OR<;DEQIAN
MM0"1Y4T+#TZ9YPA(@+_']+%+O(.<>Z=2=; DD!X4=BOG0.6;.40?96=.2>>O
M+D:O%?R;.G(3>98L=?9S-HEB1'UE-KXXK#:WAB-^WU?DZ(!79'$YJZ&+"-*&
MIRL2,^S(\2Q49_ACWJ ;-$1SO9[;]?J+CN>67K',UY!N9-3CZVY9<Y\SO.7)
M1>85J;((W&)P7J<?MHR>*XY$K:2SQ"G#[[CK"F%V)A[<S1&&&(JD^DI=KCXS
MC>K<M^H<UU=UYMA0K\+A>,SK((VI+MA4UB04K!SF0K+.J-0.Q_DUM;J7E%C+
MB'<J-5;6G#Y[M5%OE>C/#)UX]F6H& H:)B:.&H2-*FBC^G2NK],8J1$D>NS@
MMA7]>]"K!9"[=NIC4EU]_/SGDDQG4U=@.09MN\(-K!IA5=(<<+NCP"]=67P,
MGH4Z%HBF9D1N1K*H/2R)F]5JPL4@/?X=5@;5@=(:5/K"Q'N2"*R:7V/_EEM#
M8R1I1S.Y.&:E;.0]$V(J-OI7V&(^$I,)=>/1?[=5ZZ*)QJ3"H&:HSY11)\V*
M\I%;J^ (RX"HXK7G2ZHE%M$S-4O0\038CI,G-KKTS.[L?^7P3F,X7\@I*(H[
M'=<!)6%E)+&R\9()K$-PNQ=%XCD<PR:6Z#;6@"*6/K;BKEKC=>"C4LYVRUA5
MA1IF6 8]XL5#5SA<PM*EZ.**F^(S54KKAR/7C,3HIXAJJZ#(E3/.!#<.$\\_
MBR!EU_'T[J?^=[ &D\A].<.F'JL/^$\>\:A-Y-K)HZ*M\%0"L56^W7(&MMQ1
MZ78F/#=Q!JHW"1B"#/(X:@TR ,<\I/W<+?(Z0/1VPN=U#H+/V[V(JEA =4RT
MWK9U5(?J^9I63\JB4_A.&.0J3*T)!54S$&0Z?MSN(33OSH)#I<,*?)>?.N#8
M%"!L?U2[-8+2&NV\ZGE"]W 8*TLPT^3,/%M9I]E$Q)RO=/YWA;69[?BA(SLI
MTC?3)"X+/LZT ]L-@^S%\9(2<85@K/'>XY@;6P'.^@W@;"? V; !G%5&(1U2
M-32XLP9WUN#.=I/+H;R)-+O'D8X5\?;"78UI/\E.7WI]%DT:U4&Y!#R3IO$H
M<Z=8DG4-T%$+2 XO\E7RVB)Z6!+)/,AIVBDNDO&.]IQWV&.J87L8Y%K_J7P9
MI>_L28ZN;?_1L48R9Z?,4. 6TEPZ$??G$H8S?64R ;.).!6[R6=)[87A@"IC
M\8+GT'_F,)R[@!U(3!F+A>_19CM5BN,:MMZHZM9[6KJP81*10DV:)3KL$HVW
M6Z+?1O +.I*QS!T3O,<%/8Y8T&HQ3V9 ,VY()C%1[891)%]$DOU,LPT.N@TF
MVVV##Z'N;D]@T8E@<]3(E52KLGQ%UB/N4$;X"/BQK.%\2BST,9#-[,, ^[AJ
MS?&')B-4C!25!M)5-\)=3??9M45^>P>)_/[+C?!^J58*K(&&<I]2NZ69&PD-
M?]3-?H/)=]0PJJS/]5&"QALTBOP=BEEN!!(6DCH&F=]4QKD>RKOX0XR%MS#@
MGF:T\T4M)UY):G4H\5I]>1RI8)[0@2.NN-"?2%)-Z@QFFR]!6_8K?#E8SD=L
MW5*QA1N]6O+=F%=6 $[N(L;?2*GJ$/GJR'9C!$1 WE0%-Q4&*H6G)#@HK#A]
M\"VWS%0@(;&2W@?)Z2S"JZ(-!<O"6'T7QR.B,0(33*"LPA<46JOI3Z>Y-_VK
M1>2-A6[&F"6'0TESQ8,OK,Q#5!I=+R$_6:*+)7+&(U2"NEU08!G!U2B./6CB
MV#O%L>^;.'93.-T$L)L ]AD&L!L;W;#1^P>QT7_2L>!J5GHI5QX:) IZ>K.(
M8*.-F>(4+#DP4NH*Y3B4-?W(;(]Q%K% NH>:R8;PWT^R?0]"(S%RBJ)+X_/E
M<DXC^7@;P[!M;BLSII NF.D30BBG%6=S+\%XDI ,QMD:J=PCK$PA5"P+WNRI
MO\1*-%S.=4;A/D5Y^@5,T7(Z=IXR=*8*TY)[_@Y4:DAM+=-JD2P4UF \-N!P
MQ!"<@L<S"#J-1U?G2ATE]F6\^5Q,L#F5_VHUY+XUUMZ#@VCOWZ;36"1)U21-
MJ5:IIVX^'GME4%8[[PENC!N2H&V7BL$2QLM2Z0%3^08B,?C;TP!#KD]W!J&>
MO@S.LT2V>?D. .K2F+DP#MA.3\2M*0+0"&-!YTM'2]00,?0B>Q&D&D$RZZ>M
MSS-<R-0YCNN#?6PNHSG';1D&TE0"%C:MH^F.W!C;VQ%1 ?'K&]_B7#T]2Z7K
M]1-HDE@=X_O";V#Y)])'?U8C&\?V#544#-]K!J'%99#AKJ&;_B6]SF7C<X[:
MT65.I4E66IH489CUV6CO$+N^ZE:4.7?Y9QCE35A?3[ZUROF[)N$'G=(PFB-U
M@(%Q'8GD!;YLR9P?ZB8/J_EE);1)OV(LWIUMS,YD*?%R[*TP=M4 7#=(,5^/
MA;;N1#&86*ZB*J?!F+T."GJ'% W.:A0+&8[.?%O:V',LL7,GSS AL*O!JY=_
M9BV=-;GTRZS\RS(%P:-7 W24TM.F4XW?R^)GM48CP0TL1J]VF9QQS?]<AHEZ
M)J]Q.+4RLS=FSA%;>$/IJHV3M!N'M U9.C-//,MWP+1UZW65YXU7K:K%\?.2
M3C-VXGX1TG.1UB]+,67;<4L&B;M4-T,IMH#/"%BU?[?H+X+HD@3* SX5@^:6
M=>(X@("K!TO>]S(+N8!O&8O,4VWSJ;PGV+Q?HJF.DI#Y3S&>!=Z?2[C\M3%.
M8!98*VHM(D-:F;Y 9$"D=-'4ZP0V4KR<3F%@=.F/L-Z2;J&)F[CDF;'<,R!U
MOCWG[E=O[OU'"L9:\K)&PA>XN^D!=_:CG[%?2LL#8$B&09(M;Z<&.8EX"B/I
M-F#3%4E]D?FDCVUB8RMSVA%'$/-(^.^:!,"@/$J['Y2K$*JFAP7SQ6EP>F^_
M$+[YX5>:?/N]_?_"L<8,$9[HV+ZA_G*R1]\[TEX9E44'#<L9Z>Y?L8ZGJ1,]
M@$-MBJKSWOX)=PV?8$*B_&F*SN+R:G9D>6NUY;E263!5GA%R-R_UTXB*H2=W
M-K^H*U]$E;QJ[_*'Z!A*Y4%;^*;T_)O,8O(,EG__76/+GLB6C2K9LK_KIBH7
MY>FN,4T?C2I.SW0*-=C3XEN0FD[:JD4U.9LVLPWZ2"(5:E2:DR=!P72W]%GA
M!@C'](R)<F<7+@*X.?_-QQ>N,8_8 =0M15:.1>/AE+3NY\87,+B<3S(BBBS@
MV!2U8$C0E4\/EVW4B1LA27PV M+A4YQ.==;!.]#(J8^06U"VC*.P'17VF[Q9
MJ;&B&LAEX76LIW0'.25.J2JXCUW*=F42,BCS^Y9AW-)&I5<K3K!<+SKYD=1R
MU>K*_:)&F6<N8U8:>@!?^!EL&5M%HS#\8F=&D=E"NO&L)TN'93MS,^8L!: V
M0(P97'R6I]H?I= ,,M$T=TYNC[JZ1B!XLG!78%=ETW;3GXVI7>J<+0_2XXI\
M;<K4+<ASYDWE!GOVHH3;O"H>#*,;:^XQ/%)EW5O:?<O%4S(.!.^\2=H]4<U'
M/JQD[?/OY;9M1"E!'1[I0\I_R7:M.D5\=Z\V%+SK5U(X'WS7F\>'RC362AFC
M_3>FZ6;WO*5!^*9>EOI8:S&TY16G"B..BHJZH*=)%[.N=FRI;K5FF",BR/>^
M"#@4:)19N/7TJ>"QD)*5&C97P .O"9?1F%/^I8J7CJ%2\OFK0+=POK/_I>;/
M13Y*!U%H0L=8\+/@COEYHH(,FY<)L_(2'9J5#(+GY'%\4[)=UP*FA@U@:B?
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MU.=($[&<- \Z7_WJC("N,8ZRS49!(*FKZ3HSEH1:A2:J8:B;40C4I@M5O\7
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MI7%;\)=92#5KFC2;7%B]D1WP*'UP&N4XA'PS15 T>09A:F!ED]>[$VBM3N?
M6DN==@V.Y5Q[ <ZXAM2EYZ1P3^9OT11#@B!<6>!MCJ,H,PI%*@/&6!2ZDEK1
MA"AE=Y+L!X></C H[F$97\@R><4N'XKM15'Q2$XD$_$EF=6WI#"1S>GO[ */
M'?@%;S=7JHKSJC_/8C\K(_&7/SZU!XY-86FP W_-9'(X6 T;[Y/K<]:#?C,"
M>_H2K;^4AS>'U,]TID?X$CG:&EG)ED(,?C=X'7@9"2%+=I38?"6V7"/4G+7
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MQ-#%3L&"-\-!N2'&&_"@\(QWQ>;V1PY>7)VOOS.JLX#4_"0#-95<;0SJ/-4
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M/]S9CWX<%MKVP!N>8"4Q2LICE^!5^ A_ER*J], )/+ML(,.[DH?"Z+T$.PK
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MX!MPO<04M,Q95>HT>;)Q]42&-/1*+-"MAU,(QCQ]EU?#^E7\_WBP?H<U54$
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M;[PL="*2H4#P!>Q>1SL'Y8$5R\1('':,)],(OP42"]3I$?2CQV;NDTS'SH7
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M</<E+(VYK?0+][=X-=DGCT\8=*A60[P(P0B**6P[(R3N,]<^J'(I<)9@L<B
M32-&,DS L76]@Z@P#4M6V-RM- P.?14 NF79?[M2]K_2*/:/%*@-MK5V.().
M@R(X?^NY?SW6\Q^NU'HN^.T%,_JT5O1QC[P*POS5Q<0/71S[ 16TG7X_:^$R
MI*/$R,W8M6C5%K^+MJJE;=7L\JTT6I75(DT5C:WG*ODVCIO+YKLM1]JUL%L"
MNR 3@Z1!HA2L$E(&\UE8GU+V&$7+8.],RT#)&4W-8+V=FL'N7@$UP_KB#39B
M^WVJ;%II21\83W#0B%H#_=RO07<JY^1H>),W9-H>:F0,;O^V,BJR,M;>?9N
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MI,OT503?ZUHFKABT5KH[W0WNSJI"I#.UP]^0GK?*?1S3EPE@/"B[96R4/5R
MU';W7NZ&WY)$)DLB@40;1.Y4N;W=Q![>U2F5?AGWV/V^[K$#76&/TZ6_.N+8
MD!?N@;PP(JMQ0Z5[OY>/,.Z R+2*3S%O.UKK2@EK'7 TLM:YWZDH9HZ3O&)
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M1.'7.[O=N[]KVW//]S$6__'73ZN! BN_<F?_ME3A^EAD1H2_LGC8R\3SO?_
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M=7S;(@2U#J.63!#V"'LIHC,9%6YV.:9*=MB:7C%N'0H(;4=@S7M( JC!$DI
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M$=?BEJ!_3*OYA#(+!>*C#?:,/D#T[/E%-[S6JB+R-@GCN5LI TI&$EV'":*
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M6P0\R\$YW>#!>1=-+;C!D(2#R;6';:=)W:AO,K1EL2>U0)T4RCMW!DHCE:9
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MR+YLF3Q8+,1AZJF%">2B8PI;>GS_JA\KV@:E<'0-I"EBF!/WSP:O9,9,MC'
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MB!Y):?(-7@Q\!\P<HZNF V7/!&MC!;2MI3I6Q]@-9)%^C0'@D3@WW%6PJWD
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MZ? %606?HFPVO!T1D/QP^4Y,,))3&Q6'_I\W5)\MD(CIM5<[7XTI&[ERJ2[
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MAY$!F $25RJ-B&.;BJQZL4CN93]&J2SE;T%<3"A#:Z!6,8!'6/34+DD^2U+
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MK_W\>K(W&AP'HZ.S8#0>[S>E5UP?IR>OOOO[;\1^E-\+=1> X3L8DP$*!J9
M@"$W=GVN\@IZU;X1]4_9JYQ$5V674(BOG->^0@7%W_W]>##   +^KW-$SN]Z
MZDD,!T?!R?DP.#\Y7WL24D+LF'G3+E%F2(M1M&&,Y:H&S*;-DC6M2+T^POI[
M3.7UB&-ZDJMY[?&R/45C-&RJE5=T=?7YF+O\N(9!+W_/*'\7A92]>@W)J!?#
MC8CA9H3KI4UL2]ZT:1FN[]^FC_O2Z6_VY>U1)_8:7'E)K:C34TYBXWI(V7[@
M?3S%[;3:8(:OGOOR7/G"7#[BISM,*X_T?.,C;3]Y9BRC\S09J[GJ'?^4B]R+
M[ L5V>_^_M&U,KOYIIK 8T#*$/3=D??-1+O6'V);3&S8&A.SUOBI[%X.!FU>
MX8AHU=HO&LE('4?K'GS?)N;5[TEM3X[/@I.SX^#L?/PL.](1MMRBJ*65F$8(
M3#TQC3];(7ZY''O=@:QI V1WUHH?UP$ZO%U[_[._4O6X!NO.LAP6PJU8FU4C
M%]LQNFZ64?^V:"8T)%9+!^?C87!Z.N:2:>]9:J9[N=@ZN3@/3L=GP5DO%]LA
M%_^SHF1<*-23QL2YMCK!^M-IF.=(.(+LNM1@0E%2#Q'A-@X([\@5ZH4 ,O_Q
MG*+RY!6DQWT%Z5H5I"=]!6E?0=I7D'[+%:3.0%W_^<M&'V69?N?.3HJ>*2S+
M<'K#-44\T]>[-J]5Z\$R.V#C([]%F41L@'JR,D5W#,"5XJHE-+3B!9)<=+"?
MR597R'TSGR2"=-V_S=17YH?^A2#!<!A'J$<A*BN9?RO"HTI<<'%1YO&DXIHF
M5=228]E4@R!>#7>19XL("P/$=*);P5@3^DG\[TI:;,P93^5>5**#?0>82HX/
M2QZ550Y[,Z'^37Q<P)17X:_=J"9PD*(/80JW+E7XB+W#-G]BVMP/T)-4)WGM
MH%U3<0:=LZP>.:2"N535_W"Y'WW!EL1PL<AB+#02U5**U+]!;/HFPR[<B&<0
M'RP"J^U0AQR3I(O. B#+&5Q0.*"=VDA2<V^%B&)'-KQXP5G"?HLO4K<UV"95
M>TFI +QYE%]CZ:LL4.."N*FY2(J$B^BR1,7#\H8C=@%=4P^ ED'&*5V!ZX'8
M83FK['="%:SU5G*JW&E\>*+Z&!!+JAH=;RCWB4$%;5_88NQ6A<9&)/CQ/)E:
M#'2;APJ'ZT_PS$-D&Z,>I$+/U<R''9C)AA=]I1K)1YO,;ZGW8S3)*[Q61F<$
M71OR*:^??0JNT"&[U<2<TH#!)GBH23H,!U,#'/:;;&SR$^TQMTX<';=L< EG
ML@A%03_&SV#ODJBD^K54,*PA&:"H.Z4VGV"L9%/R1T.D'H!_W8&GPR$-ZXJP
M0WDWX4PH8B-&1\I<Q^A>C_=?4S_&&5B7"=J;FAPDQN:EW!%)$1Z8PS\-S@>#
MX/SXM&$KVW+IR>Y;:*-JCQH'"S8R^WYX*^"=@U9\B\ANI=#^M:@66G*KQ>;T
MZ9/*[_@\&(U/@^'@R+L35TB]A55-*JDM83JCF ES8Q11?ALCI2Q^]0K^EK>V
MP3H*CLZ/@_'QN;_L39[UIE"_J_ZJ,.6F61'V\8HQWZ'Y/86A+2WR^HMZD7,7
MN>')&4C)&*3ES+ OVOP<H1::8M-ALM:H&%!43H+3H[/@Z.1LJ:C83V?5*(3%
M>SQA"=">_I>@CVDGU "E'MNM#6'#HZ+,TJCP=/]YR:^I?;VZ'4#=<@OEJ-*W
MM&&=R3:]HW.FN&93NZZ/-4FJ7*QY5!*5S"CE*K@CF+$>H:3ZY#%&9>?@-G%>
MZ,_.1O+BA\C_@T\_&!X?'HV700F>/-\S[O,]:^5[3OM\3Y_OZ?,]?;YGM_(]
M6];$Q&SDM?K;'V04=9Y(6V>4=1_RJ(&&\Y/3\V5%1:L,\#%']#-Z."ZH&\;2
MQ(7194RXT**S YO &%A^W<1K;A4R:[MI<1XN,>B"MC^ NV>L%EI *Q2$.3!F
M=#^DS2Q\V*S\F!64Z7K<4;;P>CS:B'^OA;E][6HIIXD&TN8FU:?YM90HV[M,
M,C7P[<RX(1A[W*R&662%!MVGH>P-&PC*;21^:066"JUY=-3".5+WG >'0\YY
MR-GAA_#.'?*E^W,8S_U?HMM[9901,S6-XWTJS/ROX& Y&K0SJFP5O<OQ*!B,
M3H*CX?'N4M0\,)BM'_]1<'SR=2Q!7W,2_[R)RVC%X_>U1^[BT/_?<0JFW&@P
M'.,)4Z5/2];[P1U?]<O+=LCI:#STT T-Z.$//N%@.H5V<Y*ZYIWQM4+[,?M/
MG&2W<"?<1D7)%/WFY;#5LCO>$G'YUF7W*;7L#TE\']Y4_ILPKZ8W6R^KHV$P
M&!X%P_'9EHC'5LGJ,#@]^C;T[)LH0:!>ME.*5@GOZ9;(R[<NO$^I:-]AIX>$
M?,CU%O+M#[]]2^)P%IR=G07CDUTV2G90L;++=3&/RS6E]":.KOPW51&GV(KX
M-P8\;>'>](+[ I3J#_,PK4"K?@S_XW^L_A.B[[7><GXRVVUAKSD!=]K"S>DE
M]V6IW!_NPT3X7[WL]K*[_5JW(QE23X2XK>P?"$7]_]E[]R8WD:1O].^C3\'K
MC7E"?4YUC[CHYIEU1(\]GO4>S^5,>_>-Y_WG"215MU@CT +J=N^G/YE5@)!
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MVW>)8H6P4OCS@X@3V&%+X<WN*X]M13_W8Q @T/VP?O;""-V%X1;N0%;MDI+
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MQ4=QEN9_%70?YGU)3ZMJW7B L8?"Q(G;0(FO@TR=&5\0EUU?&>$_IN^+B[_
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MQJ&&2BJHE-[#8.PC.GAPD9JQ7S6'R]MB*M#?K->VM74LX <K9C(,8KV(0I*
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M%<7W"7*7?RE\"'L9^[(#LAZ];2M48.6!CS$/'9 (1<IR>JFU[Y*#0A;R@S^
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M>P:YXEG/($3/U&=4]O;H@@4#1S8>(R7U;<_ROQ)E9OIT@>MRW!708G/2\+U
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MO"ISF]5YN:A!^B9N'6HBG&C,*FH>63H?%N133L=D$C'M=WP5-A?>\,%[:(L
M&S"8FN0 DU,S:D1D&[]X9G^,AJ@EZG2HPRO)L#",?IN#7$0_392V.3UX#9/Q
M4,'CAL#F\;%MD1Z.;S&4L? F<V#AC-8,AK!2BQ1+H@7Q5<"GHY/!B]AZT;(6
M&_:-J#""73G1DU/?18K"+R;/-=_L<#V19;?QPQ]@" FD%*X6?CD"=>'T0'Q
M#]BB9+"%DTD7NP+%V13MT&&=CI8&R'SJ_"4UC$"1*T-&KDI%KD8R<B4C5^(O
M0T:N+NQD=SH>Q3CP8<>G;/T"XF0?7O2NS\Q(9C:LW&=^BM[NK?'"T\?%+K,L
MWT":/3.Q#)32Z2?5^>"#!9[5@M&]>?<S&*;N*TW5>YXLB6L;3R\!N-:P-#8F
M-&&0N+#,-$8@J%XIT(T)=&/;^LD)3.?)@GM-7-$+PU#B$LCZ4GQFL(P+OKU)
M,G]',D4YQ"TX:\* U[)41#[TI:L ZXTRI%U9[XPZ]-'JT@XOK$=P]F@2_N_Z
M%_W%#4S[TATE@FO/ZX.;;A;V]\V[G\*TC\D3YW\WG0UF\F/$:2%:(-0T8%%[
M^C=48DQ3&((M(K_-H\I5,FESZX].1J/#9[!UP')OWKT/\6!X604KUENM-V$:
MF+= LS![G/PXZE9DN!)%,6V'H@#:]E6BIF=MIA]X4S,=J8[="_%C-$SIS$OM
MC#Y,(08>W!>1KOE](@\#_)XXE7P$D+M:>W2)4##/A\_I42.I.!I<<X">*2#G
MKB&:=IX!VDE0S&OG@!2!:D3@XH97)A)GPM/+JED_M7*AT3RUT4EX\JL&,ST-
MM'+-R]<&W1Y23X9&IT?4ZT37JSD (IOOXGG/D]1U>2$7325Z>@35Q1SYM#)N
MWHWOJV0\R.%!UTZ'/LK/C8O;3=)CEMZ"9$#^(2B=GPDD1: :$1#)[CKE/&.:
M--4^WF[[.1UK[Y+[H)+1M-,S@52UT^&#B='M23AD,*@F>G8 :_+2S;1#V4Q;
MJIEV+)MI93.M^,N0S;2RF?;B4#GJ,-S3+TL*>HZY+MB9VMABJA[GEK<_]7)=
MISD<S>,UR.+"W6>.J,@)]I_S%:DE-54C+LJVR8$7YZ^VFH$7 LA?!?&X4OH@
MT_2IS/!GUU%H7C ZHX:&V;N=$97Y%$NE6J3!-H>QD5DI_0<?1M;'[K$;A;LG
M(9:$ZX39FGUQJ+L,7!UDUX'WU3$9J*EIM4=?=",*\:-T67/>EYPO4S75L2<F
M@H9]O#B^SF3@L^&8.Y^+%@7A"O''&-(IHR0<>4J5)1Q-&S'-]O'N5A0<@WC:
M7H3-YB\I#?A4TKKSML-Q2MR:SQX/)\6R^N+IH%-ZYV5)G22&7UJ:@BW@:JC"
MMZBY%<@1HO$Y=!-X)@,=K+TL842,=+BU><E287>+M7[4IHN.7;=GR-E#8 :;
MP/5>XQ$>K4\VYK:NTU1\)Q??A'*L298Q4!2AIRI];IN!\HRU';]4PXFKUR?W
M?9V,)R=+7 ]N?\H2;!T#M'2E89DR T',R1/^=8.UBJ<_*#8QXME[N?;V4\:\
M;(2*3@P(X=C^C!8.R/Q6/.X+18P@9SM-XV^N<QN"GV-@/K[&V##R;W2UYAC6
M[$JKV^@5IJ=62U><M.R@9Q@IL)>NA^ 9";B:>-C]@<$4X=B#R+7C$.J.NS?R
M8Z?$N';/:*#E</T;JNM7=4&\M'.E(WNL#_?@9W1N;OQP]@A=[<][04J8 .!=
M$?!GA!-:/#]0 FM5=S0H5>9Z(7GHIZW@0^9NB[V=#PGU$0: 9J9O1>-+&!4K
ML!HV'BMI8"J&80HJ17&RA+;YR32-N]"Y\NKQR<K<BSH^Q\H$J[69DR$ 1L4V
M#!">D:(--M4797Y_?B%V^^J0SUZT2J9Z)?V[NU)>S\#SBQ7^>?QX#$Z7T'&^
M%*S+ZFG#&$+_4^2,U%B.58R/;:]I:GDYTL?0WF1COIG%2AT<@_;CS/N>4]"V
M:B59:-2NU5ZBT*B<3W"\Z"14K7P^F0_Z#%.U#NBK9PJ>OYTVVR]5M*$;(S(]
M@O]9_$5-K\#0#3*>I*('8I2>G!8*-BUO7RIJ<JM'!AFHJ;V^5,Q')8,T7JH8
MT<'#VV;.<<2CBW,V:^:/0:9Y<"(;V:L1&0R+R<U%JBAVB&%C#;8V;ML#!%G1
MVJY%250R2A>*729.4CQH:(25NA$9LW>Y?/CT-RIH*CU*1AG?'AYHJ!-P\+4\
M"SOHY%\S>X8Z&6%I;Z7LN:)0R-&WI=]SM!-X)#N!2W4"3V0GL' !0=D)+%@G
M\#DK;*H3^" !R?M#@";AD7*KO'?] %.>OFDW$XR.$E:&,;PS]M3+M82C1>F^
M;"Y*S8+4<8":49(.4L=T&6^*+K1VYG$SKM?BS981<!D!WT;-GF%16)X/!Y25
MME!0Q Z&/,,F)3R_H@21U?&(3$9MF-YT: 7C*5%'J:J"BT7!WT6W>D.A;7VD
MD;$F"C:P84Q!G'*TOUT\N/W'QILOL41][JY6EN^#E59[=?* Z%-1LA#:D$R&
MQ<I@&\P8_9,?'B7P3,=?NU[ S.B:63(DPZDPTZ'(N/'=*7.,/M"U1\'OQ.UA
M=9KF"G;+^@_[0>VZCXQ541#:,<A9+&O5X''ZN*$V4<!Z\Z@"_PK 1?/HVK0\
M7KX?7E7*(ZW_NB*#B3 ]&D0WQ&F_?_=@VF8#Z56-:%-1VA\THA9,RU=OK_UJ
M^1CH,!WJ;FJO0Q#E]B^88+]TK\$.79^I[X?UT'N>%G46QWRLUJ5]^^H$KA6C
M?/J[_8W1?>Z@EH<&J*I9)F=5QK4GN_6)"C?X5":[#[!GJI&I.FDPV2T\>FB)
MY,A8N54>,"G"K%-XVE<:8/PL:H^Y$(ZJS(K(K(C,BEPZ3R"S(FW,BD3.;9SO
M5LPG7J,@1A9!U<A@FHI;MR@-H@Z(,4F=#0&; >X7[*'^MK4;Y0$Q)5=N T%>
MX).:]J@NU0J@$[5@.*R#85Z## ?%4DIUQB^'>>8]7N9HO??HP@J4N>DM_ ;S
M6H8FS.ZDY_Q<_# ="+EDAAU;&Z;1.]^BD483%AK'XMKC5-J8J-AD)\-4![@S
M4JON6.E:E&JBW"J_4(=ZILU-HL7*<BP_P,\_4QFLDL&JW,&J?$ 3,EK5OOB-
MC%:U.EH5AB<0\]*C-L,F7)NO*Y$B5SJ9CE-%4"T*7!DMB5OA6 O*_&FX[^%V
M?+;F#=3JC*>BE/;J9*BFRJPO[EVG"?C]\1%V!LPD"]02-L75C1VJ@0 78TR=
MM.CCID,@N4_018.(&E%'PH1]R6!0K&ZUUL+#)BO@$ M1%(VF$GTB; 7\%P:+
MC:>D@:I<X$1!1*(Z:=$*'M1:#\=[4$T;NY'^ Y6HFCB[8.A-M_'D/QN>^4P9
MB)@Y\URS <#XM(5ZP=/1-&!\A;6[/YD+94%G:>^I=?'^%&)\UQ(>JMHNY.YK
MSWBH(S(=#67&XR!W)D;59<L7S7@<Q8$:2QRH4CA04XD#U7SNK3WH3E41?!#'
M26D"QZG\^:P5QZDT60FY//.UJ.@;UU5%!QDH!?[1IO'0@X]<LA)M%$1Q:+ C
M7%L55RV2HDQ37T6:6O947'RS99:ZG5GJ1$0QK[)/*^Q801\),25X=R0B==ZW
M+Y^@_X2;2?V 30J<F<Y79!,P<1WR49CLO*J2<7ET*@$68! ]W2XA8'K^)]?!
M*;-<+&K/)4X&XF1\,\HG+AX03A/PD88#8H^=UAH3*Z),E,")KX),E#BA5ED#
M2<"ZM,!3M=D\;TZ6^>11NE,$52.S1,F\3(?B8*8TFK(7939NVFX3Y=C\_&V^
M-)TGJH ZHUDS:NLZ'H+L3#$)D4U7,@4I$ ,:2T"FV=EFWO<QHW9ZK.TU0U--
MLFK9&@>F*F.,%P]!>/29.AN:)P)Q_GUR^H,-7FXEB.F Z3$2:$@?5J:+8YL?
M\Z[X/$7W4=DZ6CA;,6HMX13"A^",U0\$.AZ*TK:O%JR?;]0CCO?,$F#/^CGD
M_*;NXR;<4<M]Y^Y,-%W0M>M;02IHV%J#)&]>XVK]@?+6J/0'SN7]F(QS)]:N
M5@!U,AZ4AZJ]L-9D!9V_T2"J0=I)/!Y?DE%F6XX7@1;8E=/5G_TI40=G5W_>
M%'A 1NZX@EK9$SGN*LIG3[PBP=,AR%81#)&\Q-^(45_;/**(/E!NE<^N[RMK
M"B=^:7KT;;O10W)-C,Q1H'5$ \*S=^7H7QL_L!Y?0=^E$]:#.VUH.9ER5V4Y
MW_W=3CG=86LYIK72UZ,(%:H23(K;+MT]=OI^K&>^<GUGC_\[8[-CAG_!P6RF
M;\T5>^? *9:O@'3--\R[Z\U>%2#(PA/ "N+8AUE!''S.# +/FFW0"PQ+>9>@
MU:CG1T,(WC.O\)558(Y_@!][\"#$DF"O\A5X.GZ,ZT1XB@G"C;7;X=>=#0."
M<1][EN]OX/=[WV^A0I!UFOELRRKJ-%UGOU3S &&R4+,UI8NR4+.Y0DW1)*H&
M_?$E[N2 *^>W3P^97DEE2N'R9:.?CU_?^_<UNV;#.WU_4R]5CXEY5SV-&7WT
M1:E<Z^6(!S^\#.U-!^6^Y#'+E$-F6<NC6.,QT>'_PVI"66WFA#$FX\F0:&F9
M;4M0+V3Q3UFN3I^W[[5\C_K@YW6Z#&5P-R@?>,]2K]?I[6_5=NA],SO@Q?25
MC0^>/JMX#AW_'6\_$1IPV$_A!Y:["+^/B&84$5SQ-]C"&]T26##C^?#I<,XT
M4>#?RHQ2!WX5>*XY1Y1@^U4Q%T@F7C/S.;M)GGJA.4)W:CMB<A=T;N$;0W)6
MU'L"$N.:[+L6A@5:%"><O?OI+BOHG1W6F[W[8-G,Q-R5I6V(.RO =B4G;I&Y
M]'2$C9^ Z-"=-KLRPFB6,[<W+$IGVK:R=@,X"-A$O__1%RM8<KH0HML"<W\>
M^'>](]2:O&N%'VF<1 X?P7"+C^N@_][ 2\+CFAE.G-&Y"?J%SRMEKV.N!U!W
M&Y'1Z(&M(*M1#(ED(I%(RB"13 82B:2 =%=@IIRX?;)B&R)"E-2[C(/ );T.
M Y>DKT;5.,;L9'9>@*PSZ&7EO>L@@?PC>,?.3!NADSD"*?S<\=%@A0WG5VA8
M_=A;FV!EM7W&A9C6YYOO,V)D1PU3LY!A"C9/H20QEKABO23*4"/F:\+(/'EL
M9'I2Q/1"(@.Y!8JI)C78:E;+W* HN<$K$*:FTH*-L;J:P'=8=!CE T>9R:7[
M^1S>$O@*1O&L9W:)H,&SH#,KB&V@G/6-^9)J)PLP2V3=\CYS>@#B)8VQ<&J)
MY7,^;6>6.CJ9;"C*K*; CW]?9T(CM:J86YT2U3B9C3M8Q9U/1L7FP(A,!BD(
M^%(<N(A&3I/T?@=H9@ZWB =F-P9SDP482I\E7SSZ;,'MM/LKN*9^L5W0UPK&
M67XUOYU,ZPF]Q49ZZ%.7)+RJY=>;S]QQ3VMM(OAR*/S";)6H?9&-IF/1F!CR
M]8E/)VTZ+%-_=NG!7=%#1=9TM;;=5TK]'N,.&'<^']8&NL-]MIB^P,Q,Q*R7
MI<O^'O%TMQ;L3DF\:Z6L4$*56=YO1T3UDMJ*;#.]X<<M3P&Z'%@;Z%X>@<,!
M6:\LH=RJ]%"^Q.#^EGVEK\J:NFNTOOT>\#H1-2 *NK:,QUF[_?[GWXGR?FG1
M1^6GC6\YU/<5/@'.@Y]_A%_^\P_</3A#"QI]$O].YTL';K*G5Y*Y8;^:COG$
MTXU_TB=6%! .+7N_-"T6(OT)CN5\B9Q@,5)X2.)+?_O_V$]CFC[09VJ[:Y:@
M5X 'L)REN>#U (Z+"4/?=1QJ*SSE[^-L-.?)#WI9BU[Q]V"P/<&ZQ<:+<JB\
M1&%;BH!YRU;)4>$TXU2F&4NE&5699FPVS2AG'EQDYD&^M325)!2JZ[2"_)_2
M1Z_-<C9T<7.A7&"U,I%,E/V-LCH>VWV)K9# #4!:H^[XL#0//@;\L+ >/(PG
M@FR'+7[A#0Y?_'X'/2;BWXF[^VUCW+R"A!K;1\M!@_JM<CNX4[DU&KF0Z"=B
M(G7OQ]6&\8\ZUX>"+ 5(X?E;Q3&#C1=Y)WE:\<7),>RT+F9,ETBU*Q9<4<7=
M2&**6>Z=S+U[AV0S)W]#E=BJ3*+,FS;?4RG"X2FDHUD!3QWM3T(HX^OK RTF
M8*$M,M0S<W61\79^.VBF5(5?U?9[)OG+>4R))4>2@\"+O;>&N29$&Z3@(ULT
MUN0L^NO%G\PIM46P.4^6(XJ-IRL4,:)IKQKDX!</&U3 'W7738QG&0]$01(>
MDI%04+12%0A-3 =400Q4[3J*[9JUZP)1ALTT/=)$:@$Q]OT*M$!.I,W_=YLY
M#CO)(S]GKZ:!T1(&JM^687\ZJ@3B)NY^"D6,()HE4411H00\F+;IO=;,=,,0
M9<S!2$V5;;9*L9S#I@,2\'LC#H:N%AL=5Q\E*M%&J>KE-BB RG<^,BQK9G@_
M-;LV_;"Z!V;T<QS[AJ=!Y38ETI3^$TLI_X"M8R6+^[5T#X'I+$QO8?UG6S$7
MA)VFB?(X9F[L%]+)FZ7\S9*JF.ZD4I'72=MLBDP-\\>)"EJI*-IC@DI%(<*^
M7X.BR!75^,-\9?6C6&CJ;]9KV\)^CVN*:(PGH@C59"S21.YJY:ARC2-J@$DH
M8EJJ=*):_+^96"("7D_?W*UPY^,A7QDI,8XGQRQ$Q$'3#U@=9"E']("\L:9:
MWV_@EI,I&Y$LFX;B*EW==.$CJJ*J=J&($>+P%[Y<'I;T$=Q5N%V<[>417BWM
MO#I4HD]%<8T-04>(7_U5TM=S!"]KC]'GID$(W2$OCK9>'!=U4'ZC =P5IO1/
M+G+!Y$A%BF:CM/=6$677^ZGVLK8D?^4=T]8[ICGGY(-I+]V5$MTO=7LF35FD
MHW&.+H#:35)UFB.^GF. D_C@"T7A?HR!A/LI!?>C2;B?8G _EQI7(1 ,4!/+
MD'-%<B'K:8-I^-I(5J]GAL@58 @QQOW^XE OANH+>Z;:M8[3*(Y_>!;BMT3G
M=;6V:;3KVYF$O<2>(\JB1RD>XJ\Q;&_8=^)O9KZUL'!,6PC1R88;WJ\]RP:1
M5Z><BWO8FM&W.1:3OUGAR^'&5N!&M9$6.(M$>5E:\V5O;GJ>Q?!28[A4/E01
MOC+ZCHUK,QUGLXJA'"V$<%KS6A(^UA$C(GNPE.KT3OG @9NT@3; +RMPXSJ+
M",H8R8OG,O;P"3ZP$>A@\L]^.W.?:19K=B!"V2(B.*@$47[$;\X?1*!28+<8
MFHZR@<-DIY T!X3!HIJV[_)(#X.C^KOI;)#]X6>2SP1F*LB^UTSF3>^&"?;=
M*;\G)GYH!HGYXL(3O1WF]':8HR284]72/]*9QU:E31@AZIUR'_!)?11DW<%)
MF_ 0_ W' #71G,$W@/2P08#QD_'=%A/*QXUMUX"DR:=&I=!$XO-6J\8JINHU
M4/4/0!T#JX7=H,^LWLI\!-%@;/QC!\#L3P9@)B=$77Y"E'IWS)N,7P='.%8'
M*F$V>-Y_X"C!F=]%8M]"X3%-8X)5X'S%PPT2M@Z%#'[*C+O;)W@MR!0-3]_V
M@E@5H@,O@E%\#_SVZ8%![O)'\JO 9[H:=!80&BLU^!I<.2NJ_#]XCWS'+P.+
M#>P$!:; (?@:U@[F_0<4&-Y4^$WT66:F3Q.DH,Y[8NM=L!FC9@+[;S105B">
M2S^F@FGB6:2+"I$!;!R.PV&E[*DVW+11H21?-9C8:_AM$E"<79XV!SQ\M#Q@
MD![2E-2]A0CAMPE8@($5;$"9F+C^>8QY"'1N]?TN49QA^'7<BI@-H-)Q$&LA
M(N8@Z7#(/69!9,J=GQ+B!66SS_!V"J^0M!07(B)QF=["A>=M\&'A6^!:-"W@
M4<QC?E,S*',P<T <X=(-MV#+)?Z#0D3@LR.3Q_+CUT>21ITYF[D;&2Q,/D$[
MXAUL6S0^GEPX%A0O<W9'FL^N5_3 'F JUUF7F9(L+X_MY:'ENSP^NK;MON >
MOH#(%M,-: &&5I:#E@88; _<0":(/A%?2F,27C1)9R"^9>""\:S%$Y(07B'%
M-#;:@2L<"L7="2.^1A:(7(J6.;\[%L_HVT9J-#H*B'\X#YC_\@Q'FYNV<'9*
M4!'.=4_X4%NWX7[FN]X,UQB/*=C>*COW1*2OJ E&'%!4B P^SWX31.?S,=K=
MMX=/9<T3;#.C=-=^7HL?U[Z9FH"3^3IKQU\O(AM;UXW-<X>S8(/88S1L;K)Y
MYR;[S1*."QMRP)V[&SPHW,%CQX=)-%YL<!6N?/ L@)JB)@6>KJUIPJQ,7-,B
M=%'QZ9P^/L3A!Z4_NT&%DOS0P1!&*980A'U^,5_YDQVV^R&Z,SNBT;R(V/*,
M:RZ8*4#9;SWJ,AO!1</-"EZ+7:A;=>3X\:B44+&QMV6J$:X\F,N'P0BT7[DB
MVX,(*4,+8W5"L:'8<*ZCW)BA48EF"/^@%5L[!M&& S(8#)1_/$1J^.8'I:"-
MT9^S7?_[!HQ?=<CO$*6/X-Z6PYS7MVQNC@:ZA8,K_QD''#X 1>BYLM^K/]Q<
MTBBI*+8W/CZAY82KA'&3\7=PVA\/7U5;4WV[S3QC%,4%$MQEYU[1OHMO+U#@
MVVDZ>V^_B7RBWHYGENUM_>X<>!U?8S_;][G9OT:Q4]W97O=]<-? 4@X/-WB%
MB8-Z(P,<E[%1];N?<H<XHN!@L?C&),OT9/+!PA04Y&$1R\A!QYHY^\S?<3%G
MU/<I'K-"E/QTL_4)MP%P=H.LUY[[S5J!E(.BF^Q&0>[#(!V<FY#*?2NZ<&Q!
M.^R+[JX/:);.G!@'Q2CJS!4-+# A?-X*POX *W.SP# 'G(DP1XAWQ,H* LKG
M[^*- 88+#P[N_*JP&[7_ZIEK>BS"MK# 9\2D.?,N?S6]^5+1##!'F6& 7PW'
MYX''Y]/5S'X]L)I").V,K>1LHHNW8/_<A 9; .M.F*'1[+JMN3VCP0L:U,ES
M6Y0Q?S.ME?*9/K^"Q<U O91/CL.*!^!JC0JW8AO>?7'X))-?O3NX/AV+VNS+
M!/3%DQFF:I;A?#V_:"0,%OK^Y]^CA?H\$HH.-H@(/ OXS])CMUB ['/C/1^G
M"E%Q@*O*_9WRWY:#+9W:0!W>Y.,1_\8]2&VQ^/D!=NZMD%G*0 $;93>+X#'"
MF7 GV%?88LYD-=80KISMM$)D%/U&5PQ4 70,'%8O3M>Z?!H?KP*(#UTQ'R]L
MWP]GXD5%(IEC8DF<OD5W[QE5-W D>@)C(0(;.[#C2]-^+!.F//QJ]J8H@'UP
MD.W2?*8\F.JS#8JMZB*T<(<,%AJ+"9R-Q4VFSMNLMV7^L5I=N[8U?_V!;4N?
M[NUT4;:8L.OH]B<2NCQ697G;(4=;\8:/NT%\=C8^QNU\]M,G"RZ?N0^F#/(+
M?E.4*7^GWL8W;;JZI+%QM'91E;6+I6H7]<[4+F*U=353[<*?147? ZSJK[EZ
M[,# *FL%Q]X._OH&C&YO#D^WG/\9:).[?ZV?8C-\&5:;J_H4C.3(C-:!A&]H
MX38W!_ "_"E6\OFK"),?A>;2PV;%<KQP.;&N 3!XWR?J2L6>E?DQ+GK]Y(">
M6K$/R$U.\>GO&X<J^H!'921_4OSI_\-AKG;=);7'1S[)M[7K;07M64W:LZ7L
M6:,S]FQ'M&VW#;.D=:5L#9B'1-?.]3-!&B[5\.<+R]9@:!@(N- \^)HS25E)
MHJPYV65&8[-FZ?U6Y/"%DTG&>,,?PL@L;H-B!W");AQK[B[H[<Q:6&\5[.@H
M-%IXEIY%&BU8^RX[4I&+ I AO'*VLZY/]\FS?%IIL(3B3/K15)8>??SKF[]\
M_9_!8)QE:B3-AWLTT%UO)YODT6<+Y(8/?V<A_=W9H^%9,-^=[#DOQ-R/M^ID
M="9;CV$/5"IPI5>9;, 777K44]*3"'-L^V,9*6'9U0[.CQ5&0K9-M5BQ8.U$
M%^H0JK$"%B/\=R*%2R#AT@H(UTY/-D^U<%%:>^YCF,NW7=\/=5:].FHJQ4@@
M,=+/$2-,2<+%AEG'9[HO5 W(4@0_*65)"%DRSK_OEJ;S1%EO>>;5QVLT:Q4I
ME=]V4UV*ED"B-:SBMMO*'/N8Z2^51]M]J56<C%"<I&4NDCB-3HD3A[2)2GT/
M2M11?)LZQ(G;XIJZ)TX[%3*UQ%5VX<_JC>'P=Q5,9.@RD5$JD3&4B8PJ3@#[
MEZE8B[^^B0)'3 '4V$UY($Y[5*_].$N%K$Z%JV8[@G Q!LMWR7?)=\EWR7?)
M=XG\KH)FJR'-UE)FZTB:K86D\GC)P)[UJE9CO5Y=:4Z)\N5DS"F=T^OER>DU
MNL1=1%Q8P&^?Z@+%O4CAQI%:C1R-OWDP_8^'K(Y.%LA [8_P_6/E@YH\.X '
M*T&)^>N;4<R74Y?!R4$!T:[<HRS\./.^?Z=$U4_[Q&=2FO&"FA>OO2E*T,D5
M1Z"H_+VZ6M'2\PZ)N+Q :=4+%"^=$UR"JEQM:I*,7.TU'9$:=&[<_M$=R;FO
M<L'EA:?<S1%:VCEMQ/<;S\-6:\2G2"2-<BP\][;D/@.G7R-IRDE3O1/ 0A-U
M9&14 8-(84:;(;#@'[!6XMFT>4IR=QV1I?O=T4QP_*EC(97,!T_WOA(/C#74
MU)S6\F]IFGR##-/S;MM#ODJ&P]1(JMQOJ6NBV:X ,W!GEG6J=3B7.B(#(\>0
ML$:&S&D#..PC48@994E)?:)1O-[CS;L_&5HPA@-"6!HZLX)X7DW-#!J-B38M
M-FRZ5M%1U90;=2%B=(-,!@4YTXA6V<J+,@^-KL#\5KNDJ$0?BK(W*AD,A1%:
MDN$>BJ5A_DF7UMRF##[7"5SOM?;[:$ST//,BFQ&6R8AH:LK2N1@U.AD5G+[<
MA%XYZ#-_XOAJP2MW[<YP57)[UWG96^Q)6]TQ2 G# 0\Y+R&2"=UF0G,*O5CL
M[RCW<X5_<D?<LF[&H4&,:<H5J/*]%UZ@KA--2QDB5[1 8TJ&X^'9"ZSK_DJ$
M(I4X%IDSL/F;Z]S.]X*6M=[\IS\H]BAXL8AIVH;^[,*E@(-!HLE4K*LK8TA4
M_7Z8IHD27C$F*=UP*4H&4^%,:G#5D;A;]_%V@W"T3,D0Q=D:T76)R)A,5%%V
M1AN0D2Y0<+*PS#:M:3Y:W^A"N6],6L9D)$PP!<P-M:!O7"-?)F,1XW^?G,!T
MGBR,_S6G4J9D-!!E8U2-#$:B:!15):K:X-U31J-\VL[_8YWH",B.&.A+TUG8
M^T.N^:P4]ZORC'7<RHH&2W=1/Q/'DX),K%.\M(DPD6X-+BP139NM/;R=+EF[
MZ3L@XZDH.W/;3CJ:MV:B2G!V62FL@)Q- GTT+2]4,L$2WO.TW,?OJ=U,%B5%
M8>BB4%*8)XTHFP_TD7HX^KF)1">H_Z$H=Y%&])$HHJ&3P4!PUTG8:)4DYH+Z
MXV!J<VO#K,/)FN&,VE2%8>MR6WJZ,K%KZ;V48=0U!JCIPJXV9#?S5.\GOG]>
M]7]N_IZ1:SO[X5&MGDI&Y;N,SLH-7BE'AV,RGJ22*9*C9W!T2,9&7K4C3![Y
MJ+%@X+Y\87.-[W?RQ 5VURBSM_ E9>%N9G;>E':!K2WP[-BB&!%5.UDOHS5Q
M6*Z G=H4RX]2(77)SI+2.1@273VIRLNR,Q.8\*K&+,W>?5E2E@E@XUHQ&> P
MT$C$=PBL8!/@R&N&%/GDF78/YZA&,VBS8"/O1 !9$&(DU5!"XI2"Q!E+2!RA
M3X$$O)& -P<O30EW(Q+T@H2[D7 WE0J4A+N1J[VF(R+A;B3<#;-?BL+=V!:X
M+S;8>U1BWEP+39?$O'E8NE[ <])SC\)Q4AX]=Y799\+*I$*_ WXU<Q=6.G%]
M*7 6P\BJ7&D1NHPQ(<-1*CS;I@6HQ-#+X_LT!)##M>C*##8>4Z+HL=K4].FN
M9JVU;&5(1@-A.JK() W*="%:AF2<[OT4I50@5)>;]=JVJ,>5H4^]9VM.L8ST
MV5HT@+NDD:DF2JF@BI@;HC1]8:YP)&+9^OU\#M\+?#"97UE(BN'+\9NV(<@E
M S-5!1%C:B-&&Q)5&&* ,Y-TAEDLC?,YO)9>V6BAF>LL:M<R8$H5;42KC9@1
MF1BB:+P2M%RVVA0\RR?KF3J*B?>58BZ>4=]$>845]9ZHIP2>Z?CFG&<02KM(
MN5W[6BL0IT2=Y(TE76T99N?K4*MA@,38R8:@4<EXE(K%7Q$$S4 CDS0HY!4M
MD*&WIK2D:+61F8="H#X22<P%%6=5.$S-Q7Q:OZM"$=-PQ_FIR'C=#IE.-&%\
M9HV,IL)@89!)49"0R\%X@0Q1NN)E24LZ_UJWU(B"%S 4!MNB0>2"$DHF<1<I
M+U:P!('QUW0>($8*RU#4KV7&8U'2$NJ8J.FVGLL%E_6B8??F]8SI^/R&<M#
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MN$(Z!#*.9?>CI$,L.C1B#$6YCR5/KHHGK6J#_)R>*+N_VM;U/'2^\TDR0#)
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MIPTM)RLPNK \.N?@NW8 =\W&L>;N@M[.K(7U5L$<ZB+K;DG>%[")]Z'UL)U
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M6K,K,5U2IN"&I<)L*Q)*V=RSSE^[$%'VB03SFJ1C4!\"-,=?X-OS%1&F]G^
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MV0/P5.'O7'VMBR+ I;+LZ)(GI PKQ9-,**ZXIC*IEO=X8O';A6""7F\Q00_
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MW-F#<&>G6]S9.L)_MKBS+>[L:>'.5M1N9HM!FPU@.%LE>N)CU>4Q'0&C+.=
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M)M\FPO$6T0VIL_59Z:WO/J_O?K1"WWV*I\YEO8T"-83D'$DSA$=UU_T=.%M
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MT=N5)U,U?%E0. %EWA[751B,MF:,G5,S9TB[ZX,=3_3 :WFABM#6I^#@1<"
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M=TDC#EB$>J $YYC)V3^-0S[*J/@WRIZ3DU\IU,Q3B^*JPQ"D&#(FE>:"JXR
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M?6EHM Y=(U_G@.?H!C21E"T4U_+\L<JN%,5RDCP<:""$T,1VAI<Y1(K8<H2
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M'HSPUR^<D;[POWT_/SM_CR20EU_]K^\^??R;D$5^_>"?]\Y^I_ST4KK);H!
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M7DUR3S0]-2OVP&MGIW;S2WRV4,[_ ;M;;*1*Z-Q-:4HZTQ/5WU=.8)T;=7"
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MGM!7^ADLP:E]$ E&Y[$J)\A7A#?,&2ATO@->"@BI_^S'2DP88(4K=%1I) X
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M=]AW%")L_WSLNO?J_/+P,O7OUA"JO<VJ\E_XW0NC#:M3L7I<K*[]?H"F&2:
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MDV$7I=0X;9>246W_&R3M6A">]'3^DX0V)](]%=A@<UT6GGY8;1"A:P.<ME&
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MB-4G1=>+&.&E[K 6$$T0-P!72=44X#+#4213[[[NN"I=&T?*C29.?2;;D98
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M%^Y^7"G X_,K.S8Y!'=93NIFZUBS=P46$T+9W;PKAM;$\_G1@AC/L'7L$NS
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M&//R<J\ IK[ L7)"F@%.P&#-D02\Z)01"#=;B!S;8%E#X%.,,:UQJ>D8W1H
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MI)@D8 BOY(?$WD<'%9;Q//FY5OUGK: 02B?[/*R:A2W*/8<E.B'3P=MBUT:
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M7H=@O]AA5\R)!%<'<%\!0@"5 @:Y[;:3,?J^AJ=%O-\>TU&QFO\J/4<O);W
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M_ FC()AQ[!BK4"S+?D?&T\9X/X0ZL$8<,DC&Q!1]/@K/I=]G!(*M8D_H<D5
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M_>8MIDS1K^G=SLC2C-WONY'[G:36^W(H?VI-0;2V&]?\W;&!>#=@[F;S/EN
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M65F%O&W8PL]3?4)P8V+O:3VJ&6Z)K&E@Y]-M'^X*G#U!,*&3Q7^D!BKZB9H
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M*5+#^-Q!I8*[-UNPFM=1.;0B0)>LLDWLNO/3T:N6[,08[0Z7E_3!)]3Q$!F
M?'\PV:42 =408#FKO.1I@JCBA%HE^7;6\U,F+#1^RT]N_)8?:?RBBE997X@1
M^W;338%%=YX)1H'"$-PZQB;%-?KK!53O)6<^.+E@?LU!^/M+'QZ/-9/3]_M
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MENQO@YE/8(,IVZ MJI):HCL/,$A%^O<3.@(24M/B%NJ->LG/NY)WI>M>AP/
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M=%#PS$.61L;Q02Y]@23ILJ&,I=5V/F'IN?@HD,!5C;W-^> V)P+Z(*LXW<A
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MIJI,S-O_@2W<'S@DAFB<G@+ZQ@-V7M;KQCH:C&!@".R=8HE.%45T(Z$A/ZK
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MC]JBLR)<"B0&#M#K-[\Q*^XEO%?Z[)MG8^4;3;%$7\P16<Z1.9**@&42X]J
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M] DN%EZ/YIA>G:-68PX$\''8-[!6BKC/X;BU0FT.TYWV.W<!!L?/ESXKUW[
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MVH^'V*5#>O"FS#4>ZTPAYB^,3@QRN@(P$E&KKN]+D0_5D<:QM7=*E2(-W2J
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M1V:B8B)#2LQ- &*CECGOU7S.\VO)4T">P)XMQ!RC6T&M)U3:P(Q^X>5&F"V
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MZE/W '!9@[KP3(*E,&=,#X<9+_XL]9I8L1HA#,J\]P\S$F>G2?HR0&@AQM;
M)4S+-?4,-*G?*3U& J<AZ9@ TS$!KA/V<ZRJRY@5@ETQJD[80:>Y.F/Q=O"
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M_GD^*8=%;PQI>R.JS+,/^'H[ :4P\)+BM7]'L8Y=;WD;75_=0(JM"YB/0:\
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MI:X2EMU4Q504B*?5:DR]F!OP>I@6;#8%QP>_3O<LC#T?"F-18>S%4!C[L7<
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M.HSVN_KS-R58(!Q_J[!*=$RK^53YX+#)M9C3/,]8D:KS=DGW[:S+6,@,S6R
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MFKR^D?"ZTQGK.[=.GMACR6[&Y,AS5,,ZAO=:S-*.2YEMEPH=53=LN^IO*_5
M6^< KL,\_C0;"Q5RRSP#X1W.:BZ!BGTUR=HZ_MAM2]%,2:<B_MV.P?TU]>F9
M[F?=.FTAHE(_*XYC_Z?%\)(<:VOR[-&.B1_P0JTC8(T?89K@+^'"IHM@'[0Y
MLDL2UG=>-IE>;<);QUP?Q%P77^?(TZ.W%1F@B]N^ &^%5]<<:O%)B.'A@A*&
MYFLV2CS1_EN=;W78VQ:O!WKH<04<87>@&/O-9]R??MBAP)XUM>=#32VJJ;T8
M:FH_[NJ'Q&/;D_-U$[.P_VG#.CP;K*U>U8P$9D3-%X184)S<#4_:[,J)+2*9
M@? ZUBH7_D1'[S)P(]LP4'N^D58#'R83E,NK-:&QP_'.) 'G!39V&2C0F\,Y
M!S^Z!KK::1 BP%,+^G>7Q[:'C4O\.9\ZX":=%_F-E.;(XU&X7>;+]6]B!0=F
MP?BH+AA_QQD#.'KH= AT]++D7ZNJ7BU(W8Z8O!"]DA*=:S20JPRDY?S=^3;O
M *\"+P#OU[3$YO@>/ER@+TQ7$\JZC$4;:>O[D9A ]7.OT9&Y1M\,:C%_5*NZ
M3(GP]'.>\.<+R+7:LQ1&@%/)OW$X=OZA($/3'0<")_R\HO_??YG!PL!B&8]F
MJD8"2D&4(,ZH\_'R$J!!=/F?'D-H!:G@VDRS==.'&-SXF ?M$"A==ET63Z0N
M'H1 G67Q34W-7=7L?K\O]779'GZ-N#6IT:W6&+H20ZXK6 ?#=P-O[C1RTS_R
M#:7T< A=(EP;+MM5_VZS'P5WV+'\S?.\X:=)D":%@5]9+R(EJ"8H7VRIB'>L
MG$T%<7AROGC:5XK>,-H1#@=D6KMP"@18!U+W98X6 LG4]Z\(;RT)!XFLH2*\
M#XQ5E*=:E-3&)[(<MOFJ&!>*(3Y<&5C"(B$^9H=WU-7AE@L)&#JVJT]% M+A
MLJJF0.F^O-HM,1ETCZ1D<S".50/2P%5)\ 5#"/L=D,)D5EB7H0 '8KHB*'?_
M4W5E) ][J>6C1!2=[=144 "#Y*I=,VA9N;);]JW&9(?5V'J)<'7R9^E=PI5Q
MN7P &O63I]-'/^DF%>/SYR$AA'-&&]8T$^O3V. QM1Y8]1D-_!Q5R=FT1,(3
M4*0J%L4\BQ4IA!+/!L!!;X49KSV/&PSU:#9*ND=XV"MKINLK[:9RT]%4+D2:
MKE\$5H7]X#002FW$ST_%O[;!8P!F@)?G2U]ILHE[V63V[65EL:A63>M,Q([/
M?,5MD.R>4PS,F"H%UYON76@X[ 5RZ7WM[M=H@M>HO"8J.2F1=H3Z30J>[P=]
MG^;[?Y_?3PE[SX3JBR&A&B54?QH2JC_V#C@[?KH/B.,#]>56M0<5#8T*"J'1
MZN -H?TFAO8#PT0(7B(,8KJ=D68CW8W*0#,W"2$7FI196YK44"\H%R\QGSJM
M)BM*LD4-<XH<@3@QQFO=V(?.<,=3+%O?Y'[LO]OCBO)WV=R&V],V2>7&<RN5
M?F\&;'IN(#ACI\0$G<VCCD35]Y>).'IK((>]@L<0R/.K8AH47VHQVH/909U,
M6@K0G\;$7JC?9?W;;-T"T,;+(X&WDDI<9B]?<%ZQ(LP!B) KO-YMAM)_R376
MUY6\",AJ+6O[["G5\I>%Q%/+&A@S/., !-E*4)I ")35!HA$R;KC$CFFQNEG
M8Z,#7L9GIJZR&ZFZ..A/+9E.H->HRNK:'OO_=O$=7LY&K02OQ\$![LI&$WE)
M0:T?_O*JKE:74%L'MQ/K/1ZJJ&'"8VZ<XHH3?M_M6_Q-G2O XS4I%.J_P6:#
MZM42:%/ A*BH,[-C(W!Y51NP%TNGQ*>O1]AU5G.1!39;U4L26&0A/4>WD+:L
M0I8HI4%H#\FIF'9=YX $Q?(-?FQW?0FIO*+\8U6*TCR/!=VO%#!P "F!"5_-
M61 1,M(KJ# !$T6JUP2\,S*X-])-@"N$2DZME4ZY"&M@H>UYID5LI*ZT6BP$
MI[?!SMDO;VD.LX\N5 7S8D9WMO^N[9ZQTSE9"K35)2@0,$Q]0RX@12@?\3H<
M?$QP=GRV5]MF7K/L(+:>4/SW[5VB[V<^SU6.U.>=G'J&:0F*P/YOA=%Q84*3
M[:DO+ZL1^50D BJI6?9T7)'?:W=(J:H^-N]8(8(16J^)*PK 2T%_3*?HA.PG
M'J%B<_!T.#Q,!J,Y$X ."96_@?$[L]&;7E%LVCL:A?AZ:@&VA#,@TQCC&\.G
M1HLL#4R,!@0V%.,Q:9+W1FHU-ACM>T,NG&^GY&<VW_S0M\;9\;.[=(B_0U#M
M$'?%<5<X/W@^FX(*.AYU T;(GN3UI$#>'J4=%_!B7;CE#T-L&2Y&B23OYQGJ
MMH: E!L*-(Z65,6RKEQE6(..TX"3?,[*<+#%X?L,PP#E%BA**=E>LA/*VZ+-
M-TI5KQ5@C^;SG1[(X /-<*AX^6+*0SGL503HLOX)Z]"\BCL)0GHLCQ,ZVKAX
M?/@-@3.B^,GTKL0]1" Y]"0UK@9QW^ZJ0*0W1,NEHF<^5;F&<#>DB=0G[7@B
MHT3H*NAEQWY3$WKP[/*3'XZ8H.451$0!P9\#SDO-[J&>=CAO]I-/E5?[/\0Z
M.1PX?0<.3]!#GCAW-.Z)&'<S&/<_Q;AO,M?)0YGKY\I<FX<QU[*G(WN=[&^O
MS;WMM7W XX<7F/WA%NF>Q<B?AF)D6(Q\]G@H1OZXJS^B.5#E,Q!XVI  74"J
M7'H'7-9"(_%[^J#[VYQ]VAPZ4<76DQ@;T9XR-GWJ>GC#&SL:#M2HFF%4=VVW
M%MVXUN-1W.6$D/=$J]@OFT;@? -=A+^NL KAC#@2URJG(VP(=_+N'3W(-):\
MEN]""@<;62IASFTU1D"/HN$*)#HU4GOA[W<-D#)#;<4D2J:U"IB#IW[\8A]/
M'6FL7^>/?BLPD6!T7!:^/2UFON/%O^W9_/V\DVX'DEPLTW8@(^Y>Q4V_B4@]
MMF[@AF+U4^O*($50JKU3K(B;:15_<PJ=0^C.7A&YE:K6.L.6(IJ?TE?9U#JO
MQ(I?(AP:>;XZF1&0==@QME]C0USN*-9Q2:*OBC_ MJ+\T9P6:"Q]$YL89S_Q
M*MY0]U 2J5RU&'T3OJ#!H!S_M(]!.?<@"F>4OX/X__N9ST^M0@]D!>S&,[M+
M)"BZ+QUHQAV&.Y6*J3/(AKG][.'P^Y 07I&(=_S5T\@#;P+)QL &<_S_'9S:
M;0_#S+()U,&SI8-!Y#7"<N!RXS4Q-#!!.-$ *O)R3W+5.#/0QBP'5N;CJKXI
M$'/A^3R0.J$H5SEA'_(E=7ILNWBG&W7L&A"0?$K^>FD]OSKC@G_8@I2J9R1.
M?'T7ZBR@-;20I$,;F^6IJ1K[ W2XD)V">&D8:0P(+__7"+F%PC#RB]*$P*R>
M;NAMG#,[\==R;V].*3/NWN)!FGZDF:.4.])>(]9/PH/(KKE7V#W-318JF[[W
M0YI@4U5$<H*7D%LD1S$J1?X2M:'MFP;AE,_I\=G1U'%Q1 ?E:]][])%[L4<&
MX>00!J'"PPJ63U5/Z%W3T2B$/'L)N2"<!&ZJ0#0">L)5+;(],-V&VJ7&P 13
MI=O6#K4QWNPY(&!?:6;"Z>9J[]3:3FVDIKMF-L06@2MP\G@?7\"ON<$!"!V
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MIGV[]E^F9I4W>P-UH67V&1)DH)F!=Z55G<(?0[IZ5-P1A>UYH,>=)GGY1T7
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M/P,C*6T%CAHP*6#V7UH>"1NMJ/CHY&,:IMB<4ATK):N$ '$XE1X\#.[QH-1
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M.$"@=Y30MB$#W5-BV\2EA S/A4BH#KM49%GV76'$ND[K1MSPFE<Y"?"#58,
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MI%A8N57AC3FA:#TFA6:V:Y\/3";_'#ECA4G#,BXQR!<!PWCRQ*ICQ5MSO?Y
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M?6_N/W>C/WRG7)94-6X>M"=4"V@B]JE71;$617X!+[=/3!J,A[<82Z?X/X+
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MZFL>>W5U4639XEYQA966$8>33E+D(2BF!KFP$W3 M;_<"6POY,Z_O@_+0Q3
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M[<F0$*/AEB?[LV5+?-8SPL#@L"=A4L97-'V?1]JN4>R#,O\<RGQ0X]^>&G=
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M47<\X2J,>8?BJ6'F@J>>BONI:P'Z?\6%0:N^@:B;#B3J&X@[!%>.!?2K(0U
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MI+_Y3?QP[Z?A)K[](^I"M249N7]/+[3N"?V05[:9I'3WEL<K?+P=L[7>8NA
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M#?1EG)3C-"_@Z,)OX+ :\[8>%V595/1/F #.ZD#P^S1+9C/:2NY%6(=$_B!
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MW+9;WJ!A+O27T?TD*BE>Q\<(^'8G $+>E16WKF"@-E4!^KSUL8,4<-&^I1D
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MD!)<X@@&2C+IS62WT?5DT@X9"&8V&3F0R?O$_@+_;1"S1Y0(/Y"D-^P^],Q
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M3"[G5TZY1!U(-UZ6)HDX,.,.[6RS>H-JAUZ^D,XA6=,,#@Z<GY%P'<:IG<K
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M?Y-W@/!EY)'"7UJWS8 +HS-X 9C]W@D.68#<!T/?$9MH,,Y.9/85@[\4K^6
MP! B2M\JC435C^W<]03#::$(2'"IXXO(?6)Y6D'UD<\JTFR!8_C6TS0?4*E:
MT^7M]P)?,X!W'XDC*HJ*O-"X0!\%#;"AP:"F(4[]$S$1YM,1!.><:\P)TB(H
M0:E;:YY# A)$24?]DD:ZX>+T J8DZ>$]O=YCXA:1AAJ,AY(1C7F12\/;[$><
M,A6U'2"?2.H\*.\,M:^-<P3<S=T=5AR>$,S1#U%=_W8[9+14<]"H$SP>V[8Z
M1POU8Z?QN:$"O:04K[ZAX!3#.E^!L;IF,\>'2!MX_?%F-M(N3:::5@P/T+CN
M4SJ3\KSL=.Q3NH8[IQU$)[T/NC;71X8YW9\ R3'\,4CAK1'.40(Y;Y<DA=1L
M/EL]Q>MM)&?OWH6\I7Z=)0LFH&C+7-'_]4B^<[\!IA"U[E\3UKIKACF5F>F4
M!%D?]Z=%*>:WP$/EV,VN"ZFWYCPS=53XRPMMQ_$Y%S1#H';#F)<F\K[3<DRV
MH3TK[2='".Z4QCHNT&G7GZLONF%$^O!(S&F' ]S.J>;,21Q65_)22N6.,-MA
M_)EQ-&RH7VZ]N1Z.O*6Q@=.&UHV+AA=)F2-!#3I3.5H.M)R859-$,X$C..5&
M)JO30E"E1155L<%HC!)P86!?MO9>;./0G9+[HTBX03]*?JFEMXH=H!&W5;F=
M1=?J#V&;*T?$;+[8)0;L2*5Q?EIO)]@OR58''<MLY(VAKS_FZ60J?AQ*U5O
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MXQ$?^ZEXOO)3L3]!A12E2F!:Q/2^,V42+;QQ9W:J%1'K%?$YDTM:C5T;_Z6
M XNP$NFOSW6-G'70WP=5G933,/'!Z00]S#5WYE$]FR;49"PG5.E5J5-0&9BX
M7Z]YTKP[6RY/\3]J-*%;9M6V5=F"44-YUC%264=F[B>W[ YU!=O2BV1VS]T+
MLD_@T!,G(&&B!'D@\\9X/^,S:PV=$PA*#0YJZ; F*)=V* LQ$]U2,-+TR/#P
M#($8S$(BX0;)1<@?#3<1)ZO!WZ@GO+U#TH-X69 S?E26X7V\_GIU\0BC1)$Y
M0^J+B5&E4@,T7([P"M(\_QI:-9R48-A+EC)/#:.QODCB2Z,_M>$K1A=1<6_P
MUY1&>,)?)\S@ZJGO%BS;C@^[>-0ZZL7*==1?DSR5\P7*".DRM5DQ*>GT3@I%
M3@[A+)@V?7Z[\*%IR9J![-%DQOTEZ.A5[,T-8Z)81J1E-$0"$)R"S8W$(QJK
MA\;/T8,TW@]NRM-D&_,@J66F0O^0,%E2L:ZTL87/(BFX%CX )LE#*AY%C?*,
M04L04,6&;]?.W6B_H0*XG-&(HDA$)]%2YGT]=.8>N5M!4%+;+!6:9V$.7B(C
MSBXB94B$C;J(!@9]>J%OT_F=GD?]J&I,:4-R,>>NLJPK'S!:49\.+$[0A(<G
M7A=*D-@X8RK\.GBK*O9>Z\(74Z:1(>.'_8Q4%!SMW/*MR10VJCP79<CVD]F?
M9KY$F:<R7N:(:&E*2Q/A@G4-_L%K8)?^5#.@TPY#\)EB'[TC]?+VE%0I1!V.
M7:9QV#(?M;3<R?@BK-ERD/^^>>+F@/9F@-!.J+<<)?4C4G=21%KM8*4_=DYV
M7%+G?:0IYG!G[\VS9TI>21\[4,0F?P@_\-SP+ 2+6*)'130=PK/@W'0PT6E.
M3,F\F'#>=F&_!65T[,4,\D<U"@3Q@Z\62NI<O+:'NM7>>%C7MK<DH$"3Q24%
M_YP.B/M58/PVWXO+)_A=\]=S2RUO;TKTK3,.$/N5UVGC.;NAM6#&>2+:45P$
MKVG,^0RBF8)+;BUZZ=I&<][VU#I( !4Y+(\' X"8\':R4D.GU'6/>3<@3IMJ
MJ&S?$*5'X+' FA2D@,L)XJF(=);^-!JAI<9G2+C# :*.: )+324[YSN>SFWK
MWCNMP@87>E=^\TZZK[:[VV_;]H&BY*0D7<U\.R/P K,!Z>NBB,3O*'D0C+6-
M\BD9Y(ZL^9FF*/D!W,YBG1=HY2K GI6X*(U0& F"-9:EC9@N/!5#-$JLZ36(
MTED\8M3S/C*2N5T=*%.>%9$$%3I#-'!"S@B?L/_(S82?=IZ*:;%Z]@B&XGB-
MXL(-")KO%-2:&9_]UN1(D/(@F^<FJ?2%9M8"'SJYD3/E0KT_?(QJ-JG)*_[-
M'+LK CR\[UD1\7GE X_VE\3#?>76,].U&54FHDB >)5SLS_M$:^S5LM%X;90
MNQG0O/8[HI&PNLA>RUV-'@Q:L7&-C(B2=L=F=TEY2O93&!H)N8F.SH#5%G@\
ME3N!TU4-8DOHB:7)D]:AJW=WS'EL,^N([T,&%G_46*M]!>88J=I7$@T>=N7F
M;?$E<@Z#7Z12#36/K\KJG$#0V9#&.\36OY)[X^0A!LZ %NH=0(F6L>#>FVIQ
MUZYHLC%%RR4P[\YG.R(37FV0"3XRX<UWC$Q80J0>:KV[%7YMBN!7N?ZO.@<3
MYN)OKK[Z)VD6)9TD[LG\87Z8;"]-&91K3CAM^").(:@?AK:>A7\IR/.@GFU0
MEJ')[YK*U9#S]<77N+(]^>Y<*?C/_@@C553"AM%>-*[&T\URQQR+[LY,#EWZ
M_#+"402\$++-LCXGH%?&?=T!\_3BJB[RCML"]R(?Q;1:<I/,  #./E)-PVGC
M96?2)BHDE<B\M-P>3JN0%/!C#[]?KSS\/E6?0OT.ZSK4I+;=@0+7-TY')O!N
M]Y]J%_;#2<[6;_O^$'[F1_8):'4"9*A[0&W>3SWLK7M <N4EO:# 92>/3 )]
MBAZ9;IOQOT.73I'6(>3GY#7EU+U:2= BRS#4:0/B^'[L OYFY0)^(*"*D1);
M+H)3D :S\7M^*?0$*M]*,&/#Y5KR@9BQ8I]B )0S6 G1S9=F*F+HEHB<*!G7
M,T R;JQJ@8U)2"[=%+AF'1J)AM"$=N6M9A8X4)Z?7;A&9B%TI]B8NJ*3W.(?
M&YH3<P?/5JIF::M9VC5Q),\1L#RE72<LQ.$%=.@EK&J ?2\JSAK;2W&6R]$$
MDPFR42C%"@@!&G%^+";]LL%EX=4^#0,+/<V"RT13%HZ0RA"%VDKYL9\+8BVK
M, W-I!M'1[G2=(ZC6Y=K_ON1*ZF]W=7#"3)QACB9-<97/\::VAR/U3U\6+E(
M.%5#]A$Y7K"^A@3;[.+90:3U,U<&ES%29)626D%OD08"VMP0R9'-;P;HIXJT
MZ,P"/ B2VS%5&$GDU$I-,@M:AJ%:!-=CMWM[RX!35R121#X_<YD0B<^!?1D*
MAV2$AOC__YIR!O1'9K)):%8Z_1 O'(TQ^G4)CO+"#N$P%54_,2VI1/WR>9%/
MSPRENQOQ!*#()>K2[*PGP&B3?= B(PT=D(*"0;@GFIGE$<V5SLS/F'V,/=>K
M,ID-]%;T-=;>ZC(:$7N9:\UKFK6Q8DG\-6-5<E!Y2P9408Y2P?(B+VX^Y32D
M;"'5;8OQO!R:"^ID#\.".?$'9SB4IA1"O)(]#B&C0N"PL(PL7 B!5^F%.,!D
MR_O!B?(H$SM6Q4@(%Q4SPV'6&!M*-G*C&%:/-YZK&)B9-)5YK.9O31,D]1IX
MSS&#)(E^ ,1"SD78DO% ,3/4IZ'A/66.'BN>&,A%,XV7PN!K'$_<(CSB[(A;
M4+*]EFM-^>^0.\ZECJN3RQ$G =S!,'QQ4( #D:)OL:,YS%_Q2:=IB;D)6)NB
M6NENC&3E%/AY5)4YSMZ\LAB"?&3CF+,S6"0HB:R,YXPCF&Q #P0^\)3&/W'&
MR86V\(A/<F#AJ<83QHQ/' W%$&W$Z$PU / 0*@T-[;K"^> K9K8(NRI!Q QK
M&?9D4U1C9D'"KB#VSA[^.#;(1J>PQ-OJ_-"MABGZ!P,57!ZL3<S&D%4(N\7H
M0F@B @M54^%*!"=H79/]KS?)?C_9O[>[R?8_OFS_7O?6A"[I?IK%/D0F7E:3
M%['+RQ@BHC<AA4;:_B))-6D@N1TN>0X1PDAM)].$$8YH'LT?(#:27ATV9=RX
MHE"<-(D9H$UY%(/RL[.)2M%4B21HLCPC*YJ8! +\WN+\Q%'W@ =,J5EW;]FG
M)>QS7@GNDLF*RT1GZQ9.WMW!O,S[@B['?FE$IK!DXR>T>L+>ZSPP;D<<99C?
M\A8N5Z>W,N;\#N;YQ[ Q\KV1=H;PIR%ZU>8X=G)Y*SF<X)\X9HPBDB26Z .-
MA_QE)*ZJ*8^XB8S$ISL*Z?G(Q^#9@ U(.GE&_YIF#*%&P',\VJZA7\#[B:@"
ME/$CFL(W3J7FH1%8/R?T#^Z&Q-OE)$G!2XDE\J$X/",C.9R.)_2'2<[I.T%4
M$4HC%+P&>C@('X$PX(R#^(&B)\?)6:'U&AW2E5TD19XQ4R!S1BD9Z<_]=\>\
M)FP9%5+2;0[YB>@>Z9[D$U)Q9[?_VX3!8QKEGT?_B8IA/B6O[AMB') L-Z?1
M8+@QT3#)(]Y(FK]->4O$A)25ZX9-0)%-J7?1=1<F,28\X^E8/4'[ RR&)2E-
M^\(,1Q\S^]SW*']^XLP<',/'B@0W#^XS&YRG>8&S6K!HETS.XVR6EL&6W9DO
M[W\IZ]L"/W.NJ.4JNBK=%J%&$W::X)GA+9Q%]"@C\JBGW-H#QP#]5GEXPS?)
M')-F=_"CNC^N ZJ:+AZ:>H6&R]3L:=\V%N405!A5QEN6Q+0/A<74]U#[!ZBP
M&4>FK(EM)/.JFC(> M><P-'&,QGJT<%AYG[Z79.1-*<A*A/S7![:N?49:&N]
M'S(4R]0X?:?9BQA\I%8#]VO#C<9='WT\>@NM5 LM-[YF8[L-I*]NK[GH=^<V
MNVZO3?;3,WU^>=M:\ 8@M]VD$U!J+LHW$&KTD,\U9W\Q,N26H6EJ=Y/..>T<
M1_ZX=7J\VIP,O]%P_EG7S!_K6TWMVM8C<_X7D<+2]?@K6/CB,<H#&>_")YK"
M1(<V-AN:Z!J>*3_CKYIZ[QE8JD*Z+D8&+V>("MTN.ID[>9AEX)DP\:'[;N@C
M%CO\G@(E9<3_G05W)A-9IO1G7-LI-L4P\G$?-Q39R.UU152XRHT3/1T8N;EW
MDNG2G$\BG'Q_1W\B(%.=K#W-*INMM=J]OM#?8O"0SN5S1FJYF14?<83,Q-2Q
M44S/O-,I*!2=.VH7]-@5X^K[M[Y0)3*9F!:I'TD594\F_B\J<RY_R;&/"!N*
M&:LI0Y<<)&\.GJ04,[&C3Z]ZD>ML=?Q;!/X&,WOR:=+?SK^1D_ "X2"'<D!>
MK8C5&,<]Q5JC$K"3+3[9=;IK9,!&:P:2RU5"#< 84*_C]-%+X^H;=8YC%9A&
MTW$]=V^ _9QSY8PI?-$H&BP'HGH'\Q&/I;>=*_;X<I.LGAB4W@D[+JRP:W "
M+*<1P5@!9Y*7%5*3G?0SLWABLC/ID99V)$-X0-U\UBR5;?/%;$TMB3W,,ZVD
M95<V#;".S';'@R[=7*:-'Z%T-.5N:^2<=A#;"L*NU$W;018W&KE0%0REL?C!
M4Y-0* ?%;.*T6AIW0J$C%:?(G>9&"DVEU\6#WGL+/^/VBY9.E4=/]+.W>K#E
M<:Q ,(/_4^22^_IMFUI9JXZZ#EL]RC975%CQ4/HDG-\Y#7!D4Q4199(MY/FW
M?H&68GJ0AE*/%X>$?U+#>/[H1348Z4N'LURQ!63TV$5N]?#'-A2\-.G10-N*
M?N3:VW%2UEI\5/U%Q;"F(HW%;\./DPZ<9J"#1M/4@ZA3 GD,(>VC+^\_73V4
M['?#\C+//>M'V5>:!C:M)57'>1;/7)H8!KM((5U(R6::>29R+HLP3?-(.5<(
MM8J(6Y&\4'\TP!;.D!=P-HW0^%"U15(TY&+1)T/#66=2[PZEE(.0]1641W"
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ML"LFK YW!TR]O6:+CD3E+W?!B?[,M/T_X2V4K.B[;2K]<+VFTDU/Z?(R_!"
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MPA*D&=?CB^!I=XV6/VXQM!?9:/[O4_/?*X7#?HMS:)6OMH538C@:2UOH96Y
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M[I ME$:<QB$ GH*,19(W=V?1V[+!XFW,][@!AQ<&:<M]N8WM2.A6]ZA,O#D
M1RFD.]T0N=TP(B>!@7,^::&R3=]&VLVCB3P 3F74*KY6>7GT6N6O9;54&3"G
MF7#:N[:J()\ZUFL?_UE_>H"4-PXJD37O4KO6M2DC2.Z<V/B6\'7L16[=^FZ.
M8&'=@U31+RG;Y42LX4.@2+"^#CN=@B WCDZJQ]&-)Y06<K$U?^>J/-(+W6>Z
M^<,8%%P.OA(79-!MIT68!KA-$^GNF_3@AXFEJ]8V Y@ 2*D,DL4%AOK\;\PK
MUP]-D 6!?( -Y9Q%5_IIP.5=U/B$15MURODQNYDT#;:?Y=+",@>VQXY]XTS0
M2? 53EO,H#58PEW3&[T3VFPP+=672DG%74W];W-U#2&AJN2 3QT[B8,T15"'
MDV6.A92/<N-"0VUQ3&1W+A952V9GN#&S "%"%D[L0H-,!+8,5ROT<&'%C]6_
M/8KJF)=C=8Q?'?-RK(X9PSY/%B9E0J-NC^A$U*,@$&TL<VFL=B>EUT?2.6A$
MD"XB;YE3[X)N(=2,@(HH4=B!_7A)>\9)-51YD32&I=2@;1KJ8)'#B)UF%U!:
M41G]5)>N/990SH705UE A4COG=(H4DL^.U?W \)<>ZE1+NH+\D(T;XONY1"%
M8$RWXU5GL1=\-F/*-GINRT1_1K8.P@P!BRG^8E7>0OZ5_DUK:0!LQ$@'[+#W
MA<NI\W7891P;LYB3$T?S%F).HO'A&]P74/:SW R]Q!!PT('%]N%+O=+(5##P
MPL#0"&$0CNG+!^)8+9!1U!XPLNJ?;,YSF$YZ9^$H#"KHY3E*@)<O(TGE0I88
M+J;)*U7*7F60S/!!@#ORA::".%,+CUT&L)B?B\@PJ)>J19X0Q;;<# ]G"&,
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MR^@U.E[0Z_HG^OK,^@9:CW);]*#[&G"" /C,3$B;X$4S"_')#'>H0%)IN8&
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M&>%=90,09@D[J["+;Z-_6:^RC3FB\C?;16XAI\M<QVU#JH="4/$D,6/@%YM
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M'18D[WT @\NH8;:;I[Z&2V#!23VQ=;>E%^JL LE\NA4,HVYXDD?^\-PD;;=
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M#!0,%K^#W1[.C,P,1P1BK/7_U%2&N$GN\"S-*5N_RM8@L;G-M1CH(."S6O[
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M N/:0@W^J^6ML.$&]1'07#7&]<M5-L^V/@1OBUQ'(*LPLBK996'C8 N(0T,
M:6J-CR-IMFPKHK<10>E4[QYK:<QH QPU^/(>D%A/93)1P4 _=@5X8\A)^8S:
MF.J\550K1JS:<$N0 %O_?RJL4TS7#,=LH_"L,<:&+A7)M\&"=<!YUEB7:(H(
M*=F;$-X$\A$WS/)DI"2I<1*M0\6:OLUCV:.VVSV<:'9U+$*R6T1JN^M!M7<Y
MIB;P,PCX+FK&*'":Q!GN*!B>BF X*O1H3U&S5K =,G\O#1!;X6&R;[%TV(@C
M@*0A5429(CY;K&ZDBC!VAOMD^;D3>@4@&S%80"DK6'R&(8Z+66LHCA9DGJN'
M8[?((BBL$+%4I,[SF%\?">R,[, _:7F69IS_U%<_:T*Q9273X+IYU%NP\&R(
M6:8N1SPM#5M8V:B%*<)F."]& 9UUA8II*>6V0S$CV$7XFN5 0'&N_0K##=+S
MQ*9T7$1;>^WY)EN7WREL665KYF8=Y>-1UTY^<WIAQ+?M>FZ[=)Y6B>0817Q\
M0^%HHHCD!7-LS2#I"KP>_B>G?G,;Q)]'TTMH>L,Q./P]M[OY9N;B[T%YO/ZH
M37!H4&3=<B(L(?,?"5M5C@#6F=-\C!O==)R<^=U.H9M1]1RUZOGV]%3/ZUQ9
MB"I83[^H-525G+(B&DD31S5$:LAGI M\0A.298^*2 <K]<S^6XM]@[/^Q<I_
MILB^*@KH;QGV\)J2GX;Z:;L:F@6 >_5QDU6)JV(@C@0_<S55I]H*?Z&'L\@3
M@MS9/]UF-#LD;@H?!%_"@> K52V4B<TJJ\ -Q8DQP9G#%BV#1;6M6+3PJLD_
M.?R-PS*(Q(&EXK3%Q?.+<^:EU'HY638 2<8TW)U*JH&%* M .1=J<.XT-=,L
M0S\EJ^3[F78=DP7"DB7E(^7=<#0LVZ4^IYN6\,N=Y.3AB+8'AFQM??-[X--\
MQT?A\ML(BAWI:G$VE(M<)KP/T/31J384RO)7+_\HQYOKZBD&4BDNQ.?R_\ZI
M!"O2\IO7?97YI@ED.:><53PQ'0#PG'+;E-\,D:B>6],"1[PU-2\OSRXO_Q@(
M$0NQ+1OHAME?JX'C$S8\D1X5Z.MT@LE($SP*)O< C5N?("+PY8@(#!"!+T=$
MX.A0'93M>%A)T#<N-Q,.QO2P\)-_@=YS^MXZH0SU<7MDHC<H$3L44&#@8-/D
MV([%J6@P]I%MYZ%_=4<65 VTT%AH 0J2[9^8"E(HJH*/YZQDH>TM_5$M$+"W
MLX1F$J##@=(MA/#0*)C*VW"+8DOA'] 6>Q/+#V]0%\H_WNBUT&/R2Y;QCRX"
M:PRB/)$[?UCYS=]YY[55A_>MW]-A=^8M5+LK1)I=Y2@&M/$GO\2[$6&=^A*!
M57.EW2UJH,52P;0L&O"G(-&(W+X(DQ0!@S7Y? EO5\!UC-+":0](KM)]CP^
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MO54=%]&O4\-.+Z5,*3 5,K*L<F' 8*GEMC[[5N]<;/YY\9(0J$&A%I73N+1
MED1MFP'&>Z!7\!<>']( F0(AR+/U^,"9:25+ZYIP,WN>5$VLF-I@1%A_203I
M!; J4-^W_(XXH@?<SK,(O/PTM=5TG/#+L.*-=C=H2<>'I+>I;4BW2?#6[MRE
M^HR.6]_+J+# J3ZS^\*:"A^!D%KHA:2? /<;.I2C&9@ X%K/#,J<8BWP<K59
M07*4]$$<+9./QLS$9D:)=D/Y\Z)IS';@8&1+\%2 _:H7[3^J(!L9?JF_JM>]
M6##-D_<$^?9WU(H:FL;5BRK;F.L#<ZDJ,.:YK3<=#PRQ5,2B)RXZ7:"TK<24
MW1A&4D2$08ZXMOAIX1EFPA[S7!@WU+8UMXJM72,FW.N*7;<,#MFGB3,@&HKT
M]$Z69ZNM"<[D^QW<NT<>3_:*.+-6AGU5]#9LK*2>PZ0C%T!"NVQ3$?C1<A71
M[\K>KYH&\%5J+J;(KD[H*EM:X8(UDO,\TT--;=,I?P[X#6-FN1/BQE.#[1F3
M(MUAWH@ S\NZK7C>L#_ZG!!_#["^,+GCP#[T[Q[U5_=ZRG=*>X)#YE]_NJ9-
MN?C R KFBJK:7,F-L:6, LUWX?P"B.P5C?1J&EF3?*#+ ,+.$J:Y@L4@/++.
MM+RQWC=.H]]8N7B571$5@A:LUVSI!"3Y[<2X0):3\.994P/9C+VA9X7);@S)
M%:R@0@)3=W#\13AP,E"[121%S,F11:%&<+0P?X6JYXOGS_Z*ACS^Z_SYL_\W
MYK8!_" K'\)#@%73 %?0HFYN[_RO9^_.'#I0(T4,+2B:\#7VU 3#FDZOM0/>
MO?[!U?PS+6=N0BFS3E(U+&/T,MZNB/W2W%(<!N ,*/*BAXQB@QN]>75X$A^!
M40>+$7?#/:$WMN4N?<6.#'T$7;= H_KETWTGEDOLER )8^(D V#PQTV>6'/M
M=H7%^=^15W<#0MILH'/TF&Z ;PL#-3 ^BU=S+KO$,^SH^?FV"=1#,_"LDMB$
MV0;5T[ &8BM!7XCUIJ%JYQMI*MF9K,O]RT:D/;-2NDDBQ$"K]:%K(:H&IJ5R
MXVJD:ZBV,R(;6\N%! %8&;?%P.MAL=;FV@:O[.0W8:XXCLY\MY5N FU$2X(@
M67PHRMM<I==4D1F8\I:N&!!+>)-0KH'Y;&T]V1;3Y)->WD$3NFSGK"H[)J8[
M]:1_H_MS1"%8K6O1XT:$QN.@M4.?'CA&<R7B-&/I1B)UH259LK@SVE]. U,4
M8LCC6+W_HP TO1H!30&@Z=4(:!JC8@<5%;L^J*@8:"H)TA(6OD>[U-WD_E"D
MFDVC3I2L<?%'$'-W NP2_NKDX$FW2Q>3BY?2+D7_M)A9ZJ(;:4JB=:Z6*VBM
MO#:@<Z*<:58E6@+ZQ"R,W6A0Q>S>X$>I#Q%T*I(!L_%GVA\9!+T%(/=[R&ZW
ML?N#8])CVY8QH_UGIF@=ZJ%JZU+/ RP5@AJT!5Y-DVHT@^#9%X)N;A!6CP:R
MLUBI\5; YL$<",9L*,4*"!0)/4%CZ*T&ET3B8DZ&2AT$^.9A*QIZ>TT1+%M)
ML.1^A[BJN8FY.*\BXPW9PKQ^#A@JQ#UU&[SU+^&L/].R!7=NDC[AUF>%V(Y
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M?4KE,?\P=LZNT(4%5 [LEAT95M9AA$"B_3N/:.K,%ZE^3/]%PUD3YM+L6SQ
M.K7X]LX!U: L?>HZ(1DRH"Z!#?-##<N#GCDCH.LDU[*/MQNJJI4V+:E(FP,9
M9,) B[<)6D0#<0Q3'R[4>VB<K3)]2_BW]$*FCN,?ZM$:^I0A_IU"*P=I_>PX
M"UGE@=&/MM)VX^3%MZ=G19E3;2VF';\9U)(>N%'T>6[(@YM06/+CQW"#)AD3
MCN,.L+WI[]MH0R.]K+6_C!VI*R<$2[V'^RI>^E\<>Z^=^*_M>RE;$XB*(%-
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M-7(OCX#F"[$3[GCJZ#?D-3(HDN7$C[!X8 O\+)E0.$[81/U444XFA)LT"/>
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M=WV^AFSH@J"@M$<-1)P9B&<?'D8E9WDS^-[WKP1/G5Z.8/R@L>)C9A9 A'H
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M3'&OG]:&N9(::!-*'\Z\2O(*!''Z&SYPO=&;YX"4OQ7T%7R->"(Y'&D8SUK
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ML0:9"H+&[F/L/H6&_M.1)%FQ\?%<A)*L):<KW(' +(U"Q^X Q6L1IK(U/?=
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M;J=2I%P!VVY;C5IUB\6\>DFX R$F>^<):*R;AQ<$P1V[4+*D5;6W%]&U:C>
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MAT+$%OLL[GD4B1 >_<L-?-:N-%O->D4N[>D_2]?"@QF=<KU:K;;JS4UMY&+
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M]M%TXJ 3JPDT:TQWR\&O9M4<QVH8T]V2\*M;C5K5:BW?''([-[JQ8NR8%</
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M[J)^0$2-D/FZ49^0%6Y<NY5=AR4?U#U-\[^<G9>_7/ZNJ;X,)Q6*&\!RY.Z
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MOWN> >17@3UPAA_TW^PIXSCZS4=D6)V<9I5?(SPAEA,,+<+8(&#VC]J C?T
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MU77_PU3W3/<?Y0V>VEM"&USD+]I>X^UE74>FC@(;64:'^QA44-X&0%-RDU,
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M!%0-"C?E0E5&IAU>$VEPGETU<LD')_Q1W9C4-Y[I0(EGV*M*4W Q!,.>;*I
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MPVJW+^?))#BEUWM;>A A23A!J B-Y+&W&R%].2HRS\SBW67C_./6?E*_\*0
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M+Q:F0?N#/_F<_&3P>;*31,/!RJ'O(EZQ$4/.T,<NB_P =-Y$F9E=Z;OI\%#
M[-@/IGQ]!4VJQX\&;,*\$-^;[D#A"=*(IOG/%8\7V6,0A\@#(;9;RJ_RI"B-
MUUS$,Y6E[D>*,=_@$B#732;;9U?,9,/*,DTJ%Z4D&=2JHN>G ? _1MYI)&HQ
MXB[[A6W]T_67K-+2JMR%^G>/[Q$IZ.E'EFV;*FY2$XR3W;+#ES\Y(=?E3B1G
MQ LFK*S(W<BE66( KL>&@#4[D.J2FV-I8Y"&>')QPE)F6PLMX0!=_#SC*Z7H
M=_B*[)(.0\<^&3?SK&1&,[;XVG'(,Y1\S+/M\D'W7"D^BC15)E_$]U*!8@;
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M#WJ5K8XB @KJ2,Z9J2;PW#H:.>,QWEBT0"#V$/('GP_%3UL<40KS(PWXF/N
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M[7H+G3'YTUQ@2/Z0/TE\LMP3F2OQ%@X:Q4"PDIB@S=6+I64]PVSC:Y@M]UZ
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M".H,;4\[DD8,Z 8/_DZJ%;61U?AP%8-I:S_I7QDI(OJI^8&\&4F</%F$D S
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M #(^X%'^*SU6Y&NR1(N:A*)'/U> D8[2"1S PC-\-7!04/CDIT4U'(6>&^$
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M(C\0@[3Y(H$XY+,JV9,3DAT KX[ @)SB++]PXC\&OC_EJ.!C(N$(H0]6KIM
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MX.6;:(8"!P_%#B.:93^VR10&!N3-;!EMS,?<4WN^Z[ 'EJX"P(T!C\D:FEG
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M/'&.X[,:2TN8"R-A]W8PPMVJN2<^XELPI\& ,4>Z7$04,F#\PG4M/46)%]Q
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M='6#+)IGZ/!D;0W%=%E4]L:HM9"0L.L.QP)Z]93*WK"U*RTS"-MWW"SMA!G
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M:I"*'8MG;'"VC1G+R=F0NW-TV[O7#?+H;&_,5_RT#+3SABC2@Y8>GQ5AH1E
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MBO88X[! !4D"U:IPEP1*DNOQE=,<MAO. DU\\;0D,8"0\.;2G?UE*8P_>;T
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MTT'E^VO<!B ]HX1@(0 =Z-(S3Q+T /)#7WKR"@6)C-L&I&>^2E\&TCC.S0Z
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M/\GV?@=C *+1&=JI4DG;SA*_*5<-*@(7+(GC1K?;RC?!S#6S5 0F9,0!$_F
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M[/B<O<P<'AK8\3EYF?F\[G!H#LB];M*?SL[ )@_TTI3%]P?C]F5F^Q ; KY
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MBDP?.9.I8S-GTQU>_1U0P;<ZFP*;L-!=_)E>6VV^_#B%J@!-2D6I0F1Z95E
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MZ)#HQ.R#<0 R<WW8T$<W]NLRLWVQ%/#2I#& ;1%V38ZS@94!R,S\(30 ?!Y
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M7 7IA[3,<C"W%NLU)* =>ON 3DQ3_+$,&&3,GT!3A*WW7IQ_/'T)%[UXAO_
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MP.OE?!Z1=\OXXN[ E9G'E5FS<:6C:%Q$ J;0$K&:H.<#1SD&8QJ'@"Y%(*6
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M&#S.Y7CLUVI&FL,BPKM=Y!73P5+,\(VI3< ,OY#A)34S-4O2%=ARJB:B:)F
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M8K:P#B(O/B<+5ZO=X2EJ6<C#?I=\@_87!K>J]I7W CK=\+7XH6[[;;^B$\G
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M?OD?80(<@ZEK_%%G6:%"_O?(7,)[EOXYI%C,[XD& >#N9 :IU/*GD*\/LZ&
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M+])@BIBI4[]GK=</#SDA1 1ZE)DN>YG V&2$('@J];P"6'>V4ZHF!>_YT<+
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MJHPI=F\\0GH^PKU.O=O"VHC,Z,@<1:9$+&S+RNA1654P,]R8O/5U*?@.':'
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ME:A+GX53B(#RXU'DCT63(I^;9F",1>IRW.>-[-N%--W!3<-K;/8^,;$6:F>
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MI32JB$@A5-D1W%*UUI+U^IZ,L9(SNF60TY*4*24,Y%[1[S"'=OTO 8X'PS"
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M9R^-DY:6BL4+D+9^'I?O9?VL_@Y02P,$%     @ &X!-6FOQ1$!-#   0D
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MJCJ[":#:@^5YHN(8:#X*JU*@WME)>2X#>D0*>@981>_N.XZ(%@511H="5,^
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MJ8;W#MBENSKUBEUP()6/J#C^>97J-OX? .X_!<#_.^"_4$L#!!0    ( !N
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MD;DMH=3 SXV--'6DJ8)!().IUQ6SE>O&Y?=;BBTU2AP8ZEW+YF/_B:/]3&?
M8^MF?ST*-I2>3Q)#M)'$@TJ2UQZ][/+(K,1FLQ51-#0"HEF*B=:A^O=6/BG-
MI\+B4'#$S\E8]-=#9>0Q_5F"O6C":[7'Z3\OT\__L/>^YWT,%< ]P0/ZV,->
MUS.[++ +8WS@E(RAXR"J![^AR;#")G"RH@4R]?R NCUG8KMY[2YN;("19WU/
M7?']@"Y#(QWU*/MC=4@?@B,<A+287$2#CD!+> #Z,]+Q"(6\UF$T<X1['#%_
MV\=18YJ Z9PMK?E%F(MGP:PAJKH!&<(&_UX:T@9*:G*//6->"][;7E0T>M&_
MM0>O&C5(E ]8['3Q3B^F9[1)]7WT:YNN5*J8M4.O J;GA1"?\SRUQE@V1M[L
MJQJXB$.[14P[<A("<W6.3I=>-H?>&-B&;Y" -G^$W1/N<G9%!J,1&# *A*;!
M3/:P@KYC+69$5^#H>N_&$AF9('""74,2=>FX,KE,FOFD(U&QU/1?,I;F+?3*
M@+(D\B315XEW*)0211&/\"!W%;=\Z9R#CJQ:<@F2+G8+W&;*6<8M:T^_=<B0
MUO@F+2'?WRM^Z0ESR#XDTC8:LJN:23#" YP,?/KTJO<U68F$@&^GNTSD$T>D
MIN?'FA[$#=@_WHZN)2FINX2^1_?,;(=%73W,IYMS6]IBP@.4T]<VI.6NUXL7
M]F=6@+O\&E92XQD;2V%!82G<= ;&8M_B^ #_-50]*7]?#&^?Z'[Q=48W=6^X
MB0A"M\."&.*B_:\W+A;P ,O$]2,\(,3QBE0)#[A$XP%(;IRZ!1X@U'.">3)K
M+(<'.$,GL:0)>$#SQBZ.R"@0#YALPP,^#@I=TQJ\V+TIPP- 2 '5 )"DK_)&
MA8LHL#HR=>UL6'T.F['QTS2$?D-][=Q6QN&,]UO1!-?$CN*_D<DZ^23Y$)!\
MLF^V+.7'V=3A)/G@K>]R2@WS65(K7<[E.@OHB5I9V/R/"\N=Z95#1X&&Q&(1
M!X.5"Q>)7+/68_YJP;6>A:G,BBH;9XZSW[M% W@ RA[+1R,M>R9^H/;*OD/9
M465U]CH(#*_4T;]:KC'),D-V9ZPU!]'_RCP263;V#Q.0]Q69,AYHJVZ[+IK$
MS>(ZRA03[JRP77]_?RSQC7;%2P)2/?.$G=AK>4YKS'PB+?DLV+R^KQJJ7KWR
M_ME?50[Z$VQ#I(7N%+>F*5I7MS5C[KA^RF)*H<!!05^RA3?C[/PR._1MWIDX
MAY _ 1M!I@GO3?$B^ZX<8#=N>L+4]]*%=^&+.N_*.AX@+ .,/% K$*OD.)Z/
M&Q@);#$-LO+?L_U6I7K*EF78Y97UEIEKMM  X_-<E#?GDS-G9_BS\0\DNP*L
MQ.P1WK)2EY90X+<%W4I(6M*?"9=<'1=]M/9T0O6P:6I7Y1JW?W40]_OSY]WJ
M=,;I= ;J@/_/!-NKW3*YJ]LK,0&VQ@^LK/[V.\-E8%GTY/2WE'O#'(*0VM,\
M\L^R;'G>(5H$\S6O*#Z0JE;Y9! K>=^9"-I= $8@SW=19U+GKCD&>DHLD%H%
MJ>7WSDL_I/ZI>E3%'^:X!?+ZGI^XO5OKY) -_0UJXN@%+2?WF?7<P=P@F_IL
M:;OX0]P4=>T1(1+,'KX7J8Q15HFB9O$C<^>Z>W/+NFYFZK-21T;ZV=QKD=O=
MLR^L-;$[D!=X0+A-Z#H'4B^9Q@7*&K:9B@<P8TVVH-'?U_  5TPQ6@^3'.B(
M(/"Q9U7Z!\N%WRBCW22U47IM2X\R)V#+ILB%I.3<AZV?J@]8:EK;'MR\BE!G
M,GDA_XJ/@#W[;G$JTQ<V*:^\:O)THSYB.4)O.;F'?_<DUCE_G2Z#"0\T)49%
M<D9\V%T6^9:%0?8BSB;%IAL#U<SJ,!>:U!P]D QC!KRA-<,FB-[N1#5 NU/<
M*+F;1,]"3EU;?3RDHE*PG">4%M<+0EK;AH.:<3W*))#0&5:TY4VY[X_(W_]$
M[V)5N[/TD!?QP%QB*STU'+6>KEGK],ZTQYLNTRAALD'TE=)YFZ3ZO0R>SO>2
MH7LJ M9"1AI_M]O-"+4:8PV?2TFJ"[T;1?V\\ZB1@']/S#]4*ZQ/$[KY&=JT
M<'13HHO@+TJ&FQT1E%B,X 'WPV >9,X-PQ5]057C]FZ(&P&8KBP$_$HDPDK4
M@SRG-8OF\LIMEI+4\902_?)VRS-P<V%(78^$3IE#$SR 2*]Y%JN"3/5+FH2#
MCV3OE5>UQL(_^C^,2O$+0=S3OFULFZP!J]HA=6./ ]+ZQAX.U942MJ)=66Z(
MWJ7Q(BQI!SWSWY_IO,BP=GPP_V/(#JY*T1*4#;%/%\-D:] =:!LDF.B;>\/$
M<E]DY>J*#6VWW$39,?Y[.VN?[:9J/2YL)SBKYV-SM*+_HW!AG'X8HSNT_A"U
M$-5LRX@!V32B>".[-,N775E$NDML5C:<+Y9##KUTW;AKT->#4WJL;S7"UE6'
MBGW8XOJ5B[2(0AU?:1$(!>U">;EFV;O_PET$T@]TLAH+E62<*T/W^R<F#KRZ
M$3-=;L'53LO*<1()B"I5'=^2>I8&_X2TY36_SOD;W=M"D@B/X_M*$7IF.WW(
MG;1^83+C>YGMSG"1E?EY59O!<T8C=4U#AV]D]37D%9QRK6)AT)+LM!.=OE7I
M<:1 >T5!H20!JH7T7:N$]N,!C85'DH'*E:CZS9-HK&/-6#FX? "A[0'LEGDY
M8Y=)_&'2KL*9L371T>LN--=#>9/FC3:SMDW8>#RZ%*->"0'<M"J+X,:#-!,A
M/J(1$&+4@6U4D$8-Q*)Z58\],K!B.<R^HJNSRS51UZ!QQF.Y'_?WQ1F#W@O+
MEB5N]9!Z(F0DA5!M7/_TK\I7O)$#)H.S&2[TKOS3Q?K-!]Z=1N <@83BVIIM
MQK<MM@IY._^\G5[D[7>!VZKU$[BT8;E&U8;Y?&NS>E8Y)59M!<-7A854>YPT
M?D=\  GPRJ$L 8Y(IX?S]Z(#L)M_V#K^K^C>'$9O,QDC,XDF;$1.)"W/WK8U
M4$P+R?FXM%7\C=$6-$'X3V>[?$ASVO/6]S*_-6B.C[W#5SZ7SE/!@-K<EUGH
M(CS@DYLR@VL/W7R+Z!+75CU,-*I <0:1N:7[N^<Q1'VNRWY3R1W%F:EU7EDO
M,XQX^;!.Q)15S?M"AOIITV6!!77XNIM04^1N3'U4]2#0<R)14WNN.KSV,'?W
MSP^O01\CO1]U 3]*@^ORZ<7E6N1%&L>V#?@Z9%5;*-P>;Y=NO3UOJ];"Y8/:
MSFVOR/=M,1R.>,"0(0>5TU?:FX92MKN>HC6G7HN0-5=L>H]@@-E65A]E3($4
M1AVE9H")A(-C"BG_F2'Q@'@IN2ZS>EV1Y&KN)2N%E:SVGA6EI#:W[56G_;>6
M)#3FN(531B#: TMS@GX;CSZY:8#P7LMC\ #$[E 8<8"5^:WRZ;(*J0S0',II
MSODS"1_GT:UHWFA>7P-39!".,R].J3U^>OA$-Y"-T&/:JX=LIL\ANVL;)<+>
M8Q4YYGF9.V38OR4G,#W(-V)4EF\!<J;G?G_"'))1I6R:Q3I7F6A.LAV0 ]R6
MG4E6>@?,*^?K%QCEKQXUL-RKK\3E[M<[G=+06DS_D=TVQ/U*6<EO]P-5*&=
MK&$K3!(=$$*Q+]RJ)1^8$[R."%+.>A@KUP%/0@DMPOHZ0-^'$C_%ACX.G9L^
MT. ;._@-\9VK.68W_\"-:)DY#T >:]C(CO@+T>L?8#;04;?LPQZZB ?<;>XV
M0G!@:7^@CS#77K5.VOX5RQ >3#2*=HB_VCI1@+$G?'@@%#BC^.R*R\5?0N5A
MSY=R3/P 6GK&>N2NC0M5OV, 5*[W39Y,\M"-GM<3L0P'$1UO&-S+H-BPI'O9
M*P]N=?$B;_O^:*D#DX:$=XY!0G)I9>+X?O6D0,W7-)\\+R;'$?K0P"6-DTP!
MPV8KC\PQT^2_[!H\2AW+%JPI'3I_V$-5Z^X?D%)MK'%N%A)B"J\U(/08%2%3
M/("FAQMCWW<A0QXZ2=%1:[Z\+BLDW27_?E^D+!KP&:>KU7OTI $01AGV +0)
M#4.^F/R PFQMBAYQI@44#^;PI_7[XT10T1$S [9,H8PNK9/<F45>%8OF)2R:
ML4",/0].!FJ52+BB0O];X@M/$G@O&D=R<\U^^]T-R.0^/* %-/0C/BPYE!<S
M4FZ%R=69!>8.H7@22P."#<^ 9 INZBJ9,#S ]D<S'J"[ "OCF95B35P&?F_6
MFN.][BQ@?+,JD_GV5GG&,L\]%S$)'_\N%VJ0A5R321J^S7?+HG\56TCS2CV'
M@'<,]!JD-0W3N>DWBS"Q76]L6%R7SM:A/Y6#(B/<GT3(U#EII&%IW6%P%6PI
M%T:Q;6X-I3X4M'/U-@S,E&2TB:N-^=:XSQ\L:TFV$BRG^8^@%]HR?#B)DKAI
M#B/">F"":P]&C5E90UQ8=6%"<!,:UG]M%B\7(TV2?22IB)GI#QEM0)BP\C%T
M"!BFS#!S+)8PW[:,RR+JU01UVC-W4<9JLW_X]#'O%382)8HCV;X6@FC]=C]?
M#*5WLJ&:Y70(%J4.T./]#=15JABG0R_(^R_%JU&3<#;EBPB7]6H_2M'E"I.Y
MW<GAP^$MVZ5Z1,DZ.VJ^$A3W#J@K6*O9NZXX^R;3 #'.0N@8K_.9,4-8M/F9
M^)!PAS>/WZ7Q\,(^1!DY,%!(V]3986,TC-4=:.^ 'RST.5CTF'S>\I(]\(J6
MKXX<=&BQB]966T\7\-%S!A[#G$/5MRB3<?(!9*EA[U >46R2@U\>\FTZ@V,Q
M]C'MC>;WWW9$:LWT.O@ALW\!G_LQ(P*+1.OF7(GT<:,E^1KIT'H/C(4M^>*A
M+4< 4%L6$!#]G+= C')Y$A33=UZ=XY^DR%AC/>!8C,D:Z!R:C?SR: 9X)'_@
MV;#E$U(POZ/IDT? *CJA/_3@PA7C@:S[Z(H T6)\!M)&4WACL2I%F) E8Q+A
M-.LY8=\1WICR7T_"%3)32.TRTJG47BV@[9&.:'<,/=(>/',8^A "1!9&US</
M,DA?73EUVKM>Y:6P.F]#.Q>(LF?_9&J/$5F(D%:N;$=J )RW/,(#09\V%A<5
MP0PH!M>D"<]4F!VWIO"(6+931;""&J-\4[7-B[R2(IFH:% 3>CHRS\CLW/D*
M['4QS4@])-L%NHO<I7S3Q17[\_L7F* 80IF[,B;#&O6Z<.X[DSF\B"4[3TE(
MV#C?C 7H:C+@/2JU_>(BQ':013G:]>%Z2[6%,\.,'AOUJ@MCZSR5KE 2_2.S
MG&>VTFJ1SR]P2$(S!CR %O?08UW1 \Y#_?/;<TRQWGM#UI06]WL[Y]8.R0\Q
M,,P:93^9:/05N@E5KH%,*MU,O+>\:PK% R*@^C/ E_)W'-V$9[0]'*HL5X>\
M@BIIF82+8LN^3&;1_) H#I/9:"H_E!$]RD"!ACFH?%^20X1N<CF&KF:<_>\N
M@GW"RH=E$[M$X=KN19JSCU,Y+\ ([10\H(F\?T7/TUYK> #)"W@#L4A%,5)[
M\=@GP/.RHA"9O%)Y?+J4\4/S)J&EF:_X82U"&H+2L-E(;LT[VJ:UY$IF255P
MU4@7CW-*9D7KK:1[B#J:S8D[F^ZL*()83*M[J6)XG4/!L,2(Q$_]/$''RZ$@
MZ\M0,KZB21"Z$P\P*S6BUV'BJ\IPA6F>_RT.P /Z;#B[Y=_&(_  2A?_N&]J
M=G952ZNV I_R8?=Y Z5]#WZ #1<WT=RJ8PR+,R=ENF/1,/AHV2;),2.Q<E2/
M(X;YF@]+@B%Q<RFD[&$/< 3/NWV-6NMZOOPR8R.^GOYN9<ZU;4=DBZB(JLP(
MN3\_"6'5TR[A$-"?1^(=B0\'JCWX:L;"[P]0F5,%;J+ZMMIV90^5#3[]$C0:
M<;&O@N?9=F=/I%=U_]LNDM-08M'76ULJK[PN)'\MVT:; O^+2F*\D[8S\\=/
MC)F\6B=?ZM*#9!:FX>YRD; F.R1[UM[]Q3N.KTYR_S\J[^[_M>!/M1^#I!;;
M.Z1GO)+.^]P;7D*A0D@5>"_9S&$._=)VY"7VDTW<R;?C*]'<QLOD;^U@ZH#J
M@77F%I;H&(B*XU?SG]OVG7/_*IKWRI8E((7R6E=)8@2TL^2(<N1DHJ(HXN/C
M (_!3M$8EL7RY06M>>%_<L*?&B_=Y(>DZEE: ]>:MS[?GY"Y*@/"'9.3R.@5
M"1V9AEE9Z$NC\EZF[U0+4*2;R(VHP$S2<X.XD5#@VZ6@X9JJ5KOTJ7&V0&@3
MNT_F[*]_^@9@D:A']HQ J0.>O2?%Z^/YI72&XKV\OVF';8A>!>DM2:-U3J9<
M\ !"87I+;8#>G\:D#W=5E'<_DYQL)"^DH1@3L8)P)K<=%#CFO)!"W?M:^,U\
MBZN>G*, @5;?<5F"F/JK"3IQ]<M\8S=ZXV)Y3,PKY/D!PBLM/EVLW07H1?\G
M]8=7N4:^]N@:G1TOKQ-,N#G)VE2&^&/_[+ ]ROS=O7NY.N9=;Q\GL83O0!IV
M*FU*^52DI[MV4LW2&A-RCISJV?& R&UD&"ZN[0,(V3 5AKD!XN2P[*2#6#,D
MX(XV+XY6F.H50-_;L7?8NH XZ#RL07+CBA>3&#@6+;E7NK,M5,I7^B/-69UG
M15NZ"PB#<"[;_O4@<9F>B0L( IMFIB2]V^9=%M<W?)]@Y,9[Z&N6L\=!ITB$
M"&X_5)39\GC@>A&LN"_<7.L^8)0/)Q3-IVKZP:G)S#F*D"&$E*IP^8>>BB>]
M(+MW?UN+5X[44V6+H.COGKKG:S',+UY%KP!%#882,RGGUW8"]+P4:0DN,V6S
M-JW><4O8[@0&Q\RWZ2X(B:X!XB\&W[99,CQE<V2S^8>D-[<U2LW/G-N <W-3
M[BD=INQ?\0"!"66/<=X<..0[Y:]04[)P3WW0\B3D[/="#%;UYILR!41R]OR(
M<MB65A$(US,;-)O:#S+)K*W2)!I86Q50H;N?,EJVM)NI+@8.F%+KAK&E$]DP
M/H@;?NT*%\NVUG_L*W9>/6$>!!2T!);R*?&KNHND6I^FYT1VN#U9!@O-*/P\
MM:03EX-Y?!@3P^0*^'FUQP4$Z)@:YGF8EBJ,YK&52M5-1S2;=AQ+PDS4^!,9
MG@A9M&+C$YHHY.WEAE^(YUR*HOMODGKNXU;"2/S"(D!L79)NM<XR#?&U9"^?
MMO8\1K[O005*AW(BDYI(=(^4CYDS^1W;HA"R0#KUUIXD<^Y%Y:+O/YJA2=-7
M\YC5Y?4E=:7B89E\<J3$@S:^OC4+:PA\]CMG..M#O^?4C=OO/TAG(P&<!%BE
MNYGO=@G)\]+B)B+?F;)2X>I-RPAHPP<-\P3M9DIC,BR!CPQ)B].%!7PRZ$F1
MJ5F*#RV]]27R'+KF:27[ILMM\@1?-8BCLX,^YW&SM%NHY41)2,8W%9M*ELN[
M8.?3N?U])Q%_T?Z8FVN=6Q(F#'/6!2_9H]MG%=509&AFS*<*7JQ@6-S[5IFL
M>1N.P%^GO#%=<H1)Z"LVM.?WVXS^M#FFXER^O#_?QC)?2-@VI(L'O FE1YE^
MW'I)J8&2B6@95QBT>3A?*^3W0-1RVMVN:P8HR-I.<\!ZK9#]Q*D\',%/;2PH
M'N[6ERZAK.QRTQ1F#XVP;3WIO96]$&K,<*F*7[G+^W?+Q'&UPJ]R!WONH0+:
M!,LPQ0-&>K129JU&NFQ-*R4- U66-3DA>\&!YL/8[5L4$B"7P@0.Y'/0<N8)
MCN3EM=O!!0&\I[A:S^-:&O)BSM0/B4OVJ;21NI*.+'=IJWMM&XU3BC).&Q O
M[B]@0IGGJG:$3S.7&%R8[\';9T0&=YIG/;LT(_)XD_KM:(K)_?B@8;2J5*9&
MT4T&M?>Z]\!6(X:Y*,]_#<SZ_)L-.I>JUMDZXV[2TQ&LF:W>7JT_#IH[0?5Q
M G'/>4SX)E1\3;PWGU1_UT_M1[%IU44$2S,SO:*:S_*'_'OHLQ=6)[AYL\W+
MK [3+7;>Z%GK^G=JZCC#DT<WHP>"GCWY%L?_\67_%B?YJY0/LD_8MAY2*F[-
M0W\YXD@=67BQ],/H;.-G)K;+A7KJI$6JI4<;X77U]$\!1#\Z>7:V-6DG(/MJ
M(V=F5^_%7M1H,0$*/LWDX %B81B!@FJ*2#R R/JFYM_EJQS$BNI-\5%+;&VM
MH4Q[>_+S5J3?88K5L. PV:2 JB%WIM:6,Y/@SSA=R@5%NA)HVUG&B$#62!,O
MJ7/UJ =90@)G1TYRMPQ=_9/N(VL_5SAF77'1FBZO@XO<AN5X8E](GUU?9^UU
MFNLXUXT45J;[7)@^[U.BQ*#[DP+%&,S(R,$]P-[3D[B5#%.M->WG= ZOGG)6
M,KGU)E!IOM"G5)4W.SO9],#(ZJ+![<B>-/9*I SZ]XP?JQ(!N*-CNA;JZ$&#
MB<V435W0%Q^JV)=/WWB7=L1=_\9ILSW32G+GB:'6*.4OCN9"+-L),KJ_DZ+^
M&Y;PIJ!'W+5 N:/Y1[0&%--0O(Q5^GV^Y-"6"IQU/S?W\"ND6\4#WCZ?6AUQ
M$$ES4XPE&Z3["7?=<NR%Z'W98?K%+1355)U0*^#IW]?':^-3#L[Q8#^<;:"Z
M^%9+876]VGEM,"%Q*$T!9.>BMEWJ&WE2&BBK/KI^NFR=U]F]TI,%XH!N_@D&
MW[.Z35H==\TH6GT]PZW-Y(\G$,_6*!((E&X,%+MU5I=@[]=:ZG]+G_T*;#AG
MVE6K$7)P=E<S6SF6-?\LK,\ QU;)ZX$5P /B YFWDA^L4Q_!!'<VHFV;;(<W
M,'P[Q=<O< M0&IPX1+QY%B(,%^6 V&"2[[4@CNZ"X]B!/4A0=,L#=PX2C!J<
M(I][(TY*E-19L'AIH!Q3:!ZM.U/C&T,FY-7_3>!*%_=@\!$>L%D11G'G22.6
M'S/ 0N/]A@''VD0I2#NF0)SEPY:V,Y)VUAI6VN3B/8:508@PW;;L!JS20* ;
M.2+!WC"O$?N,BW#+L/;M5KQ!1D=I5/JW6?>"\AVO:D4S>CLO=\59E!__7"3?
MDW+M8$OOKHT!$=/Z@-(FT)1#BA;7_5&5!WELG_*B)EGU/37#)KX62(OK%-C\
M$^\\)'974;U/3CS6SO:&H&TFR?U5$.5/(ULGS9^7J@U<21H4(<1<\]!DI7RY
M-9-2'7?G?O>)TX2TA"S@;$M"2;/S7]^9)MNF40I+GUGGEH#66A%4D.6TS7&G
MI?Z%&2C!%G-K8-%FO]W^03]!6W@C%66<RUV")C*J(?*8+ 2K O!!;6GD35('
M7+NE.OL%8T_#6L6RN?6:UD0KNL%RJ.714& ]EA5\[0T*QP9O01?K$1QQ1S.]
M/?)-LSAN+#MNJ3LX6(D6ALZB B4H\K]MRR)S=G9&O&37%789G9ZB/>IYU#Q[
M;,@OZG[,#MXOQY%6(K/ZPACQ@%>4R\DJJ-!DYZJR%&0R+%0"B5T@=IA(1DR2
M[RTGE<./+)?"4Y\T]B2XO>S58P7?^9F=@0< P4O#QMU-F%UD#AJF$<@X=.76
M_*[:BY4LT%)/6IIFN=G,*V8]\ O+O/EN;&E&[1HWI/# EE+,'$2KJ%3>'Y#3
M.& O02]42"0+M$G_N^4CI"B6G3-5RVMC,/!B4)?24*#$56?<,.>3YMD%N[UD
MS]TAE.BM.9#L-+:WE1GS9NLS+@X?:SQLXOXE;OZ+K#HBKI(WIOZCG[VLAJ\=
MB>Z*8;7LZ=B-RU:Z+H/PU@/F3Q"K.*95+>B/TU4:<K?40-XZ)G(6[&\\(#P/
M-]$CB/F+%'QZVX%"X*(8G2Z?32C+OF5M5&[Y^(/:%:<V])DSR[_:VA'!'352
M&\TJ,DG.#VM60PIU?_W\L+DW7_Z3Q""64.*Z9'AAC' (JA#>&7,4T3GTQRM@
MXUEK1,W;!=V%7XGE-LN6*R<,G>\;:\-X!B,F9,0Y?M?W3BY;P2F/:.'.$#"R
M:1!M&6\1DJ/D,W#!?U.( )%OK-L5SRBJ%%FG^)2L6KN1N>_P1ANL=$X;1G)S
M< ^Q,P:D;7+0;F+JZDRK?X]5P3)-!BV>5YF.AN1M6<;W[YA4CI8T'JH'+&2(
MVL4:)CCP:2YK#V+<Z5')?=#2>L"N,H>:4NU 8!O5GX:Q,QNJX4D23?F^V<K#
MW9OZ#*/!H8&'NI0)Q@<.[8=":UH&B2"WB 'IU;#/MG<Q'L;(X>&-NP$>EC-U
MYR$> X5,7?SE!SE^!\/H,>;F$\:]SG>CJ0,9&8CV[)\QYM4Z,6 >:-,)<\!&
M'QYPJ\JJ @9@5SU?X-UD:N%6N4>VQC^21I<5G!Y%665I$"I8$U((SQG_?,/Z
MVM1=\)(&<UG#&PE]5QB[SOTYY@@"1 W^G2%S^O2S]<HCMKG6\H\:*>7ZSZ-W
M;ZD!SYLB7Y-M+I2'SG*TNK==&V#U?Z?!) ^4F6X*SY/IG$X\-M?8=W"LL8H@
MQ\I]F<[H&*PV82)M,O.RE96MC?/3@9VG9;*;OL2%!Y/,$/E)10L8QC;_M4N7
M**4#&[&5Y*2D2UAWK7R[=9O(KP8Y=P*2$[/*Y'I=:B/*Z%K3=&1S53M"L%Q#
MHMP(0[MWM.5(?O/P%/I0PL^PS'^0.9G=L_Z^I[1!X=C2]-"6Q-67>?.SYQ=2
M S F<F4RLIC*J*&%VDGF+B72"=H='<\;LL@>OEL.-^KA7E[;L/P+HL #7D.C
M>W@"'S5WZXYS66 ::IS-BK@8J4^23!PR>9,0=QN7,6]AIJI'B!G[2@O<?(!F
MOPT+$ASMZW$_P%9WIEF)8*#5E$4DH]CY]Q!1V9>RI0QJ2TV6)SK?3 VX,IZ^
MS>Y*L%A,&X<(Q<//L"!D,40D^9GR?9:'<9C7*\]<WTP)']K'$48)NBH\;7W_
MX+X";SB1NG9;E(DWHIM:F,7B0M'@FV*F=V,Z4012EU4>Q!K#*0US6U0(9$O!
M2L(@ND9R]3>?/HQ5>^X2_Z%W,1PYU3;1_U')K %LP!R;D+8G_&4VS*U,AB%8
M\TE& Q1_+&X6,8%O7B#;!KI$2?NAS#N!)>W5R5B5I)=FR0&MAG[.UZ)50C96
MF<@U9OVJL0 CH8K]323='C#JESW36Z8A(WH+G8+,WG:M!*^*72=9;)AR,,#%
MN_:Z1HS)89+S>#<%LT6(ZR+]K$[U1Y-)N8@1RW]MEIP1L-^[M;^/,>OG9OK1
M9]&]VN*AZ[+BAEVZEA&]S?V)DEWA)W]UOUA9+6DZOCV:1C/<FN"O__W/]/_S
M45''G$JR=L_"+B4]J+&8"D1#I*O52_]*X]:$!U$G1>6TS-V.F:7JZOJ<SLLT
MV8Y^SX0\;CY]\9QUFG1NIO' ?L.$K#P#+"JLS[7.?660@TAJ2VC!]$&QJW\6
MB]7(DTR:]:%*-4(9"8MC,6TOU^V&J/<)8PQ:&LR[_=#-Q(NKR+8CS;K]UL95
M2W.70HJ6^)5K)NY4,H657-=N$J[.'RT:YN[NPENI?E'.J=JO:;2H%X()CO
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M2YMN1XGNVS<9WTS]8]XY:BWP_[LF7/Q5)BWR(_YC&B_AIY01Q6U_1^(913R
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MX*].\V?J;N(H\M\V 9_,<D:G#*? ,>>UTBNV3=T_DE0<$.![:_K,[O_Z3_$
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M"H]P^:Q^*)D3E!3KC/*!X0%,76;5&*N^'@:DTG%DR:2/],?-<=VASIW*L)J
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M%7S:(8P=&ONY9LWVY($O<4PFX+V,=1>0#%;^FZ$557Z^Y"$'H HE,+F](KU
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M9#Y@M(*L3C0;%(I&,@2;8416H&@H#5F(%)>LQ49 IO0J3&KQYJ8@44GA/HY
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M&_HP&-YH7)!8N,UBD@)YMQDO_X+V'\C^SX %_S\A^SNP?^"" ["1$/X4#XD
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M(E6"HSGC/N=&;OLD8TJ7\7"-_E<-M!3*EM().AV-6?LLMU[C%>37+VC/Q%<
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M"7[]"S.%&M8(?6PI<W&CN=:0HW^G@QBZ!9I$+A 4'#W[MV9$THBI X.&5!T
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M\U<@4N]0)92W9@@A3B*%6[#! M$P[^\[LJMM=["J)YW/>Z'JM25SY-1# G*
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M,;"(Q5ZAX9\4,=!C.K(OI\=R+FN#AVDTC*!05V@JS$*;Y=<$4Y]RS;U,\&G
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M[B'BBOA8I,39U/Q*IJ"2CNV:I$=HWR$TCC"CO'Y ^UWVW\'H_Y?L3]B_7..
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M"7?!)X4*H&/?GF32H%;GTTL?T7EJ2A+"M=D$5@<4WS<E5PT"L,^/W R@KB'
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M>UI%]K^\:/<VNUUS6O/3*;5)]4U+LO?>27LU$KD5J^\5Z,OK9U3).2>\'SU
MX9(ZND9@</*T]0]^]*R%J:%>RJ!J#.QV"^5"R P'RZ\2^\G/2>);'33$W/*S
MDK"98JEKQ1PK/F9D]MG^OEJ\Y%7>"9J;LF7]^%3( 9;'KOV9U<[K_GSNK#J;
M>K03_4<3E4S7F6KW9%[5V. !ZLM*B1<ZQ'I+?THOU/N0!V'"3)5I,'$WKQ9O
MB.=O;.H7#9YL6K-/\&R?EQ>A'WI $>'KNHR6-':ZK'[T]&F_M7/UYA5.II49
M7!1HV7/Z]=7"ZB\'L#V*C;HK;34FXO-:LM*C"4M+LO1P2)2ZV[G7X>*-U/>'
MED^HL<;%,CFZ!@6J.K597J19,\0E9V2VQ Z3C(]54I=D?&!4QJ(UI;.@VHKA
MB@JJC^3+;,5]<VJ5\VL.GYW/JMVJWE1<?2 EG'(NZ"E%E'U43A5>]F9@Q,O!
MB98W(0JV BM:-N1";K4N9[#O92AP +)+WS@'>YG%6B8M+Y$F\0KU\;K85/<]
M=4?@C**\ 6UVRZ79(<3U4]-;+5?0$_M-B(4N06I%3S7;[Y;,!;T6JHYL7T.1
M2.K4M 6W],Z(O6.QCQ^+LB0/92\KI9,60C6+\G/L&:>3#E=67+1 VLG[COV2
M^ICB":3*O&\:5^.QKW?%/<35H:S]7S;Y'N([.O%0??)J7UW-JU6K95R?:VUM
M<%>F] EW?Z+2E]897U-:F8OO0"=]@5E>:VDR*A:&4>D0=$O.Z@U'.70(+><7
M<"3&>9WU.9:F JV^J_(9IK*>;,HST!O4L9;<#LZLFUMXHSH7OS)L1^17H$[)
MEM^\3Z*J\G+RG(C;$B[0Y'^E1;Y2O=7%VN_4FEG7%=;@.H?ALGTM2*U^SSGH
M,;UI5I\T/:6W)MMN8Y"K*D3?UP67SVJI"G3F]JP)??%9]J4';TT_MMDWO\&M
MX^+-A S-X'D_BH^7H\6'M2J21O4!>FCHT!/_6O[ !I:JFE>IV.2H%?&B4^N'
M+3)9G4VC/W;:S=\6'Y])VJ_,X19Y+&-L$N*QB-F[K!5[>(5T:HTF<_Y=;DVU
MXW58Z]D7D[QOX8SMC)#EDMOXKA*_D(+!9C_OO!=*F;[NRDS3+G%A[_SA<%,3
M_<OCWL:;^A:9+=-=!JL'<8M3!WH.X&ID1HKX_%4%Z44^/\D&\2?FS:UE#=*U
MSOS\;-_\D:H'*ER!S6OJ_ VAYO""J,#\9;;H=V3]FZXA*3];J\-MT'Z+B8[6
MZ03<AUDUOOR[>ZIC?=*#RIO]30T_&RKF??]>HR/V4$N#C6RB"S$AQ9AX3F;#
MT]="KM1OT#YCC9Z2+70YO(46(BS%BB4^Q9O8Y2+LF;I.Z (LS ZH?,QNCR=_
MUQUX>_"_ 5!+ P04    "  ;@$U:9L3/"$ #   J!   "P   &9I;E\P,#8N
M:G!G^W_C_P,& 2\W3S<&1D9&A@0@9/A_F\$9Q*,(@ RAU S&_P<8!#D8>!CX
MF1F5&)@$&9D%&?\?89!G8&!DA2A@@ )&)F865C9V#DXN;J""K0(,3(S,S$PL
MS*RL+"Q V5J@/ .+(*N0HJ$CFW!@(KM2H8A1X\2%',I.&P^*!EW\H&*<5-3$
MR24F+B$II:JFKJ&I96)J9FYA:>7LXNKF[N'I%1P2&A8>$1F5G)*:EIZ1F55<
M4EI67E%9U=S2VM;>T=DU:?*4J=.FSY@Y:]'B)4N7+5^Q<M6FS5NV;MN^8^>N
M0X>/'#UV_,3)4Y<N7[EZ[?J-F[<>/GK\Y.FSYR]>OOKXZ?.7K]^^__CY"^0O
M1@9FN->Q^DL0Z"\F%A9F%G:0OQB9RD$*!%E8%0W9A!P#V1,+A96,&CE$G"8N
MW'B04]DXZ(-H4M%%+C$5DX>J'T%> _N,.(\UD>4SN,<0_KK%P,/,"(P\9D$&
M>X9_B^LS]]_>?31^D_A;U\4O[47VZ#Y\6_Q-;></YX?Y0C6Q/PX^.&M]A/?Q
M_AN/C]JI?GRW\\%ZCAJ/OPO6+-V[\U)I_<W+C^X^[?W7O.C'\D-2L=MV?E@=
M]*/TL;Q(Q;^[^^2VS%/_</W6_4WU1_XSR/U)_J'X,+]+7K#&_.%Z[E?WC*_M
M4WEU3VKCA[:UA>M>2&T_Y/S1^5C8?B:;].15]QPS2TON"]1Q1-?8?'SZ_-9:
MG;3M^S^*/ETRJ[;[MK1V7IK\S?"#%_]=DA?YSY"Y>K[$C^]ALQ^7'[C/\N]<
MO- _CM?U'QI>_6=@VN/]L+XM3N-'Y[H*YZ/B<?+[/_#<,[?3W[S]Q\*/XH>G
M?_O/\&%#?\/6L\S'I*94W6\LY0VZ['JU9)7]IO8WDQ_DWRQ_^/SP^79YGIKB
MCTWQ;?\9.)[\N/_P/<,/]J/W['=\=&_[$L_VQ^7'2O5N&_,'[=Z_&5=FQ4G^
M$%[Z<D*-Q0]^ON4KX[+J.'YDJOR3VG_5QE5[V5*YD)7JW#O5S1VKS35VJFK-
MZ+Q2..W]=\W?.K8>)XLNK [K]=AQ\>"GE+L6I[QF3ZE4;P_NBMDX)XS5TM-Z
M7V3(RM]G?**F9">)? S9.^5CQ(KS_V\" %!+ P04    "  ;@$U:DCN:%CT"
M  #Q @  "P   &9I;E\P,#<N:G!G^W_C_P,& 2\W3S<&1D9&A@0@9/A_F\&9
M@8.-C9V-E8.=G9V3DX.+1X27AYN;1U)(F%]$5DI>3E9*1D9!14]=04E'649&
MPUQ3Q\#0Q,1$7MW2UL+(1L_8Q AD"",')R</-X\$+Z^$D:*,HA')X/\!!D$.
M!AX&/F9&)08F049F0<;_1QCD&1@861G!@ $*&)F865C9V#DXN;B!"K8*,# Q
M,C,SL3"SLK*P &5K@?(,+(*L0HJ&CFS"@8GL2H4B1HT3%W(H.VT\*!IT\8.*
M<5)1$R>7F+B$I)2JFKJ&II:)J9FYA:65LXNKF[N'IU=P2&A8>$1D5')*:EIZ
M1F96<4EI67E%955S2VM;>T=GUZ3)4Z9.FSYCYJQ%BY<L7;9\Q<I5FS9OV;IM
M^XZ=NPX=/G+TV/$3)T]=NGSEZK7K-V[>>OCH\9.GSYZ_>/GJXZ?/7[Y^^_[C
MYR^0OQ@9F!EA *N_!('^8F)A869A!_F+D:D<I$"0A571D$W(,9 ]L5!8R:B1
M0\1IXL*-!SF5C8,^B"857>024S%YJ/H1Y#6PSXCS6!-9/H-[#.&O6PP\S(S
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MPXEGSG-UFUI#IU?\"__?! !02P,$%     @ &X!-6@1_% D< @  T0(   L
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M@WL,X:];##S,C,#(8Q9DL&?X)B_\:M>TR;(]NTK,@F>N"Q-K>^8L.;G @N.
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M1_D;;#@A\X#_^?$J\?GS_S#4Q<5_\)O4Y3AW<9EQ7Z$K@ZY(H ,K$,O_OPD
M4$L#!!0    ( !N 35I='0YH6P(   T#   +    9FEN7S Q-"YJ<&?[?^/_
M P8!+S=/-P9&1D:&!"!D^'^;P9F!@XV-G8V5@YV=G9.3@XM'A)>'FYM'4DB8
M7T162EY.5DI&1D%%3UU!24=91D;#7%/'P-#$Q$1>W=+6PLA&S]C$"&0((P<G
M)P\WCP0OKX21HHRB$<G@_P$&00X&?@9!9D8E!B9!1F9!QO]'&.09&!A9&<&
M 0H8F9A96-G8.3BYN($*M@HP,#$R,S.Q,+.RLK  96N!\@PL@JQ"BH:.;,*!
MB>Q*A2)&C1,7<B@[;3PH&G3Q@XIQ4E$3)Y>8N(2DE*J:NH:FEHFIF;F%I96S
MBZN;NX>G5W!(:%AX1&14<DIJ6GI&9E9Q26E9>45E57-+:UM[1V?7I,E3IDZ;
M/F/FK$6+ERQ=MGS%RE6;-F_9NFW[CIV[#AT^<O38\1,G3UVZ?.7JM>LW;MYZ
M^.CQDZ?/GK]X^>KCI\]?OG[[_N/G+Y"_&!F8&6$ J[\$@?YB8F%A9F$'^8N1
MJ1RD0)"%5=&03<@QD#VQ4%C)J)%#Q&GBPHT'.96-@SZ()A5=Y!)3,7FH^A'D
M-;#/B/-8$UD^@WL,X:];##S,C,#(8Q9DL&?XYNM\9&+F/=7+6R)UEZ;O;\I,
MFB*X94N";$.YBE ]U]D/SWOTO_I6/7:]5F-MUUTUH789:W7+S+3VLCOOXAA/
M2L85!E=<=KSRM;O6ZKWSK$NZ\;Z[Q<W>EN\^E<>U:=N] N>R+TLOF=06"1>N
MSOI>9F[U9D.EX1K!3=$..\]=/:GCF.=I,X>/3:-__OP_#-.G?[WS<L6*XM*7
M_,_J#W6M%C[[I/[_30!02P,$%     @ &X!-6MX6"]D6 @  RP(   L   !F
M:6Y?,#$U+FIP9_M_X_\#!@$O-T\W!D9&1H8$(&3X?YO!F8&#C8V=C96#G9V=
MDY.#BT>$EX>;FT=22)A?1%9*7DY62D9&045/74%)1UE&1L-<4\? T,3$1%[=
MTM;"R$;/V,0(9 @C!R<G#S>/!"^OA)&BC*(1R>#_ 09!#@9!!GYF1B4&)D%&
M9D'&_T<8Y!D8&%D9P8 !"AB9F%E8V=@Y.+FX@0JV"C P,3(S,[$PL[*RL !E
M:X'R#"R"K$**AHYLPH&)[$J%(D:-$Q=R*#MM/"@:=/&#BG%241,GEYBXA*24
MJIJZAJ:6B:F9N86EE;.+JYN[AZ=7<$AH6'A$9%1R2FI:>D9F5G%):5EY1655
M<TMK6WM'9]>DR5.F3IL^8^:L18N7+%VV?,7*59LV;]FZ;?N.G;L.'3YR]-CQ
M$R=/7;I\Y>JUZS=NWGKXZ/&3I\^>OWCYZN.GSU^^?OO^X^<OD+\8&9@980"K
MOP2!_F)B86%F80?YBY&I'*1 D(55T9!-R#&0/;%06,FHD4/$:>+"C0<YE8V#
M/H@F%5WD$E,Q>:CZ$>0UL,^(\U@363Z#>PSAKUL,/,R,P,AC%F2P9_C&_M%B
MV\>4*M%W<TMSMBO\[?JXX6*,0>R9!4U>&R0?;IPC=7_5I)<7_%<ZUNH]GW97
M,BFH+D3W:L._;Q;GE]7Z>N>J7#H@5V'3R:EP?(\96X6EW.+YQ_H:K\SJTEC
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M_ ^S=6UE^QH_2WG6+>/_-P%02P,$%     @ &X!-6DCASCUQ @  ( ,   L
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MI\^>OWCYZN.GSU^^?OO^X^<OD+\8&9@980"KOP2!_F)B86%F80?YBY&I'*1
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MYZ8C#=9<FKOCG0*WNXH$202ZBC#^OPD 4$L#!!0    ( !N 35IJ)$U%9 (
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M16U7O\@DW-K_JC=+8U&34Y?& O[_-P%02P,$%     @ &X!-6O#J?&F# @
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MW<_"3<?5=WX1<5][\,O&*Q==11C_WP0 4$L#!!0    ( !N 35KC]T?IL0(
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M]D7J3U5@ZA9TL)OQSE=U^]=[]Z^?_"Y]\3]#[/[UKXZ'/[PO^J).9W/U6O[
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M-M0C/9P;4'!>DQ^]F4WOU:@OH+X!;%[\-ZV&%B3(@,3Y5E/Z\C=02P,$%
M  @ &X!-6HV>*446)P  32@   L   !F:6Y?,#(X+FIP9[V9950<7[#@&P9W
M @2'(,$]N$,"! @,[NX2+-C@%MPA0 +!72>X#L$)(4!P=P(A,(1!!U_^_[=O
MWSE[WH?=_;#5ISYTW^KJ^O6]M[KJ],/"PP9 I**HK B@H*  %H\'\+ ,O 2P
M,# P,="Q,#$QL;&Q</!(\?%P<?$HGY 0DM)2T=/14M'0/&/F87W&R,5$0\,F
MPL[%QR\H*$C/*B8E*B#)\T)0X!\G*%C8V'BX>!3X^!0"##0, O_7\M #$&,!
MM2AA(!1& )48!42,\C  T , "CK*OP+\3T%!!:&A8V!B8>/@/AHT$P&H*" 0
M*AH('1T-[7$TZ'$<0"-&?\+ +X=!HFF)R>A!*A"66HC%)%_?2Z8U><S\PNI=
M.#;.4W(*2JKG+*QL[!R"0L(BHF+B+U\I*"J]5E;1UM'5TS<P-+*VL;6S=W!T
M\O3R]O&%^/E'O(^,BHZ)C4M+_Y"1F?7Q4W91<4EI67E%955#8U-S2VM;>T=?
M_\#@T/"WD>]3TS.S<_,+BTN;6]L[OW;W?N__09R<GIU?7"*OKO_A0@% */\I
M_RT7\2,7*AH:" WS'RX45-]_#(C1T!GX,9[(:6):>I P"H1AD<JG%M;W8C.]
MT#HFLWHWB?.467#S.>(?M'_)_L_ PO^?R/X7V']Q+0%X()3'R0,1 S+ Y35;
MR?X#<%" 7I1M %JK7'7RT0LY."HV=UDHP)W1X[UEOI;VZP;WS!ZX*,X=V^%&
M!HN#9,G9*OI%+%/_0,K#^65Q%1A$R?!:B?HVE#F*K9^1Q %Y<36\M?4/ #WQ
M ["N$]0Q?Q_,] !T5Z".D1G#Y[Z>(NCOSM7)-416\R0? )@LR>0;O=5O8J3M
MHMOY0Z&T"B)YZOX(C9Q1;]$7!4SAN!KH<1RMR[4A>ULR-W^26XT>@(F!D,M9
MP+"H^E_7UH^N*T>]W1BN[.2#0!IH9SJ6K70$"A*2YP68FFJW3I1'6BOX1QA!
M:B#E5AN#HHK:,[1P5U+[NZI<YB<<']??74<H"_9GJF[IL195P68T-XTTRE>F
MI===DI%(D^2+2G:&$^7#^":=5SNN^+W[8TRT[59(,E4MTVL23=W$&16!*;;K
M['<F"L^NF#$11;_+*7U8BS[EB;J-1XF"H)MRY/0*.IE';#LH9;H7+"EF/>#K
M<ZG0587)P+1I^5]DQ"EH*\. [YC^35 ],VXD?2(5MJ+6(KE#5;W)H!BC6$00
MOFIZ BJDK'F!JK'Q>5&1Q7+8R/!<EB^S?8)WB4HG<U%%\WE'RWH3+VVPDX&;
MU></RG*N"T*2W[J5E^#D#F4,DN\<SU_5AL>Q%:!-B%89)16ZE"T)C8U6#767
MUZI)]J$YTGZ)$1/:""'NLN1IKZ3&-10V[%$WH.]R &D/RCR%UK&DS2MIXC%%
M,/QQGN!I5E,\Y?;TY<I) H\EZ"K@'593Y1X%:XBGFXY''+<:S6XI'Y$:%?N?
M%Q!0!_"$!#R[7'."9]97+O!E+YW8</X\8H&]N7T*YMV9T33NEJL##\C@"R7B
M46XGNCZC'\AU !4>YP]6EV9+J#D^57!%*PZ7+H+Y3YW@CGKEK<DQN_V,N^(+
MKWE9-O];J=2?M]^-LCLK.%OW+++VEZ@B:RD0T"8FRM@ELG54&N2RY0PI:$][
M?B(G 6Z'NN%18&BG)D3 3>9C LE*D6G[/&XOVO7=2%%.Z^>\GPW?L[P(]LI?
M%L^Z0[.[/5B-[@L"@3Z%J)@C=:XQ:[Z6 A"EB_'2Y"NLL:N9U(..&E=*;^RP
M89ISJ(?;^R7 K.$^XSLR9Y._I24 QJAV(Z B8J*!*59XJS;?](E\(@O.MX=N
MX',.=3J^C(5+*EFPM#Y[#:Q\VNVV31..TC<DC7H9I6VJU _W.Y-YLLQRV,^_
MU),G5D!8@L7 )PK-.E\UUZ9C^(IZ;XLK4:$1-!8DES*Y)X:9QQD+0UH7FIFJ
M>@MOG/!;*<$ "-^<D "!$':2>,+D';1R[UZ>)-C[Z[9S$+G:K%I2^DB"E>)Y
M#3>Y<ON\D.BA"_GS9.:+ HR0MTY!?_>&Y_+I.JN'EK,T/UJOP7*4D:JEQLO0
M99,1:6G+I>J#=:P:'NYL-6%MF@J!JH!L8./,/#;XV91IX'[DC-@-M'<P0"0R
MT-IV*\!T$H7L>W*V0$A&X':%P439GQ=+9@R&6Q+!;=7=5'-[/[W;7+?>$7TA
M>+$4*EU&^=?,&J%RM$O(.I);/'&IYL^2[T=76-[O2?PM50XJA*Q] +B"FS-<
M&/T_Z5AS:6E)(IJE9"M03TQ0#LQFCT\<[8X'WJDR2=BC-4/LK<W6C[>9^BK/
MZ[@D<U+/NE[*?V936OSL.] YVAEDQK;1!ND]B#"QF#E'>3:X4V(_US$1>W6_
M%"V=,4#?)37&,>U4%AUL&EW.]21=N9/NTJ5&H0SBL[9[(@_.%+^$2B(P!P)N
M%HVD)+$8,5%N4DVC"HN$6S<.'(I%4XF(_P[Z':5N!&EKP!Q*$@926RCRSIO5
M@W4F3Q=P#%Z/>W-*Y0U)=HR7NZO";DNN([2-D%GZ31G,2? 1\TWKN<Z#_,C,
MW1]-VGRYBAX+\]GKBZKE9K"FZEC2K?;=JOXU>]C[3!#%JF@MV/0X.G&H07K,
M[_UGE/0#TPD3,K&M;N?INIWZ[JBM%^$)*)=D9^HYGA<P8=S((3J^$)7#8MTQ
M^A>YM@?8NN\.)Z@0L+L=:?9LT:,2'5"!4&RYDSZ\TIB],R69S\9^K2D0$K)5
MG;]OT.%V&\G]]:#H 1#?_OP+3EC=;UG9A6<##Z"[\W7A/@H_'F8W-.+-@"',
MR$*D:\M7NTA6?M0ER#$?!V><T7Y\ .1C/WJ9S)-MKV,GJB]":],OJP1D:9T;
MFFPVO0(S#>,2N5Y&JKYK\;N,E@0'E#JE=C5V]H%_8$.]OL"2[I<D8@Q(/=+A
MYD(-#?5)"AQ_5F[T XYO!EWLO>;(75^Y76+7N)_3F',EVXN-6K,%.+'6IWG$
M50>J[)^F#-!&H^E,?J\I_+##]ZWJ.FSHD\A-])5^P&+C-OMZ[JNK/W^UOY)?
MRIJ.)NZ@9/^6!(7XL<9N&?*4> W+.V=V/@ ID1-W7C+C'>!HCT^2&N^]<$)R
M_=QS/.NOZ3@)540QX+7)OF8SUU87Y?-E+3+BE@JDVL1#@:]FQ],WHY<6TDR@
M1E=C*U]YQ]6WSZ$6R$F/,'N,+=*ROWMF"GC!-L<#?BM]H5+:FVX13!W:U>O#
M[?IW!I9KL$1@^+MP!059QF:U3LOQ^6<'X60NDKC9<<Q '#0VD".M@M"V?FS&
MD&X45@6/6U&3 H\L%X3VCT.)P#,+_GPCWG>U06 29/DFVI2-J=D4PTZGY:P2
M:M>/US]3)M,_WELH:9JK0;;&>"7I*Q2WF5DV\U;F?T!Z>B;6GNU-A=&K0SAU
MJ5JCN.W&MX@X;6YTX=JFTTUV">8FS'(=KJ[-_;>TGT<*NXP;B/+W#,VI4XT/
M@02//!DJX @\0$\ 7?L:?W]-UEGZ)W.IN76)V\:040I+#)I."6AAT36?Z??]
M6MY\?8>]'0? $=FQQ7IX)>XK.DT_G@Q<%!#F2#,YCI8BNR$?+&VHV\C&C"5>
M^J'%SXCGSW5^C9_BA'0(@79/KF0RW''X&5/\\(K/"PBKO92-@NB67LZFV%5"
M6G74Z.7:V[FC.,.TD8XJ$/\)C[U1RMOJ".1P!<79<H NL]N!+!V_)-S3_;3]
M>8F5LI3SS#W>OBKSO'A$G3M?^SF4I9<];&%#?Y(>CTLA*Y+X^V;)VQT-S+=$
MWD/XZ"ABDM/1,&X DCS$3<LP8]4M%_'L*H96S<\1A.<NX6&VATC5OR%8K!\_
M'8,XD.+3R]WR=8L$DRAPJ2JZ"_CC]"-KI^AKU8Y=Y9<4^GPP"O\]M3;?E#+)
MOT/0V2[,MP6*/@"INM+-FW>) =']P8&<]'-MQ_DDTODQ\T>:_;?@QY4X(Z.R
MI;1N7NM+3TKZ +C('>&[;U//K\2-0Q$$A[7F:##"HB[)L";5MZ<GA+^,PI]K
M]M!GV"+=<I\LW_7>5IO!1)U)3KM>.M7 % \UQ/5C;E^',2(H;%%\"3S68%UG
M4%)DGM+%H?U2_< M)C0E!%8<<T\,-Y>'O-[KU\L__Q;"<?7[MLKYMPQ6R+=Z
MQP? )/JD+I!EN'W@*QJ8$;%WF^AYQTFN_AAF*?3.RWS/V$QJ>U#[CI-$36R6
M.^3?M#$4,BCU1N !L$@N/ O*$M;8NVEF2L# $ZCAUUQ V!+>-&-45PR6+8Y(
MU@&:J=GG/HD38[;8X\4:1W[V [RX\9S%%<L\"_E9FL-"O4Q=;Y/*=[4SZJ('
M[GDZYWD-15*=8.2TSI_1X)@T>1F_]')7)Z_U3-4;^Q4I(A8#<;<^S+A$YO8G
M-Q4,"TT=S$LKQGNPN<8H<O8(KLJ;"E]SQBSCE7-'C-3-#YA)F()?&3LHTD:/
M<U:1;>WG2\6/5"F1D:N9:X>GQH\QT=7LI)NN]RT_S=)NZP+MR'W1QZ9Q88Z)
MS>3RB+LT!SF,EC@0_^+GBO;4$X6<JN^5YEF1X0E$ZWDK_]3>CQTFO3Z;",5A
M*PJ53-^6^I2V-+5!0.H"I8V];=_Z$(*+ZKQ/2/N[MA;BY#!C9W!O>P[-^958
MF/W:5DMXAPI%<-LG2&;3&'E.2+"DDH"E \SF@G5:IVN9V]I2."HVP?XG]%%F
M/#G@Q,.CG\T%6KTW.#E:L[R2SG7QJAIJ5=($4ISBZ;]^_NW;?*YWNL19.8_T
MJY-4KARI6OGE0I3ZQ#]IJ/.]5E> QUF5OU[NTYSR?D<*%&N-+IQ&3V_T#]Q"
M _%4%7NLM3H^8APC8D82-)=)YUB'DK3^4WSXC"[TN8%3V-2Q9T+K@8J(\EMF
M?9:AB?C7R6/WL^[ULI<OAO$X?DRUS)(IVK?>TC;Q08)*.1-WLK\C%R]K9%;O
MRV"X?4;@"YEH%Y?7_8?H7ZE.)Q*_!CPN>-_K;."$E3Y@WUSQ]G'9I"I278U=
MBTQU)R+M'P#&!%*4A3TRFC0TO('C8F]VUE89E9U ORV(%RV5 H'T-..FK&0<
M@ B)$4_[D\?7D4&@&ZQ;(R6]L.:4F3DZ^PN8T7I]2=)U<G?I,KQOFM^/C]X<
M0M+_#I'/N,PSD 2K *V=?9.>*#<>" GC-^-'I/WU::=MDV1,DL&Y).J4!8XY
M]\"QK>:.B,2><?D4&0Y@QUKK=)B"WB\R2&[3V,-ELYJM?KS'>3>(@R7?H"G!
M\Q-ZD';YLWCUEC? *PL-],*Y#].>2=N".=',(NKM<%DZ6T3F)D:R&R;BB1H$
M<E.0K'(&CC?ZXT1U;2"_G$E3310PGXN_N%3\>2/@)V;;+4UD^LOLE[=JNO><
M7M$'IC+],,']-9)(0Y\1UC&3B4'7E#MGJ@< ^\#F ?CK<$HW!!O>;+V-F[QS
M[I]X^5@-K3/U(?(6Z[B8+C^=TRC='WT:O-5$<]:[_RCSO4UXV]F^<,P_>C >
MXP0.U?1L_C*[BX>!Q52Q5=;@5#K>E>D$$;+^[8;SYOE/[H\A[GJ+EG-MX&CQ
MJM5]U-D5S.2USG>CPXPP#G V:\]V90<D5M%TD#L/'9(U\.F).5%5Q#>RP]/O
M+1<GWP\!79;N((30]1_QP^F(% )TZSA'^>'Z_J:5>IJ[A/33P.[F,]Y(C>'-
M:B&9T\?<<RPEO0KE+8S$4&VCKPTB*Y>[,!5?PPNI3@!=Z5$H%$O1/:^ +7A+
M*@U_1E:%E%KN1]RS9*Z?3X;DNB)/[Q7;NS.BRT.^Z2W?=_">UOD] *077]:/
MB,^D$QM9#S6MI[-/_L8N;:N)[_]L0;T[I#J[,40U4!PN,'/>^TN\2CWFOSG"
M2J 80G4$9:6R'[%9T#6F6,F,*;9_Z^9:U"H7P81BUNR[@:LL*5K?%VK*B+%J
M%K Q&M*$S%ZQ9E#T,$-B,"U!*'8;^[6UD\H+\ZV=INN*U1:9=JNK_;CJS"BW
M&17>:J/>_D9-: 7F*P/ECE.S095&O./Y?K('9CJA%;T;>\FU[V;+1R2XDPMZ
MK*WC2\?4;D;H2C?646M0I5YJ,"Q&[6A.P3CXB-@T4,-".<=N05NS;9%>RT/+
MS('LK+7^*@U? )J\(1B->&*3-*8 )-JTZN8)U$1[/T9LKU:ZU3[SG_;/ABLG
M# V5PB(.,4&-?*'>/(=_EL5.VWEBC9D6G'&X"&5&5CI+F"Y_(\OFWU]JK/A%
M!LF%</!5&RH&T""?DG>X?YG*^9YRG?"TJM\@I]>-HE76]=M5=+/V3VY7'J%E
M, ,UXYL=G6".22'/FC&)I5%6T6\T5E^*QS37E)JS9Y*H< F5-@-RB9 C%5@^
M01_MZ?W;73R'KKO;7N>YI#X WFJ/';R=6=+3)3<+O::SOU@'XA_B4HU$)WR,
M#F 7TFYNWA0OQ7I&^6_'_+_VRZ!U-0Q7K[_2$^I_9CERMM7<Q71<AR^MTS43
MDZDYWC\%$Q"=HI@3G6&VL&"C92/F.+^ F\D@6O\:A'3>J04 4'KD\G]DI5#)
MV.Z#(,[?$U'M#\![>;S'Y--]H#^9CR^SH]E:0. Y&$)J,WF._9:[0-H*T9;$
M.7*>ZWIIUN6<TXYK&PN2Q(%+6F[ G1Z 07*29>.LV E,TFR9/A<M> 8T.8/.
MGU %V&I*Y-@S^JHJ\<I1A/Y3Z ;.]8N^/.KX?G\3'T3%J4$@7"DZD-UR,P?,
M,_=<@*Z!>,R+J4!*#6#93#@#S76;(KPGE@+!P5<3?TT(Q[MS.WDO#%L $Q:%
MP/T*"*]YVTQ=V0T3T<D+4+*V+&D@)4H;PC3;6O19]K62SM?DUU/,G1X9D7ZH
M7;X]=$2S;P,ULL@S?VDJH<6=K=,:K9I#U(_6QGQ5%GI(4;X/(^)5;-T$L%^R
M;^_4$!(%FJ9=+,+/%K*E;I\RD?6J;N;:86A</#G:8W7A@/@:^&!E"N ] (VR
ME--@YM.N!NDKFIWZ\[KXGGN:G &C%;&$NSS>3RMGHK5!H$W7VLH.J:DK/M<1
MS$HRN#AF]&&7C.6%\^N>X371/4&44C=48V,E5(",%,7,'&'P %2<C_D7[*>;
M>2-8%6$S[^EMDGT(A3(<3E^=G;0/492RTRGZ$YMM'V_G8P\G_]7/H,<Z>!GA
MZK==ZK\7]K;\R_&2G'LI,V9A'1<W*^7*-=VS(:T!C00+8X1PBE M(P3KJN67
MYX$9MI^S4.+TLDJIJ;H8M/0!B&:VF:?=RL=8/B@L4\#VF&?L<)[RG*73T_S4
MQ:VN_-9/.+K.Q$&_SR'8^YXA^ZR3/G;)>GG774M](REC+SOK?;.I:,;-"_&(
MRP]ZVON7LINU^?1'IR9QNI:%9Q\3I$%4[2O-$B$DM_+WTZ%+"[:Z'?7;<1M^
M_?Q7L9+9[1CI0>_^I!JWCPP)SSMNKD?KDWQO=))A9/\&-E)3+[X,%_KBYR4U
M7!$H=KR]LAJ_N#W@X(MW"34!04M?.COB)W;TXW!P)%CH',IM=W-.EH(7!Y"?
M?00,LL=K6GY#9)+=)?5%INH%C[R-W])?.<CD^M )'.]6!FV)E4>A3J;VHC:\
ME62M>5EA+-;B4MC+2K8[_F'5.-\E>LARCH#OW=QP2QE&"M8#D.=WQ[D7)+NG
MV7Y^2G'??/;&X[57/S&]\ _K=;(MD362.;IK/_1VCA\>PS"O+6N6-*78-/UR
ME::5A<<W>T7'DKQO=N21E.L\+$F].:8U8::\%YE!ZCD80(57<5[K_D<S=B1O
MIERK(T/$2TF07?)-@D")2R^4"-$:1?^JV[% WF6U@; TH%S.D&HNXVFC[?.F
MT"=*&'6U0FR?#7V$-JO*&Z3]6]O3YFSS7IQ6CBL$A(0'*M%UEJ*_0Q\())-R
M_L'315:]O#I*JO$T0>2;AY$T]<_F.U[C*)W85/ 3?_WGZ&P2+_9/[2,'-;03
M8-O+3%*-6KH!%CYU?V%)3H/^F .&W$2:"J3 .+]NW:$+=.NDSM+PL2R'V-7"
MM]+=:!VH7"2*.29DI\XN\=T<GXC^_MY<9)68Y<S8<$VLY0)7G%3L_U#*&[M2
M)W@C<W4>?W]5.268@/Y*%_2%=(-?58[1A7)<K!@TE1D'\(\[#P<+WQT07H94
M0JV@M,@EQ1N4Z5]_SP51=L"7QK^=?Z]'A9RP]9Z1G<;31('R"%6N)3;S;^,T
MDC9P@,-Z!5(-5!>Z#Q;^6I.RV$W^ 9IA^ZH*  N&9U@V:MC/QXM8FF!=S#_L
M: X$\FRW[#,:J&28%<4.9Z5%H22@J<IU4R/# =MV]QB9V$C3*O','.<J69>C
MR3RFB;5!%$]QF2<.6E\4NN(]]HUB-N/@2QH)462]R/Z>);6Z,.[9& AK?(;%
MSMY24S"UTQ.G8)(XU7"C5U:?S[<RPEK&PR_-IKWVB-=,2]0#B-4;9VN$@.!A
M;YKNM@HA7KQ]\:YN;WBG!"_HL_['@VN_8_/X0]OI/>^6;-E:RK?'CC'GG;$;
MK9%E;0Q6H%TN3DIO*+[*!G5\8.O+I.9FH2:JC)BX39&!WP0R.-NW:AN)3Z10
M=XTA>%J*I1\BOE76.[TS?@%MCIH98HYDY/ GI77ZB9M@8=4&CA1I7$4&0W93
MOJ:SS'+/T\P'A:DQL[)<VH!;TY10*Y>=]$32E4E)N)(I&4*E.'X-H0F03+OR
MFYD?K]K0L<_C<N6\&@M?UY[ZF-=!%QU2L;A?17>ADQRR.B8]?C]^+W71R%R%
MH;XV^[2^:.& R*4K'B+K'L09BG2/6AXPJOWL&ABY@;=',VG1*85QHU4_[2,T
ML\4W\,[)DEF15^0=*<B=J9 L<CL 7^!O?RO]DH"?').$"=T[='=I$D2CP;XO
ME7I5'5^D16KTFMG,XXQ#K2L6UV.EAP6^Z<"M)*B,82KCWQVVVS\K'KD72SG'
M(@TM)<6]?_WX\YW'WCY9^K,N86SIUTW&GZ',&%D4F"O>!80J:5YQF-GR3_G'
M_SJ-FI/^?K.!NS,B6LNVD72@_KJ4NM@+B# 9K]S QU$3MR0EI-[(L/6<"_4_
M\B8:PT/4U#=\*SG6+WT94&%DP.7BS5@TTC/A:19P7*Z9V[U>KLST/?-4@//I
M!# +C6?H[B]]KR_:A@8_V\U(.9IX&5H3QZR%DR='^\>IL!A5,$<#(FU0?39
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M)ET+OX/80!^./>XGD?'5*R:Y)[(?$XV1?C1Q9P'Q#G66:>0H:0I+<F=U3Q\
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M!'^BEG&2^93IK=%OJ+Q'IO)!,R<K<26PM?:QFP#P?!'1%2,4F$T92V[D8QZ
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M)6FET6/ 6SP*ND?]V+UB.O!$J]X(6]$<YY02SKOELDIEG.%GF'G+L&$V!@W
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M-VWVKG<>O.ST"%&9\3T!\Y+<7!9F*L;(97:T?U#16G:J4/4&2'SM2*BVNVE
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MS38OG_'6?KP3RG@'\FH/-0GUKS2L6Q690#I9/?#5FRAA ]Q?OO;>!/SVIT-
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M"M]Q-\9Q^NMYB'J8\>;< S;P&;N(<=LMVO\"^9WX>K0MI=%L#W)(A@P>%,T
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M-%UG_GL2R=]YK2R:#92;Q3=I_2;]EA0*LZ4?VM-R:3[: /?X3$_\:2<49G1
MI-F 8?/Z*8] SR^A^K=D!J\\Z5M9?O;V<57"16&%H02-G ]1=D?%#E\ (SY>
M^OGAPH4$VZ*A /<U-F"6NO3SL9WX4&F9QRQAD15#9ET+=OGD_-%3,^O3LPU\
M[6GU=8^UTOOE%G>.=9P*7BBFK&V[V5UK=UC;V@BVEWV3^A!W*"'W@9#9TDCP
MDW.&.86AL ];(X8/$J,LG_8NF'P;G'Q>4:OQHG=$4X79K"Q+<K@: JVP)<S
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M14B=GQPOO'GESOWHHBTR:#N%3Q^I'J_5@$0E^(8Z;I60+*\&N71<KO<:;QU
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ML0]:_-OX0T[:2_SP51Z\47JNHHVQQW@05Q+&9TS\!DWK?=;KY I"M]U,T$3
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MP$U75FB3_)V%@]9UAWMVHTW*&6(U@48[T7 U--9+I RJJRJ<#5C+LH&^,\T
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M^=L[=<G4N< > Q&RVJ\JIK<W8K3FK"=;#V$8J<[T=#'5_"%X'3<1<R2%1]+
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MVZ3.??Z!X'[-)Z7Q>]PSU >_3]=*+=ZI+WYU]R<+DNXY2,@Q/OE93/%IPQ9
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M>"23#+FJG$XT[YGS/D8PLTF_$<[G=&U32F%Q'MH*_13\X:VR'3Z<A:D)>H^
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MWDCN2Q'&?U'0NO+XO7?&RO]#\K_X=A%=$9*+<R*\4VM#'.%ZCBU!G .W?!Z
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M<+0,0HVVAU4\_.KZMIIB@1;#QGU3VVV?2.@+4SURC0Z6QPM,-2Z&:,QXC3P
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M%7VQ "!B6$S(.Z.R=PEG^NALYW;B-G&*W].KYCH<<B^KP32O+R3:&UR"%NX
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M O@OL!%A<H-^X "(0F/5( O%ZP+!%VFJH[5Q<2[OB?NC4#B2?^K\4/(FY4,
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MHM,&LO2B>7(?@Q0#2Y:!BT%.<UG0L3_P:TM)Z@;)Z[#D:N+Q0J!HVH]19EN
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MS(5%+H[4]U>@C\ID9&H_@.;S>R1-:JI,T5<E-7!SQ7:'H)*QD%*D9)50C9W
MG*"BQ>^#[]H]]W*+$L<%QI.DU4US1$T8(WM6]VSJOD6_*5+U&/;>BL_085=
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M[9[QV.ZXX>MG8;U$?]ZK#>]QCBN.]#WV+1_^\K>@</.$Y_UEGRX^6WBG.-
MJZH @,M6;&6.I2C&@(*D/MV6B_=O] Q\B]IU+QHQB7\Z4YH3SKOKHZ^C"HS1
M>.>ERAM:TI;C8"#PP;=(;!@@.&LTODE-DR SS)1]G)-[4BJN[KQMEYPN8S]I
M:OW"Q'C(6!4KO;CU6UF;Y]2@3MF^M:!7LUS*]'[>!7Y$P*X=U5)RE:8'OSYL
M'/IR:#Y@]0\=FW<$VXQ?[/E@%%IEZM;89']J6K)VYJ6XGCGH73=HQ?8$J+/O
MRP? 2#-/T;%GB)_ T*>125_THB +VZ,*!-_G<1C)D0<M:RK@UD.!L#"W(=8
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MOR.N_;28I+&OGNUQF6&[NR?A%N+1[SL!R[N):TWAKD,'\E-ZX<K]=7@CC45
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MBU30C=-.)(/N'*4WM+EUQ>>Q$KV7I?R=RF_D[#HI;ETWZ3*SD,Y]WOILSF-
MA3:8&?T?"TR7Y;]>XE:/0G226= ZVGXC. ,Z8#IFDV'_LDW3(3NF5)3<TB#J
MOH1#U:?KDDF.3/941TJ/<]SI1BFD'F*O,.'7-5_BQ.V>0XG%+*5!87#0R[YY
MU-=(OX^1DO)[[_8B)C82HBYBJ<AM[=L0 +/I$1P\;YYI]K.LX.$"V[*C23B,
M3FI6TC>G6@%C:Q]R_\;]QN]]552;U0'4S?PS]YVEH-B;E?#S1J+MW9 #WNM?
M]UPJF*QC /?FKZ1!4Y;\5CYIJ@Y;VDPOL4RA4:9X0(XTJ,/Z_K*C]DY\:\A^
M9 N,B MAGLQA;)9YK7O;]C_]I(D?T0[3DNW<F\ Y GMO0ZA9Q1$N,\OK:X%?
MEH7QPV*0Q"=\B@_)!55J;<P5[&^=.KVX/]UE/P<.V#JB/-@^X8R;66!*EC'4
M-6X:W'C*&/WQCEPE1$(@8,P?S_6$&E;73Y]\%->%ALB&D2KCM._5R7BD :#R
MGRF/./;S[TACZNO7/@9AL] O^D2LD%EB;>,WQKWEY'C5Y6^_3CYK91OZUW1#
MQO':OW[_K+W*).!.!\W;BDTI2P5%HE-[^1;GY<B[97T#H*,X9L6'FB:010U%
MT<"HR<TA80<0J,9N@<?S 5TP)K#_)U8:XQ7FJ$3++LY.M_9_5M$ %LMK2:3)
M=H;-@<JQX>GM8I3P(NS5LFO3Q+0EZS>"8?G0E,.!QD]&-FJ,7YF:.?EL,A[D
M'<;@,<"K-/<9[;O+N ?>&KFOE)POV3/=\_.+Q,@=',"-Y,HRN EJ?UE1UA5[
M<_\!7"$EUBS3>/8%* K[VH"C+)DE\TZ63,WXO=IKK"W?!&XWJ,$/%FAGE!_6
MV<KG\J9MTW+NWWSW<.*U/BH:$5CEJL;6C+!\D.:6[^Y&VKZ++/ZW-)3'2$ZA
MJ>8-;]YA<XJ?6)RS/2*L)LTL"JV^<.^'J/I\B)V!UW!^=EM'O^V9FIR>EZF/
MY?))J32Z'M,.!8<)Z2TCL"9)IQ+[E<F #,[69K9% &O:JMF;K'*T*L/=.,]
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MAC\8O3_ZARZ^^*_I"+V:L%M"L'_:(0$YY[YX)@_HL$T.]F%!JX^[?2?11FY
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MS/2]H>7QL3#M&XB\):C08#M7^M_2ZE/*7#.3Q_L[O;G:_'^)B%A\ V*=<WP
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M=M'O9.^<>7;#(>(T$8V<4NGO -&=IY00:A&._CB.^HC,-ZAS:V-"QWT\<5E
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MI23 @*GE0<VL566HMN18O]Y2Z,N$@HRNU'(S-H7?\-%K;167-!W/-9%%+<V
MG+]0VX]*1!'H; EML"7.2UW24=IQ3FDWI[U?L[B$O,6JW]3>D%=O.\0GXF_
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MXJ2&^$*QT-LM>^6T#XFY3IB8-^,8K7*L%7PO1^;;;(=++$:]K-G,3*]X?C.
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M3MAVD[.U?V+)G[TVN[=/=?6CXY;J#?&\ZHM0(G*_^YJ,5J/T#S8_B^#9R8;
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M?PQ.<)F+SXURZY;:)8F\O[!:CPO6D<-K$Z[!PHHL#\%9K"UMF9[\1=$JPD/
MRH[/Y&%6];#WY/<.?6OP>8R&-)I%,&&O<+-N!2L1C</G.CL'E\W+7X8K- H
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MM0L#A7^N'J;U=!!T_NW:-=F/656A68S&BLL%[UOT4ZOE[:PK 0+BZR;3J&C
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M]L<-<=G#Q)KUC!R21VH[;/#82A:4Q[4\-ZXME2QM&UHLHE2[;<6ZDUW;3)3
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M#6E^[HHQ+O [U%RT;2^^,QR45(!Z2^8K:*>[:M<U%" 2IR3 />47 +484&G
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M3RN']Z570^2W7?JW_?9J T_4:&O]E(Z:IZ5'62!I79FLGJ271V(>+L? 9\(
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M)"0W0#7_#NW]UT^.!6TY%3,V$9N52);YC/; M@5[=X]19LD!D='[Q1^J=?,
M@,.J_E)ARP:@5@:@5$%)SOW=5?B0QNQN',[=@SUKI@;)4M[:D #$F(GQ^35/
MI@I$S/ TW,U_S$PN,X9=$>!58,'QD-8(TQ[.01F[Q4\TZ6B^L3X8OI_Z=V_G
M1:J#/L=S+_E;,1RS1XLU_SR48+A=!_.6K]N,*M64GYUHZ>UA?[B5LA)9@CVJ
M,(Q-;]?<\@:/<=+11]XB43KY'W\;N[D)KT?G='2F^>K;2,:5 ZI.$2?+W=8/
MF7PK^0-[!+!?')\%F9#+LRY]C68\GSJTC&B)Y.)F53!(%DWSRRT>WA>Y.M@[
M;9MOQ^YD#817_[WB5-"L91(N*78.3C70!VHOX=, FU4 =U^"Y84WR=W[UL]0
MNTU/EE$47V.*@9S=KL?]CS?=*F&!$0-Z\%#X-1EYR67V!<VY8=A4&!\II>1"
MU!-+/;F2%4/?=S;[0\Q.3N_6!2!_K\]XW$_L9F^+*WHNI&QI&^;N[=>3=_]3
M]RFMCOO]JF4?X+^.?EQ^DMVW(=ON>8$[@51;L']X9\M9\K95[Q%@Y.E[R6R"
M6MSXU4]N@IZ5#Z>([C_761=!?Z%/F%PN0ZXD<T'@,F)VGC1;8W/P_-+;><X0
M3S^(H7Z^*V+[TZ?7$Y2?\#H:)D;5CHREBF9L\MDR6S\T&=T$*_HR*@':RIM(
M1V3-4E8]1FIH@"[R4)@$6=E$*Z:6ZLU/)3;S%>$ \HO-/F5[V3"L:4/XF&EL
MN'T=-?0MP;J#@#;Y5T@5POH[[N^J\KBPC;Z7\60GJ7\_X^R *=]QQ%,QK0(1
M1.Y(F?F$2O&DNJ(MNODED'7"*VSO$F-S8J4)3"TV.7&)AA#S_@*T.OI!,?*^
M='*DS0,)#'\)"#PQ6F&E!.%26J;0XSO-_"3MZ2\VC)A02!<->QW!*.7.=_75
M_%_TO.EP.%>Q5MI_$#9V3<8JL_C$NB](/*MPJUV9L#B4S%B-+4W=#G8L.,G(
MSU&NR5),08B$"!=KW>I^WM!AH7%.?]6OQKQR31;5&D0X"[4W)OT3]Z@@WU"\
M'@-HU%\NT7WW^(>O&!J+A[ %M(EO\KE*9:K:Q4G=L6)+]Z)^T]MK[&I7J:@?
MS0:7$=3.LW%9DZ$8>'*2HJVO[0%0-65TIW \Z!TKYZ 6,^K1[U:8RH,^[>ID
MR)#1+6@,S-T86M/7E8JT2X.5K/EUY(:&>4:=G49Y^LEESW09M=6#G O^L4B\
MDNN[+]QZ7ZQN_)YOH+C!$W8\:WO+!_G;I/W.&&-TWIUN]GD6D_4?OY%)0+>M
MB5T[*3TO<=':,G!@2!QOM-;!..,38MZ2!_-9 ?K?=_*ZZCO0>YB&DXFE?<#)
MW1TF>H^SA7$QS(H7EOY)U[B?[ZU@-6WX#Z4.^_2FW()(U!VZA\B,XU'Z ?78
M'_)T-A]:O12 7<&?]!892WQ%"RA=##OM<JJ%S >\W7W]//.LA<^Q5R^-?OK&
M-R1DBMQ.YVZ:R-LM.RWY'S+.,Z@)Y@OW^/I:D-X%!*1WD"XUKR E(" =$HJ*
M""$&I <I4>E=0E.JU-!12*B!2!<0D2ZA)C0I@000(@2\_K_=._?SSNS.[CE[
MGN>WLW..FQ, [VDY-'<]]@GL'1@Z[-S8NFLJ")RPP<19XZGV==+D8,$TX\.9
MCJF]>3;Y [MJXCQ5 KO9 ^#95Y7MO.7F17'V>JD6#0H'V<H=4YPM)J^V3RO4
M]S*@.MFPHS"8KQSWAE&JYI?7MS2.)6L0W7H ][Q./4L,C:<1.>SE.D/T1<-C
MUF/7\J_%NC7OI0(#SI QPWHJ;^?NEE[0$\[8^;5AFI&7X-Z(QC)_G9Q@4 %I
MZM"(_EGAZMD]!?#+UQLJGYC74C[<(/81/_KG9DJ9LIY)BZWSJM4D8>OD2;(N
MVGIQ+K?R[E1D[7P/V!';R,1TYH=RS0S55^]4T?9VW-"_&I)Q7K)N\7<@^/.T
MZ' U@K;XQ*Z:[T=@Y?*]QV&<DVK$^2&!)-WUS-JT?WV^TY/=%XKY6GW9:"$3
M#33#>JCTRKF/$\8%=/C09-9JHB166#5N&/]VSGG8S*AR0BE8^+5SDS^B,@'A
MGC87L;>[_C>/><F_+=ZS]S^O(=1X"7/78*85XEO3OO7V)9U1Y%Y5#MWB/F5X
M0+4B>^MJS< 4"<MOY.];^X@(,<$C&=+0G_\A)9J0&->+W_Z.OOI8Y(K[6S.!
MFLV[X?>E)^MB"QQ[G$\*C'G#E=XD(5/6,D4*%MO*UG;;"99Q?H'EFH-<^AE9
M^S*!VZ;F+=)FBYE9:KR:7IF^7#=K.IUH(?,TR/0S5@' YY>OGHI5\F1\HY=]
MM=PV$4I(<^EH7%BSM>]2IO97J2)_(NB#.JI\A#8+1XPI\E\*NN\^>HY.?QN
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MP,Y]E"&T9M'U["<L+KBZR$.Q:W"U]J5$[J'.VX$F61/0?0>AY^VWK[*H#G?
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MFSOG@I_/V?4VQD79<;<\SAF-/!B0\BECF]].'X)PE"^\N ;6D+TR\/2)+,-
M4:-#=T/\RW]!QGU"<3.N(I,D$A[?O5>W>\1[="B3_X?.PQND#UYRXA3]9AAK
MQ:]TU6O.,;:-P(2X1SXA\9QY;1=J42SC:/1,F)//\>@V+(3HPM#3[@Z:IZGE
M0M_7SCI-?6"/*31*)1P=O<^V2OCO[6ZM)?_%0M''S5<EZ3HV9Z94!_#T/[Y:
M#CUG"/;P^VU.O'8/1%8-)Z_&(TVNL_]N[Y')XI_V2PQ<3TCRC]X6AYK:[C-
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M /N7=8C+I']UM F^L3C&<,]5%]>)88#"R+TDT/3XAX24=VUY8Y!:U1%_]ZM
M/K#)(^5XT3F?=". 1=?5/W3=5W%07T$0I'TPK8*,ZA'@'0(7 %S:<API3QDX
M^\40N_-7D!-J?MC/DVXR[3$>P^K0XYQC XIQ="0O=625N[QZF0HFX**?U_Y
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M8'J\/-LAZ]95MA7I[\?*J%L*(CA=OL!,+LB!Y6)R78C\E&_8UHH;YMIGWQ1
MHV7OR#(?[?[XWM-Q'ZP5BJHW\G!29[X&&/3E.:HSS13L^-0,NV  "6H$_[2^
MO?)VMY8/Z[8*H'$B5A7[]M]HN')W3<A%WOSA.E326[T=*3"M*$;Q3) //.=%
M%\B:36&N7\V[ ?*6&CLFZ802M[[> ?JIFHCX?O]#1Y4R)FE0C(^+SPMT!,A%
M]ZA^5;3[U"@$Q40LU_C59G/3 5;MVAM/[D+IF=WZ0J/6-YL.4]ESXF9P6.V'
M%BD%>\A-R;5K;W >OJD7<LUIEA2A[OWD4^XL0H&R(\VJZAXYS9ER$E,?:'YI
ME0<TA1>H5=I6MBPIK>HLLB@HM1(9+K_W4"]*JB&'N/5P<&.\=VKP$2J^X,8=
MK$.G16Z*L9&=>*W[_MTY(P7Y >G2P6\OYK)=$OK60R-%,'+,ZH6"7-[#,CX6
M#VW63B=0@G:"P07EHU+#$S!M(<YPIO.\<#>*;W^Z-QX0A76JVGGIT5^+M]D"
MAOW3]]RGM+TQ5%$DZ4QO8H/^=BK14GWK%E/>Y:?5?^@<A3XV?U*,4@7< M,@
ME,(FHF7";/L?NE@'6[[C9E]^X&11[\???/>7H5[8LR0@;#5^N4G'R^+'6KKH
M;YP<5GH%$ TRS,]UZ"WB"M=UL<:+37P0Y*%6452.?2B+WS[^ "HH'BG&UU3"
MW4DWI?D4\:*QFB'&KS[ =FD PC)>\G.+=-@'>--J2USAANWK_7#PBN+5B^^N
M#+AVI*6<JRM\D+#Q0>TR]+#LX5B(K[\\B?/3C=?VR;UJQ2EEI5(&+'R^>'WK
M)/_P*I2DN(]I<(<?2%?L6&WDKD_]59O:3\HUH/9.Q\-(TL"XJ1)P*8@+:>U]
M;/US[&> "R4RI1IRW%PG\#7[P:."S7M0T<7YWI</#8Z;C:(_<Z6NIT0C99+]
M[[RX8-R>57?E:>764 ([%7%19\\%/=D_I(0;O'R+5E[+Q*0N/X[5,?KTT>^6
M]X=+U!8B2YH0>C/*U.M"L_D\_^+VQMI6LP->*$D-$,/W:Z/JEFP +W>7J%F$
M]'[)V__#T7E'L_W]?UP_'5JJ:J^B-:KVJ$TI+8JB]J9J1AJQ!:FTM?>F=HN(
MG2+V%J.T]DC%3*+V2+1("?WY_OYX__D^YYY[[O/U?#SON?=UHSW$#]3&6=JC
M,LI=J9?#6"ZF3R_QZ>"F$8)B1+Y*&MP#2332V>ST+]\*1\/N4IYL>&;+;$MD
M#?4I-Y7 Q".,?TQI!4BEUH*< '<4J%1CWGA/1<#O:2GI&67E(10;)0\$EOX8
MJ"W-;W>T,V\,[_[-+)))RU01!51CQ#(:'0Z<?W1[PA;&<4-H7BP;/AIM%.>@
M2*["&?CID22C&WGO )>9B%T%!/K;UI  %!U/J+V$O3PH2&^F..V)INCWO%:G
M.!BJ9CBAX?Y/M:'SPF[@)?BOL,EVL[:28(G442AN=XT953F2>C_LSA$$!-6Z
MT5X2OW F6O,8/0%DL^&8#&!?CP/6V&!'1+_5EH2Z%S#_@&4[7DJSO_L.Q>Z\
M6%6'Q(1.V<XZ]>IT=?VU +10X/2J\!*;F!_@/D^<,1X&RJ;85A?+IOF_F*<N
M=%FN.J1^3P$%X3I#];(O&!V9-FW\@T0PON2@5[DJI5$*2[0UI=E2/Y?X7E0Z
MJ*1L3M[H-[G+#T:41)0XTNM-ZB^9'J?F)3_V/&WQV-\_:8K^-O?#1_&MO8<<
MI*^DK'@JUS@AS0 P)[)M,4\9WV;"_]KH'6<)PW0]*EP8O.#I:HSO7[GZNHY$
M)6TU A+\VI1G+E4+OQXQH>')T/\!'QLWF/QP[8;>^2OR:3>#FC!%DIQ.1.)^
MK-!!C5:MPF2AC\CQ<,_3KA)@)5U0'R]]P!Z3.>EA4C:GW%+?XC!^IYVU,<[4
M1TR\].5Q@]CU$<RA$PE\_'D*3''$/0$>>X?WK]#_D:3U2/6,'ECFGTF.Z;#'
M']SE,RA=AB!LFS#:%0B->U%8H(%(GQ7297JW=BU*&!];_)&W4(Y^(9T05E4B
MGXQ<(2M81P'V&JF[DWLNV"8#MB1*(.M:Z?;$_3RX9]32+[MQ%S?YJ4$>X0<>
M:WQM834"7Y1]#6=*:,U.EO(S%DZ0<\(266 #K^ _/JD9)&*^>>4;?B$1@"[E
MSF)#R/S#]*ZI-O4)2=S)'K<[[IT[KGPV[#^H.%GCFJ7RHL,34E8!W,K&@6S;
MHQP4?7 )]A-@2P-[WQ/+O-VF+.6/G1O9XAV^*M^F]+1@CXN(9N^4?U_0S)(>
MHT\1?48)/$Q$9+2J,*YU_X]15!'7GP-6"'4_%MHED#=:1Z+^E.N&*#7PD<\&
MN+(N6-L O=.>0?1E(V'W\>=P&(B7FFQJ1!J,/7M!T9V&2L/ @N>)-=']_ZCN
MR@:*!U48N)P:';/,SLR15!\//1:/&R39S NX%,"?>0!XB:8K"V&3Q<"#1 4U
MD:0E@9M0)QR8BES^:4TDX386$^55JQ; 99WURMYHS"^_S;MHCC\F4HM#X[NG
M;Z"OWO&&7:=RU_E;L 7$&B?BY&E2=4LOUVS'^%6)_'E5Y4;,K_J:T0"Z!S=*
MV#UVU_X6T<-Z!;H]]JX@)1OIP*L#M?$ @5'U?NY0?',TJNBZ=4W'\O/I(3DT
MG9Y46O3U?=GRM6SG8-'W>?^H&@[(0M2]X/F#5<==;F)=8]7_KHFBQOO5/U[(
MDC:2_8VXR# #V%V(91\O(]0BUW0GA?)D]J#F>4B:1U-6FWWB>)Q '<32/&YS
M7MNUR5'R[^.F2X&74F 8V>[=9 XR]7$("1XQJ=U<@:?_&,;Z+&10^[J[,M.6
MM*$UU6(9E7R2AB++GZ#P?U2KM;QL?$0]J-)TV#4*'8JH$%%[G_1S BJR+$ND
M2UO94L[L_*,@79M*$'5O/],N_EJ=^SAX8J4/>6TN?2$J9B\^TTXOP6ZK7:F9
MC=9OQ-@'E<^2UF[0M-]8-QS1]_K11%YZ_\S@6.,C39GRKMJOS>G5K4_R$2+3
M/GJ2N7<3F.;V=X[0>/">) [)';;0?2>,!U(TX.NPXT"=;4K^1=)<OZ"MVJ/%
MA87#M9AYN,%WM[\U8#V:"^^#;/S*!KPGE\:#!*[@S=ON7+IA-TI]H(@L.I=-
MZB9(1D%I\4;)%[PDNI5$N:+X9?;9,":H-^9HZ?%3,D<Y.>D$W<5,Q$3]0=XB
MQ\'HT3BE ):FG <-=;;K,^++2M438+D9J/KE?%9 )8DK46'B$-6+P3#FV"X%
M2!:,"6I"<DLEA0^ED*<'E%NSA%EMDYD\CT_'X'<*/.Y;^2]Q2Z@WR)Z](RXL
M#";U$.>ZF]EVQWU(2#-R0^W%."^#V)^S[FBLT ?4"BT$1J"+URW;MI&,078\
M\\/#]I:<^]@8QP5'EM"N  2\FM;M36AJX-XC+8ABA]C:]J.9J<2\N%R_."]$
M:3#\.Y<G@7D!U/#2I>"MZH.HFEWXGFB%-FV62#Z<QI\0K#)B5Y?QZQ%6(3-K
M:/-DESKH']5U'G(G3C*YB*Y[%:'.T24)6&GXWR&'J!#ZZ##>'1@WY1D(;VOP
M&-_OH$0\KL.U(^DADA8%4/-JSV9Y>6QF:V-CL[ZV!2]X)&+AU!X_"NM9YCB'
M_Z-R [\_]?KDWWV;(C6A]L .HMX7+Y>@<-+F& U5YXDM)Q>3;<>:#CTY"[OQ
MSN7;TQ^^.C@N#I8*YB2$,=K!>G6ZG4<-"7TG(=&]!]AX0QC=SJE[[)^C!G(5
M<?]"&"G;.M ?B-$Q)H:H8/5%/GC7<07/WY@I8"FEGNIB^_^_U>FA3TG- T_<
M>QQ1X_$=?OA1IE?$@NQ85?M:BMS,$?TUB*WIW)'CW95-!]90V4:IG\M SF:L
MY.W^<54;MVPO-X:GE;X_S.W,S4T2%4OQ>$* X6COX-83L73047=%UW_L4#E.
MJ2KE3!_&3!T'N&[O= 2_!5,))\@!-)+O/CZ&-6=1''C4_ Y)%NZF,,<?+Y&?
MG;F23W"\NSB2* $1KL9(IM8G=D?*=BK@FBD"4F2P/8EC\O,,Q1QIZ[!YZAUO
MW-HQVRA4!RR70!CD^@-IWY?>_$?EE+R@?T$S0'+''Z!!@02\T)X2B6TU.U+M
M$83:D#S ?)H=%P"[O0!Y-J!\WA5;B854ZDYY9!NUUW6U)&UY+0XQ>TQ))QKG
MJ!;AZ??:SQX">.DHSSY31'EY"*3&[]030[%B%*62S;O+WT.Y_YQ@.$\B54VZ
M!!ISAZ.Q8D[UMT#B4Z4*]VUDRU=<H$Z7,J! ' F.?=TWH<(D-O1<\Y2_Y)UY
M:W*5(W$OOXC^R(AS^ZOMS8,;)4ZXT(K=M2D+\^94QG7=C=QMH4Y>]\>RM%NJ
MMG#M+,Y(Q86?@P5Z:0D"4\:_\B+/]]V96^UWX:$\ E(_*_ ^+)[XX/M5(Y6(
MTJ47AJ892@*=8_X99EF37H=30^50#K+3_QX>5K\,Q]%0%AR2V8CPQ*@/=E<=
M\%/"2QWU( _]V$,4S\NQB15<3_>\G:IYPGHJ*W)B;#<NL&S+\/![E,9O:@KK
M-#ZJ"%=CBV/K6=@,X) #LY/Y3@:KP,7VM)N$M@ML#( 7-,DZ!3BZD?KG#%DO
MGM%D:LVG[R/6?!?UJO!QWPJJ+6PLE[?/,8'G =G8W15W_@;&82L^L+",W6D;
M.(C_DZ@R&/)XRV+"T;$!\DR;N)(@2T*,>HL=1"%@,.Y=JF+9(N6PN94FA=V]
M,R/R]CB!/DZ5E@#DY?7@N=9,U(EN!$D.8.%EX9\!@6IV5#9D?T#Q+S"RIE;B
MPRQNK@9>5Q#Q;:5#9-E<<2;)-;HVHX!&PB]O8RW=4^H8H(@%-8>%V:<!W?E_
M)A!)(](S7PQ-!BQ>(?3SR*\V(LQMZIO;A35%,W5L1]LW4__67,XEAX??5I,X
MGI=9Q]DO*"C@^EY!6J+FH:BH0I-6]FYUBN[MH$DC?JMW<&X>*T%&I:'1<[U_
M5+WL':'$"\>/O(P=TKC6QJ!Z8E@K3E'L'Q5.(-OHG><O.7N)_6 O1I4;N2,J
M@>W R"3L"UQ'8ZQSTJ&<*^'O\M<IV&J>35B[#YZ%-+3GX^/C?2G!-Q!JW-LF
M5G$5U7'7Z^<'":R_7S4W!G,N+V^?,N>Z)+IEL2]AY<YYSK-AJV7==>.[EP6'
MEG-#DQB]QTNR-"='GK]O#@J3:" KK9X]X5M!Y[X;B&!MT\[!<7F\S5BJ&<)*
MU+I'V5:X/_UM((I*6AX#QT%^*#24KJTA.)1]$\QXNUD"3!RI^4 U>0WO.-:\
MC]G.U!D<:D5O&>@ULFLF">/Y6;2TO0)LT'V,?IF0<E.?O/ (Y_TNM[VS/%(5
MH3"'Z'><?OY)]IU&VG<K<G()] 4&^ACI&=A$Z+O>H<+]OI-8VP![K/4V@)?I
M9Z+.RVB]IY-+_;U<P05F%P!H*%F7&'J\-1. Q-JK<A&0\_&##7K0!WC>._(5
M](D4Q2XNLKN'ZN-B^50XT(%G<A]EK1WK"N1ZF",WF-O0R[>@XQO4<;FBIM2)
M%D4_"<?9]613,"%Y'DD(=X#>(VE"VGN;L98#E_ YM+?C?:+N-(-3OH$ J^6(
M_>)Q8F:P5TQZU/&/2ICEJJKCI36@B5YP7+L1G>W%6)@,QE]<8E3,'\C+!G5M
M:.%T+:A2G5@ '&YU7=5OIW7)LG[H(2[!KYVF[;;\PZ;%-S>]S]CH[GJ5D W3
ML8&!XHC?*^]0_46SA:;<KJ&&O'>.K'7,%;C-&83M=H#P&[BPMEF!HD,G[YLB
MV4S=5C^#L^-72:-%P+#OW0W5*PVLF244X_,"-59R.F%\8)QU<9/G!HDZ$>K$
MO5_SA?P8!TN64[$%WP.&*$3)>LC2/4;?]@>&@K GL>JHI'21:!K6IQQ%1"LP
M!_0969^HL\J6J,;TOSUW@2*"W-+\-/CM:G=H)K$HG*);LR,?Z_U&TO705K-^
MF_7CK:E!*#A)(:5YG;7J<C:&R;%^(!!N_ [E*C$P_8O(+_\E=[QE?Z?-Q"?I
M-:XJ.GX3XF@FP5G-'?O@D;:&"7=X,._@"EFT>\@H,7G5&)\<K7[U\U>R'QX$
M'&B33V>+4GT&*UT&\O 1L[ZL%NB<!0Z9D+1^A-2D>^0F3L7_-V$C^TNP-2G
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MPFC_S'?,NT3W\/ZGQKGYX_"[4$[KKZ)G,P]3"S7'QL62!CZ\UE@$LO47$4W
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M#1E#FN[)!8=W*%1ZY&+BP2!5'?R2\\"RW!334U3+!7I"UOIU)Z=:XN?:]@I
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M8W(K?DNADX$/BLL8O5-8OJN;;2MAB>0=A0FM+H$Q!W^@:55,@LSTFU-4%3\
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M=R1[Y+6V*<C='ECX&!HEY/&5?!#N6;K\",RAV(>T7B_![)"+8OX&2YR!SQ,
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MD\/C_,>$DP$?#E@[/'Y*.&GM<//Q\X^$XS-A35/FAUWSHO<>MO_M?WG#:2(
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MAR6T9R)XAS*;[K2Q+X1KK"("V8I%(1MK?(AT"1@-Q#J":O[,1Q>Y^>VG> :
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M<[$=MNV3YR=R?)*F/N\#&"#% W*@^[,01!"K"P_U2Q3>XH)"8O8!RJ&5*L*
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MBAQT% 8NM$8O^$8D&&D$S+T.M]B.=DKD7\Y>.3G]\9UD\'E+:_O7L(,30HK
M5,D/ G@FC.<M2IBY(8KG#E_A3:4NCM%YO\6\5.GZKB&,71. !?N,?)V9<59G
M]0##54F9\S\*(])>U'H[Q,;%!D=@XN*B(?3Q".#.>[B:R6#[=I=5[Y95P\W5
M(4XP=GKN&?0D*;=NO-5!%Q)L[<'+*/!J4HL9;UI?Z4B*DCM^M_3>=ORRHNU;
MAKO?X[13YJ3DPN64AXM#$U5I%0Z#*1BT6_ELDE7]/L"@]1_C5^"E1^E16PWB
M3:36?.O=0'I,)JG.AI72UYN>MB=_F(S46G =C:&-;I690A4>/\4&"6Q&_43&
MDZ]S*\+^Z W,"CQ5M*N+[_4VS<#]?%H$YY'W3%@)Q5F-Z#F@4$YL#,KL.GR$
MS!NVB:DXY/H6JBFJW =X"8Q2**81VF='J3-YTM@XNWRV4Z:F]1$GRZ 'L/H=
M?1C?>!G215QE'[D[W3\_;4F[)51@44O_&J_&>2QG+&7S8!BW&H2K2Y.7#YVO
M$EP^.S\SZSX<L[E7G1:'SKZS0A7(P+:Q_:DUJO;3MDJS&F%C'ON 0F_ZS7F1
M?L6TJ%Z')"##IR(E9CZ^[W _3T"<^'+3!"9G[D40RD#QW?2[M9X?A+(UC:*
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M8A=4^;R-3TI);J3CZ\#WY2.9/OYK0%)B15R@#SG>J>%0:W&3[!C>4F[V)F)
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M%0([@VLHRWC)WJ"R>6H54ZC"\(D5K6V-9&VS)>/,^:6<!2Y@!T^<5UH$IWN
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M$BR?G$9840$=13LT]IF0:&EM?X"$Q&?KC3I6-F6MJ.YX5PXRT_"!#V$W'NM
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M)C<CZ^  7%+=62GQ"O&[=A&/LQIZE3&(4Z-ZU%?--7YXA*PU.O8J04S4;'Q
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MR,UD704)8B!ZS,0?:<>5O]:9B!DI%P2\#)SX=(YE<AT63)#FI4HMP?CDQ.F
M725P -]L170?0S?B0E::W<H9N7$&K9)Q687A@<!)[)REJ,(!T06TN+,3J/;$
MUBM_)HXPZ:]%L+L"3=GA<C+*)\O:^-@Y\W*F0B\)_>KZ(,#^%87!7@L440DH
MT#XM_@Q,/)?;P$=0-84%18.M[V3$93-8=>KY-M<N6FBI/S4?B:=_[%F?.#5I
M0U@+#TORN.)^QWW2JWYP4%]3S(#IZT/&6*W>L#GK\Q>.,3E_AK*5A-U+1I9L
M!SUD=7#B0X4]'"6FI&5;U.93'0Y!C?VB:[:DQ>$U![(/YI3",;OR!@;B-9I-
MU]?%[YW">P2;'WH9K%\>L/?\5,RJQSP4]O&"/TX](X1?#UF?-;QBE6M@1L:F
M8X6)_":=!\4^5PM="XZ.^S!L]C6<Q@GMNP*E)DQNUJE8.B7)]VVYH9O)E5O[
M?RY(N?-^T^E"PQ7=E\^R]A]__7-^X0?_23_.KW\E9WRR8_ZKN<4>'D<T2_)'
MA$3%-H',]691.( *H<1^&6-B7#/ C/@2_;#W?:SH5!K.X?=/)S]^_M [1'A+
M^1Z-5K0"+5GUL=RA;N*'9\"4*;L3;ZK"W$SGB3X?56&Z"7B8J >\2WW%_<!4
M84KP*Q6?VO?J*W\#UC/O *"'AY6SFVP*-@R][^\O\D?ECZ;3J\JZZK0Q(1DW
M.,S?&/)I=:ZI9>\F\]1G!WMU G_X?1%2CU;(KVE%<1']YT:4<A"".M!_&#WO
M5DB7^V0_L@M281"/5=7(RS\LD8=G7>8"ZKFS%EM%,CQ:I,:T@_XB:9&3F*7_
M5]#J BLMAX,==^QK A,S<[X_$>[Y//&AP0\KCV^(7>H--:^\?OE^:-^SR_?-
M+VX]_]=O'EV8/#TP<.PQFAT3E]ZUQD3:3-9%/378)N3%!IN_*'J_).N'G_A;
M3RTY?-'Z\/&V7CRJGW=-H;,1KW^ )GFDVY^^^<;$3O\/Y<TF\K0IZD1=?[8*
M8U\1_]5GM<[_?8WY?.2I, M0H-YDP_$JS*E/8J+2CV@0.4>56U[ECCBC2#"O
M)"-1D;.HMKK\IKFX67X45HL.J#7N2Y 3J4?OU=!SSQ3M1E5D0Q/\T,#^\O#1
M[MSWVN:G?CF>O\UQ]:4#4>9,-HS&UE(=C?AWWZ,9>/A1Z%">#?#2F(PTW28A
M3#Z3<>[P7B",V>(VD:58)D<.<B5894Y;.G'FA,*"/7:!>XL(KSUWX5=F)8DA
MV%_[^,E3L_+/:>DM]\,%1K_:8!76E,0U!;XVE9[K.[R&[/TR6O+S'5>L^.V)
MF]+EJPE7*@*E68I?EY*4J4^(2M<FLZXO@N>EL0MZ)=4(D_<7?%8YJS;G]]=C
M .!5&#"(,EM)DI>1Y<TEGULF\M#VZLYG%.DWNH'9RK_SF4&YX1<Z>X[<CJ]%
M#&-Z59CRBIQ2W._-BDTXAU?R@Y4/8^6?#+/*)Q#OYO[AV/3W]-N#GQ6_!J'\
M5<-"BJ'A>ACMY,P/1JLPYU!MZS?8-CR6MH']P6766OEEC_L1=)8*&IK;-04J
MS(,0R7K@Q"U%.%!OHXNRSFD5YE(DZZV_L)\)^PT<^)QY0Q1@0="F[=X6F_DH
M:+2CI6;U2 YE3>\ZZXRA32N8<HVOH:'1K,+,6O\HDEMN8<X];L6.4M SO?NE
M&7CS24^%N;\S]B_ZZPMW_9^>4(>//ES7%7*QK#CZ9.S9H:VZ;WQ)12_6KCF_
MIOII5Z7?TC07@YN3NWSUYYEO\@C\9RN1@79G"4M0GG5H(,NL1XAS$15EV?]0
MNO_M0'R!P:?$CVCHL=R) 9HE6KLL):W D>XOO5W]#\"[<<0,Z*V#41GC36K,
M5@(O1+,[5E#D>J',N8P$HBT4B>P3JC RV]^!:<1<$96?9B7?@_@33W 'DT5?
MS"X#4+-^7\R*[?[5+):+FEVMPJ!VR[_8;8A 6"5P;3,.-<V4ZYT YC*N$HN_
MM/<W[).5&=LI2F(2>K7<U42/OU_T5TWB]%9R&U%AF(-$'4'&LQ!H3+F]?FIV
M1YVS"A--4AZ1MB5 #LB^7\>1415FKKR>V>:\_##Y;?)'OSFTM,QGH?P%PRC!
M1+NI,$>;^?N1EU9PWS_#?8)4A5%D[J0H;_Y"4OH.)4]7)P ?#X1P)V)359BN
M574;\M,4MLHP]"_,/SH4;5]V*_SIL:/G,?@JV<=6K=Q&Q?6+7AWMI;J2[WPW
M^F;/C?W^6G_^LT]E=P,?U/MRNK\W^ZI&H?50)BM!JY]/*A?$U7,5/>W*YRCD
M7M^24!2:($6%L:O\6]7\OVJ4X"-:"A8\KGWZ7/F IF;S*BO^7@W2-J!_-2!"
M-_S&@1'".IIWL&/5K?MCYR46F]OOQW9$0<_"CBVE6,[XD5NP"D,-M$Z(/Z-U
MXHH*@Q8*/[9 @0+@YB54H#^V1]%U_\WV3R0#[KL,-#%##J ((4E(34(4@A6D
M]P4R/611;LR9DV@Q0P*B-LN]SRN9=<=65G6^ZUQW>YG"%?9J.A_E<[C3YH_]
MAT.^O5G7]V[WHR>+38ECQO*X8ZARL>*+8,-!$1(9.9N,PLP,>"E0H%US>2P4
MBCQD7NE6DGR@F&ODCS]L)<HL?D,OT'@%X 5[H!0=A94;G1+- 4O/$ON$;.7B
M( L5Y@471>BG +>O7>2YE_X-/?,O#<3\>12Y3: P]$;&Y,C*R$G'S:R"63)8
M6P6$M11XR#+0JG2_.I;8:U157/WR#2=4B+\Z6_P^]FE6"Y(V/CN,SND3T/H
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M(6/,.58S4P,ML==W"I2=J&(+32#F74 I[AGV7?DT%ED<?C+T_M]4S<2,ID?
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MA22MC:^N/N=LXZQ==:/XX,_]=[TW'>^2AEO<ZLX9O5\6^E6([R/UW<!(-.2
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M%@@V_596YF-#>*V8%U9F:0;JXP  BZF+G27J?KIA39ABCHUA#>2R;\966.=
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M G8WP+>\:5;*"PJ5#!?/-NJ5<17-QBZ[ G<\' HXHOKN1X&_<!I\.W2F@UP
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M"\Y3 =WX2)C@F@ZJ"-?7-50X\NOP$>>COS/F_?/[8AE2B]M4?,S?EB'$!?F
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MY%&]6[1WT/TZ057?8H5'BGK_N$_CX<ITK9?_7"Y"\E)97P XF.(BU2>#M!*
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M\LQADOJ3BL/-1F,\7TP<-0?IU91X&FBO;?[%0:NB::^!'7X<UDB<Z29)!'U
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MJG>Z*#?VVK(2%OV%D#L&]Z _3;DNZQG-+DXZHX\1S*3,^!ZV+9WU-I@F'D_
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MA]A%&_P<&=F.^^>&)D;2XQH67!.\-?O#ZPQV :"ZF/MO4$L#!!0    ( !N
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M..B3>3//?4V=IB9,<WK+K(Q3VU(YX\W1X"V? 6FY:3C3B$0N!3N8GXXNWT
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MG;GT)]M%@)D.P]QN]0]ZSXGKM;V<R-^K AU,Q)F3N=9HC8=?.G#4\$6?5^X
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MK4,Q'NL7^<Y"_MY/7A>OE_1N,BV_"ZEG#E=^\KM[)UIUYW[4AD7)'I&8@0?
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M_\Y?0__5>/;W:V/]6^:]B8U-(QZ%!H!BPC^3R8XC@&%^!'"X\J"R&#-1G!#
MZ1#DYC?L9]A_6_[;\O^S!20>P&_X.K3(VQY*J !"S/P/4$L#!!0    ( !N
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MF#02<X\LVMN&C]H).!KN2,'&!:NJB9IE;=EDP\;;+P703;ZPY.]4X8$>2\;
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MAIM!4DQ?1_2C,P\NH,*GM48/!SQ4ZR8(K\WH].H/54.[<IKS.?/G\ZO=O\[
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MK(,X5,ID+AL?+U7TASTH=,]?>M11DFVWK_EKNV"B./<G3=\VD$CY"MU4-I!
MU?;=+.4-RW/8R'=5\1KVJBP6H4(C?(L2::Z,QO^ *B;H_-:W;09<&OC"!'GM
M45G>8%*_"KY_=?I?R/ Q=$SCOWIP?WGHA#$3Y%K,!'T6*?V/*3YLJ7S73&;\
MZK-_2H]#2E4A?9+^[N8RSS_87[E^8R[>X;KYJ4,!M)_0Q38(V38 -YM.36\%
M0LCK+CF(;PU4S&03[!B@JG^CU$U_8/Y"E#EK?PO1KKY-4CHYV9(KE .)+KC*
M!(44=X5@^,VU$[;I]IBN1]# .6/J)7J"-O8H4LXF$$H:V(1$/B)G=^UE;4?
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M%X)H]X@7BB^K!&ZIJ6J24GBN#LJT/:A6<C,^%O[HZ?5F%%L>)IS.K5LI7UA
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M&4;[R=&$2VBZ%'0Q>8G:18]18X@#*Q??GC<Z"^%#F9 0L4:R8[_'E60::)I
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MUT!$)I9-3=K!,.BC\(G(*+&CA ](V>J0YY#ICX-!80%!4@]") 6VLH[6SN+
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M6:XB]RPC3Q]!OJY0/X=(V ,A+),4*6+=R2 A,Z%;"^&X!=AHD3Z7[&V>H#S
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MMBAWG>H1.+\O'JB)P'IM>[U<R$(<>_)KM6;Z)('^GA 3,O4'@/.<3Y!!0%@
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M?4:X],<X2B09^C*=[EE54,*#0YB2VP_S##E:BT*PR77QM8\/:^3#M!NX[5)
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MZV59?UB#-? [J)/,FV"_)%D7(.+#VI!CI?##*M?+,HO)LLA:4GSXS4_H1S6
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MELI%EK% 00PGD@]/^XU\.GA1QBZ?'17J_*!X*=QO)5)V8_0*-33AVJ-HLX"
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M=P<LF042U(71;;J"-]13??151M8T3MQ/?*0<&';E56#?L;8SD>'M-ZNK:Z)
MMK$>&OQ=F @I;>  G=\)\*#SF(?W.@\*\[2P8V@9$$!ABQ'@T?ZM1KD$E.+[
M*$>"Y3&?S&=^2G[O_KQ#:/:LGFDAU$=#E/$C&VX2/1MB;OU<T2S0?8<HE/U9
M[-Z#)0/K*$?;H/-=19)M!0K_%V_?'<[6__Z=#E6K:L0>;5&;VK,415'4WO)1
M-4)CU&@0TM;>K;U5B4UJ;T&"%J5V;8E5JY)6"2(>G^_SSW-=O^_S_/GDRI4K
M)U?.R3DYY_T:[_L^]ZT)=>]+KL\3,"IYB%!"D-@'2)[]]L;9S\%N3;M886P=
M4!C-7[*#Q6>QF^5]Q(JIRSIX?&]"Q&!"/!I>I[D8,2;8:#-;M</NF&A?>1&8
M>"])#Y'R9"WN9EICP]"O*BZ&CR?YFZ_X+$#Y\8!"*6;*O^=P4+F9#4//K<J>
MV^@[7 _6I0LJ>WZS_1/^Y<[LG@"J9^R*@T=AG<M1+%YPM;NM$N8^'787ID[,
M!3^,'@CEQ!Y$CT58H=N/JBIVR$P$JQA_7L[!M0L @/AHM[TE!J97LG0!Z*.L
MC,\2%^?+V)S1[$+UT4>H?S[>EW,F\#G@0>@JWBNV4)4!93+*K6CQ*X'Z9H!0
M8[Z=-0J/?/.2],]\:94+'.O-"E,?=YW^"[KE?FI91+AFF+-@,R7N16L [L!4
MY(^7<:1"@R?+].66@B;2.0J^/L.<6]J/FYKZINORN@F43 9.2)1TSV12X"J-
MTH5<%94#=L\$HR+=G[N+[#1?58IXF&_%KE7 G+?FR-K%KJ,ZX?6IC%?E/%Q]
MM7&E67=/"HZ ABWT9Q9RJMVT&Z,-CN[CC0VN^57%4U@6==5IU9AYL6N@ 2O:
M&%/88,L_&TSSY$/LX:<VIW-<6"\*;W(P5T6F9L6?D!SP9IB!L7Y;,7GT()Q:
MU4"@*3F91!>B3%M;5"I6+2?.H_=ZT GW4&@1;/512-IN,:/)^ \=$87?=2 :
M$A0&>.EA^K(FU5"X:6*I&E?.K] K>W_C12%^^JE/()J* 4)[O 93+^=I($9L
M 2H6ZFY3? :M"& 17GTMN1\^UX%+CNR6(3$2"JI6U6.6Z;L,N@3M)S:<N#$"
MF?O!:DW/!_?:9]Y6/J9KKBC>8?@&?NVU5_VV3YFH=$SIDDWFW6T5FNQUWC&S
M ,\B@!QLT4)_A)Y7]$DEY+Z.1][4K'Z15U)9@@N-IB!68529DH)T?%5U("G8
MW6$Z$&5LA3 .+U6F[B:21?T78>KS++'T<[J',;VBXL"MB+P7J%G7.-*_$[N&
MEV/;0HT'WJM+9OH*/ 47T)X7A_'^L!DD.&-+S-+C7KP2_T@8"\_ CAPO,\RX
ML;DLB0^$ERM-'/SXU=#6<>Z+[*MK%;-TB*L)'S!-Y]*F:C6/Z":.,L[[;W$:
MY:U!1\5ECTW(0T-^+U&JPY_;:JUBHR2O)914CM=0_LY7?N^=D^YAUJ4\59JV
M/14?;_AJR(79Q+[LT[^I&7"12W-KK7YB= $@<2Y< )R/!U?.[^#3X19 4M7E
M3O]S =A0N?R*M_=Y\@HO_#"\S^+<_!GE?[O/]G?I?YND_?='@"=ZEU['_KQ!
M\#RGFTY[E?[JSKO)-<H!&L]SP<>M+9F0@XA._A@(20.W0?T:[?\X7._[NN(%
M(#;BC_W PAY=6(6CPP+X*-/JN&$0XN8">;BT-%+-*!KBZ9X#WDI/IN$RX?NR
M!Z4N*4@GB8;-@QKO%YT9A4VH,Y"%OOF)=?- ;+UIH=33/[+V5)FP<XBZB>O"
MQR9-@G:)CNOE/)#^/T_F% >WNUE\FM3X</35:\*5V:X&'-#%IX*<DYCG+J8_
MN,0FC:0C*B<S[C5R3Y5CI_CS//0,3M#;"KA_R]G2;9SH"&")R0DBSZ43NIN$
M6V=[7#Y_0N2[^N?9YBM/X:<K5A^D6^2K.CJ)?$ZIB"[%_AY3$LA??^T:Q)\^
MK^>2HB/)7_]EO3%E:&]"CX]Q=&\$DV+(; *:=3LQ/(=;=9PMA-I!FH?^CW+%
M'"/EB"RL^8M"[X_KA8^D]59I9_O4\9>F=0$,=T9>6R'1$ITJ3T!-F?WTM%FJ
MX)H?P_$K<RW8Z-AJ-OEX"HSW)GB%@WSOY[&HP()N_:40.WYW8/K@J/ON[#7K
ML]E]T)D5T>V(E:CE3% C<TLZ$/\0KDX0X*ZH:.4\'\=>L!B]0,D*KZIOR8AQ
M]BJ2"L0WN JY_^LN:Y*JLP>RV>&:]A0"OG&PBNQ1GW<^^DM<J':_ -PZ5+\-
M,R=FXI:LGA&B,9(<NRTX;CYM!T>RW;?7@W!&DG>5'D\J]AO?OHS]THK':?^Z
M&JRCIOI>1U<*C9+Z-8)Q4N5H"5$ANLRT691!$>OG\4-QJL;6#"ED%J47GGAS
MNLJ*P=%">') Y':%U?'[X>T!"P_<<U0[.;Z;HO)W+Q0QH"C[>2H'@W<TBR]S
ML47(+RH6<^I4FQXQN["K1J5;OYJNHG*3-DKGJILZ21D:N@!8H!HG&W<-N@S,
MIFI7Z^OJZM]Y#I^=[7[-H/$T,+!F-(BOZJB*962[$\F?$U1BO:83"+@ Z/%^
M'B,QO!I$O_\)8KL >#^4^*72EC)K@W^]E^\"E\_%B6NR,TCXG]NM;3;]L_MZ
MU>$&5M^8%_U-PI^P67?%?,8%CRAN7R07P7O5_TU#H$&]*+6[ $0_^+G" 0?G
M/N2 &/?#&T$Q:Y_'58'X]N&7EK/C,(YF@M^/'T3]4?9?K$;><=U"OU7M:@Q]
M*K!5ZK?F%\5>G1/#J$DF'4T-,ZC/84O>-=]"7\DQU&XKU!*T()4>?KOMC1>
M><9O;B4K\^ZG-7\S4!6-EK:=@:D&X "?,=[LT^-W%P!M&.WN/\3X 9@KDW#1
M2S71:SW NL//01DB<A7#3)$5_<!B6Z#T#O#G1+[["T6/[R,$YN<7@$;/5?>Q
MG6E4,^$$T[6C>+,]!=)GG=;VJ23//!V(5$W-,RN?C'N5+)(*+JSDQ5]BP_R
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MV7>?*&,?7NS=3-%G\\!O!D9(&>K2.(@**V%W5(98U;OFA3ZA;J@W_AN/H]\
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MO+E]"]H?FK+,1RS&DT,%&E=XB3D#PZ:33C,D01S]3>+NLRF2 "Z9'E1[ILY
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MSS"K6(Q%=7'8]P0LQ<9U>$.G0LIW["C/%RB<=K+HP_J<JYF^GEV!4A@E362
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M_=4RN4DTS0PBC<PB[GK;US>\46^?=_AZ_=$@C7'VM4"HGEI4,X3./<5@8::
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MZM=A;9H$JN6R[#_R;V2,AX023.Z3OXZHG0*(2B:G@/3L/-Z%EZ;&^FFNK2-
M'"%-GIUD)>3;9UX3,R*95+3[M8'I?J+@9XR0]O?LON.FZ1?J+!T4GCK$;NFW
M%:%;4%.S]?;51AF!%HI3^QVC"1,[!2/S]7B=W\]9_NT&QG?])X M.32LWA\8
MI$]53X-6>VA0/+-,CCX=!A#ZX_E9V28=AEV5ROJN4T8$AY,R.;Q@W^[HL-/_
MFJSV9]<R:,)[$6?T*;<VQ(#Y@UEQ&G\WQ;&^05!95BRF]FJN9_=-TDJM6Y^_
MUP_D)9LV<PVZ0;U%0]@I?CC-EO N81H,]_K;E7E/[#/[6*=[WIJ..,'6Z0/6
M3V%@@8O+/3[<HD4L?6C*3$SVMT =IW1%9^[H&W/5\J6W(N1OO^8LT8,QR[IV
M5DMCF"#<]GRY;&JJ%:;QF_A<V^$$>^Y>5P4LPM/4S+Q$'CKPW9<PULMEAC5T
MNG.[I2(8$U1O'9JMRV,SE!W!8_:7^/\<O_@_;U_P_$'U[MOGL:=)'E9/:+L%
MP>^NYK\].T&<R-V78?VJ]*8? EX8;$P3+#?Q]G)SBP:KOAH3T=.SO#QL&S%4
M,\Y!0[E_[&X0SJ>9G0+X#J.%0KI?4*J-HD>S_4Z*XO^YF;.B=L1/M>B=H*T<
MED\&\P._9?D[ T_B0!XH=D,4C[%VNEQUL"%-M%3MZTNM:X\.>[^-UFE5?/K$
MF7GO>JC3&55]$ZQP^ !V"F!7(8\*OPH/H"OL<A3IN0);CKV7;H^%AO=8TD&Y
M;+@3_\I8M),-+N2>R^K[X@U--9VZ\0,A*TF$S=P\T=ZZ&S@]WM/ABEEI4GS^
ML$,,MYI&\>UYSJ$=^/;6):/;T[$?Z@_ QS#.^Y[*[+M?&=4EX$QE#_QOLV/F
MZN#7T]4Z )K*"CI,6PH>Y$9>T/J(I1/!,6JNZ/$B#[$;G9-7WWU3YYOI]L;O
MD*?-7!O?D"+M\.EMMJE[XU3(+GL9D:Y'Y7BCS?%A,U0NZ2]:T$JG6XTD_M',
M45(?F$6_=)PCS'],>E@/VW%E?NLB$4^MR66:DHK 9D>CYS9T>&@*'SQ0YX-%
M*2#[#BR5+X($9D6"<;<\F36M%LNTK_G/O:C)!4IYUVNWO';J[/NG7^&#<.'7
M3Z;PQ6 VFI,?>9P&!FK+E'J$J@NAHJLDJ9"HW0\3![/9_=?^J/*4"W'G,B!V
MK"V(JLD%CZ0^3]UW40C_OC@C&_'",B3"J+$H>C2=!6KXXW&Y;%4G^6Z)/>)Z
MN5[N2;]0W>%4ZK2=U,70;!$-'D+OZE3ZK4AQ7HL_</MJ)3+G-U<\)GS'7<,/
M!5[/(HTZ7T\:$TVKQ6#L1KF"+IL_K"J3*.WDU:AHNL*'K[26/@:7F!(!$;3+
M>JQ@W$CHN#VQ38#R3-'@/\$\+8>KS0WH0=6GWX53S>0[ JRWX*4)\R,($%&_
M7\CZ#:8:0\)PZ%$]:"/5P?(3P \9?6(*DQ\:)^@@_IB2&82 _]V;:KFF:W=E
M/D-5.^4GK\[H.-[?E#!TKRG6%EP6YT#RF^;A#(WGAVJ:C'/]K B(D;FFA  [
M0@V7;+6:"=BB':C6/^\P/T\LNAHK"X=_: F3)2=8MXU9+ ^&-6F9//VJU%2R
M -.YV4;=WM94;PHJW7X=$*OLO^$?-_;  /\!I07FMW?4ZPU"-G@#&Z>*]()'
M8Q*"&[;5UA6U2_00<L,Y@7 !*;O//NB+1K<B9"Y\6 %!K4MD9=&FQ6M+#VLS
MCT<HJ04);V_ZEUFCG1WIWZM6(RTW/S=Y-JX+M998ZTRJ0>5Y9 F8.[<)1:;)
MSH(AQT;(&$ZZ;N$L\D&?SOEZ_,]3P/GQRKFO6W60+<;-Z6!NY5B,6L(U_H7S
M8KRQOW:P5F-IFYH?[?:4M#<61WN4,?1+-'0YW9U2#+G"#9Y2W;^X=7AXB53
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M2&<N@Z)^((5[LL+!,@/SW0E"24F-'#'.\MA$@Y5F2F(,Z00&F:3KE\-LKCG
MC.<G>#\EKFE!0\Q. <MY8M)UU-R=4%$"@P_* $SOA0*VS&F1Z[BLOE. H+9*
M"$5?K_W8$^GN;"/T].SI \AGWAJA]5NJ(0]G@D>\'^M"W_U>I=KF6 (KTS,O
M/3#]?NCO+MAK(KV<T?0JU<+7?U-#T$A);@./^)65G-8<5GE;JQ\14)IB A5J
M"G1TA89&XJC9I-&CR+KS8D *GJ@<]5.?T#3.KTO.9S4FA5S5+2O-5<\M7QK$
MJ!+X*8;7;XT=MMO")1,]WE7WXZHNH'%+B:#+.M=IUX[)ZE$U]G,T=5Q?EQ2E
M,>NP#>%2LID"H4&<L93=@^GF JF5V;'2!4^^9-1S9\SGD5DQ.<Y[_TB%^MBA
M>M3HNB0'Y0ANI+(CS8QI!L<1Y?SGA#(=6(%TL(KK$><*=B>!8[%)?:+.OP:^
MS&5Z*_V$OUXR&R167\4?>*C-L^L<D15&/,[S=E//'5K3WBTOS2;_6&[.+Z%)
M#HJI3H,\G#C(@A/:"B03/?&H5^EBUTX*_/>C;>S]:&Y[[*< NJ2.V)32]21K
MCV_6R:P.V3];'B^Y5:S&KCEN@;,Y3('2*6F."'E>>8= O=N>R1A>I&_%JTHI
MS9B>,:GAY:^=Q*;K688E;.KRQ="65ZFKU@D"&OMH1=URM)!W]L]T\1C(Y6I%
MNEK9/.U73\,F0Z43KM'+/X',UTV>ZA<*"\S>T;[KFU$J^I3*9JY W-SWT<3>
MNL4L#'M' >VR4Y3)UOF7RY>]XYP!5-&T\=BF,X6S'W(AARB,ME,#(@X4$F0@
ME-V2CE\WOBYX8IT+8'<[QW([S(TP@D\P@FRHVZMGR@E#9MC0PC_0COM?+_VM
M-J9E0P7%'"P)TQ4G$>!HQD5:P'(I@8[X0!L8?TP#,T=X5WE5-]G._-42;A_7
M]Q)*R!JCUY1=4DP9;<@OGD M9_]2"*QQV'Y]IN#P'6"'UK$%,HCT*UJ5@W5<
M/)9^)^!8%TF<'^#+NX7<XQ-5'^D/%8M>]+#Y]=JR\BXC9^C0Z?[H5\?"_LGX
M;'/?5?A]]="?+XAK<#W'(2*?H6%[:>Z= =VT23##V2))Q43974;MSKR-N/O>
MT(#)4,GU%"NY8?%76Y!&4&_V71BI.::4EC72GQQL3OU<1]G&89/"O57W_U=M
MWQG55!:US8R5KM)K!I$B!!"D&V 0I45@Z!U$1&H($)!0,Q:*%)'0%(1(":&%
M(J%(BY3  "+2 H2:(" "D@C$C(3PQM_OO#^^']^/N]8]=ZUSU]G[[/+LN^Y^
MSJ4MX1ZE3Y$JX ']2E1]D#[DX%-@%L0'[5%;D6R1_[E?H*_,,?8+R)>60VY[
MM-/EJ-U 6>*#V/<N"],4,K007%L=/7EQE/TRAOV=!&_W_*G^]-C"C.^D>:4;
M9NM_.!7^)COXMAR0Q))D];,,/O7(,W48&(H4C&R6O!<OL:;&];4#\Y@E H]S
MF^R2J@I8YF5X4[Q3B/HM%3HK_MD@__KQ!O0R%F;0, \\R-0?-4_;M(4+'W9-
MV1UG)LHSW1D%1Z9+'O.,<^^EQ6981O"%P64 K;*<[.G M*.=+DQY#U$F$[-]
M_;$$Q:8",F&=A8F6;P!>5UD?ZRD(+Z\L(;!(+QVCRFH&D78H554'OQ%L4*1B
M!R]A^/:1Y53N.W\Y;7S8KMWKFC15T,'BU%^P?E.P>WVTXRQ1R68Q0_;,E5RU
MH[DVSL%7/[/(@&>&O#1,<KPZ!2OKT?B\G]#Q %4=Z#3[H]6IXX7^\Y1SJ;/6
MG6]UU*Z(=U=FZ2^O;,W'I9L+6Z!MN<2490ROQ^MWL_Y!_4GS3F;:H[_&%F\4
M1&$9T01ID>G(3#ZPE/X/^W:42Z=GX.EK%<("R>Z.G>UWQ"H>J=@%KC$G9_%W
MH>F-7T0,!7,HB"=80_&MM_"&P:FO;N>20?8(F@'3@L(_O\82XD.C Q]>6R:@
M/0):2>B:;6&+4R<<(4$DSZ6/R;0%CW^=[>!#CQ"^WL_P.'5&$26X^%2O]YD#
M*3/7J<BQL\19<EM:_*ER>,W'*7HH3:>W&&P_%2^#E0 (S+L2ZN!I5T\X<%K=
MAGW@(^4;Z>ZB&',??%'-)Q@R_8=#D/78C4'UCL=%$XG?R^BVMMUFTF[#BA:#
MJKFAU4>!53#%0?NT[LI)B*G4-%0G>H=RPA%U5<_-Y@>@OT>9BL\ ;D['*U"L
MS@W\3&C9'2P*3R#O>ML00U:G5<Z[UXK51VZGO[S7U0;L26CN&!->5_U;(X?L
M+6@4/#Z?M0I-,R*?96!H*;T]O].<Z5&MN$C>>\%5:HCF%C$%X=G!&\%7R[_7
M5SQ.P.)A&GH^)=9J.VM'NE94 8*1<(LR^(2#7R&YYX]>:M:11'^BQ&3%)+N<
M64E9X=5L^'U[=FJA?D$O-/YV#)I0E5!V'AG]2,9]LY#,/?MYDRG8QN)<.K)F
M32%P>"9P[VF/-#41359C./>(4O=(47C1K9]R>_22O/":T1C 7.B]F/A<]_;X
M=VV0"!<.[<*?SP5'W@)G=>' '[JLX=%$3&H=K6<RZ31-\[6CN,Y 'UIMV2LB
M+1S6;&&A.X;_P'2DA&J1K05=VWZGXG_.HT"S*GTG'/>!VD9B(6>5A- 9!'W7
MA'A#>8:9N,.Z4>!.N8+\FN+'8KR?H6#B-*IY;\BBZS:4FD+!)(,0X63E\U$V
M%WO?6$5I=C@F#;^"?%-UBG.YEJ/5-2K=-Y +XKN.Z =(,P&4:I"\2B1*+/ A
M2P<_#>Q2CZ/P\]F4NP5-!'88$-^%5R]81%U[.)F965%YHUF45]84+>1AD.C*
M1CXJ1CX(TCFZ"XU_2&(EH\,HZ2#8"  '_SD1R7D $'"%/UO^/K)M']<<=:;"
M%G>1(+5XI^[S,^MUKU<-C3C4_/5!D_>Q@$=[7;?)>/Y,+H"P>R:TO[ @XS#N
MV()I058QZZ^NTH"G;8M?H5G!3C>[!.R;^="]<6;0]9%[/CW1>6%$[Z('HD"\
M#NO3>UN7<T^'CH*B##!M?;/5Z<%?<;[6S?V4A"2=\X,:MAOI/]#C?-+<%,2%
M9I;@/\W/_R [O_!O?^>?KOD/J]J;_S#Z\8?&7(UV_"[(ZHZID"^57\S3L5K_
M!>QSH=='KCP;G%E&EWBK<$<- ],/K@S2J>P;M14GO@1"6Z0VY)M;.T0,;X]M
MOD2+GR_>X*D0_-=:;Y0_?84O"L6/Z+-Z ^\TGHW<DI^! $U1=8'/PJN#Q.4^
MT&/SBWVE#I<*1V,@45#@I5OCHDY_?1C)D&2RH='>?*<']6$MV>CB'"G>H!W?
M5.#T9*#C;*U.6LON6>,:*1D)@K1D!S%Q)@8#+U6)1..0\LU@3HC?A6?ED3$;
M(RGT.YWZ!M]RHJ)7W[GU]Z*$F')DY?6)4!ZB!M.$%LV\DE]XN'CG\0V(-9%D
M$;ED"O[]_BLA<5*D&5)]+<'YJATRW\?.PA+4;(NN<W3M"\_5N[^P[H 1&RQ+
MQ^BU#Q46/3ILT*#$W'Q=BO0AZU@VX-!*[2E!]4E*.#FNCV%I63<&[*HM(SW(
M7GE*L"JRJR/"UQ6><@O?DV/1.A.YI?42"&F1Z!92VUF?"<&JSMP16)KK!^7T
M"B8]KOC0<R=%VN,Y5TX_TXPQ2ZTE<TZ:#> E TKX]+<Z/&6/[KF6'\6\=2%]
M,5XWUK[##?3[ 7D?GC&K14TA)W92B2<< P]_?&?8.T\>@N</W8TN&OO%G,NL
M5X4FE=M4;A=HE"]X;'6$/\(>O/-YQT]7K",C)X4?O6)9LY'"8]:'%6&C@(<,
MKT2QP [Y-R 5M=05%]8<<1>7=35*,<1NZA^1\RL!P$\67?*@KM]CT[[3LC&F
M,!<WE,OC#$E_Z+-A+W">X@@(^_W[R+Y'6T[\R$H30R>;.BL6GF^"9&25(*J8
M-[+R'S1[K%.NP?WSZU2]TQL>]RBK8]+>MZ43/O5_HC_/0=MO*PG*<@YN$GO.
M'Z-[3C$M:%)M3[NX:4;]A@HTN?7NI:7ZK$H;F-QG(E']6?W&;21)<_ZT6?S3
M=IG84^Y."+%XV;A:FXHKTG^T^LUH0;AMIAL.P+4JW&[$ V^C79)U3MUXZV#P
M)PCF@MQ ZVB83\YP]-P<L^TXXX3C'B(+<2;1D(&@\&=%0GE<&<'6G[JL?&#A
ME?#"<;LN<+&]C3#]$9"<>3\RQO1*V/O+WXV%?HJR*RJF?[5;D*'X3 N>AT!6
MIS0(,#JM6.,MTY^)>PV',5%B!T56;N!\,/B&E?[:7QI+K<4;8[&MM+[,T*RK
MH8H?<<A0809N/9;T5VN]14/X&!:@62[ZI2CX4.UBNT!OCP!ET=2VKRM!6I6\
M^>+SRZ\QE+'&*'\3]4'?ZS6N]=)/(SPJ73SZ+_Z-?CJ,D6QMFUY7TDN6Q]&R
M(ZOU$_>"*5;BZW>=IT,@4+E)"M';^AV^R?T(HN]P*:&><O[;_860O\G?LDMF
M_\A[5<!CS[J4Q:<I#"/4!^IP5AO#PM'I":8?_6=\<69Q3RIKK*UHJ:8+K/&-
M$"432._0AT+GG84H/^TW6H$X@$ _K%0.6]>17$[)-(P+7B/7\O./5V)[BG5;
M/'F.,[^IU(OHY&\K8>8]U_;=" 4[_S9H-Y"/;0;TB9F4BW[H0**(NH5\$_J$
MPQ=<'B2>1']EF"*-A*A$G5N(/NT\%?20CO2R"J:_(]I?[W78=/:SGMV.0]<1
M.SU)UV+C&@IWJ^;5'M7VQ_\F1@Q;2\O!6+^NZ353S?"Z;,.;VL!C*.806@%Q
MTVP\5'B>+QZH(&[9(RN0$HDO03&49I]I_FIE@")6EZ "6Y=7 SM6,A)!WO/<
M[5WIV:=;#07F-TW>,=_IZEGM9KFQFK;_E6/[R1O&@\U>%-4-Q="1[9LM"//V
M#$A48NSZ&*SCH((BEV[[DF].$B2?=BB'_N-TY4DAJ[4V=#F-U>K,#(V7#N01
M HYK8/(=HB)(,<G:)=Y.=KGKSJ=XO"[KZB-?;TV^7K?GE@0M8BQS*SZO*T5^
M7I3]#X+5@J-(UF3'YD[.D1Z\=BTZ)5X-S1AR^-6PDJDO=<X5WSD5HFKO1=S5
MK*Y ?ANY6G]Q=ZT]L-SQIM2T\@7>^*FC!ZR9BXG#B!9H+T!\B37NW:*P>\:?
MDC6_LE:0C&\V\MM[4IA%./;OC]9>$3#\[:M% F4;K&(&SKHYV4"YM+#5!O.P
M_%'0NK\P=%8VQGYMCZ3 XC*F/J&7,ESKF%(,]BZ>9H>AQP.HL]MM';>/&=3-
M'41] *F!I&EU4\IZ:!@OK?!Z !7TV$COEO^'K(C[_EJ;&].TPXBNOGQG)TV8
MTDO0K6M"&,4^P::(RADN9.[6S%-?\7S(2)YY?2/RTX]V;I&^=FD=,A JN5K[
MP$/L*46R]B+!-5$Z+^B0]NX,T"X_,*G<C#_]O7.M7:LX-4E?=U'.PD FM>)X
M;=10FIVPX3TJ\'$*_]]=8E%'!DS#IA9:2F;75;)[^A>0#T7,_VT;C:_;I\(J
MAL?.10FLA7.&:-J^<XB^[:Q4D7TTL[9W ?YQA0)]' D]!2^&UM_OFEJG.3^R
M3O<U+/!;W;K?(8Y_QB[3+C1S[U[^DDIYTO]P BSAO7+KTY!?#+?G&(39RGC
M/Z?6YR5/74F/S&+(HY@BBD'+0K2SF12(XB)KK/" CB?%\I5#:EP2*OEWT?N[
MK)E@D6).OTM#[W1XYP%H\3:FD,[JMT[*J+=4T K5,HNAA-U+W\D?AC"-%7;
M#95EM94X[-T&H)=&IK^["6C%WW726#2[[V_1M'^E14<9R\D $3[%#V&,D<G!
MU1JRDBW!>"1?.$^_0>@,4/X<MW1L2P+R<X,U3LYJFN$W/'KT([/+\R#PPWZ]
M!($AT_MO [_?RU  )43M ADFF751U'>_#A*BJ:'47(H*-XW1(X>UFV5&A8LE
M*J@1?+:'N,B[1G%Z">MOF.8,G"KNA".)I4A[CB7CG\7NI=L!+FSK+S]:'=X!
M*90NPN,&O/Z8//?XA*/I<Y'YS*X6\1-I<-DJT71&17B95HG;%Q=3GF<*T$P\
M:"M]W1H;&P"!P!+UZ7C!CNF?L\E=*O1,PV\;-X9#$)17[<161N*>\\P9/&D'
M%_-M7=TL L,OKJSS^=>?XJAX/G'I:C+;JTX7LH<5AL^P0>'!^M@,5".Q06GE
M:R/@(.[HV6<:;+%E[.W&C<#3[Q=N?C<^5\"#-%URJCWA./.0$8=E1#'E:A"]
MJFR@4AN=*![G'JRVXW2<VI*Z(]O2K%YD?C<9(#RH,CG=?['M.\\#@ KH;>?M
M!'G J2PT5W9UNJ->XTB&8(US'LG*K"0B<.JU3KY\FJ.Z0*V=X]6IC,";J#6]
M(8&PUKO4/=[^$P[[:LF/^1K=0;H>;;SB@:99;24 _IO7H\(.7R=D2N:(V;D
MY7CD.(<D4@GWPJ-JCIO03!=&*:PT7IXVGAHU%CK[GCCU-59G( '<+PV@UA64
M$VP97XUX T@V&9$)=@^F<55C;]')/<L7GN^X!1<(&#0;Y)J/#FTC<"F$+.X
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MW#B@:QT_9_%=+N;(#X[?ZAP 7-KINKX&.=7[LZ0H2I%FE@VM\-[2&*I9NHT
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M&7>\\>Y[]Y]W8(Q:H6JF5LVJ6=_\/I):PE[A,+#=RMS2'%BS9@UP%OD%A .
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M'MX)-M17&-FF#:=LFW*OC!J@R;XY7"V=67>GE+T$]OT.T=FQ):MHJ)*= :)
MOPA4C(H4),8BQN;(%/#&:+"J(!?T3WJ(:E#(2@\F0=:LV ?2!6F2[>?.\D[
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M[=9(8I"Q(PEZRM380WI"X._7ORV%4UD6RDPX9OZ=BN&=2?1!<XMG_*9C)\#
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M)\C[#&C%NLZ#PQ0W@6(1[;O37RKVY?%_*HF'P5A$9Q"UQI3_<5FG@5*L@\]
MEGAKYF;:+6M]Q :1=PT0E">G]+^Q^?@K.$X>>/;U;!/HIA3IUS'!(GHLSTB&
M6N:CA BASF@N3FK3E>!&+^^#E=^88R215S)IHYM+:=_B%9T1IMU([0^"?DE!
M#,)0 YLVTZ!W+,2=_U1X+K;_D/!;9+\"B56:PB;IB^T,R8,^IG0+PAYK)X>6
M/JJ&B+;.NQR<> V$\,$17QL)D;83;_ZEG39D7(,\L@:&ZO&_.]OZ1W83=ON:
MW1L25_]6ZTE; MIQ=R9>(2MI)$R.;9TR3D]ND-$G'1U[:K+FQQ@-L3\RU(H,
M3;A4U1Z.'7@YX.I^<[[.WH\,R7X#NM2H]>C[7?,"9X]J-,('C\!K\*)Q1()9
M'\7E:_(9$B2DZU8<?SEB<\CFE.WZ!5^OR"?K10,%N/U?0Q:>CN"]7 =/^-V[
MN$(9ZNG76>1%-"SF 9!!K1?W$2KD!U9OESZ'<8%[ (ZWQ(:I29>L+6@$KMS=
M;@91".,>F#&@)%>B#]>58W)"!V:98XW(1S Q=T:SI#HBH.?]0()G0%N,<.-1
M&2H]8@<T%K&Q^9I%!LC9I5:'J!VYO8(BJLUXV,0:C/5S=<2:3\Q9HT.X&=V$
MSPA *\)_K7JMT>@3C<MO@Q'XNTX?-F6'6*<+3#GABS=AUY!Q6E%?2>46:\%\
M&6HA"<1G@<5V3S;9_?)LW(YPG%8N,+]D^MURWB#J\X)Y6%.^X]/(*MP2=VO<
M4?K/[ J-M24-WFK-\]Z<RDRY(!?192\UT3+W-90 (\_<N\R4W0#(F@F.ND33
M"B#CP6#N?"+<&#V2+RGC,E^#G-/NP' [3MSK,?X$@<VLG_P^0NY XVAV2(1$
M"R(N."(H6,-ZLV73 B/[_FD-&YEK.F4H$)$'_$)XKII.C=CRN]E-!.V"?3MN
M1%]D3/.^X#5PGZ Y<J6^XJQ0AHKP,$>&[LW]-L'QUF!EZ9VA@4:1BQ]FR1D1
M[7/M_9^ _M%4^J^^S+Y!RV'BED&,9&;TO_CU98.-=UM CTD,"<'2#:\K.H;\
M-+KKP#>#S?*.;]Y,<,F#)\<:8SKHUX.FVR,T[[+=A+FZ.W)B983*_*]2]!"]
MER&\)G :@K\0IE_@/BP[05[/]RZ(X,_P<]1,266D\I;1NX"D87S(6[L:'/0A
M"Q0E1HG&@@;,6DVR\?!BOE@'^%R)0?0N/Z:7-MRB)^X%RL"E2&-R"MHR4SJ(
MS6VZ27LV03RN'+9N@1SDL>.H5J3)X9D!2#;-T4#@VCP6%AF.^R*(C&W<2"_2
MXKM>4H]W$1 BCN]8W9$7FC1]CW_'--B",K,C,3_,3%.&.O5H=*SSW3N1VZW]
M$K4$/9%G",)2(3,D=_Z@H90_Z\)P..937+B8?07Q7=W_LTIQU/R/*:*G)LIC
M)3]@5^84B4N-@%+5V<1FA\KD6UJP<FBX9]Q5&>JF0ZFQ1&<\>.JR4C3B!+3(
M_I@0X"RXY-OF+GR$\]H".3,N?C[)?-L53S&=V4<("5@%=+9P<?T PL>B*"K.
MDI^YSM-;BRX)US_8"/YH4JNAO25HB7')9 SR"+:NQYVB1WYKI;V&M#TCA@5J
M93N+8V$E"19D2G2X,A2D3:RXE<O^QN-A'Z"-KE$6(<[Q@L27\[@8UQL/J/*U
M)-$2A#Q<\4C;?K)F4\8KP"'K;K9P+9)GHW/?20K_)B*+OXI[0 J9W1;S'=
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M^-^#$49BX79\#?*)R$\ ?_B)##6\:-Q2LJ-?^8!878:ZN4P/=@;B[/\-:D>
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MT7L^\15:MQQ,_B WL&ETTUL,XZ?',-%%AO(&!^_#2[78A+&8\;#>5#E9\_\
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M<?:]O9X<1O['R1;)GN [:Y2;D!^E-H<K4TSTJO"%R5[9I84X"]_P:U1A2VK
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M^I)H2O3D7;%N_&*9%O>E;**YP%7C&D^'I^>\BR9\Z*V^'(_A)+%7X/4;IY2
M>YY:[YZ>NNX0E8O.CE9_4WMC24C\!OZ\J^!E^1G%[U&(K  5E:,-4<IXGF[^
M:]Y5+H,Z1[RY_SS[IK-W4#DI#7(N^K9#YM6^0Z8R97Y6CGI\MOM8G\X^_7R,
ME>4%1_/\<)7QY0.\T!7L S:;(>?[?W=21QQ^AJXG5[1Y'W<!-_L!ON'R.__E
M,X1U1F[*",5>#.ST;V8"E%O?,;O!SG^2MVDO1:R8P-U#$-+<_,RX6_H?FF/O
M !,X<%3;,P)5GN+3T7)\5QFVDXH07M0.UOP*=C1 (J0=16<IHO P.$4A]%JA
M0-!5H27 R,DZ7$2'1,"&@R/D3X,4HV"^(WM/-;/IA5G:$(-;&4:W6-#M@Y=9
MRS!&F0#[GWTTT)UNE4#K3DLM5*5?']N8VV,#.Z=H<": 70.9@''/#=S[98;@
M+KP('=2*I-R^B]S23X9_A1N<GHD24?<'J2T/ZYG ^*_SD!+!%1O-];^+E@;^
M-UZL?T?8-/P= ?2>]:^6_DM9.W!@,YR"7(3OBAN7,IYRRF+(9HS3M21*B7K(
M'RIQ1FT<;CI13EB4[5*=RECI8N1D\O?,DN_#%B^*$!LEC?4]YV+^C'OG>JUP
M(R^U(R$*<Z3I["1-B;KF3%JY53$:S$==)S:FQC0))!R=5 C?Q$0HN\9@I]"U
M^&GQQN%UDZ%;M2-WDZZ.>2C<K?G86-DX.%_UJ\7@,MQI  5,!P_"X;[(< VC
M-5DLE8OP%<E:S9/COCW-58TC<U#KLP//D\7R/!SRT14KYBE:!-DUZVXC7!E9
MOH00$Z0QTSV4^VGH[<@D8ZPG?06,!GEHETCIA(B8)IF5=\3U*Z34B%+5';E5
MWDL_WE\]M53W**LDS+W'GO+$0+,[F&=-P$N0,Y\(7!*+IC8V*3+Z09BJ9]CC
M@G;<09IB2#.<C^9(8 ) M].L#1/@[B1BPNVER!D^ZF$.9#Y*I?@BX^Q0#\V+
MZF/5.%"BXEGIEGH4987WN_-#-4>] YD0K%%&32*SS]:&-@FB A6I'EAJ+7XR
M*#5. 6$ C]64L:-=_%A?00[K"/?TC3" M]0H+T\&9[]%WPVZWV'EOM<M,.QY
MM[+L8Q@OZ]JR+%'A")2HHXQ+RX_J_%>_Y5#%^HP&&6)4X0Y--;)1&VIMJEY4
MV8R:D*]?1/7\;&T?0W"OYYIJ=.O6KTDW)HMAY7:7=@.];T\T>_AX!33!/:BL
MY =,@+@=4FVGU2H&CVAI4B$YQS88D!8ZLN#531I9F8[$F8/3<EG9:@G!Y"NJ
MTU$?M.1*BW*[??9;RCH]X567<0[7O0-[^+LR_]XB1'#LV((ZC4^+80!K15$N
MTBXQ@>'$R:9N?-^./!7)Z!*I9 )&7W;$-)E HG@,<O7*&W#I-?R+>0?M21\3
ML'5B OU". ?D;/;,AB'.46%/0A%<OC [27ORD0DD!#"!E5C<+JOEJA2-]R)#
M;VP5LK\7KD#710A;!P]Z[IPKAUK/- \3,*UP[*>GS6R\,,.MZKT&EVLU-)_0
M0Y#S:PQH(HU1<$S@_8\\U+ ?*(\L<Z9EXJ .M<L8@SJ,R'#1;CR6D)#-!&CI
M/T]"#:8%QRCTSMD#E_*8@)1X.!-8C6IA LO_/OEG_V.B;F#C< (()$F*$!'=
M)(O.[[ 8KE+@L+&V<^.W%CEGZY;4X?_>VK4\YOJ#4KD[CZRPXO['C(YS%[W0
M8S'2$>"*[+A;-GY64I"HB*[;+!MWXQWTD[TK.QPGH_(V3UJ[-T^OG;N!B)4,
MD/R YXO"SY:-Q]Z7+Y9V>/A*ANBENFQW-8Z3][M%B=7'=N];!8;',DH$+VI/
MRBW2+:)IF2!5%O*;$OTE\##Y7JC%7;:XM_-K^U\@B6]7.A90>:C#B"=Y@<8D
M]M#@4RZ/QD8?(V.K9$5!P^KAN6BYJUP&5T^J&-MK[Z]L2?J0<;V\YQ3KP+B/
M_0__9IH1WE?ZKL_7)-'D_M;1%+$P6S.7=CYW'4Q-\ODG" /_+X7R_N@V;WK^
M)L(V/>:\9Z3[*/[>FUXN)6Q$GM#6DD.>A4F>COFE5V[ZDP[O\P2,-V1O&*6O
M3IE^?!<M^Z,O^_^SZT6L">3UJ 9Q IQC16@F?NOZIB>G[H.SU9F&CD$B_"EU
MZ:49][+F#"WJ*D*KNXIK%_M+HA7K$HG3Y]/NT3Z/T=A)*Q;4M"8>^LL&BR:)
M2FH1*80(41?&!:NE:<EAQDGJ@[ZK1FS3':05JWIR"C:H= :-:I6=<^^VDS48
M_*.:ZC#BNZ9O6H?1<:K8\V94=_.:MDGP=(CT]PBWJ2B]Z^0MOYXG$7_]*V_B
MA:/)OG?,7R7?N7*J<K.11[M_+D54X/K@)OJ^E\2 Z^.@?(Q(A4RHE:3^=0<K
MT5L'#LV6W>(5\;H,3PT^3<41%")GRD\GDZ0NUQ\+]"'[XYG X4!>Y,&XAI?H
M%2UR7.YCY_# ZVD+$8ZQTRZ3SA$G*X:KB[ZY[4JKO,R;[ @0_?KRFPU'XS8E
MTT.9R/[9,P[#@N#X,$DM(B[@UR."#Y(M"F;M%/.2[!+']$?.(HS>VJ0["NF>
MS9(S8E_FU["K?=U"N;^GTE5XLF]"<;$.H?%JLM7:\ T_UNMX=)#%12ZSX8+(
M_<8B8]U'ZQ+/E;\+#;!Z&*D8=GR6QD7"7B$I1#+$T2V3Q#U+LE'K.G=;*37&
M;L2@?H;KDD:7G#*^2:C2'7WGMB_LL"NYL2G9S3S7\E/]IX\I[C%1$B?@IP*M
MJ)]($&.)'V*P4 4(ZI%R@59$.9\Y]194I#4E(;_C;%WM,P2<M(>J(2=$5<.$
MK60$2)DCH9-F8J)!%VWX_2O<_7,,PSE.1X.RZ51U,@0HE=LMR!@X1[#X\L B
M_)@FG':9VIYF%.)W\(% *WBT& 'UW*/4HL\:V.<JS3QN8@I5Y*#21B=')[^\
M-M^5#VU!CH\]?E2F>RY^RXK+==U6KZT1LDAW#'C_Y_UA^=55#X]2S^_R/YT:
MLXXGVA1R_?G3WO]E;7V-=VOBG,[ ND*)GWZCE$'=\*K.E*@.L7WTR8IJM]J4
MS:>[[C%>GR;*#T4J?7F<] +6E3#!LHF#JMZ<[/FT";$\BH$YD?OPV)#@2Z2?
MC<0W23?[5;F^P9N-"%AAM.:,;?V9^X':A,-:1E6)*Y=Y@@J+JZ775PDI4I]\
M=^LIEX<\%_J#SP7J?BQO&JK"QH*B@7YD@99;;FJI_ +^8D?J$_0&$,BB3B=_
M$4N+\I6:NC,C:XX?HR]8]VY,6ES[=37A0[4<_/KHW6A11_VAZMMW7MEJ'<ES
M] CB5?Y043R@Z\=;*))M]>KZT_,6=X3WA[S]UX.EQX$C / 0$#T R$$L];C_
MX^/U'Q/!M2#OJ6"DC^O[XQY# "P1>:9F01"1D6@0[ <VWZH"RQB=FN+I>Z96
M$+^,'B-L[%B._2"*P+DO*SDJOI>XIY0QKU3(_ARV%/?W2.]J( +"L?40J+F^
MZT9NTOI>SJWOG#I?R6@53&6\>49KLP7?_]NB2G #V'SE+*.;M$VYX%EM_Q4"
M,XY3WK7^;+Z1D%ZY.$N\QFD6<,/G.<N)L"OM1\"3/_\3,>: B/$1Z$Y^>X+@
MQ,D8B*+VL8WBJM(9-\^"J_ZAJ!TPD0F\7 SN\=RY+H.B2'Y!;EEEPC48+67T
M'$H959L]\Q+N31"65:XJ7' 8!G.3"'VQSTSMW+A(H7@C:, $2'&P71@ZE0FP
M%3"!V+%?<G^7$!_?A=[H;"3R0442+\X$S#Y9[L"GF("!PLX%$74(B0T%F(#E
MI^8>L$4%N7B)B*()81C**.G@20:"7/L9,['0ACNF*8;&F%21+1) PM03X3C;
MYA(K">N42G?'1Q6NVP_I62:47^=UO.K4)Q>OB- +40#8; C.]P6?@/BVY6^4
M3KQM2<$=(#RD3BL08L64PLX:"O!E?7^E>/XQR5QZ+,>2[_APGD6ZJV$&\:LS
M_V#B  8?Z!#5>H=J&J6(OC'R<+Q83>^-)9XHW3-4HE.-4,DS+#F3^U6*0U*Z
M\_30:,<<]#Q)IL@IMO-2+P.#LA_$"]ZSI2I<$?<6/_?G1H"@Z,6Q32M24#5*
MB"9-=2?2G[1:;];-1".X"':@9<KHEH=<WG!UT+$N!N6ZW-V(KIJP4JD7;?M!
M";UJ@9/>8%P]EKI5!^74/8%^;(O^BM$+;ES6Y 0G9$F0B!%R"OX^UW&(]%/K
MU</O?R1)="M]^)@Q!M?G-F4)#1?R*S3M=AD.TT@,_=YWT"PIP_3&H <F!GVR
M-8 1D+:P61F[H-1SQF'C"Y\U+WF\D'A2)_>74-6"28;S\8U>W\'0M =D/3&H
M3 _V0Z6X'062W$!J#_RO'KN^-JB,&8A0_2NS0 >H^C@'@MOVQ )=,MQVO_=^
M@VO3>WZ\=:Y]&&C\+E:/.THK_@KKB7#S$^20[;Q ?<@<*H0D52I$J.X$02]-
MXHXU89Z#\Q4$Y-X9)23=B@!+GU/8D4 7,#J_KD#5]+%RQQ!#MYWYJ;=.DQK%
M%<$G*EOMV4A]JV,D#H0-66:L15TC @^'V5I-+$\K#*DH5&F)?BA.G+29Z>;2
M.W2S16F [=J.<?Q/7)<O1,U^, %O(_J!HDU/2LUSCB:>X-;[+B=?)4S0 :4V
MD5!8C=5#KJ([0;*;N *X"+'A BE5GOA5S"Z\QWT6C>&(".<2B&QU<#&SBH,5
M]GJ7A!585-E)=T]>T3E\0S_%0,XH;!=&.B+0.B/@]54T[@O92@<.QY^GW22/
M(]3@ O:O*KJPP@=UPF7R9)3,G>#.ZC)1[0IIZBD1FSP%Z!F"13GHG.>*%-R,
M,S(=EK)Q/WS1B!J6/8VR_WK^_FTY#X^?$EG$^^9WRUOCY\^<N".TJ4#5B:"S
M-T I#3%E NWN.W;TEW)RII0<*ENG^Q^QN&.^[XI?7"N&C6_QO.AZ&O+SB/MN
M!Y:(W!]HWH$N?[D04(,\W7RO6BF#&&_)>?SL?05APP:9[U7E/ZL68G-T'J8E
MZ^I=Y7XE8I(4V-M!24@0X[Z#@/=5B& 4^A0GUA!S$B5IP]B$YCLD56G#%%=+
M!3/7H69++$?+K?P/GWJ-TY*\C+_K98S1Q+48(=.23*"YD G,J?S%Y+>3X]LS
MICK\94?0_<N?4!T<N"SR#T;A9?GG$/]_'$*P[E$Z/4L2[CF,#1PLT(@;J%-<
MVW_WE+$:6^]MG\0#KL;_QV[ ![> S5JX^<S@=A3E^EU()?LT5U.WO9B V"](
MH0J"FVS8<2.JM#\M"3O>S>@\A-J-1ZM5T7-G_F.5Z][O52[<]Q.%X'C2.28P
M\L W</OO K<M>*=OYR((]?\M.A9JD!<*+;=$47BX%A/84?\*_>L4!M)-ONM2
M(#?U&8:ZAYG ! ^DE$9^/.0CL=-X%Q@WMXDP>E@@_'><85!8?Q^7MUG 3L\6
M),78";F;RD,UC0?G8XG8/:E?*/JUE[3:;V!'R1C]B2VXF(I=9*5$T'.:Y!A]
MF,K:51^%ED9/_0%,&^;PFL/8D8*W$RO/B9?@S0S.)*.C)5/2-8I-.;[WSF!4
M--@Z4I1I3. _#S6^/H5G&'13^"&Q'N '*7MG_.2NYR1/VH\ J6=)/4I_X 63
M[]^VG4S".V[0M&_*RX<4179*C_BZ#VXO[=U0E3'!*+09^L0,WOR%=*XQ3G:>
M1A"\B]?EFN_OW)>5;2VV0+TF%!))Z#!=]LRQW"*'9<;/=P76R1IE/ZANIJ&C
MY3H=JVU[?L&#N&,,).TL22 6846 ,.T0.J?5=&FW)[,@I*I1X\<3LP%5]Y'K
MGG=>YM4Z>+FR"ES6,[^'4,1.IS$L<'<]=R["GF$HZM_ 956LY98^JGE&.UB<
M>$1RME>\W8O?/\WY=3&2EVX=+J7:/MIAF1/!:/ML0>']8+&=K3_9ZQ<@4-]W
M0?]1WT]L'D0@%KB\<(?N4-U/=7D?.BT5FB7+'=Y)4GG(*TL$:RLYX;>+;D34
M:TRW9YQYHO=DNI<[OO/ ?P'9D]@H</8=))OOXX0@A@N#7BX;O[.D*.R':*!3
M"T@QN8?9K6R!MWUU@@H]@1>JFHN9X'(M/WAFB D4I=,[D9O\V$'89#=#3WT5
MFISW6)";%5TX]06()JKO)8*+<JA<>'4J+=%S/(GQYSYPR2GY,:JJB&'\ TZQ
MG =W'Y_&5>HS3#20%%TRC)'S90,[(<PPC)F5HK^*DV4"UZME&&6R.TCZ2]S\
M8M,^<.+Z(&XSQ@2[L@_WC!$!W] A)]"37Z/HSF4=V^"0(T,_&.+1%4@HNA)Y
M:>EWT0P<,J8E6OKMOM_7)]QQ- Z?Q4)J^C2'%'![Z=(D2/H6.IE?^Z&/K[5_
M_+;-7._'1-GKSI_\#/"RAY0N]'&ZYV(AZN1AM*,*3T!2#+>P=#:93>] 401>
MO:MB=S!#>JX2@3M@X?O5_/I@V]S#CVZ)^?-Y?.=;&KZS2W?)W$ ,N"WM[-3(
MY[/*]"ANYG",-#N-TYRDS4Q\OYMRA;02S[2_BXG-D-10-#5^=8_XO6NHTO8)
MU#*0CGZQ73/"FR>BPZ]V:).=.06\I!@2@K,^]DY[3HR)IC-48<)Z2)8T5=^1
M@.1SP?#^L=5C**?5>G2YY8QOM_XESE\WZLKB)VTNS D\7.[=D!N^TA+9WGJG
M!??Z$]1SN\#=S72H&UX*;F%\@V]XPLO6Z4GI.+H. F:^^666BD;.3CNT-@AB
MG%_?_)%_D2,L+Z[0$E@FW"G?L424_<PZT&98@M"V5A6]X7=JR>#]^^X9.]Q5
MAK2] GKD%:E/Z-X%L8L2\5RBT25/X\[ZE[?U.$T4%8A<S=)0>G7&//M&HRK$
MQF7*# V-M^&.I!D&IS]YJ(T)< ?#J;HF)!!_6V6=#SW5TB0\+%49T;KO)Y><
MCVWYT(/\:J69JJO$\_)V!"59'0E.NQOS\&]UC*N:;%"=/J J0_T-15A@Y*49
M@/9;M)A-ZSE-V3E$:JR7B#GFON!6()O/*P>2N=>O[ L.[\>Z%%573/-6S[V^
MEF-2)6YB.Y#^([KJ7>,8W6^S:C;XZ&SL^O.'-''\A#_LUA=OVP7N^+S4JPTG
MH[$1O>=>29M_*)I3C.M-%NS-L'4ZT"V%[MS[$ZM)+9\+T!0*/$=]1N84O> 7
M$,@SRP2.4O,OR2VH%;YOBLC[NBQ[?^RDI-J*]RA1_%R\UG&/9N'CFB'V''L0
MZ>NL#GP,E:W>W#I=IUJ(\;%ST:3UQXZA4,.EO$.&KBD.*Z8>>1JJOT0.<Y8]
MD-,[,UAB(A!C8CL68Z*'G<N8K+;5-$^[*]V=6 ,_^\5]($WOHWGVT_;1/)7<
M#)LP:[/OKE("W:ZGTXTV7,!FIVKBL[[/EY"O#B=0#9TV>Y'S'*@*D$WS1#<9
M1=#%ST29+KF^,Y@#.5W%))*NZR>ATWR64PJ]/?@7.S@^WM9?/?8Z1R%VU3Z9
MAL+N0IAL&\%XANI'1N/<8'#&%TSYS&K0!S27'JFFR(LXP^;Z^'YNEG3-\,^[
MX3-&I+:25=A]E6^Z1O>2\[PK!-/,%4D?2GJ"/VVF=#<@21'/'M(<#E746#YK
MN?\@RQEU@)[]AN@<7G@U3N9<06A);%+Z[08#0:2SM(%NFJ&AHA>82A?V0@3-
ML8N.S/[Y0T49@1=./?/=5W'PL]/KVT17<ZQUU3)Q:78P/XN'RUIV4L?+^WMT
M]*M7J:NJ?%1! IPJH[[&@D77MSP^O!#:Q-?A7$K%X'?EOJ;L>D99$"_:65I6
MEGU,9 .Y-3@2A2-<8G+>OCASS^F T7HF*(4.(B9P4--U55H?EOS17H+(JN&!
MQ07$6]G(O7)S=!G%7C&)<]OZYE+G*W.A2U[FF'&,0:<JW92H'DIS(-@%YL#:
MAKV[5)7KCG_187'Z5')H4*G@&58+%NF7IPN+,+OWX>Z9]SHW#+V\$UVU\XVU
M _K:84>7IX]1C<CJ;=:'R),KP<(D]IBM;V(_;I^JBYXQ&_0]?)71$B!78!%.
M.%7W_(P01_*[9+/<:/-([&#9L%1T*X%4]=7\IN&I<*'T=#?._%.-(@B121,W
M&;_9^>%[PV9I!KF8[]3H?KP#^7A:M&&64%B@MO;^C*_G-MTMTZ(?G.ELB1TV
M=;UP/G_0 ZOS#I?R)Q.8+8#7V.@*J[<:'4[\,Q1#M;0_)BAY10KN,"=5#5Z>
MJ42UB>JV,X'*@N:^2-RQP"NY"E&!SK/?%,Q&56435M?V#4)R\)/>O8PI:UF;
MR<LW3D.F4])FYF=Y ?=U]!C^YM[3BE4UUZR[&P$.7K<[GH>6H2<K'WXH^]7J
M8X[.D#^2<>;\E3:]$=S%V "_3R2:,%%>K^-"N/C9SH=OZMH<RF($SQ/+?&<+
M],;BX2F)^+M>R5*F6;:],LF?>/."S@8):_MHM0?#[INC^-&N;U[+O!_SK?CR
MY;+Y+?D*JRB I5."I<>W>J=19E/VUQ/.35GOJ?3QT1R;E.U:]?(2RQ3*HQ_?
M&S.QSIX#,@0R[X6@)K'&(^X;>X_Y%GVLQ[Y3AEU^62_3&D;K&DM++3-IUM08
M!U("H2"NZ;1;6M"/D@*T.'Z,<:IQR'<[3 'KL4EMF)!;LR>D\+WI..ATY\VR
M^X#L#X4I78:!UAP3H"<I'&,"2R>QSN(M QW.5II<W ((366U[G.O(]L-CR4?
M,G1XCA^-=88_/I8L,W(L(VBQ)K<Z&A&XP&-S(.D']0OBE3M!J:&#[ZI)=(:C
M#>Q9VUC>F:OVJ\-N)OE?G7YV2@GD.+?,,;@$2*^?@@1CFHX@P 0ZUB-P.Z=Q
M^L'L@5:#C LT61+8YB%P8UC%0+F=GP<UZ6I=--4)WG\Q_>UVE;^"V_J#7ON1
MC./C<<5O?Z4QE%/?[L*^HT;6:3QSC)N_9A/H,;40:P1'BK83CB,T"(8PPFK]
MN3_+T,6:LMP9>'8+OU\B%O(*L+-'9.JC"^RD=>P'7\$UMHLS'OU!0[9X'CV/
MB5&F!;->;".4'_]#TQAA)VW\V:&LPGPN#F]LXB?=Y*H[,9PV'[PVF;($OV^L
MS4?[ 5[YE[WK_W2)/9D%=SAI5R%1, C2E9?X%LT7FMB9P MLJ\*>J!1$AC5?
MVH==%OGK3?V_E1*;+"'$&-S1<31H44_*3W FPKCQ+@LZ UN';[G4"(Q]Z7JI
M^^2#L#O>V2T]=NQ87DEKOO3$R:COOGR_U%Z2YSH8'-0D.-YSDAW/V#\ MZ'Z
MS\&BL@3)$?@X?]M1%9;<0,TD0S'%P08M1Z*!U/613;I.>Y]%V<A9SY*[]4.>
M:UG$\>K&[S6=P1'49W/K!VER),LHQBGT+^LJTGH(#9[S;27KQ*CG[9+&>(R3
MV X<$$ASM;G'7S,@V^?G=U:M7R+I1N0,QEZTD@F$QPXQ%&BWQVB6!&'/2";
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M4B2L"-@IV(:B&/W [4:)[T36,8$$&^PNY2.$0 JH\IG:"%IZZJH<)+(W5IC
MK;Z(:NJ<'Q,0JY4:G/2)[]@V:J9<.AS<'/R54M&\APC&;S32OTWVD7:_)\HF
M<<1/B<%(7!XA7=%J7-6CB.N#HB^E+M;RK# &9G9T5RWI<0\AK$Y_\7+O//C]
ME-+,'K\CN&6'P2@S6F<V'L%9D:N>D#O#[O;8Y11<,FJ\YG0ZI8@*/]8C5X^,
M*;V<MN^=64>$ZJ@D5]';LRQ7;ZCQI;.>%]\-8WQN8 +9Z79,H&D5N<.&>Z8)
MU=45LBX]!;[WN1M'2%@WRL?2,HY 3*?B#!24OYA3]N!8*XYD#.XHH^) "OL
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M#$++AX ,L7/B0[D-Z''+8*"7ZPG(EB3:(W4P@3$13(9@\W>"^%HNG5LERR/
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M[.PWZ7[X]&BKG7R8"C1B+.%P*%72S-29A+*Y80YQ!)$V,[7>5Q,?C*D7XS9
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M+3TH[^,@%8APZHU"9^@CZ#A-<MTJC$;/U8X+ED>[!0[M,/?VL=P_Z.=^0J!
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MLY$J-L)"IFB9_FL% KHU69^G0&"CL/^I$2%3VG7B8+ "<3]6K#Q[I=6^XZ$
M!@&W<!C&?9O"P4]8SU'_22;ZO]K]J]V_VOVKW;_:_:O=O]K]J]W_O]JIC$\?
ME%L-.5AO^^SAW)L:/A0=C>Y^^E2GN^SCB&ARMO;U?CNK#5N6N7TE]!'>SH^I
M+1K)\K _]:J0Z"+Z;#' D^N04+Q"-)-?N+$?Q4=IL$E$./!B<:0<Q3QFP.S@
MZ$)=)^J0)9$&/N6OK&+61-M07BPFUH94I#]\O]1Y':L8^U]02P,$%     @
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MTS(8_=TZ/,M3^>.@JJKN?9N1!MN<B8:8FU3O1?6=<CIU6_(;F?4LC0_*WL#
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M?T*#7]NK*W.*-J ?U9I?+';:R3Y;A.&F?3L-&#^K%VRIRK 2Y/V?F,"0^.
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MM99L>B:J!H ZOLJ:M&=')LVQI?(K2&0:8B69(A<39BU]3UCI$OZLS)R8>FV
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ME.4$3Q'(Z[=EHQOIT!/(S)A;7V?W#C-'K\9UYQB;PR=EKVY-SH%5>>^I$N1
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MMWU.C)@[.%Q"E':3G6Y9'=YYA/%+A,KT41NMOO&&N5:$42VSDY9H892Q.F-
M7BQ01Q\!D:EB+5 E/.#BTY[0"L^5V&VY0W5S6<.*R%*_%1_@).M>OSE+-8F
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M<1I#:<-#&$*>@SJS$R/"]]W#ZS(J='$;0]V0%#Y(AGB>W=()/F1V>H4GS2[
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MA@]"85FE-S$1F+6'/(GHCO*M?FX<3+>5#WI:^#=[J\T)[*Z8]#+A@_8&\T'
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M_\9&OCK+5[6<S0EW[_6MO7FI:F#D8'M#ELSK!N\'E^F J#Y(+/L])2I0X.0
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MT3R%@GCMH#>5?>IVKZ[C::J>:R)M[P<W37>%EQ/O*\Q4U[26@('<4,T]<'3
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ME4)I:FU(/)5H"_3F8#8@232+2Y4+!:?BO >6-)E#\MTCLV;WE89QQKL/)&L
MKN7KM\==]:G+MTJ2OT3K#TYZ']9S5 P_*5")M')9^.$Z9U=B5U_*P^2]\3:O
MQHZ]ZY+#V!WY\;)(Y<H+JN[W-YL!/SJ+3T#(.<+C6TWBPSQH/*7&ILMD'[C"
M/Y@-T-L:X(=\/5R%DL:[ZUSE. 1/9<24?63,!\N]BSNV4147]NJK*.?AZV)O
MV+B9K_GW.62MK?&WF];B=;!W6VI?EZAP*Y>D)W8 T<*G;Z&RB #H+DFOAAY
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M>;%!VTJB-5C"AT2;HSM2I3$%>NQMJ>CL]O^0XRFQ^0Y/61IP"HR'-1\ML'0
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M]R2YEII^T\8Z];,H8"J=!B*]&IJ:ZH><)\8_7/C%2,?7/L=V(.Z;*P8Y3MJ
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MQUGXOZI\/@5F$2QL:";Q:]CX/^I>;YZ= *F;0:QWBL5*(PE*W'YXCX)AE(W
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MI-;4)3)CA_VO275_3:Q.\S?UU3%@L8]@#<4!?'_ NY27OBUW%*\/L>9E >\
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MCM\4$Z$#P-1H=R%"40K'E"D!@L>KV(UM.16_948_7;'1#*]>^9FF %;*@N]
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M?IU%C1> .1'E%?3ZZ\;4;DPBG7)^[$=PNDJT]7J@>='9P49\UI6+W=_"^&G
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M>[>%W7(B^U[^02:_##HX[KPF[_P&?5US5ON=P>+G=VJ*KC[\&X"G[[[(01*
M*<6^PH;/IVSW4&/(!;I<PT2A$-D)^@67N.2NC8/>C-B!9GH@3((%B^]V:]["
M'/@J5X/(ZHWEMDP(Q^F637PCY-<VM%G2P5*V:_^J.![VU*[$LD9]Z$-N'N%"
MQ8 JU@*,PNLX?K9*0-GD[R6VYG38E]VTT7;%2\&LF_=%]'.)[K5C7FN%W1'P
M'N.1:%.S2FR=$\>VA25?;:3D0 <KC(0'S!,L'[8V)^BT0]2*_$.QVI[15Y/K
MX2'!OM\$H[]]'E% :ZT"#?T6$Z:7ZY9GSW=$F)A3QG37@U*NF7FP_TQ_;UO
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M85WZ@3)H\9N?T3#2*-_"VU]&9[U'*PC=8'"@$SM$%%0U;OW=+9>6F)2T?-6
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M7W=R.<?8:2W;Y::8>9""C*[*J7M9GDXZJ7F9.X>DCI=9V=$#(B?&>;51:$;
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M)/_$G7T1[H[1_T+]+]3_0OTOU/]"_2_4_Y^A+NM0OP2.0=;^4Q.U_.A?=_<
M:6/I$FG"<4(EVLLA?79P<?!,7![F846._?1[Y>PX%QUS\NW_>.@]L8HL2"!]
M*Z413_EZ3+87.A8Z??2GMC-\-GW5T8Q1=WEW)8?]J?\#4$L#!!0    ( !N
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MGHA4_!2UVO_'B?8K[&R@Y!CE'$D8#^W\(;5M=6>@ P:M'^G]('7F)Z91:B@
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M$7%3@L2VAB*]LR:K @A6DC2D0YH*2#VU(4I-T&VWY(.@QI9X31%QC-\\5$S
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MT^$?5LUM:S_5C%W$C79.,A:+;MC>%\-E_[J>Y->I%DV?^CUYAS/;==O\[;S
MTM<!J8(N]O7/"&EZ#7N6ZF@_2]>EZCGO2I:\S"GLG(]+3=KE; N=R/UG4-DX
M436.C]?:Q"NX61S#/YC#O+("+7\5&>W+.Z$=UH2=OY7]F5!7<ZLP.MG(HB7?
MJ"#_<>ERL'\@<_UX&>6*D['_1'OSI)BX;&:0^<9-@E?QW=)Y@8U9O-Q!NHC(
M%G#ZQYO3KN/3A/;U=0K+"N8<&XKAU"(-FEA8:$ %6,[GWO!;M1J#R7,>[1^_
M>['VUN5")Q9,4,]2883+I>>[R]:U#U3][H0+>W\0GEC[8N0ZD>)<;%1NK%]L
MG%^H[^F9Z?CA4AX+BV]NDG;=CR0MXS^S8\9[SS;?HR(4R&4P"'+Z)K'P.#%5
M;#[L'4QC]74W'^.1@A1G= ],"5F.WPN.FNR"F9-K#\AI;9()-N?!=K-*!=31
MH>4&9(XIE>!!-W "JQ B]4+L%$WF%^KJ21E3O? C5C"90<B<-]59%T6)<P&H
M0+K%T^2MDT%4H'#UUGFFPYT-^-#!7JD0/=\GVGHP\<H?)+[LAXY3X(ORI0SO
MP(1#D@UI+ABIOG"X=W_D9YH9^^/HZWGZVQJB\<;RN:K@"SYAW@A'^X?W/V?V
MP)BJQ\1JFS&L1+6I>ZUN=>:;"]$M<-</UG5FOM.NTFMZJ^FQ[&;WZYK?1JBS
MG6([_P(W_P[+98%-B-M=X"[XF7V^#;^?YUYQ^Y&L6E-C7=*,4?PTWXC1GH8Q
M#BDLQ%MCP%_4HV.802HE!N&RF-MM\#I#8>" @\3J62/R>J8R$F(HEW]G0&-@
M4$3HUAVBA0<.?@$1ET<HC"D7KXF)&1"CZZ)PM$4:102X.G_$I&],WM 4O\9S
M"_[H%X$U0G1+9E-QJX>;M7:\-BQ:^XI.,^%:I&N1*],WWP[QA,<>2);Y\DN;
MB>[BJ'-?=-1XQ-6$_Y26_^;FCA!!,2%>=5&XZ[/=>>=7NA7_).?,ZGJ$!,;X
M[04,7'=\?X(^0M#O%D\=X&43,86A=:]!,9)LB!JY3MDWB#%+T,L(]WVC87 T
M@4<?1D;LI3<G:^)UDG.FB9G68WL#ZSZH=CV$;N]E&#_A<JMST4"AU3GA7S]B
M7[CR%@19$;:7'A#D>C'TB*$^^'F2U9+-JQG'=D@<G&ZIM@UO7% VHTKXO=8A
M<V [;#SC=X\B-#JCI'L64?E!2UW82$*L\T\.9.QUHI6^D3?BY[TD!3X?\'K.
MSA]_ST&#SYLGZ9Z#NCX[H]#IIJWI55_*!%\\I!W*C$*3+"5.3GU=J.H+"W1<
MU)T>6IP*@_&T#B"F;N%AF;85?0$*32W5F8,-V6,ZS5GO9K3*I74RAG11XA3+
MM,'+OZ8S=G7#%'5[IY'.S:])LK@M&C,7";QK]\Z,=A'QA5YC?4P7%<!G(^X'
M17A'F\YH:VV><Q2<20VSMC3X./K$'""_S&T#P5U8P'X9%<B-PF=2 ?IS8/M.
M^OV?+M*NFHO\0A/5,2Y#A]=1]!C\&Q !B"?\QX406.K_9ON_V?YOMO\%MLDY
MP1.:C'+=-F$E.1<U\/%5 &TQ_X]%FKD,ND@JX%)% V6"77QSZVK"&5?^"WXG
MF5Z$GOGM1+OJ\O^WGO8H-7*QFUT2;@5GTGD%P:N69%:(_UA^22\W].NVA@ N
ME[=(].O78RS&0C")@S^%Q/N_>+T5*(#O,\4[]G*Y:L.L/\##2(PX>N\ K50W
MM.O^;I+IBC#".===\#F/6=-49+:'N&J7M[/)MQUA-I;7Q1N?:O)+37IP:_D_
M5[$WY#796IX)ZT6WD",NYSM_S-(8T[81KEU]J#&1$?XCM]8S>9--5=,S.-%W
M;>1PP>9$\ 22JS9.;=]FNGZQM7:RE:#;>Z,BLWS>^>N"(SXB 4$WR[W]2[E,
M3G^Z^F!Y^O+DJ+KH@U%>=-QO##M\\4/;C?&ISI% B>% ":_BZ=)K&&3ND*MS
M_EU)AJD=W1=*%N>B%YIB7'7X18Y:7EH7XV/VK8F;^ 1]@ES4+NKU L3'G94X
MCT"W:*"),5W^%04E[+/>U3,6\Z*?.T<JN/(?G=BRMPPM"0F\^3C;@=,WKXLD
M<E?QR_9[@V*M*/E2:,J25&38P(]KI<OON#@GLYE9;>3[>I%&:>+RNJ7V;_TG
M/!AJ'VCEG?'\5D;PS8LT<AY+G0B\M_H%)2I6KJB9&YMEMI#^3CWMO47J7%GZ
M!&B)"[\Q)]NN.'&?'GT<]4=,+&G):CQ-UJPVR!/+LL=X\/[<5MO3?)[IE@8]
MEN?2UETVLLA.E2-CY,@](CB\AD6 TUR_=U[70JVU6C /Z5JO&A+W9O)XB$BO
M)/5-8C0&\&P/2FE?#3R_Q!/1\>C&^/.WEBJR3OH?[KQW'@O]L\GMW#]O4*R8
M>FU9,3EY,XQ/ARGL8JPM"UM!E8:9Q/H+W[VG!UW8:BA1M6ZW%X-#]\%XQI'?
M1)KXS]>NP!DH$ZRAFQ<IIH[CK$:$BPO:3^-86J9B*A9BWCV*:G/*2;+:O.26
M=H_'(M$Z1$='UW_C^J_ :R^")^%TG\$X=R4\0/[4!8>U\F!OA#I%I^OX+8AD
M]VCDH717[:'$+:AX\ QFVQ7%AMRPKJ("XZ_4T5%BS)?KFM5)3;/@;/N4;PD^
MVC9'K@$GV:G@&U3@.P8<=HM/)]BPF@L>BJ%M][6>TE !2[X<.EY_SP#4#HAW
M226=@H6"C2"2A+\KO@RWIGLD_$4U6S$ J>]W^)"6=^%*9-0/?FNCD6@IE)']
MU>*_=+(YZ7+-I#&_%[]8&)X</9C]$GK&ZNAO*MT;Z7KE)9GNU[0OAY"V6PND
M?5R9*#(*G "GMG/HZ"LT/W_$!25?&*.5R7^@=F,T]'M*[%G6.;73$!9E_3F^
M9UI1PQO; V6C(FQ]W&:/V@\02XYS7#='10,/43H+*R1<&;_9\?<G*!$AO/?Z
M%X/E^^$X5^2BU%-RR1(W!G1X-/T>6!W"%^.IP I+=F+\W/EWI(8^%C1>\@YE
MXLT2!IP%<:@^BCCDY6_:78?HZSDG_I=7O'-N?;392B)OQ)EYYX+$T'P/M8*?
MB=\7A7F%'.R> _P$FROJ1P&4P<TRRU5F!,JHYO)4TO<LX_7;+0EJ:4X.-^X/
M+PCY(,*BGQ^=?NC>SC84DTG@OOU&6=2K947LB_5-@P@F![8F4YLRS:171<4!
M)L["@?B5Y.=AEK@"/07^[6+S.&X;5^-+![-Z*TD)TL:MZ)FU([$7L,'<1K)$
M3S#;Y.93M SJ@M-,>%V>,\M>;%U37#[&N2;K;H_'1='FKT\+BQ\:AI;1GJ!+
M(=F0\]I82)>J0VU8UP=N%@=R.F=SCR0?&5A@W@C-7/SVX]V'J/>B#LYU16*I
M)ATL(_'?/-_7TYI(]_U"G+UFI<:4]< MT.J,;1Y[48-Y2:FLG)X.][=+$^:I
MEHO%8YDI[@:E.A=\!.75Z*WZ^Z]/;Y;_V/)QM6K^_6Y#\5MS+M&WT\W 9J)F
M\XI.O9H?VD?ILVAYGA&[W9BE!L=SI1,:BX &^IW/UNSC?:]A98U<HALIP+FD
MOTPQ;^V0T]%@V/L5WX$'EXU!>+=OI_I)J(#XV:NL[^^%).X(=J)"%?LV/4K6
M41PP^!"N*% @H'P(VK45>2[ KV 5[S19H:^466I0I1H^]?2QG:K 7/;3A*M&
MMX*_OMJW(*,VO;ELNGPQC. T^]'UC:I[\<EJA^;41_WA.$R:AOAF05243]*,
M4Z:?0/V3E<5/!RM0@MIE!=39Y3F5Q"=[R\+3SP2C"M_A=AZ,,6H6V#RV-K,^
MD78YS2CB:YYJ +M=)0MA_$9#- )CNWG)22M>UN/MZYWA< Z9S%8%D_VD8GVA
M9JWI#E6#V-&Q=XU%_9I3PWL2C,2=CN";K'V=W$+#+9HR_7R1#RD]XYL^D,I^
MX?0H\5,U26RQT?3:W\_2=,C+CLY9SIJKC5E9WG9C.#$DUEW9Q5$26RW]^4O)
M)4^-JS3].(PRR> (2AS (J,-^A:J3%YO!#(%74N1&7S<D3%7SVI^K:(2GRPZ
M=<WGHMS%&\WG^;("/W/)73H["K>#,B/^S+E":R"]*"XBRF+\W1\?"8B38O<D
MC+O2[VVSV4RE(^3BB8<'OH2>XX_SBD[7%O1P^A8H5]5'CJ'?CV29*/M"E3IM
MY34K6#/@QMW8:LNGPK]DA0U7GJ-#TDPXK>A'BO6^&#IJQ-E)(KL0-]=*YSU*
MV;#OW?\TC&=XN<U_XQYZ)S,_"'TX<*1- EY9@87\F4T,[*RVI=*]82YS/H8'
MZ.4:B4":2K-7A.7:=G>7K<TV?I)*RR1=Y*:R&]8BZ^E,P?;JF_6FI^EQSE?/
M)I<)/3?+LW_47J$S>H7M5XO+[+X"^;U;BXRR!!5@Z+N7/3;P?2:\;T9@\F>R
MLX'G3'V&>-B*0%5LY9^?ZB&G_+HQ>%W=Z29MZ2,5;_>+77(S/YLHDS'=]:4E
M&V\NU"&=KAML>#C^]?#CB5!X,[G%@BOG-A%-?RFYYEMZ_>&0]$:;(6^;*"M,
M1+2GB\G<<B"9BVVD"^UH,&/KIFA<\=0?[$2F&@L6PK4?W/_,&_[,/](V5U3J
M,PQJ/3L\IU;5(>K532K[]+E*K>NCT7!5=A!]L<@V%5BDBQ_;-R4F+U&!Z75<
M7<OABU<? E L)#G"S6;ET%$KKI1^L=PYC50;J4L_EJ_BMA7X )FW-ZD ]C%E
M&%Z[7XP[)[&X3((RMC&8KNGFZRX=Y+X+5,6=R?LR!TNY?5'-_HZINHL>CUJ8
MKH*OK66#._-SEBJ2*+**L$>L:Y.X,2",M[9<M=MY>M,Q=3Q5V=N#Q47KW%W&
MU%%=R.MXKSC30*X'XA(0_0RT?G!W:ORK,.0+!3O.0KJ(\ )]6:%F[9L'AL[E
M'*7BI@U?Q*R:H06$N=DOFYPF%_IY@XA+:7+>5,"/)48"=TK;)E-Q:T,!YTYK
M^AV!643V(-D%>\1X?S'VKQ#4ZF4RU*.RSNQ@6U]?UO+Q:-A('HJX)W8E_G;)
MZM'MX%$J ,BNFNS'XDT)J%>UKC*M]01HUP\5AYBNOXPO5<I^L<SRZR5DV&<9
MI9PC:-0LKHK#>I=9%.0'PG:><7<UZKLKM'_C5.\B^LLNP1U%NR0'BL;0H:4Z
M92H1UZ0'1/0*A.[43\+*!8P@[,+:HCK<!9<VCS[+6L<:Z,SMA.J(R3J+JZ6.
M_5H>)XOGMNQ@43UP6I(E?@(='<A88;[.X=-9E'']A_%?7130^O&#D\6WVFPI
MWU2?F6[F*S=.3D63W,D5,*Y GK2E+E^(7#R,KY\M01MO$\FT]2?N9]=EPIJ7
M>5GN(*-4>BP=ZIF)G>3GPZ\OF/$4JY2[L%Y'-@8S59?GQ1%]ZDPZY:)VQ:S"
M#SN$Q6L?N+GT>XYT89U-T/KNB?JQ*2F*@M:Q0B6CI:>T\Y=@3\;15>&9GN[Y
M=IGN6KZ'==&DL5',4V0<Y70\;F#)9.,(Y[ZIHB_3BG\_SU35D#:#E3#Q^9A5
M%"H>)M6IV2?:D73K!?WC<V-5^+Y-<*K?ODGI)U9CW5D#Q0GW6#7< VR+5EE-
MFKSI)22M-(*CF").Q&;^[?W)U7U1TD8ZDF 0*OPE5=38S400;?!.)SXHS:%1
MYM,$LV6*I(_'=)"R.)3)_)QQUVBV6-,NM+90W'3P[JFWMA::1ES7_AI]T$\7
M6657Z%#5*-?_->&2A79O*T+'M+PX\@YDQV]]+PN$^ 01W+LY4KQD*Q(67?W<
MOZK)*L%F%5[[T>3/,+S^T7G9*Q8(A'<NU+'V8 #BVOS6_EN\%U$$.Y3@O5H+
MI]=V_:BY@W"ZM?')PD6JK\TL W?C),&2Z7E\OV*1\757+ESDJ46/E.>HF9'>
M,9_5AWT.9FX<#:3T:X>===P?/=[;YAF(=>BCC0U_WR8_:\G3S^=RTBL<U!<W
M)8D^R=M42)>*73FYHIDNU[EF:/W3P%=C1\L8;>^+>>B$_H:Z$#PS+T1\*4?B
M0U6K=V(N(KI,FQJW/Q#47\OT;P3*GJKQ<Q9/]XA[\J48&'Q>60+;+FMG*'4\
M>DY<ZJC/$*OO@[YLX\/#WM2C<XF9/9]$=YS3,C(*_ZQ4O4QL67<^+> CO>)J
M=_GI(T<)%L0U67/*2*_6B0(&Y&S*]M-?A9"FJO>VBJZ*$99XK>]JWFLX$8T^
M1LV4);F8K (V].99,8J"O%-K28'>2+,_VN7#0*YS/TE(:4=Z-[1AT 8G%R)#
MS\WEWCO/,OHQCGW^"CG@05TJ"XS@5-!HPO:'864& V\).-(@_MU_TQ"#-=GH
M^4",U/TTF1]@PQQH,%%SE"75ISEZ1L]SYFD%7<JHVA,#J6;+^S=[3O1^,SU\
M$086/Y1--26QP*P'%\1G2/C8O-QSK;C<9:8W!_44@_WC&#TS[Y3$5I!2Q_>8
M[RE<^C+_N+CT(/$5BW4"C3U[L$_ZH]$(D=<[L5U74G^F>NC[+VY'1@Y4LK7,
M>]MNV54:"HVVCZ1\4&.+5547O[MN)*)1)B!O%.:=ZE^=I:AC,Z";=MZ(8UY?
MX[93<O*L#0ZZN8!G;:^?Y A&E5DC#OU^48&H3.(UMCTMMXL];/1;Z&?S]Q^]
M47W_VFU>[5%YZ]+!BR"!14PT-T ,QWYN,<%"69P.>R/P!]L_NOP8KERMC.)/
M>!AAHO'4/MQK1=TS,:5#N>B':1LSD17_JGVRWC?X,O$%UDV8Z\X7;:6'0@6S
M<]I!CZ_/RI9/],P,R0P_@$]V_GF<'/?EN>1.>C3\$33T<+[:K]2)=?X&GJNM
ME,?-YA[^8[U86ES E?<M(@X=X2VZ/UBR)4?TU"\=D S;#=.D"K@OX(1-4Y9$
MDT]90-]HB:08%4UTKK"'25*!&>^UF_-2V=+T8:6GD]O[>W>G SNY=^(YJM))
M3:^RH([3)=4K^U'D@NL]Z.KOV^YQ(':(0CK];2%>.9)WH@@V1AQ9QJ@3D-W?
M<]*&;E6.\62R5DXOS#9KL)16_<G8-JG+,'TLY'8R5+NG[01QZDB5,C0C'"A(
M?(6_VXMD=M\5*JS"%\:0X,I3OAG?4CDC-T8LK<525Q-M7\LE*E?4:]%'SR/N
MJC=A;L'825)X9"><WIG"B%=[V_0L[A%[F\/.LRWQ)[]<!XYR/_RI^*C<@OY^
MZF$)4$%I>#['V/T]UAQGV157?183(RF/P'HP7N]8=,53&,4")[BUP[]XL>C'
M"\O[[QQV2P?>C8#5B5^L6.)@-O5AZC3QW-_IT6&+$F /N-XQ$J="3G$>E 7_
M^9)?+B?2REQYT.AU9!T\7&]22<R\3W[;HL?:5<Z-*&O1<$=RK1(>_#4X5W&H
MS\]$R]*\:.]]]/;;K0S3@;BV+CP5V)\A*N#6X1<@S',+@3<(=!%\V4$67;";
MJI7CL1>$? /.TNROGK])3N73:OU)0RMN&A1NS4?@V_<D2A(<]2)-"5,O:\IM
M3$+47AG:*'ZC..4^ZC\WV)/_IO;K739&^-L[I)SP]HKI)S >^Q<]]I;.D3B.
M"0$A.ZEOPE]NO%4^6:#H];'DD4?C*47$UT8]EW!36P$M]LCRZR9&PAVX2T4+
ME;T&?XMQJ0Y;"#NAWAMN']'T>IH/M=3RG%5G3%ZDI;1!@D<7SE#DU7W;Z D7
MXS1[S2X',9K=&]U#"URA]SN74@V?<1-@LT^;U] \<7*5.;!V<[#8N?]J^!XC
M_]LW)[5]3GS6^'W2X59W]IS)%]1%*F"W\ IZX9G,H*[VV%8PU_KA@YO[=3,+
M+P4YQ+JF9U5_]ISZ>B,\PN%^B%$#C3CDFL:30;\O5*!#"79AX(KEFK48,:O8
ME?0V\+9<]$>+!BC%K*EO6?XQ].JSY#<>B4;JDH2[=) 2.X1CA-?,;JU?+^3U
M2B)6,F6CP#X5M_VUCS6LY^,/.4B94<=@KRR?,8-GV"GEP*#IAQ^,T <!#-]2
MGF#6YSXHJ%F4>LFW<DW,V#B:!M[&BQ>7+R#<=0B1$5L^Y!OAF)'-VDQZGRO&
M5[FJ9O)_&=DF-IP24+QQN@$:O\"E+((7;)_*%I_\LO9BD-]7$1+I)FZG?==B
MXID<8X"I^A;W=5;GI%_K7Q)M8Q^)W"?D!1Y0@?,$XJ4FL:Q\5FNI&@)76=4<
M/'8S\+:RXO)R=YEIO_>=M^P/J4"IH:']BA0GH7H1^=T "P\G:1<BJKL5,3$4
MWK4FV6Y6\SN(/M.DP]XO <Z739_<C/2<8UO6X^7_9G<6YO3=4<'XJ[)A-[9D
M<14_=<Z^X>L32R?'&SBSQY\:[XG(9%FJF5D(%41]E7PKK)\<)ZIBNEAI^O;V
MSEA7X[7W._2J/0\_T&LX&YEXQ2GMI<II:WI&KU[^("10U?C37ZY](8X*U-XL
M\%E")P3S3[6Q(W@/1^<0!EATV)ZTN\)8Q06M7VN-4OP."#-SXV8S"8<77:KN
M%T4?_\%$0.F5:?$!79\0KNWFIRH2GD2C7!H9!,9K%29NR9FG'B7 _KS@XV\^
M,Y;O]"IZ]\WQ\URTP'F -H?VTR63YBX22_(3V>5WGI.#B- 6A\HY]4Q#Q-<%
M%L51@[(/QFXC[;8% @.Z=&E8O*F_H:UFM!$?XX"YO+FA17:MB"9I;PWFDN3V
M8VTWS/]ZARI_TL35W&B1]?@WN='7:7=TL1VT7>>RX;@<@@DE7S'.=^,G7AY:
M7 '!3E.!:/O6TQA<7L+1VUI.*B"\R9@]AX3C<\Y"3[]!ND+"Y*\N8>M[E(^"
M=[I:77>?8>1(S%1 \#$^@=*/Z8&2(5VUA[=O0<4I,\AM5PP;?,.FD@J,1ZJC
MXY_F48%[-7^"^UW[5RFY\*F]7VU]Y)H(I/U6+.U4USX?%1#GXFY3K[HE)MK.
M#G]2"\*R!WR;PT%.-/K,$Y6'A*EZ]E(M*.TGLF[K_>*AXN-O0V9\*MY,)F&&
MRH%[E8<>?_Q1E/I5X\M2ZE_@W92[&>]X_R ANJL'$P6Z.EG'7YFD7*)AN$=G
MK5N/7"<:I29,X6FI0/GJIGZ)_WDEU XI<M4@E].#>/RNTE3.F4FXY>-A9*(Y
M]*2)^Z:9>Z_T$1Q1&A\0> </1T]F)#Y.?D\I+%S>73<./BN^,%,W%0LA.FZQ
M@,/->=:7& Z ?.X__T2=H!M+!;C;H"0F?%LA&H$RJPS2G)\Q*$"XS&^?GJS-
M)+G55]?7F#CGF0D("S0D27)*TB&S4O@\'!3B:84Z[*0YAU@CVQ>?IQ1:,$5U
M3X0+&ZZ.Q19>6U90S]!6+3((S3)/]@A7]'J_Q"K]7JC7H%C@3,_-Y6M)&B)[
M/_8U-YOY,QTK+>>GI\_,;/^9&7%(O1I>X1A-([K-J7[6P>0V?P7B_I1X7_C)
MJ?>H.!MZ9LN)%EF);O<SMRM^FU$FQY[)-HLX;T23=]\,B7K().XFR>?[\5TM
MBRX[@PXEL1XID=3()=A,7/TF,P[#3'35FLQ+6F^'0@*5$(?>P5QC*_I/:X62
M['TB[D0(V<5].+(:MJFQTLFVZU7)NTT.@3N6*]VM&O/YP6Q$L"YV?R&VO! E
M*V9W.&4\OOSNKXQ)I&[V/&LM+0//=Z\!Z33^J95=^?2$ZL\CO6#KH5M&**,N
M%+SNP!$+E;H?>7R?XTIQTC'3L0KIQGGV+_DMQ7:)6FF.QI\7EB^1D91=[45Q
MH&-*G?6Z#.*$ D;2>,L^*/3E>6/I-3-3#_*^SNH1DY(U@C3<"!+8P3FFN5G$
MWX[JV]=_<,;@W*ZXGG_'WD*WP[*-W#0Y4J]XE>,,/1]\EIBI.T$1"[PSL4MF
M5 ,'?__]*8/&$=$M 4;8QR=UKJ]Y&H)Y:L^;I4M]?2S"K?.5"GR";O3+C&I1
M@3.^I6<2Z_V,*<)3V%#X_N,X]^<Q&TH[<U,%) ER&N4,Z>H$_U0@Z^( PJ>^
M/=)THJ*BME6MWS?5?NR/C\(S[FYY.Z[REGK;CJ<>NC?R<,]\PLI3C+J>H\\/
M]ZG:5KZ;-\MV5(BP#^OX]M"T<?FMYCN=TS?ZC+M*QI_7EMHM<7*ND^TLM_-.
M,INN57K/.>D9_+4WSG))?F\W\\L;M]JWX-$4X_G7XM?DYP.(!='Y*,"90[P9
MOZ1+0$<&\_[FOC%J/(]D6Y]*_.YR2-/T\O'XQF+R$_V25&<>M0M?J]337Y?6
M31RBL)B-'OQ6)Q4X76,3GBV(GPS'235I=>'.W<'UTHNC9;66)8JL+!9:[FSS
M)BM8F%U6?6(Z$L+.V_8VMU6YL&LC0:37I'<2G>E851Q2FFI;1+AF*[H?895F
M)U*F(W@JU/20Q448D3&0T?I ^ZDQ;_ZEZT<^FN]YKA2^*M#1T1XOF^.2+]G9
M_W+IYT$!V\['3<'FY&17K6G^0 !U_ F]\?#3L18+@J!V8[S)Y;_&V=<:8F>G
MI=.TV+"QO&>6^FG&B^TT1))<Q]HN4WHQ=!1VUP$<AL^44!C->Y>K KVD?7NO
MKLIZT-'-$WW)"S +7)&Z0??SC)KK.H?( ]9(9<9T7-'C&X%B*7K=MHX<;_V.
M&&H?JY5)])MG<:I),$<8?4!Z5G=IYHMQ:ZCVBHO+B_+S%W"JR%YO[IENEJW6
MU$]YU@2S0"=5&QFQZ+'H73IE^)#%Z%:[T4, [!  H&A0E-LVOL9P/3?D^%*V
MP"ULD/'-2UY.4H%WAL\7RT4^B^M%>;A[":3\NLE34-F4QM2VI/LN1:;NZYVT
M?F-]G2!XUSSG<*!@OMEO;H[1I][:5W1C51T_K@X+M):=41)U4G!0;FYT]!JH
MYG9UB=[YO:Q@#87&##X_\&6(=TP(%T;,=:9=CI5L*'H8'<YFTMV+JBOF\-"4
MC,DPCO5+F7N$9<B2_V9TZ6JADI"VJI"&@+V?^9^!H2V&T%\S\]OSKA8-/$UU
M#7&YV?,XF0SZW.=&2VE"M/ROO]RWM[_Z*E387Z2U@'\\R?ECAK/,F/8_?\>O
M:\:T"QT[K&7)K\4,NOU1T<%T)'4"I".S-8@_QF941BW)ZOR>H,/1W=G9LI+]
MV-\;E_G/5C9*,'>?']E8.'G\E%7$PLE'23L/:M*[@V^T\5K9]&;SS :56UMF
M6VW^S/QZ=/9!=]UGT\\: K^>+@9!50/CZ4(:[HH-<GN$?L;7>)3XN RWE$YT
M/G*U$QB*0J<M3Y1.#E3-$-\%3*P_NF'JDLI=7^CGY767/B)<UYE#SZ#9]06;
M0J#.!<_GK])-SJAB>,[0L0.+/Y_0OEJ3'IZ211,E.F'"]4TU!,&(&I5GC-_/
MU8ZNF=L7C W2L&W/.-LYAX;<MZH2LL'R-KF(K)4^S'M=*&P:+>,ZFN'B73I:
M8/X^64=,,\O<QY9_24AU'J(A6^V\*Y-?-NJ\ZRS[5V9JT0\9VL8 3B->01XE
M"&@[C!,_G^=S(<)U4[''>#67#F8^**+%KXE\?:^_X?DTIXE'.2+@-D&@J(IP
M.JY@W=<V1JRNU-8-R5#))IHXU\>;Q]1A3U/9ZV%QR00&%1OX]-8DM'.9R'F3
MOE'A$9XH*L#)_W[&R[-+O^LN1/!F<G(JNX),YK,O_7>8$OAMS_0=&-KE55#6
MHLT/+\F QXZ4\WX:E5GG$N]EJA/1ADTR*CGU @<\]?>7.&F26 4YD_5<.:XE
MX*ZP>[>^T/HT*;/ZCL."2W.4<=:,X^:/*S6L]/SVB8W&LXTZS]6T7?2LQ.-8
M-8:]G17/<P\.>Q<WB6<U!F7FKC;IH,3?QZ<+U/RL>U556U;N:OYE<M/5?-ZX
M/O&NSFC-(/>T:$V68M^#:MU&U\*9VX[/&MAP5Q!+L9PO9I/G)@ZOEX3QG.F]
M$&M[IH"MDRF6AZT\C^W.C5C]WWEL!2,\^6E19K[F$NW7<Z-S_BT%_X=+.+ZP
M^+M3DQNELN1'1^&JOU'J9%[1@M7]2@NS[]-W_K*:F%RL9.2\<?O* %]RN"K_
M+GH >1'9\1CS6(QWP,R-T8I0'RL;I/+,;DRF_$J'XI>/F"#&MSEUG\8K>+2,
MXM>T/RJ]>]ZF-U_9[!;7^CXOTFN#/&$FKO?6(;O3,,_:5%EFW>"#\&")9JU6
M9ZIXL)F&PKC&':G,Y3![V>5?9O-ZR27NLE\_(2"N'$GYE49+.CY&_*UY!3JC
MQ09I!-TDR'R*'5I(36+O#@['>%^PJ2E#*<#5*3\;YY?U..(,CUJ2F7WB9\-X
M&>,7OCQ&M^UNL1"7T,'S\)J530@!TFM]@OP*=IZ([(%=QG.CK[VJ(-D3_N2(
MM8AYE/!I,%F)G\-W"50F"9F?V)*98KKG2,_Y0+I[%7D6\\R=>#T?@H/$S-\8
MQ]@CITO-WVOGDV[@OU[L65JXC CZK@'9_S%PQ>+EN0T!C4S#Q$?]$J=C'P)(
MLS9:TBFBZY$<26$TF)4D.J*3@&T56VY,7'G[P\6\KM"G>C.C#>W?8;WSL/EZ
MJ,;-7%Y^#U5.C]RBPZ&2YV!3&JG8D=C(%L9%*7H7VU](XV-]\],W.>W:1\?8
MKLG.X4$OM@*.2WAYQ8D;IGXE8]UVKM^8/@9N37IE7R]6?82L001$CF9IODO)
M4S_WWF%*PQ8;TF52\+HT_5'!"_./$BR:;$W#WMB[$$VIE*&7QX_?=SZ"74;X
M!%^]^3;PJ> D%< *47H41N'UYZN#R#G>.R&PP?TXBK54LT<-KO7Y)TZD,)8$
M=",\0JA #HC+O?K(#Q03[E)8IDU6]M:._"=* Q1E@FK-4X/BN5%57:/[R2GD
M5 ;+L7U#YQU/_<(AF*9'F$+!P(M]P^(C8<-BKXG2C>).5&TYW-F\D)\/XFQ<
M**I28+:]8XCB]UL1TDJ3J^K&*UTFE[4Q[=)26.I[)$ PWXH\_(X>521-XX7H
M]JN(&O$+Y]J$D+^#N="C+I^'#Y#[(U0@V8;82@4>78&0[WN['&@.PD?$E"!5
MYBCT'[[CYWK:RLDU\)_?81+([W2ZX"P0HX9^*XH]G@4$X815URE*@_HL"2D,
M>'Z0WX /Z5(PD^6\;IM#]6,'1Y1:WK[-E^MSNWLKAT9A"6,OU_RI &J,D'->
MKL]]2<G]%")[";NA>)9R\Y4J!M45@WO1: /I*[KM)CHRYY+[67:\;A(G+50?
MYH!-M7,P\N7;*3G:3R,7_D$N9IJ_V)3&#J#"^Y;$,W,0KRP)==6E",]591ZN
MPHA V^+?)DG$%YTW=RZEK1W.],J+N6T]TY^AYW<M9OO$:/.QB0I$EI.T/ZSY
MGYK8K_UHOC:9-#WGPLTUCE*?7 RUE_SJ3=;FR2I;1DSG296)^TI:>B7N[$(K
MZSO>PNAUCY34/0ABL(M60P$"0Y&L."YB4V/->$5!V[B,F8^M[7[U!VN;(5ER
M;P8F^(]:BD[(!@ 5(NF02]OD5R\OU$C$*_,@%\E*(**J^I-ZI&B%B.G@0(5_
MF)#5C:I'LBCS8*%7B(V/IGXV1J]WKG)GX6I&23)I#RV?M57Y%<Q578"](OX@
MN..: AWQZ1VZ88=_(UI.!111OK7!R#FU-LS$O,[]>0DY+6S<W2.^^_CRBG<O
MO%S/@1#394JQKJA*!M_N>^]E6BL(AB"+WC-M[RI<..2B9"UF171/3J\17+)%
MQ\7+E/U1YYZ8P;B'""*Z]S_4$>)60DFEB!J1F/PZR=D9<POK@LW6%H]SNLR4
M+\C3)'NQVE^UA8AR65<+%*L,[.J8LG/9=T3L;XI*ZC5"Y*LG$Q/+[XFL5HGJ
M,\KB,5SE#:*B]K6BYB$WD0Y#48?IO4,A"PQM(JX<AHKBU4L)]+,N,W69SVPV
MT@Y3Y.3,@W:FHT[O53<U5"7]F;@BP),MO]UQ6Q%^/ECL'&0_1ZX0F]ZS:;"!
M/*ULDGO%ZDK[7_/P97  #OO;L7/.^LL/\8=#'Q)=>"C#9YF'&NIB*QQ.M^IV
M4: C).E<9VX._)]WSKF_.4YG.N<[-:F&V3&JR&E71KEMBHDM_2Q[V/W2LR??
M=Z!9J5IRA'B_&>ER=)4>S)1 @B.E#'Z"L)L#\03Q2*SN(0\5J#&A<#1O473S
M*!R2\-^1E!$;HLL6Y@#6%I\; O/X?X^LS,J].YL;/WYSBIMG2B;K/.- T4;Y
MM8E:1BN84F8C<F+VUE_][BIP.NGBN-CM%6MH6*P3*V!<J^GMW"&HF.IR)U7^
MVKA!JF9UH8[0%[UHS_<&GM$ZVQH?1TW<^.O=\M-+W22Z\1BB4S<5R(4>J2*Q
MI6U4X.<A')O'3'F-W&0!):PX.GZLPP(GMRF-OXNU')DA=O7-J+1]X -D!F47
MS,8?L_4'Q%A)/K.>!J[^6NPVY2QZ=%Y%H@.F@"_LMCEGBFCN:!JLJ,]QT:N>
MM;&09&#@U+I$^'S1P@^KK'7V<Y*:1^.MJR@E2/:3AI9@/N%.AP,'$>G.L?V&
M]QA(0J=)K^WJ#_7L.NY4_U3G'DV]V/=Y?Q14M0T\X[!&!4)-'L7TAM$M.86L
M_'7-T6[EP7_JE /^@P5;UGL7Z@6[$B*WNPJ)A>THUETN7\J/7R,U;@'M4QR&
MAZ6E)^_;)OXIO%!3\3Q."IC;/#>\LW 1\U1K4ZO;'-.Y-3W088X&K0.=:>W-
M\BOOH-=E1/@2M&X+=$^)O=Y2S6^8V]9R=1#0_ZB1<L&70D/YPD1TU*<"X:6$
M*A+I'G&H%#-;@:XU0]9X#YT=Y!&O:WJ@#^'5BO&!F<R$N9Z]ZN?K<57U'47Z
M2L]WTE]6 _[%,[:$B57#8G597)D5QYZ\%^^^D4JJBZE?T4@$\KV04&>:S4NT
ML@!]Q]"-WLX+WHZ#H@_6^D<["A2N33RXE^SM-#V=OY'JDEEP1N[2%(8_%?6-
M"ER@P(*_VS"+UI"5.C GVZX&RN(C:F^XHEF=_,_UO2:I_1_LO7=44]^W+QI%
M18HBO4A1Z5V0WJ(B74!Z)U] NG20 ($H5;ITI8KTWJM(@%"D2Y>>A-XTH<0@
M(;GQW'//N^^>WQCOCO'>'^^]<3+&WG_LS*P]]UQ[?>;GD['6FE*NW8>MV#Y-
MSC6S=WFCU\+LE&Y0I9FJL$.$<6J(5>WU?H(H3O#B!=X84^S+.];Y*X%PU\T,
MVX>Q@A9XE&J%_9-0_?'E"63%I^<!S-2EMIHYYMQJ0/41ZKF3;,*)FV$D&M=]
M'\OX$,SZ=%RDC1O^-%,WW"VPH!6L9"K:<EU$9].L'+%W(I2QI:2KYJ[=DFOG
MM5G"4*%AV]68N9 9,WYPH?8LKKR #.H2^>Q%>3RZ\LS$1)W11 U-6?G?_WFS
MSR,";K$4G*H2 2YU>.G =7P!2,, %!Q0($<:$^K\EW>(@"5ADHW-;R* ?^I?
M&3_F^B_3_S+]_[KIPBCA$1$0WD#XMGX;KUL)?C3$EMRO?PM<]:S]@J^A<)_S
MZJS:SX\!+=:]X/I)$1_MRIY.9I'<:$""V1J0H2NP%"*!\]F OK,<Z&?J#(S
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ML%N8L1>)I,4\&IO.T8-:U*@GZ4;D";?HE5#KN1NF]5<.^TT;EPO/N/EZ;R>
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MRN%),;>Q4JQ&:[FS6[U,],OX!LR$4JG($^9 :/T\Q0%0HUX%FF:(BZWNP7R
MV64.Q*!(37D["EH(6@4NB@98E7-G.4;%.K;+Q/*8,36>ST][/&4-=D%/WL:(
MT=-RWNK??C_QT*3<I";+1^P1=Y^(DQ5I+":8DM.JES+3,&>8&&3*,%;)3UZ7
MC8^2/MQYOE-5X!S$Q)?0_CD:)-+$J%>C8+X23Y5C;\O,H35H[(WKE!9<J)YW
MT!V1LS L+J0V-F4S"IM^!"RL%,8 G^(<28"8T#V5-=@(>86S*CE0P.78IB%;
MVXJ7Q[HY4I_R-Z,WS=XOYVAR2Z10?UOPO<R#\\R0WWIW-JY/H%+$B,-_$V@C
M>F'755A*QIOSV><A-C=:W#I'XQ.65W$Q\.*UB=:H!^(B-]:HPF7)KM!Y+(\3
M/AMEZ%E"W'M:!&?**U '2MB2ZU&N)?)"X(36O.<O'7A-'X*YO-@:2SL<64Q+
M9&%_5J5ONZ+;F/H"[NW$%#=^, GXF9-@O;M11BV5[;_%&X^5+"T]_[RE5\Q\
MQ%C:5+2^HN]J5^7:UO:Z.#['2N? *B?>MZ8E$@T7'J:X=9SRH/9NQ+CEER_-
M]:WYV#_[:R,3\_S9VS]_NAS5U" 3/(/*\ITT"V,9Z(XU]^-N:%V%T5?#$*F<
MDFBFCTA]1CS3947W _#=C3>),?U>+.MNS$NU,:B@%MHOQFGZTXO9.MST337E
M'<Q/$:B@[#759B\0M%>(( BN7;[@0G$=S6#:!FR99XMC"'1>-$I:UVOK7%Y:
MB!T^@RU]C&-%?ZMV^.=3N+W<LAY$OM=V2J_@G3$3HU:?3Q7<8F$AITB6;;KL
M:4*E79[0B!*.+4/"(*!(+M0^G[4REG92KBQE$,)L=<!>:>!_<EB!I*M@%#+(
MLVR(@KKJ=C^WOA^36B(P^6.V-O?N9>B4D@DRF:Z?#_WK7;/RZP=?(K-5:NPJ
MQ-8-7^WDD!TDF)Z%/=TO0&O (K/9X\LA-+AQ#!PQV,0FMIS'/["@,)#S[5UY
M+=:P.Q_PBLG[98J.Q/W'J'J-0Q(>7*?$:03"$,E'->()IZMZ(FY8$+-_A=C:
M_)[*UF!^!18WI\WQD7YP<6(7$V$!K>KB38!AG3F0+MI:%PKLJJE.'XUK6U(K
MXGN[%J[3!)IKV>CII S>*@5AU^GL8.LX55I3P=K@#C&/K&U:U]T\)17A"T5&
M86"LHN_ B:V65-B8 2A>MH"$P^5$0./X)'9A !K3S7A90>#0*ZRK);#VD)(
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MI9E H36,XS)[Q)'7#R!V[3M)*9-ROT(D0517O)>+387#QL8%RH2G\I&K3].
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MPR@1:^MZ(_RUUPZ<_.=DM!8NFDU@KQ%\Q!@0C^%H0T_Z,^#P$W@7F=\L>\A
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MKPP)A#S7YR[KW?LGY5R]" 1]A1]#Y3;<ZP.J4$)X\.FA.8W@R@OT-]2N"U\
METB(LW.@!-D5 SAUA6,S4')OJ&I'V*B+X+_CE@U44"^5(67ZPF>3#+OEK'N$
M85.HFRHPF%D)LB3@?&<L;XI_"'3=MV=%8%A 9CABV-]@<7UB<87UQ@@Y:^*
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MQ:%A;L1(6,]<9QG6=T;MN6^SNF/DR(]M5J"4QJP.1 UW^91'C<,XM27*J8$
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M]$34T5':,>3^@L>>"2A53F7^ +;@J$Y 1JQJC>L\40_,(,S)/PT#9HFW,I@
MK^X%71>A'Z]<@%E"A%C^-2 /AW-V >.TK_!DE_JJSRY]/;_PZ<2N&9?E->'K
MY( 495#9B5\%?:Y3"OG>[*TZ>FX1"KP^F'E^KF_@:]KW8(.2=;F7!7(?KOWS
M*,Q.A*Y@6>@FXJ8R>8DF,(^C&>-*O=] 7^.)Q0_Q/^-1$?32CZ"O'U1!$VXL
MH,?/@?MT?ONWOU66W\\Y2895!=#;"7=P"4.7P,#B OJW&0SXW(+XHZ>K<PPA
M=GP\AGPO.%!+AOP=IO'S;- 2O0;P5/46!#7;D*HB-WMT?BP##08\Q/\5[TPK
MB=8-"IAC(TYGTDY3PSWOVN1V"CO7U]=UVY[Y'G-6]/SU4X+\(.=>P5$>_CYZ
M+GUO@ [ F\.'-T"9ON:PD\94-X!,!(&5ENJO5Z^'E6V(BZM]C*OY[BORI#QZ
MP> #D]J,--K=N_:!*Y0IO>2GA^)4D,J]R9"-Z^;J9BJDA3(F&1])<XZ%8(?&
MH]<IB0V_+@Q,CFA$J']2<N[)RG%+'GZOJK@KZ,G+=^.M^P^3CJM2*FONDNY2
MZEZ;4Z5\AG^GP.ICR"D ]#_=64K"?_7H@3=M=RDD-O/;%J&N8G\>\%05,4^I
M+ER0:NR8S907L%):?#'E_*E^Y.2M?IMF]KS41[,'6"J/-6D[P;^3!W6S;E:7
M'ZFV/C=O0H&GMU]:]LNGU):]O<G#TM_2.GFKA:5BR:E:B\Y.R +;RP[%'#IH
MDQR[;%W^X:LKP#'$:7AMVKDU5=<EM2:60/*(F*OA?VB9TA#TJ'CWB8:)98 3
M)D*OWU5YCTMJE>4BZ9/M26S3D/)#1>)F6V(PJ@A[.0UPB)=6D9Y*?NTSFZ8]
M>K5#PZ[,_)W[!R[HCQ326#<]8T[MS]*8:5-T/]GRC 9?&^CF[^67V&*J0EE\
M#I"K0841CQZ2N#JGFEA>2A1(CNP8!_EQ9[H_-\]3EJV6S#(\@H/L=&H*!"4.
M;Z",_GU\$$J<[8O4LVJHX\<D%(S=:)J2;S?S#.!OKE9M?AGP9*]-=7*A3K]K
M01;=SMP>=Z1 V8]NAU'TNA<O HP9C0(P3A#>YQCRT19?["N]Y57QY9-- 1^J
M)=WFTKAHNM';=/OO-Y$+#M=QA&U0<K8+SA+UC^FA<M0,OF$@E@Z2IQRCQJ+D
MQMO%2#4B!+65H;F=+LVFV?PVZUS3X?#U"9<YER5?)6=G"Z%/4K(C3?I/7KP3
M5DCPM1GX\8@P\0]15EY$<3CR]:JEI 8Q*+2NX5&.-\Y-$_EQ;BC4SVUEX</J
MU<A:PUX^WA3P 2-+4)_V+!_),]QAT;KG]7T*TO&"21:.^>6,7KY7H]1XJ37,
M\OX+E!?TQU9_'NQT_LJ4"&L@&*YXY$$ON#AZ(97P4;;IU;HU>PP1'?^W;(/I
M9:M.GHE@ &C?KS#P73*;(9TQ,#IU+I5\&:]V3'<&H#1/+"G@')*7J+"I3F95
M'SB&-,+[%H*OC:OL3ZBL[4JB&'TJ_EHC7!#BQ??RK'VOQ!^*=TG$CYS;MS[O
M9J-]>G43]J^& )^29,92:=I'=2%+;-1[@*BF/ZZG!M9C5MF]S&H^-WTOW]J"
M8^WQL(];P%'5ISHCF%GGX:URXP!TX.6;?WPIIR0<0QZUL\E<#8G,QCDQ:*M/
M^TAGYCI8'XR8#''V]J<^F3XK==7D=IETSJJ<KAX#44T$FD]L$-8@H;()+^Y#
M!<[AY$D/= -WO@7WS);%E*4XZ$(5BB18<VP'ID*D[[]X:97&SW7EPAS2^;YP
MP>K_.EK_=Y#+P=_%SUL/P/E0^A387MC1VQ SD6Y$XVSW@H&33O"MR?%W[[0]
M2ZXM6E*$TWQD<L7$3M3:_M/T+J]AWM6IJG>[Y<]ZQP,V=>@+M^)D@HGYZ]=$
MR:D4K&VNHW6N9J.?=?8CK&.NT1#GLR8S\5>II1* LQG! <?D=2$U6P-KH%%U
MGD"2LNN9C9=AR.CVD+3NNQLLV,9G)FW_Z8P6BV,N2EX\OXU>J3D^TV6VN?#_
M(1;+O /^A[#=$I(D;"SDD<;5UE9W\Z9EGM?]2S9W3IIR0!A$2;D.+C;CN>,Y
M2O7/AX8(TD.$BY6GSE^_&)O9=\++[^O<7D<AK@/7M%6#B_#S\T6M_D=@2_\?
M,(\PF!3+TQ#)\GEKY!8G[."9.Z-!2E=5$,TR^BY]65+V5^^_4QJ?4#F-*YGN
MX'!L7DP2K?UW3ABSY@FCO[/_+Y31D=%-NPIX]0I)-2TQ(*NO4:)2\\/4H%7(
M8)OZZ4VK@U$][NG2;U]&5(R#&"BBM[JGN!_X>XI#N:DW <:G=[-6^SO5@?QG
M;]+%7[ZE2"0V%G(]\2X;EIQZN#5GD>-IJWH_ZN0940;AF?S+U5M2AVJU51%&
MTOY^514K;V8R;+2\=S^OV<MZ]+;S=Y,6E91#?L3:.YOV]9<TK0TSUVUS\M5Z
M+T+9WG[()=7BOJ/_@Q+3+>:DEEUVJ%S@ZL.7S*(? -'FG_8Q-Q(*=KG>0YZ_
M^1YMKH$;S4B! ?9FXDN]!S.YATHH%LK %B\QX(2IRA([%5WLL/YXD6_R@5R2
M4\:F\5;C84M'[@4>AU\W+0<OW$__^OE)+@E_ GX/E@H'+.5D[([*\'[05 R_
M-I28<0%,L,,0O;J7F#9:.GDF_UB<)012?%IVYDD*#1Q<?;[ZQ:T=]C_:6E_:
MVF>V,U&XF7=GH!+%LO-<"X;RQNUJ;(6:MC8RIC#'U(H[,1737'6T1:MJI)R(
M%*R*2+WTZ?>W6I0>B<U++_JWY#M1*6US8;Y9=G=*ZZ_P%\Z=&2P__J;)CK$D
M%G%P?/(U5:=]PAI"B(D%'8XA2YM<Z,8[V9)9T!BTD+R(Z%,Q?/2/U@R1BIU+
M[2'__%+._&9'.H9L^5 <M_=6C^IHG+31 EATE/@2501DJM8GX].+^)J J4ED
M?.2C&2)K,^;)6SWE$P$GSS[(]2JTM]#^?7'+=82$ 2406PZ'R@)X'AJ]W@=2
M<8XK"\1I&B?5;6;T0ZGO?7M'ALAR7\>8;_;=:$[XG&7M V*FJ!'UPS?YH4,)
M&M/1H8 S;:@3,MN4(;PATK<DU"F[C@%RJ?84YZPCG.:['V4N+.8=SY_LK'V,
M^&=SXL/)]:TB3WW]5#:4Z:>&Y!>H!N[<F2ZW4M<+KT<;JRU[W8(N/- NM4KG
M9'7-3JFBV)#-W"]IJI29Q$E55DIG!GP97 /"$E[<FDVKUU4?1E9K5.:Y/XIB
M'O[YXT.\=9'GU1D_@W*HXEC#.YP0_^<N0Y&A:O<?.23%O_%JZ>K* [<+F2;S
M.-ZZ;37CA4?2:IIRL5WH#)Z]O$ ]/[\ 7D);3C)+!')&\E+:Z5$.C5+]FY8]
M5=$:W/#_%&:=U?X\PS>CN.;]F_^/U\+_N8"^^A\@XV.XQ?3(:*QK*<.C" _@
M'K;2H:CJ0"GY5-2YM?W[OW1N;'8'^>S51/2JGYGY#1?_]67LG:N1?VVQZ(M:
MMX4?(WP_1&U=IU6RGCZ'C_W](YAY9\Y*0;5/D-Q+DZ#"24]0\#%T>-+WU2(\
M%D[']YIKPBV'BA_0<Y-=3[: ,9*\9HCR3QT-1L&P0=Q77ZK;4=YK_);/LL5U
M^CI%6%Q_+#B[N?N_N =3W)>;!-\A>QY#WM;-:OWG-YP>/WLEPV%!;?T:R7@@
MJW+"'Z,-'<,3+7D8<#]N>=&V5S-^'$-FN6$ST8*?G+Z$6S,Q5%*U)OD.H6-4
M:4U(D#N:0-TOYV"T-O-BP$K\J7C9EDV+C(/HO-)FP]0\&7MF1 ]@T[@.W@O'
MYW4,88-%5W=ZC3$\/2C866)$#\[]Q.\%N"H=0Z83_NTPY5KB4VQE4YYD'\IZ
M^:3NF^?ZI@@H6+HG" PDHXQKD5FKI+&^#8?=$9-5J[R)^=XNQ[FFX6VUO:K/
M#TV12?/G[A4FQ0DIH;1W!(J6*]U^9-Z[$SPW+3VJD6S3\%K>3%!'C,W;QN:*
M_2W'VE7K_:A1]M@8Y]_99B+2]36G"OE-&@+NK/?GYK:TE\ILE#7^BFS:2T'_
MW88>'5G0I#,:G8XA8TCT]CJ:8@/ J5J'/; _]KI*:.(M/-4] PS;?P;_68>Z
M1W=)+]%@'VIV;S\1\2<@$ Z^_@&GKEX]:E:G11<?0^+H^NROPQ_>K1.'1BCE
MH]>HTR0+8>2&C0,9F$G@39( 9C)U<L>2 _ZHS:J,0;_Y?GR8(?=)><'>'K'>
M7$+;8LSTC6L?9/"WW1\"Y[O0[Z$]&6= \G4PH=JW2 &,)<'90*T^W9.3LP..
MA;5MI;!S2+Q=_<RN'TOAY?5^(WDF?%U+WADO)N')%R_K")L%A\Z=S4J=+*Q.
MBMT#\OU3;\N2N@B\ID*"<K;?RTPTAE1^3O2*YMRKNI'#N?KC1[M39."CH)37
M=T1G.TZ+J?+.OQ0M6\]BEEG&@U)V_=!$V"GT/=P%))[8DD0&T216IW[T69KP
M(M6R8'%T1>$9C0?,IUCTZ)ZFA/5B%*P:.R9*/@(M":H+)MNW.J>7_45,IA<)
M-E/[]E\M!,!1?&0EK0]QGJH.$(B&_=LPVF<8!]H[%,#'TCBHT*.J3ETP'P&,
MQ32ER4.%D:4(,+>6ZCZC DM"<(>,B/0?1"6\6[/EUSY I%R:0ND1#X58NCZZ
MOBR?\[7]&.9FN#[-#?H 9!KS+"5[H%.RV2_C*_369UT!1V3+\NI3;7V2%$VU
M9C]YF9+?KP7G]#Y )&C#B=7HA.JW&U8^PKI S73A3(=Z<L@VRQ((MYYHZH#;
MYR/X,^+>/>*D,6]0FN$GD*5]!9C-AF4=7B? :W/\T)H:1%&(;4*G+4I,4J\7
M@PU[SI-1@N"  QA)<KF\L=P8/O;,,)G*0F'[MJ;>*3KY(+0-S>.SX;O(_Q'(
MJRE'?KP+7926 <+H61CS/FHR7#B%PM*KCGB?'UWZ&<47<'A[G<?Q&[[1Y??<
M>KCA9B&Q T92Z&6UW3>WB)WP*[CGN!\=^D)66\Q#^%5DI06%F>E/H?D,H<=-
M^^YT.YHNB)/!88\JE&TG:''(#N+ZZ1JHG9W$"N^.X@,SR?#SX  1]ZSI&"*T
M1E,#<#':7D0SPSX[#/,N_JQ\27[X2DLE4@G^O]'UY=%0AO_;4Q(EC7UGRIZU
MLA6::;,EA.PQE;UIDFPCPQ39MU"$&+MD2PS99F(L11)CEV5&0LB,93PQQCM]
MU]_O?<][SLP_SW+/Y_Y\KOOZ7->9\]S/4013%6M+0BN'*L2I,B!RPTT@\'23
M\H8//7NO G8/\E2W^R/D$,J4C@&T:)#N&:$6-EI$)U0U;F-N(88A2H:PWV-%
MHG^J&)CK2!>SQ850?:R&6RP+EIM4MG=@45LF_MS@&W!^DT+,@\4)BVB%$:T]
M\9_P* C52CT!(ZF9R$%1J]T]CPIIAQRZLU?*.$*-&[WU#>8%B[$E\/O ZO'B
M#@S'>IK*])$!//]B5EA9D7>66F.A%_XDU:65,K99Z6,GEM6I5ECHY#T1"7"L
M;@D"07/[($ I>E5R%A8]PX5V%EZQ W>H!M&SWY-:,+NG4*9DC@Z" ./F,%.&
MH9!-;EWH-+N#]BX"3,F"K!FQTQ0N4S=0&)/FVH9O+:94O 4/*DX''L>[Z&A;
M6&ZT:;3JONO,N 08%*#Y@>Q95F$'@0*SD%G/539:^F@[7@[H9JF#*#M'HSBF
M&%H8'K/\]QVA3$EJZ3.T*]E'8/R7XT$@VR3#:M0=G]P6IDGR-[,V&?1)=<IQ
MN@;:TR\@L#-/8MH,P[30CH =C3B;E$E5(Y(75H_F<@!/R[][-X%7Q:L DY8S
MU()^^AW C+9L2?.,8)[V@G(.^B"AYP ?$V!KUEG/A/HUJ3Y,4NI$W3 .!CC8
MZLJ_U"Z\E?$4,UN.J6OM#M<WR6.H[B7KV]!*2+-!;5P6J_V)!#ZT.V4M*O<8
M#=OI$X7APDL"Q.ZFXX2YWIE(IASUN^-VLDJ+2?EGZL[DE1%]&XH9O,-1J[,A
M0=/BB-.RF//*+.1;I>"ZW8K)K@&JD%ZUAVV!T98[PGBHV*<K^D%5P/N%CQ/"
M4?KNY4#[)AI*"ECNDVF?2$Z:&V&(SR8:M<%X TR=1'U:G*E?UTR;AL(@\.MX
MD=$ (9I@5(WKG:U*D("EP?_W*]C]=PNKV?ZX,)Y1?38:!W$B**[E)$7/H@;A
M*%3.F=O%G/EB8B.7\/Q1:E>JX2^;@0$'8^EF,25WD:]GG\V)MOOZOE805.PY
M:W;M;$):0J'LA'=)%E*3I)7O4B^&DS 7P]V"RH!M<^X)+M[,$1M2MGI]SZK<
ML/+4Y6*ENE^7-4JM7I//F9]YX2XJ._H4K;*73O!,#O<S"* VL!#R%"V..1KL
M^RO+-M*KZ6V955'BM9OI-(<7+SU,7CPWOF >2H]3\K8LO'PTY^C--R2GRXGG
MK,)#_WBW\Q)RJG_Z)'_Q.T;B57'Q3.[Z:=]8;B'XRO6,_?>KJ<AB):#%4+X\
M#HF#>!54K0KZ4=>81SUG5S'T,&!C]T+8S SWIO+R9X9@==ML?T+@A.1KTO=?
MT\>'.%X*]FW:?KI>3I=O(DU[OWPR[I'PD;VR6AC3=B],\+LAEEH$Y61X .TC
MO(D6G<*V82+- W5KX$5M,OQF:SK%_D&N0T5:V(\SG9SNO:81W:N2PY65*WR.
MTY-.4Q-?BN7KFZ+T8N2N#+M%V:!^6$\Y&-,K$C7:\2(#MS_4#S#.YRUI;WO+
M!MWP;C+$NG)_>10N9QI364DQ2;UH')#B<(M/A,?71?!Z(<1",+$RW<.?*N!W
M]'G'W5.F;!:"Y^[FFUCEW-=_:QMY+O3NZ:+E+O^2[P7SPGW*U:1WZ-#V#RWQ
MT6=_:\Q6V G\U#\5V>G.0GT&/^71=:B,;'5BKAYWQL^ZAXUA"J*QP3;7#;5%
MD==$>G@CE:B%CFJ)@D=0:RLSNV9HV;VW89)C#"/ A"*RA=2V4L6%RL]R(4.(
MCN_?Z(B9-Y?4BE:JY2/;=4ZT^8EL('\$*/@0](J,UXV7)7S+]5/U#EV]RIXS
M]2K2QH8]\]63/#[C@P2V?9 W+*JI@<&/H.=0^U<3J1KMCX<(M80.Y4Q_R,05
M\NBSU06LV3>SH0([FD%2FNBNW NKW\C+7;;KR/LX/43Y%=7*G!U5"$Z!(:C7
M#H.$B3NCN?9BD?J8.4S<C-!"#36@(6:UY62%]X1%E&9E0"2^/#! .#8AZ#-2
M-OWG[8*)$5C=%Q*CIJ9=W\""W4CPBH[_DL<'[=EW0S?7,C<,]%713=G/2L]1
M7A<>L3:WX'::L"Z3$S&TVD*@+L51](ER??K0) W(QY:KA3&Y?J]ZN1\<\2^_
M)CKBT#GVP:XPFCCZB7QT+,N^['*"7T+S+U2+G*A-M6V.-O,;H8ZC&P(H=B<Q
MS'85P[I/WY,2!BZ1*P,VDQ,A=0+K%NZEMW)T'81"N:XV-GC]1)SRC$E6&KD2
M6E9WY:#R[:[:?9 G!E $)\+NPKF(NSK,[W#N,*7Q&?2%(2U5CG:,L.;JX8T.
M7>%8M"KBX<RXJN]CPH69M .3B% !4D8MPEX^T3WR%;,JK(M0JQX-8TF\)],\
M@$VAK/4O.KV\'#5ZBY/@3>.(WQ(PP87LQGX\>SWVO/8(WA4_B;I9-;6BO&1F
M=W4@8-G5L\I;S*/6RR_;V;9]]$;#^2Z,7Y# P,+3K]^I%Y04W<:+YBVT<KVM
MP:]'2H8?^Q5+F#N;@JU(47 )A;JB%Z?[2K=>W;2/':637KQV*VCXPK@Z^UB@
M!GTD>C9!S8<\XAR?L-[B?"S@%C:>EEDOC@7'4B8RU]OG;I4O: Y?PXP!";+O
M*[1MWXG<N^D]4FQ51X"PQ'CX][ ^WR^K'.W[H FQC6LF4.=',^26!;/4(2F?
M5,,6,/UVXZ/.2Q.Z=NEAPZPV2P"'#3*/#.R#/&;&K-:<: N=A"152!3.V674
M>*CN#1,"!/ZQ">C&?V@)YSU>3#?,XHHM]/-QO:_PXKO&V0.[K_&BU(F)T*=H
M6(%J<BJ2V=5D\Z1N5^^48<0*Y?N5'R_DCCEI"\I=FZ4T@@^CQ0!3ZJ^=-6NJ
M,!%V$-"QQ'OGKN^#B"Y" _Z(WO0/=TF9#^ZKS&8R?LKV<)$_ZSVMBAL/Q,24
MZE^XM<Q)!6)V]:\NSB>#XTJOF2FEM-],4JL\][581S=LL$ZBK,RO[?SJ_#S#
MF6QN$T]<$ $?UUC\.6YF$]]S^D^RF'7?NHHM],6M=P$;WR71T1QQY5<XXI(@
MXEOZ3:VZ]CTO;"&\BN2I8L#=<Y>=.3GS[L5C\YI=;A1]E'(8.V?&8?J-*<^X
M0$/7FY0NA9W.';H2-!?*IWJ)4IO:T[5NE"MDU13>)OSR409O;WUK/SF#P<?1
MEGLZDA&R>P_%:NY8J3!U5-+:KF>';W5<@+-.NQCRQ]CSI72A^D'#[?21CE<)
M"2=BVR.CY&*X9^I>6!>W_S$[+Z<44$[V7H[NK='Z-=I+):7&E5DEB3V:7WA#
M*=HK+^<TZ1N,A'GK+231B,DU+Q1T[5N:E?O/((VT*2O92FWS+0XY=Y:N%;U#
M72>>)P[09^S:NBK*VF:79LLIIXC<$H$*@EO7]9(S&:H 2XK/5D>LHMFIS6V.
MX CTJ7N1AFE%#@;'[-1Z;$W6?IPL(7QX(;3AT9QJA_QR5H#2*JUXMR'V9+@B
M.4KNB("E=+> 5^'16#'VJS82[#= $@>L+%WV=/V7+@O\_;0K\42>,^1Y)C20
MX"K2=<:9SR08;KW^VE9=,*G#KG/.]UR"BS*_K0WMW&N;QV-Q0-P&\BONWO!;
MFS+;BFSTL)*Y7XB?[ M+ P&;UV0#@1L'6%^.6?WW[(31T0\TH]@=3]BZ!!ZV
MD%6Q?BS5@KRT!WNI_>M&4T8,Z)>^)>7^SC[HTZ-MQL8HSLI3TF1I+' ?!.YZ
M<J&<;I6&8;GLIV/HLT!\0[)3#AN4\9CIO$S/(@CL@]RZP+L.@.(.6@.(X2B!
MDO(V=[8O+-/?_WV4L68?]&,"?VH?-*9S=1\T5'ZI4N^R64[&'FJ<"5FLL?5<
M3=D'R0_3+)AM_WR,T:7.CZZL@NE/?-6_U]3YB77RB:H&^\[.S>N=B7*G\;JW
M=_=!V(6+QV6/X_C/0(DD1JAWQ53_/!.RL%6=@_%63\"?!L#4A8X90<UJ=A3+
M AZGPJ)P/GPH/(:/<3F[S?$95VEW4Z_I-Z0KE?F^Z6MQQ5>K]J[#6=]:&?21
M.=^,AZ ="?PYB5WZ/FB9^5(P#+5,:!B@TE]2?/CN0=BU 'T-:CR1P*Y5/:']
M&\-K3ZQ *^&!F6)O,7I:_F+3F:=%M)R%B#K5D&LC^O?;G957A.Q.J@@QUT]5
MI@W@SS%'YLB><?I.9!@'XUPKD!E*[9V=8:C/Q-6V54^@'H.Y&-HAL;;#_LFX
M2P^9)VA1Q:Z(D'+O'4XG4X?[JDY?A_)SKSY[$IK0EZ2+G=_:!QV=U1?M7_4L
M2)NA/Z:Q\O@E=A::.UQ-!@LL29VG)D?J^^:9JC2!$QA:^4"U82H%ID2N(_ L
MI4]4QC3&J_[X7HD;\O85^LG[I>KI*U!W*C6PM<!@UWY)7:VVJ"L%#:(EUB7M
M)&:I!$&H[UJ.=4T;>C]QH'>M_JB7G4B:?%CT!-R\6*$.7-/7V@==$8I<V@>=
M#(55:20#P.;"4I\Z0TY*C'7LB% DUF(5 :YF,![[711GL<;?$_N@_/C+:_N@
M,XCC8_V,EL!/_4.6K&N-HJ+AO%[.OJRA$,<;NV!S<U6H'=H_[Y)E_KTK^LKF
M/N@Y+OK6'(1&6^X>26/R)7/[[X.>Q5_N9V->WL%8/>1@H(-.//VM>$#?DHSA
M!F:(C]<B&*[YWE!%:FGL9ODJ5X>+Q&B%*LY,V&D IQ>LJL6M<9-4+9,U0N]:
MGW X\:$^5R'.?NKEBPCX*7M,VP7,W3X=LC:!JCM*1U&%&4HS+(MB2$NO)<>_
MPB'F?"G)W-E^Y+X',[?P0[_UC4JF@9"5WKWP"8]JCRP=;)CF$$XLMY!>7;X/
M(BM01_>.Z4*8W!47^EG9.(AA6S+Z.RU)])7\?=#L!'$?E*K(-G?!AWDD>Y<=
MB'<08];NJJ//M ZS]S]1/]1WYPV18R),R-LN"T+\G!A97WP\%]ZN:YL?ZEWX
M<RA&Z#?%D,],^9/K,&NL3,@[*&&66YSL@=M50Y\9AD( S V:2VD1ZBZ]VSJW
M?62N6_<"-IKA<"!HJ&_X:T:5EV-@3I'S8D,0_R+1G%2W>^Z^='C/L/3NE;_Y
M=8514[SLN_SV*N\DN)[?!R4GO6)5&$)]@?+RA$I_^["\#^)''-<-V <9;T->
MY8&?DIA'E/=!ARAF8"9OS:X<^HPN>(SA5*J=<8(F4)\Z!M O:$/$)_HELI:S
M8]!./H5+Z?B3)@D1=G6U48.[7^NY^?UW1AG\,G0.FL1.3E<#*PD:0UB']U3G
MI%+)SI*WR*HY(-B3/ 5K&U7WR"IPE"\K&$-9$---*@T.WMM.;S+#X0M#@WA?
MRNY>!;#$*]4Q_F>VABLXF-__8@P615B\\VT?1$7>64[^ VS-+5^44J41Z3?V
M6/2A!SF\1)"$\J/@%)M2XF1S\PR[>HP,7@/U:.X&#E<S9)X3Y![B&9AR+]#6
MMOYQ3EW:9^2;B:NJU7=S#_L_.$*X#1[[EIU#J)UYDN_4G^AHMRKL*XC#%R,.
M8<7K]!0WIV0HL/%5G$B>!<_2CO_I,2<3"817NJ4!@FY]R%ML[SH+L(6D#D?>
M)9+MNPM^R7]0:Q')^9MYJ$*B46E,G<SF< 68^?T&1W<#AFK6/^:QV\XRD,[=
M*Z/4;29OLA P#8F9^)IVR+&SR'3NG+!5DB3",)=D$[Y&E#\7$&H^I:*OY5OD
M?7=BAS*Y O=\WNU<W84=BZ:;[Q7<I3Z#B.$/HQ0H[ U/]-4I$';469)=.),+
M=AQET1FHG>49J\FM3;I.>%<?;392URONK'>CX<SI#^\2QFMV]5.[]D&&^Z!V
M2W(5X3\X(55AYN9*SO\#) AFE"K7/NCPB%0FB[N3S<->?^/H"")03;& PG1Q
MZ7*3\SYHI9S:M-[?,:TXP/"L5NU,*E/M*J4X<[0WX \/;HEG_QSFI@DQCPVI
MH4_)I=Z2QP:1R8@BEXE;]F/V;<@R=0:_-9TWBWG!C*7(8%'MZZK\[6%21DFD
MFU&0%<+!S_FF9+D0XP#-NO3=*U!1*L/V<<=SZ#MD7;RX2?4\[NF=ZO>P?R_.
M?U)/83B+>FIF!_X!EV0+GD7T0PP%>:?MZYE]$$2J)=2+K2^,F]D/8X=Y-ON(
MCS,$@0#R/BA:&\NG'TR!Q#+/UU-7[$Y?H<!CH"I-(6O\J ;+I)#L9TB$,S[5
MM,_JUTG>EJ:4W_*VF>/]M?^#VOY)B-\A?U K*$U,N\5?-.B*]LLPY4<D+[#R
M.?;M\+Q@]'^"\B0P(BMTI:*94$46 182X9MGO." ]KO-O^SBM_GSB8YB!>PO
M/Y.8?*I<4.S$" 3^!]C\F0R8,/YR]G'64!$(,-,XC[M'&<SDPW!COA'SM_=!
MKW#1KA'[('7)9(YO _][R?PR8HT=#LW;N?&?4/YS;A_T6:KKOX,O_R.5T>=@
M--H,Q[KF@48#UA6L257OB/C#&.+VCSV981?.[_@-_O>6&>;=$<FF?5!O]_V$
M'8]_QO^_SM5@_Z!64[!O"O\_T?Y?O6(?U(9C!2G[WW6_,\>\/")I<8E51TDS
MT -+>PPU#6 !5!*<BZ5IOUN0D6&Z7#@ ,_^[CR&6E='3BVA6PXG]QRC_G?(^
MZ'_,60#S[TE9_.&R#YAC-<"_+,C*Z;%_L\]DCB.Q^CJFN[OZ/Q=#/_RCC_VC
M707T0QQ! _AW-<,JO^M6S7M(EJ2UO-01>OO.M'BS7J_WBZ*1;=N&([+"/->>
M%:5<2Q8O4^JY)-VX#^)&@3\RCUV!/-,7)\.Y9 Y6Y$I2F6D%45:/KG!K#TX^
M5'AS/X[P?T4\4\IH"?I/_O[==Y1NG?A10N8X5U*H(])H<&'(C3(OL%,LB[W9
MY^K2<LK\F?)HY-'W5N67!9<O1SH8.)XM,]0J-"PJJ$MX:U6F6"DC6_>O6NG\
MC]+G^/U=+:__B:!N.,\BA@5.EAR,*Y1Y%,?ZT6?91 PKP?\^"B/+4V?^U2!A
M?Z3_5?T6G?\BM92%/=K?EBG^OZK[[[KH_(]9;OV#:;S^UX^PQ&U_=^F_@6A&
M)OP+B)AUHP^,Q?\G'M#W@II_Q23VKYB2_Q7/X?^NG"9E?B:?#_<^Z%O;?YNX
ME#QU_)S4B8$C%T##]X\L_,UX'OAC]A_M7],RED.H\H[9.28QB)"QL8C0^J$
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MCQNL6S1*R4.+9G'FG?W#^U-A*$#4-0EJ65WM=H.[8WZ.IA,9)MY+Z0N<O#:
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MN2&QTEW-U@VTSEYNT="F%UKOC<Y3].'1)N[6EA';B0M$%%='I6HDKIADXH=
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M[< ,GL-MJ-=V?81#,,_^V+!#0#-5IU,(@H-T$226;*$J P3R*6I0!P$P"("
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MJ>VHWO8=@2.5TUX["C'%0^KW Y!0ROFZNK,&Y;B^H@%I9B+Z,C6 Y>J8_"Z
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MP#%]>N;B;:N8PYZ2+D2'(1VH'5>G%DJC:)=@!60CQ:;BG&76&O78Y?CU(29
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MK^6"[<6A%Z<7=O$[?4ON.I<99 ;DD:]K'P9P%D<5I00R08>FJXBG;Z<2ZE3
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MYQI1)^JOS:4X*M>!.;<O_H&&I9IW1\;A6]Z=X<Z.>W8^G2 [7(N[$J3V$,Z
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M<Q&S8Z36<MT%B-21+T[IXRY 0G:,J !=]X$I[HLQ<$#NKL.ZP3 2$B;-MJJ
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ML:FY ]?9U8W_WM,[,CHV/C$Y]7.:0"3]7ORS]'=YA;*UO;.[MT\]./P7+@8
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M >%OT;PX*9K\O AW&EZA Z2H(3--,/Y]GBD 6:.7 -)U)ZOBKC<@+@TK*'X
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MN>$L<6-G_?)9_&M>^YD[\#[X0&6 W#T;O4PN*/[STLSG9;R@Z G@[$&[UPF
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MP%K(2SV/< V<-CX5<8D^A#@["8D':1'\?J;-XZ:K)FK1S#>?3W<>(C)<2SS
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M8J\5.&6 #( ")M+?,;B?$@5.>7?-U'(#^&;]6#'28\E>ALZ>/!9?BA\9L9\
M=$1?8BI[PU&ZDX+J 3 + $"4K"FZV\;8-! 0->D+]H(4#^H.(#"I8_OK0R,O
M[\JK1HPEKPOA'3GC=DEB',B+ 7YB%*PX"5G;2$K61"=1^NX^AF6!^U7?6B2]
M05\5S]<1LN6(Q?3+&*N1L^7E+\\L1C8=1W2 6-M%&2,>N#.2X]C]8QE6Y34X
MGF@YF9ZK-K^_U&G5MK#\.,!R,=FR.*F;N'2%OU^CD9W4X"A^, @=%$O5_9IS
M,W=O9W=U[%1IK^H*?%/DU'!9'%#M8:$?B%$&E-$$40OQ<!9-O%/34BK&5_/
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MD+E_@9MLL61ECD0DV;%[;\(+'Q.A*1N2F3F&V?0I%L@V%AUOSTQ5YKH%5\M
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MYUISS?F;<ZU-G:$N@S@,]0ST0#0T-* 'IQ\0=0YTZ^]__Z7K[T[^JWW04+^
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M:CL^5Q=_%!,"X7+T:KH.UYL@Z4"2JQ1J-&^WO?_M!,;/9 U:X&-2)B<"OW\
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M:B-LD6T"#OXP:[\Q7KWV"FF[Q>FH\P!3;'6*IN\QK$;LH=F3[/92*4)PCR9
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M(AKW1/IE;.!H$4\J*#ZEB[.Y&<>BS=CXU-WF_)&L5U@V,9OU01'ONLPKIU.
MP#&8)HYP1K])#C29_D8@07(E3O1/%!*O[>?N%!D:$[7["SOU&\EM"+?6+ZH0
M[FR]$7\.P+ROC1'J09G$[Y:;],M;@'1&+FN%9IXX4+[;32V=KJO4)9;BA?%=
M49GQ1Q!(\Y!O6C_OY*VT&\*\XBP00?Q[VT%L%$XSG1=<HCZ;)52V9'S^31H[
M[(19T(CS"\G9D!,H!3RTWBMOF\5:)Y8=67B,6EB_W\SG[^3>UC%)(VA@?Y6#
MA1'U) _L8/?L9H/]EAEWWLSY:2^ORDU5X(2MK,S)HVQ6P;=&,>_-OAM\'=,9
MS?[&#6@H>?']JD#+YY*8_@>U!L>:*HH<^0/U:P0U/Y=HOQO?VZ]V#3@1>I>O
MS1C(^L-PGVS<JZ<V[2NL;YX:#B/D"8L/XCBTH_ICWX^)ZNHI/<7*;=>G:;L^
MPPC#V1IT\G^VTR[+WH/:IYU ;"=201LSVX&?2$94T 4M?4H+DI*2^DSU?V2W
M7E;8_)25/78J:,8*0;Z^-5G_#W[F VL.L,4^9XU%S768M<7%D6S+-B+!8Y2+
M6U9VF)KG%495!OC^7G7_J []$F/LD*I#*T$A)B2)^K??C<S%RH(%-L.Y8>]&
MUFW5+[V,[$4.Q2.6\_,BRU:>GIP:U$TKN^PDI1'!KH_ "GJ1(ZL?Q]X3X>)$
MT,[%H1A\$,+*PI_##_0)$RB61CFPJ2G+',;+[IKG)<\'K6/58EG#]]B]LHDM
MM6E.T]I@9+=_O#580%/:[2D.S$N2:>C *P\W%P*7!@W'&F,(A=NO "2%T]C4
M8.+A5)72T*5QTZFU223IIL+O !?AS>;7O?1'N_7XNI&[4*&:M[BG:='$UX"]
M"4&R]W?S& [?'-.($H0A3 @2T27>;8^.WT5*O5;)F8IQ^;C%)R2^$)M6M6VE
M[O9S4 ;:F'V%"JIK[ID \G&(-"*8&\[O3$#V+W*U EXKC--?[#[W/W,&8%>4
MXH/MH:P;YL#W[:R\2S\:4R2@G!)E%4#<_=J)&N5J_;MMXRZU45W5?][K$\_6
M?<:?;<>S:D8T$^&$F--H0)D*XO4TVQ"G7)SWZ>3 +\4U6"3=)7A[>Q5A-HX7
M*[ *[$"V>>H*6M4:O]!?X=6D>F\&VDN\P%X>R4<*&J>(;6/28I!P$1P*!&3-
M=>>=!Z)+-BA7A(1/>Z,A/#J.*8W#&:DIB;C81&%,FS;#LM0[$\H'O*H\FQ^>
MVY,+=4!??OH>OH)/6D8E=ES$S2'!I-N$K%<K['QH_$IW/J.2;8<&=O T?+&B
ML./?4\HJY8O*9YU\[':FG20)9RL_:BU6*G\>JLGTX"VI+GWKS/5D?_!W".@_
M>"^N9>D?3D;\=?Z?WXJK^>>S$3_.BN23XAI'C@]'4;]%;C;+LHU0;F'6R>$;
M2\=L!?89_Y<=-1Z0!;_*U/1+(Y\G_O2351LN>9@UJ?4HS[G85!LWJ]3;SI,B
MMJ8!YJ,&)6(K8B6"$B6"XE(#2N-FR:^-E3!>I3F^2N->#?-V&?;)A1-%4LV"
M>@:E)8*Z??>]BL=/JTCD>"D/E47#+W+WBSGQXN<#;V^*F4G$E5[NOW35%;;@
M>^MR$>CKMUNR(!TZIDVIPOJ2FS'TXGHQ0C+&:C)*GJ-FWING]PIII5R# 8-B
MC+'CDF'C]G1 R/9T#2XG">G4Z,&S@$FJMJM/])68<##W4LDU*$R4JKX;=0HN
MF*Q/$46DRI*-K5/JF_;&J)\NJ=>4_#38_[?VWCP:RO_O'Y]6R3+914R[(D9E
M*<E4*B%-J1 QE4H(*<NH,5>RKU,IBIA*2)8I:Q@&,TPEV4V(V2K9YQ+CRHR9
MW]5]SO=[SGU_WO<?G_OW.[^_;G^,<ZXSO)[KX_EX7,OK^G#;&55 T(<N%FUW
M=^.V1YBN9^-Q>/L#->W'O[?G5^]M:+?DW':^<^0FSWC/.E=?M8C&2ZF=14Y(
MF7AL[R7C)U$2[RP\@8Z*]'$Y3MPGNVU<(XKI>:/8:I3[[LG5>@>4E0^Y%)CH
M++IGBHP@RU^6-R:09+W-]%!NVG<N681L4FOY1FR"&X116-G-=4B)CX@.4!P?
MUN^P$^4+/:I]UJ0T'V#Z^XZ[&HR ZV0;-?-^Q'&&58OUJ#_H3S=[L:%'I=3]
M1V8*5'X)AM<'_E36U_0WXRT8N[ZYP2/\Z9X46U17;DWM=O#^ *7;+<9)D(G>
MF8=!9 NP6K-"QVEX-Y>=5+^O8J:+?>I]C.&]\;-U)\]NPCY]_/2)?TC(YJR#
MHHUL[_$J.JZ</;GO!>>B52>HW,W0K]OYH.2:,_'"<OEXN65)Z[Z/C+7)2?8;
MT29V%L,(.3!364B2;&A?QG1=MS>RT8IDV.RUUXT$.9UCN&@R)4-YQ5W, /'A
MX?WI()2IG>)<>RY/95/;(_+\L"_]7!3,&P/.  5@$_&+%*%;WIF,%'Z&TA_+
MM,(MGM- 1E(=VK4)W8ODW*<[(VJGIOY4:[\_"GF)O$83J^P7\^I1OJ);Y5 ^
MYW%NIFW$S)_\ ^"Z%:%KS/_@6T8&]IP/?W $-;;RR(KK1KL3C=4'Q\[?:E%]
M%+XA[DN9Q>T@ZI;?8P#C2/O/Z80&0<C%T-"YJ26<-R4X7K;VQD]CXWV]F]@V
M54Q93]%M;[O5X[0R5.(Y&_LZ/9Y>C*LCXD?]Q\ W.X[$?3<XIA'6,GE778IH
M\A/=]":#(L$^3GI\ BE3HD1+6&A)_OF ]=>76#JEC*C(WCTU[<[\X2/:FH#I
MJ2GO??O,C[=2:W [J*BR*V$NQ8^N6846$8LH/1A6@JDVOGZY8$0M-&S/C>'=
M.U)G'#]"A2MA">7OF%SC9LT/A49%)T:/G:@6K1MW3BI,LU*":CD.E]<A,UOM
M&=UKVS\-JB6H//IBKO.:7(%++CHZK4S\($64$],*(PVN+2!C"$XJZ^KIKR#2
M?.T-T:&;D'N.8H70014H/(^UE2+*\,G9Y8\?W5+4X5";;W\YU7HS(_7W_ O
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M0P6U*4I&@_6EOKZ9%J,16[T$MZ@+92M0&5 ._ZHWM\\FHNT'5WAKK>=NU[
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M.("7Y7E:<(+"*YC;6QR$6C5FOA-"-;,<W0='4:7$5>!A*W,!+HK@[9<_9N%
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ME' 2VO?&QAL&1E=L4@5MW:^,WHK*QZIA;&4,I[#>1!#$UJR@R$H^#)N [?2
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M:+'$C=>6\9+K7_"*;_'3TH)T['[3'6&%6U8[V,[KA0(+"9;O!&Q&:V+.*P?
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MG$MPJ8WE;7W,PZH0'"$J69#L?0J2(K =5#M#,9*C'=MK&K &GTKW6 \NYCW
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MQ (<HKY$0V$"H!*BH!&B/ X#Z $ %(S_-@'PWR\45#1T#,QG6-C/<9XFM!(
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MSU4KI;EP<+8Z\XSW\R&J]=[OVB2+?&_-]21#")4K;=JWX9@YU4:)B#=6WB2
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M)*8@H[0E34K@+J$]03"N'%ZK]K2-WS@!04*#Y.]HO>7J7M24E02]/-;"\P$
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M1[I AJA8<P?R'.QLV]0EH["J'1P9_7A[&-T8N3SL/8)*MLZS>[R;HHC52*[
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M5#1SU;E4%D?ZYB-@-1O]?!,^^-[G2D-6:)OY$8#^Z[Z@+D6CW,&,]HZWQN:
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M5_@!67/K?>@X614\%O)"1!R[I36UA^]6TTX0NS:[>W5,V'\YM)9*^B7#Y",
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MD5B8,W-]X45-T2^/^-_1",C'IP8 S=^/5T-Y&JR=^=[!%K>%+]XT^4C3[(_
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MWWF'+W)?YJ-5\HMBK+#M#5'3(RUF=:DYR+LUHR,M;JY=XQE<]S4_T6#&]JO
MFNYGJ&O#WI%G=9;IO(,]WN>H?J5'XCM)/T:/)579HR0E<S"OK"T^^M7WB+DQ
MC+96=+4B,JO"I6PD/17T$B0#OU$HNGZ\(D+LDMI*VK3%OUN<:YZ.)PMDA5F]
MXRGELG:[_4I:V"PU32)RD+(NQ/7R/ED'E I(,U#XHE+I6Z"CK-[+T^\%PQ.6
M7K1[.V:'81MEJ*,DQONUMZZGVATNTI$FJE;GU%!/1;#,/Q:1-63*&MFFY+5G
MM*GZ]FV$ZGYTQ>E/$*]U!QX)V;'G,D$8+WNFSOJ8 ZS&RYVO]@&H12AGR,.<
MDC4<4^,<\_[D)[4WV@G\J=.S8A(E(_LD:>QKJH/U Z)W_Q#ZJJ,;-R9NP)MR
M="?R:ZN*H?6.]UZ 03WO2IF) F6R3X24T1=%H1.U;PQ1@-"Z72M<WBS;E3/
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M-,K0BJ[)S2!N6XNCT_;#9U?R8P@CL'1;*#2.*K34P=2@>B0!8:7P3+PKX>&
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MM8>O[%NHQ1YU2GR_J&VD,:&$_Z'/ (84<?,;+&L&9,I\ \HPR*P9]$9!<RL
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M228DBG\N6S(U#(=YTXKIEZ[8MD7#\#31O_$?T4&I\3Q%=6:<U)<SY/:BGGK
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M=U'9=919:SII.!%+;V$I4@ILI\B[^;87)\U#-8>ER25:W[/7WU(=?Q\AA)8
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M_:37/GVBS;98^25N.7&/=I<;Z3R)C&)9Y(Y8ZT/E9<73W2EZO.P8]^%DM0-
M\PY P4-HP'>C-U,2E)@#I"\?D8/>$1)#7EV$?BO#;I 3Y+5;4@;2 X)(OS#>
M @;]WPH7U5AK8^55RGYA?$SHD G0@+ZW:J2!%8GA;GHD!!ZCCA0C'#2^'#<U
MDM*:\FF=&F]9BN%8(0QLL20I+UGWRH5E294\+K'%1#?0%A6[Y-R4PB[4+LK3
M*T<\N<J*S=<M+]##*9'>(?:XL_PGG7A?=,R50*T+ICX.NR:V,I#/N.CN6\=D
M%B$/A,])*OKK=77@OC4P%W5&3)O/J4XYHQWW>9567!R\'R0$E)P+X;+B2_.'
M_XZPB"!QL*];-<<)5D2X(7B0:GC_ [S7GZV.E.%SN86IS.&*.N'<ZMQK.]WO
MOFC4G,$MP'3^9N7\P*09T03H\KVT, =)QTD8$6RP*SVL(4H(O&,+7KGWO*,G
M"G/:MTZ#@Q3$^"IJ#AIC_D-[.:<X0Z/9*[-BJP [G=EMT+5%=PE$(<CMPOY7
M$#1:N94B2HGOH)L",2-![KK1=PMXZM- !V9]>!7LZ5DV419P,]&+](/E<\*8
MQ3"_=9Q4#(2'BXJ8'6<ICKJXUW?_$-<4@[0GUL)&%Y'20<>QZ=B8!"$%_ZT#
M$5IG:YH0:Y=2 L0!/Q*%<@!O3LF__5X'SS[DF;OBQVAD;RHRCO1?E']FO-36
MKYSVP90-EPC6S(;P7<.NA'"Y)KC$'.58WYI;P,,0X;DKZ](K%ISZ3G<N;0'N
M5 >_MM-U'%O'L2!45[)PI99:U^S2071@0JU=_&M6SZ'CW(48"P@.3^G9UE\,
M/_C:<).%0=M8_*_QRV?!_[LHDWO,K^ M9 .TP76;]4;S,OR2^ECY[(^=97#H
MXM[W/WMSW?)!WQ^DJ7@<(G;)HJ%BIKM-<5C''#)-SU [L'@Z)-B!FMXWE-V7
M8]"#TK=BA(VL_&6C1H36S?0]%_<AA4KSW_U,3'%T1Z)#;M1'=%:,\]POT8N7
M23=1E?FO09&DU"#HJA4XYG-KL98PX^RX'3]?NE[$OJ=KV%0PR6 W$YKHR]I3
MTV_XT3N"25 6'RC2U0#X<UIN_+.J@]=?SU(7R57:%'?:"2-D7#[3+>"QZ$CL
M>Z'JEU.G?(!&B[%V[LCJ&&2TLWN]*A$[I^&R"Q(9H4VTOM)D=B;R5"ULC#_6
MYZ ]<7^[K45-):E<3.%D_%L3OX5.X$/*U?U@&AN09= ZNXG%S!?24*\EZHK!
M:3;5=[U-[$S!!;Q"%; 4*''KI.C>W'2S0\2L_,N_8<\Z>2!#12S^T?5_5Q4T
MZ/_>E7'\+%W@Z4, \ZX)\R QM1^T*Y:G?<[K?EJH\&J'*&_13)IX!_JE2T!9
MGU.G"#L\5M.O6+8H/A1QE3B D7K9)L%<0/T71>IT%]ZB\R'R?,9L'$:8GZDE
MCBI,VI_(N/GL^81W5#PK]KRL-#D]XTIXIG _X^?KX)[\RQO3YS&.KK-<@V\8
MUT_^,=<+NY,.D9$*6 \_U0D^#SC*4&T /?CL&L;*P\*CD0;R#WDA#'1P/IE#
M9IZ;?12&H6E'=&%^H)ZU7)U9@A<^0KBL[(D3[NC;K*VS'1E B#.XE$HPG2%I
MOD6P4?T9';1R,'H=3#C:CHV] D+<WIC#<FX!OSH6\QEWQZ5Y;.*<[H7$/?4,
MS1LWXX !)9O;1,[C;L9G%5H"@@TS%3J[J,&N5BQMI\)?[6)+$XRVVE;WT=)M
MT):7,U.>C\3Y7SDV-\*N(:-WN(>^)6RI7%:QNJ=SC[77**G&D:6NKOW#[@<:
MV,?/D@Z$Q5<I#DH=.!<K/UE9@:48SOD_O%*U_P_RM'?%OA,M4]%X-5V5@EZ>
M'_-W:%-%7/AE*Z[:BI.)TCGBD'&1$3+S_\PCH]4@_2VZ[]*53CT%AMCYRU;V
MGT"CC@6+,E[#NCD;$^$FL!;>%ORS5\ :M4SK^WG:''Q3J\-L8'':%_V+$RX>
M)Z1C2;F8W5.-[O>/:PJCQ G&+[T2:VM9!2D81ZD"YX)6^CR9=*#9):832V;6
M5@/.9$_N&Z6KX)W)8#.1+5]&V.Y^>.B@Q9ZA!IDE!E=EVK;F!#.!S4JAK3KW
M!'8FJIS]Y\K73#38+56!/9F_]8WI]4N:[32I AO_@)R%A>KK]4>C3($V%:XF
M^\P.$;)EX@3HX!-@D_ KL_711QT]$](%K"@(%/N?DPNPUKPNZ)8)J+=^3,@U
M:$P81.2$I13OR;5>UVI.+/BXM%8*_6AM QL[<]$V6PS48B30G.)ZC?]XXGJ<
M]3"+?%04CVXF3/*?-4JE:8,K ]).#?!&K:6Z#HR5EG3]<I;(%?A$Y$.'F<4?
M2<+VXD>O[.S/G!TR#XS>N2[V_F"*Y/?>#=BG9W2GCL_C+N/%EG'QOA:SR%C-
M<9WIW%&X^)?Y2.*KN4]3VW89K]=.&__2\FF_+E5"HD.TOF>&!2AOWE!OO;G]
M@FAW8I?8N#V0<3-B/#4A]%7P$D6FT+B&F4TC^FSIY<WW"*W9Z2':95H^T4&;
M,5H.[<*EZL_3@CI0Y[^TGJ!5&? >Q"W2VJ5CQI=AP<1JEB'I)C- [3.Q3KVR
M6/BFW578PF8&X1)[G*+$M#)F9_\7IG3_.OU/7'GTO3QM.[!(@H*1<*=$^3),
M[U#DR9#S,(-^GIVGDYG$+6#YKV5FS) (AN>\'%]:Q3\6[(3M,L2R?I3XM_Y;
M)M7ZDJ[_/WSZ$P4KLR'2?K \"\F9]"*BZ?_!=A;>[!6D?)QG^"$=-#?N-;DE
M55!<9YP,_!2T%P[F/3QV] AWW?W3LR;CQ/STO"IG5U;7A()[S[ NSW;V .K
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MN20>&@/KF SLKNXO/K(*Z/L(L_GS#H;^Y&,+FN94)V^/6N.,.=RA"@;?G^>
M"W 7<)95S"J8WV$4;)LK-]W>,+9:5.%^@QS6Z%XG)04&#\_;ZO'9;YQ;?B;
M%B<?#MR_5(Z3Z*653;[^> NH"]Q1?!&0)V7<(5@@..Y5Q;5LW+?3P'!Z<0N0
MM@+OL^X/ZRAZ!H1HV%^@5L2FQ&60W7#/P/C^$!AI5H407$%Z0+G%^O#?C\[E
M7=PMH*\@QB_K$2*M=>HXIE;R($X)S5$,FJIS;5Q?G[#Q&T]S[N8R6X0H;0N:
MY^6;2^@<(3Q5[PK5U56VQ$R?I*W/,@73T2$N8:)WU90FH%@(MX369IN/I<!@
M(_&)PD+O:X\1<8M.R;4Q0Z>?@7%D7(^ YP6(=7+9HS@I$S'A-6B_<(_S+&LH
M5C!QW'40<40EDQRHKY 0P)EDCTR3;I8!RPLD5![=T6%T=()0#/:*?L_.X9ME
M+V7EH/MB=TIR^29,F3FYX'3+LPUED54R9.OYK*8Y/L*2JAE9%=7[WN/)=N\/
M#U/><&X*DJC^H8M:*<:HJ]6\W/VUM4.&D$RR9*E__B:\>U#.[R]KS8Y;Z9];
M"X-J!*I,*V*O7O0=V[0[M<'?II+PO?'LQBN($C\9NM=HJ=L\B-!AD\+X'NW7
M=H?%2:21?F4U08;+:Z-$,>L=Q=H,\;R.J7VP_1MCZ<*J\.8!+_3WF&01(4Z$
M@!V62=YS9\7J&2B@?,K<Z+/@CX>/@%05J:$*^H+^XOV+,/U5D(:#F?J?H[HT
M3%5[O+^UB#DN]5W.N,%%CD"DAD*,F<>4R->=QLZVU(J3.!GXO",JBLE9# H$
MB3S9:RRTJ103_HJ5?V8^Z)!172T"JV[AJ'0 U536"QTEC%#+BKE*+P8%:W##
MF!"#87RXR]W]M8QI^VJMM"*PD:A6VN@$/0(1M]76WMKQP2Q;>AFSNL]J#VUU
M/A97R.&&?T DA4R3C3TAUS'J!">E^%:-FO]6**$7JM_I^)CHP=<&MB./;K6Y
M3UQWR=I"&-YXF$8L Z"F-3%C@_$:WWGJ,?7LF'.1ST'@(\0FW(-%K_47.M].
MK]3U<PUP<TSY^S'F>0/UZ[Z99/7YDRF?&GXMW,KZZH8JR<D]]&OV3SIXV@*R
MAX+0[.&"^KWQIK#SP,]E=J3%G)_75CF*K72@DG5?4=$BXM[[TGYR[UO-A.U@
MOM8$K:L7?F^0JD<>_]HT!$W-TDQ_?IWJ6!DA4E7 69H.V4^3#H!]/2#TKN8*
M)]J<",;#UU.%%CU+7&I/)E[2I@Y6,<&>D?P6XHY8JK_S5L2767C<AF. >#3P
M/9XB^J=19[*HY)\\5RU_<$=OS1,M#.\F,L[.,5#H?7/FHGRH\I$HW/$6H(IR
M8V8R2F1 R7LW-:RQ$ZMY#<AU\J]:'Z?]5E:4!JEZ2Q[RJRF[=P A.>Y=3E2O
M%CNB=S\-+C:IVG+=-WHTNNF?S)WVVU_>O3S>N@5T8J]^\[T3WICV?0S\#)5"
M2= YGR"SGZ8:'4N[PYD:V (2+QM895J@BLYY"&6\8')1+^S(G"EF89_C>"41
M? 8]O/9;?9%:9OLE:%54 -XD[RYLVXY I(D]J@YM>1<QK#GI2>>'Q%-$K2G-
M^3Z7BXH$/1U=]A<=33-7/\]Z$O6$4W!FPH6E@)-KJR4>+X18<T:[ <T.BO2N
MV$5BN9-(I20P"]G3N9(KDV@/*#70 >J'GN%><<@Y/JQ]CB>NZRB<_0/9<$+[
M_ %Y\[?P%C[XLAD%,$)J;2&BB2V8:B3FRM(GXGLSU-/"R=;&AR'*^@;N<$65
M1']W&![^<O54U,S8X";D8;_9W3?H[R+94"C7@$232)S$AK#TG.1,DK15XI#;
M[)CPH_E(B]%]G3]GB>I#_=HTM2]D,S?O_WT;/PZR7I-'V"U>T2YE?+C(4UF+
MMA1J2A)E'N"TG7T(2%S1<>NP2(N*0 >9W\\:D"9>=;FHV,"AI@7TJ$:8WA)'
MAW/>3UK*6[,D,5C]FLZW%EZC[MYM*-DG)D8HZ!\,1,?X=/C8N3@]4N=OGGC&
M&['Z:DP\&S(';/M<C-%16C8/)[5&C-7]YN#^.X"$/*4#L1O'V20SE'EQMW5E
MWBRX?X$![;^LO;(' L.E@+:-!\;.J4FL@RI1R-AB(XUL_S*-"85@,FFD,Y'E
MZ@A7:^F;*J^WN5,:I.H(X[0S>:V<GY^TS*!?=^;9Q.C'GM.QF"DL:B3ONN38
M1Z'0(-!RO5U<.0(.V]9F[NIN?1_/-1>B&M6XX!:Q=Z+--7&?MTB5I.3SOX^_
MW>W:$4C2YQUOU6_*(#:<H)L-=FJ*N! E@LO1".;L[+&VY%2U&$W.>TJ(VIOT
M";"_<X[W](DJ%WIIN?Y*UI-'ZK12C.!W%9DF&4O%T'ST4W3,MU)K-S@@FRN-
MR67=6347& B=O,\$T9@DS@+BV>P>Q+&35@3&+Q62DK++:3-I/E(Y]Z@W'>/^
MRIPTF9A WM^BS;41(RD&Q,1F-H0(B,NMQ6[)\VO<5]S6%)@\47^:.B;AN6JI
M]U0#R 3,G3\I^>] !O\%I9'A5E1"F=>?*2VU_I(E-]);:N4(U&1^93S',FPB
M$*#2#HSYQ?ELK_G]M%N QPI6F9RJKK+Q\LU]@_[B>&Z?-%EWYKK%A1+[K+&<
M?B$EEWD)?^(ZDODKY2![/S&-.I[("L?6-!$ATP\/=-=]F/XB\+(YF("Z26$T
MB82^Y7X0)&,3L_$VR0%&#GV9QW.>(XA&B#:WGSH)/2-IHEUC2WZXH#'&TXQH
M:DO=>J*YDY%NB/M=Q'[GX<N_W4S=WHKH+/="+GD"MVDYJW/7J7U'(S C$)(6
M^#,NL_;H#^D\<L6N<J768ZR$D-&B4J7"W)7>+%](/?*T^3"U_ICSRY2O@CA7
M*]RP=3JC^/?)<#_0<E%Z@FD\YV?TADL/0FSMI8/_^Y>"@<$3V09ZDJ4([5F7
M8E!%SC.="HSU^N;6S7RC3>= SK;!=8IA+Z(CM91M[]X)K9Y0N1@#3Z:PS8<^
M3TY<LV9@M8H#!S]F U2;1-M3./%$[M>:?WG_R_?S^=)JE&7SJ2M<S:6N"4\Q
M(7(AI]42;QOA#_2_B[3IO>!-[TN+@CE?=</(:Y1.!='DXD#'YKJAH3SOW-@2
M(1ORQ6(AD'O9_?GT@1N.Q[8]4>JULYIL;P!:M ]+*.@1T1((MI"VI(4,N="!
MCQ*BO1QT=%;T\]SZG+_H-WZ9)]!XP?:KHV\!,A+>K[;^?E:1\)<&1.=(:!^>
M74[4S=:XPA*I(-2#^%2[@ A2TKC$OB_H2$M4Y8;[O/V7*4^Y,6:4E+^(3]-@
MRX8*F*N-MB-#OV6@BF 6*S>O_D<+N).96D@Y6$<\G4'U72/IGG%+'TNN1*<5
M+V1VRNIX0%HM4W3K&VYJ0ELA-?!M="'IFRE:,HC(EY-I<;F!9J?.F+NG[RAY
M8T$';X</NY]_?_:P]8N*G _76N9*[,[+2?9DY>;1CV9O8!/E%NUF"ZJ"S6.;
M.F^'H_?G_,]CHG?YNNR27FG>T]?AM5$<6FD,EEESREFE@0EV1>6A*5R'CH6^
M<J2_Q'_@)M>)-#Z14%>I/?(VGD.)VRFUU@4DLU*XP*;\PSVK][,8_3)=B"?Y
MRX_?>?LRHV@ONAK_TP<%J<,'L>^FO8G:->_SOZO0R-M?J-+-Y/?TKC*NTS(H
MTZ4TR=@WJI'SV>OGD^:;KWJHSKV:IE-3H5OFFO%KIL*@U;4E2>Z=\]Q_L\W3
M7#2>5AE4&-=IC\%+'OE4Z^J4T4O-2I6FIL8'&L@_B%Y+<U'S[HP=/)>S1WJ.
M/0/ZWX%*#]P(6)C!'\'HTG-C!*<?,JKP:XM\/8\KH^Y[I.YU$:GUOFV>'9[&
MND:(9@H9J-D35IJN,75O;TILX@\S1UU7A3%N3 EGXF8'1EB?^7YYWH$$LT:S
MT*5;XPZ-;[Q"BQ?_#ILGY7_=#%"0#>T0]P0+E[%]%W[KIIG,R8U*OT&'*:9A
MY8/# 5?W9AW2F (JT% 0-GR0R+TZ?:]I$D&YUTT^5[_%[C2GH.WM7SDX!Y?S
MUCVIGSLQV,I+1I4!.<QB:-")>;(R()&Z7!L[F4X9XV^KC<^D8W;\#;VQ9*I1
M!9+R%=2'=KUF-RRB-04*R,@7)_$%<.SJ<+)>0J94?84FF_ZD3 GU9(['.X(_
M687OA!'/9'=Q6V<$J=GO>JO9 =WXJ=TV5+MMCCJBP(/SM+S@B&H3)5DM)S9=
M1N5+0;[ZH"U#\S&:!,Q)X03U=IOP)A^JSW]:-RFN&4KZDF?V<,, +O#4ANA?
M-PU>S? :IA6;?+Y9:CFR:W?)&R!OG0J]$0X8P2H/7[_3"_1ZCZ_OX<J*-GDK
MP( "4\28WPMRBBE9<$/8'JBAXH_^@%^DJ7C+^UQPJ,\)P=<$].8D=E+T9LZ.
M6$B9F$CE@QUF):X9["YED1&CYM56 >X!)5KU9\Y;IPH<C40,29DQ51G8TRN'
MUPO>%ED/TC85\Y2J5"\=&1!@N63HURW8 V)-WOZY=^V!?#:>[5'AKMO5QN^P
M>:B\K0<#2_P^? X,N]**P\':U]Z4UW$*!;Q1DL2'BW?-HI6ZO1,J]T^]%X9^
M>*TJ-^_X5':DN<J[3HFS36*MX3J<8B-4(UY_<>X1H /2P,@J,):4/GMSWHU;
M'XREC\R"Z8\VM&;O:MZ]0[>\^?%]H)%=!#B7%"R;/338J!;%/2]!_LJ')+24
MDNLF+N3(M_5YG+D,=[0:U3_O-0'EY<TVC3:$YA=.':ZHK]=GQB6'10Q4ED1#
MA<V"8)K$<KXOCV#T%:F+JOZ5VLJ8"I@LC!0,0G8GOTA;-3<=@]P"J-;\UM?*
MXB_?^%$2(@:G?$E[\D9#!_HX14O^Y;NYB9^;U@O5U]LY\C&1P*^5];N-/+#K
M+F0WC/A[5%\25]P:N%:9O"-G_U57HX4$=-C,2F)!^]26O2%5Q^R1S0-V]2ZX
MM(ZRC$I$-S=R8@^O,VX<#L,5/X1RQJ\)K4R<0+;:FJ)GL2;).T="LPNZ127K
M/]3#2VFH">9&E]Y%"2[4N09VX6+:S<;CLB5M'7"[D\IT701J?JCH5*$]YNMF
M 3599"YMRY?2NQ]X])\Z\R05Q5&M!]HY0S#8;TS F%.14F0S94+NU /]?+9K
M9#GMS?>9!MU?XYI-"R2/FX<$'SV?E#I=65O-?O\PI%T0/O7J#_-@H7C"UP>#
MC13<\P_A!\MJU;]P[&OPB9O<*E3TO@D9%:G LONF:#^:LO_\QNIKW?)*YX 2
M[&B'@)AO/1,<:W=^\4^_9&4-+B]4=K+;"D>V)<O+EGKZ<Y7GP<!<OV-\^2L7
M)&P5KFEQ3 6\(XQM@$9_-8W%]D#.=D<W08]U"^O^(BZ4< 3]H8*VTUT*Y'([
M;="?- A<F\6#K]HND\.+71WDPA5#*=Z+\/YAM6H.ZI@0N>*X^*S"TE(T&@Z'
MOW@SFOJAMK4D0C-9'>9R;CM+8M?6CDSC2E)H=W.KK\]9Z$:3>5,*1VW=,TZ6
M3Z?)Z :]G-_C:$N*2?4/J?T+%?A2@@3&2=*_L:GG5$.0.F$%9):N*W25._#V
MLEH.D,&WQ'&<HHZ2"5[\?7>0:1K]&GV<C;/VJ*0M[2*H:"EN(YYZ>^YU67>)
M6*=T]L8OIEM "\<I2R#K-&K][^LJ+U/+;P_;WI&RYK6M<&C<U>H=12D&SKXT
MEW!L^\R':'>P(X8WAJ8%TKM2J[HM1MT"FJ ,=HS',::A)6H9ZL_CU>*TSEC)
M*[)*5G@XW+)>$GDA.TV.#"%&G>KJ;8G"][RB+$;@3QY*W#$<5I+"Q0RL/;*F
M#O@YF",=>:5,O)M=,5$+1I]?0"(V#N2B$.FER]?%.S.,!_KS#4)NM3\,[/.Q
M 5M)0$EODUL P\U3%ZOG:)1 5<A+7%=,K()HZ=I!T$UV8/7*RE397DYH:]?O
M(L6)\0E 6O_XR;>3BQFNX EY8"<P-Y8C8I>$$[>!V?BA-ZB7E,^ 0.*DXZY$
M(5)QY:Z0<H+F4#=SYSP\^!9 8[V^1V*#A2T(7JF72D:7;1ZQD+M/O 8FD.NN
ML8(Z.M6CSP6T-_\=8\,/V_'(X02*Z$/X+>!1@A[1S<P-VW6%1 H]L(%4JYM#
MJ:1:&TL*C9(.DD%TSE\I99WN^^>S++0JOH:H:G[2FO%QX8!HZ7&UQCY8]0[[
MSDH,.2-G&I)FI;KB@1:"+S)_IY;MB^]KDWGMR]G7W*^!>#Z-1S(&.Y^,48&I
M7%]@5$L#SX^JM%V13QCD(-18_X%C2D*-.4XC"GM-:H1WBK%+L[1[U=*=#+J4
M^9$C$%RQI 2*:NS()U74PJ!N <M9Z:I.E:$YN^_BNBFZ"23X]BL0W@EKB?P4
M(NL=B#_MOP50HRC"?S!-TRYI/AC00MD5ARCBSE.P24!]H.S9]).Z,RN2CGD%
MB$UAS7IC^ZP0_'QA?7%?;3_<";J,_F\WH(T/-S1XT\8LE>O<$$4\5 6./SG0
MW]BWIBW :E38*154CI64VEZ^3%N?Q>AH#FG76JQ*3L>FS>\UA+LQWKR@@(>$
MW@+8DUMN 19'X6?=BYV/MJ[^MP2PM?%_TW"!O\)B$,%!_A?^]2K_SU\KJF>*
MCRGT#'LO<@#X/\)-:G61\0)>#);;/?#DX5U[.KZ?$#%7.9KYR*_&?JPNN#+T
M&*3C_F@G/]]Z&G]+-J0P4T0X4;V>QG\99.6JSV>/TNI7CKE29U&?9Q(4N=M-
M;A3U._%M5R?HPX2GI_OY"PMWL9<*-0>Y L$1Q@*7ON]SZI.D?TNV,1T9Q]M3
MZ//K/<HRK!B!TG3/[&@JKB4&^:YHV)L6AY_E3I-;6I!C/GKY,C\P< 2%F!/W
M$E>:!W(:6.WL!G*U&S\A!2.[XHE!G:4?*N.GK9-?C%41WE,TN<)>HV=8E9Q>
M<_'3,(JT5 LU^IRH2G:X9(E5CYT[1Z0K1PNKBJWU$SIQ+5GY9,5L9-DBG!1/
M(Y9VL4PN:;MF"TISE&:'$"A41>B\,GTB705/QLGUX\G>W^TV5[=PB#$9\YOD
MN;68$P;A4E2\6!;:D>MZ#1EKFYA:]^MYN).KWX!O?)9?(2EEQ(9 E>,II([!
M,:/D@;%W.0;H\XX.]N()P6[HT\^NWNA+XF8S#IW=P,_9(=-RV$V6=0[FL?FZ
M3:.<'<'Q?]I8YSN^7;B?5X'@12SH;+*'KXY_M2-Z*GY02.LME;>;1,T<?<;0
M+K4 P>IHGOPU+?2(E7Q4%11V*"S(BR*C[/XV_7/ >4]>CRD[7=SEW&M-S:,^
MU>9*&OMNY\<[^+SIY/;;>R7C1CRT$X]6%&IIS/>G?/9^\@GPOZ!0CA'F=+/>
M.[[)VKS<V'A)]JCT5;%Q:#)]PX50S8CB0&1_:4H%1B?L:;/*TUSK@3!AUIYY
MGA6[$+H)A@]<EUJ<R>IB@2V6@I]?L7?*);Z0H#.A-!]5@.,57OQ.O@5H0@DP
M5Q@#"GG?,#X[)S3QW5(M^_SKD,KZTA9+J9,W\O\,J#F[63LSQ-;W!G-O 12Z
M+ %2(SLY@.P)IQ"'J9$"A<:.X2:K6X SB.(LKN[].]$4*M 1T=M9T#71H&=4
M)LDZMB0RJ1XT?E*,S+$(A$@6F^I)7UC$45="--7:4^,6S\I9_&.$OPPY,]+/
MS_,QK[KU)GC4GR\:J'.F2;C9"5XX?)U:#4A;7W^QB1+ RDSG\ML*O<TRS!+;
M&+6U]Q630%/WX_MG+)E?+=M'[V+'&<2?*G&U$J?]U,T@E[9*"%U]#7SV(7"X
MR@;O+F1HD*N*?_#Q6"+0/:GSUSK[W)^$X FM+Q(=#N5%6&9V @QAT,3,,3B\
MYN0D=2XF87:RCV+A)8PY"G$NA#'L!4T--EMT#:&C%*S!+B&2P5I>)Q@7N:.H
MPJ9%\NZP%7NG$\E@539[6_^>_(!/6UF#(J0'0?^%_3<3/?0A-J5[XJ[< X/=
M#%"BL<TD\Z%Z.SIJ9[QKF !\P?V,^354#-BE_!:AHZK3*2)(V<<XT,(-Q9!B
M6Z8\*:^3E93&JR\@\"K?ZA#QE&G-S/S9V8M? :,]Z143_%,E!V][\N=XEHX=
M?)(6>IZ,>/R^#Y-GLN;!6P^[LPP:#=L>O.N?&[(CM'"76=6SH_9G^W="'#:M
MGVQ6O=];K)*QP2T)[LJ\-@TP*(JL;,05<>UI)C6/#LN$^%/@;N27-"28]?X$
M*T[@Q=Z]<[$R74TNIUXQ"OMVTL!/XV ,6?"JW-U1-M!+:#:[_GQ00''#$>#*
M4(Q*DWT08SW(J%[[Z%^/*9UZ/F'=)2C"1I*4P<[ZD,1O['TO1?JKN2V]_B-U
MJD5KFCV$V*I&X_6G(64,(T=[DMEF<U?7_.'1M@ UA?0K].::+R03T6XP!3M1
M(]P"\$VEZM;+#[;X<H ),S\K8KN9!GS0?OJ0X!\)6!H$8@'A('QTU617UP?3
M*N5NKE>2#+&9KQL 7M)=O>K0JOWMOIEBA&?M_W<H=%3>'KLQ!&4>;O!5@-%M
MDTA"%!?J?3H_)4@A7Y5ZA8('43TWZMV\VRC5AU<2,M.]W9Q])I5=OTVG)7#'
M8N.,Z7\-JYMY_ .#:4I?WP+, FB[,PG!RKWCF&G>R98@O![*8_D60&IK"&JE
M2[9LORAX8[8: !R\Y$3D#N1S@*I83#%L19;_M?[GAG*#M-CUB4':F6%\DOCN
MW)]+WO6=; =_M:+**RF"=U@<U\^!X[M6(75^:<J?)$!I;)GK KDK F82<UR+
M!1[-8RPMY18O.K^O:T,AV9$>.?^(#.9#0*&BL*WSNXLE^8O8]55M\-9&S(6*
M'F*84\NI9[8U6%,TXA?&KSF1,RD"8ZEUR$61Y7X+>'8X57'%7M#B-,)*_J4>
M:BRIAZ'N>ZVS!I=UL=:;_^T;K/7'6B1 5$Y0^GSI10T#W5T\Q9!%S_7E0#<]
M-D!=?F'S,==67@R- 7J1P3HVG_9U),C8E2*V-G?'U^ :JX3L_9+RP^E_6%$,
M0\&]+<_Y18R"AFI<),;2OE$:44WA](=SHV6Z-W>2J>?3!H6_FLTGKU_&?L7$
MG;> E&"[<!<:%%HN=#Z&D2?^79QZKQ;4[HYI'E/!LO</>1FIC<=UA]MW]Q<<
M9GW#J5Q,JKP26/Z\6';%]T&P(*/'BXL<O@6QV%,K679.NY_.5TZ7[J::KCX;
MG_+9YM_'SX(KM_#*"4K4KO)G*VBCSFC96G>)B2K!KQIK&M]4=O?V5V9Y==',
MB&R\ZCD&P0>M"1N_H5Q@3PX&TJ4I)RK1SSH$\\5!Q'B<?_L^]'LU*)Q>*S@E
M!(^G"H8)L:,;,@B=<<-88VHI7.[0#6M-,8R[X='.OYMWN1 KV0)R/+,F;XWE
MN)DB#\12THEF(CY97R.W)@I+1FO#^N^O'A]VE99_/<!M))H/<U$C:+&PT-ZJ
M<^%RG:7TM/I^4P<AH7AX4;A8AP(;GEP4)7'VI6QHGA92,]Y@[]!_<,$9.[LW
MY^AL\#[?COQ2$=0[6_\5'[PUG/ L8E996"3>).O<<Z3)L3GJMR^S\-E4X918
MT5R(1B_<O^"7^! +?8'RO))TV/Q%,,?JS7#'PN"L);!CZS5AZ$?G/VI3!/*D
ML#M-0$C*S':1[>,C^L6U.DF0HPM7ZY>.+H_F&W0X\^&X<,6EL.KFHH.OYF(W
MFU2V'=/4BYOOL=K*4=M(1LMI9<B<E0;0>,/;#3=>F#QY"QC^SU8(QG"/*[W!
MXQA^[;*02W9L7G&D@X"Y^,CN,_'H\<(_+3^_V= OM^N*ZFJ8/A-VR.Z;GQ#3
M?3[YOB&\<ML,QA_D>_[4<$@2LR1K70Q57<_]T9/\'O7%Q1J>,LSD!"((TT@R
M0>^[(E."H6V*Z:V['XQ\1^LROF3Y+_^Y='S$Y>!53;AY%N+]@<,L;.:OH5I*
MI94L.HR&H&=H,E>_-K2[)+2A)SY$_?.&BH+B0UWYZ-O>&-OTK0N1(SK\A$7J
MG"9!")>O<>KFDXGHN2X)D:(YI+0'@]ZH%PL=@%04LF?^4%6%N_B,,4\VJP&L
M5D/4KAOJ9^P3SJ&$4 \K[-$6;&.K/G\VW'5I$[(3K[+9<A<\4_SAV>Z$62PT
MD\N"\?S$FHH@'><L:$+NF"F3_@A;VJ2@^*FJX.U.J*5%+E..!BVBNK@4_:[#
M<XL?*[9WJ3# BQ4DU]L>\5@/CBBH$!87Z=>^RD#ERL%P/4?B]L4R84)7_ OH
MPQJP[W4K#FW8J(G(R_;!!WH7!\2]=K;GM--#V_!YEX].0#MX1 S9PQ:?W%T/
M[_T:M+/VP042XKE9,[)X]''IC?J?IW.M92W&SA:4T-J]HV:-+\^4!6X!)!M'
MD:EQD%N TW1DHP;"RYK3/YS1W5%K\%1T 559>\72#^9@\ZS[-2O_A<>.*Z>(
M<I-UZ!: 8!K'K5[=(4BQB4#M/-"LSUIIXWRR*<M:Z-(K/N4$^O3 1Y/*]M]&
MHQ"=IG6EWE1O8C A.I&Z&\MYNM<R(+F6RRV6ZW>0NMD6F5M J_,MX+NPZ[58
MGF_K'^"9'#>>YTC9MH[_2IR@6<,.2N@4+0RXM$1^F)!(HH4+"?E"*6AR[K\R
M-/W^\V6'K>;YBKW9,F.M-IYHJRO1N^X6</C3P1_":-H[47)EB5L[$]M#JI2V
M A,2UN1U83IRLF(8X4I+IUEW535'T7J]%PJ6E^ Q]B@"'TYD&H;=4P[%IP\V
MN2ICI/3O0-L+<<];D8MIQ!.Z']W^@"U*BQ8^TQ?A-8_R)CBW?ASW,ADR-Z'@
M 3=" <4G%&+[?G('H*61'[YI0)N/UUVE$Z<@OOM#''G1)=<. ](.&9Z&_LBK
MM'_5NFNYM5EEF.Z/UU7 FP^GX5<26/1/B9ZGOMKX!*P.?$4R?+D%.P_A.AF0
MR/%K_0$QQ@+;I')!K6!+=W&'ZF7S:*"TZ5;*H'&4%=[LYQOVL.\0$CA=P;UN
M1>>A]7^;'7HQ;S=&7-E/.;HZFEKG6D'P=C@JM*;6V>O.4W&)K,6E %43L8N_
M1\6TH, PAK!OR@[&2'@'!5Y\1,1=HC,VP:QL;>2*?7NJ IXFX)*3Z.8NT7YW
MI;.67=^88Z$'4J6OC(V^SJ\3^;V39\&%3K[R5!@Q;B%E_I(&UGO<1Y,/1[PH
MP>@RN/T!4DUX-8]Q!M)1Z?LC@$.0LN#P&M-?&S,33#3A BF7NA1NCZ%[UUFQ
MUKX'9>'9=11'TKA=F1(=O9>$LI*2Y9I_03W]&\^8!()I,#-+:U8C95/GUR^F
M.RP%3(S!1\+[SIDM]/94!9B2'R8Y8\K)PA+M9H5M7WT+R DM6B@7&^A9X''^
ME@HP6,>OSY_);//S"B&5IJZA7T,,=0IF1:P4:^737^<"3K:ZF@)"=/!DFUQ>
M.8.+QBV_)BY+*#^#S15Z6YOOYP]+Y-X#>ORGZI\^N4E,+SN;J<U@)$PP,8.=
MO\);A%_J")'W+WWT+IT2X)UKO<MR_";7HSW[N?"=FR;U\D75(??%N6NKVOR>
MK:GG!5_S(V[FK,]$OBGC5B3_86>6^RZU0NZV2W5;#U/<51L]645^K50!LW.M
M&@@-S9JZ4JZ,0<A7,EG8<7LLII__(9*9Z:1BCHAPXAX?KBP)'I6/]HII\3I=
M4X7Q1O$!9UL>+]-"'[G$Y6^ E/$OOHLH?T\U9U["KQP_#D.;G(*ZRWYL+#/I
M=[@(DP^:T%J)2!N"$?KM<[8=;1US]EJML38F-V/9^O!K76X1WV>%PK;_V:++
MA,S?GL/ERQ?@'^;:E8(==(E0G\[L74W1?4-5FSK"8RT.@ZATXUGN-AZ?"+ 1
M54T7ZP$7U]6;]/@]D=TL\BU^$9!-TU)[V2W /8A;^4A&).%.;I]_H$-@V-.:
MA?!_(NO!!U>>!.'+F"NA\)@3^=><['KTOV:FN::R+1N$!J4%;=&UMO3-\]^9
M('Y3!HN''_P-ZV[$KS@SJ6SPAIN7&M^_JG!;/W5V'CEBV^J<YVC-V9.:\C"R
MPS^(S$L(^,Z42^7PF>C4SM6:UJ<L_5+UG PGM-;5 >I/(SAA*?J[S-<MQ8Y>
M"Z'>6CE?^&YC..<*Q%8,UH4/W9<TN?I7AF<>_D8Y5PE^LKK^@ J]UP--T8-A
M!_J525#J/X%/3*)5A*(;'2'&@[Q2)F#(N:(#F?XJB5F?X;7+.,>5]9&;]'64
MQT^J&>"B]5) ;-G/:?>IF/-NDI!PB__NPKIY<K9@Z[I /WQ[\52IZ!80U8"K
M]AB#X 4V!R*3Y?DH0\!%],:+/^WZ;#@WW!_?,+>[M9:7%^Y;_1>Y:E.^W!<&
M7>D2P)[L%5>"X7>G/26G8?$AD,VV^MUVN(L:KX4K\?M%-\A\N /8Y8MD+HWI
M\3+C2_"V">$K3H,]9M"ZV62PZWE";E*Z==A$T_X+30DJ98PO+T@[XIR/49?.
MXGL_G(BI5B&M+(E!2?1FR)V6V7!S,7.SB=-K1T'[4B9@0#M"AAXP8V&%C-CP
M^^CYW P[S_YY/\AH\//*;]C=&?T;I$?_;'G@A\)+VXJX/N4"=/,A33<D*.;\
MFQ&\B1 $;74Q*KP%G'0S1G6?'I83$GY(7F^S*.%L-8I!2SLM>-J(/A:M=::N
M5YBQXPBF9?%M<!A=:O>@G>/\$7/]!\/2$+L?'YG8\-!/M*+W]#/"J??H:%]]
MVQQ#1 !36DE^*RAZBPK9>3Q802D'F$:"P\!;I*SQUCB]B:.F^A(<"XFYU'TA
M<'\/+L7JRY8'OD_>54XHCS8G"KG>.-^SM6& ')2>B7'(Z;"4TEL"FW/K2+^[
MSFY@FDC>2_KOU2(-?CSW8OPMI(0]$4*6*H#K?GF[?83<U2MG5>C(SU'0'&B+
MAK'&BO%/=?+.??.JTNX>5\:(IH=9($\DHIU@1C<L=EE3Y\GR]S?*NN%?K^K"
M.?:7%/0V5V)D\,)18F-BK[RQ0H(265)N.J54UF7?)A1?]P,>Q]0.:^')N.SF
M$4_*ZRIB)>0_L$Q;SY3EB_H&$IFY,MI9#._79Z$[?.._Z3<HK#6!NUGRKI,O
M[,XG3,0V]:87_T/T6X!#DD,BQC\JC&B?K)A.Q":P9&U9G7EIF>B;D"^WBX^E
MRK(Y"4P$^:L9>4P%]!!MOP60C>%8SD:80M@(H4KV:6OL0.YX;:[/)!PM;9W-
M'48MJ!,BJ8_5]X,M#:8RU@\[ E:#X ?ZM>V5BR7FBK\62XQ"SZH7K..6&?I=
M<7G<G?T>.9>;L@V#YWRM0@*'+1J8Y-BFP48UCIN%UG9X_/#N_EKD?9-,IX40
M>7\!K5N ,_3LF&*-@?V#)(HS8<X*)-Y!VFEP+/%DE6/?[_N4T%#W7T2,0:<F
M'[@24YAL26?^(;6>-[K_OW7\"S^0ULTCO0W-+0.XX+Y4B:;A/4E$>G6?/[NJ
M<A;7<+;[W]S-^:,5DBKG63&N2:V_?EY2>T97IR/6CWOLK*.=C_%$;PCZFX'+
MV'QYTFNH65M7MF/*7R*=F<-6L]:O3IK=)ZLOV1KEHC.#S!*A[DU'(\S)O3M?
M7+],3C-]FFCTR=S'GI(9,Q%%E_?TQ Z;#.@G!/->:LHJ<I",SX0N/>M\,27Z
M#B?K2,2<;0>6-^C;(2A8R=,8_=D>^(%;JIX%'@&7*]7!<I_CO:QM!CQ)2PVN
MJVEA*HKCKPN<S/(=$L.=+4%++6ZM/19'>+H8O0O),_5RN!U_IB!9[9>D.IUJ
M-<,GG99[,RYHL4$KW@UH=N!F9SNIXM3<+:",8+#U5VH<,L9Q&B3R^$H17Q,;
M1A(VNBZ$=RAYC3<GU(Q@CF.5J )>Y"Y]+5Q3CO4UQI.?KM"HSQQ+3%%)SMM!
MV=TF[>Z?%UP^.;CA:V^:1[E@UZ@W=SX@4E?Z>N[57FFAJ0?<.WTENO!ZB7]
M>_628-F0EJIE,V=,T'KQF%#$Z,?7(9,R$P^2\VP&_AF'#J9F%'=W9CFT]&[/
M)/CY*B,#HLUH+:U(@L=VSKRM?*%.LJ<:>OO\'AK2(I$_!P-[*'"H(@;ERMW
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M^]H[HT)V[)MW7IGL-R_(N'?>CNPW TC[:^^\TA6O= CRS#I+7E0SWOC!:&O
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M@Z=?2"#UQ^Y9._0XQ1)W=" CG!>9++U>8(4,U7Q/6B?>_SWW:*&U>6FU2S\
MFBQ<>5WFJ#$O1$O]W-CZ!=F^$DN[+9.![,9F[FR/A/.RB?P]1T<$RHD*= Q:
M-/(6?7?"WC._Z*4,W]+JPTW'O0N$NB!UO[0D-MY+'6P$_,!H,IH'6O_Z#E^<
M65Z%)!G,+K])MPAX%=@L?,3J>Q-3*8&\;UIG1];<)GTO\04[R+D4&!=-/*B;
M#@*MKFG13;4C'S+U=_/&_J.>9$=VNS#<I>^>GY,9-,]./Z*2<3X*FPZ:O4>E
MY_U(-LZM=>?56)WS/>)%"1PZ5<TJM)7J6V/U$?(]>0W?LIM.8^NW:>'%IX&)
MW4\*>([D B=OZ/-0*PLO?MUQE79^K/JF87?:AX4^?A7>E'X^T4(E&$<7AS7S
M.Y!34IK"TD\V.+A/T@L:O.(DCEF&*3<#&8SU);.6ZOU&!MW[74+8?/G3:_=B
MI"^X]C0UDY>)-6:SO^ET[5ZM<+/>5Q4V.?P.#'"(5%RUL@KAP'Z74J;4X;"G
M2W7'2#.Q]3P6=OBL0%M',_-550$INF*KPAJWM3I6_:MM&<MD+74A8_:E$-"R
MRSQ9*FN+ZYU9G=S?#;@%S$+JG+J20KJ:AN]U/\._;AZT=LP.%)BZ;'GT:H(W
MFT7G0&&N9N39VWV-30YG]]]L*;]Y$NQ,5NJ6GTJ9[^83F?9;YBVX%0$2_(QH
M3^Q)E>%+I 8AZ;%)P_^N>,3SK)V7Q'_)Y;O?,?WP60N=.\&'[/P'6Q+3G5R&
M#!T=[?00&QFP%UT)8:=^Z/#1ILO3(V3NK<!,5_EBGR/2 RBU(,29<S2"Y\W5
M7=,Q#?2B: D'97?<5=FX!&5SHYI&S)1@];!Q! GESJXV]5\$K"-IE2U1JC*N
ML[^;,^4](E(=',KQS0]%RA8U4,OX\;.%EOY0]4#X3^XMA7,;AU0[_!N5IMIE
M-^<0/7HSFZ2$S))I,T,6M8_&I$DK$/-@":0C']N)N9I<5HPP<TN]\WMX!_/?
MT5PJQ?T[@O(_A02A 7HKOQWBU4W?=P?'&IBZ\S0AOQKYW *H7Z5EM+5FDN=W
ME9-4_!_*OBL:#N\+=]*4(%IT(3HQ0_3H1#=$$+U%KV/T$D+T3@Q&^R$ZT1F#
M,8C>H[=11PW1AD1&M)O_ZUWK/MS7\[+/VF=_>W_?7F?MW9*$\3KXY1--H[BM
M1J40T!3M_&OQ2$ ';CFP0OQ/@QR7I+C7%4O+[L8(20Q9?U+=39=@44<38+ )
M*P^$5R;BZ#/56B*,9BFW2:ABI] 2FP8^M-_,]J>1V)W1]^K3ZESJS4ILK3:<
MR5,0Z)I/$L;Y2UB)SN$ZM<K3=E^P7Q([CC8[E5%DY#5 _51$-'$DQMM4#6@D
M08DZCM=!F"P?2/P8.5M^SG;-6ML; ?&0FZA I[21%JE""DU_KVF4I#XC7&KF
M:6U1>M2'JXX%':+5H&@U+G16$TXV?_]H*UT$-0.N;R@J(6V(=3 X ZZ9/0Q+
M2>,W-0G>W5-J?1[J_J,?H_-D+'C':9)84R3**+112X&"+ODP@M+!'HXA4],S
M&8;3$'?UA'#JW@&H9MFGO3C?)MZ3\:Q^W!C=8JQ''-^<T9!#?R1@ES(&D1L4
M]/3]L@*F9&&;LC?LJ)\%6RC8A-F*<7ZU5]/C6)0;AXKZ4R/FPZ;@F]/S?['(
MCM5XJ$:PY.8K8R;P^HOI"S4G^^1""6W.W(=231(8+P8VV@^Y6O5'@;:@1EF1
M/IP:FP:$(3*$8T:Q5=E;B(]*J[[:GLV7@.&3J^M]#K!W[#9$? S,KXV]S'[L
M:LGJN;M/1Q TQ_NUD8)$HY-\\S]$&J*PV #<@@I_F3;ANU.EYKPYZB/9&NM6
MC^/J.JXI^MS QS3 :> Q&9O4T2MX'&%ZD[Q3;+*VAGG=5!OALY]"XT056K8_
M@313>JQ:TG,6EYX&\0 D3UFP"E+M]&*6)WSL$M<6JX+7J'&OMQ=7*9K:EIOS
M!<;>Z++-OD*MMEF?">;LW%L5G7K KK(Y](!B,F4%7[L^QL><>ZM PJU=/.K1
MJONHO1_8V-%%>$0+AUDJ=\FECVQJD_0Y7?VJO%A<&[-;I[2.5O4P'A=RA6'M
MKV3\U]W"%Y?!'*R_A0(&UH2-0M8/5_W5V6R35A/BL1'!HZ0'-33#!$RL4LN'
M?=7Z,H:J'D=?OA_0]>73O^!"=,J[)')Z7D8-_.&/@ C,QP.F1B;$.GMN?6BG
M5Q,#<^2N-;#_('),J-.^;,^9F]ZKIHH2<VC1]G->%=N>L52\L:I;[]KTEBH(
MOZ:I6_F.Z8J2D:Q\0"HQM:+]96G(P Z.3?J[/.HFH(VHKNYD/[U.]B430X]6
M6?$V.J:F;83VMI+"C)U;;I]EE\4[9/;*\2P@*N 'AN?O-3 CMV!/[,^T!@3(
MW"QCYG%6,Q#UDB4+1E1GSZ)R_A(V2S8)9 QK(Q$6+5/)@,G3=3.1G2=-!N1/
MJMV/66_5<J<-S1QNQ53Z**DYC--'%?PYJ\D5==C3SOM,3A/PEAJ4N 3C2KF7
MN^%=]SA8<%-&:<"QD_E4P#D9TG7$K$:\_?1<A>>B,'=#>*Q8,O)?O=X6B9V]
M Y3'M$1LNG.,8@_K36Y]HXOO ')\NUE[T:Y-/?-]-O5)H;Y8YE!4(/2:7Y#*
MS!N[GA!*"2*_2+-4I$7]%8QCMOB60HIT0C6G4R^[?JZT:\BK+4;,'QJ4)&O0
M0F8+ENX 3*+&(_NW OB@377V0(&:3+W3_)J2*N?SABOH9U%P;D6)1IDJXUK4
MA6H;\O/HA\\5QO_]S6JE("3 F(M2,M#:1IZ-!M:;65EPPN"33&R_!"DJC2:'
MXN>-OML(,Y#"['JKA"3H2>NY:K\LD% 72Q6/))0'--(74*X_I0B(T61Y?2)R
M;,5T^WR!V-IWR%N' J]2'J 6A=;%/7@05?:KA=OHO[UK:%K% $8_$-K4@MK8
M.LXK^.GN;'1S1?9Y-\'A7(!IJ,H@$]_P2NN)=@+T:MUX]V?00:#H&AN^K9SX
M#H"XI?F1LRTDEM<FQXI;C6PP-\X&8TK'3,>;$\]^3*++( 1'[OT#!:%7;<<>
MG)'#@@/TU0^W^O+OX:L* XUT>_X(XYT.@']>Y&NNEE[$B?VB1?5_,5<,^=]
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MS>SH"%?>OHS -6?NU:M*]@B]H&6GT=M="?OF)AQ74<651<- WB:3@7/8YST
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ME'6F/J!UE5<5;NB'HGP_[/HOP):/CH)QE$*M\8*,RX,Q6:3[.=_3SIID$A4
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M>F))O2S&4_D$J?=5(1#[^(,S;CN-<A)K:,4Z_XDS%Z$<R?P&M\%SE<I&H6Y
M*O=#0!*D7L6CNZ:8SI#547B09@P.K\X]"1;??=W)WI#VIY-E-I9VR(B*(Y\K
MZME0BA-%_XOUU:%_+]QKUE]IE>GG:\LH$8U^$^^@N.,\(_->6.16]3+CF"60
M2Z 3/$A0SK5:[?8=LN5G9J9#:5K]WH46E"1OV4RP(S, ,K!NBXN7FK!YJR0[
M"W6)$RO"M'/ZT]$:)FIERM$ZFVS._;H,0\^(B7#.QSXWSO_$HRIRL^7UW9%S
M@U.B[(!W^O6;\81R/))S3V\Z_2;-8J8^Q*_5GK(=2,(R\(DOVH0"F]30XO"N
M%=[#32428-&;6K=/'A<L?8O" */>-\F\+ ;@7A0MFVH*",H,<22;O#4U<Z%[
M@MVC$B+#IE!\,]7U>(_L\F@8>MS//D+LS)!7Z[%FIMSB\'>2UE.8[ZP&;>9"
M(5YEDS4C]D,"Z/!Z#/ @TID]?'%@L= :^!V0K$>[QB>H.U?:[/VX)?+:6'X:
MHF$6N";NO[Z&#VZ881>\R+O]N %%JJ9:;%N,D6-LM;[\YY.:GLKQ0.#-W_-A
M=]M8 I.:R%#'-K0J 9];YUAP7?.JTM.:/=;'34.]?1]DLM#3QR:6W<J>A7)1
MV,FJDF\4@'"SFD_F8M-'5^^6_<P;''+87UJGQMD2*ZR_%+TWAE_ ZO2FQ"[D
M"!1N%1 XR?',RKQ"17X@*/RZQ/D'(_JA<9F[DB4WX+'YTF!%:=Y7*[6'%9G.
MT,=O&H$NCX+J(@H>0YM3*/#A?[![D8)B=;3.U$YR7+.U"'Z2A#QO]39D2Q.J
M87;-R=RBW]_1T='5;SH:=H 9^4X2 ^,'^Z2P;I[T=^'?;7VCTMA8I\"7S0RR
M4J(Y3O_^U)TJGSJJEN$,MJHQ<1(W/6[GKJPP-9]P0B47.T)IDE-<*PXD]-1W
MWL<3.>3)6 T4(,7#-CZ^V3B0(U@X#N8)PM&9XD$;Z]1+!SF*:?U=# C7@L.I
MC8I?)MO1'[D'W\U_F?VE+=+7T@)QP42GA"P@_<1!MH$?[AU[79/B)>62L"?D
M.J<3W=X_\I_."HA!R9V;?HA3FSE_2#HL"KIJI54WR='6]-5HUI$LM7BCOAGT
MN]6IF'_*J>!)\"-L'>7/6\'3.T"DC&QQ0'$_J5D?XT5>J:GIP8<JF2J9@>,#
M7KBJA!%OIE&[Y@WJB*,=?7ZLR\4J9G$[?[:LO5E KG):9]J!CSE=F^G_N]=/
M3H#!YRJ=78M@Y0E,\-!W[0L("[^ #21.*^<X8W.<\6</QMPO1WN@4/@ _N&_
M'"#*T_DO-*JKF2<FY,7/?.(4M=.U4M>-E 0IG42Q@HA;Z;2W#:U(7$=FF$ -
M*%B1:SZ.JK886]J:?'@0\DQBPLOW(S=F<W?'IZJ0)O$+R][6R>53WX*_>_^$
M;NE%\Z(1Z_]U\):0Y0YP)K]\!U@L"+P#E%<Q_ER6-F/X_D1HX=71B7G$_WO]
M(.!,%^KTN9BHAL.X9O<]CT$G$FRR>%-KZ+2Y'OIE932J2[OGCT(GVVSL$V4K
MQT@1%1#:FFX8 >??9Q-@@/.YU0A""Z6?E&P@.IEPI,]-065 P>&VG=7'<LN.
M,4 ED8%Y(02["=N+!:]%$W2DZ:J)LE#-#R\"JZ?]N:U&TNF+Y\^%R%^ 51+-
M&LB9K2#U8#H/QWQI<V+!8!'1[Y7^[M]G\-ZZ\AQ$"H![7.$,]/2%@J*9<G[L
M+>$D2P)'W\Y+HQ@XHB=,FY'FKJ8RV2USAP;'0/VQ7(CB4\-2@^MV"K)V\\*K
M5TZ/,D9>MJ*0$4^.L-+1E]PS5E+E,7N"'A,[#ZV?O\Y%_W(:>!]NUXX&5@DE
MRS>86*[32?_F>0[^@N]0,)GL+1TS5>;:SDBL9N3.V+E2AGU.C3WF1+VN\]L4
M781_6"UY868Y*;^UWB?^!4%$6EUR'S$_N>?FH9;TV81^L>>9?U974_5.&XMI
MQW6D2(!1WVBN[UN;6>.VWL5D(H8,=+HP$S*X%\KL3_;1Q<2BN"5@[=6UBC.
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MB_$<^]T=(M5ZV%%\F$=G\01L]4@(CAF,VVXGE,4L^[US,&F;8VJ\*SWK38@
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M*HD>:*YC,(C=U5'+R1*>[PIAFZQ7YL#8.0+/HO+7TU7-COV>0(3"XS8AM%>
M!KP"UZF-\T@2LL40C2GN6[^!\0< WVX?#I3AA7*$"!TW +]?AAF4]/,%SO.
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ML180B-%!2[6OH&,0[%B?E6- N A.'XBLBPJ#=RGBRPZ5I:0R,T[CT=V.\]A
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M*:7<(^B-;7M6[\+N.*SV"++U=*D.T8-/P)T]@I"\P22R,DU)'G8*:9J[F2T
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MOZ2_;8P\IN5Q';A_SDS]8CN*]%QG$9.\8I:D1[!J(B; O_])PGEYV5&#P#1
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MALOSY5(29 PS72WN%@N.QXM#10.?.<D.WR6S=66ZRIJHKH1]=A7V>5.PPC2
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M8%*.^T38!8!D5(L1OE8@T!3KP*-R0#7%_R+QX$FKU_/G4?YDN@M =/X.3^Y
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M8(H]W&=?%1_D]["8)BN^@T4.Y%^OJ=OE^7H4 62JAF6<<!W\J%689%Q:\[D
M8#FQ+^\Y[RIQ/&ECV/8[M8+9&9$$-P0Y2+E@@LG(<#U?U&0G8IB)$<[11-1-
M+R<MX&^_O]STG(86>#B? T6K=JQ(Z;;IYK-[T%"TRB+6-YUU>%0D<Q1ZMV[W
M*(M$[WEJ!!<A"O9->."9TL_Y2=#A&Y-(4MT% #<Q&??SL!O1?Q)7A$#NNK)T
M=Q"5X\AF?AR)=0X[3 +OYI5L\]_^=CL50_H"IVY#!YB6ROIZKVOP7[K&A<[/
M'41.)](SW'@)+4P./Y)VL$_E"K<E3,9_XE2*T(F+QZ=R]CO*.-H3MDH"6QT5
MYO-#0V3,=6Z_/3XV"P)N"!:!&Y3);+V#ZSQP;_P$TR93@@;USAK_3*]GLAFV
MWIQ(W7<*XMX&$RJ%FN813<"G! ^\9WU*"[^6B_90#U5<Y/T"M.]0J)O,JYT[
MKCXYQK*:)UU'6D2]/4&BW)%6,OZ\NVY;GOR0]"UH$Y3<RQB*2, ^)EY*XD@,
M)KS6^3*)P%E1BR1'67G'KBF@^H;V6Q?PBY"SMLBJM1WZVQ7(:7M, 3Z=S!JU
M.UC"="[YHY-ZN%<0MHX/'TD6C.^EZQ&_G'JS=LE/0&SFTL>L<@Z;PV)&2ACA
MU&X;('J2T0!69R%9H4.QP.#7HZFR7/NYEL0P\(V=-C/_QZCCML']E_EF@^DQ
MQ=(D:0B>B1VN_ 5HL;%$IN?H(BQ8MA&.DS!W2R<?Y7NMT^T$+X$'D,X#%:4-
M;84.8_Y[JYA7&31?_V'ZF$Y_ >A[< & H/4&HNX0?*:BKL%Z\8P7@+VAC?7%
MKHW)$?!U2+%" XES4WHU\@%F 1BT"8'+BR<<JH?;"M([&<XV,^J9?H$_"MV#
M#H*]&MKF9:?G3_16B95[4Z<VEU79&#Z<GFI0%?4IBI[8^Q-)]-OT[JM/?G(N
M]:7GEN^: &EH,STNHB>UDL2I2]*LV%Z3GFF!7E\EFYNXKPW+@NR[B+8H3_S]
M@OOT]$XU>L5;@N6A9B2Q^H$S\8V1^'/J%7( B8@B>> F$R]+<F'#J[HS?4#]
MZB"( F-'&#W4^Q)6$J^LP4[R+(7\GJQ"^*U6)KH3B_/P'\,.,NPP9LTKJRMF
MF76(OMM1[#N.H'Y_D#YI\O0?F(<-R8(H/;+.:S>DY"I,T&BK)1UOQ@_Z#6$6
MHN3(6LW$^,L0SDP*<2$.O5#F6./L;OL2>BI([^AB()#H!I$)-+E!G4:&GW6#
M?,QBSF^?Y=PJ7MC(B:TFAZ8?(=*=S@K(8-QZ(@>")?285!9^/8_(<X)(F=[)
MA_:GT\@-C,]4(3RW'<^R3M(:0Q/1=<Q0N<?H1V>Y]2_.)<\_1/&2OOGC4JDW
M.?>NGNK!-0G77D4)K,$*<#GU^$FJ)9(<7JR7@/T]:34%U\%7*8#C3[R:()$H
MW\YG.2B\D2"MGP;/5%CD;EC!Z;U%S(MSTMLK21+_ 9HZ%H>;Q2IBI\#?VK>T
M@[[5]CRH36F8^ 8:E<OZ"LJY $CO85=8P8*0]:L::I#C#)<^8G_D742M4=4.
M09O]D+SP:+MA<41B]M"FH\0/>,\PWVQI<[IY?I;_Y^OR&9E/ZQYVSTDU ^M<
M<ACM$+'83?OF]6NKI/RM2*1^'U$T)SUHP^= V@7T3ZJ"@3^#;90<1+$QMS'1
M*V_ZEXN7M%%X _0-WECL>G,@+,645VG(C$FM <E0>:?^19&BI8*+X=Q9FAP=
M4E?J3JQA1D@HRA#2'U@BTLW7@[97:]Z>[9^Q87,NEGHI+1G<4=7/-UO=(OYD
MDRU7(<M?HN73>PP]H6Q3X#6^F]J1.#ET3 QX788LC]=.&]O!T@;@".>E9<"T
M?4E(!:NK^D';,<M]7ZL5H^_VV&0G"J:9L.^"3.!A#@'^M'$\^USJ?H),"^3@
MZZP"ZE= IFWT@V@CIZZJB:+:)PMZD]GBK2]XIK$J+%82" 6]'_+.V@&Q6Z^%
M+68; %$]<W,#)#B'X#5<],GOH^G*!+3>W6'\7=*.HI35D6%VQ)LD4OZKK"BT
M)3.2IS'^US<UOQS(.##,<*8F8FWHMZ352\(!Y$NIRK#S9_-4%:N4S*/7F9E)
MN9BLHIGFMQ2%#(\RGHWN^(H7JWR-4_9DE,<8Y%CD<8@7/+0,MA_B2W]^G9VK
M,*B$CQ@_LAY73.\=;TWD?XU)5VUL#0D/?TT66YLUDA)TV7D;KN[WO9[Y?,65
M97H/6M=<?]TO_VU32T?7QZ3YR4F.]\ M!676?<:;Z>YYPGSO13P4"<Y6F^O1
MSJR%;NWAR4"[#;[<A* W9 &;^(]W^4QRW4,ZO%3CE&ES-MZ'!==6.ZS=IW5L
MO2\8/5"UQ1;\RV AN?XPPA?IZ/H9W =T*WA8X^4 9?@.J^UBBJ]/KDF/<TFH
MC$[C9-1JE69V5"DT[)NJH8/!%2-2<=\2@ZVQ%=4&PZRGY6I_7\ _##]8YV%X
M-HCE?L&]0AOVE?CQZCRR?G"YER0KW@]BA#QQK$^-XH?_\^7M[*%1D9Q1NL%E
M"C.0Z?5H:NGNR/FAC:B@9TN]C=,O S<WUXJ ;FIV]1*\R1R((WDB\,NR;]3=
M!3BOPB=4U]#Y]87F9?O1FU%'YY_7K1K_H1@-S_/@4@T"3R^6T)-U^ON1AH7L
M@R%(W3#)V9K8\6_I%94ZO^>2<ES /%^WNW3A6=\A*.G12N@X 0[MY_IAB8K#
M&U=8U-/,ENT%R=%]IVTMN^WLR2>=E)E2^'1%CO>^R RB+M0N 7[O[%W/=3AX
M9L:*%$:D[B^6:WIT?086Z3+3 I9@?GV4X!\@TM&B(BP=QB"CRD#!5>^7Y%.I
M*6+:*,3-4'[G^XK=H%TIF-&Q0I!5JY676=>4/9"4K_C^<-L$RM-\EZW*ME*4
MW"*I^5<1=7"P8X6FF2NS+'*T<OY28U@N-5,(MK=&JF5M8395Y>X92KQKE/E?
MGY;\)Z0_1TF2F@8U& BI6PTX!)-RPF'&GA_$UWVVLJ4EW^C^J'_=/OH@DE_/
MNGAI_V;K3(:TM&YX5V_+G^]-S9R<.>>I]AJ2"R <-V$A :AW5A)>@W#SP>;4
MA8YS^PMA>ES4IOU:6UKSS[>FQR0K[)-$<I7O:+W\]92-[NL("GC]KAX[D*$'
M[0IV1IHJ^KI90TR#Z^F"8W549V+5,E*>%:Y.![VL*.7VTT0Z9F_K-AZ]<AVV
M#$K5_<9596@PA)0TE.SQV>XR:.WQ:#E[VR/>7R-01A <2I7MGG_M'7K+:;&^
M#GN"M7M:&WHX7=E"'Q98PY]D5/T">L5Y C7J2Q2Y=S+2+R= &A^9[^PIP_=2
MNI $N.P,S\<:NCFABJ-%<HAFP3T[I7G7B#Z9.P\L9&_=&=]"1284<Q?$8<[*
M#XK4ZSTO "^5G0L,9\0:X_9MVGJGD3&F39A,VQGTKQ9[C:FC(N6)A5"_ HFW
M^4HYS^Z/SV>]<;P??B)OTM,T)[/78J(1&5G#:#D_?S[V&PM6XAUW*H!]B]X2
M_\#(]@KCSTOQ1\CVIC?[[PY^P_;"Q\XJ7:P%,_VH2#@#@4OF7I:O+IK'IMJV
M\F6I*UIEKE)BV+J@3&IV05W/-FI8HUA1JXBCV,:(5@H=;&NS:P,9&@Y^Z2;5
M]%)D4P2;75$J/BY@\_D/T+PSM3<.;J$<'_^Z7BFQ9K+"".K!_W.O=@0Y+E"@
MO)B2LUMEFCGD^WK9" CVL2]KE==]>8_LX!=YJKGM:!<#=PBK)-4,(Q:U;1IZ
MIRH)9"4-B?G:T(FPW'.6 L_99I0BF&Y'XVYK]\Q!_4_NQX]F:P_NF[B'@AY"
M6[%G/_3-'1( #!FF ($MS/((F#V*CZPX7=>RS@,K>T#8RO-.3J[9,SRA5S'/
M$+(+_HR65O5,9+?5"W^D8^O^KM=D/$0Y)GF@]AHGOXRM6*Q*]<$WM3E15Y8^
MJS[S+,[6HS>H^4K36#662VE.]V10I)O[QF7T-42F1Z6B@64$?^?.@-O.F"72
MENV'E?6.-J>,39BE1>EXO#52*J.VS, B)*S&JKS -94A5>:N/A$H)Q+4-2!D
M)2+S@_M=<,I'UWM/&FP]15C*4W@R>N_ +TN ROJL *,HTEK,AV"'3>L[?,@<
M.*$DVH]]R.Q4UW8N,#:P*0!A]+]:%:;4,<)^7QJZA^3KGK.WQ4EVFT8NG(;3
MBJDAYCVG43$AD?QIR94KOG;T4.20BE-!7EG;76WFGEC@B.5OJFL]<?%QA<^2
MRF1T!%@^>^C<#B6R2;J)X%>LK2$>=]\\?E 0)L0ULB@Y.B:U\HE0#8OO8PMB
M(V3B4RHJQ)#Z4REW#G?P,RCQL<R:E_T+I;S-^^).&4K^HSK.9R7O>EF!RI<T
MQL^R#@TVDQT;2 6X\B?F 8IRE(JKG0$JG]+?^49DO?CG?AZF6)UV.&J5I'<Y
MFNHLJT=A NJYD9X21=\S%T!C?V"T9^S#LWO_QI7;Z7C*&;FO<&(CEZ=[(%70
MU@K5\%]VR84)DE[";[*ZPJJQ";R,6T;A5ENVL2D'UPX;OG,,Z6AA9"?2HI["
MR1KXRU/1[&JQIWUUXY-4*=@.76W!DFXVQ&UGXJ\6:T2-3HF?A;5,RWW> [N6
M]C3S#S>N,KS2U1R.N %39[(8 M=GK/O_9W#[?X/TP+DR^1]BY8O0;BZ8^(">
M\VQ8P7Y3RTI^5$>U$Y9&+K397XU7EMZT-_OPF>W8'_/V&;%9Y$RH/:M^=^3I
M(:))$X38W&<KN49R/75U$ID5H#U8UM]#MD?Z&.<7(R$5Y3.C5-W?EC4?+[AO
MP6H?UT,KDL33IJ>?+MWXVY-'S#DYEQ7;0= 852SZM?(X8Z-03U'E$1[K+I]*
M @R@^5-":6/]_;*&9U_=VZ;TD&;\1R6>BH,T4:Q*1.CS=N4DB<!C9@^DS#QW
M%+T**@=8?W_(_'SR4\,;3/W5Q"&/>V1&N!A'K/, TV'48UMI>D/%:C?40KT!
MOJIR=QH'/%4;\]V\M]BI\G0!'1-WCRN%36JX1Z"(SR0BU,?=3PMI4 M<Z0TW
M+/]K8V#ULCMKZ1L'HADQ2"+WMI"IB492NVH!>2$LC%XF =#F[>/'#QQ]87 (
M<<V7DZ,5&]O@8J*P*RMLF5A?GK2#W5$\J(]&, /M-A,QFBA2_8?$#5Z'/:#<
M[1**AMXT$R?'WBZB22M:>$<9&Y6G>-#:BO5*]I9A<9!IE=<!5FQ%WE^^5Z(Y
M3/R8>+D5ZMU*%'[-I::FKUQ3%FWS>N":K:4UB@HVI!.DV-+.Z@RT2!A@SS!Y
M6R7,V)(N+!S7Q\W'M[#3\@?8Q1J',F-\C0MLN<L<?UN<*75X(2@Y2TIOL;_\
MNRY\6T<JU92 BH"XLN1^-!]OHF/?MJXO<@^R_M&QSF1'&U/&W<8]<)R)I)ES
M;NN5"CK>Z%AVGC*504E19W-.\ JEME(_90-FL'WF+AAW;JP+;,CYP(VJ^89(
M[&U9^/F-X-\SCI],$.!MG/V9H8^?DA%3ZVGCT'55G [-ZL:\6"0\(/85;KRG
M7!B.$K\ 1'?!>6:V,N082/(C:Z(V(J)][V<4C,+[5!Z&R>KMW7>JG_"M4Z%2
MW>R5WBB^/2E$UZ''>.EP65Q_B3[T-1\P<4%*N <%]YGGM]1+A4D-'S?GMY!"
M;M_%&><$(_.)U\UBZJGWW;ZE5CJQ4GO")IEBT^YA1(KVN&>0(FU)X4:'TTED
MK?D+P$9S+P-9'+F=WYL<Q04['UZWGSODE^J7%6KF#X"2LI>VCW/ME!UZ9R@E
MQE':?'=UO2$\JD8*'CX!(WU@@I/<XO%@R!"T;E?C+L'HHS4WW&H#;2LM,1Z4
M)Q>J.U^:JKDS\?+JEN@_8MV&/1RP5-T4(E-T>W0+70C*-"P0)K&Y46E0-9=T
MDB;-KJH6['OO:]E]P^T0A4^$E9 ^4OMT]G7AL7PTS2QRKV;RTFNI2HPM8C3X
M=8PR;+]GW<X^, $?W4LB@&)!S=\_[*<^,7A&F,2;O01ZL-[Z./K6KY7SV%P:
MH(<-)7WCB2T5'&RS?=]X\)#F5O>:Y+NBJP.W]./+A*\)EBH2N5*4Q*E=*W@Y
MXP?=[BIXCMLQ)I6"Z1.0<M]JM%GUF!P+IK;5+'J-T&852-OLB$"T%EKJP%>Z
M'\W3O&N9OT_77&U3J?B=>_SSI):CQ+L&!3J)=\__GZBG(VT2TXU(-KC1 %HC
MM"]!O2>S4CHV8^M'J5 )9?.3+U=$.@J@']_8?$I[3KX L!/MKA- C-\+W88Z
M>IB$<'5\XT&JK6$%FSN10"7ZJ['QBH89C=F&<[ZFUN\7C6\+%#UV5>9-['_X
M/DL:WV -T?C9)#/R736.26J,T!+4D>:64!G;A_/1RT?ZSKF4L4?JWDBR0MFB
M#;2R>11VYFM4+)&JLH@D,#=0DM!EY-?M3G0],A_WJ%AFSSDY>JCQ]4: H%0&
M<+1<DD$[CQ]&_4<<K[?'OGD!2)!?T60_6./_LEID93PC'MJ><\MTO76];JG<
MR^K/$'4FC0C*@5K\(]D"7Q0R[#BQUHWGW8:VT+>Y.RS^M24&B,KZWQ*IY9CR
MIN4Y5 V7$Y9O X'_M!T@STJC1$D3;[8*[^+J/ I(?CAG7[N^J=)L?+4GQFUH
MT48JJU@YL:F6*@+VJ8LVM:(;J<$U&K0(O,W+9*L0\GA<90AC#+D /(5!-RYO
M8HX@XQOB-4'Z0:#Q)ET3*A')IVN3/=?L^3-XA1]FF!K1[/EK_-ZP!=JV?.-[
M[ !.,E+YYM>FNZ)YB5Y>(DWR?#E>JC(&7S,,Q-%Z,EIX[K?"@<62;M)G."D%
M&#G<O;Q2:$#RX"'" OR]AYH?3/'F89.:?.[\>RZR@*=N65;A>=.+$3=Y.JN0
M ,N0D^'K67\+@K>."X*[$!WN$E:#;@U<OHEJ]BGJ<$7])8?I>JU6@: 6M+=I
M\Z:?J+>?DS:A<I.LRT1/,KUV^@4V.62NS+7%+ZR70%S.KL_9_<F$+5[X2>_M
MV>;32BK8_)$5VB]:5]"4'BH5M(R$(\ GU@1=3R,U7$J-6JFH&O=GGK@0W:#P
ME*KO7'RY*DB)GFKK)M]@LVK((6@KJ94%1HNA>C!G3%FS(27>67Q5L."A5TE^
M,9U!_CD?D2D!R%^S3(KIYSEJP9E$3 WF="[$'1JMLEK'+E"R=\]4M.5E/?12
MY=YT&Q!F2#K+/,L";31> #A[N-8AQ3QGI0]+\.G1 T./SQ5F9/?V@(@RS:*X
M[^:-\3]/P,D/$^]XT@KDU=Z+\VSOSDHH(=HF.=M]6)$>7C1P4\D4Z_=8%RG5
MYBOEX:Z@;9XNII<OH]F44%$J1W6V$*9]Y^YDW_I:@LX@"H0-S,W!*P7!#!U9
MU6XK1<8"MR9<55)$#=38V3*:\F/51N_W8QQM+P!:@M&] AH\Y$B"5^9F2=R:
MY#3< K?G*GN$C2L(Y+=]9"._Y.JD8H2^;]GLQ;P&:?NRO.8X^GN"[IM1I#KB
M2DECY9X'4>](CQ0+W00!P"9/WX*=E^52R5?#PD4<F5(4%M]0KPHXJM\?Y'B?
MJZ;;38GP:<U]S*FUU?>M#;1,_7/\5(]T]2B?Y();3W2EF!WZE5N[[)^/=7^]
M$Z&!@K:JFVG-^[/GH16?27U](R>DFMJ7MK/ZM;D]VN[\"A'<#UP8>!P&U%'+
MEC?E&IG/!K8IA\Y*?4%#K!T"_$SS0ZL\;%3&K*5GOO5O*: ^(ZF,F,V88RK/
ME/N<@Z+Q*\!MPQM]6R1[27<"\)<YRG1'CC,Z:UW=^'Z!!<K4#AU;6,93%UII
MB.E)?I<D_?OJK^C_T7[Z+^3)6$RRO1I+%+'2)1KQ)=5EZ-W*"@U]:#,UF^WY
MT.;%S6A:MA-)A7Q(^8R)PJ&)PHQ)F(E2_DZ!9FM-&"H)KHP[4G[Y(T)3+5EX
MAW([1V_OMY[/8^&< RZ:KIS[U_PDUC;TIY:ZEH5NW!="H7W7! EIA6$FNGXF
M]P8,&WR8\\I:6IH;4QX80WA^QDED:=+=DGK^3B'M3MDW>5+FH!HT3B%YU<.F
M,VGZ\]B:4V)%7K_NZ\'8O+STA]2:HRH EG] K\"\&DI^(/:6O'=)?LD@VJ7/
MZTN= 5LI:S]%Q$JK)$# - V_R"=C3D*4,7>]!,?!AF;E^Q3/.$FWB\,+<8%_
MOW-[E]@C^_B88]%&]"F?B>VVJ\Z3=^M-"W>^.2MFX:4MBSWS.]FE;0?GXARR
M+(:\2*C9\0N  6%]H'9_$+YF;RSJ^$:FC.KGM\+O[$)26>]#?6OT&.-?(KGP
M37PV*H8J<&6@&UU0CCBGFKVCH>)9 7YA+Z36C]7YQP6 B6*FE@TC5[^B4U#P
M(H-^^RB#\7TEMU$R,ES=E@J7WG^NW-I)>H'TPT(3H+]:5 ]WZ6M4H8JT7SNS
MQ?)HVTK@M4,Z+1_CPJRQU1Z\U@]ML-+G,+CVB3/L$.^=H$J=@-$><<AF&'BI
M4BF&/V?X>"]B,:7^)<Q*&?=SDZ+H:TMPG<" >]G+&B?JY/$[214>^9AEY>&9
MDT]!JBG"R6A-1-C7<_9 )8.!CEQ&MWM 16>!L*S-QL>[G"FQ0%-(_D83\+HX
M15IE\LALQ<XP^P_WW6 <8=VFWR*S8MMMN8PN_FO8''HH=FXN%<M5]S/ NZDS
M-8XA7*D1PUK*]VR).5YSF%$S[ )PZSBM]V<1:?\"8%&DVSUS%$OH^Q)U<\77
M?*AQ9$BI88?(;GD#7"$;IM^WC9GD"W],33Z_NJZ("P?_EH/MGH^NIUT #KEG
M_<YWX=Q$*U'B2%\Z(_ A;M^;KW*PF!87<+LL'FEADP9.GO#Q#/Y\+]%TK[-#
M_(8;+%ZDNM(WR<&:7W\XC ?T/3Y9Y;X@[CCQZ3&EE_,D=_^*7=JHMVW0-U@^
ME[$+HLK#LM'Y#;FQU2$]V777OJ.J]5WZY+<?&C%_K1Q55E"/;!\]_#C(^'$L
MN#;U^'76[]KR.\!H1M4(IK?GUBUG&N[/1DZ5_VWX@R#K2Q6_^Y?_(:*_IV&8
M?:;*UYG(B*=/T9#H.?U5CD2TD4C^?KP7C5+_?*[5HA"=Z(R71=+YNUX/)I+$
M?E\Z=MG$1,X8D]D/9GDLR_$L!+>04-F6[MQF@VT"_VBC;5P>[+S5\=U\QMHL
M@(8G-379(YPHZG@N2+S6C9.-U">:Q8:AS0:BQ AG!VK%\?4_%BSM=SIMR(R=
MTC7WJQ)@*\&-0JL,1/D^8/" \/!Z,BQQ T$;-,2@*T<=-T#89U'Y'!H"[V*D
M4WEL$ZDJX:T:):#@XR$Y6YQ]-Q3B]D?*^7.M'W[%A:?D;6!]0L?Z]5FD-K-C
MG5]6)=?L!WSU90Q4.#"U9[!Q,$73#BL'E5F&!68VOD1-=:($#Z!Z#FQJ=SS=
M7GWX>B."V;1^^ ) $C,CLSV9/"KX<@' V<--\T<,2*LX?U6Q;GU,EQ.3P(_W
M3P-[DYKIW0<^8EY@%8EBR<R>[XNM>YH$E]HH9!$>LW$4+SX*WTRZ (!4,N/E
MTU@_!W5<BWR9PW3WPZP%BO[/%-H0,A8G1^N@>V=P@VB=@8X;U S^?-VB$&*+
M=(T5W"97*GWP?AHE*#_N5TUR-H9R.^4@58?'T'0'R\%(UY1+5XBL?9297*0Z
M@[+P>9=$F'SPOPND'Q<4^*4'\T/S;9O\CFI4Q5H[Z)K,_(&<MG;,JTNNCBY8
M(ZK5HF]%LW>='5<=)]@()CR88$GV3RYD>4+86K;GN]8"$377O$KG;6P8NOO;
M+.11;GAK9^S0RFW/I[R6.;\^2SZ:%7L:X"D;V/AQ-RQ8=+_F>TFZ(&]S26R^
M^&NV+RZP JLTO#JOP9\I[T[8:^-C,76\E;<[OP@F0]&]>NQY7*#=1OLN-6[+
M[C51F2=HS2S#>BPXBF?8'9:K//*H1GZPCF?4+6'"#[>K1QLSY&7_\[9 $"IA
M8$-BINY;4A&GX8TLR/R'TZ>RCT]94\8;X;F<*6GBG&^F*W/=?#8UT$:G>ES;
M.#?+ZVA?^PA%*7$NZWI532F+$GG(F&+S^2VX$\&L+YW)87%<0L[;DS$N^1VV
M%ROGG31&&4WC8<#5F\MR2R17OG.X?7S,^?EZ@2#S!< 'G"!XH[(]_E3+_^J#
M5^]-Y(SR\!GZ31^Z>TPRC0>??8W_&*,JX!2F88"78_9SE9[[=;@:=>*B;=7]
M"M-D:+KX)<-R;0V8'8V]^62(SLTZ.%S52R7[ J".,.C%7L6;I7 50FE@D.1/
M&%E",CVMY],HJPQWT6PBB,43%F%$I57)ZO77W]<^Y3I=S_58+@N<<S)W]/@=
M>STCVC<>(=6$NH5CN_@HZL + )U567X0E0R(A6BBVZ!(A(WYL>9ZDO)&YPN#
M5\3$6"L=FZ4^!SPM5DI];.*+F?.QZ.LW-_MS 3B*)[PB7 #21>?1^&4//,FT
M^M'5]#T?0^T:8=5OQ0X,G"-!(@5MPUH+,0L_*D? M(A^FPU&+2,89L)L 'W6
M7;GG_'$*.SR.6A93/3LOGN[Y0@M!;QS4?WZO"4C3Y*:>Y;D 5(*6; Y2$/HE
MI=\!"Q-_.-,VZVFSX#<WXQV;:E+K[6+OJ.CT+:U)?@Y!*Y<0^'[390S:!,-2
MPIFV_&=1-K:@$42%>.P%@,@ #\2K/'R_;H?[I=#+^Y6.[>^=@\U"=VE$P(;$
M[^$[X*45';XAJ:"VIH&M-^ G=P*!N9O[Y,2H*Q> AJ9AT(DGH07>!+:"/[L
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MT0SY6X'0$DP%MR(;FHB4KS9]H(D"4IT6*0RNI,B!!7B@RMG?$5]2<*]F+[0
MW 0K,?0OU5E/N WEY!_L828<&)NY&[]2%7FF%FWV?0+QH^9 >[)WON3=^M1^
MPJJ>H\-"C :7QXX---]&:G+@G+9_H;!\.<",.1NO6N#_)P3L5/*G$I_C<O8:
M;Y? #9:3^D#LY7+;9*LMHQIRUG/,-WJ049E2^:C9H.:R>L%3WGVQ42F75E"A
MU^],^\B)M%L!4=NJ% '3:DCL.#YYL2GM@(0V^/"L#B9ZOH7-LXD_DH4 415^
M*:514V7.>9ZB!R0:\E9%ITP"L7VL,]MM)HY+1?C5,YJO GJ*.*(<DR?&[K47
M7+U@VB90M8*C0J#L6S)*J\S4_K$7_ZB&L2T]*X\*1O'!C(W/[];M>33WB:HN
M)'DT1$8 \J)$3)S:4=&MQKR&*0Y-AU*<T&,VF"VSO7T<:X2<,"U(/U&'Y!)V
M;,U=^G>V97R7;!FN_Z/*4![-9*YY,TV/TC8VRNV2E42OCU']I1]O;(LI<>GQ
MV^>$W9@D_!F2GQ"*3"[89]"C5 M JKK;CU;_8(78!?PT,E!M?R*:J'CR%/Q-
M-S)S4R52;:)1)L*(-W-+!=-U Y__\GLL6LJW15'V6<ZMW/>#4ST]XZRF>\U+
M9\B<S1]>>5'T]P:4""2R+(.-]'+^7;2I?&!V\W<D"&+XY#04^2A3\U)"LI[\
M+PJB^.964P.%-8<( 7!5I$33M%Z5U+!Y'P2 71T\E^X);#VYG8ZH:A=AO !X
MMF98OT2T -^I6/&[?-C_1S#G M"&V..O-L(G0V-[KL^:U/)(:U:1&K>8^5 A
M(;?^YO P?-R9&@UH8.^>=7/[TYSSFH\M!"P,\QAQ?-+CT=3%#(D88*P)^-P_
M]O?YK@>PUCBX#=S@K)H)U%0<615@K_.+2$]L08,''3$3&JBZ'>7\UE+I!B^_
M@NWB<.?B)X-\VEP_&H83WDH]O_=QTO$\\D3S&3=0ZD2?\#,X37V,GV&?(K[>
M**Y]73R509D]<,ZPSN9I8/O8J] FO@I8+L_B9\$)7-)80_!WE-FI/*_$EO2O
M=MY!4]%+QR% =!"3-*-V+1=]\XC4II;GY<:%Y)U%<DNZ$0V+<$;\L:%$A5P9
MS\,DR2\:?3>C-2EO!%Y"SUSS*_.*@(XH#!JG<6O5GJ96\8]2Z4.E<KL=X(3A
MF"*%S:-1:O/6?P#+PL^J104[<_ZAU%N6K?.O]\=A&MOC?DUO!$1O43.Q/0_C
M%KRG7R02IV-0!M1/@M7_73@Q?'8#:'NBL-6$&E01/$Q_WO"F3?L6D?-6/][[
M-7[5P 3W7G7U6HV["EB]2 4ITZ28/^"^HU7;Z+RL^*X[6W ?Q(2QQI7<>#^F
M0K=N_GG;\OOP5RYLUKQ2KI3K=.MU2'^Q9[1EA/N=T5DD)WMR/^[1WTH<J!D<
M!VH#7@M+\)"+Q#D-S;[@-RT(:9VQ,K.LXEG[F?8/QZ=!!E8PQ2KB8_=F_:EX
MU/T+P*RW1?W\[JZTO^G8'Q.,IFAQ*23$(XP7H+V\VD\P+A=03=,=*>W;2%GX
M!DI2\"NY/D#4UL10.O\X9R"E5G[4%_[$L28P.RT9%U%+2/BNI2)YZW5?_0GM
MV<MS=42=!@4I?N,Z-.VH8S(&;J.=2/**=<3,(3\("&^I1)"2%(0E58%*>B-+
M 7XZP_09L1IBY?G1->QR?^2VSW"31^))A>QX4WJFT1>;*?PR)4HH&D?Z!)+K
M=39OB_*,FC>!6W+T"E__5AM)%AP7\O>J<;X]8?IFI-]-_04AY7@!>-=$LO\W
MO.QB*#;7.>"RQ+;8<V$8JTW! R(B)BS2'ZHU6^I%<=N_X#BG39^&D^=)6<#T
MHJ]M1D#2SC >YF*ZH7?L=,H;-:TA<%;5<PTFAT^+LUU[YF2FA#U*WWK:!$,,
MGD XBF]^J?3XPUJY0RN^5!X0H/"W]E<'ZU5PGV@4_E)'F,Y!*R3E35"*QM6=
MMJ%0P803*]+(@.WOL0>VY[<)GRP&:OL"XK_9S0/OWUK13TZ_9\+H'/<X_QQV
MHANH>%UHXR]1E^,EHA5FRL0J]3[ZZ$UM'-HQZ-/[%A[GF32Z,(C7&[^.2'$S
M?J[?_<U3)R6Q0#TKZ4F/S/FJ"T#3GXY(B7Z3WQ:?2FF!HCYB>YP)*>(Q-7XA
M?]P*,*4<"/M02TF&TG@M"OZ3Z86_9(3I_R(N[".PA>$G4=0SC\.,]I1M9_?V
M%2-=1-]-H6U__[H:QCB[[N?GE2.6LT;5 E5UD]/@AE>5/Q;Z_1$! 0-6C-26
M%TD5D; M;:H#-;9]OY!*!:7/V#:FHV0C,XW-GZ^0!QPS*V-Q, \_9L65FX):
M%JZ7)4CO7_>8# HK)VG;]T*9M_/%4&Z4N9TN-6J[:LWY'DLB)3[MB?NA) \U
MY*AW6K\)$-BZ\(>K\'K-ARBU!N)6=DB5DX,KQ,Z6YV6G+:K<5XCJJ*!*DT'>
M !KX)4_VT2K?J,(][&00Y?P^VZC</MU-JGT>4HTQ 1P7EL[BQVFQM(W5B9T[
M6_T43\_872NG,"UH617O>_A$2-?@2F\!4PJ(X_ "D+S.'&8F %YQ7KX:Z$:8
MJ_[TXT0L%2K-2R/D>7,DY.8%P*C[=>#TJB$N\8&.8&4)P6(_\0]$@/E+#R]D
M@9'M_ XFLLA>=PA\2J_G4Y'#V4<]WC,KTA([K '#Y3%1QI"6#) BFR*76J5K
MD6&94B8Q=B^E3/3?;R2WKD66)[?AY;FDKI:_P@RD(A_2//-OXU)AQJ#B/_J8
M8MTS_8@;;K,IC@$8HN..;*N*(FNKM(GF*!TJ)+5A:4U5Y;H2=N7NZ!W])Z/;
MY>PB-S2I*05HA*MN]6C<O'$9J:*9M-09(Z OHVZ:5-"$3@0A.V?8:/;V Z?7
M(..OV/D>=:]FI $;C8]V/XD]$-"\ -P\?U/2A* 8 F'7Q,[X?Z^(60Q.'_U-
MOP%ST5Y\V.AZ"W4Z1BJ$4OXQC&.]-2EMA+5!#82)QWT,\9W./5)WCKF#YKLF
M?5+27R*X^ZW7%K<&'+09\AS/B*-.%)]TXGZ>WD47&I(L.3>\@>_PX.N7JE"F
MI^QIX?.GZ9P]^QC[T&;.A=NP4X6A+H6N\=XK;6E)J0_1-"(\Y#Y2)DZ7 $X-
M6Z6RR/DL7=(*,=9C@=C];6_$1@@*.:!Y^47: @-UI0]^2[JU)TDG/WW7WE9$
M^=Z,/E$H7_X#;!7F^5GSQ]B'FMB'UO#N4U.8\9H/5B\%[?[I1&%]R;%,8ERI
M "&VJUIR]1=VASLY1# +[/&V/N8L^5S=2^/:F:R\V=7VT<U@8/J(,:,KS= W
MU2$971<[,:+3R\HW6X7<AY^NJW'YMLN,W+&&U40WL.U^*7.9^Q1<JS!;'Y]"
MAE8BX@Y43OL*00)?I\K2/I'O#XYH()/Z#8N%/%2TE>T?"R!X;*HZ7Z/C!T*^
M<>\ITW[.3V/EMG&<XR%/D4XO +? SWM_/B:FG^?!9<$R"[/K@HBO1@3.L]3B
MNQ> &;G8FF_YEUY&@_<RJ#[J_>F1C]AY9$8\^6^AE$[B73>^OU<3M%$(;CE'
MGHK#8=,E=K->9B]+6.2:UZ_#=1J><F$A5B9JV!]1*G$R>VF[_[07:J,^OE7\
M_$+]:S"+OW\*HB1T0><U-]\U/5M=JZGL%PQ,#91)Q/9XH7%8F<@G$D+Y7<VW
MOW4<%1P8?T&(P6B(^9!Y5N81K%;@ED(0S+'Z,_L/;5>#N933W[63G)E>*L:3
M5RUFAA[N:K4HAX\K%%5;5&<Z'_A-ATG,QTQ;[QCMZ5X'_3BN />A%I?!3J-\
M7RZS>L,X:^UK_<9;G9B ES7#.WVO9[/#A+*R;\Z=D-$7@&B=J"_A"#Z0IR C
M!'MX"H9UX3Q7+@",<$W@]--<NR ?VZ/?)#_+=J_[:T;KC,Z0J5$A[AS\-"Y1
MMKUD3NH"(*42+S)$6(LL##S76'<:;>)S!3M:F-ZI)APZ0_"2E?]7,V?UUE;7
MM?M4*5:*.Q1W=TBAI0U:0G%W]V(E0 HM[N[Z4 @0( 3W0O'BQ8N6!/<$"J3H
M[O-^W[L/]E^P#\:R@W5=<ZXUQWW_UIIC5I1%]XX0QY3D+Y9%Q[BU2/X''@8B
MW#+6O($2-Q$*A*\I-23SB@XM\W95$3([LWJ.$U<SN75M_WJ[!+]_TR]EM8?K
M04>HOY^;HZ [V=3/Y0F*^^@]D%_"(K-$YE@!*$%)1<<GH7Q3-UPZ\LI _9=X
M\*+^8_7 DMH"$3]WVY!SE13(P=8KSIWJ GPRN\\]PU:^:5P9K_6%8COH47<
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M_3LGK%Q5^#.P:^(7%Z>6B.IL*\K^LQ&4=5B((90-ZW%>.7/V_1@JALES-J?
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M\AF[=#7VH?.%W50M(E:^S=NGK[^VXX B[P"/N&XB+&_@G52K&FN[Q9/RG)
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M*LNV(40*U&)'Y/.5=L.ALTVCLLIYRZ4W%^*:HC#488X5PD/]>JJ?3C!3UK>
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MZP*SRYP7P'81]L(!W,CNJU0KQ[D>C+Q1U)AG75P1T9)T$?"Q062J!F]#W1W
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M/*3#-.;W-UX,>,3*LV/5!K2V?W0PER[A7JME16A/#L%7U"OWO?I>LL0Q6W[
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M^_I9U'0O#X=0I9Z3B8+JE&N#"3>_Z_.8U=4GQ1'21?&L"=)H4(+TNDI/B>=
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M90C TA6(G[,%5Y'H8<# :?2'Z&)<[T=/Q1YGASL+"0>\[KZZ7?>'L33,&?R
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M7POK_8<2L=7HS*'_@XVBZ9B"T8H:L/+3S*KX9Y8HXR)BK'KOLOBYNIKKEYQ
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M6Y4BHY12W,8*QS;6QU3(*=??)EOH4H9@M(VUS-VS&-4)<@0](QX',A4%Y+O
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MI/FO7CR?QE2E:3\I!G(OCYC(>N5 4^^=&F;;E,YZ!$P12XF>(E,FA##Z6*C
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M'*3S'DJ[2C:$*H9,##S]4^>&=\,URJ[L.=TG95&]<\);1]<KNVL9N4**" '
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M54C8BP*SGQ?DDKBA!&E1V<9$E'N(52,PFL^OT.<C$MW;J"4EHE]9H%;Z'L2
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M?&,"T=$33]&]1NM3$%KGFI$I![0.8QA[WM<+SL0H5^B0<5N]9";ZSEYP7 +
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M<K3\PJJ&>%DEJ.;L/M(;-"WB%VYUSW<NTI" .*-ZY3GNUZ*=R;SSG(0=642
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M(KL\\9G://$Y6IKJ)]+7\_@9\AF+KY#B I.WU8\C=#),[PG ^O_YG-?)+-%
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MOCTPO3-@G.PTK-?R!PRYC8_K@88FT!J$I0^E$J0ZAD!-!K2D9X3K!86P.#2
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M\"MO>JDN@W"EH[.X5*D9UQHPO9.<[/4.?\_O+C=^]#^Q_L*JS]E!3G<YH:4
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M+' \5QMHP+N9CIEF\!RJ9EI!=_OOZMFM^L7OP)=6J6&G:\CR&P>G8AL5B"=
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MHW>M $O-OZ3-:9'B<I_E2;[H6,O=O8+"DUO4H9G>!"HG7+N1% !ACFYE<L\
M1FH &>6L"=??8[8$M?"Y?P863QB&+D$"6W+"#DAD+I^ @(#%0\+%^")]3.QL
M4^S =7V)CU=J]^W9+',CVY_B$YHK/M@I<EMEO"\^Q3JV;XT'CGI9E\R*-S%,
M 1WAW&9/9^QJUCI8C./,R;\,57GBXB_A9&&?S%[6+.E<J518GS(3,ZQ]_'!M
MA%B=B;H\56I1,^J54:H[:&B27&F=D95A;]M8M7)C!8523P@\=\!5JG+_W%GF
M^[+V(F)['-'[$=7?7]/?_[OX]NVG%74YTLG[271J(DD*36;=M54=L"7.DA[D
M]4EED>N*3QZ07O2)9$/M-:E#*$@.VWZ_Z WOZSEJQIW.N.H6P=KOME+!(;T:
M* &D(T)T.(W(\33O$^L[Y<%+O,?\O_O.N[:^)'!$;DEO*1BP6H^5^AD +2M;
M1Q6"99[4ZV>!S$8/>""2!XPJQS-/G!NJ6VHR;*$?>#W3N+@>K2CLV=EVD)AD
M^F2M-91%56)G%BL]Q,UO*ZU[9W1B"TMYC%_Y;HPNZ[5RYWM(%:S]!)JV-UM_
MP+L&APWN$I<+T<X)[0W?1W_=.4X.[<*(;W_]^[4(L[[;X$@P^S89/U4;;[1W
M>V/'[.\6B0;(&46#D8LH&@#_>"Z(>)>@U=M]J@PSTJ- KB .CR7YDTE&_V]P
M@2D_Y;E2,@OVXSA'\KUL[=NDNUUC1?GCFO(&>EH33V-L:8 ?RA<OJO, !]'A
MU<V1<IB26984U]_^#S@BDR<<S+S97 8VO:T\ZHQ+(\HY]\8*^2Q;#/,@D_D6
MGY#H5_PW?W[/%>]T4]:XI13'+^:9!\44"[/;7H[-_[7T@#TRY9/X6%KBGV)#
M<]&)? N_A<_'-$"\#W<C%L-S,B)&UG0\ON*SK6KYA ;PI0)_62J7,F?,48Q3
M#JC7E,F)'M2H8P'G5A3NA9%6?ZHK'-0=$-RH!YXVD]W'M9;G2'LZ'!=L32!5
M@V5>@FSQ.LHEN0$NGS0[&L)I@#0)A:ZGXOI]KY;%[DZ7$7TE#Z"4.^9)H]A'
M^ >>5UXG,1? UF;YFZ>:2$!B! $4OA3/O6M*S\Y\Y9=KW7N=)^:#;$]Q[X+E
M$G0&=\:#04-[14.'B1AR,<7K2T*W(]_J1(K)U/NZQ<VI:2^CU,3=6ZW,S-$6
MQ89WD+^23$Y&IU9\]L>T2;7X3.S#RQ <GP"CXK'+90KJ&;N9,L#+S^[JG8#%
M1?K*0L1@!J*)=0&N05#,*NYH:W[M"IM\>?N207YUTQ'U(OHVMO%[;7)P\^A#
M3<;=2D!V<T+D;ME>YP([W!+3%);6;]P8GNOR%&\DY/D^Y,XY3W79H;_0F2]=
M*2AW9_>-KRLQRXGE>S)=A.)G[#<#,!+RV<U)GO!Z"*5W)%N89(OSHO^Q5N2>
M_OXKZ\E2^,RM<]]?TK_?R5CD5Q9PJA(49**O2@6]+W?$&VU]P3(\C#4BR"LZ
MW*BZ(?3.XYUD0M\PYO<K[_?91\<9Q"9DU$(UN,L%.!LHE,V)SM+YZ//,K*U*
MMOWYE6]/7KV\".L)5K>QBF,2=H@0$$-7WZK9K8:4S1FIY$N^X*NU9;Z5/A,3
M2.DK;R-UQ)RH;!#]\*#HX3]D$.EM_ESZ^6ZW )4'LD)_Q?K]5N@2';,E?L)U
M3E3@C_%'_M3>8.WI5P^)=%N7VOSY'397Z"JZ/=;T8;L#2#\4Z6IQ)\1'DYAB
M0S8?HOM:=\#,N#%C6P5>NSOY*R]T>?;'9Y:II):60 L)";%.,=/5MM C[D@N
M'5CM>LX!*:-0VU87I/TAQ5CK4<?_NA_F/S,"_2D9Y,?S7*1V3/P>9\D!L1$_
ML+H"+2N^?#VHK4]5@?/Y],O+C FW;4&E0D_?!28P(MBL'?Y ZM,"4W-K_ /]
MYFHI-5'=?-*2R_I1UE:O\G2Y=Y793T(_0RWF!8=]P5>G*Z">7GH5$P*"O RS
M[BO/;NH">@6;GW_.*LDW$D#WR\Q<:*<!S+ )%W"-;)[Z:GV5?V0_3,1)9CN^
M<P+5O)JR@%@/%AAE.A6:+K\PY+S+=N3H<O!)V6:_DO/U 4II(H2ZI=6O&B#6
M#CJ!3?Z3M;*O\>Y_9J=\>_8]Y,;CI)X/&VF\"#XHTV&WBGI,LM3/9^=ZEH#9
MACI+YIR&+T;"\DY$ZX\9M4U>Q]DB=-%]?.PW;VKK ICRWM$M0[MKA^(R^#^4
MU\&TY^]8N0DJKWL/*>'BGIV0CW R,_Z&53%VX)ZWYY#]YISGU $W7J^,H2^V
MV-W2^>@LE"JIH*]8\@=LZULYJR/=/05-2BDY/@WG/TXL3NQ']_==OS=&L=.)
M<[+VVGU:O'*XW)S;A>;:5Q<04RO$7C@'[Q[/IJ,3>;O.I.+7C; CX8AE&4O+
ML4;9T#35-[*5T\GK<W0-?3<2LM$RI&3L3BS\_JY72]*,B%1J_&P W41U^['E
MW!*"UZGXU1 /R(7#=;SF-0U /T'>#+[(&B%N.-JEGPKQ/:S_.DX!DI)/S*>G
M)0F]W\ZNO+S,^]$+NRBJFN"S-EL+E\4A9SBZ6@4"OE:F/;KYKF*/+^&1\I(9
M__=>D86$B;U?8P.OEJV7DB"<20[:DEW9S<G&EFO*;O1+RL^=^^XK>&C/D[&E
M2-%2C9,<X_"?%1^L\KD]3, >NEY_T8-+_7/W#XT_HEH:TK 60FGO^_TVSRB=
M^VVN(EJ>IZLES)9D(Y2D*R.4I+^M+I1DH==?]4^FW 4$]51E,IT"2B;CB1Y<
MMXY2B+BSRBC3!@KC%PPG<WWU>'TH:PNW(A7F&ES8RA"H@3!]642?G9/D.#YB
M%JXK+F=@9$Q[]'2"7>,V#1#B@6Q7U! \?:"FADC+]V"C=C  SAKLL<!.%1<N
MT+LX_3+[(E[?$.TZ3O8KF06F4SQ1$9M\M?'FAI);,J#ANQB.#J_S< $\70CU
M&ED:/U<>C@"2SFE6XJ?"U=1=6KY6C&Z:>LA7-\@Y@.<?N[:.'S!$!&4],&YH
M;/GNFO9:@:@F\ZZ?PX(K0CKGA(_+YTG8U,F N[[NJ]I2>A.[4:^Y8A/9D.4X
M\;O;+LH^I4I8J,[A57\4EPQV0)TO>W]Q8C;04%?+7DQN0EY*!7I2T>U_/?C7
MR]NZRHOBBTS-3\_\.,=9GNNK?Z&Z3K.>SGV?]]A[Z FRK\RH P&\7BDT^,&)
M+2[!)T'ETXG?6M]6HHYQ#4#5<FUEDN&_9M3^;\DW_:<]>U\28_Y&F?,OT@%-
M"=P#L<,<I8V7HB]N7E_T723V\F8'X4ZYVNC;WVAADY(S/P1SD'L[^Y^9H\C>
MBXG,,'3G_$T\*$%--9]4W,$O-KHC#[I&\K*K3CAY-%F3N?KK[NN[DU4A55H"
M[WYL5 4%I*EF0IR^1RB;DD[5=T@2LEV4>@/Q8R8!38!B&--*"71$</92>1XZ
MKBX7NQ/JM/M:4)O04J+WP@]XV48UO^X][H=SDM";=D^LMTO@A:6%PW\*-.KX
MEDKJ1G;RAN_\1@1[_\9#.P[BV83\+>X27]I/V[>K9VUE+=586EC6^;,TWU5,
M3TLNJ;";^7-_B+&[MNO5 [7'A!\))0_@2$Z\H5'/APL1OVZLXFX3,OOW5&1C
MNY\6&=CWVHJ3;)*,_?"IPGVJ/F.IW.L*X!F\$=^*'>.'9@=;!?"%J%2%#TOF
M*\)AO::A56GI,+B]4H,X9Z/Q2C@ERVJJ\Z=9+M6I*^)QX?FKG%<US_N=9WFG
MR1NBI!!>4N;X%MTD6$@#O+U" QCU*E!TD.V:R,5(?\M#J@!IX(1YVNK^E"O.
MDB"R.:$VO#89L1B1L;NR.%GZ:@/R[/ 5JSB,SB9MP2CA/H$49%:K':D/_"42
M*Q]O>Z]E0DT=RR=H@3^,(H,*-;+*8/[@L1?[P?X/QV]*)DU[S!B0GSC\MOL"
M7-\6,!9@$7I,J&I"Z"S2 (QNK4#2'N:7CYVJE9TEBUG_R^G4"V*+WBE[:N4J
M;3)NYN5S$\G%^CD,X.FI@ME#<2WM//1S0E",$K++Z(R:3F&*DQ-!R8$/]1%;
M]>M!F-P51KMZA3[OG9D1](Z8SO2D&0&&A$1^2_+PS1<S2606\>H]-G=;U\@9
MGTCG/;>3.$0#3)C_*T+U:  ;5/W"$6@7] -;?4 &]12#YD&1N^PNQXFH P7[
M?Z]]H-@)07>RQ!CYYS]ZJC _@;@]O7>AJW(QY&Q#V^)K-1.0\3ZUH!@-[B1[
MF$+F%'-\9Y"![L4BN;K%I=P&7M,%";WZI'"L/;]9$/1HO/"\_*L^UKC .[>Y
M%E^32>6!>-16  '8^>-=61-\N.!,S%K\+QBOL[35UC;L\!B>^:_UH%*_L5_>
M->QK6!$73Z&C]#]]V;8A7>"9)^$GW:]:@IG'^ 2)?[B3+L%-,5OG;+0[?NS.
M/DRJP*EK^WQB#;GXJ*Q*)@Y8C8Z=XAX*F]7.MKN8T=VF)?7.2A27<*\-.(F^
M]2UF>_W<AS+AN(1,^TBCYSC>_55H70XK3FS-Y)-X*:CQF-S('^S TZ&WG:J7
MLN YY3"S#[(&=R"KEQOS:Q*Y#0I^D(OL >Q&3VW?]C[H]?CUG<3QU3Y^ABY1
M'CJL;2R4H>"<T\A\X^_?UWS4VB-_YFB%3)]=AT>OL^_Z;,WR-1TLUY4B!$@Q
M?1&S'Y7:+]QZSVSW%S#GTWNK$=<-\\]_+O]UKE97_6#-.<-.+@K<T27VVJ 6
MT>(+NN?5>H'4,7MK>E-FK%KS95C]XBE5J^V76>Q@$N,V^ZZY[REQ+=_A]1YZ
M 1*<;+6L(!&P_>PSC6DH3E,RQXO.N)4(KWZ45V=A#:6@V9KIW ;'WV>\CVPT
MI]!"""5^:NT8OV"_<%.*NBDXHS*LZLH@C[#PWZ\[AW)3VVHR6 :GAS,&Z[C"
MJ]5G2&^@4ILRN4+J^1WOQSG!B63_\GJ;I:>40H4.Q:%@WD]/CX:_'+9+YGVB
M! \]7V.>L5\"/,YX%G8P=_;*\<HL&7>K+B$@M?_Y?0>#7O*IZ^WG2'$UGH\=
M.ZFBL%)KY1_?*9^/T3S0!OXR?5VQ7@(Z1V7/7JCAS[G]JT[%]IC\UN?(+8X&
M>/\8Q..K3*5^1%',WB;!-.8T6I=KK%OMB%V].Y$T@)#K[I_ ^="#FE&R$^3I
M,?#'2.@J4M#*! [&G[AQ!V>L_/$;>JIRT&V2C)V,\(E5==GOD1M+4$6*\WNF
MEQ]%)2[PH?%2[2Z_#VF VSLTP"T:X*]A,=TP53ONGXI0V&>DRCR?.AZ7#;*>
M]\&-XQ,$9TD#51JRR!<R[9V-^T(#*!U3&_I5^IW*"%=I@+;/:.*RW:N2#EO'
M)1K@S0 -L(7*]Q2I7^G=*Y]@GC;MBB\G"X[MK^E"RR^O6\XP;#OIUKAQ1V1K
MJK,]@ V_;6@(V[]@AA >(D3\>A8P+#,2Z8"<P6WL#_$A"B@?T1!],-,:0K$J
M6/.:V,Y^YKC!3[H,J;+2N72A=];WS][1;%._IT#.W>_MW]V6QEL">27"X6,W
ML=)\@U6S\BL<IAQ@D5^"[/RG[E#FUTS2",CY(I4M:)K)^.,#(,/()T>++)M7
MAR*> BB>.=\4$%".Z!=EG.8"=FH+1/!1/)KF9G4.5Z(##[Q_/]O72#VJ+D),
MO@Y]:3O-NT)B8.D3B3M#>MTK(HC*7D?6^@XT:Q'3A[ZBU?R%WO8M(M^4[WHD
M7G!C]PRT2]\N/:H))M^Y\KP^5']T(0LM>&"#ZU(QJ/B5[OW4K_,<!:FWO*,A
MX*[X!3W*$C6HX:4Y%>>]OS)N^5>Q\L1P8XJG=8"- HKO("3OY!@5,*MO]/MY
M)<S+M4A5>5]5K?S(]^, ]_8(*4ZL:.7#>=C.FH>ISD,"MMBFY_0CH/JX)(<J
M_5WT0>6)3!$<,B+9Z9G-/IN#M2,<W&J.[0+7%*2Z SE& $V-*L0A=1AQ:Q-*
M.#0AO<>>8#OL;5PL)"_%O>\=3UX/H $VIE@"BCSN)O2L'Z^_"CQ*?J3Y@Z_^
MS+'EV%.R4GO'8(N?2)"-[*O)J7D+VP#^+";NSFZ4"7QFIB\ 7/[EV N;.#/3
M<4Z@MU""]]U9W>R5=VP).IS4[_]6%S9?MYP=,^*XQOJ.,REVJ$&Y=^P VZJ<
MG-5U, 3N,F,_4#)DZ:M(@S)O<==55QE-:"%0E3JB;2.UA6(*Y-G@_EUU?3M2
M"TX*DN-W8MO31>"1TV!"1B?(#:DYQ^P5MVA3CV+G[?_8R?;=LK:/5$>8O-[;
M+S*S'#;N=,2O:<=SFR6-O+HO1B&BL8%74889-3<YRT7S23,T0)2Q%GN#XW_L
MII.\:F=O9VL]8_MGWF'>B#T_-36U><J_OM[G>P*#OJKJL[3E[?6 2X^D2K%)
MD$]A\5Q1;&?8$7FGZE0)O9@&Y$)[E5]KQW*<N'6"I_L?CI,3.>$.XY(?<VR2
M!I]QS+.3W!R5XM7TL;IGH$%9CT%$NLC+$#^)CV6CZHI>PV#2Z?@D7X7V(J\I
M@)C@+I1ZWU@:('*!X4N0I_-#TK7#:U;DAZ2PMQ;8(2IK?:W7W;;L:PW,5Z:X
M'V7![8O;^ =AOJ+" 7G4#C+[J?@B&77.T(7 &3$#P [$57QK)O0K"=I!Y1LK
MW2]EN#_JR=%?.[;?HC@B6%]3&_WJ]5=7'1GY :$J7<'@ JV.6EE#SI)!UMR(
M43-\&;XT:AIE"C'^>J)A,W$]VB3T%8((3OY9;%[IG2+FQ6U(R#(L'"JYN92W
M-,/B#P>V);Y%,M( ;@L1&DPD*;Q_!W&>E81<+#[CG+MFT3F0C858Z7^#JG1O
MB&::3]5FU@5M@<V;I+P#_&X*Y8E=,:;X8T ,YQG4UO[PF[V2.SJ)0]SS3>[D
MOVIUWT!E]_4GEM6+ZL%!SNJR&0?N-QY=%0  ^ "XX]/P8;GV)$RL0WZMYW:8
M(.?]JWJR84XISIS=0BE.2;K"S](7#F1C8HQCC.-,XIQ2DW2MA=*BA4K>5715
M?-8" &3;>OES5H[-:HS-_NLBS/_'G'VN_S99#& SUOIO36'$CMWQ'8P&4$?+
MVKUHP@1!2;^C>K!,EPYZ'0 T@$9'DY[*,%U_XU2$]/ZA$\O',VIO=[95?-6#
MH7L/B-A_X(@ZB*S73A3N[6*\M=&&YI L&9WJS.&%,WNZ>.*@EQ;II6IVKLW:
M":QE:^ W/5IMW*E"UJZ5\=,UGOKZZ<N@^L-&EQ8LNR^=>J#/8! E&*FW6XIL
M"Z_O?]ZBJ[1RP_D+U]:GE?5@\2\BAG5 %@;QWX\-KKARETNZJ'"62%E-=CJ)
M*6O;I7XSC\E2>:]G[%]=@^(JE ZTBKGVBFC5K"A(%UV0K]33RLJN9^:MY%%T
M+;$FU^&?V;E4C-(,H=E1%/D)O/61!CC?2"D%.?E.J.GC$NG;"2*+ _%=K4:]
MS.'X>8]YKLI*N4M;(H25R&Q% D?G[$>31Y,0!?T@-'-I.VSKX&B"@7E05M*T
MFW>XCW?XQQ=<FHBUH-]3^BJ5:R5YON*/R@]4QO>5%ZVW7FP)?J]MB+"%9@9]
M</Y>VUCW\;&/K;WM8/F%[F9"90(T(!?F&O]12%M;''D%_7R!=--RL_U$9V$!
MMK+8C:&DMHK/]?D'?!M8C#\[948RQ9X<??UEA#6*Z%DQJAW>MEDR+_-+/&_O
M/J:79*<^^?&;7>-/=-W+G5@I44=84J3BB'4V4W:3#:E$R('B8GKEI.$)B O+
MS,"ZTH7?"O(227=:ATS,,L8FC?C&J^G-]%FX$7C^U8\!J@C0:"N%4HQ<_ BL
MR]D,DBXNA.N1#) XHX@,ZSOE/8FA!# ,U\;H!/:PWZBK2^O'EE_X_C/X*_#:
M:EI=7?>X=.Y+=#,HQ]MN=JXK>6:(_9=,T_.*1U7:OY64G@D]X[^D%MH.(("+
MGU8_;E+(Y36TC^O$B=:TK+,+BEP_6"HT7,\7F]Z@3\$(EV49_20TN#JFFL/@
MO711'>:6AU#3%&>A3+OQ=>NQ0OY1E ETS%'H7W%>?FHZF5KK9+B0N%^T^YJ,
MS'_-J_5O3XKNFAZ !LM F@<T .AGT=UY^9RUXZX-5-,>>&K97.V:NGB+]0O4
M.C++\M_K*R,R^N)(O<XZVJ3)#V1*7N?X!P;&!PX3IX[VGJ"-]T^?,MB :MRG
M6(\PXM:.V8$D-'##?+W_WYMK7=1S#B;X^#207Q@H.!+RYI.^60(U58Z"V_F/
M7WWJ4T-[\I'@]+\Q)DB.J>,)-W_.SHJ-D:C]P^([OE[E!T5)_QBO<W"4V>M"
M%3EB44OR/NG=(7MN[9Q^&:'DQ'D0$NOE%9CV?W;447TAB:)N&"7L]G6A:O/^
M:'^26I_L6DN+1JVAVXM7 [-<SEL[!Q2/SG_M,;^UCL@]LI2L\^K?!R_[=4M(
M7>_?%>\;(]  W(>@D/Z3')8ZT%+=IX9CG9>_>W&?<&@;?.^J!GIXJHE\';B*
M$'@1T%)A1VRK2ZT\Z!LJ11CAY!O@*D.@%EO11.J%3,<%ZBP- -A_M7/X 1D!
M/GZ8OAXD?^JVYD"3U04[^\#!&I<=ZAJU-E.&@ ".HB,Q1 3XX_Z0W^JI[/NX
M2P-P8"@2T@@: *\REEEXG+AD[7-XG+,L,9R'YJ$^SF](E@%WHS\4)?XS1QUN
MD[X#[#W*P1?%CU,,7G>B2#D8($FX%U5,%C!/S@U&EFJ:_'@EMSY-]6-W]_@/
MY_?HU[?\CR%%<6E.9]^NZ[:=^S-\=F2L-+CR1/*?8V>1SX&S_+9!Y2$@NMKB
M(3K=E^_LR$\(WOR,)#>G@GO)>JUBDR9"DQE_KNW:P%RG;%L61>LOI(/&138A
M-,#%8^H0\&*F 2%]2Z>D^T0/KOFV=!N##[.8FF%N][RXK@9*OQ6W=ZL>-Q5-
M#+T;M5PQ*B2;!%<C_- *4G[]X..RX9W<^V:K^I;19?EZB3(PQ8:- /$G2<C!
M--1K#NENIQ*,04\F#9!>*W/)MK%Q.2=/8(?<[W,437F'7OR44YNS58]D0U]$
M\/ZQ(3%*7^,SQ1XF<",9R'?&V"JM#>H:?%[LD;[NLELXYY,,QZR:I*\K4W_R
MZJ&G=3:Y3CUA/"4;[=BB.-L]XU>:W@.<>6AE</HEDGMM]((3.QL_$7<_5Y."
M,&%!'^!\^9+)ZJ4]E6SU#I+C)54O%)0>,#RB 2SA($RFO:K!F!H(0Q'HU1JN
M@3[RW0)JC4IZ[@\ =<>V1DSF>Q^/E3A%_.P893.W*BW]$B,$<-1!V@PW7Q9,
M25NZ?8>)"<G<BU(F:M  7UW4Y-[T\T(-@KTX>!0<:IS[#.U7C0]S+S::919:
M%OG.+QB$_JP@:1?0 ,'6R/Z^_'Z.^4\*QL'Y(F)$;S553%JQ#Z[]&^0X/':U
M]0[^+\$:UMEIVK=L!ZGW$8,I,(A9O1A7 Y4(U [&%]^0_=-APQ5CWZFFOZFA
M-B$_% IB4/,G@$S'"B8<\3)AM>6L?07M MV*GX_-XZ9DK25+Z-ND71^&KXAW
M"/F_*_9LGR5X=5PZZ!]@[9IG)S!.O8$C,227RC&R/0HR&5AL[Y[^:8'D#Q[9
M^2CIM\7M-NL']7K=+_VQ4(O]( S_2%BW9 W)I*9;Z.X@C:_O+N>U(9OBAV)]
M(;X26=S("VL:["%2&D2&?GL;KF>C7B)I!#\>:$J4EZSZES>ZYZ*%)%LG[RA]
M7"2\;#<+YWV&__[AZ89YHKJX4@-FHY?!(D_R:&VTZV>X;L]0QM6DZI;\!7OS
M5.Z1+TICY>(*SMH^=B/A$--OA8;&)\;AEH8F-G-:Q:K3I(1D@B6VOI,YXAW<
MB;12 KL+'B8;?"4Y>-)A=CK!%SW2^&^--3OC;"G28YW\5T;]2DV[[TXZB'$D
MK5="QM8MB0@@B[T6<:!G:*!7!FLT$]IUW!O5R@.SU!NN70C/EAVC 2# 4\2\
M0I4D270-D]QLF[P889T=&2O1ST'5M5GB*[8CVS5;'J.3DS _>^YCU7Y(Z7+M
MZ[#M/?6SS-,,';NP.WN8[1:"#@X40[YY/2??"O9 =ZK9-O_' O-0Y($^([@S
M,"?"CX&9Z;>')?=4I'1-T_F1 S"K/2D".S-ZL<;K#D-L2KJ.'B69S.(2D+>1
M@8HA!V-S.*WAYOB5[BUP3[; A#SD-%"PD1([ AD7(IK5"S8DG#]#C@W0D?(M
M_+OZ4'N1^Z/[WCRA2CD#2:[)BR)O<=&F'9B*O6P>ALW;8!O8KQ6ZQ)Y^5B/6
MD.(/0R?WL[G3)#)93,)6WD;PF;2-]1?A7GXHNMWE=+L&3P.HX(_VXL7-EL3-
M@K.8H5N$<6_V.:N)+VJ/6ZNYGY0&)J'$''$&#YBOR&^,E%XPR1<=W2N5(/XQ
M\&M6S+C;9A3+L8-K O+IXRE)&VWO;$G53TB>WXS<< Q6*XT$LW^.A/O\=D?J
MP-/E^>*XF4)+BISAV;K\J:U*#+2%[OY4,S-^ <N<B&D@F=+UE'/,N.=V!@8O
MO&D%]OLAG0X#&S<"E[,S"NKJ [6KWL&0]X-.3K[+%Q=_TPS]"5$7[ 16B[QM
M%@-V_-BG@+OEF,/>D8U#.WNV#PW>S9=W?RQ;)ER>5"L5!ZJ79.P:YV8:5<;Z
MF7'<QT=(M0%_)V+FT)%D5<P6:R^0C2QS,16_;136>K,9?Q@E#Y78 <)5D\W&
M_9PQ0]?[9"*E'2ES/:6%W5Y%JU?=;09:\BD3)98;;'EGA@FWV, GKF=;K$=0
MOU+5,N+U%%K2KOM800S#*L; MH51^<I.&*5F-+.(EJ2?!_N#:<)#1S)<7?<G
MR_+AR]LI(GUZ)D2#,:)!$,0\+,N]3TWAUF*:0+XROQ?'UOMOL""L2 ^?F]DP
MW!3G]79&''YAPC>'E83H[+1( S&1%0B@#J*_3#%4=GY^K55PBN?)Q($M0V8L
M@WZPS9Y^C7ZTXFPG,(78K$Y8P5Y$$7+:J&SUA.#Y7,R ,S&=\KF5#VH1&!FA
M)HMBQ2R<)9WMM,5O1Z/LUVB YPTY1F,*8@-SK4WRDRKSWZIJ5#YI//;^LM_B
M3Y0D.9=!;;K728E8_GA,^;6[G3 U(_S*PZF:#=!96*06R=019452O3=>L^:K
M'_\8,AF?/V/GH.M6/+/.\5?7TSMPTH3'<>HTSE8SOY4WXE[C5ZZ9:'XR4Q![
M.N!!W;/ZNE[RG2C@5;(AGH*.5&C1L'(>=?ZPFJ:H.-*79ZOCS3?7TF.S3-R6
MJI1FJVK52!-(\5;Z"3;/S^QG%S/Y!>EXU3GQJX)4M+^F8AP/6;Q^G5T4@[>.
MK.M^TJ)WM9!7?M'MB@B+RCMSZ(/?G=P;=WD?.XOHP8K\/+29+AM:^6G?01DF
MB&37J@Y^>E:H)S)Z&JP1V<%6_V.C_!D3&H"JYH7<&%VA 1ZV(%PLUTK_"Q]]
M9AY>B 3O"I",J&TV2&J4WN9&',F/!A"0":,!-B^@:(#5L++!_YX/]I\-*O"]
M$Z#S'65\CY>:CSE1W7\Z4H95V>+:F4J ]ON5GU'92?K][-6]<UR+Q*V$4/+*
MGT+Z",ZGEPX_,R>5RT-/+KYWN$MO_G[W3D*"8O,+E/CJ3[W&BF=^PE97'Y7W
M@6<RJ9=&3N@1X^D9B=$R5!X[."LIM=#.;GX>KD-B\88L!NN;C;]@?V!/RNSH
M&-QK=Q!2'7GV[L^JQ515P_N$SXEJ0R+[K$&Y-@YBEM%,/DEF;G0;[X?&CJ?.
M%<'.7JY7:+P@(G+&NP^8@,B"HB[']SR5D-1F8(_JL$B8>'G@IF<Q/_HWR33Q
MT(VK]P2E*$$7UFOB*_O!@[/HSGRV0(IXK[UT"O:/?>NX\&4DC,H <D>3[N82
M.TAVC6GU>+J>UO,4%%S*(^F/[:H<.\F>\/(!FX:S)G]\\9]YF%P71Y42K!0W
M!C= ]?NVTT]W2Q:^ #$C1&#GL#+M1BQ .O)SD@\.'9HM8>T2Y@YF59,I(NDM
M8[#O'JX8-HQO8<=JHQY^UVH<E9$I?>9TWD<6BY[0,<$[?''5?32=XO99_<S6
MV[Z#(9+S3XT;<%F\6U<6/9(>;HRG"T,(D%R714*"S_4B.$::K?/D7[T1,JN<
M>E[^.:RQ*"+I0HPA&]VBY6J 90S7,G-:MK->!$376KE/4E&\O[PVGT,OEP;@
M$ZU?*,1SH2(";LEE%)S-AU<5-ST)/>YAKZ<!#(O0D M+AL6ZSQ-W1R63;OBZ
M^*E%6%S)"[KZ2#W8H_I?'0V> _<B23=DR*S]V-76<366Q2$NQ !"M-$_5<$K
MQ$&TL0:_;H@3&L"?=$.Q0'J>UR^Y2FN:@OG,_86+9R*NH./1?#3 XBQZ!M7N
M%52(&$3R:'# 7X_D[KG4X!>Z)&S180Z@W1&^T3\>QL"K,$&3[\'%5P-D]D7[
M&]^%79\^O@C&@IF<S9RCTP2EBO;K;F5F"<VAERA " .X))?Q;B6>M,#D0V9-
MJ5B/<#:0XN='"=M*E\6_T'7H=_]IL^5S-/<OZ]Q;@-$ V<U34V@.]&).3GUY
MFZ,WJ-OK]PDN(KG MEA7)HHL@GE/D.O "I\_0MF1 KRQJNXL;<[<#K&VD>:N
MNX"+K=+)-F."S>E&#8W<B'R&(Y^UC#Q32&#*M3>78X(8[ZM"OPL#(F3[KRF=
MY_LNT%H4 4G#85&AO1A96>3>"HN>EZ4?K'!/I&Q Y"^\3D3B5X5!+\?;;LP,
M#9!3(][M?JRAG=-7A?M?0$J"W3G5Y>D]98LKH-M&CADQ_U!0J7!ICK[7F/\$
MA/1A;%XCYXMQ8TXAU<^FI-[T0,&F.FUHC%SBZXLHWGUF],^2S+?_ ,:L?]=K
MSF>A@6MVM7<=$O\#RDS^!0>SY'H<1?Q/%L\&Q2/OGSNL,SM=_CE@/2_U[_^D
MS6/SZ'_PLOA?N^(.TU&KOJ;3Q]1PRY->//5^D<$X16>WV.M?4C'[EV7LDJ>/
M$5$;MC):1^S@?_*#'C@<X:V07=5=4D,JJ>_X(Z][9>#O_LM:PZ"+VO*>W@U'
MM;9>J'Y7S=XQ)5 XX@'N60-<=<!RS[GJ5'0O&^C3 )[J:@U@=F;1NS1 DNV!
MN@<82P;ENQDLK(-2W?O)X,C]DK7&G&]4<[(!<_4N.3%OO06X[*;GDW-8>716
M0MJKB1JLY:&_0,%1H+<0"Y$'9<?VH+)PKE>4O=->RIGS%![GK%CD+>ZM40S<
M2@J%^CT9 J9,;B=(N)_)7M;EW7J$JX]2&]Q>$!>XZ?J"C=6^8FV=!A"*OSE&
MG2>_9]@'@E<]Q(_[,3J;$B>N<+]=6XS19B<AIUO1)WEIXQI,PA2__'87)WPJ
MM]@+(O-N=%XTF<II?EQS7S..6@MGI %"O=$>IUC:$O&%,(8%=]  ;QLE5ZL=
M(#9:W5-=- "O%I<C-4%R_VT!S&9R+5<XU "K6ANAN63P G$0^,$.)=>C</"<
MZ=;7((/15!6; S^HN-G6<KY@71H#N\-\/[.%+@5%QQFX-W!?<?\Y%;91A@=V
M[O"330F,Z+!6+IA@-YI%S=A/R%L3<XI(I"!S@F+1J-Z].%U(GLV<>I6BIIQ]
MP&T!5UVA1Q,?D"_0YY"+"XF_53&!:U,T $MIZTW$,%6@6D)HE[3394+RZN P
M]3P32;[IP."IP#VNM"<0^F3R0(P]VEHD36YI:M.RPRL$S$"E)R%D+I&OD\"+
MY>&M?/'7Y?)AK)W<;I&.W^E'56K)Q\'-EADI;Y<_=C7&#XQ_R7\7>;0 T@]=
M+/'4SH_O&NE\X$]OV66QC]Y>U3K:,YQW*]:Y62ZA<N"HI^[,/&\T2MUD/?HY
M[T8P.+F+;$>#ZLI[;KJ4D)]F=N14BX1MG^T7<E#(_.?HM-$'C8)5P+.P%TM?
MQ@J2Q/ARJ0N$BQ_6A&1XB2.N=Y&KJD0S&B"$']$%JC:?S\1ZL<"@)I1<#8&U
M <8N_END7O9P&B"B9NZ^&/SWCCPH@B@K$KZ5'QTB) >%8AG"K0XO&^>E &>#
M0>W'J3@Q=[W0N;>\.*7]E7J-%IC"JHUEY]^XDG1Q3KQWW.)*=IO;JL]4;? +
MNHBJ3PQQN,CC;O?IHM\%Q?)35F.0)Z&M1>,%4SKCQ)='%@S,$'&'2:A#X/P)
MVN]ZJM*1#=/<$/=HS45]6P-5@\J07L.J<*F2YY)2CE45577WSMI.6]OJL)>6
ML(3N:GI=\2YWX2I_- *GDTPH?W6)CN[*;=E/?_="$_X<QQR<\#']'+CWR/0&
MDUX((@LT]*4T5<N0_3X1VX(;42Z5Z;2PH,][^"42#I_/.D8>;.0]? @0?T/W
M&  :.M@Q^A\"X\B?6$8X["H/S[E2NQ/5>I'@U7E*038P_4=-XZ@:0GI$+?(:
M&(9VN--.%TGF^=J+@AX+3-O!0I9-4>W>O"JU)^ !-[Z6Q!2W5,37\FR$''5(
M!=F#9"'1=4VA631NPE0.,2U+\Z68?J/+0QAK^;"I;7.GT"[+#*.89BDLE*'4
M2S]T(/11:Q+CC,>?(:FBWE=8;ZPWG^3/5H.$+RG:Q;^@IO&2DJLX7-KX%Y7D
M)[#\Z)1G.1."8DX6P#_'?U=-._1*Q<TWQNVX/LF:WU986TR9O^7])&\->_VZ
MV9*8:&-1L0%BZ:[E=%#K]%@XAY)VOJX,B+#0O1,WSY-.M!XO&&T6QI2"L%-Q
M5'[2 RPPPH^'T=:8H)%> D/=F_0+]C(:>]%-R<[)GW7?A8S,ZD@-M**"%3IU
M>2O;WEW/'%#S)/3CACK!L:"KC@3&7%3HCA.!*1D_W]EE8QDA[W6F9'C:_6XK
M)\$%%?=\)X^@_04%X?8GWW*X06KU^[98@5].S8/4-=Z_E5MHW>ZWC61!NA8B
MA&4Z72<1BF1P92/)62.U>/6P\3&:^6F."2$B(2/L>O;=R6LK;1ROQV"AFQE9
M<Y_>3;>[?)%GNC22]OQGX X'^1P^/?$6(7XJ5L'HVGI]MC1>",B$;8*>/!+&
ME[WA5QW0-F(0X@ZT_>V1L5WIY5*RD3[UQ"'K_LKCT5)^X=%]DB1=/W:W5;)K
MB!M/^M7+(&[UJ9PU;:(T<Y%/A=H?N?%T3]PJ0\E.E<BVX:J7%>CK3%]S78;%
ME/OKZA/4H]UB1[F8,G15>70>QO*R)8,8[O:V@O*=M9'N^R5BIO#WV1)I>4]S
M51 S><5Y:V-QAO48G>B:<@ZR.KZU*9>TW8MUJ1W,Y#4E+1A&]$Q.@<=+K4MK
M56LJQKZ&3!F O&)\53PZ$IVNVO:W/H0 AS>&-#CA2J/44Y=$96E1-9]2TU28
MK"R%Q=H2@-$O),L4=JZ2(KM4PF:R*TO6$PM^KP4ZV<W;&_;VC=7,,B@Y/\)%
M3)]-FH\$>Z5+FK0]S8U'&:;=4;)AZ1K+M_%;ZZB!?!N4+;<P%S>OE[0K,LS7
MU7OU;<ZFT;QP&Y/J$OFYN.=V2:&IN?/EGWG."FQYJ;H->D$2/TV27[TZ7,G[
M:ZS%_OO%?RYI_.\I"_Y_:1)'AQ,@=YG8V\AV!:1[#D=YCQ=W)P'<B:X'Q2&X
MW*DW:8"P42*(;[7N ;%KF*R>!P>-;<]L>A"C:8!+Z@M$PQS,]_L_YSD;=I_6
MJL _:LP;)5D.\IA!1W.?(TS?($;9W2"N$P1?,0M$GZKI%TFA)7-5/3WO)Y!"
M?D7/3R,_K_E]&R^&,T$2[)+S&7HE<L/+39*(I0[Y[M@OW 8.LM[)&=7Q-,#G
M& G"((ZX3<F7TE""%708T<.OIB^"0]%>Z(O4[GKB&EU"+JFR:(9\?]3W\GXY
MEPVXKH[*,K:,G\PMG^'94/;M_TO@>]^8<!Z_3_36_P8#;JZ=6,.]Z_!N;ZB7
MX1?&-%AAT&[J36#=2B_H*@E-#"6(=(/Y8-9P.7PL,7RJ64A- C/]@NS)'+/M
ME^6Q3?((S%H:BEZX1T)B5O4A5&!3I;XM ])$C2.C\5JI^ =1&S8)\,:35'I?
M#Q/B!"JFE-O0*O"#A]_+%[[.$=UZ7AR&LJD8T^2!=$X7CV;WGNP[EEF!%L<E
M.)M\#[_@>$Y,H=[7>)B3N$GW-_,T00;.$J$ET1G?HW]? Y[UE!I#\JECV6)X
MBQ:"/B:],S&$6R9,C>&$G<Q#*2<[?X;?XU<?;];])A-W2HK7UC0D\,!P!74Z
MB]&:,2]_+TQ_+)J>5&\Z]NNU^Z17T-<-%@_)8Z\Q(-XTAY5L3P"V&TW[/R#Q
M$1[TG,H#LB-AC/B>9+S8!&8EB71QJ#!5>C''DF_B& T['Z'')6T4&T:%)SUK
M4B>>+RC6OVM[6*GRIA:X_MI-!YC^U/N@PDIFZXH67+Y898>#EPW_V\[B3G7W
M:$>[6:(TSV6+JGBQ29^0QB0$+K^[P>\YDV-\VVB/L\:7R-RH>':=]:J>!RS1
MG8YBDL*/'\\I^SC)FA7J3L3SZS8IU>Z43ZS=B#&.O*=)!&*LTK/Y*AKI?/63
M]W>FZH?]UL"#%Z:V&@C5Q%12YLDUV$H;FJ49^4]]*2 C0@;1#SI' [BC&6 O
MB"N:HW"_$RVRU3C99('CU(<7=(SW9%"S%ODXVFXS;\:^FWQ]B)"-GA21:U<(
MMEY<((ER;,GB-LI#YX7J1S3.K>8P(:%&'-11((,&@WM=!6S,@E2,3SQ5<!?W
MP<"Y57YI4AFH'C>B!LZ?^P.[AB%#,#G,[JUL3?CH27EW4+W?]:3[%*6R\X.W
M*_)6+"]LN1BQ2!IP3:9R83PP&TZY!Q ]WR+M%H\/DL)V@^*)PDJ+1VQ%:EHV
M\A(^F.\+HEV#1?%J;M7FMPF=D^&<DPGBJ8%*;@?AG&8H<38(3M:L:EJE>0\V
M&&1J)C91JG,0^804["GK?&E&5ZFMC4O]!]#0$,E$-J<!.D]^WQFYZ)WD7;._
M,0A8&46+T@!NS+,<Q D"N)T&^%V,P9'J%YEC-!01HS0 @X8PW"44Q]RUP$"J
M-L*GI>,/,8A,#!K4V7H#?QA&-O^2PT8VGE3("K164'?NG)IGP\^'8C)Y2DVI
M+-"UDCGIH(40)/X)<":(F$00Z2!I<).52&)?5S-R-M.0$&!4AE>L I!UH,@C
M<#F2<+<7R*C ? ZN1) ,'$S\;./>*C^N)@M!8H9X244_/4&=*G;5#NMU@?AL
MT2U\UTL'K\@TB8PR:W$K96RN36-O#]N$F@+<D,O2H^RZ7+R: 9S_5AJ7GG1>
MD7$A=PU^Q+C8\CF(<TDI/'PI_T-/F32GI5[DN-VZRH<,)?B#KUF2C[^(?_!0
M:E:P>Q!KAJ,?GQ/#"BWIY2S<6549S#[!66,=/ZD]7OWC_R?\$7_MWD(W>CJ4
M&$Q:<;N514 OBG2 8A3+FOB:?4[_=YV!$W\@WZLY:V/CU3R(H<H0_JDG;Z/Z
MG+2A#90PD'L.$#'J<)[0#X>,-?-@RN. S&JV$ PZ"L@HSWP!MM,6N-/):&J&
MWT['BL)%L%L\O8'9C7[0[T_'U;98>S4X)[?),KCXB_I2_H]K1KM&K<OKR?ZQ
M_+QC< ;,&!') ;>8O(E7C/6F#]5(1MEW2RW$DA^QP3O4Z3KJ9O([?EXR;\WH
M$-Q['+, BF_'5GWR@_-!Q&$EDN,B:NH0/<;O]_-$M%M +EMBANPW5?P@:#>3
M:_%ZKPH-7Q:"@B[$=KI^%^=LE/7I='JZQ.DD)CH@K#R6(O&D<$L]ZY'A)XQ)
M"@T08.B=(J[-?E/IP=$:@8Y\%4J]'$P8TF\@N(5KL,!U22+\Y4%%6@5V<'%2
M(=: V2!MON,X2,+331<_CQ:)E>=1EZ9\#BC9NEE99_V<J"KPT<*4D-@%)BGL
M8;9Z9U DA1-7LA&^*ZYI2QX= V0B2^%B+]FY'5[S<. ;5Q,LE+_CJ/D]B2<Z
M5_A#YYWP..2SZSE7X*"\M< 7L7G3^069>5;6:QG!-<Y1DILW]*&PO9P/4;DF
M@VWIKP:[JJ^]*J/R].C*/CLW6ZYVXHPG[G2_=OR>J-%A^]OU]^]\J+9?EOO:
MZ$2J 6AK)\<TF:7SZ)8X=4&BO:]EB5L\I26@4"7PZ#?US#\!M+T.6;\0\>Q[
M,F:JVVLZ%[N5P3>YYE<*Z\1DETO> Z;9!GMUSM1E2$>P!7BO2YVK)KP\FPP6
M(-53+R73 !=L\+#4OY34IX3P9DF=&0U^L@7)"ZN3XQ%QBU'%Z.IOCVXCT0+]
M2_V/Z$5!8E[[2=])_K"<]<%[6PE&AM0%S<G*9;QV\?5'B:^5=\;P^XN4X.(_
MN5CF:R:ZAJT\5],29S#8S /?%2!%B%#\4H39O"F>?E]F-$W 0$9+J7\/U'\J
MQRN06WMX4@,!O0DZ,7*/Y;3?M2%+3:D97.>4DQ DF4@]5[E:XB_:=FZY_8;E
M #<-$*GFC0F8G^H&,6J(P9S6K_;8>ETEWR5D)ZK=4^QXED #:+\=E@@I;=#F
M9%^7H'@D1OHU>1WH>P,I/FX.+8@U!_1*K6FZWL0/ :N5=[=OAKWI^\X2PBG[
M/.3R>=Z_?NMG]B&DY(^0K0I.O;0-^E0(E4D.'+UBAM^01+;W8->.].2+W)MW
M.$C O\8^Y6MUF-;QJ=>PI=99U(+UYLX>Y>N\>@NS"&^(A SUVLX5O?N]Y9#G
MFC?>!C!I[M^HN)&PN*LZ=?QG'<S8+%&T0YTF(1<'[/JI%>OSC/AYU/(5&J#?
M-+C J'D7%OQ;9#QC3\J+:$7Y1-:[1*#;G,9S6/W<O'6R.-79QR"-)3FU\MY?
M4)6[IBN4G 0MXA<V.PFPH0'J925H@!<%"6Z8"06\ZZMY*A585IRW8'0:-L3N
M$OA#O..=#7=H )DGB486W\!=*BP]"L%*!S1 ^O=@]$SY@;+7;QFBK*NKU^\=
M(E3REW4B6<P(L/M+5X@&Z(HM%$K6/<4OUA-.Y$@6=0!)<E&[0 /\%*_'JHN\
MWFUL)':9[%.-99A1?-6B\%4C&B )]/.HEL(JC*Y]?FD;,7:=CK^II5@1U\W/
M9QHQ63.LRPGTB$J>?</Y=R7.;P!9!*&\03HE>_.-4.*1KJ$^UU)BG/%&;;8C
MND)%.9MJ3Y,"0\>G@G,1/]'5B9%U-( C8@!\QK<T7(\'% IB&B[4F@G7AWG^
M$&\6HQ,L\QEP!EU=JW5?2E6P66 QD.E@[O]2 Z/7UW6]77_H;D@#Q"6!^B;5
M'7ZN,E=FQO[:13M7-S4PSB[=[CA:5R]>]WK+S1RG,"!B4HL_/$7.J&S!IAPK
M\YC9^_B[T;6Z6:U]7.:/-O?[[#^&GF43$WHE!UXW1<'%\=H?V""@*\UG\CTY
M-0M@S!T9+\U__ !7KN(]^3\#E,HFIQZ.W]"*&1S;K"R?2Y@\7QO_Z(SF9?J>
MSXL7SE]Y U@\ ^;J^=B!XXVITS();1LMCVEW$G90$+2!KONAK#4?I+$<_BF9
M3?V:NKGMCX%)9_-__4;8RS3VKG$779VH3]6I_T+U;.6F)" ]P7SB]:$T@//0
MC)RUM:$@!,$%2]2VO($3G]E*R\@W5%*MF-/L5=BGBT OOD/B31,Y/@R@-PN+
M2:[*%W$R"7#((IB>,^),5X6'@Z#^._*6K,[YI(M_Z!UU@:O:\HPO</Q/&Y#'
MJ]M_G$<^-C(CJ2V_X:Q%_7%=EDH;U$#?@Y49M&@NAFAJ.#_&&E<,]=R$;*UQ
M54]%,F'8&S8L<U#5B3E:(@UD-1(KE1%+:6PVN9'9BP!1<EK99O4$DJP*",Q1
M:CZ%;0GL>0GZ8"9W"7?I7 N7F<:X=Q\M^1&_E$] ;0MX3[K0X0<BW48S>SV!
MQ2XV03*18,8:]8O\BFD1JC0 *U1EOTH">#N@UZC^)9?L57%_I/4D#< L ^8A
MT<V*@,"%Y]!&-@NUI.<-E#5<7"+\\$:@_\Z.0RT3RP]W6TJ2><:&0XOU G4N
M-!^XWNNBEBD=26XX):+R5!&9=B7!HSV2VZEZO72JE%_#+B[/G'3Q,Y'2"0CB
M&09YY#6$P+K!UR$U389'Q\QAI7 Y3R$Y%3E]%W_O( \+[;C<&^S'8'P.49^2
M0;VLQ0:\>"J'D&$@9FXVLX2]SASF_4M^P3&:YLGVC55-4\)G4I2L_>C.:BZ+
M1PKEH+?@9U#=(:L\7.MG1(Z8?2C0+W7XP4RON/L?>2DC4\IK8^3#<C?F=!>2
M?K#MA?"ODZ/A]' :@'3'N-"4!A#1\523YD[$?S,.W>'V7J8!VC)2T+O.*THU
M!DZ'3A59$^S&[-/3QFR.QF>$!$0[BMZ<C0, L(T\,F? @SH?FLZ<4S[&?:=F
M?^_11H3$=$RRA$73O6!CDDU8&"P5+Z),G%N5J/FS&PS"_#7>@O2)?._EHW-0
M;Z*J;]14X;O#/W!&ZW+^?1/HOXKX?GCC);3@ZYL;,3.<]RZ]<?[]F@P:FLK(
M_K^II_#_6XK?/XU]S_YPT^=$T@/)(4C:^P8_3W+V)P1*F3#"8.M(AM\:9=2;
M=9$_Z@A"J\XG%WJC/7/II<A:WF[2M>=TV-Z#A=YK;^SGLX]$=F,K$G([L)5*
M;C8IWRQ@S[4\F$JYR+X>C0H0E91\8N' (-,V86*!GF2G*&9J]4D1>.W;>+R'
M/LO]>#^]&@WZF@D/<W.5RA.%F_T*^?E?ZZ/[3I3@]&DKYDW)&/^P[!5;4E,N
M/&BBP!-TQP/(!5=+8UG-82DS^KA'RGQL(&=DJ[^M5@EA_O%ZKP.62[Q)25*#
M+E+.M6E(G(XR;NC\57Q]M)H1=H=I-2/B+=OD\=THN&>1/=1!=EQ2>+[^)3/;
M>GW]W?F;U;:)%5#6'XR4D@U>O1S3$=L'\K_6]%CS/^#6?GY*P8C#_M@)7^[A
M'[P3]B4J-BX5Y*TGI<"@J6'VM3+;-MTL+M=4IFT\#HM1&J(+_^3&932C)Q>'
MWS6)S6D=3S;T3[8;Z"-95)_(4H=:;_#+&( QS&^WL82=3D_6Q</8K8C8"RT%
M#?CZ3B-_D4CR!3\WZ%^;7DP65WD9#5!=T^3^-&3"S3?:7/';9K,Q/@>#CI<B
M7X!BT1=7 P_0'30 .PQY"IC,CN-2\+_XQ%BXA)<W!#. U.9)WYQ)2/3T\[Z0
MLG WE7>PR1"*0<_&FI#>+N[$+50D1C>+$,!8G8@:+P[$Y *SQG42"G.J. Z:
M/ 7;J+?PV]68Q*B,R3*XD8LS2JN8% (]\HT7GWM>:^"*>U@;TJ;KF=<;(']H
MA"_?NGOR8J/P)! N,H+$O( ;D'3Q&QB.+9U%4 C'*>?(ES.2=<?DA^("79LP
M]LY6I$2"2/>A#3C";1ANCY%@OJ:_2 .<A3'<JYGPXXD6KB%8Q@B/?:U.&8+N
M3[_0_+2,;S?O=/4KTBZPSW 5:W!5$ D-@%=R03NU94O%DTMCE]*NLU>LRXL-
MERI$97Q&<:.5/ZPT:)NJN? :VNIE1CBFN6R)+MZ\8O-+\,%MJX^ZH_%*)AWS
M2A]'RY9L\@-OPV J@TSIF]VHS9:3_Z.]<X]F.TWC^*]CMHBJ49=3H<V6FMH8
M=$YE6Y<FRPQ&*G&)*!&B37<(C?LE5)L>1101IC&V5;3"*#]IQKJMEKC%I36#
MN$0QJ*B,R]@F+A6$;.;/[9[9/_;L_-<_GC_>]YSWG,]YSON^S_=YS_L^K^.R
M+-D0IJ[0)NLHK"OW.8[@14,M7R60(:G]I4P?TD%6[\D:L</\97_F!\.SVI>E
MC%^J]L[3U,6,+#Z"=NYU63=/.Q4O"QB;#I+U%LX_-Z9&KF-B"K8F%^Z3S[X*
MBAB"\ML2JKZ@Q'&1DG'SYZ&Q<UG/) 6JY/J&/$,V,,_*=4P0JSQ.ZH$9*) ,
M\6KJ)[)F5NL5&4Q H+,.S&F#=( 6B&6)K9_/\XXHX/*-/6<*0<*4=I&.RE$"
M:%)ZJI8TJ8-0Q3(.4'F2IX6FI_ U4]VD23USZ64ZR-,*9(Y7LY24H["J7.&?
MJ!]?(PS@1S<W@&;,.5QC1$[[&:_1TVF7M 27GO?SA=13F?]<,2TZ1BX)B7,$
MM3UU/1UZ),=->B$Y F\>,_-D(_Q5JK6Y4 #_QV R?/Q/L[;P83;<IU/(LXM[
M%G_JJ2=S(,[1Q<-Q/?53->.B%R)?2^_.P39H RB.?LE5]]1\ ?LKEN/#1;>&
M8I]:<S7<[I6V*@A[[S3VF0B8FDYF47L]HVNR51/&3(C*:II5">'TE N;^ZC>
ME$W-".[J U*A*9%R+EQ4T$=Y,K5<3_ /)IA.>X9)+7)3MA@=J+0IO_+=IT72
M[LZ4A#=E6ER^YN=UP[5<JEN7@P,(#I 8[E6=4(I,CM4JGFXACY@U!H9$F@<5
M'^>F+!IL;)WS&&Q(#I<$9/BWX(N9'HG6%<FK-V!49(#X6DO-?O =T#+.-YYB
M]Q+[T.3F2G)DH/N&SX!4OW( :S(F]4?'ON&LW61''7$D6=E$!>&8.Y2:<5\S
M Y_PX$.OHR;C7J.ZYH#P]B.W#%.1H_SC-(= D9X VLCH'E@C=T[L9M89-6C1
M$WA+!.:W[;9=QL:73DG"KW.PS3D8O*&%51]F'I96^I&4E&4FPQ;JW+79>F6[
MUV8]J 1ZD'^6L7*OC=8V:EI5MK,\6#WV$M[1!]O<T.O-<9-N'V_K.N</F'T)
M@064MX"7N7=!'[YI(]$EY>\_@X0V="'H>\_=SA?T2X!C_7+QBW8.IWG7OEGF
MN.:=9%M<6?9Y[,I.I@@Y6/UJ7#9UO:OD@O-#L\09C@;8M)8X;5&>W3_LH3:F
MTX_S\&[VQ6VI[>"6'D$D(C41 B4U4 *0C(95MU7(+7@%>1T<\SJ,"Q/IB#2&
MFH911#VO$C7LF4^G4"_H\@?3Y;?/*H%YV"C]YRE4/UUF2^]"?:<$AAKH^4I
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M:IJAB(CKK@>SY-TMD;Q.Z\3>+TTF\\2N*(1\>32:M/FU5>=I':X5NJ1>X_S
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MGNJ@QU*<&,,OUBC+4;1.0)#TS]Q)??7R(CK(0;\4A)B7 !Q9!"M&*I/^*C>
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M4CL ZO:HFIP*P^*"Q]-I,-BB$,;_K3/#V4\T5U"#=L!!G:FEL@5W=USVTL/
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M U8$9:L*/_Z4!=P)D1%L]\? 2PUCA)*\I_6V6*5.^(-!^#F?_:NPDRN&7 L
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M-Q1X^DXFASDCZ?M7H5$H]S))Z"]JJ-\]1"X$)G=W9PWU7\-_PN,@SP%' NF
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M,B$=L)1:OW=>=_L$"?9"U=N'^\G =XFZEEM_48.>274<R(IXU5/>:XU8WC5
MVA"40U/Z&Y:(:62S76-PUZ@>C&7NPH\B76Q !,O!M8[5V,%KM"] @/9TZ/QM
M+7WWWL] D\*22=B7S>U<-6.5(U^<K(]OEVAX5X;,6W.HGC3UZ.QVF:DY<ORH
MWME3ZVT[^N,8.)<+'S="61E%DLZ1=[0->8.%\8N-I 0J/RF4(4G=%LJ:-R%=
MVR4T/]YA/2L4E+8G29QIK'__L:3"?670Y@41SJ67Z7V=UJKG^.6R"J=]V+R/
M1_4H?M(JQ=^.?0C!+W*BVW3)AWKOA"IH,\L7:Z -YC"I<2(R1\!4V787"SC-
MV22UTFU%]#7HV2XCMM_[,<9%UCMII(W)545>HJ(4&A,-YEK15PY)6NF @^.
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MCBG3AE/WF[I'1L54H7\IH?'T214(5O;[ (YO)QRIT[<XC(*"Y@Q(4@T2@;*
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M;, 5(^'_#)%$XHPTU:)POO;9.8%"E65#G4'G7Y7$GFU^U6&;SS>/V^?^O*N
M'J:*_.\ D2@XPXC^!$^D&+"B%O]%2R[O%,JSNN*]1L*2D]=UH.3D>_5)RU[&
MOFOS86D,CKVI*YR$:(=ZAVX@^@P#[#JF>D9'$,XI_HC_BY<#EV4,AI128_WX
M7A764O-;#4+3(=/VP9O:\/TLUK%.U:FE[0XK9I74YZM5Y]J-8FOT+YT6B4K\
M@G<?X^&7RI5UR@JHLJVQZ;"),XLSZQXIUR,M6BM;<ANV;ZX5[_*CO[H)[I4=
M<'A#A$#,CB](?8_TIT=+[HNO4LZ-:QER]P:7+DUJYS![KVY:C6SSQ&B<4ETC
M>&0PF=:GTN0>73Q*)?")@7 F)H:B[$<5IHB X72T83V >ZFOPY 5!R%N@#Z%
M9U1U@RV-1[[X32]48"TFN!B/;^TFR)$ 2P+.?_),D>]#QZGEB+2\,G'[OWUS
MR\HJ7QB%G)]8%%'!.)HGL/T=%:@:IB[L&8MSX;//%JCBZLS%0;'BPQ6W2'=&
M4OU"J5?G0QZ_')\ Q[?>,>&28,R%_KH-808*_Y!\[1VK]7[%,9OKG?,3#2ZY
MWKIW?U9TDM$Z?&E%;G$ZQUX6BE3!D^E]*66W/F1BE>O+V>YSQ!<&UX&_Z &]
M#?QAPCOAC,0QJ6LMI>Q+ [/I]F_L&H?U7010-DU-0S_&()HJUU^_OQG%[#_3
MLU?>C+) A :'(/9R^&L;^#J7,77>*45@4509DOC/FTZ*,&":C!8!]P,?05+=
M-%B]F-AM# <2WA;QH'J4(O/U*R6+.94JV"[#:Q%*RWWI( *X56%W;@0&V/>9
M;1YP_.-O\-M^:&M"[<,(0LV YM+UDW"QE=Q REBY6_[GZ6?]U_6;'P>?WA:O
M75'/%O_+MW9?J'RPHL?:[I)]EL_W3K_0P@L499R^]&6GCZ/$2Z%/FE^%+7?G
M%RDU''!<HH,Y[=?0/,(Q6%4J7PSQ97',4$&$0-L@?7[K"5F@C4FMMT,ITP:Q
M%D,I_N6("JBY0$5G);[G5TL7^MB( 1>*DQ60JX_F'S[@\%&3G M/9'NR>LQ)
M'Y]7Z4<Q-Q,P_/HNG@9QKH&,42V?;<A1]C\?9<ZIN_2?B0\.@%Q^I]DJ'G1Q
M%\? /:_?C"L\PL(\UVST74=I?)A8)D9>B,784&[_0EAXK!T-=UO5RV_,)?R:
M3\D)?W--KD;Q?6T+:Y_24^8[KF=0/VE0A/?MB?+2RBZ9=*OPEFL.JGG0>$6S
ML^<>*4NA>H1@U!%Z/%&-,*2BTJFMS!+W4J4@I%64] TX>6^)^$\P6&^=-3TO
M:1>+V[<WARG;XRW/QCH.T"CV([C+IW^GU)"-L]VKD3GKROISNGT 2/45K[14
M42><,.**MRIPLNEYTC34V<\33X#SZ^E^Z[J:=<VJ^/,M3-=,O6D,V8$)$5EJ
MS.6+1P1ZC,F>P=:/BX@0]*WN\UKNV_!47PPHO)^P&]W\Z3?Q= WH!0A#*J79
M@DS-V]3:\*?#WY0ON-[N6PM_? @G,I\$X:69#C]Q4GMG0,,T<.[&7&6T&&!_
M3!JS,%(7 9X6X8LO?U"]C;?I7B[75/8HZQ%6MO"RS4,\7'$CN%Q7?OKW;E['
M_7'YS]5.:E(X5:+IB=AL$>$*NRZ3>L8ECX>+NL.YI26%"F9*5?"G-WZ$&*BP
MR(7RK4-67_QQ=$\FC\N$#I/)I:5R'5D9%"CHSJM%^J+R.+WUM+6Q)%[Q>5<T
MC9=IQHC[;94#:QXG;J6+=Q#O=ZET'5N1Z,MRQ_H,.,><W*R><G'L3&\)SNA5
M34H;(D7>$-X3S&6)\BV*D1_IB$L%CZGW!9'+YN0M,?IE@_3.DDN1XL-V>/=E
M6_H 05ZO_C'X!2$1:@L@+E!D>3"/Q*!"U5NNLE[&SMQAMMCN1>N2#XM]V!Z]
MK(MZKRS5\Y?<Y^7F3=3^\+/B*H0<LG,DC--J//$@A/;WQA?S2K-2BY,X1C\I
MX[5E]A/*Q,,6L_7@LT5Q+O_()U3@!9V7T%KUF-NC"VETQQ'564 D1XNT4)+]
M^^QR,ZDWMC-/K;/(OU2^=6_^U7"[SD]CKZ!QE:O=L?.IDW"'\L:<,>>PDXOW
MR*2:!GM;_^2>A, '9Q9/E3I]OWBZ*]9ZPO/3R=K[G&\&RRJ&NAZ!#L:[4 UL
M"MW:5E&*)IZO;&GS":I+K&!Z)?^M##V1A(N)\WJKJE$"\+RQPWB6[Z^N?'7^
M6?E-GC.>8&UGNS1*[\X_S[WQ&.$[DN(7Y62#=UD!T0@=Z$]@W9!FH#PXU/MA
M2%/:_A'K#(9A_CJT3)\K,$IX :?5GN1,F_WF^W^U<J714#!0>RJEJ+QDLH8L
M6<<D!FF,2@C9E^Q"LDQ#RC"RE6WL(KL08V?(,O:EC*7(-F/)6&?L:S,QFC+X
M^OY^O[_GG.><^^_><\^Y]S[/G^LJ3U'4/FVD/&'AF$IQH]XH]6"I!35/.)#Z
M/Q^0[.<::X\2RFP=&'"C"9#DA%.VONP/4PMXPT-LM6@>W\Y:[K-+]4_S^A)3
M1'4%JI*_5JRO?TD>>^/JZRIA;?U0YO.[>RQ<E]1:,.12#NU4Z<#G!&/,!;/N
MBN8/(,<*[6(9[LU63VN$!EPM[<6/($=<KV&'IVHKMR<93@Y.@QBN]4S'5^AY
M\5H-FZY6#NI57=/A&T\U[R+9AH556F: I(CQY<,OL&S8@6/3X_^F:N1P>Y6A
MK@Z;?YOPAQJ7@[&<HK$&EHK5T!- VU4R8N=1QJ0709-?/ 4ST%A[?ND> 66D
MV36V&Z0%^OT^P<R$N+L3;YIEC6D:5<I5<Y$W46YIK<]W'_1*<DEA!SID&([O
MSSD/7--Y."Z'-("M?3]4/\[U/TM//3:O8>DTF&A(^0).@YIJWO@F\+2V'8'6
M/KT3R.=_?GDZ1.5LMI-;?&5,-Z%/.\WS1V^,55IF*\Z'-]Y Z_ZMOL<5-,5R
M>D6:JUIB",&L;'6VQ<>Z$58L9\G.:9C+.YZK:EE #QA-N^!4E.K>G;K"@S:?
MY7;5(H0G@<4B^.N8YB> L*^,G_VP\V,:;M^@P"4C( -FH&_'B!,J/+Y*NUSY
M$59PK3J#;-FH/TG8Q1H0;)6(2NRWD3'%R>^D_22IU5M+:_T^\)<Z?2-Q3^("
MHL4HX+A[+-H_1!)L11)[7LH>7F1,'2HS>8X*GU!7FOJ$SWY9XH5*P$I?D1EK
MX_1<)8^]+4[K+V5?2W7&?0\R9[6</(OL^"R@'UW.6P^BKIP OBB&.EMS+H6&
MJ07H6&H+4U-14VE/-"]#=?+NB78%DZL5R4R,9/<3A6E$D/:-"!I7N26O7&O#
MTPJ*F\T%\YZ0 [M/*7&KTY4Z<P^/]O +5YN%(YO-9+\IY@GW+=4+ A_YTGBS
M;QOJQ)::JL9W-\JD)#R'6\7\,OGP9,) E!BAWI.8XS"&@+XZ! 4!C;@8:WBU
ML[.=UQCJ%$XD39XLS[RV%.PUB,_V*X+*+I5Y0T!J]MYZ-*5"O\XF'JP_:/G%
M0C1X?KIJ]R:,+\B3>I"%92J//=]?0)\ S@>Q!K/V(P1ZLG70Q=1E#0ZD8[30
MN8GV"Y#.\L4NX(R5^\'KDJQR*\].B0D$B3U8[==^?T5OA57.#MO:U\/3PBP,
M/3";1PAK!IYD<0*(:$" ]<=\CU@MZ]%6Q$*BKZT[2*DM0&1\<L<+UG^V@5VP
M2>AY&X9+L2'+Q3GT/,-TZQ&QP;;F(NKUFL[8:E,+P3=KWUX9H:C?W' 9)$FL
M$F^$VTIC-9N;TDE2>?_MBKG.OOISV#>6JF!>RD8H=03&8?44TM1\,(*/?!3B
M_YBME%OFXS"J]ZLD#-/T9'QEQMZGRH1(R&V=,4T'7W*\%(N]W^B4X_R"&D_=
M+X@HSC3O'2]5\_7:L.SIMGA!B.L92^E60UJR \];H-RH->@0,&.&<B[F$#JS
MH<%_ B +T[H2H9(?44O]T:VA>/?VVZZ+JI" ]'\N\?'5UC5T-5)BDND-3B:#
M+VRTVJ_@RM]YVORRJ7I]B=J\W1":^+>Q5!)O='$>U7__?6^GR-%'F#Q3@^:&
MME!"3A*[.X&-C%K_XHW?:N8F[!V@[6TE,)L]K$BDJ:6]"1Y0E.<ZP3M"AZSA
MD]#9$0=3CX_/4%WI$ZG*DY/^*GD\H[MN#4UU_BG#[!XEM0$B403=:SN%,<DB
M_GXQ)IGO*SJ!U%9/XM8&N>,L9"9+-'W-QE[8R-Z&8@6:)_"YC6LUMZ<_1#Q-
M(4FF/'/?64891\^ESMD].U=ZRTI72J/*\.9*MP-09KQ7[[^U! EI,MFP@S\H
MY3>&[K?1-4]*<WX57]BD4C^P::;K[&D<%F7-JMTI6@U7[;;P<"*;5G-%^/R
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M3X@E7"\3B,Q88*=EK3$!DG,);?<FP^'WXLQ(W%[>)!*E("TFD(I?Z*<7D)F
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M[N!I<FC^ZW1$!>7D#(=D_>SY>1-CY2<"MJ.?KSFW2MP?&%5L<YT:+(&A"A$
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M!S)L<TS%YLO*#Z(DI"]MK"JT\*WJ[HUC2^OSOT_ E+M737EH:S<O)[:>[DG
MBL?K9I[N<14A5FR-G/@6GQKCWW?4W7 *JQSMJ,BK9L?7<U],\MVPSD,*<I&+
M=H]JH8,SKF*\7Z^BF2Y)YCW\3O>=Z##>T#Z7=$/5AV]#8Z')I5O.UZ!$7%"J
M9*J[/V?#LPD2'J@V@L]9%T4T J/S@3@??(( WK/(0YD/2+6\]/WHI%C+JU%9
M\SF1^\+/=/^[,EI?H[)^B;W>*4Z9;D0732]:%3@F;V/01:S*$H1+"WUK.ON4
M>_5+3I$28ZOC_5),69#)4_1N7JU[2?(WKU="7ZGM#4.$)_CQ%!@OED?*#<<B
M&I79%WH]WSF;ZQ*3-_)4#(O)*5=][=U_MDI8NW"'::[\]!+!Y&K*35 :Z%Y,
M8&U*1@17G)NVGF'D',1(O.7'Z?B36R%=>G8&.?B>\8=5^>Z[XRN45L5U>5&7
MQK'!$-_6^<.M9*G]=CWE];6S@J@?7)NHV;]^7/$/4B8__-?7&/]8/&F_R1#X
M"S'8 QEM:L$ YQ\_!(WZ![\[LSV]F0S!7.$;$B:7.4MQ=6#]4 @4NDR' <KF
M,02Y[ T\GP.9@)@F$W@VWS13T((<V$N$'C.!E:<()I"(ZT/.N?W^M #F'><*
M07K%!I9J<1-^7@/?A*?N5R]88?AOA=D(Z&H!_UOL>@A,EU[CZ1GA3&#*!GI/
M)C(X\2OS_##AP^*9@,T^=WD:>DC\%A^I]1YU5B+X<FK'D W5<_Q,*_<A[ E*
MQ;X0P9BXWJ5Y'RL"4H8)M+3[(E8[I0+HR[_;:\.A= 3C=6-$+C@1."J]CX @
M%V XIN)E7_&*.LY<%G%'O[EI;L'W^1L\@Q%2P]#+IF6T>&2V\H^H=2>=E$SS
MXFPELW..;28)1=KBM9$BE0C#L#<ZG.%OPMYPV5_ENIXF<+XJ^92RN_X3_W<C
M:4G)":[K+EM5&\V,-_G(NTQ@4&4CA)'I4GU2%?0F7YW Q08+-XQW+=J^*8A(
M;3#>-($EBN8Y;3\JO&3-.2([EI\6,$ 6_UK6\VD/F(0:3(7V5U!P+5U8?/'F
M%X;FQM'OJJ?>83RIY>-@J ZI'84U#RL^%Y5^GF*=.*%2<Z?W.F[BWJO*U)GB
MN>Z1BS';8>GGGKCN&;W6XL$$#, RS85-D*8/?266@ M3$XQ 77)P.:5J0K01
M&1: CI+7X4Q#W?A>0#?)G!.P>I_UP7$C8=C*VFP()>=I>=E-U5";^U-LPR2R
ME7VA&.:365 WN /IT#4X/_GT,\T2<XRR_Q'98I*_83G*9.Q8#WW'I(7SHG%#
MW9A,#\8D>];<KK^Y:&"@/*5HML"-MW'NN[J[3(?<_8\SQ/Y@8 **-J*R- [Z
MS4?[W5?,8&0@N4@Y?G%[J"E(REZ_J2FOHC;,T<>-Y-5O_%%QXU)Y73$?N[^H
M(9)<]9**$J\':SBMED;5212I_K!O72]W.:K-\-W7.;T>J5$@VA<,]U>OZ<6@
MU"#<!N.!D>M+W[-BPM:O!</U>U6#SMX_XLXQ4D&[IOH3!.=O6@Y;7*S"Q[]\
M$(/R_-Q=$S#=$QVMXG)-]3D3P$:H!" '\ E&"P4UI>MS@2VK%!A/),#E-4'%
M0APVE.CQY/J"?="W(;#E)21.OTAAQUKH?Z:^#!R/3CMM)8P.VBDIUJY;1-:,
MZOQ(.)#9\;.XIBE'@^^"35G:B\H '/V@&[1GZR.,><RK52C$QI26+WG(<2\B
M:VD7RRQ?68HO=@D3R!\I6>V9.4_X]<LQGWYJXJQ<]MH@1M6&IMR 298>E4AW
MD>+1(/[^HLL-/Q[)!(XAQ[,0@J!]5S1Z%R1-EZ':\M<Q < ).ECYB3*62M*I
M:D^S!OG@V6KX?B[%I5+0Y$!I]?'#[QY/&%Q+X77_I2G,NDZDGO"E<U\EM="Y
MRQO $HU02B#)K8$)1!)P M57QR5MU1.^) DP7BE?Q#]>Z^(VM]ZGN_YUW/$]
M/K7QY@ONH9.%F;FQ(D^^1N#[*[[Q=\<&'3D[>?X''4F_@>RG.EYE0_&3CGY+
MOT>_3MK&F!;^N*%A6JW\5!.QUX1MH$WT,7QG]>6]I=Q39A_=R9,2TS2[9GUP
M4#%O^<*$DI):5KB7TMVL=;SC.C'W8]3-GQO!G4-.3 !3I/9#"4%9",1NS95\
MT!RR_PGFE"]=O ?G]FX9S53H.MA2N ZC])QER%TO:F#T?J9=) MKN9VP$JO<
MC^4?,825N"5$XV83FJJ2TPSN5Q/%F) EL0N(B5'KAHGI1MP1/V[)^],;#_LE
M1/I:PE2U<Z@^G=MS/<@GY85F(W/N,\L^&S>MK"0K9-[J*C?V*JY/T,[2G9#P
MB>LE']UXG' )S:']^\P]5!-KG;#K TL)#?%^RPT";A$_N_F-%,I$#:RDEX>Z
MW6(37U8>Y(C-9?OF3$=C8&P:8H1TP0M05R??9[\.[L45QPCQ4/,HSHTPHS]1
MU$\_.ZE4FLK65ZU+NNBISN&3I,CUWKK!AG1VP9NW)%TKRSC.*$U!&FIC K9P
MS<)]M1B_D$=3P>RD\&6_IR984\^2[2>ZZD?MT3UY2ZYR-?:WR)JA<C4[:8:]
MKOFC2Z\_U7PN2B(-B(?)OI,YD\R5 A5N7S;8EKH:<F$?E7>W(6G(/^5-TVI6
M&O51*NI\*Y)TF.H<!?5\(X_8)MB]M-9-Q1]RMSX]%=_NYW;PQ>W)YW8OU<1X
MIT*;;B:0B[+2@FQY&>^7+]=3 WOK>V]FKX_<]3\A<5&[,Q.9K<FF%M#&O9&0
M?=1:8EOL![9HOZ9V(':Y]<HG!:6OO_K2,ZKOO7[<,[Q G#.$+ *80)?V19JA
M<>?P K %MW,AF!2MML^/X1.P7I 7.#[!BZ6);F@G.&V%W*)V/KZQ;^*H'M7A
M^JXYWI>7A=^(J41![G0Y>#9R:(;NFL!1KU>+*3\=.]Z[2BP%-8CD!R[2IZ-I
M(L_5T=04^CUXNMXFAK5\OO@#\J9/SNP2=^.F7M=)#AM$-*5S:XU-3#ZZZZ^J
M_OZMR#WCR\)?%SY$I+X<";UI^N@28F9*Y'MTQ.6D\U=0KRHI4$Z!JKX@>:L8
MVI:JQJUT(Z=3:(0=%$U2<GW7XUK^"FHH);QE;#<5/:ZK$*@CJ=FLAJ3P82>0
M>P>MYS:3AH(3'7WSYI.-S;WX!6+7NLW-KDK67^SX%KGWQ)2WX2H\"^NTP?&T
M')$W>-?E00D^NWH<%LW9%W.<78ER?%JX4"V<]<Y#M5[9*Y*W_+L?P+61%#ED
MM)EM[8>9 8/X1Y,A<U&:T#H%05>%N]S(;2,D3' 7XJK.?J6ND_%NW"Q?F, 3
MK"IV(V"U-T4$KJQ$L$YI0&N4"=Q'#0K([[Q,Z\(2.87W:ED"%HUOM ^+'NEZ
MK?J=?;BPB^NEXO);&IQ$21[(7[3FDFCXPC,X UL^OUU@ A>%-PLB"= >-(S>
M2%PGD.6HA4>K,G%,X @[^;700?XCL-U7=W^Z/WX@W9MY#3F>B2/KH4[*,8&P
M6<8S1:D$N#/O8R=GL=N^N8 @)]S]N7.727RPBX<#R]+I%![/_:<BH"7K>*F/
M@;T9*5(*X%C+9@8$-\YTYV4TIS;<V)7@4%Q/U=]G5"-M&QT&U+W<AO@GKE2(
MVK."]:AFZ:]WN%19.CA@P8NPH M[(G9QBB9D$_7;/RXRKHA-J2L*F%/A60YI
M H(:B]4W+H"!"%-D+#A=$KQ.UP/KG!;7N:A^Q"9QZEJ-GM6I8 &HJ_+N]HBQ
MA_;;H3D")$ -R9X=,AI[G=56WN>]3Z5A>VHQL9C>.SR;?/^=ZTUB+QTD&[I1
M3Z\.:T32?(-;EDN:DE!#/!,6^0;7/&1J3XL([I=AOZG'+D_W!NOLD8[H4#P_
M?ORM$&\%E9]27H?@QAR<='4;'T^?GBB(64/S4MT:\>0G&![JE.-'C<UMMM$-
M7)!HZ#)&.^MJ(+>E7(K+T.A;O<+2H;LL-!AF/KY7Q 0:JN%^>N,9!U5TW#/F
M$1.02$ 25@JJSIF![JM2=$S#2  N@*H"<>#<]N+)*-3@OG>Q9O@);3_!N^MU
ML=HS@4FB%/E-HX[,3S2U$RCJ=G0Y;6QMQQU[E +A%WJ]BWX5"IK>?*N!*AE.
M:V_T/:P2#HJ.O4GJ'.XH8[2!><$MN!'=9:V-)*)CN=!UV_:*BURY:FL[%*9H
MM[>2H8M8F.M?-!E[%?/^%_CBX,_A302Q8O-C<\_PXD/_L]BB\L/(U4&N/#&S
MX:"/X$C6=FIP"VU3"+;.QUC_(7);6T@)L5JONEGP$G31-I8:U-QX^MR&7A *
M*;YX/Z[H;RY74*XZZ?-=-B3F5VU<5.=P5Q6C!S%V3;H+48$EUF *:"YUA\#"
MS47E[M<P%0Y%3;[Y['$4\:-S]'*7$3OY?7Z*LU>O=?9[_*$G/8Y9Q;I(C13P
MR4N*(<;BR2MX%*OTL3"!$XB;7/2MGO\#2CY602)AP"Y'<$WA@_/"?P'<)Z#W
M#_X'R.P VRWE8G 2MPR0]'!-NN0'<,::";3!]?E3F1)PA@F8RH+;G/ K%T#(
M&/$_ >LFT=V:VW6I\$MH2!^&_FT-#-T)_#8_.#4@Q022V0[I6TNO[U _=),=
M2P]BO*Y5@;XAR*B"X8))Q (AUW&(OQG)17>EJMM-6*&,NB54K]KOG ^0JG<5
M-^'*G//0M%/1R1@A7L/*[N!4?(%3S@/E"#@R6HHJ&9:2<XK8M&\'M]F1 TWD
MH_6*[RJ?:K2?S;>6JX\_TF\K,F&:$,58@NOQH8- 5R1^_#F1?)/!?ZFRI+3?
M34T6(Q2H[?:KHJPXQG2&N&>=LT"!U'DT^L.0CH5C/,\AW9?TS*!"N1@D#L\.
MUAUF FY!A@VU"(I"'.TJG:NTB"(5+F?EU-E[D\+5I-(J*2$?I$8P+"F+5\(<
M=7<]UE2M>%!=W(+^ICON6$8SIK7>,$=?XYQQ0DVEU79>1\)UL:4A[JM,@!W>
MF[K;7F?LRFNHG\D]5Y*Y?K7G8W:0EX=L$I_N*U8<7AB0O[);R_KBG,=G56 *
MGO%)X'C^Y2O8:-RN/0\!)A#-.='S0!.AN/%K*6V_YXQS!D64SAVXL49&/JG6
M)W4=P%@R$NGJF7ZVE_J\:?,J.6!$D96NZUNSCB#E(3GK?84:M9^?\D4I5B6^
M734SB\)TH)T=<607XF(K*>TH:L [S7=#@,=984!@Z)TRL=F"\P>R1.)MI<)V
M3!EQ;[FN+XM>MZ5+NHY/DDQW\@ZAMS>?2V3R'YTK&!CRM=6]F-8%'WK2*2Q5
M/%V:"7"ZC7=>8 (IG!/?_9B @_.CVBREBQVNIF!=.Y%L=."VE07)OGXK45N1
MVQ'/2C^[]]OE.V&'E[Q#=K=\/7;WE-;>2ZT[/X/4LUST@\*3670>[,;]/B;@
MN!P]=IS*F4.]JD<!0^F'O*3"A%2I;]Q)G&D6S;X)0[.;T>S1P<?,9[MLWY=6
M%X^=) Y?*#.P-1'3@NY[=ST-X(WMR4]T<\PVU_JTJXFQIJA0W"KH=JJJR?O]
ML+;'G7.7TT?-=PV7'HO(/L(PF"62/9+IAY3)ZHPWE)SZ@!NI5J.HA=7Q=NJD
M7=M'_Z0A^AW;DVE?GNS)"OG:$; _&=Y<^/C47?9.0A4&]R$Y5$<TWA\M>%C+
M^RE1:/+^C]'[ZWZVCCN.6@JWQ96; <?+5V$6R[I Y:3 ,-^>INN(+\)_>8$Y
M,H$3G+/>3W&+G:2P-UZT-R\AY]7&C0^K..>IGT.K=Y=*ZI\[-[0T--!BE]IL
M_U)U0&ME<GLGDNR$HA_ZM$Y-HYU\Y27:1.310R)W</TZPU)="9\&$EAG4B!L
M4<.RD4B]TMTVW>;(!.P1[.A!QJL'[;P=R9&><H\O(?UC]LJD:XAWE:*IY\+I
M?$-?2I(01R!@7G_B4"KZ8;! 285(,9#C[%L &)_W54U_P.ZS,[ZBH(D)4,_X
M+F12"!#'50JA ;\34J*N3M1TQ6 TR2W:U#SG'(P4A3^FP"O0E<N(PA]9??']
M+*$0[2#@O3UG?Y-<FR'+6N:LM6A?_JH-#."?Q+,%CP2K5 R4='$Q4B_UZRY.
MFC;YDJR,)$HJ^"Y8)5G@#YS**Q+QD+@K4;Y/]9?C >U7,'[Z_K003O\A./T.
MJJHK^^Q)4O6C2AI'WN,V7,FKYL\N[U$?,:<GO4Z\,HSY/J$QK3_PN1N6EP#K
MK)6$)Z7J0A)P6XJXO3@]'.6F()=-4[":U&)%97BD5]<N1P27W+( VLG8QY?'
MVL^PL5RY+-3Y5,>3RM#UW +/MY=56C,LU(_W8P<WKG6W%Z;QBTI94#/'T4<N
MCSOFU@I08>QB0ID.@X'$(:O+XTR 3]<UQ^\,%6SRK3W<M[;,]^CMZ>1S>;0(
M^J6W3=ZF6=VE1R\6!567EMQ&%$U"^XWAO:O>\8B2,-XI@T(6=X5%_HSW5SO>
M93C?I K'VH$@F^B*-=RL<(M"[BR5W?>\IXEW<V$]@U6C/$P;V-759-Q9K_M&
M9.SNEO_-PX+0.<4&USN2UO5$\W[58^,XKC%J@N9W;RY>:H%9-;8!XBX?<'-9
M3+6FR"^F)ZA^GTF1S)N;&VH:S2OIXDMC7=PK8WG\(52$@>? X_W!O<C]2+NJ
MY:'I9D0)>L'F77"'[QA;CZI=)L8&C!022Z@7Z K'N+K9\X?([SNW@F#7EJ-0
M\Z=->US6;G\_D32M7_;49O_T&;;T#9^AC<"AC<%Y5Y?\Q;R\;)HDO"\&T'<X
M4ZJ2M!-@G6RML!^J4=\/#==T:C-_[>F^M3R%[C8U/+EX A\IO[ODA=MD=5CS
MZ3[R'3;1.,F^*PBE $@>>6<Y*B4K&GD?,=A&FY2*H*,H7-HXTOV7 K-CQZNK
M*/L^$,Z-5X8W$,HJ]VXF;1N55+I%B/1Z'U[*6R0INPVJC0K*M+H)NC)"P+HN
M(6[R<B32IHMZ2HI^:B@)[_QZ1DV(LK_85^I)2;OD59/*IRWCF@VY@\-J68&.
M6:9- <1 @RJ9S(^A1F7IVKQ<*_.T8W[\]4-2$;5<U(2&L@"GL7GT(?K94^]S
M2(@][1^HG58G$1$!TD^/R*\-[,)EC9Q+EJR\,624F)<1+VC1<3S188&F\@@*
M09,]57GF0+)65VQ T.,C;OEJ)S&[PT8%B$;/Y HH%@VFPT()1_I/G3#Z<3HE
MST=KIW2K/.1X=0*,D4SR1WZ2&T[V32)=E0H-5K:RU#EA693U(GI5X8LP5BQS
MF/6#"';M&SQJGA>LCXI#'!<IOD;DYA?>N .S>&Z(9<QAV_AP-&VF5HSJHGZ?
M=O=):%#+A209+4!!BYT^ZHT>PFX\^2YL47  <T)7H4WG;K5.R]/IA5\<5TON
M]VKG:G+?-_UYYVF[V$<^AW[_UURGU3@H,?'G8)P\9^P.3'5DU1.C%8M5!/V=
MHQG&9S+4MZ(/G7J1R )PVU21<1%K,S=6J,*-0X^%CFE^<3L\!VD)1JJFZ1@G
MWAD)-A1A^7;;I[SM0KD4_1"J\>>+#'(G3O!-6;A"4=O#L+IQOU#>1S.'M0#:
MX,E*+=!U.<)P)#.BIUIZ8U;DH.3K6)%G;?ZF_1D40XVE+[%OCA5IZ2>1'JH6
M&RILNT:/^874UTJ1I]X9-&?<1 W6ZZAX=.:S*BH*]&]_R2Q+BKRY[!%+$/3T
MH$;7)VU[XR)<E[WYOB^Y+:VUN]Y?GD ]*:GBR9LM'+8DSG)(]JW4G<ZP<0VT
M\?5V2BCY/DPTZQ#1%J3(,AS?4I<GL8O\'V<0>TI08=M=$9C+)$E]\P9U,CK<
M;1U]T*K#U29[I-HX0+<L,]O2:DL HT@HDM#GDS97";MFQA(<!];)@^-CB&%A
M:(\\3<G/%D7Y9GV*D5B+\//=B*>T1'NC^>AWR8H1+O)<!_Q4FJP!LD:L;RY=
MA:SP5LY5QYJ@43[!8B/=]ZY;S@:1(+%=YMHS-,Y"?B\5*<02=\^BXP9*9,KH
M_AMR<L.BFI]'L#TW9^"GG_'OJB.:C/0.+<D+ULJ0KUR?W_69M_'Z)>V4R8G%
MS\]N<V,B54\(GSZ<.!6IXKN7Y1&#TLH$=MG#%!!S]JTCP5J%D8MTH*E\21HH
MWU[O+"5GU)NKO<EAO7.WJ+!/]93_L8<O)&)WO?)6F=9J8)&;TADPH5_Y_<OO
MUVUO@P?!8WVM0@K82)"U-5%;PNHRV?&"RTZ?G\?>A3Q6!T . :E&U&[S;S;)
MC=P6PS<\B/84Q.,2ZN2SO1QW+;C8DE]&/>+.MGQ8]VCK4D$^= "&).90-Z+H
M?9RG?:Y97@Y=AR 2;F'&HX\@/W/8SC66:1/I+<D0X?<9NA4_V"6$8_6PV+W!
M?ND8$W#&CQ<1R6Z:=)YRB&.8MA-S@Y$5O ?JP?%#)^C7R<M1P8)^]O7IO 2Z
M,QEO^7W]Z#(?M0#5(\_>)X%1FLA3,?8NZ?[95[I[;& %>5KGKK^!UM4=5%XX
MR+X02VH&I:#16IDR5D-"\XYA9,E!CZD^DV8$^6.7' E#-=^&Y)^=G/._\6EH
M9MKL<5M_Z@+9?VG^R/';+ Q[_/A+< 4K-<A53C=#LG@S@7QMM,\(#/WQ:)A+
MO>[:Q*,"J%(P^Q+$PK96&<\&SPG ,&V/SI=)I[<'H=P#P;=10.A\YW>4R/12
M580HH_D<$5*[TVD;G=4!=0#FR0SO H873**OZ< XMJ4#S_"L@![TF]W&=90Q
M 9W@NPGL;5CLB,[BU0;WC0CV(:*:)7U+W_V;4-^.V[#\#!,H,/[]ZPL]F-KA
MH(IA<,97WJ2M@O]VT ?<FFUKF"S,^Q]M++8$W(J:7C1D IE@^]'@3YH,6KHR
M=G7V$M^)%IP_0>VNV1H3T!>21@L'CPZ%EB70>*'^[=+99V:.2#9(Q"DY[#!]
M4/U]VD1.SG#"(3.T@CXK]^')D5K;1=WV5]C<.T^G.V$\I WXQX'M;#"Y/SA-
MS9F 4>:K37.0SI.PL8Y_ZBWS([@-7[)O325OTMLL%SKBO*DOVSS5<VO?[GV'
MH@S43UF9Z>UF7YT-A%O8#<:SQ8%?VZMFU+BL'QIWTTG0YL1"CK.C:T7QB.4+
M^9S(@<//EIXUL?:(A90I"K/#.0C'EVB&0Q)4'3W*<@-7&*)$$8OAR4DM?$?-
M:4"RTDT^.%0^*_P<WS.;N]22=$KKODT2O^M#-XUC.50E1BHXGB6TG^II.^G*
M,\D$%AZ1#3>>H0[Z>1 N?W?S%N_BIBM1N$)*%PU1U65E!(DI<MY:@"M9QHEO
MTT2!L&W84*4;ZMK#Z_B#"000/Y5C@\]2 R&.3-IA!]QN2-B,JF+2@[$BU=@W
M?R)V^+]'Y5,]VIM3/GSJ-:?[B3=MQ+XFCG4:-OKXN)O-N;I*N-IZ'HK[I-9I
M<O5@RN2'VX[]#1-3%D-(MXA8M(VV8:9QWIRR?K;<N]GFY^8AUCUY*J5"]ZJ_
M]1[3$?M":+F5@>814.L0.PS:+7ZL3,PV*)4WSA1SK;N5:"8JQT@3>/718"IZ
M#;_7+[VA*<X)O%-,D*O1N=('%JE>G>CB<4B&!"F:X=Y7LWXX9=OD.YB_TK?^
MT7'NY4?'3;*2F62^9#XI?LQ?@YQVPE@P\?9%+>&M* B#'\]%< 9+T,UA\!(/
M=1/YU/9;PP>KP:2+7-^K21"EN):'> _T>76%X+DF*E9"-XK?S?/Y'$TS/EIX
M1T13XX#F@X>5]' W"A+:<XR,O%Q%D</S0"=_4#VOE2@&O,]SIB37X8Z4=*C5
MCX#OQIC ;6H1$VA25$C1?2R.\E9VU!K8F%E153$*]0BR:ZHPRCK3N5\_I?25
M'=^DR*3X=4FYWNA^N5["_7[>"\T/GML=4;\NHWM=)B8>OA3//IWBF/,^Q6G>
M<+OE+?Z%%3NT)XMVSY%/F[5RN0'!FY/KH?[1#S<1B)Z3:;XI\_DS.2L:<RI3
M*T%<XM';GN_GC[_A[/NXW7^NEPE\<=O&QFV!:.'M@+>?\;Q^O77IK+V=>9/8
MPWZ&=0$W+[BBFM*%N^E*6=F(>D)*S51:A9NZS-TU((6ZW((F&Z!^3'_)DZ^@
MYC !CH&L_<O4YW19,E1 FLW?&2]KG[M;;GGWZ*[;EZ3]GH?T<>_.>Y6!B-*W
MSI,BK)W\1GL;13>DX.E\FE>QG>54,S)7HW(.=WVO.36.%(ML&'B)\!JCHALH
M3@%%9W_BBN=S-5GD*2U/F<!X-KJ4&/WDV:R0,)F]ODK\89L+G7-"KL_;@>6N
M\ \_7),)?^4[F7.7#09XSHUSL!]6TCFH[3*"KT^E6\5=YUY;1[Y&#PE#!_WQ
MMY'#]C<H03]]4M290#,^7#FT3Q,<EK\H6I^^A^I&PG//*INWT+H6)6T;MG4W
M0K(J;072B[.^B$191%A73VHSWH/W8'P$DUJUHZ94VB3ZH:JXIQMYLWX7\5(_
MW=4NGYIY7 WQ*6F?DN1BYN<!^:JJW4<D,!070G+8B(Y$L%>,^&K+A%MXK2(=
M!1>@#=2'$PR6\2,VILOV\I.DPE3UQX>9 /?8,L%;A6%K2E9\=+*RUB)05ZW/
M]#!=Y8/5;-S0X)7HS*%9R>,56 O<5^A!M2PEN4$B859-$ 9)4J=+C)Y@.1WX
MS)\(Q"ZX=%O*.BGXWJ3Z\/S*48VWGFOU+S]M89?@L=]TX$&:=O/9U9IS&P,,
M13GWRNLT'V36\I BM">6)C='W!=\W(_K2QF2!Q,$DHC[YJQYROK7EG=K3P2Q
MHRH)_5[/*_')S81TP8%3A>6*UBY%L\H:;WL:L[[N_U;**)\E:SK;V+IR?U1W
MLW=E=7@=:DH*%5:_Z;_GXVO ']A+V-I+36TD\BR72!I#PPV5_&$N)30E>6FW
M/*=-Y5_XX$I;R94ABV&';G/'%*..B3*^.?O4FPJ+9^+VQGS,8IP!QY_AR3=Q
M/+\_NT;:,6PGW6+4.*TPNPET<<K51@1G?O41_WPKYY61AHE1EOJATC+\1LZB
ME'95A--9TJZ(X0ZG8?/N=SJ129<:TO/%>/+T8N8,8YV>S]W*U$R1SE;VRF0S
M?A"2K#JI9^3X,3[&/"1[O[V0 ]'/QEGUHN6ML[H3'_HS-$K=?./3G"@Y8G)3
M_MF>MV(%\E5+IHX:)LN-;]W"PVQL?#Y/U)* 'T_LF:D]VK.^S]FR'^D /DFJ
M]$G(M"@=RP"E$D@OQS@M[K)-@Z>/B#@D'XU7$ G=A>^4FFBA\T1/+L<LY+FM
M7Y1J@#@^U524?59,EZ"PO>V,J[[4<: ;<W%_5G "!TY\W\*V__GSVCO;VYC
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M0BC S,,=M.W,C5@'3A'2'?F_2K-RY#FO'+ME%88W"7NB537<CW6%>:+'"<K
M=J-$O%O/CRMUEYVXDW*]>B@P]U_-Z20#QJR&4[7_>&?MJAY[SZ(R[XLS+6Z/
M9NBN4UM<CKE_,>N,#<EL.!Q5]C#GZ:V4L[T?3PCJ%L?YV%C)^1B6G<3D!YE^
M*Q72N/;-I#]MKP?)MZ2%6;VX#R38?YFX?3NWY6&$QK:)]JGEZ9!5H^3FD4N2
M*;YO[JIF-MV]5O**_\YA_")5=JF*L7NYAK'=?1=E2?&[.#)\F@F*6ZKY1Y,=
M;33_KLY@CFCU^N37YM[R/AZSLW)&P5-U)4<BF??JGQ9!\XB3,UMA8554BV-A
M8=X6E_O*$>9!BE7COU'^@(?V-L^Y59_".&2U?<**])%OADH1'W[6YKRHWBF:
M?$D\S<"KGEOV]6CE!A/ICJA@TNB#HZ-7C_S3L)1[MO+N<;=!NL/[4LWW5J!!
M;%4>+EQ@]_P>91^H$ED^^%\'$WI"Y!#;IXJIEN0;"<8L(/DQK=@C$;&V2=W:
M.D^:2B?GQV[<HJ0N6(U.>$G6[035EKW!>GF>*?$:G*R9E:UU9MBJL=20S_7/
M1O;N ]4/TG8OLN]SBII%F>8S_'6E<SN@^'M#;1[F2"&,!W6E;$8PS.Q<.'Q&
MA(=58<>J\J*Y,3Z5Y%I_)*Y=K6_XF;;Z[$,:663=N03SS@&N)(-]7GW$9H3T
M1:=FLRTY2 539F,F>MM>/LOL8L)R6O+GW\==!#%IV=_#"./E<44SN18G=4^4
MLLW<L1[H8#Y)#2_D4:A=76V6]I.6@S\S>O]=/I/VPKSO6/97ER\VEA9?YM?6
M>OH"[+6SZIH;BE8?9JMUEM><J::)%SQH:"CZ-J7W!S/WL^"K[),O["FQJ@&.
M.5=5F'%#\J&^[%[_% ]"GD'9HC%62;)CZ*[) ZPIIC.)R%/#1"7LR6 :(T3:
MB1=9[OD8;PO&QM8^(!XI[ZDSG'X',X,\SDK@?R-4JWV\\<>$EYC*[Z]>LE-0
M):[RB>;RVY?:4X*M.E[.#!+R:.Y-9EUWLEV/DUC3T$;%Z*)U\R "'A9&W:X;
M.G9$<Z:F_R/?X+N44H% SDDN?;I?/XD?Z MD[@-Z] ZG ^M0>2U^:UBL9^N/
M+NG9IQ.%EY%5;KU;41,?7"2]'Y%CH?9OG0^&(]-L?3[G?BA]9"O9>$7 YM^D
MKD9]K7SZOY\%U3U&0^\5]5T/G$W0(^T)[@/_5XG)Q%+SB4=9 N_VOC@?0-QC
M((T&*\J#IB0Z9B(TIZ?B_U(4XX9NR=CHIU%E)3%I75V2SYM'>^J.9(YL'_V@
M_('QNDW[?W>Z&>GCSLB;44NP:*EO'6&'N+[+K1;R=; 8W,#,)H[<.@LDZHXO
MEA;<4,U0R9*+*IC.&__H6O=37V:^,6BKJ&3>:FYLN?L8*DR""]?PX7M56624
MI\+59V4V?<?^"F5(KF0<%GNXEX'MT*T(5Y^>&BVWL/+6EAW=\?G66)>XDO::
M8MRJ]I_CI"%6W'.]<&LGX([IX ?+M9[!:L&3C;.\G$M<+[S*^[\BWUYO7G3;
MQC6["8KL6M=>Z\E]8/3]^OB>@'?%?*L<-QK\]TBA=?'E2YMEI^G4O-A;)W95
M"CWM'3S"'-X_.6C>A?9""]52LJK.!1\/]K?@=NR.]LGL13F:^^^F;%CO [*B
MM.UYRE]N4F'K5_,\<-X<:=O\@>*(GA+A?N,>U&8_[5_73?<<>G^-K!O]6VK*
M%&D?0+B1&;L[*?-7OJ*W7B('D7\(^\ :4_8#<FD?L#8XCOW_#["NY3$WD1Q_
M;GH96'E8D>N_56E1N@^DN+:_$M@'[%N'SU$.+*"WC)$-==1KKV0ODAP'#I:8
MKI>3_!5#V"[X5@C7OLQ?K^WV!*9WT?-. 0[[P,.];TA(]4?_D]EXWM)P..7<
MTQ]R;FI@XXB5Z,'7-TJ"%"_LWC_S;KT\953VM.EZPLG_E?X8 <;>TR*L,^0D
M+12(ZWM=K,_KX,\R17EQ&R];@7"KH;::37A9U@]5<V?&TB1TH"PJQPCO76;B
M^%-K6;^G#[^XN%ARCG9$M?,,-P#E4>"]#F?I9EGQG-;D=_.1B,&RHJ&5L>U.
M^X\.SY?/A3?XEJM5'[$N6_G6^4/WE?4YQ9]/'5X+G'T3O]/#75K\)%Z-==IY
MB:EUO7OB-F9GOA]S#-O9Q73C_2K;V21W)67UN![3F3Z%3(+2#4?4U#94[MIW
M;'QWFE239JNTX6=^K.B6.=@RDG$[\<]6SXN'V-4UAE^R$YNG5)D\K+JLN@SA
MBVX;N+)WZ$T>ZXG(TGBZP-YGYI;I'(I]+D7:;4^)&#NGS/N/FT-C2MFGVUA<
M'QUTYI05-IJ;-LM/BQQE"_I)."ENI2U\G:YE@:A^1S$)C^2)F!R'KTD.IEH0
MU>>W*79,_HP3O6EF6H.1YABF23+["A-I.QQX&Z$;,J,[X78Z!<3E9^+S3?<\
M&T_EWB[T)_D4Q&L?1Y-DJBL=%']4?5?IG:I ,FZC$IT ULU=;.3/XS+TQ&K(
MI>X\,;8_8\0B4O?5;&VV,4,M1E^(?4X?4CD<A*VT*/:D3)YCAA=;@VXV)\(V
M1 3FE;S'%RA6=7\DNZ=DV?(I#E5#'VKTQ#IWBK8RBN?'"G-ZBD/$[61>C]1!
M"]Y=WU/*&JQ6-;/$G?MP<MBG0E559IIX).JI06[5M>_%837>QGU-3:O![[*#
M@T,?ZGIN7INXV$0I?DNYJZ,:J!_ ,O<OMV>I=.WX)7SS"Q*.=PTI_MV%OKB1
M[B4VL9 3D=PRF#,Y:5I^+ML4H[W:>"NV]_/PM_+N<F07$=(VB*V-BZ6]]C#U
M0AB6CTZ.-^L$)RRE;7SWL(Y1#LS^*;#7/W1/X_K(UA/?D897A==]^\X\W_!.
M>9ZC]!QAZW]D.;O;6123EOZDE7F\@8IZOI/^;9!__?CV9YV1>,V)_FLO!,\-
M(9*K56H#0B_^1$/O5S+%'Y]>XF2T.^DUW3R;_ZFRCC&(OV2=DLU7QXC]T5:5
M$'[EWI>R%[G\8!5[!Y>4YFXQ:5Y/^L :R##;:";,- M5Y6!T]+? T;'/Q]>C
M<A/S>7H!-AVF .!P45AA)WE6W6G"^;@TQM>9O4;5-LK"3G$4PI6Z*C!V/ A_
MJ9Y24R$RULWH4SEY\E15WQF7U _XRR_#04K=%4E(T681QMCJW8SILQB:;;WY
M^]<BTZ3$\RO->M-WC_?0[S(K$C=1$IAQLQ_5[T^H'<;8HG[6?.V;_J%V7\T+
M?'AA_33VD\B8:W?G-C4O674T^&+WI,0->8EX=O(.SY%T*:5OPF92)!!OQ<PE
MML256R,;Y*.1Y. <;6[:+PM",T6Z=K@2ZXSOQ610-VIZXM(=QMZ;DV_2+51N
M5C^)V1E53%K^J#9*5P.]$OM][[O EYV>L?!RC[.$&GE!YU>7PI;]%%:G1E-F
M9-FJ(JR3P6QQA9X!S[&*.,1%Y+(9]:Y:^YXL1<VEH9&Q#W3Y"<TY\VR('+A]
M_3Y:XFELUY/CDHTO"HDWVT=6:QP6YT9V=F;S_K9U433/)Q4YW)D?>F;NX%F8
M9>MWSRU_-.+-^?S9OA('Z1Q=+XL/#]Q?%)ZZ?;5[\X'7]Z+)O*UE(ZT)X[\C
MNS8_:#\O2E6_-M[JN';':6K>VHE4[#0QIBQP\//WZO2W;Y7OBVK/8N_/[5G%
M[NKT7JXL:NR1?'3_4'GD*/CL>^5N_XF,@.= ]]0%V+^K,E!GFH7Y[9R1=9.1
M<.OI/*'1AR?'>G]Y6>A7S/C8:%]N+,_U\!W0-&ALJ4XW*IXP\X%,)#U?D8$;
M;\@.Q2^AN<!QGY.Z#]P3B=Z)[VH;;=JRX8)*KM>4\*8?^*$3;'BYQEDFLE]?
MD5),J>$@+3X-!]5&N)>MOF%P6LJ3W/FRCUWQDGB9(.,I4:2+)82E',"<7%F[
M:[S8F7.PYXU>=[:ML]F#Y+!3W<4:EI0#ULHO&DZ]J,J( DZ_GV3K,6YN%FUF
MYAS)5,%ZZQ4.C3?/P_#3$,C/Y/'21]#C1ICQM),Z6;;9"D$WS<Y:]&@\TRXM
MOJ6>FY2^]:GY;>%,PQM4UC'_I&S-Q#_CX]>TW"^+E;^Q"5RX]6ZAYG+0F;.)
MA-=2]F(O+MH\?'V-,!3SVDCX)AP=\;\?"UWEZ@&W"M:9)W4SV.?[@- >*'(L
MU&/9Y+^\ YZA>4FMJIBOTTK/(X^.8LP[CR[(!%6?F:YX1O;_K[7MWJG/+=]K
M)I(XQ,EY]UU'38O'Q]I>JTEZMHGY7)P2Q\CL=N:HEFU5N1'%TI'+7T%9/B=)
MW?8/JBE9#RGR&WWE],%E.<%PU7<UB2N>;D;$,\?:#(,<1.*P@AL5M=XYVAE*
MN;"ZFI0NIQ/I$">J>4RI?[%GMFN_E_O=[VB)FJ)<TP/_G.[_;<4Q))>#F.2N
M'+58M@!55H;MQ4!%;9PX%"@K.(;!+FE''A^L+OLQ>>7P5R^)<:Q'X=J7C*]A
MB*H.+:)C%\\W'ULKVRWU8K/AW/<W>S+]=)*-X'TF:9:%F?<)"W#M O'?F38)
M.NME2ZT?;6J"X@O ^E#-LM,E T^+E:UCLW6+C8^56O>\N"A5>B/7L?E[6P;R
MGC,?6_8CJR"?Y;KUH9[5QQ2D[KV>5CO:%<(@;]UDTI^6(2*F]P&9!0&W1FPB
MG<)&N2/CJN_R[^B&32"=&'^:/WY%!YUZW4=<7E8D;WVD5K#4E+HD&*_W@7B$
MP*X^-]/>"$(>8I__0>F@-!)?<:<:?;O59?J)T1:_]#RYYL'0+T>41W[-"_:G
MN'1#<*E*^<P-K+;MW@BVYG/U*01RUY1M-OC@5>>$X[L"G^]MW[X=.V'N+7]N
MSY4_H=SIML+]'XAC:V7;4TNNY9BFSUP-X[PL]A^+W&._#R2S;WY@-<T<6- _
MR_19F%S4P9$9L9U9M9_N?O4Y4E,?\T/M] F,#S51677F-BU%\&O7@--(8>$,
MW5IQP3A3P<;J79[BPQOF.6]3$ TW\E2U9DM[SMH$X&Z=C^Q,5F[X3\O]TF'-
M]_ ?3Q?KP[R&WG'&?(NKXG7M7EB:-J;[GE'[XCQ^:>LP*X\I1FI$X=M<5G\%
M;\WE3O<44<E+$Y9#6Z^:&$;[0+<$I2:LS))+U9H^9G=N/\EYR+IE#@_,+3LK
M^RFB]+SOIJS&@^BWB6KIS5P:RC?"O=<Y]JP?^\#GM$A2GDRS=,E#F0?/\M\5
MW7LS1]D)E+%,=KWW[J[A>\P#BVM_A[JS0FM?%XTE<336W0G9CX:J[7"E4GO,
M<-&9I'_A)ZCSIQ*(=Q"GIFM?_[1L_^&9!1\K%FJF>RI&B93 YY'3)X>#U_W.
MP.6MY/O.\7<^/>\?_7NK=[-(QJK8PKI(:K#X1$D/3M[R@DU&9H."E#(IQR;#
MYS+[1V;KZ?'&^L2?BV2QA%*$Q4-">='UJ_1;0>![AQ_3,](S&^0M"?=SS;..
M)FW?S&/>C>!:M<!I/&["%)_ZY$?")K1JQ5NNG]ML@WK9B\M$)$G<D1MDJTZ+
M55PI\$R]_/FF$--^?JO5,?BH?<C'3_IN4PQ+698RM#G]ZTS>J/G,/O \"(*U
MK!JZ/Y3Z+OXMZ]86;6E;<GM/A7FDO +ZL6*N4CGO>GQ7Y)&:']6[+XN:TA?\
ME,<=[;8&3S?\I_U#U<.QO.>>&+NL=VP4I !1'UX?>Q&4?"_C3V7#F,&AJQH7
M[HO .JG8XSP@56+]9P_PQ5.7X.@;P3:)I><]#0O3,^__+-*;JBE=?J@R=JQ(
M/,VF^^=CJQ35BQ[2.O[6F4,M,[,UN(MUGXJ72IN<_/\;]V!**K&/96RM-E2V
M4IJ-=N4Q5=VAPQ;N;QW"M2NQH/E)*4HU!ZZ8.'7#Y\GM<[X(T6E2O(N?H*?F
M;TSN3?1?[TA%KZA7=>&GN >8S:FI$6B^\@'#17ZF=L)_#[."[T\9#MIU[BC%
ME;F%\==6#FG5QMZ\6CWTP;J@1H//Q]5&]'M01.CSR1M38Y\6&L?51^\%TN,>
M.7Q_820?Z5+2T8LX8"D >&C1AR]223)!*_S2=DL9TU6=M#,O'A'KV1B^N_;J
M95_^@\-._RXMM9> 9MVTJ2H]5(-],%O:-SJ<?#7S4)%]8,CKBQ+:Z<DF)_J)
MVX&YC4\+7[\VDK11806\&W_UCPL.!W.X:M9Y[ H5Q!:;ZL >WN-A>R;=84DK
ML'1)JC,H@;FQB)K^IAED'/0XHR4K;9J&3+B_-ZBYH"\UPI?S]E%=956T&E3Z
MEAN^33@<_I9%HC:P"F;:DIQDVECN3,%.(K26D1T5KCH#L;L>ENN0DJ@365TW
M)78?WS_S^/VT6KR.1V)^A.VWXXT>SYN-IL=O5ZZCM+!#><L0_3IT8?@9_#JJ
M*4Z=V=11E&/N'=74DSUS/U'P9-RIZ'9$QK"0S%X05Q6^T3%.*]T;WM.I'-E8
M5!GWGGHZ=:AZM\GBLN):N=:\2=**4[]I48?WG?.7ORM>.;2FMGK)YW-@0,4#
M>MEP9G@;F0EOF*JYL536^R>RKFW"E1JA[]!V?++CO:<]0MWKN"^VLN:(B66:
MUAR^2W9KOG94HJ>FU%SLT_R3DL';\UO?JG[?37I?=&%KS"GEW>B$X[5/IXO+
MJUV<IB8BB!&V7Y1.B@H]Y,]UK^>%%%4?W_H3%7RLW\GC[Z:(T%QJ!%%5Q9#Q
MR7@P,ZSLVIY#F/>IR\<NUGVLU:T P$E!]97/3=:2,A_QOBA@7V)Y%S1-?+\W
MG91\Z\'Y;:)/4<[G%^YKYU33%[5'8L/8R:>ZUZI>G?=5>OE*2 :"2G"K&5C5
M0AUS4GPRHJTQ.9]3O=;^D03-_<_ +<X+D@FH;IJKG#(./W=_)01VLH#E-XV2
M9ENE!58<FI,A%@3/@-J8I\LX*5[2(T$8<MK?^3')G $IK3*9CFJ.]OH=,[Y/
MXIAJ7$'$)_#7?4"8?:&MJO[3L&3GNM>V\K&U+SX/>D>__3<=1>1O^;5[UXI-
MBTE$37Q87"3SS=LXO,M&OY%&I%=.**4$ELF,#)Q6, ]^<=&ZY*2&<ONGJOH$
M5Z-;P#-[8(=DR<EIA9T=G\_QZ\!*=*:.P^NJ+=1,JQ)5'-Q"3@5="GW=TGCE
ML$KS)T24B_J3<R'K/@Y;#UF[XF/8**V\. T3'Z;DW4\,RM.@(Q[.#/?L>#:R
MXN')=5N=6V6EMQ<;7W^N?1&0X_ZS'__5'1;W( /UHB#*H25\2VLJ?N==D7#9
MC,AQUG4M&TZAUQ844=\H-G&H,%IQN$;E^WVEMD2I5[CC@UY;1_\U.?TYC[/V
MV3'?<FIF^;GNHB+[U^>)"HQN=,5GW<N=2 FO9-FL\#,S?[Q.):PV$]X9W%&4
MNLP2$A0:M@E(#(,K<D[8G;8HZ2L;=G JU4XI;I;G L@NYR,BZ ,FR6P((<#X
MHGJE*]63LI,9+"O!1H+-9)\[V.P>Z%"O[OY1\F,EZW'^(^/GOKK/H2D@]K'B
MK=%,Y*OIMM@LX4*?1&Q"K9WEO/1!-Y/*H<)DZ]O+5U/C;QW,!-#.'V7YV3[3
M7U$);1+L-BF6OO)45YM0PB6H*F/6\$L;;OAY\W<CB<X8WO_2!],;I.0H@RE,
M20.I=02:&GGMA0I-[4AJ!S/Y<]"EWX:0CS$\>LHYUIGIH\@U"3C\LD983;"/
M3M6_MZPZKB4W.1_WSK*<5/G_Z(MZVMT*Q=GC7WV8;Q,=TWU_B6=YU2?V7?8^
M -UYD3GD8*E=_[OO_(@;0 O_7VU#)G(B#W2*J4=,8]I2:RNF4Z3F,N;&N!SF
M(ED*T[@#2O/IMK<L]@3%%20.V?XH/*"@Y:-H=TOU8L&1=THI.P%Y,\YQ;^\.
M8?:!]H]&+W#51 W&;\P#\MGETF6^5)C<[)KZ9[M]X%G1-(^TP@RR:Y-/<FH?
M$*B(/[QD9?8;61VWW.ZAIY-&D3A%D&6+JG0@:_.63)B)Y*U 5D%%^ 4F:HG,
MI-QDJF[%3N<=P61TZV15,4@S62^FWT^)D\M8#U0=S&MJD[J<SE8-G%]BF[SM
M8>8/6\15/.Q#V'V<W ?N4'CU36J^>6S<XWBS(CGU;3X<NRTT0[9++6D?.*"O
MP]+LFA*M%L'I:+]RK9C+8,F2@G7T\V92A##%5W_ZGD<@RXW*O&SF5_T":RG!
MME[K7^]GG&-6/[J4\H+,/OY^[_"K5)%E1Q)?@/YAMK <4;<BZB,K4&X#807:
M$;?8:QWB_,-NF _L \Q-8!]X9[L/P-HZV\C.>[+<(SEHKBBV:Z=O=PH[\X4M
MO(@32F$91,V*S0\?!0'??;C?/W&=4^1 AG1P_E.H7^L2.4VCYK73$[J2BT-3
M>&:C'G_%'?T"_]_$EV7_<>E$G3/G_;5823O0R F_P7)D3QN9O">;S)W'>*)^
M[T>H_G(35S =UJ0^I[YN1U/#(]T(='%L%[.-6M)1A^VZYCF;FL^E5\DL^=Z[
MW2+_1'LNW&E"M_?J <@!;;5-BO/F#R1'%!)IRF6UZ$.RC&MM8[]>"!^?FO;V
M<1<2UH>SSR-B#L%Z0L"B.7NWN7PD9A;;85V0:HKUY,C<_%W.[&/H4M\6OCS<
M9);2(5K/!Q06E,X%Z%#PD8/[ .,&>9RT5<8Z0ZL8W0=HLCW)LO8L/^;Q*=-:
MYOE716P5%GIZ<;QH(-RH@/7^^M%%'=GX#<[];I,R3WNW']^+)\?N-I]15'?L
M=&R,BK28F-L)M'YHCW^&#IE.MG2X=[%[3+%G9)+]R[>E.L5VZ%I-W!MQ2<&_
M;U&^G]U/&XPGD'?@V X)&RK7K@O[P(,AB6[__,'FB+6:ALQ]H,^4^7R1?CJD
M7]^)3?E7[VW-RNO<RK9:/'H$98$Y79=TV^SJ/:'>>\_-L<JFM%.%UEMW']D[
M/A,X4MLPXV/\X.8^8.;'.KEHY,Z]H%V<UP>_#1JD>K4BH_\0K\;(T6:P.)>[
MY#-&* V;DNC>^_VER21QGO6'[*LLRO^>85]I\R2/KAMPTMO<\Z0Q"MU0/3\)
MKWU -E('DS@R=/-G4!,JN@TTV\"XF_?,IUEAQEGTH:#[.6\O5_1]W[(?X@TY
MIO?,O8+#D,LJ^X#@/K 5PH+/I"3Q;FEPG1/.-M*7]%&""@\U6T1,^Z!N)5G]
M]-'ZEWW])\*5$=-U6?*6M6-K_CEZ4YQYB>H#_'C@GOVEM09N+(6QIFEY<<Z,
M6ZBQ]/7V5N6\3OUS#&(#8X'6M:<\R#XEM'>>,;8XQ:-_XDK0I7CV_4:CD8)B
MP?I333%&'UML#Z/0HK>_K3:M=_6TU="7>9F7KLM<^NR<1%1F-13V=)JK*LR0
MGV7/:">_^YU0MG)P&9\\DRQF-:30M%[F<W?2_ Y?WH-GBL8&5E'AZ[LF;"^=
M?6#9<-=B85)A(%R>@>[>J2/Y/;>G/X\\ULXW)M*U?,5Q1'$8SP6.H[^2(,CN
MT).?->[>F?SE57NKL@OA?SG=V,98Y>5/M^&@$XOO)YRO,^C):GZ^*Q4K%WV<
MNW;>Q8=O2Z:_\M 8&\.XWJK\A_^9H,6J;CIQ6R&N?P@5-WDH4YQG=Q] LL7;
M.I)XCF_GG? ]+1N@R:BC_GSITJV2AO8OG1KO_M+@)G:'+/I8H@"8]4AAG4F)
M[Y!M9C$ JUBH .>U 6\%[ZZ8(A'=.QL(/LQ^VJ\#9NC@?R&X%Y6R2 JOD)K=
MWM@$043^_-I)A0$<$V8V6URAJQ7&()9-Z]WOHE%K?[K6WGGP*6G+M=H]ZZM5
MW?!249PQRTOUM[ROC^JW)+K9^0GFO^37I+\B>&=I?>'(P4^8^\C$',EE>) ?
M=;'I-:IK#:/4\[^WV+'E]X97?54?O%IU0PI</-[PS")3_[K+VQCGX$GZGT?"
M.D']('U.&&TH'[(68#=$;/FGI^/"L33=E*8R9#+,"L=008,)/:JE6H0L\G\Z
MBQ5"D5\/+O^IXPHVW]'::S)A<*0G-DHFHJ5;\5BO1S7K.$7TZ+5ES]ZSO$+$
M,\Z7.5F7D=G4BO$@MU^=FDK+-QG/TIQ!]X)0T6^^@#I<BFY'7?[TD;]!*$AZ
M"QS<+] ^ZP$$]T<$*-/* PS[>B(B6#NN#1O2A9I-M36<K#<QAU;T1?=^;@>+
M=J>1GV"]VX3&3[RZ^:2Y9U+V:>OUT\8GOEF')Z1*XF[FWML]/U[3D4LM7H9$
M@'$RHWYMWJ_>-%1;%$JDWU69YI2U]#WPV6U^*KA]F6&V7MXB+(RZGAX:B5@S
M#I4=("NN2.OIY].'-TB0 !TWIH&$2!=7W^\Y2\RWGAY&"##?=ZO_TB2AB[RG
MH/DU8>,BZK-U0_<H@2('QQZ.7!@WO=G-K+)<.UNO_.U;Q&EFVX-1Z@O5-@]R
M0J5C/?3&-K;VTN=1JC$(GJ7K<U8P01)(+M4!4]/;CV+ 'D/22$N=#>EYW%X(
M@DH-G@NXH!G[;S>42()]!T+=9+*7IL753926ZMZC%*T_^/@K+4?O7OV0T:A\
M1.7M-U$GVZP@H\,?3*WX5880/+M7N%S4+ZXFA1\#HBJ&2CZKX5S;!VQ_;F!9
M#U/&M%?TC-=M*FM^^+DWYRRLF/WZ/9]U*\NFT*8P\KJ<<8F9TE^\7F.$.J5>
M28$8@>F;KJS?H$'_S8;2IB 8L!@>-^1]8RQBJ#('99QQ-Z>1C6J,9XN#9BRJ
MYDN+V,B8KZ@?2S[5NWJGG<?4MJ*:*AW";ENT-/N)W2VX5MGQI_#:#_?PDE\9
M U7<I!D3R[X[[*-8C>*=NZ6B*9]CJJ\=_J0^1#1$U"?OAB#45$@Q.<M(P1/V
M0(+1YEQ"I8*W(3#8ZAP,S. 9(M:3RTWV 4<Z;$''PU\\+N*S+%N<=X;PV.00
MRYDQC?/_</\OZGD>^$'CN9*CCJ9KF'Q%BK2^JV:)F6*?^UCWS4-(7ZY3JM=0
MC*%IW^*+W4DJOQ<FY5A503J51@8?I9I=_<35IZ^$>$&%<O-*8:PJ:&L+C$YY
M XY-5:<4E_";./LB>3>5%'=F_0G0=EGGWWOC6+&5\J=KX4@68F2PR<ROZ+<#
MVZCY8ZW'\Y[(8.:P9/#MKXVY"0[>K9=?E^+HG$_Z2B_OQ5 ZG/D#-Y]>*SO+
M\NMI+-Q64:F*/C>6W7U:^>2Y1<D,G#Q/@NA[D<S00#9LLY\_!$$K05Z),55?
MIH#R];!'820G:N"8,N]\2_#6)U92^>WQ,3.J<U1HQ.<7$^5OBA^.. MMSE]4
MU;6J%DYS&JLM8A[?&?6];D,6ZQWY]D<IPUL!"98@]Y2YWFK)N\FTZT2.VI%"
M)SH=.BX]1P3OZLSKGZ(0O_2:UNJ$#*^P[=.3]7LM'ONH7GX677X>+/97S.D*
M:7-^9S:#0O  AY.BSD3 0'@!1.1=8WX!\LW%OI-)+>7+X\43E1\JPE26P[RW
M5T(5D6**M8V[=^LZD+]FSAADRB,_93\];W/J)7N0!*$_+U<X+'E(XUF[8!R?
MF\;NC#N'W:<U)8!U*WEUU+C4:_=LN%Y-U,$'NLT5M5_7/S[2C3L1DY+I0R>'
M\>8Y89V=)E!.IN"!0[/@O)(-,)XD%WDB8>,[K]X#.LTY<67FJ!EC=\L>KUZ7
M*S*J25W&]8L^/F[^;,@]C=9QL, EN-[FV[5UU0J2FO2OL9;DXECL@_$P#PUU
MP=VS["-9-])OBC97DH.GO4O?9JK]#@I0<!<6H_1^\N_1L(R @Y1:T>G\(IN%
M'7J<EG6<ZU"I_JL^/7B^R,V/K"$:1\>O>O0.6ZZ.8.QZ#-NEP^9_N?3XTAF'
ME/@U4I:\Y?*S:)"7-)P0'L*JD)@;5JTA'YK/SMTN;%3K\(N6N3P.%D>Z.J#B
M3IH;G86OO>-+[\XC)*[I%_*DN!(_O]"1M1)QQ(\6L.*'@T'I9AS=#?IB#K!]
MD?-N'_"4NIE%F7E::Y@;ENL<+\L7^V7<BE>K#BE8[OXX2E:5]VPY73Y8_=2/
MR&%D=7@MV9M+)3+L\=(8]SJ&;(?@$Y#<'ZC:L\,WL@SKRP6 &)-KC#16 ,AW
MU@6-VP33WK ]]5"E?7Q/]N3'\3S[ ,]OWE]NG+=(3P'^T4@-3/K-(R^.L9#4
M[D2I0)\R1FFVW 6Y:.*A%2-T"M-UIKM\K:T[XFYA&@X_Q4ADGSWX.N%!@.1T
MK]6=NL?_O2?X6%U0B0$+&QO P,37Z)0@/08,3K8!!Z @EOX=)&S^=$-_R**!
MC-.9D9HV\&<O4/+F569$S8MANY%4[T@(X_KCKF AVRL'OQPYT3EV13)&)>&I
MDZM.BOJK6 UYQR$B;,]Q5];II0(#+!K+!-"X (!\KWV553JG(\$[!"5X2%.Q
M"#19%U4&*.G'QNCYKY)M#M$K&D YA^AO$*$>2@.$O.O"ADO"D0R3"E]ZGA76
M.9Q?K^.[%.30ZEPHP84J8F6,/&#\,Y]W:$[$2@<]@%[]Y:'H H[%H\>92*?+
MVU*KZQ&FKM"\EXN$S7Z08Z@'?._D%7EH._W-/*F<AXLO))0+T!Q,RU\Q@2/C
MJ1$=U/3XNCDT3LC_]X9"W5 I<%X3Y[H/E+&.8<^!=PB5ZO.D)V1$J!#/^ 9(
M"IQZZ$^R4MSM4X:*FD:*FL:CH^<T%4S.7;<3NDE[8-RE]I7@$N6]B(Q#UF&7
M"QA^T\[Q>X?"M3D%[*#IU6=0"8?G;#WJ?%GSI0_V7OZ.WA3H:4^;;=O!E8O2
MZ:I/%KQWL=6.O8Q>5XNEHQZS>\(P.@.^2,@8:NC1C;A0#UL<H"FPRP])]\)7
M+'GZ@$7V32:2ADS94\309DC=:GBL%!M-\WN>\U2G+L'O8AMDX<F.J_/XG=OS
MMX;F0T_'!29KFN]JIQ7--UX5\!/^M3$N>/L$-ONOS)4>IXO[P!L:28D"O<BT
M\Z7MG>:HXUO0I#J=L(WE5#-@<YL&B>Z8T]F$+9D8DN#+Y"N]D'9([[P!1(1]
MVDD;M@\DTD@*^#UMIBG9<1_XYH+=C%,N#][8!S >4WAAG0V.A3C0 NO7H3?,
MTA!$-CX4[$L_8HX/H:Y3UC>I>)1O,V$ZT0,<3+:-)D6^I H+PU$V1Z#U_:%1
MC_487(W66D^E*_NG&0AN[@.+L<-1_H0]!)IHN6!)2L%>(2F\Q;DB""DEH RY
MT% &*-QEENJRA0Q,BZWY:+#W"@YB(O B)3W8YD*T :A8:I[R$0)OA[--*@2'
M%?0X)E<&0MUP+IM2T'I!0CQC'C]+JP3GE<,5(WYT)?*L#A47&V X800TT0X<
M!69.\1'P(4H5NR;@#6ASHBY#O4]/9TU/H)=69YEOLZG?TB@2CC<@(]::H1AP
M)GU]DS87*BP@W;$X3S@&A%%I$/AR+R)2"8'.V/L.J>K7\:B#Z($@+6NHZQ+T
M.<U4S/+F)H)*]-]\>(584 =G5\6(# <OIUL>!$X;@_R)89%7AMI\V[J(=D.I
M(KQU<.KC, (UD(937G C&JYHMO?I1^' 5.; 9O^D,M(P!8M>SNOBS4B-)0P<
M (=%\,-X$2(V9G0B"FYU22R?CPB"S6Y"U*.)[1[I&OR2Z2WQ][$'0/#Y(>E_
M*4;;#[DXNTMLWU;(UPNM =1X$5QI.?4UNGV+GISOJD6@@5-*V7"%.BFR[;9=
MB_1BQN(47G?VR7):#.I+O5.QU%PH30J$8&@NQJ!3&B_ M0 PCH.R)>Q"NVK]
M>P G98A(9/[L]C8]-BV+_@Q,+P,B#NV@TP8X8<I4^M\.K<<@!=CFB@%DE\;"
M!W3[; '\NJ[I8;MK&J#+_AES!2.9T<F_R CBX]#HY?11&&_4!;-WS*&T#B5I
M4 8Q1-%7+T"/_R",L(/S@$G3@0SR.W\*?C(3( 1@$&+$?)JTGG\<PNT)6,2H
MGQ_EVP+T[HXB.+1VZ*]">FJSVRS/.$R0X/],6E$HI;17;AXW>^"QR$V!@?7?
MM6:]='@^X#J$%VBG_:SJ6,71YL*L=#WXV(5XZ@''-!)K8][$$!>@'17![/=?
M$!;6V9KO# BAI7X.42H= UU/FR<["="U .'\G4<D.#4&=2_OJU+^L@&U5'8I
M8WFQ'ZL_48IR7!.>^=4AU<G3'TIL($G1,DSA<CC:G\TM\$YPC_]G * *MR2P
MI5+\%C?;BV9=*Z001 T!V>DE4)D2GRAAVJ$8&13-%[0Z7@8+0.U^$T;GO>3?
MTN.*S]-18HMXS<5^$?T"Q6,!F![/'H'V^6<KD2O^'>U_T*3P2./' K2W:>.0
M&_O 9GT[LD287WP#!OEG_4*!*"!-<@*!K7CRK@>U*PI;PJ"S%2!\^V-C3TB\
M- P@\. B6X8YH%!'^GP/#,;38$L"B^)22.*B><-,LIZ44%ZW_T8^K]2<L$YD
M! B[[:#'"%TWFU^EI M A#$T3H6C1[%6(.FZ_[J;2\80'J8@WT;ZCZ87#][%
MX3&;3D^#P5!_ X&\^7[+B,:@94*0E)R;C%,L?#X#CQ3:F5WON<13CQZ>[]%Q
M<9$E-9 -UURE$!&&Q)!5"A'DWV_:MS@0@T[7 90LB^L^;J]8H@F; ,-PXC,D
MDM@<N*THTNOZ^[WK6?1O*.WCXK KY1>C*VT=*H:\PMJ339O/F(KKUP!X%X>D
M2;P5?SC\(GP' JZD] 9N]6YV+(Z7Z@%(=?W8\38IJG #-8A74?AIA?BK%>RK
M!1V>7FB+L(C\8V-EGI#-'5H;>BZRH"X\H)NM.POEH,=YTWIY\2Q@19"$_%K:
M3L=M05^N\ +\9J1:%'VQ=P7EZ%$G#;8ZX#%<22XER48I42JN,XF%!8I/D%8&
M?-L*Y]K>((WFC0 I]EH$'$Y=V81W7@JG_HT"3>,>P]IG:;\\3H5%_#F9(0=-
MPD'1)$3&'FWV26>Z1O./C8V]J\PA6 ^5WSK.4%J*/TKLK'_?K$>,;G2_/RYM
M8$-!OC*DJ!W,W.@)D58"TQ5B4YK5.T[B7\DJLR_H]<.[A/&O3E2]T#/B2YO'
M!7)#<9+@_\M=-Z/'0)*]-1=1"=(#61/?F!7VZET*HD,20-!X18]2+GQ'%>0Y
M_9L?V(+/YQEWV!()8B8(@BCN,8@6343_+H7W_9,*S.=%TC86!P[HB#C%YV5K
M^<^%A?(LP*A0&D1/0$D+35$DJE/RBB_[#RD(Z:B[7$"U9VR"<?XLC_%[M#\0
M3X VP WN:&)\;/M\!OF^^F=>^.+R<,H[7?0X(51"T86.XXV.I4AU4.DEO>U?
MQ?;ZQ%V):!P-I,#HT=P XNYM?U+F\4\-T6MDDDMHT*:60XHKG^7W =EB+.FO
M@O2>/.XHK$AN]PGM20B9]PW?9OM<\^/"@-_@&'5"S(60O<*\K:I4S3AQ8 EZ
MP<0*:1V-SVV1?+NYFG,E.B6<5L(GTD*&\3:A":*IZID;N\UH O7"/_3X2FS7
M)6.YQUY<VX+Z%#W2ICB#; 28^#+_8.]JE(:P_]!N,:C-HJ 2#E\T/=0N1:XD
MHP=D>S\N3U7RA\WZ#R&H7,\%^$?QK&@$6%K"^]5)$QN(Z(S?U%E7WI3LTGQ>
M.*E8,334=X>W$U^\7J3T*PH&!-'SMY5*P5$ZLVL'4,-Q"M$=< 1O;_ML%CA=
MX]I,!M+9D:;0H*0'(_,^ [TF:0&%1TT78_.N$P,F1(# 'D,M I%CIZ3W9$=X
M]R6--Y\O)H)GO(0,$3FL2XCN6\)01:M]_F!7*U9%AYY-VV7$IFOB"[=Y2P !
MZ5[I?G[8W>_1[>U2UGFE2SK6\\.NW!RB]O<QJ2(<FIFG+:#[":ZXOJY.DH)Q
M%^=3UK-4-P"#W?# #E:T;\%_.,]2]S"@WJ%$O"1;*K48=4'X,3<?6AK8@'BC
M>,\R--NYE A,AZASE&FPGH O.BG3_3Q;9,-A8N1S#?\.WO.CO7HL!%'$[YX!
M/_HW^'U:CXC2 A;U(Y66+G+Y]0X-?T%#,R9 6!VW =,YP&4S=M&]I,A_LT(0
M4J+M8.NJ]=1OD7(X;XHET&]P8-;M@&X])"S*G[)!6R_L11#6>'%H'#B8MVZ(
MZ)]H34&J[9"=GKQ0@C;H-45J><! 4KHDD((<0SW%DOA:3P,@'#"D24.$#U?V
MKO;#0!1&OEBJKC\N]!V:Y%@)FQ42&>XW<;K&2S0\A4)$Z(60*[5R/Z:+2 O#
MR$<Z5C>AK;%Z!I"T<3G_?AX>Q\AZ_=>?, 5YD?5]I$F(YL"1=G_\A"?5/Z-#
M00H^UNY:9V *7O]G(T2838^<A^E9N4$%%A=Q&\XN0"B@$TC/IRLT' 3)[=*D
MJ:7]J,MZ$?V 7NNM/?E_'H33.D$=*YK;4=+2Y,A9MR!%L/5B-*488KC[Q7\
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M/W*A'@-MIR &>/"O]H&'&L$9BW6_\YI#4S7S_N,9.,8-YQ-XZ5!78FPZZC(
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MLHMR<+_B%Q(28F 3EQ83D.(5%!+X)P0%"QL;#Q>/$A^?4N E[4N!_]?C\0^
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M&+YE9=JJP'P$5#1!:-Y5C963CW02T\JM9ZQ7G;,UED +IF[(D.P:7^\3'8>
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M3;Q;1,>5%-'!NMPI8;Q SGT#*> ?$OYY(JCH(G>=S]E=+//5^UDK6YKX:"W
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M_)X.]$2[C''@=, Q;97MP)_.NYCB97EC![# XMTT#WS \6B9U+@48U;K:?I
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M=TY2,+P0YQZ@A;O9"O#XHX1@*.'2EA-- =Z9TR%ANKM;^2J_F/(1>X5@N1O
M_JZ?#FX[5S@$RVL$KI($E.;M9]P<N[4_:K4XHJD_VLV..M6<B>ZH S@JJ9)5
M)-+M'(Z2JVF?F].1\MI;^\F=3$XEF\]BR0.W*=5L !16OE0_[?JUI544>41$
M(K0 U2K^(=4I!QKI\Q3:CBDN!'C^4-9K/(_:JL]0LG(;.VX7Y&R"ZO>JVGT!
MC+\#H:RH!2^1I96<^SGB- [F-4'4;T\([:P9YR[P>QGL@D7&6H,<D[(1BL'D
M)/94EH:VN#X!8=25_(G6Q ;.YGH@..>@(Q>>^PK;' (2ML&C?;7I6W[%3Q0_
MZ=2^L>KW @BT8G[7C";F?)U&4+$&_LP8R%?,/MI6;9AC&,=%=KI3,#9B9_^<
M-1IP^?MH161(P4:W&W/L)<[9V=6TY+"2^*Z,1* 4+EA;77)HC +-:>VW\%MY
MD;1&=5V TLM-:-C*V3/=V7HY0"9U2T998D6<Y,CM-UT'MP3_N.JC CAF5=)E
M ;:J\KRE18%$_[R%N[F0I"K!"."+E*4%3$I8'/]Q/28EGKM9VM&"7BUHX2R9
MT;D!<Q8:#G)1:-TTH_H]?-+2D'0/*RU4B1/TB3S!.R^VJ:2PG9&";%SVW,JA
MLS.5$YW/=M/E*8Q[93>FWZ/)%/(Z,2,!VQW<F\@Q:/;4,@Y;25J0-=VL^-/U
MO?&Z=PAV\(/T@NP]COGK?27+BBB>15=;<KT?0UJ#M0GNN)_DDB'0?C=.R(P(
MJ7?!L^#K6$MM*+\@PLF":X3*C?61PXXZKSJ#)*S;8\\4L=&U/DT81WDG*?^Q
M;X01Z .S16O@(*(197QFZ)23+K'&"S9,G[X7WV6%63/LUZZ0\[.J@L;N[VX.
M5#_;?BXQ5+0.D;QI5M<^",4A*5&<;%O+DR1<1HVN33DK/YXSC<WW!K,;G'8)
M@/==Q ;-;)7;C:X\G+C)HVX_>/%4$T84B2#\4?<7$YL"OT6UEI?&D\+<BA9?
M>,*?<Z]Y&(2Q-.>GFN\/?EW8/L'+Q_HILCJ ZQPD*Y^N_,UN9*9*SK8E+0F<
M7LGXNO$3"OKPQTVQL]-%V$*9_&<A>^ICQ0A[CD^.IK3N'?J"\JNCW>[:X;W-
M7UMX>4X-0B0 +GP:0576<M9%XB6ZU/'67#?FT8]74@E?Y'.2T)RT7$0.@!2O
M'Y$3BP_C5ZGC_+E UQ(HFAZ[F^D?$(59>%?(*4JFC@VB) !.%UYBYU]#!\\&
M&H8Y@;H1A1_[K#XUF27!6UU\%X!7S-QY[K@$V_;IR)\EH^4NWK,J.GM[+7XU
M5BEK3]:TFBJ"0/,">8G(/DQ9E^L8-,ZR]908K"4CN6CX+QGV<5;^.F0N%"J:
MHA^Y&SMD2K%Z^A4<'9!<*P%P=GI0>6%.])]H;0K3]==@ #I^6I ?7JM#^8X
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M4#*Z.]XI5U25XN(T7U60$#6KL 0TJAI>"$+KRXX2ZZWK!WP_2IMWAA0FC.U
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ML]X/'?<,/WTN0_-PR)GCFAV1\'PBN- GN2FJ:%E^'[*TTD<+YQ#+J?H8I->
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MS(GL+_KCNC5QS.U1]*8LYV.*QJS[D[T!U#>NME9_N.YC4$HMZ5:CV4-I/JK
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M.V\2;\I7;1R.G7,21_\)YP<O>D[OW+Q\!TWHJ[^B2EXDL.;1Z=_,!2HV(2V
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M>]0K/]HME.1CU,I*IXA1:"A6#.I:F6.J 4E/#RP2EZ(O*K2@:RG;1I%RB8I
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ML<MF+*Q'NYA*>\."\AQ#&X([JW>EEGJO ZS8&5G/IB<8ZIZ\WC7.U(_2L2U
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M"4[?J#$6[9Q5>SX6U1=[%4K+++B1M3U5NV1?CB5G"OT<DYD-9_%:K>;.Z^
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MF7$:Y/V_TI-AH30OY%_IJ]^I+"49[G_$ZB)D\6Y$A+<YIB#X0 ROI1!6@1H
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MY"Y4^>\C8A9]602>* ,2AX^_'XL.2RW+T*V\\U.-%:>HJ:-KQ-R<_MI447,
M=7I6Q1 @-.TA^),AZ=#)!\KYX5"M>=JB,M $+W$I9O=1GGOI6V+#AGM@/\^'
M4B8:[FS9?O?%;Q8J !L]/*A6RD5\*WXMJ7]N<\[6$[6A2^L9CN/F+9N1!K\I
M:=5O'0LN"LHPE54X< >D\\)9<,NG8V%W><\8-B1O]?#^]W[7W7^$[@&_',2N
MR', ]\OM!TOF3S)&$)&[,** QM5D=308-(1LDIWY:E0&>'X;:J P<GPAO#4*
M6B03.YE^7&"+CA;A:2(0AO*/WD'51%@%@CK\BU=QN-D.NXB% Q0BDS?V@7!
M&"]1SSNQQNEZCOF0N>]@BS:MGNTTY4\1"_(8# N<,PX'%D(O"4]@Z_6M"-]]
M%:QW<P$'PHMEBXVPH"!/O41$-X]=>HHC6BT<)+_E]5BPS5QZ.C@P)@';A"GS
M^56)]=DKB#BC[I1,(<Q-_':&':K27[@$9S+GR8_N?YEB0572S7J\:+0Q^R<G
MP0V19/AV&6Z<D>;%&TV&['S<<AXS["RL.?I8JJ[:S!MCQZ#<?$[P4D8"RQMJ
M5KQ]I;,1S![,K\7(8<7/X$;;-7]3=@0Y-:5%LA-YCHO4>G'=' -[5CMRZH%S
MQ<.G+Q56CD6_]I0T98(8$<-*?=9],LG+GT\192@>(LB?_-PU$Q>I_^))2\#B
M IK6)AI7DHAAA(9-\$ G#>GXR(B"(!I")E"N^)_<433TPH\(&A9$>4Z0D7+'
MQQA!M#% ([\422@#!$P+2\GP(3HE$B2/TD-7D]D/,)F8T*:@*LCT$_R7_:+@
M=;E+(WJ->@-6*X*P>,BV=Y'8L@8<@%!O_ZEDH/C[P$X=@L5<Q*P[>^ JZ!)<
M=?TQQKX%1D7HB"D<V.^$!KM:N(2V8)T2-ET?(D(]W=B_@5W_VP81ZN4@)G 5
M<)O/28Q#$) MLEO*3.<N_BN%AY)<*O:7*;Q):"@W^%?(6'<U^>F7?FW(72$H
M4@KAN?9D[B<861_T.@"\\.1";;US&"&_J'5=[,^/IS2N:@+JCIA;DW@*%#Z9
M)PX18<^_I]N.UX^VJSM7U%9Y5(>QE:EOJ&H=OLL0 O&T.UT.# PV;[7Q?<62
MF!<6-L7_=G&C<DS@@#E3C3F6MU-*Q"[9:H)_&$?LOK/TUV,JW['J2YZWNUO0
M!(_AB^W-0=LK=QP=&YX4(_EXQ\@0EEV)CN^9MFNXL\-Q$?[_U&YD,D8R>9"!
M.+@#89.( QYDI,19&@/4'\5EJ(T!T.BM*W\T*L,==XM>7^11:C6-089>)'':
MHW92<8"C<=9P'." .TV+-*9D?"LOS8M$A /R#RVR+A)>5H,&<.J=CC#?H*MI
M:<>T%5_B6#;]V;'O_=FQ?_[EV O^^ PF:>:!_XWHK6/OSA]EZ(,]@@.=C;\/
M1_*G?I-<(_#^*;]>Q&U+LX>=2C1P0.&6Y"J.4@O41/ZA7G%_1[T6H*&:?U(O
MPH._<O2;NEE/%B^3_XC(;A!*E5:'%8=H(J4A3LJ-*" UJ)O*IHP"*;$-\PN"
MC+66UC34C,4B@'1X)< '-SC*X+U8?S=4X([;.(^.DWRHK&H2,[MO[CMRWTG[
M.MQ/E),\93<O32\U>+LV29_;](IS#6**,$<WJO:/Z$^Z#&YHKT[O99(EX/]@
MD9#TQ^88JC;':HCP5-B<3.WJKV;GZ8Y1D'A&/]31_TCYW<T.^@;5 0^6^6EF
MUY =Y3L%E==^[LA)ZI&OT]+9[JQ6Y3_6J/78W3G.&R2\/RM5=?][4>=#5HD-
M:Z[=D3)&!P_E]KL8I)N:]_F= D((ZK^U7Y(MZ'NQ')UNT:Z]ZPM)@ZQ333K@
MQ1EHF:=UX8J_(R?OW1 0$'!P*YXGMB^TH'<+#'2AJA$58[4.PNKAR.WDOTQM
M+E2GHS8>EDG+2/T'*(^H2;DG"*A)B9-&*"G61 0"/ $9@G30-, F:DP=+X@$
M&C$QR1@"9$ CD3+47@_I:+-0PJ7BC+DR^\D1%]>D_=9S$8 '9!C_7_++WNTN
M(7 HHH,(F<6;3EAT=&S!. *K$G4(KA\._OF^-/^ K8X)#KAEPYY?)CT7P57[
M[%GZQ_?*7$-;F"_.QYL0SIO=5=6LGQ\;W-E8^%OYS?Y&^>/89-*J>&VF<M81
M2I^\B(!7F9C?J0DAA3DRT&U^KNQ,?,<'0IO[]!:ZQ]QY$6BZ\@>:\D[Z0GG_
MQ7W/YB,B/'3H>0!X?O)";>O7LS@D@WA _L_%,7S<KA!>#UL,O6LIZ7 5^4*2
M%J9"E7=$C6,8T%2/2[8A>R_:B_)-^'MZ2Y($.$"@D-R;R;*<V+B[DCW"SL[I
M+B]+BP2\=?D27O7T^_:V0CMN>)?&7D9,$ I]"E9/9CH(\'K984"#FH0*"L^G
M"!L!^7-U Y[$\H5U3M>,$$T$8/4C].2?\FO")B'T*@4E'30[+(B9T?\,%)N"
MTD]MPA9'"U!'(@Z&[CP6E\']-'2'\+6)#(?78Y"B@C0:^<CZ5PPF$V!)A!-4
M#NP,(["W_U?G)YNR[0IB]A-D;4P'7<LCER'4\2R=?^Q7%8^<P8K_GI78NZ%B
M"'V= S>1P?P8\@8K;).Q0Z$*3MK@7G$X<,*B,7Y!,!<#!QI&3\4@PW^-U<D'
M8<L+JK>:#0>HB\7[7:I:]&&A^>!)Q)61:ND;TPT) @?#EWY.,#B@M';Y; KQ
MIJ\5DDT1J&T83W?3=ZNMHAZYI<ESOV@G'E8 &<>_4MQ1*/]*Q]GO@;VEN(-]
M_X4CGC\2%9X>O_7V^B_T]O:1=8SZ0O[\T,TI+!M[UTILNZ(>.4CM\=:K%GNT
M@]6_3]Y9.V?N\Q9:18\PD>"KA%'_?F'WO5MKWL?+/O0=\#B^4CJ6&:P@.$M!
M-0P:M?LEXX_'N%4C3OXQHVFO6VO\_U\I!17!08.&[JQ'@K[<:BYN['E&/T"0
M$O?:!,&;Q66>@3XAD)+#QX1-^@Y$DO:.^\A'Z7Y<+P^"K/6@(>1C49/8-"\R
M$4X'HAP$ CLIU"(0^;_B0/L\N/RZ0:GE>%JCQ3 V\6$*N<&]NZ>%-V.6F;3'
MU,'&*E&$X;DDHS5+B"#6YR(9YLT*7FB# \LY<.#3$\3.R8-(& Q! O!TEVJ#
MX$#"),WXL]DK@=-X/&@)%-QW  <NA-SEX(!@K,#^,OA0&=R"M@R^NML-!\"/
M$<2WV+J?*.<J@\?_JA\"4X<)K#N#H>2-"'DITLGGAP(7>0)+*(<"-W<0Y+4I
M  ZTJU5;ICN0*?LCR*Y&B5XO62=T@&9I(B#7^- 46;["&#W$E[7'SLMN:-)&
M9DYT:^N3,F5/:'+;\H> @FT9TTZ%V\+T! ?*U8Y%!WJQ38G:X#$,'IXD$CAP
MGSF@Z2<>S0U4#D8?>B%4+X.XY>P_-[J7[F!SHT@RF*4M Y&<S4=0;C:$0_CK
M6U/X)00._'S\6TI#*\@R?2ML[S_^+EST/M8S%&TFT5?4UG\S3@GBWV#*)E!$
M%=8MO'V.G]DR2JIB@2&=RAUC*O14B84I6W1U.7.:Q)0Y68C[!;@AEEN<\LC_
M[H/5X4A!S+3X2#'^+\"MI(V16U6A#KKEJW-C!D-_445T"U$V&Z<=APB=:T"_
M3NTA7,D674TZ->(B:AEJF5NY=@A^[ **S<B@ON46-1FW2!U[FM'_'!&,(;BS
M].BMG1 @HC4$T#]'%!IG&4* 9)!A;)SV< H6 D*0I>($>4"6ORSF%CW/T_E/
M?J/GS\&&WQ#KRK;_&V+G@Z[_NU>:?+*BQ<CMTN1:Q5G;,'8/@[N'2_QH!N;J
MQ;_'4W)2U,M_&@!>DJ%4'"=2JI;*K#=N$U5G6ON\0_)D[9V432$FC7QE8@&O
M##A'1X*Z,.UYO6-9P%,7\Y)\? 78J!%_Q?!<.S=4Z.!T-J9*MNJ1'"QHCS<'
M)G*=AZI79":YT:+)/C?FQ";,P)W'$%K./^7C,?C2:*/S6B6;W;?@_&QRI+-V
M?>RE[Y&GSBPGF:]:+ ?7J!5C4SN1!N'5ED.R;.PGQ5=3^ 3.\L"-K5EAO[(;
MFMI8VI@F[US[X]<1EKR4Q.$AB7D#'IOVXAZ6_]=W,,$,>3;Z?.1-7/]8V.:!
M.%44=D] PZ.5Z&X8]D0EV[Y&[<#'K.V#9OQTW C&^D9S7>U! C78F3)$&I-,
M=M2P9NS$@U+1Q]D^<*JHF'QT+;PTW%>/D2CAJG)^*J-6*K_)EW/C6O*(_5NT
M\PI+=U]7Q*Y\GZ@X\M!94:/>0Q/%J4YS.&#.KYREGLD9$:O__J5CEY;U2J7I
MPAEI'(@M+? MZ"A)XQ/+FEU2@UW2R16J4LBA2EW%:7O_3=3-7-ZFI+E!.?CB
M].L=C?AU(KDYGM!,1UW2NNJ&@X$8!X=(&_8"JV=\/XHU"W,O]"3&UV__/6YI
MV[-WQ'L^XIW/B.DN8WY,M-!3T),_A-S)(0%.4LU;\\AN?4D#P?EOA[,OZO'S
MM\,93G;][7!.C.9_.YS_ATK!8XASX=N"6+@U69;GH-@-+@%)(++B[J'TW)XQ
MX@\9WYE=RZU+)K^;]R7)X'KO1Z8S\B#]L(_A-R8^*SI3R=2OY_5ZOZZL?7,R
M6O^)R7%U?EHX-[\>EA!:+]; @&>77 M^)*'/WTQ1@AY0HN3Y\EJK6._4Y:1[
M<VIDUHRC^T4!1TL5>OWNJ\]5"]U\-J.\JK"E+1.L/I;(4,L3=:X@(9N\?@M]
MNT<Q&\&?4E7<:M]]<]N9%VLJE+"_:FU^5\FI^B)8(*:*"X=::,.[RM,&#FQ/
MWGVH,[\>^' #%$-*8<X;?>1W^846@;I91GP"VRG$CE#3E>#W$@74.L,U57?L
M[YJK\5:1*81<])L;)67%6)^FM:Z_3(O4C3%^.URT=O>+3!M)?%UXAT'G=7JQ
MDVQMVZ@Z=WU8Y,/R9HY=M6F[SC'(]""?\6 #/J8^)EU%;R"?$-.[HTR.W=5+
M<WX8YEQC\LJF/+W9IK6V2W!5;X 4O^@XSCV/FJU.$ZC:2"T_I^7^2 SEV/#;
M=:Z-2#W,KO :#,JL ^4/S@]G3U9HD,F&^DWL\E],6 ^XQ-M8;W&*Y@<]#JGS
M)U-D,'Z$I225[/KB"0O"MYKQYS[L7G]>JLW&WY+'$7PMADI%%I9P?H-=N&]1
MM/?!.YM^DN!FM6!1;,V21YCCGK;^86$(,OZ>,XB8-<P%M1#_"8LW+HS">-7(
MW^R9#D1%O=$FX68^EC^1+L"C&)0D[UW?'FB#CALB7;\1&K\6BAR2S3]'NI,D
M\ZQYS_C;97T0 =4DI"#5@%^K\L=W01W'[O*JE;4#/E-<"_?:NE;F5W<ME2J<
MNM P8RWBL7B-*NQC.UW9!C5?$'?H)E,737+5RWS;^S#CG5BGG$],FK%WUS[/
M>G"9H/+RFXN^I[5C0E '2_AF+'@_O'M_R#*%&-U.Q-<N0<M#9R<[-FG3DO?G
M6>=1Z)<\RTX:+V%8!7O==HF.,'K NN!#OR\K5!:*4Z13YAX\YW,##_CZ"6X[
M=MSA,]->'/D15:E7EEB7RO,.9:,TJ#_)9:94OR$#46Q1BB_A2ZT7-]\'QK^O
M/N[D8QN;F-BWDWFJ^(-FG8L+I*[VLG_P,W)WO'FN",.W8H*II(8.;:?K]% -
MU16U4$F3(F^I:.='HI\+E#F^7YQR&4%]S0U]A/9%_.V23.I?^T*TH@T=>&M7
MB.1)!?;3O<3X*RP731FSNHDR2N76@>#'GV&*Z>NO*+TD%AV^7TVDO_-&?<5G
M(VHCXMMG-]*>]RG*QKFO3PV<@.NQ/OT#8XB)]1ZKS9[I+,6E00.8?C'=/:]4
MFO,1IWOWV!U;0/<>T'TR]K8X:'5QHY .I,X5XO%^_(D9JR[VM[! #D<X4#!;
M8W@9RN(E!Q:*\_CB^K6QT@7=[T>1..OC*NK7HD[N/_KTJ8BO[;3,D>^PNIR\
MRB &N)%$_/MX^$^4[$04J!?"GT"/]7HBNP)A+L5K(KA>>A3,E^M-4:1O]([[
MP?2T*<B_SXC]K@>A!8XHX$"2V:7"J@@<X)T\2H, O)^;-N)@RB[8X$%V:$Z:
M%];_BOA?$?\KXI\MXO'O2Z3^I0;Z[U/7O )_$KJ#"#W^JN3N-4C@N!M,S]^/
M!3WZU<Z_54";YB4 G_H_4$L#!!0    ( !N 35IW" -.O"<  '<H   -
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MNZ?A;\.2CRNM#T##E7;R#]'.X*DXP:</+;IER3^W6(?Y]GRFE(\0O(DRPF+
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MA 90IL5%(KO3\/O;Z6A%\:N29E<>R=&)BC)[<7AZII;]X4D([W!7_*CWI(*
MKNC[QEM8UHLXCW,F9NA9L;R,5W[<EMJ1UX$XNS".?(3',/O</&W#+Q=HG*HG
M@61L5F5.R)2#X!Z)/!C@97L ,AY$ ]AG'BI#/5LP8/8:)OI-4'N:B]2FY8:G
M4"*-.O8:WWM:E/69-ZSGAO4LV(30[OS>MNA4L$NG]N?0[^CH1/*#T^;'/^L4
MGV2N X#U@/1KLIZE_)VUTEJ\GY,YQ'4/&Q16T 4EVJ/RT<'KM >N+%#PEG]N
ME]J<+W\K1$$V8A#ATQP,FZWCRTCG%0;!O>'3(F13&7YU<W'/M>:83#8^66^8
M[\M[DY>4YL/M@(K7R?KDXX(&T%66"2'@*%([\UH?PC<?=><51A$T&XJIS;)Z
MS>%F:"9$LT'^9K=)/M-PO&D[FZ!@X8ILK),#=IU^9[VW:WT5-Y8;UM='\^Y%
M".7*5FWN)<,G"','$B;//-C?>ZKYQCMN$9K:NEWK<,4CDMOZADJGP:BR6"7.
M":&9<JL=.]-YE2;%'\_,^(YI]H*FE230</N[(Z8WT_>6,FT'.=\5_]?3]*:4
MH2K$%5W3I5L95KVXDLDE)F5#3 =1^VR^_?4\>\XJ'E-SHBV*'IS8Z[!S6^UV
MBK)?(SV)(BI5W3["ED#LV*CA+Y6:X@K?Y=8>WS\<VG8OFFKD<Y>0\C'$H$V#
MX;1U^T^0"&Y=W61,TX& C72I%?PS9QF#T_*N*!+URH9Q3GZ?Z7@*_,%?YKY.
M^]?A*_P<SK8 F:2?U5XO64Q N-XKZ:'+I::,&E 5I=:G P?DQTJ+5,4BW<_[
M-$@"VZC/")4O2EM#YZ(+U@B?&N_>?AM=FV*0[:L\!^':]J=T(YI<N3MB Q@^
MD&Q$QF YQ7]5Q1 :4:Q=E0R#18>6*0@$EV!M'?I6.1"L;*0B3>*7E[((>LM\
M-6M]#!E8DR/*9XZ?;U+T'H6A+%L0X$;;% %9-$ G'(.N;]IIG9"HN_Q.] LD
MMF67$09G-2!S!YA$+Q+X)?19N[^[ZH/6)KPUC6[1EJ4UJ.<NI;6(_-N7;''.
M,QU2LKMFXE&^*/[$W66&/UQ[4YA"3)/K0%CYI?B>R\1<DZ'T8V \WQ .1B]-
ME')25K-E$XZO.%_/LTTA<1NLDX7&OK8B-TK?L'/#+W=##JN_W?_]&1+?-;4U
MW27XH5YS%@W(!,HX*2PN'.C3GCE4+@6W;,/.<5ID)#P;DE"WOWBOX\YKNY81
MLZ5'+JSI TD!ZIS!B5G =U[VI*>"FK&\K[HL3CFS[@35"9%6-L77\1J'/I+W
M=P(<V7#=J85<$5"X@"T7I]"A8^:R@V_+X6>)#W]2-_PTC3MA;I-#/7G"#(M4
MBQ"6G[XI]4']%WUE4H9Z6YOMS0E;P ##*AF=>,,&6VD[EA]=7C,ZL3<:5M:6
M@@8MMBF9I?0QF?/-T].7I?:"/=X5Y.[D5U-GO,$AW!_B? CN;>,M.;NAWCJ;
MGA:$SZN$=@8^RW!:UK'WW;[$*Y42I;?FZ$X8:MS,:J@AR$4<]Y59(MJ;9 ;+
MN68.S2R%&7 LHN1&+0*-%.[S?+V7#/R7I]  *NL_S>(.^9)7HQ-;[\^JQS=/
M:)/JV2?8T #+7?"Y8AY+($>%LL<TKMP[9!TJNX&P]J'*'.EJ1<SF(C5[[Q!)
M*"1_6:BE^W8[7R#R-Z2W6AJ%;U-];:X1P/<R#VN2\O7>'FB]KI'(RU7$8$!R
MQ3+M:K_UYC8#A:+B#+5T/94KZ?$?N[27>*ACG4\(M\-G)LI;5# #5,S)-K[<
M-8?UWV$+;#,E"HO!7)U;5!H)IFBZ!=Y\6_.9+(S;ZL\E'^]\(=7-#" *W"-X
M]<@\1>J+!1HP^VHXZU2B +>0\/GACA&WB@XM-YPG)!J+<IA;3C+-6*11++(\
M@T5-F\FW"C_^@^'ND,.SN$'5<8SCBXO<Q%V'S4]GB;S>A4Q!QT,>?RCC%4_)
M4MV)=Y_Z6\WWZ*V=#)HO4J$!3X&)=F[K-/V%M3V+T013XVN+42/89L_;C["W
M2O8$DV!K>(WDW*0'<T' ?ZY0W:AO??=22=I&LL3\$FREJJSM.>U]^_X8#%@P
M)7P [(<;2>^ZX [H-QM*/?LJ%^+Z&=*K*5&[L NKF2NK%I_L"$[Y&^IIE RD
M+#,ZFSL;..GV( K]Q!SZL/=<$4,*63975X+UQ(O5@:P4[(T[-CDY)).TF?HP
MYP$&N9@+S1*F4X_0$_PDM4)QG.#6CMR&4[F0O%JK^ \_CBEN3.V"YFOM-DH^
M#AS9+,__+=W=>[I&Q/NZ/*.!P.N>/?@(K]\ID*;)5)IG+BPG@.^BL$5\C89]
M:OMO^KE;ZH!YLOR+0W%4YKDV4_Q[:XW^HGY?1KON,$'[6X<70'6L..KX3P)O
M2L4[;[2\WN]\9(R_H%N_T0INX=Z9LYBK'>&,^,'1;WFHY_$,YCS?SZ_'CU!C
M[9/FAR3>VB\:>:T9$_\M,V0HK9\IS32,G0=Q!"U4BBO<?MB*FW JK!M,9CK/
M2Y2-:6XFIK@T [^VZ0[NF!=-B,I=/BM4G_&/TJAM5/*:W QDB?RR,Q^P'+:A
M#KO2\IC9(F-ACXT//-PWV.KNGRW+<Y?_:.:G1J8 B [)KSJ!A@E00NSY(ZHH
M5@U'>UH1$R;:<JMH *$MKW6QETNQ@8XT"QO6U?E'NB7 ETF$N(^V,LP-QA I
MV@>Z[6?Z9'Y\3J(B4V40QUPU[@:FN';X0N,FRL&G6=TD[9?$FT B\JB8G?=$
M@5JP:?OZE^"Y:ZF:/+/KI^"[1JHW Y74Q(1.F@X:Q6EH /<()IRY3?U6JUCZ
MY9&;$JL)MAB5L2"LJZ*%_CVG')TK&J#8NC5ID/)L2I5MOH='XSW\C\?O9WBT
M"NO0&VHN-. P Q6AQR9FX[*VOXX&&* !%WIC.GQ91'V]4\6M#.4"N=\NP<,Y
M2-+08@Y[2S,8GXZ&;&UT2G-)PQT[7AIW-XE0K#PM/%771GY0+!774<#:GBZV
M47C]9:#YF[,@!Z=]W=DD5\WL$O'40B_ _1-YU_G2K):X=Y0KX5JFKNK9!;:B
MP?LDN)]B61!/R$U=Y604-O[>=]ZH>:GY?T9IZ$9^)'U(5L!'= /0?]L8_.S<
M,PO4:DY?/#(D@#$[#RGVYT>K9?RHG^M!6R1Q 4/).S<FWI)*^;&^5K<?*^&?
M9BTNC8=_Z$DB$F%-))4B8(+[(7)Q*6K@-=5$[31]Y<0Q1^FA['[NS!F?JX$[
M\,Z66D\0T;NIBJ0KR<@3#>^+.X<T_/XR,3#.34%Y(!ZLB0U8IK_E<E&/$ !)
MF-X5R>1:G VJL+B+YFJ=IZ0&N-QJ)L$M/!?%:C!.4PD5/6;6:'ZB^%=ML5'X
M]RK4)<*Q&;]_6_/:*@T$^/]EOMMU J !B:]N( //^*0;=@8E0KXJ4<<IB ]9
M"4OY:7R02'CNU,,C\W7S-9VT6C=3A7)5[UE3:E#D"DI :$X?7]YH ]<:TK"R
MX9[S@]/5VSA,0-@8@?BU?5\9YT^U8S8Y$RTGL%T9*21<EMBQ(09(Q:)^:OO^
M(V/^LR6SE>@G&EYOA(UZ\S3"UV$5UZXC>3ST:\[<&N=Z%49>L8^\$254E8YO
M>GO-WSY_=!+TE=U)B%$@N87*,YX4^QP->$:SQ-HB>>2_@R<CM^:2061(AY"\
M>)Q=:;E3<%_@A0:(MYZ.H4@SYK3]SZ?1 !JZ51E2P^"8UG_T^7]U^=LH>)AF
MWD!ZCA4:@,N:??!:RC+FT@;BQDU!3,6:O6J"5&Z6.EYQ7=%8UV@QBC='/9+L
M"&=MT'&:/ YK_TF'M&Q=A3Q'QD^]0P-\"4^RPSG)J1RVQ'7\EQGOV%JMDI#+
MF?_82$;B']YR_FT?=.[S#11BA_6AO22%?":4 !]#KK[[_[[%9<U]=)]M?.SW
M%5JC='\\"I$1#?CRO^G/R((.B=$ GPO2_]@?/J4;J;&\?/^89<X2]9 \L&9'
MA+?_9S*),2Y$ZSL94@,SKW%_[_CA>"0<(@\<\C^&;+4B"K,#,%X'Y5!Y-OVD
M#KU_3*K>3!;+8"/H%*/E3G%%9F)[^Y,""::['/+_EQ9\N*B$\I,\>S@Z@H&&
M\%"EC#NG__3XWS'IE=\]Y(D; @_^DUQEF&S=/D #EFO_VYOASP1Y%X<GAI$;
M=A\KL#[SS(6SYO*A9_\+4$L#!!0    ( !N 35J\5#8;=R8  $LG   -
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M5T3N+U2>5XFV-*& 7S1F1RC@PT1G;%>>N^O.8-'I13!E: +&A; U:$>!>#<
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M#0I8>K*9+AA^:MRRR[1[U^>.S/Z. L3-4$"+RZ;1S(5,01X*J&:])X%:SJ$
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M (LF&)Y6V@)'RB1[B*YK,P*/0<:\3'[TJ-H/S?[7%//ZW]+L3\7^TFL&0(0
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M/U/S2%-;%+(URM50=JN9ODL6A_<$LT/,]S4@ \_86+/N+J ^@-WA7*@O%/=
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MW6%TRGHFJT'A02'IX[QD8^C,6Y:57+CF@N=8:R'3&_+."';?,M?6UIY4]H(
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M.@XBRCXLV;\>3,J1E<,^-.!L0':;63EC;,_>;V;;J"::+0+Z&(>EE\C ,F5
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M>2%=IASAJI6A1/=[UB?>%!\B4FUW-:#0P+ZJ..G)>7<H3IF#TR:=-3CBY*B
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MJC6YT2G1R,';-,<89=A"X\0M[Q9,T1M8_U90B86_ER&E:=&#LL %K=V>_7.
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M>CU_\1)4>-OX&B"QJ8-N14H-C,Z%NNGZKY\#N&.VL49\!X;'Q2(9%>0:*=N
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M'%/O+XGW/GKV?)I&XG9'Y?4:!PQXR=:,NU]"S4]')?:9G8/8O3[Q+LU&$O>
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M/UA%>,?;MK,FI:EB^.?"_AAL[';M=DW>[S$Y7$3G\YZB^5$OS15&#P!1*Z<
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M9FMD,V/Z<S:V*_I5!3:FCZZW3V-9TAM,Y&\EO]"U3T57+V^']W1-IO<1*\B
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M* EVRM=7<YX8 _4 M+3XLV3@+AA&!O"6-5 %MB>BUI('2 'X'@+=3:)C$(&
M]-YW8,+&']\.3J0@B4'<&X<C V1 \/F?JZ.""A_1 A)$IR#^G5='K(7]-?S&
MX23MP0&L%N;1ASP--C:23I"!7M@<@L3J!%7F5M8G!/81Y']?H? ?",^X2#];
M(X.V^]&9CUWLA_7+D*%ZFXIV&[P&8W1E12F;6*7$X4VK?/^DB:/^$+PX6"]?
M1X4Z>$=X1I [YX4G QO<C]^2SK!BA? E!6%^Z(4PK_U#&PGZ=E=E.V$T2[2^
MT\IVD>IZV6::RJTC[E&MYKZX"3(@-;XKMY%6QPAM(X! #6U#OP5&$(-=1!SH
M*!%DX3,(XHFZ&]!V/^)?'P>F<>4CZF ;0:"*7U\^($YC-:N6"@(0& R*8DLL
MT_=9:WE]).P0=OAN (W!@!3@$A,ND@R<:X4>#G2,==JW+_>Y9+YI>ASB^^U1
MI@!WOWKNMS*;\<[X]QDE+L7;<LO00J" ;+YZ$D6,Q<5$'J9SR!W'4QRB!7G2
MB0N)FBWR9,#-NK61##A+./%V:5=WX'S @?>AJVX(%+;WJ"P$KT3BX,0RDU[_
M#1/[9"!6'(V%M.X5>H?Z^+WJ0.-6B,%S<DAM78@E))3S>@;:? P96)R56T^K
MH_]7Z83]B_'9Q*A$L!?-2@;>\,*,/Y,!!-=^^L:8$ :.]P)_( \I"5"M-8K,
M00+]N!><^3Q]PD.=OT].C&66#J*VAH\XO+"%\*VO9,""XYZ9]QV;5KXNBWX(
MMN5%>PRPX2]V-MF6?L.MDR7Z"ZF00E+I$#_Z2A3<PTP:^)I&ZM;T:H:(E.#]
M3Q/NI:X]5\NY%3$"9_0Q5FG)"#]]&Z L=U8!9_*119$X8U_(##>>Q_&1@0^E
M)17@[9 %;[-;P[7$=VO6[/Z7M5_H#/GP%*3T] ]4=\7P>$1+;48<[!,1JMP-
MUY=(J36>=UH'EER1"45@O0':8EEN!\;>RHW#LLT^6B4#+\Q P??@3!ZLR)Y+
M@+J5:WP!?Q;''P%NG!%BBK9^_#N6/>DBAJ_K5HY&ROBP>FO4MO2M<4_3EQ][
M;G68>AV96)G$"M7GS-ILMVCM&SD[[ULDVN0N;40.\$]FP6KJ?^^UO)!:CH!X
M37NM]6[%>H<;876;!SV31P:*7EX?<,(UT3J]0M$'0=:AEXT) NB;(E(;'E:)
MGQ\@!?,UH5;3AC0YNZS6MI*?O1D6>)0:/GI').L]D^PTO[NEU)SHN%0F:5?]
M#MM4GX_=Y\.GWP_A"]-SBHU+Z"0PW/]Y)%Z(;^V3ZU%DA#5I"=[TFK"CBL2_
MA*U!68;@"/7/L%?3]#?Q<P^@U0RM-=L08\./840&.$&[>2=[,XJ],MX+FT7[
M[@Y+-:.'QO]^]F-8_"(#EHB#/?P\!">V60AC C8=4)(MB!_ D)&Y>!(+^!XV
MH)!.-.L$EW2/(2I*!K@4/CY%C;[9M8%EAF4(2&F]'I<F>A5$(9P84+\*]M)[
MI/&T.+$[X)+^(+63$VZ_X'P\Z4S'$;^PO4)!JS!4NP_89E4VQ'[TN7BM(Z5(
M0RBL-FJT=39RK0NW^H/C4C_IEJF=G!!>9PY.:Z  AZQ"<%SFM]WP,UO=D]1)
MZ1>,E( S(V>CK$)*V%U\-8NU-5QCI16-Q">TG8>O"\TN3)8ZXH);,>F*6GN/
M<K15<2H""KR)PZ97=DO+AHFT@_!13R>"V$C]Q"Z"EB#9[0,VU0E;U?ZVP/A)
MUY,J%FO]I7TAY7^3Y-]51X67Q\XUF%TKQ(^>*H?*DN9YHE7Z.<0)TK4>1M?Q
MT:9,;8.=-^%;]L*/DV\IG:0SJX01F.+W'EL=Y-=)S5%'89EG[W)E$^]%;N4[
M>_,Z:&=,B"8_S&G/F$P1R-:XH#&1NJH]KZ<Z4;YUH]%*RLAMNCQ3-;(Z;UK8
MIMDF;_ZE@DB2S=B1K7_"FESH03F^[V^90R8BL7N(47F2'TD:8L) /,1F[:H(
MS!I8%$0X(KC^66$0FW^([2 5+"!V!%N@=N0]U&R4[]7IDX%[7K0$@2 R<-4_
M[I^FY2.=:3OBISUXBNL$)ZGP?X!Q[]4A_H&03 :V6X]QH/D>0<C(JO 4?6DI
M-4V@0VS1KH?EDMZZS*^&O"$#XYH#YX/Z0,A$7WYQTL=]D75O=W=S/4Q_P8EP
M)WY/DPRD(MC1V 9?%8C$>&#8/>0H@N3EZP*M]^S?&($!TSG:NF_H*/-A(S'Q
ML_:>IFZ:\=KN7_?8Z"%^9;M#:CLT_V[QFS(FJBWGULP%)8T$5LKRY8&<W06T
M&(A9AQ5%$K!XB.4"&68UCW$,50*5)3%F/ _&7K5(4H8W?4/C>;*O<W1_O3>0
M\Z93>"@I@B,-'3.R.*AYJVWV(&?.90BJ*8-LYOVMNNSE?K\^2,C$- HZ=?\L
MZ?9W_"'3<U:#3RRVY:A\E>3GHQ7O.K \V;1DE?5/Z,,N$IC$]JQQ&L5YSWUD
M""85@SLT]ANEZE*$2[@MTT:;KPDM27(M_?M4'\9,HE6?O)/B8E]6X^R:8])@
M=93X:G-/\K[-F. 8H5PB[FF 5MBD@8143HZ.[0M;HRE1O07-=#7=KTK+ZDQ8
M\%CV$7Y<<Y+'JDU"X?A;ES5AQ[K]JG;G'UQ#%"$7L9;7D_J(U-TR)2#I*[N>
M6Q9QF"AL=J59Y;&>C\?V_Y? ?"7]_ >!ZB4#J*BCOO\O%P(;9<TFGL6A\->>
M[E;!MK<0/L<+H'/"\X,_[*]4*;4\^3537N\$HT"!^ \[7T#,+(SR]C*"!3SV
M4N &_Y 2;Y=%DJ&_D,:.58)H2V^HVG3*T";--L_OR2&4L;&#9BU_P=L@ J/D
M#-2+?M1L@1/$..1:%]RB-)%X?NL?J-G^NINT1Y"$MRYG)'9[ZUFK2\JB65DR
M/?GNVPJX.TRU7<]?>^S\.+-<LOL64;/ZRY]& J0@ Y!K"#IV#4VTI,=0PTM[
M%@]YP+L%80B\E=Q5<"NK\#"+C^0+A8K"\LC''_0D,&Q4"6&T(.2=Q9^?5L4W
MXWU9H+CL]MN _\*%#+07"Q;J0"YD\*V#P/T/F9<&BE6^]2BJ-?5I=.OY)>Q#
M&4<=AQ@&.1]1$/,1!WD(01M: B-BYNIR!L$"L:_HZXO89WB\93\D5(-FWOI\
M"Y[?2WKI\Z?\P_!>09#\G_2U@%P9'H_Z 5IL_]\\YHW#*1C)G^L_<0]]_W(T
M^"^3^R_1I9]$.L.%%4%X54FV%-)8Z#OAM=!T5_1% LWY^V]1U5,[2YFI_%QF
MZ! [X^'^PBM$I2PF1]59/?,EGW5^::%64U_LNK:,4*W^2YA/'U*.<)&8(7>%
MX!?9U#5CG**;A8WX[)"UZF$T%?1E27\O7K+LQ<JM7)ZX3$9)@;KN66;.=)B7
M3\@^L=/[T<UDUY&#V8K5!B^K(0,5":M^?0^?[ &E:=+YKRFV[L:/HCT\)IWV
M(],2:CRI"?_6DO0DD(&>*A2>D@R('F (?4>]AP))K9^)B);P/]L>):@*4.X(
M+#7IZ3^U-#T ^UXWHB7"FA#+3*PB YW2<X0^_W 3/\9.]"?(KX5S6E'#X*LZ
M@LGH9[D0/-B(JD8'/LLDBVO*AIZG'W_K__'*6ROY#YGD)XLG8HWX*.+NWEMZ
MH0C*ZJGVG*!GG7&_S\EA-N35F7Q17_A>HVMO6#).7V_AZHUOU?KSK+*$&M>W
MZT92YK%)V5? 9J([TKMS=7Z5](RY0+1\L=+I]QUV6$/\6>(FP6U(S)V%=0J%
MVEI(VON)KD$OXC[+7R8UZ;<K.C'%*8P9!"/]+ <V%=;@^VC<@"+ST31^^2O"
M/O2H@P1>EAMEWH^'8D5,E3PPWW^(-&F'BN<:B@0!8)SY.WJ*#+2JLR WP;FL
M+\0B^";\@/#\R (YA=S&]ZWAT!VPJJ>[G06D-P*07B&)A2(_0AUAYRK:?G*Q
M*=O_]ITP_R1U9W6[>HZJ]%OV<6T1HT3FPWE*43/H=2&?WAYK)T\[MZ<5^&?F
M'L8??]^4?3K><96+T.KTB4A945O>W9(H8<,H*/#D2LAW7[BT-!!VH6YBI FD
MKY$N0)(FT<6TH6LE^69.9Y:0I^40!G:)->HW^W>ZE/23,*O/A_4?%GY,M\-9
M>Q?Q1AEI%DL]\DBI>HK%?QQ,)M:),GRPYCOSPJR+OZ$G]H@98967_'NA7[\F
M/=UPI-F2X1V7#&Y*P*5]56\'GY*PIT_@JH-1\RGVZZ]F_B*"BT&(2"-G[%X
M0>9Z=./(D> /<+V2Y)Z_]Y$-5A.9.AY$38"((R@MZ0O#/"W=_@2B9RO3<':\
MJ'EN3H38I5MK*BWRTJ0"<NTMT8FYS)?Z%UQ,]5 V'J+4026R9. GLPH'&1C5
M0Q B-<C NY=0L_))+A92LEPX22E?LTR>N(3>_*PTSDG:0>[WYCE ]?QI G)^
M/%"97MNK5"(0@_[,70*(C7P.[E#WH[&ZEM"T.V##G<_'C:,JI :Z\9 9',[^
M:Y+T]3_(@ _\:$G+WIIX:@%Y (=4F-;A ]CS$SQ.*G0QS1[$IG?]A* <ZB$)
MD6I_/W,'\BQ4,IYD@#4?\=?25/:67$2Y8'M]FCNYX;+VWTBU'[_I>GI>\4-X
M7B(RM116FE[ZP,,JO9P1,^XP48Z.DB?1$2DC\3'+0JD J7W@<$Z*#$2Z+JN;
M4C=VCNNK]I\>RW^;:7 !QNE]ZX?%#*'63RF_<C._I7= X<QB_'8L;=;-UZEU
M%=U4!F%ON9U%@P)4 [:++$05Y;T_)]W&*G-6_+:^DWOZV4IO=/A#1<OK-BY9
MRX,O8JHT=15X2TV&8Z,=RO)=RRX$>%7JA(RNII>%;V;/;PN #1)I8"_;<:@T
M4%#P!O_YQ%!?GZG9,-A)VK-<TP<[%RRP"^^".\?D8DK.1;OEG@.D^4*?>$$N
M7_6;&RUM )P8E>%PA@T!9=5MZX)<3ZI_;/_DS\(?:^TFOKFOJ@\\SIPV6Q&+
MVV&5"+\R5&TA=H]7,Z;NVM>.L/D+%%QLSI'VKH;=69S5C73A6='Z$5?,F#?Y
MVH145DH]^FS219-^:-M*Y;1(<.3<&IAW[%B_7KZAP\'1R^)XF3?ZWA)8)"P-
M"Z^#Q/V=Y_TKXNJ09Z.Z17E@G#C"_/TBS4TR,&U'.A6__MWC^-N[D-/4Z@GS
M\7,5T]]"$O(B;3Z,XTO621)DH&VB]>]HY(TY1B,M21&JZ/\[IG3*Q$AO7>$$
MZ-D/[W7;$8MK""R<=(S8?\)V.HENG9;TZE"?="8/?<!1*C=*NY]&!NH"8/9!
M1WW@]/U0<\22)-3%M($'RB_MTTG^T/ 39& ]#(U7*D$<4BXC\8)%9."W3Z ?
M]?UPV99^MT)V;T_=_C5_2Q.&"F_6AE?*8Y+LN+&RNK_/?$]DOOJ&O/"]-GVZ
M'+:$1_.!U,(LSA$IKAH(DU#-U<JDLCV546.]=:4'U3L$I7670-3FDQ+0:6M_
M?RWRK35V^*TW%$RFP.$Y^?[K>4%K>HYSW^.5!GZ_84V:"VW=^UYD7/(T46P>
MMXTI4I0N*-'_,76.FJ^>Q,HQ#57FXC3D/L#6 M6#UVXB-@BGMW-TV;:-#2AL
M&PH;&6Z9BEPKP"M'-L]] 2V8MYIXM;+ +!K?KO8*EX\=^J,PA^"YC]L;/[;7
M29JVJ[G"KMFPO<Z&B:CBF@_YF\:Q4AFS4U]511#>VW<<6E6SU-<M;5>3$K*]
M,[^6DOH]QCL*NR)/XH7!3A0F%6H2X#8(PGOEJ=-80W:OVXVL^]@]*+\_ ZN>
M>IZ2?NXZ?9V"H'A!#M61"1^;(>T@]K$@3J(S,Q0*M'UG%2@)Y=SIQZKSCUJ=
M]D2?;)G!P3&?;.[5["["B,K4(1>4VW>P>O0.GQ>2#)R>A,#WQXHF_KXO,QFX
M[QD(8E/[P0/Z*J?2>N(2N#ES_*O_1R:PJ2 2B9;$&^&+/"8C-[1R$._9.LB9
MO5T&M^]UPD[BQ<K?$D01&V;0X(L#(.8TU@FD\3*_ @U/[?<!9ZZX(^S>'D%N
M=[J>##3ULU4 ?&ZR)[RB7%L)IR+LC2&?V=FQ 2:]9>:ELIW2LLPMM=4O&AHG
MIK_D<[K-WD/@E#M-!CZK-<+PFLL(0H!6^1M9AD&\4B/7U>,77>YD<#!:S!$9
MV&F=3%Q-;Z#?)5/ B'O9A[2+NEDUY3;O-$7OLPN>8G@GW$\?$O*Q>U9Y3&7%
MQ_QKBHGI><N0+D&Y'$4=#S)0X9:Q/KEC^B9YRUY>->6Y4+4-S\%+S98% (MX
M\Q'CRX<)^^V.W8N@Y7KQP^[A+26$1FNF"M\KPH6^#M0I+\.."_H09_(\2*+@
MSQ#Y=))>N7YWH>KYF\I(ETN/$=7;S/LA/\^]['Y9SBW)>M)G:()VPS^4)-%9
M;*BQUV+U86W=R3)8?]5MB E$<A6QR KK:)4,>%9_,"TI+>@\M%N=1[/746.?
M4Y($:,]%4%,V'HI1M-XUZRR_(HUX>$X;\:;F4HAI#0_FU5=1%>Q>&,"!%HE3
M]S" 31"9";:U':WL8,V]TE^*9Z]5G1BM=TYE?/([E9IU]BO+0;?6FTZQ6[_[
MD=5Y24Y'_9F6_EL#%9KG@Q[%.&=:H' \5!H=!].B^R]7JMC?8ZW?#%Z2H\=^
M!UZ!LZA^S:D?[&=EMY076;(AX(J'14+9IHXB XQ_(M4=?64RIV6OS&_QFG+"
MO6O"91<H?K)(<R3K%I2.I\K+O_U)G&&'X4]_B\/9D<S%Q ^GX!OEQ9IU9,"Y
M=0V+W.7;\I^*T=0?686][J2%L)6,1S12#Y $UB&P1E'!(3A MOGS[48$7O.X
M4$PE_ZT,Q/V^T6Y"' 12DP$&M20(T_<2XDD::/[(&*II?H@1=] 'GQ:.\8DD
MGIYBA<#S$NJB?T-=_S^?6:X;H=Z'B!3]]OC/5-9?@#ZP(SP"GRA=".ZP)H"_
MH5XNV.5)]3P,+P>)C_B?(/UWJU+Z?UVFTBTXZ:T8G !-$W7A(;-O.AF@'B #
M"V]CXNLY:)YQ0?5ZNR$S8W[0"U2]P,5R^_T1AU@%1=@^1T)!@#^;%ZB@B>>G
M78?9.:4O>U0]\V7',W/?BK*Y['.WW 41Z3]<?VE"L&VKM3:0Z?L-8Z;#B_MZ
M=?;!UO?W+]#I20/15W-^GG0-;%F;<6^Y/=(B1XG=#!9&.,(C.42K^DN#"0+?
M"'QXR?3GAZ6MR56F+9\_28:#I=?T++8L4JAVORW0.QZ,<"7NW.AO5I1 C!53
M=RGJ54=7^X9.UQ@]BK$5^::74KLSB9(3]);9L\WT$N [.22@4*\B5'J:=X1W
MSW?8QJE8KH&#O3>(3[F_8@Z28DK<L<\8D1N$&B*EG7_4CT'F*#HR(-PZB_A(
M!E9A3R&SM1NZS;0X&'==QZ/%BL[.G6J#D)0IM/IM;2SE8<H]H[S+VXEU4SJ0
M-F$X(-Y9HLT$9[Y""A>U]']W<%_^01]CUXLB#PYH"5 JR_Y+DZ7]ZCD\WXG>
M0I*T.<8A"*(@$?Z!/C*'_Z6M6GLRNA&TA5UU")D76%( 5$/TZNRND(_+A[J\
ML.'X\:>[P4>.E.)G?ZG4TT7B+Z=Z[1A5#+24S.^NM72X33A-*ZP-@*Z"4FM%
M,8]GYOCNN$7[K(]\[):A#JI?5.G7?^-,C'G:>Q&Q^&N?*VPQT07_\J[+_649
ME:NQK7OJKZ0!AK#Q<S-TT:*G;+VOK_].N":6I]#2]#A9J+TUY>LGRNH(6EG*
MD%K'%I6M);1@W+NH]^;Z+)P??K^I?Z&AZ&,^ LL?RM867]'OM%A8J\V4/I*V
MLVL[8OFFN..RH.)9%_3LL=V]]F0WFU7+[&_3\9U=4+3L'D#1NG4<K11H?U%?
M_N.IW/2T*K\\,I! 7.OX]0WZVM&%F3PE<>Y0+OK4C"CDY"RPU)<FVYC./N>
M:<7UBSMOVT,:IOOZH'(NU'7)#GP4RQ5.^>7V+\RH9"M'\Y3A=D.$%%^MM9*W
M?;T:2T+D9GG+XU.G>Y,I6[OPBTS)7Y\Y3MQDP2LI=-PSB_:HBXS6<_+TK R;
M,M4PJ0B)"C>]GIS8E]NJ83GP$ZI+F@V(#>[^:=ADH':=!?)'DS1N?>(H I,!
M[;RCG?GZ=Q_(D_D5X!\Y/5U[1C" +0E*%T8/K"8DHO4@- EQ#K6#B^N(#R/+
MMQ,H&\<XP-^G,R+!M5P.Q)99RG^P]$:HOVQ6Y%^8TO@'+(T<8^G[GUARA?][
MGQ;Y3^9K\,@",15*.F3T*X)M*D#K.R/RCRT*Y_\1XBN5V(WPVCE3(=4Q;14>
MY9TC/1[3%TG]R@_N1F=0W55Z],-SXJ_IF1Y-C0<^]^WM$6KCO%'71J=[C^Y-
MI=3**>>8U,"RS[OSDK;XJI6>1*G(-P)VG95/:5]FY>?>*<@1*_B@"-_O#=_1
MB_8$I1'U)GC-/:/2\C)B-N@0;)]N_!+BSYJ3>D,BG\O4O)DQ\0%,L?2,RC]<
MJS3$HIN#VPIZ'ZU\/$#+'N%226C25[SGWLM>@GP:J6^Z#!;L'LZG5]A78SY7
M<&)%[G)='8.2)6B91;B%K8OR&/9_)NS8YF<G(Z:X)AJ9ZB*T_M25,<7LZAVU
M"],#AR$KK3K-E7 ;)M8C0:/;:/=Z*0<_;]/):=U)LQM>>;E)$P6P$.,VH>KJ
M<=T1S2CPC/?Y^N7Z]+^U_K#2)JFI&N>1.P@ZI?%KI"TH42T5M7\V\\K3JPE(
MXDF=/_/V;._/OO_OH\H4B//'+V# _GH9X,[?VG^Y2J@T>A40?^8'_A2L)0,1
MB317DN1^7?M[^V]S>4N6731FE_(0-:]4W%(K#0WCN"T4LJ"[7 [SONXP-B1R
M^*M:X1&S;9/O#Q_?N5T 5'U_W=P[5<QY_KM#@U3V>>Z:"[[?*1XAJKOO+N:D
M/<8YHS?F))@\VQ/[#\O]\D$N5<- V,61HNCU3-3R+](U,C#S*54"%Q=S]-S7
M?T"\A]DK6W.@)!(V.683IV=V;5C$P7Y]+F18>3:0Q8G^3LA&IZ000_7)J-=(
MR!$VM.(#SYJWUHFS>IJ3 2:-ZOV$]] WL,DV[D,/IAU(6!EEQ='EU.M7"\.G
M<2[PJ&2_WH:I'G[-9Y[G )F1YJ38S.@[*T7WH]5=V=@E\DY?#9XP<=YZ8&&A
M\,28]P'+8N1.QRN\78 MUNE4#RSF=RG.H.;29?="EN1B"KU:&XV TY)Z^2;<
M*[J.Z^72;;5(UP.AX$+O9O;6D$QY6&2XK)S@U\]GO&H><JH(EC*+\#<4A8M'
MJ_#S?XOKNY* C\*=^PWCP$/R?";%%5JJ)AF0[0<;6O !9$!^,1R!_3H"'LA5
MC/P(6 P+#4[[Q?M<#A18Y#9JO7K;H\VK?=F^YOUER9-?6+D" W0W=/.O>?L&
MSU>P<44[<:V?$A<TB*-;E*8\2==K5=?"SM @_O59.C$T2L7/-C>2P&.9KP@?
M'1/$WZ$O+E+A\;N4W0,Z66VEOW-BCG3Q4I7M]\I3^Y!YU%&)</"8BG?<5/>X
M#<<;3%]$+_GBLDE,1IMD@*^/#)QEFV4FTJ:*0VG(-86XX7#V8>&)%8N[VA*Q
M@3Z*C2YHC7<N<B4'-.]G(IPF5=S,+T6A:=T7Y'HF^+MG4-Y;^C2B8OTEOISU
M.R-B;:)L(A+MHN-F9BOH(Y@W/.4]::K+?%/63*:#E.;,D6+GG8(B"#L%(W?D
MO/X,F"<9B($$,R <=Y84U',9Q.A"[+[EY^S8( X7V+J;J,RB\JJ#V_&G/&T2
M15G<?5%#Q1>T3 PF#UB'V+K=+\W3<U8N'#T,O^Q]=7WZ^S?+WR>ULY-GL[*I
ML8&Z5#H,T1:B!N$VV_.&]M%U$S6_)!V&A[\/>R;IXIT_;B0]*X012J_TX<-Q
M-+$(; J^@W^\%\5H9Y%+\<K%J<AK=V[LHQPGX>X)3?RWFF</BY/BS6?][-')
M!H66KKZF%%;<:4QAN-BKYUQX)4]B6%OZS2U8#4?U75M/S_E&889&7N5%B'IL
MGV@/W].J-I]4$L]E>Z+"^,)^V\Q]L4-WFYG[TN:RJHEDXU8F#<;E7( ";[K4
MO+2M2ZC#:.D;C>YUQ\UB7L-N^]J1T-9;J?FSSK1=3L8]\Q,;"(PY 7(6G[=;
M0/QC.Q0A18D@# ;[@LW><PB"H$2W%&*':.(5@HRR"%&V^L,Q<.K1)>^Y[CYQ
MY=-ZP=^OWK3DSCWGK![P<"WG@F54EIU[.%-"XF/AHB^<'K0\@QD)3TOQK*R<
M8*ZL^)PB2U[HU<PCO%E:N\NO;HV!?38#[K%XJ\FUE&^AAE.N$C\+*P/B:YWR
M9[W=^N20#HZU)<?((@,7(97PQ:%(3)<7(6Q!S>!9V"P,PI88A*UT$PA;*W.$
M'-6-+924"P,@?3.\_ZJVMP7[=^JP"%N6W]MFS].4H@W,57C"]:^'S-\]:7$N
M934J<82IH4: O25,X'<EP]OY&CW=>)?JTAJ]"ST+ <)'M[+KQ"X?33,$$VV)
M4(];!D$I$D<+00ER[1BM;^"6.PQ;2.*$R/+@SQ#UD#2^R3Q^Z7HCY3+#R6?Z
MVZ<F6NJ#W5=C&V+&PWSZ6P(-HA?H>4JC8NE7Q#Y>5GQ29^#ZMM:ULF6"ZN3O
MJ)" !A.A,\4+;5NW96+ZYKW=HQ?BX@Y3W]M'ZZDI%#'O;3CN&G2ZIZ(WI<++
M(7H?<XQH)%U"-"$.8;+6T+H4*\E VR (45W0,3% :HO],H(XD*G8"U$>LXQZ
MZ,2(&T^KX/R6\4$Z<NV31?LW+F[8AS_T([SL'"*4RE,?E%>'9ZH(+XI<Z1>_
M\3[!2#3[Y&>V>XXJ]:W<[KT81\;\B&S55/6H\176Y$RJ6,OA#W.*;[/YF-Z6
M9)[Z/3-68Y*D;AJE+]:=6]\M'6BN]FOEX&9%A:F:U8$=7S;\YRYXBJ"*#TX5
MP4*+?+?9<KZ\R4>(@N^]Q/N+<8,BLT_:>.:X3BE9"O[(H8[Z@P;R(Y/T4[S%
M RR?1:B2K_$*__[B]4%.Q;SB^Q6D\\XU=/=V_7A/2(W@_!4F2'7_8'\:3!HL
MK6_1I'Z[^K-@1Z7O@K!]4'XF>N$9;-8.G[XL$#=39 ^>&?B!N5'!KU]OI?WU
M^T<?J>=#T2WM=+&Z]V-YI/GE'OS.&/0;7/]\M/GNUYJC&*W^JE2-!F<S?&Y6
M2,].!>QICUES[%-@(K3[]VH/<JG8+X;<J^269_NFW(YH;Q2\QWHR[ W-"HT$
MX;Q_'^*BK+?3T3V"5<ATRY1(>:@F/G>NFHW_"8ZC\-RMX3A__F&1_$\A+ 7T
M/,I/(J1B?O_49>7>1DXK;!)>MN'!F\C%@2,EL*WQ^,W5HGH< QG07G=$?Y$+
M^WCN@GF2LX-P(]6[5NW,:,Q*?W98XZ-FG6S]\3FN=9M&.M6\ISIQ@K*X,$N+
MV+5H9*17H5$9C%(U\TSI\\?SY27IVF[9=NL]IQ7U1BJ;"IJ0P:HG"B((5L 2
M B,P0KM=UP4_+G808L[C_\\0#K4#,;EA:>BBZ7,O1DHZF ^KHXR\F 4*UGS+
MIV._'/63@6?[F;E#DRN[@X13<38)%4_'.YW7*VVGQ.C'^XU)1\B$T3]U]]^#
M,7&:KHY;2+.XU5^4T]%W^7=2T^&J<69R7-L)A6QAR09O"V9$W<$[=(TPS:\S
M!5=TQB;43E99[F@E?=G9L]?XR5NL(JFL+10,NQEM=O>4;H3J15JF^O<_I3PB
MSK+Q8Q<4YUD>.\?OR1E[E3([ZN\*9?L/2Z0G6CE6:=YH+77+PWD%P2J'[;!'
M/85N!:^09;SEF/.W6^+*ZP3+^R1,96U]E*OQ2=:6WZ:7!1@=JS(XKM3BN&7F
M#TV:A77R]"Z[14<)ON909MHV)MS'1S$N4.-0$9RQ/]S**G%6^4R=CY2$6F6+
M<VUISD7.MQ<J7=X('Y1MY[J*@N)T#E^.0:^'PQN0M%!$-.? MXA2I7<U=\QG
MR$#0R"4;811MC:YKYJBAP?-A^JD4[7K"'<^<<0.%VWY!#VI%61:LK&[F.+X\
MNMRS]YB8M.;[,@,/KZ]#X OFP! Y?FQ+[:QF<"IKOS^7P?.RRZ=2/J_ ;6RR
M\:G=A],JB9YU-<ST1L$3C;(6!P&Z2AA6D'[F!DN-&353P^@E.-,Y[4SY\SH"
M'<\5[I?@+B3%7:]C9C@S6&FCH=4DJ.7;\4N&[H-W_(AV_5SAHT!.JXHEQ0SI
ME,*/<3'A:?TAN6RW\\W]:T:LFU+9G,+-N+'3[PG&6?CQ)LT,O$%>W=6(_5FI
MHKKB,N%<)]Y(:]=O]:ZYXE^QQ"PV?J<L0^X_!'D;F$=EX5C)/30N\NW.=+ 9
M1TPS[-=8O[SGY^O%.+D.^=K!V62A5KG0SW8<?(4C&PZ6M!P_Q[H-LW\J4RJS
MZ-=YW< +S2+7)H],"0I.@?X7L2VYZ<MFERI[LT(?#(1X@:;1XPKQCX?<E+O>
M76OOT*J6+%9X:G^U[#7\DM16X?755 9<00-J#-V(H"+!\*U-)!D\'^ZH04:W
M/,B?S2M7+<)XDQI?.QO13WLAM#)SJ"0+V]49'RS7(X?*MA4=9^UH4'M0N=SM
M:E(YZ+Z,)6D&-@XT]>I."L=0(D=U4CDD3.ZD<HCS:(M^73P3^\'I?K*N06\^
MU76S$&DKR81MJXI]']=2W*^/61O14[EJ"FE'ZF/+J&0=?,>L7+R[9]:$5WGK
M]ZZL#F\;87V.FW716U>T^!+@#XN:O\0V?Q=KHYG<>WI9,>*RWVC&-'T=E^%X
MF_B4+.Y=W/#W,6X&E=E:*\."=_^+L?>.:JK[^GUC1ZKT#DJ5+KT%>!3I M*;
M$)$:$! $"1"(TCO2!8&(E-![J"&1+B @74!*$@%IDD@Q0@B'Y]QV[OF]]X[W
MWSW&'FOOM>;\SL]WS5W2NV@Z*&,5+*8M5YG84ES,BBZGWMB2Z1N[/+2&^62:
M&B%,]'L-9"4JXT!]]4EQQJU$MC8W<(@'PCBD!#SJ+X*X-I<'*1)NS)AXG']B
MQ&MEOERW<:I]1=)S8PZY1F.Z>*-'JUEY8(*.+$8(.@<D0[WQO"][^.X0XJ(/
MN_@O04S[\_UBC^AD3*>"ZAM(L$>G2KE/6W]_^>.^9)SGRN[I\.7;S2,Q(H;:
MN<R4SB%&SFX2>I@C#:$M1V"HG1;YVR'LY@INUZR/1,W?(U3N=LI9L<SG_WXT
M4JAG<^IQKWM_^.B+8\UR$7IEWMY.:#]LM?AO^2ICA.#].Y%XW(VD3Z[6,7BB
M;NL8\ #ZD8H'Q)$X2(WY0G-97ZCH,J)_(O[WPW]?:Q@:? L,JZTKSAS@^C'*
M_8#RR(?GL1>=FI.3.'=IR/W6W^35+'=94 V,$2B,@&".0:11T<1?&+="HWX8
MPQ'LIA'V-.V-O6\B4 ?;E93&]/,D?"6SWL@-"V(P;MOMPF4$M^<;B.0;$Y-_
MN1SGSP+5L6&8-Z K9%E"&W8^YG _"4:#YAG%UW/HK*TR.)'ZOR]#_/IRY;RX
M(FJ5"NDH[\/"-D=%E_;\IM8DQZ^D"WID7AOJ8'.Q^69&.(@MG37\:M'*E?'B
M0^6(E8QD1O;W2DMSLS+#QYM/$C^:R*M5N]IN/[8J\DG-54LQ]G^7&Q&&/ ?(
M+*Z&1]C;DHNU&"EW!!4\AE:DTVMI/V*?$:U;7#V/T^ZL<KVY-2JQ;R6W^ZA"
M_9_K[S2%H ]N,^(Q7+0'4;C"Y^E%_;7'-WEO\C!/)YX!SA#H>Y!@+&9 )I'_
M,E2+ ,(^AS, E<M!$,,I#B@#]I2?9\+?#?RJ%2TV X5=?[LBV-UAX&'PZT-[
MOC[6P6?GY9U\8TQ>GO7Z+=VXK&19?ZXBJRMO:6(X'O=?_N3ZVD3BL(BE[T<(
MA0]21>9\Z_:UD(OUIZ[""Y6_EF7Q3P[7528D/U:89IB]+.\N25Z*:\E/D_]+
MAA+;Q71EO_AG=F4YG(S?L1N0J/7JJF[SF/5V:_ROZE#:?]*D#:=.> "VB+OS
M(J##!)=A7TJD?F&VJ0XP+;+G@$/>BU-[\R^,8LON!?G];YCL-'P*A.J2WH@.
M82)?&.'3V";H)@;@<:TVMR9P4DX0!!)-],WT";[:./;J)W'B:AIWM=A?6_S5
M#;1GO>M9(>P'ADQW4>P'"*/G  L-+K1%"B0X;NM%,#=.S-5.49STG$_.-O3P
M=PV:M<)00=9$KL2:0W\\,RD1/)W%!58XM#Z4DQRZ1_G>9W%R++_0V6 "GVOD
M27'TQ.^%V/_E_\GO0VOX]$6[ZYL[%AVI KV%J P&<7H<C?]\IGT8^_21%M[2
MYT2;L@W[*= B0?[TWF=[:?75.2#?R>-8B5.F^O$KF\"/2TU=K^R[%2-<7LD@
MMF&#C:C[WM?FTL.O#J/%I#;LV,.*)=:U+J5GSVS>$/^4_,+;MUGQ-7UAH-RE
M>R/7PQ]=^-5YA,ZP53E>3*=RH%*G9=K<6&&Z$[R=OSC_TR,U,8>!F<]*8C*_
MV0 1V *NULJC0"/D+FS3%0JS']O8.>#F1++5Q93?GG?^"S2NU8V\$PPT3.!R
MJO'\>._6<YU// 'R3S[]Z[( -]* [@# I8LS=#N^OM!:/VE&.?O30# #)D_N
MPEB\?S*V/[,^P29<Z3S=;+L_UQ'7'JDEJ9"T 337?\8IIVMNE2*0[?][[$7M
MYE*Y?@9@HD-_";2-H"5L4GNH!M-/48:'>8-R>B%YJ&:9( GC!R4!M<K1&Y4B
M<TWO,S$6I%/E 7>%@QI'<4B!I=B@.5+EF80NX_3NH"*+S;!@QW_'-FAZ_GA3
M**QK\\39/P.+QO[#\(5GW:+<]I:_6:QN3^K#[!=&+:Y-@WTYJ=IO6A\^MLOR
MH"[]@>NV)< 8!F92)),$*JGFZJ^)9KM-^64@]9'!D7[+_NM&'PWX))N?S-$-
M[=BVN1^=# 3/G@.F^UK^.]>C<C>8L7<+F'+Y>Q^/4-<3A_:1,:I/*]%/?^RI
M"%XN8?IGE#9R@T'$68PY5X#CB^$7:VN)+ \W6=U[P88/"/1>WB_0.K%Q%])C
M$W#3FZ/T-[2Q?&.W!<(-?FHW![X1\LS_U1+IJ.@<\.?6'NR_=)W_;Q"-8ZHT
MQVN:5S5F)>L=)%?]VFE/+G!I'.:H=! O\C=_^EW0;I#65.PVE5ESYAW)$E^U
MAHWF<X#5;P.]1:.X)BJ=;0Q64,KH'/"X*ZOY^51=-7.2T[O$BV1&POK.-I]%
M")#OBXI>(.E$/5F8:R74I7ZI^2LN^]_#.E8@7LCG:U:/85C1N3\^9C'7*,L=
MKX<'<?Z9V][)[K:]>50III(3GQ)"1D>3L__I ZMHR5[AV2A(=+LK>(;->9CX
M749DP\[DF^#K%XYUW/&7EE $_:HTVA^MJ #:V#&I)FBSU87>O).R ?4OG08K
M&#RP37;Y\:03)]'=LF/V;1?SWYB:1+V$S;#[DL]^L;BW(Z42]AK?L@4-,K[#
M6EY_:B0C"-0GCC%)YBH=+#[<?F(0Q)EPU84S8$A5Y_/HW:=R&CH>FES8_%!<
M $]D?F:+_8C<YPX#K]FYF\INE;7 ?<6*TI+$P3K+PAR1SN6E,B/>M/\8O>(_
M(\F_0OE#GMQQO](2TMK[E>O57?H/C2\_F35?3<]0[4^AK13-%?+A_(W/:DZI
M$$QGG1W>_2 7^_FS*,?. VP$4U'C<)-4_3E  -6UWDJ[7EW@(=;EXG^ZVV@;
M,_NJ>HF@MO_?VP; %=D*OM61)/0/:(N]NO.$!P_N&5;YQ//RS4K1([#$@-#D
MPY'BN'<##Z/7HI-CA.$N?H. ;S<G6/.Q=>R5:+WT/@0Y,> B53IAA$V?)ZL*
M^=!WW[UV2Q+[01NSEJ] _WNNE/R'#Y\=JI*7NZPD64Q. ,4C C_]_A@1;+C
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MV(UGL\LX!I[BQ2KKM5GU)"ECM3?#[LYF3247X(-^E6)]@X/"?3$$"0D^XW/
MU4-UC$_:0L.>E0M1T&B%I5);]%M]<!/C6[-W3 BAMR\SZ$W_N/DM_=1*K\?!
MCY\0<OOJKU[<@@[&8Y^!+$F<P3!"^;WQ^[1&'KB0&FP3>-]7(2P/*7$UDO6?
M9],RM*UFC[:%\U6BF\B[LV<UVG^(2S<.^<]"R2Y;_,DGYP">KP-AXC/=K091
M%<7Q"#7%+#<+EJEJW5(7\ZRI[JUQ<;-)A?=-9T:]*+7B7)P@YZ#_1FB?[<^2
MYBYCZ13/T4 S'1@07EUD1/R&7]L?N'(.L#P8/ ><)'L%44+U]H?/ 3[-,^<
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M*0)*U=@[0G(-X3:OYGA=FR=;Q&J/S(X'8U<6&.L<%SY2ES8HMIWJ0>4(V>>
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M'32>6 =_.KD 7QNMA&NCM8LW) %>37"2 #NLU;2_P4H8!"$G6>($00*4&KN
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MOA=>J>; ]E=+Q;]\WS[TTMK8<H.JO^MM5=^UR/$S+3;+?&Y:5AH;'P"G]'?
M'I55'&$J;4W@5D:G2:VK3[RS^_!QJA;=\OTR$-VISEPOV\.F'"N/3N(R#K1_
M ]N+F=A_A+RGRF.YJX/=[6%3J<U'@RE=<UZ\S5UI3O <0[^KLLC-?5[=A4*4
M-NPXA<$]\J8D_L8.AQS&(IMH(Y0]R : U 3ON5!']#X00QLGK1*D.1-*@?Y!
MT(>AE\0IGX7!?^$#J<AF_5^WU#4U=23/* =)U'Q9U&9X:D) YL6RPZ$9:I[T
M9L\XG_YXJ)341YCZ?(1J7LZ@1,D\Z6<U9-&/8V5Y)%5^ERV33*EE8R,]Z_S]
MB-,\(@Z+NB'RN)AREEM@JE@K VTD5GI;4\D@8T<-<<BSMZ/[I;ILG7U03\'&
M,CZJ6$SK4%AZNF&K*XFO<5K/:G 7]'V"<QO%!H,@XL&<C:YB7[#FT<JTN,=6
MS;.U8B7:*;H)W6TY>"<(W;^.EQ[$"H@/I;6.5$+P<]>-S.5R0@-.MHJS& -C
M@'C_A51"V)J+&%+.+SIGG/,_!@Y9.KUY-ZY3 Z:%D@ #X?>F0_6*\7Y]<A>J
MV>L<BM-Z.)G,PM0'5IV9B0UC;K>'GC2^X\[:<OZ'.4[VB,MWC49%K;J*[Z?:
M-Q]6$L#,0L-AB,/ UV;CZM!3V(X5G?/ICF*GJ1)ZV3OCZTQ3^#B+NV14J: .
M_X29WUGF1JN;FOE6QE1PC -NYM$.?]#H!LKL1&^(!\F\0/FR2&"0%\JO,,01
M_"7G<V6TB,6[I+&9R[P@N#EJ]>)L_G#^1-5^\6#)=FGJXC:_WS'76(6;4N%G
MHH<-'G6F0P+,[\D1LU]^(P$H6TI@@OGBD23 !@0[<95HQ47,VZ^Z8I NQ..F
M28#=510)\/0Z=RK]U\WXQSRZ\)*E$7BEL&1^P>,&Q*W#KX?J1!+_;2(8'G\E
M =(0#TF NA<DP/&^U 59-W+-006HY7E-G(2\\"W33A(@)1A(NR5,N("Y'I[+
M>R6#3RU4'\%V;&OF+ZCL2(#!CL+8OXS$,&!C$"%/;E#\4H2+'G@B-K=[@?A3
M1P(\KGUR/3H-%PE@)#&X;B<.^]&6C8<9]^]NTRX@UNXB]LDPM,SXP-U^4704
M]C R@/:^(-N;M_$[4Q;Z__!])+Y>02PH]S[,]#09'<95QB7OI>3N'H<0*1JR
M\)$X7Q6,3/H:*FYVX1.C[E79*+HEJ4^"W8>51H=%YBJ@_U<E7HRK0/RNH%HG
M=>9,J7S))JO0^=LV RF0CH[,\$&N[OA8^,TLPYA'76"MFLY\W8[ZKKF-\I.E
M:G/C#= _Q DP1SAO]YWB-=KH GF<:GZP:DV9ROB[S\O0R(GVJ5OD]*6CUGPM
MD)3CWBQ(VO;6NZ_F*K4$ 7PN&L&VA+]IB0UOAT./#DP:8&0K?SS<JF4V(I]L
MG\E:Y^B=9=U[,,EJ(JTO=%M]4Q#HJXE!T>-=B!1C1<_0G0Z7&O&[F.86>U__
MTQRJ;ZG.=<GTF6.'"^O4EP9[]5>_'6YP.;A:E:56A+I>9<@4,MBY-4"7S*\^
M$2RO8C$>'F9\LZ%&4P3UZ>-/H7!73EM+2U'1+VXFZ?>?[.NC;8@O")J8/$9^
M!?LB9:48L?M%Y.87@RT]TYDN@L.@A>'<>!__[>G3#QDVR\L<Q:=5W"-6+8TI
M<FU+GLK-Z9>'X36+BQ:$ 'PZEFH=W)VD.F^#+\(V#*J2304 N!MF0W5*5BR6
MM ZD1%L*Q9F9<'0,*^SN2VH%-I"FK\HQ/([>]A)#O 3W=E%'D.2P=; !=80J
M_0^CW_9/V=GU_%)/><]ZO!:K!IC#'V,Y.QTQF2TXEWYA#\Y+35S2\)\L.SY<
MV'(;NK%CTAE'WW3I_'$IX(Z;_Z><Q1L^G@W/J[$'YXB!+AH<U[\$1XSX/]#Z
M?FE;V+.9@<(:R]Q+I:J0.XWT(-$/;4TY&M"#+S!N#OY7-=P.>%:N+]Z%S%NL
M,0P, S,],P,3CT;A\F@.33(#^5$/>5!:C6Y#@MG+]-/T%)4:'A1/> C]O[V&
M@[/1LE=YKV_E5:^LR.OL5+=XU-QK)L(T0@WQK&A8+)B*>$N]ZJKMFM'[+Q.2
M7,P*+;IRJ/2 =_E:9#-+5&I3'T(+F:2V$6QD293)[(R_B#])@(;"O1.LL D.
M%'G"E82BERE\;\7TT;/67P+;_ ,?9-35J1>W5R-R,KW.G*HZZP/A 3W:'NW6
ME1U<H[6[:ND 8KSH0S6O\J1AY#>45D+9L3*Q438VE@M+BSNBZ'PRHP(]JIJG
M"9"FB*-%"Q=Z'6'VAL@?CSJ%U[+?_U=?SY4$8/6G7?I'Q9,$0#='8B?ZCG84
MD7VTM%9_?-VZ^*<;DS2/=90%:R?*W#[L*I:5!I:*8)H*C:FDZ=(I[@FD'SUP
MN><"?9#"/8J%5LY,UWQL:Q2<*=7M=#4?,-HHVYZX:Q=0,1GEJ.9?(20C[C;L
M5@4L_KYIH>P(?4N(%U(>!EE4= LK5? @ J>#;$5K"R7P>J<:>)C]FE=LN  >
MA7,TPSMB:!/G(X"Q;\4R/ZMC9&:EO\_+RK9879W,-17K%3^[JH+K>29Q='TN
M,XD P*"!!#@N%UU6BG7$V+5CU_L4,[LJ@M$K:I"LF3<N$C8[S9/ZC[;3;+:'
M*=-YE,;G"I[*T;'\!9<A.3JX*@G>L:?".'CW/N5A'R?3E#\5[.[J1&E)6QK4
MS./QX,46(H VCCBT)1;IZU\5-&NV:Z*G%/RE@,7A+F^?$%'J$HSGZB<!V(A2
M!&]\)'9QEF")O42+-J>\7K>U8E\1>[(/H2G)9E"_R8(02Q/_NLQ*'$Y[D+%H
M4O][&<TI/;:+J30=]3'>K%"H,*I$L\E;);"*B%*:%#9$;2M6J(EE!L_D6TT%
M" )?"V@D_N;Y_O)S)JOF@F?^<K;HTMO&_=K*(=[:BH^<U%=IX<RRD=@"% ;9
M7T@'!0VB6#SV PIOXT-ZD+35)]\\_)=6U,+DM+/-D5[TVT8+GV02E**0AA#Y
MF#Z*H6R?1-_P!U<?G.IPVOT@O 7GDY1>NYMX[=H=-O/WRFYP6OQSF9!\SZ.M
MK3"&);V?SKF@F$/C&>ER+\_]-P9P^N88P5?QVAIB,(VN![N<@GCKS\31_VIF
MTM[<07%T2&$**?C*5?G%4OTJE@BB(&;4SBK33'4'?<6OI?X[L:I)+NP[7K3Q
M2Z9.66Y\2??U.!E^X;/1A=V(11CZ]]X^IE-] $A/4,'%:L^+RY"+OCE!,.ZP
MW3YIB1.3H7!L@@@Z=K1->2&JJV44T'5I]UM%ZDJ>[T1B<,IA_72C#?$F.PY"
MDQ6?' 2,_$Z%LMC21^N@,#>=@9P"UNE2\NY!IBI^^8'.9:<*I $KDRDU)Y.[
M_ZQV3+$"S\%R/J6QVZY+L.S5DNOB=@!VOCOE';*A,*G#!1/T,U1O'12O>@M+
MUDM+CY\WQIXVH/OP/AA]8^-)Z21KH\:8S3V90KHQEP<-;C\JGDCE#ZC197;O
M*EM>/H):6^)^1YT@R2QVB'1XXTKHK5!#G'Y7ITC;>!7V4JN^->5Y1YV'[O;G
MK(LP%T.GY '!I#B+IN=BQB$:J4,[A8UE2!RSUCS,.84!*O<R_=E518<F6CY4
M?#W8GUV/)>!WP;[9ZC '6%_/97K/_EMK5T<R=D>6G%KK6=N3ZI&]MV3QHJ'6
M"'SNVEFBF -^=AU(C1<-Y\8?"+?'>7JH"D(/?EG^F>OZ)PO56P,?SZ&)+4;Q
MS)N9B4.4=NTX=9(FLK?4'Z70X;1N,L8.]C#N7H;"G\ -QSM^N_92R<\B> TR
MV>YE:O.@XTVVRX?'#9-83) <#Y#B568O\]896>T4A96.S3VM+.WD/)=D%X%R
MJE30QVOP :]%F0[Z$M>"A]-=7- I6^/>ZZ.S5FC;VC'C$:H.4Y:]$)ACTDCL
M#KDW_+EW2W<2^+%R/PTTLBKPTS-4&"/J^#1+4-0@NV9'5C%1;F-$2J7ZJ-O3
MCW\L+?7[#JCN=\75PYD.5K37W?#K8%B?>19-8/98HV7 Y\"BB6(X_HC&THZF
MK]@N1*6>1\#5._@""N0#NSUSKV,.F["4"Q]]^-S)?F((V 19&+K4"'V9 DH2
M08,8E _?A+]B;-R53I,%7/N@']]HI0!/*;_O'X(1WE[TC@TV8^-5V0T5/;_X
M*F9\ [CEG>6%C#(W]D=XF4K.8<%F-' IH^?G>Y=B17<ZT_4'S*_5J<.JI=!T
M0<E:_7?;*6AAGJA' GQ'78J J9$G4I-5 [L+0!?PN3@)<!.V5Q<J20+,3&@A
M2M<+SQ_)7Q*_^R O')F"SYD)*5CDR077)V)$UO^G7);7%->9,0GPC+$(O"E]
M=GGM]BJX%BV\SMX KX)C-R+JFQ#G=U9@\X+ 8^.YFM<0\-'=-A*@U@CV!UY*
M&Z]:GNAU6<9/[)@XTCY?@$X0M<692(!?0[4DP';/5FO.=H?+M=/+3H#M.<W#
MCM%^-F,P!*OY909L+[\7MLT2B6^1)P%2MZ0(ID"^^X::0?:PE6U8!/#B!8C^
MX J\U=/5<!5+\"C%,Y^F8_DJ*D"W A??S1#$0].M![TQ7,QNYJOL7]/H'XMG
M[9:[NX9^]_T']X/QZ+5-?5?K=*T'XLV&[%FS7&#+J9Q/?L.BW0*(8ZQF5/RG
M#C5V\!$9=6YVIH+,E@_3S4MC_H'-1;GD4A$>8_U:=VR%@9Q.V53>ET5]V71;
M@U'D?2STX[SU@)05+)CW(KC08&>5!A^&)@$6M3'@V'!Q/&*@@/)GJ,HZB'GE
M63D4W/T2OW5F:!$*$FD+;HT_M/T9/G*KN?5UW]]_R0%TM\/ N/G37/R-<D(0
M5GN?%^LW@+S6=5:H\WH/FQAB;=_Z>^"B>.QAHZB4&<,JJAE.&W<XR@R!! 1B
MEMWJ_YG44MZ\FT$8P[DD*FNNCSGO]JE*S_S&\34%GM9>)!?5>=ZTZIO\YVZE
M=3&K+Z?Q(P67EU!6LMS5C:H? Y93_._$V/_12)K-!CS44 IBH%#SA:"+T?O*
MGL*W/SI(!,S/2)YDS!63:=K#C4J%,G;X*>Q7-*KTZ'X+7#I-;QCZZ%2$('=O
MI;EI>NZ=;,VNA%6Y;<\>EB(-O&"N7@O3Z/[! ?$X\"T9+RX(F+Y+\M=$R8XB
M."Y4L8 =>Q:17%RY $TW:V^<?S@GHSUW:&TZO4CEZC3=>"3BN?I,@.[<%ZAS
M50)T@;&YH\A5%4.-NG#$3[@0M$%JL=O<ZOWI#BG.)C0M^RKTP3/9%&DB7ZY%
M?=I8 "0F4R:$=[)V\I&K:<':*]K1?^H^/<H>>8D5^Q7W@QR$"FOM58YJD'@5
M[-A"]0ZT^NQ?P84'!E,Z=)MBMLT;(^T\#VI!V0T*IXS1M.3>\M!*R7Z'8B&_
MM,SGLW"VY-R2KU.];II:TASDE3I:=)79754#B$.*4,/W"?41C>9"9Z]/;6=:
M\(BM>0-KKE=0VG7DN\?X7!QDO259I$G?#\/7Y!<2C!UYUC*U/M,A4;)[QO3!
M;4QTG]#PY5=W&304%.*Q^4MG<^>EYE>M7YEAO]? ^Z;87 -L=N2)5V(X+^X*
MD1C.%*HU1^1;!*$1=\5J2O&5'EZ&K;/Z9>VUJ@WV8ND>71KJOJ(!=X='!^A,
M;IY'UFEXD0.>_OV40_\A-S!1[8DZ>53D^.722!K5FW.W0+Z-5T\<Q1P!A*K.
M2/I&0G7KS1N]-Y)5.M_ 8O"4^.!NT\J\5L;M<:&7<,KPH<FH?(7%3(O6RHH*
M X/J3;8/A3P5'S =)OQ</EW.LSEAAV%G!G/;7Z:1VZ#O^9X[(VCPOAMNR;0!
MPJ'4MTCS"9VK%]61!J&Z<K2>.Q YH5+R=RU.UOLHG6\V'KP%7E7\4=<6K>E,
MF-<6;.,^$^.A<"/VW9)"JGP=OC&X_M/< 4FG[-Q%E8M>Q,=<A=*K-J\^SNY]
MU2-]-L>I]+RD\]6C>PU#C$F5DHT#3QX9Q55;ICRHO/^<3&GJ^<^"%VHZ&E&#
MT[<\**52&S]H!=<2F7]4.9GB_/(RBJSI-K7H]2M-N+4R632'2I9+T(H-5@-2
MA2+65I^VH(>UTU%E.6=>?!?-2S#>$/%GKE_B+QVW>N(%:D-=L%CD*0>(!- O
MUB8> G&(*UXN9UBW"G#C!.F,NA3,\2*F@LW/[,E6P6>PSP@TD$BQ30+PUUS*
MD@ ++Z9AQ_$7R'9RU2,2H/WJ-NQ6F !P8V."V&\".SYX2,S&QA(U&;O %SJ^
M\0*(K?63Z9%P.1PV"%-TC/=;AUUI!2B2 ,I=RD,4VY?+5W+Q)( Z,)F?BTQ5
MJ( $P-:&>J2 SIF:@/-EPH2_P&1U$L 6>2P!7@!KM K,8LY5.J-ODP 98LC:
M=JZ) CDC+_I>OX:&&F-L^8?E RG)N%7VF+80K4).?V<]F$C&.$;![DDP 7),
M=2VQ#$!G(&?X&)"FZWZH.CX%=_-[UV,LQT%3<)A8-'9Q!'.[M+_F%%%NR_1-
M#W7_SZ,)R&H?,]5#H1OK\HB)[U4=/W9X8.(.S.,.E\MEY*R_E2-47,]Q G]M
M6#&7RGVW[CRG$F[4C^XV<S(*V:#F F^_N.2&YZ&/D)#XP;4BBKGR.LN@RQG>
MO=<T%G#=>I\*UF\F!KDV;2M*4D=O$%PGNN>SFB/"(%I.2[NY *,%Z8N@(Z Z
M00''?^H8N1;;=PW[65^X,CX^5*X2BC3 N;Q3#B'KW;7@G34;W[(LJFN;9.Y;
M-<B_WR,<X,=9[$_O[%C7 YC[C>^_5 PUP0=A'37Q8QBNN O:N'!JOM+/KE;-
M*6M_.C3A! ULO?O%7*NCEY^/*K*,!.AA]IX/&H&K;.;LBM<O>=(6_"C,VX[3
M"\NC\C^:?!PO:24?Z-FKP2-FVF6?EZ9J.%@)^*Q8&9VLG[M^._Y#<MK:'=%&
MZ1^\K[Z-I!/X/4)K'_<L9W.>[_Q^H+VO,*MI9%@U#M]SC,U;ORQ)KS*0K7!=
M:-7I-IX4.^F[-VLI/5N#LGOM$03R>&NYXG7!C&->E]MKP%6=1C3@0(G2".9!
M;*P&7N\SU%Y:A<F\"2>;@$'1; =F*=KFHM25@YA_6F5TO*]U>M*QQ#@J-/8.
M-_AO0+LX-<$4F]SNYB5W"HHA!'V&)B[I*W'K*P[V,64K9-G6_+;KS/RJ8S@C
M'<\DFT[V^%V6<UZZO.53-[LG)@+O-SU&1S:C>#:HO<0O\NH2O9JL6$8-B^@U
MLZD>#,JW&K$H?-(Q:O]4?/O^GO+O/]@'[-'=FRP==RE_5?YZ"WW^RI[RA&^^
MKICR^/PJ(W-[KKJ.4:7C?'E'YUF7^?U@A$*5T'1F<X7@ZER0AXI'FYF963U0
MAP1P5V%&WX<UA2/+"1;9_4\("OB$M3#:@2?X!(U&8962+H&I8UO/N>?23AT1
M*).P1TKGTK@MN^YO&_=8?)N&=V!,,!=4)/).*!@[LH9\K^R'V24!XK-/S< ,
M'7[KM#2#:^U7]WK;-$94LS\OX-^B+.?MN_35K,>,YG;0)\)JDR_DU!_:QF(.
MF:&7 W8J39-[':\Q5(?TUJY6-FRRN9Q%&_?N?((\H%M:)(MA<9)09VPD?_?Q
M0QV"/^_(2(<G><I+R)*#_,9S[GG/YZ^^UR>;?/ .WK6CH>V-A^[=82L09[0S
M["ZW2N2EA+J?N#97F%;0.NSJFLP("I3&1<OM7>'U5Y#@NWT,1?N\3ITE;TJ(
MO$&!6160JK=<E>$\^*I+9C"!&3O1#8Y!,:N*$$2P@[]$X?C$'.T>O;N^,&9H
MZOJE%^$%P2844FIWEY,].X:\<=NC]J%&2X1I=S1=* 21LM \CU:M@>,=8 \@
M0+;8)"]B-T:PF@+KA[>CBGC8ZD%UJ67-'3KY->CI(-GF7P,=1+ZZ#G(\F&HY
MTR0DBY(WE5Y-J*V<WM[1]*F&?<2[(07>=A.6B'_KNGE')S5:R=.7,UQR:S$[
M/R@C^F_LE/A8.75Q3 ]5M6HS)U=V-3S0#1#N.4LHO\HH!='JF@KHZ L:Y97D
MN4W&9YAP 3G%5?)= LA%1;^$N-76NZF(Y337M$/@O]I2!KABN[BN,AL/(U T
MXUT%,CC/%A* @FQ J2(?'6D$S6%I7!)5,'+A8W>9/FY?>'1NIE)O;[ R@.JF
MFEB07>2Z 6T86)7$IZ\AXL(99A!>,@AJO%=/W6Z.7<?BZ\7!,MOF1B+W5.GD
MZLZR= N]-GR%"OYQ=/S%0V3_FD^,L[.:?GO>G>95\@\::HGO[[>U?$+>2)XB
MOZ6JEB:2^G%&D\?G89+O+6?I12>MR\L-H-*!\^TV@#S"" ZP_TTQ4/"HD\RL
MH^Y>E6XIT$-.+EC-J$:K,2P]J:)<0$S7QQ N8-D2/RZT#;4;'I+>ZYC-F;M
M5<TN7P;9X='8; QB'[CNE:2J_%.F!5L='MB)!M_=GK/W#$#1N35/C93RO\_3
M8]67/#B:&Q!]/L2!H5+WMA+4,FR'Q0";M'M1S-M<+(V%R6S()'\E&"N^O;>
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M<8EKHQFM/(:IF;@E4#R8OZ']$]G_L\#"_E]%]M\#^Q]Q30&TI"3$S2.E!\
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MC.'%_W:7AEL]="C 6Q*_@0-__.+:9+#*Y\B\?G)HC_8D !14641\/$'X8 @
M$Q3U1F9=I1FCPOMM"8&L"F%_H',$'D2Z(Q=0H%,5LY.+9+I(BS.SQ0R<C"M\
M$YH--?/S*6UCD2[8WBA#SGW"!V.ST@02#\CU19VRU1+DBM-UUYI/_KA*K)6G
M'75)W_J]G$!1#:FZ\]V#"3PG6G6N18,3:%:9D.(%5(98]5B[C#S\E^8)@!V4
M(D@>T]U)K,AU)(/-^!WTDXIYYV1'7SZX2O7$R'34N7F%9--L0;AEN<&Y9D6P
MFU!V8L\!'RW)6<4B=#MP@0W&]G2.87ROF35(<%B.K)D'PQOM&F0 #W*.P=\=
MJXK>CH2YHP+!5Q4+^[DGCM<%7XIIU$;O&T4$7^45;UMP4HHP-/CV0)-1)E=;
MO_*TI+HZ"[$G[T:::GV@IB?*X&2)HC0HCM)*9;$XD<NH"6E<QXTD*'"K\X>1
M1MKJO%'K:'L8V7NJ_*= _GD=&+KK9I&1TY#%%'_SZ66K6Z])%:BCG-^75C6&
MY:5:?4GH8O-CO>#%JIX_Q-W&V&6C2B$=\KRQ76"*G2 -?@MG?3RH%NN^*-"3
MOK,Y['S67.-9W+ZP<YTF8C]C2[\\;4Y*_<50VHM?V+5C12RT$*<_4=H(+C$-
MNH\63D6OTK$[F0N.>3> $T1GNV\Z^]Y,A44UJJ,<Y,3A6\:ZU0&O')UOO?6@
M84HSRDOVSM:2@5U[Z7-L&'U:GUP^6;K8F'9>42\GD*FI=K\T8C5UY_RC5P/4
MN3P0E!GY=/8.5TFR4J'>C8?Y2>.FBAP+C/G7:K(4."G'$[;?4*=KY_\ZC6Y@
MG/6LELD[3]NKO737BI*:A%5G*.#B?@T!"/.=FO$KFFR[AG,+AZ28ADV:HDFQ
MB2WUR<\6BP,3:0F 6]-.&4*XRMFEP)^I;7?XU8K))W7%Y7>D4L,M<_BN9H:1
MO2.=,IQ;307Z)"J(#T4 ;OIUFT2U!.3EMI]5-[EX^^9.PZX45(I(E@[8AP#5
M]34BR^_OV[!,Y-@K(=%9Q\B.%:R)06[Y5OD=..WJ!Y$=9TNS!JTP C!=>0JC
M3&U[2%J7^WCGY@4Z;^E+2\^F4H"GBM+O--^+F><-)S66W>1*AAS0>F6DVED4
MBJ)-)"I'%F/187;7Q< 4PQ&/0EQUOCD8NAA+[G;E;BG4NF#(DW%FCJ4QZD7S
MJ$O4AVO3 _Y<*:PI S2<>IMX#OP@GA3[#NWY#*.?N93Y,81_"WGM<(_\]X9!
MAN3/^N=HT\Z2\L[C>7F6K^G]HU_M/):OEUSR;.^PDUCOY.4[N$ $:IX)^#BL
MYJ<9>/-JAO29)DS&78<\W:W9<]-9XI/J.! L*_S>ON;_J4\E3U2!0ZPSCU^/
MY 7-:Q7V7Y3\)5<5[T@OA)$6OKH6&+=P?H*HP3\,&811-3,'T:&[XQL9,5<)
M0'>(T)C\';_,-G.>"5";<6+8*R^W[4>\CYNK?D2ICNT>T<2_HBG5U#7I=^ZQ
M"EZ(;E6$17\*1Y5OJY6MINP]C""9=P0^V_4+VO,P1 BJ#+B\[1SMW/?H*TK.
MGIW)1<\^O)OBM*=<,6O&8O6]ZGX?0LZQ5EH:1^_RP!ZI0234-W<N#MDOCO#^
MW0@WS0"#LUO$+G43NL(.KF +P!ITP-%$(B$ G;EGDZ>+(O.)%Y@+YPLZ\$(\
M:#^> /R)Q7="KD,W6S"V(3I+QLVD-+Z\_F/&-17M/1?P]7--^@$!50&IW U,
M61I85V=7Y+P8%R&; 7.'SEHL\XWCMNC"0*A$?'+BMGW#$323^M[70H7_U4W\
MOVSLT'HHW2K?6"\590=MEM>@^ "SND'Y^/I<K,'7\9WR\7<%H^H^&6:23M.P
MUB$<.Q<!X*-I)@#E"NA^ J#>J&,1)31V 3E S%A@I1_#L'YZ&WL$@#H<E:!<
MX-:HU8HC &=SR"B-?Y[90EP%5:+8V=[:C!34O$TW.E&O!P_-TZ?BG@TX\H(<
M6<?J5^/3JF3G9K4FL%Q=>#YL<%GG(HC2H@Q6S'U]2F+DC^/4V^M&@\.5QR=2
M ?E-XZF=C9'W<#TK81JMCZ<4)'=.P-5TW=-(9L=FZ5I,@/P7^/H^UF=NA([&
M3VJ^?3U9:&0Z,YY)B$E(UCO&>5Y2KI_U4NW5S_?)@EHV;['ZDX57(>MG/R8\
M()GU$-_D5[4)?,?KV%C!GJ/XC-8]>H3OMC=4]$W/^Q]:61$[O8CRG)NIRJRZ
M[76]3T17W2?ZSISJQ1>_^V69W3.(H,:\9>)O6MP<343Z>3Y4<SR>F AFJY!/
MCCTNQ9XZ%W4&Y$A6<FCF7BT%IZ/ Y*U?9C;I3088T@R,91W<?\^:]$W>4$-K
M6',+8P2^"S),FJ' TXE+B5%!6D789N<=-HN)O2 0.-RJ#HE>BQ0ZO'5#6>KL
M[9/ *Y='GX<___"S_NVBRLHHS^,?=Z]YT'67D\$X HKY52KN*,D5XE9HO\R2
MW!Z\59'3\&[KN5^[!_#DVE.I*T7?5VHXM5IF2@Q\60Y+^%=J39_RJ'G=DA[L
MTWGAVBO)DV?MZ\M0::;9^<E. E1]]C.XOTE .V5R=IBO^F3]T]$VM,9^YZ'@
M\*8(1FWN>--D%;8S*4^#_A;^[.F(_?"7T<,2/YM''^ZVAJKLC$CWB]_HO=NX
M]^0B3U[40?[.>)!)@5_U0)69A>KW7T</L]6?C1QQ!7.DLF,>NTJ87 BOJ5LR
M3_'L0WXKIZY*:WQ)"!(R6S+*C5G%/A--4"2K21ZXI,'N?%/E?781=1'ZD?^
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MV1'!N]D[KN^,MW&+_S7+?L;9_TW57YX/XL>%2/@18::/5/ZWZ?)!S/+,I/^
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M\>F&:]?A6NB*[V)]>=!0D"W9B/[.+5?$P8'#Z2UY8G4^4>,#E\/#+3B#VI?
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M4.AB&I6^L/8S)E8U_3X/J"%J=8KI\E_],\B#$= Y'HK->""".XPB$@D!D$N
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MDO>O[(;R0R9PVM]_-7JC/=O3Y"4F2H-842([(E&R<E)G=L7H  +0DC&1)%6
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M.ASJ-XC.A_]U%UM#HOM6J;N_W-EG1\=BRTFI+R\!], +R6R"+<LEX->O7Y>
MW:N'K9QR A7?,G _^:_'\ F?T;9' [29;_?J;9[N.T_=^([=3V+-ZZ*,Y8:L
MO[! S'%5#!CL">PQO 1DD\9AW3\)_LM0YHML?E!A^>DREU3#:<FAV5\5YRE5
MB8HYM9\,/VD%S+G>GAKJ+/$8'8VOPO](/<=U-)C\1WP7A@5?D^K>ZN!O+/<L
M+Y&U)'X;F-<*NQ SO6.G5Z<V_;?2;\ZA;9P0'^:^4 )2+-A4(3.8M(/XKAI;
MKUC,G@I:E%H-/+E(_^\N6!X'L;IXOY3WE5JZ7*!-\QYT48XTX7X):$0.T$N0
M!;?JRN*#2TG&N$CDAS;-0AM^&[?,H D0K85"N+AF4+UFQ:PV#W\3F^R\)B'V
M1G\K:S+X.#KJ,W2 6\V<Y:.??Z2M1;][P/93IOF@-._S?1@?L3ENV -OJJHH
MJO7T96[:Q&Q/6NKT:=%!;^>?*BQCHJJS4!J6[S9$K/L7&%/  "FVZ<3?;%4O
M8"THWYE;W$\I2D$:9MB20?,/>*>SV3RUSC>6GAZVC.]F8VL8C:8135!7W+CQ
M;_GE&+:(VZC:$SY6FWF/EMHZ@98OL?Y?MV)+K+LK9GLR@X%N+JW(PYBNQ+>C
MH3<SSH.)_W1QZ^71U1U<4 %WQQ^X_*QP;.4Q(Y/1E1>ZJXEAO*,4LRM.,JJ!
M7[%:*ZJT)>B]1;7\#L=SIN=5#^O%X-F,<\G]$\N;YISFD6U4F',0(]]VP>WJ
M78F 46,O(3ZFQ5]5I:.)>^DYU?]>NF?I5RT/>T\:\.WW"5A+W\\]5@YH2FHU
M_YBQU Z&;U<?H+Q00*E*DV@W-6&>%H7R=<] ]($:G_'%.W7Y+4ZS/*R:9S_L
M9L XC><EP/L=F5\?JRNN*L!G$,<!+^Z<*?K-L2NYCVV-?:.G(6>MWVQ9_*?:
M$V)'N$G\A;V@M<#S10?"HUJ6$CW#)9/M)9#Q\ <M^)Q>>\)RXR9;99'\W"BB
MM1C$EM[[SOVA%RT[E<<5:]VB7_4<95KN^7?%@NJTPRLQ"CR>QM,D%L5WV'#-
MWCER#9;:2^) 2LI+ OJ2,)SY R12.LDTL,]2GZ-KN^7-]&P:TBY,Z$ ?)\H>
MZ"&)[KB_!FHG- HP.MI6 S\6G$#:G,+'3/7;*%2?M,W664"50O_(=X_BE[E[
M6<%*UYV13DFJ#W44(W5[7K5O*G&HJ#F7I\SJ=9@\]$D7LY(4[7=O['!UQOD3
M.(G%V ,VN]GM#DF<^?NL'OJ5=3QO<3A6K.;A1B\R9XVMWJTB"^_>X>O(D[B5
M\_1W@]>M#,:FO:&FBRQ2&/[Z'-H.=6)$U9:9I5R\8W>WS00O974EYV;TT@OW
MT0JY\:.LOF7N6#%[=V<!KR!)[YJ9V4S!\)W?(%CW$Q+,JW1+T0M7M3+E@'J)
MZ_'T5T_$<@W#.1FI^OT]RSKC6-%]F(,2R'[MK5S!'WR=!?P;!FV,49UOX%P0
M?X-H@_BN3@9)DN1968U[..;QL8UO@('>N"G".15MC%">L]4%NZ"-@KWDS5\,
MU#\0DVOP9B\[XG7=$SEO:XSSG;.>7PZ;-UR.C9@7GYPNR&]$(;TN ;7OB10$
M,>('O!#A2)\8N J.Y)5X!E\^5Y:X.\A6QLAB.^928)&FF:1&ZU('M@\2>H]]
M_)\8^'&2("6T%T+NM56=DE]FWLGGQ0=_V"-QK=2P!*I=Q<&@^KWFB1M_B][O
MI6G]KL%^GS8FZDI\T_PKGSE@KUP\ ."HQX#GT_K5*7+^N!7<)-]TGW!7;@CM
MC%KG5(I!"."F@G V5JJA3%L1#Q,Q80>(^/@8,.?>I'-?7'4"@C7M/)"XK)6!
MR(5%V=U*L_9B?(&;M]5UK!H96()(\L?WR5R1.PWC[+RQ>7NFKC.D)&[=ZVO<
MW(W4Q[3_6RG)0![*>KCE=.4@=VS.HV?\6$A6L>V+<PN'\(^=]<.DU[]5PRHL
M/0DMP3$DN0J+K4Q.:!;CS23A[&KT>.KZ-:>Z!\9+P;-<Z\Y"ZKZV\!IR-Y!-
M/AYRHC_.36(',_1?U)5O\_(C\>VK1)CN3)OB/1MSPREX<G36+KI>;<33]4YL
MPAYS=P+HY@$3,?A<%S*.*<E_H,S2&!D6@FVWLC&R:BEX-I4ZA_GK[^>@0:CH
MB4S7CBF,??'.MS]T*?K<BZ2):E.KA&B:X("]RRQ$,3,TR1[;#NX]NRC[.O=\
M#AY?@L@U9<O\OA.$1(V7Y;X6[T?T.?"+OW^5Y7=CM]]T_''A>>?ZHOI$Y\CA
M]^E'@0,1)-L?X<K-(05"Q+0GEX"/83;3#2(G-11]GJ4C]Y67HQ2HIE6!%:)Q
M2DK*+E\)!'B@1ZJ*55O9T@/)HAR)IB>C%TZ7@.X?EX!# ?+T,N$1].$E8 HV
MP$)J@&Q@#;-60;1BM'R1, 82+4MCI7^U[2C&D\<8_0*A6YTS1J\X1/YGT=%@
M(%-Z9['!N%^^1A7U8(3C/?Q$ZG\2?0GXF79N#ON#^=^"A"L]93?OA62KOFFR
M@EDGBYF*G*MQMFQ YPE!0$U<XOI!D@_L16IZR,-S$$@WK"VK<<[?,@A8F7Z>
M3#Z]!,QZZ-)0_[G6-$#3=0_G%^;C(?]_OKNUW-.X+[Y]/:'A=19WTMOK1IU4
M">A# M/#5ZX<[AR&+],.?77)] 5SIB6KL94B54/R@B*UAZ_6)D\;DO_JD&_)
MX?D)$*+@N3NDO!_(HAH,<ZPB&> 8>Y(IYMWS>7"UV=C1IX/=RH:EV!B2?\DV
M(2>JKJ0VSQ$;+FSU?H!KRC/:U^NQ=('(39(?T;\X8OA,)S[ P$4J%G9=J@9*
ML7K59 ^T$J]DKF'C-")<V 0WUEZQR6\T,6_4B9P>3?Q;6;9ETJ^V)DK?_P4O
MUO0N.+@ Y^.9\;\?:Z]ZDST[@A[ZJ!V1S9_Z3+,[&!NB^-BZ*#?AAL2G9U1I
M"6C,' @<D,J2)#)5O^#R7^+O[[*G01Z['-W-]JI?]"-EZ=ZJVVU[4_W\WI1_
MM\>0/;9_+!U,VU^R*OSC96)^K.UY>.YBYQ6',]4OV'(EX/5JJ!N^#9OE[<$4
MCW>.EF;T">;]!2P=W)#!P0Y1O$UG'-#Y:@@Y;:$2N!%>ZE;T,8SA$M#3ANH8
M+XE$!\"8-W]L*BF_"5VU;LS/_-Z>L0I,B:";^ 0=34Z"(8#=R52;0;SL..V4
ME>18*XFLF T\PX?2/SL/T,]PYK&HIZB/RN@H\;WCG5Q(<;1I?9*C,V60] *H
M?^W9#O='QOZGZK][Q%)QHV("[NR)93]:I,@=V[#[P>(_I,VC98LP)5R,+M5W
MGEFS%X$?*C1=4^K_()X(_O)LX_QMZ"HB7(N7LW<@I]#DCA"ZLVI6WZ7A,(@T
MGM[G^VI59TY<]>Y?WU#)S,Z_L*=L?%=PYWH0&Z$^ ;6Y8@">B'%>(00^^&,$
MY]85$1P?Q CK9ME-(%2 T4&?1CIXVUHG [D2U;%J>LM.<UX-F2E,/%<B\P"Y
MD;6G7P/EGHE@(LFAR!S#*[1P7G<EJQ&[NX*XA" K+T)IM8U&>;_$V#NL/I?%
M"0^HEYI?7,(U;FAQ]5SO,R#[Z,BURR@R$\BJZBN46#OL6PYQ&7\R%9C,;-NO
MJN][,ZU\%.PM]'$7:B..FB]MNM.LN'??8H%^=8>/.F((1@GU6N&+M!6;4 #?
M'LF!QY!%W*Y&^,W!#XF#!J/H',9H1-4YF&&H\<6[JF4K#[3/E@F'E(-^IV#)
M^\";BNM1;#<R'2N5$6M;6J.C_FX'AD7FEP!D3D1Y(-U8AVLF^M5WO*E3Y:$"
MC^DWE/<R8=MS7TWNU<6/-AF,%W"%-4K^@(;8V<?+-'EL(<_(M9T3<]3!2C65
MJ68>\66&[<5V)MS=M^)#V<+B[+Q6,*2E"^B)2%":R.<G=IZK#E\E"A=D1P_/
MMOL/3I0U\,2RMGY3;'<L\NQD18!C?MAH *-/$OE?=DR6397BEHH#P&4(C6^#
MS!,9_4T4M$<2R[N(<WGW?&I<UD#\9[+D.&X#JT7JN(W[%[FGJO$5&2]O=-=R
M![5YVR-GI@&J))E]\3;3RKG+4\/>TW=C&.R-=O!Y><;C2J:9QVV1#*H@KCUD
MJ=:I0#L&XK@&KJ,8 C7"$$%F$XC<JN&0ACR)M4A[W$;L<=-N@K%N+<WO!6MM
MK<\6SIJ#L949,WU 1U#F8=BCFGFPI_=\6CC(:[%QW(C6A">Z%^ZIH2* 2-X(
MO.#_>@F(C,6-@X@I>#N[5KS.+MP7VZ[9I\[<T=*&#N"CU\"T:V*6,S _I?:.
M7P2(5=2T65)E5 [L@=^DIC [+5WOD["[37*\R&OH3+1C##BXL5E0/U:.(P_8
ML4&B7ZB+3C;P2.FVM"1;UK$JYAPD.$XHJ&DT_+)O;<YX4_HCG[Y.^[U:724?
MJR?LQ][ !\QX(GV%Y<)6OAC1#EQ.3#8$ >]N*LVQ7)E-GM#AWF[G=N1=C3 _
MN$1?O5K[]M?/LC%35=<.*=A79:MTN+(C^OV<+=9;9A\^Z0+-C7I;,7G31>+/
MNY8L'JTJ+$</5S5U_T[/XQ(T'"6):2U_"[>K4GUCZQN3L*UEOUH,<S5(N[ \
MTZR"9&&L@8UET37NL-L=7,(?X.+>SJW3)"7,(ENO.@UN#7G']J&5>\&LGD3M
M@\2X@RG.I4DS;3/I=6;>XNZS_&3<QK.+(M*]2P!KIXL1TQQ)(^Y?GY7S8B*Y
M ,MC(*X3=SQK-:B'ALM3@QL2'<(?#<L3%.W$E!>B\MZZ@H>=V1AIN-9!3X,5
MNIN0NB8=W;3"7QZQSR>L?Q>=O2Z?.>>^FCE]Y!UG*BG@1^T9Z^@D^9KZ@$/\
M6V2VA<RJVK1LFQ/&4'72UR2^OG/6W,9DHN3"N)T0$:YZ8AQ8&E],C0HH*]KM
M4%QUAO\+29XMX(-\P( 3.P#$0<S&NPC1B!%;/MQ&L@(PDA%W]BN07N4)OO67
M?7@UCP'4T]?QZW"09'51&VIT.3>D0E9EQ/)S*NBL[$H;5$K,+@$X0[O9ECF5
M5OTU!.X2$+>;N)[0$9Y^X(H7'KC=UGB4D3SR7COALY-(Z41ZAO4*+&^QST_+
MRV^FBM+'B/G 2_SC:*!KI5[Y>',<M8W3J[R/MB!J CS=T !6""?=^=5V0!1F
MW.UJ&@%CPB'6XC$S0S5\2:IFFM^&[KQ+?<WX6-PB7RZ'%-]OQ2)B[W:N$[SG
M+!S>4(1J;=WBX<VKF;HH[ZH>IX\9]0@32 V:0\_HNK4<(+V,I@7O?4OY><_4
M<_F$D;Q6<':M2D172P#@(WN-DF(YI?LLKB:,7'@)6$B[!#Q1()HJ00W8EL8/
M?%U/A%3(6DW+9R=7TY$?WSKFW,"1S&E$>/NKZRJ-4/@PX=^PGFZT'^S::$0*
M5)ZXO@)GC!@"T@3,VW%"@5-@5>:.!S-M^BN)YJOH6!*M4(V]5]G679V2'2!C
M )QQVTHIKFAZM'0T;78;R6M809>9Q=?BX'D$(WQ>)600288^Z@I0FS'E2\"O
MI^A0GY#CE:.Y-GW7S_B%AMK3CB8FU51M9(W+>WX'.BZ6QOEG*-6"YG6[OP!S
M@I!IEO'@6K9FY4L40?ZN6=#?O^7:.SB[-5C!;)FG>'V,?S^G;^5>W9WVZ;U?
M5Z47R)S3E!#'"9JXX$026^&F(I!6U0SZLF@)T@T.W F7E+JU:7<;H=/ZA6C2
MI_1WB#0+41_7;&I.5=%P]7USUJ;HSZ,@:"__AIB(-R&$(E E* $<NHOF9@VV
M\WK_ZC L*C0B%GO?LSAS*CJ&JT?]09KF!#P@3.7KVB]W>[ 7X,Z\4PJ3%PD2
M>PV9KQ/[*V-$*CB(=M2=HXG^[R"SPV/IB;>%&<_FUOP>E7Q^,R^OEZKI*3%U
M1Y\'T:.KD-,BSJ9/49>ZOOI$+R:];NEIPA=ST$_I6'_EL8E_9,GO;7!B*#NL
M^J1\_^&=MHO^HB7;;9+5GXO'%Z5M!KC&\YZ.Z[E&>,8N'G ?J]U=^[9)>,3M
M3:L;&0/)*Z\F R9<W5?-4 &C"OL(\)Y >YRE=\[6IU^TL993(L=\=Z"PBQPA
M/*SOCWS!K3];'0^NY&/'\2L(JA&-K6T.4+CP&T+U!)WE169%+^LG_1+ZWHQL
M0G@^.[CUU%&Z\M9-=5:B/RZMIV6PEY&3I(?O:*UT9\UQJ2IRC^ )$TI^B9)2
MV%+@$3V)]V?):#NRNH&[F B#-8R4@NM2UV*J=L9O1USA;?V_MX%[80-S><M]
M[4:8_!0,W\?)>;<S07*V,S87SD)ZCO-"Q@IVA@V/7O\[-][K\SQK."B+]>%Y
MV8^;)Y9&N>O8S=>B8A<.>NAIW<%&@L>YF(V:9 >JL_ C/+EZDG G&#:,WM\-
M>TA<)CCC=:)(HL46O\Z5(79:J)7?X 8PD\UV(S^6+B=MV0&[/-C!><7^$ VO
M$IN0V[T5RU?M44.49 5?GPE*'DHK0I-%H0P3XB2^:HC< *P>'*UJ[UKN85"]
MI<[3@I)LD\)Z#L/8X\6>5>\-1#O?+*WX593R31^LE@YI>+\/5DAXHKN!O@1\
M=^VRHX4<#JZXQB#@,6+847-=/&-"F]RJBEK8T[3NJQX-+]W<JRK+JYD=+!H.
M4V]GLMQ.#'RX[:-S:]B3?TX[6S:DH_G\)A'V"M=8A66,YMS9%J.*5'"O[FP@
MF6#FPY^N&J/:C,#E6D%2@OH@ WV-=M1JCDU.@)A":=\, :WT'N*22/H\?,/J
M1\<#?;=MU.S9+NK*N*@Q6GGRZ,7#S).RPH)M<PEJV[V$3T1[S#(/I&.\3UWD
M(E]A3VZ KT$H3:*/#Q<'<>U3I\WMGDMJEUWVR)%,#"\;++?49\G-YC)I1"8Y
MW12F3W^AKD9T=EUA9":I7U2T,=KCN3!9O>>)L/Y5,]Q/?&;[)8#ZHK;0G;6^
M6*]Q[L:"(ML/RRK0O*Y\T$P=]6BCR7WVU;X(01+7#YQ.+_@Z5*.A89KIP (-
MM5F18G9#6S5F^Y;/>T1PV/!*/-W0M'BMZ]20<2)'4++</^2_X9Q6 YUG?H,/
MSQNY^[R8!FJZDLIZ%"^0IB]&[62:[-5X_4-;(+:CG"8=@V=^)9U1,"/(/I ,
M:DCSF+N(5*^IVM^%'S:UH>]$58W'%;-$QWN7Y?@M#:.7?/?\3^:?$*-QJZ\N
M 5&PWU";5:/9*N/D'G5N/#IZ3X&F.L# F$N*Q>TL*_I-@'XG$V(IIA.,*DNB
MW6)[T7;D#.E.V]T8]5&%$U9:)MI@)=!'>(7HODO .ZNDTA5X9 ZSNN $F7N;
M0)@)YDQ$QREL*KK/*20E.[L'>7FM-3:U'[%2T'<>W,1]*S^*;3M=X.#ZF62:
MN?P"B4Q5&^5I%??TI^[FW],,J![B\KW_;M>#'X0U?H!DE*UV48S" H\5'>HI
M_JK+^-Z!%*]0W!>X#JGYGBTIQ1@;7RE<DNM>M72^$U83./EOWI';UO]#GWW!
MCS@K4/G)A4=0!+6]5 *)Q^?K7A.>,?K+[?<B"_0.733W$W5?,G]@2)!I?N9P
M#7X"G "NW2F]!*!I81<L/+",Y;>3STB.*\2U5T_S!7[_YY' +MA)6$R>+>X2
M=D_BB='H_JEZZQ+PRN N68/3[L+G?SMYO$1C;14U9[&X[S"7A"RRD2ZY_-A\
M8B8"Q9AK=%I*150XXW(\4")1G9K2:[&#QK;_B.<RY[_-X#\ZV#,?7 (3&0^_
ML1W>C+-(_N^Z=M?&-=V5C:W3"!;B.H??A?E8@/D2'&EC?#Z^Z=&!WK;,JC//
M*3<M/0*.\1%\B>7%)$'B'GZP_]]<7F*+0.=M\;W74R6LJR_8V#@7V%J>)\?>
MTJJV&A;*\?D!/M?03GBO<0;"9.UIX(('"JB@5YS)X@9DZ.!UL^+KA]$2LWKL
MZ,&!U%)[8/)L,21SPWKZ[[1W0*OE[$ 5))E:41;F6(IRGYF4IPHA?28F&<-B
MR&I?_L,ID83419TQ!!6=6KL,07/*_&L44Q3C>FO\]__94*]F%[PQHM\U[OO=
M\^JBI"^R: $U4B6O0_?<<7WI,7SWC:()B.M=EUY^XF3YMXE60<\&N'--9J7-
M'#KX$J"./]U7N9'_]V$I\YYMV=8!S+9%CB!YA,WJ!;-!-5 (K@/VB%']:L8/
M5MSJMSKQO'F%2A^.U4 &S7B)L<H2R,Y_6=H%!LH)C3]FM1P),7 GSUAM.J>;
M:L+]!;$%C%#-4K<SOMU_YT])(D2>&K=09/0)8ZQGX8X[;KC75KJ94]6@HO8#
M7U0-- ]L)#<BF$0;#[)(3EO[/&T2&"$JV&;<)SZIR='<A)1H3U4)JW.^ET?M
MVFTI++$>XF*4"[AQ<D9%\"%:ED.M\<56.V>1?S,P4O2;9V7-6+&JD)K5*4S]
M>U=4L:=@)L?SNOCY> N&^1#"P(C?]7WNSPGOV75$9_H,_Z6E_D7DS7LLP@,/
ME7U(NB ^!<-'D&67R1T$^>@8O/*W'<<#]<*&APUTJ!'I5VWD7A'SP21P.)Y?
M?T(^K&J<UGK;^&?.>#0\IQ>4?V"8N;"H]XFU/FI+M>[^R_>(>U?>2TZX'TZW
M-7,FW&7CVML"C$00VT3FDE(*W6UOUTT+3"-.B]75T/<G]M>FO9SJ/X?'GM#2
M_GBOSY["XI  SX,,$W2)5!@X+4D9C\A(CD7P7<L%TEE#T'T1G,38E7$.XK<-
M<S2S"L3." >,J@9##3!Y3_%?FZ*?AX<]SU?,"JWV9Q>R.EU='>SM?,]'W_&
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M78TVJ/L1-3,Y1)L[?UM8'V3!I.LM[$Z1S8T<Z19 Q@ED?Q_U]Q77I_F3TB<
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M*[U*GZ"LC0'WY"]?CNS?_;<CC1<[[$05 8JDQ2V8TTN06:_P^DG@J60Q>68
M>!K=KW )\+T$F(.["$ >J.TEX.,X9ORM.L\66*U/_38GH:VE='RY$P^,+T2Q
MF5BR9[F<R[<\IV=W^,_%Y0^; !_GYP=#$]<M8E;-^2],?*I7I!:Q7GUX='[1
MIY#X<X1Q)O[T"/3@R1!^:;P!T=LDH!SUW_WKE2NDM7SJB4R9.Y8@3U;Z=1GO
M)PN,:K1,BRVKE$=6@]<K%(S9<T1[38>5W9>]'KNT'A_)5"9E0/3R^6GL9HUT
MD;<22P-F\#!WR>)014RO%VTKL3'I^D;M;V6&]Y_>#HI?4WFZ=AA4*5Z5-C;M
M8,'P-O7)KTIH_<5LY\$P+)'7DKR[_&^]<Z"A+1]^QZ!CWZ>3G.EWN'X).%K]
MWV&FKRX!_"4X("FIX^XCRH*[D#"!DU7+.HH":[[?8:X7+P+X"G2_WSM&-/#/
MR]0^(R4;(L@6MC1Q1L3G))YUD1 !/#C:04;O/W%^941QPW"K"B&=MN'UVH:J
M^5D>,3#=W0P6YCI;O4K?L '1NN'[A^X]Z-'&)Y5+@ IQ5"_/VO!&F-;C%H7'
M<QF3'C5"C6G3I9Z22^4G1A-G<J5TKRI1E70*VGD* BC?EQ5Y*+V=_+,S'L[K
M-WV;'#LO ;85'AJV-"Q/*%<R*6Z\I>]6]=T-G<E)"'B3;&0T-6-Z.D][)Q7T
ME6-7VB^$Y_PBS!S;L"KE&?W1MJZ2!HCKV8+W\TU:K+.]&]1=E*J:-LIHV)_<
M\VQ7LR2;+S/)JM\GDKC?JCICWX3Q[0WOR\SS;XI%.UCO^S<WK7<X'B9("0NO
M<S-J=&%;.V-E"H@6=K>YVYZ7#W0(:QVN65JO@MH=H(CU9^O/2&,W?.:-_CE=
M CJ][!8LY;?U;[PM59Y:N<@ (EE:S.9T3P[JR%X;?E4?Q^4XT[]/?QN<-S*_
ME3;;"N: @1+N2;_0?GK[5TJ/])JLD[W%;6JQG_?,ZTCTQ-PP7.M@4,X4ZWB8
M:XASA7M.WJ>XI8#F^LR9L(RX9[4QL:OG;UX8_O3C^"U#B4["1',)JEX)G1*Y
M^&QU*6>BU<N>Z_W'#)AHK,GO=%7[N'7_#]WJB!T'G'05:T>]%C)L*6#QBG/O
MDKQ#&F0>):@N0C">Y8^5,U]M2[@LY.AJ!::A<.K=DS#O\>0(7AMYHL-&5VA$
M09GU)M*,5;'@ECI/-K9UTE;G>S.>LN8KU8QD=7:\AF^%;IB\K/P>5Y7>>G,R
M-QD-Y(AX0/]THR^-*&PZ17IRYJ#K"\858!:C"OD(O' O>+^ >6,+??N(>4_8
M/<G:U6SA MVQ O%)J[MO(ESC^.\$QCWV6G6G*/C1AVO+-7R2U_@]_2Q?.?^A
M2ZKQ_"4@U,;/7C)AR3+@<,T;,/PSLCB(TCLVSK$=<NRG]S)/>QO3OGZCJA@N
M_@4)[F@)5.-LTXCOT_YBR\64(2P6ALCJ=SJ37/8]%HX&>@#CR=3X)/AJ'IOE
MA,#4R>F;_4 Q& <$IH4F*3VP$HAY;7#W)>K$1L:!UUO^)[FGTOE-#?V/;@Z9
M+[GC<RK8/70,5 -;T:8)=L4RLA&S_L-'%/I+%KC*!\\51 ?2&I@;93Y;0T#6
MOS<V?X^<&?M/$</R6P/Q62E27$;(4B(*!,[FZAGW)E)1]@^*3LI:[!H/CWD\
MF3R0XE]\K"5&M70Q=%M3P)%;E#+!?^J$9?(P1[?Y_(W"Y-*QE-N2;N#L\H&+
MF&+_571C:P(G.[-._IPEK1+*\.:Q->HBR\1:[+(I?KR?GE6*<ED]M\1]3C+;
MO3"[.E!EN#7,1GUIC!JZL\<[7>)6,U$28ODETT5X_1,[8&1[6.3(\=;(4$KG
MHM;BOZ<KI&) T+:'KG-3]NQ&YJ'VB*\V('#6Y<&\ )5(L'SJC7 2X.:M+VO:
M*7M<K(I) J?WM6([GF7MB]WY]]D_LVN<3X3% B*R9_7^.& 2Z2D6H0G/=N"%
MT]B<M@3RD! ?F%.[;@J^W:3YR?<DU)A74W3=HM)9C;WL:28/S8MGQOX)7QR%
M"I"SY'S0)2 *:&70N?LK^6QM^2O9%"WBI\?"^B I56_(1W>7\)?TQB<<=L?V
MR^:%'B*G-:LN;V8'YEJ^[#C;Z7)P^FCY[3W>3HX.M@@@WGHSFZ^ B#Z+W[H$
MB#_[N/Z^>:.6EB*)W.;_.\S\-(@\&GL)X&##W?C7!R!.X-JI0U@$Z%3!A=*\
M(.@L]-T[%-Q0[.*_@$M -D7 0PZ+.S\%$NC^ 1R_!._9C:DKGGLTEYE(NNG)
M))1#FCK]9./"E&9>GAP!JSN2Y0N-)$? G)^^I+:DIMK8V0!K!S*87]HE\$W>
M__\?JOPI]+;;-_SNF[?4CTE-9_E-9<TO&$+]B>\L.\%[S*8B34#$R'Y6N03\
M2,@D42$4GG("ND CURQ_GO!]+N:?BG"HK"I_]/-DYQ* +C^PL_M]"8@,"%.:
MGCWC$#>X65LJU'H()S^K3]D&RNA_"N6>MMG9.>/#%8>>D:-)#YUI!/?G#'=T
M]N%J@?._81;%I,E+0!=L);.R]/=KUA=& %8*X=_^H\:9&G5O*5,9 "JZZJ._
M^*Q=43E$U$ G$K8+QZWVYQR\@]KA77MS8'%0P<K:V%IW<V2C9V#9=K([N/*4
M[:9^W<-'/]J1Z6)%>;7E90\+]:J1<4:_%L%+PP>R^4 J(R+B"W!O>KXU XG"
MR\' X#]5/4!D5H](! UQM3_T$O"AP1/&MAFA@)PF"?.DMPS.!:CPF/U\,ORM
MV]_^:D9#?*F06?L(R$<0]\"7@)M3Y/&CC+L1OSNY;F?()JL8X&2'[RH-#<<$
M:- ,?=UI_CY+I8K>*;H$=.L"'9T6'ESAF7MZ/2ML3_\QP"\B@)Y0>%CL_&13
M)NZ*)=ZGD0<?J73($D%\A-L_@.5S5<O#,B2#S)>5^A0Q?9/%IK_ZC0OJ]601
M#<E*<KIN^^V2T"3_#)RWORT+?FISJHK&UB^#77<J-;2U,<=H(Z*:E XF_G^,
MO7D\E-_?/SZE4@F1)>M42/:2+=M4*D5,*7O,NR1;#-E&F"E"99DBE# 5$F+*
MGFTP(:3)OIL92W9FK!=FKOE>>M_W[_'[WO?GC^\__7&YNLXYK^6YG./A: 6O
M/>2268L&.G_[=[*@/%-85W36*-@5?D#+=RWXR*&MBR%NXR[@N1'N14C+F[#=
M.+"H5]A&ZHIME0H']K@'Q4I&PAD6E#ZZ-X+NB['GD@RM:,T&=Z^OMP48&8X=
M/M=H&W<F[YO:2+-239+9RDP0=08?M3KC:ZQ$OB/^W"(Z:W=+ K#P;G/Z7OSR
MMPT%R#"V@134B@]*',>PIZ%!B^O_^Y'U[/8%0TE@XR2Q$<4#1Y?UXY:L%$B,
M)4K?(!@-C^# &(9-'%C\M/)6K'VG:*P'J8PP[@J<)I?4F#Y!EA5%44 '0GP4
MR/N>3>!F#1DWI@8@^D>X)YG@]TP$PY-_;@WW9Q2K@=^*PL@06HTT-X<Y,'Z5
M[?LMIPH!%)14$10KT0P*1"*X'8@05<0\V+0YE$)<38Y!3-V.1:U#ON>-4A@@
M 3[RG@5I%BB\PH8<M X*2'%YO'61Y49! \F # ?VZDXR>#2532!-C8(:.%IE
M'9R52>QIY\!V*[%CGW&!HFH1%7%8JO,&TT\1"00AYZ RN)A!A@-P)PZLV5)]
MU%P],=6GKSFH8LEJ:>8J(/\HRRNDC/?ZH/%<SE1EB%0@0H8T*D;IWP+CU,:,
M09XJ 0ZLQ>3Z]E]C!"G?)K?SCO?4JX.FVRF?CRW'D5MP3OA-%>G#4-MMP4&3
M=U!AFN"<7K:P7!EU!H])A?!/%7OB1U4U*DI/'T[K3OEN,KUNYS?TFH&$7;H>
MW^+=W/"14!@9JY?-\$,<)8"\&6S"]5+\@,S8]5WI*>BP8/C63B<$VYV]!\I?
M"*Y.!2N%JS/4-V8J?:_A EZ.$2613)FKOXM5+E$;DQ[R5FFUNP:6K2<MWMOD
M([B=H1[/.F$8_$7">'B\%S*RY%:$$W53>40$FF,L@0.3@\+&K\S&XZ:*,!!8
M[]'"L9)MG8H,%7\JZ.KD L]_QQ<GVA7FB-E^)(K9.FBDK?^>:REW>J(><I?Y
MVD3HMH49*2#FG^[%XE?^U+*7ZW)5[U\+7Q*XKWB7Z[[]&$[YT_(IU7/<\>4Z
MLH<:_:Z^/C\8Q9V>9H!]LXCB:H;2)<?&N\2=V[YLCUSPM4FV0T.[Q^O8<R&W
MN_$WUNH*-2_<+].G"<3TQK5![SYC/W[S[EOTV#V"9M:"7%E%D8BHUJ%!NX,=
MNN::-XTD6Q73:O^)0[HS$(5%)L_.W!X:SZ0:I%1XL7*4YDL6<;6;)2G.?O+.
M3R>J"86%A<N5'K8&J(I2^W2H/'=OQS44*KO]NVF471BU)JP6$Q&NP8%Q8>(G
MO_<$IDN&FZ7_^?-GV:R\PU8,/:_:^<_S<<9-O^;#?TB*QR!H<\6Y-*=<.;3V
M%.@^>%U2VGK-Y7&2I@BM4=R@XCCRS?KKK[*I?M.H#^$@C]+6;LD=S+<F34XU
M=9?T_+K*Q\K<H;K:_8(=]IH 5&U>6WRQQDUD?\=1L-V+_S!#D,G7UC#&]KQ"
MBP_]@P(?YLL$XBS1!LCDML(%P;99MM,I\O5\\QZ"ID[SE:D/"SWXE&%^"AR(
M]%W#<F 9T=LW6H8M[L(MQ>/_PS.2$0=&9U*_6+-%8I7 S:\<V$0$G $L]BF!
MT9<2.;!0&PYLJ;X"5P90P' ?'&"(&P^"SY B22NJ]1P8[1/T4_E)',M(;\L0
MOU%.BAD#Z>!>Z"-R)Z"0N)!<AL(Y,%YA9MJC>3:!%H--D<-&E+%$U-:X[S4#
ME*RD:;SZ][NAB&)CPPTI!8C3=\>Q'_=F-\:>V,2NM7)@2<=31E45[?0IAW-5
M:+G5LB7NZS4I'NB7WG34 45#FXGR*S?[B4X\RP^7$#++O>#1=VP"8HH.GL;1
M2'4(5F8&>)3P_SVIW'Y"_+T(A"3/\<=A3T^'Q)U2P>N/I<Y(&81&&6UCT@]L
M+0>V8KN2&L">V+XG]<2MBXW)'-C+2*U3TW)/'V[8FZ>[&&_&UJK?:O_!\(U;
M]WG>65V=L(+0Q[,D#+8,7S;-\S-3G<H[JPYM_R&'A,U.Q*@8M1_ M36P7.'K
M? QC#DQ!:<4 BELAZLM9299K)_=6H<TXD["YEV$P WF]W?'LQV\)@(,(+/VD
M]/>U7[[L3&[D<AMB%1]MV.,2@UH7)K6E)F),R0]5NQ_,J8A.7%+O+-FP0!C\
MBU1E\Z+,#.@K(W\S &<>F)QC<V#&__^'V"@\H!PU)_ 8'RMN;+[H1&@"CQNX
M_EU['7S%#@+N!0C^DRP1@RR73HGH,B2UU8L0$05^ CPXL/,L-7!?-F@\&<4R
M,MA"J,FO/0-^U3ZX.3VRC^R4*NGZIF[*AY*%?0,!$XZ69K@#*K+@*:J !GXG
M9JMAY-17("K7=>!7YLCQD@Z9I('0G52+DHBCXIZQ93]F<TW3\R-N!19X0XAT
M%_%/C&2(:P=BL1(.VG0Y@3SR6[NA.I(C7&4Y?T5LO?Q\RF;AQ,\OW2?[6LIC
M+IZQ:_$_TV57::9@7U"A\?",XXVZ,ZJJAW\6IDDJ9P3JU,>(%C]\4)EGV^"@
M(CTYXYF=(I!T]AWW,96L: V,!<^";'+SF;4&VS>)[WU;8>4;EX=3'_7-!8TQ
M9)ZS4KL0M"+<%Y7JXN334++&XOJ4(]KG+$/JC5_N?>%NZZ9Z=^?A4:[UN)9W
M$WEO2Z'5CF!KD0K/!T=#QU\.#C8'!K1F][]Z[&AYX#"O_8&0YK-B@R]_6T<H
M9ZB/3]R\FYF4X.E@HNUN-5A2XM9ONQ"J:2[7[&!:=2F^X]K$K7P#<: TOKJ[
MN+*CYPQQ,!S<V\[ KPT"H]@S&,HH$<]2R#>E5XN2OTZ!DD6_595KVNC]Z.P(
MPM8-LXJ?,?[<!TP3=22"?AE>PH.\']CI0VCT@-*8Q<(0 /YDZ-**O 9V3MT^
M*U8+\^/2[QV&,UAJ@'PO6]B4R!*VQ2V-X@&L*.O0+/@\JQ?<_YFTX>,X<:#S
M.://!*-[..:BHE_\]?'<T>*R/I/AS56L<=.8NM>>)J<9)Z:0FWF6U6#T>^Y[
M"\.9"ZOHKXS>[4HQ/'T;YTJ,E><*\UO<Y<*!77VS: I1^B\LA;KB@Q-',!QH
M>$B:#!$8+ 0@WS<><K."P@Z#QO5VXV>)<H/[%KM!A6'"QS=W$4E?@GLM*)BV
MK)  K>83>5:OT@D:^05-^A@GLEV)>$X2/5N;J/&I3B.]];)!Y<9,R)G_/8X%
M[OMI:E'+R2"<*R[6[*M#8@V9EF73IWK.W^$PFG)XMXU/C"_J 3^@"H6 %DIY
M'AA:,9UDS%WF@$I=H2Q/7]_F+/(V693Q,^WFO.1N%B3?U4JH:P9[#S>>E<(F
MX@93_TGCP(I/3;L1B]UF/Z8O0_;G>#8/X&/BKJ$>(Y-'E%GSL5MJX<"<<K\!
MR5LNN#HXXBZUCTA.W\E$QM:H@NV@6B% 8')=!)RRF^BA\O2;ZGVHF9GU:P[#
M6MD?;49_R7B^N>HI.[GP(=X'Y2;/DC#=,D0@!^!CET*+%W<]@/KNB_Q&0PCS
MWSOG(.T+3;DXF0Q_7,%?3WDJZ&&-%0*FZ4C1F? MW>X!7H3IH>BR>G?U%U8B
M]^0?-^G[HO*WVQ#ZKS2"R3?(A.0%XI%S@\?.Z7!@GTC9I'P_RIG1J>L1%]_<
M.^3[QU,QODHPX-;(^H =434[S3BB7/VCXJU^*Q%%9MG":.<B^@'%8:L/"(&^
M6$0MFCX#+[9N?#R#**H2Z&6T7\[DP)ZZ(%P6-W5(L7! ]5^(7(!(:??W;9WS
M50?(]J]K8H7-O=7GXL#.X7'@EPQP6Z;N@B#V0XX_]%*>&GC+^A %:"N[[W6J
M8*$X82/SH;_.#7+$&<5O7A(#\HO@'T*#,[M[/$3[/Q0#!-2G"46T&P2H/RX%
M-8._& C<5IC?6#HB*Q1"0O[Z[4SCVF]60/.WA,A %2*V*#J$<*2I7 <<+1=B
MJ62A]-!&+^I\>;74"O&H<:2^5I2VJD.D^74?TM?LK(%0I_$0>2A)B"U]W<+F
M+:,0EY>7)^YV5HGDX6]]C";)?&K"/62WLA-)+K'\:Y; (1KBT8A4[RI*< J$
M=2ZLY,O<Z+E=^GQM6K7$S,C>I7QKU\$+>]]>3S07N)D[EM [RO\_>]68A> !
M]ZU":M<"<I*[K5"L<J+VZ08?0P^S&PW6^8;6_HH)_G8!'N8N$GK:N0;ZA-UU
M;Z1<[+G,T\X8OLS:2R371,UV"6K]8-5'']TOJ5"_8' ^<M(+(S:9;XS9-2VK
MUQ^8^73_[OLBYRN__=#S+=_)ASQ\C'3D/12G?BA&"'2!3!E^M&IJZ5>>4)E6
M:<#+DJ&WL26%B+6\L(X"UH[F_M]QW'94A@VU3TM,JYD9U[A/2TG_ALHK9YOT
MK%^9II([Z@[#7/1["0>R3]Z(Z19;EI.R'G!3*BM(]JG)[<4F;]HP^<Z=,'G;
MF%LUU'+-^XKLX#I6WJ^@NZS8.AC.%P+53[A_S0[6!>9Z'"OH$\L?(&;..)YA
M6C^M,@M%9[J-'$H::9S\OMDV4JD?L(C+,!G5F:CPX_8]>6W'&<V?N.U:8'!@
M;_\OA82C+Q&V!9*G$@A"Z-@(-3<_I-404\5N\/7A;:&0-^7TUN>>^,'L*.*S
MC+V9WYPL&U6;Y9R%VU47ETD_1LN#'_FL9C]MO/UE=>*,MJCBP2ITH%I0OM=\
MN]VP%Q;S=]1UMB2J$<\2Q6Q;FU=P0"MP+522,* V=HD;]5^&)W$3_K]&SN%G
MB>BM<7O?9+EVG!R2-'BJO\6!N3)O%H'J9MIQ#9EI@Y83?DF+'UL6QWT+!!G=
M&N#["*L>L#X]J6?+KP2B\D?;TA7ADM$)&9H.; HNC!^DY5"9O-QSFU"[1T8!
M':$<6%'(MODYA7H/<;'P%E=3Y]BE5X:%?00*>%R'#;FK$/R<D"[+K0./6.[X
M+DU=%5BGF)1]3[4!)3NEY"9MB?5SN!E*5&=*MO&^R%PJVZ@3@O\K+I-!_\IF
M<AW[@Z$&'C>WN.M ( ?V#OX0TDT<6#]CA?VA1A,.64EY:/66F[(X6B'BRREN
M4,TP*?1GCS[6+LJQFNU&8FS ^X[X >V9^"TWR-NU"MP O_JDL8>PV@EYF&?R
MN LI\SV39N8\M%RM!ZU?A@H4S4T2#0ZAL^6=AUB0,W\*3:&. ],68&9WRILS
M$-"RR^6X0%Y(3,(CH!F<CO'EP(Y 1F!KTS5Q4Q(JW<4^J4C^QC19EP+9KY/+
M7;CTT*]F2$#998[OR4MFQI5QI^1M'?WT/1,NHME2I._T:2VJ]&%-;_6F=IE1
M+(,:N>#8\E'TP(2\%S+/HJAD^&W)8M;:%#;H7RCZOPOA?]?&?ZJ"3_]9P$&
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M]7NSKRA6$%<B)@,OC[LE^R@"?9T)9PGQ@/M=&+@ZR)37RS I:SZ]Q>BH9+O
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MVCVO6*>!@(> :-TD..$IRH&]\  0"(;#(J"@GO&#*LQ2%#1X/P@*HQ^!%L#
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M2A/L0HCA/$C]Z!M ";/5NE.3(-[$5/H.'DJ:-?GME[^_S]:U1WQW6P5/J.)
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M31DDK(6R"[&&+&G @\E%MH.'5?&/;AF</E_TC6$=667DLV9;I?E^YD#'\,R
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M#V8.OIC]"GP8I4Y7BX.)Z!TJF7-<J?>FP85%5-_5?A??TH;:J7>=*8L""S_
M5\P?%S46NV-9]/E.U:6*"1IQB0_:E?6) P@GQRK6.(;E8A4K<YH9T) 35M@,
MSW'P&)?[UI]32:ISBA%Q7\ISTE^SW&QX[%[S76ZP%-)D6E0B8FDAMUR58JI?
M;5&X>NW+*"26X(*ZZ7LW^\K,^,4KWH@!9]2F@9#51F<W<S1@12]J<NM,??>U
M5G1AT-*_ZFQY7M<U/NBS*+-PER2<]Z,=>8=Y$-YOL@!/AG.X+P 7%0X&<LN
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M/5D[2AN>2)3>O=Y<R_'!RL$+N]]BAP'OZ23\=.S'DHZAXB"7AEXXSZ7[QX9
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M_MMK<T!P\.RNI:*#)>9U5HJ]Z>B8?:TN\N+MS>%^2,<> M*_'GPK$1G]:D5
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M^;QD=LRGP?6P(-LJEDR^JV+LDQI\96BC7D0GN9_HZ&CD$2AS37SFZOT;[N_
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MF@;M=F!1'&CY7(A%9G_(*X]:[_7-+Z-C;97GU@0M2UY9&=@]LJ[1^XMM'>1
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M*F3N[>R(:S'!>.IB^NCLA:XG=DQ:YI55Q[J_1Z./C 5,%?,%E&*T5#^Z11-
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MBIR9C@%0?WP',+@Z$(0QR]^!/B3!(Q,D0AY:,29B31[X]!0P;LLRCVZT+)I
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M/HZ.<!;Z+Q^L]6\&%//7UF8(+\.P<SK_M*KQ'8$@8TDC":?_[RY:R 1X"^9
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MJI<-W=)#SIC!^_*D$=&R5@=-EM!#3F)>QC$HB]\G(:V=G9'6F$C95#*D]2
M3X;D-"H1'Y<>RUA3[OL2^NXC^XD76P$#0<(X+49X$]@.0>QF=_#?D#]5^N7Y
M.:>!GFU.9;RLCV6HT;QBY>O?^0<?B6F4+J/%P/46=5"%#V+6!7)R=CZ2(4VV
M<PP%/UCTT$-Y)B!H]6C#2N"$4.M]5RPQ9:NEN'BLFE9IOFIS;I?"XZDH(@>*
M@Z,(?$MO8--?TCD(L;-T(>F4>(.W_3.UQ1G+1VDYX9C2ZN/0O5]^&HO=RHHH
MI]?9HHP?[L+N2%FV.L.Z8^(X)/>9YS^I-8=_H-4]_>3]:[EI[1'F%M%FI"D&
M9W\F7F4:.UHB93HNRR%(,.PU57G=%VI4!F5,V)'@(\T_M7>L=H87PZZU !P+
MOO?B=9MGAG\6\S]4S$'G:NF8CA>:H!)5U;-3X\>L<P_\V3VSTIR8KCX36<=>
M#DGGR+2:8.=.^*+=+3UH6VC$RX#CZZ;*'OM5BA@(2@G_QHC\8!=?2OVPKF[^
MSAGVMS N[>X43G?-"Y"[J7RKE-PX2:RW[S-]D4OV]?.G M)%#/XL%?N_K$"(
MW(SX_'KNK.&Y,Z=IJ=/I^C T#3MZ&5MMN5+M B9B!>4U!<F_;,J.')#P84V]
MU6-)F#6K=G).EX2/HK::RL3/../[>SW$IR0T;+J$#*&"/1>.8H*=)EKC2F?I
MPF4?0H-=X5?&5OVO5>!6;4K&[+:G&G-:U($L>Y'26M3-]:\QY[LO^GI!B>SE
MQW)5\P 6P9(88&DI 5!ILS!GO![=?# NB=7J\H<CZ^OG6T\.P_T5[;K"3!#&
MS2HHSXS\G#?S3!T5_LA^>:$M3E'.]'@6<YDF7JIS-5+N5$SKZS&5ZZ<"2HON
ML-42E](Q/>S\,]EZ:?/,I@T%6\:9NCF\QID^V<DZ:EF[:F;NL 3)I6;3XQNS
MMS00(;GFB=0N<9'<&=QQCM9\JOKE5;787%),-$'*8M^+<HF$DA.=&SVN(_G0
MNHW[D"%[*\A9GN@1+!"Y-0<'*#V9R) /Y<17GQ@,!2',;Q](",51:I_K#I0=
M*"@J_/'5\AEZ08*6KON!.37R\G4ZXR,5SWNQ<OIKW.//IX[UU/> PVU-?&/X
M%5N&[[:RV"<6KPO[UUL*&=J(Q7%;D[_<^X\Y_S&YX$<24Y$(PK5I1P"A!>+L
M+?_N3-"\TASC\RFDH(ZX.Y3W0UD)@'_M'M&!S]TMU.*FTO/W;V?0HK<]^-BD
MN"BY_O33A/V07?^LP/9Q/F:\0C?6J=)P@YF+2VJ/0;"^.BQE20]T-M^JHOVD
MNR?4;\RAF!^I:C99:B779&VPE??#568MKZ48Y]0FN</RR9#1"\"%D6-!H&>*
M6E8=E]*$..,OMVR,"%W"K1]X_PS_YBMGKSI.<&P:%0X3TCY3,\Q;QG]_*/1L
MV:RR"8G#2-4^@2OZ%4B76^OK3(Y$T:D67R3(%P%*V\.M.HB6[Z_;S;14@V@-
M36M/IT)<HE*CNQ-57J@P7M=68>5^YCPO%O;@A0XZZ<P;I5=AZ)F;B@<GJ[O9
M"&*,,+MDFZZ;/B^?'D>100Z2=-^Q#FAK/<DVF1TRA!D,57SK$3(@98T,N=O?
MOW:8+ ]*32%_++L%:!9[) '!+0HZ4K>_&]$N/R0R2_<<ST,NR4KG+[*-C+/N
M.)HW.<>-%#7WY67S3S]^TG4I]3&:UNSK#4-E)BMW!LOK1^Q]X$ IQ-3X?44>
MW)F:RAW4:9433Y.4M!!)U"KVR]'8F-BL*4Q*&H&.@%8U, EC'25Z#/.U(0I7
M7SQ"-N%0K<S$%EU05W1@2NL@PNN'^'R,R18%=*&(8AQLD:U7V\*M,:6D1D'>
M483=Z=?G99P&+,;[HY3.B8B<@J[0]08_I'1\XDR'N5F*"CQD/]2U0E6GF$\B
M+J*VRS;0.H:>:\VZRUVS>&;I2(5MDI9.HM[]6^..>L[&![[YYF;>L/5$S(G(
M6;T7NT!"^8OF93K,V0\'6C[7?7$QUDYCB;>">8\3XX*T@H["Y$G?@%-$.0+(
ML>I<FCW5,GA*>-5 @5B-79N]QM %,X1FKQFOB<K-:.28Z^&I&^WON-80BUR7
M/W1&MR>K&4D4\:A5,E4<LN>]Y?*/;F->I5,E0^1A!"XC&]AT*JJ4>UM1MVT&
M=>4P;]/R4*=U4DA3Q_FMO#0E14"2Y!+#(?:]+$/"ZR&.A._ND2I=+>J#N>)Q
M.?R(R10UAR[SH1]'!N]JN9?8C3[J9GR2_IC,_S)+(_6*A@KO<978YN!N=5+H
MY-+JHSJ>:-&W70=15.8U =J2YH'W'^0=.*M QL-8&/E3.FCSN2/97ZVP6_XY
MW4V I[PYSQU5GL%R]@+-&]U+)S(EMIOV/)8WN7N@3[C4,>X&%U]\NPQ%F89N
MT1YE_UOE%LB]P].-_>DW(_CS%2IVC+4/BJV R0^_'"WS?RZ3P'EKU%<_*S P
MV!^DHG!?RKY[-C&NO !=.SJE<SA$" +3D9%X%D<7+>LX?2$Z ,FX=U&ISE\0
MSQ14;I+O4TS=:N\F$5P>7D,+S+9BARS<Y;ULG_@,R[ E=CEC\%>6UG>F]OT(
MO>!,FCSW5]#Q394-#*L?*P$]5V1;5#((<_CG,B_&YA\)P69D\92CLK-9):SV
MT16YJZ(#%DV-_.<?VSY^DP![Z5)-J\)L[I1N=^3(B4/=;%WPE#5[J1BI.I A
M/N%5_'*)675%0QLM?*^0S>@^?*YSK27J1MM.:BM52--POBI#Y;/S?1GW5![I
M<=D=4TETV8]Y+%3!2D )XK(/"L2,?V\@'S@3/L"L4Z,)K5.1E"M^TZ\ YF$[
MPOCYSNV6[Z=QCTL[OWI,L#]I#^>*K.:WUJ,<?).-V6P4;;IT0[-I7'(4(?/P
MT'/\5&O/<+[PN6U:(Q>]H$I+M[T4\8(M.Z,-/QUUA^3Q'<RL'%ZM3[0HI5<Z
MX>6WF[L:CG\$'\I(_<I74)DP7COFA>&<#];Q8R "_)5&E%@ I4R,O',R$V&E
MC7>L0/@76S![H;6_13%O?X8!NS\C^6I^J8*Y10J0>,@S>9=*^-)%SO /XV^F
MWT[QUUW'*ZI=/7WKDXDM,DOJ=AT'TX6V:0 R3"/+-E-\Z";H2H;X%DRU[R'F
M#8A*MR6=G#T[<V+M',='QW:_8610@UM-C@3AD'4TGJT5<<'7PP^G-+>?\LU7
M8("HD&?CKB^!H3/'ZL8W);MEI[AQ?+WM%LICN#%7JG+]6/3QI(7X=D> .1C<
MRT) ]W$C:F1N[J%@A!5(7,&BJ(WQ)0X"Y>?B.4/EB("&HOXZMRI?CM=WFGUB
M5];V<L2OMA1$L.H),4M$?M!4YO9-??.P"[2CEZRYDVI')ROR0'7?UY8SAV)1
M%?XS6Q+$895E#3=:Z9S:,O^)1L3!2J()H1[[WM/(QOM$FVD+ %9-=P3JM)US
MH%K#.4^M[]:=.K[O:\V^D[)%$;U0A)0&Q%7TPKS:[P3_X4^7]QSCI/MEXU(:
M.68"E5]1/2]\QO9=FQN;F@/*]KE5)(6HK(6UP!?V^#_\&<#U(07X5*+KW#5C
MP[S0,7M23O)5HOT</^_&71;?#'M]E@:]T:J^5-TE+_/A Y[-'5],"=V),O2^
MAK3&1C0"4]67R9".50_BXQ_']SU(Z8 HP#1Y'DS$E>(YUQ>-[#.B-"6R=SOV
MD_YLM[A7VX[=,3)Y2WF]I^G;V9AO3XU4*EZ?9X\32?OQ"!=R'56O QJ</.1V
MRS,PX)C0&WCLI1H;!>2F&-)J%!0XL<<R:]*;05^0#>\)F)RV(MM]Z2<>'O$$
M;3L[&^%L0ZYD"^O\SEF>V 'VVW/IIV8Q&6HF+95J+-3<=GYG7+A?22B'4.]P
ME9R+N&J@F?&:IW0LY_ I@=%H&E\<U.E<56;.A1OKL-A'7Y!U7AVZ%5GJ0)/"
M+/8B5X;J>A@9HA-Y]D%?V=>KKQB3WK%OQK3C/\?\@$DHF*:[8#7(D%C/^$9)
M.>;<X,9ISCE^1>U<@U'=;ZOW)&U3L_A&^)U'A/H])J#5GE(MGMUWHBQU1/.U
MJ[(L'R7TO<T<UP]]J./]JVM'!>U7:/'J\_@#"O2S_NB<0JM5IBNC0HWR=CP=
M2J?BSO?.*%8F\,L]\;?X3*-QSN1"_$&0/836FX8.._I][^G4BT^-BCP*0F=*
M.&,=ZMA_2;75R^XRUR]BY(*D](\*] Q4*GOWX_1)LPD(L6O]?>K9Z\4YOXJB
M]T9_[!N:VGL]'-2=T>H+$=MB8MHLM\DO*S,=-EYS1TK5W@"A)!9F74/9Q+KY
MA@PY)7=GO#8T?VIYPX-A*3")K2-2>E'-:')<K9#K/?$WBN-Y;MV*X1Q :T1*
M]P&P*):=#>0TLK6H2AJ9:K -Q=]+@KZOE?TT$9E":&T*'F(9KY]W'!:VF+@2
M.7VK9%-3<3RIY;X7B]Y,?%L2/7N6Q>O(US,_.]-?/#Y='4J_:&I]?7CW)[1!
M-I[^78->I&N.?BJ/Q-ZG_)^)NRXJ#DBVQ711/(?9)XN7JH:AVAGZ3N_T)$?Y
MQ>.JLCP<Q4GP]7?(^@YH*8;$-M62L8O!P<@0X8M0_)76]2W0KQ_@0?5%0:0#
M\[@=$/\8%+G@*A#[.4Y)XO\CZ[RCDO[B_T_3S)0RT]SEK%R5*Q=4IF:FI.9.
M*<T4<:0Y<%*6>Y":6IJ:*6XE!^) R9V:FN(*!X*Y12$7*>+/S^]\?[]S?N?W
MQST<WI<WW#?W-9Z/>\Z]+_>2Z/8(I[\O>8:.K-U!/U&;*NKRX1002/CI<M'[
M;R@QJ<\/V7ZQF[!X&4FQ@+ ?SCNH>H<D?X#/Q=Y\8&IQ3=54KQ2M2IN%Y0\E
MSUDFN_4Z[R<CVXW^9QB80X[\;QB'X3HZ]0#@XBAM>2@25*I^]$S8'@"^O[YL
M7]?%@E2/^-S1,>S40@KG"C;<6]AY970 $/=BETS*/3P O%IK+T,/T,,Y"U1B
M2^N3[J[?WQ%.[_QWZE1]EZ5\KH&/0;DX@Z/J@6W#3O-H!\0(/NKU \D01O2<
M^V I>W6NJ%RZ'_TSK7>Z70T7;/>373; $HC;M@*+40X5+Q<+>0!X%P[D< .=
M0=W;\VI[D\^E\,!8QM"S-\&)5C#'DW3JMLO?2OE/NA%=]84LD4,B+8H*6-UG
ME!A$O=P0.GR S)P ^Q:_&4WOOZ^#$^%,DB) JO-ZE?:]?30S6>VJA'CZNN31
M,BVQJWM/TDPY>TJT@#4@B^>.T5US,\I'CRS>SV4:)1L9V#3'[1?86S1^'&)@
MXHK4KUG\C5:;\#!VF\:$&)%_L7L(5!GQWT1VPL(A-)S1_F\"2>#__Q);Y?-'
MJK+FA>C[EV\*1YV6OO3MKG\H]<BMS9.?+_1$G1,MD[S<_&M<PCR:\1<I2 EU
M0U*Y_R W]I&4AX2?2X?3P^A$;I[_L'^H<-/%?]L<^L1'I(LC#_GWPJQ^Z!;P
MV.PAEL?L\+7]MQX;-J ]NQW([,L.6A;C[#1P0.(:K1C%C6?.%O[TN9L9U=W2
M,NN"X5O/%,97''LG2^,Y.2][VF0:+Z:3:'R>'B 9H3)B<55C8G\>8JR"N[FQ
M^! ?2BVZ>FWD\M5;.,&97,ZAQ%W#'M5R'<6QFT]J0YH@-"O* 8 E J<?ZV)K
MT5W>R+./A=A_PS,*8U7 G+^AD].(.ZNK6PI(<^Q060(YI=Q0*7T[\X?1Q\'$
M(>\^Y#U_*Y^IBSNW?T6^>9ZRD!!OEFI&!W4]:[I8]=G9T$SWK#ZR%[?M]I)<
M _VNOG$*AXPGG+D[T=[Y3*&+)4.Z%!EXY.K?+L56$QYM_((&9@LXE'>C_?4[
MP]/G;UFWQJ"ESE_R?AN_-GN<>_RX(T&*<3[BI;9J=,NC5F-IAYNI]_<,U$$&
M%WHF,V%&F2:666-ZA'6'LXQFY\Z+\G[NW?TUQ0< 'C_)BW^AN.H(%9I'!GQS
M=()-#/,]S* P@J;?A7^$2C0K;OU_+Y%UJO^WE#F(VR]@+0V;KL*0$GMS!X!N
MP!2!IKY@^$TL/^>0>\LA7S/0IQJ+\L?L""/?)&ZX,*-WO??=;*^4>T[O<_CO
M+(9!#N7)\]D8Y$P&H8:4ACOE"SD-\K394&(]4>*LO#\BIO8"[ O@N2TIB-E@
MT5'1-)8<=9^C V=Y]57!4L!;,_MKG$E>A2DF:<JROV>G!X039DZDR3R]S_U#
MXP"@-\"\@J<B?PM3\SUR%[,OU28JG>Z6R:1*1</&])6$$/Z/:V(U%-84UK8X
MDA[;D>P[TU),G!)ALP8NXCU1G>(14!ZV!,N6>3WG@J\P] SBU9,&!@QR0OP8
MXAA%/0&;=<]-\PJ6CHUAPOP]/#W6[B6WP,N@</X=HCQ<)=?!H&MMFM<DXHP:
M>"+4#;Z3,12;FEQ0WG1_>:MI.ZP6_$G;IP5O(/!R2T]$VQMJCG>VJ:DG!.TO
M!6L8&7AFNI>%#!2RQ\G5F B\Q>R  -. 8M"AM>]$7=54C4JDA1A3O7BX;VKI
M*!K!:&O:<B=J,PNG2&X$MVA:-CMX/'+<OU742"QR9WN""2]?RA:B9Z?0%V85
M*_.80A/M+H;#=G9T-C;P&57I'#QIQ7]HV:-P<5WYM^M[X:D;\6\LGK3;]]_T
M9-DQE?>40N3IVX19N?5P$"ARMUM;0I8.CF%Y%-LMA_%IIL=+#&'%JXP*F.EF
M[!%@_GW%(:/N43MOI8PW0JINSCFK*W3@]VPY.BY*'U,\.<TR'*P(DUI*61)3
M&E6) P.99O06;X&HK4[BEK!WD8-=1]EX_L:T],^-;A<Y(\F:>,BT+O"#X\C#
M>],N'-=&4E-O[<<FQ[J-9]JP9?^H]5]?SH>_8#ZX:;&"<;Z+GY04L Q):[H6
M5/>[UU@Z&/HJO6:_"7^NB&G0T7R,L?X6=&79EC]O%B.*R-W2D>L04@$I)B)Y
M84%ZJ65!^E6C/K!!&-VH@"-9JC:T:.AHV\MVD/0^ :]5RJS^GNPZ?9:!QD1I
M2Q9IZA488<:[ HLGU-L2K-K\US%3$UUGU---R0XM?O/ME\VE;K#JQ=6?' "J
M75I6@'Q,H'$S4S4LAV-K+_0F')GXC64XE@_2&%65*P@7/PV;%@HU=:]!,0VE
M[.RO3W]7>$$,F\:IM1M>E'S-Q-+C9E#A8%?RV]T+A,,8Q\M2IF.B\QK3.QV$
M&)85JJ[/U 2L1DG"L(9JN&WY\.RC^IHA16=UH'L?=_NO.M=>.0MYD(7)5U\Q
MEVO%*A^*#=+Z;*$;O%NX]U;9+D;<\O<V&LP*/DO,GJY.-7%+GDM(,;6$4'=J
M[&0K_R([UA/2<B[4D 'C%5E%2[NHM]H*!4RX0^/("_7D9:Y"4HN'W\+#.\F4
MW.N$]^]O^6^(/W6"/NO8"V$JKE/V0@13ML-^8? <A0A=7?IH5-"8>EKSY:&Q
MVV/IG?RX':M7RW&%]N>IX)M_VN O9.U<]/Q:TRIFJ>P(AIQ]-8,GAM'[G<S1
M+!(BBF6F4TK!0,00L4WL+#VL23:J #_L5)-B,J)]^6M!8<7D)$D?=6O4DVIC
M[ZC\PZB19Z(CIUIIM9J"0SVJ8ZK/9DD:#\K[&1L9VP=WD?(U.5!Y./K/AH3R
MJ=IR)ZH=S7;\"9D5=ZHJ1M#Q[(5S-VR'_*[W4@L_>F:_MROT*VDWJ IM4!DA
M_FFC5+LE;S/Z844Z[LN03*B<:O7:@&K5?G,8!TS3?N4P37$WRR_AFB^-:G.5
M,-E48L>T4!K95NPT?:WXRR20ISS[LZ?*AVP/PX)WRT-/[B5%V.#JSMQ"11X
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M(S5[>LL&'8P-/>^/U%'X.ESVW$?I^0(/?T%RPE:I"LU#9=M_;'@>I!G6RW\
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MO2!WV(J$J>$)6%@9=B]+ :]3+!]78*+PM*:V(>/J):=+SU2>,G/BD:X$TO2
M :,@B1IZK&W[_8HZF)Z(*&P_'Z)&-\9%*ZC:._[5<;=%7>@H0'I-&,B/=G4;
M&1&J[28BL!$1525CF2M(,; K)BJHN;@ $4D5%38?]26<"FWN>O1+1:-\S?<
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M^,M3?\;^S@NDCP]D]&@/S7LYBUD$_[-=V#EA)1V;DECUV"YV7?KDV*P34_\
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M]JE/('V,/9V/T;]&%+F1-^F'S$ZY0P$1]3GR$XV N&.+M(D(!NE/[37RI_9
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MUROQ53J><Z\LYG'Y[PD6!W"*(F26#O?4 F035.A6:C;A07'"#2'J"Q>'P1S
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M+7E\>;;^)T$I8GUM'^:1G2 $2J3)4*GY5$K&IP4;"Q1--BAUUH0H/PW7<)#
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MDX"I07^&U7&$]Q59);T^!R$UC*1N ]S!1DV&.X MD8):;N<9RK-5_8,(1_Y
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MNL+"=":WH_W8EJS"4G@3&&1*E4UY ?(@3H0OEYVO[6<VUM&'DOA)S6&2V>S
M-DELAP=;"][K'#D:R')F,(IQF<$FB5S[8_L!A9)H"4:;#&9M6=?2+&6.,FO5
MLH+<)/$;&FHX_Z"9/B6)'7.,P?!HI50I29SU)C6XG\J /4ELVQ^;M$2& O-D
MCQJ9.0P'Y\I%.,G*K^I\)AD@F^>B?N[+S6=2I(<28&0E768.D\)4/ZA)XM?]
M?+R:N\A"JM 7^&C$.BG?-XQU$3:#8X]&2 !#600YQ7GJVCJD*L^?*-I1C &3
MXDFO([ *BB3_YE4%IHGN88XXS=_@(6^J;][TAU>4M(QKM@WB5!O5<K1=PF[P
M%# L'L'K V U?%D3-(P$*P2FA'F]!>0%1I&ZK:&'G6T#RR!)U' C PX8122F
M@]ZG/V+8%0;D,]4:4*T%@:\Y2",0?7-@$ :59&'KHX14U\I@/3()'D'RPS?Q
M"J+7JR))_GTH&;,\>M%N,T2173QBBQ$?;GV:H7KI9"*Z_CSXFJ79=O^&**C7
M;[]]_?Z[-Q0 ^>+X7Z_##/[[^ FEK2(RARVDL5H2EHH5'OD_8A<]!4F9N.MH
M?1SPI?IJR<D"MA>&Q:K&LI(PU>U1C5[!;*O+_SR3H64&(P!_^.8M'D4WT5_"
M),,&W@_?X-M'\\%(AWT%A!C(';Y#PSBL"FCYY*<D/JU%SXO)LA2ON/Z.SW5-
M_;3!5ARVZ+87V)[#&)/;%4+83 71 OGBNQ)2\V6^&NTK"7AO6@(J$:1!PL<@
M>.>;O >_/MWGQE4N/2L&?LMEH![_:,CT08^XYQ\/_ESYQZ5GQ;\_&N9?G3$3
M.^19$V;3WIL5HUJ$JYCSIR&K:)1^K$OLN=6*S>I\,V11AW85D_YL? >UG@@0
MW<$/FR#]D&71<TRNEL[VE0B3N7)2@L85=[^SH!_+-SUTW2K&Z5!7LN#/EY,<
M>E;\^R\;]LFG+ U+7="K6>K23.&C<;2?9\5,$7$KGGX_<"SJ<;5^-2:Y4]3'
M73\=.V,H'X.9\G* I/7M?]#IH\?(H_ XWI ]P+,U1/LDK/DUX*[19IAC-LV=
M.5V6#/A/M%E"[_IXQU)M?$BTSNC/]\5NE\0 NN.8'#;S=(I+4KIFMFE?2PM\
M=;DYEM+VP=\N$G.U2H<I6_.3[WL9=[FO0@?J>*.]ZVM^#_Y<V<BE9\W! 0?-
M* [2X,I6?72W'.S!GSD'^_2L.<CWWHSDH$?FO2"^L5C&=\F,OC1XVW<#*,S6
M5ATB:\U+OGMF1) *"1.]A6 ;%UN'C[P-H/.T1MMTJSG$=[;H<><.( "?P++,
MXGIL1/.ZVVU#.,R3=X-4K=_:^?X6/59ZLS/9!N8<^<8U+=_;<+8<I.3R:[@)
MTC6XB%<K@#5T"- RI='I214.['HG"C&:+8L5B%[SWH97AUY%R_2.ZS3'\)$[
MYS8+]GP#G9B4K%G']]'H;]H\(#7>+@.8QNG:Y2G9 3SC+=@E8<VN 1>,-L-*
MT5CD944^6O,Q6SZG *+EZC: +E^5)%"9[SZ4H7/-YZ%(&OU+(ZFZF"7X[^M:
M$;B],;+@S_7&SZ5GS4+CGIJZ/9W3O3A?)5J3J^;'@!MFK.HDR;#N?3!,X#-]
M?6<3LF;=H-=EK ^M$65Z48 KO*1N/SGG/C4A2O.\]*O0O&;]H#OGKV_:N6?'
M7+XQ.6EENOYAF=^TR-I*2],-J6O-[SP/C0=_E,U/&\$X-/5+>#[W@8"-78N^
M(I X?TSS&2=#>$/2^JSNWF\:,#V;"4K,:-%*F-JEQX]&A5QG_&C"G!,_6K02
M)EKINQ+Q"DAVWP7>BTE&8_NJ&MI.W8=\+'Q?;14UVB!!A>E6^L]E9-]BJ#<!
M_!60$ABNF<A%8%;\XY-1F&FE;_EL=T$,"6ZDL!XV K-U&B-B<96[?TD+[DTH
MH<00OG-2QL9X),P)TSQ8R_J"6'(7T193DJPECY^ :RT@PF-./!?2U%+J6"E1
M1)[(%?!0RG(18N!N?2EB3/SZ*978*4%68;;8J&"6Y>J(PG)US'+" O;W#*__
M)[R$ N)_EP4X07250=JAI70#W8!\0[K*NSK/S:$\+PO (*N$V6O: E7ZF$"Y
M,F<RT88ZH[W?(9>U#+0*#KE*N]/2+:"S\?VT22633#;V-#TCC93 0_#5P_EY
MA#TK9<@DGLU$LA([#*8RLLJZJP76K-6!G:4NLZPED)F312M'78FLM+%;T<,.
M]/L&J+GK[&6-'6%,(L1%$IT9F1RR!)9((QN_W]HH^ YZ4<5K-C:-,L$E,M T
M>4\ZQH=UI%RS?YTS+O,QF(\F'J"B./5,CW$7<5+DQR!'+ZP;PF$VFW&0D!)9
M:+KI%.T&IV5W26><8T.?DXW*H9]$JIEFZ8KHEP)A>'[Y-HS%K.Z, H**,]*J
MI9H+8Z*@-UF" :/20?> Z?4^@]_RHYA&5]8^IUDBZ#HM(6),RS9:[ARX$KB,
MJ-'+G;UJ;.=]E<UFI39V3G!\<AT(!A2)0<?Y+*)J/U *VY58;B\3.NR';U#9
M\,R":X9T1,Y2DHNX7%6!J5]CEV%53/"6S!%F5P559K=V0C?8BDU,"3^H*>Y=
M5+TMO/'OHMD>P\[AUFODP6;AL&B+.%<34AC$:)9S_WX[#=Y99ES=+<8>YP@A
MQ:7L3=0QN&E964ZK&=RT&Z;XL2-%2HA?R:"FG$RC">,5#1RS38S)G+@H05=[
MFZ]NO^68@QVPOJ]O:@SKTDS<XT&;/8P<;,><XF/@U4FIQK$!,EKJ[R!=#<&7
MZI3$RZ<S4U.-RE)<(E[93"4#YRQF@I\3)]GTD^@6H?D,2%\:';.I!70^S&G3
M2AC@:[CL@&,>#6,Q+ZM%0%&)R-Y3 0*]=&<U#V>G_H#->+_?79"1-E-8 4=F
M')!EV^3+KP"&,<+62WVY:/.&VV^9,7 RE5%D2,Q?OM&$SA+,-4)%?<\^#W9Q
M'B2? $:4_LY,!.+276JJ>:D@%1K92].\3D-(RJA>@/+_'S8P*]:;OH0X/E54
M\9I(J0TU-:=,?'LYG^4C.?6"76708Q%5(2*SY+28O/9Z\^'#- 0@HEEF),":
MQ@&2R.KE:@*!EZJHS=:@4>:!^+(WX@&(GB]5-1^2\N+V#:@'?5Y'MY"6<GF;
M=NHBD9[(5TGVS TE4I&: KU>!\'N2* >/1@"LPK0(^5%-9K*RQN0Y*C^A9IX
M5# & &A<@GNSB6)_1J%Z#.AQ$LXCY@6131X)Q@?J:'MG889V@&0U@P5I/A12
MM_ BC5I_(MW=ZW ^EV$\NOC98KLPT&=8QGNN73WBB\-^M-]I"*#(_3-,$^P$
M(GQ&;HO>6TR+JE:#$AJ0'$;\,#CH-<['(O_DPG]T[P+@*<X*E.SO?>Q##GB?
M5SJV1NI:[VRJG7S&IO@A9]L,.HC-<Z%]:;\ .PA(U8URER^V&<QC1/_INJB1
M,F(^?-2J+%6GMJ6:D&U$NH6VG@!$0;)<R17@\B02(Y'V<AL?)R]CV2035';R
MK$Z+YP-NU,&7$B.,;%7P<>I!$^$QP]W+(*:KIPZR_0'Z@->%ENE%C'89U1O>
M.K[K83>_ UZ:[D8+5):/KBQ,RNKV6Q"@ E:NX.OT"92?7:>'&OHL<> ^6QL
M-.'=;(Z8$G%M9G8[,0 PY 1XN&&),9G?+F;24_CZ8>8Z5KZ9UV_HURF-.C^4
MT6STKO!V+Y/'<&ZFEQ+U9:I.FKFK=>(IKDD<>@2JHIC82'2:":Z#VX2U_4BB
M2Y2XM"H#:40EM,+'V\5<$KOYG032=+>642[24$VQ/.JGR1P.'/3\1+V;/AUX
MM)<IW6E'&H@]FN()7)8O5\%I?AI 0&-K53P;6#QD#(/TT/3@$-KS)8._8B.E
MBK?UP7X]1&>G"S3Y(:XQJEUUI J.HC?4S]0/[+.?@20Z<] %LI25*"]JC+5]
MC41>>V$<5F%RV#@A_T<B_9Z"Q*DSW@RV\U (ACACKS:I%(+WFPSF.8#;"[ C
M?31)[X6C4VMBDB-"=J8:18,KXK*HNC$:!0PW 2I;<V!-E^]ODR#-,7PBM;3-
MVGD2(!2O8A M4(F4I[8YXU&=A6/"!$MD"K&.%YF&B![,H<9OT^BX8PC=.803
M&6*,1%%8$[)3I8A<3UMDU+&<F9+18H1TN5G=\D7DV*0NEEU.3T[:0;*%;*MC
MU%3.*!NXS\'*L<*S.IK)D(^U?.@]"G[G_7:17P4Q_"E(BCJ#E1\"QWTJUYU]
MLJ?+2*+5++31U*BEPEH-0J>B#?0QG/Y+Z@CJUT)AIDK#X%7+)_<ET9F#>I>E
M;,W9 9>GAL9N9!TS"DW@>U%=8""M:TZ0,+PJP%I:<X^$,ETV&J)BS5OSI>^:
MJ(EJVCA*X^=4R)DD?^4)6;/06'F&2K3*N.6^T%39Y ]9G7IT"V#<O<?Q=Z3J
MM)/?@LITJAEFOE1>;93?!G'4/+ K^\[+@:F"TW1YK4GCFM4#'CO=.I5E5L%R
M]9$XFS_&P6.<4*!3X;L^AC,PD_6I7TL$WPVGKJJKZWFVHB\.#P!NSR&(XISV
M;B=W>%ES26*B*3_KR5.CYH*%D#^&5>US&TJB,P?-*TO9.L_*>!1?/XZ0_1Y<
M]G^^7*U F!^+4-_A559A)0X/7U,8ST% #/*GEB'C50XF$-O!#M:8.&\%D1??
MFBP.>D>:\66K I6^KRHS]S<0?8GSS7D&L?FWR]((JYW6\;^7/65UIY_P&]18
MPM5L---\H38$UC%IODB(I%Q-ES-XJAME>,4U=0T%ME7E8;E9<Y(D'IA@\I(^
MM/B:VB;30C^G.WS?;%;>E15DULCI&_',]=:$'<S%5*<M/5JB)^*[(2%:'[,@
M13=!!$B$,'7AW :P>[<3/D%P^6$*VN2WB#&RUFPWG;39*GQ:QWLOGU-\0]S$
MN\8#]WWQB.(H#IPF9.AA-P<S79/NM1@8ZFI="NE-D1=!0M],ZGO <K6$V$0)
MX)[5UYJ[KV5FFNQK@P(Q:C8X[$G] 6#9.";#]*K&ZG>6R:EJ*GN"?=TE04J^
MWU^G^'ZX+>L[==IW.^@S(X_3B)>"BQ@1MA40<[@B;PM"5N0'L^8@.JB!CS."
MC,?4:UEN#1EK:TL#G)*IN6EVQ]['^-ZWBD,2X5S&'.(S_39+XK!QA#+VL0EQ
M/API1\B7V*; ],*,<+V=E1$SM*<9L&KR^][$DJAYW;6Z\L3?NK(,F<A>_7L1
MK4M%4B\U2+%]CHKMCO8&(.YW3-D-Z3F\"TJ/0[;"_V;H(D/G=FFC2&*[Z&%+
MJNH=4&V$/#)U)EM/<&T_QTCIF;IND'S _#W#:/PZ*=(=L?)R;?8IND?SWKD
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MBL3 LK#QO;L44?3A?3<A* ,!RHH\<K\YR]=QTS9D.:OS@ZP#UER<6*/*[QU
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M-'UV6+5+V4Y2A*0Q?DEZ2(%/M8-+&/I@P_DQE6(Q(_%\2:(C6Q;FW:!+U)+
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MQ5@]E0J:F6(JW<G&^+ V&<QS +>7VUV2[0$X RFF;XZH1@X2AXY)(2:3JQ/
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M*EBWWT@S?\)U#0L6< \/G2J*J=MHA$4^:R5GZ&G]CG5:.T^E%R#B,Y]>]C+
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M28@7CU%&"^9:V!7Z68#6T9B$U3T)X=+-/M367CW+IH_WH\*F> !P^TY%K*S
MGT; W3B!LL,8LS[7;G+F$D9Q&L#]T?DK>_$;GF/F_!002.SPM!7!T?:CM=RS
MJ,H]JM9H-U!C"(]E"P_]> P-&+J*M0ZNZ\8!E?-+HBZ89 +&_@BV'?>&B%86
M^_0,X=]&OX'<==I7O4?%[/,ATAC^_GUL(R7+ 8LM&/NMD-P*JW,2%9@D(!K&
M25&EZ$"8QA%L5.5H$=I>/VYY6<4V70Q%J$Y4%<GC/@6'@P=%I,!<&\8\8W-4
MR!(+T)8:D@?QTNP>/3J[BY$8E%1)?">KBE3P_UU:18HLMI!TPM@GU7W;EBZ2
MFWX2+DM;FDB2PD9+^^N(IQ2>$]4^\KC_3@TA!>9*]3FPX4$C'4:RU7V0 -)H
M^@/,$+J%V2K.38=QW8$GD!842@FS_D$"%\VJZ49!ZKK2#""A4BC=&#A+U@*G
M.KH-Z6A&E)GB@8%ZZ)IGRGF0@W4&8Z*L[@"-1+T-(&G%X+1$N@ -6Y<;R:KI
MIC=;MR7T, O$!=2-\]YQ374A(O8[LP]66)?;)+)<E:[";HFM#@NSRS#6<ZUV
M&[R5K>>N<>XOML%O67H% &*UA>:>W[UAGOM#R:J>XV';7[C1'-\2R&T!PPTQ
MJ#]D6:1&8>90KSV;U&G,7KXE2;['?\ 7'24BM\?X;<ZI3M[.BJW4B+J"]!ZI
M1-7VF+E1M;-BB>KGZE0EUMUR17?%?2;=2*,[RIN+WNXUJ$<<V= $&XZ'1131
M<:1*S"J#6QHAEF?YIL0^6Y6KRN!'O$+3S@@EX)HX:SHMO*"FZ]QPB*R*$\0Y
M6FZ=)3ZEMV'G.>>]:^=+5=HJQ=H+W.?XA*-YB!_)M]1-W/.[\.N"#<YA,3)%
MTF_B:Q\W.YX/4MFP:T4 L[1@6+X5=0ZWYO+B'E$08PE^M&ECITRQ#.RN<V0\
M9[SX-^PQ1\JWH=._9@U(^^#*YJ\S397N,<-S^ S44U()S48T@T2QU*RNEY.C
M=D7GC/;W6*M)?"X9[&2BWX$U*022P3TYW0!"]  D13/QN0>U]H/2E#/<'FHD
MDPE0'5=^XQ:"$'\0AT%RGQ=1K,PN\4S>7 C:+)*@CM!EH^&P&<$']EB/<4V:
MM.?00"JK2I7<&[ E-3OVF,]7V&(GVY(@J$;WX4GF)OHBFEB("9SUX] H8G-?
MAX;+/_\NGBS&64',-XN!@#(=NG:.[XL8'Q7X6Z0LR1(3S=#.D2%/Q9C_,FS=
MG!4H3@'QLAPJ9FF9HN)Y9K<S)$A3,>5[6S>%D;<"S@W@K__]]>M7_^?+S4]_
M_K__Y^=P5WS]9_JG[Z/?OGM:_W.??KXHGC]\![__[L?WOWQ^V*/DNZ?PM[?)
MW_,W^3WX^V_???OKUW?AQ_SMOZZNWM__^.;IZ]GY/]\^1??PG]=/T=OMV3I]
M^N7LUP]ODZ+8Y?_ZZ2%[F][!#V\1N+@*_OQA]6%_]J^K#]N[G_\K_O+3%?@Y
M>/OQS=/B^?G/SU_>?'>__Y)]OBG>79_?_NW397CWM^3]%Y0L?_SSK__SP^W?
MGL-XG15OW^^7\;=WB_5^\>/Y;S]B8<CA3^<_O_UP_T=T\>WR\>ON^3^7O_UG
M^_TO[\)__?''?Q28T'?A^\W-3_?7%X\W\6]!]N5?;]+M;W_[1W*V^^<_X-G/
M/^W0KG@.O@O>[1_^^5WZ,_IEM_GGPW<?SK_;+/>WT?KM/[]F/_]C^6Z]O?O3
MW?_\U_KVQ]W9[;>/_[JZ2<_AU;_.P)M5N'___?5OSU=_NRR6OWW_CQ]^^+^O
MSN_O7K^>GR[B"Y_8EZHNZLO5*@[!#<8D!Z2[ [@C4<YC[L0J,\Y.)2F1J^:7
MZ;B.LC%9!JG3BCH;TZC6E5HL4YC05RZ2)K]42%6SRW"MFT\@/]^0I('K]%#&
M8[DZM-G^& >/I)03B;\ *%ZGQ ^YR ^?/FQ@5JPWY8/,DC[(*/'6&OC9[5U[
MC*@E9R@D1J]V9D@1)J68+N+5"D" 50[""U$2 >$T,]O48K+4#!G,4M5O0U5K
MCNK5X"&K"T^K:5W)V69XGY(F5,THDSX:LC,!NL*KN,-('ZIRMQMZ'K;] G^L
MR+@1 &:G-,<0LV;N@(=(:QN6X&KA:O0J^T@Z#*KQ4FZNF2E(20+5_#'L:VI#
MI[)3UQ1<D/#([3:FKI8QC!+/.FN621"M9MZ@/\I4K?L:+=GZBJ)9/+J_IQ&#
M)R2SI?9J]R#!?U@+BL&WN6PQ>TD2'7^GIF]I4>><.'9")SA_NPO2/2ISY%>E
M3;!<53\OPC K2+[\5087^>5_BCC?8UM<]DU2:^[?KT2,XHCAA)BC=%;'5WGX
M.5,?;:B_7YG@\L%6G[,*#,E+<9?!W@+JR[R;'*LK'LBT3K>1#526\*DJ]I+$
M)K( TO< 4W8#B#XJ<KK8C"JI6U#6+S:=%]2<>Q&AT?AIY@!91T/7K+>$F$IN
MCU44W.;QN)*VMAO&'O_\%4>Y SG,J',"V["+W2Z)R]LR#<EN_ G?E^H;M=.J
M*;KX>2ZGXF*[MT\C;49:J[U208I87B:K$M,":]-Y+UE;9>0>Z_*Y3569# D3
M_'-84H7!0:_U4RSR3ZZ,BA[_;B%XBK,")?M['_N0 ][]O4&DD=K\X5'-<+[>
M</-L=^<K&[I'][!+TT[(!(L=*,K[)L&4/#6<8WLO3@O2)@;;%U6D3)[#^!$O
M"I_Y#QDM$1+&._RW=%UZE*Y3A/&@CQPT_.EA$Z2M+C.4/-=IW8$9#SP+4!Q>
M!C#%_XTJ,AVG<:@;)KAX?^XK/S(_2298.PTOXJ2@?OK5BK[$+I*DB7W:T0"'
MWC2MU3C;(&:P]1FXXD>F#7'9FIM^$?U2( S?[Z$_C,7O3VH$7#%<;\NW!J9[
M!$2_5RM N'QO69B_)S- +(0R?4XLO:E42T_7]Z7;5=@"4=<D061-!7E [H'D
MO'Q8M3FDT-$L3=.;<8#<&H\;VM/;N^KVWBYT.=_(?M$FHK\7AAH?I\\&+:"6
M7$Z23P%C!;\;A=2DIH3O?B37')=)[X"=@/.>);YLEDA7]C+!$8?N> 9/O+KC
M53DB6ZI<_4R[@,6Z$3VJ%$[-'NNY9CE[UQ_/'\Z"K=2R6Z;X-T#+]:JEO_;&
M^7QR$%&4L4H[LGJ)[568!DE=%UF2FKUAGB54UW+J+]]6;XH* KE,$;969:,=
M/IXRP?O< ^H\$U/3EIOX>KL+8D@P(U?2.Q!FZS2FEU=ZLR5W;0@VY*!Z<AUL
MJX&:U^8,8]BNPP9+U>].L?=F-/"XB/G!S.XQOGB*-@;:E;@G %&0+%=\26PF
MHCMVW1M">G9GN2WFR01OZQPF50)A=8BY3N[B@)^K*<"CIK#*H(;2?PB^,KG%
MU>2- 3,[=/L+MM3;]_C0X.&%:6Y<89--IC:A)G>H7566#W#&GB;,&9]%+=()
MJQ2.8$^C0HY;'C4!SYU1+2(*RQ=:>F$\"Q*2.X:>XWS3[@$F>&K4.,I@D*(@
MI"^Y01KQ(<M@IYF691<'30>C#:14GBSMP;?X;,))R'(B9 UKQ1[K##R4ZFGX
M4YMJB<=4ZWO6>-_J4^=JRP^TI\[5%AE[ZERMRN ?P?XF2(,U/2UN 419FH)D
MN;I,\SC?+R'&A?-4;)'52DCYB?]5UWQMMJO1W5HV%[UBM+%VS&L^!EY=('I<
M'2"GZ6?R!JH%)++BV!G2ANHO&<F9*<\EN+V4YD]9&GIA;@^PQPQ+#PSNT]W6
M^WTE2CX\90S0O\==S/*OB2JZVW"Q-2F@ZF;3Z)M4P5VVX'[IP5T\DH*!H6R
M@/*TFKZPX7*8DL@*)O&65Z/+&]EJH?9NBV6P2X PHB&(=SFJXZ 0J?]</H>B
MZ_3O&:;)3QBC O]PG@0(Q:L81 M4UHB.T_6"%*CP\'!@&'=_^G2,#%GFIZ0A
M;.49 Z1X;([RC'W],IDWU>5##?N! UM;TTI/K+^OV1.34"BL4&C2W?TF@SD6
MB.WE=I=D>P!JK#S[#.1P])E"K"\A,@X%21Z9/1#*A8D1.OZ9],V3%'SE::>@
MA'58JTM%6U<5&0$+('AL].>>U.;OXN;Q2NMRS_=8XO&.<^B-E*U()=M#1Q!Z
M[K[E'KQCCMU&YZ:')DCMXU8XH7;,3*\K"NV>PF@IY3VT?SRF$[A<R4H&JXKR
M*"89K]+5;%U'SX$L2;)G:G9O8GS_H[EO<4(:VZ6RT1ZRLTW#=%+AI2*U++Z]
ME:&2J$HM2"]BM,O*./ #<J3_8-F$#E^FJA4V_NHX,G44JI,X;_4VO0E&"8]=
M1V=NCG&,\7%+]9?Q@[<SOR0:FF%ZAH#I76]& 5>)NS, R&'1$!MBT-3:XXD^
M/F+N5%A$)Q;.W(8YE1@YE1AAU\WPQY/??8F15N);<P<?:ZR17/CG^'ABN,@H
M%&#BL[^JZ2-2B0.6MN0I2=GC-<>F2%E)8+:@?-IX7H =!&%,7:&NTYG%F+Q,
MY2/! 5]W84$:&_\B/)5\+=4;\BF1[93(=DID.R6RG1+9#(C#*9'ME,AV2F2;
M:B+;*9-)F9?C,IDLZ-Y3,N*,DA&'-O$ID6U.*3"G1+:7RN!3(MOO@,GS2V0;
M<+0Y<2<-H^C.UZ:(A^*KC%VT+'O<%'"PMMG-^=ST!&Z4WTV%B:-];R?/VY0\
M;^K[U[SW[>1\.SG?3LZWE^U\ZRNH?H*Q4B\<J:D\%W15\;"H$,A20,Y@*0!G
MNVX8"Y\Y)$Z-.6FVV//$G$HT3*5$@R?)\U73P6=)AZ' GE-1AU-1!^-[^U34
MX534X534X534X7=1U*&=$8]-F<,OC2<)\3D\KLQ#&XD%&PG]H@]JTQLQT$E"
M,?X_TEON"9MG+K.]AW!PWX[+#*\Y5C"+RK;2U>JC^@+L,H3U0].L]L5J):2F
M85*9X+\:+ZQ%O'S,\(4.+V 1/='+GS.V]P!/XN TP=D^28TW6CT"PQ?R"-"+
M]!,YW]SQKP?XQ?"O3U*9EJH:QL.'[ G E!;_*'*L#AB^+*YEP!X[<QX,DL52
MR]$JS-3]!NH!GCGSAD@J[CBJM8$:Y6VNTP[FDOMH<(HIW/''[J9A&@D[E^J>
M2X/<<%<8;A)EW@QL*1[C!AN;JF^H<PBB."?^>+J'93=1;]C,51F/&$9;E99
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MWX03"JPL7Z%,^\$I9F@MRQ#&1F^U&@P$V[C8*K.!.WS.FI]+$L/9PD=3Z@J
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MW2'M6RN0SBOJ#+K@<TA+N--<EF.R$;07I#>&*HOD?E!XDL2RUI2E7F!OZ(-
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M'A7W'Y+C#(K;*RXA$,IUO:U3J*/K UX%#&Y&<_JZ0G[/PG.T+V.5M4%"UA4
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M-<IIQ9U%[V]'-AI&U0T>A<JL4CM4)XXHV S/Q2 : #=%"R!&.:<-&G'5WCR
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MO4%*M\&KRO.)G6V"G$.8U;F@*OU >HGH\8:@X8@&8OM*9BI=/65PR#WDAFW
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M$&9+((NN072U=!%J@Y)5AL*KZNQ1YEQ%G'4JMG3\2B"E9E58@HA+%2DIE(W
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M'QWLPZN@_ZC@8%V$,<TUF1WBM1<\W00A"\8RFZI4VQPH&:D*1T/U%5:5F_6
MVX>N;[M[RZN%>H E((F(64\QXIY8^\V(/2)&RSVVW;5+I199]\D*G?$FQ)@E
M,N5/RC>N;Q&\,24#L^::1NOZ]  J4)?XKG"WR4&XDF&G8*1J.=]>L-<A^I-7
MU7#L.\,H@ED"Q'Q^?QM(S;WP@C5Z2@)7!/4O!U/^DD?O]MJ7-4QT;A',O@9%
ME2Z9 Z7-L=T5!1BD(E?"<%V'RX^C^YYX9\6'T(V?KVL%0824+$TQFWQ3W%I
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MI'UK@-J)=<?W69=/U?+P+&1/>K/UBK[['8P''S7!8#[XJ &:-A."UND6?L)
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M+/NA=[TVES+=&Y> +ZDFP0BUXFH\<3" TFI-C-%Z\([EUCK66N,66C.M! A
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M"HVCF<A^5^0[6E0'\+]54%&3O4Z\H65H9<X7H+ "CB]85I<<GPXRSDXN\(9
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M-!W<#^WHN"IZ8JL7M8+<VR5?HY+IR0H&S1_P!&#PJ.*SGTH!C;Q8R$[ 0[8
MT$R>G)/0U'.+'<\V5*FE4^5ED<7U;SXET5.2#N9.6795IU8/M\$TOTR;M>>R
M9[P(,; I1A 3^][1).W''&Y)J ()6:Q0.6E9N$+0'XT<;_]/5WMXU1KV^, 7
M1#XPK\XDBS_-1@KQH(B;_=XD119 P:%93) OP7.<S4BSZ.,QQ!\SWNA'453H
MR>+EOBJ9K!*SAT+OH##%XA!M-8N#JEW$KN"\^42[Z<1\+ U#Y!A@LA<Q$0+8
M-!AUE81!^@M-GC=0!)!MS^B9?OA&BU524A 96D8.?T^(^4UN*X2P&[[*+Y-(
M?)IIA^+;7*S36Y/(6?,X^">AGWL;G9!%J/+=8Q'%]$[4DG/[95M;I8)IJ@8=
M>C2;#1\W"PVH8]_T7TJZWC-9< VAMD)&K$2%GWOPQWI&XW3\G 65T5NP-I.L
MU[6ZKT3O2A4]*GA(V6QN>G]RN#D]EJQ8M_^^*)L8ZU(4*N&[T_]F;Q]3&0I1
MRDHMG<.*Q%M/+&TL'44DG /]DL0TB_^_A+H3X9JT>%%WC%OQ5_#<QG()PFO0
M,OVHMKJ(XD@MPYW1CHMKKM,(8&)CCSXX9M5]>F /]6K/R,6?<^Y,6M/BFO((
MSJ6LP,?_YE&5,F;K@8#$%Y1<J>223/J60;2=NGZH?!I%  ,C)Q PN+#S@0>/
M/531;W23IS$MRGL(>+*Q4PR'2/UZ/'L5LV?,HN$6%/H,<>**<L9$]'-33[J=
M0GYF8$"33B^#S/4"X#-I7V#'RL"3 0J$/Q#?1*PD+W:QS3/?ZTW6(:5R.F;8
MOQD% ^T=J"+8V)16N%RK+CO#-25JA9O]_%7.0J5\%P43U<UHXEQ 4J3Z1\ZD
M)S"PNS4G)8"]U,.5KB2+DX)"[R65-7.ZDAGY8/A*PM0P(FOMU^J9V 5/!_)U
MDZPV;(#X?%(V@#(HUNE^5>T!"MFA.P+),LECD1ND+:I]3S8W,'KIH+*V (#K
M2 D,Y::RJ&"B*7U)6I4Z(=HMR?;YODP//-:$ 1VS&5R7A$$%K?9%!J50-)J\
ML$M%P<E72K844Q;J[Q/3QC;O):2-7=$B8QHL?:'9WGZ!ZU>)F,$8PJ<@6VVZ
M")CH;4(Q^(,)KMS;J/B-NNL8PS"RY>-F49^[ W:?O$:\,!1F+1QC;&NK]IU[
M8Q(/40C?0\=,?@O6*%M<PM)6VF1 U!1F= O8]PP3F(PQ8NGDD8,N"**D!ICF
MB7!>38(QRXZ]:"8'14/"R84>LK.A_=!1^3C*9C<79G@=#2L54!X32E7PKY45
ME-8!TYC740.I@;Q=-,*_"0DTL&)P#)=Z;8<1MLW::[X,65-T>:B/CX'L-J3#
MNX1^!ATIXV4%]M4F+YR!=LU@$C6C$3>W$?H^O1U(!M_P7AWD1-\XU1,.>4L/
M-%:S]5,+O9-O,L;6*+W*(;ZJE,&NULM$C@:[@APNS!ZX;FDS#GV:NW!%D%4D
M.,-JE:+Z3"SL/;BME#:V!@Y-Y+HW]$"WP%I5TCIA]UL&8I"[@X&)W$8D<<E]
M%R6>NJE.\!V;-1=R P9.8C<H8DC3+4 .[@M$)_"A5TX9F<H'VR5BQ@_IG>P"
M,RQZ&\AN;+<P ^J[Y.YAU)$X4E&VL@+F.7+P08Q4Q&=#T;=_%W83V<WXH1(;
M8O(&R0S>)>0[O('63M@&%Y2'LBE,MTGHBVSB_3$IRNHV2=G?\LRS&ZG6:'V=
MIVG^532AJE<5FCY;EVS5PNC;WP-Y$^.\:8;+4:>@V8S#;V[4A=E)<\P6!@T8
M']46U_; X(&Q=9K0CD[GP!B."B)WG$B[F.9!K?#6,PT\ABVW4,N0N/$7'D2>
ME=H*\V!7!RTGAXPD0#Q@-UD[%78T3Y*LFT&,Z<BR(^;BBID(B%PIKQV2EY45
M4-/YS2R(S^%W45Q#$$69+LL]E%"K.Z/SIL!K'B[%&]7[/2V)7*;=$E[T41:+
MD3VLABV #6%KX)0?@7"T$PG;<EU#YXZ<?;2RJA?YC\F>'CYVMEA0QSQ*TODL
M<W=OLGM:0HR>'E)SDRW6ZR1-7%JEQJ96TC.1-4W@O2G$TOV'*%++X^JCDRCB
M8O9XRB*(>4/0+E=5_D2+\W?G[^5KFSW?0X2J+?^@$_!>[P29(]_>"')U LLK
M@80IQ@5\ -E?-9DP$[;$ )&1[VL+T!Q J'9<5S@^>CL4<LE^I>E9;H$V!2;P
MW41"#*O($)P/&YI"F17^W[WUQ1[[#)2P+,0"R'7GSN\.&28PW$A(M./=@?,S
MK61Y#QDYY>)SG\F\LS%_W?F?^P%B6#P=0M/,1S_BA-<V;>57/%Q=CBHUI:7'
M. [#W/A9^.5#%"Q1VPA<>23+WMCZPL^(:^4DMO4H$_R8_1<]W$89^[YTI99Y
MEM%4+W_;_/DCI5;QI]NO5ZLD7.7D-WH@VWH=8*?X#KR3/",N+[;<T-V,65/4
ML,2Q=.DS?1IE4=[(3S0JN<GW9LN$E!=WT[MZ,$FTT8BL,D+?YX<#R>"G[E-2
MJE((SA#')@XLY3/J-XRG=[)C)'Z!^I!U<3%0WHAM>*+GV?,C+;;#KU&_YDJ:
M0P%;-AF7U#T,#,2V8(ERL=SNJWV4<LZK%'NW/UI,D/*VJB" [YJVXM&G_P#*
M&(*9 :1NFIJ?,V=KY$X_A0_3Q>:!K!?3S!3"8)^P+#%X.L)CD]UF$\BRCDU*
MYO#K$C:8I5M-(%1L(*_((*03U#O/C7V?E3[4PN2B!HRL?P'5R&Y$R1'. AG7
MN&@8X%ESI4X3I,W"4+-/M,:+51V& XT*Q+OT&$+8V3V=K#/9##(?\K0;0?7J
MD/4^YLE]+\R].#^"AL&E3P.XY1784-/TU%Q?J67GS7=?]+U8/XZ6X?V/+9!+
M[7$Z+FDVZU;=TMYV7(.T!\(#C'51">/27JK6RU"C[8K)1X=U7GR-BKA\C+ZY
MU9JV&,W=!W4K:RA;QXYLLQRIHF\D*M5S7=!=7O"1<3MT(#A+/0C09ZDWU5!8
MVA+Q>6OEPEZ98=DI5!+)\;@'S8R#@1$.7!%\L:/*QS0OW6"Q&&P&6.M@N.O"
MS(#X4#49CJ,KK:9[!&H!4\[%3[<91,V3,WUJH%C0VK#=186SM%B7/;NHF$6)
M,3,60YQH8XM^1SWD]BK=]@NJ9+,0Y>X^"D-4;]#$V?#C6M?<M<1AOZ8T"%SP
M;4 SV&L&G1\>SORE;] %/B.<;GL?;WUH=DB-]F->W!5TF^P]O%ER"B\JOQ.3
MYA-0X<"GSY!!Y/$8,IH;;DY@\<&?"0X.!&9 #4'?Z#_P>+@L*QY/27@F#:-J
MX)<O?3 4<!TX<<=.[6'7]]G+IV?^/>O&$\'-Y3&$Q&:ZZKCT0LME<0WG<26J
MAO.&2W<%V,FJPQUC=<50@1X).Y=)''9!W;_J!>RAT%&E6546&^=%S<5[*#[P
MAD!GIXKO$JH^@FE4. &-W)OD*,)CO+,%_5CG]S%$^%;VO-AYM)3(>WRK)3ZB
M\M>$CH%C=JR#&XU:L+C#1MKTETX*._61R6^+"K$BC"#D%!2*D2WB%W!S^;D9
M=F(.B<0D3+FE!;V1T#WL,&C,KHFAF\4:>8E 5 U<$TU[V*#8#U194=[2J$X;
M8M"]\+3M-04/]=A2*:JLJFSVI*5C[<3"[$>Q,BJ#/# W,<Z;8"C/<!NZ3O80
M=+B5O7PRE4@$" Q5VN[>7%WV&E+M>-MA^2T](XOOA'DD91U)K.&],8GZ6->
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MIE7!\"1(R Z]6A;70_*<)>MD%675AQ>>JK4O1'_7>[ICFB3XMVB1Y'&KI>5
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MZ"M$[Q"CIOQ1[4L%8\D4NET<?ZWDA>I76T#&TZ[$G#?=-Q\YF-^.C^59'R)
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M\O<I3 &6)3%/6I_X3,P+RHW3@!' 0@.DG'@P/6=57B2TY/W>L]+.%-WO+>>
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MR!",*9=YMB]%15D5.& /X&5#9:E<H@:CTMX ?)_>5@S#UI&F,6-XMT/C<,4
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M.I:GV!MCB^]X),6"FH?_BQYNHRP2%378@2[S+*.I7KJKY[RT\94M1;;U6F#
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M> \V_?J3O?BOSBNEY<N!>+"YX[V61:JS!)P2XDZW'EREOX3;_N!XZ\%0_W-
M92SWN?7 :O\8/*31=,'UL:?\%E!*%<ZF'I#M'P/CLN*"ZB)1]A&HRU%V2?6
MDGTR7"0KW\A"-JI?0B)-YJ?J =CR)>CUKO17]<#L_![6%LP?/?1 *__M "\X
M*L]+\S[56 +N'E&Z87K =GT.R9%&#I@>^#9+0AZIYJSI 2W_"!*LAN.FJ3H5
MGP%>U=J>FO8]9+0<K+(H/ X]6&M_#?L^N-B09>J3<'5&=A'AAA9#"8U//7^1
M"CPP&;E+(H^N-TR5!UP_T7C^*+RW3S%9I?X5767W9*=^@]P+U!<Z '9P'?3/
M<OQD(,)470E]P&K?#01=FT>A#VOK*H!:Y+CCA4>CGSP_)>)=^>AP& +>OLQ
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MH%P'_1B[]F#:Q53V5?I^_WSI[2X,LK/EE1E?J,O4:>GVN%>#IA*HIU++$0E
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MK&2$JRAX]L3L;W-%'HD?E_*&_L'\/X;(3=?P/^@J^U8P4%[ AM)#]4K\=@*
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MQ]8Y N[P,:ZV\3@MV Z:MB$2W3N1'<*]852G\60I+$<GZ'R:09* "[U3:G%
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M*:=&!EA*%JA$WFV(SV=PBG^FVK4&ILM.4-.:HPXJ=&L[IF41\3S ,Y+]_V6
M;Y^:P(0=%.EW&QMA'RI<#*H);L-4@'<>1:%VEKKIJOAQA$%401UW<"4JP.I^
MODA"QI6,DM_FP?5@+8"'HK=Z@^=X!;2@,V>!/^-<!C+GP.&8+J6W-3D6Z$9I
M3NCO8(;7N\O$?O+B4\]?I#XOP1)/9\F&5)-#Q<- 1#E77X=+TA'4 $K2_MR
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MN,6GO)K&]X?3;-H[H$]\<*#=]-$]NC2J%LX__[*CT41UG#[L+SK.B-*P25A
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MJT8G7*/G7L+):Z?=-4VJ;(J1D-K%WE+1S'$T@:KRK.5E/@Z+5]!S_N1#36G
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M[B:9US%<^&.V7%+^'>?A51AMQ2))R$>9\,X9X2J;9Q2*>49#M524 G$?WN=
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M"0Z B#GIFGBO?31:'5\_'%+%5!4,PRFKBH]'$0O60'KC4@49&&)34E1N3"5
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M0%=TX3%;]I%;.,LT8D*?;,@MV87LP,&:Z04:+B%#T?R5S0_C-.)/UG4 S@0
M]PT Y-%I=3_ 7GN8EXP8XM&HTL5J;>.. 8:[F(:>[=?'TM@@;"J29^R8 Z^\
MY248K7[-["/H+\'HEV#TD,'HC^3I-#0-0-<^PA]AHXW5^G'!8C,F./^!K%;Q
M";,>EV8#6)O?X3^QZJ-><FKX;.DIJ?4>YI/S0'_1:R;W^->>:2^=TH>3N(2E
MSIH,"U#C?^P-KWCC\'9EFTU%X+I"]0)Q2"4]9_E.'(@\QTW7*Y)^BI+K#$$/
M.2*PRFC*D4OCSDJ*CR<M+BJ$@(7EC1*="3%\6BY_@52""$&%RL&AXNDFF#\)
M@S3.PI)%KPY-"LB^Q,HJAB"%%!-(TX9>&A8/81>H>AI;A.%[Y6E<ISQ=72C@
MXNG:Z+U$_?UDC846E$ 5WIC*8+6P9+;X+:619=G:X>-)6PPJA("5VEBU:!1E
M0)I4J7TTY=NJ?G[ @4-&9%C^DL9)T3BR-!/1B"SMBTQ6J74A!VQ@D9%:>PK8
MMQNZ,_:"9%].682DF( ;960H25>4L\JQN;8F41J?3=@9:J( 9\+1:;AE>VV8
MC<B<@*LPCN?!,>U3.Z>E;8TIBTT'=@ '(T&76F9GGJW8/N8Y+=8>7#ESX&,8
M>.)28-N6H-'*;AG0V>L!HGGVL@813!)B]-<;!-2&B " >U7.=D%\ >S/N2([
M6Y_@>$DNFL=SF?!B !+*0!93.:XUQC- .%KNBQZ0CO-@C(#"3R,PERP;1I'G
MRQ@]$*4/,?DM)85I9)2_H?AXJMA7X0(EI^:.^68>@_(BC,C"BTTIH_@:)9[=
MFRXJ5,"]JEJF*OA>'!^Z!.>OBF[30Y40X,P>ZG<[MN 3LR^P%"S7:: M,"!G
M@'8)@0:- ?(^CSM4 _8RM3D@G:2;(VM=0PK)\8=3]/N2C^] Z^KEX%M$M@!4
M[TL:_C33\._.;V9F%NOQ@ZF@LGQ&'/5X37_WC+!<^F J6"Z?$<?@OUO0.W8F
MLY*2VD<3*BFI'Q<E-?*:)N$I.];/ANQ=_6HZ/%X[+5R/ <O^F"(5R:5A==P1
M*WS4TXPJH<R>>I;5+#4H'-M&Y3W1]5R#<R544M@WUD@_"9,DW#(AYXL[=CAE
M>^,'8#NH($68A0GU?28U 4GZIQS?ASL<"C8V'KL,-3%E89=)2#<-C6_X/&Z?
M2M_?>[Z)P@4ARYA/,143&.I]XYWQ>#<D. E<5KD.56G00#)42:5E#(5/Q<YZ
M]UU[2W*R/P\2FNQ5O:3=A50,X1JKANC@#V/TP\^(-$X >!F$"$3\UD&((->E
M01VHR"ZUJP*M?SHI690?'JD18T1V'EW.EH^\MYHF"6H?(=F'UOBOGQEE9MIL
ML8B8\-4Z'NB+@?K[2<E""QIPAJ0=KT=CDD@_G10UY(?'&9)V&<2)Y_L"F*QO
M@3%!6I>8UA7>C@V,J6@%&!'9TG1K3!OEYY.[391X0*G(/-IZ%X3,@J40Z3AF
M"'1=NZ[:?[*>M1*A]E6?S4'B1C9$').$@909E&FTV'@Q.72Y-:K]U%AI4C>9
M%FK *C][Y)/$?'P%_[_SWU+ZZ/G\O)>K,[IBP+#_YE&<.X9J ?9\=4$#9K-2
MS[\)8]KLN3UP9ZI^D$[KP@6E$60YJQVC"7EP%TO+MYO:7=[$%USIJR'ILJ@<
M8ZM?R2;T&1"Q>.'0U.>JKZ<E@TH<P%6W6KYJ$W:DE'#!OPWWGL]S*-P];\LV
MGQ9ANS!9T!=BIH61SRD"HDS9UX=MF+N>&BM-RJ#20DU!-[Q&73=1*(X4!O/5
MH;-$$5VZ#'A)%5U2+]J[?&K4A&BZMZ4!U@L6 8@F6?-( 6IE;,N-1Y=%QSGQ
M"U$5QOY(:OZY8Q\(8"?K<L.0JN"Y_LW+[!@NTYUYH0M2QD,;#).ZB#316M#<
M(OK6+RA3?FE7\*S#E 85!%.U%UMP6E <J/D:8,>;SUX4>7Q 36=S&Q-&*U8U
MG,+4^,R8PVO',6D3(_W4\.&AMD:#8<Q N"IW><&X)55DY'POQS1$?Q;KK%3V
M5_%\-6.>^9+Z:<)$CS]-1:E(*'*:H:\!"E;B<9N$U')7-?")UX^G'3K':?U:
MP*#G*NL+B DC0%<(% SJ.+6\MBU^78 MM>KXLQ=1E;$Y(FVEOG ANF"89:M5
M<YMY_M9\=1,Q5R]A_\'V9^:D=A*;SEHCN4&D5K$F-N &Z!C'4CE$AW:['#2R
M2KFM^RF@VN-8NM=!\65T"*2! JSD:@;'Q0$.H]'ULB^13>>.9,_F0:'JMJTQ
MSEQ> 8L-S@_?CN*VZ$;Z\:PX*<['6_O\"XD6-,YRKYL3U><[4?'P_NV[[YU9
M1 8@843I=(AMAU_[I.NZQ=2_%JV >[XJSNOR=:@-C-%>;?J(M$_C;IK&P'&Y
MLW A#/U9L,Q2#2Z#51AMO7)B52-(9\)N;1N8#D_76<I8-RX)/:Q<6E 2TJO(
M0$P6?UB'CV_8YX+[^7\(H 7 K8M:V"J*]12!O_Z UD*"SN7/A&NX++83L61A
MFAOQ?.D,AMERR3 0DSC_#^XY=X3[NI'?L32*]M,1B0+K7:B!B=0:4ZP$1V>,
MKIM(S=4P+!%]3BR((\%"O_ 97_0DC9EVB./3D!U[D73&S[K1*U\1R:,RQ[("
M(< ]BD<J_^VW4LG+M.2VC!2G;(?(\R^9 ?+E1]*6N:2K<>LK(G*;SL5>5;<-
M=  &N,Q5+8-]R>$_(_$BHKN.G'P-;2M;<$R"H*2.'!5(\Y_+P'/5!6(CBH6P
M+C\34E1/CA'M.HKK+5E3;K,&R4=OVX\.T@4G(1MR5,#%PRQI<QDLPF@79MDT
MHH3EE,_(B_:GX1*"5.WK3XAR'8B":X_8SSO+_X\?YAV<8U99=4)$DR(%:91T
M&U3O!R'5^VF3ZCUDWX%^I#IE_SF/[L.G?I:=:DV<(%,O.I4Q C88NA>-;D+>
M'^'?= =T<TF7G92;)$<,6$^"WD*5W9^ $I4O.#VM=T %TO1H#A"7Z%E$O-[B
M4UEH"KY2]>1P+0%,*7#%?N/?;,* 9$W:>E&AL=A$5%<3"6"E\\82D04T;]@B
M81 0O[?W*EUP$MI*C@JTTOB& A4.V3RZB<)'VNABU^=.J2\\05.M@1O R=!V
M1#O?DFA-@_6'*'Q*-GR.M1= V 'R=:=P!;7B!:X6WCJV?>%[ZUX$JJXT#2FJ
MG1ZPM%V9Q/*W-QR"!R\F_%__'U!+ 0(4 Q0    ( !N 35JBL;Q5U-@- *IO
M@0 ;              "  0    !E83 R,S X,C$M9C1A,E]S8VES<&%R8RYH
M=&U02P$"% ,4    "  ;@$U:5BPZHC8^  !RW $ '@              @ $-
MV0T 96$P,C,P.#(Q,#%E>#$P+39?<V-I<W!A<F,N:'1M4$L! A0#%     @
M&X!-6C.M>?P[.0  ,YX! !X              ( !?Q<. &5A,#(S,#@R,3 Q
M97@Q,"TW7W-C:7-P87)C+FAT;5!+ 0(4 Q0    ( !N 35K"85:CL (  ((*
M   >              "  ?90#@!E83 R,S X,C$P,65X,C,M,5]S8VES<&%R
M8RYH=&U02P$"% ,4    "  ;@$U:F))\TB<#  !="P  '@
M@ 'B4PX 96$P,C,P.#(Q,#%E>#(S+3)?<V-I<W!A<F,N:'1M4$L! A0#%
M  @ &X!-6FOQ1$!-#   0D   !T              ( !15<. &5A,#(S,#@R
M,3 Q97@X+3%?<V-I<W!A<F,N:'1M4$L! A0#%     @ &X!-6@>*Q"D6#
MI0P   L              ( !S6,. &9I;E\P,#$N:G!G4$L! A0#%     @
M&X!-6L0$I]).9   _G<   L              ( !#' . &9I;E\P,#(N:G!G
M4$L! A0#%     @ &X!-6JC.KI9X*P  8#(   L              ( !@]0.
M &9I;E\P,#,N:G!G4$L! A0#%     @ &X!-6DVVJ_\_!P  W@<   L
M         ( !)  / &9I;E\P,#0N:G!G4$L! A0#%     @ &X!-6A6U3GC?
M$   M2$   L              ( !C </ &9I;E\P,#4N:G!G4$L! A0#%
M  @ &X!-6F;$SPA  P  *@0   L              ( !E!@/ &9I;E\P,#8N
M:G!G4$L! A0#%     @ &X!-6I([FA8] @  \0(   L              ( !
M_1L/ &9I;E\P,#<N:G!G4$L! A0#%     @ &X!-6AO-'GDH @  W (   L
M             ( !8QX/ &9I;E\P,#@N:G!G4$L! A0#%     @ &X!-6@1_
M% D< @  T0(   L              ( !M" / &9I;E\P,#DN:G!G4$L! A0#
M%     @ &X!-6A>1\>I! @  ] (   L              ( !^2(/ &9I;E\P
M,3 N:G!G4$L! A0#%     @ &X!-6DG"%3D6 @  RP(   L
M ( !8R4/ &9I;E\P,3$N:G!G4$L! A0#%     @ &X!-6I42&@L@ @  U0(
M  L              ( !HB</ &9I;E\P,3(N:G!G4$L! A0#%     @ &X!-
M6K'HZ*=6 @  "@,   L              ( !ZRD/ &9I;E\P,3,N:G!G4$L!
M A0#%     @ &X!-6ET=#FA; @  #0,   L              ( !:BP/ &9I
M;E\P,30N:G!G4$L! A0#%     @ &X!-6MX6"]D6 @  RP(   L
M     ( ![BX/ &9I;E\P,34N:G!G4$L! A0#%     @ &X!-6L7O50&' @
M-0,   L              ( !+3$/ &9I;E\P,38N:G!G4$L! A0#%     @
M&X!-6DCASCUQ @  ( ,   L              ( !W3,/ &9I;E\P,3<N:G!G
M4$L! A0#%     @ &X!-6O79]%]7 @  "0,   L              ( !=S8/
M &9I;E\P,3@N:G!G4$L! A0#%     @ &X!-6C\:(LU] @  +0,   L
M         ( !]S@/ &9I;E\P,3DN:G!G4$L! A0#%     @ &X!-6KZL,(^.
M @  /0,   L              ( !G3L/ &9I;E\P,C N:G!G4$L! A0#%
M  @ &X!-6EHG_7R6 @  10,   L              ( !5#X/ &9I;E\P,C$N
M:G!G4$L! A0#%     @ &X!-6FHD345D @  %0,   L              ( !
M$T$/ &9I;E\P,C(N:G!G4$L! A0#%     @ &X!-6G1[9V&/ @  /@,   L
M             ( !H$,/ &9I;E\P,C,N:G!G4$L! A0#%     @ &X!-6O#J
M?&F# @  ,P,   L              ( !6$8/ &9I;E\P,C0N:G!G4$L! A0#
M%     @ &X!-6M/3P[5% @  ]P(   L              ( !!$D/ &9I;E\P
M,C4N:G!G4$L! A0#%     @ &X!-6N/W1^FQ @  7@,   L
M ( !<DL/ &9I;E\P,C8N:G!G4$L! A0#%     @ &X!-6L45>*6)!@  $P<
M  L              ( !3$X/ &9I;E\P,C<N:G!G4$L! A0#%     @ &X!-
M6HV>*446)P  32@   L              ( !_E0/ &9I;E\P,C@N:G!G4$L!
M A0#%     @ &X!-6E>>_H,;*P  72\   T              ( !/7P/ &EM
M86=E7S P,2YJ<&=02P$"% ,4    "  ;@$U:/'!'MS^2 0!OE0$ #0
M        @ &#IP\ :6UA9V5?,# R+FIP9U!+ 0(4 Q0    ( !N 35JI/.\(
MR%T  ,%E   -              "  >TY$0!I;6%G95\P,#,N:G!G4$L! A0#
M%     @ &X!-6H/P9BFE1P  +UP   T              ( !X)<1 &EM86=E
M7S P-"YJ<&=02P$"% ,4    "  ;@$U:=JTDB54L  #"+0  #0
M    @ &PWQ$ :6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( !N 35K3 9WLFBL
M %\W   -              "  3 ,$@!I;6%G95\P,#8N:G!G4$L! A0#%
M  @ &X!-6L6\'5?M9P$ 1'X!  T              ( !]3<2 &EM86=E7S P
M-RYJ<&=02P$"% ,4    "  ;@$U:6P5\0I1_  #IE@  #0
M@ $-H!, :6UA9V5?,# X+FIP9U!+ 0(4 Q0    ( !N 35J.Y9BK5J$   ;.
M   -              "  <P?% !I;6%G95\P,#DN:G!G4$L! A0#%     @
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M2P$"% ,4    "  ;@$U:AV2A0D!! 0"53 $ #0              @ %3,!@
M:6UA9V5?,#$T+FIP9U!+ 0(4 Q0    ( !N 35I<-: .1(   +>"   -
M          "  ;YQ&0!I;6%G95\P,34N:G!G4$L! A0#%     @ &X!-6MR:
ML:4_"@$ 5AH!  T              ( !+?(9 &EM86=E7S Q-BYJ<&=02P$"
M% ,4    "  ;@$U:X0E*5GB:  "CG0  #0              @ &7_!H :6UA
M9V5?,#$W+FIP9U!+ 0(4 Q0    ( !N 35K>H1V..GL  #F/   -
M      "  3J7&P!I;6%G95\P,3@N:G!G4$L! A0#%     @ &X!-6E)[65;!
MO0  YM<   T              ( !GQ(< &EM86=E7S Q.2YJ<&=02P$"% ,4
M    "  ;@$U:=P@#3KPG  !W*   #0              @ &+T!P :6UA9V5?
M,#(P+FIP9U!+ 0(4 Q0    ( !N 35J\5#8;=R8  $LG   -
M  "  7+X' !I;6%G95\P,C$N:G!G4$L! A0#%     @ &X!-6JL5K&RV9
MRWX   T              ( !%!\= &EM86=E7S R,BYJ<&=02P$"% ,4
M"  ;@$U: AWTXNK1   UX   #0              @ 'U@QT :6UA9V5?,#(S
M+FIP9U!+ 0(4 Q0    ( !N 35K7A,$01IT! "RM 0 -              "
M 0I6'@!I;6%G95\P,C0N:G!G4$L! A0#%     @ &X!-6@Q+^V"D*0  )#0"
M !(              ( !>_,? '-P<F-Y+3(P,C0P-C,P+GAS9%!+ 0(4 Q0
M   ( !N 35IT\049JP\  +G(   6              "  4\=( !S<')C>2TR
M,#(T,#8S,%]C86PN>&UL4$L! A0#%     @ &X!-6O5T<"4V9@  2V\& !8
M             ( !+BT@ '-P<F-Y+3(P,C0P-C,P7V1E9BYX;6Q02P$"% ,4
M    "  ;@$U:02C2;ZG]  ")@0P %@              @ &8DR  <W!R8WDM
M,C R-# V,S!?;&%B+GAM;%!+ 0(4 Q0    ( !N 35IE55%<#VL  'CZ!@ 6
M              "  761(0!S<')C>2TR,#(T,#8S,%]P<F4N>&UL4$L%!@
0   _ #\ V X  +C\(0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>ea0230821-f4a2_scisparc_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sprcy="http://trpx.com/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sprcy-20240630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CoeruleusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:CapitalPointWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-11-29</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-11-29</startDate>
            <endDate>2020-11-29</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-25</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-25</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-06-25</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-06-25</startDate>
            <endDate>2023-06-25</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-03-19</startDate>
            <endDate>2020-03-19</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-03-19</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-19</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-19</startDate>
            <endDate>2020-03-19</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-23</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2017-04-11</startDate>
            <endDate>2017-04-11</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-02</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-22</startDate>
            <endDate>2022-03-22</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:OverAllotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-13</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sprcy:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2019-03-12</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2019-10-10</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-10-10</startDate>
            <endDate>2019-10-10</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-01-15</startDate>
            <endDate>2020-01-15</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ClearmindMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ClearmindMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:NewCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-21</startDate>
            <endDate>2024-01-21</endDate>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-01-21</instant>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMotorsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-25</instant>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sprcy:InvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:BridgeLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:BridgeLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-06-09</startDate>
            <endDate>2024-06-09</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:BridgeLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-09</startDate>
            <endDate>2024-06-09</endDate>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:BridgeLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:TransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:TransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:TransactionsWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MizaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-08</startDate>
            <endDate>2024-07-08</endDate>
        </period>
    </context>
    <context id="c384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MizaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-08</instant>
        </period>
    </context>
    <context id="c385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-08</instant>
        </period>
    </context>
    <context id="c386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-08</instant>
        </period>
    </context>
    <context id="c387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-08</instant>
        </period>
    </context>
    <context id="c388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-08</instant>
        </period>
    </context>
    <context id="c389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-17</instant>
        </period>
    </context>
    <context id="c390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="c391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="c393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="c396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:ScenarioForecastsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:AmendmentDescription contextRef="c0" id="ixv-104933">Amendment No. 2</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-73">SciSparc Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-104934">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-104935">20 Raul Wallenberg Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-104936">Tower A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-104937">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-104938">6971916</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-104939">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c0" id="ixv-104940">(+972)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-104941">(3) 717-5777</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-142">Puglisi &amp; Associates</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-104942">850 Library Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-104943">Suite 204</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-104944">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c1" id="ixv-104945">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-104946">19711</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c1" id="ixv-104947">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-104948">738-6680</dei:LocalPhoneNumber>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-257">false</dei:EntityEmergingGrowthCompany>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-104949" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-104950" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-104951" unitRef="usd">65000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-104952" unitRef="usd">60000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="-3" id="ixv-104953" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentTradeReceivables contextRef="c2" decimals="-3" id="ixv-104954" unitRef="usd">22000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c3" decimals="-3" id="ixv-104955" unitRef="usd">77000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-104956" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c3" decimals="-3" id="ixv-104957" unitRef="usd">131000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:Inventories contextRef="c2" decimals="-3" id="ixv-104958" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c3" decimals="-3" id="ixv-104959" unitRef="usd">668000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" id="ixv-104960" unitRef="usd">6445000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="-3" id="ixv-104961" unitRef="usd">4510000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-104962" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-104963" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentsInAssociates contextRef="c2" decimals="-3" id="ixv-104964" unitRef="usd">781000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates contextRef="c3" decimals="-3" id="ixv-104965" unitRef="usd">591000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-104966" unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c3" decimals="-3" id="ixv-104967" unitRef="usd">730000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-104968" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-104969" unitRef="usd">57000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" id="ixv-104970" unitRef="usd">4737000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="-3" id="ixv-104971" unitRef="usd">6095000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" id="ixv-104972" unitRef="usd">11182000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="-3" id="ixv-104973" unitRef="usd">10605000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-104974" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-104975" unitRef="usd">1199000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-104976" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-104977" unitRef="usd">193000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentWarrantLiability contextRef="c2" decimals="-3" id="ixv-104978" unitRef="usd">532000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentWarrantLiability contextRef="c3" decimals="-3" id="ixv-104979" unitRef="usd">2737000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-104980" unitRef="usd">52000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-104981" unitRef="usd">27000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="-3" id="ixv-104982" unitRef="usd">1571000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c3" decimals="-3" id="ixv-104983" unitRef="usd">4156000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-104984" unitRef="usd">24000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:SharePremium contextRef="c2" decimals="-3" id="ixv-104985" unitRef="usd">64526000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c3" decimals="-3" id="ixv-104986" unitRef="usd">58592000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="-3" id="ixv-104987" unitRef="usd">5282000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="-3" id="ixv-104988" unitRef="usd">5180000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantLiability contextRef="c2" decimals="-3" id="ixv-104989" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c3" decimals="-3" id="ixv-104990" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c2" decimals="-3" id="ixv-104991" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c3" decimals="-3" id="ixv-104992" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherEquityInterest contextRef="c2" decimals="-3" id="ixv-104993" unitRef="usd">810000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c3" decimals="-3" id="ixv-104994" unitRef="usd">559000</ifrs-full:OtherEquityInterest>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-104995" unitRef="usd">-68691000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="-3" id="ixv-104996" unitRef="usd">-63569000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c2" decimals="-3" id="ixv-104997" unitRef="usd">7614000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c3" decimals="-3" id="ixv-104998" unitRef="usd">6449000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c2" decimals="-3" id="ixv-104999" unitRef="usd">1973000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-105000" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-105001" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" id="ixv-105002" unitRef="usd">11182000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c3" decimals="-3" id="ixv-105003" unitRef="usd">10605000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue contextRef="c6" decimals="-3" id="ixv-105004" unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c7" decimals="-3" id="ixv-105005" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c6" decimals="-3" id="ixv-105006" unitRef="usd">683000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c7" decimals="-3" id="ixv-105007" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c6" decimals="-3" id="ixv-105008" unitRef="usd">2196000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c7" decimals="-3" id="ixv-105009" unitRef="usd">1025000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-105010" unitRef="usd">1641000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-105011" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c8" decimals="-3" id="ixv-105012" unitRef="usd">1990000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-105013" unitRef="usd">1297000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c7" decimals="-3" id="ix_4_fact" unitRef="usd">537000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c6" decimals="-3" id="ixv-105015" unitRef="usd">1042000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-105016" unitRef="usd">5031000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ix_5_fact" unitRef="usd">5972000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c8" decimals="-3" id="ixv-105018" unitRef="usd">3778000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c6" decimals="-3" id="ixv-105019" unitRef="usd">-6815000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c7" decimals="-3" id="ixv-105020" unitRef="usd">-8287000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c8" decimals="-3" id="ixv-105021" unitRef="usd">-5768000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c6" decimals="-3" id="ixv-105022" unitRef="usd">-210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c7" decimals="-3" id="ixv-105023" unitRef="usd">-109000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome contextRef="c6" decimals="-3" id="ixv-105024" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c7" decimals="-3" id="ixv-105025" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c6" decimals="-3" id="ixv-105026" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c7" decimals="-3" id="ixv-105027" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c8" decimals="-3" id="ixv-105028" unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c6" decimals="-3" id="ixv-105029" unitRef="usd">-5861000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c7" decimals="-3" id="ixv-105030" unitRef="usd">-2578000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c8" decimals="-3" id="ixv-105031" unitRef="usd">-5789000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c6" decimals="-3" id="ixv-105032" unitRef="usd">22000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c7" decimals="-3" id="ixv-105033" unitRef="usd">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-105034" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-105035" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c8" decimals="-3" id="ixv-105036" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c6" decimals="-3" id="ixv-105037" unitRef="usd">-5122000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c7" decimals="-3" id="ixv-105038" unitRef="usd">-2592000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c8" decimals="-3" id="ixv-105039" unitRef="usd">-5789000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c6" decimals="-3" id="ixv-105040" unitRef="usd">-761000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-105041" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-105042" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c8" decimals="-3" id="ixv-105043" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c6"
      decimals="2"
      id="ixv-105044"
      unitRef="usdPershares">14.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c7"
      decimals="2"
      id="ix_0_fact"
      unitRef="usdPershares">14.82</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c8"
      decimals="2"
      id="ix_1_fact"
      unitRef="usdPershares">73.58</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c6"
      decimals="2"
      id="ixv-105047"
      unitRef="usdPershares">14.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c7"
      decimals="2"
      id="ix_2_fact"
      unitRef="usdPershares">14.82</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c8"
      decimals="2"
      id="ix_3_fact"
      unitRef="usdPershares">73.58</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Equity
      contextRef="c10"
      decimals="-3"
      id="ixv-105052"
      unitRef="usd">49040000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c11"
      decimals="-3"
      id="ixv-105053"
      unitRef="usd">4315000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c12"
      decimals="-3"
      id="ixv-105054"
      unitRef="usd">2207000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c13"
      decimals="-3"
      id="ixv-105055"
      unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c14"
      decimals="-3"
      id="ixv-105056"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c15"
      decimals="-3"
      id="ixv-105057"
      unitRef="usd">-55188000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c16"
      decimals="-3"
      id="ixv-105058"
      unitRef="usd">1430000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c18"
      decimals="-3"
      id="ixv-105059"
      unitRef="usd">1430000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="c24"
      decimals="-3"
      id="ixv-105060"
      unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c25"
      decimals="-3"
      id="ixv-105061"
      unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c8" decimals="-3" id="ixv-105062" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <sprcy:ExerciseOfWarrants
      contextRef="c19"
      decimals="-3"
      id="ixv-105063"
      unitRef="usd">6110000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants
      contextRef="c21"
      decimals="-3"
      id="ixv-105064"
      unitRef="usd">-1352000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants
      contextRef="c25"
      decimals="-3"
      id="ixv-105065"
      unitRef="usd">4758000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c8" decimals="-3" id="ixv-105066" unitRef="usd">4758000</sprcy:ExerciseOfWarrants>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c19"
      decimals="-3"
      id="ixv-105067"
      unitRef="usd">3364000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c21"
      decimals="-3"
      id="ixv-105068"
      unitRef="usd">4335000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c25"
      decimals="-3"
      id="ixv-105069"
      unitRef="usd">7699000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c8" decimals="-3" id="ixv-105070" unitRef="usd">7699000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c19"
      decimals="-3"
      id="ixv-105071"
      unitRef="usd">27000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c20"
      decimals="-3"
      id="ixv-105072"
      unitRef="usd">-27000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c20"
      decimals="-3"
      id="ixv-105073"
      unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c25"
      decimals="-3"
      id="ixv-105074"
      unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c8" decimals="-3" id="ixv-105075" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity
      contextRef="c27"
      decimals="-3"
      id="ixv-105076"
      unitRef="usd">58541000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c28"
      decimals="-3"
      id="ixv-105077"
      unitRef="usd">4331000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c29"
      decimals="-3"
      id="ixv-105078"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c30"
      decimals="-3"
      id="ixv-105079"
      unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c31"
      decimals="-3"
      id="ixv-105080"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c32"
      decimals="-3"
      id="ixv-105081"
      unitRef="usd">-60977000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c33"
      decimals="-3"
      id="ixv-105082"
      unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c35"
      decimals="-3"
      id="ixv-105083"
      unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="c41"
      decimals="-3"
      id="ixv-105084"
      unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c42"
      decimals="-3"
      id="ixv-105085"
      unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-105086" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <sprcy:ExerciseOfWarrants
      contextRef="c36"
      decimals="-3"
      id="ixv-105087"
      unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants
      contextRef="c42"
      decimals="-3"
      id="ixv-105088"
      unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c7" decimals="-3" id="ixv-105089" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c36"
      decimals="-3"
      id="ixv-105090"
      unitRef="usd">48000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c37"
      decimals="-3"
      id="ixv-105091"
      unitRef="usd">849000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c42"
      decimals="-3"
      id="ixv-105092"
      unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c7" decimals="-3" id="ixv-105093" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity
      contextRef="c44"
      decimals="-3"
      id="ixv-105094"
      unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c45"
      decimals="-3"
      id="ixv-105095"
      unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c46"
      decimals="-3"
      id="ixv-105096"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c47"
      decimals="-3"
      id="ixv-105097"
      unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c48"
      decimals="-3"
      id="ixv-105098"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c49"
      decimals="-3"
      id="ixv-105099"
      unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c50"
      decimals="-3"
      id="ixv-105100"
      unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-105101" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="c57"
      decimals="-3"
      id="ixv-105102"
      unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c58"
      decimals="-3"
      id="ixv-105103"
      unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c59"
      decimals="-3"
      id="ixv-105104"
      unitRef="usd">-761000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-105105" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c55"
      decimals="-3"
      id="ixv-105106"
      unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c58"
      decimals="-3"
      id="ixv-105107"
      unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c59"
      decimals="-3"
      id="ixv-105108"
      unitRef="usd">2734000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c6" decimals="-3" id="ixv-105109" unitRef="usd">2985000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c52"
      decimals="-3"
      id="ixv-105110"
      unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c58"
      decimals="-3"
      id="ixv-105111"
      unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c6" decimals="-3" id="ixv-105112" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c52"
      decimals="-3"
      id="ixv-105113"
      unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c58"
      decimals="-3"
      id="ixv-105114"
      unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c6" decimals="-3" id="ixv-105115" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c52"
      decimals="-3"
      id="ixv-105116"
      unitRef="usd">94000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c53"
      decimals="-3"
      id="ixv-105117"
      unitRef="usd">102000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c58"
      decimals="-3"
      id="ixv-105118"
      unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c6" decimals="-3" id="ixv-105119" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity
      contextRef="c60"
      decimals="-3"
      id="ixv-105120"
      unitRef="usd">64526000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c61"
      decimals="-3"
      id="ixv-105121"
      unitRef="usd">5282000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c62"
      decimals="-3"
      id="ixv-105122"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c63"
      decimals="-3"
      id="ixv-105123"
      unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c64"
      decimals="-3"
      id="ixv-105124"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c65"
      decimals="-3"
      id="ixv-105125"
      unitRef="usd">-68691000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c66"
      decimals="-3"
      id="ixv-105126"
      unitRef="usd">7614000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c67"
      decimals="-3"
      id="ixv-105127"
      unitRef="usd">1973000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-105128" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="c95"
      decimals="-3"
      id="ixv-105129"
      unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-105130" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c8" decimals="-3" id="ixv-105131" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="c95"
      decimals="-3"
      id="ixv-105132"
      unitRef="usd">538000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c7" decimals="-3" id="ixv-105133" unitRef="usd">187000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c8" decimals="-3" id="ixv-105134" unitRef="usd">33000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c95"
      decimals="-3"
      id="ixv-105135"
      unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c95"
      decimals="-3"
      id="ixv-105136"
      unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c7" decimals="-3" id="ixv-105137" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c8" decimals="-3" id="ixv-105138" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="c95"
      decimals="-3"
      id="ixv-105139"
      unitRef="usd">2205000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c7" decimals="-3" id="ixv-105140" unitRef="usd">6585000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c8" decimals="-3" id="ixv-105141" unitRef="usd">-9000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="c95"
      decimals="-3"
      id="ixv-105142"
      unitRef="usd">210000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c7" decimals="-3" id="ixv-105143" unitRef="usd">109000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets
      contextRef="c95"
      decimals="-3"
      id="ixv-105144"
      unitRef="usd">1048000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c7" decimals="-3" id="ixv-105145" unitRef="usd">770000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="c95"
      decimals="-3"
      id="ixv-105146"
      unitRef="usd">829000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c7" decimals="-3" id="ixv-105147" unitRef="usd">-4622000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c8" decimals="-3" id="ixv-105148" unitRef="usd">85000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="c95"
      decimals="-3"
      id="ixv-105149"
      unitRef="usd">-409000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c7" decimals="-3" id="ixv-105150" unitRef="usd">3000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c8" decimals="-3" id="ixv-105151" unitRef="usd">170000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="c95"
      decimals="-3"
      id="ixv-105152"
      unitRef="usd">-397000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c8" decimals="-3" id="ixv-105153" unitRef="usd">353000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="c95"
      decimals="-3"
      id="ixv-105154"
      unitRef="usd">-8000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c7" decimals="-3" id="ixv-105155" unitRef="usd">39000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c8" decimals="-3" id="ixv-105156" unitRef="usd">120000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="c95"
      decimals="-3"
      id="ixv-105157"
      unitRef="usd">55000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c7" decimals="-3" id="ixv-105158" unitRef="usd">-77000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="c95"
      decimals="-3"
      id="ixv-105159"
      unitRef="usd">-74000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c7" decimals="-3" id="ixv-105160" unitRef="usd">-668000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital
      contextRef="c95"
      decimals="-3"
      id="ixv-105161"
      unitRef="usd">-833000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c7" decimals="-3" id="ixv-105162" unitRef="usd">-703000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c8" decimals="-3" id="ixv-105163" unitRef="usd">643000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="c95"
      decimals="-3"
      id="ixv-105164"
      unitRef="usd">-5887000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-105165" unitRef="usd">-7917000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c8" decimals="-3" id="ixv-105166" unitRef="usd">-5061000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents
      contextRef="c95"
      decimals="-3"
      id="ixv-105167"
      unitRef="usd">-5000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c7" decimals="-3" id="ixv-105168" unitRef="usd">-15000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c8" decimals="-3" id="ixv-105169" unitRef="usd">-35000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c95"
      decimals="-3"
      id="ixv-105170"
      unitRef="usd">-3000000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c7" decimals="-3" id="ixv-105171" unitRef="usd">8000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c8" decimals="-3" id="ixv-105172" unitRef="usd">35000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="c95"
      decimals="-3"
      id="ixv-105173"
      unitRef="usd">400000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c7" decimals="-3" id="ixv-105174" unitRef="usd">700000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="c95"
      decimals="-3"
      id="ixv-105175"
      unitRef="usd">689000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c95"
      decimals="-3"
      id="ixv-105176"
      unitRef="usd">2985000</ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c7" decimals="-3" id="ixv-105177" unitRef="usd">-1500000</sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c7" decimals="-3" id="ixv-105178" unitRef="usd">4861000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="c95"
      decimals="-3"
      id="ixv-105179"
      unitRef="usd">-1109000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-105180" unitRef="usd">-7084000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c8" decimals="-3" id="ixv-105181" unitRef="usd">-70000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses
      contextRef="c95"
      decimals="-3"
      id="ixv-105182"
      unitRef="usd">-5552000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c7" decimals="-3" id="ixv-105183" unitRef="usd">-9005000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c8" decimals="-3" id="ixv-105184" unitRef="usd">-7699000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c7" decimals="-3" id="ixv-105185" unitRef="usd">2770000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c8" decimals="-3" id="ixv-105186" unitRef="usd">2568000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod contextRef="c7" decimals="-3" id="ixv-105187" unitRef="usd">3000</sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="c95"
      decimals="-3"
      id="ixv-105188"
      unitRef="usd">7000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c7" decimals="-3" id="ixv-105189" unitRef="usd">8000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="c95"
      decimals="-3"
      id="ixv-105190"
      unitRef="usd">47000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c7" decimals="-3" id="ixv-105191" unitRef="usd">70000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c8" decimals="-3" id="ixv-105192" unitRef="usd">19000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <sprcy:ReceiptofShortTermCreditFromOthers contextRef="c8" decimals="-3" id="ixv-105193" unitRef="usd">-188000</sprcy:ReceiptofShortTermCreditFromOthers>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="c95"
      decimals="-3"
      id="ixv-105194"
      unitRef="usd">5498000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c7" decimals="-3" id="ixv-105195" unitRef="usd">11700000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c8" decimals="-3" id="ixv-105196" unitRef="usd">10060000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="c95"
      decimals="-3"
      id="ixv-105197"
      unitRef="usd">-1498000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c7" decimals="-3" id="ixv-105198" unitRef="usd">-3301000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c8" decimals="-3" id="ixv-105199" unitRef="usd">4929000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c96"
      decimals="-3"
      id="ixv-105200"
      unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c35"
      decimals="-3"
      id="ixv-105201"
      unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c18"
      decimals="-3"
      id="ixv-105202"
      unitRef="usd">1946000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c97"
      decimals="-3"
      id="ixv-105203"
      unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-105204" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c35"
      decimals="-3"
      id="ixv-105205"
      unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c95"
      decimals="-3"
      id="ixv-105206"
      unitRef="usd">102000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c8" decimals="-3" id="ixv-105207" unitRef="usd">78000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <sprcy:RegistrationOfWarrants contextRef="c8" decimals="-3" id="ixv-105208" unitRef="usd">2480000</sprcy:RegistrationOfWarrants>
    <sprcy:InvestmentInFinancialAsset
      contextRef="c95"
      decimals="-3"
      id="ixv-105209"
      unitRef="usd">288000</sprcy:InvestmentInFinancialAsset>
    <sprcy:UnpaidIssueExpenses contextRef="c8" decimals="-3" id="ixv-105210" unitRef="usd">290000</sprcy:UnpaidIssueExpenses>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c6" id="ixv-40958">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 1:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GENERAL&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly
    known as Therapix Biosciences Ltd.) (&#x201c;SciSparc&#x201d; or the &#x201c;Company&#x201d; or the &#x201c;Group&#x201d;), a pharmaceutical
    company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries
    at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#x2019;s own patents in the immunotherapy
    field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of
    approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on
    &#x394;9-tetrahydrocannabinol (&#x201c;THC&#x201d;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#x2019;s
    disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel
    Aviv, Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#x201c;SPRC&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2023, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#x201c;Evero&#x201d;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#x201c;Brain Bright&#x201d;); and a company incorporated
under the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#x201c;Subsidiaries&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
board of directors (&#x201c;Board&#x201d;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1, which
became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these interim consolidated financial statements for all periods presented.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
of the Company for the year ended December&#160;31, 2023, were approved on March 31, 2024, and signed on April 1, 2024 (the &#x201c;Approval
Date&#x201d;).&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2023, the Group had an accumulated deficit of approximately $68,691 as a result of recurring operating losses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2023, the Company&#x2019;s
cash and cash equivalents totaled $2,076. In the period ended December 31, 2023, the Company had an operating loss of $5,883 and negative
cash flows from operating activities of $5,887. The Company&#x2019;s current cash and cash equivalents position is not sufficient to fund
the Company&#x2019;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its
liabilities arising from normal business operations when they become due. While the Company has successfully raised funds in the past,
there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially
reasonable terms, would have serious consequences on our financial condition and results of operations. In addition, the Group has started
recognizing revenues from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing
and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue
from its products. These above-mentioned factors raise substantial doubt about the Group&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Definitions and Meanings:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly
    known as Therapix Biosciences Ltd.) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Group&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly
    Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Companies that are controlled
    by the Company, as defined in IFRS 10, &#x201c;&lt;i&gt;Consolidated Financial Statements&lt;/i&gt;&#x201d;, and whose accounts are consolidated
    with those of the Company (if active).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Associates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An entity over which the
    Company has significant influence, as defined in IAS 28, &#x201c;&lt;i&gt;Investment in Associates and Joint Ventures&lt;/i&gt;&#x201d; and is
    not a Subsidiary.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related Parties&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As defined in IAS 24, &#x201c;&lt;i&gt;Related
    Party Disclosures&lt;/i&gt;&#x201d;. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IAS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International Accounting
    Standards issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International Financial
    Reporting Standards issued by the IASB.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-105211" unitRef="usd">-68691000</ifrs-full:RetainedEarnings>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-105212" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-105213" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-105214" unitRef="usd">-5887000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c6" id="ixv-41159">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following accounting policies
have been applied consistently in the financial statements for all periods presented, unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment in joint arrangements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint ventures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments accounted for using the equity method:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Group&#x2019;s investments in associates
and joint ventures are accounted for using the equity method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#x2019;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s business
    model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual cash flow
    terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured
    at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured
    at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity instruments and
    other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial
    assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized
only when:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual rights
    to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has transferred
    substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has
    neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset;
    or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has retained
    its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows
    in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured
    at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured
    at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial
    liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offsetting financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compound financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices (unadjusted)
    in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than quoted
    prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs that are not based
    on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and
other service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-employment benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision in accordance with IAS
37, &#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease extension and termination
    options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment to IAS 1, &#x201c;Disclosure of Accounting Policies&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In February 2021, the IASB issued
an amendment to IAS 1, &#x201c;Presentation of Financial Statements&#x201d; (&#x201c;the Amendment&#x201d;), which replaces the requirement
to disclose &#x2019;significant&#x2019; accounting policies with a requirement to disclose &#x2018;material&#x2019; accounting policies.
One of the main reasons for the Amendment is the absence of a definition of the term &#x2019;significant&#x2019; in IFRS whereas the term
&#x2018;material&#x2019; is defined in several standards and particularly in IAS 1.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment is applicable for annual
periods beginning on January 1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The application of the above Amendment
had an effect on the disclosures of the Company&#x2019;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment to IAS 8, &#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;In February 2021, the IASB issued an amendment to IAS 8,
&#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d; (&#x201c;the Amendment&#x201d;), in which it introduces a
new definition of &#x201c;accounting estimates&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Accounting estimates are defined as
&#x201c;monetary amounts in financial statements that are subject to measurement uncertainty&#x201d;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#x201c;FIFO&#x201d;) and the cost of inventory includes shipment and freight
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;y.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company sells products directly to customers mainly through its online Amazon stores.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Under
the Company&#x2019;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;z.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
accordance with Amazon&#x2019;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Cost
of sales primarily consists of expenses related to Amazon&#x2019;s commissions, storage costs and freight.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <sprcy:BasisOfPresentationOfFinancialStatements contextRef="c6" id="ixv-41171">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;</sprcy:BasisOfPresentationOfFinancialStatements>
    <sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory contextRef="c6" id="ixv-41192">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory>
    <sprcy:OperatingTerm contextRef="c6" id="ixv-105215">P1Y</sprcy:OperatingTerm>
    <sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements contextRef="c6" id="ixv-41204">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c6" id="ixv-41260">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <sprcy:DescriptionOfAcquisitionOfASingleAssetCompany contextRef="c6" id="ixv-41272">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.&lt;/p&gt;</sprcy:DescriptionOfAcquisitionOfASingleAssetCompany>
    <sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit contextRef="c6" id="ixv-41284">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory contextRef="c6" id="ixv-41296">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment in joint arrangements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint ventures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory>
    <sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock contextRef="c6" id="ixv-41373">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments accounted for using the equity method:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Group&#x2019;s investments in associates
and joint ventures are accounted for using the equity method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#x2019;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c6" id="ixv-41439">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory contextRef="c6" id="ixv-41451">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c98"
      decimals="2"
      id="ixv-105216"
      unitRef="pure">0.06</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c99"
      decimals="2"
      id="ixv-105217"
      unitRef="pure">0.50</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly
      contextRef="c100"
      decimals="2"
      id="ixv-105218"
      unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c101"
      decimals="2"
      id="ixv-105219"
      unitRef="pure">0.33</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c102"
      decimals="2"
      id="ixv-105220"
      unitRef="pure">0.50</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly
      contextRef="c103"
      decimals="2"
      id="ixv-105221"
      unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c104"
      decimals="2"
      id="ixv-105222"
      unitRef="pure">0.20</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c105"
      decimals="2"
      id="ixv-105223"
      unitRef="pure">0.33</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly
      contextRef="c106"
      decimals="2"
      id="ixv-105224"
      unitRef="pure">0.25</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife contextRef="c107" id="ixv-105225">see below</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c6" id="ixv-41504">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c6" id="ixv-41519">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c6" id="ixv-41569">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s business
    model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual cash flow
    terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured
    at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured
    at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity instruments and
    other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial
    assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized
only when:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual rights
    to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has transferred
    substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has
    neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset;
    or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has retained
    its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows
    in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured
    at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured
    at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial
    liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offsetting financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compound financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c6" id="ixv-41878">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="c6" id="ixv-41893">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c6" id="ixv-41905">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices (unadjusted)
    in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than quoted
    prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs that are not based
    on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory contextRef="c6" id="ixv-42014">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c6" id="ixv-42104">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and
other service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c6" id="ixv-42135">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c6" id="ixv-42191">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-employment benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c6" id="ixv-42230">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision in accordance with IAS
37, &#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c6" id="ixv-42253">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease extension and termination
    options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <sprcy:DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock contextRef="c6" id="ixv-42410">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment to IAS 1, &#x201c;Disclosure of Accounting Policies&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In February 2021, the IASB issued
an amendment to IAS 1, &#x201c;Presentation of Financial Statements&#x201d; (&#x201c;the Amendment&#x201d;), which replaces the requirement
to disclose &#x2019;significant&#x2019; accounting policies with a requirement to disclose &#x2018;material&#x2019; accounting policies.
One of the main reasons for the Amendment is the absence of a definition of the term &#x2019;significant&#x2019; in IFRS whereas the term
&#x2018;material&#x2019; is defined in several standards and particularly in IAS 1.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment is applicable for annual
periods beginning on January 1, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The application of the above Amendment
had an effect on the disclosures of the Company&#x2019;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock>
    <sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors contextRef="c6" id="ixv-42428">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment to IAS 8, &#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;In February 2021, the IASB issued an amendment to IAS 8,
&#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d; (&#x201c;the Amendment&#x201d;), in which it introduces a
new definition of &#x201c;accounting estimates&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Accounting estimates are defined as
&#x201c;monetary amounts in financial statements that are subject to measurement uncertainty&#x201d;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.&lt;/p&gt;</sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c6" id="ixv-42446">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#x201c;FIFO&#x201d;) and the cost of inventory includes shipment and freight
costs.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c6" id="ixv-42459">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;y.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company sells products directly to customers mainly through its online Amazon stores.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Under
the Company&#x2019;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock contextRef="c6" id="ixv-42481">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;z.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
accordance with Amazon&#x2019;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Cost
of sales primarily consists of expenses related to Amazon&#x2019;s commissions, storage costs and freight.&lt;/span&gt;&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock>
    <sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock contextRef="c6" id="ixv-42525">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 3:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING
    JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Judgments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discount rate for a lease
    liability:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental
borrowing rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar
security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there
are no financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk,
the lease term and other economic variables deriving from the lease contract&#x2019;s conditions and restrictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective control:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#x2019;
meetings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determining the fair value
    of share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates and assumptions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal claims:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on
its management&#x2019;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are
based, among others, on management&#x2019;s familiarity of and proximity to the circumstances, and also on the legal counsels&#x2019; best
professional judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the
outcome of the claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease extension and/or
    termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or
not exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying
asset to the Company&#x2019;s operation and whether it is a specialized asset, the company&#x2019;s past experience with similar leases,
etc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value of financial
    instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;When the fair values of financial
assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value
is determined using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken
from observable markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models
are tested for validity by calibrating to prices from any observable current market transactions in the same instrument when available.&lt;/p&gt;</sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c6" id="ixv-42669">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 4:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CASH&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,076&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,574&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock contextRef="c6" id="ixv-42679">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,076&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,574&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c109"
      decimals="-3"
      id="ixv-105226"
      unitRef="usd">1866000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c110"
      decimals="-3"
      id="ixv-105227"
      unitRef="usd">3443000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c111"
      decimals="-3"
      id="ixv-105228"
      unitRef="usd">210000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="c112"
      decimals="-3"
      id="ixv-105229"
      unitRef="usd">131000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-105230" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-105231" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c6" id="ixv-42761">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 5:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <sprcy:DisclosureOfInvertoryTextBlock contextRef="c6" id="ixv-42771">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfInvertoryTextBlock>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c2" decimals="-3" id="ixv-105232" unitRef="usd">73000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c3" decimals="-3" id="ixv-105233" unitRef="usd">198000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:FinishedGoods contextRef="c2" decimals="-3" id="ixv-105234" unitRef="usd">669000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c3" decimals="-3" id="ixv-105235" unitRef="usd">470000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories contextRef="c2" decimals="-3" id="ixv-105236" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c3" decimals="-3" id="ixv-105237" unitRef="usd">668000</ifrs-full:Inventories>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c6" id="ixv-42829">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 6:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <sprcy:DisclourseOfAccountsReceivablesTableTextBlock contextRef="c6" id="ixv-42839">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclourseOfAccountsReceivablesTableTextBlock>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c2" decimals="-3" id="ixv-105238" unitRef="usd">62000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c3" decimals="-3" id="ixv-105239" unitRef="usd">45000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-105240" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c3" decimals="-3" id="ixv-105241" unitRef="usd">46000</ifrs-full:OtherReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c2" decimals="-3" id="ixv-105242" unitRef="usd">275000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c3" decimals="-3" id="ixv-105243" unitRef="usd">40000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-105244" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c3" decimals="-3" id="ixv-105245" unitRef="usd">131000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory contextRef="c6" id="ixv-42907">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 7:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT IN ASSOCIATES
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sale of Orimmune Bio Ltd.:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On June 22, 2016, the Company entered
into a share transfer agreement (the &#x201c;Transfer Agreement&#x201d;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#x201c;Orimmune&#x201d;)
and Karma Link Ltd. (the &#x201c;Buyer&#x201d;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On December 13, 2018, an additional
amendment to the Transfer Agreement was signed between the parties, under which it was agreed that Orimmune will be assigned certain
rights in intellectual property (&#x201c;IP&#x201d;) related to the licensed technology owned by the Company subject to certain conditions
precedent which were still not met as of December 31, 2023. As of the Approval Date, the conditions precedent have not yet been completed
and the assignment of the IP related to the licensed technology owned by us has not yet been transferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Coeruleus - Joint Venture
    Transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On May 15, 2020, the Company entered
into a series of transactions (together, the &#x201c;Joint Venture Transaction&#x201d;), including a definitive share transfer agreement
with Capital Point Ltd. (&#x201c;Capital Point&#x201d;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital
Point sold to Evero 5,952,469 ordinary shares, NIS 0.01 par value each, of Coeruleus Ltd. (the &#x201c;Purchased Coeruleus Shares&#x201d;
and &#x201c;Coeruleus,&#x201d; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately 46%), engaged in,
among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce
the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic
encephalopathy. The Purchased Coeruleus Shares represented approximately 35% of the issued and outstanding share capital of Coeruleus.
In consideration thereof, Evero issued and sold to Capital Point 176,470 ordinary shares, NIS 1.00 par value each, constituting 15% of
the issued and outstanding share capital of Evero, which was valued at $351, based on apportionment of the fair market value of the Company
as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately 11% of Coeruleus&#x2019; issued
and outstanding share capital. The transaction costs of $51 were also capitalized as part of the investment in associate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#x201c;Capital Point Warrant&#x201d;) to purchase
$340 of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is
equal to the closing price of the Company&#x2019;s ordinary shares on the trading day on which the notice of exercise was actually received
by the Company and shall be paid by transferring to the Company a duly executed share transfer deed for 9,577 ordinary shares of Evero.
The Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $30. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than 1% of the issued and outstanding shares of
Coeruleus. As of December 31, 2023, the fair value of the Company&#x2019;s investment in Coeruleus is $&lt;span style="-sec-ix-hidden: hidden-fact-148"&gt;nil&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;MitocareX - Joint Venture
    Transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#x201c;MitoCareX&#x201d;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns
31.48% of the outstanding shares of MitocareX.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $600 in MitoCareX and increase its share ownership in MitoCareX Bio from 41.92% to 52.73%. Notwithstanding the above, the
Company and MitoCare X agreed for the additional $600 installment to be deferred to March 25, 2024. As of the date of this report the
$600 installment has been paid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $210 (for the year ended December 31, 2022
- $109).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;781&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
    <sprcy:OrdinarySharesSold
      contextRef="c113"
      decimals="0"
      id="ixv-105246"
      unitRef="shares">5952469</sprcy:OrdinarySharesSold>
    <sprcy:OrdinarySharesParValue
      contextRef="c114"
      decimals="2"
      id="ixv-105247"
      unitRef="ilsPershares">0.01</sprcy:OrdinarySharesParValue>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c115"
      decimals="2"
      id="ixv-105248"
      unitRef="pure">0.46</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital
      contextRef="c115"
      decimals="2"
      id="ixv-105249"
      unitRef="pure">0.35</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <sprcy:OrdinarySharesSold
      contextRef="c116"
      decimals="0"
      id="ixv-105250"
      unitRef="shares">176470</sprcy:OrdinarySharesSold>
    <sprcy:OrdinarySharesParValue
      contextRef="c117"
      decimals="2"
      id="ixv-105251"
      unitRef="ilsPershares">1</sprcy:OrdinarySharesParValue>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital
      contextRef="c114"
      decimals="2"
      id="ixv-105252"
      unitRef="pure">0.15</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <sprcy:FairMarketValue
      contextRef="c115"
      decimals="-3"
      id="ixv-105253"
      unitRef="usd">351000</sprcy:FairMarketValue>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital
      contextRef="c118"
      decimals="2"
      id="ixv-105254"
      unitRef="pure">0.11</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
      contextRef="c115"
      decimals="-3"
      id="ixv-105255"
      unitRef="usd">51000</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <sprcy:PurchaseOfOrdinaryShares
      contextRef="c119"
      decimals="-3"
      id="ixv-105256"
      unitRef="usd">340000</sprcy:PurchaseOfOrdinaryShares>
    <sprcy:DulyExecutedShareTransferDeedForOrdinaryShares
      contextRef="c120"
      decimals="0"
      id="ixv-105257"
      unitRef="shares">9577</sprcy:DulyExecutedShareTransferDeedForOrdinaryShares>
    <sprcy:InvestmentFromShareholders
      contextRef="c121"
      decimals="-3"
      id="ixv-105258"
      unitRef="usd">30000</sprcy:InvestmentFromShareholders>
    <sprcy:IssuedAndOutstandingSharesPercentage
      contextRef="c122"
      decimals="2"
      id="ixv-105259"
      unitRef="pure">0.01</sprcy:IssuedAndOutstandingSharesPercentage>
    <sprcy:InitialInvestment
      contextRef="c123"
      decimals="-3"
      id="ixv-105260"
      unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:AdditionalInvestment
      contextRef="c124"
      decimals="-3"
      id="ixv-105261"
      unitRef="usd">1000000</sprcy:AdditionalInvestment>
    <sprcy:OwnershipPercentage
      contextRef="c125"
      decimals="4"
      id="ixv-105262"
      unitRef="pure">0.5001</sprcy:OwnershipPercentage>
    <sprcy:InitialInvestment
      contextRef="c126"
      decimals="-3"
      id="ixv-105263"
      unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:OutstandingSharesPercentage
      contextRef="c127"
      decimals="4"
      id="ixv-105264"
      unitRef="pure">0.3148</sprcy:OutstandingSharesPercentage>
    <sprcy:AdditionalInvestment
      contextRef="c128"
      decimals="-3"
      id="ixv-105265"
      unitRef="usd">400000</sprcy:AdditionalInvestment>
    <sprcy:OwnershipPercentage
      contextRef="c129"
      decimals="4"
      id="ixv-105266"
      unitRef="pure">0.3148</sprcy:OwnershipPercentage>
    <sprcy:OwnershipPercentage
      contextRef="c130"
      decimals="4"
      id="ixv-105267"
      unitRef="pure">0.4192</sprcy:OwnershipPercentage>
    <sprcy:AdditionalInvestment
      contextRef="c131"
      decimals="-3"
      id="ixv-105268"
      unitRef="usd">600000</sprcy:AdditionalInvestment>
    <sprcy:OwnershipPercentage
      contextRef="c132"
      decimals="4"
      id="ixv-105269"
      unitRef="pure">0.4192</sprcy:OwnershipPercentage>
    <sprcy:OwnershipPercentage
      contextRef="c133"
      decimals="4"
      id="ixv-105270"
      unitRef="pure">0.5273</sprcy:OwnershipPercentage>
    <sprcy:AdditionalInstallment
      contextRef="c134"
      decimals="-3"
      id="ixv-105271"
      unitRef="usd">600000</sprcy:AdditionalInstallment>
    <sprcy:InstallmentPaid
      contextRef="c134"
      decimals="-3"
      id="ixv-105272"
      unitRef="usd">600000</sprcy:InstallmentPaid>
    <sprcy:EquityLossesFromInvestment
      contextRef="c135"
      decimals="-3"
      id="ixv-105273"
      unitRef="usd">210000</sprcy:EquityLossesFromInvestment>
    <sprcy:EquityLossesFromInvestment
      contextRef="c127"
      decimals="-3"
      id="ixv-105274"
      unitRef="usd">109000</sprcy:EquityLossesFromInvestment>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c6" id="ixv-43008">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;781&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <sprcy:InvestmentsDate contextRef="c7" decimals="-3" id="ixv-105275" unitRef="usd">700000</sprcy:InvestmentsDate>
    <sprcy:EquityLossesFromInvestment contextRef="c7" decimals="-3" id="ixv-105276" unitRef="usd">109000</sprcy:EquityLossesFromInvestment>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c3" decimals="-3" id="ixv-105277" unitRef="usd">591000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <sprcy:InvestmentAchievementOfFirstMilestone contextRef="c6" decimals="-3" id="ixv-105278" unitRef="usd">400000</sprcy:InvestmentAchievementOfFirstMilestone>
    <sprcy:EquityLossesFromInvestment contextRef="c6" decimals="-3" id="ixv-105279" unitRef="usd">210000</sprcy:EquityLossesFromInvestment>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c2" decimals="-3" id="ixv-105280" unitRef="usd">781000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory contextRef="c6" id="ixv-43094">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 8:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT IN FINANCIAL
    ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (&#x201c;Clearmind&#x201d;) and received 230,769 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol &#x201c;CMND&#x201d; and the Frankfurt Stock Exchange under the symbol &#x201c;CWY.&#x201d; &#160; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company&#x2019;s shares in Clearmind was reduced from 230,769 common shares to 7,692. As of December 31, 2023, the listed share price of Clearmind on Nasdaq was $2.81, and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2023, of $727 on its investment (for the year ended December 31, 2022 - $771). &#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 25, 2023, the Company entered into an investment agreement (the &#x201c;Agreement&#x201d;) with AutoMax Motors Ltd. (&#x201c;AutoMax&#x201d;), an Israeli company traded on the Tel Aviv Stock Exchange (&#x201c;TASE&#x201d;) and the leading parallel importer and distributor of vehicles in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS 2,500,000 in cash, in exchange for ordinary shares, NIS 0.05 par value, of AutoMax based on a price per share of NIS 0.5. As of December 31, 2023, the listed share price of AutoMax on the TASE was NIS 0.384, and the Company has recorded a loss in its statements of comprehensive loss of $158 on its investment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
    <sprcy:InvestmentAmount
      contextRef="c136"
      decimals="-3"
      id="ixv-105281"
      unitRef="usd">1500000</sprcy:InvestmentAmount>
    <ifrs-full:NumberOfSharesIssuedButNotFullyPaid
      contextRef="c137"
      decimals="0"
      id="ixv-105282"
      unitRef="shares">230769</ifrs-full:NumberOfSharesIssuedButNotFullyPaid>
    <sprcy:ShareCapitalPercentage
      contextRef="c136"
      decimals="4"
      id="ixv-105283"
      unitRef="pure">0.0933</sprcy:ShareCapitalPercentage>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c138"
      decimals="0"
      id="ixv-105284"
      unitRef="shares">230769</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c139"
      decimals="0"
      id="ixv-105285"
      unitRef="shares">7692</ifrs-full:NumberOfSharesOutstanding>
    <sprcy:SharePricePerShare
      contextRef="c6"
      decimals="2"
      id="ixv-105286"
      unitRef="usdPershares">2.81</sprcy:SharePricePerShare>
    <sprcy:ComprehensiveLoss contextRef="c6" decimals="-3" id="ixv-105287" unitRef="usd">727000</sprcy:ComprehensiveLoss>
    <sprcy:ComprehensiveLoss contextRef="c7" decimals="-3" id="ixv-105288" unitRef="usd">771000</sprcy:ComprehensiveLoss>
    <ifrs-full:Cash
      contextRef="c140"
      decimals="-3"
      id="ixv-105289"
      unitRef="ils">2500000</ifrs-full:Cash>
    <ifrs-full:ParValuePerShare
      contextRef="c141"
      decimals="2"
      id="ixv-105290"
      unitRef="ilsPershares">0.05</ifrs-full:ParValuePerShare>
    <sprcy:PricePerShare
      contextRef="c142"
      decimals="1"
      id="ixv-105291"
      unitRef="ilsPershares">0.5</sprcy:PricePerShare>
    <sprcy:SharePricePerShare
      contextRef="c142"
      decimals="3"
      id="ixv-105292"
      unitRef="ilsPershares">0.384</sprcy:SharePricePerShare>
    <sprcy:ComprehensiveLoss
      contextRef="c142"
      decimals="-3"
      id="ixv-105293"
      unitRef="usd">158000</sprcy:ComprehensiveLoss>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c6" id="ixv-43122">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 9:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LEASES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 1, 2020, the Company
entered into a one-year lease agreement with a third party for an area of approximately 100 square meters for the Company&#x2019;s offices
in the district of Tel Aviv, Israel. The yearly lease fee was set at approximately $44, linked to the NIS. The lease expired on August
31, 2021. The Company did not exercise its option to extend the lease until August 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 1, 2021, the Company entered
into a two-year joint lease agreement with a third party and for a total area of approximately 240 square meters, whereby the Company
occupies approximately 120 square meters for the Company&#x2019;s offices, in the district of Tel Aviv, Israel. The Company and the third
party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately $40, linked to the NIS.
On July 7, 2023, the lease was extended until June 30, 2025.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <sprcy:SquareMeters
      contextRef="c143"
      decimals="0"
      id="ixv-105294"
      unitRef="pure">100</sprcy:SquareMeters>
    <sprcy:LeaseFee
      contextRef="c143"
      decimals="-3"
      id="ixv-105295"
      unitRef="usd">44000</sprcy:LeaseFee>
    <sprcy:ExpireTerm contextRef="c144" id="ixv-105296">2021-08-31</sprcy:ExpireTerm>
    <sprcy:SquareMeters
      contextRef="c145"
      decimals="0"
      id="ixv-105297"
      unitRef="pure">240</sprcy:SquareMeters>
    <sprcy:SquareMeters
      contextRef="c146"
      decimals="0"
      id="ixv-105298"
      unitRef="pure">120</sprcy:SquareMeters>
    <sprcy:LeaseFee
      contextRef="c145"
      decimals="-3"
      id="ixv-105299"
      unitRef="usd">40000</sprcy:LeaseFee>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c6" id="ixv-43162">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 10:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPERTY AND EQUIPMENT,
    NET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Assets owned and used by the Company&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Right-of-&lt;br/&gt; use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Lab&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture&lt;br/&gt; and&lt;br/&gt;
    equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; office&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;New lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Purchases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Depreciation expenses for the years
ended December 31, 2023, 2022 and 2021 amounted to $52, $43 and $32, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c6" id="ixv-43172">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Assets owned and used by the Company&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Right-of-&lt;br/&gt; use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Lab&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture&lt;br/&gt; and&lt;br/&gt;
    equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; office&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;New lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Purchases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c147"
      decimals="-3"
      id="ixv-105300"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c149"
      decimals="-3"
      id="ixv-105301"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c150"
      decimals="-3"
      id="ixv-105302"
      unitRef="usd">78000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c3" decimals="-3" id="ixv-105303" unitRef="usd">122000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c107"
      decimals="-3"
      id="ixv-105304"
      unitRef="usd">103000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c6" decimals="-3" id="ixv-105305" unitRef="usd">103000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c153"
      decimals="-3"
      id="ixv-105306"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c155"
      decimals="-3"
      id="ixv-105307"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c108"
      decimals="-3"
      id="ixv-105308"
      unitRef="usd">181000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c2" decimals="-3" id="ixv-105309" unitRef="usd">225000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c147"
      decimals="-3"
      id="ixv-105310"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c149"
      decimals="-3"
      id="ixv-105311"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c150"
      decimals="-3"
      id="ixv-105312"
      unitRef="usd">59000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation contextRef="c3" decimals="-3" id="ixv-105313" unitRef="usd">65000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c103"
      decimals="-3"
      id="ixv-105314"
      unitRef="usd">3000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c152"
      decimals="-3"
      id="ixv-105315"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c107"
      decimals="-3"
      id="ixv-105316"
      unitRef="usd">47000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c6" decimals="-3" id="ixv-105317" unitRef="usd">52000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c153"
      decimals="-3"
      id="ixv-105318"
      unitRef="usd">6000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c155"
      decimals="-3"
      id="ixv-105319"
      unitRef="usd">5000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c108"
      decimals="-3"
      id="ixv-105320"
      unitRef="usd">106000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation contextRef="c2" decimals="-3" id="ixv-105321" unitRef="usd">117000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c153"
      decimals="-3"
      id="ixv-105322"
      unitRef="usd">5000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c155"
      decimals="-3"
      id="ixv-105323"
      unitRef="usd">28000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c108"
      decimals="-3"
      id="ixv-105324"
      unitRef="usd">75000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated contextRef="c2" decimals="-3" id="ixv-105325" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c156"
      decimals="-3"
      id="ixv-105326"
      unitRef="usd">7000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c158"
      decimals="-3"
      id="ixv-105327"
      unitRef="usd">29000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c159"
      decimals="-3"
      id="ixv-105328"
      unitRef="usd">78000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c35"
      decimals="-3"
      id="ixv-105329"
      unitRef="usd">114000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c160"
      decimals="-3"
      id="ixv-105330"
      unitRef="usd">4000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c162"
      decimals="-3"
      id="ixv-105331"
      unitRef="usd">4000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-105332" unitRef="usd">8000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c147"
      decimals="-3"
      id="ixv-105333"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c149"
      decimals="-3"
      id="ixv-105334"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c150"
      decimals="-3"
      id="ixv-105335"
      unitRef="usd">78000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c3" decimals="-3" id="ixv-105336" unitRef="usd">122000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c156"
      decimals="-3"
      id="ixv-105337"
      unitRef="usd">1000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c158"
      decimals="-3"
      id="ixv-105338"
      unitRef="usd">1000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c159"
      decimals="-3"
      id="ixv-105339"
      unitRef="usd">20000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c35"
      decimals="-3"
      id="ixv-105340"
      unitRef="usd">22000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c160"
      decimals="-3"
      id="ixv-105341"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c162"
      decimals="-3"
      id="ixv-105342"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c163"
      decimals="-3"
      id="ixv-105343"
      unitRef="usd">39000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-105344" unitRef="usd">43000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c147"
      decimals="-3"
      id="ixv-105345"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c149"
      decimals="-3"
      id="ixv-105346"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c150"
      decimals="-3"
      id="ixv-105347"
      unitRef="usd">59000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation contextRef="c3" decimals="-3" id="ixv-105348" unitRef="usd">65000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c147"
      decimals="-3"
      id="ixv-105349"
      unitRef="usd">8000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c149"
      decimals="-3"
      id="ixv-105350"
      unitRef="usd">30000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c150"
      decimals="-3"
      id="ixv-105351"
      unitRef="usd">19000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated contextRef="c3" decimals="-3" id="ixv-105352" unitRef="usd">57000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:DepreciationExpense contextRef="c6" decimals="-3" id="ixv-105353" unitRef="usd">52000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c7" decimals="-3" id="ixv-105354" unitRef="usd">43000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c8" decimals="-3" id="ixv-105355" unitRef="usd">32000</ifrs-full:DepreciationExpense>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c6" id="ixv-43797">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 11:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INTANGIBLE ASSET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On September 30, 2022, the Company
announced the closing of the acquisition of Wellution&lt;sup&gt;TM&lt;/sup&gt;, a top seller Amazon.com Marketplace account (the &#x201c;Brand&#x201d;),
American food supplements and cosmetics brand and trademark (the &#x201c;Acquisition&#x201d;). In connection with the Acquisition, the
Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#x201c;M.R.M&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#x2019;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In addition, the Company issued to
M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00 per share (with a cashless exercise
mechanism) and with an exercise period of five years from the closing of the Acquisition (the &#x201c;September 2022 Warrants&#x201d;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100 million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,042.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of 8.7
years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined
based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#x2019;s expectations
that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter of 13.8%
and a declining growth rate for the long term, reaching 2% at the terminal year. Theoretical royalties arising from the brand were capitalized
at a discount rate of 20.6%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Purchase date September 30, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During the year ended December 31,
2023, the Company recognized depreciation expenses in respect to intangible asset in the amount of $486 (for the year ended December
31, 2022 - $144).&#160;&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:Cash contextRef="c2" decimals="-3" id="ixv-105356" unitRef="usd">4540000</ifrs-full:Cash>
    <ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount contextRef="c2" decimals="-3" id="ixv-105357" unitRef="usd">1120000</ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount>
    <sprcy:PurchaseCosts contextRef="c6" decimals="-3" id="ixv-105358" unitRef="usd">321000</sprcy:PurchaseCosts>
    <sprcy:WarrantsToPurchase contextRef="c6" decimals="-3" id="ixv-105359" unitRef="usd">15000000</sprcy:WarrantsToPurchase>
    <sprcy:ExercisePrice1
      contextRef="c6"
      decimals="2"
      id="ixv-105360"
      unitRef="usdPershares">7</sprcy:ExercisePrice1>
    <sprcy:ExercisePeriod contextRef="c6" id="ixv-105361">P5Y</sprcy:ExercisePeriod>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c164"
      decimals="-6"
      id="ixv-105362"
      unitRef="usd">100000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:pricePerShare
      contextRef="c164"
      decimals="2"
      id="ixv-105363"
      unitRef="usdPershares">10</sprcy:pricePerShare>
    <sprcy:AmountTotal contextRef="c6" decimals="-3" id="ixv-105364" unitRef="usd">4861000</sprcy:AmountTotal>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c6" id="ixv-105365">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c6" decimals="-3" id="ixv-105366" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <sprcy:RevenueTerm contextRef="c6" id="ixv-105367">P8Y8M12D</sprcy:RevenueTerm>
    <sprcy:GrowthRatePercentage contextRef="c6" decimals="3" id="ixv-105368" unitRef="pure">0.138</sprcy:GrowthRatePercentage>
    <sprcy:LongTermPercentage contextRef="c6" decimals="2" id="ixv-105369" unitRef="pure">0.02</sprcy:LongTermPercentage>
    <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="c2" decimals="3" id="ixv-105370" unitRef="pure">0.206</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock contextRef="c6" id="ixv-43858">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Purchase date September 30, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock>
    <sprcy:PurchaseofAssets contextRef="c7" decimals="-3" id="ixv-105371" unitRef="usd">4861000</sprcy:PurchaseofAssets>
    <ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost contextRef="c3" decimals="-3" id="ixv-105372" unitRef="usd">144000</ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-105373" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c6" decimals="-3" id="ixv-105374" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost contextRef="c2" decimals="-3" id="ixv-105375" unitRef="usd">486000</ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-105376" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c6" decimals="-3" id="ixv-105377" unitRef="usd">486000</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c7" decimals="-3" id="ixv-105378" unitRef="usd">144000</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c6" id="ixv-43922">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 12:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TRADE PAYABLES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Open debts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,199&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <sprcy:DisclosureOfTradePayables contextRef="c6" id="ixv-43932">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Open debts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,199&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfTradePayables>
    <sprcy:AccruedExpenses contextRef="c2" decimals="-3" id="ixv-105379" unitRef="usd">538000</sprcy:AccruedExpenses>
    <sprcy:AccruedExpenses contextRef="c3" decimals="-3" id="ixv-105380" unitRef="usd">901000</sprcy:AccruedExpenses>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-105381" unitRef="usd">264000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-105382" unitRef="usd">298000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-105383" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-105384" unitRef="usd">1199000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <sprcy:DisclosureOfOtherAccountsPayableTextBlock contextRef="c6" id="ixv-44014">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 13:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER ACCOUNTS PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfOtherAccountsPayableTextBlock>
    <ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory contextRef="c6" id="ixv-44024">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c2" decimals="-3" id="ixv-105385" unitRef="usd">48000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c3" decimals="-3" id="ixv-105386" unitRef="usd">102000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:Accruals contextRef="c2" decimals="-3" id="ixv-105387" unitRef="usd">104000</ifrs-full:Accruals>
    <ifrs-full:Accruals contextRef="c3" decimals="-3" id="ixv-105388" unitRef="usd">77000</ifrs-full:Accruals>
    <ifrs-full:OtherPayables contextRef="c2" decimals="-3" id="ixv-105389" unitRef="usd">33000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="c3" decimals="-3" id="ixv-105390" unitRef="usd">14000</ifrs-full:OtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-105391" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-105392" unitRef="usd">193000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c6" id="ixv-44092">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 14:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification of financial
    assets and financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The tables below are a comparison
between the carrying amount and fair value of the Company&#x2019;s financial instruments as of December 31, 2023, and 2022, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Fair
                                            Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Carrying amount&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dekel&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#x201c;Dekel&#x201d;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#x201c;Private Placement&#x201d;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#x201c;Notes&#x201d;), with an aggregate original principal amount of approximately
$350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to 12,088 ordinary shares of the Company (the &#x201c;Private Placement Warrant&#x201d;) and 1,538 ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $5,148. The Notes are
unsecured, have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of
the holder, into ordinary shares at an initial conversion price of $0.35 per ordinary share (the &#x201c;Fixed Conversion Price&#x201d;),
subject to adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower
of the Fixed Conversion Price or 70% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which
the ordinary shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion
is received by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing
date and on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $0.35
per ordinary share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by
the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The warrants&#x2019; fair value was
calculated using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March&#160;23,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Underlying Share Price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial risk factors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#x2019;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#x2019;s
financial performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;Foreign currency risk:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2023, the Company expects
to settle all of its financial liabilities in less than one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Refer to Note 14a for more information.&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities contextRef="c6" id="ixv-44110">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The tables below are a comparison
between the carrying amount and fair value of the Company&#x2019;s financial instruments as of December 31, 2023, and 2022, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Fair
                                            Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Carrying amount&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-105393" unitRef="usd">2141000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-105394" unitRef="usd">3634000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="-3" id="ixv-105395" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <sprcy:GovernmentAuthorities contextRef="c2" decimals="-3" id="ixv-105396" unitRef="usd">62000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities contextRef="c3" decimals="-3" id="ixv-105397" unitRef="usd">45000</sprcy:GovernmentAuthorities>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-105398" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c3" decimals="-3" id="ixv-105399" unitRef="usd">46000</ifrs-full:OtherReceivables>
    <sprcy:InvestmentsInFinancialAssets contextRef="c2" decimals="-3" id="ixv-105400" unitRef="usd">-659000</sprcy:InvestmentsInFinancialAssets>
    <sprcy:InvestmentsInFinancialAssets contextRef="c3" decimals="-3" id="ixv-105401" unitRef="usd">-591000</sprcy:InvestmentsInFinancialAssets>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c2" decimals="-3" id="ixv-105402" unitRef="usd">6065000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c3" decimals="-3" id="ixv-105403" unitRef="usd">4316000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <sprcy:CreditFromOthers contextRef="c2" decimals="-3" id="ixv-105404" unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:CreditFromOthers contextRef="c3" decimals="-3" id="ixv-105405" unitRef="usd">102000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability contextRef="c2" decimals="-3" id="ixv-105406" unitRef="usd">532000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability contextRef="c3" decimals="-3" id="ixv-105407" unitRef="usd">2737000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="-3" id="ixv-105408" unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c3" decimals="-3" id="ixv-105409" unitRef="usd">27000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c2" decimals="-3" id="ixv-105410" unitRef="usd">656000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c3" decimals="-3" id="ixv-105411" unitRef="usd">2866000</ifrs-full:FinancialLiabilities>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c169"
      decimals="-3"
      id="ixv-105412"
      unitRef="usd">2141000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c172"
      decimals="-3"
      id="ixv-105413"
      unitRef="usd">2141000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c169"
      decimals="-3"
      id="ixv-105414"
      unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c172"
      decimals="-3"
      id="ixv-105415"
      unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <sprcy:GovernmentAuthorities
      contextRef="c169"
      decimals="-3"
      id="ixv-105416"
      unitRef="usd">62000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities
      contextRef="c172"
      decimals="-3"
      id="ixv-105417"
      unitRef="usd">62000</sprcy:GovernmentAuthorities>
    <ifrs-full:OtherReceivables
      contextRef="c169"
      decimals="-3"
      id="ixv-105418"
      unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="c172"
      decimals="-3"
      id="ixv-105419"
      unitRef="usd">203000</ifrs-full:OtherReceivables>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c169"
      decimals="-3"
      id="ixv-105420"
      unitRef="usd">-659000</sprcy:InvestmentsInFinancialAssets>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c172"
      decimals="-3"
      id="ixv-105421"
      unitRef="usd">-659000</sprcy:InvestmentsInFinancialAssets>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c169"
      decimals="-3"
      id="ixv-105422"
      unitRef="usd">6065000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c172"
      decimals="-3"
      id="ixv-105423"
      unitRef="usd">6065000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <sprcy:CreditFromOthers
      contextRef="c169"
      decimals="-3"
      id="ixv-105424"
      unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:CreditFromOthers
      contextRef="c172"
      decimals="-3"
      id="ixv-105425"
      unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability
      contextRef="c169"
      decimals="-3"
      id="ixv-105426"
      unitRef="usd">532000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability
      contextRef="c172"
      decimals="-3"
      id="ixv-105427"
      unitRef="usd">532000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities
      contextRef="c169"
      decimals="-3"
      id="ixv-105428"
      unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="c172"
      decimals="-3"
      id="ixv-105429"
      unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="c169"
      decimals="-3"
      id="ixv-105430"
      unitRef="usd">656000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="c172"
      decimals="-3"
      id="ixv-105431"
      unitRef="usd">656000</ifrs-full:FinancialLiabilities>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c173"
      decimals="-3"
      id="ixv-105432"
      unitRef="usd">3634000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c176"
      decimals="-3"
      id="ixv-105433"
      unitRef="usd">3634000</ifrs-full:RestrictedCashAndCashEquivalents>
    <sprcy:GovernmentAuthorities
      contextRef="c173"
      decimals="-3"
      id="ixv-105434"
      unitRef="usd">45000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities
      contextRef="c176"
      decimals="-3"
      id="ixv-105435"
      unitRef="usd">45000</sprcy:GovernmentAuthorities>
    <ifrs-full:OtherReceivables
      contextRef="c173"
      decimals="-3"
      id="ixv-105436"
      unitRef="usd">46000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="c176"
      decimals="-3"
      id="ixv-105437"
      unitRef="usd">46000</ifrs-full:OtherReceivables>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c173"
      decimals="-3"
      id="ixv-105438"
      unitRef="usd">-591000</sprcy:InvestmentsInFinancialAssets>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c176"
      decimals="-3"
      id="ixv-105439"
      unitRef="usd">-591000</sprcy:InvestmentsInFinancialAssets>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c173"
      decimals="-3"
      id="ixv-105440"
      unitRef="usd">4316000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c176"
      decimals="-3"
      id="ixv-105441"
      unitRef="usd">4316000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <sprcy:CreditFromOthers
      contextRef="c173"
      decimals="-3"
      id="ixv-105442"
      unitRef="usd">102000</sprcy:CreditFromOthers>
    <sprcy:CreditFromOthers
      contextRef="c176"
      decimals="-3"
      id="ixv-105443"
      unitRef="usd">102000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability
      contextRef="c173"
      decimals="-3"
      id="ixv-105444"
      unitRef="usd">2737000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability
      contextRef="c176"
      decimals="-3"
      id="ixv-105445"
      unitRef="usd">2737000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities
      contextRef="c173"
      decimals="-3"
      id="ixv-105446"
      unitRef="usd">27000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="c176"
      decimals="-3"
      id="ixv-105447"
      unitRef="usd">27000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="c173"
      decimals="-3"
      id="ixv-105448"
      unitRef="usd">2866000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="c176"
      decimals="-3"
      id="ixv-105449"
      unitRef="usd">2866000</ifrs-full:FinancialLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="c165"
      decimals="-3"
      id="ixv-105450"
      unitRef="usd">350000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash
      contextRef="c166"
      decimals="-3"
      id="ixv-105451"
      unitRef="usd">315000</ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c167"
      decimals="0"
      id="ixv-105452"
      unitRef="shares">12088</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c166"
      decimals="0"
      id="ixv-105453"
      unitRef="shares">1538</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:CashOutflowForLeases
      contextRef="c168"
      decimals="-3"
      id="ixv-105454"
      unitRef="usd">220000</ifrs-full:CashOutflowForLeases>
    <sprcy:PurchasePrice
      contextRef="c168"
      decimals="-3"
      id="ixv-105455"
      unitRef="usd">5148000</sprcy:PurchasePrice>
    <sprcy:MaturityDate contextRef="c165" id="ixv-105456">2021-03-23</sprcy:MaturityDate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c166"
      decimals="2"
      id="ixv-105457"
      unitRef="pure">0.12</ifrs-full:BorrowingsInterestRate>
    <sprcy:InitialConversionPrice
      contextRef="c166"
      decimals="2"
      id="ixv-105458"
      unitRef="usdPershares">0.35</sprcy:InitialConversionPrice>
    <sprcy:ConversionPrice
      contextRef="c165"
      decimals="2"
      id="ixv-105459"
      unitRef="pure">0.70</sprcy:ConversionPrice>
    <sprcy:OrdinaryShareExercisePrice
      contextRef="c165"
      decimals="2"
      id="ixv-105460"
      unitRef="usdPershares">0.35</sprcy:OrdinaryShareExercisePrice>
    <sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock contextRef="c6" id="ixv-44944">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The warrants&#x2019; fair value was
calculated using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March&#160;23,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Underlying Share Price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock>
    <sprcy:DividendYield contextRef="c6" decimals="2" id="ixv-105461" unitRef="pure">0</sprcy:DividendYield>
    <sprcy:DividendYield contextRef="c7" decimals="2" id="ixv-105462" unitRef="pure">0</sprcy:DividendYield>
    <sprcy:DividendYield
      contextRef="c177"
      decimals="2"
      id="ixv-105463"
      unitRef="pure">0</sprcy:DividendYield>
    <sprcy:ExpectedVolatility contextRef="c6" decimals="2" id="ixv-105464" unitRef="pure">0.72</sprcy:ExpectedVolatility>
    <sprcy:ExpectedVolatility contextRef="c7" decimals="2" id="ixv-105465" unitRef="pure">0.72</sprcy:ExpectedVolatility>
    <sprcy:ExpectedVolatility
      contextRef="c177"
      decimals="4"
      id="ixv-105466"
      unitRef="pure">1.2201</sprcy:ExpectedVolatility>
    <sprcy:RiskFreeInterestRate contextRef="c6" decimals="4" id="ixv-105467" unitRef="pure">0.0384</sprcy:RiskFreeInterestRate>
    <sprcy:RiskFreeInterestRate contextRef="c7" decimals="4" id="ixv-105468" unitRef="pure">0.04</sprcy:RiskFreeInterestRate>
    <sprcy:RiskFreeInterestRate
      contextRef="c177"
      decimals="4"
      id="ixv-105469"
      unitRef="pure">0.0038</sprcy:RiskFreeInterestRate>
    <sprcy:UnderlyingAdsPrice
      contextRef="c6"
      decimals="2"
      id="ixv-105470"
      unitRef="usdPershares">4.88</sprcy:UnderlyingAdsPrice>
    <sprcy:UnderlyingAdsPrice
      contextRef="c7"
      decimals="2"
      id="ixv-105471"
      unitRef="usdPershares">19.66</sprcy:UnderlyingAdsPrice>
    <sprcy:UnderlyingAdsPrice
      contextRef="c177"
      decimals="2"
      id="ixv-105472"
      unitRef="usdPershares">11.18</sprcy:UnderlyingAdsPrice>
    <sprcy:ExercisePricePerShare
      contextRef="c6"
      decimals="0"
      id="ixv-105473"
      unitRef="usdPershares">637</sprcy:ExercisePricePerShare>
    <sprcy:ExercisePricePerShare
      contextRef="c7"
      decimals="0"
      id="ixv-105474"
      unitRef="usdPershares">637</sprcy:ExercisePricePerShare>
    <sprcy:ExercisePricePerShare
      contextRef="c177"
      decimals="0"
      id="ixv-105475"
      unitRef="usdPershares">637</sprcy:ExercisePricePerShare>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c6"
      decimals="0"
      id="ixv-105476"
      unitRef="usdPershares">0</sprcy:WarrantsFairValueinDollarsPerShares>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c7"
      decimals="0"
      id="ixv-105477"
      unitRef="usdPershares">0</sprcy:WarrantsFairValueinDollarsPerShares>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c177"
      decimals="2"
      id="ixv-105478"
      unitRef="usdPershares">0.36</sprcy:WarrantsFairValueinDollarsPerShares>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c6" id="ixv-45122">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 15:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EMPLOYEE BENEFIT LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Employee benefits consist of short-term
benefits and post-employment benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Post-employment benefits:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#x201c;Severance Pay Law&#x201d;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#x2019;s liability is accounted for as a post-employment benefit. The computation of the Company&#x2019;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#x2019;s salary and employment
term which establish the entitlement to receive the compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Defined contribution plans:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. These contributions and contributions for compensation represent defined contribution plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 61%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses
    in respect of defined contribution plans&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;105&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory contextRef="c6" id="ixv-105479">These contributions and contributions for compensation represent defined contribution plans.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 61%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses
    in respect of defined contribution plans&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;105&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c6" decimals="-3" id="ixv-105480" unitRef="usd">105000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c7" decimals="-3" id="ixv-105481" unitRef="usd">115000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c8" decimals="-3" id="ixv-105482" unitRef="usd">98000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c6" id="ixv-45196">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 16:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TAXES ON INCOME&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax rates applicable to
    the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Israeli statutory corporate tax
rate and real capital gains tax rate were 23% in 2023, 2022, and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The assessments of the Company are
deemed final through the 2016 tax year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Carryforward tax losses
    and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has accumulated tax losses
since its inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2023, the Company&#x2019;s
net carryforward tax losses are estimated to grow to approximately $62,000.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate contextRef="c6" decimals="2" id="ixv-105483" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c7" decimals="2" id="ixv-105484" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c8" decimals="2" id="ixv-105485" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <sprcy:OperatingLossCarryforwardsTaxAmount contextRef="c2" decimals="-3" id="ixv-105486" unitRef="usd">62000000</sprcy:OperatingLossCarryforwardsTaxAmount>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c6" id="ixv-45264">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 17:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CONTINGENT LIABILITIES,
    COMMITMENTS, CLAIMS AND LIENS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License Agreement with
    Dekel Pharmaceuticals Ltd.:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#x201c;Dekel License Agreement&#x201d;). The Dekel License Agreement became effective
in August 2015.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments
include: (i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 14, 2019, an amendment to
the Dekel License Agreement was signed (the &#x201c;Amendment&#x201d;), which encompasses the Company and Dekel&#x2019;s original intention
to exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which
are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field
of activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect
the foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment also prescribes for
a specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined
under the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment
also included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#x2019;s former Executive
Chairman of the Board and former interim Chief Executive Officer, towards the Company&#x2019;s field of activity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License Agreement with
    Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#x201c;Yissum&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#x201c;Yissum License Agreement&#x201d;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#x2019;s share in such joint patents shall be automatically included in the Yissum License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agreement with Hannover
    Medical School:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#x201c;MHH&#x201d;) to conduct during 2018 a phase IIb clinical
trial titled &#x201c;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#x201d; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount
of approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of
the first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under
a new agreement or will be paid back to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Agreement with Yale University:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 2, 2023, Capital Point Ltd. (&#x201c;Capital Point&#x201d;) filed with the Tel Aviv-Jaffa District Court (the &#x201c;Court&#x201d;) a suit against the Company, case number 2050-05-23 (the &#x201c;Suit&#x201d;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Suit challenges a certain warrant issued by the Company to Capital Point (the &#x201c;Capital Point Warrant&#x201d;) to purchase $340,000 of ordinary shares of the Company (the &#x201c;Warrant Shares&#x201d;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#x2019;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As of December 31, 2023, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <sprcy:DekelLicenseAgreementDescription contextRef="c6" id="ixv-105487">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.</sprcy:DekelLicenseAgreementDescription>
    <sprcy:AnnualInvestment contextRef="c6" decimals="-3" id="ixv-105488" unitRef="usd">350000</sprcy:AnnualInvestment>
    <sprcy:AdditionalMilestoneAmount
      contextRef="c178"
      decimals="-3"
      id="ixv-105489"
      unitRef="usd">75000</sprcy:AdditionalMilestoneAmount>
    <sprcy:InstallmentAmount
      contextRef="c179"
      decimals="-3"
      id="ixv-105490"
      unitRef="usd">122000</sprcy:InstallmentAmount>
    <sprcy:EstimatedAmount
      contextRef="c179"
      decimals="-3"
      id="ixv-105491"
      unitRef="usd">776000</sprcy:EstimatedAmount>
    <sprcy:EstimatedAmount
      contextRef="c180"
      decimals="-3"
      id="ixv-105492"
      unitRef="usd">1385000</sprcy:EstimatedAmount>
    <sprcy:EstimatedAmount
      contextRef="c181"
      decimals="-3"
      id="ixv-105493"
      unitRef="usd">370000</sprcy:EstimatedAmount>
    <ifrs-full:IssuedCapitalOrdinaryShares contextRef="c2" decimals="-3" id="ixv-105494" unitRef="usd">340000000</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:CapitalCommitments contextRef="c2" decimals="-3" id="ixv-105495" unitRef="ils">10000000000</ifrs-full:CapitalCommitments>
    <ifrs-full:CapitalCommitments contextRef="c2" decimals="-4" id="ixv-105496" unitRef="usd">2750000</ifrs-full:CapitalCommitments>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c6" id="ixv-45421">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 18:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December&#160;31, 2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December&#160;31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;261,494&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Reverse Share Splits&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#x2019;s share capital
to 75,000,000 ordinary shares with &lt;span style="-sec-ix-hidden: hidden-fact-208"&gt;no&lt;/span&gt; par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#x2019;s share capital
up to a ratio of 30:1 (the &#x201c;Third Reverse Split&#x201d;). Following the implementation of the Third Reverse Split, the Company&#x2019;s
authorized share capital was adjusted under the Company&#x2019;s Articles, which as of the date hereof consists of 75,000,000 ordinary
shares, &lt;span style="-sec-ix-hidden: hidden-fact-209"&gt;no&lt;/span&gt; par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes in share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number
                                            of&lt;br/&gt; ordinary&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;261,494&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issuance of share capital &#x2013; in respect of investment in
    affiliate (Note 18f)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share issued to a consultant (Note 19(a)(5))&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of shelf prospectus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of August 2023 financing round (Note 18i)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of rounding errors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Issuance of share capital &#x2013; in respect of October 2023 financing round
    (Note 18j)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,905&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rights attached to shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Voting rights at the shareholders
meeting, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capital management in the
    Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s capital management
objectives are to preserve the Company&#x2019;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional issuance of
    ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 2, 2022, the Company issued
a consultant 923 ordinary shares in respect of services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 1, 2022, the Company issued
a consultant 1,423 ordinary shares in respect of services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 22, 2023, the Company issued
13,858 ordinary shares in respect of the stock purchase&lt;span style="text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;agreement entered
into by and among Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo&#x201d;) (see also note 25a)&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 2021 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 44,332 units, as follows: (a) 35,243 units at a price of $183.82 per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#x201c;2021 Series A Warrants&#x201d;) and a Series B
Warrant (the &#x201c;2021 Series B Warrants&#x201d; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase
half the number of units, and (b) 9,089 pre-funded units at a price of $183.79 per unit, consisting of (i) one pre-funded warrant to
purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The 2021 Series A Warrants have an
exercise price of&#160;$183.82&#160;per ordinary share and the 2021 Series B Warrants have an exercise price of&#160;$275.60&#160;per
ordinary share). Both were exercisable upon issuance and will expire five years from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2021, the Company issued 4,929 ordinary shares in respect of the exercise of 385 2021 Series A Warrants and the exercise of 4,544 of
pre-funded warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2022, the Company issued 3,846 ordinary shares in respect of the exercise of 3,846 pre-funded warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 2022 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210(the &#x201c;June 2022 Financing Round&#x201d;), providing for the issuance
of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,885 units at a price of $74.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 123,504 pre-funded units at a price of $73.29 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants have an exercise
price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from
the date of issuance.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Underlying share price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2022, the Company issued 123,504 ordinary shares in respect of the exercise of 123,504 pre-funded warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;August 2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 14, 2023, the Company closed
an underwritten public offering (the &#x201c;2023 Public Offering&#x201d;) of 212,500 ordinary shares, at a purchase price of $5.20 per
ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#x201c;Aegis&#x201d;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to
cover over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;October 2023 Financing
    Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees to the placement agent and other offering expenses payable by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the private placement,
the Company issued an aggregate of 1,930,108 units, each unit consisting of two pre-funded warrants, or Pre-Funded Warrants. The Pre-Funded
Warrants have an exercise price of $0.001, are immediately exercisable upon issuance and have a term of five years from the date of issuance.&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c6" id="ixv-45437">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December&#160;31, 2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December&#160;31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;261,494&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c2"
      decimals="INF"
      id="ixv-105497"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-105498"
      unitRef="shares">706683</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c3"
      decimals="INF"
      id="ixv-105499"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-105500"
      unitRef="shares">261494</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c182"
      decimals="0"
      id="ixv-105501"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:DescriptionOfReverseShareSplit contextRef="c184" id="ixv-105502">the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#x2019;s share capital
up to a ratio of 30:1</sprcy:DescriptionOfReverseShareSplit>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c184"
      decimals="0"
      id="ixv-105503"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:DisclosureOfIssuedAndOutstandingShareCapital contextRef="c6" id="ixv-45556">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number
                                            of&lt;br/&gt; ordinary&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;261,494&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issuance of share capital &#x2013; in respect of investment in
    affiliate (Note 18f)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share issued to a consultant (Note 19(a)(5))&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of shelf prospectus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of August 2023 financing round (Note 18i)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of rounding errors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Issuance of share capital &#x2013; in respect of October 2023 financing round
    (Note 18j)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,905&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfIssuedAndOutstandingShareCapital>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-105504"
      unitRef="shares">261494</ifrs-full:NumberOfSharesIssued>
    <sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate
      contextRef="c6"
      decimals="INF"
      id="ixv-105505"
      unitRef="shares">13858</sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate>
    <sprcy:ShareIssuedToAConsultant
      contextRef="c6"
      decimals="INF"
      id="ixv-105506"
      unitRef="shares">7942</sprcy:ShareIssuedToAConsultant>
    <sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus
      contextRef="c6"
      decimals="INF"
      id="ixv-105507"
      unitRef="shares">296</sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-105508"
      unitRef="shares">237500</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors
      contextRef="c6"
      decimals="INF"
      id="ixv-105509"
      unitRef="shares">2688</sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors>
    <sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound
      contextRef="c6"
      decimals="INF"
      id="ixv-105510"
      unitRef="shares">182905</sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-105511"
      unitRef="shares">706683</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c186"
      decimals="0"
      id="ixv-105512"
      unitRef="shares">923</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c187"
      decimals="0"
      id="ixv-105513"
      unitRef="shares">1423</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c188"
      decimals="0"
      id="ixv-105514"
      unitRef="shares">13858</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:GrossProceeds
      contextRef="c189"
      decimals="-3"
      id="ixv-105515"
      unitRef="usd">8150000</sprcy:GrossProceeds>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c190"
      decimals="0"
      id="ixv-105516"
      unitRef="shares">44332</sprcy:IssuanceOfAggregateShares>
    <sprcy:AggregateUnits
      contextRef="c190"
      decimals="0"
      id="ixv-105517"
      unitRef="shares">35243</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c190"
      decimals="2"
      id="ixv-105518"
      unitRef="usdPershares">183.82</sprcy:AggregateUnitsPerShare>
    <sprcy:AggregateUnits
      contextRef="c191"
      decimals="0"
      id="ixv-105519"
      unitRef="shares">9089</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c191"
      decimals="2"
      id="ixv-105520"
      unitRef="usdPershares">183.79</sprcy:AggregateUnitsPerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c192"
      decimals="2"
      id="ixv-105521"
      unitRef="usdPershares">183.82</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c193"
      decimals="2"
      id="ixv-105522"
      unitRef="usdPershares">275.6</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <sprcy:DateOfIssuance contextRef="c194" id="ixv-105523">P5Y</sprcy:DateOfIssuance>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c195"
      decimals="0"
      id="ixv-105524"
      unitRef="shares">4929</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c8"
      decimals="0"
      id="ixv-105525"
      unitRef="shares">385</sprcy:WarrantsAndExercise>
    <sprcy:WarrantsAndExercise
      contextRef="c196"
      decimals="0"
      id="ixv-105526"
      unitRef="shares">4544</sprcy:WarrantsAndExercise>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c197"
      decimals="0"
      id="ixv-105527"
      unitRef="shares">3846</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c198"
      decimals="0"
      id="ixv-105528"
      unitRef="shares">3846</sprcy:WarrantsAndExercise>
    <sprcy:GrossProceeds
      contextRef="c199"
      decimals="-3"
      id="ixv-105529"
      unitRef="usd">10210000</sprcy:GrossProceeds>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c200"
      decimals="0"
      id="ixv-105530"
      unitRef="shares">136388</sprcy:IssuanceOfAggregateShares>
    <sprcy:AggregateUnits
      contextRef="c201"
      decimals="0"
      id="ixv-105531"
      unitRef="shares">12885</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c200"
      decimals="2"
      id="ixv-105532"
      unitRef="usdPershares">74.88</sprcy:AggregateUnitsPerShare>
    <sprcy:AggregateUnits
      contextRef="c202"
      decimals="0"
      id="ixv-105533"
      unitRef="shares">123504</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c202"
      decimals="2"
      id="ixv-105534"
      unitRef="usdPershares">73.29</sprcy:AggregateUnitsPerShare>
    <sprcy:WarrantsExercisePrice
      contextRef="c203"
      decimals="2"
      id="ixv-105535"
      unitRef="pure">68.38</sprcy:WarrantsExercisePrice>
    <sprcy:DateOfIssuance contextRef="c200" id="ixv-105536">P7Y</sprcy:DateOfIssuance>
    <ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory contextRef="c6" id="ixv-45861">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Underlying share price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c6" decimals="2" id="ixv-105537" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c7" decimals="2" id="ixv-105538" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c6" decimals="2" id="ixv-105539" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c7" decimals="2" id="ixv-105540" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c6" decimals="5" id="ixv-105541" unitRef="pure">0.03872</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c7" decimals="4" id="ixv-105542" unitRef="pure">0.0397</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c6"
      decimals="2"
      id="ixv-105543"
      unitRef="usdPershares">4.88</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c7"
      decimals="3"
      id="ixv-105544"
      unitRef="usdPershares">19.656</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c6"
      decimals="2"
      id="ixv-105545"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c7"
      decimals="2"
      id="ixv-105546"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c2" decimals="-3" id="ixv-105547" unitRef="usd">192000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c3" decimals="-3" id="ixv-105548" unitRef="usd">2396000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c204"
      decimals="0"
      id="ixv-105549"
      unitRef="shares">123504</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c205"
      decimals="0"
      id="ixv-105550"
      unitRef="shares">123504</sprcy:WarrantsAndExercise>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c206"
      decimals="0"
      id="ixv-105551"
      unitRef="shares">212500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c206"
      decimals="2"
      id="ixv-105552"
      unitRef="usdPershares">5.2</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c207"
      decimals="0"
      id="ixv-105553"
      unitRef="shares">37500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c207"
      decimals="3"
      id="ixv-105554"
      unitRef="usdPershares">5.174</sprcy:PurchasePricePerShare>
    <sprcy:AggregateGrossProceeds
      contextRef="c206"
      decimals="-3"
      id="ixv-105555"
      unitRef="usd">1300000</sprcy:AggregateGrossProceeds>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c208"
      decimals="0"
      id="ixv-105556"
      unitRef="shares">37500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="c209"
      decimals="-3"
      id="ixv-105557"
      unitRef="usd">5026000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c210"
      decimals="0"
      id="ixv-105558"
      unitRef="shares">1930108</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c211"
      decimals="3"
      id="ixv-105559"
      unitRef="usdPershares">0.001</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c6" id="ixv-45986">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 19:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SHARE-BASED PAYMENT
    TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The cost of share-based
    payment recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The 2005 and 2015 ESOP
    and 2023 Plan of the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#x201c;2023 Plan&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. &lt;/span&gt;Under the 2023 Plan, the Company may grant its employees and other
service providers equity based incentive awards (&#x201c;Share Options&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On December 28, 2023, the Board approved
to reserve for &lt;span style="background-color: white"&gt;issuance under the 2023 Plan &lt;span style="-sec-ix-hidden: hidden-fact-210"&gt;1,000,0000&lt;/span&gt; Ordinary Shares. As &lt;/span&gt;of the date of
this report, no shares were issued.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 12, 2019, the Board approved and granted 45 ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $10,920.00 per share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected life of share options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of the Share Options
was set at $5,824 per Share Option.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 10, 2019 (the &#x201c;2019 Grant Date&#x201d;), the Board approved the grant of 3 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2019 General Meeting&#x201d;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 1 Share Options was not granted. Out of the 2 Share Options that were granted, 1 Share Options didn&#x2019;t require the general meeting&#x2019;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $5,460.00 per Share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;According to IFRS 2, &#x201c;&lt;i&gt;Share-based
Payment&lt;/i&gt;&#x201d;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#x2019;s approval was calculated based on parameters as of December 31,
2019.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;October&#160;10,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,031.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,004&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the 2019 General Meeting (valuated as of December 31, 2019) was
set at $2,966.6 and $1,328.6, per Share Option, respectively.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 3, 2022 (the &#x201c;2022 Grant Date&#x201d;), the Board approved the grant of 6,851 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2022 General Meeting&#x201d;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $169 per Share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February&#160;10,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 3,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;129.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;174.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of the Share Options
granted on January 3, 2022, was set at $158.34 per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $114.66 per Share Option. The Share Options&#x2019; vesting period was set to commence retroactively from April 21, 2021, and
end at April 21, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2023, the Company issued to consultants 7,942 ordinary shares in respect of services rendered. The ordinary shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $94. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movement during the year:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Share&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt;
    price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;2023:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the
    year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options cancelled during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;2022:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;76.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options granted during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,851&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;169&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of
    the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of
    the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;163.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No Share Options were granted
    during 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life of the Share Options outstanding was 4.03 years and 5.03 years as of December 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The range of exercise prices of Share Options outstanding at the end of the year was $169 - $21,944 (inclusive) as of December 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock contextRef="c6" id="ixv-46004">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock>
    <sprcy:ResearchAndDevelopmentsExpenses contextRef="c6" decimals="-3" id="ixv-105560" unitRef="usd">34000</sprcy:ResearchAndDevelopmentsExpenses>
    <sprcy:ResearchAndDevelopmentsExpenses contextRef="c7" decimals="-3" id="ixv-105561" unitRef="usd">264000</sprcy:ResearchAndDevelopmentsExpenses>
    <sprcy:ResearchAndDevelopmentsExpenses contextRef="c8" decimals="-3" id="ixv-105562" unitRef="usd">27000</sprcy:ResearchAndDevelopmentsExpenses>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c6" decimals="-3" id="ixv-105563" unitRef="usd">68000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c7" decimals="-3" id="ixv-105564" unitRef="usd">633000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c8" decimals="-3" id="ixv-105565" unitRef="usd">16000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c6" decimals="-3" id="ixv-105566" unitRef="usd">102000</sprcy:ExpensesDueToSharebasedCompensation>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c7" decimals="-3" id="ixv-105567" unitRef="usd">897000</sprcy:ExpensesDueToSharebasedCompensation>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c8" decimals="-3" id="ixv-105568" unitRef="usd">43000</sprcy:ExpensesDueToSharebasedCompensation>
    <sprcy:OrdinarySharesGranted
      contextRef="c213"
      decimals="0"
      id="ixv-105569"
      unitRef="shares">45</sprcy:OrdinarySharesGranted>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c213"
      decimals="2"
      id="ixv-105570"
      unitRef="usdPershares">10920</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock contextRef="c6" id="ixv-46154">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected life of share options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;October&#160;10,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,031.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,004&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February&#160;10,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 3,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;129.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;174.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed contextRef="c6" decimals="2" id="ixv-105571" unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate contextRef="c6" decimals="2" id="ixv-105572" unitRef="pure">0.76</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate contextRef="c6" decimals="4" id="ixv-105573" unitRef="pure">0.0261</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c6" id="ixv-105574">P10Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueOfShareOption
      contextRef="c6"
      decimals="-3"
      id="ixv-105575"
      unitRef="usdPershares">5824000</sprcy:FairValueOfShareOption>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c214"
      decimals="2"
      id="ixv-105576"
      unitRef="usdPershares">5460</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c219"
      decimals="2"
      id="ixv-105577"
      unitRef="usdPershares">2031.12</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c215"
      decimals="0"
      id="ixv-105578"
      unitRef="usdPershares">4004</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c219"
      decimals="2"
      id="ixv-105579"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c215"
      decimals="2"
      id="ixv-105580"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c219"
      decimals="2"
      id="ixv-105581"
      unitRef="pure">0.73</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c215"
      decimals="2"
      id="ixv-105582"
      unitRef="pure">0.70</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c219"
      decimals="4"
      id="ixv-105583"
      unitRef="pure">0.0191</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c215"
      decimals="4"
      id="ixv-105584"
      unitRef="pure">0.0167</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c219" id="ixv-105585">P9Y9M10D</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c215" id="ixv-105586">P10Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueOfShareOption
      contextRef="c215"
      decimals="1"
      id="ixv-105587"
      unitRef="usdPershares">2966.6</sprcy:FairValueOfShareOption>
    <sprcy:FairValueOfShareOption
      contextRef="c216"
      decimals="1"
      id="ixv-105588"
      unitRef="usdPershares">1328.6</sprcy:FairValueOfShareOption>
    <sprcy:ShareOptionsGranted
      contextRef="c217"
      decimals="0"
      id="ixv-105589"
      unitRef="shares">6851</sprcy:ShareOptionsGranted>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c217"
      decimals="0"
      id="ixv-105590"
      unitRef="usdPershares">169</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c220"
      decimals="2"
      id="ixv-105591"
      unitRef="usdPershares">129.74</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c221"
      decimals="2"
      id="ixv-105592"
      unitRef="usdPershares">174.98</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c220"
      decimals="2"
      id="ixv-105593"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c221"
      decimals="2"
      id="ixv-105594"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c220"
      decimals="2"
      id="ixv-105595"
      unitRef="pure">1.33</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c221"
      decimals="2"
      id="ixv-105596"
      unitRef="pure">1.34</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c220"
      decimals="4"
      id="ixv-105597"
      unitRef="pure">0.02</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c221"
      decimals="4"
      id="ixv-105598"
      unitRef="pure">0.0146</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c220" id="ixv-105599">P6Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c221" id="ixv-105600">P6Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueOfShareOptionsGranted
      contextRef="c217"
      decimals="2"
      id="ixv-105601"
      unitRef="usdPershares">158.34</sprcy:FairValueOfShareOptionsGranted>
    <sprcy:FairValueOfShareOptionsGranted
      contextRef="c218"
      decimals="2"
      id="ixv-105602"
      unitRef="usdPershares">114.66</sprcy:FairValueOfShareOptionsGranted>
    <sprcy:OrdinarySharesIssued
      contextRef="c6"
      decimals="0"
      id="ixv-105603"
      unitRef="shares">7942</sprcy:OrdinarySharesIssued>
    <sprcy:OrdinarySharesGrantedDiscountRate contextRef="c6" decimals="2" id="ixv-105604" unitRef="pure">0.25</sprcy:OrdinarySharesGrantedDiscountRate>
    <sprcy:FairValueOfOrdinarySharesGranted contextRef="c6" decimals="0" id="ixv-105605" unitRef="usd">94</sprcy:FairValueOfOrdinarySharesGranted>
    <sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock contextRef="c6" id="ixv-46453">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Share&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt;
    price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;2023:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the
    year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options cancelled during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;2022:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;76.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options granted during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,851&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;169&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of
    the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of
    the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;163.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c3"
      decimals="0"
      id="ixv-105606"
      unitRef="shares">7060</sprcy:NumberOfOutstandingShareOption>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-105607"
      unitRef="usdPershares">166.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfShareOptionsCancelledInSharebasedPaymentArrangement
      contextRef="c6"
      decimals="0"
      id="ixv-105608"
      unitRef="shares">-47</sprcy:NumberOfShareOptionsCancelledInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c6"
      decimals="2"
      id="ixv-105609"
      unitRef="usdPershares">144.55</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c2"
      decimals="0"
      id="ixv-105610"
      unitRef="shares">7013</sprcy:NumberOfOutstandingShareOption>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="2"
      id="ixv-105611"
      unitRef="usdPershares">166.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement
      contextRef="c6"
      decimals="0"
      id="ixv-105612"
      unitRef="shares">5869</sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="2"
      id="ixv-105613"
      unitRef="usdPershares">165.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c35"
      decimals="0"
      id="ixv-105614"
      unitRef="shares">209</sprcy:NumberOfOutstandingShareOption>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c35"
      decimals="2"
      id="ixv-105615"
      unitRef="usdPershares">76.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfShareOptionGrantedInSharebasedPaymentArrangement
      contextRef="c7"
      decimals="0"
      id="ixv-105616"
      unitRef="shares">6851</sprcy:NumberOfShareOptionGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c7"
      decimals="0"
      id="ixv-105617"
      unitRef="usdPershares">169</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c3"
      decimals="0"
      id="ixv-105618"
      unitRef="shares">7060</sprcy:NumberOfOutstandingShareOption>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-105619"
      unitRef="usdPershares">166.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement
      contextRef="c7"
      decimals="0"
      id="ixv-105620"
      unitRef="shares">4141</sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-105621"
      unitRef="usdPershares">163.8</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption contextRef="c6" id="ixv-105622">P4Y10D</sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption>
    <sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption contextRef="c7" id="ixv-105623">P5Y10D</sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c2"
      decimals="0"
      id="ixv-105624"
      unitRef="usdPershares">169</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c3"
      decimals="0"
      id="ixv-105625"
      unitRef="usdPershares">21944</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c6" id="ixv-46658">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;20:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;REVENUES AND COST OF
    REVENUES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company sells products directly
to customers mainly through its online Amazon stores.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Under the Company&#x2019;s standard
contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return, the Company recognizes
revenue based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a
significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable
if it expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its
estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December
31, 2023, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables.
A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the
customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In certain contracts, the Company
evaluates the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining
the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis
based upon its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible
for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other
factors. Based on its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore,
sales are recorded on a gross basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022(*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Amazon fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Purchased goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Storage&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Freight&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reclassified to correlate with common practice in industry and better reflect profit and loss.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock contextRef="c6" id="ixv-46674">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022(*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Amazon fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Purchased goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Storage&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Freight&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;322&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reclassified to correlate with common practice in industry and better reflect profit and loss.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock>
    <sprcy:CostOfGoodsSold
      contextRef="c225"
      decimals="-3"
      id="ixv-105626"
      unitRef="usd">672000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold
      contextRef="c226"
      decimals="-3"
      id="ix_9_fact"
      unitRef="usd">301000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold
      contextRef="c231"
      decimals="-3"
      id="ixv-105628"
      unitRef="usd">11000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold
      contextRef="c232"
      decimals="-3"
      id="ix_10_fact"
      unitRef="usd">21000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold contextRef="c6" decimals="-3" id="ixv-105630" unitRef="usd">683000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold contextRef="c7" decimals="-3" id="ix_11_fact" unitRef="usd">322000</sprcy:CostOfGoodsSold>
    <ifrs-full:DisclosureOfAdditionalInformationExplanatory contextRef="c6" id="ixv-46831">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;21:-
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ADDITIONAL INFORMATION
    TO THE ITEMS OF PROFIT OR LOSS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 58%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Research
    and development expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages
    and related expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;392&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;436&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;357&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
    payment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;264&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory,
    professional and other expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;719&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;750&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;934&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and preclinical studies&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;703&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
    studies&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;254&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chemistry
    and formulations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;141&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;281&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;335&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,641&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,803&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,990&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;General
    and administrative expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages
    and related expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;415&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;437&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;256&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
    payment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;633&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amazon
    fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,042&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;424&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Storage&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;145&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt; width: 58%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    and directors&#x2019; fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,594&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,499&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,417&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Business
    development expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;161&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory
    expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;202&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;162&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    maintenance, rent and other expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;135&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor
    relations and business expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,486&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;784&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,972&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,778&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Other
    expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company&#x2019;s
    share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;210&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;109&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Finance
    income:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net change
    in fair value of financial liabilities designated at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,205&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,832&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange
    rate differences, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,219&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,832&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Finance
    expenses:&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    expenses related to warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,204&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange
    rate differences, net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Losses
    from remeasurement of investment in financial assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,046&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;770&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance
    expense in respect of leases&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance
    expenses from interest and commissions&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,055&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,014&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reclassified to correlate with common practice
                                            in industry and better reflect profit and loss.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationExplanatory>
    <sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss contextRef="c6" id="ixv-46841">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 58%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Research
    and development expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages
    and related expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;392&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;436&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;357&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
    payment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;264&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory,
    professional and other expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;719&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;750&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;934&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and preclinical studies&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;703&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
    studies&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;254&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chemistry
    and formulations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;141&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;281&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;335&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,641&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,803&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,990&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;General
    and administrative expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages
    and related expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;415&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;437&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;256&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
    payment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;633&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amazon
    fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,042&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;424&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Storage&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;145&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt; width: 58%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    and directors&#x2019; fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,594&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,499&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,417&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Business
    development expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;161&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory
    expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;202&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;162&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    maintenance, rent and other expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;135&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor
    relations and business expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,486&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;784&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,972&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,778&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Other
    expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company&#x2019;s
    share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;210&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;109&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Finance
    income:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net change
    in fair value of financial liabilities designated at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,205&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,832&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange
    rate differences, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,219&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,832&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Finance
    expenses:&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    expenses related to warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,204&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange
    rate differences, net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Losses
    from remeasurement of investment in financial assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,046&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;770&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance
    expense in respect of leases&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance
    expenses from interest and commissions&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,055&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,014&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reclassified to correlate with common practice
                                            in industry and better reflect profit and loss.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c234"
      decimals="-3"
      id="ixv-105633"
      unitRef="usd">392000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c235"
      decimals="-3"
      id="ixv-105634"
      unitRef="usd">436000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c236"
      decimals="-3"
      id="ixv-105635"
      unitRef="usd">357000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c237"
      decimals="-3"
      id="ixv-105636"
      unitRef="usd">34000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c238"
      decimals="-3"
      id="ixv-105637"
      unitRef="usd">264000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c239"
      decimals="-3"
      id="ixv-105638"
      unitRef="usd">27000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c240"
      decimals="-3"
      id="ixv-105639"
      unitRef="usd">719000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c241"
      decimals="-3"
      id="ixv-105640"
      unitRef="usd">750000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c242"
      decimals="-3"
      id="ixv-105641"
      unitRef="usd">934000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c243"
      decimals="-3"
      id="ixv-105642"
      unitRef="usd">101000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c244"
      decimals="-3"
      id="ixv-105643"
      unitRef="usd">703000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c245"
      decimals="-3"
      id="ixv-105644"
      unitRef="usd">165000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c246"
      decimals="-3"
      id="ixv-105645"
      unitRef="usd">254000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c247"
      decimals="-3"
      id="ixv-105646"
      unitRef="usd">369000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c248"
      decimals="-3"
      id="ixv-105647"
      unitRef="usd">172000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c249"
      decimals="-3"
      id="ixv-105648"
      unitRef="usd">141000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c250"
      decimals="-3"
      id="ixv-105649"
      unitRef="usd">281000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c251"
      decimals="-3"
      id="ixv-105650"
      unitRef="usd">335000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c6" decimals="-3" id="ixv-105651" unitRef="usd">1641000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c7" decimals="-3" id="ixv-105652" unitRef="usd">2803000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c8" decimals="-3" id="ixv-105653" unitRef="usd">1990000</sprcy:ResearchAndDevelopmentExpenses1>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c234"
      decimals="-3"
      id="ixv-105654"
      unitRef="usd">415000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c235"
      decimals="-3"
      id="ixv-105655"
      unitRef="usd">437000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c236"
      decimals="-3"
      id="ixv-105656"
      unitRef="usd">256000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c237"
      decimals="-3"
      id="ixv-105657"
      unitRef="usd">68000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c238"
      decimals="-3"
      id="ixv-105658"
      unitRef="usd">633000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c239"
      decimals="-3"
      id="ixv-105659"
      unitRef="usd">16000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c252"
      decimals="-3"
      id="ixv-105660"
      unitRef="usd">1042000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c253"
      decimals="-3"
      id="ixv-105661"
      unitRef="usd">424000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c255"
      decimals="-3"
      id="ixv-105662"
      unitRef="usd">145000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c256"
      decimals="-3"
      id="ixv-105663"
      unitRef="usd">90000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c257"
      decimals="-3"
      id="ixv-105664"
      unitRef="usd">2594000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c258"
      decimals="-3"
      id="ixv-105665"
      unitRef="usd">2499000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c259"
      decimals="-3"
      id="ixv-105666"
      unitRef="usd">2417000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c260"
      decimals="-3"
      id="ixv-105667"
      unitRef="usd">86000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c261"
      decimals="-3"
      id="ixv-105668"
      unitRef="usd">161000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c262"
      decimals="-3"
      id="ixv-105669"
      unitRef="usd">5000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c263"
      decimals="-3"
      id="ixv-105670"
      unitRef="usd">202000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c264"
      decimals="-3"
      id="ixv-105671"
      unitRef="usd">162000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c265"
      decimals="-3"
      id="ixv-105672"
      unitRef="usd">165000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c266"
      decimals="-3"
      id="ixv-105673"
      unitRef="usd">110000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c267"
      decimals="-3"
      id="ix_12_fact"
      unitRef="usd">80000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c268"
      decimals="-3"
      id="ixv-105675"
      unitRef="usd">135000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c269"
      decimals="-3"
      id="ixv-105676"
      unitRef="usd">369000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c270"
      decimals="-3"
      id="ixv-105677"
      unitRef="usd">1486000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c271"
      decimals="-3"
      id="ixv-105678"
      unitRef="usd">784000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-105679" unitRef="usd">5031000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-105680" unitRef="usd">5972000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c8" decimals="-3" id="ixv-105681" unitRef="usd">3778000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c6" decimals="-3" id="ixv-105682" unitRef="usd">210000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c7" decimals="-3" id="ixv-105683" unitRef="usd">109000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:FinanceIncome
      contextRef="c272"
      decimals="-3"
      id="ixv-105684"
      unitRef="usd">2205000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c273"
      decimals="-3"
      id="ixv-105685"
      unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c275"
      decimals="-3"
      id="ixv-105686"
      unitRef="usd">14000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c6" decimals="-3" id="ixv-105687" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c7" decimals="-3" id="ixv-105688" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="c279"
      decimals="-3"
      id="ixv-105689"
      unitRef="usd">1204000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c280"
      decimals="-3"
      id="ixv-105690"
      unitRef="usd">6000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c276"
      decimals="-3"
      id="ixv-105691"
      unitRef="usd">4000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c277"
      decimals="-3"
      id="ixv-105692"
      unitRef="usd">3000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c281"
      decimals="-3"
      id="ixv-105693"
      unitRef="usd">1046000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c282"
      decimals="-3"
      id="ixv-105694"
      unitRef="usd">770000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c284"
      decimals="-3"
      id="ixv-105695"
      unitRef="usd">9000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c285"
      decimals="-3"
      id="ixv-105696"
      unitRef="usd">15000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c286"
      decimals="-3"
      id="ixv-105697"
      unitRef="usd">4000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c288"
      decimals="-3"
      id="ixv-105698"
      unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c289"
      decimals="-3"
      id="ixv-105699"
      unitRef="usd">8000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c6" decimals="-3" id="ixv-105700" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c7" decimals="-3" id="ixv-105701" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c8" decimals="-3" id="ixv-105702" unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c6" id="ixv-47700">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 22:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LOSS PER SHARE/ADS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares
    (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares
    (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In&lt;br/&gt; thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;In&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In&lt;br/&gt; thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Continuing operations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Basic loss per share&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;408&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;79&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of potential dilutive ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;176&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Loss per share retroactively adjusted in these
                                            consolidated statements of comprehensive loss to reflect &#x201c;Reverse Split&#x201d; (see
                                            note 18a).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The computation of diluted
    loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive
    effect):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share Options to employees,
    officers, directors and consultants; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable warrants
    to investors.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c6" id="ixv-47716">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares
    (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares
    (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In&lt;br/&gt; thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;In&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In&lt;br/&gt; thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Continuing operations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Basic loss per share&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;408&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;79&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of potential dilutive ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;176&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Loss per share retroactively adjusted in these
                                            consolidated statements of comprehensive loss to reflect &#x201c;Reverse Split&#x201d; (see
                                            note 18a).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="c95"
      decimals="-3"
      id="ixv-105703"
      unitRef="shares">408000</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c6" decimals="-3" id="ixv-105704" unitRef="usd">-5883000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:WeightedAverageShares
      contextRef="c7"
      decimals="-3"
      id="ixv-105705"
      unitRef="shares">176000</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c7" decimals="-3" id="ixv-105706" unitRef="usd">-2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:WeightedAverageShares
      contextRef="c8"
      decimals="-3"
      id="ixv-105707"
      unitRef="shares">79000</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c8" decimals="-3" id="ixv-105708" unitRef="usd">-5789000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c95"
      decimals="-3"
      id="ixv-105709"
      unitRef="shares">408000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c6" decimals="-3" id="ixv-105710" unitRef="usd">-5883000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c7"
      decimals="-3"
      id="ixv-105711"
      unitRef="shares">176000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c7" decimals="-3" id="ixv-105712" unitRef="usd">-2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c8"
      decimals="-3"
      id="ixv-105713"
      unitRef="shares">79000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c8" decimals="-3" id="ixv-105714" unitRef="usd">-5789000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c6" id="ixv-48016">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;23:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OPERATING SEGMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies the principles
of IFRS 8,&#160;&#x201c;&lt;i&gt;Operating Segments&lt;/i&gt;&#x201d;&lt;i&gt;&#160;&lt;/i&gt;(&#x201c;IFRS 8&#x201d;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#x2019;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#x201c;CODM&#x201d;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#x2019;s management determined that it has two reportable segments &#x2013; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#x2019;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The review of the CODM is carried
out according to the results of the segment&#x2019;s activity. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Group&#x2019;s CODM is the CEO
of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt;
    Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt;
    Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,359&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,773&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,164&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment
    loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Company&#x2019;s share of losses of company accounted for at equity,
    net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,818&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment
    loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,789&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,595&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,605&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c6" id="ixv-48032">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Group&#x2019;s CODM is the CEO
of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt;
    Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt;
    Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,359&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,773&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,164&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment
    loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Company&#x2019;s share of losses of company accounted for at equity,
    net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,818&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment
    loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,789&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,595&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,605&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <sprcy:ExternalRevenues
      contextRef="c291"
      decimals="-3"
      id="ixv-105715"
      unitRef="usd">2879000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c6" decimals="-3" id="ixv-105716" unitRef="usd">2879000</sprcy:ExternalRevenues>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c291"
      decimals="-3"
      id="ixv-105717"
      unitRef="usd">2879000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c6" decimals="-3" id="ixv-105718" unitRef="usd">2879000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c290"
      decimals="-3"
      id="ixv-105719"
      unitRef="usd">5359000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c291"
      decimals="-3"
      id="ixv-105720"
      unitRef="usd">414000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c6" decimals="-3" id="ixv-105721" unitRef="usd">5773000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c6" decimals="-3" id="ixv-105722" unitRef="usd">210000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c6" decimals="-3" id="ixv-105723" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:InterestRevenueExpense contextRef="c6" decimals="-3" id="ixv-105724" unitRef="usd">-1164000</ifrs-full:InterestRevenueExpense>
    <sprcy:TaxExpense contextRef="c6" decimals="-3" id="ixv-105725" unitRef="usd">22000</sprcy:TaxExpense>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-105726" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <sprcy:ExternalRevenues
      contextRef="c293"
      decimals="-3"
      id="ixv-105727"
      unitRef="usd">1347000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c7" decimals="-3" id="ixv-105728" unitRef="usd">1347000</sprcy:ExternalRevenues>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c293"
      decimals="-3"
      id="ixv-105729"
      unitRef="usd">1347000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c7" decimals="-3" id="ixv-105730" unitRef="usd">1347000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c292"
      decimals="-3"
      id="ixv-105731"
      unitRef="usd">8405000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c293"
      decimals="-3"
      id="ixv-105732"
      unitRef="usd">-118000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c7" decimals="-3" id="ixv-105733" unitRef="usd">8287000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c7" decimals="-3" id="ixv-105734" unitRef="usd">109000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c7" decimals="-3" id="ixv-105735" unitRef="usd">-5818000</ifrs-full:InterestRevenueExpense>
    <sprcy:TaxExpense contextRef="c7" decimals="-3" id="ixv-105736" unitRef="usd">14000</sprcy:TaxExpense>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-105737" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c294"
      decimals="-3"
      id="ixv-105738"
      unitRef="usd">5768000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c8" decimals="-3" id="ixv-105739" unitRef="usd">5768000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:InterestRevenueExpense contextRef="c8" decimals="-3" id="ixv-105740" unitRef="usd">21000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:ProfitLoss contextRef="c8" decimals="-3" id="ixv-105741" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherAssets
      contextRef="c296"
      decimals="-3"
      id="ixv-105742"
      unitRef="usd">7069000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c297"
      decimals="-3"
      id="ixv-105743"
      unitRef="usd">4113000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c2" decimals="-3" id="ixv-105744" unitRef="usd">11182000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c296"
      decimals="-3"
      id="ixv-105745"
      unitRef="usd">1441000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c297"
      decimals="-3"
      id="ixv-105746"
      unitRef="usd">154000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c2" decimals="-3" id="ixv-105747" unitRef="usd">1595000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherAssets
      contextRef="c298"
      decimals="-3"
      id="ixv-105748"
      unitRef="usd">9664000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c299"
      decimals="-3"
      id="ixv-105749"
      unitRef="usd">941000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c3" decimals="-3" id="ixv-105750" unitRef="usd">10605000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c298"
      decimals="-3"
      id="ixv-105751"
      unitRef="usd">4021000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c299"
      decimals="-3"
      id="ixv-105752"
      unitRef="usd">135000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c3" decimals="-3" id="ixv-105753" unitRef="usd">4156000</ifrs-full:OtherLiabilities>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c6" id="ixv-48691">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;24:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TRANSACTIONS AND BALANCES
    WITH RELATED PARTIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;208&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale of minority interest in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;962&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Management fees (see also note 25a)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;779&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 23, 2023, the Company entered into an agreement with Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo Inc.&#x201d;), a newly-formed wholly owned subsidiary of Jeffs&#x2019; Brands. Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#x2019;&#160;Brands (see also note 25a).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#x201c;Cooperation Agreement&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2023 and 2022, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $40 and $208, respectively.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 17, 2022, we invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 7,692 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind (see also note 8).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Amitai Weiss, our chairman
    of the board of directors, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory contextRef="c6" id="ixv-48707">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory>
    <ifrs-full:CurrentAssets
      contextRef="c303"
      decimals="-3"
      id="ixv-105754"
      unitRef="usd">121000</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c303"
      decimals="-3"
      id="ixv-105755"
      unitRef="usd">108000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentLiabilities
      contextRef="c302"
      decimals="-3"
      id="ixv-105756"
      unitRef="usd">95000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c304"
      decimals="-3"
      id="ixv-105757"
      unitRef="usd">70000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c305"
      decimals="-3"
      id="ixv-105758"
      unitRef="usd">55000</ifrs-full:CurrentLiabilities>
    <sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory contextRef="c6" id="ixv-48812">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;208&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale of minority interest in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c6" decimals="-3" id="ixv-105759" unitRef="usd">40000</sprcy:ResearchAndDevelopmentExpenses>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c7" decimals="-3" id="ixv-105760" unitRef="usd">208000</sprcy:ResearchAndDevelopmentExpenses>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities contextRef="c6" decimals="-3" id="ixv-105761" unitRef="usd">2985000</ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c6" id="ixv-48871">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;962&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Management fees (see also note 25a)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;779&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c6" decimals="-3" id="ixv-105762" unitRef="usd">1204000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c7" decimals="-3" id="ixv-105763" unitRef="usd">1940000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c8" decimals="-3" id="ixv-105764" unitRef="usd">962000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c6" decimals="-3" id="ixv-105765" unitRef="usd">220000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c6" decimals="-3" id="ixv-105766" unitRef="usd">84000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c7" decimals="-3" id="ixv-105767" unitRef="usd">779000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c8" decimals="-3" id="ixv-105768" unitRef="usd">43000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c6" decimals="-3" id="ixv-105769" unitRef="usd">40000</sprcy:ResearchAndDevelopmentExpenses>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c7" decimals="-3" id="ixv-105770" unitRef="usd">208000</sprcy:ResearchAndDevelopmentExpenses>
    <ifrs-full:CurrentInvestments
      contextRef="c300"
      decimals="-5"
      id="ixv-105771"
      unitRef="usd">1500000</ifrs-full:CurrentInvestments>
    <sprcy:ExchangeOfCommonShares
      contextRef="c301"
      decimals="0"
      id="ixv-105772"
      unitRef="shares">7692</sprcy:ExchangeOfCommonShares>
    <sprcy:OutstandingShareCapital
      contextRef="c301"
      decimals="4"
      id="ixv-105773"
      unitRef="pure">0.0933</sprcy:OutstandingShareCapital>
    <sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock contextRef="c6" id="ixv-49022">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px; text-align: left"&gt;&lt;b&gt;NOTE 25:- &lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;SIGNIFICANT EVENTS DURING THE
                                            REPORTING PERIOD&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 23, 2023, the Company entered into an agreement with Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo Inc.&#x201d;), a newly-formed wholly owned subsidiary of Jeffs&#x2019; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#x2019;s wholly owned subsidiary, SciSparc US which owns Wellution&lt;sup&gt;TM&lt;/sup&gt;, for $2,500 in cash, and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#x201c;Price Adjustment&#x201d;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#x201c;Holdback Shares&#x201d;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#x2019; Brands, the Company holds approximately 51% of the share capital of SciSparc US.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="text-indent: 1.25in; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Pursuant to the agreement, at the
closing of the transaction, Jeffs&#x2019; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#x2019;
Brands provides management services to SciSparc US for the Wellution&lt;sup&gt;TM &lt;/sup&gt;brand for a monthly fee of $20 and Jeffs&#x2019; Brands
received a one-time signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated
by either party with 30 days advance notice. On November 2023 the monthly fee reduced to $10 thousand. For the year ended December 31,
2023, the Company has recorded management services expenses in the amount of $220.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition, in connection with the
closing of the transaction, the Company and Jeffs&#x2019; Brands, engaged in a mutual share exchange in the amount of $288,238 of ordinary
shares from each of the Company and Jeffs&#x2019; Brands. The number of shares in the share exchange was calculated based on the average
closing price of the relevant company&#x2019;s shares for 30 consecutive trading days ending on the third trading day immediately prior
to the closing. Accordingly, the Company acquired 35,345 ordinary shares of Jeffs&#x2019; Brands and Jeffs&#x2019; Brands acquired 13,858
ordinary shares of the Company having an aggregate value of $288,238, which was adjusted from $300,000 according to the 4.99% ownership
limit included in the definitive agreements. As of December 31, 2023, the listed share price of Jeff&#x2019;s Brands on the NASDAQ was
$ 3.05, and the Company has recorded a loss in its statements of comprehensive loss of $180 on its investment.&lt;/p&gt;</sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock>
    <sprcy:InterestPercentgae
      contextRef="c306"
      decimals="2"
      id="ixv-105774"
      unitRef="pure">0.49</sprcy:InterestPercentgae>
    <ifrs-full:Cash
      contextRef="c307"
      decimals="-3"
      id="ixv-105775"
      unitRef="usd">2500000</ifrs-full:Cash>
    <sprcy:DeferredCashPayments
      contextRef="c306"
      decimals="-3"
      id="ixv-105776"
      unitRef="usd">489330000</sprcy:DeferredCashPayments>
    <sprcy:ShareCapitalPercentage
      contextRef="c308"
      decimals="2"
      id="ixv-105777"
      unitRef="pure">0.51</sprcy:ShareCapitalPercentage>
    <sprcy:FeeExpenses contextRef="c6" decimals="-3" id="ixv-105778" unitRef="usd">20000</sprcy:FeeExpenses>
    <sprcy:BonusAmountReceived contextRef="c6" decimals="-3" id="ixv-105779" unitRef="usd">51000</sprcy:BonusAmountReceived>
    <sprcy:FeeExpenses
      contextRef="c309"
      decimals="-3"
      id="ixv-105780"
      unitRef="usd">10000</sprcy:FeeExpenses>
    <ifrs-full:ServicesExpense contextRef="c6" decimals="-3" id="ixv-105781" unitRef="usd">220000</ifrs-full:ServicesExpense>
    <sprcy:MutualShareExchangeAmount contextRef="c6" decimals="-3" id="ixv-105782" unitRef="usd">288238000</sprcy:MutualShareExchangeAmount>
    <sprcy:OrdinarySharesAcquired
      contextRef="c6"
      decimals="0"
      id="ixv-105783"
      unitRef="shares">35345</sprcy:OrdinarySharesAcquired>
    <sprcy:OrdinarySharesAcquired
      contextRef="c310"
      decimals="0"
      id="ixv-105784"
      unitRef="shares">13858</sprcy:OrdinarySharesAcquired>
    <sprcy:AggregateValue contextRef="c6" decimals="-3" id="ixv-105785" unitRef="usd">288238000</sprcy:AggregateValue>
    <sprcy:AdjustedAmountOfAggregateValue
      contextRef="c310"
      decimals="-3"
      id="ixv-105786"
      unitRef="usd">300000000</sprcy:AdjustedAmountOfAggregateValue>
    <sprcy:OwnershipPercentage contextRef="c6" decimals="4" id="ixv-105787" unitRef="pure">0.0499</sprcy:OwnershipPercentage>
    <sprcy:ListedSharePrice
      contextRef="c2"
      decimals="2"
      id="ixv-105788"
      unitRef="usdPershares">3.05</sprcy:ListedSharePrice>
    <sprcy:ComprehensiveLossOnInvestment contextRef="c2" decimals="-3" id="ixv-105789" unitRef="usd">180000</sprcy:ComprehensiveLossOnInvestment>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c6" id="ixv-49072">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;26:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EVENTS AFTER THE REPORTING
    DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;), as amended on February 26, 2024, with YA II PN, LTD (&#x201c;YA&#x201d;),
which provided for the sale of up to $20,000 of the Company&#x2019;s Ordinary Shares (the &#x201c;Advance Shares&#x201d;). Of the $20,000
eligible to be sold pursuant to the SEPA, or the Commitment Amount, Company has sold 925,159 ordinary shares as of the issuance date
of these financial statements. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of 97%
of the market price, which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive
trading days commencing on the trading day immediately following the delivery of an advance notice to YA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000, each a Pre-Paid Advance. Each Pre-Paid Advance will
be evidenced by a promissory note, each, a Promissory Note. Each Promissory Note will fully mature 24-months following its issuance and
shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to 18% per annum upon an Event
of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note, the Company shall pay to
YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued interest, payable in cash
or by submitting an advance notice, where YA will offset the amount due to be paid to us under such notice against an equal amount of
the monthly installment amount, at the Company&#x2019;s option. If the Company elects to pay in cash, the installment amount shall also
include a payment premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note contains the Company&#x2019;s
customary representations and warranties and Events of Default.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of 55,293 of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $200.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred to register under the Securities Act the offer
and sale of the Ordinary Shares pursuant to the SEPA by YA.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="c311"
      decimals="-3"
      id="ixv-105790"
      unitRef="usd">20000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="c311"
      decimals="-3"
      id="ixv-105791"
      unitRef="usd">20000000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c312"
      decimals="0"
      id="ixv-105792"
      unitRef="shares">925159</ifrs-full:NumberOfSharesIssued>
    <sprcy:SharePricePercentage
      contextRef="c311"
      decimals="2"
      id="ixv-105793"
      unitRef="pure">0.97</sprcy:SharePricePercentage>
    <sprcy:PrepaidAdvance contextRef="c6" decimals="-3" id="ixv-105794" unitRef="usd">5000000</sprcy:PrepaidAdvance>
    <sprcy:AccruedInterestPercentage contextRef="c6" decimals="2" id="ixv-105795" unitRef="pure">0.05</sprcy:AccruedInterestPercentage>
    <sprcy:CommitmentPercentage contextRef="c6" decimals="2" id="ixv-105796" unitRef="pure">0.18</sprcy:CommitmentPercentage>
    <sprcy:InstallmentPaymentPercentage contextRef="c6" decimals="2" id="ixv-105797" unitRef="pure">0.10</sprcy:InstallmentPaymentPercentage>
    <sprcy:PaymentPremiumPercentage contextRef="c6" decimals="2" id="ixv-105798" unitRef="pure">0.05</sprcy:PaymentPremiumPercentage>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c313"
      decimals="0"
      id="ixv-105799"
      unitRef="shares">55293</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:FeeAndCommissionExpense contextRef="c6" decimals="-3" id="ixv-105800" unitRef="usd">200000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-105801" unitRef="usd">252000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-105802" unitRef="usd">2081000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-105803" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-105804" unitRef="usd">64000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-105805" unitRef="usd">44000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-105806" unitRef="usd">65000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c4" decimals="-3" id="ixv-105807" unitRef="usd">2308000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="-3" id="ixv-105808" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentTradeReceivables contextRef="c4" decimals="-3" id="ixv-105809" unitRef="usd">19000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c5" decimals="-3" id="ixv-105810" unitRef="usd">43000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c2" decimals="-3" id="ixv-105811" unitRef="usd">22000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c4" decimals="-3" id="ixv-105812" unitRef="usd">298000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c5" decimals="-3" id="ixv-105813" unitRef="usd">815000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-105814" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:Inventories contextRef="c4" decimals="-3" id="ixv-105815" unitRef="usd">415000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c5" decimals="-3" id="ixv-105816" unitRef="usd">660000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c2" decimals="-3" id="ixv-105817" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets contextRef="c4" decimals="-3" id="ixv-105818" unitRef="usd">3356000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c5" decimals="-3" id="ixv-105819" unitRef="usd">3643000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" id="ixv-105820" unitRef="usd">6445000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-105821" unitRef="usd">3006000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c5" decimals="-3" id="ixv-105822" unitRef="usd">4474000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-105823" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentReceivablesDueFromRelatedParties contextRef="c4" decimals="-3" id="ixv-105824" unitRef="usd">2448000</ifrs-full:NoncurrentReceivablesDueFromRelatedParties>
    <ifrs-full:InvestmentsInAssociates contextRef="c4" decimals="-3" id="ixv-105825" unitRef="usd">1196000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates contextRef="c5" decimals="-3" id="ixv-105826" unitRef="usd">893000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates contextRef="c2" decimals="-3" id="ixv-105827" unitRef="usd">781000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c4" decimals="-3" id="ixv-105828" unitRef="usd">403000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c5" decimals="-3" id="ixv-105829" unitRef="usd">849000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-105830" unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-105831" unitRef="usd">73000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-105832" unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-105833" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c4" decimals="-3" id="ixv-105834" unitRef="usd">7126000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c5" decimals="-3" id="ixv-105835" unitRef="usd">6249000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" id="ixv-105836" unitRef="usd">4737000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c4" decimals="-3" id="ixv-105837" unitRef="usd">10482000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c5" decimals="-3" id="ixv-105838" unitRef="usd">9892000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" id="ixv-105839" unitRef="usd">11182000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c4" decimals="-3" id="ixv-105840" unitRef="usd">1164000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c5" decimals="-3" id="ixv-105841" unitRef="usd">1247000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-105842" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c4" decimals="-3" id="ixv-105843" unitRef="usd">253000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c5" decimals="-3" id="ixv-105844" unitRef="usd">153000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-105845" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentWarrantLiability contextRef="c4" decimals="-3" id="ixv-105846" unitRef="usd">345000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentWarrantLiability contextRef="c5" decimals="-3" id="ixv-105847" unitRef="usd">1714000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentWarrantLiability contextRef="c2" decimals="-3" id="ixv-105848" unitRef="usd">532000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c4" decimals="-3" id="ixv-105849" unitRef="usd">38000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-105850" unitRef="usd">52000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c4" decimals="-3" id="ixv-105851" unitRef="usd">1800000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c5" decimals="-3" id="ixv-105852" unitRef="usd">3114000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="-3" id="ixv-105853" unitRef="usd">1571000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c4" decimals="-3" id="ixv-105854" unitRef="usd">26000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-105855" unitRef="usd">24000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:SharePremium contextRef="c4" decimals="-3" id="ixv-105856" unitRef="usd">67258000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c5" decimals="-3" id="ixv-105857" unitRef="usd">58898000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c2" decimals="-3" id="ixv-105858" unitRef="usd">64526000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c4" decimals="-3" id="ixv-105859" unitRef="usd">5298000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c5" decimals="-3" id="ixv-105860" unitRef="usd">5248000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="-3" id="ixv-105861" unitRef="usd">5282000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantLiability contextRef="c4" decimals="-3" id="ixv-105862" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c5" decimals="-3" id="ixv-105863" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c2" decimals="-3" id="ixv-105864" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c4" decimals="-3" id="ixv-105865" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c5" decimals="-3" id="ixv-105866" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c2" decimals="-3" id="ixv-105867" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherEquityInterest contextRef="c4" decimals="-3" id="ixv-105868" unitRef="usd">810000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c5" decimals="-3" id="ixv-105869" unitRef="usd">712000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c2" decimals="-3" id="ixv-105870" unitRef="usd">810000</ifrs-full:OtherEquityInterest>
    <ifrs-full:RetainedEarnings contextRef="c4" decimals="-3" id="ixv-105871" unitRef="usd">-72133000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c5" decimals="-3" id="ixv-105872" unitRef="usd">-66449000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-105873" unitRef="usd">-68691000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c4" decimals="-3" id="ixv-105874" unitRef="usd">6920000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c5" decimals="-3" id="ixv-105875" unitRef="usd">4096000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c2" decimals="-3" id="ixv-105876" unitRef="usd">7614000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-105877" unitRef="usd">1736000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c5" decimals="-3" id="ixv-105878" unitRef="usd">2682000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c2" decimals="-3" id="ixv-105879" unitRef="usd">1973000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c4" decimals="-3" id="ixv-105880" unitRef="usd">8656000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="-3" id="ixv-105881" unitRef="usd">6778000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-105882" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c4" decimals="-3" id="ixv-105883" unitRef="usd">10482000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c5" decimals="-3" id="ixv-105884" unitRef="usd">9892000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" id="ixv-105885" unitRef="usd">11182000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue contextRef="c0" decimals="-3" id="ixv-105886" unitRef="usd">840000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c9" decimals="-3" id="ixv-105887" unitRef="usd">1972000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c6" decimals="-3" id="ixv-105888" unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c0" decimals="-3" id="ixv-105889" unitRef="usd">366000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c9" decimals="-3" id="ixv-105890" unitRef="usd">508000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c6" decimals="-3" id="ixv-105891" unitRef="usd">683000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c0" decimals="-3" id="ixv-105892" unitRef="usd">474000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c9" decimals="-3" id="ixv-105893" unitRef="usd">1464000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c6" decimals="-3" id="ixv-105894" unitRef="usd">2196000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-105895" unitRef="usd">841000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c9" decimals="-3" id="ixv-105896" unitRef="usd">781000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-105897" unitRef="usd">1641000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-105898" unitRef="usd">528000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c9" decimals="-3" id="ixv-105899" unitRef="usd">729000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-105900" unitRef="usd">1297000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c6" decimals="-3" id="ixv-105901" unitRef="usd">1042000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-105902" unitRef="usd">2632000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c9" decimals="-3" id="ixv-105903" unitRef="usd">2921000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-105904" unitRef="usd">5031000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-105905" unitRef="usd">-3527000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c9" decimals="-3" id="ixv-105906" unitRef="usd">-2967000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c6" decimals="-3" id="ixv-105907" unitRef="usd">-6815000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-105908" unitRef="usd">-208000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c9" decimals="-3" id="ixv-105909" unitRef="usd">-99000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c6" decimals="-3" id="ixv-105910" unitRef="usd">-210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-105911" unitRef="usd">323000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c9" decimals="-3" id="ixv-105912" unitRef="usd">1024000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c6" decimals="-3" id="ixv-105913" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-105914" unitRef="usd">272000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c9" decimals="-3" id="ixv-105915" unitRef="usd">877000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c6" decimals="-3" id="ixv-105916" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="-3" id="ixv-105917" unitRef="usd">-3684000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c9" decimals="-3" id="ixv-105918" unitRef="usd">-2919000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c6" decimals="-3" id="ixv-105919" unitRef="usd">-5861000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="-3" id="ixv-105920" unitRef="usd">-5000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c9" decimals="-3" id="ixv-105921" unitRef="usd">13000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c6" decimals="-3" id="ixv-105922" unitRef="usd">22000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-105923" unitRef="usd">-3679000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c9" decimals="-3" id="ixv-105924" unitRef="usd">-2932000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-105925" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c0" decimals="-3" id="ixv-105926" unitRef="usd">-3442000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c9" decimals="-3" id="ixv-105927" unitRef="usd">-2880000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c6" decimals="-3" id="ixv-105928" unitRef="usd">-5122000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-105929" unitRef="usd">-237000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c9" decimals="-3" id="ixv-105930" unitRef="usd">-52000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c6" decimals="-3" id="ixv-105931" unitRef="usd">-761000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-105932" unitRef="usd">-3679000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c9" decimals="-3" id="ixv-105933" unitRef="usd">-2932000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-105934" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c0"
      decimals="-3"
      id="ixv-105935"
      unitRef="shares">2166282000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="-3"
      id="ixv-105936"
      unitRef="shares">2166282000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c9"
      decimals="-3"
      id="ixv-105937"
      unitRef="shares">270354000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c9"
      decimals="-3"
      id="ixv-105938"
      unitRef="shares">270354000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c6"
      decimals="-3"
      id="ixv-105939"
      unitRef="shares">407681000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c6"
      decimals="-3"
      id="ixv-105940"
      unitRef="shares">407681000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-105941"
      unitRef="usdPershares">1.7</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-105942"
      unitRef="usdPershares">1.7</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c9"
      decimals="2"
      id="ix_6_fact"
      unitRef="usdPershares">10.85</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c9"
      decimals="2"
      id="ix_7_fact"
      unitRef="usdPershares">10.85</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c6"
      decimals="2"
      id="ixv-105945"
      unitRef="usdPershares">14.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c6"
      decimals="2"
      id="ixv-105946"
      unitRef="usdPershares">14.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:Equity
      contextRef="c60"
      decimals="-3"
      id="ixv-105948"
      unitRef="usd">64526000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c61"
      decimals="-3"
      id="ixv-105949"
      unitRef="usd">5282000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c62"
      decimals="-3"
      id="ixv-105950"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c63"
      decimals="-3"
      id="ixv-105951"
      unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c64"
      decimals="-3"
      id="ixv-105952"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c65"
      decimals="-3"
      id="ixv-105953"
      unitRef="usd">-68691000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c66"
      decimals="-3"
      id="ixv-105954"
      unitRef="usd">7614000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c67"
      decimals="-3"
      id="ixv-105955"
      unitRef="usd">1973000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-105956" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="c68"
      decimals="-3"
      id="ixv-105957"
      unitRef="usd">-3442000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c69"
      decimals="-3"
      id="ixv-105958"
      unitRef="usd">-3442000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c70"
      decimals="-3"
      id="ixv-105959"
      unitRef="usd">-237000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-105960" unitRef="usd">-3679000</ifrs-full:ProfitLoss>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c71"
      decimals="-3"
      id="ixv-105961"
      unitRef="usd">2722000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c69"
      decimals="-3"
      id="ixv-105962"
      unitRef="usd">2722000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c0" decimals="-3" id="ixv-105963" unitRef="usd">2722000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c71"
      decimals="-3"
      id="ixv-105964"
      unitRef="usd">10000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c72"
      decimals="-3"
      id="ixv-105965"
      unitRef="usd">16000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c69"
      decimals="-3"
      id="ixv-105966"
      unitRef="usd">26000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-105967" unitRef="usd">26000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity
      contextRef="c73"
      decimals="-3"
      id="ixv-105968"
      unitRef="usd">67258000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c74"
      decimals="-3"
      id="ixv-105969"
      unitRef="usd">5298000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c75"
      decimals="-3"
      id="ixv-105970"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c76"
      decimals="-3"
      id="ixv-105971"
      unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c77"
      decimals="-3"
      id="ixv-105972"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c78"
      decimals="-3"
      id="ixv-105973"
      unitRef="usd">-72133000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c79"
      decimals="-3"
      id="ixv-105974"
      unitRef="usd">6920000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c80"
      decimals="-3"
      id="ixv-105975"
      unitRef="usd">1736000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c4" decimals="-3" id="ixv-105976" unitRef="usd">8656000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c44"
      decimals="-3"
      id="ixv-105977"
      unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c45"
      decimals="-3"
      id="ixv-105978"
      unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c46"
      decimals="-3"
      id="ixv-105979"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c47"
      decimals="-3"
      id="ixv-105980"
      unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c48"
      decimals="-3"
      id="ixv-105981"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c49"
      decimals="-3"
      id="ixv-105982"
      unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c50"
      decimals="-3"
      id="ixv-105983"
      unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-105984" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="c81"
      decimals="-3"
      id="ixv-105985"
      unitRef="usd">-2880000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c82"
      decimals="-3"
      id="ixv-105986"
      unitRef="usd">-2880000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c83"
      decimals="-3"
      id="ixv-105987"
      unitRef="usd">-52000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c9" decimals="-3" id="ixv-105988" unitRef="usd">-2932000</ifrs-full:ProfitLoss>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c84"
      decimals="-3"
      id="ixv-105989"
      unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c82"
      decimals="-3"
      id="ixv-105990"
      unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c9" decimals="-3" id="ixv-105991" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c85"
      decimals="-3"
      id="ixv-105992"
      unitRef="usd">153000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c82"
      decimals="-3"
      id="ixv-105993"
      unitRef="usd">153000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c83"
      decimals="-3"
      id="ixv-105994"
      unitRef="usd">2734000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c9" decimals="-3" id="ixv-105995" unitRef="usd">2887000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c84"
      decimals="-3"
      id="ixv-105996"
      unitRef="usd">-45000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c82"
      decimals="-3"
      id="ixv-105997"
      unitRef="usd">-45000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c9" decimals="-3" id="ixv-105998" unitRef="usd">-45000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c84"
      decimals="-3"
      id="ixv-105999"
      unitRef="usd">63000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c86"
      decimals="-3"
      id="ixv-106000"
      unitRef="usd">68000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c82"
      decimals="-3"
      id="ixv-106001"
      unitRef="usd">131000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c9" decimals="-3" id="ixv-106002" unitRef="usd">131000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity
      contextRef="c87"
      decimals="-3"
      id="ixv-106003"
      unitRef="usd">58898000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c88"
      decimals="-3"
      id="ixv-106004"
      unitRef="usd">5248000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c89"
      decimals="-3"
      id="ixv-106005"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c90"
      decimals="-3"
      id="ixv-106006"
      unitRef="usd">712000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c91"
      decimals="-3"
      id="ixv-106007"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c92"
      decimals="-3"
      id="ixv-106008"
      unitRef="usd">-66449000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c93"
      decimals="-3"
      id="ixv-106009"
      unitRef="usd">4096000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c94"
      decimals="-3"
      id="ixv-106010"
      unitRef="usd">2682000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="-3" id="ixv-106011" unitRef="usd">6778000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c44"
      decimals="-3"
      id="ixv-106012"
      unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c45"
      decimals="-3"
      id="ixv-106013"
      unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c46"
      decimals="-3"
      id="ixv-106014"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c47"
      decimals="-3"
      id="ixv-106015"
      unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c48"
      decimals="-3"
      id="ixv-106016"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c49"
      decimals="-3"
      id="ixv-106017"
      unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c50"
      decimals="-3"
      id="ixv-106018"
      unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-106019" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="c57"
      decimals="-3"
      id="ixv-106020"
      unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c58"
      decimals="-3"
      id="ixv-106021"
      unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="c59"
      decimals="-3"
      id="ixv-106022"
      unitRef="usd">-761000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-106023" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c55"
      decimals="-3"
      id="ixv-106024"
      unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c58"
      decimals="-3"
      id="ixv-106025"
      unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c59"
      decimals="-3"
      id="ixv-106026"
      unitRef="usd">2734000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c6" decimals="-3" id="ixv-106027" unitRef="usd">2985000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c52"
      decimals="-3"
      id="ixv-106028"
      unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c58"
      decimals="-3"
      id="ixv-106029"
      unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c6" decimals="-3" id="ixv-106030" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c52"
      decimals="-3"
      id="ixv-106031"
      unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c58"
      decimals="-3"
      id="ixv-106032"
      unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c6" decimals="-3" id="ixv-106033" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c52"
      decimals="-3"
      id="ixv-106034"
      unitRef="usd">94000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c53"
      decimals="-3"
      id="ixv-106035"
      unitRef="usd">102000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c58"
      decimals="-3"
      id="ixv-106036"
      unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c6" decimals="-3" id="ixv-106037" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity
      contextRef="c60"
      decimals="-3"
      id="ixv-106038"
      unitRef="usd">64526000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c61"
      decimals="-3"
      id="ixv-106039"
      unitRef="usd">5282000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c62"
      decimals="-3"
      id="ixv-106040"
      unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c63"
      decimals="-3"
      id="ixv-106041"
      unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c64"
      decimals="-3"
      id="ixv-106042"
      unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c65"
      decimals="-3"
      id="ixv-106043"
      unitRef="usd">-68691000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c66"
      decimals="-3"
      id="ixv-106044"
      unitRef="usd">7614000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="c67"
      decimals="-3"
      id="ixv-106045"
      unitRef="usd">1973000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-106046" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-106047" unitRef="usd">-3679000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c9" decimals="-3" id="ixv-106048" unitRef="usd">-2932000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-106049" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c0" decimals="-3" id="ixv-106050" unitRef="usd">219000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c9" decimals="-3" id="ixv-106051" unitRef="usd">267000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c6" decimals="-3" id="ixv-106052" unitRef="usd">538000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c6" decimals="-3" id="ixv-106053" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-106054" unitRef="usd">26000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c9" decimals="-3" id="ixv-106055" unitRef="usd">131000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c6" decimals="-3" id="ixv-106056" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-106057" unitRef="usd">206000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c9" decimals="-3" id="ixv-106058" unitRef="usd">1023000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c6" decimals="-3" id="ixv-106059" unitRef="usd">2205000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c0" decimals="-3" id="ixv-106060" unitRef="usd">185000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c9" decimals="-3" id="ixv-106061" unitRef="usd">98000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c6" decimals="-3" id="ixv-106062" unitRef="usd">210000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c0" decimals="-3" id="ixv-106063" unitRef="usd">256000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c9" decimals="-3" id="ixv-106064" unitRef="usd">855000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c6" decimals="-3" id="ixv-106065" unitRef="usd">1048000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c0" decimals="-3" id="ixv-106066" unitRef="usd">480000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c9" decimals="-3" id="ixv-106067" unitRef="usd">328000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c6" decimals="-3" id="ixv-106068" unitRef="usd">829000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c0" decimals="-3" id="ixv-106069" unitRef="usd">242000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c9" decimals="-3" id="ixv-106070" unitRef="usd">-684000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c6" decimals="-3" id="ixv-106071" unitRef="usd">-409000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="-3" id="ixv-106072" unitRef="usd">362000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c9" decimals="-3" id="ixv-106073" unitRef="usd">48000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c6" decimals="-3" id="ixv-106074" unitRef="usd">-397000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="-3" id="ixv-106075" unitRef="usd">68000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c9" decimals="-3" id="ixv-106076" unitRef="usd">-40000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c6" decimals="-3" id="ixv-106077" unitRef="usd">-8000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c0" decimals="-3" id="ixv-106078" unitRef="usd">3000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c9" decimals="-3" id="ixv-106079" unitRef="usd">39000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c6" decimals="-3" id="ixv-106080" unitRef="usd">55000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c0" decimals="-3" id="ixv-106081" unitRef="usd">327000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c9" decimals="-3" id="ixv-106082" unitRef="usd">8000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c6" decimals="-3" id="ixv-106083" unitRef="usd">-74000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c0" decimals="-3" id="ixv-106084" unitRef="usd">1002000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c9" decimals="-3" id="ixv-106085" unitRef="usd">-629000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c6" decimals="-3" id="ixv-106086" unitRef="usd">-833000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-106087" unitRef="usd">-2197000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c9" decimals="-3" id="ixv-106088" unitRef="usd">-3233000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-106089" unitRef="usd">-5887000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-106090" unitRef="usd">1000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c9" decimals="-3" id="ixv-106091" unitRef="usd">16000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c6" decimals="-3" id="ixv-106092" unitRef="usd">-5000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c0" decimals="-3" id="ixv-106093" unitRef="usd">692000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c6" decimals="-3" id="ixv-106094" unitRef="usd">-3000000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c0" decimals="-3" id="ixv-106095" unitRef="usd">1000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-106096" unitRef="usd">600000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c9" decimals="-3" id="ixv-106097" unitRef="usd">400000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c6" decimals="-3" id="ixv-106098" unitRef="usd">400000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod contextRef="c6" decimals="-3" id="ixv-106099" unitRef="usd">689000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <sprcy:CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities contextRef="c0" decimals="-3" id="ixv-106100" unitRef="usd">2400000</sprcy:CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c9" decimals="-3" id="ixv-106101" unitRef="usd">-687000</sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-106102" unitRef="usd">-2308000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c9" decimals="-3" id="ixv-106103" unitRef="usd">-1071000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c6" decimals="-3" id="ixv-106104" unitRef="usd">-4094000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c0" decimals="-3" id="ixv-106105" unitRef="usd">-2722000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c9" decimals="-3" id="ixv-106106" unitRef="usd">50000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c6" decimals="-3" id="ixv-106107" unitRef="usd">-5552000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-106108" unitRef="usd">41000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c9" decimals="-3" id="ixv-106109" unitRef="usd">26000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c6" decimals="-3" id="ixv-106110" unitRef="usd">47000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c6" decimals="-3" id="ixv-106111" unitRef="usd">7000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c9" decimals="-3" id="ixv-106112" unitRef="usd">2887000</ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c6" decimals="-3" id="ix_8_fact" unitRef="usd">2985000</ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-106114" unitRef="usd">2681000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c9" decimals="-3" id="ixv-106115" unitRef="usd">2811000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c6" decimals="-3" id="ixv-106116" unitRef="usd">8483000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c0" decimals="-3" id="ixv-106117" unitRef="usd">-1824000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c9" decimals="-3" id="ixv-106118" unitRef="usd">-1493000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c6" decimals="-3" id="ixv-106119" unitRef="usd">-1498000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-106120" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-106121" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-106122" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-106123" unitRef="usd">252000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-106124" unitRef="usd">2081000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-106125" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <sprcy:MutualShareExchangeOfOrdinaryShares contextRef="c9" decimals="-3" id="ixv-106127" unitRef="usd">288000</sprcy:MutualShareExchangeOfOrdinaryShares>
    <sprcy:MutualShareExchangeOfOrdinaryShares contextRef="c6" decimals="-3" id="ixv-106128" unitRef="usd">288000</sprcy:MutualShareExchangeOfOrdinaryShares>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c6" decimals="-3" id="ixv-106129" unitRef="usd">102000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c0" id="ixv-53746">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;NOTE 1:-
GENERAL&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#x201c;SciSparc&#x201d;
    or the &#x201c;Company&#x201d; or the &#x201c;Group&#x201d;), a specialty clinical-stage pharmaceutical company, was incorporated in
    Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged
    in developing several innovative immunotherapy products and SciSparc&#x2019;s own patents in the immunotherapy field. In August 2015,
    the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on
    cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#x394;9-tetrahydrocannabinol
    (&#x201c;THC&#x201d;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#x2019;s disease and agitation,
    autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s ordinary shares are
        listed on Nasdaq and are trading under the symbol &#x201c;SPRC&#x201d;.&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2024, the Company had three
    private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#x201c;Evero&#x201d;);
    an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#x201c;Brain Bright&#x201d;); and a company incorporated
    under the laws of the State of Delaware: SciSparc Nutraceuticals Inc. (&#x201c;SciSparc Nutraceuticals&#x201d;) (together with Evero
    and Brain Bright, the &#x201c;Subsidiaries&#x201d;).&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
    board of directors (the &#x201c;Board&#x201d;) resolved that the final ratio for the Third Reverse Split (as defined below) will be
    26:1, which became effective on September 28, 2023. Consequently, all share numbers, share prices, and exercise prices have been
    retroactively adjusted in these interim consolidated financial statements for all periods presented.&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;These interim consolidated financial statements should be read in conjunction
    with the Company&#x2019;s annual financial statements for the year ended December 31, 2023, and accompanying notes, that were approved
    on March 31, 2024, and signed on April 1, 2024 (the &#x201c;2023 Annual Consolidated Financial Statements&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company incurred a net loss of $3,679 and had negative cash flows from operating activities of $2,197 for the six-month period ended June 30, 2024. As of June 30, 2024, the Company had an accumulated deficit of $72,133 as a result of recurring operating losses. As of June 30, 2024, the Company&#x2019;s cash and cash equivalents position is not sufficient to fund the Company&#x2019;s planned operations for at least a year beyond the date of the filing date of the consolidated financial statements. The Company&#x2019;s pharmaceuticals operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue from its pharmaceutical products. These above-mentioned factors raise substantial doubt about the Group&#x2019;s ability to continue as a going concern.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand and issuing equity and/or debt securities.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The interim consolidated financial statements for the period ended June 30, 2024, do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The interim consolidated financial statements of the Company for the
    six-month period ended on June&#160;30, 2024, were approved for issuance on October 22, 2024 (the &#x201c;Approval Date&#x201d;). In
    connection with the preparation of the interim consolidated financial statements and in accordance with authoritative guidance for
    subsequent events, the Company evaluated subsequent events after the consolidated statements of financial position date of June 30,
    2024, through November 4, 2024, the date on which the unaudited interim consolidated financial statements were available to be issued.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-106130" unitRef="usd">-3679000</ifrs-full:ProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-106131" unitRef="usd">-2197000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:RetainedEarnings contextRef="c4" decimals="-3" id="ixv-106132" unitRef="usd">-72133000</ifrs-full:RetainedEarnings>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-53831">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;NOTE 2:-
SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;b&gt;Unaudited Interim Financial Information&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s unaudited condensed
consolidated financial statements have been prepared in accordance with International Accounting Standard (&#x201c;IAS&#x201d;) 34, &#x201c;Interim
Financial Reporting&#x201d;. The significant accounting policies adopted in the preparation of the interim consolidated financial statements
are consistent with those followed in the preparation of the 2023 Annual Consolidated Financial Statements. Accordingly, these condensed
consolidated financial statements should be read in conjunction with the 2023 Annual Consolidated Financial Statements. The results for
any interim period are not necessarily indicative of results for any future period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The unaudited condensed consolidated
financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#x2019;s
management, the accompanying unaudited condensed consolidated financial statements contain all adjustments that are necessary to present
fairly the Company&#x2019;s financial position and results of operations for the interim periods presented. The results for the six-month
period ended June 30, 2024, are not necessarily indicative of the results for the year ending December&#160;31, 2024, or for any future
period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of June 30, 2024, there have been
no material changes in the Company&#x2019;s significant accounting policies from those that were disclosed in the 2023 Annual Consolidated
Financial Statements.&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory contextRef="c0" id="ixv-53869">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;NOTE 3:-
INVESTMENT IN ASSOCIATE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#x201c;MitoCareX&#x201d;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owned
31.48% of the outstanding shares of MitoCareX.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $400 in MitoCareX and increased its share ownership in MitoCareX from 31.48% to 41.92%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $600 in MitoCareX and increased its share ownership in MitoCareX from 41.92% to 52.73%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $600 installment to be deferred to March 25, 2024, and the $600 installment was paid March 11,
2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During the six months ended June 30,
2024, and 2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $185 and $98, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of second milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(185&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,196&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
    <ifrs-full:InvestmentIncome
      contextRef="c123"
      decimals="-3"
      id="ixv-106133"
      unitRef="usd">700000</ifrs-full:InvestmentIncome>
    <ifrs-full:OtherIncome
      contextRef="c125"
      decimals="-3"
      id="ixv-106134"
      unitRef="usd">1000000</ifrs-full:OtherIncome>
    <sprcy:OwnershipPercentage
      contextRef="c125"
      decimals="4"
      id="ixv-106135"
      unitRef="pure">0.5001</sprcy:OwnershipPercentage>
    <ifrs-full:InvestmentIncome
      contextRef="c126"
      decimals="-3"
      id="ixv-106136"
      unitRef="usd">700000</ifrs-full:InvestmentIncome>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="c127"
      decimals="4"
      id="ixv-106137"
      unitRef="pure">0.3148</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:OtherIncome
      contextRef="c314"
      decimals="-3"
      id="ixv-106138"
      unitRef="usd">400000</ifrs-full:OtherIncome>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="c129"
      decimals="4"
      id="ixv-106139"
      unitRef="pure">0.3148</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="c130"
      decimals="4"
      id="ixv-106140"
      unitRef="pure">0.4192</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:OtherIncome
      contextRef="c315"
      decimals="-3"
      id="ixv-106141"
      unitRef="usd">600000</ifrs-full:OtherIncome>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="c132"
      decimals="4"
      id="ixv-106142"
      unitRef="pure">0.4192</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="c133"
      decimals="4"
      id="ixv-106143"
      unitRef="pure">0.5273</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:OtherIncome
      contextRef="c120"
      decimals="0"
      id="ixv-106144"
      unitRef="usd">600</ifrs-full:OtherIncome>
    <sprcy:InstallmentPaid
      contextRef="c316"
      decimals="0"
      id="ixv-106145"
      unitRef="usd">600</sprcy:InstallmentPaid>
    <ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments
      contextRef="c317"
      decimals="0"
      id="ixv-106146"
      unitRef="usd">185</ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments
      contextRef="c318"
      decimals="0"
      id="ixv-106147"
      unitRef="usd">98</ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c0" id="ixv-53881">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of second milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(185&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,196&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c3" decimals="-3" id="ixv-106148" unitRef="usd">591000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <sprcy:InvestmentFollowingAchievementMilestone contextRef="c6" decimals="-3" id="ixv-106149" unitRef="usd">400000</sprcy:InvestmentFollowingAchievementMilestone>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments contextRef="c6" decimals="-3" id="ixv-106150" unitRef="usd">210000</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c2" decimals="-3" id="ixv-106151" unitRef="usd">781000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <sprcy:InvestmentFollowingAchievementMilestone contextRef="c0" decimals="-3" id="ixv-106152" unitRef="usd">600000</sprcy:InvestmentFollowingAchievementMilestone>
    <ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments contextRef="c0" decimals="-3" id="ixv-106153" unitRef="usd">185000</ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-106154" unitRef="usd">1196000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c0" id="ixv-53969">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4:- INTANGIBLE ASSET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On September 30, 2022, the Company
announced the closing of the acquisition (&#x201c;Wellution Acquisition&#x201d;) of Wellution&lt;sup&gt;TM&lt;/sup&gt;, an Amazon Marketplace account
and American food supplement and cosmetics brand and trademark (the &#x201c;Brand&#x201d;). In connection with the Wellution Acquisition,
the Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#x201c;M.R.M&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;At the closing, the Company paid a
cash payment of $4,540 and an additional $321 in purchase costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In addition, the Company issued to
M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00 per share (with a cashless exercise
mechanism) and with an exercise period of five years from the closing of the Wellution Acquisition (the &#x201c;September 2022 Warrants&#x201d;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100 million of gross sales by the Brand
in the aggregate or (ii) if the price of the Company&#x2019;s ordinary shares closes at $10.00 per share or above.&#160;On March 26, 2024,
M.R.M. agreed with the Company to waive all its rights under the M.R.M. Warrants and have the M.R.M. warrants cancelled for no consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under International Financial Reporting Standard (&#x201c;IFRS&#x201d;) 3, Business Combinations, for the transaction and
determined that the fair value of the gross assets acquired was concentrated in a single identifiable asset, a brand. Accordingly, the
Company treated the transaction as an asset acquisition. On the closing date of the Wellution Acquisition, the Company fully recognized
the Wellution Acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,042.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that the owner of the asset would have been required to pay
if instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of
8.7 years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined
based on the current period revenues, assuming a short-term growth rate that is consistent with management&#x2019;s expectations that
revenues of the Brand will resume their past extent, as of the date of purchase of the Brand, a growth rate thereafter of 13.8% and a
declining growth rate for the long term, reaching 2% at the terminal year. Theoretical royalties arising from the Brand were capitalized
at a discount rate of 20.6%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(183&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During the six months ended June 30,
2024, and 2023, the Company recorded depreciation expenses with respect to intangible asset in the amount of $183 and $ 243, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:Cash contextRef="c4" decimals="-3" id="ixv-106155" unitRef="usd">4540000</ifrs-full:Cash>
    <sprcy:PurchaseCostsValue contextRef="c4" decimals="0" id="ixv-106156" unitRef="usd">321</sprcy:PurchaseCostsValue>
    <sprcy:WarrantsToPurchase contextRef="c0" decimals="-3" id="ixv-106157" unitRef="usd">15000000</sprcy:WarrantsToPurchase>
    <sprcy:ExercisePrice1
      contextRef="c0"
      decimals="2"
      id="ixv-106158"
      unitRef="usdPershares">7</sprcy:ExercisePrice1>
    <sprcy:ExercisePeriod contextRef="c0" id="ixv-106159">P5Y</sprcy:ExercisePeriod>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c164"
      decimals="-6"
      id="ixv-106160"
      unitRef="usd">100000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:pricePerShare
      contextRef="c164"
      decimals="2"
      id="ixv-106161"
      unitRef="usdPershares">10</sprcy:pricePerShare>
    <sprcy:AmountTotal contextRef="c0" decimals="-3" id="ixv-106162" unitRef="usd">4861000</sprcy:AmountTotal>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c0" id="ixv-106163">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c6" decimals="-3" id="ixv-106164" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <sprcy:RevenueTerm contextRef="c6" id="ixv-106165">P8Y8M12D</sprcy:RevenueTerm>
    <sprcy:GrowthRatePercentage contextRef="c6" decimals="3" id="ixv-106166" unitRef="pure">0.138</sprcy:GrowthRatePercentage>
    <sprcy:LongTermPercentage contextRef="c6" decimals="2" id="ixv-106167" unitRef="pure">0.02</sprcy:LongTermPercentage>
    <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="c2" decimals="3" id="ixv-106168" unitRef="pure">0.206</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock contextRef="c0" id="ixv-53986">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(183&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-106169" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c6" decimals="-3" id="ixv-106170" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c6" decimals="-3" id="ixv-106171" unitRef="usd">486000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-106172" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c0" decimals="-3" id="ixv-106173" unitRef="usd">183000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-106174" unitRef="usd">3006000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="0" id="ixv-106175" unitRef="usd">183</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c9" decimals="0" id="ixv-106176" unitRef="usd">243</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory contextRef="c0" id="ixv-54070">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5:- INVESTMENT IN FINANCIAL ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Share Purchase Agreement&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On June 25, 2023, the Company entered
into a share purchase agreement (the &#x201c;Share Purchase Agreement&#x201d;) with AutoMax Motors Ltd. (&#x201c;AutoMax&#x201d;), an Israeli
company traded on the Tel Aviv Stock Exchange (&#x201c;TASE&#x201d;) and the leading parallel importer and distributor of vehicles in Israel,
pursuant to which, at the closing and upon the terms and conditions set forth in the Share Purchase Agreement, the Company invested NIS
2,500 (approximately $689) in cash, in exchange for ordinary shares, NIS 0.05 par value, of AutoMax (the &#x201c;AutoMax Shares&#x201d;)
based on a price per share of NIS 0.5. As of June 30, 2024, the listed share price of AutoMax on the TASE was NIS 0.213, and the Company
has recorded a loss in its statements of comprehensive loss of $246 on its investment. &#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Bridge Loan Agreement &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On January 16, 2024, the Company entered,
as a lender, into an agreement (the &#x201c;Bridge Loan Agreement&#x201d;) with AutoMax, pursuant to which AutoMax received from the Company
a bridge loan (the &#x201c;Bridge Loan&#x201d;) in the amount of $1,400, further to the previously announced non-binding letter of intent
for the Company to acquire AutoMax (the &#x201c;AutoMax Acquisition&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Bridge Loan Agreement states that
the principal amount of the Bridge Loan will bear interest at a rate of 7% per annum (or 9% per annum if the AutoMax Acquisition is not
consummated prior to the repayment date), compounded annually. The Bridge Loan amount, together with any accrued interest (the &#x201c;Owed
Amount&#x201d;), may be repaid in part or in whole at the discretion of AutoMax prior to the repayment date. The repayment of the Owed
Amount will be due at the earlier date of: (a) the consummation of the Merger (as defined below), in which the Owed Amount shall be deemed
a part of, and set-off against, the financing amount the Company will provide AutoMax with upon Closing, which is expected to be $4,250;
or (b) if the definitive agreement for the AutoMax Acquisition is terminated in accordance with its terms, within three months from such
termination date; or (c) July 15, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On June 9, 2024, the Company entered
into an amendment (the &#x201c;Amendment&#x201d;) to the Bridge Loan Agreement with AutoMax. Pursuant to the Amendment, the Company extended
an additional loan in the amount of $1,000 to AutoMax under terms similar to the Bridge Loan Agreement, bringing the total Bridge Loan
amount to $2,400. In addition, the repayment date was amended such as that the Owed Amount will be due at the earlier date of: (a) the
consummation of the Merger, in which the Owed Amount shall be deemed a part of, and set-off against, the financing amount the Company
will provide AutoMax with upon Closing, which is expected to be $4,250; or (b) if the definitive agreement for the AutoMax Acquisition
is terminated in accordance with its terms, within three months from such termination date. As of June 30, 2024, the loan amount and
accrued interest stand at $2,448.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On September 5, 2024, the Company
entered into a second amendment (the &#x201c;Second Amendment&#x201d;) to the Bridge Loan Agreement with AutoMax. Pursuant to the Second
Amendment, the Company extended an additional loan in the amount of $1,850 to AutoMax under terms similar to the Bridge Loan Agreement,
bringing the total Bridge Loan amount to $4,250. In consideration for the loan amount, AutoMax established a first ranking fixed charge
security interest on AutoMax&#x2019;s shares of its wholly-owned subsidiary AutoMax Leasing Ltd. in favor of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Merger Agreement &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On April 10, 2024, the Company entered
into an Agreement and Plan of Merger, as amended (the &#x201c;Merger Agreement&#x201d;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli
limited company and wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;). Upon the terms and subject to the satisfaction
of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#x2019;s shareholders and AutoMax&#x2019;s
shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the
Company (the &#x201c;Merger&#x201d;) (see also note 6).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At the
effective time of the Merger (the &#x201c;Effective Time&#x201d;, as further defined in the Merger Agreement): (a)&#160;each outstanding
share of AutoMax&#x2019;s share capital will be converted into the right to receive ordinary shares of the Company, equal to the exchange
ratio set forth in the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;). Under the Exchange Ratio, following the Effective Time, the
former AutoMax shareholders immediately before the Merger (other than the Company) are expected to hold together approximately 47.49%
(minus the Finder Fee, as defined in the Merger Agreement) of the aggregate number of the outstanding ordinary shares of the Company
on fully diluted basis (subject to certain exceptions). The shareholders of the Company, together with the holders of the Company&#x2019;s
convertible securities, immediately before the Merger are expected to hold together approximately 52.51% of the aggregate number of the
outstanding ordinary shares of the Company on fully diluted basis (subject to certain exceptions); (b) subject to the consummation of
the Merger (as defined in the Merger Agreement, the &#x201c;Closing&#x201d;), and immediately after the Effective Time, AutoMax shall have
the right to (i) designate two members to the Company&#x2019;s board of directors (the &#x201c;Company&#x2019;s Board&#x201d;) if the Company&#x2019;s
Board is comprised of five or six directors; or (ii) designate three members if the Company&#x2019;s Board is comprised of seven directors.
At least one such designee shall be an independent director, as defined under the Nasdaq Stock Market listing rules.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
    <ifrs-full:Cash
      contextRef="c140"
      decimals="-3"
      id="ixv-106177"
      unitRef="ils">2500000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="c141"
      decimals="-3"
      id="ixv-106178"
      unitRef="usd">689000</ifrs-full:Cash>
    <ifrs-full:ParValuePerShare
      contextRef="c141"
      decimals="2"
      id="ixv-106179"
      unitRef="ilsPershares">0.05</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c319"
      decimals="1"
      id="ixv-106180"
      unitRef="ilsPershares">0.5</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-106181"
      unitRef="ilsPershares">0.213</ifrs-full:ParValuePerShare>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c320"
      decimals="-3"
      id="ixv-106182"
      unitRef="usd">246000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:LoansReceived
      contextRef="c321"
      decimals="-3"
      id="ixv-106183"
      unitRef="usd">1400000</ifrs-full:LoansReceived>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c322"
      decimals="2"
      id="ixv-106184"
      unitRef="pure">0.07</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c323"
      decimals="2"
      id="ixv-106185"
      unitRef="pure">0.09</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:FinanceIncome
      contextRef="c324"
      decimals="-3"
      id="ixv-106186"
      unitRef="usd">4250000</ifrs-full:FinanceIncome>
    <sprcy:AdditionalLoan
      contextRef="c325"
      decimals="-3"
      id="ixv-106187"
      unitRef="usd">1000000</sprcy:AdditionalLoan>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties
      contextRef="c326"
      decimals="-3"
      id="ixv-106188"
      unitRef="usd">2400000</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <sprcy:RepaymentClosingAmount
      contextRef="c325"
      decimals="-3"
      id="ixv-106189"
      unitRef="usd">4250000</sprcy:RepaymentClosingAmount>
    <ifrs-full:InterestExpense contextRef="c0" decimals="-3" id="ixv-106190" unitRef="usd">2448000</ifrs-full:InterestExpense>
    <sprcy:AdditionalLoan
      contextRef="c327"
      decimals="-3"
      id="ixv-106191"
      unitRef="usd">1850000</sprcy:AdditionalLoan>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties
      contextRef="c328"
      decimals="-3"
      id="ixv-106192"
      unitRef="usd">4250000</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <sprcy:FinderFeePercentage contextRef="c0" decimals="4" id="ixv-106193" unitRef="pure">0.4749</sprcy:FinderFeePercentage>
    <sprcy:NumberOfSharesOutstandingPercentage contextRef="c0" decimals="4" id="ixv-106194" unitRef="pure">0.5251</sprcy:NumberOfSharesOutstandingPercentage>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c0" id="ixv-54125">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6:- TRANSACTIONS AND BALANCES WITH RELATED
PARTIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;167&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;See note 5.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 6c):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale of minority interest in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;(*)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Sale of approximately 49% of the outstanding shares of Scisparc Nutraceuticals Inc. to Jeffs&#x2019; Brands Holdings Inc.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;438&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;585&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Management fees&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 23, 2023, the Company entered into an agreement with Jeffs&#x2019; Brands Ltd. (&#x201c;Jeffs&#x2019; Brands&#x201d;) and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;Jeffs&#x2019; Holdings&#x201d;), a newly-formed wholly owned subsidiary of Jeffs&#x2019; Brands, in which Jeffs&#x2019; Holdings acquired from the Company common stock of SciSparc Nutraceuticals equal to approximately a 49% for a cash consideration of $2,500. In consideration, the Company received from Jeffs&#x2019; Brands an additional amount accounting for certain purchase price adjustments related to inventory and working capital. Mr. Oz Adler, the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#x2019;&#160;Brands.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; width: 48px"&gt;&lt;span style="font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2022, the Company entered into a cooperation agreement with Clearmind Medicine Inc. (&#x201c;Clearmind&#x201d;) in which the Company and Clearmind test and integrate their core technologies with a view to developing novel psychedelic drug candidates (the &#x201c;Cooperation Agreement&#x201d;). Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Amitai Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors of Clearmind.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the six-month period ended June 30, 2024, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $26.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Mr. Weiss, our chairman of the board of directors, is the chairman of the board of directors of&#160;AutoMax (see Note 5).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory contextRef="c0" id="ixv-54137">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;167&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;See note 5.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory>
    <ifrs-full:CurrentAssets
      contextRef="c330"
      decimals="-3"
      id="ixv-106195"
      unitRef="usd">15000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="c303"
      decimals="-3"
      id="ixv-106196"
      unitRef="usd">121000</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c330"
      decimals="-3"
      id="ix_13_fact"
      unitRef="usd">2554000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c303"
      decimals="-3"
      id="ixv-106198"
      unitRef="usd">108000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentLiabilities
      contextRef="c331"
      decimals="-3"
      id="ixv-106199"
      unitRef="usd">167000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c302"
      decimals="-3"
      id="ixv-106200"
      unitRef="usd">95000</ifrs-full:CurrentLiabilities>
    <sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory contextRef="c0" id="ixv-54241">&lt;span style="font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 6c):&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale of minority interest in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;(*)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Sale of approximately 49% of the outstanding shares of Scisparc Nutraceuticals Inc. to Jeffs&#x2019; Brands Holdings Inc.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c332"
      decimals="-3"
      id="ixv-106202"
      unitRef="usd">26000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c334"
      decimals="-3"
      id="ixv-106203"
      unitRef="usd">40000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c334"
      decimals="-3"
      id="ix_14_fact"
      unitRef="usd">2985000</ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities>
    <sprcy:PercentageOfOutstandingShareCapital contextRef="c0" decimals="2" id="ixv-106206" unitRef="pure">0.49</sprcy:PercentageOfOutstandingShareCapital>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c0" id="ixv-54316">&lt;span style="font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;438&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;585&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Management fees&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c0" decimals="-3" id="ixv-106207" unitRef="usd">438000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c9" decimals="-3" id="ixv-106208" unitRef="usd">585000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c6" decimals="-3" id="ixv-106209" unitRef="usd">1204000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c0" decimals="-3" id="ixv-106210" unitRef="usd">60000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c9" decimals="-3" id="ixv-106211" unitRef="usd">80000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c6" decimals="-3" id="ixv-106212" unitRef="usd">220000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c0" decimals="-3" id="ixv-106213" unitRef="usd">11000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c9" decimals="-3" id="ixv-106214" unitRef="usd">54000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c6" decimals="-3" id="ixv-106215" unitRef="usd">84000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <sprcy:CashConsideration
      contextRef="c329"
      decimals="-3"
      id="ixv-106216"
      unitRef="usd">2500000</sprcy:CashConsideration>
    <sprcy:CooperationAgreementAmount contextRef="c0" decimals="-3" id="ixv-106217" unitRef="usd">26000</sprcy:CooperationAgreementAmount>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c0" id="ixv-54476">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7:- FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Classification of financial assets
and financial liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unaudited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Audited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-left: 9pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;316&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Short-term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Loans to related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Trade receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;715&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;403&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;849&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,665&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,788&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;409&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,714&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities contextRef="c0" id="ixv-54482">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unaudited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Audited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-left: 9pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;316&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Short-term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Loans to related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Trade receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;715&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;403&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;849&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,665&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,788&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;409&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,714&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-106218" unitRef="usd">316000</ifrs-full:OtherCashAndCashEquivalents>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-106219" unitRef="usd">2081000</ifrs-full:OtherCashAndCashEquivalents>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-106220" unitRef="usd">2141000</ifrs-full:OtherCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c4" decimals="-3" id="ixv-106221" unitRef="usd">2308000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="-3" id="ixv-106222" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:LoansAndAdvances contextRef="c4" decimals="-3" id="ixv-106223" unitRef="usd">2448000</ifrs-full:LoansAndAdvances>
    <ifrs-full:TradeReceivables contextRef="c4" decimals="-3" id="ixv-106224" unitRef="usd">19000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables contextRef="c5" decimals="-3" id="ixv-106225" unitRef="usd">43000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables contextRef="c2" decimals="-3" id="ixv-106226" unitRef="usd">22000</ifrs-full:TradeReceivables>
    <sprcy:GovernmentAuthorities contextRef="c4" decimals="-3" id="ixv-106227" unitRef="usd">74000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities contextRef="c5" decimals="-3" id="ixv-106228" unitRef="usd">100000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities contextRef="c2" decimals="-3" id="ixv-106229" unitRef="usd">62000</sprcy:GovernmentAuthorities>
    <ifrs-full:OtherReceivables contextRef="c4" decimals="-3" id="ixv-106230" unitRef="usd">97000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c5" decimals="-3" id="ixv-106231" unitRef="usd">715000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-106232" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <sprcy:InvestmentsInFinancialAssets contextRef="c4" decimals="-3" id="ixv-106233" unitRef="usd">-403000</sprcy:InvestmentsInFinancialAssets>
    <sprcy:InvestmentsInFinancialAssets contextRef="c5" decimals="-3" id="ixv-106234" unitRef="usd">-849000</sprcy:InvestmentsInFinancialAssets>
    <sprcy:InvestmentsInFinancialAssets contextRef="c2" decimals="-3" id="ixv-106235" unitRef="usd">-659000</sprcy:InvestmentsInFinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c4" decimals="-3" id="ixv-106236" unitRef="usd">5665000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c5" decimals="-3" id="ixv-106237" unitRef="usd">3788000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c2" decimals="-3" id="ixv-106238" unitRef="usd">6087000</ifrs-full:FinancialAssets>
    <sprcy:CreditFromOthers contextRef="c2" decimals="-3" id="ixv-106239" unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability contextRef="c4" decimals="-3" id="ixv-106240" unitRef="usd">345000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability contextRef="c5" decimals="-3" id="ixv-106241" unitRef="usd">1714000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability contextRef="c2" decimals="-3" id="ixv-106242" unitRef="usd">532000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities contextRef="c4" decimals="-3" id="ixv-106243" unitRef="usd">64000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="-3" id="ixv-106244" unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c4" decimals="-3" id="ixv-106245" unitRef="usd">409000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c5" decimals="-3" id="ixv-106246" unitRef="usd">1714000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c2" decimals="-3" id="ixv-106247" unitRef="usd">656000</ifrs-full:FinancialLiabilities>
    <sprcy:WarrantsTextBlock contextRef="c0" id="ixv-54881">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;NOTE 8:-
WARRANTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#x201c;June 2022 Private Placement&#x201d;), providing for the
issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting
of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The June 2022 Warrants have an exercise
price of $68.38 per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the date of
issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Underlying share price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The June 2022 Warrants are classified
as current warrant liability in the Company&#x2019;s balance sheet, as they are exercisable at any given time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During the six months ended June 30,
2024, and 2023, the Company recorded finance income from the change in fair value of the June 2022 Warrants in the amount of $188 and
$1,023, respectively.&lt;/p&gt;</sprcy:WarrantsTextBlock>
    <sprcy:ProceedsFromIssuanceOfPrivateOffering
      contextRef="c199"
      decimals="-3"
      id="ixv-106248"
      unitRef="usd">10210000</sprcy:ProceedsFromIssuanceOfPrivateOffering>
    <sprcy:IssuanceAggregateOfPrefundedUnits
      contextRef="c199"
      decimals="0"
      id="ixv-106249"
      unitRef="shares">136388</sprcy:IssuanceAggregateOfPrefundedUnits>
    <sprcy:PreFundedUnitShares
      contextRef="c199"
      decimals="0"
      id="ixv-106250"
      unitRef="shares">12884</sprcy:PreFundedUnitShares>
    <sprcy:PreFundedUnitPerShare
      contextRef="c199"
      decimals="2"
      id="ixv-106251"
      unitRef="usdPershares">74.88</sprcy:PreFundedUnitPerShare>
    <sprcy:PreFundedUnitShares
      contextRef="c335"
      decimals="0"
      id="ixv-106252"
      unitRef="shares">123504</sprcy:PreFundedUnitShares>
    <sprcy:PreFundedUnitPerShare
      contextRef="c335"
      decimals="3"
      id="ixv-106253"
      unitRef="usdPershares">73.294</sprcy:PreFundedUnitPerShare>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c4"
      decimals="2"
      id="ixv-106254"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock contextRef="c0" id="ixv-54899">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Underlying share price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c6" decimals="2" id="ixv-106255" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c0" decimals="2" id="ixv-106256" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c6" decimals="2" id="ixv-106257" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c0" decimals="2" id="ixv-106258" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c6" decimals="5" id="ixv-106259" unitRef="pure">0.03872</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c0" decimals="5" id="ixv-106260" unitRef="pure">0.04324</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c6"
      decimals="2"
      id="ixv-106261"
      unitRef="usdPershares">4.88</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="2"
      id="ixv-106262"
      unitRef="usdPershares">0.8</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c6"
      decimals="2"
      id="ixv-106263"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="2"
      id="ixv-106264"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c2" decimals="-3" id="ixv-106265" unitRef="usd">192000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c4" decimals="-3" id="ixv-106266" unitRef="usd">4000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c336"
      decimals="-3"
      id="ixv-106267"
      unitRef="usd">188000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c337"
      decimals="-3"
      id="ixv-106268"
      unitRef="usd">1023000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0" id="ixv-55001">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;NOTE 9:-
EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Reverse Share Split&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#x2019;s share capital
up to a ratio of 30:1. Following the implementation of the Reverse Split, the Company&#x2019;s authorized share capital was not adjusted
under the Company&#x2019;s Articles, which as of the date of these financial statements consisted of 75,000,000 ordinary shares, &lt;span style="-sec-ix-hidden: hidden-fact-270"&gt;no&lt;/span&gt; par
value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Composition of share capital as of June 30, 2024, June 30, 2023, and December 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 27%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Ordinary
    shares, no par value &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,586,104&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;282,782&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Changes in share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; ordinary&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of Standby Equity Purchase Agreement (Note 6j)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;980,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Shares issued to consultants (Note 6e)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Issuance of share in respect of exercise of pre-funded October 2023 Warrants (Note 6i)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,893,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,586,104&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Rights attached to shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Voting rights at shareholders meetings,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Capital management in the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s capital management
objectives are to preserve the Company&#x2019;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Additional issuance of ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 26, 2024, the Company
issued a consultant 3,465 ordinary shares in respect of services rendered in the amount of $10.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On April 9, 2024, the Company issued
2,404 ordinary shares to two consultants in respect of services rendered in the amount of $7.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;March 2021 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 44,331 units, as follows: (a) 35,242 units at a price of $&lt;span style="-sec-ix-hidden: hidden-fact-269"&gt;183,82&lt;/span&gt; per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#x201c;2021 Series A Warrants&#x201d;) and a Series B
Warrant (the &#x201c;2021 Series B Warrants&#x201d; and, collectively with the 2021 Series A Warrants, the &#x201c;March 2021 Warrants)
to purchase half the number of units, and (b) 9,089 pre-funded units at a price of $183.794 per unit, consisting of (i) one pre-funded
warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Series A Warrants have an exercise
price of&#160;$183.82&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$275.60&#160;per ordinary share).
Both were exercisable upon issuance and will expire five years from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The March 2021 Warrants are classified
as issued warrants in the Company&#x2019;s equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the six-month period ended
June 30, 2024, and the year ended December 31, 2023, there were no exercises of the 2021 Series A Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;June 2022 Financing Round (see also note 8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On June 1, 2022, the Company completed
the June 2022 Private Placement with an investor for gross proceeds of $10,210, providing for the issuance of an aggregate of 136,388
units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting of (i) one ordinary share of
the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;), and (b) 123,504 pre-funded
units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) two June
2022 Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants have an exercise
price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from
the date of issuance.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants are classified
as current warrant liability in the Company&#x2019;s balance sheet, as they are exercisable at any given time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the six-month period ended
June 30, 2024, and the year ended December 31, 2023, there were no exercises of the June 2022 Warrants.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;August 2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 14, 2023, the Company closed
an underwritten public offering (the &#x201c;2023 Public Offering&#x201d;) of 212,500 ordinary shares, at a purchase price of $5.20 per
ordinary share, and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp,
the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement, the Company
also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments.
This 45-day option was not exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;October 2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees related to the placement agent and other offering expenses payable by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the private placement,
the Company issued an aggregate of 1,930,108 units, each unit consisting of two pre-funded warrants (the &#x201c;October 2023 Warrants&#x201d;).
The October 2023 Warrants have an exercise price of $0.001, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the six-month period ended
June 30, 2024, 1,893,100 ordinary shares were issued in respect to the exercise of 1,893,100 October 2023 Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the period between July 1,
2024, and through to the date of this report, 1,784,211 ordinary shares were issued in respect to the exercise of 1,784,211 October 2023
Warrants. As of the date of these financial statements, there are no outstanding October 2023 Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;January 2024 Standby Equity Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;), as amended on February 26, 2024, with YA II PN, LTD. (&#x201c;YA&#x201d;),
which provided for the sale of up to $20,000 of the Company&#x2019;s Ordinary Shares (the &#x201c;Advance Shares&#x201d;). As of June 30,
2024, of the $20,000 eligible to be sold pursuant to the SEPA (the &#x201c;Commitment Amount&#x201d;), the Company has sold 925,159 ordinary
shares. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price equal to 97% of the market price,
which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing
on the trading day immediately following the delivery of an advance notice to YA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000 (each a &#x201c;Pre-Paid Advance&#x201d;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#x201c;Promissory Note&#x201d;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to
18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued
interest, payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such
notice against an equal amount of the monthly installment amount, at the Company&#x2019;s option. If the Company elects to pay in cash,
the installment amount shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The
Promissory Note contains the Company&#x2019;s customary representations and warranties and events of default.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of 55,293 of its Ordinary Shares in satisfaction of payment of the commitment fee of $200.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA. See also note 11b.&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <sprcy:DescriptionOfReverseShareSplit contextRef="c184" id="ixv-106269">the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#x2019;s share capital
up to a ratio of 30:1</sprcy:DescriptionOfReverseShareSplit>
    <sprcy:CapitalRatio contextRef="c185" id="ixv-106270">30:1</sprcy:CapitalRatio>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c184"
      decimals="0"
      id="ixv-106271"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0" id="ixv-55020">&lt;span style="font-size: 10pt"&gt;Composition of share capital as of June 30, 2024, June 30, 2023, and December 31, 2023:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 27%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Ordinary
    shares, no par value &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,586,104&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;282,782&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c4"
      decimals="INF"
      id="ixv-106272"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-106273"
      unitRef="shares">3586104</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c2"
      decimals="INF"
      id="ixv-106274"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-106275"
      unitRef="shares">706683</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c5"
      decimals="INF"
      id="ixv-106276"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-106277"
      unitRef="shares">282782</ifrs-full:NumberOfSharesOutstanding>
    <sprcy:DisclosureOfIssuedAndOutstandingShareCapital contextRef="c0" id="ixv-55104">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; ordinary&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of Standby Equity Purchase Agreement (Note 6j)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;980,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Shares issued to consultants (Note 6e)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Issuance of share in respect of exercise of pre-funded October 2023 Warrants (Note 6i)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,893,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,586,104&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfIssuedAndOutstandingShareCapital>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-106278"
      unitRef="shares">706683</ifrs-full:NumberOfSharesIssued>
    <sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors
      contextRef="c0"
      decimals="INF"
      id="ixv-106279"
      unitRef="shares">980452</sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors>
    <sprcy:ShareIssuedToAConsultant
      contextRef="c0"
      decimals="INF"
      id="ixv-106280"
      unitRef="shares">5869</sprcy:ShareIssuedToAConsultant>
    <sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound
      contextRef="c0"
      decimals="INF"
      id="ixv-106281"
      unitRef="shares">1893100</sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-106282"
      unitRef="shares">3586104</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c338"
      decimals="0"
      id="ixv-106283"
      unitRef="shares">3465</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ServicesExpense
      contextRef="c338"
      decimals="0"
      id="ixv-106284"
      unitRef="usd">10</ifrs-full:ServicesExpense>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c339"
      decimals="0"
      id="ixv-106285"
      unitRef="shares">2404</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ServicesExpense
      contextRef="c339"
      decimals="-3"
      id="ixv-106286"
      unitRef="usd">7000</ifrs-full:ServicesExpense>
    <sprcy:GrossProceeds
      contextRef="c189"
      decimals="-3"
      id="ixv-106287"
      unitRef="usd">8150000</sprcy:GrossProceeds>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c194"
      decimals="0"
      id="ixv-106288"
      unitRef="shares">44331</sprcy:IssuanceOfAggregateShares>
    <sprcy:AggregateUnits
      contextRef="c194"
      decimals="0"
      id="ixv-106289"
      unitRef="shares">35242</sprcy:AggregateUnits>
    <sprcy:AggregateUnits
      contextRef="c191"
      decimals="0"
      id="ixv-106290"
      unitRef="shares">9089</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c191"
      decimals="3"
      id="ixv-106291"
      unitRef="usdPershares">183.794</sprcy:AggregateUnitsPerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c192"
      decimals="2"
      id="ixv-106292"
      unitRef="usdPershares">183.82</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c193"
      decimals="2"
      id="ixv-106293"
      unitRef="usdPershares">275.6</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <sprcy:DateOfIssuance contextRef="c194" id="ixv-106294">P5Y</sprcy:DateOfIssuance>
    <sprcy:GrossProceeds
      contextRef="c199"
      decimals="-3"
      id="ixv-106295"
      unitRef="usd">10210000</sprcy:GrossProceeds>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c200"
      decimals="0"
      id="ixv-106296"
      unitRef="shares">136388</sprcy:IssuanceOfAggregateShares>
    <sprcy:AggregateUnits
      contextRef="c200"
      decimals="0"
      id="ixv-106297"
      unitRef="shares">12884</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c200"
      decimals="2"
      id="ixv-106298"
      unitRef="usdPershares">74.88</sprcy:AggregateUnitsPerShare>
    <sprcy:AggregateUnits
      contextRef="c202"
      decimals="0"
      id="ixv-106299"
      unitRef="shares">123504</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c202"
      decimals="3"
      id="ixv-106300"
      unitRef="usdPershares">73.294</sprcy:AggregateUnitsPerShare>
    <sprcy:WarrantsExercisePrice
      contextRef="c340"
      decimals="2"
      id="ixv-106301"
      unitRef="pure">68.38</sprcy:WarrantsExercisePrice>
    <sprcy:DateOfIssuance contextRef="c341" id="ixv-106302">P7Y</sprcy:DateOfIssuance>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c206"
      decimals="0"
      id="ixv-106303"
      unitRef="shares">212500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c206"
      decimals="2"
      id="ixv-106304"
      unitRef="usdPershares">5.2</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c207"
      decimals="0"
      id="ixv-106305"
      unitRef="shares">37500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c207"
      decimals="3"
      id="ixv-106306"
      unitRef="usdPershares">5.174</sprcy:PurchasePricePerShare>
    <sprcy:AggregateGrossProceeds
      contextRef="c206"
      decimals="-3"
      id="ixv-106307"
      unitRef="usd">1300000</sprcy:AggregateGrossProceeds>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c208"
      decimals="0"
      id="ixv-106308"
      unitRef="shares">37500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="c209"
      decimals="-3"
      id="ixv-106309"
      unitRef="usd">5026000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c210"
      decimals="0"
      id="ixv-106310"
      unitRef="shares">1930108</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c211"
      decimals="3"
      id="ixv-106311"
      unitRef="usdPershares">0.001</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c342"
      decimals="0"
      id="ixv-106312"
      unitRef="shares">1893100</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c343"
      decimals="0"
      id="ixv-106313"
      unitRef="shares">1893100</sprcy:WarrantsAndExercise>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c344"
      decimals="0"
      id="ixv-106314"
      unitRef="shares">1784211</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c345"
      decimals="0"
      id="ixv-106315"
      unitRef="shares">1784211</sprcy:WarrantsAndExercise>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="c311"
      decimals="-3"
      id="ixv-106316"
      unitRef="usd">20000000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <sprcy:CommitmentAmount
      contextRef="c311"
      decimals="-3"
      id="ixv-106317"
      unitRef="usd">20000000</sprcy:CommitmentAmount>
    <sprcy:SaleOfOrdinaryShares
      contextRef="c311"
      decimals="0"
      id="ixv-106318"
      unitRef="shares">925159</sprcy:SaleOfOrdinaryShares>
    <sprcy:SharePriceRate
      contextRef="c312"
      decimals="2"
      id="ixv-106319"
      unitRef="pure">0.97</sprcy:SharePriceRate>
    <sprcy:CommitmentAmount contextRef="c0" decimals="-3" id="ixv-106320" unitRef="usd">5000000</sprcy:CommitmentAmount>
    <sprcy:InterestRate
      contextRef="c346"
      decimals="2"
      id="ixv-106321"
      unitRef="pure">0.05</sprcy:InterestRate>
    <sprcy:InterestRate
      contextRef="c347"
      decimals="2"
      id="ixv-106322"
      unitRef="pure">0.18</sprcy:InterestRate>
    <sprcy:InstallmentPayment contextRef="c4" decimals="2" id="ixv-106323" unitRef="pure">0.10</sprcy:InstallmentPayment>
    <sprcy:PaymentForPremiumPercentage contextRef="c0" decimals="2" id="ixv-106324" unitRef="pure">0.05</sprcy:PaymentForPremiumPercentage>
    <sprcy:AggregateIssuedAmount
      contextRef="c0"
      decimals="0"
      id="ixv-106325"
      unitRef="shares">55293</sprcy:AggregateIssuedAmount>
    <ifrs-full:FeeAndCommissionExpense contextRef="c0" decimals="-3" id="ixv-106326" unitRef="usd">200000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:DisclosureOfAdditionalInformationExplanatory contextRef="c0" id="ixv-55362">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;NOTE 10:-
ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Six months ended&lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unaudited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Audited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;a. Research and development expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Wages and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;224&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;202&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Clinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Regulatory, professional and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Research and preclinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Chemistry and formulations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;141&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;781&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,641&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;b. General and administrative expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Wages and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;311&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Professional and directors&#x2019; fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Business development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office maintenance, rent and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Investor relations and business expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Wellution operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amazon fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Regulatory expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,632&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,921&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationExplanatory>
    <sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss contextRef="c0" id="ixv-55367">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Six months ended&lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unaudited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Audited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;a. Research and development expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Wages and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;224&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;202&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Clinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Regulatory, professional and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Research and preclinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Chemistry and formulations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;141&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;781&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,641&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;b. General and administrative expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Wages and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;311&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Professional and directors&#x2019; fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Business development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office maintenance, rent and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Investor relations and business expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Wellution operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amazon fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Regulatory expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,632&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,921&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c348"
      decimals="-3"
      id="ixv-106327"
      unitRef="usd">224000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c349"
      decimals="-3"
      id="ixv-106328"
      unitRef="usd">202000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c234"
      decimals="-3"
      id="ixv-106329"
      unitRef="usd">392000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c350"
      decimals="-3"
      id="ixv-106330"
      unitRef="usd">8000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c351"
      decimals="-3"
      id="ixv-106331"
      unitRef="usd">23000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c237"
      decimals="-3"
      id="ixv-106332"
      unitRef="usd">34000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c352"
      decimals="-3"
      id="ixv-106333"
      unitRef="usd">117000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c353"
      decimals="-3"
      id="ixv-106334"
      unitRef="usd">145000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c246"
      decimals="-3"
      id="ixv-106335"
      unitRef="usd">254000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c354"
      decimals="-3"
      id="ixv-106336"
      unitRef="usd">386000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c355"
      decimals="-3"
      id="ixv-106337"
      unitRef="usd">366000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c240"
      decimals="-3"
      id="ixv-106338"
      unitRef="usd">719000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c356"
      decimals="-3"
      id="ixv-106339"
      unitRef="usd">100000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c357"
      decimals="-3"
      id="ixv-106340"
      unitRef="usd">45000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c243"
      decimals="-3"
      id="ixv-106341"
      unitRef="usd">101000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c358"
      decimals="-3"
      id="ixv-106342"
      unitRef="usd">6000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c249"
      decimals="-3"
      id="ixv-106343"
      unitRef="usd">141000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-106344" unitRef="usd">841000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c9" decimals="-3" id="ixv-106345" unitRef="usd">781000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-106346" unitRef="usd">1641000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c348"
      decimals="-3"
      id="ixv-106347"
      unitRef="usd">311000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c349"
      decimals="-3"
      id="ixv-106348"
      unitRef="usd">217000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c234"
      decimals="-3"
      id="ixv-106349"
      unitRef="usd">415000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c350"
      decimals="-3"
      id="ixv-106350"
      unitRef="usd">8000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c351"
      decimals="-3"
      id="ixv-106351"
      unitRef="usd">45000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c237"
      decimals="-3"
      id="ixv-106352"
      unitRef="usd">68000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c360"
      decimals="-3"
      id="ixv-106353"
      unitRef="usd">1670000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c361"
      decimals="-3"
      id="ixv-106354"
      unitRef="usd">1366000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c257"
      decimals="-3"
      id="ixv-106355"
      unitRef="usd">2594000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c362"
      decimals="-3"
      id="ixv-106356"
      unitRef="usd">53000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c363"
      decimals="-3"
      id="ixv-106357"
      unitRef="usd">38000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c260"
      decimals="-3"
      id="ixv-106358"
      unitRef="usd">86000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c364"
      decimals="-3"
      id="ixv-106359"
      unitRef="usd">68000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c365"
      decimals="-3"
      id="ixv-106360"
      unitRef="usd">48000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c266"
      decimals="-3"
      id="ixv-106361"
      unitRef="usd">110000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c366"
      decimals="-3"
      id="ixv-106362"
      unitRef="usd">57000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c367"
      decimals="-3"
      id="ixv-106363"
      unitRef="usd">310000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c269"
      decimals="-3"
      id="ixv-106364"
      unitRef="usd">369000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c368"
      decimals="-3"
      id="ixv-106365"
      unitRef="usd">101000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c369"
      decimals="-3"
      id="ixv-106366"
      unitRef="usd">107000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c370"
      decimals="-3"
      id="ixv-106367"
      unitRef="usd">145000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c371"
      decimals="-3"
      id="ixv-106368"
      unitRef="usd">297000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c372"
      decimals="-3"
      id="ixv-106369"
      unitRef="usd">686000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c252"
      decimals="-3"
      id="ixv-106370"
      unitRef="usd">1042000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c373"
      decimals="-3"
      id="ixv-106371"
      unitRef="usd">67000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c374"
      decimals="-3"
      id="ixv-106372"
      unitRef="usd">104000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c263"
      decimals="-3"
      id="ixv-106373"
      unitRef="usd">202000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-106374" unitRef="usd">2632000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c9" decimals="-3" id="ixv-106375" unitRef="usd">2921000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-106376" unitRef="usd">5031000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c0" id="ixv-55762">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;11:-&lt;/b&gt;&lt;/span&gt; &lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;OPERATING SEGMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company applies the principles of IFRS
8,&#160;&#x201c;&lt;i&gt;Operating Segments&lt;/i&gt;&#x201d;&lt;i&gt;&#160;&lt;/i&gt;(&#x201c;IFRS 8&#x201d;), regarding operating segments. The segment reporting
is based on internal management reports of the Company&#x2019;s management, which are regularly reviewed by the Chief Operating Decision
Maker (&#x201c;CODM&#x201d;) to make decisions about resources to be allocated and assess performance. According to the principles of IFRS
8, the Company&#x2019;s management determined that it has two reportable segments &#x2013; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#x2019;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The review of the CODM is carried out according
to the results of the segment&#x2019;s activity. His review does not include certain expenses that are not related specifically to the
activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Group&#x2019;s CODM is the CEO of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Six months ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online &lt;br/&gt;
Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;External&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,527&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;208&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Tax expense (income)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,679&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Six months ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online &lt;br/&gt;
Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;External&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,972&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,972&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,772&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;195&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,967&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(147&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,932&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year ended December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug Development&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online &lt;br/&gt;
Sales&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;External&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,879&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,879&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,879&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,879&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment loss (gain)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,359&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;414&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,773&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;210&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of intangible asset&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,042&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,164&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;22&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,883&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug &lt;br/&gt;
Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online&lt;br/&gt;
 Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,834&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,648&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,742&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,826&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug&lt;br/&gt;
 Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online&lt;br/&gt;
 Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,290&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,602&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,892&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,741&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;373&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,114&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug&lt;br/&gt; Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online&lt;br/&gt; Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,069&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,113&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11,182&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,595&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c0" id="ixv-55780">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Group&#x2019;s CODM is the CEO of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Six months ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online &lt;br/&gt;
Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;External&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;840&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,527&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;208&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Tax expense (income)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,679&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Six months ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online &lt;br/&gt;
Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;External&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,972&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,972&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,972&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,772&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;195&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,967&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(147&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,932&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year ended December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug Development&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online &lt;br/&gt;
Sales&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;External&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,879&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,879&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,879&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,879&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment loss (gain)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,359&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;414&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,773&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;210&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss on impairment of intangible asset&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,042&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,164&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;22&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,883&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug &lt;br/&gt;
Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online&lt;br/&gt;
 Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,834&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,648&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,742&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,826&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug&lt;br/&gt;
 Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online&lt;br/&gt;
 Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,290&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,602&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,892&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,741&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;373&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,114&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Drug&lt;br/&gt; Development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Online&lt;br/&gt; Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,069&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,113&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11,182&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Segment Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,595&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <sprcy:ExternalRevenues
      contextRef="c376"
      decimals="-3"
      id="ixv-106377"
      unitRef="usd">840000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c0" decimals="-3" id="ixv-106378" unitRef="usd">840000</sprcy:ExternalRevenues>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c376"
      decimals="-3"
      id="ixv-106379"
      unitRef="usd">840000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c0" decimals="-3" id="ixv-106380" unitRef="usd">840000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c375"
      decimals="-3"
      id="ixv-106381"
      unitRef="usd">3040000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c376"
      decimals="-3"
      id="ixv-106382"
      unitRef="usd">487000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-106383" unitRef="usd">3527000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c0" decimals="-3" id="ixv-106384" unitRef="usd">208000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c0" decimals="-3" id="ixv-106385" unitRef="usd">-51000</ifrs-full:InterestRevenueExpense>
    <sprcy:TaxExpense contextRef="c0" decimals="-3" id="ixv-106386" unitRef="usd">-5000</sprcy:TaxExpense>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-106387" unitRef="usd">-3679000</ifrs-full:ProfitLoss>
    <sprcy:ExternalRevenues
      contextRef="c378"
      decimals="-3"
      id="ixv-106388"
      unitRef="usd">1972000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c9" decimals="-3" id="ixv-106389" unitRef="usd">1972000</sprcy:ExternalRevenues>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c378"
      decimals="-3"
      id="ixv-106390"
      unitRef="usd">1972000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c9" decimals="-3" id="ixv-106391" unitRef="usd">1972000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c377"
      decimals="-3"
      id="ixv-106392"
      unitRef="usd">2772000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c378"
      decimals="-3"
      id="ixv-106393"
      unitRef="usd">195000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c9" decimals="-3" id="ixv-106394" unitRef="usd">2967000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c9" decimals="-3" id="ixv-106395" unitRef="usd">99000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c9" decimals="-3" id="ixv-106396" unitRef="usd">-147000</ifrs-full:InterestRevenueExpense>
    <sprcy:TaxExpense contextRef="c9" decimals="-3" id="ixv-106397" unitRef="usd">13000</sprcy:TaxExpense>
    <ifrs-full:ProfitLoss contextRef="c9" decimals="-3" id="ixv-106398" unitRef="usd">-2932000</ifrs-full:ProfitLoss>
    <sprcy:ExternalRevenues
      contextRef="c291"
      decimals="-3"
      id="ixv-106399"
      unitRef="usd">2879000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c6" decimals="-3" id="ixv-106400" unitRef="usd">2879000</sprcy:ExternalRevenues>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c291"
      decimals="-3"
      id="ixv-106401"
      unitRef="usd">2879000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c6" decimals="-3" id="ixv-106402" unitRef="usd">2879000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c290"
      decimals="-3"
      id="ixv-106403"
      unitRef="usd">5359000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c291"
      decimals="-3"
      id="ixv-106404"
      unitRef="usd">414000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c6" decimals="-3" id="ixv-106405" unitRef="usd">5773000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c6" decimals="-3" id="ixv-106406" unitRef="usd">210000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c6" decimals="-3" id="ixv-106407" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:InterestRevenueExpense contextRef="c6" decimals="-3" id="ixv-106408" unitRef="usd">-1164000</ifrs-full:InterestRevenueExpense>
    <sprcy:TaxExpense contextRef="c6" decimals="-3" id="ixv-106409" unitRef="usd">22000</sprcy:TaxExpense>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-106410" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherAssets
      contextRef="c379"
      decimals="-3"
      id="ixv-106411"
      unitRef="usd">6834000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c380"
      decimals="-3"
      id="ixv-106412"
      unitRef="usd">3648000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c4" decimals="-3" id="ixv-106413" unitRef="usd">10482000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c379"
      decimals="-3"
      id="ixv-106414"
      unitRef="usd">1742000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c380"
      decimals="-3"
      id="ixv-106415"
      unitRef="usd">84000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c4" decimals="-3" id="ixv-106416" unitRef="usd">1826000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherAssets
      contextRef="c381"
      decimals="-3"
      id="ixv-106417"
      unitRef="usd">4290000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c382"
      decimals="-3"
      id="ixv-106418"
      unitRef="usd">5602000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c5" decimals="-3" id="ixv-106419" unitRef="usd">9892000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c381"
      decimals="-3"
      id="ixv-106420"
      unitRef="usd">2741000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c382"
      decimals="-3"
      id="ixv-106421"
      unitRef="usd">373000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c5" decimals="-3" id="ixv-106422" unitRef="usd">3114000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherAssets
      contextRef="c296"
      decimals="-3"
      id="ixv-106423"
      unitRef="usd">7069000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c297"
      decimals="-3"
      id="ixv-106424"
      unitRef="usd">4113000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c2" decimals="-3" id="ixv-106425" unitRef="usd">11182000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c296"
      decimals="-3"
      id="ixv-106426"
      unitRef="usd">1441000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c297"
      decimals="-3"
      id="ixv-106427"
      unitRef="usd">154000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c2" decimals="-3" id="ixv-106428" unitRef="usd">1595000</ifrs-full:OtherLiabilities>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-57152">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 12:-
EVENTS AFTER THE REPORTING PERIOD &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;a.&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 8, 2024, the Company announced that it signed a non-binding letter of intent (the &#x201c;LOI&#x201d;) to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. (collectively, the &#x201c;Target Assets&#x201d;). The LOI references a proposed asset and share purchase agreement (the &#x201c;Asset and Share Purchase Agreement&#x201d;), the definitive agreement of which is to be negotiated between the Company and Miza III Ventures Inc. (&#x201c;Miza&#x201d;) (TSXV: MIZA.P), a publicly traded company on the Toronto Stock Exchange Venture in Canada.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Asset and Share Purchase Agreement is based on the approximate total USD 3.3 million (CAD 4.5 million) enterprise value of Miza, when including its $1,000 cash position, and an approximate $11,600 (CAD 15.8 million) value of SciSparc&#x2019;s assets.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the LOI, SciSparc will sell, assign, convey and transfer to Miza the Target Assets in consideration for 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately 75% to a maximum of 84.53%, will be active in both the pharmaceutical and supplement sectors.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;b.&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From July 16, 2024, through September 17, 2024, the Company has sold 4,817,626 ordinary shares in respect of the SEPA for proceeds of $3,576.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 13, 2024, the Company entered into an exclusive patent license agreement (the &#x201c;License Agreement&#x201d;) for the out-licensing of its SCI-160 program (the &#x201c;Assets&#x201d;) with Polyrizon Ltd. (the &#x201c;Licensee&#x201d;). According to the License Agreement, SciSparc granted the Licensee a royalty-bearing, exclusive, sub-licensable right and license to the Assets (the &#x201c;License&#x201d;). In consideration for the License, the Company received and will receive certain shares of the Licensee, reflecting an issue price of $3,000, and royalties from sales related to and income generated from the Assets. Further, the Licensee will pay SciSparc pre-determined fees upon the completion of certain development milestones relating to the Assets.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 26, 2024, the Company signed a non-binding letter of intent (&#x201c;LOI&#x201d;) to sell its entire ownership interest in MitoCareX to a publicly-traded company in the United States (&#x201c;the Purchaser&#x201d;). SciSparc currently owns 52.73% of the issued and outstanding share capital of MitoCareX. Pursuant to the terms of the LOI, initially, in exchange for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute 27% of the Company&#x2019;s ownership in MitoCareX, SciSparc will receive in cash consideration of $700. Subsequent to this first phase, SciSparc will transfer to the Purchaser the remaining 73% of its ownership stake in MitoCareX in exchange for a certain number of shares based on the valuation of the Purchaser equal to $8,000 and a valuation of MitoCareX equal to $5,000 (the latter of which includes the $700 in cash consideration for SciSparc&#x2019;s shares described above). The LOI also includes provisions for additional milestones that, upon achievement, could increase the consideration paid by the Purchaser to SciSparc from $5,000 to $7,000. The details of the full terms of this transaction are subject to negotiation and execution of definitive agreements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <sprcy:AssetAndSharePurchaseAgreementValue
      contextRef="c383"
      decimals="-5"
      id="ixv-106429"
      unitRef="usd">3300000</sprcy:AssetAndSharePurchaseAgreementValue>
    <sprcy:AssetAndSharePurchaseAgreementValue
      contextRef="c383"
      decimals="-5"
      id="ixv-106430"
      unitRef="cad">4500000</sprcy:AssetAndSharePurchaseAgreementValue>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="c384"
      decimals="-3"
      id="ixv-106431"
      unitRef="usd">1000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:Assets
      contextRef="c385"
      decimals="-3"
      id="ixv-106432"
      unitRef="usd">11600000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="c385"
      decimals="-5"
      id="ixv-106433"
      unitRef="cad">15800000</ifrs-full:Assets>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c386"
      decimals="0"
      id="ixv-106434"
      unitRef="shares">63300000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c384"
      decimals="0"
      id="ixv-106435"
      unitRef="shares">48000000</ifrs-full:NumberOfSharesIssued>
    <sprcy:EntityStakeholdersRange
      contextRef="c387"
      decimals="2"
      id="ixv-106436"
      unitRef="pure">0.75</sprcy:EntityStakeholdersRange>
    <sprcy:EntityStakeholdersRange
      contextRef="c388"
      decimals="4"
      id="ixv-106437"
      unitRef="pure">0.8453</sprcy:EntityStakeholdersRange>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c389"
      decimals="0"
      id="ixv-106438"
      unitRef="shares">4817626</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="c390"
      decimals="-3"
      id="ixv-106439"
      unitRef="usd">3576000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:RevenueFromRoyalties
      contextRef="c391"
      decimals="-3"
      id="ixv-106440"
      unitRef="usd">3000000</ifrs-full:RevenueFromRoyalties>
    <sprcy:IssuedAndOutstandingSharePercentage
      contextRef="c392"
      decimals="4"
      id="ixv-106441"
      unitRef="pure">0.5273</sprcy:IssuedAndOutstandingSharePercentage>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c393"
      decimals="2"
      id="ixv-106442"
      unitRef="pure">0.27</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="c393"
      decimals="-3"
      id="ixv-106443"
      unitRef="usd">700000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c394"
      decimals="2"
      id="ixv-106444"
      unitRef="pure">0.73</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="c392"
      decimals="-3"
      id="ixv-106445"
      unitRef="usd">8000000</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="c395"
      decimals="-3"
      id="ixv-106446"
      unitRef="usd">5000000</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="c394"
      decimals="-3"
      id="ixv-106447"
      unitRef="usd">700000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="c396"
      decimals="-3"
      id="ixv-106448"
      unitRef="usd">5000000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="c397"
      decimals="-3"
      id="ixv-106449"
      unitRef="usd">7000000</ifrs-full:ConsiderationPaidReceived>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">F-4/A</dei:DocumentType>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncontrollingInterests
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c5"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivablesDueFromRelatedParties
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivablesDueFromRelatedParties
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="c5"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="c5"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c8"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c8"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c8"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c7"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c8"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="c8"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c8"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c8"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c7"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c8"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c0"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c9"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c17"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c19"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c20"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c21"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c22"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c23"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c26"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c20"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c22"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c23"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c24"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c26"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c20"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c22"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c23"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c24"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c26"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c21"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c22"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c23"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c24"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c25"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c26"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c8"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c19"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c21"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c22"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c23"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c24"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c26"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c34"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c36"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c37"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c38"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c39"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c40"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c43"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c37"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c38"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c39"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c40"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c41"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c43"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c38"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c39"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c40"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c41"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c43"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c51"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c52"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c53"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c54"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c55"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c56"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c52"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c53"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c54"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c56"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c57"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c53"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c54"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c55"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c56"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c57"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c59"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c53"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c54"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c55"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c56"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c57"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c59"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c54"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c55"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c56"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c57"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c59"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c7"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c8"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="c8"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets
      contextRef="c8"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="c7"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="c8"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="c8"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c7"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c8"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c95"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="c8"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="c7"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="c8"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c7"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c8"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c95"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c8"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c95"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c8"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c95"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c95"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c8"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="c8"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ReceiptofShortTermCreditFromOthers
      contextRef="c95"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ReceiptofShortTermCreditFromOthers
      contextRef="c7"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c7"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RegistrationOfWarrants
      contextRef="c95"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RegistrationOfWarrants
      contextRef="c7"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentInFinancialAsset
      contextRef="c7"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentInFinancialAsset
      contextRef="c8"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:UnpaidIssueExpenses
      contextRef="c95"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:UnpaidIssueExpenses
      contextRef="c7"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c0"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c9"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c9"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c9"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c6"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="c0"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="c9"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities
      contextRef="c9"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities
      contextRef="c6"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c0"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c6"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="c0"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="c9"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries
      contextRef="c0"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:MutualShareExchangeOfOrdinaryShares
      contextRef="c0"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c0"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c9"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:LeaseholdImprovements
      contextRef="c108"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="c35"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:FairValueOfInvestment
      contextRef="c6"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c148"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c103"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c151"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c152"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c154"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c148"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c151"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c154"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c154"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c157"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c161"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c163"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c148"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c157"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c161"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c148"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c148"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="c35"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c3"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c170"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c171"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c170"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c171"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:GovernmentAuthorities
      contextRef="c170"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:GovernmentAuthorities
      contextRef="c171"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="c170"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="c171"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c170"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c171"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c170"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c171"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c170"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c171"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c170"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c171"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c170"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c171"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c170"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c174"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c175"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c173"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c174"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c175"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c176"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:GovernmentAuthorities
      contextRef="c174"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:GovernmentAuthorities
      contextRef="c175"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="c174"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="c175"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c174"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c175"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c174"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c175"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c174"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c175"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c174"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c175"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c174"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c175"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c174"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c183"
      id="hidden-fact-208"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c185"
      id="hidden-fact-209"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c212"
      decimals="0"
      id="hidden-fact-210"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesIssued>
    <sprcy:CostOfGoodsSold
      contextRef="c222"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c223"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c224"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c227"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c228"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c229"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c230"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c233"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c8"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c254"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet
      contextRef="c8"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c274"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c276"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c277"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c8"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c278"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c275"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c283"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c287"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c95"
      id="hidden-fact-230"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c7"
      id="hidden-fact-231"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c8"
      id="hidden-fact-232"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c290"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c290"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c292"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c292"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c294"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c295"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c8"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c294"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c295"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c8"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c295"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c302"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c304"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c305"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c302"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c304"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c305"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentLiabilities
      contextRef="c303"
      id="hidden-fact-250"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ResearchAndDevelopmentExpenses
      contextRef="c8"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c7"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c8"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:KeyManagementPersonnelCompensationManagementFees
      contextRef="c7"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:KeyManagementPersonnelCompensationManagementFees
      contextRef="c8"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c302"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c302"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentLiabilities
      contextRef="c330"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentLiabilities
      contextRef="c303"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c333"
      id="hidden-fact-260"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c332"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c333"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c5"
      id="hidden-fact-263"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LoansAndAdvances
      contextRef="c5"
      id="hidden-fact-264"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LoansAndAdvances
      contextRef="c2"
      id="hidden-fact-265"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c4"
      id="hidden-fact-266"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c5"
      id="hidden-fact-267"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c5"
      id="hidden-fact-268"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AggregateUnitsPerShare
      contextRef="c194"
      decimals="0"
      id="hidden-fact-269"
      unitRef="usdPershares">18382</sprcy:AggregateUnitsPerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c185"
      id="hidden-fact-270"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c359"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c375"
      id="hidden-fact-272"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c375"
      id="hidden-fact-273"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c0"
      id="hidden-fact-274"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c377"
      id="hidden-fact-275"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c377"
      id="hidden-fact-276"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c9"
      id="hidden-fact-277"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c290"
      id="hidden-fact-278"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c290"
      id="hidden-fact-279"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-106732">0001611746</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-106733">true</dei:AmendmentFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Loss per share retroactively adjusted in these consolidated statements of comprehensive loss to reflect &#x201c;Reverse Split&#x201d; (see note 18a).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified to correlate with common practice in industry and better reflect profit and loss.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Loss per share retroactively adjusted in these consolidated statements of comprehensive loss to reflect &#x201c;Reverse Share Split&#x201d;. See Note 9.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-216"
          xlink:label="hidden-fact-216"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-212"
          xlink:label="hidden-fact-212"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified to correlate with common practice in industry and better reflect profit and loss.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-216"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-212"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See note 5.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Sale of approximately 49% of the outstanding shares of Scisparc Nutraceuticals Inc. to Jeffs&#x2019; Brands Holdings Inc.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366479981536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001611746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment No. 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">F-4/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SciSparc Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 Raul Wallenberg Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Tower A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6971916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(+972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(3) 717-5777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">850 Library Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">738-6680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Puglisi & Associates<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366483282880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">$ 2,081<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted deposit</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposit</a></td>
<td class="nump">2,308<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">3,356<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">3,643<span></span>
</td>
<td class="nump">4,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible asset, net</a></td>
<td class="nump">3,006<span></span>
</td>
<td class="nump">3,189<span></span>
</td>
<td class="nump">4,474<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentReceivablesDueFromRelatedParties', window );">Related parties</a></td>
<td class="nump">2,448<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociates', window );">Investment in company account for at equity</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">7,126<span></span>
</td>
<td class="nump">4,737<span></span>
</td>
<td class="nump">6,249<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">10,482<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">10,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">1,164<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Warrants</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liability</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">3,114<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share capital and premium</a></td>
<td class="nump">67,258<span></span>
</td>
<td class="nump">64,526<span></span>
</td>
<td class="nump">58,898<span></span>
</td>
<td class="nump">58,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserve from share-based payment transactions</a></td>
<td class="nump">5,298<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">5,248<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrants</a></td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Foreign currency translation reserve</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Transactions with non-controlling interests</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(72,133)<span></span>
</td>
<td class="num">(68,691)<span></span>
</td>
<td class="num">(66,449)<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total</a></td>
<td class="nump">6,920<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
<td class="nump">4,096<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">8,656<span></span>
</td>
<td class="nump">9,587<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 10,482<span></span>
</td>
<td class="nump">$ 11,182<span></span>
</td>
<td class="nump">$ 9,892<span></span>
</td>
<td class="nump">$ 10,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482477424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Profit or Loss and Other Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(508)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(683)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,196<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,632<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,778<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,815<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,768<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Company&#8217;s share of losses of companies accounted for at equity, net</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(323)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">877<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="nump">3,684<span></span>
</td>
<td class="nump">2,919<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,861<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Total comprehensive loss</a></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,883<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Equity holders of the Company</a></td>
<td class="nump">3,442<span></span>
</td>
<td class="nump">2,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,122<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">761<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit loss</a></td>
<td class="nump">$ 3,679<span></span>
</td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,883<span></span>
</td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average outstanding shares (basic) (in Shares)</a></td>
<td class="nump">2,166,282<span></span>
</td>
<td class="nump">270,354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">407,681<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average outstanding shares (diluted) (in Shares)</a></td>
<td class="nump">2,166,282<span></span>
</td>
<td class="nump">270,354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">407,681<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 14.43<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 73.58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 14.43<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 73.58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified to correlate with common practice in industry and better reflect profit and loss.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Loss per share retroactively adjusted in these consolidated statements of comprehensive loss to reflect &#8220;Reverse Share Split&#8221;. See Note 9.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Loss per share retroactively adjusted in these consolidated statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see note 18a).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482768976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Share capital and premium</div></th>
<th class="th"><div>Reserve from share-based payment transactions</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Transactions with non- controlling interests</div></th>
<th class="th"><div>Foreign currency translation reserve</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non- controlling interests</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 49,040<span></span>
</td>
<td class="nump">$ 4,315<span></span>
</td>
<td class="nump">$ 2,207<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (55,188)<span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">6,110<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,352)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,758<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issuance of shares, net of issuance expenses</a></td>
<td class="nump">3,364<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,335<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,699<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Expiration of share options</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">58,541<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(60,977)<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">58,592<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,880)<span></span>
</td>
<td class="num">(2,880)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(2,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests', window );">Sale of minority interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance of share capital in respect of investment in affiliate</a></td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issuance of shares, net of issuance expenses</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">58,898<span></span>
</td>
<td class="nump">5,248<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(66,449)<span></span>
</td>
<td class="nump">4,096<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">58,592<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance of share capital in respect of investment in affiliate</a></td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issuance of shares, net of issuance expenses</a></td>
<td class="nump">5,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">64,526<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(68,691)<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">9,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,442)<span></span>
</td>
<td class="num">(3,442)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="num">(3,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issuance of shares, net of issuance expenses</a></td>
<td class="nump">2,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 67,258<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (72,133)<span></span>
</td>
<td class="nump">$ 6,920<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">$ 8,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssueOfShareCapitalNetOfIssueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue of share capital, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssueOfShareCapitalNetOfIssueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366469868656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="num">$ (3,679)<span></span>
</td>
<td class="num">$ (2,932)<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="num">$ (5,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdjustmentsToTheProfitOrLossItemsAbstract', window );"><strong>Adjustments to the profit or loss items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">187<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">897<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance expenses, net</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(1,023)<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,585)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Group&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets', window );">Losses from remeasurement of investment in financial assets</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">770<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments to the profit or loss</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,622)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WorkingCapitalAdjustmentssAbstract', window );"><strong>Working capital adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Decrease (increase) in other accounts receivable</a></td>
<td class="nump">242<span></span>
</td>
<td class="num">(684)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in trade payables</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase (decrease) in other accounts payable</a></td>
<td class="nump">68<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(668)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital', window );">Increase (decrease) in working capital</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="num">(629)<span></span>
</td>
<td class="num">(833)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(703)<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,197)<span></span>
</td>
<td class="num">(3,233)<span></span>
</td>
<td class="num">(5,887)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,917)<span></span>
</td>
<td class="num">(5,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents', window );">Investment (withdrawal) in restricted bank deposits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Investment (withdrawal) in short-term bank deposits</a></td>
<td class="nump">692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property and equipment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Investment in a company accounted for at equity</a></td>
<td class="num">(600)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(700)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(689)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities', window );">Loans to related parties</a></td>
<td class="num">(2,400)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities', window );">Sale of minority interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Purchase of financial assets at fair value through profit or loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(687)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,861)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="num">(2,308)<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(4,094)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,084)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses', window );">Proceeds from issuance of share capital and warrants (net of issuance expenses)</a></td>
<td class="nump">2,722<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,005<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod', window );">Payment of issuance expenses related to previous period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid on lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries', window );">Proceeds from issuance of shares to minority interests in a subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,887<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ReceiptofShortTermCreditFromOthers', window );">Repayment of short-term credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">8,483<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,700<span></span>
</td>
<td class="nump">10,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,824)<span></span>
</td>
<td class="num">(1,493)<span></span>
</td>
<td class="num">(1,498)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,301)<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,875<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">6,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantNonCashTransactionsAbstract', window );"><strong>(a) Significant non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_MutualShareExchangeOfOrdinaryShares', window );">Mutual share exchange of ordinary shares (see note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RegistrationOfWarrants', window );">Registration of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentInFinancialAsset', window );">Investment in financial asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_UnpaidIssueExpenses', window );">Unpaid issue expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously Stated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdjustmentsToTheProfitOrLossItemsAbstract', window );"><strong>Adjustments to the profit or loss items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance expenses, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Group&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets', window );">Losses from remeasurement of investment in financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments to the profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WorkingCapitalAdjustmentssAbstract', window );"><strong>Working capital adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Decrease (increase) in other accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase (decrease) in other accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease (increase) in trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital', window );">Increase (decrease) in working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(833)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,887)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents', window );">Investment (withdrawal) in restricted bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Investment (withdrawal) in short-term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Investment in a company accounted for at equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod', window );">Investments in financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(689)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities', window );">Sale of minority interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Purchase of financial assets at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses', window );">Proceeds from issuance of share capital and warrants (net of issuance expenses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod', window );">Payment of issuance expenses related to previous period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid on lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ReceiptofShortTermCreditFromOthers', window );">Repayment of short-term credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,498)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantNonCashTransactionsAbstract', window );"><strong>(a) Significant non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RegistrationOfWarrants', window );">Registration of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentInFinancialAsset', window );">Investment in financial asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_UnpaidIssueExpenses', window );">Unpaid issue expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of interests in joint ventures (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities. [Refer: Total for all joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 42A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 42B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses from remeasurement of investment in financial assets

  to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsToTheProfitOrLossItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsToTheProfitOrLossItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash advances and loans made to other parties (other than advances and loans made by a financial institution), classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentInFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentInFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MutualShareExchangeOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of mutual share exchange of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MutualShareExchangeOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from issue of share capital and warrants net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of financial assets at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReceiptofShortTermCreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReceiptofShortTermCreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RegistrationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Registration of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RegistrationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset recognized with corresponding lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantNonCashTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantNonCashTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnpaidIssueExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid issue expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnpaidIssueExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WorkingCapitalAdjustmentssAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WorkingCapitalAdjustmentssAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366474645952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 1:-
GENERAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221;
    or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a specialty clinical-stage pharmaceutical company, was incorporated in
    Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged
    in developing several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy field. In August 2015,
    the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on
    cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#916;9-tetrahydrocannabinol
    (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s disease and agitation,
    autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s ordinary shares are
        listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, the Company had three
    private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
    an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated
    under the laws of the State of Delaware: SciSparc Nutraceuticals Inc. (&#8220;SciSparc Nutraceuticals&#8221;) (together with Evero
    and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2023, the Company&#8217;s
    board of directors (the &#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be
    26:1, which became effective on September 28, 2023. Consequently, all share numbers, share prices, and exercise prices have been
    retroactively adjusted in these interim consolidated financial statements for all periods presented.&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">These interim consolidated financial statements should be read in conjunction
    with the Company&#8217;s annual financial statements for the year ended December 31, 2023, and accompanying notes, that were approved
    on March 31, 2024, and signed on April 1, 2024 (the &#8220;2023 Annual Consolidated Financial Statements&#8221;).</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.5in"><span style="font-size: 10pt">c.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred a net loss of $3,679 and had negative cash flows from operating activities of $2,197 for the six-month period ended June 30, 2024. As of June 30, 2024, the Company had an accumulated deficit of $72,133 as a result of recurring operating losses. As of June 30, 2024, the Company&#8217;s cash and cash equivalents position is not sufficient to fund the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the consolidated financial statements. The Company&#8217;s pharmaceuticals operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue from its pharmaceutical products. These above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand and issuing equity and/or debt securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interim consolidated financial statements for the period ended June 30, 2024, do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The interim consolidated financial statements of the Company for the
    six-month period ended on June&#160;30, 2024, were approved for issuance on October 22, 2024 (the &#8220;Approval Date&#8221;). In
    connection with the preparation of the interim consolidated financial statements and in accordance with authoritative guidance for
    subsequent events, the Company evaluated subsequent events after the consolidated statements of financial position date of June 30,
    2024, through November 4, 2024, the date on which the unaudited interim consolidated financial statements were available to be issued.</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly
    known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a pharmaceutical
    company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries
    at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy
    field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of
    approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on
    &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s
    disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel
    Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">The Company&#8217;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated
under the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
board of directors (&#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1, which
became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these interim consolidated financial statements for all periods presented.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
of the Company for the year ended December&#160;31, 2023, were approved on March 31, 2024, and signed on April 1, 2024 (the &#8220;Approval
Date&#8221;).</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2023, the Group had an accumulated deficit of approximately $68,691 as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company&#8217;s
cash and cash equivalents totaled $2,076. In the period ended December 31, 2023, the Company had an operating loss of $5,883 and negative
cash flows from operating activities of $5,887. The Company&#8217;s current cash and cash equivalents position is not sufficient to fund
the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its
liabilities arising from normal business operations when they become due. While the Company has successfully raised funds in the past,
there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially
reasonable terms, would have serious consequences on our financial condition and results of operations. In addition, the Group has started
recognizing revenues from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing
and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue
from its products. These above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly
    known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly
    Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies that are controlled
    by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts are consolidated
    with those of the Company (if active).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity over which the
    Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221; and is
    not a Subsidiary.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Parties</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in IAS 24, &#8220;<i>Related
    Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Accounting
    Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial
    Reporting Standards issued by the IASB.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366480134112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 2:-
SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b>Unaudited Interim Financial Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s unaudited condensed
consolidated financial statements have been prepared in accordance with International Accounting Standard (&#8220;IAS&#8221;) 34, &#8220;Interim
Financial Reporting&#8221;. The significant accounting policies adopted in the preparation of the interim consolidated financial statements
are consistent with those followed in the preparation of the 2023 Annual Consolidated Financial Statements. Accordingly, these condensed
consolidated financial statements should be read in conjunction with the 2023 Annual Consolidated Financial Statements. The results for
any interim period are not necessarily indicative of results for any future period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The unaudited condensed consolidated
financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#8217;s
management, the accompanying unaudited condensed consolidated financial statements contain all adjustments that are necessary to present
fairly the Company&#8217;s financial position and results of operations for the interim periods presented. The results for the six-month
period ended June 30, 2024, are not necessarily indicative of the results for the year ending December&#160;31, 2024, or for any future
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of June 30, 2024, there have been
no material changes in the Company&#8217;s significant accounting policies from those that were disclosed in the 2023 Annual Consolidated
Financial Statements.<b>&#160;</b></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies
have been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">20-33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business
    model for managing financial assets; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow
    terms of the financial asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured
    at amortized cost when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured
    at fair value through profit or loss when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and
    other financial assets held for trading:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial
    assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized
only when:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights
    to the cash flows from the financial asset have expired;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred
    substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has
    neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset;
    or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained
    its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows
    in full without material delay to a third party.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured
    at amortized cost:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured
    at fair value through profit or loss:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial
    liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted)
    in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted
    prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based
    on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and
other service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination
    options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies&#8221;:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In February 2021, the IASB issued
an amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; (&#8220;the Amendment&#8221;), which replaces the requirement
to disclose &#8217;significant&#8217; accounting policies with a requirement to disclose &#8216;material&#8217; accounting policies.
One of the main reasons for the Amendment is the absence of a definition of the term &#8217;significant&#8217; in IFRS whereas the term
&#8216;material&#8217; is defined in several standards and particularly in IAS 1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is applicable for annual
periods beginning on January 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The application of the above Amendment
had an effect on the disclosures of the Company&#8217;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a
new definition of &#8220;accounting estimates&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">y.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">The
Company sells products directly to customers mainly through its online Amazon stores.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">z.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366483700976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract', window );"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock', window );">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING
    JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount rate for a lease
    liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental
borrowing rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar
security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there
are no financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk,
the lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the fair value
    of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on
its management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are
based, among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best
professional judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the
outcome of the claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and/or
    termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or
not exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying
asset to the Company&#8217;s operation and whether it is a specialized asset, the company&#8217;s past experience with similar leases,
etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial
    instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When the fair values of financial
assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value
is determined using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken
from observable markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models
are tested for validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366477987536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">CASH</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,866</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,443</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,076</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,574</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366480698160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">INVENTORY</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">198</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">668</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366480422928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">OTHER ACCOUNTS RECEIVABLE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481807872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract', window );"><strong>Investment in Associates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory', window );">INVESTMENT IN ASSOCIATES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 3:-
INVESTMENT IN ASSOCIATE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owned
31.48% of the outstanding shares of MitoCareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $400 in MitoCareX and increased its share ownership in MitoCareX from 31.48% to 41.92%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $600 in MitoCareX and increased its share ownership in MitoCareX from 41.92% to 52.73%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $600 installment to be deferred to March 25, 2024, and the $600 installment was paid March 11,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the six months ended June 30,
2024, and 2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $185 and $98, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">591</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">781</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of second milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(185</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,196</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES
    </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of Orimmune Bio Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 22, 2016, the Company entered
into a share transfer agreement (the &#8220;Transfer Agreement&#8221;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#8220;Orimmune&#8221;)
and Karma Link Ltd. (the &#8220;Buyer&#8221;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On December 13, 2018, an additional
amendment to the Transfer Agreement was signed between the parties, under which it was agreed that Orimmune will be assigned certain
rights in intellectual property (&#8220;IP&#8221;) related to the licensed technology owned by the Company subject to certain conditions
precedent which were still not met as of December 31, 2023. As of the Approval Date, the conditions precedent have not yet been completed
and the assignment of the IP related to the licensed technology owned by us has not yet been transferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coeruleus - Joint Venture
    Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On May 15, 2020, the Company entered
into a series of transactions (together, the &#8220;Joint Venture Transaction&#8221;), including a definitive share transfer agreement
with Capital Point Ltd. (&#8220;Capital Point&#8221;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital
Point sold to Evero 5,952,469 ordinary shares, NIS 0.01 par value each, of Coeruleus Ltd. (the &#8220;Purchased Coeruleus Shares&#8221;
and &#8220;Coeruleus,&#8221; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately 46%), engaged in,
among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce
the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic
encephalopathy. The Purchased Coeruleus Shares represented approximately 35% of the issued and outstanding share capital of Coeruleus.
In consideration thereof, Evero issued and sold to Capital Point 176,470 ordinary shares, NIS 1.00 par value each, constituting 15% of
the issued and outstanding share capital of Evero, which was valued at $351, based on apportionment of the fair market value of the Company
as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately 11% of Coeruleus&#8217; issued
and outstanding share capital. The transaction costs of $51 were also capitalized as part of the investment in associate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#8220;Capital Point Warrant&#8221;) to purchase
$340 of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is
equal to the closing price of the Company&#8217;s ordinary shares on the trading day on which the notice of exercise was actually received
by the Company and shall be paid by transferring to the Company a duly executed share transfer deed for 9,577 ordinary shares of Evero.
The Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $30. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than 1% of the issued and outstanding shares of
Coeruleus. As of December 31, 2023, the fair value of the Company&#8217;s investment in Coeruleus is $<span style="-sec-ix-hidden: hidden-fact-148">nil</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitocareX - Joint Venture
    Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns
31.48% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $600 in MitoCareX and increase its share ownership in MitoCareX Bio from 41.92% to 52.73%. Notwithstanding the above, the
Company and MitoCare X agreed for the additional $600 installment to be deferred to March 25, 2024. As of the date of this report the
$600 installment has been paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $210 (for the year ended December 31, 2022
- $109).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">781</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of associates. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B4<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B4_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366502712832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Investment in Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory', window );">INVESTMENT IN FINANCIAL ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5:- INVESTMENT IN FINANCIAL ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i><span style="text-decoration:underline">Share Purchase Agreement</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On June 25, 2023, the Company entered
into a share purchase agreement (the &#8220;Share Purchase Agreement&#8221;) with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;), an Israeli
company traded on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) and the leading parallel importer and distributor of vehicles in Israel,
pursuant to which, at the closing and upon the terms and conditions set forth in the Share Purchase Agreement, the Company invested NIS
2,500 (approximately $689) in cash, in exchange for ordinary shares, NIS 0.05 par value, of AutoMax (the &#8220;AutoMax Shares&#8221;)
based on a price per share of NIS 0.5. As of June 30, 2024, the listed share price of AutoMax on the TASE was NIS 0.213, and the Company
has recorded a loss in its statements of comprehensive loss of $246 on its investment. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i><span style="text-decoration:underline">Bridge Loan Agreement </span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On January 16, 2024, the Company entered,
as a lender, into an agreement (the &#8220;Bridge Loan Agreement&#8221;) with AutoMax, pursuant to which AutoMax received from the Company
a bridge loan (the &#8220;Bridge Loan&#8221;) in the amount of $1,400, further to the previously announced non-binding letter of intent
for the Company to acquire AutoMax (the &#8220;AutoMax Acquisition&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Bridge Loan Agreement states that
the principal amount of the Bridge Loan will bear interest at a rate of 7% per annum (or 9% per annum if the AutoMax Acquisition is not
consummated prior to the repayment date), compounded annually. The Bridge Loan amount, together with any accrued interest (the &#8220;Owed
Amount&#8221;), may be repaid in part or in whole at the discretion of AutoMax prior to the repayment date. The repayment of the Owed
Amount will be due at the earlier date of: (a) the consummation of the Merger (as defined below), in which the Owed Amount shall be deemed
a part of, and set-off against, the financing amount the Company will provide AutoMax with upon Closing, which is expected to be $4,250;
or (b) if the definitive agreement for the AutoMax Acquisition is terminated in accordance with its terms, within three months from such
termination date; or (c) July 15, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On June 9, 2024, the Company entered
into an amendment (the &#8220;Amendment&#8221;) to the Bridge Loan Agreement with AutoMax. Pursuant to the Amendment, the Company extended
an additional loan in the amount of $1,000 to AutoMax under terms similar to the Bridge Loan Agreement, bringing the total Bridge Loan
amount to $2,400. In addition, the repayment date was amended such as that the Owed Amount will be due at the earlier date of: (a) the
consummation of the Merger, in which the Owed Amount shall be deemed a part of, and set-off against, the financing amount the Company
will provide AutoMax with upon Closing, which is expected to be $4,250; or (b) if the definitive agreement for the AutoMax Acquisition
is terminated in accordance with its terms, within three months from such termination date. As of June 30, 2024, the loan amount and
accrued interest stand at $2,448.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 5, 2024, the Company
entered into a second amendment (the &#8220;Second Amendment&#8221;) to the Bridge Loan Agreement with AutoMax. Pursuant to the Second
Amendment, the Company extended an additional loan in the amount of $1,850 to AutoMax under terms similar to the Bridge Loan Agreement,
bringing the total Bridge Loan amount to $4,250. In consideration for the loan amount, AutoMax established a first ranking fixed charge
security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Leasing Ltd. in favor of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i><span style="text-decoration:underline">Merger Agreement </span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On April 10, 2024, the Company entered
into an Agreement and Plan of Merger, as amended (the &#8220;Merger Agreement&#8221;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli
limited company and wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction
of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#8217;s shareholders and AutoMax&#8217;s
shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the
Company (the &#8220;Merger&#8221;) (see also note 6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">At the
effective time of the Merger (the &#8220;Effective Time&#8221;, as further defined in the Merger Agreement): (a)&#160;each outstanding
share of AutoMax&#8217;s share capital will be converted into the right to receive ordinary shares of the Company, equal to the exchange
ratio set forth in the Merger Agreement (the &#8220;Exchange Ratio&#8221;). Under the Exchange Ratio, following the Effective Time, the
former AutoMax shareholders immediately before the Merger (other than the Company) are expected to hold together approximately 47.49%
(minus the Finder Fee, as defined in the Merger Agreement) of the aggregate number of the outstanding ordinary shares of the Company
on fully diluted basis (subject to certain exceptions). The shareholders of the Company, together with the holders of the Company&#8217;s
convertible securities, immediately before the Merger are expected to hold together approximately 52.51% of the aggregate number of the
outstanding ordinary shares of the Company on fully diluted basis (subject to certain exceptions); (b) subject to the consummation of
the Merger (as defined in the Merger Agreement, the &#8220;Closing&#8221;), and immediately after the Effective Time, AutoMax shall have
the right to (i) designate two members to the Company&#8217;s board of directors (the &#8220;Company&#8217;s Board&#8221;) if the Company&#8217;s
Board is comprised of five or six directors; or (ii) designate three members if the Company&#8217;s Board is comprised of seven directors.
At least one such designee shall be an independent director, as defined under the Nasdaq Stock Market listing rules.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN FINANCIAL
    ASSETS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received 230,769 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; &#160; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company&#8217;s shares in Clearmind was reduced from 230,769 common shares to 7,692. As of December 31, 2023, the listed share price of Clearmind on Nasdaq was $2.81, and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2023, of $727 on its investment (for the year ended December 31, 2022 - $771). &#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 25, 2023, the Company entered into an investment agreement (the &#8220;Agreement&#8221;) with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;), an Israeli company traded on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) and the leading parallel importer and distributor of vehicles in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS 2,500,000 in cash, in exchange for ordinary shares, NIS 0.05 par value, of AutoMax based on a price per share of NIS 0.5. As of December 31, 2023, the listed share price of AutoMax on the TASE was NIS 0.384, and the Company has recorded a loss in its statements of comprehensive loss of $158 on its investment.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 11A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478235680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 1, 2020, the Company
entered into a one-year lease agreement with a third party for an area of approximately 100 square meters for the Company&#8217;s offices
in the district of Tel Aviv, Israel. The yearly lease fee was set at approximately $44, linked to the NIS. The lease expired on August
31, 2021. The Company did not exercise its option to extend the lease until August 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 1, 2021, the Company entered
into a two-year joint lease agreement with a third party and for a total area of approximately 240 square meters, whereby the Company
occupies approximately 120 square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel. The Company and the third
party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately $40, linked to the NIS.
On July 7, 2023, the lease was extended until June 30, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366483541568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY AND EQUIPMENT,
    NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Assets owned and used by the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/>
    equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">122</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">New lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">117</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">75</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">108</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">57</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2023, 2022 and 2021 amounted to $52, $43 and $32, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482953120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">INTANGIBLE ASSET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4:- INTANGIBLE ASSET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition (&#8220;Wellution Acquisition&#8221;) of Wellution<sup>TM</sup>, an Amazon Marketplace account
and American food supplement and cosmetics brand and trademark (the &#8220;Brand&#8221;). In connection with the Wellution Acquisition,
the Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
cash payment of $4,540 and an additional $321 in purchase costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, the Company issued to
M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00 per share (with a cashless exercise
mechanism) and with an exercise period of five years from the closing of the Wellution Acquisition (the &#8220;September 2022 Warrants&#8221;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100 million of gross sales by the Brand
in the aggregate or (ii) if the price of the Company&#8217;s ordinary shares closes at $10.00 per share or above.&#160;On March 26, 2024,
M.R.M. agreed with the Company to waive all its rights under the M.R.M. Warrants and have the M.R.M. warrants cancelled for no consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under International Financial Reporting Standard (&#8220;IFRS&#8221;) 3, Business Combinations, for the transaction and
determined that the fair value of the gross assets acquired was concentrated in a single identifiable asset, a brand. Accordingly, the
Company treated the transaction as an asset acquisition. On the closing date of the Wellution Acquisition, the Company fully recognized
the Wellution Acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,042.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that the owner of the asset would have been required to pay
if instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of
8.7 years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined
based on the current period revenues, assuming a short-term growth rate that is consistent with management&#8217;s expectations that
revenues of the Brand will resume their past extent, as of the date of purchase of the Brand, a growth rate thereafter of 13.8% and a
declining growth rate for the long term, reaching 2% at the terminal year. Theoretical royalties arising from the Brand were capitalized
at a discount rate of 20.6%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,717</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(183</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,006</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the six months ended June 30,
2024, and 2023, the Company recorded depreciation expenses with respect to intangible asset in the amount of $183 and $ 243, respectively.</p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;),
American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the
Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, the Company issued to
M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00 per share (with a cashless exercise
mechanism) and with an exercise period of five years from the closing of the Acquisition (the &#8220;September 2022 Warrants&#8221;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100 million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,042.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of 8.7
years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined
based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#8217;s expectations
that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter of 13.8%
and a declining growth rate for the long term, reaching 2% at the terminal year. Theoretical royalties arising from the brand were capitalized
at a discount rate of 20.6%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,717</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2023, the Company recognized depreciation expenses in respect to intangible asset in the amount of $486 (for the year ended December
31, 2022 - $144).&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481960736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">TRADE PAYABLES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADE PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">901</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,199</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482942160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfOtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfOtherAccountsPayableTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">102</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">193</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfOtherAccountsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfOtherAccountsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481249920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7:- FINANCIAL INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Classification of financial assets
and financial liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221;:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">316</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Loans to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,448</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">403</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">849</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,665</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,788</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">345</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total financial and lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">409</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,714</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of financial
    assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,065</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,316</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison
between the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2023, and 2022, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair
                                            Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,065</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="text-align: left"></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="text-align: left"></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dekel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#8220;Dekel&#8221;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#8220;Private Placement&#8221;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#8220;Notes&#8221;), with an aggregate original principal amount of approximately
$350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to 12,088 ordinary shares of the Company (the &#8220;Private Placement Warrant&#8221;) and 1,538 ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $5,148. The Notes are
unsecured, have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of
the holder, into ordinary shares at an initial conversion price of $0.35 per ordinary share (the &#8220;Fixed Conversion Price&#8221;),
subject to adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower
of the Fixed Conversion Price or 70% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which
the ordinary shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion
is received by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing
date and on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $0.35
per ordinary share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.36</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2023, the Company expects
to settle all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Refer to Note 14a for more information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366474645952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">EMPLOYEE BENEFIT LIABILITIES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment
term which establish the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. These contributions and contributions for compensation represent defined contribution plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
    in respect of defined contribution plans</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481513984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXES ON INCOME</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to
    the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Israeli statutory corporate tax
rate and real capital gains tax rate were 23% in 2023, 2022, and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward tax losses
    and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company&#8217;s
net carryforward tax losses are estimated to grow to approximately $62,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481690208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract', window );"><strong>Contingent Liabilities, Commitments, Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES,
    COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with
    Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments
include: (i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 14, 2019, an amendment to
the Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention
to exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which
are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field
of activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect
the foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment also prescribes for
a specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined
under the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment
also included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive
Chairman of the Board and former interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with
    Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement with Hannover
    Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount
of approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of
the first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under
a new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.</p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit challenges a certain warrant issued by the Company to Capital Point (the &#8220;Capital Point Warrant&#8221;) to purchase $340,000 of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of December 31, 2023, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482954640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 9:-
EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Reverse Share Split</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital
up to a ratio of 30:1. Following the implementation of the Reverse Split, the Company&#8217;s authorized share capital was not adjusted
under the Company&#8217;s Articles, which as of the date of these financial statements consisted of 75,000,000 ordinary shares, <span style="-sec-ix-hidden: hidden-fact-270">no</span> par
value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.75in; font-size: 10pt">&#160;</td> <td style="width: 0.5in; font-size: 10pt"><span style="font-size: 10pt">a.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Composition of share capital as of June 30, 2024, June 30, 2023, and December 31, 2023:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 27%; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Ordinary
    shares, no par value </span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,586,104</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">706,683</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">282,782</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> ordinary<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">706,683</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of Standby Equity Purchase Agreement (Note 6j)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">980,452</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued to consultants (Note 6e)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,869</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Issuance of share in respect of exercise of pre-funded October 2023 Warrants (Note 6i)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,893,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,586,104</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at shareholders meetings,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Capital management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Additional issuance of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 26, 2024, the Company
issued a consultant 3,465 ordinary shares in respect of services rendered in the amount of $10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 9, 2024, the Company issued
2,404 ordinary shares to two consultants in respect of services rendered in the amount of $7.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 44,331 units, as follows: (a) 35,242 units at a price of $<span style="-sec-ix-hidden: hidden-fact-269">183,82</span> per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series B
Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the &#8220;March 2021 Warrants)
to purchase half the number of units, and (b) 9,089 pre-funded units at a price of $183.794 per unit, consisting of (i) one pre-funded
warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Series A Warrants have an exercise
price of&#160;$183.82&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$275.60&#160;per ordinary share).
Both were exercisable upon issuance and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The March 2021 Warrants are classified
as issued warrants in the Company&#8217;s equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the six-month period ended
June 30, 2024, and the year ended December 31, 2023, there were no exercises of the 2021 Series A Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">June 2022 Financing Round (see also note 8)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 1, 2022, the Company completed
the June 2022 Private Placement with an investor for gross proceeds of $10,210, providing for the issuance of an aggregate of 136,388
units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting of (i) one ordinary share of
the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;), and (b) 123,504 pre-funded
units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) two June
2022 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from
the date of issuance.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants are classified
as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the six-month period ended
June 30, 2024, and the year ended December 31, 2023, there were no exercises of the June 2022 Warrants.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">August 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 14, 2023, the Company closed
an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of 212,500 ordinary shares, at a purchase price of $5.20 per
ordinary share, and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp,
the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement, the Company
also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments.
This 45-day option was not exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">i.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">October 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees related to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the private placement,
the Company issued an aggregate of 1,930,108 units, each unit consisting of two pre-funded warrants (the &#8220;October 2023 Warrants&#8221;).
The October 2023 Warrants have an exercise price of $0.001, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the six-month period ended
June 30, 2024, 1,893,100 ordinary shares were issued in respect to the exercise of 1,893,100 October 2023 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the period between July 1,
2024, and through to the date of this report, 1,784,211 ordinary shares were issued in respect to the exercise of 1,784,211 October 2023
Warrants. As of the date of these financial statements, there are no outstanding October 2023 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">j.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">January 2024 Standby Equity Purchase Agreement</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD. (&#8220;YA&#8221;),
which provided for the sale of up to $20,000 of the Company&#8217;s Ordinary Shares (the &#8220;Advance Shares&#8221;). As of June 30,
2024, of the $20,000 eligible to be sold pursuant to the SEPA (the &#8220;Commitment Amount&#8221;), the Company has sold 925,159 ordinary
shares. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price equal to 97% of the market price,
which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing
on the trading day immediately following the delivery of an advance notice to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000 (each a &#8220;Pre-Paid Advance&#8221;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#8220;Promissory Note&#8221;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to
18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued
interest, payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such
notice against an equal amount of the monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash,
the installment amount shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The
Promissory Note contains the Company&#8217;s customary representations and warranties and events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of 55,293 of its Ordinary Shares in satisfaction of payment of the commitment fee of $200.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA. See also note 11b.</p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">706,683</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">261,494</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#8217;s share capital
to 75,000,000 ordinary shares with <span style="-sec-ix-hidden: hidden-fact-208">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital
up to a ratio of 30:1 (the &#8220;Third Reverse Split&#8221;). Following the implementation of the Third Reverse Split, the Company&#8217;s
authorized share capital was adjusted under the Company&#8217;s Articles, which as of the date hereof consists of 75,000,000 ordinary
shares, <span style="-sec-ix-hidden: hidden-fact-209">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number
                                            of<br/> ordinary</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">261,494</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; in respect of investment in
    affiliate (Note 18f)</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">13,858</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share issued to a consultant (Note 19(a)(5))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of shelf prospectus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of August 2023 financing round (Note 18i)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of rounding errors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,688</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of October 2023 financing round
    (Note 18j)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,905</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">706,683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at the shareholders
meeting, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital management in the
    Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuance of
    ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 2, 2022, the Company issued
a consultant 923 ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 1, 2022, the Company issued
a consultant 1,423 ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 22, 2023, the Company issued
13,858 ordinary shares in respect of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement entered
into by and among Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also note 25a)</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 44,332 units, as follows: (a) 35,243 units at a price of $183.82 per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series B
Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase
half the number of units, and (b) 9,089 pre-funded units at a price of $183.79 per unit, consisting of (i) one pre-funded warrant to
purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The 2021 Series A Warrants have an
exercise price of&#160;$183.82&#160;per ordinary share and the 2021 Series B Warrants have an exercise price of&#160;$275.60&#160;per
ordinary share). Both were exercisable upon issuance and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2021, the Company issued 4,929 ordinary shares in respect of the exercise of 385 2021 Series A Warrants and the exercise of 4,544 of
pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2022, the Company issued 3,846 ordinary shares in respect of the exercise of 3,846 pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210(the &#8220;June 2022 Financing Round&#8221;), providing for the issuance
of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,885 units at a price of $74.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 123,504 pre-funded units at a price of $73.29 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from
the date of issuance.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.656</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,396</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2022, the Company issued 123,504 ordinary shares in respect of the exercise of 123,504 pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 14, 2023, the Company closed
an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of 212,500 ordinary shares, at a purchase price of $5.20 per
ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#8220;Aegis&#8221;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to
cover over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2023 Financing
    Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the private placement,
the Company issued an aggregate of 1,930,108 units, each unit consisting of two pre-funded warrants, or Pre-Funded Warrants. The Pre-Funded
Warrants have an exercise price of $0.001, are immediately exercisable upon issuance and have a term of five years from the date of issuance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478161232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract', window );"><strong>Share-Based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE-BASED PAYMENT TRANSACTIONS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT
    TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based
    payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">897</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2005 and 2015 ESOP
    and 2023 Plan of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#8220;2023 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="background-color: white">The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. </span>Under the 2023 Plan, the Company may grant its employees and other
service providers equity based incentive awards (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board approved
to reserve for <span style="background-color: white">issuance under the 2023 Plan <span style="-sec-ix-hidden: hidden-fact-210">1,000,0000</span> Ordinary Shares. As </span>of the date of
this report, no shares were issued.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board approved and granted 45 ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $10,920.00 per share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.61</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
was set at $5,824 per Share Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 10, 2019 (the &#8220;2019 Grant Date&#8221;), the Board approved the grant of 3 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2019 General Meeting&#8221;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 1 Share Options was not granted. Out of the 2 Share Options that were granted, 1 Share Options didn&#8217;t require the general meeting&#8217;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $5,460.00 per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">According to IFRS 2, &#8220;<i>Share-based
Payment</i>&#8221;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#8217;s approval was calculated based on parameters as of December 31,
2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,031.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,004</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9.78</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the 2019 General Meeting (valuated as of December 31, 2019) was
set at $2,966.6 and $1,328.6, per Share Option, respectively.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of 6,851 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $169 per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;10,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">129.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">174.98</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
granted on January 3, 2022, was set at $158.34 per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $114.66 per Share Option. The Share Options&#8217; vesting period was set to commence retroactively from April 21, 2021, and
end at April 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company issued to consultants 7,942 ordinary shares in respect of services rendered. The ordinary shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $94. </span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/>
    price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the
    year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">166.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165.58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">76.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,851</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of
    the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">166.14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of
    the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">163.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Share Options were granted
    during 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was 4.03 years and 5.03 years as of December 31, 2023, and 2022, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices of Share Options outstanding at the end of the year was $169 - $21,944 (inclusive) as of December 31, 2023, and 2022, respectively.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482296960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">REVENUES AND COST OF REVENUES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES AND COST OF
    REVENUES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company sells products directly
to customers mainly through its online Amazon stores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s standard
contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return, the Company recognizes
revenue based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a
significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable
if it expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its
estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December
31, 2023, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables.
A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the
customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In certain contracts, the Company
evaluates the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining
the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis
based upon its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible
for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other
factors. Based on its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore,
sales are recorded on a gross basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022(*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Amazon fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Purchased goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Storage</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice in industry and better reflect profit and loss.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478742640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory', window );">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 10:-
ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify">a. Research and development expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">224</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">392</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">254</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">719</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">841</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">781</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,641</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: justify">b. General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">311</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Investor relations and business expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Wellution operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amazon fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Regulatory expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,921</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:-
    </b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION
    TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year ended December&#160;31,</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Research
    and development expenses:</span></i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and related expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">392</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">436</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">357</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory,
    professional and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">719</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">934</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and preclinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">703</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">254</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">369</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemistry
    and formulations</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">281</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">335</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,641</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,803</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,990</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">General
    and administrative expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and related expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">415</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">437</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">633</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td>
    <td>&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amazon
    fees</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,042</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">424</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    and directors&#8217; fees</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,594</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,499</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,417</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    development expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    maintenance, rent and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
    relations and business expenses</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">369</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,486</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">784</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,031</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,972</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,778</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Other
    expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company&#8217;s
    share of losses of company accounted for at equity, net</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Finance
    income:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change
    in fair value of financial liabilities designated at fair value through profit or loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,205</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,832</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    rate differences, net</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,219</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,832</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance
    expenses:</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    expenses related to warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,204</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    rate differences, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses
    from remeasurement of investment in financial assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,046</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">770</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    expense in respect of leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    expenses from interest and commissions</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,055</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,014</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice
                                            in industry and better reflect profit and loss.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfAdditionalInformationTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482922880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share/Ads [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE/ADS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 22:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS PER SHARE/ADS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares
    (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares
    (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>In</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>thousands</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">408</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,883</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,592</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">79</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,789</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">408</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,883</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">176</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,592</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,789</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Loss per share retroactively adjusted in these
                                            consolidated statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see
                                            note 18a).</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The computation of diluted
    loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive
    effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Options to employees,
    officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable warrants
    to investors.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482941536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">OPERATING SEGMENTS</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="-sec-ix-redline:true;font-size: 10pt"><b>NOTE&#160;11:-</b></span> <span style="-sec-ix-redline:true;font-size: 10pt"><b>OPERATING SEGMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company applies the principles of IFRS
8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment reporting
is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating Decision
Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles of IFRS
8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The review of the CODM is carried out according
to the results of the segment&#8217;s activity. His review does not include certain expenses that are not related specifically to the
activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Group&#8217;s CODM is the CEO of the Company.</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Six months ended June 30, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online <br/>
Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="-sec-ix-redline:true;text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">External</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">840</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">840</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">840</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">840</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment loss (gain)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,040</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">487</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,527</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">208</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of intangible asset</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Finance expense (income), net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(51</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Tax expense (income)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,679</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Six months ended June 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online <br/>
Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="-sec-ix-redline:true;text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">External</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,972</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,972</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,972</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,972</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment loss (gain)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,772</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">195</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,967</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">99</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of intangible asset</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Finance expense (income), net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(147</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">13</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Year ended December&#160;31, 2023</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug Development</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online <br/>
Sales</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="-sec-ix-redline:true;text-decoration:underline">Revenues</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">External</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,879</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,879</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,879</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,879</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment loss (gain)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,359</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">414</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,773</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">210</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of intangible asset</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,042</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Finance expense (income), net</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,164</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Tax expense</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">22</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;Loss</span></td>
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,883</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">As of June 30, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug <br/>
Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online<br/>
 Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,834</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,648</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,482</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,742</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">84</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,826</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">As of June 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug<br/>
 Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online<br/>
 Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,290</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,602</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,892</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,741</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">373</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,114</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">As of December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug<br/> Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online<br/> Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,069</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,113</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11,182</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">154</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,595</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The review of the CODM is carried
out according to the results of the segment&#8217;s activity. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
    Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
    Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,359</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,773</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,164</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,883</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment
    loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Company&#8217;s share of losses of company accounted for at equity,
    net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,818</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,592</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">External</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment
    loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,768</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,768</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,789</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,182</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,441</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,595</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">941</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,605</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,021</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482546096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:- TRANSACTIONS AND BALANCES WITH RELATED
PARTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Balances with related parties:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">15</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">121</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,554</td><td style="padding-bottom: 2.5pt; text-align: left">(*)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">167</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">See note 5.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Transactions with related parties (not including amounts described in Note 6c):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,985</td><td style="padding-bottom: 2.5pt; text-align: left">(*)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Sale of approximately 49% of the outstanding shares of Scisparc Nutraceuticals Inc. to Jeffs&#8217; Brands Holdings Inc.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Benefits to key management personnel (including directors):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">438</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">585</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,204</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management fees</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">54</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands Ltd. (&#8220;Jeffs&#8217; Brands&#8221;) and Jeffs&#8217; Brands Holdings Inc. (&#8220;Jeffs&#8217; Holdings&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, in which Jeffs&#8217; Holdings acquired from the Company common stock of SciSparc Nutraceuticals equal to approximately a 49% for a cash consideration of $2,500. In consideration, the Company received from Jeffs&#8217; Brands an additional amount accounting for certain purchase price adjustments related to inventory and working capital. Mr. Oz Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="text-align: justify; width: 48px"><span style="font-size: 10pt">e.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, the Company entered into a cooperation agreement with Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) in which the Company and Clearmind test and integrate their core technologies with a view to developing novel psychedelic drug candidates (the &#8220;Cooperation Agreement&#8221;). Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Amitai Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors of Clearmind.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six-month period ended June 30, 2024, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $26.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Mr. Weiss, our chairman of the board of directors, is the chairman of the board of directors of&#160;AutoMax (see Note 5).</span></td></tr> </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS AND BALANCES
    WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">121</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">208</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,204</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,940</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">962</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands. Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands (see also note 25a).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#8220;Cooperation Agreement&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $40 and $208, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, we invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 7,692 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind (see also note 8).</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Amitai Weiss, our chairman
    of the board of directors, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482541216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract', window );"><strong>Significant Events during the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock', window );">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px; text-align: left"><b>NOTE 25:- </b></td><td style="text-align: justify"><b>SIGNIFICANT EVENTS DURING THE
                                            REPORTING PERIOD</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution<sup>TM</sup>, for $2,500 in cash, and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#8217; Brands, the Company holds approximately 51% of the share capital of SciSparc US.</span></td></tr> </table>

<p style="text-indent: 1.25in; margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the agreement, at the
closing of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217;
Brands provides management services to SciSparc US for the Wellution<sup>TM </sup>brand for a monthly fee of $20 and Jeffs&#8217; Brands
received a one-time signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated
by either party with 30 days advance notice. On November 2023 the monthly fee reduced to $10 thousand. For the year ended December 31,
2023, the Company has recorded management services expenses in the amount of $220.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, in connection with the
closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $288,238 of ordinary
shares from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average
closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior
to the closing. Accordingly, the Company acquired 35,345 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858
ordinary shares of the Company having an aggregate value of $288,238, which was adjusted from $300,000 according to the 4.99% ownership
limit included in the definitive agreements. As of December 31, 2023, the listed share price of Jeff&#8217;s Brands on the NASDAQ was
$ 3.05, and the Company has recorded a loss in its statements of comprehensive loss of $180 on its investment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481806576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Events After the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">EVENTS AFTER THE REPORTING PERIOD</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b style="-sec-ix-redline:true;-keep: true">NOTE 12:-
EVENTS AFTER THE REPORTING PERIOD </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a.</p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2024, the Company announced that it signed a non-binding letter of intent (the &#8220;LOI&#8221;) to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. (collectively, the &#8220;Target Assets&#8221;). The LOI references a proposed asset and share purchase agreement (the &#8220;Asset and Share Purchase Agreement&#8221;), the definitive agreement of which is to be negotiated between the Company and Miza III Ventures Inc. (&#8220;Miza&#8221;) (TSXV: MIZA.P), a publicly traded company on the Toronto Stock Exchange Venture in Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Asset and Share Purchase Agreement is based on the approximate total USD 3.3 million (CAD 4.5 million) enterprise value of Miza, when including its $1,000 cash position, and an approximate $11,600 (CAD 15.8 million) value of SciSparc&#8217;s assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LOI, SciSparc will sell, assign, convey and transfer to Miza the Target Assets in consideration for 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately 75% to a maximum of 84.53%, will be active in both the pharmaceutical and supplement sectors.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b.</p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From July 16, 2024, through September 17, 2024, the Company has sold 4,817,626 ordinary shares in respect of the SEPA for proceeds of $3,576.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">c.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 13, 2024, the Company entered into an exclusive patent license agreement (the &#8220;License Agreement&#8221;) for the out-licensing of its SCI-160 program (the &#8220;Assets&#8221;) with Polyrizon Ltd. (the &#8220;Licensee&#8221;). According to the License Agreement, SciSparc granted the Licensee a royalty-bearing, exclusive, sub-licensable right and license to the Assets (the &#8220;License&#8221;). In consideration for the License, the Company received and will receive certain shares of the Licensee, reflecting an issue price of $3,000, and royalties from sales related to and income generated from the Assets. Further, the Licensee will pay SciSparc pre-determined fees upon the completion of certain development milestones relating to the Assets.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2024, the Company signed a non-binding letter of intent (&#8220;LOI&#8221;) to sell its entire ownership interest in MitoCareX to a publicly-traded company in the United States (&#8220;the Purchaser&#8221;). SciSparc currently owns 52.73% of the issued and outstanding share capital of MitoCareX. Pursuant to the terms of the LOI, initially, in exchange for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute 27% of the Company&#8217;s ownership in MitoCareX, SciSparc will receive in cash consideration of $700. Subsequent to this first phase, SciSparc will transfer to the Purchaser the remaining 73% of its ownership stake in MitoCareX in exchange for a certain number of shares based on the valuation of the Purchaser equal to $8,000 and a valuation of MitoCareX equal to $5,000 (the latter of which includes the $700 in cash consideration for SciSparc&#8217;s shares described above). The LOI also includes provisions for additional milestones that, upon achievement, could increase the consideration paid by the Purchaser to SciSparc from $5,000 to $7,000. The details of the full terms of this transaction are subject to negotiation and execution of definitive agreements.</p></td></tr> </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS AFTER THE REPORTING
    DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On January 21, 2024, the Company entered
into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD (&#8220;YA&#8221;),
which provided for the sale of up to $20,000 of the Company&#8217;s Ordinary Shares (the &#8220;Advance Shares&#8221;). Of the $20,000
eligible to be sold pursuant to the SEPA, or the Commitment Amount, Company has sold 925,159 ordinary shares as of the issuance date
of these financial statements. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of 97%
of the market price, which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive
trading days commencing on the trading day immediately following the delivery of an advance notice to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000, each a Pre-Paid Advance. Each Pre-Paid Advance will
be evidenced by a promissory note, each, a Promissory Note. Each Promissory Note will fully mature 24-months following its issuance and
shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to 18% per annum upon an Event
of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note, the Company shall pay to
YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued interest, payable in cash
or by submitting an advance notice, where YA will offset the amount due to be paid to us under such notice against an equal amount of
the monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash, the installment amount shall also
include a payment premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note contains the Company&#8217;s
customary representations and warranties and Events of Default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of 55,293 of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $200.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred to register under the Securities Act the offer
and sale of the Ordinary Shares pursuant to the SEPA by YA.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482853984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>NOTE 8:-
WARRANTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#8220;June 2022 Private Placement&#8221;), providing for the
issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting
of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The June 2022 Warrants have an exercise
price of $68.38 per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the date of
issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.324</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The June 2022 Warrants are classified
as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the six months ended June 30,
2024, and 2023, the Company recorded finance income from the change in fair value of the June 2022 Warrants in the amount of $188 and
$1,023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the entire disclosure of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482801776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BasisOfPresentationOfFinancialStatements', window );">Basis of presentation of the financial statements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory', window );">The operating cycle</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements', window );">Consolidated financial statements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Functional currency and foreign currency</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany', window );">Acquisition of a single asset company</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit', window );">Restricted deposits</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory', window );">Investment in joint arrangements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock', window );">Investments accounted for using the equity method</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment, net</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">20-33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business
    model for managing financial assets; and</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow
    terms of the financial asset.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured
    at amortized cost when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured
    at fair value through profit or loss when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and
    other financial assets held for trading:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial
    assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized
only when:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights
    to the cash flows from the financial asset have expired;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred
    substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has
    neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset;
    or</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained
    its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows
    in full without material delay to a third party.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured
    at amortized cost:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured
    at fair value through profit or loss:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial
    liabilities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenditures</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance income and expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted)
    in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted
    prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based
    on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory', window );">Taxes on income</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and
other service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings (loss) per share</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefit liabilities</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination
    options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock', window );">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies&#8221;:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In February 2021, the IASB issued
an amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; (&#8220;the Amendment&#8221;), which replaces the requirement
to disclose &#8217;significant&#8217; accounting policies with a requirement to disclose &#8216;material&#8217; accounting policies.
One of the main reasons for the Amendment is the absence of a definition of the term &#8217;significant&#8217; in IFRS whereas the term
&#8216;material&#8217; is defined in several standards and particularly in IAS 1.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is applicable for annual
periods beginning on January 1, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The application of the above Amendment
had an effect on the disclosures of the Company&#8217;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors', window );">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a
new definition of &#8220;accounting estimates&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">y.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">The
Company sells products directly to customers mainly through its online Amazon stores.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock', window );">Cost of sales</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">z.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Total for all associates [member]; Total for all joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BasisOfPresentationOfFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes inrBasis of presentation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BasisOfPresentationOfFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of Accounting Policy Amendment to IAS 1, &#8220;Disclosure of Accounting Policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy cost of sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in Consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for investments in associates. The description of the entity's material accounting policy information for investments accounted for using the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in operating cycle Explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for acquisition of a single asset company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAcquisitionOfASingleAssetCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for changes to accounting estimates and errors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478749808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory', window );">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">20-33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for useful life of the assets at annual rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478254704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,866</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,443</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,076</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,574</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosue of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482952256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfInvertoryTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">198</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">668</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInvertoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInvertoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366480134720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock', window );">Schedule of Other Accounts Receivable</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounts receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclourseOfAccountsReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481248176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract', window );"><strong>Investment in Associates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of Fair Value of the Investment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">591</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">781</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of second milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(185</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,196</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">781</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478740672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Assets owned and used by the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/>
    equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">122</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">New lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">117</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">75</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">108</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">57</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366503557344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock', window );">Schedule of Fair Value of the Intangible Asset</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,717</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(183</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,006</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,717</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value of the intangible asset text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478787296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfTradePayables', window );">Schedule of Trade Payables</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">901</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">802</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,199</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfTradePayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfTradePayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366477419488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfOtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">102</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">193</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366550548016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221;:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">316</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Loans to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,448</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">403</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">849</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,665</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,788</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9pt">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">345</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total financial and lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#8239;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">409</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,714</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,065</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,316</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison
between the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2023, and 2022, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair
                                            Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,065</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="text-align: left"></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="text-align: left"></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock', window );">Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.36</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of financial assets and financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481694448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory', window );">Schedule of Defined Contribution Plans</a></td>
<td class="text">These contributions and contributions for compensation represent defined contribution plans.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
    in respect of defined contribution plans</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about defined contribution plans explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478120032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital</a></td>
<td class="text"><span style="font-size: 10pt">Composition of share capital as of June 30, 2024, June 30, 2023, and December 31, 2023:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 27%; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Ordinary
    shares, no par value </span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,586,104</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">706,683</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">282,782</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">706,683</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">261,494</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital', window );">Schedule of Issued and Outstanding Share Capital</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> ordinary<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">706,683</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of Standby Equity Purchase Agreement (Note 6j)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">980,452</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued to consultants (Note 6e)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,869</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Issuance of share in respect of exercise of pre-funded October 2023 Warrants (Note 6i)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,893,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,586,104</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number
                                            of<br/> ordinary</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">261,494</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; in respect of investment in
    affiliate (Note 18f)</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">13,858</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share issued to a consultant (Note 19(a)(5))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of shelf prospectus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of August 2023 financing round (Note 18i)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of rounding errors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,688</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of October 2023 financing round
    (Note 18j)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,905</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">706,683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.656</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,396</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed inforamtion about issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366480422928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract', window );"><strong>Share-Based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock', window );">Schedule of Expenses Due to Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">897</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock', window );">Schedule of Fair Value for Share Options Granted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.61</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,031.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,004</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9.78</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;10,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">129.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">174.98</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock', window );">Schedule of Weighted Average Exercise Prices of Share Options</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/>
    price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the
    year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">166.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165.58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">76.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,851</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of
    the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">166.14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of
    the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">163.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expenses due to share-based compensation explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value for share options granted explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of share options and weighted average exercise prices of share options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366483697904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock', window );">Schedule of Cost of Sales and Gross Profit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022(*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Amazon fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Purchased goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Storage</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">322</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice in industry and better reflect profit and loss.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481698336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss', window );">Schedule of Additional Information to the Items of Profit or Loss</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audited</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify">a. Research and development expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">224</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">392</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">254</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">719</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">841</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">781</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,641</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: justify">b. General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">311</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Investor relations and business expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Wellution operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amazon fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Regulatory expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,921</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year ended December&#160;31,</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Research
    and development expenses:</span></i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and related expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">392</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">436</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">357</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory,
    professional and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">719</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">934</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and preclinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">703</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">254</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">369</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemistry
    and formulations</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">281</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">335</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,641</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,803</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,990</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">General
    and administrative expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and related expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">415</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">437</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">633</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td>
    <td>&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amazon
    fees</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,042</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">424</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    and directors&#8217; fees</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,594</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,499</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,417</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    development expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    maintenance, rent and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
    relations and business expenses</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">369</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,486</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">784</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,031</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,972</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,778</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Other
    expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company&#8217;s
    share of losses of company accounted for at equity, net</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Finance
    income:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change
    in fair value of financial liabilities designated at fair value through profit or loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,205</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,832</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    rate differences, net</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,219</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,832</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance
    expenses:</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    expenses related to warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,204</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    rate differences, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses
    from remeasurement of investment in financial assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,046</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">770</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    expense in respect of leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    expenses from interest and commissions</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,055</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,014</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice
                                            in industry and better reflect profit and loss.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfAdditionalInformationTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disclosure of information to the items of profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366474645952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share/Ads [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares
    (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares
    (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>In</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>thousands</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">408</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,883</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,592</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">79</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,789</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">408</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,883</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">176</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,592</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,789</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Loss per share retroactively adjusted in these
                                            consolidated statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see
                                            note 18a).</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481702368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Operating Segments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Group&#8217;s CODM is the CEO of the Company.</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Six months ended June 30, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online <br/>
Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="-sec-ix-redline:true;text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">External</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">840</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">840</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">840</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">840</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment loss (gain)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,040</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">487</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,527</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">208</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of intangible asset</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Finance expense (income), net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(51</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Tax expense (income)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,679</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Six months ended June 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online <br/>
Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="-sec-ix-redline:true;text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">External</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,972</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,972</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,972</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,972</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment loss (gain)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,772</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">195</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,967</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">99</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of intangible asset</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Finance expense (income), net</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(147</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">13</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;Loss</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Year ended December&#160;31, 2023</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug Development</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online <br/>
Sales</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left"><span style="-sec-ix-redline:true;text-decoration:underline">Revenues</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">External</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,879</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,879</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,879</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,879</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Segment loss (gain)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,359</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">414</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,773</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Company&#8217;s share of losses of company accounted for at equity, net</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">210</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Loss on impairment of intangible asset</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,042</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Finance expense (income), net</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,164</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Tax expense</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">22</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;Loss</span></td>
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,883</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">As of June 30, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug <br/>
Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online<br/>
 Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,834</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,648</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,482</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,742</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">84</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,826</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">As of June 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug<br/>
 Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online<br/>
 Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,290</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,602</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,892</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,741</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">373</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,114</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">As of December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Drug<br/> Development</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Online<br/> Sales</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Assets</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,069</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,113</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11,182</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="-sec-ix-redline:true;-keep: true">Segment Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">154</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,595</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
    Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
    Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,359</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,773</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,164</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,883</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment
    loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Company&#8217;s share of losses of company accounted for at equity,
    net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,818</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,592</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">External</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment
    loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,768</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,768</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,789</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,182</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,441</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,595</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">941</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,605</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,021</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366470562304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory', window );">Schedule of Balances with Related Parties</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">15</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">121</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,554</td><td style="padding-bottom: 2.5pt; text-align: left">(*)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">167</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">See note 5.</td>
</tr></table><span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">121</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory', window );">Schedule of Transactions with Related Parties</a></td>
<td class="text"><span style="font-size: 10pt">Transactions with related parties (not including amounts described in Note 6c):</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,985</td><td style="padding-bottom: 2.5pt; text-align: left">(*)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Sale of approximately 49% of the outstanding shares of Scisparc Nutraceuticals Inc. to Jeffs&#8217; Brands Holdings Inc.</td>
</tr></table><span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">208</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Schedule of Benefits to Key Management Personnel</a></td>
<td class="text"><span style="font-size: 10pt">Benefits to key management personnel (including directors):</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">438</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">585</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,204</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management fees</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">54</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,204</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,940</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">962</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about balance with relate parties explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about transactions with relate parties explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>239
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478254704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock', window );">Schedule of Fair Value was Calculated using the Black&#8211;Scholes Option Pricing Model</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.324</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the tabular disclosure of fair value was calculated using the black&#8211;scholes option pricing model.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>240
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478869888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">$ (72,133)<span></span>
</td>
<td class="num">$ (66,449)<span></span>
</td>
<td class="num">$ (68,691)<span></span>
</td>
<td class="num">$ (63,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Operating loss</a></td>
<td class="num">(3,679)<span></span>
</td>
<td class="num">(2,932)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="num">$ (2,197)<span></span>
</td>
<td class="num">$ (3,233)<span></span>
</td>
<td class="num">$ (5,887)<span></span>
</td>
<td class="num">$ (7,917)<span></span>
</td>
<td class="num">$ (5,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>241
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366470607104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OperatingTerm', window );">Operating term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>242
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481340224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife', window );">Straight-line basis over the useful life of the assets, description</a></td>
<td class="text">see below<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LeaseholdImprovements', window );">Leasehold improvements (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 122<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_122_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful lives or depreciation rates used for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>243
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366477982544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash - Schedule of Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CashScheduleofCashDetailsLineItems', window );"><strong>Cash - Schedule of Cash (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">$ 2,081<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CashScheduleofCashDetailsLineItems', window );"><strong>Cash - Schedule of Cash (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CashScheduleofCashDetailsLineItems', window );"><strong>Cash - Schedule of Cash (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashScheduleofCashDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashScheduleofCashDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>244
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478916400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfInventoryAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInventoriesInTransit', window );">Goods in transit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total Inventory</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">$ 660<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInventoriesInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInventoriesInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>245
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366470425008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Receivable - Schedule of Other Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfOtherAccountsReceivableAbstract', window );"><strong>Schedule of Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ValueAddedTaxReceivables', window );">Government authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables related to a value added tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfOtherAccountsReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfOtherAccountsReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>246
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366503854128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 25, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 15, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2020 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FairMarketValue', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentFromShareholders', window );">Investment from shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuedAndOutstandingSharesPercentage', window );">Issued and outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FairValueOfInvestment', window );">Fair value of Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInstallment', window );">Additional installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InstallmentPaid', window );">Installment paid</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityLossesFromInvestment', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember', window );">Evero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesSold', window );">Ordinary shares sold (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,952,469<span></span>
</td>
<td class="nump">5,952,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesParValue', window );">Ordinary shares par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DulyExecutedShareTransferDeedForOrdinaryShares', window );">Duly executed share transfer deed for ordinary shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember', window );">Capital Point [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesSold', window );">Ordinary shares sold (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,470<span></span>
</td>
<td class="nump">176,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesParValue', window );">Ordinary shares par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CoeruleusMember', window );">Coeruleus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInvestment', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInvestment', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OutstandingSharesPercentage', window );">Outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityLossesFromInvestment', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember', window );">Capital Point Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchaseOfOrdinaryShares', window );">Purchase of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment income, such as interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing accumulated gains and losses from investments in equity instruments that the entity has designated at fair value through other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional installment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DulyExecutedShareTransferDeedForOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of duly executed share transfer deed for ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DulyExecutedShareTransferDeedForOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesFromInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity losses from investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesFromInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair market value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of Investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of installment paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentFromShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment from shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentFromShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuedAndOutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding shares, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuedAndOutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares par value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CoeruleusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CoeruleusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>247
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366477734480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates - Schedule of Fair Value of the Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueOfTheInvestmentAbstract', window );"><strong>Schedule of Fair Value of the Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at beginning</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentsDate', window );">Investment date March 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityLossesFromInvestment', window );">Equity losses from investment in MitoCareX</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at ending</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentAchievementOfFirstMilestone', window );">Investment following achievement of first milestone</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesFromInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity losses from investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesFromInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment following achievement of first milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment date,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueOfTheInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueOfTheInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>248
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366503740384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets (Details)<br> &#8362; / shares in Units, $ / shares in Units, &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 05, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 09, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th">
<div>Jun. 25, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 25, 2023 </div>
<div>USD ($) </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Nov. 17, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jan. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 25, 2023 </div>
<div>ILS (&#8362;) </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Mar. 19, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentAmount', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid', window );">Received shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Common shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,586,104<span></span>
</td>
<td class="nump">282,782<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SharePricePerShare', window );">Share price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ComprehensiveLoss', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
<td class="nump">$ 771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">&#8362; 689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value, per share (in New Shekels per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">&#8362; 0.05<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PricePerShare', window );">Price Per Share (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">$ 2,967<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="nump">$ 5,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">$ 1,024<span></span>
</td>
<td class="nump">$ 2,219<span></span>
</td>
<td class="nump">$ 7,832<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalLoan', window );">Additional loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RepaymentClosingAmount', window );">Repayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FinderFeePercentage', window );">Finder fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfSharesOutstandingPercentage', window );">Outstanding, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Common shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Common shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMotorsLtdMember', window );">AutoMax Motors Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value, per share (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_BridgeLoansMember', window );">Bridge Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Loan received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxAcquisitionMember', window );">AutoMax Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember', window );">AutoMax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=currency_ILS', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember', window );">Scenario Forecasts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalLoan', window );">Additional loan</a></td>
<td class="nump">$ 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember', window );">Scenario Forecasts [Member] | Bridge Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties', window );">Loan amount</a></td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=sprcy_InvestmentMember', window );">Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of advances and loans from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has not been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedButNotFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of additional loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinderFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the percentage of finder fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinderFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the percentage of number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RepaymentClosingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the value of repayment closing amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RepaymentClosingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMotorsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMotorsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_BridgeLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_BridgeLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sprcy_InvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sprcy_InvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>249
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366480675920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SquareMeters', window );">Square meters</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LeaseFee', window );">Lease fee (in Dollars)</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExpireTerm', window );">Lease expired</a></td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember', window );">2021 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SquareMeters', window );">Square meters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SquareMeters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SquareMeters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>250
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481889968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyandEquipmentNetDetailsLineItems', window );"><strong>Disclosure of property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PropertyandEquipmentNetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PropertyandEquipmentNetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>251
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366473975088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 77<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_77_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross carrying amount of fully depreciated property, plant and equipment that is still in use. [Refer: Gross carrying amount [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>252
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366472883040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 25, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount', window );">Exceeds amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchaseCosts', window );">Purchase costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsToPurchase', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExercisePrice1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExercisePeriod', window );">Exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Gross sales</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_pricePerShare', window );">Ordinary shares price closes (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AmountTotal', window );">Amount total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Amortized over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment to its intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,042,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenueTerm', window );">Revenue term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GrowthRatePercentage', window );">Growth rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LongTermPercentage', window );">Long term, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 486,000<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchaseCostsValue', window );">Purchase costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which a cash-generating unit's (group of units') recoverable amount exceeds its carrying amount. [Refer: Carrying amount [member]; Total for all cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 134<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_134_f_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 135<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_135_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining amortisation period of individual intangible assets that are material to the entity&#8217;s financial statements. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AmountTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AmountTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GrowthRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GrowthRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LongTermPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of long term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LongTermPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of purchase costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RevenueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RevenueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_pricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_pricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>253
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366479033232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems', window );"><strong>Schedule of Fair Value of the Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning</a></td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchaseofAssets', window );">Purchase date September 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost', window );">Depreciation of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at ending</a></td>
<td class="nump">3,006<span></span>
</td>
<td class="nump">4,474<span></span>
</td>
<td class="nump">3,189<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,042)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 30<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_30&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseofAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseofAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>254
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366483541568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Payables - Schedule of Trade Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfTradePayablesAbstract', window );"><strong>Schedule of Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Open debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 1,164<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="nump">$ 1,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfTradePayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfTradePayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>255
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366472886112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable - Schedule of Other Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfOtherAccountsPayableAbstract', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employees and payroll accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accrued vacation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>256
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366483646592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 19, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash paid for principal amount</a></td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash', window );">Purchase price</a></td>
<td class="nump">$ 315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued of warrant (in Shares) | shares</a></td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_MaturityDate', window );">Maturity date</a></td>
<td class="text">Mar. 23,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InitialConversionPrice', window );">Initial conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ConversionPrice', window );">Conversion price</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinaryShareExercisePrice', window );">Ordinary share exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash paid for principal amount</a></td>
<td class="nump">$ 220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued of warrant (in Shares) | shares</a></td>
<td class="nump">12,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 5,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prices specified in forward agreements to purchase financial assets for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph B11D<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B11D_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinaryShareExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinaryShareExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>257
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366473954112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="nump">$ 2,308<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember', window );">Carrying amount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of credit of others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentsInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentsInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>258
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366474610800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems', window );"><strong>Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DividendYield', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExpectedVolatility', window );">Expected volatility (%)</a></td>
<td class="nump">122.01%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">3.84%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_UnderlyingAdsPrice', window );">Underlying Share Price ($)</a></td>
<td class="nump">$ 11.18<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 19.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExercisePricePerShare', window );">Exercise price ($)</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsFairValueinDollarsPerShares', window );">Warrants fair value ($)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate for the option contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnderlyingAdsPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnderlyingAdsPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsFairValueinDollarsPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsFairValueinDollarsPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>259
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366480757232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDefinedContributionPlansAbstract', window );"><strong>Schedule of Defined Contribution Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Expenses in respect of defined contribution plans</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfDefinedContributionPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfDefinedContributionPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>260
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366472928112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TaxesonIncomeDetailsLineItems', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OperatingLossCarryforwardsTaxAmount', window );">Carryforward tax losses (in Dollars)</a></td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingLossCarryforwardsTaxAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net operating loss carryforward tax as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingLossCarryforwardsTaxAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>261
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366474644160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens (Details)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 13, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract', window );"><strong>Contingent Liabilities, Commitments, Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DekelLicenseAgreementDescription', window );">Milestone payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AnnualInvestment', window );">Annual investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalMilestoneAmount', window );">Additional milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InstallmentAmount', window );">Installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EstimatedAmount', window );">Estimated amount</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 1,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Capital purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalCommitments', window );">Capital warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">&#8362; 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future capital expenditures that the entity is committed to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AnnualInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AnnualInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DekelLicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dekel license agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DekelLicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EstimatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EstimatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of installment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>262
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366502951104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 09, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 26, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 21, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 13, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 25, 2023 </div>
<div>&#8362; / shares</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="nump">2,404<span></span>
</td>
<td class="nump">3,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">212,500<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value (in Dollars per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.213<span></span>
</td>
<td class="nump">&#8362; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfReverseShareSplit', window );">Description of reverse share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital
up to a ratio of 30:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GrossProceeds', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfAggregateShares', window );">Issuance of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units Per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DateOfIssuance', window );">Expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,586,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,784,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateGrossProceeds', window );">Aggregate gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross cash proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,026,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CapitalRatio', window );">Capital ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Services rendered amount (in Dollars) | $</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Purchase sale (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CommitmentAmount', window );">Commitment amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SaleOfOrdinaryShares', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SharePriceRate', window );">Share price rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InstallmentPayment', window );">Installment payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PaymentForPremiumPercentage', window );">Payment for premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateIssuedAmount', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Commitment fee (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InterestRate', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InterestRate', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units Per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183.794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,930,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="nump">4,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member] | March 2021 Financing Round [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember', window );">Over Allotment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously Stated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfAggregateShares', window );">Issuance of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units Per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
<td class="nump">1,784,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember', window );">June 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsExercisePrice', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateIssuedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate issued amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateIssuedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateUnitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share of aggregate units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateUnitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CapitalRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CapitalRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DateOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DateOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfReverseShareSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfReverseShareSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Installment payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The issuance of aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentForPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for premium percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentForPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SaleOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number of ordinary shares sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SaleOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePriceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePriceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsAndExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsAndExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>263
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366503038528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Schedule of Share Capital (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, issued and outstanding</a></td>
<td class="nump">3,586,104<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">282,782<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>264
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366477424672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Issued and Outstanding Share Capital (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract', window );"><strong>Schedule of Issued and Outstanding Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance</a></td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate', window );">Issuance of share capital &#8211; in respect of investment in affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareIssuedToAConsultant', window );">Share issued to a consultant</a></td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus', window );">Issuance of share capital &#8211; in respect of shelf prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Issuance of share capital &#8211; in respect of August 2023 financing round</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors', window );">Issuance of share capital &#8211; in respect of rounding errors</a></td>
<td class="nump">980,452<span></span>
</td>
<td class="nump">2,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound', window );">Issuance of share capital &#8211; in respect of October 2023 financing round</a></td>
<td class="nump">1,893,100<span></span>
</td>
<td class="nump">182,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance</a></td>
<td class="nump">3,586,104<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital &#8211; in respect of investment in affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share capital issued in respect of October 2023 financing round.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share capital issued in respect of rounding errors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital &#8211; in respect of shelf prospectus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareIssuedToAConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares were issued to a consultant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareIssuedToAConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>265
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366503041056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract', window );"><strong>Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.324%<span></span>
</td>
<td class="nump">3.872%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price ($) (in Dollars per share)</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 19.656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price ($) (in Dollars per share)</a></td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Warrants fair value ($) (in Dollars)</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 2,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>266
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366469911200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2020</div></th>
<th class="th"><div>Oct. 10, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jan. 21, 2024</div></th>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Mar. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
<td class="nump">3,586,104<span></span>
</td>
<td class="nump">925,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesGranted', window );">Ordinary shares granted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 21,944<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 10,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FairValueOfShareOption', window );">Fair value of share options</a></td>
<td class="nump">$ 1,328.6<span></span>
</td>
<td class="nump">$ 2,966.6<span></span>
</td>
<td class="nump">$ 5,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareOptionsGranted', window );">Share options granted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FairValueOfShareOptionsGranted', window );">Fair value of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.66<span></span>
</td>
<td class="nump">$ 158.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesIssued', window );">Ordinary shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesGrantedDiscountRate', window );">Ordinary shares granted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FairValueOfOrdinarySharesGranted', window );">Fair value of ordinary shares granted (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 days<span></span>
</td>
<td class="text">5 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfOrdinarySharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of ordinary shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfOrdinarySharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value Of share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesGrantedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares granted discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesGrantedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedPaymentTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual lifes of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>267
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482301536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract', window );"><strong>Schedule of Expenses Due to Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentsExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExpensesDueToSharebasedCompensation', window );">Total</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpensesDueToSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpensesDueToSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>268
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366546599696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 10, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract', window );"><strong>Schedule of Fair Value for Share Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">133.00%<span></span>
</td>
<td class="nump">134.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.91%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">2.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1', window );">Expected life of share options (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">9 years 9 months 10 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_UnderlyingOrdinarySharePrices', window );">Underlying ordinary share price (in Dollars per share)</a></td>
<td class="nump">$ 129.74<span></span>
</td>
<td class="nump">$ 174.98<span></span>
</td>
<td class="nump">$ 2,031.12<span></span>
</td>
<td class="nump">$ 4,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnderlyingOrdinarySharePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underlying ordinary share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnderlyingOrdinarySharePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>269
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366470601632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>2023:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfOutstandingShareOption', window );">Number of Share Options , Share Options outstanding at the beginning of the year</a></td>
<td class="nump">7,060<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options outstanding at the beginning of the year</a></td>
<td class="nump">$ 166.14<span></span>
</td>
<td class="nump">$ 76.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options granted during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options granted during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options cancelled during the year</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options cancelled during the year</a></td>
<td class="nump">$ 144.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfOutstandingShareOption', window );">Number of Share Options, Share Options outstanding at the end of the year</a></td>
<td class="nump">7,013<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options outstanding at the end of the year</a></td>
<td class="nump">$ 166.28<span></span>
</td>
<td class="nump">$ 166.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options exercisable at the end of the year</a></td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options exercisable at the end of the year</a></td>
<td class="nump">$ 165.58<span></span>
</td>
<td class="nump">$ 163.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share option outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options exercisable at the end of the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options cancelled during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>270
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482690480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">$ 683<span></span>
</td>
<td colspan="2" class="nump">$ 322<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AmazonFeesMember', window );">Amazon fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_PurchasedGoodsMember', window );">Purchased goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">672<span></span>
</td>
<td colspan="2" class="nump">301<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_StorageMember', window );">Storage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_FreightMember', window );">Freight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">$ 11<span></span>
</td>
<td colspan="2" class="nump">$ 21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified to correlate with common practice in industry and better reflect profit and loss.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AmazonFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AmazonFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_PurchasedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_PurchasedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_StorageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_StorageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_FreightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_FreightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>271
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366480538192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_COtherExpensesAbstract', window );"><strong>c. Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">$ 208<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DFinanceIncomeAbstract', window );"><strong>d. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(323)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember', window );">Wages and related expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember', window );">Share-based payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember', window );">Regulatory, professional and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember', window );">Research and preclinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember', window );">Clinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember', window );">Chemistry and formulations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember', window );">Amazon Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_StorageMember', window );">Storage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember', window );">Professional and directors&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember', window );">Business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember', window );">Regulatory expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember', window );">Office maintenance, rent and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember', window );">Investor relations and business expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember', window );">Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DFinanceIncomeAbstract', window );"><strong>d. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember', window );">Exchange rate differences, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DFinanceIncomeAbstract', window );"><strong>d. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember', window );">Issuance expenses related to warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember', window );">Losses from remeasurement of investment in financial assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember', window );">Finance expense in respect of leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember', window );">Finance expenses from interest and commissions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified to correlate with common practice in industry and better reflect profit and loss.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BGeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BGeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_COtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_COtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EFinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EFinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_StorageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_StorageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>272
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366502930080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ContinuingOperationsAbstract', window );"><strong>Continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic loss per share, Weighted number of shares</a></td>
<td class="nump">2,166,282<span></span>
</td>
<td class="nump">270,354<span></span>
</td>
<td class="nump">407,681<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument', window );">Basic loss per share, Loss (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="num">$ (5,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares', window );">Effect of potential dilutive ordinary shares, Weighted number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted loss per share, Weighted number of shares</a></td>
<td class="nump">2,166,282<span></span>
</td>
<td class="nump">270,354<span></span>
</td>
<td class="nump">407,681<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument', window );">Diluted loss per share, Loss (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="num">$ (5,789)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ContinuingOperationsAbstract', window );"><strong>Continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic loss per share, Weighted number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares', window );">Effect of potential dilutive ordinary shares, Weighted number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted loss per share, Weighted number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity&#8217;s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations used in calculating basic earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph A14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_A14&amp;doctype=Appendix&amp;subtype=A<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations used in calculating diluted earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph A14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_A14&amp;doctype=Appendix&amp;subtype=A<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>273
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366472810368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments - Schedule of Operating Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Finance expense (income), net</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
<td class="num">(5,818)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TaxExpense', window );">Tax expense</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">5,883<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">10,482<span></span>
</td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="nump">10,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="nump">3,114<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember', window );">Drug Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">3,040<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">8,405<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">6,834<span></span>
</td>
<td class="nump">4,290<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
<td class="nump">9,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,742<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember', window );">Online Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">3,648<span></span>
</td>
<td class="nump">5,602<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExternalRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of external revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExternalRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SegmentReportingRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SegmentReportingRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>274
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366470584560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses', window );">Recognized expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfOutstandingShareCapital', window );">Outstanding share capital, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CashConsideration', window );">Cash consideration</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CooperationAgreementAmount', window );">Cooperation agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ClearmindMedicineIncMember', window );">Clearmind Medicine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Invested amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExchangeOfCommonShares', window );">Exchange of common shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OutstandingShareCapital', window );">Outstanding share capital, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of cash consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CooperationAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of cooperation agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CooperationAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExchangeOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExchangeOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the percentage of outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ClearmindMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ClearmindMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>275
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366478234880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">95<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Schedule of Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">121<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">2,554<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">108<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>276
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366477418000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract', window );"><strong>Schedule of Transactions with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities', window );">Sale of minority interest in subsidiary</a></td>
<td class="nump">$ 2,985<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of interests in joint ventures (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities. [Refer: Total for all joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>277
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482933280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract', window );"><strong>Schedule of Benefits to Key Management Personnel[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="nump">$ 1,204<span></span>
</td>
<td class="nump">$ 1,940<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_KeyManagementPersonnelCompensationManagementFees', window );">Management fees (see also note 25a)</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Cost of share-based payment</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_KeyManagementPersonnelCompensationManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of management fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_KeyManagementPersonnelCompensationManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>278
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366503702976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2024</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 25, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InterestPercentgae', window );">Interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540,000<span></span>
</td>
<td class="nump">$ 4,540,000<span></span>
</td>
<td class="nump">$ 689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DeferredCashPayments', window );">Deferred cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,330,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FeeExpenses', window );">Fee expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BonusAmountReceived', window );">Bonus amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Management services expenses</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_MutualShareExchangeAmount', window );">Mutual share exchange amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Acquired ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateValue', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ListedSharePrice', window );">Listed share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ComprehensiveLossOnInvestment', window );">Loss on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember', window );">NewCo Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Acquired ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdjustedAmountOfAggregateValue', window );">Adjusted amount of aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustedAmountOfAggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The adjusted amount of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustedAmountOfAggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of ordinary shares of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BonusAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bonus amount received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BonusAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ComprehensiveLossOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of comprehensive loss on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ComprehensiveLossOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DeferredCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DeferredCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FeeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fee expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FeeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestPercentgae">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest percentgae.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestPercentgae</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ListedSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of listed shares price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ListedSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MutualShareExchangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mutual share exchange amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MutualShareExchangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>279
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366472766096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Period (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 13, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 08, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jan. 21, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>May 15, 2020</div></th>
<th class="th">
<div>Sep. 17, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 08, 2024 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,586,104<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SharePricePercentage', window );">Shareprice, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PrepaidAdvance', window );">Prepaid advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccruedInterestPercentage', window );">Accrued interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CommitmentPercentage', window );">Increasing per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InstallmentPaymentPercentage', window );">Installment payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PaymentPremiumPercentage', window );">Payment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Payment commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,482<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,892<span></span>
</td>
<td class="nump">$ 10,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Number of shares valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember', window );">SEPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member] | SEPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,817,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member] | Miza [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AssetAndSharePurchaseAgreementValue', window );">Enterprise value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Cash position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member] | SciSparc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member] | SciSparc [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EntityStakeholdersRange', window );">Stakeholder's entity range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member] | SciSparc [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EntityStakeholdersRange', window );">Stakeholder's entity range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member] | Common shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember', window );">Scenario Forecasts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuedAndOutstandingSharePercentage', window );">Issued and outstanding shares percentage</a></td>
<td class="nump">52.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration received</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Number of shares valuation</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember', window );">Scenario Forecasts [Member] | SciSparc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration received</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember', window );">Scenario Forecasts [Member] | SciSparc [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration paid</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember', window );">Scenario Forecasts [Member] | SciSparc [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration paid</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember', window );">Scenario Forecasts [Member] | MitoCareX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Number of shares valuation</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccruedInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccruedInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AssetAndSharePurchaseAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset and share purchase agreement value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AssetAndSharePurchaseAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EntityStakeholdersRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity stakeholders range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EntityStakeholdersRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EventsAftertheReportingPeriodDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EventsAftertheReportingPeriodDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Installment payment percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuedAndOutstandingSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuedAndOutstandingSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment premium percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PrepaidAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid advance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PrepaidAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MizaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MizaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SciSparcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SciSparcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_ScenarioForecastsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>280
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366472276016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associate - Schedule of Fair Value of the Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueOfTheInvestmentAbstract', window );"><strong>Schedule of Fair Value of the Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at beginning</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentFollowingAchievementMilestone', window );">Investment following achievement milestone</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments', window );">Equity losses from investment in MitoCareX</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at ending</a></td>
<td class="nump">$ 1,196<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) on disposal of investments and changes in the value of investments. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_ix&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentFollowingAchievementMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of investment achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentFollowingAchievementMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueOfTheInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueOfTheInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>281
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366500962480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems', window );"><strong>Schedule of Fair Value of the Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning</a></td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of intangible asset</a></td>
<td class="num">(183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at ending</a></td>
<td class="nump">$ 3,006<span></span>
</td>
<td class="nump">$ 4,474<span></span>
</td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>282
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366482074384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 121<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">2,554<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">108<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>283
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366474645456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) - Transactions with related parties [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Sale of approximately 49% of the outstanding shares of Scisparc Nutraceuticals Inc. to Jeffs&#8217; Brands Holdings Inc.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of interests in joint ventures (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities. [Refer: Total for all joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_TransactionsWithRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_TransactionsWithRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>284
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366503577952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract', window );"><strong>Schedule of Benefits to Key Management Personnel[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="nump">$ 1,204<span></span>
</td>
<td class="nump">$ 1,940<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_KeyManagementPersonnelCompensationManagementFees', window );">Management fees</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Cost of share-based payment</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_KeyManagementPersonnelCompensationManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of management fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_KeyManagementPersonnelCompensationManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>285
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366469687264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 2,141<span></span>
</td>
<td class="nump">$ 2,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="nump">2,308<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LoansAndAdvances', window );">Loans to related party</a></td>
<td class="nump">2,448<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total</a></td>
<td class="nump">5,665<span></span>
</td>
<td class="nump">6,087<span></span>
</td>
<td class="nump">3,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">$ 2,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansAndAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loans and advances the entity has made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansAndAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of credit of others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentsInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentsInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>286
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481832880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Oct. 10, 2019</div></th>
<th class="th"><div>Mar. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ProceedsFromIssuanceOfPrivateOffering', window );">Gross proceeds of private offering</a></td>
<td class="nump">$ 10,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceAggregateOfPrefundedUnits', window );">Issuance aggregate of pre-funded units</a></td>
<td class="nump">136,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PreFundedUnitShares', window );">Pre-funded unit</a></td>
<td class="nump">12,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PreFundedUnitPerShare', window );">Pre-funded unit per share</a></td>
<td class="nump">$ 74.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
<td class="nump">$ 10,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
<td class="nump">$ 2,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PreFundedUnitShares', window );">Pre-funded unit</a></td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PreFundedUnitPerShare', window );">Pre-funded unit per share</a></td>
<td class="nump">$ 73.294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceAggregateOfPrefundedUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the issuance of aggregate of prefunded units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceAggregateOfPrefundedUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PreFundedUnitPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the price of pre-funded unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PreFundedUnitPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PreFundedUnitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number pre-funded unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PreFundedUnitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ProceedsFromIssuanceOfPrivateOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of proceeds from issuance of private offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ProceedsFromIssuanceOfPrivateOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>287
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366481861216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Schedule of Fair Value was Calculated using the Black&#8211;Scholes Option Pricing Model (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract', window );"><strong>Schedule Of Fair Value Was Calculated Using The Black Scholes Option Pricing Model Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">4.324%<span></span>
</td>
<td class="nump">3.872%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price (in Dollars per share)</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 19.656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Warrants fair value (in Dollars)</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 2,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>288
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366470381312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Schedule of Share Capital (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfSharesAbstract0', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, issued and outstanding</a></td>
<td class="nump">3,586,104<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">282,782<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>289
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366550495856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Issued and Outstanding Share Capital (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract', window );"><strong>Schedule of Issued and Outstanding Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance</a></td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors', window );">Issuance of share capital &#8211; in respect of Standby Equity Purchase Agreement (Note 6j)</a></td>
<td class="nump">980,452<span></span>
</td>
<td class="nump">2,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareIssuedToAConsultant', window );">Shares issued to consultants (Note 6e)</a></td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound', window );">Issuance of share in respect of exercise of pre-funded October 2023 Warrants (Note 6i)</a></td>
<td class="nump">1,893,100<span></span>
</td>
<td class="nump">182,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance</a></td>
<td class="nump">3,586,104<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share capital issued in respect of October 2023 financing round.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share capital issued in respect of rounding errors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareIssuedToAConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares were issued to a consultant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareIssuedToAConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>290
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366473988304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,632<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">$ 5,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember', window );">Wages and related expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember', window );">Share-based payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember', window );">Clinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember', window );">Regulatory, professional and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember', window );">Research and preclinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember', window );">Chemistry and formulations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember', window );">Professional and directors&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember', window );">Business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember', window );">Office maintenance, rent and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember', window );">Investor relations and business expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember', window );">Wellution operating expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember', window );">Amazon Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember', window );">Regulatory expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems', window );"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified to correlate with common practice in industry and better reflect profit and loss.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>291
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45366472826528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments - Schedule of Operating Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Finance expense (income), net</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
<td class="num">(5,818)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TaxExpense', window );">Tax expense (income)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">5,883<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">10,482<span></span>
</td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="nump">10,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="nump">3,114<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember', window );">Drug Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">3,040<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">8,405<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">6,834<span></span>
</td>
<td class="nump">4,290<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
<td class="nump">9,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,742<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember', window );">Online Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">3,648<span></span>
</td>
<td class="nump">5,602<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExternalRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of external revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExternalRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SegmentReportingRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SegmentReportingRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>292
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>398</ContextCount>
  <ElementCount>426</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Profit or Loss and Other Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Changes in Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Cash</Role>
      <ShortName>Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsReceivable</Role>
      <ShortName>Other Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Investment in Associates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociates</Role>
      <ShortName>Investment in Associates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Investment in Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinFinancialAssets</Role>
      <ShortName>Investment in Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAsset</Role>
      <ShortName>Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Trade Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TradePayables</Role>
      <ShortName>Trade Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Employee Benefit Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EmployeeBenefitLiabilities</Role>
      <ShortName>Employee Benefit Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Share-Based Payment Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactions</Role>
      <ShortName>Share-Based Payment Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Revenues and Cost of Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/RevenuesandCostofRevenues</Role>
      <ShortName>Revenues and Cost of Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Additional Information to the Items of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</Role>
      <ShortName>Additional Information to the Items of Profit or Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Loss Per Share/Ads</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LossPerShareAds</Role>
      <ShortName>Loss Per Share/Ads</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Operating Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegments</Role>
      <ShortName>Operating Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Transactions and Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedParties</Role>
      <ShortName>Transactions and Balances with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Significant Events during the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantEventsduringtheReportingPeriod</Role>
      <ShortName>Significant Events during the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Events After the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EventsAftertheReportingPeriod</Role>
      <ShortName>Events After the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/CashTables</Role>
      <ShortName>Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Cash</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Inventory</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Other Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsReceivableTables</Role>
      <ShortName>Other Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsReceivable</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Investment in Associates (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesTables</Role>
      <ShortName>Investment in Associates (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociates</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Intangible Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAssetTables</Role>
      <ShortName>Intangible Asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAsset</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Trade Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TradePayablesTables</Role>
      <ShortName>Trade Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/TradePayables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsPayable</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstruments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Employee Benefit Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EmployeeBenefitLiabilitiesTables</Role>
      <ShortName>Employee Benefit Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/EmployeeBenefitLiabilities</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Equity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Share-Based Payment Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactionsTables</Role>
      <ShortName>Share-Based Payment Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Revenues and Cost of Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/RevenuesandCostofRevenuesTables</Role>
      <ShortName>Revenues and Cost of Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/RevenuesandCostofRevenues</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables</Role>
      <ShortName>Additional Information to the Items of Profit or Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Loss Per Share/Ads (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LossPerShareAdsTables</Role>
      <ShortName>Loss Per Share/Ads (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/LossPerShareAds</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Operating Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegmentsTables</Role>
      <ShortName>Operating Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OperatingSegments</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Transactions and Balances with Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</Role>
      <ShortName>Transactions and Balances with Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedParties</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Warrants</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996020 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/General</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable</Role>
      <ShortName>Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Cash - Schedule of Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofCashTable</Role>
      <ShortName>Cash - Schedule of Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOtherAccountsReceivableTable</Role>
      <ShortName>Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Investment in Associates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesDetails</Role>
      <ShortName>Investment in Associates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociatesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Investment in Associates - Schedule of Fair Value of the Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable</Role>
      <ShortName>Investment in Associates - Schedule of Fair Value of the Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Investment in Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinFinancialAssetsDetails</Role>
      <ShortName>Investment in Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinFinancialAssets</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/Leases</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAssetDetails</Role>
      <ShortName>Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAssetTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable</Role>
      <ShortName>Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTradePayablesTable</Role>
      <ShortName>Trade Payables - Schedule of Trade Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOtherAccountsPayableTable</Role>
      <ShortName>Other Accounts Payable - Schedule of Other Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable</Role>
      <ShortName>Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Financial Instruments - Schedule of Warrants Fair Value Using Black???Scholes OPM (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable</Role>
      <ShortName>Financial Instruments - Schedule of Warrants Fair Value Using Black???Scholes OPM (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofDefinedContributionPlansTable</Role>
      <ShortName>Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TaxesonIncome</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Equity - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Equity - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable</Role>
      <ShortName>Equity - Schedule of Issued and Outstanding Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Equity - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable</Role>
      <ShortName>Equity - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Share-Based Payment Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactionsDetails</Role>
      <ShortName>Share-Based Payment Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable</Role>
      <ShortName>Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable</Role>
      <ShortName>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable</Role>
      <ShortName>Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOperatingSegmentsTable</Role>
      <ShortName>Operating Segments - Schedule of Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Significant Events during the Reporting Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails</Role>
      <ShortName>Significant Events during the Reporting Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantEventsduringtheReportingPeriod</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Events After the Reporting Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EventsAftertheReportingPeriodDetails</Role>
      <ShortName>Events After the Reporting Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EventsAftertheReportingPeriod</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Investment in Associate - Schedule of Fair Value of the Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0</Role>
      <ShortName>Investment in Associate - Schedule of Fair Value of the Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996061 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0</Role>
      <ShortName>Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996062 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>996063 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>996064 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0</Role>
      <ShortName>Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>996066 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/WarrantsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>996067 - Disclosure - Warrants - Schedule of Fair Value was Calculated using the Black???Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable</Role>
      <ShortName>Warrants - Schedule of Fair Value was Calculated using the Black???Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>996068 - Disclosure - Equity - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofShareCapitalTable0</Role>
      <ShortName>Equity - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>996069 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0</Role>
      <ShortName>Equity - Schedule of Issued and Outstanding Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>996070 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0</Role>
      <ShortName>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="ea0230821-f4a2_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>996071 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOperatingSegmentsTable0</Role>
      <ShortName>Operating Segments - Schedule of Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="F-4/A" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0230821-f4a2_scisparc.htm">ea0230821-f4a2_scisparc.htm</File>
    <File>sprcy-20240630.xsd</File>
    <File>sprcy-20240630_cal.xml</File>
    <File>sprcy-20240630_def.xml</File>
    <File>sprcy-20240630_lab.xml</File>
    <File>sprcy-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>fin_002.jpg</File>
    <File>fin_003.jpg</File>
    <File>fin_004.jpg</File>
    <File>fin_005.jpg</File>
    <File>fin_006.jpg</File>
    <File>fin_007.jpg</File>
    <File>fin_008.jpg</File>
    <File>fin_009.jpg</File>
    <File>fin_010.jpg</File>
    <File>fin_011.jpg</File>
    <File>fin_012.jpg</File>
    <File>fin_013.jpg</File>
    <File>fin_014.jpg</File>
    <File>fin_015.jpg</File>
    <File>fin_016.jpg</File>
    <File>fin_017.jpg</File>
    <File>fin_018.jpg</File>
    <File>fin_019.jpg</File>
    <File>fin_020.jpg</File>
    <File>fin_021.jpg</File>
    <File>fin_022.jpg</File>
    <File>fin_023.jpg</File>
    <File>fin_024.jpg</File>
    <File>fin_025.jpg</File>
    <File>fin_026.jpg</File>
    <File>fin_027.jpg</File>
    <File>fin_028.jpg</File>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
    <File>image_018.jpg</File>
    <File>image_019.jpg</File>
    <File>image_020.jpg</File>
    <File>image_021.jpg</File>
    <File>image_022.jpg</File>
    <File>image_023.jpg</File>
    <File>image_024.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1326">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>294
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0230821-f4a2_scisparc.htm": {
   "nsprefix": "sprcy",
   "nsuri": "http://trpx.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "ea0230821-f4a2_scisparc.htm"
     ]
    },
    "schema": {
     "local": [
      "sprcy-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sprcy-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sprcy-20240630_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sprcy-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sprcy-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 235,
   "keyCustom": 191,
   "axisStandard": 19,
   "axisCustom": 1,
   "memberStandard": 26,
   "memberCustom": 54,
   "hidden": {
    "total": 282,
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 190,
    "http://trpx.com/20240630": 89,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 398,
   "entityCount": 1,
   "segmentCount": 84,
   "elementCount": 690,
   "unitCount": 7,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 1326,
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://trpx.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://trpx.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CurrentRestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://trpx.com/role/ConsolidatedIncomeStatement",
     "longName": "002 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Loss",
     "shortName": "Consolidated Statements of Profit or Loss and Other Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://trpx.com/role/ShareholdersEquityType2or3",
     "longName": "003 - Statement - Consolidated Statements of Changes in Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c10",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c10",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://trpx.com/role/ConsolidatedCashFlow",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://trpx.com/role/General",
     "longName": "005 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://trpx.com/role/SignificantAccountingPolicies",
     "longName": "006 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements",
     "longName": "007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "shortName": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://trpx.com/role/Cash",
     "longName": "008 - Disclosure - Cash",
     "shortName": "Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://trpx.com/role/Inventory",
     "longName": "009 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://trpx.com/role/OtherAccountsReceivable",
     "longName": "010 - Disclosure - Other Accounts Receivable",
     "shortName": "Other Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://trpx.com/role/InvestmentinAssociates",
     "longName": "011 - Disclosure - Investment in Associates",
     "shortName": "Investment in Associates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://trpx.com/role/InvestmentinFinancialAssets",
     "longName": "012 - Disclosure - Investment in Financial Assets",
     "shortName": "Investment in Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://trpx.com/role/Leases",
     "longName": "013 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://trpx.com/role/PropertyandEquipmentNet",
     "longName": "014 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://trpx.com/role/IntangibleAsset",
     "longName": "015 - Disclosure - Intangible Asset",
     "shortName": "Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://trpx.com/role/TradePayables",
     "longName": "016 - Disclosure - Trade Payables",
     "shortName": "Trade Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://trpx.com/role/OtherAccountsPayable",
     "longName": "017 - Disclosure - Other Accounts Payable",
     "shortName": "Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://trpx.com/role/FinancialInstruments",
     "longName": "018 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://trpx.com/role/EmployeeBenefitLiabilities",
     "longName": "019 - Disclosure - Employee Benefit Liabilities",
     "shortName": "Employee Benefit Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://trpx.com/role/TaxesonIncome",
     "longName": "020 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens",
     "longName": "021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://trpx.com/role/Equity",
     "longName": "022 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactions",
     "longName": "023 - Disclosure - Share-Based Payment Transactions",
     "shortName": "Share-Based Payment Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://trpx.com/role/RevenuesandCostofRevenues",
     "longName": "024 - Disclosure - Revenues and Cost of Revenues",
     "shortName": "Revenues and Cost of Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss",
     "longName": "025 - Disclosure - Additional Information to the Items of Profit or Loss",
     "shortName": "Additional Information to the Items of Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://trpx.com/role/LossPerShareAds",
     "longName": "026 - Disclosure - Loss Per Share/Ads",
     "shortName": "Loss Per Share/Ads",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://trpx.com/role/OperatingSegments",
     "longName": "027 - Disclosure - Operating Segments",
     "shortName": "Operating Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedParties",
     "longName": "028 - Disclosure - Transactions and Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://trpx.com/role/SignificantEventsduringtheReportingPeriod",
     "longName": "029 - Disclosure - Significant Events during the Reporting Period",
     "shortName": "Significant Events during the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://trpx.com/role/EventsAftertheReportingPeriod",
     "longName": "030 - Disclosure - Events After the Reporting Period",
     "shortName": "Events After the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://trpx.com/role/Warrants",
     "longName": "031 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:WarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:WarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://trpx.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:BasisOfPresentationOfFinancialStatements",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:BasisOfPresentationOfFinancialStatements",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://trpx.com/role/SignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://trpx.com/role/CashTables",
     "longName": "996002 - Disclosure - Cash (Tables)",
     "shortName": "Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://trpx.com/role/InventoryTables",
     "longName": "996003 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfInvertoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfInvertoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://trpx.com/role/OtherAccountsReceivableTables",
     "longName": "996004 - Disclosure - Other Accounts Receivable (Tables)",
     "shortName": "Other Accounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://trpx.com/role/InvestmentinAssociatesTables",
     "longName": "996005 - Disclosure - Investment in Associates (Tables)",
     "shortName": "Investment in Associates (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://trpx.com/role/PropertyandEquipmentNetTables",
     "longName": "996006 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://trpx.com/role/IntangibleAssetTables",
     "longName": "996007 - Disclosure - Intangible Asset (Tables)",
     "shortName": "Intangible Asset (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://trpx.com/role/TradePayablesTables",
     "longName": "996008 - Disclosure - Trade Payables (Tables)",
     "shortName": "Trade Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfTradePayables",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfTradePayables",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://trpx.com/role/OtherAccountsPayableTables",
     "longName": "996009 - Disclosure - Other Accounts Payable (Tables)",
     "shortName": "Other Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://trpx.com/role/FinancialInstrumentsTables",
     "longName": "996010 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://trpx.com/role/EmployeeBenefitLiabilitiesTables",
     "longName": "996011 - Disclosure - Employee Benefit Liabilities (Tables)",
     "shortName": "Employee Benefit Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://trpx.com/role/EquityTables",
     "longName": "996012 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactionsTables",
     "longName": "996013 - Disclosure - Share-Based Payment Transactions (Tables)",
     "shortName": "Share-Based Payment Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://trpx.com/role/RevenuesandCostofRevenuesTables",
     "longName": "996014 - Disclosure - Revenues and Cost of Revenues (Tables)",
     "shortName": "Revenues and Cost of Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables",
     "longName": "996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)",
     "shortName": "Additional Information to the Items of Profit or Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://trpx.com/role/LossPerShareAdsTables",
     "longName": "996016 - Disclosure - Loss Per Share/Ads (Tables)",
     "shortName": "Loss Per Share/Ads (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://trpx.com/role/OperatingSegmentsTables",
     "longName": "996017 - Disclosure - Operating Segments (Tables)",
     "shortName": "Operating Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables",
     "longName": "996018 - Disclosure - Transactions and Balances with Related Parties (Tables)",
     "shortName": "Transactions and Balances with Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://trpx.com/role/WarrantsTables",
     "longName": "996019 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:WarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:WarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://trpx.com/role/GeneralDetails",
     "longName": "996020 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://trpx.com/role/SignificantAccountingPoliciesDetails",
     "longName": "996021 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
     "longName": "996022 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c100",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c100",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://trpx.com/role/ScheduleofCashTable",
     "longName": "996023 - Disclosure - Cash - Schedule of Cash (Details)",
     "shortName": "Cash - Schedule of Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c109",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://trpx.com/role/ScheduleofInventoryTable",
     "longName": "996024 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInvertoryTextBlock",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInvertoryTextBlock",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable",
     "longName": "996025 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)",
     "shortName": "Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ValueAddedTaxReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ValueAddedTaxReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://trpx.com/role/InvestmentinAssociatesDetails",
     "longName": "996026 - Disclosure - Investment in Associates (Details)",
     "shortName": "Investment in Associates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c115",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c115",
      "name": "sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
     "longName": "996027 - Disclosure - Investment in Associates - Schedule of Fair Value of the Investment (Details)",
     "shortName": "Investment in Associates - Schedule of Fair Value of the Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:InvestmentsDate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
     "longName": "996028 - Disclosure - Investment in Financial Assets (Details)",
     "shortName": "Investment in Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c136",
      "name": "sprcy:InvestmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c136",
      "name": "sprcy:InvestmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://trpx.com/role/LeasesDetails",
     "longName": "996029 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c143",
      "name": "sprcy:SquareMeters",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c143",
      "name": "sprcy:SquareMeters",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://trpx.com/role/PropertyandEquipmentNetDetails",
     "longName": "996030 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996031 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c35",
      "name": "ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://trpx.com/role/IntangibleAssetDetails",
     "longName": "996032 - Disclosure - Intangible Asset (Details)",
     "shortName": "Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
     "longName": "996033 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)",
     "shortName": "Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:PurchaseofAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://trpx.com/role/ScheduleofTradePayablesTable",
     "longName": "996034 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)",
     "shortName": "Trade Payables - Schedule of Trade Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "sprcy:AccruedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayables",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "sprcy:AccruedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayables",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://trpx.com/role/ScheduleofOtherAccountsPayableTable",
     "longName": "996035 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "shortName": "Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://trpx.com/role/FinancialInstrumentsDetails",
     "longName": "996036 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c165",
      "name": "ifrs-full:CashOutflowForLeases",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c165",
      "name": "ifrs-full:CashOutflowForLeases",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
     "longName": "996037 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)",
     "shortName": "Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable",
     "longName": "996038 - Disclosure - Financial Instruments - Schedule of Warrants Fair Value Using Black\u2013Scholes OPM (Details)",
     "shortName": "Financial Instruments - Schedule of Warrants Fair Value Using Black\u2013Scholes OPM (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c177",
      "name": "sprcy:DividendYield",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c177",
      "name": "sprcy:DividendYield",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://trpx.com/role/ScheduleofDefinedContributionPlansTable",
     "longName": "996039 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)",
     "shortName": "Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://trpx.com/role/TaxesonIncomeDetails",
     "longName": "996040 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails",
     "longName": "996041 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://trpx.com/role/EquityDetails",
     "longName": "996042 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c339",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c339",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://trpx.com/role/ScheduleofShareCapitalTable",
     "longName": "996043 - Disclosure - Equity - Schedule of Share Capital (Details)",
     "shortName": "Equity - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
     "longName": "996044 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)",
     "shortName": "Equity - Schedule of Issued and Outstanding Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
     "longName": "996045 - Disclosure - Equity - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)",
     "shortName": "Equity - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock",
       "sprcy:WarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
     "longName": "996046 - Disclosure - Share-Based Payment Transactions (Details)",
     "shortName": "Share-Based Payment Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c213",
      "name": "sprcy:OrdinarySharesGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
     "longName": "996047 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:ResearchAndDevelopmentsExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:ResearchAndDevelopmentsExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
     "longName": "996048 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c220",
      "name": "sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c220",
      "name": "sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable",
     "longName": "996049 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "sprcy:NumberOfOutstandingShareOption",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c35",
      "name": "sprcy:NumberOfOutstandingShareOption",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable",
     "longName": "996050 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)",
     "shortName": "Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:CostOfGoodsSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:CostOfGoodsSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
     "longName": "996051 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)",
     "shortName": "Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:ResearchAndDevelopmentExpenses1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:ResearchAndDevelopmentExpenses1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
     "longName": "996052 - Disclosure - Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)",
     "shortName": "Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "ifrs-full:AdjustedWeightedAverageShares",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
     "longName": "996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)",
     "shortName": "Operating Segments - Schedule of Operating Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R87": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "996054 - Disclosure - Transactions and Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:ResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:PercentageOfOutstandingShareCapital",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
     "longName": "996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c331",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable",
     "longName": "996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "sprcy:ResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R90": {
     "role": "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable",
     "longName": "996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
     "longName": "996058 - Disclosure - Significant Events during the Reporting Period (Details)",
     "shortName": "Significant Events during the Reporting Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c306",
      "name": "sprcy:InterestPercentgae",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c306",
      "name": "sprcy:InterestPercentgae",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
     "longName": "996059 - Disclosure - Events After the Reporting Period (Details)",
     "shortName": "Events After the Reporting Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c311",
      "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c311",
      "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0",
     "longName": "996060 - Disclosure - Investment in Associate - Schedule of Fair Value of the Investment (Details)",
     "shortName": "Investment in Associate - Schedule of Fair Value of the Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:InvestmentFollowingAchievementMilestone",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0",
     "longName": "996061 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)",
     "shortName": "Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForDepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0",
     "longName": "996062 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c330",
      "name": "ifrs-full:CurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R96": {
     "role": "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0",
     "longName": "996063 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c332",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c332",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0",
     "longName": "996064 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0",
     "longName": "996065 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)",
     "shortName": "Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:OtherCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:OtherCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://trpx.com/role/WarrantsDetails",
     "longName": "996066 - Disclosure - Warrants (Details)",
     "shortName": "Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c199",
      "name": "sprcy:ProceedsFromIssuanceOfPrivateOffering",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "sprcy:WarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c199",
      "name": "sprcy:ProceedsFromIssuanceOfPrivateOffering",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "sprcy:WarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable",
     "longName": "996067 - Disclosure - Warrants - Schedule of Fair Value was Calculated using the Black\u2013Scholes Option Pricing Model (Details)",
     "shortName": "Warrants - Schedule of Fair Value was Calculated using the Black\u2013Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock",
       "sprcy:WarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R101": {
     "role": "http://trpx.com/role/ScheduleofShareCapitalTable0",
     "longName": "996068 - Disclosure - Equity - Schedule of Share Capital (Details)",
     "shortName": "Equity - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R102": {
     "role": "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0",
     "longName": "996069 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)",
     "shortName": "Equity - Schedule of Issued and Outstanding Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R103": {
     "role": "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0",
     "longName": "996070 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)",
     "shortName": "Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c348",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://trpx.com/role/ScheduleofOperatingSegmentsTable0",
     "longName": "996071 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)",
     "shortName": "Operating Segments - Schedule of Operating Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230821-f4a2_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "sprcy_AResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AResearchAndDevelopmentExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "a. Research and development expenses:",
        "label": "AResearch And Development Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Accruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Accruals",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued vacation",
        "label": "Accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "sprcy_AccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccruedInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AccruedInterestPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest percentage",
        "documentation": "Accrued interest percentage.",
        "label": "Accrued Interest Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedDepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AccumulatedDepreciationAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases",
        "label": "Acquisitions through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRates",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate, percentage",
        "label": "Actuarial assumption of discount rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Information to the Items of Profit or Loss [Abstract]",
        "terseLabel": "Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdditionalInstallment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional installment",
        "documentation": "The amount of additional installment.",
        "label": "Additional Installment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdditionalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional investment",
        "documentation": "The amount of additional investment.",
        "label": "Additional Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdditionalLoan",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional loan",
        "documentation": "Represent the amount of additional loan.",
        "label": "Additional Loan"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdditionalMilestoneAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone amount",
        "label": "Additional Milestone Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New lease",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdjustedAmountOfAggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdjustedAmountOfAggregateValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted amount of aggregate value",
        "documentation": "The adjusted amount of aggregate value.",
        "label": "Adjusted Amount Of Aggregate Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average outstanding shares (diluted) (in Shares)",
        "verboseLabel": "Diluted loss per share, Weighted number of shares",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in inventory",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in other accounts receivable",
        "label": "Adjustments for decrease (increase) in other operating receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of intangible asset",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses, net",
        "label": "Adjustments for finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/IntangibleAssetDetails",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on impairment of intangible asset",
        "negatedLabel": "Loss on impairment of intangible asset",
        "verboseLabel": "Impairment to its intangible asset",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in trade payables",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in other accounts payable",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets",
        "documentation": "Adjustments for losses from remeasurement of investment in financial assets\r     \n  to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Losses From Remeasurement Of Investment In Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group\u2019s share of losses of company accounted for at equity, net",
        "label": "Adjustments for losses (gains) on disposal of non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments to the profit or loss",
        "label": "Adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of share-based payment",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in working capital",
        "label": "Adjustments to reconcile profit (loss) other than changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "sprcy_AdjustmentsToTheProfitOrLossItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AdjustmentsToTheProfitOrLossItemsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to the profit or loss items:",
        "label": "Adjustments To The Profit Or Loss Items Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AggregateGrossProceeds",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds (in Dollars)",
        "documentation": "Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.",
        "label": "Aggregate Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateIssuedAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AggregateIssuedAmount",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares",
        "documentation": "Aggregate issued amount.",
        "label": "Aggregate Issued Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AggregateUnits",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units",
        "documentation": "Number of shares issued.",
        "label": "Aggregate Units"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateUnitsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AggregateUnitsPerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units Per share (in Dollars per share)",
        "documentation": "Per share of aggregate units.",
        "label": "Aggregate Units Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AggregateValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate value",
        "documentation": "The amount of ordinary shares of aggregate value.",
        "label": "Aggregate Value"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AmazonFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AmazonFeesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amazon fees [Member]",
        "verboseLabel": "Amazon Fees [Member]",
        "label": "Amazon Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceeds amount",
        "label": "Amount by which unit's recoverable amount exceeds its carrying amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount by which a cash-generating unit's (group of units') recoverable amount exceeds its carrying amount. [Refer: Carrying amount [member]; Total for all cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81"
     ]
    },
    "sprcy_AmountTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AmountTotal",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount total",
        "label": "Amount Total"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AnnualInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AnnualInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual investment",
        "documentation": "Amount of annual investment.",
        "label": "Annual Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax rate",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "sprcy_AssetAndSharePurchaseAgreementValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AssetAndSharePurchaseAgreementValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise value",
        "documentation": "Asset and share purchase agreement value.",
        "label": "Asset And Share Purchase Agreement Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r125",
      "r126",
      "r127",
      "r170",
      "r173"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AutoMaxAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AutoMaxAcquisitionMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AutoMax Acquisition [Member]",
        "label": "Auto Max Acquisition Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AutoMaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AutoMaxMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AutoMax [Member]",
        "label": "Auto Max Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AutoMaxMotorsLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "AutoMaxMotorsLtdMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AutoMax Motors Ltd [Member]",
        "label": "Auto Max Motors Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "BGeneralAndAdministrativeExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "b. General and administrative expenses:",
        "label": "BGeneral And Administrative Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70"
     ]
    },
    "sprcy_BasisOfPresentationOfFinancialStatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "BasisOfPresentationOfFinancialStatements",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation of the financial statements",
        "documentation": "The description of the entity's accounting policy changes inrBasis of presentation of the financial statements.",
        "label": "Basis Of Presentation Of Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BonusAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "BonusAmountReceived",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus amount",
        "documentation": "Bonus amount received.",
        "label": "Bonus Amount Received"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate percentage",
        "verboseLabel": "Interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range [Member]",
        "verboseLabel": "Bottom of Range [Member]",
        "netLabel": "Bottom of range [member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r129",
      "r137",
      "r145",
      "r203",
      "r204",
      "r239"
     ]
    },
    "sprcy_BridgeLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "BridgeLoansMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loans [Member]",
        "label": "Bridge Loans Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_BusinessCombinationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BusinessCombinationsDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r152"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "sprcy_BusinessDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "BusinessDevelopmentExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business development expenses [Member]",
        "label": "Business Development Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_COtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "COtherExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "c. Other expenses:",
        "label": "COther Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital warrant",
        "label": "Capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of future capital expenditures that the entity is committed to make."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "sprcy_CapitalPointMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CapitalPointMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Point [Member]",
        "label": "Capital Point Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CapitalPointWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CapitalPointWarrantMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Point Warrant [Member]",
        "label": "Capital Point Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CapitalRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CapitalRatio",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital ratio",
        "documentation": "Capital ratio.",
        "label": "Capital Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [Member]",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r42",
      "r85",
      "r90",
      "r91",
      "r92",
      "r151",
      "r157",
      "r158"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "verboseLabel": "Cash payments",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_CashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CashAdvancesAndLoansMadeToRelatedPartiesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loans to related parties",
        "documentation": "The amount of cash advances and loans made to other parties (other than advances and loans made by a financial institution), classified as investing activities.",
        "label": "Cash Advances And Loans Made To Related Parties Classified As Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/GeneralDetails",
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash for immediate withdrawal",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r102",
      "r121"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash position",
        "label": "Cash and cash equivalents if different from statement of financial position"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "sprcy_CashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CashConsideration",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration",
        "documentation": "Represent the amount of cash consideration.",
        "label": "Cash Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment (withdrawal) in restricted bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment (withdrawal) in short-term bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r103"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r103"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r103"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for principal amount",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashRepaymentsOfAdvancesAndLoansFromRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount",
        "label": "Cash repayments of advances and loans from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of advances and loans from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "sprcy_CashScheduleofCashDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CashScheduleofCashDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash - Schedule of Cash (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashScheduleofCashDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CashScheduleofCashDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash - Schedule of Cash (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Categories of financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/LeasesDetails",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable",
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/LeasesDetails",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "sprcy_ChemistryAndFormulationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ChemistryAndFormulationsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry and formulations [Member]",
        "label": "Chemistry And Formulations Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r128",
      "r133"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r128",
      "r133"
     ]
    },
    "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEmployeeBenefitsExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEntitysOwnEquityInstrumentsAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEntitysOwnEquityInstrumentsDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments issued by the entity. It also represents the standard value for the 'Classes of entity's own equity instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r161",
      "r162",
      "r181",
      "r182"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r161",
      "r162",
      "r181",
      "r182"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "sprcy_ClearmindMedicineIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ClearmindMedicineIncMember",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clearmind Medicine Inc [Member]",
        "label": "Clearmind Medicine Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ClinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ClinicalStudiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical studies [Member]",
        "label": "Clinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CoeruleusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CoeruleusMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coeruleus [Member]",
        "label": "Coeruleus Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CommitmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment amount (in Dollars)",
        "documentation": "Commitment amount.",
        "label": "Commitment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CommitmentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CommitmentPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increasing per annum",
        "documentation": "Commitment percentage.",
        "label": "Commitment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactions",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment amount",
        "label": "Commitments made by entity, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_CommunicationAndNetworkEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CommunicationAndNetworkEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Communication and network equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CompanysShareOfLossesOfCompanyAccountedForAtEquityNet",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company\u2019s share of losses of company accounted for at equity, net",
        "documentation": "Company\u2019s share of losses of company accounted for at equity, net.",
        "label": "Companys Share Of Losses Of Company Accounted For At Equity Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sprcy_ComprehensiveLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ComprehensiveLoss",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "documentation": "Comprehensive loss.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ComprehensiveLossOnInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ComprehensiveLossOnInvestment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on investment",
        "documentation": "Amount of comprehensive loss on investment.",
        "label": "Comprehensive Loss On Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ConsiderationPaidReceived",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid",
        "label": "Consideration paid (received)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ConsolidatedStatementsOfChangesInEquityDeficitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Changes In Equity Deficit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ContingentLiabilitiesCommitmentsClaimsAndLiensAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities, Commitments, Claims and Liens [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ContinuingOperationsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations:",
        "label": "Continuing Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ConversionPrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CooperationAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CooperationAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cooperation agreement amount",
        "documentation": "Represent the amount of cooperation agreement.",
        "label": "Cooperation Agreement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CostAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost:",
        "label": "Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CostOfGoodsSold",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of goods sold",
        "documentation": "The amount of cost of goods sold.",
        "label": "Cost Of Goods Sold"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of goods sold",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r32"
     ]
    },
    "ifrs-full_CreationDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CreationDateAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Creation date [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106"
     ]
    },
    "sprcy_CreditFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "CreditFromOthers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit from others",
        "documentation": "The amount of credit of others.",
        "label": "Credit From Others"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r117",
      "r202"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInventoriesInTransit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentInventoriesInTransit",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods in transit",
        "label": "Current inventories in transit"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invested amount",
        "label": "Current investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liability",
        "terseLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r119",
      "r202"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_CurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposit",
        "label": "Current restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r188"
     ]
    },
    "ifrs-full_CurrentWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Current warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "sprcy_DFinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DFinanceIncomeAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "d. Finance income:",
        "label": "DFinance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DateOfIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DateOfIssuance",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expire term",
        "label": "Date Of Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefaultFinancialStatementsDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DefaultFinancialStatementsDateMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Default financial statements date [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Creation date' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106"
     ]
    },
    "sprcy_DeferredCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DeferredCashPayments",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred cash payments",
        "documentation": "Deferred cash payments.",
        "label": "Deferred Cash Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DekelLicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DekelLicenseAgreementDescription",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments, description",
        "documentation": "Dekel license agreement description.",
        "label": "Dekel License Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44"
     ]
    },
    "ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over the useful life of the assets, description",
        "label": "Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment to IAS 1, \u201cDisclosure of Accounting Policies",
        "documentation": "Description of Accounting Policy Amendment to IAS 1, \u201cDisclosure of Accounting Policies.",
        "label": "Description Of Accounting Policy Amendment To IAS1 Disclosure Of Accounting Policies Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "documentation": "Description of accounting policy cost of sales.",
        "label": "Description Of Accounting Policy Cost Of Sales Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfAccountingPolicyForConsolidatedfinancialstatements",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated financial statements",
        "documentation": "The description of the entity's accounting policy changes in Consolidated financial statements.",
        "label": "Description Of Accounting Policy For Consolidatedfinancialstatements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (loss) per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit liabilities",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income and expenses",
        "label": "Description of accounting policy for finance income and costs [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency and foreign currency",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of non-financial assets",
        "label": "Description of accounting policy for impairment of non-financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "documentation": "The description of the entity's accounting policy for investments in associates. The description of the entity's material accounting policy information for investments accounted for using the equity method.",
        "label": "Description Of Accounting Policy For Investment Accounted For Using The Equity Methodtext Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in joint arrangements",
        "label": "Description of accounting policy for investment in associates and joint ventures [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Total for all associates [member]; Total for all joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for measuring inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenditures",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfAccountingPolicyForRestrictedDeposit",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposits",
        "label": "Description Of Accounting Policy For Restricted Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment transactions",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Description of accounting policy for taxes other than income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfAccountingPolicyForoperatingcycleExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The operating cycle",
        "documentation": "The description of the entity's accounting policy changes in operating cycle Explanatory.",
        "label": "Description Of Accounting Policy Foroperatingcycle Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAcquisitionOfASingleAssetCompany": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfAcquisitionOfASingleAssetCompany",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of a single asset company",
        "documentation": "The description of the entity's accounting policy for acquisition of a single asset company.",
        "label": "Description Of Acquisition Of ASingle Asset Company"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment to IAS 8, \u201cAccounting Policies, Changes to Accounting Estimates and Errors\u201d",
        "documentation": "The description of the entity's accounting policy for changes to accounting estimates and errors.",
        "label": "Description Of Amendment To IAS8 Accounting Policies Changes To Accounting Estimates And Errors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "verboseLabel": "Expected volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "sprcy_DescriptionOfReverseShareSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DescriptionOfReverseShareSplit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of reverse share split",
        "label": "Description Of Reverse Share Split"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "verboseLabel": "Risk-free interest rate",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70"
     ]
    },
    "ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of potential dilutive ordinary shares, Weighted number of shares",
        "label": "Dilutive effect of all instruments on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity\u2019s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosueOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://trpx.com/role/CashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash",
        "documentation": "The entire disclosue of cash and cash equivalents.",
        "label": "Disclosue Of Cash And Cash Equivalents Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/OtherAccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "label": "Disclosure of accrued expenses and other liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_DisclosureOfAdditionalInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAdditionalInformationExplanatory",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS",
        "label": "Disclosure of additional information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "sprcy_DisclosureOfAdditionalInformationTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfAdditionalInformationTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://trpx.com/role/Cash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balances with Related Parties",
        "documentation": "Disclosure of detailed information about balance with relate parties explanatory.",
        "label": "Disclosure Of Detailed Information About Balance With Relate Parties Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Contribution Plans",
        "documentation": "Disclosure of detailed information about defined contribution plans explanatory.",
        "label": "Disclosure Of Detailed Information About Defined Contribution Plans Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r159",
      "r163"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transactions with Related Parties",
        "documentation": "Disclosure of detailed information about transactions with relate parties explanatory.",
        "label": "Disclosure Of Detailed Information About Transactions With Relate Parties Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/LossPerShareAds"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE/ADS",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT LIABILITIES",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://trpx.com/role/OperatingSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING SEGMENTS",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EVENTS AFTER THE REPORTING PERIOD",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Due to Share-Based Compensation",
        "documentation": "Disclosure of expenses due to share-based compensation explanatory.",
        "label": "Disclosure Of Expenses Due To Share Based Compensation Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value for Share Options Granted",
        "documentation": "Disclosure of fair value for share options granted explanatory.",
        "label": "Disclosure Of Fair Value For Share Options Granted Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Investment",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN FINANCIAL ASSETS",
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
        "label": "Disclosure of fair value of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfFairValueOfTheIntangibleAssetTextBlock",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Intangible Asset",
        "documentation": "Disclosure of fair value of the intangible asset text block.",
        "label": "Disclosure Of Fair Value Of The Intangible Asset Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelTextBlock",
     "presentation": [
      "http://trpx.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value was Calculated using the Black\u2013Scholes Option Pricing Model",
        "documentation": "Represent the tabular disclosure of fair value was calculated using the black\u2013scholes option pricing model.",
        "label": "Disclosure Of Fair Value Was Calculated Using The Black Scholes Option Pricing Model Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/RevenuesandCostofRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES AND COST OF REVENUES",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilities",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities",
        "documentation": "The tabular disclosure of financial assets and financial liabilities.",
        "label": "Disclosure Of Financial Assets And Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://trpx.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://trpx.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefits to Key Management Personnel",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfInformationToTheItemsOfProfitOrLoss",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information to the Items of Profit or Loss",
        "documentation": "Tabular disclosure of disclosure of information to the items of profit or loss.",
        "label": "Disclosure Of Information To The Items Of Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/IntangibleAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSET",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://trpx.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "sprcy_DisclosureOfInvertoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfInvertoryTextBlock",
     "presentation": [
      "http://trpx.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "documentation": "Disclosure of inventory.",
        "label": "Disclosure Of Invertory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfIssuedAndOutstandingShareCapital": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfIssuedAndOutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Issued and Outstanding Share Capital",
        "documentation": "Disclosure of detailed inforamtion about issued and outstanding share capital.",
        "label": "Disclosure Of Issued And Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://trpx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Segments",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Segments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfOtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfOtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfOtherAccountsPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfOtherAccountsPayableTextBlock",
     "presentation": [
      "http://trpx.com/role/OtherAccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "label": "Disclosure Of Other Accounts Payable Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Financial Liabilities [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://trpx.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Exercise Prices of Share Options",
        "documentation": "The tabular disclosure of share options and weighted average exercise prices of share options",
        "label": "Disclosure Of Share Options And Weighted Average Exercise Prices Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT TRANSACTIONS",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT EVENTS DURING THE REPORTING PERIOD",
        "label": "Disclosure Of Significant Events During The Reporting Period Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN ASSOCIATES",
        "label": "Disclosure of associates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r124"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023:",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://trpx.com/role/TradePayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE PAYABLES",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "sprcy_DisclosureOfTradePayables": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfTradePayables",
     "presentation": [
      "http://trpx.com/role/TradePayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Payables",
        "documentation": "The disclosure of trade payables.",
        "label": "Disclosure Of Trade Payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life",
        "documentation": "The entire disclosure for useful life of the assets at annual rates.",
        "label": "Disclosure Of Useful Life Of Assets At Annual Rates Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyLineItems",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclourseOfAccountsReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DisclourseOfAccountsReceivablesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Receivable",
        "documentation": "The disclosure of accounts receivables.",
        "label": "Disclourse Of Accounts Receivables Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DividendYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DividendYield",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted.",
        "label": "Dividend Yield"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DrugDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DrugDevelopmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Development [Member]",
        "label": "Drug Development Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DulyExecutedShareTransferDeedForOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "DulyExecutedShareTransferDeedForOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duly executed share transfer deed for ordinary shares (in Shares)",
        "documentation": "Number of duly executed share transfer deed for ordinary shares.",
        "label": "Duly Executed Share Transfer Deed For Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EFinanceExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EFinanceExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "e. Finance expenses:",
        "label": "EFinance Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share/Ads [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/LossPerShareAdsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofDefinedContributionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses in respect of defined contribution plans",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r32",
      "r183"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "sprcy_EntityStakeholdersRange": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EntityStakeholdersRange",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stakeholder's entity range",
        "documentation": "Entity stakeholders range.",
        "label": "Entity Stakeholders Range"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r18",
      "r107",
      "r110",
      "r125",
      "r126",
      "r127"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "sprcy_EquityDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EquityDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityLossesFromInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EquityLossesFromInvestment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity losses from investment in MitoCareX",
        "terseLabel": "Equity losses from the investment",
        "documentation": "Amount of equity losses from investment.",
        "label": "Equity Losses From Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EstimatedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EstimatedAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amount",
        "label": "Estimated Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EventsAftertheReportingPeriodDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EventsAftertheReportingPeriodDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EventsAftertheReportingPeriodDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EventsAftertheReportingPeriodDetailsTable",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Period (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EveroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "EveroMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evero [Member]",
        "label": "Evero Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExchangeOfCommonShares",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of common shares (in Shares)",
        "documentation": "Number of shares exchanged.",
        "label": "Exchange Of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeRateDifferencesNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExchangeRateDifferencesNetMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate differences, net [Member]",
        "label": "Exchange Rate Differences Net Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "documentation": "Amount of exercise of warrants.",
        "label": "Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExercisePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExercisePeriod",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise period",
        "label": "Exercise Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExercisePrice1",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise Price1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "verboseLabel": "Exercise price per share",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "sprcy_ExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExercisePricePerShare",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($)",
        "label": "Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($) (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "verboseLabel": "Dividend yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "sprcy_ExpectedVolatility": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExpectedVolatility",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.",
        "label": "Expected Volatility"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExpensesDueToSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExpensesDueToSharebasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Expenses Due To Sharebased Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExpireTerm": {
     "xbrltype": "dateItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExpireTerm",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expired",
        "label": "Expire Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExternalRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ExternalRevenues",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External",
        "documentation": "Amount of external revenue.",
        "label": "External Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FairMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value",
        "documentation": "Fair market value.",
        "label": "Fair Market Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FairValueOfInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Investment",
        "documentation": "The amount of fair value of Investment.",
        "label": "Fair Value Of Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfOrdinarySharesGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FairValueOfOrdinarySharesGranted",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of ordinary shares granted (in Dollars)",
        "documentation": "The amount of fair value of ordinary shares granted.",
        "label": "Fair Value Of Ordinary Shares Granted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfShareOption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FairValueOfShareOption",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share options",
        "documentation": "Fair value Of share options.",
        "label": "Fair Value Of Share Option"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfShareOptionsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FairValueOfShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share options granted",
        "documentation": "Fair value of share options granted.",
        "label": "Fair Value Of Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment fee (in Dollars)",
        "verboseLabel": "Payment commitment fee",
        "label": "Fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "sprcy_FeeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FeeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee expense",
        "documentation": "Fee expenses.",
        "label": "Fee Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "sprcy_FinanceExpenseInRespectOfLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinanceExpenseInRespectOfLeasesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense in respect of leases [Member]",
        "label": "Finance Expense In Respect Of Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinanceExpensesFromInterestAndCommissionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinanceExpensesFromInterestAndCommissionsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses from interest and commissions [Member]",
        "label": "Finance Expenses From Interest And Commissions Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income",
        "negatedTerseLabel": "Finance income",
        "terseLabel": "Financing amount",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r157",
      "r158",
      "r160",
      "r209"
     ]
    },
    "sprcy_FinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinancialAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Financial Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets at amortized cost",
        "label": "Financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "label": "Financial assets measured at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "sprcy_FinancialInstrumentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinancialInstrumentsDetailsTable",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinancialInstrumentsScheduleofFinancialAssetsandFinancialLiabilitiesDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Fair Value Using Black\u2013Scholes OPM [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinancialInstrumentsScheduleofWarrantsFairValueUsingBlackScholesOPMDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Warrants Fair Value Using Black\u2013Scholes OPM (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial and lease liabilities",
        "terseLabel": "Total financial and lease liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "sprcy_FinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinancialLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Financial Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinderFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FinderFeePercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finder fee percentage",
        "documentation": "Represent the percentage of finder fee.",
        "label": "Finder Fee Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r229"
     ]
    },
    "sprcy_FreightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "FreightMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Freight [Member]",
        "label": "Freight Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "sprcy_GeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "GeneralAndAdministrativeExpenses",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": "sprcy_ExpensesDueToSharebasedCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r194",
      "r205",
      "r207"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r194",
      "r205",
      "r207"
     ]
    },
    "sprcy_GovernmentAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "GovernmentAuthorities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "documentation": "Government authorities.",
        "label": "Government Authorities"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "GrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds (in Dollars)",
        "documentation": "Gross proceeds.",
        "label": "Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "sprcy_GrowthRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "GrowthRatePercentage",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Growth rate, percentage",
        "label": "Growth Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "currency_ILS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "ILS",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIS [Member]",
        "verboseLabel": "Israel [Member]",
        "label": "Israel, New Shekels"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment loss (gain)",
        "verboseLabel": "Comprehensive loss",
        "label": "Impairment loss recognised in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible asset",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IncomeStatementsLocationsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statements Locations [Axis]",
        "label": "Income Statements Locations Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IncomeStatementsLocationsDomainDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeStatementsLocationsDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r35",
      "r36",
      "r37",
      "r63",
      "r123",
      "r169"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of August 2023 financing round",
        "label": "Increase (decrease) in number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration of share options",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "sprcy_InitialConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InitialConversionPrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial conversion price (in Dollars per share)",
        "documentation": "Initial conversion price.",
        "label": "Initial Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InitialInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InitialInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial investment amount",
        "documentation": "Initial investment.",
        "label": "Initial Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InstallmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment amount",
        "documentation": "Amount of installment amount.",
        "label": "Installment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InstallmentPaid",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment paid",
        "documentation": "The amount of installment paid.",
        "label": "Installment Paid"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InstallmentPayment",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment payment, percentage",
        "documentation": "Installment payment.",
        "label": "Installment Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InstallmentPaymentPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment payment percentage",
        "documentation": "Installment payment percentage.",
        "label": "Installment Payment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetFairValueUsedAsDeemedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of intangible asset",
        "label": "Intangible asset fair value used as deemed cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Intangible Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "terseLabel": "Intangible asset, net",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r85"
     ]
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r167",
      "r174"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid on lease liability",
        "label": "Interest paid, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "sprcy_InterestPercentgae": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InterestPercentgae",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest percentage",
        "documentation": "Interest percentgae.",
        "label": "Interest Percentgae"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InterestRate",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, percentage",
        "documentation": "Interest rate.",
        "label": "Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestRevenueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestRevenueExpense",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense (income), net",
        "label": "Interest income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r174",
      "r226"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Inventory",
        "terseLabel": "Inventory",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r50",
      "r186"
     ]
    },
    "sprcy_InventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentAchievementOfFirstMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentAchievementOfFirstMilestone",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment following achievement of first milestone",
        "documentation": "The amount of investment following achievement of first milestone.",
        "label": "Investment Achievement Of First Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment amount",
        "documentation": "Investment amount.",
        "label": "Investment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentFollowingAchievementMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentFollowingAchievementMilestone",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment following achievement milestone",
        "documentation": "Represent the amount of investment achievement of milestone.",
        "label": "Investment Following Achievement Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentFromShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentFromShareholders",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment from shareholders",
        "documentation": "The amount of investment from shareholders.",
        "label": "Investment From Shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentInFinancialAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentInFinancialAsset",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in financial asset",
        "documentation": "The amount of investment in financial asset.",
        "label": "Investment In Financial Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentIncome",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial investment amount",
        "label": "Investment income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investment income, such as interest and dividends."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r226"
     ]
    },
    "sprcy_InvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment [Member]",
        "label": "Investment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentinAssociatesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentinAssociatesDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinFinancialAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentinFinancialAssetsDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentsDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentsDate",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment date March 31, 2022",
        "documentation": "The amount of investment date,",
        "label": "Investments Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsInAssociates",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in company account for at equity",
        "label": "Investments in associates reported in separate financial statements"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "sprcy_InvestmentsInFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestmentsInFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments in financial assets",
        "label": "Investments In Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestorRelationsAndBusinessExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "InvestorRelationsAndBusinessExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor relations and business expenses [Member]",
        "label": "Investor Relations And Business Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceAggregateOfPrefundedUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuanceAggregateOfPrefundedUnits",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance aggregate of pre-funded units",
        "documentation": "Represent the issuance of aggregate of prefunded units.",
        "label": "Issuance Aggregate Of Prefunded Units"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceExpensesRelatedToWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuanceExpensesRelatedToWarrantsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance expenses related to warrants [Member]",
        "label": "Issuance Expenses Related To Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuanceOfAggregateShares",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of aggregate shares",
        "documentation": "The issuance of aggregate shares.",
        "label": "Issuance Of Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of investment in affiliate",
        "documentation": "Issuance of share capital \u2013 in respect of investment in affiliate.",
        "label": "Issuance Of Share Capital In Respect Of Investment In Affiliate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of October 2023 financing round",
        "verboseLabel": "Issuance of share in respect of exercise of pre-funded October 2023 Warrants (Note 6i)",
        "documentation": "Number of share capital issued in respect of October 2023 financing round.",
        "label": "Issuance Of Share Capital In Respect Of October2023 Financing Round"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuanceOfShareCapitalInRespectOfRoundingErrors",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of rounding errors",
        "verboseLabel": "Issuance of share capital \u2013 in respect of Standby Equity Purchase Agreement (Note 6j)",
        "documentation": "Number of share capital issued in respect of rounding errors.",
        "label": "Issuance Of Share Capital In Respect Of Rounding Errors"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuanceOfShareCapitalInRespectOfShelfProspectus",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of shelf prospectus",
        "documentation": "Issuance of share capital \u2013 in respect of shelf prospectus.",
        "label": "Issuance Of Share Capital In Respect Of Shelf Prospectus"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssueOfShareCapitalNetOfIssueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssueOfShareCapitalNetOfIssueExpense",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares, net of issuance expenses",
        "documentation": "Issue of share capital, net of issue expenses.",
        "label": "Issue Of Share Capital Net Of Issue Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuedAndOutstandingSharePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuedAndOutstandingSharePercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and outstanding shares percentage",
        "documentation": "Issued and outstanding shares percentage.",
        "label": "Issued And Outstanding Share Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuedAndOutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "IssuedAndOutstandingSharesPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and outstanding shares percentage",
        "documentation": "Issued and outstanding shares, percentage.",
        "label": "Issued And Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital purchase",
        "verboseLabel": "Number of shares valuation",
        "label": "Issued capital, ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "sprcy_JeffsBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "JeffsBrandsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jeffs\u2019 Brands [Member]",
        "label": "Jeffs Brands Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_June2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "June2022WarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2022 Warrants [Member]",
        "label": "June2022 Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_KeyManagementPersonnelCompensationManagementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "KeyManagementPersonnelCompensationManagementFees",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable",
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees (see also note 25a)",
        "verboseLabel": "Management fees",
        "documentation": "The amount of compensation to key management personnel in the form of management fees.",
        "label": "Key Management Personnel Compensation Management Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable",
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of share-based payment",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable",
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key management personnel [Member]",
        "label": "Key management personnel of entity or parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "sprcy_LeaseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LeaseFee",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease fee (in Dollars)",
        "label": "Lease Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "sprcy_LeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LeaseMember",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Lease [Member]",
        "label": "Lease Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeaseholdImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LeaseholdImprovements",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements (in Dollars)",
        "documentation": "Leasehold improvements.",
        "label": "Leasehold Improvements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "sprcy_LeasesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LeasesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r78",
      "r79",
      "r126"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r126"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r126"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r126"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r126"
     ]
    },
    "sprcy_ListedSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ListedSharePrice",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Listed share price (in Dollars per share)",
        "documentation": "Amount of listed shares price per share.",
        "label": "Listed Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansAndAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LoansAndAdvances",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans to related party",
        "label": "Loans and advances"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans and advances the entity has made."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan received",
        "label": "Loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LongTermPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LongTermPercentage",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term, percentage",
        "documentation": "The percentage of long term.",
        "label": "Long Term Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LossPerShareAdsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share/Ads - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "LossesFromRemeasurementOfInvestmentInFinancialAssetsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets [Member]",
        "label": "Losses From Remeasurement Of Investment In Financial Assets Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_March2021FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "March2021FinancingRoundMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2021 Financing Round [Member]",
        "label": "March2021 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "MaturityDate",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXBioLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "MitoCareXBioLtdMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCare X Bio Ltd [Member]",
        "label": "Mito Care XBio Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "MitoCareXMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCareX [Member]",
        "label": "Mito Care XMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MizaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "MizaMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miza [Member]",
        "label": "Miza Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MutualShareExchangeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "MutualShareExchangeAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual share exchange amount",
        "documentation": "Mutual share exchange amount.",
        "label": "Mutual Share Exchange Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MutualShareExchangeOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "MutualShareExchangeOfOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual share exchange of ordinary shares (see note 10)",
        "documentation": "The amount of mutual share exchange of ordinary shares.",
        "label": "Mutual Share Exchange Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]",
        "label": "Net Change In Fair Value Of Financial Liabilities Designated At Fair Value Through Profit Or Loss Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NewCoIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NewCoIncMember",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NewCo Inc. [Member]",
        "label": "New Co Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r112",
      "r114"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "terseLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r118",
      "r202"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES:",
        "verboseLabel": "NON-LIABILITIES",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Non-current receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfOutstandingShareOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NumberOfOutstandingShareOption",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Share Options , Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Number of Share Options, Share Options outstanding at the end of the year",
        "documentation": "The number of share option outstanding in a share-based payment arrangement.",
        "label": "Number Of Outstanding Share Option"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NumberOfShareOptionExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options exercisable at the end of the year",
        "documentation": "Number of share options exercisable at the end of the year.",
        "label": "Number Of Share Option Exercisable In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NumberOfShareOptionGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options granted during the year",
        "documentation": "Number of share options granted during the year.",
        "label": "Number Of Share Option Granted In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NumberOfShareOptionsCancelledInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options cancelled during the year",
        "documentation": "Number of share options cancelled during the year.",
        "label": "Number Of Share Options Cancelled In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NumberOfSharesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number Of Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfSharesAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NumberOfSharesAbstract0",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number Of Shares Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable",
      "http://trpx.com/role/ScheduleofShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, authorized",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of ordinary shares (in Shares)",
        "netLabel": "Shares issued (in Shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued of warrant (in Shares)",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedButNotFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedButNotFullyPaid",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received shares (in Shares)",
        "label": "Number of shares issued but not fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has not been received."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofShareCapitalTable",
      "http://trpx.com/role/ScheduleofShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, issued and outstanding",
        "verboseLabel": "Common shares (in Shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "sprcy_NumberOfSharesOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "NumberOfSharesOutstandingPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, percentage",
        "documentation": "Represent the percentage of number of shares outstanding.",
        "label": "Number Of Shares Outstanding Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "sprcy_OfficeEquipmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OfficeEquipmentsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipments Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OfficeMaintenanceRentAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OfficeMaintenanceRentAndOtherExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office maintenance, rent and other expenses [Member]",
        "label": "Office Maintenance Rent And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OnlineSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OnlineSalesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Online Sales [Member]",
        "label": "Online Sales Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingLossCarryforwardsTaxAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OperatingLossCarryforwardsTaxAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward tax losses (in Dollars)",
        "documentation": "The amount of net operating loss carryforward tax as of the reporting date.",
        "label": "Operating Loss Carryforwards Tax Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OperatingSegmentsScheduleofOperatingSegmentsDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments - Schedule of Operating Segments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OperatingTerm",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating term",
        "label": "Operating Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinaryShareExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OrdinaryShareExercisePrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share exercise price (in Dollars per share)",
        "label": "Ordinary Share Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OrdinarySharesAcquired",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired ordinary shares (in Shares)",
        "documentation": "Ordinary shares acquired.",
        "label": "Ordinary Shares Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OrdinarySharesGranted",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares granted (in Shares)",
        "documentation": "Number of ordinary shares granted.",
        "label": "Ordinary Shares Granted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesGrantedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OrdinarySharesGrantedDiscountRate",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares granted discount rate",
        "documentation": "Ordinary shares granted discount rate.",
        "label": "Ordinary Shares Granted Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OrdinarySharesIssued",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued (in Shares)",
        "label": "Ordinary Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares [Member]",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "sprcy_OrdinarySharesParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OrdinarySharesParValue",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares par value (in New Shekels per share)",
        "documentation": "Ordinary shares par value.",
        "label": "Ordinary Shares Par Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OrdinarySharesSold",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares sold (in Shares)",
        "documentation": "Number of ordinary shares sold.",
        "label": "Ordinary Shares Sold"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Assets",
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_OtherCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Other cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Other cash receipts from sales of interests in joint ventures, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of interests in joint ventures (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities. [Refer: Total for all joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts receivable",
        "terseLabel": "Other accounts receivable",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_OtherEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEquityInterest",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non-controlling interests",
        "label": "Other equity interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_OtherEquityInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEquityInterestMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non- controlling interests",
        "label": "Other equity interest [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional investment",
        "label": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r183",
      "r184"
     ]
    },
    "ifrs-full_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Liabilities",
        "label": "Other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in financial assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Other property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0",
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties [Member]",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "sprcy_OutstandingShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding share capital, percentage",
        "documentation": "Percentage of outstanding share capital.",
        "label": "Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OutstandingSharesPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares",
        "documentation": "Outstanding shares percentage.",
        "label": "Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OverAllotmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OverAllotmentMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over Allotment [Member]",
        "label": "Over Allotment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "OwnershipPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value, per share (in New Shekels per share)",
        "verboseLabel": "Par value (in Dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParentMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an entity that controls one or more entities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "sprcy_PaymentForPremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PaymentForPremiumPercentage",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for premium percentage",
        "documentation": "Payment for premium percentage.",
        "label": "Payment For Premium Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PaymentOfIssuanceExpensesRelatedToPreviousPeriod",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of issuance expenses related to previous period",
        "label": "Payment Of Issuance Expenses Related To Previous Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PaymentPremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PaymentPremiumPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment premium percentage",
        "documentation": "Payment premium percentage.",
        "label": "Payment Premium Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liability",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "sprcy_PercentageOfOutstandingShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PercentageOfOutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding share capital, percentage",
        "documentation": "Represent the percentage of outstanding share capital.",
        "label": "Percentage Of Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PercentageOfSharesIssuedAndOutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of issued and outstanding share capital",
        "documentation": "The percentage of shares issued and outstanding share capital.",
        "label": "Percentage Of Shares Issued And Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates",
        "documentation": "The useful lives or depreciation rates used for property, plant and equipment.",
        "label": "Percentage Of Useful Lives Or Depreciation Rates Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration received",
        "label": "Portion of consideration paid (received) consisting of cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "sprcy_PreFundedUnitPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PreFundedUnitPerShare",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded unit per share",
        "documentation": "Represent the price of pre-funded unit.",
        "label": "Pre Funded Unit Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PreFundedUnitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PreFundedUnitShares",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded unit",
        "documentation": "Represent the number pre-funded unit.",
        "label": "Pre Funded Unit Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "verboseLabel": "Pre-funded warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PrepaidAdvance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PrepaidAdvance",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid advance",
        "documentation": "The amount of prepaid advance.",
        "label": "Prepaid Advance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PreviouslyStatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PreviouslyStatedMember",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Stated",
        "verboseLabel": "Previously stated [member]",
        "netLabel": "Previously Stated [Member]",
        "label": "Previously stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r104",
      "r105",
      "r106"
     ]
    },
    "sprcy_PricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PricePerShare",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price Per Share (in New Shekels per share)",
        "documentation": "price per share.",
        "label": "Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Prices specified in forward agreements to purchase financial assets for cash"
       }
      },
      "en": {
       "role": {
        "documentation": "Prices specified in forward agreements to purchase financial assets for cash."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "sprcy_PrivatePlacementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PrivatePlacementsMember",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placements [Member]",
        "verboseLabel": "Private Placement [Member]",
        "label": "Private Placements Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromChangesInOwnershipInterestsInSubsidiaries",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of shares to minority interests in a subsidiary",
        "label": "Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100"
     ]
    },
    "ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromContributionsOfNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Proceeds from contributions of non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "verboseLabel": "Warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "sprcy_ProceedsFromIssuanceOfPrivateOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ProceedsFromIssuanceOfPrivateOffering",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds of private offering",
        "documentation": "Represent the amount of proceeds from issuance of private offering.",
        "label": "Proceeds From Issuance Of Private Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from ordinary shares",
        "label": "Proceeds from issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from issuance of share capital and warrants (net of issuance expenses)",
        "documentation": "The amount of proceeds from issue of share capital and warrants net of issuance expenses.",
        "label": "Proceeds From Issue Of Share Capital And Warrantsnet Of Issuance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross cash proceeds (in Dollars)",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "sprcy_ProfessionalAndDirectorsFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ProfessionalAndDirectorsFeesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and directors\u2019 fees [Member]",
        "label": "Professional And Directors Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/GeneralDetails",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Total comprehensive loss",
        "negatedTotalLabel": "Profit loss",
        "terseLabel": "Income (loss)",
        "verboseLabel": "Loss",
        "negatedLabel": "Loss",
        "netLabel": "Operating loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r25",
      "r94",
      "r108",
      "r111",
      "r170",
      "r172",
      "r202",
      "r206"
     ]
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to:",
        "label": "Profit (loss), attributable to [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r113"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity holders of the Company",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r183",
      "r184",
      "r211",
      "r212"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share, Loss (in Dollars)",
        "label": "Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating basic earnings (loss) per instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations used in calculating basic earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share, Loss (in Dollars)",
        "label": "Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating diluted earnings (loss) per instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations used in calculating diluted earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r226"
     ]
    },
    "ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity losses from investment in MitoCareX",
        "label": "Profit (loss) on disposal of investments and changes in value of investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) on disposal of investments and changes in the value of investments. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r42"
     ]
    },
    "sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PropertyPlantAndEquipmentAccumulatedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accumulated depreciation, Beginning balance",
        "periodEndLabel": "Accumulated depreciation, Ending balance",
        "documentation": "Represents the amount of accumulated depreciation.",
        "label": "Property Plant And Equipment Accumulated Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cost, Beginning balance",
        "periodEndLabel": "Cost, Ending balance",
        "label": "Property, plant and equipment, revalued assets, at cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciated cost",
        "label": "Property, plant and equipment, gross carrying amount of fully depreciated assets still in use"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross carrying amount of fully depreciated property, plant and equipment that is still in use. [Refer: Gross carrying amount [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "sprcy_PropertyandEquipmentNetDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PropertyandEquipmentNetDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PropertyandEquipmentNetDetailsTable",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r116"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r115"
     ]
    },
    "sprcy_PurchaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PurchaseCosts",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase costs",
        "label": "Purchase Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseCostsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PurchaseCostsValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase costs",
        "documentation": "Represent the amount of purchase costs.",
        "label": "Purchase Costs Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of financial assets at fair value through profit or loss",
        "documentation": "Purchase of financial assets at fair value through profit or loss.",
        "label": "Purchase Of Financial Assets At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible asset",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments in financial assets",
        "label": "Purchase of interests in investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in a company accounted for at equity",
        "label": "Purchase of investments other than investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "sprcy_PurchaseOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PurchaseOfOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of ordinary shares",
        "documentation": "Purchase of ordinary shares.",
        "label": "Purchase Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "sprcy_PurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "documentation": "The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PurchasedGoodsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased goods [Member]",
        "label": "Purchased Goods Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseofAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "PurchaseofAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase date September 30, 2022",
        "label": "Purchaseof Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r129",
      "r137",
      "r145",
      "r203",
      "r204",
      "r239"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r129",
      "r137",
      "r145",
      "r203",
      "r204",
      "r239"
     ]
    },
    "sprcy_ReceiptofShortTermCreditFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ReceiptofShortTermCreditFromOthers",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of short-term credit",
        "label": "Receiptof Short Term Credit From Others"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegistrationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RegistrationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registration of warrants",
        "documentation": "Registration of warrants.",
        "label": "Registration Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RegulatoryExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory expenses [Member]",
        "label": "Regulatory Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryProfessionalAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RegulatoryProfessionalAndOtherExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory, professional and other expenses [Member]",
        "label": "Regulatory Professional And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized over period",
        "label": "Remaining amortisation period of intangible assets material to entity"
       }
      },
      "en": {
       "role": {
        "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "sprcy_RepaymentClosingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RepaymentClosingAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment amount",
        "documentation": "Represent the value of repayment closing amount.",
        "label": "Repayment Closing Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0",
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "sprcy_ResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Recognized expenses",
        "label": "Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndDevelopmentExpenses1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ResearchAndDevelopmentExpenses1",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.",
        "label": "Research And Development Expenses1"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndDevelopmentsExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ResearchAndDevelopmentsExpenses",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": "sprcy_ExpensesDueToSharebasedCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "The amount of research and development expenses.",
        "label": "Research And Developments Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndPreclinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ResearchAndPreclinicalStudiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and preclinical studies [Member]",
        "label": "Research And Preclinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r185"
     ]
    },
    "ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity losses from the investment",
        "label": "Reserve of gains and losses from investments in equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing accumulated gains and losses from investments in equity instruments that the entity has designated at fair value through other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_RestatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestatedMember",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r104",
      "r105",
      "r106",
      "r136",
      "r220"
     ]
    },
    "ifrs-full_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and restricted deposits",
        "label": "Restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r185"
     ]
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r104",
      "r105",
      "r106"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r120",
      "r153",
      "r166",
      "r171",
      "r176",
      "r177",
      "r179",
      "r183",
      "r184",
      "r202"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Royalty income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from royalties."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total",
        "label": "Revenue from sale of goods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "sprcy_RevenueTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RevenueTerm",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue term",
        "documentation": "Revenue term.",
        "label": "Revenue Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cost of Sales and Gross Profit [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset",
        "label": "Reversal of impairment loss recognised in other comprehensive income, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross sales",
        "label": "Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RightofuseAssetRecognizedWithCorrespondingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset recognized with corresponding lease liability",
        "documentation": "Right-of-use asset recognized with corresponding lease liability.",
        "label": "Rightofuse Asset Recognized With Corresponding Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "RiskFreeInterestRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "documentation": "The risk-free interest rate for the option contractual term.",
        "label": "Risk Free Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SEPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SEPAMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA [Member]",
        "label": "SEPAMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SaleOfOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of ordinary shares",
        "documentation": "Represent the number of ordinary shares sold.",
        "label": "Sale Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SaleOrIssueOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase sale (in Dollars)",
        "label": "Sale or issue of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "label": "Sales and marketing expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "sprcy_ScenarioForecastsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScenarioForecastsMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario Forecasts [Member]",
        "label": "Scenario Forecasts Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Additional Information To The Items Of Profit Or Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances With Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfBenefitsToKeyManagementPersonnelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Benefits to Key Management Personnel[Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfCashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfCostOfSalesAndGrossProfitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cost Of Sales And Gross Profit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDefinedContributionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfDefinedContributionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Contribution Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfExpensesDueToShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Expenses Due to Share-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfFairValueForShareOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value for Share Options Granted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfFairValueOfTheIntangibleAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Intangible Asset Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheInvestmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfFairValueOfTheInvestmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Investment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Was Calculated Using The Black Scholes Option Pricing Model Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets And Financial Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfInventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfInventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfIssuedAndOutstandingShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Issued and Outstanding Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Number Of Shares And Loss Used In The Computation Of Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Segments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsReceivableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfOtherAccountsReceivableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/RevenuesandCostofRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cost of Sales and Gross Profit",
        "label": "Schedule Of Revenues And Cost Of Revenues Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Capital Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfTradePayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfTradePayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfTransactionsWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transactions with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants Fair Value Using Black Scholes Opm Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Fair Value Using Black\u2013Scholes OPM",
        "label": "Schedule Of Warrants Fair Value Using Blackscholes Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Exercise Prices Of Share Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SciSparcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SciSparcMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SciSparc [Member]",
        "label": "Sci Sparc Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SegmentReportingRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SegmentReportingRevenueAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Segment Reporting Revenue Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0",
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r130",
      "r170",
      "r195",
      "r208"
     ]
    },
    "ifrs-full_SegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0",
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r130",
      "r175",
      "r195",
      "r208"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "sprcy_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Warrants [Member]",
        "verboseLabel": "Series A Warrants [Member]",
        "label": "Series AWarrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Warrants [Member]",
        "label": "Series BWarrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services rendered amount (in Dollars)",
        "verboseLabel": "Management services expenses",
        "label": "Services expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from services."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Volatility Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Range Of Dividend Used"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Risk Free Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareBasedPaymentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment [Member]",
        "label": "Share Based Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareBasedPaymentTransactionsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareBasedPaymentTransactionsDetailsTable",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareCapitalPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital percentage",
        "documentation": "Share capital percentage.",
        "label": "Share Capital Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital in respect of investment in affiliate",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "sprcy_ShareIssuedToAConsultant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareIssuedToAConsultant",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued to a consultant",
        "verboseLabel": "Shares issued to consultants (Note 6e)",
        "documentation": "The shares were issued to a consultant.",
        "label": "Share Issued To AConsultant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Company\u2019s share of losses of companies accounted for at equity, net",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r168",
      "r174"
     ]
    },
    "sprcy_ShareOptionsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "ShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options granted (in Shares)",
        "documentation": "Number of share options granted.",
        "label": "Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sprcy_SharePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SharePricePerShare",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "documentation": "Share price.",
        "label": "Share Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SharePricePercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareprice, percentage",
        "documentation": "Share price percentage.",
        "label": "Share Price Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharePriceRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SharePriceRate",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price rate",
        "documentation": "Share price rate.",
        "label": "Share Price Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life of share options (years)",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumption Expected Term1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposit",
        "verboseLabel": "Short term deposits",
        "netLabel": "Short-term deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and payroll accruals",
        "label": "Short-term employee benefits accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS",
        "documentation": "The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.",
        "label": "Significant Accounting Judgments Estimates And Assumptions Used In Preparation Of Financial Statements Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SignificantEventsduringtheReportingPeriodDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events During the Reporting Period [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsduringtheReportingPeriodDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SignificantEventsduringtheReportingPeriodDetailsTable",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantNonCashTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SignificantNonCashTransactionsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(a) Significant non-cash transactions:",
        "label": "Significant Non Cash Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SquareMeters": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SquareMeters",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square meters",
        "label": "Square Meters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StorageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "StorageMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Storage [Member]",
        "label": "Storage Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates mainly",
        "label": "Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SubsequentEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "SubsequentEventsMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Member]",
        "label": "Subsequent Events Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense",
        "verboseLabel": "Tax expense (income)",
        "documentation": "Tax expense.",
        "label": "Tax Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesonIncomeDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TaxesonIncomeDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesonIncomeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TaxesonIncomeDetailsTable",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range [Member]",
        "verboseLabel": "Top of Range [Member]",
        "netLabel": "Top of range [member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r129",
      "r137",
      "r145",
      "r203",
      "r204",
      "r239"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts payable",
        "terseLabel": "Other accounts payable",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open debts",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r224"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Trade payables",
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "sprcy_TransactionsWithRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TransactionsWithRelatedPartiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with related parties [Member]",
        "label": "Transactions With Related Parties Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balances with Related Parties [Line Items]",
        "terseLabel": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofTransactionswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "TwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan [Member]",
        "label": "Two Thousand Twenty Three Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD [Member]",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnderlyingAdsPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "UnderlyingAdsPrice",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Share Price ($)",
        "label": "Underlying Ads Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnderlyingOrdinarySharePrices": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "UnderlyingOrdinarySharePrices",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying ordinary share price (in Dollars per share)",
        "documentation": "Underlying ordinary share price.",
        "label": "Underlying Ordinary Share Prices"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnpaidIssueExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "UnpaidIssueExpenses",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid issue expenses",
        "documentation": "Unpaid issue expenses.",
        "label": "Unpaid Issue Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "label": "Value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables related to a value added tax."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "sprcy_WagesAndRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WagesAndRelatedExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wages and related expenses [Member]",
        "label": "Wages And Related Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "sprcy_WarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsAndExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsAndExercise",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and exercise",
        "label": "Warrants And Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsDetailsTable",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsExercisePrice": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsExercisePrice",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise price",
        "documentation": "Warrants exercise price.",
        "label": "Warrants Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsFairValueinDollarsPerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsFairValueinDollarsPerShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($)",
        "label": "Warrants Fair Valuein Dollars Per Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants liability",
        "label": "Warrants Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants [member]",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for warrants."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "sprcy_WarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsTextBlock",
     "presentation": [
      "http://trpx.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WARRANTS",
        "documentation": "Represent the entire disclosure of warrant.",
        "label": "Warrants Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WarrantsToPurchase",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase",
        "label": "Warrants To Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options exercisable at the end of the year",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options cancelled during the year",
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options granted during the year",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Weighted average exercise price, Share Options outstanding at the end of the year",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r143"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($) (in Dollars)",
        "verboseLabel": "Warrants fair value (in Dollars)",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WeightedAverageRemainingContractualLifesOfOutstandingShareOption",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "The weighted average remaining contractual lifes of outstanding share options.",
        "label": "Weighted Average Remaining Contractual Lifes Of Outstanding Share Option"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValuewasCalculatedusingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying share price ($) (in Dollars per share)",
        "verboseLabel": "Underlying share price (in Dollars per share)",
        "label": "Weighted average share price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average outstanding shares (basic) (in Shares)",
        "verboseLabel": "Basic loss per share, Weighted number of shares",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sprcy_WellutionOperatingExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WellutionOperatingExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wellution operating expenses [Member]",
        "label": "Wellution Operating Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WorkingCapitalAdjustmentssAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "WorkingCapitalAdjustmentssAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital adjustments:",
        "label": "Working Capital Adjustmentss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_pricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20240630",
     "localname": "pricePerShare",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares price closes (in Dollars per share)",
        "label": "price Per Share"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "77",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_77_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_ix&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "135",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_135_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_v&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "40",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42B&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "30",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_30&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "11A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_11A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_21_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11D_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "144",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "A14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_A14&doctype=Appendix&subtype=A",
   "URIDate": "2024-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
